Anti O -
- O -
Ro O +
( O +
SSA O +
) O +
autoantibodies O +
are O +
associated O +
with O +
T O +
cell O +
receptor O +
beta O +
genes O +
in O +
systemic O +
lupus O +
erythematosus O +
patients O +
. O +

Several O +
of O +
the O +
heterogeneous O +
clinical O +
manifestations O +
of O +
systemic O +
lupus O +
erythematosus O +
have O +
been O +
associated O +
with O +
specific O +
autoantibodies O +
. O +

Associations O +
between O +
HLA O +
class O +
II O +
antigens O +
and O +
autoantibodies O +
to O +
the O +
ribonucleoproteins O +
Ro O +
( O +
SSA O +
) O +
and O +
La O +
( O +
SSB O +
) O +
have O +
been O +
reported O +
in O +
these O +
patients O +
. O +

Because O +
HLA O +
class O +
II O +
molecules O +
present O +
antigen O +
to O +
T O +
cell O +
receptors O +
( O +
TCRs O +
) O +
, O +
we O +
have O +
searched O +
for O +
a O +
TCR O +
gene O +
associated O +
with O +
the O +
production O +
of O +
anti O -
- O -
Ro O +
( O +
SSA O +
) O +
antibodies O +
. O +

A O +
pair O +
of O +
restriction O +
fragment O +
length O +
polymorphisms O +
( O +
RFLPs O +
) O +
, O +
one O +
of O +
which O +
hybridizes O +
to O +
the O +
TCR O +
constant O +
region O +
C O +
beta O +
1 O +
and O +
the O +
other O +
to O +
the O +
C O +
beta O +
2 O +
gene O +
, O +
has O +
been O +
identified O +
, O +
suggesting O +
these O +
may O +
be O +
genotypic O +
markers O +
for O +
an O +
extended O +
region O +
of O +
the O +
TCR O +
beta O +
locus O +
. O +

This O +
RFLP O +
pair O +
occurs O +
in O +
76 O +
% O +
of O +
patients O +
with O +
Ro O +
( O +
SSA O +
) O +
precipitins O +
, O +
84 O +
% O +
of O +
anti- O +
Ro O +
( O +
SSA O +
) O +
-positive O +
patients O +
lacking O +
La O +
( O +
SSB O +
) O +
precipitins O +
, O +
but O +
only O +
41 O +
% O +
of O +
the O +
patients O +
lacking O +
both O +
precipitins O +
( O +
P O +
= O +
0.0004 O +
) O +
. O +

This O +
disproportionate O +
occurrence O +
in O +
a O +
subset O +
of O +
lupus O +
patients O +
indicates O +
that O +
these O +
RFLPs O +
are O +
not O +
disease O +
susceptibility O +
markers O +
, O +
but O +
rather O +
are O +
important O +
markers O +
for O +
TCR O +
genes O +
whose O +
products O +
are O +
involved O +
in O +
the O +
production O +
of O +
anti O -
- O -
Ro O +
( O +
SSA O +
) O +
antibodies O +
. O +

The O +
majority O +
of O +
patients O +
who O +
have O +
these O +
RFLPs O +
and O +
HLA O +
class O +
II O +
antigens O +
previously O +
associated O +
with O +
the O +
anti- O +
Ro O +
( O +
SSA O +
) O +
response O +
make O +
this O +
antibody O +
, O +
suggesting O +
that O +
interactions O +
between O +
products O +
of O +
these O +
loci O +
occur O +
in O +
response O +
to O +
Ro O +
( O +
SSA O +
) O +
. O +

Characterization O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
enhancer O -
- O -
binding O +
proteins O +
from O +
the O +
human B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
Jurkat B-CellLine +
. O +

The O +
transcription O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
is O +
under O +
the O +
control O +
of O +
cellular O +
proteins O +
that O +
bind O +
to O +
the O +
viral O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
. O +

Among O +
the O +
protein O -
- O -
binding O +
regions O +
of O +
the O +
HIV-1 O +
LTR O +
is O +
the O +
transcription O -
- O -
enhancer O +
region O +
. O +

We O +
show O +
that O +
at O +
least O +
one O +
inducible O +
, O +
C1 O +
, O +
and O +
one O +
constitutive O +
, O +
C2 O +
, O +
protein O +
can O +
bind O +
to O +
the O +
HIV O +
enhancer O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

The O +
two O +
proteins O +
differ O +
in O +
their O +
surface O +
charge O +
, O +
since O +
they O +
are O +
separable O +
by O +
anion O -
- O -
exchange O +
chromatography O +
. O +

Bivalent O +
cations O +
such O +
as O +
Mg2 O -
+ O +
and O +
Zn2 O -
+ O +
differentially O +
affect O +
their O +
binding O +
to O +
oligonucleotides O +
which O +
contain O +
the O +
HIV O -
- O -
enhancer O +
domain O +
. O +

Both O +
C1 O +
and O +
C2 O +
proteins O +
also O +
bind O +
to O +
a O +
similar O +
sequence O +
found O +
in O +
the O +
interleukin-2-receptor O +
alpha O -
- O -
subunit O +
enhancer O +
. O +

The O +
inducible O +
C1 O +
protein O +
was O +
partially O +
purified O +
by O +
three O +
chromatographic O +
steps O +
and O +
characterized O +
by O +
u.v O -
. O +
cross O -
- O -
linking O +
as O +
a O +
47 O +
kDa O +
protein O +
. O +

NF O -
- O -
kappa O +
B O +
as O +
inducible O +
transcriptional O +
activator O +
of O +
the O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
gene O +
. O +

The O +
expression O +
of O +
the O +
gene O +
encoding O +
the O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
is O +
induced O +
upon O +
activation O +
of O +
T O +
cells O +
with O +
phytohemagglutinin O +
and O +
active O +
phorbolester O +
and O +
upon O +
expression O +
of O +
tax1 O +
, O +
a O +
transactivating O +
protein O +
of O +
the O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
. O +

The O +
same O +
agents O +
induce O +
transcription O +
from O +
the O +
interleukin-2 O +
receptor O +
alpha O -
- O -
chain O +
and O +
interleukin-2 O +
genes O +
, O +
depending O +
on O +
promoter O +
elements O +
that O +
bind O +
the O +
inducible O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
( O +
or O +
an O +
NF O -
- O -
kappa O +
B O -
- O -
like O +
factor O +
) O +
. O +

We O +
therefore O +
tested O +
the O +
possibility O +
that O +
the O +
GM O -
- O -
CSF O +
gene O +
is O +
also O +
regulated O +
by O +
a O +
cognate O +
motif O +
for O +
the O +
NF O -
- O -
kappa O +
B O +
transcription O +
factor O +
. O +

A O +
recent O +
functional O +
analysis O +
by O +
Miyatake O +
et O +
al. O +
( O +
S. O +
Miyatake O +
, O +
M. O +
Seiki O +
, O +
M. O +
Yoshida O +
, O +
and O +
K. O +
Arai O +
, O +
Mol O -
. O +
Cell O -
. O +
Biol O -
. O +
8 O +
: O +
5581 O -
- O -
5587 O +
, O +
1988 O +
) O +
described O +
a O +
short O +
promoter O +
region O +
in O +
the O +
GM O -
- O -
CSF O +
gene O +
that O +
conferred O +
strong O +
inducibility O +
by O +
T O -
- O -
cell O -
- O -
activating O +
signals O +
and O +
tax1 O +
, O +
but O +
no O +
NF O -
- O -
kappa O +
B O -
- O -
binding O +
motifs O +
were O +
identified O +
. O +

Using O +
electrophoretic O +
mobility O +
shift O +
assays O +
, O +
we O +
showed O +
binding O +
of O +
purified O +
human O +
NF O -
- O -
kappa O +
B O +
and O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
activated O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
to O +
an O +
oligonucleotide O +
comprising O +
the O +
GM O -
- O -
CSF O +
promoter O +
element O +
responsible O +
for O +
mediating O +
responsiveness O +
to O +
T O -
- O -
cell O -
- O -
activating O +
signals O +
and O +
tax1 O +
. O +

As O +
shown O +
by O +
a O +
methylation O +
interference O +
analysis O +
and O +
oligonucleotide O +
competition O +
experiments O +
, O +
purified O +
NF O -
- O -
kappa O +
B O +
binds O +
at O +
positions O +
-82 O +
to O +
-91 O +
( O +
GGGAACTACC O +
) O +
of O +
the O +
GM O -
- O -
CSF O +
promoter O +
sequence O +
with O +
an O +
affinity O +
similar O +
to O +
that O +
with O +
which O +
it O +
binds O +
to O +
the O +
biologically O +
functional O +
kappa O +
B O +
motif O +
in O +
the O +
beta O +
interferon O +
promoter O +
( O +
GGGAAATTCC O +
) O +
. O +

Two O +
kappa O +
B O -
- O -
like O +
motifs O +
at O +
positions O +
-98 O +
to O +
-108 O +
of O +
the O +
GM O -
- O -
CSF O +
promoter O +
were O +
also O +
recognized O +
but O +
with O +
much O +
lower O +
affinities O +
. O +

Our O +
data O +
provide O +
strong O +
evidence O +
that O +
the O +
expression O +
of O +
the O +
GM O -
- O -
CSF O +
gene O +
following O +
T O -
- O -
cell O +
activation O +
is O +
controlled O +
by O +
binding O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
transcription O +
factor O +
to O +
a O +
high O -
- O -
affinity O +
binding O +
site O +
in O +
the O +
GM O -
- O -
CSF O +
promoter O +
. O +

Octamer O +
transcription O +
factors O +
and O +
the O +
cell O +
type O -
- O -
specificity O +
of O +
immunoglobulin O +
gene O +
expression O +
. O +

Antibodies O +
are O +
produced O +
exclusively O +
in O +
B O +
lymphocytes O +
. O +

The O +
expression O +
of O +
the O +
antibody O -
- O -
encoding O +
genes O +
, O +
the O +
immunoglobulin O +
( O +
Ig O +
) O +
genes O +
, O +
is O +
also O +
restricted O +
to O +
B O +
cells O +
. O +

The O +
octamer O +
sequence O +
ATGCAAAT O +
is O +
present O +
in O +
the O +
promoter O +
and O +
the O +
enhancer O +
of O +
Ig O +
genes O +
, O +
and O +
plays O +
an O +
important O +
role O +
in O +
its O +
tissue O -
- O -
specific O +
expression O +
. O +

This O +
sequence O +
motif O +
is O +
a O +
binding O +
site O +
for O +
nuclear O +
proteins O +
, O +
the O +
so O -
- O -
called O +
octamer O +
transcription O +
factors O +
( O +
Oct O +
or O +
OTF O +
factors O +
) O +
. O +

The O +
Oct-1 O +
protein O +
is O +
present O +
in O +
all O +
cell O +
types O +
analyzed O +
so O +
far O +
, O +
whereas O +
Oct-2A O +
and O +
Oct-2B O +
are O +
found O +
mainly O +
in O +
B O +
lymphocytes O +
. O +

All O +
three O +
proteins O +
show O +
the O +
same O +
sequence O +
specificity O +
and O +
binding O +
affinity O +
. O +

It O +
appears O +
that O +
the O +
B O +
cell O -
- O -
specific O +
expression O +
of O +
Ig O +
genes O +
is O +
mediated O +
at O +
least O +
in O +
part O +
by O +
cell O +
type O -
- O -
specific O +
Oct O +
factors O +
, O +
and O +
that O +
there O +
are O +
both O +
quantitative O +
and O +
qualitative O +
differences O +
between O +
Oct-1 O +
and O +
Oct-2 O +
factors O +
. O +

Recently O +
, O +
a O +
number O +
of O +
other O +
octamer O +
factor O +
variants O +
were O +
identified O +
. O +

Many O +
of O +
these O +
may O +
be O +
created O +
by O +
alternative O +
splicing O +
of O +
a O +
primary O +
transcript O +
of O +
one O +
Oct O +
factor O +
gene O +
and O +
may O +
serve O +
a O +
specific O +
function O +
in O +
the O +
fine O +
tuning O +
of O +
gene O +
expression O +
. O +

Steroid O +
mediated O +
lysis O +
of O +
lymphoblasts O +
requires O +
the O +
DNA O +
binding O +
region O +
of O +
the O +
steroid O +
hormone O +
receptor O +
. O +

Glucocorticoids O +
kill O +
certain O +
types O +
of O +
lymphoblasts O +
, O +
but O +
the O +
mechanisms O +
are O +
unknown O +
. O +

It O +
is O +
clear O +
that O +
sufficient O +
numbers O +
of O +
functional O +
glucocorticoid O +
receptors O +
are O +
required O +
to O +
mediate O +
lysis O +
, O +
but O +
whether O +
they O +
do O +
so O +
through O +
the O +
classical O +
model O +
of O +
steroid O +
hormone O +
activation O +
and O +
modulation O +
of O +
gene O +
expression O +
has O +
not O +
been O +
established O +
. O +

In O +
this O +
report O +
we O +
have O +
asked O +
which O +
region O +
( O +
s O +
) O +
of O +
the O +
steroid O +
receptor O +
are O +
important O +
for O +
mediating O +
lysis O +
in O +
leukemic O +
T O +
lymphoblasts O +
. O +

CEM B-CellLine -
- I-CellLine -
ICR I-CellLine +
27 I-CellLine +
leukemic I-CellLine +
lymphoblasts I-CellLine +
, O +
a O +
clone O +
of O +
CEM B-CellLine +
cells I-CellLine +
which O +
lack O +
functional O +
glucocorticoid O +
receptors O +
and O +
therefore O +
are O +
neither O +
lysed O +
by O +
dexamethasone O +
nor O +
capable O +
of O +
showing O +
glutamine O +
synthetase O +
induction O +
, O +
were O +
provided O +
with O +
steroid O +
receptors O +
by O +
DNA O +
transfections O +
of O +
various O +
receptor O +
gene O +
constructs O +
. O +

We O +
measured O +
steroid O +
mediated O +
lysis O +
, O +
receptor O +
number O +
and O +
induction O +
of O +
glutamine O +
synthetase O +
in O +
the O +
transfected B-CellLine +
cells I-CellLine +
. O +

Our O +
results O +
provide O +
evidence O +
that O +
the O +
lysis O +
mechanism O +
in O +
the O +
ICR27 B-CellLine +
lymphoblasts I-CellLine +
is O +
restored O +
when O +
functional O +
receptor O +
number O +
is O +
restored O +
. O +

The O +
DNA O +
binding O +
region O +
specifying O +
high O +
affinity O +
for O +
GRE O +
sites O +
is O +
required O +
. O +

Lysis O +
is O +
mediated O +
by O +
any O +
steroid O +
that O +
allows O +
for O +
activation O +
of O +
the O +
receptor O +
containing O +
such O +
a O +
region O +
. O +

Our O +
data O +
support O +
the O +
view O +
that O +
steroid O -
- O -
mediated O +
cell O +
death O +
occurs O +
by O +
a O +
process O +
requiring O +
direct O +
interaction O +
of O +
steroid O -
- O -
receptor O +
complexes O +
with O +
the O +
genome O +
. O +

Tax O +
-independent O +
binding O +
of O +
multiple O +
cellular O +
factors O +
to O +
Tax O -
- O -
response O +
element O +
DNA O +
of O +
HTLV O -
- O -
I O +
. O +

The O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
promoter O +
contains O +
three O +
copies O +
of O +
imperfect O +
repeats O +
of O +
a O +
21-base O +
pair O +
sequence O +
designated O +
here O +
as O +
TRE O +
( O +
Tax O -
- O -
response O +
element O +
) O +
that O +
is O +
responsive O +
to O +
the O +
virally O +
encoded O +
transactivator O +
protein O +
Tax O +
. O +

We O +
have O +
identified O +
and O +
separated O +
four O +
nuclear O +
proteins O +
from O +
C81 O -
- O -
66 O -
- O -
45 O +
cells O +
, O +
an O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine +
immortalized I-CellLine +
Tax I-CellLine -
- I-CellLine -
expressing I-CellLine +
human I-CellLine +
T I-CellLine -
- I-CellLine -
lymphocyte I-CellLine +
line I-CellLine +
( O +
Salahuddin O +
et O +
al. O +
, O +
1983 O +
) O +
, O +
that O +
interact O +
with O +
the O +
TRE O -
- O -
DNA O +
, O +
none O +
of O +
which O +
are O +
identical O +
with O +
the O +
Tax O -
- O -
protein O +
. O +

The O +
proteins O +
identified O +
have O +
molecular O +
weights O +
of O +
about O +
32 O +
, O +
36 O +
to O +
42 O +
, O +
50 O +
and O +
110 O +
kD O +
. O +

Four O +
different O +
methods O +
were O +
used O +
to O +
identify O +
the O +
proteins O +
. O +

First O +
, O +
from O +
different O +
cell O +
lines O +
three O +
or O +
all O +
four O +
of O +
the O +
nuclear O +
proteins O +
were O +
specifically O +
cross O -
- O -
linked O +
by O +
UV O +
irradiation O +
to O +
the O +
radioactively O +
labeled O +
TRE O -
- O -
DNA O +
fragment O +
. O +

Second O +
, O +
TRE O -
- O -
DNA O +
binding O +
proteins O +
sedimented O +
through O +
a O +
glycerol O +
density O +
gradient O +
at O +
rates O +
corresponding O +
to O +
proteins O +
of O +
native O +
molecular O +
weights O +
of O +
35 O +
to O +
50 O +
kD O +
and O +
110 O +
kD O +
. O +

Third O +
, O +
only O +
the O +
50 O +
kD O +
protein O +
was O +
retained O +
on O +
a O +
biotinylated O +
DNA O -
- O -
streptavidin O +
matrix O +
when O +
the O +
DNA O +
fragment O +
contained O +
the O +
TRE O -
- O -
DNA O +
. O +

Fourth O +
, O +
extensive O +
purification O +
by O +
several O +
cycles O +
of O +
TRE O +
-DNA O +
affinity O +
chromatography O +
resulted O +
in O +
the O +
32 O +
, O +
36 O +
to O +
42 O +
and O +
110 O +
kD O +
proteins O +
and O +
to O +
less O +
extent O +
the O +
50 O +
kD O +
factor O +
. O +

Two O +
abundant O +
proteins O +
of O +
75 O +
and O +
80 O +
kD O +
were O +
competed O +
out O +
by O +
poly O +
[ O +
d O +
( O +
I O -
- O -
C O +
) O +
] O +
in O +
all O +
reactions O +
. O +

The O +
cAMP O -
- O -
response O +
element O +
CRE O +
, O +
TGACGTCA O +
, O +
present O +
in O +
the O +
21 O +
base O -
- O -
pair O +
sequence O +
, O +
appears O +
to O +
be O +
essential O +
for O +
specific O +
protein- O +
TRE O +
-DNA O +
interactions O +
because O +
mutation O +
of O +
the O +
two O +
G O +
's O +
destroys O +
this O +
complex O +
. O +

This O +
result O +
suggests O +
that O +
the O +
cAMP O +
response O +
element O +
binding O +
protein O +
, O +
CREB O +
, O +
is O +
involved O +
in O +
the O +
protein O -
- O -
TRE O -
- O -
DNA O +
complex O +
and O +
in O +
mediating O +
the O +
Tax O +
response O +
. O +

Megakaryocytic B-CellLine +
and I-CellLine +
erythrocytic I-CellLine +
lineages I-CellLine +
share O +
specific O +
transcription O +
factors O +
. O +

Erythroid O -
- O -
specific O +
genes O +
contain O +
binding O +
sites O +
for O +
NF O -
- O -
E1 O +
( O +
also O +
called O +
GF-1 O +
and O +
Eryf-1 O +
; O +
refs O +
1 O -
- O -
3 O +
respectively O +
) O +
, O +
the O +
principal O +
DNA O -
- O -
binding O +
protein O +
of O +
the O +
erythrocytic O +
lineage O +
. O +

NF O -
- O -
E1 O +
expression O +
seems O +
to O +
be O +
restricted O +
to O +
the O +
erythrocytic O +
lineage O +
. O +

A O +
closely O +
related O +
( O +
if O +
not O +
identical O +
) O +
protein O +
is O +
found O +
in O +
both O +
a O +
human B-CellLine +
megakaryocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
and O +
purified B-CellLine +
human I-CellLine +
megakaryocytes I-CellLine +
; O +
it O +
binds O +
to O +
promoter O +
regions O +
of O +
two O +
megakaryocytic O -
- O -
specific O +
genes O +
. O +

The O +
binding O +
sites O +
and O +
partial O +
proteolysis O +
profile O +
of O +
this O +
protein O +
are O +
indistinguishable O +
from O +
those O +
of O +
the O +
erythroid O +
protein O +
; O +
also O +
, O +
NF O -
- O -
E1 O +
messenger O +
RNA O +
is O +
the O +
same O +
size O +
in O +
both O +
the O +
megakaryocytic B-CellLine +
and I-CellLine +
erythroid I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Furthermore O +
, O +
point O +
mutations O +
that O +
abolish O +
binding O +
of O +
NF O -
- O -
E1 O +
result O +
in O +
a O +
70 O +
% O +
decrease O +
in O +
the O +
transcriptional O +
activity O +
of O +
a O +
megakaryocytic O -
- O -
specific O +
promoter O +
. O +

We O +
also O +
find O +
that O +
NF O -
- O -
E2 O +
, O +
another O +
trans O -
- O -
acting O +
factor O +
of O +
the O +
erythrocytic O +
lineage O +
, O +
is O +
present O +
in O +
megakaryocytes B-CellLine +
. O +

Transcriptional O +
effects O +
in O +
both O +
lineages O +
might O +
then O +
be O +
mediated O +
in O +
part O +
by O +
the O +
same O +
specific O +
trans O -
- O -
acting O +
factors O +
. O +

Our O +
data O +
strengthen O +
the O +
idea O +
of O +
a O +
close O +
association O +
between O +
the O +
erythrocytic B-CellLine +
and I-CellLine +
the I-CellLine +
megakaryocytic I-CellLine +
lineages I-CellLine +
and O +
could O +
also O +
explain O +
the O +
expression O +
of O +
markers O +
specific O +
to O +
the O +
erythrocytic O +
and O +
megakaryocytic O +
lineages O +
in O +
most O +
erythroblastic B-CellLine +
and I-CellLine +
megakaryoblastic I-CellLine +
permanent I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

A O +
new O +
member O +
of O +
the O +
leucine O +
zipper O +
class O +
of O +
proteins O +
that O +
binds O +
to O +
the O +
HLA O +
DR O +
alpha O +
promoter O +
. O +

Several O +
mutants O +
derived O +
from O +
transformed B-CellLine +
human I-CellLine +
B I-CellLine +
cell I-CellLine +
lines I-CellLine +
are O +
defective O +
in O +
expressing O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
class O +
II O +
genes O +
. O +

The O +
failure O +
to O +
express O +
a O +
class O +
II O +
gene O +
in O +
at O +
least O +
one O +
such O +
mutant B-CellLine +
line I-CellLine +
has O +
been O +
mapped O +
to O +
the O +
MHC O +
class O +
II O +
X O +
box O +
, O +
a O +
conserved O +
transcriptional O +
element O +
in O +
the O +
promoter O +
region O +
. O +

A O +
complementary O +
DNA O +
encoding O +
a O +
DNA O -
- O -
binding O +
protein O +
( O +
human O +
X O +
box O +
binding O +
protein O +
, O +
hXBP-1 O +
) O +
whose O +
target O +
is O +
the O +
human O +
DR O +
alpha O +
X O +
box O +
and O +
the O +
3 O +
' O +
flanking O +
region O +
has O +
now O +
been O +
cloned O +
. O +

This O +
complementary O +
DNA O +
encoded O +
a O +
protein O +
with O +
structural O +
similarities O +
to O +
the O +
c O -
- O -
jun O +
proto O -
- O -
oncogene O +
product O +
, O +
and O +
its O +
target O +
sequence O +
was O +
closely O +
related O +
to O +
the O +
palindromic O +
target O +
sequence O +
of O +
c O -
- O -
jun O +
. O +

Mutation O +
of O +
the O +
hXBP-1 O +
DNA O +
target O +
sequence O +
decreased O +
DR O +
alpha O +
promoter O +
activity O +
in O +
vivo O +
. O +

These O +
studies O +
suggest O +
that O +
the O +
hXBP-1 O +
protein O +
acts O +
as O +
a O +
transcription O +
factor O +
in O +
B O +
cells O +
. O +

Identification O +
of O +
a O +
novel O +
factor O +
that O +
interacts O +
with O +
an O +
immunoglobulin O +
heavy O -
- O -
chain O +
promoter O +
and O +
stimulates O +
transcription O +
in O +
conjunction O +
with O +
the O +
lymphoid O +
cell O -
- O -
specific O +
factor O +
OTF2 O +
. O +

The O +
tissue O -
- O -
specific O +
expression O +
of O +
the O +
MOPC O +
141 O +
immunoglobulin O +
heavy O -
- O -
chain O +
gene O +
was O +
studied O +
by O +
using O +
in O +
vitro O +
transcription O +
. O +

B O -
- O -
cell O -
- O -
specific O +
transcription O +
of O +
this O +
gene O +
was O +
dependent O +
on O +
the O +
octamer O +
element O +
5'-ATGCAAAG-3 O +
' O +
, O +
located O +
in O +
the O +
upstream O +
region O +
of O +
this O +
promoter O +
and O +
in O +
the O +
promoters O +
of O +
all O +
other O +
immunoglobulin O +
heavy- O +
and O +
light O -
- O -
chain O +
genes O +
. O +

The O +
interaction O +
of O +
purified O +
octamer O +
transcription O +
factors O +
1 O +
and O +
2 O +
( O +
OTF1 O +
and O +
OTF2 O +
) O +
with O +
the O +
MOPC O +
141 O +
promoter O +
was O +
studied O +
by O +
using O +
electrophoretic O +
mobility O +
shift O +
assays O +
and O +
DNase O +
I O +
footprinting O +
. O +

Purified O +
OTF1 O +
from O +
HeLa B-CellLine +
cells I-CellLine +
and O +
OTF1 O +
and O +
OTF2 O +
from O +
B O +
cells O +
bound O +
to O +
identical O +
sequences O +
within O +
the O +
heavy O -
- O -
chain O +
promoter O +
. O +

The O +
OTF O +
interactions O +
we O +
observed O +
extended O +
over O +
the O +
heptamer O +
element O +
5'-CTCAGGA-3 O +
' O +
, O +
and O +
it O +
seems O +
likely O +
that O +
the O +
binding O +
of O +
the O +
purified O +
factors O +
involves O +
cooperation O +
between O +
octamer O +
and O +
heptamer O +
sites O +
in O +
this O +
promoter O +
. O +

In O +
addition O +
to O +
these O +
elements O +
, O +
we O +
identified O +
a O +
second O +
regulatory O +
element O +
, O +
the O +
N O +
element O +
with O +
the O +
sequence O +
5'-GGAACCTCCCCC-3 O -
' O +
. O +

The O +
N O +
element O +
could O +
independently O +
mediate O +
low O +
levels O +
of O +
transcription O +
in O +
both O +
B O -
- O -
cell O +
and O +
HeLa O -
- O -
cell O +
extracts O +
, O +
and O +
, O +
in O +
conjunction O +
with O +
the O +
octamer O +
element O +
, O +
it O +
can O +
promote O +
high O +
levels O +
of O +
transcription O +
in O +
B O -
- O -
cell O +
extracts O +
. O +

The O +
N O +
element O +
bound O +
a O +
transcription O +
factor O +
, O +
NTF O +
, O +
that O +
is O +
ubiquitous O +
in O +
cell O -
- O -
type O +
distribution O +
, O +
and O +
NTF O +
was O +
distinct O +
from O +
any O +
of O +
the O +
previously O +
described O +
proteins O +
that O +
bind O +
to O +
similar O +
sequences O +
. O +

Based O +
on O +
these O +
results O +
, O +
we O +
propose O +
that O +
NTF O +
and O +
OTF2 O +
interactions O +
( O +
both O +
with O +
their O +
cognate O +
DNA O +
elements O +
and O +
possibly O +
at O +
the O +
protein O -
- O -
protein O +
level O +
) O +
may O +
be O +
critical O +
to O +
B O -
- O -
cell O -
- O -
specific O +
expression O +
and O +
that O +
these O +
interactions O +
provide O +
additional O +
pathways O +
for O +
regulating O +
gene O +
expression O +
. O +

1 O +
, O +
25 O +
( O +
OH O +
) O +
2D2 O +
production O +
by O +
T O +
lymphocytes O +
and O +
alveolar O +
macrophages O +
recovered O +
by O +
lavage O +
from O +
normocalcemic O +
patients O +
with O +
tuberculosis O +
. O +

To O +
compare O +
extra O -
- O -
renal O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
production O +
in O +
different O +
types O +
of O +
granulomatous O +
disease O +
, O +
and O +
to O +
identify O +
the O +
cell O +
types O +
responsible O +
, O +
we O +
have O +
evaluated O +
the O +
conversion O +
of O +
25 O +
( O +
OH O +
) O +
D3 O +
in O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
by O +
uncultured O +
cells O +
recovered O +
by O +
bronchoalveolar O +
lavage O +
and O +
blood O +
mononuclear O +
cells O +
from O +
normocalcemic O +
patients O +
with O +
sarcoidosis O +
and O +
tuberculosis O +
. O +

1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
was O +
produced O +
both O +
by O +
lavage O +
cells O +
( O +
12 O -
/ O -
12 O +
tuberculosis O +
patients O +
, O +
2 O -
/ O -
6 O +
sarcoidosis O +
patients O +
) O +
and O +
blood O +
mononuclear O +
cells O +
( O +
3 O -
/ O -
5 O +
tuberculosis O +
patients O +
, O +
0 O -
/ O -
3 O +
sarcoidosis O +
patients O +
) O +
from O +
patients O +
but O +
not O +
controls O +
, O +
but O +
significantly O +
greater O +
amounts O +
were O +
produced O +
by O +
lavage O +
cells O +
from O +
tuberculosis O +
patients O +
than O +
those O +
of O +
sarcoidosis O +
patients O +
( O +
P O +
less O +
than O +
0.001 O +
) O +
. O +

1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
production O +
by O +
lavage O +
cells O +
from O +
tuberculosis O +
patients O +
correlated O +
with O +
the O +
number O +
of O +
CD8 O -
+ O +
T O +
lymphocytes O +
present O +
but O +
not O +
other O +
cell O +
types O +
. O +

T O +
lymphocytes O +
appeared O +
to O +
be O +
an O +
important O +
source O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
production O +
, O +
since O +
purified O +
T O +
lymphocytes O +
from O +
all O +
patients O +
with O +
tuberculosis O +
produced O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
, O +
and O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
production O +
by O +
these O +
cells O +
correlated O +
closely O +
with O +
that O +
produced O +
by O +
unseparated O +
lavage O +
cells O +
. O +

Because O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
can O +
improve O +
the O +
capacity O +
of O +
macrophages O +
to O +
kill O +
mycobacteria O +
, O +
our O +
results O +
support O +
the O +
conclusion O +
that O +
macrophage O -
- O -
lymphocyte O +
interactions O +
, O +
mediated O +
at O +
least O +
in O +
part O +
by O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
, O +
may O +
be O +
an O +
important O +
component O +
of O +
a O +
successful O +
antituberculous O +
immune O +
response O +
. O +

Effects O +
of O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
on O +
the O +
human B-CellLine +
chronic I-CellLine +
myelogenous I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
RWLeu-4 B-CellLine +
. O +

The O +
effects O +
of O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
VD3 O +
) O +
on O +
proliferation O +
, O +
differentiation O +
, O +
and O +
macromolecular O +
synthesis O +
in O +
the O +
new O +
Philadelphia B-CellLine +
chromosome I-CellLine -
- I-CellLine -
positive I-CellLine +
chronic I-CellLine +
myelogenous I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
RWLeu-4 B-CellLine +
, O +
were O +
investigated O +
. O +

Binding O +
of O +
[ O +
3H O +
] O +
VD3 O +
was O +
saturable O +
, O +
with O +
approximately O +
2000 O -
- O -
3000 O +
sites O -
/ O -
cell O +
, O +
and O +
half O -
- O -
maximal O +
binding O +
occurring O +
at O +
0.21 O -
- O -
0.33 O +
nM O +
. O +

Treatment O +
of O +
RWLeu-4 B-CellLine +
cells I-CellLine +
with O +
VD3 O +
induced O +
24R O -
- O -
hydroxylase O +
activity O +
, O +
a O +
marker O +
of O +
vitamin O +
D3 O +
responsiveness O +
in O +
many O +
tissues O +
. O +

Exposure O +
of O +
RWLeu-4 B-CellLine +
cells I-CellLine +
to O +
VD3 O +
also O +
inhibited O +
proliferation O +
and O +
DNA O +
synthesis O +
with O +
a O +
50 O +
% O +
effective O +
dose O +
of O +
3.5 O -
- O -
10 O +
nM O +
within O +
72 O +
h O +
; O +
in O +
addition O +
, O +
protein O +
and O +
RNA O +
synthesis O +
were O +
inhibited O +
by O +
VD3 O +
treatment O +
. O +

Exposure O +
of O +
RWLeu-4 B-CellLine +
cells I-CellLine +
to O +
5 O +
nM O +
VD3 O +
for O +
72 O +
h O +
caused O +
50 O +
% O +
of O +
the O +
cells O +
to O +
differentiate O +
into O +
macrophage O -
/ O -
monocyte O +
type O +
cells O +
as O +
judged O +
by O +
nitroblue O +
tetrazolium O +
staining O +
and O +
adherence O +
to O +
plastic O +
. O +

Progressive O +
expression O +
of O +
cell O +
surface O +
maturation O -
- O -
specific O +
antigens O +
of O +
the O +
monocyte O -
/ O -
macrophage O +
lineage O +
was O +
induced O +
by O +
treatment O +
of O +
RWLeu-4 B-CellLine +
cells I-CellLine +
with O +
VD3 O +
for O +
24 O +
to O +
72 O +
h O +
at O +
doses O +
that O +
inhibited O +
cellular O +
proliferation O +
. O +

c O -
- O -
myc O +
RNA O +
, O +
which O +
is O +
constitutively O +
expressed O +
in O +
RWLeu-4 B-CellLine +
cells I-CellLine +
, O +
increased O +
after O +
0.5 O +
h O +
of O +
treatment O +
with O +
50 O +
nM O +
VD3 O +
and O +
then O +
rapidly O +
decreased O +
to O +
barely O +
detectable O +
levels O +
after O +
4 O +
h O +
of O +
treatment O +
. O +

Finally O +
, O +
the O +
in O +
vitro O +
tyrosine O +
kinase O +
activity O +
associated O +
with O +
the O +
p210bcr O -
- O -
abl O +
oncogene O +
product O +
was O +
decreased O +
approximately O +
50 O +
% O +
by O +
VD3 O +
treatment O +
. O +

Because O +
of O +
the O +
presence O +
of O +
a O +
functional O +
receptor O -
- O -
effector O +
system O +
for O +
VD3 O +
and O +
multiple O +
biological O +
responses O +
to O +
the O +
hormone O +
, O +
these O +
cells O +
provide O +
a O +
unique O +
model O +
system O +
with O +
which O +
to O +
probe O +
the O +
specific O +
effects O +
of O +
VD3 O +
on O +
cell O +
growth O +
and O +
differentiation O +
in O +
chronic O +
myelogenous O +
leukemia O +
. O +

Type O +
II O +
estrogen O +
binding O +
sites O +
in O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
: O +
variations O +
during O +
the O +
menstrual O +
cycle O +
. O +

We O +
have O +
previously O +
reported O +
that O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
contain O +
type O +
II O +
estrogen O +
binding O +
sites O +
( O +
type O +
II O +
EBS O +
) O +
. O +

In O +
this O +
study O +
, O +
the O +
fluctuations O +
of O +
type O +
II O +
EBS O +
during O +
the O +
menstrual O +
cycle O +
were O +
analyzed O +
in O +
6 O +
normally O +
menstruating O +
women O +
. O +

Approximately O +
3 O +
times O +
higher O +
levels O +
of O +
type O +
II O +
EBS O +
were O +
found O +
in O +
the O +
periovulatory O +
period O +
with O +
respect O +
to O +
both O +
follicular O +
and O +
luteal O +
phases O +
. O +

In O +
postmenopausal O +
women O +
the O +
mean O +
type O +
II O +
EBS O +
levels O +
were O +
similar O +
to O +
those O +
observed O +
in O +
the O +
follicular O +
phase O +
of O +
the O +
cycle O +
. O +

However O +
, O +
in O +
3 O +
postmenopausal O +
patients O +
a O +
short O +
course O +
of O +
estrogen O +
or O +
tamoxifen O +
resulted O +
in O +
a O +
marked O +
increase O +
of O +
type O +
II O +
EBS O +
levels O +
. O +

Tamoxifen O +
was O +
also O +
found O +
to O +
compete O +
with O +
17 O +
beta O -
- O -
estradiol O +
for O +
type O +
II O +
EBS O +
in O +
PBMC O +
, O +
although O +
to O +
a O +
lesser O +
extent O +
than O +
diethylstilbestrol O +
. O +

Lymphocyte B-CellLine +
cell I-CellLine +
lines I-CellLine +
from O +
vitamin O +
D O -
- O -
dependent O +
rickets O +
type O +
II O +
show O +
functional O +
defects O +
in O +
the O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
receptor O +
. O +

Lymphocyte B-CellLine +
cell I-CellLine +
lines I-CellLine +
were O +
established O +
from O +
five O +
patients O +
with O +
vitamin O +
D O -
- O -
dependent O +
rickets O +
, O +
type O +
II O +
( O +
VDDR O -
- O -
II O +
) O +
. O +

These O +
lines O +
were O +
established O +
by O +
infection O +
with O +
human O +
T O -
- O -
lymphotrophic O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
. O +

Binding O +
of O +
[ O +
3H O +
] O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
) O +
to O +
its O +
receptor O +
in O +
these O +
cell O +
lines O +
was O +
compared O +
to O +
binding O +
studies O +
using O +
a O +
T B-CellLine -
- I-CellLine -
lymphocyte I-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
S B-CellLine -
- I-CellLine -
LB1 I-CellLine +
) O +
from O +
a O +
normal O +
individual O +
. O +

The O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
of O +
S B-CellLine -
- I-CellLine -
LB1 I-CellLine +
was O +
comparable O +
to O +
the O +
well O -
- O -
characterized O +
chick O +
intestinal O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
in O +
terms O +
of O +
its O +
ligand O +
binding O +
affinity O +
and O +
capacity O +
, O +
its O +
mobility O +
on O +
5 O -
- O -
20 O +
% O +
sucrose O +
gradients O +
, O +
and O +
its O +
adsorption O +
to O +
and O +
elution O +
properties O +
from O +
DNA O -
- O -
cellulose O +
. O +

Three O +
cell B-CellLine +
lines I-CellLine +
established O +
from O +
patients O +
with O +
VDDR O -
- O -
II O +
( O +
Rh- O +
VDR O +
, O +
Sh- O +
VDR O +
, O +
and O +
Ab- O +
VDR O +
) O +
showed O +
no O +
specific O +
binding O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
to O +
a O +
receptor O +
and O +
treatment O +
of O +
the O +
cultured B-CellLine +
cells I-CellLine +
with O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
did O +
not O +
stimulate O +
production O +
of O +
24 O +
, O +
25-dihydroxy O -
- O -
vitamin O +
D3 O +
( O +
24 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
) O +
, O +
a O +
response O +
which O +
is O +
diagnostic O +
of O +
the O +
presence O +
of O +
a O +
functional O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
. O +

In O +
a O +
fourth O +
cell B-CellLine +
line I-CellLine +
, O +
A1-VDR B-CellLine +
, O +
the O +
receptor O +
for O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
had O +
a O +
low O +
binding O +
capacity O +
and O +
25 O +
( O +
OH O +
) O +
D3 O -
- O -
24-hydroxylase O +
activity O +
was O +
not O +
detectable O +
. O +

Induction O +
of O +
24 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
synthesis O +
by O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
was O +
observed O +
in O +
the O +
fifth O +
cell B-CellLine +
line I-CellLine +
, O +
designated O +
Ro B-CellLine -
- I-CellLine -
VDR I-CellLine +
, O +
although O +
the O +
sensitivity O +
to O +
hormone O +
treatment O +
was O +
lower O +
than O +
in O +
the O +
control B-CellLine +
cell I-CellLine +
line I-CellLine +
from O +
a O +
normal O +
donor O +
. O +

The O +
capacity O +
of O +
the O +
receptor O +
for O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
was O +
low O +
in O +
Ro B-CellLine -
- I-CellLine -
VDR I-CellLine +
. O +

In O +
all O +
cell B-CellLine +
lines I-CellLine +
where O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
binding O +
to O +
a O +
receptor O +
was O +
detectable O +
, O +
the O +
receptor O +
had O +
the O +
typical O +
sedimentation O +
coefficient O +
of O +
3.7 O +
S O +
on O +
sucrose O +
density O +
gradient O +
analysis O +
. O +

Binding O +
and O +
elution O +
properties O +
to O +
DNA O -
- O -
cellulose O +
, O +
however O +
, O +
differed O +
from O +
normal O +
in O +
both O +
Ro B-CellLine -
- I-CellLine -
VDR I-CellLine +
and O +
A1-VDR B-CellLine +
cells I-CellLine +
where O +
elution O +
from O +
DNA O -
- O -
cellulose O +
occurred O +
at O +
a O +
lower O +
salt O +
concentration O +
than O +
is O +
typical O +
of O +
the O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
. O +

While O +
Ro B-CellLine -
- I-CellLine -
VDR I-CellLine +
cells I-CellLine +
showed O +
typical O +
nuclear O +
localization O +
of O +
the O +
unoccupied O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
, O +
neither O +
the O +
unoccupied O +
nor O +
the O +
occupied O +
receptor O +
from O +
A1-VDR B-CellLine +
cells I-CellLine +
was O +
completely O +
localized O +
in O +
the O +
nucleus O +
. O +

In O +
a O +
series O +
of O +
functional O +
studies O +
we O +
found O +
that O +
modulation O +
of O +
the O +
level O +
of O +
the O +
mRNAs O +
coding O +
for O +
both O +
the O +
c O -
- O -
myc O +
oncogene O +
and O +
the O +
growth O +
factor O +
known O +
as O +
granulocyte O -
- O -
monocyte O +
colony O +
stimulating O +
activity O +
by O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
correlated O +
with O +
the O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
status O +
of O +
these O +
cells O +
. O +

Use O +
of O +
these O +
cell B-CellLine +
lines I-CellLine +
will O +
facilitate O +
further O +
study O +
of O +
the O +
molecular O +
defect O +
( O +
s O +
) O +
in O +
the O +
receptor O +
for O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
in O +
vitamin O +
D O -
- O -
dependent O +
rickets O +
type O +
II O +
and O +
will O +
allow O +
a O +
correlation O +
with O +
impairment O +
of O +
cellular O +
functions O +
. O +

Heterogeneity O +
of O +
antigen O +
molecules O +
recognized O +
by O +
anti O -
- O -
tax1 O +
monoclonal O +
antibody O +
Lt-4 O +
in O +
cell O +
lines O +
bearing O +
human O +
T O +
cell O +
leukemia O +
virus O +
type O +
I O +
and O +
related O +
retroviruses O +
. O +

Using O +
a O +
monoclonal O +
antibody O +
, O +
Lt-4 O +
, O +
directed O +
against O +
human O +
T O +
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
trans O -
- O -
activator O +
( O +
tax1 O +
) O +
antigen O +
, O +
we O +
examined O +
the O +
expression O +
of O +
tax1 O +
and O +
related O +
antigens O +
in O +
a O +
variety O +
of O +
T B-CellLine +
cell I-CellLine +
lines I-CellLine +
bearing O +
HTLV O -
- O -
I O +
and O +
related O +
retroviruses O +
, O +
simian O +
T O +
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
STLV O -
- O -
I O +
) O +
and O +
HTLV O -
- O -
II O +
, O +
by O +
immunofluorescence O +
and O +
immunoblot O +
assays O +
. O +

Lt-4 O +
reacted O +
with O +
all O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine -
- I-CellLine -
bearing I-CellLine +
cell I-CellLine +
lines I-CellLine +
tested O +
and O +
five O +
out O +
of O +
eight O +
simian B-CellLine +
cell I-CellLine +
lines I-CellLine +
bearing O +
STLV O -
- O -
I O +
, O +
but O +
not O +
with O +
an O +
HTLV B-CellLine -
- I-CellLine -
II I-CellLine -
- I-CellLine -
bearing I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Lt-4 O +
detected O +
40 O +
kd O +
tax1 O +
antigen O +
molecules O +
in O +
most O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine -
- I-CellLine -
bearing I-CellLine +
cell I-CellLine +
lines I-CellLine +
except O +
one O +
cell O +
line O +
that O +
expressed O +
39 O +
kd O +
tax1 O +
antigen O +
. O +

In O +
the O +
STLV B-CellLine -
- I-CellLine -
I I-CellLine -
- I-CellLine -
bearing I-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
tax1-related O +
antigen O +
molecules O +
detected O +
by O +
Lt-4 O +
were O +
heterogeneous O +
, O +
having O +
molecular O +
weights O +
in O +
the O +
range O +
of O +
36 O -
- O -
41 O +
kd O +
. O +

The O +
expression O +
of O +
c O -
- O -
fos O +
, O +
c O -
- O -
jun O +
, O +
and O +
c O -
- O -
myc O +
genes O +
is O +
regulated O +
by O +
heat O +
shock O +
in O +
human O +
lymphoid O +
cells O +
. O +

The O +
effect O +
of O +
heat O +
shock O +
on O +
the O +
expression O +
of O +
the O +
nuclear O +
protooncogenes O +
c O -
- O -
fos O +
, O +
c O -
- O -
jun O +
, O +
and O +
c O -
- O -
myc O +
was O +
studied O +
in O +
human O +
lymphoid O +
cells O +
. O +

Heat O +
shock O +
caused O +
an O +
increase O +
in O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
mRNA O +
levels O +
and O +
a O +
decrease O +
in O +
c O -
- O -
myc O +
mRNA O +
levels O +
in O +
pre B-CellLine -
- I-CellLine -
B I-CellLine +
( I-CellLine +
Hyon I-CellLine +
) I-CellLine +
and I-CellLine +
T I-CellLine +
( I-CellLine +
DND-41 I-CellLine +
) I-CellLine +
cell I-CellLine +
lines I-CellLine +
as O +
well O +
as O +
in O +
freshly O +
isolated O +
normal O +
human O +
thymocytes O +
. O +

The O +
changes O +
in O +
the O +
mRNA O +
levels O +
of O +
these O +
protooncogenes O +
in O +
Hyon B-CellLine +
cells I-CellLine +
were O +
most O +
pronounced O +
at O +
42 O +
and O +
43 O +
degrees O +
C O +
; O +
kinetic O +
analysis O +
demonstrated O +
that O +
the O +
changes O +
could O +
be O +
detected O +
within O +
30 O +
min O +
of O +
heat O +
shock O +
. O +

Altered O +
transcription O +
of O +
c O -
- O -
fos O +
and O +
c O -
- O -
myc O +
genes O +
was O +
the O +
primary O +
effect O +
of O +
heat O +
shock O +
. O +

Secondarily O +
, O +
heat O +
shock O +
of O +
Hyon B-CellLine +
cells I-CellLine +
stabilized O +
the O +
c O -
- O -
myc O +
mRNA O +
level O +
by O +
increasing O +
its O +
half O -
- O -
life O +
from O +
24 O +
to O +
45 O +
min O +
. O +

The O +
overall O +
effect O +
of O +
heat O +
shock O +
on O +
c O -
- O -
myc O +
mRNA O +
level O +
, O +
however O +
, O +
was O +
a O +
marked O +
inhibition O +
of O +
its O +
transcription O +
. O +

These O +
results O +
demonstrate O +
that O +
the O +
transcription O +
of O +
nuclear O +
protooncogenes O +
is O +
regulated O +
by O +
heat O +
shock O +
indicating O +
a O +
role O +
for O +
nuclear O +
protooncogenes O +
in O +
the O +
stress O +
response O +
of O +
lymphoid O +
cells O +
. O +

A O +
novel O +
T O -
- O -
cell O +
protein O +
which O +
recognizes O +
a O +
palindromic O +
sequence O +
in O +
the O +
negative O +
regulatory O +
element O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
long O +
terminal O +
repeat O +
. O +

Two O +
major O +
protein O -
- O -
binding O +
sites O +
within O +
the O +
negative O +
regulatory O +
element O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
long O +
terminal O +
repeat O +
have O +
been O +
identified O +
. O +

One O +
( O +
site O +
B O +
) O +
contained O +
a O +
palindromic O +
sequence O +
with O +
homology O +
to O +
steroid O -
/ O -
thyroid O +
hormone O +
response O +
elements O +
but O +
was O +
distinct O +
from O +
previously O +
described O +
binding O +
sites O +
of O +
this O +
class O +
. O +

A O +
novel O +
T O -
- O -
cell O +
protein O +
recognized O +
the O +
palindromic O +
sequence O +
within O +
site O +
B O +
and O +
also O +
bound O +
estrogen- O +
or O +
thyroid O +
hormone O -
- O -
response O +
elements O +
with O +
lower O +
affinity O +
. O +

A O +
7-base O -
- O -
pair O +
mutation O +
in O +
the O +
site O +
B O +
palindrome O +
, O +
which O +
destroyed O +
protein O +
binding O +
, O +
resulted O +
in O +
increased O +
expression O +
from O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
long O +
terminal O +
repeat O +
in O +
T O +
cells O +
. O +

Epstein O -
- O -
Barr O +
virus O +
nuclear O +
antigen O +
2 O +
transactivates O +
latent O +
membrane O +
protein O +
LMP1 O +
. O +

Several O +
lines O +
of O +
evidence O +
are O +
compatible O +
with O +
the O +
hypothesis O +
that O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
nuclear O +
antigen O +
2 O +
( O +
EBNA-2 O +
) O +
or O +
leader O +
protein O +
( O +
EBNA O -
- O -
LP O +
) O +
affects O +
expression O +
of O +
the O +
EBV O +
latent O +
infection O +
membrane O +
protein O +
LMP1 O +
. O +

We O +
now O +
demonstrate O +
the O +
following O +
. O +

( O +
i O +
) O +
Acute O +
transfection O +
and O +
expression O +
of O +
EBNA-2 O +
under O +
control O +
of O +
simian O +
virus O +
40 O +
or O +
Moloney O +
murine O +
leukemia O +
virus O +
promoters O +
resulted O +
in O +
increased O +
LMP1 O +
expression O +
in O +
P3HR-1-infected B-CellLine +
Burkitt I-CellLine +
's I-CellLine +
lymphoma I-CellLine +
cells I-CellLine +
and O +
the O +
P3HR-1 B-CellLine +
or O +
Daudi B-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

( O +
ii O +
) O +
Transfection O +
and O +
expression O +
of O +
EBNA O -
- O -
LP O +
alone O +
had O +
no O +
effect O +
on O +
LMP1 O +
expression O +
and O +
did O +
not O +
act O +
synergistically O +
with O +
EBNA-2 O +
to O +
affect O +
LMP1 O +
expression O +
. O +

( O +
iii O +
) O +
LMP1 O +
expression O +
in O +
Daudi B-CellLine +
and O +
P3HR-1-infected B-CellLine +
cells I-CellLine +
was O +
controlled O +
at O +
the O +
mRNA O +
level O +
, O +
and O +
EBNA-2 O +
expression O +
in O +
Daudi B-CellLine +
cells I-CellLine +
increased O +
LMP1 O +
mRNA O +
. O +

( O +
iv O +
) O +
No O +
other O +
EBV O +
genes O +
were O +
required O +
for O +
EBNA-2 O +
transactivation O +
of O +
LMP1 O +
since O +
cotransfection O +
of O +
recombinant O +
EBNA-2 O +
expression O +
vectors O +
and O +
genomic O +
LMP1 O +
DNA O +
fragments O +
enhanced O +
LMP1 O +
expression O +
in O +
the O +
EBV B-CellLine -
- I-CellLine -
negative I-CellLine +
B I-CellLine -
- I-CellLine -
lymphoma I-CellLine +
cell I-CellLine +
lines I-CellLine +
BJAB B-CellLine +
, O +
Louckes B-CellLine +
, O +
and O +
BL30 B-CellLine +
. O +

( O +
v O +
) O +
An O +
EBNA-2-responsive O +
element O +
was O +
found O +
within O +
the O +
-512 O +
to O +
+ O -
40 O +
LMP1 O +
DNA O +
since O +
this O +
DNA O +
linked O +
to O +
a O +
chloramphenicol O +
acetyltransferase O +
reporter O +
gene O +
was O +
transactivated O +
by O +
cotransfection O +
with O +
an O +
EBNA-2 O +
expression O +
vector O +
. O +

( O +
vi O +
) O +
The O +
EBV O +
type O +
2 O +
EBNA-2 O +
transactivated O +
LMP1 O +
as O +
well O +
as O +
the O +
EBV O +
type O +
1 O +
EBNA-2 O +
. O +

( O +
vii O +
) O +
Two O +
deletions O +
within O +
the O +
EBNA-2 O +
gene O +
which O +
rendered O +
EBV O +
transformation O +
incompetent O +
did O +
not O +
transactivate O +
LMP1 O +
, O +
whereas O +
a O +
transformation O -
- O -
competent O +
EBNA-2 O +
deletion O +
mutant O +
did O +
transactivate O +
LMP1 O +
. O +

LMP1 O +
is O +
a O +
potent O +
effector O +
of O +
B O -
- O -
lymphocyte O +
activation O +
and O +
can O +
act O +
synergistically O +
with O +
EBNA-2 O +
to O +
induce O +
cellular O +
CD23 O +
gene O +
expression O +
. O +

Thus O +
, O +
EBNA-2 O +
transactivation O +
of O +
LMP1 O +
amplifies O +
the O +
biological O +
impact O +
of O +
EBNA-2 O +
and O +
underscores O +
its O +
central O +
role O +
in O +
EBV O -
- O -
induced O +
growth O +
transformation O +
. O +

Protein O +
kinase O +
inhibitor O +
H-7 O +
blocks O +
accumulation O +
of O +
unspliced O +
mRNA O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
. O +

Rex O +
, O +
the O +
post O -
- O -
transcriptional O +
regulator O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
, O +
is O +
known O +
to O +
induce O +
accumulation O +
of O +
the O +
unspliced O +
viral O +
gag O -
- O -
pol O +
mRNA O +
. O +

Rex O +
is O +
a O +
phosphoprotein O +
found O +
in O +
the O +
cell O +
nucleolus O +
, O +
whose O +
function O +
may O +
be O +
regulated O +
by O +
its O +
localization O +
and O +
phosphorylation O +
. O +

We O +
have O +
examined O +
the O +
role O +
of O +
phosphorylation O +
on O +
Rex O +
function O +
by O +
using O +
a O +
protein O +
kinase O +
inhibitor O +
, O +
H-7 O +
[ O +
1- O +
( O +
5-isoquinolinyl O -
- O -
sulfonyl O +
) O +
-2-methylpiperazine O +
] O +
. O +

Treatment O +
of O +
an O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine +
infected I-CellLine +
human I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
with O +
H-7 O +
blocked O +
specifically O +
accumulation O +
of O +
the O +
unspliced O +
gag O -
- O -
pol O +
mRNA O +
, O +
resulting O +
in O +
the O +
decreased O +
Gag O +
protein O +
synthesis O +
that O +
corresponds O +
with O +
the O +
decreased O +
in O +
vivo O +
phosphorylation O +
of O +
Rex O +
. O +

In O +
contrast O +
, O +
other O +
viral O +
and O +
cellular O +
products O +
have O +
not O +
been O +
influenced O +
by O +
the O +
level O +
of O +
H-7 O +
used O +
. O +

Therefore O +
, O +
the O +
phosphorylation O +
of O +
Rex O +
is O +
required O +
for O +
the O +
viral O +
RNA O +
partition O +
of O +
HTLV O -
- O -
I O +
. O +

Lipopolysaccharide O +
is O +
a O +
potent O +
monocyte O -
/ O -
macrophage O -
- O -
specific O +
stimulator O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
expression O +
. O +

Lipopolysaccharide O +
( O +
LPS O +
) O +
potently O +
stimulates O +
human O +
immunodeficiency O +
virus O +
type O +
1-long O +
terminal O +
repeat O +
( O +
HIV-1-LTR O +
) O +
CAT O +
constructs O +
transfected O +
into O +
monocyte B-CellLine -
/ I-CellLine -
macrophage I-CellLine -
- I-CellLine -
like I-CellLine +
cell I-CellLine +
lines I-CellLine +
but O +
not O +
a O +
T B-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

This O +
effect O +
appears O +
to O +
be O +
mediated O +
through O +
the O +
induction O +
of O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
demonstrate O +
that O +
LPS O +
induces O +
a O +
DNA O +
binding O +
activity O +
indistinguishable O +
from O +
NF O -
- O -
kappa O +
B O +
in O +
U937 B-CellLine +
and O +
THP-1 B-CellLine +
cells I-CellLine +
. O +

LPS O +
is O +
also O +
shown O +
to O +
dramatically O +
increase O +
HIV-1 O +
production O +
from O +
a O +
chronically B-CellLine +
infected I-CellLine +
monocyte I-CellLine -
/ I-CellLine -
macrophage I-CellLine -
- I-CellLine -
like I-CellLine +
cloned I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
U1 B-CellLine +
, O +
which O +
produces O +
very O +
low O +
levels O +
of O +
HIV-1 O +
at O +
baseline O +
. O +

The O +
stimulation O +
of O +
viral O +
production O +
from O +
this O +
cell O +
line O +
occurs O +
only O +
if O +
these O +
cells O +
are O +
treated O +
with O +
granulocyte O -
/ O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
before O +
treatment O +
with O +
LPS O +
. O +

This O +
stimulation O +
of O +
HIV-1 O +
production O +
is O +
correlated O +
with O +
an O +
increase O +
in O +
the O +
level O +
of O +
HIV-1 O +
RNA O +
and O +
and O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

LPS O +
is O +
not O +
able O +
to O +
induce O +
HIV-1 O +
production O +
in O +
a O +
cloned O +
T B-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

The O +
effect O +
of O +
LPS O +
on O +
HIV-1 O +
replication O +
occurs O +
at O +
picogram O +
per O +
milliliter O +
concentrations O +
and O +
may O +
be O +
clinically O +
significant O +
in O +
understanding O +
the O +
variability O +
of O +
the O +
natural O +
history O +
of O +
HIV-1 O +
infection O +
. O +

Stimulation O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
2 O +
( O +
HIV-2 O +
) O +
gene O +
expression O +
by O +
the O +
cytomegalovirus O +
and O +
HIV-2 O +
transactivator O +
gene O +
. O +

Human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
often O +
causes O +
latent O +
infection O +
. O +

Transactivation O +
by O +
some O +
DNA O +
viruses O +
has O +
been O +
implicated O +
in O +
inducing O +
HIV-1 O +
replication O +
and O +
pathogenesis O +
. O +

The O +
transactivator O +
( O +
IE-2 O +
) O +
gene O +
of O +
the O +
human O +
cytomegalovirus O +
( O +
CMV O +
) O +
can O +
enhance O +
HIV-2 O +
as O +
well O +
as O +
HIV-1 O +
gene O +
expression O +
in O +
vitro O +
. O +

This O +
inducer O +
can O +
act O +
in O +
concert O +
with O +
the O +
HIV-2 O +
tat O +
gene O +
and O +
T O -
- O -
cell O +
activation O +
in O +
enhancing O +
gene O +
expression O +
in O +
human O +
CD4 O -
+ O +
lymphocytes O +
. O +

While O +
the O +
HIV-2 O +
and O +
HIV-1 O +
tat O +
genes O +
and O +
T O -
- O -
cell O +
activators O +
apparently O +
employ O +
independent O +
modes O +
of O +
action O +
, O +
the O +
CMV O +
transactivator O +
in O +
combination O +
with O +
the O +
HIV-2 O +
tat O +
or O +
T O -
- O -
cell O +
activators O +
may O +
employ O +
a O +
gene O +
activation O +
pathway O +
with O +
some O +
common O +
and O +
some O +
distinct O +
components O +
. O +

Both O +
HIV-2 O +
and O +
CMV O +
transactivators O +
enhance O +
HIV-2 O +
gene O +
expression O +
by O +
transcriptional O +
activation O +
involving O +
transcript O +
initiation O +
as O +
well O +
as O +
elongation O +
, O +
with O +
CMV O +
transactivator O +
affecting O +
elongation O +
more O +
than O +
the O +
initiation O +
. O +

A O +
significant O +
proportion O +
of O +
transcripts O +
appear O +
to O +
terminate O +
prematurely O +
in O +
the O +
absence O +
of O +
transactivators O +
. O +

Deletion O +
mutation O +
analysis O +
of O +
the O +
HIV-2 O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
suggests O +
that O +
the O +
element O +
that O +
responds O +
to O +
CMV O +
transactivation O +
in O +
human O +
CD4 O -
+ O +
lymphocytes O +
is O +
either O +
a O +
diffuse O +
one O +
or O +
located O +
downstream O +
of O +
the O +
HIV-2 O +
enhancer O +
element O +
. O +

Sequence O -
- O -
specific O +
DNA O +
binding O +
of O +
the O +
proto O -
- O -
oncoprotein O +
ets-1 O +
defines O +
a O +
transcriptional O +
activator O +
sequence O +
within O +
the O +
long O +
terminal O +
repeat O +
of O +
the O +
Moloney O +
murine O +
sarcoma O +
virus O +
. O +

The O +
ets O +
proto O -
- O -
oncogene O +
family O +
is O +
a O +
group O +
of O +
sequence O -
- O -
related O +
genes O +
whose O +
normal O +
cellular O +
function O +
is O +
unknown O +
. O +

In O +
a O +
study O +
of O +
cellular O +
proteins O +
involved O +
in O +
the O +
transcriptional O +
regulation O +
of O +
murine O +
retroviruses O +
in O +
T O +
lymphocytes O +
, O +
we O +
have O +
discovered O +
that O +
a O +
member O +
of O +
the O +
ets O +
gene O +
family O +
encodes O +
a O +
sequence O -
- O -
specific O +
DNA O -
- O -
binding O +
protein O +
. O +

A O +
mouse O +
ets-1 O +
cDNA O +
clone O +
was O +
obtained O +
by O +
screening O +
a O +
mouse O +
thymus O +
cDNA O +
expression O +
library O +
with O +
a O +
double O -
- O -
stranded O +
oligonucleotide O +
probe O +
representing O +
20 O +
bp O +
of O +
the O +
Moloney O +
murine O +
sarcoma O +
virus O +
( O +
MSV O +
) O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
. O +

The O +
cDNA O +
sequence O +
has O +
an O +
813-bp O +
open O +
reading O +
frame O +
( O +
ORF O +
) O +
whose O +
predicted O +
amino O +
acid O +
sequence O +
is O +
97.6 O +
% O +
identical O +
to O +
the O +
272 O +
carboxy O -
- O -
terminal O +
amino O +
acids O +
of O +
the O +
human O +
ets-1 O +
protein O +
. O +

The O +
ORF O +
was O +
expressed O +
in O +
bacteria O +
, O +
and O +
the O +
30-kD O +
protein O +
product O +
was O +
shown O +
to O +
bind O +
DNA O +
in O +
a O +
sequence O -
- O -
specific O +
manner O +
by O +
mobility O -
- O -
shift O +
assays O +
, O +
Southwestern O +
blot O +
analysis O +
, O +
and O +
methylation O +
interference O +
. O +

A O +
mutant O +
LTR O +
containing O +
four O +
base O +
pair O +
substitutions O +
in O +
the O +
ets-1 O +
binding O +
site O +
was O +
constructed O +
and O +
was O +
shown O +
to O +
have O +
reduced O +
binding O +
in O +
vitro O +
. O +

Transcriptional O +
efficiency O +
of O +
the O +
MSV O +
LTR O +
promoter O +
containing O +
this O +
disrupted O +
ets-1 O +
binding O +
site O +
was O +
compared O +
to O +
the O +
activity O +
of O +
a O +
wild O -
- O -
type O +
promoter O +
in O +
mouse O +
T O +
lymphocytes O +
in O +
culture O +
, O +
and O +
15- O +
to O +
20-fold O +
reduction O +
in O +
expression O +
of O +
a O +
reporter O +
gene O +
was O +
observed O +
. O +

We O +
propose O +
that O +
ets-1 O +
functions O +
as O +
a O +
transcriptional O +
activator O +
of O +
mammalian O +
type O -
- O -
C O +
retroviruses O +
and O +
speculate O +
that O +
ets O -
- O -
related O +
genes O +
constitute O +
a O +
new O +
group O +
of O +
eukaryotic O +
DNA O -
- O -
binding O +
proteins O +
. O +

Cloning O +
of O +
a O +
transcriptionally O +
active O +
human O +
TATA O +
binding O +
factor O +
. O +

Transcription O +
factor O +
IID O +
( O +
TFIID O +
) O +
binds O +
to O +
the O +
TATA O +
box O +
promoter O +
element O +
and O +
regulates O +
the O +
expression O +
of O +
most O +
eukaryotic O +
genes O +
transcribed O +
by O +
RNA O +
polymerase O +
II O +
. O +

Complementary O +
DNA O +
( O +
cDNA O +
) O +
encoding O +
a O +
human O +
TFIID O +
protein O +
has O +
been O +
cloned O +
. O +

The O +
human O +
TFIID O +
polypeptide O +
has O +
339 O +
amino O +
acids O +
and O +
a O +
molecular O +
size O +
of O +
37 O +
, O +
745 O +
daltons O +
. O +

The O +
carboxyl O -
- O -
terminal O +
181 O +
amino O +
acids O +
of O +
the O +
human O +
TFIID O +
protein O +
shares O +
80 O +
% O +
identity O +
with O +
the O +
TFIID O +
protein O +
from O +
Saccharomyces O +
cerevisiae O +
. O +

The O +
amino O +
terminus O +
contains O +
an O +
unusual O +
repeat O +
of O +
38 O +
consecutive O +
glutamine O +
residues O +
and O +
an O +
X O -
- O -
Thr O -
- O -
Pro O +
repeat O +
. O +

Expression O +
of O +
DNA O +
in O +
reticulocyte O +
lysates O +
or O +
in O +
Escherichia O +
coli O +
yielded O +
a O +
protein O +
that O +
was O +
competent O +
for O +
both O +
DNA O +
binding O +
and O +
transcription O +
activation O +
. O +

The O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
BMRF1 O +
promoter O +
for O +
early O +
antigen O +
( O +
EA O -
- O -
D O +
) O +
is O +
regulated O +
by O +
the O +
EBV O +
transactivators O +
, O +
BRLF1 O +
and O +
BZLF1 O +
, O +
in O +
a O +
cell O -
- O -
specific O +
manner O +
. O +

The O +
Epstein O -
- O -
Barr O +
virus O +
early O +
antigen O +
diffuse O +
component O +
( O +
EA O -
- O -
D O +
) O +
is O +
essential O +
for O +
Epstein O -
- O -
Barr O +
virus O +
DNA O +
polymerase O +
activity O +
, O +
and O +
its O +
activity O +
is O +
suppressed O +
during O +
latent O +
infection O +
. O +

We O +
investigated O +
the O +
regulation O +
of O +
the O +
promoter O +
( O +
BMRF1 O +
) O +
for O +
this O +
early O +
gene O +
by O +
studying O +
its O +
responsiveness O +
in O +
vitro O +
to O +
two O +
immediate O -
- O -
early O +
viral O +
transactivators O +
, O +
BZLF1 O +
( O +
Z O +
) O +
and O +
BRLF1 O +
( O +
R O +
) O +
, O +
focusing O +
on O +
the O +
differences O +
in O +
response O +
in O +
lymphoid O +
cells O +
and O +
epithelial O +
cells O +
. O +

In O +
lymphoid O +
cells O +
, O +
Z O +
or O +
R O +
alone O +
produced O +
only O +
small O +
increases O +
in O +
EA O -
- O -
D O +
promoter O +
activity O +
, O +
whereas O +
both O +
transactivators O +
together O +
produced O +
a O +
large O +
stimulatory O +
effect O +
. O +

In O +
epithelial O +
cells O +
, O +
the O +
Z O +
transactivator O +
alone O +
produced O +
maximal O +
stimulation O +
of O +
the O +
EA O -
- O -
D O +
promoter O +
; O +
the O +
effect O +
of O +
R O +
and O +
Z O +
together O +
was O +
no O +
greater O +
than O +
that O +
of O +
Z O +
alone O +
. O +

Deletional O +
analysis O +
and O +
site O -
- O -
directed O +
mutagenesis O +
of O +
the O +
EA O -
- O -
D O +
promoter O +
demonstrated O +
that O +
in O +
epithelial O +
cells O +
the O +
potential O +
AP-1 O +
binding O +
site O +
plays O +
an O +
essential O +
role O +
in O +
Z O +
responsiveness O +
, O +
although O +
sequences O +
further O +
upstream O +
are O +
also O +
important O +
. O +

In O +
lymphoid O +
cells O +
, O +
only O +
the O +
upstream O +
sequences O +
are O +
required O +
for O +
transactivation O +
by O +
the O +
Z O -
/ O -
R O +
combination O +
, O +
and O +
the O +
AP-1 O +
site O +
is O +
dispensable O +
. O +

These O +
data O +
suggest O +
that O +
EA O -
- O -
D O +
( O +
BMRF1 O +
) O +
promoter O +
regulation O +
by O +
Z O +
and O +
R O +
is O +
cell O +
type O +
specific O +
and O +
appears O +
to O +
involve O +
different O +
mechanisms O +
in O +
each O +
cell O +
type O +
. O +

Inducible O +
nuclear O +
factor O +
binding O +
to O +
the O +
kappa O +
B O +
elements O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
enhancer O +
in O +
T O +
cells O +
can O +
be O +
blocked O +
by O +
cyclosporin O +
A O +
in O +
a O +
signal O -
- O -
dependent O +
manner O +
. O +

Cyclosporin O +
A O +
( O +
CsA O +
) O +
is O +
thought O +
to O +
exert O +
its O +
immunosuppressive O +
effects O +
by O +
inhibiting O +
the O +
expression O +
of O +
a O +
distinct O +
set O +
of O +
lymphokine O +
genes O +
which O +
are O +
induced O +
upon O +
T O -
- O -
cell O +
activation O +
, O +
among O +
them O +
the O +
gene O +
coding O +
for O +
interleukin-2 O +
. O +

In O +
addition O +
, O +
the O +
activation O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
is O +
partially O +
suppressed O +
. O +

To O +
better O +
understand O +
the O +
molecular O +
mechanisms O +
underlying O +
suppression O +
by O +
CsA O +
, O +
we O +
have O +
investigated O +
the O +
effects O +
of O +
this O +
drug O +
on O +
transcription O +
factors O +
in O +
T O +
cells O +
. O +

Here O +
we O +
report O +
that O +
the O +
formation O +
of O +
two O +
distinct O +
mitogen O -
- O -
inducible O +
DNA O -
- O -
binding O +
complexes O +
, O +
the O +
kappa O +
B O +
complex O +
within O +
the O +
HIV O +
enhancer O +
and O +
the O +
NFAT-1 O +
complex O +
within O +
the O +
interleukin-2 O +
enhancer O +
, O +
is O +
inhibited O +
in O +
the O +
presence O +
of O +
CsA O +
. O +

The O +
kappa O +
B O -
- O -
binding O +
activity O +
with O +
the O +
HIV O +
enhancer O +
is O +
inhibited O +
only O +
if O +
it O +
is O +
activated O +
via O +
the O +
mitogen O +
phytohemagglutinin O +
whereas O +
phorbol O +
myristate O +
acetate O -
- O -
mediated O +
activation O +
is O +
completely O +
insensitive O +
to O +
the O +
drug O +
. O +

This O +
suggests O +
a O +
model O +
in O +
which O +
functionally O +
indistinguishable O +
kappa O +
B O +
complexes O +
can O +
be O +
activated O +
via O +
two O +
separate O +
pathways O +
of O +
signal O +
transduction O +
distinguishable O +
by O +
CsA O +
. O +

Complementary O +
DNA O +
encoding O +
the O +
human O +
T O -
- O -
cell O +
FK506-binding O +
protein O +
, O +
a O +
peptidylprolyl O +
cis O -
- O -
trans O +
isomerase O +
distinct O +
from O +
cyclophilin O +
. O +

The O +
recently O +
discovered O +
macrolide O +
FK506 O +
has O +
been O +
demonstrated O +
to O +
have O +
potent O +
immunosuppressive O +
activity O +
at O +
concentrations O +
100-fold O +
lower O +
than O +
cyclosporin O +
A O +
, O +
a O +
cyclic O +
undecapeptide O +
that O +
is O +
used O +
to O +
prevent O +
rejection O +
after O +
transplantation O +
of O +
bone O +
marrow O +
and O +
organs O +
, O +
such O +
as O +
kidney O +
, O +
heart O +
, O +
and O +
liver O +
. O +

After O +
the O +
recent O +
discovery O +
that O +
the O +
cyclosporin O +
A O -
- O -
binding O +
protein O +
cyclophilin O +
is O +
identical O +
to O +
peptidylprolyl O +
cis O -
- O -
trans O +
isomerase O +
, O +
a O +
cellular O +
binding O +
protein O +
for O +
FK506 O +
was O +
found O +
to O +
be O +
distinct O +
from O +
cyclophilin O +
but O +
to O +
have O +
the O +
same O +
enzymatic O +
activity O +
. O +

In O +
this O +
study O +
, O +
we O +
isolated O +
a O +
cDNA O +
coding O +
for O +
FK506-binding O +
protein O +
( O +
FKBP O +
) O +
from O +
human O +
peripheral O +
blood O +
T O +
cells O +
by O +
using O +
mixed O +
20-mer O +
oligonucleotide O +
probes O +
synthesized O +
on O +
the O +
basis O +
of O +
the O +
sequence O +
, O +
Glu O -
- O -
Asp O -
- O -
Gly O -
- O -
Lys O -
- O -
Lys O -
- O -
Phe O -
- O -
Asp O +
, O +
reported O +
for O +
bovine O +
FKBP O +
. O +

The O +
DNA O +
isolated O +
contained O +
an O +
open O +
reading O +
frame O +
encoding O +
108 O +
amino O +
acid O +
residues O +
. O +

The O +
first O +
40 O +
residues O +
of O +
the O +
deduced O +
amino O +
acid O +
sequence O +
were O +
identical O +
to O +
those O +
of O +
the O +
reported O +
amino O -
- O -
terminal O +
sequence O +
of O +
bovine O +
FKBP O +
, O +
indicating O +
that O +
the O +
DNA O +
sequence O +
isolated O +
represents O +
the O +
gene O +
coding O +
for O +
FKBP O +
. O +

Computer O -
- O -
assisted O +
analysis O +
of O +
the O +
deduced O +
amino O +
acid O +
sequence O +
indicates O +
that O +
FKBP O +
exhibits O +
no O +
internal O +
homology O +
and O +
does O +
not O +
have O +
significant O +
sequence O +
similarity O +
to O +
any O +
other O +
amino O +
acid O +
sequences O +
of O +
known O +
proteins O +
, O +
including O +
cyclophilin O +
. O +

This O +
result O +
suggests O +
that O +
two O +
catalytically O +
similar O +
proteins O +
, O +
cyclophilin O +
and O +
FKBP O +
, O +
evolved O +
independently O +
. O +

In O +
Northern O +
blot O +
analysis O +
, O +
mRNA O +
species O +
of O +
approximately O +
1.8 O +
kilobases O +
that O +
hybridized O +
with O +
human O +
FKBP O +
cDNA O +
were O +
detected O +
in O +
poly O +
( O +
A O +
) O +
+ O +
RNAs O +
from O +
brain O +
, O +
lung O +
, O +
liver O +
, O +
and O +
placental O +
cells O +
and O +
leukocytes O +
. O +

Induction O +
of O +
Jurkat B-CellLine +
leukemic I-CellLine +
T I-CellLine +
cells I-CellLine +
with O +
phorbol O +
12-myristate O +
13-acetate O +
and O +
ionomycin O +
did O +
not O +
affect O +
the O +
level O +
of O +
FKBP O +
mRNA O +
. O +

Southern O +
blot O +
analysis O +
of O +
human O +
genomic O +
DNA O +
digested O +
with O +
different O +
restriction O +
enzymes O +
suggests O +
the O +
existence O +
of O +
only O +
a O +
few O +
copies O +
of O +
the O +
DNA O +
sequence O +
encoding O +
FKBP O +
. O +

This O +
is O +
in O +
contrast O +
to O +
the O +
result O +
that O +
as O +
many O +
as O +
20 O +
copies O +
of O +
the O +
cyclophilin O +
gene O +
and O +
possible O +
pseudogenes O +
may O +
be O +
present O +
in O +
the O +
mammalian O +
genome O +
. O +

The O +
56 O -
- O -
59-kilodalton O +
protein O +
identified O +
in O +
untransformed O +
steroid O +
receptor O +
complexes O +
is O +
a O +
unique O +
protein O +
that O +
exists O +
in O +
cytosol O +
in O +
a O +
complex O +
with O +
both O +
the O +
70- O +
and O +
90-kilodalton O +
heat O +
shock O +
proteins O +
. O +

It O +
has O +
previously O +
been O +
shown O +
that O +
9S O +
, O +
untransformed O +
progestin O +
, O +
estrogen O +
, O +
androgen O +
, O +
and O +
glucocorticoid O +
receptor O +
complexes O +
in O +
rabbit O +
uterine O +
and O +
liver O +
cytosols O +
contain O +
a O +
59-kDa O +
protein O +
[ O +
Tai O +
, O +
P.K. O +
, O +
Maeda O +
, O +
Y. O +
, O +
Nakao O +
, O +
K. O +
, O +
Wakim O +
, O +
N.G. O +
, O +
Duhring O +
, O +
J.L. O +
, O +
& O +
Faber O +
, O +
L.E. O +
( O +
1986 O +
) O +
Biochemistry O +
25 O +
, O +
5269 O -
- O -
5275 O +
] O +
. O +

In O +
this O +
work O +
we O +
show O +
that O +
the O +
monoclonal O +
antibody O +
KN O +
382 O -
/ O -
EC1 O +
raised O +
against O +
the O +
rabbit O +
59-kDa O +
protein O +
reacts O +
with O +
9S O +
, O +
untransformed O +
glucocorticoid O +
receptor O +
complexes O +
in O +
cytosol O +
prepared O +
from O +
human B-CellLine +
IM-9 I-CellLine +
lymphocytes I-CellLine +
but O +
not O +
with O +
4S O +
salt O -
- O -
transformed O +
receptors O +
. O +

The O +
human O +
protein O +
recognized O +
by O +
the O +
EC1 O +
antibody O +
is O +
a O +
56-kDa O +
protein O +
( O +
p56 O +
) O +
of O +
moderate O +
abundance O +
located O +
predominantly O +
in O +
the O +
cytoplasm O +
by O +
indirect O +
immunofluorescence O +
. O +

There O +
are O +
at O +
least O +
six O +
isomorphs O +
of O +
p56 O +
by O +
two O -
- O -
dimensional O +
gel O +
analysis O +
. O +

N O -
- O -
Terminal O +
sequencing O +
( O +
20 O +
amino O +
acids O +
) O +
shows O +
that O +
p56 O +
is O +
a O +
unique O +
human O +
protein O +
. O +

When O +
p56 O +
is O +
immunoadsorbed O +
from O +
IM-9 B-CellLine +
cell I-CellLine +
cytosol O +
, O +
both O +
the O +
70- O +
and O +
90-kDa O +
heat O +
shock O +
proteins O +
are O +
coadsorbed O +
in O +
an O +
immune O -
- O -
specific O +
manner O +
. O +

Neither O +
heat O +
shock O +
protein O +
reacts O +
directly O +
with O +
the O +
EC1 O +
antibody O +
. O +

We O +
conclude O +
that O +
p56 O +
exists O +
in O +
cytosol O +
in O +
a O +
higher O +
order O +
complex O +
containing O +
hsp70 O +
and O +
hsp90 O +
, O +
both O +
of O +
which O +
in O +
turn O +
have O +
been O +
found O +
to O +
be O +
associated O +
with O +
untransformed O +
steroid O +
receptors O +
. O +

A O +
novel O +
B O -
- O -
cell O +
lineage O -
- O -
specific O +
transcription O +
factor O +
present O +
at O +
early O +
but O +
not O +
late O +
stages O +
of O +
differentiation O +
. O +

A O +
novel O +
B O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
, O +
BSAP O +
, O +
was O +
identified O +
as O +
a O +
mammalian O +
homolog O +
of O +
the O +
sea O +
urchin O +
protein O +
TSAP O +
, O +
which O +
interacts O +
with O +
the O +
promoters O +
of O +
four O +
tissue O -
- O -
specific O +
late O +
histone O +
H2A-2 O +
and O +
H2B-2 O +
genes O +
. O +

As O +
shown O +
by O +
mobility O -
- O -
shift O +
, O +
methylation O +
interference O +
, O +
and O +
mutational O +
analyses O +
, O +
the O +
mammalian O +
protein O +
BSAP O +
recognizes O +
all O +
four O +
sea O +
urchin O +
binding O +
sites O +
in O +
a O +
manner O +
indistinguishable O +
from O +
TSAP O +
; O +
however O +
, O +
the O +
two O +
proteins O +
differ O +
in O +
molecular O +
weight O +
. O +

BSAP O +
is O +
exclusively O +
restricted O +
to O +
the O +
B O -
- O -
cell O +
lineage O +
of O +
lymphoid O +
differentiation O +
. O +

Its O +
expression O +
appears O +
to O +
be O +
activated O +
during O +
pro O -
- O -
B O -
- O -
cell O +
development O +
, O +
is O +
abundant O +
at O +
the O +
pre O -
- O -
B- O +
and O +
mature O +
B O -
- O -
cell O +
stages O +
, O +
but O +
is O +
absent O +
in O +
terminally O +
differentiated O +
plasma O +
cells O +
. O +

Moreover O +
, O +
BSAP O +
is O +
clearly O +
a O +
B O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
, O +
as O +
a O +
wild O -
- O -
type O +
but O +
not O +
a O +
mutant O +
TSAP O -
- O -
binding O +
site O +
of O +
the O +
sea O +
urchin O +
functions O +
only O +
in O +
transfected B-CellLine +
B I-CellLine +
cells I-CellLine +
as O +
an O +
upstream O +
promoter O +
element O +
. O +

Competition O +
experiments O +
did O +
not O +
reveal O +
any O +
high O -
- O -
affinity O +
binding O +
site O +
for O +
BSAP O +
in O +
known O +
regulatory O +
regions O +
of O +
immunoglobulin O +
and O +
class O +
II O +
major O +
histocompatibility O +
( O +
MHC O +
) O +
genes O +
, O +
suggesting O +
that O +
BSAP O +
is O +
a O +
regulator O +
of O +
a O +
different O +
set O +
of O +
B O -
- O -
lymphoid O -
- O -
specific O +
genes O +
. O +

Nuclear O +
3 O +
, O +
5 O +
, O +
3'-triiodothyronine O +
receptors O +
( O +
T3R O +
) O +
of O +
circulating O +
human O +
lymphocytes O +
in O +
hyper- O +
and O +
hypothyroidism O +
and O +
nonthyroidal O +
diseases O +
. O +

The O +
clinical O +
implications O +
of O +
nuclear O +
T3R O +
alterations O +
of O +
circulating O +
lymphocytes O +
in O +
hyperthyroidism O +
, O +
hypothyroidism O +
and O +
nonthyroidal O +
diseases O +
were O +
investigated O +
. O +

Nuclear O +
T3R O +
in O +
lymphocytes O +
was O +
determined O +
by O +
radio O -
- O -
ligand O +
binding O +
analysis O +
. O +

The O +
results O +
showed O +
that O +
in O +
hyper- O +
and O +
hypothyroid O +
patients O +
the O +
nuclear O +
affinity O +
( O +
Ka O +
) O +
for O +
T3 O +
was O +
similar O +
to O +
that O +
of O +
normal O +
subjects O +
. O +

In O +
hyperthyroidism O +
nuclear O +
T3 O +
maximal O +
binding O +
capacity O +
( O +
MBC O +
) O +
was O +
unaltered O +
, O +
whereas O +
in O +
hypothyroidism O +
the O +
MBC O +
was O +
significantly O +
increased O +
. O +

In O +
the O +
patients O +
with O +
diabetes O +
mellitus O +
, O +
chronic O +
renal O +
failure O +
and O +
hepatic O +
cirrhosis O +
, O +
the O +
nuclear O +
T3R O +
MBC O +
of O +
lymphocytes O +
was O +
about O +
1.5 O -
- O -
1.6 O +
times O +
of O +
the O +
normal O +
controls O +
. O +

It O +
was O +
concluded O +
that O +
there O +
existed O +
hormonal O +
regulation O +
of O +
nuclear O +
T3R O +
, O +
and O +
up O -
- O -
regulation O +
was O +
seen O +
in O +
hypothyroidism O +
and O +
low O +
T3 O +
syndrome O +
. O +

Cell O +
type O +
specificity O +
and O +
activation O +
requirements O +
for O +
NFAT-1 O +
( O +
nuclear O +
factor O +
of O +
activated O +
T O -
- O -
cells O +
) O +
transcriptional O +
activity O +
determined O +
by O +
a O +
new O +
method O +
using O +
transgenic O +
mice O +
to O +
assay O +
transcriptional O +
activity O +
of O +
an O +
individual O +
nuclear O +
factor O +
. O +

Nuclear O +
factor O +
of O +
activated O +
T O -
- O -
cells O +
( O +
NFAT-1 O +
) O +
is O +
a O +
transcription O +
factor O +
which O +
is O +
considered O +
to O +
be O +
an O +
important O +
regulator O +
in O +
early O +
T O -
- O -
cell O +
activation O +
. O +

We O +
have O +
developed O +
a O +
system O +
to O +
monitor O +
the O +
transcriptional O +
activity O +
of O +
NFAT-1 O +
at O +
the O +
single O +
cell O +
level O +
in O +
whole O +
animals O +
. O +

The O +
system O +
is O +
based O +
on O +
the O +
use O +
of O +
an O +
oligomerized O +
NFAT-1 O +
binding O +
motif O +
that O +
directs O +
transcription O +
of O +
SV40 O +
T O -
- O -
antigen O +
in O +
transgenic O +
mice O +
. O +

This O +
report O +
represents O +
the O +
first O +
demonstration O +
that O +
a O +
multimerized O +
short O +
binding O +
motif O +
can O +
function O +
appropriately O +
in O +
transgenic O +
mice O +
. O +

NFAT-1 O +
activity O +
had O +
previously O +
been O +
thought O +
to O +
be O +
confined O +
to O +
activated O +
T O -
- O -
lymphocytes O +
upon O +
release O +
of O +
intracellular O +
calcium O +
. O +

By O +
targeting O +
NFAT-1 O +
-dependent O +
gene O +
expression O +
in O +
transgenic O +
mice O +
we O +
discovered O +
new O +
sites O +
of O +
NFAT-1 O +
activity O +
. O +

Besides O +
in O +
T O -
- O -
lymphocytes O +
NFAT-1 O +
activity O +
could O +
also O +
be O +
induced O +
in O +
T O -
- O -
lymphocyte O -
- O -
depleted O +
spleen O +
cells O +
and O +
purified O +
B O -
- O -
lymphocytes O +
and O +
requires O +
agents O +
that O +
both O +
release O +
intracellular O +
calcium O +
and O +
activate O +
protein O +
kinase O +
C O +
. O +

A O +
difference O +
in O +
the O +
time O +
course O +
of O +
appearance O +
of O +
NFAT-1 O +
activity O +
between O +
T O -
- O -
lymphocytes O +
and O +
non O -
- O -
T O -
- O -
lymphocytes O +
was O +
revealed O +
. O +

Constitutive O +
expression O +
was O +
observed O +
in O +
a O +
small O +
population O +
of O +
cells O +
in O +
the O +
dermis O +
and O +
some O +
mice O +
have O +
developed O +
skin O +
lesions O +
. O +

Interestingly O +
, O +
the O +
tissue O +
pattern O +
of O +
expression O +
of O +
the O +
NFAT-1 O +
activity O +
resembles O +
the O +
expression O +
pattern O +
described O +
for O +
HIV O -
- O -
LTR O -
/ O -
tat O +
transgenic O +
mice O +
( O +
Vogel O +
, O +
J. O +
, O +
Hinrichs O +
, O +
S. O +
H. O +
, O +
Reynolds O +
, O +
R. O +
K. O +
, O +
Luciw O +
, O +
P. O +
A. O +
, O +
and O +
Jay O +
, O +
G. O +
( O +
1988 O +
) O +
Nature O +
335 O +
, O +
606 O -
- O -
611 O +
) O +
. O +

This O +
similarity O +
in O +
expression O +
and O +
the O +
fact O +
that O +
NFAT-1 O +
has O +
been O +
shown O +
to O +
bind O +
functional O +
sequences O +
in O +
HIV O -
- O -
LTR O +
suggest O +
a O +
role O +
for O +
NFAT-1 O +
in O +
dermal O +
activation O +
of O +
the O +
HIV O -
- O -
LTR O +
. O +

Induction O +
of O +
immediate O +
early O +
response O +
genes O +
by O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
in O +
normal O +
human O +
monocytes O +
. O +

A O +
group O +
of O +
coordinately O +
induced O +
protooncogenes O +
, O +
cytoskeletal O +
, O +
and O +
extracellular O +
matrix O +
genes O +
have O +
been O +
termed O +
immediate O +
early O +
response O +
genes O +
, O +
and O +
their O +
induction O +
has O +
been O +
associated O +
with O +
growth O +
factor O +
-stimulated O +
cell O +
proliferation O +
. O +

We O +
have O +
investigated O +
the O +
induction O +
of O +
these O +
genes O +
by O +
macrophage O -
- O -
CSF O +
( O +
M O -
- O -
CSF O +
) O +
in O +
human O +
monocytes O +
that O +
do O +
not O +
proliferate O +
in O +
response O +
to O +
M O -
- O -
CSF O +
but O +
require O +
the O +
factor O +
for O +
optimal O +
cell O +
differentiation O +
. O +

Normal O +
human O +
monocytes O +
were O +
isolated O +
, O +
carefully O +
washed O +
, O +
and O +
incubated O +
for O +
36 O +
to O +
48 O +
h O +
in O +
fetal O +
bovine O +
serum O -
- O -
containing O +
medium O +
. O +

At O +
the O +
end O +
of O +
this O +
incubation O +
the O +
resting O +
cells O +
were O +
stimulated O +
with O +
M O -
- O -
CSF O +
, O +
and O +
RNA O +
was O +
isolated O +
for O +
analysis O +
by O +
Northern O +
blotting O +
. O +

RNA O +
from O +
control O +
resting O +
cells O +
contained O +
low O +
to O +
undetectable O +
levels O +
of O +
c O -
- O -
jun O +
, O +
fibronectin O +
receptor O +
, O +
and O +
actin O +
mRNA O +
. O +

Within O +
15 O +
to O +
30 O +
min O +
of O +
addition O +
of O +
M O -
- O -
CSF O +
, O +
however O +
, O +
there O +
was O +
a O +
dramatic O +
coordinate O +
induction O +
of O +
these O +
genes O +
. O +

The O +
c O -
- O -
jun O +
gene O +
expression O +
was O +
very O +
transient O +
and O +
was O +
not O +
detectable O +
by O +
60 O +
min O +
after O +
M O -
- O -
CSF O +
addition O +
. O +

In O +
contrast O +
, O +
the O +
expression O +
of O +
actin O +
and O +
fibronectin O +
receptor O +
mRNA O +
was O +
more O +
sustained O +
, O +
and O +
the O +
expression O +
of O +
these O +
genes O +
remained O +
elevated O +
at O +
24 O +
to O +
48 O +
h O +
after O +
M O -
- O -
CSF O +
addition O +
. O +

We O +
also O +
observed O +
the O +
induction O +
of O +
the O +
myelomonocytic O +
specific O +
tyrosine O +
kinase O +
hck O +
gene O +
simultaneously O +
with O +
the O +
other O +
immediate O +
early O +
response O +
genes O +
. O +

The O +
protein O +
synthesis O +
inhibitor O +
cycloheximide O +
did O +
not O +
block O +
the O +
induction O +
of O +
any O +
of O +
these O +
genes O +
, O +
and O +
in O +
fact O +
, O +
super O -
- O -
induced O +
the O +
expression O +
of O +
c O -
- O -
jun O +
and O +
hck O +
. O +

Nuclear O +
run O +
on O +
transcription O +
of O +
the O +
c O -
- O -
jun O +
, O +
hck O +
, O +
and O +
actin O +
genes O +
. O +

Therefore O +
, O +
in O +
normal O +
human O +
monocytes O +
M O -
- O -
CSF O +
induces O +
immediate O +
early O +
response O +
genes O +
without O +
inducing O +
cell O +
proliferation O +
. O +

These O +
genes O +
may O +
then O +
play O +
a O +
role O +
in O +
altering O +
the O +
physiologic O +
status O +
of O +
the O +
cells O +
in O +
response O +
to O +
CSF O +
. O +

Cell O -
- O -
specific O +
differences O +
in O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
regulatory O +
elements O +
of O +
human O +
immunodeficiency O +
virus O +
and O +
beta O +
interferon O +
promoters O +
by O +
tumor O +
necrosis O +
factor O +
. O +

Three O +
aspects O +
of O +
the O +
involvement O +
of O +
tumor O +
necrosis O +
factor O +
in O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
pathogenesis O +
were O +
examined O +
. O +

Tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
mRNA O +
production O +
was O +
analyzed O +
by O +
polymerase O +
chain O +
reaction O +
amplification O +
in O +
monocytic B-CellLine +
U937 I-CellLine +
cells I-CellLine +
and O +
in O +
a O +
chronically B-CellLine +
HIV I-CellLine +
infected I-CellLine +
U937 I-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
U9-IIIB B-CellLine +
) O +
. O +

TNF O -
- O -
alpha O +
RNA O +
was O +
undetectable O +
in O +
U937 B-CellLine +
cells I-CellLine +
, O +
whereas O +
a O +
low O +
constitutive O +
level O +
was O +
detected O +
in O +
U9-IIIB B-CellLine +
cells I-CellLine +
. O +

Paramyxovirus O +
infection O +
induced O +
a O +
5- O +
to O +
10-fold O +
increase O +
in O +
the O +
steady O -
- O -
state O +
level O +
of O +
TNF O -
- O -
alpha O +
RNA O +
in O +
U9-IIIB B-CellLine +
cells I-CellLine +
compared O +
with O +
U937 B-CellLine +
cells I-CellLine +
, O +
suggesting O +
that O +
HIV B-CellLine -
- I-CellLine -
infected I-CellLine +
monocytic I-CellLine +
cells I-CellLine +
produced O +
higher O +
levels O +
of O +
TNF O -
- O -
alpha O +
than O +
did O +
normal O +
cells O +
after O +
a O +
secondary O +
virus O +
infection O +
. O +

The O +
effects O +
of O +
TNF O -
- O -
alpha O +
on O +
gene O +
expression O +
were O +
examined O +
by O +
transient O +
expression O +
assays O +
using O +
reporter O +
chloramphenicol O +
acetyltransferase O +
plasmids O +
linked O +
to O +
regulatory O +
elements O +
from O +
the O +
HIV O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
and O +
the O +
beta O +
interferon O +
promoter O +
. O +

In O +
U937 B-CellLine +
and I-CellLine +
Jurkat I-CellLine +
T I-CellLine +
lymphoid I-CellLine +
cells I-CellLine +
, O +
the O +
inducibility O +
of O +
the O +
different O +
hybrid O +
promoters O +
by O +
TNF O -
- O -
alpha O +
or O +
phorbol O +
ester O +
varied O +
in O +
a O +
cell O +
type- O +
and O +
promoter O +
context O -
- O -
specific O +
manner O +
; O +
the O +
levels O +
of O +
gene O +
activity O +
of O +
NF O -
- O -
kappa O +
B O -
- O -
containing O +
plasmids O +
correlated O +
directly O +
with O +
induction O +
of O +
NF O -
- O -
kappa O +
B O +
DNA O -
- O -
binding O +
activity O +
. O +

Although O +
the O +
intact O +
beta O +
interferon O +
promoter O +
was O +
only O +
weakly O +
stimulated O +
by O +
phorbol O +
ester O +
or O +
TNF O -
- O -
alpha O +
, O +
multimers O +
of O +
the O +
PRDII O +
NF O -
- O -
kappa O +
B O -
- O -
binding O +
domain O +
were O +
inducible O +
by O +
both O +
agents O +
. O +

TNF O -
- O -
alpha O +
was O +
able O +
to O +
increase O +
expression O +
of O +
the O +
HIV O +
LTR O +
in O +
T O +
cells O +
, O +
but O +
in O +
monocytic O +
cells O +
, O +
TNF O -
- O -
alpha O +
did O +
not O +
induce O +
the O +
HIV O +
LTR O +
above O +
a O +
constitutive O +
level O +
of O +
activity O +
. O +

This O +
level O +
of O +
NF O -
- O -
kappa O +
B O +
-independent O +
activity O +
appears O +
to O +
be O +
sufficient O +
for O +
virus O +
multiplication O +
, O +
since O +
TNF O -
- O -
alpha O +
treatment O +
had O +
no O +
effect O +
on O +
the O +
kinetics O +
of O +
de O +
novo O +
HIV O +
type O +
1 O +
( O +
HIV-1 O +
) O +
infection O +
and O +
viral O +
RNA O +
production O +
in O +
U937 B-CellLine +
cells I-CellLine +
. O +

However O +
, O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
TNF O -
- O -
alpha O +
dramatically O +
enhanced O +
the O +
spread O +
of O +
HIV-1 O +
through O +
the O +
cell O +
population O +
and O +
increased O +
viral O +
RNA O +
synthesis O +
, O +
indicating O +
that O +
in O +
T O +
cells O +
HIV-1 O +
multiplication O +
was O +
stimulated O +
by O +
TNF O -
- O -
alpha O +
treatment O +
. O +

Retroviral O +
mediated O +
transfer O +
and O +
expression O +
of O +
exogenous O +
genes O +
in O +
primary O +
lymphoid O +
cells O +
: O +
assaying O +
for O +
a O +
viral O +
transactivator O +
activity O +
in O +
normal O +
and O +
malignant O +
cells O +
. O +

In O +
this O +
report O +
we O +
describe O +
the O +
use O +
of O +
recombinant O +
retroviruses O +
to O +
characterize O +
the O +
activity O +
of O +
an O +
exogenous O +
promoter O +
in O +
primary O +
cells O +
obtained O +
from O +
patients O +
with O +
lymphoproliferative O +
disorders O +
. O +

The O +
infection O +
of O +
a O +
variety O +
of O +
cultured O +
and O +
primary O +
lymphoid O +
cells O +
with O +
a O +
recombinant O +
retrovirus O +
containing O +
a O +
histone O +
promoter O -
- O -
driven O +
beta O -
- O -
galactosidase O +
gene O +
is O +
shown O +
to O +
result O +
in O +
the O +
expression O +
of O +
beta O -
- O -
galactosidase O +
in O +
50 O +
% O +
to O +
100 O +
% O +
of O +
the O +
cells O +
. O +

A O +
similar O +
infection O +
with O +
a O +
recombinant O +
retrovirus O +
containing O +
the O +
beta O -
- O -
galactosidase O +
gene O +
with O +
an O +
adenovirus O +
E2 O +
promoter O +
, O +
results O +
in O +
beta O -
- O -
galactosidase O +
activity O +
in O +
a O +
limited O +
number O +
of O +
cultured B-CellLine +
and O +
primary O +
cells O +
. O +

Since O +
the O +
adenovirus O +
E2 O +
promoter O +
has O +
been O +
well O +
characterized O +
and O +
is O +
known O +
to O +
be O +
regulated O +
by O +
transactivators O +
encoded O +
by O +
many O +
viruses O +
, O +
the O +
activity O +
of O +
this O +
promoter O +
in O +
specific O +
cell O +
types O +
is O +
discussed O +
in O +
reference O +
to O +
both O +
the O +
biology O +
of O +
the O +
cell O +
and O +
the O +
possible O +
presence O +
of O +
as O +
yet O +
undetected O +
viral O +
gene O +
products O +
. O +

[ O +
The O +
role O +
of O +
glucocorticoid O +
receptors O +
and O +
HLA O +
antigens O +
in O +
the O +
pathogenesis O +
of O +
Cushing O +
's O +
syndrome O +
] O +

Lymphocytic O +
levels O +
of O +
glucocorticoid O +
receptors O +
were O +
evaluated O +
in O +
114 O +
patients O +
suffering O +
from O +
Icenko O -
- O -
Cushing O +
's O +
syndrome O +
. O +

Incidence O +
of O +
HLA O +
antigens O +
was O +
determined O +
in O +
94 O +
of O +
them O +
. O +

A O +
significant O +
rise O +
of O +
A10 O +
and O +
B27 O +
antigen O +
incidence O +
compared O +
to O +
that O +
in O +
normal O +
subjects O +
allows O +
these O +
antigens O +
to O +
be O +
considered O +
genetic O +
markers O +
of O +
Icenko O -
- O -
Cushing O +
's O +
syndrome O +
. O +

The O +
levels O +
of O +
glucocorticoid O +
receptors O +
in O +
lymphocytes O +
of O +
the O +
patients O +
are O +
lower O +
than O +
in O +
normal O +
subjects O +
both O +
in O +
the O +
active O +
stage O +
of O +
the O +
disease O +
and O +
following O +
bilateral O +
total O +
adrenalectomy O +
. O +

The O +
patients O +
carrying O +
B27 O +
antigen O +
had O +
lymphocytic O +
receptor O +
concentrations O +
under O +
the O +
levels O +
of O +
such O +
in O +
patients O +
free O +
of O +
the O +
antigen O +
carriage O +
. O +

Antigen O +
B27 O +
seems O +
to O +
be O +
a O +
cause O +
of O +
lower O +
levels O +
of O +
glucocorticoid O +
receptors O +
in O +
blood O +
lymphocytes O +
. O +

Progesterone O +
suppression O +
of O +
pregnancy O +
lymphocytes O +
is O +
not O +
mediated O +
by O +
glucocorticoid O +
effect O +
. O +

This O +
study O +
investigated O +
whether O +
the O +
suppressive O +
effect O +
of O +
progesterone O +
on O +
pregnancy O +
lymphocytes O +
is O +
mediated O +
by O +
specific O +
progesterone O +
receptors O +
. O +

The O +
effects O +
of O +
a O +
competitive O +
progesterone O +
antagonist O +
( O +
RU486 O +
) O +
and O +
a O +
specific O +
glucocorticoid O +
receptor O +
blocker O +
( O +
RU43044 O +
) O +
were O +
tested O +
on O +
the O +
release O +
of O +
a O +
blocking O +
factor O +
by O +
progesterone B-CellLine -
- I-CellLine -
treated I-CellLine +
pregnancy I-CellLine +
lymphocytes I-CellLine +
. O +

RU O +
486 O +
tested O +
at O +
an O +
equal O +
concentration O +
as O +
progesterone O +
significantly O +
inhibited O +
the O +
production O +
of O +
the O +
blocking O +
factor O +
, O +
while O +
RU O +
43044 O +
was O +
without O +
effect O +
. O +

These O +
data O +
suggest O +
that O +
in O +
pregnancy O +
, O +
lymphocyte O +
progesterone O +
acts O +
on O +
specific O +
progesterone O +
receptors O +
and O +
glucocorticoid O +
binding O +
sites O +
are O +
not O +
involved O +
. O +

Decreased O +
concentration O +
of O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
receptors O +
in O +
peripheral O +
mononuclear O +
cells O +
of O +
patients O +
with O +
X O -
- O -
linked O +
hypophosphatemic O +
rickets O +
: O +
effect O +
of O +
phosphate O +
supplementation O +
. O +

Abnormal O +
renal O +
tubular O +
phosphate O +
transport O +
is O +
considered O +
to O +
be O +
the O +
primary O +
defect O +
in O +
X O -
- O -
linked O +
hypophosphatemic O +
rickets O +
( O +
XLH O +
) O +
. O +

However O +
, O +
the O +
resistance O +
to O +
vitamin O +
D O +
treatment O +
in O +
XLH O +
can O +
not O +
be O +
explained O +
by O +
hypophosphatemia O +
alone O +
. O +

Since O +
most O +
of O +
the O +
actions O +
of O +
vitamin O +
D O +
are O +
mediated O +
by O +
its O +
receptors O +
( O +
VDR O +
) O +
, O +
abnormalities O +
of O +
VDR O +
have O +
been O +
postulated O +
in O +
XLH O +
. O +

In O +
order O +
to O +
investigate O +
this O +
possibility O +
, O +
we O +
measured O +
the O +
concentration O +
of O +
VDR O +
in O +
PHA B-CellLine -
- I-CellLine -
activated I-CellLine +
peripheral I-CellLine +
mononuclear I-CellLine +
cells I-CellLine +
from O +
10 O +
XLH O +
patients O +
. O +

Patients O +
without O +
phosphate O +
supplementation O +
showed O +
significantly O +
lower O +
concentration O +
( O +
21.7 O +
+ O -
/- O +
5.1 O +
fmol O -
/ O -
mg O +
protein O +
, O +
mean O +
+ O -
/- O +
SEM O +
) O +
compared O +
to O +
the O +
normal O +
controls O +
( O +
60.7 O +
+ O -
/- O +
4.0 O +
) O +
. O +

On O +
the O +
contrary O +
, O +
there O +
was O +
no O +
significant O +
difference O +
between O +
the O +
phosphate O -
- O -
supplemented O +
patients O +
( O +
58.3 O +
+ O -
/- O +
2.7 O +
) O +
and O +
controls O +
. O +

There O +
was O +
a O +
significant O +
positive O +
correlation O +
between O +
VDR O +
concentration O +
and O +
serum O +
phosphate O +
( O +
P O +
less O +
than O +
0.05 O +
) O +
. O +

In O +
two O +
patients O +
, O +
VDR O +
was O +
increased O +
after O +
daily O +
phosphate O +
supplementation O +
was O +
started O +
. O +

These O +
results O +
indicate O +
that O +
a O +
decreased O +
concentration O +
of O +
VDR O +
secondary O +
to O +
persistent O +
hypophosphatemia O +
is O +
one O +
of O +
the O +
causes O +
of O +
vitamin O +
D O +
resistance O +
in O +
XLH O +
. O +

NF O -
- O -
X2 O +
that O +
binds O +
to O +
the O +
DRA O +
X2-box O +
is O +
activator O +
protein O +
1 O +
. O +

Expression O +
cloning O +
of O +
c O -
- O -
Jun O +
. O +

Human O +
class O +
II O +
MHC O +
Ag O +
are O +
a O +
family O +
of O +
cell O +
surface O +
glycoproteins O +
. O +

Their O +
constitutive O +
expression O +
is O +
limited O +
to O +
B O +
lymphocytes O +
and O +
thymic O +
epithelial O +
cells O +
. O +

In O +
many O +
other O +
cells O +
their O +
expression O +
can O +
be O +
induced O +
by O +
IFN O -
- O -
gamma O +
. O +

Conserved O +
upstream O +
promoter O +
sequences O +
regulate O +
this O +
tissue O -
- O -
specific O +
expression O +
of O +
class O +
II O +
genes O +
. O +

In O +
the O +
DRA O +
promoter O +
, O +
one O +
of O +
these O +
cis O -
- O -
acting O +
regulatory O +
motifs O +
is O +
the O +
X2-box O +
to O +
which O +
nuclear O +
factor O +
X2 O +
( O +
NF O -
- O -
X2 O +
) O +
binds O +
. O +

Here O +
, O +
we O +
present O +
the O +
isolation O +
and O +
characterization O +
of O +
the O +
full O -
- O -
length O +
cDNA O +
clone O +
encoding O +
NF O -
- O -
X2 O +
. O +

This O +
cDNA O +
clone O +
was O +
isolated O +
by O +
expression O +
cDNA O +
cloning O +
, O +
and O +
encodes O +
the O +
human O +
c O -
- O -
Jun O +
protein O +
, O +
which O +
together O +
with O +
c O -
- O -
Fos O +
forms O +
the O +
heterodimeric O +
activator O +
protein-1 O +
transcription O +
complex O +
. O +

Whereas O +
c O -
- O -
Fos O -
/ O -
c O -
- O -
Jun O +
heterodimers O +
do O +
not O +
exist O +
in O +
B B-CellLine +
cells I-CellLine +
, O +
they O +
form O +
and O +
bind O +
to O +
the O +
X2-box O +
in O +
class B-CellLine +
II I-CellLine +
nonexpressing I-CellLine +
cells I-CellLine +
. O +

Thus O +
, O +
c O -
- O -
Fos O -
/ O -
c O -
- O -
Jun O +
heterodimers O +
might O +
contribute O +
to O +
the O +
repression O +
of O +
DRA O +
gene O +
expression O +
. O +

Immunohistochemical O +
study O +
of O +
steroid O +
hormones O +
and O +
an O +
estrogen O +
binding O +
assay O +
in O +
malignant O +
soft O +
tissue O +
tumors O +
. O +

Immunohistochemically O +
, O +
the O +
immunoreaction O +
against O +
5 O +
steroid O +
hormone O +
anti O -
- O -
sera O +
( O +
estradiol O +
, O +
estriol O +
, O +
cortisol O +
, O +
progesterone O +
and O +
testosterone O +
) O +
was O +
examined O +
in O +
39 O +
cases O +
with O +
the O +
malignant O +
soft O +
tissue O +
tumors O +
( O +
fibrosarcoma O +
: O +
8 O +
, O +
malignant O +
fibrous O +
histiocytoma O +
: O +
6 O +
, O +
rhabdomyosarcoma O +
: O +
10 O +
, O +
leiomyosarcoma O +
: O +
10 O +
, O +
liposarcoma O +
: O +
5 O +
) O +
. O +

Seventeen O +
cases O +
revealed O +
distinct O +
immunostaining O +
against O +
at O +
least O +
1 O +
of O +
the O +
5 O +
steroid O +
hormones O +
. O +

Immunostained O +
tumor O +
cells O +
were O +
more O +
frequently O +
distributed O +
in O +
the O +
area O +
where O +
tumor O +
cell O +
infiltration O +
was O +
more O +
invasive O +
. O +

The O +
majority O +
of O +
the O +
positive O +
cases O +
occurred O +
in O +
female O +
cases O +
. O +

Furthermore O +
, O +
the O +
existence O +
of O +
estrogen O +
receptor O +
( O +
estrogen O +
binding O +
activity O +
) O +
was O +
examined O +
histochemically O +
in O +
39 O +
cases O +
and O +
it O +
was O +
detected O +
in O +
8 O +
. O +

We O +
concluded O +
that O +
steroid O +
hormones O +
might O +
be O +
closely O +
related O +
to O +
tumor O +
cell O +
infiltration O +
of O +
some O +
malignant O +
soft O +
tissue O +
tumors O +
. O +

Interferon O -
- O -
gamma O +
and O +
the O +
sexual O +
dimorphism O +
of O +
autoimmunity O +
. O +

The O +
sexual O +
difference O +
in O +
the O +
incidence O +
of O +
autoimmune O +
diseases O +
has O +
remained O +
an O +
enigma O +
for O +
many O +
years O +
. O +

In O +
the O +
examination O +
of O +
the O +
induction O +
of O +
autoimmunity O +
in O +
transgenic O +
mice O +
, O +
evidence O +
has O +
been O +
obtained O +
further O +
implicating O +
the O +
lymphokine O +
interferon O -
- O -
gamma O +
in O +
the O +
etiology O +
of O +
autoimmunity O +
. O +

Sex O +
steroid O +
regulation O +
of O +
the O +
production O +
of O +
this O +
molecule O +
, O +
as O +
well O +
as O +
other O +
cytokines O +
, O +
may O +
help O +
explain O +
the O +
gender O -
- O -
specific O +
differences O +
in O +
the O +
immune O +
system O +
, O +
including O +
autoimmunity O +
. O +

[ O +
The O +
effect O +
of O +
24 O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
dioxyvit O +
) O +
on O +
Ca O +
metabolism O +
and O +
immune O +
status O +
during O +
chronic O +
kidney O +
failure O +
] O +

Active O +
metabolite O +
of O +
vitamin O +
D3 O +
, O +
24R O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
( O +
dioxyvit O +
) O +
was O +
used O +
at O +
a O +
daily O +
dose O +
of O +
100 O +
micrograms O +
in O +
treatment O +
of O +
children O +
affected O +
with O +
tubulointerstitial O +
disease O +
of O +
kidney O +
and O +
with O +
chronic O +
glomerulonephritis O +
under O +
conditions O +
of O +
kidney O +
insufficiency O +
. O +

The O +
drug O +
exhibited O +
distinct O +
normalizing O +
effect O +
on O +
patterns O +
of O +
calcium O +
metabolism O +
: O +
increase O +
of O +
total O +
and O +
ionized O +
Ca2 O -
+ O +
and O +
of O +
25-OHD O +
, O +
decrease O +
in O +
concentration O +
of O +
parath O +
hormone O +
and O +
osteocalcine O +
in O +
blood O +
serum O +
as O +
well O +
as O +
on O +
immunological O +
parameters O +
: O +
restoration O +
of O +
decreased O +
content O +
of O +
T- O +
and O +
0-lymphocytes O +
. O +

Concentration O +
of O +
receptors O +
of O +
hormonal O +
form O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
was O +
found O +
to O +
be O +
minimal O +
in O +
lymphocytes O +
under O +
conditions O +
of O +
chronic O +
kidney O +
insufficiency O +
, O +
while O +
their O +
expression O +
, O +
after O +
the O +
dioxyvit O +
action O +
, O +
was O +
detected O +
only O +
in O +
patients O +
with O +
glomerulonephritis O +
. O +

Specific O +
calcitropic O +
effect O +
of O +
dioxyvit O +
with O +
simultaneous O +
correction O +
of O +
vitamin O +
D O +
deficiency O +
were O +
apparently O +
responsible O +
for O +
high O +
efficacy O +
of O +
the O +
drug O +
in O +
treatment O +
of O +
calcium O +
metabolism O +
and O +
immunity O +
impairments O +
in O +
children O +
with O +
renal O +
deteriorations O +
at O +
the O +
step O +
of O +
chronic O +
kidney O +
insufficiency O +
. O +

Extrarenal O +
receptor O -
- O -
effector O -
- O -
mechanisms O +
for O +
aldosterone O +
: O +
the O +
sequence O +
of O +
effects O +
on O +
the O +
cellular O +
electrolyte O +
transport O +
in O +
human O +
lymphocytes O +
and O +
their O +
implications O +
for O +
disorders O +
of O +
the O +
water O +
and O +
electrolyte O +
balances O +
. O +

High O +
affinity O +
aldosterone O +
binding O +
sites O +
have O +
not O +
only O +
been O +
described O +
in O +
the O +
classic O +
target O +
tissues O +
such O +
as O +
the O +
renal O +
tubules O +
, O +
but O +
also O +
in O +
non O -
- O -
classic O +
target O +
tissues O +
such O +
as O +
the O +
hippocampus O +
, O +
mammary O +
gland O +
, O +
endothelial O +
cells O +
and O +
, O +
recently O +
, O +
human O +
mononuclear O +
leukocytes O +
. O +

An O +
in O +
vitro O +
effect O +
of O +
aldosterone O +
on O +
intracellular O +
sodium O +
, O +
potassium O +
and O +
calcium O +
concentrations O +
and O +
cell O +
volume O +
was O +
shown O +
in O +
human O +
mononuclear O +
leukocytes O +
. O +

In O +
the O +
absence O +
of O +
aldosterone O +
, O +
the O +
intracellular O +
Na+ O +
, O +
K+ O +
and O +
Ca2 O -
+ O +
concentrations O +
and O +
the O +
cell O +
volume O +
decreased O +
significantly O +
, O +
but O +
remained O +
constant O +
when O +
aldosterone O +
( O +
1.4 O +
nmol O -
/ O -
l O +
) O +
was O +
added O +
to O +
the O +
incubation O +
medium O +
. O +

These O +
effects O +
of O +
aldosterone O +
were O +
blocked O +
by O +
the O +
aldosterone O +
antagonist O +
canrenone O +
( O +
140 O +
nmol O -
/ O -
l O +
) O +
. O +

The O +
sodium O -
/ O -
proton O +
exchanger O +
of O +
the O +
cell O +
membrane O +
could O +
be O +
identified O +
as O +
the O +
primary O +
target O +
of O +
the O +
aldosterone O +
action O +
, O +
possibly O +
non O -
- O -
genomically O +
mediated O +
through O +
membrane O +
receptors O +
. O +

The O +
clinical O +
significance O +
of O +
this O +
model O +
was O +
underlined O +
by O +
the O +
demonstration O +
of O +
absent O +
or O +
a O +
decreased O +
number O +
of O +
mineralocorticoid O +
receptors O +
and O +
the O +
lack O +
of O +
electrolyte O +
response O +
to O +
aldosterone O +
in O +
human O +
mononuclear O +
leukocytes O +
of O +
patients O +
with O +
pseudohypoaldosteronism O +
and O +
aldosteronism O +
. O +

Additionally O +
, O +
an O +
abnormal O +
effector O +
mechanism O +
could O +
be O +
demonstrated O +
in O +
human O +
mononuclear O +
leukocytes O +
from O +
essential O +
hypertensives O +
. O +

These O +
studies O +
are O +
the O +
first O +
to O +
demonstrate O +
the O +
significance O +
of O +
extrarenal O +
, O +
nonepithelial O +
mineralocorticoid O +
receptors O +
and O +
the O +
related O +
effector O +
mechanism O +
in O +
different O +
disorders O +
of O +
the O +
water O +
and O +
electrolyte O +
balance O +
in O +
man O +
. O +

Two O +
distinct O +
signal O +
transmission O +
pathways O +
in O +
T O +
lymphocytes O +
are O +
inhibited O +
by O +
complexes O +
formed O +
between O +
an O +
immunophilin O +
and O +
either O +
FK506 O +
or O +
rapamycin O +
. O +

Proliferation O +
and O +
immunologic O +
function O +
of O +
T O +
lymphocytes O +
are O +
initiated O +
by O +
signals O +
from O +
the O +
antigen O +
receptor O +
that O +
are O +
inhibited O +
by O +
the O +
immunosuppressant O +
FK506 O +
but O +
not O +
by O +
its O +
structural O +
analog O +
, O +
rapamycin O +
. O +

On O +
the O +
other O +
hand O +
, O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
-induced O +
signals O +
are O +
blocked O +
by O +
rapamycin O +
but O +
not O +
by O +
FK506 O +
. O +

Remarkably O +
, O +
these O +
two O +
drugs O +
inhibit O +
each O +
other O +
's O +
actions O +
, O +
raising O +
the O +
possibility O +
that O +
both O +
act O +
by O +
means O +
of O +
a O +
common O +
immunophilin O +
( O +
immunosuppressant O +
binding O +
protein O +
) O +
. O +

We O +
find O +
that O +
the O +
dissociation O +
constant O +
of O +
rapamycin O +
to O +
the O +
FK506 O +
binding O +
protein O +
FKBP O +
( O +
Kd O +
= O +
0.2 O +
nM O +
) O +
is O +
close O +
to O +
the O +
dissociation O +
constant O +
of O +
FK506 O +
to O +
FKBP O +
( O +
Kd O +
= O +
0.4 O +
nM O +
) O +
and O +
to O +
their O +
effective O +
biologic O +
inhibitory O +
concentrations O +
. O +

However O +
, O +
an O +
excess O +
of O +
rapamycin O +
is O +
needed O +
to O +
revert O +
FK506-mediated O +
inhibition O +
of O +
IL-2 O +
production O +
, O +
apoptosis O +
, O +
and O +
transcriptional O +
activation O +
of O +
NF O -
- O -
AT O +
, O +
a O +
T O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
necessary O +
for O +
IL-2 O +
gene O +
activation O +
. O +

Similarly O +
, O +
an O +
excess O +
of O +
FK506 O +
is O +
needed O +
to O +
revert O +
rapamycin O -
- O -
mediated O +
inhibition O +
of O +
IL-2 O +
-induced O +
proliferation O +
. O +

The O +
drug O +
concentrations O +
required O +
for O +
antagonism O +
may O +
be O +
explained O +
by O +
the O +
relative O +
affinity O +
of O +
the O +
drugs O +
to O +
, O +
and O +
by O +
the O +
abundance O +
of O +
, O +
the O +
immunophilin O +
FKBP O +
. O +

FKBP O +
has O +
been O +
shown O +
to O +
catalyze O +
the O +
interconversion O +
of O +
the O +
cis- O +
and O +
trans O -
- O -
rotamers O +
of O +
the O +
peptidyl O -
- O -
prolyl O +
amide O +
bond O +
of O +
peptide O +
substrates O +
; O +
here O +
we O +
show O +
that O +
rapamycin O +
, O +
like O +
FK506 O +
, O +
is O +
a O +
potent O +
inhibitor O +
of O +
the O +
rotamase O +
activity O +
of O +
FKBP O +
( O +
Ki O +
= O +
0.2 O +
nM O +
) O +
. O +

Neither O +
FKBP O +
binding O +
nor O +
inhibition O +
of O +
rotamase O +
activity O +
of O +
FKBP O +
alone O +
is O +
sufficient O +
to O +
explain O +
the O +
biologic O +
actions O +
of O +
these O +
drugs O +
. O +

Rather O +
, O +
these O +
findings O +
suggest O +
that O +
immunophilin O +
bound O +
to O +
FK506 O +
interferes O +
with O +
antigen O +
receptor O +
-induced O +
signals O +
, O +
while O +
rapamycin O +
bound O +
to O +
the O +
immunophilin O +
interferes O +
with O +
IL-2 O +
-induced O +
signals O +
. O +

Disruption O +
of O +
the O +
human O +
SCL O +
locus O +
by O +
` O -
` O +
illegitimate O +
'' O +
V- O +
( O +
D O +
) O +
-J O +
recombinase O +
activity O +
. O +

A O +
fusion O +
complementary O +
DNA O +
in O +
the O +
T B-CellLine +
cell I-CellLine +
line I-CellLine +
HSB-2 I-CellLine +
elucidates O +
a O +
provocative O +
mechanism O +
for O +
the O +
disruption O +
of O +
the O +
putative O +
hematopoietic O +
transcription O +
factor O +
SCL O +
. O +

The O +
fusion O +
cDNA O +
results O +
from O +
an O +
interstitial O +
deletion O +
between O +
a O +
previously O +
unknown O +
locus O +
, O +
SIL O +
( O +
SCL O +
interrupting O +
locus O +
) O +
, O +
and O +
the O +
5 O +
' O +
untranslated O +
region O +
of O +
SCL O +
. O +

Similar O +
to O +
1 O +
; O +
14 O +
translocations O +
, O +
this O +
deletion O +
disrupts O +
the O +
SCL O +
5 O +
' O +
regulatory O +
region O +
. O +

This O +
event O +
is O +
probably O +
mediated O +
by O +
V- O +
( O +
D O +
) O +
-J O +
recombinase O +
activity O +
, O +
although O +
neither O +
locus O +
is O +
an O +
immunoglobulin O +
or O +
a O +
T O +
cell O +
receptor O +
. O +

Two O +
other O +
T B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
CEM B-CellLine +
and O +
RPMI B-CellLine +
8402 I-CellLine +
, O +
have O +
essentially O +
identical O +
deletions O +
. O +

Thus O +
, O +
in O +
lymphocytes O +
, O +
growth O -
- O -
affecting O +
genes O +
other O +
than O +
immune O +
receptors O +
risk O +
rearrangements O +
. O +

Induction O +
of O +
NF O -
- O -
KB O +
during O +
monocyte O +
differentiation O +
by O +
HIV O +
type O +
1 O +
infection O +
. O +

The O +
production O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
progeny O +
was O +
followed O +
in O +
the O +
U937 B-CellLine +
promonocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
after O +
stimulation O +
either O +
with O +
retinoic O +
acid O +
or O +
PMA O +
, O +
and O +
in O +
purified O +
human O +
monocytes O +
and O +
macrophages O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
and O +
Southwestern O +
blotting O +
experiments O +
were O +
used O +
to O +
detect O +
the O +
binding O +
of O +
cellular O +
transactivation O +
factor O +
NF O -
- O -
KB O +
to O +
the O +
double O +
repeat O -
- O -
KB O +
enhancer O +
sequence O +
located O +
in O +
the O +
long O +
terminal O +
repeat O +
. O +

PMA O +
treatment O +
, O +
and O +
not O +
retinoic O +
acid O +
treatment O +
of O +
the O +
U937 B-CellLine +
cells I-CellLine +
acts O +
in O +
inducing O +
NF O -
- O -
KB O +
expression O +
in O +
the O +
nuclei O +
. O +

In O +
nuclear O +
extracts O +
from O +
monocytes O +
or O +
macrophages O +
, O +
induction O +
of O +
NF O -
- O -
KB O +
occurred O +
only O +
if O +
the O +
cells O +
were O +
previously O +
infected O +
with O +
HIV-1 O +
. O +

When O +
U937 B-CellLine +
cells I-CellLine +
were O +
infected O +
with O +
HIV-1 O +
, O +
no O +
induction O +
of O +
NF O -
- O -
KB O +
factor O +
was O +
detected O +
, O +
whereas O +
high O +
level O +
of O +
progeny O +
virions O +
was O +
produced O +
, O +
suggesting O +
that O +
this O +
factor O +
was O +
not O +
required O +
for O +
viral O +
replication O +
. O +

These O +
results O +
indicate O +
that O +
in O +
monocytic B-CellLine +
cell I-CellLine +
lineage I-CellLine +
, O +
HIV-1 O +
could O +
mimic O +
some O +
differentiation O -
/ O -
activation O +
stimuli O +
allowing O +
nuclear O +
NF O -
- O -
KB O +
expression O +
. O +

Activation O +
of O +
human B-CellLine +
CD4 I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
. O +

Interaction O +
of O +
fibronectin O +
with O +
VLA-5 O +
receptor O +
on O +
CD4 B-CellLine +
cells I-CellLine +
induces O +
the O +
AP-1 O +
transcription O +
factor O +
. O +

Fibronectin O +
synergized O +
with O +
anti O -
- O -
CD3 O +
antibody O +
to O +
promote O +
CD4 O +
cell O +
proliferation O +
in O +
a O +
serum O -
- O -
free O +
culture O +
system O +
whereas O +
no O +
proliferation O +
was O +
observed O +
when O +
CD4 B-CellLine +
cells I-CellLine +
were O +
cultured O +
with O +
anti O -
- O -
CD3 O +
alone O +
or O +
fibronectin O +
alone O +
. O +

In O +
addition O +
, O +
anti O -
- O -
CD29 O +
( O +
integrin O +
beta O +
1 O +
) O +
as O +
well O +
as O +
anti O -
- O -
VLA-5 O +
( O +
human O +
fibronectin O +
receptor O +
) O +
antibodies O +
blocked O +
this O +
CD4 B-CellLine +
cell I-CellLine +
activation O +
in O +
this O +
system O +
. O +

Although O +
anti O -
- O -
CD3 O +
alone O +
or O +
fibronectin O +
alone O +
can O +
not O +
induce O +
IL-2 O +
message O +
by O +
CD4 B-CellLine +
cells I-CellLine +
, O +
the O +
combination O +
of O +
anti O -
- O -
CD3 O +
plus O +
fibronectin O +
induced O +
IL-2 O +
message O +
by O +
CD4 B-CellLine +
cells I-CellLine +
. O +

In O +
an O +
analysis O +
of O +
the O +
molecular O +
mechanism O +
by O +
which O +
IL-2 O +
message O +
was O +
generated O +
, O +
we O +
showed O +
that O +
a O +
fibronectin O +
-VLA-5 O +
fibronectin O +
receptor O +
interaction O +
may O +
contribute O +
an O +
independent O +
signal O +
distinct O +
from O +
the O +
CD3 O +
pathway O +
of O +
activation O +
by O +
the O +
induction O +
of O +
an O +
AP-1 O +
transcriptional O +
factor O +
. O +

Thus O +
the O +
VLA-5 O +
fibronectin O +
receptor O +
on O +
CD4 B-CellLine +
cells I-CellLine +
can O +
play O +
a O +
complementary O +
role O +
in O +
CD3 O +
- O +
TCR O +
-mediated O +
signal O +
transduction O +
through O +
its O +
interaction O +
with O +
fibronectin O +
. O +

TAR O +
independent O +
activation O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
in O +
phorbol O +
ester O +
stimulated O +
T O +
lymphocytes O +
. O +

Multiple O +
regulatory O +
elements O +
in O +
the O +
human O +
immunodeficiency O +
virus O +
long O +
terminal O +
repeat O +
( O +
HIV O +
LTR O +
) O +
are O +
required O +
for O +
activation O +
of O +
HIV O +
gene O +
expression O +
. O +

Previous O +
transfection O +
studies O +
of O +
HIV O +
LTR O +
constructs O +
linked O +
to O +
the O +
chloramphenicol O +
acetyltransferase O +
gene O +
indicated O +
that O +
multiple O +
regulatory O +
regions O +
including O +
the O +
enhancer O +
, O +
SP1 O +
, O +
TATA O +
and O +
TAR O +
regions O +
were O +
important O +
for O +
HIV O +
gene O +
expression O +
. O +

To O +
characterize O +
these O +
regulatory O +
elements O +
further O +
, O +
mutations O +
in O +
these O +
regions O +
were O +
inserted O +
into O +
both O +
the O +
5 O +
' O +
and O +
3 O +
' O +
HIV O +
LTRs O +
and O +
infectious O +
proviral O +
constructs O +
were O +
assembled O +
. O +

These O +
constructs O +
were O +
transfected O +
into O +
either O +
HeLa B-CellLine +
cells I-CellLine +
, O +
Jurkat B-CellLine +
cells I-CellLine +
or O +
U937 B-CellLine +
cells I-CellLine +
in O +
both O +
the O +
presence O +
and O +
absence O +
of O +
phorbol O +
esters O +
which O +
have O +
previously O +
been O +
demonstrated O +
to O +
activate O +
HIV O +
gene O +
expression O +
. O +

Viral O +
gene O +
expression O +
was O +
assayed O +
by O +
the O +
level O +
of O +
p24 O +
gag O +
protein O +
released O +
from O +
cultures O +
transfected O +
with O +
the O +
proviral O +
constructs O +
. O +

Results O +
in O +
all O +
cell O +
lines O +
indicated O +
that O +
mutations O +
of O +
the O +
SP1 O +
, O +
TATA O +
and O +
the O +
TAR O +
loop O +
and O +
stem O +
secondary O +
structure O +
resulted O +
in O +
marked O +
decreases O +
in O +
gene O +
expression O +
while O +
mutations O +
of O +
the O +
enhancer O +
motif O +
or O +
TAR O +
primary O +
sequence O +
resulted O +
in O +
only O +
slight O +
decreases O +
. O +

However O +
, O +
viruses O +
containing O +
mutations O +
in O +
either O +
the O +
TAR O +
loop O +
sequences O +
or O +
stem O +
secondary O +
structure O +
which O +
were O +
very O +
defective O +
for O +
gene O +
expression O +
in O +
untreated O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
gave O +
nearly O +
wild O -
- O -
type O +
levels O +
of O +
gene O +
expression O +
in O +
phorbol B-CellLine +
ester I-CellLine -
- I-CellLine -
treated I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
but O +
not O +
in O +
phorbol B-CellLine +
ester I-CellLine -
- I-CellLine -
treated I-CellLine +
HeLa I-CellLine +
or O +
U937 B-CellLine +
cells I-CellLine +
. O +

High O +
level O +
gene O +
expression O +
of O +
these O +
TAR O +
mutant O +
constructs O +
in O +
phorbol B-CellLine +
ester I-CellLine -
- I-CellLine -
treated I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
was O +
eliminated O +
by O +
second O +
site O +
mutations O +
in O +
the O +
enhancer O +
region O +
or O +
by O +
disruption O +
of O +
the O +
tat O +
gene O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

Positive O +
and O +
negative O +
regulation O +
of O +
immunoglobulin O +
gene O +
expression O +
by O +
a O +
novel O +
B O -
- O -
cell O -
- O -
specific O +
enhancer O +
element O +
. O +

A O +
new O +
B O -
- O -
cell O -
- O -
specific O +
enhancer O +
element O +
has O +
been O +
identified O +
3 O +
' O +
of O +
E4 O +
and O +
the O +
octamerlike O +
motifs O +
in O +
the O +
human O +
immunoglobulin O +
heavy O -
- O -
chain O +
gene O +
enhancer O +
. O +

Tandem O +
copies O +
of O +
this O +
67-bp O +
MnlI O -
- O -
AluI O +
fragment O +
, O +
when O +
fused O +
to O +
the O +
chloramphenicol O +
acetyltransferase O +
gene O +
driven O +
by O +
the O +
conalbumin O +
promoter O +
, O +
stimulated O +
transcription O +
in O +
B O +
cells O +
but O +
not O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
or O +
HeLa B-CellLine +
cells I-CellLine +
. O +

Footprinting O +
analysis O +
revealed O +
that O +
the O +
identical O +
sequence O +
CCGAAACTGAAAAGG O +
, O +
designated O +
E6 O +
, O +
was O +
protected O +
by O +
nuclear O +
extracts O +
from O +
B O +
cells O +
, O +
T O +
cells O +
, O +
or O +
HeLa O +
cells O +
. O +

Gel O +
mobility O +
shift O +
assays O +
using O +
a O +
synthetic O +
E6 O +
motif O +
detected O +
a O +
B O -
- O -
cell O -
- O -
specific O +
complex O +
in O +
addition O +
to O +
a O +
ubiquitous O +
band O +
found O +
also O +
in O +
T O +
cells O +
and O +
HeLa B-CellLine +
cells I-CellLine +
. O +

In O +
agreement O +
with O +
the O +
results O +
of O +
gel O +
retardation O +
assays O +
, O +
tandem O +
copies O +
of O +
the O +
E6 O +
motif O +
stimulated O +
transcription O +
in O +
ARH77 B-CellLine +
and O +
Raji B-CellLine +
cells I-CellLine +
but O +
not O +
in O +
Jurkat B-CellLine +
or O +
HeLa B-CellLine +
cells I-CellLine +
. O +

Furthermore O +
, O +
a O +
mutant O +
E6 O +
motif O +
lost O +
both O +
in O +
vitro O +
binding O +
activity O +
and O +
in O +
vivo O +
enhancer O +
activity O +
. O +

In O +
striking O +
contrast O +
to O +
the O +
mouse O +
Ig O +
heavy O -
- O -
chain O +
enhancer O +
, O +
in O +
which O +
the O +
octamer O +
motif O +
acts O +
as O +
a O +
B O -
- O -
cell O -
- O -
specific O +
enhancer O +
element O +
, O +
the O +
human O +
enhancer O +
contains O +
an O +
octamerlike O +
sequence O +
with O +
one O +
base O +
substitution O +
which O +
bound O +
octamer O -
- O -
binding O +
proteins O +
with O +
only O +
very O +
low O +
affinity O +
and O +
showed O +
no O +
enhancer O +
activity O +
of O +
its O +
own O +
. O +

Interestingly O +
, O +
the O +
MnlI O -
- O -
AluI O +
fragment O +
could O +
suppress O +
the O +
basal O -
- O -
level O +
activity O +
of O +
the O +
conalbumin O +
promoter O +
in O +
both O +
Jurkat B-CellLine +
and O +
HeLa B-CellLine +
cells I-CellLine +
. O +

Moreover O +
, O +
simian O +
virus O +
40 O +
enhancer O +
activity O +
was O +
blocked O +
by O +
the O +
MnlI O -
- O -
AluI O +
fragment O +
in O +
HeLa B-CellLine +
cells I-CellLine +
but O +
not O +
in O +
B O +
cells O +
. O +

Thus O +
, O +
the O +
novel O +
enhancer O +
element O +
identified O +
in O +
this O +
study O +
is O +
probably O +
a O +
target O +
site O +
for O +
both O +
positive O +
and O +
negative O +
factors O +
. O +

[ O +
Effect O +
of O +
the O +
regimen O +
of O +
kidney O -
- O -
tonifying O +
and O +
qi O -
- O -
invigorating O +
on O +
aging O +
changes O +
of O +
glucocorticoid O +
receptor O +
] O +

The O +
plasma O +
cortisol O +
concentration O +
and O +
the O +
sites O +
of O +
glucocorticoid O +
receptor O +
( O +
GCR O +
) O +
in O +
the O +
peripheral O +
lymphocytes O +
were O +
measured O +
in O +
32 O +
healthy O +
aged O +
persons O +
and O +
13 O +
young O +
adults O +
. O +

In O +
animal O +
experiment O +
, O +
GCR O +
of O +
spleen O +
lymphocytic O +
cell O +
was O +
also O +
measured O +
in O +
18 O +
aged O +
rats O +
and O +
9 O +
young O +
rats O +
. O +

The O +
results O +
showed O +
that O +
GCR O +
was O +
significantly O +
lower O +
in O +
the O +
aged O +
persons O +
or O +
rats O +
than O +
that O +
in O +
the O +
young O +
while O +
the O +
plasma O +
cortisol O +
level O +
did O +
n't O +
change O +
with O +
aging O +
. O +

So O +
we O +
think O +
that O +
GCR O +
is O +
more O +
sensitive O +
than O +
the O +
plasma O +
cortisol O +
level O +
to O +
reflect O +
the O +
aging O +
change O +
of O +
the O +
adrenal O +
cortex O +
function O +
. O +

After O +
the O +
treatment O +
with O +
the O +
regimen O +
of O +
Kidney O -
- O -
tonifying O +
and O +
Qi O -
- O -
invigorating O +
, O +
the O +
GCR O +
of O +
the O +
aged O +
persons O +
and O +
rats O +
was O +
enhanced O +
, O +
and O +
in O +
this O +
way O +
, O +
the O +
function O +
of O +
the O +
aged O +
adrenal O +
cortex O +
was O +
improved O +
. O +

An O +
in O +
vitro O +
globin O +
gene O +
switching O +
model O +
based O +
on O +
differentiated O +
embryonic O +
stem O +
cells O +
. O +

We O +
used O +
mouse O +
embryonic O +
stem O +
( O +
ES O +
) O +
cells O +
to O +
study O +
globin O +
gene O +
expression O +
and O +
switching O +
in O +
vitro O +
. O +

We O +
show O +
that O +
ES O -
- O -
derived O +
embryoid O +
bodies O +
express O +
the O +
full O +
complement O +
of O +
mouse O +
embryonic O +
globin O +
genes O +
in O +
the O +
correct O +
temporal O +
order O +
and O +
that O +
on O +
further O +
differentiation O +
, O +
a O +
switch O +
occurs O +
to O +
the O +
fetal O -
/ O -
adult O +
genes O +
. O +

In O +
addition O +
, O +
the O +
erythroid O -
- O -
specific O +
transcription O +
factor O +
NF O -
- O -
E1 O +
was O +
shown O +
to O +
be O +
expressed O +
coordinately O +
with O +
that O +
of O +
globin O +
in O +
embryoid O +
bodies O +
. O +

We O +
conclude O +
from O +
these O +
experiments O +
that O +
the O +
ES O +
cell O +
system O +
provides O +
a O +
good O +
model O +
to O +
study O +
hematopoietic O +
development O +
. O +

When O +
the O +
human O +
epsilon- O +
or O +
beta O -
- O -
globin O +
genes O +
driven O +
by O +
the O +
dominant O +
control O +
region O +
( O +
DCR O +
) O +
are O +
introduced O +
into O +
this O +
system O +
, O +
the O +
human O +
epsilon O -
- O -
globin O +
gene O +
, O +
in O +
contrast O +
to O +
the O +
beta O -
- O -
globin O +
gene O +
, O +
is O +
not O +
deregulated O +
by O +
the O +
presence O +
of O +
the O +
DCR O +
and O +
is O +
expressed O +
strictly O +
as O +
an O +
embryonic O +
gene O +
. O +

We O +
conclude O +
from O +
this O +
that O +
the O +
epsilon O -
- O -
globin O +
gene O +
is O +
not O +
regulated O +
by O +
competition O +
with O +
other O +
genes O +
in O +
the O +
human O +
beta O -
- O -
globin O +
locus O +
. O +

The O +
NF O +
kappa O +
B O +
independent O +
cis O -
- O -
acting O +
sequences O +
in O +
HIV-1 O +
LTR O +
responsive O +
to O +
T O -
- O -
cell O +
activation O +
. O +

The O +
rate O +
of O +
transcription O +
initiation O +
directed O +
by O +
the O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
of O +
HIV-1 O +
increases O +
in O +
response O +
to O +
mitogenic O +
stimuli O +
of O +
T O +
cells O +
. O +

Here O +
we O +
show O +
that O +
the O +
response O +
of O +
the O +
HIV-1 O +
LTR O +
may O +
be O +
governed O +
by O +
two O +
independent O +
sequences O +
located O +
5 O +
' O +
to O +
the O +
site O +
of O +
transcription O +
initiation O +
sequences O +
that O +
bind O +
either O +
NFAT-1 O +
or O +
NF O +
kappa O +
B O +
. O +

The O +
rate O +
of O +
LTR O +
-directed O +
gene O +
expression O +
increased O +
in O +
response O +
to O +
treatment O +
with O +
either O +
a O +
phorbol O +
ester O +
or O +
tumor O +
necrosis O +
factor O +
alpha O +
if O +
either O +
the O +
NFAT-1 O +
or O +
NF O +
kappa O +
B O +
binding O +
sites O +
were O +
deleted O +
, O +
but O +
failed O +
to O +
respond O +
to O +
these O +
mitogenic O +
stimuli O +
if O +
both O +
sequences O +
were O +
absent O +
. O +

The O +
HIV-1 O +
mutant O +
virus O +
containing O +
both O +
NF O +
kappa O +
B O +
and O +
NFAT-1 O +
deletion O +
was O +
able O +
to O +
replicate O +
although O +
at O +
a O +
much O +
decreased O +
growth O +
rate O +
, O +
while O +
the O +
deletion O +
of O +
NFAT-1 O +
alone O +
increased O +
the O +
viral O +
growth O +
rate O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

Neither O +
deletion O +
of O +
NF O +
kappa O +
B O +
nor O +
deletion O +
of O +
NFAT-1 O +
decreased O +
activation O +
of O +
viral O +
replication O +
by O +
phorbol O +
ester O +
. O +

Identification O +
and O +
cloning O +
of O +
TCF-1 O +
, O +
a O +
T O +
lymphocyte O -
- O -
specific O +
transcription O +
factor O +
containing O +
a O +
sequence O -
- O -
specific O +
HMG O +
box O +
. O +

CD3 O +
-epsilon O +
expression O +
is O +
controlled O +
by O +
a O +
downstream O +
T O +
lymphocyte O -
- O -
specific O +
enhancer O +
element O +
. O +

We O +
report O +
the O +
identification O +
of O +
a O +
T O +
cell O -
- O -
specific O +
transcription O +
factor O +
, O +
TCF-1 O +
, O +
binding O +
to O +
this O +
element O +
. O +

The O +
multimerized O +
recognition O +
motif O +
of O +
TCF-1 O +
constituted O +
a O +
T O +
cell O -
- O -
specific O +
enhancer O +
. O +

Subsequent O +
cloning O +
of O +
TCF-1 O +
identified O +
three O +
splice O +
alternatives O +
. O +

TCF-1 O +
contained O +
a O +
single O +
DNA O -
- O -
binding O +
HMG O +
box O +
most O +
closely O +
related O +
to O +
similar O +
boxes O +
in O +
the O +
putative O +
mammalian O +
sex O -
- O -
determining O +
gene O +
SRY O +
and O +
in O +
the O +
Schizosaccharomyces O +
pombe O +
Mc O +
mating O +
type O +
gene O +
. O +

TCF-1 O +
mRNA O +
was O +
expressed O +
uniquely O +
in O +
T O +
lymphocytes O +
. O +

Upon O +
cotransfection O +
into O +
non O -
- O -
T O +
cells O +
, O +
TCF-1 O +
could O +
transactivate O +
through O +
its O +
cognate O +
motif O +
. O +

These O +
results O +
identify O +
TCF-1 O +
as O +
a O +
T O +
cell O -
- O -
specific O +
transcription O +
factor O +
, O +
which O +
might O +
play O +
a O +
role O +
in O +
the O +
establishment O +
of O +
the O +
mature O +
T O +
cell O +
phenotype O +
. O +

Expression O +
of O +
c O -
- O -
jun O +
, O +
jun O +
B O +
and O +
jun O +
D O +
proto O -
- O -
oncogenes O +
in O +
human O +
peripheral O -
- O -
blood O +
granulocytes O +
. O +

We O +
have O +
found O +
that O +
purified O +
human O +
peripheral O -
- O -
blood O +
granulocytes O +
express O +
constitutively O +
significant O +
levels O +
of O +
proto O -
- O -
oncogenes O +
c O -
- O -
jun O +
, O +
jun O +
B O +
and O +
jun O +
D O +
mRNA O +
. O +

Upon O +
functional O +
activation O +
of O +
granulocytes O +
by O +
4 O +
beta O -
- O -
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
, O +
the O +
levels O +
of O +
c O -
- O -
jun O +
, O +
jun O +
B O +
and O +
jun O +
D O +
transcripts O +
were O +
increased O +
. O +

The O +
three O +
jun O +
genes O +
showed O +
a O +
similar O +
time O +
course O +
in O +
their O +
induction O +
by O +
PMA O +
, O +
maximal O +
mRNA O +
levels O +
being O +
reached O +
after O +
60 O +
min O +
of O +
induction O +
. O +

These O +
results O +
suggest O +
that O +
expression O +
of O +
c O -
- O -
jun O +
, O +
jun O +
B O +
and O +
jun O +
D O +
genes O +
might O +
be O +
involved O +
in O +
terminal O +
granulocyte O +
differentiation O +
or O +
in O +
regulating O +
granulocyte O +
functionality O +
. O +

Oestrogen O +
receptor O +
( O +
ER O +
) O +
analysis O +
in O +
B O -
- O -
cell O +
chronic O +
lymphocytic O +
leukemia O +
: O +
correlation O +
of O +
biochemical O +
and O +
immunocytochemical O +
methods O +
. O +

Oestrogen O +
receptors O +
( O +
ER O +
) O +
are O +
present O +
in O +
neoplastic O +
lymphoid O +
cells O +
and O +
have O +
been O +
considered O +
a O +
physiological O +
marker O +
of O +
growth O +
rate O +
or O +
differentiation O +
. O +

Tamoxifen O +
, O +
an O +
oestrogen O +
antagonist O +
, O +
has O +
been O +
given O +
in O +
some O +
patients O +
with O +
CLL O +
and O +
Hodgkin O +
's O +
disease O +
, O +
with O +
dramatic O +
response O +
in O +
single O +
cases O +
. O +

Until O +
now O +
, O +
ER O +
status O +
has O +
been O +
assessed O +
using O +
a O +
steroid O +
binding O +
assay O +
( O +
SBA O +
) O +
which O +
has O +
many O +
inherent O +
problems O +
. O +

Recently O +
, O +
the O +
development O +
of O +
monoclonal O +
antibodies O +
directed O +
against O +
ER O +
has O +
been O +
applied O +
to O +
the O +
study O +
of O +
breast O +
carcinomas O +
and O +
results O +
obtained O +
show O +
good O +
correlation O +
with O +
the O +
quantitative O +
SBA O +
. O +

We O +
studied O +
49 O +
cases O +
of O +
B O -
- O -
cell O +
chronic O +
lymphocytic O +
leukemia O +
( O +
CLL O +
) O +
using O +
immunostaining O +
of O +
cytospin O +
preparations O +
. O +

In O +
30 O +
of O +
these O +
cases O +
ER O +
enzyme O +
immunoassay O +
( O +
ER O +
-EIA O +
) O +
was O +
also O +
performed O +
. O +

Cultured B-CellLine +
MCF-7 I-CellLine +
cells I-CellLine +
, O +
derived O +
from O +
a O +
pleural O +
effusion O +
of O +
a O +
breast O +
cancer O +
patient O +
, O +
known O +
to O +
contain O +
high O +
levels O +
of O +
ER O +
were O +
used O +
as O +
a O +
positive O +
control O +
( O +
40 O -
- O -
48 O +
% O +
ER O +
positive O +
cells O +
by O +
immunocytochemistry O +
; O +
200 O +
fmol O -
/ O -
mg O +
protein O +
by O +
EIA O +
) O +
. O +

All O +
of O +
the O +
CLL O +
cases O +
except O +
two O +
( O +
96 O +
% O +
) O +
were O +
negative O +
for O +
ER O +
( O +
less O +
than O +
1 O +
% O +
staining O +
; O +
less O +
than O +
4 O +
fmol O -
/ O -
mg O +
protein O +
) O +
. O +

The O +
two O +
positive O +
cases O +
expressed O +
granular O +
ER O +
staining O +
over O +
the O +
nucleus O +
( O +
9.2 O +
and O +
12.1 O +
% O +
positive O +
cells O +
) O +
and O +
were O +
positive O +
by O +
EIA O +
and O +
SBA O +
. O +

It O +
is O +
concluded O +
that O +
( O +
i O +
) O +
patients O +
with O +
CLL O +
rarely O +
express O +
ER O +
and O +
( O +
ii O +
) O +
immunocytochemical O +
staining O +
of O +
cytospin O +
preparations O +
is O +
a O +
valid O +
technique O +
for O +
the O +
measurement O +
of O +
ER O +
. O +

It O +
is O +
of O +
interest O +
that O +
one O +
of O +
the O +
positive O +
cases O +
was O +
diagnosed O +
as O +
CLL O +
with O +
Richter O +
's O +
transformation O +
confirming O +
earlier O +
findings O +
. O +

Platelet O -
- O -
activating O +
factor O +
induces O +
phospholipid O +
turnover O +
, O +
calcium O +
flux O +
, O +
arachidonic O +
acid O +
liberation O +
, O +
eicosanoid O +
generation O +
, O +
and O +
oncogene O +
expression O +
in O +
a O +
human B-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Platelet O -
- O -
activating O +
factor O +
is O +
a O +
potent O +
mediator O +
of O +
the O +
inflammatory O +
response O +
. O +

Studies O +
of O +
the O +
actions O +
of O +
platelet O -
- O -
activating O +
factor O +
have O +
centered O +
mainly O +
around O +
neutrophils O +
, O +
monocytes O +
, O +
and O +
platelets O +
. O +

In O +
this O +
report O +
we O +
begin O +
to O +
uncover O +
the O +
influence O +
of O +
platelet O -
- O -
activating O +
factor O +
on O +
B O +
lymphocytes O +
. O +

Employing O +
the O +
EBV B-CellLine -
- I-CellLine -
transformed I-CellLine +
human I-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
SKW6.4 B-CellLine +
, O +
we O +
demonstrate O +
that O +
platelet O -
- O -
activating O +
factor O +
significantly O +
alters O +
membrane O +
phospholipid O +
metabolism O +
indicated O +
by O +
the O +
incorporation O +
of O +
32P O +
into O +
phosphatidylcholine O +
, O +
phosphatidylinositol O +
, O +
and O +
phosphatidic O +
acid O +
but O +
not O +
significantly O +
into O +
phosphatidylethanolamine O +
at O +
concentrations O +
ranging O +
from O +
10 O +
( O +
-9 O +
) O +
to O +
10 O +
( O +
-6 O +
) O +
M O +
. O +

The O +
inactive O +
precursor O +
, O +
lyso O -
- O -
platelet O -
- O -
activating O +
factor O +
, O +
at O +
a O +
concentration O +
as O +
high O +
as O +
10 O +
( O +
-7 O +
) O +
M O +
had O +
no O +
effect O +
on O +
any O +
of O +
the O +
membrane O +
phospholipids O +
. O +

We O +
also O +
show O +
that O +
platelet O -
- O -
activating O +
factor O +
from O +
10 O +
( O +
-12 O +
) O +
to O +
10 O +
( O +
-6 O +
) O +
M O +
induced O +
rapid O +
and O +
significant O +
elevation O +
in O +
intracellular O +
calcium O +
levels O +
, O +
whereas O +
lyso- O +
platelet O -
- O -
activating O +
factor O +
was O +
again O +
ineffective O +
. O +

We O +
further O +
demonstrate O +
the O +
impact O +
of O +
platelet O -
- O -
activating O +
factor O +
binding O +
to O +
B O +
cells O +
by O +
measuring O +
platelet O -
- O -
activating O +
factor O +
induced O +
arachidonic O +
acid O +
release O +
and O +
5-hydroxyeicosatetraenoic O +
acid O +
production O +
. O +

Moreover O +
, O +
platelet O -
- O -
activating O +
factor O +
was O +
capable O +
of O +
inducing O +
transcription O +
of O +
the O +
nuclear O +
proto O -
- O -
oncogenes O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
. O +

Finally O +
we O +
explored O +
the O +
possible O +
role O +
of O +
5-hydroxyeicosatetraenoic O +
acid O +
as O +
a O +
regulator O +
of O +
arachidonic O +
acid O +
liberation O +
demonstrating O +
that O +
endogenous O +
5-lipoxygenase O +
activity O +
modulates O +
platelet O -
- O -
activating O +
factor O +
induced O +
arachidonic O +
acid O +
release O +
perhaps O +
acting O +
at O +
the O +
level O +
of O +
phospholipase O +
A2 O +
. O +

In O +
summary O +
, O +
platelet O -
- O -
activating O +
factor O +
is O +
shown O +
here O +
to O +
have O +
a O +
direct O +
and O +
profound O +
effect O +
on O +
a O +
pure B-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

[ O +
Glucocorticoid O +
receptors O +
in O +
peripheral O +
blood O +
lymphocytes O +
of O +
patients O +
with O +
bronchial O +
asthma O +
] O +

Quantitation O +
of O +
glucocorticoid O +
receptors O +
( O +
GCR O +
) O +
and O +
the O +
study O +
of O +
their O +
affinity O +
for O +
glucocorticosteroids O +
( O +
GCS O +
) O +
were O +
made O +
in O +
peripheral O +
blood O +
lymphocytes O +
of O +
bronchial O +
asthma O +
( O +
BA O +
) O +
patients O +
in O +
consideration O +
of O +
GCR O +
treatment O +
and O +
serum O +
levels O +
of O +
endogenous O +
cortisol O +
. O +

It O +
is O +
stated O +
that O +
GCR O +
of O +
healthy O +
controls O +
and O +
GCS O -
- O -
untreated O +
patients O +
outnumbered O +
those O +
of O +
cortisol O -
- O -
dependent O +
BA O +
patients O +
on O +
hormone O +
therapy O +
. O +

Following O +
discontinuation O +
of O +
glucocorticoid O +
drugs O +
GCR O +
count O +
in O +
cortisol O -
- O -
dependent O +
BA O +
tends O +
to O +
rise O +
. O +

Endogenous O +
cortisol O +
has O +
no O +
effect O +
on O +
GCR O +
level O +
estimated O +
by O +
3H O -
- O -
triamcinolone O +
acetonide O +
. O +

1 O +
, O +
25-Dihydroxyvitamin O +
D3 O +
receptor O +
RNA O +
: O +
expression O +
in O +
hematopoietic O +
cells O +
. O +

1 O +
, O +
25-Dihydroxyvitamin O +
D3 O +
[ O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
] O +
induces O +
differentiation O +
and O +
inhibits O +
proliferation O +
of O +
myeloid O +
leukemic O +
cells O +
from O +
various O +
lines O +
and O +
patients O +
; O +
these O +
effects O +
are O +
probably O +
mediated O +
through O +
the O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
. O +

Little O +
is O +
known O +
of O +
expression O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
RNA O +
in O +
hematopoietic O +
cells O +
. O +

We O +
examined O +
the O +
expression O +
and O +
modulation O +
of O +
expression O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
RNA O +
in O +
various O +
proliferating O +
and O +
nonproliferating O +
hematopoietic O +
cells O +
. O +

Constitutive O +
expression O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
RNA O +
was O +
detected O +
in O +
various O +
kinds O +
of O +
hematopoietic O +
cells O +
, O +
including O +
macrophages O +
and O +
activated O +
T O +
lymphocytes O +
, O +
as O +
well O +
as O +
in O +
cell O +
lines O +
KG-1 B-CellLine +
( O +
myeloblasts B-CellLine +
) O +
, O +
HL-60 B-CellLine +
( O +
promyelocytes B-CellLine +
) O +
, O +
ML-3 B-CellLine +
( O +
myelomonoblasts B-CellLine +
) O +
, O +
U937 B-CellLine +
, O +
THP-1 B-CellLine +
( O +
monoblasts B-CellLine +
) O +
, O +
K562 B-CellLine +
( O +
erythroblasts B-CellLine +
) O +
, O +
and O +
S B-CellLine -
- I-CellLine -
LB1 I-CellLine +
( O +
HTLV-1-transfected B-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
) O +
. O +

Receptor O +
transcripts O +
were O +
4.6 O +
kilobases O +
( O +
kb O +
) O +
, O +
and O +
no O +
variant O +
sizes O +
were O +
observed O +
. O +

All O +
cell O +
lines O +
examined O +
in O +
this O +
group O +
also O +
expressed O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptors O +
. O +

Most O +
B B-CellLine +
lymphocyte I-CellLine +
lines I-CellLine +
expressed O +
negligible O +
levels O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
RNA O +
and O +
protein O +
; O +
however O +
; O +
analysis O +
of O +
a O +
lymphoid B-CellLine -
/ I-CellLine -
myeloid I-CellLine +
somatic I-CellLine +
hybrid I-CellLine +
suggested O +
that O +
suppression O +
of O +
expression O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
RNA O +
in O +
B O +
lymphocytes O +
may O +
be O +
a O +
dominant O +
characteristic O +
. O +

HL-60 B-CellLine +
cells I-CellLine +
were O +
cultured O +
with O +
10 O +
( O +
-7 O +
) O +
mol O -
/ O -
L O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
for O +
24 O +
to O +
72 O +
hours O +
, O +
and O +
levels O +
of O +
expression O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
and O +
its O +
RNA O +
were O +
examined O +
. O +

Levels O +
of O +
RNA O +
coding O +
for O +
the O +
receptor O +
were O +
not O +
modulated O +
by O +
exposure O +
to O +
high O +
levels O +
of O +
ligand O +
. O +

Levels O +
of O +
occupied O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
protein O +
increased O +
in O +
these O +
HL-60 B-CellLine +
cells I-CellLine +
; O +
but O +
the O +
total O +
number O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptors O +
decreased O +
about O +
50 O +
% O +
at O +
24 O +
hours O +
and O +
returned O +
toward O +
normal O +
at O +
72 O +
hours O +
. O +

Steady O -
- O -
state O +
levels O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
RNA O +
were O +
not O +
affected O +
by O +
terminal O +
differentiation O +
of O +
HL-60 B-CellLine +
toward O +
either O +
granulocytes O +
or O +
macrophages O +
. O +

Nondividing O +
macrophages O +
from O +
normal O +
individuals O +
also O +
expressed O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
RNA O +
. O +

In O +
contrast O +
, O +
nondividing O +
peripheral O +
blood O +
lymphocytes O +
from O +
normal O +
individuals O +
did O +
not O +
express O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
RNA O +
; O +
with O +
stimulation O +
of O +
proliferation O +
of O +
these O +
cells O +
, O +
accumulation O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
RNA O +
increased O +
markedly O +
. O +

Half O -
- O -
life O +
( O +
t1 O -
/ O -
2 O +
) O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
RNA O +
in O +
T O +
lymphocytes O +
was O +
short O +
( O +
1 O +
hour O +
) O +
as O +
determined O +
by O +
measuring O +
decay O +
of O +
the O +
message O +
after O +
addition O +
of O +
actinomycin O +
D O +
. O +

Consistent O +
with O +
this O +
short O +
t1 O -
/ O -
2 O +
, O +
accumulation O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
RNA O +
increased O +
in O +
cells O +
as O +
their O +
protein O +
synthesis O +
was O +
inhibited O +
. O +

Further O +
studies O +
are O +
required O +
to O +
understand O +
the O +
physiologic O +
role O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptors O +
in O +
myeloid O +
cells O +
and O +
proliferating O +
T O +
lymphocytes O +
. O +

Kappa O +
B O +
binding O +
proteins O +
are O +
constitutively O +
expressed O +
in O +
an O +
IL-2 B-CellLine +
autocrine I-CellLine +
human I-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

The O +
IL-2 O +
and O +
the O +
IL-2-R O +
alpha O +
genes O +
are O +
both O +
expressed O +
transiently O +
in O +
normal O +
T O +
lymphocytes O +
after O +
Ag O +
or O +
mitogen O +
activation O +
. O +

In O +
contrast O +
, O +
the O +
human B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
IARC B-CellLine +
301 I-CellLine +
, O +
expresses O +
these O +
two O +
genes O +
constitutively O +
and O +
we O +
have O +
previously O +
demonstrated O +
that O +
its O +
growth O +
depends O +
on O +
the O +
autocrine O +
production O +
of O +
this O +
T O +
cell O +
growth O +
factor O +
and O +
high O +
affinity O +
IL-2R O +
. O +

To O +
dissect O +
the O +
molecular O +
basis O +
for O +
the O +
unusual O +
persistent O +
expression O +
of O +
the O +
IL-2 O +
and O +
IL-2-R O +
alpha O +
genes O +
in O +
these O +
IARC B-CellLine +
301 I-CellLine +
T O +
cells O +
, O +
we O +
have O +
analyzed O +
the O +
interactions O +
of O +
constitutively O +
expressed O +
nuclear O +
proteins O +
with O +
the O +
5 O +
' O +
flanking O +
regions O +
of O +
the O +
IL-2 O +
and O +
IL-2-R O +
alpha O +
genes O +
using O +
both O +
DNase O +
I O +
footprinting O +
and O +
gel O +
retardation O +
techniques O +
. O +

We O +
have O +
found O +
that O +
a O +
region O +
in O +
both O +
genes O +
( O +
-276 O +
to O +
-250 O +
for O +
IL-2-R O +
alpha O +
and O +
-203 O +
to O +
-183 O +
for O +
IL-2 O +
) O +
, O +
which O +
corresponds O +
to O +
a O +
kappa O +
B O +
enhancer O +
element O +
, O +
is O +
specifically O +
protected O +
by O +
nuclear O +
proteins O +
from O +
IARC B-CellLine +
301 I-CellLine +
. O +

In O +
agreement O +
with O +
this O +
finding O +
, O +
both O +
the O +
IL-2 O +
and O +
IL-2-R O +
alpha O +
promoters O +
are O +
active O +
in O +
transient O +
transfection O +
assays O +
in O +
IARC B-CellLine +
301 I-CellLine +
cells I-CellLine +
. O +

In O +
contrast O +
, O +
mutation O +
of O +
the O +
kappa O +
B O +
enhancer O +
results O +
in O +
markedly O +
attenuated O +
activities O +
of O +
both O +
promoters O +
. O +

Two O +
proteins O +
binding O +
the O +
kappa O +
B O +
sequence O +
, O +
NF O -
- O -
kappa O +
B O +
and O +
KBF1 O +
, O +
are O +
constitutively O +
expressed O +
in O +
IARC B-CellLine +
301 I-CellLine +
nuclei O +
and O +
induced O +
by O +
PMA O +
and O +
PHA O +
in O +
Jurkat B-CellLine +
. O +

They O +
bind O +
to O +
the O +
kappa O +
B O +
motifs O +
with O +
different O +
relative O +
affinities O +
that O +
may O +
reflect O +
their O +
different O +
contribution O +
in O +
the O +
expression O +
of O +
various O +
promoters O +
. O +

Isolation O +
of O +
a O +
rel O -
- O -
related O +
human O +
cDNA O +
that O +
potentially O +
encodes O +
the O +
65-kD O +
subunit O +
of O +
NF O -
- O -
kappa O +
B O +
[ O +
published O +
erratum O +
appears O +
in O +
Science O +
1991 O +
Oct O +
4 O +
; O +
254 O +
( O +
5028 O +
) O +
: O +
11 O +
] O +

A O +
DNA O +
probe O +
that O +
spanned O +
a O +
domain O +
conserved O +
among O +
the O +
proto O -
- O -
oncogene O +
c O -
- O -
rel O +
, O +
the O +
Drosophila O +
morphogen O +
dorsal O +
, O +
and O +
the O +
p50 O +
DNA O +
binding O +
subunit O +
of O +
NF O -
- O -
kappa O +
B O +
was O +
generated O +
from O +
Jurkat O +
T O +
cell O +
complementary O +
DNA O +
with O +
the O +
polymerase O +
chain O +
reaction O +
( O +
PCR O +
) O +
and O +
degenerate O +
oligonucleotides O +
. O +

This O +
probe O +
was O +
used O +
to O +
identify O +
a O +
rel O -
- O -
related O +
complementary O +
DNA O +
that O +
hybridized O +
to O +
a O +
2.6-kilobase O +
messenger O +
RNA O +
present O +
in O +
human O +
T O +
and O +
B O +
lymphocytes O +
. O +

In O +
vitro O +
transcription O +
and O +
translation O +
of O +
the O +
complementary O +
DNA O +
resulted O +
in O +
the O +
synthesis O +
of O +
a O +
protein O +
with O +
an O +
apparent O +
molecular O +
size O +
of O +
65 O +
kilodaltons O +
( O +
kD O +
) O +
. O +

The O +
translated O +
protein O +
showed O +
weak O +
DNA O +
binding O +
with O +
a O +
specificity O +
for O +
the O +
kappa O +
B O +
binding O +
motif O +
. O +

This O +
protein O -
- O -
DNA O +
complex O +
comigrated O +
with O +
the O +
complex O +
obtained O +
with O +
the O +
purified O +
human O +
p65 O +
NF O -
- O -
kappa O +
B O +
subunit O +
and O +
binding O +
was O +
inhibited O +
by O +
I O +
kappa O +
B O -
- O -
alpha O +
and O +
-beta O +
proteins O +
. O +

In O +
addition O +
, O +
the O +
65-kD O +
protein O +
associated O +
with O +
the O +
p50 O +
subunit O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
the O +
kappa O +
B O +
probe O +
to O +
form O +
a O +
complex O +
with O +
the O +
same O +
electrophoretic O +
mobility O +
as O +
the O +
NF O -
- O -
kappa O +
B O -
- O -
DNA O +
complex O +
. O +

Therefore O +
the O +
rel O -
- O -
related O +
65-kD O +
protein O +
may O +
represent O +
the O +
p65 O +
subunit O +
of O +
the O +
active O +
NF O -
- O -
kappa O +
B O +
transcription O +
factor O +
complex O +
. O +

Transcriptional O +
down O -
- O -
regulation O +
of O +
c O -
- O -
myc O +
expression O +
by O +
protein O +
synthesis O -
- O -
dependent O +
and O +
-independent O +
pathways O +
in O +
a O +
human B-CellLine +
T I-CellLine +
lymphoblastic I-CellLine +
tumor I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

We O +
show O +
that O +
in O +
the O +
human B-CellLine +
T I-CellLine +
lymphoblastic I-CellLine +
tumor I-CellLine +
cell I-CellLine +
line I-CellLine +
Molt4 O +
c O -
- O -
myc O +
mRNA O +
and O +
protein O +
expression O +
is O +
down O -
- O -
regulated O +
after O +
exposure O +
to O +
dimethyl O +
sulfoxide O +
, O +
to O +
phorbol O +
myristate O +
acetate O +
, O +
or O +
to O +
the O +
calcium O +
ionophore O +
A23187 O +
, O +
which O +
raises O +
the O +
intracellular O +
calcium O +
concentration O +
. O +

A O +
block O +
to O +
RNA O +
elongation O +
is O +
largely O +
responsible O +
for O +
decreased O +
c O -
- O -
myc O +
transcription O +
. O +

Although O +
negative O +
regulation O +
by O +
dimethyl O +
sulfoxide O +
takes O +
place O +
even O +
when O +
protein O +
synthesis O +
is O +
inhibited O +
by O +
cycloheximide O +
, O +
the O +
phorbol O +
myristate O +
acetate O +
effect O +
is O +
blocked O +
to O +
some O +
extent O +
only O +
by O +
cycloheximide O +
. O +

The O +
calcium O +
ionophore O -
- O -
induced O +
c O -
- O -
myc O +
suppression O +
, O +
however O +
, O +
strictly O +
requires O +
de O +
novo O +
protein O +
synthesis O +
. O +

Therefore O +
, O +
two O +
different O +
negative O +
regulatory O +
pathways O +
are O +
involved O +
in O +
c O -
- O -
myc O +
regulation O +
: O +
one O +
which O +
is O +
independent O +
and O +
one O +
which O +
depends O +
on O +
de O +
novo O +
protein O +
synthesis O +
. O +

The O +
latter O +
one O +
appears O +
to O +
be O +
mediated O +
by O +
a O +
rapidly O +
calcium O -
- O -
dependent O +
induced O +
gene O +
product O +
. O +

Human O +
immunodeficiency O +
virus O +
type-2 O +
gene O +
expression O +
: O +
two O +
enhancers O +
and O +
their O +
activation O +
by O +
T O -
- O -
cell O +
activators O +
. O +

The O +
human O +
immunodeficiency O +
viruses O +
( O +
HIVs O +
) O +
may O +
include O +
a O +
spectrum O +
of O +
retroviruses O +
with O +
varying O +
potential O +
to O +
infect O +
their O +
host O +
, O +
undergo O +
long O +
periods O +
of O +
latent O +
infection O +
, O +
and O +
induce O +
pathology O +
. O +

Since O +
expression O +
of O +
the O +
viruses O +
is O +
in O +
large O +
part O +
regulated O +
by O +
the O +
sequence O +
elements O +
in O +
their O +
long O +
terminal O +
repeats O +
( O +
LTRs O +
) O +
, O +
this O +
study O +
was O +
directed O +
to O +
an O +
analysis O +
of O +
the O +
regulatory O +
elements O +
in O +
the O +
HIV-2 O +
LTR O +
. O +

The O +
HIV-2 O +
LTR O +
was O +
found O +
to O +
contain O +
two O +
enhancers O +
. O +

One O +
of O +
these O +
enhancers O +
is O +
, O +
in O +
part O +
, O +
identical O +
to O +
the O +
HIV-1 O +
enhancer O +
. O +

This O +
enhancer O +
in O +
HIV-1 O +
is O +
the O +
T O -
- O -
cell O +
activation O +
response O +
element O +
; O +
in O +
HIV-2 O +
, O +
however O +
, O +
it O +
is O +
the O +
second O +
enhancer O +
that O +
is O +
mainly O +
responsible O +
for O +
activation O +
in O +
response O +
to O +
T O -
- O -
cell O +
activators O +
. O +

The O +
second O +
enhancer O +
interacts O +
with O +
two O +
nuclear O +
binding O +
proteins O +
( O +
85 O +
kD O +
and O +
27 O +
kD O +
mobility O +
) O +
that O +
appear O +
to O +
be O +
required O +
for O +
optimal O +
enhancer O +
function O +
and O +
activation O +
. O +

Observations O +
such O +
as O +
these O +
encourage O +
the O +
speculation O +
that O +
there O +
may O +
be O +
subtle O +
differences O +
in O +
the O +
regulation O +
of O +
HIV-1 O +
and O +
HIV-2 O +
expression O +
that O +
may O +
be O +
relevant O +
to O +
the O +
possible O +
longer O +
latency O +
and O +
reduced O +
pathogenicity O +
of O +
HIV-2 O +
. O +

Suppression O +
of O +
signals O +
required O +
for O +
activation O +
of O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
in O +
cells O +
constitutively O +
expressing O +
the O +
HTLV O -
- O -
I O +
Tax O +
protein O +
. O +

Transient O +
short O -
- O -
term O +
expression O +
of O +
the O +
Tax O +
protein O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O -
- O -
I O +
( O +
HTLV O -
- O -
I O +
) O +
leads O +
to O +
activation O +
of O +
the O +
pleiotropic O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
. O +

Consistent O +
with O +
findings O +
obtained O +
with O +
transient O +
expression O +
assays O +
, O +
we O +
observed O +
marked O +
accumulation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
in O +
the O +
nucleus O +
of O +
Namalwa B-CellLine +
B I-CellLine +
lymphoid I-CellLine +
cells I-CellLine +
, O +
which O +
constitutively O +
express O +
Tax O +
. O +

In O +
contrast O +
, O +
NF O -
- O -
kappa O +
B O +
activity O +
was O +
not O +
detected O +
in O +
the O +
nucleus O +
following O +
long O -
- O -
term O +
expression O +
of O +
Tax O +
in O +
Jurkat B-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
. O +

The O +
ability O +
of O +
both O +
mitogens O +
and O +
cytokines O +
to O +
activate O +
NF O -
- O -
kappa O +
B O +
was O +
also O +
blocked O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
constitutively O +
expressing O +
Tax O +
. O +

However O +
, O +
the O +
activation O +
of O +
other O +
mitogen O -
- O -
inducible O +
transcription O +
factors O +
, O +
such O +
as O +
Fos O +
and O +
Jun O +
, O +
was O +
unaffected O +
. O +

Thus O +
, O +
depending O +
on O +
the O +
cellular O +
environment O +
, O +
the O +
short- O +
and O +
long O -
- O -
term O +
effects O +
of O +
Tax O +
expression O +
can O +
be O +
quite O +
different O +
. O +

Consequently O +
, O +
one O +
function O +
of O +
Tax O +
in O +
cells O +
infected O +
with O +
HTLV O -
- O -
I O +
might O +
involve O +
cell O -
- O -
type O -
- O -
specific O +
suppression O +
, O +
as O +
opposed O +
to O +
activation O +
, O +
of O +
distinct O +
signal O +
pathways O +
. O +

The O +
cells O +
lines O +
described O +
here O +
should O +
be O +
useful O +
for O +
the O +
delineation O +
of O +
signaling O +
pathways O +
utilized O +
in O +
the O +
selective O +
regulation O +
of O +
gene O +
expression O +
. O +

A O +
thymus O -
- O -
specific O +
member O +
of O +
the O +
HMG O +
protein O +
family O +
regulates O +
the O +
human O +
T O +
cell O +
receptor O +
C O +
alpha O +
enhancer O +
. O +

The O +
human O +
T O +
cell O -
- O -
specific O +
transcription O +
factor O +
TCF-1 O +
alpha O +
plays O +
a O +
key O +
role O +
in O +
the O +
tissue O -
- O -
specific O +
activation O +
of O +
the O +
T O +
cell O +
receptor O +
( O +
TCR O +
) O +
C O +
alpha O +
enhancer O +
and O +
binds O +
to O +
pyrimidine O -
- O -
rich O +
elements O +
( O +
5'-PyCTTTG-3 O +
' O +
) O +
present O +
in O +
a O +
variety O +
of O +
other O +
T O +
cell O -
- O -
specific O +
control O +
regions O +
. O +

Using O +
amino O +
acid O +
sequence O +
information O +
derived O +
from O +
the O +
DNA O +
affinity O -
- O -
purified O +
protein O +
, O +
we O +
have O +
now O +
isolated O +
cDNA O +
clones O +
encoding O +
TCF-1 O +
alpha O +
. O +

The O +
TCF-1 O +
alpha O +
cDNA O +
contains O +
a O +
single O +
68-amino O -
- O -
acid O +
domain O +
that O +
is O +
homologous O +
to O +
a O +
region O +
conserved O +
among O +
high O -
- O -
mobility O +
group O +
( O +
HMG O +
) O +
and O +
nonhistone O +
chromosomal O +
proteins O +
. O +

Expression O +
of O +
full O -
- O -
length O +
and O +
mutant O +
cDNA O +
clones O +
in O +
bacteria O +
reveal O +
that O +
the O +
single O +
HMG O +
motif O +
, O +
which O +
is O +
predicted O +
to O +
contain O +
two O +
extended O +
alpha O -
- O -
helical O +
segments O +
, O +
is O +
sufficient O +
to O +
direct O +
the O +
sequence O -
- O -
specific O +
binding O +
of O +
TCF-1 O +
alpha O +
to O +
DNA O +
. O +

Northern O +
blot O +
experiments O +
demonstrate O +
further O +
that O +
TCF-1 O +
alpha O +
mRNA O +
is O +
highly O +
tissue O +
specific O +
, O +
found O +
primarily O +
in O +
the O +
thymus B-CellLine +
or I-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

The O +
immature B-CellLine +
CEM I-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
expresses O +
relatively O +
low O +
levels O +
of O +
TCF-1 O +
alpha O +
mRNA O +
, O +
which O +
are O +
increased O +
upon O +
activation O +
of O +
these O +
cells O +
by O +
phorbol O +
esters O +
. O +

Interestingly O +
, O +
the O +
cloned O +
TCF-1 O +
alpha O +
protein O +
is O +
a O +
potent O +
transcriptional O +
activator O +
of O +
the O +
human O +
TCR O +
alpha O +
enhancer O +
in O +
nonlymphoid B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
whereas O +
the O +
activity O +
of O +
the O +
endogenous O +
protein O +
in O +
T B-CellLine +
cell I-CellLine +
lines I-CellLine +
is O +
strongly O +
dependent O +
on O +
an O +
additional O +
T B-CellLine +
cell I-CellLine -
- I-CellLine -
specific I-CellLine +
protein I-CellLine +
that O +
interacts O +
with O +
the O +
core O +
enhancer O +
. O +

TCF-1 O +
alpha O +
is O +
currently O +
unique O +
among O +
the O +
newly O +
emerging O +
family O +
of O +
DNA O -
- O -
binding O +
regulatory O +
proteins O +
that O +
share O +
the O +
HMG O +
motif O +
in O +
that O +
it O +
is O +
a O +
highly O +
tissue O -
- O -
specific O +
RNA O +
polymerase O +
II O +
transcription O +
factor O +
. O +

Immune O +
response O +
of O +
peripheral O +
blood O +
mononuclear O +
cells O +
to O +
HBx O -
- O -
antigen O +
of O +
hepatitis O +
B O +
virus O +
. O +

The O +
hepatitis O +
B O +
virus O +
genome O +
encodes O +
a O +
transcriptional O +
transactivator O +
protein O +
designated O +
HBxAg O +
. O +

We O +
have O +
investigated O +
whether O +
this O +
antigen O +
is O +
a O +
target O +
structure O +
for O +
human O +
T O -
- O -
lymphocytes O +
. O +

Using O +
recombinant O +
HBxAg O +
protein O +
, O +
we O +
found O +
HBxAg O +
-specific O +
stimulation O +
of O +
peripheral O +
blood O +
mononuclear O +
cells O +
in O +
patients O +
with O +
acute O +
hepatitis O +
B O +
virus O +
infection O +
( O +
6 O +
of O +
6 O +
) O +
and O +
chronic O +
hepatitis O +
B O +
virus O +
infection O +
( O +
6 O +
of O +
17 O +
) O +
but O +
not O +
in O +
healthy O +
individuals O +
. O +

With O +
HBxAg O +
-specific O +
synthetic O +
polypeptides O +
, O +
several O +
T O -
- O -
cell O +
epitopes O +
were O +
identified O +
. O +

Most O +
were O +
located O +
in O +
the O +
carboxyterminal O +
half O +
of O +
the O +
HBxAg O +
protein O +
. O +

Five O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
specific O +
for O +
a O +
T O -
- O -
cell O +
epitope O +
located O +
at O +
the O +
carboxyterminal O +
region O +
of O +
HBxAg O +
were O +
established O +
and O +
found O +
to O +
belong O +
to O +
the O +
CD2 B-CellLine -
/ I-CellLine -
CD4-positive I-CellLine +
, I-CellLine +
CD8-negative I-CellLine +
subtype I-CellLine +
. O +

These O +
data O +
establish O +
for O +
the O +
first O +
time O +
HBxAg O +
as O +
an O +
antigen O +
in O +
the O +
cellular O +
immune O +
response O +
. O +

A O +
study O +
on O +
the O +
circadian O +
rhythm O +
of O +
glucocorticoid O +
receptor O +
. O +

Circadian O +
rhythm O +
in O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
was O +
studied O +
in O +
the O +
rat O +
liver O +
and O +
human O +
peripheral O +
leukocytes O +
. O +

For O +
rats O +
exposed O +
to O +
a O +
natural O +
environmental O +
photic O +
cycle O +
or O +
a O +
12L O +
: O +
12D O +
artificial O +
light O +
regime O +
, O +
peak O +
values O +
of O +
hepatic O +
GR O +
were O +
detected O +
between O +
23 O +
: O +
00 O +
and O +
02 O +
: O +
00 O +
h O +
. O +

Except O +
for O +
a O +
4-hour O +
advancement O +
of O +
the O +
peak O +
, O +
a O +
similar O +
circadian O +
rhythm O +
of O +
hepatic O +
GR O +
was O +
detected O +
in O +
rats O +
reared O +
under O +
a O +
reversed O +
lighting O +
regimen O +
( O +
12D O +
: O +
12L O +
; O +
lights O +
on O +
between O +
18 O +
: O +
30 O +
and O +
06 O +
: O +
30 O +
h O +
) O +
. O +

In O +
human O +
leukocytes O +
, O +
the O +
peak O +
value O +
of O +
GR O +
was O +
found O +
to O +
parallel O +
that O +
of O +
plasma O +
cortisol O +
with O +
high O +
and O +
low O +
values O +
detected O +
at O +
04 O +
: O +
00 O -
- O -
08 O +
: O +
00 O +
h O +
and O +
23 O +
: O +
00 O -
- O -
24 O +
: O +
00 O +
h O +
, O +
respectively O +
. O +

In O +
patients O +
suffering O +
from O +
Cushing O +
's O +
syndrome O +
, O +
the O +
circadian O +
rhythm O +
of O +
plasma O +
cortisol O +
either O +
disappeared O +
or O +
was O +
inverted O +
while O +
that O +
of O +
GR O +
did O +
not O +
significantly O +
deviate O +
from O +
the O +
normal O +
subjects O +
. O +

For O +
apoplexic O +
patients O +
with O +
lesions O +
localized O +
to O +
the O +
base O +
of O +
the O +
brain O +
as O +
indicated O +
by O +
computerized O +
tomography O +
, O +
the O +
diurnal O +
variation O +
of O +
GR O +
was O +
abolished O +
. O +

Conversely O +
, O +
diurnal O +
rhythmicity O +
persisted O +
in O +
apoplexy O +
patients O +
whose O +
lesions O +
were O +
in O +
the O +
cerebral O +
cortex O +
. O +

Thus O +
, O +
we O +
postulated O +
that O +
the O +
circadian O +
modification O +
of O +
GR O +
was O +
independent O +
of O +
the O +
diurnal O +
fluctuations O +
in O +
plasma O +
cortisol O +
level O +
or O +
the O +
circadian O +
variations O +
in O +
environmental O +
lighting O +
and O +
that O +
the O +
rhythmicity O +
might O +
be O +
regulated O +
by O +
the O +
' O -
circadian O +
pacemaker O +
' O +
located O +
in O +
the O +
human O +
basal O +
brain O +
. O +

These O +
diurnal O +
variations O +
in O +
GR O +
might O +
serve O +
to O +
coordinate O +
the O +
reactivity O +
of O +
the O +
target O +
cells O +
to O +
cortisol O +
because O +
the O +
diurnal O +
rhythms O +
of O +
a O +
GR O +
-mediated O +
response O +
, O +
the O +
fractional O +
inhibition O +
of O +
chemotactic O +
migration O +
rate O +
of O +
polymorphonuclear O +
leukocytes O +
by O +
cortisol O +
, O +
were O +
found O +
to O +
be O +
synchronous O +
with O +
those O +
of O +
GR O +
. O +

Purification O +
of O +
TCF-1 O +
alpha O +
, O +
a O +
T O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
that O +
activates O +
the O +
T O -
- O -
cell O +
receptor O +
C O +
alpha O +
gene O +
enhancer O +
in O +
a O +
context O -
- O -
dependent O +
manner O +
. O +

The O +
differentiation O +
of O +
T O +
cells O +
into O +
functionally O +
diverse O +
subpopulations O +
is O +
controlled O +
in O +
part O +
, O +
by O +
transcriptional O +
activation O +
and O +
silencing O +
; O +
however O +
, O +
little O +
is O +
known O +
in O +
detail O +
about O +
the O +
proteins O +
that O +
influence O +
this O +
developmental O +
process O +
. O +

We O +
have O +
purified O +
a O +
new O +
T O -
- O -
cell O -
- O -
specific O +
factor O +
, O +
TCF-1 O +
alpha O +
, O +
that O +
is O +
implicated O +
in O +
the O +
activation O +
of O +
genes O +
encoding O +
a O +
major O +
component O +
of O +
the O +
human O +
T O -
- O -
cell O +
receptor O +
( O +
TCR O +
) O +
. O +

TCF-1 O +
alpha O +
, O +
originally O +
identified O +
and O +
purified O +
through O +
its O +
binding O +
sites O +
on O +
the O +
HIV-1 O +
promoter O +
, O +
was O +
found O +
to O +
bind O +
to O +
the O +
TCR O +
alpha O +
enhancer O +
and O +
to O +
promoters O +
for O +
several O +
genes O +
expressed O +
at O +
significantly O +
earlier O +
stages O +
of O +
T O -
- O -
cell O +
development O +
than O +
the O +
TCR O +
alpha O +
gene O +
( O +
e.g. O +
, O +
p56lck O +
and O +
CD3 O +
delta O +
) O +
. O +

Sequences O +
related O +
to O +
the O +
TCF-1 O +
alpha O +
binding O +
motif O +
( O +
5'-GGCACCCTTTGA-3 O +
' O +
) O +
are O +
also O +
found O +
in O +
the O +
human O +
TCR O +
delta O +
( O +
and O +
possibly O +
TCR O +
beta O +
) O +
enhancers O +
. O +

Southwestern O +
and O +
gel O +
renaturation O +
experiments O +
with O +
the O +
use O +
of O +
purified O +
protein O +
fractions O +
revealed O +
that O +
TCF-1 O +
alpha O +
activity O +
is O +
derived O +
from O +
a O +
family O +
of O +
57- O +
to O +
53-kD O +
proteins O +
that O +
are O +
abundantly O +
expressed O +
in O +
mature B-CellLine +
and I-CellLine +
immature I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
( O +
Jurkat B-CellLine +
, O +
CCRF B-CellLine -
- I-CellLine -
CEM I-CellLine +
) O +
and O +
not O +
in O +
mature B-CellLine +
B I-CellLine +
cells I-CellLine +
( O +
JY B-CellLine +
, O +
Namalwa B-CellLine +
) O +
or O +
nonlymphoid B-CellLine +
( I-CellLine +
HeLa I-CellLine +
) I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

A O +
small O +
95-bp O +
fragment O +
of O +
the O +
TCR O +
alpha O +
control O +
region O +
that O +
contains O +
the O +
TCF-1 O +
alpha O +
binding O +
site O +
juxtaposed O +
between O +
a O +
cAMP O -
- O -
response O +
element O +
( O +
the O +
CRE O +
or O +
T O +
alpha O +
1 O +
motif O +
) O +
and O +
the O +
binding O +
site O +
for O +
a O +
distinct O +
lymphoid O -
- O -
specific O +
protein O +
( O +
TCF-2 O +
alpha O +
) O +
behaved O +
as O +
a O +
potent O +
T O -
- O -
cell O -
- O -
specific O +
enhancer O +
in O +
vivo O +
. O +

Tandem O +
copies O +
of O +
this O +
enhancer O +
functioned O +
synergistically O +
in O +
mature B-CellLine +
( I-CellLine +
Jurkat I-CellLine +
) I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
as O +
well O +
as O +
resting O +
and O +
activated O +
immature B-CellLine +
( I-CellLine +
CCRF I-CellLine -
- I-CellLine -
CEM I-CellLine +
) I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
. O +

Mutation O +
of O +
the O +
TCF-1 O +
alpha O +
binding O +
site O +
diminished O +
enhancer O +
activity O +
and O +
disrupted O +
the O +
synergism O +
observed O +
in O +
vivo O +
between O +
tandem O +
enhancer O +
repeats O +
. O +

The O +
TCF-1 O +
alpha O +
binding O +
site O +
was O +
also O +
required O +
for O +
TCR O +
alpha O +
enhancer O +
activity O +
in O +
transcriptionally O +
active O +
extracts O +
from O +
Jurkat B-CellLine +
but O +
not O +
HeLa B-CellLine +
cells I-CellLine +
, O +
confirming O +
that O +
TCF-1 O +
alpha O +
is O +
a O +
T O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
. O +

Curiously O +
, O +
the O +
TCF-1 O +
alpha O +
binding O +
element O +
was O +
inactive O +
in O +
vivo O +
when O +
removed O +
from O +
its O +
neighboring O +
elements O +
on O +
the O +
TCR O +
alpha O +
enhancer O +
and O +
positioned O +
in O +
one O +
or O +
more O +
copies O +
upstream O +
of O +
a O +
heterologous O +
promoter O +
. O +

Thus O +
, O +
the O +
transcriptional O +
activity O +
of O +
TCF-1 O +
alpha O +
appears O +
to O +
depend O +
on O +
the O +
TCF-2 O +
alpha O +
and O +
T O +
alpha O +
1 O +
( O +
CREB O +
) O +
transcription O +
factors O +
and O +
the O +
context O +
of O +
its O +
binding O +
site O +
within O +
the O +
TCR O +
alpha O +
enhancer O +
. O +

Processing O +
of O +
the O +
precursor O +
of O +
NF O -
- O -
kappa O +
B O +
by O +
the O +
HIV-1 O +
protease O +
during O +
acute O +
infection O +
. O +

Transcription O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type-1 O +
( O +
HIV-1 O +
) O +
genome O +
is O +
regulated O +
in O +
part O +
by O +
cellular O +
factors O +
and O +
is O +
stimulated O +
by O +
activation O +
of O +
latently O +
infected O +
T O +
cells O +
. O +

T O -
- O -
cell O +
activation O +
also O +
correlates O +
with O +
the O +
induction O +
of O +
the O +
factor O +
NF O -
- O -
kappa O +
B O +
which O +
binds O +
to O +
two O +
adjacent O +
sites O +
in O +
the O +
HIV-1 O +
long O +
terminal O +
repeat O +
. O +

This O +
factor O +
consists O +
of O +
two O +
DNA O -
- O -
binding O +
subunits O +
of O +
relative O +
molecular O +
mass O +
50 O +
, O +
000 O +
( O +
50 O -
K O +
) O +
associated O +
with O +
two O +
65 O -
K O +
subunits O +
. O +

It O +
is O +
located O +
in O +
the O +
nucleus O +
in O +
mature O +
B O +
cells O +
, O +
but O +
is O +
present O +
in O +
other O +
cell O +
types O +
as O +
an O +
inactive O +
cytoplasmic O +
complex O +
. O +

External O +
stimuli O +
, O +
including O +
those O +
that O +
activate O +
T O +
cells O +
, O +
result O +
in O +
nuclear O +
translocation O +
of O +
active O +
NF O -
- O -
kappa O +
B O +
. O +

The O +
cloning O +
of O +
the O +
complementary O +
DNA O +
for O +
the O +
50 O -
K O +
subunit O +
helped O +
to O +
identify O +
an O +
exclusively O +
cytoplasmic O +
105 O -
K O +
precursor O +
( O +
p105 O +
) O +
( O +
V.B. O +
, O +
P.K. O +
and O +
A.I. O +
, O +
manuscript O +
submitted O +
) O +
. O +

The O +
expression O +
of O +
active O +
NF O -
- O -
kappa O +
B O +
might O +
therefore O +
also O +
be O +
regulated O +
by O +
the O +
extent O +
of O +
processing O +
of O +
p105 O +
. O +

Because O +
HIV-1 O +
requires O +
active O +
NF O -
- O -
kappa O +
B O +
for O +
efficient O +
transcription O +
, O +
we O +
tested O +
the O +
effect O +
of O +
HIV-1 O +
infection O +
on O +
the O +
processing O +
of O +
the O +
human O +
105 O -
K O +
precursor O +
. O +

We O +
show O +
here O +
that O +
the O +
HIV-1 O +
protease O +
can O +
process O +
p105 O +
and O +
increases O +
levels O +
of O +
active O +
nuclear O +
NF O -
- O -
kappa O +
B O +
complex O +
. O +

Vitamin O +
D O +
receptor O +
expression O +
in O +
human O +
lymphocytes O +
. O +

Signal O +
requirements O +
and O +
characterization O +
by O +
western O +
blots O +
and O +
DNA O +
sequencing O +
. O +

The O +
signals O +
controlling O +
the O +
expression O +
of O +
the O +
receptor O +
protein O +
for O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
in O +
normal O +
human O +
lymphocytes O +
and O +
the O +
relationship O +
of O +
this O +
protein O +
to O +
the O +
classical O +
vitamin O +
D O +
receptor O +
were O +
examined O +
. O +

Lymphocytes O +
activated O +
with O +
the O +
OKT3 O +
antibody O +
to O +
the O +
T O -
- O -
cell O +
antigen O +
receptor O +
expressed O +
fewer O +
binding O +
sites O +
as O +
compared O +
to O +
lymphocytes O +
that O +
were O +
activated O +
by O +
the O +
polyclonal O +
activator O +
phytohemagglutinin O +
( O +
PHA O +
) O +
. O +

However O +
, O +
combination O +
of O +
OKT3 O +
and O +
phorbol O +
myristate O +
acetate O +
produced O +
a O +
concentration O +
of O +
binding O +
sites O +
similar O +
to O +
the O +
PHA B-CellLine -
- I-CellLine -
activated I-CellLine +
cells I-CellLine +
. O +

The O +
receptor O +
from O +
OKT3 O +
and O +
OKT3 O +
+ O +
phorbol O +
myristate O +
acetate O +
-activated O +
lymphocytes O +
exhibited O +
decreased O +
binding O +
to O +
DNA O -
- O -
cellulose O +
compared O +
to O +
PHA O -
- O -
activated O +
lymphocytes O +
. O +

In O +
lymphocytes O +
activated O +
either O +
by O +
PHA O +
or O +
OKT3 O +
( O +
but O +
not O +
in O +
resting O +
cells O +
) O +
, O +
a O +
50-kDa O +
species O +
cross O -
- O -
reacting O +
with O +
a O +
monoclonal O +
antibody O +
against O +
the O +
intestinal O +
vitamin O +
D O +
receptor O +
was O +
detected O +
. O +

Finally O +
, O +
RNA O +
from O +
activated O +
lymphocytes O +
was O +
amplified O +
by O +
polymerase O +
chain O +
reaction O +
using O +
oligonucleotide O +
primers O +
flanking O +
the O +
196 O +
base O +
pair O +
long O +
region O +
encoding O +
the O +
DNA O -
- O -
binding O +
domain O +
of O +
the O +
human O +
intestinal O +
receptor O +
. O +

The O +
amplified O +
product O +
showed O +
an O +
identical O +
nucleotide O +
sequence O +
to O +
the O +
DNA O -
- O -
binding O +
domain O +
of O +
the O +
human O +
intestinal O +
receptor O +
. O +

These O +
findings O +
suggest O +
that O +
expression O +
of O +
the O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
receptor O +
in O +
lymphocytes O +
is O +
triggered O +
by O +
distinct O +
and O +
contingent O +
signals O +
, O +
and O +
that O +
the O +
protein O +
and O +
the O +
mRNA O +
encoding O +
it O +
are O +
identical O +
to O +
the O +
classical O +
vitamin O +
D O +
receptor O +
. O +

Role O +
for O +
the O +
Epstein O -
- O -
Barr O +
virus O +
nuclear O +
antigen O +
2 O +
in O +
viral O +
promoter O +
switching O +
during O +
initial O +
stages O +
of O +
infection O +
. O +

During O +
latent O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
infection O +
of O +
human O +
B O +
lymphocytes O +
, O +
six O +
viral O +
nuclear O +
antigen O +
( O +
EBNAs O +
) O +
are O +
expressed O +
from O +
long O +
primary O +
transcripts O +
by O +
means O +
of O +
alternative O +
splicing O +
and O +
alternative O +
polyadenylylation O +
sites O +
. O +

These O +
transcripts O +
initiate O +
from O +
one O +
of O +
two O +
promoters O +
, O +
Cp O +
or O +
Wp O +
, O +
that O +
function O +
in O +
a O +
mutually O +
exclusive O +
fashion O +
. O +

Wp O +
is O +
exclusively O +
utilized O +
during O +
the O +
initial O +
stages O +
of O +
infection O +
of O +
primary O +
B O +
lymphocytes O +
, O +
followed O +
by O +
a O +
switch O +
to O +
Cp O +
usage O +
. O +

These O +
studies O +
have O +
been O +
extended O +
to O +
show O +
that O +
( O +
i O +
) O +
a O +
mutant O +
EBV O +
strain O +
lacking O +
the O +
gene O +
encoding O +
EBNA O +
2 O +
fails O +
to O +
switch O +
from O +
Wp O +
to O +
Cp O +
usage O +
in O +
primary O +
B O +
lymphocytes O +
, O +
although O +
the O +
virus O +
contains O +
a O +
functional O +
Cp O +
; O +
( O +
ii O +
) O +
a O +
region O +
from O +
-429 O +
to O +
-245 O +
base O +
pairs O +
upstream O +
of O +
Cp O +
is O +
essential O +
for O +
Cp O +
activity O +
in O +
B O +
lymphocytes O +
, O +
but O +
only O +
in O +
the O +
context O +
of O +
upstream O +
and O +
downstream O +
sequences O +
; O +
( O +
iii O +
) O +
this O +
region O +
contains O +
an O +
EBNA O +
2-dependent O +
enhancer O +
; O +
and O +
( O +
iv O +
) O +
DNase O +
I O +
protection O +
employing O +
nuclear O +
extracts O +
from O +
B O +
and O +
T O +
lymphocytes O +
revealed O +
a O +
B O -
- O -
cell O -
- O -
specific O +
footprint O +
in O +
the O +
region O +
of O +
the O +
EBNA O +
2-dependent O +
enhancer O +
. O +

These O +
results O +
support O +
a O +
model O +
for O +
viral O +
promoter O +
switching O +
during O +
the O +
initial O +
stages O +
of O +
infection O +
in O +
which O +
Wp O +
activity O +
leads O +
to O +
the O +
expression O +
of O +
EBNA O +
2 O +
, O +
followed O +
by O +
activation O +
of O +
Cp O +
through O +
the O +
EBNA O +
2-dependent O +
enhancer O +
. O +

Glucocorticoid O +
receptor O +
characteristics O +
in O +
monocytes O +
of O +
patients O +
with O +
corticosteroid O -
- O -
resistant O +
bronchial O +
asthma O +
. O +

The O +
mechanism O +
of O +
corticosteroid O +
resistance O +
in O +
bronchial O +
asthma O +
has O +
been O +
studied O +
by O +
determining O +
the O +
rank O +
order O +
of O +
potency O +
for O +
different O +
corticosteroids O +
in O +
inhibiting O +
the O +
generation O +
of O +
a O +
3 O +
kD O +
molecule O +
from O +
peripheral O +
blood O +
monocytes O +
isolated O +
from O +
corticosteroid O -
- O -
sensitive O +
( O +
CS O +
) O +
and O +
corticosteroid O -
- O -
resistant O +
( O +
CR O +
) O +
asthmatic O +
subjects O +
, O +
which O +
augments O +
leukotriene O +
B4 O +
( O +
LTB4 O +
) O +
generation O +
by O +
human O +
neutrophils O +
( O +
PMN O +
) O +
stimulated O +
by O +
calcium O +
ionophore O +
. O +

In O +
addition O +
, O +
binding O +
studies O +
with O +
( O +
3H O +
) O +
dexamethasone O +
have O +
been O +
performed O +
to O +
determine O +
the O +
dissociation O +
constant O +
( O +
Kd O +
) O +
and O +
receptor O +
numbers O +
( O +
Ro O +
) O +
in O +
the O +
monocytes O +
of O +
these O +
two O +
groups O +
of O +
subjects O +
. O +

The O +
concentration O +
of O +
corticosteroid O +
producing O +
50 O +
% O +
inhibition O +
( O +
IC50 O +
) O +
was O +
600 O +
nM O +
, O +
70 O +
nM O +
, O +
and O +
0.5 O +
nM O +
for O +
hydrocortisone O +
, O +
methylprednisolone O +
, O +
and O +
dexamethasone O +
, O +
respectively O +
, O +
in O +
monocytes O +
from O +
CS O +
individuals O +
. O +

There O +
was O +
only O +
weak O +
inhibition O +
of O +
the O +
generation O +
of O +
enhancing O +
activity O +
by O +
the O +
corticosteroids O +
in O +
the O +
CR O +
asthmatic O +
individuals O +
. O +

The O +
dexamethasone O +
Kd O +
was O +
2.45 O +
+ O -
/- O +
0.58 O +
nM O +
( O +
mean O +
+ O -
/- O +
SEM O +
, O +
n O +
= O +
6 O +
) O +
in O +
the O +
CS O +
group O +
and O +
1.6 O +
+ O -
/- O +
0.35 O +
nM O +
( O +
mean O +
+ O -
/- O +
SEM O +
, O +
n O +
= O +
6 O +
) O +
in O +
the O +
CR O +
group O +
of O +
patients O +
( O +
p O +
= O +
0.14 O +
) O +
. O +

The O +
Ro O +
in O +
the O +
CS O +
group O +
was O +
3 O +
, O +
605 O +
+ O -
/- O +
984 O +
binding O +
sites O +
per O +
nucleus O +
( O +
mean O +
+ O -
/- O +
SEM O +
, O +
n O +
= O +
6 O +
) O +
and O +
4 O +
, O +
757 O +
+ O -
/- O +
692 O +
binding O +
sites O +
per O +
nucleus O +
( O +
mean O +
+ O -
/- O +
SEM O +
, O +
n O +
= O +
6 O +
) O +
in O +
the O +
CR O +
group O +
( O +
p O +
= O +
0.23 O +
) O +
. O +

These O +
findings O +
indicate O +
that O +
corticosteroid O +
resistance O +
in O +
bronchial O +
asthma O +
can O +
not O +
be O +
explained O +
by O +
abnormalities O +
in O +
corticosteroid O +
receptor O +
characteristics O +
. O +

Tissue O -
- O -
specific O +
expression O +
of O +
the O +
platelet O +
GPIIb O +
gene O +
. O +

One O +
of O +
the O +
major O +
objectives O +
in O +
the O +
study O +
of O +
thrombogenesis O +
is O +
to O +
determine O +
the O +
mechanisms O +
by O +
which O +
a O +
hematopoietic O +
progenitor O +
is O +
activated O +
and O +
committed O +
to O +
the O +
megakaryocytic O +
lineage O +
. O +

Recent O +
development O +
of O +
primary B-CellLine +
cultures I-CellLine +
of O +
human B-CellLine +
megakaryocytes I-CellLine +
and O +
the O +
molecular O +
cloning O +
of O +
genes O +
that O +
are O +
specific O +
to O +
this O +
lineage O +
offer O +
the O +
possibility O +
of O +
getting O +
some O +
insights O +
into O +
the O +
genetic O +
mechanisms O +
that O +
control O +
megakaryocytopoiesis O +
. O +

One O +
gene O +
of O +
interest O +
is O +
the O +
glycoprotein O +
IIb O +
( O +
GPIIb O +
) O +
gene O +
; O +
GPIIb O +
, O +
the O +
alpha O +
subunit O +
of O +
the O +
platelet O +
cytoadhesin O +
GPIIb O -
- O -
IIIa O +
, O +
is O +
produced O +
in O +
megakaryocytes B-CellLine +
at O +
an O +
early O +
stage O +
of O +
the O +
differentiation O +
, O +
whereas O +
the O +
other O +
subunit O +
of O +
this O +
complex O +
, O +
GPIIIa O +
, O +
is O +
expressed O +
in O +
other O +
cells O +
. O +

For O +
these O +
reasons O +
, O +
the O +
5'-flanking O +
region O +
of O +
the O +
GPIIb O +
gene O +
was O +
used O +
to O +
identify O +
the O +
regions O +
that O +
interact O +
with O +
DNA O -
- O -
binding O +
nuclear O +
factors O +
. O +

A O +
fragment O +
extending O +
from O +
-643 O +
to O +
+ O -
33 O +
is O +
capable O +
of O +
controlling O +
the O +
tissue O -
- O -
specific O +
expression O +
of O +
the O +
CAT O +
gene O +
in O +
transfection O +
experiments O +
. O +

Within O +
this O +
region O +
, O +
we O +
have O +
identified O +
several O +
sequences O +
that O +
are O +
implicated O +
in O +
DNA O +
protein O +
interactions O +
as O +
shown O +
in O +
DNAse O +
I O +
footprints O +
and O +
gel O +
mobility O +
shift O +
assays O +
. O +

One O +
region O +
, O +
centered O +
at O +
-54 O +
, O +
is O +
similar O +
to O +
a O +
nuclear O +
factor O +
E1-binding O +
site O +
, O +
and O +
a O +
region O +
located O +
at O +
position O +
-233 O +
contains O +
a O +
CCAAT O +
motif O +
. O +

Two O +
domains O +
centered O +
at O +
positions O +
-345 O +
and O +
-540 O +
, O +
respectively O +
, O +
bind O +
proteins O +
that O +
are O +
present O +
in O +
megakaryocytic B-CellLine +
cells I-CellLine +
and O +
nonrelated O +
cells O +
as O +
well O +
. O +

Finally O +
, O +
two O +
other O +
domains O +
, O +
located O +
at O +
positions O +
-460 O +
and O +
-510 O +
, O +
interact O +
with O +
proteins O +
that O +
are O +
only O +
present O +
in O +
megakaryocytic B-CellLine +
cells I-CellLine +
. O +

In O +
addition O +
, O +
deletion O +
of O +
the O +
region O +
containing O +
these O +
two O +
domains O +
results O +
in O +
a O +
significant O +
decrease O +
of O +
the O +
promoter O +
activity O +
. O +

It O +
is O +
very O +
likely O +
that O +
these O +
domains O +
bind O +
megakaryocyte O -
- O -
specific O +
nuclear O +
proteins O +
acting O +
as O +
positive O +
transcription O +
factors O +
. O +

Demonstration O +
of O +
estrogen O +
and O +
progesterone O +
receptors O +
as O +
well O +
as O +
Ki-67 O +
and O +
p-145 O +
antigens O +
in O +
single O +
tumor O +
cells O +
from O +
blood O +
and O +
pleural O +
effusions O +
using O +
a O +
slide O +
assay O +
. O +

We O +
describe O +
a O +
slide O +
assay O +
that O +
allows O +
the O +
demonstration O +
of O +
antigens O +
localized O +
in O +
the O +
nucleus O +
from O +
isolated O +
white O +
blood O +
cells O +
as O +
well O +
as O +
from O +
single O +
tumor O +
cells O +
derived O +
from O +
malignant O +
effusions O +
. O +

With O +
the O +
antibodies O +
Ki-67 O +
and O +
anti O -
- O -
p-145 O +
an O +
increased O +
rate O +
of O +
nuclear O +
and O +
nucleolar O +
staining O +
resulted O +
in O +
cells O +
from O +
highly O +
malignant O +
lymphomas O +
. O +

An O +
almost O +
identical O +
reaction O +
was O +
obtained O +
when O +
tumor O +
cells O +
from O +
malignant O +
effusions O +
were O +
tested O +
. O +

Cells O +
isolated O +
from O +
the O +
blood O +
of O +
patients O +
with O +
leukemic O +
spread O +
of O +
lymphomas O +
of O +
low O +
malignancy O +
yielded O +
a O +
weak O +
staining O +
comparable O +
to O +
that O +
of O +
normal O +
mesothelial O +
cells O +
from O +
non O -
- O -
tumorous O +
cavity O +
fluids O +
. O +

The O +
detection O +
of O +
estrogen O +
and O +
progesterone O +
receptors O +
( O +
ER O +
and O +
PR O +
) O +
localized O +
in O +
the O +
cell O +
nucleus O +
can O +
be O +
achieved O +
by O +
the O +
same O +
assay O +
. O +

The O +
reaction O +
is O +
enhanced O +
by O +
incubation O +
of O +
the O +
tumor O +
cells O +
for O +
30 O +
min O +
at O +
37 O +
degrees O +
C O +
prior O +
to O +
fixation O +
. O +

Pleural O +
effusions O +
from O +
20 O +
patients O +
with O +
breast O +
cancer O +
were O +
tested O +
. O +

ER O +
was O +
positive O +
in O +
13 O +
and O +
PR O +
was O +
positive O +
in O +
12 O +
of O +
the O +
20 O +
samples O +
. O +

In O +
5 O +
cases O +
there O +
was O +
a O +
divergent O +
reaction O +
with O +
ER O +
and O +
PR O +
antibody O +
. O +

The O +
hormone O +
receptors O +
of O +
the O +
primary O +
tumor O +
were O +
known O +
in O +
15 O +
( O +
ER O +
) O +
and O +
14 O +
( O +
PR O +
) O +
patients O +
, O +
respectively O +
. O +

In O +
each O +
cohort O +
there O +
was O +
only O +
one O +
case O +
with O +
a O +
negative O +
reaction O +
of O +
the O +
primary O +
tumor O +
and O +
a O +
positive O +
reaction O +
with O +
the O +
isolated O +
tumor O +
cells O +
from O +
the O +
pleural O +
effusions O +
. O +

These O +
results O +
indicate O +
that O +
the O +
demonstration O +
of O +
hormone O +
receptor O +
proteins O +
in O +
cells O +
from O +
malignant O +
effusions O +
is O +
possible O +
and O +
that O +
there O +
is O +
a O +
correlation O +
with O +
the O +
status O +
of O +
the O +
primary O +
site O +
of O +
cancer O +
. O +

Differentiation O -
- O -
associated O +
expression O +
of O +
the O +
Epstein O -
- O -
Barr O +
virus O +
BZLF1 O +
transactivator O +
protein O +
in O +
oral O +
hairy O +
leukoplakia O +
. O +

The O +
BZLF1 O +
protein O +
of O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
is O +
a O +
key O +
immediate O -
- O -
early O +
protein O +
which O +
has O +
been O +
shown O +
to O +
disrupt O +
virus O +
latency O +
in O +
EBV O -
- O -
infected O +
B O +
cells O +
. O +

We O +
have O +
generated O +
a O +
monoclonal O +
antibody O +
, O +
BZ1 O +
, O +
to O +
BZLF1 O +
which O +
reacts O +
in O +
immunohistology O +
, O +
immunoblotting O +
, O +
and O +
immunoprecipitation O +
and O +
which O +
recognizes O +
both O +
the O +
active O +
, O +
dimeric O +
form O +
and O +
the O +
inactive O +
, O +
monomeric O +
form O +
of O +
the O +
protein O +
. O +

Biopsies O +
of O +
oral O +
hairy O +
leukoplakia O +
, O +
an O +
AIDS O -
- O -
associated O +
lesion O +
characterized O +
by O +
high O -
- O -
level O +
EBV O +
replication O +
, O +
were O +
examined O +
by O +
immunohistochemistry O +
using O +
the O +
BZ1 O +
monoclonal O +
antibody O +
. O +

A O +
differentiation O -
- O -
associated O +
pattern O +
of O +
BZLF1 O +
expression O +
was O +
observed O +
, O +
BZ1 O +
reacting O +
with O +
nuclei O +
of O +
the O +
upper O +
spinous O +
layer O +
of O +
the O +
lesion O +
. O +

This O +
finding O +
suggests O +
that O +
the O +
BZLF1 O +
promoter O +
may O +
be O +
regulated O +
by O +
the O +
degree O +
of O +
squamous O +
differentiation O +
. O +

A O +
comparison O +
of O +
in O +
situ O +
hybridization O +
to O +
EBV O +
DNA O +
and O +
viral O +
capsid O +
antigen O +
staining O +
with O +
BZ1 O +
reactivity O +
suggested O +
that O +
BZLF1 O +
expression O +
precedes O +
rampant O +
virus O +
replication O +
. O +

The O +
inability O +
to O +
detect O +
EBV O +
in O +
the O +
lower O +
epithelial O +
layers O +
of O +
oral O +
hairy O +
leukoplakia O +
raises O +
questions O +
concerning O +
the O +
nature O +
of O +
EBV O +
latency O +
and O +
persistence O +
in O +
stratified O +
squamous O +
epithelium O +
. O +

Transactivation O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
promoter O +
by O +
human O +
herpesvirus O +
6 O +
( O +
HHV-6 O +
) O +
strains O +
GS O +
and O +
Z-29 O +
in O +
primary O +
human O +
T O +
lymphocytes O +
and O +
identification O +
of O +
transactivating O +
HHV-6 O +
( O +
GS O +
) O +
gene O +
fragments O +
. O +

Human O +
herpesvirus O +
6 O +
( O +
HHV-6 O +
) O +
can O +
activate O +
the O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
promoter O +
and O +
accelerate O +
cytopathic O +
effects O +
in O +
HIV O -
- O -
infected O +
human O +
T O +
cells O +
. O +

This O +
study O +
examines O +
the O +
regions O +
of O +
the O +
HIV O +
promoter O +
required O +
for O +
HHV-6 O +
transactivation O +
in O +
a O +
heterogeneous O +
population O +
of O +
primary O +
human O +
T O +
lymphocytes O +
with O +
or O +
without O +
antigenic O +
stimulation O +
. O +

Two O +
different O +
strains O +
of O +
HHV-6 O +
, O +
GS O +
and O +
Z29 O +
, O +
transactivated O +
the O +
HIV O +
promoter O +
. O +

The O +
GS O +
strain O +
transactivated O +
the O +
promoter O +
in O +
both O +
stimulated O +
and O +
resting O +
T O +
cells O +
, O +
while O +
the O +
Z29 O +
strain O +
increased O +
HIV O +
promoter O +
activity O +
only O +
in O +
stimulated O +
T O +
cells O +
. O +

Three O +
DNA O +
clones O +
containing O +
HHV-6 O +
( O +
GS O +
) O +
genomic O +
fragments O +
transactivated O +
the O +
HIV O +
promoter O +
in O +
cotransfected B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

A O +
21.4-kb O +
DNA O +
clone O +
, O +
pZVB70 O +
, O +
showed O +
the O +
highest O +
transactivating O +
ability O +
, O +
while O +
two O +
other O +
DNA O +
fragments O +
, O +
pZVB10 O +
( O +
6.2 O +
kb O +
) O +
and O +
pZVH14 O +
( O +
8.7 O +
kb O +
) O +
, O +
showed O +
lower O +
activity O +
. O +

One O +
of O +
these O +
clones O +
, O +
pZVH14 O +
, O +
activated O +
the O +
HIV O +
promoter O +
construct O +
containing O +
a O +
mutation O +
in O +
the O +
NF O +
kappa O +
B O +
site O +
. O +

However O +
, O +
this O +
mutated O +
NF O +
kappa O +
B O +
promoter O +
was O +
not O +
transactivated O +
during O +
HHV-6 O +
( O +
GS O +
) O +
infection O +
or O +
after O +
cotransfection O +
with O +
pZVB70 O +
or O +
pZVB10 O +
. O +

These O +
data O +
indicate O +
that O +
the O +
NF O +
kappa O +
B O +
sites O +
of O +
the O +
HIV O +
promoter O +
are O +
essential O +
for O +
its O +
transactivation O +
during O +
HHV-6 O +
( O +
GS O +
) O +
infection O +
. O +

By O +
increasing O +
HIV O +
promoter O +
activity O +
in O +
primary O +
T O +
lymphocytes O +
, O +
HHV-6 O +
may O +
consequently O +
increase O +
HIV O +
replication O +
, O +
leading O +
to O +
an O +
increase O +
in O +
the O +
cytopathic O +
effect O +
on O +
coinfected O +
human O +
T O +
cells O +
. O +

The O +
rhombotin O +
family O +
of O +
cysteine O -
- O -
rich O +
LIM O -
- O -
domain O +
oncogenes O +
: O +
distinct O +
members O +
are O +
involved O +
in O +
T O -
- O -
cell O +
translocations O +
to O +
human O +
chromosomes O +
11p15 O +
and O +
11p13 O +
. O +

A O +
chromosomal O +
translocation O +
in O +
a O +
T O -
- O -
cell O +
leukemia O +
involving O +
the O +
short O +
arm O +
of O +
human O +
chromosome O +
11 O +
at O +
band O +
11p15 O +
disrupts O +
the O +
rhombotin O +
gene O +
. O +

This O +
gene O +
encodes O +
a O +
protein O +
with O +
duplicated O +
cysteine O -
- O -
rich O +
regions O +
called O +
LIM O +
domains O +
, O +
which O +
show O +
homology O +
to O +
zinc O -
- O -
binding O +
proteins O +
and O +
to O +
iron O -
- O -
sulfur O +
centers O +
of O +
ferredoxins O +
. O +

Two O +
homologues O +
of O +
the O +
rhombotin O +
gene O +
have O +
now O +
been O +
isolated O +
. O +

One O +
of O +
these O +
, O +
designated O +
Rhom-2 O +
, O +
is O +
located O +
on O +
human O +
chromosome O +
11 O +
at O +
band O +
11p13 O +
, O +
where O +
a O +
cluster O +
of O +
T O -
- O -
cell O +
leukemia O -
- O -
specific O +
translocations O +
occur O +
; O +
all O +
translocation O +
breakpoints O +
at O +
11p13 O +
are O +
upstream O +
of O +
the O +
Rhom-2 O +
gene O +
. O +

Human O +
and O +
mouse O +
Rhom-2 O +
are O +
highly O +
conserved O +
and O +
, O +
like O +
rhombotin O +
, O +
encode O +
two O +
tandem O +
cysteine O -
- O -
rich O +
LIM O +
domains O +
. O +

Rhom-2 O +
mRNA O +
is O +
expressed O +
in O +
early O +
mouse O +
development O +
in O +
central O +
nervous O +
system O +
, O +
lung O +
, O +
kidney O +
, O +
liver O +
, O +
and O +
spleen O +
but O +
only O +
very O +
low O +
levels O +
occur O +
in O +
thymus O +
. O +

The O +
other O +
gene O +
, O +
designated O +
Rhom-3 O +
, O +
is O +
not O +
on O +
chromosome O +
11 O +
but O +
also O +
retains O +
homology O +
to O +
the O +
LIM O +
domain O +
of O +
rhombotin O +
. O +

Since O +
the O +
Rhom-2 O +
gene O +
is O +
such O +
a O +
common O +
site O +
of O +
chromosomal O +
damage O +
in O +
T O -
- O -
cell O +
tumors O +
, O +
the O +
consistency O +
of O +
translocations O +
near O +
the O +
rhombotin O +
gene O +
was O +
further O +
examined O +
. O +

A O +
second O +
translocation O +
adjacent O +
to O +
rhombotin O +
was O +
found O +
and O +
at O +
the O +
same O +
position O +
as O +
in O +
the O +
previous O +
example O +
. O +

Therefore O +
, O +
chromosome O +
bands O +
11p15 O +
( O +
rhombotin O +
) O +
and O +
11p13 O +
( O +
Rhom-2 O +
) O +
are O +
consistent O +
sites O +
of O +
chromosome O +
translocation O +
in O +
T O -
- O -
cell O +
leukemia O +
, O +
with O +
the O +
11p15 O +
target O +
more O +
rarely O +
involved O +
. O +

The O +
results O +
define O +
the O +
rhombotin O +
gene O +
family O +
as O +
a O +
class O +
of O +
T O -
- O -
cell O +
oncogenes O +
with O +
duplicated O +
cysteine O -
- O -
rich O +
LIM O +
domains O +
. O +

The O +
human B-CellLine +
myelomonocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
U-937 I-CellLine +
as O +
a O +
model O +
for O +
studying O +
alterations O +
in O +
steroid O -
- O -
induced O +
monokine O +
gene O +
expression O +
: O +
marked O +
enhancement O +
of O +
lipopolysaccharide O -
- O -
stimulated O +
interleukin-1 O +
beta O +
messenger O +
RNA O +
levels O +
by O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
. O +

The O +
active O +
metabolite O +
of O +
vitamin O +
D O +
, O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
[ O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
] O +
, O +
is O +
a O +
potent O +
regulator O +
of O +
human O +
monocyte O -
/ O -
macrophage O +
function O +
in O +
vitro O +
. O +

To O +
establish O +
a O +
model O +
for O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
regulation O +
of O +
human O +
monocyte O +
monokine O +
synthesis O +
, O +
three O +
human B-CellLine +
cell I-CellLine +
lines I-CellLine +
( O +
U-937 B-CellLine +
, O +
THP-1 B-CellLine +
, O +
and O +
HL-60 B-CellLine +
) O +
were O +
examined O +
for O +
: O +
1 O +
) O +
the O +
presence O +
of O +
functional O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
receptors O +
; O +
2 O +
) O +
the O +
accumulation O +
of O +
interleukin-1 O +
beta O +
( O +
IL-1 O +
beta O +
) O +
mRNA O +
and O +
IL-1 O +
beta O +
protein O +
in O +
response O +
to O +
lipopolysaccharide O +
( O +
LPS O +
) O +
; O +
and O +
3 O +
) O +
the O +
regulation O +
of O +
this O +
response O +
by O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
. O +

All O +
three O +
cell O +
lines O +
expressed O +
vitamin O +
D O +
receptor O +
and O +
had O +
increased O +
levels O +
of O +
IL-1 O +
beta O +
mRNA O +
in O +
response O +
to O +
LPS O +
. O +

Preincubation O +
of O +
cells O +
with O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
augmented O +
IL-1 O +
beta O +
mRNA O +
levels O +
only O +
in O +
U-937 B-CellLine +
and O +
HL-60 B-CellLine +
cells O +
. O +

From O +
these O +
data O +
, O +
and O +
taking O +
into O +
consideration O +
their O +
state O +
of O +
differentiation O +
and O +
relative O +
ease O +
of O +
culture O +
, O +
U-937 B-CellLine +
was O +
chosen O +
over O +
HL-60 B-CellLine +
and O +
THP-1 B-CellLine +
as O +
the O +
cell O +
line O +
we O +
further O +
characterized O +
. O +

In O +
U-937 B-CellLine +
cells I-CellLine +
, O +
optimum O +
time O +
and O +
dose O +
of O +
pretreatment O +
with O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
were O +
determined O +
to O +
be O +
12 O -
- O -
24 O +
h O +
at O +
a O +
receptor O +
saturating O +
concentration O +
of O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
( O +
10 O +
nM O +
) O +
. O +

Preincubation O +
of O +
cells O +
with O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
had O +
no O +
effect O +
on O +
the O +
time O +
course O +
of O +
IL-1 O +
beta O +
mRNA O +
appearance O +
in O +
response O +
to O +
LPS O +
. O +

However O +
, O +
exposure O +
of O +
U-937 B-CellLine +
cells I-CellLine +
to O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
increased O +
by O +
200 O +
% O +
the O +
level O +
of O +
IL-1 O +
beta O +
mRNA O +
detected O +
and O +
decreased O +
by O +
three O +
orders O +
of O +
magnitude O +
the O +
concentration O +
of O +
LPS O +
required O +
to O +
achieve O +
steady O +
state O +
mRNA O +
levels O +
equivalent O +
to O +
those O +
observed O +
in O +
U-937 B-CellLine +
cells I-CellLine +
not O +
preincubated O +
with O +
the O +
hormone.2+o O +

A O +
case O +
of O +
hypersensitivity O +
to O +
thyroid O +
hormones O +
with O +
normally O +
functioning O +
thyroid O +
gland O +
and O +
increased O +
nuclear O +
triiodothyronine O +
receptors O +
. O +

A O +
52-year O -
- O -
old O +
male O +
presented O +
himself O +
with O +
tachycardia O +
crises O +
which O +
appeared O +
first O +
during O +
childhood O +
, O +
increased O +
in O +
frequency O +
without O +
goiter O +
or O +
exophthalmos O +
. O +

Cardiac O +
and O +
adrenergic O +
diseases O +
were O +
excluded O +
. O +

The O +
thyroid O +
function O +
was O +
normal O +
regarding O +
T4 O +
, O +
free O +
T4 O +
and O +
T3 O +
, O +
TBG O +
, O +
radioiodine O +
uptake O +
, O +
TSH O +
and O +
T3 O +
suppressibility O +
; O +
however O +
the O +
TSH O +
response O +
to O +
TRH O +
was O +
decreased O +
. O +

The O +
lymphocyte O +
nuclear O +
T3 O +
receptor O +
was O +
found O +
with O +
an O +
affinity O +
close O +
to O +
that O +
of O +
normal O +
volunteers O +
( O +
Ka O +
: O +
1.42 O +
x O +
10 O +
( O +
10 O +
) O +
M-1 O +
vs O +
1.95 O +
+ O -
/- O +
0.35 O +
x O +
10 O +
( O +
10 O +
) O +
M-1 O +
) O +
and O +
a O +
binding O +
capacity O +
markedly O +
increased O +
( O +
9.9 O +
vs O +
3.7 O +
+ O -
/- O +
0.4 O +
fmol O +
T3 O -
/ O -
100 O +
micrograms O +
DNA O +
) O +
. O +

Pindolol O +
was O +
inefficient O +
on O +
the O +
dysrhythmia O +
which O +
disappeared O +
with O +
carbimazole O +
and O +
relapsed O +
after O +
withdrawal O +
of O +
the O +
antithyroid O +
drug O +
. O +

Under O +
carbimazole O +
, O +
the O +
plasma O +
T4 O +
markedly O +
decreased O +
( O +
27.7 O +
+ O -
/- O +
3.6 O +
nmol O -
/ O -
l O +
) O +
but O +
the O +
patient O +
remained O +
euthyroid O +
. O +

The O +
clinical O +
course O +
and O +
the O +
laboratory O +
data O +
suggest O +
that O +
the O +
tachycardia O +
crises O +
are O +
the O +
consequence O +
of O +
a O +
hypersensitivity O +
of O +
the O +
heart O +
to O +
thyroid O +
hormones O +
, O +
associated O +
with O +
an O +
increased O +
number O +
of O +
T3 O +
nuclear O +
receptor O +
sites O +
in O +
lymphocytes O +
. O +

Expression O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptors O +
on O +
alveolar O +
lymphocytes O +
from O +
patients O +
with O +
pulmonary O +
granulomatous O +
diseases O +
. O +

1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
is O +
known O +
to O +
be O +
produced O +
at O +
sites O +
of O +
granulomatous O +
reactions O +
. O +

In O +
order O +
to O +
characterize O +
the O +
cell O +
types O +
that O +
are O +
targets O +
for O +
this O +
immunoregulatory O +
hormone O +
, O +
we O +
have O +
evaluated O +
the O +
expression O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptors O +
on O +
peripheral O +
blood O +
T O -
- O -
lymphocytes O +
and O +
those O +
recovered O +
from O +
the O +
lung O +
by O +
bronchoalveolar O +
lavage O +
from O +
patients O +
with O +
pulmonary O +
granulomatous O +
diseases O +
( O +
tuberculosis O +
and O +
sarcoidosis O +
) O +
and O +
from O +
normal O +
control O +
subjects O +
using O +
combined O +
autoradiographic O +
and O +
immunohistochemical O +
techniques O +
. O +

Lavage O +
T O -
- O -
lymphocytes O +
from O +
patients O +
with O +
tuberculosis O +
or O +
with O +
sarcoidosis O +
, O +
but O +
not O +
those O +
from O +
normal O +
control O +
subjects O +
, O +
expressed O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptors O +
as O +
demonstrated O +
by O +
binding O +
of O +
[ O +
3H O +
] O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
, O +
which O +
was O +
inhibited O +
by O +
the O +
presence O +
of O +
excess O +
unlabeled O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
, O +
but O +
not O +
by O +
the O +
presence O +
of O +
unlabeled O +
25 O +
( O +
OH O +
) O +
D3 O +
( O +
receptor O -
- O -
positive O +
lymphocytes O +
: O +
sarcoidosis O +
, O +
20 O +
+ O -
/- O +
12 O +
% O +
; O +
tuberculosis O +
, O +
31 O +
+ O -
/- O +
17 O +
% O +
) O +
. O +

In O +
contrast O +
, O +
blood O +
lymphocytes O +
from O +
patients O +
with O +
granulomatous O +
diseases O +
did O +
not O +
express O +
detectable O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptors O +
. O +

The O +
percentage O +
of O +
lavage O +
T O -
- O -
lymphocytes O +
expressing O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptors O +
was O +
significantly O +
greater O +
for O +
patients O +
with O +
tuberculosis O +
presenting O +
with O +
isolated O +
hilar O +
adenopathy O +
than O +
for O +
patients O +
with O +
pulmonary O +
infiltrates O +
and/or O +
cavities O +
. O +

1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptors O +
were O +
expressed O +
to O +
a O +
greater O +
extent O +
on O +
CD8 O -
+ O +
T O -
- O -
lymphocytes O +
than O +
on O +
CD4 O -
+ O +
T O -
- O -
lymphocytes O +
in O +
sarcoidosis O +
, O +
whereas O +
a O +
greater O +
proportion O +
of O +
CD4 O -
+ O +
than O +
of O +
CD8 O -
+ O +
T O -
- O -
lymphocytes O +
from O +
patients O +
with O +
tuberculosis O +
were O +
receptor O -
- O -
positive O +
. O +

These O +
findings O +
support O +
the O +
conclusion O +
that O +
the O +
interaction O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
with O +
its O +
receptor O +
on O +
T O -
- O -
lymphocytes O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
regulation O +
of O +
granulomatous O +
reactions O +
, O +
but O +
because O +
these O +
receptors O +
are O +
expressed O +
on O +
different O +
lymphocyte O +
populations O +
, O +
the O +
net O +
effect O +
of O +
this O +
potent O +
immunoregulatory O +
molecule O +
is O +
likely O +
different O +
in O +
sarcoidosis O +
and O +
tuberculosis O +
. O +

Inhibition O +
of O +
transcription O +
factors O +
belonging O +
to O +
the O +
rel O -
/ O -
NF O -
- O -
kappa O +
B O +
family O +
by O +
a O +
transdominant O +
negative O +
mutant O +
. O +

The O +
KBF1 O +
factor O +
, O +
which O +
binds O +
to O +
the O +
enhancer O +
A O +
located O +
in O +
the O +
promoter O +
of O +
the O +
mouse O +
MHC O +
class O +
I O +
gene O +
H-2Kb O +
, O +
is O +
indistinguishable O +
from O +
the O +
p50 O +
DNA O +
binding O +
subunit O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
, O +
which O +
regulates O +
a O +
series O +
of O +
genes O +
involved O +
in O +
immune O +
and O +
inflammatory O +
responses O +
. O +

The O +
KBF1 O -
/ O -
p50 O +
factor O +
binds O +
as O +
a O +
homodimer O +
but O +
can O +
also O +
form O +
heterodimers O +
with O +
the O +
products O +
of O +
other O +
members O +
of O +
the O +
same O +
family O +
, O +
like O +
the O +
c O -
- O -
rel O +
and O +
v O -
- O -
rel O +
( O +
proto O +
) O +
oncogenes O +
. O +

The O +
dimerization O +
domain O +
of O +
KBF1 O -
/ O -
p50 O +
is O +
contained O +
between O +
amino O +
acids O +
201 O +
and O +
367 O +
. O +

A O +
mutant O +
of O +
KBF1 O -
/ O -
p50 O +
( O +
delta O +
SP O +
) O +
, O +
unable O +
to O +
bind O +
to O +
DNA O +
but O +
able O +
to O +
form O +
homo- O +
or O +
heterodimers O +
, O +
has O +
been O +
constructed O +
. O +

This O +
protein O +
reduces O +
or O +
abolishes O +
in O +
vitro O +
the O +
DNA O +
binding O +
activity O +
of O +
wild O -
- O -
type O +
proteins O +
of O +
the O +
same O +
family O +
( O +
KBF1 O -
/ O -
p50 O +
, O +
c- O +
and O +
v O -
- O -
rel O +
) O +
. O +

This O +
mutant O +
also O +
functions O +
in O +
vivo O +
as O +
a O +
trans O -
- O -
acting O +
dominant O +
negative O +
regulator O +
: O +
the O +
transcriptional O +
inducibility O +
of O +
the O +
HIV O +
long O +
terminal O +
repeat O +
( O +
which O +
contains O +
two O +
potential O +
NF O -
- O -
kappa O +
B O +
binding O +
sites O +
) O +
by O +
phorbol O +
ester O +
( O +
PMA O +
) O +
is O +
inhibited O +
when O +
it O +
is O +
co O -
- O -
transfected O +
into O +
CD4 B-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
with O +
the O +
delta O +
SP O +
mutant O +
. O +

Similarly O +
the O +
basal O +
as O +
well O +
as O +
TNF O +
or O +
IL1-induced O +
activity O +
of O +
the O +
MHC O +
class O +
I O +
H-2Kb O +
promoter O +
can O +
be O +
inhibited O +
by O +
this O +
mutant O +
in O +
two O +
different O +
cell B-CellLine +
lines I-CellLine +
. O +

These O +
results O +
constitute O +
the O +
first O +
formal O +
demonstration O +
that O +
these O +
genes O +
are O +
regulated O +
by O +
members O +
of O +
the O +
rel O -
/ O -
NF O -
- O -
kappa O +
B O +
family O +
. O +

Human O +
erythroid O +
5-aminolevulinate O +
synthase O +
: O +
promoter O +
analysis O +
and O +
identification O +
of O +
an O +
iron O -
- O -
responsive O +
element O +
in O +
the O +
mRNA O +
. O +

5-Aminolevulinate O +
synthase O +
( O +
ALAS O +
) O +
catalyzes O +
the O +
first O +
step O +
of O +
the O +
heme O +
biosynthetic O +
pathway O +
. O +

cDNA O +
clones O +
for O +
the O +
human O +
erythroid O +
ALAS O +
isozyme O +
were O +
isolated O +
from O +
a O +
fetal O +
liver O +
library O +
. O +

It O +
can O +
be O +
deduced O +
that O +
the O +
erythroid O +
ALAS O +
precursor O +
protein O +
has O +
a O +
molecular O +
weight O +
of O +
64.6 O +
kd O +
, O +
and O +
is O +
similar O +
in O +
size O +
to O +
the O +
previously O +
isolated O +
human O +
housekeeping O +
ALAS O +
precursor O +
of O +
molecular O +
weight O +
70.6 O +
kd O +
. O +

The O +
mature O +
mitochondrial O +
forms O +
of O +
the O +
erythroid O +
and O +
housekeeping O +
ALAS O +
isozymes O +
are O +
predicted O +
to O +
have O +
molecular O +
weights O +
of O +
59.5 O +
kd O +
and O +
64.6 O +
kd O +
, O +
respectively O +
. O +

The O +
two O +
isozymes O +
show O +
little O +
amino O +
acid O +
identity O +
in O +
their O +
N O -
- O -
terminal O +
signal O +
sequences O +
but O +
have O +
considerable O +
sequence O +
identity O +
in O +
the O +
C O -
- O -
terminal O +
two O -
- O -
thirds O +
of O +
their O +
proteins O +
. O +

An O +
analysis O +
of O +
the O +
immediate O +
promoter O +
of O +
the O +
human O +
erythroid O +
ALAS O +
gene O +
revealed O +
several O +
putative O +
erythroid O -
- O -
specific O +
cis O -
- O -
acting O +
elements O +
including O +
both O +
a O +
GATA-1 O +
and O +
an O +
NF O -
- O -
E2 O +
binding O +
site O +
. O +

An O +
iron O -
- O -
responsive O +
element O +
( O +
IRE O +
) O +
motif O +
has O +
been O +
identified O +
in O +
the O +
5'-untranslated O +
region O +
of O +
the O +
human O +
erythroid O +
ALAS O +
mRNA O +
, O +
but O +
is O +
not O +
present O +
in O +
the O +
housekeeping O +
ALAS O +
mRNA O +
. O +

Gel O +
retardation O +
experiments O +
established O +
that O +
this O +
IRE O +
motif O +
formed O +
a O +
protein O +
- O +
RNA O +
complex O +
with O +
cytosolic O +
extracts O +
from O +
human B-CellLine +
K562 I-CellLine +
cells I-CellLine +
and O +
this O +
binding O +
was O +
strongly O +
competed O +
with O +
IRE O +
transcripts O +
from O +
ferritin O +
or O +
transferrin O +
receptor O +
mRNAs O +
. O +

A O +
transcript O +
of O +
the O +
ALAS O +
IRE O +
, O +
mutated O +
in O +
the O +
conserved O +
loop O +
of O +
the O +
IRE O +
, O +
did O +
not O +
readily O +
form O +
this O +
protein O +
- O +
RNA O +
complex O +
. O +

These O +
results O +
suggest O +
that O +
the O +
IRE O +
motif O +
in O +
the O +
ALAS O +
mRNA O +
is O +
functional O +
and O +
imply O +
that O +
translation O +
of O +
the O +
mRNA O +
is O +
controlled O +
by O +
cellular O +
iron O +
availability O +
during O +
erythropoiesis O +
. O +

Human O +
tumor O +
necrosis O +
factor O +
alpha O +
gene O +
regulation O +
in O +
phorbol O +
ester O +
stimulated B-CellLine +
T I-CellLine +
and I-CellLine +
B I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

The O +
minimal O +
region O +
of O +
the O +
human O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
gene O +
promoter O +
necessary O +
for O +
its O +
transcriptional O +
induction O +
by O +
phorbol O +
esters O +
( O +
PMA O +
) O +
in O +
human B-CellLine +
T I-CellLine +
and I-CellLine +
B I-CellLine +
lymphocyte I-CellLine +
cell I-CellLine +
lines I-CellLine +
has O +
been O +
localized O +
between O +
-52 O +
and O +
+ O -
89 O +
nucleotides O +
( O +
nt O +
) O +
relative O +
to O +
the O +
gene O +
's O +
transcriptional O +
start O +
site O +
. O +

Comparison O +
of O +
these O +
sequences O +
to O +
those O +
required O +
to O +
mediate O +
virus O +
or O +
lipopolysaccharide O +
( O +
LPS O +
) O +
induction O +
of O +
the O +
gene O +
reveal O +
significant O +
differences O +
, O +
and O +
thus O +
, O +
the O +
sequence O +
requirements O +
for O +
PMA O +
induction O +
are O +
distinct O +
from O +
those O +
that O +
mediate O +
induction O +
by O +
virus O +
or O +
LPS O +
. O +

Although O +
three O +
sites O +
in O +
the O +
TNF O -
- O -
alpha O +
promoter O +
( O +
kappa O +
1 O +
, O +
kappa O +
2 O +
, O +
and O +
kappa O +
3 O +
) O +
specifically O +
bind O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
in O +
lymphoid O +
nuclear O +
extracts O +
, O +
TNF O -
- O -
alpha O +
mRNA O +
induction O +
by O +
PMA O +
does O +
not O +
correlate O +
with O +
NF O -
- O -
kappa O +
B O +
binding O +
activities O +
displayed O +
by O +
different O +
T B-CellLine +
and I-CellLine +
B I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Moreover O +
, O +
kappa O +
1-kappa O +
3 O +
can O +
each O +
be O +
deleted O +
from O +
the O +
TNF O -
- O -
alpha O +
promoter O +
with O +
little O +
effect O +
on O +
the O +
gene O +
's O +
inducibility O +
by O +
PMA O +
. O +

Therefore O +
, O +
TNF O -
- O -
alpha O +
mRNA O +
induction O +
by O +
PMA O +
, O +
like O +
its O +
induction O +
by O +
virus O +
and O +
LPS O +
, O +
is O +
not O +
primarily O +
mediated O +
by O +
NF O -
- O -
kappa O +
B O +
, O +
but O +
rather O +
is O +
mediated O +
through O +
other O +
sequences O +
and O +
protein O +
factors O +
. O +

Surprisingly O +
, O +
multimers O +
of O +
kappa O +
1-kappa O +
3 O +
can O +
confer O +
PMA O +
inducibility O +
on O +
a O +
heterologous O +
promoter O +
in O +
a O +
B B-CellLine +
( I-CellLine +
Raji I-CellLine +
) I-CellLine +
, I-CellLine +
but I-CellLine +
not I-CellLine +
a I-CellLine +
T I-CellLine +
( I-CellLine +
HUT78 I-CellLine +
) I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

However O +
they O +
are O +
not O +
functional O +
on O +
a O +
truncated O +
TNF O -
- O -
alpha O +
promoter O +
, O +
indicating O +
that O +
promoter O +
context O +
and O +
cell O +
type O +
specificity O +
influence O +
the O +
PMA O +
inducible O +
function O +
of O +
these O +
NF O -
- O -
kappa O +
B O +
binding O +
sites O +
. O +

Cloning O +
of O +
a O +
human O +
homeobox O +
gene O +
that O +
resembles O +
a O +
diverged O +
Drosophila O +
homeobox O +
gene O +
and O +
is O +
expressed O +
in O +
activated O +
lymphocytes O +
. O +

A O +
new O +
homeobox O +
gene O +
, O +
HB24 O +
, O +
has O +
been O +
isolated O +
from O +
a O +
human O +
B O -
- O -
lymphocyte O +
cDNA O +
library O +
. O +

Northern O +
blot O +
analysis O +
of O +
polyadenylated O +
RNA O +
purified O +
from O +
activated O +
human O +
B O +
cells O +
revealed O +
a O +
single O +
mRNA O +
transcript O +
of O +
approximately O +
2.3 O +
kb O +
. O +

Two O +
cDNA O +
clones O +
were O +
sequenced O +
and O +
provided O +
2 O +
, O +
250 O +
nucleotides O +
( O +
nt O +
) O +
of O +
DNA O +
sequence O +
information O +
. O +

There O +
is O +
a O +
single O +
methionine O +
codon O -
- O -
initiated O +
open O +
reading O +
frame O +
of O +
1 O +
, O +
458 O +
nt O +
in O +
frame O +
with O +
a O +
homeobox O +
and O +
a O +
CAX O +
repeat O +
, O +
and O +
the O +
open O +
reading O +
frame O +
is O +
predicted O +
to O +
encode O +
a O +
protein O +
of O +
51 O +
, O +
659 O +
daltons O +
. O +

When O +
the O +
homeodomain O +
from O +
HB24 O +
was O +
compared O +
to O +
known O +
mammalian O +
and O +
Drosophila O +
homeodomains O +
it O +
was O +
found O +
to O +
be O +
only O +
moderately O +
conserved O +
, O +
but O +
when O +
it O +
was O +
compared O +
to O +
a O +
highly O +
diverged O +
Drosophila O +
homeodomain O +
, O +
H2.0 O +
, O +
it O +
was O +
found O +
to O +
be O +
80 O +
% O +
identical O +
. O +

The O +
HB24 O +
mRNA O +
was O +
absent O +
or O +
present O +
at O +
low O +
levels O +
in O +
normal O +
B O +
and O +
T O +
lymphocytes O +
; O +
however O +
, O +
with O +
the O +
appropriate O +
activation O +
signal O +
HB24 O +
mRNA O +
was O +
induced O +
within O +
several O +
hours O +
even O +
in O +
the O +
presence O +
of O +
cycloheximide O +
. O +

Characterization O +
of O +
HB24 O +
expression O +
in O +
lymphoid O +
and O +
select O +
developing O +
tissues O +
was O +
performed O +
by O +
in O +
situ O +
hybridization O +
. O +

Positive O +
hybridization O +
was O +
found O +
in O +
thymus O +
, O +
tonsil O +
, O +
bone O +
marrow O +
, O +
developing O +
vessels O +
, O +
and O +
in O +
fetal O +
brain O +
. O +

HB24 O +
is O +
likely O +
to O +
have O +
an O +
important O +
role O +
in O +
lymphocytes O +
as O +
well O +
as O +
in O +
certain O +
developing O +
tissues O +
. O +

Severe O +
5-fluorouracil O +
toxicity O +
secondary O +
to O +
dihydropyrimidine O +
dehydrogenase O +
deficiency O +
. O +

A O +
potentially O +
more O +
common O +
pharmacogenetic O +
syndrome O +
. O +

This O +
study O +
describes O +
the O +
inheritance O +
of O +
a O +
defect O +
in O +
pyrimidine O +
catabolism O +
and O +
its O +
association O +
with O +
drug O -
- O -
induced O +
toxicity O +
in O +
a O +
patient O +
receiving O +
5-fluorouracil O +
( O +
FUra O +
) O +
as O +
adjuvant O +
chemotherapy O +
for O +
breast O +
carcinoma O +
. O +

The O +
study O +
population O +
included O +
the O +
affected O +
patient O +
( O +
proband O +
) O +
, O +
nine O +
of O +
her O +
blood O +
relatives O +
, O +
and O +
seven O +
healthy O +
volunteers O +
. O +

The O +
activity O +
of O +
dihydropyrimidine O +
dehydrogenase O +
( O +
DPD O +
) O +
, O +
the O +
initial O +
enzyme O +
of O +
pyrimidine O +
( O +
and O +
FUra O +
) O +
catabolism O +
, O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
was O +
measured O +
in O +
each O +
subject O +
by O +
a O +
specific O +
radiometric O +
assay O +
using O +
FUra O +
as O +
the O +
substrate O +
. O +

The O +
proband O +
had O +
no O +
detectable O +
DPD O +
activity O +
. O +

When O +
enzyme O +
levels O +
in O +
the O +
proband O +
and O +
relatives O +
were O +
compared O +
with O +
that O +
in O +
controls O +
, O +
an O +
autosomal O +
recessive O +
pattern O +
of O +
inheritance O +
was O +
demonstrated O +
. O +

This O +
is O +
the O +
third O +
patient O +
with O +
severe O +
FUra O +
toxicity O +
secondary O +
to O +
an O +
alteration O +
in O +
pyrimidine O +
catabolism O +
and O +
the O +
second O +
from O +
our O +
clinic O +
population O +
suggesting O +
that O +
the O +
frequency O +
of O +
this O +
genetic O +
defect O +
may O +
be O +
greater O +
than O +
previously O +
thought O +
. O +

Monitoring O +
DPD O +
activity O +
may O +
be O +
important O +
in O +
the O +
management O +
of O +
patients O +
experiencing O +
severe O +
toxicity O +
secondary O +
to O +
FUra O +
chemotherapy O +
. O +

Characterization O +
of O +
an O +
immediate O -
- O -
early O +
gene O +
induced O +
in O +
adherent O +
monocytes O +
that O +
encodes O +
I O +
kappa O +
B O +
-like O +
activity O +
. O +

We O +
have O +
cloned O +
a O +
group O +
of O +
cDNAs O +
representing O +
mRNAs O +
that O +
are O +
rapidly O +
induced O +
following O +
adherence O +
of O +
human O +
monocytes O +
. O +

One O +
of O +
the O +
induced O +
transcripts O +
( O +
MAD-3 O +
) O +
encodes O +
a O +
protein O +
of O +
317 O +
amino O +
acids O +
with O +
one O +
domain O +
containing O +
five O +
tandem O +
repeats O +
of O +
the O +
cdc10 O -
/ O -
ankyrin O +
motif O +
, O +
which O +
is O +
60 O +
% O +
similar O +
( O +
46 O +
% O +
identical O +
) O +
to O +
the O +
ankyrin O +
repeat O +
region O +
of O +
the O +
precursor O +
of O +
NF O -
- O -
kappa O +
B O -
/ O -
KBF1 O +
p50 O +
. O +

The O +
C O -
- O -
terminus O +
has O +
a O +
putative O +
protein O +
kinase O +
C O +
phosphorylation O +
site O +
. O +

In O +
vitro O +
translated O +
MAD-3 O +
protein O +
was O +
found O +
to O +
specifically O +
inhibit O +
the O +
DNA O -
- O -
binding O +
activity O +
of O +
the O +
p50 O -
/ O -
p65 O +
NF O -
- O -
kappa O +
B O +
complex O +
but O +
not O +
that O +
of O +
the O +
p50 O -
/ O -
p50 O +
KBF1 O +
factor O +
or O +
of O +
other O +
DNA O -
- O -
binding O +
proteins O +
. O +

The O +
MAD-3 O +
cDNA O +
encodes O +
an O +
I O +
kappa O +
B O -
- O -
like O +
protein O +
that O +
is O +
likely O +
to O +
be O +
involved O +
in O +
regulation O +
of O +
transcriptional O +
responses O +
to O +
NF O -
- O -
kappa O +
B O +
, O +
including O +
adhesion O -
- O -
dependent O +
pathways O +
of O +
monocyte O +
activation O +
. O +

Reactive O +
oxygen O +
intermediates O +
as O +
apparently O +
widely O +
used O +
messengers O +
in O +
the O +
activation O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
transcription O +
factor O +
and O +
HIV-1 O +
. O +

Hydrogen O +
peroxide O +
and O +
oxygen O +
radicals O +
are O +
agents O +
commonly O +
produced O +
during O +
inflammatory O +
processes O +
. O +

In O +
this O +
study O +
, O +
we O +
show O +
that O +
micromolar O +
concentrations O +
of O +
H2O2 O +
can O +
induce O +
the O +
expression O +
and O +
replication O +
of O +
HIV-1 O +
in O +
a O +
human B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

The O +
effect O +
is O +
mediated O +
by O +
the O +
NF O -
- O -
kappa O +
B O +
transcription O +
factor O +
which O +
is O +
potently O +
and O +
rapidly O +
activated O +
by O +
an O +
H2O2 O +
treatment O +
of O +
cells O +
from O +
its O +
inactive O +
cytoplasmic O +
form O +
. O +

N O -
- O -
acetyl O -
- O -
L O -
- O -
cysteine O +
( O +
NAC O +
) O +
, O +
a O +
well O +
characterized O +
antioxidant O +
which O +
counteracts O +
the O +
effects O +
of O +
reactive O +
oxygen O +
intermediates O +
( O +
ROI O +
) O +
in O +
living O +
cells O +
, O +
prevented O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
by O +
H2O2 O +
. O +

NAC O +
and O +
other O +
thiol O +
compounds O +
also O +
blocked O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
by O +
cycloheximide O +
, O +
double O -
- O -
stranded O +
RNA O +
, O +
calcium O +
ionophore O +
, O +
TNF O -
- O -
alpha O +
, O +
active O +
phorbol O +
ester O +
, O +
interleukin-1 O +
, O +
lipopolysaccharide O +
and O +
lectin O +
. O +

This O +
suggests O +
that O +
diverse O +
agents O +
thought O +
to O +
activate O +
NF O -
- O -
kappa O +
B O +
by O +
distinct O +
intracellular O +
pathways O +
might O +
all O +
act O +
through O +
a O +
common O +
mechanism O +
involving O +
the O +
synthesis O +
of O +
ROI O +
. O +

ROI O +
appear O +
to O +
serve O +
as O +
messengers O +
mediating O +
directly O +
or O +
indirectly O +
the O +
release O +
of O +
the O +
inhibitory O +
subunit O +
I O +
kappa O +
B O +
from O +
NF O -
- O -
kappa O +
B O +
. O +

[ O +
Differential O +
diagnostic O +
value O +
of O +
receptors O +
of O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
calcitriol O +
) O +
determination O +
in O +
lymphocytes O +
of O +
children O +
with O +
rickets O +
and O +
rickets O -
- O -
like O +
diseases O +
] O +

The O +
authors O +
provide O +
the O +
results O +
of O +
studying O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
calcitriol O +
) O +
in O +
lymphocytes O +
of O +
children O +
with O +
rickets O +
and O +
rickets O -
- O -
like O +
diseases O +
. O +

It O +
is O +
proposed O +
that O +
the O +
character O +
of O +
their O +
expression O +
under O +
the O +
influence O +
of O +
vitamin O +
D O +
may O +
be O +
used O +
with O +
differential O +
diagnostic O +
purposes O +
in O +
view O +
. O +

Enhancement O +
of O +
human O +
immunodeficiency O +
virus O +
1 O +
replication O +
in O +
monocytes O +
by O +
1 O +
, O +
25-dihydroxycholecalciferol O +
. O +

Human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
expression O +
and O +
replication O +
are O +
under O +
tight O +
regulatory O +
control O +
. O +

We O +
demonstrate O +
that O +
1 O +
, O +
25-dihydroxycholecalciferol O +
[ O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
] O +
enhances O +
the O +
replication O +
of O +
monocyte- O +
and O +
lymphocyte O -
- O -
tropic O +
strains O +
of O +
HIV-1 O +
up O +
to O +
10 O +
, O +
000-fold O +
in O +
monocyte B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
peripheral O +
blood O +
monocytes O +
, O +
and O +
unfractionated O +
peripheral O +
blood O +
mononuclear O +
cells O +
. O +

1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
is O +
therefore O +
one O +
of O +
the O +
most O +
potent O +
regulators O +
of O +
HIV-1 O +
replication O +
described O +
to O +
date O +
. O +

Precursors O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
enhance O +
HIV-1 O +
replication O +
in O +
proportion O +
to O +
their O +
affinity O +
for O +
the O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
intracellular O +
receptor O +
, O +
suggesting O +
that O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
influences O +
HIV-1 O +
replication O +
by O +
mechanisms O +
involving O +
this O +
receptor O +
. O +

These O +
studies O +
may O +
have O +
important O +
implications O +
for O +
the O +
design O +
of O +
effective O +
therapy O +
of O +
HIV-1 O +
infection O +
. O +

Inhibition O +
of O +
HIV-1 O +
replication O +
and O +
NF O -
- O -
kappa O +
B O +
activity O +
by O +
cysteine O +
and O +
cysteine O +
derivatives O +
. O +

HIV-1 O +
proviral O +
DNA O +
contains O +
two O +
binding O +
sites O +
for O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
. O +

HIV-1-infected O +
individuals O +
have O +
, O +
on O +
average O +
, O +
abnormally O +
high O +
levels O +
of O +
tumour O +
necrosis O +
factor O +
alpha O +
( O +
TNF O +
alpha O +
) O +
and O +
abnormally O +
low O +
plasma O +
cysteine O +
levels O +
. O +

We O +
therefore O +
investigated O +
the O +
effects O +
of O +
cysteine O +
and O +
related O +
thiols O +
on O +
HIV-1 O +
replication O +
and O +
NF O -
- O -
kappa O +
B O +
expression O +
. O +

The O +
experiments O +
in O +
this O +
report O +
show O +
that O +
cysteine O +
or O +
N O -
- O -
acetylcysteine O +
( O +
NAC O +
) O +
raise O +
the O +
intracellular O +
glutathione O +
( O +
GSH O +
) O +
level O +
and O +
inhibit O +
HIV-1 O +
replication O +
in O +
persistently O +
infected O +
Molt-4 B-CellLine +
and O +
U937 B-CellLine +
cells I-CellLine +
. O +

However O +
, O +
inhibition O +
of O +
HIV-1 O +
replication O +
appears O +
not O +
to O +
be O +
directly O +
correlated O +
with O +
GSH O +
levels O +
. O +

Cysteine O +
and O +
NAC O +
also O +
inhibit O +
NF O -
- O -
kappa O +
B O +
activity O +
as O +
determined O +
by O +
electrophoretic O +
mobility O +
shift O +
assays O +
and O +
chloramphenicol O +
acetyl O -
- O -
transferase O +
( O +
CAT O +
) O +
gene O +
expression O +
under O +
control O +
of O +
NF O -
- O -
kappa O +
B O +
binding O +
sites O +
in O +
uninfected O +
cells O +
. O +

This O +
suggests O +
that O +
the O +
cysteine O +
deficiency O +
in O +
HIV-1-infected O +
individuals O +
may O +
cause O +
an O +
over O -
- O -
expression O +
of O +
NF O -
- O -
kappa O +
B O -
- O -
dependent O +
genes O +
and O +
enhance O +
HIV-1 O +
replication O +
. O +

NAC O +
may O +
be O +
considered O +
for O +
the O +
treatment O +
of O +
HIV-1-infected O +
individuals O +
. O +

Glucocorticoid O +
receptors O +
in O +
systemic O +
lupus O +
erythematosus O +
. O +

Glucocorticosteroids O +
remain O +
the O +
major O +
treatment O +
modality O +
for O +
systemic O +
lupus O +
erythematosus O +
( O +
SLE O +
) O +
, O +
but O +
their O +
mechanism O +
of O +
action O +
is O +
unclear O +
. O +

Over O +
the O +
past O +
decade O +
it O +
has O +
become O +
clear O +
that O +
glucocorticosteroid O +
receptors O +
play O +
a O +
significant O +
role O +
in O +
the O +
mechanism O +
of O +
glucocorticosteroid O +
action O +
. O +

We O +
studied O +
glucocorticosteroid O +
receptor O +
density O +
and O +
affinity O +
on O +
peripheral O +
blood O +
mononuclear O +
cells O +
by O +
the O +
glucocorticosteroid O +
binding O +
assay O +
in O +
33 O +
patients O +
with O +
SLE O +
who O +
had O +
taken O +
no O +
glucocorticosteroid O +
for O +
the O +
previous O +
6 O +
months O +
and O +
in O +
32 O +
healthy O +
controls O +
. O +

Patients O +
' O +
disease O +
activity O +
was O +
measured O +
by O +
the O +
SLE O +
Disease O +
Activity O +
Index O +
( O +
SLEDAI O +
) O +
. O +

Glucocorticosteroid O +
receptors O +
on O +
leukocytes O +
of O +
patients O +
with O +
SLE O +
were O +
significantly O +
higher O +
than O +
in O +
healthy O +
controls O +
( O +
4419 O +
+ O -
/- O +
306 O +
vs O +
3369 O +
+ O -
/- O +
196 O +
, O +
p O +
less O +
than O +
0.005 O +
) O +
. O +

The O +
binding O +
affinity O +
was O +
not O +
different O +
between O +
patients O +
and O +
controls O +
. O +

There O +
was O +
no O +
correlation O +
between O +
glucocorticosteroid O +
receptor O +
number O +
and O +
SLE O +
disease O +
activity O +
. O +

[ O +
Changes O +
in O +
levels O +
of O +
leucocytic O +
estrogen O +
receptor O +
in O +
patients O +
with O +
menopausal O +
type O +
II O +
diabetes O +
and O +
its O +
significance O +
] O +

The O +
number O +
of O +
estrogen O +
receptors O +
( O +
ER O +
) O +
in O +
human O +
peripheral O +
leucocytes O +
in O +
12 O +
women O +
with O +
menopausal O +
type O +
II O +
diabetes O +
was O +
measured O +
with O +
radio O -
- O -
ligand O +
binding O +
method O +
. O +

The O +
results O +
were O +
compared O +
with O +
those O +
of O +
12 O +
menopausal O +
women O +
without O +
diabetes O +
and O +
12 O +
normal O +
women O +
of O +
childbearing O +
age O +
. O +

It O +
was O +
found O +
that O +
the O +
number O +
of O +
ER O +
in O +
the O +
patients O +
was O +
significantly O +
decreased O +
. O +

Our O +
data O +
indicate O +
that O +
decrease O +
of O +
ER O +
level O +
in O +
leukocytes O +
may O +
be O +
related O +
to O +
the O +
pathogenesis O +
of O +
type O +
II O +
diabetes O +
in O +
menopausal O +
period O +
. O +

Nuclear O +
association O +
of O +
a O +
T O -
- O -
cell O +
transcription O +
factor O +
blocked O +
by O +
FK-506 O +
and O +
cyclosporin O +
A O +
[ O +
see O +
comments O +
] O +

Cyclosporin O +
A O +
and O +
FK506 O +
inhibit O +
T- O +
and O +
B O -
- O -
cell O +
activation O +
and O +
other O +
processes O +
essential O +
to O +
an O +
effective O +
immune O +
response O +
. O +

In O +
T O +
lymphocytes O +
these O +
drugs O +
disrupt O +
an O +
unknown O +
step O +
in O +
the O +
transmission O +
of O +
signals O +
from O +
the O +
T O -
- O -
cell O +
antigen O +
receptor O +
to O +
cytokine O +
genes O +
that O +
coordinate O +
the O +
immune O +
response O +
. O +

The O +
putative O +
intracellular O +
receptors O +
for O +
FK506 O +
and O +
cyclosporin O +
are O +
cis O -
- O -
trans O +
prolyl O +
isomerases O +
. O +

Binding O +
of O +
the O +
drug O +
inhibits O +
isomerase O +
activity O +
, O +
but O +
studies O +
with O +
other O +
prolyl O +
isomerase O +
inhibitors O +
and O +
analysis O +
of O +
cyclosporin B-CellLine -
- I-CellLine -
resistant I-CellLine +
mutants I-CellLine +
in O +
yeast O +
suggest O +
that O +
the O +
effects O +
of O +
the O +
drug O +
result O +
from O +
the O +
formation O +
of O +
an O +
inhibitory O +
complex O +
between O +
the O +
drug O +
and O +
isomerase O +
, O +
and O +
not O +
from O +
inhibition O +
of O +
isomerase O +
activity O +
. O +

A O +
transcription O +
factor O +
, O +
NF O -
- O -
AT O +
, O +
which O +
is O +
essential O +
for O +
early O +
T O -
- O -
cell O +
gene O +
activation O +
, O +
seems O +
to O +
be O +
a O +
specific O +
target O +
of O +
cyclosporin O +
A O +
and O +
FK506 O +
action O +
because O +
transcription O +
directed O +
by O +
this O +
protein O +
is O +
blocked O +
in O +
T O +
cells O +
treated O +
with O +
these O +
drugs O +
, O +
with O +
little O +
or O +
no O +
effect O +
on O +
other O +
transcription O +
factors O +
such O +
as O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B O +
. O +

Here O +
we O +
demonstrate O +
that O +
NF O -
- O -
AT O +
is O +
formed O +
when O +
a O +
signal O +
from O +
the O +
antigen O +
receptor O +
induces O +
a O +
pre O -
- O -
existing O +
cytoplasmic O +
subunit O +
to O +
translocate O +
to O +
the O +
nucleus O +
and O +
combine O +
with O +
a O +
newly O +
synthesized O +
nuclear O +
subunit O +
of O +
NF O -
- O -
AT O +
. O +

FK506 O +
and O +
cyclosporin O +
A O +
block O +
translocation O +
of O +
the O +
cytoplasmic O +
component O +
without O +
affecting O +
synthesis O +
of O +
the O +
nuclear O +
subunit O +
. O +

NF O -
- O -
kappa O +
B O +
activation O +
by O +
tumor O +
necrosis O +
factor O +
alpha O +
in O +
the O +
Jurkat B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
is O +
independent O +
of O +
protein O +
kinase O +
A O +
, O +
protein O +
kinase O +
C O +
, O +
and O +
Ca O +
( O +
2 O -
+ O +
) O +
-regulated O +
kinases O +
. O +

NF O -
- O -
kappa O +
B O +
is O +
a O +
DNA O -
- O -
binding O +
regulatory O +
factor O +
able O +
to O +
control O +
transcription O +
of O +
a O +
number O +
of O +
genes O +
, O +
including O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
genes O +
. O +

In O +
T O +
cells O +
, O +
NF O -
- O -
kappa O +
B O +
is O +
activated O +
upon O +
cellular O +
treatment O +
by O +
phorbol O +
esters O +
and O +
the O +
cytokine O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O +
alpha O +
) O +
. O +

In O +
the O +
present O +
work O +
, O +
we O +
investigated O +
the O +
molecular O +
events O +
leading O +
to O +
NF O -
- O -
kappa O +
B O +
activation O +
by O +
TNF O +
alpha O +
in O +
a O +
human B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
Jurkat B-CellLine +
) O +
and O +
its O +
subclone O +
JCT6 B-CellLine +
, O +
which O +
presents O +
a O +
deficiency O +
in O +
the O +
PKA O +
transduction O +
pathway O +
. O +

We O +
found O +
that O +
in O +
both O +
cell O +
lines O +
, O +
both O +
phorbol O +
ester O +
and O +
TNF O +
alpha O +
were O +
able O +
to O +
activate O +
NF O -
- O -
kappa O +
B O +
. O +

Phorbol O +
activation O +
was O +
positively O +
modulated O +
by O +
Ca2 O -
+ O +
influx O +
while O +
TNF O +
alpha O +
activation O +
was O +
not O +
. O +

Furthermore O +
, O +
while O +
PMA O +
activation O +
was O +
inhibited O +
by O +
the O +
PKC O +
inhibitor O +
staurosporin O +
, O +
the O +
TNF O +
alpha O +
effect O +
was O +
unchanged O +
. O +

TNF O +
alpha O +
did O +
not O +
activate O +
cAMP O +
production O +
and O +
its O +
signal O +
was O +
not O +
modulated O +
by O +
cAMP O +
activators O +
. O +

Moreover O +
, O +
cAMP O +
activators O +
did O +
not O +
activate O +
NF O -
- O -
kappa O +
B O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

Thus O +
, O +
TNF O +
alpha O +
-induced O +
NF O -
- O -
kappa O +
B O +
activation O +
was O +
found O +
to O +
be O +
mediated O +
by O +
none O +
of O +
the O +
major O +
signal O -
- O -
mediating O +
kinases O +
such O +
as O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
, O +
protein O +
kinase O +
A O +
, O +
or O +
Ca O +
( O +
2 O -
+ O +
) O +
-regulated O +
kinases O +
. O +

Furthermore O +
, O +
we O +
found O +
that O +
cytoplasmic O +
acidification O +
facilitated O +
NF O -
- O -
kappa O +
B O +
activation O +
by O +
both O +
TNF O +
alpha O +
and O +
PKC O +
, O +
by O +
a O +
mechanism O +
that O +
increases O +
NF O -
- O -
kappa O +
B O +
/I O +
kappa O +
B O +
dissociation O +
without O +
affecting O +
the O +
NF O -
- O -
kappa O +
B O +
translocation O +
step O +
. O +

NF O -
- O -
kappa O +
B O +
activity O +
in O +
T O +
cells O +
stably O +
expressing O +
the O +
Tax O +
protein O +
of O +
human O +
T O +
cell O +
lymphotropic O +
virus O +
type O +
I O +
. O +

The O +
effect O +
of O +
constitutive O +
Tax O +
expression O +
on O +
the O +
interaction O +
of O +
NF O -
- O -
kappa O +
B O +
with O +
its O +
recognition O +
sequence O +
and O +
on O +
NF O -
- O -
kappa O +
B O +
-dependent O +
gene O +
expression O +
was O +
examined O +
in O +
T B-CellLine +
lymphoid I-CellLine +
Jurkat I-CellLine +
cell I-CellLine +
lines I-CellLine +
( O +
19D B-CellLine +
and O +
9J B-CellLine +
) O +
stably O +
transformed O +
with O +
a O +
Tax O +
expression O +
vector O +
. O +

Tax B-CellLine +
expressing I-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
contained O +
a O +
constitutive O +
level O +
of O +
NF O -
- O -
kappa O +
B O +
binding O +
activity O +
, O +
detectable O +
by O +
mobility O +
shift O +
assay O +
and O +
uv O +
cross O -
- O -
linking O +
using O +
a O +
palindromic O +
NF O -
- O -
kappa O +
B O +
probe O +
homologous O +
to O +
the O +
interferon O +
beta O +
PRDII O +
site O +
. O +

In O +
Jurkat O +
and O +
NC2.10 O +
induction O +
with O +
phorbol O +
esters O +
resulted O +
in O +
the O +
appearance O +
of O +
new O +
DNA O +
binding O +
proteins O +
of O +
85 O +
, O +
75 O +
, O +
and O +
54 O +
kDa O +
, O +
whereas O +
in O +
Tax B-CellLine +
expressing I-CellLine +
cells I-CellLine +
the O +
85-kDa O +
protein O +
and O +
a O +
92-kDa O +
DNA O +
binding O +
protein O +
were O +
constitutively O +
induced O +
. O +

Expression O +
of O +
Tax O +
protein O +
in O +
19D B-CellLine +
and O +
9J B-CellLine +
resulted O +
in O +
transcription O +
of O +
the O +
endogenous O +
NF O -
- O -
kappa O +
B O -
- O -
dependent O +
granulocyte O -
- O -
macrophage O +
colony O +
stimulating O +
factor O +
gene O +
and O +
increased O +
basal O +
level O +
expression O +
of O +
transfected O +
NF O -
- O -
kappa O +
B O -
- O -
regulated O +
promoters O +
. O +

Nonetheless O +
transcription O +
of O +
both O +
the O +
endogenous O +
and O +
the O +
transfected O +
gene O +
was O +
inducible O +
by O +
PMA O +
treatment O +
. O +

Tax O +
expression O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
may O +
alter O +
the O +
stoichiometry O +
of O +
NF O -
- O -
kappa O +
B O +
DNA O +
binding O +
proteins O +
and O +
thus O +
change O +
the O +
expression O +
of O +
NF O -
- O -
kappa O +
B O -
- O -
regulated O +
promoters O +
. O +

Glucocorticoid O +
receptors O +
in O +
lymphocytes O +
in O +
anorexia O +
nervosa O +
. O +

OBJECTIVE O +
: O +
The O +
aim O +
was O +
to O +
explore O +
the O +
down O -
- O -
regulation O +
of O +
the O +
glucocorticoid O +
receptors O +
during O +
hypercortisolaemia O +
in O +
anorexia O +
nervosa O +
. O +

DESIGN O +
: O +
Urine O +
and O +
plasma O +
samples O +
were O +
obtained O +
for O +
cortisol O +
determination O +
and O +
blood O +
lymphocytes O +
were O +
isolated O +
for O +
receptor O +
binding O +
studies O +
. O +

PATIENTS O +
: O +
Sixteen O +
anorexic O +
patients O +
, O +
aged O +
16 O -
- O -
27 O +
years O +
, O +
with O +
a O +
mean O +
+ O -
/- O +
SEM O +
body O +
mass O +
index O +
of O +
14.2 O +
+ O -
/- O +
2.0 O +
( O +
ranging O +
from O +
11.1 O +
to O +
17.4 O +
) O +
, O +
and O +
15 O +
normal O +
women O +
were O +
studied O +
. O +

Six O +
patients O +
were O +
reinvestigated O +
after O +
a O +
significant O +
weight O +
gain O +
. O +

MEASUREMENTS O +
: O +
The O +
binding O +
capacity O +
and O +
affinity O +
of O +
the O +
glucocorticoid O +
receptors O +
were O +
measured O +
with O +
dexamethasone O +
as O +
ligand O +
on O +
lymphocytes O +
. O +

RESULTS O +
: O +
In O +
patients O +
, O +
both O +
total O +
and O +
free O +
plasma O +
cortisol O +
concentrations O +
were O +
higher O +
than O +
in O +
the O +
normal O +
women O +
, O +
as O +
was O +
their O +
urinary O +
free O +
cortisol O +
; O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
per O +
cell O +
( O +
Ro O +
) O +
and O +
the O +
binding O +
affinity O +
( O +
Kd O +
) O +
for O +
dexamethasone O +
were O +
, O +
however O +
, O +
not O +
significantly O +
different O +
( O +
Ro O +
: O +
7687 O +
+ O -
/- O +
1750 O +
vs O +
7347 O +
+ O -
/- O +
1285 O +
sites O -
/ O -
cell O +
; O +
Kd O +
: O +
7.7 O +
+ O -
/- O +
2.4 O +
vs O +
7.4 O +
+ O -
/- O +
1.7 O +
nM O +
at O +
24 O +
degrees O +
C O +
) O +
. O +

After O +
weight O +
gain O +
( O +
14 O +
+ O -
/- O +
2 O +
to O +
16 O +
+ O -
/- O +
2 O +
kg O -
/ O -
m2 O +
) O +
, O +
receptor O +
numbers O +
were O +
8421 O +
+ O -
/- O +
2126 O +
( O +
pre O +
) O +
and O +
9011 O +
+ O -
/- O +
500 O +
( O +
post O +
) O +
sites O -
/ O -
cell O +
, O +
which O +
are O +
not O +
significantly O +
different O +
( O +
P O +
greater O +
than O +
0.2 O +
) O +
; O +
the O +
Kd O +
was O +
unchanged O +
( O +
9.3 O +
+ O -
/- O +
2.6 O +
vs O +
9.2 O +
+ O -
/- O +
2.4 O +
nM O +
) O +
. O +

CONCLUSIONS O +
Hypercortisolaemia O +
does O +
not O +
down O -
- O -
regulate O +
the O +
lymphocyte O +
glucocorticoid O +
receptors O +
in O +
anorexia O +
nervosa O +
and O +
a O +
post O -
- O -
receptor O +
defect O +
might O +
be O +
involved O +
in O +
peripheral O +
tissue O +
resistance O +
to O +
the O +
effects O +
of O +
glucocorticoid O +
hormones O +
in O +
undernutrition O +
. O +

Tumor O +
necrosis O +
factor O -
- O -
alpha O +
mRNA O +
accumulation O +
in O +
human B-CellLine +
myelomonocytic I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Role O +
of O +
transcriptional O +
regulation O +
by O +
DNA O +
sequence O +
motifs O +
and O +
mRNA O +
stabilization O +
. O +

The O +
cytokine O +
TNF O +
mediates O +
many O +
of O +
the O +
pathologic O +
signs O +
of O +
cachexia O +
, O +
inflammation O +
, O +
and O +
sepsis O +
. O +

The O +
current O +
work O +
describes O +
the O +
regulation O +
of O +
TNF O +
in O +
human B-CellLine +
myelomonocytic I-CellLine +
cell I-CellLine +
lines I-CellLine +
after O +
PMA O +
stimulation O +
. O +

The O +
cell B-CellLine +
lines I-CellLine +
exhibit O +
a O +
low O +
level O +
of O +
constitutive O +
TNF O +
mRNA O +
expression O +
. O +

Within O +
2 O +
to O +
4 O +
h O +
of O +
PMA O +
exposure O +
, O +
steady O +
state O +
levels O +
of O +
TNF O +
mRNA O +
are O +
markedly O +
elevated O +
in O +
all O +
myelomonocytic B-CellLine +
cell I-CellLine +
lines I-CellLine +
studied O +
. O +

This O +
rise O +
is O +
due O +
to O +
increased O +
mRNA O +
stability O +
, O +
which O +
increased O +
by O +
almost O +
twofold O +
, O +
and O +
to O +
an O +
overall O +
increase O +
in O +
transcription O +
, O +
which O +
rises O +
by O +
more O +
than O +
sixfold O +
. O +

At O +
the O +
level O +
of O +
the O +
genomic O +
TNF O +
gene O +
, O +
a O +
DNase O +
I O +
hypersensitive O +
site O +
is O +
detected O +
within O +
the O +
TNF O +
promoter O +
between O +
-200 O +
to O +
-100 O +
bp O +
relative O +
to O +
the O +
transcription O +
initiation O +
site O +
. O +

Although O +
absent O +
in O +
nonexpressing B-CellLine +
erythroleukemia I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
the O +
DNase O +
I O +
site O +
is O +
present O +
in O +
uninduced B-CellLine +
myelomonocytic I-CellLine +
cell I-CellLine +
lines I-CellLine +
and O +
is O +
not O +
changed O +
after O +
PMA O +
induction O +
. O +

The O +
PMA O +
induction O +
of O +
c O -
- O -
fos O +
mRNA O +
correlated O +
well O +
with O +
TNF O +
gene O +
induction O +
; O +
expression O +
of O +
genes O +
encoding O +
other O +
proteins O +
in O +
the O +
AP-1 O +
complex O +
( O +
junB O +
and O +
junD O +
) O +
were O +
also O +
induced O +
by O +
PMA O +
. O +

The O +
nuclear O +
extracts O +
from O +
resting O +
and O +
induced B-CellLine +
ML-1 I-CellLine +
cells I-CellLine +
contain O +
proteins O +
binding O +
specifically O +
to O +
the O +
AP-1 O +
, O +
AP-2 O +
, O +
and O +
NF O +
kappa O +
B O +
sequence O +
located O +
within O +
the O +
TNF O +
promoter O +
. O +

PMA O +
induction O +
increases O +
the O +
level O +
of O +
a O +
number O +
of O +
specific O +
binding O +
complexes O +
relative O +
to O +
the O +
resting O +
cells O +
. O +

The O +
regulatory O +
mechanisms O +
of O +
the O +
human O +
and O +
murine O +
TNF O +
genes O +
are O +
discussed O +
. O +

The O +
effect O +
of O +
toremifene O +
therapy O +
on O +
serum O +
immunoglobulin O +
levels O +
in O +
breast O +
cancer O +
. O +

Estrogens O +
and O +
anti O -
- O -
estrogens O +
enhance O +
the O +
number O +
of O +
immunoglobulin O +
( O +
Ig O +
) O +
-secreting O +
cells O +
in O +
pokeweed B-CellLine +
mitogen I-CellLine +
( I-CellLine +
PWM I-CellLine +
) I-CellLine +
-stimulated I-CellLine +
lymphocyte I-CellLine +
cultures I-CellLine +
. O +

Lymphocytes O +
from O +
patients O +
who O +
have O +
received O +
anti O -
- O -
estrogen O +
therapy O +
show O +
similar O +
enhancement O +
of O +
Ig O -
- O -
secreting O +
cells O +
after O +
PWM O +
stimulation O +
. O +

In O +
this O +
study O +
the O +
effect O +
of O +
anti O -
- O -
estrogen O +
( O +
toremifene O +
) O +
therapy O +
on O +
serum O +
immunoglobulin O +
( O +
IgA O +
, O +
IgM O +
, O +
IgG O +
) O +
levels O +
in O +
breast O +
cancer O +
patients O +
was O +
investigated O +
. O +

Serum O +
Ig O +
levels O +
were O +
followed O +
up O +
to O +
two O +
years O +
after O +
or O +
during O +
the O +
therapy O +
. O +

An O +
unexpected O +
finding O +
was O +
that O +
the O +
Ig O +
levels O +
decreased O +
during O +
the O +
follow O -
- O -
up O +
period O +
. O +

This O +
decrease O +
was O +
seen O +
in O +
patients O +
who O +
responded O +
to O +
the O +
therapy O +
as O +
well O +
as O +
in O +
those O +
who O +
did O +
not O +
. O +

HIV1 O +
infection O +
of O +
human O +
monocytes O +
and O +
macrophages O +
promotes O +
induction O +
or O +
translocation O +
of O +
NF O -
- O -
KB O -
- O -
related O +
factors O +
. O +

In O +
1991 O +
, O +
we O +
demonstrated O +
, O +
using O +
electrophoretic O +
mobility O +
shift O +
assays O +
, O +
that O +
3 O +
different O +
factors O +
( O +
termed O +
B1 O +
, O +
B2 O +
and O +
B3 O +
) O +
with O +
affinity O +
for O +
the O +
KB O -
- O -
enhancer O +
target O +
sequence O +
were O +
specifically O +
detected O +
in O +
nuclear O +
extracts O +
from O +
HIV1-infected O +
monocytes O +
and O +
macrophages O +
. O +

The O +
B2 O +
factor O +
was O +
induced O +
in O +
the O +
nuclei O +
of O +
these O +
cells O +
only O +
upon O +
HIV1 O +
infection O +
. O +

The O +
B3 O +
factor O +
was O +
only O +
slightly O +
evident O +
in O +
nuclei O +
of O +
uninfected O +
cells O +
but O +
was O +
readily O +
detectable O +
in O +
nuclei O +
of O +
infected O +
monocytes O +
. O +

Its O +
expression O +
remained O +
very O +
low O +
in O +
nuclei O +
of O +
HIV1-infected O +
macrophages O +
. O +

In O +
this O +
paper O +
, O +
we O +
demonstrate O +
that O +
the O +
B2 O +
factor O +
is O +
expressed O +
in O +
the O +
cytosol O +
of O +
monocytes O +
and O +
macrophages O +
as O +
a O +
DNA O -
- O -
binding O +
protein O +
, O +
indicating O +
that O +
it O +
is O +
not O +
associated O +
with O +
an O +
inhibitor O +
( O +
IKB O +
) O +
. O +

This O +
factor O +
remained O +
clustered O +
in O +
the O +
cytosol O +
and O +
was O +
translocated O +
to O +
the O +
nuclei O +
only O +
after O +
HIV1 O +
infection O +
. O +

The O +
B3 O +
factor O +
is O +
detected O +
in O +
the O +
cytosol O +
only O +
when O +
cells O +
are O +
HIV1-infected O +
. O +

The O +
role O +
of O +
HIV1 O +
infection O +
in O +
the O +
expression O +
and O +
the O +
translocation O +
of O +
these O +
factors O +
is O +
discussed O +
. O +

A O +
nuclear O +
factor O +
NF O -
- O -
GM2 O +
that O +
interacts O +
with O +
a O +
regulatory O +
region O +
of O +
the O +
GM O -
- O -
CSF O +
gene O +
essential O +
for O +
its O +
induction O +
in O +
responses O +
to O +
T O -
- O -
cell O +
activation O +
: O +
purification O +
from O +
human O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
leukemia I-CellLine +
line I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
and O +
similarity O +
to O +
NF O -
- O -
kappa O +
B O +
. O +

Activation O +
of O +
T O +
cells O +
by O +
antigen O +
, O +
lectin O +
, O +
or O +
a O +
combination O +
of O +
phorbol-12-myristate O +
acetate O +
( O +
PMA O +
) O +
and O +
calcium O +
ionophore O +
( O +
A23187 O +
) O +
leads O +
to O +
the O +
induction O +
of O +
genes O +
for O +
a O +
set O +
of O +
lymphokines O +
, O +
including O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
. O +

We O +
demonstrated O +
in O +
earlier O +
studies O +
that O +
the O +
upstream O +
region O +
of O +
the O +
mouse O +
GM O -
- O -
CSF O +
promoter O +
at O +
positions O +
between O +
-95 O +
and O +
-73 O +
is O +
essential O +
for O +
transcriptional O +
activation O +
in O +
response O +
to O +
PMA O -
/ O -
A23187 O +
. O +

This O +
region O +
contains O +
two O +
DNA O -
- O -
binding O +
motifs O +
, O +
GM2 O +
and O +
GC O -
- O -
box O +
. O +

The O +
GM2 O +
sequence O +
( O +
GGTAGTTCCC O +
) O +
is O +
recognized O +
by O +
an O +
inducible O +
factor O +
NF O -
- O -
GM2 O +
; O +
the O +
other O +
( O +
CCGCCC O +
) O +
by O +
constitutive O +
factors O +
A1 O +
, O +
A2 O +
, O +
and O +
B O +
. O +

To O +
elucidate O +
the O +
mechanism O +
of O +
GM O -
- O -
CSF O +
gene O +
activation O +
, O +
we O +
have O +
purified O +
the O +
inducible O +
factor O +
NF O -
- O -
GM2 O +
from O +
the O +
nuclear O +
extract O +
of O +
stimulated O +
Jurkat B-CellLine +
cells I-CellLine +
on O +
the O +
basis O +
of O +
specific O +
DNA O -
- O -
binding O +
activity O +
. O +

The O +
purified O +
NF O -
- O -
GM2 O +
consists O +
of O +
50 O +
( O +
p50 O +
) O +
and O +
65 O +
kDa O +
( O +
p65 O +
) O +
polypeptides O +
and O +
has O +
a O +
binding O +
activity O +
specific O +
for O +
both O +
the O +
GM O -
- O -
CSF O +
and O +
immunoglobulin O +
kappa O +
( O +
GGAAAGTCCC O +
) O +
enhancers O +
. O +

Electrophoretically O +
purified O +
p50 O +
alone O +
can O +
form O +
a O +
protein O -
- O -
DNA O +
complex O +
, O +
but O +
in O +
the O +
mixture O +
, O +
p50 O +
associates O +
preferentially O +
with O +
p65 O +
to O +
form O +
the O +
NF O -
- O -
GM2 O +
complex O +
. O +

In O +
addition O +
, O +
p65 O +
gave O +
per O +
se O +
, O +
with O +
low O +
affinity O +
, O +
a O +
protein O -
- O -
DNA O +
complex O +
that O +
migrated O +
more O +
slowly O +
than O +
native O +
NF O -
- O -
GM2 O +
complex O +
. O +

Furthermore O +
, O +
an O +
antiserum O +
against O +
KBF1 O +
( O +
identical O +
to O +
50 O +
kDa O +
NF O -
- O -
kappa O +
B O +
protein O +
) O +
reacted O +
with O +
the O +
p50 O +
of O +
NF O -
- O -
GM2 O +
, O +
indicating O +
that O +
the O +
NF O -
- O -
GM2 O +
polypeptide O +
can O +
not O +
be O +
immunologically O +
differentiated O +
from O +
the O +
50 O +
kDa O +
subunit O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

The O +
purified O +
NF O -
- O -
GM2 O +
activated O +
in O +
vitro O +
transcription O +
from O +
the O +
kappa O +
B O +
enhancer O +
, O +
while O +
it O +
failed O +
to O +
stimulate O +
transcription O +
from O +
the O +
GM O -
- O -
CSF O +
promoter O +
harboring O +
the O +
GM2 O +
sequence O +
. O +

This O +
suggests O +
that O +
the O +
activation O +
mechanism O +
of O +
the O +
GM O -
- O -
CSF O +
gene O +
through O +
the O +
GM2 O -
/ O -
GC O -
- O -
box O +
sequence O +
is O +
different O +
from O +
that O +
of O +
genes O +
carrying O +
the O +
kappa O +
B O +
enhancer O +
alone O +
. O +

To O +
be O +
or O +
not O +
to O +
be O +
a O +
responder O +
in O +
T O -
- O -
cell O +
responses O +
: O +
ubiquitous O +
oligopeptides O +
in O +
all O +
proteins O +
. O +

Amino O +
acid O +
sequences O +
of O +
all O +
proteins O +
are O +
essays O +
written O +
in O +
the O +
same O +
language O +
. O +

Accordingly O +
, O +
the O +
same O +
set O +
of O +
words O +
and O +
phrases O +
( O +
oligopeptides O +
) O +
appear O +
in O +
totally O +
unrelated O +
proteins O +
. O +

The O +
reason O +
that O +
only O +
certain O +
individuals O +
of O +
particular O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
haplotypes O +
can O +
mount O +
T O -
- O -
cell O +
responses O +
against O +
a O +
given O +
antigen O +
of O +
pathogens O +
is O +
found O +
in O +
the O +
fact O +
that O +
T O -
- O -
cell O +
receptors O +
are O +
designed O +
to O +
recognize O +
18 O -
- O -
20 O +
residue O -
- O -
long O +
peptide O +
fragments O +
sandwiched O +
between O +
two O +
alpha O -
- O -
helices O +
of O +
class O +
I O +
or O +
class O +
II O +
MHC O +
molecules O +
. O +

At O +
this O +
range O +
of O +
peptide O +
lengths O +
, O +
most O +
would O +
appear O +
as O +
self O +
, O +
while O +
nonselfness O +
of O +
the O +
remainders O +
are O +
destined O +
to O +
be O +
quite O +
ambiguous O +
, O +
hence O +
creating O +
responders O +
and O +
nonresponders O +
. O +

Anti O -
- O -
CD2 O +
receptor O +
antibodies O +
activate O +
the O +
HIV O +
long O +
terminal O +
repeat O +
in O +
T O +
lymphocytes O +
. O +

The O +
CD2 O +
T O +
lymphocyte O +
glycoprotein O +
surface O +
molecule O +
mediates O +
both O +
cell O +
to O +
cell O +
adhesion O +
and O +
T O +
cell O +
activation O +
, O +
two O +
processes O +
that O +
are O +
involved O +
in O +
the O +
spread O +
of O +
HIV O +
infection O +
. O +

Treatment O +
of O +
chronically B-CellLine +
HIV I-CellLine -
- I-CellLine -
infected I-CellLine +
PBMC I-CellLine +
with O +
anti O -
- O -
CD2 O +
mAb O +
has O +
been O +
shown O +
to O +
induce O +
the O +
expression O +
of O +
infectious O +
virus O +
from O +
these O +
cultures O +
. O +

In O +
this O +
study O +
we O +
investigated O +
the O +
mechanisms O +
whereby O +
anti O -
- O -
CD2 O +
antibodies O +
stimulate O +
viral O +
production O +
. O +

We O +
demonstrate O +
that O +
treatment O +
of O +
transiently O +
transfected O +
T O +
lymphocytes O +
with O +
anti O -
- O -
CD2 O +
antibodies O +
results O +
in O +
activation O +
of O +
the O +
HIV O +
long O +
terminal O +
repeat O +
. O +

Furthermore O +
, O +
CAT O +
assays O +
using O +
mutated O +
HIV O +
long O +
terminal O +
repeat O -
- O -
CAT O +
constructs O +
and O +
gel O +
shift O +
assays O +
demonstrate O +
that O +
this O +
activation O +
is O +
dependent O +
on O +
the O +
NF O -
- O -
kappa O +
B O +
enhancer O +
. O +

These O +
studies O +
suggest O +
that O +
interaction O +
of O +
CD2 O +
with O +
its O +
natural O +
ligand O +
, O +
LFA-3 O +
, O +
may O +
play O +
a O +
role O +
in O +
regulation O +
of O +
HIV O +
expression O +
. O +

Nuclear O +
transcription O +
factors O +
that O +
bind O +
to O +
elements O +
of O +
the O +
IL-2 O +
promoter O +
. O +

Induction O +
requirements O +
in O +
primary O +
human O +
T O +
cells O +
. O +

Prior O +
studies O +
have O +
identified O +
several O +
elements O +
that O +
contribute O +
to O +
the O +
activity O +
of O +
the O +
IL-2 O +
promoter O +
in O +
the O +
stimulated O +
T B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
Jurkat B-CellLine +
. O +

The O +
sites O +
and O +
their O +
corresponding O +
nuclear O +
binding O +
factors O +
include O +
: O +
NF O -
- O -
kappa O +
B O +
, O +
AP-1 O +
, O +
AP-3 O +
, O +
OCT-1 O +
, O +
and O +
NF O -
- O -
AT O +
. O +

The O +
latter O +
` O -
` O +
nuclear O +
factor O +
for O +
activated O +
T O +
cells O +
` O -
` O +
likely O +
contributes O +
to O +
the O +
tissue O +
specificity O +
of O +
IL-2 O +
gene O +
expression O +
. O +

Using O +
electrophoretic O +
mobility O +
shift O +
assays O +
, O +
we O +
have O +
studied O +
these O +
transcription O +
factors O +
in O +
primary O +
T O +
cells O +
from O +
human O +
blood O +
to O +
verify O +
their O +
presence O +
in O +
a O +
physiologic O +
setting O +
and O +
to O +
identify O +
the O +
signals O +
that O +
stimulate O +
factor O +
activity O +
. O +

All O +
factors O +
are O +
induced O +
in O +
the O +
nuclei O +
of O +
T O +
cells O +
upon O +
activation O +
with O +
mitogens O +
but O +
not O +
with O +
exogenous O +
IL-2 O +
growth O +
factor O +
. O +

However O +
, O +
the O +
signaling O +
requirements O +
and O +
sensitivity O +
to O +
protein O +
synthesis O +
inhibitors O +
differ O +
considerably O +
. O +

Only O +
the O +
activities O +
for O +
NF O -
- O -
AT O +
and O +
AP-1 O +
sites O +
require O +
two O +
signals O +
for O +
optimal O +
induction O +
, O +
i.e. O +
, O +
PMA O +
plus O +
either O +
lectin O +
or O +
antibody O +
to O +
the O +
CD3 O +
or O +
CD28 O +
surface O +
molecules O +
. O +

Other O +
factors O +
are O +
induced O +
by O +
lectin O +
, O +
antibody O +
, O +
and/or O +
PMA O +
alone O +
. O +

After O +
appropriate O +
stimulation O +
, O +
both O +
NF O -
- O -
AT O +
and O +
AP-1 O +
are O +
peculiarly O +
sensitive O +
to O +
the O +
protein O +
synthesis O +
inhibitor O +
anisomycin O +
. O +

Our O +
data O +
correlate O +
the O +
activity O +
of O +
NF O -
- O -
AT O +
and O +
AP-1 O +
in O +
gel O +
shift O +
assays O +
with O +
the O +
two O +
signals O +
requirements O +
for O +
IL-2 O +
gene O +
expression O +
. O +

An O +
erythroid O +
specific O +
enhancer O +
upstream O +
to O +
the O +
gene O +
encoding O +
the O +
cell O -
- O -
type O +
specific O +
transcription O +
factor O +
GATA-1 O +
. O +

The O +
transcription O +
factor O +
GATA-1 O +
is O +
expressed O +
in O +
a O +
subset O +
of O +
hemopoietic O +
cells O +
, O +
where O +
it O +
mediates O +
the O +
cell O -
- O -
type O +
specific O +
expression O +
of O +
several O +
genes O +
. O +

We O +
have O +
cloned O +
the O +
mouse O +
and O +
human O +
GATA-1 O +
genes O +
. O +

A O +
region O +
upstream O +
to O +
the O +
first O +
exon O +
, O +
and O +
highly O +
conserved O +
between O +
mouse O +
and O +
man O +
, O +
acts O +
as O +
an O +
erythroid O +
specific O +
enhancer O +
in O +
transient O +
assays O +
, O +
if O +
linked O +
to O +
the O +
GATA-1 O +
or O +
to O +
the O +
SV40 O +
promoter O +
. O +

The O +
activity O +
of O +
the O +
enhancer O +
is O +
almost O +
completely O +
dependent O +
on O +
the O +
integrity O +
of O +
a O +
dimeric O +
GATA-1 O +
binding O +
site O +
. O +

Demonstration O +
of O +
a O +
1 O +
, O +
25-dihydroxyvitamin O +
D3-responsive O +
protein O +
in O +
human O +
lymphocytes O +
: O +
immunologic O +
crossreactivity O +
and O +
inverse O +
regulation O +
with O +
the O +
vitamin O +
D O +
receptor O +
. O +

Using O +
Western O +
blot O +
analysis O +
with O +
a O +
monoclonal O +
antibody O +
recognizing O +
a O +
17-amino O +
acid O +
epitope O +
of O +
the O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
[ O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
] O +
receptor O +
, O +
we O +
have O +
detected O +
two O +
crossreacting O +
proteins O +
in O +
activated O +
normal O +
human O +
lymphocytes O +
. O +

The O +
smaller O +
of O +
the O +
two O +
proteins O +
( O +
50 O +
kDa O +
) O +
was O +
indistinguishable O +
from O +
the O +
classical O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
and O +
, O +
similar O +
to O +
the O +
classical O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
receptor O +
, O +
was O +
upregulated O +
in O +
a O +
dose O -
- O -
dependent O +
fashion O +
by O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
. O +

The O +
larger O +
crossreacting O +
protein O +
exhibited O +
an O +
electrophoretic O +
mobility O +
of O +
80 O +
kDa O +
, O +
was O +
localized O +
in O +
the O +
cell O +
cytosol O +
, O +
and O +
appeared O +
to O +
be O +
specific O +
for O +
activated O +
lymphocytes O +
since O +
it O +
was O +
not O +
detected O +
in O +
several O +
other O +
human O +
cells O +
including O +
monocytes O +
. O +

More O +
strikingly O +
, O +
the O +
80-kDa O +
protein O +
was O +
downregulated O +
in O +
a O +
dose O -
- O -
dependent O +
fashion O +
by O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
; O +
this O +
effect O +
was O +
independent O +
of O +
the O +
mode O +
of O +
lymphocyte O +
activation O +
and O +
specific O +
for O +
the O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
metabolite O +
of O +
vitamin O +
D3 O +
. O +

However O +
, O +
two O +
potent O +
immunosuppressive O +
agents O +
, O +
glucocorticoids O +
and O +
cyclosporin O +
A O +
, O +
also O +
inhibited O +
the O +
80-kDa O +
protein O +
. O +

T O -
- O -
helper O -
- O -
cell O +
determinants O +
in O +
protein O +
antigens O +
are O +
preferentially O +
located O +
in O +
cysteine O -
- O -
rich O +
antigen O +
segments O +
resistant O +
to O +
proteolytic O +
cleavage O +
by O +
cathepsin O +
B O +
, O +
L O +
, O +
and O +
D O +
. O +

We O +
report O +
on O +
a O +
computer O +
algorithm O +
capable O +
of O +
predicting O +
the O +
location O +
of O +
T O -
- O -
helper O -
- O -
cell O +
epitopes O +
in O +
protein O +
antigen O +
( O +
Ag O +
) O +
by O +
analysing O +
the O +
Ag O +
amino O +
acid O +
sequence O +
. O +

The O +
algorithm O +
was O +
constructed O +
with O +
the O +
aim O +
of O +
identifying O +
segments O +
in O +
Ag O +
which O +
are O +
resistant O +
to O +
proteolytic O +
degradation O +
by O +
the O +
enzymes O +
cathepsin O +
B O +
, O +
L O +
, O +
and O +
D O +
. O +

These O +
are O +
prominent O +
enzymes O +
in O +
the O +
endocytic O +
pathway O +
through O +
which O +
soluble O +
protein O +
Ag O +
enter O +
APC O +
, O +
and O +
resistant O +
segments O +
in O +
Ag O +
may O +
, O +
therefore O +
, O +
be O +
expected O +
to O +
contain O +
more O +
T O -
- O -
cell O +
determinants O +
than O +
susceptible O +
segments O +
. O +

From O +
information O +
available O +
in O +
the O +
literature O +
on O +
the O +
substrate O +
specificity O +
of O +
the O +
three O +
enzymes O +
, O +
it O +
is O +
clear O +
that O +
a O +
cysteine O +
is O +
not O +
accepted O +
in O +
any O +
of O +
the O +
S2 O +
, O +
S1 O +
, O +
S1 O +
' O +
, O +
and O +
S2 O +
' O +
subsites O +
of O +
cathepsin O +
B O +
and O +
L O +
, O +
and O +
not O +
in O +
the O +
S1 O +
and O +
S1 O +
' O +
subsites O +
of O +
cathepsin O +
D O +
. O +

Moreover O +
, O +
we O +
have O +
noticed O +
that O +
cysteine O -
- O -
containing O +
T O -
- O -
cell O +
determinants O +
in O +
a O +
number O +
of O +
protein O +
Ag O +
are O +
particularly O +
rich O +
in O +
the O +
amino O +
acids O +
alanine O +
, O +
glycine O +
, O +
lysine O +
, O +
leucine O +
, O +
serine O +
, O +
threonine O +
, O +
and O +
valine O +
. O +

By O +
searching O +
protein O +
Ag O +
for O +
clusters O +
of O +
amino O +
acids O +
containing O +
cysteine O +
and O +
two O +
of O +
the O +
other O +
amino O +
acids O +
we O +
were O +
able O +
to O +
predict O +
17 O +
out O +
of O +
23 O +
empirically O +
known O +
T O -
- O -
cell O +
determinants O +
in O +
the O +
Ag O +
with O +
a O +
relatively O +
low O +
number O +
of O +
false O +
( O +
positive O +
) O +
predictions O +
. O +

Furthermore O +
, O +
we O +
present O +
a O +
new O +
principle O +
for O +
searching O +
Ag O +
for O +
potential O +
amphipatic O +
alpha O -
- O -
helical O +
protein O +
segments O +
. O +

Such O +
segments O +
accord O +
well O +
with O +
empirically O +
known O +
T O -
- O -
cell O +
determinants O +
and O +
our O +
algorithm O +
produces O +
a O +
lower O +
number O +
of O +
false O +
positive O +
predictions O +
than O +
the O +
principle O +
based O +
on O +
discrete O +
Fourier O +
transformations O +
previously O +
described O +
. O +

v O -
- O -
erbA O +
overexpression O +
is O +
required O +
to O +
extinguish O +
c O -
- O -
erbA O +
function O +
in O +
erythroid O +
cell O +
differentiation O +
and O +
regulation O +
of O +
the O +
erbA O +
target O +
gene O +
CAII O +
. O +

The O +
v O -
- O -
erbA O +
oncoprotein O +
represents O +
a O +
retrovirus O -
- O -
transduced O +
oncogenic O +
version O +
of O +
the O +
thyroid O +
hormone O +
( O +
T3 O -
/ O -
T4 O +
) O +
receptor O +
c O -
- O -
erbA O +
( O +
type O +
alpha O +
) O +
. O +

It O +
contributes O +
to O +
virus O -
- O -
induced O +
erythroleukemia O +
by O +
efficiently O +
arresting O +
differentiation O +
of O +
red O +
cell O +
progenitors O +
and O +
by O +
suppressing O +
transcription O +
of O +
erythrocyte O -
- O -
specific O +
genes O +
. O +

Here O +
, O +
we O +
show O +
that O +
v O -
- O -
erbA O +
and O +
c O -
- O -
erbA O +
bind O +
directly O +
to O +
sequences O +
within O +
the O +
promoter O +
of O +
the O +
erythrocyte O -
- O -
specific O +
carbonic O +
anhydrase O +
II O +
( O +
CAII O +
) O +
, O +
a O +
gene O +
whose O +
transcription O +
is O +
efficiently O +
suppressed O +
by O +
v O -
- O -
erbA O +
. O +

This O +
erbA O -
- O -
binding O +
site O +
confers O +
thyroid O +
hormone O +
responsiveness O +
to O +
a O +
heterologous O +
promoter O +
in O +
transient O +
expression O +
experiments O +
and O +
is O +
a O +
target O +
for O +
efficient O +
down O -
- O -
regulation O +
of O +
CAII O +
transcription O +
by O +
the O +
v O -
- O -
erbA O +
oncoprotein O +
. O +

In O +
stably B-CellLine +
transformed I-CellLine +
erythroblasts I-CellLine +
coexpressing O +
the O +
v O -
- O -
erbA O +
oncoprotein O +
and O +
the O +
c O -
- O -
erbA O -
/ O -
T3 O +
receptor O +
at O +
an O +
approximately O +
equimolar O +
ratio O +
, O +
c O -
- O -
erbA O +
activity O +
is O +
dominant O +
over O +
v O -
- O -
erbA O +
. O +

T3 O +
efficiently O +
induced O +
erythroid O +
differentiation O +
in O +
these O +
cells O +
, O +
thus O +
overcoming O +
the O +
v O -
- O -
erbA O +
-mediated O +
differentiation O +
arrest O +
. O +

Likewise O +
, O +
T3 O +
activated O +
CAII O +
transcription O +
as O +
well O +
as O +
transient O +
expression O +
of O +
a O +
T3-responsive O +
reporter O +
gene O +
containing O +
the O +
CAII O -
- O -
specific O +
erbA O -
- O -
binding O +
site O +
. O +

The O +
c O -
- O -
erbA O +
-dependent O +
activation O +
of O +
this O +
CAII O +
reporter O +
construct O +
could O +
only O +
be O +
suppressed O +
by O +
very O +
high O +
amounts O +
of O +
v O -
- O -
erbA O +
. O +

Our O +
results O +
suggest O +
that O +
overexpression O +
of O +
v O -
- O -
erbA O +
is O +
required O +
for O +
its O +
function O +
as O +
an O +
oncoprotein O +
. O +

Charybdotoxin O -
- O -
sensitive O +
, O +
Ca O +
( O +
2 O -
+ O +
) O +
-dependent O +
membrane O +
potential O +
changes O +
are O +
not O +
involved O +
in O +
human O +
T O +
or O +
B O +
cell O +
activation O +
and O +
proliferation O +
. O +

The O +
involvement O +
of O +
ion O +
channels O +
in O +
B O +
and O +
T O +
lymphocyte O +
activation O +
is O +
supported O +
by O +
many O +
reports O +
of O +
changes O +
in O +
ion O +
fluxes O +
and O +
membrane O +
potential O +
after O +
mitogen O +
binding O +
. O +

Human O +
T O +
and O +
B O +
lymphocytes O +
demonstrate O +
an O +
early O +
and O +
transient O +
hyperpolarization O +
after O +
ligand O +
binding O +
. O +

Inasmuch O +
as O +
the O +
change O +
in O +
membrane O +
potential O +
is O +
dependent O +
on O +
elevation O +
of O +
free O +
cytosolic O +
calcium O +
, O +
the O +
hyperpolarization O +
is O +
presumably O +
through O +
opening O +
of O +
Ca O +
( O +
2 O -
+ O +
) O +
-stimulated O +
K+ O +
channels O +
. O +

We O +
have O +
used O +
charybdotoxin O +
, O +
a O +
known O +
inhibitor O +
of O +
Ca O +
( O +
2 O -
+ O +
) O +
-dependent O +
K+ O +
channels O +
, O +
to O +
study O +
the O +
role O +
of O +
these O +
channels O +
in O +
lymphocyte O +
activation O +
and O +
mitogenesis O +
. O +

We O +
demonstrate O +
that O +
charybdotoxin O +
inhibits O +
the O +
ligand O -
- O -
induced O +
transient O +
membrane O +
hyperpolarization O +
in O +
B O +
and O +
T O +
cells O +
in O +
a O +
dose O -
- O -
dependent O +
fashion O +
, O +
without O +
affecting O +
changes O +
in O +
cytosolic O +
Ca2 O -
+ O +
. O +

However O +
, O +
blockade O +
of O +
the O +
Ca O +
( O +
2 O -
+ O +
) O +
-activated O +
K+ O +
channel O +
is O +
not O +
associated O +
with O +
changes O +
in O +
cell O -
- O -
cycle O +
gene O +
activation O +
, O +
IL-2 O +
production O +
, O +
IL-2R O +
expression O +
or O +
B O +
and O +
T O +
cell O +
mitogenesis O +
. O +

These O +
results O +
imply O +
that O +
membrane O +
potential O +
changes O +
secondary O +
to O +
the O +
ligand O -
- O -
dependent O +
opening O +
of O +
Ca O +
( O +
2 O -
+ O +
) O +
-activated O +
K+ O +
channels O +
are O +
not O +
involved O +
in O +
B O +
and O +
T O +
lymphocyte O +
activation O +
and O +
mitogenesis O +
. O +

Evaluation O +
of O +
the O +
role O +
of O +
ligand O +
and O +
thermal O +
activation O +
of O +
specific O +
DNA O +
binding O +
by O +
in O +
vitro O +
synthesized O +
human O +
glucocorticoid O +
receptor O +
. O +

We O +
have O +
used O +
a O +
DNA O -
- O -
binding O -
/ O -
immunoprecipitation O +
assay O +
to O +
analyze O +
the O +
capacity O +
of O +
human O +
glucocorticoid O +
receptor O +
( O +
hGR O +
) O +
, O +
generated O +
in O +
rabbit O +
reticulocyte O +
lysates O +
, O +
to O +
bind O +
DNA O +
. O +

In O +
vitro O +
translated O +
hGR O +
was O +
indistinguishable O +
from O +
native O +
hGR O +
, O +
as O +
determined O +
by O +
migration O +
on O +
sodium O +
dodecyl O +
sulfate O -
- O -
polyacrylamide O +
gels O +
, O +
sedimentation O +
on O +
sucrose O +
density O +
gradients O +
, O +
and O +
reactivity O +
with O +
antipeptide O +
antibodies O +
generated O +
against O +
hGR O +
. O +

In O +
addition O +
, O +
cell O -
- O -
free O +
synthesized O +
hGR O +
was O +
capable O +
of O +
specific O +
binding O +
to O +
glucocorticoid O +
response O +
element O +
( O +
GRE O +
) O +
-containing O +
DNA O +
fragments O +
. O +

Using O +
this O +
assay O +
system O +
, O +
we O +
have O +
evaluated O +
the O +
contributions O +
of O +
ligand O +
binding O +
and O +
heat O +
activation O +
to O +
DNA O +
binding O +
by O +
these O +
glucocorticoid O +
receptors O +
. O +

In O +
vitro O +
translated O +
hGR O +
was O +
capable O +
of O +
selective O +
DNA O +
binding O +
even O +
in O +
the O +
absence O +
of O +
glucocorticoid O +
. O +

Treatment O +
with O +
dexamethasone O +
or O +
the O +
antiglucocorticoid O +
RU486 O +
had O +
no O +
additional O +
effect O +
on O +
the O +
DNA O -
- O -
binding O +
capacity O +
when O +
receptor O +
preparations O +
were O +
maintained O +
at O +
0 O +
C O +
( O +
no O +
activation O +
) O +
. O +

In O +
contrast O +
, O +
addition O +
of O +
either O +
ligand O +
or O +
antagonist O +
in O +
combination O +
with O +
a O +
heat O +
activation O +
step O +
promoted O +
DNA O +
binding O +
by O +
approximately O +
3-fold O +
over O +
that O +
of O +
heat O -
- O -
activated O +
unliganded O +
receptors O +
. O +

Agonist O +
( O +
dexamethasone O +
) O +
was O +
slightly O +
more O +
effective O +
in O +
supporting O +
specific O +
DNA O +
binding O +
than O +
antagonist O +
( O +
RU486 O +
) O +
. O +

DNA O +
binding O +
by O +
in O +
vitro O +
synthesized O +
GR O +
was O +
blocked O +
by O +
the O +
addition O +
of O +
sodium O +
molybdate O +
to O +
the O +
receptor O +
preparations O +
before O +
steroid O +
addition O +
and O +
thermal O +
activation O +
. O +

Addition O +
of O +
KCl O +
resulted O +
in O +
less O +
DNA O +
binding O +
either O +
due O +
to O +
blockage O +
of O +
DNA- O +
receptor O +
complex O +
formation O +
or O +
disruption O +
of O +
the O +
complexes O +
. O +

The O +
specificity O +
of O +
DNA O +
binding O +
by O +
cell O -
- O -
free O +
synthesized O +
hGR O +
was O +
analyzed O +
further O +
by O +
examining O +
the O +
abilities O +
of O +
various O +
DNAs O +
to O +
compete O +
for O +
binding O +
to O +
a O +
naturally O +
occurring O +
GRE O +
found O +
in O +
the O +
mouse O +
mammary O +
tumor O +
virus O -
- O -
long O +
terminal O +
repeat O +
. O +

Oligonucleotides O +
containing O +
the O +
consensus O +
GRE O +
were O +
the O +
most O +
efficient O +
competitors O +
, O +
and O +
fragments O +
containing O +
regulatory O +
sequences O +
from O +
glucocorticoid O -
- O -
repressible O +
genes O +
were O +
somewhat O +
competitive O +
, O +
whereas O +
single O +
stranded O +
oligonucleotides O +
were O +
unable O +
to O +
compete O +
for O +
mouse O +
mammary O +
tumor O +
virus O -
- O -
long O +
terminal O +
repeat O +
DNA O +
binding O +
, O +
except O +
when O +
competitor O +
was O +
present O +
at O +
extremely O +
high O +
concentrations O +
. O +

Together O +
these O +
studies O +
indicate O +
that O +
hGR O +
synthesized O +
in O +
rabbit O +
reticulocyte O +
lysates O +
displays O +
many O +
of O +
the O +
same O +
properties O +
, O +
including O +
GRE O +
-specific O +
DNA O +
binding O +
, O +
observed O +
for O +
glucocorticoid O +
receptor O +
present O +
in O +
cytosolic O +
extracts O +
of O +
mammalian O +
cells O +
and O +
tissues O +
. O +

Similarities O +
between O +
the O +
effects O +
of O +
dexamethasone O +
and O +
RU486 O +
suggest O +
that O +
the O +
antiglucocorticoid O +
properties O +
of O +
RU486 O +
do O +
not O +
occur O +
at O +
the O +
level O +
of O +
specific O +
DNA O +
binding O +
. O +

One O +
base O +
pair O +
change O +
abolishes O +
the O +
T O +
cell O -
- O -
restricted O +
activity O +
of O +
a O +
kB O -
- O -
like O +
proto O -
- O -
enhancer O +
element O +
from O +
the O +
interleukin O +
2 O +
promoter O +
. O +

The O +
inducible O +
, O +
T O +
cell O -
- O -
specific O +
enhancers O +
of O +
murine O +
and O +
human O +
Interleukin O +
2 O +
( O +
Il-2 O +
) O +
genes O +
contain O +
the O +
kB O -
- O -
like O +
sequence O +
GGGATTTCACC O +
as O +
an O +
essential O +
cis O -
- O -
acting O +
enhancer O +
motif O +
. O +

When O +
cloned O +
in O +
multiple O +
copies O +
this O +
so O -
- O -
called O +
TCEd O +
( O +
distal O +
T O +
cell O +
element O +
) O +
acts O +
as O +
an O +
inducible O +
proto O -
- O -
enhancer O +
element O +
in O +
E14 B-CellLine +
T I-CellLine +
lymphoma I-CellLine +
cells I-CellLine +
, O +
but O +
not O +
in O +
HeLa B-CellLine +
cells I-CellLine +
. O +

In O +
extracts O +
of O +
induced O +
, O +
Il-2 B-CellLine +
secreting I-CellLine +
El4 I-CellLine +
cells I-CellLine +
three O +
individual O +
protein O +
factors O +
bind O +
to O +
TCEd O +
DNA O +
. O +

The O +
binding O +
of O +
the O +
most O +
prominent O +
factor O +
, O +
named O +
TCF-1 O +
( O +
T O +
cell O +
factor O +
1 O +
) O +
, O +
is O +
correlated O +
with O +
the O +
proto O -
- O -
enhancer O +
activity O +
of O +
TCEd O +
. O +

TCF-1 O +
consists O +
of O +
two O +
polypeptides O +
of O +
about O +
50 O +
kD O +
and O +
105 O +
kD O +
; O +
the O +
former O +
seems O +
to O +
be O +
related O +
to O +
the O +
50 O +
kD O +
polypeptide O +
of O +
NF O -
- O -
kB O +
. O +

Purified O +
NF O -
- O -
kB O +
is O +
also O +
able O +
to O +
bind O +
to O +
the O +
TCEd O +
, O +
but O +
TCF-1 O +
binds O +
stronger O +
than O +
NF O -
- O -
kB O +
to O +
TCEd O +
DNA O +
. O +

The O +
conversion O +
of O +
the O +
TCEd O +
to O +
a O +
' O -
perfect O +
' O +
NF O -
- O -
kB O +
binding O +
site O +
leads O +
to O +
a O +
tighter O +
binding O +
of O +
NF O -
- O -
kB O +
to O +
TCEd O +
DNA O +
and O +
, O +
as O +
a O +
functional O +
consequence O +
, O +
to O +
the O +
activity O +
of O +
the O +
' O -
converted O +
' O +
TCEd O +
motifs O +
in O +
HeLa B-CellLine +
cells I-CellLine +
. O +

Thus O +
, O +
the O +
substitution O +
of O +
the O +
underlined O +
A O +
residue O +
to O +
a O +
C O +
within O +
the O +
GGGATTTCACC O +
motif O +
abolishes O +
its O +
T O +
cell O -
- O -
restricted O +
activity O +
and O +
leads O +
to O +
its O +
functioning O +
in O +
both O +
El4 B-CellLine +
cells I-CellLine +
and O +
HeLa B-CellLine +
cells I-CellLine +
. O +

These O +
results O +
indicate O +
that O +
lymphocyte O -
- O -
specific O +
factors O +
binding O +
to O +
the O +
TCEd O +
are O +
involved O +
in O +
the O +
control O +
of O +
T O +
cell O +
specific O -
- O -
transcription O +
of O +
the O +
Il-2 O +
gene O +
. O +

Negative O +
regulation O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
expression O +
in O +
monocytes O +
: O +
role O +
of O +
the O +
65-kDa O +
plus O +
50-kDa O +
NF O -
- O -
kappa O +
B O +
dimer O +
. O +

Although O +
monocytic O +
cells O +
can O +
provide O +
a O +
reservoir O +
for O +
viral O +
production O +
in O +
vivo O +
, O +
their O +
regulation O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
transcription O +
can O +
be O +
either O +
latent O +
, O +
restricted O +
, O +
or O +
productive O +
. O +

These O +
differences O +
in O +
gene O +
expression O +
have O +
not O +
been O +
molecularly O +
defined O +
. O +

In O +
THP-1 B-CellLine +
cells I-CellLine +
with O +
restricted O +
HIV O +
expression O +
, O +
there O +
is O +
an O +
absence O +
of O +
DNA O -
- O -
protein O +
binding O +
complex O +
formation O +
with O +
the O +
HIV-1 O +
promoter O -
- O -
enhancer O +
associated O +
with O +
markedly O +
less O +
viral O +
RNA O +
production O +
. O +

This O +
absence O +
of O +
binding O +
was O +
localized O +
to O +
the O +
NF O -
- O -
kappa O +
B O +
region O +
of O +
the O +
HIV-1 O +
enhancer O +
; O +
the O +
65-kDa O +
plus O +
50-kDa O +
NF O -
- O -
kappa O +
B O +
heterodimer O +
was O +
preferentially O +
lost O +
. O +

Adding O +
purified O +
NF O -
- O -
kappa O +
B O +
protein O +
to O +
nuclear O +
extracts O +
from O +
cells O +
with O +
restricted O +
expression O +
overcomes O +
this O +
lack O +
of O +
binding O +
. O +

In O +
addition O +
, O +
treatment O +
of O +
these O +
nuclear O +
extracts O +
with O +
sodium O +
deoxycholate O +
restored O +
their O +
ability O +
to O +
form O +
the O +
heterodimer O +
, O +
suggesting O +
the O +
presence O +
of O +
an O +
inhibitor O +
of O +
NF O -
- O -
kappa O +
B O +
activity O +
. O +

Furthermore O +
, O +
treatment O +
of O +
nuclear O +
extracts O +
from O +
these O +
cells O +
that O +
had O +
restricted O +
expression O +
with O +
lipopolysaccharide O +
increased O +
viral O +
production O +
and O +
NF O -
- O -
kappa O +
B O +
activity O +
. O +

Antiserum O +
specific O +
for O +
NF O -
- O -
kappa O +
B O +
binding O +
proteins O +
, O +
but O +
not O +
c O -
- O -
rel O -
- O -
specific O +
antiserum O +
, O +
disrupted O +
heterodimer O +
complex O +
formation O +
. O +

Thus O +
, O +
both O +
NF O -
- O -
kappa O +
B O -
- O -
binding O +
complexes O +
are O +
needed O +
for O +
optimal O +
viral O +
transcription O +
. O +

Binding O +
of O +
the O +
65-kDa O +
plus O +
50-kDa O +
heterodimer O +
to O +
the O +
HIV-1 O +
enhancer O +
can O +
be O +
negatively O +
regulated O +
in O +
monocytes O +
, O +
providing O +
one O +
mechanism O +
restricting O +
HIV-1 O +
gene O +
expression O +
. O +

Isolation O +
of O +
a O +
candidate O +
repressor O -
/ O -
activator O +
, O +
NF O -
- O -
E1 O +
( O +
YY-1 O +
, O +
delta O +
) O +
, O +
that O +
binds O +
to O +
the O +
immunoglobulin O +
kappa O +
3 O +
' O +
enhancer O +
and O +
the O +
immunoglobulin O +
heavy O -
- O -
chain O +
mu O +
E1 O +
site O +
. O +

We O +
have O +
determined O +
that O +
the O +
developmental O +
control O +
of O +
immunoglobulin O +
kappa O +
3 O +
' O +
enhancer O +
( O +
kappa O +
E3 O +
' O +
) O +
activity O +
is O +
the O +
result O +
of O +
the O +
combined O +
influence O +
of O +
positive- O +
and O +
negative O -
- O -
acting O +
elements O +
. O +

We O +
show O +
that O +
a O +
central O +
core O +
in O +
the O +
kappa O +
E3 O +
' O +
enhancer O +
is O +
active O +
at O +
the O +
pre O -
- O -
B O -
- O -
cell O +
stage O +
but O +
is O +
repressed O +
by O +
flanking O +
negative O -
- O -
acting O +
elements O +
. O +

The O +
negative O -
- O -
acting O +
sequences O +
repress O +
enhancer O +
activity O +
in O +
a O +
position- O +
and O +
orientation O -
- O -
independent O +
manner O +
at O +
the O +
pre O -
- O -
B O -
- O -
cell O +
stage O +
. O +

We O +
have O +
isolated O +
a O +
human O +
cDNA O +
clone O +
encoding O +
a O +
zinc O +
finger O +
protein O +
( O +
NF O -
- O -
E1 O +
) O +
that O +
binds O +
to O +
the O +
negative O -
- O -
acting O +
segment O +
of O +
the O +
kappa O +
E3 O +
' O +
enhancer O +
. O +

This O +
protein O +
also O +
binds O +
to O +
the O +
immunoglobulin O +
heavy O -
- O -
chain O +
enhancer O +
mu O +
E1 O +
site O +
. O +

NF O -
- O -
E1 O +
is O +
encoded O +
by O +
the O +
same O +
gene O +
as O +
the O +
YY-1 O +
protein O +
, O +
which O +
binds O +
to O +
the O +
adeno O -
- O -
associated O +
virus O +
P5 O +
promoter O +
. O +

NF O -
- O -
E1 O +
is O +
also O +
the O +
human O +
homologue O +
of O +
the O +
mouse O +
delta O +
protein O +
, O +
which O +
binds O +
to O +
ribosomal O +
protein O +
gene O +
promoters O +
. O +

The O +
predicted O +
amino O +
acid O +
sequence O +
of O +
this O +
protein O +
contains O +
features O +
characteristic O +
of O +
transcriptional O +
activators O +
as O +
well O +
as O +
transcriptional O +
repressors O +
. O +

Cotransfection O +
studies O +
with O +
this O +
cDNA O +
indicate O +
that O +
it O +
can O +
repress O +
basal O +
promoter O +
activity O +
. O +

The O +
apparent O +
dual O +
function O +
of O +
this O +
protein O +
is O +
discussed O +
. O +

cAMP O -
- O -
dependent O +
regulation O +
of O +
proenkephalin O +
by O +
JunD O +
and O +
JunB O +
: O +
positive O +
and O +
negative O +
effects O +
of O +
AP-1 O +
proteins O +
. O +

We O +
demonstrate O +
that O +
JunD O +
, O +
a O +
component O +
of O +
the O +
AP-1 O +
transcription O +
factor O +
complex O +
, O +
activates O +
transcription O +
of O +
the O +
human O +
proenkephalin O +
gene O +
in O +
a O +
fashion O +
that O +
is O +
completely O +
dependent O +
upon O +
the O +
cAMP O -
- O -
dependent O +
protein O +
kinase O +
, O +
protein O +
kinase O +
A O +
. O +

Activation O +
of O +
proenkephalin O +
transcription O +
by O +
JunD O +
is O +
dependent O +
upon O +
a O +
previously O +
characterized O +
cAMP- O +
, O +
phorbol O +
ester- O +
, O +
and O +
Ca O +
( O +
2 O -
+ O +
) O +
-inducible O +
enhancer O +
, O +
and O +
JunD O +
is O +
shown O +
to O +
bind O +
the O +
enhancer O +
as O +
a O +
homodimer O +
. O +

Another O +
component O +
of O +
the O +
AP-1 O +
transcription O +
complex O +
, O +
JunB O +
, O +
is O +
shown O +
to O +
inhibit O +
activation O +
mediated O +
by O +
JunD O +
. O +

As O +
a O +
homodimer O +
JunB O +
is O +
unable O +
to O +
bind O +
the O +
enhancer O +
; O +
however O +
in O +
the O +
presence O +
of O +
c O -
- O -
Fos O +
, O +
high O -
- O -
affinity O +
binding O +
is O +
observed O +
. O +

Furthermore O +
, O +
JunD O +
is O +
shown O +
to O +
activate O +
transcription O +
of O +
genes O +
linked O +
to O +
both O +
cAMP O +
and O +
phorbol O +
ester O +
response O +
elements O +
in O +
a O +
protein O +
kinase O +
A O +
-dependent O +
fashion O +
, O +
further O +
blurring O +
the O +
distinction O +
between O +
these O +
response O +
elements O +
. O +

These O +
results O +
demonstrate O +
that O +
the O +
transcriptional O +
activity O +
of O +
an O +
AP-1-related O +
protein O +
is O +
regulated O +
by O +
the O +
cAMP O -
- O -
dependent O +
second O -
- O -
messenger O +
pathway O +
and O +
suggest O +
that O +
JunD O +
and O +
other O +
AP-1-related O +
proteins O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
regulation O +
of O +
gene O +
expression O +
by O +
cAMP O -
- O -
dependent O +
intracellular O +
signaling O +
pathways O +
. O +

Glucocorticoid O +
resistance O +
in O +
chronic O +
asthma O +
. O +

Glucocorticoid O +
pharmacokinetics O +
, O +
glucocorticoid O +
receptor O +
characteristics O +
, O +
and O +
inhibition O +
of O +
peripheral O +
blood O +
T O +
cell O +
proliferation O +
by O +
glucocorticoids O +
in O +
vitro O +
. O +

A O +
total O +
of O +
37 O +
chronic O +
, O +
severe O +
, O +
nonsmoking O +
asthmatic O +
patients O +
with O +
documented O +
reversible O +
airways O +
obstruction O +
were O +
classified O +
as O +
glucocorticoid O -
- O -
sensitive O +
or O +
-resistant O +
on O +
the O +
basis O +
of O +
changes O +
in O +
FEV1 O +
, O +
FVC O +
, O +
and O +
peak O +
expiratory O +
flow O +
( O +
PEF O +
) O +
after O +
oral O +
prednisolone O +
. O +

The O +
resistant O +
patients O +
showed O +
no O +
significant O +
improvements O +
in O +
airflow O +
limitation O +
. O +

Phytohemagglutinin O +
( O +
PHA O +
) O +
-induced O +
proliferation O +
of O +
peripheral O +
blood O +
T O +
lymphocytes O +
from O +
the O +
sensitive O +
but O +
not O +
the O +
resistant O +
asthmatic O +
patients O +
was O +
significantly O +
( O +
p O +
less O +
than O +
0.01 O +
) O +
inhibited O +
by O +
dexamethasone O +
( O +
10 O +
( O +
-7 O +
) O +
mol O -
/ O -
L O +
) O +
, O +
reflecting O +
a O +
shift O +
of O +
the O +
dose O -
- O -
response O +
curve O +
. O +

When O +
all O +
the O +
asthmatic O +
patients O +
were O +
analyzed O +
together O +
, O +
there O +
was O +
a O +
significant O +
correlation O +
between O +
the O +
degree O +
of O +
sensitivity O +
of O +
T O +
cells O +
to O +
dexamethasone O +
and O +
the O +
clinical O +
responsiveness O +
to O +
prednisolone O +
( O +
p O +
less O +
than O +
0.01 O +
) O +
. O +

No O +
differences O +
were O +
observed O +
between O +
six O +
of O +
the O +
sensitive O +
and O +
resistant O +
patients O +
in O +
the O +
clearance O +
of O +
plasma O +
prednisolone O +
derived O +
from O +
orally O +
administered O +
prednisone O +
. O +

Peripheral O +
blood O +
mononuclear O +
cell O +
glucocorticoid O +
receptors O +
were O +
also O +
characterized O +
in O +
five O +
sensitive O +
and O +
seven O +
resistant O +
patients O +
. O +

The O +
numbers O +
and O +
binding O +
affinities O +
of O +
these O +
receptors O +
could O +
not O +
account O +
for O +
the O +
observed O +
difference O +
in O +
the O +
susceptibility O +
of O +
these O +
cells O +
to O +
functional O +
inhibition O +
by O +
dexamethasone O +
in O +
vitro O +
. O +

These O +
results O +
suggest O +
that O +
clinical O +
glucocorticoid O +
resistance O +
in O +
chronic O +
asthma O +
does O +
not O +
reflect O +
abnormal O +
glucocorticoid O +
clearance O +
but O +
may O +
be O +
due O +
at O +
least O +
partly O +
to O +
a O +
relative O +
insensitivity O +
of O +
T O +
lymphocytes O +
to O +
glucocorticoids O +
. O +

This O +
lack O +
of O +
sensitivity O +
is O +
unexplained O +
but O +
is O +
not O +
attributable O +
to O +
abnormalities O +
of O +
cellular O +
glucocorticoid O +
receptors O +
. O +

Identification O +
of O +
transcriptional O +
suppressor O +
proteins O +
that O +
bind O +
to O +
the O +
negative O +
regulatory O +
element O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
. O +

Two O +
different O +
proteins O +
which O +
independently O +
bound O +
to O +
neighboring O +
sequences O +
within O +
the O +
negative O +
regulatory O +
element O +
( O +
NRE O +
) O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
were O +
detected O +
in O +
the O +
nuclear O +
extract O +
of O +
a O +
virus B-CellLine -
- I-CellLine -
infected I-CellLine +
human I-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

One O +
of O +
the O +
factors O +
bound O +
to O +
a O +
novel O +
dyad O +
symmetrical O +
sequence O +
. O +

This O +
sequence O +
is O +
well O +
conserved O +
in O +
various O +
HIV-1 O +
isolates O +
and O +
partial O +
homology O +
was O +
found O +
with O +
the O +
promoter O +
region O +
of O +
the O +
human O +
retinoblastoma O +
gene O +
. O +

Similar O +
DNA O +
binding O +
activity O +
was O +
detected O +
in O +
a O +
variety O +
of O +
virus B-CellLine -
- I-CellLine -
uninfected I-CellLine +
human I-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
and O +
HeLa B-CellLine +
cells I-CellLine +
by O +
means O +
of O +
a O +
gel O +
mobility O +
shift O +
assay O +
. O +

The O +
other O +
factor O +
bound O +
to O +
a O +
putative O +
AP-1 O +
recognition O +
sequence O +
predicted O +
for O +
the O +
HIV-1 O +
NRE O +
. O +

However O +
, O +
this O +
factor O +
did O +
not O +
bind O +
to O +
a O +
typical O +
AP-1 O +
site O +
. O +

The O +
insertion O +
of O +
multiple O +
copies O +
of O +
the O +
binding O +
site O +
for O +
the O +
former O +
or O +
latter O +
factor O +
into O +
a O +
heterologous O +
promoter O +
reduced O +
the O +
promoter O +
activity O +
to O +
one O -
- O -
tenth O +
or O +
one O -
- O -
third O +
, O +
respectively O +
. O +

Thus O +
, O +
each O +
factor O +
may O +
function O +
as O +
a O +
novel O +
negative O +
regulator O +
of O +
transcription O +
. O +

Constitutive O +
activation O +
of O +
NF O -
- O -
kB O +
in O +
human O +
thymocytes O +
. O +

NF O -
- O -
kB O +
is O +
a O +
eukaryotic O +
transcription O +
regulatory O +
factor O +
. O +

In O +
T O +
cells O +
and O +
T B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
NF O -
- O -
kB O +
is O +
bound O +
to O +
a O +
cytoplasmic O +
proteic O +
inhibitor O +
, O +
the O +
IkB O +
. O +

Treatment O +
of O +
T O +
cells O +
with O +
mitogens O +
( O +
phorbol O +
esters O +
) O +
or O +
cytokines O +
( O +
TNF O +
alpha O +
) O +
induces O +
NF O -
- O -
kB O +
nuclear O +
translocation O +
and O +
the O +
subsequent O +
expression O +
of O +
NF O -
- O -
kB O +
dependent O +
T O +
cell O +
genes O +
. O +

Here O +
we O +
examined O +
the O +
activation O +
of O +
NF O -
- O -
kB O +
in O +
human O +
T O +
cell O +
thymic O +
progenitors O +
. O +

We O +
report O +
differences O +
in O +
( O +
Ca2 O -
+ O +
) O +
i O +
requirement O +
for O +
NF O -
- O -
kB O +
activation O +
in O +
thymocytes O +
as O +
compared O +
to O +
mature O +
T O +
cells O +
. O +

Furthermore O +
, O +
our O +
results O +
indicated O +
that O +
thymocytes O +
have O +
a O +
constitutively O +
active O +
form O +
of O +
NF O -
- O -
kB O +
, O +
suggesting O +
that O +
they O +
are O +
activated O +
in O +
vivo O +
. O +

TCF-1 O +
, O +
a O +
T O +
cell O -
- O -
specific O +
transcription O +
factor O +
of O +
the O +
HMG O +
box O +
family O +
, O +
interacts O +
with O +
sequence O +
motifs O +
in O +
the O +
TCR O +
beta O +
and O +
TCR O +
delta O +
enhancers O +
. O +

We O +
have O +
recently O +
identified O +
and O +
cloned O +
TCF-1 O +
, O +
a O +
T O +
cell O -
- O -
specific O +
transcription O +
factor O +
with O +
specificity O +
for O +
the O +
AACAAAG O +
motif O +
in O +
the O +
CD3 O +
epsilon O +
enhancer O +
and O +
for O +
the O +
TTCAAAG O +
motif O +
in O +
the O +
TCR O +
alpha O +
enhancer O +
. O +

TCF-1 O +
belongs O +
to O +
the O +
family O +
of O +
transcription O -
- O -
regulating O +
proteins O +
which O +
share O +
a O +
region O +
of O +
homology O +
termed O +
the O +
HMG O -
- O -
box O +
. O +

Here O +
, O +
we O +
show O +
by O +
gel O +
retardation O +
analysis O +
that O +
TCF-1 O +
specifically O +
recognizes O +
the O +
T O +
beta O +
5 O +
element O +
of O +
the O +
TCR O +
beta O +
enhancer O +
and O +
the O +
T O +
delta O +
7 O +
element O +
of O +
the O +
TCR O +
delta O +
enhancer O +
. O +

Comparison O +
of O +
the O +
sequences O +
of O +
all O +
elements O +
recognized O +
by O +
TCF-1 O +
defines O +
a O +
consensus O +
motif O +
A O -
/ O -
T O +
A O -
/ O -
T O +
C O +
A O +
A O -
/ O -
G O +
A O +
G O +
. O +

These O +
observations O +
imply O +
that O +
TCF-1 O +
is O +
involved O +
in O +
the O +
control O +
of O +
several O +
T O +
cell O -
- O -
specific O +
genes O +
and O +
might O +
thus O +
play O +
an O +
important O +
role O +
in O +
the O +
establishment O +
and O +
maintenance O +
of O +
the O +
mature O +
T O +
cell O +
phenotype O +
. O +

The O +
cellular O +
oncogene O +
c O -
- O -
myb O +
can O +
interact O +
synergistically O +
with O +
the O +
Epstein O -
- O -
Barr O +
virus O +
BZLF1 O +
transactivator O +
in O +
lymphoid O +
cells O +
. O +

Regulation O +
of O +
replicative O +
functions O +
in O +
the O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
genome O +
is O +
mediated O +
through O +
activation O +
of O +
a O +
virally O +
encoded O +
transcription O +
factor O +
, O +
Z O +
( O +
BZLF1 O +
) O +
. O +

We O +
have O +
shown O +
that O +
the O +
Z O +
gene O +
product O +
, O +
which O +
binds O +
to O +
AP-1 O +
sites O +
as O +
a O +
homodimer O +
and O +
has O +
sequence O +
similarity O +
to O +
c O -
- O -
Fos O +
, O +
can O +
efficiently O +
activate O +
the O +
EBV O +
early O +
promoter O +
, O +
BMRF1 O +
, O +
in O +
certain O +
cell O +
types O +
( O +
i.e. O +
, O +
HeLa B-CellLine +
cells I-CellLine +
) O +
but O +
not O +
others O +
( O +
i.e. O +
, O +
Jurkat B-CellLine +
cells I-CellLine +
) O +
. O +

Here O +
we O +
demonstrate O +
that O +
the O +
c O -
- O -
myb O +
proto O -
- O -
oncogene O +
product O +
, O +
which O +
is O +
itself O +
a O +
DNA O -
- O -
binding O +
protein O +
and O +
transcriptional O +
transactivator O +
, O +
can O +
interact O +
synergistically O +
with O +
Z O +
in O +
activating O +
the O +
BMRF1 O +
promoter O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
( O +
a O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
) O +
or O +
Raji B-CellLine +
cells I-CellLine +
( O +
an O +
EBV B-CellLine -
- I-CellLine -
positive I-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
) O +
, O +
whereas O +
the O +
c O -
- O -
myb O +
gene O +
product O +
by O +
itself O +
has O +
little O +
effect O +
. O +

The O +
simian O +
virus O +
40 O +
early O +
promoter O +
is O +
also O +
synergistically O +
activated O +
by O +
the O +
Z O -
/ O -
c O -
- O -
myb O +
combination O +
. O +

Synergistic O +
transactivation O +
of O +
the O +
BMRF1 O +
promoter O +
by O +
the O +
Z O -
/ O -
c O -
- O -
myb O +
combination O +
appears O +
to O +
involve O +
direct O +
binding O +
by O +
the O +
Z O +
protein O +
but O +
not O +
the O +
c O -
- O -
myb O +
protein O +
. O +

A O +
30-bp O +
sequence O +
in O +
the O +
BMRF1 O +
promoter O +
which O +
contains O +
a O +
Z O +
binding O +
site O +
( O +
a O +
consensus O +
AP-1 O +
site O +
) O +
is O +
sufficient O +
to O +
transfer O +
high O -
- O -
level O +
lymphoid O -
- O -
specific O +
responsiveness O +
to O +
the O +
Z O -
/ O -
c O -
- O -
myb O +
combination O +
to O +
a O +
heterologous O +
promoter O +
. O +

That O +
the O +
c O -
- O -
myb O +
oncogene O +
product O +
can O +
interact O +
synergistically O +
with O +
an O +
EBV O -
- O -
encoded O +
member O +
of O +
the O +
leucine O +
zipper O +
protein O +
family O +
suggests O +
c O -
- O -
myb O +
is O +
likely O +
to O +
engage O +
in O +
similar O +
interactions O +
with O +
cellularly O +
encoded O +
transcription O +
factors O +
. O +

[ O +
Endocrine O +
status O +
changes O +
in O +
children O +
with O +
bronchial O +
asthma O +
] O +

A O +
study O +
was O +
made O +
of O +
adrenocortical O +
function O +
by O +
measuring O +
blood O +
plasma O +
cortisol O +
concentration O +
and O +
amount O +
of O +
glucocorticoid O +
receptors O +
in O +
lymphocytes O +
as O +
well O +
as O +
thyroid O +
function O +
by O +
measuring O +
blood O +
plasma O +
triidothyronine O +
and O +
thyroxine O +
concentration O +
in O +
58 O +
bronchial O +
asthma O +
children O +
aged O +
1 O +
to O +
14 O +
years O +
. O +

The O +
authors O +
revealed O +
alterations O +
in O +
the O +
functional O +
activity O +
of O +
the O +
indicated O +
endocrine O +
glands O +
depending O +
on O +
the O +
intensity O +
of O +
bronchial O +
patency O +
disorders O +
and O +
the O +
nature O +
of O +
the O +
therapeutic O +
measures O +
carried O +
out O +
. O +

High O +
affinity O +
aldosterone O +
binding O +
to O +
plasma O +
membrane O +
rich O +
fractions O +
from O +
mononuclear O +
leukocytes O +
: O +
is O +
there O +
a O +
membrane O +
receptor O +
for O +
mineralocorticoids O +
? O +

In O +
vitro O +
effects O +
of O +
aldosterone O +
on O +
the O +
intracellular O +
concentrations O +
of O +
sodium O +
, O +
potassium O +
and O +
calcium O +
, O +
cell O +
volume O +
and O +
the O +
sodium O -
- O -
proton O -
- O -
antiport O +
have O +
been O +
described O +
in O +
intact O +
human O +
mononuclear O +
leukocytes O +
( O +
HML O +
) O +
. O +

In O +
the O +
present O +
paper O +
, O +
the O +
binding O +
of O +
a O +
[ O +
125I O +
] O +
-labeled O +
aldosterone O +
derivative O +
to O +
plasma O +
membrane O +
rich O +
fractions O +
of O +
HML O +
was O +
studied O +
. O +

High O +
affinity O +
binding O +
of O +
the O +
radioligand O +
with O +
an O +
apparent O +
Kd O +
of O +
approximately O +
0.1 O +
nM O +
was O +
found O +
. O +

Aldosterone O +
displaced O +
the O +
tracer O +
at O +
a O +
similar O +
Kd O +
. O +

Both O +
canrenone O +
and O +
cortisol O +
were O +
inactive O +
as O +
ligands O +
up O +
to O +
concentrations O +
of O +
0.1 O +
microM O +
. O +

The O +
findings O +
are O +
the O +
first O +
to O +
demonstrate O +
membrane O +
binding O +
sites O +
with O +
a O +
high O +
affinity O +
for O +
aldosterone O +
, O +
but O +
not O +
for O +
cortisol O +
. O +

These O +
data O +
are O +
perfectly O +
compatible O +
with O +
major O +
properties O +
of O +
steroidal O +
effects O +
on O +
the O +
sodium O -
- O -
proton O -
- O -
antiport O +
in O +
HML O +
and O +
thus O +
very O +
likely O +
represent O +
membrane O +
receptors O +
for O +
aldosterone O +
. O +

Transcription O +
factor O +
requirements O +
for O +
U2 O +
snRNA O +
-encoding O +
gene O +
activation O +
in O +
B O +
lymphoid O +
cells O +
. O +

Transcription O +
of O +
a O +
human O +
U2 O +
small O +
nuclear O +
RNA O +
( O +
snRNA O +
) O +
-encoding O +
gene O +
in O +
HeLa B-CellLine +
cells I-CellLine +
requires O +
a O +
distal O +
enhancer O +
element O +
, O +
which O +
is O +
composed O +
of O +
one O +
octamer O +
motif O +
( O +
Oct O +
) O +
and O +
three O +
Sp O +
1-binding O +
sites O +
. O +

To O +
study O +
the O +
transcription O +
factor O +
requirement O +
in O +
B O -
- O -
cells O +
, O +
different O +
U2 O +
enhancer O +
constructions O +
were O +
transfected O +
into O +
the O +
lymphoid B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
BJA B-CellLine -
- I-CellLine -
B I-CellLine +
. O +

The O +
results O +
showed O +
that O +
the O +
activation O +
of O +
U2 O +
snRNA O +
transcription O +
in O +
B O -
- O -
cells O +
also O +
requires O +
an O +
enhancer O +
comprising O +
both O +
the O +
Oct O +
and O +
at O +
least O +
one O +
Sp O +
1-binding O +
site O +
. O +

Deletion O +
of O +
all O +
the O +
Sp O +
1-binding O +
sites O +
from O +
the O +
enhancer O +
reduces O +
transcription O +
by O +
80 O -
- O -
90 O +
% O +
in O +
HeLa O +
, O +
as O +
well O +
as O +
in O +
BJA B-CellLine -
- I-CellLine -
B I-CellLine +
cells I-CellLine +
, O +
whereas O +
the O +
removal O +
of O +
the O +
octamer O -
- O -
binding O +
site O +
reduces O +
transcription O +
to O +
levels O +
below O +
detection O +
in O +
both O +
cell O +
types O +
. O +

Enhancers O +
containing O +
a O +
single O +
Oct O +
have O +
, O +
nevertheless O +
, O +
the O +
capacity O +
to O +
partially O +
activate O +
U2 O +
snRNA O +
transcription O +
in O +
both O +
HeLa B-CellLine +
cells I-CellLine +
, O +
in O +
which O +
only O +
OTF-1 O +
is O +
expressed O +
, O +
and O +
in O +
BJA B-CellLine -
- I-CellLine -
B I-CellLine +
cells I-CellLine +
in O +
which O +
OTF-2 O +
is O +
the O +
predominantly O +
expressed O +
octamer O -
- O -
binding O +
factor O +
. O +

The O +
most O +
likely O +
interpretation O +
of O +
our O +
results O +
is O +
that O +
both O +
the O +
ubiquitous O +
transcription O +
factor O +
, O +
OTF-1 O +
, O +
and O +
the O +
B O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
, O +
OTF-2 O +
, O +
can O +
activate O +
U2 O +
snRNA O +
transcription O +
. O +

The O +
results O +
also O +
revealed O +
a O +
similar O +
functional O +
cooperation O +
between O +
the O +
transcription O +
factors O +
which O +
bind O +
to O +
the O +
Oct O +
and O +
the O +
adjacent O +
Sp O +
1-binding O +
site O +
in O +
BJA B-CellLine -
- I-CellLine -
B I-CellLine +
cells I-CellLine +
, O +
as O +
has O +
been O +
observed O +
in O +
HeLa B-CellLine +
cells I-CellLine +
, O +
since O +
a O +
template O +
which O +
contains O +
a O +
weak O +
binding O +
site O +
for O +
OTFs O +
expresses O +
wild O -
- O -
type O +
levels O +
of O +
U2 O +
snRNA O +
in O +
both O +
cell O +
types O +
when O +
the O +
weak O +
octamer O -
- O -
binding O +
site O +
is O +
combined O +
with O +
a O +
Sp O +
1-binding O +
site O +
. O +

Kappa O +
B O -
- O -
specific O +
DNA O +
binding O +
proteins O +
are O +
differentially O +
inhibited O +
by O +
enhancer O +
mutations O +
and O +
biological O +
oxidation O +
. O +

Kappa O +
B O +
( O +
kappa O +
B O +
) O +
enhancer O +
binding O +
proteins O +
isolated O +
from O +
the O +
nuclei O +
of O +
activated O +
human O +
T O +
cells O +
produce O +
two O +
distinct O +
nucleoprotein O +
complexes O +
when O +
incubated O +
with O +
the O +
kappa O +
B O +
element O +
from O +
the O +
interleukin-2 O +
receptor O -
- O -
alpha O +
( O +
IL-2R O +
alpha O +
) O +
gene O +
. O +

These O +
two O +
DNA O -
- O -
protein O +
complexes O +
are O +
composed O +
of O +
at O +
least O +
four O +
host O +
proteins O +
( O +
p50 O +
, O +
p55 O +
, O +
p75 O +
, O +
p85 O +
) O +
, O +
each O +
of O +
which O +
shares O +
structural O +
similarity O +
with O +
the O +
v O -
- O -
rel O +
oncogene O +
product O +
. O +

Nuclear O +
expression O +
of O +
these O +
proteins O +
is O +
induced O +
with O +
distinctly O +
biphasic O +
kinetics O +
following O +
phorbol O +
ester O +
activation O +
of O +
T O +
cells O +
( O +
p55 O -
/ O -
p75 O +
early O +
and O +
p50 O -
/ O -
p85 O +
late O +
) O +
. O +

DNA O -
- O -
protein O +
crosslinking O +
studies O +
have O +
revealed O +
that O +
the O +
more O +
rapidly O +
migrating O +
B2 O +
complex O +
contains O +
both O +
p50 O +
and O +
p55 O +
while O +
the O +
more O +
slowly O +
migrating O +
B1 O +
complex O +
is O +
composed O +
of O +
p50 O +
, O +
p55 O +
, O +
p75 O +
, O +
and O +
p85 O +
. O +

Site O -
- O -
directed O +
mutagenesis O +
of O +
the O +
wild O -
- O -
type O +
IL-2R O +
alpha O +
kappa O +
B O +
enhancer O +
( O +
GGGGAATCTCCC O +
) O +
has O +
revealed O +
that O +
the O +
binding O +
of O +
p50 O +
and O +
p55 O +
( O +
B2 O +
complex O +
) O +
is O +
particularly O +
sensitive O +
to O +
alteration O +
of O +
the O +
5 O +
' O +
triplet O +
of O +
deoxyguanosine O +
residues O +
. O +

In O +
contrast O +
, O +
formation O +
of O +
the O +
B1 O +
complex O +
, O +
reflecting O +
the O +
binding O +
of O +
p75 O +
and O +
p85 O +
, O +
critically O +
depends O +
upon O +
the O +
more O +
3 O +
' O +
sequences O +
of O +
this O +
enhancer O +
element O +
. O +

DNA O +
binding O +
by O +
all O +
four O +
of O +
these O +
Rel O -
- O -
related O +
factors O +
is O +
blocked O +
by O +
selective O +
chemical O +
modification O +
of O +
lysine O +
and O +
arginine O +
residues O +
, O +
suggesting O +
that O +
both O +
of O +
these O +
basic O +
amino O +
acids O +
are O +
required O +
for O +
binding O +
to O +
the O +
kappa O +
B O +
element O +
. O +

Similarly O +
, O +
covalent O +
modification O +
of O +
free O +
sulfhydryl O +
groups O +
with O +
diamide O +
( O +
reversible O +
) O +
or O +
N O -
- O -
ethylmaleimide O +
( O +
irreversible O +
) O +
results O +
in O +
a O +
complete O +
loss O +
of O +
DNA O +
binding O +
activity O +
. O +

In O +
contrast O +
, O +
mild O +
oxidation O +
with O +
glucose O +
oxidase O +
selectively O +
inhibits O +
p75 O +
and O +
p85 O +
binding O +
while O +
not O +
blocking O +
p50 O +
and O +
p55 O +
interactions O +
. O +

These O +
findings O +
suggest O +
that O +
reduced O +
cysteine O +
thiols O +
play O +
an O +
important O +
role O +
in O +
the O +
DNA O +
binding O +
activity O +
of O +
this O +
family O +
of O +
Rel O -
- O -
related O +
transcription O +
factors O +
. O +

A O +
novel O +
mitogen O -
- O -
inducible O +
gene O +
product O +
related O +
to O +
p50 O -
/ O -
p105-NF O -
- O -
kappa O +
B O +
participates O +
in O +
transactivation O +
through O +
a O +
kappa O +
B O +
site O +
. O +

A O +
Rel O -
- O -
related O +
, O +
mitogen O -
- O -
inducible O +
, O +
kappa O +
B O -
- O -
binding O +
protein O +
has O +
been O +
cloned O +
as O +
an O +
immediate O -
- O -
early O +
activation O +
gene O +
of O +
human O +
peripheral O +
blood O +
T O +
cells O +
. O +

The O +
cDNA O +
has O +
an O +
open O +
reading O +
frame O +
of O +
900 O +
amino O +
acids O +
capable O +
of O +
encoding O +
a O +
97-kDa O +
protein O +
. O +

This O +
protein O +
is O +
most O +
similar O +
to O +
the O +
105-kDa O +
precursor O +
polypeptide O +
of O +
p50-NF O -
- O -
kappa O +
B O +
. O +

Like O +
the O +
105-kDa O +
precursor O +
, O +
it O +
contains O +
an O +
amino O -
- O -
terminal O +
Rel O -
- O -
related O +
domain O +
of O +
about O +
300 O +
amino O +
acids O +
and O +
a O +
carboxy O -
- O -
terminal O +
domain O +
containing O +
six O +
full O +
cell O +
cycle O +
or O +
ankyrin O +
repeats O +
. O +

In O +
vitro O -
- O -
translated O +
proteins O +
, O +
truncated O +
downstream O +
of O +
the O +
Rel O +
domain O +
and O +
excluding O +
the O +
repeats O +
, O +
bind O +
kappa O +
B O +
sites O +
. O +

We O +
refer O +
to O +
the O +
kappa O +
B O -
- O -
binding O +
, O +
truncated O +
protein O +
as O +
p50B O +
by O +
analogy O +
with O +
p50-NF O -
- O -
kappa O +
B O +
and O +
to O +
the O +
full O -
- O -
length O +
protein O +
as O +
p97 O +
. O +

p50B O +
is O +
able O +
to O +
form O +
heteromeric O +
kappa O +
B O -
- O -
binding O +
complexes O +
with O +
RelB O +
, O +
as O +
well O +
as O +
with O +
p65 O +
and O +
p50 O +
, O +
the O +
two O +
subunits O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

Transient O -
- O -
transfection O +
experiments O +
in O +
embryonal B-CellLine +
carcinoma I-CellLine +
cells I-CellLine +
demonstrate O +
a O +
functional O +
cooperation O +
between O +
p50B O +
and O +
RelB O +
or O +
p65 O +
in O +
transactivation O +
of O +
a O +
reporter O +
plasmid O +
dependent O +
on O +
a O +
kappa O +
B O +
site O +
. O +

The O +
data O +
imply O +
the O +
existence O +
of O +
a O +
complex O +
family O +
of O +
NF O -
- O -
kappa O +
B O -
- O -
like O +
transcription O +
factors O +
. O +

[ O +
Changes O +
in O +
leucocytic O +
estrogen O +
receptor O +
levels O +
in O +
patients O +
with O +
climacteric O +
syndrome O +
and O +
therapeutic O +
effect O +
of O +
liuwei O +
dihuang O +
pills O +
] O +

The O +
numbers O +
of O +
estrogen O +
receptor O +
( O +
ER O +
) O +
in O +
human O +
peripheral O +
leucocytes O +
in O +
22 O +
women O +
with O +
climacteric O +
syndrome O +
were O +
measured O +
by O +
radioligand O +
method O +
. O +

The O +
results O +
were O +
compared O +
with O +
those O +
of O +
12 O +
normal O +
child O -
- O -
bearing O -
- O -
age O +
women O +
. O +

It O +
wat O +
found O +
that O +
the O +
contents O +
of O +
leucocytic O +
ER O +
in O +
climacteric O +
syndrome O +
patients O +
were O +
significantly O +
lower O +
than O +
normal O +
child O -
- O -
bearing O -
- O -
age O +
women O +
. O +

The O +
authors O +
used O +
a O +
Chinese O +
prescription O +
-- O +
Liuwei O +
Dihuang O +
Pills O +
( O +
LDP O +
) O +
to O +
treat O +
the O +
patients O +
for O +
2 O +
months O +
. O +

The O +
numbers O +
of O +
leucocytic O +
ER O +
were O +
significantly O +
increased O +
after O +
treatment O +
. O +

The O +
data O +
indicate O +
that O +
decrease O +
of O +
ER O +
levels O +
in O +
cell O +
may O +
involve O +
in O +
the O +
pathogenesis O +
of O +
climacteric O +
syndrome O +
. O +

LDP O +
not O +
only O +
increases O +
plasma O +
estradiol O +
levels O +
, O +
but O +
also O +
increases O +
the O +
leucocytic O +
ER O +
levels O +
. O +

This O +
may O +
be O +
the O +
basis O +
of O +
the O +
therapeutic O +
effect O +
on O +
the O +
disease O +
. O +

A O +
novel O +
primer O +
extension O +
method O +
to O +
detect O +
the O +
number O +
of O +
CAG O +
repeats O +
in O +
the O +
androgen O +
receptor O +
gene O +
in O +
families O +
with O +
X O -
- O -
linked O +
spinal O +
and O +
bulbar O +
muscular O +
atrophy O +
. O +

X O -
- O -
linked O +
spinal O +
and O +
bulbar O +
muscular O +
atrophy O +
( O +
SBMA O +
) O +
, O +
an O +
adult O -
- O -
onset O +
form O +
of O +
motor O +
neuron O +
disease O +
, O +
was O +
recently O +
reported O +
to O +
be O +
caused O +
by O +
amplification O +
of O +
the O +
CAG O +
repeats O +
in O +
the O +
androgen O +
receptor O +
gene O +
. O +

We O +
report O +
here O +
a O +
simple O +
and O +
rapid O +
strategy O +
to O +
detect O +
the O +
precise O +
number O +
of O +
the O +
CAGs O +
. O +

After O +
the O +
DNA O +
fragment O +
containing O +
the O +
CAG O +
repeats O +
is O +
amplified O +
by O +
the O +
polymerase O +
chain O +
reaction O +
, O +
a O +
primer O +
extension O +
is O +
carried O +
out O +
; O +
the O +
extension O +
of O +
the O +
end O -
- O -
labelled O +
reverse O +
primer O +
adjacent O +
to O +
3 O +
' O +
end O +
of O +
CAG O +
repeats O +
stops O +
at O +
the O +
first O +
T O +
after O +
CAG O +
repeats O +
with O +
the O +
incorporation O +
of O +
dideoxy O +
ATP O +
in O +
the O +
reaction O +
mixture O +
. O +

The O +
resultant O +
primer O +
products O +
are O +
analysed O +
by O +
denaturing O +
polyacrylamide O +
gel O +
electrophoresis O +
and O +
autoradiography O +
. O +

This O +
method O +
could O +
be O +
quite O +
useful O +
to O +
detect O +
not O +
only O +
CAG O +
repeats O +
in O +
SBMA O +
but O +
also O +
other O +
polymorphic O +
dinucleotide O +
and O +
trinucleotide O +
repeats O +
. O +

Structure O +
function O +
analysis O +
of O +
vitamin O +
D O +
analogs O +
with O +
C O -
- O -
ring O +
modifications O +
. O +

Analogs O +
of O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
1 O +
alpha O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
) O +
with O +
substitutions O +
on O +
C-11 O +
were O +
synthesized O +
. O +

Small O +
apolar O +
substitutions O +
( O +
11 O +
alpha O -
- O -
methyl O +
, O +
11 O +
alpha O -
- O -
fluoromethyl O +
) O +
did O +
not O +
markedly O +
decrease O +
the O +
affinity O +
for O +
the O +
vitamin O +
D O +
receptor O +
, O +
but O +
larger O +
( O +
11 O +
alpha O -
- O -
chloromethyl O +
or O +
11 O +
alpha- O +
or O +
11 O +
beta O -
- O -
phenyl O +
) O +
or O +
more O +
polar O +
substitutions O +
( O +
11 O +
alpha O -
- O -
hydroxymethyl O +
, O +
11 O +
alpha- O +
( O +
2-hydroxyethyl O +
] O +
decreased O +
the O +
affinity O +
to O +
less O +
than O +
5 O +
% O +
of O +
that O +
of O +
1 O +
alpha O +
, O +
25-OH O +
) O +
2D3 O +
. O +

Their O +
affinity O +
for O +
the O +
vitamin O +
D O -
- O -
binding O +
protein O +
, O +
however O +
, O +
increased O +
up O +
to O +
4-fold O +
. O +

The O +
biological O +
activity O +
of O +
11 O +
alpha O -
- O -
methyl-1 O +
alpha O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
closely O +
resembled O +
that O +
of O +
the O +
natural O +
hormone O +
on O +
normal O +
and O +
leukemic O +
cell O +
proliferation O +
and O +
bone O +
resorption O +
, O +
whereas O +
its O +
in O +
vivo O +
effect O +
on O +
calcium O +
metabolism O +
of O +
the O +
rachitic O +
chick O +
was O +
about O +
50 O +
% O +
of O +
that O +
of O +
1 O +
alpha O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
. O +

The O +
11 O +
beta O -
- O -
methyl O +
analog O +
had O +
a O +
greater O +
than O +
10-fold O +
lower O +
activity O +
. O +

The O +
differentiating O +
effects O +
of O +
the O +
other O +
C-11 O +
analogs O +
on O +
human B-CellLine +
promyeloid I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
( O +
HL-60 B-CellLine +
) O +
agreed O +
well O +
with O +
their O +
bone O -
- O -
resorbing O +
activity O +
and O +
receptor O +
affinity O +
, O +
but O +
they O +
demonstrated O +
lower O +
calcemic O +
effects O +
in O +
vivo O +
. O +

Large O +
or O +
polar O +
substitutions O +
on O +
C-11 O +
of O +
1 O +
alpha O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
thus O +
impair O +
the O +
binding O +
of O +
the O +
vitamin O +
D O +
receptor O +
but O +
increase O +
the O +
affinity O +
to O +
vitamin O +
D O -
- O -
binding O +
protein O +
. O +

The O +
effects O +
of O +
many O +
C-11-substituted O +
1 O +
alpha O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
analogs O +
on O +
HL-60 B-CellLine +
cell O +
differentiation O +
exceeded O +
their O +
activity O +
on O +
calcium O +
metabolism O +
. O +

The O +
AP-1 O +
site O +
at O +
-150 O +
bp O +
, O +
but O +
not O +
the O +
NF O -
- O -
kappa O +
B O +
site O +
, O +
is O +
likely O +
to O +
represent O +
the O +
major O +
target O +
of O +
protein O +
kinase O +
C O +
in O +
the O +
interleukin O +
2 O +
promoter O +
. O +

Stimulation O +
of O +
T O +
cells O +
with O +
antigen O +
results O +
in O +
activation O +
of O +
several O +
kinases O +
, O +
including O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
, O +
that O +
may O +
mediate O +
the O +
later O +
induction O +
of O +
activation O -
- O -
related O +
genes O +
. O +

We O +
have O +
examined O +
the O +
potential O +
role O +
of O +
PKC O +
in O +
induction O +
of O +
the O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
gene O +
in O +
T O +
cells O +
stimulated O +
through O +
the O +
T O +
cell O +
receptor O -
/ O -
CD3 O +
complex O +
. O +

We O +
have O +
previously O +
shown O +
that O +
prolonged O +
treatment O +
of O +
the O +
untransformed O +
T B-CellLine +
cell I-CellLine +
clone I-CellLine +
Ar-5 I-CellLine +
with O +
phorbol O +
esters O +
results O +
in O +
downmodulation O +
of O +
the O +
alpha O +
and O +
beta O +
isozymes O +
of O +
PKC O +
, O +
and O +
abrogates O +
induction O +
of O +
IL-2 O +
mRNA O +
and O +
protein O +
. O +

Here O +
we O +
show O +
that O +
phorbol O +
ester O +
treatment O +
also O +
abolishes O +
induction O +
of O +
chloramphenicol O +
acetyltransferase O +
activity O +
in O +
Ar-5 B-CellLine +
cells I-CellLine +
transfected O +
with O +
a O +
plasmid O +
containing O +
the O +
IL-2 O +
promoter O +
linked O +
to O +
this O +
reporter O +
gene O +
. O +

The O +
IL-2 O +
promoter O +
contains O +
binding O +
sites O +
for O +
nuclear O +
factors O +
including O +
NFAT-1 O +
, O +
Oct O +
, O +
NF O -
- O -
kappa O +
B O +
, O +
and O +
AP-1 O +
, O +
which O +
are O +
all O +
potentially O +
sensitive O +
to O +
activation O +
of O +
PKC O +
. O +

We O +
show O +
that O +
induction O +
of O +
a O +
trimer O +
of O +
the O +
NFAT O +
and O +
Oct O +
sites O +
is O +
not O +
sensitive O +
to O +
phorbol O +
ester O +
treatment O +
, O +
and O +
that O +
mutations O +
in O +
the O +
NF O -
- O -
kappa O +
B O +
site O +
have O +
no O +
effect O +
on O +
inducibility O +
of O +
the O +
IL-2 O +
promoter O +
. O +

In O +
contrast O +
, O +
mutations O +
in O +
the O +
AP-1 O +
site O +
located O +
at O +
-150 O +
bp O +
almost O +
completely O +
abrogate O +
induction O +
of O +
the O +
IL-2 O +
promoter O +
, O +
and O +
appearance O +
of O +
an O +
inducible O +
nuclear O +
factor O +
binding O +
to O +
this O +
site O +
is O +
sensitive O +
to O +
PKC O +
depletion O +
. O +

Moreover O +
, O +
cotransfections O +
with O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
expression O +
plasmids O +
markedly O +
enhance O +
induction O +
of O +
the O +
IL-2 O +
promoter O +
in O +
minimally B-CellLine +
stimulated I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Our O +
results O +
indicate O +
that O +
the O +
AP-1 O +
site O +
at O +
-150 O +
bp O +
represents O +
a O +
major O +
, O +
if O +
not O +
the O +
only O +
, O +
site O +
of O +
PKC O +
responsiveness O +
in O +
the O +
IL-2 O +
promoter O +
. O +

Interleukin O +
6-induced O +
differentiation O +
of O +
a O +
human B-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
into O +
IgM O -
- O -
secreting O +
plasma O +
cells O +
is O +
mediated O +
by O +
c O -
- O -
fos O +
. O +

The O +
role O +
of O +
the O +
protooncogene O +
c O -
- O -
fos O +
in O +
interleukin O +
( O +
IL O +
) O +
6 O +
-induced O +
B O +
cell O +
differentiation O +
was O +
assessed O +
. O +

Treatment O +
of O +
SKW O +
6.4 O +
cells O +
with O +
IL O +
6 O +
induced O +
a O +
transient O +
and O +
early O +
stimulation O +
of O +
c O -
- O -
fos O +
sense O +
mRNA O +
expression O +
. O +

The O +
effect O +
appeared O +
within O +
30 O +
min O +
and O +
returned O +
to O +
basal O +
levels O +
after O +
2 O +
h O +
. O +

The O +
addition O +
of O +
antisense O +
oligonucleotides O +
to O +
c O -
- O -
fos O +
significantly O +
inhibited O +
IL O +
6 O +
-induced O +
IgM O +
production O +
by O +
SKW B-CellLine +
6.4 I-CellLine +
cells I-CellLine +
( O +
p O +
less O +
than O +
0.001 O +
) O +
, O +
whereas O +
control O +
oligonucleotides O +
had O +
no O +
inhibitory O +
effect O +
. O +

These O +
results O +
indicate O +
that O +
activation O +
of O +
c O -
- O -
fos O +
is O +
involved O +
in O +
IL O +
6 O +
-induced O +
differentiation O +
of O +
SKW B-CellLine +
6.4 I-CellLine +
cells I-CellLine +
into O +
IgM B-CellLine -
- I-CellLine -
secreting I-CellLine +
cells I-CellLine +
. O +

Gangliosides O +
suppress O +
tumor O +
necrosis O +
factor O +
production O +
in O +
human O +
monocytes O +
. O +

Both O +
normal O +
and O +
malignant O +
cells O +
contain O +
gangliosides O +
as O +
important O +
cell O +
membrane O +
constituents O +
that O +
, O +
after O +
being O +
shed O +
, O +
may O +
influence O +
cells O +
of O +
the O +
immune O +
system O +
. O +

We O +
have O +
studied O +
the O +
impact O +
of O +
gangliosides O +
on O +
the O +
expression O +
of O +
TNF O +
in O +
blood O +
monocytes O +
and O +
in O +
the O +
monocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
Mono I-CellLine +
Mac I-CellLine +
6 I-CellLine +
. O +

Although O +
under O +
standard O +
culture O +
conditions O +
, O +
bovine O +
brain O +
gangliosides O +
( O +
100 O +
micrograms O -
/ O -
ml O +
) O +
suppressed O +
LPS O -
- O -
stimulated O +
TNF O +
production O +
5-fold O +
in O +
PBMC O +
and O +
10-fold O +
in O +
Mono B-CellLine +
Mac I-CellLine +
6 I-CellLine +
cells I-CellLine +
, O +
suppression O +
was O +
more O +
efficient O +
under O +
serum O -
- O -
free O +
conditions O +
. O +

Looking O +
at O +
highly O +
purified O +
gangliosides O +
, O +
GD3 O +
, O +
GD1a O +
, O +
GM3 O +
, O +
GM2 O +
, O +
and O +
GM1 O +
were O +
all O +
effective O +
in O +
reducing O +
TNF O +
production O +
in O +
PBMC O +
, O +
and O +
in O +
Mono B-CellLine +
Mac I-CellLine +
6 I-CellLine +
by O +
factor O +
10 O +
to O +
50 O +
. O +

The O +
suppressive O +
activity O +
was O +
lost O +
in O +
molecules O +
, O +
lacking O +
the O +
sugar O +
moiety O +
or O +
the O +
lipid O +
moiety O +
. O +

Gangliosides O +
appear O +
to O +
act O +
at O +
an O +
early O +
step O +
of O +
activation O +
in O +
that O +
TNF O +
transcripts O +
were O +
reduced O +
and O +
the O +
mobilization O +
of O +
the O +
nuclear O +
factor O +
kappa O +
B O +
was O +
blocked O +
. O +

Furthermore O +
, O +
in O +
time O +
kinetics O +
, O +
gangliosides O +
were O +
effective O +
for O +
up O +
to O +
30 O +
min O +
after O +
addition O +
of O +
LPS O +
, O +
but O +
not O +
thereafter O +
. O +

However O +
, O +
the O +
expression O +
of O +
the O +
CD14 O +
Ag O +
, O +
a O +
receptor O +
molecule O +
for O +
LPS O -
- O -
LPS O +
binding O +
protein O +
complexes O +
, O +
was O +
unaffected O +
by O +
gangliosides O +
. O +

Finally O +
, O +
when O +
using O +
Staphylococcus O +
aureus O +
or O +
platelet O +
activating O +
factor O +
as O +
a O +
stimulus O +
, O +
gangliosides O +
were O +
able O +
to O +
suppress O +
TNF O +
production O +
in O +
Mono B-CellLine +
Mac I-CellLine +
6 I-CellLine +
cells I-CellLine +
by O +
factor O +
5 O +
to O +
10 O +
, O +
as O +
well O +
. O +

On O +
the O +
other O +
hand O +
, O +
phorbol O +
ester O -
- O -
induced O +
production O +
of O +
O2- O +
was O +
similar O +
in O +
cells O +
treated O +
with O +
and O +
without O +
gangliosides O +
. O +

Taken O +
together O +
, O +
our O +
data O +
demonstrate O +
that O +
TNF O +
gene O +
expression O +
in O +
monocytes O +
induced O +
by O +
different O +
types O +
of O +
stimuli O +
can O +
be O +
blocked O +
by O +
gangliosides O +
at O +
an O +
early O +
step O +
of O +
signal O +
transduction O +
. O +

T O +
cell O -
- O -
specific O +
negative O +
regulation O +
of O +
transcription O +
of O +
the O +
human O +
cytokine O +
IL-4 O +
. O +

IL-4 O +
secreted O +
by O +
activated O +
T O +
cells O +
is O +
a O +
pleiotropic O +
cytokine O +
affecting O +
growth O +
and O +
differentiation O +
of O +
diverse O +
cell O +
types O +
such O +
as O +
T O +
cells O +
, O +
B O +
cells O +
, O +
and O +
mast O +
cells O +
. O +

We O +
investigated O +
the O +
upstream O +
regulatory O +
elements O +
of O +
the O +
human O +
IL-4 O +
promoter O +
. O +

A O +
novel O +
T O +
cell O -
- O -
specific O +
negative O +
regulatory O +
element O +
( O +
NRE O +
) O +
composed O +
of O +
two O +
protein O -
- O -
binding O +
sites O +
were O +
mapped O +
in O +
the O +
5 O +
' O +
flanking O +
region O +
of O +
the O +
IL-4 O +
gene O +
: O +
-311CTCCCTTCT-303 O +
( O +
NRE O -
- O -
I O +
) O +
and O +
-288CTTTTTGCTT O -
- O -
TGC-300 O +
( O +
NRE O -
- O -
II O +
) O +
. O +

A O +
T O +
cell O -
- O -
specific O +
protein O +
Neg-1 O +
and O +
a O +
ubiquitous O +
protein O +
Neg-2 O +
binding O +
to O +
NRE O -
- O -
I O +
and O +
NRE O -
- O -
II O +
, O +
respectively O +
, O +
were O +
identified O +
. O +

Furthermore O +
, O +
a O +
positive O +
regulatory O +
element O +
was O +
found O +
45 O +
bp O +
downstream O +
of O +
the O +
NRE O +
. O +

The O +
enhancer O +
activity O +
of O +
the O +
PRE O +
was O +
completely O +
suppressed O +
when O +
the O +
NRE O +
was O +
present O +
. O +

These O +
data O +
suggest O +
that O +
IL-4 O +
promoter O +
activity O +
is O +
normally O +
down O -
- O -
regulated O +
by O +
an O +
NRE O +
via O +
repression O +
of O +
the O +
enhancer O +
positive O +
regulatory O +
element O +
. O +

These O +
data O +
may O +
have O +
implications O +
for O +
the O +
stringent O +
control O +
of O +
IL-4 O +
expression O +
in O +
T O +
cells O +
. O +

[ O +
Regulatory O +
effect O +
of O +
insulin O +
on O +
glucocorticoid O +
receptor O +
in O +
human O +
peripheral O +
leukocytes O +
] O +

The O +
regulatory O +
effect O +
of O +
insulin O +
on O +
the O +
specific O +
binding O +
power O +
of O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
of O +
human O +
leukocytes O +
was O +
assessed O +
by O +
the O +
unoccupied O +
receptor O +
sites O +
capable O +
of O +
combining O +
with O +
[ O +
3H O +
] O +
labelled O +
dexamethasone O +
measured O +
at O +
3 O +
and O +
24 O +
h O +
after O +
incubation O +
with O +
various O +
concentrations O +
of O +
insulin O +
added O +
to O +
the O +
medium O +
. O +

After O +
3 O +
h O +
incubation O +
the O +
specific O +
binding O +
power O +
with O +
[ O +
3H O +
] O +
Dex O +
was O +
decreased O +
by O +
23.3 O +
+ O -
/- O +
10.0 O +
, O +
32.2 O +
+ O -
/- O +
13.2 O +
and O +
54.3 O +
+ O -
/- O +
9.2 O +
% O +
( O +
P O +
greater O +
than O +
0.05 O +
, O +
P O +
greater O +
than O +
0.05 O +
and O +
P O +
less O +
than O +
0.01 O +
as O +
compared O +
with O +
the O +
control O +
value O +
of O +
100 O +
in O +
the O +
absence O +
of O +
insulin O +
) O +
respectively O +
in O +
the O +
presence O +
of O +
20 O +
mU O -
/ O -
L O +
( O +
physiological O +
testing O +
concentration O +
) O +
, O +
200 O +
mU O -
/ O -
L O +
( O +
physiological O +
upper O +
limit O +
) O +
and O +
2 O +
, O +
000 O +
mU O -
/ O -
L O +
( O +
pharmacological O +
concentration O +
) O +
insulin O +
in O +
the O +
incubation O +
medium O +
. O +

After O +
24 O +
h O +
incubation O +
the O +
decrease O +
of O +
these O +
values O +
increased O +
respectively O +
to O +
43.5 O +
+ O -
/- O +
19.0 O +
, O +
56.1 O +
+ O -
/- O +
20.7 O +
and O +
80.2 O +
+ O -
/- O +
15.5 O +
( O +
P O +
less O +
than O +
0.05 O +
, O +
P O +
less O +
than O +
0.01 O +
and O +
P O +
less O +
than O +
0.01 O +
compared O +
with O +
control O +
) O +
. O +

Thus O +
the O +
inhibitory O +
effect O +
of O +
insulin O +
on O +
the O +
GR O +
binding O +
power O +
is O +
both O +
dose- O +
and O +
time O -
- O -
dependent O +
, O +
which O +
strongly O +
suggests O +
that O +
GR O +
is O +
tonically O +
controlled O +
by O +
insulin O +
concentration O +
change O +
under O +
physiological O +
conditions O +
. O +

Human O +
T O +
cell O +
activation O +
through O +
the O +
activation O -
- O -
inducer O +
molecule O -
/ O -
CD69 O +
enhances O +
the O +
activity O +
of O +
transcription O +
factor O +
AP-1 O +
. O +

The O +
induction O +
of O +
the O +
AP-1 O +
transcription O +
factor O +
has O +
been O +
ascribed O +
to O +
the O +
early O +
events O +
leading O +
to O +
T O +
cell O +
differentiation O +
and O +
activation O +
. O +

We O +
have O +
studied O +
the O +
regulation O +
of O +
AP-1 O +
activity O +
in O +
human O +
peripheral O +
blood O +
T O +
lymphocytes O +
stimulated O +
through O +
the O +
activation O +
inducer O +
molecule O +
( O +
AIM O +
) O +
/ O +
CD69 O +
activation O +
pathway O +
. O +

Phorbol O +
esters O +
are O +
required O +
to O +
induce O +
AIM O -
/ O -
CD69 O +
cell O -
- O -
surface O +
expression O +
as O +
well O +
as O +
for O +
triggering O +
the O +
proliferation O +
of O +
T O +
cells O +
in O +
conjunction O +
with O +
anti O -
- O -
AIM O +
mAb O +
. O +

Mobility O +
shift O +
assays O +
showed O +
that O +
addition O +
of O +
anti O -
- O -
AIM O +
mAb O +
to O +
PMA O -
- O -
treated O +
T O +
lymphocytes O +
markedly O +
enhanced O +
the O +
binding O +
activity O +
of O +
AP-1 O +
to O +
its O +
cognate O +
sequence O +
, O +
the O +
phorbol O +
ester O +
response O +
element O +
. O +

In O +
contrast O +
, O +
anti O -
- O -
AIM O +
mAb O +
did O +
not O +
induce O +
any O +
change O +
in O +
the O +
binding O +
activity O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
a O +
transcription O +
factor O +
whose O +
activity O +
is O +
also O +
regulated O +
by O +
protein O +
kinase O +
C O +
. O +

The O +
increase O +
in O +
AP-1 O +
-binding O +
activity O +
was O +
accompanied O +
by O +
the O +
marked O +
stimulation O +
of O +
the O +
transcription O +
of O +
c O -
- O -
fos O +
but O +
not O +
that O +
of O +
c O -
- O -
jun O +
. O +

Blockade O +
of O +
the O +
DNA O -
- O -
binding O +
complexes O +
with O +
an O +
anti O -
- O -
Fos O +
mAb O +
demonstrated O +
a O +
direct O +
participation O +
of O +
c O -
- O -
Fos O +
in O +
the O +
AP-1 O +
complexes O +
induced O +
by O +
anti O -
- O -
AIM O +
mAb O +
. O +

Most O +
of O +
the O +
AP-1 O +
activity O +
could O +
be O +
eliminated O +
when O +
the O +
anti O -
- O -
AIM O +
mAb O +
was O +
added O +
to O +
the O +
culture O +
medium O +
in O +
the O +
presence O +
of O +
cycloheximide O +
, O +
suggesting O +
that O +
de O +
novo O +
protein O +
synthesis O +
is O +
crucial O +
for O +
the O +
induction O +
of O +
AP-1 O +
-binding O +
activity O +
. O +

These O +
data O +
provide O +
the O +
evidence O +
that O +
activation O +
of O +
human O +
peripheral O +
blood O +
T O +
cells O +
through O +
the O +
AIM O +
activation O +
pathway O +
regulate O +
the O +
activity O +
of O +
AP-1 O +
. O +

Therefore O +
, O +
this O +
pathway O +
appears O +
as O +
a O +
crucial O +
step O +
in O +
the O +
initiation O +
of O +
early O +
T O +
cell O +
activation O +
events O +
. O +

cis O -
- O -
acting O +
sequences O +
required O +
for O +
inducible O +
interleukin-2 O +
enhancer O +
function O +
bind O +
a O +
novel O +
Ets O -
- O -
related O +
protein O +
, O +
Elf-1 O +
. O +

The O +
recent O +
definition O +
of O +
a O +
consensus O +
DNA O +
binding O +
sequence O +
for O +
the O +
Ets O +
family O +
of O +
transcription O +
factors O +
has O +
allowed O +
the O +
identification O +
of O +
potential O +
Ets O +
binding O +
sites O +
in O +
the O +
promoters O +
and O +
enhancers O +
of O +
many O +
inducible O +
T O -
- O -
cell O +
genes O +
. O +

In O +
the O +
studies O +
described O +
in O +
this O +
report O +
, O +
we O +
have O +
identified O +
two O +
potential O +
Ets O +
binding O +
sites O +
, O +
EBS1 O +
and O +
EBS2 O +
, O +
which O +
are O +
conserved O +
in O +
both O +
the O +
human O +
and O +
murine O +
interleukin-2 O +
enhancers O +
. O +

Within O +
the O +
human O +
enhancer O +
, O +
these O +
two O +
sites O +
are O +
located O +
within O +
the O +
previously O +
defined O +
DNase O +
I O +
footprints O +
, O +
NFAT-1 O +
and O +
NFIL-2B O +
, O +
respectively O +
. O +

Electrophoretic O +
mobility O +
shift O +
and O +
methylation O +
interference O +
analyses O +
demonstrated O +
that O +
EBS1 O +
and O +
EBS2 O +
are O +
essential O +
for O +
the O +
formation O +
of O +
the O +
NFAT-1 O +
and O +
NFIL-2B O +
nuclear O +
protein O +
complexes O +
. O +

Furthermore O +
, O +
in O +
vitro O +
mutagenesis O +
experiments O +
demonstrated O +
that O +
inducible O +
interleukin-2 O +
enhancer O +
function O +
requires O +
the O +
presence O +
of O +
either O +
EBS1 O +
or O +
EBS2 O +
. O +

Two O +
well O -
- O -
characterized O +
Ets O +
family O +
members O +
, O +
Ets-1 O +
and O +
Ets-2 O +
, O +
are O +
reciprocally O +
expressed O +
during O +
T O -
- O -
cell O +
activation O +
. O +

Surprisingly O +
, O +
however O +
, O +
neither O +
of O +
these O +
proteins O +
bound O +
in O +
vitro O +
to O +
EBS1 O +
or O +
EBS2 O +
. O +

We O +
therefore O +
screened O +
a O +
T O -
- O -
cell O +
cDNA O +
library O +
under O +
low O -
- O -
stringency O +
conditions O +
with O +
a O +
probe O +
from O +
the O +
DNA O +
binding O +
domain O +
of O +
Ets-1 O +
and O +
isolated O +
a O +
novel O +
Ets O +
family O +
member O +
, O +
Elf-1 O +
. O +

Elf-1 O +
contains O +
a O +
DNA O +
binding O +
domain O +
that O +
is O +
nearly O +
identical O +
to O +
that O +
of O +
E74 O +
, O +
the O +
ecdysone O -
- O -
inducible O +
Drosophila O +
transcription O +
factor O +
required O +
for O +
metamorphosis O +
( O +
hence O +
the O +
name O +
Elf-1 O +
, O +
for O +
E74-like O +
factor O +
1 O +
) O +
. O +

Elf-1 O +
bound O +
specifically O +
to O +
both O +
EBS1 O +
and O +
EBS2 O +
in O +
electrophoretic O +
mobility O +
shift O +
assays O +
. O +

It O +
also O +
bound O +
to O +
the O +
purine O -
- O -
rich O +
CD3R O +
element O +
from O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
2 O +
long O +
terminal O +
repeat O +
, O +
which O +
is O +
required O +
for O +
inducible O +
virus O +
expression O +
in O +
response O +
to O +
signalling O +
through O +
the O +
T O -
- O -
cell O +
receptor O +
. O +

Taken O +
together O +
, O +
these O +
results O +
demonstrate O +
that O +
multiple O +
Ets O +
family O +
members O +
with O +
apparently O +
distinct O +
DNA O +
binding O +
specificities O +
regulate O +
differential O +
gene O +
expression O +
in O +
resting O +
and O +
activated O +
T O +
cells O +
. O +

Mineralocorticoids O +
and O +
mineralocorticoid O +
receptors O +
in O +
mononuclear O +
leukocytes O +
in O +
patients O +
with O +
pregnancy O -
- O -
induced O +
hypertension O +
. O +

To O +
examine O +
the O +
role O +
of O +
mineralocorticoids O +
in O +
the O +
pathophysiology O +
of O +
pregnancy O -
- O -
induced O +
hypertension O +
( O +
PIH O +
) O +
, O +
we O +
studied O +
plasma O +
aldosterone O +
and O +
18-hydroxycorticosterone O +
levels O +
in O +
25 O +
women O +
with O +
PIH O +
and O +
25 O +
normal O +
pregnant O +
women O +
, O +
as O +
controls O +
. O +

Furthermore O +
, O +
we O +
evaluated O +
the O +
mineralocorticoid O +
receptor O +
( O +
MR O +
) O +
status O +
in O +
mononuclear O +
leukocytes O +
in O +
the O +
2 O +
groups O +
. O +

MR O +
count O +
was O +
significantly O +
( O +
P O +
less O +
than O +
0.0005 O +
) O +
decreased O +
in O +
the O +
PIH O +
group O +
( O +
148 O +
+ O -
/- O +
9 O +
binding O +
sites O -
/ O -
cell O +
) O +
compared O +
with O +
the O +
control O +
group O +
( O +
300 O +
+ O -
/- O +
17 O +
binding O +
sites O -
/ O -
cell O +
; O +
mean O +
+ O -
/- O +
SEM O +
) O +
. O +

Plasma O +
aldosterone O +
in O +
women O +
with O +
PIH O +
was O +
281 O +
+ O -
/- O +
61 O +
pmol O -
/ O -
L O +
; O +
in O +
normal O +
pregnant O +
women O +
it O +
was O +
697 O +
+ O -
/- O +
172 O +
pmol O -
/ O -
L O +
( O +
P O +
less O +
than O +
0.025 O +
) O +
. O +

Plasma O +
18-hydroxycorticosterone O +
was O +
also O +
significantly O +
( O +
P O +
less O +
than O +
0.025 O +
) O +
lower O +
( O +
PIH O +
, O +
1071 O +
+ O -
/- O +
149 O +
pmol O -
/ O -
L O +
; O +
controls O +
, O +
1907 O +
+ O -
/- O +
318 O +
pmol O -
/ O -
L O +
) O +
. O +

These O +
values O +
were O +
determined O +
at O +
the O +
onset O +
of O +
clinical O +
symptoms O +
of O +
PIH O +
. O +

These O +
results O +
can O +
not O +
be O +
explained O +
by O +
receptor O +
down O -
- O -
regulation O +
due O +
to O +
higher O +
levels O +
of O +
mineralocorticoids O +
in O +
PIH O +
; O +
a O +
hitherto O +
unknown O +
mineralocorticoid O +
may O +
, O +
thus O +
, O +
be O +
responsible O +
for O +
the O +
hypertension O +
and O +
altered O +
MR O +
status O +
. O +

A O +
lymphoid O +
cell O -
- O -
specific O +
nuclear O +
factor O +
containing O +
c O -
- O -
Rel O -
- O -
like O +
proteins O +
preferentially O +
interacts O +
with O +
interleukin-6 O +
kappa O +
B O -
- O -
related O +
motifs O +
whose O +
activities O +
are O +
repressed O +
in O +
lymphoid O +
cells O +
. O +

The O +
proto O -
- O -
oncoprotein O +
c O -
- O -
Rel O +
is O +
a O +
member O +
of O +
the O +
nuclear O +
factor O +
kappa O +
B O +
transcription O +
factor O +
family O +
, O +
which O +
includes O +
the O +
p50 O +
and O +
p65 O +
subunits O +
of O +
nuclear O +
factor O +
kappa O +
B O +
. O +

We O +
show O +
here O +
that O +
c O -
- O -
Rel O +
binds O +
to O +
kappa O +
B O +
sites O +
as O +
homodimers O +
as O +
well O +
as O +
heterodimers O +
with O +
p50 O +
. O +

These O +
homodimers O +
and O +
heterodimers O +
show O +
distinct O +
DNA O -
- O -
binding O +
specificities O +
and O +
affinities O +
for O +
various O +
kappa O +
B O +
motifs O +
. O +

In O +
particular O +
, O +
the O +
c O -
- O -
Rel O +
homodimer O +
has O +
a O +
high O +
affinity O +
for O +
interleukin-6 O +
( O +
IL-6 O +
) O +
and O +
beta O +
interferon O +
kappa O +
B O +
sites O +
. O +

In O +
spite O +
of O +
its O +
association O +
with O +
p50 O +
in O +
vitro O +
, O +
however O +
, O +
we O +
found O +
a O +
lymphoid O +
cell O -
- O -
specific O +
nuclear O +
factor O +
in O +
vivo O +
that O +
contains O +
c O -
- O -
Rel O +
but O +
not O +
p50 O +
epitopes O +
; O +
this O +
factor O +
, O +
termed O +
IL-6 O +
kappa O +
B O +
binding O +
factor O +
II O +
, O +
appears O +
to O +
contain O +
the O +
c O -
- O -
Rel O +
homodimer O +
and O +
preferentially O +
recognizes O +
several O +
IL-6 O +
kappa O +
B O -
- O -
related O +
kappa O +
B O +
motifs O +
. O +

Although O +
it O +
has O +
been O +
previously O +
shown O +
that O +
the O +
IL-6 O +
kappa O +
B O +
motif O +
functions O +
as O +
a O +
potent O +
IL-1 O -
/ O -
tumor O +
necrosis O +
factor O -
- O -
responsive O +
element O +
in O +
nonlymphoid O +
cells O +
, O +
its O +
activity O +
was O +
found O +
to O +
be O +
repressed O +
in O +
lymphoid O +
cells O +
such O +
as O +
a O +
Jurkat B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
. O +

We O +
also O +
present O +
evidence O +
that O +
IL-6 O +
kappa O +
B O +
binding O +
factor O +
II O +
functions O +
as O +
a O +
repressor O +
specific O +
for O +
IL-6 O +
kappa O +
B O -
- O -
related O +
kappa O +
B O +
motifs O +
in O +
lymphoid O +
cells O +
. O +

Modulation O +
of O +
normal O +
erythroid O +
differentiation O +
by O +
the O +
endogenous O +
thyroid O +
hormone O +
and O +
retinoic O +
acid O +
receptors O +
: O +
a O +
possible O +
target O +
for O +
v O -
- O -
erbA O +
oncogene O +
action O +
. O +

The O +
v O -
- O -
erbA O +
oncogene O +
, O +
a O +
mutated O +
version O +
of O +
the O +
thyroid O +
hormone O +
receptor O +
alpha O +
( O +
c O -
- O -
erbA O -
/ O -
TR O -
- O -
alpha O +
) O +
, O +
inhibits O +
erythroid O +
differentiation O +
and O +
constitutively O +
represses O +
transcription O +
of O +
certain O +
erythrocyte O +
genes O +
, O +
suggesting O +
a O +
normal O +
function O +
of O +
the O +
proto O -
- O -
oncogene O +
c O -
- O -
erbA O +
in O +
erythropoiesis O +
. O +

Here O +
we O +
demonstrate O +
that O +
the O +
endogenous O +
thyroid O +
hormone O +
receptor O +
alpha O +
( O +
c O -
- O -
erbA O -
/ O -
TR O -
- O -
alpha O +
) O +
and O +
the O +
closely O +
related O +
retinoic O +
acid O +
receptor O +
alpha O +
( O +
RAR O -
- O -
alpha O +
) O +
play O +
a O +
role O +
in O +
the O +
regulation O +
of O +
normal O +
erythroid O +
differentiation O +
. O +

Retinoic O +
acid O +
( O +
RA O +
) O +
distinctly O +
modulated O +
the O +
erythroid O +
differentiation O +
program O +
of O +
normal O +
erythroid O +
progenitors O +
and O +
erythroblasts O +
reversibly O +
transformed O +
by O +
a O +
conditional O +
tyrosine O +
kinase O +
oncogene O +
. O +

When O +
added O +
pulsewise O +
to O +
immature O +
cells O +
, O +
differentiation O +
was O +
accelerated O +
while O +
more O +
mature O +
cells O +
underwent O +
premature O +
cell O +
death O +
. O +

Thyroid O +
hormone O +
( O +
T3 O +
) O +
alone O +
caused O +
similar O +
but O +
weaker O +
effects O +
. O +

Interestingly O +
, O +
T3 O +
strongly O +
enhanced O +
the O +
action O +
of O +
RA O +
, O +
suggesting O +
cooperative O +
action O +
of O +
the O +
two O +
receptors O +
in O +
modulating O +
erythroid O +
differentiation O +
. O +

Expression O +
of O +
the O +
human O +
RAR O -
- O -
alpha O +
in O +
receptor B-CellLine -
- I-CellLine -
negative I-CellLine +
erythroblasts I-CellLine +
conferred O +
RA O -
- O -
induced O +
regulation O +
of O +
differentiation O +
to O +
the O +
otherwise O +
unresponsive O +
cells O +
, O +
thus O +
showing O +
that O +
the O +
RAR O -
- O -
alpha O +
is O +
essential O +
for O +
the O +
RA O +
effect O +
. O +

Likewise O +
, O +
enhanced O +
expression O +
of O +
exogenous O +
c O -
- O -
erbA O -
/ O -
TR O -
- O -
alpha O +
in O +
erythroblasts O +
rendered O +
them O +
susceptible O +
to O +
modulation O +
of O +
differentiation O +
by O +
T3 O +
, O +
suggesting O +
a O +
similar O +
function O +
of O +
both O +
receptors O +
. O +

Glucocorticoid O +
receptor O +
binding O +
in O +
three O +
different O +
cell O +
types O +
in O +
major O +
depressive O +
disorder O +
: O +
lack O +
of O +
evidence O +
of O +
receptor O +
binding O +
defect O +
. O +

1 O +
. O +

In O +
order O +
to O +
further O +
understand O +
the O +
apparent O +
glucocorticoid O +
resistance O +
in O +
major O +
depressive O +
disorder O +
, O +
circadian O +
variation O +
in O +
cortisol O +
concentration O +
, O +
dexamethasone O +
suppression O +
and O +
glucocorticoid O +
receptor O +
binding O +
in O +
mononuclear O +
leukocytes O +
, O +
polymorphonuclear O +
leukocytes O +
and O +
cultured B-CellLine +
skin I-CellLine +
fibroblasts I-CellLine +
were O +
measured O +
in O +
rigidly O +
defined O +
major O +
depressive O +
disorder O +
patients O +
and O +
non O -
- O -
depressed O +
psychiatric O +
controls O +
. O +

2 O +
. O +

Mononuclear O +
leukocytes O +
binding O +
to O +
glucocorticoid O +
correlated O +
significantly O +
with O +
polymorphonuclear O +
leukocytes O +
binding O +
to O +
glucocorticoid O +
, O +
but O +
both O +
determinations O +
failed O +
to O +
differentiate O +
major O +
depressive O +
disorder O +
and O +
control O +
subjects O +
. O +

3 O +
. O +

Initial O +
and O +
post O -
- O -
dexamethasone O +
in O +
vitro O +
fibroblast O +
binding O +
to O +
glucocorticoid O +
was O +
not O +
different O +
between O +
major O +
depressive O +
disorder O +
and O +
non O -
- O -
depressed O +
control O +
subjects O +
. O +

4 O +
. O +

The O +
phenomenon O +
of O +
glucocorticoid O +
resistance O +
in O +
major O +
depressive O +
disorder O +
remains O +
unexplained O +
. O +

The O +
B O +
cell O -
- O -
specific O +
nuclear O +
factor O +
OTF-2 O +
positively O +
regulates O +
transcription O +
of O +
the O +
human O +
class O +
II O +
transplantation O +
gene O +
, O +
DRA O +
. O +

The O +
promoter O +
of O +
the O +
major O +
histocompatibility O +
class O +
II O +
gene O +
DRA O +
contains O +
an O +
octamer O +
element O +
( O +
ATTTGCAT O +
) O +
that O +
is O +
required O +
for O +
efficient O +
DRA O +
expression O +
in O +
B O +
cells O +
. O +

Several O +
DNA O -
- O -
binding O +
proteins O +
are O +
known O +
to O +
bind O +
this O +
sequence O +
. O +

The O +
best O +
characterized O +
are O +
the O +
B O +
cell O -
- O -
specific O +
OTF-2 O +
and O +
the O +
ubiquitous O +
OTF-1 O +
. O +

This O +
report O +
directly O +
demonstrates O +
that O +
OTF-2 O +
but O +
not O +
OTF-1 O +
regulates O +
the O +
DRA O +
gene O +
. O +

In O +
vitro O +
transcription O +
analysis O +
using O +
protein O +
fractions O +
enriched O +
for O +
the O +
octamer O -
- O -
binding O +
protein O +
OTF-2 O +
demonstrate O +
a O +
positive O +
functional O +
role O +
for O +
OTF-2 O +
in O +
DRA O +
gene O +
transcription O +
. O +

In O +
contrast O +
, O +
OTF-1 O +
-enriched O +
protein O +
fractions O +
did O +
not O +
affect O +
DRA O +
gene O +
transcription O +
although O +
it O +
functionally O +
enhanced O +
the O +
transcription O +
of O +
another O +
gene O +
. O +

Recombinant O +
OTF-2 O +
protein O +
produced O +
by O +
in O +
vitro O +
transcription O -
/ O -
translation O +
could O +
also O +
enhance O +
DRA O +
gene O +
transcription O +
in O +
vitro O +
. O +

In O +
vivo O +
transient O +
transfection O +
studies O +
utilizing O +
an O +
OTF-2 O +
expression O +
vector O +
resulted O +
in O +
similar O +
findings O +
: O +
that O +
OTF-2 O +
protein O +
enhanced O +
DRA O +
gene O +
transcription O +
, O +
and O +
that O +
this O +
effect O +
requires O +
an O +
intact O +
octamer O +
element O +
. O +

Together O +
these O +
results O +
constitute O +
the O +
first O +
direct O +
evidence O +
of O +
a O +
positive O +
role O +
for O +
the O +
lymphoid O -
- O -
specific O +
octamer O -
- O -
binding O +
factor O +
in O +
DRA O +
gene O +
transcription O +
. O +

[ O +
Regulation O +
of O +
intracellular O +
cholesterol O +
synthesis O +
in O +
hypercholesterolemia O +
by O +
glucocorticoids O +
] O +

The O +
rate O +
of O +
endogenous O +
cholesterol O +
synthesis O +
in O +
blood O +
lymphocytes O +
and O +
skin O +
fibroblasts O +
from O +
patients O +
with O +
type O +
IIa O +
hyperlipidemia O +
was O +
found O +
to O +
be O +
increased O +
in O +
comparison O +
with O +
healthy O +
donors O +
. O +

The O +
cells O +
of O +
hyperlipidemic O +
patients O +
had O +
lowered O +
levels O +
of O +
glucocorticoid O +
receptors O +
concomitantly O +
with O +
a O +
partial O +
loss O +
of O +
their O +
sensitivity O +
to O +
glucocorticoids O +
. O +

In O +
fibroblasts O +
from O +
patients O +
with O +
hereditary O +
hypercholesteremia O +
of O +
homozygous O +
type O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
did O +
not O +
exceed O +
10 O +
% O +
of O +
their O +
content O +
in O +
normal O +
cells O +
. O +

The O +
decrease O +
of O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
in O +
patients O +
with O +
type O +
IIa O +
hyperlipidemia O +
seems O +
to O +
be O +
a O +
compensatory O +
response O +
of O +
cells O +
culminating O +
in O +
activation O +
of O +
endogenous O +
cholesterol O +
synthesis O +
. O +

Transcription O +
factor O +
activation O +
and O +
functional O +
stimulation O +
of O +
human O +
monocytes O +
. O +

Activation O +
of O +
expression O +
of O +
genes O +
encoding O +
transcription O +
factors O +
: O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
and O +
formation O +
of O +
AP1 O +
transcriptional O +
complex O +
in O +
human O +
monocytes O +
was O +
investigated O +
. O +

It O +
was O +
found O +
that O +
lipopolysaccharide O +
induced O +
strongly O +
both O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
expression O +
as O +
well O +
as O +
AP1 O +
formation O +
. O +

Interferon O +
gamma O +
activated O +
strongly O +
c O -
- O -
fos O +
and O +
weakly O +
c O -
- O -
jun O +
and O +
AP1 O +
. O +

Tumor O +
necrosis O +
factor O +
induced O +
slightly O +
c O -
- O -
fos O +
and O +
had O +
almost O +
no O +
effect O +
on O +
c O -
- O -
jun O +
and O +
AP1 O +
. O +

The O +
data O +
suggest O +
that O +
differences O +
in O +
functional O +
responses O +
elicited O +
in O +
monocytes O +
by O +
all O +
three O +
factors O +
may O +
be O +
dependent O +
on O +
different O +
routes O +
on O +
nuclear O +
signalling O +
employed O +
by O +
the O +
factors O +
. O +

Corticosteroid O +
receptors O +
and O +
lymphocyte O +
subsets O +
in O +
mononuclear O +
leukocytes O +
in O +
aging O +
. O +

Plasma O +
cortisol O +
and O +
aldosterone O +
levels O +
and O +
number O +
of O +
related O +
receptors O +
in O +
mononuclear O +
leukocytes O +
were O +
measured O +
in O +
49 O +
healthy O +
aged O +
subjects O +
( O +
62 O -
- O -
97 O +
yr O +
) O +
and O +
in O +
21 O +
adult O +
controls O +
( O +
21 O -
- O -
50 O +
yr O +
) O +
. O +

In O +
all O +
subjects O +
, O +
in O +
addition O +
, O +
lymphocyte O +
subsets O +
were O +
determined O +
as O +
an O +
index O +
of O +
corticosteroid O +
action O +
. O +

The O +
mean O +
number O +
of O +
type O +
I O +
and O +
type O +
II O +
receptors O +
was O +
significantly O +
lower O +
in O +
aged O +
subjects O +
than O +
in O +
controls O +
( O +
respectively O +
, O +
198 O +
+ O -
/- O +
96 O +
and O +
272 O +
+ O -
/- O +
97 O +
receptors O +
/cell O +
for O +
type O +
I O +
, O +
and O +
1 O +
, O +
794 O +
+ O -
/- O +
803 O +
and O +
3 O +
, O +
339 O +
+ O -
/- O +
918 O +
for O +
type O +
II O +
receptors O +
) O +
. O +

Plasma O +
aldosterone O +
and O +
cortisol O +
and O +
lymphocyte O +
subsets O +
were O +
not O +
different O +
in O +
the O +
two O +
groups O +
. O +

All O +
of O +
the O +
parameters O +
were O +
also O +
tested O +
for O +
correlation O +
, O +
and O +
a O +
significant O +
inverse O +
correlation O +
was O +
found O +
between O +
age O +
and O +
type O +
I O +
and O +
type O +
II O +
receptors O +
when O +
all O +
subjects O +
were O +
plotted O +
and O +
between O +
aged O +
and O +
CD4 O +
and O +
age O +
and O +
CD4 O -
/ O -
CD8 O +
in O +
the O +
aged O +
group O +
. O +

These O +
data O +
show O +
that O +
aged O +
subjects O +
have O +
reductions O +
of O +
corticosteroid O +
receptors O +
that O +
are O +
not O +
associated O +
with O +
increase O +
of O +
related O +
steroids O +
and O +
that O +
this O +
situation O +
probably O +
represents O +
a O +
concomitant O +
of O +
the O +
normal O +
aging O +
process O +
. O +

Stable O +
expression O +
of O +
HB24 O +
, O +
a O +
diverged O +
human O +
homeobox O +
gene O +
, O +
in O +
T O +
lymphocytes O +
induces O +
genes O +
involved O +
in O +
T O +
cell O +
activation O +
and O +
growth O +
. O +

A O +
diverged O +
homeobox O +
gene O +
, O +
HB24 O +
, O +
which O +
is O +
known O +
to O +
be O +
induced O +
following O +
lymphocyte O +
activation O +
, O +
was O +
introduced O +
into O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
under O +
the O +
control O +
of O +
a O +
constitutive O +
promoter O +
. O +

Stable O +
transfectants O +
of O +
HB24 O +
were O +
established O +
that O +
expressed O +
high O +
levels O +
of O +
HB24 O +
mRNA O +
and O +
possessed O +
an O +
altered O +
phenotype O +
suggestive O +
of O +
activated O +
T O +
cells O +
. O +

A O +
number O +
of O +
genes O +
known O +
to O +
be O +
induced O +
following O +
T O +
cell O +
activation O +
and O +
associated O +
with O +
cell O +
growth O +
were O +
increased O +
in O +
the O +
transfectants B-CellLine +
, O +
including O +
c O -
- O -
fos O +
, O +
c O -
- O -
myc O +
, O +
c O -
- O -
myb O +
, O +
HLA O -
- O -
DR O +
, O +
lck O +
, O +
NF O -
- O -
kappa O +
B O +
, O +
interleukin-2 O +
and O +
interleukin-2 O +
receptor O +
alpha O +
( O +
IL-2R O +
alpha O +
) O +
. O +

Analysis O +
of O +
IL-2R O +
alpha O +
expression O +
by O +
transient O +
transfection O +
of O +
IL-2R O +
alpha O +
promoter O +
constructs O +
into O +
the O +
HB24 B-CellLine +
transfectants I-CellLine +
revealed O +
constitutive O +
expression O +
( O +
about O +
60 O +
% O +
of O +
phytohemagglutinin- B-CellLine +
and I-CellLine +
phorbol I-CellLine +
ester I-CellLine -
- I-CellLine -
activated I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
) O +
that O +
was O +
dependent O +
on O +
the O +
kappa O +
B O +
site O +
in O +
the O +
IL-2R O +
alpha O +
promoter O +
. O +

Furthermore O +
, O +
as O +
a O +
consequence O +
of O +
the O +
increased O +
HB24 O +
mRNA O +
levels O +
, O +
the O +
Jurkat B-CellLine +
HB24 I-CellLine +
transfectants I-CellLine +
proliferated O +
more O +
rapidly O +
than O +
control B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Thus O +
, O +
stable O +
expression O +
of O +
HB24 O +
confers O +
an O +
activation O +
phenotype O +
on O +
a O +
human B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
implicating O +
this O +
gene O +
as O +
an O +
important O +
transcriptional O +
factor O +
during O +
T O +
cell O +
activation O +
and O +
growth O +
. O +

Interferon O -
- O -
gamma O +
potentiates O +
the O +
antiviral O +
activity O +
and O +
the O +
expression O +
of O +
interferon O -
- O -
stimulated O +
genes O +
induced O +
by O +
interferon B-CellLine -
- I-CellLine -
alpha I-CellLine +
in I-CellLine +
U937 I-CellLine +
cells I-CellLine +
. O +

Binding O +
of O +
type O +
I O +
interferon O +
( O +
IFN O -
- O -
alpha O -
/ O -
beta O +
) O +
to O +
specific O +
receptors O +
results O +
in O +
the O +
rapid O +
transcriptional O +
activation O +
, O +
independent O +
of O +
protein O +
synthesis O +
, O +
of O +
IFN O -
- O -
alpha O -
- O -
stimulated O +
genes O +
( O +
ISGs O +
) O +
in O +
human O +
fibroblasts O +
and O +
HeLa B-CellLine +
and O +
Daudi B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

The O +
binding O +
of O +
ISGF3 O +
( O +
IFN O -
- O -
stimulated O +
gene O +
factor O +
3 O +
) O +
to O +
the O +
conserved O +
IFN O -
- O -
stimulated O +
response O +
element O +
( O +
ISRE O +
) O +
results O +
in O +
transcriptional O +
activation O +
. O +

This O +
factor O +
is O +
composed O +
of O +
a O +
DNA O -
- O -
binding O +
protein O +
( O +
ISGF3 O +
gamma O +
) O +
, O +
which O +
normally O +
is O +
present O +
in O +
the O +
cytoplasm O +
, O +
and O +
other O +
IFN O -
- O -
alpha O -
- O -
activated O +
proteins O +
which O +
preexist O +
as O +
latent O +
cytoplasmic O +
precursors O +
( O +
ISGF3 O +
alpha O +
) O +
. O +

We O +
have O +
found O +
that O +
ISG O +
expression O +
in O +
the O +
monocytic B-CellLine +
U937 I-CellLine +
cell I-CellLine +
line I-CellLine +
differs O +
from O +
most O +
cell B-CellLine +
lines I-CellLine +
previously O +
examined O +
. O +

U937 B-CellLine +
cells I-CellLine +
express O +
both O +
type O +
I O +
and O +
type O +
II O +
IFN O +
receptors O +
, O +
but O +
only O +
IFN O -
- O -
alpha O +
is O +
capable O +
of O +
inducing O +
antiviral O +
protection O +
in O +
these O +
cells O +
. O +

Pretreatment O +
with O +
IFN O -
- O -
gamma O +
potentiates O +
the O +
IFN O -
- O -
alpha O +
-induced O +
protection O +
, O +
but O +
IFN O -
- O -
gamma O +
alone O +
does O +
not O +
have O +
any O +
antiviral O +
activity O +
. O +

ISG15 O +
mRNA O +
accumulation O +
in O +
U937 B-CellLine +
cells I-CellLine +
is O +
not O +
detectable O +
before O +
6 O +
h O +
of O +
IFN O -
- O -
alpha O +
treatment O +
, O +
peaks O +
at O +
24 O +
h O +
, O +
and O +
requires O +
protein O +
synthesis O +
. O +

Although O +
IFN O -
- O -
gamma O +
alone O +
does O +
not O +
induce O +
ISG O +
expression O +
, O +
IFN O -
- O -
gamma O +
pretreatment O +
markedly O +
increases O +
and O +
hastens O +
ISG O +
expression O +
and O +
transcriptional O +
induction O +
. O +

Nuclear O +
extracts O +
assayed O +
for O +
the O +
presence O +
of O +
ISRE O +
binding O +
factors O +
by O +
electrophoretic O +
mobility O +
shift O +
assays O +
show O +
that O +
ISGF3 O +
is O +
induced O +
by O +
IFN O -
- O -
alpha O +
within O +
6 O +
h O +
from O +
undetectable O +
basal O +
levels O +
in O +
untreated O +
U937 B-CellLine +
cells I-CellLine +
. O +

Activation O +
of O +
ISGF3 O +
alpha O +
, O +
the O +
latent O +
component O +
of O +
ISGF3 O +
, O +
occurs O +
rapidly O +
. O +

However O +
, O +
the O +
increase O +
in O +
ISGF3 O +
activity O +
ultimately O +
correlates O +
with O +
the O +
accumulation O +
of O +
ISGF3 O +
gamma O +
induced O +
by O +
IFN O -
- O -
alpha O +
or O +
IFN O -
- O -
gamma O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

[ O +
Plasma O +
cortisol O +
concentration O +
and O +
blood O +
leukocyte O +
content O +
of O +
glucocorticoid O +
receptors O +
in O +
patients O +
with O +
deficiency O -
- O -
cold O +
vs O +
deficiency O -
- O -
heat O +
syndromes O +
] O +

Plasma O +
cortisol O +
concentration O +
and O +
blood O +
leukocyte O +
content O +
of O +
glucocorticoid O +
receptors O +
( O +
GCR O +
) O +
were O +
assayed O +
in O +
20 O +
patients O +
with O +
deficiency O +
syndromes O +
, O +
10 O +
cold O +
in O +
property O +
( O +
deficiency O -
- O -
cold O +
) O +
, O +
the O +
other O +
10 O +
hot O +
in O +
property O +
( O +
deficiency O -
- O -
heat O +
) O +
, O +
and O +
also O +
in O +
10 O +
healthy O +
individuals O +
as O +
normal O +
control O +
for O +
the O +
purpose O +
of O +
investigating O +
the O +
nature O +
of O +
cold O +
and O +
heat O +
syndromes O +
. O +

As O +
a O +
result O +
, O +
the O +
cases O +
of O +
deficiency O -
- O -
cold O +
syndrome O +
( O +
DCS O +
) O +
had O +
a O +
normal O +
concentration O +
of O +
plasma O +
cortisol O +
but O +
a O +
lowered O +
content O +
of O +
GCR O +
in O +
leukocytes O +
when O +
compared O +
with O +
the O +
normal O +
control O +
( O +
P O +
less O +
than O +
0.05 O +
) O +
; O +
the O +
cases O +
of O +
deficiency O -
- O -
heat O +
syndrome O +
( O +
DHS O +
) O +
had O +
a O +
higher O +
concentration O +
of O +
plasma O +
cortisol O +
than O +
the O +
normal O +
control O +
( O +
P O +
less O +
than O +
0.05 O +
) O +
and O +
a O +
slightly O +
higher O +
content O +
of O +
GCR O +
in O +
leukocytes O +
. O +

It O +
was O +
concluded O +
that O +
the O +
DCS O +
is O +
characterized O +
by O +
diminished O +
biological O +
effects O +
of O +
adrenocortical O +
activity O +
, O +
while O +
the O +
DHS O +
, O +
by O +
augmented O +
biological O +
effects O +
of O +
adrenocortical O +
activity O +
. O +

Protein O +
kinase O +
C O +
activation O +
and O +
protooncogene O +
expression O +
in O +
differentiation O -
/ O -
retrodifferentiation O +
of O +
human B-CellLine +
U-937 I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
. O +

Human B-CellLine +
U-937 I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
differentiate O +
along O +
the O +
monocytic O +
lineage O +
following O +
3-day O +
exposures O +
to O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
. O +

This O +
induction O +
of O +
differentiation O +
is O +
accompanied O +
by O +
adherence O +
and O +
loss O +
of O +
proliferation O +
, O +
as O +
well O +
as O +
expression O -
/ O -
repression O +
of O +
differentiation O -
- O -
associated O +
genes O +
. O +

Long O +
term O +
culture O +
of O +
TPA O -
- O -
differentiated O +
U-937 O +
cells O +
in O +
the O +
absence O +
of O +
phorbol O +
ester O +
for O +
32 O -
- O -
36 O +
days O +
resulted O +
in O +
a O +
process O +
of O +
retrodifferentiation O +
. O +

The O +
retrodifferentiated O +
cells O +
detached O +
from O +
the O +
substrate O +
and O +
reinitiated O +
proliferation O +
. O +

Other O +
cellular O +
parameters O +
, O +
such O +
as O +
glycosidase O +
activities O +
, O +
cytokine O +
release O +
, O +
and O +
filament O +
expression O +
, O +
returned O +
to O +
levels O +
similar O +
to O +
that O +
observed O +
in O +
uninduced O +
cells O +
. O +

Treatment O +
of O +
U-937 B-CellLine +
cells I-CellLine +
with O +
TPA O +
resulted O +
in O +
a O +
rapid O +
translocation O +
of O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
from O +
the O +
cytosol O +
to O +
cell O +
membrane O +
fractions O +
within O +
2 O -
- O -
8 O +
min O +
. O +

Increased O +
levels O +
of O +
membrane O -
- O -
associated O +
PKC O +
activity O +
persisted O +
until O +
17 O -
- O -
29 O +
days O +
. O +

However O +
, O +
longer O +
periods O +
of O +
incubation O +
were O +
associated O +
with O +
a O +
return O +
to O +
the O +
distribution O +
of O +
PKC O +
in O +
control O +
cells O +
. O +

Activation O +
of O +
PKC O +
has O +
been O +
implicated O +
in O +
the O +
regulation O +
of O +
certain O +
immediate O +
early O +
response O +
genes O +
, O +
and O +
in O +
the O +
present O +
studies O +
, O +
TPA O +
rapidly O +
induced O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
gene O +
expression O +
. O +

Levels O +
of O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
transcripts O +
remained O +
elevated O +
during O +
periods O +
of O +
PKC O +
activation O +
and O +
also O +
returned O +
to O +
levels O +
observed O +
in O +
control O +
cells O +
by O +
30 O -
- O -
36 O +
days O +
, O +
when O +
the O +
cells O +
entered O +
retrodifferentiation O +
. O +

Staurosporine O +
, O +
a O +
nonspecific O +
inhibitor O +
of O +
PKC O +
, O +
partially O +
blocked O +
TPA O -
- O -
induced O +
adherence O +
and O +
growth O +
inhibition O +
and O +
concomitantly O +
prevented O +
TPA O -
- O -
induced O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
gene O +
expression O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

The O +
promoter O +
of O +
the O +
CD19 O +
gene O +
is O +
a O +
target O +
for O +
the O +
B O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
BSAP O +
. O +

The O +
CD19 O +
protein O +
is O +
expressed O +
on O +
the O +
surface O +
of O +
all O +
B O -
- O -
lymphoid O +
cells O +
with O +
the O +
exception O +
of O +
terminally O +
differentiated O +
plasma O +
cells O +
and O +
has O +
been O +
implicated O +
as O +
a O +
signal O -
- O -
transducing O +
receptor O +
in O +
the O +
control O +
of O +
proliferation O +
and O +
differentiation O +
. O +

Here O +
we O +
demonstrate O +
complete O +
correlation O +
between O +
the O +
expression O +
pattern O +
of O +
the O +
CD19 O +
gene O +
and O +
the O +
B O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
BSAP O +
in O +
a O +
large O +
panel O +
of O +
B B-CellLine -
- I-CellLine -
lymphoid I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

The O +
human O +
CD19 O +
gene O +
has O +
been O +
cloned O +
, O +
and O +
several O +
BSAP O -
- O -
binding O +
sites O +
have O +
been O +
mapped O +
by O +
in O +
vitro O +
protein O -
- O -
DNA O +
binding O +
studies O +
. O +

In O +
particular O +
, O +
a O +
high O -
- O -
affinity O +
BSAP O -
- O -
binding O +
site O +
instead O +
of O +
a O +
TATA O +
sequence O +
is O +
located O +
in O +
the O +
-30 O +
promoter O +
region O +
upstream O +
of O +
a O +
cluster O +
of O +
heterogeneous O +
transcription O +
start O +
sites O +
. O +

Moreover O +
, O +
this O +
site O +
is O +
occupied O +
by O +
BSAP O +
in O +
vivo O +
in O +
a O +
CD19-expressing B-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
but O +
not O +
in O +
plasma O +
or O +
HeLa B-CellLine +
cells I-CellLine +
. O +

This O +
high O -
- O -
affinity O +
site O +
has O +
been O +
conserved O +
in O +
the O +
promoters O +
of O +
both O +
human O +
and O +
mouse O +
CD19 O +
genes O +
and O +
was O +
furthermore O +
shown O +
to O +
confer O +
B O -
- O -
cell O +
specificity O +
to O +
a O +
beta O -
- O -
globin O +
reporter O +
gene O +
in O +
transient O +
transfection O +
experiments O +
. O +

In O +
addition O +
, O +
BSAP O +
was O +
found O +
to O +
be O +
the O +
only O +
abundant O +
DNA O -
- O -
binding O +
activity O +
of O +
B O -
- O -
cell O +
nuclear O +
extracts O +
that O +
interacts O +
with O +
the O +
CD19 O +
promoter O +
. O +

Together O +
, O +
this O +
evidence O +
strongly O +
implicates O +
BSAP O +
in O +
the O +
regulation O +
of O +
the O +
CD19 O +
gene O +
. O +

Eicosanoids O +
in O +
breast O +
cancer O +
patients O +
before O +
and O +
after O +
mastectomy O +
. O +

In O +
19 O +
patients O +
with O +
a O +
malignant O +
breast O +
tumor O +
, O +
tumor O +
tissue O +
and O +
blood O +
were O +
taken O +
to O +
determine O +
the O +
eicosanoid O +
profile O +
and O +
platelet O +
aggregation O +
. O +

Values O +
were O +
compared O +
with O +
those O +
of O +
patients O +
with O +
benign O +
tumors O +
( O +
n O +
= O +
4 O +
) O +
, O +
or O +
undergoing O +
a O +
mammary O +
reduction O +
( O +
n O +
= O +
7 O +
) O +
. O +

Postoperatively O +
, O +
blood O +
was O +
taken O +
as O +
well O +
in O +
order O +
to O +
compare O +
pre- O +
and O +
postoperative O +
values O +
. O +

Eicosanoids O +
were O +
measured O +
in O +
peripheral O +
blood O +
monocytes O +
and O +
mammary O +
tissue O +
by O +
means O +
of O +
HPLC O +
; O +
furthermore O +
, O +
TXA2 O +
, O +
6-keto O -
- O -
PGF1 O +
alpha O +
, O +
and O +
PGE2 O +
were O +
determined O +
by O +
RIA O +
. O +

Differences O +
in O +
pre- O +
and O +
postoperative O +
values O +
of O +
cancer O +
patients O +
were O +
seen O +
in O +
plasma O +
RIA O +
values O +
: O +
PGE2 O +
and O +
6-k O -
- O -
PGF1 O +
alpha O +
were O +
significantly O +
higher O +
preoperatively O +
when O +
compared O +
with O +
postoperatively O +
, O +
however O +
, O +
such O +
differences O +
were O +
seen O +
in O +
the O +
control O +
groups O +
as O +
well O +
. O +

Compared O +
to O +
benign O +
tumor O +
or O +
mammary O +
reduction O +
test O +
material O +
the O +
eicosanoid O +
profile O +
of O +
tissue O +
obtained O +
from O +
malignant O +
mammary O +
tumors O +
showed O +
important O +
differences O +
. O +

Except O +
for O +
PGF2 O +
alpha O +
, O +
HHT O +
and O +
15-HETE O +
no O +
detectable O +
quantities O +
of O +
eicosanoids O +
were O +
found O +
in O +
the O +
non O -
- O -
tumor O +
material O +
, O +
whereas O +
in O +
the O +
malignant O +
tumor O +
material O +
substantial O +
quantities O +
of O +
a O +
number O +
of O +
eicosanoid O +
metabolites O +
were O +
present O +
. O +

Statistically O +
significant O +
correlations O +
could O +
be O +
established O +
between O +
patient O -
/ O -
histopathology O +
data O +
and O +
the O +
results O +
of O +
the O +
platelet O +
aggregation O +
assays O +
, O +
e.g. O +
between O +
menopausal O +
status O +
and O +
ADP O +
aggregation O +
; O +
oestrogen O +
receptor O +
( O +
+ O -
/- O +
) O +
and O +
collagen O +
and O +
arachidonic O +
acid O +
aggregation O +
, O +
inflammatory O +
cell O +
infiltration O +
score O +
and O +
arachidonic O +
acid O +
aggregation O +
and O +
fibrosis O +
score O +
and O +
ADP O +
aggregation O +
. O +

The O +
results O +
show O +
that O +
eicosanoid O +
synthesis O +
in O +
material O +
from O +
mammary O +
cancer O +
patients O +
is O +
different O +
from O +
that O +
in O +
benign O +
mammary O +
tissue O +
. O +

The O +
implications O +
, O +
in O +
particular O +
, O +
in O +
relation O +
to O +
future O +
prognosis O +
of O +
the O +
patient O +
, O +
remain O +
obscure O +
. O +

c O -
- O -
myc O +
mRNA O +
expression O +
in O +
minor O +
salivary O +
glands O +
of O +
patients O +
with O +
Sjogren O +
's O +
syndrome O +
. O +

c O -
- O -
myc O +
protooncogene O +
is O +
implicated O +
in O +
the O +
pathogenesis O +
of O +
B O +
cell O +
lymphoid O +
malignancies O +
and O +
high O +
levels O +
of O +
c O -
- O -
myc O +
mRNA O +
expression O +
are O +
observed O +
in O +
activated O +
blood O +
mononuclear O +
cells O +
. O +

Sjogren O +
's O +
syndrome O +
( O +
SS O +
) O +
is O +
characterized O +
by O +
lymphocytic O +
infiltrates O +
of O +
exocrine O +
glands O +
, O +
remarkable O +
B O +
cell O +
hyperreactivity O +
and O +
a O +
strong O +
predisposition O +
to O +
B O +
cell O +
neoplasia O +
. O +

In O +
this O +
study O +
, O +
c O -
- O -
myc O +
protooncogene O +
mRNA O +
expression O +
in O +
29 O +
labial O +
minor O +
salivary O +
gland O +
biopsies O +
from O +
patients O +
with O +
primary O +
SS O +
and O +
15 O +
controls O +
was O +
examined O +
using O +
in O +
situ O +
hybridization O +
histochemistry O +
. O +

Two O +
40mer O +
oligonucleotides O +
from O +
the O +
1st O +
and O +
the O +
2nd O +
exon O +
of O +
the O +
c O -
- O -
myc O +
gene O +
, O +
labeled O +
with O +
35S O +
, O +
were O +
used O +
as O +
probes O +
. O +

To O +
detect O +
the O +
origin O +
of O +
the O +
cell O +
hybridized O +
with O +
a O +
c O -
- O -
myc O +
probe O +
, O +
a O +
combined O +
immunochemistry O +
in O +
situ O +
hybridization O +
histochemistry O +
technique O +
was O +
used O +
. O +

High O +
c O -
- O -
myc O +
mRNA O +
expression O +
was O +
detected O +
on O +
acinar O +
epithelial O +
cells O +
. O +

c O -
- O -
myc O +
did O +
not O +
correlate O +
with O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
protein O +
expression O +
. O +

Stronger O +
c O -
- O -
myc O +
mRNA O +
expression O +
was O +
detected O +
in O +
labial O +
salivary O +
glands O +
of O +
patients O +
with O +
longer O +
disease O +
duration O +
( O +
p O +
less O +
than O +
or O +
equal O +
to O +
0.002 O +
) O +
and O +
more O +
intense O +
T O +
lymphocyte O +
infiltrates O +
( O +
p O +
less O +
than O +
0.05 O +
) O +
although O +
these O +
patients O +
revealed O +
no O +
hypergammaglobulinemia O +
. O +

No O +
correlation O +
was O +
observed O +
between O +
c O -
- O -
myc O +
mRNA O +
and O +
B O +
lymphocyte O +
monoclonicity O +
or O +
lymphoma O +
. O +

In O +
conclusion O +
, O +
strong O +
c O -
- O -
myc O +
mRNA O +
expression O +
was O +
observed O +
on O +
epithelial O +
cells O +
of O +
labial O +
salivary O +
glands O +
from O +
patients O +
with O +
primary O +
SS O +
. O +

Our O +
findings O +
may O +
indicate O +
the O +
presence O +
of O +
a O +
reactivated O +
virus O +
hosted O +
in O +
these O +
cells O +
. O +

Cytoplasmic O +
domain O +
heterogeneity O +
and O +
functions O +
of O +
IgG O +
Fc O +
receptors O +
in O +
B O +
lymphocytes O +
. O +

B O +
lymphocytes O +
and O +
macrophages O +
express O +
closely O +
related O +
immunoglobulin O +
G O +
( O +
IgG O +
) O +
Fc O +
receptors O +
( O +
Fc O +
gamma O +
RII O +
) O +
that O +
differ O +
only O +
in O +
the O +
structures O +
of O +
their O +
cytoplasmic O +
domains O +
. O +

Because O +
of O +
cell O +
type O -
- O -
specific O +
alternative O +
messenger O +
RNA O +
splicing O +
, O +
B O -
- O -
cell O +
Fc O +
gamma O +
RII O +
contains O +
an O +
insertion O +
of O +
47 O +
amino O +
acids O +
that O +
participates O +
in O +
determining O +
receptor O +
function O +
in O +
these O +
cells O +
. O +

Transfection O +
of O +
an O +
Fc B-CellLine +
gamma I-CellLine +
RII I-CellLine -
- I-CellLine -
negative I-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
with O +
complementary O +
DNA O +
's O +
encoding O +
the O +
two O +
splice O +
products O +
and O +
various O +
receptor O +
mutants O +
indicated O +
that O +
the O +
insertion O +
was O +
responsible O +
for O +
preventing O +
both O +
Fc O +
gamma O +
RII O +
-mediated O +
endocytosis O +
and O +
Fc O +
gamma O +
RII O +
-mediated O +
antigen O +
presentation O +
. O +

The O +
insertion O +
was O +
not O +
required O +
for O +
Fc O +
gamma O +
RII O +
to O +
modulate O +
surface O +
immunoglobulin O +
-triggered O +
B O -
- O -
cell O +
activation O +
. O +

Instead O +
, O +
regulation O +
of O +
activation O +
involved O +
a O +
region O +
of O +
the O +
cytoplasmic O +
domain O +
common O +
to O +
both O +
the O +
lymphocyte O +
and O +
macrophage O +
receptor O +
isoforms O +
. O +

In O +
contrast O +
, O +
the O +
insertion O +
did O +
contribute O +
to O +
the O +
formation O +
of O +
caps O +
in O +
response O +
to O +
receptor O +
cross O -
- O -
linking O +
, O +
consistent O +
with O +
suggestions O +
that O +
the O +
lymphocyte O +
but O +
not O +
macrophage O +
form O +
of O +
the O +
receptor O +
can O +
associate O +
with O +
the O +
detergent O -
- O -
insoluble O +
cytoskeleton O +
. O +

Heterodimerization O +
and O +
transcriptional O +
activation O +
in O +
vitro O +
by O +
NF O -
- O -
kappa O +
B O +
proteins O +
. O +

The O +
NF O -
- O -
kappa O +
B O +
family O +
of O +
transcription O +
proteins O +
represents O +
multiple O +
DNA O +
binding O +
, O +
rel O +
related O +
polypeptides O +
that O +
contribute O +
to O +
regulation O +
of O +
genes O +
involved O +
in O +
immune O +
responsiveness O +
and O +
inflammation O +
, O +
as O +
well O +
as O +
activation O +
of O +
the O +
HIV O +
long O +
terminal O +
repeat O +
. O +

In O +
this O +
study O +
multiple O +
NF O -
- O -
kappa O +
B O +
related O +
polypeptides O +
ranging O +
from O +
85 O +
to O +
45 O +
kDa O +
were O +
examined O +
for O +
their O +
capacity O +
to O +
interact O +
with O +
the O +
PRDII O +
regulatory O +
element O +
of O +
interferon O +
beta O +
and O +
were O +
shown O +
to O +
possess O +
distinct O +
intrinsic O +
DNA O +
binding O +
affinities O +
for O +
this O +
NF O -
- O -
kappa O +
B O +
site O +
and O +
form O +
multiple O +
DNA O +
binding O +
homo- O +
and O +
heterodimer O +
complexes O +
in O +
co O -
- O -
renaturation O +
experiments O +
. O +

Furthermore O +
, O +
using O +
DNA O +
templates O +
containing O +
two O +
copies O +
of O +
the O +
PRDII O +
domain O +
linked O +
to O +
the O +
rabbit O +
beta O +
globin O +
gene O +
, O +
the O +
purified O +
polypeptides O +
specifically O +
stimulated O +
NF O -
- O -
kappa O +
B O +
dependent O +
transcription O +
in O +
an O +
in O +
vitro O +
reconstitution O +
assay O +
as O +
heterodimers O +
but O +
not O +
as O +
p50 O +
homodimers O +
. O +

These O +
experiments O +
emphasize O +
the O +
role O +
of O +
NF O -
- O -
kappa O +
B O +
dimerization O +
as O +
a O +
distinct O +
level O +
of O +
transcriptional O +
control O +
that O +
may O +
permit O +
functional O +
diversification O +
of O +
a O +
limited O +
number O +
of O +
regulatory O +
proteins O +
. O +

Induction O +
of O +
the O +
POU O +
domain O +
transcription O +
factor O +
Oct-2 O +
during O +
T O -
- O -
cell O +
activation O +
by O +
cognate O +
antigen O +
. O +

Oct-2 O +
is O +
a O +
transcription O +
factor O +
that O +
binds O +
specifically O +
to O +
octamer O +
DNA O +
motifs O +
in O +
the O +
promoters O +
of O +
immunoglobulin O +
and O +
interleukin-2 O +
genes O +
. O +

All O +
tumor B-CellLine +
cell I-CellLine +
lines I-CellLine +
from O +
the O +
B O -
- O -
cell O +
lineage O +
and O +
a O +
few O +
from O +
the O +
T O -
- O -
cell O +
lineage O +
express O +
Oct-2 O +
. O +

To O +
address O +
the O +
role O +
of O +
Oct-2 O +
in O +
the O +
T O -
- O -
cell O +
lineage O +
, O +
we O +
studied O +
the O +
expression O +
of O +
Oct-2 O +
mRNA O +
and O +
protein O +
in O +
nontransformed B-CellLine +
human I-CellLine +
and I-CellLine +
mouse I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Oct-2 O +
was O +
found O +
in O +
CD4 B-CellLine -
+ I-CellLine +
and I-CellLine +
CD8 I-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
prepared O +
from O +
human O +
peripheral O +
blood O +
and O +
in O +
mouse O +
lymph O +
node O +
T O +
cells O +
. O +

In O +
a O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
clone I-CellLine +
specific O +
for O +
pigeon O +
cytochrome O +
c O +
in O +
the O +
context O +
of O +
I O -
- O -
Ek O +
, O +
Oct-2 O +
was O +
induced O +
by O +
antigen O +
stimulation O +
, O +
with O +
the O +
increase O +
in O +
Oct-2 O +
protein O +
seen O +
first O +
at O +
3 O +
h O +
after O +
activation O +
and O +
continuing O +
for O +
at O +
least O +
24 O +
h O +
. O +

Oct-2 O +
mRNA O +
induction O +
during O +
antigen O -
- O -
driven O +
T O -
- O -
cell O +
activation O +
was O +
blocked O +
by O +
cyclosporin O +
A O +
, O +
as O +
well O +
as O +
by O +
protein O +
synthesis O +
inhibitors O +
. O +

These O +
results O +
suggest O +
that O +
Oct-2 O +
participates O +
in O +
transcriptional O +
regulation O +
during O +
T O -
- O -
cell O +
activation O -
. O +
The O +
relatively O +
delayed O +
kinetics O +
of O +
Oct-2 O +
induction O +
suggests O +
that O +
Oct-2 O +
mediates O +
the O +
changes O +
in O +
gene O +
expression O +
which O +
occur O +
many O +
hours O +
or O +
days O +
following O +
antigen O +
stimulation O +
of O +
T O +
lymphocytes O +
. O +

[ O +
Changes O +
in O +
plasma O +
interleukin-1 O +
and O +
their O +
possible O +
relationship O +
with O +
the O +
changes O +
in O +
glucocorticoid O +
receptor O +
in O +
aged O +
long O -
- O -
distance O +
runner O +
] O +

For O +
the O +
study O +
of O +
the O +
changes O +
in O +
plasma O +
interleukin-1 O +
( O +
IL-1 O +
) O +
and O +
their O +
possible O +
relationship O +
with O +
the O +
changes O +
in O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
, O +
plasma O +
IL-1 O +
and O +
GR O +
in O +
peripheral O +
blood O +
leukocytes O +
in O +
aged O +
long O -
- O -
distance O +
runner O +
were O +
measured O +
simultaneously O +
. O +

The O +
activity O +
of O +
IL-1 O +
was O +
expressed O +
as O +
its O +
ability O +
to O +
stimulate O +
3H O -
- O -
TdR O +
incorporation O +
in O +
the O +
thymocytes O +
of O +
C57 O +
mice O +
. O +

GR O +
was O +
determined O +
by O +
whole O +
cell O +
assay O +
with O +
3H O -
- O -
Dex O +
. O +

The O +
results O +
showed O +
that O +
the O +
activity O +
of O +
plasma O +
IL-1 O +
in O +
aged O +
long O -
- O -
distance O +
runner O +
was O +
209 O +
% O +
, O +
223 O +
% O +
and O +
145 O +
% O +
of O +
the O +
control O +
at O +
14.7 O -
- O -
18.7 O +
, O +
3.8 O -
- O -
7.0 O +
and O +
1.5 O -
- O -
2.6 O +
KD O +
fractions O +
. O +

The O +
GR O +
in O +
peripheral O +
blood O +
leukocytes O +
in O +
aged O +
runner O +
was O +
65 O +
% O +
of O +
the O +
control O +
. O +

Possible O +
relationship O +
between O +
the O +
changes O +
in O +
IL-1 O +
and O +
GR O +
in O +
aged O +
long O -
- O -
distance O +
runner O +
and O +
its O +
physiological O +
significance O +
are O +
discussed O +
. O +

Transcription O +
factor O +
AP-2 O +
activates O +
gene O +
expression O +
of O +
HTLV O -
- O -
I O +
. O +

The O +
HTLV O -
- O -
I O +
LTR O +
contains O +
three O +
conserved O +
regulatory O +
elements O +
known O +
as O +
21 O +
base O +
pair O +
repeats O +
which O +
are O +
required O +
for O +
stimulation O +
of O +
gene O +
expression O +
by O +
the O +
transactivator O +
protein O +
tax O +
. O +

Mutagenesis O +
indicates O +
that O +
the O +
21 O +
bp O +
repeats O +
can O +
be O +
subdivided O +
into O +
three O +
motifs O +
, O +
A O +
, O +
B O +
and O +
C O +
, O +
each O +
of O +
which O +
influences O +
the O +
level O +
of O +
tax O +
activation O +
. O +

The O +
A O +
site O +
in O +
the O +
21 O +
bp O +
repeat O +
has O +
strong O +
homology O +
with O +
previously O +
described O +
binding O +
sites O +
for O +
the O +
transcription O +
factor O +
AP-2 O +
. O +

We O +
demonstrated O +
that O +
AP-2 O +
mRNA O +
was O +
present O +
in O +
T O -
- O -
lymphocytes O +
and O +
that O +
cellular O +
factors O +
from O +
both O +
non O -
- O -
transformed O +
and O +
transformed O +
T O -
- O -
lymphocytes O +
specifically O +
bound O +
to O +
the O +
consensus O +
motif O +
for O +
AP-2 O +
in O +
each O +
21 O +
bp O +
. O +

To O +
determine O +
the O +
role O +
of O +
AP-2 O +
in O +
the O +
regulation O +
of O +
the O +
HTLV O -
- O -
I O +
LTR O +
gene O +
expression O +
, O +
we O +
used O +
an O +
AP-2 O +
cDNA O +
in O +
DNA O +
binding O +
and O +
transient O +
expression O +
assays O +
. O +

Gel O +
retardation O +
and O +
methylation O +
interference O +
studies O +
revealed O +
that O +
bacterially O +
produced O +
AP-2 O +
bound O +
specifically O +
and O +
with O +
high O +
affinity O +
to O +
all O +
three O +
21 O +
bp O +
repeats O +
, O +
and O +
that O +
it O +
required O +
the O +
core O +
sequence O +
AGGC O +
for O +
specific O +
binding O +
. O +

Binding O +
of O +
AP-2 O +
prevented O +
the O +
subsequent O +
binding O +
of O +
members O +
of O +
the O +
CREB O -
/ O -
ATF O +
family O +
to O +
an O +
adjacent O +
regulatory O +
motif O +
in O +
the O +
21 O +
bp O +
repeat O +
. O +

Transfection O +
of O +
an O +
AP-2 O +
expression O +
construct O +
into O +
T O -
- O -
lymphocytes O +
activated O +
gene O +
expression O +
from O +
the O +
HTLV O -
- O -
I O +
LTR O +
. O +

At O +
least O +
two O +
21 O +
bp O +
repeats O +
were O +
required O +
for O +
high O +
levels O +
of O +
AP-2 O +
activation O +
and O +
mutagenesis O +
of O +
the O +
AP-2 O +
consensus O +
binding O +
sequences O +
in O +
the O +
21 O +
bp O +
repeats O +
eliminate O +
this O +
activation O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

In O +
vivo O +
footprint O +
analysis O +
of O +
the O +
HLA O -
- O -
DRA O +
gene O +
promoter O +
: O +
cell O -
- O -
specific O +
interaction O +
at O +
the O +
octamer O +
site O +
and O +
up O -
- O -
regulation O +
of O +
X O +
box O +
binding O +
by O +
interferon O +
gamma O +
. O +

Analysis O +
of O +
the O +
major O +
histocompatibility O +
complex O +
class O +
II O +
gene O +
promoter O +
DRA O +
has O +
previously O +
identified O +
at O +
least O +
five O +
cis O -
- O -
acting O +
regions O +
required O +
for O +
maximal O +
expression O +
. O +

We O +
have O +
examined O +
the O +
DRA O +
promoter O +
for O +
protein O -
- O -
DNA O +
interactions O +
in O +
the O +
intact O +
cell O +
, O +
which O +
may O +
mediate O +
transcriptional O +
activation O +
. O +

Using O +
in O +
vivo O +
genomic O +
footprinting O +
we O +
identified O +
interactions O +
in O +
B B-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
at O +
the O +
octamer O +
site O +
and O +
the O +
Y O +
, O +
X1 O +
, O +
and O +
X2 O +
boxes O +
. O +

Class B-CellLine +
II I-CellLine +
antigen I-CellLine +
expressing I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
maintained O +
contacts O +
identical O +
to O +
B B-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
, O +
while O +
class B-CellLine +
II I-CellLine -
- I-CellLine -
negative I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
exhibited O +
no O +
interactions O +
. O +

In O +
lymphoid B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
the O +
octamer O +
site O +
is O +
occupied O +
and O +
required O +
for O +
maximal O +
expression O +
. O +

This O +
is O +
most O +
likely O +
due O +
to O +
the O +
presence O +
of O +
the O +
lymphoid O -
- O -
specific O +
OTF-2 O +
factor O +
. O +

In O +
contrast O +
, O +
the O +
class B-CellLine +
II I-CellLine -
- I-CellLine -
positive I-CellLine +
nonlymphoid I-CellLine +
glioblastoma I-CellLine +
cell I-CellLine +
line I-CellLine +
does O +
not O +
exhibit O +
interactions O +
at O +
the O +
octamer O +
site O +
despite O +
the O +
presence O +
of O +
the O +
ubiquitous O +
OTF-1 O +
factor O +
and O +
an O +
open O +
binding O +
site O +
. O +

Thus O +
, O +
the O +
DRA O +
promoter O +
discriminates O +
against O +
OTF-1 O +
activation O +
at O +
the O +
level O +
of O +
DNA O +
binding O +
in O +
the O +
glioblastoma B-CellLine +
line I-CellLine +
. O +

Interferon O +
gamma O +
induces O +
class O +
II O +
expression O +
in O +
this O +
glioblastoma B-CellLine +
cell I-CellLine +
line I-CellLine +
and O +
, O +
in O +
parallel O +
, O +
up O -
- O -
regulates O +
X1 O +
and O +
X2 O +
box O +
protein O -
- O -
DNA O +
interactions O +
, O +
while O +
all O +
other O +
interactions O +
remain O +
unchanged O +
. O +

These O +
results O +
suggest O +
that O +
interferon O +
gamma O +
functions O +
on O +
a O +
poised O +
promoter O +
by O +
altering O +
weak O +
, O +
nonproductive O +
interactions O +
at O +
the O +
X O +
boxes O +
to O +
strong O +
interactions O +
. O +

These O +
findings O +
provide O +
direct O +
in O +
vivo O +
evidence O +
to O +
strongly O +
suggest O +
that O +
the O +
modulation O +
of O +
X1 O +
and O +
X2 O +
interactions O +
is O +
an O +
important O +
constituent O +
of O +
the O +
interferon O +
gamma O +
induction O +
pathway O +
. O +

Simple O +
derivation O +
of O +
TFIID O -
- O -
dependent O +
RNA O +
polymerase O +
II O +
transcription O +
systems O +
from O +
Schizosaccharomyces O +
pombe O +
and O +
other O +
organisms O +
, O +
and O +
factors O +
required O +
for O +
transcriptional O +
activation O +
. O +

Resolution O +
of O +
whole O +
cell O +
extract O +
through O +
two O +
chromatographic O +
steps O +
yields O +
a O +
single O +
protein O +
fraction O +
requiring O +
only O +
the O +
addition O +
of O +
TFIID O +
for O +
the O +
initiation O +
of O +
transcription O +
at O +
RNA O +
polymerase O +
II O +
promoters O +
. O +

This O +
approach O +
allows O +
the O +
convenient O +
generation O +
of O +
RNA O +
polymerase O +
II O +
transcription O +
systems O +
from O +
Saccharomyces O +
cerevisiae O +
, O +
human O +
lymphocytes O +
, O +
and O +
Schizosaccharomyces O +
pombe O +
. O +

TFIIDs O +
from O +
all O +
three O +
organisms O +
are O +
interchangeable O +
among O +
all O +
three O +
systems O +
. O +

The O +
S. O +
cerevisiae O +
and O +
Sch O -
. O +
pombe O +
systems O +
support O +
effects O +
of O +
acidic O +
activator O +
proteins O +
, O +
provided O +
a O +
further O +
protein O +
fraction O +
from O +
S. O +
cerevisiae O +
is O +
supplied O +
. O +

This O +
further O +
fraction O +
is O +
distinct O +
from O +
the O +
mediator O +
of O +
transcriptional O +
activation O +
described O +
previously O +
and O +
represents O +
a O +
second O +
component O +
in O +
addition O +
to O +
general O +
initiation O +
factors O +
that O +
may O +
facilitate O +
a O +
response O +
to O +
acidic O +
activators O +
. O +

The O +
development O +
of O +
functionally O +
responsive O +
T O +
cells O +
. O +

The O +
work O +
reviewed O +
in O +
this O +
article O +
separates O +
T O +
cell O +
development O +
into O +
four O +
phases O +
. O +

First O +
is O +
an O +
expansion O +
phase O +
prior O +
to O +
TCR O +
rearrangement O +
, O +
which O +
appears O +
to O +
be O +
correlated O +
with O +
programming O +
of O +
at O +
least O +
some O +
response O +
genes O +
for O +
inducibility O +
. O +

This O +
phase O +
can O +
occur O +
to O +
some O +
extent O +
outside O +
of O +
the O +
thymus O +
. O +

However O +
, O +
the O +
profound O +
T O +
cell O +
deficit O +
of O +
nude O +
mice O +
indicates O +
that O +
the O +
thymus O +
is O +
by O +
far O +
the O +
most O +
potent O +
site O +
for O +
inducing O +
the O +
expansion O +
per O +
se O +
, O +
even O +
if O +
other O +
sites O +
can O +
induce O +
some O +
response O +
acquisition O +
. O +

Second O +
is O +
a O +
controlled O +
phase O +
of O +
TCR O +
gene O +
rearrangement O +
. O +

The O +
details O +
of O +
the O +
regulatory O +
mechanism O +
that O +
selects O +
particular O +
loci O +
for O +
rearrangement O +
are O +
still O +
not O +
known O +
. O +

It O +
seems O +
that O +
the O +
rearrangement O +
of O +
the O +
TCR O +
gamma O +
loci O +
in O +
the O +
gamma O +
delta O +
lineage O +
may O +
not O +
always O +
take O +
place O +
at O +
a O +
developmental O +
stage O +
strictly O +
equivalent O +
to O +
the O +
rearrangement O +
of O +
TCR O +
beta O +
in O +
the O +
alpha O +
beta O +
lineage O +
, O +
and O +
it O +
is O +
not O +
clear O +
just O +
how O +
early O +
the O +
two O +
lineages O +
diverge O +
. O +

In O +
the O +
TCR O +
alpha O +
beta O +
lineage O +
, O +
however O +
, O +
the O +
final O +
gene O +
rearrangement O +
events O +
are O +
accompanied O +
by O +
rapid O +
proliferation O +
and O +
an O +
interruption O +
in O +
cellular O +
response O +
gene O +
inducibility O +
. O +

The O +
loss O +
of O +
conventional O +
responsiveness O +
is O +
probably O +
caused O +
by O +
alterations O +
at O +
the O +
level O +
of O +
signaling O +
, O +
and O +
may O +
be O +
a O +
manifestation O +
of O +
the O +
physiological O +
state O +
that O +
is O +
a O +
precondition O +
for O +
selection O +
. O +

Third O +
is O +
the O +
complex O +
process O +
of O +
selection O +
. O +

Whereas O +
peripheral O +
T O +
cells O +
can O +
undergo O +
forms O +
of O +
positive O +
selection O +
( O +
by O +
antigen O -
- O -
driven O +
clonal O +
expansion O +
) O +
and O +
negative O +
selection O +
( O +
by O +
abortive O +
stimulation O +
leading O +
to O +
anergy O +
or O +
death O +
) O +
, O +
neither O +
is O +
exactly O +
the O +
same O +
phenomenon O +
that O +
occurs O +
in O +
the O +
thymic O +
cortex O +
. O +

Negative O +
selection O +
in O +
the O +
cortex O +
appears O +
to O +
be O +
a O +
suicidal O +
inversion O +
of O +
antigen O +
responsiveness O +
: O +
instead O +
of O +
turning O +
on O +
IL-2 O +
expression O +
, O +
the O +
activated O +
cell O +
destroys O +
its O +
own O +
chromatin O +
. O +

The O +
genes O +
that O +
need O +
to O +
be O +
induced O +
for O +
this O +
response O +
are O +
not O +
yet O +
identified O +
, O +
but O +
it O +
is O +
unquestionably O +
a O +
form O +
of O +
activation O +
. O +

It O +
is O +
interesting O +
that O +
in O +
humans O +
and O +
rats O +
, O +
cortical O +
thymocytes O +
undergoing O +
negative O +
selection O +
can O +
still O +
induce O +
IL-2R O +
alpha O +
expression O +
and O +
even O +
be O +
rescued O +
in O +
vitro O +
, O +
if O +
exogenous O +
IL-2 O +
is O +
provided O +
. O +

Perhaps O +
murine O +
thymocytes O +
are O +
denied O +
this O +
form O +
of O +
rescue O +
because O +
they O +
shut O +
off O +
IL-2R O +
beta O +
chain O +
expression O +
at O +
an O +
earlier O +
stage O +
or O +
because O +
they O +
may O +
be O +
uncommonly O +
Bcl-2 O +
deficient O +
( O +
cf O -
. O +
Sentman O +
et O +
al. O +
, O +
1991 O +
; O +
Strasser O +
et O +
al. O +
, O +
1991 O +
) O +
. O +

Even O +
so O +
, O +
medullary O +
thymocytes O +
remain O +
at O +
least O +
partially O +
susceptible O +
to O +
negative O +
selection O +
even O +
as O +
they O +
continue O +
to O +
mature O +
. O +

SRC O -
- O -
related O +
proto O -
- O -
oncogenes O +
and O +
transcription O +
factors O +
in O +
primary O +
human O +
T O +
cells O +
: O +
modulation O +
by O +
cyclosporin O +
A O +
and O +
FK506 O +
. O +

Activation O +
of O +
T O +
lymphocytes O +
induces O +
transcription O +
of O +
genes O +
encoding O +
for O +
lymphokines O +
. O +

Interleukin-2 O +
( O +
IL-2 O +
) O +
gene O +
expression O +
is O +
controlled O +
transcriptionally O +
by O +
the O +
cooperative O +
activity O +
of O +
specific O +
trans O -
- O -
activating O +
factors O +
that O +
bind O +
to O +
the O +
IL-2 O +
enhancer O +
. O +

Cyclosporin O +
A O +
( O +
CsA O +
) O +
and O +
FK506 O +
inhibit O +
the O +
production O +
of O +
IL-2 O +
in O +
T O +
lymphocytes O +
at O +
the O +
level O +
of O +
gene O +
transcription O +
. O +

A O +
member O +
of O +
the O +
src O +
gene O +
family O +
, O +
the O +
lymphocyte O -
- O -
specific O +
protein O +
tyrosine O +
kinase O +
, O +
p56lck O +
, O +
has O +
been O +
implicated O +
in O +
IL-2 O +
production O +
. O +

CsA O +
was O +
found O +
not O +
to O +
inhibit O +
lck O +
gene O +
expression O +
, O +
nor O +
the O +
activity O +
of O +
the O +
lck O +
gene O +
product O +
. O +

However O +
, O +
CsA O +
and O +
FK506 O +
inhibit O +
the O +
appearance O +
of O +
DNA O +
binding O +
activity O +
of O +
factors O +
that O +
bind O +
to O +
the O +
NF O -
- O -
AT O +
and O +
AP-1 O +
sites O +
in O +
the O +
IL-2 O +
enhancer O +
. O +

Since O +
the O +
induction O +
of O +
NF O -
- O -
AT O +
and O +
AP-1 O +
is O +
induced O +
by O +
the O +
same O +
stimuli O +
that O +
stimulate O +
IL-2 O +
production O +
, O +
these O +
results O +
indicate O +
that O +
the O +
immunosuppressant O +
action O +
of O +
CsA O +
and O +
FK506 O +
is O +
exerted O +
at O +
the O +
level O +
of O +
these O +
trans O -
- O -
activating O +
factors O +
. O +

Bcl-2 O +
: O +
a O +
repressor O +
of O +
lymphocyte O +
death O +
. O +

The O +
genes O +
and O +
mechanisms O +
that O +
control O +
programmed O +
cell O +
death O +
are O +
currently O +
the O +
subject O +
of O +
intense O +
study O +
. O +

The O +
bcl-2 O +
gene O +
, O +
a O +
repressor O +
of O +
lymphocyte O +
death O +
, O +
is O +
perhaps O +
the O +
best O +
understood O +
of O +
the O +
programmed O +
cell O +
death O +
associated O +
genes O +
. O +

Here O +
, O +
Stanley O +
Korsmeyer O +
provides O +
a O +
brief O +
overview O +
of O +
bcl-2 O +
, O +
concentrating O +
on O +
its O +
roles O +
in O +
B- O +
and O +
T O -
- O -
cell O +
development O +
and O +
in O +
oncogenesis O +
. O +

Mitogen O +
stimulation O +
of O +
T O -
- O -
cells O +
increases O +
c O -
- O -
Fos O +
and O +
c O -
- O -
Jun O +
protein O +
levels O +
, O +
AP-1 O +
binding O +
and O +
AP-1 O +
transcriptional O +
activity O +
. O +

We O +
have O +
analysed O +
the O +
effect O +
of O +
mitogenic O +
lectins O +
on O +
c O -
- O -
Fos O +
and O +
c O -
- O -
Jun O +
protein O +
levels O +
as O +
well O +
as O +
on O +
activator O +
protein-1 O +
( O +
AP-1 O +
) O +
binding O +
and O +
enhancer O +
activity O +
in O +
Jurkat O +
T O -
- O -
cells O +
. O +

Both O +
c O -
- O -
Fos O +
and O +
c O -
- O -
Jun O +
protein O +
levels O +
were O +
increased O +
after O +
Con O +
A O +
and O +
PHA O +
stimulation O +
. O +

Since O +
T O -
- O -
cell O +
stimulation O +
increases O +
both O +
intracellular O +
Ca2 O -
+ O +
and O +
cAMP O +
levels O +
and O +
activates O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
, O +
the O +
possible O +
involvement O +
of O +
these O +
intracellular O +
messengers O +
in O +
c O -
- O -
Fos O +
and O +
c O -
- O -
Jun O +
induction O +
was O +
tested O +
. O +

PMA O +
, O +
which O +
directly O +
activates O +
PKC O +
, O +
mimicked O +
the O +
effect O +
of O +
the O +
lectins O +
on O +
c O -
- O -
Fos O +
and O +
c O -
- O -
Jun O +
, O +
but O +
elevation O +
of O +
either O +
intracellular O +
Ca2 O -
+ O +
or O +
cAMP O +
levels O +
had O +
little O +
or O +
no O +
effect O +
. O +

The O +
mitogen O -
- O -
induced O +
increase O +
of O +
c O -
- O -
Fos O +
and O +
c O -
- O -
Jun O +
immunoreactivity O +
was O +
inhibited O +
by O +
H-7 O +
, O +
a O +
kinase O +
inhibitor O +
with O +
relatively O +
high O +
specificity O +
for O +
PKC O +
, O +
and O +
less O +
efficiently O +
by O +
H-8 O +
, O +
a O +
structurally O +
related O +
kinase O +
inhibitor O +
less O +
active O +
on O +
PKC O +
, O +
but O +
more O +
active O +
on O +
cyclic O +
nucleotide O -
- O -
dependent O +
kinases O +
. O +

Con O +
A O +
stimulation O +
was O +
found O +
to O +
increase O +
both O +
binding O +
of O +
AP-1 O +
to O +
the O +
AP-1 O +
consensus O +
sequence O +
, O +
TRE O +
, O +
and O +
AP-1 O +
enhancer O +
activity O +
, O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

PMA O +
was O +
also O +
found O +
to O +
increase O +
the O +
AP-1 O +
enhancer O +
activity O +
, O +
whereas O +
elevation O +
of O +
Ca2 O -
+ O +
or O +
cAMP O +
had O +
only O +
minor O +
effects O +
. O +

We O +
conclude O +
that O +
stimulation O +
with O +
mitogenic O +
lectins O +
is O +
sufficient O +
to O +
increase O +
both O +
c O -
- O -
Fos O +
and O +
c O -
- O -
Jun O +
protein O +
levels O +
, O +
AP-1 O +
binding O +
and O +
AP-1 O +
enhancer O +
activity O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
and O +
that O +
they O +
act O +
via O +
mechanisms O +
that O +
could O +
involve O +
the O +
activation O +
of O +
PKC O +
. O +

Functional O +
interaction O +
between O +
the O +
two O +
zinc O +
finger O +
domains O +
of O +
the O +
v O -
- O -
erb O +
A O +
oncoprotein O +
. O +

The O +
v O -
- O -
erb O +
A O +
oncogene O +
of O +
avian O +
erythroblastosis O +
virus O +
is O +
a O +
mutated O +
and O +
virally O +
transduced O +
copy O +
of O +
a O +
host O +
cell O +
gene O +
encoding O +
a O +
thyroid O +
hormone O +
receptor O +
. O +

The O +
protein O +
expressed O +
by O +
the O +
v O -
- O -
erb O +
A O +
oncogene O +
binds O +
to O +
DNA O +
and O +
acts O +
as O +
a O +
dominant O +
negative O +
inhibitor O +
of O +
both O +
the O +
thyroid O +
hormone O +
receptor O +
and O +
the O +
closely O +
related O +
retinoic O +
acid O +
receptor O +
. O +

The O +
v O -
- O -
erb O +
A O +
protein O +
has O +
sustained O +
two O +
amino O +
acid O +
alterations O +
within O +
its O +
DNA O -
- O -
binding O +
domain O +
relative O +
to O +
that O +
of O +
c O -
- O -
erb O +
A O +
, O +
one O +
of O +
which O +
, O +
at O +
serine O +
61 O +
, O +
is O +
known O +
to O +
be O +
important O +
for O +
v O -
- O -
erb O +
A O +
function O +
in O +
the O +
neoplastic O +
cell O +
. O +

We O +
report O +
here O +
that O +
the O +
second O +
alteration O +
, O +
at O +
threonine O +
78 O +
, O +
also O +
plays O +
an O +
important O +
, O +
although O +
more O +
indirect O +
, O +
role O +
: O +
alteration O +
of O +
the O +
sequence O +
at O +
threonine O +
78 O +
such O +
that O +
it O +
resembles O +
that O +
of O +
c O -
- O -
erb O +
A O +
can O +
act O +
as O +
an O +
intragenic O +
suppressor O +
and O +
can O +
partially O +
restore O +
function O +
to O +
a O +
v O -
- O -
erb O +
A O +
protein O +
rendered O +
defective O +
due O +
to O +
a O +
mutation O +
at O +
position O +
61 O +
. O +

Threonine O +
78 O +
lies O +
within O +
the O +
D O -
- O -
box O +
of O +
the O +
v O -
- O -
erb O +
A O +
protein O +
, O +
a O +
region O +
thought O +
to O +
mediate O +
receptor O -
- O -
receptor O +
dimerizations O +
, O +
and O +
is O +
not O +
in O +
physical O +
proximity O +
to O +
the O +
serine O +
at O +
position O +
61 O +
. O +

It O +
therefore O +
appears O +
that O +
an O +
indirect O +
interaction O +
occurs O +
between O +
these O +
two O +
sites O +
and O +
that O +
this O +
interaction O +
is O +
crucial O +
for O +
v O -
- O -
erb O +
A O +
function O +
. O +

Pax-5 O +
encodes O +
the O +
transcription O +
factor O +
BSAP O +
and O +
is O +
expressed O +
in O +
B O +
lymphocytes O +
, O +
the O +
developing O +
CNS O +
, O +
and O +
adult O +
testis O +
. O +

BSAP O +
has O +
been O +
identified O +
previously O +
as O +
a O +
transcription O +
factor O +
that O +
is O +
expressed O +
at O +
early O +
, O +
but O +
not O +
late O +
, O +
stages O +
of O +
B O -
- O -
cell O +
differentiation O +
. O +

Biochemical O +
purification O +
and O +
cDNA O +
cloning O +
has O +
now O +
revealed O +
that O +
BSAP O +
belongs O +
to O +
the O +
family O +
of O +
paired O +
domain O +
proteins O +
. O +

BSAP O +
is O +
encoded O +
by O +
the O +
Pax-5 O +
gene O +
and O +
has O +
been O +
highly O +
conserved O +
between O +
human O +
and O +
mouse O +
. O +

An O +
intact O +
paired O +
domain O +
was O +
shown O +
to O +
be O +
both O +
necessary O +
and O +
sufficient O +
for O +
DNA O +
binding O +
of O +
BSAP O +
. O +

Binding O +
studies O +
with O +
several O +
BSAP O +
recognition O +
sequences O +
demonstrated O +
that O +
the O +
sequence O +
specificity O +
of O +
BSAP O +
differs O +
from O +
that O +
of O +
the O +
distantly O +
related O +
paired O +
domain O +
protein O +
Pax-1 O +
. O +

During O +
embryogenesis O +
, O +
the O +
BSAP O +
gene O +
is O +
transiently O +
expressed O +
in O +
the O +
mesencephalon O +
and O +
spinal O +
cord O +
with O +
a O +
spatial O +
and O +
temporal O +
expression O +
pattern O +
that O +
is O +
distinct O +
from O +
that O +
of O +
other O +
Pax O +
genes O +
in O +
the O +
developing O +
central O +
nervous O +
system O +
( O +
CNS O +
) O +
. O +

Later O +
, O +
the O +
expression O +
of O +
the O +
BSAP O +
gene O +
shifts O +
to O +
the O +
fetal O +
liver O +
where O +
it O +
correlates O +
with O +
the O +
onset O +
of O +
B O +
lymphopoiesis O +
. O +

BSAP O +
expression O +
persists O +
in O +
B O +
lymphocytes O +
and O +
is O +
also O +
seen O +
in O +
the O +
testis O +
of O +
the O +
adult O +
mouse O +
. O +

All O +
of O +
this O +
evidence O +
indicates O +
that O +
the O +
transcription O +
factor O +
BSAP O +
may O +
not O +
only O +
play O +
an O +
important O +
role O +
in O +
B O -
- O -
cell O +
differentiation O +
but O +
also O +
in O +
neural O +
development O +
and O +
spermatogenesis O +
. O +

A O +
novel O +
Ets O -
- O -
related O +
transcription O +
factor O +
, O +
Elf-1 O +
, O +
binds O +
to O +
human O +
immunodeficiency O +
virus O +
type O +
2 O +
regulatory O +
elements O +
that O +
are O +
required O +
for O +
inducible O +
trans O +
activation O +
in O +
T O +
cells O +
. O +

Human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
and O +
HIV-2 O +
are O +
structurally O +
related O +
retroviruses O +
which O +
both O +
cause O +
AIDS O +
in O +
humans O +
. O +

Although O +
both O +
viruses O +
establish O +
latency O +
in O +
quiescent O +
human O -
- O -
peripheral O -
- O -
blood O +
T O +
cells O +
, O +
the O +
asymptomatic O +
phase O +
of O +
HIV-2 O +
infection O +
may O +
be O +
more O +
prolonged O +
than O +
that O +
of O +
HIV-1 O +
. O +

The O +
latent O +
phases O +
of O +
both O +
HIV-1 O +
and O +
HIV-2 O +
infection O +
have O +
been O +
shown O +
to O +
be O +
disrupted O +
by O +
T O -
- O -
cell O +
activation O +
, O +
a O +
process O +
that O +
requires O +
host O +
cell O +
transcription O +
factors O +
. O +

In O +
the O +
case O +
of O +
HIV-1 O +
, O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
is O +
sufficient O +
for O +
inducible O +
transcriptional O +
activation O +
. O +

In O +
contrast O +
, O +
factors O +
in O +
addition O +
to O +
NF O -
- O -
kappa O +
B O +
are O +
required O +
to O +
activate O +
HIV-2 O +
transcription O +
in O +
infected O +
T O +
cells O +
. O +

In O +
this O +
report O +
, O +
we O +
demonstrate O +
that O +
a O +
novel O +
Ets O -
- O -
related O +
transcription O +
factor O +
, O +
Elf-1 O +
, O +
binds O +
specifically O +
to O +
two O +
purine O -
- O -
rich O +
motifs O +
in O +
the O +
HIV-2 O +
enhancer O +
. O +

Mutagenesis O +
experiments O +
demonstrated O +
that O +
these O +
Elf-1 O +
binding O +
sites O +
are O +
required O +
for O +
induction O +
of O +
HIV-2 O +
transcription O +
following O +
T O -
- O -
cell O -
- O -
receptor O -
- O -
mediated O +
T O -
- O -
cell O +
activation O +
. O +

Moreover O +
, O +
Elf-1 O +
is O +
the O +
only O +
factor O +
present O +
in O +
activated O +
T O -
- O -
cell O +
nuclear O +
extracts O +
that O +
binds O +
to O +
these O +
sites O +
in O +
electrophoretic O +
mobility O +
shift O +
assays O +
. O +

Thus O +
, O +
Elf-1 O +
is O +
a O +
novel O +
transcription O +
factor O +
that O +
appears O +
to O +
be O +
required O +
for O +
the O +
T O -
- O -
cell O -
- O -
receptor O -
- O -
mediated O +
trans O +
activation O +
of O +
HIV-2 O +
gene O +
expression O +
. O +

These O +
results O +
may O +
explain O +
differences O +
in O +
the O +
clinical O +
spectra O +
of O +
diseases O +
caused O +
by O +
HIV-1 O +
and O +
HIV-2 O +
and O +
may O +
also O +
have O +
implications O +
for O +
the O +
design O +
of O +
therapeutic O +
approaches O +
to O +
HIV-2 O +
infection O +
. O +

Human O +
immunodeficiency O +
virus O +
type O +
1 O +
Nef O +
protein O +
inhibits O +
NF O -
- O -
kappa O +
B O +
induction O +
in O +
human O +
T O +
cells O +
. O +

Human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
can O +
establish O +
a O +
persistent O +
and O +
latent O +
infection O +
in O +
CD4 O -
+ O +
T O +
lymphocytes O +
( O +
W.C.Greene O +
, O +
N.Engl O -
. O -
J. O +
Med.324 O +
: O +
308 O -
- O -
317 O +
, O +
1991 O +
; O +
S.M.Schnittman O +
, O +
M.C.Psallidopoulos O +
, O +
H.C. O +
Lane O +
, O +
L.Thompson O +
, O +
M.Baseler O +
, O +
F.Massari O +
, O +
C.H.Fox O +
, O +
N.P.Salzman O +
, O +
and O +
A.S.Fauci O +
, O +
Science O +
245 O +
: O +
305 O -
- O -
308 O +
, O +
1989 O +
) O +
. O +

Production O +
of O +
HIV-1 O +
from O +
latently O +
infected O +
cells O +
requires O +
host O +
cell O +
activation O +
by O +
T O -
- O -
cell O +
mitogens O +
( O +
T.Folks O +
, O +
D.M.Powell O +
, O +
M.M.Lightfoote O +
, O +
S.Benn O +
, O +
M.A. O +
Martin O +
, O +
and O +
A.S.Fauci O +
, O +
Science O +
231 O +
: O +
600 O -
- O -
602 O +
, O +
1986 O +
; O +
D.Zagury O +
, O +
J. O +
Bernard O +
, O +
R.Leonard O +
, O +
R.Cheynier O +
, O +
M.Feldman O +
, O +
P.S.Sarin O +
, O +
and O +
R.C. O +
Gallo O +
, O +
Science O +
231 O +
: O +
850 O -
- O -
853 O +
, O +
1986 O +
) O +
. O +

This O +
activation O +
is O +
mediated O +
by O +
the O +
host O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
[ O +
G.Nabel O +
and O +
D.Baltimore O +
, O +
Nature O +
( O +
London O +
) O +
326 O +
: O +
711 O -
- O -
717 O +
, O +
1987 O +
] O +
. O +

We O +
report O +
here O +
that O +
the O +
HIV-1-encoded O +
Nef O +
protein O +
inhibits O +
the O +
induction O +
of O +
NF O -
- O -
kappa O +
B O +
DNA O -
- O -
binding O +
activity O +
by O +
T- O +
cell O +
mitogens O +
. O +

However O +
, O +
Nef O +
does O +
not O +
affect O +
the O +
DNA O -
- O -
binding O +
activity O +
of O +
other O +
transcription O +
factors O +
implicated O +
in O +
HIV-1 O +
regulation O +
, O +
including O +
SP-1 O +
, O +
USF O +
, O +
URS O +
, O +
and O +
NF O -
- O -
AT O +
. O +

Additionally O +
, O +
Nef O +
inhibits O +
the O +
induction O +
of O +
HIV-1- O +
and O +
interleukin O +
2-directed O +
gene O +
expression O +
, O +
and O +
the O +
effect O +
on O +
HIV-1 O +
transcription O +
depends O +
on O +
an O +
intact O +
NF O -
- O -
kappa O +
B O -
- O -
binding O +
site O +
. O +

These O +
results O +
indicate O +
that O +
defective O +
recruitment O +
of O +
NF O -
- O -
kappa O +
B O +
may O +
underlie O +
Nef O +
's O +
negative O +
transcriptional O +
effects O +
on O +
the O +
HIV-1 O +
and O +
interleukin O +
2 O +
promoters O +
. O +

Further O +
evidence O +
suggests O +
that O +
Nef O +
inhibits O +
NF O -
- O -
kappa O +
B O +
induction O +
by O +
interfering O +
with O +
a O +
signal O +
derived O +
from O +
the O +
T O -
- O -
cell O +
receptor O +
complex O +
. O +

[ O +
Effect O +
of O +
antihypertensive O +
therapy O +
with O +
captopril O +
on O +
gluco- O +
and O +
mineralocorticoid O +
receptors O +
of O +
peripheral O +
blood O +
lymphocytes O +
in O +
hypertensive O +
patients O +
of O +
various O +
age O +
] O +

Binding O +
of O +
3H O -
- O -
dexamethasone O +
and O +
3H O -
- O -
aldosterone O +
by O +
peripheral O +
lymphocyte O +
receptors O +
was O +
investigated O +
in O +
healthy O +
persons O +
and O +
hypertensive O +
patients O +
before O +
and O +
after O +
2-week O +
captopril O +
treatment O +
. O +

The O +
number O +
of O +
glucocorticoid O +
and O +
mineralocorticoid O +
binding O +
sites O +
was O +
increased O +
in O +
hypertensives O +
vs O +
normotensives O +
. O +

The O +
treatment O +
with O +
the O +
ACE O +
inhibitor O +
captopril O +
led O +
to O +
activation O +
of O +
hormone O -
- O -
receptor O +
interactions O +
. O +

There O +
was O +
a O +
more O +
marked O +
rise O +
of O +
the O +
number O +
of O +
receptors O +
in O +
middle O -
- O -
aged O +
( O +
44 O -
- O -
55 O +
years O +
) O +
hypertensives O +
vs O +
elderly O +
( O +
61 O -
- O -
80 O +
years O +
) O +
subjects O +
after O +
captopril O +
treatment O +
. O +

Leukotriene O +
B4 O +
transcriptionally O +
activates O +
interleukin-6 O +
expression O +
involving O +
NK O -
- O -
chi O +
B O +
and O +
NF O -
- O -
IL6 O +
. O +

Leukotriene O +
B4 O +
( O +
LTB4 O +
) O +
is O +
a O +
notable O +
participant O +
in O +
inflammation O +
and O +
chemotaxis O +
. O +

It O +
is O +
, O +
however O +
, O +
still O +
unclear O +
whether O +
LTB4 O +
acts O +
in O +
this O +
regard O +
directly O +
or O +
indirectly O +
by O +
stimulating O +
the O +
release O +
of O +
chemotactic O +
and O +
inflammatory O +
cytokines O +
. O +

Here O +
we O +
report O +
that O +
LTB4 O +
induces O +
synthesis O +
of O +
interleukin O +
( O +
IL O +
) O +
-6 O +
by O +
human O +
blood O +
monocytes O +
through O +
transcriptional O +
activation O +
of O +
the O +
IL-6 O +
gene O +
. O +

We O +
furthermore O +
demonstrate O +
that O +
this O +
process O +
involves O +
activation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
chi O +
B O +
and O +
, O +
to O +
a O +
lesser O +
extent O +
, O +
of O +
NF O -
- O -
IL6 O +
, O +
while O +
the O +
activity O +
of O +
the O +
transcription O +
factor O +
AP-1 O +
, O +
shown O +
to O +
otherwise O +
confer O +
IL-6 O +
inducibility O +
, O +
appeared O +
to O +
be O +
unaffected O +
by O +
LTB4 O +
. O +

Involvement O +
of O +
NF O -
- O -
chi O +
B O +
and O +
NF O -
- O -
IL6 O +
in O +
induction O +
of O +
IL-6 O +
transcription O +
by O +
monocytes O +
was O +
demonstrated O +
using O +
deleted O +
forms O +
of O +
the O +
IL-6 O +
promoter O +
. O +

Activation O +
of O +
the O +
IL-6 O +
promoter O +
by O +
LTB4 O +
was O +
not O +
only O +
associated O +
with O +
accumulation O +
of O +
the O +
respective O +
transcripts O +
but O +
resulted O +
in O +
synthesis O +
of O +
functional O +
IL-6 O +
protein O +
as O +
well O +
. O +

In O +
addition O +
, O +
LTB4 O +
mediated O +
transactivation O +
of O +
a O +
heterologous O +
promoter O +
construct O +
containing O +
the O +
NF O -
- O -
chi O +
B O +
or O +
the O +
NF O -
- O -
IL6 O +
enhancer O +
, O +
but O +
not O +
the O +
AP-1 O +
enhancer O +
. O +

The O +
signaling O +
events O +
mediating O +
this O +
effect O +
appeared O +
to O +
involve O +
the O +
release O +
of O +
H2O2 O +
, O +
since O +
LTB4 O +
failed O +
to O +
induce O +
NF O -
- O -
chi O +
B O +
or O +
NF O -
- O -
IL6 O +
in O +
the O +
presence O +
of O +
the O +
scavenger O +
of O +
H2O2 O +
, O +
N O -
- O -
acetyl O -
- O -
L O -
- O -
cysteine O +
. O +

Estrogen O +
binding O +
sites O +
in O +
peripheral O +
blood O +
monocytes O +
and O +
effects O +
of O +
danazol O +
on O +
their O +
sites O +
in O +
vitro O +
. O +

1 O +
. O +

This O +
study O +
was O +
designed O +
to O +
investigate O +
the O +
presence O +
of O +
estrogen O +
type O +
I O +
( O +
high O +
affinity O +
, O +
low O +
capacity O +
) O +
and O +
type O +
II O +
( O +
low O +
affinity O +
, O +
high O +
capacity O +
) O +
binding O +
sites O +
in O +
human O +
peripheral O +
blood O +
monocytes O +
and O +
the O +
effects O +
of O +
danazol O +
on O +
these O +
sites O +
. O +

2 O +
. O +

These O +
two O +
types O +
of O +
estrogen O +
binding O +
sites O +
existed O +
in O +
human O +
peripheral O +
blood O +
monocytes O +
. O +

3 O +
. O +

Danazol O +
bound O +
to O +
these O +
sites O +
in O +
high O +
concentration O +
( O +
10 O +
( O +
-6 O +
) O +
M O +
, O +
clinical O +
serum O +
concentration O +
during O +
danazol O +
therapy O +
) O +
and O +
decreased O +
the O +
number O +
of O +
both O +
sites O +
. O +

4 O +
. O +

It O +
is O +
suggested O +
that O +
danazol O +
has O +
an O +
anti O -
- O -
estrogenic O +
action O +
to O +
the O +
monocytes O +
through O +
the O +
competition O +
and O +
suppression O +
of O +
estrogen O +
binding O +
sites O +
as O +
seen O +
in O +
the O +
estrogen O +
target O +
organ O +
. O +

[ O +
Mechanism O +
of O +
action O +
of O +
steroid O +
hormones O -
. O +
I. O +
Estrogens O +
] O +

The O +
steroid O +
hormone O +
are O +
very O +
versatile O +
molecules O +
: O +
although O +
they O +
are O +
related O +
among O +
them O +
by O +
their O +
chemical O +
structure O +
, O +
they O +
have O +
very O +
diverse O +
functions O +
and O +
including O +
antagonic O +
. O +

Their O +
action O +
mechanism O +
is O +
not O +
completely O +
cleared O +
. O +

The O +
estrogens O +
participate O +
in O +
the O +
regulation O +
of O +
practically O +
all O +
the O +
reproductive O +
and O +
sexual O +
events O +
of O +
the O +
female O +
, O +
although O +
the O +
intracellular O +
actions O +
by O +
which O +
they O +
take O +
place O +
are O +
not O +
well O +
known O +
and O +
the O +
proposed O +
models O +
do O +
not O +
adequately O +
satisfy O +
the O +
questions O +
. O +

Currently O +
it O +
is O +
accepted O +
the O +
existence O +
of O +
a O +
cytoplasmic O +
and/or O +
nuclear O +
receptor O +
, O +
without O +
explaining O +
satisfactorily O +
how O +
the O +
hormones O +
come O +
to O +
the O +
nucleus O +
. O +

The O +
endocrine O +
events O +
that O +
are O +
rapidly O +
expressed O +
( O +
seconds O +
) O +
are O +
due O +
to O +
a O +
possible O +
interaction O +
with O +
cellular O +
membrane O +
. O +

The O +
purpose O +
of O +
this O +
review O +
is O +
to O +
analyze O +
and O +
concilliate O +
the O +
reported O +
data O +
on O +
the O +
mechanism O +
of O +
action O +
of O +
estrogens O +
. O +

Stable O +
expression O +
of O +
transdominant O +
Rev O +
protein O +
in O +
human O +
T O +
cells O +
inhibits O +
human O +
immunodeficiency O +
virus O +
replication O +
. O +

The O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
Rev O +
protein O +
is O +
essential O +
for O +
viral O +
structural O +
protein O +
expression O +
( O +
Gag O +
, O +
Pol O +
, O +
and O +
Env O +
) O +
and O +
, O +
hence O +
, O +
for O +
viral O +
replication O +
. O +

In O +
transient O +
transfection O +
assays O +
, O +
mutant O +
forms O +
of O +
Rev O +
have O +
been O +
identified O +
that O +
inhibit O +
wild O -
- O -
type O +
Rev O +
activity O +
and O +
therefore O +
suppress O +
viral O +
replication O +
. O +

To O +
determine O +
whether O +
such O +
transdominant O +
Rev O +
proteins O +
could O +
provide O +
long O -
- O -
term O +
protection O +
against O +
HIV O +
infection O +
without O +
affecting O +
T O +
cell O +
function O +
, O +
T B-CellLine +
leukemia I-CellLine +
cell I-CellLine +
lines I-CellLine +
were O +
stably O +
transduced O +
with O +
a O +
retroviral O +
vector O +
encoding O +
a O +
transdominant O +
mutant O +
of O +
the O +
Rev O +
protein O +
, O +
M10 O +
. O +

While O +
all O +
the O +
M10-expressing B-CellLine +
cell I-CellLine +
lines I-CellLine +
remained O +
infectable O +
by O +
HIV-1 O +
, O +
these O +
same O +
cells O +
failed O +
to O +
support O +
a O +
productive O +
replication O +
cycle O +
when O +
infected O +
with O +
a O +
cloned O +
isolate O +
of O +
HIV-1 O +
. O +

In O +
addition O +
, O +
two O +
out O +
of O +
three O +
M10-expressing B-CellLine +
CEM I-CellLine +
clones I-CellLine +
were O +
also O +
resistant O +
to O +
highly O +
productive O +
infection O +
by O +
a O +
heterogeneous O +
HIV-1 O +
pool O +
. O +

Expression O +
of O +
M10 O +
did O +
not O +
affect O +
induction O +
of O +
HIV O +
transcription O +
mediated O +
by O +
the O +
kappa O +
B O +
regulatory O +
element O +
or O +
Tat O +
. O +

Importantly O +
, O +
constitutive O +
expression O +
of O +
Rev O +
M10 O +
did O +
not O +
alter O +
the O +
secretion O +
of O +
interleukin O +
2 O +
in O +
response O +
to O +
mitogen O +
stimulation O +
of O +
EL-4 B-CellLine +
and O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

The O +
inhibition O +
of O +
HIV O +
infection O +
in O +
cells O +
stably O +
expressing O +
a O +
transdominant O +
Rev O +
protein O +
, O +
in O +
the O +
absence O +
of O +
any O +
deleterious O +
effect O +
on O +
T O +
cell O +
function O +
, O +
suggests O +
that O +
such O +
a O +
strategy O +
could O +
provide O +
a O +
therapeutic O +
effect O +
in O +
the O +
T O +
lymphocytes O +
of O +
acquired O +
immunodeficiency O +
syndrome O +
patients O +
. O +

Glucocorticoid O +
receptor O +
in O +
patients O +
with O +
lupus O +
nephritis O +
: O +
relationship O +
between O +
receptor O +
levels O +
in O +
mononuclear O +
leukocytes O +
and O +
effect O +
of O +
glucocorticoid O +
therapy O +
. O +

We O +
investigated O +
the O +
clinical O +
significance O +
of O +
glucocorticoid O +
receptor O +
determination O +
in O +
20 O +
patients O +
with O +
systemic O +
lupus O +
erythematosus O +
( O +
SLE O +
) O +
who O +
afterwards O +
developed O +
nephrotic O +
syndrome O +
. O +

Glucocorticoid O +
receptor O +
concentrations O +
in O +
mononuclear O +
leukocytes O +
( O +
MNL O +
) O +
in O +
these O +
patients O +
were O +
comparable O +
with O +
those O +
in O +
both O +
other O +
patients O +
with O +
SLE O +
and O +
healthy O +
persons O +
. O +

Improvement O +
in O +
urinary O +
protein O +
excretion O +
and O +
in O +
disease O +
activity O +
, O +
which O +
was O +
scored O +
according O +
to O +
the O +
SLE O +
Disease O +
Activity O +
Index O +
system O +
of O +
the O +
University O +
of O +
Toronto O +
, O +
closely O +
related O +
to O +
the O +
glucocorticoid O +
receptor O +
concentrations O +
in O +
MNL O +
isolated O +
from O +
the O +
corresponding O +
patients O +
. O +

In O +
summary O +
, O +
glucocorticoid O +
receptor O +
determination O +
in O +
patients O +
with O +
lupus O +
nephritis O +
may O +
be O +
a O +
predictive O +
clue O +
for O +
assessing O +
responsiveness O +
to O +
glucocorticoid O +
therapy O +
. O +

Selection O +
of O +
optimal O +
kappa O +
B O -
/ O -
Rel O +
DNA O -
- O -
binding O +
motifs O +
: O +
interaction O +
of O +
both O +
subunits O +
of O +
NF O -
- O -
kappa O +
B O +
with O +
DNA O +
is O +
required O +
for O +
transcriptional O +
activation O +
. O +

Analysis O +
of O +
the O +
p50 O +
and O +
p65 O +
subunits O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
transcription O +
factor O +
complex O +
has O +
revealed O +
that O +
both O +
proteins O +
can O +
interact O +
with O +
related O +
DNA O +
sequences O +
through O +
either O +
homo- O +
or O +
heterodimer O +
formation O +
. O +

In O +
addition O +
, O +
the O +
product O +
of O +
the O +
proto O -
- O -
oncogene O +
c O -
- O -
rel O +
can O +
bind O +
to O +
similar O +
DNA O +
motifs O +
by O +
itself O +
or O +
as O +
a O +
heterodimer O +
with O +
p50 O +
or O +
p65 O +
. O +

However O +
, O +
these O +
studies O +
have O +
used O +
a O +
limited O +
number O +
of O +
known O +
kappa O +
B O +
DNA O +
motifs O +
, O +
and O +
the O +
question O +
of O +
the O +
optimal O +
DNA O +
sequences O +
preferred O +
by O +
each O +
homodimer O +
has O +
not O +
been O +
addressed O +
. O +

Using O +
purified O +
recombinant O +
p50 O +
, O +
p65 O +
, O +
and O +
c O -
- O -
Rel O +
proteins O +
, O +
optimal O +
DNA O -
- O -
binding O +
motifs O +
were O +
selected O +
from O +
a O +
pool O +
of O +
random O +
oligonucleotides O +
. O +

Alignment O +
of O +
the O +
selected O +
sequences O +
allowed O +
us O +
to O +
predict O +
a O +
consensus O +
sequence O +
for O +
binding O +
of O +
the O +
individual O +
homodimeric O +
Rel O -
- O -
related O +
proteins O +
, O +
and O +
DNA O -
- O -
protein O +
binding O +
analysis O +
of O +
the O +
selected O +
DNA O +
sequences O +
revealed O +
sequence O +
specificity O +
of O +
the O +
proteins O +
. O +

Contrary O +
to O +
previous O +
assumptions O +
, O +
we O +
observed O +
that O +
p65 O +
homodimers O +
can O +
interact O +
with O +
a O +
subset O +
of O +
DNA O +
sequences O +
not O +
recognized O +
by O +
p50 O +
homodimers O +
. O +

Differential O +
binding O +
affinities O +
were O +
also O +
obtained O +
with O +
p50- O +
and O +
c O -
- O -
Rel O -
- O -
selected O +
sequences O +
. O +

Using O +
either O +
a O +
p50- O +
or O +
p65- O +
selected O +
kappa O +
B O +
motif O +
, O +
which O +
displayed O +
differential O +
binding O +
with O +
respect O +
to O +
the O +
other O +
protein O +
, O +
little O +
to O +
no O +
binding O +
was O +
observed O +
with O +
the O +
heterodimeric O +
NF O -
- O -
kappa O +
B O +
complex O +
. O +

Similarly O +
, O +
in O +
transfection O +
experiments O +
in O +
which O +
the O +
selective O +
kappa O +
B O +
binding O +
sites O +
were O +
used O +
to O +
drive O +
the O +
expression O +
of O +
a O +
chloramphenicol O +
acetyltransferase O +
reporter O +
construct O +
, O +
the O +
p65 O +
-and O +
p50-selected O +
motifs O +
were O +
activated O +
only O +
in O +
the O +
presence O +
of O +
p65 O +
and O +
p50 O -
/ O -
65 O +
( O +
a O +
chimeric O +
protein O +
with O +
the O +
p50 O +
DNA O +
binding O +
domain O +
and O +
p65 O +
activation O +
domain O +
) O +
expression O +
vectors O +
, O +
respectively O +
, O +
and O +
neither O +
demonstrated O +
a O +
significant O +
response O +
to O +
stimuli O +
that O +
induce O +
NF O -
- O -
kappa O +
B O +
activity O +
. O +

These O +
findings O +
demonstrate O +
that O +
interaction O +
of O +
both O +
subunits O +
of O +
the O +
heterodimeric O +
NF O -
- O -
kappa O +
B O +
complex O +
with O +
DNA O +
is O +
required O +
for O +
DNA O +
binding O +
and O +
transcriptional O +
activation O +
and O +
suggest O +
that O +
transcriptional O +
activation O +
mediated O +
by O +
the O +
individual O +
rel O -
- O -
related O +
proteins O +
will O +
differ O +
dramatically O +
, O +
depending O +
on O +
the O +
specific O +
kappa O +
B O +
motifs O +
present O +
. O +

The O +
candidate O +
oncoprotein O +
Bcl-3 O +
is O +
an O +
antagonist O +
of O +
p50 O -
/ O -
NF O -
- O -
kappa O +
B O +
-mediated O +
inhibition O +
. O +

The O +
candidate O +
oncogene O +
bcl-3 O +
was O +
discovered O +
as O +
a O +
translocation O +
into O +
the O +
immunoglobulin O +
alpha O -
- O -
locus O +
in O +
some O +
cases O +
of O +
B O -
- O -
cell O +
chronic O +
lymphocytic O +
leukaemias O +
. O +

The O +
protein O +
Bcl-3 O +
contains O +
seven O +
so O -
- O -
called O +
ankyrin O +
repeats O +
. O +

Similar O +
repeat O +
motifs O +
are O +
found O +
in O +
a O +
number O +
of O +
diverse O +
regulatory O +
proteins O +
but O +
the O +
motifs O +
of O +
Bcl-3 O +
are O +
most O +
closely O +
related O +
to O +
those O +
found O +
in O +
I O +
kappa O +
B O +
proteins O +
in O +
which O +
the O +
ankyrin O +
repeat O +
domain O +
is O +
thought O +
to O +
be O +
directly O +
involved O +
in O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
activity O +
. O +

No O +
biological O +
function O +
has O +
yet O +
been O +
described O +
for O +
Bcl-3 O +
, O +
but O +
it O +
was O +
noted O +
recently O +
that O +
Bcl-3 O +
interferes O +
with O +
DNA O -
- O -
binding O +
of O +
the O +
p50 O +
subunit O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
vitro O +
. O +

Here O +
we O +
demonstrate O +
that O +
Bcl-3 O +
can O +
aid O +
kappa O +
B O +
site O +
-dependent O +
transcription O +
in O +
vivo O +
by O +
counteracting O +
the O +
inhibitory O +
effects O +
of O +
p50 O -
/ O -
NF O -
- O -
kappa O +
B O +
homodimers O +
. O +

Bcl-3 O +
may O +
therefore O +
aid O +
activation O +
of O +
select O +
NF O -
- O -
kappa O +
B O -
- O -
regulated O +
genes O +
, O +
including O +
those O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
. O +

A O +
microtitre O +
assay O +
system O +
for O +
glucocorticoid O +
receptors O +
: O +
decreased O +
receptor O +
concentration O +
in O +
myocardial O +
infarction O +
. O +

A O +
major O +
difficulty O +
in O +
determination O +
of O +
glucocorticoid O +
receptor O +
sites O +
is O +
the O +
very O +
complicated O +
assay O +
procedure O +
. O +

Therefore O +
, O +
we O +
describe O +
a O +
microtitre O +
assay O +
system O +
for O +
glucocorticoid O +
receptors O +
which O +
is O +
a O +
whole O -
- O -
cell O +
competitive O +
binding O +
radioassay O +
using O +
[ O +
3H O +
] O +
-dexamethasone O +
as O +
radioligand O +
. O +

This O +
modification O +
of O +
a O +
previously O +
described O +
protocol O +
simplifies O +
and O +
reduces O +
laboratory O +
work O +
and O +
allows O +
assay O +
reproducibility O +
to O +
be O +
controlled O +
more O +
reliably O +
. O +

Thus O +
enabled O +
to O +
perform O +
the O +
test O +
on O +
multiple O +
blood O +
samples O +
in O +
parallel O +
, O +
we O +
investigated O +
cardiac O +
infarction O +
patients O +
over O +
a O +
12-day O +
period O +
to O +
test O +
if O +
glucocorticoid O +
receptor O +
binding O +
is O +
altered O +
in O +
this O +
' O -
stressful O +
' O +
disease O +
. O +

On O +
the O +
first O +
day O +
of O +
the O +
disease O +
, O +
glucocorticoid O +
receptor O +
capacity O +
was O +
significantly O +
decreased O +
without O +
alteration O +
of O +
the O +
receptor O -
- O -
ligand O +
affinity O +
, O +
whereas O +
on O +
days O +
4 O +
and O +
12 O +
the O +
number O +
of O +
receptor O +
sites O +
was O +
normal O +
again O +
. O +

This O +
result O +
fits O +
well O +
into O +
the O +
general O +
observation O +
of O +
stress O -
- O -
induced O +
down O -
- O -
regulation O +
of O +
immune O +
responses O +
. O +

Regulation O +
of O +
c O -
- O -
jun O +
expression O +
during O +
induction O +
of O +
monocytic O +
differentiation O +
by O +
okadaic O +
acid O +
. O +

The O +
present O +
work O +
has O +
examined O +
the O +
effects O +
of O +
okadaic O +
acid O +
, O +
an O +
inhibitor O +
of O +
type O +
1 O +
and O +
2A O +
protein O +
phosphatases O +
, O +
on O +
the O +
regulation O +
of O +
c O -
- O -
jun O +
expression O +
during O +
monocytic O +
differentiation O +
of O +
U-937 B-CellLine +
leukemia I-CellLine +
cells I-CellLine +
. O +

The O +
results O +
demonstrate O +
that O +
okadaic O +
acid O +
treatment O +
is O +
associated O +
with O +
induction O +
of O +
a O +
differentiated O +
monocyte O +
phenotype O +
characterized O +
by O +
: O +
( O +
a O +
) O +
growth O +
arrest O +
; O +
( O +
b O +
) O +
increases O +
in O +
Mac-1 O +
cell O +
surface O +
antigen O +
expression O +
; O +
( O +
c O +
) O +
down O -
- O -
regulation O +
of O +
c O -
- O -
myc O +
transcripts O +
; O +
and O +
( O +
d O +
) O +
induction O +
of O +
tumor O +
necrosis O +
factor O +
gene O +
expression O +
. O +

This O +
induction O +
of O +
monocytic O +
differentiation O +
was O +
associated O +
with O +
transient O +
increases O +
in O +
c O -
- O -
jun O +
mRNA O +
levels O +
, O +
which O +
were O +
maximal O +
at O +
6 O +
h O +
. O +

Similar O +
effects O +
were O +
obtained O +
for O +
the O +
c O -
- O -
fos O +
gene O +
. O +

Run O -
- O -
on O +
analysis O +
demonstrated O +
detectable O +
levels O +
of O +
c O -
- O -
jun O +
transcription O +
in O +
U-937 B-CellLine +
cells I-CellLine +
and O +
that O +
this O +
rate O +
is O +
increased O +
approximately O +
40-fold O +
following O +
okadaic O +
acid O +
exposure O +
. O +

c O -
- O -
jun O +
mRNA O +
levels O +
were O +
superinduced O +
in O +
cells O +
treated O +
with O +
both O +
okadaic O +
acid O +
and O +
cycloheximide O +
, O +
whereas O +
inhibition O +
of O +
protein O +
synthesis O +
had O +
little O +
, O +
if O +
any O +
, O +
effect O +
on O +
okadaic O +
acid O -
- O -
induced O +
c O -
- O -
jun O +
transcription O +
. O +

The O +
half O -
- O -
life O +
of O +
c O -
- O -
jun O +
mRNA O +
was O +
similar O +
( O +
45 O -
- O -
50 O +
min O +
) O +
in O +
both O +
untreated O +
and O +
okadaic B-CellLine +
acid I-CellLine -
- I-CellLine -
induced I-CellLine +
cells I-CellLine +
. O +

In O +
contrast O +
, O +
treatment O +
with O +
both O +
okadaic O +
acid O +
and O +
cycloheximide O +
was O +
associated O +
with O +
stabilization O +
( O +
t O +
1 O -
/ O -
2 O +
= O +
90 O +
min O +
) O +
of O +
c O -
- O -
jun O +
transcripts O +
. O +

Taken O +
together O +
, O +
these O +
findings O +
indicate O +
that O +
the O +
induction O +
of O +
c O -
- O -
jun O +
transcription O +
by O +
okadaic O +
acid O +
is O +
controlled O +
primarily O +
by O +
a O +
transcriptional O +
mechanism O +
. O +

Since O +
previous O +
studies O +
have O +
demonstrated O +
that O +
the O +
c O -
- O -
jun O +
gene O +
is O +
autoinduced O +
by O +
Jun O -
/ O -
AP-1 O +
, O +
we O +
also O +
studied O +
transcription O +
of O +
c O -
- O -
jun O +
promoter O +
( O +
positions O +
-132 O -
/ O -
+170 O +
) O +
-reporter O +
gene O +
constructs O +
with O +
and O +
without O +
a O +
mutated O +
AP-1 O +
element O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

Activation O +
of O +
NF O -
- O -
kappa O +
B O +
by O +
interleukin O +
2 O +
in O +
human O +
blood O +
monocytes O +
. O +

We O +
report O +
here O +
that O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
acts O +
on O +
human O +
blood O +
monocytes O +
by O +
enhancing O +
binding O +
activity O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
to O +
its O +
consensus O +
sequence O +
in O +
the O +
5 O +
' O +
regulatory O +
enhancer O +
region O +
of O +
the O +
IL-2 O +
receptor O +
alpha O +
chain O +
( O +
p55 O +
) O +
. O +

Similarly O +
, O +
IL-2 O +
activates O +
NF O -
- O -
kappa O +
B O +
in O +
the O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
U I-CellLine +
937 I-CellLine +
, O +
but O +
not O +
in O +
resting O +
human O +
T O -
- O -
cells O +
. O +

This O +
effect O +
is O +
detectable O +
within O +
15 O +
min O +
and O +
peaks O +
1 O +
h O +
after O +
exposure O +
to O +
IL-2 O +
. O +

Enhanced O +
NF O -
- O -
kappa O +
B O +
binding O +
activity O +
is O +
followed O +
by O +
functional O +
activation O +
in O +
that O +
inducibility O +
of O +
the O +
IL-2 O +
receptor O +
alpha O +
chain O +
is O +
mediated O +
by O +
enhanced O +
NF O -
- O -
kappa O +
B O +
binding O +
and O +
that O +
a O +
heterologous O +
promoter O +
containing O +
the O +
NF O -
- O -
kappa O +
B O +
consensus O +
sequence O +
( O +
-291 O +
to O +
-245 O +
) O +
of O +
the O +
IL-2 O +
receptor O +
alpha O +
chain O +
gene O +
is O +
activated O +
. O +

In O +
addition O +
, O +
IL-2 O +
is O +
capable O +
of O +
increasing O +
transcript O +
levels O +
of O +
the O +
p50 O +
gene O +
coding O +
for O +
the O +
p50 O +
subunit O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
transcription O +
factor O +
, O +
whereas O +
mRNA O +
levels O +
of O +
the O +
p65 O +
NF O -
- O -
kappa O +
B O +
gene O +
remained O +
unchanged O +
. O +

Single O +
point O +
estimation O +
of O +
glucocorticoid O +
receptors O +
in O +
lymphocytes O +
of O +
normal O +
subjects O +
and O +
of O +
children O +
under O +
long O +
term O +
glucocorticoid O +
treatment O +
. O +

A O +
single O +
point O +
assay O +
of O +
glucocorticoid O +
receptors O +
( O +
GR O +
) O +
in O +
human O +
lymphocytes O +
based O +
on O +
the O +
measurement O +
of O +
specific O +
dexamethasone O +
binding O +
has O +
been O +
developed O +
and O +
compared O +
with O +
a O +
common O +
multi O -
- O -
point O +
Scatchard O +
analysis O +
. O +

The O +
assay O +
conditions O -
- O -
concentration O +
of O +
the O +
ligand O +
20 O +
nmol O -
/ O -
l O +
, O +
incubation O +
time O +
2 O +
h O +
and O +
the O +
cell O +
count O +
2 O -
- O -
6 O +
mil O +
. O +

cells O -
/ O -
tube O +
in O +
the O +
assay O +
volume O +
0.25 O +
ml O +
were O +
found O +
to O +
be O +
optimal O +
. O +

An O +
attempt O +
was O +
also O +
undertaken O +
to O +
use O +
a O +
cell O +
harvester O +
for O +
the O +
separation O +
of O +
cells O +
from O +
unbound O +
ligand O +
. O +

Though O +
specifically O +
bound O +
dexamethasone O +
measured O +
by O +
whole O -
- O -
cell O +
assay O +
and O +
that O +
using O +
cell O +
harvester O +
correlated O +
well O +
, O +
almost O +
by O +
one O +
order O +
lower O +
values O +
obtained O +
with O +
the O +
latter O +
method O +
render O +
it O +
non O -
- O -
applicable O +
for O +
receptor O +
quantitation O +
. O +

The O +
results O +
from O +
9 O +
healthy O +
volunteers O +
( O +
average O +
GR O +
concentration O +
7131 O +
+ O -
/- O +
1256 O +
sites O -
/ O -
cell O +
) O +
correlated O +
excellently O +
with O +
those O +
obtained O +
by O +
the O +
Scatchard O +
analysis O +
. O +

The O +
single O +
point O +
assay O +
has O +
been O +
also O +
applied O +
for O +
determination O +
of O +
GH O +
in O +
10 O +
children O +
treated O +
with O +
large O +
doses O +
of O +
prednisone O +
. O +

The O +
average O +
values O +
from O +
healthy O +
volunteers O +
did O +
not O +
differ O +
significantly O +
from O +
those O +
found O +
in O +
these O +
children O +
, O +
though O +
much O +
broader O +
range O +
was O +
found O +
in O +
patients O +
. O +

The O +
regulation O +
of O +
the O +
human O +
tumor O +
necrosis O +
factor O +
alpha O +
promoter O +
region O +
in O +
macrophage B-CellLine +
, O +
T B-CellLine +
cell I-CellLine +
, O +
and O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

The O +
1311-base O +
pair O +
human O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
alpha O +
promoter O +
region O +
was O +
fused O +
to O +
the O +
luciferase O +
( O +
Luc O +
) O +
reporter O +
gene O +
and O +
studied O +
in O +
a O +
transient O +
transfection O +
system O +
in O +
three O +
TNF B-CellLine +
producing I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
the O +
U937 B-CellLine +
macrophage I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
the O +
MLA B-CellLine +
144 I-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
and O +
the O +
729 B-CellLine -
- I-CellLine -
6 I-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

This O +
full O +
length O +
promoter O +
construct O +
can O +
be O +
induced O +
by O +
phorbol O +
13-myristate O +
acetate O +
( O +
PMA O +
) O +
in O +
each O +
of O +
these O +
cell O +
types O +
. O +

Analysis O +
of O +
a O +
series O +
of O +
5'-truncations O +
showed O +
several O +
peaks O +
of O +
basal O +
and O +
PMA O +
induced O +
activity O +
suggesting O +
the O +
presence O +
of O +
several O +
positive O +
and O +
negative O +
regulatory O +
elements O +
. O +

A O +
PMA O +
responsive O +
element O +
was O +
localized O +
to O +
a O +
region O +
between O +
-95 O +
and O +
-36 O +
bp O +
relative O +
to O +
the O +
transcription O +
start O +
site O +
. O +

Within O +
this O +
region O +
, O +
single O +
AP-2- O +
and O +
AP-1- O +
like O +
consensus O +
sequences O +
were O +
noted O +
. O +

These O +
AP-2 O +
and O +
AP-1 O +
sites O +
were O +
each O +
modified O +
with O +
a O +
double O +
point O +
mutation O +
. O +

A O +
modest O +
( O +
20 O -
- O -
50 O +
% O +
) O +
reduction O +
in O +
TNF O +
promoter O +
activity O +
was O +
observed O +
with O +
the O +
AP-2 O +
site O +
mutation O +
. O +

However O +
, O +
mutation O +
of O +
the O +
AP-1 O +
site O +
markedly O +
diminished O +
both O +
the O +
basal O +
and O +
PMA O -
- O -
activated O +
promoter O +
activity O +
. O +

Also O +
co O -
- O -
transfections O +
of O +
the O +
wild O -
- O -
type O +
promoter O +
construct O +
with O +
an O +
AP-1 O -
/ O -
c O -
- O -
jun O +
expression O +
vector O +
resulted O +
in O +
augmented O +
basal O +
and O +
PMA O -
- O -
induced O +
promoter O +
activity O +
. O +

Redox O +
status O +
of O +
cells O +
influences O +
constitutive O +
or O +
induced O +
NF O -
- O -
kappa O +
B O +
translocation O +
and O +
HIV O +
long O +
terminal O +
repeat O +
activity O +
in O +
human B-CellLine +
T I-CellLine +
and I-CellLine +
monocytic I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

We O +
have O +
tested O +
the O +
hypothesis O +
that O +
cellular O +
activation O +
events O +
occurring O +
in O +
T O +
lymphocytes O +
and O +
monocytes O +
and O +
mediated O +
through O +
translocation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
are O +
dependent O +
upon O +
the O +
constitutive O +
redox O +
status O +
of O +
these O +
cells O +
. O +

We O +
used O +
phenolic O +
, O +
lipid O -
- O -
soluble O +
, O +
chain O -
- O -
breaking O +
antioxidants O +
( O +
butylated O +
hydroxyanisole O +
( O +
BHA O +
) O +
, O +
nordihydroquairetic O +
acid O +
, O +
or O +
alpha O -
- O -
tocopherol O +
( O +
vitamin O +
E O +
) O +
to O +
show O +
that O +
peroxyl O +
radical O +
scavenging O +
in O +
unstimulated B-CellLine +
and I-CellLine +
PMA- I-CellLine +
or I-CellLine +
TNF I-CellLine -
- I-CellLine -
stimulated I-CellLine +
cells I-CellLine +
blocks O +
the O +
functions O +
depending O +
on O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

BHA O +
was O +
found O +
to O +
suppress O +
not O +
only O +
PMA- O +
or O +
TNF O -
- O -
induced O +
, O +
but O +
also O +
constitutive O +
, O +
HIV O -
- O -
enhancer O +
activity O +
concomitant O +
to O +
an O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
binding O +
activity O +
in O +
both O +
lymphoblastoid B-CellLine +
T I-CellLine +
( O +
J.Jhan B-CellLine +
) O +
and O +
monocytic B-CellLine +
( I-CellLine +
U937 I-CellLine +
) I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

This O +
was O +
also O +
true O +
for O +
KBF O +
( O +
p50 O +
homodimer O +
) O +
binding O +
activity O +
in O +
U937 B-CellLine +
cells I-CellLine +
. O +

Secretion O +
of O +
TNF O +
, O +
the O +
product O +
of O +
another O +
NF O -
- O -
kappa O +
B O -
- O -
dependent O +
gene O +
, O +
was O +
abolished O +
by O +
BHA O +
in O +
PMA B-CellLine -
- I-CellLine -
stimulated I-CellLine +
U937 I-CellLine +
cells I-CellLine +
. O +

The O +
anti O -
- O -
oxidative O +
effect O +
of O +
BHA O +
was O +
accompanied O +
by O +
an O +
increase O +
in O +
thiol O +
, O +
but O +
not O +
glutathione O +
, O +
content O +
in O +
stimulated B-CellLine +
and I-CellLine +
unstimulated I-CellLine +
T I-CellLine +
cell I-CellLine +
, O +
whereas O +
TNF O +
stimulation O +
itself O +
barely O +
modified O +
the O +
cellular O +
thiol O +
level O +
. O +

Oxidative O +
stress O +
obtained O +
by O +
the O +
addition O +
of O +
H2O2 O +
to O +
the O +
culture O +
medium O +
of O +
J.Jhan B-CellLine +
or O +
U937 B-CellLine +
cells I-CellLine +
could O +
not O +
by O +
itself O +
induce O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

These O +
observations O +
suggest O +
that O +
TNF O +
and O +
PMA O +
do O +
not O +
lead O +
to O +
NF O -
- O -
kappa O +
B O +
activation O +
through O +
induction O +
of O +
changes O +
in O +
the O +
cell O +
redox O +
status O +
. O +

Rather O +
, O +
TNF O +
and O +
PMA O +
can O +
exert O +
their O +
effect O +
only O +
if O +
cells O +
are O +
in O +
an O +
appropriate O +
redox O +
status O +
, O +
because O +
prior O +
modification O +
toward O +
reduction O +
with O +
BHA O +
treatment O +
prevents O +
this O +
activation O +
. O +

It O +
appears O +
that O +
a O +
basal O +
redox O +
equilibrium O +
tending O +
toward O +
oxidation O +
is O +
a O +
prerequisite O +
for O +
full O +
activation O +
of O +
transduction O +
pathways O +
regulating O +
the O +
activity O +
of O +
NF O -
- O -
kappa O +
B O -
- O -
dependent O +
genes O +
. O +

Expression O +
of O +
c O -
- O -
fos O +
, O +
c O -
- O -
jun O +
and O +
jun O +
B O +
in O +
peripheral O +
blood O +
lymphocytes O +
from O +
young O +
and O +
elderly O +
adults O +
. O +

The O +
expression O +
of O +
c O -
- O -
fos O +
, O +
c O -
- O -
jun O +
and O +
jun O +
B O +
proto O -
- O -
oncogenes O +
was O +
studied O +
in O +
phytohemagglutinin B-CellLine +
( I-CellLine +
PHA I-CellLine +
) I-CellLine +
activated I-CellLine +
peripheral I-CellLine +
blood I-CellLine +
lymphocytes I-CellLine +
( O +
PBL O +
) O +
from O +
young O +
and O +
aged O +
humans O +
. O +

Specific O +
mRNAs O +
for O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
were O +
detectable O +
within O +
30 O +
min O +
after O +
cell O +
activation O +
and O +
reached O +
maximal O +
levels O +
within O +
2 O +
h O +
. O +

Both O +
c O -
- O -
fos O +
and O +
jun O +
B O +
mRNAs O +
decreased O +
to O +
pre O -
- O -
activation O +
levels O +
within O +
6 O +
h O +
, O +
while O +
c O -
- O -
jun O +
mRNA O +
remained O +
elevated O +
. O +

In O +
PHA B-CellLine -
- I-CellLine -
activated I-CellLine +
PBL I-CellLine +
, O +
no O +
age O -
- O -
related O +
differences O +
were O +
observed O +
in O +
c O -
- O -
fos O +
or O +
jun O +
B O +
mRNA O +
expression O +
. O +

However O +
, O +
c O -
- O -
jun O +
mRNA O +
levels O +
decreased O +
significantly O +
( O +
1.73 O +
+ O -
/- O +
0.08 O +
vs. O +
1.16 O +
+ O -
/- O +
0.09 O +
arbitrary O +
units O +
, O +
P O +
< O +
0.01 O +
, O +
young O +
vs. O +
old O +
) O +
in O +
PBL O +
from O +
elderly O +
individuals O +
activated O +
with O +
PHA O +
. O +

Because O +
previous O +
work O +
has O +
demonstrated O +
that O +
T O +
cells O +
from O +
elderly O +
individuals O +
may O +
display O +
normal O +
proliferative O +
responses O +
when O +
activated O +
via O +
the O +
anti O -
- O -
CD2 O +
pathway O +
, O +
c O -
- O -
jun O +
and O +
jun O +
B O +
mRNA O +
expression O +
was O +
also O +
studied O +
in O +
anti B-CellLine -
- I-CellLine -
CD2-activated I-CellLine +
purified I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

No O +
age O -
- O -
related O +
differences O +
were O +
found O +
in O +
the O +
expression O +
of O +
either O +
of O +
these O +
two O +
proto O -
- O -
oncogenes O +
by O +
anti O -
- O -
CD2 O +
activated O +
T O +
cells O +
. O +

These O +
results O +
suggest O +
that O +
the O +
decreased O +
IL-2 O +
production O +
and O +
proliferative O +
response O +
displayed O +
by O +
PHA B-CellLine -
- I-CellLine -
activated I-CellLine +
PBL I-CellLine +
from O +
elderly O +
adults O +
may O +
be O +
related O +
to O +
age O -
- O -
related O +
changes O +
in O +
c O -
- O -
jun O +
mRNA O +
expression O +
and O +
in O +
the O +
ratio O +
of O +
c O -
- O -
fos O +
to O +
c O -
- O -
jun O +
mRNA O +
. O +

Characterization O +
of O +
a O +
novel O +
T O +
lymphocyte O +
protein O +
which O +
binds O +
to O +
a O +
site O +
related O +
to O +
steroid O -
/ O -
thyroid O +
hormone O +
receptor O +
response O +
elements O +
in O +
the O +
negative O +
regulatory O +
sequence O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
long O +
terminal O +
repeat O +
. O +

We O +
have O +
previously O +
identified O +
a O +
T O +
lymphocyte O +
protein O +
which O +
binds O +
to O +
a O +
site O +
within O +
the O +
LTR O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
and O +
exerts O +
an O +
inhibitory O +
effect O +
on O +
virus O +
gene O +
expression O +
. O +

The O +
palindromic O +
site O +
( O +
site O +
B O +
) O +
recognized O +
by O +
this O +
protein O +
is O +
related O +
to O +
the O +
palindromic O +
binding O +
sites O +
of O +
members O +
of O +
the O +
steroid O -
/ O -
thyroid O +
hormone O +
receptor O +
family O +
. O +

Here O +
we O +
characterize O +
the O +
T O +
cell O +
protein O +
binding O +
to O +
this O +
site O +
as O +
a O +
100 O +
kD O +
protein O +
which O +
is O +
most O +
abundant O +
in O +
T O +
cells O +
and O +
which O +
binds O +
to O +
site O +
B O +
as O +
a O +
200 O +
kD O +
complex O +
. O +

This O +
protein O +
is O +
distinct O +
from O +
other O +
members O +
of O +
the O +
steroid O -
/ O -
thyroid O +
hormone O +
receptor O +
family O +
including O +
the O +
COUP O +
protein O +
which O +
has O +
a O +
closely O +
related O +
DNA O +
binding O +
specificity O +
. O +

Reticuloendotheliosis O +
virus O +
long O +
terminal O +
repeat O +
elements O +
are O +
efficient O +
promoters O +
in O +
cells O +
of O +
various O +
species O +
and O +
tissue O +
origin O +
, O +
including O +
human O +
lymphoid O +
cells O +
. O +

Promiscuous O +
transcriptional O +
activity O +
of O +
the O +
reticuloendotheliosis O +
virus O +
( O +
REV O +
) O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
was O +
detected O +
in O +
transient O +
expression O +
assays O +
using O +
LTR O -
- O -
chloramphenicol O +
acetyltransferase O -
- O -
encoding O +
gene O +
chimeras O +
, O +
and O +
cells O +
of O +
diverse O +
species O +
and O +
tissue O +
type O +
; O +
levels O +
of O +
expression O +
from O +
two O +
different O +
REV O +
LTRs O +
correlate O +
with O +
reports O +
of O +
pathogenicity O +
of O +
the O +
respective O +
viruses O +
in O +
vivo O +
. O +

REVs O +
do O +
not O +
encode O +
a O +
transactivator O +
targeted O +
to O +
the O +
viral O +
LTR O +
, O +
and O +
cells O +
infected O +
with O +
Marek O +
's O +
disease O +
virus O +
, O +
a O +
herpesvirus O +
with O +
an O +
overlapping O +
host O +
range O +
, O +
do O +
not O +
express O +
factors O +
that O +
preferentially O +
enhance O +
expression O +
from O +
REV O +
or O +
avian O +
sarcoma O -
/ O -
leukemia O +
virus O +
LTRs O +
. O +

REV O +
LTRs O +
work O +
efficiently O +
in O +
human O +
lymphoid O +
cells O +
, O +
and O +
are O +
viable O +
alternatives O +
to O +
promoters O +
commonly O +
used O +
for O +
expression O +
of O +
cloned O +
genes O +
. O +

They O +
may O +
also O +
prove O +
useful O +
in O +
the O +
identification O +
of O +
new O +
, O +
ubiquitous O +
cellular O +
transcription O +
factors O +
. O +

SCL O +
and O +
related O +
hemopoietic O +
helix O -
- O -
loop O -
- O -
helix O +
transcription O +
factors O +
. O +

The O +
helix O -
- O -
loop O -
- O -
helix O +
( O +
HLH O +
) O +
proteins O +
are O +
a O +
family O +
of O +
transcription O +
factors O +
that O +
include O +
proteins O +
critical O +
to O +
differentiation O +
and O +
development O +
in O +
species O +
ranging O +
from O +
plants O +
to O +
mammals O +
. O +

Five O +
members O +
of O +
this O +
family O +
( O +
MYC O +
, O +
SCL O +
, O +
TAL-2 O +
, O +
LYL-1 O +
and O +
E2A O +
) O +
are O +
implicated O +
in O +
oncogenic O +
events O +
in O +
human O +
lymphoid O +
tumors O +
because O +
of O +
their O +
consistent O +
involvement O +
in O +
chromosomal O +
translocations O +
. O +

Although O +
activated O +
in O +
T O +
cell O +
leukemias O +
, O +
expression O +
of O +
SCL O +
and O +
LYL-1 O +
is O +
low O +
or O +
undetectable O +
in O +
normal O +
T O +
cell O +
populations O +
. O +

SCL O +
is O +
expressed O +
in O +
erythroid O +
, O +
megakaryocyte O +
and O +
mast O +
cell O +
populations O +
( O +
the O +
same O +
cell O +
lineages O +
as O +
GATA-1 O +
, O +
a O +
zinc O -
- O -
finger O +
transcription O +
factor O +
) O +
. O +

In O +
addition O +
, O +
both O +
SCL O +
and O +
GATA-1 O +
undergo O +
coordinate O +
modulation O +
during O +
chemically O +
induced O +
erythroid O +
differentiation O +
of O +
mouse O +
erythroleukemia O +
cells O +
and O +
are O +
down O -
- O -
modulated O +
during O +
myeloid O +
differentiation O +
of O +
human B-CellLine +
K562 I-CellLine +
cells I-CellLine +
, O +
thus O +
implying O +
a O +
role O +
for O +
SCL O +
in O +
erythroid O +
differentiation O +
events O +
. O +

However O +
, O +
in O +
contrast O +
to O +
GATA-1 O +
, O +
SCL O +
is O +
expressed O +
in O +
the O +
developing O +
brain O +
. O +

Studies O +
of O +
the O +
function O +
of O +
SCL O +
suggest O +
it O +
is O +
also O +
important O +
in O +
proliferation O +
and O +
self O -
- O -
renewal O +
events O +
in O +
erythroid O +
cells O +
. O +

Phorbol O +
ester O +
reduces O +
constitutive O +
nuclear O +
NF O +
kappa O +
B O +
and O +
inhibits O +
HIV-1 O +
production O +
in O +
mature O +
human O +
monocytic O +
cells O +
. O +

NF O +
kappa O +
B O +
is O +
a O +
potent O +
mediator O +
of O +
specific O +
gene O +
expression O +
in O +
human O +
monocytes O +
and O +
has O +
been O +
shown O +
to O +
play O +
a O +
role O +
in O +
transcription O +
of O +
the O +
HIV-1 O +
genome O +
in O +
promonocytic O +
leukemias O +
. O +

There O +
is O +
little O +
information O +
available O +
on O +
the O +
response O +
of O +
NF O +
kappa O +
B O +
to O +
cytokines O +
in O +
normal O +
human O +
monocytes O +
. O +

We O +
have O +
used O +
a O +
32P O -
- O -
labeled O +
oligonucleotide O +
derived O +
from O +
human O +
immunodeficiency O +
virus O +
( O +
HIV-1 O +
) O +
long O +
terminal O +
repeat O +
, O +
which O +
contains O +
a O +
tandem O +
repeat O +
of O +
the O +
NF O +
kappa O +
B O +
binding O +
sequence O +
, O +
as O +
a O +
probe O +
in O +
a O +
gel O +
retardation O +
assay O +
to O +
study O +
this O +
transcription O +
factor O +
. O +

Using O +
this O +
assay O +
, O +
we O +
have O +
detected O +
NF O +
kappa O +
B O +
in O +
extracts O +
of O +
nuclei O +
from O +
normal O +
human O +
monocytes O +
. O +

Treatment O +
of O +
normal O +
monocytes O +
with O +
12 O -
- O -
0-tetradecanoyl O +
phorbol-13-acetate O +
( O +
TPA O +
) O +
for O +
4 O -
- O -
24 O +
h O +
caused O +
the O +
complete O +
disappearance O +
of O +
NF O +
kappa O +
B O +
from O +
nuclear O +
extracts O +
of O +
monocytes O +
. O +

A O +
similar O +
result O +
was O +
obtained O +
with O +
the O +
mature B-CellLine +
monocytic I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
THP-1 B-CellLine +
. O +

The O +
constitutive O +
transcription O +
factor O +
SP1 O +
was O +
unaffected O +
by O +
addition O +
of O +
TPA O +
. O +

The O +
disappearance O +
of O +
NF O +
kappa O +
B O +
from O +
the O +
nucleus O +
was O +
concentration O +
dependent O +
between O +
10 O +
and O +
50 O +
ng O -
/ O -
ml O +
of O +
phorbol O +
ester O +
. O +

In O +
THP-1 O +
cells O +
, O +
TPA O +
also O +
induced O +
a O +
new O +
, O +
faster O -
- O -
migrating O +
NF O +
kappa O +
B O +
species O +
not O +
induced O +
in O +
monocytes O +
. O +

Protein O +
kinase O +
C O +
inhibitor O +
staurosporine O +
, O +
but O +
not O +
cyclic O +
nucleotide O -
- O -
dependent O +
protein O +
kinase O +
inhibitor O +
HA-1004 O +
, O +
also O +
dramatically O +
reduced O +
constitutive O +
levels O +
of O +
nuclear O +
NF O +
kappa O +
B O +
. O +

Finally O +
, O +
TPA O +
addition O +
to O +
monocytes O +
infected O +
with O +
HIV-1 O +
inhibited O +
HIV-1 O +
replication O +
, O +
as O +
determined O +
by O +
reverse O +
transcriptase O +
assays O +
, O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O +
. O +

These O +
results O +
are O +
in O +
striking O +
contrast O +
to O +
the O +
increase O +
in O +
nuclear O +
NF O +
kappa O +
B O +
and O +
HIV-1 O +
replication O +
induced O +
by O +
phorbol O +
esters O +
in O +
promonocytic B-CellLine +
leukemia I-CellLine +
cells I-CellLine +
U937 I-CellLine +
and O +
HL-60 B-CellLine +
, O +
and O +
emphasize O +
the O +
importance O +
of O +
studying O +
cytokine O +
regulation O +
of O +
HIV-1 O +
in O +
normal O +
monocytes O +
. O +

Inhibition O +
of O +
anti O -
- O -
CD3 O +
monoclonal O +
antibody O +
-induced O +
T O -
- O -
cell O +
proliferation O +
by O +
dexamethasone O +
, O +
isoproterenol O +
, O +
or O +
prostaglandin O +
E2 O +
either O +
alone O +
or O +
in O +
combination O +
. O +

1 O +
. O +

The O +
purpose O +
of O +
these O +
studies O +
was O +
to O +
investigate O +
the O +
modulation O +
of O +
the O +
proliferation O +
of O +
human O +
T O +
cells O +
obtained O +
from O +
peripheral O +
blood O +
by O +
dexamethasone O +
( O +
DEX O +
) O +
, O +
isoproterenol O +
( O +
ISO O +
) O +
, O +
and O +
prostaglandin O +
E2 O +
( O +
PGE2 O +
) O +
. O +

The O +
former O +
two O +
substances O +
interact O +
with O +
T O +
cells O +
via O +
the O +
glucocorticoid O +
and O +
beta O -
- O -
adrenergic O +
receptors O +
respectively O +
. O +

When O +
occupied O +
by O +
their O +
natural O +
ligands O +
, O +
glucocorticosteroids O +
and O +
catecholamines O +
, O +
these O +
receptors O +
have O +
a O +
role O +
in O +
modulating O +
T O -
- O -
cell O +
function O +
during O +
stress O +
. O +

During O +
the O +
inflammatory O +
response O +
increased O +
levels O +
of O +
PGE2 O +
bind O +
to O +
their O +
receptors O +
on O +
T O +
cells O +
and O +
thus O +
alter O +
responsiveness O +
. O +

Proliferation O +
of O +
T O +
cells O +
was O +
induced O +
by O +
immobilized O +
anti O -
- O -
CD3 O +
monoclonal O +
antibody O +
( O +
mAb O +
) O +
in O +
the O +
presence O +
or O +
absence O +
of O +
an O +
additional O +
costimulatory O +
signal O +
delivered O +
by O +
anti O -
- O -
CD28 O +
mAb O +
. O +

2 O +
. O +

Various O +
physiologic O +
concentrations O +
of O +
DEX O +
, O +
ISO O +
, O +
or O +
PGE2 O +
were O +
added O +
at O +
the O +
time O +
of O +
initiation O +
of O +
the O +
cultures O +
and O +
subsequent O +
proliferation O +
of O +
the O +
unstimulated O +
T O +
cells O +
was O +
determined O +
. O +

The O +
results O +
demonstrate O +
that O +
physiologic O +
concentrations O +
of O +
all O +
three O +
of O +
these O +
agents O +
inhibit O +
the O +
anti O -
- O -
CD3 O +
mAb O +
-induced O +
proliferation O +
of O +
T O +
cells O +
. O +

3 O +
. O +

Although O +
DEX O +
and O +
PGE2 O +
were O +
equipotent O +
in O +
suppressing O +
T O -
- O -
cell O +
proliferation O +
, O +
ISO O +
was O +
much O +
less O +
effective O +
. O +

4 O +
. O +

Because O +
concomitant O +
elevations O +
in O +
the O +
peripheral O +
levels O +
of O +
these O +
substances O +
may O +
occur O +
, O +
experiments O +
were O +
performed O +
to O +
determine O +
the O +
T O -
- O -
cell O +
inhibitory O +
effects O +
of O +
DEX O +
together O +
with O +
either O +
PGE2 O +
or O +
ISO O +
. O +

Synergistic O +
suppression O +
of O +
T O -
- O -
cell O +
proliferation O +
was O +
observed O +
when O +
various O +
concentrations O +
of O +
DEX O +
and O +
PGE2 O +
, O +
but O +
not O +
DEX O +
and O +
ISO O +
, O +
were O +
added O +
to O +
cultures O +
. O +

This O +
synergistic O +
suppression O +
could O +
not O +
be O +
explained O +
by O +
an O +
increase O +
in O +
cAMP O +
accumulation O +
in O +
T O +
cells O +
stimulated O +
with O +
DEX O +
and O +
PGE2 O +
. O +

5 O +
. O +

Finally O +
, O +
the O +
addition O +
of O +
anti O -
- O -
CD28 O +
mAb O +
to O +
anti O -
- O -
CD3 O +
mAb O -
- O -
stimulated O +
T O +
cells O +
overcame O +
much O +
of O +
the O +
suppression O +
of O +
proliferation O +
induced O +
by O +
PGE2 O +
or O +
ISO O +
but O +
less O +
so O +
than O +
that O +
induced O +
by O +
DEX O +
. O +

Involvement O +
of O +
Alu O +
sequences O +
in O +
the O +
cell O -
- O -
specific O +
regulation O +
of O +
transcription O +
of O +
the O +
gamma O +
chain O +
of O +
Fc O +
and O +
T O +
cell O +
receptors O +
. O +

The O +
Fc O +
epsilon O +
RI O -
- O -
gamma O +
chains O +
are O +
expressed O +
in O +
a O +
variety O +
of O +
hematopoietic O +
cells O +
where O +
they O +
play O +
a O +
critical O +
role O +
in O +
signal O +
transduction O +
. O +

They O +
are O +
part O +
of O +
the O +
high O +
affinity O +
IgE O +
receptor O +
in O +
mast O +
cells O +
, O +
basophils O +
, O +
Langerhans O +
cells O +
, O +
and O +
possibly O +
other O +
cells O +
; O +
a O +
component O +
of O +
the O +
low O +
affinity O +
receptor O +
for O +
IgG O +
( O +
Fc O +
gamma O +
RIIIA O +
or O +
CD16 O +
) O +
in O +
natural O +
killer O +
cells O +
and O +
macrophages O +
; O +
and O +
part O +
of O +
the O +
T O +
cell O +
antigen O +
receptor O +
in O +
subsets O +
of O +
T O +
cells O +
. O +

Here O +
we O +
have O +
investigated O +
the O +
transcriptional O +
regulation O +
of O +
the O +
gamma O +
chain O +
gene O +
by O +
analyzing O +
the O +
2.5-kilobase O +
sequence O +
upstream O +
of O +
the O +
transcription O +
start O +
site O +
. O +

This O +
sequence O +
contains O +
a O +
promoter O +
specific O +
to O +
cells O +
of O +
hematopoietic O +
lineage O +
. O +

However O +
, O +
the O +
tissue O +
specificity O +
of O +
this O +
promoter O +
is O +
only O +
partial O +
because O +
it O +
is O +
active O +
in O +
all O +
of O +
the O +
hematopoietic O +
cells O +
tested O +
here O +
, O +
regardless O +
of O +
whether O +
they O +
constitutively O +
express O +
Fc O +
epsilon O +
RI- O +
gamma O +
chain O +
transcripts O +
. O +

We O +
have O +
identified O +
two O +
adjacent O +
cis O -
- O -
acting O +
regulatory O +
elements O +
, O +
both O +
of O +
which O +
are O +
part O +
of O +
an O +
Alu O +
repeat O +
. O +

The O +
first O +
( O +
-445 O -
/ O -
-366 O +
) O +
is O +
a O +
positive O +
element O +
active O +
in O +
both O +
basophils O +
and O +
T O +
cells O +
. O +

The O +
second O +
( O +
-365 O -
/ O -
-264 O +
) O +
binds O +
to O +
nuclear O +
factors O +
, O +
which O +
appear O +
to O +
be O +
different O +
in O +
basophils O +
and O +
T O +
cells O +
, O +
and O +
acts O +
as O +
a O +
negative O +
element O +
in O +
basophils O +
and O +
as O +
a O +
positive O +
one O +
in O +
T O +
cells O +
. O +

Thus O +
, O +
this O +
Alu O +
repeat O +
( O +
90 O +
% O +
identical O +
to O +
Alu O +
consensus O +
sequences O +
) O +
has O +
evolved O +
to O +
become O +
both O +
a O +
positive O +
and O +
negative O +
regulator O +
. O +

Human O +
immunodeficiency O +
viruses O +
containing O +
heterologous O +
enhancer O -
/ O -
promoters O +
are O +
replication O +
competent O +
and O +
exhibit O +
different O +
lymphocyte O +
tropisms O +
. O +

The O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
type O +
1 O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
contains O +
binding O +
sites O +
for O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
and O +
the O +
constitutively O +
expressed O +
transcription O +
factor O +
Sp1 O +
, O +
both O +
of O +
which O +
are O +
highly O +
conserved O +
in O +
HIV O +
and O +
simian O +
immunodeficiency O +
virus O +
isolates O +
. O +

To O +
delineate O +
the O +
effects O +
of O +
these O +
motifs O +
on O +
the O +
replicative O +
capacity O +
of O +
HIV O +
and O +
to O +
explore O +
the O +
possibility O +
of O +
extending O +
the O +
virus O +
host O +
range O +
, O +
known O +
heterologous O +
enhancer O -
/ O -
promoters O +
were O +
inserted O +
into O +
the O +
HIV-1 O +
LTR O +
in O +
place O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
and O +
Sp1 O +
binding O +
sites O +
. O +

The O +
effects O +
of O +
these O +
substitutions O +
on O +
viral O +
replication O +
in O +
transfected O +
HeLa B-CellLine +
cells I-CellLine +
and O +
on O +
HIV O +
infection O +
of O +
human O +
peripheral O +
blood O +
lymphocytes O +
or O +
continuous B-CellLine +
T I-CellLine -
- I-CellLine -
leukemia I-CellLine +
cell I-CellLine +
lines I-CellLine +
were O +
evaluated O +
. O +

HIVs O +
in O +
which O +
the O +
NF O -
- O -
kappa O +
B O -
/ O -
Sp1 O +
enhancer O +
plus O +
the O +
downstream O +
TATA O +
element O +
were O +
replaced O +
with O +
heterologous O +
enhancer O -
/ O -
promoters O +
were O +
also O +
constructed O +
. O +

Viruses O +
containing O +
the O +
human O +
cytomegalovirus O +
immediate O -
- O -
early O +
enhancer O +
exhibited O +
infectious O +
kinetics O +
similar O +
to O +
that O +
of O +
wild O -
- O -
type O +
HIV O +
in O +
activated O +
human O +
peripheral O +
blood O +
lymphocytes O +
and O +
AA2 B-CellLine +
cells I-CellLine +
but O +
replicated O +
less O +
efficiently O +
in O +
H9 B-CellLine +
and I-CellLine +
CEM I-CellLine +
cells I-CellLine +
. O +

These O +
studies O +
indicate O +
that O +
heterologous O +
enhancer O +
elements O +
are O +
capable O +
of O +
restoring O +
Tat O +
responsiveness O +
to O +
the O +
HIV O +
LTR O +
in O +
the O +
context O +
of O +
directing O +
reporter O +
gene O +
expression O +
as O +
well O +
as O +
in O +
the O +
production O +
of O +
infectious O +
progeny O +
virions O +
. O +

Photoaffinity O +
labeling O +
of O +
plasma O +
membrane O +
receptors O +
for O +
aldosterone O +
from O +
human O +
mononuclear O +
leukocytes O +
. O +

Non O -
- O -
genomic O +
effects O +
of O +
aldosterone O +
on O +
the O +
sodium O -
- O -
proton O -
- O -
antiport O +
have O +
been O +
shown O +
in O +
human O +
mononuclear O +
leukocytes O +
which O +
could O +
be O +
related O +
to O +
a O +
new O +
aldosterone O +
membrane O +
receptor O +
. O +

In O +
the O +
present O +
paper O +
plasma O +
membranes O +
from O +
human O +
mononuclear O +
leukocytes O +
were O +
covalently O +
photolabeled O +
with O +
a O +
[ O +
125I O +
] O +
-aldosterone O +
derivative O +
. O +

Sodium O +
dodecyl O +
sulfate O -
- O -
polyacrylamide O +
gel O +
electrophoresis O +
showed O +
significant O +
aldosterone O +
binding O +
at O +
a O +
molecular O +
weight O +
of O +
approximately O +
50000 O +
Dalton O +
which O +
was O +
absent O +
with O +
1 O +
microM O +
cold O +
aldosterone O +
, O +
but O +
not O +
cortisol O +
in O +
the O +
binding O +
media O +
. O +

The O +
presence O +
of O +
the O +
sulfhydryl O +
agent O +
dithiothreitol O +
did O +
not O +
affect O +
results O +
suggesting O +
the O +
absence O +
of O +
disulfide O +
bridges O +
in O +
the O +
steroid O +
binding O +
domain O +
of O +
the O +
receptor O +
. O +

These O +
data O +
are O +
the O +
first O +
to O +
define O +
the O +
molecular O +
weight O +
of O +
the O +
membrane O +
receptor O +
for O +
aldosterone O +
. O +

Alpha O -
- O -
lipoic O +
acid O +
is O +
a O +
potent O +
inhibitor O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
human O +
T O +
cells O +
. O +

Acquired O +
immunodeficiency O +
syndrome O +
( O +
AIDS O +
) O +
results O +
from O +
infection O +
with O +
a O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
. O +

The O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
region O +
of O +
HIV O +
proviral O +
DNA O +
contains O +
binding O +
sites O +
for O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
, O +
and O +
this O +
transcriptional O +
activator O +
appears O +
to O +
regulate O +
HIV O +
activation O +
. O +

Recent O +
findings O +
suggest O +
an O +
involvement O +
of O +
reactive O +
oxygen O +
species O +
( O +
ROS O +
) O +
in O +
signal O +
transduction O +
pathways O +
leading O +
to O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

The O +
present O +
study O +
was O +
based O +
on O +
reports O +
that O +
antioxidants O +
which O +
eliminate O +
ROS O +
should O +
block O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
subsequently O +
HIV O +
transcription O +
, O +
and O +
thus O +
antioxidants O +
can O +
be O +
used O +
as O +
therapeutic O +
agents O +
for O +
AIDS O +
. O +

Incubation O +
of O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
( O +
1 O +
x O +
10 O +
( O +
6 O +
) O +
cells O -
/ O -
ml O +
) O +
with O +
a O +
natural O +
thiol O +
antioxidant O +
, O +
alpha O -
- O -
lipoic O +
acid O +
, O +
prior O +
to O +
the O +
stimulation O +
of O +
cells O +
was O +
found O +
to O +
inhibit O +
NF O -
- O -
kappa O +
B O +
activation O +
induced O +
by O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
25 O +
ng O -
/ O -
ml O +
) O +
or O +
by O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
50 O +
ng O -
/ O -
ml O +
) O +
. O +

The O +
inhibitory O +
action O +
of O +
alpha O -
- O -
lipoic O +
acid O +
was O +
found O +
to O +
be O +
very O +
potent O +
as O +
only O +
4 O +
mM O +
was O +
needed O +
for O +
a O +
complete O +
inhibition O +
, O +
whereas O +
20 O +
mM O +
was O +
required O +
for O +
N O -
- O -
acetylcysteine O +
. O +

These O +
results O +
indicate O +
that O +
alpha O -
- O -
lipoic O +
acid O +
may O +
be O +
effective O +
in O +
AIDS O +
therapeutics O +
. O +

A O +
human O +
putative O +
lymphocyte O +
G0 O -
/ O -
G1 O +
switch O +
gene O +
homologous O +
to O +
a O +
rodent O +
gene O +
encoding O +
a O +
zinc O -
- O -
binding O +
potential O +
transcription O +
factor O +
. O +

G0S24 O +
is O +
a O +
member O +
of O +
a O +
set O +
of O +
genes O +
( O +
putative O +
G0 O -
/ O -
G1 O +
switch O +
regulatory O +
genes O +
) O +
that O +
are O +
expressed O +
transiently O +
within O +
1 O -
- O -
2 O +
hr O +
of O +
the O +
addition O +
of O +
lectin O +
or O +
cycloheximide O +
to O +
human O +
blood O +
mononuclear O +
cells O +
. O +

Comparison O +
of O +
a O +
full O -
- O -
length O +
cDNA O +
sequence O +
with O +
the O +
corresponding O +
genomic O +
sequence O +
reveals O +
an O +
open O +
reading O +
frame O +
of O +
326 O +
amino O +
acids O +
, O +
distributed O +
across O +
two O +
exons O +
. O +

Potential O +
phosphorylation O +
sites O +
include O +
the O +
sequence O +
PSPTSPT O +
, O +
which O +
resembles O +
an O +
RNA O +
polymerase O +
II O +
repeat O +
reported O +
to O +
be O +
a O +
target O +
of O +
the O +
cell O +
cycle O +
control O +
kinase O +
cdc2 O +
. O +

Comparison O +
of O +
the O +
derived O +
protein O +
sequence O +
with O +
those O +
of O +
rodent O +
homologs O +
allows O +
classification O +
into O +
three O +
groups O +
. O +

Group O +
1 O +
contains O +
G0S24 O +
and O +
the O +
rat O +
and O +
mouse O +
TIS11 O +
genes O +
( O +
also O +
known O +
as O +
TTP O +
, O +
Nup475 O +
, O +
and O +
Zfp36 O +
) O +
. O +

Members O +
of O +
this O +
group O +
have O +
three O +
tetraproline O +
repeats O +
. O +

Groups O +
1 O +
and O +
2 O +
have O +
a O +
serine O -
- O -
rich O +
region O +
and O +
an O +
` O -
` O +
arginine O +
element O +
` O -
` O +
( O +
RRLPIF O +
) O +
at O +
the O +
carboxyl O +
terminus O +
. O +

All O +
groups O +
contain O +
cysteine- O +
and O +
histidine O -
- O -
rich O +
putative O +
zinc O +
finger O +
domains O +
and O +
a O +
serine O -
- O -
phenylalanine O +
` O -
` O +
SFS O +
'' O +
domain O +
similar O +
to O +
part O +
of O +
the O +
large O +
subunit O +
of O +
eukaryotic O +
RNA O +
polymerase O +
II O +
. O +

Comparison O +
of O +
group O +
1 O +
human O +
and O +
mouse O +
genomic O +
sequences O +
shows O +
high O +
conservation O +
in O +
the O +
5 O +
' O +
flank O +
and O +
exons O +
. O +

A O +
CpG O +
island O +
suggests O +
expression O +
in O +
the O +
germ O +
line O +
. O +

G0S24 O +
has O +
potential O +
sites O +
for O +
transcription O +
factors O +
in O +
the O +
5 O +
' O +
flank O +
and O +
intron O +
; O +
these O +
include O +
a O +
serum O +
response O +
element O +
. O +

Protein O +
and O +
genomic O +
sequences O +
show O +
similarities O +
with O +
those O +
of O +
a O +
variety O +
of O +
proteins O +
involved O +
in O +
transcription O +
, O +
suggesting O +
that O +
the O +
G0S24 O +
product O +
has O +
a O +
similar O +
role O +
. O +

Interleukin-4 O +
inhibits O +
the O +
lipopolysaccharide O -
- O -
induced O +
expression O +
of O +
c O -
- O -
jun O +
and O +
c O -
- O -
fos O +
messenger O +
RNA O +
and O +
activator O +
protein-1 O +
binding O +
activity O +
in O +
human O +
monocytes O +
. O +

We O +
studied O +
the O +
effect O +
of O +
interleukin-4 O +
( O +
IL-4 O +
) O +
on O +
the O +
lipopolysaccharide O +
( O +
LPS O +
) O +
induction O +
of O +
two O +
immediate O +
early O +
genes O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
. O +

These O +
genes O +
encode O +
proteins O +
that O +
form O +
the O +
dimeric O +
complex O +
activator O +
protein-1 O +
( O +
AP-1 O +
) O +
, O +
which O +
is O +
active O +
as O +
a O +
transcriptional O +
factor O +
. O +

Maximal O +
accumulation O +
of O +
either O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
messenger O +
RNA O +
( O +
mRNA O +
) O +
occurred O +
30 O +
minutes O +
after O +
LPS O +
addition O +
. O +

When O +
cells O +
were O +
treated O +
with O +
IL-4 O +
for O +
5 O +
hours O +
before O +
LPS O +
activation O +
, O +
both O +
the O +
c O -
- O -
fos O +
and O +
the O +
c O -
- O -
jun O +
mRNA O +
expression O +
was O +
decreased O +
. O +

The O +
inhibition O +
of O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
expression O +
by O +
IL-4 O +
in O +
LPS O -
- O -
treated O +
cells O +
was O +
shown O +
to O +
be O +
due O +
to O +
a O +
lower O +
transcription O +
rate O +
of O +
the O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
genes O +
. O +

IL-4 O +
did O +
not O +
affect O +
the O +
stability O +
of O +
the O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
transcripts O +
. O +

Finally O +
, O +
using O +
electrophoretic O +
mobility O +
shift O +
assays O +
, O +
evidence O +
was O +
obtained O +
that O +
IL-4 O +
inhibits O +
LPS O -
- O -
induced O +
expression O +
of O +
AP-1 O +
protein O +
. O +

These O +
data O +
indicate O +
that O +
IL-4 O +
suppresses O +
the O +
induction O +
of O +
transcription O +
factors O +
in O +
human O +
activated O +
monocytes O +
. O +

Ras O +
oncogene O +
transformation O +
of O +
human O +
B O +
lymphoblasts O +
is O +
associated O +
with O +
lymphocyte O +
activation O +
and O +
with O +
a O +
block O +
of O +
differentiation O +
. O +

The O +
p21ras O +
small O +
GTP O +
binding O +
proteins O +
participate O +
in O +
signal O +
transduction O +
from O +
cell O +
surface O +
receptors O +
and O +
affect O +
neoplastic O +
transformation O +
and O +
development O +
in O +
many O +
different O +
cell O +
types O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
examined O +
the O +
relationship O +
between O +
ras O +
transformation O +
and O +
differentiation O +
of O +
human O +
B O +
lymphocytes O +
. O +

We O +
show O +
that O +
the O +
constitutive O +
expression O +
of O +
the O +
T24 O +
Ha O -
- O -
ras O +
oncogene O +
in O +
EBV B-CellLine -
- I-CellLine -
immortalized I-CellLine +
B I-CellLine +
lymphoblasts I-CellLine +
was O +
associated O +
with O +
the O +
induction O +
of O +
the O +
interleukin O +
2 O +
receptor O +
alpha O +
subunit O +
, O +
with O +
an O +
impaired O +
immunoglobulin O +
gene O +
expression O +
, O +
altered O +
adhesion O +
properties O +
and O +
increased O +
survival O +
in O +
serum O -
- O -
free O +
medium O +
. O +

Since O +
induction O +
of O +
the O +
IL-2 O +
receptor O +
alpha O +
subunit O +
is O +
a O +
hallmark O +
of O +
lymphocyte O +
activation O +
, O +
we O +
suggest O +
that O +
p21ras O +
naturally O +
triggers O +
B O +
cell O +
activation O +
. O +

The O +
ras B-CellLine -
- I-CellLine -
transformed I-CellLine +
lymphocytes I-CellLine +
displayed O +
a O +
fully O +
functional O +
IL-2r O +
, O +
as O +
assessed O +
by O +
c O -
- O -
fos O +
induction O +
following O +
treatment O +
with O +
IL-2 O +
; O +
nevertheless O +
, O +
they O +
were O +
not O +
growth O +
stimulated O +
by O +
this O +
lymphokine O +
. O +

The O +
decreased O +
expression O +
of O +
immunoglobulin O +
genes O +
indicates O +
that O +
the O +
ras O +
oncogene O +
blocks O +
terminal O +
differentiation O +
to O +
plasma O +
cells O +
, O +
possibly O +
by O +
inhibiting O +
the O +
activity O +
of O +
lymphocyte O -
- O -
specific O +
transcription O +
factors O +
. O +

Somewhat O +
unexpectedly O +
, O +
the O +
constitutive O +
p21ras O +
activity O +
did O +
not O +
cause O +
an O +
increased O +
DNA O +
binding O +
of O +
transcription O +
factors O +
PEA1 O +
( O +
AP1 O +
) O +
, O +
PEA3 O +
, O +
Oct-2 O +
or O +
NF O -
- O -
kB O +

Transcription O +
factor O +
GATA-1 O +
and O +
erythroid O +
development O +
. O +

In O +
summary O +
, O +
we O +
derived O +
an O +
experimental O +
system O +
that O +
allows O +
us O +
to O +
dissect O +
the O +
function O +
of O +
GATA-1 O +
in O +
red O +
cell O +
development O +
at O +
a O +
genetic O +
level O +
. O +

We O +
have O +
established O +
the O +
essential O +
nature O +
of O +
GATA-1 O +
during O +
both O +
primitive O +
and O +
definitive O +
erythropoiesis O +
. O +

By O +
ablating O +
the O +
expression O +
of O +
the O +
endogenous O +
GATA-1 O +
gene O +
, O +
we O +
are O +
in O +
a O +
position O +
to O +
introduce O +
a O +
variety O +
of O +
constructs O +
that O +
harbor O +
subtle O +
modifications O +
in O +
flanking O +
or O +
protein O -
- O -
coding O +
sequences O +
. O +

We O +
can O +
now O +
study O +
regulatory O +
regions O +
and O +
functional O +
domains O +
of O +
the O +
protein O +
in O +
the O +
context O +
of O +
a O +
true O +
erythroid O +
environment O +
, O +
experiments O +
that O +
have O +
not O +
been O +
possible O +
heretofore O +
. O +

Although O +
the O +
assay O +
involves O +
the O +
dramatic O +
loss O +
of O +
red O +
cell O +
production O +
, O +
it O +
should O +
be O +
possible O +
to O +
define O +
important O +
regulatory O +
domains O +
that O +
can O +
then O +
be O +
assayed O +
using O +
less O +
stringent O +
systems O +
, O +
such O +
as O +
cell O -
- O -
free O +
extracts O +
for O +
in O +
vitro O +
transcription O +
. O +

The O +
ideal O +
situation O +
would O +
be O +
analyses O +
conducted O +
in O +
GATA-1 B-CellLine +
-erythroid I-CellLine +
cells I-CellLine +
. O +

However O +
, O +
these O +
cells O +
have O +
been O +
impossible O +
to O +
generate O +
given O +
the O +
requirement O +
of O +
GATA-1 O +
for O +
Epo O +
receptor O +
expression O +
and O +
red O +
cell O +
viability O +
( O +
C. O +
Simon O +
and O +
S. O +
Orkin O +
, O +
unpublished O +
observations O +
) O +
. O +

It O +
may O +
be O +
possible O +
to O +
produce O +
such O +
cells O +
by O +
first O +
expressing O +
the O +
Epo O +
receptor O +
under O +
the O +
influence O +
of O +
a O +
constitutive O +
promoter O +
and O +
then O +
targeting O +
the O +
GATA-1 O +
gene O +
. O +

If O +
GATA-1 B-CellLine +
-red I-CellLine +
cells I-CellLine +
were O +
available O +
, O +
the O +
analyses O +
would O +
involve O +
the O +
actual O +
transcription O +
of O +
or O +
chromatin O +
structure O +
surrounding O +
the O +
globin O +
genes O +
. O +

Structure O -
- O -
function O +
studies O +
of O +
the O +
GATA-1 O +
protein O +
could O +
be O +
greatly O +
simplified O +
and O +
a O +
larger O +
number O +
of O +
mutants O +
studied O +
. O +

However O +
, O +
the O +
ES O +
cell O +
system O +
can O +
be O +
used O +
as O +
an O +
alternative O +
until O +
targeted B-CellLine +
erythroleukemia I-CellLine +
cells I-CellLine +
become O +
available O +
. O +

Other O +
applications O +
involve O +
the O +
introduction O +
of O +
other O +
GATA O -
- O -
binding O +
protein O +
family O +
members O +
to O +
determine O +
whether O +
they O +
rescue O +
the O +
mutation O +
. O +

If O +
they O +
can O +
not O +
, O +
chimeric O +
proteins O +
can O +
be O +
tested O +
to O +
identify O +
which O +
amino O +
acids O +
distinguish O +
the O +
different O +
family O +
members O +
. O +

We O +
feel O +
that O +
these O +
experiments O +
are O +
vital O +
to O +
understanding O +
the O +
function O +
of O +
GATA-1 O +
during O +
erythroid O +
ontogeny O +
. O +

How O +
does O +
GATA-1 O +
regulate O +
red O +
cell O +
genes O +
like O +
globin O +
or O +
the O +
Epo O +
receptor O +
? O +
Once O +
we O +
identify O +
the O +
functional O +
domains O +
of O +
the O +
GATA O -
- O -
binding O +
proteins O +
, O +
we O +
hope O +
to O +
learn O +
what O +
proteins O +
GATA-1 O +
binds O +
to O +
in O +
the O +
basic O +
transcription O +
machinery O +
or O +
in O +
chromatin O +
. O +

Is O +
GATA-1 O +
necessary O +
for O +
globin O +
gene O +
switching O +
? O +
GATA-1 O +
may O +
be O +
modified O +
differently O +
during O +
development O +
so O +
that O +
the O +
locus O +
control O +
region O +
can O +
interact O +
with O +
different O +
globin O +
promoters O +
. O +

We O +
may O +
find O +
that O +
one O +
region O +
of O +
the O +
protein O +
is O +
required O +
for O +
embryonic O +
expression O +
and O +
another O +
for O +
adult O +
globin O +
gene O +
expression O +
. O +

Activation O +
of O +
lymphokine O +
genes O +
in O +
T O +
cells O +
: O +
role O +
of O +
cis O -
- O -
acting O +
DNA O +
elements O +
that O +
respond O +
to O +
T O +
cell O +
activation O +
signals O +
. O +

Activation O +
of O +
T O +
cells O +
is O +
initiated O +
by O +
the O +
recognition O +
of O +
antigen O +
on O +
antigen O +
presenting O +
cells O +
to O +
exert O +
the O +
effector O +
functions O +
in O +
immune O +
and O +
inflammatory O +
responses O +
. O +

Two O +
types O +
of O +
helper B-CellLine +
T I-CellLine +
cell I-CellLine +
( I-CellLine +
Th I-CellLine +
) I-CellLine +
clones I-CellLine +
( O +
Th1 B-CellLine +
and O +
Th2 B-CellLine +
) O +
are O +
defined O +
on O +
the O +
basis O +
of O +
different O +
patterns O +
of O +
cytokine O +
( O +
lymphokine O +
) O +
secretion O +
. O +

They O +
determine O +
the O +
outcome O +
of O +
an O +
antigenic O +
response O +
toward O +
humoral O +
or O +
cell O -
- O -
mediated O +
immunity O +
. O +

Although O +
lymphokine O +
genes O +
are O +
coordinately O +
regulated O +
upon O +
antigen O +
stimulation O +
, O +
they O +
are O +
regulated O +
by O +
the O +
mechanisms O +
common O +
to O +
all O +
as O +
well O +
as O +
those O +
which O +
are O +
unique O +
to O +
each O +
gene O +
. O +

For O +
most O +
lymphokine O +
genes O +
, O +
a O +
combination O +
of O +
phorbol O +
esters O +
( O +
phorbol O +
12-myristate O +
13 O +
acetate O +
, O +
PMA O +
) O +
and O +
calcium O +
ionophores O +
( O +
A23187 O +
) O +
is O +
required O +
for O +
their O +
maximal O +
induction O +
. O +

Yet O +
phorbol O +
ester O +
alone O +
or O +
calcium O +
ionophore O +
alone O +
produce O +
several O +
lymphokines O +
. O +

The O +
production O +
of O +
the O +
granulocyte O -
- O -
macrophage O +
colony O +
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
is O +
completely O +
dependent O +
on O +
the O +
two O +
signals O +
. O +

We O +
have O +
previously O +
found O +
a O +
cis O -
- O -
acting O +
region O +
spanning O +
the O +
GM O -
- O -
CSF O +
promoter O +
region O +
( O +
positions O +
-95 O +
to O +
+ O -
27 O +
) O +
that O +
confers O +
inducibility O +
to O +
reporter O +
genes O +
in O +
transient O +
transfection O +
assays O +
. O +

Further O +
analysis O +
identified O +
three O +
elements O +
required O +
for O +
efficient O +
induction O +
, O +
referred O +
to O +
as O +
GM2 O +
, O +
GC O -
- O -
box O +
and O +
conserved O +
lymphokine O +
element O +
( O +
CLE0 O +
) O +
. O +

GM2 O +
defines O +
a O +
binding O +
site O +
for O +
protein O +
( O +
s O +
) O +
whose O +
binding O +
is O +
inducible O +
by O +
PMA O +
. O +

One O +
protein O +
, O +
NF O -
- O -
GM2 O +
is O +
similar O +
to O +
the O +
transcription O +
factor O +
NF O -
- O -
kB O +
. O +

GC O -
- O -
box O +
is O +
a O +
binding O +
site O +
for O +
constitutively O +
bound O +
proteins O +
. O +

CLEO O +
defines O +
a O +
binding O +
site O +
for O +
protein O +
( O +
s O +
) O +
whose O +
optimum O +
binding O +
is O +
stimulated O +
by O +
PMA O +
and O +
A23187 O +
. O +

Viral O +
trans O -
- O -
activators O +
such O +
as O +
Tax O +
( O +
human O +
T O +
cell O +
leukemia O +
virus-1 O +
, O +
HTLV-1 O +
) O +
and O +
E2 O +
( O +
bovine O +
papilloma O +
virus O +
, O +
BPV O +
) O +
proteins O +
are O +
other O +
agents O +
which O +
activate O +
lymphokine O +
gene O +
expression O +
by O +
bypassing O +
T O +
cell O +
receptor O +
( O +
TCR O +
) O +
mediated O +
signaling O +
. O +

The O +
trans O -
- O -
activation O +
domain O +
of O +
E2 O +
and O +
Tax O +
is O +
interchangeable O +
although O +
they O +
have O +
no O +
obvious O +
sequence O +
homology O +
between O +
them O +
. O +

The O +
viral O +
trans O -
- O -
activators O +
appear O +
to O +
target O +
specific O +
DNA O +
binding O +
protein O +
such O +
as O +
NF O -
- O -
kB O +
and O +
Sp1 O +
to O +
cis O -
- O -
acting O +
DNA O +
site O +
and O +
promote O +
lymphokine O +
gene O +
expression O +
without O +
TCR O +
-mediated O +
stimulation O +
. O +

Cell O -
- O -
type O -
- O -
specific O +
transactivation O +
of O +
the O +
parathyroid O +
hormone O -
- O -
related O +
protein O +
gene O +
promoter O +
by O +
the O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
tax O +
and O +
HTLV O -
- O -
II O +
tax O +
proteins O +
. O +

The O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
and O +
HTLV O -
- O -
II O +
Tax O +
proteins O +
are O +
potent O +
transactivators O +
of O +
viral O +
and O +
cellular O +
gene O +
expression O +
. O +

Using O +
deletion O +
mutants O +
, O +
the O +
downstream O +
parathyroid O +
hormone O -
- O -
related O +
protein O +
( O +
PTHrP O +
) O +
promoter O +
is O +
shown O +
to O +
be O +
responsive O +
to O +
both O +
HTLV O -
- O -
I O +
and O +
HTLV O -
- O -
II O +
Tax O +
as O +
well O +
as O +
the O +
AP1 O -
/ O -
c O -
- O -
jun O +
proto O -
- O -
oncogene O +
. O +

Transactivation O +
of O +
PTHrP O +
by O +
Tax O +
was O +
seen O +
in O +
T O +
cells O +
but O +
not O +
in O +
B B-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
or O +
fibroblasts B-CellLine +
. O +

A O +
carboxy O +
terminal O +
Tax O +
deletion O +
mutant O +
was O +
deficient O +
in O +
transactivation O +
of O +
both O +
the O +
PTHrP O +
and O +
IL2R O +
alpha O +
promoters O +
but O +
not O +
the O +
HTLV O -
- O -
I O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
. O +

Exogenous O +
provision O +
of O +
NFkB O +
rescued O +
IL2R O +
alpha O +
expression O +
but O +
not O +
the O +
PTHrP O +
promoter O +
. O +

Thus O +
, O +
HTLV O -
- O -
I O +
Tax O +
, O +
HTLV O -
- O -
II O +
Tax O +
, O +
and O +
c O -
- O -
jun O +
transactivate O +
PTHrP O +
and O +
may O +
contribute O +
to O +
the O +
pathogenesis O +
of O +
hypercalcemia O +
in O +
adult O +
T O -
- O -
cell O +
leukemia O +
. O +

I O +
kappa O +
B O -
/ O -
MAD-3 O +
masks O +
the O +
nuclear O +
localization O +
signal O +
of O +
NF O -
- O -
kappa O +
B O +
p65 O +
and O +
requires O +
the O +
transactivation O +
domain O +
to O +
inhibit O +
NF O -
- O -
kappa O +
B O +
p65 O +
DNA O +
binding O +
. O +

The O +
active O +
nuclear O +
form O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
transcription O +
factor O +
complex O +
is O +
composed O +
of O +
two O +
DNA O +
binding O +
subunits O +
, O +
NF O -
- O -
kappa O +
B O +
p65 O +
and O +
NF O -
- O -
kappa O +
B O +
p50 O +
, O +
both O +
of O +
which O +
share O +
extensive O +
N O -
- O -
terminal O +
sequence O +
homology O +
with O +
the O +
v O -
- O -
rel O +
oncogene O +
product O +
. O +

The O +
NF O -
- O -
kappa O +
B O +
p65 O +
subunit O +
provides O +
the O +
transactivation O +
activity O +
in O +
this O +
complex O +
and O +
serves O +
as O +
an O +
intracellular O +
receptor O +
for O +
a O +
cytoplasmic O +
inhibitor O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
termed O +
I O +
kappa O +
B O +
. O +

In O +
contrast O +
, O +
NF O -
- O -
kappa O +
B O +
p50 O +
alone O +
fails O +
to O +
stimulate O +
kappa O +
B O -
- O -
directed O +
transcription O +
, O +
and O +
based O +
on O +
prior O +
in O +
vitro O +
studies O +
, O +
is O +
not O +
directly O +
regulated O +
by O +
I O +
kappa O +
B O +
. O +

To O +
investigate O +
the O +
molecular O +
basis O +
for O +
the O +
critical O +
regulatory O +
interaction O +
between O +
NF O -
- O -
kappa O +
B O +
and O +
I O +
kappa O +
B O -
/ O -
MAD-3 O +
, O +
a O +
series O +
of O +
human O +
NF O -
- O -
kappa O +
B O +
p65 O +
mutants O +
was O +
identified O +
that O +
functionally O +
segregated O +
DNA O +
binding O +
, O +
I O +
kappa O +
B O +
-mediated O +
inhibition O +
, O +
and O +
I O +
kappa O +
B O +
-induced O +
nuclear O +
exclusion O +
of O +
this O +
transcription O +
factor O +
. O +

Results O +
from O +
in O +
vivo O +
expression O +
studies O +
performed O +
with O +
these O +
NF O -
- O -
kappa O +
B O +
p65 O +
mutants O +
revealed O +
the O +
following O +
: O +
1 O +
) O +
I O +
kappa O +
B O -
/ O -
MAD-3 O +
completely O +
inhibits O +
NF O -
- O -
kappa O +
B O +
p65 O +
-dependent O +
transcriptional O +
activation O +
mediated O +
through O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
kappa O +
B O +
enhancer O +
in O +
human O +
T O +
lymphocytes O +
, O +
2 O +
) O +
the O +
binding O +
of O +
I O +
kappa O +
B O -
/ O -
MAD-3 O +
to O +
NF O -
- O -
kappa O +
B O +
p65 O +
is O +
sufficient O +
to O +
retarget O +
NF O -
- O -
kappa O +
B O +
p65 O +
from O +
the O +
nucleus O +
to O +
the O +
cytoplasm O +
, O +
3 O +
) O +
selective O +
deletion O +
of O +
the O +
functional O +
nuclear O +
localization O +
signal O +
present O +
in O +
the O +
Rel O +
homology O +
domain O +
of O +
NF O -
- O -
kappa O +
B O +
p65 O +
disrupts O +
its O +
ability O +
to O +
engage O +
I O +
kappa O +
B O -
/ O -
MAD-3 O +
, O +
and O +
4 O +
) O +
the O +
unique O +
C O -
- O -
terminus O +
of O +
NF O -
- O -
kappa O +
B O +
p65 O +
attenuates O +
its O +
own O +
nuclear O +
localization O +
and O +
contains O +
sequences O +
that O +
are O +
required O +
for O +
I O +
kappa O +
B O +
-mediated O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
p65 O +
DNA O +
binding O +
activity O +
. O +

Together O +
, O +
these O +
findings O +
suggest O +
that O +
the O +
nuclear O +
localization O +
signal O +
and O +
transactivation O +
domain O +
of O +
NF O -
- O -
kappa O +
B O +
p65 O +
constitute O +
a O +
bipartite O +
system O +
that O +
is O +
critically O +
involved O +
in O +
the O +
inhibitory O +
function O +
of O +
I O +
kappa O +
B O -
/ O -
MAD-3 O +
. O +

Unexpectedly O +
, O +
our O +
in O +
vivo O +
studies O +
also O +
demonstrate O +
that O +
I O +
kappa O +
B O -
/ O -
MAD-3 O +
binds O +
directly O +
to O +
NF O -
- O -
kappa O +
B O +
p50 O +
. O +

This O +
interaction O +
is O +
functional O +
as O +
it O +
leads O +
to O +
retargeting O +
of O +
NF O -
- O -
kappa O +
B O +
p50 O +
from O +
the O +
nucleus O +
to O +
the O +
cytoplasm O +
. O +

However O +
, O +
no O +
loss O +
of O +
DNA O +
binding O +
activity O +
is O +
observed O +
, O +
presumably O +
reflecting O +
the O +
unique O +
C O -
- O -
terminal O +
domain O +
that O +
is O +
distinct O +
from O +
that O +
present O +
in O +
NF O -
- O -
kappa O +
B O +
p65 O +
. O +

Surrogate O +
thyroglobulin O +
receptors O +
and O +
T O +
cell O +
proliferation O +
in O +
Hashimoto O +
's O +
thyroiditis O +
. O +

Immunoglobulin O +
molecules O +
on O +
the O +
surface O +
of O +
a O +
B O +
lymphocyte O +
are O +
the O +
endogenous O +
` O -
` O +
receptors O +
'' O +
to O +
which O +
specific O +
antigens O +
bind O +
. O +

Studies O +
in O +
mice O +
have O +
shown O +
that O +
a O +
monoclonal O +
antibody O +
, O +
conjugated O +
with O +
palmitate O +
to O +
provide O +
a O +
lipid O +
tail O +
, O +
can O +
be O +
inserted O +
into O +
the O +
cell O +
membrane O +
to O +
provide O +
a O +
` O -
` O +
surrogate O +
'' O +
antigen O +
receptor O +
. O +

We O +
have O +
investigated O +
whether O +
a O +
palmitate O +
conjugate O +
of O +
a O +
human O +
monoclonal O +
antibody O +
specific O +
for O +
thyroglobulin O +
( O +
TG O +
) O +
could O +
function O +
as O +
a O +
surrogate O +
TG O +
receptor O +
on O +
blood O +
mononuclear O +
cells O +
separated O +
into O +
fractions O +
enriched O +
for O +
T O +
cells O +
or O +
depleted O +
of O +
T O +
cells O +
( O +
non O -
- O -
T O +
cells O +
) O +
. O +

Using O +
flow O +
cytometry O +
, O +
we O +
detected O +
surrogate O +
TG O +
receptors O +
on O +
non O -
- O -
T O +
( O +
but O +
not O +
on O +
T O +
) O +
cells O +
from O +
11 O +
of O +
11 O +
individuals O +
studied O +
( O +
5 O +
Hashimoto O +
patients O +
and O +
6 O +
control O +
donors O +
) O +
. O +

In O +
contrast O +
, O +
endogenous O +
TG O +
receptors O +
could O +
only O +
be O +
detected O +
on O +
non O -
- O -
T O +
cells O +
from O +
1 O +
of O +
3 O +
Hashimoto O +
patients O +
and O +
from O +
0 O +
of O +
4 O +
control O +
donors O +
. O +

Because O +
of O +
the O +
efficient O +
binding O +
of O +
TG O +
by O +
surrogate O +
receptors O +
on O +
non O -
- O -
T O +
cells O +
, O +
we O +
assessed O +
the O +
ability O +
of O +
such O +
cells O +
to O +
present O +
TG O +
to O +
T O +
cells O +
. O +

Proliferation O +
in O +
response O +
to O +
TG O +
was O +
observed O +
in O +
T O +
cells O +
from O +
only O +
1 O +
of O +
5 O +
Hashimoto O +
patients O +
. O +

This O +
low O +
frequency O +
of O +
response O +
was O +
no O +
different O +
from O +
that O +
previously O +
detected O +
using O +
cultures O +
of O +
T O +
cells O +
and O +
autologous O +
dendritic O +
cells O +
. O +

Therefore O +
, O +
the O +
successful O +
generation O +
of O +
surrogate O +
receptors O +
on O +
non O -
- O -
T O +
cells O +
is O +
not O +
associated O +
with O +
more O +
efficient O +
TG O +
presentation O +
of O +
T O +
cells O +
. O +

Furthermore O +
, O +
the O +
significance O +
of O +
the O +
present O +
study O +
is O +
that O +
the O +
T O +
cells O +
, O +
not O +
the O +
antigen O -
- O -
presenting O +
cells O +
, O +
are O +
likely O +
to O +
be O +
the O +
limiting O +
element O +
in O +
the O +
T O +
cell O +
proliferative O +
response O +
to O +
TG O +
and O +
other O +
thyroid O +
autoantigens O +
. O +

The O +
Epstein O -
- O -
Barr O +
virus O +
nuclear O +
antigen O +
2 O +
interacts O +
with O +
an O +
EBNA2 O +
responsive O +
cis O -
- O -
element O +
of O +
the O +
terminal O +
protein O +
1 O +
gene O +
promoter O +
. O +

The O +
Epstein O -
- O -
Barr O +
virus O +
protein O +
EBNA2 O +
acts O +
as O +
a O +
transcriptional O +
activator O +
of O +
cellular O +
and O +
viral O +
genes O +
and O +
plays O +
a O +
crucial O +
role O +
in O +
the O +
immortalization O +
of O +
human O +
primary O +
B O -
- O -
cells O +
by O +
EBV O +
. O +

We O +
have O +
shown O +
previously O +
that O +
EBNA2 O +
transactivates O +
the O +
promoters O +
of O +
the O +
latent O +
membrane O +
antigens O +
LMP O +
, O +
TP1 O +
and O +
TP2 O +
. O +

The O +
promoter O +
of O +
the O +
TP1 O +
gene O +
was O +
chosen O +
as O +
a O +
model O +
system O +
to O +
study O +
the O +
molecular O +
mechanism O +
of O +
EBNA2 O +
mediated O +
transactivation O +
. O +

To O +
identify O +
an O +
EBNA2 O +
dependent O +
cis O -
- O -
acting O +
element O +
, O +
various O +
TP1 O +
promoter O -
- O -
reporter O +
gene O +
constructs O +
were O +
transfected O +
in O +
the O +
absence O +
and O +
presence O +
of O +
an O +
EBNA2 O +
expression O +
vector O +
into O +
the O +
established O +
B B-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
BL41-P3HR1 I-CellLine +
. O +

We O +
were O +
able O +
to O +
delineate O +
an O +
81 O +
bp O +
EBNA2 O +
responsive O +
region O +
between O +
-258 O +
and O +
-177 O +
relative O +
to O +
the O +
TP1 O +
RNA O +
start O +
site O +
. O +

The O +
element O +
worked O +
in O +
either O +
orientation O +
and O +
could O +
mediate O +
EBNA2 O +
dependent O +
transactivation O +
on O +
a O +
heterologous O +
promoter O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
revealed O +
three O +
specific O +
protein O -
- O -
DNA O +
complexes O +
formed O +
with O +
sequences O +
of O +
the O +
EBNA2 O +
responsive O +
element O +
. O +

Two O +
of O +
these O +
were O +
not O +
cell O +
type O +
specific O +
, O +
but O +
the O +
third O +
was O +
detected O +
only O +
in O +
EBNA2 O +
positive O +
cell O +
extracts O +
. O +

Gel O -
- O -
shift O +
analysis O +
in O +
the O +
presence O +
of O +
EBNA2 O +
specific O +
monoclonal O +
antibodies O +
revealed O +
that O +
EBNA2 O +
is O +
a O +
component O +
of O +
the O +
third O +
complex O +
. O +

Thus O +
, O +
these O +
experiments O +
demonstrate O +
that O +
EBNA2 O +
interacts O +
with O +
an O +
EBNA2 O +
responsive O +
cis O -
- O -
element O +
of O +
the O +
TP1 O +
promoter O +

The O +
c O -
- O -
rel O +
protooncogene O +
product O +
represses O +
NF O -
- O -
kappa O +
B O +
p65 O +
-mediated O +
transcriptional O +
activation O +
of O +
the O +
long O +
terminal O +
repeat O +
of O +
type O +
1 O +
human O +
immunodeficiency O +
virus O +
. O +

The O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
of O +
the O +
type O +
1 O +
human O +
immunodeficiency O +
virus O +
( O +
HIV-1 O +
) O +
and O +
the O +
5 O +
' O +
regulatory O +
region O +
of O +
the O +
gene O +
encoding O +
the O +
interleukin O +
2 O +
receptor O +
alpha O +
subunit O +
( O +
IL-2R O +
alpha O +
) O +
share O +
functional O +
kappa O +
B O +
enhancer O +
elements O +
involved O +
in O +
the O +
regulation O +
of O +
these O +
inducible O +
transcription O +
units O +
during O +
T O -
- O -
cell O +
activation O +
. O +

These O +
kappa O +
B O +
enhancer O +
elements O +
are O +
recognized O +
by O +
a O +
structurally O +
related O +
family O +
of O +
interactive O +
proteins O +
that O +
includes O +
p50 O +
, O +
p65 O +
, O +
and O +
the O +
product O +
of O +
the O +
c O -
- O -
rel O +
protooncogene O +
( O +
c O -
- O -
Rel O +
) O +
. O +

Recent O +
biochemical O +
studies O +
have O +
shown O +
that O +
p65 O +
and O +
p50 O +
form O +
the O +
prototypical O +
NF O -
- O -
kappa O +
B O +
complex O +
, O +
which O +
is O +
rapidly O +
translocated O +
from O +
the O +
cytoplasm O +
to O +
the O +
nucleus O +
during O +
T O -
- O -
cell O +
activation O +
. O +

This O +
intracellular O +
signaling O +
complex O +
potently O +
stimulates O +
kappa O +
B O -
- O -
directed O +
transcription O +
from O +
either O +
the O +
HIV-1 O +
LTR O +
or O +
the O +
IL-2R O +
alpha O +
promoter O +
via O +
the O +
strong O +
transactivation O +
domain O +
present O +
in O +
p65 O +
. O +

We O +
now O +
demonstrate O +
that O +
nuclear O +
expression O +
of O +
human O +
c O -
- O -
Rel O +
, O +
which O +
is O +
induced O +
by O +
either O +
phorbol O +
ester O +
or O +
tumor O +
necrosis O +
factor O +
alpha O +
with O +
delayed O +
kinetics O +
relative O +
to O +
p65 O +
, O +
markedly O +
represses O +
p65 O +
-mediated O +
activation O +
of O +
these O +
transcription O +
units O +
. O +

These O +
inhibitory O +
effects O +
of O +
c O -
- O -
Rel O +
correlate O +
with O +
its O +
DNA O -
- O -
binding O +
activity O +
but O +
not O +
with O +
its O +
ability O +
to O +
heterodimerize O +
with O +
p50 O +
, O +
suggesting O +
that O +
c O -
- O -
Rel O +
inhibition O +
involves O +
competition O +
with O +
p50 O -
/ O -
p65 O +
for O +
occupancy O +
of O +
the O +
kappa O +
B O +
enhancer O +
element O +
. O +

Together O +
, O +
these O +
findings O +
suggest O +
that O +
one O +
function O +
of O +
c O -
- O -
Rel O +
is O +
as O +
a O +
physiologic O +
repressor O +
of O +
the O +
HIV-1 O +
LTR O +
and O +
IL-2R O +
alpha O +
promoters O +
, O +
serving O +
to O +
efficiently O +
counter O +
the O +
strong O +
transcriptional O +
activating O +
effects O +
of O +
p65 O +
. O +

Protease O +
treatment O +
of O +
nuclear O +
extracts O +
distinguishes O +
between O +
class O +
II O +
MHC O +
X1 O +
box O +
DNA O -
- O -
binding O +
proteins O +
in O +
wild B-CellLine -
- I-CellLine -
type I-CellLine +
and I-CellLine +
class I-CellLine +
II I-CellLine -
- I-CellLine -
deficient I-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

The O +
X O +
box O +
region O +
is O +
critical O +
for O +
directing O +
the O +
expression O +
of O +
class O +
II O +
major O +
histocompatibility O +
complex O +
genes O +
in O +
B O +
lymphocytes O +
. O +

Although O +
several O +
class O +
II O +
promoter O -
- O -
specific O +
DNA O +
binding O +
factors O +
have O +
been O +
described O +
, O +
only O +
the O +
X O +
box O +
region O +
factor O +
, O +
RFX O +
, O +
shows O +
a O +
genetic O +
correlation O +
with O +
class O +
II O +
expression O +
, O +
being O +
deficient O +
in O +
some O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
derived O +
from O +
patients O +
with O +
class O +
II O -
- O -
deficient O +
congenital O +
immunodeficiency O +
. O +

To O +
further O +
evaluate O +
the O +
role O +
of O +
X O +
box O +
DNA O -
- O -
binding O +
proteins O +
in O +
class O +
II O +
gene O +
expression O +
, O +
the O +
role O +
of O +
the O +
X O +
box O +
region O +
was O +
examined O +
in O +
both O +
class B-CellLine +
II I-CellLine -
- I-CellLine -
positive I-CellLine +
and O +
-negative B-CellLine +
lymphoid I-CellLine +
cells I-CellLine +
. O +

In O +
addition O +
to O +
the O +
wild B-CellLine -
- I-CellLine -
type I-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
Raji I-CellLine +
, O +
two B-CellLine +
class I-CellLine +
II I-CellLine +
transcriptional I-CellLine +
mutant I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
SJO B-CellLine +
and O +
RJ2.2.5 B-CellLine +
, O +
and O +
Jurkat B-CellLine +
, O +
a O +
class B-CellLine +
II I-CellLine +
negative I-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
were O +
examined O +
. O +

In O +
contrast O +
to O +
wild B-CellLine -
- I-CellLine -
type I-CellLine +
B I-CellLine +
cells I-CellLine +
, O +
neither O +
of O +
the O +
class B-CellLine +
II I-CellLine +
mutant I-CellLine +
cell I-CellLine +
lines I-CellLine +
could O +
use O +
the O +
X O +
box O +
region O +
to O +
direct O +
the O +
expression O +
of O +
a O +
transiently O +
transfected O +
reporter O +
gene O +
, O +
indicating O +
that O +
the O +
X O +
box O -
- O -
dependent O +
transcriptional O +
pathway O +
is O +
defective O +
in O +
these O +
cells O +
. O +

The O +
binding O +
activity O +
of O +
the O +
X1 O +
box O +
DNA O -
- O -
binding O +
protein O +
RFX O +
was O +
examined O +
and O +
found O +
to O +
be O +
present O +
in O +
wild B-CellLine -
- I-CellLine -
type I-CellLine +
B I-CellLine +
cells I-CellLine +
and O +
the O +
mutant O +
RJ2.2.5 B-CellLine +
but O +
was O +
absent O +
in O +
SJO B-CellLine +
and O +
Jurkat B-CellLine +
. O +

However O +
, O +
other O +
X1 O +
box O -
- O -
specific O +
activities O +
were O +
detected O +
in O +
all O +
these O +
cell B-CellLine +
lines I-CellLine +
. O +

To O +
determine O +
whether O +
these O +
different O +
X1 O +
box O +
activities O +
represented O +
distinct O +
DNA O +
binding O +
proteins O +
or O +
multimeric O +
forms O +
of O +
the O +
same O +
factor O +
( O +
s O +
) O +
, O +
protease O +
treatment O +
of O +
the O +
crude O +
nuclear O +
extracts O +
followed O +
by O +
DNA O -
- O -
binding O +
assays O +
were O +
carried O +
out O +
and O +
demonstrated O +
that O +
B O +
cell O +
extracts O +
contain O +
at O +
least O +
two O +
X1-specific O +
factors O +
. O +

One O +
of O +
these O +
cleaved O +
products O +
( O +
band O +
1 O +
pk O +
) O +
correlates O +
with O +
RFX O +
activity O +
. O +

A O +
similar O +
comparison O +
with O +
protease O -
- O -
treated O +
extracts O +
prepared O +
from O +
Jurkat B-CellLine +
cells I-CellLine +
demonstrated O +
the O +
presence O +
of O +
the O +
band O +
1pk O +
activity O +
despite O +
an O +
absence O +
of O +
the O +
native O +
RFX O +
activity O +
. O +

In O +
contrast O +
, O +
protease O +
treatment O +
and O +
analysis O +
of O +
SJO B-CellLine +
extracts O +
showed O +
no O +
detectable O +
levels O +
of O +
the O +
band O +
1pk O +
activity O +
. O +

These O +
results O +
demonstrate O +
that O +
multiple O +
X1 O +
box O -
- O -
specific O +
DNA O -
- O -
binding O +
activities O +
exist O +
in O +
all O +
lymphoid O +
cells O +
, O +
but O +
the O +
presence O +
of O +
an O +
actively O +
binding O +
RFX O +
species O +
correlates O +
with O +
class O +
II O +
transcription O +
. O +

Dimerization O +
of O +
NF O -
- O -
KB2 O +
with O +
RelA O +
( O +
p65 O +
) O +
regulates O +
DNA O +
binding O +
, O +
transcriptional O +
activation O +
, O +
and O +
inhibition O +
by O +
an O +
I O +
kappa O +
B O -
- O -
alpha O +
( O +
MAD-3 O +
) O +
. O +

Inducible O +
expression O +
of O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
is O +
regulated O +
by O +
a O +
cellular O +
transcription O +
factor O +
, O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
. O +

NF O -
- O -
kappa O +
B O +
is O +
composed O +
of O +
distinct O +
subunits O +
; O +
five O +
independent O +
genes O +
, O +
NFKB1 O +
( O +
p105 O +
) O +
, O +
NFKB2 O +
( O +
p100 O +
) O +
, O +
RelA O +
( O +
p65 O +
) O +
, O +
c O -
- O -
rel O +
and O +
relB O +
, O +
that O +
encode O +
related O +
proteins O +
that O +
bind O +
to O +
kappa O +
B O +
DNA O +
elements O +
have O +
been O +
isolated O +
. O +

We O +
have O +
previously O +
found O +
that O +
NFKB2 O +
( O +
p49 O -
/ O -
p52 O +
) O +
acts O +
in O +
concert O +
with O +
RelA O +
( O +
p65 O +
) O +
to O +
stimulate O +
the O +
HIV O +
enhancer O +
in O +
Jurkat O +
T B-CellLine -
- I-CellLine -
leukemia I-CellLine +
cells I-CellLine +
. O +

Here O +
we O +
examine O +
the O +
biochemical O +
basis O +
for O +
the O +
transcriptional O +
regulation O +
of O +
HIV O +
by O +
NFKB2 O +
. O +

Using O +
Scatchard O +
analysis O +
, O +
we O +
have O +
determined O +
the O +
dissociation O +
constants O +
of O +
homodimeric O +
p49 O +
and O +
heterodimeric O +
p49 O -
/ O -
p65 O +
for O +
binding O +
to O +
the O +
HIV O +
kappa O +
B O +
site O +
. O +

p49 O +
has O +
a O +
approximately O +
18-fold O -
- O -
lower O +
affinity O +
for O +
the O +
HIV O +
kappa O +
B O +
site O +
( O +
KD O +
= O +
69.1 O +
pM O +
) O +
than O +
does O +
the O +
approximately O +
50-kDa O +
protein O +
NFKB1 O +
( O +
p50 O +
) O +
derived O +
from O +
p105 O +
( O +
KD O +
= O +
3.9 O +
pM O +
) O +
. O +

In O +
contrast O +
, O +
the O +
affinity O +
of O +
heterodimeric O +
NFKB2 O +
( O +
p49 O +
) O +
/RelA O +
( O +
p65 O +
) O +
for O +
this O +
site O +
is O +
approximately O +
6-fold O +
higher O +
( O +
KD O +
= O +
11.8 O +
pM O +
) O +
than O +
that O +
of O +
p49 O +
alone O +
. O +

Consistent O +
with O +
these O +
findings O +
, O +
in O +
vitro O +
transcription O +
was O +
stimulated O +
18-fold O +
by O +
the O +
addition O +
of O +
preformed O +
, O +
heterodimeric O +
NFKB2 O +
( O +
p49 O +
) O +
/RelA O +
( O +
p65 O +
) O +
protein O +
. O +

Transcriptional O +
activation O +
of O +
the O +
HIV O +
enhancer O +
was O +
also O +
subject O +
to O +
regulation O +
by O +
recently O +
cloned O +
I O +
kappa O +
B O -
- O -
alpha O +
( O +
MAD-3 O +
) O +
. O +

Recombinant O +
I O +
kappa O +
B O -
- O -
alpha O +
( O +
MAD-3 O +
) O +
inhibited O +
the O +
DNA O +
binding O +
activity O +
of O +
p65 O +
, O +
p49 O -
/ O -
p65 O +
, O +
and O +
p50 O -
/ O -
p65 O +
but O +
stimulated O +
the O +
binding O +
of O +
NFKB2 O +
( O +
p49 O +
) O +
or O +
NFKB1 O +
( O +
p50 O +
) O +
. O +

Functional O +
activation O +
of O +
an O +
HIV O +
reporter O +
plasmid O +
by O +
p49 O -
/ O -
p65 O +
in O +
transiently B-CellLine +
transfected I-CellLine +
Jurkat I-CellLine +
T I-CellLine -
- I-CellLine -
leukemia I-CellLine +
cells I-CellLine +
was O +
also O +
inhibited O +
by O +
coexpression O +
of O +
MAD-3 O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

The O +
human O +
prointerleukin O +
1 O +
beta O +
gene O +
requires O +
DNA O +
sequences O +
both O +
proximal O +
and O +
distal O +
to O +
the O +
transcription O +
start O +
site O +
for O +
tissue O -
- O -
specific O +
induction O +
. O +

In O +
these O +
studies O +
, O +
we O +
have O +
identified O +
DNA O +
sequences O +
and O +
specific O +
protein O +
interactions O +
necessary O +
for O +
transcriptional O +
regulation O +
of O +
the O +
human O +
prointerleukin O +
1 O +
beta O +
( O +
proIL-1 O +
beta O +
) O +
gene O +
. O +

A O +
cell O -
- O -
type O -
- O -
independent O +
lipopolysaccharide O +
( O +
LPS O +
) O +
-responsive O +
enhancer O +
element O +
located O +
between O +
-3757 O +
and O +
-2729 O +
bp O +
upstream O +
from O +
the O +
transcription O +
start O +
site O +
( O +
cap O +
site O +
) O +
consisted O +
of O +
at O +
least O +
six O +
discrete O +
subregions O +
which O +
were O +
essential O +
to O +
the O +
maximal O +
induction O +
by O +
LPS O +
in O +
transfected B-CellLine +
monocytes I-CellLine +
. O +

The O +
enhancer O +
also O +
appeared O +
to O +
mediate O +
phorbol O +
myristate O +
acetate O +
induction O +
in O +
monocytes O +
and O +
IL-1 O +
responsiveness O +
in O +
fibroblasts O +
. O +

Deletion O +
and O +
base O +
substitution O +
mutations O +
along O +
with O +
DNA O +
binding O +
studies O +
demonstrated O +
that O +
the O +
enhancer O +
contained O +
a O +
minimum O +
of O +
three O +
functional O +
protein O +
binding O +
sequences O +
, O +
two O +
of O +
which O +
appeared O +
to O +
be O +
important O +
for O +
gene O +
induction O +
. O +

One O +
of O +
the O +
essential O +
proteins O +
which O +
bound O +
to O +
the O +
enhancer O +
was O +
similar O +
or O +
identical O +
to O +
members O +
of O +
the O +
C O -
/ O -
EBP O +
family O +
of O +
transcription O +
factors O +
required O +
for O +
both O +
IL-1 O +
-and O +
LPS O -
- O -
specific O +
induction O +
of O +
the O +
IL-6 O +
gene O +
( O +
i.e. O +
, O +
the O +
NF O -
- O -
IL6 O +
proteins O +
) O +
. O +

When O +
ligated O +
to O +
the O +
proIL-1 O +
beta O +
cap O +
site O +
-proximal O +
region O +
( O +
located O +
between O +
-131 O +
to O +
+ O -
12 O +
) O +
, O +
both O +
the O +
proIL-1 O +
beta O +
and O +
the O +
simian O +
virus O +
40 O +
enhancer O +
elements O +
functioned O +
more O +
efficiently O +
in O +
monocytes O +
than O +
in O +
HeLa O +
cells O +
, O +
which O +
are O +
not O +
normally O +
competent O +
for O +
IL-1 O +
beta O +
expression O +
. O +

When O +
ligated O +
to O +
the O +
murine O +
c O -
- O -
fos O +
promoter O +
, O +
however O +
, O +
the O +
proIL-1 O +
beta O +
enhancer O +
was O +
inducible O +
in O +
phorbol B-CellLine +
myristate I-CellLine +
acetate I-CellLine -
- I-CellLine -
stimulated I-CellLine +
HeLa I-CellLine +
cells I-CellLine +
, O +
suggesting O +
the O +
existence O +
of O +
a O +
proIL-1 O +
beta O +
promoter O -
- O -
proximal O +
requirement O +
for O +
tissue O +
specificity O +
. O +

Expression O +
of O +
PILOT O +
, O +
a O +
putative O +
transcription O +
factor O +
, O +
requires O +
two O +
signals O +
and O +
is O +
cyclosporin O +
A O +
sensitive O +
in O +
T O +
cells O +
. O +

Few O +
known O +
genes O +
( O +
IL-2 O +
, O +
members O +
of O +
the O +
IL-8 O +
family O +
, O +
interferon O -
- O -
gamma O +
) O +
are O +
induced O +
in O +
T O +
cells O +
only O +
through O +
the O +
combined O +
effect O +
of O +
phorbol O +
myristic O +
acetate O +
( O +
PMA O +
) O +
and O +
a O +
Ca O +
( O +
2 O -
+ O +
) O +
-ionophore O +
, O +
and O +
expression O +
of O +
only O +
these O +
genes O +
can O +
be O +
fully O +
suppressed O +
by O +
Cyclosporin O +
A O +
( O +
CyA O +
) O +
. O +

We O +
have O +
identified O +
a O +
putative O +
transcription O +
factor O +
, O +
designated O +
PILOT O +
, O +
with O +
an O +
identical O +
dual O +
signal O +
requirement O +
for O +
expression O +
. O +

Induction O +
of O +
the O +
PILOT O +
gene O +
is O +
detectable O +
in O +
human O +
T O +
cells O +
20 O +
min O +
following O +
activation O +
in O +
the O +
presence O +
of O +
cycloheximide O +
and O +
is O +
fully O +
suppressed O +
by O +
CyA O +
. O +

The O +
PILOT O +
protein O +
has O +
a O +
calculated O +
M O +
( O +
r O +
) O +
of O +
42.6 O +
kDa O +
and O +
contains O +
three O +
zinc O +
fingers O +
of O +
the O +
C2H2-type O +
at O +
the O +
carboxyl O -
- O -
terminus O +
which O +
are O +
highly O +
homologous O +
to O +
the O +
zinc O +
finger O +
regions O +
of O +
the O +
transcription O +
factors O +
EGR1 O +
, O +
EGR2 O +
, O +
and O +
pAT O +
133 O +
. O +

In O +
contrast O +
to O +
T O +
cells O +
, O +
in O +
fibroblasts O +
PILOT O +
gene O +
expression O +
requires O +
only O +
one O +
signal O +
( O +
PMA O +
) O +
and O +
is O +
not O +
affected O +
by O +
CyA O +
. O +

This O +
observation O +
directly O +
demonstrates O +
the O +
existence O +
of O +
a O +
Ca2 O -
+ O +
signal O -
- O -
dependent O +
regulatory O +
element O +
obligatory O +
for O +
expression O +
of O +
some O +
genes O +
in O +
T O +
cells O +
but O +
not O +
in O +
fibroblasts O +
. O +

This O +
differential O +
expression O +
model O +
will O +
be O +
valuable O +
in O +
the O +
dissection O +
of O +
the O +
dual O +
signal O +
pathway O +
in O +
T O +
cells O +
and O +
the O +
effects O +
of O +
CyA O +
upon O +
it O +
. O +

A O +
serum O +
response O +
element O +
and O +
a O +
binding O +
site O +
for O +
NF O -
- O -
Y O +
mediate O +
the O +
serum O +
response O +
of O +
the O +
human O +
thrombospondin O +
1 O +
gene O +
. O +

The O +
expression O +
of O +
thrombospondin O +
1 O +
( O +
TSP O +
1 O +
) O +
, O +
a O +
member O +
of O +
the O +
TSP O +
gene O +
family O +
, O +
is O +
rapidly O +
induced O +
by O +
growth O +
factors O +
. O +

We O +
tested O +
the O +
ability O +
of O +
human O +
TSP O +
1-chloramphenicol O +
acetyltransferase O +
constructs O +
to O +
respond O +
to O +
serum O +
in O +
stably O +
transfected O +
NIH-3T3 O +
cells O +
. O +

Two O +
transcriptional O +
elements O +
in O +
the O +
TSP O +
1 O +
promoter O +
, O +
a O +
distal O +
element O +
at O +
-1280 O +
and O +
a O +
proximal O +
element O +
at O +
-65 O +
, O +
were O +
required O +
for O +
the O +
response O +
of O +
the O +
human O +
TSP O +
1 O +
gene O +
to O +
serum O +
. O +

The O +
distal O +
element O +
contains O +
the O +
5'-CC O +
( O +
A O +
+ O +
T O +
) O +
6GG-3 O +
' O +
consensus O +
sequence O +
characteristic O +
of O +
a O +
serum O -
- O -
response O +
element O +
( O +
SRE O +
) O +
. O +

Deletions O +
or O +
mutations O +
in O +
this O +
element O +
reduced O +
the O +
serum O +
response O +
of O +
the O +
TSP O +
1 O +
gene O +
by O +
80 O -
- O -
90 O +
% O +
. O +

In O +
gel O -
- O -
shift O +
assays O +
, O +
the O +
-1280 O +
element O +
and O +
the O +
c O -
- O -
fos O +
SRE O +
cross O +
-competed O +
, O +
whereas O +
their O +
functional O +
and O +
binding O +
mutants O +
did O +
not O +
. O +

The O +
proximal O +
element O +
contains O +
the O +
sequence O +
5'-GGCCAATGGG-3 O +
' O +
, O +
which O +
closely O +
resembles O +
the O +
consensus O +
binding O +
motif O +
for O +
the O +
CCAAT O -
- O -
binding O +
factor O +
NF O -
- O -
Y O +
( O +
CBF O +
, O +
CP1 O +
, O +
alpha O +
CP1 O +
) O +
. O +

Deletions O +
or O +
mutations O +
in O +
this O +
element O +
also O +
reduced O +
the O +
serum O +
response O +
by O +
80 O -
- O -
90 O +
% O +
. O +

Methylation O +
interference O +
analysis O +
of O +
the O +
-65 O +
region O +
identified O +
a O +
pattern O +
of O +
contacts O +
with O +
nuclear O +
factors O +
resembling O +
that O +
for O +
NF O -
- O -
Y O +
, O +
and O +
an O +
NF O -
- O -
Y O -
- O -
binding O +
site O +
and O +
the O +
proximal O +
TSP O +
1 O +
element O +
cross O -
- O -
competed O +
in O +
gel O -
- O -
shift O +
assays O +
, O +
whereas O +
their O +
binding O +
mutants O +
did O +
not O +
. O +

Finally O +
, O +
an O +
abbreviated O +
TSP O +
1 O +
promoter O -
/ O -
5'-flank O +
, O +
containing O +
the O +
SRE- O +
and O +
NF O -
- O -
Y O -
- O -
binding O +
sites O +
, O +
mediated O +
a O +
serum O +
response O +
that O +
was O +
close O +
in O +
magnitude O +
to O +
that O +
of O +
the O +
parent O +
promoter O +
. O +

We O +
conclude O +
that O +
the O +
serum O +
response O +
of O +
the O +
human O +
TSP O +
1 O +
gene O +
requires O +
the O +
coordinated O +
function O +
of O +
an O +
SRE- O +
and O +
NF O -
- O -
Y O -
- O -
binding O +
site O +
. O +

Suppression O +
of O +
a O +
cellular O +
differentiation O +
program O +
by O +
phorbol O +
esters O +
coincides O +
with O +
inhibition O +
of O +
binding O +
of O +
a O +
cell O -
- O -
specific O +
transcription O +
factor O +
( O +
NF O -
- O -
E2 O +
) O +
to O +
an O +
enhancer O +
element O +
required O +
for O +
expression O +
of O +
an O +
erythroid O -
- O -
specific O +
gene O +
. O +

Induction O +
by O +
hemin O +
increases O +
, O +
while O +
induction O +
with O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
represses O +
, O +
erythroid O -
- O -
specific O +
gene O +
expression O +
in O +
the O +
human B-CellLine +
cell I-CellLine +
line I-CellLine +
K562 I-CellLine +
. O +

We O +
analyzed O +
the O +
effects O +
of O +
hemin O +
or O +
TPA O +
induction O +
on O +
the O +
binding O +
and O +
activity O +
of O +
transcription O +
factors O +
at O +
a O +
regulatory O +
element O +
found O +
within O +
the O +
transcriptional O +
regulatory O +
sequences O +
of O +
many O +
erythroid O -
- O -
specific O +
genes O +
. O +

TPA O +
induction O +
increases O +
the O +
binding O +
of O +
ubiquitous O +
AP-1 O +
factors O +
to O +
this O +
element O +
. O +

TPA O +
induction O +
inhibits O +
the O +
binding O +
of O +
the O +
lineage O +
limited O +
transcription O +
factor O +
NF O -
- O -
E2 O +
to O +
this O +
transcriptional O +
control O +
element O +
. O +

Hemin O +
induction O +
of O +
K562 B-CellLine +
cells I-CellLine +
does O +
not O +
facilitate O +
the O +
binding O +
of O +
NF O -
- O -
E2 O +
to O +
its O +
recognition O +
site O +
. O +

Hemin O +
induction O +
appears O +
to O +
nonspecifically O +
increase O +
the O +
expression O +
of O +
transiently O +
transfected O +
genes O +
in O +
K562 B-CellLine +
cells I-CellLine +
. O +

Beyond O +
this O +
nonspecific O +
increase O +
in O +
gene O +
expression O +
, O +
hemin O +
induction O +
acts O +
to O +
increase O +
the O +
activity O +
of O +
the O +
lineage O +
limited O +
transcription O +
factor O +
NF O -
- O -
E2 O +
. O +

The O +
divergent O +
effects O +
of O +
hemin O +
and O +
TPA O +
on O +
gene O +
expression O +
in O +
K562 B-CellLine +
cells I-CellLine +
are O +
mediated O +
, O +
in O +
part O +
, O +
by O +
their O +
contrasting O +
effects O +
on O +
the O +
transcription O +
factor O +
NF O -
- O -
E2 O +
. O +

The O +
interleukin O +
2 O +
CD28-responsive O +
complex O +
contains O +
at O +
least O +
three O +
members O +
of O +
the O +
NF O +
kappa O +
B O +
family O +
: O +
c O -
- O -
Rel O +
, O +
p50 O +
, O +
and O +
p65 O +
. O +

Optimal O +
activation O +
of O +
T O +
cells O +
requires O +
at O +
least O +
two O +
signals O +
. O +

One O +
signal O +
can O +
be O +
delivered O +
by O +
the O +
antigen O -
- O -
specific O +
T O -
- O -
cell O +
receptor O +
, O +
and O +
the O +
second O +
signal O +
is O +
provided O +
by O +
the O +
costimulatory O +
molecule O +
( O +
s O +
) O +
delivered O +
by O +
the O +
antigen O -
- O -
presenting O +
cell O +
. O +

CD28 O +
is O +
a O +
T O -
- O -
cell O +
surface O +
molecule O +
and O +
stimulation O +
through O +
this O +
protein O +
plays O +
an O +
important O +
role O +
in O +
delivering O +
the O +
second O +
activation O +
signal O +
. O +

In O +
this O +
report O +
, O +
we O +
show O +
that O +
in O +
human O +
peripheral O +
blood O +
T O +
cells O +
, O +
CD28 O +
-mediated O +
signal O +
transduction O +
involves O +
the O +
rel O +
family O +
proteins O +
-- O +
c O -
- O -
Rel O +
, O +
p50 O +
, O +
and O +
p65 O +
. O +

Treatment O +
of O +
peripheral O +
blood O +
T O +
cells O +
with O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
and O +
anti O -
- O -
CD28 O +
monoclonal O +
antibody O +
( O +
mAb O +
) O +
results O +
in O +
augmentation O +
of O +
nuclear O +
c O -
- O -
Rel O +
, O +
p50 O +
, O +
and O +
p65 O +
, O +
and O +
this O +
augmentation O +
can O +
occur O +
in O +
the O +
presence O +
of O +
the O +
immunosuppressant O +
cyclosporin O +
A O +
. O +

It O +
is O +
also O +
shown O +
in O +
this O +
report O +
that O +
, O +
in O +
response O +
to O +
PMA O -
/ O -
anti O -
- O -
CD28 O +
mAb O +
or O +
anti O -
- O -
CD3 O -
/ O -
anti O -
- O -
CD28 O +
mAb O +
, O +
c O -
- O -
Rel O +
, O +
p50 O +
, O +
and O +
p65 O +
are O +
associated O +
with O +
CD28-responsive O +
element O +
present O +
in O +
the O +
promoter O +
of O +
the O +
human O +
interleukin O +
2 O +
gene O +
. O +

The O +
functional O +
significance O +
of O +
c O -
- O -
Rel O +
involvement O +
in O +
the O +
CD28-responsive O +
complex O +
is O +
demonstrated O +
by O +
transient O +
transfection O +
analysis O +
, O +
where O +
cotransfection O +
of O +
c O -
- O -
Rel O +
augments O +
the O +
level O +
of O +
expression O +
of O +
a O +
chloramphenicol O +
acetyltransferase O +
reporter O +
gene O +
linked O +
to O +
the O +
CD28-responsive O +
element O +
. O +

Transcriptional O +
regulation O +
of O +
interleukin O +
3 O +
( O +
IL3 O +
) O +
in O +
primary O +
human O +
T O +
lymphocytes O +
. O +

Role O +
of O +
AP-1- O +
and O +
octamer O -
- O -
binding O +
proteins O +
in O +
control O +
of O +
IL3 O +
gene O +
expression O +
. O +

We O +
have O +
investigated O +
the O +
molecular O +
and O +
biochemical O +
basis O +
for O +
activation O +
of O +
interleukin O +
3 O +
( O +
IL3 O +
) O +
gene O +
expression O +
in O +
primary O +
human O +
T O +
lymphocytes O +
following O +
CD3 O +
and O +
CD2 O +
receptor O +
stimulation O +
or O +
activation O +
by O +
phytohemagglutinin O +
plus O +
phorbol O +
12-myristate O +
13-acetate O +
. O +

Using O +
transfection O +
and O +
reporter O +
gene O +
assays O +
specifically O +
designed O +
for O +
primary O +
T O +
lymphocytes O +
in O +
conjunction O +
with O +
gel O +
retardation O +
assays O +
, O +
Western O +
blot O +
analyses O +
and O +
UV O +
cross O -
- O -
linking O +
studies O +
, O +
we O +
found O +
that O +
c O -
- O -
Jun O +
, O +
c O -
- O -
Fos O +
, O +
and O +
octamer O -
- O -
binding O +
proteins O +
play O +
a O +
major O +
role O +
in O +
transcriptional O +
activation O +
of O +
the O +
IL3 O +
gene O +
via O +
their O +
interaction O +
with O +
two O +
specific O +
regions O +
contained O +
within O +
the O +
IL3 O +
5'-flanking O +
sequence O +
. O +

Additionally O +
, O +
the O +
region O +
between O +
bases O +
-107 O +
and O +
-59 O +
of O +
the O +
IL3 O +
promoter O +
containing O +
putative O +
AP-2 O +
and O +
Sp1 O +
binding O +
motifs O +
appears O +
necessary O +
for O +
basal O +
level O +
expression O +
of O +
the O +
IL3 O +
gene O +
. O +

The O +
data O +
also O +
indicate O +
that O +
CD2 O +
receptor O +
activation O +
and O +
phytohemagglutinin O +
plus O +
phorbol O +
12-myristate O +
13-acetate O +
stimulation O +
augment O +
T O +
cell O +
IL3 O +
gene O +
expression O +
through O +
the O +
same O +
cis- O +
and O +
trans O -
- O -
activating O +
signals O +
. O +

These O +
results O +
should O +
contribute O +
to O +
a O +
better O +
understanding O +
of O +
the O +
regulation O +
of O +
IL3 O +
gene O +
expression O +
in O +
human O +
T O +
lymphocytes O +
. O +

Transcriptional O +
activation O +
of O +
human O +
zeta O +
2 O +
globin O +
promoter O +
by O +
the O +
alpha O +
globin O +
regulatory O +
element O +
( O +
HS-40 O +
) O +
: O +
functional O +
role O +
of O +
specific O +
nuclear O +
factor O -
- O -
DNA O +
complexes O +
. O +

We O +
studied O +
the O +
functional O +
interaction O +
between O +
human O +
embryonic O +
zeta O +
2 O +
globin O +
promoter O +
and O +
the O +
alpha O +
globin O +
regulatory O +
element O +
( O +
HS-40 O +
) O +
located O +
40 O +
kb O +
upstream O +
of O +
the O +
zeta O +
2 O +
globin O +
gene O +
. O +

It O +
was O +
shown O +
by O +
transient O +
expression O +
assay O +
that O +
HS-40 O +
behaved O +
as O +
an O +
authentic O +
enhancer O +
for O +
high O -
- O -
level O +
zeta O +
2 O +
globin O +
promoter O +
activity O +
in O +
K562 B-CellLine +
cells I-CellLine +
, O +
an O +
erythroid O +
cell O +
line O +
of O +
embryonic O +
and/or O +
fetal O +
origin O +
. O +

Although O +
sequences O +
located O +
between O +
-559 O +
and O +
-88 O +
of O +
the O +
zeta O +
2 O +
globin O +
gene O +
were O +
dispensable O +
for O +
its O +
expression O +
on O +
enhancerless O +
plasmids O +
, O +
they O +
were O +
required O +
for O +
the O +
HS-40 O +
enhancer O +
-mediated O +
activity O +
of O +
the O +
zeta O +
2 O +
globin O +
promoter O +
. O +

Site O -
- O -
directed O +
mutagenesis O +
demonstrated O +
that O +
this O +
HS-40 O +
enhancer- O +
zeta O +
2 O +
globin O +
promoter O +
interaction O +
is O +
mediated O +
by O +
the O +
two O +
GATA-1 O +
factor O +
binding O +
motifs O +
located O +
at O +
-230 O +
and O +
-104 O +
, O +
respectively O +
. O +

The O +
functional O +
domains O +
of O +
HS-40 O +
were O +
also O +
mapped O +
. O +

Bal O +
31 O +
deletion O +
mapping O +
data O +
suggested O +
that O +
one O +
GATA-1 O +
motif O +
, O +
one O +
GT O +
motif O +
, O +
and O +
two O +
NF O -
- O -
E2 O -
/ O -
AP1 O +
motifs O +
together O +
formed O +
the O +
functional O +
core O +
of O +
HS-40 O +
in O +
the O +
erythroid O -
- O -
specific O +
activation O +
of O +
the O +
zeta O +
2 O +
globin O +
promoter O +
. O +

Site O -
- O -
directed O +
mutagenesis O +
further O +
demonstrated O +
that O +
the O +
enhancer O +
function O +
of O +
one O +
of O +
the O +
two O +
NF O -
- O -
E2 O -
/ O -
AP1 O +
motifs O +
of O +
HS-40 O +
is O +
mediated O +
through O +
its O +
binding O +
to O +
NF O -
- O -
E2 O +
but O +
not O +
AP1 O +
transcription O +
factor O +
. O +

Finally O +
, O +
we O +
did O +
genomic O +
footprinting O +
of O +
the O +
HS-40 O +
enhancer O +
region O +
in O +
K562 B-CellLine +
cells I-CellLine +
, O +
adult B-CellLine +
nucleated I-CellLine +
erythroblasts I-CellLine +
, O +
and O +
different O +
nonerythroid O +
cells O +
. O +

All O +
sequence O +
motifs O +
within O +
the O +
functional O +
core O +
of O +
HS-40 O +
, O +
as O +
mapped O +
by O +
transient O +
expression O +
analysis O +
, O +
appeared O +
to O +
bind O +
a O +
nuclear O +
factor O +
( O +
s O +
) O +
in O +
living O +
K562 B-CellLine +
cells I-CellLine +
but O +
not O +
in O +
nonerythroid O +
cells O +
. O +

On O +
the O +
other O +
hand O +
, O +
only O +
one O +
of O +
the O +
apparently O +
nonfunctional O +
sequence O +
motifs O +
was O +
bound O +
with O +
factors O +
in O +
vivo O +
. O +

In O +
comparison O +
to O +
K562 B-CellLine +
, O +
nucleated B-CellLine +
erythroblasts I-CellLine +
from O +
adult O +
human O +
bone O +
marrow O +
exhibited O +
a O +
similar O +
but O +
nonidentical O +
pattern O +
of O +
nuclear O +
factor O +
binding O +
in O +
vivo O +
at O +
the O +
HS-40 O +
region O +
. O +

These O +
data O +
suggest O +
that O +
transcriptional O +
activation O +
of O +
human O +
embryonic O +
zeta O +
2 O +
globin O +
gene O +
and O +
the O +
fetal O -
/ O -
adult O +
alpha O +
globin O +
genes O +
is O +
mediated O +
by O +
erythroid O +
cell O -
- O -
specific O +
and O +
developmental O +
stage O -
- O -
specific O +
nuclear O +
factor O -
- O -
DNA O +
complexes O +
which O +
form O +
at O +
the O +
enhancer O +
( O +
HS-40 O +
) O +
and O +
the O +
globin O +
promoters O +
. O +

Interaction O +
between O +
NF O -
- O -
kappa O +
B O +
-and O +
serum O +
response O +
factor O +
-binding O +
elements O +
activates O +
an O +
interleukin-2 O +
receptor O +
alpha O -
- O -
chain O +
enhancer O +
specifically O +
in O +
T O +
lymphocytes O +
. O +

We O +
find O +
that O +
a O +
short O +
enhancer O +
element O +
containing O +
the O +
NF O -
- O -
kappa O +
B O +
binding O +
site O +
from O +
the O +
interleukin-2 O +
receptor O +
alpha O -
- O -
chain O +
gene O +
( O +
IL-2R O +
alpha O +
) O +
is O +
preferentially O +
activated O +
in O +
T O +
cells O +
. O +

The O +
IL-2R O +
alpha O +
enhancer O +
binds O +
NF O -
- O -
kappa O +
B O +
poorly O +
and O +
is O +
only O +
weakly O +
activated O +
by O +
the O +
NF O -
- O -
kappa O +
B O +
site O +
alone O +
. O +

Serum O +
response O +
factor O +
( O +
SRF O +
) O +
binds O +
to O +
a O +
site O +
adjacent O +
to O +
the O +
NF O -
- O -
kappa O +
B O +
site O +
in O +
the O +
IL-2R O +
enhancer O +
, O +
and O +
both O +
sites O +
together O +
have O +
strong O +
transcriptional O +
activity O +
specifically O +
in O +
T O +
cells O +
. O +

Surprisingly O +
, O +
the O +
levels O +
of O +
SRF O +
constitutively O +
expressed O +
in O +
T O +
cells O +
are O +
consistently O +
higher O +
than O +
in O +
other O +
cell O +
types O +
. O +

Overexpression O +
of O +
SRF O +
in O +
B O +
cells O +
causes O +
the O +
IL-2R O +
enhancer O +
to O +
function O +
as O +
well O +
as O +
it O +
does O +
in O +
T O +
cells O +
, O +
suggesting O +
that O +
the O +
high O +
level O +
of O +
SRF O +
binding O +
in O +
T O +
cells O +
is O +
functionally O +
important O +
. O +

The O +
transcriptionally O +
active O +
factors O +
mediating O +
the O +
effect O +
of O +
the O +
HTLV O -
- O -
I O +
Tax O +
transactivator O +
on O +
the O +
IL-2R O +
alpha O +
kappa O +
B O +
enhancer O +
include O +
the O +
product O +
of O +
the O +
c O -
- O -
rel O +
proto O -
- O -
oncogene O +
. O +

The O +
transactivator O +
HTLV O -
- O -
I O +
Tax O +
activates O +
the O +
promoter O +
of O +
the O +
gene O +
coding O +
for O +
the O +
interleukin O +
2 O +
alpha O -
- O -
chain O +
receptor O +
( O +
IL-2R O +
alpha O +
) O +
via O +
a O +
kappa O +
B O +
site O +
that O +
can O +
bind O +
several O +
protein O +
species O +
of O +
the O +
rel O +
family O +
. O +

Tax1 O +
strongly O +
activates O +
the O +
enhancer O +
activity O +
of O +
this O +
motif O +
, O +
in O +
both O +
epithelial B-CellLine +
HeLa I-CellLine +
and O +
lymphoid O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

This O +
activation O +
was O +
not O +
observed O +
in O +
undifferentiated O +
embryocarcinoma O +
F9 O +
cells O +
. O +

Overexpression O +
of O +
the O +
p50 O +
, O +
p65 O +
and O +
Rel O +
proteins O +
in O +
these O +
cells O +
showed O +
that O +
significant O +
activation O +
of O +
the O +
IL-2R O +
alpha O +
kappa O +
B O +
site O +
was O +
observed O +
only O +
with O +
Rel O +
and O +
Rel O +
plus O +
p65 O +
. O +

Moreover O +
, O +
whereas O +
both O +
Tax O +
and O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
are O +
able O +
to O +
efficiently O +
induce O +
the O +
binding O +
of O +
NF O -
- O -
kappa O +
B O +
to O +
the O +
IL-2R O +
alpha O +
kappa O +
B O +
site O +
, O +
PMA O +
is O +
functionally O +
inactive O +
. O +

Using O +
the O +
DNA O +
affinity O +
precipitation O +
assay O +
, O +
we O +
observed O +
that O +
Tax1 O +
is O +
able O +
to O +
efficiently O +
induce O +
the O +
binding O +
of O +
Rel O +
, O +
whereas O +
PMA O +
is O +
not O +
. O +

This O +
established O +
a O +
clear O +
difference O +
between O +
both O +
stimuli O +
, O +
indicating O +
that O +
Rel O +
is O +
the O +
functionally O +
active O +
factor O +
. O +

We O +
conclude O +
from O +
these O +
results O +
that O +
the O +
functional O +
activity O +
of O +
members O +
of O +
the O +
rel O +
family O +
is O +
regulated O +
by O +
their O +
interaction O +
with O +
DNA O +
and O +
that O +
Rel O +
can O +
be O +
a O +
potent O +
transcriptional O +
activator O +
on O +
specific O +
kappa O +
B O +
sites O +
. O +

p105 O +
and O +
p98 O +
precursor O +
proteins O +
play O +
an O +
active O +
role O +
in O +
NF O -
- O -
kappa O +
B O +
-mediated O +
signal O +
transduction O +
. O +

The O +
Rel O -
/ O -
NF O -
- O -
kappa O +
B O +
family O +
of O +
transcription O +
factors O +
is O +
composed O +
of O +
two O +
distinct O +
subgroups O +
, O +
proteins O +
that O +
undergo O +
proteolytic O +
processing O +
and O +
contain O +
SWI6 O -
/ O -
ankyrin O +
repeats O +
in O +
their O +
carboxyl O +
termini O +
( O +
p105 O +
, O +
p98 O +
) O +
, O +
and O +
those O +
without O +
such O +
repeats O +
that O +
do O +
not O +
require O +
processing O +
( O +
p65 O +
, O +
c O -
- O -
Rel O +
, O +
RelB O +
, O +
and O +
Dorsal O +
) O +
. O +

We O +
demonstrate O +
that O +
the O +
p105 O +
and O +
p98 O +
precursors O +
share O +
functional O +
properties O +
with O +
the O +
I O +
kappa O +
B O +
proteins O +
, O +
which O +
also O +
contain O +
SWI6 O -
/ O -
ankyrin O +
repeats O +
. O +

Both O +
p105 O +
and O +
p98 O +
were O +
found O +
to O +
form O +
stable O +
complexes O +
with O +
other O +
Rel O -
/ O -
NF O -
- O -
kappa O +
B O +
family O +
members O +
, O +
including O +
p65 O +
and O +
c O -
- O -
Rel O +
. O +

Association O +
with O +
the O +
precursors O +
is O +
sufficient O +
for O +
cytoplasmic O +
retention O +
of O +
either O +
p65 O +
or O +
c O -
- O -
Rel O +
, O +
both O +
of O +
which O +
are O +
otherwise O +
nuclear O +
. O +

These O +
complexes O +
undergo O +
stimulus O -
- O -
responsive O +
processing O +
to O +
produce O +
active O +
p50 O -
/ O -
c O -
- O -
Rel O +
and O +
p55 O -
/ O -
c O -
- O -
Rel O +
complexes O +
. O +

These O +
observations O +
suggest O +
a O +
second O +
pathway O +
leading O +
to O +
NF O -
- O -
kappa O +
B O +
induction O +
, O +
in O +
which O +
processing O +
of O +
the O +
precursors O +
rather O +
than O +
phosphorylation O +
of O +
I O +
kappa O +
B O +
plays O +
a O +
major O +
role O +
. O +

Mutual O +
regulation O +
of O +
the O +
transcriptional O +
activator O +
NF O -
- O -
kappa O +
B O +
and O +
its O +
inhibitor O +
, O +
I O +
kappa O +
B O -
- O -
alpha O +
. O +

The O +
NK O -
- O -
kappa O +
B O +
transcription O +
factor O +
complex O +
is O +
sequestered O +
in O +
the O +
cytoplasm O +
by O +
the O +
inhibitory O +
protein O +
I O +
kappa O +
B O -
- O -
alpha O +
( O +
MAD-3 O +
) O +
. O +

Various O +
cellular O +
stimuli O +
relieve O +
this O +
inhibition O +
by O +
mechanisms O +
largely O +
unknown O +
, O +
leading O +
to O +
NF O -
- O -
kappa O +
B O +
nuclear O +
localization O +
and O +
transactivation O +
of O +
its O +
target O +
genes O +
. O +

It O +
is O +
demonstrated O +
here O +
with O +
human O +
T O +
lymphocytes O +
and O +
monocytes O +
that O +
different O +
stimuli O +
, O +
including O +
tumor O +
necrosis O +
factor O +
alpha O +
and O +
phorbol O +
12-myristate O +
13-acetate O +
, O +
cause O +
rapid O +
degradation O +
of O +
I O +
kappa O +
B O -
- O -
alpha O +
, O +
with O +
concomitant O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
followed O +
by O +
a O +
dramatic O +
increase O +
in O +
I O +
kappa O +
B O -
- O -
alpha O +
mRNA O +
and O +
protein O +
synthesis O +
. O +

Transfection O +
studies O +
reveal O +
that O +
the O +
I O +
kappa O +
B O -
- O -
alpha O +
mRNA O +
and O +
the O +
encoded O +
protein O +
are O +
potently O +
induced O +
by O +
NF O -
- O -
kappa O +
B O +
and O +
by O +
homodimers O +
of O +
p65 O +
and O +
of O +
c O -
- O -
Rel O +
. O +

We O +
propose O +
a O +
model O +
in O +
which O +
NF O -
- O -
kappa O +
B O +
and O +
I O +
kappa O +
B O -
- O -
alpha O +
mutually O +
regulate O +
each O +
other O +
in O +
a O +
cycle O +
: O +
saturating O +
amounts O +
of O +
the O +
inhibitory O +
I O +
kappa O +
B O -
- O -
alpha O +
protein O +
are O +
destroyed O +
upon O +
stimulation O +
, O +
allowing O +
rapid O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

Subsequently O +
, O +
I O +
kappa O +
B O -
- O -
alpha O +
mRNA O +
and O +
protein O +
levels O +
are O +
quickly O +
induced O +
by O +
the O +
activated O +
NF O -
- O -
kappa O +
B O +
. O +

This O +
resurgence O +
of O +
I O +
kappa O +
B O -
- O -
alpha O +
protein O +
acts O +
to O +
restore O +
an O +
equilibrium O +
in O +
which O +
NF O -
- O -
kappa O +
B O +
is O +
again O +
inhibited O +
. O +

The O +
Sp1 O +
transcription O +
factor O +
binds O +
the O +
CD11b O +
promoter O +
specifically O +
in O +
myeloid O +
cells O +
in O +
vivo O +
and O +
is O +
essential O +
for O +
myeloid O -
- O -
specific O +
promoter O +
activity O +
. O +

The O +
myeloid O +
integrin O +
CD11b O +
is O +
expressed O +
selectively O +
on O +
the O +
surface O +
of O +
mature O +
macrophages O +
, O +
monocytes O +
, O +
neutrophils O +
, O +
and O +
natural O +
killer O +
cells O +
. O +

Lineage O -
- O -
specific O +
expression O +
is O +
controlled O +
at O +
the O +
level O +
of O +
mRNA O +
transcription O +
. O +

Recent O +
isolation O +
of O +
the O +
CD11b O +
promoter O +
shows O +
that O +
92 O +
base O +
pairs O +
( O +
bp O +
) O +
of O +
5'-flanking O +
DNA O +
are O +
sufficient O +
to O +
direct O +
myeloid O -
- O -
specific O +
expression O +
of O +
a O +
reporter O +
gene O +
. O +

To O +
characterize O +
regulatory O +
sequences O +
important O +
for O +
promoter O +
activity O +
, O +
we O +
performed O +
linker O +
scanning O +
analysis O +
of O +
the O +
92-bp O +
CD11b O +
promoter O +
and O +
demonstrate O +
that O +
a O +
sequence O +
at O +
bp O +
-60 O +
is O +
essential O +
for O +
CD11b O +
promoter O +
activity O +
. O +

We O +
show O +
that O +
this O +
sequence O +
binds O +
the O +
transcription O +
factor O +
Sp1 O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

In O +
vivo O +
the O +
Sp1 O +
site O +
is O +
bound O +
only O +
in O +
myeloid B-CellLine +
( I-CellLine +
U937 I-CellLine +
) I-CellLine +
cells I-CellLine +
, O +
not O +
in O +
cervical B-CellLine +
carcinoma I-CellLine +
( I-CellLine +
HeLa I-CellLine +
) I-CellLine +
cells I-CellLine +
. O +

In O +
addition O +
, O +
the O +
macrophage O +
transcription O +
factor O +
PU.1 O +
binds O +
the O +
CD11b O +
promoter O +
in O +
vitro O +
and O +
in O +
vivo O +
close O +
to O +
the O +
Sp1 O +
site O +
. O +

We O +
propose O +
a O +
model O +
in O +
which O +
binding O +
of O +
a O +
myeloid O -
- O -
specific O +
factor O +
( O +
PU.1 O +
) O +
allows O +
a O +
general O +
factor O +
( O +
Sp1 O +
) O +
to O +
bind O +
in O +
a O +
tissue O -
- O -
specific O +
fashion O +
thereby O +
contributing O +
to O +
the O +
myeloid O -
- O -
specific O +
expression O +
of O +
CD11b B-CellLine +
. O +

Costimulation O +
of O +
peripheral O +
blood O +
T O +
cell O +
activation O +
by O +
human O +
endothelial O +
cells O +
. O +

Enhanced O +
IL-2 O +
transcription O +
correlates O +
with O +
increased O +
c O -
- O -
fos O +
synthesis O +
and O +
increased O +
Fos O +
content O +
of O +
AP-1 O +
. O +

Endothelial O +
cells O +
( O +
EC O +
) O +
act O +
as O +
APC O +
for O +
resting O +
PBL O +
in O +
vitro O +
, O +
and O +
may O +
have O +
important O +
roles O +
in O +
vivo O +
in O +
the O +
pathogenesis O +
of O +
allograft O +
rejection O +
and O +
delayed O +
hypersensitivity O +
. O +

We O +
previously O +
reported O +
that O +
human O +
umbilical O +
vein O +
EC O +
provide O +
costimulatory O +
signals O +
to O +
PHA O -
- O -
stimulated O +
PBL O +
via O +
CD2 O +
: O +
lymphocyte O +
function O -
- O -
associated O +
Ag-3 O +
and O +
an O +
unidentified O +
ligand O +
pair O +
, O +
resulting O +
in O +
a O +
three- O +
to O +
eight O -
- O -
fold O +
enhancement O +
of O +
IL-2 O +
production O +
. O +

The O +
physiologic O +
relevance O +
of O +
this O +
increase O +
was O +
demonstrated O +
by O +
the O +
proliferative O +
advantage O +
provided O +
by O +
EC O +
to O +
PBL O +
suboptimally O +
stimulated O +
with O +
mAb O +
OKT3 O +
. O +

We O +
now O +
report O +
that O +
EC O +
costimulation O +
causes O +
increased O +
levels O +
of O +
IL-2 O +
mRNA O +
as O +
a O +
result O +
of O +
increased O +
IL-2 O +
transcription O +
in O +
PBL O +
. O +

We O +
therefore O +
examined O +
the O +
effects O +
of O +
EC O +
on O +
T O +
cell O +
nuclear O +
factors O +
known O +
to O +
regulate O +
IL-2 O +
transcription O +
, O +
including O +
c O -
- O -
jun O +
and O +
c O -
- O -
fos O -
- O -
two O +
components O +
of O +
the O +
transcription O +
factor O +
AP-1 O +
, O +
NFAT O +
, O +
and O +
others O +
. O +

PBL O +
constitutively O +
express O +
c O -
- O -
jun O +
transcripts O +
, O +
and O +
the O +
level O +
of O +
c O -
- O -
jun O +
mRNA O +
is O +
not O +
altered O +
by O +
PHA O +
activation O +
in O +
the O +
absence O +
or O +
presence O +
of O +
EC O +
. O +

In O +
contrast O +
, O +
c O -
- O -
fos O +
mRNA O +
is O +
absent O +
from O +
resting O +
T O +
cells O +
and O +
is O +
induced O +
on O +
PHA O +
activation O +
. O +

EC O +
alone O +
do O +
not O +
induce O +
c O -
- O -
fos O +
mRNA O +
but O +
augment O +
the O +
level O +
of O +
c O -
- O -
fos O +
mRNA O +
in O +
PHA O -
- O -
activated O +
T O +
cells O +
by O +
3- O +
to O +
10-fold O +
. O +

This O +
effect O +
is O +
largely O +
independent O +
of O +
the O +
CD2 O +
: O +
lymphocyte O +
function O -
- O -
associated O +
Ag-3 O +
pathway O +
. O +

Gel O -
- O -
shift O +
analysis O +
reveals O +
the O +
constitutive O +
presence O +
of O +
nuclear O +
factors O +
in O +
resting O +
PBL O +
that O +
bind O +
to O +
the O +
proximal O +
AP-1 O +
site O +
of O +
the O +
IL-2 O +
promoter O +
and O +
that O +
contain O +
immunoreactive O +
c O -
- O -
Jun O +
but O +
not O +
c O -
- O -
Fos O +
protein O +
. O +

In O +
contrast O +
, O +
AP-1 O +
from O +
PHA O -
- O -
activated O +
cells O +
contains O +
c O -
- O -
Jun O +
and O +
low O +
levels O +
of O +
c O -
- O -
Fos O +
. O +

Strikingly O +
, O +
costimulation O +
with O +
EC O +
results O +
in O +
a O +
dramatic O +
increase O +
( O +
up O +
to O +
15-fold O +
) O +
in O +
the O +
c O -
- O -
Fos O +
content O +
of O +
AP-1 O +
. O +

Levels O +
of O +
other O +
nuclear O +
factors O +
involved O +
in O +
IL-2 O +
regulation O +
were O +
not O +
altered O +
by O +
EC O +
, O +
although O +
NFAT O -
- O -
DNA O +
complexes O +
migrated O +
at O +
a O +
slightly O +
different O +
mobility O +
. O +

In O +
summary O +
, O +
our O +
data O +
suggest O +
that O +
changes O +
in O +
the O +
composition O +
of O +
transcription O +
factor O +
AP-1 O +
is O +
a O +
key O +
molecular O +
mechanism O +
for O +
increasing O +
IL-2 O +
transcription O +
and O +
may O +
underlie O +
the O +
phenomenon O +
of O +
costimulation O +
by O +
EC O +
. O +

Functional O +
antagonism O +
between O +
vitamin O +
D3 O +
and O +
retinoic O +
acid O +
in O +
the O +
regulation O +
of O +
CD14 O +
and O +
CD23 O +
expression O +
during O +
monocytic O +
differentiation O +
of O +
U-937 B-CellLine +
cells I-CellLine +
. O +

1 O +
, O +
25 O +
alpha O -
- O -
Dihydroxicholecalciferol O +
( O +
VitD3 O +
) O +
and O +
retinoic O +
acid O +
( O +
RA O +
) O +
are O +
important O +
regulators O +
of O +
the O +
proliferation O +
and O +
differentiation O +
of O +
several O +
cell O +
types O +
. O +

This O +
paper O +
describes O +
how O +
the O +
expression O +
of O +
the O +
monocyte O -
- O -
macrophage O +
Ag O +
, O +
CD14 O +
, O +
and O +
the O +
low O +
affinity O +
Fc O +
receptor O +
for O +
IgE O +
, O +
CD23 O +
, O +
were O +
inversely O +
regulated O +
during O +
VitD3 O +
-and O +
RA O -
- O -
induced O +
monocytic O +
differentiation O +
of O +
human B-CellLine +
U-937 I-CellLine +
monoblasts I-CellLine +
. O +

PMA O +
induced O +
the O +
expression O +
of O +
both O +
CD14 O +
and O +
CD23 O +
mRNA O +
and O +
protein O +
. O +

Exposure O +
to O +
VitD3 O +
rapidly O +
induced O +
the O +
de O +
novo O +
expression O +
of O +
CD14 O +
mRNA O +
and O +
protein O +
. O +

The O +
addition O +
of O +
cycloheximide O +
completely O +
blocked O +
the O +
VitD3 O +
induction O +
of O +
CD14 O +
mRNA O +
expression O +
, O +
indicating O +
that O +
the O +
induction O +
was O +
dependent O +
on O +
ongoing O +
protein O +
synthesis O +
. O +

While O +
inducing O +
CD14 O +
expression O +
, O +
VitD3 O +
concomitantly O +
suppressed O +
the O +
basal O +
, O +
PMA- O +
, O +
and O +
RA O -
- O -
inducible O +
CD23 O +
expression O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
. O +

In O +
contrast O +
, O +
U-937 B-CellLine +
cells I-CellLine +
induced O +
by O +
RA O +
strongly O +
increased O +
their O +
expression O +
of O +
CD23 O +
mRNA O +
and O +
protein O +
, O +
whereas O +
they O +
completely O +
lacked O +
detectable O +
CD14 O +
cell O +
surface O +
or O +
mRNA O +
expression O +
. O +

Furthermore O +
, O +
the O +
VitD3 O +
-and O +
the O +
PMA O -
- O -
induced O +
CD14 O +
expression O +
was O +
inhibited O +
as O +
a O +
temporal O +
consequence O +
of O +
the O +
RA O -
- O -
induced O +
differentiation O +
. O +

The O +
results O +
suggest O +
that O +
there O +
exists O +
a O +
functional O +
antagonism O +
between O +
VitD3 O +
and O +
RA O +
that O +
may O +
have O +
important O +
implications O +
for O +
the O +
regulation O +
of O +
certain O +
immune O +
and O +
inflammatory O +
responses O +
through O +
their O +
inverse O +
effects O +
on O +
CD14 O +
and O +
CD23 O +
gene O +
expression O +
. O +

Negative O +
transcriptional O +
regulation O +
of O +
human O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
gene O +
by O +
glucocorticoids O +
through O +
interference O +
with O +
nuclear O +
transcription O +
factors O +
AP-1 O +
and O +
NF O -
- O -
AT O +
. O +

IL-2 O +
gene O +
transcription O +
is O +
affected O +
by O +
several O +
nuclear O +
proteins O +
. O +

We O +
asked O +
whether O +
dexamethasone O +
( O +
Dex O +
) O +
and O +
cyclosporin O +
A O +
( O +
CsA O +
) O +
inhibit O +
IL-2 O +
gene O +
transcription O +
by O +
interfering O +
with O +
the O +
activity O +
of O +
nuclear O +
proteins O +
that O +
bind O +
to O +
the O +
IL-2 O +
promoter O +
. O +

Nuclear O +
extracts O +
from O +
primary O +
human O +
T O +
lymphocytes O +
were O +
analyzed O +
by O +
electrophoretic O +
DNA O +
mobility O +
shift O +
assays O +
. O +

Both O +
Dex O +
and O +
CsA O +
inhibited O +
the O +
binding O +
of O +
transcription O +
factors O +
AP-1 O +
and O +
NF O -
- O -
AT O +
, O +
but O +
not O +
of O +
NF O -
- O -
kB O +
and O +
OCT-1 O -
/ O -
OAF O +
, O +
to O +
their O +
corresponding O +
sites O +
on O +
the O +
IL-2 O +
gene O +
promoter O +
. O +

To O +
correlate O +
changes O +
in O +
nuclear O +
factor O +
binding O +
in O +
vitro O +
with O +
transcriptional O +
activity O +
in O +
vivo O +
and O +
define O +
the O +
structural O +
requirements O +
for O +
IL-2 O +
promoter O +
repression O +
, O +
we O +
used O +
transient O +
DNA O +
transfections O +
. O +

Jurkat B-CellLine +
cells I-CellLine +
were O +
transfected O +
with O +
plasmids O +
containing O +
either O +
the O +
intact O +
IL-2 O +
promoter O +
or O +
its O +
AP-1 O +
, O +
NF O -
- O -
AT O +
, O +
and O +
NF O -
- O -
kB O +
motifs O +
. O +

Dex O +
inhibited O +
the O +
IL-2 O +
promoter O +
and O +
the O +
AP-1 O +
, O +
but O +
not O +
the O +
NF O -
- O -
AT O +
and O +
NF O -
- O -
kB O +
plasmids O +
. O +

In O +
contrast O +
, O +
CsA O +
inhibited O +
the O +
IL-2 O +
promoter O +
and O +
the O +
NF O -
- O -
AT O +
, O +
but O +
not O +
the O +
AP-1 O +
and O +
NF O -
- O -
kB O +
plasmids O +
. O +

These O +
results O +
suggest O +
that O +
in O +
human O +
T O +
lymphocytes O +
both O +
Dex O +
and O +
CsA O +
inhibited O +
IL-2 O +
gene O +
transcription O +
through O +
interference O +
with O +
transcription O +
factors O +
AP-1 O +
and O +
NF O -
- O -
AT O +
. O +

We O +
propose O +
that O +
, O +
while O +
maximum O +
inhibition O +
may O +
involve O +
interaction O +
with O +
both O +
transcription O +
factors O +
, O +
AP-1 O +
is O +
the O +
primary O +
target O +
of O +
Dex O +
. O +

Lymphocytes O +
from O +
the O +
site O +
of O +
disease O +
suggest O +
adenovirus O +
is O +
one O +
cause O +
of O +
persistent O +
or O +
recurrent O +
inflammatory O +
arthritis O +
. O +

The O +
assessment O +
of O +
synovial O +
lymphocyte O +
reactivity O +
to O +
adenovirus O +
antigen O +
stimulation O +
was O +
undertaken O +
in O +
patients O +
with O +
persistent O +
or O +
recurrent O +
inflammatory O +
arthritis O +
. O +

The O +
3H O -
- O -
thymidine O +
uptake O +
procedure O +
was O +
employed O +
, O +
incorporating O +
multiple O +
microbiological O +
antigens O +
. O +

Five O +
patients O +
were O +
found O +
with O +
repeated O +
maximal O +
responses O +
to O +
adenovirus O +
antigen O +
; O +
in O +
one O +
of O +
these O +
adenovirus O +
nucleotide O +
sequences O +
were O +
present O +
in O +
a O +
synovial O +
biopsy O +
specimen O +
. O +

It O +
is O +
concluded O +
that O +
adenovirus O +
may O +
be O +
one O +
cause O +
of O +
persistent O +
or O +
recurrent O +
inflammatory O +
arthritis O +
. O +

Cell O -
- O -
specific O +
expression O +
of O +
helix O -
- O -
loop O -
- O -
helix O +
transcription O +
factors O +
encoded O +
by O +
the O +
E2A O +
gene O +
. O +

The O +
E2A O +
gene O +
encodes O +
transcription O +
factors O +
of O +
the O +
helix O -
- O -
loop O -
- O -
helix O +
family O +
that O +
are O +
implicated O +
in O +
cell O -
- O -
specific O +
gene O +
expression O +
as O +
part O +
of O +
dimeric O +
complexes O +
that O +
interact O +
with O +
E O +
box O +
enhancer O +
elements O +
. O +

It O +
has O +
previously O +
been O +
shown O +
that O +
transcripts O +
of O +
the O +
E2A O +
gene O +
can O +
be O +
detected O +
in O +
a O +
wide O +
range O +
of O +
cell O +
types O +
. O +

We O +
have O +
now O +
examined O +
expression O +
of O +
the O +
mouse O +
E2A O +
gene O +
at O +
the O +
protein O +
level O +
using O +
polyclonal O +
antisera O +
directed O +
against O +
distinct O +
portions O +
of O +
the O +
E2A O +
protein O +
to O +
probe O +
blots O +
of O +
cellular O +
extracts O +
. O +

A O +
73 O +
kDa O +
protein O +
was O +
identified O +
by O +
this O +
analysis O +
: O +
this O +
protein O +
is O +
highly O +
enriched O +
in O +
cell B-CellLine +
lines I-CellLine +
of I-CellLine +
B I-CellLine +
lymphoid I-CellLine +
origin I-CellLine +
as O +
compared O +
to O +
pancreatic O +
beta O -
- O -
cells O +
and O +
fibroblast O +
cells O +
. O +

The O +
detection O +
of O +
this O +
protein O +
selectively O +
in O +
extracts O +
of O +
lymphoid O +
cells O +
correlates O +
with O +
the O +
presence O +
of O +
the O +
E O +
box O +
-binding O +
activity O +
LEF1 O -
/ O -
BCF1 O +
in O +
these O +
cells O +
; O +
this O +
binding O +
activity O +
was O +
previously O +
shown O +
to O +
be O +
efficiently O +
recognized O +
by O +
antiserum O +
directed O +
against O +
E2A O +
gene O +
products O +
. O +

Transfection O +
of O +
cells O +
with O +
full O +
length O +
E2A O +
cDNA O +
leads O +
to O +
appearance O +
of O +
protein O +
co O -
- O -
migrating O +
with O +
the O +
73 O +
kDa O +
protein O +
on O +
SDS O +
gel O +
electrophoresis O +
and O +
co O -
- O -
migrating O +
with O +
LEF1 O -
/ O -
BCF1 O +
on O +
mobility O +
shift O +
analysis O +
. O +

Our O +
results O +
are O +
consistent O +
with O +
the O +
view O +
that O +
the O +
DNA O -
- O -
binding O +
activity O +
LEF1 O -
/ O -
BCF1 O +
is O +
a O +
homodimer O +
of O +
E2A O +
proteins O +
; O +
the O +
selective O +
appearance O +
of O +
this O +
putative O +
cell O -
- O -
specific O +
transcription O +
factor O +
in O +
B O +
lymphoid O +
cells O +
seems O +
to O +
be O +
attributable O +
, O +
at O +
least O +
in O +
part O +
, O +
to O +
the O +
elevated O +
E2A O +
protein O +
concentrations O +
in O +
these O +
cells O +
. O +

HIV-1 O +
Nef O +
protein O +
inhibits O +
the O +
recruitment O +
of O +
AP-1 O +
DNA O -
- O -
binding O +
activity O +
in O +
human O +
T O -
- O -
cells O +
. O +

The O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
long O +
terminal O +
repeat O +
, O +
HIV-1-LTR O +
, O +
contains O +
binding O +
sites O +
for O +
several O +
cellular O +
transcription O +
factors O +
which O +
contribute O +
to O +
HIV-1 O +
gene O +
expression O +
. O +

Our O +
previous O +
studies O +
on O +
the O +
function O +
of O +
the O +
HIV-1-encoded O +
Nef O +
protein O +
suggested O +
that O +
Nef O +
may O +
be O +
an O +
inhibitor O +
HIV-1 O +
transcription O +
. O +

To O +
determine O +
whether O +
Nef O +
affects O +
the O +
binding O +
of O +
cellular O +
factors O +
implicated O +
in O +
HIV-1 O +
regulation O +
, O +
32P O -
- O -
labeled O +
oligonucleotides O +
corresponding O +
to O +
the O +
binding O +
sites O +
were O +
incubated O +
with O +
nuclear O +
extracts O +
prepared O +
from O +
Nef B-CellLine -
- I-CellLine -
expressing I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
that O +
were O +
not O +
stimulated O +
or O +
were O +
stimulated O +
with O +
T O -
- O -
cell O +
mitogens O +
. O +

We O +
found O +
that O +
Nef O +
inhibited O +
the O +
recruitment O +
of O +
AP-1 O +
DNA O -
- O -
binding O +
activity O +
in O +
mitogen O -
- O -
stimulated O +
human O +
T O -
- O -
cells O +
. O +

Additionally O +
, O +
Nef B-CellLine +
expressing I-CellLine +
cells I-CellLine +
were O +
transiently O +
transfected O +
with O +
a O +
plasmid O +
in O +
which O +
HIV-1 O +
AP-1 O +
DNA O +
recognition O +
sequences O +
were O +
cloned O +
downstream O +
of O +
the O +
chloramphenicol O +
acetyltransferase O +
( O +
CAT O +
) O +
gene O +
. O +

Mitogen O -
- O -
mediated O +
transcriptional O +
activation O +
of O +
the O +
CAT O +
gene O +
in O +
this O +
construct O +
was O +
inhibited O +
in O +
Nef B-CellLine -
- I-CellLine -
expressing I-CellLine +
cells I-CellLine +
but O +
not O +
in O +
control O +
cells O +
. O +

These O +
studies O +
suggest O +
that O +
, O +
by O +
inhibiting O +
AP-1 O +
activation O +
, O +
Nef O +
may O +
play O +
a O +
role O +
in O +
regulating O +
HIV-1 O +
gene O +
expression O +
in O +
infected O +
T O -
- O -
cells O +
. O +

Adenovirus O +
E1A O +
inhibits O +
IFN O +
-induced O +
resistance O +
to O +
cytolysis O +
by O +
natural O +
killer O +
cells O +
. O +

Infection O +
of O +
target O +
cells O +
with O +
cytopathic O +
viruses O +
inhibits O +
IFN O +
induction O +
of O +
cytolytic O +
resistance O +
to O +
NK O +
cell O -
- O -
mediated O +
cytolysis O +
[ O +
IFN O +
-mediated O +
cytoprotection O +
( O +
IFN O +
-MCP O +
) O +
] O +
. O +

It O +
has O +
been O +
thought O +
that O +
the O +
virally O +
induced O +
inhibition O +
of O +
IFN O +
-MCP O +
is O +
secondary O +
to O +
the O +
shutdown O +
of O +
cellular O +
macromolecular O +
synthesis O +
that O +
accompanies O +
cytopathic O +
virus O +
infections O +
. O +

Group O +
C O +
, O +
adenovirus O +
serotype O +
5 O +
( O +
Ad5 O +
) O +
infection O +
inhibits O +
both O +
IFN O +
-MCP O +
and O +
cellular O +
protein O +
synthesis O +
. O +

This O +
study O +
determined O +
if O +
the O +
Ad5-induced O +
inhibition O +
of O +
IFN O +
-MCP O +
was O +
independent O +
of O +
adenovirus O +
( O +
Ad O +
) O +
infection O +
and O +
secondary O +
only O +
to O +
the O +
expression O +
of O +
the O +
Ad O +
early O +
region O +
1A O +
gene O +
( O +
E1A O +
) O +
. O +

To O +
test O +
this O +
hypothesis O +
, O +
4-h O +
NK O +
cytolysis O +
assays O +
were O +
performed O +
on O +
IFN B-CellLine -
- I-CellLine -
gamma I-CellLine -
- I-CellLine -
treated I-CellLine +
human I-CellLine +
cells I-CellLine +
infected O +
with O +
an O +
Ad5 O +
E1A O +
deletion O +
mutant O +
, O +
dl343 O +
, O +
or O +
transfected O +
with O +
the O +
Ad5 O +
E1A O +
gene O +
. O +

IFN O +
-MCP O +
was O +
not O +
inhibited O +
by O +
infection O +
with O +
dl343 O +
, O +
despite O +
the O +
production O +
of O +
large O +
amounts O +
of O +
both O +
early O +
( O +
E1B O +
, O +
p55 O +
) O +
and O +
late O +
( O +
hexon O +
) O +
Ad O +
proteins O +
. O +

In O +
contrast O +
to O +
E1A B-CellLine -
- I-CellLine -
negative I-CellLine +
, I-CellLine +
parental I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
IFN O +
-MCP O +
was O +
blocked O +
in O +
Ad5 O +
E1A B-CellLine -
- I-CellLine -
transfected I-CellLine +
epithelial I-CellLine +
and O +
fibroblastic B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Genetic O +
mapping O +
studies O +
within O +
the O +
E1A O +
gene O +
demonstrated O +
that O +
expression O +
of O +
only O +
the O +
first O +
exon O +
of O +
E1A O +
was O +
sufficient O +
to O +
inhibit O +
IFN O +
-MCP O +
. O +

DNA O +
sequence O +
homology O +
of O +
E1A O +
genes O +
between O +
different O +
Ad O +
groups O +
( O +
group O +
A O +
, O +
Ad12 O +
; O +
group O +
C O +
, O +
Ad5 O +
) O +
is O +
limited O +
almost O +
entirely O +
to O +
three O +
conserved O +
regions O +
located O +
within O +
the O +
first O +
exon O +
of O +
E1A O +
. O +

Because O +
IFN O +
-MCP O +
was O +
also O +
blocked O +
in O +
Ad12 B-CellLine +
E1A I-CellLine -
- I-CellLine -
transfected I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
expression O +
of O +
one O +
or O +
more O +
of O +
the O +
E1A O -
- O -
conserved O +
regions O +
may O +
be O +
necessary O +
to O +
inhibit O +
IFN O +
-MCP O +
. O +

In O +
summary O +
, O +
the O +
expression O +
of O +
E1A O +
gene O +
products O +
inhibited O +
IFN O +
-MCP O +
independently O +
of O +
virus O +
infection O +
. O +

E1A O +
's O +
inhibition O +
of O +
IFN O +
-MCP O +
has O +
the O +
net O +
effect O +
of O +
promoting O +
the O +
selective O +
NK O +
cell O -
- O -
mediated O +
clearance O +
of O +
Ad O -
- O -
infected O +
or O +
Ad B-CellLine -
- I-CellLine -
transformed I-CellLine +
human I-CellLine +
cells I-CellLine +
. O +

A O +
chimeric O +
type O +
II O -
/ O -
type O +
I O +
interleukin-1 O +
receptor O +
can O +
mediate O +
interleukin-1 O +
induction O +
of O +
gene O +
expression O +
in O +
T O +
cells O +
. O +

The O +
type O +
I O +
interleukin-1 O +
receptor O +
( O +
IL-1R O +
) O +
is O +
capable O +
of O +
transducing O +
a O +
signal O +
resulting O +
in O +
promoter O +
activation O +
in O +
T O +
cells O +
. O +

This O +
signal O +
transduction O +
is O +
dependent O +
on O +
the O +
cytoplasmic O +
domain O +
, O +
which O +
consists O +
of O +
213 O +
amino O +
acids O +
. O +

In O +
contrast O +
to O +
the O +
type O +
I O +
receptor O +
, O +
the O +
type O +
II O +
IL-1R O +
has O +
a O +
small O +
cytoplasmic O +
tail O +
, O +
and O +
it O +
is O +
not O +
clear O +
whether O +
this O +
receptor O +
is O +
a O +
signal O -
- O -
transducing O +
or O +
a O +
regulatory O +
molecule O +
. O +

Here O +
we O +
report O +
that O +
the O +
type O +
II O +
IL-1R O +
does O +
not O +
mediate O +
gene O +
activation O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

However O +
, O +
a O +
hybrid O +
receptor O +
composed O +
of O +
the O +
extracellular O +
and O +
transmembrane O +
regions O +
of O +
the O +
human O +
type O +
II O +
interleukin-1 O +
fused O +
to O +
the O +
cytoplasmic O +
domain O +
of O +
the O +
human O +
type O +
I O +
IL-1R O +
was O +
capable O +
of O +
transducing O +
a O +
signal O +
across O +
the O +
membrane O +
resulting O +
in O +
a O +
pattern O +
of O +
gene O +
activation O +
identical O +
to O +
that O +
mediated O +
by O +
the O +
type O +
I O +
IL-1R O +
. O +

Our O +
results O +
indicated O +
that O +
the O +
extracellular O +
domain O +
of O +
the O +
type O +
II O +
IL-1R O +
was O +
capable O +
of O +
functionally O +
interacting O +
with O +
interleukin-1 O +
and O +
transmitting O +
the O +
resulting O +
signal O +
to O +
a O +
heterologous O +
cytoplasmic O +
domain O +
. O +

A O +
mutation O +
of O +
the O +
glucocorticoid O +
receptor O +
in O +
primary O +
cortisol O +
resistance O +
. O +

The O +
precise O +
molecular O +
abnormalities O +
that O +
cause O +
primary O +
cortisol O +
resistance O +
have O +
not O +
been O +
completely O +
described O +
. O +

In O +
a O +
subject O +
with O +
primary O +
cortisol O +
resistance O +
we O +
have O +
observed O +
glucocorticoid O +
receptors O +
( O +
hGR O +
) O +
with O +
a O +
decreased O +
affinity O +
for O +
dexamethasone O +
. O +

We O +
hypothesize O +
that O +
a O +
mutation O +
of O +
the O +
hGR O +
glucocorticoid O -
- O -
binding O +
domain O +
is O +
the O +
cause O +
of O +
cortisol O +
resistance O +
. O +

Total O +
RNA O +
isolated O +
from O +
the O +
index O +
subject O +
's O +
mononuclear O +
leukocytes O +
was O +
used O +
to O +
produce O +
first O +
strand O +
hGR O +
cDNAs O +
, O +
and O +
the O +
entire O +
hGR O +
cDNA O +
was O +
amplified O +
in O +
segments O +
and O +
sequenced O +
. O +

At O +
nucleotide O +
2 O +
, O +
317 O +
we O +
identified O +
a O +
homozygous O +
A O +
for O +
G O +
point O +
mutation O +
that O +
predicts O +
an O +
isoleucine O +
( O +
ATT O +
) O +
for O +
valine O +
( O +
GTT O +
) O +
substitution O +
at O +
amino O +
acid O +
729 O +
. O +

When O +
the O +
wild O -
- O -
type O +
hGR O +
and O +
hGR O -
- O -
Ile O +
729 O +
were O +
expressed O +
in O +
COS-1 B-CellLine +
cells I-CellLine +
and O +
assayed O +
for O +
[ O +
3H O +
] O +
-Dexamethasone O +
binding O +
, O +
the O +
dissociation O +
constants O +
were O +
0.799 O +
+ O -
/- O +
0.068 O +
and O +
1.54 O +
+ O -
/- O +
0.06 O +
nM O +
( O +
mean O +
+ O -
/- O +
SEM O +
) O +
( O +
P O +
< O +
0.01 O +
) O +
, O +
respectively O +
. O +

When O +
the O +
wild O -
- O -
type O +
hGR O +
and O +
hGR O -
- O -
Ile O +
729 O +
were O +
expressed O +
in O +
CV-1 B-CellLine +
cells I-CellLine +
that O +
were O +
cotransfected O +
with O +
the O +
mouse O +
mammary O +
tumor O +
virus O +
long O +
terminal O +
repeat O +
fused O +
to O +
the O +
chloramphenicol O +
acetyl O +
transferase O +
( O +
CAT O +
) O +
gene O +
, O +
the O +
hGR O -
- O -
Ile O +
729 O +
conferred O +
a O +
fourfold O +
decrease O +
in O +
apparent O +
potency O +
on O +
dexamethasone O +
stimulation O +
of O +
CAT O +
activity O +
. O +

The O +
isoleucine O +
for O +
valine O +
substitution O +
at O +
amino O +
acid O +
729 O +
impairs O +
the O +
function O +
of O +
the O +
hGR O +
and O +
is O +
the O +
likely O +
cause O +
of O +
primary O +
cortisol O +
resistance O +
in O +
this O +
subject O +
. O +

Mice O +
deficient O +
for O +
the O +
55 O +
kd O +
tumor O +
necrosis O +
factor O +
receptor O +
are O +
resistant O +
to O +
endotoxic O +
shock O +
, O +
yet O +
succumb O +
to O +
L. O +
monocytogenes O +
infection O +
. O +

The O +
multiple O +
biological O +
activities O +
of O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
are O +
mediated O +
by O +
two O +
distinct O +
cell O +
surface O +
receptors O +
of O +
55 O +
kd O +
( O +
TNFRp55 O +
) O +
and O +
75 O +
kd O +
( O +
TNFRp75 O +
) O +
. O +

Using O +
gene O +
targeting O +
, O +
we O +
generated O +
a O +
TNFRp55 O +
-deficient O +
mouse O +
strain O +
. O +

Cells O +
from O +
TNFRp55- O -
/ O -
-mutant O +
mice O +
lack O +
expression O +
of O +
TNFRp55 O +
but O +
display O +
normal O +
numbers O +
of O +
high O +
affinity O +
TNFRp75 O +
molecules O +
. O +

Thymocyte O +
development O +
and O +
lymphocyte O +
populations O +
are O +
unaltered O +
, O +
and O +
clonal O +
deletion O +
of O +
potentially O +
self O -
- O -
reactive O +
T O +
cells O +
is O +
not O +
impaired O +
. O +

However O +
, O +
TNF O +
signaling O +
is O +
largely O +
abolished O +
, O +
as O +
judged O +
by O +
the O +
failure O +
of O +
TNF O +
to O +
induce O +
NF O -
- O -
kappa O +
B O +
in O +
T O +
lymphocytes O +
from O +
TNFRp55 O +
-deficient O +
mice O +
. O +

The O +
loss O +
of O +
TNFRp55 O +
function O +
renders O +
mice O +
resistant O +
to O +
lethal O +
dosages O +
of O +
either O +
lipopolysaccharides O +
or O +
S. O +
aureus O +
enterotoxin O +
B O +
. O +

In O +
contrast O +
, O +
TNFRp55-deficient O +
mice O +
are O +
severely O +
impaired O +
to O +
clear O +
L. O +
monocytogenes O +
and O +
readily O +
succumb O +
to O +
infection O +
. O +

Thus O +
, O +
the O +
55 O +
kd O +
TNFR O +
plays O +
a O +
decisive O +
role O +
in O +
the O +
host O +
's O +
defense O +
against O +
microorganisms O +
and O +
their O +
pathogenic O +
factors O +
. O +

Cloning O +
and O +
functional O +
characterization O +
of O +
early O +
B O -
- O -
cell O +
factor O +
, O +
a O +
regulator O +
of O +
lymphocyte O -
- O -
specific O +
gene O +
expression O +
. O +

Early O +
B O -
- O -
cell O +
factor O +
( O +
EBF O +
) O +
was O +
identified O +
previously O +
as O +
a O +
tissue O -
- O -
specific O +
and O +
differentiation O +
stage O -
- O -
specific O +
DNA O -
- O -
binding O +
protein O +
that O +
participates O +
in O +
the O +
regulation O +
of O +
the O +
pre O -
- O -
B O +
and O +
B O +
lymphocyte O -
- O -
specific O +
mb-1 O +
gene O +
. O +

Partial O +
amino O +
acid O +
sequences O +
obtained O +
from O +
purified O +
EBF O +
were O +
used O +
to O +
isolate O +
cDNA O +
clones O +
, O +
which O +
by O +
multiple O +
criteria O +
encode O +
EBF O +
. O +

The O +
recombinant O +
polypeptide O +
formed O +
sequence O -
- O -
specific O +
complexes O +
with O +
the O +
EBF O -
- O -
binding O +
site O +
in O +
the O +
mb-1 O +
promoter O +
. O +

The O +
cDNA O +
hybridized O +
to O +
multiple O +
transcripts O +
in O +
pre B-CellLine -
- I-CellLine -
B I-CellLine +
and I-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
, O +
but O +
transcripts O +
were O +
not O +
detected O +
at O +
significant O +
levels O +
in O +
plasmacytoma B-CellLine +
, O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
, O +
and O +
nonlymphoid B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Expression O +
of O +
recombinant O +
EBF O +
in O +
transfected B-CellLine +
nonlymphoid I-CellLine +
cells I-CellLine +
strongly O +
activated O +
transcription O +
from O +
reporter O +
plasmids O +
containing O +
functional O +
EBF O -
- O -
binding O +
sites O +
. O +

Analysis O +
of O +
DNA O +
binding O +
by O +
deletion O +
mutants O +
of O +
EBF O +
identified O +
an O +
amino O -
- O -
terminal O +
cysteine O -
- O -
rich O +
DNA O -
- O -
binding O +
domain O +
lacking O +
obvious O +
sequence O +
similarity O +
to O +
known O +
transcription O +
factors O +
. O +

DNA O -
- O -
binding O +
assays O +
with O +
cotranslated O +
wild O -
- O -
type O +
and O +
truncated O +
forms O +
of O +
EBF O +
indicated O +
that O +
the O +
protein O +
interacts O +
with O +
its O +
site O +
as O +
a O +
homodimer O +
. O +

Deletions O +
delineated O +
a O +
carboxy O -
- O -
terminal O +
dimerization O +
region O +
containing O +
two O +
repeats O +
of O +
15 O +
amino O +
acids O +
that O +
show O +
similarity O +
with O +
the O +
dimerization O +
domains O +
of O +
basic O -
- O -
helix O -
- O -
loop O -
- O -
helix O +
proteins O +
. O +

Together O +
, O +
these O +
data O +
suggest O +
that O +
EBF O +
represents O +
a O +
novel O +
regulator O +
of O +
B O +
lymphocyte O -
- O -
specific O +
gene O +
expression O +
. O +

Regulation O +
of O +
the O +
Ets O -
- O -
related O +
transcription O +
factor O +
Elf-1 O +
by O +
binding O +
to O +
the O +
retinoblastoma O +
protein O +
. O +

The O +
retinoblastoma O +
gene O +
product O +
( O +
Rb O +
) O +
is O +
a O +
nuclear O +
phosphoprotein O +
that O +
regulates O +
cell O +
cycle O +
progression O +
. O +

Elf-1 O +
is O +
a O +
lymphoid O -
- O -
specific O +
Ets O +
transcription O +
factor O +
that O +
regulates O +
inducible O +
gene O +
expression O +
during O +
T O +
cell O +
activation O +
. O +

In O +
this O +
report O +
, O +
it O +
is O +
demonstrated O +
that O +
Elf-1 O +
contains O +
a O +
sequence O +
motif O +
that O +
is O +
highly O +
related O +
to O +
the O +
Rb O +
binding O +
sites O +
of O +
several O +
viral O +
oncoproteins O +
and O +
binds O +
to O +
the O +
pocket O +
region O +
of O +
Rb O +
both O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

Elf-1 O +
binds O +
exclusively O +
to O +
the O +
underphosphorylated O +
form O +
of O +
Rb O +
and O +
fails O +
to O +
bind O +
to O +
Rb O +
mutants O +
derived O +
from O +
patients O +
with O +
retinoblastoma O +
. O +

Co O -
- O -
immunoprecipitation O +
experiments O +
demonstrated O +
an O +
association O +
between O +
Elf-1 O +
and O +
Rb O +
in O +
resting O +
normal O +
human O +
T O +
cells O +
. O +

After O +
T O +
cell O +
activation O +
, O +
the O +
phosphorylation O +
of O +
Rb O +
results O +
in O +
the O +
release O +
of O +
Elf-1 O +
, O +
which O +
is O +
correlated O +
temporally O +
with O +
the O +
activation O +
of O +
Elf-1 O +
-mediated O +
transcription O +
. O +

Overexpression O +
of O +
a O +
phosphorylation O -
- O -
defective O +
form O +
of O +
Rb O +
inhibited O +
Elf-1 O +
-dependent O +
transcription O +
during O +
T O +
cell O +
activation O +
. O +

These O +
results O +
demonstrate O +
that O +
Rb O +
interacts O +
specifically O +
with O +
a O +
lineage O -
- O -
restricted O +
Ets O +
transcription O +
factor O +
. O +

This O +
regulated O +
interaction O +
may O +
be O +
important O +
for O +
the O +
coordination O +
of O +
lineage O -
- O -
specific O +
effector O +
functions O +
such O +
as O +
lymphokine O +
production O +
with O +
cell O +
cycle O +
progression O +
in O +
activated O +
T O +
cells O +
. O +

Expression O +
levels O +
of O +
the O +
thyrotropin O +
receptor O +
gene O +
in O +
autoimmune O +
thyroid O +
disease O +
: O +
coregulation O +
with O +
parameters O +
of O +
thyroid O +
function O +
and O +
inverse O +
relation O +
to O +
major O +
histocompatibility O +
complex O +
classes O +
I O +
and O +
II O +
. O +

Using O +
a O +
human O +
TSH O +
receptor O +
( O +
TSH O -
- O -
R O +
) O +
cDNA O +
probe O +
, O +
we O +
investigated O +
TSH O -
- O -
R O +
transcript O +
levels O +
in O +
13 O +
human O +
thyroid O +
fragments O +
by O +
Northern O +
blot O +
analysis O +
; O +
7 O +
Graves O +
' O +
disease O +
, O +
2 O +
Hashimoto O +
's O +
disease O +
, O +
3 O +
endemic O +
goiter O +
, O +
and O +
1 O +
healthy O +
thyroid O +
gland O +
were O +
studied O +
. O +

TSH O -
- O -
R O +
expression O +
levels O +
were O +
variable O +
, O +
but O +
displayed O +
a O +
close O +
correlation O +
to O +
the O +
expression O +
of O +
thyroid O +
peroxidase O +
( O +
r O +
= O +
0.703 O +
; O +
P O +
< O +
0.05 O +
) O +
, O +
thyroglobulin O +
( O +
r O +
= O +
0.817 O +
; O +
P O +
< O +
0.01 O +
) O +
, O +
and O +
the O +
nuclear O +
oncogene O +
c O -
- O -
fos O +
( O +
r O +
= O +
0.935 O +
; O +
P O +
< O +
0.001 O +
) O +
, O +
but O +
not O +
c O -
- O -
myc O +
. O +

Overall O +
, O +
TSH O -
- O -
R O +
transcript O +
levels O +
were O +
low O +
or O +
absent O +
in O +
those O +
thyroids O +
in O +
which O +
expression O +
of O +
the O +
major O +
histocompatibility O +
complex O +
class O +
I O +
or O +
II O +
( O +
MHC O +
I O +
or O +
II O +
) O +
was O +
high O +
, O +
thus O +
establishing O +
an O +
inverse O +
relation O +
( O +
MHC O +
I O +
, O +
r O +
= O +
-0.791 O +
; O +
P O +
< O +
0.01 O +
; O +
MHC O +
II O +
, O +
r O +
= O +
-0.784 O +
; O +
P O +
< O +
0.01 O +
) O +
. O +

In O +
situ O +
hybridization O +
showed O +
that O +
apart O +
from O +
lymphocytes O +
, O +
thyroid O +
cells O +
themselves O +
were O +
the O +
source O +
of O +
MHC O +
II O +
transcripts O +
. O +

gamma O -
- O -
Interferon O +
expression O +
was O +
only O +
detectable O +
in O +
1 O +
Hashimoto O +
's O +
goiter O +
. O +

Our O +
findings O +
suggest O +
that O +
next O +
to O +
lymphocyte O +
infiltration O +
, O +
active O +
regulatory O +
events O +
in O +
the O +
thyrocyte O +
are O +
responsible O +
for O +
the O +
inverse O +
relation O +
between O +
functional O +
parameters O +
( O +
TSH O -
- O -
R O +
, O +
thyroid O +
peroxidase O +
, O +
thyroglobulin O +
, O +
and O +
c O -
- O -
fos O +
) O +
and O +
immunological O +
markers O +
( O +
MHC O +
I O +
and O +
II O +
) O +
. O +

Regulation O +
of O +
the O +
interleukin-1 O +
beta O +
( O +
IL-1 O +
beta O +
) O +
gene O +
by O +
mycobacterial O +
components O +
and O +
lipopolysaccharide O +
is O +
mediated O +
by O +
two O +
nuclear O +
factor O -
- O -
IL6 O +
motifs O +
. O +

The O +
cytokines O +
interleukin-1 O +
beta O +
( O +
IL-1 O +
beta O +
) O +
and O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
are O +
released O +
by O +
mononuclear O +
phagocytes O +
in O +
vitro O +
after O +
stimulation O +
with O +
mycobacteria O +
and O +
are O +
considered O +
to O +
mediate O +
pathophysiologic O +
events O +
, O +
including O +
granuloma O +
formation O +
and O +
systemic O +
symptoms O +
. O +

We O +
demonstrated O +
that O +
the O +
Mycobacterium O +
tuberculosis O +
cell O +
wall O +
component O +
lipoarabinomannan O +
( O +
LAM O +
) O +
is O +
a O +
very O +
potent O +
inducer O +
of O +
IL-1 O +
beta O +
gene O +
expression O +
in O +
human O +
monocytes O +
and O +
investigated O +
the O +
mechanism O +
of O +
this O +
effect O +
. O +

We O +
localized O +
the O +
LAM- O +
, O +
lipopolysaccharide O +
( O +
LPS O +
) O +
- O +
, O +
and O +
TNF O -
- O -
alpha O +
-inducible O +
promoter O +
activity O +
to O +
a O +
-131 O -
/ O -
+15 O +
( O +
positions O +
-131 O +
to O +
+ O -
15 O +
) O +
DNA O +
fragment O +
of O +
the O +
IL-1 O +
beta O +
gene O +
by O +
deletion O +
analysis O +
and O +
chloramphenicol O +
acetyltransferase O +
assay O +
. O +

Within O +
this O +
DNA O +
fragment O +
, O +
there O +
were O +
two O +
novel O +
9-bp O +
motifs O +
( O +
-90 O -
/ O -
-82 O +
and O +
-40 O -
/ O -
-32 O +
) O +
with O +
high O +
homology O +
to O +
the O +
nuclear O +
factor O -
- O -
IL6 O +
( O +
NF O -
- O -
IL6 O +
) O +
binding O +
site O +
. O +

Site O -
- O -
directed O +
mutagenesis O +
demonstrated O +
that O +
the O +
two O +
NF O -
- O -
IL-6 O +
motifs O +
could O +
be O +
independently O +
activated O +
by O +
LAM O +
, O +
LPS O +
, O +
or O +
TNF O -
- O -
alpha O +
and O +
that O +
they O +
acted O +
in O +
an O +
orientation O -
- O -
independent O +
manner O +
. O +

DNA O +
mobility O +
shift O +
assay O +
revealed O +
specific O +
binding O +
of O +
nuclear O +
protein O +
( O +
s O +
) O +
from O +
LAM- B-CellLine +
, I-CellLine +
LPS- I-CellLine +
, I-CellLine +
or I-CellLine +
TNF I-CellLine -
- I-CellLine -
alpha- I-CellLine +
stimulated I-CellLine +
THP-1 I-CellLine +
cells I-CellLine +
to O +
the O +
NF O -
- O -
IL6 O +
motifs O +
. O +

We O +
conclude O +
that O +
the O +
two O +
NF O -
- O -
IL6 O +
sites O +
mediate O +
induction O +
of O +
IL-1 O +
beta O +
in O +
response O +
to O +
the O +
stimuli O +
LAM O +
, O +
LPS O +
, O +
and O +
TNF O -
- O -
alpha O +
. O +

Calcium O +
dependent O +
activation O +
of O +
the O +
NF O -
- O -
AT O +
transcription O +
factor O +
by O +
p59fyn O +
. O +

A O +
reporter O +
gene O +
under O +
the O +
control O +
of O +
a O +
T O -
- O -
cell O +
antigen O +
receptor O +
element O +
was O +
activated O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
by O +
antigen O +
receptor O +
triggering O +
or O +
by O +
a O +
combination O +
of O +
phorbol O +
myristate O +
acetate O +
, O +
which O +
activates O +
protein O +
kinase O +
C O +
, O +
and O +
a O +
calcium O +
ionophore O +
. O +

Both O +
these O +
signals O +
were O +
necessary O +
for O +
expression O +
of O +
the O +
reporter O +
gene O +
. O +

When O +
co O -
- O -
transfected O +
with O +
a O +
construct O +
capable O +
of O +
overexpressing O +
the O +
tyrosine O +
kinase O +
p59fyn O +
, O +
the O +
reporter O +
gene O +
was O +
activated O +
by O +
PMA O +
alone O +
. O +

Thus O +
p59fyn O +
could O +
replace O +
the O +
calcium O +
ionophore O +
but O +
not O +
activation O +
of O +
protein O +
kinase O +
C O +
. O +

The O +
activation O +
by O +
p59fyn O +
plus O +
PMA O +
was O +
blocked O +
by O +
EGTA O +
and O +
by O +
the O +
immunosuppressant O +
drug O +
cyclosporin O +
A O +
. O +

Cell O -
- O -
specific O +
bifunctional O +
role O +
of O +
Jun O +
oncogene O +
family O +
members O +
on O +
glucocorticoid O +
receptor O +
-dependent O +
transcription O +
. O +

Interaction O +
between O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
- O +
and O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
-mediated O +
signaling O +
is O +
suggested O +
by O +
the O +
ability O +
of O +
the O +
PKC O +
activating O +
phorbol O +
ester O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
to O +
inhibit O +
GR O +
-dependent O +
transcription O +
of O +
the O +
mouse O +
mammary O +
tumor O +
virus O +
( O +
MMTV O +
) O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
. O +

Here O +
we O +
report O +
that O +
this O +
interference O +
is O +
cell O +
specific O +
, O +
as O +
TPA O +
augmented O +
dexamethasone O -
- O -
induced O +
transcriptional O +
activation O +
of O +
the O +
MMTV O +
LTR O +
in O +
several O +
T B-CellLine +
cell I-CellLine +
lines I-CellLine +
but O +
was O +
inhibitory O +
in O +
NIH-3T3 B-CellLine +
fibroblasts I-CellLine +
. O +

TPA O -
- O -
GR O +
synergism O +
was O +
determined O +
to O +
have O +
occurred O +
at O +
the O +
GR O -
- O -
responsive O +
element O +
( O +
GRE O +
) O +
level O +
by O +
functional O +
analysis O +
of O +
deletion O +
mutants O +
or O +
synthetic O +
GRE O +
oligonucleotides O +
driving O +
chloramphenicol O +
acetyl O -
- O -
transferase O +
expression O +
. O +

Synergism O +
required O +
an O +
intact O +
GR O +
DNA O -
- O -
binding O +
domain O +
, O +
whereas O +
amino- O +
or O +
carboxyl O -
- O -
terminal O +
domains O +
were O +
dispensable O +
. O +

The O +
effect O +
was O +
abrogated O +
by O +
the O +
PKC O +
inhibitor O +
staurosporine O +
, O +
suggesting O +
a O +
role O +
for O +
PKC O +
. O +

Increased O +
c O -
- O -
jun O +
, O +
jun O -
- O -
B O +
, O +
and O +
jun O -
- O -
D O +
expression O +
above O +
basal O +
levels O +
and O +
increased O +
transcriptional O +
activity O +
of O +
AP-1 O -
/ O -
TPA O +
responsive O +
elements O +
fused O +
to O +
chloramphenicol O +
acetyl O -
- O -
transferase O +
vectors O +
were O +
observed O +
in O +
T O +
cells O +
treated O +
with O +
TPA O +
alone O +
or O +
in O +
combination O +
with O +
dexamethasone O +
. O +

The O +
ability O +
of O +
Jun O +
proteins O +
to O +
cooperate O +
with O +
GR O +
in O +
T O +
cells O +
has O +
been O +
investigated O +
after O +
transfection O +
of O +
c O -
- O -
jun O +
, O +
jun O -
- O -
B O +
, O +
or O +
jun O -
- O -
D O +
expression O +
vectors O +
, O +
which O +
augmented O +
GR O +
-dependent O +
transcription O +
from O +
either O +
MMTV O +
LTR O +
or O +
GRE O +
. O +

Conversely O +
, O +
c O -
- O -
jun O +
and O +
jun O -
- O -
B O +
transfection O +
blunted O +
GR O +
-dependent O +
transcription O +
in O +
HeLa B-CellLine +
cells I-CellLine +
. O +

The O +
presence O +
of O +
c O -
- O -
fos O +
had O +
a O +
negative O +
influence O +
on O +
GR O +
function O +
and O +
correlated O +
with O +
the O +
cell O -
- O -
specific O +
synergistic O +
or O +
antagonistic O +
activity O +
of O +
Jun O +
with O +
respect O +
to O +
GR O +
; O +
high O +
basal O +
expression O +
of O +
c O -
- O -
fos O +
as O +
well O +
as O +
AP-1 O +
DNA O +
binding O +
and O +
transcriptional O +
activity O +
were O +
observed O +
in O +
HeLa B-CellLine +
cells I-CellLine +
, O +
but O +
not O +
in O +
T O +
cells O +
. O +

Furthermore O +
overexpression O +
of O +
exogenous O +
c O -
- O -
fos O +
has O +
an O +
inhibitory O +
effect O +
on O +
GR O +
-dependent O +
transcription O +
from O +
GRE O +
in O +
T O +
cells O +
. O +

We O +
propose O +
that O +
Jun O +
plays O +
a O +
bifunctional O +
role O +
on O +
GR O +
-dependent O +
transcriptional O +
activation O +
of O +
GRE O +
, O +
selecting O +
either O +
synergistic O +
or O +
antagonistic O +
activity O +
depending O +
on O +
the O +
cell O -
- O -
specific O +
microenvironment O +
. O +

In O +
this O +
regard O +
, O +
intracellular O +
levels O +
of O +
c O -
- O -
fos O +
appear O +
to O +
be O +
influential O +
. O +

Regulation O +
of O +
the O +
beta O -
- O -
globin O +
locus O +
. O +

Transcription O +
of O +
the O +
human O +
beta O -
- O -
globin O +
gene O +
cluster O +
depends O +
upon O +
upstream O +
regulatory O +
sequences O +
, O +
which O +
are O +
collectively O +
termed O +
the O +
locus O +
control O +
region O +
. O +

Recent O +
studies O +
have O +
provided O +
new O +
insights O +
into O +
how O +
the O +
individual O +
genes O +
of O +
the O +
cluster O +
are O +
regulated O +
through O +
development O +
. O +

The O +
crux O +
of O +
transcriptional O +
activation O +
is O +
how O +
the O +
locus O +
control O +
region O +
communicates O +
with O +
the O +
gene O -
- O -
proximal O +
regulatory O +
elements O +
. O +

Ectopic O +
expression O +
of O +
a O +
conditional O +
GATA-2 O -
/ O -
estrogen O +
receptor O +
chimera O +
arrests O +
erythroid O +
differentiation O +
in O +
a O +
hormone O -
- O -
dependent O +
manner O +
. O +

The O +
GATA O +
factors O +
are O +
a O +
family O +
of O +
transcriptional O +
regulatory O +
proteins O +
in O +
eukaryotes O +
that O +
share O +
extensive O +
homology O +
in O +
their O +
DNA O -
- O -
binding O +
domains O +
. O +

One O +
enigmatic O +
aspect O +
of O +
GATA O +
factor O +
expression O +
is O +
that O +
several O +
GATA O +
proteins O +
, O +
which O +
ostensibly O +
share O +
the O +
same O +
DNA O -
- O -
binding O +
site O +
specificity O +
, O +
are O +
coexpressed O +
in O +
erythroid O +
cells O +
. O +

To O +
elucidate O +
the O +
roles O +
of O +
individual O +
GATA O +
factors O +
in O +
erythropoiesis O +
, O +
conditional O +
alleles O +
of O +
GATA-1 O +
, O +
GATA-2 O +
, O +
and O +
GATA-3 O +
were O +
prepared O +
by O +
fusing O +
each O +
of O +
the O +
factors O +
to O +
the O +
hormone O -
- O -
binding O +
domain O +
of O +
the O +
human O +
estrogen O +
receptor O +
( O +
ER O +
) O +
. O +

These O +
GATA O -
/ O -
ER O +
chimeric O +
factors O +
were O +
shown O +
to O +
be O +
hormone O -
- O -
inducible O +
trans O -
- O -
activating O +
proteins O +
in O +
transient O +
transfection O +
assays O +
. O +

When O +
stably O +
introduced O +
into O +
primary O +
erythroblasts O +
or O +
conditionally B-CellLine +
transformed I-CellLine +
erythroid I-CellLine +
progenitors I-CellLine +
cells I-CellLine +
, O +
exogenous O +
GATA-2 O -
/ O -
ER O +
promoted O +
proliferation O +
and O +
inhibited O +
terminal O +
differentiation O +
in O +
an O +
estrogen O -
- O -
dependent O +
manner O +
. O +

These O +
phenotypic O +
effects O +
are O +
specifically O +
attributable O +
to O +
the O +
action O +
of O +
ectopically O +
expressed O +
GATA-2 O -
/ O -
ER O +
because O +
erythroblasts O +
expressing O +
exogenous O +
GATA-2 O +
are O +
constitutively O +
arrested O +
in O +
differentiation O +
and O +
because O +
erythroid B-CellLine +
progenitors I-CellLine +
expressing O +
either O +
Gal O -
/ O -
ER O +
or O +
GATA-3 O -
/ O -
ER O +
do O +
not O +
display O +
a O +
hormone O -
- O -
responsive O +
block O +
in O +
differentiation O +
. O +

Thus O +
, O +
the O +
GATA-2 O +
transcription O +
factor O +
appears O +
to O +
play O +
a O +
role O +
in O +
regulating O +
the O +
self O -
- O -
renewal O +
capacity O +
of O +
early O +
erythroid O +
progenitor O +
cells O +
. O +

Proliferation O +
index O +
as O +
a O +
prognostic O +
marker O +
in O +
breast O +
cancer O +
. O +

BACKGROUND O +
. O +

The O +
proliferative O +
activity O +
of O +
tumors O +
has O +
been O +
extensively O +
investigated O +
with O +
different O +
approaches O +
, O +
among O +
which O +
the O +
use O +
of O +
the O +
monoclonal O +
antibody O +
Ki-67 O +
represents O +
an O +
easy O +
and O +
reliable O +
means O +
of O +
assessing O +
cell O +
proliferation O +
. O +

In O +
this O +
study O +
, O +
the O +
proliferative O +
activity O +
of O +
129 O +
primary O +
breast O +
cancers O +
was O +
investigated O +
, O +
and O +
the O +
results O +
were O +
related O +
to O +
prognosis O +
. O +

METHODS O +
. O +

Tumor O +
samples O +
, O +
obtained O +
from O +
129 O +
patients O +
who O +
underwent O +
surgery O +
between O +
January O +
1987 O +
and O +
December O +
1988 O +
, O +
were O +
processed O +
for O +
staining O +
by O +
an O +
immunohistochemical O +
procedure O +
( O +
avidin O -
- O -
biotin O +
complex O +
) O +
. O +

The O +
median O +
time O +
of O +
observation O +
was O +
42 O +
months O +
( O +
range O +
, O +
31 O -
- O -
55 O +
months O +
) O +
. O +

Life O -
- O -
table O +
analysis O +
( O +
Mantel O -
- O -
Cox O +
) O +
was O +
used O +
to O +
assess O +
the O +
probability O +
of O +
disease O -
- O -
free O +
survival O +
( O +
DFS O +
) O +
and O +
overall O +
survival O +
( O +
OS O +
) O +
. O +

RESULTS O +
. O +

Tumors O +
with O +
high O +
Ki-67 O +
proliferation O +
indices O +
( O +
> O +
20 O +
% O +
) O +
were O +
associated O +
with O +
a O +
higher O +
4-year O +
probability O +
of O +
relapse O +
of O +
disease O +
( O +
55.3 O +
% O +
versus O +
79.1 O +
% O +
; O +
P O +
= O +
0.003 O +
) O +
and O +
death O +
( O +
71 O +
% O +
versus O +
95.6 O +
% O +
; O +
P O +
= O +
0.00005 O +
) O +
when O +
compared O +
with O +
tumors O +
with O +
low O +
Ki-67 O +
values O +
. O +

In O +
addition O +
, O +
this O +
proliferative O +
parameter O +
maintained O +
its O +
prognostic O +
significance O +
when O +
the O +
patients O +
were O +
stratified O +
according O +
to O +
lymph O +
node O +
involvement O +
, O +
menopausal O +
status O +
, O +
and O +
nuclear O +
estrogen O +
receptor O +
content O +
. O +

CONCLUSIONS O +
. O +

Tumor O +
proliferative O +
activity O +
as O +
evaluated O +
by O +
the O +
monoclonal O +
antibody O +
Ki-67 O +
seems O +
to O +
be O +
an O +
effective O +
indicator O +
of O +
prognosis O +
in O +
breast O +
cancer O +
for O +
DFS O +
and O +
OS O +
. O +

Glucocorticoid O +
receptors O +
in O +
mononuclear O +
cells O +
of O +
patients O +
with O +
sepsis O +
. O +

Glucocorticoid O +
receptor O +
( O +
GR O +
) O +
hormone O -
- O -
binding O +
activity O +
was O +
studied O +
by O +
a O +
whole O -
- O -
cell O +
method O +
in O +
mononuclear O +
cells O +
( O +
MNC O +
) O +
from O +
peripheral O +
blood O +
of O +
7 O +
patients O +
during O +
the O +
hemodynamic O +
compensatory O +
phase O +
of O +
sepsis O +
. O +

4 O +
patients O +
were O +
receiving O +
dopamine O +
, O +
which O +
did O +
not O +
affect O +
the O +
GR O +
count O +
. O +

The O +
patients O +
' O +
plasma O +
cortisol O +
concentrations O +
were O +
normal O +
or O +
slightly O +
elevated O +
. O +

Despite O +
a O +
wide O +
range O +
, O +
the O +
mean O +
GR O +
count O +
and O +
affinity O +
in O +
MNC O +
from O +
septic O +
patients O +
did O +
not O +
differ O +
from O +
those O +
in O +
normal O +
controls O +
, O +
suggesting O +
that O +
glucocorticoids O +
could O +
still O +
be O +
effective O +
in O +
the O +
hemodynamic O +
compensatory O +
phase O +
of O +
sepsis O +
. O +

Dependence O +
for O +
the O +
proliferative O +
response O +
to O +
erythropoietin O +
on O +
an O +
established O +
erythroid O +
differentiation O +
program O +
in O +
a O +
human B-CellLine +
hematopoietic I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
UT-7 B-CellLine +
. O +

Erythroid O +
differentiation O +
involves O +
the O +
activation O +
of O +
a O +
number O +
of O +
erythroid O -
- O -
specific O +
genes O +
, O +
most O +
of O +
which O +
, O +
including O +
the O +
globin O +
genes O +
and O +
the O +
erythropoietin O +
receptor O +
( O +
Epo O -
- O -
R O +
) O +
gene O +
, O +
are O +
, O +
at O +
least O +
in O +
part O +
, O +
regulated O +
by O +
the O +
transcription O +
factor O +
GATA-1 O +
. O +

In O +
order O +
to O +
understand O +
the O +
relationship O +
, O +
if O +
any O +
, O +
between O +
expression O +
of O +
GATA-1 O +
, O +
response O +
to O +
Epo O +
and O +
erythroid O +
differentiation O +
, O +
we O +
analyzed O +
the O +
expression O +
of O +
GATA-1 O +
, O +
Epo O -
- O -
R O +
and O +
globin O +
genes O +
in O +
an O +
Epo O -
- O -
dependent O +
human O +
cell O +
line O +
, O +
UT-7 B-CellLine +
Epo O +
. O +

The O +
results O +
were O +
compared O +
to O +
those O +
obtained O +
with O +
the O +
parental B-CellLine +
granulocyte I-CellLine -
- I-CellLine -
macrophage I-CellLine +
colony I-CellLine -
- I-CellLine -
stimulating I-CellLine +
factor I-CellLine +
( I-CellLine +
GM I-CellLine -
- I-CellLine -
CSF I-CellLine +
) I-CellLine +
-dependent I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
UT-7 B-CellLine +
, O +
which O +
has O +
a O +
predominantly O +
megakaryoblastic O +
phenotype O +
and O +
is O +
unable O +
to O +
proliferate O +
continuously O +
in O +
the O +
presence O +
of O +
Epo O +
. O +

UT-7 O +
Epo O +
and O +
UT-7 B-CellLine +
expressed O +
similar O +
levels O +
of O +
GATA-1 O +
mRNA O +
and O +
binding O +
activity O +
. O +

The O +
two O +
lines O +
also O +
expressed O +
comparable O +
levels O +
of O +
Epo O -
- O -
R O +
mRNA O +
while O +
the O +
number O +
of O +
Epo O +
-binding O +
sites O +
on O +
UT-7 B-CellLine +
Epo I-CellLine +
cells I-CellLine +
was O +
one O -
- O -
sixth O +
the O +
number O +
of O +
UT-7 B-CellLine +
cells I-CellLine +
( O +
2400 O +
+ O -
/- O +
3 O +
vs. O +
13 O +
, O +
800 O +
+ O -
/- O +
300 O +
) O +
. O +

This O +
difference O +
in O +
the O +
number O +
of O +
binding O +
sites O +
could O +
be O +
due O +
to O +
differences O +
in O +
cell O +
surface O +
( O +
UT-7 B-CellLine +
cells I-CellLine +
are O +
20 O +
% O +
smaller O +
than O +
the O +
parental O +
UT-7 B-CellLine +
cells I-CellLine +
) O +
or O +
in O +
receptor O +
turnover O +
. O +

By O +
Northern O +
analysis O +
, O +
UT-7 B-CellLine +
cells I-CellLine +
expressed O +
detectable O +
levels O +
of O +
beta- O +
and O +
gamma O -
- O -
globin O +
but O +
not O +
alpha O -
- O -
globin O +
. O +

In O +
comparison O +
, O +
UT-7 B-CellLine +
Epo I-CellLine +
cells I-CellLine +
expressed O +
alpha O -
- O -
globin O +
and O +
higher O +
levels O +
of O +
gamma O -
- O -
globin O +
( O +
5-fold O +
) O +
and O +
beta O -
- O -
globin O +
( O +
from O +
barely O +
to O +
clearly O +
detectable O +
) O +
. O +

Globin O +
chains O +
( O +
alpha O +
, O +
beta O +
and O +
gamma O +
) O +
were O +
clearly O +
detectable O +
by O +
affinity O +
chromatography O +
in O +
UT-7 O +
Epo O +
but O +
not O +
in O +
UT-7 B-CellLine +
cells I-CellLine +
. O +

The O +
frequency O +
of O +
the O +
cells O +
which O +
expressed O +
beta- O +
and O +
gamma- O +
globin O +
genes O +
in O +
the O +
two O +
cell O +
populations O +
was O +
measured O +
by O +
immunofluorescence O +
with O +
beta- O +
and O +
gamma O -
- O -
specific O +
antibodies O +
. O +

The O +
number O +
of O +
gamma B-CellLine -
- I-CellLine -
positive I-CellLine +
cells I-CellLine +
and O +
their O +
fluorescence O +
intensity O +
were O +
higher O +
in O +
UT-7 O +
Epo O +
than O +
in O +
UT-7 B-CellLine +
cells I-CellLine +
( O +
0 O +
to O +
17 O +
% O +
barely O +
positive O +
cells O +
and O +
23 O +
to O +
40 O +
% O +
clearly O +
positive O +
cells O +
, O +
respectively O +
) O +
, O +
indicating O +
that O +
the O +
increase O +
in O +
globin O +
mRNA O +
observed O +
in O +
UT-7 O +
Epo O +
is O +
due O +
to O +
both O +
an O +
increase O +
of O +
gene O +
expression O +
per O +
cell O +
and O +
an O +
increase O +
in O +
numbers O +
of O +
cells O +
containing O +
gamma O -
- O -
globin O +
. O +

The O +
levels O +
of O +
GATA-1 O +
, O +
Epo O -
- O -
R O +
and O +
globin O +
mRNA O +
expressed O +
were O +
not O +
affected O +
by O +
a O +
24-hour O +
incubation O +
of O +
either O +
cell O +
line O +
with O +
Epo O +
, O +
GM O -
- O -
CSF O +
or O +
interleukin-3 O +
( O +
IL-3 O +
) O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
400 O +
WORDS O +
) O +

Comparative O +
analysis O +
of O +
NFAT O +
( O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
) O +
complex O +
in O +
human O +
T O +
and O +
B O +
lymphocytes O +
. O +

Nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
is O +
a O +
transcriptional O +
activator O +
that O +
binds O +
to O +
sequences O +
in O +
the O +
interleukin-2 O +
( O +
IL-2 O +
) O +
promoter O +
and O +
is O +
thought O +
to O +
be O +
largely O +
responsible O +
for O +
the O +
T O +
cell O -
- O -
specific O +
inducibility O +
of O +
IL-2 O +
expression O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
( O +
EMSA O +
) O +
showed O +
that O +
specific O +
NFAT O +
binding O +
activity O +
could O +
also O +
be O +
induced O +
in O +
human O +
B O +
cells O +
. O +

The O +
B O +
cell O +
NFAT O +
complex O +
, O +
however O +
, O +
was O +
not O +
functional O +
, O +
since O +
it O +
failed O +
to O +
activate O +
transcription O +
from O +
an O +
NFAT O -
- O -
driven O +
chloramphenicol O +
acetyltransferase O +
( O +
CAT O +
) O +
construct O +
. O +

Competition O +
with O +
an O +
AP-1 O +
motif O +
or O +
with O +
anti O -
- O -
Jun O +
and O +
anti O -
- O -
Fos O +
antibodies O +
abolished O +
binding O +
to O +
the O +
NFAT O +
motif O +
in O +
both O +
T O +
and O +
B O +
cells O +
, O +
indicating O +
that O +
Jun O +
and O +
Fos O +
are O +
critical O +
for O +
NFAT O +
complex O +
formation O +
in O +
both O +
cell O +
types O +
. O +

Purified O +
recombinant O +
Jun O +
and O +
Fos O +
proteins O +
failed O +
to O +
bind O +
directly O +
to O +
the O +
NFAT O +
motif O +
. O +

However O +
, O +
when O +
combined O +
with O +
unstimulated O +
B O +
or O +
T O +
cell O +
extracts O +
, O +
full O -
- O -
length O +
, O +
but O +
not O +
truncated O +
, O +
Jun O -
/ O -
Fos O +
heterodimers O +
were O +
able O +
to O +
form O +
an O +
NFAT O +
complex O +
, O +
indicating O +
the O +
presence O +
of O +
a O +
constitutively O +
expressed O +
nuclear O +
factor O +
( O +
s O +
) O +
in O +
B O +
and O +
T O +
cells O +
necessary O +
for O +
the O +
formation O +
of O +
the O +
NFAT O +
complex O +
in O +
both O +
cell O +
types O +
. O +

An O +
NFAT O +
oligonucleotide O +
carrying O +
mutations O +
in O +
the O +
5 O +
' O +
purine O -
- O -
rich O +
part O +
of O +
the O +
NFAT O +
sequence O +
failed O +
to O +
form O +
a O +
complex O +
and O +
to O +
compete O +
with O +
the O +
wild O +
type O +
motif O +
for O +
NFAT O +
complex O +
formation O +
in O +
both O +
T O +
and O +
B O +
cells O +
. O +

We O +
therefore O +
propose O +
a O +
model O +
whereby O +
a O +
core O +
NFAT O +
complex O +
consisting O +
of O +
Jun O +
, O +
Fos O +
, O +
and O +
a O +
constitutive O +
nuclear O +
factor O +
is O +
formed O +
in O +
both O +
T O +
and O +
B O +
cells O +
, O +
but O +
an O +
additional O +
factor O +
and/or O +
post O -
- O -
translational O +
modification O +
of O +
a O +
factor O +
, O +
missing O +
in O +
B O +
cells O +
, O +
might O +
be O +
required O +
for O +
transactivation O +
by O +
NFAT O +
. O +

1 O +
, O +
25-Dihydroxy O +
vitamin O +
D3 O +
and O +
12-O O -
- O -
tetradecanoyl O +
phorbol-13-acetate O +
synergistically O +
induce O +
monocytic O +
cell O +
differentiation O +
: O +
FOS O +
and O +
RB O +
expression O +
. O +

1 O +
, O +
25-dihydroxy O +
vitamin O +
D3 O +
and O +
12-O O -
- O -
tetradecanoyl O +
phorbol-13-acetate O +
( O +
TPA O +
) O +
interact O +
synergistically O +
to O +
induce O +
monocytic O +
differentiation O +
of O +
U937 B-CellLine +
histiocytic I-CellLine +
lymphoma I-CellLine +
cells I-CellLine +
. O +

Addition O +
of O +
TPA O +
causes O +
an O +
otherwise O +
ineffective O +
dose O +
of O +
1 O +
, O +
25-dihydroxy O +
vitamin O +
D3 O +
to O +
induce O +
differentiation O +
. O +

The O +
induced O +
differentiation O +
depends O +
on O +
the O +
simultaneous O +
( O +
vs. O +
sequential O +
) O +
presence O +
of O +
both O +
agents O +
. O +

The O +
kinetics O +
of O +
induced O +
differentiation O +
are O +
consistent O +
with O +
a O +
G1 O +
specific O +
cellular O +
response O +
to O +
initiate O +
the O +
metabolic O +
cascade O +
culminating O +
in O +
cell O +
differentiation O +
. O +

The O +
induced O +
differentiation O +
occurs O +
with O +
down O -
- O -
regulation O +
of O +
c O -
- O -
fos O +
protein O +
and O +
an O +
accompanying O +
up O -
- O -
regulation O +
of O +
RB O +
protein O +
expression O +
, O +
consistent O +
with O +
a O +
possible O +
need O +
for O +
up O -
- O -
regulated O +
RB O +
expression O +
to O +
maintain O +
a O +
given O +
differentiated O +
phenotype O +
and O +
suppress O +
transcriptional O +
activators O +
that O +
might O +
typically O +
be O +
associated O +
with O +
proliferation O +
. O +

Differential O +
autoregulation O +
of O +
glucocorticoid O +
receptor O +
expression O +
in O +
human B-CellLine +
T- I-CellLine +
and I-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
. O +

Regulation O +
of O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
expression O +
by O +
its O +
cognate O +
ligand O +
was O +
examined O +
in O +
the O +
glucocorticoid B-CellLine -
- I-CellLine -
sensitive I-CellLine +
human I-CellLine +
leukemic I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
6TG1.1 I-CellLine +
and O +
in O +
the O +
human B-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
IM-9 I-CellLine +
. O +

In O +
contrast O +
to O +
the O +
decrease O +
in O +
GR O +
mRNA O +
seen O +
in O +
IM-9 B-CellLine +
cells I-CellLine +
after O +
treatment O +
with O +
1 O +
microM O +
dexamethasone O +
for O +
16 O -
- O -
18 O +
h O +
, O +
treatment O +
of O +
6TG1.1 B-CellLine +
cells I-CellLine +
resulted O +
in O +
an O +
8-fold O +
increase O +
in O +
GR O +
mRNA O +
, O +
as O +
determined O +
by O +
Northern O +
blot O +
and O +
RNase O +
protection O +
analysis O +
, O +
with O +
a O +
corresponding O +
3- O +
to O +
4-fold O +
increase O +
in O +
GR O +
protein O +
. O +

Half O -
- O -
maximal O +
induction O +
of O +
GR O +
mRNA O +
and O +
protein O +
in O +
6TG1.1 B-CellLine +
cells I-CellLine +
was O +
observed O +
between O +
10 O -
- O -
100 O +
nM O +
dexamethasone O +
, O +
and O +
inclusion O +
of O +
1 O +
microM O +
RU O +
38486 O +
completely O +
blocked O +
the O +
effects O +
of O +
100 O +
nM O +
dexamethasone O +
, O +
demonstrating O +
that O +
positive O +
autoregulation O +
of O +
GR O +
expression O +
in O +
6TG1.1 B-CellLine +
cells I-CellLine +
is O +
a O +
receptor O -
- O -
mediated O +
response O +
. O +

Positive O +
autoregulation O +
of O +
GR O +
expression O +
was O +
also O +
observed O +
in O +
glucocorticoid B-CellLine -
- I-CellLine -
resistant I-CellLine +
CEM I-CellLine -
- I-CellLine -
C1 I-CellLine +
cells I-CellLine +
, O +
which O +
contain O +
functional O +
GR O +
, O +
but O +
whose O +
growth O +
is O +
unaffected O +
by O +
glucocorticoids O +
. O +

Thus O +
, O +
positive O +
autoregulation O +
is O +
neither O +
a O +
consequence O +
nor O +
the O +
sole O +
cause O +
of O +
growth O +
arrest O +
. O +

The O +
degree O +
of O +
negative O +
autoregulation O +
in O +
IM-9 B-CellLine +
cells I-CellLine +
and O +
positive O +
autoregulation O +
in O +
6TG1.1 B-CellLine +
cells I-CellLine +
was O +
unaffected O +
by O +
inhibition O +
of O +
protein O +
synthesis O +
with O +
cycloheximide O +
. O +

Measurement O +
of O +
GR O +
mRNA O +
turnover O +
in O +
6TG1.1 B-CellLine +
cells I-CellLine +
treated O +
with O +
actinomycin O -
- O -
D O +
revealed O +
a O +
half O -
- O -
life O +
of O +
2.5 O +
h O +
, O +
which O +
was O +
unaffected O +
by O +
dexamethasone O +
treatment O +
. O +

A O +
similar O +
half O -
- O -
life O +
was O +
determined O +
in O +
IM-9 B-CellLine +
cells I-CellLine +
and O +
was O +
also O +
unaffected O +
by O +
steroid O +
treatment O +
. O +

These O +
results O +
are O +
consistent O +
with O +
the O +
interpretation O +
that O +
glucocorticoid O -
- O -
mediated O +
autoregulation O +
of O +
GR O +
expression O +
is O +
a O +
tissue O -
- O -
specific O +
primary O +
transcriptional O +
response O +
. O +

The O +
p65 O +
subunit O +
of O +
NF O -
- O -
kappa O +
B O +
regulates O +
I O +
kappa O +
B O +
by O +
two O +
distinct O +
mechanisms O +
. O +

Transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
( O +
p50 O -
/ O -
p65 O +
) O +
is O +
generally O +
localized O +
to O +
the O +
cytoplasm O +
by O +
its O +
inhibitor O +
I O +
kappa O +
B O +
. O +

Overproduced O +
I O +
kappa O +
B O +
, O +
free O +
from O +
NF O -
- O -
kappa O +
B O +
, O +
is O +
rapidly O +
degraded O +
. O +

Overexpression O +
of O +
p65 O +
increases O +
endogenous O +
I O +
kappa O +
B O +
protein O +
in O +
both O +
carcinoma O +
and O +
lymphoid O +
cells O +
by O +
two O +
mechanisms O +
: O +
protein O +
stabilization O +
and O +
increased O +
transcription O +
of O +
I O +
kappa O +
B O +
mRNA O +
. O +

In O +
contrast O +
, O +
p65 O +
delta O +
, O +
a O +
naturally O +
occurring O +
splice O +
variant O +
, O +
fails O +
to O +
markedly O +
augment O +
I O +
kappa O +
B O +
protein O +
levels O +
. O +

Both O +
overexpressed O +
p65 O +
and O +
coexpressed O +
p50 O +
are O +
cytoplasmic O +
, O +
whereas O +
p65 O +
delta O +
is O +
partly O +
nuclear O +
, O +
indicating O +
that O +
the O +
I O +
kappa O +
B O +
induced O +
by O +
p65 O +
can O +
maintain O +
NF O -
- O -
kappa O +
B O +
in O +
the O +
cytoplasm O +
. O +

Thus O +
, O +
p65 O +
and O +
I O +
kappa O +
B O +
are O +
linked O +
in O +
an O +
autoregulatory O +
loop O +
, O +
ensuring O +
that O +
NF O -
- O -
kappa O +
B O +
is O +
held O +
in O +
the O +
cytoplasm O +
until O +
cells O +
are O +
specifically O +
induced O +
to O +
translocate O +
it O +
to O +
the O +
nucleus O +
. O +

Occurrence O +
of O +
a O +
silencer O +
of O +
the O +
interleukin-2 O +
gene O +
in O +
naive O +
but O +
not O +
in O +
memory O +
resting O +
T O +
helper O +
lymphocytes O +
. O +

In O +
the O +
immune O +
system O +
the O +
first O +
activation O +
of O +
a O +
naive O +
T O +
cell O +
by O +
antigen O +
is O +
a O +
key O +
step O +
in O +
the O +
shaping O +
of O +
the O +
peripheral O +
T O +
cell O +
specificity O +
repertoire O +
and O +
maintenance O +
of O +
self O -
- O -
tolerance O +
. O +

In O +
the O +
present O +
study O +
, O +
analysis O +
of O +
the O +
interleukin-2 O +
( O +
IL-2 O +
) O +
gene O +
activation O +
shows O +
that O +
naive O +
human O +
helper O +
T O +
cells O +
( O +
cord O +
blood O +
CD4 O -
+ O +
T O +
cells O +
, O +
adult O +
CD4+CD45RO- O +
T O +
cells O +
) O +
regulate O +
IL-2 O +
transcription O +
by O +
a O +
mechanism O +
involving O +
both O +
a O +
silencer O +
and O +
an O +
activator O +
acting O +
on O +
the O +
purine O -
- O -
rich O +
IL-2 O +
promoter O +
elements O +
( O +
NF O -
- O -
AT O +
binding O +
sites O +
) O +
. O +

By O +
contrast O +
, O +
memory O +
cells O +
, O +
either O +
in O +
vitro B-CellLine +
activated I-CellLine +
helper I-CellLine +
T I-CellLine +
cells I-CellLine +
reverting O +
to O +
a O +
resting O +
state O +
, O +
or O +
CD4 B-CellLine -
+ I-CellLine +
T I-CellLine +
( I-CellLine +
memory I-CellLine +
) I-CellLine +
clones I-CellLine +
, O +
or O +
CD4+CD45RO+ B-CellLine +
T I-CellLine +
cells I-CellLine +
isolated O +
ex O +
vivo O +
, O +
no O +
longer O +
have O +
a O +
silencer O +
. O +

Their O +
IL-2 O +
transcription O +
seems O +
to O +
be O +
controlled O +
solely O +
by O +
the O +
transition O +
from O +
inactive O +
to O +
active O +
functional O +
state O +
of O +
a O +
positive O +
transcription O +
factor O +
binding O +
to O +
these O +
promoter O +
elements O +
as O +
well O +
as O +
its O +
cytoplasmic O +
or O +
nuclear O +
location O +
: O +
in O +
resting O +
memory O +
T O +
cells O +
the O +
activator O +
is O +
located O +
in O +
the O +
cytoplasm O +
and O +
is O +
inactive O +
, O +
whereas O +
in O +
stimulated B-CellLine +
cells I-CellLine +
it O +
is O +
functional O +
in O +
promoting O +
transcription O +
and O +
now O +
resides O +
in O +
the O +
nucleus O +
. O +

Thus O +
, O +
the O +
regulation O +
of O +
the O +
gene O +
coding O +
for O +
the O +
main O +
T O +
cell O +
growth O +
factor O +
changes O +
irreversibly O +
after O +
the O +
first O +
encounter O +
of O +
T O +
cells O +
with O +
antigen O +
. O +

It O +
is O +
most O +
likely O +
that O +
the O +
presence O +
of O +
a O +
silencer O +
contributes O +
to O +
the O +
more O +
stringent O +
activation O +
requirements O +
of O +
naive O +
CD4 O -
+ O +
T O +
cells O +
. O +

Single O +
strand O +
conformation O +
polymorphism O +
analysis O +
of O +
androgen O +
receptor O +
gene O +
mutations O +
in O +
patients O +
with O +
androgen O +
insensitivity O +
syndromes O +
: O +
application O +
for O +
diagnosis O +
, O +
genetic O +
counseling O +
, O +
and O +
therapy O +
. O +

Recent O +
studies O +
indicate O +
that O +
mutations O +
in O +
the O +
androgen O +
receptor O +
gene O +
are O +
associated O +
with O +
androgen O +
insensitivity O +
syndromes O +
, O +
a O +
heterogeneous O +
group O +
of O +
related O +
disorders O +
involving O +
defective O +
sexual O +
differentiation O +
in O +
karyotypic O +
males O +
. O +

In O +
this O +
report O +
, O +
we O +
address O +
the O +
possibility O +
of O +
rapid O +
mutational O +
analysis O +
of O +
the O +
androgen O +
receptor O +
gene O +
for O +
initial O +
diagnosis O +
, O +
genetic O +
counseling O +
, O +
and O +
molecular O +
subclassification O +
of O +
affected O +
patients O +
and O +
their O +
families O +
. O +

DNA O +
from O +
peripheral O +
blood O +
leukocytes O +
of O +
six O +
patients O +
from O +
five O +
families O +
with O +
various O +
degrees O +
of O +
androgen O +
insensitivity O +
was O +
studied O +
. O +

Exons O +
2 O +
to O +
8 O +
of O +
the O +
androgen O +
receptor O +
gene O +
were O +
analyzed O +
using O +
a O +
combination O +
of O +
single O +
strand O +
conformation O +
polymorphism O +
analysis O +
and O +
direct O +
DNA O +
sequencing O +
. O +

Female O +
family O +
members O +
were O +
also O +
studied O +
to O +
identify O +
heterozygote O +
carriers O +
. O +

Point O +
mutations O +
in O +
the O +
AR O +
gene O +
were O +
identified O +
in O +
all O +
six O +
patients O +
, O +
and O +
all O +
mutations O +
caused O +
amino O +
acid O +
substitutions O +
. O +

One O +
patient O +
with O +
incomplete O +
androgen O +
insensitivity O +
was O +
a O +
mosaic O +
for O +
the O +
mutation O +
. O +

Four O +
of O +
the O +
five O +
mothers O +
, O +
as O +
well O +
as O +
a O +
young O +
sister O +
of O +
one O +
patient O +
, O +
were O +
carriers O +
of O +
the O +
mutation O +
present O +
in O +
the O +
affected O +
child O +
. O +

Our O +
data O +
show O +
that O +
new O +
mutations O +
may O +
occur O +
in O +
the O +
androgen O +
receptor O +
gene O +
leading O +
to O +
sporadic O +
androgen O +
insensitivity O +
syndrome O +
. O +

Molecular O +
genetic O +
characterization O +
of O +
the O +
variant O +
allele O +
can O +
serve O +
as O +
a O +
primary O +
tool O +
for O +
diagnosis O +
and O +
subsequent O +
therapy O +
, O +
and O +
can O +
provide O +
a O +
basis O +
for O +
distinguishing O +
heterozygous O +
carriers O +
in O +
familial O +
androgen O +
resistance O +
. O +

The O +
identification O +
of O +
carriers O +
is O +
of O +
substantial O +
clinical O +
importance O +
for O +
genetic O +
counseling O +
. O +

Minimally O +
modified O +
low O +
density O +
lipoprotein O +
-induced O +
inflammatory O +
responses O +
in O +
endothelial O +
cells O +
are O +
mediated O +
by O +
cyclic O +
adenosine O +
monophosphate O +
. O +

We O +
have O +
previously O +
shown O +
that O +
minimally B-CellLine +
oxidized I-CellLine +
LDL I-CellLine +
( I-CellLine +
MM I-CellLine -
- I-CellLine -
LDL I-CellLine +
) I-CellLine +
activated I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
to O +
increase O +
their O +
interaction O +
with O +
monocytes O +
but O +
not O +
neutrophils O +
, O +
inducing O +
monocyte O +
but O +
not O +
neutrophil O +
binding O +
and O +
synthesis O +
of O +
monocyte O +
chemotactic O +
protein-1 O +
and O +
monocyte O +
colony O -
- O -
stimulating O +
factor O +
( O +
M O -
- O -
CSF O +
) O +
. O +

In O +
the O +
present O +
studies O +
we O +
have O +
examined O +
the O +
signaling O +
pathways O +
by O +
which O +
this O +
monocyte O -
- O -
specific O +
response O +
is O +
induced O +
. O +

Both O +
induction O +
of O +
monocyte O +
binding O +
and O +
mRNA O +
levels O +
for O +
M O -
- O -
CSF O +
by O +
MM O -
- O -
LDL O +
were O +
not O +
inhibited O +
in O +
protein O +
kinase O +
C O -
- O -
depleted O +
endothelial O +
cells O +
. O +

A O +
number O +
of O +
our O +
studies O +
indicate O +
that O +
cAMP O +
is O +
the O +
second O +
messenger O +
for O +
the O +
effects O +
of O +
MM O -
- O -
LDL O +
cited O +
above O +
. O +

Incubation O +
of O +
endothelial O +
cells O +
with O +
MM O -
- O -
LDL O +
caused O +
a O +
173 O +
% O +
increase O +
in O +
intracellular O +
cAMP O +
levels O +
. O +

Agents O +
which O +
increased O +
cAMP O +
levels O +
, O +
including O +
cholera O +
toxin O +
, O +
pertussis O +
toxin O +
, O +
dibutyryl O +
cAMP O +
, O +
and O +
isoproterenol O +
mimicked O +
the O +
actions O +
of O +
MM O -
- O -
LDL O +
. O +

Agents O +
which O +
elevated O +
cAMP O +
were O +
also O +
shown O +
to O +
activate O +
NF O +
kappa O +
B O +
, O +
suggesting O +
a O +
role O +
for O +
this O +
transcription O +
factor O +
in O +
activation O +
of O +
monocyte O -
- O -
endothelial O +
interactions O +
. O +

Although O +
endothelial O +
leukocyte O +
adhesion O +
molecule O +
( O +
ELAM O +
) O +
mRNA O +
synthesis O +
can O +
be O +
regulated O +
by O +
NF O +
kappa O +
B O +
, O +
ELAM O +
was O +
not O +
expressed O +
and O +
ELAM O +
mRNA O +
was O +
only O +
slightly O +
elevated O +
in O +
response O +
to O +
MM O -
- O -
LDL O +
. O +

We O +
present O +
evidence O +
that O +
induction O +
of O +
neutrophil O +
binding O +
by O +
LPS O +
is O +
actually O +
suppressed O +
by O +
agents O +
that O +
elevated O +
cAMP O +
levels O +
. O +

Costimulation O +
of O +
cAMP O +
and O +
protein O +
kinase O +
C O +
pathways O +
inhibits O +
the O +
CD3 O +
-dependent O +
T O +
cell O +
activation O +
and O +
leads O +
to O +
a O +
persistent O +
expression O +
of O +
the O +
AP-1 O +
transcription O +
factor O +
. O +

The O +
effects O +
mediated O +
by O +
a O +
combined O +
stimulation O +
of O +
cAMP O +
-and O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
-dependent O +
pathways O +
have O +
been O +
investigated O +
in O +
different O +
cellular O +
systems O +
, O +
and O +
it O +
has O +
been O +
shown O +
that O +
they O +
may O +
complement O +
each O +
other O +
in O +
activating O +
cell O +
proliferation O +
and O +
differentiation O +
. O +

In O +
this O +
report O +
, O +
we O +
show O +
that O +
upon O +
the O +
stimulation O +
of O +
both O +
pathways O +
T O +
lymphocytes O +
became O +
refractory O +
to O +
activation O +
via O +
the O +
CD3 O -
/ O -
T O +
cell O +
receptor O +
( O +
TcR O +
) O +
complex O +
. O +

T O +
cells O +
preincubated O +
with O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
and O +
dibutyryl O +
cAMP O +
( O +
Bt2cAMP O +
) O +
displayed O +
a O +
deficient O +
proliferative O +
ability O +
in O +
response O +
to O +
anti O -
- O -
CD3 O +
mAb O +
stimulation O +
, O +
whereas O +
lymphocytes O +
treated O +
individually O +
with O +
either O +
Bt2cAMP O +
or O +
PMA O +
responded O +
comparably O +
to O +
untreated O +
samples O +
. O +

We O +
detected O +
an O +
association O +
between O +
the O +
reduced O +
mitogenic O +
response O +
and O +
low O +
expression O +
of O +
both O +
interleukin-2 O +
( O +
IL-2 O +
) O +
and O +
the O +
alpha O +
chain O +
( O +
CD25 O +
) O +
of O +
the O +
IL-2 O +
receptor O +
( O +
IL-2R O +
) O +
. O +

Analysis O +
of O +
intracellular O +
Ca2 O -
+ O +
mobilization O +
suggested O +
that O +
the O +
CD3 O +
/ O +
TcR O +
-dependent O +
signal O +
transduction O +
was O +
impaired O +
in O +
PMA B-CellLine -
/ I-CellLine -
Bt2cAMP I-CellLine -
- I-CellLine -
treated I-CellLine +
cells I-CellLine +
. O +

Remarkably O +
, O +
we O +
observed O +
that O +
these O +
samples O +
displayed O +
a O +
persistent O +
expression O +
of O +
the O +
c O -
- O -
fos O +
protooncogene O +
, O +
associated O +
to O +
an O +
increased O +
AP-1 O +
DNA O -
- O -
binding O +
activity O +
, O +
whereas O +
no O +
variations O +
of O +
CREB O +
or O +
NF O -
- O -
kB O +
were O +
detected O +
. O +

Neither O +
Bt2cAMP O +
nor O +
PMA O +
individually O +
mediated O +
these O +
sustained O +
effects O +
, O +
which O +
therefore O +
appear O +
as O +
a O +
consequence O +
of O +
the O +
interplay O +
between O +
both O +
metabolic O +
stimuli O +
. O +

Altogether O +
, O +
the O +
data O +
provide O +
the O +
evidence O +
that O +
both O +
pathways O +
complement O +
each O +
other O +
in O +
regulating O +
gene O +
expression O +
and O +
, O +
conversely O +
, O +
downregulate O +
the O +
TcR O +
transduction O +
mechanisms O +
. O +

Human O +
T O +
cell O +
transcription O +
factor O +
GATA-3 O +
stimulates O +
HIV-1 O +
expression O +
. O +

A O +
family O +
of O +
transcriptional O +
activating O +
proteins O +
, O +
the O +
GATA O +
factors O +
, O +
has O +
been O +
shown O +
to O +
bind O +
to O +
a O +
consensus O +
motif O +
through O +
a O +
highly O +
conserved O +
C4 O +
zinc O +
finger O +
DNA O +
binding O +
domain O +
. O +

One O +
member O +
of O +
this O +
multigene O +
family O +
, O +
GATA-3 O +
, O +
is O +
most O +
abundantly O +
expressed O +
in O +
T O +
lymphocytes O +
, O +
a O +
cellular O +
target O +
for O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
infection O +
and O +
replication O +
. O +

In O +
vitro O +
DNase O +
I O +
footprinting O +
analysis O +
revealed O +
six O +
hGATA-3 O +
binding O +
sites O +
in O +
the O +
U3 O +
region O +
( O +
the O +
transcriptional O +
regulatory O +
domain O +
) O +
of O +
the O +
HIV-1 O +
LTR O +
. O +

Cotransfection O +
of O +
an O +
hGATA-3 O +
expression O +
plasmid O +
with O +
a O +
reporter O +
plasmid O +
whose O +
transcription O +
is O +
directed O +
by O +
the O +
HIV-1 O +
LTR O +
resulted O +
in O +
6- O +
to O +
10-fold O +
stimulation O +
of O +
LTR O +
-mediated O +
transcription O +
, O +
whereas O +
site O +
specific O +
mutation O +
of O +
these O +
GATA O +
sites O +
resulted O +
in O +
virtual O +
abrogation O +
of O +
the O +
activation O +
by O +
hGATA-3 O +
. O +

Further O +
, O +
deletion O +
of O +
the O +
hGATA-3 O +
transcriptional O +
activation O +
domain O +
abolished O +
GATA O -
- O -
dependent O +
HIV-1 O +
trans O -
- O -
activation O +
, O +
showing O +
that O +
the O +
stimulation O +
of O +
viral O +
transcription O +
observed O +
is O +
a O +
direct O +
effect O +
of O +
cotransfected O +
hGATA-3 O +
. O +

Introduction O +
of O +
the O +
HIV-1 O +
plasmids O +
in O +
which O +
the O +
GATA O +
sites O +
have O +
been O +
mutated O +
into O +
human O +
T O +
lymphocytes O +
also O +
caused O +
a O +
significant O +
reduction O +
in O +
LTR O +
-mediated O +
transcription O +
at O +
both O +
the O +
basal O +
level O +
and O +
in O +
( O +
PHA- O +
plus O +
PMA- O +
) O +
stimulated B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

These O +
observations O +
suggest O +
that O +
in O +
addition O +
to O +
its O +
normal O +
role O +
in O +
T O +
lymphocyte O +
gene O +
regulation O +
, O +
hGATA-3 O +
may O +
also O +
play O +
a O +
significant O +
role O +
in O +
HIV-1 O +
transcriptional O +
activation O +
. O +

Enhancing O +
effect O +
of O +
17 O +
beta O -
- O -
estradiol O +
on O +
human O +
NK O +
cell O +
activity O +
. O +

The O +
in O +
vitro O +
effect O +
of O +
17 O +
beta O -
- O -
estradiol O +
on O +
NK O +
activity O +
was O +
studied O +
. O +

The O +
proliferation O +
and O +
NK O +
activity O +
of O +
YT B-CellLine -
- I-CellLine -
N17 I-CellLine +
( O +
a O +
human B-CellLine +
NK I-CellLine -
- I-CellLine -
like I-CellLine +
cell I-CellLine +
line I-CellLine +
) O +
were O +
enhanced O +
by O +
17 O +
beta O -
- O -
estradiol O +
( O +
E2 O +
) O +
, O +
and O +
the O +
enhancement O +
was O +
blocked O +
by O +
tamoxifen O +
( O +
Tx O +
) O +
, O +
an O +
antagonist O +
of O +
E2 O +
. O +

On O +
the O +
contrary O +
, O +
other O +
steroid O +
hormones O +
such O +
as O +
Tx O +
, O +
progesterone O +
, O +
and O +
testosterone O +
had O +
no O +
effect O +
. O +

YT B-CellLine -
- I-CellLine -
N17 I-CellLine +
contained O +
11.8 O +
fmol O -
/ O -
mg O +
protein O +
of O +
estrogen O +
receptor O +
( O +
mean O +
of O +
two O +
independent O +
assays O +
) O +
, O +
a O +
value O +
which O +
was O +
5 O -
- O -
10-fold O +
higher O +
than O +
that O +
of O +
other O +
hematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

An O +
enhancement O +
of O +
NK O +
activity O +
by O +
E2 O +
was O +
also O +
seen O +
in O +
large O +
granular O +
lymphocytes O +
obtained O +
from O +
normal O +
subjects O +
, O +
and O +
it O +
was O +
again O +
suppressed O +
by O +
Tx O +
. O +

These O +
data O +
suggest O +
that O +
E2 O +
is O +
one O +
of O +
the O +
activating O +
factors O +
for O +
NK B-CellLine -
/ I-CellLine -
LGL I-CellLine +
cells I-CellLine +
. O +

Cytokine O +
modulation O +
of O +
HIV O +
expression O +
. O +

Cytokines O +
, O +
the O +
peptide O +
hormones O +
which O +
control O +
the O +
homeostasis O +
of O +
the O +
immune O +
system O +
and O +
also O +
play O +
a O +
fundamental O +
role O +
in O +
inflammatory O +
and O +
immune O +
mediated O +
reactions O +
, O +
have O +
been O +
involved O +
at O +
multiple O +
levels O +
in O +
the O +
pathogenesis O +
of O +
the O +
acquired O +
immune O +
deficiency O +
syndrome O +
( O +
AIDS O +
) O +
. O +

Infection O +
with O +
the O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
has O +
been O +
shown O +
to O +
induce O +
production O +
of O +
several O +
cytokines O +
both O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

Conversely O +
, O +
several O +
cytokines O +
modulate O +
the O +
levels O +
of O +
HIV O +
expression O +
in O +
infected O +
cells O +
of O +
both O +
T O +
lymphocytic O +
and O +
mononuclear O +
phagocytic O +
lineage O +
. O +

Activated O +
mononuclear O +
cells O +
, O +
particularly O +
B O +
cells O +
which O +
are O +
in O +
a O +
state O +
of O +
chronic O +
activation O +
in O +
HIV O +
infected O +
individuals O +
, O +
release O +
HIV O -
- O -
inductive O +
cytokines O +
and O +
thus O +
play O +
a O +
potentially O +
important O +
role O +
in O +
the O +
pathogenesis O +
of O +
HIV O +
infection O +
. O +

Tumor O +
necrosis O +
factor O +
receptor O +
expression O +
and O +
signal O +
transduction O +
in O +
HIV-1-infected O +
cells O +
. O +

OBJECTIVE O +
: O +
To O +
examine O +
the O +
inter O -
- O -
relationship O +
between O +
HIV-1 O +
infection O +
and O +
the O +
cell O +
surface O +
receptors O +
for O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
-alpha O +
, O +
an O +
immunoregulatory O +
cytokine O +
that O +
can O +
enhance O +
HIV-1 O +
replication O +
. O +

DESIGN O +
: O +
Infected O +
promyelocytic O +
and O +
promonocytic O +
cells O +
were O +
examined O +
because O +
they O +
normally O +
express O +
both O +
types O +
of O +
TNF O +
receptors O +
. O +

METHODS O +
: O +
TNF O +
receptor O +
surface O +
expression O +
was O +
determined O +
by O +
specific O +
monoclonal O +
antibody O +
recognition O +
and O +
flow O +
cytometry O +
, O +
and O +
signal O +
transduction O +
was O +
detected O +
by O +
gel O +
shift O +
analysis O +
. O +

HIV-1 O +
activation O +
and O +
expression O +
was O +
quantitated O +
by O +
reverse O +
transcriptase O +
assay O +
. O +

RESULTS O +
: O +
In O +
the O +
OM-10.1 O +
promyelocytic O +
model O +
of O +
chronic O +
infection O +
, O +
TNF O -
- O -
alpha O -
- O -
induced O +
HIV-1 O +
expression O +
also O +
resulted O +
in O +
a O +
substantial O +
increase O +
in O +
75 O +
kd O +
TNF O +
receptor O +
( O +
TR75 O +
) O +
expression O +
although O +
55 O +
kD O +
TNF O +
receptor O +
( O +
TR55 O +
) O +
levels O +
were O +
not O +
dramatically O +
altered O +
. O +

A O +
series O +
of O +
uninfected B-CellLine +
parental I-CellLine +
HL-60 I-CellLine +
subclones I-CellLine +
all O +
reduced O +
TR75 O +
surface O +
expression O +
in O +
response O +
to O +
TNF O -
- O -
alpha O +
treatment O +
. O +

Enhanced O +
TR75 O +
expression O +
on O +
OM-10.1 O +
cells O +
followed O +
the O +
same O +
TNF O -
- O -
alpha O +
-dose O +
dependency O +
as O +
that O +
observed O +
for O +
HIV-1 O +
production O +
. O +

An O +
increase O +
in O +
TR75 O +
expression O +
was O +
also O +
evident O +
during O +
the O +
peak O +
of O +
an O +
acute O +
HIV-1 O +
infection O +
of O +
HL-60 B-CellLine +
promyelocytes I-CellLine +
. O +

Although O +
TR55 O +
expression O +
was O +
unaltered O +
during O +
TNF O -
- O -
alpha O +
-induced O +
HIV O +
activation O +
, O +
this O +
receptor O +
was O +
still O +
involved O +
in O +
the O +
viral O +
activation O +
process O +
. O +

Antibody O +
cross O -
- O -
linking O +
of O +
TR55 O +
, O +
in O +
the O +
absence O +
of O +
exogenous O +
TNF O -
- O -
alpha O +
, O +
induced O +
maximal O +
HIV-1 O +
expression O +
, O +
an O +
up O -
- O -
modulation O +
of O +
surface O +
TR75 O +
, O +
and O +
nuclear O +
NF O -
- O -
kappa O +
B O +
activity O +
in O +
OM-10.1 O +
cultures O +
. O +

Surprisingly O +
, O +
this O +
was O +
the O +
case O +
even O +
when O +
an O +
antagonistic O +
anti O -
- O -
TR55 O +
antibody O +
was O +
used O +
. O +

Anti O -
- O -
TR55 O +
antibody O +
cross O -
- O -
linking O +
in O +
chronically B-CellLine +
infected I-CellLine +
U1 I-CellLine +
promonocytic I-CellLine +
cultures I-CellLine +
could O +
only O +
partially O +
substitute O +
for O +
TNF O -
- O -
alpha O -
- O -
induced O +
HIV-1 O +
expression O +
. O +

CONCLUSIONS O +
: O +
Our O +
results O +
demonstrated O +
that O +
HIV-1 O +
infection O +
can O +
selectively O +
influence O +
the O +
surface O +
expression O +
of O +
TNF O +
receptors O +
, O +
potentially O +
influencing O +
its O +
own O +
expression O +
and O +
altering O +
normal O +
immunoregulatory O +
signal O +
transduction O +
. O +

Inhibition O +
of O +
HIV-1 O +
latency O +
reactivation O +
by O +
dehydroepiandrosterone O +
( O +
DHEA O +
) O +
and O +
an O +
analog O +
of O +
DHEA O +
. O +

The O +
initial O +
infection O +
with O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
in O +
most O +
individuals O +
usually O +
results O +
in O +
the O +
establishment O +
of O +
a O +
latent O +
or O +
chronic O +
infection O +
before O +
eventual O +
progression O +
toward O +
acquired O +
immunodeficiency O +
syndrome O +
. O +

HIV-1 O +
can O +
also O +
establish O +
a O +
latent O +
or O +
persistent O +
infection O +
in O +
some O +
T B-CellLine +
cell I-CellLine +
lines I-CellLine +
that O +
show O +
minimal O +
constitutive O +
virus O +
expression O +
. O +

However O +
, O +
activation O +
of O +
the O +
T B-CellLine +
cell I-CellLine +
lines I-CellLine +
leading O +
to O +
enhanced O +
HIV-1 O +
replication O +
can O +
be O +
induced O +
by O +
antigens O +
, O +
mitogens O +
, O +
and O +
cytokines O +
( O +
tumor O +
necrosis O +
factor O +
alpha O +
[ O +
TNF O -
- O -
alpha O +
] O +
, O +
interleukin O +
1 O +
, O +
and O +
interleukin-2 O +
) O +
. O +

Various O +
gene O +
products O +
from O +
other O +
viruses O +
( O +
HTLV-1 O +
, O +
HSV O +
, O +
EBV O +
, O +
CMV O +
, O +
HBV O +
, O +
and O +
HHV-6 O +
) O +
can O +
also O +
enhance O +
HIV-1 O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
-driven O +
reporter O +
gene O +
activity O +
. O +

On O +
the O +
basis O +
of O +
these O +
observations O +
, O +
it O +
has O +
been O +
proposed O +
that O +
reactivation O +
of O +
latent O +
HIV-1 O +
harbored O +
in O +
chronically O +
infected O +
T O +
lymphocytes O +
, O +
monocytes O +
, O +
or O +
macrophages O +
plays O +
an O +
important O +
role O +
in O +
the O +
pathogenesis O +
of O +
AIDS O +
. O +

So O +
far O +
, O +
there O +
are O +
no O +
drugs O +
or O +
therapy O +
available O +
that O +
can O +
provide O +
protection O +
against O +
HIV-1 O +
latency O +
reactivation O +
. O +

ACH-2 B-CellLine +
, O +
derived O +
from O +
a O +
human B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
CEM B-CellLine +
) O +
, O +
is O +
chronically O +
infected O +
with O +
HIV-1 O +
, O +
with O +
low O +
levels O +
of O +
constitutive O +
virus O +
expression O +
. O +

ACH-2 B-CellLine +
can O +
be O +
converted O +
to O +
productive O +
infection O +
by O +
stimulation O +
of O +
the O +
cells O +
with O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
, O +
mitogen O +
or O +
cytokines O +
( O +
TNF O -
- O -
alpha O +
) O +
, O +
or O +
infection O +
with O +
HSV O +
. O +

Therefore O +
the O +
ACH-2 B-CellLine +
cell O +
line O +
is O +
a O +
good O +
candidate O +
for O +
studying O +
the O +
effects O +
of O +
drugs O +
on O +
HIV-1 O +
activation O +
. O +

Previously O +
, O +
we O +
have O +
reported O +
that O +
DHEA O +
and O +
synthetic O +
analogs O +
of O +
DHEA O +
can O +
be O +
modest O +
inhibitors O +
of O +
HIV-1 O +
IIIB O +
replication O +
in O +
phytohemagglutinin B-CellLine -
- I-CellLine -
stimulated I-CellLine +
peripheral I-CellLine +
blood I-CellLine +
lymphocyte I-CellLine +
cultures I-CellLine +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

Visualization O +
of O +
the O +
endogenous O +
NF O -
- O -
kappa O +
B O +
p50 O +
subunit O +
in O +
the O +
nucleus O +
of O +
follicular O +
dendritic O +
cells O +
in O +
germinal O +
centers O +
. O +

NF O -
- O -
kappa O +
B O +
, O +
a O +
50 O +
kDa O -
/ O -
65 O +
kDa O +
( O +
p50 O -
/ O -
p65 O +
) O +
heterodimer O +
, O +
is O +
a O +
ubiquitous O +
transcription O +
factor O +
involved O +
in O +
the O +
positive O +
regulation O +
of O +
various O +
immune O +
genes O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
determine O +
whether O +
NF O -
- O -
kappa O +
B O +
is O +
related O +
to O +
a O +
particular O +
cell O +
type O +
and/or O +
differentiation O +
step O +
during O +
immunopoiesis O +
. O +

Using O +
in O +
situ O +
hybridization O +
on O +
sections O +
from O +
non O +
HIV O +
hyperplastic O +
lymph O +
nodes O +
, O +
we O +
found O +
that O +
the O +
gene O +
of O +
the O +
105 O +
kDa O +
precursor O +
of O +
p50 O +
was O +
overexpressed O +
in O +
the O +
light O +
zone O +
of O +
germinal O +
centers O +
, O +
with O +
a O +
network O +
aspect O +
, O +
which O +
suggested O +
the O +
involvement O +
of O +
follicular O +
dendritic O +
cells O +
( O +
FDC O +
) O +
. O +

By O +
immunohistochemistry O +
, O +
p50 O +
protein O +
was O +
detected O +
in O +
the O +
cytoplasm O +
and O +
nucleus O +
of O +
FDC O +
, O +
confirming O +
the O +
involvement O +
of O +
FDC O +
. O +

Furthermore O +
, O +
p50 O +
protein O +
was O +
detected O +
in O +
the O +
cytoplasm O +
of O +
all O +
lymphocytes O +
. O +

Thus O +
, O +
we O +
focused O +
our O +
study O +
on O +
isolated O +
FDC O +
clusters O +
from O +
normal O +
tonsils O +
. O +

As O +
showed O +
on O +
tissue O +
sections O +
, O +
we O +
detected O +
the O +
p50 O +
in O +
both O +
cytoplasm O +
and O +
nucleus O +
of O +
FDC O +
. O +

Nuclei O +
of O +
lymphocytes O +
from O +
FDC O +
clusters O +
were O +
negative O +
. O +

We O +
next O +
studied O +
p65 O +
and O +
c O -
- O -
Rel O +
protein O +
expression O +
in O +
FDC O +
clusters O +
. O +

p65 O +
was O +
detected O +
in O +
the O +
cytoplasm O +
of O +
FDC O +
, O +
whereas O +
nuclei O +
were O +
negative O +
. O +

Furthermore O +
, O +
p65 O +
was O +
detected O +
in O +
the O +
nuclei O +
of O +
some O +
lymphocytes O +
. O +

c O -
- O -
Rel O +
protein O +
was O +
detected O +
only O +
in O +
the O +
cytoplasm O +
of O +
lymphocytes O +
and O +
not O +
in O +
the O +
nucleus O +
and O +
cytoplasm O +
of O +
FDC O +
. O +

Our O +
results O +
indicated O +
that O +
, O +
in O +
the O +
context O +
of O +
T O +
cell O -
- O -
dependent O +
B O +
cell O +
immunopoiesis O +
occurring O +
in O +
FDC O +
clusters O +
, O +
p50 O +
is O +
mainly O +
related O +
to O +
FDC O +
with O +
a O +
massive O +
overexpression O +
in O +
the O +
nuclei O +
, O +
whereas O +
p65 O +
is O +
expressed O +
in O +
a O +
scattered O +
manner O +
in O +
the O +
nuclei O +
of O +
lymphocytes O +
and O +
c O -
- O -
Rel O +
protein O +
exclusively O +
in O +
the O +
cytoplasm O +
of O +
lymphocytes O +
from O +
FDC O +
clusters O +
. O +

These O +
results O +
suggested O +
that O +
the O +
two O +
subunits O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
the O +
c O -
- O -
Rel O +
protein O +
have O +
different O +
roles O +
in O +
different O +
cell O +
types O +
during O +
B O +
cell O +
immunopoiesis O +
. O +

Involvement O +
of O +
transcription O +
factor O +
YB-1 O +
in O +
human O +
T O -
- O -
cell O +
lymphotropic O +
virus O +
type O +
I O +
basal O +
gene O +
expression O +
. O +

Sequences O +
which O +
control O +
basal O +
human O +
T O -
- O -
cell O +
lymphotropic O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
transcription O +
likely O +
play O +
an O +
important O +
role O +
in O +
initiation O +
and O +
maintenance O +
of O +
virus O +
replication O +
. O +

We O +
previously O +
identified O +
and O +
analyzed O +
a O +
45-nucleotide O +
sequence O +
( O +
downstream O +
regulatory O +
element O +
1 O +
[ O +
DRE O +
1 O +
] O +
) O +
, O +
+ O -
195 O +
to O +
+ O -
240 O +
, O +
at O +
the O +
boundary O +
of O +
the O +
R O -
/ O -
U5 O +
region O +
of O +
the O +
long O +
terminal O +
repeat O +
which O +
is O +
required O +
for O +
HTLV O -
- O -
I O +
basal O +
transcription O +
. O +

We O +
identified O +
a O +
protein O +
, O +
p37 O +
, O +
which O +
specifically O +
bound O +
to O +
DRE O +
1 O +
. O +

An O +
affinity O +
column O +
fraction O +
, O +
containing O +
p37 O +
, O +
stimulated O +
HTLV O -
- O -
I O +
transcription O +
approximately O +
12-fold O +
in O +
vitro O +
. O +

We O +
now O +
report O +
the O +
identification O +
of O +
a O +
cDNA O +
clone O +
( O +
15B-7 O +
) O +
, O +
from O +
a O +
Jurkat O +
expression O +
library O +
, O +
that O +
binds O +
specifically O +
to O +
the O +
DRE O +
1 O +
regulatory O +
sequence O +
. O +

Binding O +
of O +
the O +
cDNA O +
fusion O +
protein O +
, O +
similarly O +
to O +
the O +
results O +
obtained O +
with O +
purified O +
Jurkat O +
protein O +
, O +
was O +
decreased O +
by O +
introduction O +
of O +
site O -
- O -
specific O +
mutations O +
in O +
the O +
DRE O +
1 O +
regulatory O +
sequence O +
. O +

In O +
vitro O +
transcription O +
and O +
translation O +
of O +
15B-7 O +
cDNA O +
produced O +
a O +
fusion O +
protein O +
which O +
bound O +
specifically O +
to O +
the O +
HTLV O -
- O -
I O +
+ O -
195 O +
to O +
+ O -
240 O +
oligonucleotide O +
. O +

The O +
partial O +
cDNA O +
encodes O +
a O +
protein O +
which O +
is O +
homologous O +
to O +
the O +
C O -
- O -
terminal O +
196 O +
amino O +
acids O +
of O +
the O +
36-kDa O +
transcription O +
factor O +
, O +
YB-1 O +
. O +

Cotransfection O +
of O +
a O +
YB-1 O +
expression O +
plasmid O +
increases O +
HTLV O -
- O -
I O +
basal O +
transcription O +
approximately O +
14-fold O +
in O +
Jurkat B-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
. O +

On O +
the O +
basis O +
of O +
the O +
molecular O +
weight O +
, O +
DNA O -
- O -
binding O +
characteristics O +
, O +
and O +
in O +
vivo O +
transactivation O +
activity O +
, O +
we O +
suggest O +
that O +
the O +
previously O +
identified O +
DRE O +
1 O +
-binding O +
protein O +
, O +
p37 O +
, O +
is O +
YB-1 O +
. O +

Chlorinated O +
dibenzo O -
- O -
p O -
- O -
dioxins O +
and O +
dibenzofurans O +
and O +
the O +
human O +
immune O +
system O +
. O +

1 O +
. O +
Blood O +
cell O +
receptors O +
in O +
volunteers O +
with O +
moderately O +
increased O +
body O +
burdens O +
. O +

Using O +
monoclonal O +
antibodies O +
( O +
mAbs O +
) O +
and O +
flow O +
cytometry O +
, O +
we O +
studied O +
a O +
variety O +
of O +
surface O +
receptors O +
on O +
lymphocyte O +
subpopulations O +
of O +
workers O +
with O +
moderately O +
increased O +
body O +
burdens O +
of O +
2 O +
, O +
3 O +
, O +
7 O +
, O +
8-tetrachlorodibenzo O -
- O -
p O -
- O -
dioxin O +
( O +
TCDD O +
) O +
and O +
of O +
other O +
polychlorinated O +
dibenzo O -
- O -
p O -
- O -
dioxins O +
and O +
dibenzofurans O +
( O +
PCDD O -
/ O -
PCDF O +
) O +
, O +
expressed O +
here O +
as O +
International O -
- O -
Toxicity O +
Equivalencies O +
( O +
I O -
- O -
TE O +
) O +
. O +

The O +
hypothesis O +
to O +
be O +
tested O +
was O +
whether O +
or O +
not O +
humans O +
exhibit O +
a O +
similar O +
susceptibility O +
to O +
PCDDs O -
/ O -
PCDFs O +
with O +
respect O +
to O +
the O +
surface O +
receptors O +
found O +
previously O +
to O +
respond O +
to O +
small O +
doses O +
of O +
2 O +
, O +
3 O +
, O +
7 O +
, O +
8-tetrachlorodibenzo O -
- O -
p O -
- O -
dioxin O +
( O +
TCDD O +
) O +
in O +
Callithrix O +
jacchus O +
. O +

These O +
are O +
: O +
helper O -
- O -
inducer O +
( O +
memory O +
) O +
T O +
cells O +
( O +
CD4+CD45R0+CD45RA O -
- O -
CD29highCD11a+ O +
) O +
, O +
CD20 O -
+ O +
B O +
cells O +
, O +
and O +
cytotoxic O +
T O +
cells O +
( O +
CD8+CD56+ O -
/ O -
CD57 O -
+ O +
) O +
. O +

Furthermore O +
, O +
68 O +
triple O -
- O -
labellings O +
with O +
mAbs O +
were O +
performed O +
on O +
the O +
cells O +
of O +
each O +
volunteer O +
to O +
possibly O +
generate O +
further O +
hypotheses O +
. O +

It O +
was O +
evaluated O +
whether O +
any O +
of O +
the O +
variables O +
might O +
be O +
used O +
as O +
a O +
biomarker O +
of O +
effects O +
for O +
this O +
class O +
of O +
compounds O +
. O +

There O +
were O +
two O +
main O +
goals O +
: O +
( O +
1 O +
) O +
to O +
evaluate O +
whether O +
workers O +
with O +
a O +
moderately O +
increased O +
PCDD O -
/ O -
PCDF O -
- O -
body O +
burden O +
[ O +
25 O -
- O -
140 O +
ppt O +
TCDD O +
or O +
104 O -
- O -
522 O +
ppt O +
I O -
- O -
TE O +
in O +
blood O +
fat O +
] O +
exhibit O +
changes O +
in O +
the O +
surface O +
receptors O +
of O +
white O +
blood O +
cells O +
, O +
as O +
observed O +
in O +
previous O +
studies O +
in O +
non O -
- O -
human O +
primates O +
, O +
and O +
( O +
2 O +
) O +
to O +
clarify O +
whether O +
persons O +
at O +
the O +
upper O +
range O +
[ O +
10 O -
- O -
23 O +
ppt O +
TCDD O +
or O +
30 O -
- O -
90 O +
ppt O +
I O -
- O -
TE O +
in O +
blood O +
fat O +
] O +
of O +
the O +
body O +
burden O +
reference O +
values O +
of O +
a O +
not O +
particularly O +
exposed O +
population O +
show O +
detectable O +
deviations O +
in O +
these O +
immunological O +
variables O +
, O +
when O +
compared O +
with O +
persons O +
at O +
the O +
lower O +
and O +
medium O +
range O +
[ O +
1 O -
- O -
3 O +
ppt O +
TCDD O +
or O +
9 O -
- O -
29 O +
ppt O +
I O -
- O -
TE O +
] O +
of O +
these O +
body O +
burden O +
reference O +
values O +
. O +

Regression O +
analysis O +
of O +
our O +
data O +
revealed O +
slight O +
trends O +
for O +
some O +
of O +
the O +
biomarkers O +
( O +
e.g. O +
CD45R0 O -
+ O +
) O +
. O +

With O +
one O +
exception O +
, O +
these O +
were O +
all O +
increases O +
. O +

None O +
of O +
the O +
alterations O +
observed O +
are O +
of O +
medical O +
relevance O +
. O +

The O +
slight O +
increase O +
in O +
the O +
percentage O +
of O +
CD4+CD45R0 O -
+ O +
cells O +
remained O +
significant O +
even O +
after O +
covariant O +
analysis O +
taking O +
age O -
- O -
related O +
changes O +
into O +
account O +
. O +

Altogether O +
, O +
the O +
data O +
do O +
not O +
provide O +
any O +
evidence O +
to O +
support O +
an O +
assumption O +
that O +
moderately O +
increased O +
body O +
burdens O +
of O +
PCDDs O -
/ O -
PCDFs O +
in O +
adults O +
induce O +
decreases O +
in O +
the O +
cellular O +
components O +
of O +
the O +
human O +
immune O +
system O +
. O +

Adult O +
humans O +
certainly O +
are O +
less O +
susceptible O +
to O +
this O +
action O +
of O +
PCDDs O -
/ O -
PCDFs O +
than O +
adolescent O +
Callithrix O +
jacchus O +

The O +
macrophage O +
transcription O +
factor O +
PU.1 O +
directs O +
tissue O -
- O -
specific O +
expression O +
of O +
the O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
receptor O +
. O +

The O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
M O -
- O -
CSF O +
) O +
receptor O +
is O +
expressed O +
in O +
a O +
tissue O -
- O -
specific O +
fashion O +
from O +
two O +
distinct O +
promoters O +
in O +
monocytes O -
/ O -
macrophages O +
and O +
the O +
placenta O +
. O +

In O +
order O +
to O +
further O +
understand O +
the O +
transcription O +
factors O +
which O +
play O +
a O +
role O +
in O +
the O +
commitment O +
of O +
multipotential O +
progenitors O +
to O +
the O +
monocyte O -
/ O -
macrophage O +
lineage O +
, O +
we O +
have O +
initiated O +
an O +
investigation O +
of O +
the O +
factors O +
which O +
activate O +
the O +
M O -
- O -
CSF O +
receptor O +
very O +
early O +
during O +
the O +
monocyte O +
differentiation O +
process O +
. O +

Here O +
we O +
demonstrate O +
that O +
the O +
human O +
monocytic O +
M O -
- O -
CSF O +
receptor O +
promoter O +
directs O +
reporter O +
gene O +
activity O +
in O +
a O +
tissue O -
- O -
specific O +
fashion O +
. O +

Since O +
one O +
of O +
the O +
few O +
transcription O +
factors O +
which O +
have O +
been O +
implicated O +
in O +
the O +
regulation O +
of O +
monocyte O +
genes O +
is O +
the O +
macrophage- O +
and O +
B O -
- O -
cell O -
- O -
specific O +
PU.1 O +
transcription O +
factor O +
, O +
we O +
investigated O +
whether O +
PU.1 O +
binds O +
and O +
activates O +
the O +
M O -
- O -
CSF O +
receptor O +
promoter O +
. O +

Here O +
we O +
demonstrate O +
that O +
both O +
in O +
vitro O -
- O -
translated O +
PU.1 O +
and O +
PU.1 O +
from O +
nuclear O +
extracts O +
bind O +
to O +
a O +
specific O +
site O +
in O +
the O +
M O -
- O -
CSF O +
receptor O +
promoter O +
just O +
upstream O +
from O +
the O +
major O +
transcription O +
initiation O +
site O +
. O +

Mutations O +
in O +
this O +
site O +
which O +
eliminate O +
PU.1 O +
binding O +
decrease O +
M O -
- O -
CSF O +
receptor O +
promoter O +
activity O +
significantly O +
in O +
macrophage B-CellLine +
cell I-CellLine +
lines I-CellLine +
only O +
. O +

Furthermore O +
, O +
PU.1 O +
transactivates O +
the O +
M O -
- O -
CSF O +
receptor O +
promoter O +
in O +
nonmacrophage O +
cells O +
. O +

These O +
results O +
suggest O +
that O +
PU.1 O +
plays O +
a O +
major O +
role O +
in O +
macrophage O +
gene O +
regulation O +
and O +
development O +
by O +
directing O +
the O +
expression O +
of O +
a O +
receptor O +
for O +
a O +
key O +
macrophage O +
growth O +
factor O +
. O +

Increased O +
natural O +
killer O +
cell O +
activity O +
correlates O +
with O +
low O +
or O +
negative O +
expression O +
of O +
the O +
HER-2 O -
/ O -
neu O +
oncogene O +
in O +
patients O +
with O +
breast O +
cancer O +
. O +

BACKGROUND O +
. O +

Increased O +
expression O +
of O +
the O +
HER-2 O -
/ O -
neu O +
oncogene O +
in O +
breast O +
cancer O +
correlates O +
with O +
decreased O +
estrogen O +
receptor O +
concentration O +
and O +
seems O +
to O +
be O +
an O +
important O +
prognostic O +
factor O +
. O +

The O +
authors O +
investigated O +
whether O +
there O +
is O +
a O +
correlation O +
between O +
HER-2 O -
/ O -
neu O +
expression O +
and O +
immunologic O +
parameters O +
representing O +
tumor O +
defense O +
in O +
patients O +
with O +
breast O +
cancer O +
. O +

METHOD O +
. O +

A O +
Western O +
blot O +
analysis O +
was O +
used O +
to O +
investigate O +
HER-2 O -
/ O -
neu O +
expression O +
, O +
whereas O +
a O +
chromium O -
- O -
release O +
assay O +
using O +
the O +
K562 B-CellLine +
cell I-CellLine +
line I-CellLine +
as O +
target O +
was O +
used O +
to O +
measure O +
natural O +
killer O +
( O +
NK O +
) O +
cell O +
activity O +
. O +

RESULTS O +
. O +

In O +
patients O +
with O +
breast O +
cancer O +
, O +
NK O +
cell O +
activity O +
was O +
significantly O +
higher O +
compared O +
with O +
patients O +
with O +
benign O +
tumors O +
( O +
P O +
= O +
0.006 O +
) O +
or O +
healthy O +
control O +
subjects O +
( O +
P O +
= O +
0.002 O +
) O +
. O +

Moreover O +
, O +
23.3 O +
% O +
of O +
patients O +
with O +
breast O +
cancer O +
showed O +
an O +
overexpression O +
of O +
HER-2 O -
/ O -
neu O +
protein O +
. O +

Within O +
this O +
group O +
of O +
patients O +
, O +
NK O +
cell O +
activity O +
was O +
significantly O +
lower O +
( O +
45.6 O +
+ O -
/- O +
16.1 O +
% O +
) O +
compared O +
with O +
the O +
group O +
with O +
no O +
HER-2 O -
/ O -
neu O +
overexpression O +
( O +
57.3 O +
+ O -
/- O +
11.0 O +
% O +
) O +
. O +

NK O +
cell O +
activity O +
did O +
not O +
increase O +
in O +
patients O +
with O +
HER-2 O -
/ O -
neu O +
overexpression O +
. O +

Thus O +
, O +
there O +
was O +
a O +
statistically O +
significant O +
correlation O +
of O +
cytolytic O +
effector O +
cell O +
function O +
with O +
HER-2 O -
/ O -
neu O +
expression O +
of O +
the O +
tumor O +
( O +
P O +
= O +
0.003 O +
) O +
, O +
and O +
HER-2 O -
/ O -
neu O +
overexpression O +
correlated O +
with O +
a O +
negative O +
estrogen O +
receptor O +
status O +
( O +
P O +
= O +
0.005 O +
) O +
. O +

CONCLUSION O +
. O +

These O +
data O +
add O +
further O +
evidence O +
to O +
previous O +
observations O +
from O +
the O +
authors O +
' O +
laboratory O +
that O +
certain O +
tumor O +
characteristics O +
may O +
be O +
associated O +
with O +
reactions O +
of O +
the O +
host O +
with O +
breast O +
cancer O +
. O +

Induction O +
of O +
tyrosine O +
phosphorylation O +
and O +
T O -
- O -
cell O +
activation O +
by O +
vanadate O +
peroxide O +
, O +
an O +
inhibitor O +
of O +
protein O +
tyrosine O +
phosphatases O +
. O +

Rapid O +
tyrosine O +
phosphorylation O +
of O +
key O +
cellular O +
proteins O +
is O +
a O +
crucial O +
event O +
in O +
the O +
transduction O +
of O +
activation O +
signals O +
to O +
T O -
- O -
lymphocytes O +
. O +

The O +
regulatory O +
role O +
of O +
protein O +
tyrosine O +
phosphatases O +
( O +
PTPases O +
) O +
in O +
this O +
process O +
was O +
explored O +
by O +
studying O +
the O +
effects O +
of O +
a O +
powerful O +
PTPase O +
inhibitor O +
, O +
vanadate O +
peroxide O +
( O +
pervanadate O +
) O +
, O +
on O +
the O +
activation O +
cascade O +
of O +
Jurkat B-CellLine +
human I-CellLine +
leukaemic I-CellLine +
T I-CellLine -
- I-CellLine -
cells I-CellLine +
. O +

Pervanadate O +
induced O +
activation O +
of O +
the O +
tyrosine O +
kinases O +
lck O +
and O +
fyn O +
( O +
4- O +
and O +
3-fold O +
respectively O +
) O +
and O +
a O +
dramatic O +
increase O +
in O +
tyrosine O +
phosphorylation O +
of O +
cellular O +
proteins O +
, O +
notably O +
phospholipase O +
C O +
gamma O +
1 O +
. O +

After O +
this O +
event O +
, O +
we O +
observed O +
a O +
rise O +
in O +
intracellular O +
Ca2 O -
+ O +
concentration O +
, O +
corresponding O +
to O +
an O +
influx O +
. O +

This O +
effect O +
required O +
surface O +
expression O +
of O +
the O +
CD45 O +
PTPase O +
and O +
was O +
not O +
observed O +
in O +
CD45-deficient B-CellLine +
variants I-CellLine +
of O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

In O +
the O +
CD45-negative B-CellLine +
variant I-CellLine +
, O +
the O +
effect O +
of O +
pervanadate O +
on O +
tyrosine O +
phosphorylation O +
was O +
globally O +
decreased O +
and O +
some O +
phosphorylated O +
substrates O +
were O +
specifically O +
missing O +
. O +

Pervanadate O +
also O +
stimulated O +
transcription O +
of O +
the O +
c O -
- O -
fos O +
gene O +
and O +
accumulation O +
of O +
its O +
mRNA O +
as O +
well O +
as O +
several O +
other O +
hallmarks O +
of O +
T O -
- O -
lymphocyte O +
activation O +
such O +
as O +
surface O +
expression O +
of O +
the O +
CD69 O +
antigen O +
and O +
the O +
interleukin O +
2 O +
receptor O +
alpha O -
- O -
chain O +
( O +
CD25 O +
) O +
. O +

Pervanadate O +
synergized O +
with O +
signals O +
delivered O +
by O +
T O -
- O -
cell O +
antigen O +
receptor O +
engagement O +
or O +
by O +
a O +
phorbol O +
ester O +
to O +
induce O +
interleukin O +
2 O +
production O +
. O +

Pervanadate O +
activated O +
NF O -
- O -
kappa O +
B O +
, O +
as O +
shown O +
by O +
an O +
increase O +
in O +
DNA O -
- O -
binding O +
activity O +
of O +
this O +
transcription O +
factor O +
. O +

We O +
thus O +
conclude O +
that O +
PTPases O +
play O +
a O +
crucial O +
role O +
in O +
the O +
negative O +
regulation O +
of O +
signal O +
transduction O +
culminating O +
in O +
T O -
- O -
lymphocyte O +
activation O +
. O +

Moreover O +
, O +
induction O +
of O +
tyrosine O +
phosphorylation O +
appears O +
sufficient O +
per O +
se O +
to O +
initiate O +
a O +
complete O +
activation O +
programme O +
. O +

Steroid O -
- O -
resistant O +
asthma O +
. O +

Cellular O +
mechanisms O +
contributing O +
to O +
inadequate O +
response O +
to O +
glucocorticoid O +
therapy O +
. O +

The O +
current O +
study O +
examined O +
whether O +
alterations O +
in O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
binding O +
contribute O +
to O +
poor O +
response O +
to O +
glucocorticoid O +
therapy O +
in O +
asthma O +
. O +

29 O +
asthma O +
patients O +
with O +
forced O +
expiratory O +
volume O +
in O +
1 O +
s O +
( O +
FEV1 O +
) O +
< O +
70 O +
% O +
predicted O +
were O +
studied O +
. O +

Patients O +
were O +
classified O +
as O +
steroid O +
sensitive O +
( O +
SS O +
) O +
if O +
their O +
morning O +
FEV1 O +
increased O +
> O +
30 O +
% O +
after O +
a O +
1-wk O +
course O +
of O +
oral O +
prednisone O +
20 O +
mg O +
twice O +
daily O +
and O +
steroid O +
resistant O +
( O +
SR O +
) O +
if O +
they O +
failed O +
to O +
increase O +
> O +
15 O +
% O +
. O +

PBMC O +
obtained O +
from O +
these O +
two O +
groups O +
, O +
17 O +
SR O +
and O +
12 O +
SS O +
, O +
as O +
well O +
as O +
12 O +
normal O +
controls O +
were O +
analyzed O -
. O +
SR O +
patients O +
had O +
two O +
distinguishable O +
GR O +
binding O +
abnormalities O +
: O +
15 O +
of O +
the O +
17 O +
SR O +
patients O +
demonstrated O +
a O +
significantly O +
reduced O +
GR O +
binding O +
affinity O +
, O +
as O +
compared O +
with O +
SS O +
patients O +
( O +
P O +
= O +
0.0001 O +
) O +
and O +
normal O +
controls O +
( O +
P O +
= O +
0.0001 O +
) O +
. O +

This O +
defect O +
was O +
localized O +
to O +
T O +
cells O +
and O +
reverted O +
to O +
normal O +
after O +
48 O +
h O +
in O +
culture O +
media O +
. O +

However O +
, O +
incubation O +
with O +
a O +
combination O +
of O +
IL-2 O +
and O +
IL-4 O +
sustained O +
this O +
abnormality O +
. O +

The O +
other O +
two O +
SR O +
patients O +
had O +
an O +
abnormally O +
low O +
GR O +
number O +
with O +
normal O +
binding O +
affinity O +
that O +
was O +
not O +
limited O +
to O +
T O +
cells O +
. O +

Furthermore O +
, O +
GR O +
number O +
failed O +
to O +
normalize O +
after O +
incubation O +
in O +
media O +
alone O +
or O +
IL-2 O +
and O +
IL-4 O +
. O +

Therefore O +
, O +
SR O +
asthma O +
may O +
be O +
due O +
to O +
more O +
than O +
one O +
abnormality O +
, O +
the O +
majority O +
related O +
to O +
a O +
reversible O +
cytokine O +
-induced O +
reduction O +
in O +
GR O +
binding O +
affinity O +
and O +
the O +
second O +
related O +
to O +
an O +
irreversible O +
reduction O +
in O +
GR O +
number O +
. O +

These O +
findings O +
may O +
have O +
important O +
implications O +
for O +
the O +
design O +
of O +
alternative O +
treatment O +
approaches O +
for O +
recalcitrant O +
asthma O +
. O +

Increased O +
proliferation O +
, O +
cytotoxicity O +
, O +
and O +
gene O +
expression O +
after O +
stimulation O +
of O +
human O +
peripheral O +
blood O +
T O +
lymphocytes O +
through O +
a O +
surface O +
ganglioside O +
( O +
GD3 O +
) O +
[ O +
published O +
erratum O +
appears O +
in O +
J O +
Immunol O +
1994 O +
Jul O +
15 O +
; O +
153 O +
( O +
2 O +
) O +
: O +
910 O +
] O +

Previous O +
studies O +
have O +
suggested O +
that O +
gangliosides O +
have O +
an O +
important O +
role O +
in O +
cell O +
signaling O +
and O +
recognition O +
. O +

However O +
, O +
their O +
specific O +
function O +
in O +
these O +
processes O +
has O +
not O +
been O +
clearly O +
defined O +
. O +

A O +
mAb O +
, O +
R24 O +
, O +
that O +
reacts O +
specifically O +
with O +
a O +
cell O +
surface O +
ganglioside O +
( O +
GD3 O +
) O +
has O +
been O +
demonstrated O +
to O +
stimulate O +
proliferation O +
of O +
T O +
cells O +
derived O +
from O +
human O +
peripheral O +
blood O +
. O +

In O +
this O +
study O +
, O +
we O +
have O +
investigated O +
the O +
mechanisms O +
by O +
which O +
the O +
R24 O +
mAb O +
affects O +
T O +
cell O +
functions O +
. O +

We O +
have O +
observed O +
that O +
the O +
R24 O +
mAb O +
stimulates O +
GD3 O -
+ O +
T O +
cell O +
proliferation O +
, O +
cytotoxicity O +
, O +
and O +
surface O +
marker O +
expression O +
of O +
IL-2R O +
alpha O -
- O -
chain O +
, O +
IL-2R O +
beta O -
- O -
chain O +
, O +
HLA O -
- O -
DR O +
, O +
CD11a O +
, O +
and O +
CD11c O +
. O +

Additionally O +
, O +
IFN O -
- O -
gamma O +
activity O +
but O +
not O +
IL-1 O +
, O +
IL-2 O +
, O +
or O +
IL-4 O +
activity O +
was O +
present O +
in O +
culture O +
supernatants O +
72 O +
h O +
after O +
R24 O +
stimulation O +
. O +

In O +
some O +
donors O +
, O +
increased O +
IL-6 O +
and O +
TNF O -
- O -
alpha O +
activity O +
also O +
was O +
detected O +
after O +
R24 O +
treatment O +
. O +

Furthermore O +
, O +
R24 O +
treatment O +
resulted O +
in O +
translocation O +
of O +
c O -
- O -
rel O +
, O +
but O +
little O +
or O +
no O +
NF O +
kappa O +
B O +
p50 O +
or O +
p65 O +
, O +
from O +
the O +
cytoplasm O +
to O +
the O +
nucleus O +
and O +
an O +
increase O +
of O +
NF O +
kappa O +
B O +
binding O +
complexes O +
containing O +
c O -
- O -
rel O +
and O +
p50 O +
. O +

This O +
treatment O +
also O +
caused O +
increased O +
tyrosine O +
phosphorylation O +
of O +
specific O +
protein O +
substrates O +
. O +

R24 O +
-stimulated O +
increases O +
in O +
proliferation O +
, O +
cytotoxicity O +
, O +
and O +
cell O +
surface O +
protein O +
expression O +
could O +
be O +
blocked O +
by O +
cyclosporin O +
and O +
staurosporin O +
, O +
indicating O +
that O +
cyclophilin O -
/ O -
calcineurin O +
and O +
protein O +
kinase O +
C O +
may O +
be O +
involved O +
in O +
the O +
R24 O +
signaling O +
pathway O +
. O +

Additionally O +
, O +
herbimycin O +
A O +
, O +
a O +
tyrosine O +
kinase O +
inhibitor O +
, O +
blocked O +
the O +
R24 O +
-stimulated O +
increase O +
in O +
proliferation O +
but O +
not O +
cytotoxicity O +
at O +
concentrations O +
consistent O +
with O +
specificity O +
for O +
tyrosine O +
kinases O +
. O +

These O +
results O +
suggest O +
that O +
multiple O +
biochemical O +
pathways O +
are O +
involved O +
in O +
the O +
activation O +
of O +
human O +
T O +
cells O +
by O +
R24 O +
. O +

Regulation O +
of O +
the O +
BZLF1 O +
promoter O +
of O +
Epstein O -
- O -
Barr O +
virus O +
by O +
second O +
messengers O +
in O +
anti B-CellLine -
- I-CellLine -
immunoglobulin I-CellLine -
- I-CellLine -
treated I-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

Initiation O +
of O +
the O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
lytic O +
cycle O +
is O +
dependent O +
on O +
the O +
transcription O +
of O +
the O +
BZLF1 O +
gene O +
. O +

The O +
BZLF1 O +
gene O +
promoter O +
( O +
Zp O +
) O +
was O +
activated O +
by O +
crosslinking O +
of O +
cell O +
surface O +
immunoglobulin O +
( O +
Ig O +
) O +
with O +
anti O -
- O -
Ig O +
antibody O +
in O +
B O +
cells O +
, O +
even O +
in O +
the O +
absence O +
of O +
other O +
viral O +
genes O +
. O +

We O +
identified O +
several O +
anti O -
- O -
Ig O +
response O +
elements O +
within O +
Zp O +
, O +
which O +
were O +
originally O +
defined O +
as O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
response O +
elements O +
( O +
ZI O +
repeats O +
and O +
ZII O +
, O +
an O +
AP-1-like O +
domain O +
) O +
. O +

Since O +
anti O -
- O -
Ig O +
crosslinking O +
leads O +
to O +
activation O +
of O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
and O +
an O +
increase O +
in O +
intracellular O +
calcium O +
level O +
, O +
Zp O +
was O +
tested O +
for O +
the O +
response O +
to O +
these O +
cellular O +
factors O +
. O +

Treatment O +
with O +
calcium O +
ionophore O +
A23187 O +
increased O +
Zp O +
activity O +
. O +

When O +
the O +
calcium O +
ionophore O +
was O +
used O +
in O +
conjunction O +
with O +
TPA O +
, O +
a O +
PKC O +
activator O +
, O +
the O +
Zp O +
induction O +
was O +
synergistically O +
enhanced O +
. O +

1- O +
( O +
5-Isoquinolinyl O +
sulfonyl O +
) O +
-2-methylpiperazine O +
, O +
an O +
inhibitor O +
of O +
PKC O +
, O +
inhibited O +
the O +
anti O -
- O -
Ig O +
inducibility O +
of O +
Zp O +
. O +

Calmodulin O +
antagonists O +
, O +
compound O +
R24571 O +
and O +
trifluoperazine O +
, O +
blocked O +
the O +
Zp O +
activation O +
with O +
anti O -
- O -
Ig O +
. O +

These O +
findings O +
suggest O +
that O +
Zp O +
responds O +
directly O +
to O +
changes O +
in O +
the O +
activity O +
of O +
both O +
PKC O +
and O +
calcium O -
/ O -
calmodulin O -
- O -
dependent O +
protein O +
kinase O +
. O +

Requirement O +
of O +
tyrosine O +
kinase O +
activation O +
for O +
the O +
anti O -
- O -
Ig O +
-mediated O +
Zp O +
activation O +
was O +
also O +
demonstrated O +
through O +
the O +
use O +
of O +
the O +
tyrosine O +
kinase O +
inhibitor O +
herbimycin O +
. O +

These O +
cellular O +
gene O +
regulatory O +
molecules O +
induced O +
with O +
anti O -
- O -
Ig O +
may O +
cooperatively O +
play O +
an O +
important O +
part O +
in O +
achieving O +
efficient O +
EBV O +
activation O +
as O +
seen O +
with O +
anti O -
- O -
Ig O +
treatment O +
in O +
B O +
cells O +
. O +

Retinoic O +
acid O +
downmodulates O +
erythroid O +
differentiation O +
and O +
GATA1 O +
expression O +
in O +
purified B-CellLine +
adult I-CellLine -
- I-CellLine -
progenitor I-CellLine +
culture I-CellLine +
. O +

All O -
- O -
trans O +
retinoic O +
acid O +
( O +
RA O +
) O +
is O +
an O +
important O +
morphogen O +
in O +
vertebrate O +
development O +
, O +
a O +
normal O +
constituent O +
in O +
human O +
adult O +
blood O +
and O +
is O +
also O +
involved O +
in O +
the O +
control O +
of O +
cell O +
growth O +
and O +
differentiation O +
in O +
acute O +
promyelocytic O +
leukemia O +
. O +

We O +
have O +
examined O +
the O +
effects O +
of O +
RA O +
on O +
normal O +
hematopoiesis O +
by O +
using O +
early O +
hematopoietic O +
progenitor O +
cells O +
( O +
HPC O +
) O +
stringently O +
purified O +
from O +
adult O +
peripheral O +
blood O +
. O +

In O +
clonogenetic B-CellLine +
fetal I-CellLine +
calf I-CellLine +
serum I-CellLine -
- I-CellLine -
supplemented I-CellLine +
( I-CellLine +
FCS+ I-CellLine +
) I-CellLine +
or I-CellLine +
-nonsupplemented I-CellLine +
( I-CellLine +
FCS- I-CellLine +
) I-CellLine +
culture I-CellLine +
treated O +
with O +
saturating O +
levels O +
of O +
interleukin-3 O +
( O +
IL-3 O +
) O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
and O +
erythropoietin O +
( O +
Ep O +
) O +
( O +
combined O +
with O +
c O -
- O -
kit O +
ligand O +
in O +
FCS O +
( O +
- O +
) O +
-culture O +
conditions O +
) O +
, O +
RA O +
induces O +
a O +
dramatic O +
dose O -
- O -
dependent O +
shift O +
from O +
erythroid O +
to O +
granulomonocytic O +
colony O +
formation O +
, O +
the O +
latter O +
colonies O +
being O +
essentially O +
represented O +
by O +
granulocytic B-CellLine +
clones I-CellLine +
. O +

This O +
shift O +
is O +
apparently O +
not O +
caused O +
by O +
a O +
recruitment O +
phenomenon O +
, O +
because O +
in O +
FCS+ B-CellLine +
culture I-CellLine +
, O +
the O +
total O +
number O +
of O +
colonies O +
is O +
not O +
significantly O +
modified O +
by O +
RA O +
addition O +
. O +

In O +
FCS- B-CellLine +
liquid I-CellLine -
- I-CellLine -
suspension I-CellLine +
culture I-CellLine +
supplemented O +
with O +
saturating O +
Ep O +
level O +
and O +
low O -
- O -
dose O +
IL-3 O -
/ O -
GM O -
- O -
CSF O +
, O +
adult O +
HPC O +
undergo O +
unilineage O +
erythropoietic O +
differentiation O +
: O +
Here O +
again O +
, O +
treatment O +
with O +
high O -
- O -
dose O +
RA O +
induces O +
a O +
shift O +
from O +
the O +
erythroid O +
to O +
granulocytic O +
differentiation O +
pathway O +
. O +

Studies O +
on O +
RA O +
time O -
- O -
response O +
or O +
pulse O +
treatment O +
in O +
semisolid O +
or O +
liquid O +
culture O +
show O +
that O +
early O +
RA O +
addition O +
is O +
most O +
effective O +
, O +
thus O +
indicating O +
that O +
early O +
but O +
not O +
late O +
HPC O +
are O +
sensitive O +
to O +
its O +
action O +
. O +

We O +
then O +
analyzed O +
the O +
expression O +
of O +
the O +
master O +
GATA1 O +
gene O +
, O +
which O +
encodes O +
a O +
finger O +
transcription O +
factor O +
required O +
for O +
normal O +
erythroid O +
development O +
; O +
addition O +
of O +
RA O +
to O +
HPC O +
stimulated O +
into O +
unilineage O +
erythropoietic O +
differentiation O +
in O +
liquid O +
culture O +
caused O +
a O +
virtually O +
complete O +
inhibition O +
of O +
GATA1 O +
mRNA O +
induction O +
. O +

These O +
results O +
indicate O +
that O +
RA O +
directly O +
inhibits O +
the O +
erythroid O +
differentiation O +
program O +
at O +
the O +
level O +
of O +
early O +
adult O +
HPC O +
, O +
and O +
may O +
lead O +
to O +
a O +
shift O +
from O +
the O +
erythroid O +
to O +
granulocytic O +
differentiation O +
pathway O +
. O +

This O +
phenomenon O +
is O +
correlated O +
with O +
inhibition O +
of O +
GATA1 O +
induction O +
in O +
the O +
early O +
stages O +
of O +
erythropoietic O +
differentiation O +
. O +

Human O +
interferon O +
regulatory O +
factor O +
2 O +
gene O +
. O +

Intron O -
- O -
exon O +
organization O +
and O +
functional O +
analysis O +
of O +
5'-flanking O +
region O +
. O +

Interferon O +
regulatory O +
factor O +
2 O +
( O +
IRF-2 O +
) O +
is O +
a O +
transcriptional O +
regulatory O +
protein O +
that O +
terminates O +
interferon O +
beta O +
expression O +
initiated O +
by O +
interferon O +
regulatory O +
factor O +
1 O +
. O +

In O +
this O +
study O +
, O +
we O +
isolated O +
the O +
genomic O +
DNA O +
for O +
human O +
IRF-2 O +
gene O +
, O +
determined O +
the O +
intron O -
- O -
exon O +
structure O +
of O +
the O +
human O +
IRF-2 O +
gene O +
, O +
mapped O +
the O +
major O +
transcription O +
initiation O +
site O +
, O +
identified O +
a O +
number O +
of O +
potential O +
regulatory O +
elements O +
in O +
the O +
5'-flanking O +
region O +
, O +
and O +
localized O +
the O +
IRF-2 O +
gene O +
on O +
human O +
chromosome O +
4 O +
. O +

The O +
IRF-2 O +
promoter O +
region O +
contains O +
a O +
CpG O +
island O +
, O +
with O +
several O +
GC O +
boxes O +
, O +
a O +
putative O +
NF O -
- O -
kappa O +
B O -
- O -
binding O +
site O +
, O +
and O +
a O +
CAAT O +
box O +
, O +
but O +
no O +
TATA O +
box O +
. O +

When O +
the O +
promoter O +
region O +
was O +
linked O +
with O +
a O +
heterologous O +
reporter O +
gene O +
, O +
we O +
found O +
that O +
the O +
promoter O +
region O +
is O +
inducible O +
by O +
both O +
interferons O +
( O +
interferon O -
- O -
alpha O +
and O +
-gamma O +
) O +
and O +
interferon O +
regulatory O +
factor O +
1 O +
. O +

The O +
region O +
which O +
induced O +
these O +
inductions O +
was O +
identified O +
as O +
being O +
confined O +
to O +
40 O +
nucleotides O +
5 O +
' O +
to O +
the O +
major O +
transcriptional O +
initiation O +
site O +
by O +
testing O +
a O +
series O +
of O +
clones O +
with O +
truncated O +
promoter O +
of O +
IRF-2 O +
. O +

This O +
region O +
contains O +
elements O +
which O +
are O +
shared O +
with O +
the O +
transcriptional O +
enhancers O +
of O +
other O +
genes O +
including O +
interferon O +
regulatory O +
factor O +
1 O +
, O +
interferon O +
beta O +
, O +
and O +
interferon O -
- O -
inducible O +
genes O +
. O +

These O +
data O +
suggest O +
that O +
interferon O +
regulatory O +
factor O +
1 O +
not O +
only O +
triggers O +
the O +
activation O +
of O +
the O +
interferon O +
signal O +
transduction O +
pathway O +
, O +
but O +
also O +
may O +
play O +
a O +
role O +
in O +
limiting O +
the O +
duration O +
of O +
this O +
response O +
by O +
activating O +
the O +
transcription O +
of O +
IRF-2 O +
. O +

rel O +
Is O +
rapidly O +
tyrosine O -
- O -
phosphorylated O +
following O +
granulocyte O -
- O -
colony O +
stimulating O +
factor O +
treatment O +
of O +
human O +
neutrophils O +
. O +

Stimulation O +
of O +
neutrophils O +
with O +
granulocyte O -
- O -
colony O +
stimulating O +
factor O +
( O +
G O -
- O -
CSF O +
) O +
results O +
in O +
an O +
enhanced O +
respiratory O +
burst O +
, O +
prolonged O +
survival O +
, O +
and O +
increased O +
tumor O +
cell O +
killing O +
. O +

The O +
effects O +
of O +
G O -
- O -
CSF O +
are O +
mediated O +
by O +
binding O +
to O +
specific O +
, O +
high O +
affinity O +
receptors O +
. O +

G O -
- O -
CSF O +
receptors O +
lack O +
intrinsic O +
tyrosine O +
kinase O +
activity O +
, O +
but O +
activation O +
of O +
the O +
receptor O +
results O +
in O +
the O +
rapid O +
induction O +
of O +
tyrosine O +
kinase O +
activity O +
. O +

Antiphosphotyrosine O +
immunoblots O +
of O +
whole O +
cell O +
lysates O +
prepared O +
from O +
neutrophils O +
show O +
that O +
the O +
G O -
- O -
CSF O +
rapidly O +
induces O +
prominent O +
tyrosine O +
phosphorylation O +
of O +
a O +
protein O +
of O +
a O +
relative O +
molecular O +
mass O +
of O +
80 O +
kDa O +
. O +

Using O +
monospecific O +
antibodies O +
, O +
the O +
80-kDa O +
tyrosine O -
- O -
phosphorylated O +
protein O +
has O +
been O +
shown O +
to O +
be O +
p80c O -
- O -
rel O +
, O +
a O +
proto O -
- O -
oncogene O +
belonging O +
to O +
a O +
family O +
of O +
transcriptional O +
regulators O +
which O +
include O +
NF O -
- O -
kB O +
. O +

The O +
induction O +
of O +
tyrosine O +
phosphorylation O +
of O +
p80c O -
- O -
rel O +
was O +
unique O +
to O +
G O -
- O -
CSF O +
in O +
that O +
granulocyte O -
- O -
macrophage O +
colony O +
stimulating O +
factor O +
which O +
also O +
stimulates O +
neutrophils O +
and O +
induces O +
tyrosine O +
phosphorylation O +
does O +
not O +
result O +
in O +
tyrosine O +
phosphorylation O +
of O +
p80c O -
- O -
rel O +
. O +

The O +
consequences O +
of O +
p80c O -
- O -
rel O +
tyrosine O +
phosphorylation O +
are O +
not O +
yet O +
known O +
; O +
however O +
, O +
tyrosine O -
- O -
phosphorylated O +
p80c O -
- O -
rel O +
is O +
capable O +
of O +
binding O +
to O +
DNA O +
, O +
and O +
G O -
- O -
CSF O +
stimulation O +
results O +
in O +
an O +
increase O +
in O +
the O +
amount O +
of O +
p80c O -
- O -
rel O +
which O +
binds O +
to O +
DNA O +
. O +

These O +
results O +
demonstrate O +
that O +
one O +
of O +
the O +
first O +
biochemical O +
events O +
which O +
occurs O +
in O +
neutrophils O +
following O +
G O -
- O -
CSF O +
stimulation O +
, O +
activation O +
of O +
a O +
tyrosine O +
kinase O +
, O +
leads O +
directly O +
to O +
the O +
tyrosine O +
phosphorylation O +
of O +
p80c O -
- O -
rel O +
. O +

Thus O +
, O +
the O +
tyrosine O +
kinase O +
activated O +
by O +
G O -
- O -
CSF O +
appears O +
to O +
directly O +
transduce O +
a O +
signal O +
to O +
a O +
protein O +
which O +
functions O +
as O +
a O +
transcriptional O +
regulator O +
. O +

Overproduction O +
of O +
NFKB2 O +
( O +
lyt-10 O +
) O +
and O +
c O -
- O -
Rel O +
: O +
a O +
mechanism O +
for O +
HTLV O -
- O -
I O +
Tax O +
-mediated O +
trans O -
- O -
activation O +
via O +
the O +
NF O -
- O -
kappa O +
B O +
signalling O +
pathway O +
. O +

Molecular O +
, O +
biochemical O +
and O +
epidemiological O +
evidence O +
implicate O +
HTLV O -
- O -
I O +
as O +
an O +
etiologic O +
agent O +
of O +
adult O +
T O +
cell O +
leukemia O +
( O +
ATL O +
) O +
. O +

The O +
Tax O +
protein O +
of O +
HTLV O -
- O -
I O +
, O +
a O +
positive O +
transcriptional O +
activator O +
of O +
HTLV O -
- O -
I O +
gene O +
expression O +
, O +
is O +
a O +
viral O +
oncogene O +
that O +
also O +
increases O +
transcription O +
of O +
cellular O +
genes O +
including O +
GM O -
- O -
CSF O +
, O +
IL-2R O +
alpha O +
and O +
IL-2 O +
. O +

One O +
of O +
the O +
cellular O +
targets O +
of O +
the O +
trans O -
- O -
activating O +
effects O +
of O +
Tax O +
is O +
the O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
family O +
of O +
transcription O +
factors O +
, O +
pleiotropic O +
regulators O +
of O +
immunoregulatory O +
, O +
cytokine O +
and O +
viral O +
gene O +
expression O +
. O +

In O +
this O +
report O +
, O +
we O +
demonstrate O +
that O +
NFKB2 O +
( O +
lyt-10 O +
) O +
and O +
c O -
- O -
Rel O +
are O +
overexpressed O +
in O +
HTLV O -
- O -
I O +
infected O +
and O +
Tax O -
- O -
expressing O +
cells O +
and O +
, O +
together O +
, O +
account O +
for O +
the O +
majority O +
of O +
the O +
constitutive O +
NF O -
- O -
kappa O +
B O +
binding O +
activity O +
in O +
these O +
cells O +
before O +
and O +
after O +
PMA O +
stimulation O +
. O +

Most O +
importantly O +
, O +
we O +
show O +
a O +
Tax O +
-dependent O +
correlation O +
between O +
expression O +
of O +
NFKB2 O +
( O +
p100 O +
) O +
and O +
processing O +
to O +
the O +
DNA O +
binding O +
NFKB2 O +
( O +
p52 O +
) O +
form O +
, O +
induction O +
of O +
c O -
- O -
Rel O +
, O +
and O +
trans O -
- O -
activation O +
of O +
NF O -
- O -
kappa O +
B O +
-mediated O +
gene O +
expression O +
. O +

Furthermore O +
, O +
the O +
NFKB2 O +
precursor O +
is O +
physically O +
associated O +
with O +
c O -
- O -
Rel O +
and O +
with O +
Tax O +
in O +
HTLV O -
- O -
I O +
infected O +
cells O +
. O +

We O +
propose O +
that O +
NFKB2 O +
synthesis O +
and O +
processing O +
allows O +
continuous O +
nuclear O +
expression O +
of O +
an O +
otherwise O +
cytoplasmic O +
protein O +
and O +
, O +
in O +
conjunction O +
with O +
overexpression O +
of O +
c O -
- O -
Rel O +
, O +
NFKB2 O +
alters O +
the O +
NF O -
- O -
kappa O +
B O +
signalling O +
pathway O +
and O +
contributes O +
to O +
leukemic O +
transformation O +
of O +
T O +
cells O +
by O +
HTLV O -
- O -
I O +
. O +

Autoregulation O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
transactivator O +
RelA O +
( O +
p65 O +
) O +
by O +
multiple O +
cytoplasmic O +
inhibitors O +
containing O +
ankyrin O +
motifs O +
. O +

RelA O +
( O +
p65 O +
) O +
functions O +
as O +
the O +
critical O +
transactivating O +
component O +
of O +
the O +
heterodimeric O +
p50-p65 O +
NF O -
- O -
kappa O +
B O +
complex O +
and O +
contains O +
a O +
high O -
- O -
affinity O +
binding O +
site O +
for O +
its O +
cytoplasmic O +
inhibitor O +
, O +
I O +
kappa O +
B O +
alpha O +
. O +

After O +
cellular O +
activation O +
, O +
I O +
kappa O +
B O +
alpha O +
is O +
rapidly O +
degraded O +
in O +
concert O +
with O +
the O +
induced O +
nuclear O +
translocation O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

The O +
present O +
study O +
demonstrates O +
that O +
tumor O +
necrosis O +
factor O +
alpha O +
-induced O +
degradation O +
of O +
I O +
kappa O +
B O +
alpha O +
in O +
human O +
T O +
cells O +
is O +
preceded O +
by O +
its O +
rapid O +
phosphorylation O +
in O +
vivo O +
. O +

However O +
, O +
these O +
effects O +
on O +
I O +
kappa O +
B O +
alpha O +
result O +
in O +
nuclear O +
mobilization O +
of O +
only O +
a O +
fraction O +
of O +
the O +
entire O +
cytoplasmic O +
pool O +
of O +
RelA O +
. O +

Subsequent O +
studies O +
have O +
revealed O +
that O +
( O +
i O +
) O +
cytoplasmic O +
RelA O +
is O +
stably O +
associated O +
not O +
only O +
with O +
I O +
kappa O +
B O +
alpha O +
but O +
also O +
with O +
other O +
ankyrin O +
motif O -
- O -
rich O +
proteins O +
including O +
the O +
products O +
of O +
the O +
NF O -
- O -
kappa O +
B2 O +
( O +
p100 O +
) O +
and O +
NF O -
- O -
kappa O +
B1 O +
( O +
p105 O +
) O +
genes O +
; O +
( O +
ii O +
) O +
in O +
contrast O +
to O +
RelA O +
-I O +
kappa O +
B O +
alpha O +
, O +
RelA O -
- O -
p100 O +
cytoplasmic O +
complexes O +
are O +
not O +
dissociated O +
following O +
tumor O +
necrosis O +
factor O +
alpha O +
activation O +
; O +
( O +
iii O +
) O +
p100 O +
functions O +
as O +
a O +
potent O +
inhibitor O +
of O +
RelA O +
-mediated O +
transcription O +
in O +
vivo O +
; O +
( O +
iv O +
) O +
the O +
interaction O +
of O +
RelA O +
and O +
p100 O +
involves O +
the O +
conserved O +
Rel O +
homology O +
domain O +
of O +
both O +
proteins O +
but O +
not O +
the O +
nuclear O +
localization O +
signal O +
of O +
RelA O +
, O +
which O +
is O +
required O +
for O +
I O +
kappa O +
B O +
alpha O +
binding O +
; O +
( O +
v O +
) O +
p100 O +
inhibition O +
of O +
RelA O +
function O +
requires O +
the O +
C O -
- O -
terminal O +
ankyrin O +
motif O +
domain O +
, O +
which O +
mediates O +
cytoplasmic O +
retention O +
of O +
RelA O +
; O +
and O +
( O +
vi O +
) O +
as O +
observed O +
with O +
I O +
kappa O +
B O +
alpha O +
, O +
nuclear O +
RelA O +
stimulates O +
p100 O +
mRNA O +
and O +
protein O +
expression O +
. O +

These O +
findings O +
thus O +
reveal O +
the O +
presence O +
of O +
a O +
second O +
inducible O +
autoregulated O +
inhibitory O +
pathway O +
that O +
helps O +
ensure O +
the O +
rapid O +
but O +
transient O +
action O +
of O +
nuclear O +
NF O -
- O -
kappa O +
B O +
. O +

Calcineurin O +
acts O +
in O +
synergy O +
with O +
PMA O +
to O +
inactivate O +
I O +
kappa O +
B O -
/ O -
MAD3 O +
, O +
an O +
inhibitor O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

The O +
interleukin-2 O +
( O +
IL-2 O +
) O +
promoter O +
consists O +
of O +
several O +
independent O +
T O +
cell O +
receptor O +
( O +
TcR O +
) O +
responsive O +
elements O +
. O +

The O +
induction O +
of O +
promoters O +
dependent O +
on O +
these O +
elements O +
is O +
inhibitable O +
by O +
the O +
immunosuppressants O +
cyclosporin O +
A O +
( O +
CsA O +
) O +
and O +
tacrolimus O +
( O +
FK-506 O +
) O +
. O +

Calcineurin O +
, O +
a O +
Ca2+ O -
/ O -
calmodulin O -
- O -
dependent O +
protein O +
phosphatase O +
, O +
is O +
the O +
FK-506 O +
-and O +
CsA O -
- O -
sensitive O +
enzyme O +
required O +
for O +
TcR O +
mediated O +
activation O +
of O +
the O +
IL-2 O +
promoter O +
. O +

We O +
report O +
that O +
a O +
constitutively O +
active O +
form O +
of O +
calcineurin O +
partially O +
substitutes O +
for O +
the O +
Ca2 O -
+ O +
co O -
- O -
stimulus O +
required O +
to O +
activate O +
the O +
IL-2 O +
promoter O +
elements O +
IL-2A O +
( O +
which O +
binds O +
the O +
factors O +
OAP O +
and O +
Oct-1 O +
) O +
and O +
IL-2E O +
( O +
which O +
binds O +
NF O -
- O -
AT O +
) O +
, O +
and O +
completely O +
substitutes O +
for O +
the O +
Ca2 O -
+ O +
co O -
- O -
stimulus O +
required O +
to O +
stimulate O +
an O +
NF O -
- O -
kappa O +
B O +
-dependent O +
element O +
. O +

Calcineurin O +
stimulates O +
the O +
NF O -
- O -
kappa O +
B O +
element O +
by O +
enhancing O +
inactivation O +
of O +
I O +
kappa O +
B O -
/ O -
MAD3 O +
, O +
an O +
inhibitor O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
thereby O +
increasing O +
the O +
amount O +
of O +
nuclear O +
NF O -
- O -
kappa O +
B O +
DNA O +
binding O +
activity O +
. O +

These O +
data O +
provide O +
the O +
first O +
demonstration O +
in O +
vivo O +
that O +
activation O +
of O +
a O +
protein O +
phosphatase O +
can O +
inactivate O +
I O +
kappa O +
B O +
, O +
and O +
suggest O +
one O +
possible O +
explanation O +
for O +
mechanism O -
- O -
based O +
toxicities O +
associated O +
with O +
FK-506 O +
and O +
CsA O +
by O +
demonstrating O +
that O +
these O +
drugs O +
can O +
inhibit O +
the O +
calcineurin O +
-dependent O +
activation O +
of O +
a O +
virtually O +
ubiquitous O +
transcription O +
factor O +
. O +

Direct O +
exposure O +
to O +
2 O +
, O +
3 O +
, O +
7 O +
, O +
8-tetrachlorodibenzo O -
- O -
p O -
- O -
dioxin O +
( O +
TCDD O +
) O +
increases O +
infectivity O +
of O +
human O +
erythrocytes O +
to O +
a O +
malarial O +
parasite O +
. O +

Direct O +
exposure O +
to O +
10 O +
nM O +
2 O +
, O +
3 O +
, O +
7 O +
, O +
8-TCDD O +
caused O +
a O +
75 O +
% O +
increase O +
and O +
a O +
2-fold O +
increase O +
in O +
the O +
infectivity O +
of O +
isolated O +
human O +
erythrocytes O +
to O +
P. O +
falciparum O +
after O +
48 O +
hours O +
when O +
the O +
parasites O +
were O +
in O +
an O +
unsynchronized O +
or O +
synchronized O +
state O +
of O +
growth O +
, O +
respectively O +
. O +

Treatment O +
of O +
human O +
erythrocytes O +
with O +
10 O +
microM O +
sodium O +
orthovanadate O +
( O +
NaOV O +
) O +
, O +
an O +
inhibitor O +
of O +
plasma O +
membrane O +
Ca O -
- O -
ATPase O +
and O +
phosphotyrosine O +
phosphatase O +
, O +
decreased O +
parasitemia O +
by O +
30 O +
% O +
. O +

Co O -
- O -
treatment O +
of O +
RBCs O +
with O +
TCDD O +
and O +
NaOV O +
completely O +
blocked O +
the O +
TCDD O -
- O -
induced O +
increase O +
in O +
parasitemia O +
. O +

Because O +
erythrocytes O +
are O +
anucleated O +
, O +
these O +
results O +
are O +
discussed O +
as O +
evidence O +
for O +
biochemical O +
changes O +
by O +
TCDD O +
without O +
requiring O +
the O +
activation O +
of O +
gene O +
products O +
. O +

trans O -
- O -
activation O +
of O +
the O +
HIV O +
promoter O +
by O +
a O +
cDNA O +
and O +
its O +
genomic O +
clones O +
of O +
human O +
herpesvirus-6 O +
. O +

Human O +
herpesvirus O +
6 O +
( O +
HHV-6 O +
) O +
is O +
a O +
lymphotropic O +
herpesvirus O +
, O +
and O +
in O +
vitro O +
, O +
it O +
can O +
productively O +
infect O +
human O +
CD4 B-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
as O +
HIV-1 O +
. O +

Co O -
- O -
infection O +
of O +
T O +
cells O +
by O +
HIV-1 O +
and O +
HHV-6 O +
can O +
lead O +
to O +
both O +
activation O +
of O +
the O +
HIV-1 O +
promoter O +
and O +
acceleration O +
of O +
the O +
cytopathic O +
effects O +
. O +

An O +
HHV-6 O +
( O +
GS O +
) O +
cDNA O +
clone O +
, O +
pCD41 O +
, O +
encoding O +
for O +
a O +
41-kDa O +
nuclear O +
protein O +
was O +
identified O +
and O +
characterized O +
previously O +
( O +
Chang O +
and O +
Balachandran O +
, O +
J. O +
Virol O -
. O +
65 O +
, O +
2884 O -
- O -
2894 O +
and O +
7085 O +
, O +
1991 O +
) O +
. O +

Sequence O +
analyses O +
show O +
that O +
this O +
protein O +
has O +
significant O +
homology O +
with O +
the O +
human O +
cytomegalovirus O +
UL44 O +
gene O +
coding O +
for O +
the O +
ICP36 O +
family O +
of O +
early O -
- O -
late O -
- O -
class O +
phosphoprotein O +
. O +

Using O +
this O +
cDNA O +
as O +
the O +
probe O +
, O +
a O +
3.8-kb O +
EcoRI O +
genomic O +
fragment O +
encoding O +
the O +
HHV-6 O +
( O +
GS O +
) O +
P41 O +
was O +
cloned O +
and O +
designated O +
as O +
pGD41 O +
. O +

When O +
cotransfected O +
with O +
the O +
HIV O +
LTR O +
CAT O +
into O +
CV-1 B-CellLine +
cells I-CellLine +
, O +
both O +
the O +
pCD41 O +
and O +
pGD41 O +
clones O +
trans O -
- O -
activated O +
the O +
HIV O +
LTR O +
. O +

Sequence O +
analyses O +
of O +
pCD41 O +
indicate O +
that O +
there O +
are O +
two O +
potential O +
open O +
reading O +
frames O +
( O +
ORFs O +
) O +
, O +
A O +
and O +
B O +
, O +
which O +
are O +
homologous O +
to O +
the O +
ORFs O +
found O +
in O +
the O +
genomic O +
clone O +
pGD41 O +
. O +

Deletion O +
constructs O +
of O +
the O +
pCD41 O +
clone O +
demonstrated O +
that O +
ORF O -
- O -
A O +
was O +
critical O +
for O +
the O +
HIV O +
LTR O +
activation O +
. O +

Deletion O +
analyses O +
of O +
the O +
pCD41 O +
ORF O -
- O -
A O +
and O +
the O +
use O +
of O +
promoter O +
constructs O +
further O +
mapped O +
an O +
internal O +
functional O +
promoter O +
within O +
the O +
pCD41 O +
sequence O +
that O +
can O +
direct O +
the O +
synthesis O +
of O +
the O +
trans O -
- O -
activating O +
protein O +
. O +

By O +
using O +
HIV O +
LTR O +
deletion O +
mutants O +
, O +
the O +
NF O -
- O -
kappa O +
B O +
binding O +
sites O +
were O +
found O +
to O +
be O +
critical O +
for O +
response O +
to O +
the O +
pCD41 O +
trans O -
- O -
activation O +
. O +

Isolation O +
and O +
characterization O +
of O +
gelatinase O +
granules O +
from O +
human O +
neutrophils O +
. O +

We O +
recently O +
confirmed O +
the O +
existence O +
of O +
gelatinase O +
granules O +
as O +
a O +
subpopulation O +
of O +
peroxidase O -
- O -
negative O +
granules O +
by O +
double O -
- O -
labeling O +
immunogold O +
electron O +
microscopy O +
on O +
intact O +
cells O +
and O +
by O +
subcellular O +
fractionation O +
. O +

Further O +
characterization O +
of O +
gelatinase O +
granules O +
has O +
been O +
hampered O +
by O +
poor O +
separation O +
of O +
specific O +
and O +
gelatinase O +
granules O +
on O +
both O +
two O -
- O -
layer O +
Percoll O +
gradients O +
and O +
sucrose O +
gradients O +
. O +

We O +
have O +
developed O +
a O +
three O -
- O -
layer O +
Percoll O +
density O +
gradient O +
that O +
allows O +
separation O +
of O +
the O +
different O +
granules O +
and O +
vesicles O +
from O +
human O +
neutrophils O +
; O +
in O +
particular O +
, O +
it O +
allows O +
separation O +
of O +
specific O +
and O +
gelatinase O +
granules O +
. O +

This O +
allows O +
us O +
to O +
characterize O +
these O +
two O +
granule O +
populations O +
with O +
regard O +
to O +
their O +
content O +
of O +
membrane O +
proteins O +
, O +
which O +
become O +
incorporated O +
into O +
the O +
plasma O +
membrane O +
during O +
exocytosis O +
. O +

We O +
found O +
that O +
gelatinase O +
granules O +
, O +
defined O +
as O +
peroxidase O -
- O -
negative O +
granules O +
containing O +
gelatinase O +
but O +
lacking O +
lactoferrin O +
, O +
contain O +
50 O +
% O +
of O +
total O +
cell O +
gelatinase O +
, O +
with O +
the O +
remaining O +
residing O +
in O +
specific O +
granules O +
. O +

Furthermore O +
, O +
we O +
found O +
that O +
20 O +
% O +
to O +
25 O +
% O +
of O +
both O +
the O +
adhesion O +
protein O +
Mac-1 O +
and O +
the O +
NADPH O -
- O -
oxidase O +
component O +
cytochrome O +
b558 O +
is O +
localized O +
in O +
gelatinase O +
granules O +
. O +

Although O +
no O +
qualitative O +
difference O +
was O +
observed O +
between O +
specific O +
granules O +
and O +
gelatinase O +
granules O +
with O +
respect O +
to O +
cytochrome O +
b558 O +
and O +
Mac-1 O +
, O +
stimulation O +
of O +
the O +
neutrophil O +
with O +
FMLP O +
resulted O +
in O +
a O +
selective O +
mobilization O +
of O +
the O +
least O +
dense O +
peroxidase O -
- O -
negative O +
granules O +
, O +
ie O +
, O +
gelatinase O +
granules O +
, O +
which O +
, O +
in O +
concert O +
with O +
secretory O +
vesicles O +
, O +
furnish O +
the O +
plasma O +
membrane O +
with O +
Mac-1 O +
and O +
cytochrome O +
b558 O +
. O +

This O +
shows O +
that O +
gelatinase O +
granules O +
are O +
functionally O +
important O +
relative O +
to O +
specific O +
granules O +
in O +
mediating O +
early O +
inflammatory O +
responses O +
. O +

Thrombin O +
and O +
thrombin O +
receptor O +
agonist O +
peptide O +
induce O +
early O +
events O +
of O +
T O +
cell O +
activation O +
and O +
synergize O +
with O +
TCR O +
cross O -
- O -
linking O +
for O +
CD69 O +
expression O +
and O +
interleukin O +
2 O +
production O +
. O +

Thrombin O +
stimulation O +
of O +
the O +
T B-CellLine +
leukemic I-CellLine +
cell I-CellLine +
line I-CellLine +
Jurkat I-CellLine +
induced O +
a O +
transient O +
increase O +
in O +
[ O +
Ca2 O -
+ O +
] O +
i O +
. O +

Proteolytic O +
activity O +
of O +
the O +
enzyme O +
was O +
required O +
for O +
this O +
effect O +
since O +
diisopropyl O +
fluorophosphate O -
- O -
thrombin O +
failed O +
to O +
increase O +
[ O +
Ca2 O -
+ O +
] O +
i O +
. O +

Furthermore O +
, O +
hirudin O +
and O +
anti O -
- O -
thrombin O +
III O +
inhibited O +
the O +
thrombin O -
- O -
induced O +
[ O +
Ca2 O -
+ O +
] O +
i O +
rise O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

A O +
synthetic O +
thrombin O +
receptor O +
agonist O +
peptide O +
( O +
TRP O +
) O +
of O +
7 O +
residues O +
( O +
SFLLRNP O +
) O +
was O +
found O +
to O +
be O +
as O +
effective O +
as O +
thrombin O +
for O +
[ O +
Ca2 O -
+ O +
] O +
i O +
mobilization O +
, O +
and O +
both O +
agonists O +
induced O +
Ca2 O -
+ O +
release O +
exclusively O +
from O +
internal O +
stores O +
. O +

Thrombin O +
stimulated O +
tyrosine O +
phosphorylation O +
of O +
several O +
proteins O +
of O +
molecular O +
mass O +
40 O +
, O +
42 O +
, O +
70 O +
, O +
120 O +
, O +
and O +
130 O +
kDa O +
. O +

There O +
was O +
a O +
good O +
correlation O +
between O +
thrombin O +
-induced O +
tyrosine O +
phosphorylation O +
of O +
the O +
latter O +
three O +
proteins O +
and O +
Ca2 O -
+ O +
mobilization O +
. O +

Thrombin O +
and O +
TRP O +
also O +
caused O +
translocation O +
of O +
protein O +
kinase O +
C O +
from O +
the O +
cytosol O +
to O +
the O +
plasma O +
membrane O +
. O +

As O +
a O +
likely O +
consequence O +
of O +
these O +
events O +
, O +
thrombin O +
activated O +
the O +
nuclear O +
factor O +
NF O -
- O -
kB O +
. O +

Several O +
cell O +
lines O +
of O +
hematopoietic O +
origin O +
including O +
the O +
leukemic B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
HPB.ALL I-CellLine +
and O +
the O +
erythroleukemic B-CellLine +
cell I-CellLine +
line I-CellLine +
K562 I-CellLine +
were O +
responsive O +
to O +
thrombin O +
, O +
whereas O +
others O +
such O +
as O +
THP1 B-CellLine +
, O +
a O +
myelomonocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
and O +
BL2 B-CellLine +
, I-CellLine +
a O +
Burkitt B-CellLine +
lymphoma I-CellLine +
were O +
refractory O +
to O +
thrombin O +
or O +
TRP O +
stimulation O +
. O +

The O +
magnitude O +
of O +
the O +
thrombin O +
response O +
in O +
the O +
different O +
cell O +
types O +
paralleled O +
the O +
expression O +
of O +
the O +
thrombin O +
receptor O +
mRNA O +
. O +

We O +
found O +
that O +
activation O +
of O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
by O +
a O +
combination O +
of O +
phytohemagglutinin O +
and O +
phorbol O +
12-myristate O +
13-acetate O +
led O +
to O +
a O +
dramatic O +
inhibition O +
of O +
thrombin O +
receptor O +
mRNA O +
expression O +
and O +
to O +
a O +
concomitant O +
loss O +
of O +
the O +
thrombin O +
response O +
. O +

Finally O +
, O +
we O +
demonstrate O +
that O +
thrombin O +
and O +
TRP O +
enhanced O +
CD69 O +
expression O +
and O +
interleukin O +
2 O +
production O +
induced O +
by O +
T O +
cell O +
receptor O +
cross O -
- O -
linking O +
in O +
both O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
and O +
peripheral O +
blood O +
lymphocytes O +
. O +

These O +
findings O +
highlight O +
the O +
role O +
of O +
thrombin O +
as O +
a O +
potential O +
regulator O +
of O +
T O +
lymphocyte O +
activation O +
. O +

Activation O +
of O +
the O +
interleukin O +
6 O +
gene O +
by O +
Mycobacterium O +
tuberculosis O +
or O +
lipopolysaccharide O +
is O +
mediated O +
by O +
nuclear O +
factors O +
NF O -
- O -
IL6 O +
and O +
NF O -
- O -
kappa O +
B O +
[ O +
published O +
erratum O +
appears O +
in O +
Proc O +
Natl O +
Acad O +
Sci O +
U O +
S O +
A O +
1995 O +
Apr O +
11 O +
; O +
92 O +
( O +
8 O +
) O +
: O +
3632 O +
] O +

The O +
host O +
response O +
to O +
Mycobacterium O +
tuberculosis O +
includes O +
granuloma O +
formation O +
at O +
sites O +
of O +
infection O +
and O +
systemic O +
symptoms O +
. O +

Cytokines O +
have O +
been O +
identified O +
by O +
immunohistochemistry O +
in O +
granulomas O +
in O +
animal O +
models O +
of O +
bacillus O +
Calmette O -
- O -
Guerin O +
( O +
BCG O +
) O +
infection O +
and O +
are O +
released O +
by O +
mononuclear O +
phagocytes O +
upon O +
stimulation O +
by O +
mycobacterial O +
proteins O +
. O +

In O +
this O +
regard O +
, O +
the O +
cytokine O +
interleukin O +
6 O +
( O +
IL-6 O +
) O +
may O +
play O +
a O +
role O +
in O +
the O +
clinical O +
manifestations O +
and O +
pathological O +
events O +
of O +
tuberculosis O +
infection O +
. O +

We O +
have O +
demonstrated O +
that O +
lipoarabinomannan O +
( O +
LAM O +
) O +
from O +
the O +
mycobacterial O +
cell O +
wall O +
, O +
which O +
was O +
virtually O +
devoid O +
of O +
lipopolysaccharide O +
( O +
LPS O +
) O +
, O +
stimulated O +
mononuclear O +
phagocytes O +
to O +
release O +
IL-6 O +
in O +
a O +
dose O -
- O -
response O +
manner O +
. O +

LAM O +
and O +
LPS O +
were O +
potent O +
inducers O +
of O +
IL-6 O +
gene O +
expression O +
in O +
peripheral O +
blood O +
monocytes O +
. O +

Both O +
LAM O +
-and O +
LPS O -
- O -
inducible O +
IL-6 O +
promoter O +
activity O +
was O +
localized O +
to O +
a O +
DNA O +
fragment O +
, O +
positions O +
-158 O +
to O +
-49 O +
, O +
by O +
deletion O +
analysis O +
and O +
chloramphenicol O +
acetyltransferase O +
assay O +
. O +

Two O +
nuclear O +
factor O +
NF O -
- O -
IL6 O +
( O +
positions O +
-153 O +
to O +
-145 O +
and O +
-83 O +
to O +
-75 O +
) O +
and O +
one O +
nuclear O +
factor O +
NF O -
- O -
kappa O +
B O +
( O +
positions O +
-72 O +
to O +
-63 O +
) O +
motifs O +
are O +
present O +
within O +
this O +
fragment O +
. O +

Site O -
- O -
directed O +
mutagenesis O +
of O +
one O +
or O +
more O +
of O +
these O +
motifs O +
within O +
the O +
IL-6 O +
promoter O +
demonstrated O +
that O +
each O +
has O +
positive O +
regulatory O +
activity O +
and O +
that O +
they O +
could O +
act O +
in O +
a O +
function- O +
and O +
orientation O -
- O -
independent O +
manner O +
. O +

Deletion O +
of O +
all O +
three O +
elements O +
abolished O +
inducibility O +
of O +
IL-6 O +
promoter O +
activity O +
by O +
both O +
LAM O +
and O +
LPS O +
. O +

We O +
conclude O +
that O +
the O +
NF O -
- O -
IL6 O +
and O +
NF O -
- O -
kappa O +
B O +
sites O +
mediate O +
IL-6 O +
induction O +
in O +
response O +
to O +
both O +
LPS O +
and O +
LAM O +
, O +
acting O +
as O +
bacterial O +
or O +
mycobacterial O +
response O +
elements O +
. O +

Calcineurin O +
activates O +
transcription O +
from O +
the O +
GM O -
- O -
CSF O +
promoter O +
in O +
synergy O +
with O +
either O +
protein O +
kinase O +
C O +
or O +
NF O -
- O -
kappa O +
B O +
/AP-1 O +
in O +
T O +
cells O +
. O +

Two O +
cis O -
- O -
acting O +
elements O +
GM O -
- O -
kappa O +
B O -
/ O -
GC O -
- O -
box O +
and O +
CLE0 O +
, O +
of O +
the O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
gene O +
are O +
required O +
for O +
maximal O +
induction O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
by O +
costimulation O +
with O +
phorbol-12-myristate O +
acetate O +
( O +
PMA O +
) O +
and O +
Ca2 O -
+ O +
ionophore O +
( O +
A23187 O +
) O +
. O +

The O +
GM O -
- O -
kappa O +
B O +
sequence O +
is O +
recognized O +
by O +
NF O -
- O -
kappa O +
B O +
, O +
which O +
is O +
mainly O +
induced O +
by O +
PMA O +
. O +

The O +
CLE0 O +
sequence O +
interacts O +
with O +
factors O +
, O +
related O +
to O +
a O +
PMA O -
- O -
induced O +
AP-1 O +
and O +
a O +
PMA O -
/ O -
A23187-induced O +
NF O -
- O -
AT O +
. O +

We O +
examined O +
whether O +
signal O +
transducing O +
components O +
in O +
T O +
cells O +
can O +
activate O +
transcription O +
of O +
the O +
GM O -
- O -
CSF O +
gene O +
. O +

Cotransfection O +
of O +
NF O -
- O -
kappa O +
B O +
( O +
p50 O -
/ O -
p65 O +
) O +
- O +
or O +
AP-1 O +
( O +
c O -
- O -
Jun O -
/ O -
c O -
- O -
Fos O +
) O +
- O +
expression O +
vectors O +
into O +
Jurkat B-CellLine +
cells I-CellLine +
with O +
a O +
luciferase O +
reporter O +
containing O +
the O +
GM O -
- O -
CSF O +
promoter O +
did O +
not O +
stimulate O +
transcription O +
from O +
the O +
GM O -
- O -
CSF O +
promoter O +
. O +

In O +
contrast O +
, O +
cotransfection O +
with O +
a O +
combination O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O +
significantly O +
augmented O +
transcription O +
from O +
the O +
GM O -
- O -
CSF O +
promoter O +
containing O +
the O +
GM O -
- O -
kappa O +
B O -
/ O -
GC O -
- O -
box O +
and O +
the O +
CLE0 O +
( O +
AP-1 O -
/ O -
NF O -
- O -
AT O +
) O +
. O +

Expression O +
of O +
a O +
constitutively O +
active O +
calcineurin O +
( O +
CN O +
) O +
, O +
a O +
Ca2+ O -
/ O -
calmodulin O -
- O -
dependent O +
protein O +
phosphatase O +
, O +
potentiated O +
by O +
two O +
fold O +
the O +
transcriptional O +
activation O +
by O +
NF O -
- O -
kappa O +
B O +
/AP-1 O +
. O +

Both O +
constitutively O +
active O +
forms O +
of O +
CN O +
and O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
synergistically O +
activated O +
transcription O +
from O +
the O +
GM O -
- O -
CSF O +
promoter O +
. O +

These O +
results O +
suggest O +
that O +
cooperation O +
among O +
NF O -
- O -
kappa O +
B- O +
, O +
AP-1- O +
and O +
NF O -
- O -
AT O -
- O -
binding O +
sequences O +
is O +
required O +
for O +
induction O +
of O +
the O +
GM O -
- O -
CSF O +
gene O +
through O +
PKC- O +
and O +
Ca2 O -
+ O -
- O +
signaling O +
pathways O +
downstream O +
of O +
T O +
cell O +
activation O +
. O +

Retinoic O +
acid O -
- O -
induced O +
expression O +
of O +
CD38 O +
antigen O +
in O +
myeloid O +
cells O +
is O +
mediated O +
through O +
retinoic O +
acid O +
receptor O -
- O -
alpha O +
. O +

CD38 O +
is O +
a O +
leukocyte O +
differentiation O +
antigen O +
that O +
has O +
been O +
thought O +
to O +
be O +
a O +
phenotypic O +
marker O +
of O +
different O +
subpopulations O +
of O +
T- O +
and O +
B- O +
lymphocytes O +
. O +

In O +
myeloid O +
cells O +
, O +
CD38 O +
is O +
expressed O +
during O +
early O +
stages O +
of O +
differentiation O +
. O +

Virtually O +
no O +
information O +
is O +
available O +
on O +
regulation O +
and O +
functions O +
of O +
CD38 O +
. O +

Recently O +
we O +
reported O +
that O +
all O -
- O -
trans O -
- O -
retinoic O +
acid O +
( O +
ATRA O +
) O +
is O +
a O +
potent O +
and O +
highly O +
specific O +
inducer O +
of O +
CD38 O +
expression O +
in O +
human O +
promyelocytic O +
leukemia O +
cells O +
. O +

Here O +
we O +
report O +
that O +
ATRA O -
- O -
induced O +
expression O +
of O +
CD38 O +
antigen O +
in O +
myeloid O +
cells O +
is O +
mediated O +
through O +
retinoic O +
acid O -
- O -
alpha O +
receptor O +
( O +
RAR O +
alpha O +
) O +
. O +

ATRA O +
failed O +
to O +
induce O +
CD38 O +
expression O +
in O +
a O +
mutant B-CellLine +
subclone I-CellLine +
of O +
the O +
HL-60 B-CellLine +
myeloid I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
designated O +
HL-60R B-CellLine +
) O +
that O +
is O +
relatively O +
resistant O +
to O +
ATRA O -
- O -
induced O +
granulocytic O +
differentiation O +
. O +

Retroviral O +
vector O -
- O -
mediated O +
transduction O +
of O +
RA O +
receptor O +
( O +
RAR O +
alpha O +
) O +
into O +
this O +
HL-60R B-CellLine +
subclone I-CellLine +
completely O +
restored O +
the O +
sensitivity O +
of O +
these O +
cells O +
to O +
ATRA O +
in O +
terms O +
of O +
their O +
ability O +
to O +
express O +
CD38 O +
. O +

In O +
contrast O +
, O +
CD38 O +
expression O +
was O +
not O +
inducible O +
by O +
ATRA O +
in O +
HL-60R B-CellLine +
cells I-CellLine +
, O +
transfected O +
with O +
a O +
functional O +
RAR O +
beta O +
, O +
RAR O +
gamma O +
, O +
or O +
RXR O +
alpha O +
receptor O +
. O +

Induction O +
of O +
CD38 O +
in O +
acute O +
promyelocytic O +
and O +
acute O +
myeloblastic O +
leukemia O +
cells O +
was O +
independent O +
of O +
ATRA O -
- O -
induced O +
cytodifferentiation O +
. O +

Following O +
culture O +
with O +
ATRA O +
, O +
increased O +
CD38 O +
protein O +
levels O +
were O +
also O +
observed O +
in O +
normal O +
CD34 O -
+ O +
bone O +
marrow O +
cells O +
, O +
but O +
not O +
on O +
normal O +
circulating O +
granulocytes O +
. O +

From O +
these O +
results O +
, O +
we O +
conclude O +
that O +
CD38 O +
is O +
ATRA O +
inducible O +
in O +
myeloid O +
leukemia O +
cells O +
and O +
normal O +
CD34 O -
+ O +
bone O +
marrow O +
cells O +
. O +

This O +
effect O +
is O +
independent O +
of O +
differentiation O +
and O +
is O +
mediated O +
by O +
RAR O +
alpha O +
in O +
HL-60 O +
cells O +
, O +
suggesting O +
a O +
similar O +
role O +
for O +
RAR O +
alpha O +
in O +
CD38 O +
expression O +
in O +
other O +
hematopoietic O +
cells O +
. O +

A O +
transcriptional O +
regulatory O +
element O +
is O +
associated O +
with O +
a O +
nuclease O -
- O -
hypersensitive O +
site O +
in O +
the O +
pol O +
gene O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
. O +

Analysis O +
of O +
the O +
chromatin O +
organization O +
of O +
the O +
integrated O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
genome O +
has O +
previously O +
revealed O +
a O +
major O +
constitutive O +
DNase O +
I O -
- O -
hypersensitive O +
site O +
associated O +
with O +
the O +
pol O +
gene O +
( O +
E. O +
Verdin O +
, O +
J. O +
Virol O -
. O +
65 O +
: O +
6790 O -
- O -
6799 O +
, O +
1991 O +
) O +
. O +

In O +
the O +
present O +
report O +
, O +
high O -
- O -
resolution O +
mapping O +
of O +
this O +
site O +
with O +
DNase O +
I O +
and O +
micrococcal O +
nuclease O +
identified O +
a O +
nucleosome O -
- O -
free O +
region O +
centered O +
around O +
nucleotides O +
( O +
nt O +
) O +
4490 O +
to O +
4766 O +
. O +

A O +
500-bp O +
fragment O +
encompassing O +
this O +
hypersensitive O +
site O +
( O +
nt O +
4481 O +
to O +
4982 O +
) O +
exhibited O +
transcription O -
- O -
enhancing O +
activity O +
( O +
two- O +
to O +
threefold O +
) O +
when O +
it O +
was O +
cloned O +
in O +
its O +
natural O +
position O +
with O +
respect O +
to O +
the O +
HIV-1 O +
promoter O +
after O +
transient O +
transfection O +
in O +
U937 B-CellLine +
and O +
CEM B-CellLine +
cells I-CellLine +
. O +

Using O +
in O +
vitro O +
footprinting O +
and O +
gel O +
shift O +
assays O +
, O +
we O +
have O +
identified O +
four O +
distinct O +
binding O +
sites O +
for O +
nuclear O +
proteins O +
within O +
this O +
positive O +
regulatory O +
element O +
. O +

Site O +
B O +
( O +
nt O +
4519 O +
to O +
4545 O +
) O +
specifically O +
bound O +
four O +
distinct O +
nuclear O +
protein O +
complexes O +
: O +
a O +
ubiquitous O +
factor O +
, O +
a O +
T O -
- O -
cell O -
- O -
specific O +
factor O +
, O +
a O +
B O -
- O -
cell O -
- O -
specific O +
factor O +
, O +
and O +
the O +
monocyte O -
/ O -
macrophage- O +
and O +
B O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
PU.1 O -
/ O -
Spi-1 O +
. O +

In O +
most O +
HIV-1 O +
isolates O +
in O +
which O +
this O +
PU O +
box O +
was O +
not O +
conserved O +
, O +
it O +
was O +
replaced O +
by O +
a O +
binding O +
site O +
for O +
the O +
related O +
factor O +
Ets1 O +
. O +

Factors O +
binding O +
to O +
site O +
C O +
( O +
nt O +
4681 O +
to O +
4701 O +
) O +
had O +
a O +
DNA O -
- O -
binding O +
specificity O +
similar O +
to O +
that O +
of O +
factors O +
binding O +
to O +
site O +
B O +
, O +
except O +
for O +
PU.1 O -
/ O -
Spi-1 O +
. O +

A O +
GC O +
box O +
containing O +
a O +
binding O +
site O +
for O +
Sp1 O +
was O +
identified O +
( O +
nt O +
4623 O +
to O +
4631 O +
) O +
. O +

Site O +
D O +
( O +
nt O +
4816 O +
to O +
4851 O +
) O +
specifically O +
bound O +
a O +
ubiquitously O +
expressed O +
factor O +
. O +

These O +
results O +
identify O +
a O +
transcriptional O +
regulatory O +
element O +
associated O +
with O +
a O +
nuclease O -
- O -
hypersensitive O +
site O +
in O +
the O +
pol O +
gene O +
of O +
HIV-1 O +
and O +
suggest O +
that O +
its O +
activity O +
may O +
be O +
controlled O +
by O +
a O +
complex O +
interplay O +
of O +
cis- O +
regulatory O +
elements O +
. O +

Detection O +
of O +
minimal O +
residual O +
disease O +
in O +
a O +
patient O +
with O +
acute O +
promyelocytic O +
leukemia O +
by O +
RT O -
- O -
PCR O +
: O +
necessity O +
of O +
chemotherapy O +
following O +
ATRA O +
therapy O +
. O +

The O +
PML O -
/ O -
RAR O +
alpha O +
fusion O +
gene O +
resulting O +
from O +
the O +
t O +
( O +
15 O +
; O +
17 O +
) O +
translocation O +
is O +
a O +
specific O +
marker O +
for O +
acute O +
promyelocytic O +
leukemia O +
( O +
APL O +
) O +
. O +

We O +
examined O +
bone O +
marrow O +
cells O +
by O +
reverse O +
transcriptase O -
- O -
polymerase O +
chain O +
reaction O +
( O +
RT O -
- O -
PCR O +
) O +
to O +
detect O +
residual O +
PML O -
/ O -
RAR O +
alpha O +
mRNA O -
- O -
containing O +
cells O +
following O +
treatment O +
with O +
all O -
- O -
trans O +
retinoic O +
acid O +
( O +
ATRA O +
) O +
and O +
cytotoxic O +
chemotherapy O +
in O +
a O +
patient O +
with O +
APL O +
. O +

This O +
RT O -
- O -
PCR O +
assay O +
can O +
detect O +
one O +
leukemic O +
cell O +
in O +
10 O +
( O +
2 O +
) O +
normal O +
cells O +
in O +
vitro O +
. O +

We O +
show O +
that O +
PML O -
/ O -
RAR O +
alpha O +
mRNA O +
was O +
still O +
detectable O +
despite O +
clinical O +
remission O +
following O +
ATRA O +
treatment O +
, O +
but O +
undetectable O +
following O +
consolidation O +
with O +
chemotherapy O +
. O +

These O +
data O +
show O +
that O +
this O +
technique O +
is O +
useful O +
for O +
the O +
identification O +
of O +
minimal O +
residual O +
disease O +
in O +
patients O +
with O +
APL O +
and O +
that O +
cytotoxic O +
chemotherapy O +
following O +
ATRA O +
therapy O +
is O +
required O +
for O +
the O +
elimination O +
of O +
APL O +
cells O +
. O +

Expression O +
of O +
v O -
- O -
src O +
in O +
T O +
cells O +
correlates O +
with O +
nuclear O +
expression O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

NF O -
- O -
kappa O +
B O +
is O +
a O +
rapidly O +
inducible O +
transcriptional O +
activator O +
that O +
responds O +
to O +
a O +
variety O +
of O +
signals O +
and O +
influences O +
the O +
expression O +
of O +
many O +
genes O +
involved O +
in O +
the O +
immune O +
response O +
. O +

Protein O +
tyrosine O +
kinases O +
transmit O +
signals O +
from O +
cytokine O +
and O +
immune O +
receptors O +
. O +

Very O +
little O +
information O +
exists O +
linking O +
these O +
two O +
important O +
classes O +
of O +
signaling O +
molecules O +
. O +

We O +
now O +
demonstrate O +
that O +
v O -
- O -
src O +
expression O +
correlates O +
with O +
nuclear O +
expression O +
of O +
a O +
kappa O +
B O +
binding O +
complex O +
similar O +
to O +
that O +
induced O +
by O +
phorbol O +
ester O +
and O +
ionomycin O +
, O +
as O +
detected O +
by O +
electrophoretic O +
mobility O +
shift O +
assay O +
using O +
a O +
variety O +
of O +
kappa O +
B O +
sites O +
. O +

This O +
complex O +
was O +
blocked O +
by O +
the O +
tyrosine O +
kinase O +
inhibitor O +
, O +
herbimycin O +
A O +
. O +

The O +
v O -
- O -
src O -
- O -
induced O +
complex O +
comprised O +
the O +
p50 O +
and O +
p65 O +
components O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
as O +
determined O +
by O +
supershift O +
and O +
immunoblot O +
analysis O +
. O +

As O +
a O +
functional O +
correlate O +
of O +
this O +
finding O +
, O +
transient O +
co O -
- O -
transfection O +
of O +
HIV-1 O +
LTR O +
reporter O +
constructs O +
in O +
a O +
different O +
T B-CellLine +
cell I-CellLine +
line I-CellLine +
demonstrated O +
that O +
v O -
- O -
src O +
activated O +
this O +
promoter O +
in O +
a O +
kappa O +
B O -
- O -
dependent O +
manner O +
. O +

We O +
found O +
that O +
transactivation O +
of O +
the O +
HIV-1 O +
LTR O +
by O +
v O -
- O -
src O +
was O +
more O +
sensitive O +
to O +
mutations O +
of O +
the O +
proximal O +
, O +
rather O +
than O +
the O +
distal O +
, O +
kappa O +
B O +
element O +
. O +

The O +
implications O +
for O +
T O +
cell O +
receptor O +
signaling O +
and O +
HIV-1 O +
gene O +
expression O +
are O +
considered O +
. O +

Comparison O +
of O +
retinoic O +
acid O +
and O +
phorbol O +
myristate O +
acetate O +
as O +
inducers O +
of O +
monocytic O +
differentiation O +
. O +

Several O +
human B-CellLine +
myeloid I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
lines I-CellLine +
growing O +
in O +
vitro O +
can O +
be O +
induced O +
to O +
differentiate O +
to O +
more O +
mature O +
monocyte O -
/ O -
macrophage O -
- O -
like O +
cells O +
by O +
treatment O +
with O +
protein O +
kinase O +
C O +
-activating O +
phorbol O +
esters O +
, O +
such O +
as O +
PMA O +
. O +

In O +
addition O +
to O +
PMA O +
, O +
cells O +
of O +
the O +
THP-1 B-CellLine +
myeloid I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
acquire O +
macrophage O -
- O -
like O +
characteristics O +
after O +
treatment O +
with O +
all O -
- O -
trans O +
retinoic O +
acid O +
( O +
RA O +
) O +
. O +

To O +
analyze O +
the O +
signal O +
transduction O +
mechanisms O +
induced O +
by O +
RA O +
, O +
we O +
first O +
compared O +
the O +
effects O +
of O +
PMA O +
and O +
RA O +
on O +
the O +
expression O +
of O +
genes O +
which O +
are O +
known O +
to O +
be O +
regulated O +
during O +
monocytic O +
differentiation O +
. O +

Both O +
RA O +
and O +
PMA O +
effectively O +
down O -
- O -
regulated O +
c O -
- O -
myc O +
expression O +
, O +
while O +
c O -
- O -
myb O +
expression O +
decreased O +
only O +
after O +
PMA O +
treatment O +
. O +

Expression O +
of O +
the O +
beta O +
2-integrin O +
genes O +
, O +
CD11a O +
and O +
CD11b O +
, O +
was O +
clearly O +
increased O +
after O +
both O +
of O +
these O +
treatments O +
. O +

Their O +
effects O +
on O +
the O +
src O -
- O -
family O +
tyrosine O +
kinase O +
genes O +
were O +
different O +
: O +
hck O +
expression O +
was O +
similarly O +
induced O +
by O +
these O +
agents O +
but O +
lyn O +
expression O +
was O +
stronger O +
and O +
more O +
rapid O +
after O +
RA O +
treatment O +
. O +

RA O +
also O +
enhanced O +
lyn O +
mRNA O +
production O +
rapidly O +
in O +
HL-60 B-CellLine +
, O +
indicating O +
that O +
the O +
activation O +
of O +
lyn O +
gene O +
expression O +
is O +
common O +
in O +
monocytic O +
and O +
granulocytic O +
maturation O +
of O +
myeloid O +
leukemia O +
cells O +
. O +

To O +
examine O +
whether O +
the O +
AP-1 O +
enhancer O +
activity O +
is O +
involved O +
in O +
RA O -
- O -
induced O +
monocytic O +
differentiation O +
, O +
THP-1 B-CellLine +
cells I-CellLine +
were O +
transiently O +
transfected O +
with O +
a O +
chloramphenicol O +
acetyl O +
transferase O +
( O +
CAT O +
) O +
-reporter O +
gene O +
containing O +
5 O +
copies O +
of O +
the O +
AP-1 O +
binding O +
sites O +
. O +

In O +
contrast O +
to O +
PMA O +
, O +
RA O +
did O +
not O +
induce O +
any O +
CAT O +
activity O +
in O +
these O +
cells O +
, O +
thus O +
suggesting O +
that O +
the O +
RA O -
- O -
induced O +
changes O +
in O +
the O +
expression O +
of O +
those O +
genes O +
described O +
above O +
were O +
not O +
dependent O +
on O +
the O +
AP-1 O +
enhancer O +
activity O +
. O +

Antigenic O +
specificities O +
of O +
human B-CellLine +
CD4 I-CellLine -
+ I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
recovered O +
from O +
recurrent O +
genital O +
herpes O +
simplex O +
virus O +
type O +
2 O +
lesions O +
. O +

Lesions O +
resulting O +
from O +
recurrent O +
genital O +
herpes O +
simplex O +
virus O +
( O +
HSV O +
) O +
infection O +
are O +
characterized O +
by O +
infiltration O +
of O +
CD4 O -
+ O +
lymphocytes O +
. O +

We O +
have O +
investigated O +
the O +
antigenic O +
specificity O +
of O +
47 O +
HSV B-CellLine -
- I-CellLine -
specific I-CellLine +
CD4 I-CellLine -
+ I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
recovered O +
from O +
the O +
HSV-2 O +
buttock O +
and O +
thigh O +
lesions O +
of O +
five O +
patients O +
. O +

Clones O +
with O +
proliferative O +
responses O +
to O +
recombinant O +
truncated O +
glycoprotein O +
B O +
( O +
gB O +
) O +
or O +
gD O +
of O +
HSV-2 O +
or O +
purified O +
natural O +
gC O +
of O +
HSV-2 O +
comprised O +
a O +
minority O +
of O +
the O +
total O +
number O +
of O +
HSV B-CellLine -
- I-CellLine -
specific I-CellLine +
clones I-CellLine +
isolated O +
from O +
lesions O +
. O +

The O +
gC2- B-CellLine +
and I-CellLine +
gD2-specific I-CellLine +
CD4 I-CellLine -
+ I-CellLine +
clones I-CellLine +
had O +
cytotoxic O +
activity O +
. O +

The O +
approximate O +
locations O +
of O +
the O +
HSV-2 O +
genes O +
encoding O +
HSV-2 O +
type O -
- O -
specific O +
CD4 O -
+ O +
antigens O +
have O +
been O +
determined O +
by O +
using O +
HSV-1 O +
x O +
HSV-2 O +
intertypic O +
recombinant O +
virus O +
and O +
include O +
the O +
approximate O +
map O +
regions O +
0.30 O +
to O +
0.46 O +
, O +
0.59 O +
to O +
0.67 O +
, O +
0.67 O +
to O +
0.73 O +
, O +
and O +
0.82 O +
to O +
1.0 O +
units O +
. O +

The O +
antigenic O +
specificity O +
of O +
an O +
HLA B-CellLine +
DQ2-restricted I-CellLine +
, I-CellLine +
HSV-2 I-CellLine +
type I-CellLine -
- I-CellLine -
specific I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clone I-CellLine +
was O +
mapped O +
to O +
amino O +
acids O +
425 O +
to O +
444 O +
of O +
VP16 O +
of O +
HSV-2 O +
by O +
sequential O +
use O +
of O +
an O +
intertypic O +
recombinant O +
virus O +
containing O +
VP16 O +
of O +
HSV-2 O +
in O +
an O +
HSV-1 O +
background O +
, O +
recombinant O +
VP16 O +
fusion O +
proteins O +
, O +
and O +
synthetic O +
peptides O +
. O +

Each O +
of O +
the O +
remaining O +
four O +
patients O +
also O +
yielded O +
at O +
least O +
one O +
type B-CellLine -
- I-CellLine -
specific I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clone I-CellLine +
reactive O +
with O +
an O +
HSV-2 O +
epitope O +
mapping O +
to O +
approximately O +
0.67 O +
to O +
0.73 O +
map O +
units O +
. O +

The O +
antigenic O +
specificities O +
of O +
lesion B-CellLine -
- I-CellLine -
derived I-CellLine +
CD4 I-CellLine -
+ I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
are O +
quite O +
diverse O +
and O +
include O +
at O +
least O +
10 O +
epitopes O +
. O +

Human B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
reactive O +
with O +
gC O +
and O +
VP16 O +
are O +
reported O +
here O +
for O +
the O +
first O +
time O +
. O +

Encephalomyocarditis O +
virus O +
internal O +
ribosomal O +
entry O +
site O +
RNA O -
- O -
protein O +
interactions O +
. O +

Translational O +
initiation O +
of O +
encephalomyocarditis O +
virus O +
( O +
EMCV O +
) O +
mRNA O +
occurs O +
by O +
ribosomal O +
entry O +
into O +
the O +
5 O +
' O +
nontranslated O +
region O +
of O +
the O +
EMCV O +
mRNA O +
, O +
rather O +
than O +
by O +
ribosomal O +
scanning O +
. O +

Internal O +
ribosomal O +
binding O +
requires O +
a O +
cis O -
- O -
acting O +
element O +
termed O +
the O +
internal O +
ribosomal O +
entry O +
site O +
( O +
IRES O +
) O +
. O +

IRES O +
elements O +
have O +
been O +
proposed O +
to O +
be O +
involved O +
in O +
the O +
translation O +
of O +
picornavirus O +
mRNAs O +
and O +
some O +
cellular O +
mRNAs O +
. O +

Internal O +
ribosome O +
binding O +
likely O +
requires O +
the O +
interaction O +
of O +
trans O -
- O -
acting O +
factors O +
that O +
recognize O +
both O +
the O +
mRNA O +
and O +
the O +
ribosomal O +
complex O +
. O +

Five O +
cellular O +
proteins O +
( O +
p52 O +
, O +
p57 O +
, O +
p70 O +
, O +
p72 O +
, O +
and O +
p100 O +
) O +
cross O -
- O -
link O +
the O +
EMCV O +
IRES O +
or O +
fragments O +
of O +
the O +
IRES O +
. O +

For O +
one O +
of O +
these O +
proteins O +
, O +
p57 O +
, O +
binding O +
to O +
the O +
IRES O +
correlates O +
with O +
translation O +
. O +

Recently O +
, O +
p57 O +
was O +
identified O +
to O +
be O +
very O +
similar O +
, O +
if O +
not O +
identical O +
, O +
to O +
polypyrimidine O +
tract O -
- O -
binding O +
protein O +
. O +

On O +
the O +
basis O +
of O +
cross O -
- O -
linking O +
results O +
with O +
21 O +
different O +
EMCV O +
IRES O +
fragments O +
and O +
cytoplasmic O +
HeLa O +
extract O +
or O +
rabbit O +
reticulocyte O +
lysate O +
as O +
the O +
source O +
of O +
polypeptides O +
, O +
consensus O +
binding O +
sites O +
for O +
p52 O +
, O +
p57 O +
, O +
p70 O +
, O +
and O +
p100 O +
are O +
proposed O +
. O +

It O +
is O +
suggested O +
that O +
each O +
of O +
these O +
proteins O +
recognizes O +
primarily O +
a O +
structural O +
feature O +
of O +
the O +
RNA O +
rather O +
than O +
a O +
specific O +
sequence O +
. O +

Human O +
immunodeficiency O +
virus O +
type O +
1 O +
Nef O +
protein O +
down O -
- O -
regulates O +
transcription O +
factors O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O +
in O +
human O +
T O +
cells O +
in O +
vitro O +
after O +
T O -
- O -
cell O +
receptor O +
stimulation O +
. O +

Human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
negative O +
factor O +
( O +
Nef O +
) O +
has O +
been O +
shown O +
to O +
down O -
- O -
regulate O +
the O +
transcription O +
factors O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O +
in O +
vitro O +
. O +

To O +
define O +
the O +
mechanism O +
of O +
action O +
of O +
the O +
Nef O +
protein O +
, O +
the O +
signal O +
transduction O +
pathways O +
which O +
may O +
be O +
affected O +
in O +
T O +
cells O +
by O +
constitutive O +
expression O +
of O +
the O +
nef O +
gene O +
were O +
examined O +
. O +

Stimulation O +
of O +
T O +
cells O +
with O +
tumor O +
necrosis O +
factor O +
, O +
interleukin-1 O +
, O +
or O +
lipopolysaccharide O +
resulted O +
in O +
the O +
recruitment O +
of O +
transcriptional O +
factors O +
to O +
a O +
similar O +
level O +
whether O +
or O +
not O +
the O +
cells O +
expressed O +
the O +
nef O +
gene O +
. O +

On O +
the O +
other O +
hand O +
, O +
stimulation O +
of O +
T O +
cells O +
by O +
mitogens O +
or O +
antibodies O +
to O +
the O +
T O -
- O -
cell O +
receptor O +
( O +
TCR O +
) O +
- O +
CD3 O +
complex O +
resulted O +
in O +
the O +
down O -
- O -
regulation O +
of O +
transcriptional O +
factors O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O +
in O +
cells O +
expressing O +
the O +
nef O +
gene O +
compared O +
with O +
cells O +
not O +
expressing O +
the O +
nef O +
gene O +
. O +

Because O +
the O +
Nef O +
protein O +
does O +
not O +
affect O +
the O +
surface O +
expression O +
of O +
the O +
CD3 O +
-TCR O +
complex O +
, O +
we O +
conclude O +
that O +
the O +
Nef O +
protein O +
down O -
- O -
regulates O +
the O +
transcriptional O +
factors O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O +
in O +
T O +
cells O +
in O +
vitro O +
through O +
an O +
effect O +
on O +
the O +
TCR O -
- O -
dependent O +
signal O +
transduction O +
pathway O +
. O +

Characterization O +
of O +
the O +
human O +
gene O +
encoding O +
LBR O +
, O +
an O +
integral O +
protein O +
of O +
the O +
nuclear O +
envelope O +
inner O +
membrane O +
. O +

We O +
have O +
characterized O +
the O +
human O +
gene O +
encoding O +
LBR O +
, O +
an O +
integral O +
protein O +
of O +
the O +
nuclear O +
envelope O +
inner O +
membrane O +
. O +

Restriction O +
mapping O +
shows O +
that O +
the O +
transcription O +
unit O +
spans O +
approximately O +
35 O +
kilobases O +
. O +

A O +
transcription O +
start O +
site O +
is O +
located O +
approximately O +
4 O +
kilobases O +
5 O +
' O +
to O +
the O +
translation O +
initiation O +
codon O +
, O +
and O +
an O +
RNA O +
splice O +
of O +
3863 O +
bases O +
occurs O +
in O +
the O +
5'-untranslated O +
region O +
to O +
generate O +
mature O +
HeLa O +
cell O +
mRNA O +
. O +

5 O +
' O +
to O +
the O +
identified O +
transcription O +
start O +
site O +
are O +
two O +
CCAAT O +
sequences O +
and O +
potential O +
recognition O +
sites O +
for O +
several O +
transcription O +
factors O +
including O +
Sp1 O +
, O +
AP-1 O +
, O +
AP-2 O +
, O +
and O +
NF O -
- O -
kB O +
. O +

There O +
are O +
13 O +
protein O +
coding O +
exons O +
in O +
the O +
LBR O +
gene O +
. O +

LBR O +
's O +
nucleoplasmic O +
domain O +
is O +
encoded O +
by O +
exons O +
1 O -
- O -
4 O +
, O +
and O +
its O +
hydrophobic O +
domain O +
, O +
with O +
eight O +
putative O +
transmembrane O +
segments O +
, O +
is O +
encoded O +
by O +
exons O +
5 O -
- O -
13 O +
. O +

The O +
hydrophobic O +
domain O +
is O +
homologous O +
to O +
three O +
yeast O +
polypeptides O +
, O +
suggesting O +
that O +
this O +
higher O +
eukaryotic O +
gene O +
could O +
have O +
evolved O +
from O +
recombination O +
between O +
a O +
gene O +
that O +
encoded O +
a O +
soluble O +
nuclear O +
protein O +
and O +
a O +
membrane O +
protein O +
gene O +
similar O +
to O +
those O +
in O +
yeast O +
. O +

These O +
results O +
are O +
the O +
first O +
to O +
demonstrate O +
the O +
structural O +
organization O +
of O +
a O +
vertebrate O +
gene O +
encoding O +
an O +
integral O +
membrane O +
protein O +
of O +
the O +
nuclear O +
envelope O +
that O +
may O +
be O +
a O +
member O +
of O +
a O +
family O +
of O +
polypeptides O +
conserved O +
in O +
evolution O +
. O +

Sp1 O +
is O +
a O +
critical O +
factor O +
for O +
the O +
monocytic O +
specific O +
expression O +
of O +
human O +
CD14 O +
. O +

CD14 O +
is O +
a O +
membrane O +
glycoprotein O +
expressed O +
specifically O +
on O +
monocytes O +
and O +
macrophages O +
, O +
and O +
its O +
expression O +
is O +
markedly O +
increased O +
during O +
the O +
process O +
of O +
monocyte O +
differentiation O +
. O +

In O +
order O +
to O +
study O +
CD14 O +
gene O +
regulation O +
, O +
the O +
human O +
CD14 O +
gene O +
was O +
cloned O +
from O +
a O +
partial O +
EcoRI O +
digested O +
chromosome O +
5 O +
library O +
. O +

A O +
5.5-kilobase O +
genomic O +
clone O +
contained O +
the O +
full O -
- O -
length O +
CD14 O +
coding O +
sequence O +
and O +
4.2 O +
kilobases O +
of O +
5'-upstream O +
sequence O +
. O +

One O +
major O +
and O +
one O +
minor O +
transcription O +
start O +
site O +
were O +
identified O +
101 O +
and O +
130 O +
base O +
pairs O +
( O +
bp O +
) O +
upstream O +
, O +
respectively O +
, O +
from O +
the O +
protein O +
translation O +
start O +
ATG O +
. O +

A O +
DNA O +
fragment O +
containing O +
128 O +
bp O +
of O +
upstream O +
sequence O +
had O +
strong O +
, O +
monocyte O -
- O -
specific O +
promoter O +
activity O +
in O +
the O +
CD14 B-CellLine +
positive I-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
Mono B-CellLine +
Mac I-CellLine +
6 I-CellLine +
as O +
compared O +
to O +
the O +
nonmonocytic B-CellLine +
cell I-CellLine +
lines I-CellLine +
HeLa B-CellLine +
and O +
REX B-CellLine +
. O +

Four O +
regions O +
in O +
this O +
DNA O +
fragment O +
interact O +
with O +
nuclear O +
proteins O +
isolated O +
from O +
monocytic O +
cells O +
. O +

The O +
Sp1 O +
transcription O +
factor O +
bound O +
to O +
three O +
different O +
regions O +
in O +
the O +
CD14 O +
promoter O +
. O +

Mutation O +
of O +
the O +
major O +
Sp1 O +
binding O +
site O +
( O +
-110 O +
bp O +
) O +
decreased O +
tissue O -
- O -
specific O +
promoter O +
activity O +
, O +
and O +
these O +
results O +
, O +
together O +
with O +
transactivation O +
experiments O +
, O +
demonstrate O +
that O +
Sp1 O +
plays O +
a O +
critical O +
role O +
in O +
the O +
tissue O -
- O -
specific O +
expression O +
of O +
CD14 O +
in O +
monocytic O +
cells O +
. O +

CD14 O +
Sp1 O +
site O +
oligonucleotides O +
bound O +
preferentially O +
to O +
a O +
105-kDa O +
Sp1 O +
species O +
, O +
which O +
is O +
present O +
in O +
higher O +
relative O +
levels O +
in O +
monocytic O +
than O +
non O -
- O -
monocytic O +
cells O +
, O +
suggesting O +
that O +
modification O +
of O +
Sp1 O +
, O +
such O +
as O +
phosphorylation O +
, O +
may O +
explain O +
how O +
the O +
Sp1 O +
site O +
mediates O +
monocytic O +
specific O +
promoter O +
activity O +
. O +

Genes O +
encoding O +
general O +
initiation O +
factors O +
for O +
RNA O +
polymerase O +
II O +
transcription O +
are O +
dispersed O +
in O +
the O +
human O +
genome O +
. O +

General O +
transcription O +
factors O +
are O +
required O +
for O +
accurate O +
initiation O +
of O +
transcription O +
by O +
RNA O +
polymerase O +
II O +
. O +

Human O +
cDNAs O +
encoding O +
subunits O +
of O +
these O +
factors O +
have O +
been O +
cloned O +
and O +
sequenced O +
. O +

Using O +
fluorescence O +
in O +
situ O +
hybridization O +
( O +
FISH O +
) O +
, O +
we O +
show O +
here O +
that O +
the O +
genes O +
encoding O +
the O +
TATA O -
- O -
box O +
binding O +
protein O +
( O +
TBP O +
) O +
, O +
TFIIB O +
, O +
TFIIE O +
alpha O +
, O +
TFIIE O +
beta O +
, O +
RAP30 O +
, O +
RAP74 O +
and O +
the O +
62 O +
kDa O +
subunit O +
, O +
of O +
TFIIH O +
are O +
located O +
at O +
the O +
human O +
chromosomal O +
bands O +
6q26 O -
- O -
27 O +
, O +
1p21 O -
- O -
22 O +
, O +
3q21 O -
- O -
24 O +
, O +
8p12 O +
, O +
13q14 O +
, O +
19p13.3 O +
and O +
11p14 O -
- O -
15.1 O +
, O +
respectively O +
. O +

This O +
dispersed O +
localization O +
of O +
a O +
group O +
of O +
functionally O +
related O +
gene O +
provides O +
insights O +
into O +
the O +
molecular O +
mechanism O +
of O +
human O +
genome O +
evolution O +
and O +
their O +
possible O +
involvement O +
in O +
human O +
diseases O +
. O +

ERP O +
, O +
a O +
new O +
member O +
of O +
the O +
ets O +
transcription O +
factor O -
/ O -
oncoprotein O +
family O +
: O +
cloning O +
, O +
characterization O +
, O +
and O +
differential O +
expression O +
during O +
B O -
- O -
lymphocyte O +
development O +
. O +

The O +
ets O +
gene O +
family O +
encodes O +
a O +
group O +
of O +
proteins O +
which O +
function O +
as O +
transcription O +
factors O +
under O +
physiological O +
conditions O +
and O +
, O +
if O +
aberrantly O +
expressed O +
, O +
can O +
cause O +
cellular O +
transformation O +
. O +

We O +
have O +
recently O +
identified O +
two O +
regulatory O +
elements O +
in O +
the O +
murine O +
immunoglobulin O +
heavy O -
- O -
chain O +
( O +
IgH O +
) O +
enhancer O +
, O +
pi O +
and O +
microB O +
, O +
which O +
exhibit O +
striking O +
similarity O +
to O +
binding O +
sites O +
for O +
ets O -
- O -
related O +
proteins O +
. O +

To O +
identify O +
ets O -
- O -
related O +
transcriptional O +
regulators O +
expressed O +
in O +
pre O -
- O -
B O +
lymphocytes O +
that O +
may O +
interact O +
with O +
either O +
the O +
pi O +
or O +
the O +
microB O +
site O +
, O +
we O +
have O +
used O +
a O +
PCR O +
approach O +
with O +
degenerate O +
oligonucleotides O +
encoding O +
conserved O +
sequences O +
in O +
all O +
members O +
of O +
the O +
ets O +
family O +
. O +

We O +
have O +
cloned O +
the O +
gene O +
for O +
a O +
new O +
ets O -
- O -
related O +
transcription O +
factor O +
, O +
ERP O +
( O +
ets O -
- O -
related O +
protein O +
) O +
, O +
from O +
the O +
murine B-CellLine +
pre I-CellLine -
- I-CellLine -
B I-CellLine +
cell I-CellLine +
line I-CellLine +
BASC B-CellLine +
6C2 I-CellLine +
and O +
from O +
mouse O +
lung O +
tissue O +
. O +

The O +
ERP O +
protein O +
contains O +
a O +
region O +
of O +
high O +
homology O +
with O +
the O +
ETS O +
DNA O -
- O -
binding O +
domain O +
common O +
to O +
all O +
members O +
of O +
the O +
ets O +
transcription O +
factor O -
/ O -
oncoprotein O +
family O +
. O +

Three O +
additional O +
smaller O +
regions O +
show O +
homology O +
to O +
the O +
ELK-1 O +
and O +
SAP-1 O +
genes O +
, O +
a O +
subgroup O +
of O +
the O +
ets O +
gene O +
family O +
that O +
interacts O +
with O +
the O +
serum O +
response O +
factor O +
. O +

Full O -
- O -
length O +
ERP O +
expresses O +
only O +
negligible O +
DNA O -
- O -
binding O +
activity O +
by O +
itself O +
. O +

Removal O +
of O +
the O +
carboxy O +
terminus O +
enables O +
ERP O +
to O +
interact O +
with O +
a O +
variety O +
of O +
ets O -
- O -
binding O +
sites O +
including O +
the O +
E74 O +
site O +
, O +
the O +
IgH O +
enhancer O +
pi O +
site O +
, O +
and O +
the O +
lck O +
promoter O +
ets O +
site O +
, O +
suggesting O +
a O +
carboxy O -
- O -
terminal O +
negative O +
regulatory O +
domain O +
. O +

At O +
least O +
three O +
ERP O -
- O -
related O +
transcripts O +
are O +
expressed O +
in O +
a O +
variety O +
of O +
tissues O +
. O +

However O +
, O +
within O +
the O +
B O -
- O -
cell O +
lineage O +
, O +
ERP O +
is O +
highly O +
expressed O +
primarily O +
at O +
early O +
stages O +
of O +
B O -
- O -
lymphocyte O +
development O +
, O +
and O +
expression O +
declines O +
drastically O +
upon O +
B O -
- O -
cell O +
maturation O +
, O +
correlating O +
with O +
the O +
enhancer O +
activity O +
of O +
the O +
IgH O +
pi O +
site O +
. O +

These O +
data O +
suggest O +
that O +
ERP O +
might O +
play O +
a O +
role O +
in O +
B O -
- O -
cell O +
development O +
and O +
in O +
IgH O +
gene O +
regulation O +
. O +

Functional O +
block O +
for O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3-mediated O +
gene O +
regulation O +
in O +
human O +
B O +
lymphocytes O +
. O +

Elements O +
necessary O +
for O +
the O +
steroid O +
hormone O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
1 O +
alpha O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
) O +
to O +
induce O +
a O +
biological O +
response O +
include O +
the O +
presence O +
of O +
specific O +
intracellular O +
receptors O +
( O +
vitamin O +
D3 O +
receptors O +
( O +
VDR O +
) O +
) O +
and O +
modulation O +
of O +
gene O +
expression O +
via O +
hormone O -
- O -
activated O +
receptor O +
binding O +
to O +
regulatory O +
regions O +
of O +
target O +
genes O +
. O +

These O +
parameters O +
were O +
examined O +
in O +
normal O +
and O +
Epstein B-CellLine -
- I-CellLine -
Barr I-CellLine +
virus I-CellLine -
- I-CellLine -
immortalized I-CellLine +
human I-CellLine +
B I-CellLine +
cells I-CellLine +
and O +
compared O +
with O +
1 B-CellLine +
alpha I-CellLine +
, I-CellLine +
25- I-CellLine +
( I-CellLine +
OH I-CellLine +
) I-CellLine +
2D3-responsive I-CellLine +
cells I-CellLine +
of O +
the O +
T O +
and O +
monocytic O +
lineages O +
. O +

Although O +
resting O +
tonsillar O +
B O +
cells O +
did O +
not O +
express O +
VDR O +
mRNA O +
, O +
activation O +
of O +
these O +
cells O +
with O +
interleukin-4 O +
induced O +
VDR O +
in O +
the O +
absence O +
of O +
exogenously O +
supplemented O +
1 O +
alpha O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
. O +

As O +
indicators O +
of O +
hormone O -
- O -
mediated O +
gene O +
regulation O +
we O +
analyzed O +
modulation O +
of O +
CD23 O +
, O +
a O +
common O +
B O +
cell O -
/ O -
monocyte O +
surface O +
antigen O +
, O +
and O +
24-hydroxylase O +
. O +

1 O +
alpha O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
inhibited O +
CD23 O +
expression O +
in O +
U937 B-CellLine +
cells I-CellLine +
, O +
yet O +
failed O +
to O +
modulate O +
CD23 O +
expression O +
in O +
B O +
cells O +
. O +

Furthermore O +
, O +
1 O +
alpha O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
induced O +
24-hydroxylase O +
mRNA O +
expression O +
and O +
metabolic O +
activity O +
in O +
both O +
U937 B-CellLine +
cells I-CellLine +
and O +
lectin O -
- O -
activated O +
T O +
cells O +
, O +
yet O +
failed O +
to O +
induce O +
24-hydroxylase O +
mRNA O +
or O +
its O +
metabolic O +
activity O +
in O +
B O +
cells O +
. O +

These O +
findings O +
suggest O +
that O +
although O +
human O +
B O +
lymphocytes O +
can O +
express O +
VDR O +
mRNA O +
and O +
protein O +
, O +
they O +
exhibit O +
a O +
functional O +
block O +
for O +
vitamin O +
D O -
- O -
dependent O +
gene O +
regulation O +
. O +

Interferon O +
alpha O +
selectively O +
affects O +
expression O +
of O +
the O +
human O +
myeloid O +
cell O +
nuclear O +
differentiation O +
antigen O +
in O +
late O +
stage O +
cells O +
in O +
the O +
monocytic O +
but O +
not O +
the O +
granulocytic O +
lineage O +
. O +

The O +
human O +
myeloid O +
cell O +
nuclear O +
differentiation O +
antigen O +
( O +
MNDA O +
) O +
is O +
expressed O +
constitutively O +
in O +
cells O +
of O +
the O +
myeloid O +
lineage O +
, O +
appearing O +
in O +
myeloblast O +
cells O +
in O +
some O +
cases O +
of O +
acute O +
myeloid O +
leukemia O +
and O +
consistently O +
being O +
detected O +
in O +
promyelocyte O +
stage O +
cells O +
as O +
well O +
as O +
in O +
all O +
later O +
stage O +
cells O +
including O +
peripheral O +
blood O +
monocytes O +
and O +
granulocytes O +
. O +

The O +
human B-CellLine +
myeloid I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
HL-60 B-CellLine +
, O +
U937 B-CellLine +
, O +
and O +
THP-1 B-CellLine +
, O +
express O +
similar O +
levels O +
of O +
immunochemically O +
detectable O +
MNDA O +
. O +

Although O +
, O +
the O +
level O +
of O +
MNDA O +
mRNA O +
in O +
primary O +
monocytes O +
is O +
very O +
low O +
it O +
was O +
up O -
- O -
regulated O +
at O +
6 O +
h O +
following O +
the O +
addition O +
of O +
interferon O +
alpha O +
. O +

The O +
effect O +
of O +
interferon O +
alpha O +
on O +
the O +
MNDA O +
mRNA O +
is O +
also O +
observed O +
in O +
the O +
cell B-CellLine +
lines I-CellLine +
HL-60 B-CellLine +
, O +
U937 B-CellLine +
, O +
and O +
THP-1 B-CellLine +
. O +

The O +
MNDA O +
mRNA O +
level O +
in O +
primary O +
granulocytes O +
was O +
unaffected O +
by O +
addition O +
of O +
interferon O +
alpha O +
and O +
other O +
agents O +
including O +
interferon O +
gamma O +
, O +
endotoxin O +
, O +
poly O +
( O +
I O +
) O +
.poly O +
( O +
C O +
) O +
, O +
and O +
FMLP O +
. O +

The O +
MNDA O +
mRNA O +
level O +
in O +
the O +
myeloid B-CellLine +
cell I-CellLine +
lines I-CellLine +
was O +
also O +
unaffected O +
by O +
the O +
latter O +
four O +
agents O +
. O +

Induction O +
of O +
differentiation O +
in O +
the O +
myeloid B-CellLine +
cell I-CellLine +
lines I-CellLine +
with O +
phorbol O +
ester O +
induces O +
monocyte O +
differentiation O +
which O +
was O +
accompanied O +
by O +
a O +
decrease O +
in O +
MNDA O +
mRNA O +
level O +
. O +

This O +
reduced O +
level O +
of O +
mRNA O +
could O +
then O +
be O +
elevated O +
with O +
subsequent O +
interferon O +
alpha O +
treatment O +
. O +

The O +
effects O +
of O +
phorbol O +
ester O +
on O +
MNDA O +
mRNA O +
appeared O +
to O +
be O +
associated O +
with O +
induced O +
differentiation O +
since O +
inhibiting O +
cell O +
proliferation O +
did O +
not O +
alter O +
the O +
level O +
of O +
MNDA O +
mRNA O +
and O +
cell O +
cycle O +
variation O +
in O +
MNDA O +
mRNA O +
levels O +
were O +
not O +
observed O +
. O +

The O +
ability O +
of O +
interferon O +
alpha O +
to O +
up O -
- O -
regulate O +
MNDA O +
mRNA O +
in O +
phorbol O +
ester O +
treated O +
myeloid B-CellLine +
cell I-CellLine +
lines I-CellLine +
is O +
consistent O +
with O +
the O +
observations O +
made O +
in O +
primary O +
monocytes O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

Induction O +
of O +
proto O -
- O -
oncogene O +
and O +
cytokine O +
expression O +
in O +
human O +
peripheral O +
blood O +
monocytes O +
and O +
the O +
monocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
THP-1 B-CellLine +
after O +
stimulation O +
with O +
mycoplasma O -
- O -
derived O +
material O +
MDHM O +
. O +

Mycoplasma O +
fermentans O -
- O -
derived O +
high O -
- O -
molecular O -
- O -
weight O +
material O +
( O +
MDHM O +
) O +
was O +
originally O +
described O +
to O +
induce O +
differentiation O +
of O +
murine O +
thymocytes O +
to O +
cytolytic O +
effector O +
T O -
- O -
cells O +
by O +
stimulating O +
IL-6 O +
release O +
from O +
adherent O +
cells O +
. O +

This O +
study O +
shows O +
that O +
human O +
peripheral O +
blood O +
monocytes O +
( O +
PBMo O +
) O +
also O +
respond O +
to O +
MDHM O +
with O +
increases O +
in O +
IL-1 O +
beta O +
, O +
IL-6 O +
and O +
TNF O +
alpha O +
expression O +
, O +
both O +
at O +
the O +
mRNA O +
and O +
protein O +
level O +
. O +

The O +
induced O +
expression O +
of O +
IL-1 O +
beta O +
and O +
TNF O +
alpha O +
mRNA O +
in O +
the O +
monocytic O +
THP-1 B-CellLine +
cell I-CellLine +
line I-CellLine +
increased O +
as O +
quickly O +
as O +
in O +
primary O +
cells O +
. O +

In O +
contrast O +
to O +
PBMo O +
, O +
THP-1 B-CellLine +
and O +
14 O +
other O +
monocytic B-CellLine -
/ I-CellLine -
myeloid I-CellLine +
leukemia I-CellLine -
- I-CellLine -
derived I-CellLine +
cell I-CellLine +
lines I-CellLine +
did O +
not O +
secrete O +
measurable O +
amounts O +
of O +
the O +
cytokines O +
upon O +
treatment O +
with O +
MDHM O +
. O +

IL-1 O +
beta O +
and O +
IL-6 O +
genes O +
contain O +
AP-1 O +
binding O +
sites O +
as O +
regulatory O +
elements O +
, O +
the O +
AP-1 O +
protein O +
being O +
composed O +
of O +
c O -
- O -
jun O +
and O +
c O -
- O -
fos O +
gene O +
products O +
. O +

In O +
THP-1 B-CellLine +
cells I-CellLine +
c O -
- O -
jun O +
mRNA O +
expression O +
increased O +
after O +
incubation O +
with O +
MDHM O +
while O +
positive O +
c O -
- O -
fos O +
expression O +
remained O +
unaffected O +
. O +

Although O +
these O +
data O +
suggest O +
AP-1 O +
regulated O +
cytokine O +
mRNA O +
expression O +
, O +
results O +
from O +
PBMo O +
are O +
not O +
in O +
accordance O +
with O +
this O +
notion O +
. O +

In O +
the O +
primary O +
cells O +
MDHM O -
- O -
induced O +
elevation O +
of O +
cytokine O +
mRNA O +
levels O +
was O +
preceded O +
by O +
a O +
downregulation O +
of O +
c O -
- O -
fos O +
expression O +
while O +
positive O +
c O -
- O -
jun O +
expression O +
was O +
not O +
modulated O +
. O +

c O -
- O -
myc O +
mRNA O +
expression O +
, O +
constitutively O +
high O +
in O +
THP-1 B-CellLine +
cells I-CellLine +
, O +
was O +
induced O +
in O +
MDHM O -
- O -
stimulated O +
PBMo O +
. O +

In O +
conclusion O +
, O +
MDHM O -
- O -
stimulated O +
induction O +
of O +
cytokine O +
mRNA O +
expression O +
was O +
accompanied O +
by O +
different O +
proto O -
- O -
oncogene O +
responses O +
in O +
PBMo O +
and O +
THP-1 B-CellLine +
cells I-CellLine +
. O +

These O +
differences O +
may O +
represent O +
different O +
regulatory O +
pathways O +
of O +
the O +
two O +
cell O +
systems O +
. O +

Alternatively O +
, O +
these O +
data O +
support O +
the O +
notion O +
that O +
neither O +
AP-1 O +
nor O +
the O +
c O -
- O -
myc O +
protein O +
are O +
involved O +
in O +
the O +
MDHM O -
- O -
induced O +
increase O +
in O +
IL-1 O +
beta O +
, O +
IL-6 O +
or O +
TNF O +
alpha O +
mRNA O +
levels O +
. O +

Furthermore O +
, O +
the O +
present O +
results O +
demonstrate O +
clearly O +
that O +
mycoplasma O +
products O +
can O +
have O +
a O +
profound O +
impact O +
on O +
the O +
activation O +
status O +
of O +
eukaryotic O +
cells O +
. O +

All O -
- O -
trans O +
retinoic O +
acid O +
and O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
co O -
- O -
operate O +
to O +
promote O +
differentiation O +
of O +
the O +
human B-CellLine +
promyeloid I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
HL60 B-CellLine +
to O +
monocytes O +
. O +

A O +
basis O +
for O +
differentiation O +
therapy O +
of O +
leukemias O +
is O +
provided O +
by O +
knowledge O +
of O +
agents O +
which O +
induce O +
specific O +
lineage O +
maturation O +
. O +

All O -
- O -
trans O +
retinoic O +
acid O +
( O +
RA O +
) O +
induces O +
differentiation O +
of O +
HL60 B-CellLine +
cells I-CellLine +
to O +
neutrophils O +
and O +
is O +
used O +
to O +
treat O +
acute O +
promyelocytic O +
leukemia O +
. O +

We O +
observed O +
that O +
RA O +
did O +
not O +
induced O +
neutrophil O +
differentiation O +
in O +
serum B-CellLine -
- I-CellLine -
free I-CellLine +
grown I-CellLine +
HL60 I-CellLine +
cells I-CellLine +
whereas O +
50 O +
nM O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
D3 O +
) O +
induced O +
maximal O +
monocyte O +
differentiation O +
. O +

Increasing O +
RA O +
concentrations O +
reduced O +
the O +
D3 O +
concentration O +
required O +
for O +
monocyte O +
differentiation O +
. O +

Cells O +
treated O +
with O +
5 O +
nM O +
D3 O +
showed O +
little O +
response O +
, O +
but O +
differentiated O +
maximally O +
with O +
5 O +
nM O +
D3 O +
and O +
10 O +
nM O +
RA O +
. O +

The O +
D3 O +
analogs O +
MC903 O +
, O +
EB1089 O +
and O +
KH1060 O +
were O +
more O +
potent O +
inducers O +
of O +
monocyte O +
differentiation O +
. O +

The O +
extent O +
to O +
which O +
analog O +
activity O +
was O +
increased O +
after O +
cotreatment O +
with O +
RA O +
was O +
inversely O +
related O +
to O +
potency O +
. O +

Twenty O -
- O -
four O +
hour O +
treatment O +
with O +
10 O +
nM O +
RA B-CellLine +
primed I-CellLine +
cells I-CellLine +
for O +
response O +
to O +
5 O +
nM O +
D3 O +
; O +
the O +
reverse O +
sequence O +
being O +
ineffective O +
. O +

Priming O +
with O +
10 O +
nM O +
RA O +
, O +
or O +
subsequent O +
treatment O +
with O +
D3 O +
( O +
5 O +
nM O +
) O +
, O +
did O +
not O +
alter O +
expression O +
of O +
mRNAs O +
encoding O +
receptors O +
for O +
D3 O +
( O +
VDR O +
) O +
, O +
RA O +
( O +
RAR O +
alpha O +
) O +
or O +
9-CIS O +
RA O +
( O +
RXR O +
alpha O +
, O +
beta O +
, O +
gamma O +
) O +
. O +

That O +
RA O +
promotes O +
both O +
neutrophil O +
and O +
monocyte O +
differentiation O +
has O +
implications O +
for O +
the O +
use O +
of O +
RA O +
and O +
D3 O +
in O +
treatment O +
of O +
leukemias O +
and O +
provides O +
insight O +
into O +
mechanisms O +
whereby O +
RAR O +
, O +
VDR O +
and O +
RXR O +
facilitate O +
monocyte O +
differentiation O +
. O +

Alternative O +
splicing O +
of O +
RNA O +
transcripts O +
encoded O +
by O +
the O +
murine O +
p105 O +
NF O -
- O -
kappa O +
B O +
gene O +
generates O +
I O +
kappa O +
B O +
gamma O +
isoforms O +
with O +
different O +
inhibitory O +
activities O +
. O +

The O +
gene O +
encoding O +
the O +
105-kDa O +
protein O +
( O +
p105 O +
) O +
precursor O +
of O +
the O +
p50 O +
subunit O +
of O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
also O +
encodes O +
a O +
p70 O +
I O +
kappa O +
B O +
protein O +
, O +
I O +
kappa O +
B O +
gamma O +
, O +
which O +
is O +
identical O +
to O +
the O +
C O -
- O -
terminal O +
607 O +
amino O +
acids O +
of O +
p105 O +
. O +

Here O +
we O +
show O +
that O +
alternative O +
RNA O +
splicing O +
generates O +
I O +
kappa O +
B O +
gamma O +
isoforms O +
with O +
properties O +
different O +
from O +
those O +
of O +
p70 O +
. O +

One O +
63-kDa O +
isoform O +
, O +
termed O +
I O +
kappa O +
B O +
gamma-1 O +
, O +
which O +
lacks O +
59 O +
amino O +
acids O +
C O -
- O -
terminal O +
to O +
ankyrin O +
repeat O +
7 O +
, O +
has O +
a O +
novel O +
35-amino O +
acid O +
C O +
terminus O +
encoded O +
by O +
an O +
alternative O +
reading O +
frame O +
of O +
the O +
p105 O +
gene O +
. O +

A O +
55-kDa O +
isoform O +
, O +
I O +
kappa O +
B O +
gamma-2 O +
, O +
lacks O +
the O +
190 O +
C O -
- O -
terminal O +
amino O +
acids O +
of O +
p70 O +
I O +
kappa O +
B O +
gamma O +
. O +

In O +
contrast O +
to O +
p70 O +
I O +
kappa O +
B O +
gamma O +
, O +
which O +
is O +
a O +
cytoplasmic O +
protein O +
, O +
I O +
kappa O +
B O +
gamma-1 O +
is O +
found O +
in O +
both O +
the O +
cytoplasm O +
and O +
nucleus O +
, O +
whereas O +
I O +
kappa O +
B O +
gamma-2 O +
is O +
predominantly O +
nuclear O +
. O +

The O +
I O +
kappa O +
B O +
gamma O +
isoforms O +
also O +
display O +
differences O +
in O +
specificity O +
and O +
affinity O +
for O +
Rel O -
/ O -
NF O -
- O -
kappa O +
B O +
proteins O +
. O +

While O +
p70 O +
I O +
kappa O +
B O +
gamma O +
inhibits O +
p50- O +
, O +
p65- O +
, O +
and O +
c O -
- O -
Rel O -
- O -
mediated O +
transactivation O +
and/or O +
DNA O +
binding O +
, O +
both O +
I O +
kappa O +
B O +
gamma-1 O +
and O +
I O +
kappa O +
B O +
gamma-2 O +
are O +
specific O +
for O +
p50 O +
and O +
have O +
different O +
affinities O +
for O +
this O +
subunit O +
. O +

The O +
absence O +
in O +
I O +
kappa O +
B O +
gamma-1 O +
and O +
I O +
kappa O +
B O +
gamma-2 O +
of O +
a O +
protein O +
kinase O +
A O +
site O +
whose O +
phosphorylation O +
modulates O +
p70 O +
I O +
kappa O +
B O +
gamma O +
inhibitory O +
activity O +
suggests O +
that O +
alternative O +
RNA O +
splicing O +
may O +
be O +
used O +
to O +
generate O +
I O +
kappa O +
B O +
gamma O +
isoforms O +
that O +
respond O +
differently O +
to O +
intracellular O +
signals O +
. O +

Some O +
antioxidants O +
inhibit O +
, O +
in O +
a O +
co O -
- O -
ordinate O +
fashion O +
, O +
the O +
production O +
of O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
, O +
IL O -
- O -
beta O +
, O +
and O +
IL-6 O +
by O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
. O +

Some O +
antioxidants O +
, O +
including O +
butylated O +
hydroxyanisole O +
( O +
BHA O +
) O +
, O +
tetrahydropapaveroline O +
( O +
THP O +
) O +
, O +
nordihydroguiauretic O +
acid O +
, O +
and O +
10 O +
, O +
11-dihydroxyaporphine O +
( O +
DHA O +
) O +
, O +
were O +
found O +
to O +
be O +
potent O +
inhibitors O +
of O +
the O +
production O +
of O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
-alpha O +
, O +
IL-1 O +
beta O +
, O +
and O +
IL-6 O +
by O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
stimulated O +
by O +
lipopolysaccharide O +
( O +
LPS O +
) O +
( O +
IC50s O +
in O +
the O +
low O +
micromolar O +
range O +
) O +
. O +

Inhibition O +
of O +
cytokine O +
production O +
was O +
gene O +
selective O +
and O +
not O +
due O +
to O +
general O +
effects O +
on O +
protein O +
synthesis O +
. O +

Inhibition O +
of O +
cytokine O +
production O +
by O +
PBMC O +
was O +
observed O +
also O +
when O +
other O +
inducers O +
were O +
used O +
( O +
staphylococci O +
, O +
silica O +
, O +
zymosan O +
) O +
. O +

Much O +
higher O +
concentrations O +
of O +
other O +
antioxidants O +
-- O +
including O +
ascorbic O +
acid O +
, O +
trolox O +
, O +
alpha O -
- O -
tocopherol O +
, O +
butylated O +
hydroxytoluene O +
, O +
and O +
the O +
5-lipoxygenase O +
inhibitor O +
zileuton O +
-- O +
did O +
not O +
affect O +
the O +
production O +
of O +
these O +
cytokines O +
. O +

The O +
active O +
compounds O +
did O +
not O +
inhibit O +
IL-1 O +
-induced O +
production O +
of O +
IL-6 O +
in O +
fibroblasts O +
, O +
showing O +
the O +
cell O +
selectivity O +
of O +
the O +
effect O +
. O +

Antioxidant O -
- O -
mediated O +
inhibition O +
of O +
cytokine O +
production O +
was O +
correlated O +
with O +
low O +
levels O +
of O +
the O +
corresponding O +
messenger O +
RNAs O +
. O +

Nuclear O +
run O -
- O -
on O +
experiments O +
showed O +
that O +
THP O +
inhibited O +
transcription O +
of O +
the O +
IL-1 O +
beta O +
gene O +
. O +

THP O +
decreased O +
the O +
concentration O +
of O +
the O +
transcription O +
factors O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O +
detected O +
in O +
nuclear O +
extracts O +
of O +
PBMC O +
cultured O +
in O +
the O +
presence O +
or O +
absence O +
of O +
LPS O +
. O +

THP O +
and O +
DHA O +
markedly O +
decreased O +
the O +
levels O +
of O +
TNF O -
- O -
alpha O +
and O +
IL-1 O +
beta O +
in O +
the O +
circulation O +
of O +
mice O +
following O +
LPS O +
injection O +
. O +

Thus O +
antioxidants O +
vary O +
widely O +
in O +
potency O +
as O +
inhibitors O +
of O +
the O +
activation O +
of O +
transcription O +
factors O +
and O +
of O +
the O +
transcription O +
of O +
genes O +
for O +
pro O -
- O -
inflammatory O +
cytokines O +
. O +

Coordinate O +
inhibition O +
of O +
the O +
transcription O +
of O +
genes O +
for O +
inflammatory O +
cytokines O +
could O +
provide O +
a O +
strategy O +
for O +
therapy O +
of O +
diseases O +
with O +
inflammatory O +
pathogenesis O +
and O +
for O +
septic O +
shock O +
. O +

An O +
intricate O +
arrangement O +
of O +
binding O +
sites O +
for O +
the O +
Ets O +
family O +
of O +
transcription O +
factors O +
regulates O +
activity O +
of O +
the O +
alpha O +
4 O +
integrin O +
gene O +
promoter O +
. O +

alpha O +
4 O +
integrins O +
mediate O +
cell O -
- O -
cell O +
and O +
cell O -
- O -
extracellular O +
matrix O +
interactions O +
that O +
are O +
critical O +
for O +
maturation O +
and O +
function O +
of O +
the O +
immune O +
system O +
as O +
well O +
as O +
differentiation O +
of O +
skeletal O +
muscle O +
. O +

Here O +
we O +
examine O +
molecular O +
mechanisms O +
controlling O +
the O +
pattern O +
of O +
alpha O +
4 O +
expression O +
. O +

The O +
activity O +
of O +
constructs O +
containing O +
5 O +
' O +
deletion O +
mutants O +
of O +
the O +
alpha O +
4 O +
gene O +
promoter O +
was O +
compared O +
in O +
transfection O +
assays O +
into O +
cell B-CellLine +
lines I-CellLine +
that O +
express O +
alpha O +
4 O +
and O +
cell B-CellLine +
lines I-CellLine +
that O +
do O +
not O +
. O +

The O +
sequence O +
between O +
position O +
-42 O +
and O +
-76 O +
base O +
pairs O +
( O +
bp O +
) O +
was O +
required O +
for O +
efficient O +
transcription O +
in O +
cells O +
that O +
express O +
alpha O +
4 O +
, O +
but O +
it O +
showed O +
no O +
activity O +
in O +
HeLa B-CellLine +
cells I-CellLine +
, O +
which O +
do O +
not O +
express O +
alpha O +
4 O +
. O +

Three O +
binding O +
sites O +
for O +
the O +
Ets O +
family O +
of O +
transcription O +
factors O +
are O +
found O +
in O +
this O +
region O +
: O +
two O +
adjacent O +
sites O +
at O +
positions O +
-50 O +
and O +
-54 O +
bp O +
and O +
a O +
more O +
5 O +
' O +
site O +
at O +
position O +
-67 O +
bp O +
. O +

Using O +
a O +
series O +
of O +
constructs O +
containing O +
deletions O +
and O +
mutations O +
in O +
this O +
region O +
, O +
we O +
found O +
that O +
the O +
3'-most O +
site O +
alone O +
was O +
sufficient O +
for O +
binding O +
GA O -
- O -
binding O +
protein O +
alpha O +
( O +
GABP O +
alpha O +
) O +
/GABP O +
beta O +
and O +
for O +
a O +
low O +
level O +
of O +
transcriptional O +
activation O +
. O +

When O +
all O +
three O +
sites O +
were O +
present O +
, O +
a O +
second O +
complex O +
` O -
` O +
a O +
'' O +
was O +
detected O +
, O +
which O +
contains O +
an O +
unknown O +
member O +
of O +
the O +
Ets O +
family O +
. O +

Formation O +
of O +
complex O +
a O +
was O +
cell O -
- O -
type O +
specific O +
and O +
correlated O +
with O +
a O +
high O +
level O +
of O +
transcription O +
. O +

Deletion O +
of O +
the O +
5'-most O +
Ets O +
site O +
had O +
no O +
effect O +
on O +
binding O +
to O +
GABP O +
alpha O -
/ O -
GABP O +
beta O +
, O +
but O +
it O +
eliminated O +
a O +
. O +

Concomitant O +
with O +
this O +
loss O +
of O +
a O +
, O +
a O +
new O +
Ets-1-containing O +
complex O +
` O -
` O +
c O +
` O -
` O +
appeared O +
. O +

Complex O +
c O +
substituted O +
efficiently O +
for O +
complex O +
a O +
in O +
transcriptional O +
activation O +
. O +

We O +
conclude O +
that O +
although O +
neither O +
of O +
the O +
two O +
5'-most O +
Ets O +
sites O +
alone O +
binds O +
nuclear O +
protein O +
, O +
they O +
appear O +
to O +
act O +
as O +
modulators O +
which O +
control O +
the O +
pattern O +
of O +
Ets O +
proteins O +
that O +
bind O +
the O +
alpha O +
4 O +
gene O +
promoter O +
. O +

This O +
arrangement O +
of O +
Ets O +
sites O +
, O +
coupled O +
with O +
the O +
tissue- O +
and O +
developmental O -
- O -
specific O +
expression O +
of O +
Ets O +
members O +
, O +
likely O +
play O +
a O +
key O +
role O +
in O +
defining O +
the O +
pattern O +
of O +
alpha O +
4 O +
integrin O +
. O +

Lipopolysaccharide O +
induction O +
of O +
tissue O +
factor O +
gene O +
expression O +
in O +
monocytic O +
cells O +
is O +
mediated O +
by O +
binding O +
of O +
c O -
- O -
Rel O -
/ O -
p65 O +
heterodimers O +
to O +
a O +
kappa O +
B O -
- O -
like O +
site O +
. O +

Exposure O +
of O +
monocytic O +
cells O +
to O +
bacterial O +
lipopolysaccharide O +
( O +
LPS O +
) O +
activates O +
the O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
family O +
of O +
proteins O +
and O +
leads O +
to O +
the O +
rapid O +
induction O +
of O +
inflammatory O +
gene O +
products O +
, O +
including O +
tissue O +
factor O +
( O +
TF O +
) O +
. O +

TF O +
is O +
the O +
primary O +
cellular O +
initiator O +
of O +
the O +
coagulation O +
protease O +
cascades O +
. O +

Here O +
we O +
report O +
the O +
characterization O +
of O +
a O +
nuclear O +
complex O +
from O +
human O +
monocytic O +
cells O +
that O +
bound O +
to O +
a O +
kappa O +
B O -
- O -
like O +
site O +
, O +
5'-CGGAGTTTCC-3 O +
' O +
, O +
in O +
the O +
5'-flanking O +
region O +
of O +
the O +
human O +
TF O +
gene O +
. O +

This O +
nuclear O +
complex O +
was O +
activated O +
by O +
LPS O +
with O +
kinetics O +
that O +
preceded O +
induction O +
of O +
the O +
TF O +
gene O +
. O +

In O +
vitro O +
binding O +
studies O +
demonstrated O +
that O +
the O +
TF O +
site O +
bound O +
translated O +
c O -
- O -
Rel O +
and O +
p65 O +
homodimers O +
but O +
not O +
p50 O -
/ O -
p65 O +
heterodimers O +
or O +
p50 O +
homodimers O +
. O +

Base O -
- O -
pair O +
substitutions O +
in O +
the O +
TF O +
site O +
indicated O +
that O +
the O +
presence O +
of O +
a O +
cytosine O +
at O +
position O +
1 O +
precluded O +
binding O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

In O +
fact O +
, O +
under O +
low O -
- O -
ionic O -
- O -
strength O +
conditions O +
, O +
the O +
TF O +
complex O +
did O +
not O +
migrate O +
with O +
translated O +
p50 O -
/ O -
p65 O +
dimers O +
but O +
instead O +
comigrated O +
with O +
c O -
- O -
Rel O -
/ O -
p65 O +
dimers O +
. O +

Antibodies O +
against O +
the O +
NF O -
- O -
kappa O +
B O +
and O +
Rel O +
proteins O +
and O +
UV O +
cross O -
- O -
linking O +
studies O +
revealed O +
the O +
presence O +
of O +
c O -
- O -
Rel O +
and O +
p65 O +
and O +
the O +
absence O +
of O +
p50 O +
in O +
the O +
TF O +
complex O +
and O +
further O +
showed O +
that O +
c O -
- O -
Rel O -
/ O -
p65 O +
heterodimers O +
selectively O +
bound O +
to O +
the O +
TF O +
kappa O +
B O -
- O -
like O +
site O +
. O +

Functional O +
studies O +
indicated O +
that O +
the O +
TF O +
site O +
conferred O +
LPS O +
inducibility O +
on O +
a O +
heterologous O +
promoter O +
and O +
was O +
transactivated O +
by O +
c O -
- O -
Rel O +
or O +
p65 O +
. O +

Taken O +
together O +
, O +
our O +
results O +
demonstrated O +
that O +
binding O +
of O +
c O -
- O -
Rel O -
/ O -
p65 O +
heterodimers O +
to O +
a O +
novel O +
kappa O +
B O -
- O -
like O +
site O +
mediated O +
LPS O +
induction O +
of O +
TF O +
gene O +
expression O +
in O +
monocytic O +
cells O +
. O +

Prenatal O +
immune O +
challenge O +
alters O +
the O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenocortical O +
axis O +
in O +
adult O +
rats O +
. O +

We O +
investigated O +
whether O +
non O -
- O -
abortive O +
maternal O +
infections O +
would O +
compromise O +
fetal O +
brain O +
development O +
and O +
alter O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenocortical O +
( O +
HPA O +
) O +
axis O +
functioning O +
when O +
adult O +
. O +

To O +
study O +
putative O +
teratogenic O +
effects O +
of O +
a O +
T O +
cell O -
- O -
mediated O +
immune O +
response O +
versus O +
an O +
endotoxic O +
challenge O +
, O +
10-d O -
- O -
pregnant O +
rats O +
received O +
a O +
single O +
intraperitoneal O +
injection O +
of O +
5 O +
x O +
10 O +
( O +
8 O +
) O +
human O +
red O +
blood O +
cells O +
( O +
HRBC O +
) O +
or O +
gram O -
- O -
negative O +
bacterial O +
endotoxin O +
( O +
Escherichia O +
coli O +
LPS O +
: O +
30 O +
micrograms O -
/ O -
kg O +
) O +
. O +

The O +
adult O +
male O +
progeny O +
( O +
3 O +
mo O +
old O +
) O +
of O +
both O +
experimental O +
groups O +
showed O +
increased O +
basal O +
plasma O +
corticosterone O +
levels O +
. O +

In O +
addition O +
, O +
after O +
novelty O +
stress O +
the O +
HRBC O +
group O +
, O +
but O +
not O +
the O +
LPS B-CellLine +
group I-CellLine +
, O +
showed O +
increased O +
ACTH O +
and O +
corticosterone O +
levels O +
. O +

Both O +
groups O +
showed O +
substantial O +
decreases O +
in O +
mineralocorticoid O +
( O +
MR O +
) O +
and O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
levels O +
in O +
the O +
hippocampus O +
, O +
a O +
limbic O +
brain O +
structure O +
critical O +
for O +
HPA O +
axis O +
regulation O +
, O +
whereas O +
GR O +
concentrations O +
in O +
the O +
hypothalamus O +
were O +
unchanged O +
and O +
in O +
anterior O +
pituitary O +
were O +
slightly O +
increased O +
. O +

HRBC O +
and O +
LPS O +
indeed O +
stimulated O +
the O +
maternal O +
immune O +
system O +
as O +
revealed O +
by O +
specific O +
anti O -
- O -
HRBC O +
antibody O +
production O +
and O +
enhanced O +
IL-1 O +
beta O +
mRNA O +
expression O +
in O +
splenocytes O +
, O +
respectively O +
. O +

This O +
study O +
demonstrates O +
that O +
a O +
T O +
cell O -
- O -
mediated O +
immune O +
response O +
as O +
well O +
as O +
an O +
endotoxic O +
challenge O +
during O +
pregnancy O +
can O +
induce O +
anomalies O +
in O +
HPA O +
axis O +
function O +
in O +
adulthood O +
. O +

Clinically O +
, O +
it O +
may O +
be O +
postulated O +
that O +
disturbed O +
fetal O +
brain O +
development O +
due O +
to O +
prenatal O +
immune O +
challenge O +
increases O +
the O +
vulnerability O +
to O +
develop O +
mental O +
illness O +
involving O +
inadequate O +
responses O +
to O +
stress O +
. O +

Tolerance O +
to O +
lipopolysaccharide O +
involves O +
mobilization O +
of O +
nuclear O +
factor O +
kappa O +
B O +
with O +
predominance O +
of O +
p50 O +
homodimers O +
. O +

Stimulation O +
of O +
the O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
Mono B-CellLine +
Mac I-CellLine +
6 I-CellLine +
with O +
lipopolysaccharide O +
( O +
LPS O +
) O +
leads O +
to O +
rapid O +
and O +
transient O +
expression O +
of O +
cytokines O +
like O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
. O +

When O +
such O +
cells O +
are O +
precultured O +
for O +
2 O +
days O +
with O +
a O +
low O +
dose O +
of O +
LPS O +
( O +
20 O +
ng O -
/ O -
ml O +
) O +
followed O +
by O +
stimulation O +
with O +
a O +
high O +
dose O +
of O +
LPS O +
( O +
1 O +
microgram O -
/ O -
ml O +
) O +
, O +
expression O +
of O +
the O +
TNF O +
gene O +
is O +
minimal O +
, O +
i.e. O +
the O +
cells O +
are O +
tolerant O +
. O +

In O +
nuclear O +
run O -
- O -
on O +
analysis O +
, O +
such O +
tolerant O +
cells O +
show O +
only O +
a O +
low O +
degree O +
of O +
transcription O +
, O +
indicating O +
that O +
tolerance O +
operates O +
at O +
or O +
upstream O +
of O +
the O +
transcription O +
level O +
. O +

The O +
CD14 O +
LPS O +
receptor O +
is O +
, O +
however O +
, O +
up O -
- O -
regulated O +
( O +
not O +
down O -
- O -
regulated O +
) O +
in O +
tolerant B-CellLine +
cells I-CellLine +
, O +
and O +
LPS O +
can O +
, O +
in O +
fact O +
, O +
still O +
lead O +
to O +
activation O +
of O +
tolerant B-CellLine +
cells I-CellLine +
as O +
evidenced O +
by O +
mobilization O +
of O +
the O +
transcription O +
factor O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
. O +

Resolution O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
complex O +
in O +
gel O +
shift O +
analysis O +
shows O +
that O +
the O +
binding O +
protein O +
, O +
mobilized O +
in O +
naive B-CellLine +
Mono I-CellLine +
Mac I-CellLine +
6 I-CellLine +
cells I-CellLine +
, O +
consists O +
mainly O +
of O +
p50-p65 O +
heterodimers O +
, O +
while O +
in O +
tolerant B-CellLine +
cells I-CellLine +
, O +
the O +
p50 O +
homodimer O +
is O +
predominant O +
. O +

This O +
increase O +
in O +
p50 O +
homodimers O +
coincides O +
with O +
an O +
increase O +
in O +
p105 O +
mRNA O +
, O +
suggestive O +
of O +
a O +
transcriptional O +
up O -
- O -
regulation O +
of O +
p50 O +
. O +

Reporter O +
gene O +
analysis O +
reveals O +
that O +
the O +
NF O -
- O -
kappa O +
B O +
complex O +
mobilized O +
in O +
tolerant B-CellLine +
cells I-CellLine +
is O +
functionally O +
inactive O +
in O +
that O +
NF O -
- O -
kappa O +
B O -
- O -
dependent O +
luciferase O +
constructs O +
containing O +
the O +
human O +
immunodeficiency O +
virus O +
long O +
terminal O +
repeat O +
or O +
the O +
TNF O +
5'-region O +
show O +
only O +
minimal O +
transactivation O +
after O +
LPS O +
stimulation O +
. O +

Similar O +
to O +
Mono B-CellLine +
Mac I-CellLine +
6 I-CellLine +
cells I-CellLine +
, O +
primary O +
blood O +
monocytes O +
, O +
when O +
precultured O +
with O +
a O +
low O +
dose O +
of O +
LPS O +
, O +
also O +
become O +
tolerant O +
and O +
produce O +
little O +
TNF O +
after O +
LPS O +
stimulation O +
. O +

The O +
tolerant O +
blood O +
monocytes O +
also O +
up O -
- O -
regulate O +
CD14 O +
, O +
and O +
they O +
mobilize O +
NF O -
- O -
kappa O +
B O +
with O +
a O +
predominance O +
of O +
p50 O +
homodimers O +
. O +

Taken O +
together O +
, O +
these O +
results O +
demonstrate O +
that O +
tolerance O +
to O +
LPS O +
is O +
determined O +
by O +
post O -
- O -
receptor O +
mechanisms O +
that O +
involve O +
an O +
altered O +
composition O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
complex O +
. O +

Analysis O +
of O +
Oct2-isoform O +
expression O +
in O +
lipopolysaccharide B-CellLine -
- I-CellLine -
stimulated I-CellLine +
B I-CellLine +
lymphocytes I-CellLine +
. O +

Oct2-isoform O +
expression O +
in O +
splenic O +
B O +
cells O +
stimulated O +
with O +
lipopolysaccharide O +
or O +
lipopolysaccharide O +
plus O +
phorbol O -
- O -
di O -
- O -
butyrate O +
was O +
analysed O +
by O +
cDNA O +
cloning O +
. O +

The O +
frequency O +
of O +
Oct2-positive B-CellLine +
clones I-CellLine +
was O +
1 O -
/ O -
15 O +
, O +
000 O +
in O +
both O +
libraries O +
. O +

Two O +
new O +
isoforms O +
were O +
found O +
that O +
generate O +
novel O +
amino- O +
or O +
carboxy O -
- O -
terminal O +
sequences O +
. O +

An O +
isoform O +
lacking O +
exon O +
11 O +
destroyed O +
the O +
carboxy O -
- O -
terminal O +
leucin O -
- O -
zipper O +
region O +
and O +
introduced O +
a O +
frame O +
shift O +
creating O +
a O +
novel O +
, O +
proline O -
- O -
rich O +
carboxy O +
terminus O +
. O +

A O +
new O +
exon O +
containing O +
a O +
highly O +
basic O +
region O +
( O +
4c O +
) O +
was O +
characterized O +
, O +
between O +
exons O +
4 O +
and O +
5 O +
. O +

This O +
exon O +
was O +
inserted O +
between O +
glutamine O -
- O -
rich O +
regions O +
2 O +
and O +
3 O +
, O +
carboxy O +
terminal O +
of O +
a O +
tentative O +
leucine O -
- O -
zipper O +
structure O +
. O +

In O +
addition O +
, O +
a O +
new O +
combination O +
isoform O +
containing O +
Oct2a O +
's O +
amino O +
terminal O +
insert O +
( O +
exon O +
7a O +
) O +
and O +
Oct2b O +
's O +
carboxy O +
terminal O +
insert O +
( O +
exon O +
13 O +
) O +
was O +
found O +
that O +
created O +
a O +
novel O +
large O +
isoform O +
, O +
Oct2ab O +
. O +

More O +
frequent O +
use O +
of O +
the O +
classical O +
Oct2a O +
and O +
Oct2b O +
isoforms O +
was O +
observed O +
in O +
the O +
lipopolysaccharide B-CellLine -
- I-CellLine -
stimulated I-CellLine +
B I-CellLine +
cells I-CellLine +
, O +
while O +
a O +
preference O +
for O +
the O +
Oct2ab O +
and O +
Oct2ba O +
isoforms O +
was O +
observed O +
in O +
lipopolysaccharide B-CellLine +
plus I-CellLine +
phorbol I-CellLine -
- I-CellLine -
di I-CellLine -
- I-CellLine -
butyrate I-CellLine -
- I-CellLine -
treated I-CellLine +
cells I-CellLine +
. O +

Function O +
and O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
the O +
immune O +
system O +
. O +

NF O -
- O -
kappa O +
B O +
is O +
a O +
ubiquitous O +
transcription O +
factor O +
. O +

Nevertheless O +
, O +
its O +
properties O +
seem O +
to O +
be O +
most O +
extensively O +
exploited O +
in O +
cells O +
of O +
the O +
immune O +
system O +
. O +

Among O +
these O +
properties O +
are O +
NF O -
- O -
kappa O +
B O +
's O +
rapid O +
posttranslational O +
activation O +
in O +
response O +
to O +
many O +
pathogenic O +
signals O +
, O +
its O +
direct O +
participation O +
in O +
cytoplasmic O -
/ O -
nuclear O +
signaling O +
, O +
and O +
its O +
potency O +
to O +
activate O +
transcription O +
of O +
a O +
great O +
variety O +
of O +
genes O +
encoding O +
immunologically O +
relevant O +
proteins O +
. O +

In O +
vertebrates O +
, O +
five O +
distinct O +
DNA O +
binding O +
subunits O +
are O +
currently O +
known O +
which O +
might O +
extensively O +
heterodimerize O +
, O +
thereby O +
forming O +
complexes O +
with O +
distinct O +
transcriptional O +
activity O +
, O +
DNA O +
sequence O +
specificity O +
, O +
and O +
cell O +
type- O +
and O +
cell O +
stage O -
- O -
specific O +
distribution O +
. O +

The O +
activity O +
of O +
DNA O +
binding O +
NF O -
- O -
kappa O +
B O +
dimers O +
is O +
tightly O +
controlled O +
by O +
accessory O +
proteins O +
called O +
I O +
kappa O +
B O +
subunits O +
of O +
which O +
there O +
are O +
also O +
five O +
different O +
species O +
currently O +
known O +
in O +
vertebrates O +
. O +

I O +
kappa O +
B O +
proteins O +
inhibit O +
DNA O +
binding O +
and O +
prevent O +
nuclear O +
uptake O +
of O +
NF O -
- O -
kappa O +
B O +
complexes O +
. O +

An O +
exception O +
is O +
the O +
Bcl-3 O +
protein O +
which O +
in O +
addition O +
can O +
function O +
as O +
a O +
transcription O +
activating O +
subunit O +
in O +
th O +
nucleus O +
. O +

Other O +
I O +
kappa O +
B O +
proteins O +
are O +
rather O +
involved O +
in O +
terminating O +
NF O -
- O -
kappa O +
B O +
's O +
activity O +
in O +
the O +
nucleus O +
. O +

The O +
intracellular O +
events O +
that O +
lead O +
to O +
the O +
inactivation O +
of O +
I O +
kappa O +
B O +
, O +
i.e. O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
are O +
complex O +
. O +

They O +
involve O +
phosphorylation O +
and O +
proteolytic O +
reactions O +
and O +
seem O +
to O +
be O +
controlled O +
by O +
the O +
cells O +
' O +
redox O +
status O +
. O +

Interference O +
with O +
the O +
activation O +
or O +
activity O +
of O +
NF O -
- O -
kappa O +
B O +
may O +
be O +
beneficial O +
in O +
suppressing O +
toxic O -
/ O -
septic O +
shock O +
, O +
graft O -
- O -
vs O -
- O -
host O +
reactions O +
, O +
acute O +
inflammatory O +
reactions O +
, O +
acute O +
phase O +
response O +
, O +
and O +
radiation O +
damage O +
. O +

The O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
by O +
antioxidants O +
and O +
specific O +
protease O +
inhibitors O +
may O +
provide O +
a O +
pharmacological O +
basis O +
for O +
interfering O +
with O +
these O +
acute O +
processes O +
. O +

Pentoxifylline O +
for O +
the O +
treatment O +
of O +
infection O +
with O +
human O +
immunodeficiency O +
virus O +
. O +

Cytokine O +
dysregulation O +
in O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
infection O +
has O +
been O +
documented O +
in O +
numerous O +
studies O +
and O +
has O +
been O +
cited O +
as O +
an O +
important O +
component O +
in O +
the O +
pathogenesis O +
of O +
this O +
retroviral O +
infection O +
. O +

Pharmacological O +
modification O +
of O +
cytokine O +
dysregulation O +
, O +
therefore O +
, O +
has O +
been O +
suggested O +
as O +
a O +
therapeutic O +
modality O +
for O +
HIV-1 O +
infection O +
. O +

Dr. O +
Dezube O +
of O +
Beth O +
Israel O +
Hospital O +
( O +
Boston O +
) O +
concisely O +
reviews O +
the O +
state O +
of O +
our O +
knowledge O +
regarding O +
the O +
effects O +
of O +
pentoxifylline O +
on O +
expression O +
of O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
, O +
a O +
cytokine O +
known O +
to O +
influence O +
HIV-1 O +
replication O +
and O +
to O +
play O +
a O +
possible O +
role O +
in O +
the O +
clinical O +
manifestations O +
of O +
advanced O +
infection O +
with O +
this O +
virus O +
. O +

Pentoxifylline O +
, O +
a O +
trisubstituted O +
xanthine O +
derivative O +
, O +
has O +
been O +
used O +
to O +
decrease O +
blood O +
viscosity O +
and O +
is O +
reasonably O +
well O +
tolerated O +
by O +
most O +
recipients O +
of O +
the O +
drug O +
. O +

Results O +
of O +
preliminary O +
studies O +
, O +
many O +
of O +
which O +
were O +
conducted O +
by O +
Dr. O +
Dezube O +
, O +
suggest O +
that O +
use O +
of O +
this O +
agent O +
in O +
combination O +
with O +
antiretroviral O +
compounds O +
may O +
prove O +
useful O +
in O +
the O +
treatment O +
of O +
patients O +
with O +
HIV-1 O +
infection O +
. O +

Increased O +
interleukin O +
2 O +
transcription O +
in O +
murine O +
lymphocytes O +
by O +
ciprofloxacin O +
. O +

The O +
fluoroquinolone O +
antibiotic O +
, O +
ciprofloxacin O +
( O +
cipro O +
) O +
, O +
induces O +
hyperproduction O +
of O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
and O +
interferon O -
- O -
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
in O +
stimulated O +
human O +
peripheral O +
blood O +
lymphocytes O +
. O +

In O +
this O +
investigation O +
an O +
enhanced O +
and O +
prolonged O +
IL-2 O +
and O +
IL-2 O +
mRNA O +
response O +
was O +
also O +
detected O +
in O +
both O +
stimulated O +
( O +
T O +
cell O +
mitogens O +
or O +
alloantigens O +
) O +
murine O +
splenocytes O +
and O +
in O +
the O +
stimulated O +
murine B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
EL-4 I-CellLine +
in O +
the O +
presence O +
of O +
ciprofloxacin O +
( O +
5 O -
- O -
80 O +
micrograms O -
/ O -
ml O +
) O +
as O +
compared O +
to O +
control O +
cells O +
without O +
antibiotics O +
. O +

However O +
, O +
in O +
contrast O +
to O +
human O +
lymphocytes O +
, O +
IFN O -
- O -
gamma O +
production O +
was O +
inhibited O +
and O +
IFN O -
- O -
gamma O +
mRNA O +
levels O +
were O +
unaffected O +
at O +
24 O +
h O +
and O +
only O +
slightly O +
upregulated O +
at O +
48 O +
and O +
72 O +
h O +
of O +
culture O +
in O +
murine O +
splenocytes O +
incubated O +
with O +
cipro O +
( O +
20 O +
micrograms O -
/ O -
ml O +
) O +
. O +

EL-4 O +
cells O +
were O +
transfected O +
with O +
a O +
plasmid O +
containing O +
the O +
IL-2 O +
promoter O +
and O +
enhancer O +
region O +
linked O +
to O +
the O +
chloramphenicol O +
acetyltransferase O +
( O +
CAT O +
) O +
reporter O +
gene O +
. O +

Analysis O +
of O +
CAT O +
activity O +
revealed O +
that O +
cipro O +
enhanced O +
IL-2 O +
gene O +
induction O +
. O +

In O +
addition O +
, O +
EL-4 O +
cells O +
incubated O +
with O +
ciprofloxacin O +
showed O +
an O +
early O +
peak O +
and O +
more O +
activated O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT-1 O +
) O +
as O +
compared O +
to O +
control O +
cells O +
without O +
antibiotics O +
. O +

Cipro O +
did O +
not O +
affect O +
the O +
nuclear O +
transcription O +
factors O +
AP-1 O +
or O +
NFIL-2A O +
. O +

Taken O +
together O +
, O +
cipro O +
inhibited O +
IFN O -
- O -
gamma O +
synthesis O +
, O +
but O +
enhanced O +
IL-2 O +
production O +
in O +
murine O +
lymphocytes O +
by O +
means O +
of O +
influencing O +
NFAT-1 O +
and O +
causing O +
an O +
increased O +
IL-2 O +
transcription O +
. O +

Nonpituitary O +
human O +
prolactin O +
gene O +
transcription O +
is O +
independent O +
of O +
Pit-1 O +
and O +
differentially O +
controlled O +
in O +
lymphocytes O +
and O +
in O +
endometrial O +
stroma O +
. O +

Expression O +
of O +
the O +
human O +
PRL O +
( O +
hPRL O +
) O +
gene O +
in O +
extrapituitary O +
sites O +
such O +
as O +
the O +
uterus O +
( O +
decidualized O +
endometrial O +
stroma O +
and O +
myometrium O +
) O +
and O +
cells O +
of O +
the O +
hematopoietic O +
lineage O +
is O +
directed O +
by O +
an O +
alternative O +
promoter O +
which O +
is O +
located O +
approximately O +
6 O +
kilobases O +
( O +
kb O +
) O +
upstream O +
of O +
the O +
pituitary O -
- O -
specific O +
start O +
site O +
. O +

In O +
order O +
to O +
delineate O +
the O +
tissue O -
- O -
specific O +
mechanisms O +
governing O +
the O +
control O +
of O +
nonpituitary O +
PRL O +
gene O +
expression O +
, O +
we O +
have O +
cloned O +
and O +
sequenced O +
3 O +
kb O +
5'-flanking O +
DNA O +
of O +
the O +
upstream O +
decidual O -
/ O -
lymphoid O +
( O +
dPRL O +
) O +
promoter O +
. O +

Based O +
on O +
sequence O +
homology O +
we O +
identified O +
two O +
binding O +
motifs O +
for O +
Pit-1 O +
and O +
seven O +
half O -
- O -
sites O +
for O +
glucocorticoid O +
receptor O -
/ O -
progesterone O +
receptor O +
( O +
PR O +
) O +
binding O +
. O +

We O +
focused O +
our O +
studies O +
on O +
the O +
role O +
of O +
Pit-1 O +
and O +
of O +
PR O +
as O +
potential O +
transcriptional O +
regulators O +
, O +
since O +
the O +
POU O +
domain O +
protein O +
Pit-1 O +
is O +
essential O +
in O +
the O +
control O +
of O +
pituitary O +
PRL O +
expression O +
, O +
and O +
progesterone O +
induces O +
decidual O +
transformation O +
of O +
the O +
endometrial O +
stroma O +
, O +
a O +
differentiation O +
process O +
during O +
which O +
the O +
decidual O +
PRL O +
gene O +
is O +
activated O +
. O +

We O +
demonstrate O +
in O +
a O +
variety O +
of O +
cell O +
types O +
, O +
including O +
lymphocytes O +
and O +
endometrial O +
stroma O +
, O +
that O +
Pit-1 O +
is O +
not O +
involved O +
in O +
the O +
regulation O +
of O +
dPRL O +
promoter O -
/ O -
reporter O +
gene O +
constructs O +
carrying O +
3 O +
kb O +
5'-flanking O +
DNA O +
. O +

Our O +
experiments O +
also O +
show O +
that O +
activated O +
PR O +
does O +
not O +
confer O +
direct O +
transcriptional O +
control O +
on O +
the O +
dPRL O +
promoter O +
. O +

When O +
we O +
compared O +
the O +
activity O +
of O +
the O +
transfected O +
dPRL O +
promoter O +
in O +
PRL O -
- O -
secreting O +
and O +
nonsecreting O +
lymphoid O +
cells O +
, O +
we O +
found O +
that O +
the O +
3 O +
kb O +
5'-flanking O +
region O +
of O +
the O +
dPRL O +
promoter O +
did O +
not O +
contain O +
elements O +
restricting O +
expression O +
to O +
only O +
those O +
lymphocytes O +
that O +
produce O +
PRL O +
but O +
allowed O +
expression O +
of O +
fusion O +
reporter O +
genes O +
irrespective O +
of O +
the O +
status O +
of O +
the O +
endogenous O +
PRL O +
gene O +
. O +

This O +
was O +
in O +
sharp O +
contrast O +
to O +
endometrial O +
cells O +
where O +
3 O +
kb O +
5'-flanking O +
DNA O +
conferred O +
strong O +
transcriptional O +
activation O +
on O +
the O +
dPRL O +
promoter O +
in O +
decidualized O +
endometrial O +
stromal O +
cells O +
actively O +
secreting O +
PRL O +
, O +
but O +
did O +
not O +
allow O +
transcription O +
in O +
undifferentiated O +
non O -
- O -
PRL O -
- O -
secreting O +
endometrial O +
stromal O +
cells O +
. O +

Activation O +
of O +
the O +
dPRL O +
promoter O +
construct O +
in O +
these O +
undifferentiated O +
cells O +
could O +
however O +
be O +
induced O +
by O +
the O +
addition O +
of O +
cAMP O +
, O +
in O +
the O +
absence O +
of O +
progesterone O +
, O +
suggesting O +
that O +
a O +
signal O +
transduced O +
through O +
the O +
cAMP O +
signaling O +
pathway O +
is O +
a O +
primary O +
inducer O +
of O +
decidual O +
PRL O +
gene O +
expression O +
. O +

Activation O +
of O +
early O +
growth O +
response O +
1 O +
gene O +
transcription O +
and O +
pp90rsk O +
during O +
induction O +
of O +
monocytic O +
differentiation O +
. O +

The O +
present O +
work O +
has O +
studied O +
mechanisms O +
responsible O +
for O +
induction O +
of O +
early O +
growth O +
response O +
1 O +
( O +
EGR-1 O +
) O +
gene O +
expression O +
during O +
monocytic O +
differentiation O +
of O +
U-937 B-CellLine +
myeloid I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
. O +

Differentiation O +
of O +
U-937 B-CellLine +
cells I-CellLine +
with O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
, O +
an O +
activator O +
of O +
the O +
serine O -
/ O -
threonine O +
protein O +
kinase O +
C O +
, O +
was O +
associated O +
with O +
transcriptional O +
activation O +
of O +
EGR-1 O +
promoter O -
- O -
reporter O +
constructs O +
. O +

The O +
EGR-1 O +
promoter O +
contains O +
six O +
CC O +
( O +
A O -
/ O -
T O +
) O +
6GG O +
( O +
CArG O +
) O +
motifs O +
. O +

The O +
two O +
5'-most O +
distal O +
CArG O +
sequences O +
conferred O +
TPA O +
inducibility O +
. O +

In O +
contrast O +
, O +
there O +
was O +
little O +
effect O +
of O +
TPA O +
on O +
EGR-1 O +
transcription O +
in O +
a O +
TPA B-CellLine -
- I-CellLine -
resistant I-CellLine +
U-937 I-CellLine +
cell I-CellLine +
variant I-CellLine +
, O +
designated O +
TUR B-CellLine +
. O +

Treatment O +
of O +
both O +
U-937 B-CellLine +
and O +
TUR B-CellLine +
cells I-CellLine +
with O +
okadaic O +
acid O +
, O +
an O +
inhibitor O +
of O +
serine O -
/ O -
threonine O +
protein O +
phosphatases O +
1 O +
and O +
2A O +
, O +
was O +
associated O +
with O +
induction O +
of O +
monocytic O +
differentiation O +
and O +
EGR-1 O +
transcription O +
through O +
the O +
5'-most O +
CArG O +
element O +
. O +

Since O +
these O +
findings O +
supported O +
the O +
involvement O +
of O +
serine O -
/ O -
threonine O +
protein O +
phosphorylation O +
in O +
the O +
regulation O +
of O +
EGR-1 O +
expression O +
, O +
we O +
studied O +
activation O +
of O +
the O +
40S O +
ribosomal O +
protein O +
S6 O +
serine O -
/ O -
threonine O +
kinases O +
, O +
pp70S6 O -
K O +
and O +
pp90rsk O +
. O +

Although O +
both O +
kinases O +
participate O +
in O +
regulating O +
cell O +
growth O +
, O +
there O +
was O +
no O +
detectable O +
activation O +
of O +
pp70S6 O -
K O +
during O +
TPA- O +
or O +
okadaic O +
acid O -
- O -
induced O +
monocytic O +
differentiation O +
. O +

Moreover O +
, O +
rapamycin O +
, O +
an O +
inhibitor O +
of O +
pp70S6 O -
K O +
activation O +
, O +
had O +
no O +
effect O +
on O +
induction O +
of O +
EGR-1 O +
expression O +
. O +

In O +
contrast O +
, O +
analysis O +
of O +
pp90rsk O +
activity O +
by O +
phosphorylation O +
of O +
a O +
peptide O +
derived O +
from O +
S6 O +
protein O +
demonstrated O +
stimulation O +
of O +
this O +
kinase O +
in O +
TPA B-CellLine -
- I-CellLine -
treated I-CellLine +
U-937 I-CellLine +
, I-CellLine +
and I-CellLine +
not I-CellLine +
TUR I-CellLine +
, I-CellLine +
cells I-CellLine +
. O +

Okadaic O +
acid O +
treatment O +
of O +
both O +
cell O +
types O +
was O +
associated O +
with O +
activation O +
of O +
pp90rsk O +
. O +

Description O +
and O +
functional O +
implications O +
of O +
a O +
novel O +
mutation O +
in O +
the O +
sex O -
- O -
determining O +
gene O +
SRY O +
. O +

The O +
sex O -
- O -
determining O +
gene O +
SRY O +
was O +
screened O +
for O +
molecular O +
alteration O +
in O +
an O +
XY O +
sex O -
- O -
reversed O +
female O +
by O +
single O -
- O -
strand O +
conformation O +
polymorphism O +
( O +
SSCP O +
) O +
technique O +
. O +

An O +
A O -
- O -
to O -
- O -
G O +
transition O +
was O +
detected O +
which O +
leads O +
to O +
an O +
exchange O +
of O +
a O +
tyrosine O +
by O +
a O +
cysteine O +
in O +
the O +
SRY O +
protein O +
. O +

The O +
affected O +
tyrosine O +
residue O +
located O +
at O +
the O +
C O +
terminus O +
of O +
the O +
DNA O +
binding O +
protein O +
is O +
evolutionarily O +
strongly O +
conserved O +
among O +
the O +
members O +
of O +
the O +
HMG O +
box O +
containing O +
proteins O +
. O +

Using O +
gel O +
shift O +
assay O +
and O +
peptide O +
synthesis O +
such O +
a O +
mutation O +
is O +
shown O +
to O +
abolish O +
the O +
SRY O +
protein O +
DNA O +
binding O +
ability O +
. O +

The O +
involvement O +
of O +
this O +
particular O +
amino O +
acid O +
in O +
the O +
binding O +
specificity O +
is O +
also O +
discussed O +
. O +

NF O -
- O -
kappa O +
B O -
- O -
dependent O +
and O +
-independent O +
pathways O +
of O +
HIV O +
activation O +
in O +
a O +
chronically B-CellLine +
infected I-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

J B-CellLine +
delta I-CellLine +
K I-CellLine +
cells I-CellLine +
were O +
isolated O +
as O +
a O +
chronically B-CellLine +
infected I-CellLine +
survivor I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
following O +
infection O +
of O +
Jurkat B-CellLine +
CD4 I-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
with O +
dl O -
- O -
NF O +
, O +
a O +
mutated O +
strain O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
containing O +
a O +
deletion O +
of O +
the O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
NF O -
- O -
kappa O +
B O +
sites O +
. O +

J B-CellLine +
delta I-CellLine +
K I-CellLine +
cells I-CellLine +
exhibited O +
very O +
low O +
levels O +
of O +
constitutive O +
HIV O +
production O +
. O +

HIV-1 O +
expression O +
was O +
activated O +
from O +
J B-CellLine +
delta I-CellLine +
K I-CellLine +
cells I-CellLine +
by O +
treatment O +
with O +
phorbol O +
myristate O +
acetate O +
( O +
PMA O +
) O +
, O +
sodium O +
butyrate O +
( O +
NaB O +
) O +
, O +
or O +
hexamethylene O +
bisacetamide O +
( O +
HMBA O +
) O +
, O +
but O +
not O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
, O +
confirming O +
the O +
role O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
mediating O +
TNF O -
- O -
alpha O +
induction O +
of O +
HIV O +
transcription O +
. O +

The O +
strong O +
induction O +
of O +
HIV O +
expression O +
by O +
NaB O +
or O +
HMBA O +
in O +
J B-CellLine +
delta I-CellLine +
K I-CellLine +
cells I-CellLine +
clearly O +
demonstrates O +
the O +
existence O +
of O +
NF O -
- O -
kappa O +
B O +
-independent O +
mechanisms O +
of O +
HIV O +
activation O +
in O +
chronically O +
infected O +
cells O +
. O +

J B-CellLine +
delta I-CellLine +
K I-CellLine +
cells I-CellLine +
may O +
provide O +
a O +
useful O +
model O +
for O +
characterizing O +
NF O -
- O -
kappa O +
B O +
-independent O +
transcriptional O +
activation O +
of O +
the O +
HIV O +
LTR O +
. O +

IL-4 O +
down O -
- O -
regulates O +
IL-2 O +
- O +
, O +
IL-3 O +
- O +
, O +
and O +
GM O -
- O -
CSF O +
-induced O +
cytokine O +
gene O +
expression O +
in O +
peripheral O +
blood O +
monocytes O +
. O +

IL-4 O +
, O +
a O +
product O +
of O +
the O +
T O -
- O -
helper O +
0 O +
( O +
Th0 O +
) O +
and O +
2 O +
( O +
Th2 O +
) O +
subset O +
, O +
was O +
originally O +
described O +
as O +
a O +
B O -
- O -
cell O +
stimulatory O +
factor O +
and O +
has O +
subsequently O +
been O +
found O +
to O +
suppress O +
IL-1 O +
alpha O +
, O +
IL-1 O +
beta O +
, O +
IL-6 O +
, O +
IL-8 O +
, O +
and O +
TNF O -
- O -
alpha O +
gene O +
expression O +
in O +
monocytes O +
stimulated O +
with O +
LPS O +
, O +
and O +
to O +
upregulate O +
IL-1 O +
receptor O +
antagonist O +
( O +
IL1-RA O +
) O +
gene O +
expression O +
. O +

In O +
this O +
study O +
we O +
investigated O +
the O +
effect O +
of O +
IL-4 O +
on O +
the O +
expression O +
of O +
cytokine O +
genes O +
in O +
monocytes O +
evoked O +
by O +
other O +
T O -
- O -
helper O +
cell O +
cytokines O +
: O +
IL-2 O +
, O +
IL-3 O +
, O +
and O +
GM O -
- O -
CSF O +
. O +

IL-4 O +
down O -
- O -
regulated O +
mRNA O +
accumulation O +
of O +
the O +
proinflammatory O +
cytokines O +
IL-1 O +
beta O +
, O +
IL-8 O +
, O +
and O +
TNF O -
- O -
alpha O +
in O +
monocytes O +
stimulated O +
with O +
IL-2 O +
, O +
IL-3 O +
, O +
and O +
GM O -
- O -
CSF O +
. O +

IL-4 O +
also O +
suppressed O +
the O +
IL-2 O +
-induced O +
IL-6 O +
mRNA O +
expression O +
. O +

Temporal O +
analysis O +
of O +
the O +
IL-4 O +
down O -
- O -
regulatory O +
effect O +
on O +
the O +
IL-2- O +
, O +
IL-3- O +
, O +
or O +
GM O -
- O -
CSF O -
- O -
induced O +
proinflammatory O +
cytokine O +
gene O +
expression O +
in O +
monocytes O +
provided O +
evidence O +
that O +
IL-4 O +
acts O +
predominantly O +
on O +
the O +
post O -
- O -
transcriptional O +
level O +
. O +

This O +
was O +
supported O +
by O +
the O +
observation O +
that O +
the O +
down O -
- O -
regulatory O +
capacity O +
of O +
IL-4 O +
appeared O +
to O +
be O +
dependent O +
on O +
de O +
novo O +
protein O +
synthesis O +
. O +

IL-4 O +
did O +
not O +
exert O +
significant O +
influence O +
on O +
the O +
induction O +
of O +
expression O +
of O +
IL-1-RA O +
or O +
various O +
CSFs O +
by O +
IL-2 O +
, O +
IL-3 O +
, O +
and O +
GM O -
- O -
CSF O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

Long O -
- O -
term O +
inositol O +
phosphate O +
release O +
, O +
but O +
not O +
tyrosine O +
kinase O +
activity O +
, O +
correlates O +
with O +
IL-2 O +
secretion O +
and O +
NF O -
- O -
AT O +
induction O +
in O +
anti B-CellLine -
- I-CellLine -
CD3-activated I-CellLine +
peripheral I-CellLine +
human I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
. O +

The O +
cascade O +
of O +
events O +
within O +
the O +
first O +
few O +
minutes O +
of O +
T O +
cell O +
stimulation O +
has O +
been O +
well O +
characterized O +
. O +

Although O +
many O +
second O +
messengers O +
have O +
been O +
shown O +
to O +
be O +
necessary O +
and O +
sufficient O +
for O +
T O +
cell O +
activation O +
in O +
a O +
number O +
of O +
model O +
systems O +
, O +
the O +
rate O -
- O -
limiting O +
step O +
in O +
peripheral O +
T O +
cells O +
has O +
not O +
been O +
demonstrated O +
. O +

To O +
model O +
effective O +
versus O +
ineffective O +
CD3 O +
-mediated O +
stimulation O +
in O +
peripheral O +
T O +
cells O +
, O +
we O +
used O +
two O +
anti O -
- O -
CD3 O +
mAbs O +
that O +
differ O +
in O +
their O +
ability O +
to O +
stimulate O +
purified O +
T O +
cells O +
: O +
OKT3 O +
, O +
which O +
causes O +
early O +
second O +
messenger O +
generation O +
but O +
is O +
unable O +
to O +
activate O +
T O +
cells O +
without O +
a O +
second O +
signal O +
, O +
and O +
64.1 O +
, O +
which O +
stimulates O +
T O +
cell O +
proliferation O +
on O +
its O +
own O +
. O +

We O +
found O +
that O +
tyrosine O +
kinase O +
activity O +
was O +
similar O +
for O +
both O +
mAbs O +
over O +
a O +
period O +
of O +
hours O +
. O +

However O +
, O +
the O +
inositol O +
phosphate O +
response O +
was O +
stronger O +
for O +
64.1 O +
than O +
for O +
OKT3 O +
. O +

To O +
tie O +
these O +
events O +
to O +
gene O +
activation O +
, O +
we O +
measured O +
NF O -
- O -
kappa O +
B O +
and O +
NF O -
- O -
AT O +
activity O +
in O +
the O +
nucleus O +
after O +
anti O -
- O -
CD3 O +
stimulation O +
. O +

Both O +
stimuli O +
induced O +
the O +
appearance O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
components O +
( O +
c O -
- O -
Rel O +
, O +
p65 O +
( O +
RelA O +
) O +
, O +
and O +
p50 O +
( O +
NF O -
- O -
kappa O +
B1 O +
) O +
) O +
and O +
NF O -
- O -
kappa O +
B O +
DNA O +
binding O +
activity O +
in O +
the O +
nucleus O +
. O +

However O +
, O +
only O +
64.1 O +
induced O +
NF O -
- O -
AT O +
in O +
the O +
nucleus O +
, O +
correlating O +
with O +
its O +
ability O +
to O +
activate O +
T O +
cells O +
. O +

Thus O +
, O +
NF O -
- O -
AT O +
induction O +
and O +
IL-2 O +
secretion O +
were O +
correlated O +
with O +
the O +
levels O +
of O +
inositol O +
phosphate O +
release O +
but O +
not O +
with O +
gross O +
levels O +
of O +
tyrosine O +
kinase O +
activity O +
induced O +
late O +
following O +
the O +
response O +
. O +

On O +
the O +
other O +
hand O +
, O +
NF O -
- O -
kappa O +
B O +
induction O +
and O +
IL-2 O +
receptor O +
expression O +
occurred O +
even O +
with O +
the O +
smaller O +
second O +
messenger O +
response O +
generated O +
by O +
OKT3 O +
. O +

Evidence O +
for O +
a O +
trans O -
- O -
acting O +
activator O +
function O +
regulating O +
the O +
expression O +
of O +
the O +
human O +
CD5 O +
antigen O +
. O +

Interspecies O +
somatic B-CellLine +
cell I-CellLine +
hybrids I-CellLine +
were O +
generated O +
by O +
fusing O +
the O +
mouse B-CellLine +
T I-CellLine -
- I-CellLine -
lymphoma I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
BW5147 B-CellLine +
, O +
with O +
normal O +
human O +
T O +
lymphocytes O +
at O +
different O +
stages O +
of O +
differentiation O +
. O +

Thymocytes O +
, O +
activated O +
peripheral O +
T O +
lymphocytes O +
, O +
or O +
an O +
activated B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clone I-CellLine +
were O +
used O +
as O +
human O +
partners O +
, O +
respectively O +
, O +
in O +
three O +
independent O +
fusions O +
. O +

Irrespective O +
of O +
the O +
human O +
cell O +
partner O +
used O +
for O +
fusion O +
, O +
a O +
certain O +
number O +
of O +
hybrids B-CellLine +
lost O +
CD5 O +
surface O +
expression O +
over O +
a O +
period O +
of O +
time O +
in O +
culture O +
. O +

Analysis O +
at O +
the O +
phenotype O +
and O +
genetic O +
level O +
showed O +
that O +
lack O +
of O +
CD5 O +
expression O +
was O +
due O +
neither O +
to O +
segregation O +
of O +
human O +
autosome O +
11 O +
, O +
on O +
which O +
the O +
CD5 O +
gene O +
has O +
been O +
mapped O +
, O +
nor O +
to O +
deletion O +
of O +
the O +
CD5 O +
structural O +
gene O +
. O +

Furthermore O +
, O +
loss O +
of O +
CD5 O +
surface O +
expression O +
correlated O +
with O +
the O +
absence O +
of O +
specific O +
mRNA O +
. O +

Since O +
these O +
hybrids O +
preferentially O +
segregate O +
human O +
chromosomes O +
, O +
these O +
results O +
indicate O +
the O +
existence O +
of O +
a O +
non O -
- O -
syntenic O +
trans O -
- O -
active O +
locus O +
, O +
or O +
loci O +
, O +
positively O +
controlling O +
the O +
expression O +
of O +
the O +
human O +
CD5 O +
gene O +
. O +

Alpha O -
- O -
tocopherol O +
inhibits O +
agonist O -
- O -
induced O +
monocytic O +
cell O +
adhesion O +
to O +
cultured B-CellLine +
human I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
. O +

Antioxidants O +
have O +
been O +
proposed O +
to O +
be O +
anti O -
- O -
atherosclerotic O +
agents O +
; O +
however O +
, O +
the O +
mechanisms O +
underlying O +
their O +
beneficial O +
effects O +
are O +
poorly O +
understood O +
. O +

We O +
have O +
examined O +
the O +
effect O +
of O +
alpha O -
- O -
tocopherol O +
( O +
alpha O -
- O -
tcp O +
) O +
on O +
one O +
cellular O +
event O +
in O +
atherosclerotic O +
plaque O +
development O +
, O +
monocyte O +
adhesion O +
to O +
stimulated O +
endothelial O +
cells O +
( O +
ECs O +
) O +
. O +

Human O +
umbilical O +
vein O +
ECs O +
were O +
pretreated O +
with O +
alpha O -
- O -
tcp O +
before O +
stimulation O +
with O +
known O +
agonists O +
of O +
monocyte O +
adhesion O +
: O +
IL-1 O +
( O +
10 O +
ng O -
/ O -
ml O +
) O +
, O +
LPS O +
( O +
10 O +
ng O -
/ O -
ml O +
) O +
, O +
thrombin O +
( O +
30 O +
U O -
/ O -
ml O +
) O +
, O +
or O +
PMA O +
( O +
10 O +
nM O +
) O +
. O +

Agonist O -
- O -
induced O +
monocytic O +
cell O +
adhesion O +
, O +
but O +
not O +
basal O +
adhesion O +
, O +
was O +
inhibited O +
in O +
a O +
time- O +
and O +
concentration O -
- O -
dependent O +
manner O +
by O +
alpha O -
- O -
tcp O +
. O +

The O +
IC50 O +
of O +
alpha O -
- O -
tcp O +
on O +
an O +
IL-1 O +
-induced O +
response O +
was O +
45 O +
microM O +
. O +

The O +
inhibition O +
correlated O +
with O +
a O +
decrease O +
in O +
steady O +
state O +
levels O +
of O +
E O -
- O -
selectin O +
mRNA O +
and O +
cell O +
surface O +
expression O +
of O +
E O -
- O -
selectin O +
which O +
is O +
consistent O +
with O +
the O +
ability O +
of O +
a O +
monoclonal O +
antibody O +
to O +
E O -
- O -
selectin O +
to O +
inhibit O +
monocytic O +
cell O +
adhesion O +
in O +
this O +
system O +
. O +

Probucol O +
( O +
50 O +
microM O +
) O +
and O +
N O -
- O -
acetylcysteine O +
( O +
20 O +
mM O +
) O +
also O +
inhibited O +
agonist O -
- O -
induced O +
monocytic O +
cell O +
adhesion O +
; O +
whereas O +
, O +
several O +
other O +
antioxidants O +
had O +
no O +
significant O +
effect O +
. O +

Protein O +
kinase O +
C O +
( O +
PKC O +
) O +
does O +
not O +
appear O +
to O +
play O +
a O +
role O +
in O +
the O +
alpha O -
- O -
tcp O +
effect O +
since O +
no O +
suppression O +
of O +
phosphorylation O +
of O +
PKC O +
substrates O +
was O +
observed O +
. O +

Activation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
is O +
reported O +
to O +
be O +
necessary O +
but O +
not O +
sufficient O +
for O +
E O -
- O -
selectin O +
expression O +
in O +
EC B-CellLine +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
failed O +
to O +
show O +
an O +
alpha O -
- O -
tcp O -
- O -
induced O +
decrease O +
in O +
activation O +
of O +
this O +
transcription O +
factor O +
after O +
cytokine O +
stimulation O +
. O +

It O +
has O +
been O +
hypothesized O +
that O +
alpha O -
- O -
tcp O +
acts O +
as O +
an O +
anti O -
- O -
atherosclerotic O +
molecule O +
by O +
inhibiting O +
generation O +
of O +
oxidized O +
LDL O +
-- O +
a O +
putative O +
triggering O +
molecule O +
in O +
the O +
atherosclerotic O +
process O +
. O +

Our O +
results O +
point O +
to O +
a O +
novel O +
alternative O +
mechanism O +
of O +
action O +
of O +
alpha O -
- O -
tcp O +
. O +

Corticosteroid O +
receptors O +
in O +
lymphocytes O +
: O +
a O +
possible O +
marker O +
of O +
brain O +
involution O +
? O +

A O +
similarity O +
has O +
recently O +
been O +
found O +
between O +
the O +
regulation O +
of O +
corticosteroid O +
receptors O +
in O +
brain O +
and O +
in O +
lymphoid O +
tissue O +
. O +

We O +
have O +
studied O +
the O +
regulation O +
of O +
corticosteroid O +
receptors O +
in O +
human O +
mononuclear O +
leukocytes O +
as O +
a O +
possible O +
marker O +
of O +
brain O +
involution O +
. O +

Type O +
I O +
corticosteroid O +
receptors O +
are O +
down O +
regulated O +
by O +
excess O +
of O +
mineralocorticoids O +
( O +
primary O +
and O +
secondary O +
hyperaldosteronism O +
, O +
pseudohyperaldosteronism O +
) O +
and O +
of O +
glucocorticoids O +
( O +
Cushing O +
's O +
syndrome O +
) O +
. O +
Type O +
II O +
corticosteroid O +
receptors O +
are O +
not O +
reduced O +
by O +
excess O +
of O +
endogenous O +
corticosteroids O +
( O +
Cushing O +
's O +
syndrome O +
) O +
. O +

In O +
normal O +
adults O +
there O +
is O +
a O +
direct O +
significant O +
correlation O +
between O +
plasma O +
cortisol O +
and O +
Type O +
I O +
and O +
between O +
plasma O +
cortisol O +
and O +
Type O +
II O +
receptors O +
in O +
mononuclear O +
leukocytes O +
, O +
while O +
in O +
Cushing O +
's O +
syndrome O +
the O +
correlation O +
is O +
inverse O +
between O +
plasma O +
cortisol O +
at O +
8 O +
a.m. O +
and O +
Type O +
II O +
receptors O +
. O +

In O +
an O +
aged O +
population O +
the O +
mean O +
numbers O +
of O +
Type O +
I O +
and O +
of O +
Type O +
II O +
receptors O +
are O +
lower O +
and O +
plasma O +
cortisol O +
is O +
higher O +
than O +
in O +
adult O +
controls O +
, O +
but O +
the O +
increase O +
of O +
plasma O +
cortisol O +
is O +
not O +
followed O +
by O +
a O +
clinical O +
picture O +
of O +
hypercorticism O +
. O +

Corticosteroid O +
Type O +
I O +
and O +
Type O +
II O +
receptors O +
are O +
inversely O +
correlated O +
with O +
age O +
. O +

After O +
dexamethasone O +
suppression O +
( O +
1 O +
mg O +
at O +
11 O +
p.m. O +
) O +
Type O +
I O +
receptors O +
always O +
decrease O +
in O +
controls O +
while O +
the O +
response O +
of O +
Type O +
II O +
is O +
not O +
homogeneous O +
. O +

In O +
an O +
aged O +
group O +
of O +
patients O +
, O +
both O +
receptors O +
are O +
reduced O +
by O +
dexamethasone O +
. O +

We O +
conclude O +
that O +
the O +
decrease O +
with O +
age O +
of O +
corticosteroid O +
receptors O +
is O +
possibly O +
related O +
to O +
a O +
physiological O +
involution O +
of O +
corticosteroid O +
receptors O +
and O +
that O +
this O +
reduction O +
does O +
increase O +
plasma O +
cortisol O +
concentration O +
, O +
without O +
affecting O +
the O +
glucocorticoid O +
effector O +
mechanism O +
. O +

Mitogen O +
activation O +
of O +
human O +
peripheral O +
T O +
lymphocytes O +
induces O +
the O +
formation O +
of O +
new O +
cyclic O +
AMP O +
response O +
element O -
- O -
binding O +
protein O +
nuclear O +
complexes O +
. O +

A O +
large O +
body O +
of O +
evidence O +
indicates O +
that O +
experimental O +
agents O +
which O +
raise O +
cellular O +
cAMP O +
levels O +
inhibit O +
T O +
cell O +
growth O +
and O +
division O +
. O +

By O +
contrast O +
, O +
many O +
studies O +
have O +
reported O +
that O +
mitogen O +
activation O +
of O +
T O +
cells O +
increases O +
cAMP O +
levels O +
, O +
implying O +
a O +
positive O +
physiological O +
role O +
for O +
cAMP O +
in O +
the O +
activation O +
process O +
. O +

In O +
the O +
present O +
study O +
we O +
demonstrate O +
that O +
mitogen O +
activation O +
of O +
human O +
peripheral O +
T O +
lymphocytes O +
induces O +
nuclear O +
factors O +
that O +
form O +
complexes O +
with O +
cyclic O +
AMP O +
response O +
element O -
- O -
binding O +
protein O +
( O +
CREB O +
) O +
. O +

Four O +
complexes O +
are O +
identified O +
by O +
the O +
electrophoretic O +
mobility O +
shift O +
assay O +
, O +
two O +
of O +
which O +
are O +
induced O +
by O +
mitogen O +
activation O +
. O +

All O +
four O +
complexes O +
contain O +
CREB O +
and O +
are O +
bound O +
to O +
the O +
cAMP O +
response O +
element O +
( O +
CRE O +
) O +
core O +
sequence O +
( O +
TGACGTCA O +
) O +
, O +
as O +
indicated O +
by O +
antibody O +
and O +
oligonucleotide O +
competition O +
experiments O +
. O +

Binding O +
of O +
the O +
four O +
complexes O +
to O +
CRE O +
is O +
prevented O +
by O +
dephosphorylation O +
of O +
nuclear O +
extracts O +
and O +
is O +
restored O +
by O +
rephosphorylation O +
with O +
cAMP O -
- O -
dependent O +
protein O +
kinase O +
or O +
endogenous O +
kinases O +
. O +

Similar O +
complexes O +
are O +
detected O +
in O +
nuclear O +
extracts O +
of O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

Mitogen O +
induction O +
of O +
the O +
electrophoretic O +
mobility O +
shift O +
assay O +
complexes O +
is O +
not O +
accounted O +
for O +
by O +
protein O +
phosphorylation O +
or O +
by O +
induction O +
of O +
CREB O +
. O +

Rather O +
, O +
the O +
data O +
indicate O +
that O +
mitogen O +
increases O +
the O +
levels O +
of O +
a O +
nuclear O +
factor O +
( O +
s O +
) O +
that O +
dimerizes O +
with O +
CREB O +
. O +

Induction O +
of O +
new O +
CREB O +
complexes O +
implies O +
a O +
physiological O +
role O +
for O +
cAMP O +
in O +
mitogen O +
activation O +
of O +
T O +
lymphocytes O +
. O +

A O +
novel O +
human O +
homeobox O +
gene O +
distantly O +
related O +
to O +
proboscipedia O +
is O +
expressed O +
in O +
lymphoid O +
and O +
pancreatic O +
tissues O +
. O +

A O +
novel O +
human O +
homeobox O +
gene O +
, O +
HB9 O +
, O +
was O +
isolated O +
from O +
a O +
cDNA O +
library O +
prepared O +
from O +
in O +
vitro O +
stimulated O +
human O +
tonsil O +
B O +
lymphocytes O +
and O +
from O +
a O +
human O +
genomic O +
library O +
. O +

The O +
HB9 O +
gene O +
is O +
composed O +
of O +
3 O +
exons O +
spread O +
over O +
6 O +
kilobases O +
of O +
DNA O +
. O +

An O +
open O +
reading O +
frame O +
of O +
1206 O +
nucleotides O +
is O +
in O +
frame O +
with O +
a O +
diverged O +
homeodomain O +
. O +

The O +
predicted O +
HB9 O +
protein O +
has O +
a O +
molecular O +
mass O +
of O +
41 O +
kilodaltons O +
and O +
is O +
enriched O +
for O +
alanine O +
, O +
glycine O +
, O +
and O +
leucine O +
. O +

The O +
HB9 O +
homeodomain O +
is O +
most O +
similar O +
to O +
that O +
of O +
the O +
Drosophila O +
melanogaster O +
homeobox O +
gene O +
proboscipedia O +
. O +

Northern O +
blot O +
analysis O +
of O +
poly O +
( O +
A O +
) O +
RNA O +
purified O +
from O +
the O +
human B-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
RPMI I-CellLine +
8226 I-CellLine +
and O +
from O +
activated O +
T O +
cells O +
revealed O +
a O +
major O +
mRNA O +
transcript O +
of O +
2.2 O +
kilobases O +
. O +

Similar O +
analysis O +
of O +
poly O +
( O +
A O +
) O +
RNA O +
from O +
a O +
variety O +
of O +
adult O +
tissues O +
demonstrated O +
HB9 O +
transcripts O +
in O +
pancreas O +
, O +
small O +
intestine O +
, O +
and O +
colon O +
. O +

Reverse O +
transcriptase O -
- O -
polymerase O +
chain O +
reaction O +
was O +
used O +
to O +
examine O +
HB9 O +
RNA O +
transcripts O +
in O +
hematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

HB9 O +
RNA O +
transcripts O +
were O +
most O +
prevalent O +
in O +
several O +
human B-CellLine +
B I-CellLine +
cell I-CellLine +
lines I-CellLine +
and O +
K562 B-CellLine +
cells I-CellLine +
. O +

In O +
addition O +
, O +
transcripts O +
were O +
detected O +
in O +
RNA O +
prepared O +
from O +
tonsil O +
B O +
cells O +
and O +
in O +
situ O +
hybridization O +
studies O +
localized O +
them O +
in O +
the O +
germinal O +
center O +
region O +
of O +
adult O +
tonsil O +
. O +

These O +
findings O +
suggest O +
the O +
involvement O +
of O +
HB9 O +
in O +
regulating O +
gene O +
transcription O +
in O +
lymphoid O +
and O +
pancreatic O +
tissues O +
. O +

ZAP-70 O +
tyrosine O +
kinase O +
, O +
CD45 O +
, O +
and O +
T O +
cell O +
receptor O +
involvement O +
in O +
UV- O +
and O +
H2O2-induced O +
T O +
cell O +
signal O +
transduction O +
. O +

Several O +
mammalian O +
responses O +
to O +
UV O +
irradiation O +
, O +
including O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
are O +
believed O +
to O +
involve O +
tyrosine O +
phosphorylation O +
. O +

UV O +
irradiation O +
and O +
H2O2 O +
treatment O +
of O +
T O +
lymphocytes O +
induce O +
protein O +
tyrosine O +
phosphorylation O +
and O +
Ca2 O -
+ O +
signals O +
similar O +
to O +
those O +
observed O +
following O +
biological O +
stimulation O +
. O +

We O +
have O +
examined O +
the O +
role O +
of O +
cell O +
surface O +
molecules O +
in O +
these O +
responses O +
. O +

Normal O +
T O +
lymphocytes O +
whose O +
surface O +
expression O +
of O +
CD3 O +
was O +
depleted O +
showed O +
impaired O +
UV O -
- O -
induced O +
tyrosine O +
phosphorylation O +
and O +
Ca2 O -
+ O +
signals O +
. O +

Similarly O +
, O +
Jurkat B-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
deficient O +
in O +
CD3 O +
or O +
CD45 O +
expression O +
also O +
gave O +
impaired O +
UV O +
responses O +
. O +

However O +
, O +
all O +
these O +
cell O +
types O +
still O +
gave O +
strong O +
Ca2 O -
+ O +
and O +
tyrosine O +
phosphorylation O +
responses O +
to O +
H2O2 O +
. O +

The O +
T O +
cell O +
tyrosine O +
kinase O +
ZAP-70 O +
was O +
found O +
to O +
be O +
highly O +
responsive O +
to O +
UV O +
and O +
H2O2 O +
treatment O +
. O +

ZAP-70 O +
responsiveness O +
to O +
UV O +
required O +
expression O +
of O +
both O +
CD3 O +
and O +
CD45 O +
, O +
whereas O +
only O +
CD3 O +
was O +
required O +
for O +
the O +
response O +
to O +
H2O2 O +
. O +

UV O -
- O -
induced O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
was O +
blocked O +
by O +
CD3 O +
depletion O +
, O +
indicating O +
the O +
importance O +
of O +
such O +
cell O +
surface O +
molecules O +
in O +
biological O +
responses O +
to O +
UV O +
. O +

In O +
nonlymphoid O +
cells O +
, O +
the O +
epidermal O +
growth O +
factor O +
receptor O +
displayed O +
increased O +
tyrosine O +
phosphorylation O +
within O +
seconds O +
of O +
UV O +
irradiation O +
. O +

These O +
results O +
suggest O +
that O +
UV O -
- O -
induced O +
signal O +
transduction O +
is O +
mediated O +
via O +
cell O +
surface O +
receptors O +
that O +
normally O +
respond O +
to O +
biological O +
stimulation O +
, O +
whereas O +
H2O2 O +
is O +
able O +
to O +
partially O +
bypass O +
this O +
requirement O +
. O +

Inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
by O +
sodium O +
salicylate O +
and O +
aspirin O +
[ O +
see O +
comments O +
] O +

The O +
transcription O +
factor O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
is O +
critical O +
for O +
the O +
inducible O +
expression O +
of O +
multiple O +
cellular O +
and O +
viral O +
genes O +
involved O +
in O +
inflammation O +
and O +
infection O +
including O +
interleukin-1 O +
( O +
IL-1 O +
) O +
, O +
IL-6 O +
, O +
and O +
adhesion O +
molecules O +
. O +

The O +
anti O -
- O -
inflammatory O +
drugs O +
sodium O +
salicylate O +
and O +
aspirin O +
inhibited O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
which O +
further O +
explains O +
the O +
mechanism O +
of O +
action O +
of O +
these O +
drugs O +
. O +

This O +
inhibition O +
prevented O +
the O +
degradation O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
inhibitor O +
, O +
I O +
kappa O +
B O +
, O +
and O +
therefore O +
NF O -
- O -
kappa O +
B O +
was O +
retained O +
in O +
the O +
cytosol O +
. O +

Sodium O +
salicylate O +
and O +
aspirin O +
also O +
inhibited O +
NF O -
- O -
kappa O +
B O +
-dependent O +
transcription O +
from O +
the O +
Ig O +
kappa O +
enhancer O +
and O +
the O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
in O +
transfected B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Inhibition O +
of O +
the O +
differentiation O +
of O +
human B-CellLine +
myeloid I-CellLine +
cell I-CellLine +
lines I-CellLine +
by O +
redox O +
changes O +
induced O +
through O +
glutathione O +
depletion O +
. O +

We O +
have O +
investigated O +
the O +
effect O +
of O +
redox O +
changes O +
in O +
vivo O +
on O +
the O +
differentiation O +
of O +
two O +
human B-CellLine +
myeloid I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
HL-60 B-CellLine +
and O +
KG-1 B-CellLine +
. O +

The O +
glutathione O -
- O -
depleting O +
agent O +
diethyl O +
maleate O +
( O +
DEM O +
) O +
prevented O +
the O +
development O +
of O +
differentiated O +
features O +
in O +
response O +
to O +
phorbol O +
esters O +
, O +
including O +
adherence O +
of O +
the O +
cells O +
to O +
plastic O +
surfaces O +
and O +
repression O +
of O +
the O +
myeloperoxidase O +
and O +
CD34 O +
genes O +
. O +

Moreover O +
, O +
DEM O +
abolished O +
phorbol O +
12-myristate O +
13-acetate O -
- O -
induced O +
activation O +
of O +
the O +
transcription O +
factors O +
AP-1 O +
and O +
Egr-1 O +
, O +
suggesting O +
that O +
inhibition O +
of O +
differentiation O +
may O +
be O +
due O +
, O +
at O +
least O +
in O +
part O +
, O +
to O +
redox O +
modifications O +
of O +
these O +
proteins O +
. O +

Effects O +
of O +
glucocorticoids O +
in O +
rheumatoid O +
arthritis O +
. O +

Diminished O +
glucocorticoid O +
receptors O +
do O +
not O +
result O +
in O +
glucocorticoid O +
resistance O +
. O +

OBJECTIVE O +
. O +

Lymphocytes O +
of O +
patients O +
with O +
rheumatoid O +
arthritis O +
( O +
RA O +
) O +
have O +
diminished O +
receptor O +
density O +
; O +
thus O +
, O +
patients O +
with O +
RA O +
should O +
show O +
partial O +
resistance O +
to O +
glucocorticoids O +
. O +

We O +
investigated O +
the O +
glucocorticoid O +
sensitivity O +
of O +
lymphocytes O +
in O +
RA O +
patients O +
compared O +
with O +
healthy O +
subjects O +
. O +

METHODS O +
. O +

We O +
determined O +
the O +
effects O +
of O +
glucocorticoids O +
on O +
lymphocyte O +
proliferation O +
and O +
cytokine O +
release O +
. O +

RESULTS O +
. O +

Proliferation O +
and O +
cytokine O +
release O +
were O +
inhibited O +
in O +
RA O +
patients O +
to O +
the O +
same O +
extent O +
as O +
in O +
healthy O +
controls O +
. O +

CONCLUSION O +
. O +

Diminished O +
receptor O +
density O +
in O +
RA O +
patients O +
does O +
not O +
result O +
in O +
glucocorticoid O +
resistance O +
. O +

Solution O +
structure O +
of O +
a O +
POU O -
- O -
specific O +
homeodomain O +
: O +
3D O -
- O -
NMR O +
studies O +
of O +
human O +
B O -
- O -
cell O +
transcription O +
factor O +
Oct-2 O +
. O +

The O +
POU O +
DNA O -
- O -
binding O +
motif O +
defines O +
a O +
conserved O +
family O +
of O +
eukaryotic O +
transcription O +
factors O +
involved O +
in O +
regulation O +
of O +
gene O +
expression O +
. O +

This O +
bipartite O +
motif O +
consists O +
of O +
an O +
N O -
- O -
terminal O +
POU O -
- O -
specific O +
domain O +
( O +
POUs O +
) O +
, O +
a O +
flexible O +
linker O +
, O +
and O +
a O +
C O -
- O -
terminal O +
POU O -
- O -
specific O +
homeodomain O +
( O +
POUHD O +
) O +
. O +

Here O +
we O +
describe O +
the O +
solution O +
structure O +
of O +
a O +
POU O -
- O -
specific O +
homeodomain O +
. O +

An O +
NMR O +
model O +
is O +
obtained O +
from O +
Oct-2 O +
, O +
a O +
human O +
B O -
- O -
cell O +
specific O +
transcription O +
factor O +
which O +
participates O +
in O +
the O +
regulation O +
of O +
immunoglobulin O +
genes O +
. O +

A O +
fragment O +
of O +
Oct-2 O +
containing O +
POUHD O +
and O +
an O +
adjoining O +
linker O +
was O +
expressed O +
in O +
Escherichia O +
coli O +
and O +
characterized O +
by O +
three O -
- O -
dimensional O +
nuclear O +
magnetic O +
resonance O +
( O +
3D O -
- O -
NMR O +
) O +
spectroscopy O +
. O +

Complete O +
1H O +
and O +
15N O +
resonance O +
assignment O +
of O +
the O +
POUHD O +
moiety O +
is O +
presented O +
. O +

The O +
POUHD O +
solution O +
structure O +
, O +
as O +
calculated O +
by O +
distance O +
geometry O +
and O +
simulated O +
annealing O +
( O +
DG O -
/ O -
SA O +
) O +
, O +
is O +
similar O +
to O +
that O +
of O +
canonical O +
homeodomains O +
. O +

A O +
salient O +
difference O +
between O +
solution O +
and O +
crystal O +
structures O +
is O +
observed O +
in O +
the O +
C O -
- O -
terminal O +
segment O +
of O +
alpha O -
- O -
helix O +
3 O +
( O +
the O +
HTH O +
recognition O +
helix O +
) O +
, O +
which O +
is O +
not O +
well O +
ordered O +
in O +
solution O +
. O +

Because O +
this O +
segment O +
presumably O +
folds O +
upon O +
specific O +
DNA O +
binding O +
, O +
its O +
flexibility O +
in O +
solution O +
may O +
reduce O +
the O +
intrinsic O +
DNA O +
affinity O +
of O +
POUHD O +
in O +
the O +
absence O +
of O +
POUs O +
. O +

Superantigens O +
activate O +
HIV-1 O +
gene O +
expression O +
in O +
monocytic O +
cells O +
. O +

Binding O +
of O +
superantigens O +
to O +
MHC O +
class O +
II O +
molecules O +
results O +
in O +
transduction O +
of O +
biochemical O +
signals O +
leading O +
to O +
cellular O +
activation O +
and O +
gene O +
expression O +
. O +

We O +
demonstrate O +
that O +
the O +
staphylococcal O +
superantigens O +
toxic O +
shock O +
syndrome O +
toxin-1 O +
( O +
TSST-1 O +
) O +
and O +
staphylococcal O +
enterotoxin O +
A O +
( O +
SEA O +
) O +
activate O +
HIV-1-LTR O +
-driven O +
transcription O +
of O +
chloramphenicol O +
acetyl O +
transferase O +
in O +
the O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
THP-1 B-CellLine +
. O +

Induction O +
of O +
HIV-1- O +
LTR O +
-driven O +
transcription O +
in O +
THP-1 B-CellLine +
cells I-CellLine +
by O +
superantigens O +
was O +
associated O +
with O +
the O +
induction O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
DNA O -
- O -
binding O +
activity O +
. O +

Superantigens O +
also O +
increased O +
viral O +
protein O +
secretion O +
from O +
the O +
granulocyte B-CellLine -
- I-CellLine -
macrophage I-CellLine +
colony I-CellLine -
- I-CellLine -
stimulating I-CellLine +
factor I-CellLine -
- I-CellLine -
pretreated I-CellLine +
chronically I-CellLine +
infected I-CellLine +
human I-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
U1 I-CellLine +
. O +

Induction O +
of O +
HIV-1 O +
gene O +
expression O +
in O +
monocytic O +
cells O +
by O +
superantigens O +
occurred O +
via O +
tumor O +
necrosis O +
factor O -
- O -
alpha O -
- O -
dependent O +
and O +
-independent O +
mechanisms O +
. O +

Our O +
results O +
suggest O +
that O +
superantigens O +
and O +
other O +
MHC O +
class O +
II O +
ligands O +
may O +
activate O +
HIV-1 O +
gene O +
expression O +
in O +
monocytes O -
/ O -
macrophages O +
. O +

Leiomyosarcoma O +
of O +
the O +
vulva O +
: O +
report O +
of O +
a O +
case O +
. O +

A O +
52-year O -
- O -
old O +
female O +
presented O +
with O +
a O +
progressively O +
enlarging O +
vulvar O +
mass O +
. O +

Pathological O +
evaluation O +
revealed O +
a O +
high O -
- O -
grade O +
vulvar O +
leiomyosarcoma O +
. O +

Immunohistochemical O +
and O +
ultrastructural O +
studies O +
were O +
performed O +
to O +
support O +
the O +
diagnosis O +
. O +

In O +
an O +
effort O +
to O +
better O +
understand O +
the O +
biology O +
of O +
this O +
tumor O +
additional O +
immunohistochemical O +
studies O +
for O +
the O +
protein O +
product O +
of O +
p53 O +
tumor O +
suppressor O +
gene O +
and O +
estrogen O +
receptor O +
expression O +
by O +
tumor O +
cells O +
, O +
as O +
well O +
as O +
the O +
type O +
of O +
immune O +
cells O +
infiltrating O +
the O +
tumor O +
were O +
performed O +
. O +

Tumor O +
cells O +
showed O +
an O +
overexpression O +
of O +
p53 O +
protein O +
and O +
were O +
estrogen O +
receptor O +
-positive O +
. O +

Macrophages O +
and O +
T O +
and O +
B O +
lymphocytes O +
infiltrated O +
the O +
tumor O +
in O +
moderate O +
numbers O +
with O +
occasional O +
lymphoid O +
aggregate O +
formation O +
. O +

This O +
study O +
is O +
the O +
first O +
attempt O +
to O +
better O +
understand O +
the O +
biology O +
of O +
these O +
tumors O +
. O +

DNA O -
- O -
binding O +
and O +
transcriptional O +
regulatory O +
properties O +
of O +
hepatic O +
leukemia O +
factor O +
( O +
HLF O +
) O +
and O +
the O +
t O +
( O +
17 O +
; O +
19 O +
) O +
acute O +
lymphoblastic O +
leukemia O +
chimera O +
E2A O -
- O -
HLF O +
. O +

The O +
t O +
( O +
17 O +
; O +
19 O +
) O +
translocation O +
in O +
acute O +
lymphoblastic O +
leukemias O +
results O +
in O +
creation O +
of O +
E2A O -
- O -
hepatic O +
leukemia O +
factor O +
( O +
HLF O +
) O +
chimeric O +
proteins O +
that O +
contain O +
the O +
DNA O -
- O -
binding O +
and O +
protein O +
dimerization O +
domains O +
of O +
the O +
basic O +
leucine O +
zipper O +
( O +
bZIP O +
) O +
protein O +
HLF O +
fused O +
to O +
a O +
portion O +
of O +
E2A O +
proteins O +
with O +
transcriptional O +
activation O +
properties O +
. O +

An O +
in O +
vitro O +
binding O +
site O +
selection O +
procedure O +
was O +
used O +
to O +
determine O +
DNA O +
sequences O +
preferentially O +
bound O +
by O +
wild O -
- O -
type O +
HLF O +
and O +
chimeric O +
E2A O -
- O -
HLF O +
proteins O +
isolated O +
from O +
various O +
t B-CellLine +
( I-CellLine +
17 I-CellLine +
; I-CellLine +
19 I-CellLine +
) I-CellLine +
-bearing I-CellLine +
leukemias I-CellLine +
. O +

All O +
were O +
found O +
to O +
selectively O +
bind O +
the O +
consensus O +
sequence O +
5'-GTTACGTAAT-3 O +
' O +
with O +
high O +
affinity O +
. O +

Wild O -
- O -
type O +
and O +
chimeric O +
HLF O +
proteins O +
also O +
bound O +
closely O +
related O +
sites O +
identified O +
previously O +
for O +
bZIP O +
proteins O +
of O +
both O +
the O +
proline O +
-and O +
acidic O +
amino O +
acid O -
- O -
rich O +
( O +
PAR O +
) O +
and O +
C O -
/ O -
EBP O +
subfamilies O +
; O +
however O +
, O +
E2A O -
- O -
HLF O +
proteins O +
were O +
significantly O +
less O +
tolerant O +
of O +
certain O +
deviations O +
from O +
the O +
HLF O +
consensus O +
binding O +
site O +
. O +

These O +
differences O +
were O +
directly O +
attributable O +
to O +
loss O +
of O +
an O +
HLF O +
ancillary O +
DNA O -
- O -
binding O +
domain O +
in O +
all O +
E2A O -
- O -
HLF O +
chimeras O +
and O +
were O +
further O +
exacerbated O +
by O +
a O +
zipper O +
mutation O +
in O +
one O +
isolate O +
. O +

Both O +
wild O -
- O -
type O +
and O +
chimeric O +
HLF O +
proteins O +
displayed O +
transcriptional O +
activator O +
properties O +
in O +
lymphoid O +
and O +
nonlymphoid O +
cells O +
on O +
reporter O +
genes O +
containing O +
HLF O +
or O +
C O -
/ O -
EBP O +
consensus O +
binding O +
sites O +
. O +

But O +
on O +
reporter O +
genes O +
with O +
nonoptimal O +
binding O +
sites O +
, O +
their O +
transcriptional O +
properties O +
diverged O +
and O +
E2A O -
- O -
HLF O +
competitively O +
inhibited O +
activation O +
by O +
wild O -
- O -
type O +
PAR O +
proteins O +
. O +

These O +
findings O +
establish O +
a O +
spectrum O +
of O +
binding O +
site O -
- O -
specific O +
transcriptional O +
properties O +
for O +
E2A O -
- O -
HLF O +
which O +
may O +
preferentially O +
activate O +
expression O +
of O +
select O +
subordinate O +
genes O +
as O +
a O +
homodimer O +
and O +
potentially O +
antagonize O +
expression O +
of O +
others O +
through O +
heteromeric O +
interactions O +
. O +

Inhibition O +
of O +
activation O +
of O +
transcription O +
factor O +
AP-1 O +
by O +
CD28 O +
signalling O +
in O +
human O +
T O -
- O -
cells O +
. O +

Co O -
- O -
stimulation O +
of O +
T O -
- O -
lymphocytes O +
by O +
T O -
- O -
cell O +
receptor O +
( O +
TcR O +
) O +
occupancy O +
and O +
activation O +
of O +
the O +
CD28 O +
surface O +
molecule O +
results O +
in O +
enhanced O +
proliferation O +
and O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
production O +
. O +

The O +
increase O +
in O +
IL-2 O +
gene O +
expression O +
triggered O +
by O +
CD28 O +
involves O +
a O +
kappa O +
B O -
- O -
like O +
sequence O +
in O +
the O +
5'-regulatory O +
region O +
of O +
the O +
IL-2 O +
promoter O +
, O +
called O +
CD28-responsive O +
element O +
. O +

Stimulation O +
of O +
T O -
- O -
cells O +
by O +
agonistic O +
anti O -
- O -
CD28 O +
antibodies O +
in O +
conjunction O +
with O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
- O +
or O +
TcR O +
-derived O +
signals O +
induces O +
the O +
enhanced O +
activation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
. O +

Here O +
we O +
report O +
that O +
CD28 O +
engagement O +
, O +
however O +
, O +
exerts O +
opposite O +
effects O +
on O +
the O +
transcription O +
factor O +
AP-1 O +
. O +

Whereas O +
anti O -
- O -
CD28 O +
together O +
with O +
PMA O +
increased O +
the O +
DNA O +
binding O +
and O +
trans O -
- O -
activation O +
activity O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
PMA O -
- O -
induced O +
activation O +
of O +
AP-1 O +
was O +
significantly O +
suppressed O +
. O +

The O +
inhibitory O +
effect O +
exerted O +
by O +
anti O -
- O -
CD28 O +
was O +
observed O +
at O +
the O +
level O +
of O +
DNA O +
binding O +
as O +
well O +
as O +
in O +
functional O +
reporter O -
- O -
gene O +
assays O +
. O +

These O +
results O +
suggest O +
that O +
the O +
two O +
transcription O +
factors O +
are O +
independently O +
regulated O +
and O +
may O +
perform O +
different O +
functions O +
during O +
T O -
- O -
cell O +
activation O +
. O +

CD14 O +
-mediated O +
translocation O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
induced O +
by O +
lipopolysaccharide O +
does O +
not O +
require O +
tyrosine O +
kinase O +
activity O +
. O +

During O +
the O +
course O +
of O +
serious O +
bacterial O +
infections O +
, O +
lipopolysaccharide O +
( O +
LPS O +
) O +
is O +
believed O +
to O +
interact O +
with O +
macrophage O +
receptors O +
, O +
resulting O +
in O +
the O +
generation O +
of O +
inflammatory O +
mediators O +
and O +
systemic O +
symptoms O +
including O +
hemodynamic O +
instability O +
and O +
shock O +
. O +

CD14 O +
, O +
a O +
glycosylphosphatidylinositol O -
- O -
linked O +
antigen O +
, O +
functions O +
as O +
an O +
LPS O +
signaling O +
receptor O +
. O +

A O +
critical O +
issue O +
concerns O +
the O +
mechanism O +
by O +
which O +
CD14 O +
, O +
which O +
has O +
no O +
transmembrane O +
domain O +
, O +
transduces O +
its O +
signal O +
following O +
LPS O +
binding O +
. O +

Recently O +
, O +
investigators O +
have O +
hypothesized O +
that O +
CD14 O +
-mediated O +
signaling O +
is O +
effected O +
through O +
a O +
receptor O -
- O -
associated O +
tyrosine O +
kinase O +
( O +
TK O +
) O +
, O +
suggesting O +
a O +
multicomponent O +
receptor O +
model O +
of O +
LPS O +
signaling O +
. O +

Wild O -
- O -
type O +
Chinese B-CellLine +
hamster I-CellLine +
ovary I-CellLine +
( I-CellLine +
CHO I-CellLine +
) I-CellLine +
-K1 I-CellLine +
cells I-CellLine +
can O +
be O +
activated O +
by O +
endotoxin O +
to O +
release O +
arachidonate O +
following O +
transfection O +
with O +
human O +
CD14 O +
( O +
CHO O -
/ O -
CD14 O +
) O +
. O +

Nuclear O +
translocation O +
of O +
cytosolic O +
NF O -
- O -
kappa O +
B O +
is O +
correlated O +
with O +
a O +
number O +
of O +
LPS O -
- O -
inducible O +
responses O +
. O +

We O +
sought O +
to O +
determine O +
if O +
this O +
pathway O +
were O +
present O +
in O +
CHO B-CellLine -
/ I-CellLine -
CD14 I-CellLine +
cells I-CellLine +
and O +
to O +
elucidate O +
the O +
relationship O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
to O +
the O +
CD14 O +
receptor O +
system O +
. O +

LPS O -
- O -
stimulated O +
translocation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
CHO B-CellLine -
/ I-CellLine -
CD14 I-CellLine +
cells I-CellLine +
resembled O +
the O +
same O +
response O +
in O +
the O +
murine B-CellLine +
macrophage I-CellLine -
- I-CellLine -
like I-CellLine +
cell I-CellLine +
line I-CellLine +
RAW B-CellLine +
264.7 I-CellLine +
. O +

Protein O +
synthesis O +
inhibitors O +
and O +
corticosteroids O +
, O +
which O +
suppress O +
arachidonate O +
release O +
and O +
the O +
synthesis O +
of O +
proinflammatory O +
cytokines O +
, O +
had O +
no O +
effect O +
on O +
translocation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
CHO O -
/ O +
CD14 O +
or O +
RAW B-CellLine +
264.7 I-CellLine +
cells I-CellLine +
, O +
demonstrating O +
that O +
NF O -
- O -
kappa O +
B O +
translocation O +
is O +
an O +
early O +
event O +
. O +

Although O +
TK O +
activity O +
was O +
consistently O +
observed O +
by O +
immunoblotting O +
extracts O +
from O +
activated O +
RAW B-CellLine +
264.7 I-CellLine +
cells I-CellLine +
, O +
LPS O -
- O -
induced O +
phosphotyrosine O +
residues O +
were O +
not O +
observed O +
from O +
similarly O +
treated O +
CHO B-CellLine -
/ I-CellLine -
CD14 I-CellLine +
cells I-CellLine +
. O +

Furthermore O +
, O +
the O +
TK O +
inhibitors O +
herbimycin O +
A O +
and O +
genistein O +
failed O +
to O +
inhibit O +
translocation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
CHO B-CellLine -
/ I-CellLine -
CD14 I-CellLine +
or O +
RAW B-CellLine +
264.7 I-CellLine +
cells I-CellLine +
, O +
although O +
both O +
of O +
these O +
agents O +
inhibited O +
LPS O -
- O -
induced O +
TK O +
activity O +
in O +
RAW B-CellLine +
264.7 I-CellLine +
cells I-CellLine +
. O +

These O +
results O +
imply O +
that O +
TK O +
activity O +
is O +
not O +
obligatory O +
for O +
CD14 O +
-mediated O +
signal O +
transduction O +
to O +
occur O +
in O +
response O +
to O +
LPS O +
. O +

Signals O +
transduced O +
through O +
the O +
CD4 O +
molecule O +
on O +
T O +
lymphocytes O +
activate O +
NF O -
- O -
kappa O +
B O +
. O +

We O +
have O +
demonstrated O +
that O +
native O +
envelope O +
glycoproteins O +
of O +
HIV-1 O +
, O +
gp160 O +
can O +
induce O +
activation O +
of O +
the O +
transcription O +
factor O +
, O +
NF O -
- O -
kappa O +
B O +
. O +

The O +
stimulatory O +
effects O +
of O +
gp160 O +
are O +
mediated O +
through O +
the O +
CD4 O +
molecule O +
, O +
since O +
pretreatment O +
with O +
soluble O +
CD4 O +
abrogates O +
its O +
activity O +
. O +

The O +
gp160-induced O +
NF O -
- O -
kappa O +
B O +
complex O +
consists O +
of O +
p65 O +
, O +
p50 O +
and O +
c O -
- O -
rel O +
proteins O +
. O +

The O +
stimulatory O +
effect O +
of O +
gp160 O +
on O +
NF O -
- O -
kappa O +
B O +
activation O +
is O +
protein O +
synthesis O +
independent O +
, O +
is O +
dependent O +
upon O +
protein O +
tyrosine O +
phosphorylation O +
, O +
and O +
abrogated O +
by O +
inhibitors O +
of O +
protein O +
kinase O +
C O +
. O +

The O +
gp160-mediated O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
CD4 O +
positive O +
T O +
cells O +
may O +
be O +
involved O +
in O +
biological O +
effects O +
, O +
e.g. O +
, O +
enhanced O +
HIV O +
replication O +
, O +
hypergammaglobulinemia O +
, O +
increased O +
cytokine O +
secretion O +
, O +
hypercellularity O +
in O +
bone O +
marrow O +
and O +
apoptosis O +
. O +

Involvement O +
of O +
phospholipase O +
D O +
in O +
the O +
activation O +
of O +
transcription O +
factor O +
AP-1 O +
in O +
human B-CellLine +
T I-CellLine +
lymphoid I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
. O +

The O +
induction O +
of O +
the O +
AP-1 O +
transcription O +
factor O +
has O +
been O +
ascribed O +
to O +
the O +
early O +
events O +
leading O +
to O +
T O +
lymphocyte O +
activation O +
. O +

We O +
have O +
examined O +
the O +
possibility O +
that O +
stimulation O +
of O +
phospholipase O +
D O +
( O +
PLD O +
) O +
may O +
regulate O +
activation O +
of O +
transcription O +
factor O +
AP-1 O +
in O +
human O +
T O +
cells O +
by O +
transfecting O +
human O +
T B-CellLine +
lymphocyte I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
with O +
a O +
plasmid O +
containing O +
an O +
AP-1 O +
enhancer O +
element O +
and O +
a O +
chloramphenicol O +
acetyltransferase O +
reporter O +
gene O +
. O +

We O +
have O +
detected O +
activatable O +
PLD O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
and O +
we O +
have O +
found O +
that O +
addition O +
of O +
phosphatidic O +
acid O +
( O +
PA O +
) O +
, O +
the O +
physiologic O +
product O +
of O +
PLD O +
action O +
on O +
phospholipids O +
, O +
is O +
rapidly O +
incorporated O +
into O +
Jurkat B-CellLine +
cells I-CellLine +
and O +
leads O +
to O +
activation O +
of O +
transcription O +
factor O +
AP-1 O +
. O +

Treatment O +
of O +
Jurkat B-CellLine +
cells I-CellLine +
with O +
anti O -
- O -
CD3 O +
mAb O +
activated O +
both O +
PLD O +
and O +
transcription O +
factor O +
AP-1 O +
. O +

Wortmannin O +
, O +
an O +
inhibitor O +
of O +
receptor O -
- O -
coupled O +
PLD O +
activation O +
, O +
blocked O +
the O +
anti O -
- O -
CD3 O +
-induced O +
increases O +
in O +
both O +
PLD O +
activity O +
and O +
AP-1 O +
enhancer O +
activity O +
. O +

We O +
found O +
a O +
good O +
correlation O +
in O +
the O +
transfected B-CellLine +
cells I-CellLine +
between O +
PLD O +
activation O +
and O +
induction O +
of O +
AP-1 O +
enhancer O +
activity O +
under O +
different O +
experimental O +
conditions O +
. O +

Furthermore O +
, O +
ethanol O +
, O +
an O +
inhibitor O +
of O +
the O +
PLD O +
pathway O +
, O +
blocked O +
the O +
anti O -
- O -
CD3-stimulated O +
AP-1 O +
enhancer O +
activity O +
. O +

However O +
, O +
this O +
anti O -
- O -
CD3 O +
-mediated O +
response O +
was O +
not O +
inhibited O +
by O +
neomycin O +
, O +
an O +
inhibitor O +
of O +
phosphoinositide O +
hydrolysis O +
. O +

The O +
increases O +
in O +
AP-1 O +
enhancer O +
activity O +
induced O +
by O +
PA O +
or O +
anti O -
- O -
CD3 O +
mAb O +
were O +
efficiently O +
abrogated O +
by O +
the O +
presence O +
of O +
propranolol O +
, O +
an O +
inhibitor O +
of O +
PA O +
phosphohydrolase O +
and O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
. O +

Furthermore O +
, O +
the O +
PA O +
-and O +
the O +
anti O -
- O -
CD3 O +
-induced O +
increases O +
in O +
AP-1 O +
enhancer O +
activity O +
were O +
blocked O +
by O +
the O +
presence O +
of O +
PKC O +
inhibitors O +
or O +
by O +
PKC O +
down O -
- O -
regulation O +
. O +

These O +
data O +
indicate O +
that O +
PLD O +
stimulation O +
can O +
activate O +
the O +
transcription O +
factor O +
AP-1 O +
in O +
T O +
lymphocytes O +
, O +
and O +
suggest O +
that O +
the O +
induction O +
of O +
AP-1 O +
enhancer O +
factor O +
activity O +
by O +
PA O +
is O +
mediated O +
via O +
PKC O +
stimulation O +
, O +
either O +
through O +
a O +
direct O +
activating O +
effect O +
of O +
PA O +
or O +
through O +
PA O -
- O -
derived O +
diacylglycerol O +
formation O +
. O +

These O +
data O +
also O +
provide O +
evidence O +
for O +
a O +
role O +
of O +
PLD O +
-derived O +
lipids O +
in O +
the O +
induction O +
of O +
AP-1 O +
enhancer O +
activity O +
resulting O +
from O +
stimulation O +
of O +
the O +
TCR O -
/ O -
CD3 O +
complex O +
, O +
suggesting O +
that O +
increased O +
PLD O +
activity O +
can O +
play O +
an O +
important O +
role O +
in O +
T O +
lymphocyte O +
activation O +
. O +

Induction O +
of O +
IL-8 O +
expression O +
in O +
T O +
cells O +
uses O +
the O +
CD28 O +
costimulatory O +
pathway O +
. O +

IL-8 O +
, O +
a O +
potent O +
chemotactic O +
factor O +
for O +
neutrophil O +
granulocytes O +
and O +
lymphocytes O +
, O +
is O +
a O +
proinflammatory O +
cytokine O +
secreted O +
by O +
a O +
variety O +
of O +
cell O +
types O +
, O +
including O +
T O +
cells O +
. O +

Stimulation O +
of O +
the O +
CD28 O +
cell O +
surface O +
molecule O +
delivers O +
costimulatory O +
signals O +
essential O +
for O +
lymphokine O +
production O +
in O +
activated O +
T O +
cells O +
via O +
a O +
conserved O +
sequence O +
element O +
found O +
in O +
the O +
promoter O +
of O +
several O +
lymphokine O +
genes O +
. O +

Anti B-CellLine -
- I-CellLine -
CD28-stimulated I-CellLine +
T I-CellLine +
cells I-CellLine +
produced O +
significant O +
amounts O +
of O +
IL-8 O +
; O +
additionally O +
, O +
costimulation O +
with O +
anti O -
- O -
CD3 O +
and O +
anti O -
- O -
CD28 O +
Abs O +
resulted O +
in O +
a O +
synergistic O +
induction O +
of O +
IL-8 O +
secretion O +
. O +

Sequence O +
homology O +
, O +
single O +
nucleotide O +
mutations O +
, O +
and O +
anti O -
- O -
CD28 O +
Ab O +
stimulation O +
studies O +
established O +
that O +
the O +
NF O -
- O -
kappa O +
B O -
- O -
like O +
sequence O +
in O +
the O +
promoter O +
of O +
the O +
IL-8 O +
gene O +
functioned O +
as O +
a O +
CD28 O +
response O +
element O +
. O +

Furthermore O +
, O +
cyclosporin O +
A O +
, O +
but O +
not O +
rapamycin O +
, O +
blocked O +
the O +
synergistic O +
induction O +
of O +
IL-8 O +
expression O +
achieved O +
with O +
anti O -
- O -
CD3 O +
and O +
anti- O +
CD28 O +
costimulation O +
. O +

The O +
involvement O +
of O +
a O +
CD28 O +
response O +
element O +
in O +
the O +
induction O +
of O +
IL-8 O +
expression O +
in O +
activated O +
T O +
cells O +
may O +
provide O +
new O +
insights O +
into O +
the O +
pathogenesis O +
and O +
persistence O +
of O +
immune O +
disorders O +
characterized O +
by O +
increased O +
levels O +
of O +
IL-8 O +
, O +
such O +
as O +
psoriasis O +
and O +
rheumatoid O +
arthritis O +
. O +

Signals O +
and O +
nuclear O +
factors O +
that O +
regulate O +
the O +
expression O +
of O +
interleukin-4 O +
and O +
interleukin-5 O +
genes O +
in O +
helper O +
T O +
cells O +
. O +

Mouse B-CellLine +
thymoma I-CellLine +
line I-CellLine +
EL-4 I-CellLine +
cells I-CellLine +
produce O +
cytokines O +
such O +
as O +
interleukin O +
( O +
IL O +
) O +
-2 O +
, O +
IL-3 O +
, O +
IL-4 O +
, O +
IL-10 O +
, O +
and O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
in O +
response O +
to O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
. O +

EL-4 B-CellLine +
cells I-CellLine +
also O +
produce O +
low O +
levels O +
of O +
IL-5 O +
when O +
stimulated O +
by O +
PMA O +
alone O +
; O +
however O +
, O +
cAMP O +
greatly O +
augments O +
PMA O -
- O -
dependent O +
IL-5 O +
production O +
. O +

A O +
transient O +
transfection O +
assay O +
revealed O +
that O +
two O +
signals O +
, O +
PMA O +
and O +
cAMP O +
, O +
are O +
required O +
for O +
optimal O +
activation O +
of O +
the O +
IL-5 O +
promoter O +
. O +

In O +
contrast O +
, O +
cAMP O +
almost O +
completely O +
inhibited O +
the O +
PMA O -
- O -
dependent O +
activation O +
of O +
the O +
endogenous O +
IL-2 O +
gene O +
, O +
as O +
well O +
as O +
the O +
transfected O +
IL-2 O +
promoter O +
. O +

These O +
results O +
indicate O +
that O +
the O +
IL-5 O +
gene O +
is O +
positively O +
regulated O +
by O +
cAMP O +
in O +
a O +
manner O +
opposite O +
to O +
that O +
for O +
the O +
IL-2 O +
gene O +
. O +

One O +
of O +
the O +
nuclear O +
factors O +
( O +
NFs O +
) O +
that O +
regulates O +
the O +
response O +
of O +
the O +
IL-5 O +
promoter O +
to O +
cAMP O +
and O +
PMA O +
has O +
properties O +
similar O +
to O +
NF O +
for O +
activated O +
t O +
cell O +
. O +

The O +
P O +
sequence O +
of O +
the O +
IL-4 O +
gene O +
, O +
defined O +
as O +
a O +
responsive O +
element O +
for O +
PMA O +
and O +
calcium O +
ionophore O +
( O +
A23187 O +
) O +
, O +
shares O +
sequence O +
similarity O +
with O +
the O +
NF O +
kappa O +
B O +
and O +
the O +
NF O -
- O -
activated O +
T O +
cell O +
binding O +
sites O +
. O +

We O +
attempted O +
to O +
determine O +
whether O +
NF O +
( O +
P O +
) O +
, O +
a O +
nuclear O +
factor O +
specific O +
for O +
the O +
P O +
sequence O +
, O +
is O +
related O +
to O +
NF O -
- O -
kappa O +
B O +
and O +
nuclear O +
factor O +
for O +
activated O +
T O +
cell O +
( O +
NF O -
- O -
AT O +
) O +
. O +

In O +
electromobility O +
shift O +
assays O +
both O +
NF O -
- O -
kappa O +
B O +
( O +
P65 O +
or O +
P65 O -
/ O -
P50 O +
heterodimer O +
) O +
and O +
NF O -
- O -
AT O +
bound O +
to O +
the O +
P O +
sequence O +
. O +

However O +
, O +
sequence O +
specificity O +
of O +
NF O -
- O -
AT O +
was O +
more O +
similar O +
to O +
that O +
of O +
NF O +
( O +
P O +
) O +
, O +
and O +
only O +
a O +
small O +
amount O +
of O +
P65 O +
was O +
detected O +
in O +
NF O +
( O +
P O +
) O +
. O +

These O +
results O +
indicate O +
that O +
a O +
component O +
or O +
components O +
of O +
NF O -
- O -
AT O +
have O +
the O +
potential O +
to O +
reconstitute O +
NF O +
( O +
P O +
) O +
, O +
whereas O +
NF O -
- O -
kappa O +
B O +
alone O +
does O +
not O +
account O +
for O +
NF O +
( O +
P O +
) O +
in O +
Jurkat O +
crude O +
extract O +
. O +

Taken O +
together O +
, O +
these O +
results O +
suggest O +
that O +
NF O -
- O -
AT O -
- O -
like O +
factors O +
are O +
involved O +
in O +
the O +
regulation O +
of O +
IL-4 O +
and O +
IL-5 O +
genes O +
. O +

Mechanisms O +
involved O +
in O +
the O +
inhibition O +
of O +
growth O +
of O +
a O +
human B-CellLine +
B I-CellLine +
lymphoma I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
B104 B-CellLine +
, O +
by O +
anti O -
- O -
MHC O +
class O +
II O +
antibodies O +
. O +

The O +
mechanisms O +
involved O +
in O +
the O +
inhibition O +
of O +
growth O +
of O +
a O +
human B-CellLine +
B I-CellLine +
lymphoma I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
B104 B-CellLine +
, O +
by O +
anti O -
- O -
MHC O +
class O +
II O +
antibodies O +
( O +
Ab O +
) O +
were O +
compared O +
with O +
those O +
in O +
anti O -
- O -
IgM O +
Ab O +
-induced O +
B104 O +
growth O +
inhibition O +
. O +

Two O +
anti O -
- O -
MHC O +
class O +
II O +
Ab O +
, O +
L227 O +
and O +
2.06 O +
, O +
inhibited O +
the O +
growth O +
of O +
B104 B-CellLine +
cells I-CellLine +
, O +
although O +
2.06 O +
, O +
but O +
not O +
L227 O +
, O +
needed O +
to O +
be O +
further O +
cross O -
- O -
linked O +
with O +
a O +
goat O +
anti O -
- O -
mouse O +
IgG O +
Ab O +
( O +
GAM O +
) O +
to O +
show O +
the O +
effect O +
. O +

L227 O +
induced O +
an O +
increase O +
in O +
intracellular O +
free O +
Ca2 O -
+ O +
concentration O +
( O +
[ O +
Ca2 O -
+ O +
] O +
i O +
) O +
from O +
the O +
intracellular O +
pool O +
and O +
little O +
or O +
no O +
protein O +
tyrosine O +
phosphorylation O +
, O +
phosphatidyl O +
inositol O +
turnover O +
, O +
or O +
expression O +
of O +
Egr-1 O +
mRNA O +
, O +
whereas O +
2.06 O +
plus O +
GAM O +
induced O +
an O +
increase O +
in O +
[ O +
Ca2 O -
+ O +
] O +
i O +
from O +
both O +
the O +
intracellular O +
and O +
, O +
in O +
particular O +
, O +
the O +
extracellular O +
pools O +
. O +

The O +
inhibition O +
of O +
B104 B-CellLine +
cell I-CellLine +
growth O +
induced O +
by O +
anti O -
- O -
MHC O +
class O +
II O +
Ab O +
was O +
Ca O +
( O +
2 O -
+ O +
) O +
-independent O +
and O +
not O +
inhibited O +
by O +
actinomycin O +
D O +
or O +
cyclosporin O +
A O +
, O +
and O +
cell O +
cycle O +
arrest O +
at O +
the O +
G2 O -
/ O -
M O +
interphase O +
was O +
not O +
observed O +
. O +

These O +
features O +
are O +
very O +
different O +
from O +
those O +
observed O +
in O +
B104 B-CellLine +
cell I-CellLine +
death O +
induced O +
by O +
anti O -
- O -
IgM O +
Ab O +
. O +

Neither O +
DNA O +
fragmentation O +
nor O +
the O +
morphology O +
of O +
apoptosis O +
was O +
observed O +
. O +

These O +
findings O +
demonstrate O +
that O +
cross O -
- O -
linking O +
of O +
MHC O +
class O +
II O +
molecules O +
transduced O +
the O +
negative O +
signals O +
through O +
intracellular O +
mechanisms O +
different O +
from O +
those O +
present O +
in O +
the O +
cross O -
- O -
linking O +
of O +
surface O +
IgM O +
. O +

Regulation O +
of O +
CD14 O +
expression O +
during O +
monocytic O +
differentiation O +
induced O +
with O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
. O +

CD14 O +
, O +
a O +
monocyte O -
/ O -
macrophage O +
receptor O +
for O +
the O +
complex O +
of O +
LPS O +
and O +
LPS O +
binding O +
protein O +
, O +
is O +
a O +
differentiation O +
marker O +
for O +
the O +
monocyte O -
/ O -
macrophage O +
lineage O +
. O +

We O +
have O +
analyzed O +
the O +
regulation O +
of O +
CD14 O +
expression O +
during O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
VitD3 O +
) O +
-induced O +
monocytic O +
differentiation O +
. O +

Using O +
FACS O +
, O +
Northern O +
blotting O +
, O +
and O +
nuclear O +
run O -
- O -
on O +
analyses O +
, O +
we O +
demonstrate O +
that O +
the O +
up O -
- O -
regulation O +
of O +
CD14 O +
expression O +
during O +
monocytic O +
cell O +
maturation O +
is O +
regulated O +
mainly O +
at O +
the O +
level O +
of O +
gene O +
transcription O +
, O +
and O +
that O +
new O +
protein O +
synthesis O +
is O +
required O +
for O +
CD14 O +
induction O +
. O +

We O +
have O +
recently O +
cloned O +
the O +
CD14 O +
5 O +
' O +
upstream O +
sequence O +
and O +
demonstrated O +
its O +
tissue O -
- O -
specific O +
promoter O +
activity O +
. O +

Using O +
stable O +
transfection O +
of O +
the O +
monocytoid B-CellLine +
U937 I-CellLine +
cell I-CellLine +
line I-CellLine +
with O +
a O +
series O +
of O +
deletion O +
mutants O +
of O +
the O +
CD14 O +
5 O +
' O +
upstream O +
sequence O +
coupled O +
to O +
a O +
reporter O +
gene O +
construct O +
, O +
we O +
show O +
that O +
bp O +
-128 O +
to O +
-70 O +
is O +
the O +
critical O +
region O +
for O +
the O +
induction O +
of O +
CD14 O +
expression O +
. O +

This O +
region O +
contains O +
two O +
binding O +
sites O +
for O +
the O +
Sp1 O +
transcription O +
factor O +
. O +

A O +
3-bp O +
mutation O +
at O +
the O +
distal O +
Sp1-binding O +
site O +
not O +
only O +
eliminates O +
Sp1 O +
interaction O +
, O +
but O +
also O +
abolishes O +
most O +
of O +
the O +
VitD3 O +
induction O +
of O +
CD14 O +
expression O +
. O +

Electrophoretic O +
mobility O +
shift O +
analysis O +
does O +
not O +
detect O +
a O +
direct O +
interaction O +
of O +
the O +
CD14 O +
distal O +
Sp1-binding O +
site O +
with O +
the O +
vitamin O +
D3 O +
receptor O +
and O +
its O +
partner O +
, O +
the O +
retinoid O +
X O +
receptor O +
. O +

These O +
data O +
demonstrate O +
that O +
VitD3 O +
induces O +
CD14 O +
indirectly O +
through O +
some O +
intermediary O +
factor O +
, O +
and O +
suggest O +
a O +
critical O +
role O +
for O +
Sp1 O +
in O +
this O +
process O +
. O +

Calcium O +
signalling O +
in O +
T O +
cells O +
stimulated O +
by O +
a O +
cyclophilin O +
B O -
- O -
binding O +
protein O +
. O +

The O +
immunosuppressant O +
drug O +
cyclosporin O +
A O +
blocks O +
a O +
calcium O -
- O -
dependent O +
signal O +
from O +
the O +
T O -
- O -
cell O +
receptor O +
( O +
TCR O +
) O +
that O +
normally O +
leads O +
to O +
T O -
- O -
cell O +
activation O +
. O +

When O +
bound O +
to O +
cyclophilin O +
, O +
cyclosporin O +
A O +
binds O +
and O +
inactivates O +
the O +
key O +
signalling O +
intermediate O +
calcineurin O +
. O +

To O +
identify O +
potential O +
cellular O +
homologues O +
of O +
cyclosporin O +
A O +
that O +
might O +
regulate O +
calcium O +
signalling O +
, O +
we O +
have O +
cloned O +
human O +
genes O +
encoding O +
cyclophilin O +
B O -
- O -
binding O -
- O -
proteins O +
using O +
the O +
yeast O +
two O -
- O -
hybrid O +
system O +
. O +

One O +
gene O +
product O +
, O +
when O +
overexpressed O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
specifically O +
induced O +
transcription O +
from O +
the O +
interleukin-2 O +
enhancer O +
, O +
by O +
activating O +
the O +
T O -
- O -
cell O -
- O -
specific O +
transcription O +
factors O +
NF O -
- O -
AT O +
and O +
NF O -
- O -
IL2A O +
. O +

This O +
protein O +
, O +
termed O +
calcium O -
- O -
signal O +
modulating O +
cyclophilin O +
ligand O +
( O +
CAML O +
) O +
, O +
acts O +
downstream O +
of O +
the O +
TCR O +
and O +
upstream O +
of O +
calcineurin O +
by O +
causing O +
an O +
influx O +
of O +
calcium O +
. O +

CAML O +
appears O +
to O +
be O +
a O +
new O +
participant O +
in O +
the O +
calcium O -
- O -
signal O +
transduction O +
pathway O +
, O +
implicating O +
cyclophilin O +
B O +
in O +
calcium O +
signalling O +
, O +
even O +
in O +
the O +
absence O +
of O +
cyclosporin O +
. O +

Role O +
of O +
HIV-1 O +
Nef O +
expression O +
in O +
activation O +
pathways O +
in O +
CD4 O +
+ O +
T O +
cells O +
. O +

The O +
role O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
( O +
HIV-1 O +
) O +
Nef O +
protein O +
in O +
T O +
cell O +
activation O +
pathways O +
was O +
investigated O +
using O +
a O +
Jurkat B-CellLine +
CD4 I-CellLine -
+ I-CellLine +
cell I-CellLine +
line I-CellLine +
stably O +
transfected O +
with O +
a O +
Nef O +
expression O +
vector O +
. O +

Secretion O +
of O +
IL-2 O +
and O +
TNF O -
- O -
alpha O +
, O +
surface O +
expression O +
of O +
IL-2R O +
, O +
and O +
DNA O -
- O -
binding O +
activity O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O +
( O +
Fos O -
/ O -
Jun O +
) O +
complex O +
in O +
response O +
to O +
phorbol O +
myristate O +
acetate O +
, O +
TNF O -
- O -
alpha O +
, O +
or O +
immobilized O +
antibodies O +
to O +
CD3 O +
were O +
monitored O +
. O +

These O +
parameters O +
were O +
not O +
modified O +
by O +
Nef O +
expression O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
whereas O +
stimulation O +
with O +
the O +
same O +
stimuli O +
resulted O +
in O +
partial O +
inhibition O +
of O +
LTR O +
activation O +
in O +
Nef+ B-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
. O +

This O +
inhibition O +
was O +
not O +
mediated O +
through O +
Nef O +
phosphorylation O +
on O +
Thr-15 O +
or O +
GTP O -
- O -
binding O +
activity O +
because O +
mutations O +
in O +
critical O +
sites O +
did O +
not O +
alter O +
this O +
inhibition O +
. O +

Analysis O +
of O +
truncated O +
LTRs O +
confirmed O +
that O +
inhibition O +
of O +
LTR O +
activation O +
was O +
not O +
mediated O +
through O +
NF O -
- O -
kappa O +
B O +
-binding O +
activity O +
but O +
through O +
the O +
region O +
containing O +
the O +
negative O +
responding O +
elements O +
( O +
NREs O +
) O +
. O +

These O +
results O +
suggest O +
that O +
Nef O +
downmodulates O +
LTR O +
activation O +
without O +
significantly O +
inhibiting O +
the O +
capacity O +
of O +
T O +
cells O +
to O +
respond O +
to O +
immunological O +
activations O +
. O +

Marked O +
basophilia O +
in O +
acute O +
promyelocytic O +
leukaemia O +
treated O +
with O +
all O -
- O -
trans O +
retinoic O +
acid O +
: O +
molecular O +
analysis O +
of O +
the O +
cell O +
origin O +
of O +
the O +
basophils O +
. O +

We O +
report O +
a O +
patient O +
with O +
acute O +
promyelocytic O +
leukaemia O +
who O +
developed O +
marked O +
basophilia O +
during O +
all O -
- O -
trans O +
retinoic O +
acid O +
treatment O +
. O +

We O +
studied O +
genomic O +
DNA O +
and O +
RNA O +
extracted O +
from O +
the O +
patient O +
's O +
peripheral O +
leucocytes O +
in O +
order O +
to O +
determine O +
the O +
origin O +
of O +
the O +
basophils O +
. O +

The O +
RAR O +
alpha O +
rearranged O +
band O +
in O +
the O +
Southern O +
blot O +
analysis O +
and O +
a O +
chimaeric O +
product O +
of O +
PML O -
- O -
RAR O +
alpha O +
by O +
polymerase O +
chain O +
reaction O +
were O +
strongly O +
visible O +
before O +
ATRA O +
treatment O +
, O +
but O +
at O +
the O +
time O +
of O +
maximal O +
basophilia O +
both O +
of O +
them O +
were O +
markedly O +
diminished O +
. O +

These O +
findings O +
suggest O +
that O +
the O +
basophils O +
which O +
appeared O +
during O +
the O +
ATRA O +
treatment O +
are O +
reactive O +
in O +
nature O +
rather O +
than O +
a O +
leukaemic B-CellLine +
clone I-CellLine +
. O +

Antioxidants O +
inhibit O +
monocyte O +
adhesion O +
by O +
suppressing O +
nuclear O +
factor O -
- O -
kappa O +
B O +
mobilization O +
and O +
induction O +
of O +
vascular O +
cell O +
adhesion O +
molecule-1 O +
in O +
endothelial O +
cells O +
stimulated O +
to O +
generate O +
radicals O +
. O +

Cell O +
adhesion O +
to O +
endothelial O +
cells O +
stimulated O +
by O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O +
) O +
is O +
due O +
to O +
induction O +
of O +
surface O +
receptors O +
, O +
such O +
as O +
vascular O +
cell O +
adhesion O +
molecule-1 O +
( O +
VCAM-1 O +
) O +
. O +

The O +
antioxidant O +
pyrrolidine O +
dithiocarbamate O +
( O +
PDTC O +
) O +
specifically O +
inhibits O +
activation O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
. O +

Since O +
kappa O +
B O +
motifs O +
are O +
present O +
in O +
VCAM-1 O +
and O +
intercellular O +
adhesion O +
molecule-1 O +
( O +
ICAM-1 O +
) O +
promoters O +
, O +
we O +
used O +
PDTC O +
to O +
study O +
the O +
regulatory O +
mechanisms O +
of O +
VCAM-1 O +
and O +
ICAM-1 O +
induction O +
and O +
subsequent O +
monocyte O +
adhesion O +
in O +
TNF B-CellLine -
- I-CellLine -
treated I-CellLine +
human I-CellLine +
umbilical I-CellLine +
vein I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
( O +
HUVECs B-CellLine +
) O +
. O +

PDTC O +
or O +
N O -
- O -
acetylcysteine O +
dose O +
dependently O +
reduced O +
TNF O -
- O -
induced O +
VCAM-1 O +
but O +
not O +
ICAM-1 O +
surface O +
protein O +
( O +
also O +
in O +
human O +
umbilical O +
arterial O +
endothelial O +
cells O +
) O +
and O +
mRNA O +
expression O +
( O +
by O +
70 O +
% O +
at O +
100 O +
mumol O -
/ O -
L O +
PDTC O +
) O +
in O +
HUVECs B-CellLine +
as O +
assessed O +
by O +
flow O +
cytometry O +
and O +
polymerase O +
chain O +
reaction O +
. O +

Gel O -
- O -
shift O +
analysis O +
in O +
HUVECs B-CellLine +
demonstrated O +
that O +
PDTC O +
prevented O +
NF O -
- O -
kappa O +
B O +
mobilization O +
by O +
TNF O +
, O +
suggesting O +
that O +
only O +
VCAM-1 O +
induction O +
was O +
controlled O +
by O +
NF O -
- O -
kappa O +
B O +
. O +

Since O +
HUVECs B-CellLine +
released O +
superoxide O +
anions O +
in O +
response O +
to O +
TNF O +
, O +
and O +
H2O2 O +
induces O +
VCAM-1 O +
, O +
PDTC O +
may O +
act O +
as O +
a O +
radical O +
scavenger O +
. O +

Although O +
ICAM-1 O +
induction O +
was O +
unaffected O +
, O +
inhibitors O +
of O +
NADPH O +
oxidase O +
( O +
apocynin O +
) O +
or O +
cytochrome O +
P-450 O +
( O +
SKF525a O +
) O +
suppressed O +
VCAM-1 O +
induction O +
by O +
TNF O +
, O +
revealing O +
that O +
several O +
radical O -
- O -
generating O +
systems O +
are O +
involved O +
in O +
its O +
regulation O +
. O +

PDTC O +
, O +
apocynin O +
, O +
or O +
SKF525a O +
decreased O +
adhesion O +
of O +
monocytic B-CellLine +
U937 I-CellLine +
cells I-CellLine +
to O +
TNF B-CellLine -
- I-CellLine -
treated I-CellLine +
HUVECs I-CellLine +
( O +
by O +
75 O +
% O +
at O +
100 O +
mumol O -
/ O -
L O +
PDTC O +
) O +
. O +

Inhibition O +
by O +
anti O -
- O -
VCAM-1 O +
monoclonal O +
antibody O +
1G11 O +
indicated O +
that O +
U937 B-CellLine +
adhesion O +
was O +
VCAM-1 O +
dependent O +
and O +
suppression O +
by O +
antioxidants O +
was O +
due O +
to O +
reduced O +
VCAM-1 O +
induction O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

Novel O +
membrane O +
receptors O +
for O +
aldosterone O +
in O +
human O +
lymphocytes O +
: O +
a O +
50 O +
kDa O +
protein O +
on O +
SDS O -
- O -
PAGE O +
. O +

Fast O +
in O +
vitro O +
effects O +
of O +
aldosterone O +
on O +
the O +
Na+ O -
/ O -
H O +
( O +
+ O +
) O +
-exchanger O +
, O +
inositoltrisphosphate O +
generation O +
and O +
corresponding O +
specific O +
binding O +
to O +
plasma O +
membranes O +
at O +
Kd O -
- O -
values O +
of O +
approximately O +
0.1 O +
nM O +
have O +
been O +
found O +
in O +
human O +
mononuclear O +
leukocytes O +
and O +
vascular O +
smooth O +
muscle O +
cells O +
. O +

The O +
novel O +
aldosterone O +
membrane O +
receptor O +
was O +
analyzed O +
on O +
SDS O -
- O -
PAGE O +
after O +
labeling O +
of O +
microsomal O +
membranes O +
from O +
human O +
mononuclear O +
leukocytes O +
with O +
a O +
[ O +
125I O +
] O +
-aldosterone O -
- O -
derivative O +
by O +
use O +
of O +
BASED O +
as O +
a O +
photoactivatable O +
crosslinker O +
. O +

Binding O +
of O +
1 O +
nM O +
[ O +
125I O +
] O +
-aldosterone O +
was O +
found O +
at O +
a O +
molecular O +
weight O +
of O +
approximately O +
50 O +
kDa O +
which O +
was O +
absent O +
with O +
1 O +
microM O +
cold O +
aldosterone O +
, O +
but O +
not O +
cortisol O +
in O +
the O +
binding O +
media O +
. O +

This O +
aldosterone O -
- O -
selectivity O +
is O +
typical O +
and O +
discriminatory O +
for O +
the O +
new O +
aldosterone O +
membrane O +
receptor O +
. O +

Solubilization O +
of O +
the O +
receptor O +
protein O +
from O +
membranes O +
by O +
high O +
salt O +
concentrations O +
( O +
1 O +
M O +
NaCl O +
, O +
1 O +
mM O +
EDTA O +
) O +
was O +
not O +
achieved O +
. O +

It O +
, O +
thus O +
, O +
appears O +
as O +
an O +
integral O +
membrane O +
protein O +
. O +

Dithiothreitol O +
, O +
a O +
sulfhydryl O +
agent O +
, O +
does O +
not O +
reduce O +
specific O +
aldosterone O +
binding O +
indicating O +
the O +
absence O +
of O +
SH O -
- O -
groups O +
in O +
the O +
binding O +
domain O +
or O +
sensitive O +
structures O +
of O +
the O +
receptors O +
. O +

The O +
results O +
are O +
the O +
first O +
to O +
characterize O +
the O +
novel O +
membrane O +
receptor O +
for O +
aldosterone O +
with O +
regard O +
to O +
molecular O +
weight O +
and O +
basic O +
properties O +
. O +

These O +
findings O +
and O +
other O +
related O +
results O +
are O +
reviewed O +
here O +
. O +

Activation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
vivo O +
is O +
regulated O +
by O +
multiple O +
phosphorylations O +
. O +

The O +
activation O +
of O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
in O +
intact O +
cells O +
is O +
mechanistically O +
not O +
well O +
understood O +
. O +

Therefore O +
we O +
investigated O +
the O +
modifications O +
imposed O +
on O +
NF O -
- O -
kappa O +
B O -
/ O -
I O +
kappa O +
B O +
components O +
following O +
stimulation O +
and O +
show O +
that O +
the O +
final O +
step O +
of O +
NF O -
- O -
kappa O +
B O +
induction O +
in O +
vivo O +
involves O +
phosphorylation O +
of O +
several O +
members O +
of O +
the O +
NF O -
- O -
kappa O +
B O -
/ O -
I O +
kappa O +
B O +
protein O +
families O +
. O +

In O +
HeLa B-CellLine +
cells I-CellLine +
as O +
well O +
as O +
in O +
B O +
cells O +
, O +
TNF O -
- O -
alpha O +
rapidly O +
induced O +
nuclear O +
translocation O +
primarily O +
of O +
p50-p65 O +
, O +
but O +
not O +
of O +
c O -
- O -
rel O +
. O +

Both O +
NF O -
- O -
kappa O +
B O +
precursors O +
and O +
I O +
kappa O +
B O +
alpha O +
became O +
strongly O +
phosphorylated O +
with O +
the O +
same O +
kinetics O +
. O +

In O +
addition O +
to O +
the O +
inducible O +
phosphorylation O +
after O +
stimulation O +
, O +
B O +
lymphocytes O +
containing O +
constitutive O +
nuclear O +
NF O -
- O -
kappa O +
B O +
revealed O +
constitutively O +
phosphorylated O +
p65 O +
and O +
I O +
kappa O +
B O +
alpha O +
. O +

Phosphorylation O +
was O +
accompanied O +
by O +
induced O +
processing O +
of O +
the O +
precursors O +
p100 O +
and O +
p105 O +
and O +
by O +
degradation O +
of O +
I O +
kappa O +
B O +
alpha O +
. O +

As O +
an O +
in O +
vitro O +
model O +
we O +
show O +
that O +
phosphorylation O +
of O +
p105 O +
impedes O +
its O +
ability O +
to O +
interact O +
with O +
NF O -
- O -
kappa O +
B O +
, O +
as O +
has O +
been O +
shown O +
before O +
for O +
I O +
kappa O +
B O +
alpha O +
. O +

Surprisingly O +
, O +
even O +
p65 O +
, O +
but O +
not O +
c O -
- O -
rel O +
, O +
was O +
phosphorylated O +
after O +
induction O +
in O +
vivo O +
, O +
suggesting O +
that O +
TNF O -
- O -
alpha O +
selectively O +
activates O +
only O +
specific O +
NF O -
- O -
kappa O +
B O +
heteromers O +
and O +
that O +
modifications O +
regulate O +
not O +
only O +
I O +
kappa O +
B O +
molecules O +
but O +
also O +
NF O -
- O -
kappa O +
B O +
molecules O +
. O +

In O +
fact O +
, O +
cellular O +
NF O -
- O -
kappa O +
B O +
activity O +
was O +
phosphorylation O -
- O -
dependent O +
and O +
the O +
DNA O +
binding O +
activity O +
of O +
p65-containing O +
NF O -
- O -
kappa O +
B O +
was O +
enhanced O +
by O +
phosphorylation O +
in O +
vitro O +
. O +

Furthermore O +
, O +
we O +
found O +
that O +
the O +
induction O +
by O +
hydrogen O +
peroxide O +
of O +
NF O -
- O -
kappa O +
B O +
translocation O +
to O +
the O +
nucleus O +
, O +
which O +
is O +
assumed O +
to O +
be O +
triggered O +
by O +
reactive O +
oxygen O +
intermediates O +
, O +
also O +
coincided O +
with O +
incorporation O +
of O +
phosphate O +
into O +
the O +
same O +
subunits O +
that O +
were O +
modified O +
after O +
stimulation O +
by O +
TNF O -
- O -
alpha O +
. O +

Thus O +
, O +
phosphorylation O +
appears O +
to O +
be O +
a O +
general O +
mechanism O +
for O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
vivo O +
. O +

An O +
active O +
v O -
- O -
abl O +
protein O +
tyrosine O +
kinase O +
blocks O +
immunoglobulin O +
light O -
- O -
chain O +
gene O +
rearrangement O +
. O +

Lymphoid O +
cells O +
transformed O +
by O +
Abelson O +
murine O +
leukemia O +
virus O +
have O +
provided O +
one O +
of O +
the O +
classic O +
models O +
for O +
study O +
of O +
early O +
B O -
- O -
cell O +
development O +
and O +
immunoglobulin O +
rearrangement O +
. O +

Most O +
of O +
these O +
cells O +
have O +
rearranged O +
their O +
heavy O -
- O -
chain O +
locus O +
but O +
not O +
their O +
light O +
chain O +
genes O +
, O +
suggesting O +
that O +
an O +
active O +
v O -
- O -
abl O +
protein O +
interferes O +
with O +
this O +
differentiation O +
step O +
. O +

To O +
test O +
this O +
hypothesis O +
, O +
light O -
- O -
chain O +
gene O +
structure O +
was O +
examined O +
in O +
pre B-CellLine -
- I-CellLine -
B I-CellLine +
cells I-CellLine +
transformed O +
by O +
temperature O -
- O -
sensitive O +
mutants O +
of O +
the O +
Abelson O +
virus O +
and O +
in O +
derivatives O +
that O +
survive O +
at O +
the O +
nonpermissive O +
temperature O +
because O +
they O +
express O +
a O +
human O +
BCL-2 O +
gene O +
. O +

Our O +
studies O +
reveal O +
that O +
inactivation O +
of O +
the O +
v O -
- O -
abl O +
protein O +
tyrosine O +
kinase O +
triggers O +
high O -
- O -
frequency O +
rearrangement O +
of O +
kappa O +
and O +
lambda O +
light O -
- O -
chain O +
genes O +
. O +

These O +
events O +
are O +
accompanied O +
by O +
marked O +
increases O +
in O +
the O +
expression O +
of O +
RAG-1 O +
and O +
RAG-2 O +
RNAs O +
. O +

These O +
increases O +
occur O +
in O +
the O +
absence O +
of O +
protein O +
synthesis O +
but O +
are O +
dependent O +
on O +
inactivation O +
of O +
the O +
v O -
- O -
abl O +
protein O +
tyrosine O +
kinase O +
. O +

As O +
documented O +
in O +
the O +
accompanying O +
paper O +
( O +
Klug O +
et O +
al. O +
, O +
this O +
issue O +
) O +
, O +
an O +
active O +
v O -
- O -
abl O +
protein O +
also O +
suppresses O +
the O +
activity O +
of O +
NF O -
- O -
kappa O +
B O -
/ O -
rel O +
and O +
expression O +
controlled O +
by O +
the O +
kappa O +
intron O +
enhancer O +
. O +

Together O +
these O +
data O +
demonstrate O +
that O +
the O +
v O -
- O -
abl O +
protein O +
specifically O +
interferes O +
with O +
light O -
- O -
chain O +
gene O +
rearrangement O +
by O +
suppressing O +
at O +
least O +
two O +
pathways O +
essential O +
for O +
this O +
stage O +
of O +
B O -
- O -
cell O +
differentiation O +
and O +
suggest O +
that O +
tyrosine O +
phosphorylation O +
is O +
important O +
in O +
regulating O +
RAG O +
gene O +
expression O +
. O +

Regulation O +
of O +
interleukin-2 O +
receptor O +
alpha O +
chain O +
expression O +
and O +
nuclear O +
factor.kappa O +
B O +
activation O +
by O +
protein O +
kinase O +
C O +
in O +
T O +
lymphocytes O +
. O +

Autocrine O +
role O +
of O +
tumor O +
necrosis O +
factor O +
alpha O +
. O +

The O +
regulation O +
of O +
interleukin-2 O +
receptor O +
alpha O +
chain O +
( O +
IL-2R O +
alpha O +
) O +
expression O +
and O +
nuclear O +
factor O +
( O +
NF O +
) O +
activation O +
by O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
in O +
resting O +
T O +
cells O +
, O +
has O +
been O +
studied O +
. O +

Treatment O +
of O +
human O +
resting O +
T O +
cells O +
with O +
phorbol O +
esters O +
strongly O +
induced O +
the O +
expression O +
of O +
IL-2R O +
alpha O +
and O +
the O +
activation O +
of O +
NF.kappa O +
B O +
. O +

This O +
activation O +
was O +
due O +
to O +
the O +
translocation O +
of O +
p65 O +
and O +
c O -
- O -
Rel O +
NF.kappa O +
B O +
proteins O +
from O +
cytoplasmic O +
stores O +
to O +
the O +
nucleus O +
, O +
where O +
they O +
bound O +
the O +
kappa O +
B O +
sequence O +
of O +
the O +
IL-2R O +
alpha O +
promoter O +
either O +
as O +
p50.p65 O +
or O +
as O +
p50.c O -
- O -
Rel O +
heterodimers O +
. O +

Interestingly O +
, O +
all O +
of O +
those O +
events O +
were O +
largely O +
indirect O +
and O +
mediated O +
by O +
endogenously O +
secreted O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O +
alpha O +
) O +
, O +
as O +
they O +
were O +
strongly O +
inhibited O +
by O +
a O +
neutralizing O +
anti O -
- O -
TNF O +
alpha O +
monoclonal O +
antibody O +
. O +

Furthermore O +
, O +
cyclosporin O +
A O +
, O +
which O +
blocked O +
TNF O +
alpha O +
production O +
induced O +
by O +
PKC O +
, O +
strongly O +
inhibited O +
IL-2R O +
alpha O +
and O +
NF.kappa O +
B O +
activation O +
. O +

The O +
addition O +
of O +
either O +
TNF O +
alpha O +
or O +
IL-2 O +
partially O +
recovered O +
cyclosporin O +
A O -
- O -
induced O +
IL-2R O +
alpha O +
inhibition O +
, O +
but O +
only O +
TNF O +
alpha O +
completely O +
recovered O +
NF.kappa O +
B O +
activation O +
. O +

Those O +
results O +
indicate O +
that O +
, O +
in O +
resting O +
T O +
cells O +
, O +
PKC O +
activation O +
has O +
only O +
a O +
triggering O +
role O +
, O +
whereas O +
the O +
endogenously O +
secreted O +
TNF O +
alpha O +
plays O +
an O +
essential O +
role O +
in O +
the O +
quantitative O +
control O +
of O +
the O +
expression O +
of O +
IL-2R O +
alpha O +
chain O +
or O +
NF.kappa O +
B O +
activation O +
. O +

The O +
role O +
of O +
cellular O +
transcription O +
factor O +
E2F O +
in O +
the O +
regulation O +
of O +
cdc2 O +
mRNA O +
expression O +
and O +
cell O +
cycle O +
control O +
of O +
human O +
hematopoietic O +
cells O +
. O +

cdc2 O +
mRNA O +
transcripts O +
were O +
detected O +
in O +
immature O +
bone O +
marrow O +
cells O +
and O +
became O +
undetectable O +
along O +
with O +
differentiation O +
. O +

Peripheral O +
blood O +
resting O +
cells O +
did O +
not O +
express O +
cdc2 O +
mRNA O +
, O +
but O +
it O +
was O +
induced O +
in O +
T O -
- O -
lymphocytes O +
when O +
the O +
cells O +
reentered O +
the O +
cell O +
cycle O +
in O +
response O +
to O +
specific O +
mitogens O +
. O +

In O +
contrast O +
, O +
cdc2 O +
mRNA O +
could O +
not O +
be O +
induced O +
in O +
granulocytes O +
and O +
monocytes O +
even O +
after O +
the O +
culture O +
with O +
the O +
appropriate O +
stimulants O +
. O +

In O +
order O +
to O +
investigate O +
the O +
mechanism O +
of O +
the O +
regulation O +
of O +
cdc2 O +
mRNA O +
expression O +
in O +
hematopoietic O +
cells O +
, O +
we O +
isolated O +
the O +
5'-flanking O +
sequence O +
of O +
the O +
cdc2 O +
gene O +
and O +
found O +
the O +
putative O +
E2F O +
binding O +
site O +
at O +
the O +
position O +
of O +
nucleotides O +
-124 O +
to O +
-117 O +
. O +

The O +
binding O +
of O +
E2F O +
at O +
this O +
region O +
was O +
detected O +
by O +
a O +
gel O -
- O -
retardation O +
assay O +
and O +
DNaseI O +
footprinting O +
in O +
phytohemagglutinin B-CellLine -
- I-CellLine -
stimulated I-CellLine +
T I-CellLine -
- I-CellLine -
lymphocytes I-CellLine +
, O +
which O +
was O +
coincident O +
with O +
the O +
expression O +
of O +
cdc2 O +
mRNA O +
. O +

E2F O +
binding O +
was O +
not O +
observed O +
in O +
both O +
granulocytes O +
and O +
monocytes O +
. O +

Transient O +
chloramphenicol O +
acetyltransferase O +
assay O +
revealed O +
that O +
the O +
region O +
containing O +
E2F O +
binding O +
site O +
had O +
a O +
strong O +
promoter O +
activity O +
, O +
and O +
introduction O +
of O +
the O +
mutation O +
at O +
the O +
E2F O +
binding O +
site O +
resulted O +
in O +
a O +
significant O +
loss O +
of O +
the O +
activity O +
. O +

E2F-1 O +
and O +
DP-1 O +
mRNAs O +
were O +
not O +
detectable O +
in O +
granulocytes O +
, O +
monocytes O +
and O +
resting O +
T O -
- O -
lymphocytes O +
but O +
were O +
induced O +
after O +
the O +
mitogenic O +
stimulation O +
of O +
T O -
- O -
lymphocytes O +
. O +

The O +
induction O +
of O +
E2F O +
activity O +
preceded O +
the O +
appearance O +
of O +
cdc2 O +
mRNA O +
, O +
which O +
is O +
consistent O +
with O +
the O +
role O +
of O +
E2F O +
in O +
the O +
regulation O +
of O +
cdc2 O +
mRNA O +
expression O +
. O +

These O +
results O +
suggest O +
that O +
cdc2 O +
mRNA O +
expression O +
is O +
related O +
to O +
the O +
cell O +
cycling O +
of O +
normal O +
human O +
hematopoietic O +
cells O +
and O +
that O +
E2F O +
plays O +
some O +
roles O +
in O +
the O +
regulation O +
of O +
its O +
expression O +
. O +

Inducible O +
binding O +
to O +
the O +
c O -
- O -
fos O +
serum O +
response O +
element O +
during O +
T O +
cell O +
activation O +
is O +
regulated O +
by O +
a O +
phosphotyrosine O -
- O -
containing O +
protein O +
. O +

The O +
proto O -
- O -
oncogene O +
c O -
- O -
fos O +
is O +
an O +
immediate O -
- O -
early O +
gene O +
, O +
and O +
one O +
of O +
the O +
first O +
genes O +
transcribed O +
after O +
stimulation O +
of O +
most O +
cells O +
with O +
a O +
variety O +
of O +
ligands O +
. O +

Fos O +
expression O +
may O +
be O +
a O +
pivotal O +
event O +
in O +
converting O +
ligand O -
- O -
receptor O +
interactions O +
at O +
the O +
membrane O +
into O +
functional O +
modulation O +
of O +
cell O +
phenotype O +
. O +

The O +
serum O +
response O +
element O +
( O +
SRE O +
) O +
in O +
the O +
c O -
- O -
fos O +
regulatory O +
region O +
participates O +
in O +
induction O +
of O +
transcription O +
by O +
various O +
growth O +
factors O +
and O +
by O +
phorbol O +
esters O +
and O +
subsequent O +
squelching O +
of O +
transcription O +
. O +

We O +
show O +
that O +
an O +
inducible O +
protein O +
complex O +
( O +
Band O +
A O +
) O +
binds O +
to O +
SRE O +
DNA O +
within O +
10 O +
min O +
after O +
mitogenic O +
stimulation O +
of O +
human B-CellLine +
PBL I-CellLine -
- I-CellLine -
T I-CellLine +
, O +
and O +
becomes O +
nondetectable O +
by O +
60 O +
min O +
. O +

Band O +
A O +
contains O +
the O +
serum O +
response O +
factor O +
plus O +
additional O +
factor O +
( O +
s O +
) O +
. O +

A O +
protein O +
that O +
is O +
phosphorylated O +
on O +
a O +
tyrosine O +
residue O +
in O +
resting B-CellLine +
PBL I-CellLine -
- I-CellLine -
T I-CellLine +
suppresses O +
binding O +
of O +
a O +
component O +
of O +
Band O +
A O +
to O +
the O +
SRE O +
motif O +
. O +

Upon O +
stimulation O +
of O +
the O +
cells O +
, O +
this O +
protein O +
no O +
longer O +
prevents O +
binding O +
of O +
DNA O +
by O +
Band O +
A O +
, O +
and O +
suppression O +
of O +
binding O +
is O +
restored O +
within O +
30 O +
min O +
. O +

The O +
phosphorylated O +
tyrosine O +
residue O +
itself O +
is O +
important O +
for O +
the O +
protein O -
- O -
protein O +
interaction O +
. O +

A O +
family O +
of O +
serine O +
proteases O +
expressed O +
exclusively O +
in O +
myelo- O +
monocytic O +
cells O +
specifically O +
processes O +
the O +
nuclear O +
factor O -
- O -
kappa O +
B O +
subunit O +
p65 O +
in O +
vitro O +
and O +
may O +
impair O +
human O +
immunodeficiency O +
virus O +
replication O +
in O +
these O +
cells O +
. O +

Two O +
groups O +
of O +
U937 B-CellLine +
promonocytic I-CellLine +
cells I-CellLine +
were O +
obtained O +
by O +
limiting O +
dilution O +
cloning O +
which O +
differed O +
strikingly O +
in O +
their O +
ability O +
to O +
support O +
human O +
immunodeficiency O +
virus O +
1 O +
( O +
HIV-1 O +
) O +
replication O +
. O +

` B-CellLine -
` I-CellLine +
Plus I-CellLine +
'' I-CellLine +
clones I-CellLine +
replicated O +
the O +
virus O +
efficiently O +
, O +
whereas O +
` B-CellLine -
` I-CellLine +
minus I-CellLine +
'' I-CellLine +
clones I-CellLine +
did O +
not O +
. O +

We O +
examined O +
these O +
clones O +
for O +
differences O +
in O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappa O +
B O +
activity O +
which O +
might O +
account O +
for O +
the O +
observed O +
phenomenon O +
. O +

Stimulation O +
of O +
plus B-CellLine +
clones I-CellLine +
liberated O +
the O +
classical O +
p50-p65 O +
complex O +
from O +
cytoplasmic O +
pools O +
, O +
whereas O +
minus B-CellLine +
clones I-CellLine +
produced O +
an O +
apparently O +
novel O +
, O +
faster O -
- O -
migrating O +
complex O +
, O +
as O +
judged O +
by O +
electrophoretic O +
mobility O +
shift O +
assays O +
. O +

It O +
is O +
surprising O +
that O +
the O +
faster O -
- O -
migrating O +
complex O +
was O +
composed O +
also O +
of O +
p50 O +
and O +
p65 O +
. O +

However O +
, O +
the O +
p65 O +
subunit O +
was O +
COOH O -
- O -
terminally O +
truncated O +
, O +
as O +
shown O +
by O +
immunoprecipitation O +
. O +

The O +
truncation O +
resulted O +
from O +
limited O +
proteolysis O +
of O +
p65 O +
during O +
cellular O +
extraction O +
which O +
released O +
particular O +
lysosomal O +
serine O +
proteases O +
, O +
such O +
as O +
elastase O +
, O +
cathepsin O +
G O +
, O +
and O +
proteinase O +
3 O +
. O +

These O +
specific O +
proteases O +
are O +
coordinately O +
expressed O +
and O +
were O +
present O +
exclusively O +
in O +
the O +
minus B-CellLine +
U937 I-CellLine +
clones I-CellLine +
, O +
but O +
not O +
in O +
the O +
plus B-CellLine +
clones I-CellLine +
, O +
as O +
demonstrated O +
in O +
the O +
case O +
of O +
cathepsin O +
G O +
. O +

In O +
addition O +
, O +
these O +
proteases O +
were O +
detected O +
in O +
certain O +
subclones O +
of O +
THP-1 B-CellLine +
and O +
HL-60 B-CellLine +
cells I-CellLine +
and O +
in O +
primary O +
monocytes O +
, O +
in O +
each O +
case O +
correlating O +
with O +
the O +
truncated O +
from O +
of O +
p65 O +
. O +

We O +
demonstrate O +
in O +
vitro O +
cleavage O +
of O +
p65 O +
by O +
purified O +
elastase O +
and O +
cathepsin O +
G O +
. O +

It O +
is O +
possible O +
that O +
particular O +
serine O +
proteases O +
may O +
have O +
inhibiting O +
effects O +
on O +
the O +
replication O +
of O +
HIV-1 O +
in O +
myelo B-CellLine -
- I-CellLine -
monocytic I-CellLine +
cells I-CellLine +
. O +

The O +
data O +
also O +
demonstrate O +
that O +
special O +
precautions O +
must O +
be O +
taken O +
when O +
making O +
extracts O +
from O +
myelo B-CellLine -
- I-CellLine -
monocytic I-CellLine +
cells I-CellLine +
. O +

Human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
Tax O +
activation O +
of O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
involves O +
phosphorylation O +
and O +
degradation O +
of O +
I O +
kappa O +
B O +
alpha O +
and O +
RelA O +
( O +
p65 O +
) O +
-mediated O +
induction O +
of O +
the O +
c O -
- O -
rel O +
gene O +
. O +

The O +
tax O +
gene O +
product O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
is O +
a O +
potent O +
transcriptional O +
activator O +
that O +
both O +
stimulates O +
viral O +
gene O +
expression O +
and O +
activates O +
an O +
array O +
of O +
cellular O +
genes O +
involved O +
in O +
T O -
- O -
cell O +
growth O +
. O +

Tax O +
acts O +
indirectly O +
by O +
inducing O +
or O +
modifying O +
the O +
action O +
of O +
various O +
host O +
transcription O +
factors O +
, O +
including O +
members O +
of O +
the O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
family O +
of O +
enhancer O -
- O -
binding O +
proteins O +
. O +

In O +
resting O +
T O +
cells O +
, O +
many O +
of O +
these O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
factors O +
are O +
sequestered O +
in O +
the O +
cytoplasm O +
by O +
various O +
ankyrin O -
- O -
rich O +
inhibitory O +
proteins O +
, O +
including O +
I O +
kappa O +
B O +
alpha O +
. O +

HTLV O -
- O -
I O +
Tax O +
expression O +
leads O +
to O +
the O +
constitutive O +
nuclear O +
expression O +
of O +
biologically O +
active O +
NF O -
- O -
kappa O +
B O +
and O +
c O -
- O -
Rel O +
complexes O +
; O +
however O +
, O +
the O +
biochemical O +
mechanism O +
( O +
s O +
) O +
underlying O +
this O +
response O +
remains O +
poorly O +
understood O +
. O +

In O +
this O +
study O +
, O +
we O +
demonstrate O +
that O +
Tax O +
-stimulated O +
nuclear O +
expression O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
both O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine -
- I-CellLine -
infected I-CellLine +
and I-CellLine +
Tax I-CellLine -
- I-CellLine -
transfected I-CellLine +
human I-CellLine +
T I-CellLine +
cells I-CellLine +
is O +
associated O +
with O +
the O +
phosphorylation O +
and O +
rapid O +
proteolytic O +
degradation O +
of O +
I O +
kappa O +
B O +
alpha O +
. O +

In O +
contrast O +
to O +
prior O +
in O +
vitro O +
studies O +
, O +
at O +
least O +
a O +
fraction O +
of O +
the O +
phosphorylated O +
form O +
of O +
I O +
kappa O +
B O +
alpha O +
remains O +
physically O +
associated O +
with O +
the O +
NF O -
- O -
kappa O +
B O +
complex O +
in O +
vivo O +
but O +
is O +
subject O +
to O +
rapid O +
degradation O +
, O +
thereby O +
promoting O +
the O +
nuclear O +
translocation O +
of O +
the O +
active O +
NF O -
- O -
kappa O +
B O +
complex O +
. O +

We O +
further O +
demonstrate O +
that O +
Tax O +
induction O +
of O +
nuclear O +
c O -
- O -
Rel O +
expression O +
is O +
activated O +
by O +
the O +
RelA O +
( O +
p65 O +
) O +
subunit O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
which O +
activates O +
transcription O +
of O +
the O +
c O -
- O -
rel O +
gene O +
through O +
an O +
intrinsic O +
kappa O +
B O +
enhancer O +
element O +
. O +

In O +
normal O +
cells O +
, O +
the O +
subsequent O +
accumulation O +
of O +
nuclear O +
c O -
- O -
Rel O +
acts O +
to O +
inhibit O +
its O +
own O +
continued O +
production O +
, O +
indicating O +
the O +
presence O +
of O +
an O +
autoregulatory O +
loop O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

Arrested O +
development O +
: O +
understanding O +
v O -
- O -
abl O +
. O +

The O +
protein O +
tyrosine O +
kinase O +
activity O +
of O +
the O +
v O -
- O -
abl O +
oncogene O +
has O +
been O +
demonstrated O +
to O +
subvert O +
the O +
normal O +
second O +
messenger O +
systems O +
used O +
by O +
lymphoid O +
cells O +
for O +
growth O +
and O +
differentiation O +
. O +

Transformation O +
of O +
bone O +
marrow O +
with O +
the O +
Abelson O +
murine O +
leukemia O +
virus O +
results O +
in O +
the O +
appearance O +
of O +
B O +
cell O +
lineage O +
cells O +
arrested O +
at O +
the O +
pre O -
- O -
B O +
cell O +
stage O +
. O +

Recent O +
reports O +
have O +
characterized O +
these O +
cells O +
expressing O +
high O +
v O -
- O -
abl O +
kinase O +
activity O +
as O +
deficient O +
in O +
detectable O +
NF O -
- O -
kappaB O +
DNA O +
binding O +
activity O +
and O +
low O +
level O +
RAG O +
gene O +
expression O +
. O +

These O +
observations O +
suggest O +
that O +
v O -
- O -
abl O +
may O +
be O +
inhibiting O +
the O +
differentiation O +
of O +
B O +
cells O +
by O +
blocking O +
these O +
two O +
crucial O +
elements O +
in O +
the O +
maturation O +
pathway O +
. O +

MHC O +
class O +
II O +
signaling O +
in O +
B O -
- O -
cell O +
activation O +
[ O +
see O +
comments O +
] O +

The O +
cognate O +
interaction O +
between O +
T O +
cells O +
and O +
antigen O -
- O -
presenting O +
cells O +
( O +
APCs O +
) O +
, O +
mediated O +
by O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
class O +
II O +
molecules O +
, O +
results O +
in O +
the O +
delivery O +
of O +
activation O +
signals O +
to O +
the O +
APC O +
. O +

These O +
signals O +
contribute O +
to O +
the O +
expression O +
of O +
co O -
- O -
stimulatory O +
activity O +
by O +
APCs O +
and O +
have O +
important O +
consequences O +
for O +
cell O +
effector O +
function O +
. O +

MHC O +
class O +
II O +
molecules O +
also O +
serve O +
as O +
receptors O +
for O +
B O -
- O -
cell O +
stimulation O +
by O +
microbial O +
superantigens O +
. O +

In O +
this O +
review O +
, O +
Paul O +
Scholl O +
and O +
Raif O +
Geha O +
discuss O +
recent O +
advances O +
in O +
our O +
understanding O +
of O +
mechanisms O +
of O +
MHC O +
class O +
II O +
signaling O +
and O +
analyse O +
their O +
role O +
in O +
human O +
B O -
- O -
cell O +
activation O +
. O +

Distinct O +
DNase O -
- O -
I O +
hypersensitive O +
sites O +
are O +
associated O +
with O +
TAL-1 O +
transcription O +
in O +
erythroid B-CellLine +
and I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
. O +

The O +
tal-1 O +
gene O +
, O +
frequently O +
activated O +
in O +
human O +
T O -
- O -
cell O +
acute O +
lymphoblastic O +
leukemia O +
( O +
T O -
- O -
ALL O +
) O +
, O +
is O +
expressed O +
in O +
the O +
erythroid O +
, O +
megakaryocytic O +
, O +
and O +
mast O +
cell O +
lineages O +
during O +
normal O +
hematopoiesis O +
. O +

To O +
gain O +
further O +
insight O +
into O +
the O +
molecular O +
mechanisms O +
that O +
control O +
tal-1 O +
expression O +
, O +
we O +
investigated O +
tal-1 O +
chromatin O +
structure O +
in O +
erythroid B-CellLine -
/ I-CellLine -
megakaryocytic I-CellLine +
cell I-CellLine +
lines I-CellLine +
and O +
in O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
either O +
with O +
or O +
without O +
tal-1 O +
rearrangements O +
. O +

Tal-1 O +
transcription O +
was O +
shown O +
to O +
be O +
monoallelic O +
in O +
Jurkat B-CellLine +
, O +
a O +
T O -
- O -
cell O +
line O +
that O +
expresses O +
tal-1 O +
in O +
the O +
absence O +
of O +
apparent O +
genomic O +
alteration O +
of O +
the O +
locus O +
. O +

Methylation O +
studies O +
indicated O +
that O +
the O +
tal-15 O +
' O +
GC O -
- O -
rich O +
region O +
behaves O +
like O +
a O +
CpG O +
island O +
, O +
hypomethylated O +
in O +
normal O +
cells O +
, O +
and O +
methylated O +
de O +
novo O +
on O +
transcriptionally O +
inactive O +
alleles O +
in O +
established B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Five O +
major O +
DNase O -
- O -
I O +
hypersensitive O +
sites O +
( O +
HS O +
) O +
were O +
mapped O +
in O +
the O +
tal-1 O +
locus O +
. O +

HS O +
I O +
, O +
IV O +
, O +
and O +
V O +
were O +
exclusively O +
observed O +
in O +
the O +
erythroid B-CellLine -
/ I-CellLine -
megakaryocytic I-CellLine +
cell I-CellLine +
lines I-CellLine +
that O +
express O +
tal-1 O +
from O +
the O +
promoters O +
1a O +
and O +
1b O +
. O +

HS O +
II O +
was O +
weak O +
in O +
hematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
absent O +
in O +
Hela B-CellLine +
, O +
and O +
greatly O +
enhanced O +
in O +
Jurkat B-CellLine +
, O +
suggesting O +
that O +
this O +
region O +
might O +
be O +
implicated O +
in O +
the O +
cis O -
- O -
activation O +
of O +
tal-1 O +
promoter O +
1b O +
in O +
this O +
cell O +
line O +
. O +

HS O +
III O +
was O +
weak O +
in O +
HEL B-CellLine +
and O +
Jurkat B-CellLine +
, O +
and O +
greatly O +
enhanced O +
in O +
DU528 B-CellLine +
, O +
a O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
that O +
bears O +
a O +
t O +
( O +
1 O +
; O +
14 O +
) O +
and O +
initiates O +
tal-1 O +
transcription O +
within O +
exon O +
4 O +
. O +

These O +
results O +
suggest O +
that O +
distinct O +
regulatory O +
elements O +
are O +
associated O +
with O +
the O +
use O +
of O +
the O +
different O +
tal-1 O +
promoters O +
. O +

Erythropoietin O +
-dependent O +
induction O +
of O +
hemoglobin O +
synthesis O +
in O +
a O +
cytokine B-CellLine -
- I-CellLine -
dependent I-CellLine +
cell I-CellLine +
line I-CellLine +
M B-CellLine -
- I-CellLine -
TAT I-CellLine +
. O +

M B-CellLine -
- I-CellLine -
TAT I-CellLine +
is O +
a O +
cytokine B-CellLine -
- I-CellLine -
dependent I-CellLine +
cell I-CellLine +
line I-CellLine +
with O +
the O +
potential O +
to O +
differentiate O +
along O +
the O +
erythroid O +
and O +
megakaryocytic O +
lineages O +
. O +

We O +
cultured O +
M B-CellLine -
- I-CellLine -
TAT I-CellLine +
cells I-CellLine +
long O +
term O +
( O +
> O +
1 O +
year O +
) O +
in O +
the O +
continuous O +
presence O +
of O +
erythropoietin O +
( O +
EPO O +
) O +
, O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
, O +
or O +
stem O +
cell O +
factor O +
( O +
SCF O +
) O +
. O +

These O +
long O +
term O +
cultures O +
are O +
referred O +
to O +
as O +
M B-CellLine -
- I-CellLine -
TAT I-CellLine -
/ I-CellLine -
EPO I-CellLine +
, I-CellLine +
M I-CellLine -
- I-CellLine -
TAT I-CellLine -
/ I-CellLine -
GM I-CellLine -
- I-CellLine -
CSF I-CellLine +
, I-CellLine +
and I-CellLine +
M I-CellLine -
- I-CellLine -
TAT I-CellLine -
/ I-CellLine -
SCF I-CellLine +
cells I-CellLine +
, O +
respectively O +
. O +

Hemoglobin O +
concentration O +
and O +
gamma O -
- O -
globin O +
and O +
erythroid O +
delta O -
- O -
aminolevulinate O +
synthase O +
mRNA O +
levels O +
were O +
significantly O +
higher O +
in O +
M B-CellLine -
- I-CellLine -
TAT I-CellLine -
/ I-CellLine -
EPO I-CellLine +
cells I-CellLine +
than O +
in O +
M B-CellLine -
- I-CellLine -
TAT I-CellLine -
/ I-CellLine -
GM I-CellLine -
- I-CellLine -
CSF I-CellLine +
cells I-CellLine +
. O +

When O +
the O +
supplemented O +
cytokine O +
was O +
switched O +
from O +
GM O -
- O -
CSF O +
to O +
EPO O +
, O +
hemoglobin O +
synthesis O +
in O +
M B-CellLine -
- I-CellLine -
TAT I-CellLine -
/ I-CellLine -
GM I-CellLine -
- I-CellLine -
CSF I-CellLine +
cells I-CellLine +
increased O +
rapidly O +
( O +
within O +
5 O +
h O +
) O +
, O +
and O +
the O +
level O +
of O +
GATA-1 O +
mRNA O +
increased O +
. O +

In O +
contrast O +
, O +
the O +
addition O +
of O +
GM O -
- O -
CSF O +
to O +
the O +
M B-CellLine -
- I-CellLine -
TAT I-CellLine -
/ I-CellLine -
EPO I-CellLine +
cell I-CellLine +
culture I-CellLine +
decreased O +
the O +
amount O +
of O +
hemoglobin O +
, O +
even O +
in O +
the O +
presence O +
of O +
EPO O +
, O +
indicating O +
that O +
the O +
EPO O +
signal O +
for O +
erythroid O +
differentiation O +
is O +
suppressed O +
by O +
GM O -
- O -
CSF O +
. O +

Thus O +
, O +
erythroid O +
development O +
of O +
M B-CellLine -
- I-CellLine -
TAT I-CellLine +
cells I-CellLine +
is O +
promoted O +
by O +
EPO O +
and O +
suppressed O +
by O +
GM O -
- O -
CSF O +
. O +

These O +
results O +
support O +
the O +
hypothesis O +
that O +
EPO O +
actively O +
influences O +
the O +
programming O +
of O +
gene O +
expression O +
required O +
for O +
erythroid O +
progenitor O +
cell O +
differentiation O +
. O +

Functional O +
Myc O -
- O -
Max O +
heterodimer O +
is O +
required O +
for O +
activation O -
- O -
induced O +
apoptosis O +
in O +
T B-CellLine +
cell I-CellLine +
hybridomas I-CellLine +
. O +

T B-CellLine +
cell I-CellLine +
hybridomas I-CellLine +
respond O +
to O +
activation O +
signals O +
by O +
undergoing O +
apoptotic O +
cell O +
death O +
, O +
and O +
this O +
is O +
likely O +
to O +
represent O +
comparable O +
events O +
related O +
to O +
tolerance O +
induction O +
in O +
immature O +
and O +
mature O +
T O +
cells O +
in O +
vivo O +
. O +

Previous O +
studies O +
using O +
antisense O +
oligonucleotides O +
implicated O +
the O +
c O -
- O -
Myc O +
protein O +
in O +
the O +
phenomenon O +
of O +
activation O -
- O -
induced O +
apoptosis O +
. O +

This O +
role O +
for O +
c O -
- O -
Myc O +
in O +
apoptosis O +
is O +
now O +
confirmed O +
in O +
studies O +
using O +
a O +
dominant O +
negative O +
form O +
of O +
its O +
heterodimeric O +
binding O +
partner O +
, O +
Max O +
, O +
which O +
we O +
show O +
here O +
inhibits O +
activation O -
- O -
induced O +
apoptosis O +
. O +

Further O +
, O +
coexpression O +
of O +
a O +
reciprocally O +
mutant O +
Myc O +
protein O +
capable O +
of O +
forming O +
functional O +
heterodimers O +
with O +
the O +
mutant O +
Max O +
can O +
compensate O +
for O +
the O +
dominant O +
negative O +
activity O +
and O +
restore O +
activation O -
- O -
induced O +
apoptosis O +
. O +

These O +
results O +
imply O +
that O +
Myc O +
promotes O +
activation O -
- O -
induced O +
apoptosis O +
by O +
obligatory O +
heterodimerization O +
with O +
Max O +
, O +
and O +
therefore O +
, O +
by O +
regulating O +
gene O +
transcription O +
. O +

Enhanced O +
responsiveness O +
to O +
nuclear O +
factor O +
kappa O +
B O +
contributes O +
to O +
the O +
unique O +
phenotype O +
of O +
simian O +
immunodeficiency O +
virus O +
variant O +
SIVsmmPBj14 O +
. O +

Infection O +
with O +
a O +
variant O +
of O +
simian O +
immunodeficiency O +
virus O +
, O +
SIVsmmPBj14 O +
, O +
leads O +
to O +
severe O +
acute O +
disease O +
in O +
macaques O +
. O +

This O +
study O +
was O +
designed O +
to O +
investigate O +
the O +
functional O +
significance O +
of O +
previously O +
described O +
mutations O +
in O +
the O +
viral O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
and O +
to O +
elucidate O +
their O +
contribution O +
to O +
the O +
unique O +
phenotype O +
of O +
SIVsmmPBj14 O +
. O +

LTR O +
-directed O +
transcription O +
was O +
measured O +
by O +
using O +
luciferase O +
reporter O +
constructs O +
that O +
were O +
transiently O +
transfected O +
into O +
cultured B-CellLine +
cells I-CellLine +
. O +

In O +
a O +
wide O +
range O +
of O +
cell O +
types O +
, O +
the O +
basal O +
transcriptional O +
activity O +
of O +
the O +
LTR O +
from O +
SIVsmmPBj14 O +
was O +
found O +
to O +
be O +
2- O +
to O +
4.5-fold O +
higher O +
than O +
that O +
of O +
an O +
LTR O +
from O +
a O +
non O -
- O -
acutely O +
pathogenic O +
strain O +
. O +

These O +
LTRs O +
differ O +
by O +
five O +
point O +
mutations O +
and O +
a O +
22-bp O +
duplication O +
in O +
SIVsmmPBj14 O +
, O +
which O +
includes O +
a O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O +
kappa O +
B O +
) O +
site O +
. O +

Transcriptional O +
differences O +
between O +
these O +
LTRs O +
were O +
further O +
enhanced O +
by O +
two- O +
to O +
threefold O +
upon O +
treatment O +
of O +
cells O +
with O +
phorbol O +
ester O +
or O +
tumor O +
necrosis O +
factor O +
alpha O +
or O +
by O +
cotransfection O +
with O +
plasmids O +
expressing O +
NF O +
kappa O +
B O +
subunits O +
. O +

Mutagenesis O +
studies O +
, O +
and O +
the O +
use O +
of O +
a O +
reporter O +
construct O +
containing O +
an O +
enhancerless O +
promoter O +
, O +
indicate O +
that O +
these O +
transcriptional O +
effects O +
are O +
due O +
principally O +
to O +
the O +
22-bp O +
sequence O +
duplication O +
and O +
the O +
NF O +
kappa O +
B O +
site O +
contained O +
within O +
it O +
. O +

Finally O +
, O +
infectious O +
virus O +
stocks O +
that O +
were O +
isogenic O +
except O +
for O +
the O +
LTR O +
were O +
generated O +
. O +

The O +
LTR O +
from O +
SIVsmmPBj14 O +
was O +
found O +
to O +
confer O +
an O +
increase O +
in O +
the O +
kinetics O +
of O +
virus O +
replication O +
in O +
cultured B-CellLine +
cells I-CellLine +
. O +

Inclusion O +
of O +
this O +
LTR O +
in O +
recombinant O +
SIVs O +
also O +
resulted O +
in O +
a O +
two- O +
to O +
threefold O +
rise O +
in O +
the O +
extent O +
of O +
cellular O +
proliferation O +
that O +
was O +
induced O +
in O +
quiescent B-CellLine +
simian I-CellLine +
peripheral I-CellLine +
blood I-CellLine +
mononuclear I-CellLine +
cells I-CellLine +
. O +

These O +
studies O +
are O +
consistent O +
with O +
the O +
hypothesis O +
that O +
LTR O +
mutations O +
assist O +
SIVsmmPBj14 O +
in O +
responding O +
efficiently O +
to O +
cellular O +
stimulation O +
and O +
allow O +
it O +
to O +
replicate O +
to O +
high O +
titers O +
during O +
the O +
acute O +
phase O +
of O +
viral O +
infection O +
. O +

Identification O +
of O +
a O +
region O +
which O +
directs O +
the O +
monocytic O +
activity O +
of O +
the O +
colony O -
- O -
stimulating O +
factor O +
1 O +
( O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
) O +
receptor O +
promoter O +
and O +
binds O +
PEBP2 O -
/ O -
CBF O +
( O +
AML1 O +
) O +
. O +

The O +
receptor O +
for O +
the O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
or O +
colony O -
- O -
stimulating O +
factor O +
1 O +
[ O +
CSF-1 O +
] O +
) O +
is O +
expressed O +
from O +
different O +
promoters O +
in O +
monocytic O +
cells O +
and O +
placental O +
trophoblasts O +
. O +

We O +
have O +
demonstrated O +
that O +
the O +
monocyte O -
- O -
specific O +
expression O +
of O +
the O +
CSF-1 O +
receptor O +
is O +
regulated O +
at O +
the O +
level O +
of O +
transcription O +
by O +
a O +
tissue O -
- O -
specific O +
promoter O +
whose O +
activity O +
is O +
stimulated O +
by O +
the O +
monocyte O -
/ O -
B O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
PU.1 O +
( O +
D O -
.- O -
E.Zhang O +
, O +
C.J.Hetherington O +
, O +
H O -
.- O -
M.Chen O +
, O +
and O +
D.G.Tenen O +
, O +
Mol O -
. O -
Cell O -
. O +
Biol.14 O +
: O +
373 O -
- O -
381 O +
, O +
1994 O +
) O +
. O +

Here O +
we O +
report O +
that O +
the O +
tissue O +
specificity O +
of O +
this O +
promoter O +
is O +
also O +
mediated O +
by O +
sequences O +
in O +
a O +
region O +
II O +
( O +
bp O +
-88 O +
to O +
- O +
59 O +
) O +
, O +
which O +
lies O +
10 O +
bp O +
upstream O +
from O +
the O +
PU.1-binding O +
site O +
. O +

When O +
analyzed O +
by O +
DNase O +
footprinting O +
, O +
region O +
II O +
was O +
protected O +
preferentially O +
in O +
monocytic O +
cells O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
confirmed O +
that O +
region O +
II O +
interacts O +
specifically O +
with O +
nuclear O +
proteins O +
from O +
monocytic O +
cells O +
. O +

Two O +
gel O +
shift O +
complexes O +
( O +
Mono O +
A O +
and O +
Mono O +
B O +
) O +
were O +
formed O +
with O +
separate O +
sequence O +
elements O +
within O +
this O +
region O +
. O +

Competition O +
and O +
supershift O +
experiments O +
indicate O +
that O +
Mono O +
B O +
contains O +
a O +
member O +
of O +
the O +
polyomavirus O +
enhancer O -
- O -
binding O +
protein O +
2 O -
/ O -
core O -
- O -
binding O +
factor O +
( O +
PEBP2 O -
/ O -
CBF O +
) O +
family O +
, O +
which O +
includes O +
the O +
AML1 O +
gene O +
product O +
, O +
while O +
Mono O +
A O +
is O +
a O +
distinct O +
complex O +
preferentially O +
expressed O +
in O +
monocytic O +
cells O +
. O +

Promoter O +
constructs O +
with O +
mutations O +
in O +
these O +
sequence O +
elements O +
were O +
no O +
longer O +
expressed O +
specifically O +
in O +
monocytes O +
. O +

Furthermore O +
, O +
multimerized O +
region O +
II O +
sequence O +
elements O +
enhanced O +
the O +
activity O +
of O +
a O +
heterologous O +
thymidine O +
kinase O +
promoter O +
in O +
monocytic O +
cells O +
but O +
not O +
other O +
cell O +
types O +
tested O +
. O +

These O +
results O +
indicate O +
that O +
the O +
monocyte O -
/ O -
B O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
PU.1 O +
and O +
the O +
Mono O +
A O +
and O +
Mono O +
B O +
protein O +
complexes O +
act O +
in O +
concert O +
to O +
regulate O +
monocyte O -
- O -
specific O +
transcription O +
of O +
the O +
CSF-1 O +
receptor O +
. O +

A O +
factor O +
that O +
regulates O +
the O +
class O +
II O +
major O +
histocompatibility O +
complex O +
gene O +
DPA O +
is O +
a O +
member O +
of O +
a O +
subfamily O +
of O +
zinc O +
finger O +
proteins O +
that O +
includes O +
a O +
Drosophila O +
developmental O +
control O +
protein O +
. O +

A O +
novel O +
DNA O +
sequence O +
element O +
termed O +
the O +
J O +
element O +
involved O +
in O +
the O +
regulated O +
expression O +
of O +
class O +
II O +
major O +
histocompatibility O +
complex O +
genes O +
was O +
recently O +
described O +
. O +

To O +
study O +
this O +
element O +
and O +
its O +
role O +
in O +
class O +
II O +
gene O +
regulation O +
further O +
, O +
a O +
cDNA O +
library O +
was O +
screened O +
with O +
oligonucleotide O +
probes O +
containing O +
both O +
the O +
S O +
element O +
and O +
the O +
nearby O +
J O +
element O +
of O +
the O +
human O +
DPA O +
gene O +
. O +

Several O +
DNA O +
clones O +
were O +
obtained O +
by O +
this O +
procedure O +
, O +
one O +
of O +
which O +
, O +
clone O +
18 O +
, O +
is O +
reported O +
and O +
characterized O +
here O +
. O +

It O +
encodes O +
a O +
protein O +
predicted O +
to O +
contain O +
688 O +
amino O +
acid O +
residues O +
, O +
including O +
11 O +
zinc O +
finger O +
motifs O +
of O +
the O +
C2H2 O +
type O +
in O +
the O +
C O -
- O -
terminal O +
region O +
, O +
that O +
are O +
Kruppel O -
- O -
like O +
in O +
the O +
conservation O +
of O +
the O +
H O -
/ O -
C O +
link O +
sequence O +
connecting O +
them O +
. O +

The O +
160 O +
N O -
- O -
terminal O +
amino O +
acids O +
in O +
the O +
nonfinger O +
region O +
of O +
clone O +
18 O +
are O +
highly O +
homologous O +
with O +
similar O +
regions O +
of O +
several O +
other O +
human O +
, O +
mouse O +
, O +
and O +
Drosophila O +
sequences O +
, O +
defining O +
a O +
subfamily O +
of O +
Kruppel O -
- O -
like O +
zinc O +
finger O +
proteins O +
termed O +
TAB O +
( O +
tramtrack O +
[ O +
ttk O +
] O +
-associated O +
box O +
) O +
here O +
. O +

One O +
of O +
the O +
Drosophila O +
sequences O +
, O +
ttk O +
, O +
is O +
a O +
developmental O +
control O +
gene O +
, O +
while O +
a O +
second O +
does O +
not O +
contain O +
a O +
zinc O +
finger O +
region O +
but O +
encodes O +
a O +
structure O +
important O +
in O +
oocyte O +
development O +
. O +

An O +
acidic O +
activation O +
domain O +
is O +
located O +
between O +
the O +
N O -
- O -
terminal O +
conserved O +
region O +
of O +
clone O +
18 O +
and O +
its O +
zinc O +
fingers O +
. O +

This O +
protein O +
appears O +
to O +
require O +
both O +
the O +
S O +
and O +
J O +
elements O +
, O +
which O +
are O +
separated O +
by O +
10 O +
bp O +
for O +
optimal O +
binding O +
. O +

Antisense O +
cDNA O +
to O +
clone O +
18 O +
inhibited O +
the O +
expression O +
of O +
a O +
reporter O +
construct O +
containing O +
the O +
DPA O +
promoter O +
, O +
indicating O +
its O +
functional O +
importance O +
in O +
the O +
expression O +
of O +
this O +
class O +
II O +
gene O +
. O +

Epstein O -
- O -
Barr O +
virus O +
SM O +
protein O +
. O +

The O +
protein O +
products O +
of O +
the O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
BMLF1 O +
open O +
reading O +
frame O +
have O +
been O +
characterized O +
in O +
the O +
early O +
productive O +
cycle O +
in O +
B95 B-CellLine -
- I-CellLine -
8 I-CellLine +
and O +
Akata B-CellLine +
cells I-CellLine +
. O +

The O +
SM O +
protein O +
derived O +
from O +
the O +
spliced O +
RNA O +
joining O +
BSLF2 O +
to O +
BMLF1 O +
is O +
much O +
the O +
most O +
abundant O +
protein O +
. O +

SM O +
is O +
a O +
phosphoprotein O +
in O +
EBV O +
-infected O +
cells O +
and O +
can O +
be O +
phosphorylated O +
in O +
vitro O +
with O +
casein O +
kinase O +
II O +
( O +
CKII O +
) O +
. O +

Computer O +
analysis O +
of O +
the O +
SM O +
protein O +
sequence O +
showed O +
a O +
C O +
terminal O +
section O +
of O +
SM O +
to O +
be O +
related O +
to O +
genome O +
positional O +
homologues O +
of O +
four O +
other O +
herpesviruses O +
and O +
revealed O +
consensus O +
CKII O +
sites O +
near O +
the O +
N O +
termini O +
of O +
the O +
EBV O +
SM O +
protein O +
, O +
the O +
herpes O +
simplex O +
virus O +
( O +
HSV O +
) O +
ICP27 O +
protein O +
and O +
the O +
herpesvirus O +
saimiri O +
( O +
HVS O +
) O +
open O +
reading O +
frame O +
57 O +
protein O +
. O +

Site O -
- O -
directed O +
mutagenesis O +
of O +
the O +
consensus O +
CKII O +
site O +
in O +
EBV O +
SM O +
greatly O +
reduced O +
the O +
in O +
vitro O +
phosphorylation O +
of O +
SM O +
by O +
CKII O +
. O +

The O +
mechanism O +
of O +
transactivation O +
by O +
BMLF1 O +
proteins O +
has O +
been O +
controversial O +
but O +
SM O +
was O +
shown O +
to O +
transactivate O +
gene O +
expression O +
from O +
a O +
CAT O +
reporter O +
construct O +
by O +
increasing O +
the O +
amount O +
of O +
cytoplasmic O +
CAT O +
mRNA O +
. O +

Mutagenesis O +
of O +
the O +
CKII O +
site O +
in O +
SM O +
made O +
no O +
difference O +
to O +
the O +
transactivation O +
in O +
this O +
transient O +
transfection O +
assay O +
. O +

The O +
role O +
of O +
NFATp O +
in O +
cyclosporin O +
A O -
- O -
sensitive O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
gene O +
transcription O +
. O +

The O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O +
alpha O +
) O +
gene O +
is O +
an O +
immediate O +
early O +
gene O +
in O +
activated O +
T O +
cells O +
, O +
in O +
that O +
it O +
is O +
rapidly O +
induced O +
without O +
a O +
requirement O +
for O +
protein O +
synthesis O +
. O +

Maximal O +
induction O +
of O +
TNF O +
alpha O +
mRNA O +
can O +
be O +
induced O +
by O +
treatment O +
of O +
T O +
cells O +
with O +
calcium O +
ionophores O +
alone O +
, O +
via O +
a O +
calcineurin O +
-dependent O +
process O +
that O +
is O +
blocked O +
by O +
cyclosporin O +
A O +
. O +

We O +
have O +
previously O +
identified O +
a O +
promoter O +
element O +
, O +
kappa O +
3 O +
, O +
that O +
is O +
required O +
for O +
calcium O -
- O -
stimulated O +
, O +
cyclosporin O +
A O -
- O -
sensitive O +
induction O +
of O +
the O +
TNF O +
alpha O +
gene O +
in O +
activated O +
T O +
cells O +
. O +

Here O +
, O +
we O +
demonstrate O +
that O +
the O +
kappa O +
3 O +
binding O +
factor O +
contains O +
NFATp O +
, O +
a O +
cyclosporin O -
- O -
sensitive O +
DNA O -
- O -
binding O +
protein O +
required O +
for O +
interleukin-2 O +
gene O +
transcription O +
. O +

NFATp O +
binds O +
to O +
two O +
sites O +
within O +
the O +
kappa O +
3 O +
element O +
, O +
and O +
occupancy O +
of O +
both O +
sites O +
is O +
required O +
for O +
TNF O +
alpha O +
gene O +
induction O +
. O +

Thus O +
, O +
although O +
the O +
kappa O +
3 O +
element O +
has O +
little O +
sequence O +
similarity O +
to O +
other O +
NFATp O -
- O -
binding O +
sites O +
, O +
it O +
appears O +
to O +
function O +
as O +
a O +
cyclosporin O -
- O -
sensitive O +
promoter O +
element O +
in O +
T O +
cells O +
by O +
virtue O +
of O +
its O +
ability O +
to O +
bind O +
NFATp O +
. O +

The O +
involvement O +
of O +
NFATp O +
in O +
transcriptional O +
activation O +
of O +
both O +
the O +
interleukin-2 O +
and O +
TNF O +
alpha O +
genes O +
suggests O +
that O +
this O +
factor O +
plays O +
an O +
important O +
role O +
in O +
the O +
coordinate O +
induction O +
of O +
multiple O +
cytokine O +
genes O +
, O +
starting O +
at O +
the O +
earliest O +
stages O +
of O +
T O +
cell O +
activation O +
. O +

Epstein O -
- O -
Barr O +
virus O +
nuclear O +
protein O +
2 O +
transactivation O +
of O +
the O +
latent O +
membrane O +
protein O +
1 O +
promoter O +
is O +
mediated O +
by O +
J O +
kappa O +
and O +
PU.1 O +
. O +

Expression O +
of O +
the O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
latent O +
membrane O +
protein O +
1 O +
( O +
LMP-1 O +
) O +
oncogene O +
is O +
regulated O +
by O +
the O +
EBV O +
nuclear O +
protein O +
2 O +
( O +
EBNA-2 O +
) O +
transactivator O +
. O +

EBNA-2 O +
is O +
known O +
to O +
interact O +
with O +
the O +
cellular O +
DNA O -
- O -
binding O +
protein O +
J O +
kappa O +
and O +
is O +
recruited O +
to O +
promoters O +
containing O +
the O +
GTGGGAA O +
J O +
kappa O +
recognition O +
sequence O +
. O +

The O +
minimal O +
EBNA-2-responsive O +
LMP-1 O +
promoter O +
includes O +
one O +
J O +
kappa O -
- O -
binding O +
site O +
, O +
and O +
we O +
now O +
show O +
that O +
mutation O +
of O +
that O +
site O +
, O +
such O +
that O +
J O +
kappa O +
can O +
not O +
bind O +
, O +
reduces O +
EBNA-2 O +
responsiveness O +
by O +
60 O +
% O +
. O +

To O +
identify O +
other O +
factors O +
which O +
interact O +
with O +
the O +
LMP-1 O +
EBNA-2 O +
response O +
element O +
( O +
E2RE O +
) O +
, O +
a O +
-236 O -
/ O -
-145 O +
minimal O +
E2RE O +
was O +
used O +
as O +
a O +
probe O +
in O +
an O +
electrophoretic O +
mobility O +
shift O +
assay O +
. O +

The O +
previously O +
characterized O +
factors O +
J O +
kappa O +
, O +
PU.1 O +
, O +
and O +
AML1 O +
bind O +
to O +
the O +
LMP-1 O +
E2RE O +
, O +
along O +
with O +
six O +
other O +
unidentified O +
factors O +
( O +
LBF2 O +
to O +
LBF7 O +
) O +
. O +

Binding O +
sites O +
were O +
mapped O +
for O +
each O +
factor O +
. O +

LBF4 O +
is O +
B- O +
and O +
T O -
- O -
cell O +
specific O +
and O +
recognizes O +
the O +
PU.1 O +
GGAA O +
core O +
sequence O +
as O +
shown O +
by O +
methylation O +
interference O +
. O +

LBF4 O +
has O +
a O +
molecular O +
mass O +
of O +
105 O +
kDa O +
and O +
is O +
probably O +
unrelated O +
to O +
PU.1 O +
. O +

LBF2 O +
was O +
found O +
only O +
in O +
epithelial B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
whereas O +
LBF3 O +
, O +
LBF5 O +
, O +
LBF6 O +
, O +
and O +
LBF7 O +
were O +
not O +
cell O +
type O +
specific O +
. O +

Mutations O +
of O +
the O +
AML1- O +
or O +
LBF4-binding O +
sites O +
had O +
no O +
effect O +
on O +
EBNA-2 O +
transactivation O +
, O +
whereas O +
mutation O +
of O +
the O +
PU.1-binding O +
site O +
completely O +
eliminated O +
EBNA-2 O +
responses O +
. O +

A O +
gst O -
- O -
EBNA-2 O +
fusion O +
protein O +
specifically O +
depleted O +
PU.1 O +
from O +
nuclear O +
extracts O +
and O +
bound O +
in O +
vitro O +
translated O +
PU.1 O +
, O +
providing O +
biochemical O +
evidence O +
for O +
a O +
direct O +
EBNA-2 O +
-PU.1 O +
interaction O +
. O +

Thus O +
, O +
EBNA-2 O +
transactivation O +
of O +
the O +
LMP-1 O +
promoter O +
is O +
dependent O +
on O +
interaction O +
with O +
at O +
least O +
two O +
distinct O +
sequence O -
- O -
specific O +
DNA O -
- O -
binding O +
proteins O +
, O +
J O +
kappa O +
and O +
PU.1 O +
. O +

LBF3 O +
, O +
LBF5 O +
, O +
LBF6 O +
, O +
or O +
LBF7 O +
may O +
also O +
be O +
involved O +
, O +
since O +
their O +
binding O +
sites O +
also O +
contribute O +
to O +
EBNA-2 O +
responsiveness O +
. O +

Pyrrolidine O +
dithiocarbamate O +
, O +
a O +
potent O +
inhibitor O +
of O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
activation O +
, O +
prevents O +
apoptosis O +
in O +
human O +
promyelocytic B-CellLine +
leukemia I-CellLine +
HL-60 I-CellLine +
cells I-CellLine +
and O +
thymocytes O +
. O +

We O +
examined O +
the O +
effect O +
of O +
pyrrolidine O +
dithiocarbamate O +
( O +
PDTC O +
) O +
, O +
which O +
potently O +
blocks O +
the O +
activation O +
of O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
, O +
on O +
the O +
induction O +
of O +
apoptosis O +
by O +
a O +
variety O +
of O +
agents O +
. O +

Treatment O +
of O +
a O +
human B-CellLine +
promyelocytic I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
HL-60 B-CellLine +
, O +
with O +
10 O +
micrograms O -
/ O -
mL O +
etoposide O +
or O +
2 O +
microM O +
1-beta O -
- O -
D O -
- O -
arabinofuranosylcytosine O +
induced O +
NF O -
- O -
kappa O +
B O +
activation O +
within O +
1 O +
hr O +
and O +
subsequently O +
caused O +
apoptosis O +
within O +
3 O -
- O -
4 O +
hr O +
. O +

The O +
simultaneous O +
addition O +
of O +
50 O -
- O -
500 O +
microM O +
PDTC O +
with O +
these O +
agents O +
blocked O +
NF O -
- O -
kappa O +
B O +
activation O +
and O +
completely O +
abrogated O +
both O +
morphologically O +
apoptotic O +
changes O +
and O +
internucleosomal O +
DNA O +
fragmentation O +
for O +
up O +
to O +
6 O +
hr O +
. O +

However O +
, O +
PDTC O +
failed O +
to O +
inhibit O +
the O +
endonuclease O +
activity O +
contained O +
in O +
the O +
whole O +
cell O +
lysates O +
. O +

The O +
inhibitory O +
effect O +
of O +
PDTC O +
was O +
also O +
observed O +
in O +
etoposide O +
-and O +
dexamethasone O -
- O -
induced O +
apoptosis O +
in O +
human O +
thymocytes O +
at O +
a O +
concentration O +
of O +
1 O -
- O -
10 O +
microM O +
. O +

Since O +
PDTC O +
has O +
both O +
antioxidant O +
and O +
metal O -
- O -
ion O +
chelating O +
activities O +
, O +
we O +
tested O +
the O +
effects O +
of O +
N O -
- O -
acetyl O -
- O -
L O -
- O -
cysteine O +
( O +
NAC O +
) O +
( O +
antioxidant O +
) O +
or O +
o O -
- O -
phenanthroline O +
( O +
OP O +
) O +
( O +
metal O -
- O -
ion O +
chelator O +
) O +
on O +
the O +
induction O +
of O +
apoptosis O +
. O +

Pretreatment O +
of O +
HL-60 O +
cells O +
or O +
thymocytes O +
with O +
100 O -
- O -
500 O +
microM O +
OP O +
for O +
2 O +
hr O +
, O +
but O +
not O +
10 O -
- O -
60 O +
mM O +
NAC O +
, O +
suppressed O +
subsequent O +
occurrence O +
of O +
apoptosis O +
induced O +
by O +
etoposide O +
. O +

These O +
results O +
suggest O +
that O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
plays O +
an O +
important O +
role O +
in O +
the O +
apoptotic O +
process O +
of O +
human O +
hematopoietic O +
cells O +
. O +

Differential O +
regulation O +
of O +
proto O -
- O -
oncogenes O +
c O -
- O -
jun O +
and O +
c O -
- O -
fos O +
in O +
T O +
lymphocytes O +
activated O +
through O +
CD28 O +
. O +

The O +
T O +
cell O +
surface O +
molecule O +
CD28 O +
binds O +
to O +
ligands O +
on O +
accessory O +
cells O +
and O +
APCs O +
, O +
playing O +
an O +
important O +
costimulatory O +
role O +
in O +
the O +
response O +
of O +
T O +
cells O +
to O +
Ags O +
. O +

Our O +
knowledge O +
of O +
the O +
intracellular O +
signaling O +
pathways O +
coupled O +
to O +
this O +
receptor O +
is O +
incomplete O +
. O +

In O +
addition O +
to O +
activation O +
of O +
phospholipase O +
C O +
gamma O +
1 O +
, O +
ligation O +
of O +
this O +
receptor O +
also O +
seems O +
to O +
activate O +
a O +
calcium O -
- O -
independent O +
, O +
CD28 O +
-specific O +
pathway O +
. O +

In O +
this O +
paper O +
, O +
we O +
report O +
that O +
cross O -
- O -
linking O +
of O +
CD28 O +
( O +
but O +
not O +
CD2 O +
, O +
CD5 O +
, O +
LFA-1 O +
, O +
or O +
CD7 O +
) O +
leads O +
to O +
an O +
elevation O +
of O +
c O -
- O -
jun O +
mRNA O +
, O +
with O +
only O +
minimal O +
activation O +
of O +
c O -
- O -
fos O +
expression O +
. O +

CD28 O +
-dependent O +
induction O +
of O +
c O -
- O -
jun O +
expression O +
requires O +
protein O +
tyrosine O +
kinase O +
activity O +
, O +
but O +
does O +
not O +
depend O +
on O +
activation O +
of O +
a O +
phorbol O +
ester O -
- O -
responsive O +
protein O +
kinase O +
C O +
or O +
elevation O +
of O +
cytosolic O +
calcium O +
. O +

Furthermore O +
, O +
CD28 O +
-dependent O +
elevation O +
of O +
c O -
- O -
jun O +
mRNA O +
does O +
not O +
appear O +
to O +
be O +
mediated O +
at O +
the O +
level O +
of O +
mRNA O +
stability O +
. O +

A O +
mechanism O +
is O +
suggested O +
whereby O +
expression O +
of O +
c O -
- O -
jun O +
and O +
junB O +
, O +
in O +
the O +
absence O +
of O +
members O +
of O +
the O +
fos O +
family O +
, O +
can O +
prevent O +
inappropriate O +
activation O +
of O +
T O +
cells O +
caused O +
by O +
ligation O +
of O +
CD28 O +
in O +
the O +
absence O +
of O +
a O +
specific O +
antigenic O +
stimulus O +
. O +

Constitutive O +
nuclear O +
NF O -
- O -
kappa O +
B O +
in O +
cells O +
of O +
the O +
monocyte O +
lineage O +
. O +

In O +
monocytes O +
, O +
the O +
nuclear O +
factor O +
NF O -
- O -
kappa O +
B O +
has O +
been O +
invoked O +
as O +
an O +
important O +
transcription O +
factor O +
in O +
the O +
expression O +
of O +
cytokine O +
genes O +
, O +
of O +
cell O -
- O -
surface O +
receptors O +
and O +
in O +
the O +
expression O +
of O +
human O +
immunodeficiency O +
virus O +
. O +

In O +
such O +
cells O +
, O +
DNA O +
binding O +
activity O +
of O +
NF O -
- O -
kappa O +
B O +
can O +
be O +
detected O +
without O +
intentional O +
stimulation O +
. O +

In O +
our O +
studies O +
, O +
cells O +
of O +
the O +
human B-CellLine +
monocytic I-CellLine +
line I-CellLine +
Mono B-CellLine +
Mac I-CellLine +
6 I-CellLine +
, O +
cultured O +
in O +
medium O +
containing O +
fetal O -
- O -
calf O +
serum O +
and O +
low O +
levels O +
of O +
lipopolysaccharide O +
( O +
LPS O +
) O +
, O +
also O +
exhibit O +
such O +
' O -
constitutive O +
' O +
NF O -
- O -
kappa O +
B O +
, O +
as O +
demonstrated O +
by O +
mobility O -
- O -
shift O +
analysis O +
of O +
nuclear O +
extracts O +
. O +

This O +
nuclear O +
NF O -
- O -
kappa O +
B O +
was O +
still O +
present O +
when O +
contaminant O +
LPS O +
was O +
removed O +
by O +
ultrafiltration O +
and O +
when O +
serum O +
was O +
omitted O +
. O +

Protein O -
- O -
DNA O +
complexes O +
of O +
constitutive O +
NF O -
- O -
kappa O +
B O +
are O +
similar O +
in O +
mobility O +
to O +
the O +
LPS O -
- O -
induced O +
NF O -
- O -
kappa O +
B O +
and O +
both O +
are O +
recognized O +
by O +
an O +
antibody O +
specific O +
to O +
the O +
p50 O +
subunit O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

By O +
contrast O +
, O +
treatment O +
of O +
cells O +
with O +
pyrrolidine O +
dithiocarbamate O +
( O +
PDTC O +
) O +
will O +
only O +
block O +
LPS O -
- O -
induced O +
NF O -
- O -
kappa O +
B O +
, O +
but O +
not O +
the O +
constitutive O +
binding O +
protein O +
. O +

Using O +
LPS O -
- O -
free O +
and O +
serum O -
- O -
free O +
conditions O +
, O +
constitutive O +
NF O -
- O -
kappa O +
B O +
can O +
be O +
detected O +
in O +
different O +
cell B-CellLine +
lines I-CellLine +
of O +
the O +
monocytic O +
lineage O +
( O +
HL60 B-CellLine +
, O +
U937 B-CellLine +
, O +
THP-1 B-CellLine +
, O +
Mono B-CellLine +
Mac I-CellLine +
1 I-CellLine +
and O +
Mono B-CellLine +
Mac I-CellLine +
6 I-CellLine +
) O +
, O +
but O +
not O +
in O +
Molt B-CellLine +
4 I-CellLine +
T I-CellLine +
cells I-CellLine +
or O +
K562 B-CellLine +
stem I-CellLine +
cells I-CellLine +
. O +

When O +
ordered O +
according O +
to O +
stage O +
of O +
maturation O +
, O +
the O +
amount O +
of O +
constitutive O +
NF O -
- O -
kappa O +
B O +
was O +
not O +
increased O +
in O +
more O +
mature B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Furthermore O +
, O +
when O +
inducing O +
differentiation O +
in O +
Mono B-CellLine +
Mac I-CellLine +
6 I-CellLine +
cells I-CellLine +
, O +
with O +
vitamin O +
D3 O +
, O +
no O +
change O +
in O +
constitutive O +
or O +
inducible O +
NF O -
- O -
kappa O +
B O +
can O +
be O +
detected O +
. O +

Analysis O +
of O +
primary O +
cells O +
revealed O +
substantial O +
constitutive O +
NF O -
- O -
kappa O +
B O +
-binding O +
activity O +
in O +
blood O +
monocytes O +
, O +
pleural O +
macrophages O +
and O +
alveolar O +
macrophages O +
. O +

The O +
constitutive O +
NF O -
- O -
kappa O +
B O +
appears O +
to O +
be O +
functionally O +
active O +
, O +
since O +
a O +
low O +
level O +
of O +
tumour O +
necrosis O +
factor O +
( O +
TNF O +
) O +
transcript O +
is O +
detectable O +
in O +
monocytes O +
, O +
and O +
this O +
level O +
can O +
be O +
increased O +
by O +
blocking O +
transcript O +
degradation O +
using O +
cycloheximide O +
. O +

The O +
level O +
of O +
constitutive O +
NF O -
- O -
kappa O +
B O +
in O +
these O +
cells O +
is O +
variable O +
and O +
is O +
frequently O +
found O +
to O +
be O +
lower O +
in O +
the O +
more O +
mature O +
macrophages O +
. O +

Constitutive O +
NF O -
- O -
kappa O +
B O +
was O +
not O +
maintained O +
by O +
autocrine O +
action O +
of O +
cytokines O +
TNF O +
, O +
interleukin O +
6 O +
, O +
interleukin O +
10 O +
, O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
or O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
, O +
since O +
neutralizing O +
antibodies O +
did O +
not O +
reduce O +
constitutive O +
DNA O -
- O -
binding O +
activity O +
. O +

Furthermore O +
, O +
blockade O +
of O +
prostaglandin O +
or O +
leukotriene O +
biosynthesis O +
did O +
not O +
affect O +
constitutive O +
NF O -
- O -
kappa O +
B O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
400 O +
WORDS O +
) O +

Platelet O -
- O -
activating O +
factor O +
( O +
PAF O +
) O +
positively O +
auto O -
- O -
regulates O +
the O +
expression O +
of O +
human O +
PAF O +
receptor O +
transcript O +
1 O +
( O +
leukocyte O -
- O -
type O +
) O +
through O +
NF O -
- O -
kappa O +
B O +
. O +

The O +
human O +
platelet O -
- O -
activating O +
factor O +
receptor O +
( O +
PAFR O +
) O +
gene O +
is O +
transcribed O +
by O +
two O +
distinct O +
promoters O +
( O +
promoter O +
1 O +
and O +
promoter O +
2 O +
) O +
to O +
generate O +
two O +
transcripts O +
( O +
designated O +
as O +
PAFR O +
transcript O +
1 O +
and O +
PAFR O +
transcript O +
2 O +
) O +
, O +
though O +
their O +
open O +
reading O +
frames O +
are O +
identical O +
. O +

By O +
primer O +
extension O +
analysis O +
to O +
discriminate O +
two O +
transcripts O +
, O +
we O +
found O +
that O +
the O +
levels O +
of O +
PAFR O +
transcript O +
1 O +
( O +
leukocyte O -
- O -
type O +
) O +
, O +
but O +
not O +
PAFR O +
transcript O +
2 O +
( O +
tissue O -
- O -
type O +
) O +
, O +
are O +
upregulated O +
by O +
PAF O +
as O +
well O +
as O +
by O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
in O +
the O +
human B-CellLine +
stomach I-CellLine +
cancer I-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
JR B-CellLine -
- I-CellLine -
St I-CellLine +
cells I-CellLine +
) O +
which O +
expresses O +
both O +
functional O +
PAFR O +
transcript O +
1 O +
and O +
PAFR O +
transcript O +
2 O +
endogenously O +
. O +

Functional O +
analysis O +
of O +
the O +
promoter O +
1 O +
with O +
a O +
transient O +
expression O +
assay O +
using O +
chloramphenicol O +
acetyltransferase O +
( O +
CAT O +
) O +
gene O +
as O +
a O +
reporter O +
showed O +
that O +
both O +
PAF O +
and O +
TPA O +
activated O +
the O +
promoter O +
1 O +
but O +
not O +
the O +
deleted O +
promoter O +
lacking O +
the O +
three O +
consensus O +
binding O +
sites O +
for O +
NF O -
- O -
kappa O +
B O +
located O +
from O +
-571 O +
bp O +
to O +
-459 O +
bp O +
. O +

These O +
findings O +
suggest O +
a O +
molecular O +
mechanism O +
of O +
positive O +
regulation O +
of O +
PAFR O +
gene O +
expression O +
by O +
PAF O +
through O +
NF O -
- O -
kappa O +
B O +
, O +
possibly O +
by O +
a O +
phosphorylation O +
reaction O +
involving O +
protein O +
kinase O +
C O +
by O +
PAF O +
. O +

Interleukin-2 O +
induces O +
tyrosine O +
phosphorylation O +
and O +
nuclear O +
translocation O +
of O +
stat3 O +
in O +
human O +
T O +
lymphocytes O +
. O +

An O +
early O +
biochemical O +
event O +
associated O +
with O +
T O +
cell O +
activation O +
through O +
the O +
interleukin-2 O +
receptor O +
( O +
IL-2R O +
) O +
is O +
tyrosine O +
phosphorylation O +
of O +
several O +
intracellular O +
substrates O +
. O +

The O +
exact O +
mechanism O +
by O +
which O +
IL-2 O +
regulates O +
transcription O +
of O +
different O +
genes O +
is O +
presently O +
unknown O +
. O +

Here O +
, O +
we O +
report O +
that O +
stimulation O +
through O +
the O +
IL-2R O +
induced O +
tyrosine O +
phosphorylation O +
and O +
subsequent O +
nuclear O +
translocation O +
of O +
stat3 O +
, O +
a O +
newly O +
identified O +
member O +
of O +
the O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
STAT O +
) O +
family O +
of O +
proteins O +
. O +

In O +
contrast O +
, O +
stat1 O +
proteins O +
were O +
not O +
tyrosine O +
phosphorylated O +
after O +
IL-2 O +
ligation O +
, O +
whereas O +
tyrosine O -
- O -
phosphorylated O +
stat1 O +
proteins O +
( O +
91 O +
and O +
84 O +
kDa O +
proteins O +
) O +
were O +
translocated O +
to O +
the O +
nucleus O +
following O +
interferon O -
- O -
gamma O +
treatment O +
of O +
HeLa B-CellLine +
cells I-CellLine +
. O +

Apart O +
from O +
stat3 O +
, O +
another O +
cytoplasmic O +
protein O +
was O +
tyrosine O +
phosphorylated O +
and O +
subsequently O +
translocated O +
to O +
the O +
nucleus O +
in O +
response O +
to O +
IL-2 O +
. O +

This O +
protein O +
had O +
an O +
apparent O +
molecular O +
mass O +
of O +
84 O +
kDa O +
and O +
was O +
not O +
recognized O +
by O +
stat3 O +
or O +
stat1 O +
mAb O +
or O +
antisera O +
. O +

Since O +
IL-2 O +
induced O +
nuclear O +
translocation O +
of O +
the O +
84 O +
kDa O +
protein O +
and O +
stat3 O +
followed O +
identical O +
kinetics O +
, O +
p84 O +
is O +
a O +
candidate O +
for O +
a O +
new O +
, O +
yet O +
undefined O +
, O +
member O +
of O +
the O +
STAT O +
family O +
. O +

Taken O +
together O +
, O +
we O +
report O +
that O +
IL-2 O +
induces O +
tyrosine O +
phosphorylation O +
and O +
subsequent O +
nuclear O +
translocation O +
of O +
stat3 O +
and O +
an O +
as O +
yet O +
undefined O +
84-kDa O +
protein O +
in O +
antigen B-CellLine -
- I-CellLine -
specific I-CellLine +
human I-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Identification O +
of O +
the O +
TCL1 O +
gene O +
involved O +
in O +
T O -
- O -
cell O +
malignancies O +
. O +

The O +
TCL1 O +
locus O +
on O +
chromosome O +
14q32.1 O +
is O +
frequently O +
involved O +
in O +
chromosomal O +
translocations O +
and O +
inversions O +
with O +
one O +
of O +
the O +
T O -
- O -
cell O +
receptor O +
loci O +
in O +
human O +
T O -
- O -
cell O +
leukemias O +
and O +
lymphomas O +
. O +

The O +
chromosome O +
14 O +
region O +
translocated O +
or O +
rearranged O +
involves O +
approximately O +
350 O +
kb O +
of O +
DNA O +
at O +
chromosome O +
band O +
14q32.1 O +
. O +

Within O +
this O +
region O +
we O +
have O +
identified O +
a O +
gene O +
coding O +
for O +
a O +
1.3-kb O +
transcript O +
, O +
expressed O +
only O +
in O +
restricted O +
subsets O +
of O +
cells O +
within O +
the O +
lymphoid O +
lineage O +
and O +
expressed O +
at O +
high O +
levels O +
in O +
leukemic O +
cells O +
carrying O +
a O +
t O +
( O +
14 O +
; O +
14 O +
) O +
( O +
q11 O +
; O +
q32 O +
) O +
chromosome O +
translocation O +
or O +
a O +
inv O +
( O +
14 O +
) O +
( O +
q11 O +
; O +
q32 O +
) O +
chromosome O +
inversion O +
. O +

The O +
cognate O +
cDNA O +
sequence O +
reveals O +
an O +
open O +
reading O +
frame O +
of O +
342 O +
nt O +
encoding O +
a O +
protein O +
of O +
14 O +
kDa O +
. O +

The O +
TCL1 O +
gene O +
sequence O +
, O +
which O +
, O +
to O +
our O +
knowledge O +
, O +
shows O +
no O +
sequence O +
homology O +
with O +
other O +
human O +
genes O +
, O +
is O +
preferentially O +
expressed O +
early O +
in O +
T- O +
and O +
B O -
- O -
lymphocyte O +
differentiation O +
. O +

The O +
transcription O +
factor O +
Sp1 O +
is O +
required O +
for O +
induction O +
of O +
the O +
murine O +
GM O -
- O -
CSF O +
promoter O +
in O +
T O +
cells O +
. O +

The O +
cis O -
- O -
acting O +
region O +
, O +
GM O -
- O -
kappa O +
B O -
/ O -
GC O -
- O -
box O +
( O +
positions O +
-95 O +
and O +
-73 O +
) O +
, O +
within O +
the O +
murine O +
GM O -
- O -
CSF O +
gene O +
promoter O +
is O +
required O +
for O +
maximal O +
induction O +
by O +
stimulation O +
with O +
phorbol-12-myristate O +
acetate O +
( O +
PMA O +
) O +
and O +
calcium O +
ionophore O +
( O +
A23187 O +
) O +
in O +
T O +
cells O +
. O +

GM O -
- O -
kappa O +
B O +
defines O +
a O +
binding O +
site O +
for O +
NF O -
- O -
kappa O +
B O +
, O +
and O +
GC O -
- O -
box O +
defines O +
a O +
binding O +
site O +
for O +
three O +
( O +
A1 O +
, O +
A2 O +
, O +
B O +
) O +
constitutive O +
proteins O +
. O +

We O +
report O +
here O +
that O +
three O +
copies O +
of O +
the O +
GC O -
- O -
box O +
can O +
functionally O +
compensate O +
for O +
the O +
GM O -
- O -
kappa O +
B O -
/ O -
GC O -
- O -
box O +
region O +
, O +
suggesting O +
that O +
the O +
GC O -
- O -
motif O +
can O +
function O +
independently O +
of O +
the O +
GM O -
- O -
kappa O +
B O +
motif O +
. O +

The O +
major O +
GC O -
- O -
box O +
binding O +
activity O +
A1 O +
was O +
purified O +
and O +
identified O +
as O +
the O +
transcription O +
factor O +
Sp1 O +
. O +

We O +
show O +
that O +
depletion O +
of O +
Sp1 O +
( O +
A1 O +
) O +
from O +
nuclear O +
extracts O +
specifically O +
decreases O +
in O +
vitro O +
transcription O +
activity O +
on O +
GM O -
- O -
CSF O +
templates O +
. O +

Since O +
the O +
human O +
GM O -
- O -
CSF O +
promoter O +
has O +
a O +
base O +
difference O +
within O +
the O +
GC O -
- O -
box O +
, O +
we O +
speculate O +
that O +
this O +
may O +
explain O +
why O +
the O +
human O +
promoter O +
is O +
weak O +
and O +
that O +
an O +
upstream O +
enhancer O +
is O +
required O +
for O +
the O +
induction O +
of O +
the O +
human O +
GM O -
- O -
CSF O +
gene O +
. O +

The O +
C O -
- O -
terminus O +
of O +
the O +
B O +
cell O +
activator O +
Oct-2 O +
functions O +
as O +
an O +
activation O +
domain O +
in O +
yeast O +
. O +

Oct-1 O +
and O +
Oct-2 O +
are O +
human O +
transcriptional O +
activators O +
that O +
bind O +
to O +
the O +
same O +
DNA O +
element O +
but O +
activate O +
distinct O +
sets O +
of O +
genes O +
. O +

We O +
expressed O +
these O +
factors O +
in O +
S. O +
cerevisiae O +
and O +
observed O +
greater O +
than O +
5-fold O +
stimulation O +
of O +
a O +
lacZ O +
reporter O +
gene O +
only O +
with O +
Oct-2 O +
. O +

Transfer O +
of O +
the O +
Oct-2 O +
C O -
- O -
terminal O +
domain O +
onto O +
either O +
Oct-1 O +
( O +
Oct1.2 O +
) O +
or O +
a O +
nonactivating O +
DNA O -
- O -
binding O +
domain O +
from O +
GAL4 O +
created O +
activators O +
capable O +
of O +
greater O +
than O +
15 O +
and O +
10-fold O +
stimulation O +
of O +
activity O +
, O +
respectively O +
. O +

Thus O +
, O +
the O +
C O -
- O -
terminus O +
of O +
Oct-2 O +
is O +
sufficient O +
to O +
confer O +
activation O +
potential O +
to O +
nonactive O +
DNA O -
- O -
binding O +
fragments O +
in O +
yeast O +
. O +

An O +
AP1 O +
binding O +
site O +
upstream O +
of O +
the O +
kappa O +
immunoglobulin O +
intron O +
enhancer O +
binds O +
inducible O +
factors O +
and O +
contributes O +
to O +
expression O +
. O +

Expression O +
of O +
the O +
kappa O +
immunoglobulin O +
light O +
chain O +
gene O +
requires O +
developmental- O +
and O +
tissue O -
- O -
specific O +
regulation O +
by O +
trans O -
- O -
acting O +
factors O +
which O +
interact O +
with O +
two O +
distinct O +
enhancer O +
elements O +
. O +

A O +
new O +
protein O -
- O -
DNA O +
interaction O +
has O +
been O +
identified O +
upstream O +
of O +
the O +
intron O +
enhancer O +
, O +
within O +
the O +
matrix O -
- O -
associated O +
region O +
of O +
the O +
J O -
- O -
C O +
intron O +
. O +

The O +
binding O +
activity O +
is O +
greatly O +
inducible O +
in O +
pre O -
- O -
B O +
cells O +
by O +
bacterial O +
lipopolysaccharide O +
and O +
interleukin-1 O +
but O +
specific O +
complexes O +
are O +
found O +
at O +
all O +
stages O +
of O +
B O +
cell O +
development O +
tested O +
. O +

The O +
footprinted O +
binding O +
site O +
is O +
homologous O +
to O +
the O +
consensus O +
AP1 O +
motif O +
. O +

The O +
protein O +
components O +
of O +
this O +
complex O +
are O +
specifically O +
competed O +
by O +
an O +
AP1 O +
consensus O +
motif O +
and O +
were O +
shown O +
by O +
supershift O +
to O +
include O +
c O -
- O -
Jun O +
and O +
c O -
- O -
Fos O +
, O +
suggesting O +
that O +
this O +
binding O +
site O +
is O +
an O +
AP1 O +
motif O +
and O +
that O +
the O +
Jun O +
and O +
Fos O +
families O +
of O +
transcription O +
factors O +
play O +
a O +
role O +
in O +
the O +
regulation O +
of O +
the O +
kappa O +
light O +
chain O +
gene O +
. O +

Mutation O +
of O +
the O +
AP1 O +
motif O +
in O +
the O +
context O +
of O +
the O +
intron O +
enhancer O +
was O +
shown O +
to O +
decrease O +
enhancer O -
- O -
mediated O +
activation O +
of O +
the O +
promoter O +
in O +
both O +
pre O -
- O -
B O +
cells O +
induced O +
with O +
LPS O +
and O +
constitutive O +
expression O +
in O +
mature O +
B O +
cells O +
. O +

Distinct O +
roles O +
of O +
the O +
molecular O +
chaperone O +
hsp90 O +
in O +
modulating O +
dioxin O +
receptor O +
function O +
via O +
the O +
basic O +
helix O -
- O -
loop O -
- O -
helix O +
and O +
PAS O +
domains O +
. O +

The O +
intracellular O +
dioxin O +
receptor O +
mediates O +
signal O +
transduction O +
by O +
dioxin O +
and O +
functions O +
as O +
a O +
ligand O -
- O -
activated O +
transcription O +
factor O +
. O +

It O +
contains O +
a O +
basic O +
helix O -
- O -
loop O -
- O -
helix O +
( O +
bHLH O +
) O +
motif O +
contiguous O +
with O +
a O +
Per O -
- O -
Arnt O -
- O -
Sim O +
( O +
PAS O +
) O +
homology O +
region O +
. O +

In O +
extracts O +
from O +
nonstimulated O +
cells O +
the O +
receptor O +
is O +
recovered O +
in O +
an O +
inducible O +
cytoplasmic O +
form O +
associated O +
with O +
the O +
90-kDa O +
heat O +
shock O +
protein O +
( O +
hsp90 O +
) O +
, O +
a O +
molecular O +
chaperone O +
. O +

We O +
have O +
reconstituted O +
ligand O -
- O -
dependent O +
activation O +
of O +
the O +
receptor O +
to O +
a O +
DNA O -
- O -
binding O +
form O +
by O +
using O +
the O +
dioxin O +
receptor O +
and O +
its O +
bHLH O -
- O -
PAS O +
partner O +
factor O +
Arnt O +
expressed O +
by O +
in O +
vitro O +
translation O +
in O +
reticulocyte O +
lysate O +
. O +

Deletion O +
of O +
the O +
PAS O +
domain O +
of O +
the O +
receptor O +
resulted O +
in O +
constitutive O +
dimerization O +
with O +
Arnt O +
. O +

In O +
contrast O +
, O +
this O +
receptor O +
mutant O +
showed O +
low O +
levels O +
of O +
xenobiotic O +
response O +
element O -
- O -
binding O +
activity O +
, O +
indicating O +
that O +
the O +
PAS O +
domain O +
may O +
be O +
important O +
for O +
DNA O -
- O -
binding O +
affinity O +
and/or O +
specificity O +
of O +
the O +
receptor O +
. O +

It O +
was O +
not O +
possible O +
to O +
reconstitute O +
dioxin O +
receptor O +
function O +
with O +
proteins O +
expressed O +
in O +
wheat O +
germ O +
lysate O +
. O +

In O +
line O +
with O +
these O +
observations O +
, O +
reticulocyte O +
lysate O +
but O +
not O +
wheat O +
germ O +
lysate O +
promoted O +
the O +
association O +
of O +
de O +
novo O +
synthesized O +
dioxin O +
receptor O +
with O +
hsp90 O +
. O +

At O +
least O +
two O +
distinct O +
domains O +
of O +
the O +
receptor O +
mediated O +
interaction O +
with O +
hsp90 O +
: O +
the O +
ligand O -
- O -
binding O +
domain O +
located O +
within O +
the O +
PAS O +
region O +
and O +
, O +
surprisingly O +
, O +
the O +
bHLH O +
domain O +
. O +

Whereas O +
ligand O -
- O -
binding O +
activity O +
correlated O +
with O +
association O +
with O +
hsp90 O +
, O +
bHLH- O +
hsp90 O +
interaction O +
appeared O +
to O +
be O +
important O +
for O +
DNA O -
- O -
binding O +
activity O +
but O +
not O +
for O +
dimerization O +
of O +
the O +
receptor O +
. O +

Several O +
distinct O +
roles O +
for O +
hsp90 O +
in O +
modulating O +
dioxin O +
receptor O +
function O +
are O +
therefore O +
likely O +
: O +
correct O +
folding O +
of O +
the O +
ligand O -
- O -
binding O +
domain O +
, O +
interference O +
with O +
Arnt O +
heterodimerization O +
, O +
and O +
folding O +
of O +
a O +
DNA O -
- O -
binding O +
conformation O +
of O +
the O +
bHLH O +
domain O +
. O +

Thus O +
, O +
the O +
dioxin O +
receptor O +
system O +
provides O +
a O +
complex O +
and O +
interesting O +
model O +
of O +
the O +
regulation O +
of O +
transcription O +
factors O +
by O +
hsp90 O +
. O +

B O -
- O -
cell O +
proliferation O +
and O +
induction O +
of O +
early O +
G1-regulating O +
proteins O +
by O +
Epstein O -
- O -
Barr O +
virus O +
mutants O +
conditional O +
for O +
EBNA2 O +
. O +

Infection O +
of O +
primary O +
B O -
- O -
lymphocytes O +
by O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
leads O +
to O +
growth O +
transformation O +
of O +
these O +
B O -
- O -
cells O +
in O +
vitro O +
. O +

EBV O +
nuclear O +
antigen O +
2 O +
( O +
EBNA2 O +
) O +
, O +
one O +
of O +
the O +
first O +
genes O +
expressed O +
after O +
EBV O +
infection O +
of O +
B O -
- O -
cells O +
, O +
is O +
a O +
transcriptional O +
activator O +
of O +
viral O +
and O +
cellular O +
genes O +
and O +
is O +
essential O +
for O +
the O +
transforming O +
potential O +
of O +
the O +
virus O +
. O +

We O +
generated O +
conditional O +
EBV O +
mutants O +
by O +
expressing O +
EBNA2 O +
as O +
chimeric O +
fusion O +
protein O +
with O +
the O +
hormone O +
binding O +
domain O +
of O +
the O +
estrogen O +
receptor O +
on O +
the O +
genetic O +
background O +
of O +
the O +
virus O +
. O +

Growth O +
transformation O +
of O +
primary O +
normal O +
B O -
- O -
cells O +
by O +
mutant O +
virus O +
resulted O +
in O +
estrogen B-CellLine -
- I-CellLine -
dependent I-CellLine +
lymphoblastoid I-CellLine +
cell I-CellLine +
lines I-CellLine +
expressing O +
the O +
chimeric O +
EBNA2 O +
protein O +
. O +

In O +
the O +
absence O +
of O +
estrogen O +
about O +
half O +
of O +
the O +
cells O +
enter O +
a O +
quiescent O +
non O -
- O -
proliferative O +
state O +
whereas O +
the O +
others O +
die O +
by O +
apoptosis O +
. O +

EBNA2 O +
is O +
thus O +
required O +
not O +
only O +
for O +
initiation O +
but O +
also O +
for O +
maintenance O +
of O +
transformation O +
. O +

Growth O +
arrest O +
occurred O +
at O +
G1 O +
and O +
G2 O +
stages O +
of O +
the O +
cell O +
cycle O +
, O +
indicating O +
that O +
functional O +
EBNA2 O +
is O +
required O +
at O +
different O +
restriction O +
points O +
of O +
the O +
cell O +
cycle O +
. O +

Growth O +
arrest O +
is O +
reversible O +
for O +
G1 O -
/ O -
G0 O +
cells O +
as O +
indicated O +
by O +
the O +
sequential O +
accumulation O +
and O +
modification O +
of O +
cell O +
cycle O +
regulating O +
proteins O +
. O +

EBV O +
induces O +
the O +
same O +
cell O +
cycle O +
regulating O +
proteins O +
as O +
polyclonal O +
stimuli O +
in O +
primary O +
B O -
- O -
cells O +
. O +

These O +
data O +
suggest O +
that O +
EBV O +
is O +
using O +
a O +
common O +
pathway O +
for O +
B O -
- O -
cell O +
activation O +
bypassing O +
the O +
requirement O +
for O +
antigen O +
, O +
T O -
- O -
cell O +
signals O +
and O +
growth O +
factors O +
. O +

Induction O +
of O +
ICAM-1 O +
and O +
LFA-3 O +
by O +
Tax1 O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
and O +
mechanism O +
of O +
down O -
- O -
regulation O +
of O +
ICAM-1 O +
or O +
LFA-1 O +
in O +
adult B-CellLine -
- I-CellLine -
T I-CellLine -
- I-CellLine -
cell I-CellLine -
- I-CellLine -
leukemia I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

The O +
present O +
study O +
was O +
undertaken O +
to O +
determine O +
the O +
role O +
of O +
HTLV O -
- O -
I O +
TaxI O +
in O +
the O +
up O -
- O -
regulation O +
of O +
ICAM O -
- O -
I O +
and O +
LFA-3 O +
in O +
human O +
T O +
cells O +
transformed O +
with O +
HTLV O -
- O -
I O +
and O +
the O +
mechanism O +
of O +
down O -
- O -
regulation O +
of O +
ICAM O -
- O -
I O +
and O +
LFA O -
- O -
I O +
in O +
ATL B-CellLine -
- I-CellLine -
derived I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Induction O +
of O +
TaxI O +
in O +
a O +
human B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
Jurkat I-CellLine +
carrying O +
the O +
TaxI O +
gene O +
under O +
the O +
metallothionein O +
promoter O +
led O +
to O +
increases O +
in O +
mRNA O +
and O +
surface O +
expression O +
of O +
ICAM O -
- O -
I O +
. O +

The O +
response O +
of O +
LFA-3 O +
to O +
TaxI O +
induction O +
was O +
, O +
on O +
the O +
other O +
hand O +
, O +
relatively O +
slow O +
and O +
weak O +
, O +
and O +
might O +
be O +
indirect O +
. O +

Transactivation O +
of O +
the O +
ICAM O -
- O -
I O +
promoter O +
by O +
TaxI O +
was O +
further O +
shown O +
by O +
co O -
- O -
transfection O +
of O +
a O +
CAT O +
reporter O +
construct O +
with O +
the O +
ICAM O -
- O -
I O +
promoter O +
and O +
a O +
plasmid O +
expressing O +
TaxI O +
. O +

The O +
mechanism O +
of O +
down O -
- O -
regulation O +
of O +
ICAM O -
- O -
I O +
or O +
LFA O -
- O -
I O +
in O +
4 B-CellLine +
ATL I-CellLine +
cell I-CellLine +
lines I-CellLine +
was O +
next O +
examined O +
. O +

ICAM O -
- O -
I O +
mRNA O +
was O +
quite O +
low O +
in O +
MT B-CellLine -
- I-CellLine -
I I-CellLine +
, O +
but O +
no O +
genomic O +
changes O +
were O +
found O +
. O +

The O +
CAT O +
reporter O +
with O +
the O +
ICAM O -
- O -
I O +
promoter O +
was O +
inactive O +
in O +
MT B-CellLine -
- I-CellLine -
I I-CellLine +
. O +

Finally O +
, O +
combined O +
treatment O +
of O +
MT B-CellLine -
- I-CellLine -
I I-CellLine +
with O +
5-azacytidine O +
and O +
IFN O -
- O -
gamma O +
induced O +
re O -
- O -
expression O +
of O +
ICAM O -
- O -
I O +
. O +

Collectively O +
, O +
( O +
a O +
) O +
transcriptional O +
factor O +
( O +
s O +
) O +
necessary O +
for O +
expression O +
of O +
ICAM O -
- O -
I O +
gene O +
may O +
be O +
repressed O +
in O +
MT B-CellLine -
- I-CellLine -
I I-CellLine +
through O +
DNA O +
methylation O +
. O +

Three O +
other O +
ATL B-CellLine +
cell I-CellLine +
lines I-CellLine +
( O +
TL B-CellLine -
- I-CellLine -
OmI I-CellLine +
, O +
H582 B-CellLine +
, O +
HuT102 B-CellLine +
) O +
were O +
found O +
to O +
have O +
little O +
mRNA O +
for O +
the O +
LFA O -
- O -
I O +
beta O +
chain O +
( O +
CD18 O +
) O +
. O +

H582 B-CellLine +
and O +
HuT102 B-CellLine +
were O +
also O +
negative O +
for O +
the O +
LFA O -
- O -
I O +
alpha O +
chain O +
( O +
CDIIa O +
) O +
mRNA O +
. O +

No O +
genomic O +
changes O +
were O +
found O +
, O +
and O +
a O +
CAT O +
reporter O +
gene O +
with O +
the O +
CD18 O +
promoter O +
was O +
inactive O +
in O +
the O +
3 O +
of O +
them O +
, O +
again O +
suggesting O +
lack O +
of O +
( O +
a O +
) O +
transcriptional O +
factor O +
( O +
s O +
) O +
necessary O +
for O +
CD18 O +
expression O +
. O +

Evaluation O +
of O +
the O +
respiratory O +
epithelium O +
of O +
normals O +
and O +
individuals O +
with O +
cystic O +
fibrosis O +
for O +
the O +
presence O +
of O +
adenovirus O +
E1a O +
sequences O +
relevant O +
to O +
the O +
use O +
of O +
E1a- O +
adenovirus O +
vectors O +
for O +
gene O +
therapy O +
for O +
the O +
respiratory O +
manifestations O +
of O +
cystic O +
fibrosis O +
. O +

Lung O +
disease O +
associated O +
with O +
disorders O +
such O +
as O +
cystic O +
fibrosis O +
( O +
CF O +
) O +
may O +
be O +
amenable O +
to O +
somatic O +
gene O +
therapy O +
in O +
which O +
there O +
is O +
delivery O +
of O +
the O +
normal O +
gene O +
directly O +
to O +
the O +
respiratory O +
epithelium O +
using O +
E1a- O +
adenovirus O +
( O +
Ad O +
) O +
type O +
2- O +
or O +
5-based O +
vectors O +
. O +

For O +
safety O +
reasons O +
, O +
the O +
Ad O +
vectors O +
are O +
rendered O +
replication O +
deficient O +
by O +
deletion O +
of O +
the O +
E1a O +
region O +
. O +

Because O +
there O +
is O +
the O +
theoretical O +
possibility O +
of O +
an O +
E1a- O +
replication O -
- O -
deficient O +
vector O +
replicating O +
as O +
a O +
result O +
of O +
recombination O +
or O +
complementation O +
with O +
Ad O +
2 O -
/ O -
5 O +
E1a O +
sequences O +
present O +
in O +
the O +
target O +
cell O +
, O +
this O +
study O +
is O +
directed O +
toward O +
evaluating O +
respiratory O +
epithelium O +
of O +
normals O +
and O +
individuals O +
with O +
CF O +
for O +
the O +
presence O +
of O +
E1a O +
sequences O +
. O +

Using O +
Ad O +
2 O -
/ O -
5 O +
E1a O -
- O -
specific O +
primers O +
and O +
the O +
polymerase O +
chain O +
reaction O +
to O +
evaluate O +
DNA O +
recovered O +
from O +
freshly O +
isolated O +
nasal O +
and O +
bronchial O +
epithelium O +
recovered O +
by O +
brushing O +
, O +
E1a O +
sequences O +
were O +
detected O +
in O +
respiratory O +
epithelium O +
of O +
19 O +
of O +
91 O +
normals O +
( O +
21 O +
% O +
) O +
. O +

In O +
the O +
E1a O -
- O -
positive O +
samples O +
, O +
the O +
average O +
of O +
E1a O +
copy O +
number O +
was O +
55 O +
+ O -
/- O +
18 O -
/ O -
10 O +
( O +
3 O +
) O +
recovered O +
cells O +
. O +

In O +
CF O +
individuals O +
, O +
7 O +
of O +
52 O +
( O +
13 O +
% O +
) O +
had O +
detectable O +
E1a O +
sequences O +
in O +
the O +
respiratory O +
epithelium O +
, O +
with O +
E1a O +
copy O +
number O +
in O +
the O +
positive O +
samples O +
of O +
80 O +
+ O -
/- O +
21 O -
/ O -
10 O +
( O +
3 O +
) O +
recovered O +
cells O +
. O +

These O +
results O +
demonstrate O +
that O +
there O +
are O +
detectable O +
Ad O +
2 O -
/ O -
5 O +
E1a O +
sequences O +
in O +
the O +
respiratory O +
epithelium O +
of O +
a O +
small O +
percentage O +
of O +
normals O +
and O +
individuals O +
with O +
CF O +
. O +

Because O +
of O +
the O +
theoretical O +
potential O +
of O +
such O +
sequences O +
supporting O +
replication O +
of O +
E1a- O +
Ad O +
vectors O +
, O +
human O +
gene O +
therapy O +
protocols O +
for O +
CF O +
utilizing O +
such O +
vectors O +
should O +
consider O +
evaluating O +
study O +
individuals O +
for O +
the O +
presence O +
of O +
Ad O +
2 O -
/ O -
5 O +
E1a O +
sequences O +
in O +
the O +
respiratory O +
epithelium O +
. O +

Biphasic O +
control O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
activation O +
by O +
the O +
T O +
cell O +
receptor O +
complex O +
: O +
role O +
of O +
tumor O +
necrosis O +
factor O +
alpha O +
. O +

The O +
regulation O +
of O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappa O +
B O +
activation O +
by O +
the O +
T O +
cell O +
receptor O +
( O +
TcR O +
) O +
/CD3 O +
complex O +
in O +
primary O +
human O +
T O +
cells O +
has O +
been O +
studied O +
at O +
various O +
times O +
after O +
activation O +
. O +

Only O +
p50 O +
NF O -
- O -
kappa O +
B O +
protein O +
bound O +
the O +
kappa O +
B O +
element O +
of O +
interleukin-2 O +
receptor O +
( O +
IL-2R O +
) O +
alpha O +
chain O +
promoter O +
on O +
resting O +
T O +
cells O +
. O +

However O +
, O +
immediately O +
after O +
TcR O -
/ O -
CD3 O +
cross O -
- O -
linking O +
( O +
after O +
approximately O +
1 O +
h O +
; O +
immediate O +
) O +
binding O +
of O +
p50.p65 O +
heterodimers O +
was O +
observed O +
. O +

p50.c O -
- O -
rel O +
heterodimers O +
were O +
also O +
detected O +
bound O +
to O +
this O +
sequence O +
at O +
early O +
time O +
points O +
( O +
7 O -
- O -
16 O +
h O +
; O +
early O +
) O +
, O +
and O +
both O +
remained O +
active O +
at O +
later O +
time O +
points O +
( O +
40 O +
h O +
; O +
late O +
) O +
after O +
activation O +
. O +

This O +
regulation O +
takes O +
place O +
mainly O +
at O +
the O +
level O +
of O +
nuclear O +
translocation O +
of O +
p65 O +
and O +
c O -
- O -
rel O +
, O +
at O +
immediate O +
and O +
early O +
time O +
points O +
. O +

Activation O +
also O +
induced O +
c O -
- O -
rel O +
and O +
p105 O -
/ O -
p50 O +
mRNA O +
synthesis O +
, O +
but O +
not O +
p65 O +
mRNA O +
whose O +
expression O +
was O +
constitutive O +
. O +

Interestingly O +
, O +
all O +
those O +
early O +
and O +
late O +
events O +
, O +
but O +
not O +
the O +
immediate O +
ones O +
, O +
were O +
inhibited O +
by O +
a O +
neutralizing O +
anti O -
- O -
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
monoclonal O +
antibody O +
. O +

Similarly O +
, O +
cycloheximide O +
prevented O +
the O +
p65 O +
and O +
c O -
- O -
rel O +
translocation O +
and O +
consequent O +
formation O +
of O +
active O +
binding O +
heterodimers O +
, O +
at O +
early O +
and O +
late O +
times O +
. O +

Cyclosporin O +
A O +
impaired O +
not O +
only O +
early O +
and O +
late O +
, O +
but O +
also O +
immediate O +
events O +
; O +
however O +
, O +
addition O +
of O +
TNF O -
- O -
alpha O +
prevented O +
all O +
inhibition O +
. O +

These O +
results O +
indicate O +
that O +
the O +
regulation O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
during O +
T O +
cell O +
activation O +
by O +
TcR O -
/ O -
CD3 O +
signals O +
is O +
biphasic O +
: O +
TcR O -
/ O -
CD3 O +
triggers O +
its O +
immediate O +
translocation O +
, O +
which O +
is O +
transient O +
if O +
no O +
TNF O -
- O -
alpha O +
is O +
present O +
. O +

TNF O -
- O -
alpha O +
, O +
therefore O +
, O +
emerges O +
as O +
the O +
main O +
factor O +
responsible O +
for O +
a O +
second O +
phase O +
of O +
NF O -
- O -
kappa O +
B O +
regulation O +
, O +
controlling O +
both O +
translocation O +
of O +
p65 O +
and O +
c O -
- O -
rel O +
, O +
and O +
new O +
mRNA O +
synthesis O +
for O +
c O -
- O -
rel O +
and O +
p105 O -
/ O -
p50 O +
. O +

Overexpression O +
of O +
protein O +
kinase O +
C O -
- O -
zeta O +
stimulates O +
leukemic O +
cell O +
differentiation O +
. O +

A O +
function O +
for O +
protein O +
kinase O +
C O -
- O -
zeta O +
( O +
PKC O -
- O -
zeta O +
) O +
, O +
a O +
member O +
of O +
the O +
phorbol O +
ester O +
nonresponsive O +
atypical O +
protein O +
kinase O +
C O +
subfamily O +
, O +
in O +
modulating O +
differentiation O +
was O +
examined O +
in O +
the O +
leukemic B-CellLine +
U937 I-CellLine +
cell I-CellLine +
. O +

Transfected O +
U937 B-CellLine +
cells I-CellLine +
stably O +
overexpressing O +
PKC O -
- O -
zeta O +
displayed O +
a O +
longer O +
doubling O +
time O +
, O +
lower O +
saturation O +
density O +
at O +
confluency O +
, O +
and O +
an O +
increase O +
in O +
adherence O +
to O +
plastic O +
as O +
compared O +
to O +
control B-CellLine +
cells I-CellLine +
. O +

PKC B-CellLine -
- I-CellLine -
zeta I-CellLine +
cells I-CellLine +
expressed O +
a O +
more O +
differentiated O +
phenotype O +
as O +
assessed O +
by O +
changes O +
in O +
morphology O +
, O +
surface O +
antigen O +
expression O +
, O +
and O +
lysosomal O +
enzyme O +
activities O +
and O +
were O +
distinct O +
from O +
parental B-CellLine +
U937 I-CellLine +
cells I-CellLine +
stimulated O +
to O +
differentiate O +
by O +
exposure O +
to O +
phorbol O +
esters O +
. O +

In O +
contrast O +
to O +
parental O +
U937 B-CellLine +
cells I-CellLine +
, O +
PKC B-CellLine -
- I-CellLine -
zeta I-CellLine +
cells I-CellLine +
constitutively O +
expressed O +
mRNA O +
transcripts O +
for O +
c O -
- O -
jun O +
and O +
a O +
low O +
mobility O +
AP-1 O +
binding O +
activity O +
. O +

Thus O +
, O +
PKC O -
- O -
zeta O +
overexpression O +
stimulates O +
a O +
type O +
of O +
phenotypic O +
differentiation O +
that O +
differs O +
significantly O +
from O +
maturation O +
occurring O +
upon O +
activation O +
of O +
other O +
PKC O +
subfamilies O +
induced O +
by O +
phorbol O +
ester O +
treatment O +
. O +

Increased O +
expression O +
of O +
the O +
c O -
- O -
jun O +
protooncogene O +
and O +
an O +
increase O +
in O +
AP-1 O +
binding O +
activity O +
in O +
PKC B-CellLine -
- I-CellLine -
zeta I-CellLine +
cells I-CellLine +
provides O +
a O +
potential O +
mechanism O +
for O +
explaining O +
the O +
altered O +
differentiation O +
status O +
of O +
this O +
cell O +
. O +

Posttranscriptional O +
regulation O +
of O +
macrophage O +
tissue O +
factor O +
expression O +
by O +
antioxidants O +
. O +

Tissue O +
factor O +
( O +
TF O +
) O +
expression O +
by O +
cells O +
of O +
monocyte O -
/ O -
macrophage O +
lineage O +
represents O +
an O +
important O +
mechanism O +
underlying O +
the O +
initiation O +
of O +
fibrin O +
deposition O +
at O +
sites O +
of O +
extravascular O +
inflammation O +
. O +

Recent O +
evidence O +
suggests O +
a O +
role O +
for O +
oxidant O +
stress O +
in O +
the O +
signalling O +
pathway O +
of O +
various O +
cell O +
types O +
by O +
virtue O +
of O +
its O +
ability O +
to O +
induce O +
DNA O +
binding O +
of O +
various O +
transcription O +
factors O +
, O +
including O +
nuclear O +
factor O +
kappa O +
B O +
and O +
AP-1 O +
. O +

The O +
effect O +
of O +
antioxidant O +
treatment O +
on O +
lipopolysaccharide O +
( O +
LPS O +
) O +
-induced O +
TF O +
expression O +
was O +
examined O +
in O +
murine O +
peritoneal O +
macrophages O +
and O +
human O +
monocytes O +
. O +

Both O +
pyrrolidine O +
dithiocarbamate O +
, O +
an O +
oxidant O +
scavenger O +
, O +
and O +
N O -
- O -
acetyl O -
- O -
cysteine O +
, O +
a O +
precursor O +
of O +
the O +
endogenous O +
antioxidant O +
glutathione O +
, O +
inhibited O +
stimulation O +
of O +
macrophage O +
procoagulant O +
activity O +
by O +
LPS O +
. O +

Northern O +
blot O +
analysis O +
showed O +
that O +
neither O +
of O +
these O +
agents O +
reduced O +
LPS O -
- O -
stimulated O +
TF O +
mRNA O +
accumulation O +
, O +
thereby O +
suggesting O +
a O +
posttranscriptional O +
mechanism O +
for O +
the O +
effect O +
. O +

Immunofluorescence O +
studies O +
of O +
human O +
monocytes O +
using O +
polyclonal O +
anti O -
- O -
TF O +
antibody O +
showed O +
that O +
N O -
- O -
acetyl O -
- O -
cysteine O +
treatment O +
prevented O +
the O +
characteristic O +
plasmalemmal O +
localization O +
of O +
TF O +
antigen O +
that O +
occurs O +
in O +
response O +
to O +
LPS O +
. O +

Western O +
blot O +
analysis O +
showed O +
that O +
N O -
- O -
acetyl O -
- O -
cysteine O +
reduced O +
the O +
accumulation O +
of O +
the O +
47-kD O +
mature O +
glycoprotein O +
in O +
LPS B-CellLine -
- I-CellLine -
treated I-CellLine +
cells I-CellLine +
, O +
a O +
finding O +
consistent O +
with O +
the O +
results O +
of O +
the O +
immunofluorescence O +
studies O +
. O +

Furthermore O +
, O +
these O +
conditions O +
did O +
not O +
result O +
in O +
an O +
accumulation O +
of O +
the O +
less O +
mature O +
forms O +
of O +
TF O +
. O +

When O +
considered O +
together O +
, O +
these O +
data O +
suggest O +
that O +
antioxidants O +
exert O +
their O +
effects O +
by O +
impairing O +
translation O +
and/or O +
by O +
causing O +
degradation O +
of O +
newly O +
translated O +
protein O +
. O +

The O +
effect O +
of O +
antioxidants O +
on O +
tumor O +
necrosis O +
factor O +
appeared O +
to O +
be O +
species O +
specific O +
, O +
with O +
no O +
effect O +
on O +
LPS O -
- O -
induced O +
tumor O +
necrosis O +
factor O +
in O +
murine O +
cells O +
, O +
but O +
with O +
inhibition O +
in O +
human O +
monocytes O +
. O +

The O +
posttranscriptional O +
effect O +
of O +
antioxidants O +
on O +
TF O +
expression O +
data O +
suggests O +
a O +
novel O +
mechanism O +
whereby O +
these O +
agents O +
might O +
modulate O +
monocyte O +
/macrophage O +
activation O +
. O +

1 O +
, O +
25-Dihydroxyvitamin O +
D3 O +
receptors O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
from O +
patients O +
with O +
primary O +
and O +
secondary O +
hyperparathyroidism O +
. O +

A O +
decreased O +
number O +
of O +
calcitriol O +
( O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
) O +
receptors O +
has O +
been O +
observed O +
in O +
parathyroid O +
glands O +
of O +
uremic O +
animals O +
. O +

In O +
humans O +
, O +
studies O +
carried O +
out O +
in O +
surgically O +
removed O +
parathyroid O +
glands O +
have O +
shown O +
that O +
calcitriol O +
binding O +
is O +
higher O +
in O +
primary O +
than O +
in O +
secondary O +
hyperparathyroidism O +
. O +

Since O +
specific O +
receptors O +
for O +
calcitriol O +
have O +
been O +
described O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
, O +
we O +
have O +
investigated O +
the O +
specific O +
uptake O +
of O +
3H O -
- O -
labelled O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
in O +
PBMC O +
of O +
12 O +
women O +
with O +
primary O +
hyperparathyroidism O +
( O +
PHP O +
) O +
, O +
8 O +
women O +
with O +
hyperparathyroidism O +
secondary O +
to O +
chronic O +
renal O +
failure O +
( O +
SH O +
) O +
, O +
9 O +
women O +
with O +
renal O +
transplant O +
( O +
RT O +
) O +
, O +
and O +
23 O +
healthy O +
women O +
. O +

The O +
median O +
dissociation O +
constant O +
( O +
Kd O +
) O +
was O +
similar O +
in O +
all O +
three O +
groups O +
of O +
patients O +
and O +
in O +
healthy O +
women O +
( O +
mean O +
+ O -
/- O +
S.D. O +
( O +
range O +
) O +
: O +
PHP O +
, O +
1.2 O +
+ O -
/- O +
1.0 O +
( O +
0.2 O -
- O -
4 O +
) O +
x O +
10 O +
( O +
-10 O +
) O +
M O +
; O +
SH O +
, O +
0.6 O +
+ O -
/- O +
0.4 O +
( O +
0.2 O -
- O -
1.2 O +
) O +
x O +
10 O +
( O +
-10 O +
) O +
M O +
; O +
RT O +
, O +
1.1 O +
+ O -
/- O +
0.5 O +
( O +
0.4 O -
- O -
1.9 O +
) O +
x O +
10 O +
( O +
-10 O +
) O +
M O +
; O +
controls O +
, O +
1.0 O +
+ O -
/- O +
0.6 O +
( O +
0.3 O -
- O -
2.6 O +
) O +
x O +
10 O +
( O +
-10 O +
) O +
M O +
) O +
. O +
However O +
, O +
the O +
maximal O +
binding O +
capacity O +
( O +
Nmax O +
) O +
was O +
significantly O +
enhanced O +
in O +
PHP O +
( O +
3.9 O +
+ O -
/- O +
1.9 O +
( O +
1.3 O -
- O -
7.6 O +
) O +
fmol O -
/ O -
10 O +
( O +
7 O +
) O +
cells O +
vs. O +
2.3 O +
+ O -
/- O +
0.9 O +
( O +
1.1 O -
- O -
4.4 O +
) O +
fmol O -
/ O -
10 O +
( O +
7 O +
) O +
cells O +
in O +
controls O +
; O +
P O +
= O +
0.0006 O +
) O +
and O +
decreased O +
in O +
SH O +
( O +
0.8 O +
+ O -
/- O +
0.5 O +
( O +
0.2 O -
- O -
1.6 O +
) O +
fmol O -
/ O -
10 O +
( O +
7 O +
) O +
cells O +
vs. O +
2.3 O +
+ O -
/- O +
0.9 O +
( O +
1.1 O -
- O -
4.4 O +
) O +
fmol O -
/ O -
10 O +
( O +
7 O +
) O +
cells O +
in O +
controls O +
; O +
P O +
= O +
0.0001 O +
) O +
, O +
whereas O +
no O +
changes O +
were O +
seen O +
in O +
RT O +
( O +
2.3 O +
+ O -
/- O +
0.7 O +
( O +
1.2 O -
- O -
3.3 O +
) O +
fmol O -
/ O -
10 O +
( O +
7 O +
) O +
cells O +
vs. O +
2.3 O +
+ O -
/- O +
0.9 O +
( O +
1.1 O -
- O -
4.4 O +
) O +
fmol O -
/ O -
10 O +
( O +
7 O +
) O +
cells O +
in O +
controls O +
) O +
. O +

In O +
three O +
patients O +
with O +
PHP O +
who O +
were O +
subjected O +
to O +
parathyroidectomy O +
, O +
the O +
calcitriol O +
number O +
came O +
down O +
to O +
normal O +
. O +

Changes O +
of O +
calcitriol O +
receptors O +
in O +
primary O +
and O +
secondary O +
hyperparathyroidism O +
could O +
magnify O +
the O +
consequences O +
of O +
disturbances O +
in O +
serum O +
concentration O +
of O +
calcitriol O +
itself O +
and O +
might O +
play O +
an O +
important O +
role O +
in O +
the O +
development O +
of O +
secondary O +
hyperparathyroidism O +
in O +
uremia O +
. O +

Effects O +
of O +
the O +
antisense O +
myb O +
expression O +
on O +
hemin- O +
and O +
erythropoietin- O +
induced O +
erythroid O +
differentiation O +
of O +
K562 B-CellLine +
cells I-CellLine +
. O +

In O +
order O +
to O +
elucidate O +
the O +
role O +
of O +
c O -
- O -
myb O +
gene O +
in O +
erythroid O +
differentiation O +
of O +
K562 B-CellLine +
cell I-CellLine +
induced O +
by O +
hemin O +
( O +
Hm O +
) O +
and O +
erythropoietin O +
( O +
Epo O +
) O +
, O +
we O +
constructed O +
recombinant O +
plasmid O +
that O +
could O +
produce O +
antisense O +
myb O +
RNA O +
after O +
induction O +
with O +
dexamethasone O +
. O +

During O +
treatment O +
with O +
Hm O +
, O +
K562 B-CellLine +
cells I-CellLine +
constitutively O +
expressed O +
c O -
- O -
myb O +
mRNA O +
, O +
and O +
50 O +
% O +
of O +
them O +
began O +
to O +
synthesize O +
hemoglobin O +
( O +
Hb O +
) O +
. O +

Expression O +
of O +
antisense O +
myb O +
RNA O +
reduced O +
the O +
amount O +
of O +
c O -
- O -
myb O +
mRNA O +
, O +
and O +
the O +
percentage O +
of O +
Hb B-CellLine -
- I-CellLine -
synthesizing I-CellLine +
cells I-CellLine +
was O +
decreased O +
to O +
20 O +
% O +
. O +

In O +
the O +
presence O +
of O +
Epo O +
, O +
c O -
- O -
myb O +
mRNA O +
declined O +
and O +
20 O +
% O +
of O +
K562 B-CellLine +
cells I-CellLine +
synthesized O +
Hb O +
regardless O +
of O +
antisense O +
myb O +
RNA O +
expression O +
. O +

It O +
is O +
suggested O +
that O +
constitutive O +
expression O +
of O +
c O -
- O -
myb O +
mRNA O +
is O +
necessary O +
for O +
Hm O +
-induced O +
differentiation O +
, O +
and O +
that O +
a O +
decrease O +
in O +
the O +
amount O +
of O +
c O -
- O -
myb O +
mRNA O +
induced O +
by O +
antisense O +
myb O +
RNA O +
expression O +
suppresses O +
Hm O +
-induced O +
differentiation O +
. O +

The O +
amount O +
of O +
c O -
- O -
myb O +
mRNA O +
in O +
K562 B-CellLine +
cells I-CellLine +
was O +
reduced O +
during O +
the O +
differentiation O +
induced O +
by O +
Epo O +
. O +

Expression O +
of O +
GATA-1 O +
mRNA O +
was O +
almost O +
constant O +
during O +
Hm O +
-induced O +
differentiation O +
, O +
but O +
increased O +
during O +
Epo O +
treatment O +
. O +

It O +
is O +
supposed O +
that O +
the O +
mechanism O +
of O +
Hm O +
-induced O +
differentiation O +
is O +
distinguished O +
from O +
that O +
of O +
Epo O +
-induced O +
differentiation O +
in O +
K562 B-CellLine +
cells I-CellLine +
. O +

Regulation O +
of O +
I O +
kappa O +
B O +
alpha O +
and O +
p105 O +
in O +
monocytes O +
and O +
macrophages O +
persistently O +
infected O +
with O +
human O +
immunodeficiency O +
virus O +
. O +

The O +
mechanisms O +
regulating O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
persistence O +
in O +
human O +
monocytes O +
/macrophages O +
are O +
partially O +
understood O +
. O +

Persistent O +
HIV O +
infection O +
of O +
U937 B-CellLine +
monocytic I-CellLine +
cells I-CellLine +
results O +
in O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

Whether O +
virus O -
- O -
induced O +
NF O -
- O -
kappa O +
B O +
activation O +
is O +
a O +
mechanism O +
that O +
favors O +
continuous O +
viral O +
replication O +
in O +
macrophages O +
remains O +
unknown O +
. O +

To O +
further O +
delineate O +
the O +
molecular O +
mechanisms O +
involved O +
in O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
HIV O -
- O -
infected O +
monocytes O +
and O +
macrophages O +
, O +
we O +
have O +
focused O +
on O +
the O +
regulation O +
of O +
the O +
I O +
kappa O +
B O +
molecules O +
. O +

First O +
, O +
we O +
show O +
that O +
persistent O +
HIV O +
infection O +
results O +
in O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
not O +
only O +
in O +
monocytic O +
cells O +
but O +
also O +
in O +
macrophages O +
. O +

In O +
HIV O -
- O -
infected O +
cells O +
, O +
I O +
kappa O +
B O +
alpha O +
protein O +
levels O +
are O +
decreased O +
secondary O +
to O +
enhanced O +
protein O +
degradation O +
. O +

This O +
parallels O +
the O +
increased O +
I O +
kappa O +
B O +
alpha O +
synthesis O +
secondary O +
to O +
increased O +
I O +
kappa O +
B O +
alpha O +
gene O +
transcription O +
, O +
i.e. O +
, O +
increased O +
RNA O +
and O +
transcriptional O +
activity O +
of O +
its O +
promoter O -
- O -
enhancer O +
. O +

Another O +
protein O +
with O +
I O +
kappa O +
B O +
function O +
, O +
p105 O +
, O +
is O +
also O +
modified O +
in O +
HIV O -
- O -
infected O +
cells O +
: O +
p105 O +
and O +
p50 O +
steady O -
- O -
state O +
protein O +
levels O +
are O +
increased O +
as O +
a O +
result O +
of O +
increased O +
synthesis O +
and O +
proteolytic O +
processing O +
of O +
p105 O +
. O +

Transcriptional O +
activity O +
of O +
p105 O +
is O +
also O +
increased O +
in O +
infected O +
cells O +
and O +
is O +
also O +
mediated O +
by O +
NF O -
- O -
kappa O +
B O +
through O +
a O +
specific O +
kappa O +
B O +
motif O +
. O +

These O +
results O +
demonstrate O +
the O +
existence O +
of O +
a O +
triple O +
autoregulatory O +
loop O +
in O +
monocytes O +
and O +
macrophages O +
involving O +
HIV O +
, O +
p105 O +
and O +
p50 O +
, O +
and O +
MAD3 O +
, O +
with O +
the O +
end O +
result O +
of O +
persistent O +
NF O -
- O -
kappa O +
B O +
activation O +
and O +
viral O +
persistence O +
. O +

Furthermore O +
, O +
persistent O +
HIV O +
infection O +
of O +
monocytes O +
and O +
macrophages O +
provides O +
a O +
useful O +
model O +
with O +
which O +
to O +
study O +
concomitant O +
modifications O +
of O +
different O +
I O +
kappa O +
B O +
molecules O +
. O +

OBF-1 O +
, O +
a O +
novel O +
B O +
cell O -
- O -
specific O +
coactivator O +
that O +
stimulates O +
immunoglobulin O +
promoter O +
activity O +
through O +
association O +
with O +
octamer O -
- O -
binding O +
proteins O +
. O +

Recent O +
biochemical O +
and O +
genetic O +
studies O +
indicate O +
that O +
in O +
addition O +
to O +
the O +
octamer O -
- O -
binding O +
proteins O +
Oct-1 O +
and O +
Oct-2 O +
, O +
other O +
B O +
cell O +
components O +
are O +
required O +
for O +
lymphoid O -
- O -
restricted O +
, O +
octamer O +
site O -
- O -
mediated O +
immunoglobulin O +
gene O +
promoter O +
activity O +
. O +

Using O +
a O +
genetic O +
screen O +
in O +
yeast O +
, O +
we O +
have O +
isolated O +
B O +
cell O -
- O -
derived O +
cDNAs O +
encoding O +
Oct O -
- O -
binding O +
factor O +
1 O +
( O +
OBF-1 O +
) O +
, O +
a O +
novel O +
protein O +
that O +
specifically O +
associates O +
with O +
Oct-1 O +
and O +
Oct-2 O +
. O +

Biochemical O +
studies O +
demonstrate O +
that O +
OBF-1 O +
has O +
no O +
intrinsic O +
DNA O -
- O -
binding O +
activity O +
and O +
recognizes O +
the O +
POU O +
domains O +
of O +
Oct-1 O +
and O +
Oct-2 O +
, O +
but O +
not O +
those O +
of O +
Oct-4 O +
and O +
Oct-6 O +
. O +

The O +
OBF-1 O +
mRNA O +
is O +
expressed O +
in O +
a O +
highly O +
cell O -
- O -
specific O +
manner O +
, O +
being O +
most O +
abundant O +
in O +
B O +
cells O +
and O +
essentially O +
absent O +
in O +
most O +
of O +
the O +
other O +
cells O +
or O +
tissues O +
tested O +
. O +

Furthermore O +
, O +
expression O +
of O +
OBF-1 O +
in O +
HeLa B-CellLine +
cells I-CellLine +
selectively O +
stimulates O +
the O +
activity O +
of O +
a O +
natural O +
immunoglobulin O +
promoter O +
in O +
an O +
octamer O +
site O +
-dependent O +
manner O +
. O +

Thus O +
, O +
OBF-1 O +
has O +
all O +
the O +
properties O +
expected O +
for O +
a O +
B O +
cell O -
- O -
specific O +
transcriptional O +
coactivator O +
protein O +
. O +

Transcription O -
- O -
independent O +
turnover O +
of O +
I O +
kappa O +
B O +
alpha O +
during O +
monocyte O +
adherence O +
: O +
implications O +
for O +
a O +
translational O +
component O +
regulating O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
mRNA O +
levels O +
. O +

We O +
identified O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
as O +
an O +
immediate O -
- O -
early O +
gene O +
in O +
human O +
monocytes O +
that O +
is O +
expressed O +
in O +
response O +
to O +
a O +
variety O +
of O +
signals O +
, O +
including O +
adhesion O +
, O +
lipopolysaccharide O +
, O +
and O +
phorbol O +
myristate O +
acetate O +
. O +

Within O +
5 O +
min O +
of O +
monocyte O +
adhesion O +
, O +
the O +
level O +
of O +
the O +
I O +
kappa O +
B O +
alpha O +
protein O +
is O +
markedly O +
diminished O +
but O +
is O +
rapidly O +
replaced O +
in O +
a O +
cycloheximide O -
- O -
sensitive O +
manner O +
within O +
20 O +
min O +
. O +

Accompanying O +
the O +
rapid O +
turnover O +
of O +
the O +
I O +
kappa O +
B O +
alpha O +
protein O +
is O +
simultaneous O +
translocation O +
of O +
NF O -
- O -
kappa O +
B O -
- O -
related O +
transcription O +
factors O +
to O +
nuclei O +
of O +
adhered O +
monocytes O +
. O +

The O +
demonstration O +
that O +
NF O -
- O -
kappa O +
B O +
can O +
regulate O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
gene O +
transcription O +
in O +
other O +
cell O +
types O +
suggested O +
that O +
the O +
rapid O +
increase O +
in O +
steady O -
- O -
state O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
mRNA O +
levels O +
we O +
observed O +
within O +
30 O +
min O +
of O +
monocyte O +
adherence O +
would O +
result O +
from O +
NF O -
- O -
kappa O +
B O +
-dependent O +
transcriptional O +
stimulation O +
of O +
the O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
gene O +
. O +

Nuclear O +
run O -
- O -
on O +
analyses O +
indicated O +
that O +
, O +
instead O +
, O +
while O +
several O +
immediate O -
- O -
early O +
cytokine O +
genes O +
, O +
such O +
as O +
the O +
interleukin O +
1 O +
beta O +
( O +
IL-1 O +
beta O +
) O +
gene O +
, O +
were O +
transcriptionally O +
activated O +
during O +
monocyte O +
adhesion O +
, O +
the O +
rate O +
of O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
gene O +
transcription O +
remained O +
constant O +
. O +

The O +
adherence O -
- O -
dependent O +
increase O +
in O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
mRNA O +
levels O +
was O +
also O +
not O +
a O +
consequence O +
of O +
mRNA O +
stabilization O +
events O +
. O +

Interestingly O +
, O +
while O +
increases O +
in O +
both O +
IL-1 O +
beta O +
and O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
mRNA O +
levels O +
were O +
detected O +
in O +
nuclei O +
of O +
adherent O +
monocytes O +
, O +
cytoplasmic O +
levels O +
of O +
IL-1 O +
beta O +
mRNA O +
increased O +
during O +
adherence O +
whereas O +
those O +
of O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
mRNA O +
did O +
not O +
. O +

Taken O +
together O +
, O +
our O +
data O +
suggest O +
that O +
two O +
interactive O +
mechanisms O +
regulate O +
monocytic O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
mRNA O +
levels O +
. O +

We O +
propose O +
that O +
adherent O +
monocytes O +
regulate O +
nuclear O +
processing O +
( O +
or O +
decay O +
) O +
of O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
mRNA O +
, O +
thereby O +
increasing O +
mRNA O +
levels O +
without O +
stimulating O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
gene O +
transcription O +
. O +

Moreover O +
, O +
since O +
inhibition O +
of O +
protein O +
synthesis O +
leads O +
to O +
accumulation O +
of O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
mRNA O +
without O +
stimulating O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
gene O +
transcription O +
, O +
we O +
suggest O +
that O +
low O +
cytoplasmic O +
levels O +
of O +
I O +
kappa O +
B O +
alpha O -
/ O -
MAD-3 O +
mRNA O +
are O +
maintained O +
by O +
a O +
translation O -
- O -
dependent O +
degradation O +
mechanism O +
. O +

Regulation O +
of O +
cell O -
- O -
type O -
- O -
specific O +
interleukin-2 O +
receptor O +
alpha O -
- O -
chain O +
gene O +
expression O +
: O +
potential O +
role O +
of O +
physical O +
interactions O +
between O +
Elf-1 O +
, O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
, O +
and O +
NF O -
- O -
kappa O +
B O +
family O +
proteins O +
. O +

The O +
interleukin O +
2 O +
receptor O +
alpha O -
- O -
chain O +
( O +
IL-2R O +
alpha O +
) O +
gene O +
is O +
rapidly O +
and O +
potently O +
induced O +
in O +
T O +
cells O +
in O +
response O +
to O +
mitogenic O +
stimuli O +
. O +

Previously O +
, O +
an O +
inducible O +
enhancer O +
between O +
nucleotides O +
-299 O +
and O +
-228 O +
that O +
contains O +
NF O -
- O -
kappa O +
B O +
and O +
CArG O +
motifs O +
was O +
identified O +
. O +

We O +
now O +
report O +
the O +
characterization O +
of O +
a O +
second O +
essential O +
positive O +
regulatory O +
element O +
located O +
between O +
nucleotides O +
-137 O +
and O +
-64 O +
that O +
binds O +
Elf-1 O +
and O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
. O +

This O +
element O +
had O +
maximal O +
activity O +
in O +
lymphoid O +
cells O +
, O +
paralleling O +
the O +
cell O +
type O +
specificity O +
of O +
Elf-1 O +
expression O +
. O +

Transcription O +
from O +
the O +
IL-2R O +
alpha O +
promoter O +
was O +
inhibited O +
when O +
either O +
the O +
Elf-1 O +
or O +
the O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
binding O +
site O +
was O +
mutated O +
. O +

Coexpression O +
of O +
both O +
proteins O +
activated O +
transcription O +
of O +
the O +
-137 O +
to O +
-64 O +
element O +
in O +
COS-7 B-CellLine +
cells I-CellLine +
. O +

Elf-1 O +
physically O +
associated O +
with O +
HMG O -
- O -
I O +
and O +
with O +
NF O -
- O -
kappa O +
B O +
p50 O +
and O +
c O -
- O -
Rel O +
in O +
vitro O +
, O +
suggesting O +
that O +
protein O -
- O -
protein O +
interactions O +
might O +
functionally O +
coordinate O +
the O +
actions O +
of O +
the O +
upstream O +
and O +
downstream O +
positive O +
regulatory O +
elements O +
. O +

This O +
is O +
the O +
first O +
report O +
of O +
a O +
physical O +
interaction O +
between O +
an O +
Ets O +
family O +
member O +
and O +
NF O -
- O -
kappa O +
B O +
family O +
proteins O +
. O +

These O +
findings O +
provide O +
significant O +
new O +
insights O +
into O +
the O +
protein O -
- O -
protein O +
and O +
protein O -
- O -
DNA O +
interactions O +
that O +
regulate O +
cell O -
- O -
type O -
- O -
specific O +
and O +
inducible O +
IL-2R O +
alpha O +
gene O +
expression O +
and O +
also O +
have O +
implications O +
for O +
other O +
genes O +
regulated O +
by O +
Elf-1 O +
and O +
NF O -
- O -
kappa O +
B O +
family O +
proteins O +
. O +

Isolation O +
of O +
cDNA O +
clones O +
for O +
42 O +
different O +
Kruppel O -
- O -
related O +
zinc O +
finger O +
proteins O +
expressed O +
in O +
the O +
human B-CellLine +
monoblast I-CellLine +
cell I-CellLine +
line I-CellLine +
U-937 I-CellLine +
. O +

To O +
study O +
the O +
complexity O +
and O +
structural O +
characteristics O +
of O +
zinc O +
finger O +
proteins O +
expressed O +
during O +
human O +
hematopoiesis O +
and O +
to O +
isolate O +
novel O +
regulators O +
of O +
blood O +
cell O +
development O +
, O +
a O +
degenerate O +
oligonucleotide O +
probe O +
specific O +
for O +
a O +
consensus O +
zinc O +
finger O +
peptide O +
domain O +
was O +
used O +
to O +
isolate O +
63 O +
cDNA O +
clones O +
for O +
Kruppel O -
- O -
related O +
zinc O +
finger O +
genes O +
from O +
the O +
human B-CellLine +
monoblast I-CellLine +
cell I-CellLine +
line I-CellLine +
U-937 I-CellLine +
. O +

By O +
extensive O +
nucleotide O +
sequence O +
and O +
Northern O +
blot O +
analysis O +
, O +
these O +
cDNA O +
clones O +
were O +
found O +
to O +
originate O +
from O +
approximately O +
42 O +
different O +
genes O +
( O +
HZF O +
1 O -
- O -
42 O +
) O +
of O +
which O +
only O +
8 O +
have O +
previously O +
been O +
described O +
. O +

Northern O +
blot O +
analysis O +
showed O +
that O +
a O +
majority O +
of O +
these O +
genes O +
were O +
expressed O +
at O +
comparable O +
levels O +
in O +
U-937 B-CellLine +
and O +
HeLa B-CellLine +
cells I-CellLine +
. O +

The O +
large O +
number O +
of O +
individual O +
genes O +
represented O +
among O +
the O +
63 O +
clones O +
and O +
their O +
apparent O +
non O -
- O -
cell O -
- O -
type O -
- O -
specific O +
expression O +
suggest O +
that O +
the O +
majority O +
of O +
the O +
Kruppel O -
- O -
related O +
zinc O +
finger O +
genes O +
are O +
likely O +
to O +
be O +
expressed O +
in O +
most O +
human O +
tissues O +
. O +

In O +
contrast O +
, O +
some O +
of O +
the O +
genes O +
displayed O +
a O +
restricted O +
expression O +
pattern O +
, O +
indicating O +
that O +
they O +
represent O +
potential O +
regulators O +
of O +
monocyte O +
differentiation O +
or O +
proliferation O +
. O +

Detailed O +
structural O +
analysis O +
of O +
the O +
first O +
12 O +
cDNAs O +
( O +
HZF O +
1 O -
- O -
10 O +
) O +
and O +
a O +
partial O +
characterization O +
of O +
HZF O +
11 O -
- O -
42 O +
revealed O +
that O +
a O +
common O +
feature O +
of O +
human O +
Kruppel O -
- O -
related O +
zinc O +
finger O +
proteins O +
is O +
the O +
presence O +
of O +
tandem O +
arrays O +
of O +
zinc O +
fingers O +
ranging O +
in O +
number O +
from O +
3 O +
to O +
over O +
20 O +
that O +
are O +
preferentially O +
located O +
in O +
the O +
carboxy O -
- O -
terminal O +
regions O +
of O +
the O +
proteins O +
. O +

In O +
addition O +
, O +
several O +
novel O +
KRAB O -
- O -
containing O +
zinc O +
finger O +
genes O +
and O +
a O +
novel O +
conserved O +
sequence O +
element O +
were O +
identified O +
. O +

Calcium O -
/ O -
calmodulin O -
- O -
dependent O +
protein O +
kinase O +
II O +
downregulates O +
both O +
calcineurin O +
and O +
protein O +
kinase O +
C O -
- O -
mediated O +
pathways O +
for O +
cytokine O +
gene O +
transcription O +
in O +
human O +
T O +
cells O +
. O +

Engagement O +
of O +
the O +
T O +
cell O +
receptor O +
for O +
antigen O +
activates O +
phospholipase O +
C O +
resulting O +
in O +
an O +
increase O +
in O +
intracellular O +
free O +
calcium O +
concentration O +
( O +
[ O +
Ca2 O -
+ O +
] O +
i O +
) O +
and O +
activation O +
of O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
. O +

Increased O +
[ O +
Ca2 O -
+ O +
] O +
i O +
activates O +
Ca2+ O -
/ O -
calmodulin O -
- O -
dependent O +
kinases O +
including O +
the O +
multifunctional O +
Ca2+ O -
/ O -
calmodulin O -
- O -
dependent O +
protein O +
kinase O +
II O +
( O +
CaM O -
- O -
K O +
II O +
) O +
, O +
as O +
well O +
as O +
calcineurin O +
, O +
a O +
type O +
2B O +
protein O +
phosphatase O +
. O +

Recent O +
studies O +
have O +
identified O +
calcineurin O +
as O +
a O +
key O +
enzyme O +
for O +
interleukin O +
( O +
IL O +
) O +
-2 O +
and O +
IL-4 O +
promoter O +
activation O +
. O +

However O +
, O +
the O +
role O +
of O +
CaM O -
- O -
K O +
II O +
remains O +
unknown O +
. O +

We O +
have O +
used O +
mutants O +
of O +
these O +
kinases O +
and O +
phosphatases O +
( O +
gamma O +
B*CaM O -
- O -
K O +
and O +
delta O +
CaM O -
- O -
AI O +
, O +
respectively O +
) O +
to O +
explore O +
their O +
relative O +
role O +
in O +
cytokine O +
gene O +
transcription O +
and O +
their O +
interactions O +
with O +
PKC O +
-dependent O +
signaling O +
systems O +
. O +

gamma O +
B*CaM O -
- O -
K O +
and O +
delta O +
CaM O -
- O -
AI O +
, O +
known O +
to O +
exhibit O +
constitutive O +
Ca O +
( O +
2 O -
+ O +
) O +
-independent O +
activity O +
, O +
were O +
cotransfected O +
( O +
alone O +
or O +
in O +
combination O +
) O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
with O +
a O +
plasmid O +
containing O +
the O +
intact O +
IL-2 O +
promoter O +
driving O +
the O +
expression O +
of O +
the O +
chloramphenicol O +
acetyltransferase O +
reporter O +
gene O +
. O +

Cotransfection O +
of O +
gamma O +
B*CaM O -
- O -
K O +
with O +
the O +
IL-2 O +
promoter O +
construct O +
downregulated O +
its O +
transcription O +
in O +
response O +
to O +
stimulation O +
with O +
ionomycin O +
and O +
phorbol O +
myristate O +
acetate O +
( O +
PMA O +
) O +
. O +

The O +
inhibitory O +
effect O +
of O +
CaM O -
- O -
K O +
II O +
on O +
IL-2 O +
promoter O +
was O +
associated O +
with O +
decreased O +
transcription O +
of O +
its O +
AP-1 O +
and O +
NF O -
- O -
AT O +
transactivating O +
pathways O +
. O +

Under O +
the O +
same O +
conditions O +
, O +
delta O +
CaM O -
- O -
AI O +
superinduced O +
IL-2 O +
promoter O +
activity O +
( O +
approximately O +
twofold O +
increase O +
) O +
. O +

When O +
both O +
mutants O +
were O +
used O +
in O +
combination O +
, O +
gamma O +
B*CaM O -
- O -
K O +
inhibited O +
the O +
induction O +
of O +
the O +
IL-2 O +
promoter O +
by O +
delta O +
CaM O -
- O -
AI O +
. O +

Similar O +
results O +
were O +
obtained O +
when O +
a O +
construct O +
containing O +
the O +
IL-4 O +
promoter O +
also O +
was O +
used O +
. O +

gamma O +
B*CaM O -
- O -
K O +
also O +
downregulated O +
the O +
activation O +
of O +
AP-1 O +
in O +
response O +
to O +
transfection O +
with O +
a O +
constitutively O +
active O +
mutant O +
of O +
PKC O +
or O +
stimulation O +
with O +
PMA O +
. O +

These O +
results O +
suggest O +
that O +
CaM O -
- O -
K O +
II O +
may O +
exert O +
negative O +
influences O +
on O +
cytokine O +
gene O +
transcription O +
in O +
human O +
T O +
cells O +
, O +
and O +
provide O +
preliminary O +
evidence O +
for O +
negative O +
cross O -
- O -
talk O +
with O +
the O +
calcineurin- O +
and O +
PKC- O +
dependent O +
signaling O +
systems O +
. O +

Deleted O +
chromosome O +
20 O +
from O +
a O +
patient O +
with O +
Alagille O +
syndrome O +
isolated O +
in O +
a O +
cell O +
hybrid O +
through O +
leucine O +
transport O +
selection O +
: O +
study O +
of O +
three O +
candidate O +
genes O +
. O +

Alagille O +
syndrome O +
( O +
AGS O +
) O +
is O +
a O +
well O -
- O -
defined O +
genetic O +
entity O +
assigned O +
to O +
the O +
short O +
arm O +
of O +
Chromosome O +
( O +
Chr O +
) O +
20 O +
by O +
a O +
series O +
of O +
observations O +
of O +
AGS O +
patients O +
associated O +
with O +
microdeletions O +
in O +
this O +
region O +
. O +

By O +
fusing O +
lymphoblastoid O +
cells O +
of O +
an O +
AGS O +
patient O +
that O +
exhibited O +
a O +
microdeletion O +
in O +
the O +
short O +
arm O +
of O +
Chr O +
20 O +
encompassing O +
bands O +
p11.23 O +
to O +
p12.3 O +
with O +
rodent B-CellLine +
thermosensitive I-CellLine +
mutant I-CellLine +
cells I-CellLine +
( O +
CHOtsH1 B-CellLine -
- I-CellLine -
1 I-CellLine +
) O +
deficient O +
in O -
- O -
leucyl O -
- O -
tRNA O +
synthetase O +
, O +
we O +
isolated O +
a O +
somatic B-CellLine +
cell I-CellLine +
hybrid I-CellLine +
segregating O +
the O +
deleted O +
human O +
Chr O +
20 O +
. O +

This O +
hybrid O +
clone O +
, O +
designated O +
NR2 B-CellLine +
, O +
was O +
characterized O +
by O +
several O +
methods O +
, O +
including O +
PCR O +
, O +
with O +
eight O +
pairs O +
of O +
oligonucleotides O +
mapped O +
to O +
Chr O +
20 O +
: O +
D20S5 O +
, O +
D20S41 O +
, O +
D20S42 O +
, O +
D20S56 O +
, O +
D20S57 O +
, O +
D20S58 O +
, O +
adenosine O +
deaminase O +
( O +
ADA O +
) O +
, O +
and O +
Prion O +
protein O +
( O +
PRIP O +
) O +
; O +
Restriction O +
Fragment O +
Length O +
Polymorphism O +
( O +
RFLP O +
) O +
analyses O +
with O +
four O +
genomic O +
anonymous O +
probes O +
( O +
D20S5 O +
, O +
cD3H12 O +
, O +
D20S17 O +
, O +
D20S18 O +
) O +
; O +
and O +
fluorescent O +
in O +
situ O +
hybridization O +
( O +
FISH O +
) O +
with O +
total O +
human O +
DNA O +
and O +
D20Z1 O +
, O +
a O +
sequence O +
specific O +
to O +
the O +
human O +
Chr O +
20 O +
centromere O +
, O +
as O +
probes O +
. O +

The O +
NR2 B-CellLine +
hybrid I-CellLine +
allowed O +
us O +
to O +
exclude O +
three O +
candidate O +
genes O +
for O +
AGS O +
: O +
hepatic O +
nuclear O +
factor O +
3 O +
beta O +
( O +
HNF3 O +
beta O +
) O +
, O +
paired O +
box O +
1 O +
( O +
PAX1 O +
) O +
, O +
and O +
cystatin O +
C O +
( O +
CST3 O +
) O +
as O +
shown O +
by O +
their O +
localization O +
outside O +
of O +
the O +
deletion O +
. O +

The O +
NR2 B-CellLine +
hybrid I-CellLine +
is O +
a O +
powerful O +
tool O +
for O +
the O +
mapping O +
of O +
new O +
probes O +
of O +
this O +
region O +
, O +
as O +
well O +
as O +
for O +
obtaining O +
new O +
informative O +
probes O +
specific O +
for O +
the O +
deletion O +
by O +
subtractive O +
cloning O +
of O +
the O +
region O +
. O +

Such O +
markers O +
will O +
be O +
useful O +
for O +
linkage O +
analysis O +
and O +
screening O +
of O +
cDNA O +
libraries O +
. O +

Missense O +
mutation O +
in O +
exon O +
7 O +
of O +
the O +
common O +
gamma O +
chain O +
gene O +
causes O +
a O +
moderate O +
form O +
of O +
X O -
- O -
linked O +
combined O +
immunodeficiency O +
. O +

Clinical O +
and O +
immunologic O +
features O +
of O +
a O +
recently O +
recognized O +
X O -
- O -
linked O +
combined O +
immunodeficiency O +
disease O +
( O +
XCID O +
) O +
suggested O +
that O +
XCID O +
and O +
X O -
- O -
linked O +
severe O +
combined O +
immunodeficiency O +
( O +
XSCID O +
) O +
might O +
arise O +
from O +
different O +
genetic O +
defects O +
. O +

The O +
recent O +
discovery O +
of O +
mutations O +
in O +
the O +
common O +
gamma O +
chain O +
( O +
gamma O +
c O +
) O +
gene O +
, O +
a O +
constituent O +
of O +
several O +
cytokine O +
receptors O +
, O +
in O +
XSCID O +
provided O +
an O +
opportunity O +
to O +
test O +
directly O +
whether O +
a O +
previously O +
unrecognized O +
mutation O +
in O +
this O +
same O +
gene O +
was O +
responsible O +
for O +
XCID O +
. O +

The O +
status O +
of O +
X O +
chromosome O +
inactivation O +
in O +
blood O +
leukocytes O +
from O +
obligate O +
carriers O +
of O +
XCID O +
was O +
determined O +
from O +
the O +
polymorphic O +
, O +
short O +
tandem O +
repeats O +
( O +
CAG O +
) O +
, O +
in O +
the O +
androgen O +
receptor O +
gene O +
, O +
which O +
also O +
contains O +
a O +
methylation O -
- O -
sensitive O +
HpaII O +
site O +
. O +

As O +
in O +
XSCID O +
, O +
X O -
- O -
chromosome O +
inactivation O +
in O +
obligate O +
carriers O +
of O +
XCID O +
was O +
nonrandom O +
in O +
T O +
and O +
B O +
lymphocytes O +
. O +

In O +
addition O +
, O +
X O +
chromosome O +
inactivation O +
in O +
PMNs O +
was O +
variable O +
. O +

Findings O +
from O +
this O +
analysis O +
prompted O +
sequencing O +
of O +
the O +
gamma O +
c O +
gene O +
in O +
this O +
pedigree O +
. O +

A O +
missense O +
mutation O +
in O +
the O +
region O +
coding O +
for O +
the O +
cytoplasmic O +
portion O +
of O +
the O +
gamma O +
c O +
gene O +
was O +
found O +
in O +
three O +
affected O +
males O +
but O +
not O +
in O +
a O +
normal O +
brother O +
. O +

Therefore O +
, O +
this O +
point O +
mutation O +
in O +
the O +
gamma O +
c O +
gene O +
leads O +
to O +
a O +
less O +
severe O +
degree O +
of O +
deficiency O +
in O +
cellular O +
and O +
humoral O +
immunity O +
than O +
that O +
seen O +
in O +
XSCID O +
. O +

LMP-1 O +
activates O +
NF O -
- O -
kappa O +
B O +
by O +
targeting O +
the O +
inhibitory O +
molecule O +
I O +
kappa O +
B O +
alpha O +
. O +

LMP-1 O +
, O +
an O +
Epstein O -
- O -
Barr O +
virus O +
membrane O +
protein O +
expressed O +
during O +
latent O +
infection O +
, O +
has O +
oncogenic O +
properties O +
, O +
as O +
judged O +
from O +
its O +
ability O +
to O +
transform O +
B O +
lymphocytes O +
and O +
rodent O +
fibroblasts O +
. O +

LMP-1 O +
induces O +
the O +
expression O +
of O +
bcl2 O +
, O +
an O +
oncogene O +
which O +
protects O +
cells O +
from O +
apoptosis O +
, O +
as O +
well O +
as O +
of O +
genes O +
encoding O +
other O +
proteins O +
involved O +
in O +
cell O +
regulation O +
and O +
growth O +
control O +
. O +

The O +
mechanisms O +
by O +
which O +
LMP-1 O +
upregulates O +
these O +
proteins O +
is O +
unknown O +
, O +
but O +
it O +
is O +
plausible O +
that O +
LMP-1 O +
modifies O +
signal O +
transduction O +
pathways O +
that O +
result O +
in O +
the O +
activation O +
of O +
one O +
or O +
more O +
transcription O +
factors O +
that O +
ultimately O +
regulate O +
transcription O +
of O +
oncogenic O +
genes O +
. O +

NF O -
- O -
kappa O +
B O +
, O +
a O +
transcription O +
factor O +
controlling O +
the O +
expression O +
of O +
genes O +
involved O +
in O +
cell O +
activation O +
and O +
growth O +
control O +
, O +
has O +
been O +
shown O +
to O +
be O +
activated O +
by O +
LMP-1 O +
. O +

The O +
mechanism O +
( O +
s O +
) O +
regulating O +
this O +
activation O +
remains O +
unknown O +
. O +

Our O +
data O +
indicate O +
that O +
increased O +
NF O -
- O -
kappa O +
B O +
DNA O +
binding O +
and O +
functional O +
activity O +
are O +
present O +
in O +
B O -
- O -
lymphoid O +
cells O +
stably O +
or O +
transiently O +
expressing O +
LMP-1 O +
. O +

I O +
kappa O +
B O +
alpha O +
is O +
selectively O +
modified O +
in O +
LMP-1-expressing B-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

A O +
phosphorylated O +
form O +
of O +
I O +
kappa O +
B O +
alpha O +
and O +
increased O +
protein O +
turnover O -
- O -
degradation O +
correlate O +
with O +
increased O +
NF O -
- O -
kappa O +
B O +
nuclear O +
translocation O +
. O +

This O +
results O +
in O +
increased O +
transcription O +
of O +
NF O -
- O -
kappa O +
B O -
- O -
dependent O -
- O -
genes O +
, O +
including O +
those O +
encoding O +
p105 O +
and O +
I O +
kappa O +
B O +
alpha O +
( O +
MAD3 O +
) O +
. O +

These O +
results O +
indicate O +
that O +
LMP-1 O +
activates O +
NF O -
- O -
kappa O +
B O +
in O +
B B-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
by O +
targeting O +
I O +
kappa O +
B O +
alpha O +
. O +

Identification O +
of O +
the O +
pathways O +
activated O +
by O +
LMP-1 O +
to O +
result O +
in O +
posttranslational O +
modifications O +
of O +
I O +
kappa O +
B O +
alpha O +
will O +
aid O +
in O +
determining O +
the O +
role O +
of O +
this O +
virus O -
- O -
host O +
cell O +
protein O +
interaction O +
in O +
Epstein O -
- O -
Barr O +
virus O -
- O -
mediated O +
oncogenesis O +
. O +

Treatment O +
of O +
HL60 B-CellLine +
cells I-CellLine +
with O +
various O +
combinations O +
of O +
retinoids O +
and O +
1 O +
alpha O +
, O +
25 O +
dihydroxyvitamin O +
D3 O +
results O +
in O +
differentiation O +
towards O +
neutrophils O +
or O +
monocytes O +
or O +
a O +
failure O +
to O +
differentiate O +
and O +
apoptosis O +
. O +

It O +
is O +
well O +
documented O +
that O +
treatment O +
of O +
serum B-CellLine -
- I-CellLine -
grown I-CellLine +
HL60 I-CellLine +
cells I-CellLine +
with O +
10 O +
( O +
-7 O +
) O +
M O +
all O -
- O -
trans O +
retinoic O +
acid O +
( O +
all O -
- O -
trans O +
RA O +
) O +
induces O +
neutrophil O +
differentiation O +
, O +
whereas O +
treatment O +
with O +
10 O +
( O +
-7 O +
) O +
M O +
1 O +
alpha O +
, O +
25 O +
dihydroxyvitamin O +
D3 O +
( O +
D3 O +
) O +
induces O +
differentiation O +
towards O +
monocytes O +
. O +

In O +
recent O +
investigations O +
, O +
using O +
serum B-CellLine -
- I-CellLine -
free I-CellLine +
grown I-CellLine +
HL60 I-CellLine +
cells I-CellLine +
, O +
we O +
observed O +
that O +
all O -
- O -
trans O +
RA O +
, O +
at O +
10 O +
( O +
-7 O +
) O +
M O +
, O +
did O +
not O +
induce O +
neutrophil O +
differentiation O +
and O +
that O +
all O -
- O -
trans O +
RA O +
, O +
at O +
10 O +
( O +
-8 O +
) O +
M O +
, O +
reduced O +
the O +
D3 O +
concentration O +
required O +
for O +
monocyte O +
differentiation O +
to O +
5 O +
x O +
10 O +
( O +
-9 O +
) O +
M O +
. O +

In O +
this O +
study O +
, O +
co O -
- O -
operative O +
interactions O +
between O +
all O -
- O -
trans O +
and O +
9-cis O +
RA O +
and O +
D3 O +
which O +
promote O +
neutrophil O +
and O +
monocyte O +
differentiation O +
of O +
HL60 B-CellLine +
cells I-CellLine +
have O +
been O +
analysed O +
in O +
detail O +
. O +

Treatment O +
of O +
serum B-CellLine -
- I-CellLine -
free I-CellLine +
grown I-CellLine +
HL60 I-CellLine +
cells I-CellLine +
with O +
5 O +
x O +
10 O +
( O +
-7 O +
) O +
M O +
all O -
- O -
trans O +
RA O +
or O +
9-cis O +
RA O +
resulted O +
in O +
sub O -
- O -
optimal O +
neutrophil O +
differentiation O +
( O +
up O +
to O +
25 O +
% O +
mature O +
cells O +
) O +
. O +

As O +
shown O +
for O +
all O -
- O -
trans O +
RA O +
, O +
9-cis O +
RA O +
cooperated O +
with O +
D3 O +
to O +
promote O +
monocyte O +
differentiation O +
. O +

Culture O +
of O +
HL60 B-CellLine +
cells I-CellLine +
in O +
5 O +
x O +
10 O +
( O +
-7 O +
) O +
M O +
9-cis O +
RA O +
together O +
with O +
a O +
wide O +
range O +
of O +
concentrations O +
of O +
D3 O +
resulted O +
in O +
promotion O +
of O +
neutrophil O +
differentiation O +
at O +
10 O +
( O +
-15 O +
) O +
-10 O +
( O +
-12 O +
) O +
D3 O +
, O +
a O +
failure O +
to O +
differentiate O +
and O +
apoptosis O +
at O +
10 O +
( O +
-11 O +
) O +
-10 O +
( O +
-10 O +
) O +
M O +
D3 O +
, O +
followed O +
by O +
co O -
- O -
operativity O +
between O +
9-cis O +
RA O +
and O +
5 O +
x O +
10 O +
( O +
-9 O +
) O +
M O +
D3 O +
in O +
inducing O +
monocyte O +
differentiation O +
in O +
the O +
absence O +
of O +
neutrophil O +
differentiation O +
. O +

Similar O +
results O +
were O +
obtained O +
when O +
HL60 B-CellLine +
cells I-CellLine +
were O +
treated O +
with O +
5 O +
x O +
10 O +
( O +
-7 O +
) O +
all O -
- O -
trans O +
RA O +
together O +
with O +
a O +
wide O +
range O +
of O +
concentrations O +
of O +
D3 O +
. O +

Cross O +
titration O +
analyses O +
of O +
the O +
effects O +
of O +
9-cis O +
RA O +
and O +
D3 O +
on O +
HL60 B-CellLine +
cell I-CellLine +
differentiation O +
were O +
undertaken O +
to O +
determine O +
the O +
boundaries O +
of O +
the O +
concentrations O +
of O +
each O +
agent O +
, O +
alone O +
and O +
in O +
combination O +
, O +
that O +
give O +
rise O +
to O +
optimal O +
neutrophil O +
and O +
monocyte O +
differentiation O +
of O +
HL60 B-CellLine +
cells I-CellLine +
. O +

The O +
observed O +
cooperativities O +
between O +
either O +
9-cis O +
RA O +
or O +
all O -
- O -
trans O +
RA O +
and O +
D3 O +
have O +
important O +
implications O +
for O +
the O +
use O +
of O +
combinations O +
of O +
these O +
agents O +
in O +
differentiation O +
therapy O +
. O +

Cloning O +
and O +
characterization O +
of O +
NF O -
- O -
ATc O +
and O +
NF O -
- O -
ATp O +
: O +
the O +
cytoplasmic O +
components O +
of O +
NF O -
- O -
AT O +
. O +

Present O +
evidence O +
indicates O +
a O +
pathway O +
of O +
signal O +
transmission O +
in O +
T O +
cells O +
that O +
is O +
outlined O +
in O +
figure O +
1 O +
. O +

The O +
elevation O +
in O +
intracellular O +
calcium O +
that O +
is O +
induced O +
by O +
interactions O +
at O +
the O +
antigen O +
receptor O +
leads O +
to O +
the O +
activation O +
of O +
the O +
calcium O -
- O -
dependent O +
phosphatase O +
calcineurin O +
. O +

This O +
in O +
turn O +
leads O +
to O +
the O +
nuclear O +
association O +
of O +
the O +
cytosolic O +
component O +
of O +
NF O -
- O -
ATc O +
. O +

The O +
activation O +
of O +
calcineurin O +
and O +
the O +
nuclear O +
import O +
of O +
NF O -
- O -
ATc O +
can O +
both O +
be O +
blocked O +
by O +
cyclosporin O +
A O +
or O +
FK506 O +
in O +
complex O +
with O +
their O +
respective O +
immunophilins O +
. O +

Once O +
in O +
the O +
nucleus O +
, O +
NF O -
- O -
ATc O +
interacts O +
with O +
NF O -
- O -
ATn O +
to O +
form O +
an O +
active O +
transcriptional O +
complex O +
. O +

NF O -
- O -
ATn O +
is O +
a O +
ubiquitous O +
protein O +
, O +
can O +
be O +
synthesized O +
in O +
response O +
to O +
PMA O +
, O +
and O +
has O +
many O +
similarities O +
to O +
AP-1 O +
. O +

The O +
mechanism O +
by O +
which O +
NF O -
- O -
ATc O +
enters O +
the O +
nucleus O +
is O +
unknown O +
, O +
and O +
although O +
it O +
appears O +
to O +
require O +
calcineurin O +
, O +
NF O -
- O -
ATc O +
has O +
not O +
yet O +
been O +
shown O +
to O +
be O +
an O +
in O +
vivo O +
substrate O +
of O +
calcineurin O +
. O +

Alternative O +
mechanisms O +
include O +
the O +
possibility O +
that O +
NF O -
- O -
ATc O +
operates O +
on O +
some O +
cytoplasmic O +
anchor O +
or O +
that O +
other O +
proteins O +
that O +
are O +
controlled O +
by O +
calcineurin O +
carry O +
out O +
the O +
nuclear O +
import O +
of O +
NF O -
- O -
ATc O +
. O +

Although O +
NF O -
- O -
ATp O +
copurifies O +
with O +
NF O -
- O -
ATc O +
, O +
there O +
is O +
as O +
yet O +
no O +
understanding O +
of O +
how O +
NF O -
- O -
ATp O +
is O +
functioning O +
in O +
vivo O +
. O +

Now O +
that O +
these O +
proteins O +
are O +
purified O +
and O +
cloned O +
, O +
the O +
major O +
goals O +
will O +
be O +
to O +
understand O +
their O +
role O +
and O +
the O +
roles O +
of O +
other O +
family O +
members O +
in O +
thymic O +
development O +
. O +

Interleukin-5 O +
signaling O +
in O +
human O +
eosinophils O +
involves O +
JAK2 O +
tyrosine O +
kinase O +
and O +
Stat1 O +
alpha O +
. O +

Signaling O +
by O +
a O +
wide O +
variety O +
of O +
cytokines O +
, O +
including O +
interferons O +
, O +
interleukins O +
, O +
and O +
growth O +
factors O +
, O +
involves O +
activation O +
of O +
JAK O +
kinases O +
and O +
Stat O +
( O +
Signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
) O +
proteins O +
. O +

At O +
present O +
, O +
not O +
much O +
is O +
known O +
about O +
the O +
molecular O +
mechanisms O +
by O +
which O +
interleukin-5 O +
( O +
IL-5 O +
) O +
exerts O +
its O +
diverse O +
biologic O +
effects O +
. O +

Human O +
eosinophils O +
are O +
one O +
of O +
the O +
most O +
important O +
target O +
cells O +
for O +
IL-5 O +
and O +
were O +
used O +
here O +
to O +
study O +
IL-5 O +
signaling O +
in O +
a O +
primary O +
human O +
cell O +
. O +

IL-5 O +
induced O +
rapid O +
and O +
transient O +
tyrosine O +
phosphorylation O +
of O +
JAK2 O +
. O +

Moreover O +
, O +
IL-5 O +
induced O +
at O +
least O +
two O +
DNA O -
- O -
binding O +
complexes O +
, O +
using O +
nuclear O +
extracts O +
from O +
normal O +
human O +
eosinophils O +
and O +
the O +
IL-6 O -
/ O -
interferon O -
- O -
gamma O +
response O +
element O +
of O +
the O +
ICAM-1 O +
promoter O +
( O +
ICAM-1 O +
pIRE O +
) O +
in O +
an O +
electromobility O +
shift O +
assay O +
. O +

From O +
supershift O +
experiments O +
it O +
was O +
concluded O +
that O +
one O +
DNA O -
- O -
binding O +
complex O +
contained O +
Stat1 O +
alpha O +
, O +
probably O +
as O +
a O +
homodimer O +
. O +

Both O +
DNA O -
- O -
binding O +
complexes O +
were O +
inhibited O +
by O +
a O +
phosphotyrosine O +
antibody O +
( O +
4G10 O +
) O +
, O +
suggesting O +
that O +
tyrosine O +
phosphorylation O +
is O +
required O +
for O +
complex O +
formation O +
. O +

IL-3 O +
and O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
induced O +
, O +
similar O +
to O +
IL-5 O +
, O +
two O +
DNA O -
- O -
binding O +
complexes O +
in O +
human O +
eosinophils O +
, O +
including O +
Stat1 O +
alpha O +
. O +

These O +
data O +
show O +
for O +
the O +
first O +
time O +
that O +
molecular O +
mechanisms O +
of O +
IL-5 O +
signaling O +
in O +
human O +
eosinophils O +
involve O +
members O +
of O +
the O +
JAK O +
kinase O +
family O +
as O +
well O +
as O +
members O +
of O +
the O +
Stat O +
family O +
. O +

E2F-1 O +
and O +
a O +
cyclin O -
- O -
like O +
DNA O +
repair O +
enzyme O +
, O +
uracil O -
- O -
DNA O +
glycosylase O +
, O +
provide O +
evidence O +
for O +
an O +
autoregulatory O +
mechanism O +
for O +
transcription O +
. O +

The O +
cell O +
cycle O -
- O -
dependent O +
transcription O +
factor O +
, O +
E2F-1 O +
, O +
regulates O +
the O +
cyclin O +
-like O +
species O +
of O +
the O +
DNA O +
repair O +
enzyme O +
uracil O -
- O -
DNA O +
glycosylase O +
( O +
UDG O +
) O +
gene O +
in O +
human B-CellLine +
osteosarcoma I-CellLine +
( I-CellLine +
Saos-2 I-CellLine +
) I-CellLine +
cells I-CellLine +
. O +

We O +
demonstrate O +
, O +
through O +
the O +
deletion O +
of O +
the O +
human O +
UDG O +
promoter O +
sequences O +
, O +
that O +
expression O +
of O +
E2F-1 O +
activates O +
the O +
UDG O +
promoter O +
through O +
several O +
E2F O +
sites O +
. O +

The O +
major O +
putative O +
downstream O +
site O +
for O +
E2F O +
, O +
located O +
in O +
the O +
first O +
exon O +
, O +
serves O +
as O +
a O +
target O +
for O +
E2F-1 O -
/ O -
DP1 O +
complex O +
binding O +
in O +
vitro O +
. O +

We O +
also O +
provide O +
evidence O +
for O +
the O +
functional O +
relationship O +
between O +
the O +
cyclin O -
- O -
like O +
UDG O +
gene O +
product O +
and O +
E2F O +
. O +

High O +
levels O +
of O +
UDG O +
expression O +
in O +
a O +
transient O +
transfection O +
assay O +
result O +
in O +
the O +
down O -
- O -
regulation O +
of O +
transcriptional O +
activity O +
through O +
elements O +
specific O +
for O +
E2F O +
-mediated O +
transcription O +
. O +

Overexpression O +
of O +
UDG O +
in O +
Saos B-CellLine +
2 I-CellLine +
cells I-CellLine +
was O +
observed O +
to O +
delay O +
growth O +
late O +
in O +
G1 O +
phase O +
and O +
transiently O +
arrest O +
these O +
cells O +
from O +
progressing O +
into O +
the O +
S O +
phase O +
. O +

This O +
hypothetical O +
model O +
integrates O +
one O +
mechanism O +
of O +
DNA O +
repair O +
with O +
the O +
cell O +
cycle O +
control O +
of O +
gene O +
transcription O +
, O +
likely O +
through O +
E2F O +
. O +

This O +
implicates O +
E2F O +
as O +
a O +
multifunctional O +
target O +
for O +
proteins O +
and O +
enzymes O +
, O +
possibly O +
, O +
responsive O +
to O +
DNA O +
damage O +
through O +
the O +
negative O +
effect O +
of O +
UDG O +
on O +
E2F O +
-mediated O +
transcriptional O +
activity O +
. O +

Mapping O +
of O +
the O +
interaction O +
site O +
of O +
the O +
defective O +
transcription O +
factor O +
in O +
the O +
class B-CellLine +
II I-CellLine +
major I-CellLine +
histocompatibility I-CellLine +
complex I-CellLine +
mutant I-CellLine +
cell I-CellLine +
line I-CellLine +
clone-13 I-CellLine +
to O +
the O +
divergent O +
X2-box O +
. O +

We O +
have O +
previously O +
described O +
a O +
mutant B-CellLine +
B I-CellLine +
lymphoblastoid I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
Clone-13 B-CellLine +
, I-CellLine +
that O +
expresses O +
HLA O -
- O -
DQ O +
in O +
the O +
absence O +
of O +
HLA O -
- O -
DR O +
and O +
-DP O +
. O +

Several O +
criteria O +
indicated O +
that O +
the O +
defect O +
in O +
this O +
cell O +
line O +
influences O +
the O +
activity O +
of O +
an O +
isotype O -
- O -
specific O +
transcription O +
factor O +
. O +

Indeed O +
, O +
transient O +
transfection O +
of O +
HLA O -
- O -
DRA O +
and O +
DQB O +
reporter O +
constructs O +
indicated O +
that O +
the O +
affected O +
factor O +
operates O +
via O +
cis O -
- O -
elements O +
located O +
between O +
-141 O +
base O +
pairs O +
and O +
the O +
transcription O +
initiation O +
site O +
. O +

A O +
series O +
of O +
hybrid O +
DRA O -
/ O -
DQB O +
reporter O +
constructs O +
was O +
generated O +
to O +
further O +
map O +
the O +
relevant O +
cis O -
- O -
elements O +
in O +
this O +
system O +
. O +

Insertion O +
of O +
oligonucleotides O +
spanning O +
the O +
DQB O +
X O -
- O -
box O +
( O +
but O +
not O +
the O +
DQB O -
- O -
W O +
region O +
or O +
the O +
DQB O +
Y O -
- O -
box O +
) O +
upstream O +
of O +
-141 O +
in O +
a O +
DRA O +
reporter O +
plasmid O +
rescued O +
expression O +
to O +
nearly O +
wild O -
- O -
type O +
levels O +
. O +

Substitution O +
promoters O +
were O +
then O +
generated O +
where O +
the O +
entire O +
X O -
- O -
box O +
, O +
or O +
only O +
the O +
X1- O +
or O +
X2-boxes O +
of O +
HLA O -
- O -
DRA O +
were O +
replaced O +
with O +
the O +
analogous O +
regions O +
of O +
HLA O -
- O -
DQB O +
. O +

The O +
DQB O +
X2-box O +
was O +
able O +
to O +
restore O +
expression O +
to O +
the O +
silent O +
DRA O +
reporter O +
construct O +
. O +

Moreover O +
, O +
replacement O +
of O +
the O +
DQB O +
X2-box O +
with O +
the O +
DRA O +
X2-box O +
markedly O +
diminished O +
the O +
activity O +
of O +
the O +
DQB O +
promoter O +
in O +
the O +
mutant B-CellLine +
cell I-CellLine +
. O +

None O +
of O +
the O +
hybrid O +
reporter O +
constructs O +
were O +
defective O +
when O +
transfected O +
into O +
the O +
wild O -
- O -
type O +
, O +
HLA B-CellLine -
- I-CellLine -
DR I-CellLine -
/ I-CellLine -
-DQ I-CellLine +
positive I-CellLine +
parental I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
Jijoye B-CellLine +
. O +

These O +
studies O +
suggest O +
that O +
the O +
divergent O +
X2-box O +
of O +
the O +
class O +
II O +
major O +
histocompatibility O +
complex O +
promoters O +
plays O +
an O +
important O +
role O +
in O +
influencing O +
differential O +
expression O +
of O +
the O +
human O +
class O +
II O +
isotypes O +
. O +

Regulation O +
and O +
specificity O +
of O +
MNDA O +
expression O +
in O +
monocytes O +
, O +
macrophages O +
, O +
and O +
leukemia B-CellLine -
/ I-CellLine -
B I-CellLine +
lymphoma I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

The O +
expression O +
of O +
the O +
human O +
myeloid O +
cell O +
nuclear O +
differentiation O +
antigen O +
( O +
MNDA O +
) O +
was O +
observed O +
specifically O +
in O +
cells O +
of O +
the O +
granulocyte O -
- O -
macrophage O +
lineage O +
in O +
our O +
earlier O +
reports O +
. O +

The O +
specificity O +
of O +
MNDA O +
expression O +
for O +
cells O +
in O +
the O +
granulocyte O -
- O -
macrophage O +
lineage O +
was O +
reexamined O +
in O +
cell B-CellLine +
lines I-CellLine +
established O +
from O +
patients O +
with O +
Philadelphia O +
chromosome O -
- O -
positive O +
chronic O +
myeloid O +
leukemia O +
. O +

Cell O +
lines O +
that O +
expressed O +
MNDA O +
exhibited O +
myeloid O +
cell O +
features O +
and O +
granulocyte O +
or O +
monocyte O +
differentiation O +
could O +
be O +
induced O +
in O +
vitro O +
, O +
while O +
cell O +
lines O +
exhibiting O +
properties O +
of O +
very O +
early O +
stage O +
cells O +
or O +
multipotential O +
cells O +
did O +
not O +
express O +
MNDA O +
. O +

Cells O +
originating O +
from O +
cases O +
of O +
Burkitt O +
's O +
lymphoma O +
were O +
negative O +
. O +

By O +
contrast O +
, O +
three O +
lymphoblastoid B-CellLine +
cell I-CellLine +
lines I-CellLine +
( O +
immortalized O +
in O +
vitro O +
with O +
Epstein O -
- O -
Barr O +
virus O +
) O +
were O +
weakly O +
positive O +
and O +
MNDA O +
was O +
up O -
- O -
regulated O +
by O +
interferon O -
- O -
alpha O +
( O +
IFN O -
- O -
alpha O +
) O +
treatment O +
. O +

As O +
we O +
reported O +
previously O +
, O +
MNDA O +
mRNA O +
level O +
in O +
adherent O +
monocytes O +
is O +
elevated O +
by O +
IFN O -
- O -
alpha O +
; O +
in O +
this O +
study O +
, O +
we O +
further O +
assessed O +
MNDA O +
expression O +
in O +
in O +
vitro O +
monocyte O -
- O -
derived O +
macrophages O +
. O +

Three O +
additional O +
agents O +
( O +
endotoxin O +
, O +
phytohemagglutinin O +
, O +
and O +
phorbol O +
ester O +
) O +
and O +
other O +
conditions O +
that O +
affect O +
function O +
, O +
cytokine O +
production O +
, O +
differentiation O +
, O +
and/or O +
growth O +
of O +
monocytes O +
were O +
examined O +
for O +
their O +
ability O +
to O +
alter O +
MNDA O +
expression O +
. O +

The O +
results O +
varied O +
with O +
the O +
agent O +
, O +
cell O +
type O +
, O +
and O +
stage O +
of O +
differentiation O +
. O +

Changes O +
in O +
MNDA O +
expression O +
occurred O +
slowly O +
( O +
hours O +
to O +
days O +
) O +
, O +
suggesting O +
that O +
MNDA O +
could O +
mediate O +
changes O +
realized O +
over O +
a O +
long O +
period O +
. O +

The O +
results O +
also O +
reveal O +
a O +
discordance O +
in O +
certain O +
MNDA B-CellLine +
positive I-CellLine +
cells I-CellLine +
between O +
steady O -
- O -
state O +
levels O +
or O +
changes O +
in O +
levels O +
of O +
protein O +
and O +
mRNA O +
indicating O +
that O +
the O +
regulation O +
of O +
MNDA O +
expression O +
occurs O +
at O +
more O +
than O +
one O +
point O +
. O +

Changes O +
in O +
MNDA O +
expression O +
are O +
consistent O +
with O +
a O +
role O +
in O +
opposing O +
macrophage O +
differentiation O +
and O +
activation O +
of O +
monocytes O +
/macrophages O +
. O +

Aspirin O +
inhibits O +
nuclear O +
factor O -
- O -
kappa O +
B O +
mobilization O +
and O +
monocyte O +
adhesion O +
in O +
stimulated B-CellLine +
human I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
. O +

BACKGROUND O +
: O +
The O +
induction O +
of O +
vascular O +
cell O +
adhesion O +
molecule-1 O +
( O +
VCAM-1 O +
) O +
and O +
E O -
- O -
selectin O +
by O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O +
) O +
is O +
mediated O +
by O +
mobilization O +
of O +
the O +
transcription O +
factor O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
. O +

Since O +
salicylates O +
have O +
been O +
reported O +
to O +
inhibit O +
NF O -
- O -
kappa O +
B O +
activation O +
by O +
preventing O +
the O +
degradation O +
of O +
its O +
inhibitor O +
I O +
kappa O +
B O +
, O +
we O +
studied O +
a O +
potential O +
inhibition O +
of O +
this O +
pathway O +
by O +
acetylsalicylate O +
( O +
aspirin O +
) O +
in O +
human B-CellLine +
umbilical I-CellLine +
vein I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
( O +
HUVECs B-CellLine +
) O +
. O +

METHODS O +
AND O +
RESULTS O +
: O +
Gel O -
- O -
shift O +
analyses O +
demonstrated O +
dose O -
- O -
dependent O +
inhibition O +
of O +
TNF O +
-induced O +
NF O -
- O -
kappa O +
B O +
mobilization O +
by O +
aspirin O +
at O +
concentrations O +
ranging O +
from O +
1 O +
to O +
10 O +
mmol O -
/ O -
L O +
. O +

Induction O +
of O +
VCAM-1 O +
and O +
E O -
- O -
selectin O +
surface O +
expression O +
by O +
TNF O +
was O +
dose O -
- O -
dependently O +
reduced O +
by O +
aspirin O +
over O +
the O +
same O +
range O +
, O +
while O +
induction O +
of O +
intercellular O +
adhesion O +
molecule-1 O +
( O +
ICAM-1 O +
) O +
was O +
hardly O +
affected O +
. O +

Aspirin O +
appeared O +
to O +
prevent O +
VCAM-1 O +
transcription O +
, O +
since O +
it O +
dose O -
- O -
dependently O +
inhibited O +
induction O +
of O +
VCAM-1 O +
mRNA O +
by O +
TNF O +
. O +

As O +
a O +
functional O +
consequence O +
, O +
adhesion O +
of O +
U937 B-CellLine +
monocytes I-CellLine +
to O +
TNF B-CellLine -
- I-CellLine -
stimulated I-CellLine +
HUVECs I-CellLine +
was O +
markedly O +
reduced O +
by O +
aspirin O +
due O +
to O +
suppression O +
of O +
VCAM-1 O +
and O +
E O -
- O -
selectin O +
upregulation O +
. O +

These O +
effects O +
of O +
aspirin O +
were O +
not O +
related O +
to O +
the O +
inhibition O +
of O +
cyclooxygenase O +
activity O +
, O +
since O +
indomethacin O +
was O +
ineffective O +
. O +

CONCLUSIONS O +
: O +
Our O +
data O +
suggest O +
that O +
aspirin O +
inhibits O +
NF O -
- O -
kappa O +
B O +
mobilization O +
, O +
induction O +
of O +
VCAM-1 O +
and O +
E O -
- O -
selectin O +
, O +
and O +
subsequent O +
monocyte O +
adhesion O +
in O +
endothelial O +
cells O +
stimulated O +
by O +
TNF O +
, O +
thereby O +
providing O +
an O +
additional O +
mechanism O +
for O +
therapeutic O +
effects O +
of O +
aspirin O +
. O +

Differences O +
in O +
binding O +
of O +
glucocorticoid O +
receptor O +
to O +
DNA O +
in O +
steroid O -
- O -
resistant O +
asthma O +
. O +

Although O +
glucocorticosteroids O +
are O +
a O +
very O +
effective O +
treatment O +
for O +
asthma O +
and O +
other O +
chronic O +
inflammatory O +
diseases O +
, O +
a O +
small O +
proportion O +
of O +
patients O +
are O +
resistant O +
to O +
their O +
therapeutic O +
effects O +
. O +

The O +
molecular O +
mechanism O +
for O +
this O +
steroid O +
resistance O +
is O +
unclear O +
. O +

Steroid O +
resistance O +
can O +
not O +
be O +
explained O +
by O +
pharmacokinetic O +
mechanisms O +
, O +
by O +
a O +
defect O +
in O +
the O +
binding O +
of O +
steroids O +
to O +
glucocorticoid O +
receptors O +
, O +
nor O +
by O +
defective O +
nuclear O +
translocation O +
of O +
this O +
receptor O +
, O +
thereby O +
suggesting O +
that O +
the O +
molecular O +
abnormality O +
lies O +
distal O +
to O +
nuclear O +
translocation O +
. O +

We O +
examined O +
the O +
ability O +
of O +
nuclear O +
translocated O +
glucocorticoid O +
receptors O +
to O +
bind O +
to O +
their O +
DNA O +
binding O +
sites O +
( O +
GRE O +
) O +
using O +
electrophoretic O +
mobility O +
shift O +
assays O +
in O +
PBMC O +
from O +
patients O +
with O +
steroid O -
- O -
sensitive O +
and O +
steroid O -
- O -
resistant O +
asthma O +
. O +

The O +
binding O +
of O +
the O +
glucocorticoid O +
receptor O +
to O +
DNA O +
in O +
these O +
patients O +
was O +
also O +
studied O +
using O +
Scatchard O +
analysis O +
. O +

Dexamethasone O +
induced O +
a O +
significant O +
rapid O +
and O +
sustained O +
twofold O +
increase O +
in O +
GRE O +
binding O +
in O +
PBMCs O +
from O +
steroid O -
- O -
sensitive O +
asthmatic O +
patients O +
and O +
nonasthmatic O +
individuals O +
, O +
but O +
this O +
was O +
markedly O +
reduced O +
in O +
steroid O -
- O -
resistant O +
asthmatic O +
patients O +
. O +

Scatchard O +
analysis O +
of O +
glucocorticoid O +
receptor O +
- O +
GRE O +
binding O +
showed O +
no O +
change O +
in O +
binding O +
affinity O +
but O +
did O +
show O +
a O +
reduced O +
number O +
of O +
receptors O +
available O +
for O +
DNA O +
binding O +
in O +
the O +
steroid O -
- O -
resistant O +
patients O +
. O +

These O +
results O +
suggest O +
that O +
the O +
ability O +
of O +
the O +
glucocorticoid O +
receptor O +
to O +
bind O +
to O +
GRE O +
is O +
impaired O +
in O +
steroid O -
- O -
resistant O +
patients O +
because O +
of O +
a O +
reduced O +
number O +
of O +
receptors O +
available O +
for O +
binding O +
to O +
DNA O +
. O +

Transcriptional O +
regulation O +
of O +
the O +
vacuolar O +
H O +
( O +
+ O +
) O +
-ATPase O +
B2 O +
subunit O +
gene O +
in O +
differentiating B-CellLine +
THP-1 I-CellLine +
cells I-CellLine +
. O +

Monocyte O -
- O -
macrophage O +
differentiation O +
was O +
used O +
as O +
a O +
model O +
system O +
for O +
studying O +
gene O +
regulation O +
of O +
the O +
human O +
vacuolar O +
H O +
( O +
+ O +
) O +
-ATPase O +
( O +
V O -
- O -
ATPase O +
) O +
. O +

We O +
examined O +
mRNA O +
levels O +
of O +
various O +
V O -
- O -
ATPase O +
subunits O +
during O +
differentiation O +
of O +
both O +
native O +
monocytes O +
and O +
the O +
cell B-CellLine +
line I-CellLine +
THP-1 B-CellLine +
, O +
and O +
found O +
that O +
transcriptional O +
and O +
post O -
- O -
transcriptional O +
mechanisms O +
could O +
account O +
for O +
increases O +
in O +
cell O +
V O -
- O -
ATPase O +
content O +
. O +

From O +
nuclear O +
runoff O +
experiments O +
, O +
we O +
found O +
that O +
one O +
subunit O +
in O +
particular O +
, O +
the O +
B2 O +
isoform O +
( O +
Mr O +
= O +
56 O +
, O +
000 O +
) O +
, O +
was O +
amplified O +
primarily O +
by O +
transcriptional O +
means O +
. O +

We O +
have O +
begun O +
to O +
examine O +
the O +
structure O +
of O +
the O +
B2 O +
subunit O +
promoter O +
region O +
. O +

Isolation O +
and O +
sequencing O +
of O +
the O +
first O +
exon O +
and O +
5'-flanking O +
region O +
of O +
this O +
gene O +
reveal O +
a O +
TATA O -
- O -
less O +
promoter O +
with O +
a O +
high O +
G O +
+ O +
C O +
content O +
. O +

Primer O +
extension O +
and O +
ribonuclease O +
protection O +
analyses O +
indicate O +
a O +
single O +
major O +
transcriptional O +
start O +
site O +
. O +

We O +
transfected O +
promoter O -
- O -
luciferase O +
reporter O +
plasmids O +
into O +
THP-1 B-CellLine +
cells I-CellLine +
to O +
define O +
sequences O +
that O +
mediate O +
transcriptional O +
control O +
during O +
monocyte O +
differentiation O +
. O +

We O +
found O +
that O +
sequences O +
downstream O +
from O +
the O +
transcriptional O +
start O +
site O +
were O +
sufficient O +
to O +
confer O +
increased O +
expression O +
during O +
THP-1 B-CellLine +
differentiation O +
. O +

DNase O +
I O +
footprinting O +
and O +
sequence O +
analysis O +
revealed O +
the O +
existence O +
of O +
multiple O +
AP2 O +
and O +
Sp1 O +
binding O +
sites O +
in O +
the O +
5'-untranslated O +
and O +
proximal O +
coding O +
regions O +
. O +

Effects O +
of O +
intranasal O +
glucocorticoids O +
on O +
endogenous O +
glucocorticoid O +
peripheral O +
and O +
central O +
function O +
. O +

Glucocorticoids O +
are O +
among O +
the O +
most O +
potent O +
antiinflammatory O +
agents O +
that O +
can O +
be O +
used O +
in O +
the O +
treatment O +
of O +
rhinitis O +
. O +

Their O +
mechanisms O +
of O +
action O +
are O +
multiple O +
and O +
complex O +
and O +
a O +
number O +
of O +
reports O +
describe O +
significant O +
systemic O +
effects O +
of O +
locally O +
administered O +
glucocorticoids O +
. O +

In O +
order O +
to O +
evaluate O +
the O +
short O -
- O -
term O +
systemic O +
effects O +
of O +
intranasally O +
administered O +
glucocorticoids O +
, O +
14 O +
normal O +
healthy O +
subjects O +
were O +
treated O +
with O +
two O +
doses O +
of O +
either O +
budesonide O +
( O +
BUD O +
) O +
or O +
fluticasone O +
propionate O +
( O +
FP O +
) O +
for O +
2 O +
weeks O +
. O +

Before O +
treatment O +
, O +
at O +
regular O +
intervals O +
during O +
the O +
treatment O +
, O +
1 O +
week O +
and O +
finally O +
6 O +
weeks O +
after O +
termination O +
of O +
treatment O +
, O +
the O +
effects O +
on O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
and O +
methallothionein O +
( O +
MTIIa O +
) O +
mRNA O +
expression O +
levels O +
were O +
examined O +
in O +
peripheral O +
lymphocytes O +
using O +
a O +
solution O +
hybridization O +
assay O +
. O +

Serum O +
cortisol O +
, O +
osteocalcin O +
and O +
urinary O +
cortisol O +
levels O +
were O +
also O +
determined O +
. O +

An O +
insulin O +
tolerance O +
test O +
( O +
ITT O +
) O +
was O +
performed O +
at O +
the O +
end O +
of O +
the O +
second O +
week O +
of O +
treatment O +
and O +
at O +
the O +
end O +
of O +
the O +
6-week O +
washout O +
period O +
with O +
no O +
statistically O +
significant O +
change O +
in O +
cortisol O +
response O +
. O +

In O +
peripheral O +
lymphocytes O +
, O +
GR O +
mRNA O +
levels O +
were O +
significantly O +
down O -
- O -
regulated O +
. O +

MTIIa O +
mRNA O +
levels O +
increased O +
significantly O +
. O +

Serum O +
osteocalcin O +
decreased O +
significantly O +
during O +
treatment O +
with O +
both O +
BUD O +
and O +
FP O +
. O +

Serum O +
cortisol O +
decreased O +
after O +
1 O +
week O +
of O +
treatment O +
whereas O +
urinary O +
cortisol O +
was O +
not O +
affected O +
until O +
the O +
second O +
week O +
of O +
treatment O +
. O +

In O +
conclusion O +
, O +
intranasal O +
glucocorticoids O +
at O +
clinically O +
recommended O +
doses O +
have O +
not O +
only O +
significant O +
systemic O +
effects O +
on O +
adrenal O +
function O +
, O +
but O +
also O +
have O +
an O +
effect O +
on O +
specific O +
gene O +
expression O +
in O +
peripheral O +
lymphocytes O +
. O +

These O +
effects O +
are O +
receptor O -
- O -
dependent O +
, O +
reversible O +
, O +
and O +
according O +
to O +
serum O +
and O +
urinary O +
cortisol O +
levels O +
and O +
ITT O +
, O +
leave O +
the O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenal O +
function O +
intact O +
. O +

Finally O +
, O +
these O +
short O -
- O -
term O +
systemic O +
effects O +
were O +
not O +
associated O +
with O +
any O +
of O +
the O +
noticeable O +
side O -
- O -
effects O +
usually O +
observed O +
during O +
long O -
- O -
term O +
treatment O +
with O +
glucocorticoids O +
. O +

Transcriptional O +
activity O +
of O +
core O +
binding O +
factor O -
- O -
alpha O +
( O +
AML1 O +
) O +
and O +
beta O +
subunits O +
on O +
murine O +
leukemia O +
virus O +
enhancer O +
cores O +
. O +

Core O +
binding O +
factor O +
( O +
CBF O +
) O +
, O +
also O +
known O +
as O +
polyomavirus O +
enhancer O -
- O -
binding O +
protein O +
2 O +
and O +
SL3 O +
enhancer O +
factor O +
1 O +
, O +
is O +
a O +
mammalian O +
transcription O +
factor O +
that O +
binds O +
to O +
an O +
element O +
termed O +
the O +
core O +
within O +
the O +
enhancers O +
of O +
the O +
murine O +
leukemia O +
virus O +
family O +
of O +
retroviruses O +
. O +

The O +
core O +
elements O +
of O +
the O +
SL3 O +
virus O +
are O +
important O +
genetic O +
determinants O +
of O +
the O +
ability O +
of O +
this O +
virus O +
to O +
induce O +
T O -
- O -
cell O +
lymphomas O +
and O +
the O +
transcriptional O +
activity O +
of O +
the O +
viral O +
long O +
terminal O +
repeat O +
in O +
T O +
lymphocytes O +
. O +

CBF O +
consists O +
of O +
two O +
subunits O +
, O +
a O +
DNA O +
binding O +
subunit O +
, O +
CBF O +
alpha O +
, O +
and O +
a O +
second O +
subunit O +
, O +
CBF O +
beta O +
, O +
that O +
stimulates O +
the O +
DNA O +
binding O +
activity O +
of O +
CBF O +
alpha O +
. O +

One O +
of O +
the O +
genes O +
that O +
encodes O +
a O +
CBF O +
alpha O +
subunit O +
is O +
AML1 O +
, O +
also O +
called O +
Cbf O +
alpha O +
2 O +
. O +

This O +
locus O +
is O +
rearranged O +
by O +
chromosomal O +
translocations O +
in O +
human O +
myeloproliferative O +
disorders O +
and O +
leukemias O +
. O +

An O +
exogenously O +
expressed O +
Cbf O +
alpha O +
2-encoded O +
subunit O +
( O +
CBF O +
alpha O +
2 O -
- O -
451 O +
) O +
stimulated O +
transcription O +
from O +
the O +
SL3 O +
enhancer O +
in O +
P19 O +
and O +
HeLa B-CellLine +
cells I-CellLine +
. O +

Activity O +
was O +
mediated O +
through O +
the O +
core O +
elements O +
. O +

Three O +
different O +
isoforms O +
of O +
CBF O +
beta O +
were O +
also O +
tested O +
for O +
transcriptional O +
activity O +
on O +
the O +
SL3 O +
enhancer O +
. O +

The O +
longest O +
form O +
, O +
CBF O +
beta-187 O +
, O +
increased O +
the O +
transcriptional O +
stimulation O +
by O +
CBF O +
alpha O +
2 O -
- O -
451 O +
twofold O +
in O +
HeLa B-CellLine +
cells I-CellLine +
, O +
although O +
it O +
had O +
no O +
effect O +
in O +
P19 B-CellLine +
cells I-CellLine +
. O +

Transcriptional O +
activation O +
by O +
CBF O +
beta O +
required O +
binding O +
to O +
the O +
CBF O +
alpha O +
subunit O +
, O +
as O +
a O +
form O +
of O +
CBF O +
beta O +
that O +
lacked O +
binding O +
ability O +
, O +
CBF O +
beta-148 O +
, O +
failed O +
to O +
increase O +
activity O +
. O +

These O +
results O +
indicated O +
that O +
at O +
least O +
in O +
certain O +
cell O +
types O +
, O +
the O +
maximum O +
activity O +
of O +
CBF O +
required O +
both O +
subunits O +
. O +

They O +
also O +
provided O +
support O +
for O +
the O +
hypothesis O +
that O +
CBF O +
is O +
a O +
factor O +
in O +
T O +
lymphocytes O +
that O +
is O +
responsible O +
for O +
recognition O +
of O +
the O +
SL3 O +
cores O +
. O +

We O +
also O +
examined O +
whether O +
CBF O +
could O +
distinguish O +
a O +
1-bp O +
difference O +
between O +
the O +
enhancer O +
core O +
of O +
SL3 O +
and O +
the O +
core O +
of O +
the O +
nonleukemogenic O +
virus O +
, O +
Akv O +
. O +

This O +
difference O +
strongly O +
affects O +
transcription O +
in O +
T O +
cells O +
and O +
leukemogenicity O +
of O +
SL3 O +
. O +

However O +
, O +
no O +
combination O +
of O +
CBF O +
alpha O +
and O +
CBF O +
beta O +
subunits O +
that O +
we O +
tested O +
was O +
able O +
to O +
distinguish O +
the O +
1-bp O +
difference O +
in O +
transcription O +
assays O +
. O +

Thus O +
, O +
a O +
complete O +
understanding O +
of O +
how O +
T O +
cells O +
recognize O +
the O +
SL3 O +
core O +
remains O +
to O +
be O +
elucidated O +
. O +

A O +
newly O +
established O +
megakaryoblastic B-CellLine -
/ I-CellLine -
erythroid I-CellLine +
cell I-CellLine +
line I-CellLine +
that O +
differentiates O +
to O +
red O +
cells O +
in O +
the O +
presence O +
of O +
erythropoietin O +
and O +
produces O +
platelet O -
- O -
like O +
particles O +
. O +

In O +
August O +
, O +
1992 O +
, O +
we O +
established O +
a O +
leukemic B-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
NS B-CellLine -
- I-CellLine -
Meg I-CellLine +
) O +
from O +
a O +
patient O +
in O +
megakaryoblastic O +
transformation O +
of O +
Philadelphia O +
chromosome O -
- O -
positive O +
chronic O +
myeloid O +
leukemia O +
. O +

The O +
NS B-CellLine -
- I-CellLine -
Meg I-CellLine +
cells I-CellLine +
were O +
positive O +
for O +
alpha O -
- O -
naphthyl O +
acetate O +
esterase O +
and O +
periodic O +
acid O -
- O -
Schiff O +
( O +
PAS O +
) O +
staining O +
and O +
for O +
surface O +
CD4 O +
, O +
CD7 O +
, O +
CD13 O +
, O +
CD34 O +
, O +
CD41a O +
, O +
and O +
glycophorin O +
A O +
antigens O +
. O +

Ultrastructurally O +
, O +
the O +
cells O +
had O +
alpha O -
- O -
granules O +
, O +
demarcation O +
membranes O +
, O +
and O +
platelet O +
peroxidase O +
activity O +
. O +

The O +
NS B-CellLine -
- I-CellLine -
Meg I-CellLine +
cells I-CellLine +
spontaneously O +
produced O +
platelet O -
- O -
like O +
particles O +
which O +
contained O +
alpha O -
- O -
granules O +
, O +
mitochondria O +
and O +
dense O +
bodies O +
, O +
strongly O +
suggesting O +
platelet O +
production O +
. O +

Erythropoietin O +
( O +
Epo O +
) O +
, O +
granulocyte O -
/ O -
macrophage O +
colony O +
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
, O +
and O +
interleukin O +
3 O +
( O +
IL-3 O +
) O +
promoted O +
the O +
growth O +
of O +
NS B-CellLine -
- I-CellLine -
Meg I-CellLine +
cells I-CellLine +
. O +

Phorbol-12-myristate-13-acetate O +
increased O +
the O +
expression O +
of O +
both O +
CD41a O +
and O +
CD61 O +
antigens O +
. O +

Ten O -
- O -
day O +
exposure O +
to O +
Epo O +
induced O +
mature O +
erythroblasts O +
and O +
red O +
cells O +
. O +

These O +
benzidine B-CellLine -
- I-CellLine -
positive I-CellLine +
cells I-CellLine +
were O +
positive O +
for O +
hemoglobin O +
F O +
staining O +
. O +

Untreated O +
NS B-CellLine -
- I-CellLine -
Meg I-CellLine +
cells I-CellLine +
expressed O +
mRNA O +
for O +
the O +
Epo O +
receptor O +
( O +
EpoR O +
) O +
, O +
for O +
GATA-1 O +
, O +
and O +
for O +
alpha O +
1 O +
, O +
alpha O +
2 O +
and O +
gamma O +
globin O +
genes O +
. O +

These O +
results O +
indicate O +
that O +
NS B-CellLine -
- I-CellLine -
Meg I-CellLine +
cells I-CellLine +
undergo O +
terminal O +
differentiation O +
of O +
both O +
megakaryocytic O +
and O +
erythroid O +
lineages O +
. O +

This O +
cell B-CellLine +
line I-CellLine +
should O +
be O +
a O +
very O +
useful O +
tool O +
for O +
the O +
investigation O +
of O +
both O +
megakaryocytic O +
and O +
erythroid O +
maturation O +
. O +

The O +
role O +
of O +
shared O +
receptor O +
motifs O +
and O +
common O +
Stat O +
proteins O +
in O +
the O +
generation O +
of O +
cytokine O +
pleiotropy O +
and O +
redundancy O +
by O +
IL-2 O +
, O +
IL-4 O +
, O +
IL-7 O +
, O +
IL-13 O +
, O +
and O +
IL-15 O +
. O +

To O +
understand O +
the O +
molecular O +
bases O +
for O +
cytokine O +
redundancy O +
and O +
pleiotropy O +
, O +
we O +
have O +
compared O +
the O +
Stat O +
proteins O +
activated O +
in O +
peripheral O +
blood O +
lymphocytes O +
( O +
PBLs O +
) O +
by O +
cytokines O +
with O +
shared O +
and O +
distinct O +
actions O +
. O +

Interleukin-2 O +
( O +
IL-2 O +
) O +
rapidly O +
activated O +
Stat5 O +
in O +
fresh O +
PBL O +
, O +
and O +
Stat3 O +
and O +
Stat5 O +
in O +
preactivated O +
PBL O +
. O +

IL-7 O +
and O +
IL-15 O +
induced O +
the O +
same O +
complexes O +
as O +
IL-2 O +
, O +
a O +
feature O +
explained O +
by O +
the O +
existence O +
of O +
similar O +
tyrosine O -
- O -
phosphorylated O +
motifs O +
in O +
the O +
cytoplasmic O +
domains O +
of O +
IL-2R O +
beta O +
and O +
IL-7R O +
that O +
can O +
serve O +
as O +
docking O +
sites O +
for O +
Stat O +
proteins O +
. O +

IL-13 O +
Induced O +
the O +
same O +
complexes O +
as O +
IL-4 O +
, O +
a O +
finding O +
explained O +
by O +
our O +
studies O +
implicating O +
IL-4R O +
as O +
a O +
shared O +
component O +
of O +
the O +
receptors O +
. O +

These O +
studies O +
demonstrate O +
that O +
a O +
single O +
cytokine O +
can O +
activate O +
different O +
combinations O +
of O +
Stat O +
proteins O +
under O +
different O +
physiological O +
conditions O +
, O +
and O +
also O +
indicate O +
two O +
mechanisms O +
by O +
which O +
distinct O +
cytokines O +
can O +
activate O +
the O +
same O +
Stat O +
protein O +
. O +

Induction O +
of O +
transcription O +
factors O +
in O +
human O +
T O +
lymphocytes O +
by O +
aspirin O -
- O -
like O +
drugs O +
. O +

Aspirin O -
- O -
like O +
drugs O +
( O +
ALD O +
) O +
induce O +
calcium O +
mobilization O +
, O +
an O +
essential O +
component O +
of O +
T O +
cell O +
activation O +
, O +
but O +
do O +
not O +
induce O +
the O +
biosynthesis O +
of O +
IL-2 O +
. O +

To O +
understand O +
the O +
extent O +
to O +
which O +
ALD O +
may O +
mimic O +
mitogenic O +
stimulation O +
, O +
we O +
studied O +
cytoplasmic O +
and O +
nuclear O +
signaling O +
steps O +
in O +
ALD B-CellLine -
- I-CellLine -
treated I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

We O +
found O +
that O +
ALD O +
induce O +
a O +
transient O +
activation O +
of O +
protein O +
kinase O +
( O +
PKC O +
) O +
but O +
have O +
no O +
effect O +
( O +
in O +
comparison O +
to O +
anti O -
- O -
CD3 O +
antibodies O +
) O +
on O +
protein O +
tyrosine O +
phosphorylation O +
nor O +
on O +
PCL O +
gamma O +
1 O +
tyrosine O +
phosphorylation O +
. O +

ALD O -
- O -
induced O +
calcium O +
mobilization O +
and O +
PKC O +
activation O +
are O +
independent O +
of O +
tyrosine O +
protein O +
kinase O +
activity O +
as O +
shown O +
by O +
the O +
lack O +
of O +
effect O +
of O +
herbimycin O +
, O +
a O +
tyrosine O -
- O -
protein O +
kinase O +
-specific O +
inhibitor O +
. O +

Although O +
we O +
detected O +
no O +
IL-2 O +
mRNA O +
in O +
ALD B-CellLine -
- I-CellLine -
treated I-CellLine +
cells I-CellLine +
, O +
the O +
nuclei O +
of O +
these O +
cells O +
contain O +
proteins O +
capable O +
of O +
binding O +
to O +
three O +
regulatory O +
sequences O +
in O +
the O +
IL-2 O +
promoter O +
region O +
: O +
NFAT O +
, O +
NF O +
kappa O +
B O +
, O +
and O +
AP-1 O +
. O +

These O +
binding O +
activities O +
are O +
expressed O +
only O +
in O +
activated O +
T O +
cells O +
. O +

The O +
expression O +
of O +
AP-1 O +
depended O +
on O +
calcium O +
mobilization O +
and O +
PKC O +
activation O +
. O +

These O +
data O +
suggest O +
that O +
ALD O +
cause O +
transient O +
but O +
significant O +
changes O +
in O +
T O +
cell O +
transmembrane O +
signaling O +
, O +
although O +
some O +
events O +
induced O +
by O +
stimulation O +
with O +
anti O -
- O -
CD3 O +
antibodies O +
are O +
not O +
induced O +
by O +
ALD O +
. O +

The O +
signal O +
is O +
transmitted O +
to O +
the O +
nucleus O +
and O +
induces O +
DNA O -
- O -
binding O +
activity O +
by O +
several O +
transcription O +
factors O +
. O +

However O +
, O +
the O +
ALD O +
stimulus O +
is O +
not O +
capable O +
of O +
causing O +
complete O +
T O +
cell O +
activation O +
. O +

Functional O +
roles O +
of O +
in O +
vivo O +
footprinted O +
DNA O +
motifs O +
within O +
an O +
alpha O -
- O -
globin O +
enhancer O +
. O +

Erythroid O +
lineage O +
and O +
developmental O +
stage O +
specificities O +
. O +

Transcriptional O +
regulation O +
of O +
the O +
human O +
alpha O -
- O -
like O +
globin O +
genes O +
, O +
embryonic O +
zeta O +
2 O +
and O +
adult O +
alpha O +
, O +
during O +
erythroid O +
development O +
is O +
mediated O +
by O +
a O +
distal O +
enhancer O +
, O +
HS-40 O +
. O +

Previous O +
protein O -
- O -
DNA O +
binding O +
studies O +
have O +
shown O +
that O +
HS-40 O +
consists O +
of O +
multiple O +
nuclear O +
factor O +
binding O +
motifs O +
that O +
are O +
occupied O +
in O +
vivo O +
in O +
an O +
erythroid O +
lineage- O +
and O +
developmental O +
stage O -
- O -
specific O +
manner O +
. O +

We O +
have O +
systematically O +
analyzed O +
the O +
functional O +
roles O +
of O +
these O +
factor O +
binding O +
motifs O +
of O +
HS-40 O +
by O +
site O -
- O -
directed O +
mutagenesis O +
and O +
transient O +
expression O +
assay O +
in O +
erythroid B-CellLine +
cell I-CellLine +
cultures I-CellLine +
. O +

Three O +
of O +
these O +
HS-40 O +
enhancer O +
motifs O +
, O +
5'NF O -
- O -
E2 O -
/ O -
AP1 O +
, O +
GT O +
II O +
, O +
and O +
GATA-1 O +
( O +
c O +
) O +
, O +
positively O +
regulate O +
the O +
zeta O +
2-globin O +
promoter O +
activity O +
in O +
embryonic B-CellLine -
/ I-CellLine -
fetal I-CellLine +
erythroid I-CellLine +
K562 I-CellLine +
cells I-CellLine +
and O +
the O +
adult O +
alpha O -
- O -
globin O +
promoter O +
activity O +
in O +
adult B-CellLine +
erythroid I-CellLine +
MEL I-CellLine +
cells I-CellLine +
. O +

On O +
the O +
other O +
hand O +
, O +
the O +
3'NF O -
- O -
E2 O -
/ O -
AP1 O +
motif O +
is O +
able O +
to O +
exert O +
both O +
positive O +
and O +
negative O +
regulatory O +
effects O +
on O +
the O +
zeta O +
2-globin O +
promoter O +
activity O +
in O +
K562 B-CellLine +
cells I-CellLine +
, O +
and O +
this O +
dual O +
function O +
appears O +
to O +
be O +
modulated O +
through O +
differential O +
binding O +
of O +
the O +
ubiquitous O +
AP1 O +
factors O +
and O +
the O +
erythroid O -
- O -
enriched O +
NF O -
- O -
E2 O +
factor O +
. O +

Mutation O +
in O +
the O +
GATA-1 O +
( O +
d O +
) O +
motif O +
, O +
which O +
exhibits O +
an O +
adult O +
erythroid O -
- O -
specific O +
genomic O +
footprint O +
, O +
decreases O +
the O +
HS-40 O +
enhancer O +
function O +
in O +
dimethyl B-CellLine +
sulfoxide I-CellLine -
- I-CellLine -
induced I-CellLine +
MEL I-CellLine +
cells I-CellLine +
but O +
not O +
in O +
K562 B-CellLine +
cells I-CellLine +
. O +

These O +
studies O +
have O +
defined O +
the O +
regulatory O +
roles O +
of O +
the O +
different O +
HS-40 O +
motifs O +
. O +

The O +
remarkable O +
correlation O +
between O +
genomic O +
footprinting O +
data O +
and O +
the O +
mutagenesis O +
results O +
also O +
suggests O +
that O +
the O +
erythroid O +
lineage- O +
and O +
developmental O +
stage O -
- O -
specific O +
regulation O +
of O +
human O +
alpha O -
- O -
like O +
globin O +
promoters O +
is O +
indeed O +
modulated O +
by O +
stable O +
binding O +
of O +
specific O +
nuclear O +
factors O +
in O +
vivo O +
. O +

Interleukin O +
( O +
IL O +
) O +
-10 O +
inhibits O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O +
kappa O +
B O +
) O +
activation O +
in O +
human O +
monocytes O +
. O +

IL-10 O +
and O +
IL-4 O +
suppress O +
cytokine O +
synthesis O +
by O +
different O +
mechanisms O +
. O +

Our O +
previous O +
studies O +
in O +
human O +
monocytes O +
have O +
demonstrated O +
that O +
interleukin O +
( O +
IL O +
) O +
-10 O +
inhibits O +
lipopolysaccharide O +
( O +
LPS O +
) O +
-stimulated O +
production O +
of O +
inflammatory O +
cytokines O +
, O +
IL-1 O +
beta O +
, O +
IL-6 O +
, O +
IL-8 O +
, O +
and O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
-alpha O +
by O +
blocking O +
gene O +
transcription O +
. O +

Using O +
electrophoretic O +
mobility O +
shift O +
assays O +
( O +
EMSA O +
) O +
, O +
we O +
now O +
show O +
that O +
, O +
in O +
monocytes O +
stimulated O +
with O +
LPS O +
or O +
TNF O +
alpha O +
, O +
IL-10 O +
inhibits O +
nuclear O +
stimulation O +
of O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O +
kappa O +
B O +
) O +
, O +
a O +
transcription O +
factor O +
involved O +
in O +
the O +
expression O +
of O +
inflammatory O +
cytokine O +
genes O +
. O +
Several O +
other O +
transcription O +
factors O +
including O +
NF- O +
IL-6 O +
, O +
AP-1 O +
, O +
AP-2 O +
, O +
GR O +
, O +
CREB O +
, O +
Oct-1 O +
, O +
and O +
Sp-1 O +
are O +
not O +
affected O +
by O +
IL-10 O +
. O +

This O +
selective O +
inhibition O +
by O +
IL-10 O +
of O +
NF O +
kappa O +
B O +
activation O +
occurs O +
rapidly O +
and O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
and O +
correlates O +
well O +
with O +
IL-10 O +
's O +
cytokine O +
synthesis O +
inhibitory O +
activity O +
in O +
terms O +
of O +
both O +
kinetics O +
and O +
dose O +
responsiveness O +
. O +

Furthermore O +
, O +
compounds O +
such O +
as O +
tosylphenylalanyl O +
chloromethyl O +
ketone O +
and O +
pyrrolidinedithiocarbamate O +
that O +
are O +
known O +
to O +
selectively O +
inhibit O +
NF O +
kappa O +
B O +
activation O +
block O +
cytokine O +
gene O +
transcription O +
in O +
LPS B-CellLine -
- I-CellLine -
stimulated I-CellLine +
monocytes I-CellLine +
. O +

Taken O +
together O +
, O +
these O +
results O +
suggest O +
that O +
inhibition O +
of O +
NF O +
kappa O +
B O +
activation O +
may O +
be O +
an O +
important O +
mechanism O +
for O +
IL-10 O +
suppression O +
of O +
cytokine O +
gene O +
transcription O +
in O +
human O +
monocytes O +
. O +

IL-4 O +
, O +
another O +
cytokine O +
that O +
inhibits O +
cytokine O +
mRNA O +
accumulation O +
in O +
monocytes O +
, O +
shows O +
little O +
inhibitory O +
effect O +
on O +
LPS O -
- O -
induced O +
NF O +
kappa O +
B O +
activation O +
. O +

Further O +
examination O +
reveals O +
that O +
, O +
unlike O +
IL-10 O +
, O +
IL-4 O +
enhances O +
mRNA O +
degradation O +
and O +
does O +
not O +
suppress O +
cytokine O +
gene O +
transcription O +
. O +

These O +
data O +
indicate O +
that O +
IL-10 O +
and O +
IL-4 O +
inhibit O +
cytokine O +
production O +
by O +
different O +
mechanisms O +
. O +

Identification O +
of O +
a O +
major O +
positive O +
regulatory O +
element O +
located O +
5 O +
' O +
to O +
the O +
human O +
zeta O -
- O -
globin O +
gene O +
. O +

The O +
function O +
of O +
the O +
zeta O -
- O -
globin O +
promoter O +
was O +
studied O +
using O +
a O +
series O +
of O +
zeta O -
- O -
globin O +
promoter O +
deletion O +
constructs O +
to O +
drive O +
luciferase O +
expression O +
in O +
transiently B-CellLine +
transfected I-CellLine +
human I-CellLine +
erythroleukemia I-CellLine +
cells I-CellLine +
. O +

The O +
promoters O +
were O +
used O +
without O +
enhancers O +
, O +
or O +
with O +
enhancers O +
derived O +
from O +
the O +
beta O -
- O -
globin O +
locus O +
control O +
region O +
and O +
the O +
alpha O -
- O -
globin O +
HS-40 O +
enhancer O +
. O +

When O +
transfected O +
into O +
K562 B-CellLine +
cells I-CellLine +
, O +
which O +
express O +
zeta O -
- O -
globin O +
, O +
comparable O +
amounts O +
of O +
activity O +
were O +
obtained O +
from O +
the O +
-557 O +
and O +
-417 O +
zeta O -
- O -
luciferase O +
constructs O +
and O +
the O +
alpha O -
- O -
luciferase O +
constructs O +
when O +
no O +
enhancers O +
or O +
the O +
alpha O -
- O -
globin O +
locus O +
enhancers O +
were O +
used O +
. O +

When O +
the O +
constructs O +
were O +
transfected O +
into O +
OCIM1 B-CellLine +
cells I-CellLine +
, O +
which O +
do O +
not O +
express O +
zeta O -
- O -
globin O +
, O +
the O +
zeta O -
- O -
globin O +
promoters O +
were O +
at O +
best O +
20 O +
% O +
as O +
active O +
as O +
the O +
alpha O -
- O -
globin O +
promoters O +
. O +

When O +
sequences O +
from O +
-417 O +
to O +
-207 O +
5 O +
' O +
to O +
the O +
zeta O -
- O -
globin O +
mRNA O +
cap O +
site O +
were O +
deleted O +
, O +
up O +
to O +
95 O +
% O +
of O +
the O +
zeta O -
- O -
globin O +
promoter O +
activity O +
was O +
lost O +
in O +
K562 B-CellLine +
cells I-CellLine +
. O +

Reinsertion O +
of O +
these O +
sequences O +
into O +
zeta O -
- O -
luciferase O +
constructs O +
missing O +
the O +
-417 O +
to O +
-207 O +
region O +
showed O +
that O +
the O +
sequences O +
lack O +
classical O +
enhancer O +
activity O +
. O +

Point O +
mutation O +
of O +
a O +
GATA-1 O +
site O +
at O +
-230 O +
reduced O +
promoter O +
activity O +
by O +
37 O +
% O +
. O +

Point O +
mutation O +
of O +
a O +
CCACC O +
site O +
at O +
-240 O +
had O +
no O +
effect O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
indicated O +
that O +
the O +
-230 O +
GATA-1 O +
site O +
has O +
a O +
relatively O +
low O +
affinity O +
for O +
GATA-1 O +
. O +

These O +
experiments O +
show O +
the O +
presence O +
of O +
a O +
strong O +
positive O -
- O -
acting O +
element O +
, O +
located O +
between O +
-417 O +
and O +
-207 O +
bp O +
5 O +
' O +
to O +
the O +
zeta O -
- O -
globin O +
mRNA O +
cap O +
site O +
, O +
is O +
necessary O +
for O +
high O -
- O -
level O +
promoter O +
activity O +
in O +
K562 B-CellLine +
cells I-CellLine +
. O +

This O +
element O +
requires O +
GATA-1 O +
and O +
additional O +
unknown O +
factors O +
for O +
maximal O +
activity O +
. O +

Activation O +
of O +
transcription O +
by O +
binding O +
of O +
NF O -
- O -
E1 O +
( O +
YY1 O +
) O +
to O +
a O +
newly O +
identified O +
element O +
in O +
the O +
first O +
exon O +
of O +
the O +
human O +
DR O +
alpha O +
gene O +
. O +

A O +
previously O +
unrecognized O +
element O +
, O +
located O +
downstream O +
of O +
the O +
start O +
site O +
of O +
transcription O +
in O +
the O +
first O +
exon O +
of O +
the O +
DR O +
alpha O +
gene O +
, O +
has O +
been O +
defined O +
that O +
enhances O +
promoter O +
activity O +
up O +
to O +
eightfold O +
in O +
a O +
position O -
- O -
dependent O +
manner O +
. O +

Mutations O +
in O +
this O +
DNA O -
- O -
binding O +
site O +
abolished O +
binding O +
of O +
a O +
nuclear O +
factor O +
in O +
human O +
B O +
cell O +
nuclear O +
extract O +
and O +
decreased O +
the O +
activity O +
of O +
the O +
DR O +
alpha O +
promoter O +
to O +
a O +
basal O +
level O +
. O +

Significant O +
sequence O +
homology O +
of O +
this O +
element O +
was O +
found O +
in O +
the O +
DNA O +
of O +
the O +
DR O +
beta O +
, O +
DP O +
alpha O +
and O +
-beta O +
, O +
and O +
DQ O +
alpha O +
genes O +
, O +
always O +
located O +
downstream O +
of O +
the O +
transcriptional O +
start O +
site O +
. O +

The O +
nuclear O +
factor O +
binds O +
to O +
the O +
DR O +
alpha O +
and O +
DP O +
alpha O +
element O +
but O +
not O +
to O +
the O +
element O +
in O +
the O +
DQ O +
alpha O +
gene O +
. O +

It O +
was O +
identified O +
as O +
NF O -
- O -
E1 O +
( O +
YY1 O +
) O +
. O +

This O +
protein O +
, O +
previously O +
identified O +
by O +
its O +
binding O +
to O +
the O +
Ig O +
kappa O +
3 O +
' O +
enhancer O +
and O +
the O +
Ig O +
heavy O +
chain O +
mu O +
E1 O +
site O +
, O +
thus O +
also O +
appears O +
to O +
be O +
quite O +
important O +
in O +
the O +
regulation O +
of O +
MHC O +
class O +
II O +
gene O +
expression O +
. O +

Monocyte O +
tethering O +
by O +
P O -
- O -
selectin O +
regulates O +
monocyte O +
chemotactic O +
protein-1 O +
and O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
secretion O +
. O +

Signal O +
integration O +
and O +
NF O -
- O -
kappa O +
B O +
translocation O +
[ O +
see O +
comments O +
] O +

Adhesion O +
molecules O +
that O +
tether O +
circulating O +
leukocytes O +
to O +
endothelial O +
cells O +
may O +
also O +
transduce O +
or O +
modulate O +
outside O -
- O -
in O +
signals O +
for O +
cellular O +
activation O +
, O +
providing O +
an O +
initial O +
regulatory O +
point O +
in O +
the O +
inflammatory O +
response O +
. O +

Adhesion O +
of O +
human O +
monocytes O +
to O +
P O -
- O -
selectin O +
, O +
the O +
most O +
rapidly O +
expressed O +
endothelial O +
tethering O +
factor O +
, O +
increased O +
the O +
secretion O +
of O +
monocyte O +
chemotactic O +
protein-1 O +
( O +
MCP-1 O +
) O +
and O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
by O +
the O +
leukocytes O +
when O +
they O +
were O +
stimulated O +
with O +
platelet O -
- O -
activating O +
factor O +
. O +

Increased O +
cytokine O +
secretion O +
was O +
specifically O +
inhibited O +
by O +
G1 O +
, O +
an O +
anti O -
- O -
P O -
- O -
selectin O +
mAb O +
that O +
prevents O +
P O -
- O -
selectin O +
from O +
binding O +
to O +
its O +
ligand O +
( O +
P O -
- O -
selectin O +
glycoprotein O +
ligand-1 O +
) O +
on O +
myeloid O +
cells O +
. O +

Moreover O +
, O +
tethering O +
by O +
P O -
- O -
selectin O +
specifically O +
enhanced O +
nuclear O +
translocation O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
, O +
a O +
transcription O +
factor O +
required O +
for O +
expression O +
of O +
MCP-1 O +
, O +
TNF O -
- O -
alpha O +
, O +
and O +
other O +
immediate O -
- O -
early O +
genes O +
. O +

These O +
results O +
demonstrate O +
that O +
P O -
- O -
selectin O +
, O +
through O +
its O +
ligands O +
on O +
monocytes O +
, O +
may O +
locally O +
regulate O +
cytokine O +
secretion O +
in O +
inflamed O +
tissues O +
. O +

Coupling O +
of O +
a O +
signal O +
response O +
domain O +
in O +
I O +
kappa O +
B O +
alpha O +
to O +
multiple O +
pathways O +
for O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

The O +
eukaryotic O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
plays O +
a O +
central O +
role O +
in O +
the O +
induced O +
expression O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
and O +
in O +
many O +
aspects O +
of O +
the O +
genetic O +
program O +
mediating O +
normal O +
T O -
- O -
cell O +
activation O +
and O +
growth O +
. O +

The O +
nuclear O +
activity O +
of O +
NF O -
- O -
kappa O +
B O +
is O +
tightly O +
regulated O +
from O +
the O +
cytoplasmic O +
compartment O +
by O +
an O +
inhibitory O +
subunit O +
called O +
I O +
kappa O +
B O +
alpha O +
. O +

This O +
cytoplasmic O +
inhibitor O +
is O +
rapidly O +
phosphorylated O +
and O +
degraded O +
in O +
response O +
to O +
a O +
diverse O +
set O +
of O +
NF O -
- O -
kappa O +
B O -
- O -
inducing O +
agents O +
, O +
including O +
T O -
- O -
cell O +
mitogens O +
, O +
proinflammatory O +
cytokines O +
, O +
and O +
viral O +
transactivators O +
such O +
as O +
the O +
Tax O +
protein O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
. O +

To O +
explore O +
these O +
I O +
kappa O +
B O +
alpha O +
-dependent O +
mechanisms O +
for O +
NF O -
- O -
kappa O +
B O +
induction O +
, O +
we O +
identified O +
novel O +
mutants O +
of O +
I O +
kappa O +
B O +
alpha O +
that O +
uncouple O +
its O +
inhibitory O +
and O +
signal O -
- O -
transducing O +
functions O +
in O +
human O +
T O +
lymphocytes O +
. O +

Specifically O +
, O +
removal O +
of O +
the O +
N O -
- O -
terminal O +
36 O +
amino O +
acids O +
of O +
I O +
kappa O +
B O +
alpha O +
failed O +
to O +
disrupt O +
its O +
ability O +
to O +
form O +
latent O +
complexes O +
with O +
NF O -
- O -
kappa O +
B O +
in O +
the O +
cytoplasm O +
. O +

However O +
, O +
this O +
deletion O +
mutation O +
prevented O +
the O +
induced O +
phosphorylation O +
, O +
degradative O +
loss O +
, O +
and O +
functional O +
release O +
of O +
I O +
kappa O +
B O +
alpha O +
from O +
NF O -
- O -
kappa O +
B O +
in O +
Tax B-CellLine -
- I-CellLine -
expressing I-CellLine +
cells I-CellLine +
. O +

Alanine O +
substitutions O +
introduced O +
at O +
two O +
serine O +
residues O +
positioned O +
within O +
this O +
N O -
- O -
terminal O +
regulatory O +
region O +
of O +
I O +
kappa O +
B O +
alpha O +
also O +
yielded O +
constitutive O +
repressors O +
that O +
escaped O +
from O +
Tax O +
-induced O +
turnover O +
and O +
that O +
potently O +
inhibited O +
immune O +
activation O +
pathways O +
for O +
NF O -
- O -
kappa O +
B O +
induction O +
, O +
including O +
those O +
initiated O +
from O +
antigen O +
and O +
cytokine O +
receptors O +
. O +

In O +
contrast O +
, O +
introduction O +
of O +
a O +
phosphoserine O +
mimetic O +
at O +
these O +
sites O +
rectified O +
this O +
functional O +
defect O +
, O +
a O +
finding O +
consistent O +
with O +
a O +
causal O +
linkage O +
between O +
the O +
phosphorylation O +
status O +
and O +
proteolytic O +
stability O +
of O +
this O +
cytoplasmic O +
inhibitor O +
. O +

Together O +
, O +
these O +
in O +
vivo O +
studies O +
define O +
a O +
critical O +
signal O +
response O +
domain O +
in O +
I O +
kappa O +
B O +
alpha O +
that O +
coordinately O +
controls O +
the O +
biologic O +
activities O +
of O +
I O +
kappa O +
B O +
alpha O +
and O +
NF O -
- O -
kappa O +
B O +
in O +
response O +
to O +
viral O +
and O +
immune O +
stimuli O +
. O +

HIV O +
type O +
1 O +
protease O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
within O +
T O +
lymphoid O +
cells O +
. O +

NF O -
- O -
kappa O +
B O +
is O +
a O +
nuclear O +
protein O +
of O +
the O +
rel O +
oncogene O +
family O +
capable O +
of O +
enhancing O +
transcription O +
of O +
several O +
cellular O +
genes O +
, O +
including O +
IL-2 O +
and O +
the O +
IL-2 O +
receptor O +
, O +
and O +
viral O +
genes O +
transcribed O +
from O +
the O +
HIV-1 O +
LTR O +
. O +

It O +
has O +
been O +
reported O +
that O +
HIV-1 O +
protease O +
may O +
cleave O +
the O +
NF O -
- O -
kappa O +
B O +
precursor O +
to O +
its O +
active O +
form O +
in O +
vitro O +
. O +

In O +
this O +
study O +
the O +
effects O +
of O +
HIV O +
protease O +
on O +
NF O -
- O -
kappa O +
B O +
precursor O +
activation O +
were O +
examined O +
in O +
Jurkat O +
T O +
cells O +
by O +
introducing O +
a O +
protease O +
expression O +
vector O +
into O +
the O +
cells O +
. O +

Increased O +
NF O -
- O -
kappa O +
B O +
activity O +
was O +
observed O +
and O +
this O +
increased O +
activity O +
was O +
blocked O +
by O +
a O +
specific O +
inhibitor O +
of O +
the O +
viral O +
protease O +
. O +

Viral O +
transcription O +
, O +
as O +
measured O +
using O +
LTR O +
-CAT O +
assays O +
, O +
was O +
only O +
slightly O +
enhanced O +
in O +
the O +
HIV O -
- O -
protease O +
expressing O +
cells O +
, O +
while O +
secretion O +
of O +
IL-2 O +
and O +
expression O +
of O +
the O +
IL-2 O +
receptor O +
were O +
not O +
affected O +
. O +

The O +
limited O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
by O +
HIV O +
protease O +
appears O +
unlikely O +
to O +
have O +
a O +
significant O +
effect O +
on O +
virus O +
expression O +
or O +
T O +
cell O +
function O +
. O +

The O +
use O +
of O +
glucocorticoids O +
in O +
acute O +
lymphoblastic O +
leukemia O +
of O +
childhood O +
. O +

Molecular O +
, O +
cellular O +
, O +
and O +
clinical O +
considerations O +
. O +

Glucocorticoids O +
have O +
been O +
included O +
in O +
almost O +
all O +
treatment O +
regimens O +
for O +
childhood O +
acute O +
lymphoblastic O +
leukemia O +
for O +
decades O +
. O +

However O +
, O +
optimal O +
agents O +
, O +
doses O +
, O +
and/or O +
schedules O +
have O +
yet O +
to O +
be O +
defined O +
despite O +
extensive O +
clinical O +
application O +
. O +

New O +
data O +
on O +
the O +
pharmacokinetics O +
, O +
pharmacodynamics O +
, O +
and O +
molecular O +
mechanisms O +
of O +
action O +
of O +
glucocorticoids O +
have O +
suggested O +
alternative O +
approaches O +
in O +
ALL O +
. O +

These O +
suggest O +
that O +
prolonged O +
, O +
i.e. O +
28 O +
day O +
, O +
glucocorticoid O +
therapy O +
may O +
be O +
unnecessary O +
as O +
exposure O +
to O +
glucocorticoid O +
induces O +
down O -
- O -
regulation O +
of O +
glucocorticoid O +
receptors O +
. O +

Dexamethasone O +
may O +
be O +
superior O +
to O +
prednisone O +
in O +
conventional O +
equi O -
- O -
effective O +
doses O +
. O +

Blast O +
sensitivity O +
to O +
glucocorticoids O +
correlates O +
closely O +
with O +
sensitivity O +
to O +
other O +
, O +
putatively O +
non O -
- O -
cross O -
- O -
resisting O +
agents O +
and O +
with O +
outcome O +
after O +
multi O -
- O -
agent O +
therapy O +
, O +
suggesting O +
overlapping O +
mechanisms O +
of O +
action O +
, O +
and O +
focusing O +
attention O +
on O +
the O +
determinants O +
of O +
the O +
threshold O +
for O +
apoptosis O +
. O +

Increasing O +
success O +
in O +
the O +
treatment O +
of O +
childhood O +
acute O +
lymphoblastic O +
leukemia O +
has O +
led O +
to O +
increasing O +
awareness O +
of O +
avascular O +
necrosis O +
of O +
bone O +
as O +
a O +
potentially O +
disabling O +
sequela O +
of O +
glucocorticoid O +
therapy O +
, O +
especially O +
in O +
adolescent O +
and O +
young O +
adult O +
patients O +
. O +

Human O +
MHC O +
class O +
II O +
gene O +
transcription O +
directed O +
by O +
the O +
carboxyl O +
terminus O +
of O +
CIITA O +
, O +
one O +
of O +
the O +
defective O +
genes O +
in O +
type O +
II O +
MHC O +
combined O +
immune O +
deficiency O +
. O +

Type O +
II O +
major O +
histocompatibility O +
complex O +
combined O +
immune O +
deficiency O +
( O +
type O +
II O +
MHC O +
CID O +
or O +
bare O +
lymphocyte O +
syndrome O +
) O +
is O +
a O +
congenital O +
immunodeficiency O +
disease O +
characterized O +
by O +
absent O +
MHC O +
class O +
II O +
expression O +
. O +

Four O +
distinct O +
complementation O +
groups O +
have O +
been O +
identified O +
. O +

Recently O +
, O +
the O +
defective O +
gene O +
in O +
group O +
II O +
type O +
II O +
MHC O +
CID O +
has O +
been O +
isolated O +
and O +
termed O +
CIITA O +
. O +

Here O +
, O +
we O +
demonstrate O +
that O +
CIITA O +
is O +
an O +
MHC O +
class O +
II O +
gene O -
- O -
specific O +
transcription O +
activator O +
. O +

The O +
transcription O +
activation O +
function O +
is O +
provided O +
by O +
the O +
N O -
- O -
terminal O +
acidic O +
domain O +
( O +
amino O +
acids O +
26 O -
- O -
137 O +
) O +
, O +
which O +
is O +
experimentally O +
exchangeable O +
with O +
a O +
heterologous O +
viral O +
transcription O -
- O -
activating O +
domain O +
. O +

The O +
specificity O +
of O +
CIITA O +
for O +
three O +
major O +
MHC O +
class O +
II O +
genes O +
, O +
DR O +
, O +
DQ O +
and O +
DP O +
, O +
is O +
mediated O +
by O +
its O +
remaining O +
C O -
- O -
terminal O +
residues O +
( O +
amino O +
acids O +
317 O -
- O -
1130 O +
) O +
. O +

The O +
transactivation O +
of O +
multiple O +
cis O +
elements O +
, O +
especially O +
S O +
and O +
X2 O +
, O +
of O +
the O +
DR O +
alpha O +
proximal O +
promoter O +
in O +
group B-CellLine +
II I-CellLine +
CID I-CellLine +
cells I-CellLine +
is O +
CIITA O +
dependent O +
. O +

Since O +
CIITA O +
overexpression O +
in O +
normal O +
cells O +
did O +
not O +
increase O +
class O +
II O +
expression O +
, O +
we O +
propose O +
that O +
initiation O +
of O +
CIITA O +
expression O +
serves O +
as O +
the O +
on O -
- O -
off O +
switch O +
, O +
while O +
availability O +
of O +
downstream O +
interactor O +
( O +
s O +
) O +
limits O +
transcription O +
. O +

CAG O +
repeat O +
length O +
variation O +
in O +
sperm O +
from O +
a O +
patient O +
with O +
Kennedy O +
's O +
disease O +
. O +

Using O +
a O +
modified O +
sperm O +
typing O +
protocol O +
, O +
the O +
mutation O +
frequency O +
of O +
the O +
CAG O +
repeat O +
region O +
at O +
the O +
androgen O +
receptor O +
locus O +
has O +
been O +
measured O +
using O +
a O +
rare O +
semen O +
sample O +
from O +
an O +
individual O +
with O +
spinal O +
and O +
bulbar O +
muscular O +
atrophy O +
( O +
SBMA O +
) O +
. O +

Among O +
258 O +
X O +
chromosome O -
- O -
containing O +
sperm O +
, O +
19 O +
% O +
had O +
a O +
repeat O +
number O +
equal O +
to O +
the O +
donor O +
's O +
somatic O +
DNA O +
( O +
47 O +
repeats O +
) O +
, O +
66 O +
% O +
were O +
expansions O +
and O +
15 O +
% O +
were O +
contractions O +
. O +

The O +
average O +
expansion O +
was O +
2.7 O +
repeats O +
. O +

More O +
than O +
half O +
of O +
the O +
expansions O +
involved O +
one O +
or O +
two O +
repeats O +
; O +
the O +
largest O +
was O +
11 O +
repeats O +
. O +

68 O +
% O +
of O +
the O +
contractions O +
were O +
also O +
one O +
or O +
two O +
repeats O +
but O +
six O +
( O +
16 O +
% O +
) O +
were O +
very O +
large O +
( O +
12 O -
- O -
25 O +
repeats O +
) O +
. O +

One O +
contraction O +
generated O +
an O +
allele O +
in O +
an O +
intermediate O +
size O +
range O +
( O +
33 O -
- O -
39 O +
repeats O +
) O +
. O +

Such O +
alleles O +
have O +
not O +
been O +
observed O +
among O +
more O +
than O +
900 O +
normal O +
and O +
SBMA O +
X O -
- O -
chromosomes O +
that O +
have O +
been O +
examined O +
. O +

Comparison O +
of O +
the O +
SBMA O +
sperm O +
typing O +
results O +
with O +
mutation O +
frequency O +
data O +
on O +
normal O +
alleles O +
supports O +
the O +
hypothesis O +
that O +
trinucleotide O +
repeat O +
expansions O +
may O +
have O +
a O +
different O +
molecular O +
origin O +
than O +
contractions O +
. O +

Isolation O +
of O +
differentially O +
expressed O +
sequence O +
tags O +
from O +
steroid O -
- O -
responsive O +
cells O +
using O +
mRNA O +
differential O +
display O +
. O +

Transcriptional O +
control O +
of O +
steroid O -
- O -
regulated O +
gene O +
networks O +
by O +
nuclear O +
receptor O +
proteins O +
results O +
in O +
the O +
coordinate O +
expression O +
of O +
a O +
limited O +
number O +
of O +
target O +
genes O +
. O +

Although O +
much O +
is O +
known O +
about O +
the O +
structure O +
and O +
function O +
of O +
steroid O +
receptors O +
, O +
relatively O +
few O +
cell O -
- O -
specific O +
steroid O -
- O -
regulated O +
genes O +
have O +
been O +
isolated O +
and O +
characterized O +
. O +

In O +
this O +
paper O +
we O +
describe O +
results O +
using O +
mRNA O +
differential O +
display O +
reverse O +
transcriptase O +
PCR O +
( O +
DDPCR O +
) O +
to O +
identify O +
and O +
isolate O +
short O +
cDNA O +
sequence O +
tags O +
from O +
thymocyte O +
and O +
prostate O +
cells O +
under O +
various O +
hormone O +
conditions O +
. O +

Using O +
this O +
technique O +
we O +
have O +
isolated O +
several O +
differentially O +
expressed O +
sequence O +
tags O +
( O +
DESTs O +
) O +
from O +
the O +
mouse B-CellLine +
thymocyte I-CellLine +
cell I-CellLine +
line I-CellLine +
WEHI B-CellLine +
7.2 I-CellLine +
. O +

Two O +
of O +
these O +
DESTs O +
, O +
GIG10 O +
and O +
GIG18 O +
, O +
are O +
rapidly O +
induced O +
by O +
dexamethasone O +
within O +
2 O +
h O +
of O +
treatment O +
. O +

GIG10 O +
is O +
a O +
novel O +
sequence O +
and O +
GIG18 O +
is O +
the O +
mouse O +
homologue O +
of O +
a O +
human O +
expressed O +
sequence O +
tag O +
isolated O +
from O +
activated O +
B O +
lymphocytes O +
. O +

We O +
also O +
used O +
DDPCR O +
to O +
isolate O +
DESTs O +
from O +
androgen O -
- O -
modulated O +
rat O +
ventral O +
prostate O +
tissue O +
, O +
one O +
of O +
which O +
we O +
characterized O +
and O +
found O +
to O +
correspond O +
to O +
the O +
3 O +
' O +
end O +
of O +
prostatic O +
spermine O +
binding O +
protein O +
mRNA O +
, O +
a O +
known O +
androgen O -
- O -
regulated O +
gene O +
. O +

Modifications O +
of O +
the O +
original O +
DDPCR O +
protocol O +
, O +
which O +
we O +
found O +
can O +
potentially O +
decrease O +
the O +
frequency O +
of O +
isolating O +
false O -
- O -
positive O +
DESTs O +
, O +
are O +
described O +
and O +
the O +
merits O +
of O +
DDPCR O +
, O +
relative O +
to O +
other O +
differential O +
cDNA O +
cloning O +
strategies O +
, O +
are O +
discussed O +
. O +

Abnormal O +
regulation O +
of O +
the O +
IL-2 O +
promoter O +
in O +
lpr O +
CD4-CD8- B-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
results O +
in O +
constitutive O +
expression O +
of O +
a O +
novel O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O -
- O -
binding O +
factor O +
. O +

The O +
inert O +
quality O +
of O +
MRL B-CellLine -
- I-CellLine -
Ipr I-CellLine -
/ I-CellLine -
Ipr I-CellLine +
( I-CellLine +
Ipr I-CellLine +
) I-CellLine +
peripheral I-CellLine +
CD4-CD8- I-CellLine +
( I-CellLine +
CD4 I-CellLine -
- I-CellLine -
8- I-CellLine +
) I-CellLine +
T I-CellLine +
cells I-CellLine +
manifests O +
primarily O +
as O +
an O +
inability O +
to O +
proliferate O +
or O +
produce O +
IL-2 O +
in O +
response O +
to O +
TCR O +
or O +
mitogenic O +
stimulation O +
. O +

Yet O +
these O +
same O +
cells O +
do O +
initiate O +
early O +
TCR O +
-mediated O +
signaling O +
events O +
, O +
such O +
as O +
generation O +
of O +
inositol O +
phosphates O +
and O +
increased O +
intracellular O +
calcium O +
. O +

They O +
also O +
display O +
constitutively O +
high O +
levels O +
of O +
p59fyn O +
and O +
CD3 O +
zeta O +
tyrosine O +
phosphorylation O +
. O +

The O +
generation O +
of O +
second O +
messengers O +
in O +
T O +
cells O +
normally O +
leads O +
to O +
downstream O +
signaling O +
that O +
results O +
in O +
transcriptional O +
activation O +
of O +
the O +
IL-2 O +
gene O +
. O +

We O +
, O +
therefore O +
, O +
compared O +
the O +
activation O +
state O +
of O +
the O +
IL-2 O +
gene O +
promoter O +
region O +
in O +
freshly O +
isolated O +
and O +
stimulated O +
Ipr B-CellLine +
CD4 I-CellLine -
- I-CellLine -
8- I-CellLine +
T I-CellLine +
cells I-CellLine +
with O +
that O +
of O +
normal O +
T O +
lymphocytes O +
. O +

Levels O +
of O +
the O +
octamer O +
, O +
NF O -
- O -
kappa O +
B O +
( O +
p50-p65 O +
heterodimer O +
) O +
, O +
and O +
AP-1 O +
transcriptional O +
factors O +
are O +
constitutively O +
elevated O +
in O +
freshly O +
isolated O +
Ipr B-CellLine +
CD4 I-CellLine -
- I-CellLine -
8- I-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
consistent O +
with O +
the O +
activated O +
phenotype O +
of O +
these O +
cells O +
. O +

Upon O +
stimulation O +
with O +
mitogens O +
, O +
formation O +
of O +
the O +
transactivating O +
complex O +
, O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NF O -
- O -
AT O +
) O +
, O +
occurs O +
with O +
normal O +
kinetics O +
in O +
Ipr B-CellLine +
CD4 I-CellLine -
- I-CellLine -
8- I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Yet O +
, O +
the O +
levels O +
of O +
the O +
activating O +
NF O -
- O -
AT O +
complex O +
never O +
reach O +
those O +
observed O +
in O +
similarly O +
stimulated O +
normal O +
T O +
cells O +
. O +

Furthermore O +
, O +
nuclear O +
extracts O +
from O +
Ipr B-CellLine +
CD4 I-CellLine -
- I-CellLine -
8- I-CellLine +
T I-CellLine +
cells I-CellLine +
display O +
high O +
levels O +
of O +
a O +
novel O +
specific O +
binding O +
activity O +
at O +
the O +
NF O -
- O -
AT O +
site O +
, O +
which O +
is O +
present O +
at O +
much O +
lower O +
levels O +
in O +
freshly O +
isolated O +
normal O +
T O +
lymphocytes O +
. O +

Upon O +
mitogenic O +
stimulation O +
, O +
the O +
binding O +
activity O +
of O +
the O +
novel O +
NF O -
- O -
AT O -
- O -
binding O +
factor O +
is O +
rapidly O +
down O -
- O -
regulated O +
in O +
normal O +
T O +
cells O +
, O +
but O +
persists O +
at O +
high O +
levels O +
in O +
Ipr B-CellLine +
CD4 I-CellLine -
- I-CellLine -
8- I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

These O +
two O +
abnormalities O +
at O +
the O +
NF O -
- O -
AT O +
site O +
provide O +
a O +
potential O +
mechanism O +
to O +
account O +
for O +
the O +
defect O +
in O +
IL-2 O +
production O +
from O +
Ipr B-CellLine +
CD4 I-CellLine -
- I-CellLine -
8- I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Ligand O -
- O -
dependent O +
repression O +
of O +
the O +
erythroid O +
transcription O +
factor O +
GATA-1 O +
by O +
the O +
estrogen O +
receptor O +
. O +

High O -
- O -
dose O +
estrogen O +
administration O +
induces O +
anemia O +
in O +
mammals O +
. O +

In O +
chickens O +
, O +
estrogens O +
stimulate O +
outgrowth O +
of O +
bone O +
marrow O -
- O -
derived O +
erythroid O +
progenitor O +
cells O +
and O +
delay O +
their O +
maturation O +
. O +

This O +
delay O +
is O +
associated O +
with O +
down O -
- O -
regulation O +
of O +
many O +
erythroid O +
cell O -
- O -
specific O +
genes O +
, O +
including O +
alpha- O +
and O +
beta O -
- O -
globin O +
, O +
band O +
3 O +
, O +
band O +
4.1 O +
, O +
and O +
the O +
erythroid O +
cell O -
- O -
specific O +
histone O +
H5 O +
. O +

We O +
show O +
here O +
that O +
estrogens O +
also O +
reduce O +
the O +
number O +
of O +
erythroid O +
progenitor O +
cells O +
in O +
primary B-CellLine +
human I-CellLine +
bone I-CellLine +
marrow I-CellLine +
cultures I-CellLine +
. O +

To O +
address O +
potential O +
mechanisms O +
by O +
which O +
estrogens O +
suppress O +
erythropoiesis O +
, O +
we O +
have O +
examined O +
their O +
effects O +
on O +
GATA-1 O +
, O +
an O +
erythroid O +
transcription O +
factor O +
that O +
participates O +
in O +
the O +
regulation O +
of O +
the O +
majority O +
of O +
erythroid O +
cell O -
- O -
specific O +
genes O +
and O +
is O +
necessary O +
for O +
full O +
maturation O +
of O +
erythrocytes O +
. O +

We O +
demonstrate O +
that O +
the O +
transcriptional O +
activity O +
of O +
GATA-1 O +
is O +
strongly O +
repressed O +
by O +
the O +
estrogen O +
receptor O +
( O +
ER O +
) O +
in O +
a O +
ligand O -
- O -
dependent O +
manner O +
and O +
that O +
this O +
repression O +
is O +
reversible O +
in O +
the O +
presence O +
of O +
4-hydroxytamoxifen O +
. O +

ER O +
-mediated O +
repression O +
of O +
GATA-1 O +
activity O +
occurs O +
on O +
an O +
artificial O +
promoter O +
containing O +
a O +
single O +
GATA O -
- O -
binding O +
site O +
, O +
as O +
well O +
as O +
in O +
the O +
context O +
of O +
an O +
intact O +
promoter O +
which O +
is O +
normally O +
regulated O +
by O +
GATA-1 O +
. O +

GATA-1 O +
and O +
ER O +
bind O +
to O +
each O +
other O +
in O +
vitro O +
in O +
the O +
absence O +
of O +
DNA O +
. O +

In O +
coimmunoprecipitation O +
experiments O +
using O +
transfected O +
COS B-CellLine +
cells I-CellLine +
, O +
GATA-1 O +
and O +
ER O +
associate O +
in O +
a O +
ligand O -
- O -
dependent O +
manner O +
. O +

Mapping O +
experiments O +
indicate O +
that O +
GATA-1 O +
and O +
the O +
ER O +
form O +
at O +
least O +
two O +
contacts O +
, O +
which O +
involve O +
the O +
finger O +
region O +
and O +
the O +
N O -
- O -
terminal O +
activation O +
domain O +
of O +
GATA-1 O +
. O +

We O +
speculate O +
that O +
estrogens O +
exert O +
effects O +
on O +
erythropoiesis O +
by O +
modulating O +
GATA-1 O +
activity O +
through O +
protein O -
- O -
protein O +
interaction O +
with O +
the O +
ER O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

Activation O +
of O +
pp90rsk O +
and O +
early O +
growth O +
response-1 O +
gene O +
expression O +
by O +
pokeweed O +
mitogen O +
in O +
human O +
B O +
cells O +
. O +

The O +
present O +
studies O +
have O +
examined O +
the O +
effects O +
of O +
pokeweed O +
mitogen O +
( O +
PWM O +
) O +
on O +
the O +
induction O +
of O +
early O +
growth O +
response-1 O +
gene O +
( O +
EGR-1 O +
) O +
in O +
normal O +
human O +
B O +
cells O +
. O +

PWM O +
regulates O +
EGR-1 O +
gene O +
expression O +
by O +
both O +
transcriptional O +
and O +
post O -
- O -
transcriptional O +
mechanisms O +
. O +

Transient O +
transfection O +
assays O +
with O +
EGR-1 O +
promoter O +
fragments O +
linked O +
to O +
the O +
chloramphenicol O +
acetyltransferase O +
( O +
CAT O +
) O +
gene O +
demonstrated O +
that O +
PWM O +
induced O +
EGR-1 O +
transcription O +
is O +
conferred O +
by O +
the O +
CArG O +
motif O +
( O +
C O +
C O +
[ O +
AT O +
] O +
6GG O +
) O +
in O +
the O +
EGR-1 O +
promoter O +
. O +

The O +
results O +
further O +
demonstrated O +
the O +
activation O +
of O +
S6 O +
kinase O +
( O +
pp90rsk O +
) O +
, O +
evidenced O +
by O +
phosphorylation O +
of O +
S6 O +
and O +
serum O +
response O +
factor O +
( O +
SRF O +
) O +
peptides O +
, O +
in O +
PWM B-CellLine +
treated I-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

Taken O +
together O +
, O +
these O +
findings O +
suggest O +
that O +
PWM O +
is O +
able O +
to O +
initiate O +
an O +
intracytoplasmic O +
signalling O +
cascade O +
and O +
EGR-1 O +
induction O +
in O +
normal O +
human O +
B O +
cells O +
. O +

Infection O +
with O +
Theileria O +
annulata O +
induces O +
expression O +
of O +
matrix O +
metalloproteinase O +
9 O +
and O +
transcription O +
factor O +
AP-1 O +
in O +
bovine O +
leucocytes O +
. O +

Theileria O +
annulata O +
infects O +
bovine O +
leucocytes O +
and O +
results O +
in O +
their O +
reversible O +
transformation O +
such O +
that O +
they O +
become O +
immortalised O +
and O +
metastatic O +
. O +

The O +
present O +
study O +
describes O +
parasite O -
- O -
induced O +
changes O +
in O +
host O +
cell O +
gene O +
expression O +
which O +
have O +
a O +
direct O +
bearing O +
on O +
this O +
transformation O +
process O +
. O +

T. O +
annulata O -
- O -
infected O +
leucocytes O +
produce O +
a O +
number O +
of O +
novel O +
metalloproteinase O +
activities O +
. O +

One O +
of O +
these O +
, O +
previously O +
called O +
B1 O +
, O +
is O +
a O +
97-kDa O +
protein O +
which O +
is O +
secreted O +
in O +
large O +
amounts O +
and O +
has O +
been O +
purified O +
from O +
protein O -
- O -
free O +
, O +
conditioned O +
medium O +
. O +

An O +
antiserum O +
to O +
this O +
enzyme O +
was O +
used O +
to O +
isolate O +
a O +
cDNA O +
clone O +
. O +

The O +
predicted O +
protein O +
sequence O +
of O +
B1 O +
is O +
81 O +
% O +
identical O +
to O +
human O +
matrix O +
metalloproteinase O +
9 O +
( O +
MMP9 O +
) O +
, O +
demonstrating O +
that O +
it O +
is O +
the O +
bovine O +
homologue O +
of O +
this O +
enzyme O +
. O +

RNAase O +
protection O +
assays O +
demonstrated O +
that O +
the O +
MMP9 O +
activity O +
, O +
unique O +
to O +
infected O +
cells O +
, O +
is O +
due O +
to O +
increased O +
MMP9 O +
mRNA O +
levels O +
. O +

We O +
also O +
assayed O +
the O +
levels O +
of O +
transcription O +
factor O +
AP-1 O +
and O +
demonstrated O +
that O +
it O +
was O +
constitutively O +
present O +
in O +
increased O +
amounts O +
in O +
Theileria O -
- O -
infected O +
cells O +
. O +

In O +
addition O +
we O +
assayed O +
the O +
level O +
of O +
mRNA O +
encoding O +
c O -
- O -
Fos O +
, O +
a O +
common O +
component O +
of O +
AP-1 O +
and O +
observed O +
that O +
it O +
was O +
indeed O +
up O -
- O -
regulated O +
in O +
infected O +
cells O +
. O +

Since O +
AP-1 O +
is O +
implicated O +
in O +
the O +
control O +
of O +
the O +
cell O +
cycle O +
, O +
and O +
MMP9 O +
can O +
confer O +
metastatic O +
properties O +
, O +
these O +
results O +
are O +
of O +
considerable O +
significance O +
with O +
respect O +
to O +
the O +
transformed O +
phenotype O +
induced O +
by O +
Theileria O +
infection O +
. O +

Reduced O +
mitogenic O +
stimulation O +
of O +
peripheral O +
blood O +
mononuclear O +
cells O +
as O +
a O +
prognostic O +
parameter O +
for O +
the O +
course O +
of O +
breast O +
cancer O +
: O +
a O +
prospective O +
longitudinal O +
study O +
. O +

Immunosuppression O +
has O +
been O +
often O +
associated O +
with O +
the O +
course O +
of O +
malignant O +
diseases O +
. O +

In O +
the O +
present O +
study O +
, O +
the O +
proliferation O +
of O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMCs O +
) O +
in O +
response O +
to O +
mitogenic O +
stimulation O +
with O +
phytohaemagglutinin O +
( O +
PHA O +
) O +
was O +
assessed O +
prospectively O +
in O +
90 O +
patients O +
with O +
stage O +
I O -
- O -
III O +
breast O +
cancer O +
. O +

Whereas O +
PHA O +
-induced O +
proliferation O +
of O +
PBMCs O +
derived O +
from O +
patients O +
with O +
breast O +
cancer O +
preoperatively O +
was O +
significantly O +
decreased O +
when O +
compared O +
with O +
data O +
obtained O +
in O +
healthy O +
control O +
individuals O +
( O +
P O +
< O +
0.001 O +
) O +
, O +
the O +
degree O +
of O +
the O +
defect O +
in O +
PHA O +
-induced O +
proliferation O +
of O +
PBMCs O +
depended O +
upon O +
the O +
tumour O +
burden O +
as O +
manifested O +
by O +
tumour O +
size O +
and O +
axillary O +
lymph O +
node O +
involvement O +
( O +
P O +
< O +
0.003 O +
in O +
each O +
case O +
) O +
. O +

PHA O +
-induced O +
proliferation O +
of O +
PBMCs O +
dropped O +
significantly O +
in O +
patients O +
who O +
received O +
adjuvant O +
chemotherapy O +
consisting O +
of O +
cyclophosphamide O +
, O +
methotrexate O +
and O +
fluorouracil O +
( O +
CMF O +
) O +
after O +
an O +
observation O +
period O +
of O +
6 O +
months O +
( O +
P O +
< O +
0.01 O +
) O +
, O +
but O +
not O +
in O +
patients O +
under O +
adjuvant O +
treatment O +
with O +
tamoxifen O +
only O +
. O +

After O +
an O +
additional O +
6 O +
months O +
( O +
i.e. O +
12 O +
months O +
after O +
surgery O +
) O +
, O +
PHA O +
-induced O +
proliferation O +
of O +
PBMCs O +
was O +
similar O +
in O +
patients O +
after O +
adjuvant O +
chemotherapy O +
with O +
CMF O +
and O +
in O +
those O +
receiving O +
continued O +
adjuvant O +
tamoxifen O +
treatment O +
( O +
P O +
> O +
0.1 O +
) O +
, O +
but O +
in O +
all O +
patients O +
still O +
significantly O +
decreased O +
as O +
compared O +
with O +
healthy O +
controls O +
( O +
P O +
< O +
0.001 O +
) O +
. O +

When O +
data O +
obtained O +
preoperatively O +
and O +
after O +
12 O +
months O +
were O +
compared O +
, O +
it O +
was O +
found O +
that O +
out O +
of O +
23 O +
patients O +
whose O +
PBMCs O +
had O +
experienced O +
a O +
drop O +
in O +
their O +
PHA O +
-induced O +
proliferation O +
, O +
14 O +
( O +
61 O +
% O +
) O +
had O +
developed O +
metastatic O +
disease O +
within O +
the O +
subsequent O +
24 O +
months O +
( O +
i.e. O +
36 O +
months O +
after O +
surgery O +
) O +
. O +

In O +
contrast O +
, O +
out O +
of O +
59 O +
patients O +
whose O +
PBMCs O +
showed O +
an O +
increase O +
in O +
their O +
PHA O +
-induced O +
proliferation O +
within O +
the O +
first O +
12 O +
months O +
after O +
surgery O +
, O +
only O +
one O +
( O +
2 O +
% O +
) O +
presented O +
with O +
disease O +
progression O +
. O +

We O +
thus O +
conclude O +
that O +
PHA O +
-induced O +
proliferation O +
of O +
PBMCs O +
derived O +
from O +
patients O +
with O +
breast O +
cancer O +
depends O +
upon O +
the O +
tumour O +
load O +
and O +
is O +
a O +
good O +
clinical O +
predictor O +
for O +
the O +
further O +
course O +
of O +
the O +
disease O +
. O +

Expression O +
of O +
Ah O +
receptor O +
( O +
TCDD O +
receptor O +
) O +
during O +
human O +
monocytic O +
differentiation O +
. O +

We O +
have O +
previously O +
found O +
a O +
high O +
expression O +
of O +
human O +
Ah O +
receptor O +
( O +
TCDD O +
receptor O +
) O +
mRNA O +
in O +
peripheral O +
blood O +
cells O +
of O +
individuals O +
. O +

In O +
this O +
paper O +
, O +
the O +
expression O +
of O +
this O +
gene O +
in O +
blood O +
cells O +
was O +
first O +
investigated O +
in O +
fractions O +
of O +
nucleated O +
cells O +
, O +
revealing O +
predominant O +
expression O +
of O +
the O +
Ah O +
receptor O +
gene O +
in O +
the O +
monocyte O +
fraction O +
. O +

Then O +
the O +
expression O +
levels O +
of O +
AhR O +
mRNA O +
in O +
various O +
hematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
were O +
examined O +
together O +
with O +
those O +
of O +
Arnt O +
and O +
P450IA1 O +
. O +

AhR O +
was O +
expressed O +
at O +
high O +
levels O +
in O +
monocytoid B-CellLine +
U937 I-CellLine +
, O +
THP1 B-CellLine +
, O +
and O +
HEL B-CellLine -
/ I-CellLine -
S I-CellLine +
cells I-CellLine +
, O +
and O +
at O +
moderate O +
levels O +
in O +
promyelocytic B-CellLine +
HL60 I-CellLine +
cells I-CellLine +
and O +
erythroblastic B-CellLine +
HEL I-CellLine +
cells I-CellLine +
. O +

However O +
, O +
it O +
was O +
not O +
detected O +
in O +
lymphoid O +
cells O +
MOLT4 B-CellLine +
( O +
T O +
cell O +
) O +
and O +
BALL1 B-CellLine +
( O +
B O +
cell O +
) O +
, O +
nor O +
in O +
K562 B-CellLine +
erythroblasts I-CellLine +
. O +

Furthermore O +
, O +
a O +
specific O +
induction O +
of O +
AhR O +
during O +
monocytic O +
differentiation O +
was O +
investigated O +
in O +
HL60 B-CellLine +
and O +
HEL B-CellLine +
cells I-CellLine +
. O +

HL60 B-CellLine +
cells I-CellLine +
were O +
induced O +
to O +
differentiate O +
toward O +
monocytes O -
- O -
macrophages O +
by O +
incubation O +
with O +
phorbol O +
ester O +
, O +
showing O +
a O +
5- O +
to O +
2-fold O +
increase O +
of O +
AhR O +
mRNA O +
. O +

The O +
incubation O +
with O +
transforming O +
growth O +
factor O +
beta O +
1 O +
and O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
resulted O +
in O +
a O +
5- O +
to O +
7-fold O +
increase O +
of O +
AhR O +
mRNA O +
. O +

The O +
HEL B-CellLine +
cells I-CellLine +
also O +
exhibited O +
a O +
similar O +
elevation O +
of O +
AhR O +
mRNA O +
level O +
, O +
when O +
they O +
had O +
differentiated O +
toward O +
monocyte O -
- O -
macrophage O +
cells O +
by O +
these O +
combined O +
inducers O +
, O +
but O +
little O +
change O +
in O +
the O +
mRNA O +
level O +
was O +
observed O +
when O +
the O +
cells O +
were O +
induced O +
to O +
differentiate O +
into O +
other O +
cell O +
types O +
. O +

Treatment O +
of O +
the O +
differentiated B-CellLine +
HL60 I-CellLine +
cells I-CellLine +
with O +
3-methylcholanthrene O +
, O +
a O +
ligand O +
of O +
AhR O +
, O +
induced O +
the O +
expression O +
of O +
the O +
P450IA1 O +
gene O +
. O +

These O +
results O +
indicated O +
that O +
expression O +
of O +
AhR O +
mRNA O +
was O +
significantly O +
induced O +
during O +
monocytic O +
differentiation O +
and O +
that O +
the O +
differentiated O +
cells O +
were O +
responsive O +
to O +
xenobiotics O +
. O +

Our O +
results O +
suggest O +
that O +
AhR O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
function O +
of O +
monocytes O +
and O +
also O +
in O +
the O +
eventual O +
activation O +
of O +
environmental O +
carcinogens O +
. O +

Danazol O +
decreases O +
transcription O +
of O +
estrogen O +
receptor O +
gene O +
in O +
human O +
monocytes O +
. O +

1 O -
. O +
Administration O +
of O +
danazol O +
for O +
over O +
one O +
month O +
reduced O +
the O +
levels O +
of O +
estrogen O +
receptor O +
( O +
ER O +
) O +
and O +
its O +
mRNA O +
to O +
approximately O +
50 O +
and O +
20 O +
% O +
, O +
respectively O +
in O +
monocytes O +
. O +

2 O -
. O +
Danazol O +
did O +
not O +
alter O +
the O +
degradation O +
rate O +
of O +
ER O +
mRNA O +
in O +
monocytes O +
. O +

3 O -
. O +
Danazol O +
decreased O +
the O +
transcription O +
rate O +
of O +
ER O +
gene O +
to O +
approximately O +
50 O +
% O +
in O +
monocytes O +
in O +
a O +
run O -
- O -
on O +
assay O +
. O +

4 O -
. O +
Danazol O +
may O +
release O +
estrogen O +
predominance O +
via O +
the O +
reduction O +
of O +
transcription O +
for O +
ER O +
gene O +
, O +
which O +
leads O +
to O +
the O +
reduction O +
of O +
ER O +
mRNA O +
and O +
ER O +
expressions O +
in O +
monocytes O +
. O +

Physiological O +
concentration O +
of O +
estradiol O +
inhibits O +
polymorphonuclear O +
leukocyte O +
chemotaxis O +
via O +
a O +
receptor O +
mediated O +
system O +
. O +

Estrogen O +
exhibits O +
a O +
variety O +
of O +
actions O +
, O +
including O +
immuno O -
- O -
modulatory O +
effects O +
, O +
in O +
vivo O +
and O +
in O +
vitro O +
. O +

The O +
mechanism O +
by O +
which O +
estrogen O +
exerts O +
its O +
anti O -
- O -
inflammatory O +
effect O +
is O +
not O +
yet O +
understood O +
. O +

We O +
investigated O +
the O +
possible O +
mechanisms O +
of O +
estradiol O +
acting O +
via O +
the O +
polymorphonuclear O +
leukocytes O +
( O +
PMNs O +
) O +
, O +
which O +
are O +
important O +
in O +
the O +
immune O +
response O +
. O +

The O +
agent O +
, O +
17 O +
beta O -
- O -
estradiol O +
, O +
but O +
not O +
17 O +
alpha O -
- O -
estradiol O +
, O +
significantly O +
reduced O +
PMNs O +
chemotaxis O +
to O +
FMLP O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O +
control O +
vs O +
estrogen O +
10 O +
( O +
-10 O +
) O +
- O +
( O +
-6 O +
) O +
M O +
, O +
P O +
< O +
0.05 O +
) O +
. O +

Physiological O +
concentrations O +
of O +
estradiol O +
significantly O +
reduced O +
the O +
chemotaxis O +
of O +
PMNs O +
( O +
10 O +
( O +
-10 O +
) O +
mol O +
) O +
. O +

Pre O -
- O -
incubation O +
with O +
clomiphene O +
or O +
tamoxifen O +
which O +
are O +
estrogen O +
receptor O +
antagonists O +
, O +
eliminated O +
the O +
inhibitory O +
effect O +
of O +
17 O +
beta O -
- O -
estradiol O +
on O +
the O +
chemotaxis O +
of O +
PMNs O +
, O +
restoring O +
it O +
to O +
the O +
control O +
level O +
. O +

These O +
observations O +
suggest O +
that O +
17 O +
beta O -
- O -
estradiol O +
suppressed O +
the O +
chemotaxis O +
of O +
PMNs O +
by O +
a O +
receptor O -
- O -
dependent O +
mechanism O +
. O +

In O +
addition O +
, O +
the O +
level O +
of O +
estradiol O +
in O +
human O +
plasma O +
, O +
which O +
PMNs O +
were O +
drawn O +
, O +
showed O +
a O +
close O +
, O +
inverse O +
correlation O +
with O +
the O +
PMNs O +
chemotaxis O +
to O +
FMLP O +
( O +
r O +
= O +
-0.821 O +
p O +
< O +
0.001 O +
) O +
. O +

Estrogen O +
may O +
modify O +
the O +
activity O +
of O +
neutrophils O +
during O +
the O +
normal O +
menstrual O +
cycle O +
, O +
not O +
only O +
during O +
pregnancy O +
, O +
and O +
influence O +
inflammation O +
. O +

Cross O -
- O -
linking O +
of O +
CD30 O +
induces O +
HIV O +
expression O +
in O +
chronically O +
infected O +
T O +
cells O +
. O +

CD30 O +
, O +
a O +
member O +
of O +
the O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
receptor O +
family O +
, O +
is O +
expressed O +
constitutively O +
on O +
the O +
surface O +
of O +
the O +
human O +
T O +
cell O +
line O +
ACH-2 O +
, O +
which O +
is O +
chronically O +
infected O +
with O +
human O +
immunodeficiency O +
virus O +
type-1 O +
( O +
HIV O +
) O +
-1 O +
. O +

We O +
demonstrate O +
that O +
cross O -
- O -
linking O +
CD30 O +
with O +
an O +
anti- O +
CD30 O +
-specific O +
monoclonal O +
antibody O +
, O +
which O +
mimics O +
the O +
described O +
biological O +
activities O +
of O +
the O +
CD30 O +
ligand O +
( O +
CD30L O +
) O +
, O +
results O +
in O +
HIV O +
expression O +
. O +

CD30 O +
cross O -
- O -
linking O +
does O +
not O +
alter O +
proliferation O +
of O +
ACH-2 B-CellLine +
cells I-CellLine +
and O +
the O +
induction O +
of O +
HIV O +
expression O +
is O +
not O +
mediated O +
by O +
endogenous O +
TNF O +
alpha O -
/ O -
beta O +
. O +

Furthermore O +
, O +
cross O -
- O -
linking O +
of O +
CD30 O +
leads O +
to O +
NF O -
- O -
kappa O +
B O +
activation O +
and O +
enhanced O +
HIV O +
transcription O +
. O +

Thus O +
, O +
CD30 O +
-CD30L O +
interactions O +
mediate O +
the O +
induction O +
of O +
HIV O +
expression O +
by O +
a O +
kappa O +
B O -
- O -
dependent O +
pathway O +
that O +
is O +
independent O +
of O +
TNF O +
. O +

This O +
mechanism O +
may O +
be O +
important O +
in O +
the O +
activation O +
of O +
HIV O +
expression O +
from O +
latently O +
infected O +
CD4 B-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
especially O +
in O +
lymphoid O +
organs O +
where O +
cell O +
to O +
cell O +
contact O +
is O +
conducive O +
to O +
receptor O -
- O -
ligand O +
interactions O +
. O +

The O +
activation O +
of O +
the O +
Jak O +
-STAT O +
1 O +
signaling O +
pathway O +
by O +
IL-5 O +
in O +
eosinophils O +
. O +

The O +
intracellular O +
signal O +
transduction O +
of O +
IL-5 O +
in O +
eosinophils O +
is O +
unknown O +
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
involvement O +
of O +
the O +
newly O +
discovered O +
Jak O +
-STAT O +
pathway O +
in O +
the O +
IL-5 O +
signal O +
transduction O +
mechanism O +
. O +

Eosinophils O +
were O +
purified O +
from O +
peripheral O +
blood O +
by O +
discontinuous O +
Percoll O +
gradients O +
and O +
stimulated O +
with O +
IL-5 O +
. O +

The O +
involvement O +
of O +
Jak O +
2 O +
was O +
investigated O +
by O +
immunoprecipitation O +
followed O +
by O +
immunoblotting O +
for O +
tyrosine O +
phosphorylation O +
. O +

The O +
activation O +
of O +
Jak O +
2 O +
was O +
studied O +
by O +
autophosphorylation O +
of O +
the O +
immunoprecipitated O +
kinase O +
. O +

Jak O +
2 O +
was O +
tyrosine O +
phosphorylated O +
within O +
1 O +
to O +
3 O +
min O +
after O +
stimulation O +
of O +
eosinophils O +
with O +
IL-5 O +
. O +

Further O +
, O +
the O +
immunoprecipitated O +
Jak O +
2 O +
obtained O +
from O +
IL-5-stimulated B-CellLine +
cells I-CellLine +
underwent O +
autophosphorylation O +
. O +

Jak O +
2 O +
coprecipitated O +
with O +
the O +
beta O -
- O -
subunit O +
of O +
the O +
IL-5 O +
receptor O +
, O +
suggesting O +
a O +
physical O +
association O +
of O +
the O +
kinase O +
with O +
the O +
receptor O +
. O +

The O +
nuclear O +
factor O +
STAT-1 O +
( O +
p91 O +
) O +
was O +
investigated O +
by O +
immunoprecipitation O +
followed O +
by O +
immunoblotting O +
for O +
tyrosine O +
phosphorylation O +
. O +

STAT-1 O +
was O +
tyrosine O +
phosphorylated O +
within O +
15 O +
min O +
of O +
IL-5 O +
stimulation O +
. O +

The O +
presence O +
of O +
STAT-1 O +
in O +
the O +
nuclear O +
extract O +
was O +
studied O +
by O +
electrophoretic O +
mobility O +
shift O +
assay O +
. O +

IL-5 O +
induced O +
two O +
proteins O +
that O +
bound O +
to O +
the O +
gamma O -
- O -
activating O +
sequence O +
. O +

In O +
the O +
presence O +
of O +
an O +
anti O -
- O -
STAT-1 O +
Ab O +
, O +
the O +
band O +
was O +
supershifted O +
. O +

Thus O +
, O +
we O +
demonstrated O +
that O +
IL-5 O +
activated O +
the O +
Jak O +
2 O +
-STAT O +
1 O +
signaling O +
pathway O +
in O +
eosinophils O +
. O +

We O +
speculate O +
that O +
the O +
Jak O +
2 O +
-STAT O +
1 O +
pathway O +
may O +
be O +
involved O +
in O +
the O +
activation O +
of O +
IL-5-inducible O +
genes O +
in O +
eosinophils O +
. O +

Constitutively O +
activated O +
Jak O +
-STAT O +
pathway O +
in O +
T O +
cells O +
transformed O +
with O +
HTLV O -
- O -
I O +
. O +

Human O +
T O +
cell O +
lymphotropic O +
virus O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
is O +
the O +
etiological O +
agent O +
for O +
adult O +
T O +
cell O +
leukemia O +
and O +
tropical O +
spastic O +
paraparesis O +
( O +
also O +
termed O +
HTLV O -
- O -
I O -
- O -
associated O +
myelopathy O +
) O +
. O +

HTLV O -
- O -
I O -
- O -
infected O +
peripheral O +
blood O +
T O +
cells O +
exhibit O +
an O +
initial O +
phase O +
of O +
interleukin-2 O +
( O +
IL-2 O +
) O +
-dependent O +
growth O +
; O +
over O +
time O +
, O +
by O +
an O +
unknown O +
mechanism O +
, O +
the O +
cells O +
become O +
IL-2 O +
-independent O +
. O +

Whereas O +
the O +
Jak O +
kinases O +
Jak1 O +
and O +
Jak3 O +
and O +
the O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
proteins O +
Stat3 O +
and O +
Stat5 O +
are O +
activated O +
in O +
normal O +
T O +
cells O +
in O +
response O +
to O +
IL-2 O +
, O +
this O +
signaling O +
pathway O +
was O +
constitutively O +
activated O +
in O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine -
- I-CellLine -
transformed I-CellLine +
cells I-CellLine +
. O +

In O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine -
- I-CellLine -
infected I-CellLine +
cord I-CellLine +
blood I-CellLine +
lymphocytes I-CellLine +
, O +
the O +
transition O +
from O +
IL-2 O +
-dependent O +
to O +
IL-2 O +
-independent O +
growth O +
correlated O +
with O +
the O +
acquisition O +
of O +
a O +
constitutively O +
activated O +
Jak O +
-STAT O +
pathway O +
, O +
which O +
suggests O +
that O +
this O +
pathway O +
participates O +
in O +
HTLV O -
- O -
I O -
- O -
mediated O +
T O +
cell O +
transformation O +
. O +

Positive O +
and O +
negative O +
regulation O +
of O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
promoter O +
activity O +
by O +
AML1-related O +
transcription O +
factor O +
, O +
PEBP2 O +
. O +

The O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
gene O +
promoter O +
contains O +
a O +
consensus O +
sequence O +
for O +
the O +
polyomavirus O +
enhancer O +
binding O -
- O -
protein O +
2 O +
( O +
PEBP2 O +
) O +
transcription O +
factor O +
, O +
which O +
consists O +
of O +
alpha O +
and O +
beta O +
subunits O +
. O +

There O +
are O +
at O +
least O +
two O +
genes O +
, O +
alpha O +
A O +
and O +
alpha O +
B O +
, O +
encoding O +
the O +
alpha O +
subunit O +
. O +

alpha O +
B O +
is O +
the O +
mouse O +
homologue O +
of O +
human O +
AML1 O +
gene O +
detected O +
at O +
the O +
breakpoints O +
of O +
t O +
( O +
8 O +
; O +
21 O +
) O +
and O +
t O +
( O +
3 O +
; O +
21 O +
) O +
myeloid O +
leukemias O +
. O +

We O +
examined O +
alpha O +
A1 O +
( O +
an O +
alpha O +
A O -
- O -
gene O +
product O +
) O +
and O +
alpha O +
B1 O +
and O +
alpha O +
B2 O +
( O +
two O +
alpha O +
B O -
- O -
encoded O +
isomers O +
) O +
for O +
their O +
effects O +
on O +
the O +
GM O -
- O -
CSF O +
promoter O +
. O +

PEBP2 O +
alpha O +
A1 O +
, O +
alpha O +
B1 O +
, O +
and O +
alpha O +
B2 O +
proteins O +
bound O +
the O +
PEBP2 O +
site O +
within O +
the O +
mouse O +
GM O -
- O -
CSF O +
promoter O +
. O +

PEBP2 O +
alpha O +
A1 O +
and O +
alpha O +
B1 O +
enhanced O +
the O +
expression O +
of O +
the O +
GM O -
- O -
CSF O +
promoter O -
- O -
driven O +
reporter O +
plasmid O +
in O +
unstimulated B-CellLine +
and I-CellLine +
12-O I-CellLine -
- I-CellLine -
tetradecanoylphorbol I-CellLine +
13-acetate I-CellLine -
/ I-CellLine -
phytohemagglutinin I-CellLine -
- I-CellLine -
stimulated I-CellLine +
human I-CellLine +
Jurkat I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

In O +
contrast O +
, O +
the O +
promoter O +
activity O +
was O +
suppressed O +
by O +
alpha O +
B2 O +
. O +

Coexpression O +
of O +
alpha O +
B1 O +
and O +
alpha O +
B2 O +
showed O +
that O +
the O +
promoter O +
activity O +
could O +
be O +
determined O +
by O +
the O +
alpha O +
B1 O +
/alpha O +
B2 O +
ratio O +
. O +

Jurkat O +
cell O +
extract O +
contained O +
PEBP2 O +
site O -
- O -
binding O +
protein O +
( O +
s O +
) O +
that O +
cross O -
- O -
reacted O +
with O +
antimouse O +
alpha O +
A1 O +
antibodies O +
. O +

Northern O +
blot O +
analysis O +
indicated O +
the O +
expression O +
of O +
human O +
PEBP2 O +
alpha O +
A O +
, O +
alpha O +
B O +
( O +
AML1 O +
) O +
, O +
and O +
beta O +
genes O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

Although O +
further O +
studies O +
are O +
required O +
to O +
determine O +
the O +
precise O +
role O +
of O +
PEBP2 O +
in O +
the O +
GM O -
- O -
CSF O +
promoter O +
activity O +
, O +
the O +
present O +
findings O +
suggested O +
the O +
importance O +
of O +
the O +
relative O +
ratio O +
of O +
different O +
PEBP2 O +
isoforms O +
in O +
regulating O +
the O +
levels O +
of O +
the O +
promoter O +
activity O +
. O +

Heterogeneous O +
expression O +
of O +
Epstein O -
- O -
Barr O +
virus O +
latent O +
proteins O +
in O +
endemic O +
Burkitt O +
's O +
lymphoma O +
. O +

Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
-infected O +
cells O +
may O +
sustain O +
three O +
distinct O +
forms O +
of O +
virus O +
latency O +
. O +

In O +
lymphoblastoid B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
six O +
EBV O -
- O -
encoded O +
nuclear O +
antigens O +
( O +
EBNA1 O +
, O +
2 O +
, O +
3A O +
, O +
3B O +
, O +
3C O +
, O +
-LP O +
) O +
, O +
three O +
latent O +
membrane O +
proteins O +
( O +
LMP1 O +
, O +
2A O +
, O +
2B O +
) O +
, O +
and O +
two O +
nuclear O +
RNAs O +
( O +
EBERs O +
) O +
are O +
expressed O +
. O +

This O +
form O +
of O +
latency O +
, O +
termed O +
latency O +
III O +
, O +
is O +
also O +
encountered O +
in O +
some O +
posttransplant O +
lymphoproliferative O +
disorders O +
. O +

In O +
EBV O -
- O -
positive O +
cases O +
of O +
Hodgkin O +
's O +
disease O +
, O +
the O +
EBERs O +
, O +
EBNA1 O +
, O +
and O +
the O +
LMPs O +
are O +
expressed O +
( O +
latency O +
II O +
) O +
, O +
whereas O +
in O +
Burkitt O +
's O +
lymphoma O +
( O +
BL O +
) O +
only O +
the O +
EBERs O +
and O +
EBNA1 O +
have O +
been O +
detected O +
( O +
latency O +
I O +
) O +
. O +

We O +
have O +
studied O +
the O +
expression O +
of O +
EBV O +
proteins O +
in O +
17 O +
cases O +
of O +
EBV O -
- O -
positive O +
endemic O +
BL O +
by O +
immunohistology O +
. O +

Expression O +
of O +
LMP1 O +
was O +
seen O +
in O +
variable O +
proportions O +
of O +
tumor O +
cells O +
in O +
two O +
cases O +
and O +
EBNA2 O +
was O +
detected O +
in O +
some O +
tumor O +
cells O +
in O +
three O +
other O +
cases O +
. O +

Also O +
, O +
the O +
BZLF1 O +
trans O -
- O -
activator O +
protein O +
was O +
expressed O +
in O +
a O +
few O +
tumor O +
cells O +
in O +
6 O +
cases O +
, O +
indicating O +
entry O +
into O +
the O +
lytic O +
cycle O +
. O +

A O +
phenotypic O +
drift O +
from O +
latency O +
I O +
to O +
latency O +
III O +
has O +
been O +
observed O +
previously O +
in O +
some O +
BL B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Our O +
results O +
suggest O +
that O +
a O +
similar O +
phenomenon O +
may O +
occur O +
in O +
BL O +
in O +
vivo O +
and O +
indicate O +
that O +
the O +
operational O +
definition O +
of O +
EBV O +
latencies O +
is O +
not O +
easily O +
applied O +
to O +
human O +
tumors O +
. O +

Integrin O -
- O -
mediated O +
tyrosine O +
phosphorylation O +
and O +
cytokine O +
message O +
induction O +
in O +
monocytic O +
cells O +
. O +

A O +
possible O +
signaling O +
role O +
for O +
the O +
Syk O +
tyrosine O +
kinase O +
. O +

Activation O +
of O +
cytoplasmic O +
tyrosine O +
kinases O +
is O +
an O +
important O +
aspect O +
of O +
signal O +
transduction O +
mediated O +
by O +
integrins O +
. O +

In O +
the O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
THP-1 I-CellLine +
, O +
either O +
integrin O +
-dependent O +
cell O +
adhesion O +
to O +
fibronectin O +
or O +
ligation O +
of O +
beta O +
1 O +
integrins O +
with O +
antibodies O +
causes O +
a O +
rapid O +
and O +
intense O +
tyrosine O +
phosphorylation O +
of O +
two O +
sets O +
of O +
proteins O +
of O +
about O +
65 O -
- O -
75 O +
and O +
120 O -
- O -
125 O +
kDa O +
. O +

In O +
addition O +
, O +
integrin O +
ligation O +
leads O +
to O +
nuclear O +
translocation O +
of O +
the O +
p50 O +
and O +
p65 O +
subunits O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
transcription O +
factor O +
, O +
to O +
activation O +
of O +
a O +
reporter O +
gene O +
driven O +
by O +
a O +
promoter O +
containing O +
NF O -
- O -
kappa O +
B O +
sites O +
, O +
and O +
to O +
increased O +
levels O +
of O +
mRNAs O +
for O +
immediate O -
- O -
early O +
genes O +
, O +
including O +
the O +
cytokine O +
interleukin O +
( O +
IL O +
) O +
-1 O +
beta O +
. O +

The O +
tyrosine O +
kinase O +
inhibitors O +
genistein O +
and O +
herbimycin O +
A O +
block O +
both O +
integrin O +
-mediated O +
tyrosine O +
phosphorylation O +
and O +
increases O +
in O +
IL-1 O +
beta O +
message O +
levels O +
, O +
indicating O +
a O +
causal O +
relationship O +
between O +
the O +
two O +
events O +
. O +

The O +
components O +
tyrosine O +
phosphorylated O +
subsequent O +
to O +
cell O +
adhesion O +
include O +
paxillin O +
, O +
pp125FAK O +
, O +
and O +
the O +
SH2 O +
domain O +
containing O +
tyrosine O +
kinase O +
Syk O +
. O +

In O +
contrast O +
, O +
integrin O +
ligation O +
with O +
antibodies O +
induces O +
tyrosine O +
phosphorylation O +
of O +
Syk O +
but O +
not O +
of O +
FAK O +
or O +
paxillin O +
. O +

In O +
adhering O +
cells O +
, O +
pre O -
- O -
treatment O +
with O +
cytochalasin O +
D O +
suppresses O +
tyrosine O +
phosphorylation O +
of O +
FAK O +
and O +
paxillin O +
but O +
not O +
of O +
Syk O +
, O +
while O +
IL-1 O +
beta O +
message O +
induction O +
is O +
unaffected O +
. O +

These O +
observations O +
indicate O +
that O +
the O +
Syk O +
tyrosine O +
kinase O +
may O +
be O +
an O +
important O +
component O +
of O +
an O +
integrin O +
signaling O +
pathway O +
in O +
monocytic O +
cells O +
, O +
leading O +
to O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
to O +
increased O +
levels O +
of O +
cytokine O +
messages O +
. O +

The O +
peri O -
- O -
kappa O +
B O +
site O +
mediates O +
human O +
immunodeficiency O +
virus O +
type O +
2 O +
enhancer O +
activation O +
in O +
monocytes O +
but O +
not O +
in O +
T O +
cells O +
. O +

Human O +
immunodeficiency O +
virus O +
type O +
2 O +
( O +
HIV-2 O +
) O +
, O +
like O +
HIV-1 O +
, O +
causes O +
AIDS O +
and O +
is O +
associated O +
with O +
AIDS O +
cases O +
primarily O +
in O +
West O +
Africa O +
. O +

HIV-1 O +
and O +
HIV-2 O +
display O +
significant O +
differences O +
in O +
nucleic O +
acid O +
sequence O +
and O +
in O +
the O +
natural O +
history O +
of O +
clinical O +
disease O +
. O +

Consistent O +
with O +
these O +
differences O +
, O +
we O +
have O +
previously O +
demonstrated O +
that O +
the O +
enhancer O -
/ O -
promoter O +
region O +
of O +
HIV-2 O +
functions O +
quite O +
differently O +
from O +
that O +
of O +
HIV-1 O +
. O +

Whereas O +
activation O +
of O +
the O +
HIV-1 O +
enhancer O +
following O +
T O -
- O -
cell O +
stimulation O +
is O +
mediated O +
largely O +
through O +
binding O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
to O +
two O +
adjacent O +
kappa O +
B O +
sites O +
in O +
the O +
HIV-1 O +
long O +
terminal O +
repeat O +
, O +
activation O +
of O +
the O +
HIV-2 O +
enhancer O +
in O +
monocytes O +
and O +
T O +
cells O +
is O +
dependent O +
on O +
four O +
cis O -
- O -
acting O +
elements O +
: O +
a O +
single O +
kappa O +
B O +
site O +
, O +
two O +
purine O -
- O -
rich O +
binding O +
sites O +
, O +
PuB1 O +
and O +
PuB2 O +
, O +
and O +
a O +
pets O +
site O +
. O +

We O +
have O +
now O +
identified O +
a O +
novel O +
cis O -
- O -
acting O +
element O +
within O +
the O +
HIV-2 O +
enhancer O +
, O +
immediately O +
upstream O +
of O +
the O +
kappa O +
B O +
site O +
, O +
designated O +
peri O -
- O -
kappa O +
B O +
. O +

This O +
site O +
is O +
conserved O +
among O +
isolates O +
of O +
HIV-2 O +
and O +
the O +
closely O +
related O +
simian O +
immunodeficiency O +
virus O +
, O +
and O +
transfection O +
assays O +
show O +
this O +
site O +
to O +
mediate O +
HIV-2 O +
enhancer O +
activation O +
following O +
stimulation O +
of O +
monocytic B-CellLine +
but O +
not O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
. O +

This O +
is O +
the O +
first O +
description O +
of O +
an O +
HIV-2 O +
enhancer O +
element O +
which O +
displays O +
such O +
monocyte O +
specificity O +
, O +
and O +
no O +
comparable O +
enhancer O +
element O +
has O +
been O +
clearly O +
defined O +
for O +
HIV-1 O +
. O +

While O +
a O +
nuclear O +
factor O +
( O +
s O +
) O +
from O +
both O +
peripheral O +
blood O +
monocytes O +
and O +
T O +
cells O +
binds O +
the O +
peri O -
- O -
kappa O +
B O +
site O +
, O +
electrophoretic O +
mobility O +
shift O +
assays O +
suggest O +
that O +
either O +
a O +
different O +
protein O +
binds O +
to O +
this O +
site O +
in O +
monocytes O +
versus O +
T O +
cells O +
or O +
that O +
the O +
protein O +
recognizing O +
this O +
enhancer O +
element O +
undergoes O +
differential O +
modification O +
in O +
monocytes O +
and O +
T O +
cells O +
, O +
thus O +
supporting O +
the O +
transfection O +
data O +
. O +

Further O +
, O +
while O +
specific O +
constitutive O +
binding O +
to O +
the O +
peri O -
- O -
kappa O +
B O +
site O +
is O +
seen O +
in O +
monocytes O +
, O +
stimulation O +
with O +
phorbol O +
esters O +
induces O +
additional O +
, O +
specific O +
binding O +
. O +

Understanding O +
the O +
monocyte O -
- O -
specific O +
function O +
of O +
the O +
peri O -
- O -
kappa O +
B O +
factor O +
may O +
ultimately O +
provide O +
insight O +
into O +
the O +
different O +
role O +
monocytes O +
and O +
T O +
cells O +
play O +
in O +
HIV O +
pathogenesis O +
. O +

The O +
Ah O +
receptor O +
recognizes O +
DNA O +
binding O +
sites O +
for O +
the O +
B O +
cell O +
transcription O +
factor O +
, O +
BSAP O +
: O +
a O +
possible O +
mechanism O +
for O +
dioxin O -
- O -
mediated O +
alteration O +
of O +
CD19 O +
gene O +
expression O +
in O +
human O +
B O +
lymphocytes O +
. O +

2 O +
, O +
3 O +
, O +
7 O +
, O +
8-tetrachlorodibenzo O -
- O -
p O -
- O -
dioxin O +
( O +
TCDD O +
) O +
inhibits O +
murine O +
and O +
human O +
B O +
lymphocyte O +
immunoglobulin O +
production O +
through O +
an O +
unknown O +
mechanism O +
. O +

This O +
study O +
investigated O +
the O +
effect O +
of O +
TCDD O +
on O +
expression O +
of O +
the O +
CD19 O +
gene O +
in O +
a O +
human B-CellLine +
B I-CellLine +
lymphocyte I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Northern O +
blot O +
analysis O +
showed O +
that O +
TCDD O +
treatment O +
decreased O +
steady O +
state O +
levels O +
of O +
CD19 O +
mRNA O +
by O +
67 O +
% O +
in O +
the O +
IM-9 B-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Using O +
a O +
gel O +
mobility O +
shift O +
assay O +
, O +
we O +
identified O +
a O +
DNA O -
- O -
binding O +
complex O +
in O +
IM-9 O +
nuclear O +
extracts O +
that O +
by O +
several O +
criteria O +
appears O +
to O +
be O +
the O +
Ah O +
receptor O +
. O +

In O +
addition O +
, O +
the O +
Ah O +
receptor O +
complex O +
recognized O +
a O +
DNA O +
binding O +
site O +
for O +
B O +
cell O +
lineage O -
- O -
specific O +
activator O +
protein O +
( O +
BSAP O +
) O +
in O +
the O +
promoter O +
region O +
of O +
the O +
human O +
CD19 O +
gene O +
which O +
is O +
similar O +
to O +
the O +
consensus O +
Ah O +
receptor O +
DNA O +
binding O +
site O +
. O +

These O +
results O +
suggest O +
that O +
the O +
AhR O +
could O +
interfere O +
with O +
BSAP O +
-stimulated O +
CD19 O +
gene O +
transcription O +
by O +
competition O +
for O +
a O +
common O +
DNA O +
binding O +
site O +
. O +

Inhibitory O +
action O +
of O +
nm23 O +
proteins O +
on O +
induction O +
of O +
erythroid O +
differentiation O +
of O +
human O +
leukemia O +
cells O +
. O +

We O +
recently O +
identified O +
a O +
differentiation O +
inhibitory O +
factor O +
( O +
I O -
- O -
factor O +
) O +
in O +
mouse B-CellLine +
myeloid I-CellLine +
leukemia I-CellLine +
M1 I-CellLine +
cells I-CellLine +
as O +
a O +
murine O +
homolog O +
of O +
the O +
human O +
nm23-H2 O +
gene O +
product O +
. O +

nm23 O +
genes O +
encode O +
proteins O +
that O +
participate O +
in O +
tumor O +
metastasis O +
regulation O +
and O +
in O +
various O +
fundamental O +
cellular O +
processes O +
, O +
although O +
their O +
mechanisms O +
of O +
action O +
are O +
still O +
unknown O +
. O +

Although O +
all O +
nm23 O +
proteins O +
contain O +
nucleoside O +
diphosphate O +
( O +
NDP O +
) O +
kinase O +
activity O +
, O +
it O +
has O +
not O +
been O +
established O +
that O +
the O +
enzyme O +
activity O +
mediated O +
the O +
various O +
functions O +
of O +
nm23 O +
proteins O +
. O +

In O +
the O +
present O +
experiment O +
, O +
we O +
examined O +
the O +
effect O +
of O +
nm23 O +
proteins O +
on O +
various O +
differentiation O +
induction O +
systems O +
of O +
human O +
leukemic O +
cells O +
including O +
HL-60 B-CellLine +
, I-CellLine +
U937 I-CellLine +
, I-CellLine +
HEL I-CellLine -
/ I-CellLine -
S I-CellLine +
, I-CellLine +
KU812F I-CellLine +
, I-CellLine +
K562 I-CellLine +
, I-CellLine +
and I-CellLine +
HEL I-CellLine +
cells I-CellLine +
. O +

Native O +
human O +
erythrocyte O +
NDP O +
kinase O +
protein O +
inhibited O +
the O +
induction O +
of O +
erythroid O +
differentiation O +
of O +
HEL B-CellLine +
, I-CellLine +
KU812 I-CellLine +
and I-CellLine +
K562 I-CellLine +
cells I-CellLine +
, O +
but O +
not O +
the O +
induction O +
of O +
monocytic O +
or O +
granulocytic O +
differentiation O +
of O +
HL-60 B-CellLine +
, I-CellLine +
U937 I-CellLine +
and I-CellLine +
HEL I-CellLine -
/ I-CellLine -
S I-CellLine +
cells I-CellLine +
. O +

The O +
erythroid O +
differentiation O +
of O +
HEL B-CellLine +
cells I-CellLine +
was O +
inhibited O +
by O +
recombinant O +
human O +
nm23-H1 O +
, O +
-H2 O +
, O +
mouse O +
nm23-M1 O +
, O +
and O +
-M2 O +
proteins O +
. O +

Moreover O +
, O +
both O +
the O +
mutant O +
nm23-H2His O +
protein O +
and O +
truncated O +
nm23-H2 O +
protein O +
containing O +
N O -
- O -
terminal O +
( O +
1 O -
- O -
60 O +
) O +
peptide O +
, O +
which O +
do O +
not O +
have O +
NDP O +
kinase O +
activity O +
, O +
also O +
inhibited O +
erythroid O +
differentiation O +
of O +
HEL B-CellLine +
cells I-CellLine +
. O +

These O +
results O +
suggest O +
that O +
( O +
1 O +
) O +
the O +
differentiation O +
inhibitory O +
activity O +
of O +
I O -
- O -
factor O -
/ O -
nm23 O +
protein O +
is O +
not O +
restricted O +
to O +
monocytic O +
differentiation O +
of O +
M1 B-CellLine +
cells I-CellLine +
, O +
( O +
2 O +
) O +
the O +
inhibitory O +
activity O +
is O +
exhibited O +
without O +
species O +
specificity O +
, O +
and O +
( O +
3 O +
) O +
the O +
differentiation O +
inhibitory O +
activity O +
of O +
the O +
nm23 O -
/ O -
NDP O +
kinase O +
protein O +
is O +
independent O +
of O +
its O +
enzyme O +
activity O +
and O +
requires O +
the O +
presence O +
of O +
N O -
- O -
terminal O +
peptides O +
. O +

A O +
conserved O +
motif O +
in O +
the O +
promoters O +
of O +
several O +
cytokines O +
expressed O +
by O +
human B-CellLine +
Th2-type I-CellLine +
lymphocytes I-CellLine +
. O +

We O +
have O +
recently O +
found O +
a O +
novel O +
conserved O +
motif O +
in O +
the O +
promoters O +
of O +
several O +
T O -
- O -
cell O -
- O -
expressed O +
cytokines O +
[ O +
human O +
interleukin-2 O +
, O +
-4 O +
, O +
-5 O +
and O +
-13 O +
and O +
human O +
and O +
mouse O +
granulocyte O -
/ O -
macrophage O -
- O -
colony O +
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
] O +
. O +

It O +
contains O +
a O +
core O +
sequence O +
CTTGG O +
... O +
CCAAG O +
which O +
is O +
present O +
as O +
part O +
of O +
larger O +
palindromic O +
sequences O +
in O +
each O +
gene O +
. O +

This O +
suggest O +
that O +
they O +
may O +
interact O +
with O +
a O +
new O +
family O +
of O +
trans O -
- O -
acting O +
factors O +
. O +

In O +
transfection O +
assays O +
, O +
the O +
human O +
GM O -
- O -
CSF O +
element O +
has O +
a O +
strong O +
positive O +
effect O +
on O +
the O +
expression O +
of O +
a O +
reporter O +
gene O +
by O +
the O +
human B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
Jurkat B-CellLine +
J6 I-CellLine +
upon O +
stimulation O +
. O +

In O +
DNA O +
mobility O +
shift O +
assays O +
, O +
this O +
sequence O +
can O +
give O +
either O +
six O +
different O +
specific O +
bands O +
which O +
are O +
competed O +
out O +
by O +
different O +
parts O +
of O +
the O +
sequence O +
or O +
one O +
specific O +
band O +
which O +
is O +
competed O +
out O +
by O +
each O +
of O +
the O +
inverted O +
repeats O +
, O +
depending O +
on O +
the O +
reconstitution O +
conditions O +
. O +

In O +
different O +
genes O +
, O +
the O +
core O +
sequences O +
are O +
separated O +
by O +
integer O +
numbers O +
of O +
helical O +
turns O +
. O +

Considering O +
the O +
strong O +
positive O +
regulatory O +
effect O +
of O +
this O +
element O +
and O +
its O +
presence O +
in O +
several O +
T O -
- O -
cell O -
- O -
expressed O +
cytokine O +
genes O +
, O +
it O +
may O +
be O +
crucial O +
to O +
the O +
coordinated O +
expression O +
of O +
these O +
cytokines O +
in O +
T O +
helper O +
cells O +
. O +

The O +
interleukin-5 O +
/receptor O +
interaction O +
activates O +
Lyn O +
and O +
Jak2 O +
tyrosine O +
kinases O +
and O +
propagates O +
signals O +
via O +
the O +
Ras O -
- O -
Raf-1-MAP O +
kinase O +
and O +
the O +
Jak O +
-STAT O +
pathways O +
in O +
eosinophils O +
. O +

We O +
have O +
shown O +
that O +
the O +
interaction O +
of O +
interleukin O +
( O +
IL O +
) O +
-5 O +
with O +
the O +
receptor O +
activates O +
Lyn O +
tyrosine O +
kinase O +
within O +
1 O +
min O +
and O +
Jak2 O +
tyrosine O +
kinase O +
within O +
1 O -
- O -
3 O +
min O +
. O +

IL-5 O +
also O +
stimulates O +
GTP O +
binding O +
to O +
p21ras O +
. O +

The O +
signal O +
is O +
subsequently O +
propagated O +
through O +
the O +
activation O +
of O +
Raf-1 O +
, O +
MEK O +
, O +
and O +
MAP O +
kinases O +
as O +
shown O +
by O +
their O +
increased O +
autophosphorylation O +
in O +
vitro O +
and O +
phosphorylation O +
in O +
situ O +
. O +

Jak2 O +
kinase O +
has O +
been O +
shown O +
to O +
phosphorylate O +
STAT O +
nuclear O +
proteins O +
. O +

The O +
activation O +
of O +
STAT O +
nuclear O +
factors O +
was O +
studied O +
by O +
electrophoretic O +
mobility O +
shift O +
assay O +
using O +
a O +
gamma O +
activation O +
site O +
( O +
GAS O +
) O +
probe O +
. O +

We O +
found O +
that O +
IL-5 O +
induces O +
two O +
GAS O -
- O -
binding O +
proteins O +
in O +
eosinophils O +
, O +
one O +
of O +
which O +
is O +
STAT1 O +
. O +

We O +
conclude O +
that O +
IL-5 O +
induced O +
signals O +
are O +
propagated O +
through O +
two O +
distinct O +
pathways O +
: O +
( O +
1 O +
) O +
Lyn O +
-- O +
> O +
Ras O +
-- O +
> O +
Raf-1 O +
-- O +
> O +
MEK O +
-- O +
> O +
MAP O +
kinase O +
and O +
( O +
2 O +
) O +
Jak2 O +
-- O +
> O +
STAT1 O +
. O +

Nitric O +
oxide O +
decreases O +
cytokine O +
-induced O +
endothelial O +
activation O +
. O +

Nitric O +
oxide O +
selectively O +
reduces O +
endothelial O +
expression O +
of O +
adhesion O +
molecules O +
and O +
proinflammatory O +
cytokines O +
. O +

To O +
test O +
the O +
hypothesis O +
that O +
nitric O +
oxide O +
( O +
NO O +
) O +
limits O +
endothelial O +
activation O +
, O +
we O +
treated O +
cytokine B-CellLine -
- I-CellLine -
stimulated I-CellLine +
human I-CellLine +
saphenous I-CellLine +
vein I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
with O +
several O +
NO O +
donors O +
and O +
assessed O +
their O +
effects O +
on O +
the O +
inducible O +
expression O +
of O +
vascular O +
cell O +
adhesion O +
molecule-1 O +
( O +
VCAM-1 O +
) O +
. O +

In O +
a O +
concentration O -
- O -
dependent O +
manner O +
, O +
NO O +
inhibited O +
interleukin O +
( O +
IL O +
) O +
-1 O +
alpha O -
- O -
stimulated O +
VCAM-1 O +
expression O +
by O +
35 O -
- O -
55 O +
% O +
as O +
determined O +
by O +
cell O +
surface O +
enzyme O +
immunoassays O +
and O +
flow O +
cytometry O +
. O +

This O +
inhibition O +
was O +
paralleled O +
by O +
reduced O +
monocyte O +
adhesion O +
to O +
endothelial O +
monolayers O +
in O +
nonstatic O +
assays O +
, O +
was O +
unaffected O +
by O +
cGMP O +
analogues O +
, O +
and O +
was O +
quantitatively O +
similar O +
after O +
stimulation O +
by O +
either O +
IL-1 O +
alpha O +
, O +
IL-1 O +
beta O +
, O +
IL-4 O +
, O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
alpha O +
) O +
, O +
or O +
bacterial O +
lipopolysaccharide O +
. O +

NO O +
also O +
decreased O +
the O +
endothelial O +
expression O +
of O +
other O +
leukocyte O +
adhesion O +
molecules O +
( O +
E O -
- O -
selectin O +
and O +
to O +
a O +
lesser O +
extent O +
, O +
intercellular O +
adhesion O +
molecule-1 O +
) O +
and O +
secretable O +
cytokines O +
( O +
IL-6 O +
and O +
IL-8 O +
) O +
. O +

Inhibition O +
of O +
endogenous O +
NO O +
production O +
by O +
L O -
- O -
N O -
- O -
monomethyl O -
- O -
arginine O +
also O +
induced O +
the O +
expression O +
of O +
VCAM-1 O +
, O +
but O +
did O +
not O +
augment O +
cytokine O -
- O -
induced O +
VCAM-1 O +
expression O +
. O +

Nuclear O +
run O -
- O -
on O +
assays O +
, O +
transfection O +
studies O +
using O +
various O +
VCAM-1 O +
promoter O +
reporter O +
gene O +
constructs O +
, O +
and O +
electrophoretic O +
mobility O +
shift O +
assays O +
indicated O +
that O +
NO O +
represses O +
VCAM-1 O +
gene O +
transcription O +
, O +
in O +
part O +
, O +
by O +
inhibiting O +
NF O -
- O -
kappa O +
B O +
. O +

We O +
propose O +
that O +
NO O +
's O +
ability O +
to O +
limit O +
endothelial O +
activation O +
and O +
inhibit O +
monocyte O +
adhesion O +
may O +
contribute O +
to O +
some O +
of O +
its O +
antiatherogenic O +
and O +
antiinflammatory O +
properties O +
within O +
the O +
vessel O +
wall O +
. O +

Does O +
thyroidectomy O +
, O +
radioactive O +
iodine O +
therapy O +
, O +
or O +
antithyroid O +
drug O +
treatment O +
alter O +
reactivity O +
of O +
patients O +
' O +
T O +
cells O +
to O +
epitopes O +
of O +
thyrotropin O +
receptor O +
in O +
autoimmune O +
thyroid O +
diseases O +
? O +

The O +
effect O +
of O +
treatment O +
on O +
thyroid O +
antibody O +
production O +
and O +
T O +
cell O +
reactivity O +
to O +
thyroid O +
antigens O +
was O +
studied O +
in O +
15 O +
patients O +
with O +
Graves O +
' O +
disease O +
( O +
GD O +
) O +
before O +
and O +
after O +
thyroidectomy O +
, O +
19 O +
patients O +
with O +
GD O +
before O +
and O +
after O +
radioactive O +
iodine O +
( O +
RAI O +
) O +
therapy O +
, O +
and O +
9 O +
patients O +
maintained O +
euthyroid O +
on O +
antithyroid O +
drugs O +
( O +
ATD O +
) O +
. O +

Twenty O +
subjects O +
matched O +
for O +
age O +
and O +
sex O +
without O +
known O +
thyroid O +
disease O +
served O +
as O +
controls O +
. O +

In O +
GD O +
patients O +
, O +
the O +
responses O +
of O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
and O +
TSH B-CellLine +
receptor I-CellLine +
( I-CellLine +
TSHR I-CellLine +
) I-CellLine +
-specific I-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
to O +
recombinant O +
human O +
TSHR O +
extracellular O +
domain O +
, O +
thyroglobulin O +
, O +
and O +
TSHR O +
peptides O +
were O +
examined O +
on O +
the O +
day O +
of O +
surgery O +
or O +
RAI O +
therapy O +
( O +
day O +
0 O +
) O +
and O +
also O +
6 O -
- O -
8 O +
weeks O +
and O +
3 O -
- O -
6 O +
months O +
thereafter O +
. O +

Reactivity O +
to O +
TSHR O +
peptides O +
before O +
surgery O +
was O +
heterogeneous O +
and O +
spanned O +
the O +
entire O +
extracellular O +
domain O +
. O +

Six O +
to O +
8 O +
weeks O +
after O +
subtotal O +
thyroidectomy O +
, O +
the O +
number O +
of O +
patients O +
' O +
PBMC O +
responding O +
to O +
any O +
peptide O +
and O +
the O +
average O +
number O +
of O +
recognized O +
peptides O +
decreased O +
. O +

A O +
further O +
decrease O +
in O +
the O +
T O +
cell O +
reactivity O +
to O +
TSHR O +
peptides O +
was O +
observed O +
3 O -
- O -
6 O +
months O +
after O +
surgery O +
. O +

The O +
responses O +
of O +
PBMC O +
from O +
Graves O +
' O +
patients O +
before O +
RAI O +
therapy O +
were O +
less O +
than O +
those O +
in O +
the O +
presurgical O +
group O +
. O +

Six O +
to O +
8 O +
weeks O +
after O +
RAI O +
therapy O +
, O +
the O +
number O +
of O +
patients O +
responding O +
to O +
any O +
peptide O +
and O +
the O +
average O +
number O +
of O +
recognized O +
peptides O +
increased O +
. O +

Three O +
to O +
6 O +
months O +
after O +
RAI O +
, O +
T O +
cell O +
responses O +
to O +
TSHR O +
peptides O +
were O +
less O +
than O +
those O +
6 O -
- O -
8 O +
weeks O +
after O +
RAI O +
therapy O +
, O +
but O +
still O +
higher O +
than O +
the O +
values O +
on O +
day O +
0 O +
. O +

Responses O +
of O +
PBMC O +
from O +
patients O +
with O +
GD O +
, O +
maintained O +
euthyroid O +
on O +
ATD O +
, O +
were O +
lower O +
than O +
those O +
before O +
surgery O +
or O +
RAI O +
therapy O +
. O +

The O +
reactivity O +
of O +
T B-CellLine +
cell I-CellLine +
lines I-CellLine +
in O +
different O +
groups O +
reflected O +
a O +
pattern O +
similar O +
to O +
PBMC O +
after O +
treatment O +
. O +

TSHR O +
antibody O +
and O +
microsomal O +
antibody O +
levels O +
decreased O +
after O +
surgery O +
, O +
but O +
increased O +
after O +
RAI O +
therapy O +
. O +

The O +
difference O +
in O +
the O +
number O +
of O +
recognized O +
peptides O +
by O +
patients O +
' O +
PBMC O +
before O +
RAI O +
and O +
surgery O +
may O +
reflect O +
the O +
effect O +
of O +
long O +
term O +
therapy O +
with O +
ATD O +
in O +
the O +
patients O +
before O +
RAI O +
vs. O +
the O +
shorter O +
period O +
in O +
patients O +
before O +
surgery O +
. O +

The O +
decreased O +
T O +
cell O +
reactivity O +
to O +
thyroid O +
antigens O +
after O +
thyroidectomy O +
could O +
be O +
the O +
result O +
of O +
removal O +
of O +
a O +
major O +
part O +
of O +
the O +
thyroid O +
gland O +
or O +
redistribution O +
of O +
suppressor O -
- O -
inducer O +
T O +
cells O +
. O +

The O +
increased O +
T O +
cell O +
response O +
after O +
RAI O +
therapy O +
is O +
probably O +
epitope O +
specific O +
, O +
rather O +
than O +
a O +
response O +
to O +
the O +
whole O +
TSHR O +
molecule O +
. O +

Synchronous O +
recognition O +
of O +
peptides O +
158 O -
- O -
176 O +
and O +
248 O -
- O -
263 O +
is O +
important O +
for O +
the O +
development O +
of O +
GD O +
, O +
and O +
the O +
loss O +
of O +
recognition O +
of O +
one O +
of O +
these O +
epitopes O +
may O +
be O +
an O +
early O +
sign O +
of O +
immune O +
remission O +
and O +
a O +
predictor O +
of O +
euthyroidism O +
. O +

Functional O +
roles O +
of O +
the O +
transcription O +
factor O +
Oct-2A O +
and O +
the O +
high O +
mobility O +
group O +
protein O +
I O -
/ O -
Y O +
in O +
HLA O -
- O -
DRA O +
gene O +
expression O +
. O +

The O +
class O +
II O +
major O +
histocompatibility O +
complex O +
gene O +
HLA O -
- O -
DRA O +
is O +
expressed O +
in O +
B O +
cells O +
, O +
activated O +
T O +
lymphocytes O +
, O +
and O +
in O +
antigen O -
- O -
presenting O +
cells O +
. O +

In O +
addition O +
, O +
HLA O -
- O -
DRA O +
gene O +
expression O +
is O +
inducible O +
in O +
a O +
variety O +
of O +
cell O +
types O +
by O +
interferon O -
- O -
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
. O +

Here O +
we O +
show O +
that O +
the O +
lymphoid O -
- O -
specific O +
transcription O +
factor O +
Oct-2A O +
plays O +
a O +
critical O +
role O +
in O +
HLA O -
- O -
DRA O +
gene O +
expression O +
in O +
class B-CellLine +
II I-CellLine -
- I-CellLine -
positive I-CellLine +
B I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
and O +
that O +
the O +
high O +
mobility O +
group O +
protein O +
( O +
HMG O +
) O +
I O -
/ O -
Y O +
binds O +
to O +
multiple O +
sites O +
within O +
the O +
DRA O +
promoter O +
, O +
including O +
the O +
Oct-2A O +
binding O +
site O +
. O +

Coexpression O +
of O +
HMG O +
I O -
/ O -
Y O +
and O +
Oct-2 O +
in O +
cell B-CellLine +
lines I-CellLine +
lacking O +
Oct-2 O +
results O +
in O +
high O +
levels O +
of O +
HLA O -
- O -
DRA O +
gene O +
expression O +
, O +
and O +
in O +
vitro O +
DNA O -
- O -
binding O +
studies O +
reveal O +
that O +
HMG O +
I O -
/ O -
Y O +
stimulates O +
Oct-2A O +
binding O +
to O +
the O +
HLA O -
- O -
DRA O +
promoter O +
. O +

Thus O +
, O +
Oct-2A O +
and O +
HMG O +
I O -
/ O -
Y O +
may O +
synergize O +
to O +
activate O +
HLA O -
- O -
DRA O +
expression O +
in O +
B O +
cells O +
. O +

By O +
contrast O +
, O +
Oct-2A O +
is O +
not O +
involved O +
in O +
the O +
IFN O -
- O -
gamma O +
induction O +
of O +
the O +
HLA O -
- O -
DRA O +
gene O +
in O +
HeLa B-CellLine +
cells I-CellLine +
, O +
but O +
antisense O +
HMG O +
I O -
/ O -
Y O +
dramatically O +
decreases O +
the O +
level O +
of O +
induction O +
. O +

We O +
conclude O +
that O +
distinct O +
sets O +
of O +
transcription O +
factors O +
are O +
involved O +
in O +
the O +
two O +
modes O +
of O +
HLA O -
- O -
DRA O +
expression O +
, O +
and O +
that O +
HMG O +
I O -
/ O -
Y O +
may O +
be O +
important O +
for O +
B O +
cell O -
- O -
specific O +
expression O +
, O +
and O +
is O +
essential O +
for O +
IFN O -
- O -
gamma O +
induction O +
. O +

RB O +
and O +
a O +
novel O +
E2F-1 O +
binding O +
protein O +
in O +
MHC B-CellLine +
class I-CellLine +
II I-CellLine +
deficient I-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
and O +
normal O +
IFN O -
- O -
gamma O +
induction O +
of O +
the O +
class O +
IL O +
transactivator O +
CIITA O +
in O +
class B-CellLine +
II I-CellLine +
non I-CellLine -
- I-CellLine -
inducible I-CellLine +
RB I-CellLine -
- I-CellLine -
defective I-CellLine +
tumor I-CellLine +
lines I-CellLine +
. O +

The O +
major O +
histocompatibility O +
( O +
MHC O +
) O +
class O +
II O +
genes O +
encode O +
cell O +
surface O +
proteins O +
that O +
bind O +
antigenic O +
peptide O +
for O +
presentation O +
to O +
T O -
- O -
cells O +
. O +

The O +
class O +
II O +
proteins O +
are O +
expressed O +
constitutively O +
on O +
B O -
- O -
cells O +
and O +
EBV B-CellLine -
- I-CellLine -
transformed I-CellLine +
B I-CellLine -
- I-CellLine -
cells I-CellLine +
, I-CellLine +
and O +
are O +
inducible O +
by O +
IFN O -
- O -
gamma O +
on O +
a O +
wide O +
variety O +
of O +
cell O +
types O +
. O +

Retinoblastoma O +
protein O +
( O +
RB O +
) O +
is O +
a O +
tumor O +
suppressor O +
and O +
functions O +
as O +
a O +
transcriptional O +
repressor O +
by O +
binding O +
and O +
inactivating O +
the O +
transactivator O +
E2F O -
- O -
I O +
. O +

RB B-CellLine -
- I-CellLine -
defective I-CellLine +
tumor I-CellLine +
lines I-CellLine +
are O +
non O -
- O -
inducible O +
for O +
MHC O +
class O +
II O +
by O +
IFN O -
- O -
gamma O +
, O +
or O +
very O +
weakly O +
inducible O +
, O +
but O +
transfection O +
of O +
2 O +
different O +
lines O +
with O +
RB O +
expression O +
vectors O +
re O -
- O -
establishes O +
or O +
substantially O +
enhances O +
class O +
II O +
inducibility O +
. O +

Therefore O +
, O +
we O +
examined O +
the O +
RB O +
status O +
of O +
a O +
series O +
of O +
B O -
- O -
cell O +
mutants O +
that O +
are O +
defective O +
in O +
class O +
II O +
expression O +
, O +
generated O +
either O +
in O +
vitro O +
or O +
derived O +
from O +
Bare O +
Lymphocyte O +
Syndrome O +
( O +
BLS O +
) O +
patients O +
. O +

Nuclear O +
matrix O -
- O -
bound O +
RB O +
was O +
detectable O +
in O +
all O +
cases O +
, O +
indicating O +
that O +
loss O +
of O +
RB O +
is O +
not O +
responsible O +
for O +
decreased O +
class O +
II O +
expression O +
in O +
these O +
lines O +
. O +

A O +
second O +
E2F O -
- O -
I O +
binding O +
protein O +
, O +
most O +
likely O +
DP O -
- O -
I O +
, O +
was O +
also O +
apparently O +
normal O +
in O +
both O +
class O +
II O -
- O -
positive O +
and O +
-negative O +
B O -
- O -
cell O +
lines O +
. O +

We O +
also O +
examined O +
the O +
IFN O -
- O -
gamma O +
induction O +
of O +
CIITA O +
in O +
RB O +
-defective O +
lines O +
. O +

CIITA O +
is O +
a O +
class O +
II O +
gene O +
transactivator O +
known O +
to O +
be O +
defective O +
in O +
one O +
form O +
of O +
BLS O +
and O +
to O +
be O +
required O +
for O +
the O +
induction O +
of O +
MHC O +
class O +
II O +
by O +
IFN O -
- O -
gamma O +
. O +

CIITA O +
mRNA O +
is O +
normally O +
inducible O +
by O +
IFN O -
- O -
gamma O +
in O +
class B-CellLine +
II I-CellLine +
non I-CellLine -
- I-CellLine -
inducible I-CellLine +
, I-CellLine +
RB I-CellLine -
- I-CellLine -
defective I-CellLine +
lines I-CellLine +
, O +
and O +
in O +
one O +
line O +
, O +
re O -
- O -
expression O +
of O +
RB O +
has O +
no O +
effect O +
on O +
CIITA O +
mRNA O +
induction O +
levels O +
. O +

Thus O +
, O +
the O +
block O +
in O +
MHC O +
class O +
II O +
inducibility O +
in O +
RB B-CellLine -
- I-CellLine -
defective I-CellLine +
cells I-CellLine +
is O +
not O +
due O +
to O +
a O +
block O +
in O +
CIITA O +
inducibility O +
. O +

Latent O +
membrane O +
protein-1 O +
induces O +
cyclin O +
D2 O +
expression O +
, O +
pRb O +
hyperphosphorylation O +
, O +
and O +
loss O +
of O +
TGF O -
- O -
beta O +
1 O +
-mediated O +
growth O +
inhibition O +
in O +
EBV O -
- O -
positive O +
B O +
cells O +
. O +

The O +
normal O +
cell O +
cycle O +
is O +
regulated O +
by O +
several O +
molecules O +
, O +
such O +
as O +
the O +
tumor O -
- O -
suppressor O +
protein O +
pRb O +
, O +
the O +
G1 O +
cyclins O +
, O +
the O +
cyclin O -
- O -
dependent O +
kinases O +
, O +
and O +
their O +
inhibitors O +
. O +

These O +
regulators O +
are O +
targeted O +
by O +
negative O +
growth O +
regulatory O +
signals O +
, O +
such O +
as O +
that O +
provided O +
by O +
TGF O -
- O -
beta O +
. O +

Here O +
, O +
we O +
show O +
that O +
the O +
presence O +
of O +
either O +
wild O -
- O -
type O +
EBV O +
or O +
its O +
transforming O +
latent O +
membrane O +
protein-1 O +
( O +
LMP-1 O +
) O +
results O +
in O +
the O +
loss O +
of O +
TGF O -
- O -
beta O +
1 O +
-mediated O +
growth O +
inhibition O +
in O +
human O +
B O +
cells O +
. O +

Chemical O +
cross O -
- O -
linking O +
with O +
125I O -
- O -
labeled O +
TGF O -
- O -
beta O +
1 O +
showed O +
an O +
essentially O +
normal O +
TGF O -
- O -
beta O +
receptor O +
profile O +
in O +
EBV B-CellLine -
- I-CellLine -
positive I-CellLine +
and I-CellLine +
EBV I-CellLine -
- I-CellLine -
negative I-CellLine +
Burkitt I-CellLine +
's I-CellLine +
lymphoma I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
and O +
these O +
receptors O +
were O +
shown O +
to O +
be O +
functional O +
in O +
transducing O +
signals O +
, O +
as O +
evidenced O +
by O +
the O +
TGF O -
- O -
beta O +
1 O +
-mediated O +
modulation O +
of O +
junB O +
gene O +
expression O +
. O +

However O +
, O +
TGF O -
- O -
beta O +
1 O +
did O +
not O +
induce O +
dephosphorylation O +
of O +
pRb O +
in O +
EBV B-CellLine +
( I-CellLine +
or I-CellLine +
LMP-1 I-CellLine +
) I-CellLine +
-positive I-CellLine +
cells I-CellLine +
as O +
opposed O +
to O +
EBV B-CellLine -
- I-CellLine -
negative I-CellLine +
cells I-CellLine +
, O +
suggesting O +
a O +
dichotomy O +
in O +
the O +
TGF O -
- O -
beta O +
1 O +
signaling O +
pathway O +
leading O +
to O +
separable O +
gene O +
regulatory O +
and O +
growth O +
inhibitory O +
responses O +
. O +

Furthermore O +
, O +
LMP-1 O +
was O +
found O +
to O +
induce O +
the O +
expression O +
of O +
cyclin O +
D2 O +
; O +
normal O +
B O +
cells O +
or O +
EBV B-CellLine -
- I-CellLine -
negative I-CellLine +
Burkitt I-CellLine +
's I-CellLine +
lymphoma I-CellLine +
cells I-CellLine +
do O +
not O +
express O +
D O -
- O -
type O +
cyclins O +
. O +

Taken O +
together O +
, O +
these O +
data O +
point O +
to O +
a O +
potential O +
mechanism O +
underlying O +
EBV O -
- O -
mediated O +
B O +
cell O +
transformation O +
whereby O +
constitutive O +
induction O +
of O +
key O +
cell O +
cycle O +
regulators O +
by O +
LMP-1 O +
can O +
lead O +
to O +
pRb O +
hyperphosphorylation O +
and O +
uncontrolled O +
cell O +
proliferation O +
. O +

Costimulation O +
of O +
human B-CellLine +
CD4 I-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
with O +
LFA-3 O +
and O +
B7 O +
induce O +
distinct O +
effects O +
on O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B O +
transcription O +
factors O +
. O +

We O +
have O +
earlier O +
shown O +
that O +
stimulation O +
of O +
human B-CellLine +
CD4 I-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
with O +
SEA O +
presented O +
on O +
Chinese B-CellLine +
hamster I-CellLine +
ovary I-CellLine +
( I-CellLine +
CHO I-CellLine +
) I-CellLine +
-DR I-CellLine +
transfectants I-CellLine +
coexpressing O +
either O +
B7 O +
or O +
LFA-3 O +
resulted O +
in O +
distinct O +
cytokine O +
profiles O +
. O +

We O +
now O +
demonstrate O +
that O +
B7 O +
, O +
but O +
not O +
LFA-3 O +
, O +
strongly O +
costimulated O +
IL-2 O +
transcription O +
and O +
mRNA O +
expression O +
in O +
CD4 B-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Maximal O +
increase O +
in O +
IL-2 O +
transcription O +
was O +
recorded O +
with O +
CHO O -
- O -
DR O -
/ O -
B7 O -
/ O -
LFA-3 O +
, O +
suggesting O +
a O +
cooperative O +
effect O +
of O +
B7 O +
and O +
LFA-3 O +
at O +
the O +
transcriptional O +
level O +
. O +

Gel O -
- O -
shift O +
analysis O +
demonstrated O +
that O +
stimulation O +
of O +
CD4 B-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
with O +
CHO O -
- O -
DR O +
and O +
staphylococcal O +
enterotoxin O +
A O +
was O +
sufficient O +
to O +
induce O +
significant O +
amounts O +
of O +
NF O -
- O -
kappa O +
B O +
binding O +
proteins O +
, O +
whereas O +
induction O +
of O +
AP-1 O +
binding O +
proteins O +
required O +
costimulation O +
. O +

LFA-3 O +
induced O +
moderate O +
levels O +
of O +
AP-1 O +
, O +
but O +
did O +
not O +
influence O +
the O +
levels O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
while O +
B7 O +
costimulation O +
strongly O +
induced O +
both O +
AP-1 O +
and O +
substantially O +
enhanced O +
NF O -
- O -
kappa O +
B O +
binding O +
proteins O +
. O +

The O +
CHO B-CellLine -
- I-CellLine -
DR I-CellLine -
/ I-CellLine -
B7 I-CellLine -
/ I-CellLine -
LFA-3 I-CellLine +
triple I-CellLine +
transfectant I-CellLine +
induced O +
a O +
further O +
increase O +
in O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B O +
binding O +
proteins O +
compared O +
with O +
the O +
double B-CellLine +
transfectants I-CellLine +
. O +

The O +
level O +
of O +
Oct-1 O +
binding O +
proteins O +
remained O +
similar O +
in O +
all O +
samples O +
. O +

Super O -
- O -
shift O +
analysis O +
revealed O +
that O +
the O +
NF O -
- O -
kappa O +
B O +
complex O +
of O +
costimulated B-CellLine +
CD4 I-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
contained O +
large O +
amounts O +
of O +
p50 O +
, O +
substantial O +
amounts O +
of O +
p65 O +
, O +
and O +
marginal O +
levels O +
of O +
c O -
- O -
Rel O +
proteins O +
. O +

The O +
AP-1 O +
binding O +
proteins O +
contained O +
c O -
- O -
Jun O +
, O +
Jun O -
- O -
D O +
, O +
and O +
Fra-1 O +
, O +
but O +
marginal O +
amounts O +
of O +
Jun O -
- O -
B O +
and O +
c O -
- O -
Fos O +
. O +

Our O +
results O +
indicate O +
distinct O +
effects O +
of O +
B7 O +
and O +
LFA-3 O +
costimulation O +
on O +
the O +
activity O +
of O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B O +
. O +

These O +
may O +
partly O +
account O +
for O +
the O +
differential O +
effects O +
of O +
B7 O +
and O +
LFA-3 O +
costimulation O +
on O +
IL-2 O +
expression O +
. O +

Multiple O +
signals O +
are O +
required O +
for O +
function O +
of O +
the O +
human O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
gene O +
promoter O +
in O +
T O +
cells O +
. O +

The O +
human O +
granulocyte O -
- O -
macrophage O +
CSF O +
( O +
GM O -
- O -
CSF O +
) O +
gene O +
is O +
expressed O +
in O +
T O +
cells O +
in O +
response O +
to O +
TCR O +
activation O +
that O +
can O +
be O +
mimicked O +
by O +
treatment O +
of O +
the O +
cells O +
with O +
PMA O +
and O +
Ca2 O -
+ O +
ionophore O +
. O +

The O +
gene O +
contains O +
a O +
proximal O +
functional O +
promoter O +
region O +
( O +
-620 O +
to O +
+ O -
34 O +
) O +
, O +
as O +
well O +
as O +
a O +
powerful O +
enhancer O +
located O +
3 O +
kb O +
upstream O +
, O +
both O +
of O +
which O +
are O +
involved O +
in O +
the O +
response O +
of O +
the O +
gene O +
to O +
TCR O +
activation O +
. O +

The O +
proximal O +
promoter O +
contains O +
a O +
region O +
termed O +
CLEO O +
( O +
-54 O +
to O +
-31 O +
) O +
that O +
consists O +
of O +
a O +
purine O -
- O -
rich O +
element O +
abutting O +
an O +
activator O +
protein-1 O +
( O +
AP-1 O +
) O +
-like O +
site O +
, O +
as O +
well O +
as O +
an O +
upstream O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
site O +
( O +
-85 O +
to O +
-76 O +
) O +
and O +
a O +
CK-1 O +
element O +
( O +
-101 O +
to O +
-92 O +
) O +
. O +

We O +
show O +
in O +
this O +
work O +
that O +
mutations O +
in O +
either O +
the O +
purine O -
- O -
rich O +
region O +
of O +
the O +
CLEO O +
element O +
or O +
the O +
NF O -
- O -
kappa O +
B O +
site O +
result O +
in O +
reduced O +
PMA O -
/ O -
Ca2 O -
+ O +
activation O +
of O +
a O +
620-bp O +
human O +
GM O -
- O -
CSF O +
promoter O -
- O -
luciferase O +
reporter O +
construct O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
by O +
65 O +
% O +
and O +
50 O +
% O +
, O +
respectively O +
. O +

The O +
major O +
inducible O +
protein O +
complex O +
that O +
binds O +
to O +
the O +
human O +
CLEO O +
( O +
hCLEO O +
) O +
element O +
is O +
an O +
AP-1-like O +
complex O +
that O +
is O +
inducible O +
by O +
PMA O +
alone O +
, O +
but O +
shows O +
increased O +
binding O +
in O +
response O +
to O +
PMA O +
together O +
with O +
Ca2 O -
+ O +
ionophore O +
. O +

Although O +
the O +
binding O +
of O +
this O +
complex O +
is O +
not O +
cyclosporin O -
- O -
sensitive O +
, O +
promoter O +
induction O +
is O +
inhibited O +
by O +
cyclosporin O +
treatment O +
. O +

A O +
second O +
weak O +
inducible O +
complex O +
resembling O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NF O -
- O -
AT O +
) O +
was O +
also O +
observed O +
binding O +
to O +
the O +
hCLEO O +
region O +
. O +

By O +
using O +
recombinant O +
proteins O +
, O +
we O +
confirmed O +
that O +
AP-1 O +
, O +
NF O -
- O -
ATp O +
, O +
and O +
a O +
higher O +
order O +
NF O -
- O -
ATp O -
/ O -
AP-1 O +
complex O +
could O +
all O +
form O +
with O +
the O +
hCLEO O +
element O +
, O +
and O +
we O +
have O +
also O +
defined O +
the O +
sequence O +
requirements O +
for O +
binding O +
of O +
each O +
of O +
these O +
complexes O +
. O +

We O +
found O +
that O +
expression O +
of O +
a O +
constitutively O +
active O +
form O +
of O +
calcineurin O +
could O +
substitute O +
for O +
Ca2 O -
+ O +
ionophore O +
and O +
synergize O +
with O +
PMA O +
to O +
activate O +
the O +
GM O -
- O -
CSF O +
promoter O +
, O +
and O +
conversely O +
that O +
mutant O -
- O -
activated O +
Ras O +
could O +
substitute O +
for O +
PMA O +
and O +
cooperate O +
with O +
Ca2 O -
+ O +
ionophore O +
. O +

Co O -
- O -
expression O +
of O +
Ras O +
and O +
calcineurin O +
, O +
however O +
, O +
did O +
not O +
activate O +
the O +
GM O -
- O -
CSF O +
promoter O +
, O +
but O +
required O +
the O +
additional O +
expression O +
of O +
NF O -
- O -
kappa O +
B O +
p65 O +
. O +

These O +
results O +
imply O +
that O +
at O +
least O +
three O +
signals O +
are O +
required O +
to O +
activate O +
the O +
GM O -
- O -
CSF O +
proximal O +
promoter O +
, O +
and O +
that O +
the O +
signals O +
impinge O +
on O +
distinct O +
transcription O +
factors O +
that O +
bind O +
to O +
the O +
hCLEO O +
and O +
NF O -
- O -
kappa O +
B O +
regions O +
of O +
the O +
promoter O +
. O +

C O -
/ O -
EBP O +
proteins O +
activate O +
transcription O +
from O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
long O +
terminal O +
repeat O +
in O +
macrophages O -
/ O +
monocytes O +
. O +

Three O +
binding O +
sites O +
for O +
C O -
/ O -
EBP O +
proteins O +
are O +
found O +
in O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
( O +
V.M. O +
Tesmer O +
, O +
A.Rajadhyaksha O +
, O +
J.Babin O +
, O +
and O +
M.Bina O +
, O +
Proc O -
. O -
Natl O -
. O -
Acad O -
. O -
Sci O -
. O +
USA O +
90 O +
: O +
7298 O -
- O -
7302 O +
, O +
1993 O +
) O +
. O +

We O +
have O +
determined O +
the O +
functional O +
role O +
of O +
C O -
/ O -
EBP O +
proteins O +
and O +
C O -
/ O -
EBP O +
sites O +
in O +
regulating O +
transcription O +
from O +
the O +
HIV- O +
1 O +
LTR O +
in O +
monocytes O -
/ O -
macrophages O +
. O +

Inhibition O +
of O +
endogenous O +
C O -
/ O -
EBP O +
proteins O +
, O +
using O +
either O +
an O +
excess O +
of O +
C O -
/ O -
EBP O +
binding O +
sites O +
or O +
a O +
trans- O +
dominant O +
negative O +
inhibitor O +
, O +
demonstrated O +
that O +
C O -
/ O -
EBP O +
proteins O +
are O +
required O +
for O +
basal O +
and O +
activated O +
levels O +
of O +
HIV-1 O +
LTR O +
transcription O +
in O +
the O +
promonocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
U937 I-CellLine +
. O +

Northern O +
( O +
RNA O +
) O +
blots O +
and O +
binding O +
assays O +
showed O +
that O +
NF O -
- O -
IL6 O +
is O +
the O +
only O +
known O +
C O -
/ O -
EBP O +
family O +
member O +
which O +
is O +
increased O +
when O +
U937 B-CellLine +
cells I-CellLine +
are O +
activated O +
. O +

Mutational O +
analyses O +
of O +
the O +
HIV-1 O +
LTR O +
showed O +
that O +
one O +
C O -
/ O -
EBP O +
site O +
is O +
required O +
for O +
normal O +
LTR O +
transcription O +
both O +
before O +
and O +
after O +
cellular O +
activation O +
and O +
that O +
the O +
two O +
3 O +
' O +
C O -
/ O -
EBP O +
sites O +
are O +
functionally O +
equivalent O +
. O +

However O +
, O +
transcription O +
from O +
crippled O +
HIV-1 O +
LTRs O +
lacking O +
C O -
/ O -
EBP O +
sites O +
can O +
still O +
be O +
induced O +
following O +
activation O +
of O +
U937 B-CellLine +
cells I-CellLine +
. O +

Several O +
models O +
are O +
suggested O +
for O +
how O +
elevated O +
NF O -
- O -
IL6 O +
may O +
participate O +
in O +
an O +
autostimulatory O +
loop O +
involving O +
HIV O +
infection O +
, O +
macrophage O +
activation O +
, O +
cytokine O +
expression O +
, O +
and O +
HIV O +
replication O +
. O +

An O +
IRF-1 O +
-dependent O +
pathway O +
of O +
DNA O +
damage O -
- O -
induced O +
apoptosis O +
in O +
mitogen B-CellLine -
- I-CellLine -
activated I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
. O +

Lymphocytes B-CellLine +
are O +
particularly O +
susceptible O +
to O +
DNA O +
damage O -
- O -
induced O +
apoptosis O +
, O +
a O +
response O +
which O +
may O +
serve O +
as O +
a O +
form O +
of O +
' O -
altruistic O +
suicide O +
' O +
to O +
counter O +
their O +
intrinsic O +
high O +
potential O +
for O +
mutation O +
and O +
clonal O +
expansion O +
. O +

The O +
tumour O +
suppressor O +
p53 O +
has O +
been O +
shown O +
to O +
regulate O +
this O +
type O +
of O +
apoptosis O +
in O +
thymocytes O +
, O +
but O +
an O +
as O +
yet O +
unknown O +
, O +
p53 O +
-independent O +
pathway O +
( O +
s O +
) O +
appears O +
to O +
mediate O +
the O +
same O +
event O +
in O +
mitogen B-CellLine -
- I-CellLine -
activated I-CellLine +
mature I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
. O +

Here O +
we O +
show O +
DNA O +
damage O -
- O -
induced O +
apoptosis O +
in O +
these O +
T O +
lymphocytes O +
is O +
dependent O +
on O +
the O +
antioncogenic O +
transcription O +
factor O +
interferon O +
regulatory O +
factor O +
( O +
IRF O +
) O +
-1 O +
. O +

Thus O +
two O +
different O +
anti O -
- O -
onco O -
- O -
genic O +
transcription O +
factors O +
, O +
p53 O +
and O +
IRF-1 O +
, O +
are O +
required O +
for O +
distinct O +
apoptotic O +
pathways O +
in O +
T O +
lymphocytes O +
. O +

We O +
also O +
show O +
that O +
mitogen O +
induction O +
of O +
the O +
interleukin-1 O +
beta O +
converting O +
enzyme O +
( O +
ICE O +
) O +
gene O +
, O +
a O +
mammalian O +
homologue O +
of O +
the O +
Caenorhabditis O +
elegans O +
cell O +
death O +
gene O +
ced-3 O +
, O +
is O +
IRF-1 O +
-dependent O +
. O +

Ectopic O +
overexpression O +
of O +
IRF-1 O +
results O +
in O +
the O +
activation O +
of O +
the O +
endogenous O +
gene O +
for O +
ICE O +
and O +
enhances O +
the O +
sensitivity O +
of O +
cells O +
to O +
radiation O -
- O -
induced O +
apoptosis O +
. O +

Sp1 O +
functions O +
in O +
a O +
chromatin O +
-dependent O +
manner O +
to O +
augment O +
human O +
alpha O -
- O -
globin O +
promoter O +
activity O +
. O +

The O +
5 O +
' O +
flanking O +
region O +
of O +
the O +
human O +
alpha O -
- O -
globin O +
gene O +
is O +
highly O +
G O +
+ O +
C O +
rich O +
and O +
contains O +
multiple O +
copies O +
of O +
the O +
consensus O +
sequence O +
for O +
the O +
Sp1 O +
binding O +
site O +
. O +

We O +
investigated O +
the O +
role O +
of O +
this O +
G O +
+ O +
C O -
- O -
rich O +
region O +
in O +
augmenting O +
alpha O -
- O -
globin O +
promoter O +
activity O +
in O +
the O +
presence O +
of O +
the O +
far O -
- O -
upstream O +
alpha O -
- O -
globin O +
enhancer O +
, O +
HS-40 O +
. O +

We O +
show O +
that O +
in O +
transiently B-CellLine +
transfected I-CellLine +
erythroid I-CellLine +
cells I-CellLine +
, O +
deletion O +
of O +
the O +
alpha O -
- O -
globin O +
G O +
+ O +
C O -
- O -
rich O +
5 O +
' O +
flanking O +
region O +
has O +
no O +
effect O +
on O +
alpha O -
- O -
globin O +
promoter O +
activity O +
. O +

However O +
, O +
upon O +
stable O +
integration O +
into O +
chromatin O +
, O +
deletion O +
of O +
this O +
region O +
causes O +
a O +
nearly O +
90 O +
% O +
decrease O +
in O +
promoter O +
activity O +
compared O +
with O +
expression O +
from O +
an O +
alpha O -
- O -
globin O +
promoter O +
retaining O +
this O +
region O +
. O +

These O +
results O +
suggest O +
that O +
the O +
alpha O -
- O -
globin O +
G O +
+ O +
C O -
- O -
rich O +
5 O +
' O +
flanking O +
region O +
augments O +
alpha O -
- O -
globin O +
promoter O +
activity O +
in O +
a O +
chromatin O +
-dependent O +
manner O +
. O +

We O +
further O +
show O +
that O +
this O +
G O +
+ O +
C O -
- O -
rich O +
region O +
is O +
required O +
for O +
the O +
activation O +
of O +
alpha O -
- O -
globin O +
gene O +
expression O +
during O +
erythroid O +
differentiation O +
. O +

Finally O +
, O +
we O +
show O +
by O +
both O +
footprint O +
analysis O +
and O +
functional O +
assays O +
that O +
the O +
ability O +
of O +
the O +
G O +
+ O +
C O -
- O -
rich O +
region O +
to O +
increase O +
alpha O -
- O -
globin O +
promoter O +
activity O +
from O +
a O +
stably O +
integrated O +
alpha O -
- O -
globin O +
gene O +
is O +
mediated O +
by O +
its O +
multiple O +
binding O +
sites O +
for O +
the O +
transcription O +
factor O +
Sp1 O +
. O +

Regulation O +
of O +
c O -
- O -
jun O +
mRNA O +
expression O +
by O +
hydroxyurea O +
in O +
human B-CellLine +
K562 I-CellLine +
cells I-CellLine +
during O +
erythroid O +
differentiation O +
[ O +
published O +
erratum O +
appears O +
in O +
Biochim O +
Biophys O +
Acta O +
1995 O +
Dec O +
27 O +
; O +
1264 O +
( O +
3 O +
) O +
: O +
409 O +
] O +

Hydroxyurea O +
( O +
HU O +
) O +
is O +
an O +
antitumor O +
agent O +
which O +
also O +
induces O +
hemoglobinization O +
during O +
erythroid O +
differentiation O +
. O +

In O +
addition O +
, O +
HU O +
stimulates O +
the O +
synthesis O +
of O +
fetal O +
hemoglobin O +
in O +
sickle O +
cell O +
anemia O +
patients O +
. O +

To O +
further O +
understand O +
its O +
mechanism O +
of O +
action O +
, O +
we O +
investigated O +
the O +
effects O +
of O +
HU O +
on O +
regulation O +
of O +
c O -
- O -
jun O +
expression O +
prior O +
to O +
the O +
onset O +
of O +
erythroid O +
differentiation O +
of O +
K562 B-CellLine +
cells I-CellLine +
. O +

HU O +
induced O +
a O +
dose O -
- O -
dependent O +
stimulation O +
of O +
c O -
- O -
jun O +
synthesis O +
. O +

The O +
levels O +
of O +
c O -
- O -
jun O +
mRNA O +
was O +
elevated O +
4 O +
to O +
7.5-fold O +
by O +
HU O +
within O +
2 O +
h O +
. O +

This O +
was O +
followed O +
by O +
a O +
gradual O +
decline O +
to O +
the O +
basal O +
level O +
by O +
24 O +
h O +
. O +

Both O +
nuclear O +
run O -
- O -
on O +
and O +
actinomycin O +
D O +
pulse O +
experiments O +
strongly O +
indicate O +
that O +
HU O +
regulates O +
c O -
- O -
jun O +
mRNA O +
expression O +
by O +
increasing O +
the O +
rate O +
of O +
synthesis O +
as O +
well O +
as O +
stabilizing O +
the O +
c O -
- O -
jun O +
mRNA O +
. O +

In O +
addition O +
, O +
the O +
level O +
of O +
jun O +
protein O +
was O +
elevated O +
by O +
2 O +
to O +
5-fold O +
within O +
4 O +
h O +
in O +
HU B-CellLine +
treated I-CellLine +
cells I-CellLine +
. O +

Furthermore O +
, O +
concentrations O +
of O +
HU O +
below O +
250 O +
microM O +
slightly O +
increased O +
the O +
5X O +
AP-1 O +
/CAT O +
activity O +
. O +

These O +
results O +
strongly O +
suggest O +
that O +
HU O +
induces O +
both O +
transcriptional O +
and O +
post O -
- O -
transcription O +
regulation O +
of O +
c O -
- O -
jun O +
during O +
erythroid O +
differentiation O +
. O +

IL-2 O +
gene O +
expression O +
and O +
NF O -
- O -
kappa O +
B O +
activation O +
through O +
CD28 O +
requires O +
reactive O +
oxygen O +
production O +
by O +
5-lipoxygenase O +
. O +

Activation O +
of O +
the O +
CD28 O +
surface O +
receptor O +
provides O +
a O +
major O +
costimulatory O +
signal O +
for O +
T O +
cell O +
activation O +
resulting O +
in O +
enhanced O +
production O +
of O +
interleukin-2 O +
( O +
IL-2 O +
) O +
and O +
cell O +
proliferation O +
. O +

In O +
primary O +
T O +
lymphocytes O +
we O +
show O +
that O +
CD28 O +
ligation O +
leads O +
to O +
the O +
rapid O +
intracellular O +
formation O +
of O +
reactive O +
oxygen O +
intermediates O +
( O +
ROIs O +
) O +
which O +
are O +
required O +
for O +
CD28 O +
-mediated O +
activation O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
/ O +
CD28-responsive O +
complex O +
and O +
IL-2 O +
expression O +
. O +

Delineation O +
of O +
the O +
CD28 O +
signaling O +
cascade O +
was O +
found O +
to O +
involve O +
protein O +
tyrosine O +
kinase O +
activity O +
, O +
followed O +
by O +
the O +
activation O +
of O +
phospholipase O +
A2 O +
and O +
5-lipoxygenase O +
. O +

Our O +
data O +
suggest O +
that O +
lipoxygenase O +
metabolites O +
activate O +
ROI O +
formation O +
which O +
then O +
induce O +
IL-2 O +
expression O +
via O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

These O +
findings O +
should O +
be O +
useful O +
for O +
therapeutic O +
strategies O +
and O +
the O +
development O +
of O +
immunosuppressants O +
targeting O +
the O +
CD28 O +
costimulatory O +
pathway O +
. O +

Flutamide O +
in O +
the O +
treatment O +
of O +
hirsutism O +
: O +
long O -
- O -
term O +
clinical O +
effects O +
, O +
endocrine O +
changes O +
, O +
and O +
androgen O +
receptor O +
behavior O +
. O +

OBJECTIVE O +
: O +
To O +
investigate O +
the O +
long O -
- O -
term O +
effects O +
of O +
treatment O +
with O +
low O +
doses O +
of O +
flutamide O +
on O +
clinical O +
and O +
hormonal O +
parameters O +
, O +
as O +
well O +
as O +
on O +
the O +
androgen O +
receptor O +
status O +
, O +
in O +
hirsute O +
women O +
. O +

DESIGN O +
: O +
Eighteen O +
hirsute O +
patients O +
with O +
regular O +
menses O +
were O +
studied O +
basally O +
and O +
during O +
treatment O +
with O +
125 O +
mg O +
flutamide O +
, O +
three O +
times O +
per O +
day O +
for O +
12 O +
months O +
. O +

Barrier O +
or O +
intrauterine O +
contraception O +
was O +
used O +
during O +
the O +
study O +
in O +
sexually O +
active O +
women O +
. O +

Safety O +
parameters O +
were O +
assessed O +
throughout O +
the O +
study O +
. O +

Hirsutism O +
, O +
graded O +
by O +
the O +
modified O +
Ferriman O -
- O -
Gallwey O +
score O +
, O +
and O +
hormonal O +
parameters O +
were O +
evaluated O +
basally O +
and O +
at O +
4-month O +
intervals O +
during O +
treatment O +
. O +

Gonadotropin O -
- O -
releasing O +
hormone O +
and O +
ACTH O +
stimulation O +
tests O +
were O +
performed O +
before O +
and O +
after O +
3 O +
to O +
4 O +
months O +
of O +
therapy O +
. O +

In O +
addition O +
, O +
the O +
concentration O +
of O +
androgen O +
receptors O +
in O +
mononuclear O +
leukocytes O +
was O +
measured O +
, O +
in O +
both O +
the O +
follicular O +
and O +
luteal O +
phases O +
of O +
the O +
menstrual O +
cycle O +
, O +
basally O +
and O +
after O +
4 O +
months O +
of O +
flutamide O +
treatment O +
. O +

RESULTS O +
: O +
Flutamide O +
was O +
well O +
tolerated O +
in O +
all O +
women O +
, O +
with O +
the O +
noticeable O +
exception O +
of O +
one O +
patient O +
who O +
presented O +
increased O +
serum O +
transaminase O +
after O +
8 O +
months O +
of O +
therapy O +
. O +

Hirsutism O +
markedly O +
improved O +
in O +
all O +
women O +
during O +
the O +
treatment O +
( O +
Ferriman O -
- O -
Gallwey O +
score O +
after O +
1 O +
year O +
: O +
4.1 O +
+ O -
/- O +
0.5 O +
versus O +
14.1 O +
+ O -
/- O +
0.9 O +
) O +
. O +

A O +
reduction O +
of O +
serum O +
androgens O +
was O +
found O +
, O +
whereas O +
no O +
change O +
was O +
observed O +
in O +
either O +
basal O +
or O +
GnRH O -
- O -
stimulated O +
gonadotropins O +
or O +
in O +
the O +
cortisol O +
and O +
17 O +
alpha O -
- O -
hydroxyprogesterone O +
response O +
to O +
ACTH O +
. O +

Cycles O +
remained O +
ovulatory O +
. O +

Before O +
treatment O +
, O +
the O +
number O +
of O +
androgen O +
receptors O +
was O +
higher O +
in O +
the O +
luteal O +
than O +
in O +
the O +
follicular O +
phase O +
. O +

This O +
rhythmic O +
differentiation O +
disappeared O +
after O +
the O +
patients O +
had O +
been O +
given O +
the O +
antiandrogen O +
drug O +
. O +

CONCLUSIONS O +
: O +
Flutamide O +
is O +
effective O +
in O +
the O +
treatment O +
of O +
hirsutism O +
but O +
requires O +
constant O +
surveillance O +
of O +
liver O +
function O +
. O +

Androgen O +
receptor O +
blockade O +
might O +
be O +
potentiated O +
by O +
a O +
reduction O +
of O +
serum O +
androgens O +
. O +

Flutamide O +
affects O +
androgen O +
receptor O +
behavior O +
during O +
the O +
menstrual O +
cycle O +
. O +

The O +
meaning O +
of O +
this O +
finding O +
remains O +
to O +
be O +
elucidated O +
. O +

Interleukin O +
2 O +
signaling O +
involves O +
the O +
phosphorylation O +
of O +
Stat O +
proteins O +
. O +

One O +
of O +
the O +
most O +
important O +
cytokines O +
involved O +
in O +
immune O +
response O +
regulation O +
is O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
, O +
a O +
potent O +
activator O +
of O +
the O +
proliferation O +
and O +
function O +
of O +
T O +
lymphocytes O +
and O +
natural O +
killer O +
cells O +
. O +

The O +
mechanisms O +
by O +
which O +
the O +
effects O +
of O +
IL-2 O +
are O +
propagated O +
within O +
cells O +
are O +
not O +
understood O +
. O +

While O +
the O +
binding O +
of O +
IL-2 O +
to O +
its O +
receptor O +
was O +
recently O +
shown O +
to O +
lead O +
to O +
the O +
activation O +
of O +
two O +
kinases O +
, O +
Jak-1 O +
and O +
Jak-3 O +
, O +
subsequent O +
steps O +
in O +
the O +
signaling O +
pathway O +
to O +
the O +
nucleus O +
that O +
lead O +
to O +
the O +
activation O +
of O +
specific O +
genes O +
had O +
not O +
been O +
characterized O +
. O +

Since O +
many O +
cytokines O +
that O +
activate O +
Jak O +
kinases O +
also O +
lead O +
to O +
the O +
tyrosine O +
phosphorylation O +
and O +
activation O +
of O +
members O +
of O +
the O +
Stat O +
family O +
of O +
transcription O +
factors O +
, O +
the O +
ability O +
of O +
IL-2 O +
to O +
trigger O +
Stat O +
phosphorylation O +
was O +
examined O +
. O +

Exposure O +
of O +
activated O +
human O +
T O +
lymphocytes O +
or O +
of O +
a O +
natural B-CellLine +
killer I-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
NKL B-CellLine +
) O +
to O +
IL-2 O +
leads O +
to O +
the O +
phosphorylation O +
of O +
Stat1 O +
alpha O +
, O +
Stat1 O +
beta O +
, O +
and O +
Stat3 O +
, O +
as O +
well O +
as O +
of O +
two O +
Stat O -
- O -
related O +
proteins O +
, O +
p94 O +
and O +
p95 O +
. O +

p94 O +
and O +
p95 O +
share O +
homology O +
with O +
Stat1 O +
at O +
the O +
phosphorylation O +
site O +
and O +
in O +
the O +
Src O +
homology O +
2 O +
( O +
SH2 O +
) O +
domain O +
, O +
but O +
otherwise O +
are O +
immunologically O +
distinct O +
from O +
Stat1 O +
. O +

These O +
Stat O +
proteins O +
were O +
found O +
to O +
translocate O +
to O +
the O +
nucleus O +
and O +
to O +
bind O +
to O +
a O +
specific O +
DNA O +
sequence O +
. O +

These O +
findings O +
suggest O +
a O +
mechanism O +
by O +
which O +
IL-2 O +
binding O +
to O +
its O +
receptor O +
may O +
activate O +
specific O +
genes O +
involved O +
in O +
immune O +
cell O +
function O +
. O +

Activation O +
of O +
the O +
HIV-1 O +
enhancer O +
by O +
the O +
LEF-1 O +
HMG O +
protein O +
on O +
nucleosome O -
- O -
assembled O +
DNA O +
in O +
vitro O +
. O +

Lymphoid O +
enhancer O -
- O -
binding O +
factor O +
1 O +
( O +
LEF-1 O +
) O +
is O +
a O +
regulatory O +
high O +
mobility O +
group O +
( O +
HMG O +
) O +
protein O +
that O +
activates O +
the O +
T O +
cell O +
receptor O +
alpha O +
( O +
TCR O +
alpha O +
) O +
enhancer O +
in O +
a O +
context O -
- O -
restricted O +
manner O +
in O +
T O +
cells O +
. O +

In O +
this O +
paper O +
we O +
demonstrate O +
that O +
the O +
distal O +
region O +
of O +
the O +
human O +
immunodeficiency O +
virus-1 O +
( O +
HIV-1 O +
) O +
enhancer O +
, O +
which O +
contains O +
DNA O -
- O -
binding O +
sites O +
for O +
LEF-1 O +
and O +
Ets-1 O +
, O +
also O +
provides O +
a O +
functional O +
context O +
for O +
activation O +
by O +
LEF-1 O +
. O +

First O +
, O +
we O +
show O +
that O +
mutations O +
in O +
the O +
LEF-1-binding O +
site O +
inhibit O +
the O +
activity O +
of O +
multimerized O +
copies O +
of O +
the O +
HIV-1 O +
enhancer O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
and O +
that O +
LEF-1 O -
/ O -
GAL4 O +
can O +
activate O +
a O +
GAL4-substituted O +
HIV-1 O +
enhancer O +
80- O +
to O +
100-fold O +
in O +
vivo O +
. O +

Second O +
, O +
recombinant O +
LEF-1 O +
is O +
shown O +
to O +
activate O +
HIV-1 O +
transcription O +
on O +
chromatin O -
- O -
assembled O +
DNA O +
in O +
vitro O +
. O +

By O +
using O +
a O +
nucleosome O +
-assembly O +
system O +
derived O +
from O +
Drosophila O +
embryos O +
, O +
we O +
find O +
that O +
the O +
packaging O +
of O +
DNA O +
into O +
chromatin O +
in O +
vitro O +
strongly O +
represses O +
HIV-1 O +
transcription O +
and O +
that O +
repression O +
can O +
be O +
counteracted O +
efficiently O +
by O +
preincubation O +
of O +
the O +
DNA O +
with O +
LEF-1 O +
( O +
or O +
LEF-1 O +
and O +
Ets-1 O +
) O +
supplemented O +
with O +
fractions O +
containing O +
the O +
promoter O -
- O -
binding O +
protein O +
, O +
Sp1 O +
. O +

Addition O +
of O +
TFE-3 O +
, O +
which O +
binds O +
to O +
an O +
E O -
- O -
box O +
motif O +
upstream O +
of O +
the O +
LEF-1 O +
and O +
Ets-1 O +
sites O +
, O +
further O +
augments O +
transcription O +
in O +
this O +
system O +
. O +

Individually O +
or O +
collectively O +
, O +
none O +
of O +
the O +
three O +
enhancer O -
- O -
binding O +
proteins O +
( O +
LEF-1 O +
, O +
Ets-1 O +
, O +
and O +
TFE-3 O +
) O +
could O +
activate O +
transcription O +
in O +
the O +
absence O +
of O +
Sp1 O +
. O +

A O +
truncation O +
mutant O +
of O +
LEF-1 O +
( O +
HMG-88 O +
) O +
, O +
which O +
contains O +
the O +
HMG O +
box O +
but O +
lacks O +
the O +
trans O -
- O -
activation O +
domain O +
, O +
did O +
not O +
activate O +
transcription O +
from O +
nucleosomal O +
DNA O +
, O +
indicating O +
that O +
bending O +
of O +
DNA O +
by O +
the O +
HMG O +
domain O +
is O +
not O +
sufficient O +
to O +
activate O +
transcription O +
in O +
vitro O +
. O +

We O +
conclude O +
that O +
transcription O +
activation O +
by O +
LEF-1 O +
in O +
vitro O +
is O +
a O +
chromatin O +
-dependent O +
process O +
that O +
requires O +
a O +
functional O +
trans O -
- O -
activation O +
domain O +
in O +
addition O +
to O +
the O +
HMG O +
domain O +
. O +

Phosphorylation O +
of O +
the O +
transcription O +
factor O +
NFATp O +
inhibits O +
its O +
DNA O +
binding O +
activity O +
in O +
cyclosporin B-CellLine +
A I-CellLine -
- I-CellLine -
treated I-CellLine +
human I-CellLine +
B I-CellLine +
and O +
T O +
cells O +
. O +

Cyclosporin O +
A O +
( O +
CsA O +
) O +
exerts O +
its O +
immunosuppressive O +
effect O +
by O +
inhibiting O +
the O +
activity O +
of O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
, O +
thus O +
preventing O +
transcriptional O +
induction O +
of O +
several O +
cytokine O +
genes O +
. O +

This O +
effect O +
is O +
thought O +
to O +
be O +
largely O +
mediated O +
through O +
inactivation O +
of O +
the O +
phosphatase O +
calcineurin O +
, O +
which O +
in O +
turn O +
inhibits O +
translocation O +
of O +
an O +
NFAT O +
component O +
to O +
the O +
nucleus O +
. O +

Here O +
we O +
report O +
that O +
CsA O +
treatment O +
of O +
Raji B-CellLine +
B I-CellLine +
and O +
Jurkat B-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
yields O +
a O +
phosphorylated O +
form O +
of O +
NFATp O +
that O +
is O +
inhibited O +
in O +
DNA O -
- O -
binding O +
and O +
in O +
its O +
ability O +
to O +
form O +
an O +
NFAT O +
complex O +
with O +
Fos O +
and O +
Jun O +
. O +

Immunoblot O +
analyses O +
and O +
metabolic O +
labeling O +
with O +
[ O +
32P O +
] O +
orthophosphate O +
show O +
that O +
CsA O +
alters O +
NFATp O +
migration O +
on O +
SDS O -
- O -
polyacrylamide O +
gel O +
electrophoresis O +
by O +
increasing O +
its O +
phosphorylation O +
level O +
without O +
affecting O +
subcellular O +
distribution O +
. O +

Dephosphorylation O +
by O +
in O +
vitro O +
treatment O +
with O +
calcineurin O +
or O +
alkaline O +
phosphatase O +
restores O +
NFATp O +
DNA O +
binding O +
activity O +
and O +
its O +
ability O +
to O +
reconstitute O +
an O +
NFAT O +
complex O +
with O +
Fos O +
and O +
Jun O +
proteins O +
. O +

These O +
data O +
point O +
to O +
a O +
new O +
mechanism O +
for O +
CsA O -
- O -
sensitive O +
regulation O +
of O +
NFATp O +
in O +
which O +
dephosphorylation O +
is O +
critical O +
for O +
DNA O +
binding O +
. O +

Regulation O +
of O +
transcription O +
of O +
the O +
human O +
erythropoietin O +
receptor O +
gene O +
by O +
proteins O +
binding O +
to O +
GATA-1 O +
and O +
Sp1 O +
motifs O +
. O +

Erythropoietin O +
( O +
Epo O +
) O +
, O +
the O +
primary O +
regulator O +
of O +
the O +
production O +
of O +
erythroid O +
cells O +
, O +
acts O +
by O +
binding O +
to O +
a O +
cell O +
surface O +
receptor O +
( O +
EpoR O +
) O +
on O +
erythroid O +
progenitors O +
. O +

We O +
used O +
deletion O +
analysis O +
and O +
transfection O +
assays O +
with O +
reporter O +
gene O +
constructs O +
to O +
examine O +
the O +
transcription O +
control O +
elements O +
in O +
the O +
5 O +
' O +
flanking O +
region O +
of O +
the O +
human O +
EpoR O +
gene O +
. O +

In O +
erythroid O +
cells O +
most O +
of O +
the O +
transcription O +
activity O +
was O +
contained O +
in O +
a O +
150 O +
bp O +
promoter O +
fragment O +
with O +
binding O +
sites O +
for O +
transcription O +
factors O +
AP2 O +
, O +
Sp1 O +
and O +
the O +
erythroid O -
- O -
specific O +
GATA-1 O +
. O +

The O +
150 O +
bp O +
hEpoR O +
promoter O +
exhibited O +
high O +
and O +
low O +
activity O +
in O +
erythroid O +
OCIM1 B-CellLine +
and O +
K562 B-CellLine +
cells I-CellLine +
, O +
respectively O +
, O +
reflecting O +
the O +
high O +
and O +
low O +
levels O +
of O +
constitutive O +
hEpoR O +
expression O +
. O +

The O +
GATA-1 O +
and O +
Sp1 O +
binding O +
sites O +
in O +
this O +
promoter O +
lacking O +
a O +
TATA O +
sequence O +
were O +
necessary O +
for O +
a O +
high O +
level O +
of O +
transcription O +
activation O +
. O +

Protein O -
- O -
DNA O +
binding O +
studies O +
suggested O +
that O +
Sp1 O +
and O +
two O +
other O +
CCGCCC O +
binding O +
proteins O +
from O +
erythroid O +
and O +
non O -
- O -
erythroid O +
cells O +
could O +
bind O +
to O +
the O +
Sp1 O +
binding O +
motif O +
. O +

By O +
increasing O +
GATA-1 O +
levels O +
via O +
co O -
- O -
transfection O +
, O +
we O +
were O +
able O +
to O +
transactivate O +
the O +
hEpoR O +
promoter O +
in O +
K562 B-CellLine +
cells I-CellLine +
and O +
non O -
- O -
erythroid O +
cells O +
, O +
but O +
not O +
in O +
the O +
highly O +
active O +
OCIM1 O +
cells O +
, O +
although O +
GATA-1 O +
mRNA O +
levels O +
were O +
comparable O +
in O +
OCIM1 B-CellLine +
and O +
K562 B-CellLine +
. O +

Interestingly O +
, O +
when O +
we O +
mutated O +
the O +
Sp1 O +
site O +
, O +
resulting O +
in O +
a O +
marked O +
decrease O +
in O +
hEpoR O +
promoter O +
activity O +
, O +
we O +
could O +
restore O +
transactivation O +
by O +
increasing O +
GATA-1 O +
levels O +
in O +
OCIM1 O +
cells O +
. O +

These O +
data O +
suggest O +
that O +
while O +
GATA-1 O +
can O +
transactivate O +
the O +
EpoR O +
promoter O +
, O +
the O +
level O +
of O +
hEpoR O +
gene O +
expression O +
does O +
not O +
depend O +
on O +
GATA-1 O +
alone O +
. O +

Rather O +
, O +
hEpoR O +
transcription O +
activity O +
depends O +
on O +
coordination O +
between O +
Sp1 O +
and O +
GATA-1 O +
with O +
other O +
cell O -
- O -
specific O +
factors O +
, O +
including O +
possibly O +
other O +
Sp1-like O +
binding O +
proteins O +
, O +
to O +
provide O +
high O +
level O +
, O +
tissue O -
- O -
specific O +
expression O +
. O +

TCL1 O +
oncogene O +
activation O +
in O +
preleukemic O +
T O +
cells O +
from O +
a O +
case O +
of O +
ataxia O -
- O -
telangiectasia O +
. O +

The O +
TCL1 O +
oncogene O +
on O +
human O +
chromosome O +
14q32.1 O +
is O +
involved O +
in O +
chromosome O +
translocations O +
[ O +
t O +
( O +
14 O +
; O +
14 O +
) O +
( O +
q11 O +
; O +
q32.1 O +
) O +
and O +
t O +
( O +
7 O +
; O +
14 O +
) O +
( O +
q35 O +
; O +
q32.1 O +
) O +
] O +
and O +
inversions O +
[ O +
inv14 O +
( O +
q11 O +
; O +
q32.1 O +
) O +
] O +
with O +
TCR O +
alpha O -
/ O -
beta O +
loci O +
in O +
T O -
- O -
cell O +
leukemias O +
, O +
such O +
as O +
T O -
- O -
prolymphocytic O +
( O +
T O -
- O -
PLL O +
) O +
. O +

It O +
is O +
also O +
involved O +
in O +
T- O +
acute O +
and- O +
chronic O +
leukemias O +
arising O +
in O +
cases O +
of O +
ataxia O -
- O -
telangiectasia O +
( O +
AT O +
) O +
, O +
an O +
immunodeficiency O +
syndrome O +
. O +

Similar O +
chromosomal O +
rearrangements O +
occur O +
also O +
in O +
the O +
clonally O +
expanded O +
T O +
cells O +
in O +
AT O +
patients O +
before O +
the O +
appearance O +
of O +
the O +
overt O +
leukemia O +
. O +

We O +
have O +
analyzed O +
the O +
expression O +
of O +
TCL1 O +
mRNA O +
and O +
protein O +
in O +
peripheral O +
blood O +
lymphocytes O +
( O +
PBLs O +
) O +
from O +
four O +
AT O +
cases O +
and O +
from O +
healthy O +
controls O +
. O +

We O +
found O +
that O +
the O +
TCL1 O +
gene O +
was O +
overexpressed O +
in O +
the O +
PBLs O +
of O +
an O +
AT O +
patient O +
with O +
a O +
large B-CellLine +
clonal I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
population I-CellLine +
exhibiting O +
the O +
t O +
( O +
14 O +
; O +
14 O +
) O +
translocation O +
but O +
not O +
in O +
the O +
lymphocytes O +
of O +
the O +
other O +
cases O +
. O +

Fluorescence O +
in O +
situ O +
hybridization O +
of O +
the O +
TCL1 O +
genomic O +
locus O +
to O +
lymphocyte O +
metaphases O +
from O +
the O +
AT O +
patient O +
with O +
the O +
T O -
- O -
cell O +
clonal O +
expansion O +
showed O +
that O +
the O +
breakpoint O +
of O +
the O +
t O +
( O +
14 O +
; O +
14 O +
) O +
translocation O +
lies O +
within O +
the O +
TCL1 O +
locus O +
and O +
is O +
accompanied O +
by O +
an O +
inverted O +
duplication O +
of O +
the O +
distal O +
part O +
of O +
chromosome O +
14 O +
. O +

These O +
data O +
indicate O +
that O +
TCL1 O +
is O +
activated O +
in O +
preleukemic B-CellLine +
clonal I-CellLine +
cells I-CellLine +
as O +
a O +
consequence O +
of O +
chromosome O +
translocation O +
involving O +
sequences O +
from O +
the O +
TCR O +
locus O +
at O +
14q11 O +
. O +

Deregulation O +
of O +
TCL1 O +
is O +
the O +
first O +
event O +
in O +
the O +
initiation O +
of O +
malignancy O +
in O +
these O +
types O +
of O +
leukemias O +
and O +
represents O +
a O +
potential O +
tool O +
for O +
clinical O +
evaluation O +
. O +

Transcriptional O +
regulation O +
of O +
the O +
gene O +
encoding O +
the O +
human O +
C O -
- O -
type O +
lectin O +
leukocyte O +
receptor O +
AIM O -
/ O -
CD69 O +
and O +
functional O +
characterization O +
of O +
its O +
tumor O +
necrosis O +
factor O -
- O -
alpha O -
- O -
responsive O +
elements O +
. O +

The O +
human O +
activation O +
antigen O +
CD69 O +
is O +
a O +
member O +
of O +
the O +
C O -
- O -
type O +
animal O +
lectin O +
superfamily O +
that O +
functions O +
as O +
a O +
signal O -
- O -
transmitting O +
receptor O +
. O +

Although O +
the O +
expression O +
of O +
CD69 O +
can O +
be O +
induced O +
in O +
vitro O +
on O +
cells O +
of O +
most O +
hematopoietic O +
lineages O +
with O +
a O +
wide O +
variety O +
of O +
stimuli O +
, O +
in O +
vivo O +
it O +
is O +
mainly O +
expressed O +
by O +
T O -
- O -
lymphocytes O +
located O +
in O +
the O +
inflammatory O +
infiltrates O +
of O +
several O +
human O +
diseases O +
. O +

To O +
elucidate O +
the O +
mechanisms O +
that O +
regulate O +
the O +
constitutive O +
and O +
inducible O +
expression O +
of O +
CD69 O +
by O +
leukocytes O +
, O +
we O +
isolated O +
the O +
promoter O +
region O +
of O +
the O +
CD69 O +
gene O +
and O +
carried O +
out O +
its O +
functional O +
characterization O +
. O +

Sequence O +
analysis O +
of O +
the O +
5'-flanking O +
region O +
of O +
the O +
CD69 O +
gene O +
revealed O +
the O +
presence O +
of O +
a O +
potential O +
TATA O +
element O +
30 O +
base O +
pairs O +
upstream O +
of O +
the O +
major O +
transcription O +
initiation O +
site O +
and O +
several O +
putative O +
binding O +
sequences O +
for O +
inducible O +
transcription O +
factors O +
( O +
NF O -
- O -
kappa O +
B O +
, O +
Egr-1 O +
, O +
AP-1 O +
) O +
, O +
which O +
might O +
mediate O +
the O +
inducible O +
expression O +
of O +
this O +
gene O +
. O +

Transient O +
expression O +
of O +
CD69 O +
promoter O -
- O -
based O +
reporter O +
gene O +
constructs O +
in O +
K562 B-CellLine +
cells I-CellLine +
indicated O +
that O +
the O +
proximal O +
promoter O +
region O +
spanning O +
positions O +
-78 O +
to O +
+ O -
16 O +
contained O +
the O +
cis O -
- O -
acting O +
sequences O +
necessary O +
for O +
basal O +
and O +
phorbol O +
12-myristate O +
13-acetate O -
- O -
inducible O +
transcription O +
of O +
the O +
CD69 O +
gene O +
. O +

Removal O +
of O +
the O +
upstream O +
sequences O +
located O +
between O +
positions O +
-78 O +
and O +
-38 O +
resulted O +
in O +
decreased O +
promoter O +
strength O +
and O +
abolished O +
the O +
response O +
to O +
phorbol O +
12-myristate O +
13-acetate O +
. O +

We O +
also O +
found O +
that O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
is O +
capable O +
of O +
inducing O +
the O +
surface O +
expression O +
of O +
the O +
CD69 O +
molecule O +
as O +
well O +
as O +
the O +
promoter O +
activity O +
of O +
fusion O +
plasmids O +
that O +
contain O +
5'-flanking O +
sequences O +
of O +
the O +
CD69 O +
gene O +
, O +
suggesting O +
that O +
this O +
cytokine O +
may O +
regulate O +
in O +
vivo O +
the O +
expression O +
of O +
CD69 O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O +
) O +

Ubiquitin O -
- O -
mediated O +
processing O +
of O +
NF O -
- O -
kappa O +
B O +
transcriptional O +
activator O +
precursor O +
p105 O +
. O +

Reconstitution O +
of O +
a O +
cell O -
- O -
free O +
system O +
and O +
identification O +
of O +
the O +
ubiquitin O -
- O -
carrier O +
protein O +
, O +
E2 O +
, O +
and O +
a O +
novel O +
ubiquitin O -
- O -
protein O +
ligase O +
, O +
E3 O +
, O +
involved O +
in O +
conjugation O +
. O +

In O +
most O +
cases O +
, O +
the O +
transcriptional O +
factor O +
NF O -
- O -
kappa O +
B O +
is O +
a O +
heterodimer O +
consisting O +
of O +
two O +
subunits O +
, O +
p50 O +
and O +
p65 O +
, O +
which O +
are O +
encoded O +
by O +
two O +
distinct O +
genes O +
of O +
the O +
Rel O +
family O +
. O +

p50 O +
is O +
translated O +
as O +
a O +
precursor O +
of O +
105 O +
kDa O +
. O +

The O +
C O -
- O -
terminal O +
domain O +
of O +
the O +
precursor O +
is O +
rapidly O +
degraded O +
, O +
forming O +
the O +
mature O +
p50 O +
subunit O +
consisted O +
of O +
the O +
N O -
- O -
terminal O +
region O +
of O +
the O +
molecule O +
. O +

The O +
mechanism O +
of O +
generation O +
of O +
p50 O +
is O +
not O +
known O +
. O +

It O +
has O +
been O +
suggested O +
that O +
the O +
ubiquitin O +
-proteasome O +
system O +
is O +
involved O +
in O +
the O +
process O +
; O +
however O +
, O +
the O +
specific O +
enzymes O +
involved O +
and O +
the O +
mechanism O +
of O +
limited O +
proteolysis O +
, O +
in O +
which O +
half O +
of O +
the O +
molecule O +
is O +
spared O +
, O +
have O +
been O +
obscure O +
. O +

Palombella O +
and O +
colleagues O +
( O +
Palombella O +
, O +
V.J. O +
, O +
Rando O +
, O +
O.J. O +
, O +
Goldberg O +
, O +
A.L. O +
, O +
and O +
Maniatis O +
, O +
T. O +
( O +
1994 O +
) O +
Cell O +
78 O +
, O +
773 O -
- O -
785 O +
) O +
have O +
shown O +
that O +
ubiquitin O +
is O +
required O +
for O +
the O +
processing O +
in O +
a O +
cell O -
- O -
free O +
system O +
of O +
a O +
truncated O +
, O +
artificially O +
constructed O +
, O +
60-kDa O +
precursor O +
. O +

They O +
have O +
also O +
shown O +
that O +
proteasome O +
inhibitors O +
block O +
the O +
processing O +
both O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

In O +
this O +
study O +
, O +
we O +
demonstrate O +
reconstitution O +
of O +
a O +
cell O -
- O -
free O +
processing O +
system O +
and O +
demonstrate O +
directly O +
that O +
: O +
( O +
a O +
) O +
the O +
ubiquitin O +
-proteasome O +
system O +
is O +
involved O +
in O +
processing O +
of O +
the O +
intact O +
p105 O +
precursor O +
, O +
( O +
b O +
) O +
conjugation O +
of O +
ubiquitin O +
to O +
the O +
precursor O +
is O +
an O +
essential O +
intermediate O +
step O +
in O +
the O +
processing O +
, O +
( O +
c O +
) O +
the O +
recently O +
discovered O +
novel O +
species O +
of O +
the O +
ubiquitin O -
- O -
carrier O +
protein O +
, O +
E2-F1 O +
, O +
that O +
is O +
involved O +
in O +
the O +
conjugation O +
and O +
degradation O +
of O +
p53 O +
, O +
is O +
also O +
required O +
for O +
the O +
limited O +
processing O +
of O +
the O +
p105 O +
precursor O +
, O +
and O +
( O +
d O +
) O +
a O +
novel O +
, O +
approximately O +
320-kDa O +
species O +
of O +
ubiquitin O -
- O -
protein O +
ligase O +
, O +
is O +
involved O +
in O +
the O +
process O +
. O +

This O +
novel O +
enzyme O +
is O +
distinct O +
from O +
E6-AP O +
, O +
the O +
p53-conjugating O +
ligase O +
, O +
and O +
from O +
E3 O +
alpha O +
, O +
the O +
` O -
` O +
N O -
- O -
end O +
rule O +
'' O +
ligase O +
. O +

Regulation O +
of O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
and O +
E O -
- O -
selectin O +
expression O +
in O +
endothelial O +
cells O +
by O +
cyclosporin O +
A O +
and O +
the O +
T O -
- O -
cell O +
transcription O +
factor O +
NFAT O +
. O +

Nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
was O +
originally O +
described O +
as O +
a O +
T O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
athat O +
supported O +
the O +
activation O +
of O +
cytokine O +
gene O +
expression O +
and O +
mediated O +
the O +
immunoregulatory O +
effects O +
of O +
cyclosporin O +
A O +
( O +
CsA O +
) O +
. O +

As O +
we O +
observed O +
that O +
activated O +
endothelial O +
cells O +
also O +
expressed O +
NFAT O +
, O +
we O +
tested O +
the O +
antiinflammatory O +
properties O +
of O +
CsA O +
in O +
endothelial O +
cells O +
. O +

Significantly O +
, O +
CsA O +
completely O +
suppressed O +
the O +
induction O +
of O +
NFAT O +
in O +
endothelial O +
cells O +
and O +
inhibited O +
the O +
activity O +
of O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
gene O +
regulatory O +
elements O +
that O +
use O +
NFAT O +
by O +
60 O +
% O +
. O +

CsA O +
similarly O +
mediated O +
a O +
reduction O +
of O +
up O +
to O +
65 O +
% O +
in O +
GM O -
- O -
CSF O +
mRNA O +
and O +
protein O +
expression O +
in O +
activated O +
endothelial O +
cells O +
. O +

CsA O +
also O +
suppressed O +
E O -
- O -
selectin O +
, O +
but O +
not O +
vascular O +
cell O +
adhesion O +
molecule-1 O +
( O +
VCAM-1 O +
) O +
expression O +
in O +
endothelial O +
cells O +
, O +
even O +
though O +
the O +
E O -
- O -
selectin O +
promoter O +
is O +
activated O +
by O +
NF O -
- O -
kappa O +
B O +
rather O +
than O +
NFAT O +
. O +

Hence O +
, O +
induction O +
of O +
cell O +
surface O +
expression O +
of O +
this O +
leukocyte O +
adhesion O +
molecule O +
by O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
-alpha O +
was O +
reduced O +
by O +
40 O +
% O +
in O +
the O +
presence O +
of O +
CsA O +
, O +
and O +
this O +
was O +
reflected O +
by O +
a O +
29 O +
% O +
decrease O +
in O +
neutrophil O +
adhesion O +
. O +

The O +
effects O +
of O +
CsA O +
on O +
endothelial O +
cells O +
were O +
also O +
detected O +
at O +
the O +
chromatin O +
structure O +
level O +
, O +
as O +
DNasel O +
hypersensitive O +
sites O +
within O +
both O +
the O +
GM O -
- O -
CSF O +
enhancer O +
and O +
the O +
E O -
- O -
selectin O +
promoter O +
were O +
suppressed O +
by O +
CsA O +
. O +

This O +
represents O +
the O +
first O +
report O +
of O +
NFAT O +
in O +
endothelial O +
cells O +
and O +
suggests O +
mechanisms O +
by O +
which O +
CsA O +
could O +
function O +
as O +
an O +
antiinflammatory O +
agent O +
. O +

The O +
hematopoietic O +
transcription O +
factor O +
PU.1 O +
is O +
downregulated O +
in O +
human B-CellLine +
multiple I-CellLine +
myeloma I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

PU.1 O +
is O +
a O +
hematopoietic O +
transcription O +
factor O +
belonging O +
to O +
the O +
Ets O -
- O -
family O +
. O +

It O +
is O +
identical O +
to O +
the O +
Spi-1 O +
oncogene O +
, O +
which O +
is O +
implicated O +
in O +
spleen O +
focus O -
- O -
forming O +
virus O -
- O -
induced O +
murine O +
erythroleukemias O +
. O +

PU.1 O +
seems O +
to O +
be O +
required O +
for O +
early O +
development O +
of O +
multiple O +
hematopoietic O +
lineages O +
, O +
but O +
its O +
expression O +
in O +
mature O +
cells O +
is O +
preferentially O +
observed O +
in O +
cells O +
of O +
the O +
B O -
- O -
cell O -
- O -
and O +
monocyte O -
/ O -
macrophage O -
- O -
differentiation O +
lineage O +
. O +

It O +
binds O +
the O +
so O -
- O -
called O +
Pu O +
box O +
, O +
an O +
important O +
tissue O -
- O -
specific O +
regulatory O +
DNA O +
element O +
present O +
in O +
a O +
number O +
of O +
genes O +
expressed O +
in O +
these O +
cell O +
lineages O +
. O +

We O +
have O +
analyzed O +
the O +
expression O +
and O +
activity O +
of O +
PU.1 O +
during O +
human O +
B O -
- O -
cell O +
development O +
using O +
a O +
panel O +
of O +
B B-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
representing O +
different O +
stages O +
of O +
maturation O +
, O +
from O +
early B-CellLine +
precursors I-CellLine +
to O +
differentiated B-CellLine +
plasma I-CellLine +
cells I-CellLine +
. O +

PU.1 O +
mRNA O +
expression O +
and O +
PU.1 O +
DNA O +
binding O +
activity O +
, O +
as O +
measured O +
by O +
Northern O +
blot O +
analysis O +
and O +
electrophoretic O +
mobility O +
shift O +
assay O +
, O +
respectively O +
, O +
were O +
evident O +
in O +
cell B-CellLine +
lines I-CellLine +
representing O +
pro B-CellLine -
- I-CellLine -
B I-CellLine +
, I-CellLine +
pre I-CellLine -
- I-CellLine -
B I-CellLine +
, I-CellLine +
and I-CellLine +
mature I-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

We O +
could O +
also O +
show O +
Pu O +
box O +
-dependent O +
transactivation O +
of O +
a O +
reporter O +
gene O +
in O +
transient O +
transfections O +
in O +
these O +
cell B-CellLine +
lines I-CellLine +
. O +

In O +
contrast O +
, O +
in O +
a O +
number O +
of O +
multiple B-CellLine +
myeloma I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
representing O +
differentiated O +
, O +
plasma O +
cell O -
- O -
like O +
B O +
cells O +
, O +
PU.1 O +
DNA O +
binding O +
activity O +
, O +
mRNA O +
expression O +
, O +
and O +
Pu O +
box O +
-dependent O +
transactivation O +
were O +
absent O +
or O +
detectable O +
at O +
a O +
very O +
low O +
level O +
. O +

In O +
lymphoblastoid B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
which O +
exemplify O +
an O +
intermediate O +
stage O +
of O +
B O -
- O -
cell O +
differentiation O +
, O +
a O +
reduced O +
expression O +
and O +
activity O +
were O +
observed O +
. O +

The O +
findings O +
in O +
the O +
human B-CellLine +
multiple I-CellLine +
myeloma I-CellLine +
cell I-CellLine +
lines I-CellLine +
represent O +
the O +
first O +
examples O +
of O +
B O +
cells O +
with O +
downregulated O +
PU.1 O +
expression O +
and O +
apparently O +
contradict O +
observations O +
in O +
the O +
murine O +
system O +
in O +
which O +
PU.1 O +
is O +
expressed O +
and O +
active O +
in O +
plasmacytoma B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

At O +
present O +
, O +
it O +
is O +
unclear O +
whether O +
the O +
lack O +
of O +
PU.1 O +
expression O +
and O +
activity O +
in O +
human B-CellLine +
multiple I-CellLine +
myeloma I-CellLine +
cell I-CellLine +
lines I-CellLine +
represents O +
a O +
malignancy O -
- O -
associated O +
defect O +
in O +
these O +
cells O +
or O +
exemplifies O +
a O +
normal O +
developmental O +
regulation O +
in O +
terminally O +
differentiated O +
B O +
cells O +
. O +

Microtubules O +
mediate O +
cellular O +
25-hydroxyvitamin O +
D3 O +
trafficking O +
and O +
the O +
genomic O +
response O +
to O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
in O +
normal O +
human O +
monocytes O +
. O +

The O +
genomic O +
actions O +
of O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
) O +
are O +
mediated O +
by O +
the O +
intracellular O +
vitamin O +
D O +
receptor O +
( O +
VDR O +
) O +
. O +

Although O +
immunocytochemistry O +
has O +
shown O +
that O +
disruption O +
of O +
microtubular O +
assembly O +
prevents O +
nuclear O +
access O +
of O +
the O +
sterol O -
- O -
VDR O +
complex O +
, O +
the O +
role O +
of O +
microtubules O +
in O +
the O +
response O +
to O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
has O +
not O +
been O +
studied O +
in O +
viable O +
cells O +
. O +

Our O +
studies O +
examined O +
this O +
interaction O +
in O +
normal O +
human O +
monocytes O +
. O +

Monocytes O +
convert O +
25 O +
( O +
OH O +
) O +
D3 O +
to O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
and O +
to O +
24-hydroxylated O +
metabolites O +
more O +
polar O +
than O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
. O +

Microtubule O +
disruption O +
totally O +
abolished O +
the O +
ability O +
of O +
exogenous O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
to O +
suppress O +
its O +
own O +
synthesis O +
and O +
to O +
induce O +
24-hydroxylase O +
mRNA O +
and O +
activity O +
, O +
without O +
affecting O +
either O +
total O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
uptake O +
or O +
maximal O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
-VDR O +
binding O +
. O +

Thus O +
, O +
intact O +
microtubules O +
are O +
essential O +
for O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3-dependent O +
modulation O +
of O +
gene O +
transcription O +
. O +

Interestingly O +
, O +
microtubule O +
disruption O +
also O +
decreased O +
monocyte O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
synthesis O +
, O +
not O +
by O +
decreasing O +
the O +
Vmax O +
of O +
monocyte O +
mitochondrial O +
1 O +
alpha O -
- O -
hydroxylase O +
but O +
through O +
an O +
increase O +
in O +
the O +
Km O +
for O +
25 O +
( O +
OH O +
) O +
2D3 O +
. O +

We O +
examined O +
25 O +
( O +
OH O +
) O +
D3 O +
transport O +
. O +

Microtubule O +
disruption O +
did O +
not O +
affect O +
total O +
cellular O +
25 O +
( O +
OH O +
) O +
D3 O +
uptake O +
but O +
reduced O +
its O +
intracellular O +
trafficking O +
to O +
the O +
mitochondria O +
. O +

Thus O +
, O +
microtubules O +
participate O +
in O +
intracellular O +
25 O +
( O +
OH O +
) O +
D3 O +
transport O +
, O +
and O +
their O +
integrity O +
determines O +
normal O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
synthesis O +
. O +

Chromosomal O +
localization O +
of O +
two O +
KOX O +
zinc O +
finger O +
genes O +
on O +
chromosome O +
bands O +
7q21-q22 O +
. O +

Human O +
cDNAs O +
encoding O +
Kruppel O -
- O -
type O +
zinc O +
finger O +
domains O +
, O +
designated O +
KOX O +
1 O -
- O -
32 O +
, O +
have O +
been O +
cloned O +
from O +
human O +
T O +
lymphocyte O +
cell O +
line O +
libraries O +
. O +

We O +
report O +
here O +
the O +
regional O +
localizations O +
by O +
in O +
situ O +
hybridization O +
of O +
KOX O +
18 O +
and O +
KOX O +
25 O +
on O +
chromosome O +
bands O +
7q21q22 O +
. O +

Pulse O -
- O -
field O +
gel O +
electrophoresis O +
( O +
PFGE O +
) O +
analysis O +
showed O +
that O +
these O +
genes O +
are O +
physically O +
located O +
within O +
a O +
DNA O +
fragment O +
of O +
250 O +
kb O +
. O +

The O +
genes O +
KOX O +
4 O +
and O +
KOX O +
9 O +
, O +
mapped O +
on O +
chromosome O +
8q24 O +
, O +
were O +
found O +
to O +
be O +
located O +
within O +
a O +
DNA O +
fragment O +
of O +
450 O +
kb O +
. O +

From O +
the O +
present O +
and O +
previous O +
data O +
, O +
eighteen O +
different O +
KOX O +
genes O +
have O +
been O +
located O +
at O +
least O +
two O +
by O +
two O +
within O +
nine O +
DNA O +
fragments O +
of O +
200 O +
to O +
580 O +
kb O +
. O +

Evidence O +
for O +
normal O +
vitamin O +
D O +
receptor O +
messenger O +
ribonucleic O +
acid O +
and O +
genotype O +
in O +
absorptive O +
hypercalciuria O +
. O +

Absorptive O +
hypercalciuria O +
( O +
a O +
stone O -
- O -
forming O +
condition O +
) O +
is O +
characterized O +
by O +
gut O +
hyperabsorption O +
of O +
calcium O +
, O +
hypercalciuria O +
, O +
and O +
reduced O +
bone O +
density O +
. O +

Inasmuch O +
as O +
these O +
features O +
implicate O +
enhanced O +
calcitriol O +
action O +
in O +
gut O +
and O +
bone O +
, O +
we O +
analyzed O +
the O +
vitamin O +
D O +
receptor O +
( O +
VDR O +
) O +
gene O +
to O +
ascertain O +
whether O +
an O +
abnormality O +
of O +
this O +
gene O +
marks O +
patients O +
with O +
intestinal O +
hyperabsorption O +
of O +
calcium O +
. O +

We O +
have O +
compared O +
the O +
frequency O +
of O +
a O +
restriction O +
fragment O +
length O +
polymorphism O +
( O +
Bsm O +
I O +
) O +
associated O +
with O +
different O +
alleles O +
of O +
the O +
VDR O +
gene O +
in O +
a O +
group O +
of O +
33 O +
well O +
characterized O +
absorptive O +
hypercalciuric O +
patients O +
and O +
a O +
group O +
of O +
36 O +
normal O +
race- O +
and O +
age O -
- O -
matched O +
control O +
subjects O +
. O +

There O +
was O +
no O +
difference O +
between O +
the O +
distribution O +
of O +
the O +
VDR O +
alleles O +
in O +
the O +
patient O +
population O +
when O +
compared O +
with O +
the O +
normal O +
population O +
. O +

The O +
coding O +
region O +
of O +
VDR O +
messenger O +
RNA O +
was O +
also O +
normal O +
, O +
as O +
determined O +
by O +
both O +
DNA O +
sequence O +
analysis O +
and O +
chemical O +
mismatch O +
cleavage O +
analysis O +
of O +
copy O +
DNA O +
from O +
11 O +
index O +
absorptive O +
hypercalciuric O +
patients O +
. O +

On O +
the O +
basis O +
of O +
these O +
results O +
, O +
we O +
propose O +
that O +
the O +
enhanced O +
intestinal O +
calcium O +
absorption O +
invariably O +
seen O +
in O +
absorptive O +
hypercalciuria O +
and O +
attendant O +
symptoms O +
of O +
this O +
disorder O +
are O +
not O +
attributable O +
to O +
mutations O +
of O +
the O +
VDR O +
and O +
are O +
not O +
linked O +
to O +
a O +
common O +
VDR O +
genotype O +
. O +

Signalling O +
via O +
CD28 O +
of O +
human B-CellLine +
naive I-CellLine +
neonatal I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
. O +

Accessory O +
molecules O +
play O +
a O +
crucial O +
role O +
in O +
the O +
development O +
of O +
the O +
T O +
cell O +
response O +
to O +
antigenic O +
challenge O +
. O +

We O +
have O +
examined O +
the O +
role O +
of O +
CD28 O +
in O +
modulating O +
the O +
' O -
naive O +
' O +
neonatal O +
T O +
cell O +
response O +
to O +
anti O -
- O -
CD2 O +
-mediated O +
activation O +
. O +

To O +
compare O +
the O +
role O +
of O +
CD28 O +
, O +
neonatal O +
and O +
adult O +
T O +
cells O +
were O +
stimulated O +
with O +
a O +
pair O +
of O +
mitogenic O +
anti O -
- O -
CD2 O +
antibodies O +
in O +
the O +
presence O +
or O +
absence O +
of O +
anti O -
- O -
CD28 O +
MoAb O +
. O +

With O +
anti O -
- O -
CD2 O +
alone O +
, O +
neonatal O +
T O +
cells O +
proliferated O +
slightly O +
but O +
produced O +
no O +
detectable O +
IL-2 O +
, O +
whereas O +
adult O +
T O +
cells O +
proliferated O +
vigorously O +
, O +
with O +
significant O +
IL-2 O +
production O +
. O +

Costimulation O +
with O +
anti O -
- O -
CD28 O +
MoAb O +
greatly O +
enhanced O +
the O +
proliferative O +
response O +
of O +
neonatal O +
T O +
cells O +
to O +
levels O +
equivalent O +
to O +
those O +
of O +
adult O +
T O +
cells O +
, O +
whereas O +
adult O +
T O +
cells O +
showed O +
only O +
slight O +
increases O +
. O +

Although O +
IL-2 O +
secretion O +
was O +
increased O +
in O +
the O +
presence O +
of O +
anti O -
- O -
CD28 O +
MoAb O +
, O +
neonatal O +
T O +
cell O +
IL-2 O +
production O +
remained O +
lower O +
than O +
in O +
adults O +
. O +

In O +
contrast O +
, O +
enhancement O +
of O +
IL-2 O +
mRNA O +
expression O +
in O +
neonates O +
was O +
similar O +
to O +
adult O +
levels O +
. O +

Anti- O +
CD28 O +
MoAb O +
costimulation O +
increased O +
NF O +
kappa O +
B O +
levels O +
in O +
neonates O +
, O +
albeit O +
to O +
levels O +
lower O +
than O +
that O +
of O +
adults O +
. O +

The O +
cellular O +
mechanism O +
governing O +
the O +
diminished O +
proliferative O +
response O +
of O +
neonatal O +
T O +
lymphocytes O +
to O +
anti O -
- O -
CD2 O +
may O +
therefore O +
be O +
due O +
to O +
decreased O +
NF O +
kappa O +
B O +
induction O +
, O +
reduced O +
IL-2 O +
mRNA O +
expression O +
and O +
deficient O +
IL-2 O +
production O +
. O +

Although O +
anti O -
- O -
CD28 O +
MoAb O +
costimulation O +
enhances O +
all O +
of O +
the O +
above O +
signals O +
, O +
NF O +
kappa O +
B O +
and O +
IL-2 O +
levels O +
remain O +
lower O +
than O +
in O +
adults O +
, O +
suggesting O +
the O +
need O +
for O +
further O +
activation O +
requirements O +
in O +
the O +
neonate O +
. O +

The O +
DNA O -
- O -
binding O +
properties O +
of O +
two O +
heat O +
shock O +
factors O +
, O +
HSF1 O +
and O +
HSF3 O +
, O +
are O +
induced O +
in O +
the O +
avian B-CellLine +
erythroblast I-CellLine +
cell I-CellLine +
line I-CellLine +
HD6 B-CellLine +
. O +

Avian O +
cells O +
express O +
three O +
heat O +
shock O +
transcription O +
factor O +
( O +
HSF O +
) O +
genes O +
corresponding O +
to O +
a O +
novel O +
factor O +
, O +
HSF3 O +
, O +
and O +
homologs O +
of O +
mouse O +
and O +
human O +
HSF1 O +
and O +
HSF2 O +
. O +

Analysis O +
of O +
the O +
biochemical O +
and O +
cell O +
biological O +
properties O +
of O +
these O +
HSFs O +
reveals O +
that O +
HSF3 O +
has O +
properties O +
in O +
common O +
with O +
both O +
HSF1 O +
and O +
HSF2 O +
and O +
yet O +
has O +
features O +
which O +
are O +
distinct O +
from O +
both O +
. O +

HSF3 O +
is O +
constitutively O +
expressed O +
in O +
the O +
erythroblast B-CellLine +
cell I-CellLine +
line I-CellLine +
HD6 I-CellLine +
, O +
the O +
lymphoblast B-CellLine +
cell I-CellLine +
line I-CellLine +
MSB I-CellLine +
, O +
and O +
embryo B-CellLine +
fibroblasts I-CellLine +
, O +
and O +
yet O +
its O +
DNA O -
- O -
binding O +
activity O +
is O +
induced O +
only O +
upon O +
exposure O +
of O +
HD6 O +
cells O +
to O +
heat O +
shock O +
. O +

Acquisition O +
of O +
HSF3 O +
DNA O -
- O -
binding O +
activity O +
in O +
HD6 B-CellLine +
cells I-CellLine +
is O +
accompanied O +
by O +
oligomerization O +
from O +
a O +
non O -
- O -
DNA O -
- O -
binding O +
dimer O +
to O +
a O +
DNA O -
- O -
binding O +
trimer O +
, O +
whereas O +
the O +
effect O +
of O +
heat O +
shock O +
on O +
HSF1 O +
is O +
oligomerization O +
of O +
an O +
inert O +
monomer O +
to O +
a O +
DNA O -
- O -
binding O +
trimer O +
. O +

Induction O +
of O +
HSF3 O +
DNA O -
- O -
binding O +
activity O +
is O +
delayed O +
compared O +
with O +
that O +
of O +
HSF1 O +
. O +

As O +
occurs O +
for O +
HSF1 O +
, O +
heat O +
shock O +
leads O +
to O +
the O +
translocation O +
of O +
HSF3 O +
to O +
the O +
nucleus O +
. O +

HSF O +
exhibits O +
the O +
properties O +
of O +
a O +
transcriptional O +
activator O +
, O +
as O +
judged O +
from O +
the O +
stimulatory O +
activity O +
of O +
transiently O +
overexpressed O +
HSF3 O +
measured O +
by O +
using O +
a O +
heat O +
shock O +
element O -
- O -
containing O +
reporter O +
construct O +
and O +
as O +
independently O +
assayed O +
by O +
the O +
activity O +
of O +
a O +
chimeric O +
GAL4-HSF3 O +
protein O +
on O +
a O +
GAL4 O +
reporter O +
construct O +
. O +

These O +
results O +
reveal O +
that O +
HSF3 O +
is O +
negatively O +
regulated O +
in O +
avian O +
cells O +
and O +
acquires O +
DNA O -
- O -
binding O +
activity O +
in O +
certain O +
cells O +
upon O +
heat O +
shock O +
. O +

A O +
central O +
role O +
for O +
a O +
single O +
c O -
- O -
Myb O +
binding O +
site O +
in O +
a O +
thymic O +
locus O +
control O +
region O +
. O +

Locus O +
control O +
regions O +
( O +
LCRs O +
) O +
are O +
powerful O +
assemblies O +
of O +
cis O +
elements O +
that O +
organize O +
the O +
actions O +
of O +
cell O -
- O -
type O -
- O -
specific O +
trans O -
- O -
acting O +
factors O +
. O +

A O +
2.3-kb O +
LCR O +
in O +
the O +
human O +
adenosine O +
deaminase O +
( O +
ADA O +
) O +
gene O +
first O +
intron O +
, O +
which O +
controls O +
expression O +
in O +
thymocytes O +
, O +
is O +
composed O +
of O +
a O +
200-bp O +
enhancer O +
domain O +
and O +
extended O +
flanking O +
sequences O +
that O +
facilitate O +
activation O +
from O +
within O +
chromatin O +
. O +

Prior O +
analyses O +
have O +
demonstrated O +
that O +
the O +
enhancer O +
contains O +
a O +
28-bp O +
core O +
region O +
and O +
local O +
adjacent O +
augmentative O +
cis O +
elements O +
. O +

We O +
now O +
show O +
that O +
the O +
core O +
contains O +
a O +
single O +
critical O +
c O -
- O -
Myb O +
binding O +
site O +
. O +

In O +
both O +
transiently B-CellLine +
cotransfected I-CellLine +
human I-CellLine +
cells I-CellLine +
and O +
stable O +
chromatin B-CellLine -
- I-CellLine -
integrated I-CellLine +
yeast I-CellLine +
cells I-CellLine +
, O +
c O -
- O -
Myb O +
strongly O +
transactivated O +
reporter O +
constructs O +
that O +
contained O +
polymerized O +
core O +
sequences O +
. O +

c O -
- O -
Myb O +
protein O +
was O +
strongly O +
evident O +
in O +
T O +
lymphoblasts O +
in O +
which O +
the O +
enhancer O +
was O +
active O +
and O +
was O +
localized O +
within O +
discrete O +
nuclear O +
structures O +
. O +

Fetal O +
murine O +
thymus O +
exhibited O +
a O +
striking O +
concordance O +
of O +
endogenous O +
c O -
- O -
myb O +
expression O +
with O +
that O +
of O +
mouse O +
ADA O +
and O +
human O +
ADA O +
LCR O +
-directed O +
transgene O +
expression O +
. O +

Point O +
mutation O +
of O +
the O +
c O -
- O -
Myb O +
site O +
within O +
the O +
intact O +
2.3-kb O +
LCR O +
severely O +
attenuated O +
enhancer O +
activity O +
in O +
transfections O +
and O +
LCR O +
activity O +
in O +
transgenic B-CellLine +
thymocytes I-CellLine +
. O +

Within O +
the O +
context O +
of O +
a O +
complex O +
enhancer O +
and O +
LCR O +
, O +
c O -
- O -
Myb O +
can O +
act O +
as O +
an O +
organizer O +
of O +
thymocyte O -
- O -
specific O +
gene O +
expression O +
via O +
a O +
single O +
binding O +
site O +
. O +

Transcriptional O +
repression O +
of O +
the O +
interleukin-2 O +
gene O +
by O +
vitamin O +
D3 O +
: O +
direct O +
inhibition O +
of O +
NFATp O -
/ O -
AP-1 O +
complex O +
formation O +
by O +
a O +
nuclear O +
hormone O +
receptor O +
. O +

T O -
- O -
lymphocyte O +
proliferation O +
is O +
suppressed O +
by O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
[ O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
] O +
, O +
the O +
active O +
metabolite O +
of O +
vitamin O +
D3 O +
, O +
and O +
is O +
associated O +
with O +
a O +
decrease O +
in O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
, O +
gamma O +
interferon O +
, O +
and O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
mRNA O +
levels O +
. O +

We O +
report O +
here O +
that O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3-mediated O +
repression O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
is O +
cycloheximide O +
resistant O +
, O +
suggesting O +
that O +
it O +
is O +
a O +
direct O +
transcriptional O +
repressive O +
effect O +
on O +
IL-2 O +
expression O +
by O +
the O +
vitamin O +
D3 O +
receptor O +
( O +
VDR O +
) O +
. O +

We O +
therefore O +
examined O +
vitamin O +
D3-mediated O +
repression O +
of O +
activated O +
IL-2 O +
expression O +
by O +
cotransfecting O +
Jurkat B-CellLine +
cells I-CellLine +
with O +
IL-2 O +
promoter O -
/ O -
reporter O +
constructs O +
and O +
a O +
VDR O +
overexpression O +
vector O +
and O +
by O +
DNA O +
binding O +
. O +

We O +
delineated O +
an O +
element O +
conferring O +
both O +
DNA O +
binding O +
by O +
the O +
receptor O +
in O +
vitro O +
and O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3-mediated O +
repression O +
in O +
vivo O +
to O +
a O +
short O +
40-bp O +
region O +
encompassing O +
an O +
important O +
positive O +
regulatory O +
element O +
, O +
NF O -
- O -
AT-1 O +
, O +
which O +
is O +
bound O +
by O +
a O +
T O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
, O +
NFATp O +
, O +
as O +
well O +
as O +
by O +
AP-1 O +
. O +

VDR O +
DNA O -
- O -
binding O +
mutants O +
were O +
unable O +
to O +
either O +
bind O +
to O +
this O +
element O +
in O +
vitro O +
or O +
repress O +
in O +
vivo O +
; O +
the O +
VDR O +
DNA O -
- O -
binding O +
domain O +
alone O +
, O +
however O +
, O +
bound O +
the O +
element O +
but O +
also O +
could O +
not O +
repress O +
IL-2 O +
expression O +
. O +

These O +
results O +
indicate O +
that O +
DNA O +
binding O +
by O +
VDR O +
is O +
necessary O +
but O +
not O +
sufficient O +
to O +
mediate O +
IL-2 O +
repression O +
. O +

By O +
combining O +
partially O +
purified O +
proteins O +
in O +
vitro O +
, O +
we O +
observed O +
the O +
loss O +
of O +
the O +
bound O +
NFATp O -
/ O -
AP-1-DNA O +
complex O +
upon O +
inclusion O +
of O +
VDR O +
or O +
VDR O -
- O -
retinoid O +
X O +
receptor O +
. O +

Order O +
of O +
addition O +
and O +
off O -
- O -
rate O +
experiments O +
indicate O +
that O +
the O +
VDR O -
- O -
retinoid O +
X O +
receptor O +
heterodimer O +
blocks O +
NFATp O -
/ O -
AP-1 O +
complex O +
formation O +
and O +
then O +
stably O +
associates O +
with O +
the O +
NF O -
- O -
AT-1 O +
element O +
. O +

This O +
direct O +
inhibition O +
by O +
a O +
nuclear O +
hormone O +
receptor O +
of O +
transcriptional O +
activators O +
of O +
the O +
IL-2 O +
gene O +
may O +
provide O +
a O +
mechanistic O +
explanation O +
of O +
how O +
vitamin O +
derivatives O +
can O +
act O +
as O +
potent O +
immunosuppressive O +
agents O +
. O +

PU.1 O +
( O +
Spi-1 O +
) O +
and O +
C O -
/ O -
EBP O +
alpha O +
regulate O +
expression O +
of O +
the O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
receptor O +
alpha O +
gene O +
. O +

Growth O +
factor O +
receptors O +
play O +
an O +
important O +
role O +
in O +
hematopoiesis O +
. O +

In O +
order O +
to O +
further O +
understand O +
the O +
mechanisms O +
directing O +
the O +
expression O +
of O +
these O +
key O +
regulators O +
of O +
hematopoiesis O +
, O +
we O +
initiated O +
a O +
study O +
investigating O +
the O +
transcription O +
factors O +
activating O +
the O +
expression O +
of O +
the O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
receptor O +
alpha O +
gene O +
. O +

Here O +
, O +
we O +
demonstrate O +
that O +
the O +
human O +
GM O -
- O -
CSF O +
receptor O +
alpha O +
promoter O +
directs O +
reporter O +
gene O +
activity O +
in O +
a O +
tissue O -
- O -
specific O +
fashion O +
in O +
myelomonocytic O +
cells O +
, O +
which O +
correlates O +
with O +
its O +
expression O +
pattern O +
as O +
analyzed O +
by O +
reverse O +
transcription O +
PCR O +
. O +

The O +
GM O -
- O -
CSF O +
receptor O +
alpha O +
promoter O +
contains O +
an O +
important O +
functional O +
site O +
between O +
positions O +
-53 O +
and O +
-41 O +
as O +
identified O +
by O +
deletion O +
analysis O +
of O +
reporter O +
constructs O +
. O +

We O +
show O +
that O +
the O +
myeloid O +
and O +
B O +
cell O +
transcription O +
factor O +
PU.1 O +
binds O +
specifically O +
to O +
this O +
site O +
. O +

Furthermore O +
, O +
we O +
demonstrate O +
that O +
a O +
CCAAT O +
site O +
located O +
upstream O +
of O +
the O +
PU.1 O +
site O +
between O +
positions O +
-70 O +
and O +
-54 O +
is O +
involved O +
in O +
positive O -
- O -
negative O +
regulation O +
of O +
the O +
GM O -
- O -
CSF O +
receptor O +
alpha O +
promoter O +
activity O +
. O +

C O -
/ O -
EBP O +
alpha O +
is O +
the O +
major O +
CCAAT O -
/ O -
enhancer O -
- O -
binding O +
protein O +
( O +
C O -
/ O -
EBP O +
) O +
form O +
binding O +
to O +
this O +
site O +
in O +
nuclear O +
extracts O +
of O +
U937 B-CellLine +
cells I-CellLine +
. O +

Point O +
mutations O +
of O +
either O +
the O +
PU.1 O +
site O +
or O +
the O +
C O -
/ O -
EBP O +
site O +
that O +
abolish O +
the O +
binding O +
of O +
the O +
respective O +
factors O +
result O +
in O +
a O +
significant O +
decrease O +
of O +
GM O -
- O -
CSF O +
receptor O +
alpha O +
promoter O +
activity O +
in O +
myelomonocytic O +
cells O +
only O +
. O +

Furthermore O +
, O +
we O +
demonstrate O +
that O +
in O +
myeloid O +
and O +
B O +
cell O +
extracts O +
, O +
PU.1 O +
forms O +
a O +
novel O +
, O +
specific O +
, O +
more O +
slowly O +
migrating O +
complex O +
( O +
PU O -
- O -
SF O +
) O +
when O +
binding O +
the O +
GM O -
- O -
CSF O +
receptor O +
alpha O +
promoter O +
PU.1 O +
site O +
. O +

This O +
is O +
the O +
first O +
demonstration O +
of O +
a O +
specific O +
interaction O +
with O +
PU.1 O +
on O +
a O +
myeloid O +
PU.1 O +
binding O +
site O +
. O +

The O +
novel O +
complex O +
is O +
distinct O +
from O +
that O +
described O +
previously O +
as O +
binding O +
to O +
B O +
cell O +
enhancer O +
sites O +
and O +
can O +
be O +
formed O +
by O +
addition O +
of O +
PU.1 O +
to O +
extracts O +
from O +
certain O +
nonmyeloid O +
cell O +
types O +
which O +
do O +
not O +
express O +
PU.1 O +
, O +
including O +
T O +
cells O +
and O +
epithelial O +
cells O +
, O +
but O +
not O +
from O +
erythroid O +
cells O +
. O +

Furthermore O +
, O +
we O +
demonstrate O +
that O +
the O +
PU O -
- O -
SF O +
complex O +
binds O +
to O +
PU.1 O +
sites O +
found O +
on O +
a O +
number O +
of O +
myeloid O +
promoters O +
, O +
and O +
its O +
formation O +
requires O +
an O +
intact O +
PU.1 O +
site O +
adjacent O +
to O +
a O +
single O -
- O -
stranded O +
region O +
. O +

Expression O +
of O +
PU.1 O +
in O +
nonmyeloid O +
cells O +
can O +
activate O +
the O +
GM O -
- O -
CSF O +
receptor O +
alpha O +
promoter O +
. O +

Deletion O +
of O +
the O +
amino O -
- O -
terminal O +
region O +
of O +
PU.1 O +
results O +
in O +
a O +
failure O +
to O +
form O +
the O +
PU O -
- O -
SF O +
complex O +
and O +
in O +
a O +
concomitant O +
loss O +
of O +
transactivation O +
, O +
suggesting O +
that O +
formation O +
of O +
the O +
PU O -
- O -
SF O +
complex O +
is O +
of O +
functional O +
importance O +
for O +
the O +
activity O +
of O +
the O +
GM O -
- O -
CSF O +
receptor O +
alpha O +
promoter O +
. O +

Finally O +
, O +
we O +
demonstrate O +
that O +
C O -
/ O -
EBP O +
alpha O +
can O +
also O +
active O +
the O +
GM O -
- O -
CSF O +
receptor O +
alpha O +
promoter O +
in O +
nonmyeloid O +
cells O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
400 O +
WORDS O +
) O +

Expression O +
of O +
the O +
chemokine O +
receptor O +
BLR2 O -
/ O -
EBI1 O +
is O +
specifically O +
transactivated O +
by O +
Epstein O -
- O -
Barr O +
virus O +
nuclear O +
antigen O +
2 O +
. O +

In O +
our O +
attempt O +
to O +
identify O +
chemokine O +
receptors O +
that O +
are O +
related O +
to O +
Burkitt O +
's O +
lymphoma O +
receptor O +
1 O +
( O +
BLR1 O +
) O +
and O +
are O +
expressed O +
in O +
activated O +
lymphocytes O +
we O +
used O +
RT O -
- O -
PCR O +
resulting O +
in O +
the O +
isolation O +
of O +
a O +
cDNA O +
encoding O +
a O +
seven O +
transmembrane O +
receptor O +
termed O +
BLR2 O +
. O +

The O +
protein O +
shows O +
significant O +
sequence O +
similarities O +
to O +
the O +
family O +
of O +
G O -
- O -
protein O +
coupled O +
chemokine O +
receptors O +
and O +
turned O +
out O +
to O +
be O +
identical O +
to O +
the O +
recently O +
described O +
receptor O +
EBI1 O +
. O +

Northern O +
blot O +
analysis O +
revealed O +
that O +
BLR2 O +
mRNA O +
could O +
be O +
highly O +
stimulated O +
in O +
mitogen- B-CellLine +
and I-CellLine +
anti I-CellLine -
- I-CellLine -
CD3-treated I-CellLine +
peripheral I-CellLine +
blood I-CellLine +
lymphocytes I-CellLine +
. O +

BLR2-specific O +
mRNA O +
could O +
be O +
detected O +
in O +
all O +
Epstein B-CellLine -
- I-CellLine -
Barr I-CellLine +
virus I-CellLine +
positive I-CellLine +
B I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

We O +
show O +
that O +
transcription O +
of O +
the O +
BLR2 O +
gene O +
could O +
be O +
specifically O +
induced O +
in O +
Epstein B-CellLine -
- I-CellLine -
Barr I-CellLine +
virus I-CellLine +
negative I-CellLine +
BL I-CellLine +
41 I-CellLine +
cells I-CellLine +
via O +
estrogen O -
- O -
mediated O +
activation O +
of O +
Epstein O -
- O -
Barr O +
virus O +
nuclear O +
antigen O +
2 O +
, O +
a O +
key O +
regulator O +
of O +
viral O +
and O +
cellular O +
genes O +
in O +
immortalized B-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

Our O +
data O +
suggest O +
an O +
involvement O +
of O +
BLR2 O +
in O +
the O +
regulation O +
of O +
migration O +
in O +
activated O +
lymphocytes O +
and O +
in O +
viral O +
pathogenesis O +
. O +

Pathogenesis O +
of O +
atherosclerosis O +
. O +

The O +
earliest O +
lesion O +
in O +
the O +
development O +
of O +
an O +
atherosclerotic O +
plaque O +
is O +
the O +
fatty O +
streak O +
. O +

This O +
chronic O +
inflammatory O +
reaction O +
results O +
from O +
a O +
sequence O +
of O +
events O +
that O +
begins O +
with O +
the O +
trapping O +
of O +
low O +
density O +
lipoprotein O +
( O +
LDL O +
) O +
in O +
the O +
subendothelial O +
space O +
of O +
the O +
artery O +
wall O +
. O +

The O +
trapped O +
LDL O +
is O +
seeded O +
with O +
oxidative O +
species O +
released O +
by O +
the O +
overlying O +
endothelium O +
, O +
and O +
lipid O +
oxidation O +
is O +
initiated O +
within O +
the O +
LDL O +
particle O -
. O +
Some O +
of O +
the O +
lipids O +
that O +
result O +
lead O +
to O +
the O +
activation O +
of O +
NFkB O -
- O -
like O +
transcription O +
factors O +
that O +
cause O +
the O +
expression O +
of O +
genes O +
whose O +
protein O +
products O +
mediate O +
monocyte O +
binding O +
, O +
monocyte O +
chemotaxis O +
into O +
the O +
subendothelial O +
space O +
, O +
and O +
conversion O +
into O +
macrophages O +
. O +

At O +
least O +
1 O +
major O +
gene O +
modulates O +
the O +
oxidation O +
of O +
LDL O +
lipids O +
and/or O +
the O +
biologic O +
response O +
to O +
these O +
lipids O +
. O +

The O +
inverse O +
relation O +
between O +
high O +
density O +
lipoprotein O +
( O +
HDL O +
) O +
and O +
atherosclerotic O +
events O +
may O +
in O +
part O +
be O +
due O +
to O +
enzymes O +
associated O +
with O +
HDL O +
that O +
destroy O +
the O +
biologically O +
active O +
lipids O +
generated O +
in O +
LDL O +
. O +

HMG O -
- O -
I O +
binds O +
to O +
GATA O +
motifs O +
: O +
implications O +
for O +
an O +
HPFH O +
syndrome O +
. O +

We O +
have O +
examined O +
binding O +
of O +
the O +
nuclear O +
protein O +
HMG O -
- O -
I O +
to O +
the O +
human O +
gamma O -
- O -
globin O +
promoter O +
. O +

We O +
find O +
that O +
HMG O -
- O -
I O +
binds O +
preferentially O +
to O +
the O +
more O +
3 O +
' O +
of O +
a O +
pair O +
of O +
GATA O +
motifs O +
in O +
the O +
gamma O -
- O -
globin O +
promoter O +
; O +
this O +
paired O +
motif O +
is O +
bound O +
by O +
the O +
erythroid O +
factor O +
GATA-1 O +
. O +

A O +
naturally O +
occurring O +
mutation O +
( O +
-175 O +
T O -
- O -
C O +
) O +
in O +
the O +
area O +
bound O +
by O +
HMG O -
- O -
I O +
results O +
in O +
overexpression O +
of O +
gamma O -
- O -
globin O +
in O +
adult O +
red O +
blood O +
cells O +
( O +
HPFH O +
) O +
and O +
up O -
- O -
regulation O +
of O +
the O +
gamma O -
- O -
globin O +
promoter O +
in O +
in O +
vitro O +
expression O +
assays O +
; O +
HMG O -
- O -
I O +
does O +
not O +
bind O +
to O +
this O +
mutant O +
sequence O +
. O +

A O +
survey O +
of O +
GATA O +
motifs O +
from O +
other O +
globin O +
cis O -
- O -
elements O +
demonstrates O +
HMG O -
- O -
I O +
binding O +
to O +
most O +
of O +
them O +
. O +

These O +
findings O +
implicate O +
HMG O -
- O -
I O +
in O +
the O +
HPFH O +
phenotype O +
; O +
we O +
speculate O +
that O +
it O +
may O +
participate O +
in O +
the O +
formation O +
of O +
multiprotein O +
complexes O +
that O +
regulate O +
globin O +
gene O +
expression O +
. O +

Multiple O +
proteins O +
interact O +
with O +
the O +
nuclear O +
inhibitory O +
protein O +
repressor O +
element O +
in O +
the O +
human O +
interleukin-3 O +
promoter O +
. O +

T O +
cell O +
expression O +
of O +
interleukin O +
3 O +
( O +
IL-3 O +
) O +
is O +
directed O +
by O +
positive O +
and O +
negative O +
cis O -
- O -
acting O +
DNA O +
elements O +
clustered O +
within O +
300 O +
base O +
pairs O +
of O +
the O +
transcriptional O +
start O +
site O +
. O +

A O +
strong O +
repressor O +
element O +
, O +
termed O +
nuclear O +
inhibitory O +
protein O +
( O +
NIP O +
) O +
, O +
was O +
previously O +
mapped O +
to O +
a O +
segment O +
of O +
the O +
IL-3 O +
promoter O +
between O +
nucleotides O +
-271 O +
and O +
-250 O +
. O +

Functional O +
characterization O +
of O +
this O +
element O +
demonstrates O +
that O +
it O +
can O +
mediate O +
repression O +
when O +
linked O +
in O +
cis O +
to O +
a O +
heterologous O +
promoter O +
. O +

DNA O +
binding O +
experiments O +
were O +
carried O +
out O +
to O +
characterize O +
the O +
repressor O +
activity O +
. O +

Using O +
varying O +
conditions O +
, O +
three O +
distinct O +
complexes O +
were O +
shown O +
to O +
interact O +
specifically O +
with O +
the O +
NIP O +
region O +
, O +
although O +
only O +
one O +
correlates O +
with O +
repressor O +
activity O +
. O +

Complex O +
1 O +
results O +
from O +
binding O +
of O +
a O +
ubiquitous O +
polypeptide O +
that O +
recognizes O +
the O +
3 O +
' O +
portion O +
of O +
this O +
sequence O +
and O +
is O +
not O +
required O +
for O +
repression O +
. O +

Complex O +
2 O +
corresponds O +
to O +
binding O +
of O +
transcription O +
factor O +
( O +
upstream O +
stimulatory O +
factor O +
) O +
to O +
an O +
E O -
- O -
box O +
motif O +
in O +
the O +
5 O +
' O +
portion O +
of O +
the O +
NIP O +
region O +
. O +

DNA O +
binding O +
specificity O +
of O +
complex O +
3 O +
overlaps O +
with O +
that O +
of O +
upstream O +
stimulatory O +
factor O +
but O +
is O +
clearly O +
distinct O +
. O +

To O +
determine O +
which O +
of O +
the O +
latter O +
two O +
complexes O +
represents O +
NIP O +
activity O +
, O +
we O +
incorporated O +
small O +
alterations O +
into O +
the O +
NIP O +
site O +
of O +
an O +
IL-3 O +
promoter O -
- O -
linked O +
reporter O +
construct O +
and O +
examined O +
their O +
effects O +
on O +
NIP O +
-mediated O +
repression O +
. O +

Functional O +
specificity O +
for O +
repression O +
matches O +
the O +
DNA O +
binding O +
specificity O +
of O +
complex O +
3 O +
; O +
both O +
repressor O +
activity O +
and O +
complex O +
3 O +
binding O +
require O +
the O +
consensus O +
sequence O +
CTCACNTNC O +
. O +

Nonopsonic O +
phagocytosis O +
of O +
Pseudomonas O +
aeruginosa O +
by O +
macrophages O +
and O +
polymorphonuclear O +
leukocytes O +
requires O +
the O +
presence O +
of O +
the O +
bacterial O +
flagellum O +
. O +

Whereas O +
the O +
mechanism O +
of O +
nonopsonic O +
phagocytosis O +
of O +
Pseudomonas O +
aeruginosa O +
has O +
been O +
described O +
, O +
the O +
bacterial O +
ligands O +
required O +
are O +
poorly O +
understood O +
. O +

To O +
identify O +
the O +
requisite O +
bacterial O +
ligands O +
, O +
studies O +
with O +
isogenic O +
mutants O +
of O +
P. O +
aeruginosa O +
PAK O +
lacking O +
pili O +
, O +
flagella O +
, O +
and O +
the O +
RpoN O +
sigma O +
factor O +
were O +
undertaken O +
. O +

The O +
RpoN O +
mutant O +
, O +
lacking O +
pili O +
, O +
flagella O +
, O +
and O +
nonpilus O +
adhesins O +
, O +
bound O +
poorly O +
and O +
was O +
resistant O +
to O +
ingestion O +
by O +
both O +
macrophages O +
and O +
neutrophils O +
. O +

Pili O +
were O +
not O +
absolutely O +
required O +
for O +
binding O +
or O +
phagocytosis O +
of O +
P. O +
aeruginosa O +
. O +

The O +
presence O +
of O +
a O +
flagellum O +
was O +
not O +
required O +
for O +
binding O +
of O +
P. O +
aeruginosa O +
to O +
macrophages O +
but O +
was O +
critical O +
for O +
the O +
subsequent O +
internalization O +
of O +
the O +
bacterium O +
, O +
suggesting O +
that O +
this O +
factor O +
or O +
a O +
surface O +
ligand O +
associated O +
with O +
its O +
assembly O +
was O +
responsible O +
for O +
stimulation O +
of O +
nonopsonic O +
phagocytosis O +
. O +

Circumvention O +
of O +
tolerance O +
for O +
the O +
nuclear O +
T O +
cell O +
protein O +
TCF-1 O +
by O +
immunization O +
of O +
TCF-1 O +
knock O -
- O -
out O +
mice O +
. O +

Molecular O +
events O +
that O +
underlie O +
the O +
well O -
- O -
defined O +
phenotypic O +
changes O +
of O +
the O +
differentiating O +
thymocyte O +
are O +
poorly O +
understood O +
. O +

A O +
candidate O +
gene O +
to O +
control O +
thymocyte O +
differentiation O +
, O +
T O +
cell O +
factor-1 O +
( O +
TCF-1 O +
) O +
* O +
encodes O +
a O +
DNA O -
- O -
binding O +
protein O +
. O +

Its O +
mRNA O +
expression O +
pattern O +
is O +
complex O +
during O +
embryogenesis O +
, O +
yet O +
restricted O +
to O +
lymphocytes O +
postnatally O +
. O +

Expression O +
studies O +
on O +
TCF-1 O +
protein O +
have O +
been O +
hampered O +
by O +
the O +
difficulty O +
to O +
raise O +
antibodies O +
due O +
to O +
extreme O +
evolutionary O +
conservation O +
. O +

TCF-1 O +
knock O -
- O -
out O +
mice O +
, O +
generated O +
recently O +
in O +
our O +
laboratory O +
, O +
have O +
strongly O +
decreased O +
numbers O +
of O +
thymocytes O +
, O +
but O +
are O +
otherwise O +
normal O +
. O +

We O +
have O +
used O +
these O +
mice O +
to O +
generate O +
anti O -
- O -
TCF-1 O +
antibodies O +
. O +

By O +
immunization O +
with O +
a O +
recombinant O +
fusion O +
protein O +
, O +
we O +
show O +
that O +
TCF-1 O +
knock O -
- O -
out O +
mice O +
readily O +
yield O +
antiserum O +
titers O +
against O +
human O +
and O +
mouse O +
TCF-1 O +
protein O +
. O +

Wild O -
- O -
type O +
littermates O +
remain O +
unresponsive O +
to O +
TCF-1 O +
while O +
they O +
mount O +
a O +
high O -
- O -
titer O +
antibody O +
response O +
to O +
the O +
fusion O +
protein O +
, O +
Maltose O +
Binding O +
Protein O +
( O +
MBP O +
) O +
. O +

Subsequently O +
, O +
TCF-1-specific B-CellLine +
hybridomas I-CellLine +
could O +
be O +
prepared O +
from O +
the O +
spleens O +
of O +
immunized O +
knock O -
- O -
out O +
mice O +
. O +

This O +
study O +
illustrates O +
the O +
almost O +
complete O +
tolerance O +
of O +
mice O +
for O +
human O +
TCF-1 O +
and O +
demonstrates O +
that O +
this O +
tolerance O +
is O +
readily O +
broken O +
by O +
gene O +
knock O -
- O -
out O +
. O +

Furthermore O +
, O +
the O +
usefulness O +
of O +
knock O -
- O -
out O +
mice O +
for O +
the O +
generation O +
of O +
monoclonal O +
antibodies O +
against O +
the O +
gene O +
product O +
of O +
interest O +
is O +
underscored O +
. O +

An O +
interferon O -
- O -
gamma O +
activation O +
sequence O +
mediates O +
the O +
transcriptional O +
regulation O +
of O +
the O +
IgG O +
Fc O +
receptor O +
type O +
IC O +
gene O +
by O +
interferon O -
- O -
gamma O +
. O +

Expression O +
of O +
the O +
IgG O +
Fc O +
receptor O +
type O +
I O +
( O +
Fc O +
gamma O +
RI O +
) O +
on O +
myeloid O +
cells O +
is O +
dramatically O +
increased O +
by O +
treatment O +
with O +
interferon O -
- O -
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
. O +

We O +
observed O +
that O +
Fc O +
gamma O +
RI O +
transcript O +
levels O +
in O +
monoblast B-CellLine -
- I-CellLine -
like I-CellLine +
U937 I-CellLine +
cells I-CellLine +
were O +
elevated O +
within O +
3 O +
hr O +
and O +
peaked O +
12 O +
hr O +
after O +
exposure O +
to O +
IFN O -
- O -
gamma O +
. O +

Treatment O +
of O +
U937 B-CellLine +
with O +
IFN O -
- O -
gamma O +
for O +
9 O +
hr O +
in O +
the O +
presence O +
of O +
cycloheximide O +
led O +
to O +
super O -
- O -
induction O +
of O +
Fc O +
gamma O +
RI O +
expression O +
. O +

Nuclear O +
run O -
- O -
on O +
analysis O +
revealed O +
that O +
the O +
rate O +
of O +
Fc O +
gamma O +
RI O +
transcription O +
was O +
increased O +
by O +
IFN O -
- O -
gamma O +
. O +

Genomic O +
sequence O +
upstream O +
of O +
the O +
Fc O +
gamma O +
RIC O +
gene O +
was O +
cloned O +
and O +
subjected O +
to O +
primer O +
extension O +
analysis O +
, O +
which O +
demonstrated O +
a O +
single O +
transcription O +
initiation O +
site O +
without O +
a O +
TATA O +
box O +
. O +

Transient O +
transfections O +
of O +
CAT O +
reporter O +
gene O +
constructs O +
containing O +
various O +
Fc O +
gamma O +
RIC O +
promoter O +
sequences O +
into O +
U937 B-CellLine +
cells I-CellLine +
revealed O +
that O +
a O +
20-bp O +
region O +
surrounding O +
the O +
transcription O +
start O +
site O +
( O +
-7 O +
to O +
+ O -
13 O +
) O +
was O +
capable O +
of O +
mediating O +
transcription O +
initiation O +
and O +
that O +
an O +
IFN O -
- O -
gamma O +
responsive O +
element O +
( O +
GIRE O +
) O +
was O +
present O +
within O +
74 O +
bp O +
upstream O +
of O +
the O +
transcription O +
initiation O +
site O +
. O +

A O +
17-bp O +
sequence O +
between O +
positions O +
-51 O +
and O +
-35 O +
conferred O +
IFN O -
- O -
gamma O +
responsiveness O +
on O +
a O +
heterologous O +
promoter O +
. O +

Double O -
- O -
stranded O +
GIRE O +
sequence O +
, O +
but O +
not O +
a O +
scrambled O +
sequence O +
, O +
was O +
specifically O +
bound O +
by O +
nuclear O +
proteins O +
from O +
IFN B-CellLine -
- I-CellLine -
gamma I-CellLine +
treated I-CellLine +
U937 I-CellLine +
cells I-CellLine +
. O +

Gel O +
shift O +
experiments O +
further O +
showed O +
that O +
the O +
STAT1 O +
alpha O +
protein O +
bound O +
to O +
the O +
Fc O +
gamma O +
RIC O +
GIRE O +
in O +
response O +
to O +
IFN O -
- O -
gamma O +
treatment O +
of O +
U937 B-CellLine +
cells I-CellLine +
. O +

The O +
Fc O +
gamma O +
RIC O +
GIRE O +
is O +
homologous O +
to O +
the O +
IFN O -
- O -
gamma O +
activation O +
sequence O +
( O +
GAS O +
) O +
of O +
the O +
guanylate O +
binding O +
protein O +
and O +
to O +
X O +
box O +
elements O +
of O +
class O +
II O +
MHC O +
genes O +
. O +

Our O +
results O +
demonstrate O +
that O +
transcriptional O +
regulation O +
of O +
the O +
Fc O +
gamma O +
RIC O +
gene O +
by O +
IFN O -
- O -
gamma O +
involves O +
the O +
binding O +
of O +
STAT1 O +
alpha O +
to O +
a O +
17-bp O +
GAS O +
homology O +
in O +
the O +
proximal O +
promoter O +
. O +

Regulation O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
and O +
cytokine O +
gene O +
expression O +
in O +
myeloid O +
cells O +
by O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
transcription O +
factors O +
. O +

CD4 B-CellLine -
+ I-CellLine +
macrophages I-CellLine +
in O +
tissues O +
such O +
as O +
lung O +
, O +
skin O +
, O +
and O +
lymph O +
nodes O +
, O +
promyelocytic O +
cells O +
in O +
bone O +
marrow O +
, O +
and O +
peripheral O +
blood O +
monocytes O +
serve O +
as O +
important O +
targets O +
and O +
reservoirs O +
for O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
replication O +
. O +

HIV-1-infected O +
myeloid O +
cells O +
are O +
often O +
diminished O +
in O +
their O +
ability O +
to O +
participate O +
in O +
chemotaxis O +
, O +
phagocytosis O +
, O +
and O +
intracellular O +
killing O +
. O +

HIV-1 O +
infection O +
of O +
myeloid O +
cells O +
can O +
lead O +
to O +
the O +
expression O +
of O +
surface O +
receptors O +
associated O +
with O +
cellular O +
activation O +
and/or O +
differentiation O +
that O +
increase O +
the O +
responsiveness O +
of O +
these O +
cells O +
to O +
cytokines O +
secreted O +
by O +
neighboring O +
cells O +
as O +
well O +
as O +
to O +
bacteria O +
or O +
other O +
pathogens O +
. O +

Enhancement O +
of O +
HIV-1 O +
replication O +
is O +
related O +
in O +
part O +
to O +
increased O +
DNA O -
- O -
binding O +
activity O +
of O +
cellular O +
transcription O +
factors O +
such O +
as O +
NF O -
- O -
kappa O +
B O +
. O +

NF O -
- O -
kappa O +
B O +
binds O +
to O +
the O +
HIV-1 O +
enhancer O +
region O +
of O +
the O +
long O +
terminal O +
repeat O +
and O +
contributes O +
to O +
the O +
inducibility O +
of O +
HIV-1 O +
gene O +
expression O +
in O +
response O +
to O +
multiple O +
activating O +
agents O +
. O +

Phosphorylation O +
and O +
degradation O +
of O +
the O +
cytoplasmic O +
inhibitor O +
I O +
kappa O +
B O +
alpha O +
are O +
crucial O +
regulatory O +
events O +
in O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
DNA O -
- O -
binding O +
activity O +
. O +

Both O +
N- O +
and O +
C O -
- O -
terminal O +
residues O +
of O +
I O +
kappa O +
B O +
alpha O +
are O +
required O +
for O +
inducer O -
- O -
mediated O +
degradation O +
. O +

Chronic O +
HIV-1 O +
infection O +
of O +
myeloid O +
cells O +
leads O +
to O +
constitutive O +
NF O -
- O -
kappa O +
B O +
DNA O -
- O -
binding O +
activity O +
and O +
provides O +
an O +
intranuclear O +
environment O +
capable O +
of O +
perpetuating O +
HIV-1 O +
replication O +
. O +

Increased O +
intracellular O +
stores O +
of O +
latent O +
NF O -
- O -
kappa O +
B O +
may O +
also O +
result O +
in O +
rapid O +
inducibility O +
of O +
NF O -
- O -
kappa O +
B O +
-dependent O +
cytokine O +
gene O +
expression O +
. O +

In O +
response O +
to O +
secondary O +
pathogenic O +
infections O +
or O +
antigenic O +
challenge O +
, O +
cytokine O +
gene O +
expression O +
is O +
rapidly O +
induced O +
, O +
enhanced O +
, O +
and O +
sustained O +
over O +
prolonged O +
periods O +
in O +
HIV-1-infected B-CellLine +
myeloid I-CellLine +
cells I-CellLine +
compared O +
with O +
uninfected O +
cells O +
. O +

Elevated O +
levels O +
of O +
several O +
inflammatory O +
cytokines O +
have O +
been O +
detected O +
in O +
the O +
sera O +
of O +
HIV-1-infected O +
individuals O +
. O +

Secretion O +
of O +
myeloid O +
cell O -
- O -
derived O +
cytokines O +
may O +
both O +
increase O +
virus O +
production O +
and O +
contribute O +
to O +
AIDS O -
- O -
associated O +
disorders O +
. O +

Cloning O +
a O +
cDNA O +
from O +
human O +
NK O -
/ O -
T O +
cells O +
which O +
codes O +
for O +
a O +
protein O +
with O +
high O +
proline O +
content O +
. O +

A O +
cDNA O +
clone O +
, O +
B4 O -
- O -
2 O +
, O +
was O +
isolated O +
from O +
a O +
natural O +
killer O +
( O +
NK O +
) O +
minus O +
T O +
cell O +
subtractive O +
library O +
. O +

The O +
B4 O -
- O -
2 O +
clone O +
coded O +
for O +
an O +
mRNA O +
of O +
2061 O +
bp O +
in O +
length O +
. O +

It O +
encodes O +
a O +
deduced O +
327 O +
aa O +
protein O +
with O +
a O +
calculated O +
molecular O +
mass O +
of O +
35.2 O +
kDa O +
. O +

Searching O +
of O +
B4 O -
- O -
2 O +
DNA O +
and O +
protein O +
sequences O +
against O +
various O +
databases O +
revealed O +
no O +
high O +
homology O +
to O +
other O +
sequences O +
. O +

However O +
, O +
B4 O -
- O -
2 O +
has O +
an O +
unusually O +
high O +
proline O +
content O +
( O +
13 O +
% O +
) O +
, O +
contains O +
a O +
putative O +
nuclear O +
targeting O +
sequence O +
, O +
and O +
has O +
several O +
SPXX O +
motifs O +
which O +
are O +
frequently O +
found O +
in O +
gene O +
regulatory O +
proteins O +
. O +

One O +
of O +
the O +
stretches O +
of O +
prolines O +
in O +
B4 O -
- O -
2 O +
closely O +
resembles O +
the O +
ligand O +
for O +
proteins O +
with O +
SH3 O +
domains O +
. O +

Northern O +
hybridization O +
data O +
showed O +
that O +
B4 O -
- O -
2 O +
is O +
not O +
a O +
lymphoid O +
specific O +
gene O +
and O +
is O +
expressed O +
in O +
a O +
hepatoma B-CellLine +
cell I-CellLine +
line I-CellLine +
and O +
also O +
weakly O +
transcribed O +
or O +
absent O +
in O +
a O +
variety O +
of O +
other O +
cells O +
. O +

A O +
polyclonal O +
antiserum O +
raised O +
against O +
recombinant O +
B4 O -
- O -
2 O +
recognizes O +
a O +
32 O -
- O -
34 O +
kDa O +
protein O +
in O +
lymphocytes O +
. O +

The O +
normal O +
cell O +
cycle O +
activation O +
program O +
is O +
exploited O +
during O +
the O +
infection O +
of O +
quiescent O +
B O +
lymphocytes O +
by O +
Epstein O -
- O -
Barr O +
virus O +
. O +

B O +
lymphocytes O +
in O +
the O +
peripheral O +
circulation O +
are O +
maintained O +
in O +
a O +
non O -
- O -
proliferative O +
state O +
. O +

Antigen O +
recognition O +
stimulates O +
limited O +
proliferation O +
, O +
whereas O +
infection O +
with O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
results O +
in O +
continual O +
proliferation O +
and O +
the O +
outgrowth O +
of O +
immortal B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Because O +
it O +
is O +
not O +
clear O +
at O +
which O +
point O +
in O +
cell O +
cycle O +
the O +
peripheral O +
B O +
lymphocytes O +
are O +
arrested O +
, O +
we O +
characterized O +
the O +
expression O +
of O +
several O +
cell O +
cycle O -
- O -
associated O +
genes O +
in O +
quiescent O +
and O +
stimulated O +
cells O +
. O +

We O +
show O +
that O +
the O +
expression O +
of O +
four O +
cell O +
genes O +
, O +
cdc-2 O +
, O +
cyclin O +
E O +
, O +
CD23 O +
, O +
and O +
cyclin O +
D2 O +
, O +
are O +
up O -
- O -
regulated O +
approximately O +
100-fold O +
as O +
a O +
result O +
of O +
EBV O -
- O -
mediated O +
immortalization O +
. O +

Because O +
these O +
genes O +
play O +
a O +
positive O +
role O +
in O +
cell O +
proliferation O +
, O +
we O +
suggest O +
that O +
this O +
regulatory O +
switch O +
contributes O +
to O +
controlling O +
entry O +
into O +
the O +
cell O +
cycle O +
. O +

Transient O +
stimulation O +
of O +
quiescent O +
B O +
lymphocytes O +
with O +
either O +
a O +
cocktail O +
of O +
anti O -
- O -
CD40 O +
, O +
anti O -
- O -
IgM O +
, O +
and O +
IL4 O +
, O +
or O +
EBV O +
results O +
in O +
the O +
rapid O +
expression O +
of O +
the O +
same O +
four O +
genes O +
, O +
suggesting O +
that O +
, O +
after O +
infection O +
, O +
EBV O +
exploits O +
the O +
normal O +
program O +
of O +
B O -
- O -
lymphocyte O +
cell O +
cycle O +
activation O +
. O +

Costimulation O +
requirement O +
for O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B O +
transcription O +
factor O +
activation O +
in O +
T O +
cells O +
. O +

The O +
transcriptional O +
activity O +
of O +
the O +
IL-2 O +
promoter O +
requires O +
T O -
- O -
cell O +
costimulation O +
delivered O +
by O +
the O +
TCR O +
and O +
the O +
auxiliary O +
receptor O +
CD28 O +
. O +

Several O +
transcription O +
factors O +
participate O +
in O +
IL-2 O +
promoter O +
activation O +
, O +
among O +
which O +
are O +
AP-1-like O +
factors O +
and O +
NF O -
- O -
kappa O +
B O +
. O +

Protein O +
phosphorylation O +
has O +
an O +
important O +
role O +
in O +
the O +
regulation O +
of O +
these O +
two O +
factors O +
: O +
( O +
1 O +
) O +
it O +
induces O +
the O +
transactivating O +
capacity O +
of O +
the O +
AP-1 O +
protein O +
c O -
- O -
Jun O +
; O +
and O +
( O +
2 O +
) O +
it O +
is O +
involved O +
in O +
the O +
release O +
of O +
the O +
cytoplasmic O +
inhibitor O +
, O +
I O +
kappa O +
B O +
, O +
from O +
NF O -
- O -
kappa O +
B O +
, O +
allowing O +
translocation O +
of O +
the O +
latter O +
into O +
the O +
nucleus O +
. O +

We O +
have O +
recently O +
shown O +
that O +
both O +
phosphorylation O +
processes O +
require O +
T O -
- O -
cell O +
costimulation O +
. O +

Furthermore O +
, O +
in O +
activated O +
T O +
cells O +
, O +
the O +
kinetics O +
of O +
the O +
two O +
phosphorylation O +
events O +
are O +
essentially O +
similar O +
. O +

According O +
to O +
our O +
results O +
, O +
however O +
, O +
the O +
kinases O +
responsible O +
for O +
the O +
two O +
processes O +
are O +
distinct O +
entities O +
. O +

Whereas O +
TPCK O +
inhibits O +
phosphorylation O +
of O +
I O +
kappa O +
B O +
and O +
, O +
consequently O +
, O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
it O +
markedly O +
enhances O +
the O +
activity O +
of O +
JNK O +
, O +
the O +
MAP O +
kinase O -
- O -
related O +
kinase O +
that O +
phosphorylates O +
the O +
transactivation O +
domain O +
of O +
c O -
- O -
Jun O +
. O +

We O +
, O +
therefore O +
, O +
propose O +
the O +
activation O +
scheme O +
presented O +
in O +
FIGURE O +
3 O +
for O +
T O -
- O -
cell O +
costimulation O +
. O +

Costimulation O +
results O +
in O +
the O +
activation O +
of O +
a O +
signaling O +
pathway O +
that O +
leads O +
to O +
the O +
simultaneous O +
induction O +
of O +
the O +
two O +
transcription O +
factors O +
, O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B O +
. O +

Integration O +
of O +
the O +
signals O +
generated O +
by O +
TCR O +
and O +
CD28 O +
engagement O +
occurs O +
along O +
this O +
pathway O +
, O +
which O +
then O +
bifurcates O +
to O +
induce O +
I O +
kappa O +
B O +
phosphorylation O +
and O +
NF O -
- O -
kappa O +
B O +
activation O +
on O +
the O +
one O +
hand O +
, O +
and O +
JNK O +
activation O +
and O +
c O -
- O -
Jun O +
phosphorylation O +
on O +
the O +
other O +
. O +

We O +
are O +
currently O +
engaged O +
in O +
defining O +
where O +
the O +
two O +
signals O +
integrate O +
along O +
the O +
AP-1 O +
/ O +
NF O -
- O -
kappa O +
B O +
pathway O +
. O +

Mutation O +
of O +
Jak3 O +
in O +
a O +
patient O +
with O +
SCID O +
: O +
essential O +
role O +
of O +
Jak3 O +
in O +
lymphoid O +
development O +
. O +

Males O +
with O +
X O -
- O -
linked O +
severe O +
combined O +
immunodeficiency O +
( O +
XSCID O +
) O +
have O +
defects O +
in O +
the O +
common O +
cytokine O +
receptor O +
gamma O +
chain O +
( O +
gamma O +
c O +
) O +
gene O +
that O +
encodes O +
a O +
shared O +
, O +
essential O +
component O +
of O +
the O +
receptors O +
of O +
interleukin-2 O +
( O +
IL-2 O +
) O +
, O +
IL-4 O +
, O +
IL-7 O +
, O +
IL-9 O +
, O +
and O +
IL-15 O +
. O +

The O +
Janus O +
family O +
tyrosine O +
kinase O +
Jak3 O +
is O +
the O +
only O +
signaling O +
molecule O +
known O +
to O +
be O +
associated O +
with O +
gamma O +
c O +
, O +
so O +
it O +
was O +
hypothesized O +
that O +
defects O +
in O +
Jak3 O +
might O +
cause O +
an O +
XSCID O -
- O -
like O +
phenotype O +
. O +

A O +
girl O +
with O +
immunological O +
features O +
indistinguishable O +
from O +
those O +
of O +
XSCID O +
was O +
therefore O +
selected O +
for O +
analysis O +
. O +

An O +
Epstein B-CellLine -
- I-CellLine -
Barr I-CellLine +
virus I-CellLine +
( I-CellLine +
EBV I-CellLine +
) I-CellLine +
-transformed I-CellLine +
cell I-CellLine +
line I-CellLine +
derived O +
from O +
her O +
lymphocytes O +
had O +
normal O +
gamma O +
c O +
expression O +
but O +
lacked O +
Jak3 O +
protein O +
and O +
had O +
greatly O +
diminished O +
Jak3 O +
messenger O +
RNA O +
. O +

Sequencing O +
revealed O +
a O +
different O +
mutation O +
on O +
each O +
allele O +
: O +
a O +
single O +
nucleotide O +
insertion O +
resulting O +
in O +
a O +
frame O +
shift O +
and O +
premature O +
termination O +
in O +
the O +
Jak3 O +
JH4 O +
domain O +
and O +
a O +
nonsense O +
mutation O +
in O +
the O +
Jak3 O +
JH2 O +
domain O +
. O +

The O +
lack O +
of O +
Jak3 O +
expression O +
correlated O +
with O +
impaired O +
B O +
cell O +
signaling O +
, O +
as O +
demonstrated O +
by O +
the O +
inability O +
of O +
IL-4 O +
to O +
activate O +
Stat6 O +
in O +
the O +
EBV B-CellLine -
- I-CellLine -
transformed I-CellLine +
cell I-CellLine +
line I-CellLine +
from O +
the O +
patient O -
. O +
These O +
observations O +
indicate O +
that O +
the O +
functions O +
of O +
gamma O +
c O +
are O +
dependent O +
on O +
Jak3 O +
and O +
that O +
Jak3 O +
is O +
essential O +
for O +
lymphoid O +
development O +
and O +
signaling O +
. O +

The O +
effect O +
of O +
Toremifene O +
on O +
the O +
expression O +
of O +
some O +
genes O +
in O +
human O +
mononuclear O +
cells O +
. O +

Toremifene O +
exerts O +
multiple O +
and O +
varied O +
effects O +
on O +
the O +
gene O +
expression O +
of O +
human O +
peripheral O +
mononuclear O +
cells O +
. O +

After O +
short O -
- O -
term O +
, O +
in O +
vitro O +
exposure O +
to O +
therapeutical O +
levels O +
, O +
distinct O +
changes O +
in O +
P O -
- O -
glycoprotein O +
, O +
steroid O +
receptors O +
, O +
p53 O +
and O +
Bcl-2 O +
expression O +
take O +
place O +
. O +

In O +
view O +
of O +
the O +
increasing O +
use O +
of O +
antiestrogens O +
in O +
cancer O +
therapy O +
and O +
prevention O +
, O +
there O +
is O +
obvious O +
merit O +
in O +
long O -
- O -
term O +
in O +
vivo O +
studies O +
to O +
be O +
conducted O +
. O +

CD30 O +
ligation O +
induces O +
nuclear O +
factor O -
- O -
kappa O +
B O +
activation O +
in O +
human B-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

CD30 O +
is O +
a O +
recently O +
described O +
member O +
of O +
the O +
tumor O +
necrosis O +
factor O -
/ O -
nerve O +
growth O +
factor O +
receptor O +
superfamily O +
. O +

In O +
this O +
report O +
, O +
we O +
show O +
that O +
following O +
incubation O +
of O +
L540 B-CellLine +
cells I-CellLine +
( O +
Hodgkin B-CellLine +
's I-CellLine +
disease I-CellLine -
- I-CellLine -
derived I-CellLine +
, I-CellLine +
T I-CellLine +
cell I-CellLine -
- I-CellLine -
like I-CellLine +
, I-CellLine +
CD30 I-CellLine -
+ I-CellLine +
cells I-CellLine +
) O +
with O +
the O +
agonistic O +
anti O -
- O -
CD30 O +
monoclonal O +
antibodies O +
( O +
mAb O +
) O +
M44 O +
and O +
M67 O +
, O +
two O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappa O +
B O +
DNA O +
binding O +
activities O +
were O +
induced O +
in O +
nuclear O +
extracts O +
, O +
as O +
determined O +
in O +
gel O +
retardation O +
assays O +
. O +

The O +
effect O +
of O +
the O +
mAb O +
towards O +
NF O -
- O -
kappa O +
B O +
activation O +
was O +
rapid O +
, O +
as O +
it O +
occurred O +
within O +
20 O +
min O +
, O +
and O +
was O +
sustained O +
for O +
up O +
to O +
6 O +
h O +
. O +

By O +
comparison O +
, O +
an O +
isotype O -
- O -
matched O +
antibody O +
had O +
no O +
effect O +
on O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

Moreover O +
, O +
in O +
human B-CellLine +
T I-CellLine +
helper I-CellLine +
( I-CellLine +
Th I-CellLine +
) I-CellLine +
clones I-CellLine +
functionally O +
characterized O +
as O +
being O +
of O +
the O +
type O +
0 O +
, O +
type O +
1 O +
and O +
type O +
2 O +
( O +
28 O +
% O +
, O +
< O +
1 O +
% O +
und O +
93 O +
% O +
CD30 O -
+ O +
, O +
respectively O +
) O +
, O +
the O +
extent O +
of O +
CD30 O +
-mediated O +
NF O -
- O -
kappa O +
B O +
activation O +
correlated O +
with O +
the O +
proportion O +
of O +
CD30 B-CellLine -
+ I-CellLine +
cells I-CellLine +
. O +

In O +
all O +
cell O +
lines O +
investigated O +
, O +
the O +
NF O -
- O -
kappa O +
B O +
complexes O +
induced O +
following O +
CD30 O +
engagement O +
were O +
shown O +
to O +
contain O +
p50 O +
NF O -
- O -
kappa O +
B1 O +
, O +
p65 O +
RelA O +
, O +
and O +
possibly O +
other O +
transcription O +
factors O +
. O +

Collectively O +
, O +
our O +
results O +
demonstrate O +
that O +
nuclear O +
translocation O +
and O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
rank O +
among O +
the O +
short O -
- O -
term O +
cellular O +
responses O +
elicited O +
following O +
CD30 O +
ligation O +
. O +

Activation O +
of O +
the O +
signal O +
transducer O +
and O +
transcription O +
( O +
STAT O +
) O +
signaling O +
pathway O +
in O +
a O +
primary O +
T O +
cell O +
response O +
. O +

Critical O +
role O +
for O +
IL-6 O +
. O +

The O +
T O +
cell O +
activation O +
is O +
initiated O +
by O +
interaction O +
of O +
specific O +
Ags O +
with O +
TCR O +
, O +
followed O +
by O +
activation O +
of O +
intracellular O +
biochemical O +
events O +
leading O +
to O +
activation O +
of O +
several O +
genes O +
. O +

The O +
activation O +
of O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
( O +
STAT O +
) O +
proteins O +
in O +
a O +
primary O +
TCR O +
-mediated O +
activation O +
of O +
T O +
cells O +
have O +
been O +
explored O +
. O +

In O +
purified O +
human O +
peripheral O +
blood O +
T O +
cells O +
, O +
nuclear O +
STAT O +
proteins O +
were O +
activated O +
approximately O +
3 O +
h O +
after O +
activation O +
by O +
cross O -
- O -
linked O +
anti O -
- O -
CD3 O +
Abs O +
. O +

These O +
STAT O +
proteins O +
were O +
detected O +
by O +
using O +
the O +
IFN O -
- O -
gamma O -
- O -
activated O +
sequence O +
( O +
GAS O +
) O +
and O +
related O +
oligonucleotides O +
as O +
probes O +
in O +
electrophoretic O +
mobility O +
shift O +
assay O +
. O +

Analysis O +
of O +
the O +
nuclear O +
extracts O +
with O +
anti O -
- O -
STAT O +
Abs O +
indicated O +
that O +
they O +
contained O +
STAT-3 O +
and O +
additional O +
proteins O +
crossreactive O +
with O +
the O +
STAT O +
family O +
. O +

The O +
induction O +
of O +
STAT O +
activity O +
was O +
inhibited O +
completely O +
by O +
pretreatment O +
with O +
either O +
cycloheximide O +
or O +
cyclosporin O +
A O +
, O +
thus O +
indicating O +
that O +
the O +
induction O +
was O +
due O +
to O +
a O +
secondary O +
factor O +
produced O +
by O +
the O +
activated O +
T O +
cells O +
. O +

As O +
neutralizing O +
anti O -
- O -
IL-6 O +
Abs O +
effectively O +
down O -
- O -
regulated O +
the O +
early O +
induction O +
of O +
STAT O +
proteins O +
and O +
as O +
exogenously O +
added O +
IL-6 O +
rapidly O +
activated O +
DNA O +
binding O +
similar O +
to O +
TCR O +
-mediated O +
bindings O +
, O +
it O +
can O +
be O +
concluded O +
that O +
IL-6 O +
is O +
the O +
factor O +
responsible O +
for O +
the O +
activation O +
of O +
STAT O +
proteins O +
in O +
a O +
primary O +
T O +
cell O +
response O +
. O +

The O +
DNA O +
and O +
steroid O +
binding O +
domains O +
of O +
the O +
glucocorticoid O +
receptor O +
are O +
not O +
altered O +
in O +
mononuclear O +
cells O +
of O +
treated O +
CLL O +
patients O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
whether O +
mutations O +
in O +
the O +
glucocorticoid O +
receptor O +
could O +
account O +
for O +
the O +
increasing O +
unresponsiveness O +
of O +
patients O +
with O +
chronic O +
lymphatic O +
leukemia O +
( O +
CLL O +
) O +
to O +
combination O +
chemotherapy O +
. O +

The O +
receptor O +
was O +
tested O +
immunocytochemically O +
, O +
in O +
steroid O +
binding O +
assays O +
, O +
and O +
by O +
a O +
mutation O +
screening O +
( O +
denaturing O +
gradient O +
gel O +
electrophoresis O +
) O +
of O +
the O +
receptor O -
- O -
cDNA O +
. O +

The O +
receptor O +
concentration O +
, O +
as O +
measured O +
by O +
staining O +
and O +
steroid O +
binding O +
test O +
, O +
varied O +
considerably O +
but O +
showed O +
no O +
clear O +
correlation O +
to O +
clinical O +
response O +
. O +

Using O +
a O +
highly O +
sensitive O +
mutation O +
screening O +
assay O +
of O +
the O +
DNA- O +
and O +
the O +
steroid O -
- O -
binding O +
region O +
, O +
none O +
of O +
the O +
treated O +
patients O +
revealed O +
any O +
mutation O +
, O +
suggesting O +
that O +
the O +
glucocorticoid O +
receptor O +
in O +
the O +
CLL O +
patients O +
tested O +
is O +
not O +
altered O +
in O +
these O +
domains O +
. O +

In O +
one O +
individual O +
who O +
had O +
not O +
been O +
treated O +
before O +
analysis O +
a O +
silent O +
mutation O +
was O +
found O +
in O +
one O +
receptor O +
allele O +
. O +

The O +
results O +
suggest O +
that O +
mechanisms O +
other O +
than O +
altered O +
ligand O +
or O +
DNA O +
binding O +
of O +
the O +
receptor O +
may O +
be O +
responsible O +
for O +
the O +
lack O +
of O +
response O +
to O +
chemotherapy O +
. O +

This O +
conclusion O +
is O +
discussed O +
in O +
relation O +
to O +
the O +
mechanism O +
of O +
corticoid O +
resistance O +
in O +
mouse B-CellLine +
and I-CellLine +
human I-CellLine +
lymphoma I-CellLine +
cells I-CellLine +
in O +
culture O +
. O +

The O +
myeloid O +
zinc O +
finger O +
gene O +
, O +
MZF-1 O +
, O +
regulates O +
the O +
CD34 O +
promoter O +
in O +
vitro O +
. O +

MZF-1 O +
is O +
a O +
C2H2 O +
zinc O +
finger O +
gene O +
encoding O +
a O +
putative O +
transcriptional O +
regulator O +
of O +
myeloid O +
differentiation O +
. O +

The O +
MZF-1 O +
protein O +
contains O +
13 O +
C2H2 O +
zinc O +
fingers O +
arranged O +
in O +
bipartite O +
DNA O +
binding O +
domains O +
containing O +
zinc O +
fingers O +
through O +
4 O +
and O +
, O +
in O +
the O +
carboxy O -
- O -
terminus O +
, O +
5 O +
through O +
13 O +
. O +

We O +
previously O +
identified O +
the O +
DNA O +
consensus O +
binding O +
site O +
recognized O +
by O +
the O +
two O +
DNA O +
binding O +
domains O +
. O +

To O +
assess O +
the O +
transcription O +
regulatory O +
function O +
of O +
MZF-1 O +
, O +
the O +
full O -
- O -
length O +
MZF-1 O +
coding O +
region O +
was O +
fused O +
to O +
the O +
DNA O +
binding O +
domain O +
of O +
the O +
yeast O +
transactivator O +
GAL4 O +
. O +

The O +
expression O +
vector O +
was O +
cotransfected O +
with O +
the O +
chloramphenicol O +
acetyl O +
transferase O +
( O +
CAT O +
) O +
reporter O +
gene O +
regulated O +
by O +
the O +
thymidine O +
kinase O +
promoter O +
containing O +
GAL4 O +
DNA O +
binding O +
sites O +
into O +
NIH B-CellLine +
3T3 I-CellLine +
, O +
293 B-CellLine +
, O +
K562 B-CellLine +
, O +
and O +
Jurkat B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

MZF-1 O +
represses O +
CAT O +
reporter O +
gene O +
expression O +
via O +
GAL4 O +
binding O +
sites O +
in O +
the O +
nonhematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
NIH B-CellLine +
3T3 I-CellLine +
and O +
293 B-CellLine +
. O +

In O +
contrast O +
, O +
MZF-1 O +
activates O +
CAT O +
reporter O +
gene O +
expression O +
in O +
the O +
hematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
K562 B-CellLine +
and O +
Jurkat B-CellLine +
. O +

The O +
MZF-1 O +
binding O +
sites O +
are O +
present O +
in O +
the O +
promoters O +
of O +
several O +
genes O +
expressed O +
during O +
myeloid O +
differentiation O +
, O +
including O +
the O +
CD34 O +
promoter O +
. O +

MZF-1 O +
transcriptional O +
regulation O +
of O +
this O +
physiologically O +
relevant O +
promoter O +
was O +
assessed O +
in O +
both O +
hematopoietic B-CellLine +
and O +
nonhematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Recombinant O +
MZF-1 O +
protein O +
specifically O +
binds O +
to O +
the O +
consensus O +
binding O +
sites O +
in O +
the O +
CD34 O +
promoter O +
in O +
mobility O +
shift O +
assays O +
. O +

MZF-1 O +
expression O +
vectors O +
were O +
cotransfected O +
with O +
the O +
luciferase O +
reporter O +
plasmids O +
regulated O +
by O +
the O +
CD34 O +
promoter O +
into O +
both O +
nonhematopoietic B-CellLine +
and I-CellLine +
hematopoietic I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

As O +
with O +
the O +
heterologous O +
DNA O +
binding O +
domain O +
, O +
MZF-1 O +
represses O +
reporter O +
gene O +
expression O +
in O +
nonhematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
and O +
activates O +
expression O +
in O +
hematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Activation O +
of O +
CD34 O +
expression O +
in O +
hematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
is O +
dependent O +
on O +
the O +
presence O +
of O +
intact O +
MZF-1 O +
binding O +
sites O +
. O +

The O +
cell O +
type O -
- O -
specific O +
regulation O +
of O +
the O +
CD34 O +
promoter O +
by O +
MZF-1 O +
suggests O +
the O +
presence O +
of O +
tissue O -
- O -
specific O +
regulators O -
/ O -
adapters O +
or O +
differential O +
MZF-1 O +
modifications O +
that O +
determine O +
MZF-1 O +
transcriptional O +
regulatory O +
function O +
. O +

Bik O +
, O +
a O +
novel O +
death O -
- O -
inducing O +
protein O +
shares O +
a O +
distinct O +
sequence O +
motif O +
with O +
Bcl-2 O +
family O +
proteins O +
and O +
interacts O +
with O +
viral O +
and O +
cellular O +
survival O -
- O -
promoting O +
proteins O +
. O +

The O +
survival O -
- O -
promoting O +
activity O +
of O +
the O +
Bcl-2 O +
family O +
of O +
proteins O +
appears O +
to O +
be O +
modulated O +
by O +
interactions O +
between O +
various O +
cellular O +
proteins O +
. O +

We O +
have O +
identified O +
a O +
novel O +
cellular O +
protein O +
, O +
Bik O +
, O +
that O +
interacts O +
with O +
the O +
cellular O +
survival O -
- O -
promoting O +
proteins O +
, O +
Bcl-2 O +
and O +
Bcl O -
- O -
xL O +
, O +
as O +
well O +
as O +
the O +
viral O +
survival O -
- O -
promoting O +
proteins O +
, O +
Epstein O +
Barr O +
virus O -
- O -
BHRF1 O +
and O +
adenovirus O +
E1B-19 O +
kDa O +
. O +

In O +
transient O +
transfection O +
assays O +
, O +
Bik O +
promotes O +
cell O +
death O +
in O +
a O +
manner O +
similar O +
to O +
the O +
death O -
- O -
promoting O +
members O +
of O +
the O +
Bcl-2 O +
family O +
, O +
Bax O +
and O +
Bak O +
. O +

This O +
death O -
- O -
promoting O +
activity O +
of O +
Bik O +
can O +
be O +
suppressed O +
by O +
coexpression O +
of O +
Bcl-2 O +
, O +
Bcl O -
- O -
XL O +
, O +
EBV O -
- O -
BHRF1 O +
and O +
E1B-19 O +
kDa O +
proteins O +
suggesting O +
that O +
Bik O +
may O +
be O +
a O +
common O +
target O +
for O +
both O +
cellular O +
and O +
viral O +
anti O -
- O -
apoptotic O +
proteins O +
. O +

While O +
Bik O +
does O +
not O +
show O +
overt O +
homology O +
to O +
the O +
BH1 O +
and O +
BH2 O +
conserved O +
domains O +
characteristic O +
of O +
the O +
Bcl-2 O +
family O +
, O +
it O +
does O +
share O +
a O +
9 O +
amino O +
acid O +
domain O +
( O +
BH3 O +
) O +
with O +
Bax O +
and O +
Bak O +
which O +
may O +
be O +
a O +
critical O +
determinant O +
for O +
the O +
death O -
- O -
promoting O +
activity O +
of O +
these O +
proteins O +
. O +

Identification O +
of O +
an O +
I O +
kappa O +
B O +
alpha O -
- O -
associated O +
protein O +
kinase O +
in O +
a O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
and O +
determination O +
of O +
its O +
phosphorylation O +
sites O +
on O +
I O +
kappa O +
B O +
alpha O +
. O +

Nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
is O +
stored O +
in O +
the O +
cytoplasm O +
as O +
an O +
inactive O +
form O +
through O +
interaction O +
with O +
I O +
kappa O +
B O +
. O +

Stimulation O +
of O +
cells O +
leads O +
to O +
a O +
rapid O +
phosphorylation O +
of O +
I O +
kappa O +
B O +
alpha O +
, O +
which O +
is O +
presumed O +
to O +
be O +
important O +
for O +
the O +
subsequent O +
degradation O +
. O +

We O +
have O +
recently O +
reported O +
the O +
establishment O +
of O +
a O +
lipopolysaccharide O +
( O +
LPS O +
) O +
-dependent O +
cell O -
- O -
free O +
activation O +
system O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
association O +
with O +
the O +
induction O +
of O +
I O +
kappa O +
B O +
alpha O +
phosphorylation O +
. O +

In O +
this O +
study O +
, O +
we O +
have O +
identified O +
a O +
kinase O +
in O +
cell O +
extracts O +
from O +
the O +
LPS B-CellLine -
- I-CellLine -
stimulated I-CellLine +
human I-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
THP-1 B-CellLine +
, O +
that O +
specifically O +
binds O +
and O +
phosphorylates O +
I O +
kappa O +
B O +
alpha O +
. O +

LPS O +
stimulation O +
transiently O +
enhanced O +
the O +
I O +
kappa O +
B O +
alpha O +
-bound O +
kinase O +
activity O +
in O +
THP-1 B-CellLine +
cells I-CellLine +
. O +

Mutational O +
analyses O +
of O +
I O +
kappa O +
B O +
alpha O +
and O +
competition O +
experiments O +
with O +
the O +
synthetic O +
peptides O +
identified O +
major O +
phosphorylation O +
sites O +
by O +
the O +
bound O +
kinase O +
as O +
Ser O +
and O +
Thr O +
residues O +
in O +
the O +
C O -
- O -
terminal O +
acidic O +
domain O +
of O +
I O +
kappa O +
B O +
alpha O +
. O +

Moreover O +
, O +
we O +
show O +
that O +
the O +
peptide O +
, O +
corresponding O +
to O +
the O +
C O -
- O -
terminal O +
acidic O +
domain O +
of O +
I O +
kappa O +
B O +
alpha O +
, O +
blocked O +
the O +
LPS O -
- O -
induced O +
NF O -
- O -
kappa O +
B O +
activation O +
as O +
well O +
as O +
inducible O +
phosphorylation O +
of O +
endogenous O +
I O +
kappa O +
B O +
alpha O +
in O +
a O +
cell O -
- O -
free O +
system O +
using O +
THP-1 B-CellLine +
cells I-CellLine +
. O +

These O +
results O +
suggested O +
that O +
the O +
bound O +
kinase O +
is O +
involved O +
in O +
the O +
signaling O +
pathway O +
of O +
LPS O +
by O +
inducing O +
the O +
phosphorylation O +
of O +
the O +
C O -
- O -
terminal O +
region O +
of O +
I O +
kappa O +
B O +
alpha O +
and O +
subsequent O +
dissociation O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
. O +
I O +
kappa O +
B O +
alpha O +
complex O +
. O +

Triggering O +
of O +
the O +
human O +
interleukin-6 O +
gene O +
by O +
interferon O -
- O -
gamma O +
and O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
in O +
monocytic O +
cells O +
involves O +
cooperation O +
between O +
interferon O +
regulatory O +
factor-1 O +
, O +
NF O +
kappa O +
B O +
, O +
and O +
Sp1 O +
transcription O +
factors O +
. O +

We O +
investigated O +
the O +
molecular O +
basis O +
of O +
the O +
synergistic O +
induction O +
by O +
interferon O -
- O -
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
/ O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
of O +
human O +
interleukin-6 O +
( O +
IL-6 O +
) O +
gene O +
in O +
THP-1 O +
monocytic O +
cells O +
, O +
and O +
compared O +
it O +
with O +
the O +
basis O +
of O +
this O +
induction O +
by O +
lipopolysaccharide O +
( O +
LPS O +
) O +
. O +

Functional O +
studies O +
with O +
IL-6 O +
promoter O +
demonstrated O +
that O +
three O +
regions O +
are O +
the O +
targets O +
of O +
the O +
IFN O -
- O -
gamma O +
and/or O +
TNF O -
- O -
alpha O +
action O +
, O +
whereas O +
only O +
one O +
of O +
these O +
regions O +
seemed O +
to O +
be O +
implicated O +
in O +
LPS O +
activation O +
. O +

The O +
three O +
regions O +
concerned O +
are O +
: O +
1 O +
) O +
a O +
region O +
between O +
-73 O +
and O +
-36 O +
, O +
which O +
is O +
the O +
minimal O +
element O +
inducible O +
by O +
LPS O +
or O +
TNF O -
- O -
alpha O +
; O +
2 O +
) O +
an O +
element O +
located O +
between O +
-181 O +
and O +
-73 O +
, O +
which O +
appeared O +
to O +
regulate O +
the O +
response O +
to O +
IFN O -
- O -
gamma O +
and O +
TNF O -
- O -
alpha O +
negatively O +
; O +
and O +
3 O +
) O +
a O +
distal O +
element O +
upstream O +
of O +
-224 O +
, O +
which O +
was O +
inducible O +
by O +
IFN O -
- O -
gamma O +
alone O +
. O +

LPS O +
signaling O +
was O +
found O +
to O +
involve O +
NF O +
kappa O +
B O +
activation O +
by O +
the O +
p50 O -
/ O -
p65 O +
heterodimers O +
. O +

Synergistic O +
induction O +
of O +
the O +
IL-6 O +
gene O +
by O +
IFN O -
- O -
gamma O +
and O +
TNF O -
- O -
alpha O +
, O +
in O +
monocytic O +
cells O +
, O +
involved O +
cooperation O +
between O +
the O +
IRF-1 O +
and O +
NF O +
kappa O +
B O +
p65 O +
homodimers O +
with O +
concomitant O +
removal O +
of O +
the O +
negative O +
effect O +
of O +
the O +
retinoblastoma O +
control O +
element O +
present O +
in O +
the O +
IL-6 O +
promoter O +
. O +

This O +
removal O +
occurred O +
by O +
activation O +
of O +
the O +
constitutive O +
Sp1 O +
factor O +
, O +
whose O +
increased O +
binding O +
activity O +
and O +
phosphorylation O +
were O +
mediated O +
by O +
IFN O -
- O -
gamma O +
. O +

Nuclear O +
factor O -
- O -
IL6 O +
activates O +
the O +
human O +
IL-4 O +
promoter O +
in O +
T O +
cells O +
. O +

Positive O +
regulatory O +
element O +
I O +
( O +
PRE O -
- O -
I O +
) O +
is O +
a O +
strong O +
enhancer O +
element O +
essential O +
for O +
expression O +
of O +
the O +
human O +
IL-4 O +
gene O +
. O +

To O +
identify O +
transcription O +
factors O +
binding O +
to O +
PRE O -
- O -
I O +
, O +
we O +
screened O +
a O +
cDNA O +
expression O +
library O +
from O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
and O +
isolated O +
a O +
cDNA O +
encoding O +
nuclear O +
factor O +
( O +
NF O +
) O +
-IL6 O +
( O +
also O +
known O +
as O +
C O -
/ O -
EBP O +
beta O +
) O +
. O +

NF O -
- O -
IL6 O +
mRNA O +
was O +
found O +
in O +
human B-CellLine +
Jurkat I-CellLine +
T I-CellLine +
cells I-CellLine +
and O +
in O +
the O +
mouse B-CellLine +
Th2 I-CellLine +
clone I-CellLine +
D10 B-CellLine +
, O +
but O +
not O +
in O +
Th1 B-CellLine +
clone I-CellLine +
29 I-CellLine +
. O +

rNF O -
- O -
IL6 O +
expressed O +
in O +
bacteria O +
was O +
shown O +
to O +
specifically O +
bind O +
to O +
PRE O -
- O -
I O +
. O +

PRE O -
- O -
I O +
forms O +
multiple O +
DNA O -
- O -
protein O +
complexes O +
with O +
nuclear O +
extracts O +
from O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

Some O +
of O +
these O +
complexes O +
were O +
demonstrated O +
to O +
contain O +
NF O -
- O -
IL6 O +
by O +
using O +
anti O -
- O -
C O -
/ O -
EBP O +
beta O +
Abs O +
. O +

Overexpression O +
of O +
NF O -
- O -
IL6 O +
enhanced O +
expression O +
of O +
the O +
chloramphenicol O +
acetyl O +
transferase O +
reporter O +
gene O +
linked O +
to O +
the O +
PRE O -
- O -
I O -
- O -
thymidine O +
kinase O +
or O +
the O +
human O +
IL-4 O +
promoter O +
more O +
than O +
10-fold O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

Promoter O +
deletion O +
studies O +
revealed O +
two O +
additional O +
NF O -
- O -
IL6 O +
binding O +
sites O +
located O +
at O +
positions O +
-44 O +
to O +
-36 O +
( O +
C O -
/ O -
EBP O +
proximal O +
) O +
and O +
-87 O +
to O +
-79 O +
( O +
C O -
/ O -
EBP O +
medial O +
) O +
, O +
respectively O +
. O +

Our O +
results O +
demonstrate O +
that O +
NF O -
- O -
IL6 O +
is O +
involved O +
in O +
transcriptional O +
activation O +
of O +
the O +
human O +
IL-4 O +
promoter O +
in O +
T O +
cells O +
. O +

Coexpression O +
of O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
and O +
Sp1 O +
transcription O +
factors O +
in O +
human O +
immunodeficiency O +
virus O +
1-induced O +
, O +
dendritic O +
cell O -
- O -
T O -
- O -
cell O +
syncytia O +
. O +

Productive O +
infection O +
of O +
T O +
cells O +
with O +
human O +
immunodeficiency O +
virus O +
1 O +
( O +
HIV-1 O +
) O +
typically O +
requires O +
that O +
the O +
T O +
cells O +
be O +
stimulated O +
with O +
antigens O +
or O +
mitogens O +
. O +

This O +
requirement O +
has O +
been O +
attributed O +
to O +
the O +
activation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
, O +
which O +
synergizes O +
with O +
the O +
constitutive O +
transcription O +
factor O +
Sp1 O +
to O +
drive O +
the O +
HIV-1 O +
promoter O +
. O +

Recently O +
, O +
we O +
have O +
found O +
that O +
vigorous O +
replication O +
of O +
HIV-1 O +
takes O +
place O +
in O +
nonactivated O +
memory O +
T O +
cells O +
after O +
syncytium O +
formation O +
with O +
dendritic O +
cells O +
( O +
DCs O +
) O +
. O +

These O +
syncytia O +
lack O +
activated O +
cells O +
as O +
determined O +
by O +
an O +
absence O +
of O +
staining O +
for O +
Ki-67 O +
cell O +
cycle O +
antigen O +
. O +

The O +
expression O +
and O +
activity O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
Sp1 O +
were O +
, O +
therefore O +
, O +
analyzed O +
in O +
isolated O +
T O +
cells O +
and O +
DCs O +
from O +
humans O +
and O +
mice O +
. O +

We O +
have O +
used O +
immunolabeling O +
, O +
Western O +
blot O +
analysis O +
, O +
and O +
electrophoretic O +
mobility O +
shift O +
and O +
supershift O +
assays O +
. O +

T O +
cells O +
lack O +
active O +
NF O -
- O -
kappa O +
B O +
but O +
express O +
Sp1 O +
as O +
expected O +
. O +

DCs O +
express O +
high O +
levels O +
of O +
all O +
known O +
NF O -
- O -
kappa O +
B O +
and O +
Rel O +
proteins O +
, O +
with O +
activity O +
residing O +
primarily O +
within O +
RelB O +
, O +
p50 O +
, O +
and O +
p65 O +
. O +

However O +
, O +
DCs O +
lack O +
Sp1 O +
, O +
which O +
may O +
explain O +
the O +
failure O +
of O +
HIV-1 O +
to O +
replicate O +
in O +
purified O +
DCs O +
. O +

Coexpression O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
Sp1 O +
occurs O +
in O +
the O +
heterologous O +
DC O -
- O -
T O -
- O -
cell O +
syncytia O +
that O +
are O +
induced O +
by O +
HIV-1 O +
. O +

Therefore O +
, O +
HIV-1-induced O +
cell O +
fusion O +
brings O +
together O +
factors O +
that O +
upregulate O +
virus O +
transcription O +
. O +

Since O +
DCs O +
and O +
memory O +
T O +
cells O +
frequently O +
traffic O +
together O +
in O +
situ O +
, O +
these O +
unusual O +
heterologous O +
syncytia O +
could O +
develop O +
in O +
infected O +
individuals O +
and O +
lead O +
to O +
chronic O +
HIV-1 O +
replication O +
without O +
ostensible O +
immune O +
stimulation O +
. O +

Down O -
- O -
regulation O +
of O +
NF O -
- O -
kappa O +
B O +
protein O +
levels O +
in O +
activated O +
human O +
lymphocytes O +
by O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
[ O +
published O +
erratum O +
appears O +
in O +
Proc O +
Natl O +
Acad O +
Sci O +
U O +
S O +
A O +
1996 O +
Jan O +
9 O +
; O +
93 O +
( O +
1 O +
) O +
: O +
524 O +
] O +

The O +
effect O +
of O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
[ O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2 O +
) O +
D3 O +
] O +
, O +
a O +
steroid O +
hormone O +
with O +
immunomodulating O +
properties O +
, O +
on O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
proteins O +
was O +
examined O +
in O +
in B-CellLine +
vitro I-CellLine +
activated I-CellLine +
normal I-CellLine +
human I-CellLine +
lymphocytes I-CellLine +
by O +
Western O +
blot O +
analysis O +
. O +

Over O +
a O +
72-hr O +
period O +
of O +
activation O +
, O +
the O +
expression O +
of O +
the O +
50-kDa O +
NF O -
- O -
kappa O +
B O +
, O +
p50 O +
, O +
and O +
its O +
precursor O +
, O +
p105 O +
, O +
was O +
increased O +
progressively O +
. O +

When O +
cells O +
were O +
activated O +
in O +
the O +
presence O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
, O +
the O +
levels O +
of O +
the O +
mature O +
protein O +
as O +
well O +
as O +
its O +
precursor O +
were O +
decreased O +
. O +

The O +
effect O +
of O +
the O +
hormone O +
on O +
the O +
levels O +
of O +
p50 O +
was O +
demonstrable O +
in O +
the O +
cytosolic O +
and O +
nuclear O +
compartments O +
; O +
it O +
required O +
between O +
4 O +
and O +
8 O +
hr O +
and O +
was O +
specific O +
, O +
as O +
25-hydroxyvitamin O +
D3 O +
and O +
24 O +
, O +
25-dihydroxyvitamin O +
D3 O +
were O +
ineffective O +
. O +

Besides O +
p50 O +
, O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
decreased O +
the O +
levels O +
of O +
another O +
NF O -
- O -
kappa O +
B O +
protein O +
, O +
namely O +
c O -
- O -
rel O +
. O +

In O +
addition O +
, O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
decreased O +
the O +
abundance O +
of O +
a O +
specific O +
DNA O -
- O -
protein O +
complex O +
formed O +
upon O +
incubation O +
of O +
nuclear O +
extracts O +
from O +
activated O +
lymphocytes O +
with O +
a O +
labeled O +
NF O -
- O -
kappa O +
B O +
DNA O +
binding O +
motif O +
. O +

Further O +
, O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
inhibited O +
the O +
transcriptional O +
activity O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
transiently O +
transfected O +
with O +
a O +
construct O +
containing O +
four O +
tandem O +
repeats O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
binding O +
sequence O +
of O +
the O +
immunoglobulin O +
kappa O +
light O +
chain O +
gene O +
linked O +
to O +
the O +
chloramphenicol O +
acetyltransferase O +
reporter O +
gene O +
. O +

These O +
observations O +
demonstrate O +
directly O +
that O +
there O +
is O +
de O +
novo O +
synthesis O +
of O +
NF O -
- O -
kappa O +
B O +
during O +
human O +
lymphocyte O +
activation O +
and O +
suggest O +
that O +
this O +
process O +
is O +
hormonally O +
regulated O +
. O +

Oncogenicity O +
of O +
human B-CellLine +
papillomavirus- I-CellLine +
or I-CellLine +
adenovirus I-CellLine -
- I-CellLine -
transformed I-CellLine +
cells I-CellLine +
correlates O +
with O +
resistance O +
to O +
lysis O +
by O +
natural O +
killer O +
cells O +
. O +

The O +
reasons O +
for O +
the O +
dissimilar O +
oncogenicities O +
of O +
human O +
adenoviruses O +
and O +
human O +
papillomaviruses O +
( O +
HPV O +
) O +
in O +
humans O +
are O +
unknown O +
but O +
may O +
relate O +
to O +
differences O +
in O +
the O +
capacities O +
of O +
the O +
E1A O +
and O +
E7 O +
proteins O +
to O +
target O +
cells O +
for O +
rejection O +
by O +
the O +
host O +
natural O +
killer O +
( O +
NK O +
) O +
cell O +
response O +
. O +

As O +
one O +
test O +
of O +
this O +
hypothesis O +
, O +
we O +
compared O +
the O +
abilities O +
of O +
E1A O +
-and O +
E7 O +
-expressing O +
human B-CellLine +
fibroblastic I-CellLine +
or I-CellLine +
keratinocyte I-CellLine -
- I-CellLine -
derived I-CellLine +
human I-CellLine +
cells I-CellLine +
to O +
be O +
selectively O +
killed O +
by O +
either O +
unstimulated O +
or O +
interferon B-CellLine +
( I-CellLine +
IFN I-CellLine +
) I-CellLine +
-activated I-CellLine +
NK I-CellLine +
cells I-CellLine +
. O +

Cells O +
expressing O +
the O +
E1A O +
oncoprotein O +
were O +
selectively O +
killed O +
by O +
unstimulated B-CellLine +
NK I-CellLine +
cells I-CellLine +
, O +
while O +
the O +
same O +
parental O +
cells O +
but O +
expressing O +
the O +
HPV O +
type O +
16 O +
( O +
HPV-16 O +
) O +
or O +
HPV-18 O +
E7 O +
oncoprotein O +
were O +
resistant O +
to O +
NK O +
cell O +
lysis O +
. O +

The O +
ability O +
of O +
IFN B-CellLine -
- I-CellLine -
activated I-CellLine +
NK I-CellLine +
cells I-CellLine +
to O +
selectively O +
kill O +
virally O +
transformed O +
cells O +
depends O +
on O +
IFN O +
's O +
ability O +
to O +
induce O +
resistance O +
to O +
NK O +
cell O +
lysis O +
in O +
normal O +
( O +
i.e. O +
, O +
non B-CellLine -
- I-CellLine -
viral I-CellLine +
oncogene I-CellLine -
- I-CellLine -
expressing I-CellLine +
) O +
but O +
not O +
virally B-CellLine +
transformed I-CellLine +
cells I-CellLine +
. O +

E1A O +
blocked O +
IFN O +
's O +
induction O +
of O +
cytolytic O +
resistance O +
, O +
resulting O +
in O +
the O +
selective O +
lysis O +
of O +
adenovirus B-CellLine -
- I-CellLine -
transformed I-CellLine +
cells I-CellLine +
by O +
IFN B-CellLine -
- I-CellLine -
activated I-CellLine +
NK I-CellLine +
cells I-CellLine +
. O +

The O +
extent O +
of O +
IFN O +
-induced O +
NK O +
cell O +
killing O +
of O +
E1A B-CellLine -
- I-CellLine -
expressing I-CellLine +
cells I-CellLine +
was O +
proportional O +
to O +
the O +
level O +
of O +
E1A O +
expression O +
and O +
correlated O +
with O +
the O +
ability O +
of O +
E1A O +
to O +
block O +
IFN O +
-stimulated O +
gene O +
expression O +
in O +
target O +
cells O +
. O +

In O +
contrast O +
, O +
E7 O +
blocked O +
neither O +
IFN O +
-stimulated O +
gene O +
expression O +
nor O +
IFN O +
's O +
induction O +
of O +
cytolytic O +
resistance O +
, O +
thereby O +
precluding O +
the O +
selective O +
lysis O +
of O +
HPV B-CellLine -
- I-CellLine -
transformed I-CellLine +
cells I-CellLine +
by O +
IFN B-CellLine -
- I-CellLine -
activated I-CellLine +
NK I-CellLine +
cells I-CellLine +
. O +

In O +
conclusion O +
, O +
E1A O +
expression O +
marks O +
cells O +
for O +
destruction O +
by O +
the O +
host O +
NK O +
cell O +
response O +
, O +
whereas O +
the O +
E7 O +
oncoprotein O +
lacks O +
this O +
activity O +
. O +

Expression O +
of O +
the O +
nucleoside O +
diphosphate O +
kinase O +
in O +
human O +
skin O +
cancers O +
: O +
an O +
immunohistochemical O +
study O +
. O +

Expression O +
of O +
nucleoside O +
diphosphate O +
( O +
NDP O +
) O +
kinase O +
, O +
which O +
is O +
homologous O +
to O +
the O +
nm23 O +
gene O +
product O +
in O +
a O +
variety O +
of O +
species O +
, O +
has O +
been O +
found O +
to O +
be O +
inversely O +
associated O +
with O +
metastatic O +
potential O +
. O +

However O +
, O +
the O +
relationship O +
remains O +
controversial O +
according O +
to O +
the O +
tumor O +
cell O +
types O +
and O +
experimental O +
system O +
, O +
with O +
conflicting O +
results O +
from O +
different O +
research O +
groups O +
. O +

In O +
order O +
to O +
determine O +
whether O +
NDP O +
kinase O +
expression O +
serves O +
as O +
a O +
marker O +
for O +
metastatic O +
potential O +
in O +
human O +
skin O +
cancer O +
, O +
we O +
assessed O +
the O +
levels O +
of O +
NDP O +
kinase O +
expression O +
in O +
9 O +
keratoacanthomas O +
( O +
KAs O +
) O +
, O +
26 O +
squamous O +
cell O +
carcinomas O +
( O +
SCCs O +
) O +
, O +
and O +
25 O +
basal O +
cell O +
carcinomas O +
( O +
BCCs O +
) O +
using O +
immunohistochemistry O +
. O +

The O +
expression O +
of O +
NDP O +
kinase O +
was O +
intense O +
in O +
KA O +
and O +
SCC O +
compared O +
with O +
BCC O +
. O +

However O +
, O +
the O +
difference O +
of O +
NDP O +
kinase O +
expression O +
between O +
KA O +
and O +
SCC O +
was O +
not O +
statistically O +
significant O +
. O +

And O +
there O +
was O +
no O +
statistically O +
significant O +
difference O +
in O +
NDP O +
kinase O +
expression O +
between O +
SCC O +
with O +
metastasis O +
and O +
SCC O +
without O +
metastasis O +
. O +

Our O +
results O +
contradict O +
the O +
hypothesis O +
concerning O +
the O +
possible O +
role O +
of O +
nm23 O +
gene O +
as O +
a O +
metastatic O +
suppressor O +
gene O +
in O +
human O +
skin O +
cancer O +
. O +

The O +
mechanism O +
of O +
overexpression O +
in O +
various O +
tumor O +
cell O +
types O +
and O +
its O +
biological O +
significance O +
in O +
cutaneous O +
carcinogenesis O +
remain O +
to O +
be O +
determined O +
. O +

Interleukin-7 O +
can O +
induce O +
the O +
activation O +
of O +
Jak O +
1 O +
, O +
Jak O +
3 O +
and O +
STAT O +
5 O +
proteins O +
in O +
murine O +
T O +
cells O +
. O +

The O +
activation O +
of O +
Janus O +
protein O +
tyrosine O +
kinases O +
( O +
Jak O +
) O +
and O +
STAT O +
( O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
) O +
proteins O +
has O +
recently O +
been O +
linked O +
to O +
the O +
signal O +
transduction O +
mechanism O +
of O +
several O +
cytokines O +
. O +

IL-7 O +
was O +
observed O +
to O +
induce O +
a O +
rapid O +
and O +
dose O -
- O -
dependent O +
tyrosine O +
phosphorylation O +
of O +
Jak O +
1 O +
and O +
Jak O +
3 O +
and O +
concomitantly O +
, O +
the O +
tyrosine O +
phosphorylation O +
and O +
DNA O +
binding O +
activity O +
of O +
multiple O +
STAT O +
proteins O +
. O +

The O +
STAT O +
proteins O +
utilized O +
by O +
IL-7 O +
were O +
identical O +
to O +
those O +
induced O +
by O +
IL-2 O +
and O +
could O +
be O +
identified O +
as O +
various O +
STAT O +
5 O +
isoforms O +
. O +

Moreover O +
, O +
the O +
induction O +
of O +
both O +
Jak O +
1 O +
and O +
3 O +
, O +
and O +
STAT O +
5 O +
activity O +
strongly O +
correlated O +
with O +
the O +
growth O -
- O -
promoting O +
effects O +
of O +
IL-7 O +
, O +
suggesting O +
that O +
this O +
signal O +
transduction O +
mechanism O +
may O +
play O +
a O +
key O +
role O +
in O +
IL-7 O +
-induced O +
proliferation O +
. O +

Constitutive O +
NF O -
- O -
kappa O +
B O +
activation O +
, O +
enhanced O +
granulopoiesis O +
, O +
and O +
neonatal O +
lethality O +
in O +
I O +
kappa O +
B O +
alpha O +
-deficient O +
mice O +
. O +

Transcription O +
factors O +
belonging O +
to O +
the O +
NF O -
- O -
kappa O +
B O +
family O +
are O +
controlled O +
by O +
inhibitory O +
I O +
kappa O +
B O +
proteins O +
, O +
mainly O +
I O +
kappa O +
B O +
alpha O +
and O +
I O +
kappa O +
B O +
beta O +
. O +

Apparently O +
normal O +
at O +
birth O +
, O +
I O +
kappa O +
B O +
alpha O +
- O -
/ O -
- O +
mice O +
exhibit O +
severe O +
runting O +
, O +
skin O +
defects O +
, O +
and O +
extensive O +
granulopoiesis O +
postnatally O +
, O +
typically O +
dying O +
by O +
8 O +
days O +
. O +

Hematopoietic O +
tissues O +
from O +
these O +
mice O +
display O +
elevated O +
levels O +
of O +
both O +
nuclear O +
NF O -
- O -
kappa O +
B O +
and O +
mRNAs O +
of O +
some O +
, O +
but O +
not O +
all O +
, O +
genes O +
thought O +
to O +
be O +
regulated O +
by O +
NF O -
- O -
kappa O +
B O +
. O +

NF O -
- O -
kappa O +
B O +
elevation O +
results O +
in O +
these O +
phenotypic O +
abnormalities O +
because O +
mice O +
lacking O +
both O +
I O +
kappa O +
B O +
alpha O +
and O +
the O +
p50 O +
subunit O +
of O +
NF O -
- O -
kappa O +
B O +
show O +
a O +
dramatically O +
delayed O +
onset O +
of O +
abnormalities O +
. O +

In O +
contrast O +
to O +
hematopoietic O +
cells O +
, O +
I B-CellLine +
kappa I-CellLine +
B I-CellLine +
alpha- I-CellLine -
/ I-CellLine -
- I-CellLine +
embryonic I-CellLine +
fibroblasts I-CellLine +
show O +
minimal O +
constitutive O +
NF O -
- O -
kappa O +
B O +
, O +
as O +
well O +
as O +
normal O +
signal O -
- O -
dependent O +
NF O -
- O -
kappa O +
B O +
activation O +
that O +
is O +
concomitant O +
with O +
I O +
kappa O +
B O +
beta O +
degradation O +
. O +

Our O +
results O +
indicate O +
that O +
I O +
kappa O +
b O +
beta O +
, O +
but O +
not O +
I O +
kappa O +
B O +
alpha O +
, O +
is O +
required O +
for O +
the O +
signal O -
- O -
dependent O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
fibroblasts O +
. O +

However O +
, O +
I O +
kappa O +
B O +
alpha O +
is O +
required O +
for O +
the O +
postinduction O +
repression O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
fibroblasts O +
. O +

These O +
results O +
define O +
distinct O +
roles O +
for O +
the O +
two O +
forms O +
of O +
I O +
kappa O +
B O +
and O +
demonstrate O +
the O +
necessity O +
for O +
stringent O +
control O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

Hemoglobin O +
switching O +
in O +
humans O +
is O +
accompanied O +
by O +
changes O +
in O +
the O +
ratio O +
of O +
the O +
transcription O +
factors O +
, O +
GATA-1 O +
and O +
SP1 O +
. O +

BACKGROUND O +
: O +
Understanding O +
the O +
mechanism O +
of O +
developmental O +
regulation O +
of O +
hemoglobin O +
switching O +
has O +
scientific O +
as O +
well O +
as O +
clinical O +
relevance O +
because O +
of O +
the O +
influence O +
of O +
fetal O +
hemoglobin O +
( O +
HbF O +
) O +
production O +
in O +
adulthood O +
on O +
the O +
clinical O +
manifestation O +
of O +
thalassemia O +
and O +
sickle O +
cell O +
anemia O +
. O +

We O +
have O +
previously O +
found O +
that O +
the O +
normal O +
developmental O +
patterns O +
of O +
globin O +
gene O +
expression O +
are O +
recapitulated O +
in O +
an O +
experimental O +
system O +
of O +
primary B-CellLine +
cultures I-CellLine +
that O +
support O +
differentiation O +
of O +
erythroid O +
progenitors O +
. O +

We O +
further O +
found O +
that O +
high O +
activities O +
of O +
the O +
transcriptional O +
activators O +
, O +
GATA-1 O +
and O +
SP1 O +
, O +
are O +
associated O +
with O +
normal O +
adult O +
erythroid O +
differentiation O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +
In O +
the O +
present O +
work O +
, O +
we O +
have O +
studied O +
, O +
the O +
activities O +
of O +
GATA-1 O +
and O +
SP1 O +
during O +
differentiation O +
of O +
cultured O +
erythroid O +
progenitors O +
derived O +
from O +
cord O +
blood O +
and O +
from O +
fetal O +
livers O +
, O +
as O +
well O +
as O +
from O +
beta O +
zero O -
- O -
thalassemia O +
patients O +
. O +

RESULTS O +
: O +
The O +
results O +
showed O +
high O +
GATA-1 O +
binding O +
activity O +
and O +
very O +
low O +
SP1 O +
activity O +
in O +
the O +
fetal B-CellLine +
liver I-CellLine +
cultures I-CellLine +
. O +

This O +
pattern O +
was O +
in O +
contrast O +
to O +
cultures O +
derived O +
from O +
normal O +
adult O +
peripheral O +
blood O +
, O +
in O +
which O +
both O +
GATA-1 O +
and O +
SP1 O +
activities O +
were O +
high O +
. O +

Cord O +
blood O +
cultures O +
showed O +
an O +
additive O +
combination O +
of O +
` O -
` O +
adult O +
'' O +
and O +
` O -
` O +
fetal O +
'' O +
patterns O +
. O +

The O +
progenitors O +
derived O +
from O +
a O +
beta O +
zero O -
- O -
thalassemia O +
patient O +
with O +
high O +
HbF O +
production O +
showed O +
` O -
` O +
fetal O +
'' O +
pattern O +
. O +

On O +
the O +
other O +
hand O +
, O +
in O +
cultures O +
of O +
2 O +
beta O +
zero O -
- O -
thalassemia O +
patients O +
without O +
high O +
HbF O +
, O +
` O -
` O +
adult O +
'' O +
pattern O +
was O +
observed O +
. O +

CONCLUSIONS O +
: O +
In O +
the O +
present O +
work O +
, O +
we O +
show O +
that O +
human O +
fetal O +
and O +
adult O +
erythroid O +
progenitors O +
are O +
distinct O +
in O +
their O +
transcription O +
factors O +
, O +
and O +
that O +
the O +
commitment O +
to O +
fetal O +
or O +
adult O +
program O +
occurs O +
at O +
a O +
very O +
early O +
differentiation O +
stage O +
. O +

Our O +
studies O +
also O +
demonstrate O +
that O +
under O +
anemic O +
stress O +
, O +
recruitment O +
of O +
fetal O +
progenitors O +
may O +
occur O +
in O +
adulthood O +
. O +

CIITA O +
activates O +
the O +
expression O +
of O +
MHC O +
class O +
II O +
genes O +
in O +
mouse O +
T O +
cells O +
. O +

It O +
has O +
long O +
been O +
a O +
puzzle O +
that O +
MHC O +
class O +
II O +
molecules O +
are O +
expressed O +
in O +
human O +
T O +
cells O +
after O +
activation O +
but O +
not O +
in O +
mouse O +
T O +
cells O +
; O +
this O +
expression O +
is O +
believed O +
to O +
play O +
a O +
role O +
in O +
the O +
cell O +
mediated O +
immune O +
response O +
. O +

Recently O +
the O +
MHC O +
class O +
II O +
transactivator O +
( O +
CIITA O +
) O +
has O +
been O +
reported O +
to O +
be O +
a O +
major O +
regulatory O +
factor O +
for O +
both O +
the O +
constitutive O +
and O +
IFN O +
inducible O +
expression O +
of O +
MHC O +
class O +
II O +
genes O +
. O +

Here O +
we O +
show O +
that O +
human O +
T O +
cells O +
expressing O +
MHC O +
class O +
II O +
have O +
CIITA O +
transcripts O +
while O +
MHC O +
class O +
II O -
- O -
negative O +
human O +
T O +
cells O +
and O +
mouse O +
T O +
cells O +
do O +
not O +
. O +

The O +
expression O +
of O +
MHC O +
class O +
II O +
genes O +
in O +
mouse O +
T O +
cells O +
can O +
be O +
reconstituted O +
upon O +
transfection O +
with O +
the O +
human O +
CIITA O +
cDNA O +
. O +

These O +
data O +
indicate O +
that O +
the O +
expression O +
of O +
CIITA O +
explains O +
the O +
expression O +
or O +
lack O +
of O +
expression O +
of O +
MHC O +
class O +
II O +
in O +
human O +
and O +
mouse O +
T O +
cells O +
respectively O +
. O +

Lymphocyte O +
glucocorticoid O +
receptor O +
: O +
predictor O +
of O +
sertraline O +
response O +
in O +
adolescent O +
major O +
depressive O +
disorder O +
( O +
MDD O +
) O +
. O +

Major O +
depressive O +
disorder O +
( O +
MDD O +
) O +
in O +
adolescents O +
demonstrates O +
resistance O +
to O +
tricyclic O +
antidepressants O +
and O +
absence O +
of O +
hypercortisolemia O +
. O +

The O +
efficacy O +
of O +
serotonin O +
reuptake O +
inhibitors O +
( O +
SRIs O +
) O +
is O +
uncertain O +
, O +
and O +
response O +
predictors O +
are O +
unavailable O +
. O +

Abnormal O +
fast O +
feedback O +
and O +
negative O +
feedback O +
of O +
the O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenal O +
axis O +
implicates O +
a O +
dampened O +
limbic O -
- O -
hippocampal O +
glucocorticoid O +
type O +
II O +
receptor O +
( O +
GCII O +
) O +
. O +

We O +
hypothesized O +
that O +
lymphocyte O +
GCII O +
is O +
altered O +
in O +
adolescent O +
MDD O +
and O +
could O +
serve O +
as O +
a O +
marker O +
for O +
response O +
to O +
SRIs O +
. O +

In O +
an O +
open O -
- O -
label O +
study O +
, O +
adolescents O +
( O +
n O +
= O +
20 O +
) O +
meeting O +
DSM O -
- O -
III O -
- O -
R O +
criteria O +
for O +
MDD O +
showed O +
baseline O +
lymphocyte O +
GCII O +
sites O +
per O +
cell O +
( O +
sites O -
/ O -
cell O +
) O +
values O +
of O +
793 O +
+ O -
/- O +
106 O +
versus O +
2 O +
, O +
563 O +
+ O -
/- O +
499 O +
( O +
+ O -
/- O +
SEM O +
) O +
for O +
matched O +
controls O +
( O +
n O +
= O +
18 O +
) O +
( O +
t O +
= O +
3.5 O +
; O +
df O +
= O +
36 O +
; O +
p O +
< O +
.001 O +
) O +
. O +

GCII O +
was O +
bimodally O +
distributed O +
, O +
with O +
SRI O +
responders O +
differing O +
from O +
nonresponders O +
( O +
t O +
= O +
3.9 O +
; O +
df O +
= O +
14 O +
; O +
p O +
< O +
.001 O +
) O +
. O +

GCII O +
accurately O +
classified O +
90 O +
percent O +
of O +
sertraline O +
responders O +
and O +
80 O +
percent O +
of O +
nonresponders O +
. O +

Only O +
SRI O +
responders O +
showed O +
GCII O +
sites O -
/ O -
cell O +
upregulated O +
after O +
6 O +
weeks O +
of O +
treatment O +
( O +
t O +
= O +
2.1 O +
, O +
df O +
= O +
10 O +
; O +
p O +
< O +
.05 O +
) O +
. O +

Transcriptional O +
activation O +
and O +
repression O +
, O +
two O +
properties O +
of O +
the O +
lymphoid O -
- O -
specific O +
transcription O +
factor O +
Oct-2a O +
. O +

The O +
lymphoid O -
- O -
specific O +
transcription O +
factor O +
Oct-2a O +
contains O +
two O +
transcriptional O +
activation O +
domains O +
which O +
are O +
located O +
within O +
the O +
N O -
- O -
terminal O +
and O +
C O -
- O -
terminal O +
regions O +
. O +

To O +
study O +
their O +
differential O +
activation O +
properties O +
, O +
we O +
linked O +
the O +
isolated O +
effector O +
domains O +
to O +
the O +
GAL4 O +
DNA O -
- O -
binding O +
domain O +
. O +

We O +
have O +
shown O +
that O +
both O +
activating O +
regions O +
of O +
Oct-2a O +
, O +
isolated O +
from O +
their O +
natural O +
context O +
, O +
can O +
activate O +
transcription O +
as O +
promoter O +
factors O +
. O +

In O +
contrast O +
to O +
the O +
C O -
- O -
terminus O +
, O +
activation O +
by O +
the O +
N O -
- O -
terminal O +
domain O +
is O +
dependent O +
on O +
a O +
yet O +
unidentified O +
factor O +
( O +
s O +
) O +
binding O +
to O +
the O +
simian O +
virus O +
40 O +
enhancer O +
. O +

The O +
results O +
obtained O +
by O +
duplication O +
of O +
activation O +
domains O +
or O +
their O +
mixed O +
combination O +
suggest O +
that O +
the O +
domains O +
are O +
functionally O +
independent O +
. O +

However O +
, O +
activation O +
from O +
a O +
remote O +
position O +
could O +
only O +
be O +
achieved O +
with O +
the O +
C O -
- O -
terminus O +
of O +
Oct-2a O +
in O +
B O +
cells O +
. O +

In O +
lymphoid O +
cells O +
, O +
higher O +
activation O +
levels O +
were O +
observed O +
, O +
suggesting O +
that O +
distinct O +
B O -
- O -
cell O -
- O -
specific O +
cofactors O +
in O +
concert O +
with O +
the O +
effector O +
domains O +
of O +
Oct-2a O +
might O +
be O +
involved O +
in O +
mediating O +
transcription O +
from O +
proximal O +
and O +
remote O +
positions O +
. O +

Furthermore O +
, O +
we O +
identified O +
a O +
repression O +
domain O +
at O +
the O +
N O -
- O -
terminus O +
of O +
Oct-2a O +
. O +

When O +
transferred O +
to O +
a O +
potent O +
activator O +
, O +
transcriptional O +
stimulation O +
was O +
inhibited O +
efficiently O +
. O +

These O +
results O +
underscore O +
the O +
modular O +
structure O +
of O +
Oct-2a O +
with O +
separable O +
domains O +
for O +
activation O +
and O +
repression O +
and O +
suggest O +
that O +
Oct-2a O +
might O +
have O +
complex O +
regulatory O +
functions O +
in O +
vivo O +
. O +

Protein O +
kinase O +
C O -
- O -
zeta O +
mediates O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
human O +
immunodeficiency O +
virus O -
- O -
infected O +
monocytes O +
. O +

The O +
molecular O +
mechanisms O +
regulating O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
persistence O +
in O +
a O +
major O +
cell O +
reservoir O +
such O +
as O +
the O +
macrophage O +
remain O +
unknown O +
. O +

NF O -
- O -
kappa O +
B O +
is O +
a O +
transcription O +
factor O +
involved O +
in O +
the O +
regulation O +
of O +
the O +
HIV O +
long O +
terminal O +
repeat O +
and O +
is O +
selectively O +
activated O +
following O +
HIV O +
infection O +
of O +
human O +
macrophages O +
. O +

Although O +
little O +
information O +
as O +
to O +
what O +
signal O +
transduction O +
pathways O +
mediate O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
monocytes O -
- O -
macrophages O +
is O +
available O +
, O +
our O +
previous O +
work O +
indicated O +
that O +
classical O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
isoenzymes O +
were O +
not O +
involved O +
in O +
the O +
HIV O -
- O -
mediated O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

In O +
this O +
study O +
, O +
we O +
have O +
focused O +
on O +
atypical O +
PKC O +
isoenzymes O +
. O +

PKC O -
- O -
zeta O +
belongs O +
to O +
this O +
family O +
and O +
is O +
known O +
to O +
be O +
an O +
important O +
step O +
in O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
other O +
cell O +
systems O +
. O +

Immunoblotting O +
experiments O +
with O +
U937 B-CellLine +
cells I-CellLine +
demonstrate O +
that O +
PKC O -
- O -
zeta O +
is O +
present O +
in O +
these O +
cells O +
, O +
and O +
its O +
expression O +
can O +
be O +
downmodulated O +
by O +
antisense O +
oligonucleotides O +
( O +
AO O +
) O +
. O +

The O +
HIV O -
- O -
mediated O +
NF O -
- O -
kappa O +
B O +
activation O +
is O +
selectively O +
reduced O +
by O +
AO O +
to O +
PKC O -
- O -
zeta O +
. O +

In O +
addition O +
, O +
cotransfection O +
of O +
a O +
negative O +
dominant O +
molecule O +
of O +
PKC O -
- O -
zeta O +
( O +
PKC O -
- O -
zeta O +
mut O +
) O +
with O +
NF O -
- O -
kappa O +
B O +
-dependent O +
reporter O +
genes O +
selectively O +
inhibits O +
the O +
HIV O +
-but O +
not O +
phorbol O +
myristate O +
acetate- O +
or O +
lipopolysaccharide O -
- O -
mediated O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

That O +
PKC O -
- O -
zeta O +
is O +
specific O +
in O +
regulating O +
NF O -
- O -
kappa O +
B O +
is O +
concluded O +
from O +
the O +
inability O +
of O +
PKC O -
- O -
zeta O +
( O +
mut O +
) O +
to O +
interfere O +
with O +
the O +
basal O +
or O +
phorbol O +
myristate O +
acetate O -
- O -
inducible O +
CREB O +
-or O +
AP1 O +
-dependent O +
transcriptional O +
activity O +
. O +

Lastly O +
, O +
we O +
demonstrate O +
a O +
selective O +
inhibition O +
of O +
p24 O +
production O +
by O +
HIV O -
- O -
infected O +
human O +
macrophages O +
when O +
treated O +
with O +
AO O +
to O +
PKC O -
- O -
zeta O +
. O +

Altogether O +
, O +
these O +
results O +
suggest O +
that O +
atypical O +
PKC O +
isoenzymes O +
, O +
including O +
PKC O -
- O -
zeta O +
, O +
participate O +
in O +
the O +
signal O +
transduction O +
pathways O +
by O +
which O +
HIV O +
infection O +
results O +
in O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
human O +
monocytic O +
cells O +
and O +
macrophages O +
. O +

Functional O +
characterization O +
of O +
the O +
murine O +
homolog O +
of O +
the O +
B O +
cell O -
- O -
specific O +
coactivator O +
BOB.1 O -
/ O -
OBF.1 O +
. O +

B O +
cell O -
- O -
specific O +
transcriptional O +
promoter O +
activity O +
mediated O +
by O +
the O +
octamer O +
motif O +
requires O +
the O +
Oct1 O +
or O +
Oct2 O +
protein O +
and O +
additional O +
B O +
cell O -
- O -
restricted O +
cofactors O +
. O +

One O +
such O +
cofactor O +
, O +
BOB.1 O -
/ O -
OBF.1 O +
, O +
was O +
recently O +
isolated O +
from O +
human O +
B O +
cells O +
. O +

Here O +
, O +
we O +
describe O +
the O +
isolation O +
and O +
detailed O +
characterization O +
of O +
the O +
murine O +
homolog O +
. O +

Full O -
- O -
length O +
cDNAs O +
and O +
genomic O +
clones O +
were O +
isolated O +
, O +
and O +
the O +
gene O +
structure O +
was O +
determined O -
. O +
Comparison O +
of O +
the O +
deduced O +
amino O +
acids O +
shows O +
88 O +
% O +
sequence O +
identity O +
between O +
mouse O +
and O +
human O +
BOB.1 O -
/ O -
OBF.1 O +
. O +

The O +
NH2-terminal O +
126 O +
amino O +
acids O +
of O +
BOB.1 O -
/ O -
OBF.1 O +
are O +
both O +
essential O +
and O +
sufficient O +
for O +
interaction O +
with O +
the O +
POU O +
domains O +
of O +
either O +
Oct1 O +
or O +
Oct2 O +
. O +

This O +
protein O -
- O -
protein O +
interaction O +
does O +
not O +
require O +
the O +
simultaneous O +
binding O +
of O +
Oct O +
proteins O +
to O +
DNA O +
, O +
and O +
high O +
resolution O +
footprinting O +
of O +
the O +
Oct O +
-DNA O +
interaction O +
reveals O +
that O +
binding O +
of O +
BOB.1 O -
/ O -
OBF.1 O +
to O +
Oct1 O +
or O +
Oct2 O +
does O +
not O +
alter O +
the O +
interaction O +
with O +
DNA O +
. O +

BOB.1 O -
/ O -
OBF.1 O +
can O +
efficiently O +
activate O +
octamer O -
- O -
dependent O +
promoters O +
in O +
fibroblasts O +
; O +
however O +
, O +
it O +
fails O +
to O +
stimulate O +
octamer O -
- O -
dependent O +
enhancer O +
activity O +
. O +

Fusion O +
of O +
subdomains O +
of O +
BOB.1 O -
/ O -
OBF.1 O +
with O +
the O +
GAL4 O +
DNA O +
binding O +
domain O +
reveals O +
that O +
both O +
NH2- O +
and O +
COOH O -
- O -
terminal O +
domains O +
of O +
BOB.1 O -
/ O -
OBF.1 O +
contribute O +
to O +
full O +
transactivation O +
function O +
, O +
the O +
COOH O -
- O -
terminal O +
domain O +
is O +
more O +
efficient O +
in O +
this O +
transactivation O +
assay O +
. O +

Consistent O +
with O +
the O +
failure O +
of O +
full O -
- O -
length O +
BOB.1 O -
/ O -
OBF.1 O +
to O +
stimulate O +
octamer O -
- O -
dependent O +
enhancer O +
elements O +
in O +
non O +
B O +
cells O +
, O +
the O +
GAL4 O +
fusions O +
likewise O +
only O +
stimulate O +
from O +
a O +
promoter O -
- O -
proximal O +
position O +
. O +

Inhibition O +
of O +
NF O -
- O -
AT O +
-dependent O +
transcription O +
by O +
NF O -
- O -
kappa O +
B O +
: O +
implications O +
for O +
differential O +
gene O +
expression O +
in O +
T O +
helper O +
cell O +
subsets O +
. O +

Activation O +
of O +
individual O +
CD4 B-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
results O +
in O +
differential O +
lymphokine O +
expression O +
: O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
is O +
preferentially O +
produced O +
by O +
T B-CellLine +
helper I-CellLine +
type I-CellLine +
1 I-CellLine +
( I-CellLine +
TH1 I-CellLine +
) I-CellLine +
cells I-CellLine +
, O +
which O +
are O +
involved O +
in O +
cell O -
- O -
mediated O +
immune O +
responses O +
, O +
whereas O +
IL-4 O +
is O +
synthesized O +
by O +
TH2 B-CellLine +
cells I-CellLine +
, O +
which O +
are O +
essential O +
for O +
humoral O +
immunity O +
. O +

The O +
Ca O +
( O +
2 O -
+ O +
) O +
-dependent O +
factor O +
NF O -
- O -
ATp O +
plays O +
a O +
key O +
role O +
in O +
the O +
inducible O +
transcription O +
of O +
both O +
these O +
lymphokine O +
genes O +
. O +

However O +
, O +
while O +
IL2 O +
expression O +
requires O +
the O +
contribution O +
of O +
Ca O +
( O +
2 O -
+ O +
) O +
- O +
and O +
protein O +
kinase O +
C O +
-dependent O +
signals O +
, O +
we O +
report O +
that O +
activation O +
of O +
human O +
IL4 O +
transcription O +
through O +
the O +
Ca O +
( O +
2 O -
+ O +
) O +
-dependent O +
pathway O +
is O +
diminished O +
by O +
protein O +
kinase O +
C O +
stimulation O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

This O +
phenomenon O +
is O +
due O +
to O +
mutually O +
exclusive O +
binding O +
of O +
NF O -
- O -
ATp O +
and O +
NF O -
- O -
kappa O +
B O +
to O +
the O +
P O +
sequence O +
, O +
an O +
element O +
located O +
69 O +
bp O +
upstream O +
of O +
the O +
IL4 O +
transcription O +
initiation O +
site O +
. O +

Human O +
IL4 O +
promoter O +
-mediated O +
transcription O +
is O +
downregulated O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
stimulated O +
with O +
the O +
NF O -
- O -
kappa O +
B O -
- O -
activating O +
cytokine O +
tumor O +
necrosis O +
factor O +
alpha O +
and O +
suppressed O +
in O +
RelA B-CellLine -
- I-CellLine -
overexpressing I-CellLine +
cells I-CellLine +
. O +

In O +
contrast O +
, O +
protein O +
kinase O +
C O +
stimulation O +
or O +
RelA O +
overexpression O +
does O +
not O +
affect O +
the O +
activity O +
of O +
a O +
human O +
IL4 O +
promoter O +
containing O +
a O +
mouse O +
P O +
sequence O +
, O +
which O +
is O +
a O +
higher O -
- O -
affinity O +
site O +
for O +
NF O -
- O -
ATp O +
and O +
a O +
lower O -
- O -
affinity O +
site O +
for O +
RelA O +
. O +

Thus O +
, O +
competition O +
between O +
two O +
general O +
transcriptional O +
activators O +
, O +
RelA O +
and O +
NF O -
- O -
ATp O +
, O +
mediates O +
the O +
inhibitory O +
effect O +
of O +
protein O +
kinase O +
C O +
stimulation O +
on O +
IL4 O +
expression O +
and O +
may O +
contribute O +
to O +
differential O +
gene O +
expression O +
in O +
TH B-CellLine +
cells I-CellLine +
. O +

Solution O +
structure O +
of O +
the O +
sequence O -
- O -
specific O +
HMG O +
box O +
of O +
the O +
lymphocyte O +
transcriptional O +
activator O +
Sox-4 O +
. O +

Two O +
groups O +
of O +
HMG O +
box O +
proteins O +
are O +
distinguished O +
. O +

Proteins O +
in O +
the O +
first O +
group O +
contain O +
multiple O +
HMG O +
boxes O +
, O +
are O +
non O -
- O -
sequence O -
- O -
specific O +
, O +
and O +
recognize O +
structural O +
features O +
as O +
found O +
in O +
cruciform O +
DNA O +
and O +
cross O -
- O -
over O +
DNA O +
. O +

The O +
abundant O +
chromosomal O +
protein O +
HMG-1 O +
belongs O +
to O +
this O +
subgroup O +
. O +

Proteins O +
in O +
the O +
second O +
group O +
carry O +
a O +
single O +
HMG O +
box O +
with O +
affinity O +
for O +
the O +
minor O +
groove O +
of O +
the O +
heptamer O +
motif O +
AACAAAG O +
or O +
variations O +
thereof O +
. O +

A O +
solution O +
structure O +
for O +
the O +
non O -
- O -
sequence O -
- O -
specific O +
C O -
- O -
terminal O +
HMG O +
box O +
of O +
HMG-1 O +
has O +
recently O +
been O +
proposed O +
. O +

Now O +
, O +
we O +
report O +
the O +
solution O +
structure O +
of O +
the O +
sequence O -
- O -
specific O +
HMG O -
- O -
box O +
of O +
the O +
SRY O -
- O -
related O +
protein O +
Sox-4 O +
. O +

NMR O +
analysis O +
demonstrated O +
the O +
presence O +
of O +
three O +
alpha O -
- O -
helices O +
( O +
Val10-Gln22 O +
, O +
Glu30-Leu41 O +
and O +
Phe50-Tyr65 O +
) O +
connected O +
by O +
loop O +
regions O +
( O +
Ser23-Ala49 O +
and O +
Leu42-Pro49 O +
) O +
. O +

Helices O +
I O +
and O +
II O +
are O +
positioned O +
in O +
an O +
antiparallel O +
mode O +
and O +
form O +
one O +
arm O +
of O +
the O +
HMG O +
box O +
. O +

Helix O +
III O +
is O +
less O +
rigid O +
, O +
makes O +
an O +
average O +
angle O +
of O +
about O +
90 O +
degrees O +
with O +
helices O +
I O +
and O +
II O +
, O +
and O +
constitutes O +
the O +
other O +
arm O +
of O +
the O +
molecule O +
. O +

As O +
in O +
HMG1B O +
, O +
the O +
overall O +
structure O +
of O +
the O +
Sox-4 O +
HMG O +
box O +
is O +
L O -
- O -
shaped O +
and O +
is O +
maintained O +
by O +
a O +
cluster O +
of O +
conserved O +
, O +
mainly O +
aromatic O +
residues O +
. O +

Dehydroepiandrosterone O +
modulation O +
of O +
lipopolysaccharide O -
- O -
stimulated O +
monocyte O +
cytotoxicity O +
. O +

Dehydroepiandrosterone O +
( O +
DHEA O +
) O +
, O +
the O +
predominant O +
androgen O +
secreted O +
by O +
the O +
adrenal O +
cortex O +
, O +
can O +
be O +
converted O +
to O +
both O +
potent O +
androgens O +
and O +
estrogens O +
. O +

In O +
addition O +
to O +
its O +
role O +
as O +
a O +
precursor O +
for O +
other O +
steroid O +
hormones O +
, O +
DHEA O +
has O +
been O +
proposed O +
to O +
play O +
an O +
important O +
role O +
in O +
immunity O +
. O +

This O +
study O +
has O +
investigated O +
DHEA O +
modulation O +
of O +
LPS O -
- O -
induced O +
monocyte O +
cytotoxicity O +
. O +

Cytotoxicity O +
markers O +
assessed O +
include O +
tumor O +
cell O +
killing O +
, O +
IL-1 O +
secretion O +
, O +
reactive O +
oxygen O +
intermediate O +
release O +
, O +
nitric O +
oxide O +
synthetase O +
activity O +
as O +
measured O +
by O +
the O +
release O +
of O +
reactive O +
nitrogen O +
intermediates O +
, O +
complement O +
receptor-1 O +
cell O +
surface O +
protein O +
, O +
and O +
TNF O -
- O -
alpha O +
protein O +
presence O +
. O +

Monocytes O +
stimulated O +
with O +
LPS O +
concentrations O +
of O +
1.0 O +
micrograms O -
/ O -
ml O +
displayed O +
the O +
above O +
cytotoxic O +
markers O +
, O +
whereas O +
monocytes O +
stimulated O +
with O +
DHEA O +
alone O +
or O +
with O +
LPS O +
at O +
a O +
lower O +
concentration O +
of O +
0.2 O +
ng O -
/ O -
ml O +
did O +
not O +
. O +

However O +
, O +
when O +
used O +
simultaneously O +
, O +
DHEA O +
and O +
LPS O +
0.2 O +
ng O -
/ O -
ml O +
displayed O +
a O +
synergistic O +
effect O +
on O +
monocyte O +
cytotoxicity O +
against O +
cancerous B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
IL-1 O +
secretion O +
, O +
reactive O +
nitrogen O +
intermediate O +
release O +
, O +
complement O +
receptor-1 O +
cell O -
- O -
surface O +
protein O +
, O +
and O +
TNF O -
- O -
alpha O +
protein O +
to O +
levels O +
comparable O +
with O +
levels O +
obtained O +
using O +
LPS O +
1.0 O +
microgram O -
/ O -
ml O +
. O +

Finally O +
, O +
Scatchard O +
plot O +
analysis O +
demonstrated O +
the O +
presence O +
of O +
a O +
DHEA O +
receptor O +
in O +
monocytes O +
, O +
suggesting O +
that O +
DHEA O +
effects O +
on O +
LPS B-CellLine -
- I-CellLine -
stimulated I-CellLine +
monocytes I-CellLine +
are O +
mediated O +
through O +
a O +
receptor O -
- O -
dependent O +
process O +
. O +

BSAP O +
: O +
a O +
key O +
regulator O +
of O +
B O -
- O -
cell O +
development O +
and O +
differentiation O +
. O +

B O -
- O -
cell O -
- O -
specific O +
activator O +
protein O +
( O +
BSAP O +
) O +
is O +
a O +
recently O +
identified O +
member O +
of O +
the O +
Pax O -
- O -
gene O +
family O +
of O +
transcription O +
factors O +
; O +
in O +
the O +
lymphoid O +
system O +
, O +
BSAP O +
is O +
produced O +
only O +
in O +
B O +
cells O +
. O +

Here O +
, O +
Markus O +
Neurath O +
, O +
Eckhard O +
Stuber O +
and O +
Warren O +
Strober O +
describe O +
the O +
molecular O +
structure O +
of O +
BSAP O +
and O +
focus O +
on O +
the O +
ability O +
of O +
this O +
protein O +
to O +
regulate O +
the O +
expression O +
of O +
B O -
- O -
cell O -
- O -
specific O +
genes O +
. O +

They O +
propose O +
that O +
BSAP O +
is O +
a O +
key O +
protein O +
of O +
B O +
cells O +
and O +
that O +
it O +
not O +
only O +
influence O +
B O -
- O -
cell O +
development O +
but O +
also O +
influences O +
the O +
balance O +
between O +
B O -
- O -
cell O +
proliferation O +
and O +
immunoglobulin O +
secretion O +
at O +
later O +
stages O +
of O +
B O -
- O -
cell O +
differentiation O +
. O +

The O +
role O +
of O +
BSAP O +
( O +
Pax-5 O +
) O +
in O +
B O -
- O -
cell O +
development O +
. O +

The O +
hierarchy O +
of O +
transcriptional O +
control O +
in O +
B O -
- O -
cell O +
development O +
has O +
recently O +
been O +
analyzed O +
by O +
targeted O +
gene O +
inactivation O +
in O +
the O +
mouse O +
. O +

In O +
this O +
manner O +
, O +
the O +
paired O +
box O +
containing O +
gene O +
Pax-5 O +
, O +
encoding O +
the O +
B O +
cell O +
specific O +
transcription O +
factor O +
BSAP O +
, O +
has O +
been O +
shown O +
to O +
play O +
a O +
key O +
role O +
in O +
early O +
B O +
lymphopoiesis O +
. O +

Other O +
experimental O +
strategies O +
have O +
implicated O +
BSAP O +
in O +
the O +
control O +
of O +
cell O +
proliferation O +
, O +
isotype O +
switching O +
and O +
transcription O +
of O +
the O +
immunoglobulin O +
heavy O -
- O -
chain O +
gene O +
at O +
late O +
stages O +
of O +
B O -
- O -
cell O +
differentiation O +
. O +

A O +
PEBP2 O +
alpha O -
/ O -
AML-1-related O +
factor O +
increases O +
osteocalcin O +
promoter O +
activity O +
through O +
its O +
binding O +
to O +
an O +
osteoblast O -
- O -
specific O +
cis O -
- O -
acting O +
element O +
. O +

To O +
identify O +
osteoblast O -
- O -
specific O +
cis O -
- O -
acting O +
elements O +
and O +
trans O -
- O -
acting O +
factors O +
, O +
we O +
initiated O +
an O +
analysis O +
of O +
the O +
promoter O +
of O +
a O +
mouse O +
osteocalcin O +
gene O +
, O +
an O +
osteoblast O -
- O -
specific O +
gene O +
. O +

In O +
this O +
promoter O +
, O +
we O +
identified O +
two O +
osteoblast O -
- O -
specific O +
cis O -
- O -
acting O +
elements O +
( O +
Ducy O +
, O +
P.and O +
Karsenty O +
, O +
G. O +
( O +
1995 O +
) O +
Mol O -
. O -
Cell O -
. O -
Biol.15 O +
, O +
1858 O -
- O -
1869 O +
) O +
. O +

The O +
sequence O +
of O +
one O +
of O +
these O +
elements O +
, O +
OSE2 O +
, O +
is O +
identical O +
to O +
the O +
DNA O -
- O -
binding O +
site O +
of O +
the O +
PEBP2 O +
alpha O -
/ O -
AML-1 O +
transcription O +
factors O +
, O +
the O +
mammalian O +
homologues O +
of O +
the O +
Drosophila O +
Runt O +
protein O +
. O +

Here O +
we O +
show O +
, O +
using O +
nuclear O +
extracts O +
, O +
recombinant O +
protein O +
, O +
and O +
a O +
specific O +
antiserum O +
against O +
AML-1 O +
proteins O +
in O +
DNA O -
- O -
binding O +
assays O +
, O +
that O +
one O +
member O +
of O +
this O +
family O +
, O +
AML-1B O +
, O +
binds O +
specifically O +
to O +
OSE2 O +
and O +
is O +
immunologically O +
related O +
to O +
OSF2 O +
, O +
the O +
factor O +
present O +
in O +
osteoblast O +
nuclear O +
extracts O +
that O +
binds O +
to O +
OSE2 O +
. O +

By O +
DNA O +
cotransfection O +
experiments O +
, O +
we O +
also O +
demonstrate O +
that O +
AML-1B O +
can O +
increase O +
the O +
activity O +
of O +
a O +
short O +
osteocalcin O +
promoter O +
through O +
its O +
binding O +
to O +
OSE2 O +
. O +

Lastly O +
, O +
the O +
different O +
mobilities O +
of O +
osteoblast O +
nuclear O +
extract O -
- O -
DNA O +
complexes O +
compared O +
with O +
T O -
- O -
cell O +
nuclear O +
extract O -
- O -
DNA O +
complexes O +
, O +
along O +
with O +
the O +
inability O +
of O +
OSF2 O +
to O +
be O +
upregulated O +
by O +
retinoic O +
acid O +
, O +
unlike O +
the O +
other O +
PEBP2 O +
alpha O +
factors O +
, O +
suggest O +
that O +
OSF2 O +
is O +
a O +
new O +
member O +
of O +
this O +
family O +
of O +
transcription O +
factors O +
. O +

Thus O +
, O +
this O +
study O +
demonstrates O +
that O +
AML-1B O +
can O +
increase O +
gene O +
expression O +
of O +
an O +
osteoblast O -
- O -
specific O +
gene O +
through O +
its O +
binding O +
to O +
an O +
osteoblast O -
- O -
specific O +
cis O -
- O -
acting O +
element O +
and O +
presents O +
evidence O +
that O +
OSF2 O +
is O +
a O +
member O +
of O +
the O +
PEBP2 O +
alpha O -
/ O -
AML-1 O +
family O +
of O +
transcription O +
factors O +
. O +

The O +
number O +
of O +
glucocorticoid O +
receptors O +
in O +
peripheral O +
human O +
lymphocytes O +
is O +
elevated O +
by O +
a O +
zinc O +
containing O +
trace O +
element O +
preparation O +
. O +

A O +
trace O +
element O +
preparation O +
( O +
Beres O +
Drops O +
Plus O +
, O +
BDP O +
) O +
elevates O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
( O +
gcR O +
) O +
in O +
peripheral O +
lymphocytes O +
isolated O +
both O +
from O +
healthy O +
blood O +
donors O +
and O +
rheumatoid O +
arthritis O +
patients O +
. O +

This O +
enhancement O +
by O +
BDP O +
was O +
found O +
either O +
for O +
constitutive O +
expression O +
of O +
gcRs O +
or O +
in O +
experiments O +
when O +
the O +
lymphocytes O +
were O +
stimulated O +
by O +
interleukin O +
( O +
IL O +
) O +
-6 O +
. O +

There O +
was O +
no O +
significant O +
effect O +
of O +
BDP O +
on O +
IL-1 O +
and O +
tumour O +
necrosis O +
factor O +
alpha O +
( O +
TNF O +
alpha O +
) O +
-induced O +
changes O +
of O +
gcRs O +
. O +

The O +
effect O +
of O +
BDP O +
was O +
greatly O +
dependent O +
on O +
the O +
presence O +
of O +
Zn++ O +
ions O +
in O +
the O +
preparation O +
, O +
since O +
the O +
augmenting O +
effect O +
was O +
abolished O +
if O +
BDP O +
did O +
not O +
contain O +
zinc O +
. O +

Activation O +
of O +
JAK3 O +
, O +
but O +
not O +
JAK1 O +
, O +
is O +
critical O +
for O +
IL-2 O +
-induced O +
proliferation O +
and O +
STAT5 O +
recruitment O +
by O +
a O +
COOH O -
- O -
terminal O +
region O +
of O +
the O +
IL-2 O +
receptor O +
beta O -
- O -
chain O +
. O +

A O +
number O +
of O +
cytokines O +
and O +
growth O +
factors O +
use O +
the O +
JAK O +
-STAT O +
pathway O +
to O +
signal O +
from O +
the O +
cell O +
membrane O +
to O +
the O +
nucleus O +
. O +

While O +
homodimerizing O +
cytokine O +
receptors O +
may O +
transmit O +
signal O +
via O +
a O +
single O +
form O +
of O +
JAK O +
( O +
i.e O +
. O +
growth O +
hormone O +
receptors O +
) O +
, O +
several O +
multicomponent O +
cytokine O +
receptors O +
have O +
been O +
shown O +
to O +
require O +
simultaneous O +
activation O +
of O +
pairs O +
of O +
different O +
JAK O +
kinases O +
( O +
i.e O +
. O +
interferon O +
receptors O +
) O +
. O +

Recent O +
evidence O +
for O +
a O +
preferential O +
coupling O +
of O +
JAK3 O +
to O +
interleukin-2 O +
receptor O -
- O -
gamma O +
( O +
IL-2R O +
gamma O +
) O +
and O +
JAK1 O +
to O +
IL-2R O +
beta O +
supports O +
the O +
concept O +
of O +
heterotrans O -
- O -
activation O +
of O +
JAK1 O +
and O +
JAK3 O +
caused O +
by O +
IL-2 O +
-induced O +
heterodimerization O +
of O +
their O +
receptor O +
partners O +
. O +

The O +
present O +
study O +
verified O +
the O +
ability O +
of O +
IL-2 O +
to O +
cause O +
tyrosine O +
phosphorylation O +
and O +
activation O +
of O +
JAK1 O +
and O +
JAK3 O +
, O +
but O +
demonstrated O +
that O +
IL-2 O +
stimulated O +
JAK3 O +
to O +
a O +
significantly O +
larger O +
extent O +
than O +
JAK1 O +
in O +
human O +
T O +
lymphocytes O +
and O +
the O +
YT B-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

This O +
conclusion O +
was O +
based O +
upon O +
several O +
independent O +
criteria O +
, O +
including O +
more O +
vigorous O +
tyrosine O +
phosphorylation O +
of O +
JAK3 O +
, O +
more O +
marked O +
enzymatic O +
activation O +
of O +
JAK3 O +
as O +
well O +
as O +
higher O +
abundance O +
of O +
JAK3 O +
in O +
activated O +
IL-2 O +
receptor O +
complexes O +
. O +

Furthermore O +
, O +
when O +
human O +
IL-2R O +
beta O +
was O +
stably O +
expressed O +
in O +
murine B-CellLine +
BA I-CellLine -
/ I-CellLine -
F3 I-CellLine +
cells I-CellLine +
, O +
robust O +
IL-2 O +
-induced O +
proliferation O +
and O +
JAK3 O +
activation O +
occurred O +
without O +
detectable O +
involvement O +
of O +
either O +
JAK1 O +
, O +
JAK2 O +
or O +
TYK2 O +
. O +

We O +
therefore O +
propose O +
that O +
IL-2 O +
receptor O +
signal O +
transduction O +
does O +
not O +
depend O +
on O +
equimolar O +
heterodimerization O +
of O +
JAK1 O +
and O +
JAK3 O +
following O +
IL-2 O +
-induced O +
heterodimerization O +
of O +
IL-2R O +
beta O +
and O +
IL-2R O +
gamma O +
. O +

Nonetheless O +
, O +
a O +
membrane O -
- O -
proximal O +
region O +
of O +
human O +
IL-2R O +
beta O +
( O +
Asn240-Leu335 O +
) O +
was O +
critical O +
for O +
JAK3 O +
activation O +
, O +
and O +
the O +
amount O +
of O +
JAK3 O +
present O +
in O +
activated O +
IL-2 O +
receptor O +
complexes O +
increased O +
with O +
time O +
, O +
suggesting O +
that O +
stabilization O +
of O +
JAK3 O +
binding O +
to O +
the O +
receptor O +
complex O +
relies O +
on O +
both O +
IL-2R O +
beta O +
and O +
IL-2R O +
gamma O +
. O +

Moreover O +
, O +
STAT5 O +
was O +
found O +
to O +
be O +
the O +
predominant O +
STAT O +
transcription O +
factor O +
used O +
by O +
IL-2 O +
in O +
human O +
T O +
cells O +
, O +
and O +
specifically O +
required O +
a O +
COOH O -
- O -
terminal O +
region O +
of O +
IL-2R O +
beta O +
( O +
Ser386-Val525 O +
) O +
, O +
while O +
STAT5 O +
recruitment O +
was O +
not O +
correlated O +
to O +
activation O +
of O +
IL-2R O +
gamma O +
or O +
JAK3 O +
. O +

Polymorphic O +
nucleotides O +
within O +
the O +
human O +
IL-4 O +
promoter O +
that O +
mediate O +
overexpression O +
of O +
the O +
gene O +
. O +

Atopy O +
, O +
which O +
predisposes O +
individuals O +
to O +
develop O +
asthma O +
, O +
severe O +
systemic O +
anaphylaxis O +
, O +
and O +
atopic O +
dermatitis O +
, O +
is O +
usually O +
associated O +
with O +
dramatically O +
elevated O +
total O +
serum O +
IgE O +
levels O +
and O +
is O +
thought O +
to O +
be O +
controlled O +
by O +
a O +
major O +
susceptibility O +
gene O +
and O +
multiple O +
minor O +
susceptibility O +
genes O +
. O +

A O +
recent O +
sib O -
- O -
pair O +
analysis O +
revealed O +
a O +
tight O +
linkage O +
between O +
markers O +
on O +
5q31.1 O +
and O +
a O +
major O +
susceptibility O +
gene O +
controlling O +
total O +
serum O +
IgE O +
levels O +
. O +

Due O +
to O +
its O +
location O +
within O +
this O +
cluster O +
and O +
its O +
biologic O +
role O +
in O +
Ig O +
class O +
switching O +
and O +
Th2 B-CellLine +
cell I-CellLine +
differentiation O +
, O +
the O +
IL-4 O +
gene O +
has O +
emerged O +
as O +
one O +
major O +
candidate O +
for O +
the O +
atopy O +
gene O +
. O +

In O +
one O +
model O +
, O +
polymorphisms O +
within O +
IL-4 O +
regulatory O +
elements O +
might O +
result O +
in O +
overexpression O +
of O +
the O +
gene O +
, O +
amplifying O +
Th2 B-CellLine +
cell I-CellLine +
differentiation O +
and O +
class O +
switching O +
to O +
IgE O +
. O +

In O +
support O +
of O +
this O +
model O +
, O +
we O +
report O +
that O +
the O +
human O +
IL-4 O +
promoter O +
exists O +
in O +
multiple O +
allelic O +
forms O +
that O +
exhibit O +
distinct O +
transcriptional O +
activities O +
in O +
IL-4-positive O +
T O +
cells O +
. O +

A O +
particular O +
allele O +
has O +
an O +
unusually O +
high O +
transcriptional O +
activity O +
. O +

A O +
nucleotide O +
substitution O +
within O +
a O +
recently O +
described O +
OAP40 O +
element O +
located O +
just O +
upstream O +
of O +
an O +
NF O -
- O -
AT O +
site O +
( O +
P O +
sequence O +
) O +
appears O +
to O +
be O +
largely O +
responsible O +
for O +
the O +
increased O +
promotor O +
strength O +
of O +
this O +
particular O +
allelic O +
form O +
of O +
the O +
IL-4 O +
promoter O +
. O +

In O +
EMSAs O +
, O +
this O +
substitution O +
results O +
in O +
a O +
markedly O +
enhanced O +
affinity O +
for O +
sequence O -
- O -
specific O +
complexes O +
exhibiting O +
an O +
AP-1 O +
specificity O +
. O +

The O +
identification O +
of O +
allelic O +
nucleotides O +
, O +
which O +
results O +
in O +
overexpression O +
of O +
the O +
IL-4 O +
gene O +
, O +
provides O +
specific O +
targets O +
for O +
a O +
comprehensive O +
screening O +
of O +
atopic O +
and O +
nonatopic O +
individuals O +
and O +
may O +
provide O +
a O +
clue O +
for O +
genetic O +
predisposition O +
for O +
atopy O +
. O +

IL-10 O +
cooperates O +
with O +
TNF O -
- O -
alpha O +
to O +
activate O +
HIV-1 O +
from O +
latently O +
and O +
acutely O +
infected O +
cells O +
of O +
monocyte O -
/ O -
macrophage O +
lineage O +
. O +

IL-10 O +
is O +
elevated O +
in O +
HIV-1-infected O +
individuals O +
and O +
has O +
been O +
implicated O +
in O +
disease O +
progression O +
. O +

In O +
this O +
study O +
, O +
we O +
investigated O +
the O +
effects O +
of O +
IL-10 O +
on O +
the O +
activation O +
of O +
HIV-1 O +
from O +
infected O +
monocytes O +
and O +
macrophages O +
. O +

Although O +
IL-10 O +
alone O +
did O +
not O +
induce O +
HIV-1 O +
replication O +
, O +
in O +
the O +
presence O +
of O +
TNF O -
- O -
alpha O +
, O +
IL-10 O +
markedly O +
enhanced O +
virion O +
production O +
from O +
a O +
chronically O +
infected O +
promonocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
U1 B-CellLine +
) O +
and O +
in O +
acutely O +
infected O +
monocyte O -
- O -
derived O +
macrophages O +
. O +

Neutralizing O +
mAbs O +
to O +
IL-10 O +
and O +
TNF O -
- O -
alpha O +
indicated O +
that O +
both O +
cytokines O +
were O +
essential O +
for O +
the O +
induction O +
and O +
were O +
required O +
to O +
generate O +
a O +
synergistic O +
increase O +
in O +
virus O +
expression O +
. O +

The O +
effects O +
of O +
the O +
two O +
cytokines O +
were O +
distinguishable O +
functionally O +
since O +
pretreatment O +
with O +
TNF O -
- O -
alpha O +
attenuated O +
the O +
cytokine O +
cooperativity O +
, O +
while O +
pretreatment O +
with O +
IL-10 O +
potentiated O +
their O +
cooperativity O +
, O +
suggesting O +
that O +
IL-10 O +
and O +
TNF O -
- O -
alpha O +
play O +
different O +
roles O +
in O +
the O +
activation O +
of O +
virus O +
. O +

Northern O +
blot O +
analysis O +
as O +
well O +
as O +
Ab O +
blocking O +
and O +
cytokine O +
secretion O +
studies O +
indicated O +
that O +
the O +
induction O +
of O +
either O +
endogenous O +
TNF O -
- O -
alpha O +
or O +
IL-10 O +
was O +
not O +
involved O +
in O +
the O +
cooperativity O +
, O +
nor O +
was O +
an O +
up O -
- O -
regulation O +
of O +
TNF O -
- O -
alpha O +
receptors O +
. O +

In O +
combination O +
with O +
TNF O -
- O -
alpha O +
, O +
IL-10 O +
stimulated O +
activating O +
protein-1 O +
( O +
AP-1 O +
) O +
and O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappa O +
B O +
binding O +
activities O +
and O +
cooperated O +
to O +
increase O +
HIV-1 O +
steady O -
- O -
state O +
mRNA O +
levels O +
and O +
enhance O +
long O +
terminal O +
repeat O +
-directed O +
transcription O +
through O +
activation O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
binding O +
sites O +
, O +
suggesting O +
the O +
IL-10 O +
effect O +
occurs O +
at O +
least O +
in O +
part O +
at O +
the O +
transcriptional O +
level O +
. O +

These O +
results O +
indicate O +
that O +
IL-10 O +
, O +
in O +
addition O +
to O +
down O -
- O -
regulating O +
the O +
cellular O +
immune O +
response O +
to O +
HIV-1 O +
, O +
may O +
also O +
play O +
a O +
role O +
in O +
TNF O -
- O -
alpha O +
-mediated O +
activation O +
of O +
HIV-1 O +
replication O +
in O +
the O +
monocyte O -
/ O -
macrophage O +
lineage O +
. O +

NF O -
- O -
M O +
( O +
chicken O +
C O -
/ O -
EBP O +
beta O +
) O +
induces O +
eosinophilic O +
differentiation O +
and O +
apoptosis O +
in O +
a O +
hematopoietic B-CellLine +
progenitor I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

CAAT O -
/ O -
enhancer O +
binding O +
proteins O +
( O +
C O -
/ O -
EBPs O +
) O +
are O +
transcriptional O +
activators O +
implicated O +
in O +
the O +
differentiation O +
processes O +
of O +
various O +
cell O +
lineages O +
. O +

We O +
have O +
shown O +
earlier O +
that O +
NF O -
- O -
M O +
, O +
the O +
chicken O +
homolog O +
of O +
C O -
/ O -
EBP O +
beta O +
, O +
is O +
specifically O +
expressed O +
in O +
myelomonocytic O +
and O +
eosinophilic O +
cells O +
of O +
the O +
hematopoietic O +
system O +
. O +

To O +
investigate O +
the O +
role O +
of O +
NF O -
- O -
M O +
in O +
hematopoietic B-CellLine +
cell I-CellLine +
lineage I-CellLine +
commitment O +
, O +
we O +
constructed O +
a O +
conditional O +
form O +
of O +
the O +
protein O +
by O +
fusing O +
it O +
to O +
the O +
hormone O +
binding O +
domain O +
of O +
the O +
human O +
estrogen O +
receptor O +
. O +

This O +
construct O +
was O +
stably O +
expressed O +
in O +
a O +
multipotent B-CellLine +
progenitor I-CellLine +
cell I-CellLine +
line I-CellLine +
transformed O +
by O +
the O +
Myb O -
- O -
Ets O +
oncoprotein O +
. O +

We O +
report O +
here O +
that O +
both O +
NF O -
- O -
M O -
- O -
dependent O +
promoter O +
constructs O +
and O +
resident O +
genes O +
could O +
be O +
activated O +
by O +
addition O +
of O +
beta O -
- O -
estradiol O +
to O +
the O +
NF B-CellLine -
- I-CellLine -
M I-CellLine -
- I-CellLine -
estrogen I-CellLine +
receptor I-CellLine +
expressing I-CellLine +
progenitors I-CellLine +
. O +

At O +
the O +
same O +
time O +
, O +
we O +
observed O +
a O +
down O -
- O -
regulation O +
of O +
progenitor O -
- O -
specific O +
surface O +
markers O +
and O +
the O +
up O -
- O -
regulation O +
of O +
differentiation O +
markers O +
restricted O +
to O +
the O +
eosinophil O +
and O +
myeloid O +
lineages O +
. O +

In O +
addition O +
to O +
the O +
onset O +
of O +
differentiation O +
, O +
cell O +
death O +
was O +
induced O +
with O +
typical O +
apoptotic O +
features O +
. O +

Our O +
results O +
suggest O +
that O +
NF O -
- O -
M O +
plays O +
an O +
important O +
role O +
in O +
commitment O +
along O +
the O +
eosinophil O +
lineage O +
and O +
in O +
the O +
induction O +
of O +
apoptosis O +
. O +

Immunophenotype O +
of O +
intraductal O +
carcinoma O +
. O +

OBJECTIVE O +
-- O +
Mammography O +
and O +
breast O -
- O -
conserving O +
therapy O +
have O +
focused O +
attention O +
on O +
the O +
classification O +
of O +
intraductal O +
carcinoma O +
( O +
IDC O +
) O +
and O +
emphasized O +
the O +
prognostic O +
importance O +
of O +
comedo O +
versus O +
noncomedo O +
variants O +
. O +

We O +
used O +
histochemical O +
markers O +
to O +
define O +
the O +
immunophenotype O +
of O +
43 O +
IDCs O +
with O +
respect O +
to O +
comedo O +
versus O +
noncomedo O +
status O +
and O +
patterns O +
of O +
angiogenesis O +
. O +

RESULTS O +
-- O +
Reactions O +
in O +
comedo O +
carcinomas O +
were O +
significantly O +
negative O +
for O +
estrogen O +
receptor O +
and O +
progesterone O +
receptor O +
, O +
and O +
positive O +
for O +
p53 O +
and O +
HER-2 O -
/ O -
neu O +
more O +
often O +
than O +
the O +
noncomedo O +
variant O +
. O +

All O +
seven O +
IDCs O +
associated O +
with O +
Paget O +
's O +
disease O +
showed O +
positive O +
reactions O +
for O +
HER-2 O -
/ O -
neu O +
. O +

Basement O +
membrane O +
immunoreactivity O +
for O +
type O +
IV O +
collagen O +
and O +
laminin O +
was O +
discontinuous O +
in O +
most O +
examples O +
of O +
IDC O +
regardless O +
of O +
type O +
, O +
with O +
a O +
trend O +
toward O +
more O +
intense O +
staining O +
in O +
comedo O +
than O +
in O +
noncomedo O +
carcinomas O +
. O +

Periductal O +
angiogenesis O +
was O +
not O +
significantly O +
related O +
to O +
the O +
type O +
of O +
IDC O +
but O +
was O +
more O +
pronounced O +
with O +
comedo O +
carcinomas O +
. O +

CONCLUSIONS O +
-- O +
These O +
observations O +
indicate O +
that O +
there O +
are O +
immunophenotypic O +
correlates O +
to O +
the O +
current O +
structural O +
classification O +
of O +
IDC O +
. O +

The O +
immunophenotype O +
of O +
IDC O +
is O +
helpful O +
in O +
subclassifying O +
an O +
IDC O +
and O +
could O +
prove O +
useful O +
as O +
a O +
prognostic O +
indicator O +
for O +
local O +
control O +
in O +
patients O +
treated O +
by O +
breast O -
- O -
conserving O +
therapy O +
. O +

Inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
human B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
by O +
anetholdithiolthione O +
. O +

Nuclear O +
factor O +
( O +
NF O +
) O +
-kappa O +
B O +
is O +
a O +
redox O +
sensitive O +
cytosolic O +
transcription O +
factor O +
. O +

Redox O +
regulation O +
of O +
NF O -
- O -
kappa O +
B O +
has O +
been O +
implicated O +
in O +
the O +
activation O +
of O +
the O +
human O +
immuno O -
- O -
deficiency O +
virus O +
( O +
HIV O +
) O +
. O +

Therefore O +
, O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
may O +
be O +
an O +
effective O +
strategy O +
for O +
acquired O +
immunodeficiency O +
syndrome O +
therapy O +
. O +

Anetholdithiolthione O +
( O +
ADT O +
, O +
5- O +
[ O +
p O -
- O -
methoxyphenyl O +
] O +
-3H-1 O +
, O +
2-dithiol-3-thione O +
) O +
is O +
an O +
antioxidant O +
which O +
has O +
been O +
used O +
to O +
protect O +
against O +
acetaminophen- O +
and O +
CCl4-induced O +
hepatotoxicity O +
, O +
lipid O +
peroxidation O +
, O +
radiation O +
injury O +
, O +
and O +
also O +
has O +
been O +
used O +
clinically O +
as O +
an O +
anti O -
- O -
choleretic O +
agent O +
. O +

The O +
present O +
study O +
examined O +
the O +
effect O +
of O +
ADT O +
pretreatment O +
on O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
response O +
to O +
a O +
variety O +
of O +
stimuli O +
such O +
as O +
H2O2 O +
, O +
phorbol O +
myristate O +
acetate O +
( O +
PMA O +
) O +
or O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O +
alpha O +
) O +
. O +

PMA O +
and O +
TNF O +
alpha O +
induced O +
activation O +
of O +
( O +
NF O +
) O +
-kappa O +
B O +
in O +
human O +
Jurkat B-CellLine +
T I-CellLine -
- I-CellLine -
cells I-CellLine +
was O +
partially O +
inhibited O +
by O +
ADT O +
( O +
0.1 O +
mM O +
) O +
pretreatment O +
. O +

ADT O +
( O +
0.1 O +
mM O +
) O +
also O +
inhibited O +
H2O2 O +
induced O +
activation O +
of O +
the O +
transcription O +
factor O +
in O +
the O +
peroxide B-CellLine +
sensitive I-CellLine +
human I-CellLine +
Wurzburg I-CellLine +
T I-CellLine -
- I-CellLine -
cells I-CellLine +
. O +

Furthermore O +
, O +
ADT O +
treated O +
Wurzburg B-CellLine +
cells I-CellLine +
had O +
significantly O +
higher O +
glutathione O +
levels O +
as O +
compared O +
with O +
untreated O +
cells O +
. O +

H2O2 O +
induced O +
lipid O +
peroxidation O +
in O +
Wurzburg B-CellLine +
cells I-CellLine +
was O +
remarkably O +
inhibited O +
by O +
ADT O +
pretreatment O +
. O +

ADT O +
, O +
a O +
pro O -
- O -
glutathione O +
antioxidant O +
, O +
was O +
observed O +
to O +
be O +
capable O +
of O +
modulating O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

Identification O +
of O +
a O +
physical O +
interaction O +
between O +
calcineurin O +
and O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFATp O +
) O +
. O +

In O +
T O +
lymphocytes O +
, O +
the O +
calcium O -
/ O -
calmodulin O -
- O -
dependent O +
serine O -
/ O -
threonine O +
phosphatase O +
, O +
calcineurin O +
, O +
plays O +
a O +
pivotal O +
role O +
in O +
transducing O +
membrane O -
- O -
associated O +
signals O +
to O +
the O +
nucleus O +
. O +

One O +
of O +
the O +
putative O +
targets O +
of O +
calcineurin O +
is O +
the O +
pre O -
- O -
existing O +
, O +
cytosolic O +
component O +
of O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFATp O +
; O +
also O +
referred O +
to O +
as O +
NFAT1 O +
) O +
, O +
which O +
is O +
one O +
of O +
several O +
transcription O +
factors O +
required O +
for O +
the O +
expression O +
of O +
interleukin O +
2 O +
. O +

Inhibition O +
of O +
calcineurin O +
by O +
the O +
immunosuppressive O +
drugs O +
cyclosporin O +
A O +
and O +
FK506 O +
prevents O +
dephosphorylation O +
of O +
NFATp O +
and O +
its O +
translocation O +
to O +
the O +
nucleus O +
. O +

However O +
, O +
a O +
physical O +
interaction O +
between O +
calcineurin O +
and O +
NFATp O +
has O +
not O +
been O +
demonstrated O +
. O +

Here O +
we O +
demonstrate O +
the O +
binding O +
of O +
NFATp O +
from O +
lysates O +
of O +
T O +
cells O +
to O +
immobilized O +
calcineurin O +
. O +

Stimulation O +
of O +
T O +
cells O +
with O +
calcium O +
ionophore O +
induced O +
a O +
shift O +
in O +
the O +
molecular O +
weight O +
of O +
NFATp O +
that O +
is O +
due O +
to O +
its O +
dephosphorylation O +
. O +

This O +
dephosphorylation O +
was O +
inhibited O +
by O +
treatment O +
of O +
T O +
cells O +
with O +
cyclosporin O +
A O +
or O +
FK506 O +
prior O +
to O +
stimulation O +
. O +

Of O +
note O +
, O +
both O +
the O +
phosphorylated O +
and O +
the O +
dephosphorylated O +
form O +
of O +
NFATp O +
bound O +
to O +
calcineurin O +
. O +

Furthermore O +
, O +
the O +
binding O +
of O +
both O +
forms O +
of O +
NFATp O +
to O +
calcineurin O +
was O +
inhibited O +
by O +
pretreatment O +
of O +
calcineurin O +
with O +
a O +
complex O +
of O +
FK506 O +
and O +
its O +
ligand O +
FKBP12 O +
. O +

Taken O +
together O +
these O +
data O +
strongly O +
suggest O +
a O +
direct O +
interaction O +
of O +
calcineurin O +
with O +
NFATp O +
and O +
that O +
this O +
interaction O +
does O +
not O +
depend O +
upon O +
the O +
phosphorylation O +
sites O +
of O +
NFATp O +
affected O +
by O +
activation O +
. O +

Distinctive O +
expression O +
pattern O +
of O +
the O +
BCL-6 O +
protein O +
in O +
nodular O +
lymphocyte O +
predominance O +
Hodgkin O +
's O +
disease O +
. O +

The O +
BCL-6 O +
gene O +
encoding O +
a O +
nuclear O -
- O -
located O +
Kruppel O -
- O -
type O +
zinc O +
finger O +
protein O +
is O +
rearranged O +
in O +
about O +
30 O +
% O +
diffuse O +
large O +
B O -
- O -
cell O +
lymphomas O +
and O +
is O +
expressed O +
predominantly O +
in O +
normal O +
germinal O +
center O +
B O +
cells O +
and O +
related O +
lymphomas O +
. O +

These O +
findings O +
suggest O +
that O +
BCL-6 O +
may O +
play O +
a O +
role O +
in O +
regulating O +
differentiation O +
of O +
normal O +
germinal O +
center O +
B O +
cells O +
and O +
that O +
its O +
deregulated O +
expression O +
caused O +
by O +
rearrangements O +
may O +
contribute O +
to O +
lymphomagenesis O +
. O +

This O +
prompted O +
us O +
to O +
investigate O +
the O +
expression O +
of O +
the O +
BCL-6 O +
protein O +
in O +
Hodgkin O +
's O +
disease O +
( O +
HD O +
) O +
, O +
focusing O +
on O +
the O +
nodular O +
lymphocyte O +
predominance O +
subtype O +
( O +
NLPHD O +
) O +
, O +
which O +
differs O +
from O +
classical O +
HD O +
by O +
virtue O +
of O +
the O +
B O -
- O -
cell O +
nature O +
of O +
the O +
malignant O +
cell O +
population O +
( O +
so O -
- O -
called O +
L O +
& O +
H O +
cells O +
) O +
and O +
its O +
relationship O +
with O +
germinal O +
centers O +
. O +

Forty O -
- O -
one O +
HD O +
samples O +
( O +
19 O +
NLPHD O +
, O +
12 O +
nodular O +
sclerosis O +
, O +
and O +
10 O +
mixed O +
cellularity O +
) O +
were O +
immunostained O +
with O +
the O +
monoclonal O +
antibodies O +
PG O -
- O -
B6 O +
and O +
PG O -
- O -
B6p O +
that O +
react O +
with O +
a O +
fixative O -
- O -
sensitive O +
and O +
a O +
formalin O -
- O -
resistant O +
epitope O +
on O +
the O +
aminoterminal O +
region O +
of O +
the O +
BCL-6 O +
gene O +
product O +
, O +
respectively O +
. O +

Strong O +
nuclear O +
positivity O +
for O +
the O +
BCL-6 O +
protein O +
was O +
detected O +
in O +
tumor O +
( O +
L O +
& O +
H O +
) O +
cells O +
in O +
all O +
cases O +
of O +
NLPHD O +
. O +

In O +
contrast O +
, O +
BCL-6 O +
was O +
expressed O +
only O +
in O +
a O +
small O +
percentage O +
of O +
Hodgkin B-CellLine +
and I-CellLine +
Reed I-CellLine -
- I-CellLine -
Sternberg I-CellLine +
cells I-CellLine +
in O +
about O +
30 O +
% O +
of O +
classical O +
HD O +
cases O +
. O +

Notably O +
, O +
the O +
nuclei O +
of O +
reactive O +
CD3+ O -
/ O -
CD4 O -
+ O +
T O +
cells O +
nearby O +
to O +
and O +
rosetting O +
around O +
L O +
& O +
H O +
cells O +
in O +
NLPHD O +
were O +
also O +
strongly O +
BCL-6 O +
+ O +
, O +
but O +
lacked O +
CD40 O +
ligand O +
( O +
CD40L O +
) O +
expression O +
. O +

This O +
staining O +
pattern O +
clearly O +
differed O +
from O +
that O +
of O +
classical O +
HD O +
, O +
whose O +
cellular O +
background O +
was O +
made O +
up O +
of O +
CD3+ O -
/ O -
CD4 O -
+ O +
T O +
cells O +
showing O +
the O +
BCL-6 O +
- O -
/ O +
CD40L O +
+ O +
phenotype O +
. O +

These O +
results O +
further O +
support O +
the O +
concept O +
that O +
NLPHD O +
is O +
an O +
histogenetically O +
distinct O +
, O +
B O -
- O -
cell O -
- O -
derived O +
subtype O +
of O +
HD O +
and O +
suggest O +
a O +
role O +
for O +
BCL-6 O +
in O +
its O +
development O +
. O +

The O +
promoter O +
and O +
5 O +
' O +
flanking O +
sequences O +
controlling O +
human O +
B29 O +
gene O +
expression O +
. O +

The O +
product O +
of O +
the O +
B O -
- O -
cell O -
- O -
specific O +
B29 O +
gene O +
( O +
B29 O +
, O +
Ig O +
beta O +
, O +
CD79b O +
) O +
is O +
essential O +
for O +
Ig O -
- O -
mediated O +
B O -
- O -
cell O +
activation O +
via O +
the O +
B O -
- O -
cell O +
antigen O +
receptor O +
complex O +
( O +
BCR O +
) O +
on O +
human O +
and O +
murine O +
B O +
lymphocytes O +
. O +

To O +
better O +
understand O +
the O +
regulation O +
of O +
this O +
pivotal O +
gene O +
, O +
we O +
have O +
analyzed O +
the O +
human O +
genomic O +
DNA O +
sequence O +
upstream O +
of O +
the O +
B29 O +
ATG O +
start O +
codon O +
for O +
transcriptional O +
control O +
activity O +
. O +

The O +
human O +
B29 O +
gene O +
lacks O +
either O +
a O +
TATA O +
or O +
a O +
CAAT O +
box O +
and O +
transcription O +
is O +
initiated O +
at O +
multiple O +
sites O +
. O +

The O +
minimal O +
promoter O +
of O +
the O +
human O +
B29 O +
gene O +
is O +
contained O +
within O +
a O +
193-bp O +
region O +
5 O +
' O +
of O +
these O +
multiple O +
start O +
sites O +
. O +

This O +
minimal O +
promoter O +
exhibits O +
B O -
- O -
cell O -
- O -
specific O +
activity O +
and O +
contains O +
SP1 O +
, O +
ETS O +
, O +
OCT O +
, O +
and O +
IKAROS O -
/ O -
LYF-1 O +
transcription O +
factor O +
motifs O +
. O +

All O +
these O +
motifs O +
are O +
strikingly O +
conserved O +
in O +
sequence O +
and O +
placement O +
relative O +
to O +
the O +
previously O +
characterized O +
murine O +
B29 O +
promoter O +
. O +

Additional O +
upstream O +
gene O +
segments O +
dramatically O +
affected O +
B29 O +
minimal O +
promoter O +
activity O +
. O +

A O +
newly O +
identified O +
motif O +
called O +
the O +
B29 O +
conserved O +
sequence O +
( O +
BCS O +
) O +
, O +
found O +
upstream O +
of O +
both O +
human O +
and O +
murine O +
B29 O +
promoters O +
, O +
appears O +
to O +
stimulate O +
B29 O +
transcription O +
through O +
a O +
novel O +
mechanism O +
. O +

A O +
single O +
BCS O +
had O +
little O +
effect O +
either O +
on O +
the O +
minimal O +
B29 O +
promoter O +
or O +
on O +
a O +
heterologous O +
promoter O +
. O +

Instead O +
, O +
the O +
BCS O +
stimulated O +
transcription O +
by O +
counteracting O +
5 O +
' O +
negative O +
regulatory O +
DNA O +
sequences O +
that O +
block O +
the O +
activity O +
of O +
the O +
B29 O +
minimal O +
promoter O +
in O +
its O +
absence O +
. O +

These O +
findings O +
indicate O +
that O +
B29 O +
gene O +
expression O +
is O +
controlled O +
by O +
the O +
complex O +
interplay O +
of O +
positive O +
and O +
negative O +
regulatory O +
elements O +
. O +

Selective O +
effects O +
of O +
DNA O +
damaging O +
agents O +
on O +
HIV O +
long O +
terminal O +
repeat O +
activation O +
and O +
virus O +
replication O +
in O +
vitro O +
. O +

Much O +
attention O +
has O +
recently O +
focused O +
on O +
the O +
observation O +
that O +
UV O +
light O +
can O +
activate O +
the O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
. O +

Although O +
the O +
mechanism O +
of O +
LTR O +
activation O +
remains O +
obscure O +
, O +
several O +
lines O +
of O +
investigation O +
have O +
suggested O +
that O +
it O +
is O +
a O +
result O +
of O +
activation O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
transcription O +
factor O +
( O +
s O +
) O +
following O +
signaling O +
events O +
related O +
to O +
generalized O +
DNA O +
damage O +
. O +

In O +
this O +
report O +
, O +
we O +
present O +
data O +
demonstrating O +
that O +
HIV O +
LTR O +
activation O +
is O +
not O +
a O +
general O +
consequence O +
of O +
cellular O +
DNA O +
damage O +
, O +
but O +
rather O +
a O +
process O +
unique O +
to O +
specific O +
genotoxic O +
stimuli O +
, O +
and O +
that O +
it O +
does O +
not O +
necessarily O +
depend O +
on O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

Furthermore O +
, O +
we O +
demonstrate O +
that O +
several O +
of O +
these O +
agents O +
can O +
significantly O +
increase O +
HIV O +
replication O +
and O +
accelerate O +
CD4 O +
-positive O +
lymphocyte O +
cytotoxicity O +
in O +
vitro O +
. O +

These O +
findings O +
, O +
therefore O +
, O +
could O +
have O +
clinical O +
significance O +
to O +
AIDS O +
patients O +
with O +
malignancies O +
who O +
are O +
undergoing O +
radiotherapy O +
and O +
chemotherapy O +
. O +

Fas O +
ligation O +
induces O +
apoptosis O +
and O +
Jun O +
kinase O +
activation O +
independently O +
of O +
CD45 O +
and O +
Lck O +
in O +
human O +
T O +
cells O +
. O +

Stimulation O +
through O +
the O +
Fas O -
/ O -
APO-1 O +
receptor O +
results O +
in O +
apoptosis O +
through O +
an O +
incompletely O +
characterized O +
signaling O +
pathway O +
. O +

More O +
is O +
known O +
regarding O +
signal O +
transduction O +
events O +
that O +
occur O +
after O +
ligation O +
of O +
the O +
T O -
- O -
cell O +
antigen O +
receptor O +
( O +
TCR O +
) O +
. O +

It O +
has O +
been O +
shown O +
that O +
TCR O +
stimulation O +
requires O +
both O +
the O +
membrane O +
tyrosine O +
phosphatase O +
, O +
CD45 O +
, O +
and O +
the O +
Src O -
- O -
family O +
kinase O +
, O +
Lck O +
, O +
to O +
result O +
in O +
cellular O +
activation O +
. O +

Although O +
prior O +
studies O +
suggest O +
a O +
role O +
for O +
protein O +
tyrosine O +
kinases O +
and O +
phosphatases O +
in O +
Fas O +
signaling O +
, O +
we O +
report O +
here O +
that O +
Fas O +
ligation O +
induces O +
apoptosis O +
in O +
T O +
cells O +
deficient O +
in O +
either O +
CD45 O +
or O +
Lck O +
. O +

Further O +
, O +
in O +
normal O +
and O +
CD45- B-CellLine +
or I-CellLine +
Lck I-CellLine -
- I-CellLine -
deficient I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
Fas O +
stimulation O +
results O +
in O +
activation O +
of O +
Jun O +
kinase O +
( O +
JNK O +
) O +
, O +
a O +
proposed O +
mediator O +
of O +
stress O +
activation O +
pathways O +
. O +

Previous O +
studies O +
have O +
also O +
demonstrated O +
a O +
role O +
for O +
endogenous O +
ceramide O +
release O +
in O +
Fas O -
- O -
mediated O +
apoptosis O +
. O +

We O +
show O +
that O +
stimulation O +
with O +
a O +
synthetic O +
ceramide O +
analog O +
results O +
in O +
JNK O +
activation O +
as O +
well O +
as O +
apoptosis O +
, O +
suggesting O +
ceramide O +
release O +
occurs O +
proximal O +
to O +
JNK O +
activation O +
in O +
Fas O +
signaling O +
. O +

Our O +
data O +
suggest O +
that O +
although O +
CD45 O +
and O +
Lck O +
are O +
not O +
required O +
for O +
Fas O +
signaling O +
, O +
JNK O +
activation O +
may O +
play O +
an O +
important O +
role O +
transducing O +
distal O +
signals O +
that O +
lead O +
to O +
apoptosis O +
after O +
Fas O +
ligation O +
. O +

Expression O +
of O +
either O +
the O +
TCL1 O +
oncogene O +
, O +
or O +
transcripts O +
from O +
its O +
homologue O +
MTCP1 O -
/ O -
c6.1B O +
, O +
in O +
leukaemic O +
and O +
non O -
- O -
leukaemic O +
T O +
cells O +
from O +
ataxia O +
telangiectasia O +
patients O +
. O +

Patients O +
with O +
the O +
recessively O +
inherited O +
disorder O +
ataxia O +
telangiectasia O +
( O +
A O -
- O -
T O +
) O +
have O +
a O +
high O +
level O +
of O +
specific O +
chromosome O +
translocations O +
which O +
can O +
be O +
easily O +
observed O +
in O +
peripheral O +
T O +
cells O +
and O +
show O +
a O +
greatly O +
increased O +
predisposition O +
to O +
leukaemia O -
/ O -
lymphoma O +
, O +
mainly O +
of O +
T O +
cell O +
origin O +
. O +

Some O +
translocation O +
cells O +
proliferate O +
into O +
a O +
large O +
clone O +
and O +
may O +
develop O +
into O +
T O +
cell O +
prolymphocytic O +
leukaemia O +
( O +
T O -
- O -
PLL O +
) O +
. O +

By O +
the O +
time O +
of O +
diagnosis O +
of O +
T O -
- O -
PLL O +
, O +
the O +
clone O +
contains O +
many O +
more O +
genetic O +
changes O +
in O +
the O +
form O +
of O +
additional O +
translocations O +
. O +

T O -
- O -
PLL O +
is O +
also O +
seen O +
in O +
non O -
- O -
A O -
- O -
T O +
individuals O +
where O +
expression O +
of O +
either O +
TCL1 O +
( O +
at O +
14q32 O +
) O +
or O +
the O +
c6.1B O -
/ O -
MTCP1 O +
A1 O +
transcript O +
( O +
at O -
- O -
Xq28 O +
) O +
has O +
been O +
demonstrated O +
in O +
just O +
a O +
few O +
instances O +
. O +

We O +
show O +
here O +
, O +
that O +
expression O +
of O +
TCL1 O +
occurs O +
in O +
leukaemic O +
T O +
cells O +
from O +
A O -
- O -
T O +
patients O +
with O +
chromosome O +
14 O +
rearrangements O +
. O +

Expression O +
of O +
TCL1 O +
also O +
occurs O +
in O +
the O +
preleukaemic O +
clone O +
cells O +
of O +
A O -
- O -
T O +
patients O +
containing O +
the O +
primary O +
translocation O +
alone O +
. O +

Some O +
expression O +
of O +
TCL1 O +
could O +
also O +
be O +
detected O +
in O +
randomly O +
selected O +
A O -
- O -
T O +
patients O +
without O +
large O +
cytogenetic O +
clones O +
and O +
without O +
any O +
evidence O +
of O +
leukaemic O +
change O +
. O +

We O +
also O +
show O +
that O +
expression O +
of O +
the O +
B1 O +
transcript O +
from O +
a O +
second O +
gene O +
, O +
MTCP1 O +
, O +
occurred O +
at O +
a O +
relatively O +
high O +
level O +
only O +
in O +
two O +
T O -
- O -
PLL O +
tumours O +
from O +
A O -
- O -
T O +
patients O +
with O +
t O +
( O +
X O +
; O +
14 O +
) O +
translocations O +
whereas O +
the O +
MTCP1 O -
/ O -
A1 O +
transcript O +
is O +
much O +
more O +
widely O +
expressed O +
in O +
both O +
tumour O +
and O +
non O +
tumour O +
cells O +
of O +
A O -
- O -
T O +
and O +
non O -
- O -
A O -
- O -
T O +
individuals O +
. O +

Human O +
herpesvirus O +
6 O +
variant O +
A O +
, O +
but O +
not O +
variant O +
B O +
, O +
infects O +
EBV B-CellLine -
- I-CellLine -
positive I-CellLine +
B I-CellLine +
lymphoid I-CellLine +
cells I-CellLine +
, O +
activating O +
the O +
latent O +
EBV O +
genome O +
through O +
a O +
BZLF-1 O +
-dependent O +
mechanism O +
. O +

Human O +
herpesvirus O +
6 O +
, O +
a O +
predominantly O +
T O +
lymphotropic O +
virus O +
, O +
has O +
been O +
recently O +
shown O +
to O +
infect O +
some O +
EBV B-CellLine -
- I-CellLine -
positive I-CellLine +
B I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
and O +
to O +
induce O +
in O +
them O +
the O +
activation O +
of O +
the O +
EBV O +
lytic O +
cycle O +
. O +

Here O +
we O +
have O +
confirmed O +
and O +
extended O +
such O +
observations O +
, O +
showing O +
that O +
( O +
1 O +
) O +
this O +
phenomenon O +
is O +
restricted O +
to O +
the O +
variant O +
A O +
of O +
HHV-6 O +
: O +
in O +
fact O +
two O +
isolates O +
belonging O +
to O +
the O +
HHV-6 O +
variant O +
B O +
( O +
BA92 O +
and O +
Z29 O +
) O +
were O +
neither O +
able O +
to O +
infect O +
any O +
B B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
independently O +
of O +
the O +
EBV O +
status O +
, O +
nor O +
to O +
induce O +
the O +
EBV O +
genome O +
expression O +
. O +

The O +
only O +
exception O +
is O +
represented O +
by O +
the O +
P3HR1 B-CellLine +
cells I-CellLine +
, O +
in O +
which O +
, O +
however O +
, O +
the O +
infection O +
by O +
the O +
variant O +
B O +
does O +
not O +
determine O +
induction O +
of O +
EBV O +
antigens O +
; O +
( O +
2 O +
) O +
the O +
presence O +
of O +
the O +
EBV O +
genome O +
contributes O +
to O +
the O +
susceptibility O +
of O +
the O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
to O +
HHV-6 O +
infection O +
, O +
increasing O +
the O +
binding O +
sites O +
and O +
the O +
percentage O +
of O +
infectable O +
cells O +
, O +
as O +
detected O +
by O +
immunoelectron O +
microscopy O +
; O +
and O +
( O +
3 O +
) O +
HHV-6 B-CellLine +
infected I-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
transfected O +
with O +
plasmids O +
bearing O +
the O +
promoter O +
regions O +
of O +
the O +
EBV O +
early O +
genes O +
BZLF1 O +
and O +
BMRF1 O +
, O +
show O +
a O +
strong O +
transactivation O +
of O +
these O +
promoters O +
. O +

In O +
vivo O +
anergized B-CellLine +
CD4 I-CellLine -
+ I-CellLine +
T I-CellLine +
cells I-CellLine +
express O +
perturbed O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B O +
transcription O +
factors O +
. O +

Anergy O +
is O +
a O +
major O +
mechanism O +
to O +
ensure O +
antigen O -
- O -
specific O +
tolerance O +
in O +
T O +
lymphocytes O +
in O +
the O +
adult O +
. O +

In O +
vivo O +
, O +
anergy O +
has O +
mainly O +
been O +
studied O +
at O +
the O +
cellular O +
level O +
. O +

In O +
this O +
study O +
, O +
we O +
used O +
the O +
T O -
- O -
cell O -
- O -
activating O +
superantigen O +
staphylococcal O +
enterotoxin O +
A O +
( O +
SEA O +
) O +
to O +
investigate O +
molecular O +
mechanisms O +
of O +
T O -
- O -
lymphocyte O +
anergy O +
in O +
vivo O +
. O +

Injection O +
of O +
SEA O +
to O +
adult O +
mice O +
activates O +
CD4 O -
+ O +
T O +
cells O +
expressing O +
certain O +
T O -
- O -
cell O +
receptor O +
( O +
TCR O +
) O +
variable O +
region O +
beta O -
- O -
chain O +
families O +
and O +
induces O +
strong O +
and O +
rapid O +
production O +
of O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
. O +

In O +
contrast O +
, O +
repeated O +
injections O +
of O +
SEA O +
cause O +
CD4 O -
+ O +
T O -
- O -
cell O +
deletion O +
and O +
anergy O +
in O +
the O +
remaining O +
CD4 O -
+ O +
T O +
cells O +
, O +
characterized O +
by O +
reduced O +
expression O +
of O +
IL-2 O +
at O +
mRNA O +
and O +
protein O +
levels O +
. O +

We O +
analyzed O +
expression O +
of O +
AP-1 O +
, O +
NF O -
- O -
kappa O +
B O +
, O +
NF O -
- O -
AT O +
, O +
and O +
octamer O +
binding O +
transcription O +
factors O +
, O +
which O +
are O +
known O +
to O +
be O +
involved O +
in O +
the O +
regulation O +
of O +
IL-2 O +
gene O +
promoter O +
activity O +
. O +

Large O +
amounts O +
of O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B O +
and O +
significant O +
quantities O +
of O +
NF O -
- O -
AT O +
were O +
induced O +
in O +
SEA B-CellLine -
- I-CellLine -
activated I-CellLine +
CD4 I-CellLine -
+ I-CellLine +
spleen I-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
whereas O +
Oct-1 O +
and O +
Oct-2 O +
DNA O +
binding O +
activity O +
was O +
similar O +
in O +
both O +
resting O +
and O +
activated O +
T O +
cells O +
. O +

In O +
contrast O +
, O +
anergic O +
CD4 O -
+ O +
T O +
cells O +
contained O +
severely O +
reduced O +
levels O +
of O +
AP-1 O +
and O +
Fos O -
/ O -
Jun O -
- O -
containing O +
NF O -
- O -
AT O +
complexes O +
but O +
expressed O +
significant O +
amounts O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
Oct O +
binding O +
proteins O +
after O +
SEA O +
stimulation O +
. O +

Resolution O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
complex O +
demonstrated O +
predominant O +
expression O +
of O +
p50-p65 O +
heterodimers O +
in O +
activated O +
CD4 O -
+ O +
T O +
cells O +
, O +
while O +
anergic O +
cells O +
mainly O +
expressed O +
the O +
transcriptionally O +
inactive O +
p50 O +
homodimer O +
. O +

These O +
alterations O +
of O +
transcription O +
factors O +
are O +
likely O +
to O +
be O +
responsible O +
for O +
repression O +
of O +
IL-2 O +
in O +
anergic O +
T O +
cells O +
. O +

Characterization O +
and O +
purification O +
of O +
a O +
protein O +
kinase O +
C O +
substrate O +
in O +
human O +
B O +
cells O +
. O +

Identification O +
as O +
lymphocyte O -
- O -
specific O +
protein O +
1 O +
( O +
LSP1 O +
) O +
. O +

Incubation O +
of O +
B B-CellLine -
- I-CellLine -
chronic I-CellLine +
lymphocytic I-CellLine +
leukemia I-CellLine +
( I-CellLine +
B I-CellLine -
- I-CellLine -
CLL I-CellLine +
) I-CellLine +
cells I-CellLine +
with O +
phorbol O +
esters O +
resulted O +
in O +
the O +
phosphorylation O +
of O +
two O +
major O +
PKC O +
substrates O +
, O +
MARCKS O +
( O +
myristoylated O +
, O +
alanine O -
- O -
rich O +
C O +
kinase O +
substrate O +
) O +
and O +
MRP O +
( O +
MARCKS O -
- O -
related O +
protein O +
) O +
, O +
and O +
of O +
a O +
third O +
protein O +
, O +
with O +
an O +
apparent O +
m.w O -
. O +
of O +
60 O +
, O +
000 O +
that O +
was O +
the O +
most O +
prominent O +
protein O +
kinase O +
C O +
substrate O +
in O +
these O +
cells O +
. O +

p60 O +
phosphorylation O +
was O +
time O +
and O +
PMA O +
dose O +
dependent O +
, O +
and O +
was O +
induced O +
by O +
cell O -
- O -
permeable O +
diacylglycerol O +
, O +
but O +
not O +
by O +
inactive O +
phorbol O +
esters O +
. O +

Two O -
- O -
dimensional O +
electrophoretic O +
analysis O +
of O +
the O +
protein O +
phosphorylation O +
pattern O +
from O +
the O +
B B-CellLine +
cell I-CellLine +
line I-CellLine +
CESS I-CellLine +
demonstrated O +
the O +
identity O +
between O +
the O +
p60 O +
protein O +
expressed O +
in O +
this O +
cell O +
line O +
and O +
that O +
expressed O +
in O +
B B-CellLine -
- I-CellLine -
CLL I-CellLine +
cells I-CellLine +
. O +

p60 O +
was O +
purified O +
from O +
CESS B-CellLine +
cells I-CellLine +
and O +
peptide O +
microsequencing O +
of O +
this O +
protein O +
revealed O +
that O +
it O +
was O +
lymphocyte O -
- O -
specific O +
protein O +
1 O +
( O +
LSP1 O +
) O +
, O +
that O +
is O +
here O +
characterized O +
as O +
the O +
most O +
prominent O +
protein O +
kinase O +
C O +
substrate O +
in O +
B O +
cells O +
. O +

Cross O -
- O -
linking O +
CD40 O +
on O +
B O +
cells O +
preferentially O +
induces O +
stress O -
- O -
activated O +
protein O +
kinases O +
rather O +
than O +
mitogen O -
- O -
activated O +
protein O +
kinases O +
. O +

The O +
B O +
cell O -
- O -
associated O +
surface O +
molecule O +
CD40 O +
plays O +
a O +
key O +
role O +
in O +
T O +
cell O -
- O -
dependent O +
B O +
cell O +
maturation O +
, O +
as O +
individuals O +
with O +
defects O +
in O +
either O +
CD40 O +
or O +
its O +
ligand O +
are O +
impaired O +
in O +
immunoglobulin O +
isotype O +
class O +
switching O +
and O +
germinal O +
center O +
formation O +
. O +

CD40 O +
signaling O +
activates O +
downstream O +
effectors O +
, O +
including O +
the O +
tyrosine O +
protein O +
kinase O +
, O +
Lyn O +
, O +
the O +
phosphatidylinositol-3-kinase O +
( O +
PI-3 O +
kinase O +
) O +
, O +
and O +
the O +
transcription O +
factor O +
, O +
NF O -
- O -
kappa O +
B O +
. O +

In O +
this O +
study O +
, O +
we O +
demonstrate O +
that O +
stress O -
- O -
activated O +
protein O +
kinases O +
( O +
SAPK O +
) O +
are O +
activated O +
after O +
CD40 O +
cross O -
- O -
linking O +
on O +
various O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
or O +
human O +
tonsillar O +
B O +
cells O +
. O +

The O +
activation O +
is O +
rapid O +
and O +
transient O +
and O +
is O +
mediated O +
through O +
a O +
cyclosporin O +
A O -
- O -
insensitive O +
pathway O +
. O +

Furthermore O +
, O +
this O +
signaling O +
pathway O +
appears O +
not O +
to O +
rely O +
on O +
protein O +
kinase O +
C O +
. O +

While O +
CD40 O +
ligation O +
strongly O +
activates O +
the O +
SAPKs O +
( O +
up O +
to O +
25-fold O +
) O +
, O +
it O +
does O +
not O +
affect O +
members O +
of O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
family O +
( O +
MAPK O +
; O +
ERK1 O +
and O +
ERK2 O +
) O +
. O +

Consistent O +
with O +
these O +
data O +
, O +
CD40 O +
signals O +
up O -
- O -
regulate O +
c O -
- O -
jun O +
but O +
not O +
c O -
- O -
fos O +
mRNA O +
and O +
alter O +
the O +
transcription O +
factor O +
ATF2 O +
but O +
not O +
the O +
Raf-1 O +
protein O +
. O +

In O +
summary O +
, O +
CD40 O +
signaling O +
preferentially O +
induces O +
SAPK O +
but O +
not O +
MAPK O +
. O +

Autocrine O +
activation O +
by O +
interferon O -
- O -
gamma O +
of O +
STAT O +
factors O +
following O +
T O +
cell O +
activation O +
. O +

The O +
activation O +
of O +
T O +
cells O +
requires O +
engagement O +
of O +
the O +
T O +
cell O +
receptor O -
/ O -
CD3 O +
complex O +
and O +
co O -
- O -
stimulatory O +
molecules O +
, O +
and O +
results O +
in O +
the O +
triggering O +
of O +
several O +
signaling O +
pathways O +
which O +
lead O +
rapidly O +
to O +
the O +
nuclear O +
translocation O +
of O +
several O +
transcription O +
factors O +
, O +
such O +
as O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappa O +
B O +
and O +
NF O -
- O -
AT O +
. O +

A O +
result O +
of O +
this O +
activation O +
process O +
is O +
the O +
induction O +
of O +
a O +
number O +
of O +
genes O +
, O +
including O +
those O +
encoding O +
cytokines O +
such O +
as O +
interleukin-2 O +
, O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
, O +
and O +
interferon O +
( O +
IFN O +
) O +
-gamma O +
which O +
have O +
important O +
immunoregulatory O +
effects O +
. O +

We O +
report O +
here O +
that O +
a O +
DNA O -
- O -
binding O +
factor O +
containing O +
STAT1 O +
also O +
becomes O +
activated O +
in O +
human O +
peripheral O +
blood O +
T O +
lymphocytes O +
or O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
although O +
not O +
until O +
1 O -
- O -
2 O +
h O +
after O +
stimulation O +
. O +

Activation O +
is O +
delayed O +
a O +
further O +
1 O -
- O -
2 O +
hr O +
when O +
mononuclear B-CellLine +
cell I-CellLine +
cultures I-CellLine +
are O +
stimulated O +
by O +
an O +
antigen O +
which O +
requires O +
processing O +
. O +

Appearance O +
of O +
the O +
STAT1 O +
factor O +
is O +
significantly O +
reduced O +
in O +
the O +
presence O +
of O +
cyclosporin O +
A O +
, O +
and O +
blocked O +
by O +
cycloheximide O +
, O +
indicating O +
that O +
its O +
activation O +
is O +
dependent O +
upon O +
a O +
protein O +
( O +
s O +
) O +
synthesized O +
in O +
response O +
to O +
initial O +
signaling O +
events O +
. O +

Neutralizing O +
antiserum O +
against O +
IFN O -
- O -
gamma O +
, O +
but O +
not O +
other O +
cytokines O +
tested O +
, O +
blocked O +
activation O +
of O +
the O +
factor O +
almost O +
completely O +
, O +
and O +
IFN O -
- O -
gamma O +
was O +
found O +
in O +
the O +
culture O +
supernatants O +
of O +
stimulated B-CellLine +
cells I-CellLine +
at O +
levels O +
at O +
which O +
recombinant O +
IFN O -
- O -
gamma O +
could O +
activate O +
the O +
factor O +
in O +
naive O +
cells O +
. O +

Therefore O +
, O +
a O +
STAT1 O +
transcription O +
factor O +
is O +
activated O +
by O +
IFN O -
- O -
gamma O +
synthesized O +
and O +
released O +
upon O +
stimulation O +
of O +
T O +
lymphocyte O +
populations O +
. O +

While O +
Jurkat B-CellLine +
cells I-CellLine +
both O +
secrete O +
and O +
respond O +
to O +
IFN O -
- O -
gamma O +
in O +
an O +
autocrine O +
loop O +
, O +
it O +
seems O +
likely O +
that O +
the O +
responding O +
cells O +
may O +
differ O +
from O +
those O +
synthesizing O +
this O +
cytokine O +
in O +
the O +
mononuclear B-CellLine +
cell I-CellLine +
cultures I-CellLine +
in O +
the O +
light O +
of O +
the O +
recent O +
report O +
that O +
Th1 B-CellLine +
cells I-CellLine +
lack O +
the O +
IFN O -
- O -
gamma O +
receptor O +
chain O +
necessary O +
for O +
activation O +
of O +
STAT1 O +
( O +
Pernis O +
, O +
A. O +
, O +
Gupta O +
, O +
S. O +
, O +
Gollob O +
, O +
K.J. O +
, O +
Garfein O +
, O +
E. O +
, O +
Coffman O +
, O +
R.L. O +
, O +
Schindler O +
, O +
C. O +
, O +
and O +
Rothman O +
, O +
P. O +
, O +
Science O +
1995 O -
. O +
269 O +
: O +
245 O +
) O +
. O +

A O +
model O +
of O +
latent O +
adenovirus O +
5 O +
infection O +
in O +
the O +
guinea O +
pig O +
( O +
Cavia O +
porcellus O +
) O +
. O +

A O +
model O +
of O +
adenovirus O +
5 O +
( O +
Ad5 O +
) O +
infection O +
was O +
developed O +
in O +
guinea O +
pigs O +
to O +
begin O +
to O +
study O +
its O +
role O +
in O +
the O +
pathogenesis O +
of O +
peripheral O +
lung O +
inflammation O +
. O +

Forty O +
animals O +
were O +
inoculated O +
intranasally O +
with O +
10 O +
( O +
7.0 O +
) O +
pfu O +
of O +
Ad5 O -
/ O -
animal O +
, O +
and O +
15 O +
animals O +
inoculated O +
with O +
sterile O +
culture O +
media O +
served O +
as O +
controls O +
. O +

Viral O +
titres O +
were O +
10 O +
( O +
4.4 O +
) O +
, O +
10 O +
( O +
6.1 O +
) O +
, O +
10 O +
( O +
5.2 O +
) O +
, O +
and O +
10 O +
( O +
2.9 O +
) O +
pfu O -
/ O -
animal O +
, O +
on O +
days O +
1 O +
, O +
3 O +
, O +
4 O +
, O +
and O +
7 O +
after O +
infection O +
, O +
respectively O +
. O +

In O +
situ O +
hybridization O +
to O +
viral O +
DNA O +
and O +
immunocytochemistry O +
for O +
Ad5 O +
E1A O +
protein O +
localized O +
the O +
virus O +
to O +
airway O +
and O +
alveolar O +
epithelial O +
cells O +
. O +

Histologic O +
examination O +
showed O +
an O +
extensive O +
inflammatory O +
cell O +
infiltration O +
around O +
the O +
airways O +
, O +
with O +
epithelial O +
necrosis O +
and O +
an O +
alveolar O +
exudate O +
that O +
caused O +
localized O +
alveolar O +
collapse O +
in O +
the O +
infected O +
areas O +
. O +

Immunocytochemistry O +
identified O +
the O +
cells O +
in O +
the O +
infiltrate O +
as O +
cytotoxic O +
T O +
cells O +
. O +

Although O +
all O +
animals O +
20 O +
and O +
47 O +
days O +
after O +
infection O +
had O +
seroconverted O +
to O +
Ad5 O +
, O +
virus O +
was O +
not O +
detected O +
in O +
these O +
groups O +
either O +
by O +
viral O +
plaque O +
assay O +
or O +
in O +
situ O +
hybridization O +
. O +

Ad5 O +
E1A O +
DNA O +
was O +
detected O +
by O +
polymerase O +
chain O +
reaction O +
in O +
five O +
of O +
six O +
animals O +
20 O +
days O +
after O +
infection O +
and O +
in O +
five O +
of O +
five O +
animals O +
47 O +
days O +
after O +
infection O +
. O +

In O +
these O +
same O +
animals O +
, O +
E1A O +
protein O +
was O +
detected O +
20 O +
days O +
after O +
infection O +
in O +
two O +
and O +
47 O +
days O +
after O +
infection O +
in O +
one O +
while O +
persistent O +
bronchiolitis O +
was O +
observed O +
in O +
four O +
and O +
three O +
animals O +
20 O +
and O +
47 O +
days O +
after O +
infection O +
, O +
respectively O +
. O +

These O +
results O +
demonstrate O +
that O +
the O +
guinea O +
pig O +
provides O +
a O +
useful O +
model O +
to O +
study O +
the O +
role O +
of O +
Ad5 O +
infection O +
in O +
chronic O +
airway O +
inflammation O +
. O +

Herpesvirus B-CellLine +
saimiri I-CellLine +
immortalized I-CellLine +
gamma I-CellLine +
delta I-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
activated O +
by O +
IL-12 O +
. O +

IL-12 O +
is O +
a O +
novel O +
heterodimeric O +
cytokine O +
important O +
for O +
the O +
regulation O +
and O +
differentiation O +
of O +
lymphocytes O +
and O +
NK O +
cells O +
. O +

Like O +
other O +
cytokines O +
, O +
IL-12 O +
mediates O +
its O +
biologic O +
activity O +
through O +
high O -
- O -
affinity O +
receptors O +
expressed O +
on O +
responsive O +
cells O +
. O +

To O +
date O +
, O +
a O +
large O +
number O +
of O +
receptors O +
for O +
IL-12 O +
have O +
been O +
found O +
only O +
on O +
PBMC O +
following O +
activation O +
with O +
PHA O +
or O +
IL-2 O +
. O +

To O +
gain O +
further O +
knowledge O +
of O +
the O +
IL-12R O +
complex O +
and O +
the O +
IL-12 O +
signal O +
transduction O +
pathway O +
in O +
cytotoxic O +
T O +
cells O +
, O +
we O +
studied O +
a O +
number O +
of O +
human B-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
that O +
had O +
been O +
transformed O +
to O +
permanent O +
growth O +
with O +
Herpesvirus O +
saimiri O +
, O +
an O +
oncogenic O +
virus O +
of O +
nonhuman O +
primates O +
. O +

This O +
paper O +
reports O +
the O +
expression O +
of O +
IL-12R O +
on O +
a O +
human B-CellLine +
gamma I-CellLine +
delta I-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
that O +
responds O +
to O +
IL-12 O +
with O +
enhanced O +
cytolytic O +
activity O +
and O +
increased O +
expression O +
of O +
cytolytic O +
effector O +
molecules O +
granzyme O +
B O +
and O +
perforin O +
. O +

Using O +
these O +
T O +
cells O +
as O +
a O +
model O +
of O +
IL-12 O +
signal O +
transduction O +
, O +
we O +
confirmed O +
that O +
these O +
events O +
involve O +
members O +
of O +
the O +
Janus O +
kinase O +
family O +
of O +
nonreceptor O +
tyrosine O +
kinases O +
JAK2 O +
, O +
TYK2 O +
, O +
and O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
4 O +
. O +

The O +
Epstein O -
- O -
Barr O +
virus O -
- O -
encoded O +
nuclear O +
antigen O +
EBNA-5 O +
accumulates O +
in O +
PML O -
- O -
containing O +
bodies O +
. O +

EBNA-5 O +
is O +
one O +
of O +
the O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
-encoded O +
nuclear O +
proteins O +
required O +
for O +
immortalization O +
of O +
human O +
B O +
lymphocytes O +
. O +

In O +
the O +
nuclei O +
of O +
EBV B-CellLine -
- I-CellLine -
transformed I-CellLine +
lymphoblastoid I-CellLine +
cell I-CellLine +
lines I-CellLine +
EBNA-5 O +
is O +
preferentially O +
targetted O +
to O +
distinct O +
nuclear O +
foci O +
. O +

Previously O +
we O +
have O +
shown O +
( O +
W.Q. O +
Jiang O +
, O +
L.Szekely O +
, O +
V.Wendel O -
- O -
Hansen O +
, O +
N.Ringertz O +
, O +
G.Klein O +
, O +
and O +
A. O +
Rosen O +
, O +
Exp O -
. O -
Cell O +
Res O +
. O +

The O +
involvement O +
of O +
p23 O +
, O +
hsp90 O +
, O +
and O +
immunophilins O +
in O +
the O +
assembly O +
of O +
progesterone O +
receptor O +
complexes O +
. O +

To O +
better O +
understand O +
the O +
assembly O +
mechanism O +
for O +
the O +
progesterone O +
receptor O +
( O +
PR O +
) O +
, O +
we O +
have O +
developed O +
cell O -
- O -
free O +
systems O +
for O +
studying O +
interactions O +
of O +
PR O +
, O +
hsp90 O +
, O +
and O +
other O +
associated O +
proteins O +
. O +

When O +
PR O +
is O +
incubated O +
in O +
rabbit O +
reticulocyte O +
lysate O +
, O +
its O +
association O +
with O +
hsp90 O +
, O +
hsp70 O +
, O +
the O +
three O +
immunophilins O +
FKBP54 O +
, O +
FKBP52 O +
and O +
CyP-40 O +
, O +
and O +
with O +
p23 O +
is O +
observed O +
. O +

These O +
interactions O +
require O +
ATP O -
/ O -
Mg2 O -
+ O +
and O +
when O +
ATP O +
is O +
limiting O +
the O +
PR O +
complex O +
is O +
altered O +
to O +
one O +
containing O +
the O +
proteins O +
p60 O +
and O +
p48 O +
, O +
but O +
lacking O +
immunophilins O +
and O +
p23 O +
. O +

We O +
have O +
studied O +
two O +
pre O -
- O -
formed O +
hsp90 O +
complexes O +
that O +
may O +
participate O +
in O +
the O +
assembly O +
of O +
PR O +
complexes O +
. O +

One O +
contains O +
hsp90 O +
bound O +
to O +
hsp70 O +
and O +
p60 O +
and O +
this O +
complex O +
forms O +
spontaneously O +
in O +
the O +
absence O +
of O +
ATP O +
. O +

A O +
second O +
complex O +
contains O +
hsp90 O +
bound O +
to O +
p23 O +
plus O +
the O +
three O +
immunophilins O +
and O +
some O +
hsp70 O +
. O +

The O +
formation O +
of O +
this O +
complex O +
requires O +
ATP O +
. O +

In O +
further O +
studies O +
we O +
have O +
shown O +
that O +
purified O +
hsp90 O +
can O +
bind O +
to O +
purified O +
p23 O +
and O +
this O +
interaction O +
requires O +
both O +
ATP O +
and O +
molybdate O +
. O +

This O +
explains O +
, O +
in O +
part O +
, O +
the O +
known O +
effects O +
of O +
ATP O +
and O +
molybdate O +
on O +
assembly O +
of O +
PR O +
complexes O +
. O +

Expression O +
of O +
Retinoid O +
X O +
Receptor O +
alpha O +
is O +
increased O +
upon O +
monocytic O +
cell O +
differentiation O +
. O +

1 O +
alpha O +
, O +
25-Dihydroxyvitamin O +
D3 O +
( O +
VD O +
) O +
is O +
a O +
potent O +
inducer O +
of O +
monocytic O +
differentiation O +
of O +
both O +
normal O +
and O +
leukemic O +
cells O +
. O +

Its O +
effects O +
are O +
mediated O +
by O +
its O +
nuclear O +
receptor O +
( O +
VDR O +
) O +
. O +

Efficient O +
gene O +
activation O +
requires O +
the O +
heterodimerization O +
of O +
VDR O +
with O +
Retinoid O +
X O +
Receptors O +
( O +
RXR O +
) O +
. O +

In O +
the O +
present O +
study O +
using O +
specific O +
antibodies O +
, O +
we O +
analyzed O +
the O +
expression O +
of O +
the O +
RXR O +
alpha O +
protein O +
in O +
blood O +
mononuclear O +
cells O +
from O +
acute O +
myeloid O +
patients O +
( O +
AML O +
) O +
( O +
10 O +
cases O +
) O +
and O +
from O +
myelomonocytic B-CellLine +
cell I-CellLine +
lines I-CellLine +
arrested O +
at O +
different O +
stages O +
of O +
differentiation O +
. O +

We O +
observed O +
that O +
the O +
RXR O +
alpha O +
expression O +
increased O +
during O +
myelomonocytic O +
differentiation O +
, O +
since O +
the O +
highest O +
levels O +
were O +
found O +
in O +
AML O +
samples O +
and O +
in O +
myelomonocytic B-CellLine +
cell I-CellLine +
lines I-CellLine +
having O +
the O +
highest O +
amounts O +
of O +
monocytic O +
precursors O +
. O +

We O +
also O +
demonstrated O +
that O +
fresh O +
leukemic O +
cells O +
, O +
whatever O +
their O +
stage O +
of O +
differentiation O +
, O +
as O +
well O +
as O +
myelomonocytic B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
respond O +
to O +
VD O +
by O +
an O +
increase O +
in O +
RXR O +
alpha O +
levels O +
. O +

Combinations O +
of O +
all O -
- O -
trans O +
retinoic O +
acid O +
( O +
RA O +
) O +
and O +
VD O +
, O +
in O +
some O +
cases O +
, O +
increased O +
this O +
effect O +
. O +

This O +
response O +
suggests O +
the O +
involvement O +
of O +
RXR O +
alpha O +
in O +
monocytic O +
differentiation O +
upon O +
VD O +
treatment O +
. O +

Coexpression O +
of O +
the O +
interleukin-13 O +
and O +
interleukin-4 O +
genes O +
correlates O +
with O +
their O +
physical O +
linkage O +
in O +
the O +
cytokine O +
gene O +
cluster O +
on O +
human O +
chromosome O +
5q23 O -
- O -
31 O +
. O +

Interleukin-13 O +
( O +
IL-13 O +
) O +
and O +
IL-4 O +
are O +
cytokines O +
produced O +
by O +
T O +
cells O +
that O +
are O +
encoded O +
by O +
the O +
q23 O -
- O -
31 O +
region O +
of O +
human O +
chromosome O +
5 O +
. O +

To O +
investigate O +
the O +
regulation O +
of O +
IL-13 O +
gene O +
expression O +
by O +
T O +
cells O +
, O +
we O +
isolated O +
and O +
sequenced O +
the O +
human O +
IL-13 O +
gene O +
, O +
analyzed O +
its O +
5'-flanking O +
region O +
for O +
potential O +
transcriptional O +
activation O +
elements O +
, O +
and O +
examined O +
its O +
expression O +
in O +
nontransformed B-CellLine +
T I-CellLine -
- I-CellLine -
lineage I-CellLine +
cell I-CellLine +
populations I-CellLine +
. O +

The O +
human O +
IL-13 O +
gene O +
was O +
located O +
12.5-kb O +
upstream O +
of O +
the O +
IL-4 O +
gene O +
and O +
2-kb O +
downstream O +
of O +
a O +
CpG O +
island O +
. O +

The O +
IL-13 O +
gene O +
5 O +
' O +
flank O +
region O +
included O +
a O +
segment O +
with O +
sequence O +
homology O +
to O +
P O +
elements O +
of O +
the O +
IL-4 O +
promoter O +
involved O +
in O +
transcriptional O +
activation O +
in O +
T O +
cells O +
. O +

Mutation O +
of O +
the O +
IL-13 O +
P O +
element O +
site O +
significantly O +
reduced O +
IL-13 O +
promoter O +
activity O +
in O +
response O +
to O +
T O -
- O -
cell O +
activation O +
. O +

Oligonucleotides O +
containing O +
the O +
IL-13 O +
or O +
IL-4 O +
P O +
element O +
sites O +
specifically O +
bound O +
the O +
transcriptional O +
activator O +
protein O +
, O +
nuclear O +
factor O -
- O -
activated O +
T O +
cells O +
, O +
preformed O +
( O +
NF O -
- O -
ATp O +
) O +
, O +
when O +
incubated O +
with O +
nuclear O +
protein O +
extracts O +
from O +
activated O +
T O +
cells O +
. O +

Similar O +
to O +
IL-4 O +
, O +
IL-13 O +
mRNA O +
expression O +
was O +
highest O +
in O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
populations I-CellLine +
enriched O +
for O +
cells O +
that O +
had O +
previously O +
been O +
primed O +
in O +
vivo O +
or O +
in O +
vitro O +
, O +
indicating O +
that O +
priming O +
increases O +
the O +
expression O +
of O +
the O +
IL-13 O +
and O +
IL-4 O +
genes O +
in O +
a O +
coordinate O +
manner O +
. O +

Because O +
the O +
primed B-CellLine +
T I-CellLine +
cells I-CellLine +
contain O +
higher O +
levels O +
of O +
nuclear O +
NF O -
- O -
ATp O +
, O +
capable O +
of O +
binding O +
to O +
P O +
elements O +
of O +
the O +
IL-4 O +
and O +
IL-13 O +
promoters O +
, O +
than O +
do O +
freshly O -
- O -
isolated O +
T O +
cells O +
, O +
the O +
NF O -
- O -
AT O -
- O -
binding O +
P O +
elements O +
are O +
attractive O +
candidates O +
to O +
mediate O +
the O +
coordinate O +
expression O +
of O +
these O +
two O +
cytokine O +
genes O +
. O +

Transactivation O +
of O +
the O +
interleukin-1alpha O +
promoter O +
by O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
and O +
type O +
II O +
Tax O +
proteins O +
. O +

Human B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
leukemia I-CellLine +
virus I-CellLine +
type I-CellLine +
I I-CellLine +
( I-CellLine +
HTLV I-CellLine -
- I-CellLine -
I I-CellLine +
) I-CellLine +
-infected I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
constitutively O +
produce O +
high O +
levels O +
of O +
interleukin-1alpha O +
( O +
IL-1alpha O +
) O +
. O +

To O +
analyze O +
the O +
mechanisms O +
that O +
lead O +
to O +
the O +
expression O +
of O +
IL-1alpha O +
in O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine -
- I-CellLine -
infected I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
we O +
studied O +
regulatory O +
regions O +
of O +
the O +
human O +
IL-1alpha O +
promoter O +
involved O +
in O +
activation O +
of O +
the O +
IL-1alpha O +
gene O +
. O +

IL-1alpha O +
promoter O +
constructs O +
drive O +
transcription O +
of O +
the O +
chloramphenicol O +
acetyltransferase O +
( O +
CAT O +
) O +
reporter O +
gene O +
in O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine -
- I-CellLine -
positive I-CellLine +
MT-2 I-CellLine +
cells I-CellLine +
, O +
which O +
constitutively O +
produce O +
IL-1alpha O +
. O +

In O +
a O +
cotransfection O +
assay O +
, O +
the O +
Tax O +
protein O +
of O +
both O +
HTLV O -
- O -
I O +
and O +
HTLV O -
- O -
II O +
specifically O +
activated O +
transcription O +
from O +
the O +
IL-1alpha O +
promoter O +
in O +
an O +
uninfected B-CellLine +
Jurkat I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

A O +
mutant O +
Tax O +
protein O +
deficient O +
in O +
transactivation O +
of O +
genes O +
by O +
the O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappaB O +
pathway O +
was O +
unable O +
to O +
induce O +
transcriptional O +
activity O +
of O +
IL-1alpha O +
promoter O -
- O -
CAT O +
constructs O +
, O +
but O +
was O +
rescued O +
by O +
exogenous O +
provision O +
of O +
p65 O -
/ O -
p50 O +
NF O -
- O -
kappaB O +
. O +

We O +
found O +
that O +
two O +
IL-1alpha O +
kappaB O -
- O -
like O +
sites O +
( O +
positions O +
-1 O +
, O +
065 O +
to O +
-1 O +
, O +
056 O +
and O +
+ O -
646 O +
to O +
+ O -
655 O +
) O +
specifically O +
formed O +
a O +
complex O +
with O +
NF O -
- O -
kappaB O +
-containing O +
nuclear O +
extract O +
from O +
MT-2 B-CellLine +
cells I-CellLine +
and O +
that O +
NF O -
- O -
kappaB O +
bound O +
with O +
higher O +
affinity O +
to O +
the O +
3 O +
' O +
NF O -
- O -
kappaB O +
binding O +
site O +
than O +
to O +
the O +
5 O +
' O +
NF O -
- O -
kappaB O +
site O +
. O +

Moreover O +
, O +
deletion O +
of O +
either O +
5 O +
' O +
or O +
3 O +
' O +
NF O -
- O -
kappaB O +
sites O +
reduced O +
IL-1alpha O +
promoter O +
activity O +
in O +
MT-2 B-CellLine +
cells I-CellLine +
and O +
transactivation O +
of O +
the O +
IL-1alpha O +
promoter O +
by O +
exogenous O +
NF O -
- O -
kappaB O +
and O +
Tax O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

These O +
data O +
suggest O +
a O +
general O +
role O +
for O +
Tax O +
induction O +
of O +
IL-1alpha O +
gene O +
transcription O +
by O +
the O +
NF O -
- O -
kappaB O +
pathway O +
. O +

Expression O +
of O +
IL-1alpha O +
by O +
HTLV O -
- O -
I O +
productively O +
infected O +
cells O +
may O +
be O +
important O +
in O +
the O +
hypercalcemia O +
, O +
osteolytic O +
bone O +
lesions O +
, O +
neutrophilia O +
, O +
elevation O +
of O +
C O -
- O -
reactive O +
protein O +
, O +
and O +
fever O +
frequently O +
seen O +
in O +
patients O +
with O +
HTLV O -
- O -
I O -
- O -
induced O +
adult O +
T O -
- O -
cell O +
leukemia O -
/ O -
lymphoma O +
. O +

A O +
mammalian O +
histone O +
deacetylase O +
related O +
to O +
the O +
yeast O +
transcriptional O +
regulator O +
Rpd3p O +
[ O +
see O +
comments O +
] O +

Trapoxin O +
is O +
a O +
microbially O +
derived O +
cyclotetrapeptide O +
that O +
inhibits O +
histone O +
deacetylation O +
in O +
vivo O +
and O +
causes O +
mammalian O +
cells O +
to O +
arrest O +
in O +
the O +
cell O +
cycle O +
. O +

A O +
trapoxin O +
affinity O +
matrix O +
was O +
used O +
to O +
isolate O +
two O +
nuclear O +
proteins O +
that O +
copurified O +
with O +
histone O +
deacetylase O +
activity O +
. O +

Both O +
proteins O +
were O +
identified O +
by O +
peptide O +
microsequencing O +
, O +
and O +
a O +
complementary O +
DNA O +
encoding O +
the O +
histone O +
deacetylase O +
catalytic O +
subunit O +
( O +
HD1 O +
) O +
was O +
cloned O +
from O +
a O +
human O +
Jurkat O +
T O +
cell O +
library O +
. O +

As O +
the O +
predicted O +
protein O +
is O +
very O +
similar O +
to O +
the O +
yeast O +
transcriptional O +
regulator O +
Rpd3p O +
, O +
these O +
results O +
support O +
a O +
role O +
for O +
histone O +
deacetylase O +
as O +
a O +
key O +
regulator O +
of O +
eukaryotic O +
transcription O +
. O +

Effects O +
of O +
interleukin-10 O +
on O +
human O +
peripheral O +
blood O +
mononuclear O +
cell O +
responses O +
to O +
Cryptococcus O +
neoformans O +
, O +
Candida O +
albicans O +
, O +
and O +
lipopolysaccharide O +
. O +

Deactivation O +
of O +
mononuclear O +
phagocytes O +
is O +
critical O +
to O +
limit O +
the O +
inflammatory O +
response O +
but O +
can O +
be O +
detrimental O +
in O +
the O +
face O +
of O +
progressive O +
infection O +
. O +

We O +
compared O +
the O +
effects O +
of O +
the O +
deactivating O +
cytokine O +
interleukin O +
10 O +
( O +
IL-10 O +
) O +
on O +
human O +
peripheral O +
blood O +
mononuclear O +
cell O +
( O +
PBMC O +
) O +
responses O +
to O +
lipopolysaccharide O +
( O +
LPS O +
) O +
, O +
Cryptococcus O +
neoformans O +
, O +
and O +
Candida O +
albicans O +
. O +

IL-10 O +
effected O +
dose O -
- O -
dependent O +
inhibition O +
of O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
release O +
in O +
PBMC O +
stimulated O +
by O +
LPS O +
and O +
C. O +
neoformans O +
, O +
with O +
significant O +
inhibition O +
seen O +
with O +
0.1 O +
U O -
/ O -
ml O +
and O +
greater O +
than O +
90 O +
% O +
inhibition O +
noted O +
with O +
10 O +
U O -
/ O -
ml O +
. O +

In O +
contrast O +
, O +
even O +
at O +
doses O +
as O +
high O +
as O +
100 O +
U O -
/ O -
ml O +
, O +
IL-10 O +
inhibited O +
TNF O -
- O -
alpha O +
release O +
in O +
response O +
to O +
C. O +
albicans O +
by O +
only O +
50 O +
% O +
. O +

IL-10 O +
profoundly O +
inhibited O +
release O +
of O +
IL-1beta O +
from O +
PBMC O +
stimulated O +
by O +
all O +
three O +
stimuli O +
. O +

TNF O -
- O -
alpha O +
mRNA O +
and O +
release O +
was O +
inhibited O +
even O +
if O +
IL-10 O +
was O +
added O +
up O +
to O +
8 O +
h O +
after O +
cryptococcal O +
stimulation O +
. O +

In O +
contrast O +
, O +
inhibition O +
of O +
IL-1 O +
beta O +
mRNA O +
was O +
of O +
lesser O +
magnitude O +
and O +
occurred O +
only O +
when O +
IL-10 O +
was O +
added O +
within O +
2 O +
h O +
of O +
cryptococcal O +
stimulation O +
. O +

IL-10 O +
inhibited O +
translocation O +
of O +
NF O -
- O -
kappaB O +
in O +
response O +
to O +
LPS O +
but O +
not O +
the O +
fungal O +
stimuli O +
. O +

All O +
three O +
stimuli O +
induced O +
IL-10 O +
production O +
in O +
PBMC O +
, O +
although O +
over O +
10-fold O +
less O +
IL-10 O +
was O +
released O +
in O +
response O +
to O +
C. O +
neoformans O +
compared O +
with O +
LPS O +
and O +
C. O +
albicans O +
. O +

Thus O +
, O +
while O +
IL-10 O +
has O +
deactivating O +
effects O +
on O +
PBMC O +
responses O +
to O +
all O +
three O +
stimuli O +
, O +
disparate O +
stimulus- O +
and O +
response O -
- O -
specific O +
patterns O +
of O +
deactivation O +
are O +
seen O +
. O +

Inhibition O +
by O +
IL-10 O +
of O +
proinflammatory O +
cytokine O +
release O +
appears O +
to O +
occur O +
at O +
the O +
level O +
of O +
gene O +
transcription O +
for O +
TNF O -
- O -
alpha O +
and O +
both O +
transcriptionally O +
and O +
posttranscriptionally O +
for O +
IL-1beta O +
. O +

Permanent O +
occupancy O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
enhancer O +
by O +
NF O -
- O -
kappa O +
B O +
is O +
needed O +
for O +
persistent O +
viral O +
replication O +
in O +
monocytes O +
. O +

This O +
work O +
aimed O +
to O +
ascertain O +
the O +
role O +
of O +
kappaB O -
- O -
responsive O +
elements O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
enhancer O +
not O +
only O +
in O +
early O +
initiation O +
but O +
also O +
in O +
long O -
- O -
term O +
maintenance O +
of O +
proviral O +
transcription O +
in O +
cells O +
of O +
the O +
monocytic O +
lineage O +
. O +

For O +
this O +
purpose O +
, O +
we O +
used O +
three O +
main O +
approaches O +
. O +

The O +
first O +
was O +
to O +
abruptly O +
terminate O +
tumor O +
necrosis O +
factor O -
- O -
induced O +
NF O -
- O -
kappaB O +
binding O +
to O +
the O +
enhancer O +
sequences O +
in O +
U1 O +
monocytic O +
cells O +
, O +
using O +
a O +
short O +
pulse O +
of O +
exogenous O +
tumor O +
necrosis O +
factor O +
. O +

This O +
resulted O +
in O +
concomitant O +
decrease O +
in O +
nuclear O +
NF O -
- O -
kappaB O +
DNA O -
- O -
binding O +
activity O +
and O +
endogenous O +
long O +
terminal O +
repeat O +
transcriptional O +
activity O +
. O +

The O +
second O +
was O +
to O +
suppress O +
the O +
permanent O +
NF O -
- O -
kappaB O +
translocation O +
induced O +
by O +
HIV-1 O +
replication O +
itself O +
in O +
chronically B-CellLine +
infected I-CellLine +
U937 I-CellLine +
cells I-CellLine +
, O +
using O +
a O +
specific O +
proteasome O +
inhibitor O +
( O +
Z O -
- O -
LLL O -
- O -
H O +
) O +
. O +

As O +
early O +
as O +
2 O +
h O +
after O +
addition O +
of O +
the O +
inhibitor O +
to O +
the O +
culture O +
medium O +
, O +
there O +
was O +
an O +
inhibition O +
of O +
both O +
constitutive O +
activation O +
of O +
NF O -
- O -
kappaB O +
and O +
HIV-1 O +
genome O +
expression O +
. O +

The O +
third O +
approach O +
was O +
to O +
monitor O +
the O +
replication O +
competence O +
in O +
U937 B-CellLine +
cells I-CellLine +
of O +
an O +
infectious O +
HIV-1 O +
provirus O +
carrying O +
point O +
mutations O +
in O +
the O +
kappaB O -
- O -
responsive O +
elements O +
of O +
both O +
long O +
terminal O +
repeats O +
. O +

Compared O +
with O +
its O +
wild O -
- O -
type O +
counterpart O +
, O +
this O +
mutated O +
provirus O +
showed O +
a O +
profoundly O +
decreased O +
, O +
Z O -
- O -
LLL O -
- O -
H O -
- O -
insensitive O +
transcriptional O +
and O +
replicative O +
activity O +
in O +
U937 B-CellLine +
monocytes I-CellLine +
. O +

Together O +
, O +
our O +
results O +
indicate O +
that O +
occupancy O +
of O +
the O +
viral O +
enhancer O +
by O +
NF O -
- O -
kappaB O +
( O +
p50 O -
/ O -
p65 O +
) O +
heterodimers O +
is O +
required O +
for O +
ongoing O +
transcription O +
of O +
integrated O +
HIV O +
provirus O +
in O +
monocytes O +
, O +
even O +
in O +
cells O +
chronically O +
infected O +
and O +
permanently O +
producing O +
functional O +
HIV O +
Tat O +
protein O +
. O +

Thus O +
, O +
the O +
ability O +
of O +
HIV-1 O +
replication O +
to O +
activate O +
NF O -
- O -
kappaB O +
is O +
crucial O +
to O +
the O +
intense O +
self O -
- O -
perpetuated O +
viral O +
transcription O +
observed O +
in O +
cells O +
of O +
the O +
monocytic O +
lineage O +
. O +

Surfactant O +
suppresses O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
human O +
monocytic O +
cells O +
. O +

In O +
addition O +
to O +
biophysical O +
properties O +
, O +
pulmonary O +
surfactant O +
has O +
immunomodulatory O +
activity O +
. O +

We O +
previously O +
demonstrated O +
that O +
both O +
synthetic O +
( O +
Exosurf O +
) O +
and O +
modified O +
natural O +
surfactant O +
( O +
Survanta O +
) O +
downregulated O +
endotoxin O -
- O -
stimulated O +
inflammatory O +
c O +
ytokine O +
mRNA O +
levels O +
and O +
protein O +
products O +
( O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
[ O +
TNF O +
] O +
, O +
interleukin-1-beta O +
[ O +
IL-1 O +
] O +
, O +
interleukin-6 O +
[ O +
IL-6 O +
] O +
) O +
in O +
human O +
alveolar O +
macrophages O +
. O +

In O +
this O +
study O +
, O +
we O +
report O +
that O +
both O +
Exosurf O +
and O +
Survanta O +
suppress O +
TNF O +
mRNA O +
and O +
secretion O +
( O +
85 O +
+ O -
/- O +
4 O +
% O +
mean O +
percent O +
inhibition O +
+ O -
/- O +
SEM O +
by O +
Exosurf O +
; O +
71 O +
+ O -
/- O +
6 O +
% O +
by O +
Survanta O +
) O +
by O +
endotoxin B-CellLine -
- I-CellLine -
stimulated I-CellLine +
THP-1 I-CellLine +
, O +
a O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Because O +
surfactant O +
downregulated O +
inflammatory O +
cytokine O +
production O +
similarly O +
in O +
both O +
normal O +
human O +
alveolar O +
macrophages O +
and O +
the O +
THP-1 B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
we O +
used O +
this O +
cell B-CellLine +
line I-CellLine +
to O +
investigate O +
whether O +
surfactant O +
affected O +
transcriptional O +
mechanisms O +
. O +

Specifically O +
, O +
we O +
examined O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
activation O +
because O +
it O +
is O +
crucial O +
in O +
transcriptional O +
regulation O +
of O +
many O +
inflammatory O +
cytokine O +
genes O +
including O +
TNF O +
, O +
IL-1 O +
, O +
and O +
IL-6 O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
showed O +
that O +
both O +
surfactants O +
decreased O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

The O +
presence O +
of O +
both O +
p65 O +
and O +
p50 O +
NF O -
- O -
kappa O +
B O +
components O +
in O +
LPS O -
- O -
activated O +
THP-1 B-CellLine +
cells I-CellLine +
was O +
confirmed O +
by O +
specific O +
antibody O +
induction O +
of O +
supershifts O +
in O +
mobility O +
assays O +
. O +

These O +
results O +
are O +
the O +
first O +
to O +
suggest O +
that O +
surfactant O +
's O +
suppressive O +
effects O +
on O +
inflammatory O +
cytokine O +
production O +
may O +
involve O +
transcriptional O +
regulation O +
through O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

Inactivation O +
of O +
IkappaBbeta O +
by O +
the O +
tax O +
protein O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
: O +
a O +
potential O +
mechanism O +
for O +
constitutive O +
induction O +
of O +
NF O -
- O -
kappaB O +
. O +

In O +
resting O +
T O +
lymphocytes O +
, O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
is O +
sequestered O +
in O +
the O +
cytoplasm O +
via O +
interactions O +
with O +
members O +
of O +
the O +
I O +
kappa O +
B O +
family O +
of O +
inhibitors O +
, O +
including O +
IkappaBalpha O +
and O +
IkappaBbeta O +
. O +

During O +
normal O +
T O -
- O -
cell O +
activation O +
, O +
IkappaBalpha O +
is O +
rapidly O +
phosphorylated O +
, O +
ubiquitinated O +
, O +
and O +
degraded O +
by O +
the O +
26S O +
proteasome O +
, O +
thus O +
permitting O +
the O +
release O +
of O +
functional O +
NF O -
- O -
kappaB O +
. O +

In O +
contrast O +
to O +
its O +
transient O +
pattern O +
of O +
nuclear O +
induction O +
during O +
an O +
immune O +
response O +
, O +
NF O -
- O -
kappaB O +
is O +
constitutively O +
activated O +
in O +
cells O +
expressing O +
the O +
Tax O +
transforming O +
protein O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
HTLV-1 O +
) O +
. O +

Recent O +
studies O +
indicate O +
that O +
HTLV-1 O +
Tax O +
targets O +
IkappaBalpha O +
to O +
the O +
ubiquitin O -
- O -
proteasome O +
pathway O +
. O +

However O +
, O +
it O +
remains O +
unclear O +
how O +
this O +
viral O +
protein O +
induces O +
a O +
persistent O +
rather O +
than O +
transient O +
NF O -
- O -
kappaB O +
response O +
. O +

In O +
this O +
report O +
, O +
we O +
provide O +
evidence O +
that O +
in O +
addition O +
to O +
acting O +
on O +
IkappaBalpha O +
, O +
Tax O +
stimulates O +
the O +
turnover O +
Of O +
IkappaBbeta O +
via O +
a O +
related O +
targeting O +
mechanism O +
. O +

Like O +
IkappaBalpha O +
, O +
Tax O +
-mediated O +
breakdown O +
of O +
IkappaBbeta O +
in O +
transfected B-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
is O +
blocked O +
either O +
by O +
cell O -
- O -
permeable O +
proteasome O +
inhibitors O +
or O +
by O +
mutation O +
Of O +
IkappaBbeta O +
at O +
two O +
serine O +
residues O +
present O +
within O +
its O +
N O -
- O -
terminal O +
region O +
. O +

Despite O +
the O +
dual O +
specificity O +
of O +
HTLV-1 O +
Tax O +
for O +
IkappaBalpha O +
and O +
IkappaBbeta O +
at O +
the O +
protein O +
level O +
, O +
Tax O +
selectively O +
stimulates O +
NF O -
- O -
kappaB O +
-directed O +
transcription O +
of O +
the O +
IkappaBalpha O +
gene O +
. O +

Consequently O +
, O +
IkappaBbeta O +
protein O +
expression O +
is O +
chronically O +
downregulated O +
in O +
HTLV-1-infected O +
T O +
lymphocytes O +
. O +

These O +
findings O +
with O +
IkappaBbeta O +
provide O +
a O +
potential O +
mechanism O +
for O +
the O +
constitutive O +
activation O +
of O +
NF O -
- O -
kappaB O +
in O +
Tax B-CellLine -
- I-CellLine -
expressing I-CellLine +
cells I-CellLine +
. O +

Genetic O +
characterization O +
of O +
transactivation O +
of O +
the O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
promoter O +
: O +
Binding O +
of O +
Tax O +
to O +
Tax O -
- O -
responsive O +
element O +
1 O +
is O +
mediated O +
by O +
the O +
cyclic O +
AMP O -
- O -
responsive O +
members O +
of O +
the O +
CREB O -
/ O -
ATF O +
family O +
of O +
transcription O +
factors O +
. O +

To O +
achieve O +
a O +
better O +
understanding O +
of O +
the O +
mechanism O +
of O +
transactivation O +
by O +
Tax O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
Tax O -
- O -
responsive O +
element O +
1 O +
( O +
TRE-1 O +
) O +
, O +
we O +
developed O +
a O +
genetic O +
approach O +
with O +
Saccharomyces O +
cerevisiae O +
. O +

We O +
constructed O +
a O +
yeast O +
reporter O +
strain O +
containing O +
the O +
lacZ O +
gene O +
under O +
the O +
control O +
of O +
the O +
CYC1 O +
promoter O +
associated O +
with O +
three O +
copies O +
of O +
TRE-1 O +
. O +

Expression O +
of O +
either O +
the O +
cyclic O +
AMP O +
response O +
element O -
- O -
binding O +
protein O +
( O +
CREB O +
) O +
or O +
CREB O +
fused O +
to O +
the O +
GAL4 O +
activation O +
domain O +
( O +
GAD O +
) O +
in O +
this O +
strain O +
did O +
not O +
modify O +
the O +
expression O +
of O +
the O +
reporter O +
gene O +
. O +

Tax O +
alone O +
was O +
also O +
inactive O +
. O +

However O +
, O +
expression O +
of O +
the O +
reporter O +
gene O +
was O +
induced O +
by O +
coexpression O +
of O +
Tax O +
and O +
CREB O +
. O +

This O +
effect O +
was O +
stronger O +
with O +
the O +
GAD O -
- O -
CREB O +
fusion O +
protein O +
. O +

Analysis O +
of O +
different O +
CREB O +
mutants O +
with O +
this O +
genetic O +
system O +
indicated O +
that O +
the O +
C O -
- O -
terminal O +
92 O +
amino O +
acid O +
residues O +
, O +
which O +
include O +
the O +
basic O +
domain O +
and O +
the O +
leucine O +
zipper O +
, O +
are O +
necessary O +
and O +
sufficient O +
to O +
mediate O +
transactivation O +
by O +
Tax O +
. O +

To O +
identify O +
cellular O +
proteins O +
binding O +
to O +
TRE-1 O +
in O +
a O +
Tax O +
-dependent O +
manner O +
, O +
this O +
strain O +
was O +
also O +
used O +
to O +
screen O +
a O +
library O +
of O +
human O +
cDNAs O +
fused O +
to O +
GAD O +
. O +

Of O +
five O +
positive O +
clones O +
isolated O +
from O +
0.75 O +
x O +
10 O +
( O +
6 O +
) O +
yeast O +
colonies O +
, O +
four O +
were O +
members O +
of O +
the O +
CREB O -
/ O -
activating O +
transcription O +
factor O +
( O +
ATF O +
) O +
family O +
: O +
CREB O +
, O +
two O +
isoforms O +
of O +
the O +
cyclic O +
AMP O -
- O -
responsive O +
element O +
modulator O +
( O +
CREM O +
) O +
, O +
and O +
ATF-1 O +
. O +

Interestingly O +
, O +
these O +
three O +
proteins O +
can O +
be O +
phosphorylated O +
by O +
protein O +
kinase O +
A O +
and O +
thus O +
form O +
a O +
particular O +
subgroup O +
within O +
the O +
CREB O -
/ O -
ATF O +
family O +
. O +

Expression O +
of O +
ATF-2 O +
in O +
S. O +
cerevisiae O +
did O +
not O +
activate O +
TRE-1 O +
in O +
the O +
presence O +
of O +
Tax O +
. O +

This O +
shows O +
that O +
in O +
a O +
eukaryotic O +
nucleus O +
, O +
Tax O +
specifically O +
interacts O +
with O +
the O +
basic O +
domain O -
- O -
leucine O +
zipper O +
region O +
of O +
ATF-1 O +
, O +
CREB O +
, O +
and O +
CREM O +
. O +

The O +
fifth O +
clone O +
identified O +
in O +
this O +
screening O +
corresponded O +
to O +
the O +
Ku O +
autoantigen O +
p70 O +
subunit O +
. O +

When O +
fused O +
to O +
GAD O +
, O +
the O +
C O -
- O -
terminal O +
region O +
of O +
Ku O +
was O +
able O +
to O +
activate O +
transcription O +
via O +
TRE-1 O +
but O +
this O +
activation O +
was O +
not O +
dependent O +
on O +
Tax O +
. O +

Role O +
of O +
EGR1 O +
in O +
regulation O +
of O +
stimulus O -
- O -
dependent O +
CD44 O +
transcription O +
in O +
B O +
lymphocytes O +
. O +

The O +
immediate O -
- O -
early O +
gene O +
egr-1 O +
encodes O +
a O +
transcription O +
factor O +
( O +
EGR1 O +
) O +
that O +
links O +
B O -
- O -
cell O +
antigen O +
receptor O +
( O +
BCR O +
) O +
signals O +
to O +
downstream O +
activation O +
events O +
through O +
the O +
regulation O +
of O +
previously O +
unidentified O +
target O +
genes O +
. O +

Here O +
we O +
identify O +
the O +
gene O +
encoding O +
the O +
lymphocyte O +
homing O +
and O +
migration O +
protein O +
CD44 O +
as O +
a O +
target O +
of O +
EGR1 O +
regulation O +
in O +
B O +
cells O +
. O +

BCR O +
-induced O +
increases O +
in O +
CD44 O +
mRNA O +
expression O +
and O +
transcription O +
levels O +
are O +
shown O +
to O +
occur O +
in O +
EGR1-expressing B-CellLine +
but I-CellLine +
not I-CellLine +
in I-CellLine +
nonexpressing I-CellLine +
subclones I-CellLine +
of O +
the O +
B B-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
WEHI-231 B-CellLine +
. O +

Kinetics O +
of O +
egr-1 O +
transcription O +
and O +
the O +
appearance O +
of O +
nuclear O +
EGR1 O +
protein O +
precede O +
CD44 O +
induction O +
and O +
occur O +
within O +
30 O +
min O +
after O +
stimulation O +
in O +
the O +
EGR1-expressing B-CellLine +
subclone I-CellLine +
. O +

A O +
single O +
EGR1 O +
binding O +
motif O +
is O +
demonstrated O +
at O +
bp O +
-301 O +
of O +
the O +
human O +
CD44 O +
promoter O +
. O +

Cotransfection O +
of O +
a O +
CD44 O +
promoter O -
- O -
chloramphenicol O +
acetyltransferase O +
reporter O +
construct O +
with O +
an O +
egr-1 O +
expression O +
vector O +
resulted O +
in O +
a O +
6.5- O +
to O +
8.5-fold O +
induction O +
of O +
transcriptional O +
activity O +
relative O +
to O +
an O +
empty O +
expression O +
vector O +
. O +

The O +
EGR1 O +
binding O +
motif O +
was O +
shown O +
to O +
be O +
necessary O +
for O +
stimulus O -
- O -
induced O +
expression O +
of O +
a O +
CD44 O +
promoter O -
- O -
chloramphenicol O +
acetyltransferase O +
reporter O +
construct O +
in O +
nontransformed O +
B O +
lymphocytes O +
and O +
was O +
required O +
for O +
transactivation O +
by O +
an O +
EGR1 O +
expression O +
vector O +
in O +
a O +
B B-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
. O +

These O +
studies O +
identify O +
EGR1 O +
as O +
an O +
intermediary O +
linking O +
BCR O +
-derived O +
signals O +
to O +
the O +
induction O +
of O +
CD44 O +
. O +

The O +
relevance O +
of O +
these O +
molecular O +
events O +
to O +
BCR O +
signal O +
transduction O +
and O +
antigen O -
- O -
stimulated O +
B O -
- O -
cell O -
- O -
mediated O +
immune O +
responses O +
is O +
discussed O +
. O +

Identification O +
of O +
an O +
inducible O +
regulator O +
of O +
c O -
- O -
myb O +
expression O +
during O +
T O -
- O -
cell O +
activation O +
. O +

Resting O +
T O +
cells O +
express O +
very O +
low O +
levels O +
of O +
c O -
- O -
Myb O +
protein O +
. O +

During O +
T O -
- O -
cell O +
activation O +
, O +
c O -
- O -
myb O +
expression O +
is O +
induced O +
and O +
much O +
of O +
the O +
increase O +
in O +
expression O +
occurs O +
at O +
the O +
transcriptional O +
level O +
. O +

We O +
identified O +
a O +
region O +
of O +
the O +
c O -
- O -
myb O +
5 O +
' O +
flanking O +
sequence O +
that O +
increased O +
c O -
- O -
myb O +
expression O +
during O +
T O -
- O -
cell O +
activation O +
. O +

In O +
vivo O +
footprinting O +
by O +
ligation O -
- O -
mediated O +
PCR O +
was O +
performed O +
to O +
correlate O +
in O +
vivo O +
protein O +
binding O +
with O +
functional O +
activity O +
. O +

A O +
protein O +
footprint O +
was O +
visible O +
over O +
this O +
region O +
of O +
the O +
c O -
- O -
myb O +
5 O +
' O +
flanking O +
sequence O +
in O +
activated O +
T O +
cells O +
but O +
not O +
in O +
unactivated O +
T O +
cells O +
. O +

An O +
electrophoretic O +
mobility O +
shift O +
assay O +
( O +
EMSA O +
) O +
with O +
nuclear O +
extract O +
from O +
activated O +
T O +
cells O +
and O +
an O +
oligonucleotide O +
of O +
this O +
binding O +
site O +
demonstrated O +
a O +
new O +
protein O -
- O -
DNA O +
complex O +
, O +
referred O +
to O +
as O +
CMAT O +
for O +
c O -
- O -
myb O +
in O +
activated O +
T O +
cells O +
; O +
this O +
complex O +
was O +
not O +
present O +
in O +
unactivated O +
T O +
cells O +
. O +

Because O +
the O +
binding O +
site O +
showed O +
some O +
sequence O +
similarity O +
with O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
binding O +
site O +
, O +
we O +
compared O +
the O +
kinetics O +
of O +
induction O +
of O +
the O +
two O +
binding O +
complexes O +
and O +
the O +
molecular O +
masses O +
of O +
the O +
two O +
proteins O +
. O +

Studies O +
of O +
the O +
kinetics O +
of O +
induction O +
showed O +
that O +
the O +
NFAT O +
EMSA O +
binding O +
complex O +
appeared O +
earlier O +
than O +
the O +
CMAT O +
complex O +
. O +

The O +
NFAT O +
protein O +
migrated O +
more O +
slowly O +
in O +
a O +
sodium O +
dodecyl O +
sulfate O -
- O -
polyacrylamide O +
gel O +
than O +
the O +
CMAT O +
protein O +
did O +
. O +

In O +
addition O +
, O +
an O +
antibody O +
against O +
NFAT O +
did O +
not O +
cross O -
- O -
react O +
with O +
the O +
CMAT O +
protein O +
. O +

The O +
appearance O +
of O +
the O +
CMAT O +
binding O +
complex O +
was O +
inhibited O +
by O +
both O +
cyclosporin O +
A O +
and O +
rapamycin O +
. O +

The O +
CMAT O +
protein O +
appears O +
to O +
be O +
a O +
novel O +
inducible O +
protein O +
involved O +
in O +
the O +
regulation O +
of O +
c O -
- O -
myb O +
expression O +
during O +
T O -
- O -
cell O +
activation O +
. O +

Identification O +
of O +
a O +
herpesvirus O +
Saimiri O +
cis O -
- O -
acting O +
DNA O +
fragment O +
that O +
permits O +
stable O +
replication O +
of O +
episomes O +
in O +
transformed O +
T O +
cells O +
. O +

Herpesvirus O +
saimiri O +
is O +
a O +
lymphotropic O +
herpesvirus O +
capable O +
of O +
immortalizing O +
and O +
transforming O +
T O +
cells O +
both O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

Immortalized O +
and O +
transformed O +
T O +
cells O +
harbor O +
several O +
copies O +
of O +
the O +
viral O +
genome O +
as O +
a O +
persisting O +
genome O +
. O +

The O +
mapping O +
of O +
the O +
cis O -
- O -
acting O +
genetic O +
cis O -
- O -
acting O +
segment O +
( O +
oriP O +
) O +
required O +
for O +
viral O +
episomal O +
maintenance O +
is O +
reported O +
here O +
. O +

Viral O +
DNA O +
fragments O +
that O +
potentially O +
contain O +
oriP O +
were O +
cloned O +
into O +
a O +
plasmid O +
that O +
contains O +
the O +
hygromycin O +
resistance O +
gene O +
. O +

After O +
several O +
round O +
of O +
subcloning O +
followed O +
by O +
transfection O +
, O +
oriP O +
was O +
mapped O +
to O +
a O +
1.955-kb O +
viral O +
segment O +
. O +

This O +
viral O +
fragment O +
permits O +
stable O +
plasmid O +
replication O +
without O +
deletion O +
or O +
rearrangement O +
as O +
well O +
as O +
episomal O +
maintenance O +
without O +
integration O +
or O +
recombination O +
. O +

The O +
function O +
of O +
oriP O +
depends O +
on O +
a O +
trans O -
- O -
acting O +
factor O +
( O +
s O +
) O +
encoded O +
by O +
the O +
viral O +
genome O +
. O +

The O +
1.955-kb O +
viral O +
segment O +
includes O +
a O +
dyad O +
symmetry O +
region O +
located O +
between O +
two O +
small O +
nuclear O +
RNA O +
genes O +
and O +
is O +
located O +
upstream O +
of O +
the O +
dihydrofolate O +
reductase O +
gene O +
homolog O +
. O +

Therefore O +
, O +
this O +
oriP O +
contains O +
novel O +
elements O +
distinct O +
from O +
those O +
of O +
other O +
DNA O +
viruses O +
. O +

Regulation O +
of O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
in O +
stably O +
transfected O +
Jurkat B-CellLine +
cell I-CellLine +
clones I-CellLine +
. O +

Two O +
Jurkat B-CellLine +
cell I-CellLine +
clones I-CellLine +
have O +
been O +
stably O +
transfected O +
with O +
a O +
reporter O +
vector O +
for O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
. O +

Upon O +
stimulation O +
, O +
they O +
express O +
high O +
levels O +
of O +
secreted O +
heat O +
stable O +
placental O +
alkaline O +
phosphatase O +
. O +

With O +
these O +
clones O +
, O +
we O +
demonstrated O +
that O +
NFAT O +
activation O +
induced O +
by O +
phorbol O +
12-myristate O +
13-acetate O +
and O +
ionomycin O +
was O +
inhibited O +
by O +
both O +
cyclosporin O +
A O +
( O +
CsA O +
) O +
( O +
IC50 O +
= O +
8 O +
nM O +
) O +
and O +
FK506 O +
( O +
IC50 O +
= O +
160 O +
pM O +
) O +
, O +
presumably O +
by O +
inhibition O +
of O +
calcineurin O +
activity O +
. O +

Selective O +
phosphatase O +
inhibitors O +
for O +
protein O +
phosphatase O +
1 O +
( O +
PP1 O +
) O +
and O +
2A O +
( O +
PP2A O +
) O +
that O +
do O +
not O +
inhibit O +
calcineurin O +
, O +
such O +
as O +
okadaic O +
acid O +
and O +
calyculin O +
A O +
, O +
also O +
inhibited O +
NFAT O +
activation O +
with O +
IC50s O +
of O +
87 O +
nM O +
and O +
4 O +
nM O +
, O +
respectively O +
, O +
suggesting O +
that O +
okadaic O +
acid O +
and O +
related O +
inhibitors O +
may O +
block O +
NFAT O +
activation O +
through O +
the O +
inhibition O +
of O +
PP1 O +
, O +
instead O +
of O +
PP2A O +
. O +

NFAT O +
activation O +
was O +
also O +
inhibited O +
by O +
agents O +
that O +
increase O +
cAMP O +
concentrations O +
such O +
as O +
dibutyryl O +
cAMP O +
, O +
forskolin O +
and O +
prostaglandin O +
E2 O +
. O +

These O +
stable O +
Jurkat B-CellLine +
cell I-CellLine +
clones I-CellLine +
provide O +
a O +
convenient O +
and O +
sensitive O +
tool O +
to O +
study O +
NFAT O +
regulation O +
. O +

Menopause O +
is O +
associated O +
with O +
a O +
significant O +
increase O +
in O +
blood O +
monocyte O +
number O +
and O +
a O +
relative O +
decrease O +
in O +
the O +
expression O +
of O +
estrogen O +
receptors O +
in O +
human O +
peripheral O +
monocytes O +
. O +

PROBLEM O +
: O +
The O +
clinical O +
significance O +
of O +
the O +
differential O +
expression O +
of O +
estrogen O +
receptor O +
( O +
ER O +
) O +
in O +
human O +
monocytes O +
was O +
evaluated O +
. O +

METHOD O +
: O +
Two O +
color O +
flow O +
cytometry O +
analysis O +
was O +
used O +
on O +
peripheral O +
blood O +
samples O +
of O +
young O +
and O +
postmenopausal O +
females O +
and O +
postmenopausal O +
females O +
treated O +
with O +
estrogen O +
replacement O +
therapy O +
. O +

In O +
addition O +
, O +
the O +
monocyte O +
and O +
lymphocyte O +
counts O +
and O +
the O +
blood O +
estrogen O +
levels O +
of O +
each O +
patient O +
were O +
determine O +
. O +

RESULTS O +
: O +
During O +
menopause O +
there O +
is O +
a O +
significant O +
decrease O +
in O +
the O +
percentage O +
of O +
ER O +
positive O +
monocytes O +
, O +
and O +
an O +
increase O +
in O +
blood O +
monocyte O +
number O +
, O +
which O +
declines O +
following O +
estrogen O +
replacement O +
therapy O +
to O +
values O +
of O +
the O +
young O +
. O +

CONCLUSIONS O +
: O +
These O +
findings O +
suggest O +
that O +
estrogen O +
modulates O +
the O +
monocyte O +
numbers O +
and O +
its O +
effects O +
may O +
be O +
mediated O +
through O +
the O +
ER O +
in O +
the O +
monocytes O +
. O +

Modulation O +
of O +
endogenous O +
IL-1 O +
beta O +
and O +
IL-1 O +
receptor O +
antagonist O +
results O +
in O +
opposing O +
effects O +
on O +
HIV O +
expression O +
in O +
chronically B-CellLine +
infected I-CellLine +
monocytic I-CellLine +
cells I-CellLine +
. O +

A O +
proportion O +
of O +
HIV O -
- O -
infected O +
individuals O +
experience O +
episodes O +
of O +
localized O +
or O +
systemic O +
bacterial O +
infections O +
caused O +
by O +
Gram O -
- O -
negative O +
bacteria O +
. O +

Many O +
of O +
the O +
clinical O +
side O +
effects O +
of O +
these O +
infections O +
are O +
associated O +
with O +
the O +
production O +
of O +
proinflammatory O +
cytokines O +
, O +
which O +
are O +
induced O +
primarily O +
by O +
LPS O +
, O +
a O +
constituent O +
of O +
the O +
bacterial O +
cell O +
wall O +
of O +
Gram O -
- O -
negative O +
bacteria O +
. O +

The O +
present O +
study O +
examines O +
the O +
mechanisms O +
involved O +
in O +
LPS O -
- O -
mediated O +
induction O +
of O +
HIV O +
expression O +
in O +
U1 B-CellLine +
cells I-CellLine +
, O +
a O +
promonocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
chronically O +
infected O +
with O +
HIV O +
. O +

Stimulation O +
of O +
U1 B-CellLine +
cells I-CellLine +
by O +
LPS O +
alone O +
induced O +
minimal O +
levels O +
of O +
HIV O +
expression O +
, O +
which O +
was O +
significantly O +
enhanced O +
by O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
. O +

Costimulation O +
of O +
U1 B-CellLine +
cells I-CellLine +
with O +
LPS O +
plus O +
GM O -
- O -
CSF O +
resulted O +
in O +
the O +
accumulation O +
of O +
steady O -
- O -
state O +
levels O +
of O +
HIV O +
RNA O +
; O +
however O +
, O +
only O +
a O +
weak O +
induction O +
of O +
HIV O +
long O +
terminal O +
repeat O +
-driven O +
transcription O +
, O +
which O +
was O +
not O +
associated O +
with O +
the O +
activation O +
of O +
the O +
cellular O +
transcription O +
factor O +
nuclear O +
factor O -
- O -
kappa O +
B O +
, O +
was O +
noted O +
. O +

Costimulation O +
of O +
cells O +
with O +
LPS O +
plus O +
GM O -
- O -
CSF O +
induced O +
the O +
production O +
of O +
proinflammatory O +
cytokines O +
, O +
IL-8 O +
, O +
IL-1 O +
beta O +
and O +
IL-6 O +
, O +
but O +
not O +
TNF O -
- O -
alpha O +
. O +

IL-1 O +
receptor O +
antagonist O +
( O +
ra O +
) O +
inhibited O +
LPS O +
enhancement O +
of O +
HIV O +
expression O +
in O +
GM B-CellLine -
- I-CellLine -
CSF I-CellLine -
- I-CellLine -
stimulated I-CellLine +
cells I-CellLine +
, O +
suggesting O +
that O +
endogenous O +
IL-1 O +
was O +
involved O +
in O +
LPS O -
- O -
mediated O +
viral O +
production O +
. O +

In O +
this O +
regard O +
, O +
anti O -
- O -
inflammatory O +
cytokines O +
inhibited O +
LPS O +
plus O +
GM O -
- O -
CSF O +
-stimulated O +
HIV O +
expression O +
, O +
and O +
this O +
effect O +
closely O +
correlated O +
with O +
inhibition O +
of O +
IL-1 O +
beta O +
release O +
and O +
, O +
in O +
particular O +
, O +
with O +
up O -
- O -
regulation O +
of O +
endogenous O +
IL-1ra O +
production O +
. O +

Thus O +
, O +
the O +
balance O +
between O +
an O +
endogenously O +
produced O +
viral O +
inducer O +
( O +
IL-1 O +
beta O +
) O +
and O +
an O +
inhibitor O +
( O +
IL-1ra O +
) O +
may O +
represent O +
an O +
important O +
pathway O +
leading O +
to O +
modulation O +
of O +
HIV O +
expression O +
from O +
monocytic O +
cells O +
. O +

Monocytic O +
cell O +
type O -
- O -
specific O +
transcriptional O +
induction O +
of O +
collagenase O +
. O +

Interstitial O +
collagenase O +
( O +
MMP-1 O +
) O +
, O +
a O +
metalloproteinase O +
produced O +
by O +
resident O +
and O +
inflammatory O +
cells O +
during O +
connective O +
tissue O +
turnover O +
, O +
cleaves O +
type O +
I O +
collagen O +
fibrils O +
. O +

This O +
catalytic O +
event O +
is O +
rate O +
limiting O +
in O +
remodeling O +
of O +
tissues O +
rich O +
in O +
fibrillar O +
collagen O +
such O +
as O +
the O +
skin O +
and O +
lungs O +
. O +

The O +
regulation O +
of O +
collagenase O +
expression O +
is O +
cell O -
- O -
type O +
specific O +
; O +
bacterial O +
LPS O +
and O +
zymosan O +
, O +
a O +
yeast O +
cell O +
wall O +
derivative O +
, O +
are O +
potent O +
inducers O +
of O +
collagenase O +
expression O +
in O +
macrophages O +
, O +
but O +
do O +
not O +
alter O +
fibroblast O +
collagenase O +
expression O +
. O +

Since O +
promoter O +
elements O +
controlling O +
collagenase O +
transcription O +
in O +
monocytic O +
cells O +
have O +
not O +
been O +
previously O +
defined O +
, O +
we O +
sought O +
to O +
delineate O +
responsive O +
cis O -
- O -
acting O +
elements O +
of O +
the O +
collagenase O +
promoter O +
in O +
transiently O +
transfected O +
human B-CellLine +
( I-CellLine +
U937 I-CellLine +
) I-CellLine +
and I-CellLine +
murine I-CellLine +
( I-CellLine +
J774 I-CellLine +
) I-CellLine +
monocytic I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Deletion O +
constructs O +
containing O +
as O +
little O +
as O +
72 O +
bp O +
of O +
5 O +
' O +
-flanking O +
sequence O +
of O +
the O +
collagenase O +
promoter O +
were O +
sufficient O +
for O +
LPS- O +
or O +
zymosan O -
- O -
mediated O +
transcriptional O +
induction O +
, O +
whereas O +
phorbol O +
inducibility O +
exhibited O +
an O +
absolute O +
requirement O +
for O +
upstream O +
elements O +
including O +
the O +
polyoma O +
enhancer O +
A O -
- O -
binding O +
protein-3 O +
site O +
( O +
-83 O +
to O +
-91 O +
) O +
and O +
TTCA O +
sequence O +
( O +
-102 O +
to O +
-105 O +
) O +
in O +
both O +
monocytic O +
cells O +
and O +
fibroblasts O +
. O +

Mutagenesis O +
of O +
the O +
activator O +
protein-1 O +
[ O +
AP-1 O +
] O +
site O +
at O +
-72 O +
abolished O +
basal O +
promoter O +
activity O +
and O +
LPS O -
/ O -
zymosan O +
inducibility O +
, O +
while O +
mutagenesis O +
of O +
an O +
NF O -
- O -
kappaB O -
- O -
like O +
site O +
at O +
-20 O +
to O +
-10 O +
had O +
no O +
effect O +
. O +

Nuclear O +
extracts O +
from O +
LPS O +
-and O +
zymosan O -
- O -
treated O +
cells O +
showed O +
strong O +
AP-1 O +
activity O +
by O +
gel O -
- O -
shift O +
analysis O +
, O +
and O +
supershift O +
analysis O +
showed O +
the O +
AP-1 O +
complexes O +
contained O +
specific O +
members O +
of O +
both O +
the O +
jun O +
and O +
fos O +
gene O +
families O +
. O +

These O +
data O +
indicate O +
that O +
, O +
in O +
contrast O +
to O +
most O +
LPS O +
effects O +
, O +
AP-1 O +
, O +
but O +
not O +
nuclear O +
factor O -
- O -
kappaB O +
, O +
mediates O +
LPS O +
induction O +
of O +
collagenase O +
transcription O +
in O +
macrophagelike O +
cells O +
. O +

Furthermore O +
, O +
as O +
compared O +
to O +
regulation O +
by O +
phorbol O +
ester O +
, O +
collagenase O +
induction O +
in O +
monocytic O +
cells O +
by O +
cell O +
wall O +
derivatives O +
of O +
bacteria O +
or O +
yeast O +
is O +
largely O +
independent O +
of O +
upstream O +
promoter O +
sequences O +
. O +

Rel O -
- O -
deficient O +
T O +
cells O +
exhibit O +
defects O +
in O +
production O +
of O +
interleukin O +
3 O +
and O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
. O +

The O +
c O -
- O -
rel O +
protooncogene O +
encodes O +
a O +
subunit O +
of O +
the O +
NF O -
- O -
kappa O +
B O -
- O -
like O +
family O +
of O +
transcription O +
factors O +
. O +

Mice O +
lacking O +
Rel O +
are O +
defective O +
in O +
mitogenic O +
activation O +
of O +
B O +
and O +
T O +
lymphocytes O +
and O +
display O +
impaired O +
humoral O +
immunity O +
. O +

In O +
an O +
attempt O +
to O +
identify O +
changes O +
in O +
gene O +
expression O +
that O +
accompany O +
the O +
T O -
- O -
cell O +
stimulation O +
defects O +
associated O +
with O +
the O +
loss O +
of O +
Rel O +
, O +
we O +
have O +
examined O +
the O +
expression O +
of O +
cell O +
surface O +
activation O +
markers O +
and O +
cytokine O +
production O +
in O +
mitogen O -
- O -
stimulated O +
Rel- O -
/ O -
- O +
T O +
cells O +
. O +

The O +
expression O +
of O +
cell O +
surface O +
markers O +
including O +
the O +
interleukin O +
2 O +
receptor O +
alpha O +
( O +
IL-2R O +
alpha O +
) O +
chain O +
( O +
CD25 O +
) O +
, O +
CD69 O +
and O +
L O -
- O -
selectin O +
( O +
CD62 O +
) O +
is O +
normal O +
in O +
mitogen B-CellLine -
- I-CellLine -
activated I-CellLine +
Rel- I-CellLine -
/ I-CellLine -
- I-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
but O +
cytokine O +
production O +
is O +
impaired O +
. O +

In O +
Rel- B-CellLine -
/ I-CellLine -
- I-CellLine +
splenic I-CellLine +
T I-CellLine +
cell I-CellLine +
cultures I-CellLine +
stimulated O +
with O +
phorbol O +
12-myristate O +
13-acetate O +
and O +
ionomycin O +
, O +
the O +
levels O +
of O +
IL-3 O +
, O +
IL-5 O +
, O +
granulocyte- O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
, O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
, O +
and O +
gamma O +
interferon O +
( O +
IFN O -
- O -
gamma O +
) O +
were O +
only O +
2- O +
to O +
3-fold O +
lower O +
compared O +
with O +
normal O +
T O +
cells O +
. O +

In O +
contrast O +
, O +
anti O -
- O -
CD3 O +
and O +
anti O -
- O -
CD28 O +
stimulated O +
Rel- B-CellLine -
/ I-CellLine -
- I-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
which O +
fail O +
to O +
proliferate O +
, O +
make O +
little O +
or O +
no O +
detectable O +
cytokines O +
. O +

Exogenous O +
IL-2 O +
, O +
which O +
restitutes O +
the O +
proliferative O +
response O +
of O +
the O +
anti B-CellLine -
- I-CellLine -
CD3- I-CellLine +
and I-CellLine +
anti I-CellLine -
- I-CellLine -
CD28-treated I-CellLine +
Rel- I-CellLine -
/ I-CellLine -
- I-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
restores O +
production O +
of O +
IL-5 O +
, O +
TNF O -
- O -
alpha O +
, O +
and O +
IFN O -
- O -
gamma O +
, O +
but O +
not O +
IL-3 O +
and O +
GM O -
- O -
CSF O +
expression O +
to O +
approximately O +
normal O +
levels O +
. O +

In O +
contrast O +
to O +
mitogen B-CellLine -
- I-CellLine -
activated I-CellLine +
Rel- I-CellLine -
/ I-CellLine -
- I-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
lipopolysaccharide O -
- O -
stimulated O +
Rel- B-CellLine -
/ I-CellLine -
- I-CellLine +
macrophages I-CellLine +
produce O +
higher O +
than O +
normal O +
levels O +
of O +
GM O -
- O -
CSF O +
. O +

These O +
findings O +
establish O +
that O +
Rel O +
can O +
function O +
as O +
an O +
activator O +
or O +
repressor O +
of O +
gene O +
expression O +
and O +
is O +
required O +
by O +
T O +
lymphocytes O +
for O +
production O +
of O +
IL-3 O +
and O +
GM O -
- O -
CSF O +
. O +

Interferon O -
- O -
gamma O +
modulates O +
the O +
lipopolysaccharide O -
- O -
induced O +
expression O +
of O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B O +
at O +
the O +
mRNA O +
and O +
protein O +
level O +
in O +
human O +
monocytes O +
. O +

Interferon O -
- O -
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
modulates O +
the O +
expression O +
of O +
several O +
cytokines O +
by O +
human O +
monocytes O +
at O +
the O +
transcriptional O +
level O +
. O +

In O +
view O +
of O +
these O +
findings O +
, O +
we O +
analyzed O +
the O +
effects O +
of O +
IFN O -
- O -
gamma O +
on O +
the O +
expression O +
of O +
different O +
transcription O +
factors O +
in O +
activated O +
human O +
monocytes O +
. O +

Priming O +
of O +
human O +
monocytes O +
with O +
IFN O -
- O -
gamma O +
resulted O +
in O +
the O +
down O +
regulation O +
of O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
mRNA O +
in O +
response O +
to O +
stimulation O +
with O +
lipopolysaccharide O +
( O +
LPS O +
) O +
compared O +
to O +
the O +
effects O +
of O +
LPS O +
alone O +
. O +

Not O +
only O +
was O +
this O +
effect O +
observed O +
at O +
the O +
mRNA O +
level O +
, O +
but O +
activator O +
protein-1 O +
( O +
AP-1 O +
) O +
DNA O +
binding O +
capacity O +
was O +
affected O +
as O +
well O +
, O +
A O +
strong O +
reduction O +
was O +
observed O +
in O +
the O +
LPS O -
- O -
induced O +
DNA O -
- O -
binding O +
activity O +
of O +
AP-1 O +
in O +
the O +
presence O +
of O +
IFN O -
- O -
gamma O +
. O +

LPS O -
- O -
stimulated O +
monocytes O +
showed O +
an O +
increased O +
expression O +
of O +
p105 O +
mRNA O +
, O +
the O +
precursor O +
of O +
the O +
p50 O +
subunit O +
of O +
the O +
transcription O +
factor O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
, O +
while O +
no O +
effect O +
was O +
noticed O +
on O +
the O +
expression O +
of O +
p65 O +
mRNA O +
. O +

In O +
contrast O +
, O +
IFN O -
- O -
gamma O +
priming O +
did O +
not O +
affect O +
the O +
expression O +
of O +
p105 O +
transcripts O +
but O +
enhanced O +
the O +
expression O +
of O +
p65 O +
mRNA O +
( O +
two O -
- O -
fold O +
) O +
. O +

Priming O +
with O +
IFN O -
- O -
gamma O +
followed O +
by O +
LPS O +
stimulation O +
resulted O +
in O +
a O +
further O +
increase O +
in O +
the O +
expression O +
of O +
p65 O +
mRNA O +
. O +

This O +
was O +
due O +
to O +
an O +
increase O +
in O +
the O +
half O -
- O -
life O +
of O +
p65 O +
mRNA O +
( O +
75 O +
vs O +
150 O +
minutes O +
) O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
( O +
EMSAs O +
) O +
demonstrated O +
that O +
unstimulated O +
monocytes O +
predominantly O +
expressed O +
p50 O +
NF O -
- O -
kappa O +
B O +
. O +

Stimulation O +
with O +
LPS O +
or O +
IFN O -
- O -
gamma O +
resulted O +
in O +
the O +
expression O +
of O +
p50 O +
and O +
p65 O +
subunits O +
, O +
while O +
the O +
combination O +
of O +
IFN O -
- O -
gamma O +
plus O +
LPS O +
caused O +
a O +
further O +
increase O +
in O +
the O +
expression O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

With O +
Western O +
blotting O +
, O +
it O +
was O +
shown O +
that O +
nuclear O +
extracts O +
from O +
monocytes O +
contained O +
p50 O +
and O +
p65 O +
protein O +
in O +
response O +
to O +
LPS O +
and O +
IFN O -
- O -
gamma O +
stimulation O +
. O +

However O +
, O +
the O +
combined O +
stimulation O +
did O +
not O +
result O +
in O +
enhanced O +
p50 O +
and O +
p65 O +
protein O +
expression O +
. O +

The O +
effects O +
of O +
IFN O -
- O -
gamma O +
on O +
the O +
transcription O +
factors O +
were O +
specific O +
, O +
since O +
no O +
change O +
was O +
observed O +
in O +
the O +
expression O +
of O +
NF O -
- O -
IL-6 O +
or O +
I O +
kappa O +
B O +
alpha O +
, O +
the O +
inhibitor O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

We O +
conclude O +
that O +
the O +
effects O +
of O +
IFN O -
- O -
gamma O +
on O +
the O +
expression O +
of O +
the O +
transcription O +
factors O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B O +
may O +
be O +
important O +
for O +
the O +
modulatory O +
effects O +
of O +
IFN O -
- O -
gamma O +
on O +
the O +
cytokine O +
expression O +
in O +
activated O +
human O +
monocytes O +
. O +

Transcriptional O +
basis O +
for O +
hyporesponsiveness O +
of O +
the O +
human O +
inducible O +
nitric O +
oxide O +
synthase O +
gene O +
to O +
lipopolysaccharide O -
/ O -
interferon O -
- O -
gamma O +
. O +

The O +
work O +
reported O +
here O +
resolves O +
, O +
at O +
the O +
level O +
of O +
gene O +
regulation O +
, O +
the O +
controversy O +
as O +
to O +
whether O +
or O +
not O +
human O +
monocytes O -
/ O -
macrophages O +
can O +
produce O +
nitric O +
oxide O +
( O +
NO O +
) O +
when O +
stimulated O +
with O +
lipopolysaccharide O +
( O +
LPS O +
) O +
, O +
with O +
or O +
without O +
co O -
- O -
stimulation O +
by O +
interferon O -
- O -
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
. O +

Studies O +
included O +
structural O +
comparison O +
of O +
the O +
promoters O +
for O +
human O +
and O +
mouse O +
inducible O +
NO O +
synthase O +
( O +
iNOS O +
) O +
genes O +
, O +
transfection O +
and O +
assay O +
of O +
human O +
and O +
mouse O +
iNOS O +
promoter O +
regions O +
in O +
response O +
to O +
LPS O +
+ O -
/- O +
IFN O -
- O -
gamma O +
, O +
and O +
electrophoretic O +
mobility O +
shift O +
assays O +
of O +
kappa O +
B O +
response O +
elements O +
. O +

Two O +
explanations O +
for O +
hyporesponsiveness O +
of O +
the O +
human O +
iNOS O +
promoter O +
to O +
LPS O +
+ O -
/- O +
IFN O -
- O -
gamma O +
were O +
found O +
: O +
( O +
1 O +
) O +
multiple O +
inactivating O +
nucleotide O +
substitutions O +
in O +
the O +
human O +
counterpart O +
of O +
the O +
enhancer O +
element O +
that O +
has O +
been O +
shown O +
to O +
regulate O +
LPS O -
/ O +
IFN O -
- O -
gamma O +
induced O +
expression O +
of O +
the O +
mouse O +
iNOS O +
gene O +
; O +
and O +
( O +
2 O +
) O +
and O +
absence O +
of O +
one O +
or O +
more O +
nuclear O +
factors O +
in O +
human O +
macrophages O +
( O +
e.g. O +
, O +
an O +
LPS O -
- O -
inducible O +
nuclear O +
factor O -
- O -
kappa O +
B O -
/ O -
Rel O +
complex O +
) O +
, O +
that O +
is O +
( O +
are O +
) O +
required O +
for O +
maximal O +
expression O +
of O +
the O +
gene O +
. O +

The O +
importance O +
of O +
resolution O +
of O +
this O +
controversy O +
is O +
that O +
future O +
research O +
in O +
this O +
area O +
should O +
be O +
directed O +
toward O +
the O +
understanding O +
of O +
alternative O +
mechanisms O +
that O +
can O +
result O +
in O +
the O +
successful O +
production O +
of O +
NO O +
. O +

STAT O -
- O -
related O +
transcription O +
factors O +
are O +
constitutively O +
activated O +
in O +
peripheral O +
blood O +
cells O +
from O +
acute O +
leukemia O +
patients O +
. O +

A O +
signal O +
transduction O +
pathway O +
activated O +
by O +
many O +
cytokines O +
has O +
recently O +
been O +
elaborated O +
. O +

The O +
JAK O +
kinases O +
and O +
the O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
STAT O +
) O +
factors O +
have O +
been O +
found O +
to O +
be O +
essential O +
components O +
. O +

In O +
this O +
report O +
, O +
we O +
describe O +
the O +
presence O +
of O +
constitutively O +
activated O +
STAT O +
factors O +
in O +
peripheral O +
blood O +
cells O +
from O +
patients O +
with O +
acute O +
leukemia O +
. O +

We O +
used O +
oligonucleotide O +
probes O +
from O +
the O +
beta O -
- O -
casein O +
and O +
IRF-1 O +
gene O +
promoters O +
and O +
the O +
ISRE O +
probe O +
to O +
detect O +
STAT O +
proteins O +
in O +
nuclear O +
extracts O +
from O +
acute O +
leukemia O +
cells O +
in O +
bandshift O +
assays O +
. O +

Specific O +
DNA O +
protein O +
complex O +
formation O +
was O +
observed O +
with O +
the O +
probes O +
from O +
the O +
beta O -
- O -
casein O +
and O +
IRF-1 O +
gene O +
promoters O +
, O +
but O +
not O +
with O +
the O +
ISRE O +
oligonucleotide O +
probe O +
, O +
when O +
cell O +
extracts O +
from O +
acute O +
lymphoblastic O +
leukemia O +
( O +
ALL O +
) O +
and O +
acute O +
myeloid O +
leukemia O +
( O +
AML O +
) O +
were O +
investigated O +
. O +

We O +
used O +
nonradioactive O +
oligonucleotides O +
as O +
competitors O +
to O +
show O +
the O +
specificity O +
of O +
the O +
complex O +
formation O +
. O +

Specific O +
antibodies O +
directed O +
against O +
the O +
individual O +
STAT O +
proteins O +
were O +
used O +
in O +
supershift O +
experiments O +
. O +

STAT5- O +
and O +
STAT1-related O +
factors O +
were O +
detected O +
in O +
ALL O +
and O +
STAT1- O +
, O +
STAT3- O +
, O +
and O +
STAT5-related O +
proteins O +
were O +
present O +
in O +
nuclear O +
cell O +
extracts O +
from O +
AML O +
. O +

Since O +
the O +
cells O +
were O +
not O +
treated O +
with O +
cytokines O +
before O +
the O +
nuclear O +
proteins O +
were O +
extracted O +
, O +
we O +
conclude O +
that O +
these O +
factors O +
are O +
constitutively O +
activated O +
in O +
vivo O +
. O +

It O +
is O +
likely O +
that O +
the O +
constitutive O +
activation O +
of O +
STAT O +
proteins O +
is O +
a O +
part O +
of O +
the O +
events O +
of O +
leukemogenesis O +
. O +

The O +
RAR O -
- O -
RXR O +
as O +
well O +
as O +
the O +
RXR O -
- O -
RXR O +
pathway O +
is O +
involved O +
in O +
signaling O +
growth O +
inhibition O +
of O +
human B-CellLine +
CD34 I-CellLine -
+ I-CellLine +
erythroid I-CellLine +
progenitor I-CellLine +
cells I-CellLine +
. O +

Previous O +
studies O +
have O +
shown O +
that O +
retinoic O +
acid O +
( O +
RA O +
) O +
, O +
similar O +
to O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
, O +
can O +
act O +
as O +
a O +
bifunctional O +
regulator O +
of O +
the O +
growth O +
of O +
bone O +
marrow O +
progenitors O +
, O +
in O +
that O +
it O +
can O +
stimulate O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
- O +
or O +
interleukin-3 O +
( O +
IL-3 O +
) O +
-induced O +
GM O +
colony O +
formation O +
, O +
but O +
potently O +
inhibit O +
G O -
- O -
CSF O +
-induced O +
growth O +
. O +

The O +
present O +
study O +
, O +
using O +
highly O +
enriched O +
human O +
CD34 O -
+ O +
as O +
well O +
as O +
Lin- B-CellLine +
murine I-CellLine +
bone I-CellLine +
marrow I-CellLine +
progenitor I-CellLine +
cells I-CellLine +
, O +
demonstrates O +
a O +
potent O +
inhibitory O +
effect O +
of O +
9-cis O -
- O -
RA O +
on O +
burst O -
- O -
forming O +
unit O -
- O -
erythroid O +
( O +
BFU O -
- O -
E O +
) O +
colony O +
formation O +
regardless O +
of O +
the O +
cytokine O +
stimulating O +
growth O +
. O +

Specifically O +
, O +
9-cis O -
- O -
RA O +
potently O +
inhibited O +
the O +
growth O +
of O +
BFU O -
- O -
E O +
response O +
to O +
erythropoietin O +
( O +
Epo O +
) O +
( O +
100 O +
% O +
) O +
, O +
stem O +
cell O +
factor O +
( O +
SCF O +
) O +
+ O +
Epo O +
( O +
92 O +
% O +
) O +
, O +
IL-3 O +
+ O +
Epo O +
( O +
97 O +
% O +
) O +
, O +
IL-4 O +
+ O +
Epo O +
( O +
88 O +
% O +
) O +
, O +
and O +
IL-9 O +
+ O +
Epo O +
( O +
100 O +
% O +
) O +
. O +

Erythroid O +
colony O +
growth O +
was O +
also O +
inhibited O +
when O +
CD34 O -
+ O +
progenitors O +
were O +
seeded O +
at O +
one O +
cell O +
per O +
well O +
, O +
suggesting O +
a O +
direct O +
action O +
of O +
RA O +
. O +

Using O +
synthetic O +
ligands O +
to O +
retinoic O +
acid O +
receptors O +
( O +
RARs O +
) O +
and O +
retinoid O +
X O +
receptors O +
( O +
RXRs O +
) O +
that O +
selectively O +
bind O +
and O +
activate O +
RAR O -
- O -
RXR O +
or O +
RXR O -
- O -
RXR O +
dimers O +
, O +
respectively O +
, O +
we O +
dissected O +
the O +
involvement O +
of O +
the O +
two O +
retinoid O +
response O +
pathways O +
in O +
the O +
regulation O +
of O +
normal O +
myeloid O +
and O +
erythroid O +
progenitor O +
cell O +
growth O +
. O +

Transactivation O +
studies O +
showed O +
that O +
both O +
the O +
RAR O +
( O +
Ro O +
13 O -
- O -
7410 O +
) O +
and O +
RXR O +
( O +
Ro O +
25 O -
- O -
6603 O +
and O +
Ro O +
25 O -
- O -
7386 O +
) O +
ligands O +
were O +
highly O +
selective O +
at O +
100 O +
nmol O -
/ O -
L O +
. O +

At O +
this O +
concentration O +
, O +
Ro O +
13 O -
- O -
7410 O +
potently O +
inhibited O +
G O -
- O -
CSF O +
-stimulated O +
myeloid O +
as O +
well O +
as O +
SCF O +
+ O +
Epo O +
-induced O +
erythroid O +
colony O +
growth O +
. O +

At O +
the O +
same O +
concentration O +
, O +
Ro O +
25 O -
- O -
6603 O +
and O +
Ro O +
25 O -
- O -
7386 O +
had O +
little O +
or O +
no O +
effect O +
on O +
G O -
- O -
CSF O +
-induced O +
colony O +
formation O +
, O +
whereas O +
they O +
inhibited O +
75 O +
% O +
and O +
53 O +
% O +
, O +
respectively O +
, O +
of O +
SCF O +
+ O +
Epo O +
-stimulated O +
BFU O -
- O -
E O +
colony O +
growth O +
. O +

Thus O +
, O +
the O +
RAR O -
- O -
RXR O +
response O +
pathway O +
can O +
signal O +
growth O +
inhibition O +
of O +
normal O +
bone O +
marrow O +
myeloid O +
and O +
erythroid O +
progenitor O +
cells O +
. O +

In O +
addition O +
, O +
we O +
demonstrate O +
a O +
unique O +
involvement O +
of O +
the O +
RXR O -
- O -
RXR O +
pathway O +
in O +
mediating O +
growth O +
inhibition O +
of O +
erythroid O +
but O +
not O +
myeloid O +
progenitor O +
cells O +
. O +

Expression O +
of O +
p13MTCP1 O +
is O +
restricted O +
to O +
mature O +
T O -
- O -
cell O +
proliferations O +
with O +
t O +
( O +
X O +
; O +
14 O +
) O +
translocations O +
. O +

T O -
- O -
cell O +
prolymphocytic O +
leukemia O +
( O +
T O -
- O -
PLL O +
) O +
, O +
a O +
rare O +
form O +
of O +
mature O +
T O -
- O -
cell O +
leukemias O +
, O +
and O +
ataxia O +
telangiectasia O +
clonal O +
proliferation O +
, O +
a O +
related O +
condition O +
occurring O +
in O +
patients O +
suffering O +
from O +
ataxia O +
telangiectasia O +
, O +
have O +
been O +
associated O +
to O +
translocations O +
involving O +
the O +
14q32.1 O +
or O +
Xq28 O +
regions O +
, O +
where O +
are O +
located O +
the O +
TCL1 O +
and O +
MTCP1 O +
putative O +
oncogenes O +
, O +
respectively O +
. O +

The O +
MTCP1 O +
gene O +
is O +
involved O +
in O +
the O +
t O +
( O +
X O +
; O +
14 O +
) O +
( O +
q28 O +
; O +
q11 O +
) O +
translocation O +
associated O +
with O +
these O +
T O -
- O -
cell O +
proliferations O +
. O +

Alternative O +
splicing O +
generates O +
type O +
A O +
and O +
B O +
transcripts O +
that O +
potentially O +
encode O +
two O +
entirely O +
distinct O +
proteins O +
; O +
type O +
A O +
transcripts O +
code O +
for O +
a O +
small O +
mitochondrial O +
protein O +
, O +
p8MTCP1 O +
, O +
and O +
type O +
B O +
transcripts O +
, O +
containing O +
an O +
additional O +
open O +
reading O +
frame O +
, O +
may O +
code O +
for O +
107 O +
amino O -
- O -
acid O +
protein O +
, O +
p13MTCP1 O +
. O +

The O +
recently O +
cloned O +
TCL1 O +
gene O +
, O +
also O +
involved O +
in O +
translocations O +
and O +
inversions O +
associated O +
with O +
T O -
- O -
cell O +
proliferations O +
, O +
codes O +
for O +
a O +
14-kD O +
protein O +
that O +
displays O +
significant O +
homology O +
with O +
p13MTCP1 O +
. O +

We O +
have O +
generated O +
rabbit O +
antisera O +
against O +
this O +
putative O +
p13MTCP1 O +
protein O +
and O +
screened O +
for O +
expression O +
of O +
p13MTCP1 O +
normal O +
lymphoid O +
tissues O +
and O +
33 O +
cases O +
of O +
immature O +
and O +
mature O +
lymphoid O +
T O -
- O -
cell O +
proliferations O +
using O +
a O +
sensitive O +
Western O +
blot O +
assay O +
. O +

We O +
also O +
investigated O +
the O +
MTCP1 O +
locus O +
configuration O +
by O +
Southern O +
blot O +
analysis O +
. O +

The O +
p13MTCP1 O +
protein O +
was O +
detected O +
in O +
the O +
three O +
T O -
- O -
cell O +
proliferations O +
with O +
MTCP1 O +
rearrangements O +
because O +
of O +
t O +
( O +
X O +
; O +
14 O +
) O +
translocations O +
, O +
but O +
neither O +
in O +
normal O +
resting O +
and O +
activated O +
lymphocytes O +
nor O +
in O +
the O +
other O +
T O -
- O -
cell O +
leukemias O +
. O +

Our O +
data O +
support O +
the O +
hypothesis O +
that O +
p13MTCP1 O +
and O +
p14TCL1 O +
form O +
a O +
new O +
protein O +
family O +
that O +
plays O +
a O +
key O +
role O +
in O +
the O +
pathogenesis O +
of O +
T O -
- O -
PLL O +
and O +
related O +
conditions O +
. O +

Activation O +
of O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
in O +
a O +
cyclosporin O +
A O -
- O -
resistant O +
pathway O +
. O +

The O +
mechanism O +
of O +
action O +
of O +
the O +
immunosuppressive O +
drug O +
cyclosporin O +
A O +
( O +
CsA O +
) O +
is O +
the O +
inactivation O +
of O +
the O +
Ca2+ O -
/ O -
calmodulin O -
- O -
dependent O +
serine O -
- O -
threonine O +
phosphatase O +
calcineurin O +
by O +
the O +
drug O -
- O -
immunophilin O +
complex O +
. O +

Inactive O +
calcineurin O +
is O +
unable O +
to O +
activate O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
, O +
a O +
transcription O +
factor O +
required O +
for O +
expression O +
of O +
the O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
gene O +
. O +

IL-2 O +
production O +
by O +
CsA B-CellLine -
- I-CellLine -
treated I-CellLine +
cells I-CellLine +
is O +
therefore O +
dramatically O +
reduced O +
. O +

We O +
demonstrate O +
here O +
, O +
however O +
, O +
that O +
NFAT O +
can O +
be O +
activated O +
, O +
and O +
significant O +
levels O +
of O +
IL-2 O +
can O +
be O +
produced O +
by O +
the O +
CsA O -
- O -
resistant O +
CD28 O +
-signaling O +
pathway O +
. O +

In O +
transient O +
transfection O +
assays O +
, O +
both O +
multicopy O +
NFAT O +
-and O +
IL-2 O +
promoter O -
- O -
beta O -
- O -
galactosidase O +
reporter O +
gene O +
constructs O +
could O +
be O +
activated O +
by O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
/alpha- O +
CD28 O +
stimulation O +
, O +
and O +
this O +
activation O +
was O +
resistant O +
to O +
CsA O +
. O +

Electrophoretic O +
mobility O +
shift O +
assay O +
showed O +
the O +
induction O +
of O +
a O +
CsA O -
- O -
resistant O +
NFAT O +
complex O +
in O +
the O +
nuclear O +
extracts O +
of O +
peripheral O +
blood O +
T O +
cells O +
stimulated O +
with O +
PMA O +
plus O +
alphaCD28 O +
. O +

Peripheral O +
blood O +
T O +
cells O +
stimulated O +
with O +
PMA O +
/alphaCD28 O +
produced O +
IL-2 O +
in O +
the O +
presence O +
of O +
CsA O +
. O +

Collectively O +
, O +
these O +
data O +
suggest O +
that O +
NFAT O +
can O +
be O +
activated O +
and O +
IL-2 O +
can O +
be O +
produced O +
in O +
a O +
calcineurin O +
independent O +
manner O +
. O +

Structural O +
and O +
functional O +
characterization O +
of O +
the O +
human O +
CD36 O +
gene O +
promoter O +
: O +
identification O +
of O +
a O +
proximal O +
PEBP2 O -
/ O -
CBF O +
site O +
. O +

CD36 O +
is O +
a O +
cell O +
surface O +
glycoprotein O +
composed O +
of O +
a O +
single O +
polypeptide O +
chain O +
, O +
which O +
interacts O +
with O +
thrombospondin O +
, O +
collagens O +
type O +
I O +
and O +
IV O +
, O +
oxidized O +
low O +
density O +
lipoprotein O +
, O +
fatty O +
acids O +
, O +
anionic O +
phospholipids O +
, O +
and O +
erythrocytes O +
parasitized O +
with O +
Plasmodium O +
falciparum O +
. O +

Its O +
expression O +
is O +
restricted O +
to O +
a O +
few O +
cell O +
types O +
, O +
including O +
monocyte O -
/ O -
macrophages O +
. O +

In O +
these O +
cells O +
, O +
CD36 O +
is O +
involved O +
in O +
phagocytosis O +
of O +
apoptotic O +
cells O +
, O +
and O +
foam O +
cell O +
formation O +
by O +
uptake O +
of O +
oxidized O +
low O +
density O +
lipoprotein O +
. O +

To O +
study O +
the O +
molecular O +
mechanisms O +
that O +
control O +
the O +
transcription O +
of O +
the O +
CD36 O +
gene O +
in O +
monocytic O +
cells O +
we O +
have O +
isolated O +
and O +
analyzed O +
the O +
CD36 O +
promoter O +
. O +

Transient O +
expression O +
experiments O +
of O +
5'-deletion O +
fragments O +
of O +
the O +
CD36 O +
promoter O +
coupled O +
to O +
luciferase O +
demonstrated O +
that O +
as O +
few O +
as O +
158 O +
base O +
pairs O +
upstream O +
from O +
the O +
transcription O +
initiation O +
site O +
were O +
sufficient O +
to O +
direct O +
the O +
monocyte O -
- O -
specific O +
transcription O +
of O +
the O +
reporter O +
gene O +
. O +

Within O +
the O +
above O +
region O +
, O +
the O +
fragment O +
spanning O +
nucleotides O +
-158 O +
to O +
-90 O +
was O +
required O +
for O +
optimal O +
transcription O +
in O +
monocytic O +
cells O +
. O +

Biochemical O +
analysis O +
of O +
the O +
region O +
-158 O -
/ O -
-90 O +
revealed O +
a O +
binding O +
site O +
for O +
transcription O +
factors O +
of O +
the O +
polyomavirus O +
enhancer O -
- O -
binding O +
protein O +
2 O -
/ O -
core O -
- O -
binding O +
factor O +
( O +
PEBP2 O -
/ O -
CBF O +
) O +
family O +
at O +
position O +
-103 O +
. O +

Disruption O +
of O +
the O +
PEBP2 O -
/ O -
CBF O +
site O +
markedly O +
diminished O +
the O +
role O +
of O +
the O +
PEBP2 O -
/ O -
CBF O +
factors O +
in O +
the O +
constitutive O +
transcription O +
of O +
the O +
CD36 O +
gene O +
. O +

The O +
involvement O +
of O +
members O +
of O +
the O +
PEBP2 O -
/ O -
CBF O +
family O +
in O +
chromosome O +
translocations O +
associated O +
with O +
acute O +
myeloid O +
leukemia O +
, O +
and O +
in O +
the O +
transcriptional O +
regulation O +
of O +
the O +
myeloid O -
- O -
specific O +
genes O +
encoding O +
for O +
myeloperoxidase O +
, O +
elastase O +
, O +
and O +
the O +
colony O -
- O -
stimulating O +
factor O +
receptor O +
, O +
highlights O +
the O +
relevance O +
of O +
the O +
regulation O +
of O +
the O +
CD36 O +
gene O +
promoter O +
in O +
monocytic O +
cells O +
by O +
members O +
of O +
the O +
PEBP2 O -
/ O -
CBF O +
family O +
. O +

Human O +
T O +
lymphotropic O +
virus O -
- O -
I O +
infection O +
of O +
human O +
T O +
lymphocytes O +
induces O +
expression O +
of O +
the O +
beta O -
- O -
galactoside O -
- O -
binding O +
lectin O +
, O +
galectin-3 O +
. O +

Animal O +
lectins O +
play O +
important O +
roles O +
in O +
a O +
variety O +
of O +
biological O +
processes O +
via O +
their O +
recognition O +
of O +
glycoconjugates O +
. O +

Galectin-3 O +
is O +
a O +
beta O -
- O -
galactoside O -
- O -
binding O +
lectin O +
previously O +
designated O +
as O +
epsilon O +
BP O +
( O +
IgE O -
- O -
binding O +
protein O +
) O +
, O +
CBP35 O +
, O +
Mac-2 O +
, O +
L-29 O +
, O +
and O +
L-34 O +
, O +
and O +
its O +
expression O +
has O +
been O +
associated O +
with O +
various O +
physiological O +
and O +
pathological O +
processes O +
, O +
including O +
cell O +
growth O +
, O +
tumor O +
transformation O +
, O +
and O +
metastasis O +
. O +

Galectin-3 O +
is O +
widely O +
distributed O +
in O +
various O +
tissues O +
and O +
cell O +
types O +
and O +
is O +
expressed O +
in O +
many O +
leukocytes O +
, O +
with O +
the O +
notable O +
exception O +
of O +
B O +
and O +
T O +
lymphocytes O +
. O +

We O +
now O +
report O +
that O +
galectin-3 O +
is O +
abundantly O +
expressed O +
in O +
a O +
number O +
of O +
human B-CellLine +
T I-CellLine +
lymphotropic I-CellLine +
virus I-CellLine +
( I-CellLine +
HTLV I-CellLine +
) I-CellLine +
-I I-CellLine -
- I-CellLine -
infected I-CellLine +
human I-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
including O +
F6 B-CellLine -
T I-CellLine +
, O +
HUT B-CellLine +
102 I-CellLine +
, O +
K3 B-CellLine -
T I-CellLine +
, O +
MT-2 B-CellLine +
, O +
and O +
SLB B-CellLine -
- I-CellLine -
I I-CellLine +
, O +
but O +
is O +
not O +
expressed O +
in O +
non B-CellLine -
- I-CellLine -
HTLV I-CellLine -
- I-CellLine -
I I-CellLine -
- I-CellLine -
infected I-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
such O +
as O +
Jurkat B-CellLine +
, O +
CEM B-CellLine +
, O +
and O +
MOLT-4 B-CellLine +
. O +

In O +
addition O +
, O +
the O +
galectin-3 O +
level O +
was O +
markedly O +
increased O +
in O +
human O +
thymocytes O +
after O +
infection O +
with O +
HTLV O -
- O -
I O +
as O +
compared O +
with O +
uninfected O +
thymocytes O +
. O +

The O +
up O -
- O -
regulation O +
of O +
galectin-3 O +
expression O +
appeared O +
to O +
correlate O +
well O +
with O +
HTLV O -
- O -
I O +
gene O +
expression O +
, O +
as O +
undetectable O +
or O +
very O +
low O +
levels O +
of O +
galectin-3 O +
were O +
found O +
in O +
the O +
S1 B-CellLine -
T I-CellLine +
and I-CellLine +
ATL-1 I-CellLine -
K I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
which O +
are O +
nonproductively O +
infected O +
with O +
HTLV O -
- O -
I O +
. O +

In O +
co O -
- O -
transfection O +
experiments O +
, O +
the O +
galectin-3 O +
promoter O +
was O +
significantly O +
up O -
- O -
regulated O +
by O +
expression O +
vectors O +
encoding O +
the O +
40-kd O +
Tax O +
protein O +
, O +
a O +
potent O +
transactivator O +
in O +
HTLV O -
- O -
I O +
. O +

Analysis O +
of O +
various O +
Tax O +
mutants O +
suggested O +
that O +
galectin-3 O +
promoter O +
induction O +
is O +
dependent O +
on O +
activation O +
of O +
the O +
cyclic O -
- O -
AMP O -
- O -
responsive O +
element O +
binding O +
protein O -
/ O -
activation O +
transcription O +
factor O +
family O +
of O +
transcription O +
factors O +
and O +
, O +
to O +
a O +
lesser O +
extent O +
, O +
nuclear O +
factor O -
- O -
kappa O +
B O -
/ O -
Rel O +
induction O +
. O +

Transfection O +
of O +
human B-CellLine +
promonocytic I-CellLine +
U-937 I-CellLine +
cells I-CellLine +
with O +
an O +
HTLV O -
- O -
I O +
Tax O +
expression O +
vector O +
induced O +
galectin-3 O +
expression O +
in O +
this O +
cell O +
line O +
. O +

Functionally O +
, O +
galectin-3 O +
was O +
shown O +
to O +
activate O +
interleukin-2 O +
production O +
in O +
Jurkat O +
T O +
cells O +
. O +

Together O +
, O +
these O +
findings O +
raise O +
the O +
possibility O +
that O +
HTLV O -
- O -
I O +
Tax O +
production O +
induces O +
the O +
transcription O +
and O +
subsequent O +
synthesis O +
and O +
secretion O +
of O +
galectin-3 O +
, O +
which O +
in O +
turn O +
may O +
further O +
activate O +
these O +
T O +
cells O +
and O +
contribute O +
to O +
the O +
altered O +
properties O +
of O +
cell O +
growth O +
found O +
in O +
adult O +
T O +
cell O +
leukemia O +
induced O +
by O +
HTLV O -
- O -
I O +
. O +

Age O -
- O -
related O +
decreases O +
in O +
IL-2 O +
production O +
by O +
human O +
T O +
cells O +
are O +
associated O +
with O +
impaired O +
activation O +
of O +
nuclear O +
transcriptional O +
factors O +
AP-1 O +
and O +
NF O -
- O -
AT O +
. O +

Although O +
transcriptional O +
factors O +
AP-1 O +
and O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NF O -
- O -
AT O +
) O +
are O +
important O +
for O +
the O +
normal O +
induction O +
of O +
IL-2 O +
, O +
it O +
is O +
unknown O +
if O +
the O +
age O -
- O -
related O +
decline O +
in O +
IL-2 O +
production O +
by O +
activated O +
human O +
T O +
cells O +
may O +
be O +
associated O +
with O +
aberrancies O +
in O +
transcriptional O +
regulatory O +
proteins O +
. O +

In O +
the O +
current O +
studies O +
, O +
IL-2 O +
production O +
by O +
T O +
cells O +
from O +
elderly O +
( O +
mean O +
78 O +
years O +
) O +
and O +
young O +
( O +
mean O +
37 O +
years O +
) O +
humans O +
was O +
measured O +
in O +
cultures O +
stimulated O +
with O +
PHA O +
, O +
PHA O +
plus O +
PMA O +
, O +
crosslinked O +
anti O -
- O -
CD3 O +
mAB O +
OKT3 O +
plus O +
PMA O +
, O +
or O +
PMA O +
plus O +
ionomycin O +
. O +

Substantial O +
decreases O +
of O +
IL-2 O +
production O +
were O +
observed O +
for O +
cell O +
cultures O +
from O +
7 O +
of O +
12 O +
elderly O +
individuals O +
in O +
response O +
to O +
the O +
different O +
stimuli O +
, O +
whereas O +
the O +
levels O +
of O +
IL-2 O +
produced O +
by O +
stimulated O +
T O +
cells O +
from O +
other O +
elderly O +
individuals O +
were O +
equivalent O +
to O +
those O +
observed O +
for O +
stimulated O +
T O +
cells O +
of O +
young O +
subjects O +
. O +

Analyses O +
of O +
nuclear O +
extracts O +
by O +
electrophoretic O +
DNA O +
mobility O +
shift O +
assays O +
showed O +
that O +
decreased O +
IL-2 O +
production O +
by O +
stimulated O +
T O +
cells O +
of O +
elderly O +
individuals O +
was O +
closely O +
associated O +
with O +
impairments O +
in O +
the O +
activation O +
of O +
both O +
AP-1 O +
and O +
NF O -
- O -
AT O +
. O +

By O +
contrast O +
, O +
T O +
cells O +
from O +
elderly O +
subjects O +
with O +
normal O +
levels O +
of O +
IL-2 O +
production O +
exhibited O +
normal O +
activation O +
of O +
AP-1 O +
and O +
NF O -
- O -
AT O +
. O +

In O +
addition O +
, O +
the O +
results O +
of O +
competition O +
experiments O +
analyzing O +
the O +
normal O +
components O +
of O +
NF O -
- O -
AT O +
showed O +
that O +
the O +
age O -
- O -
related O +
reductions O +
in O +
stimulus O -
- O -
dependent O +
NF O -
- O -
AT O +
complexes O +
corresponded O +
to O +
the O +
slow O +
migrating O +
complexes O +
that O +
were O +
composed O +
of O +
c O -
- O -
Fos O -
/ O -
c O -
- O -
Jun O +
AP-1 O +
. O +

The O +
resting O +
and O +
stimulated O +
levels O +
of O +
NF O +
kappa O +
B O +
were O +
reduced O +
in O +
T O +
cells O +
from O +
certain O +
elderly O +
individuals O +
; O +
however O +
, O +
alterations O +
of O +
NF O +
kappa O +
B O +
did O +
not O +
correlate O +
with O +
changes O +
in O +
IL-2 O +
expression O +
. O +

Thus O +
, O +
these O +
results O +
show O +
that O +
age O -
- O -
related O +
impairments O +
in O +
the O +
activation O +
of O +
AP-1 O +
and O +
NF O -
- O -
AT O +
are O +
closely O +
associated O +
with O +
decreased O +
expression O +
of O +
IL-2 O +
and O +
further O +
suggest O +
that O +
aberrancies O +
in O +
the O +
signaling O +
pathways O +
important O +
for O +
the O +
induction O +
of O +
transcriptionally O +
active O +
c O -
- O -
Fos O -
/ O -
c O -
- O -
Jun O +
AP-1 O +
may O +
contribute O +
to O +
the O +
impaired O +
activation O +
of O +
NF O -
- O -
AT O +
. O +

Inhibitory O +
effect O +
of O +
E3330 O +
, O +
a O +
novel O +
quinone O +
derivative O +
able O +
to O +
suppress O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
generation O +
, O +
on O +
activation O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
. O +

( O +
2E O +
) O +
-3- O +
[ O +
5- O +
( O +
2 O +
, O +
3-Dimethoxy-6-methyl-1 O +
, O +
4-benzoquinoyl O +
) O +
] O +
-2-nonyl-2- O +
propenoic O +
acid O +
( O +
E3330 O +
) O +
, O +
is O +
a O +
novel O +
agent O +
with O +
hepatoprotective O +
activity O +
. O +

We O +
report O +
the O +
effect O +
of O +
E3330 O +
on O +
transcriptional O +
activation O +
of O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
-alpha O +
gene O +
and O +
on O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappa O +
B O +
activation O +
. O +

Nuclear O +
run O -
- O -
on O +
experiments O +
showed O +
that O +
E3330 O +
decreases O +
transcriptional O +
activation O +
of O +
TNF O -
- O -
alpha O +
gene O +
induced O +
by O +
lipopolysaccharide O +
( O +
LPS O +
) O +
stimulation O +
in O +
human O +
peripheral O +
monocytes O +
. O +

To O +
investigate O +
the O +
inhibitory O +
mechanisms O +
, O +
we O +
constructed O +
a O +
secreted O -
- O -
type O +
placental O +
alkaline O +
phosphatase O +
( O +
PLAP O +
) O +
reporter O +
gene O +
whose O +
transcription O +
is O +
controlled O +
by O +
a O +
1.4-kb O +
human O +
TNF O -
- O -
alpha O +
promoter O +
. O +

A O +
stable O +
transformant O +
of O +
the O +
PLAP O +
reporter O +
gene O +
derived O +
from O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
showed O +
very O +
little O +
activity O +
on O +
the O +
promoter O +
before O +
stimulation O +
, O +
whereas O +
LPS O +
stimulation O +
led O +
to O +
a O +
dramatic O +
increase O +
in O +
PLAP O +
activity O +
. O +

E3330 O +
inhibited O +
this O +
induced O +
promoter O +
activity O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
. O +

There O +
are O +
four O +
putative O +
NF O -
- O -
kappa O +
B O +
binding O +
sites O +
( O +
kappa O +
B-1 O +
, O +
kappa O +
B-2 O +
, O +
kappa O +
B-3 O +
, O +
kappa O +
B-4 O +
) O +
in O +
human O +
TNF O -
- O -
alpha O +
promoter O +
. O +

By O +
using O +
mutated O +
promoter O -
- O -
PLAP O +
plasmids O +
, O +
we O +
established O +
that O +
these O +
NF O -
- O -
kappa O +
B O +
sites O +
were O +
necessary O +
for O +
induction O +
of O +
TNF O -
- O -
alpha O +
transcription O +
on O +
stimulation O +
with O +
LPS O +
. O +

A O +
gel O +
retardation O +
experiment O +
with O +
synthetic O +
double O -
- O -
stranded O +
oligonucleotides O +
showed O +
that O +
activated O +
NF O -
- O -
kappa O +
B O +
consisting O +
of O +
p50 O -
/ O -
p65 O +
heterodimer O +
bound O +
to O +
all O +
four O +
putative O +
NF O -
- O -
kappa O +
B O +
DNA O +
probes O +
, O +
suggesting O +
that O +
all O +
four O +
putative O +
NF O -
- O -
kappa O +
B O +
recognition O +
sites O +
play O +
an O +
important O +
role O +
in O +
inducible O +
TNF O -
- O -
alpha O +
expression O +
. O +

E3330 O +
decreased O +
activated O +
NF O -
- O -
kappa O +
B O +
in O +
nuclei O +
, O +
suggesting O +
that O +
E3330 O +
inhibits O +
NF O -
- O -
kappa O +
B O +
activation O +
and/or O +
translocation O +
of O +
the O +
nuclei O +
. O +

Western O +
blotting O +
analysis O +
with O +
anti O -
- O -
I O +
kappa O +
B O -
- O -
alpha O +
antibody O +
indicated O +
that O +
E3330 O +
inhibited O +
degradation O +
of O +
I O +
kappa O +
B O -
- O -
alpha O +
, O +
which O +
is O +
an O +
inhibitory O +
protein O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
in O +
LPS B-CellLine -
- I-CellLine -
stimulated I-CellLine +
monocytes I-CellLine +
. O +

E3330 O +
may O +
suppress O +
the O +
production O +
of O +
active O +
oxygen O +
species O +
serving O +
as O +
common O +
messengers O +
to O +
activate O +
NF O -
- O -
kappa O +
B O +
. O +

Ubiquitinylation O +
of O +
transcription O +
factors O +
c O -
- O -
Jun O +
and O +
c O -
- O -
Fos O +
using O +
reconstituted O +
ubiquitinylating O +
enzymes O +
. O +

Recombinant O +
c O -
- O -
Jun O +
and O +
c O -
- O -
Fos O +
were O +
ubiquitinylated O +
by O +
the O +
ubiquitin O +
carrier O +
enzymes O +
E214 O -
K O +
, O +
E220 O -
K O +
, O +
or O +
E232 O -
K O +
in O +
the O +
presence O +
of O +
the O +
ubiquitin O -
- O -
activating O +
enzyme O +
, O +
E1 O +
. O +

Addition O +
of O +
ubiquitin O +
protein O +
ligase O +
E3 O +
substantially O +
enhanced O +
the O +
E214 O -
K O +
-mediated O +
ubiquitinylation O +
of O +
c O -
- O -
Jun O +
and O +
c O -
- O -
Fos O +
. O +

Truncated O +
c O -
- O -
Jun O +
and O +
c O -
- O -
Fos O +
mutant O +
proteins O +
including O +
wbJun O +
and O +
wbFos O +
were O +
also O +
ubiquitinylated O +
under O +
the O +
same O +
conditions O +
, O +
suggesting O +
the O +
sites O +
of O +
ubiquitinylation O +
are O +
located O +
within O +
the O +
dimerization O +
and O +
DNA O +
binding O +
domains O +
of O +
c O -
- O -
Jun O +
and O +
c O -
- O -
Fos O +
. O +

The O +
E3-dependent O +
ubiquitinylation O +
of O +
c O -
- O -
Jun O +
was O +
inhibited O +
upon O +
the O +
heterodimerization O +
of O +
c O -
- O -
Jun O +
with O +
c O -
- O -
Fos O +
. O +

Further O +
addition O +
of O +
E220 O -
K O +
significantly O +
enhanced O +
ubiquitinylation O +
of O +
c O -
- O -
Jun O +
in O +
the O +
heterodimer O +
suggesting O +
a O +
regulatory O +
role O +
of O +
E220 O -
K O +
. O +

Polyubiquitinylated O +
c O -
- O -
Jun O +
, O +
wbFos O +
, O +
and O +
wbJun O +
, O +
but O +
not O +
E220K O -
- O -
ubiquitinylated O +
c O -
- O -
Jun O +
, O +
were O +
readily O +
degraded O +
by O +
the O +
ATP O -
- O -
dependent O +
26 O +
S O +
multicatalytic O +
proteases O +
. O +

These O +
results O +
suggest O +
that O +
the O +
temporal O +
control O +
of O +
c O -
- O -
Jun O +
and O +
c O -
- O -
Fos O +
may O +
be O +
regulated O +
through O +
the O +
ubiquitinylation O +
pathways O +
, O +
and O +
the O +
ubiquitinylation O +
of O +
c O -
- O -
Jun O +
and O +
c O -
- O -
Fos O +
may O +
in O +
turn O +
be O +
regulated O +
in O +
response O +
to O +
the O +
heterodimerization O +
between O +
them O +
and O +
the O +
cooperation O +
between O +
E220 O -
K O +
and O +
E3 O +
mediated O +
polyubiquitinylation O +
. O +

Transcriptional O +
regulation O +
of O +
the O +
interleukin-2 O +
gene O +
in O +
normal O +
human O +
peripheral O +
blood O +
T O +
cells O +
. O +

Convergence O +
of O +
costimulatory O +
signals O +
and O +
differences O +
from O +
transformed O +
T O +
cells O +
. O +

To O +
study O +
transcriptional O +
regulation O +
in O +
normal O +
human O +
T O +
cells O +
, O +
we O +
have O +
optimized O +
conditions O +
for O +
transient O +
transfection O +
. O +

Interleukin-2 O +
( O +
IL-2 O +
) O +
promoter O +
-reporter O +
gene O +
behavior O +
closely O +
parallels O +
the O +
endogenous O +
gene O +
in O +
response O +
to O +
T O +
cell O +
receptor O +
and O +
costimulatory O +
signals O +
. O +

As O +
assessed O +
with O +
mutagenized O +
promoters O +
, O +
the O +
most O +
important O +
IL-2 O +
cis O -
- O -
regulatory O +
elements O +
in O +
normal O +
T O +
cells O +
are O +
the O +
proximal O +
AP-1 O +
site O +
and O +
the O +
NF- O +
kappaB O +
site O +
. O +

Both O +
primary O +
activation O +
, O +
with O +
phytohemagglutinin O +
or O +
antibodies O +
to O +
CD3 O +
, O +
and O +
costimulation O +
, O +
provided O +
by O +
pairs O +
of O +
CD2 O +
antibodies O +
or O +
B7-positive O +
( O +
B O +
cells O +
) O +
or O +
B7-negative O +
( O +
endothelial O +
) O +
accessory O +
cells O +
, O +
are O +
mediated O +
through O +
the O +
same O +
cis O -
- O -
elements O +
. O +

Interestingly O +
, O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cell O +
sites O +
are O +
much O +
less O +
important O +
in O +
normal O +
T O +
cells O +
than O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

We O +
conclude O +
that O +
IL-2 O +
transcriptional O +
regulation O +
differs O +
in O +
tumor B-CellLine +
cell I-CellLine +
lines I-CellLine +
compared O +
with O +
normal O +
T O +
cells O +
and O +
that O +
different O +
costimulatory O +
signals O +
converge O +
on O +
the O +
same O +
cis O -
- O -
elements O +
in O +
the O +
IL-2 O +
promoter O +
. O +

Nuclear O +
appearance O +
of O +
a O +
factor O +
that O +
binds O +
the O +
CD28 O +
response O +
element O +
within O +
the O +
interleukin-2 O +
enhancer O +
correlates O +
with O +
interleukin-2 O +
production O +
. O +

Activation O +
of O +
T O +
lymphocytes O +
requires O +
the O +
combined O +
signaling O +
of O +
the O +
T O +
cell O +
receptor O +
and O +
costimulatory O +
molecules O +
such O +
as O +
CD28 O +
. O +

The O +
ability O +
of O +
T O +
cells O +
to O +
produce O +
interleukin-2 O +
( O +
IL-2 O +
) O +
is O +
a O +
critical O +
control O +
point O +
in O +
T O +
lymphocyte O +
activation O +
. O +

The O +
IL-2 O +
enhancer O +
contains O +
a O +
functional O +
motif O +
named O +
CD28 O +
response O +
element O +
( O +
CD28RE O +
) O +
that O +
serves O +
a O +
role O +
as O +
a O +
target O +
for O +
mitogenic O +
T O +
cell O +
activation O +
signals O +
. O +

The O +
CD28RE O +
sequence O +
reveals O +
similarity O +
to O +
the O +
consensus O +
kappaB O +
binding O +
motif O +
. O +

Here O +
we O +
demonstrate O +
that O +
CD28RE O +
binds O +
an O +
inducible O +
protein O +
with O +
a O +
molecular O +
mass O +
of O +
approximately O +
35 O +
kDa O +
called O +
nuclear O +
factor O +
of O +
mitogenic O -
- O -
activated O +
T O +
cells O +
( O +
NF O -
- O -
MATp35 O +
) O +
that O +
is O +
clearly O +
different O +
from O +
the O +
known O +
NF- O +
kappaB O -
/ O -
Rel O +
family O +
members O +
. O +

Induction O +
of O +
NF O -
- O -
MATp35 O +
was O +
shown O +
to O +
depend O +
on O +
de O +
novo O +
protein O +
synthesis O +
and O +
was O +
restricted O +
to O +
T O +
cells O +
that O +
received O +
a O +
mitogenic O +
combination O +
of O +
T O +
cell O +
stimuli O +
, O +
not O +
necessarily O +
including O +
CD28 O +
signaling O +
. O +

Nonmitogenic O +
T O +
cell O +
stimulation O +
did O +
not O +
result O +
in O +
appearance O +
of O +
NF O -
- O -
MATp35 O +
. O +

These O +
results O +
indicate O +
that O +
mitogenic O +
combinations O +
of O +
T O +
cell O +
activation O +
signals O +
are O +
integrated O +
at O +
the O +
level O +
of O +
NF O -
- O -
MATp35 O +
induction O +
. O +

Similar O +
to O +
its O +
effect O +
on O +
IL-2 O +
production O +
, O +
cyclosporin O +
A O +
inhibited O +
the O +
induction O +
of O +
NF O -
- O -
MATp35 O +
. O +

Taken O +
together O +
, O +
these O +
data O +
demonstrate O +
that O +
the O +
nuclear O +
appearance O +
of O +
NF O -
- O -
MATp35 O +
shows O +
excellent O +
correlation O +
with O +
IL-2 O +
production O +
, O +
which O +
is O +
a O +
unique O +
characteristic O +
among O +
nuclear O +
factors O +
implicated O +
in O +
the O +
control O +
of O +
IL-2 O +
gene O +
expression O +
. O +

Heat O +
shock O +
induces O +
HIV-1 O +
replication O +
in O +
chronically O +
infected O +
promyelocyte B-CellLine +
cell I-CellLine +
line I-CellLine +
OM10.1 I-CellLine +
. O +

A O +
long O +
period O +
of O +
clinical O +
latency O +
before O +
development O +
of O +
symptoms O +
is O +
characteristic O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
infection O +
. O +

OM10.1 B-CellLine +
, O +
a O +
promyelocyte B-CellLine +
cell I-CellLine +
line I-CellLine +
latently O +
infected O +
with O +
HIV-1 O +
, O +
has O +
been O +
developed O +
as O +
a O +
model O +
for O +
studying O +
the O +
mechanism O +
of O +
viral O +
latency O +
and O +
the O +
activation O +
of O +
virus O +
expression O +
. O +

We O +
found O +
that O +
this O +
latently O +
infected O +
cell O +
line O +
with O +
heat O +
shock O +
at O +
42 O +
degrees O +
C O +
for O +
2 O +
h O +
resulted O +
in O +
a O +
high O +
level O +
of O +
HIV-1 O +
production O +
without O +
addition O +
of O +
any O +
cytokines O +
. O +

The O +
mechanism O +
of O +
activation O +
was O +
analyzed O +
by O +
using O +
anti O -
- O -
TNF O -
- O -
alpha O +
antibody O +
and O +
various O +
inhibitors O +
. O +

Although O +
the O +
TNF O -
- O -
alpha O +
level O +
in O +
culture O +
supernatants O +
was O +
below O +
the O +
sensitivity O +
of O +
an O +
ELISA O +
assay O +
system O +
, O +
addition O +
of O +
anti- O +
TNF O -
- O -
alpha O +
antibody O +
in O +
culture O +
medium O +
could O +
partially O +
suppress O +
the O +
heat O +
shock O +
induced O +
HIV-1 O +
production O +
. O +

Staurosporine O +
( O +
PKC O +
inhibitor O +
) O +
, O +
pentoxifylline O +
( O +
NF O -
- O -
kappa O +
B O +
inhibitor O +
) O +
, O +
and O +
Ro5 O -
- O -
3335 O +
( O +
HIV-1 O +
Tat O +
inhibitor O +
) O +
also O +
inhibited O +
significantly O +
the O +
heat O +
shock O +
induced O +
virus O +
activation O +
. O +

In O +
particular O +
, O +
staurosporine O +
achieved O +
approximately O +
90 O +
% O +
inhibition O +
of O +
the O +
HIV-1 O +
antigen O +
expression O +
in O +
heat B-CellLine +
shock I-CellLine -
- I-CellLine -
treated I-CellLine +
OM10.1 I-CellLine +
at O +
a O +
non O -
- O -
toxic O +
concentration O +
. O +

Although O +
the O +
mechanism O +
of O +
HIV-1 O +
activation O +
with O +
heat O +
shock O +
has O +
not O +
been O +
fully O +
elucidated O +
yet O +
, O +
it O +
is O +
presumed O +
PKC O +
plays O +
an O +
important O +
role O +
in O +
HIV-1 O +
activation O +
. O +

Thus O +
, O +
the O +
present O +
observations O +
will O +
provide O +
a O +
further O +
insight O +
into O +
the O +
pathogenesis O +
of O +
HIV-1 O +
infections O +
. O +

Granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
stimulates O +
JAK2 O +
signaling O +
pathway O +
and O +
rapidly O +
activates O +
p93fes O +
, O +
STAT1 O +
p91 O +
, O +
and O +
STAT3 O +
p92 O +
in O +
polymorphonuclear O +
leukocytes O +
. O +

Granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
, O +
supports O +
proliferation O +
, O +
differentiation O +
, O +
and O +
functional O +
activation O +
of O +
hemopoietic O +
cells O +
by O +
its O +
interaction O +
with O +
a O +
heterodimeric O +
receptor O +
. O +

Although O +
GM O -
- O -
CSF O +
receptor O +
is O +
devoid O +
of O +
tyrosine O +
kinase O +
enzymatic O +
activity O +
, O +
GM B-CellLine -
- I-CellLine -
CSF I-CellLine -
- I-CellLine -
induced I-CellLine +
peripheral I-CellLine +
blood I-CellLine +
polymorphonuclear I-CellLine +
leukocytes I-CellLine +
( O +
PMN O +
) O +
functional O +
activation O +
is O +
mediated O +
by O +
the O +
phosphorylation O +
of O +
a O +
large O +
number O +
of O +
intracellular O +
signaling O +
molecules O +
. O +

We O +
have O +
previously O +
shown O +
that O +
JAK2 O +
becomes O +
tyrosine O -
- O -
phosphorylated O +
in O +
response O +
to O +
GM O -
- O -
CSF O +
in O +
PMN O +
. O +

In O +
the O +
present O +
study O +
we O +
demonstrate O +
that O +
also O +
the O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
STAT O +
) O +
family O +
members O +
STAT1 O +
p91 O +
and O +
STAT3 O +
p92 O +
and O +
the O +
product O +
of O +
the O +
c O -
- O -
fps O -
/ O -
fes O +
protooncogene O +
become O +
tyrosine O -
- O -
phosphorylated O +
upon O +
GM O -
- O -
CSF O +
stimulation O +
and O +
physically O +
associated O +
with O +
both O +
GM O -
- O -
CSF O +
receptor O +
beta O +
common O +
subunit O +
and O +
JAK2 O +
. O +

Moreover O +
GM O -
- O -
CSF O +
was O +
able O +
to O +
induce O +
JAK2 O +
and O +
p93fes O +
catalytic O +
activity O +
. O +

We O +
also O +
demonstrate O +
that O +
the O +
association O +
of O +
the O +
GM O -
- O -
CSF O +
receptor O +
beta O +
common O +
subunit O +
with O +
JAK2 O +
is O +
ligand O -
- O -
dependent O +
. O +

Finally O +
we O +
demonstrate O +
that O +
GM O -
- O -
CSF O +
induces O +
a O +
DNA O -
- O -
binding O +
complex O +
that O +
contains O +
both O +
p91 O +
and O +
p92 O +
. O +

These O +
results O +
identify O +
a O +
new O +
signal O +
transduction O +
pathway O +
activated O +
by O +
GM O -
- O -
CSF O +
and O +
provide O +
a O +
mechanism O +
for O +
rapid O +
activation O +
of O +
gene O +
expression O +
in O +
GM O -
- O -
CSF O -
- O -
stimulated O +
PMN O +
. O +

Abundant O +
expression O +
of O +
erythroid O +
transcription O +
factor O +
P45 O +
NF O -
- O -
E2 O +
mRNA O +
in O +
human O +
peripheral O +
granurocytes O +
. O +

Transcription O +
factor O +
NF O -
- O -
E2 O +
is O +
crucial O +
for O +
regulation O +
of O +
erythroid O -
- O -
specific O +
gene O +
expression O +
. O +

p45 O +
subunit O +
of O +
NF O -
- O -
E2 O +
contains O +
a O +
basic O -
- O -
leucine O +
zipper O +
domain O +
and O +
dimerizes O +
with O +
the O +
small O +
Maf O +
family O +
protein O +
to O +
form O +
functional O +
NF O -
- O -
E2 O +
complex O +
. O +

While O +
p45 O +
expression O +
was O +
shown O +
to O +
be O +
restricted O +
to O +
erythroid O +
cells O +
, O +
megakaryocytes O +
and O +
mast O +
cells O +
in O +
hematopoietic O +
lineage O +
, O +
we O +
found O +
in O +
this O +
study O +
that O +
p45 O +
mRNA O +
is O +
abundantly O +
transcribed O +
in O +
the O +
granulocyte O +
fraction O +
of O +
human O +
peripheral O +
blood O +
cells O +
. O +

As O +
neutrophils O +
occupy O +
approximately O +
92 O +
% O +
of O +
the O +
cells O +
in O +
granulocyte O +
fraction O +
of O +
human O +
peripheral O +
blood O +
cells O +
. O +

As O +
neutrophils O +
occupy O +
approximately O +
92 O +
% O +
of O +
the O +
cells O +
in O +
this O +
fraction O +
, O +
the O +
cells O +
expressing O +
p45 O +
is O +
most O +
likely O +
to O +
be O +
neutrophils O +
. O +

p45 O +
mRNA O +
is O +
also O +
expressed O +
in O +
HL-60 B-CellLine +
promyelocytes I-CellLine +
, O +
albeit O +
the O +
expression O +
level O +
is O +
much O +
lower O +
than O +
that O +
of O +
the O +
granulocyte O +
fraction O +
. O +

HL-60 B-CellLine +
cells I-CellLine +
were O +
found O +
to O +
express O +
mafK O +
mRNA O +
, O +
indicating O +
the O +
presence O +
of O +
genuine O +
NF O -
- O -
E2 O +
complex O +
in O +
the O +
cells O +
. O +

Although O +
p45 O +
mRNA O +
is O +
transcribed O +
from O +
two O +
different O +
promoters O +
, O +
aNF O -
- O -
E2 O +
promoter O +
and O +
fNF O -
- O -
E2 O +
promoter O +
, O +
in O +
erythroid O +
and O +
megakaryocytic O +
lineage O +
cells O +
, O +
p45 O +
mRNA O +
is O +
transcribed O +
only O +
from O +
aNF O -
- O -
E2 O +
promoter O +
. O +

The O +
expression O +
of O +
p45 O +
megakaryocytic O +
lineage O +
cells O +
, O +
p45 O +
mRNA O +
is O +
transcribed O +
only O +
from O +
aNF O -
- O -
E2 O +
promoter O +
. O +

The O +
expression O +
of O +
p45 O +
mRNA O +
in O +
the O +
neutrophils O +
declined O +
rapidly O +
after O +
transfer O +
of O +
the O +
cells O +
to O +
in O +
vitro O +
culture O +
and O +
G O -
- O -
CSF O +
could O +
not O +
sustain O +
the O +
expression O +
from O +
the O +
down O -
- O -
regulation O +
, O +
suggesting O +
the O +
E2 O +
may O +
also O +
participate O +
in O +
the O +
regulation O +
of O +
neutrophil O -
- O -
specific O +
gene O +
expression O +
. O +

Preassociation O +
of O +
STAT1 O +
with O +
STAT2 O +
and O +
STAT3 O +
in O +
separate O +
signalling O +
complexes O +
prior O +
to O +
cytokine O +
stimulation O +
. O +

A O +
variety O +
of O +
cytokines O +
and O +
growth O +
factors O +
act O +
through O +
an O +
induction O +
of O +
gene O +
expression O +
mediated O +
by O +
a O +
family O +
of O +
latent O +
transcription O +
factors O +
called O +
STAT O +
( O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
) O +
proteins O +
. O +

Ligand O -
- O -
induced O +
tyrosine O +
phosphorylation O +
of O +
the O +
STATs O +
promotes O +
their O +
homodimer O +
and O +
heterodimer O +
formation O +
and O +
subsequent O +
nuclear O +
translocation O +
. O +

We O +
demonstrate O +
here O +
that O +
STAT O +
protein O +
heterocomplexes O +
exist O +
prior O +
to O +
cytokine O +
treatment O +
. O +

When O +
unstimulated B-CellLine +
HeLa I-CellLine +
cells I-CellLine +
are O +
ruptured O +
in O +
hypotonic O +
buffer O +
without O +
salt O +
or O +
detergent O +
, O +
immunoadsorption O +
of O +
either O +
STAT1 O +
or O +
STAT2 O +
from O +
the O +
resulting O +
cytosol O +
yields O +
coimmunoadsorption O +
of O +
the O +
other O +
STAT O +
protein O +
. O +

Similarly O +
, O +
STAT1 O +
-STAT3 O +
heterocomplexes O +
are O +
coimmunoadsorbed O +
from O +
hypotonic O +
cytosol O +
. O +

STAT1 O +
and O +
STAT2 O +
or O +
STAT1 O +
and O +
STAT3 O +
translated O +
in O +
reticulocyte O +
lysate O +
spontaneously O +
form O +
heterocomplexes O +
when O +
the O +
translation O +
lysates O +
are O +
mixed O +
at O +
0 O +
degrees O +
C O +
. O +

Our O +
data O +
suggest O +
that O +
interferon O -
- O -
alpha O +
/beta O -
- O -
induced O +
tyrosine O +
phosphorylation O +
increases O +
the O +
stability O +
of O +
a O +
preexisting O +
, O +
latent O +
, O +
STAT1 O +
- O +
STAT2 O +
signaling O +
complex O +
. O +

Newly O +
translated O +
STAT1 O +
binds O +
in O +
equilibrium O +
fashion O +
to O +
STAT2 O +
and O +
STAT3 O +
, O +
but O +
we O +
show O +
that O +
STAT2 O +
and O +
STAT3 O +
exist O +
in O +
separate O +
heterocomplexes O +
with O +
STAT1 O +
, O +
consistent O +
with O +
a O +
model O +
in O +
which O +
STAT1 O +
contains O +
a O +
common O +
binding O +
site O +
for O +
other O +
STAT O +
proteins O +
. O +

A O +
hydrophobic O +
domain O +
of O +
Ca2 O -
+ O -
-modulating O +
cyclophilin O +
ligand O +
modulates O +
calcium O +
influx O +
signaling O +
in O +
T O +
lymphocytes O +
. O +

Ca2 O -
+ O -
-modulating O +
cyclophilin O +
ligand O +
( O +
CAML O +
) O +
was O +
originally O +
described O +
as O +
a O +
cyclophilin O +
B O -
- O -
binding O +
protein O +
whose O +
overexpression O +
in O +
T O +
cells O +
causes O +
a O +
rise O +
in O +
intracellular O +
calcium O +
, O +
thus O +
activating O +
transcription O +
factors O +
responsible O +
for O +
the O +
early O +
immune O +
response O +
. O +

As O +
reported O +
here O +
, O +
structure O -
- O -
function O +
analysis O +
of O +
the O +
CAML O +
gene O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
indicates O +
that O +
two O +
of O +
CAML O +
's O +
putative O +
membrane O -
- O -
spanning O +
domains O +
are O +
necessary O +
and O +
sufficient O +
for O +
the O +
modulation O +
of O +
intracellular O +
calcium O +
. O +

We O +
propose O +
that O +
the O +
hydrophobic O +
C O -
- O -
terminal O +
tail O +
of O +
CAML O +
forms O +
its O +
effector O +
domain O +
, O +
thus O +
implicating O +
the O +
N O -
- O -
terminal O +
hydrophilic O +
domain O +
in O +
a O +
regulatory O +
role O +
. O +

These O +
findings O +
define O +
a O +
novel O +
protein O +
motif O +
that O +
functions O +
in O +
intracellular O +
calcium O +
signaling O +
. O +

Interactions O +
of O +
a O +
transcriptional O +
activator O +
in O +
the O +
env O +
gene O +
of O +
the O +
mouse O +
mammary O +
tumor O +
virus O +
with O +
activation O -
- O -
dependent O +
, O +
T O +
cell O -
- O -
specific O +
transacting O +
factors O +
. O +

The O +
mouse O +
mammary O +
tumor O +
virus O +
env O +
gene O +
contains O +
a O +
transcriptional O +
activator O +
( O +
META O +
) O +
that O +
can O +
control O +
transcription O +
of O +
the O +
adjacent O +
long O +
terminal O +
repeat O +
region O +
. O +

Transcriptional O +
control O +
by O +
META O +
parallels O +
that O +
of O +
several O +
lymphokine O +
genes O +
, O +
being O +
specific O +
to O +
T O +
cells O +
, O +
dependent O +
on O +
their O +
activation O +
, O +
and O +
inhibited O +
by O +
the O +
immunosuppressive O +
drug O +
cyclosporine O +
( O +
CsA O +
) O +
. O +

DNase O +
I O +
footprinting O +
indicated O +
that O +
nuclear O +
factors O +
from O +
activated O +
T O +
lymphocytes O +
bound O +
a O +
promoter O -
- O -
proximal O +
site O +
, O +
META O +
( O +
P O +
) O +
, O +
and O +
a O +
promoter O -
- O -
distal O +
site O +
, O +
META O +
( O +
D+ O +
) O +
, O +
within O +
the O +
400-base O +
pair O +
META O +
region O +
. O +

Nuclear O +
factors O +
from O +
unstimulated O +
, O +
but O +
not O +
from O +
activated O +
cells O +
, O +
bound O +
a O +
site O +
, O +
META O +
( O +
D- O +
) O +
, O +
adjacent O +
to O +
META O +
( O +
D+ O +
) O +
. O +

META O +
( O +
D+ O +
) O +
directed O +
transcription O +
of O +
a O +
linked O +
luciferase O +
gene O +
, O +
and O +
gel O +
shift O +
analysis O +
revealed O +
binding O +
of O +
inducible O +
, O +
CsA O -
- O -
sensitive O +
T O +
cell O +
factors O +
, O +
in O +
parallel O +
with O +
transfection O +
results O +
. O +

Authentic O +
NFAT O +
and O +
NF O -
- O -
kappaB O +
targets O +
did O +
not O +
compete O +
for O +
the O +
META O +
( O +
D+ O +
) O +
binding O +
factor O +
( O +
s O +
) O +
. O +

The O +
SV40 O +
core O +
sequence O +
competed O +
for O +
META O +
( O +
D+ O +
) O +
binding O +
factors O +
, O +
but O +
META O +
( O +
D+ O +
) O +
failed O +
to O +
compete O +
for O +
the O +
complexes O +
obtained O +
with O +
the O +
SV40 O +
probe O +
. O +

Our O +
results O +
, O +
taken O +
together O +
, O +
indicate O +
that O +
META O +
( O +
D+ O +
) O +
is O +
a O +
novel O +
transcriptional O +
enhancer O +
element O +
that O +
is O +
similar O +
in O +
its O +
cell O -
- O -
type O +
specificity O +
, O +
activation O +
dependence O +
, O +
and O +
CsA O +
sensitivity O +
to O +
the O +
NFAT O +
element O +
. O +

It O +
may O +
be O +
relevant O +
to O +
the O +
role O +
of O +
MMTV O +
in O +
expression O +
of O +
Mls O +
antigens O +
or O +
the O +
induction O +
of O +
T O +
cell O +
lymphomas O +
. O +

Expression O +
of O +
Id2 O +
and O +
Id3 O +
mRNA O +
in O +
human O +
lymphocytes O +
. O +

Helix O -
- O -
loop O -
- O -
helix O +
( O +
HLH O +
) O +
transcription O +
factors O +
are O +
involved O +
in O +
cellular O +
growth O +
and O +
differentiation O +
. O +

The O +
I O -
d O +
( O +
inhibitor O +
of O +
DNA O +
binding O +
and O +
differentiation O +
) O +
HLH O +
proteins O +
, O +
in O +
a O +
dominantly O +
negative O +
fashion O +
, O +
regulate O +
transcriptional O +
activities O +
of O +
basic O +
HLH O +
proteins O +
. O +

We O +
examined O +
by O +
northern O +
hybridization O +
the O +
expression O +
of O +
Id2 O +
and O +
Id3 O +
mRNA O +
in O +
human B-CellLine +
leukemia I-CellLine -
/ I-CellLine -
lymphoma I-CellLine +
lines I-CellLine +
and O +
patient O +
samples O +
, O +
as O +
well O +
as O +
resting O +
and O +
activated B-CellLine +
normal I-CellLine +
human I-CellLine +
lymphocytes I-CellLine +
from O +
peripheral O +
blood O +
( O +
PBL O +
) O +
. O +

The O +
Id2 O +
mRNA O +
was O +
abundantly O +
expressed O +
in O +
5 B-CellLine -
/ I-CellLine -
12 I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
and O +
3 B-CellLine -
/ I-CellLine -
4 I-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
, O +
and O +
Id3 O +
mRNA O +
was O +
detected O +
in O +
4 B-CellLine -
/ I-CellLine -
12 I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
and O +
3 B-CellLine -
/ I-CellLine -
4 I-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
. O +

Interestingly O +
, O +
Id2 O +
, O +
but O +
not O +
Id3 O +
, O +
mRNA O +
was O +
strongly O +
expressed O +
in O +
4 B-CellLine -
/ I-CellLine -
5 I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
infected O +
with O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
( O +
ATL-1k B-CellLine +
, O +
MT-2 B-CellLine +
, O +
S B-CellLine -
- I-CellLine -
LB1 I-CellLine +
) O +
and O +
type O +
II O +
( O +
Mo B-CellLine +
) O +
. O +

Another O +
unexpected O +
finding O +
was O +
that O +
T O -
- O -
cell O +
leukemias O +
and O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
often O +
expressed O +
either O +
Id2 O +
or O +
Id3 O +
mRNA O +
. O +

In O +
addition O +
, O +
resting O +
PBL O +
constitutively O +
expressed O +
prominent O +
levels O +
of O +
Id2 O +
mRNA O +
, O +
but O +
not O +
Id3 O +
mRNA O +
. O +

Upon O +
PHA O +
-stimulation O +
, O +
Id2 O +
expression O +
decreased O +
and O +
Id3 O +
levels O +
increased O +
with O +
biphasic O +
kinetics O +
. O +

Taken O +
together O +
, O +
our O +
studies O +
revealed O +
three O +
unexpected O +
findings O +
which O +
require O +
further O +
analysis O +
: O +
( O +
1 O +
) O +
expression O +
of O +
Id2 O +
mRNA O +
is O +
often O +
associated O +
with O +
lymphocytic O +
transformation O +
by O +
HTLV O -
- O -
I O +
or O +
-II O +
; O +
( O +
2 O +
) O +
T O -
- O -
cells O +
usually O +
express O +
either O +
Id2 O +
or O +
Id3 O +
mRNA O +
, O +
but O +
B O -
- O -
cells O +
often O +
express O +
both O +
simultaneously O +
; O +
( O +
3 O +
) O +
non O -
- O -
dividing O +
, O +
normal O +
PBL O +
express O +
high O +
levels O +
of O +
Id2 O +
and O +
no O +
Id3 O +
mRNA O +
; O +
and O +
with O +
the O +
onset O +
of O +
cellular O +
proliferation O +
, O +
levels O +
of O +
Id2 O +
mRNA O +
decrease O +
while O +
levels O +
of O +
Id3 O +
mRNA O +
increase O +
, O +
suggesting O +
that O +
regulation O +
of O +
expression O +
of O +
these O +
closely O +
related O +
genes O +
is O +
disparate O +
. O +

Identification O +
of O +
a O +
human O +
LIM O -
- O -
Hox O +
gene O +
, O +
hLH-2 O +
, O +
aberrantly O +
expressed O +
in O +
chronic O +
myelogenous O +
leukaemia O +
and O +
located O +
on O +
9q33 O -
- O -
34.1 O +
. O +

We O +
describe O +
the O +
isolation O +
of O +
human O +
LH-2 O +
, O +
a O +
putative O +
transcription O +
factor O +
containing O +
two O +
cysteine O -
- O -
rich O +
regions O +
( O +
LIM O +
domains O +
) O +
and O +
a O +
homeobox O +
( O +
Hox O +
) O +
DNA O -
- O -
binding O +
domain O +
. O +

High O +
levels O +
of O +
hLH-2 O +
expression O +
were O +
observed O +
in O +
all O +
cases O +
of O +
chronic O +
myelogenous O +
leukaemia O +
( O +
CML O +
) O +
tested O +
, O +
regardless O +
of O +
disease O +
status O +
. O +

hLH-2 O +
was O +
mapped O +
to O +
chromosome O +
9Q33 O -
- O -
34.1 O +
, O +
in O +
the O +
same O +
region O +
as O +
the O +
reciprocal O +
translocation O +
that O +
creates O +
the O +
BCR O -
- O -
ABL O +
chimera O +
of O +
the O +
Philadelphia O +
chromosome O +
( O +
Ph O +
' O +
) O +
, O +
the O +
hallmark O +
of O +
CML O +
; O +
hLH-2 O +
was O +
retained O +
on O +
the O +
derivative O +
9 O +
chromosome O +
and O +
is O +
therefore O +
centromeric O +
of O +
c O -
- O -
ABL O +
. O +

The O +
proximity O +
of O +
hLH-2 O +
to O +
the O +
breakpoint O +
on O +
chromosome O +
9 O +
raises O +
the O +
possibility O +
of O +
cis O -
- O -
activation O +
by O +
the O +
t O +
( O +
9 O +
; O +
22 O +
) O +
( O +
q34 O +
; O +
q11 O +
) O +
translocation O +
. O +

In O +
addition O +
to O +
finding O +
hLH-2 O +
expression O +
in O +
all O +
cases O +
of O +
CML O +
, O +
expression O +
was O +
observed O +
in O +
lymphoid O +
malignancies O +
and O +
myeloid B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
but O +
not O +
in O +
primary O +
cases O +
of O +
acute O +
myelogenous O +
leukaemia O +
. O +

The O +
role O +
of O +
hLH-2 O +
in O +
the O +
development O +
or O +
progression O +
of O +
leukaemia O +
is O +
not O +
known O +
. O +

However O +
, O +
hLH-2 O +
may O +
prove O +
useful O +
as O +
a O +
marker O +
of O +
CML O +
for O +
monitoring O +
residual O +
disease O +
. O +

A O +
cell O +
type O -
- O -
specific O +
enhancer O +
in O +
the O +
human O +
B7.1 O +
gene O +
regulated O +
by O +
NF O -
- O -
kappaB O +
. O +

The O +
costimulatory O +
molecule O +
B7.1 O +
provides O +
a O +
second O +
signal O +
critical O +
for O +
T O +
cell O +
activation O +
. O +

The O +
distribution O +
of O +
this O +
integral O +
membrane O +
protein O +
is O +
restricted O +
to O +
certain O +
tissues O +
where O +
its O +
level O +
of O +
expression O +
is O +
modulated O +
by O +
multiple O +
exogenous O +
stimuli O +
. O +

To O +
identify O +
the O +
molecular O +
basis O +
for O +
specificity O +
and O +
inducibility O +
, O +
the O +
chromatin O +
configuration O +
of O +
the O +
human O +
B7.1 O +
gene O +
was O +
examined O +
in O +
intact O +
nuclei O +
from O +
various O +
cell O +
types O +
. O +

The O +
identification O +
of O +
a O +
tissue O -
- O -
specific O +
deoxyribonuclease O +
I O +
hypersensitive O +
site O +
approximately O +
3 O -
kb O +
upstream O +
of O +
the O +
transcription O +
start O +
site O +
led O +
to O +
the O +
characterization O +
of O +
a O +
cell O +
type O -
- O -
specific O +
enhancer O +
region O +
. O +

This O +
183-bp O +
region O +
was O +
both O +
cell O +
type O +
specific O +
and O +
responsive O +
to O +
two O +
distinct O +
stimuli O +
, O +
lipopolysaccharide O +
and O +
dibutyryl O +
cAMP O +
, O +
known O +
to O +
regulate O +
B7.1 O +
expression O +
. O +

Deletional O +
and O +
site O -
- O -
directed O +
mutagenesis O +
revealed O +
the O +
presence O +
of O +
multiple O +
functionally O +
critical O +
cis O +
elements O +
within O +
this O +
region O +
, O +
one O +
of O +
which O +
was O +
a O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappaB O +
consensus O +
sequence O +
. O +

In O +
B7.1-positive O +
B O +
cells O +
, O +
this O +
element O +
bound O +
several O +
members O +
of O +
the O +
NF O -
- O -
kappaB O +
family O +
, O +
transcription O +
factors O +
already O +
implicated O +
in O +
signal O +
transduction O +
pathways O +
relevant O +
to O +
B7.1 O +
expression O +
. O +

This O +
is O +
the O +
first O +
description O +
, O +
to O +
our O +
knowledge O +
, O +
of O +
regulatory O +
elements O +
that O +
control O +
expression O +
of O +
a O +
gene O +
encoding O +
a O +
B7 O +
costimulatory O +
molecule O +
. O +

HLA O -
- O -
DQB1 O +
codon O +
57 O +
is O +
critical O +
for O +
peptide O +
binding O +
and O +
recognition O +
. O +

The O +
association O +
of O +
specific O +
HLA O -
- O -
DQ O +
alleles O +
with O +
autoimmunity O +
is O +
correlated O +
with O +
discrete O +
polymorphisms O +
in O +
the O +
HLA O -
- O -
DQ O +
sequence O +
that O +
are O +
localized O +
within O +
sites O +
suitable O +
for O +
peptide O +
recognition O +
. O +

The O +
polymorphism O +
at O +
residue O +
57 O +
of O +
the O +
DQB1 O +
polypeptide O +
is O +
of O +
particular O +
interest O +
since O +
it O +
may O +
play O +
a O +
major O +
structural O +
role O +
in O +
the O +
formation O +
of O +
a O +
salt O +
bridge O +
structure O +
at O +
one O +
end O +
of O +
the O +
peptide O -
- O -
binding O +
cleft O +
of O +
the O +
DQ O +
molecules O +
. O +

This O +
polymorphism O +
at O +
residue O +
57 O +
is O +
a O +
recurrent O +
feature O +
of O +
HLA O -
- O -
DQ O +
evolution O +
, O +
occurring O +
in O +
multiple O +
distinct O +
allelic O +
families O +
, O +
which O +
implies O +
a O +
functional O +
selection O +
for O +
maintaining O +
variation O +
at O +
this O +
position O +
in O +
the O +
class O +
II O +
molecule O +
. O +

We O +
directly O +
tested O +
the O +
amino O +
acid O +
polymorphism O +
at O +
this O +
site O +
as O +
a O +
determinant O +
for O +
peptide O +
binding O +
and O +
for O +
antigen O -
- O -
specific O +
T O +
cell O +
stimulation O +
. O +

We O +
found O +
that O +
a O +
single O +
Ala O +
-- O +
> O +
Asp O +
amino O +
acid O +
57 O +
substitution O +
in O +
an O +
HLA O -
- O -
DQ3.2 O +
molecule O +
regulated O +
binding O +
of O +
an O +
HSV-2 O +
VP-16-derived O +
peptide O +
. O +

A O +
complementary O +
single O -
- O -
residue O +
substitution O +
in O +
the O +
peptide O +
abolished O +
its O +
binding O +
to O +
DQ3.2 O +
and O +
converted O +
it O +
to O +
a O +
peptide O +
that O +
can O +
bind O +
to O +
DQ3.1 O +
and O +
DQ3.3 O +
Asp-57-positive O +
MHC O +
molecules O +
. O +

These O +
binding O +
studies O +
were O +
paralleled O +
by O +
specific O +
T O +
cell O +
recognition O +
of O +
the O +
class O +
II O -
- O -
peptide O +
complex O +
, O +
in O +
which O +
the O +
substituted O +
peptide O +
abolished O +
T O +
cell O +
reactivity O +
, O +
which O +
was O +
directed O +
to O +
the O +
DQ3.2-peptide O +
complex O +
, O +
whereas O +
the O +
same O +
T B-CellLine +
cell I-CellLine +
clone I-CellLine +
recognized O +
the O +
substituted O +
peptide O +
presented O +
by O +
DQ3.3 O +
, O +
a O +
class O +
II O +
restriction O +
element O +
differing O +
from O +
DQ3.2 O +
only O +
at O +
residue O +
57 O +
. O +

This O +
structural O +
and O +
functional O +
complementarity O +
for O +
residue O +
57 O +
and O +
a O +
specific O +
peptide O +
residue O +
identifies O +
this O +
interaction O +
as O +
a O +
key O +
controlling O +
determinant O +
of O +
restricted O +
recognition O +
in O +
HLA O -
- O -
DQ O -
- O -
specific O +
immune O +
response O +
. O +

Transcription O +
factors O +
of O +
T O +
and O +
B O +
lymphocytes O +
-- O +
basic O +
research O +
and O +
clinical O +
perspectives O +
for O +
gastroenterology O +
. O +

Tissue O +
specific O +
regulation O +
of O +
gene O +
expression O +
by O +
transcription O +
factors O +
is O +
a O +
fascinating O +
new O +
field O +
in O +
molecular O +
immunology O +
. O +

This O +
review O +
summarizes O +
data O +
on O +
specific O +
regulation O +
of O +
promoters O +
and O +
enhancers O +
by O +
nuclear O +
trans O -
- O -
acting O +
factors O +
in O +
lymphocytes O +
. O +

The O +
structural O +
classes O +
of O +
transcription O +
factors O +
are O +
described O +
and O +
basic O +
methods O +
for O +
detection O +
and O +
analysis O +
of O +
transcription O +
factors O +
are O +
detailed O +
. O +

Furthermore O +
, O +
the O +
most O +
important O +
trans O -
- O -
acting O +
factors O +
of O +
T O +
and O +
B O +
lymphocytes O +
( O +
e.g O +
. O +
NF O -
- O -
kB O +
, O +
NF O -
- O -
AT O +
and O +
STAT O +
families O +
) O +
and O +
their O +
functional O +
importance O +
are O +
described O +
. O +

Several O +
methods O +
for O +
specific O +
down O -
- O -
regulation O +
of O +
transcription O +
factors O +
are O +
shown O +
that O +
may O +
be O +
relevant O +
to O +
treatment O +
of O +
human O +
disease O +
. O +

The O +
data O +
are O +
discussed O +
with O +
regard O +
to O +
their O +
potential O +
clinical O +
relevance O +
for O +
gastroenterology O +
. O +

Inhibition O +
of O +
alpha O +
interferon O +
but O +
not O +
gamma O +
interferon O +
signal O +
transduction O +
by O +
phorbol O +
esters O +
is O +
mediated O +
by O +
a O +
tyrosine O +
phosphatase O +
. O +

Previous O +
studies O +
have O +
indicated O +
that O +
the O +
expression O +
of O +
viral O +
oncoproteins O +
, O +
cell O +
transformation O +
, O +
or O +
phorbol O +
ester O +
treatment O +
of O +
cells O +
can O +
inhibit O +
alpha O -
/ O -
beta O +
interferon O +
( O +
IFN O -
- O -
alpha O -
/ O -
beta O +
) O +
-induced O +
gene O +
expression O +
. O +

The O +
mechanisms O +
by O +
which O +
these O +
promoters O +
of O +
cell O +
growth O +
exert O +
their O +
inhibitory O +
effects O +
vary O +
, O +
but O +
in O +
most O +
instances O +
they O +
involve O +
a O +
disruption O +
of O +
the O +
IFN O -
- O -
alpha O -
/ O -
beta O -
- O -
induced O +
transcription O +
complex O +
ISGF3 O +
such O +
that O +
the O +
DNA O -
- O -
binding O +
component O +
of O +
this O +
complex O +
( O +
the O +
48-kDa O +
ISGF3gamma O +
protein O +
) O +
does O +
not O +
bind O +
to O +
the O +
interferon O -
- O -
stimulated O +
response O +
element O +
( O +
ISRE O +
) O +
. O +

In O +
this O +
report O +
, O +
we O +
demonstrated O +
that O +
phorbol O +
ester O +
treatment O +
of O +
human O +
peripheral O +
blood O +
monocytes O +
dramatically O +
inhibits O +
activation O +
of O +
IFN O -
- O -
alpha O -
/ O -
B O -
- O -
stimulated O +
early O +
response O +
genes O +
but O +
by O +
a O +
mechanism O +
which O +
does O +
not O +
involve O +
abrogation O +
of O +
the O +
ISRE O +
binding O +
of O +
ISGF3gamma O +
. O +

Phorbol O +
ester O +
treatment O +
of O +
monocytes O +
inhibited O +
IFN O +
alpha O -
- O -
stimulated O +
tyrosine O +
phosphorylation O +
of O +
the O +
transcription O +
factors O +
Stat1alpha O +
, O +
Stat2 O +
, O +
and O +
Stat3 O +
and O +
of O +
the O +
tyrosine O +
kinase O +
Tyk2 O +
but O +
had O +
no O +
effect O +
on O +
IFN O -
- O -
gamma O +
activation O +
of O +
Stat1alpha O +
. O +

IFNalpha O -
- O -
stimulated O +
tyrosine O +
phosphorylation O +
of O +
Jak1 O +
and O +
the O +
alpha O +
subunit O +
of O +
the O +
IFN O -
- O -
alpha O +
receptor O +
were O +
unaffected O +
by O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
. O +

Moreover O +
, O +
PMA O +
caused O +
the O +
dephosphorylation O +
of O +
Tyk2 O +
but O +
not O +
of O +
Jak1 O +
, O +
which O +
was O +
activated O +
by O +
IFN O +
. O +

Pretreatment O +
of O +
cells O +
with O +
vanadate O +
prevented O +
the O +
effects O +
of O +
PMA O +
with O +
regard O +
to O +
PMA O -
- O -
induced O +
Tyk2 O +
dephosphorylation O +
. O +

These O +
observations O +
suggest O +
that O +
PMA O +
exerts O +
its O +
inhibitory O +
effects O +
by O +
activation O +
of O +
a O +
tyrosine O +
phosphatase O +
which O +
selectively O +
regulates O +
Tyk2 O +
but O +
not O +
Jak1 O +
activity O +
. O +

Inhibition O +
of O +
p105 O +
processing O +
by O +
NF O -
- O -
kappaB O +
proteins O +
in O +
transiently B-CellLine +
transfected I-CellLine +
cells I-CellLine +
. O +

Regulation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
involves O +
proteasome O -
- O -
mediated O +
processing O +
of O +
the O +
NF O -
- O -
kappaB1 O +
p105 O +
precursor O +
protein O +
, O +
which O +
generates O +
the O +
p50 O +
subunit O +
of O +
NF O -
- O -
kappaB O +
. O +

The O +
processing O +
of O +
p105 O +
occurs O +
constitutively O +
in O +
vivo O +
but O +
can O +
be O +
markedly O +
enhanced O +
by O +
various O +
cellular O +
activation O +
agents O +
, O +
although O +
the O +
underlying O +
regulatory O +
mechanism O +
is O +
not O +
yet O +
clear O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
demonstrate O +
that O +
signal O -
- O -
mediated O +
induction O +
of O +
p105 O +
processing O +
in O +
human O +
T O +
cells O +
is O +
associated O +
with O +
de O +
novo O +
synthesis O +
of O +
this O +
precursor O +
protein O +
. O +

Transient O +
transfection O +
studies O +
performed O +
in O +
COS7 B-CellLine +
cells I-CellLine +
revealed O +
that O +
the O +
newly O +
synthesized O +
p105 O +
protein O +
appears O +
to O +
be O +
more O +
rapidly O +
processed O +
compared O +
to O +
its O +
accumulated O +
form O +
that O +
is O +
already O +
associated O +
with O +
the O +
processed O +
product O +
p50 O +
. O +

Interestingly O +
, O +
the O +
processing O +
rate O +
of O +
p105 O +
is O +
markedly O +
inhibited O +
in O +
cells O +
co O -
- O -
transfected O +
with O +
p50 O +
or O +
other O +
NF O -
- O -
kappaB O +
subunits O +
, O +
including O +
RelA O +
and O +
c O -
- O -
Rel O +
, O +
that O +
physically O +
interact O +
with O +
p105 O +
. O +

These O +
findings O +
suggest O +
that O +
the O +
processing O +
of O +
p105 O +
is O +
subject O +
to O +
negative O +
regulation O +
by O +
the O +
various O +
NF O -
- O -
kappaB O +
subunits O +
. O +

We O +
further O +
demonstrate O +
that O +
p105 O +
undergoes O +
degradation O +
in O +
lipopolysaccharide B-CellLine -
- I-CellLine -
stimulated I-CellLine +
human I-CellLine +
monocytic I-CellLine +
cells I-CellLine +
. O +

However O +
, O +
the O +
inducible O +
degradation O +
of O +
p105 O +
is O +
not O +
coupled O +
with O +
the O +
generation O +
of O +
p50 O +
. O +

Together O +
, O +
these O +
studies O +
demonstrate O +
that O +
the O +
processing O +
and O +
inducible O +
degradation O +
of O +
p105 O +
are O +
differentially O +
regulated O +
. O +

BCL-6 O +
expression O +
during O +
B O -
- O -
cell O +
activation O +
. O +

Translocations O +
involving O +
the O +
BCL-6 O +
gene O +
are O +
common O +
in O +
the O +
diffuse O +
large O +
cell O +
subtype O +
of O +
non O -
- O -
Hodgkin O +
's O +
lymphoma O +
. O +

Invariably O +
, O +
the O +
BCL-6 O +
coding O +
region O +
is O +
intact O +
, O +
but O +
its O +
5 O +
' O +
untranslated O +
region O +
is O +
replaced O +
with O +
sequences O +
from O +
the O +
translocation O +
partner O +
. O +

The O +
present O +
study O +
shows O +
that O +
BCL-6 O +
expression O +
is O +
regulated O +
in O +
lymphocytes O +
during O +
mitogenic O +
stimulation O +
. O +

Resting O +
B O +
and O +
T O +
lymphocytes O +
contain O +
high O +
levels O +
of O +
BCL-6 O +
mRNA O +
. O +

Stimulation O +
of O +
mouse O +
B O +
cells O +
with O +
anti O -
- O -
IgM O +
or O +
IgD O +
antibodies O +
, O +
bacterial O +
lipopolysaccharide O +
, O +
phorbol O +
12-myristate O +
13-acetate O +
plus O +
ionomycin O +
, O +
or O +
CD40 O +
ligand O +
led O +
to O +
a O +
five O -
- O -
fold O +
to O +
35-fold O +
decrease O +
in O +
BCL-6 O +
mRNA O +
levels O +
. O +

Similar O +
downregulation O +
of O +
BCL-6 O +
mRNA O +
was O +
seen O +
in O +
human O +
B O +
cells O +
stimulated O +
with O +
Staphylococcus O +
aureus O +
plus O +
interleukin-2 O +
or O +
anti O -
- O -
IgM O +
antibodies O +
and O +
in O +
human O +
T O +
lymphocytes O +
stimulated O +
with O +
phytohemagglutinin O +
. O +

BCL-6 O +
mRNA O +
levels O +
began O +
to O +
decrease O +
8 O +
to O +
16 O +
hours O +
after O +
stimulation O +
, O +
before O +
cells O +
entered O +
S O +
phase O +
. O +

Although O +
polyclonal O +
activation O +
of O +
B O +
cells O +
in O +
vitro O +
invariably O +
decreased O +
BCL-6 O +
MRNA O +
expression O +
, O +
activated O +
B O +
cells O +
from O +
human O +
germinal O +
centers O +
expressed O +
BCL-6 O +
mRNA O +
at O +
levels O +
comparable O +
to O +
the O +
levels O +
in O +
resting O +
B O +
cells O +
. O +

Despite O +
these O +
similar O +
mRNA O +
levels O +
, O +
BCL-6 O +
protein O +
expression O +
was O +
threefold O +
to O +
34-fold O +
higher O +
in O +
germinal O +
center O +
B O +
cells O +
than O +
in O +
resting O +
B O +
cells O +
, O +
suggesting O +
that O +
BCL-6 O +
protein O +
levels O +
are O +
controlled O +
by O +
translational O +
or O +
posttranslational O +
mechanisms O +
. O +

These O +
observations O +
suggest O +
that O +
the O +
germinal O +
center O +
reaction O +
provides O +
unique O +
activation O +
signals O +
to O +
B O +
cells O +
that O +
allow O +
for O +
continued O +
, O +
high O -
- O -
level O +
BCL-6 O +
expression O +
. O +

Modulation O +
of O +
the O +
expression O +
of O +
the O +
IFN O -
- O -
gamma O +
receptor O +
beta O -
- O -
chain O +
controls O +
responsiveness O +
to O +
IFN O -
- O -
gamma O +
in O +
human O +
peripheral O +
blood O +
T O +
cells O +
. O +

IFN O -
- O -
gamma O +
has O +
potent O +
antiproliferative O +
and O +
apoptotic O +
effects O +
in O +
T O +
cells O +
that O +
are O +
important O +
in O +
determining O +
T O +
cell O +
development O +
and O +
polarized O +
differentiation O +
. O +

Therefore O +
, O +
any O +
event O +
that O +
enables O +
T O +
cells O +
to O +
become O +
less O +
responsive O +
to O +
IFN- O +
gamma O +
may O +
potentially O +
alter O +
immune O +
responsiveness O +
to O +
Ag O +
. O +

In O +
this O +
work O +
, O +
we O +
show O +
that O +
human O +
peripheral O +
blood O +
T O +
cells O +
that O +
are O +
stimulated O +
through O +
the O +
TCR O +
and O +
expanded O +
with O +
IL-2 O +
are O +
unresponsive O +
to O +
IFN O -
- O -
gamma O +
, O +
as O +
determined O +
by O +
a O +
lack O +
of O +
activation O +
of O +
jak O +
kinases O +
and O +
the O +
transcription O +
factor O +
, O +
STAT1 O +
( O +
alpha O +
) O +
, O +
a O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
. O +

This O +
nonresponsiveness O +
occurs O +
because O +
of O +
a O +
lack O +
of O +
expression O +
of O +
the O +
beta- O +
chain O +
( O +
accessory O +
factor O +
) O +
of O +
the O +
IFN O -
- O -
gamma O +
receptor O +
, O +
while O +
at O +
the O +
same O +
time O +
maintaining O +
IFN O -
- O -
gamma O +
receptor O +
alpha O -
- O -
chain O +
expression O +
. O +

Expression O +
of O +
the O +
beta O -
- O -
chain O +
can O +
be O +
restored O +
by O +
secondary O +
TCR O +
ligation O +
or O +
PMA O +
treatment O +
. O +

T O +
cell O +
blasts O +
treated O +
with O +
PMA O +
are O +
now O +
responsive O +
to O +
IFN O -
- O -
gamma O +
. O +

When O +
freshly O +
isolated O +
, O +
highly O +
enriched O +
( O +
> O +
98 O +
% O +
) O +
T O +
cells O +
are O +
examined O +
for O +
IFN O -
- O -
gamma O +
responsiveness O +
; O +
these O +
cells O +
can O +
respond O +
to O +
IFN O -
- O -
gamma O +
and O +
express O +
beta O -
- O -
chain O +
. O +

Therefore O +
, O +
as O +
T O +
cells O +
progress O +
from O +
primary O +
TCR O +
activation O +
through O +
IL-2 O +
-dependent O +
proliferation O +
, O +
followed O +
by O +
secondary O +
TCR O +
stimulation O +
, O +
their O +
responsiveness O +
to O +
IFN O -
- O -
gamma O +
varies O +
, O +
and O +
this O +
may O +
affect O +
their O +
ability O +
to O +
participate O +
in O +
an O +
ongoing O +
immune O +
response O +
. O +

Antisense O +
inhibition O +
of O +
vitamin O +
D O +
receptor O +
expression O +
induces O +
apoptosis O +
in O +
monoblastoid B-CellLine +
U937 I-CellLine +
cells I-CellLine +
. O +

The O +
active O +
vitamin O +
D3 O +
metabolite O +
1 O +
, O +
25-dihydroxycholecalciferol O +
( O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
) O +
acts O +
as O +
an O +
antiproliferative O +
and O +
differentiating O +
agent O +
for O +
the O +
monoblastoid B-CellLine +
cell I-CellLine +
line I-CellLine +
U937 I-CellLine +
and O +
as O +
an O +
important O +
immunologic O +
mediator O +
implicated O +
particularly O +
in O +
the O +
function O +
of O +
cells O +
belonging O +
to O +
the O +
monocyte O -
/ O -
macrophage O +
lineage O +
. O +

These O +
effects O +
are O +
controlled O +
by O +
the O +
vitamin O +
D O +
receptor O +
( O +
VDR O +
) O +
, O +
a O +
member O +
of O +
the O +
steroid O +
hormone O +
receptor O +
family O +
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
develop O +
U937 B-CellLine +
transfectants O +
expressing O +
antisense O +
VDR O +
mRNA O +
, O +
and O +
to O +
use O +
these O +
to O +
examine O +
the O +
role O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
-VDR O +
interaction O +
in O +
this O +
lineage O +
. O +

A O +
2-kb O +
VDR O +
cDNA O +
insert O +
( O +
including O +
the O +
complete O +
VDR O +
coding O +
region O +
) O +
was O +
cloned O +
in O +
an O +
antisense O +
orientation O +
into O +
the O +
EBV O +
episomal O +
vector O +
pMEP4 O +
under O +
the O +
control O +
of O +
an O +
inducible O +
promoter O +
and O +
transfected O +
into O +
U937 B-CellLine +
. O +

The O +
resultant B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
DH42 B-CellLine +
, O +
was O +
hygromycin O +
resistant O +
, O +
contained O +
VDR O +
cDNA O +
, O +
expressed O +
fewer O +
VDRs O +
than O +
controls O +
, O +
and O +
showed O +
a O +
substantial O +
decrease O +
in O +
antiproliferative O +
response O +
to O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
. O +

However O +
, O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
increased O +
the O +
number O +
of O +
cells O +
expressing O +
macrophage O +
cell O +
surface O +
Ags O +
, O +
including O +
CD14 O +
and O +
CD11b O +
. O +

A O +
subpopulation O +
of O +
smaller O +
cells O +
did O +
not O +
express O +
the O +
differentiation O +
markers O +
after O +
cadmium O +
stimulation O +
. O +

Cell O +
cycle O +
analysis O +
showed O +
shifts O +
in O +
the O +
distribution O +
of O +
cells O +
from O +
G1 O +
to O +
S O +
phase O +
, O +
which O +
were O +
more O +
pronounced O +
after O +
cadmium O +
treatment O +
. O +

A O +
considerable O +
proportion O +
of O +
cells O +
were O +
outside O +
the O +
cycle O +
and O +
DNA O +
fragmentation O +
confirmed O +
apoptosis O +
. O +

Thus O +
, O +
the O +
functional O +
outcome O +
of O +
the O +
VDR O +
antisense O +
transfection O +
suggests O +
that O +
in O +
the O +
myelomonocytic O +
lineage O +
, O +
VDR O +
expression O +
may O +
act O +
as O +
a O +
protective O +
mechanism O +
against O +
programmed O +
cell O +
death O +
. O +

Opposing O +
effects O +
of O +
glucocorticoids O +
on O +
the O +
rate O +
of O +
apoptosis O +
in O +
neutrophilic O +
and O +
eosinophilic O +
granulocytes O +
. O +

Eosinophils O +
and O +
neutrophils O +
are O +
closely O +
related O +
, O +
terminally O +
differentiated O +
cells O +
that O +
in O +
vitro O +
undergo O +
constitutive O +
cell O +
death O +
by O +
apoptosis O +
. O +

The O +
onset O +
of O +
apoptosis O +
in O +
both O +
cell O +
types O +
can O +
be O +
delayed O +
by O +
hemopoietins O +
and O +
inflammatory O +
mediators O +
. O +

Although O +
there O +
have O +
been O +
a O +
number O +
of O +
reports O +
demonstrating O +
that O +
glucocorticoids O +
( O +
in O +
particular O +
dexamethasone O +
) O +
antagonize O +
the O +
eosinophil O +
life O -
- O -
prolonging O +
effects O +
of O +
hemopoietins O +
, O +
direct O +
effects O +
of O +
dexamethasone O +
on O +
eosinophil O +
apoptosis O +
have O +
not O +
been O +
documented O +
. O +

In O +
this O +
study O +
we O +
examined O +
the O +
direct O +
effects O +
of O +
glucocorticoids O +
on O +
eosinophil O +
and O +
neutrophil O +
apoptosis O +
in O +
light O +
of O +
their O +
common O +
therapeutic O +
use O +
as O +
anti O -
- O -
inflammatory O +
and O +
anti O -
- O -
allergic O -
/ O -
hypereosinophilic O +
agents O +
. O +

We O +
found O +
that O +
treatment O +
with O +
dexamethasone O +
induced O +
eosinophil O +
apoptosis O +
. O +

In O +
contrast O +
, O +
dexamethasone O +
was O +
a O +
potent O +
inhibitor O +
of O +
neutrophil O +
apoptosis O +
. O +

The O +
effect O +
of O +
dexamethasone O +
on O +
both O +
cell O +
types O +
was O +
mediated O +
through O +
the O +
glucocorticoid O +
receptor O +
, O +
i.e. O +
, O +
it O +
was O +
abolished O +
by O +
the O +
glucocorticoid O +
receptor O +
antagonist O +
RU38486 O +
. O +

This O +
is O +
the O +
first O +
description O +
of O +
an O +
agent O +
that O +
promotes O +
eosinophil O +
apoptosis O +
while O +
inhibiting O +
neutrophil O +
apoptosis O +
, O +
and O +
thus O +
presents O +
a O +
novel O +
approach O +
to O +
the O +
study O +
of O +
control O +
of O +
apoptosis O +
in O +
these O +
closely O +
related O +
cell O +
types O +
as O +
well O +
as O +
increases O +
our O +
understanding O +
of O +
the O +
clinical O +
action O +
of O +
glucocorticoids O +
in O +
inflammation O +
. O +

Recombinant O +
NFAT1 O +
( O +
NFATp O +
) O +
is O +
regulated O +
by O +
calcineurin O +
in O +
T O +
cells O +
and O +
mediates O +
transcription O +
of O +
several O +
cytokine O +
genes O +
. O +

Transcription O +
factors O +
of O +
the O +
NFAT O +
family O +
play O +
a O +
key O +
role O +
in O +
the O +
transcription O +
of O +
cytokine O +
genes O +
and O +
other O +
genes O +
during O +
the O +
immune O +
response O +
. O +

We O +
have O +
identified O +
two O +
new O +
isoforms O +
of O +
the O +
transcription O +
factor O +
NFAT1 O +
( O +
previously O +
termed O +
NFATp O +
) O +
that O +
are O +
the O +
predominant O +
isoforms O +
expressed O +
in O +
murine O +
and O +
human O +
T O +
cells O +
. O +

When O +
expressed O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
recombinant O +
NFAT1 O +
is O +
regulated O +
, O +
as O +
expected O +
, O +
by O +
the O +
calmodulin O -
- O -
dependent O +
phosphatase O +
calcineurin O +
, O +
and O +
its O +
function O +
is O +
inhibited O +
by O +
the O +
immunosuppressive O +
agent O +
cyclosporin O +
A O +
( O +
CsA O +
) O +
. O +

Transactivation O +
by O +
recombinant O +
NFAT1 O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
requires O +
dual O +
stimulation O +
with O +
ionomycin O +
and O +
phorbol O +
12-myristate O +
13-acetate O +
; O +
this O +
activity O +
is O +
potentiated O +
by O +
coexpression O +
of O +
constitutively O +
active O +
calcineurin O +
and O +
is O +
inhibited O +
by O +
CsA O +
. O +

Immunocytochemical O +
analysis O +
indicates O +
that O +
recombinant O +
NFAT1 O +
localizes O +
in O +
the O +
cytoplasm O +
of O +
transiently O +
transfected O +
T O +
cells O +
and O +
translocates O +
into O +
the O +
nucleus O +
in O +
a O +
CsA O -
- O -
sensitive O +
manner O +
following O +
ionomycin O +
stimulation O +
. O +

When O +
expressed O +
in O +
COS B-CellLine +
cells I-CellLine +
, O +
however O +
, O +
NFAT1 O +
is O +
capable O +
of O +
transactivation O +
, O +
but O +
it O +
is O +
not O +
regulated O +
correctly O +
: O +
its O +
subcellular O +
localization O +
and O +
transcriptional O +
function O +
are O +
not O +
affected O +
by O +
stimulation O +
of O +
the O +
COS B-CellLine +
cells I-CellLine +
with O +
ionomycin O +
and O +
phorbol O +
12-myristate O +
13-acetate O +
. O +

Recombinant O +
NFAT1 O +
can O +
mediate O +
transcription O +
of O +
the O +
interleukin-2 O +
, O +
interleukin-4 O +
, O +
tumor O +
necrosis O +
factor O +
alpha O +
, O +
and O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
promoters O +
in O +
T O +
cells O +
, O +
suggesting O +
that O +
NFAT1 O +
contributes O +
to O +
the O +
CsA O -
- O -
sensitive O +
transcription O +
of O +
these O +
genes O +
during O +
the O +
immune O +
response O +
. O +

Epstein O -
- O -
Barr O +
virus O +
nuclear O +
antigen O +
2 O +
and O +
latent O +
membrane O +
protein O +
independently O +
transactivate O +
p53 O +
through O +
induction O +
of O +
NF O -
- O -
kappaB O +
activity O +
. O +

B O -
- O -
cell O +
immortalization O +
by O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
is O +
dependent O +
on O +
permanent O +
control O +
of O +
the O +
cellular O +
processes O +
which O +
normally O +
regulate O +
cell O +
division O +
and O +
apoptosis O +
, O +
functions O +
possessed O +
by O +
p53 O +
in O +
a O +
number O +
of O +
normal O +
cell O +
types O +
. O +

In O +
studies O +
initiated O +
to O +
evaluate O +
relationships O +
between O +
EBV O +
latent O +
genes O +
and O +
p53 O +
, O +
p53 O +
levels O +
were O +
found O +
to O +
increase O +
approximately O +
10-fold O +
4 O +
to O +
5 O +
days O +
after O +
EBV O +
infection O +
of O +
purified O +
resting O +
human O +
B O +
cells O +
; O +
the O +
induced O +
p53 O +
was O +
transcriptionally O +
active O +
. O +

Latent O +
membrane O +
protein O +
1 O +
and O +
, O +
to O +
a O +
lesser O +
extent O +
, O +
EBV O +
nuclear O +
antigen O +
2 O +
mediated O +
the O +
increase O +
in O +
p53 O +
levels O +
via O +
activation O +
of O +
the O +
NF O -
- O -
kappaB O +
transcription O +
factor O +
. O +

Interleukin O +
10 O +
induced O +
c O -
- O -
fos O +
expression O +
in O +
human O +
B O +
cells O +
by O +
activation O +
of O +
divergent O +
protein O +
kinases O +
. O +

IL-10 O +
is O +
a O +
potent O +
mediator O +
of O +
human O +
B O +
cell O +
growth O +
and O +
plasma O +
cell O +
formation O +
. O +

However O +
, O +
signal O +
transduction O +
of O +
IL-10 O +
in O +
B O +
cells O +
is O +
poorly O +
understood O +
. O +

In O +
this O +
study O +
the O +
effect O +
of O +
IL-10 O +
on O +
the O +
expression O +
of O +
the O +
protooncogene O +
c O -
- O -
fos O +
was O +
investigated O +
, O +
because O +
Fos O +
plays O +
a O +
potential O +
role O +
in O +
the O +
regulation O +
of O +
B O +
cell O +
proliferation O +
and O +
differentiation O +
. O +

B O +
cells O +
were O +
purified O +
from O +
buffy O +
coat O +
preparations O +
of O +
healthy O +
blood O +
donors O +
by O +
positive O +
selection O +
using O +
an O +
anti O +
CD20 O +
monoclonal O +
antibody O +
and O +
a O +
MiniMACS O +
separation O +
unit O +
. O +

B O +
cells O +
were O +
prestimulated O +
with O +
SAC O +
for O +
48 O +
hrs O +
. O +

Then O +
, O +
cells O +
were O +
incubated O +
with O +
medium O +
or O +
IL-10 O +
( O +
100 O +
ng O -
/ O -
ml O +
) O +
for O +
10 O +
to O +
120 O +
min O +
. O +

RNA O +
was O +
extracted O +
by O +
phenol O -
/ O -
chloroform O +
and O +
c O -
- O -
fos O +
expression O +
was O +
analyzed O +
by O +
PCR O +
assisted O +
mRNA O +
assay O +
. O +

A O +
significant O +
2 O -
- O -
4 O +
fold O +
increase O +
of O +
c O -
- O -
fos O +
expression O +
was O +
observed O +
within O +
30 O +
min O +
of O +
stimulation O +
with O +
IL-10 O +
( O +
p O +
< O +
0.01 O +
) O +
. O +

After O +
2 O +
hrs O +
c O -
- O -
fos O +
expression O +
declined O +
to O +
basal O +
levels O +
. O +

The O +
effect O +
of O +
IL-10 O +
was O +
dose O -
- O -
dependent O +
with O +
a O +
maximum O +
stimulation O +
using O +
100 O +
ng O -
/ O -
ml O +
of O +
IL-10 O +
. O +

The O +
IL-10 O +
effect O +
on O +
c O -
- O -
fos O +
expression O +
was O +
not O +
blocked O +
by O +
polymyxin O +
B O +
. O +

Using O +
the O +
tyrosine O +
kinase O +
inhibitor O +
genistein O +
( O +
10 O +
microM O +
) O +
a O +
complete O +
inhibition O +
of O +
IL-10 O +
induced O +
c O -
- O -
fos O +
expression O +
was O +
observed O +
. O +

In O +
addition O +
, O +
H-7 O +
( O +
10 O +
microM O +
) O +
, O +
a O +
specific O +
inhibitor O +
of O +
serine O -
/ O -
threonine O +
kinases O +
, O +
significantly O +
blocked O +
IL-10 O +
mediated O +
c O -
- O -
fos O +
expression O +
( O +
p O +
< O +
0.05 O +
) O +
. O +

In O +
conclusion O +
, O +
these O +
data O +
show O +
that O +
IL-10 O +
induces O +
c O -
- O -
fos O +
expression O +
in O +
human O +
B O -
- O -
cells O +
by O +
activation O +
of O +
tyrosine O +
and O +
serine O -
/ O -
threonine O +
kinases O +
. O +

Since O +
this O +
is O +
the O +
first O +
report O +
on O +
IL-10 O +
induced O +
signal O +
transduction O +
, O +
these O +
data O +
may O +
help O +
to O +
identify O +
the O +
intracellular O +
mechanisms O +
by O +
which O +
IL-10 O +
stimulates O +
human O +
B O -
- O -
cells O +
. O +

An O +
alternatively O +
spliced O +
isoform O +
of O +
the O +
Spi O -
- O -
B O +
transcription O +
factor O +
. O +

Spi O -
- O -
B O +
is O +
an O +
Ets O +
transcription O +
factor O +
related O +
to O +
the O +
oncoprotein O +
Spi-1 O -
/ O -
PU.1 O +
and O +
highly O +
expressed O +
in O +
B O +
lymphoid O +
cells O +
. O +

The O +
Ets O +
proteins O +
share O +
a O +
conserved O +
Ets O +
domain O +
that O +
mediates O +
specific O +
DNA O +
binding O +
. O +

Spi O -
- O -
B O +
binds O +
DNA O +
sequences O +
containing O +
a O +
core O +
5'-GGAA-3 O +
' O +
and O +
activates O +
transcription O +
through O +
this O +
motif O +
. O +

Up O +
to O +
date O +
, O +
the O +
biological O +
function O +
of O +
Spi O -
- O -
B O +
remains O +
unknown O +
. O +

Here O +
, O +
we O +
describe O +
the O +
characterization O +
of O +
an O +
alternatively O +
spliced O +
variant O +
of O +
Spi O -
- O -
B O +
, O +
named O +
deltaSpi O -
- O -
B O +
, O +
which O +
has O +
lost O +
the O +
Ets O +
domain O +
. O +

In O +
B O +
lymphoid O +
cells O +
, O +
deltaspi O -
- O -
B O +
and O +
spi O -
- O -
B O +
mRNAs O +
were O +
present O +
simultaneously O +
in O +
a O +
ratio O +
of O +
around O +
10 O +
% O +
. O +

DeltaSpi O -
- O -
B O +
product O +
was O +
not O +
able O +
to O +
bind O +
DNA O +
and O +
was O +
recovered O +
in O +
cytoplasmic O +
cellular O +
extracts O +
. O +

We O +
raise O +
the O +
hypothesis O +
that O +
delta O +
Spi O -
- O -
B O +
might O +
affect O +
Spi O -
- O -
B O +
function O +
by O +
recruiting O +
factors O +
involved O +
in O +
Spi O -
- O -
B O +
activity O +
. O +

Differential O +
utilization O +
of O +
Janus O +
kinase O +
-signal O +
transducer O +
activator O +
of O +
transcription O +
signaling O +
pathways O +
in O +
the O +
stimulation O +
of O +
human O +
natural O +
killer O +
cells O +
by O +
IL-2 O +
, O +
IL-12 O +
, O +
and O +
IFN O -
- O -
alpha O +
. O +

IL-2- O +
, O +
IL-12- O +
, O +
and O +
IFN O -
- O -
alpha O -
- O -
mediated O +
signaling O +
pathways O +
were O +
analyzed O +
in O +
primary O +
NK O +
cells O +
and O +
in O +
the O +
NK3.3 B-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Gel O +
mobility O +
shift O +
and O +
immunoprecipitation O +
analyses O +
revealed O +
that O +
in O +
addition O +
to O +
activating O +
STAT3 O +
( O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription-3 O +
) O +
and O +
STAT5 O +
, O +
IL-2 O +
induced O +
tyrosine O +
and O +
serine O +
phosphorylation O +
of O +
STAT1 O +
alpha O +
, O +
which O +
formed O +
IFN O -
- O -
gamma O -
- O -
activated O +
sequence O -
- O -
binding O +
complexes O +
by O +
itself O +
and O +
with O +
STAT3 O +
. O +

Although O +
IL-2 O +
and O +
IFN O -
- O -
alpha O +
activated O +
STAT1 O +
alpha O +
and O +
STAT5 O +
, O +
IL-2 O +
predominantly O +
activated O +
STAT5 O +
, O +
while O +
IFN O -
- O -
alpha O +
predominantly O +
activated O +
STAT1 O +
alpha O +
. O +

IL-2 O +
induced O +
less O +
STAT1 O +
alpha O +
activation O +
and O +
IFN O -
- O -
alpha O +
induced O +
greater O +
STAT5 O +
activation O +
in O +
NK3.3 B-CellLine +
cells I-CellLine +
compared O +
with O +
preactivated B-CellLine +
primary I-CellLine +
NK I-CellLine +
cells I-CellLine +
. O +

In O +
NK3.3 B-CellLine +
cells I-CellLine +
, O +
IL-2 O +
induced O +
comparable O +
formation O +
of O +
c O -
- O -
fos O +
promoter O +
sis O -
- O -
inducible O +
element O +
IFN O -
- O -
gamma O -
- O -
activated O +
sequence O -
- O -
binding O +
complexes O +
containing O +
STAT3 O +
alone O +
with O +
complexes O +
containing O +
STAT3 O +
and O +
STAT1 O +
alpha O +
, O +
while O +
in O +
preactivated B-CellLine +
primary I-CellLine +
NK I-CellLine +
cells I-CellLine +
, O +
it O +
preferentially O +
induced O +
complexes O +
containing O +
STAT3 O +
and O +
STAT1 O +
alpha O +
. O +

Thus O +
, O +
signaling O +
in O +
NK3.3 B-CellLine +
cells I-CellLine +
is O +
not O +
always O +
identical O +
with O +
that O +
in O +
primary O +
NK O +
cells O +
. O +

In O +
contrast O +
to O +
IL-2 O +
and O +
IFN O -
- O -
alpha O +
, O +
IL-12 O +
induced O +
strong O +
tyrosine O +
phosphorylation O +
of O +
STAT4 O +
and O +
variable O +
weak O +
phosphorylation O +
of O +
STAT3 O +
. O +

However O +
, O +
supershift O +
analyses O +
using O +
the O +
c O -
- O -
fos O +
promoter O +
sis O -
- O -
inducible O +
element O +
probe O +
showed O +
that O +
IL-12 O +
activated O +
STAT4 O +
, O +
STAT1 O +
alpha O +
, O +
and O +
STAT3 O +
, O +
and O +
induced O +
complexes O +
containing O +
STAT4 O +
only O +
, O +
STAT4 O +
with O +
STAT1 O +
alpha O +
, O +
STAT3 O +
with O +
STAT1 O +
alpha O +
, O +
or O +
STAT1 O +
alpha O +
only O +
in O +
preactivated B-CellLine +
primary I-CellLine +
NK I-CellLine +
cells I-CellLine +
. O +

STAT1 O +
alpha O +
activation O +
by O +
IL-12 O +
correlated O +
with O +
increased O +
phosphorylation O +
of O +
serine O +
, O +
but O +
not O +
tyrosine O +
. O +

Finally O +
, O +
IL-2 O +
induced O +
tyrosine O +
phosphorylation O +
of O +
JAK1 O +
and O +
JAK3 O +
, O +
while O +
IL-12 O +
induced O +
phosphorylation O +
of O +
JAK2 O +
and O +
TYK2 O +
in O +
both O +
preactivated B-CellLine +
primary I-CellLine +
NK I-CellLine +
and I-CellLine +
NK3.3 I-CellLine +
cells I-CellLine +
. O +

Differential O +
phosphorylation O +
and O +
consequent O +
differential O +
activation O +
of O +
both O +
separate O +
and O +
overlapping O +
STAT O +
proteins O +
by O +
IL-2 O +
, O +
IL-12 O +
, O +
and O +
IFN O -
- O -
alpha O +
may O +
provide O +
a O +
molecular O +
basis O +
for O +
the O +
similarities O +
and O +
differences O +
in O +
the O +
actions O +
of O +
these O +
cytokines O +
on O +
NK O +
cells O +
. O +

Glucocorticoids O +
and O +
interferon O -
- O -
alpha O +
in O +
the O +
acquired O +
immunodeficiency O +
syndrome O +
. O +

Some O +
patients O +
with O +
acquired O +
immunodeficiency O +
syndrome O +
( O +
AIDS O +
) O +
develop O +
glucocorticoid O +
resistance O +
characterized O +
by O +
low O +
receptor O +
affinity O +
( O +
Kd O +
) O +
for O +
glucocorticoids O +
in O +
mononuclear O +
, O +
cells O +
and O +
high O +
values O +
of O +
ACTH O +
and O +
cortisol O +
. O +

As O +
glucocorticoids O +
regulate O +
interferon O -
- O -
alpha O +
( O +
IFN O +
alpha O +
) O +
production O +
, O +
we O +
hypothesized O +
that O +
IFN O +
alpha O +
, O +
a O +
cytokine O +
produced O +
predominantly O +
by O +
monocytes O +
in O +
AIDS O +
, O +
should O +
be O +
increased O +
in O +
cortisol O -
- O -
resistant O +
AIDS O +
, O +
attributing O +
the O +
lack O +
of O +
cortisol O +
inhibition O +
to O +
IFN O +
alpha O +
production O +
. O +

Therefore O +
, O +
we O +
examined O +
glucocorticoid O +
receptor O +
characteristics O +
on O +
monocytes O +
by O +
[ O +
3H O +
] O +
dexamethasone O +
binding O +
and O +
measured O +
IFN O +
alpha O +
, O +
cortisol O +
, O +
and O +
ACTH O +
in O +
AIDS O +
patients O +
with O +
( O +
AIDS O -
- O -
GR O +
) O +
or O +
without O +
glucocorticoid O +
resistance O +
( O +
AIDS O -
- O -
C O +
) O +
and O +
controls O +
( O +
C O +
) O +
. O +

Monocytes O +
of O +
AIDS O -
- O -
GR O +
patients O +
had O +
a O +
receptor O +
Kd O +
of O +
10.5 O +
+ O -
/- O +
4.2 O +
nmol O -
/ O -
L O +
that O +
was O +
higher O +
than O +
that O +
in O +
the O +
AIDS O -
- O -
C O +
group O +
( O +
2.9 O +
+ O -
/- O +
0.8 O +
nmol O -
/ O -
L O +
) O +
and O +
normal O +
subjects O +
( O +
2.0 O +
+ O -
/- O +
0.8 O +
nmol O -
/ O -
L O +
; O +
P O +
< O +
0.01 O +
) O +
. O +

IFN O +
alpha O +
levels O +
were O +
increased O +
in O +
the O +
AIDS O -
- O -
GR O +
group O +
( O +
17 O +
+ O -
/- O +
6 O +
vs O +
. O +

4 O +
+ O -
/- O +
1 O +
U O -
/ O -
mL O +
in O +
the O +
AIDS O -
- O -
C O +
group O +
and O +
2 O +
+ O -
/- O +
0.5 O +
U O -
/ O -
mL O +
in O +
the O +
C O +
group O +
; O +
P O +
< O +
0.01 O +
) O +
. O +

Correlations O +
were O +
found O +
between O +
plasma O +
IFN O +
alpha O +
and O +
receptor O +
Kd O +
on O +
monocytes O +
of O +
AIDS O -
- O -
GR O +
( O +
r O +
= O +
0.77 O +
) O +
and O +
between O +
IFN O +
alpha O +
and O +
plasma O +
cortisol O +
in O +
the O +
same O +
group O +
( O +
r O +
= O +
0.74 O +
) O +
. O +

The O +
poly O +
( O +
I O +
) O +
-poly O +
( O +
C O +
) O +
-induced O +
IFN O +
alpha O +
production O +
by O +
monocytes O +
was O +
inhibited O +
by O +
glucocorticoids O +
in O +
the O +
C O +
and O +
AIDS O -
- O -
C O +
groups O +
( O +
approximately O +
80 O +
% O +
inhibition O +
in O +
both O +
groups O +
) O +
; O +
the O +
effect O +
was O +
reversed O +
by O +
the O +
receptor O +
antagonist O +
RU-38486 O +
. O +

By O +
contrast O +
, O +
glucocorticoids O +
failed O +
to O +
inhibit O +
IFNalpha O +
production O +
from O +
AIDS O -
- O -
GR O +
monocytes O +
( O +
approximately O +
20 O +
% O +
inhibition O +
) O +
. O +

In O +
conclusion O +
, O +
elevated O +
IFN O +
alpha O +
levels O +
in O +
AIDS O -
- O -
GR O +
may O +
be O +
due O +
to O +
the O +
lack O +
of O +
inhibitory O +
effect O +
of O +
cortisol O +
on O +
IFN O +
alpha O +
production O +
due O +
to O +
cortisol O +
resistance O +
in O +
monocytes O +

Receptors O +
for O +
interleukin O +
( O +
IL O +
) O +
-10 O +
and O +
IL-6-type O +
cytokines O +
use O +
similar O +
signaling O +
mechanisms O +
for O +
inducing O +
transcription O +
through O +
IL-6 O +
response O +
elements O +
. O +

The O +
cytoplasmic O +
domain O +
of O +
the O +
receptor O +
for O +
interleukin O +
10 O +
( O +
IL-10R O +
) O +
contains O +
two O +
box O +
3 O +
sequence O +
motifs O +
that O +
have O +
been O +
identified O +
in O +
the O +
signal O -
- O -
transducing O +
receptor O +
subunits O +
for O +
IL-6-type O +
cytokines O +
and O +
noted O +
to O +
be O +
required O +
for O +
activating O +
STAT3 O +
and O +
inducing O +
transcription O +
through O +
IL-6-responsive O +
elements O +
. O +

To O +
determine O +
whether O +
the O +
IL-10R O +
has O +
signaling O +
functions O +
similar O +
to O +
IL-6R O +
in O +
cells O +
normally O +
expressing O +
these O +
receptors O +
, O +
leukocytes O +
of O +
the O +
B- O +
, O +
T- O +
, O +
and O +
NK O -
- O -
cell O +
lineages O +
were O +
treated O +
with O +
either O +
cytokine O +
. O +

Both O +
cytokines O +
activated O +
factors O +
that O +
bound O +
to O +
the O +
sis O -
- O -
inducible O +
element O +
and O +
included O +
STAT1 O +
and O +
STAT3 O +
. O +

The O +
cell O +
response O +
to O +
IL-10 O +
characteristically O +
differed O +
from O +
that O +
to O +
IL-2 O -
/ O -
IL-15 O +
, O +
IL-4 O +
, O +
and O +
interferon O +
gamma O +
. O +

The O +
signaling O +
capabilities O +
of O +
the O +
IL-10R O +
for O +
activating O +
specific O +
STAT O +
proteins O +
and O +
inducing O +
gene O +
transcription O +
were O +
defined O +
by O +
reconstitution O +
of O +
receptor O +
functions O +
in O +
transfected B-CellLine +
tissue I-CellLine +
culture I-CellLine +
cells I-CellLine +
. O +

COS-1 B-CellLine +
cells I-CellLine +
, O +
co O -
- O -
expressing O +
the O +
human O +
IL-10R O +
and O +
individual O +
STAT O +
proteins O +
, O +
confirmed O +
a O +
preference O +
of O +
the O +
IL-10R O +
for O +
STAT3 O +
and O +
STAT1 O +
. O +

Unlike O +
many O +
hematopoietin O +
receptors O +
, O +
the O +
IL-10R O +
did O +
not O +
detectably O +
activate O +
STAT5 O +
. O +

The O +
IL-10R O +
, O +
together O +
with O +
reporter O +
gene O +
constructs O +
containing O +
different O +
IL-6-responsive O +
gene O +
elements O +
, O +
reconstituted O +
in O +
hepatoma O +
cells O +
an O +
induction O +
of O +
transcription O +
by O +
IL-10 O +
that O +
was O +
comparable O +
to O +
that O +
by O +
IL-6 O +
. O +

This O +
regulation O +
could O +
not O +
be O +
appreciably O +
modified O +
by O +
enhanced O +
expression O +
of O +
STAT O +
proteins O +
. O +

The O +
similar O +
actions O +
of O +
IL-10R O +
and O +
IL-6R O +
on O +
the O +
induction O +
of O +
endogenous O +
IL-6-responsive O +
genes O +
were O +
demonstrated O +
in O +
hepatoma O +
cells O +
stably O +
expressing O +
the O +
IL-10R O +
. O +

These O +
receptor O +
functions O +
required O +
the O +
presence O +
of O +
the O +
box O +
3 O +
motifs O +
, O +
as O +
shown O +
by O +
the O +
analysis O +
of O +
the O +
mouse O +
IL-10R O +
constructs O +
containing O +
progressively O +
truncated O +
cytoplasmic O +
domains O +
. O +

The O +
data O +
demonstrate O +
that O +
the O +
IL-10R O +
, O +
unlike O +
other O +
members O +
of O +
the O +
interferon O +
receptor O +
family O +
, O +
is O +
highly O +
effective O +
in O +
recruiting O +
the O +
signaling O +
pathways O +
of O +
IL-6-type O +
cytokine O +
receptors O +
. O +

DNA O +
triplex O +
formation O +
selectively O +
inhibits O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
gene O +
expression O +
in O +
human O +
T O +
cells O +
. O +

Granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
is O +
a O +
hemopoietic O +
growth O +
factor O +
that O +
is O +
expressed O +
in O +
activated O +
T O +
cells O +
, O +
fibroblasts O +
, O +
macrophages O +
, O +
and O +
endothelial O +
cells O +
. O +

Although O +
GM O -
- O -
CSF O +
does O +
not O +
appear O +
to O +
be O +
essential O +
for O +
normal O +
hemopoiesis O +
, O +
overexpression O +
of O +
GM O -
- O -
CSF O +
has O +
been O +
implicated O +
in O +
the O +
pathogenesis O +
of O +
some O +
diseases O +
such O +
as O +
myeloid O +
leukemia O +
and O +
chronic O +
inflammation O +
. O +

An O +
NF O -
- O -
kappaB O +
/Rel O +
binding O +
site O +
within O +
the O +
GM O -
- O -
CSF O +
promoter O +
, O +
termed O +
the O +
kappaB O +
element O +
appears O +
to O +
be O +
important O +
for O +
controlling O +
expression O +
in O +
reporter O +
gene O +
assays O +
in O +
response O +
to O +
a O +
number O +
of O +
stimuli O +
in O +
T O +
cells O +
. O +

We O +
investigated O +
oligonucleotide O -
- O -
directed O +
triple O +
helix O +
formation O +
across O +
this O +
regulatory O +
sequence O +
as O +
a O +
potential O +
tool O +
to O +
inhibit O +
GM O -
- O -
CSF O +
gene O +
transcription O +
. O +

A O +
15-base O +
oligonucleotide O +
, O +
GM3 O +
, O +
was O +
targeted O +
to O +
a O +
purine O -
- O -
rich O +
region O +
in O +
the O +
GM O -
- O -
CSF O +
proximal O +
promoter O +
, O +
which O +
overlaps O +
the O +
kappaB O +
element O +
. O +

Gel O +
mobility O +
shift O +
assays O +
and O +
DNase O +
I O +
footprinting O +
demonstrated O +
that O +
GM3 O +
formed O +
a O +
sequence O -
- O -
specific O +
collinear O +
triplex O +
with O +
its O +
double O -
- O -
stranded O +
DNA O +
target O +
. O +

Triplex O +
formation O +
by O +
GM3 O +
blocked O +
recombinant O +
and O +
nuclear O +
NF O -
- O -
kappaB O +
proteins O +
binding O +
to O +
the O +
GM O -
- O -
CSF O +
element O +
. O +

GM3 O +
also O +
caused O +
selective O +
inhibition O +
of O +
the O +
human O +
T O -
- O -
cell O +
lymphotrophic O +
virus-1 O +
Tax O +
transactivator O -
- O -
induced O +
luciferase O +
activity O +
from O +
a O +
reporter O +
construct O +
driven O +
by O +
the O +
GM O -
- O -
CSF O +
promoter O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Finally O +
, O +
GM3 O +
greatly O +
reduced O +
the O +
concentration O +
of O +
endogenous O +
GM O -
- O -
CSF O +
mRNA O +
induced O +
by O +
different O +
stimuli O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
but O +
did O +
not O +
affect O +
interleukin O +
3 O +
mRNA O +
levels O +
in O +
the O +
same O +
cells O +
. O +

We O +
conclude O +
that O +
the O +
kappaB O +
element O +
in O +
the O +
GM O -
- O -
CSF O +
promoter O +
plays O +
a O +
central O +
role O +
in O +
the O +
transcriptional O +
activation O +
of O +
the O +
endogenous O +
GM O -
- O -
CSF O +
gene O +
. O +

Colinear O +
triplex O +
formation O +
acts O +
as O +
a O +
selective O +
transcriptional O +
repressor O +
of O +
the O +
GM O -
- O -
CSF O +
gene O +
and O +
may O +
have O +
potential O +
therapeutic O +
application O +
in O +
cases O +
of O +
undesirable O +
overexpression O +
of O +
this O +
protein O +
. O +

Octamer O +
binding O +
factors O +
and O +
their O +
coactivator O +
can O +
activate O +
the O +
murine O +
PU.1 O +
( O +
spi-1 O +
) O +
promoter O +
. O +

PU.1 O +
( O +
spi-1 O +
) O +
, O +
a O +
member O +
of O +
the O +
Ets O +
transcription O +
factor O +
family O +
, O +
is O +
predominantly O +
expressed O +
in O +
myeloid O +
and O +
B O +
cells O +
, O +
activates O +
many O +
B O +
cell O +
and O +
myeloid O +
genes O +
, O +
and O +
is O +
critical O +
for O +
development O +
of O +
both O +
of O +
these O +
lineages O +
. O +

Our O +
previous O +
studies O +
( O +
Chen O +
, O +
H.M. O +
, O +
Ray O -
- O -
Gallet O +
, O +
D. O +
, O +
Zhang O +
, O +
P. O +
, O +
Hetherington O +
, O +
C.J. O +
, O +
Gonzalez O +
, O +
D.A. O +
, O +
Zhang O +
, O +
D O -
.- O -
E. O +
, O +
Moreau O -
- O -
Gachelin O +
, O +
F. O +
, O +
and O +
Tenen O +
, O +
D.G. O +
( O +
1995 O +
) O +
Oncogene O +
11 O +
, O +
1549 O -
- O -
1560 O +
) O +
demonstrate O +
that O +
the O +
PU.1 O +
promoter O +
directs O +
cell O +
type O -
- O -
specific O +
reporter O +
gene O +
expression O +
in O +
myeloid O +
cell O +
lines O +
, O +
and O +
that O +
PU.1 O +
activates O +
its O +
own O +
promoter O +
in O +
an O +
autoregulatory O +
loop O +
. O +

Here O +
we O +
show O +
that O +
the O +
murine O +
PU.1 O +
promoter O +
is O +
also O +
specifically O +
and O +
highly O +
functional O +
in O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
as O +
well O +
. O +

Oct-1 O +
and O +
Oct-2 O +
can O +
bind O +
specifically O +
to O +
a O +
site O +
at O +
base O +
pair O +
-55 O +
in O +
vitro O +
, O +
and O +
this O +
site O +
is O +
specifically O +
protected O +
in O +
B O +
cells O +
in O +
vivo O +
. O +

We O +
also O +
demonstrate O +
that O +
two O +
other O +
sites O +
contribute O +
to O +
promoter O +
activity O +
in O +
B O +
cells O +
; O +
an O +
Sp1 O +
binding O +
site O +
adjacent O +
to O +
the O +
octamer O +
site O +
, O +
and O +
the O +
PU.1 O +
autoregulatory O +
site O +
. O +

Finally O +
, O +
we O +
show O +
that O +
the O +
B O +
cell O +
coactivator O +
OBF-1 O -
/ O -
Bob1 O -
/ O -
OCA O -
- O -
B O +
is O +
only O +
expressed O +
in O +
B O +
cells O +
and O +
not O +
in O +
myeloid O +
cells O +
, O +
and O +
that O +
OBF-1 O -
/ O -
Bob1 O -
/ O -
OCA O -
- O -
B O +
can O +
transactivate O +
the O +
PU.1 O +
promoter O +
in O +
HeLa B-CellLine +
and O +
myeloid O +
cells O +
. O +

This O +
B O +
cell O +
restricted O +
coactivator O +
may O +
be O +
responsible O +
for O +
the O +
B O +
cell O +
specific O +
expression O +
of O +
PU.1 O +
mediated O +
by O +
the O +
octamer O +
site O +
. O +

Multiple O +
transcription O +
factors O +
are O +
required O +
for O +
activation O +
of O +
human O +
interleukin O +
9 O +
gene O +
in O +
T O +
cells O +
. O +

The O +
genetic O +
elements O +
and O +
regulatory O +
mechanisms O +
responsible O +
for O +
human O +
interleukin O +
9 O +
( O +
IL-9 O +
) O +
gene O +
expression O +
in O +
a O +
human B-CellLine +
T I-CellLine +
cell I-CellLine +
leukemia I-CellLine +
virus I-CellLine +
type I-CellLine +
I I-CellLine -
- I-CellLine -
transformed I-CellLine +
human I-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
C5MJ2 B-CellLine +
, O +
were O +
investigated O +
. O +

We O +
demonstrated O +
that O +
IL-9 O +
gene O +
expression O +
is O +
controlled O +
, O +
at O +
least O +
in O +
part O +
, O +
by O +
transcriptional O +
activation O +
. O +

Transient O +
expression O +
of O +
the O +
luciferase O +
reporter O +
gene O +
linked O +
to O +
serially O +
deleted O +
sequences O +
of O +
the O +
5'-flanking O +
region O +
of O +
the O +
IL-9 O +
gene O +
has O +
revealed O +
several O +
positive O +
and O +
negative O +
regulatory O +
elements O +
involved O +
in O +
the O +
basal O +
and O +
inducible O +
expression O +
of O +
the O +
IL-9 O +
gene O +
in O +
C5MJ2 B-CellLine +
cells I-CellLine +
. O +

An O +
AP-1 O +
site O +
at O +
-146 O +
to O +
-140 O +
was O +
shown O +
to O +
be O +
involved O +
in O +
the O +
expression O +
of O +
the O +
IL-9 O +
gene O +
. O +

A O +
proximal O +
region O +
between O +
-46 O +
and O +
-80 O +
was O +
identified O +
as O +
the O +
minimum O +
sequence O +
for O +
the O +
basal O +
and O +
inducible O +
expression O +
of O +
the O +
IL-9 O +
gene O +
in O +
C5MJ2 B-CellLine +
cells I-CellLine +
. O +

Within O +
this O +
region O +
, O +
an O +
NF O -
- O -
kappaB O +
site O +
at O +
-59 O +
to O +
-50 O +
and O +
its O +
adjacent O +
20-base O +
pair O +
upstream O +
sequence O +
were O +
demonstrated O +
to O +
play O +
a O +
critical O +
role O +
for O +
the O +
IL-9 O +
promoter O +
activity O +
. O +

DNA O -
- O -
protein O +
binding O +
studies O +
indicated O +
that O +
NF O -
- O -
kappaB O +
, O +
c O -
- O -
Jun O +
, O +
and O +
potentially O +
novel O +
proteins O +
( O +
around O +
35 O +
kDa O +
) O +
can O +
bind O +
to O +
this O +
important O +
sequence O +
. O +

Mutations O +
at O +
different O +
sites O +
within O +
this O +
proximal O +
promoter O +
region O +
abolished O +
the O +
promoter O +
activity O +
as O +
well O +
as O +
the O +
DNA O +
binding O +
. O +

Taken O +
together O +
, O +
these O +
results O +
suggest O +
that O +
the O +
cooperation O +
of O +
different O +
transcription O +
factors O +
is O +
essential O +
for O +
IL-9 O +
gene O +
expression O +
in O +
T O +
cells O +
. O +

A O +
3 O +
' O +
-- O +
> O +
5 O +
' O +
XPB O +
helicase O +
defect O +
in O +
repair O -
/ O -
transcription O +
factor O +
TFIIH O +
of O +
xeroderma O +
pigmentosum O +
group O +
B O +
affects O +
both O +
DNA O +
repair O +
and O +
transcription O +
. O +

XPB O +
is O +
a O +
subunit O +
of O +
the O +
basal O +
transcription O +
factor O +
TFIIH O +
, O +
which O +
is O +
also O +
involved O +
in O +
nucleotide O +
excision O +
repair O +
( O +
NER O +
) O +
and O +
potentially O +
in O +
cell O +
cycle O +
regulation O +
. O +

A O +
frameshift O +
mutation O +
in O +
the O +
3'-end O +
of O +
the O +
XPB O +
gene O +
is O +
responsible O +
for O +
a O +
concurrence O +
of O +
two O +
disorders O +
: O +
xeroderma O +
pigmentosum O +
( O +
XP O +
) O +
and O +
Cockayne O +
's O +
syndrome O +
( O +
CS O +
) O +
. O +

We O +
have O +
isolated O +
TFIIH O +
from O +
cells O +
derived O +
from O +
a O +
patient O +
( O +
XP11BE O +
) O +
who O +
carries O +
this O +
frameshift O +
mutation O +
( O +
TFIIHmut O +
) O +
and O +
from O +
the O +
mother O +
of O +
this O +
patient O +
( O +
TFIIHwt O +
) O +
to O +
determine O +
the O +
biochemical O +
consequences O +
of O +
the O +
mutation O +
. O +

Although O +
identical O +
in O +
composition O +
and O +
stoichiometry O +
to O +
TFIIHwt O +
, O +
TFIIHmut O +
shows O +
a O +
reduced O +
3 O +
' O +
-- O +
> O +
5 O +
' O +
XPB O +
helicase O +
activity O +
. O +

A O +
decrease O +
in O +
helicase O +
and O +
DNA O -
- O -
dependent O +
ATPase O +
activities O +
was O +
also O +
observed O +
with O +
the O +
mutated O +
recombinant O +
XPB O +
protein O +
. O +

The O +
XPB O +
mutation O +
causes O +
a O +
severe O +
NER O +
defect O +
. O +

In O +
addition O +
, O +
we O +
provide O +
evidence O +
for O +
a O +
decrease O +
in O +
basal O +
transcription O +
activity O +
in O +
vitro O +
. O +

The O +
latter O +
defect O +
may O +
provide O +
an O +
explanation O +
for O +
many O +
of O +
the O +
XP O +
and O +
CS O +
symptoms O +
that O +
are O +
difficult O +
to O +
rationalize O +
based O +
solely O +
on O +
an O +
NER O +
defect O +
. O +

Thus O +
, O +
this O +
work O +
presents O +
the O +
first O +
detailed O +
analysis O +
of O +
a O +
naturally O +
occurring O +
mutation O +
in O +
a O +
basal O +
transcription O +
factor O +
and O +
supports O +
the O +
concept O +
that O +
the O +
combined O +
XP O -
/ O -
CS O +
clinical O +
entity O +
is O +
actually O +
the O +
result O +
of O +
a O +
combined O +
transcription O -
/ O -
repair O +
deficiency O +
. O +

Cytokine O +
-modulating O +
activity O +
of O +
tepoxalin O +
, O +
a O +
new O +
potential O +
antirheumatic O +
. O +

Tepoxalin O +
is O +
a O +
new O +
dual O +
cyclooxygenase O -
/ O -
5-lipoxygenase O +
anti O -
- O -
inflammatory O +
compound O +
currently O +
under O +
clinical O +
investigation O +
. O +

It O +
has O +
been O +
shown O +
to O +
possess O +
anti O -
- O -
inflammatory O +
activity O +
in O +
a O +
variety O +
of O +
animal O +
models O +
and O +
more O +
recently O +
to O +
inhibit O +
IL-2 O +
induced O +
signal O +
transduction O +
. O +

The O +
current O +
study O +
was O +
conducted O +
to O +
evaluate O +
the O +
cytokine O +
modulating O +
activity O +
of O +
tepoxalin O +
and O +
the O +
role O +
of O +
iron O +
in O +
these O +
effects O +
. O +

In O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
stimulated O +
with O +
OKT3 O -
/ O -
PMA O +
, O +
tepoxalin O +
inhibited O +
lymphocyte O +
proliferation O +
with O +
an O +
IC50 O +
of O +
6 O +
microM O +
. O +

Additionally O +
, O +
it O +
inhibited O +
the O +
production O +
of O +
LTB4 O +
( O +
IC50 O +
= O +
0.5 O +
microM O +
) O +
and O +
the O +
cytokines O +
IL-2 O +
, O +
IL-6 O +
and O +
TNF O +
alpha O +
( O +
IC50 O +
= O +
10 O -
- O -
12 O +
microM O +
) O +
. O +

Cytotoxicity O +
was O +
not O +
demonstrated O +
at O +
these O +
concentrations O +
. O +

Add O -
- O -
back O +
experiments O +
with O +
either O +
cytokines O +
( O +
IL-2 O +
or O +
IL-6 O +
) O +
, O +
LTB4 O +
or O +
conditioned O +
media O +
failed O +
to O +
restore O +
the O +
proliferative O +
response O +
in O +
the O +
presence O +
of O +
tepoxalin O +
. O +

However O +
, O +
the O +
concurrent O +
addition O +
of O +
iron O +
( O +
in O +
the O +
form O +
of O +
ferrous O +
or O +
ferric O +
chloride O +
and O +
other O +
iron O +
salts O +
) O +
reversed O +
the O +
inhibition O +
of O +
proliferation O +
caused O +
by O +
tepoxalin O +
. O +

Tepoxalin O +
also O +
inhibits O +
the O +
activation O +
of O +
NF O +
kappa O +
B O +
, O +
a O +
transcription O +
factor O +
which O +
acts O +
on O +
several O +
cytokine O +
genes O +
. O +

Tepoxalin O +
's O +
effect O +
on O +
NF O +
kappa O +
B O +
is O +
also O +
reversed O +
by O +
the O +
addition O +
of O +
iron O +
salts O +
. O +

These O +
data O +
suggest O +
that O +
the O +
action O +
of O +
tepoxalin O +
to O +
inhibit O +
proliferation O +
in O +
PBMC O +
may O +
be O +
at O +
least O +
in O +
part O +
due O +
to O +
its O +
ability O +
to O +
reduce O +
the O +
amount O +
of O +
available O +
iron O +
resulting O +
in O +
decreased O +
activation O +
of O +
NF O +
kappa O +
B O +
and O +
subsequent O +
inhibition O +
of O +
cytokine O +
production O +
. O +

Characterization O +
of O +
Grb2-binding O +
proteins O +
in O +
human O +
platelets O +
activated O +
by O +
Fc O +
gamma O +
RIIA O +
cross O -
- O -
linking O +
. O +

Glutathione O -
- O -
S O -
- O -
transferase O +
( O +
GST O +
) O +
-Grb2 O +
fusion O +
proteins O +
have O +
been O +
used O +
to O +
identify O +
the O +
potential O +
role O +
of O +
Grb2-binding O +
proteins O +
in O +
platelet O +
activation O +
by O +
the O +
platelet O +
low O -
- O -
affinity O +
IgG O +
receptor O +
, O +
Fc O +
gamma O +
RIIA O +
. O +

Two O +
tyrosine O +
phosphoproteins O +
of O +
38 O +
and O +
63 O +
kD O +
bind O +
to O +
the O +
SH2 O +
domain O +
of O +
Grb2 O +
following O +
Fc O +
gamma O +
RIIA O +
stimulation O +
of O +
platelets O +
. O +

Both O +
are O +
located O +
in O +
the O +
particulate O +
fraction O +
following O +
platelet O +
activation O +
and O +
are O +
also O +
able O +
to O +
bind O +
to O +
a O +
GST O -
- O -
construct O +
containing O +
the O +
SH2 O +
and O +
SH3 O +
domains O +
of O +
phospholipase O +
C O +
gamma O +
1 O +
. O +

p38 O +
also O +
forms O +
a O +
complex O +
with O +
the O +
tyrosine O +
kinase O +
csk O +
in O +
stimulated O +
cells O +
and O +
is O +
a O +
substrate O +
for O +
the O +
kinase O +
. O +

The O +
SH3 O +
domains O +
of O +
Grb2 O +
form O +
a O +
stable O +
complex O +
with O +
SOS1 O +
and O +
two O +
proteins O +
of O +
75 O +
kD O +
and O +
120 O +
kD O +
, O +
which O +
undergo O +
tyrosine O +
phosphorylation O +
in O +
Fc B-CellLine +
gamma I-CellLine +
RIIA I-CellLine +
stimulated I-CellLine +
cells I-CellLine +
. O +

The O +
75-kD O +
protein O +
is O +
recognized O +
by O +
antibodies O +
to O +
SLP-76 O +
, O +
which O +
has O +
recently O +
been O +
isolated O +
from O +
T O +
cells O +
and O +
sequenced O +
. O +

Tyrosine O +
phosphorylation O +
of O +
p38 O +
and O +
p63 O +
is O +
also O +
observed O +
in O +
platelets O +
stimulated O +
by O +
the O +
tyrosine O +
kinase O +
-linked O +
receptor O +
agonist O +
collagen O +
and O +
by O +
the O +
G O +
protein O +
-coupled O +
receptor O +
agonist O +
thrombin O +
, O +
although O +
phosphorylation O +
of O +
SLP-76 O +
is O +
only O +
observed O +
in O +
collagen O +
-stimulated O +
platelets O +
. O +

p38 O +
and O +
p63 O +
may O +
provide O +
a O +
docking O +
site O +
for O +
Grb2 O +
, O +
thereby O +
linking O +
Grb2 O +
SH3-binding O +
proteins O +
SOS1 O +
, O +
SLP-76 O +
, O +
and O +
p120 O +
to O +
downstream O +
signalling O +
events O +
. O +

Retinoic O +
acid O +
activates O +
interferon O +
regulatory O +
factor-1 O +
gene O +
expression O +
in O +
myeloid O +
cells O +
. O +

All O -
- O -
trans O -
- O -
retinoic O +
acid O +
( O +
ATRA O +
) O +
is O +
the O +
drug O +
of O +
choice O +
in O +
the O +
treatment O +
of O +
acute O +
promyelocytic O +
leukemia O +
( O +
APL O +
) O +
. O +

ATRA O +
induces O +
both O +
in O +
vitro O +
and O +
in O +
vivo O +
differentiation O +
of O +
APL B-CellLine +
cells I-CellLine +
into O +
mature O +
granulocytes O +
. O +

However O +
, O +
the O +
molecular O +
mechanisms O +
involved O +
in O +
ATRA O -
- O -
dependent O +
growth O +
inhibition O +
and O +
cellular O +
differentiation O +
are O +
not O +
presently O +
understood O +
. O +

The O +
NB4 B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
which O +
is O +
derived O +
from O +
the O +
bone O +
marrow O +
of O +
a O +
patient O +
with O +
APL O +
during O +
relapse O +
, O +
can O +
be O +
used O +
as O +
a O +
model O +
system O +
to O +
study O +
the O +
growth O +
and O +
differentiation O +
of O +
APL B-CellLine +
cells I-CellLine +
. O +

Because O +
interferon O +
( O +
IFN O +
) O +
regulatory O +
factors O +
( O +
IRF-1 O +
and O +
IRF-2 O +
) O +
and O +
other O +
IFN O -
- O -
inducible O +
gene O +
products O +
regulate O +
cell O +
growth O +
, O +
we O +
analyzed O +
the O +
effects O +
of O +
ATRA O +
on O +
the O +
expression O +
of O +
these O +
genes O +
. O +

We O +
show O +
that O +
ATRA O +
directly O +
activates O +
IRF-1 O +
gene O +
expression O +
, O +
followed O +
by O +
activation O +
of O +
IRF-2 O +
and O +
2'-5 O +
' O +
oligoadenylate O +
synthetase O +
( O +
OAS O +
) O +
gene O +
expression O +
with O +
slower O +
kinetics O +
. O +

In O +
addition O +
to O +
NB4 O +
cells O +
, O +
ATRA O +
also O +
activated O +
IRF-1 O +
gene O +
expression O +
in O +
HL-60 B-CellLine +
, O +
U937 B-CellLine +
, O +
and O +
THP-1 B-CellLine +
cells I-CellLine +
, O +
which O +
all O +
respond O +
to O +
ATRA O +
by O +
growth O +
inhibition O +
. O +

A O +
more O +
than O +
additive O +
increase O +
in O +
IRF-1 O +
gene O +
expression O +
was O +
seen O +
with O +
ATRA O +
and O +
IFN O -
- O -
gamma O +
in O +
NB4 B-CellLine +
cells I-CellLine +
. O +

ATRA O +
did O +
not O +
activate O +
nuclear O +
factor O +
kappa O +
B O +
or O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
( O +
STAT O +
) O +
activation O +
pathways O +
, O +
suggesting O +
that O +
an O +
alternate O +
mechanism O +
is O +
involved O +
in O +
IRF-1 O +
gene O +
activation O +
. O +

The O +
ATRA O -
- O -
induced O +
expression O +
of O +
IRF-1 O +
, O +
an O +
activator O +
of O +
transcription O +
and O +
repressor O +
of O +
transformation O +
, O +
may O +
be O +
one O +
of O +
the O +
molecular O +
mechanisms O +
of O +
ATRA O -
- O -
induced O +
growth O +
inhibition O +
, O +
and O +
the O +
basis O +
for O +
the O +
synergistic O +
actions O +
of O +
ATRA O +
and O +
IFNs O +
in O +
myeloid B-CellLine +
leukemia I-CellLine +
cells I-CellLine +
. O +

The O +
c O -
- O -
Jun O +
delta O -
- O -
domain O +
inhibits O +
neuroendocrine O +
promoter O +
activity O +
in O +
a O +
DNA O +
sequence- O +
and O +
pituitary O -
- O -
specific O +
manner O +
. O +

The O +
transcription O +
and O +
transformation O +
activity O +
of O +
c O -
- O -
Jun O +
is O +
governed O +
by O +
a O +
27-amino O +
acid O +
regulatory O +
motif O +
, O +
labeled O +
the O +
delta O -
- O -
domain O +
, O +
which O +
is O +
deleted O +
in O +
v O -
- O -
Jun O +
. O +

We O +
have O +
previously O +
shown O +
that O +
c O -
- O -
Jun O +
is O +
a O +
potent O +
inhibitor O +
of O +
the O +
rat O +
prolactin O +
( O +
rPRL O +
) O +
promoter O +
activity O +
induced O +
by O +
either O +
oncogenic O +
Ras O +
or O +
phorbol O +
esters O +
. O +

Here O +
, O +
we O +
have O +
characterized O +
the O +
structural O +
and O +
cell O -
- O -
specific O +
requirements O +
for O +
this O +
c O -
- O -
Jun O +
inhibitory O +
response O +
, O +
and O +
we O +
show O +
that O +
this O +
c O -
- O -
Jun O +
inhibitory O +
response O +
mapped O +
to O +
the O +
rPRL O +
footprint O +
II O +
repressor O +
site O +
, O +
was O +
pituitary O -
- O -
specific O +
and O +
required O +
the O +
c O -
- O -
Jun O +
delta O -
- O -
domain O +
. O +

Moreover O +
, O +
alteration O +
of O +
any O +
one O +
of O +
these O +
features O +
( O +
e.g. O +
, O +
cis O -
- O -
element O +
, O +
trans O -
- O -
factor O +
, O +
or O +
cell O -
- O -
specific O +
background O +
) O +
switched O +
c O -
- O -
Jun O +
to O +
a O +
transcriptional O +
activator O +
of O +
the O +
rPRL O +
promoter O +
. O +

In O +
HeLa B-CellLine +
nonpituitary I-CellLine +
cells I-CellLine +
, O +
c O -
- O -
Jun O +
alone O +
activated O +
the O +
rPRL O +
promoter O +
via O +
the O +
most O +
proximal O +
GHF-1 O -
/ O -
Pit-1 O +
binding O +
site O +
, O +
footprint O +
I O +
, O +
and O +
synergized O +
with O +
GHF-1 O +
. O +

Finally O +
, O +
recombinant O +
GHF-1 O +
interacted O +
directly O +
with O +
c O -
- O -
Jun O +
but O +
not O +
c O -
- O -
Fos O +
proteins O +
. O +

These O +
data O +
provide O +
important O +
fundamental O +
insights O +
into O +
the O +
molecular O +
mechanisms O +
by O +
which O +
the O +
c O -
- O -
Jun O +
delta O -
- O -
domain O +
functions O +
as O +
a O +
modulatory O +
switch O +
and O +
further O +
imply O +
that O +
the O +
functional O +
role O +
of O +
c O -
- O -
Jun O +
is O +
dictated O +
by O +
cell O -
- O -
specific O +
influences O +
and O +
the O +
delta O -
- O -
domain O +
motif O +
. O +

BCL-6 O +
, O +
a O +
POZ O -
/ O -
zinc O -
- O -
finger O +
protein O +
, O +
is O +
a O +
sequence O -
- O -
specific O +
transcriptional O +
repressor O +
. O +

Approximately O +
40 O +
% O +
of O +
diffuse O +
large O +
cell O +
lymphoma O +
are O +
associated O +
with O +
chromosomal O +
translocations O +
that O +
deregulate O +
the O +
expression O +
of O +
the O +
BCL6 O +
gene O +
by O +
juxtaposing O +
heterologous O +
promoters O +
to O +
the O +
BCL-6 O +
coding O +
domain O +
. O +

The O +
BCL6 O +
gene O +
encodes O +
a O +
95-kDa O +
protein O +
containing O +
six O +
C O -
- O -
terminal O +
zinc O -
- O -
finger O +
motifs O +
and O +
an O +
N O -
- O -
terminal O +
POZ O +
domain O +
, O +
suggesting O +
that O +
it O +
may O +
function O +
as O +
a O +
transcription O +
factor O +
. O +

By O +
using O +
a O +
DNA O +
sequence O +
selected O +
for O +
its O +
ability O +
to O +
bind O +
recombinant O +
BCL-6 O +
in O +
vitro O +
, O +
we O +
show O +
here O +
that O +
BCL-6 O +
is O +
present O +
in O +
DNA O -
- O -
binding O +
complexes O +
in O +
nuclear O +
extracts O +
from O +
various O +
B B-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
. O +

In O +
transient O +
transfectin O +
experiments O +
, O +
BCL6 O +
can O +
repress O +
transcription O +
from O +
promoters O +
linked O +
to O +
its O +
DNA O +
target O +
sequence O +
and O +
this O +
activity O +
is O +
dependent O +
upon O +
specific O +
DNA O -
- O -
binding O +
and O +
the O +
presence O +
of O +
an O +
intact O +
N O -
- O -
terminal O +
half O +
of O +
the O +
protein O +
. O +

We O +
demonstrate O +
that O +
this O +
part O +
of O +
the O +
BCL6 O +
molecule O +
contains O +
an O +
autonomous O +
transrepressor O +
domain O +
and O +
that O +
two O +
noncontiguous O +
regions O +
, O +
including O +
the O +
POZ O +
motif O +
, O +
mediate O +
maximum O +
transrepressive O +
activity O +
. O +

These O +
results O +
indicate O +
that O +
the O +
BCL-6 O +
protein O +
can O +
function O +
as O +
a O +
sequence O -
- O -
specific O +
transcriptional O +
repressor O +
and O +
have O +
implications O +
for O +
the O +
role O +
of O +
BCL6 O +
in O +
normal O +
lymphoid O +
development O +
and O +
lymphomagenesis O +
. O +

Mechanisms O +
of O +
transactivation O +
by O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells-1 O +
. O +

Nuclear O +
factor O +
of O +
activated O +
T O +
cells O -
- O -
family O +
proteins O +
( O +
NFAT1 O -
/ O -
NFATp O +
, O +
NFATc O +
, O +
NFAT3 O +
, O +
and O +
NFAT4 O -
/ O -
NFATx O -
/ O -
NFATc3 O +
) O +
play O +
a O +
key O +
role O +
in O +
the O +
transcription O +
of O +
cytokine O +
genes O +
and O +
other O +
genes O +
during O +
the O +
immune O +
response O +
. O +

We O +
have O +
defined O +
the O +
mechanisms O +
of O +
transactivation O +
by O +
NFAT1 O +
. O +

NFAT1 O +
possesses O +
two O +
transactivation O +
domains O +
whose O +
sequences O +
are O +
not O +
conserved O +
in O +
the O +
other O +
NFAT O -
- O -
family O +
proteins O +
, O +
and O +
a O +
conserved O +
DNA O -
- O -
binding O +
domain O +
that O +
mediates O +
the O +
recruitment O +
of O +
cooperating O +
nuclear O +
transcription O +
factors O +
even O +
when O +
it O +
is O +
expressed O +
in O +
the O +
absence O +
of O +
other O +
regions O +
of O +
the O +
protein O +
. O +

The O +
activity O +
of O +
the O +
NH2-terminal O +
transactivation O +
domain O +
is O +
modulated O +
by O +
an O +
adjacent O +
regulatory O +
region O +
that O +
contains O +
several O +
conserved O +
sequence O +
motifs O +
represented O +
only O +
in O +
the O +
NFAT O +
family O +
. O +

Our O +
results O +
emphasize O +
the O +
multiple O +
levels O +
at O +
which O +
NFAT O -
- O -
dependent O +
transactivation O +
is O +
regulated O +
, O +
and O +
predict O +
significant O +
differences O +
in O +
the O +
architecture O +
of O +
cooperative O +
transcription O +
complexes O +
containing O +
different O +
NFAT O -
- O -
family O +
proteins O +
. O +

The O +
Ets O +
protein O +
Spi O -
- O -
B O +
is O +
expressed O +
exclusively O +
in O +
B O +
cells O +
and O +
T O +
cells O +
during O +
development O +
. O +

Spi O -
- O -
B O +
and O +
PU.1 O +
are O +
hematopoietic O -
- O -
specific O +
transcription O +
factors O +
that O +
constitute O +
a O +
subfamily O +
of O +
the O +
Ets O +
family O +
of O +
DNA O -
- O -
binding O +
proteins O +
. O +

Here O +
we O +
show O +
that O +
contrary O +
to O +
previous O +
reports O +
, O +
PU.1 O +
and O +
Spi O -
- O -
B O +
have O +
very O +
different O +
expression O +
patterns O +
. O +

PU.1 O +
is O +
expressed O +
at O +
high O +
levels O +
in O +
B O +
cells O +
, O +
mast O +
cells O +
, O +
megakaryocytes O +
, O +
macrophages O +
, O +
neutrophils O +
, O +
and O +
immature O +
erythroid O +
cells O +
and O +
at O +
lower O +
levels O +
in O +
mature O +
erythrocytes O +
. O +

PU.1 O +
is O +
completely O +
absent O +
from O +
peripheral O +
T O +
cells O +
and O +
most O +
T B-CellLine +
cell I-CellLine +
lines I-CellLine +
based O +
on O +
sensitive O +
RT O -
- O -
PCR O +
assays O +
. O +

In O +
contrast O +
, O +
Spi O -
- O -
B O +
is O +
expressed O +
exclusively O +
in O +
lymphoid O +
cells O +
and O +
can O +
be O +
detected O +
in O +
early O +
fetal O +
thymus O +
and O +
spleen O +
. O +

In O +
situ O +
hybridizations O +
of O +
adult O +
murine O +
tissues O +
demonstrate O +
Spi O -
- O -
B O +
mRNA O +
in O +
the O +
medulla O +
of O +
the O +
thymus O +
, O +
the O +
white O +
pulp O +
of O +
the O +
spleen O +
, O +
and O +
the O +
germinal O +
centers O +
of O +
lymph O +
nodes O +
. O +

Spi O -
- O -
B O +
expression O +
is O +
very O +
abundant O +
in O +
B O +
cells O +
and O +
both O +
Spi O -
- O -
B O +
mRNA O +
and O +
protein O +
are O +
detected O +
in O +
some O +
T O +
cells O +
. O +

In O +
situ O +
hybridization O +
and O +
Northern O +
blot O +
analysis O +
suggest O +
that O +
Spi O -
- O -
B O +
gene O +
expression O +
increases O +
during O +
B O +
cell O +
maturation O +
and O +
decreases O +
during O +
T O +
cell O +
maturation O +
. O +

Gel O -
- O -
retardation O +
experiments O +
show O +
that O +
Spi O -
- O -
B O +
can O +
bind O +
to O +
all O +
putative O +
PU.1 O +
binding O +
sites O +
, O +
but O +
do O +
not O +
reveal O +
any O +
preferred O +
Spi O -
- O -
B O +
binding O +
site O +
. O +

Finally O +
, O +
both O +
PU.1 O +
and O +
Spi O -
- O -
B O +
function O +
as O +
transcriptional O +
activators O +
of O +
the O +
immunoglobulin O +
light O -
- O -
chain O +
enhancer O +
E O +
lambda O +
2.4 O +
when O +
coexpressed O +
with O +
Pip O +
( O +
PU.1-interaction O +
partner O +
) O +
in O +
NIH-3T3 B-CellLine +
cells I-CellLine +
. O +

Taken O +
together O +
, O +
these O +
data O +
suggest O +
that O +
differences O +
in O +
patterns O +
of O +
expression O +
between O +
Spi O -
- O -
B O +
and O +
PU.1 O +
distinguish O +
the O +
function O +
of O +
each O +
protein O +
during O +
development O +
of O +
the O +
immune O +
system O +
. O +

Precise O +
alignment O +
of O +
sites O +
required O +
for O +
mu O +
enhancer O +
activation O +
in O +
B O +
cells O +
. O +

The O +
lymphocyte O -
- O -
specific O +
immunoglobulin O +
mu O +
heavy O -
- O -
chain O +
gene O +
intronic O +
enhancer O +
is O +
regulated O +
by O +
multiple O +
nuclear O +
factors O +
. O +

The O +
previously O +
defined O +
minimal O +
enhancer O +
containing O +
the O +
muA O +
, O +
muE3 O +
, O +
and O +
muB O +
sites O +
is O +
transactivated O +
by O +
a O +
combination O +
of O +
the O +
ETS O -
- O -
domain O +
proteins O +
PU.1 O +
and O +
Ets-1 O +
in O +
nonlymphoid O +
cells O +
. O +

The O +
core O +
GGAAs O +
of O +
the O +
muA O +
and O +
muB O +
sites O +
are O +
separated O +
by O +
30 O +
nucleotides O +
, O +
suggesting O +
that O +
ETS O +
proteins O +
bind O +
to O +
these O +
sites O +
from O +
these O +
same O +
side O +
of O +
the O +
DNA O +
helix O +
. O +

We O +
tested O +
the O +
necessity O +
for O +
appropriate O +
spatial O +
alignment O +
of O +
these O +
elements O +
by O +
using O +
mutated O +
enhancers O +
with O +
altered O +
spacings O +
. O +

A O +
4- O +
or O +
10-bp O +
insertion O +
between O +
muE3 O +
and O +
muB O +
inactivated O +
the O +
mu O +
enhancer O +
in O +
S194 B-CellLine +
plasma I-CellLine +
cells I-CellLine +
but O +
did O +
not O +
affect O +
in O +
vitro O +
binding O +
of O +
Ets-1 O +
, O +
PU.1 O +
, O +
or O +
the O +
muE3-binding O +
protein O +
TFE3 O +
, O +
alone O +
or O +
in O +
pairwise O +
combinations O +
. O +

Circular O +
permutation O +
and O +
phasing O +
analyses O +
demonstrated O +
that O +
PU.1 O +
binding O +
but O +
not O +
TFE3 O +
or O +
Ets-1 O +
bends O +
mu O +
enhancer O +
DNA O +
toward O +
the O +
major O +
groove O +
. O +

We O +
propose O +
that O +
the O +
requirement O +
for O +
precise O +
spacing O +
of O +
the O +
muA O +
and O +
muB O +
elements O +
is O +
due O +
in O +
part O +
to O +
a O +
directed O +
DNA O +
bend O +
induced O +
by O +
PU.1 O +
. O +

Stimulation O +
of O +
the O +
T O -
- O -
cell O +
antigen O +
receptor O -
- O -
CD3 O +
complex O +
signaling O +
pathway O +
by O +
the O +
tyrosine O +
phosphatase O +
inhibitor O +
pervanadate O +
is O +
mediated O +
by O +
inhibition O +
of O +
CD45 O +
: O +
evidence O +
for O +
two O +
interconnected O +
Lck O -
/ O -
Fyn- O +
or O +
zap-70-dependent O +
signaling O +
pathways O +
. O +

The O +
tyrosine O +
phosphatase O +
specific O +
inhibitor O +
pervanadate O +
is O +
a O +
potent O +
activator O +
of O +
T O +
lymphocytes O +
through O +
induction O +
of O +
tyrosine O +
phosphorylation O +
and O +
downstream O +
events O +
of O +
the O +
activation O +
cascade O +
. O +

Using O +
CD45- B-CellLine +
or I-CellLine +
CD3-negative I-CellLine +
variants I-CellLine +
of O +
the O +
Jurkat B-CellLine +
leukemic I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
we O +
show O +
that O +
the O +
different O +
biochemical O +
events O +
induced O +
by O +
pervanadate O +
appeared O +
to O +
be O +
dependent O +
on O +
the O +
presence O +
at O +
the O +
cell O +
surface O +
of O +
either O +
CD45 O +
or O +
CD3 O +
. O +

CD45 O +
-dependent O +
events O +
such O +
as O +
tyrosine O +
phosphorylation O +
of O +
Shc O +
, O +
activation O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
, O +
activator O +
protein-1 O +
( O +
AP-1 O +
) O +
, O +
transcription O +
factors O +
, O +
and O +
stimulation O +
of O +
interleukin-2 O +
( O +
IL-2 O +
) O +
promoter O +
and O +
of O +
CD69 O +
and O +
CD25 O +
surface O +
expression O +
paralleled O +
activation O +
of O +
the O +
tyrosine O +
kinases O +
lck O +
and O +
fyn O +
. O +

By O +
contrast O +
, O +
stimulation O +
of O +
calcium O +
influx O +
, O +
a O +
CD3 O +
-dependent O +
event O +
, O +
paralleled O +
zap-70 O +
activation O +
. O +

The O +
data O +
demonstrate O +
that O +
the O +
T O -
- O -
cell O +
antigen O +
receptor O +
-CD3 O +
( O +
TcR O -
- O -
CD3 O +
) O +
complex O +
is O +
functionally O +
linked O +
to O +
two O +
different O +
protein O +
tyrosine O +
kinase O +
( O +
PTK O +
) O +
modules O +
with O +
separate O +
specific O +
functions O +
and O +
that O +
CD45 O +
may O +
be O +
an O +
important O +
regulator O +
of O +
this O +
coupling O +
. O +

C O -
/ O -
EBP O +
activators O +
are O +
required O +
for O +
HIV-1 O +
replication O +
and O +
proviral O +
induction O +
in O +
monocytic B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Previous O +
work O +
has O +
shown O +
that O +
C O -
/ O -
EBP O +
sites O +
and O +
C O -
/ O -
EBP O +
transcriptional O +
activators O +
are O +
necessary O +
for O +
HIV-1 O +
LTR O +
activity O +
in O +
monocytes O -
/ O -
macrophages O +
. O +

We O +
have O +
investigated O +
the O +
role O +
that O +
C O -
/ O -
EBP O +
proteins O +
play O +
in O +
induction O +
and O +
replication O +
of O +
HIV-1 O +
. O +

Ectopic O +
expression O +
of O +
the O +
dominant O +
negative O +
C O -
/ O -
EBP O +
protein O +
LIP O +
inhibited O +
HIV-1 O +
mRNA O +
and O +
virus O +
production O +
in O +
activated B-CellLine +
U1 I-CellLine +
cells I-CellLine +
, O +
demonstrating O +
that O +
C O -
/ O -
EBP O +
proteins O +
are O +
required O +
for O +
provirus O +
induction O +
. O +

U1 B-CellLine +
lines I-CellLine +
overexpressing O +
C O -
/ O -
EBP O +
activator O +
NF O -
- O -
IL-6 O +
produced O +
more O +
viral O +
mRNA O +
and O +
virus O +
particles O +
following O +
cellular O +
activation O +
than O +
control B-CellLine +
lines I-CellLine +
, O +
demonstrating O +
that O +
C O -
/ O -
EBP O +
proteins O +
are O +
limiting O +
for O +
virus O +
transcription O +
. O +

HIV-1 O +
harboring O +
mutations O +
within O +
two O +
C O -
/ O -
EBP O +
sites O +
were O +
crippled O +
in O +
their O +
ability O +
to O +
replicate O +
in O +
U937 B-CellLine +
promonocytic I-CellLine +
cells I-CellLine +
, O +
indicating O +
that O +
these O +
sites O +
are O +
required O +
for O +
replication O +
. O +

These O +
data O +
identify O +
C O -
/ O -
EBP O +
proteins O +
as O +
regulators O +
of O +
HIV-1 O +
expression O +
in O +
monocytes O -
/ O -
macrophages O +
. O +

Reversal O +
of O +
apoptosis O +
by O +
the O +
leukaemia O -
- O -
associated O +
E2A O -
- O -
HLF O +
chimaeric O +
transcription O +
factor O +
. O +

The O +
E2A O -
- O -
HLF O +
( O +
for O +
hepatic O +
leukaemia O +
factor O +
) O +
fusion O +
gene O +
, O +
formed O +
by O +
action O +
of O +
the O +
t O +
( O +
17 O +
; O +
19 O +
) O +
( O +
q22 O +
; O +
p13 O +
) O +
chromosomal O +
translocation O +
, O +
drives O +
the O +
leukaemic O +
transformation O +
of O +
early O +
B O -
- O -
cell O +
precursors O +
, O +
but O +
the O +
mechanism O +
of O +
this O +
activity O +
remains O +
unknown O +
. O +

Here O +
we O +
report O +
that O +
human O +
leukaemia O +
cells O +
carrying O +
the O +
translocation O +
t O +
( O +
17 O +
; O +
19 O +
) O +
rapidly O +
died O +
by O +
apoptosis O +
when O +
programmed O +
to O +
express O +
a O +
dominant O -
- O -
negative O +
suppressor O +
of O +
the O +
fusion O +
protein O +
E2A O -
- O -
HLF O +
, O +
indicating O +
that O +
the O +
chimaeric O +
oncoprotein O +
probably O +
affects O +
cell O +
survival O +
rather O +
than O +
cell O +
growth O +
. O +

Moreover O +
, O +
when O +
introduced O +
into O +
murine B-CellLine +
pro I-CellLine -
- I-CellLine -
B I-CellLine +
lymphocytes I-CellLine +
, O +
the O +
oncogenic O +
E2A O -
- O -
HLF O +
fusion O +
protein O +
reversed O +
both O +
interleukin-3-dependent O +
and O +
p53-mediated O +
apoptosis O +
. O +

The O +
close O +
homology O +
of O +
the O +
basic O +
region O -
/ O -
leucine O +
zipper O +
( O +
bZIP O +
) O +
DNA O -
- O -
binding O +
and O +
dimerization O +
domain O +
of O +
HLF O +
to O +
that O +
of O +
the O +
CES-2 O +
cell O -
- O -
death O +
specification O +
protein O +
of O +
Caenorhabditis O +
elegans O +
suggests O +
a O +
model O +
of O +
leukaemogenesis O +
in O +
which O +
E2A O -
- O -
HLF O +
blocks O +
an O +
early O +
step O +
within O +
an O +
evolutionarily O +
conserved O +
cell O -
- O -
death O +
pathway O +
. O +

Interleukin-7 O +
signaling O +
in O +
human B-CellLine +
B I-CellLine +
cell I-CellLine +
precursor I-CellLine +
acute I-CellLine +
lymphoblastic I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
and O +
murine B-CellLine +
BAF3 I-CellLine +
cells I-CellLine +
involves O +
activation O +
of O +
STAT1 O +
and O +
STAT5 O +
mediated O +
via O +
the O +
interleukin-7 O +
receptor O +
alpha O +
chain O +
. O +

Interleukin-7 O +
( O +
IL-7 O +
) O +
stimulates O +
the O +
proliferation O +
of O +
normal O +
and O +
leukemic O +
B O +
and O +
T O +
cell O +
precursors O +
and O +
T O +
lymphocytes O +
. O +

Activation O +
of O +
the O +
JAK O +
/STAT O +
pathway O +
has O +
been O +
implicated O +
in O +
IL-7R O +
signaling O +
. O +

We O +
investigated O +
which O +
STAT O +
complexes O +
are O +
formed O +
upon O +
stimulation O +
of O +
B B-CellLine +
cell I-CellLine +
precursor I-CellLine +
acute I-CellLine +
lymphoblastic I-CellLine +
leukemia I-CellLine +
( I-CellLine +
BCP I-CellLine -
- I-CellLine -
ALL I-CellLine +
) I-CellLine +
cells I-CellLine +
with O +
IL-7 O +
. O +

Gel O +
retardation O +
assays O +
with O +
STAT O -
- O -
binding O +
oligonucleotides O +
showed O +
that O +
IL-7 O +
induces O +
the O +
formation O +
of O +
two O +
major O +
STAT O +
complexes O +
in O +
BCP B-CellLine -
- I-CellLine -
ALL I-CellLine +
cells I-CellLine +
. O +

Supershifts O +
with O +
anti O -
- O -
STAT O +
antibodies O +
identified O +
these O +
as O +
STAT1 O +
and O +
STAT5 O +
complexes O +
. O +

This O +
pattern O +
of O +
STAT O +
activation O +
was O +
seen O +
in O +
all O +
BCP O -
- O -
ALL O +
cases O +
that O +
respond O +
to O +
IL-7 O +
in O +
proliferation O +
assays O +
. O +

IL-7 O +
also O +
induced O +
STAT O +
/DNA O +
binding O +
in O +
BCP O -
- O -
ALL O +
cases O +
that O +
failed O +
to O +
proliferate O +
in O +
response O +
to O +
IL-7 O +
, O +
suggesting O +
that O +
the O +
ability O +
of O +
IL-7R O +
to O +
activate O +
the O +
JAK O +
/STAT O +
pathway O +
per O +
se O +
is O +
not O +
sufficient O +
for O +
proliferation O +
induction O +
. O +

To O +
determine O +
the O +
contribution O +
of O +
the O +
cytoplasmic O +
domain O +
of O +
the O +
IL-7 O +
receptor O +
alpha O +
chain O +
( O +
IL-7R O +
alpha O +
) O +
to O +
activation O +
of O +
STAT O +
proteins O +
, O +
transfectants O +
of O +
the O +
murine B-CellLine +
pro I-CellLine -
- I-CellLine -
B I-CellLine +
cell I-CellLine +
line I-CellLine +
BAF3 I-CellLine +
were O +
made O +
that O +
express O +
chimeric O +
receptors O +
consisting O +
of O +
the O +
extracellular O +
domain O +
of O +
human O +
granulocyte O +
colony O -
- O -
stimulating O +
factor O +
receptor O +
( O +
G O -
- O -
CSF O -
- O -
R O +
) O +
and O +
the O +
transmembrane O +
and O +
intracellular O +
domains O +
of O +
human O +
IL-7R O +
alpha O +
. O +

Activation O +
of O +
the O +
chimeric O +
G O -
- O -
CSF O -
- O -
R O -
/ O -
IL-7R O +
alpha O +
with O +
G O -
- O -
CSF O +
resulted O +
in O +
a O +
full O +
proliferative O +
response O +
and O +
induced O +
the O +
phosphorylation O +
of O +
JAK1 O +
but O +
not O +
JAK2 O +
. O +

Major O +
STAT O +
complexes O +
activated O +
by O +
G O -
- O -
CSF O -
- O -
R O -
/ O -
IL-7R O +
alpha O +
contained O +
STAT1 O +
or O +
STAT5 O +
, O +
while O +
some O +
formation O +
of O +
STAT3-containing O +
complexes O +
was O +
also O +
seen O +
. O +

These O +
findings O +
establish O +
that O +
STAT1 O +
and O +
STAT5 O +
, O +
and O +
possibly O +
STAT3 O +
, O +
are O +
activated O +
upon O +
stimulation O +
of O +
precursor O +
B O +
cells O +
with O +
IL-7 O +
. O +

The O +
data O +
further O +
indicate O +
that O +
the O +
IL-7R O +
alpha O +
chains O +
are O +
directly O +
involved O +
in O +
the O +
activation O +
of O +
JAKs O +
and O +
STATs O +
and O +
have O +
a O +
major O +
role O +
in O +
proliferative O +
signaling O +
in O +
precursor O +
B O +
cells O +
. O +

Involvement O +
of O +
tyrosine O +
phosphorylation O +
in O +
endothelial O +
adhesion O +
molecule O +
induction O +
. O +

Induction O +
of O +
endothelial O +
adhesion O +
molecules O +
by O +
the O +
cytokine O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O +
) O +
can O +
occur O +
independently O +
of O +
protein O +
kinase O +
C O +
and O +
activation O +
of O +
a O +
protein O +
tyrosine O +
kinase O +
( O +
PTK O +
) O +
has O +
recently O +
been O +
implicated O +
in O +
the O +
upregulation O +
of O +
vascular O +
cell O +
adhesion O +
molecule O +
1 O +
( O +
VCAM-1 O +
) O +
by O +
interleukin-4 O +
( O +
IL-4 O +
) O +
on O +
endothelial O +
cells O +
. O +

We O +
demonstrate O +
that O +
the O +
PTK O +
inhibitors O +
herbimycin O +
A O +
or O +
genistein O +
suppress O +
induction O +
of O +
endothelial O +
VCAM-1 O +
and O +
E O -
- O -
selectin O +
, O +
as O +
well O +
as O +
subsequent O +
monocytic O +
cell O +
adhesion O +
to O +
endothelial O +
cells O +
stimulated O +
by O +
TNF O +
. O +

Inhibition O +
studies O +
indicate O +
that O +
specific O +
tyrosine O +
phosphorylation O +
following O +
PTK O +
activation O +
is O +
involved O +
in O +
the O +
mobilization O +
of O +
the O +
transcription O +
factor O +
, O +
nuclear O +
factor O +
kappa O +
B O +
, O +
and O +
VCAM-1 O +
mRNA O +
expression O +
. O +

This O +
may O +
have O +
implications O +
for O +
pathophysiological O +
conditions O +
that O +
involve O +
the O +
upregulation O +
of O +
these O +
molecules O +
( O +
e.g. O +
inflammation O +
and O +
atherosclerosis O +
) O +
. O +

Inhibition O +
of O +
transcription O +
factor O +
Stat1 O +
activity O +
in O +
mononuclear B-CellLine +
cell I-CellLine +
cultures I-CellLine +
and O +
T O +
cells O +
by O +
the O +
cyclic O +
AMP O +
signaling O +
pathway O +
. O +

Activation O +
of O +
T O +
cells O +
results O +
in O +
a O +
cascade O +
of O +
gene O +
activation O +
and O +
subsequent O +
proliferation O +
and O +
differentiation O +
into O +
effector O +
phenotypes O +
. O +

The O +
regulation O +
of O +
transcription O +
factors O +
belonging O +
to O +
the O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
( O +
STAT O +
) O +
family O +
was O +
analyzed O +
in O +
PHA B-CellLine -
- I-CellLine -
activated I-CellLine +
mononuclear I-CellLine +
cells I-CellLine +
and O +
in O +
purified B-CellLine +
T I-CellLine +
cells I-CellLine +
activated O +
by O +
cross O -
- O -
linking O +
cell O +
surface O +
CD3 O +
. O +

Cell O +
activation O +
resulted O +
in O +
a O +
delayed O +
induction O +
of O +
STAT O +
DNA O -
- O -
binding O +
activity O +
, O +
which O +
was O +
sustained O +
for O +
several O +
days O +
, O +
was O +
composed O +
predominantly O +
of O +
Stat1 O +
and O +
Stat3 O +
, O +
and O +
was O +
blocked O +
by O +
cycloheximide O +
and O +
actinomycin O +
D O +
. O +

Increased O +
Stat1 O +
and O +
Stat3 O +
mRNA O +
and O +
protein O +
levels O +
were O +
detected O +
, O +
respectively O +
4 O +
and O +
24 O +
h O +
after O +
activation O +
. O +

Stimulation O +
of O +
the O +
cAMP O +
signal O +
transduction O +
pathway O +
, O +
which O +
skews O +
cytokine O +
production O +
toward O +
a O +
Th2 O +
pattern O +
, O +
resulted O +
in O +
the O +
preferential O +
suppression O +
of O +
Stat1 O +
activity O +
. O +

cAMP O +
inhibited O +
the O +
induction O +
of O +
expression O +
of O +
IL-2 O +
receptor O +
components O +
, O +
but O +
did O +
not O +
inhibit O +
IL-4 O +
receptor O +
alpha O -
- O -
chain O +
and O +
CD69 O +
expression O +
or O +
the O +
induction O +
of O +
activator O +
protein O +
1 O +
transcription O +
factors O +
. O +

cAMP O +
signaling O +
inhibited O +
Stat1 O +
at O +
several O +
different O +
levels O +
, O +
including O +
suppression O +
of O +
DNA O +
binding O +
and O +
down O -
- O -
regulation O +
of O +
Stat1 O +
protein O +
and O +
mRNA O +
levels O +
. O +

Our O +
results O +
demonstrate O +
the O +
regulation O +
of O +
STAT O +
activity O +
by O +
a O +
signaling O +
pathway O +
that O +
regulates O +
the O +
T O +
cell O +
functional O +
phenotype O +
and O +
is O +
distinct O +
from O +
the O +
cytokine O +
-activated O +
Janus O +
kinase O +
-STAT O +
signaling O +
pathway O +
. O +

Various O +
modes O +
of O +
basic O +
helix O -
- O -
loop O -
- O -
helix O +
protein O +
-mediated O +
regulation O +
of O +
murine O +
leukemia O +
virus O +
transcription O +
in O +
lymphoid B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

The O +
transcriptionally O +
regulatory O +
regions O +
of O +
the O +
lymphomagenic O +
Akv O +
and O +
SL3 O -
- O -
3 O +
murine O +
leukemia O +
retroviruses O +
( O +
MLVs O +
) O +
contain O +
two O +
types O +
of O +
E O -
- O -
box O +
consensus O +
motifs O +
, O +
CAGATG O +
. O +

One O +
type O +
, O +
EA O -
/ O -
S O +
, O +
is O +
located O +
in O +
the O +
upstream O +
promoter O +
region O +
, O +
and O +
the O +
other O +
, O +
E O +
( O +
gre O +
) O +
, O +
is O +
located O +
in O +
a O +
tandem O +
repeat O +
with O +
enhancer O +
properties O +
. O +

We O +
have O +
examined O +
the O +
requirements O +
of O +
the O +
individual O +
E O -
- O -
boxes O +
in O +
MLV O +
transcriptional O +
regulation O +
. O +

In O +
lymphoid B-CellLine +
cell I-CellLine +
lines I-CellLine +
only O +
, O +
the O +
E O +
( O +
gre O +
) O +
-binding O +
protein O +
complexes O +
included O +
ALF1 O +
or O +
HEB O +
and O +
E2A O +
basic O +
helix O -
- O -
loop O -
- O -
helix O +
proteins O +
. O +

Ectopic O +
ALF1 O +
and O +
E2A O +
proteins O +
required O +
intact O +
E O +
( O +
gre O +
) O +
motifs O +
for O +
mediating O +
transcriptional O +
activation O +
. O +

ALF1 O +
transactivated O +
transcription O +
of O +
Akv O +
MLV O +
through O +
the O +
two O +
E O +
( O +
gre O +
) O +
motifs O +
equally O +
, O +
whereas O +
E2A O +
protein O +
required O +
the O +
promoter O -
- O -
proximal O +
E O +
( O +
gre O +
) O +
motif O +
. O +

In O +
T- B-CellLine +
and I-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
, O +
the O +
E O +
( O +
gre O +
) O +
motifs O +
were O +
of O +
major O +
importance O +
for O +
Akv O +
MLV O +
transcriptional O +
activity O +
, O +
while O +
the O +
EA O -
/ O -
S O +
motif O +
had O +
some O +
effect O +
. O +

In O +
contrast O +
, O +
neither O +
E O +
( O +
gre O +
) O +
nor O +
EA O -
/ O -
S O +
motifs O +
contributed O +
pronouncedly O +
to O +
Akv O +
MLV O +
transcription O +
in O +
NIH B-CellLine +
3T3 I-CellLine +
cells I-CellLine +
lacking O +
DNA O -
- O -
binding O +
ALF1 O +
or O +
HEB O +
and O +
E2A O +
proteins O +
. O +

The O +
Id1 O +
protein O +
was O +
found O +
to O +
repress O +
ALF1 O +
activity O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

Moreover O +
, O +
ectopic O +
Id1 O +
repressed O +
E O +
( O +
gre O +
) O +
-directed O +
but O +
not O +
EA O -
/ O -
S O +
-directed O +
MLV O +
transcription O +
in O +
lymphoid B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

In O +
conclusion O +
, O +
E O +
( O +
gre O +
) O +
motifs O +
and O +
interacting O +
basic O +
helix O -
- O -
loop O -
- O -
helix O +
proteins O +
are O +
important O +
determinants O +
for O +
MLV O +
transcriptional O +
activity O +
in O +
lymphocytic B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

The O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
posttranscriptional O +
trans O -
- O -
activator O +
Rex O +
contains O +
a O +
nuclear O +
export O +
signal O +
. O +

The O +
Rex O +
protein O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
is O +
required O +
for O +
the O +
nuclear O +
export O +
of O +
unspliced O +
viral O +
mRNA O +
and O +
, O +
therefore O +
, O +
for O +
virus O +
replication O +
. O +

In O +
this O +
manuscript O +
, O +
we O +
demonstrate O +
that O +
Rex O +
shuttles O +
between O +
the O +
nucleus O +
and O +
the O +
cytoplasm O +
and O +
that O +
its O +
activation O +
domain O +
constitutes O +
a O +
nuclear O +
export O +
signal O +
that O +
specifies O +
efficient O +
transport O +
to O +
the O +
cytoplasm O +
. O +

These O +
findings O +
are O +
consistent O +
with O +
a O +
model O +
for O +
Rex O +
-mediated O +
trans O -
- O -
activation O +
in O +
which O +
Rex O -
- O -
viral O +
mRNA O +
complexes O +
are O +
targeted O +
for O +
nuclear O +
export O +
by O +
the O +
direct O +
action O +
of O +
the O +
activation O +
domain O +
. O +

Multiple O +
p21ras O +
effector O +
pathways O +
regulate O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
. O +

The O +
transcription O +
factor O +
, O +
Nuclear O +
Factor O +
of O +
Activated O +
T O +
cells O +
( O +
NFAT O +
) O +
is O +
a O +
major O +
target O +
for O +
p21ras O +
and O +
calcium O +
signalling O +
pathways O +
in O +
the O +
IL-2 O +
gene O +
and O +
is O +
induced O +
by O +
p21ras O +
signals O +
acting O +
in O +
synergy O +
with O +
calcium O +
/calcineurin O +
signals O +
. O +

One O +
p21ras O +
effector O +
pathway O +
involves O +
the O +
MAP O +
kinase O +
ERK-2 O +
, O +
and O +
we O +
have O +
examined O +
its O +
role O +
in O +
NFAT O +
regulation O +
. O +

Expression O +
of O +
dominant O +
negative O +
MAPKK-1 O +
prevents O +
NFAT O +
induction O +
. O +

Constitutively O +
active O +
MAPKK-1 O +
fully O +
activates O +
ERK-2 O +
and O +
the O +
transcription O +
factor O +
Elk-1 O +
, O +
but O +
does O +
not O +
substitute O +
for O +
activated O +
p21ras O +
and O +
synergize O +
with O +
calcium O +
/calcineurin O +
signals O +
to O +
induce O +
NFAT O +
. O +

Expression O +
of O +
dominant O +
negative O +
N17Rac O +
also O +
prevents O +
TCR O +
and O +
p21ras O +
activation O +
of O +
NFAT O +
, O +
but O +
without O +
interfering O +
with O +
the O +
ERK-2 O +
pathway O +
. O +

The O +
transcriptional O +
activity O +
of O +
the O +
NFAT O +
binding O +
site O +
is O +
mediated O +
by O +
a O +
complex O +
comprising O +
a O +
member O +
of O +
the O +
NFAT O +
group O +
and O +
AP-1 O +
family O +
proteins O +
. O +

The O +
induction O +
of O +
AP-1 O +
by O +
p21ras O +
also O +
requires O +
Rac-1 O +
function O +
. O +

Activated O +
Rac-1 O +
could O +
mimic O +
activated O +
p21ras O +
to O +
induce O +
AP-1 O +
but O +
not O +
to O +
induce O +
NFAT O +
. O +

Moreover O +
, O +
the O +
combination O +
of O +
activated O +
MAPKK-1 O +
and O +
Rac-1 O +
could O +
not O +
substitute O +
for O +
activated O +
p21ras O +
and O +
synergize O +
with O +
calcium O +
signals O +
to O +
induce O +
NFAT O +
. O +

Thus O +
, O +
p21ras O +
regulation O +
of O +
NFAT O +
in O +
T O +
cells O +
requires O +
the O +
activity O +
of O +
multiple O +
effector O +
pathways O +
including O +
those O +
regulated O +
by O +
MAPKK-1 O +
/ERK-2 O +
and O +
Rac-1 O +
. O +

Granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
preferentially O +
activates O +
the O +
94-kD O +
STAT5A O +
and O +
an O +
80-kD O +
STAT5A O +
isoform O +
in O +
human O +
peripheral O +
blood O +
monocytes O +
. O +

Granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
induces O +
immediate O +
effects O +
in O +
monocytes O +
by O +
activation O +
of O +
the O +
Janus O +
kinase O +
( O +
JAK2 O +
) O +
and O +
STAT O +
transcription O +
factor O +
( O +
STAT5 O +
) O +
pathway O +
. O +

Recent O +
studies O +
have O +
identified O +
homologues O +
of O +
STAT5 O +
, O +
STAT5A O +
, O +
and O +
STAT5B O +
, O +
as O +
well O +
as O +
lower O +
molecular O +
weight O +
variants O +
of O +
STAT5 O +
. O +

To O +
define O +
the O +
activation O +
of O +
the O +
STAT5 O +
homologues O +
and O +
lower O +
molecular O +
weight O +
variant O +
in O +
human O +
monocytes O +
and O +
monocytes O +
differentiated O +
into O +
macrophages O +
by O +
culture O +
in O +
macrophage O -
- O -
CSF O +
( O +
M O -
- O -
CSF O +
) O +
, O +
we O +
measured O +
the O +
GM O -
- O -
CSF O +
induced O +
tyrosine O +
phosphorylation O +
of O +
STAT5A O +
, O +
STAT5B O +
, O +
and O +
any O +
lower O +
molecular O +
weight O +
STAT5 O +
isoforms O +
. O +

Freshly O +
isolated O +
monocytes O +
expressed O +
94-kD O +
STAT5A O +
, O +
92-kD O +
STAT5B O +
, O +
and O +
an O +
80-kD O +
STAT5A O +
molecule O +
. O +

Whereas O +
94-kD O +
STAT5A O +
was O +
clearly O +
tyrosine O +
phosphorylated O +
and O +
bound O +
to O +
the O +
enhancer O +
element O +
, O +
the O +
gamma O +
response O +
region O +
( O +
GRR O +
) O +
, O +
of O +
the O +
Fc O +
gamma O +
RI O +
gene O +
, O +
substantially O +
less O +
tyrosine O +
phosphorylated O +
STAT5B O +
bound O +
to O +
the O +
immobilized O +
GRR O +
element O +
. O +

Macrophages O +
lost O +
their O +
ability O +
to O +
express O +
the O +
80-kD O +
STAT5A O +
protein O +
, O +
but O +
retained O +
their O +
ability O +
to O +
activate O +
STAT5A O +
. O +

STAT5A O -
- O -
STAT5A O +
homodimers O +
and O +
STAT5A O -
- O -
STAT5B O +
heterodimers O +
formed O +
in O +
response O +
to O +
GM O -
- O -
CSF O +
. O +

Therefore O +
, O +
activation O +
of O +
STAT5A O +
predominates O +
compared O +
to O +
STAT5B O +
when O +
assayed O +
by O +
direct O +
immunoprecipitation O +
and O +
by O +
evaluation O +
of O +
bound O +
STATs O +
to O +
immobilized O +
GRR O +
. O +

Selective O +
activation O +
of O +
STAT5 O +
homologues O +
in O +
addition O +
to O +
generation O +
of O +
lower O +
molecular O +
isoforms O +
may O +
provide O +
specificity O +
and O +
control O +
to O +
genes O +
expressed O +
in O +
response O +
to O +
cytokines O +
such O +
as O +
GM O -
- O -
CSF O +
. O +

Abnormalities O +
of O +
p16 O +
, O +
p15 O +
and O +
CDK4 O +
genes O +
in O +
recurrent O +
malignant O +
astrocytomas O +
. O +

Abnormalities O +
in O +
the O +
p16 O +
, O +
p15 O +
and O +
CDK4 O +
genes O +
that O +
regulate O +
transition O +
through O +
the O +
G1 O +
phase O +
of O +
the O +
cell O +
cycle O +
have O +
been O +
implicated O +
in O +
the O +
malignant O +
progression O +
of O +
astrocytomas O +
. O +

The O +
results O +
of O +
the O +
present O +
study O +
demonstrate O +
that O +
dysfunction O +
of O +
these O +
genes O +
also O +
occurs O +
during O +
recurrence O +
of O +
glial O +
tumors O +
that O +
were O +
highly O +
malignant O +
at O +
first O +
presentation O +
. O +

Analysis O +
of O +
10 O +
matched O +
pairs O +
of O +
high O +
grade O +
malignant O +
astrocytomas O +
and O +
their O +
subsequent O +
recurrences O +
identified O +
three O +
distinct O +
groups O +
. O +

The O +
primary O +
and O +
recurrent O +
tumors O +
in O +
Group O +
A O +
did O +
not O +
show O +
structural O +
alterations O +
in O +
the O +
p16 O +
, O +
p15 O +
or O +
CDK4 O +
genes O +
, O +
whereas O +
homozygous O +
codeletion O +
of O +
p16 O +
and O +
p15 O +
was O +
observed O +
in O +
both O +
primary O +
and O +
recurrent O +
tumors O +
in O +
Group O +
B O +
. O +

The O +
primary O +
tumors O +
in O +
Group O +
C O +
had O +
a O +
normal O +
profile O +
of O +
p16 O +
, O +
p15 O +
and O +
CDK4 O +
at O +
presentation O +
. O +

Upon O +
recurrence O +
, O +
however O +
, O +
the O +
tumors O +
sustained O +
either O +
deletion O +
of O +
p16 O +
alone O +
or O +
codeletion O +
of O +
both O +
p16 O +
and O +
p15 O +
or O +
amplification O +
of O +
CDK4 O +
. O +

Analysis O +
of O +
the O +
molecular O +
differences O +
between O +
primary O +
anaplastic O +
astrocytomas O -
/ O -
glioblastomas O +
and O +
their O +
subsequent O +
recurrences O +
, O +
which O +
are O +
clinically O +
indistinguishable O +
, O +
may O +
provide O +
better O +
therapeutic O +
options O +
for O +
treatment O +
. O +

CTL O +
recognition O +
of O +
an O +
altered O +
peptide O +
associated O +
with O +
asparagine O +
bond O +
rearrangement O +
. O +

Implications O +
for O +
immunity O +
and O +
vaccine O +
design O +
. O +

The O +
extent O +
to O +
which O +
peptides O +
containing O +
chemically O +
and O +
post O -
- O -
translationally O +
modified O +
amino O +
acid O +
side O +
chains O +
are O +
recognized O +
by O +
primed B-CellLine +
CTL I-CellLine +
has O +
not O +
been O +
clearly O +
defined O +
. O +

We O +
report O +
on O +
the O +
CTL O +
recognition O +
of O +
a O +
MHC O +
class O +
I O -
- O -
restricted O +
peptide O +
containing O +
a O +
cyclized O +
asparagine O +
( O +
succinimide O +
) O +
residue O +
. O +

This O +
modification O +
of O +
the O +
asparagine O +
side O +
chain O +
is O +
a O +
common O +
intermediate O +
structure O +
during O +
deamidation O +
, O +
isomerization O +
, O +
and O +
bond O +
rearrangements O +
of O +
amide O -
- O -
containing O +
amino O +
acids O +
and O +
also O +
occurs O +
as O +
a O +
side O +
reaction O +
in O +
peptide O +
synthesis O +
. O +

The O +
CTL O +
specifically O +
recognized O +
the O +
succinimide O -
- O -
containing O +
peptide O +
showing O +
only O +
weak O +
cross O -
- O -
reactivity O +
at O +
high O +
concentrations O +
of O +
the O +
parent O +
peptide O +
containing O +
unmodified O +
asparagine O +
. O +

Similarly O +
, O +
CTL O +
raised O +
against O +
the O +
parent O +
peptide O +
did O +
not O +
recognize O +
the O +
succinimide O +
derivative O +
of O +
this O +
peptide O +
. O +

Naturally O +
processed O +
forms O +
of O +
these O +
structures O +
are O +
likely O +
to O +
occur O +
given O +
the O +
importance O +
and O +
frequency O +
of O +
deamidation O +
both O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

Moreover O +
, O +
since O +
succinimide O +
intermediates O +
of O +
deamidated O +
peptides O +
can O +
occasionally O +
be O +
very O +
stable O +
, O +
these O +
peptides O +
have O +
the O +
potential O +
to O +
act O +
as O +
altered O +
self O -
- O -
Ags O +
with O +
significant O +
implications O +
for O +
autoimmunity O +
. O +

In O +
addition O +
, O +
unwanted O +
and O +
potentially O +
hazardous O +
specificities O +
may O +
be O +
elicited O +
when O +
using O +
synthetic O +
peptides O +
in O +
subunit O +
vaccines O +
in O +
which O +
succinimide O +
residues O +
may O +
form O +
spontaneously O +
during O +
storage O +
or O +
chemical O +
synthesis O +
. O +

Regulation O +
of O +
gene O +
expression O +
at O +
early O +
stages O +
of O +
B O -
- O -
cell O +
and O +
T O -
- O -
cell O +
differentiation O +
. O +

The O +
expression O +
of O +
distinct O +
sets O +
of O +
genes O +
at O +
different O +
stages O +
of O +
B O -
- O -
lymphocyte O +
and O +
T O -
- O -
lymphocyte O +
differentiation O +
is O +
controlled O +
at O +
the O +
level O +
of O +
transcription O +
. O +

A O +
number O +
of O +
recent O +
studies O +
have O +
described O +
interactions O +
between O +
transcription O +
factors O +
in O +
lymphocytes O +
that O +
provide O +
new O +
insights O +
into O +
mechanisms O +
regulating O +
gene O +
expression O +
. O +

These O +
mechanisms O +
include O +
the O +
assembly O +
of O +
higher O +
order O +
nucleoprotein O +
complexes O +
and O +
other O +
protein O -
- O -
protein O +
interactions O +
that O +
enhance O +
the O +
functional O +
specificity O +
of O +
transcriptional O +
regulators O +
in O +
lymphocytes O +
. O +

X O +
inactivation O +
analysis O +
in O +
a O +
female O +
with O +
hypomelanosis O +
of O +
Ito O +
associated O +
with O +
a O +
balanced O +
X O +
; O +
17 O +
translocation O +
: O +
evidence O +
for O +
functional O +
disomy O +
of O +
Xp O +
. O +

X O +
inactivation O +
analysis O +
was O +
performed O +
on O +
normal O +
and O +
hypopigmented O +
skin O +
samples O +
obtained O +
from O +
a O +
female O +
with O +
hypomelanosis O +
of O +
Ito O +
associated O +
with O +
a O +
balanced O +
whole O +
arm O +
X O +
; O +
17 O +
translocation O +
. O +

Severe O +
skewing O +
of O +
X O +
inactivation O +
resulting O +
in O +
inactivity O +
of O +
the O +
intact O +
X O +
was O +
found O +
in O +
blood O +
and O +
cultures O +
of O +
both O +
types O +
of O +
skin O +
, O +
but O +
analysis O +
of O +
DNA O +
prepared O +
directly O +
from O +
hypopigmented O +
skin O +
showed O +
significant O +
inactivation O +
of O +
the O +
translocated O +
X O +
, O +
inconsistent O +
with O +
the O +
usual O +
mechanism O +
of O +
phenotypic O +
expression O +
in O +
X O +
; O +
autosome O +
translocations O +
. O +

In O +
addition O +
, O +
dual O +
colour O +
FISH O +
analysis O +
using O +
centromere O +
specific O +
probes O +
for O +
chromosomes O +
X O +
and O +
17 O +
showed O +
that O +
the O +
breakpoints O +
on O +
both O +
chromosomes O +
lie O +
within O +
the O +
alphoid O +
arrays O +
, O +
making O +
interruption O +
of O +
a O +
locus O +
on O +
either O +
chromosome O +
unlikely O +
. O +

While O +
partial O +
variable O +
monosomy O +
of O +
loci O +
on O +
chromosome O +
17p O +
can O +
not O +
be O +
excluded O +
as O +
contributing O +
to O +
the O +
phenotype O +
in O +
this O +
patient O +
, O +
it O +
is O +
argued O +
that O +
the O +
major O +
likely O +
factor O +
is O +
partial O +
functional O +
disomy O +
of O +
sequences O +
on O +
Xp O +
in O +
cell O +
lineages O +
that O +
have O +
failed O +
to O +
inactivate O +
the O +
intact O +
X O +
chromosome O +
. O +

Interaction O +
of O +
the O +
human O +
T O -
- O -
cell O +
lymphotropic O +
virus O +
type O +
1 O +
tax O +
transactivator O +
with O +
transcription O +
factor O +
IIA O +
. O +

The O +
Tax O +
protein O +
of O +
human O +
T O -
- O -
cell O +
lymphotropic O +
virus O +
type O +
1 O +
( O +
HTLV-1 O +
) O +
is O +
a O +
40-kDa O +
transcriptional O +
activator O +
which O +
is O +
critical O +
for O +
HTLV-1 O +
gene O +
regulation O +
and O +
virus O -
- O -
induced O +
cellular O +
transformation O +
. O +

Tax O +
is O +
localized O +
to O +
the O +
DNA O +
through O +
its O +
interaction O +
with O +
the O +
site O -
- O -
specific O +
activators O +
cyclic O +
AMP O -
- O -
responsive O +
element O -
- O -
binding O +
protein O +
, O +
NF O -
- O -
kappaB O +
, O +
and O +
serum O +
response O +
factor O +
. O +

It O +
has O +
been O +
suggested O +
that O +
the O +
recruitment O +
of O +
Tax O +
to O +
the O +
DNA O +
positions O +
Tax O +
for O +
interaction O +
with O +
the O +
basal O +
transcriptional O +
machinery O +
. O +

On O +
the O +
basis O +
of O +
several O +
independent O +
assays O +
, O +
we O +
now O +
report O +
a O +
physical O +
and O +
functional O +
interaction O +
between O +
Tax O +
and O +
the O +
transcription O +
factor O +
, O +
TFIIA O +
. O +

First O +
, O +
Tax O +
was O +
found O +
to O +
interact O +
with O +
the O +
35-kDa O +
( O +
alpha O +
) O +
subunit O +
of O +
TFIIA O +
in O +
the O +
yeast O +
two O -
- O -
hybrid O +
interaction O +
system O +
. O +

Importantly O +
, O +
two O +
previously O +
characterized O +
mutants O +
with O +
point O +
mutations O +
in O +
Tax O +
, O +
M32 O +
( O +
Y196A O +
, O +
K197S O +
) O +
and O +
M41 O +
( O +
H287A O +
, O +
P288S O +
) O +
, O +
which O +
were O +
shown O +
to O +
be O +
defective O +
in O +
Tax O +
-activated O +
transcription O +
were O +
unable O +
to O +
interact O +
with O +
TFIIA O +
in O +
this O +
assay O +
. O +

Second O +
, O +
a O +
glutathione O -
- O -
S O -
- O -
transferase O +
( O +
GST O +
) O +
affinity O -
- O -
binding O +
assay O +
showed O +
that O +
the O +
interaction O +
of O +
holo- O +
TFIIA O +
with O +
GST O -
- O -
Tax O +
was O +
20-fold O +
higher O +
than O +
that O +
observed O +
with O +
either O +
the O +
GST O -
- O -
Tax O +
M32 O +
activation O +
mutant O +
or O +
the O +
GST O +
control O +
. O +

Third O +
, O +
a O +
coimmunoprecipitation O +
assay O +
showed O +
that O +
in O +
HTLV-1-infected B-CellLine +
human I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
, O +
Tax O +
and O +
TFIIA O +
were O +
associated O +
. O +

Finally O +
, O +
TFIIA O +
facilitates O +
Tax O +
transactivation O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

In O +
vitro O +
transcription O +
studies O +
showed O +
reduced O +
levels O +
of O +
Tax O +
-activated O +
transcription O +
in O +
cell O +
extracts O +
depleted O +
of O +
TFIIA O +
. O +

In O +
addition O +
, O +
transfection O +
of O +
human O +
T O +
lymphocytes O +
with O +
TFIIA O +
expression O +
vectors O +
enhanced O +
Tax O +
-activated O +
transcription O +
of O +
an O +
HTLV-1 O +
long O +
terminal O +
repeat O -
- O -
chloramphenicol O +
acetyltransferase O +
reporter O +
construct O +
. O +

Our O +
study O +
suggests O +
that O +
the O +
interaction O +
of O +
Tax O +
with O +
the O +
transcription O +
factor O +
TFIIA O +
may O +
play O +
a O +
role O +
in O +
Tax O +
-mediated O +
transcriptional O +
activation O +
. O +

Transgenic O +
expression O +
of O +
PML O -
/ O -
RARalpha O +
impairs O +
myelopoiesis O +
. O +

The O +
translocation O +
found O +
in O +
acute O +
promyelocytic O +
leukemia O +
rearranges O +
the O +
promyelocytic O +
leukemia O +
gene O +
( O +
PML O +
) O +
on O +
chromosome O +
15 O +
with O +
the O +
retinoic O +
acid O +
receptor O +
alpha O +
( O +
RARalpha O +
) O +
on O +
chromosome O +
17 O +
. O +

This O +
yields O +
a O +
fusion O +
transcript O +
, O +
PML O -
/ O -
RARalpha O +
, O +
a O +
transcription O +
factor O +
with O +
reported O +
dominant O +
negative O +
functions O +
in O +
the O +
absence O +
of O +
hormone O +
. O +

Clinical O +
remissions O +
induced O +
with O +
all O -
- O -
trans O +
retinoic O +
acid O +
( O +
RA O +
) O +
treatment O +
in O +
acute O +
promyelocytic O +
leukemia O +
are O +
linked O +
to O +
PML O -
/ O -
RARalpha O +
expression O +
in O +
leukemic O +
cells O +
. O +

To O +
evaluate O +
the O +
PML O -
/ O -
RARalpha O +
role O +
in O +
myelopoiesis O +
, O +
transgenic O +
mice O +
expressing O +
PML O -
/ O -
RARalpha O +
were O +
engineered O +
. O +

A O +
full O -
- O -
length O +
PML O -
/ O -
RARalpha O +
cDNA O +
driven O +
by O +
the O +
CD11b O +
promoter O +
was O +
expressed O +
in O +
transgenic O +
mice O +
. O +

Expression O +
was O +
confirmed O +
in O +
the O +
bone O +
marrow O +
with O +
a O +
reverse O +
transcription O +
PCR O +
assay O +
. O +

Basal O +
total O +
white O +
blood O +
cell O +
and O +
granulocyte O +
counts O +
did O +
not O +
appreciably O +
differ O +
between O +
PML O -
/ O -
RARalpha O +
transgenic O +
and O +
control O +
mice O +
. O +

Cell O +
sorter O +
analysis O +
of O +
CD11b+ O +
bone O +
marrow O +
cells O +
revealed O +
similar O +
CD11b+ O +
populations O +
in O +
transgenic O +
and O +
control O +
mice O +
. O +

However O +
, O +
in O +
vitro O +
clonal O +
growth O +
assays O +
performed O +
on O +
peripheral O +
blood O +
from O +
transgenic O +
versus O +
control O +
mice O +
revealed O +
a O +
marked O +
reduction O +
of O +
myeloid O +
progenitors O +
, O +
especially O +
in O +
those O +
responding O +
to O +
granulocyte O -
/ O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
. O +

Granulocyte O -
/ O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
and O +
kit O +
ligand O +
cotreatment O +
did O +
not O +
overcome O +
this O +
inhibition O +
. O +

Impaired O +
myelopoiesis O +
in O +
vivo O +
was O +
shown O +
by O +
stressing O +
these O +
mice O +
with O +
sublethal O +
irradiation O +
. O +

Following O +
irradiation O +
, O +
PML O -
/ O -
RARalpha O +
transgenic O +
mice O +
, O +
as O +
compared O +
with O +
controls O +
, O +
more O +
rapidly O +
depressed O +
peripheral O +
white O +
blood O +
cell O +
and O +
granulocyte O +
counts O +
. O +

As O +
expected O +
, O +
nearly O +
all O +
control O +
mice O +
( O +
94.4 O +
% O +
) O +
survived O +
irradiation O +
, O +
yet O +
this O +
irradiation O +
was O +
lethal O +
to O +
45.8 O +
% O +
of O +
PML O -
/ O -
RARalpha O +
transgenic O +
mice O +
. O +

Lethality O +
was O +
associated O +
with O +
more O +
severe O +
leukopenia O +
in O +
transgenic O +
versus O +
control O +
mice O +
. O +

Retinoic O +
acid O +
treatment O +
of O +
irradiated O +
PML O -
/ O -
RARalpha O +
mice O +
enhanced O +
granulocyte O +
recovery O +
. O +

These O +
data O +
suggest O +
that O +
abnormal O +
myelopoiesis O +
due O +
to O +
PML O -
/ O -
RARalpha O +
expression O +
is O +
an O +
early O +
event O +
in O +
oncogenic O +
transformation O +
. O +

Alpha O +
4 O +
beta O +
1 O +
( O +
CD49d O -
/ O -
CD29 O +
) O +
integrin O +
costimulation O +
of O +
human O +
T O +
cells O +
enhances O +
transcription O +
factor O +
and O +
cytokine O +
induction O +
in O +
the O +
absence O +
of O +
altered O +
sensitivity O +
to O +
anti O -
- O -
CD3 O +
stimulation O +
. O +

The O +
integrin O +
alpha O +
4 O +
beta O +
1 O +
can O +
provide O +
a O +
costimulus O +
to O +
induce O +
IL-2 O +
secretion O +
and O +
IL-2R O +
expression O +
leading O +
to O +
enhanced O +
proliferation O +
of O +
purified O +
, O +
peripheral O +
blood O +
T O +
cells O +
. O +

Similar O +
to O +
expression O +
of O +
IL-2 O +
, O +
we O +
demonstrated O +
that O +
recombinant O +
vascular O -
- O -
cell O +
adhesion O +
molecule-1 O +
, O +
when O +
co O -
- O -
immobilized O +
with O +
anti O -
- O -
CD3 O +
mAb O +
, O +
significantly O +
enhanced O +
the O +
induction O +
of O +
transcription O +
factors O +
NF O -
- O -
AT O +
, O +
AP-1 O +
, O +
and O +
NF O -
- O -
kappa O +
B O +
as O +
determined O +
by O +
electromobility O +
shift O +
assays O +
. O +

alpha O +
4 O +
beta O +
1 O +
ligation O +
alone O +
had O +
no O +
effect O +
on O +
transcription O +
factor O +
binding O +
. O +

The O +
requirements O +
for O +
induction O +
of O +
transcription O +
factors O +
reflected O +
the O +
requirements O +
for O +
the O +
secretion O +
of O +
multiple O +
cytokines O +
, O +
including O +
IL-2 O +
, O +
TNF O -
- O -
alpha O +
, O +
IFN O -
- O -
gamma O +
, O +
and O +
granulocyte O +
macrophage O -
- O -
CSF O +
. O +

In O +
contrast O +
to O +
freshly O +
isolated O +
T O +
cells O +
, O +
in O +
vitro B-CellLine -
- I-CellLine -
cultured I-CellLine +
T I-CellLine +
cells I-CellLine +
did O +
not O +
require O +
costimulation O +
for O +
cytokine O +
secretion O +
in O +
response O +
to O +
anti O -
- O -
CD3 O +
alone O +
. O +

Comparison O +
of O +
the O +
dose O +
response O +
to O +
anti O -
- O -
CD3 O +
stimulation O +
demonstrated O +
that O +
half O -
- O -
maximal O +
induction O +
of O +
IL-2 O +
was O +
achieved O +
using O +
the O +
same O +
dose O +
of O +
anti O -
- O -
CD3 O +
for O +
both O +
freshly O +
isolated O +
and O +
cultured B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Furthermore O +
, O +
the O +
dose O +
of O +
OKT3 O +
required O +
to O +
achieve O +
half O -
- O -
maximal O +
activation O +
was O +
the O +
same O +
using O +
PMA O +
or O +
different O +
concentrations O +
of O +
alpha O +
4 O +
beta O +
1 O +
ligands O +
. O +

Therefore O +
, O +
costimulation O +
by O +
alpha O +
4 O +
beta O +
1 O +
ligands O +
was O +
not O +
due O +
to O +
stabilization O +
of O +
the O +
interaction O +
of O +
the O +
cells O +
with O +
its O +
substrate O +
. O +

We O +
conclude O +
, O +
rather O +
, O +
that O +
alpha O +
4 O +
beta O +
1 O +
in O +
freshly O +
isolated O +
T O +
cells O +
delivers O +
a O +
distinct O +
signal O +
that O +
synergizes O +
early O +
with O +
signals O +
initiated O +
by O +
TCR O -
/ O -
CD3 O +
ligation O +
to O +
induce O +
DNA O +
binding O +
of O +
multiple O +
transcription O +
factors O +
required O +
for O +
cytokine O +
gene O +
induction O +
. O +

Elevated O +
cyclic O +
AMP O +
inhibits O +
NF O -
- O -
kappaB O +
-mediated O +
transcription O +
in O +
human O +
monocytic O +
cells O +
and O +
endothelial O +
cells O +
. O +

The O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
family O +
of O +
transcription O +
factors O +
regulates O +
the O +
inducible O +
expression O +
of O +
many O +
genes O +
in O +
activated O +
human O +
monocytes O +
and O +
endothelial O +
cells O +
. O +

In O +
this O +
study O +
, O +
we O +
examined O +
the O +
molecular O +
mechanism O +
by O +
which O +
agents O +
that O +
elevate O +
intracellular O +
cAMP O +
inhibit O +
the O +
expression O +
of O +
the O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNFalpha O +
) O +
, O +
tissue O +
factor O +
, O +
endothelial O +
leukocyte O +
adhesion O +
molecule-1 O +
, O +
and O +
vascular O +
cell O +
adhesion O +
molecule-1 O +
genes O +
. O +

Both O +
forskolin O +
and O +
dibutyryl O +
cAMP O +
, O +
which O +
elevate O +
intracellular O +
cAMP O +
by O +
independent O +
mechanisms O +
, O +
inhibited O +
TNFalpha O +
and O +
tissue O +
factor O +
expression O +
at O +
the O +
level O +
of O +
transcription O +
. O +

Induction O +
of O +
NF O -
- O -
kappaB O +
-dependent O +
gene O +
expression O +
in O +
transiently O +
transfected O +
human B-CellLine +
monocytic I-CellLine +
THP-1 I-CellLine +
cells I-CellLine +
and O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
was O +
inhibited O +
by O +
elevated O +
cAMP O +
and O +
by O +
overexpression O +
of O +
the O +
catalytic O +
subunit O +
of O +
protein O +
kinase O +
A O +
( O +
PKA O +
) O +
. O +

Elevated O +
cAMP O +
did O +
not O +
prevent O +
nuclear O +
translocation O +
of O +
p50 O -
/ O -
p65 O +
and O +
c O -
- O -
Rel O -
/ O -
p65 O +
heterodimers O +
, O +
decrease O +
nuclear O +
translocation O +
of O +
p65 O +
, O +
or O +
significantly O +
modify O +
TNFalpha O +
-induced O +
phosphorylation O +
of O +
p65 O +
. O +

Functional O +
studies O +
demonstrated O +
that O +
transcriptional O +
activation O +
of O +
a O +
plasmid O +
containing O +
multimerized O +
kappaB O +
sites O +
by O +
p65 O +
was O +
inhibited O +
by O +
agents O +
that O +
elevate O +
cAMP O +
and O +
by O +
overexpression O +
of O +
the O +
catalytic O +
subunit O +
of O +
PKA O +
. O +

This O +
study O +
indicates O +
that O +
activation O +
of O +
PKA O +
reduces O +
the O +
induction O +
of O +
a O +
distinct O +
set O +
of O +
genes O +
in O +
monocytes O +
and O +
endothelial O +
cells O +
by O +
inhibiting O +
NF O -
- O -
kappaB O +
-mediated O +
transcription O +
. O +

Activation O +
of O +
human O +
monocytic O +
cells O +
by O +
Treponema O +
pallidum O +
and O +
Borrelia O +
burgdorferi O +
lipoproteins O +
and O +
synthetic O +
lipopeptides O +
proceeds O +
via O +
a O +
pathway O +
distinct O +
from O +
that O +
of O +
lipopolysaccharide O +
but O +
involves O +
the O +
transcriptional O +
activator O +
NF O -
- O -
kappa O +
B O +
. O +

There O +
is O +
increasing O +
evidence O +
that O +
lipoproteins O +
of O +
Treponema O +
pallidum O +
and O +
Borrelia O +
burgdorferi O +
are O +
key O +
inflammatory O +
mediators O +
during O +
syphilis O +
and O +
Lyme O +
disease O +
. O +

A O +
principal O +
objective O +
of O +
the O +
present O +
study O +
was O +
to O +
identify O +
more O +
precisely O +
similarities O +
and O +
divergences O +
among O +
lipopolysaccharide O +
( O +
LPS O +
) O +
- O +
and O +
lipoprotein O -
- O -
lipopeptide O -
- O -
induced O +
immune O +
cell O +
signaling O +
events O +
. O +

Like O +
LPS O +
, O +
purified O +
native O +
B. O +
burgdorferi O +
OspA O +
and O +
synthetic O +
analogs O +
of O +
OspA O +
, O +
OspB O +
, O +
and O +
two O +
T. O +
pallidum O +
lipoproteins O +
( O +
Tpp47 O +
and O +
Tpp17 O +
) O +
all O +
induced O +
NF O -
- O -
kappa O +
B O +
translocation O +
in O +
THP-1 O +
human O +
monocytoid O +
cells O +
. O +

Acylation O +
of O +
OspA O +
and O +
the O +
synthetic O +
peptides O +
was O +
requisite O +
for O +
cell O +
activation O +
. O +

Polymyxin O +
B O +
abrogated O +
only O +
the O +
response O +
to O +
LPS O +
. O +

By O +
using O +
70Z B-CellLine -
/ I-CellLine -
3-derived I-CellLine +
pre I-CellLine -
- I-CellLine -
B I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
either O +
lacking O +
or O +
expressing O +
human O +
CD14 O +
( O +
the O +
LPS O +
receptor O +
) O +
, O +
it O +
was O +
observed O +
that O +
expression O +
of O +
human O +
CD14 O +
imparted O +
responsiveness O +
to O +
LPS O +
but O +
not O +
to O +
OspA O +
or O +
spirochetal O +
lipopeptides O +
( O +
assessed O +
by O +
induction O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
expression O +
of O +
surface O +
immunoglobulin O +
M O +
) O +
. O +

Finally O +
, O +
the O +
biological O +
relevance O +
of O +
the O +
observation O +
that O +
T. O +
pallidum O +
lipoproteins O +
-lipopeptides O +
induce O +
both O +
NF O -
- O -
kappa O +
B O +
and O +
cytokine O +
production O +
in O +
monocytes O +
was O +
supported O +
by O +
the O +
ability O +
of O +
the O +
synthetic O +
analogs O +
to O +
promote O +
human O +
immunodeficiency O +
virus O +
replication O +
in O +
chronically O +
infected O +
U1 O +
monocytoid O +
cells O +
; O +
these O +
observations O +
also O +
suggest O +
a O +
potential O +
mechanism O +
whereby O +
a O +
syphilitic O +
chancre O +
can O +
serve O +
as O +
a O +
cofactor O +
for O +
human O +
immunodeficiency O +
virus O +
transmission O +
. O +

The O +
combined O +
data O +
lend O +
additional O +
support O +
to O +
the O +
proposal O +
that O +
spirochetal O +
lipoproteins O +
and O +
LPS O +
initiate O +
monocyte O +
activation O +
via O +
different O +
cell O +
surface O +
events O +
but O +
that O +
the O +
signaling O +
pathways O +
ultimately O +
converge O +
to O +
produce O +
qualitatively O +
similar O +
cellular O +
responses O +
. O +

Transcription O +
specific O +
differences O +
visualized O +
by O +
fluorescence O +
in O +
situ O +
hybridization O +
pattern O +
on O +
interphase O +
nuclei O +
of O +
different O +
cell O +
types O +
. O +

Application O +
of O +
a O +
` O -
` O +
formamide O +
free O +
'' O +
and O +
thus O +
` O -
` O +
material O +
preserving O +
'' O +
in O +
situ O +
hybridization O +
technique O +
using O +
the O +
cDNA O +
of O +
the O +
myf3 O +
gene O +
revealed O +
the O +
following O +
results O +
: O +
Human O +
rhabdomyosarcoma O +
cells O +
, O +
characterized O +
by O +
a O +
high O +
expression O +
of O +
myf3 O +
show O +
intensive O +
hybridization O +
signals O +
in O +
their O +
interphase O +
. O +

RNase O +
treatment O +
prior O +
to O +
hybridization O +
considerably O +
reduces O +
the O +
size O +
of O +
this O +
signals O +
. O +

In O +
comparison O +
, O +
isolated O +
nuclei O +
of O +
human O +
lymphocytes O +
in O +
which O +
no O +
need O +
for O +
the O +
expression O +
of O +
this O +
gene O +
exists O +
, O +
show O +
barely O +
hybridization O +
signals O +
. O +

Correspondingly O +
, O +
RNase O +
treatment O +
had O +
no O +
effect O +
on O +
hybridization O +
pattern O +
at O +
all O +
. O +

In O +
conclusion O +
an O +
increased O +
transcription O +
efficiency O +
of O +
a O +
cell O +
type O +
specific O +
gene O +
is O +
accompanied O +
by O +
a O +
higher O +
hybridization O +
accessibility O +
in O +
the O +
corresponding O +
cell O +
nuclei O +
. O +

Chronic O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
infection O +
of O +
myeloid O +
cells O +
disrupts O +
the O +
autoregulatory O +
control O +
of O +
the O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
pathway O +
via O +
enhanced O +
IkappaBalpha O +
degradation O +
. O +

Productive O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
infection O +
causes O +
sustained O +
NF O -
- O -
kappaB O +
DNA O -
- O -
binding O +
activity O +
in O +
chronically O +
infected O +
monocytic O +
cells O +
. O +

A O +
direct O +
temporal O +
correlation O +
exists O +
between O +
HIV O +
infection O +
and O +
the O +
appearance O +
of O +
NF O -
- O -
kappaB O +
DNA O -
- O -
binding O +
activity O +
in O +
myelomonoblastic B-CellLine +
PLB-985 I-CellLine +
cells I-CellLine +
. O +

To O +
examine O +
the O +
molecular O +
basis O +
of O +
constitutive O +
NF O -
- O -
kappaB O +
DNA O -
- O -
binding O +
activity O +
in O +
HIV1 O +
-infected O +
cells O +
, O +
we O +
analyzed O +
the O +
phosphorylation O +
and O +
turnover O +
of O +
IkappaBalpha O +
protein O +
, O +
the O +
activity O +
of O +
the O +
double O -
- O -
stranded O +
RNA O -
- O -
dependent O +
protein O +
kinase O +
( O +
PKR O +
) O +
and O +
the O +
intracellular O +
levels O +
of O +
NF O -
- O -
kappaB O +
subunits O +
in O +
the O +
PLB-985 B-CellLine +
and O +
U937 B-CellLine +
myeloid I-CellLine +
cell I-CellLine +
models I-CellLine +
. O +

HIV-1 O +
infection O +
resulted O +
in O +
constitutive O +
, O +
low O -
- O -
level O +
expression O +
of O +
type O +
1 O +
interferon O +
( O +
IFN O +
) O +
at O +
the O +
mRNA O +
level O +
. O +

Constitutive O +
PKR O +
activity O +
was O +
also O +
detected O +
in O +
HIV-1-infected B-CellLine +
cells I-CellLine +
as O +
a O +
result O +
of O +
low O -
- O -
level O +
IFN O +
production O +
, O +
since O +
the O +
addition O +
of O +
anti O -
- O -
IFN O -
- O -
alpha O -
/ O -
beta O +
antibody O +
to O +
the O +
cells O +
decreased O +
PKR O +
expression O +
. O +

Furthermore O +
, O +
the O +
analysis O +
of O +
IkappaBalpha O +
turnover O +
demonstrated O +
an O +
increased O +
degradation O +
of O +
IkappaBalpha O +
in O +
HIV-1-infected B-CellLine +
cells I-CellLine +
that O +
may O +
account O +
for O +
the O +
constitutive O +
DNA O +
binding O +
activity O +
. O +

A O +
dramatic O +
increase O +
in O +
the O +
intracellular O +
levels O +
of O +
NF O -
- O -
kappaB O +
subunits O +
c O -
- O -
Rel O +
and O +
NF O -
- O -
kappaB2 O +
p100 O +
and O +
a O +
moderate O +
increase O +
in O +
NF O -
- O -
kappaB2 O +
p52 O +
and O +
RelA O +
( O +
p65 O +
) O +
were O +
detected O +
in O +
HIV-1-infected B-CellLine +
cells I-CellLine +
, O +
whereas O +
NF O -
- O -
kappaB1 O +
p105 O -
/ O -
p50 O +
levels O +
were O +
not O +
altered O +
relative O +
to O +
the O +
levels O +
in O +
uninfected O +
cells O +
. O +

We O +
suggest O +
that O +
HIV-1 O +
infection O +
of O +
myeloid O +
cells O +
induces O +
IFN O +
production O +
and O +
PKR O +
activity O +
, O +
which O +
in O +
turn O +
contribute O +
to O +
enhanced O +
IkappaBalpha O +
phosphorylation O +
and O +
subsequent O +
degradation O +
. O +

Nuclear O +
translocation O +
of O +
NF O -
- O -
kappaB O +
subunits O +
may O +
ultimately O +
increase O +
the O +
intracellular O +
pool O +
of O +
NF O -
- O -
kappaB O -
/ O -
IkappaBalpha O +
by O +
an O +
autoregulatory O +
mechanism O +
. O +

Enhanced O +
turnover O +
of O +
IkappaBalpha O +
and O +
the O +
accumulation O +
of O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
proteins O +
may O +
contribute O +
to O +
the O +
chronically O +
activated O +
state O +
of O +
HIV-1-infected B-CellLine +
cells I-CellLine +
. O +

Sequence O -
- O -
specific O +
DNA O +
binding O +
of O +
the O +
B O -
- O -
cell O -
- O -
specific O +
coactivator O +
OCA O -
- O -
B O +
. O +

B O -
- O -
cell O -
- O -
specific O +
transcription O +
of O +
immunoglobulin O +
genes O +
is O +
mediated O +
by O +
the O +
interaction O +
of O +
a O +
POU O +
domain O +
containing O +
transcription O +
factor O +
Oct-1 O +
or O +
Oct-2 O +
, O +
with O +
the O +
B O -
- O -
cell O -
- O -
specific O +
coactivator O +
OCA O -
- O -
B O +
( O +
Bob-1 O +
, O +
OBF-1 O +
) O +
and O +
a O +
prototype O +
octamer O +
element O +
. O +

We O +
find O +
that O +
OCA O -
- O -
B O +
binds O +
DNA O +
directly O +
in O +
the O +
major O +
groove O +
between O +
the O +
two O +
subdomains O +
of O +
the O +
POU O +
domain O +
, O +
requiring O +
both O +
an O +
A O +
at O +
the O +
fifth O +
position O +
of O +
the O +
octamer O +
element O +
and O +
contact O +
with O +
the O +
POU O +
domain O +
. O +

An O +
amino O -
- O -
terminal O +
fragment O +
of O +
OCA O -
- O -
B O +
binds O +
the O +
octamer O +
site O +
in O +
the O +
absence O +
of O +
a O +
POU O +
domain O +
with O +
the O +
same O +
sequence O +
specificity O +
. O +

Coactivator O +
OCA O -
- O -
B O +
may O +
undergo O +
a O +
POU O -
- O -
dependent O +
conformational O +
change O +
that O +
exposes O +
its O +
amino O +
terminus O +
, O +
allowing O +
it O +
to O +
recognize O +
specific O +
DNA O +
sequences O +
in O +
the O +
major O +
groove O +
within O +
the O +
binding O +
site O +
for O +
Oct-1 O +
or O +
Oct-2 O +
. O +

The O +
recognition O +
of O +
both O +
the O +
POU O +
domain O +
and O +
the O +
octamer O +
sequence O +
by O +
OCA O -
- O -
B O +
provides O +
a O +
mechanism O +
for O +
differential O +
regulation O +
of O +
octamer O +
sites O +
containing O +
genes O +
by O +
the O +
ubiquitous O +
factor O +
Oct-1 O +
. O +

Cross O +
talk O +
between O +
cell O +
death O +
and O +
cell O +
cycle O +
progression O +
: O +
BCL-2 O +
regulates O +
NFAT O +
-mediated O +
activation O +
. O +

BCL-2-deficient B-CellLine +
T I-CellLine +
cells I-CellLine +
demonstrate O +
accelerated O +
cell O +
cycle O +
progression O +
and O +
increased O +
apoptosis O +
following O +
activation O +
. O +

Increasing O +
the O +
levels O +
of O +
BCL-2 O +
retarded O +
the O +
G0 O +
-- O +
> O +
S O +
transition O +
, O +
sustained O +
the O +
levels O +
of O +
cyclin O -
- O -
dependent O +
kinase O +
inhibitor O +
p27Kip1 O +
, O +
and O +
repressed O +
postactivation O +
death O +
. O +

Proximal O +
signal O +
transduction O +
events O +
and O +
immediate O +
early O +
gene O +
transcription O +
were O +
unaffected O +
. O +

However O +
, O +
the O +
transcription O +
and O +
synthesis O +
of O +
interleukin O +
2 O +
and O +
other O +
delayed O +
early O +
cytokines O +
were O +
markedly O +
attenuated O +
by O +
BCL-2 O +
. O +

In O +
contrast O +
, O +
a O +
cysteine O +
protease O +
inhibitor O +
that O +
also O +
blocks O +
apoptosis O +
had O +
no O +
substantial O +
affect O +
upon O +
cytokine O +
production O +
. O +

InterleUkin O +
2 O +
expression O +
requires O +
several O +
transcription O +
factors O +
of O +
which O +
nuclear O +
translocation O +
of O +
NFAT O +
( O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
) O +
and O +
NFAT O +
-mediated O +
transactivation O +
were O +
impaired O +
by O +
BCL-2 O +
. O +

Thus O +
, O +
select O +
genetic O +
aberrations O +
in O +
the O +
apoptotic O +
pathway O +
reveal O +
a O +
cell O +
autonomous O +
coregulation O +
of O +
activation O +
. O +

Apoptosis O +
mediated O +
by O +
HIV O +
protease O +
is O +
preceded O +
by O +
cleavage O +
of O +
Bcl-2 O +
. O +

Expression O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV O +
) O +
protease O +
in O +
cultured B-CellLine +
cells I-CellLine +
leads O +
to O +
apoptosis O +
, O +
preceded O +
by O +
cleavage O +
of O +
bcl-2 O +
, O +
a O +
key O +
negative O +
regulator O +
of O +
cell O +
death O +
. O +

In O +
contrast O +
, O +
a O +
high O +
level O +
of O +
bcl-2 O +
protects O +
cells O +
in O +
vitro O +
and O +
in O +
vivo O +
from O +
the O +
viral O +
protease O +
and O +
prevents O +
cell O +
death O +
following O +
HIV O +
infection O +
of O +
human O +
lymphocytes O +
, O +
while O +
reducing O +
the O +
yields O +
of O +
viral O +
structural O +
proteins O +
, O +
infectivity O +
, O +
and O +
tumor O +
necrosis O +
factor O +
alpha O +
. O +

We O +
present O +
a O +
model O +
for O +
HIV O +
replication O +
in O +
which O +
the O +
viral O +
protease O +
depletes O +
the O +
infected O +
cells O +
of O +
bcl-2 O +
, O +
leading O +
to O +
oxidative O +
stress O -
- O -
dependent O +
activation O +
of O +
NF O +
kappa O +
B O +
, O +
a O +
cellular O +
factor O +
required O +
for O +
HIV O +
transcription O +
, O +
and O +
ultimately O +
to O +
cell O +
death O +
. O +

Purified O +
bcl-2 O +
is O +
cleaved O +
by O +
HIV O +
protease O +
between O +
phenylalanine O +
112 O +
and O +
alanine O +
113 O +
. O +

The O +
results O +
suggest O +
a O +
new O +
option O +
for O +
HIV O +
gene O +
therapy O +
; O +
bcl-2 O +
muteins O +
that O +
have O +
noncleavable O +
alterations O +
surrounding O +
the O +
HIV O +
protease O +
cleavage O +
site O +
. O +

Activation O +
of O +
Stat O +
5b O +
in O +
erythroid O +
progenitors O +
correlates O +
with O +
the O +
ability O +
of O +
ErbB O +
to O +
induce O +
sustained O +
cell O +
proliferation O +
. O +

Self O +
renewal O +
of O +
normal O +
erythroid O +
progenitors O +
is O +
induced O +
by O +
the O +
receptor O +
tyrosine O +
kinase O +
c O -
- O -
ErbB O +
, O +
whereas O +
other O +
receptors O +
( O +
c O -
- O -
Kit O -
/ O -
Epo O -
- O -
R O +
) O +
regulate O +
erythroid O +
differentiation O +
. O +

To O +
address O +
possible O +
mechanisms O +
that O +
could O +
explain O +
this O +
selective O +
activity O +
of O +
c O -
- O -
ErbB O +
, O +
we O +
analyzed O +
the O +
ability O +
of O +
these O +
receptors O +
to O +
activate O +
the O +
different O +
members O +
of O +
the O +
Stat O +
transcription O +
factor O +
family O +
. O +

Ligand O +
activation O +
of O +
c O -
- O -
ErbB O +
induced O +
the O +
tyrosine O +
phosphorylation O +
, O +
DNA O -
- O -
binding O +
, O +
and O +
reporter O +
gene O +
transcription O +
of O +
Stat O +
5b O +
in O +
erythroblasts O +
. O +

In O +
contrast O +
, O +
ligand O +
activation O +
of O +
c O -
- O -
Kit O +
was O +
unable O +
to O +
induce O +
any O +
of O +
these O +
effects O +
in O +
the O +
same O +
cells O +
. O +

Activation O +
of O +
the O +
erythropoietin O +
receptor O +
caused O +
specific O +
DNA O -
- O -
binding O +
of O +
Stat O +
5b O +
, O +
but O +
failed O +
to O +
induce O +
reporter O +
gene O +
transcription O +
. O +

These O +
biochemical O +
findings O +
correlate O +
perfectly O +
with O +
the O +
selective O +
ability O +
of O +
c O -
- O -
ErbB O +
to O +
cause O +
sustained O +
self O +
renewal O +
in O +
erythroid O +
progenitors O +
. O +

Retinoid O +
differentiation O +
therapy O +
in O +
promyelocytic O +
leukemia O +
. O +

Acute O +
promyelocytic O +
leukemia O +
( O +
APL O +
) O +
is O +
a O +
specific O +
type O +
of O +
acute O +
myeloid O +
leukemia O +
characterized O +
by O +
the O +
morphology O +
of O +
the O +
blast O +
cells O +
, O +
a O +
specific O +
t O +
( O +
15 O +
; O +
17 O +
) O +
translocation O +
, O +
and O +
risks O +
of O +
definite O +
coagulopathy O +
. O +

Recently O +
this O +
leukemia O +
was O +
further O +
characterized O +
by O +
an O +
exquisite O +
sensitivity O +
to O +
all O -
- O -
trans O +
retinoic O +
acid O +
's O +
differentiation O +
effect O +
and O +
the O +
production O +
of O +
a O +
fusion O +
gene O +
altering O +
the O +
gene O +
of O +
RARalpha O +
and O +
a O +
novel O +
gene O +
PML O +
. O +

In O +
vivo O +
differentiation O +
therapy O +
with O +
retinoids O +
in O +
APL O +
patients O +
follows O +
strict O +
guidelines O +
related O +
both O +
to O +
the O +
APL O +
cell O +
and O +
the O +
biodisposal O +
of O +
all O -
- O -
trans O +
retinoic O +
acid O +
. O +

Evidence O +
for O +
lowered O +
induction O +
of O +
nuclear O +
factor O +
kappa O +
B O +
in O +
activated O +
human O +
T O +
lymphocytes O +
during O +
aging O +
. O +

Transcription O +
factor O +
NF O +
kappa O +
B O +
( O +
nuclear O +
factor O +
kappa O +
B O +
) O +
is O +
induced O +
in O +
T O +
lymphocytes O +
from O +
young O +
individuals O +
following O +
activation O +
with O +
a O +
variety O +
of O +
stimuli O +
including O +
anti O -
- O -
CD3 O +
, O +
phorbol O +
myristate O +
acetate O +
( O +
PMA O +
) O +
, O +
and O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
. O +

In O +
contrast O +
, O +
activated O +
T O +
lymphocytes O +
from O +
older O +
individuals O +
show O +
a O +
significant O +
reduction O +
in O +
the O +
induction O +
of O +
NF O +
kappa O +
B O +
in O +
response O +
to O +
the O +
same O +
stimuli O +
. O +

The O +
age O -
- O -
related O +
decline O +
in O +
induction O +
of O +
NF O +
kappa O +
B O +
could O +
not O +
be O +
attributed O +
to O +
alteration O +
in O +
the O +
composition O +
of O +
subunits O +
, O +
p50 O +
and O +
p65 O +
were O +
found O +
to O +
be O +
the O +
predominant O +
subunits O +
of O +
induced O +
NF O +
kappa O +
B O +
in O +
T O +
cells O +
from O +
young O +
as O +
well O +
as O +
elderly O +
donors O +
. O +

Furthermore O +
, O +
similar O +
levels O +
of O +
NF O +
kappa O +
B O +
were O +
found O +
in O +
the O +
cytosols O +
of O +
unactivated O +
T O +
cells O +
from O +
both O +
young O +
and O +
elderly O +
donors O +
suggesting O +
that O +
precursor O +
levels O +
of O +
NF O +
kappa O +
B O +
remain O +
unaltered O +
during O +
aging O +
. O +

These O +
results O +
suggest O +
that O +
an O +
age O -
- O -
associated O +
decline O +
in O +
the O +
induction O +
of O +
NF O +
kappa O +
B O +
in O +
activated O +
T O +
cells O +
from O +
elderly O +
individuals O +
may O +
be O +
attributable O +
to O +
altered O +
regulation O +
of O +
the O +
inhibitor O +
, O +
I O +
kappa O +
B O +
, O +
and O +
may O +
play O +
an O +
important O +
role O +
in O +
immune O +
dysregulation O +
accompanying O +
aging O +
. O +

Interaction O +
of O +
HTLV O -
- O -
I O +
Tax O +
with O +
the O +
human O +
proteasome O +
: O +
implications O +
for O +
NF O -
- O -
kappa O +
B O +
induction O +
. O +

The O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
has O +
been O +
etiologically O +
associated O +
with O +
the O +
development O +
of O +
the O +
adult O +
T O -
- O -
cell O +
leukemia O +
( O +
ATL O +
) O +
as O +
well O +
as O +
degenerative O +
neurologic O +
syndrome O +
termed O +
tropical O +
spastic O +
paraparesis O +
( O +
TSP O +
) O +
. O +

HTLV O -
- O -
I O +
encodes O +
a O +
potent O +
transactivator O +
protein O +
termed O +
Tax O +
that O +
appears O +
to O +
play O +
an O +
important O +
role O +
in O +
the O +
process O +
of O +
T O -
- O -
cell O +
immortalization O +
. O +

Even O +
though O +
the O +
mechanisms O +
by O +
which O +
Tax O +
induces O +
transformation O +
are O +
still O +
unknown O +
, O +
it O +
seems O +
likely O +
that O +
the O +
ability O +
of O +
Tax O +
to O +
alter O +
the O +
expression O +
of O +
many O +
cellular O +
genes O +
plays O +
an O +
important O +
part O +
in O +
this O +
process O +
. O +

Tax O +
does O +
not O +
bind O +
directly O +
to O +
DNA O +
but O +
rather O +
deregulates O +
the O +
activity O +
of O +
cellular O +
transcription O +
factors O +
. O +

One O +
family O +
of O +
host O +
transcription O +
factors O +
whose O +
activity O +
is O +
altered O +
by O +
Tax O +
includes O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
. O +

These O +
transcription O +
factors O +
are O +
post O -
- O -
transcriptionally O +
regulated O +
by O +
their O +
assembly O +
with O +
a O +
second O +
family O +
of O +
inhibitory O +
proteins O +
termed O +
I O +
kappa O +
B O +
that O +
serve O +
to O +
sequester O +
the O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
complexes O +
in O +
the O +
cytoplasm O +
. O +

Upon O +
cellular O +
activation O +
, O +
I O +
kappa O +
B O +
alpha O +
is O +
phosphorylated O +
, O +
polyubiquitinated O +
, O +
and O +
degraded O +
in O +
the O +
proteasome O +
. O +

This O +
proteolytic O +
event O +
liberates O +
NF O -
- O -
kappa O +
B O +
, O +
permitting O +
its O +
rapid O +
translocation O +
into O +
the O +
nucleus O +
where O +
it O +
binds O +
to O +
its O +
cognate O +
enhancer O +
elements O +
. O +

Similarly O +
, O +
the O +
p105 O +
precursor O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
p50 O +
subunit O +
is O +
also O +
post O -
- O -
translationally O +
processed O +
in O +
the O +
proteasome O +
. O +

The O +
mechanisms O +
by O +
which O +
Tax O +
activates O +
NF O -
- O -
kappa O +
B O +
remain O +
unclear O +
, O +
and O +
findings O +
presented O +
in O +
the O +
literature O +
are O +
often O +
controversial O +
. O +

We O +
identified O +
a O +
physical O +
interaction O +
between O +
Tax O +
and O +
the O +
HsN3 O +
subunit O +
of O +
the O +
human O +
proteasome O +
. O +

This O +
raises O +
the O +
intriguing O +
possibility O +
that O +
physical O +
association O +
of O +
the O +
HsN3 O +
proteasome O +
subunit O +
with O +
HTLV O -
- O -
I O +
Tax O +
coupled O +
with O +
the O +
independent O +
interaction O +
of O +
Tax O +
with O +
either O +
p100 O +
or O +
p65- O +
I O +
kappa O +
B O +
alpha O +
targets O +
these O +
cytoplasmic O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
complexes O +
to O +
the O +
proteasome O +
for O +
processing O +
. O +

Epstein O -
- O -
Barr O +
viral O +
latency O +
is O +
disrupted O +
by O +
the O +
immediate O -
- O -
early O +
BRLF1 O +
protein O +
through O +
a O +
cell O -
- O -
specific O +
mechanism O +
. O +

Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
, O +
the O +
causative O +
agent O +
of O +
infectious O +
mononucleosis O +
, O +
is O +
a O +
human O +
herpesvirus O +
associated O +
with O +
epithelial O +
cell O +
malignancies O +
( O +
nasopharyngeal O +
carcinoma O +
) O +
as O +
well O +
as O +
B O -
- O -
cell O +
malignancies O +
. O +

Understanding O +
how O +
viral O +
latency O +
is O +
disrupted O +
is O +
a O +
central O +
issue O +
in O +
herpesvirus O +
biology O +
. O +

Epithelial O +
cells O +
are O +
the O +
major O +
site O +
of O +
lytic O +
EBV O +
replication O +
within O +
the O +
human O +
host O +
, O +
and O +
viral O +
reactivation O +
occurs O +
in O +
EBV O -
- O -
associated O +
nasopharyngeal O +
carcinomas O +
. O +

It O +
is O +
known O +
that O +
expression O +
of O +
a O +
single O +
viral O +
immediate O -
- O -
early O +
protein O +
, O +
BZLF1 O +
, O +
is O +
sufficient O +
to O +
initiate O +
the O +
switch O +
from O +
latent O +
to O +
lytic O +
infection O +
in O +
B O +
cells O +
. O +

Cellular O +
regulation O +
of O +
BZLF1 O +
transcription O +
is O +
therefore O +
thought O +
to O +
play O +
a O +
key O +
role O +
in O +
regulating O +
the O +
stringency O +
of O +
viral O +
latency O +
. O +

Here O +
we O +
show O +
that O +
, O +
unexpectedly O +
, O +
expression O +
of O +
another O +
viral O +
immediate O -
- O -
early O +
protein O +
, O +
BRLF1 O +
, O +
can O +
disrupt O +
viral O +
latency O +
in O +
an O +
epithelial O +
cell O -
- O -
specific O +
fashion O +
. O +

Therefore O +
, O +
the O +
mechanisms O +
leading O +
to O +
disruption O +
of O +
EBV O +
latency O +
appear O +
to O +
be O +
cell O -
- O -
type O +
specific O +
. O +

IL4 O +
and O +
IL13 O +
receptors O +
share O +
the O +
gamma O +
c O +
chain O +
and O +
activate O +
STAT6 O +
, O +
STAT3 O +
and O +
STAT5 O +
proteins O +
in O +
normal O +
human O +
B O +
cells O +
. O +

IL13 O +
induces O +
the O +
same O +
biological O +
effects O +
as O +
IL4 O +
in O +
normal O +
human O +
B O +
cells O +
. O +

We O +
show O +
that O +
as O +
in O +
the O +
IL4R O +
complex O +
, O +
both O +
IL4R O +
alpha O +
and O +
IL2R O +
gamma O +
c O +
are O +
components O +
of O +
the O +
IL13R O +
and O +
that O +
both O +
cytokines O +
induced O +
STAT6 O +
, O +
STAT3 O +
and O +
STAT5 O +
activation O +
in O +
B O +
cells O +
. O +

In O +
spite O +
of O +
this O +
similar O +
downstream O +
signalling O +
, O +
IL4 O +
and O +
IL13 O +
used O +
a O +
different O +
set O +
of O +
Janus O +
kinases O +
: O +
IL13 O +
is O +
unable O +
to O +
activate O +
JAK1 O +
and O +
JAK3 O +
. O +

Attenuated O +
function O +
of O +
a O +
variant O +
form O +
of O +
the O +
helix O -
- O -
loop O -
- O -
helix O +
protein O +
, O +
Id-3 O +
, O +
generated O +
by O +
an O +
alternative O +
splicing O +
mechanism O +
. O +

The O +
I O -
d O +
family O +
of O +
helix O -
- O -
loop O -
- O -
helix O +
proteins O +
function O +
as O +
negative O +
regulators O +
of O +
DNA O +
binding O +
, O +
basic O +
helix O -
- O -
loop O -
- O -
helix O +
proteins O +
in O +
the O +
regulation O +
of O +
cell O +
growth O +
and O +
differentiation O +
. O +

We O +
report O +
here O +
on O +
the O +
identification O +
of O +
a O +
17 O +
kDa O +
variant O +
of O +
the O +
14 O +
kDa O +
Id-3 O +
protein O +
termed O +
Id-3L O +
( O +
long O +
version O +
) O +
which O +
possesses O +
a O +
unique O +
60 O +
amino O +
acid O +
carboxy O -
- O -
terminus O +
generated O +
by O +
read O +
through O +
of O +
a O +
' O +
coding O +
intron O +
' O +
and O +
alternative O +
splicing O +
. O +

Northern O +
analysis O +
revealed O +
expression O +
of O +
a O +
minor O +
1.1 O +
kb O +
Id-3L O +
transcript O +
together O +
with O +
the O +
predominant O +
0.95 O +
kb O +
Id-3 O +
transcript O +
in O +
the O +
majority O +
of O +
adult O +
human O +
tissues O +
analysed O +
. O +

The O +
variant O +
Id-3L O +
protein O +
is O +
functionally O +
distinguishable O +
from O +
conventional O +
Id-3 O +
since O +
in O +
in O +
vitro O +
DNA O +
mobility O +
shift O +
assays O +
, O +
it O +
was O +
greatly O +
impaired O +
in O +
its O +
ability O +
to O +
abrogate O +
binding O +
of O +
the O +
basic O +
helix O -
- O -
loop O -
- O -
helix O +
protein O +
, O +
E47 O +
, O +
to O +
an O +
E O +
box O +
recognition O +
sequence O +
. O +

Multifactor O +
cis O -
- O -
dominant O +
negative O +
regulation O +
of O +
IL-2 O +
gene O +
expression O +
in O +
anergized O +
T O +
cells O +
. O +

The O +
molecular O +
mechanism O +
underlying O +
IL-2 O +
transcriptional O +
blockade O +
in O +
anergic B-CellLine +
T I-CellLine +
cell I-CellLine +
clones I-CellLine +
is O +
not O +
fully O +
understood O +
. O +

To O +
examine O +
whether O +
an O +
active O +
negative O +
regulatory O +
process O +
occurs O +
, O +
we O +
created O +
a O +
reporter O +
construct O +
containing O +
as O +
an O +
enhancer O +
four O +
copies O +
of O +
the O +
NF O -
- O -
AT O +
site O +
and O +
one O +
copy O +
of O +
the O +
octamer O +
site O +
( O +
4X O +
NF O -
- O -
AT O -
- O -
Oct O +
) O +
. O +

This O +
construct O +
was O +
only O +
slightly O +
reduced O +
( O +
1.3-fold O +
) O +
in O +
its O +
expression O +
when O +
stimulated O +
under O +
anergic O +
conditions O +
, O +
while O +
a O +
whole O +
mouse O +
IL-2 O +
enhancer O +
construct O +
showed O +
a O +
reduction O +
of O +
4.3-fold O +
. O +

Addition O +
of O +
the O +
-176 O +
to O +
-96 O +
sequence O +
to O +
the O +
4X O +
NF O -
- O -
AT O -
- O -
Oct O +
construct O +
did O +
not O +
impart O +
the O +
ability O +
to O +
be O +
affected O +
by O +
anergy O +
, O +
but O +
addition O +
of O +
the O +
-236 O +
to O +
-96 O +
sequence O +
did O +
, O +
demonstrating O +
that O +
anergy O +
is O +
an O +
active O +
inhibitory O +
process O +
and O +
that O +
more O +
than O +
the O +
presence O +
of O +
the O +
-150 O +
AP-1 O +
binding O +
site O +
( O +
-152 O +
to O +
-147 O +
) O +
is O +
required O +
to O +
mediate O +
the O +
effect O +
. O +

Mutational O +
studies O +
of O +
the O +
-236 O +
to O +
-96 O +
sequence O +
indicated O +
that O +
the O +
presence O +
of O +
both O +
the O +
-130 O +
AP-1-like O +
site O +
( O +
-187 O +
to O +
-181 O +
) O +
and O +
the O +
-150 O +
proximal O +
AP-1 O +
site O +
were O +
necessary O +
to O +
observe O +
anergy O +
. O +

Because O +
the O +
-180 O +
site O +
is O +
not O +
required O +
for O +
trans O -
- O -
activation O +
, O +
it O +
was O +
possible O +
to O +
confirm O +
by O +
mutation O +
in O +
the O +
normal O +
mouse O +
IL-2 O +
enhancer O +
that O +
this O +
site O +
is O +
absolutely O +
essential O +
for O +
anergy O +
induction O +
. O +

The O +
simplest O +
model O +
to O +
explain O +
these O +
results O +
is O +
that O +
anergy O +
is O +
mediated O +
by O +
a O +
complex O +
of O +
multiple O +
transcription O +
factors O +
that O +
exert O +
a O +
cis O -
- O -
acting O +
dominant O +
negative O +
regulatory O +
effect O +
on O +
the O +
trans O -
- O -
activation O +
of O +
the O +
IL-2 O +
gene O +
. O +

Regulation O +
of O +
GM O -
- O -
CSF O +
gene O +
transcription O +
by O +
core O -
- O -
binding O +
factor O +
. O +

GM O -
- O -
CSF O +
gene O +
activation O +
in O +
T O +
cells O +
is O +
known O +
to O +
involve O +
the O +
transcription O +
factors O +
nuclear O +
factor O -
- O -
kappa O +
B O +
, O +
AP-1 O +
, O +
NFAT O +
, O +
and O +
Sp1 O +
. O +

Here O +
we O +
demonstrate O +
that O +
the O +
human O +
GM O -
- O -
CSF O +
promoter O +
and O +
enhancer O +
also O +
encompass O +
binding O +
sites O +
for O +
core O -
- O -
binding O +
factor O +
( O +
CBF O +
) O +
. O +

Significantly O +
, O +
the O +
CBF O +
sites O +
are O +
in O +
each O +
case O +
contained O +
within O +
the O +
minimum O +
essential O +
core O +
regions O +
required O +
for O +
inducible O +
activation O +
of O +
transcription O +
. O +

Furthermore O +
, O +
these O +
core O +
regions O +
of O +
the O +
enhancer O +
and O +
promoter O +
each O +
encompass O +
closely O +
linked O +
binding O +
sites O +
for O +
CBF O +
, O +
AP-1 O +
, O +
and O +
NFATp O +
. O +

The O +
GM O -
- O -
CSF O +
promoter O +
CBF O +
site O +
TGTGGTCA O +
is O +
located O +
51 O +
bp O +
upstream O +
of O +
the O +
transcription O +
start O +
site O +
and O +
also O +
overlaps O +
a O +
YY-1 O +
binding O +
site O +
. O +

A O +
2-bp O +
mutation O +
within O +
the O +
CBF O +
site O +
resulted O +
in O +
a O +
2 O -
- O -
3-fold O +
decrease O +
in O +
the O +
activities O +
of O +
both O +
a O +
69-bp O +
proximal O +
promoter O +
fragment O +
and O +
a O +
627-bp O +
full O -
- O -
length O +
promoter O +
fragment O +
. O +

Stepwise O +
deletions O +
into O +
the O +
proximal O +
promoter O +
also O +
revealed O +
that O +
the O +
CBF O +
site O +
, O +
but O +
not O +
the O +
YY-1 O +
site O +
, O +
was O +
required O +
for O +
efficient O +
induction O +
of O +
transcriptional O +
activation O +
. O +

The O +
AML1 O +
and O +
CBF O +
beta O +
genes O +
that O +
encode O +
CBF O +
each O +
have O +
the O +
ability O +
to O +
influence O +
cell O +
growth O +
and O +
differentiation O +
and O +
have O +
been O +
implicated O +
as O +
proto O -
- O -
oncogenes O +
in O +
acute O +
myeloid O +
leukemia O +
. O +

This O +
study O +
adds O +
GM O -
- O -
CSF O +
to O +
a O +
growing O +
list O +
of O +
cytokines O +
and O +
receptors O +
that O +
are O +
regulated O +
by O +
CBF O +
and O +
which O +
control O +
the O +
growth O +
, O +
differentiation O +
, O +
and O +
activation O +
of O +
hemopoietic O +
cells O +
. O +

The O +
GM O -
- O -
CSF O +
locus O +
may O +
represent O +
one O +
of O +
several O +
target O +
genes O +
that O +
are O +
dysregulated O +
in O +
acute O +
myeloid O +
leukemia O +
. O +

Mechanisms O +
that O +
contribute O +
to O +
the O +
development O +
of O +
lymphoid O +
malignancies O +
: O +
roles O +
for O +
genetic O +
alterations O +
and O +
cytokine O +
production O +
. O +

Recent O +
studies O +
have O +
defined O +
genetic O +
alterations O +
commonly O +
associated O +
with O +
transformed B-CellLine +
lymphocytes I-CellLine +
. O +

This O +
review O +
suggests O +
roles O +
for O +
these O +
alterations O +
in O +
the O +
development O +
of O +
lymphoid O +
neoplasms O +
. O +

Damage O +
to O +
the O +
genes O +
encoding O +
proteins O +
that O +
function O +
in O +
intracellular O +
signaling O +
, O +
transcription O +
, O +
or O +
regulation O +
of O +
the O +
cell O +
cycle O +
has O +
been O +
identified O +
and O +
linked O +
at O +
varying O +
degrees O +
to O +
the O +
progression O +
of O +
certain O +
lymphoid O +
malignancies O +
. O +

An O +
understanding O +
of O +
the O +
mechanistic O +
consequences O +
following O +
such O +
genetic O +
alterations O +
is O +
essential O +
to O +
an O +
understanding O +
of O +
the O +
development O +
of O +
these O +
lymphoid O +
neoplasms O +
. O +

In O +
contrast O +
, O +
it O +
is O +
also O +
becoming O +
clear O +
that O +
the O +
dysregulated O +
expression O +
of O +
proteins O +
that O +
are O +
not O +
genetically O +
altered O +
can O +
also O +
contribute O +
to O +
the O +
progression O +
of O +
lymphoid O +
malignancies O +
. O +

One O +
such O +
example O +
is O +
the O +
excessive O +
expression O +
of O +
` O -
` O +
normal O +
'' O +
lymphokines O +
of O +
cytokines O +
which O +
accompanies O +
many O +
lymphoproliferative O +
diseases O +
. O +

The O +
dysregulated O +
expression O +
of O +
cytokines O +
during O +
malignancy O +
can O +
result O +
in O +
the O +
augmentation O +
of O +
growth O +
of O +
transformed B-CellLine +
lymphocytes I-CellLine +
, O +
as O +
well O +
as O +
an O +
alteration O +
of O +
the O +
anti O -
- O -
tumor O +
immune O +
response O +
. O +

The O +
latter O +
mechanism O +
is O +
especially O +
important O +
because O +
evasion O +
of O +
the O +
impending O +
immune O +
response O +
is O +
a O +
prerequisite O +
for O +
the O +
progression O +
of O +
lymphoproliferative O +
diseases O +
. O +

Taken O +
together O +
, O +
this O +
review O +
supports O +
the O +
notion O +
that O +
the O +
development O +
of O +
lymphoid O +
malignancies O +
is O +
multifactorial O +
, O +
involving O +
genetic O +
alterations O +
as O +
well O +
as O +
dysregulated O +
cytokine O +
expression O +
. O +

Tyloxapol O +
inhibits O +
NF O -
- O -
kappa O +
B O +
and O +
cytokine O +
release O +
, O +
scavenges O +
HOCI O +
, O +
and O +
reduces O +
viscosity O +
of O +
cystic O +
fibrosis O +
sputum O +
. O +

Cystic O +
fibrosis O +
( O +
CF O +
) O +
patients O +
develop O +
progressive O +
cytokine O +
-mediated O +
inflammatory O +
lung O +
disease O +
, O +
with O +
abundant O +
production O +
of O +
thick O +
, O +
tenacious O +
, O +
protease O +
-and O +
oxidant O -
- O -
rich O +
purulent O +
airway O +
secretions O +
that O +
are O +
difficult O +
to O +
clear O +
even O +
with O +
physiotherapy O +
. O +

In O +
the O +
search O +
for O +
a O +
potential O +
treatment O +
, O +
we O +
have O +
tested O +
tyloxapol O +
, O +
an O +
alkylaryl O +
polyether O +
alcohol O +
polymer O +
detergent O +
previously O +
used O +
as O +
a O +
mucolytic O +
agent O +
in O +
adult O +
chronic O +
bronchitis O +
. O +

Tyloxapol O +
inhibits O +
activation O +
of O +
the O +
transcription O +
factor O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NK O -
- O -
kappa O +
B O +
) O +
, O +
reduces O +
resting O +
secretion O +
of O +
the O +
cytokine O +
interleukin-8 O +
( O +
IL-8 O +
) O +
in O +
cultured B-CellLine +
human I-CellLine +
monocytes I-CellLine +
, O +
and O +
inhibits O +
lipopolysaccharide O +
( O +
LPS O +
) O +
-stimulated O +
release O +
of O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
, O +
IL-1 O +
beta O +
, O +
IL-6 O +
, O +
IL-8 O +
, O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
, O +
and O +
the O +
eiconsanoids O +
thromboxane O +
A2 O +
and O +
leukotriene O +
B4 O +
( O +
LTB4 O +
) O +
. O +

We O +
have O +
previously O +
shown O +
that O +
tyloxapol O +
is O +
a O +
potent O +
antioxidant O +
for O +
hydroxyl O +
radicals O +
( O +
OH O +
) O +
. O +

Tyloxapol O +
( O +
0.05 O +
to O +
0.1 O +
% O +
wt O -
/ O -
vol O +
) O +
effectively O +
scavenges O +
the O +
oxidant O +
hypochlorous O +
acid O +
( O +
HOCl O +
; O +
1 O +
to O +
7.5 O +
mM O +
) O +
in O +
vitro O +
, O +
and O +
protects O +
from O +
HOCl O -
- O -
mediated O +
lung O +
injury O +
in O +
rats O +
. O +

Tyloxapol O +
also O +
reduces O +
the O +
viscosity O +
of O +
CF O +
sputum O +
( O +
from O +
463 O +
+ O -
/- O +
133 O +
to O +
128 O +
+ O -
/- O +
52 O +
centipoise O +
) O +
. O +

We O +
conclude O +
that O +
tyloxapol O +
is O +
potentially O +
useful O +
as O +
a O +
new O +
antiinflammatory O +
therapy O +
for O +
CF O +
lung O +
disease O +
, O +
and O +
could O +
possibly O +
promote O +
clearance O +
of O +
secretions O +
in O +
the O +
CF O +
airway O +
. O +

Requirements O +
for O +
induction O +
of O +
vitamin O +
D O -
- O -
mediated O +
gene O +
regulation O +
in O +
normal O +
human O +
B O +
lymphocytes O +
. O +

Mature O +
human O +
lymphocytes O +
are O +
unique O +
targets O +
of O +
1 O +
alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
1 O +
alpha O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
) O +
in O +
that O +
vitamin O +
D O +
receptors O +
( O +
VDR O +
) O +
are O +
not O +
constitutively O +
expressed O +
, O +
and O +
specific O +
cellular O +
activation O +
signals O +
are O +
required O +
for O +
both O +
the O +
up O -
- O -
regulation O +
of O +
VDR O +
and O +
establishment O +
of O +
reactivity O +
to O +
the O +
lipophilic O +
ligand O +
. O +

Treatment O +
of O +
B O +
lymphocytes O +
with O +
the O +
cytokine O +
IL-4 O +
( O +
IL-4 O +
) O +
, O +
in O +
the O +
absence O +
of O +
prior O +
activation O +
, O +
induces O +
a O +
weak O +
up O -
- O -
regulation O +
of O +
VDR O +
expression O +
but O +
fails O +
to O +
generate O +
vitamin O +
D O -
- O -
responsive O +
element O +
( O +
VDRE O +
) O +
-reactive O +
nuclear O +
protein O +
complexes O +
or O +
to O +
initiate O +
the O +
genomic O +
transcription O +
of O +
25-hydroxyvitamin O +
D3 O +
24-hydroxylase O +
. O +

Stimulation O +
of O +
B O +
lymphocytes O +
by O +
either O +
ligation O +
of O +
CD40 O +
Ag O +
or O +
cross O -
- O -
linking O +
the O +
Ig O +
receptor O +
is O +
also O +
insufficient O +
to O +
render O +
B O +
lymphocytes O +
responsive O +
to O +
1 O +
alpha O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
. O +

However O +
, O +
this O +
apparent O +
lack O +
of O +
response O +
to O +
the O +
secosterol O +
can O +
be O +
overcome O +
by O +
stimulation O +
of O +
B O +
lymphocytes O +
with O +
a O +
combination O +
of O +
these O +
cellular O +
activation O +
signals O +
, O +
which O +
are O +
sufficient O +
to O +
lead O +
to O +
G1 O +
cell O +
cycle O +
progression O +
. O +

In O +
the O +
presence O +
of O +
1 O +
alpha O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
, O +
cellular O +
activation O +
associated O +
with O +
stimulation O +
of O +
such O +
a O +
progression O +
appears O +
to O +
be O +
sufficient O +
for O +
the O +
up O -
- O -
regulation O +
of O +
VDR O +
message O +
and O +
protein O +
and O +
necessary O +
for O +
the O +
establishment O +
of O +
VDRE O +
binding O +
complexes O +
and O +
the O +
induction O +
of O +
24-hydroxylase O +
message O +
. O +

Furthermore O +
, O +
biologic O +
functions O +
are O +
modulated O +
, O +
in O +
that O +
the O +
hormone O +
inhibits O +
proliferation O +
in O +
a O +
subset O +
of O +
the O +
activated O +
B O +
cells O +
. O +

These O +
observations O +
suggest O +
that O +
reactivity O +
to O +
1 O +
alpha O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
is O +
tightly O +
regulated O +
in O +
B O +
lymphocytes O +
, O +
requiring O +
specific O +
signals O +
for O +
its O +
initiation O +
. O +

Analysis O +
of O +
the O +
ligand O -
- O -
binding O +
domain O +
of O +
human O +
retinoic O +
acid O +
receptor O +
alpha O +
by O +
site O -
- O -
directed O +
mutagenesis O +
. O +

Three O +
subtypes O +
of O +
retinoic O +
acid O +
receptors O +
( O +
RAR O +
) O +
, O +
termed O +
RAR O +
alpha O +
, O +
RAR O +
beta O +
, O +
and O +
RAR O +
gamma O +
, O +
have O +
been O +
described O +
. O +

They O +
are O +
composed O +
of O +
different O +
structural O +
domains O +
, O +
including O +
distinct O +
domains O +
for O +
DNA O +
and O +
ligand O +
binding O +
. O +

RARs O +
specifically O +
bind O +
all O -
- O -
trans O -
- O -
retinoic O +
acid O +
( O +
RA O +
) O +
, O +
9-cis O -
- O -
RA O +
, O +
and O +
retinoid O +
analogs O +
. O +

In O +
this O +
study O +
, O +
we O +
examined O +
the O +
functional O +
role O +
of O +
cysteine O +
and O +
arginine O +
residues O +
in O +
the O +
ligand O -
- O -
binding O +
domain O +
of O +
hRAR O +
alpha O +
( O +
hRAR O +
alpha O -
- O -
LBD O +
, O +
amino O +
acids O +
154 O +
to O +
462 O +
) O +
. O +

All O +
conserved O +
cysteine O +
and O +
arginine O +
residues O +
in O +
this O +
domain O +
were O +
mutated O +
by O +
site O -
- O -
directed O +
mutagenesis O +
, O +
and O +
the O +
mutant O +
proteins O +
were O +
characterized O +
by O +
blocking O +
reactions O +
, O +
ligand O -
- O -
binding O +
experiments O +
, O +
transactivation O +
assays O +
, O +
and O +
protease O +
mapping O +
. O +

Changes O +
of O +
any O +
cysteine O +
residue O +
of O +
the O +
hRAR O +
alpha O -
- O -
LBD O +
had O +
no O +
significant O +
influence O +
on O +
the O +
binding O +
of O +
all O -
- O -
trans O +
RA O +
or O +
9-cis O +
RA O +
. O +

Interestingly O +
, O +
residue O +
C-235 O +
is O +
specifically O +
important O +
in O +
antagonist O +
binding O +
. O +

With O +
respect O +
to O +
arginine O +
residues O +
, O +
only O +
the O +
two O +
single O +
mutations O +
of O +
R-276 O +
and O +
R-394 O +
to O +
alanine O +
showed O +
a O +
dramatic O +
decrease O +
of O +
agonist O +
and O +
antagonist O +
binding O +
whereas O +
the O +
R272A O +
mutation O +
showed O +
only O +
a O +
slight O +
effect O +
. O +

For O +
all O +
other O +
arginine O +
mutations O +
, O +
no O +
differences O +
in O +
affinity O +
were O +
detectable O +
. O +

The O +
two O +
mutations O +
R217A O +
and O +
R294A O +
caused O +
an O +
increased O +
binding O +
efficiency O +
for O +
antagonists O +
but O +
no O +
change O +
in O +
agonist O +
binding O +
. O +

From O +
these O +
results O +
, O +
we O +
can O +
conclude O +
that O +
electrostatic O +
interactions O +
of O +
retinoids O +
with O +
the O +
RAR O +
alpha O -
- O -
LBD O +
play O +
a O +
significant O +
role O +
in O +
ligand O +
binding O +
. O +

In O +
addition O +
, O +
antagonists O +
show O +
distinctly O +
different O +
requirements O +
for O +
efficient O +
binding O +
, O +
which O +
may O +
contribute O +
to O +
their O +
interference O +
in O +
the O +
ligand O -
- O -
inducible O +
transactivation O +
function O +
of O +
RAR O +
alpha O +
. O +

Cloning O +
and O +
characterization O +
of O +
the O +
beta O +
subunit O +
of O +
human O +
proximal O +
sequence O +
element O -
- O -
binding O +
transcription O +
factor O +
and O +
its O +
involvement O +
in O +
transcription O +
of O +
small O +
nuclear O +
RNA O +
genes O +
by O +
RNA O +
polymerases O +
II O +
and O +
III O +
. O +

The O +
proximal O +
sequence O +
element O +
( O +
PSE O +
) O +
-binding O +
transcription O +
factor O +
( O +
PTF O +
) O +
, O +
which O +
binds O +
the O +
PSE O +
of O +
both O +
RNA O +
polymerase O +
II O +
-and O +
RNA O +
polymerase O +
III O -
- O -
transcribed O +
mammalian O +
small O +
nuclear O +
RNA O +
( O +
snRNA O +
) O +
genes O +
, O +
is O +
essential O +
for O +
their O +
transcription O +
. O +

We O +
previously O +
reported O +
the O +
purification O +
of O +
human O +
PTF O +
, O +
a O +
complex O +
of O +
four O +
subunits O +
, O +
and O +
the O +
molecular O +
cloning O +
and O +
characterization O +
of O +
PTF O +
gamma O +
and O +
delta O +
subunits O +
. O +

Here O +
we O +
describe O +
the O +
isolation O +
and O +
expression O +
of O +
a O +
cDNA O +
encoding O +
PTF O +
beta O +
, O +
as O +
well O +
as O +
functional O +
studies O +
using O +
anti O -
- O -
PTF O +
beta O +
antibodies O +
. O +

Native O +
PTF O +
beta O +
, O +
in O +
either O +
protein O +
fractions O +
or O +
a O +
PTF O -
- O -
Oct-1-DNA O +
complex O +
, O +
can O +
be O +
recognized O +
by O +
polyclonal O +
antibodies O +
raised O +
against O +
recombinant O +
PTF O +
beta O +
. O +

Immunodepletion O +
studies O +
show O +
that O +
PTF O +
beta O +
is O +
required O +
for O +
transcription O +
of O +
both O +
classes O +
of O +
snRNA O +
genes O +
in O +
vitro O +
. O +

In O +
addition O +
, O +
immunoprecipitation O +
analyses O +
demonstrate O +
that O +
substantial O +
and O +
similar O +
molar O +
amounts O +
of O +
TATA O -
- O -
binding O +
protein O +
( O +
TBP O +
) O +
and O +
TFIIIB90 O +
can O +
weakly O +
associate O +
with O +
PTF O +
at O +
low O +
salt O +
conditions O +
, O +
but O +
this O +
association O +
is O +
dramatically O +
reduced O +
at O +
high O +
salt O +
concentrations O +
. O +

Along O +
with O +
our O +
previous O +
demonstration O +
of O +
both O +
physical O +
interactions O +
between O +
PTF O +
gamma O -
/ O -
PTF O +
delta O +
and O +
TBP O +
and O +
the O +
involvement O +
of O +
TFIIIB90 O +
in O +
the O +
transcription O +
of O +
class O +
III O +
snRNA O +
genes O +
, O +
these O +
results O +
are O +
consistent O +
with O +
the O +
notion O +
that O +
a O +
TBP O -
- O -
containing O +
complex O +
related O +
to O +
TFIIIB O +
is O +
required O +
for O +
the O +
transcription O +
of O +
class O +
III O +
snRNA O +
genes O +
, O +
and O +
acts O +
through O +
weak O +
interaction O +
with O +
the O +
four O -
- O -
subunit O +
PTF O +
. O +

Cytomegalovirus O +
modulates O +
interleukin-6 O +
gene O +
expression O +
. O +

Complications O +
after O +
lung O +
transplantation O +
include O +
the O +
development O +
of O +
rejection O +
and O +
an O +
increased O +
incidence O +
of O +
infection O +
, O +
particularly O +
with O +
cytomegalovirus O +
( O +
CMV O +
) O +
. O +

Several O +
recent O +
studies O +
have O +
suggested O +
that O +
interleukin O +
( O +
IL O +
) O +
-6 O +
may O +
be O +
used O +
to O +
detect O +
both O +
infection O +
and O +
rejection O +
after O +
lung O +
transplantation O +
. O +

In O +
addition O +
, O +
IL-6 O +
may O +
play O +
a O +
role O +
in O +
the O +
development O +
of O +
bronchiolitis O +
obliterans O +
after O +
transplantation O +
. O +

Because O +
CMV O +
is O +
also O +
associated O +
with O +
the O +
development O +
of O +
bronchiolitis O +
obliterans O +
after O +
transplantation O +
, O +
we O +
determined O +
whether O +
CMV O +
induces O +
IL-6 O +
gene O +
expression O +
. O +

We O +
demonstrated O +
that O +
CMV O +
infection O +
increased O +
both O +
IL-6 O +
protein O +
and O +
mRNA O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
. O +

We O +
also O +
demonstrated O +
that O +
the O +
CMV O +
immediate O +
early O +
1 O +
gene O +
product O +
increased O +
expression O +
of O +
the O +
IL-6 O +
promoter O +
. O +

This O +
effect O +
of O +
the O +
CMV O +
immediate O +
early O +
1 O +
gene O +
product O +
was O +
dependent O +
upon O +
the O +
presence O +
of O +
specific O +
transcription O +
factor O +
binding O +
sites O +
in O +
the O +
IL-6 O +
promoter O +
. O +

These O +
studies O +
demonstrate O +
that O +
CMV O +
may O +
be O +
an O +
important O +
cofactor O +
in O +
the O +
development O +
of O +
rejection O +
and O +
infection O +
after O +
transplantation O +
through O +
its O +
effects O +
on O +
IL-6 O +
. O +

Suppression O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
long O +
terminal O +
repeat O +
by O +
CD8 O -
+ O +
T O +
cells O +
is O +
dependent O +
on O +
the O +
NFAT-1 O +
element O +
. O +

CD8 O -
+ O +
T O +
lymphocytes O +
of O +
HIV-1 O +
infected O +
individuals O +
produce O +
a O +
soluble O +
factor O +
that O +
efficiently O +
suppresses O +
HIV-1 O +
replication O +
at O +
the O +
transcriptional O +
level O +
. O +

We O +
show O +
here O +
that O +
the O +
response O +
of O +
the O +
HIV-1 O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
to O +
mitogenic O +
or O +
Tat O +
-mediated O +
activation O +
is O +
sensitive O +
to O +
the O +
suppressive O +
action O +
of O +
a O +
Herpesvirus B-CellLine +
saimiri I-CellLine +
( I-CellLine +
HVS I-CellLine +
) I-CellLine +
-transformed I-CellLine +
CD8 I-CellLine -
+ I-CellLine +
T I-CellLine +
cell I-CellLine +
clone I-CellLine +
from O +
an O +
HIV O -
- O -
infected O +
individual O +
and O +
supernatants O +
from O +
CD8 O -
+ O +
T O +
cells O +
of O +
HIV-1-infected O +
asymptomatic O +
subjects O +
( O +
CD4 O -
+ O +
> O +
350 O -
/ O -
microliters O +
) O +
. O +

Mutagenesis O +
of O +
NF O +
kappa O +
B O +
or O +
Sp-1 O +
elements O +
within O +
the O +
LTR O +
resulted O +
in O +
no O +
change O +
in O +
the O +
ability O +
of O +
CD8 O -
+ O +
T O +
cell O +
supernatants O +
to O +
inhibit O +
Tat- O +
or O +
mitogen O -
- O -
mediated O +
LTR O +
transcription O +
. O +

However O +
, O +
the O +
response O +
to O +
HIV-1 O +
Tat O +
by O +
a O +
LTR O +
in O +
which O +
the O +
interleukin O +
( O +
IL O +
) O +
-2 O +
homology O +
NFAT-1 O +
region O +
was O +
mutated O +
resulted O +
in O +
almost O +
complete O +
elimination O +
of O +
suppression O +
by O +
CD8 O -
+ O +
T O +
cells O +
. O +

This O +
was O +
not O +
observed O +
when O +
the O +
NFAT-1 O +
mutant O +
LTR O +
was O +
activated O +
by O +
mitogen O +
. O +

We O +
have O +
previously O +
shown O +
that O +
gene O +
expression O +
directed O +
by O +
the O +
HIV-1 O +
NF O +
kappa O +
B O +
elements O +
is O +
inhibited O +
by O +
CD8 O +
+ O +
cell O -
- O -
derived O +
supernatants O +
( O +
Copeland O +
et O +
al. O +
, O +
AIDS O +
Res O +
Hum O +
Retroviruses O +
, O +
1995 O +
; O +
11 O +
: O +
1321 O -
- O -
1326 O +
) O +
. O +

Taken O +
together O +
, O +
these O +
observations O +
suggest O +
that O +
mitogenic O +
activation O +
, O +
mediated O +
primarily O +
through O +
the O +
NF O +
kappa O +
B O +
enhancer O +
, O +
is O +
susceptible O +
to O +
CD8 O +
-mediated O +
inhibition O +
, O +
however O +
, O +
inhibition O +
of O +
Tat O +
-mediated O +
activation O +
may O +
rely O +
upon O +
a O +
different O +
pathway O +
that O +
is O +
NFAT-1 O +
dependent O +
. O +

Interstitial O +
deletion O +
constitutes O +
the O +
major O +
mechanism O +
for O +
loss O +
of O +
heterozygosity O +
on O +
chromosome O +
20q O +
in O +
polycythemia O +
vera O +
. O +

An O +
acquired O +
deletion O +
of O +
the O +
long O +
arm O +
of O +
chromosome O +
20 O +
is O +
a O +
recurrent O +
abnormality O +
in O +
myeloproliferative O +
disorders O +
, O +
particularly O +
polycythemia O +
vera O +
and O +
myelodysplastic O +
syndromes O +
. O +

The O +
association O +
of O +
20q O +
deletions O +
with O +
myeloid O +
` O -
` O +
stem O +
cell O +
'' O +
disorders O +
suggests O +
that O +
the O +
deletions O +
mark O +
the O +
site O +
of O +
one O +
or O +
more O +
genes O +
, O +
loss O +
or O +
inactivation O +
of O +
which O +
plays O +
a O +
role O +
in O +
the O +
regulation O +
of O +
normal O +
hematopoietic O +
progenitors O +
. O +

We O +
have O +
recently O +
performed O +
a O +
detailed O +
molecular O +
analysis O +
of O +
20q O +
deletions O +
in O +
peripheral O +
blood O +
( O +
PB O +
) O +
granulocytes O +
and O +
defined O +
a O +
commonly O +
deleted O +
region O +
of O +
16 O +
to O +
21 O +
centimorgan O +
( O +
cM O +
) O +
. O +

To O +
further O +
reduce O +
the O +
size O +
of O +
the O +
common O +
deleted O +
region O +
we O +
have O +
searched O +
for O +
small O +
deletions O +
or O +
mitotic O +
recombination O +
events O +
, O +
neither O +
of O +
which O +
would O +
be O +
detected O +
by O +
conventional O +
cytogenetics O +
. O +

We O +
have O +
studied O +
48 O +
patients O +
with O +
polycythemia O +
vera O +
and O +
four O +
patients O +
with O +
idiopathic O +
myelofibrosis O +
. O +

In O +
each O +
case O +
, O +
cytogenetic O +
analysis O +
had O +
either O +
failed O +
or O +
had O +
shown O +
no O +
abnormalities O +
of O +
chromosome O +
20 O +
. O +

Seventeen O +
microsatellite O +
markers O +
that O +
span O +
the O +
common O +
deleted O +
region O +
were O +
used O +
to O +
search O +
for O +
loss O +
of O +
heterozygosity O +
in O +
granulocyte O +
DNA O +
. O +

No O +
instance O +
of O +
microsatellite O +
instability O +
was O +
observed O +
in O +
a O +
total O +
of O +
880 O +
comparisons O +
of O +
granulocyte O +
and O +
T O -
- O -
cell O +
DNA O +
. O +

Granulocyte O +
DNA O +
from O +
four O +
patients O +
exhibited O +
allele O +
loss O +
on O +
20q O +
. O +

In O +
each O +
case O +
the O +
allele O +
loss O +
was O +
caused O +
by O +
an O +
interstitial O +
deletion O +
because O +
heterozygosity O +
at O +
distal O +
markers O +
was O +
retained O +
and O +
because O +
quantitative O +
Southern O +
blotting O +
demonstrated O +
hemizygosity O +
. O +

Loss O +
of O +
heterozygosity O +
in O +
PB O +
granulocytes O +
would O +
be O +
masked O +
by O +
the O +
presence O +
of O +
significant O +
numbers O +
of O +
normal O +
granulocytes O +
not O +
derived O +
from O +
the O +
malignant B-CellLine +
clone I-CellLine +
. O +

Therefore O +
, O +
the O +
human O +
androgen O +
receptor O +
assay O +
( O +
HUMARA O +
) O +
was O +
used O +
to O +
determine O +
granulocyte O +
clonality O +
. O +

In O +
21 O +
of O +
27 O +
informative O +
female O +
patients O +
the O +
majority O +
of O +
the O +
granulocytes O +
were O +
clonally O +
derived O +
. O +

In O +
5 O +
patients O +
the O +
granulocytes O +
appeared O +
polyclonal O +
and O +
in O +
1 O +
patient O +
unilateral O +
X O +
inactivation O +
was O +
observed O +
in O +
both O +
granulocytes O +
and O +
T O +
cells O +
. O +

These O +
results O +
show O +
that O +
, O +
in O +
the O +
vast O +
majority O +
of O +
patients O +
presented O +
here O +
, O +
the O +
failure O +
to O +
detect O +
loss O +
of O +
heterozygosity O +
can O +
not O +
be O +
attributed O +
to O +
the O +
presence O +
of O +
normal B-CellLine +
polyclonal I-CellLine +
granulocytes I-CellLine +
. O +

Our O +
results O +
therefore O +
show O +
that O +
allele O +
loss O +
on O +
chromosome O +
20q O +
in O +
polycythemia O +
vera O +
does O +
not O +
commonly O +
involve O +
mitotic O +
recombination O +
or O +
chromosome O +
loss O +
and O +
that O +
microsatellite O +
instability O +
is O +
a O +
rare O +
event O +
in O +
this O +
disorder O +
. O +

Selenium O -
- O -
mediated O +
inhibition O +
of O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
and O +
HIV-1 O +
LTR O +
promoter O +
activity O +
. O +

The O +
eukaryotic O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
is O +
involved O +
in O +
the O +
inducible O +
expression O +
of O +
various O +
inflammatory O +
genes O +
as O +
well O +
as O +
in O +
HIV-1 O +
replication O +
. O +

Activation O +
of O +
NF O -
- O -
kappa O +
B O +
is O +
induced O +
by O +
prooxidants O +
and O +
several O +
stimuli O +
eliciting O +
oxidative O +
stress O +
, O +
such O +
as O +
cytokines O +
, O +
lipopolysaccharide O +
, O +
UV O +
irradiation O +
and O +
other O +
mediators O +
. O +

Various O +
antioxidants O +
inhibit O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
response O +
to O +
these O +
stimuli O +
. O +

In O +
this O +
study O +
, O +
we O +
have O +
investigated O +
the O +
effects O +
of O +
selenium O +
, O +
an O +
integral O +
component O +
of O +
glutathione O +
peroxidase O +
( O +
GPX O +
) O +
, O +
on O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

In O +
selenium B-CellLine -
- I-CellLine -
deprived I-CellLine +
Jurkat I-CellLine +
and O +
ESb B-CellLine -
- I-CellLine -
L I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
, O +
supplementation O +
of O +
selenium O +
led O +
to O +
a O +
substantial O +
increase O +
of O +
GPX O +
activity O +
. O +

Analysis O +
of O +
DNA O +
binding O +
revealed O +
that O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
response O +
to O +
TNF O +
was O +
significantly O +
inhibited O +
under O +
these O +
conditions O +
. O +

Likewise O +
, O +
reporter O +
gene O +
assays O +
using O +
luciferase O +
constructs O +
driven O +
by O +
the O +
HIV-1 O +
long O +
terminal O +
repeat O +
showed O +
a O +
dose O -
- O -
dependent O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
controlled O +
gene O +
expression O +
by O +
selenium O +
. O +

The O +
effects O +
of O +
selenium O +
were O +
specific O +
for O +
NF O -
- O -
kappa O +
B O +
, O +
since O +
the O +
activity O +
of O +
the O +
transcription O +
factor O +
AP-1 O +
was O +
not O +
suppressed O +
. O +

These O +
data O +
suggest O +
that O +
selenium O +
supplementation O +
may O +
be O +
used O +
to O +
modulate O +
the O +
expression O +
of O +
NF O -
- O -
kappa O +
B O +
target O +
genes O +
and O +
HIV-1 O +
. O +

Transcriptional O +
and O +
posttranscriptional O +
regulation O +
of O +
erythroid O +
gene O +
expression O +
in O +
anthracycline O -
- O -
induced O +
differentiation O +
of O +
human O +
erythroleukemic O +
cells O +
. O +

Aclacinomycin O +
( O +
ACLA O +
) O +
and O +
doxorubicin O +
( O +
DOX O +
) O +
were O +
used O +
at O +
subtoxic O +
concentrations O +
to O +
induce O +
erythroid O +
differentiation O +
in O +
the O +
human B-CellLine +
leukemic I-CellLine +
cell I-CellLine +
line I-CellLine +
K562 I-CellLine +
. O +

Cell O +
hemoglobinization O +
was O +
accompanied O +
by O +
the O +
increased O +
expression O +
of O +
genes O +
encoding O +
gamma O -
- O -
globin O +
and O +
porphobilinogen O +
deaminase O +
( O +
PBGD O +
) O +
, O +
an O +
enzyme O +
of O +
heme O +
synthesis O +
. O +

By O +
using O +
run O -
- O -
on O +
assays O +
, O +
ACLA O +
was O +
shown O +
to O +
induce O +
an O +
enhancement O +
of O +
the O +
transcription O +
of O +
erythroid O +
genes O +
, O +
including O +
gamma O -
- O -
globin O +
, O +
PBGD O +
, O +
erythropoietin O +
receptor O +
, O +
and O +
GATA-1 O +
transcription O +
factor O +
. O +

In O +
contrast O +
, O +
in O +
DOX B-CellLine -
- I-CellLine -
treated I-CellLine +
cells I-CellLine +
, O +
the O +
transcription O +
rate O +
of O +
these O +
genes O +
was O +
unchanged O +
in O +
comparison O +
with O +
control O +
cells O +
. O +

In O +
addition O +
, O +
inhibition O +
of O +
mRNA O +
synthesis O +
with O +
actinomycin O +
D O +
indicated O +
that O +
DOX O +
induced O +
an O +
increased O +
stability O +
of O +
PBGD O +
and O +
GATA-1 O +
mRNAs O +
, O +
whereas O +
ACLA O +
did O +
not O +
affect O +
the O +
half O -
- O -
lives O +
of O +
these O +
mRNAs O +
. O +

Because O +
the O +
increase O +
in O +
erythroid O +
mRNA O +
steady O -
- O -
state O +
level O +
in O +
anthracycline O -
- O -
treated O +
cells O +
was O +
inhibited O +
by O +
cycloheximide O +
, O +
this O +
suggests O +
that O +
transcriptional O +
activation O +
in O +
ACLA B-CellLine -
- I-CellLine -
treated I-CellLine +
cells I-CellLine +
and O +
mRNA O +
stabilization O +
in O +
DOX O -
- O -
treated O +
cells O +
were O +
dependent O +
on O +
de O +
novo O +
protein O +
synthesis O +
. O +

Finally O +
, O +
GATA-1 O +
protein O +
level O +
was O +
shown O +
to O +
be O +
increased O +
in O +
ACLA B-CellLine -
- I-CellLine -
treated I-CellLine +
but I-CellLine +
not I-CellLine +
in I-CellLine +
DOX I-CellLine -
- I-CellLine -
treated I-CellLine +
cells I-CellLine +
. O +

These O +
two O +
anthracyclines O +
, O +
although O +
closely O +
related O +
in O +
their O +
structures O +
, O +
appeared O +
to O +
act O +
as O +
differentiation O +
inducers O +
by O +
distinct O +
mechanisms O +
. O +

Indeed O +
, O +
erythroid O +
gene O +
expression O +
was O +
demonstrated O +
to O +
be O +
regulated O +
transcriptionally O +
by O +
ACLA O +
and O +
mainly O +
posttranscriptionally O +
by O +
DOX O +
. O +

Uneven O +
X O +
inactivation O +
in O +
a O +
female O +
monozygotic O +
twin O +
pair O +
with O +
Fabry O +
disease O +
and O +
discordant O +
expression O +
of O +
a O +
novel O +
mutation O +
in O +
the O +
alpha O -
- O -
galactosidase O +
A O +
gene O +
. O +

We O +
describe O +
two O +
female O +
monozygotic O +
( O +
MZ O +
) O +
twins O +
heterozygous O +
for O +
Fabry O +
disease O +
, O +
an O +
X O +
linked O +
disorder O +
resulting O +
from O +
the O +
deficient O +
activity O +
of O +
alpha O -
- O -
galactosidase O +
A O +
. O +

While O +
one O +
of O +
the O +
twins O +
was O +
clinically O +
affected O +
, O +
the O +
other O +
was O +
asymptomatic O +
. O +

Enzymatic O +
assay O +
of O +
alpha O -
- O -
galactosidase O +
in O +
blood O +
leucocytes O +
, O +
skin O +
fibroblasts O +
, O +
Epstein B-CellLine -
- I-CellLine -
Barr I-CellLine +
virus I-CellLine +
transformed I-CellLine +
lymphoid I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
and O +
hair O +
follicles O +
of O +
the O +
twins O +
and O +
their O +
parents O +
confirmed O +
the O +
heterozygous O +
status O +
of O +
the O +
twins O +
and O +
indicated O +
that O +
Fabry O +
disease O +
had O +
occurred O +
as O +
a O +
result O +
of O +
a O +
de O +
novo O +
mutation O +
. O +

The O +
son O +
of O +
the O +
unaffected O +
twin O +
sister O +
was O +
shown O +
to O +
be O +
hemizygous O +
. O +

Molecular O +
analysis O +
of O +
the O +
alpha O -
- O -
galactosidase O +
A O +
gene O +
permitted O +
the O +
identification O +
of O +
an O +
as O +
yet O +
undescribed O +
point O +
mutation O +
at O +
position O +
10182 O +
of O +
exon O +
5 O +
which O +
causes O +
an O +
Asp O +
to O +
Asn O +
substitution O +
at O +
codon O +
231 O +
. O +

Single O +
strand O +
conformation O +
polymorphism O +
( O +
SSCP O +
) O +
analysis O +
again O +
showed O +
the O +
heterozygous O +
status O +
of O +
the O +
twins O +
and O +
a O +
normal O +
pattern O +
in O +
their O +
parents O +
. O +

The O +
basis O +
for O +
the O +
discordant O +
expression O +
of O +
this O +
d O +
novo O +
mutation O +
in O +
the O +
twins O +
was O +
investigated O +
by O +
studying O +
their O +
X O +
inactivation O +
status O +
. O +

Analysis O +
of O +
the O +
inactive O +
X O +
specific O +
methylation O +
at O +
the O +
androgen O +
receptor O +
gene O +
showed O +
unbalanced O +
inactivation O +
in O +
the O +
twins O +
' O +
fibroblasts O +
and O +
in O +
opposite O +
directions O +
. O +

While O +
the O +
maternally O +
derived O +
X O +
chromosome O +
was O +
preferentially O +
active O +
in O +
the O +
asymptomatic O +
twin O +
, O +
the O +
paternal O +
X O +
chromosome O +
was O +
active O +
in O +
the O +
other O +
, O +
affected O +
twin O +
and O +
was O +
found O +
in O +
her O +
hemizygotic O +
nephew O +
. O +

These O +
data O +
suggest O +
that O +
the O +
paternal O +
X O +
chromosome O +
carries O +
the O +
de O +
novo O +
alpha O -
- O -
galactosidase O +
A O +
mutation O +
and O +
that O +
uneven O +
X O +
inactivation O +
is O +
the O +
underlying O +
mechanism O +
for O +
disease O +
expression O +
in O +
this O +
novel O +
female O +
MZ O +
twin O +
pair O +
. O +

This O +
is O +
the O +
first O +
documented O +
case O +
of O +
female O +
twins O +
discordant O +
for O +
Fabry O +
disease O +
. O +

Signaling O +
by O +
IL-2 O +
and O +
related O +
cytokines O +
: O +
JAKs O +
, O +
STATs O +
, O +
and O +
relationship O +
to O +
immunodeficiency O +
. O +

Cytokines O +
that O +
bind O +
to O +
the O +
interleukin-2 O +
( O +
IL-2 O +
) O +
receptor O +
common O +
gamma O +
chain O +
( O +
gamma O +
c O +
) O +
, O +
including O +
IL-2 O +
, O +
IL-4 O +
, O +
IL-7 O +
, O +
IL-9 O +
, O +
and O +
IL-15 O +
, O +
are O +
important O +
for O +
the O +
growth O +
and O +
differentiation O +
of O +
T O +
and O +
B O +
lymphocytes O +
, O +
natural O +
killer O +
cells O +
, O +
macrophages O +
, O +
and O +
monoctyes O +
. O +

These O +
cytokines O +
have O +
overlapping O +
biological O +
effects O +
that O +
in O +
part O +
result O +
from O +
the O +
use O +
of O +
the O +
shared O +
receptor O +
subunit O +
gamma O +
c O +
. O +

Recently O +
it O +
has O +
become O +
clear O +
that O +
these O +
cytokines O +
activate O +
a O +
number O +
of O +
important O +
intracellular O +
signaling O +
molecules O +
, O +
including O +
the O +
Janus O +
kinases O +
JAK1 O +
and O +
JAK3 O +
and O +
members O +
of O +
the O +
transcription O +
factor O +
family O +
of O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
STATs O +
) O +
. O +

The O +
discovery O +
of O +
these O +
signaling O +
pathways O +
has O +
led O +
to O +
important O +
new O +
insights O +
into O +
their O +
role O +
in O +
lymphocyte O +
maturation O +
, O +
as O +
it O +
has O +
emerged O +
that O +
mutations O +
in O +
the O +
genes O +
encoding O +
both O +
gamma O +
c O +
and O +
JAK3 O +
result O +
in O +
similar O +
forms O +
of O +
severe O +
combined O +
immunodeficiency O +
( O +
SCID O +
) O +
. O +

In O +
this O +
review O +
we O +
examine O +
the O +
structure O +
and O +
function O +
of O +
cytokine O +
receptors O +
and O +
the O +
signaling O +
pathways O +
involved O +
in O +
their O +
regulation O +
of O +
gene O +
expression O +
. O +

Furthermore O +
, O +
we O +
discuss O +
recent O +
advances O +
that O +
have O +
led O +
to O +
a O +
better O +
understanding O +
of O +
how O +
cytokines O +
elicit O +
intracellular O +
responses O +
, O +
as O +
well O +
as O +
their O +
role O +
in O +
normal O +
lymphoid O +
development O +
. O +

Eosinophil O +
priming O +
by O +
cytokines O +
: O +
from O +
cellular O +
signal O +
to O +
in O +
vivo O +
modulation O +
. O +

Eosinophils O +
play O +
an O +
important O +
role O +
in O +
the O +
effector O +
phase O +
of O +
allergic O +
inflammation O +
. O +

This O +
review O +
will O +
focus O +
on O +
the O +
conversion O +
of O +
the O +
unprimed O +
eosinophil O +
phenotype O +
in O +
the O +
peripheral O +
blood O +
of O +
normal O +
individuals O +
to O +
the O +
primed O +
phenotype O +
found O +
in O +
the O +
peripheral O +
blood O +
and O +
tissues O +
of O +
allergic O +
patients O +
, O +
a O +
phenomenon O +
called O +
priming O +
. O +

Recent O +
data O +
on O +
the O +
signals O +
initiated O +
after O +
cytokine O +
receptor O +
activation O +
on O +
eosinophils O +
will O +
be O +
reviewed O +
. O +

Molecular O +
mechanisms O +
of O +
steroid O +
action O +
: O +
a O +
novel O +
type O +
of O +
cross O -
- O -
talk O +
between O +
glucocorticoids O +
and O +
NF O -
- O -
kappa O +
B O +
transcription O +
factors O +
. O +

Despite O +
the O +
widespread O +
use O +
of O +
glucocorticoids O +
in O +
the O +
treatment O +
of O +
diseases O +
characterized O +
by O +
inflammation O +
, O +
the O +
molecular O +
mechanism O +
( O +
s O +
) O +
by O +
which O +
these O +
hormones O +
exert O +
this O +
beneficial O +
effect O +
in O +
patients O +
with O +
asthma O +
remains O +
to O +
be O +
elucidated O +
. O +

Therefore O +
, O +
we O +
have O +
studied O +
the O +
transcriptional O +
regulation O +
of O +
intercellular O +
adhesion O +
molecule-1 O +
( O +
ICAM-1 O +
) O +
as O +
adhesion O +
molecules O +
are O +
likely O +
to O +
play O +
a O +
causal O +
role O +
in O +
inflammation O +
in O +
promoting O +
cell O -
- O -
cell O +
and O +
cell O -
- O -
matrix O +
interactions O +
. O +

We O +
observed O +
that O +
in O +
a O +
monocytic B-CellLine +
( I-CellLine +
U937 I-CellLine +
) I-CellLine +
and O +
a O +
bronchial B-CellLine +
epithelial I-CellLine +
( I-CellLine +
H292 I-CellLine +
) I-CellLine +
cell I-CellLine -
- I-CellLine -
line I-CellLine +
dexamethasone O +
strongly O +
suppressed O +
basal O +
and O +
induced O +
ICAM-1 O +
expression O +
. O +

Subsequent O +
analysis O +
of O +
the O +
human O +
ICAM-1 O +
promoter O +
has O +
revealed O +
that O +
both O +
12-O O -
- O -
tetradecanoylphorbol O +
13-acetate O +
( O +
TPA O +
) O +
and O +
tumour O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
upregulate O +
ICAM-1 O +
expression O +
through O +
the O +
presence O +
of O +
a O +
nuclear O +
factor O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
target O +
sequence O +
( O +
TGGAAATTCC O +
) O +
. O +

No O +
glucocorticoid O +
recognition O +
sequences O +
are O +
present O +
in O +
this O +
promoter O +
region O +
and O +
dexamethasone O +
is O +
still O +
able O +
to O +
repress O +
transcription O +
when O +
the O +
multimerized O +
NF O -
- O -
kappa O +
B O +
sequence O +
is O +
transactivated O +
by O +
TNF O -
- O -
alpha O +
upon O +
transfection O +
in O +
293 B-CellLine +
cells I-CellLine +
. O +

We O +
propose O +
that O +
direct O +
interaction O +
between O +
the O +
glucocorticoid O +
receptor O +
and O +
nuclear O +
factor O -
- O -
kappa O +
B O +
factors O +
is O +
at O +
least O +
a O +
partial O +
explanation O +
for O +
the O +
effects O +
of O +
this O +
hormone O +
in O +
inflammatory O +
diseases O +
. O +

The O +
suppression O +
of O +
T O +
cell O +
function O +
and O +
NF O +
( O +
kappa O +
) O +
B O +
expression O +
by O +
serine O +
protease O +
inhibitors O +
is O +
blocked O +
by O +
N O -
- O -
acetylcysteine O +
. O +

Direct O +
evidence O +
that O +
N O -
- O -
acetylcysteine O +
( O +
NAC O +
) O +
enhances O +
the O +
immune O +
response O +
of O +
peripheral O +
blood O +
T O +
cells O +
at O +
the O +
level O +
of O +
NF O +
( O +
kappa O +
) O +
B O +
is O +
presented O +
. O +

In O +
addition O +
, O +
NAC O +
blocks O +
the O +
suppression O +
of O +
T O +
cell O +
mitogenesis O +
and O +
cytokine O +
production O +
by O +
protease O +
inhibitors O +
such O +
as O +
N O -
- O -
tosylphenylalanine O +
chloromethyl O +
ketone O +
( O +
TPCK O +
) O +
. O +

The O +
proliferative O +
responses O +
of O +
purified O +
CD4 O -
+ O +
or O +
CD8 O -
+ O +
T O +
cells O +
are O +
suppressed O +
more O +
strongly O +
by O +
TPCK O +
when O +
anti O -
- O -
CD28 O +
rather O +
than O +
the O +
phorbol O +
ester O +
PMA O +
is O +
used O +
as O +
the O +
mitogenic O +
coactivator O +
. O +

Cytokine O +
( O +
IL-2 O +
, O +
IL-6 O +
, O +
INF O -
- O -
gamma O +
) O +
production O +
is O +
inhibited O +
95 O -
- O -
100 O +
% O +
by O +
concentrations O +
of O +
TPCK O +
that O +
totally O +
suppress O +
the O +
mitogenesis O +
of O +
CD4 O -
+ O +
or O +
CD8 O -
+ O +
cells O +
. O +

Using O +
electrophoretic O +
mobility O +
shift O +
assays O +
, O +
we O +
find O +
that O +
TPCK O +
virtually O +
abolishes O +
( O +
to O +
less O +
than O +
1 O +
% O +
) O +
the O +
levels O +
of O +
NF O +
( O +
kappa O +
) O +
B O +
( O +
but O +
not O +
Oct-1 O +
) O +
found O +
in O +
nuclear O +
and O +
whole O +
cell O +
extracts O +
of O +
activated O +
T O +
cells O +
. O +

Strikingly O +
, O +
the O +
immunosuppressive O +
effects O +
of O +
TPCK O +
are O +
blocked O +
when O +
T O +
cells O +
are O +
pretreated O +
for O +
15 O +
min O +
with O +
5 O +
mM O +
NAC O +
. O +

NAC O +
not O +
only O +
blocks O +
the O +
effect O +
of O +
TPCK O +
but O +
enhances O +
mitogenesis O +
and O +
cytokine O +
production O +
( O +
> O +
2.5-fold O +
in O +
some O +
cases O +
) O +
upon O +
activation O +
of O +
unsuppressed O +
T O +
cells O +
. O +

Our O +
data O +
support O +
the O +
notion O +
that O +
NF O +
( O +
kappa O +
) O +
B O +
and O +
I O +
( O +
kappa O +
) O +
B O +
proteases O +
play O +
obligate O +
roles O +
in O +
T O +
cell O +
activation O +
and O +
mitogenesis O +
, O +
roles O +
that O +
are O +
enhanced O +
significantly O +
by O +
NAC O +
. O +

IL-12 O +
-induced O +
activation O +
of O +
NK O +
and O +
T O +
cells O +
occurs O +
in O +
the O +
absence O +
of O +
immediate O -
- O -
early O +
activation O +
gene O +
expression O +
. O +

The O +
responses O +
of O +
lymphocytes O +
to O +
IL-2 O +
and O +
IL-12 O +
, O +
involving O +
proliferation O +
, O +
differentiation O +
, O +
and O +
cytokine O +
production O +
, O +
are O +
only O +
partially O +
overlapping O +
, O +
and O +
may O +
depend O +
on O +
induced O +
differential O +
expression O +
of O +
specific O +
sets O +
of O +
genes O +
. O +

Using O +
reverse O -
- O -
transcription O +
PCR O +
differential O +
display O +
, O +
we O +
isolated O +
an O +
mRNA O +
species O +
expressed O +
in O +
IL-2 O +
-but O +
not O +
IL-12-stimulated O +
NK O +
cells O +
. O +

This O +
was O +
identified O +
as O +
the O +
mRNA O +
encoding O +
the O +
transcription O +
factor O +
egr-1 O +
, O +
which O +
is O +
expressed O +
with O +
fast O +
kinetics O +
in O +
T O +
and O +
NK O +
cells O +
upon O +
IL-2 O +
, O +
but O +
not O +
IL-12 O +
, O +
stimulation O +
. O +

Analysis O +
of O +
the O +
accumulation O +
of O +
mRNA O -
- O -
encoding O +
members O +
of O +
the O +
AP-1 O +
transcription O +
factor O +
family O +
demonstrated O +
that O +
c O -
- O -
fos O +
and O +
junB O +
are O +
also O +
expressed O +
upon O +
stimulation O +
of O +
NK O +
and O +
T O +
cells O +
with O +
IL-2 O +
, O +
but O +
not O +
IL-12 O +
, O +
whereas O +
expression O +
of O +
c O -
- O -
jun O +
and O +
junD O +
is O +
not O +
modified O +
by O +
either O +
cytokine O +
. O +

Accordingly O +
, O +
increased O +
AP-1 O +
DNA O -
- O -
binding O +
activity O +
and O +
AP-1 O +
-dependent O +
transcriptional O +
activity O +
were O +
detected O +
exclusively O +
in O +
IL-2-stimulated B-CellLine +
cells I-CellLine +
. O +

Analysis O +
of O +
the O +
expression O +
of O +
genes O +
reported O +
to O +
regulate O +
cytokine O +
-induced O +
proliferation O +
demonstrated O +
that O +
both O +
IL-2 O +
and O +
IL-12 O +
induce O +
c O -
- O -
myc O +
mRNA O +
accumulation O +
in O +
NK O +
and O +
T O +
cells O +
, O +
whereas O +
only O +
IL-2 O +
induces O +
bcl-2 O +
expression O +
. O +

Our O +
data O +
provide O +
the O +
first O +
demonstration O +
that O +
IL-12 O +
-mediated O +
activation O +
of O +
T O +
and O +
NK O +
cells O +
does O +
not O +
involve O +
expression O +
of O +
members O +
of O +
the O +
immediate O -
- O -
early O +
activation O +
genes O +
family O +
( O +
egr-1 O +
, O +
c O -
- O -
fos O +
, O +
and O +
junB O +
) O +
, O +
AP-1 O +
transcriptional O +
activity O +
, O +
or O +
bcl-2 O +
expression O +
. O +

This O +
indicates O +
that O +
functional O +
differences O +
observed O +
in O +
IL-2- B-CellLine +
and I-CellLine +
IL-12-stimulated I-CellLine +
cells I-CellLine +
may O +
depend O +
, O +
at O +
least O +
in O +
part O +
, O +
on O +
differential O +
gene O +
regulation O +
. O +

Induction O +
of O +
activator O +
protein O +
( O +
AP O +
) O +
-1 O +
and O +
nuclear O +
factor O -
- O -
kappaB O +
by O +
CD28 O +
stimulation O +
involves O +
both O +
phosphatidylinositol O +
3-kinase O +
and O +
acidic O +
sphingomyelinase O +
signals O +
. O +

A O +
major O +
obstacle O +
in O +
understanding O +
the O +
signaling O +
events O +
that O +
follow O +
CD28 O +
receptor O +
ligation O +
arises O +
from O +
the O +
fact O +
that O +
CD28 O +
acts O +
as O +
a O +
costimulus O +
to O +
TCR O +
engagement O +
, O +
making O +
it O +
difficult O +
to O +
assess O +
the O +
relative O +
contribution O +
of O +
CD28 O +
signals O +
as O +
distinct O +
from O +
those O +
of O +
the O +
TCR O +
. O +

To O +
overcome O +
this O +
problem O +
, O +
we O +
have O +
exploited O +
the O +
observation O +
that O +
activated O +
human O +
T O +
cell O +
blasts O +
can O +
be O +
stimulated O +
via O +
the O +
CD28 O +
surface O +
molecule O +
in O +
the O +
absence O +
of O +
antigenic O +
challenge O +
; O +
thus O +
, O +
we O +
have O +
been O +
able O +
to O +
observe O +
the O +
response O +
of O +
normal O +
T O +
cells O +
to O +
CD28 O +
activation O +
in O +
isolation O +
. O +

Using O +
this O +
system O +
, O +
we O +
observed O +
that O +
CD28 O +
stimulation O +
by O +
B7-transfected B-CellLine +
CHO I-CellLine +
cells I-CellLine +
induced O +
a O +
proliferative O +
response O +
in O +
T O +
cells O +
that O +
was O +
not O +
accompanied O +
by O +
measurable O +
IL-2 O +
production O +
. O +

However O +
, O +
subsequent O +
analysis O +
of O +
transcription O +
factor O +
generation O +
revealed O +
that O +
B7 O +
stimulation O +
induced O +
both O +
activator O +
protein-1 O +
( O +
AP-1 O +
) O +
and O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
complexes O +
, O +
but O +
not O +
NF O -
- O -
AT O +
. O +

In O +
contrast O +
, O +
engagement O +
of O +
the O +
TCR O +
by O +
class O +
II O +
MHC O -
/ O -
superantigen O +
, O +
either O +
with O +
or O +
without O +
CD28 O +
ligation O +
, O +
resulted O +
in O +
the O +
induction O +
of O +
NF O -
- O -
AT O +
, O +
AP-1 O +
, O +
and O +
NF O -
- O -
kappaB O +
as O +
well O +
as O +
IL-2 O +
production O +
. O +

Using O +
selective O +
inhibitors O +
, O +
we O +
investigated O +
the O +
signaling O +
pathways O +
involved O +
in O +
the O +
CD28 O +
-mediated O +
induction O +
of O +
AP-1 O +
and O +
NF O -
- O -
kappaB O +
. O +

This O +
revealed O +
that O +
NF O -
- O -
kappaB O +
generation O +
was O +
sensitive O +
to O +
chloroquine O +
, O +
an O +
inhibitor O +
of O +
acidic O +
sphingomyelinase O +
, O +
but O +
not O +
to O +
the O +
phosphatidylinositol O +
3-kinase O +
inhibitor O +
, O +
wortmannin O +
. O +

In O +
contrast O +
, O +
AP-1 O +
generation O +
was O +
inhibited O +
by O +
wortmannin O +
and O +
was O +
also O +
variably O +
sensitive O +
to O +
chloroquine O +
. O +

These O +
data O +
suggest O +
that O +
in O +
activated O +
normal O +
T O +
cells O +
, O +
CD28 O +
-derived O +
signals O +
can O +
stimulate O +
proliferation O +
at O +
least O +
in O +
part O +
via O +
NF O -
- O -
kappaB O +
and O +
AP-1 O +
generation O +
, O +
and O +
that O +
this O +
response O +
uses O +
both O +
acidic O +
sphingomyelinase O +
and O +
phosphatidylinositol O +
3-kinase O +
-linked O +
pathways O +
. O +

A O +
critical O +
role O +
of O +
Sp1- O +
and O +
Ets O -
- O -
related O +
transcription O +
factors O +
in O +
maintaining O +
CTL O -
- O -
specific O +
expression O +
of O +
the O +
mouse O +
perforin O +
gene O +
. O +

This O +
study O +
was O +
designed O +
to O +
determine O +
the O +
potential O +
cis O -
- O -
elements O +
involved O +
in O +
transcriptional O +
regulation O +
of O +
the O +
mouse O +
perforin O +
gene O +
. O +

DNase O +
I O +
hypersensitive O +
site O +
( O +
DHS O +
) O +
mapping O +
revealed O +
that O +
the O +
perforin O +
locus O +
contained O +
six O +
DHS O +
within O +
7.0 O +
kb O +
of O +
the O +
5 O +
' O +
upstream O +
sequence O +
( O +
-7.0 O +
kb O +
) O +
and O +
two O +
DHS O +
in O +
intron O +
2 O +
. O +

The O +
six O +
5 O +
' O +
upstream O +
and O +
one O +
intronic O +
DHS O +
were O +
detected O +
in O +
only O +
perforin O -
- O -
expressing O +
lymphocytes O +
. O +

Chloramphenicol O +
acetyltransferase O +
( O +
CAT O +
) O +
activities O +
directed O +
by O +
5 O +
' O +
upstream O +
promoter O +
were O +
detected O +
preferentially O +
in O +
perforin B-CellLine -
- I-CellLine -
expressing I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

A O +
construct O +
termed O +
PFP5a O +
containing O +
-795 O +
bp O +
exhibited O +
the O +
highest O +
CAT O +
activity O +
, O +
and O +
PFP9a20 O +
containing O +
only O +
-73 O +
bp O +
also O +
produced O +
significantly O +
high O +
CAT O +
activity O +
in O +
CTLL B-CellLine -
- I-CellLine -
R8 I-CellLine +
cells I-CellLine +
. O +

The O +
proximal O +
region O +
in O +
PFP9a20 O +
contained O +
two O +
potential O +
Sp1 O +
binding O +
sites O +
( O +
GC O +
box O +
and O +
GT O +
box O +
) O +
and O +
one O +
Ets O +
binding O +
site O +
( O +
EBS O +
) O +
. O +

Electrophoretic O +
mobility O +
shift O +
assay O +
showed O +
that O +
each O +
of O +
the O +
cis O -
- O -
elements O +
bound O +
specific O +
protein O +
factors O +
. O +

When O +
single O -
- O -
point O +
mutation O +
was O +
introduced O +
to O +
each O +
GC O +
box O +
, O +
EBS O +
, O +
and O +
GT O +
box O +
in O +
PFP9a20 O +
, O +
at O +
least O +
3-fold O +
less O +
CAT O +
activity O +
was O +
observed O +
in O +
CTLL B-CellLine -
- I-CellLine -
R8 I-CellLine +
cells I-CellLine +
. O +

To O +
confirm O +
the O +
importance O +
of O +
the O +
three O +
cis O -
- O -
acting O +
elements O +
in O +
the O +
perforin O +
gene O +
expression O +
, O +
point O +
mutation O +
was O +
introduced O +
again O +
to O +
each O +
proximal O +
GC O +
box O +
, O +
EBS O +
, O +
and O +
GT O +
box O +
of O +
PFP5a O +
. O +

The O +
point O +
mutations O +
resulted O +
in O +
a O +
2.5- O +
to O +
3-fold O +
reduction O +
of O +
CAT O +
activity O +
. O +

The O +
results O +
suggest O +
that O +
a O +
combination O +
of O +
the O +
three O +
proximal O +
cis O -
- O -
acting O +
elements O +
may O +
constitute O +
a O +
minimal O +
region O +
responsible O +
for O +
CTL O -
- O -
specific O +
expression O +
of O +
perforin O +
. O +

Stimulation O +
of O +
human O +
lymphocyte O +
proliferation O +
and O +
CD40 O +
antigen O +
expression O +
by O +
phosphorothioate O +
oligonucleotides O +
complementary O +
to O +
hepatitis O +
B O +
virus O +
genome O +
. O +

We O +
have O +
studied O +
the O +
proliferation O +
and O +
CD40 O +
antigen O +
expression O +
of O +
lymphocytes O +
, O +
and O +
the O +
cytotoxicity O +
to O +
monocytes O +
, O +
of O +
antisense O +
phosphorothioate O +
oligodeoxynucleotides O +
complementary O +
to O +
the O +
SP O +
II O +
promoter O +
of O +
HBV O +
mRNA O +
( O +
sequence O +
I O +
) O +
and O +
the O +
X O +
gene O +
( O +
sequence O +
II O +
) O +
in O +
patients O +
with O +
chronic O +
hepatitis O +
B O +
. O +

The O +
oligo O +
sequence O +
I O +
stimulated O +
proliferation O +
of O +
both O +
T O +
and O +
, O +
to O +
a O +
lesser O +
extent O +
, O +
B O +
cells O +
. O +

The O +
percentage O +
of O +
cells O +
expressing O +
CD40 O +
in O +
T B-CellLine +
and I-CellLine +
B I-CellLine +
cell I-CellLine +
co I-CellLine -
- I-CellLine -
cultures I-CellLine +
increased O +
from O +
4.2 O +
% O +
to O +
13.8 O +
% O +
after O +
oligo O +
stimulation O +
in O +
patients O +
, O +
while O +
it O +
increased O +
form O +
4.7 O +
% O +
to O +
48.6 O +
% O +
in O +
healthy O +
controls O +
. O +

The O +
sense O +
sequence O +
( O +
sequence O +
III O +
) O +
of O +
the O +
X O +
gene O +
also O +
enhanced O +
the O +
expression O +
of O +
CD40 O +
antigen O +
in O +
patients O +
with O +
hepatitis O +
B O +
. O +

The O +
proportion O +
of O +
CD40 B-CellLine +
cells I-CellLine +
( O +
26 O +
% O +
) O +
in O +
a O +
resting B-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
preparation I-CellLine +
from O +
hepatitis O +
B O +
patients O +
decreased O +
to O +
zero O +
after O +
a O +
5-day O +
culture O +
with O +
sequence O +
I O +
, O +
but O +
IgG O +
levels O +
in O +
the O +
culture O +
supernatant O +
increased O +
. O +

The O +
cytotoxic O +
properties O +
of O +
monocytes O +
were O +
not O +
influenced O +
by O +
the O +
oligos O +
. O +

These O +
findings O +
indicate O +
that O +
antisense O +
oligos O +
against O +
hepatitis O +
B O +
virus O +
( O +
HBV O +
) O +
have O +
mitogenic O +
effects O +
on O +
the O +
proliferation O +
of O +
human O +
lymphocytes O +
in O +
a O +
non O -
- O -
specific O +
manner O +
and O +
may O +
activate O +
T O +
cells O +
to O +
express O +
CD40 O +
antigen O +
. O +

Soluble O +
factors O +
secreted O +
by O +
activated O +
T O -
- O -
lymphocytes O +
modulate O +
the O +
transcription O +
of O +
the O +
immunosuppressive O +
cytokine O +
TGF O -
- O -
beta O +
2 O +
in O +
glial O +
cells O +
. O +

Coordination O +
of O +
the O +
immune O +
response O +
to O +
injury O +
or O +
disease O +
in O +
the O +
brain O +
is O +
postulated O +
to O +
involve O +
bi O -
- O -
directional O +
discourse O +
between O +
the O +
immune O +
system O +
and O +
the O +
central O +
nervous O +
system O +
. O +

This O +
cross O +
communication O +
involves O +
soluble O +
mediators O +
, O +
including O +
various O +
growth O +
factors O +
, O +
cytokines O +
, O +
and O +
neuropeptides O +
. O +

In O +
this O +
report O +
, O +
we O +
demonstrate O +
that O +
the O +
supernatant O +
from O +
activated O +
T O -
- O -
lymphocytes O +
is O +
able O +
to O +
induce O +
the O +
transcription O +
of O +
a O +
potent O +
cytokine O +
, O +
TGF O -
- O -
beta O +
2 O +
in O +
glial O +
cells O +
. O +

The O +
activating O +
stimulus O +
invokes O +
signaling O +
mechanisms O +
distinct O +
from O +
known O +
kinase O +
or O +
protease O +
pathways O +
. O +

Activation O +
of O +
TGF O -
- O -
beta O +
2 O +
transcription O +
correlates O +
with O +
the O +
loss O +
of O +
binding O +
activity O +
for O +
an O +
80 O +
kDA O +
glial O +
labile O +
repressor O +
protein O +
, O +
GLRP O +
, O +
to O +
a O +
responsive O +
region O +
within O +
the O +
TFG O -
- O -
beta O +
2 O +
promoter O +
. O +

Although O +
GLRP O +
shares O +
some O +
characteristics O +
with O +
the O +
inducible O +
transcription O +
factor O +
AP-1 O +
, O +
it O +
appears O +
to O +
be O +
distinct O +
from O +
known O +
AP-1 O +
family O +
members O +
. O +

These O +
data O +
along O +
with O +
previous O +
observations O +
demonstrating O +
the O +
potent O +
immunosuppressive O +
activity O +
of O +
TGF O -
- O -
beta O +
2 O +
, O +
support O +
a O +
model O +
for O +
a O +
feedback O +
mechanism O +
between O +
the O +
activated O +
T O -
- O -
lymphocytes O +
and O +
astrocytes O +
via O +
TGF O -
- O -
beta O +
2 O +
to O +
regulate O +
the O +
immune O +
response O +
. O +

Vitamin O +
D3- O +
and O +
retinoic O +
acid O -
- O -
induced O +
monocytic O +
differentiation O +
: O +
interactions O +
between O +
the O +
endogenous O +
vitamin O +
D3 O +
receptor O +
, O +
retinoic O +
acid O +
receptors O +
, O +
and O +
retinoid O +
X O +
receptors O +
in O +
U-937 B-CellLine +
cells I-CellLine +
. O +

Retinoic O +
acid O +
( O +
RA O +
) O +
and O +
1 O +
, O +
25 O +
alpha O -
- O -
dihydroxycholecalciferol O +
( O +
VitD3 O +
) O +
are O +
potent O +
regulators O +
of O +
hematopoletic O +
differentiation O +
. O +

Yet O +
, O +
little O +
is O +
known O +
as O +
to O +
how O +
the O +
RA O +
and O +
VitD3 O +
receptor O +
network O +
operates O +
in O +
hematopoietic O +
cells O +
, O +
and O +
whether O +
receptor O +
interactions O +
can O +
explain O +
the O +
interplay O +
between O +
the O +
RA O +
-and O +
VitD3-signaling O +
pathways O +
during O +
differentiation O +
. O +

Therefore O +
, O +
we O +
analyzed O +
the O +
expression O +
, O +
DNA O +
binding O +
, O +
and O +
transcriptional O +
activity O +
of O +
the O +
endogenous O +
RA O +
and O +
VitD3 O +
receptors O +
[ O +
retinoic O +
acid O +
receptors O +
( O +
RARs O +
) O +
, O +
retinoid O +
X O +
receptors O +
( O +
RXRs O +
) O +
, O +
and O +
VitD3 O +
receptor O +
( O +
VDR O +
) O +
] O +
in O +
the O +
U-937 B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
in O +
which O +
RA O +
and O +
VitD3 O +
induce O +
distinct O +
monocytic O +
differentiation O +
pathways O +
. O +

VitD3 O +
induction O +
resulted O +
in O +
the O +
formation O +
of O +
VDR O -
/ O -
RXR O +
DNA O -
- O -
binding O +
complexes O +
on O +
both O +
VitD3 O +
response O +
elements O +
and O +
RA O +
response O +
elements O +
( O +
RAREs O +
) O +
. O +

However O +
, O +
transcriptional O +
activation O +
was O +
only O +
observed O +
from O +
a O +
VitD3 O +
response O +
element O -
- O -
driven O +
reporter O +
construct O +
. O +

Several O +
DNA O -
- O -
binding O +
complexes O +
were O +
detected O +
on O +
RAREs O +
in O +
undifferentiated O +
cells O +
. O +

Stimulation O +
by O +
RA O +
resulted O +
in O +
increased O +
RAR O +
beta O +
/RXR O +
DNA O +
binding O +
, O +
activated O +
RARE O +
-dependent O +
transcription O +
, O +
and O +
increased O +
expression O +
of O +
RAR O -
- O -
beta O +
. O +

Concomitant O +
stimulation O +
by O +
VitD3 O +
inhibited O +
the O +
RA O -
- O -
stimulated O +
formation O +
of O +
RAR O +
beta O -
/ O -
RXR O +
heterodimers O +
, O +
favoring O +
VDR O +
/RXR O +
binding O +
to O +
the O +
RARE O +
. O +

Also O +
, O +
VitD3 O +
inhibited O +
the O +
expression O +
of O +
CD23 O +
and O +
CD49f O +
, O +
characteristic O +
markers O +
of O +
retinoid O -
- O -
induced O +
U-937 B-CellLine +
cell I-CellLine +
differentiation O +
. O +

In O +
contrast O +
, O +
neither O +
the O +
RA O -
- O -
stimulated O +
, O +
RARE O +
-mediated O +
transcription O +
nor O +
the O +
induced O +
RAR O -
- O -
beta O +
expression O +
was O +
suppressed O +
by O +
VitD3 O +
, O +
suggesting O +
that O +
VitD3 O +
selectively O +
inhibited O +
the O +
retinoid O -
- O -
induced O +
differentiation O +
program O +
but O +
not O +
the O +
RARE O +
-mediated O +
signal O +
. O +

These O +
results O +
demonstrate O +
a O +
complex O +
role O +
for O +
VitD3 O +
in O +
modifying O +
the O +
retinoid O +
differentiation O +
pathway O +
and O +
may O +
have O +
implications O +
for O +
differentiation O -
- O -
inducing O +
therapy O +
of O +
hematopoietic O +
tumors O +
. O +

Calcium O -
- O -
dependent O +
immediate O -
- O -
early O +
gene O +
induction O +
in O +
lymphocytes O +
is O +
negatively O +
regulated O +
by O +
p21Ha O -
- O -
ras O +
. O +

The O +
induction O +
of O +
immediate O -
- O -
early O +
( O +
IE O +
) O +
response O +
genes O +
, O +
such O +
as O +
egr-1 O +
, O +
c O -
- O -
fos O +
, O +
and O +
c O -
- O -
jun O +
, O +
occurs O +
rapidly O +
after O +
the O +
activation O +
of O +
T O +
lymphocytes O +
. O +

The O +
process O +
of O +
activation O +
involves O +
calcium O +
mobilization O +
, O +
activation O +
of O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
, O +
and O +
phosphorylation O +
of O +
tyrosine O +
kinases O +
. O +

p21 O +
( O +
ras O +
) O +
, O +
a O +
guanine O +
nucleotide O +
binding O +
factor O +
, O +
mediates O +
T O -
- O -
cell O +
signal O +
transduction O +
through O +
PKC O +
-dependent O +
and O +
PKC O +
-independent O +
pathways O +
. O +

The O +
involvement O +
of O +
p21 O +
( O +
ras O +
) O +
in O +
the O +
regulation O +
of O +
calcium O -
- O -
dependent O +
signals O +
has O +
been O +
suggested O +
through O +
analysis O +
of O +
its O +
role O +
in O +
the O +
activation O +
of O +
NF O -
- O -
AT O +
. O +

We O +
have O +
investigated O +
the O +
inductions O +
of O +
the O +
IE O +
genes O +
in O +
response O +
to O +
calcium O +
signals O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
( O +
in O +
the O +
presence O +
of O +
activated O +
p21 O +
( O +
ras O +
) O +
) O +
and O +
their O +
correlated O +
consequences O +
. O +

The O +
expression O +
of O +
activated O +
p21 O +
( O +
ras O +
) O +
negatively O +
regulated O +
the O +
induction O +
of O +
IE O +
genes O +
by O +
calcium O +
ionophore O +
. O +

This O +
inhibition O +
of O +
calcium O -
- O -
activated O +
IE O +
gene O +
induction O +
was O +
reversed O +
by O +
treatment O +
with O +
cyclosporin O +
A O +
, O +
suggesting O +
the O +
involvement O +
of O +
calcineurin O +
in O +
this O +
regulation O +
. O +

A O +
later O +
result O +
of O +
inhibition O +
of O +
this O +
activation O +
pathway O +
by O +
p21 O +
( O +
ras O +
) O +
was O +
down O -
- O -
regulation O +
of O +
the O +
activity O +
of O +
the O +
transcription O +
factor O +
AP-1 O +
and O +
subsequent O +
coordinate O +
reductions O +
in O +
IL-2 O +
gene O +
expression O +
and O +
protein O +
production O +
. O +

These O +
results O +
suggest O +
that O +
p2l O +
( O +
ras O +
) O +
is O +
an O +
essential O +
mediator O +
in O +
generating O +
not O +
only O +
positive O +
but O +
also O +
negative O +
modulatory O +
mechanisms O +
controlling O +
the O +
competence O +
of O +
T O +
cells O +
in O +
response O +
to O +
inductive O +
stimulations O +
. O +

CD14 O +
-mediated O +
signal O +
pathway O +
of O +
Porphyromonas O +
gingivalis O +
lipopolysaccharide O +
in O +
human O +
gingival O +
fibroblasts O +
. O +

Lipopolysaccharide O +
( O +
LPS O +
) O +
induces O +
expression O +
of O +
inflammatory O +
cytokines O +
in O +
monocytes O -
/ O -
macrophages O +
via O +
CD14 O +
, O +
one O +
of O +
the O +
LPS O +
receptors O +
, O +
which O +
is O +
expressed O +
predominantly O +
in O +
these O +
cells O +
. O +

It O +
has O +
been O +
demonstrated O +
that O +
Porphyromonas O +
gingivalis O +
LPS O +
( O +
P O -
- O -
LPS O +
) O +
also O +
is O +
able O +
to O +
induce O +
inflammatory O +
cytokines O +
in O +
human O +
gingival O +
fibroblasts O +
. O +

Therefore O +
, O +
it O +
is O +
important O +
to O +
determine O +
whether O +
CD14 O +
is O +
expressed O +
in O +
gingival O +
fibroblasts O +
and O +
to O +
define O +
the O +
P O -
- O -
LPS O -
- O -
mediated O +
signal O -
- O -
transducing O +
mechanism O +
in O +
the O +
cells O +
. O +

In O +
this O +
study O +
, O +
we O +
observed O +
unexpectedly O +
by O +
immunohistochemical O +
, O +
Western O +
blotting O +
( O +
immunoblotting O +
) O +
, O +
and O +
Northern O +
( O +
RNA O +
) O +
blotting O +
assays O +
that O +
CD14 O +
is O +
expressed O +
at O +
high O +
density O +
in O +
human O +
gingival O +
fibroblasts O +
. O +

P O -
- O -
LPS O -
- O -
induced O +
expression O +
of O +
the O +
monocyte O +
chemoattractant O +
protein O +
1 O +
( O +
MCP-1 O +
) O +
gene O +
in O +
the O +
cells O +
was O +
inhibited O +
markedly O +
by O +
treatment O +
with O +
anti O -
- O -
human O +
CD14 O +
antibody O +
and O +
was O +
completely O +
inhibited O +
by O +
herbimycin O +
A O +
, O +
a O +
potent O +
inhibitor O +
of O +
tyrosine O +
kinase O +
. O +

The O +
inhibitor O +
also O +
dramatically O +
inhibited O +
monocyte O +
chemotactic O +
activity O +
of O +
and O +
MCP-1 O +
production O +
by O +
the O +
cells O +
. O +

Furthermore O +
, O +
P O -
- O -
LPS O -
- O -
induced O +
expression O +
of O +
the O +
MCP-1 O +
gene O +
in O +
the O +
cells O +
also O +
was O +
blocked O +
by O +
inhibitors O +
of O +
two O +
transcription O +
factors O +
, O +
i.e. O +
, O +
curcumin O +
, O +
an O +
inhibitor O +
of O +
AP-1 O +
, O +
and O +
pyrolidine O +
dithiocarbamate O +
, O +
an O +
inhibitor O +
of O +
NF O -
- O -
kappaB O +
. O +

Both O +
inhibitors O +
inhibited O +
monocyte O +
chemotactic O +
activity O +
in O +
the O +
culture O +
supernatant O +
of O +
P O -
- O -
LPS O -
- O -
treated O +
cells O +
. O +

Gel O +
shift O +
mobility O +
assay O +
showed O +
stimulation O +
of O +
the O +
AP-1 O +
and O +
NF O -
- O -
kappaB O +
contents O +
in O +
P O -
- O -
LPS O -
- O -
treated O +
cells O +
. O +

This O +
study O +
is O +
the O +
first O +
to O +
demonstrate O +
the O +
expression O +
of O +
CD14 O +
in O +
human O +
gingival O +
fibroblasts O +
and O +
to O +
show O +
that O +
the O +
signal O -
- O -
transducing O +
pathway O +
of O +
P O -
- O -
LPS O +
in O +
the O +
cells O +
is O +
mediated O +
by O +
CD14 O +
. O +

Tyrosines O +
113 O +
, O +
128 O +
, O +
and O +
145 O +
of O +
SLP-76 O +
are O +
required O +
for O +
optimal O +
augmentation O +
of O +
NFAT O +
promoter O +
activity O +
. O +

SLP-76 O +
( O +
SH2 O +
domain O +
leukocyte O +
protein O +
of O +
76 O +
kDa O +
) O +
is O +
a O +
recently O +
identified O +
substrate O +
of O +
the O +
TCR O -
- O -
stimulated O +
protein O +
tyrosine O +
kinases O +
that O +
functions O +
in O +
the O +
signal O +
transduction O +
cascade O +
linking O +
the O +
TCR O +
with O +
IL-2 O +
gene O +
expression O +
. O +

In O +
this O +
report O +
, O +
we O +
demonstrate O +
that O +
engagement O +
of O +
the O +
TCR O +
results O +
in O +
tyrosine O +
phosphorylation O +
of O +
SLP-76 O +
in O +
its O +
amino O -
- O -
terminal O +
acidic O +
region O +
. O +

Two O +
tyrosines O +
( O +
Y113 O +
and O +
Y128 O +
) O +
fall O +
within O +
an O +
identical O +
five O +
amino O -
- O -
acid O +
motif O +
and O +
are O +
shown O +
to O +
be O +
phosphorylated O +
upon O +
TCR O +
ligation O +
. O +

Although O +
mutation O +
of O +
either O +
Y113 O +
and O +
Y128 O +
has O +
a O +
minimal O +
effect O +
on O +
SLP-76 O +
function O +
, O +
mutation O +
of O +
both O +
residues O +
decreases O +
significantly O +
the O +
ability O +
of O +
SLP-76 O +
to O +
promote O +
T O +
cell O +
activation O +
. O +

A O +
third O +
tyrosine O +
within O +
the O +
amino O -
- O -
terminal O +
region O +
( O +
Y145 O +
) O +
appears O +
to O +
be O +
the O +
most O +
important O +
for O +
optimal O +
SLP-76 O +
function O +
, O +
as O +
altering O +
it O +
alone O +
to O +
phenylalanine O +
has O +
a O +
potent O +
impact O +
on O +
SLP-76 O +
augmentation O +
of O +
NFAT O +
promoter O +
activity O +
. O +

Apoptosis O +
signaling O +
pathways O +
in O +
normal O +
T O +
cells O +
: O +
differential O +
activity O +
of O +
Bcl-2 O +
and O +
IL-1beta O -
- O -
converting O +
enzyme O +
family O +
protease O +
inhibitors O +
on O +
glucocorticoid- O +
and O +
Fas O -
- O -
mediated O +
cytotoxicity O +
. O +

Fas O +
-mediated O +
apoptosis O +
plays O +
an O +
important O +
role O +
in O +
regulating O +
the O +
immune O +
response O +
in O +
peripheral O +
T O +
cells O +
. O +

Restimulation O +
of O +
T O +
cell O +
blasts O +
up O -
- O -
regulates O +
Fas O +
and O +
Fas O +
ligand O +
expression O +
, O +
with O +
subsequent O +
interaction O +
leading O +
to O +
cell O +
death O +
. O +

Overexpression O +
of O +
Bcl-2 O +
in O +
tumor O +
cells O +
blocks O +
apoptosis O +
induced O +
by O +
many O +
stimuli O +
, O +
but O +
inhibition O +
of O +
Fas O +
-mediated O +
killing O +
has O +
not O +
been O +
consistently O +
observed O +
. O +

To O +
examine O +
the O +
behavior O +
of O +
Bcl-2 O +
in O +
normal O +
cells O +
, O +
T O +
cell O +
blasts O +
were O +
transiently O +
transfected O +
with O +
Bcl-2 O +
and O +
related O +
gene O +
products O +
to O +
determine O +
the O +
effect O +
on O +
apoptotic O +
signaling O +
. O +

Transient O +
overexpression O +
of O +
Bcl-2 O +
in O +
mouse O +
and O +
human O +
T O +
cell O +
blasts O +
did O +
not O +
block O +
Fas O +
-mediated O +
apoptosis O +
, O +
whereas O +
etoposide- O +
and O +
glucocorticoid O -
- O -
induced O +
cytotoxicity O +
was O +
potently O +
inhibited O +
. O +

Expression O +
of O +
Bcl O -
- O -
xL O +
and O +
adenovirus O +
E1B O +
19 O -
K O +
did O +
not O +
interfere O +
with O +
anti- O +
Fas O +
killing O +
. O +

In O +
contrast O +
, O +
interleukin-1beta O -
- O -
converting O +
enzyme O +
family O +
protease O +
inhibitors O +
Ac O -
- O -
DEVD O -
- O -
CHO O +
and O +
CrmA O +
blocked O +
Fas O +
-mediated O +
apoptosis O +
. O +

These O +
results O +
suggest O +
that O +
peripheral O +
T O +
cells O +
use O +
distinct O +
apoptosis O +
signaling O +
pathways O +
with O +
differential O +
sensitivity O +
to O +
Bcl-2 O +
and O +
interleukin-1beta O -
- O -
converting O +
enzyme O +
family O +
protease O +
inhibitors O +
. O +

Since O +
T O +
cells O +
normally O +
express O +
Bcl-2 O +
and O +
Bcl O -
- O -
xL O +
following O +
activation O +
, O +
their O +
inability O +
to O +
block O +
Fas O +
-mediated O +
apoptosis O +
may O +
allow O +
for O +
the O +
elimination O +
of O +
self O -
- O -
reactive O +
cells O +
and O +
the O +
appropriate O +
regulation O +
of O +
immune O +
responses O +
. O +

Rapid O +
shuttling O +
of O +
NF O -
- O -
AT O +
in O +
discrimination O +
of O +
Ca2 O -
+ O +
signals O +
and O +
immunosuppression O +
. O +

Cells O +
need O +
to O +
distinguish O +
between O +
transient O +
Ca2 O -
+ O +
signals O +
that O +
induce O +
events O +
such O +
as O +
muscle O +
contraction O +
, O +
secretion O +
, O +
adhesion O +
and O +
synaptic O +
transmission O +
, O +
and O +
sustained O +
Ca2 O -
+ O +
signals O +
that O +
are O +
involved O +
in O +
cell O +
proliferation O +
and O +
differentiation O +
. O +

The O +
latter O +
class O +
of O +
events O +
is O +
blocked O +
in O +
lymphocytes O +
by O +
the O +
immunosuppressive O +
drugs O +
cyclosporin O +
A O +
and O +
FK506 O +
, O +
which O +
inhibit O +
calcineurin O +
, O +
a O +
Ca2 O -
+ O -
-activated O +
serine O -
/ O -
threonine O +
phosphatase O +
necessary O +
for O +
the O +
nuclear O +
import O +
of O +
NF O -
- O -
AT O +
transcription O +
factors O +
. O +

Here O +
we O +
report O +
that O +
sustained O +
high O +
concentrations O +
of O +
Ca2 O -
+ O +
, O +
but O +
not O +
transient O +
pulses O +
, O +
are O +
required O +
to O +
maintain O +
NF O -
- O -
AT O +
transcription O +
factors O +
in O +
the O +
nucleus O +
, O +
where O +
they O +
participate O +
in O +
Ca2 O -
+ O -
-dependent O +
induction O +
of O +
genes O +
required O +
for O +
lymphocyte O +
activation O +
and O +
proliferation O +
. O +

Furthermore O +
, O +
overexpression O +
and O +
constitutive O +
nuclear O +
localization O +
of O +
NF O -
- O -
AT O +
, O +
but O +
not O +
Jun O +
, O +
Fos O +
, O +
NF O -
- O -
kappaB O +
, O +
Oct O +
or O +
Ets O +
family O +
members O +
, O +
renders O +
the O +
interleukin-2 O +
enhancer O +
in O +
Jurkat B-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
resistant O +
to O +
FK506 O +
and O +
cyclosporin O +
A O +
. O +

Thus O +
a O +
primary O +
effect O +
of O +
these O +
immunosuppressive O +
reagents O +
is O +
to O +
control O +
the O +
subcellular O +
localization O +
of O +
the O +
NF O -
- O -
AT O +
family O +
of O +
transcription O +
factors O +
. O +

Susceptibility O +
to O +
natural O +
killer O +
cells O +
and O +
down O +
regulation O +
of O +
MHC O +
class O +
I O +
expression O +
in O +
adenovirus B-CellLine +
12 I-CellLine +
transformed I-CellLine +
cells I-CellLine +
are O +
regulated O +
by O +
different O +
E1A O +
domains O +
. O +

All O +
human O +
adenoviruses O +
transform O +
rodent O +
cells O +
in O +
vitro O +
, O +
but O +
only O +
cells O +
transformed O +
by O +
serotypes O +
belonging O +
to O +
subgroups O +
A O +
( O +
Ad12 O +
) O +
and O +
B O +
( O +
Ad3 O +
) O +
are O +
tumorigenic O +
for O +
immunocompetent O +
animals O +
. O +

In O +
these O +
cells O +
, O +
the O +
expression O +
of O +
MHC O -
- O -
class O +
I O +
antigens O +
is O +
repressed O +
and O +
might O +
allow O +
them O +
to O +
escape O +
from O +
recognition O +
by O +
cytotoxic O +
T O +
lymphocytes O +
( O +
CTL O +
) O +
and O +
to O +
develop O +
in O +
tumor O +
. O +

Furthermore O +
, O +
these O +
cell B-CellLine +
lines I-CellLine +
appear O +
resistant O +
to O +
lysis O +
by O +
natural O +
killer O +
( O +
NK O +
) O +
cells O +
. O +

To O +
determine O +
the O +
E1A O +
domain O +
( O +
s O +
) O +
responsible O +
for O +
these O +
properties O +
several O +
cell B-CellLine +
lines I-CellLine +
were O +
created O +
by O +
transforming O +
baby B-CellLine +
rat I-CellLine +
kidney I-CellLine +
( I-CellLine +
BRK I-CellLine +
) I-CellLine +
cells I-CellLine +
with O +
a O +
set O +
of O +
plasmids O +
expressing O +
different O +
Ad2 O -
/ O -
Ad12 O +
hybrid O +
E1A O +
gene O +
products O +
. O +

The O +
MHC O +
class O +
1 O +
gene O +
expression O +
was O +
inhibited O +
in O +
cells O +
expressing O +
the O +
Ad12 O +
13S O +
mRNA O +
product O +
and O +
in O +
cells O +
transformed O +
with O +
Ad2 O -
/ O -
Ad12 O +
hybrid O +
E1A O +
gene O +
product O +
harboring O +
the O +
C O -
- O -
terminal O +
part O +
of O +
the O +
conserved O +
region O +
( O +
CR O +
) O +
3 O +
of O +
Ad12 O +
. O +

Susceptibility O +
of O +
these O +
transformed O +
cell B-CellLine +
lines I-CellLine +
to O +
NK O +
cells O +
was O +
determined O +
by O +
cytolytic O +
assays O +
. O +

The O +
results O +
obtained O +
suggest O +
that O +
two O +
Ad12 O +
E1A O +
domains O +
are O +
required O +
to O +
induce O +
resistance O +
of O +
the O +
cell B-CellLine +
lines I-CellLine +
to O +
NK O +
cells O +
. O +

An O +
IL-2 O +
response O +
element O +
in O +
the O +
human O +
IL-2 O +
receptor O +
alpha O +
chain O +
promoter O +
is O +
a O +
composite O +
element O +
that O +
binds O +
Stat5 O +
, O +
Elf-1 O +
, O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
and O +
a O +
GATA O +
family O +
protein O +
. O +

Expression O +
of O +
the O +
human O +
interleukin-2 O +
( O +
IL-2 O +
) O +
receptor O +
alpha O +
chain O +
gene O +
is O +
potently O +
upregulated O +
by O +
its O +
own O +
ligand O +
, O +
IL-2 O +
. O +

In O +
this O +
study O +
, O +
we O +
characterize O +
an O +
essential O +
upstream O +
IL-2 O +
response O +
element O +
that O +
contains O +
both O +
consensus O +
and O +
non O -
- O -
consensus O +
GAS O +
motifs O +
, O +
two O +
putative O +
Ets O +
binding O +
sites O +
( O +
EBS O +
) O +
, O +
one O +
of O +
which O +
overlaps O +
the O +
consensus O +
GAS O +
motif O +
, O +
and O +
a O +
GATA O +
motif O +
, O +
which O +
overlaps O +
the O +
non O -
- O -
consensus O +
GAS O +
motif O +
. O +

We O +
demonstrate O +
that O +
although O +
the O +
individual O +
components O +
of O +
this O +
element O +
do O +
not O +
respond O +
to O +
IL-2 O +
, O +
together O +
they O +
form O +
a O +
composite O +
element O +
capable O +
of O +
conferring O +
IL-2 O +
responsiveness O +
to O +
a O +
heterologous O +
promoter O +
. O +

Multiple O +
factors O +
including O +
Stat5 O +
, O +
Elf-1 O +
, O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
and O +
GATA O +
family O +
proteins O +
bind O +
to O +
the O +
IL-2 O +
response O +
element O +
and O +
mutation O +
of O +
any O +
one O +
of O +
these O +
binding O +
sites O +
diminishes O +
the O +
activity O +
of O +
this O +
element O +
. O +

An O +
unidentified O +
Ets O +
family O +
protein O +
binds O +
to O +
the O +
EBS O +
overlapping O +
the O +
consensus O +
GAS O +
motif O +
and O +
appears O +
to O +
negatively O +
regulate O +
the O +
human O +
IL-2R O +
alpha O +
promoter O +
. O +

Thus O +
, O +
IL-2 O +
-induced O +
IL-2R O +
alpha O +
promoter O +
activity O +
requires O +
a O +
complex O +
upstream O +
element O +
, O +
which O +
appears O +
to O +
contain O +
binding O +
sites O +
for O +
both O +
positive O +
and O +
negative O +
regulatory O +
factors O +
. O +

Tyrosine O +
kinase O +
and O +
cAMP O -
- O -
dependent O +
protein O +
kinase O +
activities O +
in O +
CD40-activated B-CellLine +
human I-CellLine +
B I-CellLine +
lymphocytes I-CellLine +
. O +

In O +
vitro O +
, O +
human O +
B O +
lymphocytes O +
undergo O +
long O -
- O -
term O +
proliferation O +
when O +
activated O +
through O +
CD40 O +
, O +
a O +
protein O +
expressed O +
on O +
their O +
cell O +
surface O +
. O +

The O +
nature O +
of O +
CD40 O +
-dependent O +
signals O +
in O +
proliferating O +
fresh O +
human B-CellLine +
Epstein I-CellLine -
- I-CellLine -
Barr I-CellLine +
virus I-CellLine -
- I-CellLine -
negative I-CellLine +
B I-CellLine +
lymphocytes I-CellLine +
is O +
currently O +
unknown O +
. O +

In O +
this O +
study O +
, O +
a O +
CD40 O +
-dependent O +
B O +
cell O +
culture O +
system O +
was O +
used O +
to O +
examine O +
the O +
role O +
of O +
different O +
signal O +
transduction O +
elements O +
. O +

Protein O +
kinase O +
C O +
( O +
PKC O +
) O +
depletion O +
generated O +
by O +
a O +
long O -
- O -
term O +
phorbol O +
12 O +
myristate O +
13-acetate O +
treatment O +
had O +
weak O +
effects O +
on O +
proliferation O +
. O +

Rather O +
, O +
tyrosine O +
phosphorylation O +
was O +
shown O +
to O +
be O +
directly O +
involved O +
in O +
mediating O +
CD40 O +
-dependent O +
signals O +
. O +

The O +
use O +
of O +
the O +
protein O +
tyrosine O +
kinase O +
( O +
PTK O +
) O +
-specific O +
inhibitor O +
herbimycin O +
A O +
dramatically O +
decreased O +
cellular O +
proliferation O +
without O +
altering O +
the O +
activity O +
of O +
the O +
human O +
immunodeficiency O +
virus-1 O +
long O +
terminal O +
repeat O +
( O +
HIV-1 O +
LTR O +
) O +
, O +
a O +
promoter O +
largely O +
dependent O +
on O +
the O +
binding O +
of O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF- O +
kappa O +
B O +
) O +
. O +

In O +
contrast O +
, O +
the O +
cAMP O -
- O -
dependent O +
protein O +
kinase O +
specific O +
inhibitor O +
H-89 O +
totally O +
inhibited O +
HIV-1 O +
LTR O +
activity O +
at O +
a O +
concentration O +
as O +
low O +
as O +
100 O +
nM O +
without O +
affecting O +
cellular O +
proliferation O +
. O +

Electrophoretic O +
mobility O +
shift O +
assay O +
( O +
EMSA O +
) O +
and O +
supershift O +
assay O +
using O +
an O +
NF O -
- O -
kappa O +
B O +
binding O +
sequence O +
from O +
the O +
kappa O +
light O +
chain O +
as O +
a O +
probe O +
, O +
revealed O +
that O +
both O +
p65 O +
( O +
RelA O +
) O +
and O +
c O -
- O -
Rel O +
were O +
present O +
in O +
CD40-stimulated O +
B O +
cells O +
. O +

While O +
PKC O +
depletion O +
did O +
not O +
alter O +
the O +
NF O -
- O -
kappa O +
B O +
level O +
, O +
treatment O +
of O +
B O +
lymphocytes O +
with O +
H-89 O +
or O +
herbimycin O +
A O +
provoked O +
a O +
decrease O +
in O +
the O +
NF O -
- O -
kappa O +
B O +
level O +
. O +

These O +
observations O +
establish O +
the O +
importance O +
of O +
different O +
signal O +
transducing O +
pathways O +
leading O +
to O +
CD40 O +
activation O +
of O +
B O +
lymphocytes O +
. O +

Active O +
suppression O +
of O +
the O +
class O +
II O +
transactivator O -
- O -
encoding O +
AIR-1 O +
locus O +
is O +
responsible O +
for O +
the O +
lack O +
of O +
major O +
histocompatibility O +
complex O +
class O +
II O +
gene O +
expression O +
observed O +
during O +
differentiation O +
from O +
B O +
cells O +
to O +
plasma O +
cells O +
. O +

In O +
this O +
study O +
the O +
genetic O +
control O +
of O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
class O +
II O +
gene O +
expression O +
during O +
the O +
transition O +
from O +
B O +
cell O +
to O +
plasma O +
cell O +
has O +
been O +
analyzed O +
. O +

Class O +
II O +
molecules O +
are O +
not O +
expressed O +
in O +
plasma O +
cells O +
because O +
of O +
an O +
active O +
suppression O +
resulting O +
in O +
the O +
abrogation O +
of O +
class O +
II O +
gene O +
transcription O +
. O +

We O +
show O +
here O +
that O +
the O +
plasma O +
cell O -
- O -
specific O +
repressor O +
function O +
, O +
designated O +
SIR O +
( O +
suppressor O +
of O +
immune O +
response O +
genes O +
) O +
, O +
does O +
not O +
act O +
directly O +
on O +
the O +
transcription O +
of O +
class O +
II O +
genes O +
, O +
but O +
instead O +
on O +
the O +
transcription O +
of O +
the O +
AIR-1 O +
gene O +
, O +
whose O +
product O +
, O +
the O +
class O +
II O +
transactivator O +
( O +
CIITA O +
) O +
, O +
is O +
fundamental O +
for O +
the O +
regulation O +
of O +
the O +
constitutive O +
and O +
inducible O +
expression O +
of O +
MHC O +
class O +
II O +
genes O +
. O +

This O +
was O +
unambiguously O +
demonstrated O +
by O +
the O +
fact O +
that O +
plasmacytoma B-CellLine +
x I-CellLine +
B I-CellLine +
cell I-CellLine +
hybrids I-CellLine +
carrying O +
an O +
AIR-1 O +
locus O +
derived O +
from O +
CIITA B-CellLine -
- I-CellLine -
expressing I-CellLine +
cells I-CellLine +
do O +
not O +
express O +
CIITA O -
- O -
specific O +
transcripts O +
. O +

Transfection O +
of O +
a O +
cDNA O +
containing O +
the O +
human O +
CIITA O +
coding O +
sequence O +
under O +
the O +
control O +
of O +
an O +
heterologous O +
promoter O +
restores O +
expression O +
of O +
human O +
MHC O +
class O +
II O +
genes O +
in O +
the O +
hybrids O +
and O +
is O +
responsible O +
for O +
de O +
novo O +
expression O +
of O +
mouse O +
MHC O +
class O +
II O +
genes O +
in O +
both O +
the O +
mouse B-CellLine +
plasmacytoma I-CellLine +
cell I-CellLine +
line I-CellLine +
and O +
the O +
hybrids B-CellLine +
. O +

These O +
results O +
confirm O +
and O +
extend O +
the O +
notion O +
of O +
the O +
functional O +
conservation O +
of O +
the O +
AIR-1 O +
gene O +
product O +
across O +
species O +
barriers O +
. O +

Interestingly O +
, O +
in O +
CIITA B-CellLine -
- I-CellLine -
transfected I-CellLine +
cell I-CellLine +
hybrids I-CellLine +
, O +
cell O +
surface O +
expression O +
of O +
the O +
human O +
HLA O -
- O -
DQ O +
heterodimer O +
was O +
not O +
observed O +
. O +

This O +
result O +
was O +
not O +
attributable O +
to O +
lack O +
of O +
HLA O -
- O -
DQ O +
alpha O +
or O +
-DQ O +
beta O +
transcription O +
, O +
because O +
both O +
transcripts O +
were O +
present O +
in O +
the O +
CIITA B-CellLine -
- I-CellLine -
transfected I-CellLine +
hybrids I-CellLine +
, O +
although O +
at O +
reduced O +
levels O +
. O +

These O +
findings O +
further O +
support O +
our O +
previous O +
observations O +
on O +
the O +
distinct O +
regulation O +
of O +
expression O +
of O +
the O +
human O +
HLA O -
- O -
DQ O +
class O +
II O +
subset O +
, O +
which O +
may O +
be O +
thus O +
controlled O +
at O +
the O +
posttranscriptional O +
level O +
by O +
a O +
CIITA O +
-independent O +
mechanism O +
. O +

Chromosome O +
1 O +
aneusomy O +
with O +
1p36 O +
under O -
- O -
representation O +
is O +
related O +
to O +
histologic O +
grade O +
, O +
DNA O +
aneuploidy O +
, O +
high O +
c O -
- O -
erb O +
B-2 O +
and O +
loss O +
of O +
bcl-2 O +
expression O +
in O +
ductal O +
breast O +
carcinoma O +
. O +

Chromosome O +
1 O +
abnormalities O +
with O +
loss O +
of O +
1p36 O +
have O +
been O +
investigated O +
in O +
95 O +
breast O -
- O -
cancer O +
samples O +
by O +
means O +
of O +
a O +
dual O -
- O -
target O +
fluorescence O +
in O -
- O -
situ O +
hybridization O +
( O +
FISH O +
) O +
technique O +
using O +
the O +
pUC O +
1.77 O +
and O +
p1 O -
- O -
79 O +
probes O +
, O +
specific O +
for O +
the O +
1q12 O +
and O +
1p36 O +
regions O +
, O +
respectively O +
. O +

Abnormalities O +
for O +
one O +
or O +
both O +
probes O +
were O +
detected O +
in O +
83 O -
/ O -
95 O +
samples O +
. O +

Relative O +
1p36 O +
under O -
- O -
representation O +
was O +
found O +
in O +
79 O -
/ O -
95 O +
. O +

The O +
clinical O +
relevance O +
of O +
these O +
alterations O +
was O +
studied O +
by O +
comparing O +
the O +
FISH O +
results O +
with O +
several O +
parameters O +
currently O +
used O +
in O +
breast O -
- O -
cancer O +
pathology O +
. O +

Distinct O +
patterns O +
of O +
chromosome O +
1 O +
abnormalities O +
were O +
found O +
among O +
the O +
histologic O +
types O +
of O +
breast O +
carcinoma O +
. O +

Lobular O +
or O +
mucinous O +
samples O +
showed O +
few O +
or O +
no O +
alterations O +
, O +
whereas O +
most O +
ductal O +
samples O +
had O +
high O +
chromosome O +
1 O +
polysomy O +
with O +
under O -
- O -
representation O +
of O +
1p36 O +
. O +

In O +
ductal O +
carcinomas O +
, O +
chromosome O +
1 O +
alterations O +
increased O +
with O +
histologic O +
grade O +
, O +
DNA O +
aneuploidy O +
, O +
loss O +
of O +
bcl-2 O +
and O +
high O +
c O -
- O -
erb O +
B-2 O +
expression O +
. O +

These O +
associations O +
were O +
found O +
to O +
be O +
statistically O +
significant O +
. O +

No O +
correlation O +
between O +
chromosome O +
1 O +
alterations O +
and O +
nuclear O +
grade O +
, O +
age O +
, O +
size O +
, O +
lymph O -
- O -
node O +
involvement O +
, O +
hormonal O +
receptor O +
presence O +
, O +
proliferation O +
activity O +
or O +
p53 O +
protein O +
expression O +
was O +
detected O +
. O +

These O +
results O +
indicate O +
the O +
utility O +
of O +
this O +
FISH O +
technique O +
for O +
a O +
better O +
definition O +
of O +
the O +
biological O +
characteristics O +
of O +
ductal O +
carcinomas O +
. O +

Nasal O +
NK- O +
and O +
T O -
- O -
cell O +
lymphomas O +
share O +
the O +
same O +
type O +
of O +
Epstein O -
- O -
Barr O +
virus O +
latency O +
as O +
nasopharyngeal O +
carcinoma O +
and O +
Hodgkin O +
's O +
disease O +
. O +

Nasal O +
T O -
/ O -
NK O -
- O -
cell O +
lymphomas O +
can O +
be O +
further O +
separated O +
into O +
those O +
of O +
natural O +
killer O +
( O +
NK O +
) O +
cell O +
lineage O +
or O +
of O +
T O -
- O -
cell O +
lineage O +
, O +
with O +
differences O +
in O +
cellular O +
phenotype O +
, O +
T O -
- O -
cell O +
receptor O +
( O +
TcR O +
) O +
gene O +
rearrangement O +
and O +
TcR O +
transcript O +
expression O +
. O +

Both O +
NK- O +
and O +
T O -
- O -
cell O +
subtypes O +
are O +
closely O +
associated O +
with O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
. O +

In O +
this O +
study O +
, O +
EBV O +
gene O +
expression O +
was O +
determined O +
in O +
23 O +
cases O +
of O +
nasal O +
lymphoma O +
( O +
NL O +
) O +
by O +
in O +
situ O +
hybridisation O +
( O +
ISH O +
) O +
, O +
reverse O +
transcriptase O +
-polymerase O +
chain O +
reaction O +
( O +
RT O -
- O -
PCR O +
) O +
and O +
immunohistochemistry O +
( O +
IH O +
) O +
. O +

Of O +
the O +
23 O +
cases O +
, O +
19 O +
were O +
classified O +
as O +
NK O -
- O -
cell O +
and O +
4 O +
as O +
T O -
- O -
cell O +
tumours O +
. O +

ISH O +
for O +
EBV O -
- O -
encoded O +
small O +
non O -
- O -
polyadenylated O +
RNAs O +
showed O +
that O +
all O +
cases O +
, O +
whether O +
NK O +
or O +
T O +
, O +
harboured O +
EBV O +
in O +
virtually O +
all O +
tumour O +
cells O +
. O +

RT O -
- O -
PCR O +
demonstrated O +
that O +
NL O +
of O +
both O +
subtypes O +
expressed O +
EBNAI O +
of O +
the O +
QUK O +
splice O +
pattern O +
, O +
the O +
latent O +
membrane O +
proteins O +
, O +
LMP1 O +
and O +
2 O +
and O +
the O +
BamHI O +
A O +
rightward O +
transcripts O +
in O +
the O +
absence O +
of O +
EBNA2 O +
mRNAs O +
, O +
compatible O +
with O +
the O +
latency O +
type O +
II O +
pattern O +
. O +

In O +
addition O +
, O +
analysis O +
of O +
EBV O +
protein O +
expression O +
by O +
IH O +
revealed O +
a O +
heterogeneous O +
pattern O +
of O +
EBV O +
gene O +
expression O +
at O +
the O +
single O -
- O -
cell O +
level O +
consisting O +
of O +
both O +
LMP1 O -
+ O +
and O +
LMP1- O +
tumour O +
cells O +
, O +
suggesting O +
a O +
mixture O +
of O +
latency O +
I O +
and O +
II O +
. O +

Although O +
2 O +
early O +
lytic O +
transcripts O +
, O +
BZLF1 O +
and O +
BHRF1 O +
, O +
were O +
also O +
detected O +
in O +
13 O +
and O +
10 O +
cases O +
, O +
respectively O +
, O +
the O +
lack O +
of O +
ZEBRA O +
staining O +
in O +
any O +
case O +
indicates O +
that O +
these O +
lytic O +
transcripts O +
are O +
most O +
likely O +
expressed O +
by O +
rare O +
cells O +
in O +
the O +
biopsies O +
entering O +
lytic O +
cycle O +
. O +

The O +
viral O +
transcriptional O +
pattern O +
similar O +
to O +
that O +
of O +
nasopharyngeal O +
carcinoma O +
and O +
Hodgkin O +
's O +
disease O +
suggests O +
that O +
EBV O +
can O +
exploit O +
common O +
regulatory O +
mechanisms O +
for O +
gene O +
transcription O +
in O +
diverse O +
host O +
cell O +
types O +
. O +

Down O -
- O -
regulation O +
of O +
immunogenic O +
proteins O +
( O +
EBNA2-EBNA6 O +
) O +
in O +
nasal O +
lymphoma O +
may O +
enable O +
tumour O +
cells O +
to O +
evade O +
host O +
cytotoxic O +
T O -
- O -
cell O +
surveillance O +
. O +

Presence O +
of O +
a O +
variant O +
form O +
of O +
the O +
estrogen O +
receptor O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
from O +
normal O +
individuals O +
and O +
lupus O +
patients O +
. O +

Estrogen O +
may O +
participate O +
in O +
the O +
pathogenesis O +
of O +
systemic O +
lupus O +
erythematosus O +
( O +
SLE O +
) O +
via O +
its O +
intracellular O +
receptor O +
. O +

To O +
investigate O +
the O +
presence O +
of O +
various O +
isoforms O +
of O +
the O +
estrogen O +
receptor O +
( O +
ER O +
) O +
in O +
SLE O +
we O +
isolated O +
RNA O +
from O +
mononuclear O +
cells O +
of O +
lupus O +
patients O +
and O +
normal O +
controls O +
. O +

Using O +
RT O -
- O -
PCR O +
we O +
were O +
able O +
to O +
identify O +
both O +
the O +
full O +
length O +
wild O -
- O -
type O +
form O +
and O +
an O +
isoform O +
of O +
the O +
ER O +
which O +
precisely O +
lacks O +
exon O +
V O +
in O +
both O +
patient O +
and O +
normal O +
individuals O +
. O +

Our O +
results O +
, O +
although O +
limited O +
, O +
suggest O +
that O +
normal O +
individuals O +
can O +
express O +
both O +
the O +
wild O -
- O -
type O +
and O +
truncated O +
version O +
at O +
the O +
same O +
time O +
, O +
whereas O +
lupus O +
patients O +
only O +
express O +
either O +
the O +
wild O -
- O -
type O +
or O +
the O +
truncated O +
ER O +
. O +

This O +
finding O +
may O +
lead O +
to O +
a O +
better O +
understanding O +
of O +
the O +
reasons O +
for O +
the O +
prevalence O +
of O +
lupus O +
in O +
females O +
and O +
of O +
the O +
estrogenic O +
effects O +
on O +
SLE O +
disease O +
activity O +
. O +

Stat3 O +
recruitment O +
by O +
two O +
distinct O +
ligand O -
- O -
induced O +
, O +
tyrosine O -
- O -
phosphorylated O +
docking O +
sites O +
in O +
the O +
interleukin-10 O +
receptor O +
intracellular O +
domain O +
. O +

Recent O +
work O +
has O +
shown O +
that O +
IL-10 O +
induces O +
activation O +
of O +
the O +
JAK O +
-STAT O +
signaling O +
pathway O +
. O +

To O +
define O +
the O +
mechanism O +
underlying O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
( O +
STAT O +
) O +
protein O +
recruitment O +
to O +
the O +
interleukin O +
10 O +
( O +
IL-10 O +
) O +
receptor O +
, O +
the O +
STAT O +
proteins O +
activated O +
by O +
IL-10 O +
in O +
different O +
cell O +
populations O +
were O +
first O +
defined O +
using O +
electrophoretic O +
mobility O +
shift O +
assays O +
. O +

In O +
all O +
cells O +
tested O +
, O +
IL-10 O +
activated O +
Stat1 O +
and O +
Stat3 O +
and O +
induced O +
the O +
formation O +
of O +
three O +
distinct O +
DNA O +
binding O +
complexes O +
that O +
contained O +
different O +
combinations O +
of O +
these O +
two O +
transcription O +
factors O +
. O +

IL-10 O +
also O +
activated O +
Stat5 O +
in O +
Ba B-CellLine -
/ I-CellLine -
F3 I-CellLine +
cells I-CellLine +
that O +
stably O +
expressed O +
the O +
murine O +
IL-10 O +
receptor O +
. O +

Using O +
a O +
structure O -
- O -
function O +
mutagenesis O +
approach O +
, O +
two O +
tyrosine O +
residues O +
( O +
Tyr427 O +
and O +
Tyr477 O +
) O +
in O +
the O +
intracellular O +
domain O +
of O +
the O +
murine O +
IL-10 O +
receptor O +
were O +
found O +
to O +
be O +
redundantly O +
required O +
for O +
receptor O +
function O +
and O +
for O +
activation O +
of O +
Stat3 O +
but O +
not O +
for O +
Stat1 O +
or O +
Stat5 O +
. O +

Twelve O +
amino O +
acid O +
peptides O +
encompassing O +
either O +
of O +
these O +
two O +
tyrosine O +
residues O +
in O +
phosphorylated O +
form O +
coprecipitated O +
Stat3 O +
but O +
not O +
Stat1 O +
and O +
blocked O +
IL-10 O +
-induced O +
Stat3 O +
phosphorylation O +
in O +
a O +
cell O -
- O -
free O +
system O +
. O +

In O +
contrast O +
, O +
tyrosine O -
- O -
phosphorylated O +
peptides O +
containing O +
Tyr374 O +
or O +
Tyr396 O +
did O +
not O +
interact O +
with O +
Stat3 O +
or O +
block O +
Stat3 O +
activation O +
. O +

These O +
data O +
demonstrate O +
that O +
Stat3 O +
but O +
not O +
Stat1 O +
or O +
Stat5 O +
is O +
directly O +
recruited O +
to O +
the O +
ligand O -
- O -
activated O +
IL-10 O +
receptor O +
by O +
binding O +
to O +
specific O +
but O +
redundant O +
receptor O +
intracellular O +
domain O +
sequences O +
containing O +
phosphotyrosine O +
. O +

This O +
study O +
thus O +
supports O +
the O +
concept O +
that O +
utilization O +
of O +
distinct O +
STAT O +
proteins O +
by O +
different O +
cytokine O +
receptors O +
is O +
dependent O +
on O +
the O +
expression O +
of O +
particular O +
ligand O -
- O -
activatable O +
, O +
tyrosine O -
- O -
containing O +
STAT O +
docking O +
sites O +
in O +
receptor O +
intracellular O +
domains O +
. O +

T O -
- O -
cell O +
-directed O +
TAL-1 O +
expression O +
induces O +
T O -
- O -
cell O +
malignancies O +
in O +
transgenic O +
mice O +
. O +

The O +
TAL-1 O +
gene O +
specifies O +
for O +
a O +
basic O +
domain O -
- O -
helix O -
- O -
loop O -
- O -
helix O +
protein O +
, O +
which O +
is O +
involved O +
in O +
the O +
control O +
of O +
normal O +
hematopoiesis O +
. O +

In O +
human O +
pathology O +
, O +
the O +
TAL-1 O +
gene O +
product O +
is O +
expressed O +
in O +
a O +
high O +
percentage O +
of O +
T O -
- O -
cell O +
acute O +
lymphoblastic O +
leukemias O +
in O +
the O +
pediatric O +
age O +
range O +
; O +
however O +
, O +
it O +
has O +
not O +
been O +
established O +
whether O +
the O +
expression O +
has O +
a O +
causal O +
role O +
in O +
oncogenesis O +
. O +

In O +
this O +
report O +
, O +
we O +
describe O +
the O +
phenotype O +
of O +
mouse B-CellLine +
transgenic I-CellLine +
lines I-CellLine +
obtained O +
by O +
inducing O +
tal-1 O +
protein O +
expression O +
in O +
lymphoid O +
tissues O +
using O +
the O +
LCK O +
promoter O +
. O +

The O +
survival O +
rate O +
of O +
tal-1 O +
transgenic O +
animals O +
was O +
much O +
lower O +
as O +
compared O +
with O +
control O +
mice O +
. O +

Histopathological O +
analysis O +
revealed O +
lymphomas O +
of O +
T O -
- O -
cell O +
type O +
, O +
often O +
comprising O +
a O +
minor O +
B O -
- O -
cell O +
component O +
. O +

Some O +
mice O +
showed O +
marked O +
splenic O +
lymphocyte O +
depletion O +
. O +

Primary B-CellLine +
lymphocyte I-CellLine +
cultures I-CellLine +
showed O +
partial O +
independence O +
from O +
exogenous O +
growth O +
stimuli O +
and O +
increased O +
resistance O +
to O +
low O -
- O -
serum O +
apoptosis O +
. O +

To O +
further O +
unravel O +
the O +
tal-1 O +
oncogenic O +
potential O +
, O +
a O +
strain O +
of O +
tal-1 O +
transgenic O +
mice O +
was O +
crossbred O +
with O +
p53- O -
/ O -
- O +
mice O +
; O +
the O +
survival O +
rate O +
in O +
these O +
animals O +
was O +
reduced O +
by O +
more O +
than O +
one O -
- O -
half O +
when O +
compared O +
with O +
that O +
of O +
tal-1 O +
mice O +
, O +
and O +
histopathological O +
analysis O +
revealed O +
exclusively O +
T O -
- O -
cell O +
lymphomas O +
. O +

These O +
data O +
indicate O +
that O +
TAL-1 O +
, O +
expressed O +
in O +
T O +
cells O +
, O +
is O +
per O +
se O +
a O +
potent O +
oncogene O +
, O +
which O +
may O +
exert O +
a O +
key O +
leukemogenetic O +
role O +
in O +
the O +
majority O +
of O +
T O -
- O -
cell O +
acute O +
lymphoblastic O +
leukemias O +
. O +

Naive O +
( O +
CD45RA+ O +
) O +
T O +
lymphocytes O +
are O +
more O +
sensitive O +
to O +
oxidative O +
stress O -
- O -
induced O +
signals O +
than O +
memory O +
( O +
CD45RO+ O +
) O +
cells O +
. O +

Formation O +
of O +
reactive O +
oxygen O +
intermediates O +
( O +
ROI O +
) O +
after O +
oxidative O +
stress O +
has O +
been O +
shown O +
to O +
be O +
an O +
activation O +
signal O +
for O +
T O +
lymphocytes O +
, O +
e.g. O +
, O +
expression O +
of O +
IL-2 O +
and O +
its O +
receptor O +
are O +
induced O +
. O +

These O +
ROI O -
- O -
induced O +
effects O +
can O +
, O +
to O +
a O +
large O +
extent O +
, O +
be O +
attributed O +
to O +
the O +
activation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
. O +

Now O +
we O +
have O +
examined O +
whether O +
naive O +
and O +
memory O +
T O +
lymphocytes O +
differ O +
in O +
their O +
sensitivity O +
to O +
ROI O -
- O -
mediated O +
signals O +
. O +

When O +
CD45RA+ O +
( O +
naive O +
) O +
and O +
CD45RO+ O +
( O +
memory O +
) O +
T O +
lymphocytes O +
were O +
directly O +
stimulated O +
with O +
H2O2 O +
, O +
NF O -
- O -
kappaB O +
nuclear O +
translocation O +
was O +
stronger O +
in O +
naive O +
cells O +
than O +
in O +
memory O +
cells O +
and O +
it O +
could O +
be O +
induced O +
with O +
lower O +
doses O +
. O +

The O +
composition O +
of O +
the O +
induced O +
nuclear O +
NF O -
- O -
kappaB O +
( O +
levels O +
of O +
p50 O +
and O +
RelA O +
proteins O +
) O +
was O +
similar O +
in O +
these O +
cell O +
types O +
. O +

The O +
magnitude O +
and O +
kinetics O +
of O +
intracellular O +
ROI O +
were O +
similar O +
, O +
suggesting O +
that O +
there O +
were O +
no O +
differences O +
in O +
ROI O -
- O -
forming O +
mechanisms O +
or O +
antioxidative O +
capacities O +
. O +

The O +
probable O +
regulatory O +
point O +
was O +
the O +
cytoplasmic O +
IkappaB O +
inhibitor O +
: O +
in O +
CD45RA+ O +
cells O +
, O +
H2O2 O +
caused O +
a O +
more O +
profound O +
depression O +
in O +
the O +
levels O +
of O +
IkappaB O +
alpha O +
. O +

These O +
findings O +
indicate O +
that O +
T O +
cells O +
representing O +
different O +
activation O +
and/or O +
differentiation O +
stages O +
can O +
be O +
differentially O +
responsive O +
to O +
ROI O -
- O -
mediated O +
signals O +
. O +

Potent O +
gene O +
regulatory O +
and O +
antiproliferative O +
activities O +
of O +
20-methyl O +
analogues O +
of O +
1 O +
, O +
25 O +
dihydroxyvitamin O +
D3 O +
. O +

The O +
biological O +
active O +
form O +
of O +
vitamin O +
D3 O +
, O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
VD O +
) O +
, O +
regulates O +
cellular O +
growth O +
and O +
differentiation O +
. O +

This O +
provides O +
the O +
hormone O +
with O +
an O +
interesting O +
therapeutic O +
potential O +
. O +

However O +
, O +
hypercalcemia O +
is O +
a O +
side O +
effect O +
, O +
which O +
is O +
caused O +
by O +
VD O +
's O +
classical O +
action O +
, O +
the O +
regulation O +
of O +
calcium O +
homeostasis O +
. O +

This O +
made O +
the O +
need O +
for O +
VD O +
analogues O +
with O +
selectively O +
increased O +
cell O +
regulatory O +
properties O +
. O +

Studies O +
with O +
20-epi O +
analogues O +
pointed O +
out O +
the O +
importance O +
of O +
the O +
carbon-20 O +
position O +
and O +
led O +
to O +
the O +
development O +
of O +
20-methyl O +
derivatives O +
of O +
VD O +
. O +

In O +
this O +
report O +
the O +
biological O +
properties O +
of O +
the O +
compounds O +
ZK161422 O +
and O +
ZK157202 O +
, O +
which O +
are O +
20-methyl- O +
and O +
20-methyl-23-eneanalogues O +
, O +
respectively O +
, O +
have O +
been O +
analyzed O +
in O +
comparison O +
with O +
VD O +
. O +

Both O +
compounds O +
show O +
about O +
2-fold O +
lower O +
affinity O +
to O +
the O +
VD O +
receptor O +
( O +
VDR O +
) O +
than O +
VD O +
. O +

However O +
, O +
compared O +
to O +
VD O +
, O +
their O +
antiproliferative O +
effect O +
is O +
up O +
to O +
30-fold O +
higher O +
on O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
and O +
even O +
up O +
to O +
300-fold O +
higher O +
on O +
human B-CellLine +
breast I-CellLine +
cancer I-CellLine +
MCF-7 I-CellLine +
cells I-CellLine +
. O +

Whereas O +
the O +
hypercalcemic O +
effect O +
for O +
ZK157202 O +
is O +
also O +
increased O +
10-fold O +
, O +
ZK161422 O +
has O +
the O +
same O +
calcium O -
- O -
mobilizing O +
potency O +
as O +
VD O +
. O +

Moreover O +
, O +
ZK161422 O +
, O +
but O +
not O +
ZK157202 O +
, O +
showed O +
preference O +
for O +
gene O +
activation O +
from O +
a O +
promoter O +
carrying O +
a O +
VD O +
response O +
element O +
with O +
a O +
palindromic O +
arrangement O +
of O +
two O +
hexameric O +
receptor O +
binding O +
sites O +
spaced O +
by O +
9 O +
nucleotides O +
( O +
IP9 O +
) O +
rather O +
than O +
for O +
activation O +
from O +
a O +
response O +
element O +
formed O +
by O +
a O +
direct O +
repeat O +
spaced O +
by O +
3 O +
nucleotides O +
( O +
DR3 O +
) O +
. O +

This O +
observation O +
supports O +
a O +
model O +
, O +
in O +
which O +
promoter O +
selectivity O +
reflects O +
the O +
selectively O +
increased O +
antiproliferative O +
effect O +
of O +
VD O +
analogues O +
. O +

Generation O +
of O +
CD1+RelB+ O +
dendritic O +
cells O +
and O +
tartrate O -
- O -
resistant O +
acid O +
phosphatase O -
- O -
positive O +
osteoclast O -
- O -
like O +
multinucleated O +
giant O +
cells O +
from O +
human O +
monocytes O +
. O +

We O +
previously O +
showed O +
that O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
and O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
M O -
- O -
CSF O +
) O +
stimulate O +
the O +
differentiation O +
of O +
human O +
monocytes O +
into O +
two O +
phenotypically O +
distinct O +
types O +
of O +
macrophages O +
. O +

However O +
, O +
in O +
vivo O +
, O +
not O +
only O +
CSF O +
but O +
also O +
many O +
other O +
cytokines O +
are O +
produced O +
under O +
various O +
conditions O +
. O +

Those O +
cytokines O +
may O +
modulate O +
the O +
differentiation O +
of O +
monocytes O +
by O +
CSFs O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
showed O +
that O +
CD14 O -
+ O +
adherent O +
human O +
monocytes O +
can O +
differentiate O +
into O +
CD1+relB+ O +
dendritic O +
cells O +
( O +
DC O +
) O +
by O +
the O +
combination O +
of O +
GM O -
- O -
CSF O +
plus O +
interleukin-4 O +
( O +
IL-4 O +
) O +
and O +
that O +
they O +
differentiate O +
into O +
tartrate O -
- O -
resistant O +
acid O +
phosphatase O +
( O +
TRAP O +
) O +
-positive O +
osteoclast O -
- O -
like O +
multinucleated O +
giant O +
cells O +
( O +
MGC O +
) O +
by O +
the O +
combination O +
of O +
M O -
- O -
CSF O +
plus O +
IL-4 O +
. O +

However O +
, O +
the O +
monocyte B-CellLine -
- I-CellLine -
derived I-CellLine +
DC I-CellLine +
were O +
not O +
terminally B-CellLine +
differentiated I-CellLine +
cells I-CellLine +
; O +
they O +
could O +
still O +
convert O +
to O +
macrophages O +
in O +
response O +
to O +
M O -
- O -
CSF O +
. O +

Tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
stimulated O +
the O +
terminal O +
differentiation O +
of O +
the O +
DC O +
by O +
downregulating O +
the O +
expression O +
of O +
the O +
M O -
- O -
CSF O +
receptor O +
, O +
cfms O +
mRNA O +
, O +
and O +
aborting O +
the O +
potential O +
to O +
convert O +
to O +
macrophages O +
. O +

In O +
contrast O +
to O +
IL-4 O +
, O +
interferon O -
- O -
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
had O +
no O +
demonstrable O +
effect O +
on O +
the O +
differentiation O +
of O +
monocytes O +
. O +

Rather O +
, O +
IFN O -
- O -
gamma O +
antagonized O +
the O +
effect O +
of O +
IL-4 O +
and O +
suppressed O +
the O +
DC O +
and O +
MGC O +
formation O +
induced O +
by O +
GM O -
- O -
CSF O +
+ O +
IL-4 O +
and O +
M O -
- O -
CSF O +
+ O +
IL-4 O +
, O +
respectively O +
. O +

Taken O +
together O +
, O +
these O +
results O +
provide O +
a O +
new O +
aspect O +
to O +
our O +
knowledge O +
of O +
monocyte O +
differentiation O +
and O +
provide O +
evidence O +
that O +
human O +
monocytes O +
are O +
flexible O +
in O +
their O +
differentiation O +
potential O +
and O +
are O +
precursors O +
not O +
only O +
of O +
macrophages O +
but O +
also O +
of O +
CD1+relB+DC O +
and O +
TRAP O -
- O -
positive O +
MGC O +
. O +

Such O +
a O +
diverse O +
pathway O +
of O +
monocyte O +
differentiation O +
may O +
constitute O +
one O +
of O +
the O +
basic O +
mechanisms O +
of O +
immune O +
regulation O +
. O +

Regulation O +
of O +
[ O +
Ca2 O -
+ O +
] O +
i O +
rise O +
activated O +
by O +
doxepin O -
- O -
sensitive O +
H1-histamine O +
receptors O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
cloned B-CellLine +
human I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
. O +

To O +
clarify O +
the O +
presence O +
of O +
histamine O +
receptor O +
and O +
its O +
transmembrane O +
mechanism O +
in O +
human O +
T O +
lymphocytes O +
, O +
we O +
investigated O +
the O +
effects O +
of O +
agonists O +
or O +
antagonists O +
of O +
histamine O +
receptor O +
subtypes O +
and O +
bacterial O +
toxins O +
on O +
intracellular O +
concentration O +
of O +
Ca2 O -
+ O +
[ O +
Ca2 O -
+ O +
] O +
i O +
) O +
, O +
[ O +
3H O +
] O +
pyrilamine O +
binding O +
and O +
c O -
- O -
fos O +
mRNA O +
expression O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
cloned O +
human O +
T O +
lymphocytes O +
. O +

H1-agonists O +
( O +
histamine O +
and O +
2-methylhistamine O +
) O +
caused O +
a O +
transient O +
rise O +
of O +
[ O +
Ca2 O -
+ O +
] O +
, O +
and O +
H1-antagonists O +
( O +
pyrilamine O +
and O +
doxepin O +
) O +
inhibited O +
the O +
histamine O -
- O -
induced O +
[ O +
Ca2 O -
+ O +
] O +
i O +
rise O +
more O +
potently O +
than O +
the O +
H2-antagonist O +
( O +
cimetidine O +
) O +
on O +
the O +
H3-antagonist O +
( O +
impromidine O +
) O +
. O +

Binding O +
parameters O +
of O +
[ O +
3H O +
] O +
pyrilamine O +
binding O +
were O +
Kd O +
= O +
5.53 O +
nM O +
and O +
Bmax O +
= O +
2 O +
, O +
647 O +
sites O -
/ O -
cell O +
. O +

Pretreatment O +
with O +
B.pertussis O +
, O +
V.cholera O -
. O +
or O +
C.botulinum O +
toxin O +
did O +
not O +
influence O +
histamine O -
- O -
induced O +
[ O +
Ca2 O -
+ O +
] O +
i O +
rise O +
. O +

Western O +
Blot O +
analysis O +
using O +
antibodies O +
against O +
subunits O +
of O +
GTP O -
- O -
binding O +
proteins O +
indicated O +
that O +
Gq O -
/ O -
G11 O +
richly O +
existed O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

Histamine O +
induced O +
mRNA O +
expression O +
of O +
an O +
immediate O +
early O +
gene O +
c O -
- O -
fos O +
. O +

Pretreatment O +
with O +
a O +
protein O +
kinase O +
C O +
activator O +
, O +
phorbol O +
12-myristate O +
13-acetate O +
, O +
caused O +
almost O +
complete O +
inhibition O +
of O +
histamine O -
- O -
induced O +
[ O +
Ca2 O -
+ O +
] O +
i O +
rise O +
, O +
but O +
did O +
not O +
do O +
so O +
by O +
activators O +
of O +
cAMP- O +
and O +
cGMP O -
- O -
dependent O +
protein O +
kinases O +
. O +

Signal O +
transduction O +
by O +
DR3 O +
, O +
a O +
death O +
domain O -
- O -
containing O +
receptor O +
related O +
to O +
TNFR-1 O +
and O +
CD95 O +
. O +

Tumor O +
necrosis O +
factor O +
receptor-1 O +
( O +
TNFR-1 O +
) O +
and O +
CD95 O +
( O +
also O +
called O +
Fas O +
or O +
APO-1 O +
) O +
are O +
cytokine O +
receptors O +
that O +
engage O +
the O +
apoptosis O +
pathway O +
through O +
a O +
region O +
of O +
intracellular O +
homology O +
, O +
designated O +
the O +
` O -
` O +
death O +
domain O +
. O +
'' O +
Another O +
death O +
domain O -
- O -
containing O +
member O +
of O +
the O +
TNFR O +
family O +
, O +
death O +
receptor O +
3 O +
( O +
DR3 O +
) O +
, O +
was O +
identified O +
and O +
was O +
shown O +
to O +
induce O +
both O +
apoptosis O +
and O +
activation O +
of O +
nuclear O +
factor O +
kappaB O +
. O +

Expression O +
of O +
DR3 O +
appears O +
to O +
be O +
restricted O +
to O +
tissues O +
enriched O +
in O +
lymphocytes O +
. O +

DR3 O +
signal O +
transduction O +
is O +
mediated O +
by O +
a O +
complex O +
of O +
intracellular O +
signaling O +
molecules O +
including O +
TRADD O +
, O +
TRAF2 O +
, O +
FADD O +
, O +
and O +
FLICE O +
. O +

Thus O +
, O +
DR3 O +
likely O +
plays O +
a O +
role O +
in O +
regulating O +
lymphocyte O +
homeostasis O +
. O +

Regulation O +
of O +
cytokine O +
and O +
cytokine O +
receptor O +
expression O +
by O +
glucocorticoids O +
. O +

Glucocorticoids O +
( O +
GCS O +
) O +
profoundly O +
inhibit O +
several O +
aspects O +
of O +
T O +
cell O +
immunity O +
largely O +
through O +
inhibition O +
of O +
cytokine O +
expression O +
at O +
the O +
transcriptional O +
and O +
posttranscriptional O +
levels O +
. O +

GCS O +
were O +
also O +
reported O +
to O +
act O +
indirectly O +
by O +
inducing O +
transforming O +
growth O +
factor O -
- O -
beta O +
expression O +
, O +
which O +
in O +
turn O +
blocks O +
T O +
cell O +
immunity O +
. O +

In O +
exerting O +
their O +
antiproliferative O +
effects O +
, O +
GCS O +
diffuse O +
into O +
target O +
cells O +
where O +
they O +
bind O +
their O +
cytoplasmic O +
receptor O +
, O +
which O +
in O +
turn O +
translocates O +
to O +
the O +
nucleus O +
where O +
it O +
inhibits O +
transcription O +
of O +
cytokine O +
genes O +
through O +
direct O +
binding O +
to O +
the O +
glucocorticoid O +
response O +
elements O +
( O +
GRE O +
) O +
, O +
which O +
are O +
located O +
in O +
the O +
promoter O +
region O +
of O +
cytokine O +
genes O +
or O +
, O +
alternatively O +
, O +
through O +
antagonism O +
of O +
the O +
action O +
of O +
transcription O +
factors O +
required O +
for O +
optimal O +
transcriptional O +
activation O +
. O +

In O +
contrast O +
to O +
their O +
inhibitory O +
effects O +
on O +
cytokine O +
expression O +
, O +
GCS O +
up O -
- O -
regulate O +
cytokine O +
receptor O +
expression O +
that O +
correlates O +
with O +
enhanced O +
cytokine O +
effects O +
on O +
target O +
cells O +
. O +

In O +
this O +
review O +
, O +
we O +
summarize O +
the O +
current O +
state O +
of O +
knowledge O +
of O +
the O +
mechanism O +
of O +
action O +
of O +
GCS O +
, O +
including O +
the O +
phenomenon O +
of O +
steroid O -
- O -
induced O +
rebound O +
, O +
which O +
ensues O +
upon O +
GCS O +
withdrawal O +
. O +

The O +
Oct-2 O +
transcription O +
factor O +
. O +

The O +
Oct-2 O +
transcription O +
factor O +
is O +
a O +
member O +
of O +
the O +
POU O +
( O +
Pit O -
- O -
Oct O -
- O -
Unc O +
) O +
family O +
of O +
transcription O +
factors O +
and O +
is O +
expressed O +
only O +
in O +
B O +
lymphocytes O +
and O +
in O +
neuronal O +
cells O +
but O +
not O +
in O +
other O +
cell O +
types O +
. O +

The O +
primary O +
RNA O +
transcript O +
of O +
the O +
gene O +
is O +
subject O +
to O +
alternative O +
splicing O +
to O +
yield O +
different O +
variants O +
which O +
can O +
either O +
activate O +
or O +
repress O +
gene O +
expression O +
. O +

The O +
forms O +
produced O +
in O +
B O +
lymphocytes O +
have O +
a O +
predominantly O +
activating O +
effect O +
on O +
gene O +
expression O +
whereas O +
those O +
produced O +
in O +
neuronal O +
cells O +
have O +
a O +
predominantly O +
inhibitory O +
effect O +
and O +
can O +
repress O +
the O +
expression O +
of O +
both O +
the O +
herpes O +
simplex O +
virus O +
immediate O -
- O -
early O +
genes O +
and O +
the O +
cellular O +
tyrosine O +
hydroxylase O +
gene O +
. O +

Thus O +
Oct-2 O +
plays O +
an O +
important O +
role O +
in O +
the O +
regulation O +
of O +
cellular O +
gene O +
expression O +
in O +
both O +
B O +
cells O +
and O +
neuronal O +
cells O +
as O +
well O +
as O +
in O +
the O +
control O +
of O +
viral O +
latency O +
. O +

Cell O +
specific O +
expression O +
of O +
human O +
Bruton O +
's O +
agammaglobulinemia O +
tyrosine O +
kinase O +
gene O +
( O +
Btk O +
) O +
is O +
regulated O +
by O +
Sp1- O +
and O +
Spi-1 O -
/ O -
PU.1-family O +
members O +
. O +

Bruton O +
's O +
agammaglobulinemia O +
tyrosine O +
kinase O +
( O +
Btk O +
) O +
is O +
a O +
cytoplasmic O +
tyrosine O +
kinase O +
involved O +
in O +
the O +
human O +
disease O +
X O -
- O -
linked O +
agammaglobulinemia O +
( O +
XLA O +
) O +
. O +

The O +
gene O +
is O +
expressed O +
in O +
all O +
hematopoietic O +
cells O +
with O +
the O +
exception O +
of O +
T O -
- O -
cells O +
and O +
plasma O +
cells O +
. O +

For O +
this O +
expression O +
pattern O +
the O +
first O +
280 O +
bp O +
upstream O +
of O +
the O +
major O +
transcriptional O +
start O +
site O +
seems O +
to O +
be O +
sufficient O +
. O +

In O +
vitro O +
footprinting O +
analysis O +
within O +
this O +
part O +
of O +
the O +
promoter O +
revealed O +
two O +
Sp1 O +
binding O +
sites O +
as O +
well O +
as O +
a O +
PU O -
- O -
box O +
. O +

The O +
transcription O +
factor O +
Spi-1 O -
/ O -
PU.1 O +
as O +
well O +
as O +
the O +
closely O +
related O +
factor O +
Spi O -
- O -
B O +
bound O +
to O +
the O +
PU O -
- O -
box O +
in O +
B O -
- O -
cells O +
. O +

In O +
the O +
erythroleukemia B-CellLine +
cell I-CellLine +
line I-CellLine +
K562 I-CellLine +
, O +
due O +
to O +
the O +
absence O +
of O +
Spi O -
- O -
B O +
, O +
only O +
PU.1 O +
bound O +
to O +
the O +
Btk O +
promoter O +
. O +

Mutation O +
of O +
either O +
site O +
reduced O +
the O +
expression O +
in O +
transient O +
transfection O +
experiments O +
. O +

However O +
, O +
mutation O +
of O +
the O +
PU O +
box O +
had O +
no O +
effect O +
in O +
the O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
Jurkat I-CellLine +
, O +
where O +
none O +
of O +
the O +
Spi-1 O +
family O +
members O +
is O +
expressed O +
. O +

In O +
addition O +
Spi O -
- O -
B O +
as O +
well O +
as O +
PU.1 O +
were O +
able O +
to O +
transactivate O +
Btk O +
expression O +
. O +

In O +
fetal O +
liver O +
of O +
PU.1- O -
/ O -
- O +
mice O +
, O +
which O +
lack O +
lymphoid O +
and O +
myeloid O +
cells O +
, O +
expression O +
of O +
Btk O +
was O +
reduced O +
two- O +
to O +
threefold O +
but O +
not O +
abolished O +
. O +

Collectively O +
this O +
study O +
shows O +
that O +
expression O +
of O +
the O +
Btk O +
gene O +
is O +
regulated O +
by O +
the O +
combined O +
action O +
of O +
Sp1- O +
and O +
PU.1-family O +
members O +
. O +

Sterol O +
dependent O +
LDL O -
- O -
receptor O +
gene O +
transcription O +
in O +
lymphocytes O +
from O +
normal O +
and O +
CML O +
patients O +
. O +

Sterol O +
regulatory O +
element O +
( O +
SRE O +
) O +
has O +
been O +
recognized O +
to O +
regulate O +
various O +
key O +
genes O +
coding O +
for O +
especially O +
low O +
density O +
lipoprotein O +
( O +
LDL O +
) O +
-receptor O +
, O +
3-hydroxy-3-methylglutaryl O +
coenzyme O +
A O +
( O +
HMG O -
- O -
CoA O +
) O +
reductase O +
and O +
HMG O -
- O -
CoA O +
synthase O +
known O +
to O +
play O +
a O +
crucial O +
role O +
in O +
the O +
cholesterol O +
feedback O +
mechanism O +
. O +

The O +
deranged O +
cholesterol O +
feedback O +
mechanism O +
has O +
been O +
widely O +
recognised O +
in O +
initiation O +
as O +
well O +
as O +
progression O +
of O +
various O +
types O +
of O +
cancers O +
including O +
chronic O +
myeloid O +
leukaemia O +
( O +
CML O +
) O +
. O +

Consequently O +
, O +
the O +
present O +
study O +
was O +
addressed O +
to O +
understand O +
this O +
phenomenon O +
and O +
revealed O +
the O +
existence O +
of O +
a O +
unique O +
47 O +
kDa O +
protein O +
factor O +
having O +
affinity O +
for O +
this O +
SRE O +
sequence O +
in O +
lymphocytes O +
from O +
normal O +
subjects O +
as O +
well O +
as O +
its O +
absence O +
in O +
lymphocytes O +
from O +
untreated O +
CML O +
patients O +
. O +

However O +
, O +
this O +
factor O +
appeared O +
when O +
the O +
CML O +
patients O +
achieved O +
complete O +
haematological O +
remission O +
( O +
CHR O +
) O +
through O +
alpha O -
- O -
interferon O +
therapy O +
. O +

Further O +
, O +
an O +
inverse O +
relationship O +
was O +
also O +
observed O +
between O +
sterol O +
modulated O +
LDL O -
- O -
receptor O +
gene O +
transcription O +
and O +
the O +
binding O +
affinity O +
of O +
this O +
47 O +
kDa O +
factor O +
to O +
the O +
SRE O +
sequence O +
. O +

Based O +
upon O +
these O +
results O +
we O +
propose O +
that O +
alpha O -
- O -
interferon O +
through O +
its O +
receptor O +
initiates O +
phosphatidic O +
acid O +
dependent O +
signalling O +
which O +
in O +
turn O +
regulates O +
the O +
affinity O +
of O +
47 O +
kDa O +
sterol O +
regulatory O +
element O +
binding O +
factor O +
as O +
well O +
as O +
LDL O -
- O -
receptor O +
gene O +
transcription O +
in O +
lymphocytes O +
from O +
CML O +
patients O +
. O +

Effects O +
of O +
Ara O -
- O -
C O +
on O +
neutral O +
sphingomyelinase O +
and O +
mitogen- O +
and O +
stress- O +
activated O +
protein O +
kinases O +
in O +
T B-CellLine -
- I-CellLine -
lymphocyte I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Neutral O +
sphingomyelinase O +
( O +
SMase O +
) O +
can O +
be O +
activated O +
by O +
extracellular O +
signals O +
to O +
produce O +
ceramide O +
, O +
which O +
may O +
affect O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
activities O +
. O +

Neutral O +
SMase O +
activity O +
was O +
assessed O +
in O +
membranes O +
from O +
Jurkat B-CellLine +
, O +
a O +
human B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
, O +
and O +
EL4 B-CellLine +
, O +
a O +
murine B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
. O +

Ara O -
- O -
C O +
activated O +
SMase O +
with O +
10 O +
minutes O +
in O +
both O +
Jurkat O +
and O +
EL4 B-CellLine +
cells I-CellLine +
, O +
while O +
phorbol O +
ester O +
( O +
PMA O +
) O +
had O +
no O +
effect O +
. O +

PMA O +
, O +
but O +
not O +
Ara O -
- O -
C O +
or O +
ceramides O +
, O +
activated O +
ERK O +
MAPKS O +
, O +
in O +
Jurkat B-CellLine +
and O +
EL4 B-CellLine +
. O +

PMA O +
acted O +
synergistically O +
with O +
ionomycin O +
to O +
activate O +
JNK O +
MAPKs O +
in O +
Jurkat B-CellLine +
and O +
EL4 B-CellLine +
within O +
10 O +
minutes O +
. O +

Ara O -
- O -
C O +
activated O +
JNKs O +
only O +
after O +
prolonged O +
incubation O +
( O +
90 O -
- O -
120 O +
minutes O +
) O +
. O +

Thus O +
, O +
ceramide O +
is O +
not O +
a O +
positive O +
signal O +
for O +
ERK O +
activation O +
in O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
. O +

The O +
effects O +
of O +
Ara O -
- O -
C O +
on O +
JNK O +
activity O +
may O +
be O +
mediated O +
through O +
secondary O +
response O +
pathways O +
. O +

Expression O +
of O +
Egr-1 O +
correlates O +
with O +
the O +
transformed O +
phenotype O +
and O +
the O +
type O +
of O +
viral O +
latency O +
in O +
EBV B-CellLine +
genome I-CellLine +
positive I-CellLine +
lymphoid I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

In O +
this O +
paper O +
we O +
have O +
investigated O +
the O +
role O +
of O +
Egr-1 O +
in O +
B O +
cell O +
growth O +
regulation O +
by O +
examining O +
the O +
gene O +
expression O +
in O +
a O +
panel O +
of O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
including O +
both O +
EBV O +
genome O +
negative O +
and O +
EBV B-CellLine +
carrying I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Egr-1 O +
expression O +
correlates O +
with O +
the O +
cellular O +
phenotype O +
and O +
the O +
specific O +
pattern O +
of O +
viral O +
latency O +
established O +
within O +
the O +
individual B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Thus O +
, O +
constitutive O +
activation O +
of O +
Egr-1 O +
gene O +
is O +
invariably O +
associated O +
with O +
unrestricted O +
expression O +
of O +
viral O +
latent O +
genes O +
in O +
all O +
group B-CellLine +
III I-CellLine +
EBV I-CellLine +
genome I-CellLine +
carrying I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

In O +
contrast O +
, O +
Egr-1 O +
expression O +
is O +
abrogated O +
in O +
group B-CellLine +
I I-CellLine +
Burkitt I-CellLine +
tumor I-CellLine +
cells I-CellLine +
, O +
irrespective O +
of O +
the O +
EBV O +
genome O +
carrying O +
status O +
. O +

Activated O +
viral O +
gene O +
expression O +
associated O +
with O +
phenotypic O +
conversion O +
of O +
group B-CellLine +
I I-CellLine +
cell I-CellLine +
lines I-CellLine +
in O +
to O +
group B-CellLine +
II I-CellLine +
or O +
III B-CellLine +
restores O +
the O +
Egr-1 O +
gene O +
expression O +
. O +

Several O +
forms O +
of O +
EGR-1 O +
protein O +
are O +
found O +
within O +
the O +
different O +
groups O +
of O +
cell O +
lines O +
, O +
and O +
the O +
binding O +
activity O +
to O +
DNA O +
consensus O +
sequences O +
was O +
investigated O +
. O +

Finally O +
, O +
time O +
course O +
analysis O +
of O +
Egr-1 O +
expression O +
during O +
the O +
early O +
steps O +
of O +
EBV O +
infection O +
in O +
vitro O +
demonstrated O +
that O +
Egr-1 O +
is O +
upregulated O +
within O +
minutes O +
from O +
the O +
initial O +
interaction O +
with O +
the O +
B O +
lymphocyte O +
. O +

Induction O +
of O +
the O +
CD11b O +
gene O +
during O +
activation O +
of O +
the O +
monocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
U937 I-CellLine +
requires O +
a O +
novel O +
nuclear O +
factor O +
MS-2 O +
[ O +
published O +
erratum O +
appears O +
in O +
J O +
Immunol O +
1999 O +
Jul O +
15 O +
; O +
163 O +
( O +
2 O +
) O +
: O +
1091 O +
] O +

The O +
differentiation O +
of O +
myeloid O +
precursors O +
into O +
mature O +
myelomonocytic O +
cells O +
is O +
characterized O +
by O +
the O +
induction O +
of O +
the O +
gene O +
encoding O +
the O +
beta2 O +
integrin O +
CD11b O +
. O +

The O +
transcription O +
factors O +
Sp1 O +
and O +
PU.1 O +
prime O +
the O +
CD11b O +
promoter O +
, O +
but O +
the O +
nature O +
of O +
the O +
factors O +
responsible O +
for O +
its O +
inducible O +
expression O +
are O +
unknown O +
. O +

In O +
addition O +
to O +
the O +
CD11b O +
gene O +
, O +
the O +
homologous O +
genes O +
encoding O +
CD11a O +
and O +
CD11c O +
also O +
exhibit O +
inducible O +
expression O +
during O +
myeloid O +
differentiation O +
. O +

Therefore O +
, O +
we O +
compared O +
the O +
nucleotide O +
sequences O +
of O +
the O +
CD11a O +
, O +
CD11b O +
, O +
and O +
CD11c O +
gene O +
promoters O +
to O +
identify O +
common O +
elements O +
that O +
might O +
contribute O +
to O +
inducible O +
expression O +
. O +

This O +
analysis O +
identified O +
one O +
such O +
element O +
repeated O +
four O +
times O +
within O +
the O +
CD11b O +
promoter O +
. O +

Mutation O +
of O +
these O +
elements O +
indicated O +
that O +
two O +
, O +
MS-2beta O +
and O +
MS-2gamma O +
, O +
are O +
critical O +
to O +
the O +
induction O +
of O +
the O +
CD11b O +
gene O +
during O +
differentiation O +
of O +
the O +
pro B-CellLine -
- I-CellLine -
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
U937 I-CellLine +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
indicate O +
that O +
MS-2beta O +
and O +
MS-2gamma O +
interact O +
with O +
nuclear O +
factors O +
that O +
are O +
induced O +
during O +
U937 B-CellLine +
differentiation O +
. O +

These O +
factors O +
are O +
detected O +
at O +
the O +
time O +
the O +
CD11b O +
promoter O +
is O +
activated O +
. O +

The O +
molecular O +
mass O +
of O +
these O +
factors O +
is O +
approximately O +
28 O +
kDa O +
, O +
and O +
their O +
DNA O +
binding O +
characteristics O +
are O +
indistinguishable O +
from O +
those O +
of O +
the O +
novel O +
nuclear O +
factor O +
MS-2 O +
. O +

Taken O +
together O +
, O +
our O +
data O +
indicate O +
that O +
MS-2 O +
mediates O +
induction O +
of O +
the O +
CD11b O +
gene O +
as O +
cells O +
of O +
the O +
monocytic O +
lineage O +
mature O +
. O +

The O +
presence O +
of O +
multiple O +
potential O +
binding O +
sites O +
for O +
MS-2 O +
in O +
the O +
promoter O +
regions O +
of O +
a O +
wide O +
range O +
of O +
genes O +
expressed O +
in O +
mature O +
myeloid O +
cells O +
suggests O +
this O +
factor O +
plays O +
a O +
general O +
role O +
in O +
myeloid O +
differentiation O +
. O +

Mutation O +
of O +
tyrosines O +
492 O -
/ O -
493 O +
in O +
the O +
kinase O +
domain O +
of O +
ZAP-70 O +
affects O +
multiple O +
T O -
- O -
cell O +
receptor O +
signaling O +
pathways O +
. O +

The O +
protein O -
- O -
tyrosine O +
kinase O +
ZAP-70 O +
is O +
implicated O +
, O +
together O +
with O +
the O +
Src O +
kinase O +
p56 O +
( O +
lck O +
) O +
, O +
in O +
controlling O +
the O +
early O +
steps O +
of O +
the O +
T O -
- O -
cell O +
antigen O +
receptor O +
( O +
TCR O +
) O +
signaling O +
cascade O +
. O +

To O +
help O +
elucidate O +
further O +
the O +
mechanism O +
by O +
which O +
ZAP-70 O +
regulates O +
these O +
initial O +
events O +
, O +
we O +
used O +
a O +
dominant O -
- O -
negative O +
mutant O +
approach O +
. O +

We O +
overexpressed O +
in O +
the O +
Jurkat B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
ZAP-70 O +
mutated O +
on O +
Tyr-492 O +
and O +
Tyr-493 O +
in O +
the O +
putative O +
regulatory O +
loop O +
of O +
its O +
kinase O +
domain O +
. O +

This O +
mutant O +
inhibited O +
TCR O +
-induced O +
activation O +
of O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
by O +
interfering O +
with O +
both O +
intracellular O +
calcium O +
increase O +
and O +
Ras O +
-regulated O +
activation O +
of O +
extracellular O +
signal O -
- O -
regulated O +
kinases O +
. O +

Moreover O +
, O +
TCR O +
-induced O +
phosphorylation O +
of O +
pp36 O -
- O -
38 O +
, O +
thought O +
to O +
play O +
a O +
role O +
upstream O +
of O +
these O +
pathways O +
, O +
was O +
found O +
to O +
be O +
reduced O +
. O +

In O +
contrast O +
, O +
overexpression O +
of O +
wild O -
- O -
type O +
ZAP-70 O +
induced O +
constitutive O +
activation O +
of O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
. O +

The O +
ZAP-70 O +
mutant O +
studied O +
here O +
could O +
be O +
phosphorylated O +
on O +
tyrosine O +
when O +
associated O +
to O +
the O +
TCR O +
zeta O +
chain O +
and O +
was O +
able O +
to O +
bind O +
p56 O +
( O +
lck O +
) O +
. O +

This O +
result O +
demonstrates O +
that O +
Tyr-492 O +
and O +
Tyr-493 O +
are O +
not O +
responsible O +
for O +
the O +
Src O +
homology O +
domain O +
2-mediated O +
association O +
of O +
p56 O +
( O +
lck O +
) O +
with O +
ZAP-70 O +
. O +

Our O +
data O +
are O +
most O +
consistent O +
with O +
a O +
model O +
in O +
which O +
recruitment O +
to O +
the O +
TCR O +
allows O +
ZAP-70 O +
autophosphorylation O +
and O +
binding O +
to O +
p56 O +
( O +
lck O +
) O +
, O +
which O +
in O +
turn O +
phosphorylates O +
Tyr-492 O +
and/or O +
Tyr-493 O +
with O +
consequent O +
up O -
- O -
regulation O +
of O +
the O +
ZAP-70 O +
kinase O +
activity O +
. O +

ZAP-70 O +
will O +
then O +
be O +
able O +
to O +
effectively O +
control O +
phosphorylation O +
of O +
its O +
substrates O +
and O +
lead O +
to O +
gene O +
activation O +
. O +

Dexamethasone O +
suppression O +
test O +
: O +
corticosteroid O +
receptors O +
regulation O +
in O +
mononuclear O +
leukocytes O +
of O +
young O +
and O +
aged O +
subjects O +
. O +

The O +
dexamethasone O +
suppression O +
test O +
( O +
DST O +
) O +
is O +
considered O +
an O +
indicator O +
of O +
the O +
function O +
of O +
the O +
adrenal O +
pituitary O +
axis O +
. O +

The O +
effect O +
of O +
the O +
steroid O +
is O +
mediated O +
by O +
its O +
binding O +
to O +
corticosteroid O +
receptors O +
. O +

We O +
previously O +
suggested O +
that O +
the O +
measurement O +
of O +
corticosteroid O +
receptors O +
in O +
lymphocytes O +
is O +
an O +
index O +
of O +
an O +
analogous O +
pattern O +
in O +
brain O +
. O +

In O +
the O +
present O +
study O +
, O +
corticosteroid O +
Type O +
I O +
and O +
Type O +
II O +
receptors O +
in O +
mononuclear O +
leukocytes O +
were O +
measured O +
in O +
10 O +
elderly O +
subjects O +
and O +
in O +
9 O +
young O +
adults O +
, O +
before O +
and O +
after O +
overnight O +
DST O +
( O +
1 O +
mg O +
) O +
. O +

Receptors O +
were O +
measured O +
by O +
radioreceptor O +
assay O +
. O +

In O +
all O +
the O +
subjects O +
, O +
dexamethasone O +
was O +
able O +
to O +
suppress O +
plasma O +
cortisol O +
. O +

The O +
number O +
of O +
Type O +
I O +
and O +
Type O +
II O +
receptors O +
before O +
the O +
test O +
was O +
lower O +
in O +
elderly O +
subjects O +
than O +
in O +
adults O +
. O +

In O +
the O +
control O +
group O +
, O +
dexamethasone O +
produced O +
a O +
significant O +
depression O +
of O +
Type O +
I O +
receptors O +
( O +
from O +
267 O +
+ O -
/- O +
72 O +
to O +
169 O +
+ O -
/- O +
71 O +
receptors O +
per O +
cell O +
) O +
, O +
which O +
can O +
be O +
interpreted O +
as O +
a O +
primary O +
involvement O +
of O +
Type O +
I O +
receptors O +
in O +
the O +
response O +
to O +
dexamethasone O +
; O +
Type O +
II O +
receptors O +
decreased O +
in O +
half O +
the O +
subjects O +
( O +
from O +
2849 O +
+ O -
/- O +
703 O +
to O +
2345 O +
+ O -
/- O +
569 O +
receptors O +
per O +
cell O +
) O +
. O +

In O +
elderly O +
healthy O +
subjects O +
, O +
Type O +
II O +
receptors O +
were O +
also O +
significantly O +
decreased O +
( O +
from O +
1796 O +
+ O -
/- O +
671 O +
to O +
720 O +
+ O -
/- O +
345 O +
) O +
. O +

We O +
suggest O +
that O +
in O +
young O +
subjects O +
Type O +
II O +
receptors O +
are O +
initially O +
up O -
- O -
regulated O +
by O +
dexamethasone O +
, O +
and O +
then O +
down O -
- O -
regulated O +
, O +
while O +
in O +
aged O +
subjects O +
an O +
up O -
- O -
regulation O +
can O +
not O +
be O +
achieved O +
, O +
as O +
suggested O +
by O +
the O +
higher O +
values O +
of O +
plasma O +
cortisol O +
usually O +
found O +
in O +
aging O +
subjects O +
. O +

A O +
novel O +
immunosuppressive O +
factor O +
in O +
bovine O +
colostrum O +
blocks O +
activation O +
of O +
the O +
interleukin O +
2 O +
gene O +
enhancer O +
at O +
the O +
NFAT O +
site O +
. O +

A O +
factor O +
in O +
bovine O +
colostrum O +
( O +
colostrum O +
inhibitory O +
factor O +
, O +
CIF O +
) O +
inhibits O +
interleukin O +
2 O +
( O +
IL2 O +
) O +
production O +
in O +
activated O +
T O +
helper O +
cells O +
by O +
blocking O +
the O +
accumulation O +
of O +
IL2 O +
mRNA O +
. O +

To O +
determine O +
whether O +
CIF O +
blocks O +
at O +
the O +
level O +
of O +
IL2 O +
transcription O +
, O +
we O +
introduced O +
reporter O +
plasmids O +
into O +
the O +
human B-CellLine +
T I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
Jurkat I-CellLine +
by O +
transient O +
transfection O +
. O +

These O +
contained O +
the O +
luciferase O +
gene O +
under O +
the O +
control O +
of O +
either O +
the O +
human O +
IL2 O +
upstream O +
enhancer O +
region O +
( O +
segments O +
-326 O +
to O +
+ O -
45 O +
) O +
or O +
three O +
repeats O +
of O +
the O +
NFAT O +
element O +
contained O +
within O +
it O +
( O +
segments O +
-255 O +
to O +
-285 O +
) O +
. O +

Expression O +
of O +
luciferase O +
in O +
these O +
cells O +
was O +
induced O +
by O +
phorbol O +
myristate O +
acetate O +
plus O +
a O +
calcium O +
ionophore O +
. O +

CIF O +
inhibited O +
induction O +
of O +
either O +
construct O +
as O +
did O +
cyclosporine O +
, O +
which O +
is O +
known O +
to O +
block O +
activation O +
of O +
the O +
NFAT O +
element O +
. O +

CIF O +
failed O +
to O +
inhibit O +
several O +
other O +
enhancer O +
elements O +
. O +

The O +
NFAT O -
- O -
controlled O +
luciferase O +
gene O +
system O +
distinguishes O +
CIF O +
from O +
other O +
T O +
cell O +
inhibitory O +
activities O +
present O +
in O +
colostrum O +
, O +
in O +
particular O +
, O +
TGF O +
beta O +
1 O +
and O +
TGF O +
beta O +
2 O +
and O +
the O +
glucocorticoids O +
. O +

Stably O +
transfected O +
Jurkat O +
cells O +
behaved O +
similarly O +
to O +
the O +
transiently O +
transfected O +
ones O +
with O +
respect O +
to O +
inhibition O +
by O +
CIF O +
and O +
cyclosporine O +
. O +

The O +
NFAT O +
-luc O +
assay O +
is O +
a O +
useful O +
technique O +
for O +
the O +
rapid O +
, O +
sensitive O +
measurement O +
of O +
CIF O +
or O +
other O +
immunosuppressants O +
with O +
a O +
similar O +
mode O +
of O +
action O +
. O +

Synergistic O +
interactions O +
between O +
overlapping O +
binding O +
sites O +
for O +
the O +
serum O +
response O +
factor O +
and O +
ELK-1 O +
proteins O +
mediate O +
both O +
basal O +
enhancement O +
and O +
phorbol O +
ester O +
responsiveness O +
of O +
primate O +
cytomegalovirus O +
major O +
immediate O -
- O -
early O +
promoters O +
in O +
monocyte O +
and O +
T O -
- O -
lymphocyte O +
cell O +
types O +
. O +

Cytomegalovirus O +
( O +
CMV O +
) O +
infection O +
is O +
nonpermissive O +
or O +
persistent O +
in O +
many O +
lymphoid O +
and O +
myeloid O +
cell O +
types O +
but O +
can O +
be O +
activated O +
in O +
differentiated O +
macrophages O +
. O +

We O +
have O +
shown O +
elsewhere O +
that O +
both O +
the O +
major O +
immediate O -
- O -
early O +
gene O +
( O +
MIE O +
) O +
and O +
lytic O +
cycle O +
infectious O +
progeny O +
virus O +
expression O +
can O +
be O +
induced O +
in O +
otherwise O +
nonpermissive O +
monocyte B-CellLine -
- I-CellLine -
like I-CellLine +
U-937 I-CellLine +
cell I-CellLine +
cultures I-CellLine +
infected O +
with O +
either O +
human O +
CMV O +
( O +
HCMV O +
) O +
or O +
simian O +
CMV O +
( O +
SCMV O +
) O +
by O +
treatment O +
with O +
the O +
phorbol O +
ester O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
. O +

Two O +
multicopy O +
basal O +
enhancer O +
motifs O +
within O +
the O +
SCMV O +
MIE O +
enhancer O +
, O +
namely O +
, O +
11 O +
copies O +
of O +
the O +
16-bp O +
cyclic O +
AMP O +
response O +
element O +
( O +
CRE O +
) O +
and O +
3 O +
copies O +
of O +
novel O +
17-bp O +
serum O +
response O +
factor O +
( O +
SRF O +
) O +
binding O +
sites O +
referred O +
to O +
as O +
the O +
SNE O +
( O +
SRF O -
/ O -
NFkappaB O -
- O -
like O +
element O +
) O +
, O +
as O +
well O +
as O +
four O +
classical O +
NFkappaB O +
sites O +
within O +
the O +
HCMV O +
version O +
, O +
contribute O +
to O +
TPA O +
responsiveness O +
in O +
transient O +
assays O +
in O +
monocyte O +
and O +
T O -
- O -
cell O +
types O +
. O +

The O +
SCMV O +
SNE O +
sites O +
contain O +
potential O +
overlapping O +
core O +
recognition O +
binding O +
motifs O +
for O +
SRF O +
, O +
Rel O -
/ O -
NFkappaB O +
, O +
ETS O +
, O +
and O +
YY1 O +
class O +
transcription O +
factors O +
but O +
fail O +
to O +
respond O +
to O +
either O +
serum O +
or O +
tumor O +
necrosis O +
factor O +
alpha O +
. O +

Therefore O +
, O +
to O +
evaluate O +
the O +
mechanism O +
of O +
TPA O +
responsiveness O +
of O +
the O +
SNE O +
motifs O +
and O +
of O +
a O +
related O +
16-bp O +
SEE O +
( O +
SRF O -
/ O -
ETS O +
element O +
) O +
motif O +
found O +
in O +
the O +
HCMV O +
and O +
chimpanzee O +
CMV O +
MIE O +
enhancers O +
, O +
we O +
have O +
examined O +
the O +
functional O +
responses O +
and O +
protein O +
binding O +
properties O +
of O +
multimerized O +
wild O -
- O -
type O +
and O +
mutant O +
elements O +
added O +
upstream O +
to O +
the O +
SCMV O +
MIE O +
or O +
simian O +
virus O +
40 O +
minimal O +
promoter O +
regions O +
in O +
the O +
U-937 B-CellLine +
, O +
K-562 B-CellLine +
, O +
HL-60 B-CellLine +
, O +
THP-1 B-CellLine +
, O +
and O +
Jurkat B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Unlike O +
classical O +
NFkappaB O +
sites O +
, O +
neither O +
the O +
SNE O +
nor O +
the O +
SEE O +
motif O +
responded O +
to O +
phosphatase O +
inhibition O +
by O +
okadaic O +
acid O +
. O +

However O +
, O +
the O +
TPA O +
responsiveness O +
of O +
both O +
CMV O +
elements O +
proved O +
to O +
involve O +
synergistic O +
interactions O +
between O +
the O +
core O +
SRF O +
binding O +
site O +
( O +
CCATATATGG O +
) O +
and O +
the O +
adjacent O +
inverted O +
ETS O +
binding O +
motifs O +
( O +
TTCC O +
) O +
, O +
which O +
correlated O +
directly O +
with O +
formation O +
of O +
a O +
bound O +
tripartite O +
complex O +
containing O +
both O +
the O +
cellular O +
SRF O +
and O +
ELK-1 O +
proteins O +
. O +

This O +
protein O +
complex O +
was O +
more O +
abundant O +
in O +
U-937 O +
, O +
K-562 O +
, O +
and O +
HeLa O +
cell O +
extracts O +
than O +
in O +
Raji B-CellLine +
, O +
HF B-CellLine +
, O +
BALB B-CellLine -
/ I-CellLine -
c I-CellLine +
3T3 I-CellLine +
, O +
or O +
HL-60 B-CellLine +
cells I-CellLine +
, O +
but O +
the O +
binding O +
activity O +
was O +
altered O +
only O +
twofold O +
after O +
TPA O +
treatment O +
. O +

A O +
40-fold O +
stimulation O +
of O +
chloramphenicol O +
acetyltransferase O +
activity O +
mediated O +
by O +
four O +
tandem O +
repeats O +
of O +
the O +
SNE O +
could O +
be O +
induced O +
within O +
2 O +
h O +
( O +
and O +
up O +
to O +
250-fold O +
within O +
6 O +
h O +
) O +
after O +
addition O +
of O +
TPA O +
in O +
DNA B-CellLine -
- I-CellLine -
transfected I-CellLine +
U-937 I-CellLine +
cells I-CellLine +
, O +
indicating O +
that O +
the O +
stimulation O +
appeared O +
likely O +
to O +
be O +
a O +
true O +
protein O +
kinase O +
C O +
-mediated O +
signal O +
transduction O +
event O +
rather O +
than O +
a O +
differentiation O +
response O +
. O +

Slight O +
differences O +
in O +
the O +
sequence O +
of O +
the O +
core O +
SRF O +
binding O +
site O +
compared O +
with O +
that O +
of O +
the O +
classical O +
c O -
- O -
Fos O +
promoter O +
serum O +
response O +
element O +
, O +
together O +
with O +
differences O +
in O +
the O +
spacing O +
between O +
the O +
SRF O +
and O +
ETS O +
motifs O +
, O +
appear O +
to O +
account O +
for O +
the O +
inability O +
of O +
the O +
SCMV O +
SNEs O +
to O +
respond O +
to O +
serum O +
induction O +
. O +

Energy O +
substrates O +
, O +
hormone O +
responses O +
and O +
glucocorticoid O +
binding O +
in O +
lymphocytes O +
during O +
intense O +
physical O +
exercise O +
in O +
humans O +
following O +
phosphocreatine O +
administration O +
. O +

Eight O +
healthy O +
untrained O +
male O +
volunteers O +
pedalled O +
a O +
cycle O +
ergometer O +
according O +
to O +
two O +
exercise O +
protocols O +
: O +
the O +
first O +
involved O +
step O -
- O -
wise O +
increasing O +
physical O +
exercise O +
to O +
maximal O +
( O +
MPE O +
) O +
; O +
the O +
second O +
involved O +
prolonged O +
( O +
35 O +
min O +
) O +
submaximal O +
physical O +
exercise O +
( O +
PPE O +
) O +
at O +
70 O +
% O +
of O +
the O +
individual O +
's O +
maximal O +
oxygen O +
uptake O +
. O +

Each O +
volunteer O +
performed O +
these O +
exercise O +
twice O +
, O +
following O +
either O +
an O +
intravenous O +
injection O +
of O +
phosphocreatine O +
( O +
PCr O +
) O +
or O +
a O +
placebo O +
of O +
an O +
isotonic O +
NaCl O +
solution O +
. O +

Anaerobic O +
threshold O +
( O +
AT O +
) O +
was O +
determined O +
from O +
the O +
point O +
of O +
departure O +
of O +
the O +
ventilatory O +
response O +
from O +
linearity O +
and O +
from O +
the O +
sudden O +
increase O +
in O +
venous O +
blood O +
lactate O +
concentrations O +
during O +
MPE O +
. O +

After O +
exercise O +
following O +
placebo O +
administration O +
we O +
observed O +
increases O +
in O +
concentrations O +
of O +
blood O +
substrates O +
, O +
plasma O +
adrenocorticotropin O +
( O +
ACTH O +
) O +
, O +
growth O +
hormone O +
and O +
cortisol O +
and O +
in O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
in O +
lymphocytes O +
without O +
changes O +
in O +
the O +
dissociation O +
constant O +
. O +

Intravenous O +
administration O +
of O +
PCr O +
( O +
starting O +
1 O +
day O +
before O +
exercise O +
) O +
led O +
to O +
an O +
increase O +
in O +
the O +
total O +
workload O +
( O +
on O +
average O +
by O +
5.8 O +
% O +
) O +
and O +
in O +
AT O +
( O +
on O +
average O +
by O +
6.8 O +
% O +
) O +
during O +
MPE O +
and O +
to O +
a O +
better O +
tolerance O +
of O +
exercise O +
during O +
PPE O +
. O +

Following O +
PCr O +
administration O +
we O +
observed O +
lower O +
blood O +
lactate O +
concentrations O +
and O +
different O +
patterns O +
of O +
some O +
enzyme O +
activities O +
, O +
less O +
pronounced O +
changes O +
in O +
plasma O +
ACTH O +
and O +
cortisol O +
concentrations O +
and O +
in O +
glucocorticoid O +
binding O +
in O +
lymphocytes O +
, O +
but O +
no O +
changes O +
in O +
plasma O +
growth O +
hormone O +
concentrations O +
compared O +
to O +
the O +
placebo O +
. O +

The O +
results O +
showed O +
that O +
intense O +
physical O +
exercise O +
led O +
not O +
only O +
to O +
increases O +
in O +
blood O +
hormone O +
concentrations O +
but O +
also O +
to O +
an O +
increase O +
in O +
the O +
density O +
of O +
glucocorticoid O +
receptors O +
in O +
lymphocytes O +
. O +

Intravenous O +
PCr O +
injection O +
led O +
to O +
smaller O +
changes O +
in O +
ACTH O +
and O +
cortisol O +
concentrations O +
as O +
well O +
as O +
to O +
a O +
lower O +
activation O +
of O +
glucocorticoid O +
binding O +
in O +
lymphocytes O +
. O +

Acetylsalicylic O +
acid O +
and O +
sodium O +
salicylate O +
inhibit O +
LPS O -
- O -
induced O +
NF O -
- O -
kappa O +
B O -
/ O -
c O -
- O -
Rel O +
nuclear O +
translocation O +
, O +
and O +
synthesis O +
of O +
tissue O +
factor O +
( O +
TF O +
) O +
and O +
tumor O +
necrosis O +
factor O +
alfa O +
( O +
TNF O -
- O -
alpha O +
) O +
in O +
human O +
monocytes O +
. O +

We O +
have O +
investigated O +
the O +
effects O +
of O +
acetylsalicylic O +
acid O +
and O +
sodium O +
salicylate O +
on O +
the O +
LPS O -
- O -
induced O +
synthesis O +
of O +
the O +
pro O -
- O -
coagulant O +
protein O +
tissue O +
factor O +
( O +
TF O +
) O +
and O +
the O +
pro O -
- O -
inflammatory O +
protein O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
, O +
as O +
well O +
as O +
the O +
prostaglandin O +
PGE2 O +
in O +
human O +
monocytes O +
. O +

Both O +
drugs O +
dose O -
- O -
dependently O +
inhibited O +
LPS O -
- O -
induced O +
TF O +
and O +
TNF O -
- O -
alpha O +
synthesis O +
at O +
the O +
mRNA O +
and O +
the O +
protein O +
level O +
, O +
and O +
reduced O +
PGE2 O +
production O +
. O +

As O +
evidenced O +
by O +
electro O +
mobility O +
shift O +
assay O +
( O +
EMSA O +
) O +
and O +
the O +
use O +
of O +
a O +
NF O -
- O -
kappa O +
B O +
prototypic O +
probe O +
, O +
these O +
drugs O +
probably O +
exert O +
their O +
inhibitory O +
effects O +
by O +
interference O +
with O +
the O +
nuclear O +
translocation O +
of O +
NF O -
- O -
kappa O +
B O -
/ O -
c O -
- O -
Rel O +
proteins O +
. O +

These O +
data O +
may O +
expand O +
the O +
understanding O +
of O +
the O +
anti O -
- O -
thrombotic O +
and O +
anti O -
- O -
inflammatory O +
effects O +
of O +
these O +
drugs O +
when O +
activation O +
of O +
monocytes O +
occurs O +
. O +

Octamer O +
independent O +
activation O +
of O +
transcription O +
from O +
the O +
kappa O +
immunoglobulin O +
germline O +
promoter O +
. O +

Previous O +
analyses O +
of O +
immunoglobulin O +
V O +
region O +
promoters O +
has O +
led O +
to O +
the O +
discovery O +
of O +
a O +
common O +
octamer O +
motif O +
which O +
is O +
functionally O +
important O +
in O +
the O +
tissue O -
- O -
specific O +
and O +
developmentally O +
regulated O +
transcriptional O +
activation O +
of O +
immunoglobulin O +
genes O +
. O +

The O +
germline O +
promoters O +
( O +
Ko O +
) O +
located O +
upstream O +
of O +
the O +
J O +
region O +
gene O +
segments O +
of O +
the O +
kappa O +
locus O +
also O +
contain O +
an O +
octamer O +
motif O +
( O +
containing O +
a O +
single O +
base O +
pair O +
mutation O +
and O +
referred O +
to O +
as O +
the O +
variant O +
octamer O +
) O +
which O +
has O +
been O +
shown O +
previously O +
to O +
bind O +
Oct-1 O +
and O +
Oct-2 O +
transcription O +
factors O +
in O +
vitro O +
. O +

To O +
further O +
elucidate O +
the O +
role O +
of O +
this O +
variant O +
octamer O +
motif O +
in O +
the O +
regulation O +
of O +
germline O +
transcription O +
from O +
the O +
unrearranged O +
kappa O +
locus O +
, O +
we O +
have O +
quantitated O +
the O +
relative O +
binding O +
affinity O +
of O +
Oct-1 O +
and O +
Oct-2 O +
for O +
the O +
variant O +
octamer O +
motif O +
and O +
determined O +
the O +
functional O +
role O +
of O +
this O +
octamer O +
motif O +
in O +
transcriptional O +
activation O +
. O +

We O +
find O +
that O +
, O +
although O +
the O +
variant O +
octamer O +
motif O +
binds O +
Oct-1 O +
and O +
Oct-2 O +
in O +
vitro O +
with O +
5-fold O +
lower O +
affinity O +
than O +
the O +
consensus O +
octamer O +
motif O +
, O +
mutation O +
of O +
the O +
variant O +
octamer O +
motif O +
to O +
either O +
a O +
consensus O +
octamer O +
or O +
non O -
- O -
octamer O +
motif O +
has O +
no O +
effect O +
on O +
transcriptional O +
activation O +
from O +
the O +
germline O +
promoter O +
. O +

We O +
also O +
find O +
significant O +
differences O +
in O +
activation O +
of O +
germline O +
and O +
V O +
region O +
promoters O +
by O +
kappa O +
enhancers O +
. O +

Our O +
results O +
suggest O +
that O +
the O +
germline O +
promoters O +
and O +
V O +
region O +
promoters O +
differ O +
in O +
their O +
dependence O +
on O +
octamer O +
for O +
activation O +
and O +
respond O +
differently O +
to O +
enhancer O +
activation O +
. O +

These O +
findings O +
have O +
important O +
implications O +
in O +
regulation O +
of O +
germline O +
transcription O +
as O +
well O +
as O +
concomitant O +
activation O +
of O +
the O +
V O -
- O -
J O +
recombination O +
of O +
the O +
kappa O +
light O +
chain O +
locus O +
. O +

Characterization O +
of O +
the O +
murine O +
cyclin O -
- O -
dependent O +
kinase O +
inhibitor O +
gene O +
p27Kip1 O +
. O +

The O +
cyclin O -
- O -
dependent O +
kinase O +
inhibitor O +
p27Kip1 O +
plays O +
an O +
important O +
role O +
in O +
regulating O +
cell O -
- O -
cycle O +
progression O +
. O +

p27Kip1 O +
directly O +
inhibits O +
the O +
catalytic O +
activity O +
of O +
cyclin O -
/ O -
cdks O +
( O +
cyclin O -
- O -
dependent O +
kinase O +
) O +
complexes O +
and/or O +
interferes O +
physically O +
with O +
cyclin O -
/ O -
cdks O +
activation O +
by O +
CAK O +
. O +

Interestingly O +
, O +
the O +
expression O +
level O +
of O +
p27Kip1 O +
mRNA O +
was O +
maximal O +
in O +
resting O +
Go O +
T O -
- O -
cells O +
and O +
rapidly O +
declined O +
following O +
anti O -
- O -
CD3 O +
activation O +
. O +

We O +
report O +
here O +
the O +
cloning O +
of O +
p27Kip1 O +
gene O +
from O +
murine O +
genomic O +
DNA O +
and O +
the O +
functional O +
analysis O +
of O +
the O +
promoter O +
of O +
the O +
p27Kip1 O +
gene O +
. O +

The O +
gene O +
consists O +
of O +
at O +
least O +
three O +
exons O +
and O +
spans O +
more O +
than O +
5.6 O +
kb O +
of O +
DNA O +
. O +

Primer O +
extension O +
and O +
nuclease O +
S1 O +
protection O +
analysis O +
revealed O +
two O +
major O +
transcription O +
initiation O +
sites O +
. O +

The O +
promoter O +
region O +
lacked O +
a O +
TATA O +
box O +
but O +
contained O +
potential O +
binding O +
sites O +
for O +
the O +
transcriptional O +
factors O +
including O +
two O +
Sp1 O +
, O +
CRE O +
, O +
Myb O +
and O +
NFkB O +
located O +
at O +
positions O +
-153 O +
, O +
-178 O +
, O +
-286 O +
, O +
-875 O +
, O +
and O +
-1011 O +
, O +
respectively O +
. O +

To O +
analyze O +
the O +
regulatory O +
mechanisms O +
controlling O +
p27Kip1 O +
gene O +
expression O +
, O +
we O +
characterized O +
the O +
5'-flanking O +
region O +
from O +
nt O +
-1609 O +
to O +
+ O -
178 O +
. O +

The O +
-326 O +
to O +
-615 O +
region O +
contained O +
positive O +
regulatory O +
elements O +
. O +

The O +
state O +
of O +
maturation O +
of O +
monocytes O +
into O +
macrophages O +
determines O +
the O +
effects O +
of O +
IL-4 O +
and O +
IL-13 O +
on O +
HIV O +
replication O +
. O +

The O +
molecular O +
mechanisms O +
of O +
the O +
effects O +
of O +
IL-4 O +
and O +
IL-13 O +
on O +
HIV O +
infection O +
in O +
human O +
monocytes O +
as O +
they O +
matured O +
into O +
monocyte O -
- O -
derived O +
macrophages O +
over O +
7 O +
days O +
were O +
investigated O +
using O +
HIV-1 O +
( O +
BaL O +
) O +
, O +
and O +
low O +
passage O +
clinical O +
strains O +
. O +

IL-4 O +
and O +
IL-13 O +
up O -
- O -
regulated O +
the O +
expression O +
of O +
both O +
genomic O +
and O +
spliced O +
HIV O +
mRNA O +
in O +
monocytes O +
cultured O +
on O +
Teflon O +
, O +
as O +
determined O +
by O +
Northern O +
analysis O +
and O +
p24 O +
Ag O +
assay O +
. O +

Using O +
a O +
nuclear O +
run O -
- O -
on O +
assay O +
, O +
IL-4 O +
stimulation O +
was O +
shown O +
to O +
enhance O +
transcription O +
by O +
two- O +
to O +
threefold O +
. O +

IL-4 O +
stimulated O +
nuclear O +
factor O -
- O -
kappaB O +
nuclear O +
translocation O +
and O +
binding O +
before O +
enhancement O +
of O +
HIV O +
RNA O +
expression O +
. O +

Conversely O +
, O +
IL-4 O +
and O +
IL-13 O +
markedly O +
and O +
significantly O +
inhibited O +
HIV O +
replication O +
at O +
the O +
transcriptional O +
level O +
in O +
monocyte O -
- O -
derived O +
macrophages O +
, O +
and O +
this O +
occurred O +
whether O +
these O +
cytokines O +
were O +
added O +
before O +
or O +
after O +
HIV O +
infection O +
. O +

The O +
reversal O +
from O +
stimulation O +
to O +
inhibition O +
occurred O +
after O +
3 O +
to O +
5 O +
days O +
of O +
adherence O +
to O +
plastic O +
. O +

IL-4 O +
had O +
no O +
significant O +
effect O +
on O +
HIV O +
reverse O +
transcription O +
. O +

The O +
effect O +
of O +
both O +
cytokines O +
on O +
the O +
monocyte O +
maturation O -
/ O -
differentiation O +
( O +
CD11b O +
, O +
CD13 O +
, O +
and O +
CD26 O +
) O +
and O +
other O +
macrophage O +
markers O +
( O +
CD14 O +
and O +
CD68 O +
) O +
was O +
examined O +
. O +

IL-4 O +
enhanced O +
CD11b O +
, O +
but O +
inhibited O +
CD26 O +
expression O +
and O +
delayed O +
CD13 O +
loss O +
. O +

IL-13 O +
had O +
similar O +
effects O +
on O +
CD11b O +
and O +
CD13 O +
, O +
but O +
no O +
effect O +
on O +
CD26 O +
. O +

Hence O +
, O +
these O +
cytokines O +
do O +
not O +
simply O +
enhance O +
monocyte O +
differentiation O +
, O +
but O +
have O +
complex O +
and O +
slightly O +
divergent O +
effects O +
that O +
impact O +
on O +
HIV O +
replication O +
probably O +
through O +
cell O +
signaling O +
pathways O +
and O +
nuclear O +
factor O -
- O -
kappaB O +
translocation O +
. O +

Effects O +
of O +
glucocorticoids O +
on O +
lymphocyte O +
activation O +
in O +
patients O +
with O +
steroid O -
- O -
sensitive O +
and O +
steroid O -
- O -
resistant O +
asthma O +
. O +

BACKGROUND O +
: O +
Glucocorticoids O +
are O +
important O +
medications O +
used O +
to O +
control O +
the O +
airway O +
inflammation O +
associated O +
with O +
asthma O +
. O +

Synthetic O +
glucocorticoids O +
vary O +
in O +
their O +
binding O +
affinity O +
for O +
the O +
glucocorticoid O +
receptor O +
( O +
GCR O +
) O +
. O +

METHODS O +
: O +
We O +
compared O +
hydrocortisone O +
, O +
beclomethasone O +
dipropionate O +
, O +
triamcinolone O +
acetonide O +
, O +
flunisolide O +
, O +
and O +
budesonide O +
with O +
regard O +
to O +
their O +
capacity O +
to O +
inhibit O +
phytohemagglutinin O +
-induced O +
peripheral O +
blood O +
mononuclear O +
cell O +
proliferation O +
from O +
six O +
patients O +
with O +
steroid O -
- O -
sensitive O +
asthma O +
and O +
seven O +
patients O +
with O +
steroid O -
- O -
resistant O +
asthma O +
. O +

Peripheral O +
blood O +
mononuclear O +
cell O +
GCR O +
binding O +
affinities O +
for O +
dexamethasone O +
and O +
budesonide O +
were O +
also O +
determined O +
for O +
both O +
patient O +
groups O +
by O +
using O +
a O +
radioligand O +
binding O +
assay O +
and O +
Scatchard O +
analysis O +
. O +

RESULTS O +
: O +
Dose O -
- O -
dependent O +
inhibition O +
was O +
demonstrated O +
for O +
all O +
glucocorticoids O +
in O +
both O +
patient O +
groups O +
, O +
with O +
the O +
steroid O -
- O -
resistant O +
group O +
requiring O +
approximately O +
2 O +
log O -
- O -
fold O +
more O +
glucocorticoids O +
for O +
an O +
equivalent O +
degree O +
of O +
inhibition O +
. O +

The O +
mean O +
concentrations O +
necessary O +
to O +
cause O +
50 O +
% O +
inhibition O +
of O +
lymphocyte O +
proliferation O +
( O +
IC50s O +
) O +
for O +
the O +
steroid O -
- O -
sensitive O +
group O +
ranged O +
from O +
2 O +
x O +
10 O +
( O +
-10 O +
) O +
mol O -
/ O -
L O +
for O +
budesonide O +
to O +
7 O +
x O +
10 O +
( O +
-8 O +
) O +
mol O -
/ O -
L O +
for O +
hydrocortisone O +
, O +
whereas O +
the O +
mean O +
IC50s O +
for O +
the O +
steroid O -
- O -
resistant O +
group O +
ranged O +
from O +
approximately O +
2 O +
x O +
10 O +
( O +
-8 O +
) O +
mol O -
/ O -
L O +
for O +
budesonide O +
to O +
greater O +
than O +
10 O +
( O +
-6 O +
) O +
mol O -
/ O -
L O +
for O +
hydrocortisone O +
. O +

In O +
addition O +
, O +
a O +
significant O +
correlation O +
was O +
noted O +
between O +
the O +
degree O +
of O +
inhibition O +
of O +
lymphocyte O +
proliferation O +
( O +
IC50 O +
) O +
and O +
the O +
binding O +
affinity O +
of O +
dexamethasone O +
to O +
the O +
GCR O +
. O +

Patients O +
with O +
steroid O -
- O -
resistant O +
asthma O +
have O +
been O +
shown O +
to O +
have O +
a O +
reduced O +
GCR O +
binding O +
affinity O +
. O +

The O +
GCR O +
binding O +
affinity O +
for O +
budesonide O +
was O +
significantly O +
higher O +
in O +
both O +
groups O +
( O +
i.e. O +
, O +
lower O +
dissociation O +
constant O +
) O +
than O +
that O +
obtained O +
for O +
dexamethasone O +
. O +

CONCLUSION O +
: O +
These O +
data O +
suggest O +
that O +
glucocorticoids O +
such O +
as O +
budesonide O +
, O +
by O +
virtue O +
of O +
their O +
high O +
GCR O +
binding O +
affinities O +
and O +
greater O +
ability O +
to O +
suppress O +
lymphocyte O +
proliferation O +
, O +
may O +
therefore O +
be O +
beneficial O +
in O +
the O +
management O +
of O +
difficult O -
- O -
to O -
- O -
control O +
asthma O +
. O +

Involvement O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
activation O +
in O +
IgE O +
synthesis O +
in O +
human O +
B O +
cells O +
. O +

Nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
is O +
a O +
transcription O +
factor O +
that O +
binds O +
to O +
the O +
consensus O +
DNA O +
sequence O +
in O +
the O +
cis O -
- O -
acting O +
elements O +
of O +
various O +
genes O +
. O +

Although O +
NF O -
- O -
kappa O +
B O +
activates O +
the O +
expression O +
of O +
many O +
genes O +
involved O +
in O +
immune O +
and O +
inflammatory O +
responses O +
, O +
little O +
is O +
known O +
about O +
the O +
role O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
the O +
induction O +
of O +
IgE O +
synthesis O +
in O +
human O +
B O +
cells O +
. O +

Therefore O +
we O +
first O +
examined O +
the O +
participation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
germline B-CellLine +
C I-CellLine +
epsilon I-CellLine +
transcription O +
in O +
a O +
human B-CellLine +
Burkitt I-CellLine +
lymphoma I-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
DND39 B-CellLine +
. O +

Stimulation O +
of O +
DND39 B-CellLine +
cells I-CellLine +
with O +
IL-4 O +
or O +
anti O -
- O -
CD40 O +
monoclonal O +
antibody O +
( O +
mAb O +
) O +
activated O +
phosphatidylinositol O +
3-kinase O +
and O +
subsequently O +
induced O +
nuclear O +
expression O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
which O +
was O +
identified O +
by O +
electrophoretic O +
mobility O +
shift O +
assays O +
. O +

n O -
- O -
Acetyl O -
- O -
L O -
- O -
cysteine O +
( O +
NAC O +
) O +
, O +
a O +
potent O +
antioxidant O +
, O +
blocked O +
NF O -
- O -
kappa O +
B O +
activation O +
caused O +
by O +
IL-4 O +
and O +
by O +
anti O -
- O -
CD40 O +
mAb O +
. O +

Although O +
inhibition O +
of O +
IL-4-driven B-CellLine +
germline I-CellLine +
C I-CellLine +
epsilon I-CellLine +
transcription O +
by O +
NAC O +
was O +
not O +
sufficient O +
, O +
the O +
agent O +
remarkably O +
diminished O +
anti O -
- O -
CD40 O +
mAb O +
-mediated O +
up O -
- O -
regulation O +
of O +
germline O +
C O +
epsilon O +
transcription O +
. O +

Second O +
, O +
we O +
studied O +
the O +
effect O +
of O +
NAC O +
on O +
IgE O +
synthesis O +
in O +
human O +
normal O +
B O +
cells O +
costimulated O +
with O +
IL-4 O +
and O +
anti O -
- O -
CD40 O +
mAb O +
. O +

NAC O +
was O +
effective O +
in O +
inhibiting O +
mature O +
C O +
epsilon O +
transcription O +
and O +
IgE O +
synthesis O +
in O +
the O +
T O +
cell O -
- O -
independent O +
culture O +
system O +
. O +

However O +
, O +
NAC O +
did O +
not O +
significantly O +
affect O +
the O +
spontaneous O +
production O +
of O +
IgE O +
by O +
atopic O +
B O +
cells O +
. O +

These O +
results O +
indicate O +
that O +
NF O -
- O -
kappa O +
B O +
activity O +
is O +
commonly O +
inducible O +
in O +
DND39 B-CellLine +
cells I-CellLine +
by O +
IL-4 O +
and O +
anti O -
- O -
CD40 O +
mAb O +
and O +
suggest O +
that O +
NF O -
- O -
kappa O +
B O +
sensitive O +
to O +
NAC O +
may O +
play O +
a O +
role O +
in O +
regulating O +
IgE O +
synthesis O +
in O +
B O +
cells O +
. O +

[ O +
Molecular O +
mechanisms O +
of O +
age O -
- O -
related O +
lymphocyte O +
dysfunction O +
] O +

Aging O +
is O +
classically O +
accompanied O +
by O +
a O +
dysregulation O +
of O +
the O +
immunologic O +
machinery O +
. O +

As O +
a O +
consequence O +
, O +
the O +
immune O +
response O +
developed O +
in O +
senescent O +
organisms O +
is O +
usually O +
inappropriate O +
, O +
often O +
inefficient O +
, O +
sometimes O +
aberrant O +
, O +
and O +
potentially O +
detrimental O +
. O +

The O +
age O -
- O -
associated O +
immune O +
dysfunction O +
may O +
be O +
implicated O +
to O +
some O +
degree O +
in O +
the O +
extreme O +
susceptibility O +
of O +
the O +
elderly O +
to O +
infection O +
and O +
neoplasia O +
and O +
may O +
even O +
participate O +
in O +
various O +
aspects O +
of O +
senescence O +
. O +

The O +
current O +
understanding O +
of O +
the O +
molecular O +
mechanisms O +
underlying O +
immunosenescence O +
is O +
still O +
fragmentary O +
. O +

The O +
most O +
extensively O +
studied O +
phenomenon O +
is O +
the O +
progressive O +
decline O +
in O +
the O +
proliferative O +
capacities O +
of O +
T O +
lymphocytes O +
with O +
aging O +
. O +

The O +
loss O +
of O +
proliferative O +
potential O +
in O +
response O +
to O +
antigenic O +
challenge O +
is O +
a O +
characteristic O +
feature O +
of O +
immune O +
senescence O +
. O +

It O +
is O +
directly O +
implicated O +
in O +
the O +
emergence O +
of O +
the O +
age O -
- O -
related O +
immune O +
deficiency O +
. O +

The O +
purpose O +
of O +
this O +
review O +
is O +
to O +
show O +
how O +
the O +
accumulation O +
of O +
various O +
biochemical O +
lesions O +
with O +
advancing O +
age O +
leads O +
to O +
the O +
failure O +
of O +
a O +
critical O +
cell O +
function O +
, O +
namely O +
the O +
activation O -
- O -
induced O +
lymphocyte O +
proliferation O +
. O +

The O +
biochemical O +
modifications O +
responsible O +
for O +
the O +
defect O +
in O +
transduction O +
and O +
execution O +
of O +
the O +
proliferative O +
signal O +
are O +
analyzed O +
as O +
a O +
function O +
of O +
age O +
. O +

The O +
multiple O +
alterations O +
observed O +
on O +
the O +
various O +
biochemical O +
pathways O +
may O +
appear O +
as O +
a O +
consequence O +
of O +
a O +
unique O +
deleterious O +
mechanism O +
more O +
fundamentally O +
related O +
to O +
the O +
process O +
of O +
senescence O +
such O +
as O +
the O +
inability O +
to O +
cope O +
with O +
oxidative O +
stress O +
. O +

Engagement O +
of O +
the O +
Lewis O +
X O +
antigen O +
( O +
CD15 O +
) O +
results O +
in O +
monocyte O +
activation O +
. O +

We O +
previously O +
reported O +
that O +
monocyte O +
adhesion O +
to O +
tumor B-CellLine +
necrosis I-CellLine +
factor I-CellLine -
- I-CellLine -
alpha I-CellLine +
( I-CellLine +
TNF I-CellLine -
- I-CellLine -
alpha I-CellLine +
) I-CellLine +
-treated I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
increased O +
expression O +
of O +
tissue O +
factor O +
and O +
CD36 O +
on O +
monocytes O +
. O +

Using O +
immunological O +
cross O -
- O -
linking O +
to O +
mimic O +
receptor O +
engagement O +
by O +
natural O +
ligands O +
, O +
we O +
now O +
show O +
that O +
CD15 O +
( O +
Lewis O +
X O +
) O +
, O +
a O +
monocyte O +
counter O -
- O -
receptor O +
for O +
endothelial O +
selectins O +
may O +
participate O +
in O +
this O +
response O +
. O +

We O +
used O +
cytokine O +
production O +
as O +
a O +
readout O +
for O +
monocyte O +
activation O +
and O +
found O +
that O +
CD15 O +
cross O -
- O -
linking O +
induced O +
TNF O -
- O -
alpha O +
release O +
from O +
peripheral O +
blood O +
monocytes O +
and O +
cells O +
from O +
the O +
monocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
MM6 I-CellLine +
. O +

Quantitative O +
reverse O +
transcriptase O +
-polymerase O +
chain O +
reaction O +
( O +
RT O -
- O -
PCR O +
) O +
showed O +
an O +
increase O +
in O +
steady O -
- O -
state O +
TNF O -
- O -
alpha O +
mRNA O +
after O +
3 O +
to O +
4 O +
hours O +
of O +
cross O -
- O -
linking O +
. O +

CD15 O +
cross O -
- O -
linking O +
also O +
concomitantly O +
increased O +
interleukin-1 O +
beta O +
( O +
IL-1 O +
beta O +
) O +
mRNA O +
, O +
while O +
no O +
apparent O +
change O +
was O +
observed O +
in O +
the O +
levels O +
of O +
beta O -
- O -
actin O +
mRNA O +
, O +
indicating O +
specificity O +
. O +

To O +
examine O +
transcriptional O +
regulation O +
of O +
cytokine O +
genes O +
by O +
CD15 O +
engagement O +
, O +
a O +
CAT O +
plasmid O +
reporter O +
construct O +
containing O +
IL-1 O +
beta O +
promoter O -
/ O -
enhancer O +
sequences O +
was O +
introduced O +
into O +
MM6 B-CellLine +
. O +

Subsequent O +
cross O -
- O -
linking O +
of O +
CD15 O +
increased O +
CAT O +
activity O +
. O +

CD15 O +
engagement O +
by O +
monoclonal O +
antibody O +
also O +
attenuated O +
IL-1 O +
beta O +
transcript O +
degradation O +
, O +
demonstrating O +
that O +
signaling O +
via O +
CD15 O +
also O +
had O +
posttranscriptional O +
effects O +
. O +

Nuclear O +
extracts O +
of O +
anti- O +
CD15 O +
cross O -
- O -
linked O +
cells O +
demonstrated O +
enhanced O +
levels O +
of O +
the O +
transcriptional O +
factor O +
activator O +
protein-1 O +
, O +
minimally O +
changed O +
nuclear O +
factor O -
- O -
kappa O +
B O +
, O +
and O +
did O +
not O +
affect O +
SV40 O +
promoter O +
specific O +
protein-1 O +
. O +

We O +
conclude O +
that O +
engagement O +
of O +
CD15 O +
on O +
monocytes O +
results O +
in O +
monocyte O +
activation O +
. O +

In O +
addition O +
to O +
its O +
well O -
- O -
recognized O +
adhesive O +
role O +
, O +
CD15 O +
may O +
function O +
as O +
an O +
important O +
signaling O +
molecule O +
capable O +
of O +
initiating O +
proinflammatory O +
events O +
in O +
monocytes O +
that O +
come O +
into O +
contact O +
with O +
activated O +
endothelium O +
. O +

Activation O +
of O +
signaling O +
pathways O +
and O +
prevention O +
of O +
apoptosis O +
by O +
cytokines O +
in O +
eosinophils O +
. O +

Inhibition O +
of O +
apoptosis O +
in O +
eosinophils O +
by O +
cytokines O +
such O +
as O +
IL-5 O +
and O +
GM O -
- O -
CSF O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
pathogenesis O +
of O +
allergic O +
and O +
parasitic O +
disorders O +
. O +

Recently O +
, O +
there O +
has O +
been O +
some O +
progress O +
in O +
the O +
understanding O +
of O +
the O +
signal O +
transduction O +
pathways O +
activated O +
by O +
these O +
cytokines O +
in O +
eosinophils O +
. O +

The O +
IL-3 O +
, O +
IL-5 O +
and O +
GM O -
- O -
CSF O +
receptors O +
share O +
a O +
common O +
signal O +
transducer O +
that O +
possesses O +
no O +
intrinsic O +
kinase O +
domain O +
. O +

It O +
has O +
been O +
shown O +
that O +
eosinophil O +
stimulation O +
by O +
these O +
cytokines O +
is O +
associated O +
with O +
increases O +
in O +
tyrosine O +
phosphorylation O +
of O +
several O +
cellular O +
substrates O +
. O +

In O +
the O +
past O +
few O +
years O +
, O +
there O +
has O +
been O +
some O +
progress O +
in O +
defining O +
the O +
tyrosine O +
kinases O +
that O +
are O +
activated O +
by O +
the O +
IL-3 O -
/ O -
IL-5 O -
/ O -
GM O -
- O -
CSF O +
receptor O +
beta O -
- O -
subunit O +
in O +
eosinophils O +
. O +

This O +
review O +
will O +
concentrate O +
on O +
this O +
topic O +
and O +
on O +
its O +
role O +
for O +
the O +
regulation O +
of O +
eosinophil O +
apoptosis O +
. O +

Stimulation O +
of O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
by O +
zinc O +
and O +
related O +
cations O +
. O +

Zinc O +
is O +
an O +
important O +
trace O +
element O +
for O +
immune O +
function O +
. O +

Here O +
, O +
we O +
show O +
that O +
zinc O +
addition O +
in O +
a O +
serum- O +
and O +
lipopolysaccharide O -
- O -
free O +
cell O +
culture O +
system O +
leads O +
to O +
significantly O +
enhanced O +
levels O +
of O +
interleukin O +
1 O +
beta O +
( O +
IL-1 O +
beta O +
) O +
and O +
tumour O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
and O +
to O +
expression O +
of O +
the O +
corresponding O +
mRNA O +
in O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
. O +

Structurally O +
related O +
divalent O +
cations O +
like O +
cobalt O +
, O +
nickel O +
, O +
and O +
mercury O +
also O +
partially O +
increase O +
monokine O +
secretion O +
but O +
to O +
a O +
much O +
lower O +
and O +
thus O +
insignificant O +
extent O +
. O +

They O +
fail O +
to O +
induce O +
mRNA O +
of O +
TNF O -
- O -
alpha O +
after O +
3 O +
h O +
of O +
culture O +
. O +

Therefore O +
, O +
monokine O +
induction O +
is O +
a O +
zinc O -
- O -
specific O +
effect O +
influenced O +
by O +
the O +
physicochemical O +
properties O +
of O +
the O +
ion O +
. O +

Confirmation O +
of O +
the O +
unique O +
significance O +
of O +
zinc O +
for O +
immune O +
function O +
provides O +
a O +
better O +
understanding O +
of O +
the O +
mechanisms O +
of O +
specific O +
zinc O -
- O -
mediated O +
immune O +
modulation O +
. O +

Sequence O +
analysis O +
and O +
expression O +
in O +
cultured O +
lymphocytes O +
of O +
the O +
human O +
FOSB O +
gene O +
( O +
G0S3 O +
) O +
. O +

G0S3 O +
is O +
a O +
member O +
of O +
a O +
set O +
of O +
putative O +
G0 O -
/ O -
G1 O +
switch O +
regulatory O +
genes O +
( O +
G0S O +
genes O +
) O +
selected O +
by O +
screening O +
cDNA O +
libraries O +
prepared O +
from O +
human O +
blood O +
mononuclear O +
cells O +
cultured O +
for O +
2 O +
hr O +
with O +
lectin O +
and O +
cycloheximide O +
. O +

The O +
sequence O +
shows O +
high O +
homology O +
with O +
the O +
murine O +
FOSB O +
gene O +
, O +
which O +
encodes O +
a O +
component O +
of O +
the O +
AP1 O +
transcriptional O +
regulator O +
. O +

Comparison O +
of O +
cDNA O +
and O +
genomic O +
sequences O +
reveals O +
a O +
4-exon O +
structure O +
characteristic O +
of O +
the O +
FOS O +
family O +
of O +
genes O +
. O +

Freshly O +
isolated O +
cells O +
show O +
high O +
levels O +
of O +
FOSB O -
/ O -
G0S3 O +
and O +
FOS O -
/ O -
G0S7 O +
mRNAs O +
, O +
which O +
decline O +
rapidly O +
during O +
incubation O +
in O +
culture O +
medium O +
. O +

The O +
kinetics O +
of O +
expression O +
suggest O +
that O +
the O +
high O +
initial O +
levels O +
are O +
caused O +
by O +
the O +
isolation O +
procedure O +
, O +
and O +
do O +
not O +
reflect O +
constitutive O +
expression O +
. O +

In O +
cells O +
preincubated O +
for O +
a O +
day O +
, O +
levels O +
of O +
FOS O +
mRNA O +
reach O +
a O +
maximum O +
20 O +
min O +
after O +
the O +
addition O +
of O +
lectin O +
and O +
decline O +
to O +
control O +
levels O +
over O +
the O +
next O +
3 O +
hr O +
. O +

Levels O +
of O +
FOSB O +
mRNA O +
reach O +
a O +
maximum O +
40 O +
min O +
after O +
the O +
addition O +
of O +
lectin O +
and O +
decline O +
to O +
control O +
levels O +
over O +
the O +
next O +
6 O +
hr O +
. O +

In O +
freshly O +
isolated O +
cells O +
, O +
both O +
FOS O +
and O +
FOSB O +
mRNAs O +
increase O +
dramatically O +
in O +
response O +
to O +
the O +
protein O +
synthesis O +
inhibitor O +
cycloheximide O +
. O +

In O +
preincubated O +
cells O +
, O +
the O +
cycloheximide O +
response O +
is O +
decreased O +
, O +
especially O +
in O +
the O +
case O +
of O +
FOSB O +
. O +

These O +
differences O +
in O +
expression O +
of O +
FOS O +
and O +
FOSB O +
suggest O +
different O +
roles O +
and O +
regulation O +
. O +

Regions O +
of O +
low O +
base O +
order O -
- O -
dependent O +
stem O -
- O -
loop O +
potential O +
in O +
the O +
region O +
of O +
the O +
gene O +
are O +
defined O +
. O +

These O +
indicate O +
where O +
base O +
order O +
has O +
been O +
adapted O +
for O +
purposes O +
other O +
than O +
stem O -
- O -
loop O +
stability O +
( O +
e.g. O +
, O +
encoding O +
proteins O +
or O +
gene O +
regulation O +
) O +
. O +

Regions O +
of O +
low O +
potential O +
in O +
a O +
68.5-kb O +
genomic O +
segment O +
containing O +
the O +
FOSB O +
gene O +
suggest O +
that O +
the O +
potential O +
may O +
help O +
locate O +
genes O +
in O +
uncharted O +
DNA O +
sequences O +
. O +

STAT1 O +
pathway O +
is O +
involved O +
in O +
activation O +
of O +
caprine O +
arthritis O -
- O -
encephalitis O +
virus O +
long O +
terminal O +
repeat O +
in O +
monocytes O +
. O +

The O +
caprine O +
arthritis O -
- O -
encephalitis O +
virus O +
( O +
CAEV O +
) O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
is O +
activated O +
by O +
gamma O +
interferon O +
( O +
IFN O -
- O -
gamma O +
) O +
in O +
promonocytic O +
cells O +
. O +

We O +
have O +
previously O +
shown O +
that O +
a O +
70-bp O +
element O +
is O +
necessary O +
and O +
sufficient O +
for O +
the O +
response O +
of O +
the O +
CAEV O +
LTR O +
to O +
this O +
cytokine O +
. O +

At O +
the O +
5 O +
' O +
end O +
, O +
this O +
70-bp O +
IFN O -
- O -
gamma O +
response O +
element O +
contains O +
sequence O +
similarity O +
to O +
the O +
gamma O +
activated O +
site O +
( O +
GAS O +
) O +
. O +

Here O +
we O +
demonstrate O +
that O +
the O +
putative O +
GAS O +
element O +
in O +
the O +
CAEV O +
LTR O +
binds O +
specifically O +
to O +
a O +
cellular O +
factor O +
induced O +
by O +
IFN O -
- O -
gamma O +
in O +
promonocytic O +
cells O +
. O +

Substitution O +
mutations O +
in O +
this O +
consensus O +
sequence O +
eliminate O +
binding O +
of O +
the O +
inducible O +
factor O +
. O +

The O +
GAS O +
element O +
from O +
the O +
70-bp O +
motif O +
is O +
sufficient O +
to O +
confer O +
responsiveness O +
to O +
IFN O -
- O -
gamma O +
using O +
a O +
heterologous O +
minimal O +
promoter O +
. O +

Consistent O +
with O +
the O +
binding O +
data O +
, O +
the O +
same O +
mutations O +
in O +
the O +
GAS O +
element O +
eliminate O +
responsiveness O +
to O +
IFN O -
- O -
gamma O +
in O +
the O +
context O +
of O +
both O +
a O +
functional O +
CAEV O +
LTR O +
and O +
a O +
heterologous O +
promoter O +
. O +

The O +
cellular O +
factor O +
that O +
binds O +
to O +
the O +
GAS O +
element O +
is O +
present O +
from O +
5 O +
min O +
to O +
14 O +
h O +
after O +
stimulation O +
with O +
IFN O -
- O -
gamma O +
. O +

Binding O +
of O +
the O +
nuclear O +
factor O +
to O +
the O +
GAS O +
element O +
in O +
the O +
CAEV O +
LTR O +
is O +
inhibited O +
by O +
antibody O +
directed O +
against O +
STAT1 O +
( O +
p91 O -
/ O -
84 O +
) O +
. O +

Thus O +
, O +
the O +
GAS O +
sequence O +
in O +
the O +
CAEV O +
LTR O +
is O +
essential O +
for O +
the O +
response O +
to O +
IFN O -
- O -
gamma O +
and O +
a O +
STAT1-like O +
factor O +
binds O +
to O +
this O +
site O +
. O +

The O +
STAT-1 O +
signaling O +
pathway O +
provides O +
at O +
least O +
one O +
mechanism O +
for O +
activation O +
of O +
the O +
CAEV O +
LTR O +
by O +
IFN O -
- O -
gamma O +
in O +
monocytes O +
. O +

These O +
data O +
are O +
the O +
first O +
demonstration O +
of O +
a O +
role O +
for O +
a O +
STAT O +
family O +
member O +
in O +
the O +
regulation O +
of O +
a O +
viral O +
promoter O +
. O +

Signaling O +
via O +
IL-2 O +
and O +
IL-4 O +
in O +
JAK3-deficient B-CellLine +
severe I-CellLine +
combined I-CellLine +
immunodeficiency I-CellLine +
lymphocytes I-CellLine +
: O +
JAK3 O +
-dependent O +
and O +
independent O +
pathways O +
. O +

Both O +
IL-2 O +
and O +
IL-4 O +
bind O +
to O +
receptors O +
containing O +
the O +
common O +
gamma O +
chain O +
and O +
JAK3 O +
. O +

Although O +
JAK3 O +
is O +
required O +
for O +
proper O +
lymphoid O +
development O +
, O +
the O +
precise O +
roles O +
of O +
this O +
kinase O +
in O +
IL-2 O +
and O +
IL-4 O +
signaling O +
in O +
lymphocytes O +
have O +
not O +
been O +
defined O +
. O +

Here O +
, O +
we O +
have O +
studied O +
IL-2 O +
and O +
IL-4 O +
signaling O +
in O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
lacking O +
JAK3 O +
. O +

Although O +
IL-2 O +
-induced O +
phosphorylation O +
of O +
IL-2R O +
beta O +
, O +
JAK1 O +
, O +
and O +
STAT5 O +
all O +
required O +
the O +
presence O +
of O +
JAK3 O +
, O +
IL-4 O +
-mediated O +
phosphorylation O +
of O +
JAK1 O +
, O +
STAT6 O +
, O +
and O +
insulin O +
receptor O +
substrates O +
1 O +
and O +
2 O +
did O +
not O +
. O +

However O +
, O +
IL-4 O +
-induced O +
effects O +
were O +
clearly O +
improved O +
following O +
JAK3 O +
expression O +
. O +

These O +
data O +
indicate O +
that O +
IL-4 O +
signaling O +
occurs O +
in O +
the O +
absence O +
of O +
of O +
JAK3 O +
, O +
but O +
is O +
comparatively O +
inefficient O +
. O +

These O +
findings O +
may O +
help O +
in O +
understanding O +
the O +
pathogenesis O +
of O +
the O +
immunodeficiency O +
that O +
occurs O +
with O +
mutations O +
of O +
JAK3 O +
and O +
may O +
suggest O +
a O +
mechanism O +
for O +
the O +
pleiotropic O +
effects O +
of O +
IL-4 O +
. O +

GATA-1 O +
DNA O +
binding O +
activity O +
is O +
down O -
- O -
regulated O +
in O +
late O +
S O +
phase O +
in O +
erythroid O +
cells O +
. O +

We O +
have O +
set O +
out O +
to O +
test O +
a O +
model O +
for O +
tissue O -
- O -
specific O +
gene O +
expression O +
that O +
relies O +
on O +
the O +
early O +
replication O +
of O +
expressed O +
genes O +
to O +
sequester O +
limiting O +
activating O +
transcription O +
factors O +
. O +

Using O +
an O +
erythroid B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
we O +
have O +
tested O +
the O +
changes O +
in O +
the O +
DNA O +
binding O +
activity O +
of O +
the O +
lineage O -
- O -
restricted O +
transcription O +
factor O +
GATA-1 O +
through O +
the O +
cell O +
cycle O +
. O +

We O +
find O +
that O +
GATA-1 O +
activity O +
is O +
low O +
in O +
G1 O +
, O +
peaks O +
in O +
mid O -
- O -
S O +
phase O +
, O +
and O +
then O +
decreases O +
in O +
G2 O -
/ O -
M O +
. O +

In O +
contrast O +
, O +
the O +
binding O +
activities O +
of O +
two O +
ubiquitous O +
transcription O +
factors O +
, O +
Oct1 O +
and O +
Sp1 O +
, O +
remain O +
high O +
in O +
G2 O -
/ O -
M O +
. O +

GATA-1 O +
protein O +
and O +
mRNA O +
vary O +
in O +
a O +
similar O +
manner O +
through O +
the O +
cell O +
cycle O +
, O +
suggesting O +
that O +
the O +
expression O +
of O +
the O +
gene O +
or O +
the O +
stability O +
of O +
its O +
message O +
is O +
regulated O +
. O +

Although O +
a O +
number O +
of O +
transcription O +
factors O +
involved O +
in O +
the O +
control O +
of O +
the O +
cell O +
cycle O +
or O +
DNA O +
replication O +
have O +
been O +
shown O +
to O +
peak O +
in O +
S O +
phase O +
, O +
this O +
is O +
the O +
first O +
example O +
of O +
a O +
lineage O -
- O -
restricted O +
transcription O +
factor O +
displaying O +
S O +
phase O -
- O -
specific O +
DNA O +
binding O +
activity O +
. O +

One O +
interpretation O +
of O +
these O +
data O +
leads O +
to O +
a O +
model O +
in O +
which O +
the O +
peak O +
in O +
GATA-1 O +
DNA O +
binding O +
amplifies O +
the O +
effect O +
of O +
early O +
replication O +
on O +
the O +
activation O +
of O +
erythroid O -
- O -
specific O +
genes O +
at O +
the O +
same O +
time O +
as O +
preventing O +
activation O +
of O +
non O -
- O -
erythroid O +
genes O +
containing O +
GATA O -
- O -
responsive O +
elements O +
. O +

These O +
results O +
may O +
also O +
relate O +
to O +
recent O +
data O +
implicating O +
GATA-1 O +
function O +
in O +
apoptosis O +
and O +
cell O +
cycle O +
progression O +

Constitutive O +
dephosphorylation O +
and O +
activation O +
of O +
a O +
member O +
of O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
, O +
NF O -
- O -
AT1 O +
, O +
in O +
Tax O -
- O -
expressing O +
and O +
type O +
I O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O -
- O -
infected O +
human O +
T O +
cells O +
. O +

The O +
tax O +
gene O +
product O +
of O +
the O +
type O +
I O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
( O +
HTLV O -
- O -
I O +
) O +
transactivates O +
interleukin-2 O +
( O +
IL-2 O +
) O +
gene O +
through O +
activation O +
of O +
an O +
enhancer O +
termed O +
CD28 O +
responsive O +
element O +
( O +
CD28RE O +
) O +
. O +

Tax O +
activation O +
of O +
the O +
CD28RE O +
is O +
partially O +
mediated O +
by O +
a O +
member O +
of O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
, O +
NF O -
- O -
AT1 O +
. O +

We O +
have O +
previously O +
shown O +
that O +
NF O -
- O -
AT1 O +
is O +
constitutively O +
active O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
stably O +
transfected O +
with O +
the O +
Tax O +
cDNA O +
, O +
although O +
the O +
underlying O +
molecular O +
mechanism O +
and O +
physiological O +
relevance O +
of O +
this O +
finding O +
remain O +
unclear O +
. O +

In O +
this O +
report O +
, O +
we O +
demonstrate O +
that O +
the O +
active O +
form O +
of O +
NF O -
- O -
AT1 O +
is O +
also O +
present O +
in O +
the O +
nuclei O +
of O +
HTLV O -
- O -
I O -
- O -
transformed O +
T O +
cells O +
that O +
express O +
the O +
Tax O +
protein O +
. O +

Interestingly O +
, O +
the O +
constitutive O +
activation O +
of O +
NF O -
- O -
AT1 O +
in O +
these O +
T O +
cells O +
is O +
associated O +
with O +
its O +
dephosphorylation O +
. O +

Furthermore O +
, O +
the O +
dephosphorylated O +
NF O -
- O -
AT1 O +
can O +
be O +
rapidly O +
rephosphorylated O +
when O +
the O +
cells O +
are O +
incubated O +
with O +
cyclosporin O +
A O +
, O +
an O +
immunosuppressant O +
inhibiting O +
the O +
serine O -
/ O -
threonine O +
phosphatase O +
calcineurin O +
. O +

These O +
results O +
suggest O +
that O +
activation O +
of O +
NF O -
- O -
AT1 O +
in O +
Tax B-CellLine -
- I-CellLine -
expressing I-CellLine +
and I-CellLine +
HTLV I-CellLine -
- I-CellLine -
I I-CellLine -
- I-CellLine -
transformed I-CellLine +
T I-CellLine +
cells I-CellLine +
results O +
from O +
its O +
dephosphorylation O +
, O +
which O +
in O +
turn O +
may O +
be O +
due O +
to O +
deregulation O +
of O +
calcineurin O +

Isolation O +
of O +
a O +
B O -
- O -
cell O -
- O -
specific O +
promoter O +
for O +
the O +
human O +
class O +
II O +
transactivator O +
. O +

The O +
class O +
II O +
transactivator O +
( O +
CIITA O +
) O +
is O +
essential O +
for O +
the O +
expression O +
of O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
class O +
II O +
antigens O +
. O +

The O +
tissular O +
patterns O +
of O +
CIITA O +
and O +
MHC O +
class O +
II O +
gene O +
expression O +
are O +
tightly O +
correlated O +
: O +
CIITA O +
mRNA O +
is O +
highly O +
expressed O +
in O +
B O +
cells O +
, O +
and O +
is O +
induced O +
by O +
interferon O +
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
in O +
macrophage B-CellLine +
and I-CellLine +
epithelial I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

We O +
first O +
isolated O +
two O +
overlapping O +
cosmids O +
encoding O +
human O +
CIITA O +
which O +
, O +
when O +
co O -
- O -
transfected O +
, O +
are O +
able O +
to O +
restore O +
MHC O +
class O +
II O +
expression O +
in O +
a O +
B B-CellLine -
- I-CellLine -
lymphoblastoid I-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
B B-CellLine -
- I-CellLine -
LCL I-CellLine +
) O +
defective O +
for O +
CIITA O +
. O +

Subsequently O +
, O +
a O +
1.8 O +
kilobase O +
( O +
kb O +
) O +
fragment O +
of O +
the O +
CIITA O +
promoter O +
was O +
isolated O +
and O +
sequenced O +
. O +

A O +
motif O +
presenting O +
a O +
strong O +
similarity O +
to O +
an O +
initiator O +
was O +
detected O +
, O +
as O +
well O +
as O +
putative O +
binding O +
sites O +
for O +
Sp1 O +
, O +
GATA-2 O +
, O +
LyF-1 O +
, O +
ets-1 O +
, O +
AP1 O +
, O +
and O +
MZF1 O +
transcription O +
factors O +
, O +
and O +
two O +
GAS O +
motifs O +
. O +

When O +
introduced O +
in O +
front O +
of O +
a O +
luciferase O +
reporter O +
gene O +
, O +
this O +
promoter O +
is O +
able O +
to O +
direct O +
a O +
high O +
luciferase O +
activity O +
in O +
a O +
human B-CellLine +
B I-CellLine -
- I-CellLine -
LCL I-CellLine +
. O +

In O +
contrast O +
, O +
luciferase O +
expression O +
was O +
not O +
stimulated O +
after O +
IFN O -
- O -
gamma O +
treatment O +
when O +
the O +
construct O +
was O +
transfected O +
in O +
macrophage O +
or O +
in O +
epithelial B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

However O +
, O +
an O +
induction O +
of O +
the O +
human O +
CIITA O +
gene O +
was O +
observed O +
in O +
mouse B-CellLine +
macrophage I-CellLine +
and I-CellLine +
fibrosarcoma I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
when O +
the O +
cells O +
were O +
transfected O +
with O +
a O +
cosmid O +
containing O +
the O +
human O +
CIITA O +
gene O +
, O +
but O +
lacking O +
the O +
1.8 O +
kb O +
promoter O +
described O +
above O +
. O +

Taken O +
together O +
, O +
these O +
data O +
suggest O +
the O +
existence O +
of O +
an O +
intragenic O +
promoter O +
driving O +
an O +
IFN O -
- O -
gamma O +
-inducible O +
expression O +
of O +
CIITA O +
. O +

Nuclear O +
factor O -
- O -
kappaB O +
activation O +
in O +
human O +
monocytes O +
stimulated O +
with O +
lipopolysaccharide O +
is O +
inhibited O +
by O +
fibroblast O +
conditioned O +
medium O +
and O +
exogenous O +
PGE2 O +
. O +

The O +
nuclear O +
factor O +
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
is O +
thought O +
to O +
be O +
crucially O +
involved O +
in O +
the O +
gene O +
activation O +
of O +
several O +
cytokines O +
, O +
including O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O +
) O +
. O +

Previously O +
, O +
we O +
showed O +
that O +
fibroblast O +
conditioned O +
medium O +
( O +
FCM O +
) O +
is O +
able O +
to O +
inhibit O +
both O +
TNF O +
mRNA O +
accumulation O +
and O +
protein O +
release O +
in O +
peripheral B-CellLine +
blood I-CellLine -
- I-CellLine -
derived I-CellLine +
human I-CellLine +
monocytes I-CellLine +
( O +
PBM B-CellLine +
) O +
stimulated O +
with O +
lipopolysaccharide O +
( O +
LPS O +
) O +
. O +

In O +
this O +
study O +
we O +
have O +
investigated O +
the O +
effect O +
of O +
FCM O +
on O +
the O +
LPS O -
- O -
induced O +
DNA O -
- O -
binding O +
activity O +
of O +
NF O -
- O -
kappaB O +
, O +
by O +
means O +
of O +
electrophoretic O +
shift O +
assay O +
( O +
EMSA O +
) O +
. O +

We O +
provide O +
evidence O +
that O +
FCM O +
strongly O +
inhibits O +
the O +
LPS O -
- O -
induced O +
NF O -
- O -
kappaB O +
activation O +
in O +
PBM B-CellLine +
. O +

Furthermore O +
, O +
we O +
show O +
that O +
exogenous O +
PGE2 O +
mimics O +
the O +
NF O -
- O -
kappaB O +
inhibitory O +
effect O +
of O +
FCM O +
. O +

On O +
the O +
other O +
hand O +
, O +
FCM O +
produced O +
in O +
the O +
presence O +
of O +
indomethacin O +
does O +
not O +
inhibit O +
NF O -
- O -
kappaB O +
activation O +
by O +
LPS O +
. O +

Our O +
results O +
lend O +
further O +
support O +
to O +
the O +
hypothesis O +
that O +
inflammatory O +
and O +
immune O +
responses O +
of O +
monocytes O -
/ O -
macrophages O +
may O +
be O +
modulated O +
at O +
the O +
molecular O +
level O +
by O +
signals O +
originating O +
from O +
tissue O +
structural O +
cells O +
such O +
as O +
fibroblasts O +
. O +

Inhibitory O +
effect O +
of O +
growth O +
hormone O +
on O +
TNF O -
- O -
alpha O +
secretion O +
and O +
nuclear O +
factor O -
- O -
kappaB O +
translocation O +
in O +
lipopolysaccharide O -
- O -
stimulated O +
human O +
monocytes O +
. O +

Several O +
studies O +
have O +
pointed O +
to O +
a O +
link O +
between O +
immune O +
and O +
endocrine O +
systems O +
, O +
including O +
a O +
regulatory O +
function O +
of O +
GH O +
on O +
monocyte O +
activation O +
. O +

The O +
present O +
study O +
demonstrates O +
that O +
human O +
THP-1 B-CellLine +
promonocytic I-CellLine +
cells I-CellLine +
, O +
engineered O +
by O +
gene O +
transfer O +
to O +
constitutively O +
produce O +
human O +
growth O +
hormone O +
( O +
hGH O +
) O +
, O +
secreted O +
depressed O +
amounts O +
of O +
TNF O -
- O -
alpha O +
in O +
response O +
to O +
challenge O +
by O +
LPS O +
. O +

The O +
effect O +
of O +
GH O +
appears O +
to O +
occur O +
in O +
an O +
autocrine O +
fashion O +
, O +
since O +
the O +
inhibitory O +
effect O +
on O +
TNF O -
- O -
alpha O +
secretion O +
by O +
constitutive O +
GH O +
production O +
could O +
be O +
abolished O +
in O +
the O +
presence O +
of O +
anti O -
- O -
hGH O +
mAb O +
. O +

The O +
GH O -
- O -
induced O +
inhibitory O +
effect O +
was O +
also O +
observed O +
using O +
normal O +
human O +
monocytes O +
and O +
monocyte O -
- O -
derived O +
macrophages O +
. O +

Inhibition O +
of O +
TNF O -
- O -
alpha O +
production O +
by O +
THP-1-hGH B-CellLine -
- I-CellLine -
transfected I-CellLine +
cells I-CellLine +
cultured O +
in O +
the O +
presence O +
of O +
LPS O +
is O +
dependent O +
on O +
a O +
selective O +
pathway O +
, O +
since O +
no O +
inhibition O +
of O +
TNF O -
- O -
alpha O +
production O +
was O +
observed O +
when O +
cells O +
were O +
cultured O +
in O +
the O +
presence O +
of O +
PMA O +
. O +

Inhibition O +
of O +
TNF O -
- O -
alpha O +
secretion O +
by O +
LPS B-CellLine -
- I-CellLine -
stimulated I-CellLine +
THP-1-hGH I-CellLine +
cells I-CellLine +
was O +
associated O +
with O +
a O +
decrease O +
in O +
nuclear O +
translocation O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
. O +

The O +
capacity O +
of O +
GH O +
to O +
inhibit O +
LPS O -
- O -
induced O +
TNF O -
- O -
alpha O +
production O +
by O +
monocytes O +
without O +
altering O +
other O +
pathways O +
leading O +
to O +
TNF O -
- O -
alpha O +
production O +
may O +
be O +
of O +
potential O +
relevance O +
in O +
septic O +
shock O +
, O +
since O +
GH O +
is O +
available O +
for O +
clinical O +
use O +
. O +

Impaired O +
induction O +
of O +
c O -
- O -
fos O -
/ O -
c O -
- O -
jun O +
genes O +
and O +
of O +
transcriptional O +
regulatory O +
proteins O +
binding O +
distinct O +
c O -
- O -
fos O -
/ O -
c O -
- O -
jun O +
promoter O +
elements O +
in O +
activated O +
human O +
T O +
cells O +
during O +
aging O +
. O +

The O +
activation O +
of O +
transcriptional O +
factor O +
c O -
- O -
Fos O -
/ O -
c O -
- O -
Jun O +
AP-1 O +
is O +
essential O +
for O +
normal O +
T O +
cell O +
responsiveness O +
and O +
is O +
often O +
impaired O +
in O +
T O +
cells O +
during O +
aging O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
investigated O +
whether O +
aberrancies O +
in O +
the O +
regulation O +
of O +
c O -
- O -
fos O -
/ O -
c O -
- O -
jun O +
at O +
the O +
mRNA O +
or O +
protein O +
level O +
might O +
underlie O +
the O +
age O -
- O -
associated O +
impairments O +
of O +
AP-1 O +
in O +
human O +
T O +
cells O +
. O +

Whereas O +
T O +
cells O +
from O +
young O +
subjects O +
stimulated O +
with O +
cross O -
- O -
linked O +
anti O -
- O -
CD3epsilon O +
mAb O +
OKT3 O +
plus O +
PMA O +
or O +
with O +
the O +
lectin O +
PHA O +
plus O +
PMA O +
demonstrated O +
considerable O +
increases O +
in O +
c O -
- O -
Fos O +
protein O +
expression O +
, O +
the O +
expression O +
of O +
c O -
- O -
Fos O +
but O +
not O +
c O -
- O -
Jun O +
was O +
markedly O +
reduced O +
in O +
stimulated O +
T O +
cells O +
from O +
certain O +
elderly O +
subjects O +
. O +

In O +
addition O +
, O +
RNase O +
protection O +
assays O +
revealed O +
that O +
anti O -
- O -
CD3 O -
/ O +
PMA O -
- O -
stimulated O +
T O +
cells O +
from O +
a O +
substantial O +
proportion O +
of O +
elderly O +
subjects O +
exhibited O +
decreased O +
levels O +
of O +
c O -
- O -
fos O +
and/or O +
c O -
- O -
jun O +
mRNA O +
compared O +
to O +
T O +
cells O +
from O +
young O +
subjects O +
. O +

Using O +
electrophoretic O +
mobility O +
shift O +
assays O +
, O +
the O +
levels O +
of O +
nuclear O +
regulatory O +
proteins O +
recognizing O +
the O +
AP-1 O +
consensus O +
TRE O +
motif O +
, O +
the O +
proximal O +
c O -
- O -
jun O +
TRE O -
- O -
like O +
promoter O +
element O +
, O +
and O +
the O +
c O -
- O -
fos O +
serum O +
response O +
element O +
( O +
SRE O +
) O +
were O +
determined O +
in O +
resting O +
and O +
stimulated O +
T O +
cells O +
. O +

Although O +
the O +
stimulation O +
of O +
T O +
cells O +
from O +
young O +
subjects O +
resulted O +
in O +
coordinated O +
increases O +
of O +
nuclear O +
protein O +
complexes O +
binding O +
the O +
AP-1 O +
TRE O +
, O +
c O -
- O -
jun O +
TRE O +
, O +
and O +
c O -
- O -
fos O +
SRE O +
DNA O +
sequence O +
motifs O +
, O +
age O -
- O -
related O +
reductions O +
in O +
the O +
activation O +
of O +
AP-1 O +
were O +
accompanied O +
by O +
decreased O +
levels O +
of O +
c O -
- O -
jun O +
TRE O +
and O +
c O -
- O -
fos O +
SRE O +
binding O +
complexes O +
. O +

Furthermore O +
, O +
the O +
nuclear O +
protein O +
complexes O +
binding O +
the O +
SRE O +
motif O +
induced O +
in O +
activated O +
T O +
cells O +
of O +
young O +
and O +
elderly O +
subjects O +
contained O +
serum O +
response O +
factor O +
and O +
Elk-1 O +
pointing O +
toward O +
age O -
- O -
related O +
defects O +
in O +
the O +
activation O +
of O +
transcriptional O +
regulatory O +
proteins O +
distinct O +
from O +
c O -
- O -
jun O -
/ O -
AP-1 O +
. O +

These O +
results O +
suggest O +
that O +
underlying O +
aberrancies O +
in O +
the O +
induction O +
of O +
c O -
- O -
fos O -
/ O -
c O -
- O -
jun O +
as O +
well O +
as O +
their O +
nuclear O +
regulatory O +
proteins O +
may O +
contribute O +
to O +
the O +
age O -
- O -
related O +
impairments O +
of O +
AP-1 O +
activation O +
in O +
human O +
T O +
cells O +
. O +

Dissociation O +
of O +
the O +
Jak O +
kinase O +
pathway O +
from O +
G O -
- O -
CSF O +
receptor O +
signaling O +
in O +
neutrophils O +
. O +

Activation O +
of O +
the O +
granulocyte O +
colony O -
- O -
stimulating O +
factor O +
receptor O +
( O +
G O -
- O -
CSFR O +
) O +
induces O +
rapid O +
tyrosine O +
phosphorylation O +
of O +
multiple O +
intracellular O +
substrates O +
in O +
proliferating O +
cells O +
and O +
nonproliferating O +
, O +
terminally O +
differentiated O +
neutrophils O +
. O +

The O +
kinases O +
that O +
couple O +
ligand O +
binding O +
to O +
tyrosine O +
phosphorylation O +
of O +
cellular O +
substrates O +
by O +
the O +
G O -
- O -
CSFR O +
with O +
activation O +
of O +
specific O +
functional O +
programs O +
are O +
largely O +
unknown O +
. O +

In O +
this O +
study O +
, O +
we O +
examined O +
early O +
signaling O +
events O +
in O +
proliferating O +
and O +
terminally O +
differentiated O +
cells O +
following O +
G O -
- O -
CSF O +
stimulation O +
to O +
determine O +
whether O +
identical O +
signaling O +
cascades O +
are O +
activated O +
. O +

In O +
murine B-CellLine +
Ba I-CellLine -
/ I-CellLine -
F3 I-CellLine +
cells I-CellLine +
transfected O +
with O +
the O +
human O +
G O -
- O -
CSFR O +
and O +
NFS-60 B-CellLine +
cells I-CellLine +
constitutively O +
expressing O +
the O +
murine O +
G O -
- O -
CSFR O +
, O +
G O -
- O -
CSF O +
induced O +
tyrosine O +
phosphorylation O +
and O +
activation O +
of O +
Jak1 O +
, O +
Jak2 O +
, O +
and O +
Tyk2 O +
. O +

Tyrosine O +
phosphorylation O +
of O +
Stat3 O +
and O +
, O +
to O +
a O +
lesser O +
extent O +
, O +
Stat1 O +
was O +
also O +
detected O +
following O +
G O -
- O -
CSF O +
stimulation O +
. O +

Using O +
a O +
mitogenically O +
incompetent O +
human O +
G O -
- O -
CSFR O +
mutant O +
in O +
which O +
Pro639 O +
and O +
Pro641 O +
were O +
substituted O +
by O +
alanine O +
, O +
the O +
box O +
1 O +
PDP O +
motif O +
was O +
found O +
to O +
be O +
required O +
for O +
activation O +
of O +
Jak O +
kinases O +
, O +
tyrosine O +
phosphorylation O +
of O +
the O +
G O -
- O -
CSFR O +
, O +
and O +
recruitment O +
of O +
Stat O +
proteins O +
. O +

Notably O +
, O +
no O +
activation O +
of O +
Jak1 O +
, O +
Jak2 O +
, O +
Tyk2 O +
, O +
Stat1 O +
, O +
or O +
Stat3 O +
was O +
observed O +
in O +
neutrophils O +
following O +
G O -
- O -
CSF O +
stimulation O +
. O +

In O +
addition O +
, O +
there O +
was O +
no O +
detectable O +
activation O +
in O +
neutrophils O +
of O +
the O +
recently O +
cloned O +
Jak3 O +
kinase O +
, O +
which O +
has O +
been O +
reported O +
to O +
be O +
expressed O +
at O +
high O +
levels O +
as O +
myeloid O +
cells O +
undergo O +
terminal O +
neutrophilic O +
maturation O +
. O +

These O +
results O +
indicate O +
a O +
lack O +
of O +
involvement O +
of O +
Jak O +
kinases O +
in O +
signaling O +
by O +
the O +
G O -
- O -
CSFR O +
in O +
neutrophils O +
, O +
and O +
suggest O +
utilization O +
of O +
alternative O +
signal O +
transduction O +
pathways O +
distinct O +
from O +
those O +
in O +
proliferating O +
cells O +
. O +

Activation O +
of O +
the O +
Jak O +
-Stat O +
pathway O +
correlates O +
with O +
proliferative O +
signaling O +
by O +
the O +
G O -
- O -
CSFR O +
and O +
requires O +
the O +
membrane O -
- O -
proximal O +
box O +
1 O +
PXP O +
motif O +
, O +
which O +
is O +
conserved O +
in O +
members O +
of O +
the O +
cytokine O +
receptor O +
superfamily O +
. O +

Adenovirus O +
E1B O +
19 O -
K O +
protein O +
is O +
required O +
for O +
efficient O +
DNA O +
replication O +
in O +
U937 B-CellLine +
cells I-CellLine +
. O +

The O +
adenovirus O +
E1B O +
19 O -
K O +
gene O +
plays O +
an O +
essential O +
role O +
in O +
transformation O +
of O +
primary O +
rodent O +
cells O +
in O +
cooperation O +
with O +
E1A O +
and O +
in O +
the O +
inhibition O +
of O +
apoptosis O +
during O +
lytic O +
infection O +
. O +

It O +
has O +
been O +
shown O +
that O +
this O +
E1B O +
19 O -
K O +
protein O +
is O +
not O +
necessary O +
for O +
viral O +
DNA O +
replication O +
in O +
human B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
such O +
as O +
HeLa B-CellLine +
and O +
KB B-CellLine +
. O +

We O +
reported O +
here O +
that O +
the O +
E1B O +
19 O -
K O +
mutant O +
viruses O +
were O +
unable O +
to O +
replicate O +
efficiently O +
in O +
a O +
monocyte B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
U937 B-CellLine +
. O +

Viral O +
DNA O +
synthesis O +
and O +
late O +
gene O +
expression O +
were O +
found O +
to O +
be O +
defective O +
in O +
U937 B-CellLine +
cells I-CellLine +
infected O +
with O +
E1B O +
19 O -
K O +
mutants O +
compared O +
with O +
wild O -
- O -
type O +
virus O +
. O +

Early O +
viral O +
RNA O +
splicing O +
patterns O +
also O +
differ O +
between O +
wild B-CellLine -
- I-CellLine -
type I-CellLine +
and I-CellLine +
dl337-infected I-CellLine +
cells I-CellLine +
. O +

Furthermore O +
, O +
the O +
defect O +
in O +
viral O +
replication O +
could O +
be O +
complemented O +
by O +
dl312 O +
virus O +
defective O +
in O +
E1A O +
expression O +
4 O +
days O +
after O +
infection O +
with O +
E1B O +
mutants O +
, O +
suggesting O +
persistence O +
of O +
the O +
E1B O +
mutant O +
genome O +
in O +
the O +
infected O +
cells O +
despite O +
defective O +
onset O +
of O +
the O +
late O +
phase O +
of O +
replication O +
. O +

These O +
results O +
imply O +
that O +
E1B O +
19 O -
K O +
is O +
required O +
for O +
efficient O +
viral O +
DNA O +
replication O +
in O +
U937 B-CellLine +
cells I-CellLine +
. O +

Inefficient O +
DNA O +
replication O +
is O +
also O +
found O +
in O +
another O +
monocyte B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
THP-1 B-CellLine +

Interaction O +
of O +
transcription O +
factors O +
RFX1 O +
and O +
MIBP1 O +
with O +
the O +
gamma O +
motif O +
of O +
the O +
negative O +
regulatory O +
element O +
of O +
the O +
hepatitis O +
B O +
virus O +
core O +
promoter O +
. O +

The O +
negative O +
regulatory O +
element O +
( O +
NRE O +
) O +
of O +
the O +
hepatitis O +
B O +
virus O +
( O +
HBV O +
) O +
core O +
promoter O +
contains O +
three O +
subregions O +
which O +
act O +
synergistically O +
to O +
suppress O +
core O +
promoter O +
activity O +
. O +

One O +
of O +
these O +
subregions O +
, O +
NRE O +
gamma O +
, O +
is O +
active O +
in O +
both O +
HeLa B-CellLine +
cervical I-CellLine +
carcinoma I-CellLine +
cells I-CellLine +
and O +
Huh7 B-CellLine +
hepatoma I-CellLine +
cells I-CellLine +
and O +
was O +
found O +
to O +
be O +
bound O +
by O +
a O +
protein O +
factor O +
present O +
in O +
both O +
cell O +
types O +
. O +

Here O +
we O +
show O +
that O +
the O +
transcription O +
factor O +
RFX1 O +
can O +
bind O +
to O +
NRE O +
gamma O +
and O +
transactivate O +
the O +
core O +
promoter O +
through O +
this O +
site O +
. O +

Mutations O +
which O +
abrogated O +
the O +
gene O -
- O -
suppressive O +
activity O +
of O +
NRE O +
gamma O +
prevented O +
RFX1 O +
from O +
binding O +
to O +
NRE O +
gamma O +
. O +

In O +
addition O +
, O +
RFX1 O +
can O +
bind O +
simultaneously O +
, O +
most O +
likely O +
as O +
a O +
heterodimer O +
, O +
with O +
the O +
transcription O +
factor O +
MIBP1 O +
to O +
NRE O +
gamma O +
. O +

In O +
the O +
absence O +
of O +
a O +
cloned O +
MIBP1 O +
gene O +
for O +
further O +
studies O +
, O +
we O +
hypothesize O +
that O +
RFX1 O +
acts O +
with O +
MIBP1 O +
to O +
negatively O +
regulate O +
the O +
core O +
promoter O +
activity O +
through O +
the O +
NRE O +
gamma O +
site O +
. O +

The O +
ability O +
of O +
RFX1 O +
to O +
transactivate O +
the O +
core O +
promoter O +
raises O +
the O +
possibility O +
that O +
RFX1 O +
may O +
play O +
a O +
dual O +
role O +
in O +
regulating O +
HBV O +
gene O +
expression O +

Evaluation O +
of O +
monoclonal O +
anti O -
- O -
D O +
reagents O +
using O +
D B-CellLine +
variant I-CellLine +
cells I-CellLine +
. O +

Monoclonal O +
anti O -
- O -
D O +
antibodies O +
submitted O +
to O +
the O +
Third O +
Monoclonal O +
International O +
Workshop O +
were O +
evaluated O +
against O +
a O +
number O +
of O +
D B-CellLine +
variant I-CellLine +
cells I-CellLine +
using O +
standard O +
serological O +
techniques O +
. O +

The O +
monoclonal O +
antibodies O +
were O +
able O +
to O +
discriminate O +
between O +
the O +
cells O +
of O +
Categories B-CellLine +
Va I-CellLine +
, I-CellLine +
VI I-CellLine +
and I-CellLine +
DFR I-CellLine +
but I-CellLine +
not I-CellLine +
Category I-CellLine +
III I-CellLine +
cells I-CellLine +
. O +

Cells O +
within O +
each O +
category O +
did O +
not O +
give O +
any O +
aberrant O +
results O +
. O +

The O +
Rh B-CellLine +
: I-CellLine +
33 I-CellLine +
cells I-CellLine +
behaved O +
as O +
normal O +
Rh O +
( O +
D O +
) O +
positive O +
cells O +
. O +

Pancreatic O +
development O +
and O +
maturation O +
of O +
the O +
islet O +
B O +
cell O +
. O +

Studies O +
of O +
pluripotent B-CellLine +
islet I-CellLine +
cultures I-CellLine +
. O +

Pancreas O +
organogenesis O +
is O +
a O +
highly O +
regulated O +
process O +
, O +
in O +
which O +
two O +
anlage O +
evaginate O +
from O +
the O +
primitive O +
gut O +
. O +

They O +
later O +
fuse O +
, O +
and O +
, O +
under O +
the O +
influence O +
of O +
the O +
surrounding O +
mesenchyme O +
, O +
the O +
mature O +
organ O +
develops O +
, O +
being O +
mainly O +
composed O +
of O +
ductal O +
, O +
exocrine O +
and O +
endocrine O +
compartments O +
. O +

Early O +
buds O +
are O +
characterized O +
by O +
a O +
branching O +
morphogenesis O +
of O +
the O +
ductal O +
epithelium O +
from O +
which O +
endocrine O +
and O +
exocrine O +
precursor O +
cells O +
bud O +
to O +
eventually O +
form O +
the O +
two O +
other O +
compartments O +
. O +

The O +
three O +
compartments O +
are O +
thought O +
to O +
be O +
of O +
common O +
endodermal O +
origin O +
; O +
in O +
contrast O +
to O +
earlier O +
hypotheses O +
, O +
which O +
suggested O +
that O +
the O +
endocrine O +
compartment O +
was O +
of O +
neuroectodermal O +
origin O +
. O +

It O +
is O +
thus O +
generally O +
believed O +
that O +
the O +
pancreatic O +
endocrine O -
- O -
lineage O +
possesses O +
the O +
ability O +
to O +
mature O +
along O +
a O +
differentiation O +
pathway O +
that O +
shares O +
many O +
characteristics O +
with O +
those O +
of O +
neuronal O +
differentiation O +
. O +

During O +
recent O +
years O +
, O +
studies O +
of O +
insulin O -
- O -
gene O +
regulation O +
and O +
, O +
in O +
particular O +
, O +
the O +
tissue O -
- O -
specific O +
transcriptional O +
control O +
of O +
insulin O -
- O -
gene O +
activity O +
have O +
provided O +
information O +
on O +
pancreas O +
development O +
in O +
general O +
. O +

The O +
present O +
review O +
summarizes O +
these O +
findings O +
, O +
with O +
a O +
special O +
focus O +
on O +
our O +
own O +
studies O +
on O +
pluripotent B-CellLine +
endocrine I-CellLine +
cultures I-CellLine +
of O +
rat O +
pancreas O +
. O +

Cloning O +
and O +
expression O +
of O +
the O +
glucocorticoid O +
receptor O +
from O +
the O +
squirrel O +
monkey O +
( O +
Saimiri O +
boliviensis O +
boliviensis O +
) O +
, O +
a O +
glucocorticoid O -
- O -
resistant O +
primate O +
. O +

New O +
World O +
primates O +
such O +
as O +
the O +
squirrel O +
monkey O +
have O +
elevated O +
cortisol O +
levels O +
and O +
glucocorticoid O +
resistance O +
. O +

We O +
have O +
shown O +
that O +
the O +
apparent O +
binding O +
affinity O +
of O +
the O +
glucocorticoid O +
receptor O +
in O +
squirrel O +
monkey O +
lymphocytes O +
is O +
5-fold O +
lower O +
than O +
that O +
in O +
human O +
lymphocytes O +
( O +
apparent O +
Kd O +
, O +
20.9 O +
+ O -
/- O +
1.8 O +
and O +
4.3 O +
+ O -
/- O +
0.2 O +
nmol O -
/ O -
L O +
, O +
respectively O +
; O +
n O +
= O +
3 O +
) O +
, O +
consistent O +
with O +
previous O +
studies O +
in O +
mononuclear O +
leukocytes O +
isolated O +
from O +
the O +
two O +
species O +
. O +

As O +
a O +
first O +
step O +
in O +
understanding O +
the O +
mechanism O +
of O +
decreased O +
binding O +
affinity O +
in O +
New O +
World O +
primates O +
, O +
we O +
used O +
reverse O +
transcription O -
- O -
PCR O +
to O +
clone O +
the O +
glucocorticoid O +
receptor O +
from O +
squirrel O +
monkey O +
liver O +
and O +
have O +
compared O +
the O +
sequence O +
to O +
receptor O +
sequences O +
obtained O +
from O +
owl O +
monkey O +
liver O +
, O +
cotton B-CellLine -
- I-CellLine -
top I-CellLine +
tamarin I-CellLine +
B95 I-CellLine -
- I-CellLine -
8 I-CellLine +
cells I-CellLine +
, O +
and O +
human O +
lymphocytes O +
. O +

The O +
squirrel O +
monkey O +
glucocorticoid O +
receptor O +
is O +
approximately O +
97 O +
% O +
identical O +
in O +
nucleotide O +
and O +
amino O +
acid O +
sequence O +
to O +
the O +
human O +
receptor O +
. O +

The O +
ligand O -
- O -
binding O +
domain O +
( O +
amino O +
acids O +
528 O -
- O -
777 O +
) O +
of O +
the O +
squirrel O +
monkey O +
glucocorticoid O +
receptor O +
contains O +
four O +
amino O +
acid O +
differences O +
( O +
Ser551 O +
to O +
Thr O +
, O +
Ser616 O +
to O +
Ala O +
, O +
Ala618 O +
to O +
Ser O +
, O +
and O +
Ile761 O +
to O +
Leu O +
) O +
, O +
all O +
of O +
which O +
are O +
present O +
in O +
owl O +
monkey O +
and O +
cotton O -
- O -
top O +
tamarin O +
receptors O +
. O +

The O +
DNA O -
- O -
binding O +
domain O +
( O +
amino O +
acids O +
421 O -
- O -
486 O +
) O +
is O +
completely O +
conserved O +
among O +
human O +
, O +
squirrel O +
monkey O +
, O +
owl O +
monkey O +
, O +
and O +
cotton O -
- O -
top O +
tamarin O +
receptors O +
. O +

Twenty O -
- O -
two O +
differences O +
from O +
the O +
human O +
sequence O +
were O +
found O +
in O +
the O +
N O -
- O -
terminal O +
region O +
( O +
amino O +
acids O +
1 O -
- O -
421 O +
) O +
of O +
the O +
squirrel O +
monkey O +
receptor O +
. O +

None O +
of O +
the O +
substitutions O +
in O +
the O +
ligand O -
- O -
binding O +
domain O +
matched O +
mutations O +
known O +
to O +
influence O +
binding O +
affinity O +
in O +
other O +
species O +
. O +

To O +
determine O +
whether O +
the O +
substitutions O +
per O +
se O +
were O +
responsible O +
for O +
decreased O +
affinity O +
, O +
squirrel O +
monkey O +
and O +
human O +
glucocorticoid O +
receptors O +
were O +
expressed O +
in O +
the O +
TNT O +
Coupled O +
Reticulocyte O +
Lysate O +
System O +
. O +

Expressions O +
of O +
human O +
and O +
squirrel O +
monkey O +
glucocorticoid O +
receptors O +
and O +
a O +
squirrel O +
monkey O +
receptor O +
in O +
which O +
Phe774 O +
was O +
mutated O +
to O +
Leu O +
( O +
F774L O +
) O +
were O +
similar O +
. O +

When O +
expressed O +
in O +
the O +
TNT O +
System O +
, O +
squirrel O +
monkey O +
and O +
human O +
glucocorticoid O +
receptors O +
had O +
similar O +
, O +
high O +
affinity O +
binding O +
for O +
dexamethasone O +
( O +
apparent O +
Kd O +
, O +
5.9 O +
+ O -
/- O +
1.2 O +
and O +
4.3 O +
+ O -
/- O +
0.5 O +
nmol O -
/ O -
L O +
, O +
respectively O +
; O +
n O +
= O +
3 O +
) O +
, O +
whereas O +
the O +
squirrel O +
monkey O +
F774L O +
receptor O +
had O +
lower O +
affinity O +
binding O +
( O +
apparent O +
Kd O +
, O +
20.4 O +
+ O -
/- O +
2.0 O +
nmol O -
/ O -
L O +
; O +
n O +
= O +
3 O +
) O +
. O +

Thus O +
, O +
substitutions O +
within O +
the O +
ligand O -
- O -
binding O +
domain O +
of O +
the O +
squirrel O +
monkey O +
glucocorticoid O +
receptor O +
can O +
not O +
account O +
for O +
the O +
decreased O +
binding O +
affinity O +
of O +
these O +
receptors O +
in O +
squirrel O +
monkey O +
cells O +
. O +

Rather O +
, O +
the O +
binding O +
affinity O +
is O +
probably O +
influenced O +
by O +
the O +
expression O +
of O +
cytosolic O +
factors O +
that O +
affect O +
glucocorticoid O +
receptor O +
function O +
. O +

Characterization O +
of O +
the O +
human O +
platelet O -
/ O -
endothelial O +
cell O +
adhesion O +
molecule-1 O +
promoter O +
: O +
identification O +
of O +
a O +
GATA-2 O +
binding O +
element O +
required O +
for O +
optimal O +
transcriptional O +
activity O +
. O +

Platelet O -
/ O -
endothelial O +
cell O +
adhesion O +
molecule-1 O +
( O +
PECAM-1 O +
) O +
is O +
a O +
130-kD O +
member O +
of O +
the O +
Ig O +
gene O +
superfamily O +
that O +
is O +
expressed O +
on O +
platelets O +
, O +
endothelial O +
cells O +
, O +
and O +
certain O +
leukocyte O +
subsets O +
. O +

To O +
examine O +
the O +
factors O +
controlling O +
vascular O -
- O -
specific O +
expression O +
of O +
PECAM-1 O +
, O +
we O +
cloned O +
the O +
5'-flanking O +
region O +
of O +
the O +
PECAM-1 O +
gene O +
and O +
analyzed O +
its O +
transcriptional O +
activity O +
. O +

5'-Rapid O +
amplification O +
of O +
cDNA O +
ends O +
( O +
5'-RACE O +
) O +
analysis O +
showed O +
that O +
transcription O +
initiation O +
occurred O +
at O +
several O +
closely O +
spaced O +
nearby O +
sites O +
originating O +
approximately O +
204 O +
bp O +
upstream O +
from O +
the O +
translation O +
start O +
site O +
. O +

Analysis O +
of O +
the O +
sequence O +
immediately O +
upstream O +
from O +
the O +
transcription O +
initiation O +
site O +
( O +
TIS O +
) O +
showed O +
no O +
canonical O +
TATA O +
or O +
CAAT O +
elements O +
, O +
however O +
an O +
initiator O +
element O +
commonly O +
found O +
in O +
TATA O -
- O -
less O +
promoters O +
encompassed O +
the O +
TIS O +
. O +

5'-serially O +
truncated O +
PECAM-1 O +
promoter O +
segments O +
cloned O +
in O +
front O +
of O +
a O +
luciferase O +
reporter O +
drove O +
transcription O +
in O +
both O +
a O +
lineage- O +
and O +
orientation O -
- O -
specific O +
manner O +
. O +

Putative O +
cis O -
- O -
acting O +
control O +
elements O +
present O +
within O +
a O +
300-bp O +
core O +
promoter O +
included O +
two O +
ets O +
sites O +
, O +
an O +
Sp1 O +
site O +
, O +
tandem O +
E O -
- O -
box O +
domains O +
, O +
two O +
GATA O -
- O -
associated O +
sites O +
( O +
CACCC O +
) O +
, O +
an O +
AP-2 O +
binding O +
site O +
, O +
and O +
a O +
GATA O +
element O +
at O +
-24 O +
. O +

Mutational O +
analysis O +
showed O +
that O +
optimal O +
transcriptional O +
activity O +
required O +
the O +
GATA O +
sequence O +
at O +
position O +
-24 O +
, O +
and O +
gel O -
- O -
shift O +
assays O +
further O +
showed O +
that O +
the O +
GATA-2 O +
transcription O +
factor O +
, O +
but O +
not O +
GATA-1 O +
, O +
bound O +
to O +
this O +
region O +
of O +
the O +
PECAM-1 O +
promoter O +
. O +

Understanding O +
the O +
cis- O +
and O +
transacting O +
factors O +
that O +
regulate O +
the O +
tissue O -
- O -
specific O +
expression O +
of O +
PECAM-1 O +
should O +
increase O +
our O +
understanding O +
of O +
the O +
mechanisms O +
by O +
which O +
vascular O -
- O -
specific O +
gene O +
expression O +
is O +
achieved O +
. O +

Expression O +
of O +
erythroid O -
- O -
specific O +
genes O +
in O +
megakaryoblastic O +
disorders O +
. O +

Currently O +
available O +
data O +
indicate O +
that O +
erythroid O +
and O +
megakaryocytic O +
differentiation O +
pathways O +
are O +
closely O +
related O +
to O +
each O +
other O +
, O +
and O +
there O +
may O +
exist O +
progenitor O +
cells O +
common O +
to O +
those O +
two O +
lineages O +
may O +
exist O +
. O +

Acute O +
megakaryoblastic O +
leukemia O +
( O +
AML O -
- O -
M7 O +
) O +
and O +
transient O +
myeloproliferative O +
disorder O +
in O +
Down O +
's O +
syndrome O +
( O +
TMD O +
) O +
are O +
characterized O +
by O +
rapid O +
growth O +
of O +
abnormal O +
blast O +
cells O +
which O +
express O +
megakaryocytic O +
markers O +
. O +

These O +
blast O +
cells O +
express O +
lineage O -
- O -
specific O +
transcription O +
factors O +
such O +
as O +
GATA-1 O +
common O +
to O +
these O +
lineages O +
and O +
frequently O +
express O +
erythroid O -
- O -
specific O +
mRNAs O +
such O +
as O +
gamma O -
- O -
globin O +
and O +
erythroid O +
delta O -
- O -
aminolevulinate O +
synthase O +
( O +
ALAS O -
- O -
E O +
) O +
, O +
indicating O +
that O +
most O +
of O +
the O +
blasts O +
in O +
M7 O +
and O +
TMD O +
cases O +
have O +
erythroid O +
and O +
megakaryocytic O +
phenotypes O +
. O +

These O +
results O +
suggest O +
that O +
blasts O +
in O +
M7 O +
and O +
TMD O +
may O +
correspond O +
to O +
progenitors O +
of O +
both O +
erythroid O +
and O +
megakaryocytic O +
lineages O +
. O +

Nuclear O +
NF O -
- O -
ATp O +
is O +
a O +
hallmark O +
of O +
unstimulated O +
B O +
cells O +
from O +
B O -
- O -
CLL O +
patients O +
. O +

B O +
lymphocytes O +
from O +
the O +
peripheral O +
blood O +
of O +
patients O +
with O +
chronic O +
lymphocytic O +
leukaemia O +
( O +
CLL O +
) O +
were O +
analysed O +
for O +
the O +
nuclear O +
presence O +
and O +
DNA O +
binding O +
of O +
a O +
panel O +
of O +
transcription O +
factors O +
which O +
are O +
involved O +
in O +
the O +
gene O +
control O +
of O +
lymphoid O +
cells O +
. O +

The O +
following O +
transcription O +
factors O +
were O +
studied O +
: O +
the O +
Octamer O +
factors O +
Oct-1 O +
and O +
Oct-2 O +
, O +
members O +
of O +
the O +
AP-1 O +
factor O +
family O +
, O +
NF O -
- O -
AT O +
factors O +
, O +
in O +
particular O +
NF O -
- O -
ATp O +
, O +
and O +
members O +
of O +
the O +
Rel O -
/ O -
NF O -
- O -
kB O +
family O +
. O +

We O +
show O +
that O +
the O +
constitutive O +
nuclear O +
translocation O +
of O +
NF O -
- O -
ATp O +
, O +
a O +
member O +
of O +
the O +
growing O +
family O +
of O +
NF O -
- O -
AT O +
factors O +
, O +
is O +
a O +
hallmark O +
of O +
nonstimulated O +
B O +
cells O +
from O +
CLL O +
patients O +
that O +
distinguishes O +
B O -
- O -
CLL O +
cells O +
from O +
' O -
normal O +
' O +
B O +
lymphocytes O +
. O +

Constitutive O +
nuclear O +
appearance O +
was O +
also O +
observed O +
for O +
NF O -
- O -
kB2 O -
/ O -
p52 O +
. O +

Constitutive O +
binding O +
of O +
further O +
factor O +
proteins O +
to O +
DNA O +
, O +
such O +
as O +
JunD O +
, O +
c O -
- O -
Fos O +
and O +
FosB O +
, O +
was O +
detected O +
in O +
several O +
patients O +
whereas O +
the O +
localisation O +
and O +
DNA O +
binding O +
of O +
other O +
factors O +
such O +
as O +
c O -
- O -
Jun O +
, O +
RelA O -
/ O -
p65 O +
and O +
c O -
- O -
Rel O +
was O +
unaltered O +
. O +

It O +
is O +
remarkable O +
that O +
in O +
B O -
- O -
CLL O +
cells O +
the O +
nuclear O +
appearance O +
and O +
DNA O +
binding O +
of O +
specific O +
transcription O +
factors O +
is O +
dramatically O +
affected O +
whereas O +
other O +
members O +
of O +
the O +
same O +
factor O +
family O +
remained O +
unaltered O +
in O +
these O +
leukemic O +
cells O +
. O +

It O +
remains O +
to O +
be O +
shown O +
which O +
molecular O +
events O +
lead O +
to O +
the O +
specific O +
' O -
pre O -
- O -
activation O +
' O +
, O +
i.e O +
. O +

constitutive O +
nuclear O +
translocation O +
and O +
DNA O +
binding O +
, O +
of O +
these O +
members O +
of O +
NF O -
- O -
AT O +
, O +
NF O -
- O -
kB O +
and O +
AP-1 O +
factor O +
families O +
. O +

Physical O +
and O +
functional O +
interaction O +
between O +
the O +
human O +
T O -
- O -
cell O +
lymphotropic O +
virus O +
type O +
1 O +
Tax1 O +
protein O +
and O +
the O +
CCAAT O +
binding O +
protein O +
NF O -
- O -
Y O +
. O +

Tax1 O +
, O +
a O +
potent O +
activator O +
of O +
human O +
T O -
- O -
cell O +
lymphotropic O +
virus O +
type O +
1 O +
( O +
HTLV-1 O +
) O +
transcription O +
, O +
has O +
been O +
shown O +
to O +
modulate O +
expression O +
of O +
many O +
cellular O +
genes O +
. O +

Tax1 O +
does O +
not O +
bind O +
DNA O +
directly O +
but O +
regulates O +
transcription O +
through O +
protein O -
- O -
protein O +
interactions O +
with O +
sequence O -
- O -
specific O +
transcription O +
factors O +
. O +

Using O +
the O +
yeast O +
two O -
- O -
hybrid O +
system O +
to O +
screen O +
for O +
proteins O +
which O +
interact O +
with O +
Tax1 O +
, O +
we O +
isolated O +
the O +
B O +
subunit O +
of O +
the O +
CCAAT O +
binding O +
protein O +
NF O -
- O -
Y O +
from O +
a O +
HeLa O +
cDNA O +
library O +
. O +

The O +
interaction O +
of O +
Tax1 O +
with O +
NF O -
- O -
YB O +
was O +
specific O +
in O +
that O +
NF O -
- O -
YB O +
did O +
not O +
interact O +
with O +
a O +
variety O +
of O +
other O +
transcription O +
factors O +
, O +
including O +
human O +
immunodeficiency O +
virus O +
Tat O +
, O +
human O +
papillomavirus O +
E6 O +
, O +
and O +
Bicoid O +
, O +
or O +
with O +
the O +
M7 O +
( O +
amino O +
acids O +
29CP O -
- O -
AS O +
) O +
Tax1 O +
mutant O +
. O +

However O +
, O +
NF O -
- O -
YB O +
did O +
interact O +
with O +
the O +
C O -
- O -
terminal O +
Tax1 O +
mutants O +
M22 O +
( O +
130TL O -
- O -
AS O +
) O +
and O +
M47 O +
( O +
319LL O -
- O -
RS O +
) O +
. O +

We O +
also O +
show O +
that O +
in O +
vitro O -
- O -
translated O +
NF O -
- O -
YB O +
specifically O +
bound O +
to O +
a O +
glutathione O +
S O -
- O -
transferase O -
- O -
Tax1 O +
fusion O +
protein O +
. O +

Further O +
, O +
Tax1 O +
coimmunoprecipitated O +
with O +
NF O -
- O -
Y O +
from O +
nuclear O +
extracts O +
of O +
HTLV-1-transformed O +
cells O +
, O +
providing O +
evidence O +
for O +
in O +
vivo O +
interaction O +
of O +
Tax1 O +
and O +
NF O -
- O -
YB O +
. O +

We O +
further O +
demonstrate O +
that O +
Tax1 O +
specifically O +
activated O +
the O +
NF O -
- O -
Y O -
- O -
responsive O +
DQbeta O +
promoter O +
, O +
as O +
well O +
as O +
a O +
minimal O +
promoter O +
which O +
contains O +
only O +
the O +
Y O -
- O -
box O +
element O +
. O +

In O +
addition O +
, O +
mutation O +
of O +
the O +
Y O -
- O -
box O +
element O +
alone O +
abrogated O +
Tax1 O +
-mediated O +
activation O +
. O +

Taken O +
together O +
, O +
these O +
data O +
indicate O +
that O +
Tax1 O +
interacts O +
with O +
NF O -
- O -
Y O +
through O +
the O +
B O +
subunit O +
and O +
that O +
this O +
interaction O +
results O +
in O +
activation O +
of O +
the O +
major O +
histocompatibility O +
complex O +
class O +
II O +
promoter O +
. O +

Through O +
activation O +
of O +
this O +
and O +
other O +
NF O -
- O -
Y O +
driven O +
promoters O +
, O +
the O +
Tax1 O +
-NF O -
- O -
Y O +
interaction O +
may O +
play O +
a O +
critical O +
role O +
in O +
causing O +
cellular O +
transformation O +
and O +
HTLV-1 O +
pathogenesis O +
. O +

Cloning O +
of O +
the O +
novel O +
human O +
myeloid O -
- O -
cell O -
- O -
specific O +
C O -
/ O -
EBP O -
- O -
epsilon O +
transcription O +
factor O +
. O +

Chicken O +
NF O -
- O -
M O +
transcription O +
factor O +
, O +
in O +
cooperation O +
with O +
either O +
c O -
- O -
Myb O +
or O +
v O -
- O -
Myb O +
, O +
is O +
active O +
in O +
the O +
combinatorial O +
activation O +
of O +
myeloid O -
- O -
cell O -
- O -
specific O +
genes O +
in O +
heterologous O +
cell O +
types O +
, O +
such O +
as O +
embryonic O +
fibroblasts O +
. O +

In O +
humans O +
, O +
similar O +
effects O +
were O +
observed O +
with O +
homologous O +
members O +
of O +
the O +
CCAAT O -
/ O -
enhancer O -
- O -
binding O +
protein O +
( O +
C O -
/ O -
EBP O +
) O +
family O +
of O +
transcriptional O +
regulators O +
, O +
especially O +
the O +
human O +
homolog O +
of O +
chicken O +
NF O -
- O -
M O +
, O +
C O -
/ O -
EBP O -
- O -
beta O +
( O +
NF O -
- O -
IL6 O +
) O +
. O +

However O +
, O +
the O +
NF O -
- O -
IL6 O +
gene O +
is O +
expressed O +
in O +
a O +
variety O +
of O +
nonmyeloid O +
cell O +
types O +
and O +
is O +
strongly O +
inducible O +
in O +
response O +
to O +
inflammatory O +
stimuli O +
, O +
making O +
it O +
an O +
unlikely O +
candidate O +
to O +
have O +
an O +
exclusive O +
role O +
as O +
a O +
combinatorial O +
differentiation O +
switch O +
during O +
myelopoiesis O +
in O +
human O +
cells O +
. O +

By O +
using O +
a O +
reverse O +
transcription O -
- O -
PCR O -
- O -
based O +
approach O +
and O +
a O +
set O +
of O +
primers O +
specific O +
for O +
the O +
DNA O -
- O -
binding O +
domains O +
of O +
highly O +
homologous O +
members O +
of O +
the O +
C O -
/ O -
EBP O +
family O +
of O +
transcriptional O +
regulators O +
, O +
we O +
have O +
cloned O +
a O +
novel O +
human O +
gene O +
encoding O +
a O +
member O +
of O +
the O +
C O -
/ O -
EBP O +
gene O +
family O +
, O +
identified O +
as O +
the O +
human O +
homolog O +
of O +
CRP1 O +
, O +
C O -
/ O -
EBP O -
- O -
epsilon O +
. O +

A O +
1.2-kb O +
cDNA O +
encoding O +
full O -
- O -
length O +
human O +
C O -
/ O -
EBP O -
- O -
epsilon O +
was O +
cloned O +
from O +
a O +
promyelocyte O -
- O -
late O +
myeloblast O -
- O -
derived O +
lambda O +
gt11 O +
library O +
. O +

Molecular O +
analysis O +
of O +
the O +
cDNA O +
and O +
genomic O +
clones O +
indicated O +
the O +
presence O +
of O +
two O +
exons O +
encoding O +
a O +
protein O +
with O +
an O +
apparent O +
molecular O +
mass O +
of O +
32 O +
kDa O +
and O +
a O +
pI O +
of O +
9.5 O +
. O +

Primer O +
extension O +
analysis O +
of O +
C O -
/ O -
EBP O -
- O -
epsilon O +
mRNA O +
detected O +
a O +
single O +
major O +
transcription O +
start O +
site O +
approximately O +
200 O +
bp O +
upstream O +
of O +
the O +
start O +
codon O +
. O +

The O +
putative O +
promoter O +
area O +
is O +
similar O +
to O +
those O +
of O +
several O +
other O +
myeloid O -
- O -
cell O -
- O -
specific O +
genes O +
in O +
that O +
it O +
contains O +
no O +
TATAAA O +
box O +
but O +
has O +
a O +
number O +
of O +
purine O -
- O -
rich O +
stretches O +
with O +
multiple O +
sites O +
for O +
the O +
factors O +
of O +
the O +
Ets O +
family O +
of O +
transcriptional O +
regulators O +
. O +

Northern O +
blot O +
analyses O +
indicated O +
a O +
highly O +
restricted O +
mRNA O +
expression O +
pattern O +
, O +
with O +
the O +
strongest O +
expression O +
occurring O +
in O +
promyelocyte B-CellLine +
and I-CellLine +
late I-CellLine -
- I-CellLine -
myeloblast I-CellLine -
- I-CellLine -
like I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Western O +
blot O +
and O +
immunoprecipitation O +
studies O +
using O +
rabbit O +
anti O -
- O -
C O -
/ O -
EBP O -
- O -
epsilon O +
antibodies O +
raised O +
against O +
the O +
N O -
- O -
terminal O +
portion O +
of O +
C O -
/ O -
EBP O -
- O -
epsilon O +
( O +
amino O +
acids O +
1 O +
to O +
115 O +
) O +
showed O +
that O +
C O -
/ O -
EBP O -
- O -
epsilon O +
is O +
a O +
32-kDa O +
nuclear O +
phosphoprotein O +
. O +

The O +
human O +
C O -
/ O -
EBP O -
- O -
epsilon O +
protein O +
exhibited O +
strong O +
and O +
specific O +
binding O +
to O +
double O -
- O -
stranded O +
DNA O +
containing O +
consensus O +
C O -
/ O -
EBP O +
sites O +
. O +

Cotransfection O +
of O +
the O +
C O -
/ O -
EBP O -
- O -
epsilon O +
sense O +
and O +
antisense O +
expression O +
constructs O +
together O +
with O +
chloramphenicol O +
acetyltransferase O +
reporter O +
vectors O +
containing O +
myeloid O -
- O -
cell O -
- O -
specific O +
c O -
- O -
mim O +
and O +
human O +
myeloperoxidase O +
promoters O +
suggested O +
a O +
role O +
for O +
C O -
/ O -
EBP O -
- O -
epsilon O +
transcription O +
factor O +
in O +
the O +
regulation O +
of O +
a O +
subset O +
of O +
myeloid O -
- O -
cell O -
- O -
specific O +
genes O +
. O +

Transient O +
tranfection O +
of O +
a O +
promyelocyte B-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
NB4 B-CellLine +
) O +
with O +
a O +
C O -
/ O -
EBP O -
- O -
epsilon O +
expression O +
plasmid O +
increased O +
cell O +
growth O +
by O +
sevenfold O +
, O +
while O +
antisense O +
C O -
/ O -
EBP O -
- O -
epsilon O +
caused O +
a O +
fivefold O +
decrease O +
in O +
clonal O +
growth O +
of O +
these O +
cells O +
. O +

Transcriptional O +
regulation O +
of O +
the O +
ferritin O +
heavy O -
- O -
chain O +
gene O +
: O +
the O +
activity O +
of O +
the O +
CCAAT O +
binding O +
factor O +
NF O -
- O -
Y O +
is O +
modulated O +
in O +
heme B-CellLine -
- I-CellLine -
treated I-CellLine +
Friend I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
and O +
during O +
monocyte O -
- O -
to O -
- O -
macrophage O +
differentiation O +
. O +

The O +
ferritin O +
H O -
- O -
chain O +
gene O +
promoter O +
regulation O +
was O +
analyzed O +
in O +
heme B-CellLine -
- I-CellLine -
treated I-CellLine +
Friend I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
( O +
FLCs B-CellLine +
) O +
and O +
during O +
monocyte O -
- O -
to O -
- O -
macrophage O +
differentiation O +
. O +

In O +
the O +
majority O +
of O +
cell B-CellLine +
lines I-CellLine +
studied O +
, O +
the O +
regulation O +
of O +
ferritin O +
expression O +
was O +
exerted O +
mostly O +
at O +
the O +
translational O +
level O +
. O +

However O +
, O +
in O +
differentiating O +
erythroid O +
cells O +
, O +
which O +
must O +
incorporate O +
high O +
levels O +
of O +
iron O +
to O +
sustain O +
hemoglobin O +
synthesis O +
, O +
and O +
in O +
macrophages O +
, O +
which O +
are O +
involved O +
in O +
iron O +
storage O +
, O +
transcriptional O +
regulation O +
seemed O +
to O +
be O +
a O +
relevant O +
mechanism O +
. O +

We O +
show O +
here O +
that O +
the O +
minimum O +
region O +
of O +
the O +
ferritin O +
H O -
- O -
gene O +
promoter O +
that O +
is O +
able O +
to O +
confer O +
transcriptional O +
regulation O +
by O +
heme O +
in O +
FLCs B-CellLine +
to O +
a O +
reporter O +
gene O +
is O +
77 O +
nucleotides O +
upstream O +
of O +
the O +
TATA O +
box O +
. O +

This O +
cis O +
element O +
binds O +
a O +
protein O +
complex O +
referred O +
to O +
as O +
HRF O +
( O +
heme O -
- O -
responsive O +
factor O +
) O +
, O +
which O +
is O +
greatly O +
enhanced O +
both O +
in O +
heme O -
- O -
treated O +
FLCs B-CellLine +
and O +
during O +
monocyte O -
- O -
to O -
- O -
macrophage O +
differentiation O +
. O +

The O +
CCAAT O +
element O +
present O +
in O +
reverse O +
orientation O +
in O +
this O +
promoter O +
region O +
of O +
the O +
ferritin O +
H O -
- O -
chain O +
gene O +
is O +
necessary O +
for O +
binding O +
and O +
for O +
gene O +
activity O +
, O +
since O +
a O +
single O +
point O +
mutation O +
is O +
able O +
to O +
abolish O +
the O +
binding O +
of O +
HRF O +
and O +
the O +
transcriptional O +
activity O +
in O +
transfected B-CellLine +
cells I-CellLine +
. O +

By O +
competition O +
experiments O +
and O +
supershift O +
assays O +
, O +
we O +
identified O +
the O +
induced O +
HRF O +
as O +
containing O +
at O +
least O +
the O +
ubiquitous O +
transcription O +
factor O +
NF O -
- O -
Y O +
. O +

NF O -
- O -
Y O +
is O +
formed O +
by O +
three O +
subunits O +
, O +
A O +
, O +
B O +
, O +
and O +
C O +
, O +
all O +
of O +
which O +
are O +
necessary O +
for O +
DNA O +
binding O +
. O +

Cotransfection O +
with O +
a O +
transdominant O +
negative O +
mutant O +
of O +
the O +
NF O -
- O -
YA O +
subunit O +
abolishes O +
the O +
transcriptional O +
activation O +
by O +
heme O +
, O +
indicating O +
that O +
NF O -
- O -
Y O +
plays O +
an O +
essential O +
role O +
in O +
this O +
activation O +
. O +

We O +
have O +
also O +
observed O +
a O +
differential O +
expression O +
of O +
the O +
NF O -
- O -
YA O +
subunit O +
in O +
heme O -
- O -
treated O +
and O +
control O +
FLCs B-CellLine +
and O +
during O +
monocyte O -
- O -
to O -
- O -
macrophage O +
differentiation O +
. O +

Identification O +
of O +
nucleotide O +
sequences O +
that O +
regulate O +
transcription O +
of O +
the O +
MCF13 O +
murine O +
leukemia O +
virus O +
long O +
terminal O +
repeat O +
in O +
activated O +
T O +
cells O +
. O +

The O +
region O +
downstream O +
of O +
the O +
enhancer O +
( O +
DEN O +
) O +
of O +
the O +
long O +
terminal O +
repeat O +
of O +
the O +
mink O +
cell O +
focus O -
- O -
forming O +
murine O +
leukemia O +
virus O +
is O +
important O +
for O +
viral O +
pathogenicity O +
. O +

Another O +
important O +
activity O +
of O +
DEN O +
is O +
its O +
control O +
of O +
transcription O +
in O +
activated O +
T O +
cells O +
, O +
and O +
we O +
have O +
determined O +
that O +
an O +
NF O -
- O -
kappaB O +
site O +
is O +
critical O +
for O +
this O +
activity O +
. O +

Activation O +
of O +
the O +
NF O -
- O -
kappaB O +
transcription O +
factor O +
in O +
a O +
T B-CellLine -
- I-CellLine -
lymphocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
by O +
hypochlorous O +
acid O +
. O +

Reactive O +
oxygen O +
species O +
( O +
ROS O +
) O +
such O +
as O +
hydrogen O +
peroxide O +
serve O +
as O +
second O +
messengers O +
in O +
the O +
induction O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
, O +
and O +
hence O +
in O +
the O +
activation O +
and O +
replication O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
in O +
human O +
cells O +
. O +

During O +
inflammatory O +
reactions O +
, O +
many O +
oxidative O +
species O +
are O +
produced O +
, O +
one O +
of O +
which O +
is O +
hypochlorous O +
acid O +
( O +
HOCl O +
) O +
, O +
which O +
is O +
responsible O +
for O +
the O +
microbicidal O +
effects O +
of O +
activated O +
human O +
polymorphonuclear O +
leukocytes O +
. O +

Treatment O +
of O +
a O +
T B-CellLine -
- I-CellLine -
lymphocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
with O +
micromolar O +
concentrations O +
of O +
HOCl O +
promoted O +
the O +
appearance O +
of O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
( O +
the O +
heterodimer O +
p50 O -
/ O -
p65 O +
) O +
in O +
the O +
nucleus O +
of O +
the O +
cells O +
, O +
even O +
in O +
the O +
absence O +
of O +
de O +
novo O +
protein O +
synthesis O +
. O +

Western O +
blot O +
analysis O +
of O +
the O +
NF O -
- O -
kappaB O +
inhibitory O +
subunits O +
( O +
IkappaB O +
) O +
demonstrated O +
that O +
both O +
IkappaB O +
-alpha O +
proteolysis O +
and O +
p105 O +
processing O +
were O +
induced O +
by O +
the O +
treatment O +
. O +

NF O -
- O -
kappaB O +
activation O +
was O +
very O +
effective O +
when O +
cells O +
were O +
subjected O +
to O +
hyperthermia O +
before O +
being O +
treated O +
with O +
HOCl O +
. O +

Various O +
antioxidants O +
, O +
such O +
as O +
pyrrolidine O +
dithiocarbamate O +
, O +
p O -
- O -
bromophenacyl O -
- O -
bromide O +
and O +
nordihydroguaiaretic O +
acid O +
could O +
strongly O +
reduce O +
NF O -
- O -
kappaB O +
translocation O +
, O +
demonstrating O +
the O +
importance O +
of O +
oxidative O +
species O +
in O +
the O +
transduction O +
mechanism O +
. O +

Moreover O +
, O +
ACH-2 B-CellLine +
cells I-CellLine +
treated O +
with O +
HOCl O +
or O +
H2O2 O +
released O +
tumour O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
in O +
the O +
supernatants O +
. O +

The O +
importance O +
of O +
TNF O -
- O -
alpha O +
release O +
in O +
NF O -
- O -
kappaB O +
induction O +
by O +
HOCl O +
or O +
H2O2 O +
was O +
demonstrated O +
by O +
the O +
fact O +
that O +
: O +
( O +
1 O +
) O +
the O +
nuclear O +
appearance O +
of O +
NF O -
- O -
kappaB O +
was O +
promoted O +
in O +
untreated B-CellLine +
cells I-CellLine +
; O +
and O +
( O +
2 O +
) O +
synergism O +
between O +
TNF O -
- O -
alpha O +
and O +
HOCl O +
was O +
detected O +
. O +

Collectively O +
, O +
these O +
results O +
suggest O +
that O +
HOCl O +
should O +
be O +
considered O +
as O +
an O +
oxidative O +
species O +
capable O +
of O +
inducing O +
NF O -
- O -
kappaB O +
in O +
a O +
T B-CellLine -
- I-CellLine -
lymphocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
through O +
a O +
transduction O +
mechanism O +
involving O +
ROS O +
, O +
and O +
having O +
a O +
long O -
- O -
distance O +
effect O +
through O +
subsequent O +
TNF O -
- O -
alpha O +
release O +
. O +

The O +
synthesis O +
and O +
immunogenicity O +
of O +
varicella O -
- O -
zoster O +
virus O +
glycoprotein O +
E O +
and O +
immediate O -
- O -
early O +
protein O +
( O +
IE62 O +
) O +
expressed O +
in O +
recombinant O +
herpes O +
simplex O +
virus-1 O +
. O +

In O +
order O +
to O +
evaluate O +
the O +
conditions O +
for O +
optimal O +
expression O +
and O +
immunogenicity O +
of O +
varicella O -
- O -
zoster O +
virus O +
( O +
VZV O +
) O +
proteins O +
in O +
a O +
herpes O +
simplex O +
virus-1 O +
( O +
HSV-1 O +
) O +
vector O +
, O +
we O +
selected O +
the O +
VZV O +
glycoprotein O +
E O +
( O +
gE O +
) O +
, O +
encoded O +
by O +
ORF O +
68 O +
and O +
the O +
VZV O +
product O +
of O +
ORF O +
62 O +
, O +
an O +
immediate O -
- O -
early O +
major O +
tegument O +
protein O +
( O +
IE62 O +
) O +
. O +

Three O +
HSV O -
/ O -
VZV O +
recombinants O +
were O +
generated O +
: O +
( O +
1 O +
) O +
VZV O +
gE O +
protein O +
coding O +
sequences O +
along O +
with O +
the O +
promoter O +
region O +
were O +
inserted O +
into O +
the O +
thymidine O +
kinase O +
( O +
TK O +
) O +
gene O +
of O +
HSV-1 O +
strain O +
KOS O +
; O +
( O +
2 O +
) O +
VZV O +
gE O +
expressed O +
from O +
the O +
HSV-1 O +
ICP4 O +
promoter O +
was O +
inserted O +
into O +
the O +
glycoprotein O +
C O +
( O +
gC O +
) O +
gene O +
of O +
HSV-1 O +
strain O +
F O +
; O +
and O +
( O +
3 O +
) O +
VZV O +
IE62 O +
protein O +
coding O +
sequences O +
under O +
the O +
control O +
of O +
the O +
HSV-1 O +
ICP4 O +
promoter O +
were O +
inserted O +
into O +
the O +
gC O +
gene O +
of O +
HSV-1 O +
strain O +
F O +
. O +

Immunoblot O +
analysis O +
and O +
immunoperoxidase O +
staining O +
of O +
infected O +
cell O +
monolayers O +
demonstrated O +
vector O +
expression O +
of O +
VZV O +
proteins O +
. O +

Following O +
intracranial O +
inoculation O +
in O +
mice O +
, O +
both O +
VZV O +
gE O -
- O -
HSV O +
( O +
TK O +
) O +
and O +
VZV O +
IE62-HSV O +
( O +
gC O +
) O +
induced O +
an O +
IgG O +
response O +
against O +
VZV O +
gE O +
or O +
VZV O +
IE62 O +
. O +

When O +
tested O +
in O +
cytotoxicity O +
assays O +
using O +
T O -
- O -
lymphocytes O +
from O +
VZV O +
immune O +
human O +
donors O +
, O +
the O +
range O +
of O +
precursor O +
frequencies O +
for O +
T O -
- O -
lymphocytes O +
that O +
recognized O +
VZV O +
gE O +
or O +
VZV O +
IE62 O +
was O +
similar O +
whether O +
these O +
proteins O +
were O +
expressed O +
by O +
HSV-1 O +
or O +
a O +
vaccinia O +
vector O +
. O +

These O +
experiments O +
demonstrate O +
that O +
HSV-1 O +
is O +
a O +
competent O +
vector O +
for O +
expression O +
of O +
these O +
VZV O +
proteins O +
and O +
support O +
the O +
feasibility O +
of O +
engineering O +
a O +
combined O +
vaccine O +
for O +
these O +
closely O +
related O +
alpha O -
- O -
herpesviruses O +
. O +

[ O +
Correlation O +
of O +
lymphocytic O +
infiltration O +
of O +
tumor O +
tissue O +
with O +
the O +
hormonal O +
and O +
metabolic O +
state O +
in O +
patients O +
with O +
breast O +
cancer O +
] O +

Lymphocyte O +
infiltration O +
of O +
tumor O +
was O +
studied O +
vis O -
- O -
a O -
- O -
vis O +
hormone O +
metabolic O +
status O +
, O +
tumor O +
tissue O +
hormone O +
sensitivity O +
and O +
tobacco O +
smoking O +
, O +
in O +
113 O +
breast O +
cancer O +
patients O +
, O +
aged O +
25 O -
- O -
77 O +
. O +

On O +
the O +
average O +
, O +
no O +
correlation O +
was O +
established O +
between O +
degree O +
of O +
lymphocyte O +
infiltration O +
in O +
breast O +
tumor O +
and O +
age O +
and O +
menopause O +
onset O +
. O +

In O +
smoking O +
menopausal O +
patients O +
, O +
lymphocyte O +
infiltration O +
was O +
found O +
to O +
be O +
higher O +
than O +
in O +
non O -
- O -
smokers O +
( O +
p O +
< O +
0.05 O +
) O +
. O +

There O +
was O +
a O +
direct O +
correlation O +
between O +
the O +
rate O +
of O +
lymphocyte O +
infiltration O +
and O +
the O +
level O +
of O +
progesterone O +
receptors O +
in O +
tumor O +
. O +

Some O +
subgroups O +
displayed O +
a O +
direct O +
correlation O +
between O +
infiltration O +
and O +
sex O -
- O -
binding O +
globulin O +
, O +
cholesterol O +
, O +
luteinizing O +
hormone O +
in O +
blood O +
, O +
and O +
lean O +
body O +
mass O +
. O +

It O +
was O +
matched O +
by O +
an O +
inverse O +
correlation O +
between O +
lymphocyte O +
infiltration O +
and O +
blood O -
- O -
thyroid O +
hormone O +
concentration O +
, O +
urine O +
catecholamines O +
and O +
free O +
cortisol O +
excretion O +
and O +
fat O -
/ O -
lean O +
body O +
mass O +
ratio O +
. O +

Considering O +
the O +
abovesaid O +
as O +
well O +
as O +
the O +
lymphocyte O +
ability O +
to O +
perform O +
the O +
dual O +
function O +
of O +
immunocytes O +
and O +
hormonocytes O +
, O +
it O +
is O +
suggested O +
that O +
the O +
results O +
may O +
be O +
used O +
in O +
both O +
the O +
study O +
of O +
lymphocyte O +
infiltration O +
and O +
research O +
in O +
means O +
of O +
its O +
control O +
. O +

Thymocytes O +
control O +
the O +
CD4 O +
gene O +
differently O +
from O +
mature O +
T O +
lymphocytes O +
. O +

We O +
analyzed O +
the O +
activity O +
of O +
the O +
enhancer O +
, O +
the O +
promoter O +
and O +
the O +
silencer O +
of O +
the O +
human O +
CD4 O +
gene O +
during O +
T O +
cell O +
development O +
using O +
transgenic O +
mice O +
. O +

Immunofluorescence O +
studies O +
on O +
thymic O +
populations O +
of O +
mice O +
carrying O +
transgenes O +
in O +
various O +
combinations O +
of O +
these O +
regulatory O +
DNA O +
elements O +
revealed O +
that O +
thymocytes O +
control O +
the O +
CD4 O +
gene O +
in O +
a O +
different O +
manner O +
than O +
mature O +
peripheral O +
T O +
lymphocytes O +
. O +

The O +
5'-positive O +
regulatory O +
unit O +
, O +
consisting O +
of O +
the O +
promoter O +
and O +
the O +
5 O +
' O +
enhancer O +
, O +
is O +
already O +
active O +
at O +
the O +
CD4 O +
- O +
CD8 O +
-double O -
- O -
negative O +
( O +
DN O +
) O +
stage O +
of O +
development O +
. O +

However O +
, O +
its O +
activity O +
becomes O +
lower O +
in O +
the O +
double O -
- O -
positive O +
and O +
a O +
fraction O +
of O +
the O +
CD4 O -
+ O +
CD8int O -
/ O -
- O +
cell O +
population O +
, O +
indicating O +
that O +
an O +
additional O +
enhancer O +
, O +
located O +
in O +
either O +
the O +
first O +
or O +
the O +
third O +
intron O +
of O +
the O +
CD4 O +
gene O +
, O +
is O +
required O +
for O +
CD4 O +
gene O +
expression O +
in O +
this O +
population O +
. O +

The O +
other O +
studied O +
regulatory O +
element O +
is O +
the O +
minimal O +
CD4 O +
silencer O +
which O +
inhibits O +
CD4 O +
gene O +
expression O +
in O +
peripheral O +
CD8 O +
T O +
lymphocytes O +
. O +

This O +
silencer O +
is O +
inactive O +
in O +
the O +
most O +
immature O +
DN O +
thymocytes O +
, O +
which O +
probably O +
use O +
a O +
distinct O +
silencer O +
mechanism O +
to O +
down O -
- O -
regulate O +
CD4 O +
gene O +
expression O +
. O +

Unexpectedly O +
, O +
the O +
CD4 O +
silencer O +
is O +
also O +
active O +
in O +
CD4 O -
+ O +
CD8int O -
/ O -
- O +
cells O +
of O +
the O +
thymus O +
, O +
implying O +
that O +
an O +
anti O -
- O -
silencer O +
may O +
be O +
required O +
to O +
resume O +
CD4 O +
expression O +
in O +
this O +
cell O +
population O +
. O +

Altogether O +
, O +
the O +
CD4 O +
gene O +
is O +
regulated O +
by O +
several O +
positive O +
and O +
negative O +
regulatory O +
mechanisms O +
which O +
come O +
into O +
play O +
in O +
a O +
developmentally O +
coordinated O +
manner O +
. O +

Heat O -
- O -
shock O +
and O +
cadmium O +
chloride O +
increase O +
the O +
vimentin O +
mRNA O +
and O +
protein O +
levels O +
in O +
U-937 B-CellLine +
human I-CellLine +
promonocytic I-CellLine +
cells I-CellLine +
. O +

Heat O -
- O -
shock O +
for O +
2 O +
hours O +
at O +
42 O +
degrees O +
C O +
, O +
or O +
the O +
administration O +
for O +
3 O +
hours O +
of O +
100 O +
or O +
150 O +
microM O +
cadmium O +
chloride O +
, O +
inhibited O +
the O +
subsequent B-CellLine +
proliferation I-CellLine +
activity I-CellLine +
, O +
induced O +
the O +
expression O +
of O +
functional O +
differentiation O +
markers O +
, O +
and O +
caused O +
an O +
increase O +
in O +
the O +
amount O +
of O +
the O +
stress O -
- O -
responsive O +
HSP70 O +
protein O +
in O +
U-937 B-CellLine +
human I-CellLine +
promonocytic I-CellLine +
cells I-CellLine +
. O +

In O +
addition O +
, O +
both O +
heat O +
and O +
cadmium O +
produced O +
an O +
increase O +
in O +
the O +
amount O +
of O +
the O +
intermediate O +
filament O +
protein O +
vimentin O +
, O +
as O +
determined O +
by O +
immunoblot O +
and O +
immunofluorescence O +
assays O +
. O +

By O +
contrast O +
, O +
the O +
amounts O +
of O +
actin O +
and O +
beta O -
- O -
tubulin O +
were O +
not O +
significantly O +
altered O +
. O +

The O +
amount O +
of O +
vimentin O +
mRNA O +
was O +
also O +
increased O +
during O +
recovery O +
from O +
stress O +
, O +
indicating O +
that O +
vimentin O +
expression O +
was O +
not O +
exclusively O +
regulated O +
at O +
the O +
protein O +
level O +
. O +

Although O +
cadmium O +
caused O +
an O +
early O +
, O +
transient O +
stimulation O +
of O +
c O -
- O -
jun O +
and O +
c O -
- O -
fos O +
expression O +
and O +
AP-1 O +
binding O +
activity O +
, O +
heat O -
- O -
shock O +
failed O +
to O +
alter O +
both O +
protooncogene O +
expression O +
and O +
transcription O +
factor O +
binding O +
, O +
indicating O +
that O +
the O +
stress O -
- O -
induced O +
vimentin O +
increase O +
was O +
not O +
the O +
result O +
of O +
AP-1 O +
-mediated O +
transcriptional O +
activation O +
. O +

Finally O +
, O +
it O +
was O +
observed O +
that O +
the O +
rate O +
of O +
decay O +
of O +
vimentin O +
mRNA O +
upon O +
actinomycin O +
D O +
administration O +
was O +
decreased O +
in O +
heat- B-CellLine +
and I-CellLine +
cadmium I-CellLine -
- I-CellLine -
pretreated I-CellLine +
cells I-CellLine +
in O +
comparison O +
to O +
untreated O +
cells O +
. O +

These O +
results O +
indicate O +
that O +
stress O +
treatments O +
cause O +
an O +
increase O +
in O +
vimentin O +
levels O +
in O +
promonocytic O +
cells O +
, O +
which O +
may O +
be O +
explained O +
at O +
least O +
in O +
part O +
by O +
transcript O +
stabilization O +
. O +

Immune O +
hyperactivation O +
of O +
HIV-1-infected O +
T O +
cells O +
mediated O +
by O +
Tat O +
and O +
the O +
CD28 O +
pathway O +
. O +

Human O +
immunodeficiency O +
virus O -
- O -
type O +
1 O +
( O +
HIV-1 O +
) O +
infection O +
is O +
characterized O +
by O +
a O +
chronic O +
state O +
of O +
immune O +
hyperactivation O +
in O +
patients O +
. O +

Infection O +
of O +
human O +
peripheral O +
blood O +
lymphocytes O +
with O +
HIV-1 O +
in O +
vitro O +
resulted O +
in O +
increased O +
interleukin-2 O +
( O +
IL-2 O +
) O +
secretion O +
in O +
response O +
to O +
T O +
cell O +
activation O +
via O +
the O +
CD3 O +
and O +
CD28 O +
receptors O +
. O +

Expression O +
of O +
the O +
HIV-1 O +
transactivator O +
Tat O +
recapitulated O +
this O +
phenotype O +
and O +
was O +
associated O +
with O +
increased O +
IL-2 O +
secretion O +
in O +
response O +
to O +
costimulation O +
with O +
CD3 O +
plus O +
CD28 O +
. O +

IL-2 O +
superinduction O +
by O +
Tat O +
occurred O +
at O +
the O +
transcriptional O +
level O +
, O +
was O +
mediated O +
by O +
the O +
CD28-responsive O +
element O +
in O +
the O +
IL-2 O +
promoter O +
, O +
and O +
was O +
exclusively O +
dependent O +
on O +
the O +
29 O +
amino O +
acids O +
encoded O +
by O +
the O +
second O +
exon O +
of O +
Tat O +
. O +

A O +
T O +
cell O -
- O -
specific O +
enhancer O +
in O +
the O +
interleukin-3 O +
locus O +
is O +
activated O +
cooperatively O +
by O +
Oct O +
and O +
NFAT O +
elements O +
within O +
a O +
DNase O +
I O -
- O -
hypersensitive O +
site O +
. O +

Interleukin-3 O +
( O +
IL-3 O +
) O +
is O +
a O +
cytokine O +
that O +
is O +
expressed O +
primarily O +
in O +
activated O +
T O +
cells O +
. O +

Here O +
we O +
identified O +
an O +
inducible O +
T O +
cell O -
- O -
specific O +
enhancer O +
14 O +
kb O +
upstream O +
of O +
the O +
IL-3 O +
gene O +
that O +
responded O +
to O +
activation O +
of O +
T O +
cell O +
receptor O +
signaling O +
pathways O +
. O +

The O +
IL-3 O +
enhancer O +
spanned O +
an O +
inducible O +
cyclosporin O +
A O -
- O -
sensitive O +
DNase O +
I O -
- O -
hypersensitive O +
site O +
found O +
only O +
in O +
T O +
cells O +
. O +

Four O +
NFAT O -
- O -
like O +
elements O +
exist O +
within O +
the O +
enhancer O +
. O +

The O +
two O +
most O +
active O +
NFAT O -
- O -
like O +
elements O +
were O +
located O +
at O +
the O +
center O +
of O +
the O +
DNase O +
I O -
- O -
hypersensitive O +
site O +
. O +

One O +
of O +
these O +
NFAT O -
- O -
like O +
elements O +
encompassed O +
overlapping O +
Oct- O +
and O +
NFATp O -
/ O -
c O -
- O -
binding O +
sites O +
, O +
which O +
functioned O +
in O +
a O +
highly O +
synergistic O +
manner O +
. O +

We O +
suggest O +
that O +
the O +
T O +
cell O -
- O -
specific O +
expression O +
of O +
the O +
IL-3 O +
gene O +
is O +
partly O +
controlled O +
through O +
the O +
enhancer O +
by O +
cooperation O +
between O +
Oct O +
and O +
NFAT O +
family O +
proteins O +
. O +

A O +
negative O +
regulatory O +
region O +
containing O +
a O +
glucocorticosteroid O +
response O +
element O +
( O +
nGRE O +
) O +
in O +
the O +
human O +
interleukin-1beta O +
gene O +
. O +

Interleukin-1 O +
beta O +
( O +
IL-1beta O +
) O +
is O +
one O +
of O +
the O +
most O +
important O +
inflammatory O +
mediators O +
in O +
human O +
inflammatory O +
and O +
immunological O +
diseases O +
. O +

The O +
regulation O +
of O +
human O +
IL-1beta O +
gene O +
expression O +
has O +
been O +
studied O +
for O +
several O +
years O +
, O +
and O +
a O +
few O +
regulatory O +
elements O +
have O +
been O +
discovered O +
in O +
the O +
promoter O +
region O +
. O +

However O +
, O +
little O +
is O +
known O +
about O +
negative O +
regulation O +
of O +
IL-1beta O +
expression O +
at O +
the O +
transcriptional O +
level O +
, O +
which O +
may O +
play O +
an O +
important O +
role O +
in O +
anti O -
- O -
inflammatory O +
and O +
immunosuppressive O +
effects O +
. O +

We O +
have O +
identified O +
a O +
negative O +
regulatory O +
element O +
located O +
in O +
the O +
region O +
between O +
-685 O +
and O +
-395 O +
. O +

Within O +
this O +
region O +
, O +
a O +
19-bp O +
nuclear O +
factor O +
binding O +
site O +
( O +
-570 O +
to O +
-552 O +
) O +
was O +
characterized O +
by O +
DNase O +
I O +
footprinting O +
and O +
electromobility O +
shift O +
assay O +
. O +

A O +
consensus O +
sequence O +
for O +
a O +
negative O +
glucocorticoid O +
response O +
element O +
( O +
nGRE O +
) O +
and O +
a O +
transcription O +
activator O +
protein-2 O +
binding O +
site O +
were O +
noted O +
within O +
this O +
footprint O +
. O +

Functional O +
studies O +
showed O +
a O +
2.5-fold O +
increase O +
in O +
promoter O +
activity O +
when O +
this O +
19-bp O +
binding O +
site O +
was O +
deleted O +
in O +
the O +
reporter O +
constructs O +
IL-1beta O +
/CAT O +
and O +
IL-1beta O +
/SV40 O +
promoter O +
/CAT O +
. O +

Dexamethasone O +
( O +
10 O +
( O +
-8 O +
) O +
M O +
) O +
repressed O +
chloramphenicol O +
acetyltransferase O +
( O +
CAT O +
) O +
production O +
by O +
75 O +
% O +
in O +
the O +
wild O -
- O -
type O +
fragment O +
but O +
not O +
in O +
a O +
deletion O +
mutant O +
lacking O +
the O +
19-bp O +
site O +
. O +

A O +
protein O +
of O +
about O +
150 O +
kD O +
that O +
bound O +
to O +
this O +
negative O +
regulatory O +
sequence O +
was O +
identified O +
by O +
UV O +
cross O -
- O -
linking O +
. O +

This O +
is O +
the O +
first O +
description O +
of O +
a O +
negative O +
regulatory O +
region O +
responsive O +
to O +
glucocorticoids O +
in O +
a O +
cytokine O +
gene O +
. O +

TRAMP O +
, O +
a O +
novel O +
apoptosis O -
- O -
mediating O +
receptor O +
with O +
sequence O +
homology O +
to O +
tumor O +
necrosis O +
factor O +
receptor O +
1 O +
and O +
Fas O +
( O +
Apo-1 O -
/ O -
CD95 O +
) O +
. O +

A O +
novel O +
member O +
of O +
the O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
receptor O +
family O +
, O +
designated O +
TRAMP O +
, O +
has O +
been O +
identified O +
. O +

The O +
structural O +
organization O +
of O +
the O +
393 O +
amino O +
acid O +
long O +
human O +
TRAMP O +
is O +
most O +
homologous O +
to O +
TNF O +
receptor O +
1 O +
. O +

TRAMP O +
is O +
abundantly O +
expressed O +
on O +
thymocytes O +
and O +
lymphocytes O +
. O +

Its O +
extracellular O +
domain O +
is O +
composed O +
of O +
four O +
cysteine O -
- O -
rich O +
domains O +
, O +
and O +
the O +
cytoplasmic O +
region O +
contains O +
a O +
death O +
domain O +
known O +
to O +
signal O +
apoptosis O +
. O +

Overexpression O +
of O +
TRAMP O +
leads O +
to O +
two O +
major O +
responses O +
, O +
NF O -
- O -
kappaB O +
activation O +
and O +
apoptosis O +
. O +

TRAMP O +
-induced O +
cell O +
death O +
is O +
inhibited O +
by O +
an O +
inhibitor O +
of O +
ICE O -
- O -
like O +
proteases O +
, O +
but O +
not O +
by O +
Bcl-2 O +
. O +

In O +
addition O +
, O +
TRAMP O +
does O +
not O +
appear O +
to O +
interact O +
with O +
any O +
of O +
the O +
known O +
apoptosis O -
- O -
inducing O +
ligands O +
of O +
the O +
TNF O +
family O +
. O +

AML1a O +
but O +
not O +
AML1b O +
inhibits O +
erythroid O +
differentiation O +
induced O +
by O +
sodium O +
butyrate O +
and O +
enhances O +
the O +
megakaryocytic O +
differentiation O +
of O +
K562 O +
leukemia O +
cells O +
. O +

AML1 O +
may O +
play O +
a O +
role O +
in O +
growth O +
and O +
differentiation O +
of O +
cells O +
along O +
erythroid O +
and/or O +
megakaryocytic O +
lineages O +
, O +
because O +
a O +
significant O +
level O +
of O +
the O +
AML1 O +
gene O +
is O +
expressed O +
in O +
these O +
cells O +
. O +

We O +
overexpressed O +
AML1a O +
( O +
without O +
the O +
transcription O -
- O -
activating O +
domain O +
) O +
and O +
AML1b O +
( O +
with O +
the O +
domain O +
) O +
proteins O +
in O +
K562 O +
leukemia O +
cells O +
, O +
which O +
can O +
be O +
induced O +
to O +
differentiate O +
into O +
hemoglobin O -
- O -
producing O +
cells O +
and O +
megakaryocytes O +
. O +

The O +
AML1a B-CellLine -
- I-CellLine -
transfected I-CellLine +
K562 I-CellLine +
cells I-CellLine +
had O +
a O +
reduced O +
capacity O +
to O +
differentiate O +
in O +
the O +
presence O +
of O +
sodium O +
n O -
- O -
butyrate O +
but O +
not O +
in O +
the O +
presence O +
of O +
other O +
inducers O +
, O +
such O +
as O +
hemin O +
, O +
1-beta O -
- O -
D O -
- O -
arabinofuranosylcytosine O +
, O +
and O +
herbimycin O +
A O +
. O +

The O +
AML1 O +
antisense O +
oligodeoxynucleotide O +
but O +
not O +
the O +
sense O +
oligomer O +
recovered O +
its O +
differentiation O -
- O -
inducing O +
capacity O +
in O +
the O +
presence O +
of O +
butyrate O +
. O +

On O +
the O +
other O +
hand O +
, O +
AML1b O +
conferred O +
a O +
similar O +
differentiation O -
- O -
inducing O +
capacity O +
upon O +
K562 B-CellLine +
cells I-CellLine +
transfected O +
with O +
vector O +
alone O +
. O +

AML1a O +
expression O +
was O +
associated O +
with O +
enhanced O +
sensitivity O +
to O +
megakaryocytic O +
differentiation O +
induced O +
by O +
phorbol O +
ester O +
. O +

These O +
results O +
provide O +
evidence O +
that O +
AML1 O +
proteins O +
play O +
a O +
role O +
in O +
erythroid O +
and O +
megakaryocytic O +
differentiation O +
. O +

Upregulation O +
of O +
c O -
- O -
Fos O +
in O +
activated O +
T O +
lymphoid O +
and O +
monocytic O +
cells O +
by O +
human O +
immunodeficiency O +
virus-1 O +
Tat O +
protein O +
. O +

The O +
regulatory O +
Tat O +
protein O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type-1 O +
( O +
HIV-1 O +
) O +
is O +
essential O +
for O +
viral O +
replication O +
and O +
also O +
shows O +
pleiotropic O +
activities O +
on O +
various O +
cell O +
functions O +
. O +

To O +
get O +
further O +
insights O +
into O +
the O +
molecular O +
mechanisms O +
underlying O +
the O +
biological O +
activity O +
of O +
Tat O +
, O +
we O +
investigated O +
the O +
effect O +
of O +
endogenous O +
and O +
exogenous O +
Tat O +
protein O +
on O +
c O -
- O -
fos O +
gene O +
expression O +
in O +
T B-CellLine +
lymphoblastoid I-CellLine +
( I-CellLine +
Jurkat I-CellLine +
) I-CellLine +
and I-CellLine +
monocytic I-CellLine +
( I-CellLine +
U937 I-CellLine +
) I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
as O +
well O +
as O +
in O +
primary O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
. O +

Transient O +
cotransfection O +
of O +
tat O +
cDNA O +
in O +
sense O +
orientation O +
( O +
tat O -
/ O -
S O +
) O +
, O +
together O +
with O +
a O +
plasmid O +
containing O +
the O +
c O -
- O -
fos O +
promoter O +
( O +
FC3 O +
, O +
from- O +
711 O +
to O +
+ O -
42 O +
) O +
in O +
front O +
of O +
the O +
bacterial O +
chloramphenicol O +
acetyltransferase O +
( O +
CAT O +
) O +
gene O +
significantly O +
enhanced O +
CAT O +
activity O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
activated O +
by O +
the O +
addition O +
of O +
15 O +
% O +
fetal O +
calf O +
serum O +
( O +
FCS O +
) O +
or O +
5 O +
micrograms O -
/ O -
mL O +
phytohemagglutinin O +
plus O +
10 O +
( O +
-7 O +
) O +
mol O -
/ O -
L O +
phorbol O +
myristate O +
acetate O +
( O +
PMA O +
) O +
and O +
U937 B-CellLine +
cells I-CellLine +
activated O +
by O +
15 O +
% O +
FCS O +
or O +
10 O +
( O +
-7 O +
) O +
mol O -
/ O -
L O +
PMA O +
. O +

This O +
effect O +
was O +
specifically O +
due O +
to O +
Tat O +
, O +
since O +
Jurkat B-CellLine +
and O +
U937 B-CellLine +
cells I-CellLine +
cotransfected O +
either O +
with O +
tat O +
cDNA O +
in O +
antisense O +
orientation O +
( O +
tat O -
/ O -
AS O +
) O +
, O +
tat O +
carrying O +
a O +
mutation O +
in O +
the O +
aminoacid O +
cys22-gly22 O +
( O +
tat O +
22 O -
/ O -
S O +
) O +
or O +
with O +
the O +
backbone O +
vector O +
alone O +
( O +
pRPneo O -
- O -
SL3 O +
) O +
did O +
not O +
show O +
any O +
significant O +
difference O +
in O +
c O -
- O -
fos O +
promoter O +
activity O +
as O +
compared O +
to O +
cells O +
transfected O +
with O +
FC3 O +
plasmid O +
alone O +
. O +

By O +
using O +
deletion O +
mutants O +
of O +
the O +
c O -
- O -
fos O +
promoter O +
, O +
we O +
found O +
that O +
the O +
minimal O +
DNA O +
sequence O +
required O +
for O +
Tat O +
activity O +
was O +
located O +
between O +
nucleotides O +
-404 O -
/ O -
-220 O +
and O +
that O +
the O +
serum O +
responsive O +
element O +
( O +
SRE O +
, O +
-317 O -
/ O -
-288 O +
) O +
, O +
present O +
within O +
this O +
region O +
, O +
was O +
still O +
responsive O +
to O +
Tat O +
. O +

A O +
single O +
point O +
mutation O +
in O +
the O +
SRE O +
completely O +
abrogated O +
the O +
responsiveness O +
to O +
tat O -
/ O -
S O +
. O +

Exogenous O +
recombinant O +
Tat O +
protein O +
was O +
also O +
able O +
to O +
upregulate O +
c O -
- O -
fos O +
promoter O +
activity O +
in O +
serum O -
- O -
activated O +
Jurkat O +
and O +
U937 B-CellLine +
cells I-CellLine +
, O +
as O +
well O +
as O +
endogenous O +
c O -
- O -
fos O +
mRNA O +
expression O +
and O +
c O -
- O -
Fos O +
protein O +
synthesis O +
in O +
both O +
serum B-CellLine -
- I-CellLine -
activated I-CellLine +
cell I-CellLine +
lines I-CellLine +
and O +
primary O +
PBMC O +
. O +

c O -
- O -
Fos O +
protein O +
was O +
shown O +
essential O +
for O +
an O +
optimal O +
transactivation O +
of O +
the O +
HIV-1 O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
by O +
Tat O +
: O +
incubation O +
of O +
Jurkat B-CellLine +
cells I-CellLine +
with O +
antisense O +
, O +
but O +
not O +
sense O +
, O +
c O -
- O -
fos O +
oligonucleotides O +
significantly O +
reduced O +
either O +
the O +
Tat O +
-enhanced O +
expression O +
of O +
an O +
LTR O -
- O -
CAT O +
reporter O +
construct O +
or O +
the O +
levels O +
of O +
gag O +
p24 O +
in O +
the O +
culture O +
supernatants O +
of O +
Jurkat B-CellLine +
cells I-CellLine +
and O +
PBMC O +
acutely O +
infected O +
with O +
HIV-1 O +
. O +

Our O +
data O +
suggest O +
that O +
the O +
c O -
- O -
fos O +
upregulation O +
mediated O +
by O +
Tat O +
might O +
play O +
a O +
significant O +
role O +
in O +
the O +
control O +
of O +
viral O +
gene O +
transactivation O +
. O +

Alteration O +
of O +
a O +
single O +
serine O +
in O +
the O +
basic O +
domain O +
of O +
the O +
Epstein O -
- O -
Barr O +
virus O +
ZEBRA O +
protein O +
separates O +
its O +
functions O +
of O +
transcriptional O +
activation O +
and O +
disruption O +
of O +
latency O +
. O +

The O +
ZEBRA O +
protein O +
from O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
activates O +
a O +
switch O +
from O +
the O +
latent O +
to O +
the O +
lytic O +
expression O +
program O +
of O +
the O +
virus O +
. O +

ZEBRA O +
, O +
a O +
member O +
of O +
the O +
bZIP O +
family O +
of O +
DNA O -
- O -
binding O +
proteins O +
, O +
is O +
a O +
transcriptional O +
activator O +
capable O +
of O +
inducing O +
expression O +
from O +
viral O +
lytic O +
cycle O +
promoters O +
. O +

It O +
had O +
previously O +
been O +
thought O +
that O +
ZEBRA O +
's O +
capacity O +
to O +
disrupt O +
EBV O +
latency O +
resided O +
primarily O +
in O +
its O +
ability O +
to O +
activate O +
transcription O +
of O +
genes O +
that O +
encode O +
products O +
required O +
for O +
lytic O +
replication O +
. O +

We O +
generated O +
a O +
point O +
mutant O +
of O +
ZEBRA O +
, O +
Z O +
( O +
S186A O +
) O +
, O +
that O +
was O +
not O +
impaired O +
in O +
its O +
ability O +
to O +
activate O +
transcription O +
; O +
however O +
, O +
this O +
mutation O +
abolished O +
its O +
ability O +
to O +
initiate O +
the O +
viral O +
lytic O +
cascade O +
. O +

The O +
mutant O +
, O +
containing O +
a O +
serine O -
- O -
to O -
- O -
alanine O +
substitution O +
in O +
the O +
DNA O -
- O -
binding O +
domain O +
of O +
the O +
protein O +
, O +
bound O +
to O +
several O +
known O +
ZEBRA O -
- O -
binding O +
sites O +
and O +
activated O +
transcription O +
from O +
reporters O +
bearing O +
known O +
ZEBRA O -
- O -
responsive O +
promoters O +
but O +
did O +
not O +
disrupt O +
latency O +
in O +
EBV B-CellLine -
- I-CellLine -
infected I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Therefore O +
, O +
initiation O +
of O +
the O +
EBV O +
lytic O +
cycle O +
by O +
the O +
ZEBRA O +
protein O +
requires O +
a O +
function O +
in O +
addition O +
to O +
transcriptional O +
activation O +
; O +
a O +
change O +
of O +
serine O +
186 O +
to O +
alanine O +
in O +
the O +
DNA O -
- O -
binding O +
domain O +
of O +
ZEBRA O +
abolished O +
this O +
additional O +
function O +
and O +
uncovered O +
a O +
new O +
role O +
for O +
the O +
ZEBRA O +
protein O +
in O +
disruption O +
of O +
EBV O +
latency O +
. O +

The O +
additional O +
function O +
that O +
is O +
required O +
for O +
initiation O +
of O +
the O +
lytic O +
viral O +
life O +
cycle O +
is O +
likely O +
to O +
require O +
phosphorylation O +
of O +
serine O +
186 O +
of O +
the O +
ZEBRA O +
protein O +
, O +
which O +
may O +
influence O +
either O +
DNA O +
recognition O +
or O +
transcriptional O +
activation O +
of O +
lytic O +
viral O +
promoters O +
in O +
a O +
chromatinized O +
viral O +
episome O +
. O +

Redox O +
regulation O +
of O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
pathway O +
during O +
lymphocyte O +
activation O +
. O +

We O +
have O +
previously O +
demonstrated O +
an O +
obligatory O +
requirement O +
for O +
intracellular O +
reactive O +
oxygen O +
species O +
generation O +
during O +
T O +
lymphocyte O +
activation O +
, O +
and O +
have O +
proposed O +
that O +
intracellular O +
reactive O +
oxygen O +
species O +
may O +
act O +
as O +
signalling O +
agents O +
in O +
the O +
regulation O +
of O +
certain O +
cellular O +
processes O +
, O +
for O +
example O +
, O +
during O +
cell O +
cycle O +
entry O +
. O +

To O +
test O +
this O +
hypothesis O +
, O +
we O +
have O +
been O +
interested O +
to O +
determine O +
which O +
, O +
if O +
any O +
, O +
cell O +
cycle O +
entry O +
events O +
are O +
affected O +
by O +
oxidative O +
signalling O +
. O +

In O +
earlier O +
studies O +
, O +
we O +
have O +
identified O +
the O +
transcription O +
factors O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O +
as O +
molecular O +
targets O +
for O +
oxidative O +
signalling O +
processes O +
during O +
cell O +
cycle O +
entry O +
, O +
and O +
have O +
shown O +
that O +
oxidative O +
signalling O +
is O +
involved O +
in O +
the O +
regulation O +
of O +
early O +
changes O +
in O +
gene O +
expression O +
during O +
the O +
G0 O +
to O +
G1 O +
phase O +
transition O +
. O +

To O +
extend O +
these O +
initial O +
observations O +
, O +
we O +
have O +
examined O +
the O +
effect O +
of O +
antioxidant O +
treatment O +
on O +
the O +
activity O +
of O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinases O +
erk1 O +
and O +
erk2 O +
, O +
as O +
members O +
of O +
a O +
signal O +
transduction O +
pathway O +
known O +
to O +
directly O +
regulate O +
transcription O +
factor O +
function O +
. O +

Using O +
as O +
a O +
probe O +
cysteamine O +
, O +
an O +
aminothiol O +
compound O +
with O +
both O +
antioxidant O +
and O +
antiproliferative O +
activity O +
, O +
we O +
have O +
identified O +
erk2 O +
, O +
a O +
key O +
element O +
of O +
the O +
MAP O +
kinase O +
pathway O +
, O +
as O +
being O +
responsive O +
to O +
oxidative O +
signalling O +
during O +
lymphocyte O +
activation O +
. O +

These O +
observations O +
provide O +
further O +
evidence O +
to O +
suggest O +
a O +
role O +
for O +
intracellular O +
oxidant O +
generation O +
as O +
a O +
regulatory O +
mechanism O +
during O +
cell O +
cycle O +
entry O +
, O +
and O +
establish O +
a O +
link O +
between O +
oxidative O +
signalling O +
and O +
other O +
aspects O +
of O +
the O +
intracellular O +
signalling O +
network O +
that O +
is O +
activated O +
in O +
response O +
to O +
mitogenic O +
stimulation O +
. O +

Identification O +
of O +
sequence O +
alterations O +
in O +
the O +
upstream O +
regulatory O +
region O +
of O +
the O +
estrogen O +
receptor O +
gene O +
in O +
an O +
ER B-CellLine -
- I-CellLine -
negative I-CellLine +
breast I-CellLine +
cancer I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Given O +
the O +
important O +
role O +
of O +
the O +
estrogen O +
receptor O +
( O +
ER O +
) O +
in O +
the O +
development O +
and O +
physiology O +
of O +
the O +
breast O +
, O +
it O +
is O +
essential O +
to O +
delineate O +
the O +
mechanisms O +
responsible O +
for O +
its O +
failed O +
expression O +
in O +
some O +
breast O +
tumors O +
. O +

We O +
have O +
cloned O +
and O +
sequenced O +
a O +
portion O +
of O +
the O +
ER O +
upstream O +
regulatory O +
region O +
from O +
the O +
ER B-CellLine -
- I-CellLine -
positive I-CellLine +
MCF-7 I-CellLine +
and O +
the O +
ER B-CellLine -
- I-CellLine -
negative I-CellLine +
MDA I-CellLine -
- I-CellLine -
MB-231 I-CellLine +
breast I-CellLine +
cancer I-CellLine +
cell I-CellLine +
lines I-CellLine +
to O +
determine O +
if O +
sequence O +
alterations O +
in O +
this O +
region O +
account O +
for O +
the O +
ER O +
-negative O +
phenotype O +
of O +
some O +
tumors O +
. O +

From O +
this O +
, O +
we O +
identified O +
a O +
number O +
of O +
variations O +
between O +
the O +
sequences O +
, O +
two O +
of O +
which O +
were O +
determined O +
to O +
be O +
associated O +
with O +
a O +
50 O +
% O +
decrease O +
in O +
CAT O +
activity O +
. O +

Control O +
of O +
NFATx1 O +
nuclear O +
translocation O +
by O +
a O +
calcineurin O -
- O -
regulated O +
inhibitory O +
domain O +
. O +

The O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
regulates O +
cytokine O +
gene O +
expression O +
in O +
T O +
cells O +
through O +
cis O -
- O -
acting O +
elements O +
located O +
in O +
the O +
promoters O +
of O +
several O +
cytokine O +
genes O +
. O +

NFATx1 O +
, O +
which O +
is O +
preferentially O +
expressed O +
in O +
the O +
thymus O +
and O +
peripheral O +
blood O +
leukocytes O +
, O +
is O +
one O +
of O +
four O +
members O +
of O +
the O +
NFAT O +
family O +
of O +
transcription O +
factors O +
. O +

We O +
have O +
performed O +
domain O +
analysis O +
of O +
NFATx1 O +
by O +
examining O +
the O +
effects O +
of O +
deletion O +
mutations O +
. O +

We O +
found O +
that O +
NFATx1 O +
DNA O +
binding O +
activity O +
and O +
interaction O +
with O +
AP-1 O +
polypeptides O +
were O +
dependent O +
on O +
its O +
central O +
Rel O +
similarity O +
region O +
and O +
that O +
transcriptional O +
activation O +
was O +
reduced O +
by O +
deletions O +
of O +
either O +
its O +
N O -
- O -
terminal O +
domain O +
or O +
its O +
C O -
- O -
terminal O +
domain O +
, O +
suggesting O +
the O +
presence O +
of O +
intrinsic O +
transcriptional O +
activation O +
motifs O +
in O +
both O +
regions O +
. O +

We O +
also O +
identified O +
a O +
potent O +
inhibitory O +
sequence O +
within O +
its O +
N O -
- O -
terminal O +
domain O +
. O +

We O +
show O +
that O +
the O +
inactivation O +
of O +
the O +
inhibition O +
was O +
dependent O +
on O +
the O +
activity O +
of O +
calcineurin O +
, O +
a O +
calcium O -
- O -
calmodulin O -
- O -
dependent O +
phosphatase O +
. O +

We O +
also O +
show O +
that O +
calcineurin O +
associated O +
with O +
the O +
N O -
- O -
terminal O +
domain O +
of O +
NFATx1 O +
at O +
multiple O +
docking O +
sites O +
and O +
caused O +
a O +
reduction O +
of O +
size O +
, O +
indicative O +
of O +
dephosphorylation O +
, O +
in O +
NFATx1 O +
. O +

We O +
have O +
mapped O +
the O +
inhibitory O +
activity O +
to O +
less O +
than O +
60 O +
residues O +
, O +
containing O +
motifs O +
that O +
are O +
conserved O +
in O +
all O +
NFAT O +
proteins O +
. O +

Finally O +
, O +
we O +
demonstrate O +
that O +
deletion O +
in O +
NFATx1 O +
of O +
the O +
mapped O +
60 O +
residues O +
leads O +
to O +
its O +
nuclear O +
translocation O +
independent O +
of O +
calcium O +
signaling O +
. O +

Our O +
results O +
support O +
the O +
model O +
proposing O +
that O +
the O +
N O -
- O -
terminal O +
domain O +
confers O +
calcium O -
- O -
signaling O +
dependence O +
on O +
NFATx1 O +
transactivation O +
activity O +
by O +
regulating O +
its O +
intracellular O +
localization O +
through O +
a O +
protein O +
module O +
that O +
associates O +
with O +
calcineurin O +
and O +
is O +
a O +
target O +
of O +
its O +
phosphatase O +
activity O +
. O +

Possible O +
role O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
activity O +
in O +
germline O +
C O +
epsilon O +
transcription O +
in O +
a O +
human B-CellLine +
Burkitt I-CellLine +
lymphoma I-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
plays O +
a O +
broad O +
role O +
in O +
gene O +
regulation O +
, O +
but O +
it O +
is O +
not O +
evident O +
whether O +
NF O -
- O -
kappa O +
B O +
acts O +
as O +
a O +
messenger O +
system O +
for O +
germline O +
C O +
epsilon O +
transcription O +
. O +

We O +
report O +
here O +
that O +
the O +
signaling O +
cascade O +
triggered O +
by O +
interleukin-4 O +
( O +
IL-4 O +
) O +
or O +
anti O -
- O -
CD40 O +
monoclonal O +
antibody O +
( O +
mAb O +
) O +
participates O +
in O +
NF O -
- O -
kappa O +
B O +
activation O +
responsible O +
for O +
germline O +
C O +
epsilon O +
transcription O +
in O +
a O +
human B-CellLine +
Burkitt I-CellLine +
lymphoma I-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
DND39 B-CellLine +
. O +

Both O +
IL-4 O +
and O +
anti- O +
CD40 O +
mAb O +
induced O +
activation O +
of O +
phosphatidylinositol O +
3-kinase O +
( O +
PI3-kinase O +
) O +
, O +
translocation O +
of O +
a O +
zeta O +
isoform O +
of O +
protein O +
kinase O +
C O +
, O +
and O +
nuclear O +
expression O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

All O +
such O +
events O +
were O +
abrogated O +
by O +
treatment O +
with O +
LY294002 O +
, O +
a O +
specific O +
inhibitor O +
of O +
PI3-kinase O +
. O +

In O +
addition O +
, O +
N O -
- O -
acetyl O -
- O -
L O -
- O -
cysteine O +
( O +
NAC O +
) O +
, O +
a O +
potent O +
antioxidant O +
, O +
decreased O +
NF O -
- O -
kappa O +
B O +
activation O +
caused O +
by O +
IL-4 O +
, O +
anti O -
- O -
CD40 O +
mAb O +
, O +
or O +
their O +
combination O +
. O +

NAC O +
was O +
also O +
effective O +
in O +
diminishing O +
germline O +
C O +
epsilon O +
transcription O +
, O +
and O +
its O +
potency O +
was O +
higher O +
in O +
cultures O +
costimulated O +
with O +
IL-4 O +
and O +
anti O -
- O -
CD40 O +
mAb O +
than O +
in O +
those O +
stimulated O +
with O +
IL-4 O +
alone O +
. O +

These O +
results O +
indicate O +
that O +
IL-4 O +
and O +
ligation O +
of O +
CD40 O +
induce O +
NF O -
- O -
kappa O +
B O +
expression O +
via O +
at O +
least O +
a O +
mechanism O +
dependent O +
on O +
the O +
PI3-kinase O +
pathway O +
and O +
suggest O +
that O +
NF O -
- O -
kappa O +
B O +
sensitive O +
to O +
NAC O +
may O +
play O +
a O +
role O +
in O +
regulating O +
germline O +
C O +
epsilon O +
transcription O +
. O +

A O +
PMLRARalpha O +
transgene O +
initiates O +
murine O +
acute O +
promyelocytic O +
leukemia O +
. O +

The O +
malignant O +
cells O +
of O +
acute O +
promyelocytic O +
leukemia O +
( O +
APL O +
) O +
contain O +
a O +
reciprocal O +
chromosomal O +
translocation O +
that O +
fuses O +
the O +
promyelocytic O +
leukemia O +
gene O +
( O +
PML O +
) O +
with O +
the O +
retinoic O +
acid O +
receptor O +
alpha O +
gene O +
( O +
RAR O +
alpha O +
) O +
. O +

To O +
test O +
the O +
hypothesis O +
that O +
the O +
chimera O +
PMLRAR O +
alpha O +
plays O +
a O +
role O +
in O +
leukemogenesis O +
, O +
we O +
expressed O +
a O +
PMLRAR O +
alpha O +
cDNA O +
in O +
myeloid O +
cells O +
of O +
transgenic O +
mice O +
. O +

PMLRAR O +
alpha O +
transgenic O +
mice O +
exhibited O +
impaired O +
neutrophil O +
maturation O +
early O +
in O +
life O +
, O +
which O +
progressed O +
at O +
a O +
low O +
frequency O +
over O +
the O +
course O +
of O +
several O +
months O +
to O +
overt O +
APL O +
. O +

Both O +
the O +
preleukemic O +
state O +
and O +
the O +
leukemia O +
could O +
be O +
transplanted O +
to O +
nontransgenic O +
mice O +
, O +
and O +
the O +
transplanted O +
preleukemia O +
could O +
progress O +
to O +
APL O +
. O +

The O +
APL O +
recapitulated O +
features O +
of O +
the O +
human O +
disease O +
, O +
including O +
a O +
response O +
to O +
retinoic O +
acid O +
. O +

Retinoic O +
acid O +
caused O +
the O +
leukemic O +
cells O +
to O +
differentiate O +
in O +
vitro O +
and O +
in O +
vivo O +
, O +
eliciting O +
remissions O +
of O +
both O +
the O +
preleukemic O +
state O +
and O +
APL O +
in O +
mice O +
. O +

Our O +
results O +
demonstrate O +
that O +
PMLRAR O +
alpha O +
impairs O +
neutrophil O +
differentiation O +
and O +
initiates O +
the O +
development O +
of O +
APL O +
. O +

The O +
transgenic O +
mice O +
described O +
here O +
provide O +
an O +
apparently O +
accurate O +
model O +
for O +
human O +
APL O +
that O +
includes O +
clear O +
evidence O +
of O +
tumor O +
progression O +
. O +

The O +
model O +
should O +
be O +
useful O +
for O +
exploring O +
the O +
molecular O +
pathogenesis O +
of O +
APL O +
and O +
the O +
mechanisms O +
of O +
the O +
therapeutic O +
response O +
to O +
retinoic O +
acid O +
, O +
as O +
well O +
as O +
for O +
preclinical O +
studies O +
of O +
therapeutic O +
regimens O +
. O +

Neuronal O +
( O +
type O +
I O +
) O +
nitric O +
oxide O +
synthase O +
regulates O +
nuclear O +
factor O +
kappaB O +
activity O +
and O +
immunologic O +
( O +
type O +
II O +
) O +
nitric O +
oxide O +
synthase O +
expression O +
. O +

Nitric O +
oxide O +
subserves O +
diverse O +
physiologic O +
roles O +
in O +
the O +
nervous O +
system O +
. O +

NO O +
is O +
produced O +
from O +
at O +
least O +
three O +
different O +
NO O +
synthase O +
( O +
NOS O +
) O +
isoforms O +
: O +
neuronal O +
NOS O +
( O +
nNOS O +
) O +
, O +
endothelial O +
NOS O +
, O +
and O +
immunologic O +
NOS O +
( O +
iNOS O +
) O +
. O +

We O +
show O +
that O +
nNOS O +
is O +
the O +
predominant O +
isoform O +
constitutively O +
expressed O +
in O +
glia O +
. O +

NO O +
derived O +
from O +
nNOS O +
in O +
glia O +
inhibits O +
the O +
transcription O +
factor O +
nuclear O +
factor O +
kappaB O +
( O +
NF O +
kappaB O +
) O +
as O +
NOS O +
inhibitors O +
enhance O +
basal O +
NF O +
kappaB O +
activation O +
. O +

Pyrrolidine O +
dithiocarbamate O +
( O +
PDTC O +
) O +
is O +
an O +
inhibitor O +
of O +
NF O +
kappaB O +
in O +
most O +
cells O +
; O +
however O +
, O +
we O +
show O +
that O +
PDTC O +
is O +
also O +
a O +
potent O +
scavenger O +
of O +
NO O +
through O +
formation O +
of O +
mononitrosyl O +
iron O +
complexes O +
with O +
PDTC O +
. O +

In O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
a O +
human O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
lymphoma I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
induces O +
NF O +
kappaB O +
activation O +
that O +
is O +
inhibited O +
by O +
PDTC O +
. O +

Contrary O +
to O +
the O +
results O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
PDTC O +
did O +
not O +
inhibit O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
-induced O +
NF O +
kappaB O +
activation O +
in O +
astrocytes O +
; O +
instead O +
PDTC O +
itself O +
induces O +
NF O +
kappaB O +
activation O +
in O +
astrocytes O +
, O +
and O +
this O +
may O +
be O +
related O +
to O +
scavenging O +
of O +
endogenously O +
produced O +
NO O +
by O +
the O +
PDTC O +
iron O +
complex O +
. O +

In O +
astrocytes O +
PDTC O +
also O +
dramatically O +
induces O +
the O +
NF O +
kappaB O -
- O -
dependent O +
enzyme O +
, O +
iNOS O +
, O +
supporting O +
the O +
physiologic O +
relevance O +
of O +
endogenous O +
NO O +
regulation O +
of O +
NF O +
kappaB O +
. O +

NF O +
kappaB O +
activation O +
in O +
glia O +
from O +
mice O +
lacking O +
nNOS O +
responds O +
more O +
rapidly O +
to O +
PDTC O +
compared O +
with O +
astrocytes O +
from O +
wild O -
- O -
type O +
mice O +
. O +

Our O +
data O +
suggest O +
that O +
nNOS O +
in O +
astrocytes O +
regulates O +
NF O +
kappaB O +
activity O +
and O +
iNOS O +
expression O +
, O +
and O +
indicate O +
a O +
novel O +
regulatory O +
role O +
for O +
nNOS O +
in O +
tonically O +
suppressing O +
central O +
nervous O +
system O +
, O +
NF O +
kappaB O -
- O -
regulated O +
genes O +
. O +

The O +
predominant O +
E2F O +
complex O +
in O +
human O +
primary O +
haemopoietic O +
cells O +
and O +
in O +
AML O +
blasts O +
contains O +
E2F-4 O +
, O +
DP-1 O +
and O +
p130 O +
. O +

The O +
E2F O +
family O +
of O +
transcription O +
factors O +
are O +
thought O +
to O +
play O +
an O +
important O +
role O +
in O +
the O +
control O +
of O +
cell O +
cycle O +
progression O +
. O +

There O +
is O +
now O +
also O +
increasing O +
evidence O +
that O +
some O +
family O +
members O +
may O +
act O +
as O +
oncogenes O +
or O +
tumour O +
suppressor O +
genes O +
. O +

The O +
characterization O +
of O +
these O +
proteins O +
in O +
human O +
primary O +
haemopoietic O +
cells O +
and O +
acute O +
myeloid O +
leukaemia O +
( O +
AML O +
) O +
blasts O +
may O +
thus O +
give O +
an O +
insight O +
to O +
the O +
molecular O +
mechanisms O +
governing O +
proliferation O +
and O +
leukaemogenesis O +
in O +
these O +
cells O +
. O +

Therefore O +
we O +
analysed O +
the O +
expression O +
of O +
E2F O +
-DNA O +
binding O +
activity O +
and O +
the O +
constituent O +
proteins O +
found O +
in O +
the O +
complexes O +
in O +
human O +
primary O +
haemopoietic O +
cells O +
of O +
various O +
lineages O +
. O +

We O +
also O +
studied O +
blasts O +
from O +
18 O +
patients O +
with O +
acute O +
myeloid O +
leukaemia O +
( O +
AML O +
) O +
. O +

On O +
electromobility O +
shift O +
assays O +
( O +
EMSA O +
) O +
a O +
single O +
E2F O -
- O -
DNA O +
binding O +
complex O +
was O +
detected O +
in O +
T O +
cells O +
, O +
B O +
cells O +
and O +
monocytes O +
which O +
was O +
shown O +
to O +
contain O +
E2F-4 O +
, O +
DP-1 O +
and O +
p130 O +
, O +
indicating O +
that O +
all O +
quiescent O +
haemopoietic O +
cells O +
have O +
the O +
same O +
complex O +
. O +

Examination O +
of O +
18 O +
AML O +
samples O +
by O +
EMSA O +
revealed O +
the O +
presence O +
of O +
E2F O +
binding O +
and O +
no O +
gross O +
abnormalities O +
were O +
detected O +
. O +

An O +
E2F-4 O -
/ O -
p130 O +
complex O +
was O +
detected O +
in O +
representative O +
samples O +
of O +
all O +
FAB O +
types O +
analysed O +
. O +

Thus O +
abnormalities O +
of O +
E2F O +
function O +
are O +
unlikely O +
to O +
play O +
a O +
primary O +
pathogenic O +
role O +
in O +
AML O +
. O +

Cell O -
- O -
to O -
- O -
cell O +
contact O +
activates O +
the O +
long O +
terminal O +
repeat O +
of O +
human O +
immunodeficiency O +
virus O +
1 O +
through O +
its O +
kappaB O +
motif O +
. O +

Cell O -
- O -
to O -
- O -
cell O +
contact O +
between O +
peripheral O +
blood O +
lymphocytes O +
and O +
transfected B-CellLine +
human I-CellLine +
colonic I-CellLine +
carcinoma I-CellLine +
cell I-CellLine +
line I-CellLine +
HT29 I-CellLine +
activates O +
transcription O +
of O +
the O +
long O +
terminal O +
repeats O +
( O +
LTR O +
) O +
of O +
human O +
immunodeficiency O +
virus O +
. O +

HIV-1 O +
LTR O +
transcription O +
is O +
controlled O +
by O +
a O +
complex O +
array O +
of O +
virus O -
- O -
encoded O +
and O +
cellular O +
proteins O +
. O +

Using O +
various O +
constructs O +
expressing O +
a O +
lacZ O +
reporter O +
gene O +
under O +
the O +
control O +
of O +
the O +
intact O +
or O +
three O +
deleted O +
forms O +
of O +
HIV-1 O +
LTR O +
, O +
we O +
obtained O +
evidence O +
that O +
the O +
kappaB O +
regulatory O +
elements O +
located O +
in O +
the O +
U3 O +
region O +
are O +
involved O +
in O +
cell O -
- O -
to O -
- O -
cell O +
activation O +
of O +
HIV-1 O +
LTR O +
. O +

Cell O -
- O -
to O -
- O -
cell O +
contact O +
activates O +
in O +
vitro O +
binding O +
of O +
the O +
nuclear O +
factor O +
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
p50 O -
/ O -
p65 O +
heterodimer O +
to O +
an O +
HIV-1 O +
kappaB O +
oligonucleotide O +
. O +

Cell O -
- O -
to O -
- O -
cell O +
contact O +
activation O +
of O +
NF O -
- O -
kappaB O +
was O +
only O +
partially O +
inhibited O +
by O +
100 O +
microM O +
pyrrolidine O +
dithiocarbamate O +
and O +
was O +
not O +
correlated O +
with O +
a O +
significant O +
decrease O +
of O +
cellular O +
inhibitor O +
kappaB O +
alpha O +
. O +

NF O -
- O -
kappaB O +
nuclear O +
activation O +
was O +
not O +
detectable O +
before O +
1 O +
h O +
after O +
cell O +
contact O +
and O +
was O +
dependent O +
on O +
protein O +
synthesis O +
. O +

Lineage- O +
and O +
stage O -
- O -
specific O +
expression O +
of O +
runt O +
box O +
polypeptides O +
in O +
primitive O +
and O +
definitive O +
hematopoiesis O +
. O +

Translocations O +
involving O +
the O +
human O +
CBFA2 O +
locus O +
have O +
been O +
associated O +
with O +
leukemia O +
. O +

This O +
gene O +
, O +
originally O +
named O +
AML1 O +
, O +
is O +
a O +
human O +
homologue O +
of O +
the O +
Drosophila O +
gene O +
runt O +
that O +
controls O +
early O +
events O +
in O +
fly O +
embryogenesis O +
. O +

To O +
clarify O +
the O +
role O +
of O +
mammalian O +
runt O +
products O +
in O +
normal O +
and O +
leukemic O +
hematopoiesis O +
, O +
we O +
have O +
studied O +
their O +
pattern O +
of O +
expression O +
in O +
mouse O +
hematopoietic O +
tissues O +
in O +
the O +
adult O +
and O +
during O +
ontogeny O +
using O +
an O +
anti O -
- O -
runt O +
box O +
antiserum O +
. O +

In O +
the O +
adult O +
bone O +
marrow O +
, O +
we O +
found O +
expression O +
of O +
runt O +
polypeptides O +
in O +
differentiating O +
myeloid O +
cells O +
and O +
in O +
B O +
lymphocytes O +
. O +

Within O +
the O +
erythroid O +
lineage O +
, O +
runt O +
expression O +
is O +
biphasic O +
, O +
clearly O +
present O +
in O +
the O +
erythroblasts O +
of O +
early O +
blood O +
islands O +
and O +
of O +
the O +
fetal O +
liver O +
, O +
but O +
absent O +
in O +
the O +
adult O +
. O +

Biochemical O +
analysis O +
by O +
Western O +
blotting O +
of O +
fetal O +
and O +
adult O +
hematopoietic O +
populations O +
shows O +
several O +
runt O +
isoforms O +
. O +

At O +
least O +
one O +
of O +
them O +
appears O +
to O +
be O +
myeloid O +
specific O +
. O +

T O -
- O -
lymphocytes O +
from O +
individuals O +
with O +
filarial O +
inflammatory O +
disease O +
have O +
increased O +
transendothelial O +
migration O +
in O +
vitro O +
. O +

The O +
in O +
vitro O +
transendothelial O +
migration O +
of O +
circulating O +
filarial O +
antigen O -
- O -
specific O +
T O -
- O -
cells O +
was O +
examined O +
in O +
Wuchereria O +
banerofti O +
infection O +
. O +

Circulating O +
T O -
- O -
cells O +
from O +
individuals O +
with O +
filaria O -
- O -
induced O +
lymphatic O +
pathology O +
( O +
LP O +
) O +
had O +
significantly O +
greater O +
migration O +
through O +
unstimulated O +
HUVEC O +
monolayers O +
than O +
did O +
T O -
- O -
cells O +
from O +
asymptomatic O +
infected O +
( O +
MF O +
) O +
individuals O +
( O +
P O +
= O +
0.04 O +
) O +
. O +

In O +
contrast O +
to O +
the O +
MF O +
individuals O +
where O +
no O +
effect O +
was O +
seen O +
, O +
transendothelial O +
migration O +
of O +
48-hr O +
filarial O +
antigen O +
stimulated O +
T O -
- O -
cells O +
from O +
LP O +
individuals O +
was O +
significantly O +
( O +
P O +
= O +
0.01 O +
) O +
greater O +
than O +
migration O +
of O +
48-hr O +
media O -
- O -
stimulated O +
T O -
- O -
cells O +
. O +

In O +
six O +
of O +
seven O +
patients O +
examined O +
, O +
inhibition O +
of O +
the O +
VLA-4 O -
/ O +
VCAM-1 O +
pathway O +
resulted O +
in O +
greater O +
than O +
50 O +
% O +
inhibition O +
of O +
transendothelial O +
migration O +
of O +
T O -
- O -
cells O +
. O +

Response O +
to O +
intranasal O +
fluticasone O +
propionate O +
in O +
perennial O +
allergic O +
rhinitis O +
not O +
associated O +
with O +
glucocorticoid O +
receptor O +
characteristics O +
. O +

BACKGROUND O +
: O +
The O +
reduction O +
of O +
symptoms O +
due O +
to O +
treatment O +
with O +
corticosteroids O +
varies O +
among O +
patients O +
with O +
perennial O +
rhinitis O +
. O +

Most O +
patients O +
will O +
respond O +
but O +
a O +
few O +
patients O +
respond O +
less O +
to O +
these O +
drugs O +
. O +

OBJECTIVE O +
: O +
To O +
investigate O +
the O +
association O +
in O +
reduction O +
of O +
symptoms O +
due O +
to O +
glucocorticoids O +
and O +
glucocorticoid O +
receptor O +
characteristics O +
in O +
patients O +
with O +
perennial O +
allergic O +
rhinitis O +
, O +
in O +
vitro O +
glucocorticoid O +
receptor O +
binding O +
studies O +
were O +
performed O +
with O +
peripheral O +
blood O +
mononuclear O +
cells O +
using O +
dexamethasone O +
and O +
in O +
vitro O +
production O +
of O +
mediators O +
were O +
measured O +
. O +

METHODS O +
: O +
During O +
a O +
double O -
- O -
blind O +
placebo O -
- O -
controlled O +
crossover O +
study O +
, O +
200 O +
micrograms O +
fluticasone O +
propionate O +
aqueous O +
nasal O +
spray O +
( O +
in O +
the O +
active O +
treatment O +
period O +
) O +
and O +
placebo O +
( O +
in O +
the O +
placebo O +
treatment O +
period O +
) O +
were O +
administered O +
twice O +
daily O +
for O +
2 O +
weeks O +
to O +
22 O +
patients O +
allergic O +
to O +
house O +
dust O +
mite O +
. O +

At O +
the O +
end O +
of O +
both O +
treatment O +
periods O +
symptoms O +
were O +
scored O +
after O +
allergen O +
provocation O +
( O +
100 O +
, O +
1000 O +
, O +
10000 O +
BU O -
/ O -
mL O +
) O +
and O +
during O +
the O +
9.5 O +
hours O +
after O +
this O +
challenge O +
. O +

Receptor O +
binding O +
studies O +
with O +
dexamethasone O +
were O +
performed O +
with O +
peripheral O +
blood O +
mononuclear O +
cells O +
. O +

Leukotriene O +
B4 O +
produced O +
by O +
monocytes O +
in O +
vitro O +
and O +
soluble O +
interleukin-2 O +
receptor O +
released O +
by O +
lymphocytes O +
in O +
vitro O +
and O +
cortisol O +
levels O +
in O +
plasma O +
were O +
determined O +
. O +

RESULTS O +
: O +
No O +
significant O +
partial O +
correlations O +
of O +
the O +
number O +
of O +
the O +
peripheral O +
blood O +
mononuclear O +
cell O +
glucocorticoid O +
receptors O +
( O +
6821 O +
+ O -
/- O +
5669 O +
binding O +
sites O +
per O +
cell O +
) O +
and O +
the O +
affinity O +
( O +
Kd O +
: O +
16.5 O +
+ O -
/- O +
13.51 O +
nmol O -
/ O -
L O +
) O +
for O +
the O +
glucocorticoid O +
receptors O +
with O +
the O +
symptom O +
score O +
( O +
placebo O +
: O +
4.3 O +
+ O -
/- O +
2.45 O +
pts O +
; O +
fluticasone O +
: O +
2.4 O +
+ O -
/- O +
1.55 O +
pts O +
) O +
after O +
active O +
treatment O +
were O +
found O +
. O +

Also O +
no O +
significant O +
partial O +
correlations O +
of O +
the O +
levels O +
of O +
leukotriene O +
B4 O +
( O +
45.6 O +
+ O -
/- O +
105.3 O +
ng O -
/ O -
10 O +
( O +
6 O +
) O +
cells O +
) O +
produced O +
by O +
monocytes O +
in O +
vitro O +
, O +
soluble O +
interleukin-2 O +
receptor O +
( O +
734 O +
+ O -
/- O +
237 O +
ng O -
/ O -
10 O +
( O +
6 O +
) O +
cells O +
) O +
released O +
by O +
lymphocytes O +
in O +
vitro O +
and O +
cortisol O +
levels O +
( O +
571 O +
+ O -
/- O +
236 O +
ng O -
/ O -
mL O +
) O +
in O +
plasma O +
with O +
the O +
symptom O +
score O +
after O +
active O +
treatment O +
were O +
found O +
. O +

CONCLUSIONS O +
: O +
The O +
reduction O +
of O +
symptoms O +
due O +
to O +
topical O +
fluticasone O +
propionate O +
in O +
patients O +
with O +
rhinitis O +
and O +
allergy O +
to O +
house O +
dust O +
mite O +
is O +
not O +
correlated O +
with O +
the O +
characteristics O +
of O +
the O +
glucocorticoid O +
receptor O +
. O +

HIV O +
does O +
not O +
replicate O +
in O +
naive O +
CD4 O +
T O +
cells O +
stimulated O +
with O +
CD3 O -
/ O -
CD28 O +
. O +

In O +
this O +
report O +
, O +
we O +
demonstrate O +
that O +
the O +
T O +
cell O +
tropic O +
strain O +
of O +
HIV O +
, O +
LAI O +
, O +
does O +
not O +
replicate O +
in O +
naive O +
CD4 O +
T O +
cells O +
stimulated O +
by O +
cross O -
- O -
linking O +
CD3 O +
and O +
CD28 O +
. O +

In O +
contrast O +
, O +
LAI O +
replicates O +
well O +
in O +
memory O +
CD4 O +
T O +
cells O +
stimulated O +
in O +
the O +
same O +
way O +
. O +

Unlike O +
this O +
physiologically O +
relevant O +
stimulation O +
, O +
PHA O +
stimulates O +
productive O +
LAI O +
replication O +
in O +
both O +
naive O +
and O +
memory O +
T O +
cells O +
. O +

These O +
studies O +
were O +
conducted O +
with O +
highly O +
purified O +
( O +
FACS O -
- O -
isolated O +
) O +
subsets O +
of O +
CD4 O +
T O +
cells O +
identified O +
by O +
expression O +
of O +
both O +
CD45RA O +
and O +
CD62L O +
. O +

Remixing O +
of O +
purified O +
T O +
cells O +
showed O +
that O +
naive O +
T O +
cells O +
do O +
not O +
suppress O +
LAI O +
replication O +
in O +
memory O +
T O +
cells O +
and O +
that O +
memory O +
T O +
cells O +
do O +
not O +
restore O +
LAI O +
expression O +
in O +
naive O +
T O +
cells O +
. O +

The O +
suppression O +
of O +
productive O +
LAI O +
replication O +
in O +
naive O +
T O +
cells O +
is O +
not O +
due O +
to O +
differential O +
expression O +
of O +
viral O +
coreceptors O +
, O +
nor O +
is O +
it O +
due O +
to O +
inhibition O +
of O +
activation O +
of O +
the O +
important O +
HIV O +
transcription O +
factors O +
, O +
nuclear O +
factor O -
- O -
kappaB O +
and O +
activator O +
protein-1 O +
. O +

The O +
inherent O +
resistance O +
of O +
naive O +
T O +
cells O +
to O +
productive O +
HIV O +
infection O +
, O +
coupled O +
with O +
their O +
proliferative O +
advantage O +
as O +
demonstrated O +
here O +
, O +
provides O +
a O +
sound O +
basis O +
for O +
proposed O +
clinical O +
therapies O +
using O +
ex O +
vivo O +
expansion O +
and O +
reinfusion O +
of O +
CD4 O +
T O +
cells O +
from O +
HIV O -
- O -
infected O +
adults O +
. O +

Physical O +
interactions O +
between O +
Ets O +
and O +
NF O -
- O -
kappaB O -
/ O -
NFAT O +
proteins O +
play O +
an O +
important O +
role O +
in O +
their O +
cooperative O +
activation O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
enhancer O +
in O +
T O +
cells O +
. O +

The O +
transcriptional O +
regulatory O +
elements O +
of O +
many O +
inducible O +
T O -
- O -
cell O +
genes O +
contain O +
adjacent O +
or O +
overlapping O +
binding O +
sites O +
for O +
the O +
Ets O +
and O +
NF O -
- O -
kappaB O -
/ O -
NFAT O +
families O +
of O +
transcription O +
factors O +
. O +

Similar O +
arrays O +
of O +
functionally O +
important O +
NF O -
- O -
kappaB O -
/ O -
NFAT O +
and O +
Ets O +
binding O +
sites O +
are O +
present O +
in O +
the O +
transcriptional O +
enhancers O +
of O +
human O +
immunodeficiency O +
viruses O +
types O +
1 O +
and O +
2 O +
( O +
HIV-1 O +
and O +
HIV-2 O +
) O +
, O +
suggesting O +
that O +
this O +
pattern O +
of O +
nuclear O +
protein O +
binding O +
sites O +
reflects O +
an O +
evolutionarily O +
conserved O +
mechanism O +
for O +
regulating O +
inducible O +
T O -
- O -
cell O +
gene O +
expression O +
that O +
has O +
been O +
co O -
- O -
opted O +
during O +
HIV O +
evolution O +
. O +

Despite O +
these O +
findings O +
, O +
the O +
molecular O +
mechanisms O +
by O +
which O +
Ets O +
and O +
NF O -
- O -
kappaB O -
/ O -
NFAT O +
proteins O +
cooperatively O +
regulate O +
inducible O +
T O -
- O -
cell O +
gene O +
expression O +
remained O +
unknown O +
. O +

In O +
the O +
studies O +
described O +
in O +
this O +
report O +
, O +
we O +
demonstrated O +
a O +
physical O +
interaction O +
between O +
multiple O +
Ets O +
and O +
NF O -
- O -
kappaB O -
/ O -
NFAT O +
proteins O +
both O +
in O +
vitro O +
and O +
in O +
activated O +
normal O +
human O +
T O +
cells O +
. O +

This O +
interaction O +
is O +
mediated O +
by O +
the O +
Ets O +
domain O +
of O +
Ets O +
proteins O +
and O +
the O +
C O -
- O -
terminal O +
region O +
of O +
the O +
Rel O +
homology O +
domains O +
of O +
NF O -
- O -
kappaB O -
/ O -
NFAT O +
proteins O +
. O +

In O +
addition O +
, O +
the O +
Ets O +
- O +
NF O -
- O -
kappaB O +
/ O +
NFAT O +
interaction O +
requires O +
the O +
presence O +
of O +
DNA O +
binding O +
sites O +
for O +
both O +
proteins O +
, O +
as O +
it O +
is O +
abolished O +
by O +
the O +
DNA O +
intercalating O +
agents O +
propidium O +
iodide O +
and O +
ethidium O +
bromide O +
and O +
enhanced O +
by O +
the O +
presence O +
of O +
synthetic O +
oligonucleotides O +
containing O +
binding O +
sites O +
for O +
Ets O +
and O +
NF O -
- O -
kappaB O +
proteins O +
. O +

A O +
dominant O -
- O -
negative O +
mutant O +
of O +
NF O -
- O -
kappaB O +
p50 O +
that O +
binds O +
DNA O +
but O +
fails O +
to O +
interact O +
with O +
Ets O +
proteins O +
inhibits O +
the O +
synergistic O +
activation O +
of O +
the O +
HIV-1 O +
and O +
HIV-2 O +
enhancers O +
by O +
NF O -
- O -
kappaB O +
( O +
p50 O +
+ O +
p65 O +
) O +
and O +
Ets-1 O +
, O +
suggesting O +
that O +
physical O +
interaction O +
between O +
Ets O +
and O +
NF O -
- O -
kappaB O +
proteins O +
is O +
required O +
for O +
the O +
transcriptional O +
activity O +
of O +
the O +
HIV-1 O +
and O +
HIV-2 O +
enhancers O +
. O +

Taken O +
together O +
, O +
these O +
findings O +
suggest O +
that O +
evolutionarily O +
conserved O +
physical O +
interactions O +
between O +
Ets O +
and O +
NF O -
- O -
kappaB O -
/ O -
NFAT O +
proteins O +
are O +
important O +
in O +
regulating O +
the O +
inducible O +
expression O +
of O +
T O -
- O -
cell O +
genes O +
and O +
viruses O +
. O +

These O +
interactions O +
represent O +
a O +
potential O +
target O +
for O +
the O +
development O +
of O +
novel O +
immunosuppressive O +
and O +
antiviral O +
therapies O +
. O +

Oxidant O -
- O -
regulation O +
of O +
gene O +
expression O +
in O +
the O +
chronically O +
inflamed O +
intestine O +
. O +

It O +
is O +
becoming O +
increasingly O +
apparent O +
that O +
the O +
chronic O +
gut O +
inflammation O +
observed O +
in O +
the O +
idiopathic O +
inflammatory O +
bowel O +
diseases O +
( O +
e.g. O +
ulcerative O +
colitis O +
, O +
Crohn O +
's O +
disease O +
) O +
is O +
associated O +
with O +
enhanced O +
production O +
of O +
leukocyte O -
- O -
derived O +
oxidants O +
. O +

Oxidants O +
such O +
as O +
hydrogen O +
peroxide O +
are O +
known O +
to O +
activate O +
certain O +
transcription O +
factors O +
such O +
as O +
nuclear O +
transcription O +
factor O +
kappa O +
beta O +
. O +

Nuclear O +
transcription O +
factor O +
kB O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
is O +
a O +
ubiquitous O +
transcription O +
factor O +
and O +
pleiotropic O +
regulator O +
of O +
numerous O +
genes O +
involved O +
in O +
the O +
immune O +
and O +
inflammatory O +
responses O +
. O +

This O +
transcription O +
factor O +
is O +
activated O +
via O +
the O +
selective O +
phosphorylation O +
, O +
ubiquination O +
and O +
degradation O +
of O +
its O +
inhibitor O +
protein O +
I O -
- O -
kB O +
thereby O +
allowing O +
translocation O +
of O +
NF O -
- O -
kappa O +
B O +
into O +
the O +
nucleus O +
where O +
it O +
upregulates O +
the O +
transcription O +
of O +
a O +
variety O +
of O +
adhesion O +
molecules O +
( O +
e.g O +
. O +
ICAM-1 O +
, O +
VCAM-1 O +
) O +
, O +
cytokines O +
( O +
TNF O +
, O +
IL-1 O +
, O +
IL-6 O +
) O +
and O +
enzymes O +
( O +
iNOS O +
) O +
. O +

The O +
proteolytic O +
degradation O +
of O +
the O +
post O -
- O -
translationally O +
modified O +
I O -
- O -
kappa O +
B O +
is O +
known O +
to O +
be O +
mediated O +
by O +
the O +
26S O +
proteasome O +
complex O +
. O +

Based O +
upon O +
work O +
from O +
our O +
laboratory O +
, O +
we O +
propose O +
that O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
produces O +
significant O +
anti O +
inflammatory O +
activity O +
which O +
may O +
be O +
mediated O +
by O +
the O +
inhibition O +
of O +
transcription O +
of O +
certain O +
pro O -
- O -
inflammatory O +
mediators O +
and O +
adhesion O +
molecules O +
. O +

Expression O +
of O +
LAZ3 O -
/ O -
BCL6 O +
in O +
follicular O +
center O +
( O +
FC O +
) O +
B O +
cells O +
of O +
reactive O +
lymph O +
nodes O +
and O +
FC O -
- O -
derived O +
non O -
- O -
Hodgkin O +
lymphomas O +
. O +

Chromosomal O +
translocation O +
resulting O +
in O +
abnormal O +
expression O +
of O +
the O +
LAZ3 O -
/ O -
BCL6 O +
gene O +
in O +
B O +
cells O +
has O +
been O +
implicated O +
in O +
the O +
tumorigenesis O +
of O +
non O -
- O -
Hodgkin O +
lymphoma O +
( O +
NHL O +
) O +
. O +

Therefore O +
we O +
studied O +
the O +
expression O +
pattern O +
of O +
LAZ3 O -
/ O -
BCL6 O +
by O +
in O +
situ O +
hybridization O +
with O +
synthetic O +
oligonucleotide O +
probes O +
in O +
frozen O +
tissue O +
sections O +
from O +
five O +
reactive O +
lymph O +
nodes O +
and O +
38 O +
B O +
cell O +
and O +
non O -
- O -
B O +
NHL O +
. O +

In O +
addition O +
, O +
we O +
investigated O +
the O +
expression O +
of O +
LAZ3 O -
/ O -
BCL6 O +
by O +
Northern O +
blot O +
analysis O +
on O +
multiple O +
human O +
tissues O +
. O +

The O +
LAZ3 O -
/ O -
BCL6 O +
transcript O +
was O +
found O +
in O +
a O +
variety O +
of O +
tissues O +
, O +
including O +
skeletal O +
muscle O +
, O +
peripheral O +
blood O +
leukocytes O +
, O +
and O +
weakly O +
in O +
normal O +
lymph O +
nodes O +
. O +

In O +
the O +
tumor O +
samples O +
, O +
expression O +
of O +
LAZ3 O -
/ O -
BCL6 O +
was O +
observed O +
in O +
68 O +
% O +
of O +
all O +
B O +
cell O +
NHL O +
and O +
none O +
of O +
the O +
non O -
- O -
B O +
lymphomas O +
. O +

All O +
cases O +
of O +
follicular O +
, O +
mixed O +
small O +
and O +
large O +
cell O +
lymphomas O +
showed O +
LAZ3 O -
/ O -
BCL6 O +
expression O +
confined O +
to O +
the O +
neoplastic O +
follicles O +
. O +

A O +
follicular O +
expression O +
pattern O +
was O +
also O +
found O +
in O +
all O +
non O -
- O -
malignant O +
reactive O +
lymph O +
nodes O +
. O +

Hence O +
, O +
the O +
expression O +
of O +
LAZ3 O -
/ O -
BCL6 O +
does O +
not O +
correlate O +
to O +
malignancy O +
, O +
but O +
reflects O +
the O +
origin O +
of O +
B O +
cells O +
from O +
the O +
germinal O +
centers O +
. O +

Two O +
distinct O +
pathways O +
of O +
interleukin-5 O +
synthesis O +
in O +
allergen B-CellLine -
- I-CellLine -
specific I-CellLine +
human I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
are O +
suppressed O +
by O +
glucocorticoids O +
. O +

Glucocorticoids O +
( O +
GC O +
) O +
have O +
long O +
been O +
used O +
as O +
the O +
most O +
effective O +
agents O +
for O +
the O +
treatment O +
of O +
allergic O +
diseases O +
accompanied O +
by O +
eosinophilia O +
such O +
as O +
chronic O +
asthma O +
and O +
atopic O +
dermatitis O +
. O +

The O +
development O +
of O +
chronic O +
eosinophilic O +
inflammation O +
is O +
dependent O +
on O +
interleukin-5 O +
( O +
IL-5 O +
) O +
, O +
a O +
selective O +
eosinophil O -
- O -
activating O +
factor O +
, O +
produced O +
by O +
helper O +
T O +
cells O +
. O +

To O +
delineate O +
the O +
regulatory O +
mechanisms O +
of O +
human O +
IL-5 O +
synthesis O +
, O +
we O +
established O +
allergen B-CellLine -
- I-CellLine -
specific I-CellLine +
CD4 I-CellLine -
+ I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
from O +
asthmatic O +
patients O +
. O +

GC O +
efficiently O +
suppressed O +
IL-5 O +
synthesis O +
of O +
T O -
- O -
cell O +
clones O +
activated O +
via O +
either O +
T O -
- O -
cell O +
receptor O +
( O +
TCR O +
) O +
or O +
IL-2 O +
receptor O +
( O +
IL-2R O +
) O +
. O +

Induction O +
of O +
IL-5 O +
mRNA O +
upon O +
TCR O +
and O +
IL-2R O +
stimulation O +
was O +
totally O +
inhibited O +
by O +
dexamethasone O +
. O +

Human O +
IL-5 O +
promoter O -
/ O -
enhancer O -
- O -
luciferase O +
gene O +
construct O +
transfected O +
to O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
was O +
transcribed O +
on O +
either O +
TCR O +
or O +
IL-2R O +
stimulation O +
and O +
was O +
clearly O +
downregulated O +
by O +
dexamethasone O +
, O +
indicating O +
that O +
the O +
approximately O +
500-bp O +
human O +
IL-5 O +
gene O +
segment O +
located O +
5 O +
' O +
upstream O +
of O +
the O +
coding O +
region O +
contains O +
activation O -
- O -
inducible O +
enhancer O +
elements O +
responsible O +
for O +
the O +
regulation O +
by O +
GC O +
. O +

Electrophoretic O +
mobility O +
shift O +
assay O +
analysis O +
suggested O +
that O +
AP-1 O +
and O +
NF O -
- O -
kappaB O +
are O +
among O +
the O +
possible O +
targets O +
of O +
GC O +
actions O +
on O +
TCR O -
- O -
stimulated O +
T O +
cells O +
. O +

NF O -
- O -
AT O +
and O +
NF O -
- O -
kappaB O +
were O +
not O +
significantly O +
induced O +
by O +
IL-2 O +
stimulation O +
. O +

Our O +
results O +
showing O +
that O +
GC O +
suppressed O +
IL-5 O +
production O +
by O +
human O +
CD4 O -
+ O +
T O +
cells O +
activated O +
by O +
two O +
distinct O +
stimuli O +
, O +
TCR O +
and O +
IL-2R O +
stimulation O +
, O +
underscore O +
the O +
efficacy O +
of O +
GC O +
in O +
the O +
treatment O +
of O +
allergic O +
diseases O +
via O +
suppression O +
of O +
T O -
- O -
cell O +
IL-5 O +
synthesis O +
. O +

Experimental O +
expression O +
in O +
mice O +
and O +
spontaneous O +
expression O +
in O +
human O +
SLE O +
of O +
polyomavirus O +
T O -
- O -
antigen O +
. O +

A O +
molecular O +
basis O +
for O +
induction O +
of O +
antibodies O +
to O +
DNA O +
and O +
eukaryotic O +
transcription O +
factors O +
. O +

We O +
have O +
previously O +
demonstrated O +
that O +
experimental O +
expression O +
of O +
the O +
polyomavirus O +
transcription O +
factor O +
T O -
- O -
antigen O +
has O +
the O +
potential O +
to O +
induce O +
anti O -
- O -
DNA O +
antibodies O +
in O +
mice O +
. O +

Two O +
sets O +
of O +
independent O +
evidences O +
are O +
presented O +
here O +
that O +
demonstrate O +
a O +
biological O +
relevance O +
for O +
this O +
model O +
. O +

First O +
, O +
we O +
describe O +
results O +
demonstrating O +
that O +
mice O +
inoculated O +
with O +
T O -
- O -
antigen O -
- O -
expressing O +
plasmids O +
produced O +
antibodies O +
, O +
not O +
only O +
to O +
T O -
- O -
antigen O +
and O +
DNA O +
, O +
but O +
also O +
to O +
the O +
DNA O -
- O -
binding O +
eukaryotic O +
transcription O +
factors O +
TATA O -
- O -
binding O +
protein O +
( O +
TBP O +
) O +
, O +
and O +
to O +
the O +
cAMP O -
- O -
response O -
- O -
element O -
- O -
binding O +
protein O +
( O +
CREB O +
) O +
. O +

Secondly O +
, O +
we O +
investigated O +
whether O +
polyomavirus O +
reactivation O +
occurs O +
in O +
SLE O +
patients O +
, O +
and O +
whether O +
antibodies O +
to O +
T O -
- O -
antigen O +
, O +
DNA O +
, O +
and O +
to O +
TBP O +
and O +
CREB O +
are O +
linked O +
to O +
such O +
events O +
. O +

Both O +
within O +
and O +
among O +
these O +
SLE O +
patients O +
, O +
frequent O +
polyomavirus O +
reactivations O +
were O +
observed O +
that O +
could O +
not O +
be O +
explained O +
by O +
certain O +
rearrangements O +
of O +
the O +
noncoding O +
control O +
regions O +
, O +
nor O +
by O +
corticosteroid O +
treatment O +
. O +

Linked O +
to O +
these O +
events O +
, O +
antibodies O +
to O +
T O -
- O -
antigen O +
, O +
DNA O +
, O +
TBP O +
, O +
and O +
CREB O +
were O +
detected O +
, O +
identical O +
to O +
what O +
we O +
observed O +
in O +
mice O +
. O +

Antibodies O +
recognizing O +
double O -
- O -
stranded O +
DNA O +
were O +
confined O +
to O +
patients O +
with O +
frequent O +
polyomavirus O +
reactivations O +
. O +

The O +
results O +
described O +
here O +
indicate O +
that O +
cognate O +
interaction O +
of O +
B O +
cells O +
recognizing O +
DNA O +
or O +
DNA O -
- O -
associated O +
proteins O +
and O +
T O +
cells O +
recognizing O +
T O +
antigen O +
had O +
taken O +
place O +
as O +
a O +
consequence O +
of O +
complex O +
formation O +
between O +
T O +
ag O +
and O +
DNA O +
in O +
vivo O +
in O +
the O +
context O +
of O +
polyomavirus O +
reactivations O +
. O +

Involvement O +
of O +
an O +
SAF O -
- O -
like O +
transcription O +
factor O +
in O +
the O +
activation O +
of O +
serum O +
amyloid O +
A O +
gene O +
in O +
monocyte O -
/ O -
macrophage O +
cells O +
by O +
lipopolysaccharide O +
. O +

Serum O +
amyloid O +
A O +
( O +
SAA O +
) O +
has O +
been O +
linked O +
to O +
atherosclerosis O +
because O +
of O +
its O +
ability O +
to O +
remodel O +
high O -
- O -
density O +
lipoprotein O +
by O +
the O +
depletion O +
of O +
apolipoprotein O +
A1 O +
, O +
its O +
ability O +
to O +
bind O +
cholesterol O +
, O +
and O +
its O +
presence O +
in O +
the O +
atherosclerotic O +
plaques O +
of O +
coronary O +
and O +
carotid O +
arteries O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
investigated O +
the O +
induction O +
mechanism O +
of O +
SAA O +
gene O +
in O +
THP-1 B-CellLine +
monocyte I-CellLine -
/ I-CellLine -
macrophage I-CellLine +
cells I-CellLine +
which O +
play O +
a O +
critical O +
role O +
in O +
the O +
development O +
of O +
atherosclerotic O +
fatty O +
streak O +
and O +
plaque O +
formation O +
. O +

We O +
and O +
others O +
have O +
shown O +
that O +
SAA O +
gene O +
is O +
induced O +
in O +
monocyte O -
/ O -
macrophage O +
cells O +
by O +
lipopolysaccharide O +
( O +
LPS O +
) O +
. O +

By O +
promoter O +
function O +
analysis O +
, O +
we O +
show O +
that O +
the O +
SAA O +
promoter O +
sequence O +
between O +
-280 O +
and O +
-226 O +
can O +
confer O +
LPS O +
responsiveness O +
. O +

Gel O +
electrophoretic O +
mobility O +
shift O +
assay O +
detected O +
an O +
induced O +
DNA O -
- O -
binding O +
activity O +
in O +
these O +
cells O +
in O +
response O +
to O +
LPS O +
. O +

Characterization O +
of O +
the O +
DNA O -
- O -
binding O +
protein O +
by O +
UV O +
cross O -
- O -
linking O +
, O +
Southwestern O +
blot O +
, O +
and O +
antibody O +
ablation O -
/ O -
supershift O +
assays O +
revealed O +
that O +
it O +
is O +
similar O +
to O +
a O +
recently O +
reported O +
nuclear O +
factor O +
designated O +
SAF O +
. O +

These O +
results O +
demonstrated O +
that O +
LPS O -
- O -
mediated O +
SAA O +
gene O +
induction O +
in O +
monocyte O -
/ O -
macrophage O +
cells O +
is O +
primarily O +
due O +
to O +
the O +
induction O +
of O +
SAF O +
activity O +
. O +

Expression O +
of O +
NFAT O -
- O -
family O +
proteins O +
in O +
normal O +
human O +
T O +
cells O +
. O +

NFAT O +
proteins O +
constitute O +
a O +
family O +
of O +
transcription O +
factors O +
involved O +
in O +
mediating O +
signal O +
transduction O +
. O +

Using O +
a O +
panel O +
of O +
specific O +
antisera O +
in O +
immunoprecipitation O +
assays O +
, O +
we O +
found O +
that O +
NFATp O +
( O +
135 O +
kDa O +
) O +
is O +
constitutively O +
expressed O +
in O +
normal O +
human O +
T O +
cells O +
, O +
while O +
synthesis O +
of O +
NFATc O +
( O +
predominant O +
form O +
of O +
86 O +
kDa O +
) O +
is O +
induced O +
by O +
ionomycin O +
treatment O +
. O +

NFAT4 O -
/ O -
x O +
was O +
very O +
weakly O +
expressed O +
in O +
unstimulated O +
cells O +
, O +
and O +
its O +
level O +
did O +
not O +
increase O +
upon O +
treatment O +
with O +
activating O +
agents O +
. O +

NFAT3 O +
protein O +
was O +
not O +
observed O +
under O +
any O +
conditions O +
. O +

Higher O -
- O -
molecular O -
- O -
weight O +
species O +
of O +
NFATc O +
( O +
of O +
110 O +
and O +
140 O +
kDa O +
) O +
were O +
also O +
detected O +
. O +

In O +
addition O +
, O +
translation O +
of O +
NFATc O +
mRNA O +
apparently O +
initiates O +
at O +
two O +
different O +
AUG O +
codons O +
, O +
giving O +
rise O +
to O +
proteins O +
that O +
differ O +
in O +
size O +
by O +
36 O +
amino O +
acids O +
. O +

Additional O +
size O +
heterogeneity O +
of O +
both O +
NFATc O +
and O +
NFATp O +
results O +
from O +
phosphorylation O +
. O +

In O +
contrast O +
to O +
ionomycin O +
treatment O +
, O +
exposure O +
of O +
cells O +
to O +
phorbol O +
myristate O +
acetate O +
( O +
PMA O +
) O +
plus O +
anti O -
- O -
CD28 O +
did O +
not O +
induce O +
NFATc O +
, O +
indicating O +
that O +
under O +
these O +
conditions O +
, O +
interleukin-2 O +
synthesis O +
by O +
these O +
cells O +
is O +
apparently O +
independent O +
of O +
NFATc O +
. O +

In O +
DNA O +
binding O +
assays O +
, O +
both O +
PMA O +
plus O +
anti O -
- O -
CD28 O +
and O +
PMA O +
plus O +
ionomycin O +
resulted O +
in O +
nuclear O +
NFAT O +
. O +

Surprisingly O +
, O +
the O +
PMA O -
- O -
ionomycin O -
- O -
induced O +
synthesis O +
of O +
NFATc O +
that O +
was O +
detected O +
by O +
immunoprecipitation O +
was O +
not O +
mirrored O +
in O +
the O +
DNA O +
binding O +
assays O +
: O +
nearly O +
all O +
of O +
the O +
activity O +
was O +
due O +
to O +
NFATp O +
. O +

This O +
is O +
the O +
first O +
study O +
of O +
expression O +
of O +
all O +
family O +
members O +
at O +
the O +
protein O +
level O +
in O +
normal O +
human O +
T O +
cells O +
. O +

Nucleolin O +
is O +
one O +
component O +
of O +
the O +
B O +
cell O -
- O -
specific O +
transcription O +
factor O +
and O +
switch O +
region O +
binding O +
protein O +
, O +
LR1 O +
. O +

LR1 O +
is O +
a O +
B O +
cell O -
- O -
specific O +
, O +
sequence O -
- O -
specific O +
DNA O +
binding O +
activity O +
that O +
regulates O +
transcription O +
in O +
activated O +
B O +
cells O +
. O +

LR1 O +
also O +
binds O +
Ig O +
heavy O +
chain O +
switch O +
region O +
sequences O +
and O +
may O +
function O +
in O +
class O +
switch O +
recombination O +
. O +

LR1 O +
contains O +
two O +
polypeptides O +
, O +
of O +
106 O +
kDa O +
and O +
45 O +
kDa O +
, O +
and O +
here O +
we O +
report O +
that O +
the O +
106-kDa O +
component O +
of O +
LR1 O +
is O +
nucleolin O +
. O +

This O +
identification O +
, O +
initially O +
made O +
by O +
microsequence O +
analysis O +
, O +
was O +
verified O +
by O +
showing O +
that O +
( O +
i O +
) O +
LR1 O +
-DNA O +
binding O +
activity O +
increased O +
in O +
B O +
cells O +
transfected O +
with O +
a O +
nucleolin O +
cDNA O +
expression O +
construct O +
; O +
( O +
ii O +
) O +
LR1 O +
-DNA O +
binding O +
activity O +
was O +
recognized O +
by O +
antibodies O +
raised O +
against O +
recombinant O +
human O +
nucleolin O +
; O +
and O +
( O +
iii O +
) O +
in O +
B O +
cells O +
transfected O +
with O +
epitope O -
- O -
tagged O +
nucleolin O +
expression O +
constructs O +
, O +
the O +
LR1-DNA O +
complex O +
was O +
recognized O +
by O +
the O +
anti O -
- O -
tag O +
antibody O +
. O +

Nucleolin O +
is O +
an O +
abundant O +
nucleolar O +
protein O +
which O +
is O +
believed O +
to O +
play O +
a O +
role O +
in O +
rDNA O +
transcription O +
or O +
organization O +
, O +
or O +
rRNA O +
processing O +
. O +

Homology O +
between O +
nucleolin O +
and O +
histone O +
H1 O +
suggests O +
that O +
nucleolin O +
may O +
alter O +
DNA O +
organization O +
in O +
response O +
to O +
cell O +
cycle O +
controls O +
, O +
and O +
the O +
nucleolin O +
component O +
of O +
LR1 O +
may O +
therefore O +
function O +
to O +
organize O +
switch O +
regions O +
before O +
, O +
during O +
, O +
or O +
after O +
switch O +
recombination O +
. O +

The O +
demonstration O +
that O +
nucleolin O +
is O +
a O +
component O +
of O +
a O +
B O +
cell O -
- O -
specific O +
complex O +
that O +
binds O +
switch O +
region O +
sequences O +
suggests O +
that O +
the O +
G O -
- O -
rich O +
switch O +
regions O +
may O +
have O +
evolved O +
from O +
rDNA O +
. O +

Human O +
neutrophil O +
elastase O +
proteolytically O +
activates O +
the O +
platelet O +
integrin O +
alphaIIbbeta3 O +
through O +
cleavage O +
of O +
the O +
carboxyl O +
terminus O +
of O +
the O +
alphaIIb O +
subunit O +
heavy O +
chain O +
. O +

Involvement O +
in O +
the O +
potentiation O +
of O +
platelet O +
aggregation O +
. O +

Neutrophil O +
elastase O +
( O +
NE O +
) O +
and O +
cathepsin O +
G O +
are O +
two O +
serine O +
proteinases O +
released O +
concomitantly O +
by O +
stimulated O +
polymorphonuclear O +
neutrophils O +
. O +

We O +
previously O +
demonstrated O +
that O +
while O +
NE O +
by O +
itself O +
does O +
not O +
activate O +
human O +
platelets O +
, O +
it O +
strongly O +
enhances O +
the O +
weak O +
aggregation O +
induced O +
by O +
a O +
threshold O +
concentration O +
of O +
cathepsin O +
G O +
( O +
threshold O +
of O +
cathepsin O +
G O +
) O +
( O +
Renesto O +
, O +
P. O +
, O +
and O +
Chignard O +
, O +
M. O +
( O +
1993 O +
) O +
Blood O +
82 O +
, O +
139 O -
- O -
144 O +
) O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
delineate O +
the O +
molecular O +
mechanisms O +
involved O +
in O +
this O +
potentiation O +
process O +
. O +

Two O +
main O +
pieces O +
of O +
data O +
prompted O +
us O +
to O +
focus O +
on O +
the O +
activation O +
of O +
the O +
platelet O +
fibrinogen O +
receptor O +
, O +
the O +
alphaIIbbeta3 O +
integrin O +
. O +

First O +
, O +
previous O +
studies O +
have O +
shown O +
this O +
integrin O +
to O +
be O +
particularly O +
prone O +
to O +
proteolytic O +
regulation O +
of O +
its O +
function O +
. O +

Second O +
, O +
we O +
found O +
that O +
the O +
potentiating O +
activity O +
of O +
NE O +
on O +
the O +
threshold O +
of O +
cathepsin O +
G O +
-induced O +
platelet O +
aggregation O +
was O +
strictly O +
dependent O +
on O +
the O +
presence O +
of O +
exogenous O +
fibrinogen O +
. O +

Using O +
flow O +
cytometry O +
analysis O +
, O +
NE O +
was O +
shown O +
to O +
trigger O +
a O +
time O -
- O -
dependent O +
binding O +
of O +
PAC-1 O +
and O +
AP-5 O +
, O +
two O +
monoclonal O +
antibodies O +
specific O +
for O +
the O +
activated O +
and O +
ligand O -
- O -
occupied O +
conformers O +
of O +
alphaIIbbeta3 O +
. O +

Furthermore O +
, O +
the O +
potentiated O +
aggregation O +
was O +
shown O +
to O +
result O +
from O +
an O +
increased O +
capacity O +
of O +
platelets O +
to O +
bind O +
fibrinogen O +
. O +

Indeed O +
, O +
the O +
combination O +
of O +
NE O +
and O +
threshold O +
of O +
cathepsin O +
G O +
increased O +
the O +
binding O +
of O +
PAC-1 O +
approximately O +
5.5-fold O +
over O +
basal O +
values O +
measured O +
on O +
nontreated O +
platelets O +
, O +
whereas O +
this O +
binding O +
raised O +
only O +
by O +
approximately O +
3-fold O +
in O +
threshold O +
of O +
cathepsin O +
G O -
- O -
stimulated O +
platelets O +
( O +
p O +
< O +
0.05 O +
) O +
. O +

By O +
contrast O +
, O +
phosphatidic O +
acid O +
accumulation O +
, O +
pleckstrin O +
phosphorylation O +
, O +
and O +
calcium O +
mobilization O +
produced O +
by O +
the O +
combination O +
of O +
NE O +
and O +
threshold O +
of O +
cathepsin O +
G O +
were O +
not O +
significantly O +
different O +
from O +
those O +
measured O +
with O +
threshold O +
of O +
cathepsin O +
G O +
alone O +
( O +
p O +
> O +
0.05 O +
) O +
, O +
indicating O +
that O +
the O +
phospholipase O +
C O +
/protein O +
kinase O +
C O +
pathway O +
is O +
not O +
involved O +
in O +
the O +
potentiation O +
of O +
aggregation O +
. O +

The O +
foregoing O +
data O +
, O +
as O +
well O +
as O +
the O +
requirement O +
of O +
catalytically O +
active O +
NE O +
to O +
trigger O +
alphaIIbbeta3 O +
activation O +
and O +
potentiate O +
threshold O +
of O +
cathepsin O +
G O +
-initiated O +
platelet O +
aggregation O +
, O +
led O +
us O +
to O +
examine O +
whether O +
the O +
structure O +
of O +
this O +
integrin O +
was O +
affected O +
by O +
NE O +
. O +

Immunoblot O +
and O +
flow O +
cytometry O +
analysis O +
revealed O +
a O +
limited O +
proteolysis O +
of O +
the O +
carboxyl O +
terminus O +
of O +
the O +
alphaIIb O +
subunit O +
heavy O +
chain O +
( O +
alphaIIbH O +
) O +
, O +
as O +
judged O +
by O +
the O +
disappearance O +
of O +
the O +
epitope O +
for O +
the O +
monoclonal O +
antibody O +
PMI-1 O +
. O +

Mass O +
spectrometry O +
studies O +
performed O +
on O +
a O +
synthetic O +
peptide O +
mapping O +
over O +
the O +
cleavage O +
domain O +
of O +
alphaIIbH O +
predicted O +
the O +
site O +
of O +
proteolysis O +
as O +
located O +
between O +
Val837 O +
and O +
Asp838 O +
. O +

Treatment O +
by O +
NE O +
of O +
ATP O -
- O -
depleted O +
platelets O +
or O +
Chinese B-CellLine +
hamster I-CellLine +
ovary I-CellLine +
cells I-CellLine +
expressing O +
human O +
recombinant O +
alphaIIbbeta3 O +
clearly O +
established O +
that O +
activation O +
of O +
the O +
integrin O +
was O +
independent O +
of O +
signal O +
transduction O +
events O +
and O +
was O +
concomitant O +
with O +
the O +
proteolysis O +
of O +
alphaIIbH O +
. O +

Activation O +
of O +
Ras O +
and O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
pathway O +
by O +
terminal O +
complement O +
complexes O +
is O +
G O +
protein O +
dependent O +
. O +

Assembly O +
of O +
terminal O +
complement O +
complexes O +
( O +
TCC O +
) O +
C5b-7 O +
, O +
C5b-8 O +
, O +
and O +
C5b-9 O +
on O +
target O +
cells O +
during O +
acute O +
and O +
chronic O +
inflammation O +
induces O +
hydrolysis O +
of O +
plasma O +
membrane O +
phospholipids O +
and O +
heterotrimeric O +
G O +
protein O +
activation O +
. O +

TCC O +
also O +
stimulate O +
a O +
variety O +
of O +
cellular O +
activities O +
, O +
which O +
include O +
cytokine O +
synthesis O +
, O +
proto O -
- O -
oncogene O +
activation O +
, O +
and O +
mitotic O +
signaling O +
. O +

Now O +
we O +
report O +
that O +
sublytic O +
TCC O +
induced O +
Ras O +
, O +
Raf-1 O +
, O +
and O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
( O +
ERK O +
) O +
1 O +
activation O +
in O +
JY25 O +
B O +
cell O +
line O +
. O +

When O +
cells O +
were O +
exposed O +
to O +
C5b-9 O +
, O +
GTP O -
- O -
bound O +
Ras O +
in O +
anti O -
- O -
C5b-9 O +
immunoprecipitates O +
was O +
increased O +
3.2-fold O +
at O +
2 O +
min O +
, O +
while O +
GTP O -
- O -
bound O +
Ras O +
in O +
anti O -
- O -
Ras O +
immunoprecipitates O +
was O +
increased O +
2-fold O +
at O +
10 O +
min O +
. O +

Both O +
C5b-9 O +
and O +
C5b-7 O +
, O +
but O +
not O +
C5b6 O +
, O +
increased O +
Raf-1 O +
kinase O +
activity O +
maximum O +
3.3-fold O +
at O +
2 O +
min O +
and O +
2.8-fold O +
at O +
5 O +
min O +
, O +
respectively O +
. O +

ERK1 O +
activity O +
was O +
2-fold O +
increased O +
by O +
C5b-9 O +
at O +
2 O +
min O +
and O +
by O +
C5b-7 O +
at O +
10 O +
min O +
, O +
over O +
the O +
C5b6 O +
level O +
. O +

The O +
role O +
of O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
pathway O +
on O +
TCC O +
-inducible O +
mitotic O +
signaling O +
was O +
evaluated O +
by O +
assessing O +
DNA O +
synthesis O +
and O +
activator O +
protein O +
1 O +
( O +
AP-1 O +
) O +
DNA O -
- O -
binding O +
activity O +
. O +

The O +
MAPK O -
/ O -
ERK O -
- O -
specific O +
inhibitor O +
PD O +
098 O +
, O +
059 O +
abolished O +
the O +
C5b-9 O +
-induced O +
DNA O +
synthesis O +
. O +

Involvement O +
of O +
G O +
protein O +
in O +
the O +
activation O +
of O +
MAPK O +
pathway O +
by O +
TCC O +
was O +
indicated O +
by O +
inhibition O +
of O +
Raf-1 O +
and O +
ERK1 O +
kinase O +
activity O +
, O +
as O +
well O +
as O +
the O +
DNA O +
synthesis O +
by O +
pretreatment O +
of O +
cells O +
with O +
pertussis O +
toxin O +
. O +

Overexpression O +
of O +
beta O -
- O -
adrenergic O +
receptor O +
kinase O +
1 O +
carboxyl O -
- O -
terminal O +
peptide O +
in O +
JY25 B-CellLine +
cells I-CellLine +
also O +
inhibited O +
Raf-1 O +
and O +
ERK1 O +
activity O +
, O +
indicating O +
a O +
direct O +
involvement O +
of O +
G O +
betagamma O +
subunits O +
in O +
the O +
signal O +
transduction O +
generated O +
through O +
activation O +
of O +
MAPK O +
pathway O +
by O +
TCC O +
assembly O +
in O +
the O +
plasma O +
membrane O +
. O +

Use O +
of O +
arsenic O +
trioxide O +
( O +
As2O3 O +
) O +
in O +
the O +
treatment O +
of O +
acute O +
promyelocytic O +
leukemia O +
( O +
APL O +
) O +
: O +
II O +
. O +

Clinical O +
efficacy O +
and O +
pharmacokinetics O +
in O +
relapsed O +
patients O +
. O +

The O +
therapeutic O +
effect O +
of O +
arsenic O +
trioxide O +
( O +
As2O3 O +
) O +
in O +
the O +
treatment O +
of O +
acute O +
promyelocytic O +
leukemia O +
( O +
APL O +
) O +
was O +
evaluated O +
among O +
15 O +
APL O +
patients O +
at O +
relapse O +
after O +
all O -
- O -
trans O +
retinoic O +
acid O +
( O +
ATRA O +
) O +
induced O +
and O +
chemotherapy O +
maintained O +
complete O +
remission O +
( O +
CR O +
) O +
. O +

As2O3 O +
was O +
administered O +
intravenously O +
at O +
the O +
dose O +
of O +
10 O +
mg O -
/ O -
d O +
. O +

Clinical O +
CR O +
was O +
achieved O +
in O +
nine O +
of O +
10 O +
( O +
90 O +
% O +
) O +
patients O +
treated O +
with O +
As2O3 O +
alone O +
and O +
in O +
the O +
remaining O +
five O +
patients O +
treated O +
by O +
the O +
combination O +
of O +
As2O3 O +
and O +
low O -
- O -
dose O +
chemotherapeutic O +
drugs O +
or O +
ATRA O +
. O +

During O +
the O +
treatment O +
with O +
As2O3 O +
, O +
there O +
was O +
no O +
bone O +
marrow O +
depression O +
and O +
only O +
limited O +
side O +
effects O +
were O +
encountered O +
. O +

Pharmacokinetic O +
studies O +
, O +
which O +
were O +
performed O +
in O +
eight O +
patients O +
, O +
showed O +
that O +
after O +
a O +
peak O +
level O +
of O +
5.54 O +
micromol O -
/ O -
L O +
to O +
7.30 O +
micromol O -
/ O -
L O +
, O +
plasma O +
arsenic O +
was O +
rapidly O +
eliminated O +
, O +
and O +
the O +
continuous O +
administration O +
of O +
As2O3 O +
did O +
not O +
alter O +
its O +
pharmacokinetic O +
behaviors O +
. O +

In O +
addition O +
, O +
increased O +
amounts O +
of O +
arsenic O +
appeared O +
in O +
the O +
urine O +
, O +
with O +
a O +
daily O +
excretion O +
accounting O +
for O +
approximately O +
1 O +
% O +
to O +
8 O +
% O +
of O +
the O +
total O +
daily O +
dose O +
administered O +
. O +

Arsenic O +
contents O +
in O +
hair O +
and O +
nail O +
were O +
increased O +
, O +
and O +
the O +
peak O +
content O +
of O +
arsenic O +
could O +
reach O +
2.5 O +
to O +
2.7 O +
microg O -
/ O -
g O +
tissue O +
at O +
CR O +
. O +

On O +
the O +
other O +
hand O +
, O +
a O +
decline O +
of O +
the O +
arsenic O +
content O +
in O +
hair O +
and O +
nail O +
was O +
observed O +
after O +
withdrawal O +
of O +
the O +
drug O +
. O +

We O +
conclude O +
that O +
As2O3 O +
treatment O +
is O +
an O +
effective O +
and O +
relatively O +
safe O +
drug O +
in O +
APL O +
patients O +
refractory O +
to O +
ATRA O +
and O +
conventional O +
chemotherapy O +
. O +

Activation O +
of O +
the O +
NF O -
- O -
kappaB O +
pathway O +
by O +
inflammatory O +
stimuli O +
in O +
human O +
neutrophils O +
. O +

Activated O +
neutrophils O +
have O +
the O +
ability O +
to O +
upregulate O +
the O +
expression O +
of O +
many O +
genes O +
, O +
in O +
particular O +
those O +
encoding O +
cytokines O +
and O +
chemokines O +
, O +
and O +
to O +
subsequently O +
release O +
the O +
corresponding O +
proteins O +
. O +

Although O +
little O +
is O +
known O +
to O +
date O +
concerning O +
the O +
regulation O +
of O +
gene O +
transcription O +
in O +
neutrophils O +
, O +
it O +
is O +
noteworthy O +
that O +
many O +
of O +
these O +
genes O +
depend O +
on O +
the O +
activation O +
of O +
transcription O +
factors O +
, O +
such O +
as O +
NF O -
- O -
kappaB O +
, O +
for O +
inducible O +
expression O +
. O +

We O +
therefore O +
investigated O +
whether O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
proteins O +
are O +
expressed O +
in O +
human O +
neutrophils O +
, O +
as O +
well O +
as O +
their O +
fate O +
on O +
cell O +
activation O +
. O +

We O +
now O +
report O +
that O +
dimers O +
consisting O +
of O +
p50 O +
NFkappaB1 O +
, O +
p65 O +
RelA O +
, O +
and/or O +
c O -
- O -
Rel O +
are O +
present O +
in O +
neutrophils O +
and O +
that O +
the O +
greater O +
part O +
of O +
these O +
protein O +
complexes O +
is O +
physically O +
associated O +
with O +
cytoplasmic O +
IkappaB O -
- O -
alpha O +
in O +
resting O +
cells O +
. O +

Following O +
neutrophil O +
stimulation O +
with O +
proinflammatory O +
agonists O +
( O +
such O +
as O +
lipopolysaccharide O +
[ O +
LPS O +
] O +
, O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
[ O +
TNF O -
- O -
alpha O +
] O +
, O +
and O +
fMet O -
- O -
Leu O -
- O -
Phe O +
) O +
that O +
induce O +
the O +
production O +
of O +
cytokines O +
and O +
chemokines O +
in O +
these O +
cells O +
, O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
proteins O +
translocated O +
to O +
nuclear O +
fractions O +
, O +
resulting O +
in O +
a O +
transient O +
induction O +
of O +
NF O -
- O -
kappaB O +
DNA O +
binding O +
activity O +
, O +
as O +
determined O +
in O +
gel O +
mobility O +
shift O +
assays O +
. O +

The O +
onset O +
of O +
both O +
processes O +
was O +
found O +
to O +
be O +
closely O +
paralleled O +
by O +
, O +
and O +
dependent O +
on O +
, O +
IkappaB O -
- O -
alpha O +
degradation O +
. O +

Proinflammatory O +
neutrophil O +
stimuli O +
also O +
promoted O +
the O +
accumulation O +
of O +
IkappaB O -
- O -
alpha O +
mRNA O +
transcripts O +
, O +
resulting O +
in O +
the O +
reexpression O +
of O +
the O +
IkappaB O -
- O -
alpha O +
protein O +
. O +

To O +
our O +
knowledge O +
, O +
this O +
constitutes O +
the O +
first O +
indication O +
that O +
NF O -
- O -
kappaB O +
activation O +
may O +
underlie O +
the O +
action O +
of O +
proinflammatory O +
stimuli O +
towards O +
human O +
neutrophil O +
gene O +
expression O +
and O +
, O +
as O +
such O +
, O +
adds O +
a O +
new O +
facet O +
to O +
our O +
understanding O +
of O +
neutrophil O +
biology O +
. O +

Preferential O +
presentation O +
of O +
herpes O +
simplex O +
virus O +
T O -
- O -
cell O +
antigen O +
by O +
HLA O +
DQA1 O -
* O -
0501 O -
/ O -
DQB1 O -
* O -
0201 O +
in O +
comparison O +
to O +
HLA O +
DQA1 O -
* O -
0201 O -
/ O -
DQB1 O -
* O -
0201 O +
. O +

The O +
HLA O +
DQA1 O +
locus O +
is O +
polymorphic O +
. O +

Haplotypes O +
containing O +
HLA O +
DQA1 O -
* O -
0501 O +
, O +
but O +
not O +
HLA O +
DQA1 O -
* O -
0201 O +
, O +
together O +
with O +
HLA O +
DQB1 O -
* O -
0201 O +
are O +
associated O +
with O +
Grave O +
's O +
disease O +
and O +
celiac O +
sprue O +
. O +

In O +
this O +
report O +
, O +
we O +
demonstrate O +
a O +
functional O +
correlate O +
of O +
DQA1 O +
polymorphism O +
. O +

T O +
cells O +
infiltrating O +
a O +
herpes O +
simplex O +
virus O +
( O +
HSV O +
) O +
lesion O +
from O +
a O +
HLA O +
DQ O +
2 O +
, O +
7 O +
individual O +
yielded O +
a O +
virus B-CellLine -
- I-CellLine -
specific I-CellLine +
CD4 I-CellLine -
+ I-CellLine +
clone I-CellLine +
restricted O +
by O +
DQ2 O +
. O +

Presentation O +
of O +
viral O +
peptide O +
and O +
protein O +
segregated O +
with O +
DQA1 O +
allele O +
, O +
because O +
cell O +
lines O +
bearing O +
DQA1 O -
* O -
0501 O -
/ O -
DQB1 O -
* O -
0201 O +
heterodimers O +
presented O +
antigen O +
in O +
proliferation O +
and O +
cytotoxicity O +
assays O +
much O +
more O +
efficiently O +
than O +
cell B-CellLine +
lines I-CellLine +
bearing O +
DQA1 O -
* O -
0201 O -
/ O -
DQB1 O -
* O -
0201 O +
. O +

Binding O +
of O +
viral O +
peptide O +
to O +
cell O +
lines O +
bearing O +
DQA1 O -
* O -
0201 O +
, O +
in O +
comparison O +
to O +
DQA1 O -
* O -
0501 O +
, O +
was O +
only O +
moderately O +
reduced O +
and O +
may O +
not O +
explain O +
this O +
effect O +
. O +

Truncation O +
and O +
substitution O +
analyses O +
of O +
peptide O +
binding O +
and O +
T O -
- O -
cell O +
activation O +
were O +
performed O +
to O +
determine O +
which O +
viral O +
peptide O +
residues O +
contacting O +
TCR O +
might O +
therefore O +
be O +
presented O +
in O +
an O +
altered O +
conformation O +
by O +
DQA1 O -
* O -
0201 O -
/ O -
DQB1 O -
* O -
0201 O +
. O +

Residues O +
432 O +
, O +
435 O +
, O +
437 O +
, O +
438 O +
, O +
and O +
440 O +
( O +
position O +
P1 O +
, O +
P4 O +
, O +
P6 O +
, O +
P7 O +
, O +
and O +
P9 O +
) O +
contributed O +
to O +
DQ2 O +
binding O +
, O +
whereas O +
residues O +
431 O +
, O +
433 O +
, O +
434 O +
, O +
and O +
436 O +
( O +
positions O +
P O +
1 O +
, O +
P2 O +
, O +
P3 O +
, O +
and O +
P5 O +
) O +
contributed O +
to O +
TCR O +
contact O +
. O +

Differential O +
presentation O +
of O +
peptide O +
by O +
HLA O +
DQ2 O +
heterodimers O +
varying O +
at O +
the O +
DQA1 O +
locus O +
may O +
have O +
relevance O +
to O +
host O +
defense O +
and O +
the O +
pathogenesis O +
of O +
HLA O +
DQ2 O +
-associated O +
autoimmune O +
diseases O +
. O +

Significance O +
of O +
quantitative O +
analysis O +
of O +
AML1 O -
/ O -
ETO O +
transcripts O +
in O +
peripheral O +
blood O +
stem O +
cells O +
from O +
t O +
( O +
8 O +
; O +
21 O +
) O +
acute O +
myelogenous O +
leukemia O +
. O +

Autologous O +
peripheral O +
blood O +
stem O +
cell O +
transplantation O +
( O +
PBSCT O +
) O +
is O +
replacing O +
autologous O +
bone O +
marrow O +
transplantation O +
( O +
BMT O +
) O +
in O +
the O +
treatment O +
of O +
leukemia O +
. O +

One O +
of O +
the O +
potential O +
advantages O +
of O +
autologous O +
PBSCT O +
is O +
the O +
possibility O +
that O +
peripheral O +
blood O +
stem O +
cells O +
( O +
PBSC O +
) O +
are O +
less O +
likely O +
to O +
be O +
contaminated O +
by O +
leukemic O +
cells O +
than O +
bone O +
marrow O +
grafts O +
. O +

However O +
, O +
the O +
major O +
problem O +
still O +
remains O +
the O +
high O +
incidence O +
of O +
leukemic O +
relapse O +
following O +
autologous O +
PBSCT O +
, O +
which O +
may O +
be O +
caused O +
by O +
the O +
reinfusion O +
of O +
PBSC O +
contaminated O +
by O +
leukemic O +
cells O +
. O +

Recently O +
, O +
we O +
have O +
developed O +
a O +
quantitative O +
assay O +
using O +
competitive O +
reverse O +
transcriptase O +
polymerase O +
chain O +
reaction O +
that O +
estimates O +
the O +
number O +
of O +
AML1 O -
/ O -
ETO O +
transcripts O +
in O +
t O +
( O +
8 O +
; O +
21 O +
) O +
acute O +
myelogenous O +
leukemia O +
( O +
AML O +
) O +
, O +
in O +
order O +
to O +
determine O +
the O +
degree O +
of O +
leukemic O +
cell O +
contamination O +
in O +
PBSC O +
harvests O +
, O +
and O +
to O +
monitor O +
minimal O +
residual O +
disease O +
( O +
MRD O +
) O +
quantitatively O +
in O +
patients O +
with O +
t O +
( O +
8 O +
; O +
21 O +
) O +
AML O +
. O +

Our O +
data O +
indicate O +
that O +
although O +
PBSC O +
harvests O +
collected O +
after O +
consolidation O +
chemotherapy O +
are O +
contaminated O +
by O +
leukemic O +
cells O +
, O +
the O +
degree O +
of O +
leukemic O +
cell O +
contamination O +
decreases O +
with O +
repeated O +
cycles O +
of O +
chemotherapy O +
. O +

Furthermore O +
, O +
the O +
MRD O +
in O +
PBSC O +
harvests O +
is O +
less O +
than O +
in O +
the O +
corresponding O +
bone O +
marrow O +
obtained O +
on O +
the O +
day O +
of O +
the O +
PBSC O +
collection O +
. O +

There O +
appears O +
to O +
be O +
no O +
relationship O +
between O +
the O +
number O +
of O +
AML1 O -
/ O -
ETO O +
transcripts O +
found O +
in O +
the O +
infused O +
PBSC O +
harvests O +
and O +
the O +
incidence O +
of O +
leukemic O +
relapse O +
following O +
autologous O +
PBSCT O +
in O +
our O +
study O +
. O +

However O +
, O +
a O +
substantial O +
decrease O +
of O +
AML1 O -
/ O -
ETO O +
transcripts O +
was O +
seen O +
following O +
autologous O +
PBSCT O +
. O +

Thus O +
, O +
the O +
quantitative O +
analysis O +
of O +
AML1 O -
/ O -
ETO O +
transcripts O +
may O +
be O +
clinically O +
useful O +
in O +
patients O +
with O +
t O +
( O +
8 O +
; O +
21 O +
) O +
AML O +
. O +

Itk O +
, O +
a O +
T O +
cell O -
- O -
specific O +
tyrosine O +
kinase O +
, O +
is O +
required O +
for O +
CD2-mediated O +
interleukin-2 O +
promoter O +
activation O +
in O +
the O +
human B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
Jurkat I-CellLine +
. O +

We O +
investigated O +
the O +
functional O +
role O +
of O +
Itk O +
, O +
a O +
member O +
of O +
the O +
cytoplasmic O +
tyrosine O +
kinase O +
Tec O +
family O +
, O +
in O +
T O +
cell O +
activation O +
. O +

Stimulation O +
of O +
either O +
CD2 O +
or O +
T O +
cell O +
receptor O +
( O +
TCR O +
) O +
/CD3 O +
on O +
Tcells O +
by O +
monoclonal O +
antibody O -
- O -
mediated O +
cross O -
- O -
linking O +
induced O +
tyrosine O +
phosphorylation O +
of O +
Itk O +
, O +
which O +
was O +
maximal O +
as O +
early O +
as O +
1 O +
min O +
after O +
stimulation O +
. O +

The O +
tyrosine O +
kinase O +
activity O +
in O +
the O +
anti- O +
Itk O +
immunoprecipitate O +
was O +
significantly O +
activated O +
upon O +
these O +
stimulations O +
. O +

Interleukin-2 O +
( O +
IL-2 O +
) O +
promoter O +
activity O +
stimulated O +
by O +
cross O -
- O -
linking O +
of O +
CD2 O +
, O +
TCR O +
/CD3 O +
, O +
and O +
CD28 O +
with O +
antibodies O +
was O +
significantly O +
reduced O +
by O +
transient O +
expression O +
of O +
an O +
Itk O +
mutant O +
lacking O +
the O +
kinase O +
activity O +
. O +

The O +
reduction O +
paralleled O +
a O +
decrease O +
in O +
tyrosine O +
phosphorylation O +
of O +
endogenous O +
wild O -
- O -
type O +
Itk O +
. O +

Stimulation O +
of O +
CD2 O +
or O +
TCR O -
/ O -
CD3 O +
induced O +
activation O +
of O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
, O +
the O +
binding O +
site O +
of O +
which O +
is O +
included O +
in O +
the O +
IL-2 O +
gene O +
promoter O +
. O +

The O +
activation O +
of O +
NFAT O +
was O +
also O +
impaired O +
by O +
expression O +
of O +
the O +
Itk O +
mutant O +
. O +

These O +
results O +
demonstrate O +
that O +
Itk O +
plays O +
a O +
role O +
in O +
IL-2 O +
production O +
, O +
indicating O +
a O +
critical O +
involvement O +
of O +
Itk O +
in O +
the O +
initial O +
stage O +
of O +
T O +
cell O +
activation O +
by O +
mediating O +
signals O +
from O +
the O +
TCR O -
/ O -
CD3 O +
complex O +
, O +
CD2 O +
, O +
and O +
CD28 O +
. O +

DNA O +
methylation O +
changes O +
in O +
hematologic O +
malignancies O +
: O +
biologic O +
and O +
clinical O +
implications O +
. O +

DNA O +
methylation O +
changes O +
are O +
among O +
the O +
most O +
common O +
detectable O +
abnormalities O +
in O +
human O +
neoplasia O +
. O +

Hypermethylation O +
within O +
the O +
promoters O +
of O +
selected O +
genes O +
appears O +
to O +
be O +
especially O +
common O +
in O +
all O +
types O +
of O +
human O +
hematopoietic O +
neoplasms O +
, O +
and O +
is O +
usually O +
associated O +
with O +
inactivation O +
of O +
the O +
involved O +
gene O +
( O +
s O +
) O +
. O +

Such O +
hypermethylation O -
- O -
associated O +
silencing O +
of O +
gene O +
expression O +
has O +
been O +
shown O +
for O +
several O +
genes O +
regulating O +
the O +
growth O +
and O +
differentiation O +
of O +
hematopoietic O +
cells O +
, O +
including O +
the O +
estrogen O +
receptor O +
( O +
ER O +
) O +
gene O +
, O +
P15 O +
, O +
P16 O +
and O +
others O +
. O +

Hypermethylation O +
within O +
the O +
promoters O +
of O +
some O +
genes O +
appear O +
to O +
be O +
an O +
early O +
event O +
in O +
the O +
pathogenesis O +
of O +
neoplasia O +
( O +
ER O +
, O +
P15 O +
) O +
, O +
while O +
other O +
genes O +
seem O +
to O +
become O +
methylated O +
during O +
the O +
progression O +
of O +
leukemias O +
( O +
HIC1 O +
, O +
c O -
- O -
abl O +
) O +
. O +

The O +
high O +
prevalence O +
of O +
promoter O +
methylation O +
suggests O +
that O +
this O +
molecular O +
abnormality O +
can O +
be O +
used O +
to O +
monitor O +
disease O +
activity O +
during O +
therapy O +
. O +

In O +
addition O +
, O +
new O +
technology O +
allows O +
the O +
sensitive O +
identification O +
of O +
gene O +
hypermethylation O +
in O +
a O +
background O +
of O +
normal O +
cells O +
, O +
suggesting O +
possible O +
new O +
strategies O +
for O +
the O +
detection O +
of O +
minimal O +
residual O +
disease O +
. O +

Finally O +
, O +
reactivation O +
of O +
tumor O -
- O -
suppressor O +
gene O +
expression O +
through O +
pharmacologic O +
inhibition O +
of O +
DNA O +
methyltransferase O +
and O +
resultant O +
DNA O +
demethylation O +
appears O +
to O +
be O +
a O +
promising O +
new O +
avenue O +
of O +
therapy O +
in O +
acute O +
leukemia O +
. O +

A O +
novel O +
genetic O +
system O +
to O +
isolate O +
a O +
dominant O +
negative O +
effector O +
on O +
DNA O -
- O -
binding O +
activity O +
of O +
Oct-2 O +
. O +

Recent O +
studies O +
have O +
revealed O +
that O +
interactions O +
between O +
transcription O +
factors O +
play O +
an O +
important O +
role O +
in O +
regulation O +
of O +
gene O +
expression O +
in O +
eukaryotic O +
cells O +
. O +

To O +
isolate O +
cDNA O +
clones O +
that O +
dominantly O +
inhibit O +
the O +
DNA O -
- O -
binding O +
activity O +
of O +
Oct-2 O +
, O +
chosen O +
as O +
a O +
representative O +
factor O +
, O +
we O +
have O +
developed O +
a O +
novel O +
screening O +
system O +
. O +

This O +
employs O +
an O +
Escherichia O +
coli O +
tester O +
strain O +
carrying O +
a O +
modified O +
lac O +
operon O +
as O +
a O +
reporter O +
gene O +
, O +
with O +
the O +
lac O +
operator O +
sequence O +
replaced O +
by O +
an O +
octamer O +
sequence O +
. O +

Oct-2 O +
expressed O +
in O +
this O +
tester O +
strain O +
represses O +
the O +
expression O +
of O +
the O +
reporter O +
gene O +
and O +
changes O +
the O +
phenotype O +
of O +
the O +
cell O +
from O +
Lac+to O +
Lac- O +
. O +

Introduction O +
of O +
a O +
cDNA O +
expression O +
library O +
prepared O +
from O +
a O +
human B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
into O +
the O +
Oct-2 O +
-harboring O +
tester O +
strain O +
allowed O +
selection O +
of O +
three O +
Lac+clones O +
out O +
of O +
1 O +
x O +
10 O +
( O +
5 O +
) O +
transformants O +
. O +

One O +
of O +
them O +
, O +
hT86 O +
, O +
encoding O +
a O +
putative O +
zinc O +
finger O +
protein O +
was O +
found O +
to O +
derepress O +
beta O -
- O -
galactosidase O +
activity O +
in O +
the O +
Oct-2 O +
-harboring O +
tester O +
strain O +
at O +
the O +
transcriptional O +
level O +
. O +

In O +
gel O +
mobility O +
shift O +
assays O +
, O +
hT86 O +
attenuated O +
the O +
intensity O +
of O +
the O +
retarded O +
band O +
composed O +
of O +
the O +
octamer O +
probe O +
and O +
Oct-2 O +
, O +
suggesting O +
a O +
dominant O +
negative O +
effect O +
on O +
the O +
DNA O -
- O -
binding O +
activity O +
of O +
Oct-2 O +
. O +

The O +
strategy O +
described O +
here O +
provides O +
a O +
new O +
approach O +
for O +
studying O +
protein O -
- O -
protein O +
interactions O +
that O +
govern O +
the O +
complex O +
regulation O +
of O +
gene O +
expression O +
. O +

A O +
negative O +
role O +
for O +
phosphoinositide O +
3-kinase O +
in O +
T O -
- O -
cell O +
antigen O +
receptor O +
function O +
. O +

BACKGROUND O +
: O +
A O +
delicate O +
balance O +
between O +
positive O +
and O +
negative O +
regulatory O +
mechanisms O +
during O +
T O -
- O -
cell O +
activation O +
determines O +
the O +
specificity O +
and O +
magnitude O +
of O +
an O +
immune O +
response O +
. O +

Phosphoinositide O +
3-kinase O +
( O +
PI O +
3-kinase O +
) O +
is O +
activated O +
by O +
a O +
diverse O +
set O +
of O +
receptors O +
that O +
determine O +
T O -
- O -
cell O +
function O +
, O +
including O +
the O +
T O -
- O -
cell O +
antigen O +
receptor O +
( O +
TCR O +
) O +
, O +
the O +
costimulatory O +
receptor O +
CD28 O +
, O +
and O +
negative O +
regulators O +
of O +
T O -
- O -
cell O +
activation O +
such O +
as O +
CTLA-4 O +
. O +

PI O +
3-kinase O +
is O +
also O +
regulated O +
by O +
the O +
haematopoietic O +
cytokines O +
that O +
determine O +
T O -
- O -
cell O +
differentiation O +
and O +
lymphocyte O +
proliferation O +
. O +

PI O +
3-kinase O +
can O +
thus O +
dynamically O +
influence O +
the O +
outcome O +
of O +
the O +
immune O +
reactions O +
at O +
various O +
stages O +
. O +

In O +
this O +
study O +
, O +
we O +
investigated O +
the O +
importance O +
of O +
PI O +
3-kinase O +
in O +
TCR O +
-directed O +
T O -
- O -
cell O +
activation O +
using O +
activated O +
or O +
inhibitory O +
versions O +
of O +
PI O +
3-kinase O +
. O +

RESULTS O +
: O +
Certain O +
aspects O +
of O +
TCR O +
responses O +
such O +
as O +
the O +
induction O +
of O +
transcriptional O +
activity O +
of O +
AP1 O +
and O +
serum O +
response O +
factor O +
were O +
not O +
affected O +
by O +
expression O +
of O +
the O +
mutant O +
forms O +
of O +
PI O +
3-kinase O +
. O +

We O +
found O +
, O +
however O +
, O +
that O +
PI O +
3-kinase O +
profoundly O +
influenced O +
the O +
transactivation O +
capacity O +
of O +
' O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
' O +
( O +
NF O -
- O -
AT O +
) O +
elicited O +
by O +
the O +
TCR O +
: O +
expression O +
of O +
an O +
activated O +
form O +
of O +
PI O +
3-kinase O +
inhibited O +
TCR O +
-mediated O +
NF O -
- O -
AT O +
responses O +
, O +
whereas O +
expression O +
of O +
a O +
dominant O +
negative O +
mutant O +
of O +
PI O +
3-kinase O +
potently O +
enhanced O +
TCR O +
-controlled O +
NF O -
- O -
AT O +
induction O +
. O +

These O +
effects O +
of O +
PI O +
3-kinase O +
were O +
not O +
mediated O +
by O +
previously O +
identified O +
PI O +
3-kinase O +
effectors O +
, O +
such O +
as O +
protein O +
kinase O +
B O +
, O +
a O +
positive O +
regulator O +
of O +
PI O +
3-kinase O +
, O +
or O +
the O +
GTPase O +
Rac O +
, O +
and O +
are O +
therefore O +
likely O +
to O +
involve O +
a O +
novel O +
, O +
as O +
yet O +
unknown O +
, O +
effector O +
molecule O +
. O +

CONCLUSIONS O +
: O +
Our O +
results O +
establish O +
that O +
PI O +
3-kinase O +
can O +
both O +
positively O +
and O +
negatively O +
regulate O +
T O -
- O -
cell O +
function O +
, O +
and O +
uncover O +
a O +
previously O +
unrecognized O +
function O +
for O +
PI O +
3-kinase O +
in O +
T O +
cells O +
as O +
a O +
selective O +
negative O +
regulator O +
of O +
TCR O +
-signalling O +
events O +
and O +
therefore O +
as O +
a O +
determinant O +
of O +
T O -
- O -
cell O +
homeostasis O +
. O +

Molecular O +
cloning O +
of O +
SLAP-130 O +
, O +
an O +
SLP-76-associated O +
substrate O +
of O +
the O +
T O +
cell O +
antigen O +
receptor O -
- O -
stimulated O +
protein O +
tyrosine O +
kinases O +
. O +

Previous O +
work O +
has O +
demonstrated O +
that O +
SLP-76 O +
, O +
a O +
Grb2-associated O +
tyrosine O -
- O -
phosphorylated O +
protein O +
, O +
augments O +
Interleukin-2 O +
promoter O +
activity O +
when O +
overexpressed O +
in O +
the O +
Jurkat B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

This O +
activity O +
requires O +
regions O +
of O +
SLP-76 O +
that O +
mediate O +
protein O -
- O -
protein O +
interactions O +
with O +
other O +
molecules O +
in O +
T O +
cells O +
, O +
suggesting O +
that O +
SLP-76 O +
-associated O +
proteins O +
also O +
function O +
to O +
regulate O +
signal O +
transduction O +
. O +

Here O +
we O +
describe O +
the O +
molecular O +
cloning O +
of O +
SLAP-130 O +
, O +
a O +
SLP-76-associated O +
phosphoprotein O +
of O +
130 O +
kDa O +
. O +

We O +
demonstrate O +
that O +
SLAP-130 O +
is O +
hematopoietic O +
cell O -
- O -
specific O +
and O +
associates O +
with O +
the O +
SH2 O +
domain O +
of O +
SLP-76 O +
. O +

Additionally O +
, O +
we O +
show O +
that O +
SLAP-130 O +
is O +
a O +
substrate O +
of O +
the O +
T O +
cell O +
antigen O +
receptor O -
- O -
induced O +
protein O +
tyrosine O +
kinases O +
. O +

Interestingly O +
, O +
we O +
find O +
that O +
in O +
contrast O +
to O +
SLP-76 O +
, O +
overexpression O +
of O +
SLAP-130 O +
diminishes O +
T O +
cell O +
antigen O +
receptor O +
-induced O +
activation O +
of O +
the O +
interleukin-2 O +
promoter O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
and O +
interferes O +
with O +
the O +
augmentation O +
of O +
interleukin-2 O +
promoter O +
activity O +
seen O +
when O +
SLP-76 O +
is O +
overexpressed O +
in O +
these O +
cells O +
. O +

These O +
data O +
suggest O +
that O +
SLP-76 O +
recruits O +
a O +
negative O +
regulator O +
, O +
SLAP-130 O +
, O +
as O +
well O +
as O +
positive O +
regulators O +
of O +
signal O +
transduction O +
in O +
T O +
cells O +
. O +

Transcriptional O +
induction O +
of O +
collagenase-1 O +
in O +
differentiated B-CellLine +
monocyte I-CellLine -
- I-CellLine -
like I-CellLine +
( I-CellLine +
U937 I-CellLine +
) I-CellLine +
cells I-CellLine +
is O +
regulated O +
by O +
AP-1 O +
and O +
an O +
upstream O +
C O -
/ O -
EBP O -
- O -
beta O +
site O +
. O +

In O +
this O +
report O +
, O +
we O +
demonstrate O +
that O +
the O +
AP-1 O +
site O +
and O +
a O +
distal O +
promoter O +
element O +
regulate O +
transcriptional O +
induction O +
of O +
collagenase-1 O +
during O +
monocytic O +
differentiation O +
. O +

Chloramphenicol O +
acetyltransferase O +
expression O +
constructs O +
containing O +
regions O +
of O +
the O +
human O +
collagenase-1 O +
promoter O +
were O +
stably O +
or O +
transiently O +
transfected O +
into O +
U937 B-CellLine +
cells I-CellLine +
, O +
and O +
reporter O +
activity O +
was O +
assessed O +
at O +
various O +
times O +
after O +
the O +
onset O +
of O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
-mediated O +
differentiation O +
. O +

Rapid O +
and O +
strong O +
induction O +
of O +
promoter O +
activity O +
was O +
lost O +
in O +
constructs O +
with O +
a O +
mutant O +
AP-1 O +
element O +
; O +
however O +
, O +
at O +
16 O -
- O -
96 O +
h O +
post O -
- O -
PMA O +
, O +
the O +
mutant O +
collagenase-1 O +
promoter O +
displayed O +
AP-1 O +
independent O +
PMA O -
- O -
mediated O +
transactivation O +
. O +

The O +
AP-1 O +
mutant O +
constructs O +
also O +
showed O +
delayed O +
transcriptional O +
activation O +
in O +
PMA B-CellLine -
- I-CellLine -
treated I-CellLine +
fibroblasts I-CellLine +
. O +

Western O +
and O +
supershift O +
analyses O +
indicated O +
that O +
functional O +
Jun O +
and O +
Fos O +
proteins O +
were O +
present O +
in O +
nuclear O +
extracts O +
of O +
PMA B-CellLine -
- I-CellLine -
differentiated I-CellLine +
U937 I-CellLine +
cells I-CellLine +
. O +

Promoter O +
deletion O +
constructs O +
demonstrated O +
the O +
potential O +
role O +
of O +
distal O +
promoter O +
sequences O +
in O +
regulating O +
collagenase-1 O +
transcription O +
. O +

In O +
particular O +
, O +
Western O +
, O +
supershift O +
, O +
and O +
promoter O +
deletion O +
analyses O +
suggested O +
a O +
role O +
for O +
CCAAT O -
/ O -
enhancer O -
- O -
binding O +
protein O -
- O -
beta O +
( O +
C O -
/ O -
EBP O -
- O -
beta O +
) O +
binding O +
site O +
between O +
-2010 O +
and O +
-1954 O +
in O +
regulating O +
transcription O +
of O +
collagenase-1 O +
in O +
monocytic O +
cells O +
. O +

Our O +
findings O +
suggest O +
that O +
distinct O +
regulatory O +
elements O +
, O +
acting O +
somewhat O +
independently O +
of O +
each O +
other O +
, O +
control O +
expression O +
of O +
collagenase-1 O +
. O +

In O +
addition O +
, O +
our O +
data O +
suggests O +
that O +
the O +
rapid O +
PMA O -
- O -
mediated O +
induction O +
of O +
collagenase-1 O +
transcription O +
is O +
controlled O +
by O +
a O +
mechanism O +
distinct O +
from O +
that O +
regulating O +
the O +
sustained O +
expression O +
of O +
this O +
proteinase O +
in O +
activated O +
macrophages O +
. O +

Jak3 O +
is O +
associated O +
with O +
CD40 O +
and O +
is O +
critical O +
for O +
CD40 O +
induction O +
of O +
gene O +
expression O +
in O +
B O +
cells O +
. O +

CD40 O +
is O +
a O +
receptor O +
that O +
is O +
critical O +
for O +
the O +
survival O +
, O +
growth O +
, O +
differentiation O +
, O +
and O +
isotype O +
switching O +
of O +
B O +
lymphocytes O +
. O +

Although O +
CD40 O +
lacks O +
intrinsic O +
tyrosine O +
kinase O +
activity O +
, O +
its O +
ligation O +
induces O +
protein O +
tyrosine O +
phosphorylation O +
, O +
which O +
is O +
necessary O +
for O +
several O +
CD40 O +
-mediated O +
events O +
. O +

We O +
show O +
that O +
engagement O +
of O +
CD40 O +
induces O +
tyrosine O +
phosphorylation O +
and O +
activation O +
of O +
Jak3 O +
as O +
well O +
as O +
of O +
STAT3 O +
. O +

Jak3 O +
is O +
constitutively O +
associated O +
with O +
CD40 O +
, O +
and O +
this O +
interaction O +
requires O +
a O +
proline O -
- O -
rich O +
sequence O +
in O +
the O +
membrane O -
- O -
proximal O +
region O +
of O +
CD40 O +
. O +

Deletion O +
of O +
this O +
sequence O +
abolishes O +
the O +
capacity O +
of O +
CD40 O +
to O +
induce O +
expression O +
of O +
CD23 O +
, O +
ICAM-1 O +
, O +
and O +
lymphotoxin O -
- O -
alpha O +
genes O +
in O +
B O +
cells O +
. O +

These O +
results O +
indicate O +
that O +
signaling O +
through O +
Jak3 O +
is O +
activated O +
by O +
CD40 O +
and O +
plays O +
an O +
important O +
role O +
in O +
CD40 O +
-mediated O +
functions O +
. O +

Structure O +
and O +
function O +
analysis O +
of O +
the O +
human O +
myeloid O +
cell O +
nuclear O +
differentiation O +
antigen O +
promoter O +
: O +
evidence O +
for O +
the O +
role O +
of O +
Sp1 O +
and O +
not O +
of O +
c O -
- O -
Myb O +
or O +
PU.1 O +
in O +
myelomonocytic O +
lineage O -
- O -
specific O +
expression O +
. O +

The O +
human O +
myeloid O +
nuclear O +
differentiation O +
antigen O +
( O +
MNDA O +
) O +
is O +
expressed O +
specifically O +
in O +
maturing O +
cells O +
of O +
the O +
myelomonocytic O +
lineage O +
and O +
in O +
monocytes O +
and O +
granulocytes O +
. O +

Epitope O +
enhancement O +
was O +
used O +
to O +
confirm O +
the O +
strict O +
lineage- O +
and O +
stage O -
- O -
specific O +
expression O +
of O +
MNDA O +
in O +
bone O +
marrow O +
as O +
well O +
as O +
in O +
other O +
paraffin O -
- O -
embedded O +
fixed O +
tissues O +
. O +

A O +
1-kb O +
region O +
of O +
the O +
gene O +
that O +
includes O +
5 O +
' O +
flanking O +
sequence O +
was O +
reported O +
earlier O +
to O +
contain O +
functional O +
promoter O +
activity O +
and O +
was O +
specifically O +
demethylated O +
in O +
expressing O +
cells O +
in O +
contrast O +
to O +
null O +
cells O +
. O +

Further O +
analysis O +
has O +
revealed O +
that O +
this O +
1-kb O +
fragment O +
promotes O +
higher O +
reporter O +
gene O +
activity O +
in O +
MNDA O +
-expressing O +
cells O +
than O +
non O -
- O -
expressing O +
cells O +
, O +
indicating O +
cell O -
- O -
specific O +
differences O +
in O +
transactivation O +
. O +

This O +
sequence O +
contains O +
consensus O +
elements O +
consistent O +
with O +
myeloid O -
- O -
specific O +
gene O +
expression O +
, O +
including O +
a O +
PU.1 O +
consensus O +
site O +
near O +
the O +
major O +
transcription O +
start O +
site O +
and O +
a O +
cluster O +
of O +
c O -
- O -
Myb O +
sites O +
located O +
several O +
hundred O +
bases O +
upstream O +
of O +
this O +
region O +
. O +

However O +
, O +
analysis O +
of O +
deletion O +
mutants O +
localized O +
nearly O +
all O +
of O +
the O +
promoter O +
activity O +
to O +
a O +
short O +
region O +
( O +
-73 O +
to O +
-16 O +
) O +
that O +
did O +
not O +
include O +
the O +
cluster O +
of O +
c O -
- O -
Myb O +
sites O +
. O +

A O +
4-bp O +
mutation O +
of O +
the O +
core O +
Sp1 O +
consensus O +
element O +
( O +
GC O +
box O +
) O +
( O +
-20 O +
) O +
reduced O +
overall O +
promoter O +
activity O +
of O +
the O +
1-kb O +
fragment O +
. O +

Mutation O +
of O +
the O +
PU.1 O +
site O +
did O +
not O +
significantly O +
affect O +
promoter O +
activity O +
. O +

Only O +
a O +
small O +
region O +
( O +
-35 O +
to O +
+ O -
22 O +
) O +
including O +
the O +
Sp1 O +
element O +
and O +
transcription O +
start O +
site O +
, O +
but O +
not O +
the O +
PU.1 O +
site O +
was O +
footprinted O +
. O +

The O +
4-bp O +
mutation O +
of O +
the O +
core O +
Sp1 O +
consensus O +
element O +
abolished O +
footprinting O +
at O +
the O +
site O +
and O +
an O +
antibody O +
super O -
- O -
shift O +
reaction O +
showed O +
that O +
Sp1 O +
is O +
one O +
of O +
the O +
factors O +
binding O +
the O +
consensus O +
site O +
. O +

The O +
Sp1 O +
site O +
also O +
co O -
- O -
localizes O +
with O +
a O +
DNase O +
I O +
hypersensitive O +
site O +
. O +

The O +
results O +
indicate O +
that O +
DNA O +
methylation O +
, O +
chromatin O +
structure O +
, O +
and O +
transactivation O +
at O +
an O +
Sp1 O +
site O +
contribute O +
to O +
the O +
highly O +
restricted O +
expression O +
of O +
this O +
myelomonocytic O +
lineage O +
specific O +
gene O +
. O +

Effects O +
of O +
TPA O +
, O +
bryostatin O +
1 O +
, O +
and O +
retinoic O +
acid O +
on O +
PO O -
- O -
B O +
, O +
AP-1 O +
, O +
and O +
AP-2 O +
DNA O +
binding O +
during O +
HL-60 O +
differentiation O +
. O +

PO O -
- O -
B O +
was O +
originally O +
characterized O +
as O +
a O +
transcriptional O +
regulatory O +
factor O +
of O +
the O +
pro O -
- O -
opiomelanocortin O +
( O +
POMC O +
) O +
gene O +
; O +
however O +
, O +
it O +
has O +
become O +
increasingly O +
clear O +
that O +
this O +
protein O +
may O +
be O +
active O +
in O +
tissues O +
outside O +
the O +
pituitary O +
, O +
since O +
it O +
is O +
present O +
in O +
diverse O +
cell O +
types O +
, O +
including O +
differentiated O +
HL-60 O +
promyelocytic O +
leukemia O +
cells O +
. O +

We O +
previously O +
showed O +
that O +
PO O -
- O -
B O +
DNA O -
- O -
binding O +
is O +
progressively O +
induced O +
during O +
differentiation O +
of O +
promyelomonocytic B-CellLine +
leukemic I-CellLine +
HL-60 I-CellLine +
cells I-CellLine +
to O +
the O +
macrophage O -
- O -
like O +
lineage O +
( O +
with O +
phorbol O +
esters O +
) O +
. O +

We O +
now O +
report O +
that O +
PO O -
- O -
B O +
DNA O -
- O -
binding O +
in O +
HL-60 B-CellLine +
cells I-CellLine +
is O +
similarly O +
induced O +
during O +
differentiation O +
to O +
the O +
granulocytic O +
lineage O +
( O +
with O +
either O +
retinoic O +
acid O +
or O +
dimethylsulfoxide O +
) O +
. O +

Either O +
a O +
genetic O +
or O +
pharmacologic O +
blockade O +
of O +
HL-60 O +
differentiation O +
prohibited O +
these O +
inductive O +
effects O +
. O +

These O +
studies O +
have O +
prompted O +
our O +
interest O +
in O +
the O +
dynamics O +
of O +
other O +
transcription O +
factor O +
changes O +
during O +
HL-60 O +
differentiation O +
. O +

Of O +
these O +
, O +
we O +
observed O +
that O +
another O +
transcription O +
factor O +
( O +
AP-1 O +
) O +
is O +
also O +
robustly O +
induced O +
at O +
the O +
DNA O -
- O -
binding O +
level O +
during O +
macrophage O -
- O -
like O +
HL-60 O +
differentiation O +
, O +
but O +
not O +
during O +
granulocytic O +
differentiation O +
. O +

Conversely O +
, O +
the O +
DNA O -
- O -
binding O +
of O +
the O +
transcription O +
factor O +
AP-2 O +
was O +
slightly O +
reduced O +
by O +
TPA O +
-induced O +
HL-60 O +
differentiation O +
but O +
unchanged O +
during O +
granulocyte O +
differentiation O +
. O +

From O +
these O +
data O +
, O +
we O +
conclude O +
that O +
the O +
induction O +
of O +
PO O -
- O -
B O +
DNA O +
binding O +
is O +
a O +
general O +
marker O +
of O +
HL-60 O +
myelomonocytic O +
differentiation O +
, O +
but O +
that O +
qualitative O +
aspects O +
of O +
the O +
induction O +
of O +
additional O +
distinct O +
transcription O +
factors O +
, O +
such O +
as O +
AP-1 O +
, O +
may O +
contribute O +
to O +
lineage O -
- O -
specific O +
determinants O +
of O +
cell O +
fate O +
. O +

Spontaneous O +
occurrence O +
of O +
early O +
region O +
1A O +
reiteration O +
mutants O +
of O +
type O +
5 O +
adenovirus O +
in O +
persistently O +
infected O +
human O +
T O -
- O -
lymphocytes O +
. O +

Mutants O +
of O +
type O +
5 O +
adenovirus O +
( O +
Ad5 O +
) O +
with O +
reiterated O +
DNA O +
sequences O +
in O +
the O +
E1a O +
region O +
appeared O +
in O +
a O +
human B-CellLine +
T I-CellLine -
- I-CellLine -
lymphocyte I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
Molt-4 B-CellLine +
, O +
persistently O +
infected O +
with O +
H5sub304 O +
, O +
a O +
deletion O -
/ O -
substitution O +
mutant O +
that O +
has O +
a O +
wild O -
- O -
type O +
phenotype O +
in O +
viral O +
replication O +
. O +

Endonuclease O +
analyses O +
and O +
DNA O +
sequencing O +
revealed O +
DNA O +
reiteration O +
in O +
each O +
mutant O +
. O +

In O +
the O +
four O +
representative O +
mutants O +
investigated O +
, O +
the O +
DNA O +
reiterations O +
all O +
started O +
within O +
a O +
six O -
- O -
base O -
- O -
pair O +
consensus O +
sequence O +
, O +
G O +
( O +
or O +
C O +
) O +
CTGTG O +
, O +
located O +
in O +
the O +
second O +
exon O +
of O +
the O +
E1a O +
region O +
( O +
at O +
nt O +
1333 O +
, O +
1367 O +
, O +
or O +
1419 O +
) O +
. O +

There O +
was O +
not O +
any O +
DNA O +
homology O +
between O +
the O +
breakpoints O +
in O +
the O +
second O +
exon O +
and O +
the O +
inserting O +
sequences O +
( O +
starting O +
at O +
nt O +
532 O +
, O +
710 O +
, O +
or O +
792 O +
) O +
. O +

Northern O +
analyses O +
suggested O +
that O +
the O +
reiterated O +
splicing O +
sites O +
of O +
the O +
representative O +
mutants O +
were O +
all O +
used O +
in O +
RNA O +
splicing O +
, O +
and O +
the O +
closest O +
donor O +
and O +
recipient O +
joints O +
were O +
used O +
most O +
frequently O +
. O +

These O +
observations O +
imply O +
that O +
during O +
persistent O +
infection O +
Ad5 O +
underwent O +
spontaneous O +
mutations O +
by O +
sequence O -
- O -
specific O +
breakage O +
and O +
nonhomologous O +
end O -
- O -
end O +
joining O +
recombination O +
events O +
. O +

These O +
E1a O +
reiteration O +
mutants O +
could O +
be O +
propagated O +
in O +
HeLa B-CellLine +
, O +
A549 B-CellLine +
, O +
and O +
KB B-CellLine +
cells I-CellLine +
; O +
they O +
were O +
genetically O +
stable O +
; O +
and O +
they O +
killed O +
CREF B-CellLine +
cells I-CellLine +
at O +
a O +
strikingly O +
high O +
frequency O +
. O +

Preliminary O +
observations O +
tend O +
to O +
correlate O +
this O +
CREF O +
cell O +
killing O +
with O +
the O +
accumulation O +
of O +
the O +
early O +
viral O +
proteins O +
and/or O +
viral O +
DNA O +
in O +
the O +
infected O +
cells O +
. O +

This O +
degree O +
of O +
cell O +
damage O +
was O +
not O +
observed O +
in O +
Ad5wt O +
or O +
H5sub304 O +
infection O +
of O +
CREF B-CellLine +
cells I-CellLine +
. O +

The O +
observed O +
E1a O +
reiterations O +
provide O +
a O +
model O +
to O +
gain O +
insight O +
into O +
understanding O +
the O +
evolutionary O +
events O +
of O +
some O +
, O +
if O +
not O +
all O +
, O +
adenovirus O +
types O +
during O +
many O +
years O +
of O +
symbiotic O +
, O +
persistent O +
relationship O +
in O +
human O +
tonsils O +
and O +
adenoids O +
and O +
possibly O +
other O +
lymphoid O +
organs O +
. O +

The O +
role O +
of O +
the O +
Ikaros O +
gene O +
in O +
lymphocyte O +
development O +
and O +
homeostasis O +
. O +

The O +
Ikaros O +
gene O +
, O +
which O +
encodes O +
a O +
family O +
of O +
hemopoietic O -
- O -
specific O +
zinc O +
finger O +
proteins O +
, O +
is O +
described O +
as O +
a O +
central O +
regulator O +
of O +
lymphocyte O +
differentiation O +
. O +

During O +
fetal O +
development O +
, O +
it O +
is O +
required O +
at O +
the O +
earliest O +
stage O +
of O +
T O +
cell O +
and O +
B O +
cell O +
specification O +
. O +

In O +
the O +
adult O +
, O +
however O +
, O +
lymphoid O +
lineages O +
rely O +
on O +
Ikaros O +
at O +
distinct O +
phases O +
of O +
their O +
development O +
. O +

Its O +
activity O +
is O +
essential O +
for O +
the O +
generation O +
of O +
B O +
cell O +
but O +
not O +
of O +
T O +
cell O +
precursors O +
, O +
although O +
the O +
differentiation O +
of O +
the O +
latter O +
is O +
not O +
normal O +
. O +

A O +
significant O +
increase O +
in O +
CD4 O +
thymocytes O +
and O +
their O +
immediate O +
precursors O +
is O +
detected O +
, O +
and O +
because O +
these O +
cells O +
lack O +
markers O +
that O +
correlate O +
with O +
positive O +
selection O +
, O +
a O +
deregulation O +
in O +
their O +
maturation O +
process O +
is O +
suggested O +
. O +

Furthermore O +
, O +
Ikaros O -
- O -
null O +
thymocytes O +
hyperproliferate O +
in O +
response O +
to O +
T O +
cell O +
receptor O +
( O +
TCR O +
) O +
signaling O +
; O +
within O +
days O +
after O +
their O +
appearance O +
in O +
the O +
thymus O +
, O +
clonally O +
expanding O +
populations O +
are O +
detected O +
. O +

Deregulated O +
TCR O +
-mediated O +
responses O +
and O +
the O +
fast O +
kinetics O +
of O +
tumor O +
development O +
in O +
these O +
mutant O +
thymocytes O +
implicate O +
Ikaros O +
as O +
a O +
central O +
tumor O +
suppressor O +
gene O +
for O +
the O +
T O +
cell O +
lineage O +
. O +

In O +
addition O +
, O +
lack O +
of O +
natural O +
killer O +
cells O +
and O +
selective O +
defects O +
in O +
gamma O +
delta O +
T O +
cells O +
and O +
dendritic O +
antigen O -
- O -
presenting O +
cells O +
point O +
to O +
Ikaros O +
as O +
an O +
essential O +
factor O +
for O +
the O +
establishment O +
of O +
early O +
branchpoints O +
of O +
the O +
T O +
cell O +
pathway O +
. O +

The O +
dominant O +
interference O +
activity O +
of O +
Ikaros O +
isoforms O +
unable O +
to O +
bind O +
DNA O +
and O +
their O +
effects O +
in O +
lymphocyte O +
development O +
suggest O +
that O +
Ikaros O +
works O +
in O +
concert O +
with O +
other O +
factors O +
. O +

The O +
role O +
of O +
Aiolos O +
, O +
a O +
lymphoid O -
- O -
restricted O +
and O +
structurally O +
related O +
gene O +
, O +
in O +
lymphoid O +
differentiation O +
is O +
discussed O +
. O +

A O +
model O +
is O +
proposed O +
that O +
defines O +
Ikaros O +
as O +
the O +
backbone O +
of O +
a O +
complex O +
regulatory O +
protein O +
network O +
that O +
controls O +
cell O +
fate O +
decisions O +
and O +
regulates O +
homeostasis O +
in O +
the O +
hemo O -
- O -
lymphoid O +
system O +
. O +

Changes O +
in O +
this O +
regulatory O +
network O +
may O +
reflect O +
differentiation O +
and O +
proliferation O +
adjustments O +
made O +
in O +
hemo O -
- O -
lymphoid O +
progenitors O +
and O +
precursors O +
as O +
they O +
give O +
rise O +
to O +
the O +
cells O +
of O +
our O +
immune O +
system O +
. O +

Quantification O +
of O +
vitamin O +
D O +
receptor O +
mRNA O +
by O +
competitive O +
polymerase O +
chain O +
reaction O +
in O +
PBMC O +
: O +
lack O +
of O +
correspondence O +
with O +
common O +
allelic O +
variants O +
. O +

It O +
has O +
been O +
recently O +
claimed O +
that O +
polymorphism O +
for O +
the O +
vitamin O +
D O +
receptor O +
( O +
VDR O +
) O +
influences O +
several O +
aspects O +
of O +
calcium O +
and O +
bone O +
metabolism O +
. O +

To O +
evaluate O +
the O +
physiologic O +
plausibility O +
of O +
these O +
claims O +
, O +
we O +
compared O +
the O +
abundance O +
of O +
the O +
VDR O +
mRNA O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMCs O +
) O +
between O +
different O +
VDR O +
genotypes O +
using O +
a O +
quantitative O +
reverse O +
transcribed O +
polymerase O +
chain O +
reaction O -
- O -
based O +
method O +
. O +

The O +
method O +
is O +
based O +
on O +
the O +
coamplification O +
of O +
VDR O +
cDNA O +
and O +
an O +
internal O +
standard O +
consisting O +
of O +
known O +
concentrations O +
of O +
a O +
human O +
VDR O +
CDNA O +
mutated O +
at O +
a O +
BglII O +
restriction O +
site O +
; O +
the O +
interassay O +
coefficient O +
of O +
variation O +
is O +
11 O +
% O +
. O +

To O +
validate O +
the O +
method O +
, O +
we O +
made O +
use O +
of O +
earlier O +
receptor O +
binding O +
studies O +
indicating O +
that O +
normal O +
human O +
monocytes O +
and O +
activated O +
, O +
but O +
not O +
resting O +
, O +
lymphocytes O +
expressed O +
the O +
VDR O +
. O +

The O +
concentration O +
of O +
the O +
VDR O +
mRNA O +
was O +
10 O +
( O +
-8 O +
) O +
to O +
10 O +
( O +
-7 O +
) O +
g O -
/ O -
g O +
of O +
total O +
RNA O +
in O +
cell O -
- O -
sorted O +
monocytes O +
and O +
in O +
in O +
vitro O +
activated O +
lymphocytes O +
, O +
but O +
only O +
10 O +
( O +
-12 O +
) O +
g O -
/ O -
g O +
of O +
total O +
mRNA O +
in O +
resting O +
lymphocytes O +
, O +
establishing O +
that O +
the O +
VDR O +
mRNA O +
determined O +
by O +
our O +
method O +
in O +
PBMCs O +
is O +
due O +
to O +
constitutive O +
expression O +
in O +
monocytes O +
. O +

Following O +
an O +
initial O +
genotype O +
screening O +
of O +
85 O +
normal O +
volunteers O +
by O +
polymerase O +
chain O +
reaction O +
or O +
restriction O +
fragment O +
length O +
polymorphism O +
analysis O +
, O +
14 O +
individuals O +
with O +
the O +
Bb O +
genotype O +
, O +
12 O +
with O +
the O +
bb O +
genotype O +
, O +
and O +
12 O +
with O +
the O +
BB O +
genotype O +
were O +
selected O +
. O +

The O +
concentration O +
of O +
the O +
VDR O +
mRNA O +
, O +
corrected O +
for O +
the O +
number O +
of O +
monocytes O +
, O +
was O +
similar O +
among O +
the O +
three O +
genotype O +
groups O +
, O +
as O +
were O +
the O +
other O +
variables O +
examined O +
: O +
serum O +
calcitriol O +
, O +
serum O +
osteocalcin O +
, O +
and O +
vertebral O +
and O +
hip O +
bone O +
density O +
. O +

We O +
conclude O +
that O +
VDR O +
polymorphism O +
does O +
not O +
affect O +
the O +
abundance O +
of O +
the O +
VDR O +
mRNA O +
. O +

Regulation O +
of O +
CD95 O +
( O +
Fas O +
) O +
ligand O +
expression O +
by O +
TCR O +
-mediated O +
signaling O +
events O +
. O +

Stimulation O +
of O +
mature O +
peripheral O +
T O +
cells O +
by O +
TCR O +
engagement O +
results O +
in O +
activation O +
of O +
signals O +
that O +
drive O +
induction O +
of O +
cytokine O +
gene O +
expression O +
and O +
clonal O +
expansion O +
. O +

However O +
, O +
under O +
some O +
conditions O +
, O +
engagement O +
of O +
the O +
TCR O +
leads O +
instead O +
to O +
apoptosis O +
. O +

Recent O +
studies O +
demonstrate O +
that O +
TCR O +
-stimulated O +
apoptosis O +
requires O +
expression O +
of O +
CD95 O +
ligand O +
on O +
activated O +
T O +
cells O +
followed O +
by O +
an O +
interaction O +
between O +
CD95 O +
ligand O +
and O +
the O +
CD95 O +
receptor O +
also O +
expressed O +
on O +
this O +
population O +
. O +

The O +
experiments O +
reported O +
in O +
this O +
study O +
were O +
designed O +
to O +
address O +
the O +
signaling O +
events O +
triggered O +
by O +
TCR O +
engagement O +
that O +
are O +
important O +
for O +
regulating O +
CD95 O +
ligand O +
gene O +
expression O +
. O +

To O +
approach O +
this O +
, O +
we O +
generated O +
a O +
luciferase O +
reporter O +
construct O +
containing O +
elements O +
of O +
the O +
CD95 O +
ligand O +
promoter O +
. O +

Using O +
a O +
previously O +
described O +
mutant O +
of O +
the O +
Jurkat B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
we O +
show O +
that O +
proximal O +
signaling O +
events O +
dependent O +
on O +
the O +
presence O +
of O +
the O +
CD45 O +
tyrosine O +
phosphatase O +
are O +
required O +
for O +
TCR O +
-stimulated O +
CD95 O +
ligand O +
expression O +
. O +

Transient O +
transfection O +
studies O +
demonstrate O +
further O +
that O +
TCR O +
-stimulated O +
activation O +
of O +
the O +
Ras O +
signaling O +
pathway O +
is O +
required O +
for O +
optimal O +
activation O +
of O +
CD95 O +
ligand O +
. O +

Next O +
, O +
in O +
an O +
effort O +
to O +
determine O +
critical O +
transcription O +
factors O +
that O +
regulate O +
CD95 O +
ligand O +
expression O +
, O +
we O +
demonstrate O +
a O +
cyclosporin O +
A O -
- O -
sensitive O +
nuclear O +
factor O -
- O -
AT O +
response O +
element O +
in O +
the O +
promoter O +
region O +
of O +
this O +
gene O +
that O +
is O +
critical O +
for O +
optimal O +
CD95 O +
ligand O +
reporter O +
activity O +
in O +
stimulated O +
T O +
cells O +
. O +

Together O +
, O +
these O +
studies O +
begin O +
a O +
dissection O +
of O +
the O +
biochemical O +
events O +
that O +
lead O +
to O +
expression O +
of O +
CD95 O +
ligand O +
, O +
a O +
required O +
step O +
for O +
TCR O +
-induced O +
apoptosis O +
. O +

Cytomegalovirus O +
immediate O +
early O +
genes O +
upregulate O +
interleukin-6 O +
gene O +
expression O +
. O +

BACKGROUND O +
: O +
The O +
immediate O +
early O +
genes O +
( O +
IE O +
) O +
of O +
human O +
cytomegalovirus O +
( O +
CMV O +
) O +
can O +
be O +
expressed O +
in O +
monocytic O +
cells O +
and O +
are O +
known O +
to O +
regulate O +
viral O +
and O +
cellular O +
genes O +
. O +

Interleukin-6 O +
( O +
IL-6 O +
) O +
plays O +
a O +
central O +
role O +
in O +
numerous O +
inflammatory O +
and O +
immune O +
processes O +
. O +

Interleukin-6 O +
levels O +
are O +
increased O +
in O +
lung O +
transplant O +
patients O +
clinically O +
diagnosed O +
with O +
CMV O +
pneumonitis O +
. O +

The O +
regulation O +
of O +
IL-6 O +
is O +
dependent O +
on O +
various O +
stimuli O +
that O +
include O +
lipopolysaccharide O +
( O +
LPS O +
) O +
, O +
viruses O +
, O +
and O +
other O +
cytokines O +
. O +

These O +
studies O +
examined O +
the O +
ability O +
of O +
CMV O +
IE O +
gene O +
products O +
to O +
modulate O +
IL-6 O +
production O +
. O +

METHODS O +
: O +
THP-1 B-CellLine +
cells I-CellLine +
, O +
a O +
monocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
were O +
transfected O +
with O +
the O +
CMV O +
IE O +
genes O +
. O +

Interleukin-6 O +
protein O +
and O +
IL-6 O +
mRNA O +
were O +
measured O +
in O +
control O +
and O +
CMV O +
immediate O +
early O +
transfected O +
cells O +
. O +

Cotransfection O +
of O +
CMV O +
IE O +
genes O +
and O +
IL-6 O +
chloramphenicol O +
acetyl O +
transferase O +
( O +
CAT O +
) O +
or O +
IL-6 O +
luciferase O +
constructs O +
were O +
used O +
to O +
study O +
IL-6 O +
promoter O +
activity O +
. O +

RESULTS O +
: O +
Interleukin-6 O +
protein O +
and O +
mRNA O +
production O +
were O +
significantly O +
increased O +
in O +
cells O +
transfected O +
with O +
the O +
CMV O +
IE O +
genes O +
and O +
stimulated O +
with O +
LPS O +
compared O +
to O +
LPS B-CellLine -
- I-CellLine -
stimulated I-CellLine +
control I-CellLine +
cells I-CellLine +
. O +

Cytomegalovirus O +
IE O +
gene O +
products O +
significantly O +
enhanced O +
LPS O +
stimulation O +
of O +
IL-6 O +
promoter O +
activity O +
in O +
both O +
IL-6 O +
CAT O +
and O +
IL-6 O +
luciferase O +
assays O +
. O +

A O +
deletion O +
construct O +
that O +
contains O +
a O +
NF O -
- O -
kappa O +
B O +
site O +
but O +
is O +
missing O +
the O +
multiple O +
response O +
region O +
demonstrated O +
a O +
continued O +
increase O +
in O +
IL-6 O +
luciferase O +
activity O +
in O +
LPS B-CellLine -
- I-CellLine -
stimulated I-CellLine +
CMV I-CellLine +
transfected I-CellLine +
cells I-CellLine +
. O +

CONCLUSION O +
: O +
Cytomegalovirus O +
immediate O +
early O +
gene O +
products O +
significantly O +
enhanced O +
expression O +
of O +
IL-6 O +
in O +
LPS O -
- O -
stimulated O +
cells O +
. O +

The O +
increase O +
in O +
IL-6 O +
luciferase O +
activity O +
occurs O +
in O +
the O +
absence O +
of O +
the O +
multiple O +
response O +
region O +
, O +
the O +
area O +
of O +
the O +
IL-6 O +
promoter O +
responsive O +
to O +
IL-1 O +
, O +
TNF O +
alpha O +
, O +
cyclic O +
amp O +
, O +
and O +
phorbol O +
12-myristate O +
13-acetate O +
. O +

The O +
ability O +
of O +
CMV O +
IE O +
gene O +
products O +
to O +
enhance O +
IL-6 O +
production O +
may O +
play O +
an O +
important O +
role O +
in O +
immune O +
inflammatory O +
states O +
associated O +
with O +
CMV O +
infection O +
. O +

Involvement O +
of O +
Stat3 O +
in O +
interleukin-6 O +
-induced O +
IgM O +
production O +
in O +
a O +
human B-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
. O +

Interleukin-6 O +
( O +
IL-6 O +
) O +
is O +
an O +
important O +
B O -
- O -
cell O +
growth O +
and O +
differentiation O +
factor O +
. O +

IL-6 O +
treatment O +
of O +
the O +
human B-CellLine +
lymphoblastoid I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
SKW6.4 B-CellLine +
, O +
leads O +
to O +
increased O +
IgM O +
production O +
. O +

We O +
have O +
previously O +
shown O +
that O +
IL-6 O +
induces O +
activation O +
of O +
JAK1 O +
and O +
JAK2 O +
in O +
human B-CellLine +
B I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

A O +
chimeric O +
IL-6 O +
receptor O +
, O +
comprised O +
of O +
the O +
intracellular O +
tail O +
of O +
the O +
IL-6 O +
receptor O +
subunit O +
gp130 O +
fused O +
to O +
the O +
extracellular O +
domain O +
of O +
the O +
epidermal O +
growth O +
factor O +
( O +
EGF O +
) O +
receptor O +
, O +
was O +
stably O +
transfected O +
into O +
SKW6.4 B-CellLine +
cells I-CellLine +
. O +

EGF O +
treatment O +
induced O +
IgM O +
production O +
in O +
cells O +
transfected O +
with O +
an O +
intact O +
gp130 O +
cytoplasmic O +
tail O +
, O +
but O +
not O +
in O +
untransfected B-CellLine +
cells I-CellLine +
or O +
cells O +
transfected O +
with O +
a O +
cytoplasmic O +
tail O +
lacking O +
all O +
four O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
Stat O +
) O +
binding O +
sites O +
. O +

Moreover O +
, O +
EGF O +
treatment O +
induced O +
Stat3 O +
phosphorylation O +
in O +
cells O +
transfected O +
with O +
the O +
intact O +
chimeric O +
EGF O -
- O -
gp130 O +
receptor O +
along O +
with O +
induction O +
of O +
DNA O -
- O -
mobility O +
shift O +
of O +
a O +
classical O +
interferon O -
- O -
gamma O -
- O -
activated O +
site O +
. O +

To O +
define O +
further O +
the O +
relation O +
between O +
Stat3 O +
activation O +
and O +
enhanced O +
IgM O +
production O +
, O +
we O +
determined O +
the O +
effect O +
of O +
chimeric O +
gp130 O +
on O +
the O +
transcriptional O +
activation O +
of O +
a O +
genetic O +
element O +
linked O +
to O +
immunoglobulin O +
production O +
, O +
namely O +
the O +
immunoglobulin O +
heavy O +
chain O +
enhancer O +
( O +
IgH O -
- O -
enhancer O +
) O +
. O +

Parental O +
as O +
well O +
as O +
transfected O +
SKW6.4 B-CellLine +
cells I-CellLine +
were O +
transiently O +
transfected O +
with O +
an O +
IgH O -
- O -
enhancer O -
- O -
luciferase O +
construct O +
. O +

The O +
transcriptional O +
activity O +
of O +
the O +
IgH O -
- O -
luciferase O +
construct O +
was O +
induced O +
upon O +
ligation O +
of O +
the O +
full O -
- O -
length O +
chimeric O +
receptor O +
but O +
not O +
by O +
truncated O +
gp130 O +
receptors O +
. O +

Moreover O +
, O +
the O +
gp130 O +
-induced O +
activity O +
of O +
this O +
reporter O +
gene O +
was O +
abrogated O +
by O +
Stat3EE O +
, O +
a O +
mutant O +
Stat3 O +
incapable O +
of O +
binding O +
DNA O +
. O +

These O +
results O +
indicate O +
that O +
IL-6 O +
-induced O +
B O -
- O -
cell O +
differentiation O +
, O +
as O +
measured O +
by O +
IgM O +
production O +
, O +
may O +
be O +
controlled O +
by O +
Stat3 O +
proteins O +
. O +

Characterization O +
of O +
peripheral O +
blood O +
T O -
- O -
lymphocytes O +
transduced O +
with O +
HTLV O -
- O -
I O +
Tax O +
mutants O +
with O +
different O +
trans O -
- O -
activating O +
phenotypes O +
. O +

Tax1 O +
, O +
a O +
transcriptional O +
trans O -
- O -
activator O +
of O +
the O +
Human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
, O +
induces O +
the O +
expression O +
of O +
many O +
cellular O +
genes O +
through O +
interaction O +
with O +
at O +
least O +
three O +
distinct O +
cellular O +
transcription O +
factors O +
; O +
CREB O -
/ O -
ATF O +
, O +
NF O -
- O -
kappaB O +
, O +
and O +
SRF O +
. O +

This O +
Tax1 O +
-induced O +
activation O +
of O +
cellular O +
genes O +
is O +
considered O +
to O +
be O +
a O +
critical O +
event O +
in O +
T O -
- O -
cell O +
transformation O +
by O +
HTLV O -
- O -
I O +
. O +

To O +
elucidate O +
the O +
role O +
of O +
each O +
Tax1 O +
-inducible O +
transcriptional O +
pathway O +
in O +
T O -
- O -
cell O +
transformation O +
, O +
we O +
introduced O +
Tax1 O +
mutants O +
with O +
different O +
trans O -
- O -
activating O +
phenotypes O +
into O +
peripheral O +
blood O +
lymphocytes O +
( O +
PBL O +
) O +
by O +
retroviral O +
vectors O +
. O +

Analysis O +
of O +
these O +
PBLs O +
revealed O +
that O +
activation O +
of O +
the O +
NF O -
- O -
kappaB O +
pathway O +
is O +
sufficient O +
to O +
promote O +
the O +
growth O +
response O +
to O +
IL-2 O +
. O +

However O +
, O +
for O +
the O +
clonal O +
expansion O +
of O +
CD4 O -
+ O +
T O -
- O -
cells O +
, O +
which O +
is O +
a O +
characteristic O +
result O +
of O +
HTLV O -
- O -
I O +
infection O +
, O +
activation O +
of O +
the O +
CREB O -
/ O -
ATF O +
and O +
SRF O +
pathways O +
is O +
also O +
required O +
. O +

Involvement O +
of O +
phosphatidylinositol O +
3-kinase O +
in O +
NFAT O +
activation O +
in O +
T O +
cells O +
. O +

Phosphatidylinositol O +
3-kinase O +
( O +
PI3-K O +
) O +
has O +
been O +
implicated O +
in O +
the O +
regulation O +
of O +
cell O +
proliferation O +
in O +
many O +
cell O +
types O +
. O +

We O +
have O +
previously O +
shown O +
that O +
in O +
T O +
cells O +
the O +
PI3-K O +
inhibitor O +
, O +
wortmannin O +
, O +
interferes O +
with O +
activation O +
of O +
the O +
mitogen O -
- O -
activated O +
kinase O +
, O +
Erk2 O +
, O +
after O +
T O +
cell O +
receptor O +
( O +
TcR O +
) O +
stimulation O +
. O +

To O +
further O +
explore O +
the O +
involvement O +
of O +
PI3-K O +
in O +
T O +
cell O +
activation O +
, O +
we O +
created O +
a O +
set O +
of O +
potentially O +
dominant O +
negative O +
PI3-K O +
constructs O +
comprising O +
individual O +
or O +
tandem O +
domains O +
of O +
the O +
regulatory O +
p85 O +
subunit O +
and O +
tested O +
their O +
effect O +
on O +
downstream O +
signaling O +
events O +
like O +
Erk2 O +
activation O +
and O +
transcription O +
from O +
an O +
NFAT O +
( O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
) O +
element O +
taken O +
from O +
the O +
interleukin-2 O +
promoter O +
. O +

Following O +
TcR O +
stimulation O +
, O +
activation O +
of O +
Erk2 O +
was O +
only O +
inhibited O +
by O +
a O +
previously O +
described O +
truncated O +
form O +
of O +
p85 O +
that O +
can O +
not O +
bind O +
the O +
catalytic O +
subunit O +
, O +
but O +
not O +
by O +
other O +
constructs O +
of O +
p85 O +
. O +

In O +
contrast O +
, O +
several O +
mutant O +
p85 O +
alleles O +
had O +
dramatic O +
effects O +
on O +
NFAT O +
activation O +
. O +

Most O +
interestingly O +
, O +
the O +
N O -
- O -
terminal O +
SH2 O +
domain O +
had O +
an O +
inhibitory O +
effect O +
, O +
whereas O +
a O +
mutant O +
p85 O +
containing O +
only O +
the O +
two O +
SH2 O +
domains O +
enhanced O +
basal O +
NFAT O +
activity O +
in O +
a O +
Ras O +
-dependent O +
manner O +
. O +

Ionomycin O +
induced O +
synergistic O +
activation O +
of O +
NFAT O +
in O +
cells O +
expressing O +
p85 O +
mutants O +
that O +
contained O +
the O +
C O -
- O -
terminal O +
SH2 O +
domain O +
. O +

Analysis O +
of O +
phosphotyrosine O -
- O -
containing O +
proteins O +
bound O +
to O +
truncated O +
p85 O +
constructs O +
revealed O +
cooperative O +
binding O +
of O +
the O +
two O +
SH2 O +
domains O +
but O +
no O +
apparent O +
differences O +
between O +
the O +
N- O +
and O +
C- O +
terminal O +
SH2 O +
domains O +
. O +

Wortmannin O +
did O +
not O +
interfere O +
with O +
NFAT O +
activation O +
, O +
although O +
it O +
inhibited O +
PI3-K O +
and O +
Erk2 O +
activation O +
in O +
the O +
same O +
experiment O +
. O +

These O +
results O +
suggest O +
that O +
PI3-K O +
is O +
involved O +
in O +
NFAT O +
activation O +
through O +
a O +
complex O +
adaptor O +
function O +
of O +
its O +
regulatory O +
subunit O +
and O +
that O +
its O +
lipid O +
kinase O +
activity O +
is O +
dispensable O +
for O +
this O +
effect O +
. O +

An O +
isotype O -
- O -
specific O +
activator O +
of O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
class O +
II O +
genes O +
that O +
is O +
independent O +
of O +
class O +
II O +
transactivator O +
. O +

Patients O +
with O +
one O +
type O +
of O +
major O +
histocompatibility O +
complex O +
class O +
II O +
combined O +
immunodeficiency O +
have O +
mutations O +
in O +
a O +
gene O +
termed O +
class O +
II O +
transactivator O +
( O +
CIITA O +
) O +
, O +
which O +
coordinately O +
controls O +
the O +
transcription O +
of O +
the O +
three O +
major O +
human O +
class O +
II O +
genes O +
, O +
HLA O -
- O -
DR O +
, O +
-DQ O +
, O +
and O +
-DP O +
. O +

However O +
, O +
the O +
experimentally O +
derived O +
B B-CellLine -
- I-CellLine -
lymphoblastoid I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
clone B-CellLine +
13 I-CellLine +
, O +
expresses O +
high O +
levels O +
of O +
HLADQ O +
in O +
the O +
absence O +
of O +
HLA O -
- O -
DR O +
and O +
HLA O -
- O -
DP O +
, O +
despite O +
its O +
mapping O +
by O +
complementation O +
analysis O +
to O +
this O +
group O +
. O +

It O +
was O +
possible O +
that O +
one O +
of O +
the O +
clone O +
13 O +
CIITA O +
alleles O +
bore O +
a O +
mutation O +
that O +
allowed O +
HLA O -
- O -
DQ O +
, O +
but O +
not O +
HLA O -
- O -
DR O +
or O +
-DP O +
transcription O +
. O +

Alternatively O +
, O +
another O +
factor O +
, O +
distinct O +
from O +
CIITA O +
, O +
might O +
control O +
HLA O -
- O -
DQ O +
expression O +
. O +

We O +
report O +
here O +
that O +
ectopic O +
expression O +
of O +
CIITA O +
cDNAs O +
derived O +
by O +
reverse O +
transcriptase O +
polymerase O +
chain O +
reaction O +
from O +
clone B-CellLine +
13 I-CellLine +
do O +
not O +
restore O +
expression O +
of O +
HLA O -
- O -
DQ O +
in O +
another O +
CIITA B-CellLine -
- I-CellLine -
deficient I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
RJ2.2.5 B-CellLine +
. O +

In O +
addition O +
, O +
no O +
CIITA O +
protein O +
is O +
detectable O +
in O +
clone B-CellLine +
13 I-CellLine +
nuclear O +
extracts O +
. O +

In O +
contrast O +
, O +
somatic O +
cell O +
fusion O +
between O +
clone B-CellLine +
13 I-CellLine +
and O +
RJ2.2.5 B-CellLine +
restored O +
expression O +
of O +
the O +
HLA O -
- O -
DQ O +
haplotype O +
encoded O +
by O +
the O +
RJ2.2.5 O +
DQB O +
gene O +
. O +

Taken O +
together O +
, O +
these O +
data O +
demonstrate O +
the O +
existence O +
of O +
an O +
HLA O -
- O -
DQ O +
isotype O -
- O -
specific O +
trans O -
- O -
acting O +
factor O +
, O +
which O +
functions O +
independently O +
of O +
CIITA O +
. O +

Uncoupling O +
of O +
cell O +
cycle O +
arrest O +
from O +
the O +
expression O +
of O +
monocytic O +
differentiation O +
markers O +
in O +
HL60 B-CellLine +
cell I-CellLine +
variants I-CellLine +
. O +

Differentiation O +
generally O +
leads O +
to O +
cell O +
cycle O +
arrest O +
. O +

Human B-CellLine +
leukemia I-CellLine +
HL60 I-CellLine +
cells I-CellLine +
respond O +
to O +
the O +
presence O +
of O +
1 O +
, O +
25-dihydroxyvitamin O +
D3 O +
( O +
1 O +
, O +
25D3 O +
) O +
by O +
expressing O +
a O +
number O +
of O +
markers O +
of O +
the O +
monocyte O -
/ O -
macrophage O +
phenotype O +
and O +
become O +
arrested O +
predominantly O +
in O +
the O +
G1 O +
phase O +
of O +
the O +
cell O +
cycle O +
. O +

We O +
have O +
recently O +
reported O +
a O +
series O +
( O +
A O +
) O +
of O +
1 O +
, O +
25D3-resistant O +
variants O +
of O +
HL60 B-CellLine +
cells I-CellLine +
which O +
proliferate O +
in O +
the O +
presence O +
of O +
1 O +
, O +
25D3 O +
and O +
do O +
not O +
express O +
differentiation O +
markers O +
( O +
Exp O -
. O +
Cell O +
Res O -
. O +
224 O +
, O +
312 O +
, O +
1996 O +
) O +
. O +

We O +
now O +
describe O +
another O +
series O +
( O +
B O +
) O +
of O +
such O +
variants O +
, O +
which O +
differ O +
from O +
A O +
series O +
cells O +
grown O +
in O +
similar O +
concentrations O +
of O +
1 O +
, O +
25D3 O +
in O +
that O +
they O +
express O +
the O +
CD14 O +
antigen O +
and O +
nonspecific O +
esterase O +
, O +
characteristic O +
of O +
the O +
monocyte O +
, O +
while O +
continuing O +
to O +
proliferate O +
and O +
they O +
develop O +
hypotetraploid O +
DNA O +
( O +
4C O +
) O +
content O +
at O +
higher O +
concentrations O +
of O +
ambient O +
1 O +
, O +
25D3 O +
than O +
the O +
A O +
series O +
cells O +
. O +

Cells O +
in O +
the O +
B O +
series O +
with O +
4C O +
DNA O +
content O +
( O +
100B O +
and O +
200B O +
) O +
also O +
differed O +
from O +
the O +
A B-CellLine +
series I-CellLine +
4C I-CellLine +
cells I-CellLine +
by O +
the O +
absence O +
of O +
DNA O +
binding O +
by O +
the O +
full O -
- O -
length O +
Sp1 O +
transcription O +
factor O +
. O +

However O +
, O +
B O +
series O +
cells O +
resembled O +
the O +
A O +
series O +
cells O +
in O +
exhibiting O +
faster O +
growth O +
rates O +
than O +
the O +
parental O +
HL60 B-CellLine +
cells I-CellLine +
and O +
showed O +
high O +
levels O +
of O +
vitamin O +
D O +
receptor O +
and O +
retinoid O +
receptor O +
X O +
proteins O +
. O +

These O +
results O +
show O +
that O +
the O +
initial O +
steps O +
in O +
the O +
1 O +
, O +
25D3 O +
signaling O +
pathway O +
are O +
intact O +
in O +
B O +
series O +
resistant O +
cells O +
and O +
lead O +
to O +
the O +
appearance O +
of O +
early O +
markers O +
of O +
monocytic O +
differentiation O +
. O +

However O +
, O +
the O +
progression O +
to O +
subsequent O +
events O +
which O +
comprise O +
terminal O +
differentiation O +
and O +
cell O +
cycle O +
arrest O +
is O +
halted O +
during O +
the O +
adaptation O +
to O +
the O +
presence O +
of O +
1 O +
, O +
25D3 O +
in O +
these O +
cells O +
. O +

Thus O +
, O +
the O +
availability O +
of O +
these O +
variant O +
cells O +
should O +
provide O +
a O +
system O +
for O +
studying O +
the O +
link O +
between O +
differentiation O +
and O +
cell O +
cycle O +
arrest O +
. O +

Induction O +
of O +
cytokine O +
expression O +
in O +
leukocytes O +
by O +
binding O +
of O +
thrombin O -
- O -
stimulated O +
platelets O +
. O +

BACKGROUND O +
: O +
Activated O +
platelets O +
tether O +
and O +
activate O +
myeloid O +
leukocytes O +
. O +

To O +
investigate O +
the O +
potential O +
relevance O +
of O +
this O +
mechanism O +
in O +
acute O +
myocardial O +
infarction O +
( O +
AMI O +
) O +
, O +
we O +
examined O +
cytokine O +
induction O +
by O +
leukocyte O -
- O -
platelet O +
adhesion O +
and O +
the O +
occurrence O +
of O +
leukocyte O -
- O -
platelet O +
conjugates O +
in O +
patients O +
with O +
AMI O +
. O +

METHODS O +
AND O +
RESULTS O +
: O +
We O +
obtained O +
peripheral O +
venous O +
blood O +
samples O +
in O +
20 O +
patients O +
with O +
AMI O +
before O +
and O +
daily O +
for O +
5 O +
days O +
after O +
direct O +
percutaneous O +
transluminal O +
coronary O +
angioplasty O +
( O +
PTCA O +
) O +
and O +
in O +
20 O +
patients O +
undergoing O +
elective O +
PTCA O +
. O +

Throughout O +
the O +
study O +
period O +
, O +
CD41 O +
immunofluorescence O +
of O +
leukocytes O +
( O +
flow O +
cytometry O +
) O +
revealed O +
increased O +
leukocyte O -
- O -
platelet O +
adhesion O +
in O +
patients O +
with O +
AMI O +
compared O +
with O +
control O +
patients O +
( O +
mean O +
+ O -
/- O +
SE O +
of O +
fluorescence O +
[ O +
channels O +
] O +
before O +
PTCA O +
: O +
77 O +
+ O -
/- O +
16 O +
versus O +
35 O +
+ O -
/- O +
9 O +
; O +
P O +
= O +
.003 O +
) O +
. O +

In O +
vitro O +
, O +
thrombin O -
- O -
stimulated O +
fixed O +
platelets O +
bound O +
to O +
neutrophils O +
and O +
monocytes O +
. O +

Within O +
2 O +
hours O +
, O +
this O +
resulted O +
in O +
increased O +
mRNA O +
for O +
interleukin O +
( O +
IL O +
) O +
, O +
1 O +
beta O +
, O +
IL-8 O +
, O +
and O +
monocyte O +
chemoattractant O +
protein O +
( O +
MCP O +
) O +
-1 O +
in O +
unfractionated O +
leukocytes O +
. O +

After O +
4 O +
hours O +
, O +
IL-1 O +
beta O +
and O +
IL-8 O +
concentration O +
of O +
the O +
cell O -
- O -
free O +
supernatant O +
had O +
increased O +
by O +
268 O +
+ O -
/- O +
36 O +
% O +
and O +
210 O +
+ O -
/- O +
7 O +
% O +
, O +
respectively O +
, O +
and O +
cellular O +
MCP-1 O +
content O +
had O +
increased O +
by O +
170 O +
+ O -
/- O +
8 O +
% O +
. O +

Addition O +
of O +
activated O +
platelets O +
to O +
adherent O +
monocytes O +
had O +
a O +
similar O +
effect O +
and O +
was O +
associated O +
with O +
nuclear O +
factor O -
- O -
kappa O +
B O +
activation O +
. O +

Inhibition O +
of O +
binding O +
by O +
anti O -
- O -
P O +
selectin O +
antibodies O +
reduced O +
the O +
effect O +
of O +
activated O +
platelets O +
on O +
cytokine O +
production O +
. O +

CONCLUSIONS O +
: O +
In O +
patients O +
with O +
AMI O +
, O +
leukocyte O -
- O -
platelet O +
adhesion O +
is O +
increased O +
. O +

Binding O +
of O +
activated O +
platelets O +
induces O +
IL-1 O +
beta O +
, O +
IL-8 O +
, O +
and O +
MCP-1 O +
in O +
leukocytes O +
. O +

Our O +
findings O +
suggest O +
that O +
leukocyte O -
- O -
platelet O +
adhesion O +
contributes O +
to O +
the O +
regulation O +
of O +
inflammatory O +
responses O +
in O +
AMI O +
. O +

Defective O +
survival O +
and O +
activation O +
of O +
thymocytes O +
in O +
transgenic O +
mice O +
expressing O +
a O +
catalytically O +
inactive O +
form O +
of O +
Ca2+ O -
/ O -
calmodulin O -
- O -
dependent O +
protein O +
kinase O +
IV O +
. O +

We O +
have O +
generated O +
transgenic O +
mice O +
that O +
express O +
a O +
catalytically O +
inactive O +
form O +
of O +
Ca2+ O -
/ O -
calmodulin O -
- O -
dependent O +
protein O +
kinase O +
IV O +
( O +
CaMKIV O +
) O +
specifically O +
in O +
thymic O +
T O +
cells O +
. O +

The O +
presence O +
of O +
this O +
protein O +
results O +
in O +
a O +
markedly O +
reduced O +
thymic O +
cellularity O +
, O +
although O +
the O +
distribution O +
of O +
the O +
remaining O +
cells O +
is O +
normal O +
based O +
on O +
evaluation O +
of O +
the O +
CD4 O +
and O +
CD8 O +
cell O +
surface O +
antigens O +
that O +
are O +
used O +
to O +
gauge O +
T O +
cell O +
development O +
. O +

Isolated O +
thymic O +
T O +
cells O +
from O +
the O +
transgenic O +
mice O +
also O +
show O +
a O +
dramatically O +
decreased O +
survival O +
rate O +
when O +
evaluated O +
in O +
culture O +
under O +
conditions O +
that O +
do O +
not O +
favor O +
activation O +
. O +

When O +
challenged O +
with O +
an O +
activating O +
stimulus O +
such O +
as O +
alpha O -
- O -
CD3 O +
or O +
a O +
combination O +
of O +
phorbol O +
ester O +
plus O +
ionophore O +
, O +
the O +
cells O +
are O +
severely O +
compromised O +
in O +
their O +
ability O +
to O +
produce O +
the O +
cytokine O +
interleukin-2 O +
( O +
IL-2 O +
) O +
. O +

Reduction O +
of O +
IL-2 O +
production O +
is O +
secondary O +
to O +
the O +
inability O +
to O +
phosphorylate O +
the O +
cAMP O +
response O +
element O +
binding O +
protein O +
, O +
CREB O +
, O +
and O +
induce O +
expression O +
of O +
the O +
immediate O +
early O +
genes O +
such O +
as O +
Fos O +
B O +
that O +
are O +
required O +
to O +
transactivate O +
the O +
IL-2 O +
promoter O +
. O +

Because O +
transgene O +
expression O +
was O +
regulated O +
by O +
the O +
proximal O +
promoter O +
of O +
the O +
murine O +
lck O +
gene O +
and O +
this O +
promoter O +
is O +
inactivated O +
in O +
T O +
cells O +
that O +
exit O +
the O +
thymus O +
, O +
the O +
mutant O +
hCaMKIV O +
is O +
not O +
present O +
in O +
peripheral O +
T O +
cells O +
. O +

Consequently O +
, O +
T O +
lymphocytes O +
present O +
in O +
the O +
spleen O +
can O +
be O +
activated O +
normally O +
in O +
response O +
to O +
either O +
stimulus O +
mentioned O +
above O +
, O +
demonstrating O +
that O +
the O +
effects O +
of O +
the O +
inactive O +
CaMKIV O +
on O +
activation O +
are O +
reversible O +
. O +

Our O +
results O +
suggest O +
that O +
CaMKIV O +
may O +
represent O +
a O +
physiologically O +
relevant O +
CREB O +
kinase O +
in O +
T O +
cells O +
and O +
that O +
the O +
enzyme O +
is O +
also O +
required O +
to O +
ensure O +
normal O +
expansion O +
of O +
T O +
cells O +
in O +
the O +
thymus O +
. O +

Whereas O +
the O +
pathway O +
responsible O +
for O +
this O +
latter O +
role O +
is O +
yet O +
to O +
be O +
elucidated O +
, O +
it O +
is O +
unlikely O +
to O +
include O +
CREB O +
phosphorylation O +
. O +

The O +
class O +
II O +
trans O -
- O -
activator O +
CIITA O +
interacts O +
with O +
the O +
TBP O -
- O -
associated O +
factor O +
TAFII32 O +
. O +

The O +
class O +
II O +
trans- O +
activator O +
( O +
CIITA O +
) O +
is O +
the O +
main O +
transcriptional O +
co O -
- O -
activator O +
for O +
the O +
expression O +
of O +
MHC O +
class O +
II O +
proteins O +
. O +

Its O +
N O -
- O -
terminal O +
125 O +
amino O +
acids O +
function O +
as O +
an O +
independent O +
transcriptional O +
activation O +
domain O +
. O +

Analyses O +
of O +
the O +
primary O +
amino O +
acid O +
sequence O +
of O +
the O +
activation O +
domain O +
predict O +
the O +
presence O +
of O +
three O +
alpha O -
- O -
helices O +
, O +
each O +
with O +
a O +
high O +
proportion O +
of O +
acidic O +
residues O +
. O +

Using O +
site O -
- O -
directed O +
mutagenesis O +
, O +
we O +
found O +
that O +
two O +
of O +
these O +
predicted O +
alpha O -
- O -
helices O +
are O +
required O +
for O +
full O +
transcriptional O +
activation O +
by O +
CIITA O +
. O +

Moreover O +
, O +
a O +
CIITA O +
protein O +
in O +
which O +
both O +
functional O +
alpha O -
- O -
helices O +
have O +
been O +
deleted O +
displays O +
a O +
dominant O +
negative O +
phenotype O +
. O +

This O +
activation O +
domain O +
of O +
CIITA O +
interacts O +
with O +
the O +
32 O +
kDa O +
subunit O +
of O +
the O +
general O +
transcription O +
complex O +
TFIID O +
, O +
TAFII32 O +
. O +

Decreased O +
transcriptional O +
activation O +
by O +
N O -
- O -
terminal O +
deletions O +
of O +
CIITA O +
is O +
correlated O +
directly O +
with O +
their O +
reduced O +
binding O +
to O +
TAFII32 O +
. O +

We O +
conclude O +
that O +
interactions O +
between O +
TAFII32 O +
and O +
CIITA O +
are O +
responsible O +
for O +
activation O +
of O +
class O +
II O +
genes O +
. O +

Constitutive O +
and O +
inducible O +
protein O -
/ O -
DNA O +
interactions O +
of O +
the O +
interferon O -
- O -
gamma O +
promoter O +
in O +
vivo O +
in O +
[ O +
corrected O +
] O +
CD45RA O +
and O +
CD45R0 O +
T O +
helper O +
subsets O +
[ O +
published O +
erratum O +
appears O +
in O +
Eur O +
J O +
Immunol O +
1997 O +
Jul O +
; O +
27 O +
( O +
7 O +
) O +
: O +
1830 O +
] O +

Interferon O -
- O -
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
is O +
a O +
key O +
cytokine O +
of O +
T O +
lymphocytes O +
with O +
major O +
regulatory O +
functions O +
in O +
the O +
immune O +
system O +
. O +

To O +
determine O +
and O +
compare O +
protein O -
/ O -
DNA O +
interactions O +
at O +
the O +
native O +
IFN O -
- O -
gamma O +
locus O +
in O +
T O +
cells O +
, O +
we O +
analyzed O +
the O +
human O +
IFN O -
- O -
gamma O +
promoter O +
by O +
ligation O -
- O -
mediated O +
polymerase O +
chain O +
reaction O +
( O +
LM O -
- O -
PCR O +
) O +
techniques O +
. O +

Accordingly O +
, O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
and O +
primary O +
CD45RA O +
and O +
CD45R0 O +
CD4 O -
+ O +
T O +
cell O +
subsets O +
isolated O +
from O +
peripheral O +
blood O +
using O +
immunomagnetic O +
beads O +
were O +
cultured O +
and O +
analyzed O +
by O +
LM O -
- O -
PCR O +
. O +

Constitutive O +
and O +
inducible O +
protein O -
/ O -
DNA O +
interactions O +
of O +
the O +
IFN O -
- O -
gamma O +
promoter O +
in O +
vivo O +
were O +
detected O +
in O +
all O +
T O +
cells O +
tested O +
. O +

Interestingly O +
, O +
an O +
inducible O +
footprint O +
between O +
-183 O +
and O +
-196 O +
was O +
consistently O +
observed O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
and O +
CD45RA O +
and O +
CD45R0 O +
T O +
helper O +
subsets O +
upon O +
stimulation O +
with O +
phorbol O +
12-myristate O +
13-acetate+ O +
phytohemagglutinin O +
( O +
PMA+ O +
PHA O +
) O +
that O +
was O +
highly O +
sensitive O +
to O +
treatment O +
with O +
corticosteroids O +
. O +

This O +
novel O +
target O +
site O +
, O +
denoted O +
the O +
C O -
- O -
site O +
, O +
was O +
shown O +
by O +
several O +
criteria O +
, O +
including O +
cell O +
distribution O +
studies O +
, O +
stimulation O +
experiments O +
, O +
supershift O +
assays O +
, O +
and O +
cross O -
- O -
competition O +
electrophoretic O +
mobility O +
shift O +
assays O +
to O +
bind O +
the O +
transcription O +
factor O +
AP-1 O +
. O +

Mutation O +
of O +
the O +
C O -
- O -
site O +
that O +
prevented O +
AP-1 O +
binding O +
to O +
this O +
site O +
was O +
sufficient O +
strikingly O +
to O +
reduce O +
inducible O +
promoter O +
activity O +
in O +
primary O +
CD45R0 O +
T O +
cells O +
. O +

In O +
summary O +
, O +
the O +
data O +
demonstrate O +
that O +
IFN O -
- O -
gamma O +
gene O +
transcription O +
in O +
primary O +
T O +
cells O +
is O +
regulated O +
in O +
vivo O +
at O +
the O +
level O +
of O +
constitutive O +
and O +
inducible O +
protein O -
/ O -
DNA O +
interactions O +
. O +

We O +
propose O +
a O +
model O +
where O +
basal O +
transcription O +
is O +
maintained O +
by O +
binding O +
of O +
various O +
transcription O +
factors O +
to O +
the O +
IFN O -
- O -
gamma O +
promoter O +
, O +
whereas O +
PMA+ O +
PHA O +
-inducible O +
IFN O -
- O -
gamma O +
transcription O +
in O +
CD45R0 O +
T O +
cells O +
is O +
associated O +
with O +
binding O +
of O +
AP-1 O +
to O +
the O +
C O -
- O -
site O +
. O +

Reactive O +
oxygen O +
species O +
and O +
antioxidants O +
in O +
inflammatory O +
diseases O +
. O +

This O +
paper O +
aims O +
to O +
review O +
the O +
role O +
of O +
free O +
radical O -
- O -
induced O +
tissue O +
damage O +
and O +
antioxidant O +
defence O +
mechanisms O +
in O +
inflammatory O +
diseases O +
that O +
involve O +
pathogenic O +
processes O +
similar O +
to O +
the O +
periodontal O +
diseases O +
. O +

There O +
is O +
a O +
clearly O +
defined O +
and O +
substantial O +
role O +
for O +
free O +
radicals O +
or O +
reactive O +
oxygen O +
species O +
( O +
ROS O +
) O +
in O +
periodontitis O +
, O +
but O +
little O +
research O +
has O +
been O +
performed O +
in O +
this O +
area O +
. O +

This O +
paper O +
reviews O +
the O +
considerable O +
data O +
available O +
relating O +
ROS O +
activity O +
and O +
antioxidant O +
defence O +
to O +
inflammatory O +
diseases O +
and O +
attempts O +
to O +
draw O +
parallels O +
with O +
periodontitis O +
, O +
in O +
an O +
effort O +
to O +
stimulate O +
more O +
periodontal O +
research O +
in O +
this O +
important O +
area O +
. O +

The O +
recent O +
discovery O +
of O +
the O +
transcription O +
factor O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
is O +
reviewed O +
and O +
several O +
potential O +
pathways O +
for O +
cytokine O +
-induced O +
periodontal O +
tissue O +
damage O +
, O +
mediated O +
by O +
NF O -
- O -
kappa O +
B1 O +
are O +
discussed O +
. O +

Emphasis O +
is O +
placed O +
on O +
cytokines O +
that O +
have O +
been O +
studied O +
in O +
periodontitis O +
, O +
principally O +
TNF O -
- O -
alpha O +
, O +
IL-1 O +
, O +
IL-6 O +
, O +
IL-8 O +
and O +
beta O -
- O -
interferon O +
. O +

The O +
link O +
between O +
cellular O +
production O +
of O +
such O +
important O +
mediators O +
of O +
inflammation O +
and O +
the O +
antioxidant O +
( O +
AO O +
) O +
thiols O +
, O +
cysteine O +
and O +
reduced O +
glutathione O +
( O +
GSH O +
) O +
, O +
is O +
discussed O +
and O +
it O +
is O +
hypothesised O +
that O +
NF O -
- O -
kappa O +
B O +
antagonists O +
may O +
offer O +
important O +
therapeutic O +
benefits O +
. O +

Transactivation O +
by O +
CIITA O +
, O +
the O +
type O +
II O +
bare O +
lymphocyte O +
syndrome O -
- O -
associated O +
factor O +
, O +
requires O +
participation O +
of O +
multiple O +
regions O +
of O +
the O +
TATA O +
box O +
binding O +
protein O +
. O +

CIITA O +
is O +
a O +
positive O +
regulator O +
of O +
class O +
II O +
major O +
histocompatibility O +
complex O +
gene O +
transcription O +
that O +
has O +
been O +
found O +
to O +
be O +
defective O +
in O +
one O +
of O +
the O +
five O +
complementation O +
groups O +
of O +
class B-CellLine +
II I-CellLine +
major I-CellLine +
histocompatibility I-CellLine +
complex I-CellLine -
- I-CellLine -
negative I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Its O +
N O -
- O -
terminal O +
region O +
is O +
capable O +
of O +
activating O +
transcription O +
from O +
a O +
reporter O +
gene O +
when O +
fused O +
to O +
a O +
DNA O +
binding O +
domain O +
. O +

We O +
have O +
investigated O +
the O +
mechanism O +
of O +
transactivation O +
mediated O +
by O +
the O +
CIITA O +
activation O +
domain O +
by O +
studying O +
its O +
role O +
in O +
the O +
process O +
of O +
transcription O +
initiation O +
and O +
elongation O +
. O +

Specifically O +
the O +
altered O +
specificity O +
TBP O +
( O +
TATA O +
box O +
binding O +
protein O +
) O +
assay O +
has O +
been O +
used O +
to O +
analyze O +
the O +
response O +
of O +
the O +
CIITA O +
activation O +
domain O +
to O +
mutations O +
in O +
TBP O +
known O +
to O +
disrupt O +
its O +
interaction O +
with O +
its O +
associated O +
general O +
factors O +
. O +

Transactivation O +
by O +
CIITA O +
was O +
extremely O +
sensitive O +
to O +
a O +
mutation O +
in O +
TBP O +
that O +
in O +
yeast O +
is O +
known O +
to O +
abolish O +
VP16 O +
-mediated O +
transcription O +
but O +
leaves O +
basal O +
transcription O +
unaffected O +
. O +

A O +
TBP O +
mutant O +
defective O +
in O +
interaction O +
with O +
TBP O -
- O -
associated O +
factor O +
TAFII250 O +
also O +
failed O +
to O +
mediate O +
transactivation O +
through O +
the O +
CIITA O +
activation O +
domain O +
. O +

Certain O +
interactions O +
between O +
TBP O +
and O +
general O +
factors O +
that O +
are O +
specifically O +
required O +
for O +
acidic O +
activation O +
domains O +
were O +
also O +
required O +
for O +
CIITA O +
-mediated O +
transactivation O +
to O +
reach O +
its O +
full O +
potential O +
. O +

Finally O +
, O +
like O +
VP16 O +
, O +
CIITA O +
was O +
able O +
to O +
stimulate O +
elongation O +
of O +
transcription O +
. O +

Overall O +
the O +
mechanism O +
of O +
transactivation O +
by O +
the O +
human O +
B O -
- O -
cell O -
- O -
specific O +
CIITA O +
is O +
very O +
similar O +
to O +
that O +
mediated O +
by O +
the O +
herpes O +
virus O +
transactivator O +
VP16 O +
in O +
the O +
ways O +
that O +
have O +
been O +
tested O +
. O +

Specific O +
complex O +
formation O +
between O +
the O +
type O +
II O +
bare O +
lymphocyte O +
syndrome O -
- O -
associated O +
transactivators O +
CIITA O +
and O +
RFX5 O +
. O +

Two O +
of O +
the O +
genes O +
defective O +
in O +
the O +
five O +
complementation O +
groups O +
identified O +
in O +
the O +
class O +
II O -
- O -
negative O +
bare O +
lymphocyte O +
syndrome O +
or O +
corresponding O +
laboratory O +
mutants O +
have O +
been O +
cloned O +
. O +

One O +
gene O +
encodes O +
a O +
protein O +
, O +
RFX5 O +
, O +
that O +
is O +
a O +
member O +
of O +
the O +
RFX O +
family O +
of O +
DNA O +
binding O +
proteins O +
. O +

The O +
other O +
, O +
CIITA O +
, O +
encodes O +
a O +
large O +
protein O +
with O +
a O +
defined O +
acidic O +
transcriptional O +
activation O +
domain O +
; O +
this O +
protein O +
does O +
not O +
interact O +
with O +
DNA O +
. O +

Expression O +
plasmids O +
encoding O +
regions O +
of O +
RFX5 O +
fused O +
to O +
the O +
GAL4 O +
DNA O +
binding O +
domain O +
activated O +
transcription O +
from O +
a O +
reporter O +
construct O +
containing O +
GAL4 O +
sites O +
in O +
a O +
cotransfection O +
assay O +
in O +
the O +
Raji B-CellLine +
human I-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

However O +
, O +
these O +
plasmids O +
produced O +
transcriptional O +
activity O +
in O +
HeLa B-CellLine +
cells I-CellLine +
only O +
in O +
conjunction O +
with O +
interferon O +
gamma O +
stimulation O +
, O +
a O +
condition O +
in O +
which O +
expression O +
of O +
both O +
CIITA O +
and O +
class O +
II O +
major O +
histocompatibility O +
complex O +
surface O +
proteins O +
are O +
induced O +
. O +

Furthermore O +
, O +
these O +
plasmids O +
were O +
not O +
active O +
in O +
RJ2.2.5 B-CellLine +
, O +
an O +
in O +
vitro O +
mutagenized O +
derivative O +
of O +
Raji B-CellLine +
in O +
which O +
both O +
copies O +
of O +
CIITA O +
are O +
defective O +
. O +

Transcriptional O +
activation O +
by O +
the O +
RFX5 O +
fusion O +
protein O +
could O +
be O +
restored O +
in O +
RJ2.2.5 B-CellLine +
by O +
cotransfection O +
with O +
a O +
CIITA O +
expression O +
plasmid O +
. O +

Finally O +
, O +
a O +
direct O +
interaction O +
between O +
RFX5 O +
and O +
CIITA O +
was O +
detected O +
with O +
the O +
yeast O +
two O -
- O -
hybrid O +
and O +
far O -
- O -
Western O +
blot O +
assays O +
. O +

Thus O +
, O +
RFX5 O +
can O +
activate O +
transcription O +
only O +
in O +
cooperation O +
with O +
CIITA O +
. O +

RFX5 O +
and O +
CIITA O +
associate O +
to O +
form O +
a O +
complex O +
capable O +
of O +
activating O +
transcription O +
from O +
class O +
II O +
major O +
histocompatibility O +
complex O +
promoters O +
. O +

In O +
this O +
complex O +
, O +
promoter O +
specificity O +
is O +
determined O +
by O +
the O +
DNA O +
binding O +
domain O +
of O +
RFX5 O +
and O +
the O +
general O +
transcription O +
apparatus O +
is O +
recruited O +
by O +
the O +
acidic O +
activation O +
domain O +
of O +
CIITA O +
. O +

Transcriptional O +
activity O +
and O +
constitutive O +
nuclear O +
localization O +
of O +
the O +
ETS O +
protein O +
Elf-1 O +
. O +

Elf-1 O +
is O +
a O +
lymphoid O -
- O -
specific O +
transcription O +
factor O +
that O +
belongs O +
to O +
the O +
ETS O +
protein O +
family O +
. O +

It O +
can O +
bind O +
to O +
DNA O +
target O +
sequences O +
within O +
a O +
variety O +
of O +
cytokine O +
genes O +
. O +

We O +
demonstrate O +
that O +
Elf-1 O +
is O +
constitutively O +
localized O +
in O +
the O +
nucleus O +
which O +
is O +
dependent O +
on O +
the O +
presence O +
of O +
amino O +
acids O +
86 O -
- O -
265 O +
. O +

Analysis O +
of O +
Gal4-Elf-1 O +
fusion O +
proteins O +
revealed O +
that O +
the O +
N O -
- O -
terminal O +
86 O +
amino O +
acids O +
of O +
Elf-1 O +
contain O +
a O +
transcriptional O +
activation O +
domain O +
, O +
the O +
activity O +
of O +
which O +
is O +
attenuated O +
by O +
an O +
internal O +
repression O +
domain O +
. O +

Furthermore O +
, O +
Elf-1 O +
interacts O +
specifically O +
with O +
the O +
E74 O +
target O +
sequence O +
and O +
can O +
stimulate O +
transcription O +
driven O +
by O +
the O +
E74 O +
site O +
independent O +
of O +
mitogenic O +
signaling O +
. O +

Thus O +
, O +
Elf-1 O +
is O +
able O +
to O +
stimulate O +
gene O +
transcription O +
which O +
may O +
be O +
required O +
for O +
the O +
development O +
and O +
activity O +
of O +
lymphocytes O +
. O +

Histamine O +
modulates O +
the O +
expression O +
of O +
c O -
- O -
fos O +
through O +
cyclic O +
AMP O +
production O +
via O +
the O +
H2 O +
receptor O +
in O +
the O +
human B-CellLine +
promonocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
U937 I-CellLine +
. O +

We O +
examined O +
the O +
effects O +
of O +
histamine O +
and O +
its O +
agonists O +
on O +
the O +
expression O +
of O +
the O +
c O -
- O -
fos O +
and O +
c O -
- O -
myc O +
proto O -
- O -
oncogenes O +
at O +
the O +
transcriptional O +
and O +
translational O +
levels O +
in O +
the O +
human B-CellLine +
promonocytic I-CellLine +
U937 I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Histamine O +
transiently O +
increased O +
cAMP O +
and O +
c O -
- O -
fos O +
expression O +
through O +
H2 O +
receptors O +
. O +

Dibutyryl O +
cAMP O +
also O +
increased O +
c O -
- O -
fos O +
mRNA O +
and O +
protein O +
, O +
and O +
levels O +
remained O +
elevated O +
even O +
after O +
12 O +
hr O +
of O +
treatment O +
. O +

Dose O -
- O -
dependence O +
studies O +
using O +
histamine O +
and O +
dimaprit O +
showed O +
that O +
the O +
EC50 O +
values O +
for O +
cAMP O +
production O +
and O +
c O -
- O -
fos O +
increase O +
were O +
similar O +
, O +
suggesting O +
that O +
cAMP O +
might O +
be O +
involved O +
in O +
c O -
- O -
fos O +
induction O +
via O +
H2 O +
receptors O +
. O +

Furthermore O +
, O +
studies O +
carried O +
out O +
using O +
H7 O +
, O +
a O +
protein O +
kinase O +
A O -
/ O -
protein O +
kinase O +
C O +
inhibitor O +
, O +
blocked O +
c O -
- O -
fos O +
induction O +
, O +
whereas O +
no O +
effect O +
was O +
observed O +
with O +
bisindolylmaleimide O +
, O +
a O +
specific O +
protein O +
kinase O +
C O +
inhibitor O +
. O +

No O +
modification O +
of O +
c O -
- O -
myc O +
expression O +
could O +
be O +
detected O +
on O +
treatment O +
with O +
histamine O +
or O +
its O +
analogues O +
. O +

Nevertheless O +
, O +
dibutyryl O +
cAMP O +
induced O +
a O +
down O -
- O -
regulation O +
of O +
the O +
levels O +
of O +
this O +
proto O -
- O -
oncogene O +
. O +

In O +
addition O +
, O +
dibutyryl O +
cAMP O +
inhibited O +
cell O +
growth O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
, O +
whereas O +
histamine O +
failed O +
to O +
affect O +
proliferation O +
and O +
differentiation O +
of O +
U937 B-CellLine +
cells I-CellLine +
. O +

Cells O +
pretreated O +
with O +
dimaprit O +
showed O +
a O +
decrease O +
in O +
the O +
cAMP O +
response O +
to O +
subsequent O +
addition O +
of O +
H2 O +
agonists O +
, O +
whereas O +
the O +
cAMP O +
response O +
to O +
prostaglandin O +
E2 O +
remained O +
unaltered O +
. O +

This O +
homologous O +
mechanism O +
of O +
H2 O +
receptor O +
desensitization O +
was O +
time O +
dependent O +
. O +

These O +
results O +
indicate O +
that O +
histamine O +
activates O +
several O +
mechanisms O +
involved O +
in O +
the O +
induction O +
of O +
differentiation O +
, O +
such O +
as O +
cAMP O +
and O +
c O -
- O -
fos O +
production O +
, O +
but O +
fails O +
to O +
promote O +
differentiation O +
of O +
U937 B-CellLine +
cells I-CellLine +
, O +
apparently O +
due O +
to O +
the O +
rapid O +
desensitization O +
of O +
H2 O +
receptors O +
. O +

Human O +
cytomegalovirus O +
induces O +
interleukin-8 O +
production O +
by O +
a O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
THP-1 B-CellLine +
, O +
through O +
acting O +
concurrently O +
on O +
AP-1- O +
and O +
NF O -
- O -
kappaB O -
- O -
binding O +
sites O +
of O +
the O +
interleukin-8 O +
gene O +
. O +

Cytomegalovirus O +
( O +
CMV O +
) O +
infection O +
induced O +
interleukin-8 O +
( O +
IL-8 O +
) O +
gene O +
transcription O +
in O +
a O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
THP-1 B-CellLine +
cells I-CellLine +
, O +
leading O +
to O +
IL-8 O +
secretion O +
. O +

The O +
functional O +
analysis O +
of O +
the O +
IL-8 O +
gene O +
revealed O +
that O +
both O +
AP-1- O +
and O +
NF O -
- O -
kappaB O +
factor O -
- O -
binding O +
elements O +
were O +
involved O +
in O +
conferring O +
the O +
responsiveness O +
to O +
CMV O +
. O +

Moreover O +
, O +
electrophoretic O +
mobility O +
shift O +
assays O +
demonstrated O +
that O +
CMV O +
induced O +
the O +
formation O +
of O +
NF O -
- O -
kappaB O +
and O +
AP-1 O +
complexes O +
. O +

These O +
results O +
suggest O +
that O +
CMV O +
activates O +
these O +
transcriptional O +
factors O +
, O +
resulting O +
in O +
IL-8 O +
gene O +
expression O +
. O +

Molecular O +
cloning O +
and O +
characterization O +
of O +
a O +
cDNA O +
, O +
CHEMR1 O +
, O +
encoding O +
a O +
chemokine O +
receptor O +
with O +
a O +
homology O +
to O +
the O +
human O +
C O -
- O -
C O +
chemokine O +
receptor O +
, O +
CCR-4 O +
. O +

Chemokines O +
refer O +
to O +
a O +
rapidly O +
expanding O +
family O +
of O +
small O +
cytokines O +
whose O +
primary O +
function O +
is O +
recruitment O +
of O +
leukocytes O +
to O +
inflammatory O +
sites O +
. O +

These O +
are O +
known O +
to O +
bind O +
to O +
seven O -
- O -
transmembrane O -
- O -
domain O +
containing O +
receptors O +
. O +

A O +
cDNA O +
clone O +
, O +
CHEMR1 O +
, O +
resembling O +
the O +
typical O +
G O +
protein O -
- O -
coupled O +
receptor O +
, O +
was O +
isolated O +
from O +
a O +
mouse O +
cytotoxic O +
T O -
- O -
lymphocyte O +
( O +
CTL O +
) O +
library O +
. O +

Northern O +
blot O +
analysis O +
in O +
mouse O +
cell O +
lines O +
suggests O +
that O +
its O +
expression O +
is O +
found O +
in O +
a O +
variety O +
of O +
cells O +
, O +
including O +
T O +
cells O +
, O +
B O +
cells O +
, O +
and O +
macrophages O +
. O +

The O +
CHEMR1 O +
gene O +
Scya3r2 O +
is O +
a O +
single O -
- O -
copy O +
gene O +
whose O +
open O +
reading O +
frame O +
may O +
be O +
in O +
a O +
single O +
exon O +
and O +
maps O +
to O +
the O +
distal O +
region O +
of O +
mouse O +
Chr O +
9 O +
where O +
the O +
mouse O +
macrophage O +
inflammatory O +
protein-1alpha O +
( O +
MIP-1alpha O +
) O +
receptor O +
gene O +
Scya3r O +
and O +
two O +
related O +
C O -
- O -
C O +
chemokine O +
receptor O -
- O -
like O +
genes O +
reside O +
. O +

Amino O +
acid O +
sequence O +
comparison O +
shows O +
that O +
CHEMR1 O +
is O +
84 O +
% O +
identical O +
to O +
human O +
CCR-4 O +
, O +
indicating O +
that O +
CHEMR1 O +
is O +
likely O +
to O +
be O +
a O +
mouse O +
CCR-4 O +
. O +

Binding O +
assays O +
using O +
125I O -
- O -
labeled O +
C O -
- O -
C O +
chemokines O +
in O +
mammalian O +
cells O +
indicated O +
that O +
CHEMR1 O +
did O +
not O +
bind O +
MIP-1alpha O +
, O +
RANTES O +
, O +
or O +
MIP-1beta O +
, O +
whereas O +
CCR-1 O +
binds O +
MIP-1alpha O +
and O +
RANTES O +
. O +

Our O +
result O +
is O +
different O +
from O +
the O +
reported O +
properties O +
of O +
human O +
CCR-4 O +
. O +

This O +
suggests O +
that O +
CHEMR1 O +
may O +
be O +
a O +
receptor O +
for O +
unidentified O +
C O -
- O -
C O +
chemokine O +
or O +
a O +
low O -
- O -
affinity O +
receptor O +
for O +
MIP-1alpha O +
. O +

Biphasic O +
control O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
induced O +
by O +
the O +
triggering O +
of O +
HLA O -
- O -
DR O +
antigens O +
expressed O +
on O +
B O +
cells O +
. O +

The O +
regulation O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
following O +
the O +
triggering O +
of O +
HLA O -
- O -
DR O +
antigens O +
by O +
mAb O +
L243 O +
has O +
been O +
studied O +
at O +
various O +
times O +
in O +
Raji B-CellLine +
cells I-CellLine +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
demonstrated O +
a O +
strong O +
increase O +
of O +
NF O -
- O -
kappa O +
B O +
DNA O +
binding O +
after O +
triggering O +
of O +
HLA O -
- O -
DR O +
antigens O +
. O +

Using O +
TNF O -
- O -
alpha O -
- O -
activity O +
neutralizing O +
antibodies O +
, O +
the O +
authors O +
demonstrated O +
that O +
the O +
upregulation O +
of O +
NF O -
- O -
kappa O +
B O +
was O +
found O +
to O +
depend O +
, O +
at O +
later O +
time O +
point O +
, O +
on O +
an O +
autocrine O +
effect O +
of O +
TNF O -
- O -
alpha O +
secreted O +
following O +
triggering O +
of O +
HLA O -
- O -
DR O +
antigens O +
. O +

In O +
contrast O +
, O +
it O +
was O +
found O +
to O +
be O +
TNF O -
- O -
alpha O +
independent O +
in O +
the O +
early O +
time O +
point O +
. O +

Moreover O +
, O +
the O +
upregulation O +
of O +
NF O -
- O -
kappa O +
B O +
binding O +
activity O +
is O +
regulated O +
by O +
the O +
triggering O +
of O +
selected O +
epitopes O +
of O +
HLA O -
- O -
DR O +
antigens O +
. O +

In O +
fact O +
, O +
mAb O +
L243 O +
but O +
not O +
the O +
staphylococcal O +
superantigens O +
, O +
staphylococcal O +
exotoxin O +
toxic O +
shock O +
syndrome O +
toxin O -
- O -
I O +
or O +
staphylococcal O +
enterotoxin O +
B O +
, O +
regulate O +
the O +
NF O -
- O -
kappa O +
B O +
binding O +
activity O +
. O +

The O +
immediate O -
- O -
early O +
gene O +
product O +
Egr-1 O +
regulates O +
the O +
human O +
interleukin-2 O +
receptor O +
beta O -
- O -
chain O +
promoter O +
through O +
noncanonical O +
Egr O +
and O +
Sp1 O +
binding O +
sites O +
. O +

The O +
interleukin-2 O +
IL-2 O +
receptor O +
beta O -
- O -
chain O +
( O +
IL-2Rbeta O +
) O +
is O +
an O +
essential O +
component O +
of O +
the O +
receptors O +
for O +
IL-2 O +
and O +
IL-15 O +
. O +

Although O +
IL-2Rbeta O +
is O +
constitutively O +
expressed O +
by O +
lymphocytes O +
, O +
its O +
expression O +
can O +
be O +
further O +
induced O +
by O +
a O +
number O +
of O +
stimuli O +
, O +
including O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
. O +

We O +
have O +
now O +
characterized O +
factors O +
that O +
bind O +
to O +
an O +
enhancer O +
region O +
located O +
between O +
nucleotides O +
-170 O +
and O +
-139 O +
of O +
the O +
human O +
IL-2Rbeta O +
promoter O +
. O +

Both O +
Sp1 O +
and O +
Sp3 O +
bound O +
to O +
the O +
5 O +
' O +
portion O +
of O +
this O +
region O +
, O +
whereas O +
a O +
PMA O -
- O -
inducible O +
factor O +
( O +
PIF O +
) O +
mainly O +
bound O +
to O +
its O +
3 O +
' O +
portion O +
and O +
bound O +
to O +
the O +
Sp O +
binding O +
motifs O +
as O +
well O +
. O +

In O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
induction O +
of O +
PIF O +
DNA O +
binding O +
activity O +
was O +
rapidly O +
induced O +
, O +
required O +
de O +
novo O +
protein O +
synthesis O +
, O +
and O +
was O +
sustained O +
at O +
a O +
high O +
level O +
for O +
at O +
least O +
23 O +
h O +
. O +

Interestingly O +
, O +
PIF O +
was O +
constitutively O +
activated O +
in O +
human B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
leukemia I-CellLine +
virus I-CellLine +
type I-CellLine +
1-transformed I-CellLine +
MT-2 I-CellLine +
cells I-CellLine +
. O +

In O +
this O +
paper O +
, O +
we O +
demonstrate O +
that O +
PIF O +
is O +
Egr-1 O +
based O +
on O +
its O +
recognition O +
by O +
anti- O +
Egr-1 O +
antisera O +
in O +
gel O +
mobility O +
shift O +
assays O +
, O +
even O +
though O +
the O +
IL-2Rbeta O +
DNA O +
binding O +
motif O +
differed O +
substantially O +
from O +
the O +
canonical O +
Egr-1 O +
binding O +
site O +
. O +

In O +
addition O +
, O +
Egr-1 O +
bound O +
to O +
the O +
Sp O +
binding O +
site O +
. O +

In O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
both O +
sites O +
were O +
required O +
for O +
maximal O +
IL-2Rbeta O +
promoter O +
activity O +
, O +
and O +
in O +
HeLaS3 O +
cells O +
, O +
transfection O +
of O +
Egr-1 O +
could O +
drive O +
activity O +
of O +
a O +
reporter O +
construct O +
containing O +
both O +
sites O +
. O +

Moreover O +
, O +
Sp1 O +
and O +
Egr-1 O +
could O +
form O +
a O +
complex O +
with O +
kinetics O +
that O +
correlated O +
with O +
the O +
production O +
of O +
Egr-1 O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
upon O +
PMA O +
stimulation O +
. O +

Thus O +
, O +
Sp1 O +
and O +
Egr-1 O +
physically O +
and O +
functionally O +
cooperate O +
to O +
mediate O +
maximal O +
IL-2Rbeta O +
promoter O +
activity O +
. O +

Anti O -
- O -
Ehrlichia O +
chaffeensis O +
antibody O +
complexed O +
with O +
E. O +
chaffeensis O +
induces O +
potent O +
proinflammatory O +
cytokine O +
mRNA O +
expression O +
in O +
human O +
monocytes O +
through O +
sustained O +
reduction O +
of O +
IkappaB O -
- O -
alpha O +
and O +
activation O +
of O +
NF O -
- O -
kappaB O +
. O +

Ehrlichia O +
chaffeensis O +
is O +
an O +
obligatory O +
intracellular O +
bacterium O +
that O +
infects O +
monocytes O +
and O +
macrophages O +
and O +
is O +
the O +
etiologic O +
agent O +
of O +
human O +
ehrlichiosis O +
in O +
the O +
United O +
States O +
. O +

Our O +
previous O +
studies O +
showed O +
that O +
the O +
exposure O +
of O +
human O +
monocytes O +
to O +
E. O +
chaffeensis O +
induces O +
the O +
expression O +
of O +
interleukin-1beta O +
( O +
IL-1beta O +
) O +
, O +
IL-8 O +
, O +
and O +
IL-10 O +
genes O +
in O +
vitro O +
but O +
not O +
the O +
expression O +
of O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
and O +
IL-6 O +
mRNAs O +
. O +

In O +
this O +
study O +
, O +
the O +
effect O +
of O +
anti O -
- O -
E. O +
chaffeensis O +
antibody O +
complexed O +
with O +
E. O +
chaffeensis O +
on O +
the O +
expression O +
of O +
major O +
proinflammatory O +
cytokines O +
in O +
human O +
monocytes O +
was O +
examined O +
. O +

Human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
THP-1 I-CellLine +
was O +
treated O +
with O +
E. O +
chaffeensis O +
which O +
had O +
been O +
preincubated O +
with O +
human O +
anti O -
- O -
E. O +
chaffeensis O +
serum O +
for O +
2 O +
h O +
, O +
and O +
the O +
levels O +
of O +
cytokine O +
mRNAs O +
were O +
evaluated O +
by O +
competitive O +
reverse O +
transcription O -
- O -
PCR O +
. O +

Anti O -
- O -
E. O +
chaffeensis O +
antibody O +
complexed O +
with O +
E. O +
chaffeensis O +
significantly O +
enhanced O +
mRNA O +
expression O +
of O +
IL-1beta O +
in O +
THP-1 B-CellLine +
cells I-CellLine +
. O +

The O +
expression O +
of O +
TNF O -
- O -
alpha O +
and O +
IL-6 O +
mRNAs O +
was O +
also O +
induced O +
. O +

The O +
levels O +
of O +
secreted O +
IL-1beta O +
, O +
TNF O -
- O -
alpha O +
, O +
and O +
IL-6 O +
during O +
24 O +
h O +
of O +
stimulation O +
were O +
comparable O +
to O +
those O +
induced O +
by O +
Escherichia O +
coli O +
lipopolysaccharide O +
at O +
1 O +
microg O -
/ O -
ml O +
. O +

Fab O +
fragment O +
of O +
anti O -
- O -
E. O +
chaffeensis O +
immunoglobulin O +
G O +
complexed O +
with O +
E. O +
chaffeensis O +
did O +
not O +
induce O +
any O +
of O +
these O +
three O +
cytokines O +
, O +
indicating O +
that O +
ehrlichial O +
binding O +
is O +
required O +
for O +
IL-1beta O +
mRNA O +
expression O +
and O +
that O +
binding O +
of O +
the O +
immune O +
complex O +
to O +
the O +
Fc O +
gamma O +
receptor O +
is O +
required O +
for O +
TNF O -
- O -
alpha O +
and O +
IL-6 O +
mRNA O +
expression O +
and O +
enhanced O +
IL-1beta O +
mRNA O +
expression O +
. O +

Furthermore O +
, O +
prolonged O +
degradation O +
of O +
IkappaB O -
- O -
alpha O +
and O +
activation O +
of O +
NF O -
- O -
kappaB O +
were O +
demonstrated O +
in O +
THP-1 B-CellLine +
cells I-CellLine +
exposed O +
to O +
anti O -
- O -
E. O +
chaffeensis O +
serum O +
and O +
E. O +
chaffeensis O +
. O +

This O +
result O +
implies O +
that O +
development O +
of O +
anti O -
- O -
E. O +
chaffeensis O +
antibody O +
in O +
patients O +
can O +
result O +
in O +
the O +
production O +
of O +
major O +
proinflammatory O +
cytokines O +
, O +
which O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
pathophysiology O +
of O +
ehrlichiosis O +
and O +
immune O +
responses O +
to O +
it O +
. O +

S O -
- O -
allyl O +
cysteine O +
inhibits O +
activation O +
of O +
nuclear O +
factor O +
kappa O +
B O +
in O +
human O +
T O +
cells O +
. O +

Reactive O +
oxygen O +
species O +
are O +
involved O +
in O +
signal O +
transduction O +
pathways O +
leading O +
to O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
activation O +
which O +
has O +
been O +
implicated O +
in O +
the O +
regulation O +
of O +
gene O +
transcription O +
. O +

We O +
recently O +
reported O +
that O +
a O +
garlic O +
compound O +
, O +
S O -
- O -
allyl O +
cysteine O +
( O +
SAC O +
) O +
, O +
protects O +
bovine O +
pulmonary O +
artery O +
endothelial O +
cells O +
from O +
oxidant O +
injury O +
induced O +
by O +
hydrogen O +
peroxide O +
( O +
H2O2 O +
) O +
. O +

In O +
this O +
study O +
we O +
determined O +
the O +
effects O +
of O +
SAC O +
on O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
human O +
T O +
lymphocytes O +
( O +
Jurkat B-CellLine +
cells I-CellLine +
) O +
induced O +
by O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF- O +
alpha O +
) O +
and O +
H2O2 O +
. O +

Activated O +
NF O -
- O -
kappa O +
B O +
in O +
nuclear O +
extracts O +
was O +
measured O +
by O +
an O +
electrophoretic O +
mobility O +
shift O +
assay O +
using O +
32P O -
- O -
labeled O +
probe O +
. O +

SAC O +
consistently O +
exhibited O +
a O +
dose O -
- O -
dependent O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
induced O +
by O +
both O +
TNF O -
- O -
alpha O +
and O +
H2O2 O +
. O +

Supershift O +
with O +
specific O +
antibodies O +
to O +
NF O -
- O -
kappa O +
B O +
subunits O +
confirmed O +
that O +
the O +
inducible O +
retarded O +
bands O +
observed O +
in O +
the O +
EMSA O +
and O +
p65-p50 O +
heterodimer O +
of O +
the O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
protein O +
. O +

Our O +
data O +
suggest O +
that O +
SAC O +
may O +
act O +
via O +
antioxidant O +
mechanisms O +
to O +
block O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

Role O +
of O +
ascorbate O +
in O +
the O +
activation O +
of O +
NF O -
- O -
kappaB O +
by O +
tumour O +
necrosis O +
factor O -
- O -
alpha O +
in O +
T O -
- O -
cells O +
. O +

The O +
first O +
product O +
of O +
ascorbate O +
oxidation O +
, O +
the O +
ascorbate O +
free O +
radical O +
( O +
AFR O +
) O +
, O +
acts O +
in O +
biological O +
systems O +
mainly O +
as O +
an O +
oxidant O +
, O +
and O +
through O +
its O +
role O +
in O +
the O +
plasma O +
membrane O +
redox O +
system O +
exerts O +
different O +
effects O +
on O +
the O +
cell O +
. O +

We O +
have O +
investigated O +
the O +
role O +
of O +
ascorbate O +
, O +
AFR O +
and O +
dehydroascorbate O +
( O +
DHA O +
) O +
in O +
the O +
activation O +
of O +
the O +
NF O -
- O -
kappaB O +
transcription O +
factor O +
in O +
Jurkat B-CellLine +
T I-CellLine -
- I-CellLine -
cells I-CellLine +
stimulated O +
by O +
tumour O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
. O +

Here O +
we O +
show O +
, O +
by O +
electrophoretic O +
mobility O +
shift O +
assays O +
, O +
that O +
ascorbate O +
increases O +
the O +
binding O +
of O +
NF O -
- O -
kappaB O +
to O +
DNA O +
in O +
TNF B-CellLine -
- I-CellLine -
alpha I-CellLine -
- I-CellLine -
stimulated I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
. O +

The O +
ability O +
of O +
ascorbate O +
to O +
enhance O +
cytoplasmic O +
inhibitory O +
IkBalpha O +
protein O +
degradation O +
correlates O +
completely O +
with O +
its O +
capacity O +
to O +
induce O +
NF O -
- O -
kappaB O +
binding O +
to O +
DNA O +
and O +
to O +
potentiate O +
NF O -
- O -
kappaB O +
-mediated O +
transactivation O +
of O +
the O +
HIV-1 O +
long O +
terminal O +
repeat O +
promoter O +
in O +
TNF B-CellLine -
- I-CellLine -
alpha I-CellLine -
- I-CellLine -
stimulated I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
but O +
not O +
in O +
cells O +
stimulated O +
with O +
PMA O +
plus O +
ionomycin O +
. O +

AFR O +
behaves O +
like O +
ascorbate O +
, O +
while O +
DHA O +
and O +
ascorbate O +
phosphate O +
do O +
not O +
affect O +
TNF O -
- O -
alpha O +
-mediated O +
NF O -
- O -
kappaB O +
activation O +
. O +

These O +
results O +
provide O +
new O +
evidence O +
for O +
a O +
possible O +
relationship O +
between O +
the O +
activation O +
of O +
the O +
electron O -
- O -
transport O +
system O +
at O +
the O +
plasma O +
membrane O +
by O +
ascorbate O +
or O +
its O +
free O +
radical O +
and O +
redox O -
- O -
dependent O +
gene O +
transcription O +
in O +
T O -
- O -
cells O +
. O +

Chimeric O +
oncoprotein O +
E2a O -
- O -
Pbx1 O +
induces O +
apoptosis O +
of O +
hematopoietic O +
cells O +
by O +
a O +
p53 O +
-independent O +
mechanism O +
that O +
is O +
suppressed O +
by O +
Bcl-2 O +
. O +

The O +
chimeric O +
oncoprotein O +
E2a O -
- O -
Pbx1 O +
results O +
from O +
fusion O +
of O +
the O +
E2A O +
and O +
PBX1 O +
genes O +
following O +
t O +
( O +
1 O +
; O +
19 O +
) O +
chromosomal O +
translocations O +
in O +
B O +
cell O +
precursor O +
acute O +
leukemias O +
. O +

Experimentally O +
B O +
cell O +
progenitors O +
do O +
not O +
tolerate O +
constitutive O +
expression O +
of O +
E2a O -
- O -
Pbx1 O +
which O +
contrasts O +
with O +
transformation O +
of O +
several O +
other O +
cell O +
types O +
following O +
its O +
stable O +
expression O +
both O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

To O +
further O +
investigate O +
the O +
effects O +
of O +
E2a O -
- O -
Pbx1 O +
on O +
the O +
B O +
cell O +
progenitors O +
, O +
we O +
conditionally O +
expressed O +
E2a O -
- O -
Pbx1 O +
under O +
control O +
of O +
a O +
metal O +
response O +
element O +
in O +
hematopoietic B-CellLine +
precursor I-CellLine +
cell I-CellLine +
lines I-CellLine +
in O +
vitro O +
. O +

Inducible O +
expression O +
of O +
E2a O -
- O -
Pbx1 O +
resulted O +
in O +
cell O +
death O +
with O +
the O +
morphologic O +
and O +
molecular O +
features O +
of O +
apoptosis O +
. O +

A O +
structure O -
- O -
function O +
analysis O +
demonstrated O +
that O +
induction O +
of O +
apoptosis O +
was O +
not O +
a O +
dominant O -
- O -
negative O +
effect O +
of O +
the O +
E2a O +
moiety O +
but O +
, O +
rather O +
, O +
required O +
the O +
DNA O -
- O -
binding O +
homeodomain O +
of O +
Pbx1 O +
. O +

E2a- O +
Pbx1 O +
-induced O +
apoptosis O +
proceeded O +
through O +
a O +
BCL2 O +
-responsive O +
checkpoint O +
eventuating O +
in O +
PARP O +
inactivation O +
but O +
did O +
require O +
p53 O +
. O +

Constitutive O +
expression O +
of O +
E2a O -
- O -
Pbx1 O +
did O +
not O +
induce O +
apoptosis O +
or O +
continued O +
cycling O +
of O +
Rat-1 B-CellLine +
fibroblasts I-CellLine +
in O +
low O +
serum O +
conditions O +
. O +

These O +
studies O +
demonstrate O +
that O +
E2a O -
- O -
Pbx1 O +
initiates O +
programmed O +
cell O +
death O +
of O +
hematopoietic O +
precursers O +
by O +
a O +
mechanism O +
that O +
requires O +
its O +
chimeric O +
transcriptional O +
properties O +
, O +
but O +
, O +
unlike O +
other O +
nuclear O +
oncoproteins O +
, O +
is O +
independent O +
of O +
p53 O +
. O +

Sp O +
family O +
members O +
preferentially O +
interact O +
with O +
the O +
promoter O +
proximal O +
repeat O +
within O +
the O +
HTLV O -
- O -
I O +
enhancer O +
. O +

Human O +
T O +
cell O +
lymphotropic O +
virus O +
type O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
encodes O +
the O +
transactivator O +
protein O +
, O +
Tax O +
, O +
which O +
facilitates O +
viral O +
transcription O +
from O +
three O +
21 O +
bp O +
repeated O +
elements O +
within O +
the O +
U3 O +
region O +
of O +
the O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
. O +

Examination O +
of O +
the O +
basal O +
factors O +
interacting O +
with O +
the O +
21 O +
bp O +
repeat O +
elements O +
through O +
electrophoretic O +
mobility O +
shift O +
( O +
EMS O +
) O +
analyses O +
has O +
demonstrated O +
the O +
formation O +
of O +
DNA O -
- O -
protein O +
complexes O +
common O +
to O +
each O +
of O +
the O +
21 O +
bp O +
repeats O +
( O +
C1-C3 O +
) O +
as O +
well O +
as O +
three O +
DNA O -
- O -
protein O +
complexes O +
specific O +
to O +
the O +
promoter O +
proximal O +
( O +
pp O +
) O +
repeat O +
( O +
U1 O +
( O +
U1A O -
/ O -
U1B O +
) O +
and O +
U2 O +
; O +
1 O -
- O -
4 O +
) O +
. O +

These O +
studies O +
have O +
indicated O +
that O +
the O +
individual O +
repeats O +
are O +
not O +
identical O +
with O +
respect O +
to O +
the O +
cellular O +
factors O +
with O +
which O +
they O +
interact O +
. O +

EMS O +
analyses O +
utilizing O +
a O +
series O +
of O +
mutated O +
pp O +
repeat O +
elements O +
demonstrate O +
that O +
the O +
nucleotide O +
sequence O +
requirements O +
for O +
U1 O +
( O +
U1A O -
/ O -
U1B O +
) O +
and O +
U2 O +
formation O +
are O +
separable O +
from O +
those O +
required O +
for O +
C1-C3 O +
formation O +
. O +

Competition O +
EMS O +
analyses O +
utilizing O +
Sp1 O +
and O +
CREB O +
binding O +
site O +
oligonucleotides O +
demonstrate O +
that O +
Sp O +
family O +
members O +
are O +
critical O +
components O +
of O +
U1 O +
( O +
U1A O -
/ O -
U1B O +
) O +
and O +
U2 O +
and O +
that O +
ATF O -
/ O -
CREB O +
family O +
members O +
are O +
critical O +
components O +
of O +
C1-C3 O +
. O +

EMS O +
supershift O +
analyses O +
have O +
demonstrated O +
that O +
Sp1 O +
is O +
involved O +
in O +
U1A O +
formation O +
while O +
Sp3 O +
is O +
involved O +
in O +
U1B O +
and O +
U2 O +
formation O +
. O +

EMS O +
analyses O +
performed O +
with O +
nuclear O +
extracts O +
from O +
Tax B-CellLine -
- I-CellLine -
expressing I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
and O +
HTLV O -
- O -
I O -
- O -
transformed O +
peripheral O +
blood O +
mononuclear O +
cells O +
demonstrate O +
that O +
Tax O +
prevents O +
the O +
formation O +
of O +
U1 O +
( O +
U1A O -
/ O -
U1B O +
) O +
and O +
U2 O +
DNA O -
- O -
protein O +
complexes O +
. O +

Therefore O +
, O +
Tax O +
appears O +
to O +
inhibit O +
the O +
interaction O +
of O +
Sp O +
family O +
members O +
with O +
the O +
pp O +
repeat O +
. O +

Based O +
on O +
these O +
observations O +
, O +
it O +
is O +
possible O +
that O +
the O +
interaction O +
of O +
Sp O +
and O +
ATF O -
/ O -
CREB O +
family O +
members O +
with O +
the O +
pp O +
repeat O +
during O +
basal O +
and O +
Tax O +
-mediated O +
transcription O +
may O +
play O +
a O +
critical O +
role O +
in O +
viral O +
gene O +
expression O +
during O +
the O +
initial O +
stages O +
of O +
virus O +
infection O +
or O +
during O +
activation O +
of O +
a O +
latent O +
infection O +
. O +

An O +
acute O +
myeloid O +
leukemia O +
gene O +
, O +
AML1 O +
, O +
regulates O +
transcriptional O +
activation O +
and O +
hemopoietic O +
myeloid O +
cell O +
differentiation O +
antagonistically O +
by O +
two O +
alternative O +
spliced O +
forms O +
. O +

The O +
AML1 O +
gene O +
on O +
chromosome O +
21 O +
is O +
disrupted O +
in O +
the O +
( O +
8 O +
; O +
21 O +
) O +
( O +
q22 O +
; O +
q22 O +
) O +
and O +
( O +
3 O +
; O +
21 O +
) O +
( O +
q26 O +
; O +
q22 O +
) O +
translocations O +
associated O +
with O +
myelogenous O +
leukemias O +
and O +
encodes O +
a O +
DNA O -
- O -
binding O +
protein O +
. O +

From O +
AML1 O +
gene O +
, O +
two O +
representative O +
forms O +
of O +
proteins O +
, O +
AML1a O +
and O +
AML1b O +
, O +
are O +
produced O +
by O +
an O +
alternative O +
splicing O +
. O +

Both O +
forms O +
have O +
DNA O -
- O -
binding O +
domain O +
, O +
but O +
AML1a O +
lacks O +
a O +
putative O +
transcriptional O +
activation O +
domain O +
which O +
AML1b O +
has O +
. O +

Here O +
we O +
demonstrate O +
that O +
AML1a O +
, O +
which O +
solely O +
has O +
no O +
effects O +
as O +
a O +
transcriptional O +
regulator O +
, O +
dominantly O +
suppresses O +
transcriptional O +
activation O +
by O +
AML1b O +
, O +
and O +
that O +
AML1a O +
exhibits O +
the O +
higher O +
affinity O +
for O +
DNA O -
- O -
binding O +
than O +
AML1b O +
. O +

Furthermore O +
a O +
dominant O +
negative O +
form O +
of O +
AML1 O +
, O +
AML1a O +
, O +
totally O +
suppressed O +
granulocytic O +
differentiation O +
otherwise O +
induced O +
by O +
granulocyte O +
colony O -
- O -
stimulating O +
factor O +
when O +
AML1a O +
was O +
overexpressed O +
in O +
32Dc13 O +
murine O +
myeloid O +
cells O +
. O +

Such O +
differentiation O +
block O +
by O +
AML1a O +
was O +
canceled O +
by O +
the O +
concomitant O +
overexpression O +
of O +
AML1b O +
. O +

These O +
data O +
strongly O +
suggest O +
that O +
a O +
transcriptionally O +
active O +
form O +
of O +
AML1 O +
is O +
essential O +
for O +
the O +
myeloid O +
cell O +
differentiation O +
. O +

In O +
addition O +
, O +
we O +
observed O +
an O +
altered O +
expression O +
level O +
of O +
AML1 O +
along O +
with O +
the O +
myeloid O +
differentiation O +
in O +
several O +
hemopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

In O +
these O +
cases O +
, O +
at O +
least O +
, O +
the O +
AML1 O +
expression O +
level O +
is O +
a O +
potential O +
regulator O +
for O +
myeloid O +
cell O +
differentiation O +
. O +

Of O +
the O +
GATA O -
- O -
binding O +
proteins O +
, O +
only O +
GATA-4 O +
selectively O +
regulates O +
the O +
human O +
IL-5 O +
gene O +
promoter O +
in O +
IL-5 O +
producing O +
cells O +
which O +
express O +
multiple O +
GATA O -
- O -
binding O +
proteins O +
. O +

Interleukin-5 O +
( O +
IL-5 O +
) O +
is O +
produced O +
by O +
T O +
lymphocytes O +
and O +
known O +
to O +
support O +
B O +
cell O +
growth O +
and O +
eosinophilic O +
differentiation O +
of O +
the O +
progenitor O +
cells O +
. O +

Using O +
ATL-16 B-CellLine -
T I-CellLine +
cells I-CellLine +
which O +
express O +
IL-5 O +
mRNA O +
, O +
we O +
have O +
identified O +
a O +
region O +
, O +
within O +
the O +
human O +
IL-5 O +
gene O +
promoter O +
, O +
that O +
regulates O +
IL-5 O +
gene O +
transcription O +
. O +

This O +
cis O -
- O -
acting O +
sequence O +
contains O +
the O +
core O +
binding O +
motif O +
, O +
( O +
A O -
/ O -
T O +
) O +
GATA O +
( O +
A O -
/ O -
G O +
) O +
, O +
for O +
GATA O -
- O -
binding O +
family O +
proteins O +
and O +
thus O +
suggests O +
the O +
involvement O +
of O +
these O +
family O +
members O +
. O +

In O +
this O +
report O +
, O +
we O +
describe O +
the O +
cloning O +
of O +
human O +
GATA-4 O +
( O +
hGATA-4 O +
) O +
and O +
show O +
that O +
hGATA-4 O +
selectively O +
interacts O +
with O +
the O +
-70 O +
GATA O +
site O +
within O +
the O +
IL-5 O +
proximal O +
promoter O +
region O +
. O +

By O +
promoter O +
deletion O +
and O +
mutation O +
analyses O +
, O +
we O +
established O +
this O +
region O +
as O +
a O +
positive O +
regulatory O +
element O +
. O +

Cotransfection O +
experiments O +
revealed O +
that O +
both O +
hGATA-4 O +
and O +
PMA O -
/ O -
A23187 O +
stimulation O +
are O +
necessary O +
for O +
the O +
IL-5 O +
promoter O +
activation O +
. O +

The O +
requirement O +
of O +
another O +
regulatory O +
element O +
called O +
CLE0 O +
, O +
which O +
lies O +
downstream O +
of O +
the O +
-70 O +
GATA O +
site O +
, O +
was O +
also O +
demonstrated O +
. O +

ATL-16 B-CellLine -
T I-CellLine +
cells I-CellLine +
express O +
mRNA O +
of O +
three O +
GATA O -
- O -
binding O +
proteins O +
, O +
hGATA-2 O +
, O +
hGATA-3 O +
and O +
hGATA-4 O +
, O +
and O +
each O +
of O +
them O +
has O +
a O +
potential O +
to O +
bind O +
to O +
the O +
consensus O +
( O +
A O -
/ O -
T O +
) O +
GATA O +
( O +
G O -
/ O +
A O +
) O +
motif O +
. O +

However O +
, O +
using O +
ATL-16 O -
T O +
nuclear O +
extract O +
, O +
we O +
demonstrated O +
that O +
GATA-4 O +
is O +
the O +
only O +
GATA O -
- O -
binding O +
protein O +
that O +
forms O +
specific O +
DNA O -
- O -
protein O +
complex O +
with O +
the O +
-70 O +
GATA O +
site O +
. O +

The O +
electrophoretic O +
mobility O +
shift O +
assay O +
with O +
extracts O +
of O +
COS B-CellLine +
cells I-CellLine +
expressing O +
GATA O -
- O -
binding O +
proteins O +
showed O +
that O +
GATA-4 O +
has O +
the O +
highest O +
binding O +
affinity O +
to O +
the O +
-70 O +
GATA O +
site O +
among O +
the O +
three O +
GATA O -
- O -
binding O +
proteins O +
. O +

When O +
the O +
transactivation O +
ability O +
was O +
compared O +
among O +
the O +
three O +
, O +
GATA-4 O +
showed O +
the O +
highest O +
activity O +
. O +

These O +
results O +
demonstrate O +
the O +
selective O +
role O +
of O +
GATA-4 O +
in O +
the O +
transcriptional O +
regulation O +
of O +
the O +
IL-5 O +
gene O +
in O +
a O +
circumstance O +
where O +
multiple O +
members O +
of O +
the O +
GATA O -
- O -
binding O +
proteins O +
are O +
expressed O +
. O +

Increased O +
expression O +
of O +
Gs O +
( O +
alpha O +
) O +
enhances O +
activation O +
of O +
the O +
adenylyl O +
cyclase O +
signal O +
transduction O +
cascade O +
. O +

Expression O +
of O +
the O +
stimulatory O +
G O +
protein O +
, O +
G O +
( O +
S O +
) O +
alpha O +
, O +
can O +
vary O +
over O +
a O +
3-fold O +
range O +
in O +
human O +
tissues O +
and O +
in O +
rodent O +
central O +
nervous O +
system O +
. O +

In O +
fact O +
, O +
the O +
offspring O +
of O +
alcoholics O +
have O +
higher O +
levels O +
of O +
G O +
( O +
S O +
) O +
alpha O +
expression O +
in O +
certain O +
tissues O +
compared O +
with O +
the O +
offspring O +
of O +
nonalcoholics O +
. O +

The O +
aim O +
of O +
this O +
research O +
was O +
to O +
test O +
the O +
hypothesis O +
that O +
a O +
causal O +
relationship O +
exists O +
between O +
the O +
level O +
of O +
expression O +
of O +
G O +
( O +
S O +
) O +
alpha O +
and O +
induction O +
of O +
the O +
adenylyl O +
cyclase O +
( O +
AC O +
) O +
cascade O +
. O +

The O +
methodology O +
employed O +
transient O +
transfection O +
of O +
HEK B-CellLine +
293 I-CellLine +
cells I-CellLine +
with O +
a O +
cDNA O +
for O +
the O +
52-kDa O +
form O +
of O +
G O +
( O +
S O +
) O +
alpha O +
under O +
regulation O +
by O +
inducible O +
metallothionein O +
promoters O +
. O +

Transfectants O +
were O +
exposed O +
to O +
varying O +
concentrations O +
( O +
0 O -
- O -
125 O +
microM O +
) O +
of O +
zinc O +
sulfate O +
that O +
produced O +
a O +
3-fold O +
range O +
of O +
membrane O +
G O +
( O +
S O +
) O +
alpha O +
expression O +
. O +

The O +
range O +
of O +
G O +
( O +
S O +
) O +
alpha O +
expression O +
produced O +
was O +
found O +
to O +
mimic O +
a O +
physiologically O +
relevant O +
spectrum O +
of O +
G O +
( O +
S O +
) O +
alpha O +
expression O +
in O +
membranes O +
derived O +
from O +
human O +
tissues O +
and O +
rat O +
brain O +
. O +

It O +
was O +
observed O +
that O +
induction O +
of O +
G O +
( O +
S O +
) O +
alpha O +
expression O +
increased O +
constitutive O +
as O +
well O +
as O +
stimulated O +
cAMP O +
accumulation O +
. O +

Moreover O +
, O +
induction O +
of O +
G O +
( O +
S O +
) O +
alpha O +
expression O +
increased O +
events O +
distal O +
to O +
the O +
accumulation O +
of O +
cAMP O +
including O +
the O +
phosphorylation O +
of O +
the O +
transcription O +
factor O +
, O +
cAMP O +
response O +
element O +
binding O +
protein O +
and O +
transcriptional O +
activation O +
of O +
cAMP O -
- O -
dependent O +
reporter O +
genes O +
. O +

In O +
summary O +
, O +
these O +
studies O +
show O +
that O +
the O +
amount O +
of O +
G O +
( O +
S O +
) O +
alpha O +
expression O +
has O +
a O +
marked O +
impact O +
on O +
the O +
level O +
of O +
activity O +
of O +
the O +
AC O +
cascade O +
from O +
the O +
membrane O +
through O +
to O +
the O +
nucleus O +
. O +

It O +
is O +
hypothesized O +
that O +
individuals O +
who O +
differ O +
in O +
G O +
( O +
S O +
) O +
alpha O +
expression O +
may O +
also O +
differ O +
in O +
the O +
expression O +
of O +
certain O +
cAMP O -
- O -
dependent O +
genes O +
. O +

gamma O -
- O -
Interferon O +
-induced O +
resistance O +
to O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2 O +
D3 O +
in O +
human O +
monocytes O +
and O +
macrophages O +
: O +
a O +
mechanism O +
for O +
the O +
hypercalcemia O +
of O +
various O +
granulomatoses O +
. O +

The O +
hypercalcemia O +
of O +
various O +
granulomatoses O +
is O +
caused O +
by O +
endogenous O +
1 O +
, O +
25-dihydroxyvitamin O +
D O +
[ O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
] O +
overproduction O +
by O +
disease O -
- O -
activated O +
macrophages O +
. O +

The O +
inability O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
to O +
suppress O +
its O +
synthesis O +
in O +
macrophages O +
contrasts O +
with O +
the O +
tight O +
control O +
of O +
its O +
production O +
in O +
macrophage O +
precursors O +
, O +
peripheral O +
blood O +
monocytes O +
( O +
PBM O +
) O +
. O +

We O +
examined O +
whether O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
resistance O +
develops O +
as O +
PBM O +
differentiate O +
to O +
macrophages O +
or O +
with O +
macrophage O +
activation O +
. O +

Normal O +
human O +
pulmonary O +
alveolar O +
macrophages O +
( O +
PAM O +
) O +
are O +
less O +
sensitive O +
to O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
than O +
PBM O +
, O +
despite O +
similar O +
vitamin O +
D O +
receptor O +
content O +
; O +
however O +
, O +
both O +
PBM O +
and O +
PAM O +
respond O +
to O +
exogenous O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
by O +
inhibiting O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
synthesis O +
and O +
inducing O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
degradation O +
through O +
enhancement O +
of O +
24-hydroxylase O +
mRNA O +
levels O +
and O +
activity O +
. O +

The O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
THP-1 B-CellLine +
mimics O +
PAM O +
in O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
synthesis O +
and O +
sensitivity O +
to O +
exogenous O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
. O +

We O +
utilized O +
THP-1 B-CellLine +
cells I-CellLine +
to O +
examine O +
the O +
response O +
to O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
with O +
macrophage O +
activation O +
. O +

Activation O +
of O +
THP-1 B-CellLine +
cells I-CellLine +
with O +
gamma O -
- O -
interferon O +
( O +
gamma O -
- O -
IFN O +
) O +
enhances O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
synthesis O +
30-fold O +
, O +
blocks O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
suppression O +
of O +
its O +
synthesis O +
, O +
and O +
reduces O +
by O +
42.2 O +
% O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
induction O +
of O +
its O +
degradation O +
. O +

The O +
antagonistic O +
effects O +
of O +
gamma O -
- O -
IFN O +
are O +
not O +
merely O +
restricted O +
to O +
enzymatic O +
activities O +
. O +

In O +
THP-1 B-CellLine +
cells I-CellLine +
and O +
in O +
normal O +
PBM O +
, O +
gamma O -
- O -
IFN O +
inhibits O +
1 O +
, O +
25- O +
( O +
OH O +
) O +
2D3 O +
induction O +
of O +
24-hydroxylase O +
mRNA O +
levels O +
without O +
reducing O +
mRNA O +
stability O +
, O +
suggesting O +
gamma O -
- O -
IFN O +
inhibition O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
transactivating O +
function O +
. O +

These O +
results O +
explain O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
overproduction O +
in O +
granulomatoses O +
and O +
demonstrate O +
potent O +
inhibition O +
by O +
gamma O -
- O -
IFN O +
of O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
action O +
in O +
immune O +
cells O +
. O +

Glucocorticoid O +
receptors O +
in O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
in O +
relation O +
to O +
age O +
and O +
to O +
sport O +
activity O +
. O +

Glucocorticoid O +
receptors O +
( O +
GR O +
) O +
are O +
ubiquitous O +
molecules O +
and O +
are O +
present O +
also O +
in O +
the O +
hippocampus O +
and O +
in O +
several O +
other O +
nervous O +
and O +
immune O +
tissues O +
. O +

Peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMCs O +
) O +
are O +
a O +
good O +
model O +
for O +
studies O +
of O +
GR O +
in O +
humans O +
. O +

Glucocorticoids O +
are O +
important O +
for O +
maintaining O +
cellular O +
and O +
humoral O +
homeostasis O +
and O +
are O +
key O +
mediators O +
of O +
neuroendocrine O -
- O -
immune O +
regulatory O +
interactions O +
. O +

The O +
increase O +
of O +
cortisol O +
is O +
immunosuppressive O +
and O +
reduces O +
GR O +
concentration O +
both O +
in O +
nervous O +
and O +
immune O +
systems O +
. O +

Variation O +
of O +
glucocorticoids O +
in O +
healthy O +
aged O +
subjects O +
and O +
athletes O +
has O +
been O +
shown O +
. O +

Prompted O +
by O +
these O +
results O +
, O +
we O +
have O +
investigated O +
in O +
man O +
a O +
possible O +
relationship O +
between O +
GR O +
binding O +
capacity O +
in O +
the O +
PBMCs O +
and O +
age O +
, O +
in O +
relation O +
also O +
to O +
plasma O +
testosterone O +
and O +
cortisol O +
. O +

The O +
same O +
parameters O +
have O +
been O +
examined O +
in O +
a O +
group O +
of O +
soccer O +
players O +
for O +
comparison O +
with O +
the O +
sedentary O +
group O +
. O +

GR O +
binding O +
capacity O +
was O +
higher O +
in O +
younger O +
subjects O +
than O +
in O +
older O +
ones O +
, O +
and O +
lower O +
in O +
the O +
group O +
of O +
athletes O +
than O +
in O +
the O +
younger O +
and O +
older O +
sedentary O +
subjects O +
. O +

In O +
the O +
sedentary O +
group O +
a O +
negative O +
correlation O +
was O +
present O +
between O +
GR O +
binding O +
capacity O +
and O +
age O +
. O +

Plasma O +
cortisol O +
was O +
higher O +
and O +
testosterone O +
lower O +
in O +
the O +
athletes O +
; O +
they O +
were O +
negatively O +
correlated O +
in O +
athletes O +
and O +
positively O +
correlated O +
in O +
the O +
sedentary O +
subjects O +
. O +

The O +
results O +
for O +
athletes O +
agree O +
with O +
their O +
lower O +
anabolic O -
/ O -
catabolic O +
balance O +
. O +

The O +
mechanism O +
of O +
reduced O +
GR O +
levels O +
in O +
relation O +
to O +
age O +
and O +
sport O +
activity O +
could O +
involve O +
a O +
loss O +
or O +
an O +
involution O +
of O +
receptor O +
synthesis O +
. O +

However O +
other O +
possibilities O +
, O +
such O +
as O +
altered O +
distribution O +
of O +
lymphocyte O +
subpopulations O +
with O +
different O +
receptor O +
concentrations O +
and O +
with O +
different O +
cytokine O +
production O +
, O +
can O +
not O +
be O +
excluded O +
. O +

Several O +
neuroendocrine O -
- O -
immune O +
interactions O +
could O +
be O +
responsible O +
for O +
reduced O +
GR O +
levels O +
with O +
age O +
and O +
sport O +
activity O +
in O +
man O +
. O +

Rescue O +
by O +
cytokines O +
of O +
apoptotic O +
cell O +
death O +
induced O +
by O +
IL-2 O +
deprivation O +
of O +
human B-CellLine +
antigen I-CellLine -
- I-CellLine -
specific I-CellLine +
T I-CellLine +
cell I-CellLine +
clones I-CellLine +
. O +

The O +
control O +
of O +
cell O +
survival O +
and O +
cell O +
death O +
is O +
of O +
central O +
importance O +
in O +
tissues O +
with O +
high O +
cell O +
turnover O +
such O +
as O +
the O +
lymphoid O +
system O +
. O +

We O +
have O +
examined O +
the O +
effect O +
of O +
cytokines O +
on O +
IL-2 O +
deprivation O -
- O -
induced O +
apoptosis O +
of O +
human B-CellLine +
antigen I-CellLine -
- I-CellLine -
specific I-CellLine +
T I-CellLine +
helper I-CellLine +
clones I-CellLine +
with O +
different O +
cytokine O +
production O +
profiles O +
. O +

We O +
found O +
that O +
IL-2 O +
, O +
interferon O -
- O -
alpha O +
( O +
IFN O -
- O -
alpha O +
) O +
, O +
and O +
IFN O -
- O -
beta O +
inhibited O +
IL-2 O +
deprivation O +
apoptosis O +
in O +
Th0 B-CellLine +
, I-CellLine +
Th1 I-CellLine +
, I-CellLine +
and I-CellLine +
Th2 I-CellLine +
clones I-CellLine +
. O +

We O +
also O +
found O +
that O +
IL-2 O +
protects O +
T B-CellLine +
cell I-CellLine +
clones I-CellLine +
from O +
IL-2 O +
deprivation O +
apoptosis O +
accompanying O +
active O +
proliferation O +
and O +
enhanced O +
expression O +
of O +
P53 O +
, O +
Rb O +
and O +
Bcl O -
- O -
xL O +
proteins O +
. O +

In O +
contrast O +
, O +
IFN O -
- O -
alpha O -
/ O -
beta O +
rescued O +
T B-CellLine +
cell I-CellLine +
clones I-CellLine +
from O +
apoptosis O +
without O +
active O +
proliferation O +
, O +
and O +
expression O +
of O +
apoptosis O -
- O -
associated O +
proteins O +
tested O +
so O +
far O +
was O +
unaffected O +
. O +

This O +
may O +
be O +
due O +
to O +
the O +
fact O +
that O +
T O +
cells O +
treated O +
with O +
IL-2 O +
contained O +
those O +
located O +
in O +
S O +
+ O +
G2 O -
/ O -
M O +
phases O +
of O +
the O +
cell O +
cycle O +
, O +
whereas O +
the O +
vast O +
majority O +
of O +
T O +
cells O +
treated O +
with O +
IFN O -
- O -
alpha O -
/ O -
beta O +
were O +
located O +
in O +
G0 O -
/ O -
G1 O +
phase O +
. O +

IFN O -
- O -
alpha O -
/ O -
beta O +
specifically O +
induced O +
tyrosine O +
phosphorylation O +
and O +
translocation O +
into O +
nucleus O +
of O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
STAT O +
) O +
2 O +
protein O +
in O +
the O +
T B-CellLine +
cell I-CellLine +
clones I-CellLine +
. O +

In O +
addition O +
, O +
over O -
- O -
expression O +
of O +
STAT2 O +
by O +
transfection O +
of O +
the O +
cDNA O +
prevented O +
apoptosis O +
of O +
the O +
T B-CellLine +
cell I-CellLine +
clones I-CellLine +
. O +

Our O +
present O +
study O +
shows O +
that O +
IFN O -
- O -
alpha O +
and O +
-beta O +
mediate O +
anti O -
- O -
apoptotic O +
effect O +
through O +
other O +
pathways O +
than O +
that O +
of O +
IL-2 O +
in O +
growth O +
factor O +
deprivation O +
apoptosis O +
. O +

The O +
cytoplasmic O +
domain O +
of O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
receptor O +
alpha O +
subunit O +
is O +
essential O +
for O +
both O +
GM O -
- O -
CSF O +
-mediated O +
growth O +
and O +
differentiation O +
. O +

Granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
GM O -
- O -
CSF O +
) O +
regulates O +
differentiation O +
, O +
survival O +
, O +
and O +
proliferation O +
of O +
colony B-CellLine -
- I-CellLine -
forming I-CellLine +
unit I-CellLine -
- I-CellLine -
granulocyte I-CellLine -
- I-CellLine -
macrophage I-CellLine +
progenitor I-CellLine +
cells I-CellLine +
. O +

The O +
biologic O +
actions O +
of O +
GM O -
- O -
CSF O +
are O +
mediated O +
by O +
binding O +
to O +
a O +
specific O +
receptor O +
consisting O +
of O +
two O +
chains O +
designated O +
as O +
alpha O +
and O +
beta O +
subunits O +
. O +

We O +
have O +
demonstrated O +
that O +
the O +
murine B-CellLine +
FDC I-CellLine -
- I-CellLine -
P1-derived I-CellLine +
cell I-CellLine +
line I-CellLine +
WT-19 B-CellLine +
transfected O +
with O +
the O +
human O +
GM O -
- O -
CSF O +
receptor O +
alpha O +
and O +
beta O +
subunits O +
( O +
GM O -
- O -
CSFRalpha O +
and O +
beta O +
) O +
can O +
be O +
induced O +
to O +
differentiate O +
by O +
the O +
addition O +
of O +
human O +
GM O -
- O -
CSF O +
( O +
hGM O -
- O -
CSF O +
) O +
. O +

By O +
expressing O +
a O +
series O +
of O +
GM O -
- O -
CSFRalpha O +
mutants O +
in O +
WT19 B-CellLine +
cells I-CellLine +
, O +
we O +
have O +
determined O +
the O +
amino O +
acid O +
domains O +
of O +
the O +
GM O -
- O -
CSFRalpha O +
cytoplasmic O +
domain O +
that O +
regulate O +
cell O +
differentiation O +
, O +
proliferation O +
, O +
and O +
survival O +
. O +

We O +
found O +
that O +
the O +
membrane O +
proximal O +
proline O -
- O -
rich O +
domain O +
and O +
adjacent O +
16 O +
residues O +
are O +
essential O +
for O +
both O +
hGM O -
- O -
CSF O +
-dependent O +
cell O +
proliferation O +
and O +
differentiation O +
. O +

In O +
contrast O +
, O +
the O +
C O -
- O -
terminal O +
region O +
of O +
the O +
GM O -
- O -
CSFRalpha O +
cytoplasmic O +
domain O +
was O +
not O +
necessary O +
for O +
cell O +
differentiation O +
mediated O +
by O +
hGM O -
- O -
CSF O +
, O +
but O +
the O +
removal O +
of O +
this O +
region O +
severely O +
impaired O +
the O +
ability O +
of O +
hGM O -
- O -
CSF O +
to O +
support O +
cell O +
survival O +
. O +

While O +
the O +
activation O +
of O +
JAK2 O +
, O +
Shc O +
, O +
Erk O +
, O +
and O +
STAT5 O +
proteins O +
correlated O +
with O +
hGM O -
- O -
CSF O +
-mediated O +
cell O +
growth O +
, O +
cellular O +
differentiation O +
occurred O +
in O +
the O +
absence O +
of O +
activation O +
of O +
these O +
signal O +
transduction O +
pathways O +
. O +

Lipopolysaccharide O +
induction O +
of O +
the O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
promoter O +
in O +
human O +
monocytic O +
cells O +
. O +

Regulation O +
by O +
Egr-1 O +
, O +
c O -
- O -
Jun O +
, O +
and O +
NF O -
- O -
kappaB O +
transcription O +
factors O +
. O +

Biosynthesis O +
of O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
is O +
predominantly O +
by O +
cells O +
of O +
the O +
monocytic O +
lineage O +
. O +

This O +
study O +
examined O +
the O +
role O +
of O +
various O +
cis O -
- O -
acting O +
regulatory O +
elements O +
in O +
the O +
lipopolysaccharide O +
( O +
LPS O +
) O +
induction O +
of O +
the O +
human O +
TNF O -
- O -
alpha O +
promoter O +
in O +
cells O +
of O +
monocytic O +
lineage O +
. O +

Functional O +
analysis O +
of O +
monocytic B-CellLine +
THP-1 I-CellLine +
cells I-CellLine +
transfected O +
with O +
plasmids O +
containing O +
various O +
lengths O +
of O +
TNF O -
- O -
alpha O +
promoter O +
localized O +
enhancer O +
elements O +
in O +
a O +
region O +
( O +
-182 O +
to O +
-37 O +
base O +
pairs O +
( O +
bp O +
) O +
) O +
that O +
were O +
required O +
for O +
optimal O +
transcription O +
of O +
the O +
TNF O -
- O -
alpha O +
gene O +
in O +
response O +
to O +
LPS O +
. O +

Two O +
regions O +
were O +
identified O +
: O +
region O +
I O +
( O +
-182 O +
to O +
-162 O +
bp O +
) O +
contained O +
an O +
overlapping O +
Sp1 O -
/ O -
Egr-1 O +
site O +
, O +
and O +
region O +
II O +
( O +
-119 O +
to O +
-88 O +
) O +
contained O +
CRE O +
and O +
NF O -
- O -
kappaB O +
( O +
designated O +
kappaB3 O +
) O +
sites O +
. O +

In O +
unstimulated O +
THP-1 B-CellLine +
, O +
CRE O -
- O -
binding O +
protein O +
and O +
, O +
to O +
a O +
lesser O +
extent O +
, O +
c O -
- O -
Jun O +
complexes O +
were O +
found O +
to O +
bind O +
to O +
the O +
CRE O +
site O +
. O +

LPS O +
stimulation O +
increased O +
the O +
binding O +
of O +
c O -
- O -
Jun O -
- O -
containing O +
complexes O +
. O +

In O +
addition O +
, O +
LPS O +
stimulation O +
induced O +
the O +
binding O +
of O +
cognate O +
nuclear O +
factors O +
to O +
the O +
Egr-1 O +
and O +
kappaB3 O +
sites O +
, O +
which O +
were O +
identified O +
as O +
Egr-1 O +
and O +
p50 O -
/ O -
p65 O +
, O +
respectively O +
. O +

The O +
CRE O +
and O +
kappaB3 O +
sites O +
in O +
region O +
II O +
together O +
conferred O +
strong O +
LPS O +
responsiveness O +
to O +
a O +
heterologous O +
promoter O +
, O +
whereas O +
individually O +
they O +
failed O +
to O +
provide O +
transcriptional O +
activation O +
. O +

Furthermore O +
, O +
increasing O +
the O +
spacing O +
between O +
the O +
CRE O +
and O +
the O +
kappaB3 O +
sites O +
completely O +
abolished O +
LPS O +
induction O +
, O +
suggesting O +
a O +
cooperative O +
interaction O +
between O +
c O -
- O -
Jun O +
complexes O +
and O +
p50 O -
/ O -
p65 O +
. O +

These O +
studies O +
indicate O +
that O +
maximal O +
LPS O +
induction O +
of O +
the O +
TNF O -
- O -
alpha O +
promoter O +
is O +
mediated O +
by O +
concerted O +
participation O +
of O +
at O +
least O +
two O +
separate O +
cis O -
- O -
acting O +
regulatory O +
elements O +
. O +

Inducible O +
expression O +
and O +
phosphorylation O +
of O +
coactivator O +
BOB.1 O -
/ O -
OBF.1 O +
in O +
T O +
cells O +
[ O +
see O +
comments O +
] O +

BOB.1 O -
/ O -
OBF.1 O +
is O +
a O +
transcriptional O +
coactivator O +
that O +
is O +
constitutively O +
expressed O +
in O +
B O +
cells O +
and O +
interacts O +
with O +
the O +
Oct1 O +
and O +
Oct2 O +
transcription O +
factors O +
. O +

Upon O +
activation O +
of O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
and O +
primary O +
murine O +
thymocytes O +
with O +
phorbol O +
esters O +
and O +
ionomycin O +
, O +
BOB.1 O -
/ O -
OBF.1 O +
expression O +
and O +
transactivation O +
function O +
were O +
induced O +
. O +

BOB.1 O -
/ O -
OBF.1 O +
was O +
phosphorylated O +
at O +
Ser184 O +
both O +
in O +
vivo O +
and O +
in O +
vitro O +
, O +
and O +
this O +
modification O +
was O +
required O +
for O +
inducible O +
activation O +
. O +

Mutation O +
of O +
Ser184 O +
also O +
diminished O +
transactivation O +
function O +
in O +
B O +
cells O +
, O +
suggesting O +
that O +
the O +
activating O +
phosphorylation O +
that O +
is O +
inducible O +
in O +
T O +
cells O +
is O +
constitutively O +
present O +
in O +
B O +
cells O +
. O +

Thus O +
, O +
BOB.1 O -
/ O -
OBF.1 O +
is O +
a O +
transcriptional O +
coactivator O +
that O +
is O +
critically O +
regulated O +
by O +
posttranslational O +
modifications O +
to O +
mediate O +
cell O +
type O -
- O -
specific O +
gene O +
expression O +
. O +

Association O +
between O +
expression O +
of O +
intercellular O +
adhesion O +
molecule-1 O +
and O +
integration O +
of O +
human O +
T O -
- O -
cell O -
- O -
leukemia O +
virus O +
type O +
1 O +
in O +
adult O +
T O -
- O -
cell O +
leukemia O +
cells O +
. O +

It O +
is O +
known O +
that O +
the O +
expression O +
levels O +
of O +
intercellular O +
adhesion O +
molecule-1 O +
( O +
ICAM-1 O +
) O +
in O +
adult O +
T O +
cell O +
leukemia O +
( O +
ATL O +
) O +
cells O +
are O +
high O +
, O +
whereas O +
those O +
in O +
T O -
- O -
lymphoid O +
cells O +
are O +
not O +
. O +

In O +
order O +
to O +
investigate O +
the O +
factors O +
that O +
influence O +
the O +
induction O +
of O +
ICAM-1 O +
molecules O +
, O +
Northern O +
blot O +
analysis O +
to O +
measure O +
the O +
expression O +
level O +
of O +
ICAM-1 O +
mRNAs O +
and O +
Southern O +
blot O +
hybridization O +
to O +
analyze O +
the O +
integration O +
of O +
human O +
T O -
- O -
cell O -
- O -
leukemia O +
virus O +
type O +
1 O +
( O +
HTLV-1 O +
) O +
provirus O +
were O +
done O +
. O +

The O +
levels O +
of O +
ICAM-1 O +
mRNA O +
expression O +
of O +
ATL B-CellLine +
cells I-CellLine +
were O +
generally O +
higher O +
than O +
those O +
of O +
T O -
- O -
lymphoid O +
cells O +
. O +

However O +
, O +
ILT B-CellLine -
- I-CellLine -
mat I-CellLine +
cells I-CellLine +
and O +
ATL16 B-CellLine -
T I-CellLine +
( I-CellLine +
- I-CellLine +
) I-CellLine +
cells I-CellLine +
, O +
although O +
they O +
were O +
ATL B-CellLine +
cells I-CellLine +
, O +
showed O +
rather O +
low O +
surface O +
ICAM-1 O +
expression O +
and O +
ICAM-1 O +
mRNA O +
expression O +
. O +

Southern O +
blot O +
hybridization O +
showed O +
that O +
only O +
two O +
and O +
four O +
bands O +
were O +
found O +
in O +
ILT B-CellLine -
- I-CellLine -
mat I-CellLine +
and O +
ATL16 B-CellLine -
T I-CellLine +
( I-CellLine +
- I-CellLine +
) I-CellLine +
cells I-CellLine +
, O +
respectively O +
, O +
whereas O +
> O +
10 O +
bands O +
were O +
detected O +
in O +
other O +
ATL B-CellLine +
cells I-CellLine +
. O +

These O +
results O +
suggest O +
that O +
monoclonal O +
integration O +
of O +
HTLV-1 O +
provirus O +
to O +
the O +
genome O +
of O +
T O +
cell O +
, O +
especially O +
the O +
number O +
of O +
integration O +
sites O +
, O +
is O +
one O +
of O +
the O +
factors O +
for O +
induction O +
of O +
ICAM-1 O +
molecules O +
. O +

Role O +
of O +
the O +
X2 O +
box O +
in O +
activated O +
transcription O +
from O +
the O +
DRA O +
promoter O +
in O +
B O +
cells O +
. O +

We O +
investigated O +
the O +
function O +
of O +
the O +
evolutionary O +
conserved O +
X2 O +
box O +
in O +
the O +
promoter O +
of O +
the O +
HLA O -
- O -
DRA O +
gene O +
from O +
the O +
human O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
in O +
resting O +
and O +
activated O +
B O +
cells O +
. O +

NF O -
- O -
X2 O +
, O +
which O +
contains O +
members O +
of O +
the O +
AP-1 O -
/ O -
ATF O -
/ O -
CREB O +
families O +
of O +
transcription O +
factors O +
, O +
interacts O +
with O +
the O +
X2 O +
box O +
( O +
5'-TGCGTCA-3 O +
' O +
) O +
from O +
positions O +
-97 O +
to O +
-91 O +
in O +
the O +
DRA O +
promoter O +
. O +

In O +
resting O +
Raji B-CellLine +
cells I-CellLine +
, O +
little O +
to O +
no O +
binding O +
to O +
the O +
X2 O +
box O +
was O +
observed O +
. O +

In O +
sharp O +
contrast O +
, O +
in O +
B O +
cells O +
treated O +
with O +
the O +
phorbol O +
ester O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
, O +
strong O +
interactions O +
between O +
the O +
X2 O +
box O +
and O +
NF O -
- O -
X2 O +
containing O +
c O -
- O -
Fos O +
were O +
observed O +
. O +

As O +
determined O +
by O +
transient O +
expression O +
and O +
RNA O +
analyses O +
, O +
the O +
activation O +
of O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
also O +
increased O +
rates O +
of O +
transcription O +
from O +
the O +
wild O -
- O -
type O +
DRA O +
promoter O +
but O +
not O +
from O +
a O +
DRA O +
promoter O +
bearing O +
clustered O +
point O +
mutations O +
in O +
the O +
X2 O +
box O +
. O +

Since O +
the O +
co O -
- O -
expression O +
with O +
a O +
dominant O +
negative O +
c O -
- O -
Fos O +
abolished O +
the O +
responsiveness O +
to O +
TPA O +
, O +
we O +
conclude O +
that O +
activated O +
transcription O +
of O +
the O +
DRA O +
gene O +
depends O +
on O +
interactions O +
between O +
the O +
X2 O +
box O +
and O +
NF O -
- O -
X2 O +
, O +
which O +
contains O +
c O -
- O -
Fos O +
. O +

Transcription O +
factor O +
binding O +
sites O +
downstream O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
transcription O +
start O +
site O +
are O +
important O +
for O +
virus O +
infectivity O +
. O +

When O +
transcriptionally O +
active O +
, O +
the O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
promoter O +
contains O +
a O +
nucleosome O -
- O -
free O +
region O +
encompassing O +
both O +
the O +
promoter O -
/ O -
enhancer O +
region O +
and O +
a O +
large O +
region O +
( O +
255 O +
nucleotides O +
[ O +
nt O +
] O +
) O +
downstream O +
of O +
the O +
transcription O +
start O +
site O +
. O +

We O +
have O +
previously O +
identified O +
new O +
binding O +
sites O +
for O +
transcription O +
factors O +
downstream O +
of O +
the O +
transcription O +
start O +
site O +
( O +
nt O +
465 O +
to O +
720 O +
) O +
: O +
three O +
AP-1 O +
sites O +
( O +
I O +
, O +
II O +
, O +
and O +
III O +
) O +
, O +
an O +
AP3-like O +
motif O +
( O +
AP3-L O +
) O +
, O +
a O +
downstream O +
binding O +
factor O +
( O +
DBF O +
) O +
site O +
, O +
and O +
juxtaposed O +
Sp1 O +
sites O +
. O +

Here O +
, O +
we O +
show O +
that O +
the O +
DBF O +
site O +
is O +
an O +
interferon O -
- O -
responsive O +
factor O +
( O +
IRF O +
) O +
binding O +
site O +
and O +
that O +
the O +
AP3-L O +
motif O +
binds O +
the O +
T O -
- O -
cell O -
- O -
specific O +
factor O +
NF O -
- O -
AT O +
. O +

Mutations O +
that O +
abolish O +
the O +
binding O +
of O +
each O +
factor O +
to O +
its O +
cognate O +
site O +
are O +
introduced O +
in O +
an O +
infectious O +
HIV-1 O +
molecular O +
clone O +
to O +
study O +
their O +
effect O +
on O +
HIV-1 O +
transcription O +
and O +
replication O +
. O +

Individual O +
mutation O +
of O +
the O +
DBF O +
or O +
AP3-L O +
site O +
as O +
well O +
as O +
the O +
double O +
mutation O +
AP-1 O +
( O +
III O +
) O +
/AP3-L O +
did O +
not O +
affect O +
HIV-1 O +
replication O +
compared O +
to O +
that O +
of O +
the O +
wild O -
- O -
type O +
virus O +
. O +

In O +
contrast O +
, O +
proviruses O +
carrying O +
mutations O +
in O +
the O +
Sp1 O +
sites O +
were O +
totally O +
defective O +
in O +
terms O +
of O +
replication O +
. O +

Virus O +
production O +
occurred O +
with O +
slightly O +
delayed O +
kinetics O +
for O +
viruses O +
containing O +
combined O +
mutations O +
in O +
the O +
AP-1 O +
( O +
III O +
) O +
, O +
AP3-L O +
, O +
and O +
DBF O +
sites O +
and O +
in O +
the O +
AP3-L O +
and O +
DBF O -
- O -
sites O +
, O +
whereas O +
viruses O +
mutated O +
in O +
the O +
AP-1 O +
( O +
I O +
, O +
II O +
, O +
III O +
) O +
and O +
AP3-L O +
sites O +
and O +
in O +
the O +
AP-1 O +
( O +
I O +
, O +
II O +
, O +
III O +
) O +
, O +
AP3-L O +
, O +
and O +
DBF O +
sites O +
exhibited O +
a O +
severely O +
defective O +
replicative O +
phenotype O +
. O +

No O +
RNA O -
- O -
packaging O +
defect O +
could O +
be O +
measured O +
for O +
any O +
of O +
the O +
mutant O +
viruses O +
as O +
determined O +
by O +
quantification O +
of O +
their O +
HIV O +
genomic O +
RNA O +
. O +

Measurement O +
of O +
the O +
transcriptional O +
activity O +
of O +
the O +
HIV-1 O +
promoter O +
after O +
transient O +
transfection O +
of O +
the O +
HIV-1 O +
provirus O +
DNA O +
or O +
of O +
long O +
terminal O +
repeat O -
- O -
luciferase O +
constructs O +
showed O +
a O +
positive O +
correlation O +
between O +
the O +
transcriptional O +
and O +
the O +
replication O +
defects O +
for O +
most O +
mutants O +
. O +

The O +
role O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
in O +
cytokine O +
gene O +
regulation O +
. O +

Transcription O +
factors O +
are O +
DNA O -
- O -
binding O +
proteins O +
that O +
regulate O +
gene O +
expression O +
. O +

Nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
is O +
a O +
critical O +
transcription O +
factor O +
for O +
maximal O +
expression O +
of O +
many O +
cytokines O +
that O +
are O +
involved O +
in O +
the O +
pathogenesis O +
of O +
inflammatory O +
diseases O +
, O +
such O +
as O +
adult O +
respiratory O +
distress O +
syndrome O +
( O +
ARDS O +
) O +
and O +
sepsis O +
syndrome O +
. O +

Activation O +
and O +
regulation O +
of O +
NF O -
- O -
kappa O +
B O +
are O +
tightly O +
controlled O +
by O +
a O +
group O +
of O +
inhibitory O +
proteins O +
( O +
I O +
kappa O +
B O +
) O +
that O +
sequester O +
NF O -
- O -
kappa O +
B O +
in O +
the O +
cytoplasm O +
of O +
immune O -
/ O -
inflammatory O +
effector O +
cells O +
. O +

NF O -
- O -
kappa O +
B O +
activation O +
involves O +
signaled O +
phosphorylation O +
, O +
ubiquitination O +
, O +
and O +
proteolysis O +
of O +
I O +
kappa O +
B O +
. O +

Liberated O +
NF O -
- O -
kappa O +
B O +
migrates O +
to O +
the O +
nucleus O +
, O +
where O +
it O +
binds O +
to O +
specific O +
promoter O +
sites O +
and O +
activates O +
gene O +
transcription O +
. O +

The O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
initiates O +
both O +
extracellular O +
and O +
intracellular O +
regulatory O +
events O +
that O +
result O +
in O +
autoregulation O +
of O +
the O +
inflammatory O +
cascade O +
through O +
modulation O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

Recently O +
, O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
has O +
been O +
linked O +
to O +
ARDS O +
and O +
has O +
been O +
shown O +
to O +
be O +
a O +
critical O +
proximal O +
step O +
in O +
the O +
initiation O +
of O +
neutrophilic O +
inflammation O +
in O +
animal O +
models O +
. O +

Activation O +
of O +
NF O -
- O -
kappa O +
B O +
can O +
be O +
inhibited O +
in O +
vivo O +
by O +
treatment O +
with O +
antioxidants O +
, O +
corticosteroids O +
, O +
and O +
the O +
induction O +
of O +
endotoxin O +
tolerance O +
. O +

Identification O +
of O +
more O +
specific O +
and O +
efficacious O +
inhibitors O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
might O +
prove O +
beneficial O +
for O +
the O +
treatment O +
of O +
cytokine O -
- O -
mediated O +
inflammatory O +
diseases O +
. O +

Pancreatic O +
islet O +
expression O +
studies O +
and O +
polymorphic O +
DNA O +
markers O +
in O +
the O +
genes O +
encoding O +
hepatocyte O +
nuclear O +
factor-3alpha O +
, O +
-3beta O +
, O +
-3gamma O +
, O +
-4gamma O +
, O +
and O +
-6 O +
. O +

The O +
genes O +
encoding O +
the O +
functionally O +
related O +
hepatocyte O +
nuclear O +
factors O +
HNF-1alpha O +
and O +
HNF-4alpha O +
play O +
a O +
critical O +
role O +
in O +
normal O +
pancreatic O +
beta O -
- O -
cell O +
function O +
. O +

Mutations O +
in O +
these O +
liver O -
- O -
enriched O +
transcription O +
factors O +
result O +
in O +
two O +
forms O +
of O +
early O -
- O -
onset O +
type O +
2 O +
diabetes O +
( O +
maturity O -
- O -
onset O +
diabetes O +
of O +
the O +
young O +
[ O +
MODY O +
] O +
) O +
, O +
MODY3 O +
and O +
MODY1 O +
, O +
which O +
are O +
characterized O +
by O +
impaired O +
glucose O -
- O -
stimulated O +
insulin O +
secretion O +
, O +
early O +
disease O +
onset O +
, O +
and O +
autosomal O +
dominant O +
inheritance O +
. O +

The O +
transcriptional O +
hierarchy O +
of O +
HNFs O +
suggests O +
that O +
other O +
proteins O +
of O +
the O +
regulatory O +
cascade O +
might O +
be O +
responsible O +
for O +
other O +
forms O +
of O +
MODY O +
and/or O +
late O -
- O -
onset O +
type O +
2 O +
diabetes O +
. O +

In O +
this O +
study O +
, O +
we O +
show O +
that O +
HNF-3alpha O +
, O +
-3beta O +
, O +
-3gamma O +
, O +
-4gamma O +
, O +
and O +
-6 O +
are O +
expressed O +
in O +
pancreatic O +
beta O -
- O -
cells O +
. O +

We O +
report O +
the O +
identification O +
and O +
characterization O +
of O +
simple O +
tandem O +
repeat O +
DNA O +
polymorphisms O +
in O +
the O +
genes O +
encoding O +
HNF-3alpha O +
, O +
-3beta O +
, O +
-3gamma O +
, O +
-4gamma O +
, O +
and O +
-6 O +
and O +
the O +
mapping O +
of O +
HNF-6 O +
to O +
chromosome O +
bands O +
15q21.1 O -
- O -
21.2 O +
by O +
fluorescence O +
in O +
situ O +
hybridization O +
. O +

These O +
markers O +
will O +
be O +
useful O +
to O +
study O +
the O +
role O +
of O +
genetic O +
variation O +
in O +
these O +
genes O +
in O +
the O +
pathogenesis O +
of O +
type O +
2 O +
diabetes O +
. O +

RP1 O +
, O +
a O +
new O +
member O +
of O +
the O +
adenomatous O +
polyposis O +
coli O -
- O -
binding O +
EB1-like O +
gene O +
family O +
, O +
is O +
differentially O +
expressed O +
in O +
activated O +
T O +
cells O +
. O +

Cross O -
- O -
linking O +
of O +
the O +
CD3 O +
and O +
CD28 O +
molecules O +
on O +
T O +
lymphocytes O +
represents O +
one O +
of O +
the O +
most O +
effective O +
signals O +
for O +
T O +
lymphocyte O +
activation O +
and O +
triggering O +
of O +
their O +
cytotoxic O +
effector O +
function O +
. O +

To O +
identify O +
genes O +
that O +
are O +
expressed O +
in O +
T O +
cells O +
after O +
stimulation O +
, O +
mRNA O +
from O +
T O +
lymphocytes O +
that O +
had O +
been O +
activated O +
by O +
the O +
simultaneous O +
stimulation O +
of O +
the O +
CD3 O +
and O +
CD28 O +
trigger O +
molecules O +
was O +
transcribed O +
for O +
a O +
differential O +
mRNA O +
display O +
analysis O +
into O +
cDNA O +
and O +
was O +
compared O +
with O +
cDNA O +
from O +
CD28 O +
-or O +
CD3 O +
-activated O +
or O +
resting O +
lymphocytes O +
. O +

Differential O +
expression O +
was O +
confirmed O +
subsequently O +
by O +
Northern O +
blot O +
analysis O +
. O +

One O +
of O +
the O +
cDNA O +
fragments O +
expressed O +
specifically O +
in O +
CD3 O +
-and O +
CD28 O +
-activated O +
T O +
cells O +
was O +
designated O +
RP1 O +
. O +

The O +
predictive O +
protein O -
- O -
coding O +
region O +
of O +
RP1 O +
had O +
a O +
significant O +
homology O +
to O +
members O +
of O +
the O +
recently O +
found O +
adenomatous O +
polyposis O +
coli O +
( O +
APC O +
) O +
protein O -
- O -
binding O +
EB1 O +
gene O +
family O +
, O +
which O +
codes O +
for O +
yet O +
unknown O +
protein O +
( O +
s O +
) O +
. O +

Bacterially O +
expressed O +
RP1 O +
protein O +
revealed O +
specific O +
binding O +
to O +
wild O -
- O -
type O +
but O +
not O +
to O +
mutated O +
APC O +
protein O +
. O +

The O +
rapid O +
up O -
- O -
regulation O +
of O +
RP1 O +
mRNA O +
in O +
properly O +
activated O +
T O +
cells O +
suggests O +
that O +
this O +
gene O +
might O +
belong O +
to O +
the O +
immediate O -
/ O -
early O +
gene O +
family O +
, O +
which O +
controls O +
the O +
signal O +
transduction O +
cascade O +
downstream O +
of O +
the O +
TCR O +
. O +

As O +
the O +
expression O +
level O +
of O +
the O +
RP1 O +
gene O +
in O +
activated O +
T O +
cells O +
and O +
a O +
spectrum O +
of O +
tumor B-CellLine -
- I-CellLine -
derived I-CellLine +
cell I-CellLine +
lines I-CellLine +
correlates O +
with O +
the O +
proliferative O +
status O +
of O +
the O +
cells O +
, O +
members O +
of O +
the O +
EB1-like O +
gene O +
family O +
may O +
not O +
only O +
be O +
involved O +
in O +
the O +
tumorigenesis O +
of O +
colorectal O +
cancers O +
but O +
may O +
also O +
play O +
a O +
role O +
in O +
the O +
proliferative O +
control O +
of O +
normal O +
cells O +
. O +

Involvement O +
of O +
Rel O +
, O +
Fos O +
, O +
and O +
Jun O +
proteins O +
in O +
binding O +
activity O +
to O +
the O +
IL-2 O +
promoter O +
CD28 O +
response O +
element O -
/ O -
AP-1 O +
sequence O +
in O +
human O +
T O +
cells O +
. O +

CD28 O +
is O +
an O +
important O +
costimulatory O +
molecule O +
in O +
the O +
activation O +
of O +
human O +
T O +
cells O +
. O +

Costimulation O +
of O +
T O +
cells O +
through O +
both O +
the O +
Ag O +
receptor O +
and O +
CD28 O +
leads O +
to O +
high O +
level O +
IL-2 O +
production O +
, O +
which O +
is O +
vital O +
to O +
the O +
development O +
of O +
an O +
immune O +
response O +
in O +
vivo O +
. O +

Previous O +
reports O +
have O +
suggested O +
the O +
CD28 O +
stimulation O +
contributes O +
to O +
the O +
activation O +
of O +
the O +
IL-2 O +
promoter O +
by O +
up O -
- O -
regulating O +
the O +
activity O +
of O +
several O +
transcription O +
factors O +
, O +
including O +
AP-1 O +
and O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
/Rel O +
family O +
members O +
as O +
well O +
as O +
an O +
uncharacterized O +
transcription O +
factor O +
called O +
CD28 O +
response O +
complex O +
. O +

While O +
several O +
lines O +
of O +
investigation O +
have O +
suggested O +
that O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
family O +
members O +
make O +
up O +
the O +
CD28 O +
response O +
complex O +
transcription O +
factor O +
, O +
other O +
work O +
has O +
not O +
supported O +
this O +
conclusion O +
. O +

Recent O +
studies O +
suggest O +
that O +
the O +
CD28 O +
response O +
element O +
( O +
CD28RE O +
) O +
does O +
not O +
function O +
independently O +
but O +
works O +
instead O +
in O +
conjunction O +
with O +
the O +
adjacent O +
promoter O +
proximal O +
AP-1-binding O +
site O +
and O +
this O +
hypothesis O +
is O +
confirmed O +
here O +
. O +

Also O +
in O +
the O +
current O +
study O +
, O +
binding O +
activity O +
to O +
the O +
CD28RE O -
/ O -
AP-1 O +
sequence O +
of O +
the O +
IL-2 O +
promoter O +
is O +
evaluated O +
. O +

Although O +
four O +
specific O +
complexes O +
can O +
be O +
detected O +
binding O +
to O +
this O +
sequence O +
, O +
only O +
one O +
of O +
these O +
complexes O +
is O +
specific O +
for O +
both O +
the O +
CD28RE O +
and O +
the O +
adjacent O +
AP-1 O +
site O +
. O +

Of O +
the O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
family O +
members O +
tested O +
, O +
this O +
CD28RE O -
/ O -
AP-1-specific O +
complex O +
contains O +
predominantly O +
c O -
- O -
Rel O +
, O +
despite O +
the O +
fact O +
that O +
both O +
p50 O +
and O +
RelA O +
can O +
efficiently O +
bind O +
to O +
the O +
CD28RE O +
. O +

c O -
- O -
Fos O +
and O +
c O -
- O -
Jun O +
are O +
also O +
found O +
in O +
this O +
CD28RE O -
/ O -
AP-1-specific O +
complex O +
. O +

These O +
data O +
indicate O +
that O +
functional O +
complexes O +
encompassing O +
both O +
the O +
CD28RE O +
and O +
the O +
AP-1-binding O +
sites O +
influence O +
IL-2 O +
promoter O +
activity O +
in O +
CD28 O +
-costimulated O +
T O +
cells O +
. O +

A O +
conserved O +
tissue O -
- O -
specific O +
structure O +
at O +
a O +
human O +
T O -
- O -
cell O +
receptor O +
beta O -
- O -
chain O +
core O +
promoter O +
. O +

The O +
T O -
- O -
cell O +
receptor O +
( O +
TCR O +
) O +
beta O -
- O -
chain O +
promoters O +
have O +
been O +
characterized O +
as O +
nonstructured O +
basal O +
promoters O +
that O +
carry O +
a O +
single O +
conserved O +
ubiquitous O +
cyclic O +
AMP O -
- O -
responsive O +
element O +
. O +

Our O +
investigation O +
of O +
the O +
human O +
TCR O +
beta O +
gene O +
uncovers O +
a O +
surprisingly O +
complex O +
and O +
tissue O -
- O -
specific O +
structure O +
at O +
the O +
TCR O +
Vbeta O +
8.1 O +
promoter O +
. O +

The O +
core O +
of O +
the O +
promoter O +
( O +
positions O +
-42 O +
to O +
+ O -
11 O +
) O +
is O +
recognized O +
by O +
the O +
lymphoid O +
cell O -
- O -
specific O +
transcription O +
factors O +
Ets-1 O +
, O +
LEF1 O +
, O +
and O +
AML1 O +
as O +
well O +
as O +
by O +
CREB O -
/ O -
ATF-1 O +
, O +
as O +
is O +
demonstrated O +
in O +
gel O +
shift O +
and O +
footprinting O +
experiments O +
. O +

With O +
the O +
exception O +
of O +
LEF1 O +
, O +
these O +
factors O +
activate O +
transcription O +
in O +
T O +
cells O +
. O +

Binding O +
sites O +
at O +
the O +
core O +
region O +
show O +
little O +
conservation O +
with O +
consensus O +
sites O +
. O +

Nonetheless O +
, O +
CREB O +
, O +
Ets-1 O +
, O +
and O +
AML1 O +
bind O +
and O +
activate O +
cooperatively O +
and O +
very O +
efficiently O +
through O +
the O +
nonconsensus O +
binding O +
sites O +
at O +
the O +
core O +
promoter O +
region O +
. O +

Moderate O +
ubiquitous O +
activation O +
is O +
further O +
induced O +
by O +
CREB O -
/ O -
ATF O +
and O +
Sp1 O +
factors O +
through O +
proximal O +
upstream O +
elements O +
. O +

The O +
tissue O -
- O -
specific O +
core O +
promoter O +
structure O +
is O +
apparently O +
conserved O +
in O +
other O +
T O -
- O -
cell O -
- O -
specifically O +
expressed O +
genes O +
such O +
as O +
the O +
CD4 O +
gene O +
. O +

Our O +
observations O +
suggest O +
that O +
both O +
the O +
enhancer O +
and O +
the O +
promoter O +
have O +
a O +
complex O +
tissue O -
- O -
specific O +
structure O +
whose O +
functional O +
interplay O +
potentiates O +
T O -
- O -
cell O -
- O -
specific O +
transcription O +
. O +

GABP O +
factors O +
bind O +
to O +
a O +
distal O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
enhancer O +
and O +
contribute O +
to O +
c O -
- O -
Raf O +
-mediated O +
increase O +
in O +
IL-2 O +
induction O +
. O +

Triggering O +
of O +
the O +
T O -
- O -
cell O +
receptor O -
- O -
CD3 O +
complex O +
activates O +
two O +
major O +
signal O +
cascades O +
in O +
T O +
lymphocytes O +
, O +
( O +
i O +
) O +
Ca2 O -
+ O -
-dependent O +
signal O +
cascades O +
and O +
( O +
ii O +
) O +
protein O +
kinase O +
cascades O +
. O +

Both O +
signal O +
cascades O +
contribute O +
to O +
the O +
induction O +
of O +
the O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
gene O +
during O +
T O -
- O -
cell O +
activation O +
. O +

Prominent O +
protein O +
kinase O +
cascades O +
are O +
those O +
that O +
activate O +
mitogen O -
- O -
activated O +
protein O +
( O +
MAP O +
) O +
kinases O +
. O +

We O +
show O +
here O +
that O +
c O -
- O -
Raf O +
, O +
which O +
is O +
at O +
the O +
helm O +
of O +
the O +
classic O +
MAP- O +
Erk O +
cascade O +
, O +
contributes O +
to O +
IL-2 O +
induction O +
through O +
a O +
distal O +
enhancer O +
element O +
spanning O +
the O +
nucleotides O +
from O +
positions O +
-502 O +
to O +
-413 O +
in O +
front O +
of O +
the O +
transcriptional O +
start O +
site O +
of O +
the O +
IL-2 O +
gene O +
. O +

Induction O +
of O +
this O +
distal O +
IL-2 O +
enhancer O +
differs O +
from O +
induction O +
of O +
the O +
proximal O +
IL-2 O +
promoter O -
- O -
enhancer O +
, O +
since O +
it O +
is O +
induced O +
by O +
phorbol O +
esters O +
alone O +
and O +
independent O +
from O +
Ca2 O -
+ O +
signals O +
. O +

In O +
DNA O -
- O -
protein O +
binding O +
studies O +
, O +
we O +
detected O +
the O +
binding O +
of O +
transcription O +
factors O +
GABP O +
alpha O +
and O +
-beta O +
to O +
a O +
dyad O +
symmetry O +
element O +
( O +
DSE O +
) O +
of O +
the O +
distal O +
enhancer O +
, O +
which O +
is O +
formed O +
by O +
palindromic O +
binding O +
sites O +
of O +
Ets O -
- O -
like O +
factors O +
. O +

Introduction O +
of O +
point O +
mutations O +
suppressing O +
GABP O +
binding O +
to O +
the O +
DSE O +
interfered O +
with O +
the O +
induction O +
of O +
the O +
distal O +
enhancer O +
and O +
the O +
entire O +
IL-2 O +
promoter O -
- O -
enhancer O +
, O +
while O +
overexpression O +
of O +
both O +
GABP O +
factors O +
enhanced O +
the O +
IL-2 O +
promoter O -
- O -
enhancer O +
induction O +
. O +

Overexpression O +
of O +
BXB O +
, O +
a O +
constitutive O +
active O +
version O +
of O +
c O -
- O -
Raf O +
, O +
and O +
of O +
further O +
members O +
of O +
the O +
Ras O +
- O +
Raf O +
- O +
Erk O +
signal O +
cascade O +
exerted O +
an O +
increase O +
of O +
GABP O +
-mediated O +
promoter O -
- O -
enhancer O +
induction O +
. O +

In O +
conjunction O +
with O +
previously O +
published O +
data O +
on O +
c O -
- O -
Raf O +
-induced O +
phosphorylation O +
of O +
GABP O +
factors O +
( O +
E.Flory O +
, O +
A. O +
Hoffmeyer O +
, O +
U.Smola O +
, O +
U.R.Rapp O +
, O +
and O +
J.T.Bruder O +
, O +
J.Virol.70 O +
: O +
2260- O +
2268 O +
, O +
1996 O +
) O +
, O +
these O +
results O +
indicate O +
a O +
contribution O +
of O +
GABP O +
factors O +
to O +
the O +
Raf O +
-mediated O +
enhancement O +
of O +
IL-2 O +
induction O +
during O +
T O -
- O -
cell O +
activation O +
. O +

The O +
product O +
of O +
the O +
murine O +
homolog O +
of O +
the O +
Drosophila O +
extra O +
sex O +
combs O +
gene O +
displays O +
transcriptional O +
repressor O +
activity O +
. O +

The O +
heterogeneous O +
nuclear O +
ribonucleoprotein O +
K O +
protein O +
represents O +
a O +
novel O +
class O +
of O +
proteins O +
that O +
may O +
act O +
as O +
docking O +
platforms O +
that O +
orchestrate O +
cross O -
- O -
talk O +
among O +
molecules O +
involved O +
in O +
signal O +
transduction O +
and O +
gene O +
expression O +
. O +

Using O +
a O +
fragment O +
of O +
K O +
protein O +
as O +
bait O +
in O +
the O +
yeast O +
two O -
- O -
hybrid O +
screen O +
, O +
we O +
isolated O +
a O +
cDNA O +
that O +
encodes O +
a O +
protein O +
whose O +
primary O +
structure O +
has O +
extensive O +
similarity O +
to O +
the O +
Drosophila O +
melanogaster O +
extra O +
sex O +
combs O +
( O +
esc O +
) O +
gene O +
product O +
, O +
Esc O +
, O +
a O +
putative O +
silencer O +
of O +
homeotic O +
genes O +
. O +

The O +
cDNA O +
that O +
we O +
isolated O +
is O +
identical O +
to O +
the O +
cDNA O +
of O +
the O +
recently O +
positionally O +
cloned O +
mouse O +
embryonic O +
ectoderm O +
development O +
gene O +
, O +
eed O +
. O +

Like O +
Esc O +
, O +
Eed O +
contains O +
six O +
WD-40 O +
repeats O +
in O +
the O +
C O -
- O -
terminal O +
half O +
of O +
the O +
protein O +
and O +
is O +
thought O +
to O +
repress O +
homeotic O +
gene O +
expression O +
during O +
mouse O +
embryogenesis O +
. O +

Eed O +
binds O +
to O +
K O +
protein O +
through O +
a O +
domain O +
in O +
its O +
N O +
terminus O +
, O +
but O +
interestingly O +
, O +
this O +
domain O +
is O +
not O +
found O +
in O +
the O +
Drosophila O +
Esc O +
. O +

Gal4-Eed O +
fusion O +
protein O +
represses O +
transcription O +
of O +
a O +
reporter O +
gene O +
driven O +
by O +
a O +
promoter O +
that O +
contains O +
Gal4-binding O +
DNA O +
elements O +
. O +

Eed O +
also O +
represses O +
transcription O +
when O +
recruited O +
to O +
a O +
target O +
promoter O +
by O +
Gal4-K O +
protein O +
. O +

Point O +
mutations O +
within O +
the O +
eed O +
gene O +
that O +
are O +
responsible O +
for O +
severe O +
embryonic O +
development O +
abnormalities O +
abolished O +
the O +
transcriptional O +
repressor O +
activity O +
of O +
Eed O +
. O +

Results O +
of O +
this O +
study O +
suggest O +
that O +
Eed O +
-restricted O +
homeotic O +
gene O +
expression O +
during O +
embryogenesis O +
reflects O +
the O +
action O +
of O +
Eed O +
as O +
a O +
transcriptional O +
repressor O +
. O +

The O +
Eed O +
-mediated O +
transcriptional O +
effects O +
are O +
likely O +
to O +
reflect O +
the O +
interaction O +
of O +
Eed O +
with O +
multiple O +
molecular O +
partners O +
, O +
including O +
K O +
protein O +
. O +

Induction O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
expression O +
in O +
monocytic O +
cells O +
by O +
Cryptococcus O +
neoformans O +
and O +
Candida O +
albicans O +
. O +

Because O +
candidiasis O +
and O +
cryptococcosis O +
are O +
common O +
in O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
-infected O +
persons O +
, O +
the O +
effect O +
of O +
Cryptococcus O +
neoformans O +
and O +
Candida O +
albicans O +
on O +
HIV O +
expression O +
in O +
monocytic O +
cells O +
was O +
examined O +
. O +

Stimulation O +
of O +
the O +
latently O +
HIV B-CellLine -
- I-CellLine -
infected I-CellLine +
myelomonocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
OM-10.1 O +
with O +
C. O +
neoformans O +
and O +
C. O +
albicans O +
in O +
the O +
presence O +
of O +
pooled O +
human O +
serum O +
caused O +
a O +
ratio O -
- O -
dependent O +
increase O +
in O +
HIV O +
production O +
. O +

Induction O +
of O +
HIV O +
by O +
C. O +
neoformans O +
was O +
enhanced O +
by O +
anti O -
- O -
capsular O +
antibody O +
, O +
while O +
induction O +
by O +
both O +
organisms O +
was O +
inhibited O +
by O +
anti O -
- O -
TNF O -
- O -
alpha O +
antibody O +
. O +

In O +
THP-1 O +
cells O +
transfected O +
with O +
HIV O +
plasmid O +
constructs O +
, O +
both O +
organisms O +
induced O +
transcription O +
from O +
the O +
HIV O +
long O +
terminal O +
repeat O +
that O +
was O +
dependent O +
on O +
intact O +
NF O -
- O -
kappaB O +
binding O +
sequences O +
. O +

Thus O +
, O +
C. O +
neoformans O +
and O +
C. O +
albicans O +
enhance O +
HIV O +
expression O +
in O +
monocytic O +
cells O +
through O +
a O +
TNF O -
- O -
alpha- O +
and O +
NF O -
- O -
kappaB O -
- O -
dependent O +
mechanism O +
. O +

In O +
HIV O -
- O -
infected O +
patients O +
, O +
such O +
enhancement O +
may O +
further O +
impair O +
host O +
immunity O +
and O +
could O +
accelerate O +
the O +
course O +
of O +
HIV O +
disease O +
. O +

Glucocorticoid O +
receptor O +
regulates O +
expression O +
of O +
L O -
- O -
selectin O +
and O +
CD11 O -
/ O -
CD18 O +
on O +
human O +
neutrophils O +
[ O +
see O +
comments O +
] O +

BACKGROUND O +
: O +
Recent O +
studies O +
have O +
raised O +
the O +
hypothesis O +
that O +
glucocorticoids O +
could O +
diminish O +
the O +
ability O +
of O +
endothelial O +
cells O +
to O +
direct O +
leukocyte O +
traffic O +
into O +
inflamed O +
tissues O +
by O +
inhibiting O +
expression O +
of O +
the O +
adhesion O +
molecules O +
endothelial O -
- O -
leukocyte O +
adhesion O +
molecule-1 O +
and O +
intercellular O +
adhesion O +
molecule-1 O +
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
whether O +
glucocorticoids O +
also O +
regulate O +
the O +
expression O +
of O +
L O -
- O -
selectin O +
and O +
CD11 O -
/ O -
CD18 O +
integrins O +
on O +
human O +
neutrophil O +
granulocytes O +
. O +

METHODS O +
AND O +
RESULTS O +
: O +
Incubation O +
of O +
human O +
whole O +
blood O +
with O +
platelet O -
- O -
activating O +
factor O +
( O +
PAF O +
, O +
1 O +
mumol O -
/ O -
L O +
) O +
evoked O +
downregulation O +
of O +
L O -
- O -
selectin O +
and O +
upregulation O +
of O +
CD11 O -
/ O -
CD18 O +
adhesion O +
receptors O +
on O +
neutrophils O +
as O +
measured O +
by O +
flow O +
cytometry O +
. O +

While O +
dexamethasone O +
( O +
0.1 O +
nmol O -
/ O -
L O +
to O +
100 O +
mumol O -
/ O -
L O +
) O +
did O +
not O +
affect O +
expression O +
of O +
adhesion O +
molecules O +
on O +
resting O +
neutrophils O +
, O +
it O +
attenuated O +
the O +
PAF O +
-induced O +
changes O +
in O +
L O -
- O -
selectin O +
and O +
CD18 O +
expression O +
in O +
a O +
time- O +
and O +
concentration O -
- O -
dependent O +
fashion O +
with O +
IC50 O +
values O +
of O +
31 O +
and O +
13 O +
nmol O -
/ O -
L O +
, O +
respectively O +
. O +

These O +
effects O +
of O +
dexamethasone O +
were O +
completely O +
aborted O +
by O +
RU-486 O +
( O +
10 O +
mumol O -
/ O -
L O +
) O +
, O +
which O +
blocks O +
transcriptional O +
activation O +
of O +
the O +
glucocorticoid O +
receptor O +
, O +
and O +
by O +
the O +
protein O +
synthesis O +
inhibitor O +
cycloheximide O +
( O +
35.5 O +
mumol O -
/ O -
L O +
) O +
. O +

Dexamethasone O +
, O +
up O +
to O +
a O +
concentration O +
of O +
1 O +
mumol O -
/ O -
L O +
, O +
neither O +
affected O +
significantly O +
the O +
release O +
of O +
granule O +
enzymes O +
nor O +
interfered O +
with O +
PAF O +
binding O +
to O +
its O +
membrane O +
receptors O +
. O +

CONCLUSIONS O +
: O +
Our O +
results O +
show O +
that O +
glucocorticoids O +
at O +
clinically O +
relevant O +
concentrations O +
exert O +
specific O +
actions O +
on O +
expression O +
of O +
adhesion O +
molecules O +
on O +
activated O +
neutrophils O +
, O +
which O +
are O +
mediated O +
through O +
ligation O +
of O +
glucocorticoid O +
receptors O +
and O +
induction O +
of O +
protein O +
synthesis O +
, O +
and O +
suggest O +
a O +
novel O +
mechanism O +
by O +
which O +
anti O -
- O -
inflammatory O +
corticosteroids O +
may O +
inhibit O +
leukocyte O +
accumulation O +
. O +

Induction O +
of O +
nuclear O +
factor O +
kappa O +
B O -
/ O -
Rel O +
nuclear O +
activity O +
in O +
human O +
peripheral O +
blood O +
T O +
lymphocytes O +
by O +
anti O -
- O -
HLA O +
class O +
I O +
monoclonal O +
antibodies O +
. O +

Monoclonal O +
antibodies O +
against O +
either O +
monomorphic O +
or O +
polymorphic O +
determinants O +
of O +
class O +
I O +
antigen O +
induced O +
in O +
PBMC O +
and O +
highly O +
purified O +
T O +
lymphocytes O +
the O +
nuclear O +
activity O +
of O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
complexes O +
. O +

These O +
included O +
both O +
p50 O -
/ O -
p50 O +
and O +
p50 O -
/ O -
p65 O +
dimers O +
, O +
recognized O +
by O +
specific O +
antibodies O +
in O +
EMSA O +
. O +

The O +
induced O +
complexes O +
were O +
detectable O +
in O +
extracts O +
of O +
cells O +
incubated O +
with O +
anti O -
- O -
class O +
I O +
monoclonal O +
antibody O +
( O +
mAb O +
) O +
for O +
1.5 O +
h O +
; O +
the O +
induction O +
was O +
maximal O +
at O +
5 O +
h O +
, O +
persistent O +
at O +
16 O +
h O +
and O +
no O +
longer O +
observed O +
at O +
40 O +
h O +
. O +

The O +
mAb O +
failed O +
to O +
induce O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
nuclear O +
activity O +
in O +
cells O +
incubated O +
in O +
the O +
presence O +
of O +
3 O +
, O +
4-dichloroisocoumarin O +
, O +
an O +
inhibitor O +
of O +
I O +
kappa O +
B O -
- O -
alpha O +
degradation O +
. O +

Together O +
, O +
these O +
results O +
suggest O +
that O +
class O +
I O +
triggering O +
can O +
induce O +
the O +
activity O +
of O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
nuclear O +
activity O +
in O +
peripheral O +
blood O +
T O +
lymphocytes O +
, O +
thereby O +
modulating O +
the O +
expression O +
of O +
genes O +
regulated O +
by O +
these O +
transcription O +
factors O +
. O +

Cyclosporin O +
A O +
interferes O +
with O +
the O +
inducible O +
degradation O +
of O +
NF O -
- O -
kappa O +
B O +
inhibitors O +
, O +
but O +
not O +
with O +
the O +
processing O +
of O +
p105 O -
/ O +
NF O -
- O -
kappa O +
B1 O +
in O +
T O +
cells O +
. O +

The O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
controls O +
the O +
induction O +
of O +
numerous O +
cytokine O +
promoters O +
during O +
the O +
activation O +
of O +
T O +
lymphocytes O +
. O +

Inhibition O +
of O +
T O +
cell O +
activation O +
by O +
the O +
immunosuppressants O +
cyclosporin O +
A O +
( O +
CsA O +
) O +
and O +
FK506 O +
exerts O +
a O +
suppressive O +
effect O +
on O +
the O +
induction O +
of O +
these O +
NF O -
- O -
kappa O +
B O -
- O -
controlled O +
cytokine O +
promoters O +
. O +

We O +
show O +
for O +
human B-CellLine +
Jurkat I-CellLine +
T I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
, O +
as O +
well O +
as O +
human O +
and O +
mouse O +
primary O +
T O +
lymphocytes O +
, O +
that O +
this O +
inhibitory O +
effect O +
is O +
accompanied O +
by O +
an O +
impaired O +
nuclear O +
translocation O +
of O +
the O +
Rel O +
proteins O +
c O -
- O -
Rel O +
, O +
RelA O -
/ O -
p65 O +
and O +
NF O -
- O -
kappa O +
B1 O -
/ O -
p50 O +
, O +
whereas O +
the O +
nuclear O +
appearance O +
of O +
RelB O +
remains O +
unaffected O +
. O +

CsA O +
does O +
not O +
interfere O +
with O +
the O +
synthesis O +
of O +
Rel O +
proteins O +
, O +
but O +
prevents O +
the O +
inducible O +
degradation O +
of O +
cytosolic O +
NF O -
- O -
kappa O +
B O +
inhibitors O +
I O +
kappa O +
B O +
alpha O +
and O +
I O +
kappa O +
B O +
beta O +
upon O +
T O +
cell O +
activation O +
. O +

CsA O +
neither O +
inhibits O +
the O +
processing O +
of O +
the O +
NF O -
- O -
kappa O +
B1 O +
precursor O +
p105 O +
to O +
p50 O +
, O +
nor O +
does O +
it O +
` O -
` O +
stabilize O +
'' O +
the O +
C O -
- O -
terminal O +
portion O +
of O +
p105 O +
, O +
I O +
kappa O +
B O +
gamma O +
, O +
which O +
is O +
degraded O +
during O +
p105 O +
processing O +
to O +
mature O +
p50 O +
. O +

These O +
results O +
indicate O +
that O +
CsA O +
interferes O +
with O +
a O +
specific O +
event O +
in O +
the O +
signal O -
- O -
induced O +
degradation O +
of O +
I O +
kappa O +
B O +
alpha O +
and O +
I O +
kappa O +
B O +
beta O +
, O +
but O +
does O +
not O +
affect O +
the O +
processing O +
of O +
NF O -
- O -
kappa O +
B1 O -
/ O -
p105 O +
to O +
p50 O +
. O +

EBF O +
and O +
E47 O +
collaborate O +
to O +
induce O +
expression O +
of O +
the O +
endogenous O +
immunoglobulin O +
surrogate O +
light O +
chain O +
genes O +
. O +

Early O +
B O +
cell O +
factor O +
( O +
EBF O +
) O +
and O +
E47 O +
participate O +
in O +
the O +
transcriptional O +
control O +
of O +
early O +
B O +
lymphocyte O +
differentiation O +
. O +

With O +
the O +
aim O +
of O +
identifying O +
genetic O +
targets O +
for O +
these O +
transcription O +
factors O +
, O +
we O +
stably O +
transfected O +
cDNAs O +
encoding O +
EBF O +
or O +
a O +
covalent O +
homodimer O +
of O +
E47 O +
, O +
individually O +
or O +
together O +
, O +
into O +
immature B-CellLine +
hematopoietic I-CellLine +
Ba I-CellLine -
/ I-CellLine -
F3 I-CellLine +
cells I-CellLine +
, O +
which O +
lack O +
both O +
factors O +
. O +

In O +
combination O +
, O +
EBF O +
and O +
E47 O +
induce O +
efficient O +
expression O +
of O +
the O +
endogenous O +
immunoglobulin O +
surrogate O +
light O +
chain O +
genes O +
, O +
lambda5 O +
and O +
VpreB O +
, O +
whereas O +
other O +
pre O -
- O -
B O +
cell O -
- O -
specific O +
genes O +
remain O +
silent O +
. O +

Multiple O +
functionally O +
important O +
EBF O +
and O +
E47 O +
binding O +
sites O +
were O +
identified O +
in O +
the O +
lambda5 O +
promoter O -
/ O -
enhancer O +
region O +
, O +
indicating O +
that O +
lambda5 O +
is O +
a O +
direct O +
genetic O +
target O +
for O +
these O +
transcription O +
factors O +
. O +

Taken O +
together O +
, O +
these O +
data O +
suggest O +
that O +
EBF O +
and O +
E47 O +
synergize O +
to O +
activate O +
expression O +
of O +
a O +
subset O +
of O +
genes O +
that O +
define O +
an O +
early O +
stage O +
of O +
the O +
B O +
cell O +
lineage O +
. O +

Nuclear O +
levels O +
of O +
NF O -
- O -
kappaB O +
correlate O +
with O +
syncytium O -
- O -
forming O +
capacity O +
of O +
8e51 B-CellLine +
cells I-CellLine +
, O +
expressing O +
a O +
defective O +
HIV O +
virus O +
. O +

The O +
double O +
NF O -
- O -
kappaB O +
site O +
identified O +
in O +
the O +
LTR O +
of O +
the O +
human O +
immunodeficiency O +
virus-1 O +
( O +
HIV-1 O +
) O +
has O +
been O +
demonstrated O +
to O +
be O +
necessary O +
for O +
efficient O +
viral O +
transcription O +
. O +

In O +
this O +
report O +
we O +
present O +
the O +
characterisation O +
of O +
NF O -
- O -
kappaB O +
subunits O +
engaged O +
in O +
complexes O +
binding O +
to O +
the O +
HIV-1 O +
NF O -
- O -
kappaB O +
site O +
in O +
human B-CellLine +
8e51 I-CellLine +
T I-CellLine -
- I-CellLine -
cells I-CellLine +
, O +
that O +
harbour O +
a O +
defective O +
HIV-1 O +
. O +

At O +
least O +
four O +
different O +
specific O +
NF O -
- O -
kappaB O +
complexes O +
are O +
present O +
in O +
the O +
nucleus O +
of O +
these O +
cells O +
. O +

With O +
the O +
use O +
of O +
specific O +
antibodies O +
we O +
have O +
determined O +
the O +
composition O +
of O +
each O +
complex O +
using O +
electrophoretic O +
mobility O +
shift O +
assays O +
. O +

The O +
results O +
show O +
the O +
presence O +
of O +
several O +
NF O -
- O -
kappaB O +
family O +
members O +
, O +
with O +
the O +
transactivating O +
RelA O +
being O +
engaged O +
in O +
multiple O +
complexes O +
. O +

The O +
importance O +
of O +
NF O -
- O -
kappaB O +
complexes O +
in O +
viral O +
functions O +
has O +
been O +
established O +
comparing O +
the O +
level O +
of O +
NF O -
- O -
kappaB O +
DNA O -
- O -
binding O +
complexes O +
with O +
syncytia O -
- O -
forming O +
activity O +
of O +
8e51 B-CellLine +
cells I-CellLine +
. O +

In O +
fact O +
, O +
8e51 B-CellLine +
cells I-CellLine +
that O +
had O +
almost O +
lost O +
their O +
syncytia O -
- O -
forming O +
capacity O +
were O +
found O +
to O +
contain O +
at O +
least O +
10 O +
times O +
less O +
active O +
NF O -
- O -
kappaB O +
DNA O -
- O -
binding O +
complex O +
than O +
the O +
actively O +
fusing O +
cells O +
. O +

The O +
correlation O +
is O +
specific O +
as O +
the O +
level O +
of O +
at O +
least O +
three O +
other O +
transcription O +
factors O +
did O +
not O +
change O +
. O +

Synthetic O +
glucocorticoids O +
that O +
dissociate O +
transactivation O +
and O +
AP-1 O +
transrepression O +
exhibit O +
antiinflammatory O +
activity O +
in O +
vivo O +
. O +

Some O +
of O +
the O +
most O +
potent O +
antiinflammatory O +
and O +
immunosuppressive O +
agents O +
are O +
synthetic O +
glucocorticoids O +
. O +

However O +
, O +
major O +
side O +
effects O +
severely O +
limit O +
their O +
therapeutic O +
use O +
. O +

The O +
development O +
of O +
improved O +
glucocorticoid O -
- O -
based O +
drugs O +
will O +
require O +
the O +
separation O +
of O +
beneficial O +
from O +
deleterious O +
effects O +
. O +

One O +
possibility O +
toward O +
this O +
goal O +
is O +
to O +
try O +
to O +
dissociate O +
two O +
main O +
activities O +
of O +
glucocorticoids O +
, O +
i.e. O +
transactivation O +
and O +
transrepression O +
. O +

Screening O +
of O +
a O +
library O +
of O +
compounds O +
using O +
transactivation O +
and O +
AP-1 O +
transrepression O +
models O +
in O +
transiently O +
transfected O +
cells O +
identified O +
dissociated O +
glucocorticoids O +
, O +
which O +
exert O +
strong O +
AP-1 O +
inhibition O +
but O +
little O +
or O +
no O +
transactivation O +
. O +

Importantly O +
, O +
despite O +
high O +
ligand O +
binding O +
affinity O +
, O +
the O +
prototypic O +
dissociated O +
compound O +
, O +
RU24858 O +
, O +
acted O +
as O +
a O +
weak O +
agonist O +
and O +
did O +
not O +
efficiently O +
antagonize O +
dexamethasone O -
- O -
induced O +
transcription O +
in O +
transfected O +
cells O +
. O +

Similar O +
results O +
were O +
obtained O +
in O +
hepatic B-CellLine +
HTC I-CellLine +
cells I-CellLine +
for O +
the O +
transactivation O +
of O +
the O +
endogenous O +
tyrosine O +
amino O +
transferase O +
gene O +
( O +
TAT O +
) O +
, O +
which O +
encodes O +
one O +
of O +
the O +
enzymes O +
involved O +
in O +
the O +
glucocorticoid O -
- O -
dependent O +
stimulation O +
of O +
neoglucogenesis O +
. O +

To O +
investigate O +
whether O +
dissociated O +
glucocorticoids O +
retained O +
the O +
antiinflammatory O +
and O +
immunosuppressive O +
potential O +
of O +
classic O +
glucocorticoids O +
, O +
several O +
in O +
vitro O +
and O +
in O +
vivo O +
models O +
were O +
used O +
. O +

Indeed O +
, O +
secretion O +
of O +
the O +
proinflammatory O +
lymphokine O +
interleukin-1beta O +
was O +
severely O +
inhibited O +
by O +
dissociated O +
glucocorticoids O +
in O +
human B-CellLine +
monocytic I-CellLine +
THP I-CellLine +
1 I-CellLine +
cells I-CellLine +
. O +

Moreover O +
, O +
in O +
two O +
in O +
vivo O +
models O +
, O +
these O +
compounds O +
exerted O +
an O +
antiinflammatory O +
and O +
immunosuppressive O +
activity O +
as O +
potent O +
as O +
that O +
of O +
the O +
classic O +
glucocorticoid O +
prednisolone O +
. O +

These O +
results O +
may O +
lead O +
to O +
an O +
improvement O +
of O +
antiinflammatory O +
and O +
immunosuppressive O +
therapies O +
and O +
provide O +
a O +
novel O +
concept O +
for O +
drug O +
discovery O +
. O +

Inhibition O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
replication O +
in O +
vitro O +
by O +
a O +
novel O +
combination O +
of O +
anti O -
- O -
Tat O +
single O -
- O -
chain O +
intrabodies O +
and O +
NF O -
- O -
kappa O +
B O +
antagonists O +
. O +

Human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
Tat O +
, O +
an O +
early O +
regulatory O +
protein O +
that O +
is O +
critical O +
for O +
viral O +
gene O +
expression O +
and O +
replication O +
, O +
transactivates O +
the O +
HIV-1 O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
via O +
its O +
binding O +
to O +
the O +
transactivation O +
response O +
element O +
( O +
TAR O +
) O +
and O +
, O +
along O +
with O +
other O +
cellular O +
factors O +
, O +
increases O +
viral O +
transcription O +
initiation O +
and O +
elongation O +
. O +

Tat O +
also O +
superactivates O +
the O +
HIV-1 O +
promoter O +
through O +
a O +
TAR O +
-independent O +
mechanism O +
, O +
including O +
tumor O +
necrosis O +
factor O +
alpha O -
- O -
induced O +
and O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
-dependent O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
and O +
inhibitors O +
of O +
Tat O +
and O +
NF O -
- O -
kappa O +
B O +
cooperatively O +
down O -
- O -
regulate O +
this O +
Tat O +
-mediated O +
LTR O +
superactivation O +
. O +

In O +
this O +
study O +
, O +
a O +
combined O +
pharmacologic O +
and O +
genetic O +
strategy O +
using O +
two O +
PKC O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
inhibitors O +
, O +
pentoxifylline O +
( O +
PTX O +
) O +
and O +
Go-6976 O +
, O +
and O +
a O +
stably O +
expressed O +
anti O -
- O -
Tat O +
single O -
- O -
chain O +
intracellular O +
antibody O +
( O +
sFv O +
intrabody O +
) O +
was O +
employed O +
to O +
obtain O +
cooperative O +
inhibition O +
of O +
both O +
HIV-1 O +
LTR O +
-driven O +
gene O +
expression O +
and O +
HIV-1 O +
replication O +
. O +

Treatment O +
of O +
cells O +
with O +
PTX O +
and O +
Go-6976 O +
resulted O +
in O +
cooperative O +
inhibition O +
of O +
both O +
HIV-1 O +
LTR O +
-driven O +
gene O +
expression O +
and O +
HIV-1 O +
replication O +
. O +

In O +
addition O +
, O +
the O +
combined O +
use O +
of O +
anti O -
- O -
Tat O +
sFv O +
intrabodies O +
and O +
the O +
two O +
NF O -
- O -
kappa O +
B O +
inhibitors O +
retained O +
the O +
virus O +
in O +
the O +
latent O +
state O +
for O +
as O +
long O +
as O +
45 O +
days O +
. O +

The O +
combined O +
treatment O +
resulted O +
in O +
more O +
durable O +
inhibition O +
of O +
HIV-1 O +
replication O +
than O +
was O +
seen O +
with O +
the O +
NF O -
- O -
kappa O +
B O +
inhibitors O +
alone O +
or O +
the O +
anti- O +
Tat O +
sFv O +
intrabodies O +
alone O +
. O +

Together O +
, O +
these O +
results O +
suggest O +
that O +
in O +
future O +
clinical O +
gene O +
therapy O +
trials O +
, O +
a O +
combined O +
pharmacologic O +
and O +
genetic O +
strategy O +
like O +
the O +
one O +
reported O +
here O +
may O +
improve O +
the O +
survival O +
of O +
transduced B-CellLine +
cells I-CellLine +
and O +
prolong O +
clinical O +
benefit O +
. O +

Activation O +
domain O +
requirements O +
for O +
disruption O +
of O +
Epstein O -
- O -
Barr O +
virus O +
latency O +
by O +
ZEBRA O +
. O +

Latent O +
infection O +
of O +
B O +
lymphocytes O +
by O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
can O +
be O +
disrupted O +
by O +
expression O +
of O +
the O +
EBV O +
ZEBRA O +
protein O +
. O +

ZEBRA O +
, O +
a O +
transcriptional O +
activator O +
, O +
initiates O +
the O +
EBV O +
lytic O +
cascade O +
by O +
activating O +
viral O +
gene O +
expression O +
. O +

ZEBRA O +
is O +
also O +
indispensable O +
for O +
viral O +
replication O +
and O +
binds O +
directly O +
to O +
the O +
EBV O +
lytic O +
origin O +
of O +
replication O +
. O +

The O +
studies O +
described O +
herein O +
demonstrate O +
that O +
the O +
activation O +
domain O +
. O +

ZEBRA O +
activation O +
can O +
be O +
replaced O +
by O +
a O +
heterologous O +
acidic O +
, O +
proline O -
- O -
rich O +
, O +
or O +
glutamine O -
- O -
rich O +
activation O +
domain O +
. O +

ZEBRA O +
activation O +
domain O +
swap O +
constructs O +
retain O +
ZEBRA O +
's O +
native O +
abilities O +
to O +
activate O +
specific O +
EBV O +
promoters O +
, O +
to O +
disrupt O +
EBV O +
latency O +
, O +
and O +
to O +
stimulate O +
replication O +
at O +
the O +
EBV O +
lytic O +
origin O +
. O +

Additional O +
work O +
, O +
employing O +
sequential O +
and O +
internal O +
deletions O +
of O +
ZEBRA O +
's O +
N O -
- O -
terminal O +
activation O +
domain O +
, O +
indicates O +
that O +
its O +
separate O +
activities O +
are O +
not O +
attributable O +
to O +
specific O +
subdomains O +
but O +
are O +
spread O +
throughout O +
its O +
N O +
terminus O +
and O +
therefore O +
can O +
not O +
be O +
inactivated O +
by O +
deleting O +
localized O +
regions O +
. O +

Critical O +
cytoplasmic O +
domains O +
of O +
human O +
interleukin-9 O +
receptor O +
alpha O +
chain O +
in O +
interleukin O +
-9-mediated O +
cell O +
proliferation O +
and O +
signal O +
transduction O +
. O +

Interleukin-9 O +
receptor O +
( O +
IL-9R O +
) O +
complex O +
consists O +
of O +
a O +
ligand O -
- O -
specific O +
alpha O +
chain O +
and O +
IL-2R O +
gamma O +
chain O +
. O +

In O +
this O +
study O +
, O +
two O +
regions O +
in O +
the O +
cytoplasmic O +
domain O +
of O +
human O +
IL-9Ralpha O +
were O +
found O +
to O +
be O +
important O +
for O +
IL-9 O +
-mediated O +
cell O +
growth O +
. O +

A O +
membrane O -
- O -
proximal O +
region O +
that O +
contains O +
the O +
BOX1 O +
consensus O +
sequence O +
is O +
required O +
for O +
IL-9 O +
-induced O +
cell O +
proliferation O +
and O +
tyrosine O +
phosphorylation O +
of O +
Janus O +
kinases O +
( O +
JAKs O +
) O +
. O +

Deletion O +
of O +
this O +
region O +
or O +
internal O +
deletion O +
of O +
the O +
BOX1 O +
motif O +
abrogated O +
IL-9 O +
-induced O +
cell O +
proliferation O +
and O +
signal O +
transduction O +
. O +

However O +
, O +
substitution O +
of O +
the O +
Pro O -
- O -
X O -
- O -
Pro O +
in O +
the O +
BOX1 O +
motif O +
with O +
Ala O -
- O -
X O -
- O -
Ala O +
failed O +
to O +
abolish O +
IL-9 O +
-induced O +
cell O +
proliferation O +
but O +
decreased O +
IL-9 O +
-mediated O +
tyrosine O +
phosphorylation O +
of O +
JAK O +
kinases O +
, O +
insulin O +
receptor O +
substrate-2 O +
, O +
and O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
3 O +
( O +
STAT3 O +
) O +
and O +
expression O +
of O +
c O -
- O -
myc O +
and O +
junB O +
. O +

Another O +
important O +
region O +
is O +
downstream O +
of O +
the O +
BOX1 O +
motif O +
and O +
contains O +
a O +
STAT3 O +
binding O +
motif O +
YLPQ O +
. O +

Deletion O +
of O +
this O +
region O +
significantly O +
impaired O +
IL-9 O +
-induced O +
cell O +
growth O +
, O +
activation O +
of O +
JAK O +
kinases O +
, O +
insulin O +
receptor O +
substrate-2 O +
, O +
and O +
STAT3 O +
and O +
expression O +
of O +
early O +
response O +
genes O +
. O +

A O +
point O +
mutation O +
changing O +
YLPQ O +
into O +
YLPA O +
greatly O +
reduced O +
IL-9 O +
-induced O +
activation O +
of O +
STAT3 O +
and O +
expression O +
of O +
c O -
- O -
myc O +
but O +
did O +
not O +
affect O +
cell O +
proliferation O +
. O +

These O +
results O +
suggest O +
that O +
cooperation O +
or O +
cross O -
- O -
talk O +
of O +
signaling O +
molecules O +
associated O +
with O +
different O +
domains O +
of O +
IL-9Ralpha O +
other O +
than O +
STAT3 O +
is O +
essential O +
for O +
IL-9 O +
-mediated O +
cell O +
growth O +
. O +

Transcription O +
factors O +
in O +
immune O -
- O -
mediated O +
disease O +
. O +

A O +
large O +
amount O +
of O +
detailed O +
information O +
about O +
the O +
intracellular O +
proteins O +
regulating O +
NF O -
- O -
kappa O +
B O +
activation O +
and O +
the O +
cellular O +
response O +
to O +
NF O -
- O -
kappa O +
B O +
activation O +
has O +
emerged O +
recently O +
. O +

Several O +
small O +
molecules O +
, O +
an O +
antisense O +
oligonucleotide O +
, O +
and O +
gene O +
therapeutic O +
agents O +
that O +
inhibit O +
NF O -
- O -
kappa O +
b O +
activation O +
have O +
been O +
described O +
. O +

Despite O +
this O +
, O +
there O +
are O +
still O +
significant O +
gaps O +
in O +
our O +
understanding O +
of O +
this O +
process O +
and O +
its O +
consequences O +
. O +

In O +
contrast O +
, O +
the O +
characterization O +
of O +
transcription O +
factors O +
selectively O +
regulating O +
cytokine O +
production O +
by O +
CD4 O -
+ O +
T O +
cell O +
subsets O +
is O +
at O +
a O +
very O +
early O +
stage O +
. O +

Three O +
interacting O +
proteins O +
have O +
recently O +
been O +
shown O +
to O +
contribute O +
to O +
subset O -
- O -
restricted O +
expression O +
of O +
the O +
IL-4 O +
gene O +
. O +

There O +
are O +
other O +
elements O +
regulating O +
IL-4 O +
gene O +
expression O +
, O +
however O +
, O +
and O +
the O +
relative O +
importance O +
of O +
these O +
recently O +
identified O +
proteins O +
has O +
yet O +
to O +
be O +
determined O +
. O +

CholecystokininB O +
receptor O +
from O +
human B-CellLine +
Jurkat I-CellLine +
lymphoblastic I-CellLine +
T I-CellLine +
cells I-CellLine +
is O +
involved O +
in O +
activator O +
protein-1 O +
-responsive O +
gene O +
activation O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
analyze O +
the O +
role O +
of O +
cholecystokinin O +
( O +
CCK O +
( O +
B O +
) O +
) O +
receptor O +
in O +
human B-CellLine +
lymphoblastic I-CellLine +
Jurkat I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

We O +
investigated O +
the O +
trophic O +
effect O +
resulting O +
from O +
activation O +
of O +
such O +
a O +
receptor O +
by O +
using O +
the O +
reporter O +
gene O +
strategy O +
. O +

For O +
this O +
purpose O +
, O +
we O +
transiently O +
transfected O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
with O +
the O +
reporter O +
plasmid O +
p O +
[ O +
( O +
TRE O +
) O +
3-tk O -
- O -
Luc O +
] O +
and O +
found O +
that O +
CCK-8 O +
was O +
able O +
to O +
dose O -
- O -
dependently O +
induce O +
luciferase O +
expression O +
related O +
to O +
activator O +
protein-1 O +
( O +
AP-1 O +
) O +
activation O +
with O +
a O +
maximal O +
response O +
identical O +
to O +
that O +
obtained O +
with O +
compounds O +
known O +
to O +
activate O +
AP-1 O +
complex O +
( O +
quantitatively O +
, O +
the O +
same O +
level O +
of O +
induction O +
was O +
obtained O +
with O +
1 O +
nM O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
, O +
100 O +
microM O +
diacylglycerol O +
, O +
or O +
4 O +
nM O +
epidermal O +
growth O +
factor O +
) O +
. O +

The O +
involvement O +
of O +
the O +
CCK O +
( O +
B O +
) O +
receptor O +
in O +
such O +
a O +
stimulation O +
was O +
demonstrated O +
by O +
the O +
inhibiting O +
effect O +
of O +
the O +
selective O +
CCK O +
( O +
B O +
) O +
receptor O +
antagonist O +
PD-135 O +
, O +
158 O +
. O +

This O +
effect O +
was O +
confirmed O +
in O +
COS-7 O +
cells O +
transfected O +
with O +
the O +
cDNA O +
of O +
CCK O +
( O +
B O +
) O +
receptor O +
cloned O +
from O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

To O +
better O +
understand O +
the O +
AP-1 O +
-dependent O +
luciferase O +
expression O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
, O +
we O +
tested O +
two O +
specific O +
inhibitors O +
of O +
serine O -
/ O -
threonine O +
phosphatases-1 O +
and O +
-2A O +
: O +
okadaic O +
acid O +
and O +
calyculin O +
A O +
. O +

These O +
compounds O +
strongly O +
increased O +
the O +
phorbol-12-myristate-13-acetate O +
response O +
, O +
whereas O +
we O +
have O +
not O +
observed O +
a O +
contribution O +
of O +
phosphatase O +
inhibitors O +
on O +
a O +
CCK-8-induced O +
luciferase O +
activity O +
. O +

To O +
confirm O +
that O +
CCK O +
( O +
B O +
) O +
receptors O +
are O +
involved O +
in O +
AP-1 O +
response O +
, O +
we O +
investigated O +
the O +
CCK-8 O +
effect O +
on O +
interleukin-2 O +
expression O +
, O +
a O +
natural O +
endogenous O +
gene O +
regulated O +
by O +
several O +
factors O +
, O +
including O +
AP-1 O +
. O +

In O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
activated O +
by O +
phorbol-12-myristate-13-acetate O +
and O +
phytohemagglutinin O +
, O +
CCK-8 O +
induced O +
IL-2 O +
expression O +
. O +

This O +
induction O +
was O +
abolished O +
by O +
PD-135 O +
, O +
158 O +
. O +

Our O +
results O +
indicate O +
that O +
CCK-8 O +
exerts O +
a O +
trophic O +
effect O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
through O +
stimulation O +
of O +
CCK O +
( O +
B O +
) O +
receptors O +
by O +
modulation O +
of O +
expression O +
of O +
AP-1-regulated O +
genes O +
. O +

Epstein O -
- O -
Barr O +
virus O +
binding O +
to O +
CD21 O +
activates O +
the O +
initial O +
viral O +
promoter O +
via O +
NF O -
- O -
kappaB O +
induction O +
. O +

Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
, O +
an O +
oncogenic O +
human O +
herpesvirus O +
, O +
binds O +
to O +
and O +
infects O +
normal O +
human O +
B O +
lymphocytes O +
via O +
CD21 O +
, O +
the O +
CR2 O +
complement O +
receptor O +
. O +

Studies O +
of O +
the O +
mechanisms O +
that O +
enable O +
EBV O +
to O +
infect O +
nonactivated O +
, O +
noncycling O +
B O +
cells O +
provide O +
compelling O +
evidence O +
for O +
a O +
sequence O +
of O +
events O +
in O +
which O +
EBV O +
binding O +
to O +
CD21 O +
on O +
purified O +
resting O +
human O +
B O +
cells O +
rapidly O +
activates O +
the O +
NF O -
- O -
kappaB O +
transcription O +
factor O +
, O +
which O +
, O +
in O +
turn O +
, O +
binds O +
to O +
and O +
mediates O +
transcriptional O +
activation O +
of O +
Wp O +
, O +
the O +
initial O +
viral O +
latent O +
gene O +
promoter O +
. O +

Thus O +
, O +
EBV O +
binding O +
to O +
its O +
cellular O +
receptor O +
on O +
resting O +
B O +
cells O +
triggers O +
an O +
NF O -
- O -
kappaB O +
-dependent O +
intracellular O +
signaling O +
pathway O +
which O +
is O +
required O +
for O +
infection O +
. O +

Human O +
monocyte O +
binding O +
to O +
fibronectin O +
enhances O +
IFN O -
- O -
gamma O +
-induced O +
early O +
signaling O +
events O +
. O +

Leukocyte O +
integrins O +
are O +
fundamentally O +
important O +
in O +
modulating O +
adhesion O +
to O +
extracellular O +
matrix O +
components O +
and O +
to O +
other O +
cells O +
. O +

This O +
integrin O -
- O -
mediated O +
adhesion O +
controls O +
leukocyte O +
arrest O +
and O +
extravasation O +
during O +
the O +
onset O +
of O +
inflammatory O +
responses O +
. O +

Moreover O +
, O +
integrin O +
-ligand O +
interactions O +
trigger O +
signaling O +
pathways O +
that O +
may O +
influence O +
leukocyte O +
phenotype O +
and O +
function O +
at O +
sites O +
of O +
inflammation O +
. O +

In O +
the O +
current O +
studies O +
, O +
we O +
evaluated O +
the O +
combinatorial O +
effects O +
of O +
monocyte O +
adhesion O +
and O +
IFN O -
- O -
gamma O +
on O +
intracellular O +
signaling O +
pathways O +
. O +

IFN O -
- O -
gamma O +
triggers O +
a O +
well O -
- O -
defined O +
signal O +
transduction O +
pathway O +
, O +
which O +
although O +
not O +
directly O +
stimulated O +
by O +
monocyte O +
adherence O +
to O +
fibronectin O +
or O +
arginine O -
- O -
glycine O -
- O -
aspartate O +
( O +
RGD O +
) O +
-coated O +
substrata O +
, O +
was O +
enhanced O +
significantly O +
in O +
these O +
matrix O -
- O -
adherent O +
cells O +
. O +

Compared O +
with O +
monocytes O +
in O +
suspension O +
or O +
adherent O +
on O +
plastic O +
surfaces O +
, O +
monocytes O +
adherent O +
to O +
fibronectin O +
or O +
RGD O +
exhibited O +
a O +
greater O +
than O +
threefold O +
increase O +
in O +
steady O +
state O +
levels O +
of O +
IFN O -
- O -
gamma O -
- O -
induced O +
mRNA O +
for O +
the O +
high O +
affinity O +
Fc O +
gammaRI O +
receptor O +
. O +

By O +
electrophoretic O +
mobility O +
shift O +
assays O +
, O +
this O +
increase O +
in O +
mRNA O +
was O +
associated O +
with O +
a O +
5- O +
to O +
10-fold O +
increase O +
in O +
the O +
STAT1-containing O +
DNA O -
- O -
binding O +
complex O +
that O +
binds O +
to O +
Fc O +
gammaRI O +
promoter O +
elements O +
. O +

Furthermore O +
, O +
the O +
tyrosine O +
phosphorylation O +
of O +
STAT1 O +
and O +
the O +
tyrosine O +
kinases O +
JAK1 O +
and O +
JAK2 O +
was O +
enhanced O +
significantly O +
in O +
RGD O -
- O -
adherent O +
monocytes O +
compared O +
with O +
control O +
cells O +
. O +

These O +
results O +
suggest O +
a O +
novel O +
mechanism O +
by O +
which O +
integrin O +
-mediated O +
cell O +
adhesion O +
can O +
modulate O +
the O +
magnitude O +
of O +
cytokine O +
-induced O +
signal O +
transduction O +
pathways O +
, O +
thereby O +
amplifying O +
cellular O +
events O +
leading O +
to O +
monocyte O +
activation O +
and O +
inflammation O +
. O +

Surfactant O +
protein O +
A O +
activates O +
NF O -
- O -
kappa O +
B O +
in O +
the O +
THP-1 B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

The O +
expression O +
of O +
many O +
genes O +
for O +
which O +
products O +
are O +
involved O +
in O +
inflammation O +
is O +
controlled O +
by O +
the O +
transcriptional O +
regulator O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappa O +
B O +
. O +

Because O +
surfactant O +
protein O +
( O +
SP O +
) O +
A O +
is O +
involved O +
in O +
local O +
host O +
defense O +
in O +
the O +
lung O +
and O +
alters O +
immune O +
cell O +
function O +
by O +
modulating O +
the O +
expression O +
of O +
proinflammatory O +
cytokines O +
as O +
well O +
as O +
surface O +
proteins O +
involved O +
in O +
inflammation O +
, O +
we O +
hypothesized O +
that O +
SP O -
- O -
A O +
exerts O +
its O +
action O +
, O +
at O +
least O +
in O +
part O +
, O +
via O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

We O +
used O +
gel O +
shift O +
assays O +
to O +
determine O +
whether O +
SP O -
- O -
A O +
activated O +
NF O -
- O -
kappa O +
B O +
in O +
the O +
THP-1 B-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
a O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Activation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
THP-1 B-CellLine +
cells I-CellLine +
by O +
SP O -
- O -
A O +
doses O +
as O +
low O +
as O +
1 O +
microgram O -
/ O -
ml O +
occurred O +
within O +
30 O +
min O +
of O +
SP O -
- O -
A O +
treatment O +
, O +
peaked O +
at O +
60 O +
min O +
, O +
and O +
then O +
declined O +
. O +

This O +
activation O +
is O +
inhibited O +
by O +
known O +
inhibitors O +
of O +
NF O -
- O -
kappa O +
B O +
or O +
by O +
simultaneous O +
treatment O +
of O +
the O +
cells O +
with O +
surfactant O +
lipids O +
. O +

Moreover O +
, O +
the O +
NF O -
- O -
kappa O +
B O +
inhibitors O +
blocked O +
SP O -
- O -
A O +
-dependent O +
increases O +
in O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
mRNA O +
levels O +
. O +

These O +
observations O +
suggest O +
a O +
mechanism O +
by O +
which O +
SP O -
- O -
A O +
plays O +
a O +
role O +
in O +
the O +
pathogenesis O +
of O +
some O +
lung O +
conditions O +
and O +
point O +
to O +
potential O +
therapeutic O +
measures O +
that O +
could O +
be O +
used O +
to O +
prevent O +
SP O -
- O -
A O +
induced O +
inflammation O +
in O +
the O +
lung O +
. O +

Distinct O +
mechanisms O +
for O +
N O -
- O -
acetylcysteine O +
inhibition O +
of O +
cytokine O -
- O -
induced O +
E O -
- O -
selectin O +
and O +
VCAM-1 O +
expression O +
. O +

We O +
have O +
examined O +
the O +
effects O +
of O +
N O -
- O -
acetyl O -
- O -
L O -
- O -
cysteine O +
( O +
NAC O +
) O +
, O +
a O +
well O -
- O -
characterized O +
, O +
thiol O -
- O -
containing O +
antioxidant O +
, O +
on O +
agonist O -
- O -
induced O +
monocytic O +
cell O +
adhesion O +
to O +
endothelial O +
cells O +
( O +
EC O +
) O +
. O +

NAC O +
inhibited O +
interleukin-1 O +
( O +
IL-1 O +
beta O +
) O +
-induced O +
, O +
but O +
not O +
basal O +
, O +
adhesion O +
with O +
50 O +
% O +
inhibition O +
at O +
approximately O +
20 O +
mM O +
. O +

Monocytic O +
cell O +
adhesion O +
to O +
EC O +
in O +
response O +
to O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
, O +
lipopolysaccharide O +
( O +
LPS O +
) O +
, O +
alpha O -
- O -
thrombin O +
, O +
or O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
was O +
similarly O +
inhibited O +
by O +
NAC O +
. O +

Unlike O +
published O +
studies O +
with O +
pyrrolidinedithiocarbamate O +
, O +
which O +
specifically O +
inhibited O +
vascular O +
cell O +
adhesion O +
molecule O +
1 O +
( O +
VCAM-1 O +
) O +
, O +
NAC O +
inhibited O +
IL-1 O +
beta O -
- O -
induced O +
mRNA O +
and O +
cell O +
surface O +
expression O +
of O +
both O +
E O -
- O -
selectin O +
and O +
VCAM-1 O +
. O +

NAC O +
had O +
no O +
effect O +
on O +
the O +
half O -
- O -
life O +
of O +
E O -
- O -
selectin O +
or O +
VCAM-1 O +
mRNA O +
. O +

Although O +
NAC O +
reduced O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
activation O +
in O +
EC O +
as O +
measured O +
by O +
gel O -
- O -
shift O +
assays O +
using O +
an O +
oligonucleotide O +
probe O +
corresponding O +
to O +
the O +
consensus O +
NF O -
- O -
kappa O +
B O +
binding O +
sites O +
of O +
the O +
VCAM-1 O +
gene O +
( O +
VCAM O -
- O -
NF O -
- O -
kappa O +
B O +
) O +
, O +
the O +
antioxidant O +
had O +
no O +
appreciable O +
effect O +
when O +
an O +
oligomer O +
corresponding O +
to O +
the O +
consensus O +
NF O -
- O -
kappa O +
B O +
binding O +
site O +
of O +
the O +
E O -
- O -
selectin O +
gene O +
( O +
E O -
- O -
selectin O +
-NF O -
- O -
kappa O +
B O +
) O +
was O +
used O +
. O +

Because O +
NF O -
- O -
kappa O +
B O +
has O +
been O +
reported O +
to O +
be O +
redox O +
sensitive O +
, O +
we O +
studied O +
the O +
effects O +
of O +
NAC O +
on O +
the O +
EC O +
redox O +
environment O +
. O +

NAC O +
caused O +
an O +
expected O +
dramatic O +
increase O +
in O +
the O +
reduced O +
glutathione O +
( O +
GSH O +
) O +
levels O +
in O +
EC O +
. O +

In O +
vitro O +
studies O +
demonstrated O +
that O +
whereas O +
the O +
binding O +
affinity O +
of O +
NF O -
- O -
kappa O +
B O +
to O +
the O +
VCAM O -
- O -
NF O -
- O -
kappa O +
B O +
oligomer O +
peaked O +
at O +
a O +
GSH O -
- O -
to O -
- O -
oxidized O +
glutathione O +
( O +
GSSG O +
) O +
ratio O +
of O +
approximately O +
200 O +
and O +
decreased O +
at O +
higher O +
ratios O +
, O +
the O +
binding O +
to O +
the O +
E O -
- O -
selectin O -
- O -
NF O -
- O -
kappa O +
B O +
oligomer O +
appeared O +
relatively O +
unaffected O +
even O +
at O +
ratios O +
> O +
400 O +
, O +
i.e. O +
, O +
those O +
achieved O +
in O +
EC O +
treated O +
with O +
40 O +
mM O +
NAC O +
. O +

These O +
results O +
suggest O +
that O +
NF O -
- O -
kappa O +
B O +
binding O +
to O +
its O +
consensus O +
sequences O +
in O +
the O +
VCAM-1 O +
and O +
E O -
- O -
selectin O +
gene O +
exhibits O +
marked O +
differences O +
in O +
redox O +
sensitivity O +
, O +
allowing O +
for O +
differential O +
gene O +
expression O +
regulated O +
by O +
the O +
same O +
transcription O +
factor O +
. O +

Our O +
data O +
also O +
demonstrate O +
that O +
NAC O +
increases O +
the O +
GSH O -
- O -
to O -
- O -
GSSG O +
ratio O +
within O +
the O +
EC O +
suggesting O +
one O +
possible O +
mechanism O +
through O +
which O +
this O +
antioxidant O +
inhibits O +
agonist O -
- O -
induced O +
monocyte O +
adhesion O +
to O +
EC O +
. O +

Regulation O +
of O +
inosine-5'-monophosphate O +
dehydrogenase O +
type O +
II O +
gene O +
expression O +
in O +
human O +
T O +
cells O +
. O +

Role O +
for O +
a O +
novel O +
5 O +
' O +
palindromic O +
octamer O +
sequence O +
. O +

Expression O +
of O +
the O +
gene O +
encoding O +
human O +
inosine- O +
5'-monophosphate O +
dehydrogenase O +
( O +
IMPDH O +
) O +
type O +
II O +
, O +
an O +
enzyme O +
catalyzing O +
the O +
rate O -
- O -
limiting O +
step O +
in O +
the O +
generation O +
of O +
guanine O +
nucleotides O +
, O +
is O +
increased O +
more O +
than O +
10-fold O +
in O +
activated O +
peripheral O +
blood O +
T O +
lymphocytes O +
and O +
is O +
required O +
for O +
T O +
cell O +
activation O +
. O +

We O +
have O +
examined O +
the O +
5'-regulatory O +
sequences O +
that O +
are O +
important O +
for O +
the O +
transcriptional O +
regulation O +
of O +
this O +
gene O +
in O +
T O +
cells O +
. O +

DNase O +
I O +
mapping O +
of O +
genomic O +
DNA O +
identified O +
a O +
hypersensitive O +
element O +
near O +
the O +
transcription O +
initiation O +
site O +
. O +

Fine O +
mapping O +
by O +
in O +
vivo O +
footprinting O +
demonstrated O +
five O +
transcription O +
factor O +
binding O +
sites O +
that O +
are O +
occupied O +
in O +
both O +
resting O +
and O +
activated O +
peripheral O +
blood O +
T O +
lymphocytes O +
; O +
these O +
are O +
tandem O +
CRE O +
motifs O +
, O +
a O +
Sp1 O +
site O +
, O +
an O +
overlapping O +
Egr-1 O -
/ O -
Sp1 O +
site O +
, O +
and O +
a O +
novel O +
palindromic O +
octamer O +
sequence O +
( O +
POS O +
) O +
. O +

The O +
tandem O +
CRE O +
and O +
POS O +
sites O +
are O +
of O +
major O +
functional O +
importance O +
as O +
judged O +
by O +
mutational O +
and O +
electrophoretic O +
mobility O +
shift O +
analyses O +
. O +

These O +
data O +
provide O +
evidence O +
that O +
expression O +
of O +
the O +
human O +
IMPDH O +
type O +
II O +
gene O +
is O +
predominantly O +
regulated O +
by O +
the O +
nuclear O +
factors O +
ATF-2 O +
and O +
an O +
as O +
yet O +
unidentified O +
POS O -
- O -
binding O +
protein O +
. O +

Additional O +
major O +
protein O -
- O -
DNA O +
interactions O +
do O +
not O +
occur O +
within O +
the O +
promoter O +
region O +
after O +
T O +
lymphocyte O +
activation O +
, O +
indicating O +
a O +
requirement O +
for O +
additional O +
protein O -
- O -
protein O +
interactions O +
and/or O +
post O -
- O -
translational O +
modifications O +
of O +
pre O -
- O -
bound O +
transcription O +
factors O +
to O +
account O +
for O +
the O +
observed O +
increase O +
in O +
IMPDH O +
type O +
II O +
gene O +
expression O +
. O +

The O +
carboxyl O -
- O -
terminal O +
cytoplasmic O +
domain O +
of O +
CD36 O +
is O +
required O +
for O +
oxidized O +
low O -
- O -
density O +
lipoprotein O +
modulation O +
of O +
NF O -
- O -
kappaB O +
activity O +
by O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
. O +

The O +
binding O +
of O +
oxidized O +
low O -
- O -
density O +
lipoprotein O +
( O +
Ox O +
LDL O +
) O +
by O +
monocyte O +
-macrophages O +
causes O +
pleiotropic O +
effects O +
, O +
including O +
changes O +
in O +
gene O +
expression O +
, O +
and O +
is O +
thought O +
to O +
represent O +
an O +
early O +
event O +
in O +
atherogenesis O +
. O +

The O +
integral O +
membrane O +
glycoprotein O +
CD36 O +
appears O +
to O +
play O +
a O +
physiological O +
role O +
in O +
binding O +
and O +
uptake O +
of O +
Ox O +
LDL O +
by O +
monocyte O -
- O -
macrophages O +
, O +
although O +
the O +
molecular O +
events O +
associated O +
with O +
CD36 O +
-Ox O +
LDL O +
interaction O +
are O +
unknown O +
. O +

To O +
approach O +
this O +
issue O +
, O +
we O +
used O +
CD36 O +
transfected O +
Chinese O +
hampster O +
ovary O +
( O +
CHO O +
) O +
cells O +
, O +
exposed O +
them O +
to O +
Ox O +
LDL O +
, O +
and O +
determined O +
changes O +
in O +
the O +
activity O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
. O +

We O +
report O +
here O +
that O +
Ox O +
LDL O +
enhanced O +
DNA O +
binding O +
activity O +
of O +
nuclear O +
extracts O +
to O +
an O +
NF O -
- O -
kappaB O +
sequence O +
following O +
activation O +
of O +
CD36-producing B-CellLine +
CHO I-CellLine +
cells I-CellLine +
with O +
the O +
proinflammatory O +
cytokine O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
. O +

This O +
enhanced O +
DNA O +
binding O +
activity O +
was O +
inhibited O +
by O +
coincubation O +
of O +
CD36 O +
transfected O +
cells O +
with O +
the O +
human O +
CD36-specific O +
antibody O +
OKM5 O +
. O +

We O +
also O +
determined O +
that O +
activation O +
of O +
NF O -
- O -
kappaB O +
DNA O +
binding O +
activity O +
required O +
an O +
intact O +
carboxyl O -
- O -
terminal O +
cytoplasmic O +
segment O +
on O +
CD36 O +
. O +

Our O +
results O +
support O +
the O +
idea O +
that O +
human O +
CD36 O +
mediates O +
signal O +
transduction O +
events O +
in O +
response O +
to O +
Ox O +
LDL O +
. O +

Transcriptional O +
regulation O +
during O +
myelopoiesis O +
. O +

The O +
coordinated O +
production O +
of O +
all O +
blood O +
cells O +
from O +
a O +
common O +
stem O +
cell O +
is O +
a O +
highly O +
regulated O +
process O +
involving O +
successive O +
stages O +
of O +
commitment O +
and O +
differentiation O +
. O +

From O +
analyses O +
of O +
mice O +
deficient O +
in O +
transcription O +
factor O +
genes O +
and O +
from O +
the O +
characterizations O +
of O +
chromosome O +
breakpoints O +
in O +
human O +
leukemias O +
, O +
it O +
has O +
become O +
evident O +
that O +
transcription O +
factors O +
are O +
important O +
regulators O +
of O +
hematopoiesis O +
. O +

During O +
myelopoiesis O +
, O +
which O +
includes O +
the O +
development O +
of O +
granulocytic O +
and O +
monocytic O +
lineages O +
, O +
transcription O +
factors O +
from O +
several O +
families O +
are O +
active O +
, O +
including O +
AML1 O -
/ O -
CBF O +
beta O +
, O +
C O -
/ O -
EBP O +
, O +
Ets O +
, O +
c O -
- O -
Myb O +
, O +
HOX O +
, O +
and O +
MZF-1 O +
. O +

Few O +
of O +
these O +
factors O +
are O +
expressed O +
exclusively O +
in O +
myeloid O +
cells O +
; O +
instead O +
it O +
appears O +
that O +
they O +
cooperatively O +
regulate O +
transcription O +
of O +
myeloid O -
- O -
specific O +
genes O +
. O +

Here O +
we O +
discuss O +
recent O +
advances O +
in O +
transcriptional O +
regulation O +
during O +
myelopoiesis O +
. O +

Transcription O +
factor O +
Egr-1 O +
activity O +
down O -
- O -
regulates O +
Fas O +
and O +
CD23 O +
expression O +
in O +
B O +
cells O +
. O +

Activation O +
of O +
mature O +
B O +
cells O +
via O +
Ag O +
receptor O +
cross O -
- O -
linking O +
induces O +
transient O +
expression O +
of O +
the O +
transcription O +
factor O +
Egr-1 O +
. O +

Although O +
the O +
activating O +
signals O +
leading O +
to O +
Egr-1 O +
induction O +
have O +
been O +
studied O +
extensively O +
, O +
little O +
is O +
known O +
about O +
the O +
genes O +
that O +
are O +
placed O +
further O +
downstream O +
within O +
this O +
activation O +
cascade O +
and O +
that O +
are O +
transcriptionally O +
regulated O +
by O +
Egr-1 O +
. O +

To O +
identify O +
such O +
target O +
genes O +
, O +
we O +
established O +
Egr-1-overexpressing B-CellLine +
transfectants I-CellLine +
from O +
the O +
murine B-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
K46 I-CellLine +
and O +
from O +
human B-CellLine +
Ramos I-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

All O +
clones O +
derived O +
from O +
K46 B-CellLine +
B I-CellLine +
cells I-CellLine +
showed O +
increased O +
expression O +
of O +
CD44 O +
. O +

Most O +
interestingly O +
, O +
expression O +
of O +
CD95 O +
( O +
Fas O -
/ O -
Apo-1 O +
) O +
and O +
of O +
CD23 O +
was O +
down O -
- O -
regulated O +
in O +
all O +
K46 B-CellLine +
transfectants I-CellLine +
. O +

As O +
a O +
consequence O +
, O +
they O +
became O +
resistant O +
to O +
apoptosis O +
induced O +
by O +
anti O -
- O -
CD95 O +
Ab O +
treatment O +
. O +

Similarly O +
, O +
the O +
Egr-1-expressing B-CellLine +
Ramos I-CellLine +
cells I-CellLine +
showed O +
reduced O +
levels O +
of O +
CD95 O +
expression O +
. O +

Thus O +
, O +
Egr-1 O +
seems O +
to O +
control O +
the O +
expression O +
of O +
downstream O +
target O +
genes O +
not O +
only O +
as O +
a O +
transcriptional O +
activator O +
, O +
but O +
also O +
as O +
a O +
repressor O +
molecule O +
. O +

In O +
B O +
cells O +
, O +
Egr-1 O +
therefore O +
plays O +
a O +
critical O +
role O +
in O +
integrating O +
the O +
short O -
- O -
lived O +
signal O +
delivered O +
by O +
triggering O +
of O +
the O +
Ag O +
receptor O +
into O +
phenotypic O +
changes O +
, O +
including O +
repression O +
of O +
CD95 O +
and O +
CD23 O +
transcription O +
. O +

Genomic O +
organization O +
, O +
sequence O +
, O +
and O +
transcriptional O +
regulation O +
of O +
the O +
human O +
eotaxin O +
gene O +
. O +

Eotaxin O +
is O +
an O +
eosinophil O +
specific O +
beta O -
- O -
chemokine O +
assumed O +
to O +
be O +
involved O +
in O +
eosinophilic O +
inflammatory O +
diseases O +
such O +
as O +
atopic O +
dermatitis O +
, O +
allergic O +
rhinitis O +
, O +
asthma O +
and O +
parasitic O +
infections O +
. O +

Its O +
expression O +
is O +
stimulus- O +
and O +
cell O -
- O -
specific O +
. O +

We O +
here O +
describe O +
the O +
genomic O +
organisation O +
( O +
3 O +
exons O +
of O +
132 O +
, O +
112 O +
and O +
542 O +
bp O +
and O +
2 O +
introns O +
of O +
1211 O +
and O +
378 O +
bp O +
) O +
and O +
sequence O +
including O +
3 O +
kb O +
of O +
DNA O +
from O +
the O +
immediate O +
5 O +
' O +
upstream O +
region O +
of O +
the O +
human O +
eotaxin O +
gene O +
. O +

Among O +
the O +
regulatory O +
promoter O +
elements O +
potentially O +
regulating O +
eotaxin O +
gene O +
expression O +
and/or O +
mediating O +
the O +
effects O +
of O +
anti O -
- O -
inflammatory O +
drugs O +
we O +
identified O +
consensus O +
sequences O +
known O +
to O +
interact O +
with O +
nuclear O +
factors O +
like O +
NF O -
- O -
IL6 O +
, O +
AP-1 O +
, O +
a O +
NF O -
- O -
kappa O -
- O -
B O +
like O +
consensus O +
sequence O +
and O +
gamma O -
- O -
interferon- O +
as O +
well O +
as O +
glucocorticoid O +
response O +
elements O +
. O +

STAT3 O +
is O +
a O +
serine O +
kinase O +
target O +
in O +
T O +
lymphocytes O +
. O +

Interleukin O +
2 O +
and O +
T O +
cell O +
antigen O +
receptor O +
signals O +
converge O +
upon O +
serine O +
727 O +
. O +

Interleukin O +
2 O +
( O +
IL-2 O +
) O +
induces O +
tyrosine O +
phosphorylation O +
of O +
STATs O +
3 O +
and O +
5 O +
( O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
) O +
. O +

We O +
now O +
show O +
that O +
IL-2 O +
regulation O +
of O +
STAT3 O +
proteins O +
in O +
T O +
cells O +
is O +
a O +
complex O +
response O +
involving O +
activation O +
of O +
two O +
forms O +
of O +
STAT3 O +
: O +
90-kDa O +
STAT3alpha O +
and O +
an O +
83-kDa O +
carboxyl O -
- O -
terminal O +
truncated O +
STAT3beta O +
. O +

The O +
phosphorylation O +
of O +
STAT O +
proteins O +
on O +
serine O +
residues O +
is O +
also O +
required O +
for O +
competent O +
STAT O +
transcription O +
. O +

A O +
critical O +
serine O +
phosphorylation O +
site O +
in O +
STAT3alpha O +
is O +
at O +
position O +
727 O +
. O +

In O +
this O +
study O +
we O +
have O +
produced O +
an O +
antisera O +
specific O +
for O +
STAT3alpha O +
proteins O +
phosphorylated O +
on O +
serine O +
727 O +
and O +
used O +
this O +
to O +
monitor O +
the O +
phosphorylation O +
of O +
this O +
residue O +
during O +
T O +
lymphocyte O +
activation O +
. O +

Our O +
results O +
show O +
that O +
phosphorylation O +
of O +
STAT3alpha O +
on O +
serine O +
727 O +
is O +
not O +
constitutive O +
in O +
quiescent O +
T O +
cells O +
but O +
can O +
be O +
induced O +
by O +
the O +
cytokine O +
IL-2 O +
. O +

Interestingly O +
, O +
triggering O +
of O +
the O +
T O +
cell O +
antigen O +
receptor O +
complex O +
or O +
activation O +
of O +
protein O +
kinase O +
C O +
with O +
phorbol O +
esters O +
also O +
induces O +
phosphorylation O +
of O +
serine O +
727 O +
but O +
without O +
simultaneously O +
inducing O +
STAT3 O +
tyrosine O +
phosphorylation O +
or O +
DNA O +
binding O +
. O +

Hence O +
, O +
the O +
present O +
results O +
show O +
that O +
STAT3 O +
serine O +
phosphorylation O +
can O +
be O +
regulated O +
independently O +
of O +
the O +
tyrosine O +
phosphorylation O +
of O +
this O +
molecule O +
. O +

IL-2 O +
and O +
T O +
cell O +
antigen O +
receptor O +
complex O +
induction O +
of O +
STAT3alpha O +
serine O +
727 O +
phosphorylation O +
is O +
dependent O +
on O +
the O +
activity O +
of O +
the O +
MEK O +
/ERK O +
pathway O +
. O +

Previous O +
studies O +
have O +
identified O +
H-7-sensitive O +
kinase O +
pathways O +
that O +
regulate O +
STAT3 O +
DNA O +
binding O +
. O +

We O +
show O +
that O +
H-7-sensitive O +
pathways O +
regulate O +
STAT3 O +
DNA O +
binding O +
in O +
T O +
cells O +
. O +

Nevertheless O +
, O +
we O +
show O +
that O +
H-7-sensitive O +
kinases O +
do O +
not O +
regulate O +
STAT3 O +
tyrosine O +
phosphorylation O +
or O +
phosphorylation O +
of O +
serine O +
727 O +
. O +

These O +
results O +
thus O +
show O +
that O +
STAT3 O +
proteins O +
are O +
targets O +
for O +
multiple O +
kinase O +
pathways O +
in O +
T O +
cells O +
and O +
can O +
integrate O +
signals O +
from O +
both O +
cytokine O +
receptors O +
and O +
antigen O +
receptors O +
. O +

Abnormal O +
apoptosis O +
and O +
cell O +
cycle O +
progression O +
in O +
humans O +
exposed O +
to O +
methyl O +
tertiary O -
- O -
butyl O +
ether O +
and O +
benzene O +
contaminating O +
water O +
. O +

1 O -
. O +
In O +
this O +
study O +
we O +
hypothesized O +
that O +
in O +
individuals O +
with O +
certain O +
genetic O +
makeup O +
, O +
MTBE O +
, O +
benzene O +
or O +
their O +
metabolites O +
act O +
as O +
adducts O +
and O +
may O +
induce O +
programmed O +
cell O +
death O +
. O +

2 O -
. O +
Our O +
study O +
involved O +
a O +
group O +
of O +
60 O +
male O +
and O +
female O +
subjects O +
who O +
were O +
exposed O +
to O +
MTBE O +
and O +
benzene O -
- O -
contaminated O +
water O +
concentrations O +
up O +
to O +
76 O +
PPB O +
for O +
MTBE O +
and O +
14 O +
PPB O +
for O +
benzene O +
, O +
for O +
a O +
period O +
of O +
5 O +
to O +
8 O +
years O +
. O +

For O +
comparison O +
, O +
we O +
recruited O +
a O +
control O +
group O +
consisting O +
of O +
32 O +
healthy O +
males O +
and O +
females O +
with O +
similar O +
age O +
distribution O +
and O +
without O +
a O +
history O +
of O +
exposure O +
to O +
MTBE O +
or O +
benzene O +
. O +

3 O +
. O +
Peripheral O +
blood O +
lymphocytes O +
( O +
PBL O +
) O +
of O +
both O +
groups O +
were O +
tested O +
for O +
the O +
percentage O +
of O +
apoptotic O +
cells O +
and O +
cell O +
cycle O +
progression O +
using O +
flow O +
cytometry O +
. O +

4 O -
. O +
When O +
apoptotic O +
lymphocytes O +
from O +
exposed O +
individuals O +
were O +
compared O +
to O +
apoptotic O +
lymphocytes O +
from O +
the O +
control O +
group O +
, O +
statistically O -
- O -
significant O +
differences O +
between O +
each O +
mean O +
group O +
were O +
detected O +
( O +
26.4 O +
+ O -
/- O +
1.8 O +
and O +
12.1 O +
+ O -
/- O +
1.3 O +
, O +
respectively O +
) O +
, O +
indicating O +
an O +
increased O +
rate O +
of O +
apoptosis O +
in O +
80.5 O +
% O +
of O +
exposed O +
individuals O +
( O +
P O +
< O +
0.0001 O +
, O +
Mann O -
- O -
Whitney O +
U O -
- O -
Test O +
) O +
. O +

MTBE O +
and O +
benzene O -
- O -
induced O +
apoptosis O +
is O +
attributed O +
to O +
a O +
discrete O +
block O +
within O +
the O +
cell O +
cycle O +
progression O +
. O +

Because O +
cell O +
cycle O +
analysis O +
showed O +
that O +
in O +
PBL O +
from O +
chemically O -
- O -
exposed O +
individuals O +
, O +
between O +
20 O -
- O -
50 O +
% O +
of O +
cells O +
were O +
accumulated O +
at O +
the O +
S O -
- O -
G2 O -
/ O -
M O +
boundaries O +
. O +

5 O -
. O +
One O +
of O +
the O +
signaling O +
molecules O +
which O +
mediates O +
programmed O +
cell O +
death O +
is O +
nuclear O +
factor O +
Kappa O -
- O -
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
. O +

NF O -
- O -
kappa O +
B O +
was O +
examined O +
as O +
one O +
of O +
the O +
many O +
molecular O +
mechanisms O +
for O +
mediating O +
cell O +
death O +
by O +
MTBE O +
and O +
benzene O +
. O +

Indeed O +
, O +
addition O +
of O +
inhibitors O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
pyrrolidine O +
dithiocarbamate O +
( O +
PDTC O +
) O +
, O +
to O +
the O +
lymphocytes O +
of O +
the O +
chemically O -
- O -
exposed O +
group O +
was O +
capable O +
of O +
inhibiting O +
programmed O +
cell O +
death O +
by O +
40 O +
% O +
. O +

This O +
reversal O +
of O +
apoptosis O +
almost O +
to O +
the O +
control O +
level O +
by O +
inhibitor O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
may O +
indicate O +
involvement O +
of O +
this O +
signaling O +
molecule O +
in O +
MTBE O +
and O +
benzene O +
induction O +
of O +
programmed O +
cell O +
death O +
. O +

Alcohol O -
- O -
induced O +
regulation O +
of O +
nuclear O +
regulatory O +
factor O -
- O -
kappa O +
beta O +
in O +
human O +
monocytes O +
. O +

Acute O +
ethanol O +
exposure O +
has O +
the O +
capacity O +
to O +
modulate O +
immune O +
functions O +
, O +
particularly O +
, O +
to O +
down O +
regulate O +
monocyte O +
production O +
of O +
inflammatory O +
cytokines O +
. O +

However O +
, O +
the O +
intracellular O +
mechanisms O +
for O +
these O +
effects O +
of O +
ethanol O +
are O +
yet O +
to O +
be O +
understood O +
. O +

Considering O +
that O +
nuclear O +
regulatory O +
factor O -
- O -
kappa O +
beta O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
/Rel O +
is O +
a O +
common O +
regulatory O +
element O +
of O +
the O +
promoter O +
region O +
of O +
the O +
inflammatory O +
cytokine O +
genes O +
, O +
herein O +
, O +
we O +
tested O +
the O +
hypothesis O +
that O +
acute O +
ethanol O +
affects O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
human O +
monocytes O +
. O +

Adherence B-CellLine -
- I-CellLine -
isolated I-CellLine +
monocytes I-CellLine +
showed O +
constitutive O +
DNA O +
binding O +
activity O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

A O +
clinically O +
relevant O +
dose O +
( O +
25 O +
mM O +
) O +
of O +
acute O +
ethanol O +
treatment O +
in O +
vitro O +
increased O +
NF O -
- O -
kappa O +
B O +
binding O +
activity O +
in O +
monocytes O +
with O +
a O +
preferential O +
induction O +
of O +
the O +
inhibitory O +
, O +
p50 O -
/ O -
p50 O +
, O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
homodimer O +
, O +
and O +
resulted O +
in O +
no O +
induction O +
of O +
the O +
p65 O -
/ O -
p50 O +
heterodimer O +
. O +

In O +
contrast O +
, O +
lipopolysaccharide O +
stimulation O +
primarily O +
induced O +
the O +
p65 O -
/ O -
p50 O +
heterodimer O +
that O +
has O +
been O +
shown O +
to O +
result O +
in O +
gene O +
activation O +
. O +

Thus O +
, O +
such O +
unique O +
activation O +
of O +
the O +
inhibitory O +
p50 O -
/ O -
p50 O +
homodimer O +
by O +
acute O +
ethanol O +
treatment O +
may O +
result O +
in O +
inhibition O +
rather O +
than O +
activation O +
of O +
NF O -
- O -
kappa O +
B O -
- O -
regulated O +
inflammatory O +
cytokine O +
genes O +
. O +

Consequently O +
, O +
these O +
results O +
suggest O +
that O +
physiologically O +
relevant O +
concentrations O +
of O +
ethanol O +
may O +
affect O +
production O +
of O +
inflammatory O +
cytokines O +
, O +
such O +
as O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
, O +
interleukin-1 O +
beta O +
, O +
and O +
interleukin-6 O +
by O +
disrupting O +
NF O -
- O -
kappa O +
B O +
signaling O +
in O +
monocytes O +
. O +

NF O -
- O -
AT O +
activation O +
induced O +
by O +
a O +
CAML O +
-interacting O +
member O +
of O +
the O +
tumor O +
necrosis O +
factor O +
receptor O +
superfamily O +
. O +

Activation O +
of O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
transcription O +
factor O +
( O +
NF O -
- O -
AT O +
) O +
is O +
a O +
key O +
event O +
underlying O +
lymphocyte O +
action O +
. O +

The O +
CAML O +
( O +
calcium O -
- O -
modulator O +
and O +
cyclophilin O +
ligand O +
) O +
protein O +
is O +
a O +
coinducer O +
of O +
NF O -
- O -
AT O +
activation O +
when O +
overexpressed O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

A O +
member O +
of O +
the O +
tumor O +
necrosis O +
factor O +
receptor O +
superfamily O +
was O +
isolated O +
by O +
virtue O +
of O +
its O +
affinity O +
for O +
CAML O +
. O +

Cross O -
- O -
linking O +
of O +
this O +
lymphocyte O -
- O -
specific O +
protein O +
, O +
designated O +
TACI O +
( O +
transmembrane O +
activator O +
and O +
CAML O -
- O -
interactor O +
) O +
, O +
on O +
the O +
surface O +
of O +
transfected B-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
with O +
TACI O -
- O -
specific O +
antibodies O +
led O +
to O +
activation O +
of O +
the O +
transcription O +
factors O +
NF O -
- O -
AT O +
, O +
AP-1 O +
, O +
and O +
NFkappaB O +
. O +

TACI O +
-induced O +
activation O +
of O +
NF O -
- O -
AT O +
was O +
specifically O +
blocked O +
by O +
a O +
dominant O -
- O -
negative O +
CAML O +
mutant O +
, O +
thus O +
implicating O +
CAML O +
as O +
a O +
signaling O +
intermediate O +
. O +

Tissue O +
transglutaminase O -
- O -
dependent O +
posttranslational O +
modification O +
of O +
the O +
retinoblastoma O +
gene O +
product O +
in O +
promonocytic B-CellLine +
cells I-CellLine +
undergoing O +
apoptosis O +
. O +

The O +
retinoblastoma O +
gene O +
product O +
( O +
pRB O +
) O +
plays O +
an O +
important O +
role O +
in O +
controlling O +
both O +
cell O +
release O +
from O +
the O +
G1 O +
phase O +
and O +
apoptosis O +
. O +

We O +
show O +
here O +
that O +
in O +
the O +
early O +
phases O +
of O +
apoptosis O +
, O +
pRB O +
is O +
posttranslationally O +
modified O +
by O +
a O +
tissue O +
transglutaminase O +
( O +
tTG O +
) O +
-catalyzed O +
reaction O +
. O +

In O +
fact O +
, O +
by O +
employing O +
a O +
novel O +
haptenized O +
lysis O +
synthetic O +
substrate O +
which O +
allows O +
the O +
isolation O +
of O +
glutaminyl O -
- O -
tTG O +
substrates O +
in O +
vivo O +
, O +
we O +
identified O +
pRB O +
as O +
a O +
potential O +
tTG O +
substrate O +
in O +
U937 B-CellLine +
cells I-CellLine +
undergoing O +
apoptosis O +
. O +

In O +
keeping O +
with O +
this O +
finding O +
, O +
we O +
showed O +
that O +
apoptosis O +
of O +
U937 B-CellLine +
cells I-CellLine +
is O +
characterized O +
by O +
the O +
rapid O +
disappearance O +
of O +
the O +
105 O +
, O +
000- O +
to O +
110 O +
, O +
000-molecular O -
- O -
weight O +
pRB O +
forms O +
concomitantly O +
with O +
the O +
appearance O +
of O +
a O +
smear O +
of O +
immunoreactive O +
products O +
with O +
a O +
molecular O +
weight O +
of O +
greater O +
than O +
250 O +
, O +
000 O +
. O +

The O +
shift O +
in O +
pRB O +
molecular O +
weight O +
was O +
reproduced O +
by O +
adding O +
exogenous O +
purified O +
tTG O +
to O +
extracts O +
obtained O +
from O +
viable O +
U937 B-CellLine +
cells I-CellLine +
and O +
was O +
prevented O +
by O +
dansylcadaverine O +
, O +
a O +
potent O +
enzyme O +
inhibitor O +
. O +

The O +
effect O +
of O +
the O +
pRB O +
posttranslational O +
modification O +
during O +
apoptosis O +
was O +
investigated O +
by O +
determining O +
the O +
E2F-1 O +
levels O +
and O +
by O +
isolating O +
and O +
characterizing O +
pRB B-CellLine -
- I-CellLine -
null I-CellLine +
clones I-CellLine +
from O +
U937 B-CellLine +
cells I-CellLine +
. O +

Notably O +
, O +
the O +
lack O +
of O +
pRB O +
in O +
these O +
U937-derived B-CellLine +
clones I-CellLine +
renders O +
these O +
p53-null B-CellLine +
cells I-CellLine +
highly O +
resistant O +
to O +
apoptosis O +
induced O +
by O +
serum O +
withdrawal O +
, O +
calphostin O +
C O +
, O +
and O +
ceramide O +
. O +

Taken O +
together O +
, O +
these O +
data O +
suggest O +
that O +
tTG O +
, O +
acting O +
on O +
the O +
pRB O +
protein O +
, O +
might O +
play O +
an O +
important O +
role O +
in O +
the O +
cell O +
progression O +
through O +
the O +
death O +
program O +
. O +

Cooperation O +
of O +
Spi-1 O -
/ O -
PU.1 O +
with O +
an O +
activated O +
erythropoietin O +
receptor O +
inhibits O +
apoptosis O +
and O +
Epo O +
-dependent O +
differentiation O +
in O +
primary O +
erythroblasts O +
and O +
induces O +
their O +
Kit O +
ligand O -
- O -
dependent O +
proliferation O +
. O +

Spi-1 O -
/ O -
PU.1 O +
is O +
a O +
myeloid- O +
and O +
B O -
- O -
cell O +
specific O +
transcription O +
factor O +
which O +
is O +
also O +
involved O +
in O +
Friend O +
virus O -
- O -
induced O +
murine O +
erythroleukemia O +
. O +

The O +
pre O -
- O -
leukemic O +
phase O +
of O +
Friend O +
erythroleukemia O +
results O +
from O +
activation O +
of O +
the O +
erythropoietin O +
receptor O +
( O +
EpoR O +
) O +
by O +
the O +
spleen O +
focus O +
forming O +
virus O +
( O +
SFFV O +
) O +
envelope O +
glycoprotein O +
, O +
followed O +
by O +
the O +
emergence O +
of O +
leukemic O +
clones O +
characterized O +
by O +
overexpression O +
of O +
Spi-1 O +
and O +
mutation O +
of O +
the O +
p53 O +
tumor O +
suppressor O +
gene O +
. O +

We O +
developed O +
a O +
heterologous O +
system O +
to O +
analyze O +
the O +
contribution O +
of O +
these O +
alterations O +
to O +
the O +
induction O +
of O +
primary O +
erythroblast O +
transformation O +
. O +

Avian O +
erythroblasts O +
expressing O +
the O +
activated O +
mouse O +
EpoR O +
( O +
R129C O +
) O +
differentiated O +
into O +
erythrocytes O +
in O +
response O +
to O +
hEpo O +
. O +

Expression O +
of O +
Spi-1 O +
in O +
these O +
cells O +
inhibited O +
this O +
ability O +
to O +
differentiate O +
and O +
rescued O +
the O +
cells O +
from O +
the O +
apoptotic O +
cell O +
death O +
program O +
normally O +
induced O +
upon O +
hEpo O +
withdrawal O +
. O +

Although O +
devoid O +
of O +
any O +
effect O +
by O +
itself O +
, O +
a O +
mutant O +
p53 O +
cooperated O +
with O +
Spi-1 O +
and O +
EpoR O +
( O +
R129C O +
) O +
to O +
reinforce O +
both O +
phenotypes O +
. O +

Analysis O +
of O +
erythroblasts O +
co O -
- O -
expressing O +
Spi-1 O +
and O +
the O +
wild O -
- O -
type O +
mouse O +
EpoR O +
showed O +
that O +
differentiation O +
arrest O +
and O +
inhibition O +
of O +
apoptosis O +
depended O +
on O +
specific O +
cooperation O +
between O +
Spi-1 O +
and O +
EpoR O +
( O +
R129C O +
) O +
. O +

This O +
cooperation O +
was O +
also O +
required O +
to O +
induce O +
the O +
sustained O +
proliferation O +
of O +
differentiation B-CellLine -
- I-CellLine -
blocked I-CellLine +
erythroblasts I-CellLine +
in O +
response O +
to O +
ligand O +
activation O +
of O +
the O +
endogenous O +
tyrosine O +
kinase O +
receptor O +
c O -
- O -
Kit O +
. O +

These O +
results O +
show O +
that O +
Spi-1 O -
/ O +
PU.1 O +
requires O +
signals O +
emanating O +
from O +
specific O +
cytokine O +
and O +
growth O +
factor O +
receptors O +
to O +
affect O +
the O +
survival O +
, O +
proliferation O +
and O +
differentiation O +
control O +
of O +
primary O +
erythroblasts O +
. O +

They O +
also O +
suggest O +
that O +
the O +
function O +
of O +
Spi-1 O -
/ O -
PU.1 O +
in O +
the O +
late O +
phase O +
of O +
Friend O +
leukemia O +
requires O +
specific O +
signaling O +
from O +
the O +
gp55-modified O +
EpoR O +
generated O +
during O +
the O +
early O +
phase O +
of O +
the O +
disease O +
. O +

Evidence O +
that O +
calcineurin O +
is O +
rate O -
- O -
limiting O +
for O +
primary O +
human O +
lymphocyte O +
activation O +
. O +

Cyclosporine O +
( O +
CsA O +
) O +
is O +
both O +
a O +
clinical O +
immunosuppressive O +
drug O +
and O +
a O +
probe O +
to O +
dissect O +
intracellular O +
signaling O +
pathways O +
. O +

In O +
vitro O +
, O +
CsA O +
inhibits O +
lymphocyte O +
gene O +
activation O +
by O +
inhibiting O +
the O +
phosphatase O +
activity O +
of O +
calcineurin O +
( O +
CN O +
) O +
. O +

In O +
clinical O +
use O +
, O +
CsA O +
treatment O +
inhibits O +
50 O -
- O -
75 O +
% O +
of O +
CN O +
activity O +
in O +
circulating O +
leukocytes O +
. O +

We O +
modeled O +
this O +
degree O +
of O +
CN O +
inhibition O +
in O +
primary O +
human O +
leukocytes O +
in O +
vitro O +
in O +
order O +
to O +
study O +
the O +
effect O +
of O +
partial O +
CN O +
inhibition O +
on O +
the O +
downstream O +
signaling O +
events O +
that O +
lead O +
to O +
gene O +
activation O +
. O +

In O +
CsA B-CellLine -
- I-CellLine -
treated I-CellLine +
leukocytes I-CellLine +
stimulated O +
by O +
calcium O +
ionophore O +
, O +
the O +
degree O +
of O +
reduction O +
in O +
CN O +
activity O +
was O +
accompanied O +
by O +
a O +
similar O +
degree O +
of O +
inhibition O +
of O +
each O +
event O +
tested O +
: O +
dephosphorylation O +
of O +
nuclear O +
factor O +
of O +
activated O +
T O +
cell O +
proteins O +
, O +
nuclear O +
DNA O +
binding O +
, O +
activation O +
of O +
a O +
transfected O +
reporter O +
gene O +
construct O +
, O +
IFN O -
- O -
gamma O +
and O +
IL-2 O +
mRNA O +
accumulation O +
, O +
and O +
IFN O -
- O -
gamma O +
production O +
. O +

Furthermore O +
, O +
the O +
degree O +
of O +
CN O +
inhibition O +
was O +
reflected O +
by O +
a O +
similar O +
degree O +
of O +
reduction O +
in O +
lymphocyte O +
proliferation O +
and O +
IFN O -
- O -
gamma O +
production O +
in O +
the O +
allogeneic B-CellLine +
mixed I-CellLine +
lymphocyte I-CellLine +
cultures I-CellLine +
. O +

These O +
data O +
support O +
the O +
conclusion O +
that O +
CN O +
activity O +
is O +
rate O -
- O -
limiting O +
for O +
the O +
activation O +
of O +
primary O +
human O +
T O +
lymphocytes O +
. O +

Thus O +
, O +
the O +
reduction O +
of O +
CN O +
activity O +
observed O +
in O +
CsA O -
- O -
treated O +
patients O +
is O +
accompanied O +
by O +
a O +
similar O +
degree O +
of O +
reduction O +
in O +
lymphocyte O +
gene O +
activation O +
, O +
and O +
accounts O +
for O +
the O +
immunosuppression O +
observed O +
. O +

The O +
DNA O +
binding O +
domain O +
of O +
the O +
A O -
- O -
MYB O +
transcription O +
factor O +
is O +
responsible O +
for O +
its O +
B O +
cell O -
- O -
specific O +
activity O +
and O +
binds O +
to O +
a O +
B O +
cell O +
110-kDa O +
nuclear O +
protein O +
. O +

Expression O +
studies O +
as O +
well O +
as O +
the O +
use O +
of O +
transgenic O +
animals O +
have O +
demonstrated O +
that O +
the O +
A O -
- O -
MYB O +
transcription O +
factor O +
plays O +
central O +
and O +
specific O +
role O +
in O +
the O +
regulation O +
of O +
mature O +
B O +
cell O +
proliferation O +
and/or O +
differentiation O +
. O +

Furthermore O +
, O +
it O +
is O +
highly O +
expressed O +
in O +
Burkitt B-CellLine +
's I-CellLine +
lymphoma I-CellLine +
cells I-CellLine +
and O +
may O +
participate O +
in O +
the O +
pathogenesis O +
of O +
this O +
disease O +
. O +

We O +
have O +
therefore O +
investigated O +
the O +
transcriptional O +
activity O +
of O +
A O -
- O -
MYB O +
and O +
its O +
regulation O +
in O +
several O +
human B-CellLine +
lymphoid I-CellLine +
cell I-CellLine +
lines I-CellLine +
using O +
co O -
- O -
transfection O +
assays O +
and O +
show O +
that O +
A O -
- O -
MYB O +
is O +
transcriptionally O +
active O +
in O +
all O +
the O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
studied O +
, O +
but O +
not O +
in O +
T O +
cells O +
. O +

In O +
particular O +
the O +
best O +
responder B-CellLine +
cell I-CellLine +
line I-CellLine +
was O +
the O +
Burkitt B-CellLine +
's I-CellLine +
cell I-CellLine +
line I-CellLine +
Namalwa I-CellLine +
. O +

The O +
activity O +
of O +
A O -
- O -
MYB O +
in O +
B O +
and O +
not O +
T O +
cells O +
was O +
observed O +
when O +
either O +
an O +
artificial O +
construct O +
or O +
the O +
c O -
- O -
MYC O +
promoter O +
was O +
used O +
as O +
a O +
reporter O +
. O +

Furthermore O +
, O +
the O +
functional O +
domains O +
responsible O +
for O +
DNA O +
binding O +
, O +
transactivation O +
, O +
and O +
negative O +
regulation O +
, O +
previously O +
characterized O +
in O +
a O +
fibroblast O +
context O +
, O +
were O +
found O +
to O +
have O +
similar O +
activity O +
in O +
B O +
cells O +
. O +

The O +
region O +
of O +
A O -
- O -
MYB O +
responsible O +
for O +
the O +
B O +
cell O +
specific O +
activity O +
was O +
defined O +
to O +
be O +
the O +
N O -
- O -
terminal O +
218 O +
amino O +
acids O +
containing O +
the O +
DNA O +
binding O +
domain O +
. O +

Finally O +
, O +
a O +
110-kDa O +
protein O +
has O +
been O +
identified O +
in O +
the O +
nuclei O +
of O +
all O +
the O +
B B-CellLine +
, I-CellLine +
but I-CellLine +
not I-CellLine +
T I-CellLine +
, I-CellLine +
cell I-CellLine +
lines I-CellLine +
that O +
specifically O +
binds O +
to O +
this O +
A O -
- O -
MYB O +
N O -
- O -
terminal O +
domain O +
. O +

We O +
hypothesize O +
that O +
this O +
110-kDa O +
protein O +
may O +
be O +
a O +
functionally O +
important O +
B O +
cell O -
- O -
specific O +
co O -
- O -
activator O +
of O +
A O -
- O -
MYB O +
. O +

Cooperation O +
of O +
binding O +
sites O +
for O +
STAT6 O +
and O +
NF O +
kappa O +
B O -
/ O -
rel O +
in O +
the O +
IL-4 O +
-induced O +
up O -
- O -
regulation O +
of O +
the O +
human O +
IgE O +
germline O +
promoter O +
. O +

Ig O +
heavy O +
chain O +
class O +
switching O +
is O +
directed O +
by O +
cytokines O +
inducing O +
transcription O +
from O +
unrearranged O +
CH O +
genes O +
. O +

Subsequently O +
, O +
such O +
primed O +
cells O +
can O +
undergo O +
switch O +
recombination O +
to O +
express O +
the O +
selected O +
new O +
isotype O +
. O +

In O +
the O +
case O +
of O +
IgE O +
class O +
switching O +
, O +
IL-4 O +
activates O +
the O +
IgE O +
germline O +
promoter O +
by O +
inducing O +
the O +
interaction O +
of O +
the O +
transcription O +
factor O +
STAT6 O +
( O +
IL-4STAT O +
) O +
with O +
a O +
responsive O +
DNA O +
element O +
in O +
the O +
proximal O +
region O +
of O +
the O +
promoter O +
. O +

This O +
study O +
describes O +
the O +
characterization O +
of O +
two O +
additional O +
cis O -
- O -
acting O +
elements O +
that O +
interact O +
with O +
members O +
of O +
the O +
NF O +
kappa O +
B O -
/ O -
rel O +
transcription O +
factor O +
family O +
in O +
an O +
IL-4 O +
-independent O +
fashion O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
show O +
that O +
the O +
nucleoprotein O +
complex O +
formed O +
on O +
the O +
upstream O +
site O +
( O +
NF O +
kappa O +
B1 O +
) O +
contains O +
the O +
classical O +
p50 O -
/ O -
p65 O +
heterodimer O +
. O +

The O +
complex O +
on O +
the O +
proximal O +
site O +
( O +
NF O +
kappa O +
B2 O +
) O +
appears O +
to O +
be O +
composed O +
of O +
p50 O +
and O +
relB O +
. O +

IgE O +
germline O +
promoter O +
reporter O +
gene O +
constructs O +
carrying O +
point O +
mutations O +
in O +
the O +
NF O +
kappa O +
B2 O +
site O +
were O +
largely O +
unresponsive O +
to O +
IL-4 O +
stimulation O +
in O +
transient O +
transfection O +
experiments O +
, O +
while O +
plasmids O +
with O +
similar O +
mutations O +
in O +
the O +
NF O +
kappa O +
B1 O +
site O +
responded O +
to O +
cytokine O +
stimulation O +
better O +
than O +
the O +
wild O -
- O -
type O +
promoter O +
. O +

The O +
NF O +
kappa O +
B2 O +
effect O +
was O +
dependent O +
on O +
the O +
presence O +
of O +
the O +
STAT6 O +
binding O +
site O +
, O +
demonstrating O +
that O +
the O +
NF O +
kappa O +
B2 O +
motif O +
is O +
necessary O +
but O +
not O +
sufficient O +
for O +
mediating O +
cytokine O +
up O -
- O -
regulation O +
. O +

In O +
addition O +
, O +
the O +
combination O +
of O +
a O +
NF O +
kappa O +
B O -
/ O -
rel O +
binding O +
site O +
and O +
the O +
STAT6 O +
response O +
element O +
conferred O +
IL-4 O +
inducibility O +
to O +
a O +
heterologous O +
minimal O +
promoter O +
, O +
while O +
the O +
individual O +
sites O +
had O +
no O +
effect O +
. O +

The O +
available O +
data O +
suggest O +
that O +
the O +
NF O +
kappa O +
B2 O +
nucleoprotein O +
complex O +
may O +
cooperate O +
with O +
DNA O -
- O -
bound O +
STAT6 O +
to O +
achieve O +
IL-4 O +
-dependent O +
activation O +
of O +
the O +
human O +
IgE O +
germline O +
gene O +
. O +

The O +
A O -
- O -
myb O +
transcription O +
factor O +
in O +
neoplastic O +
and O +
normal O +
B O +
cells O +
. O +

The O +
myb O +
family O +
of O +
transcription O +
factors O +
has O +
been O +
strongly O +
implicated O +
in O +
the O +
regulation O +
of O +
cell O +
growth O +
and O +
differentiation O +
in O +
the O +
haematopoietic O +
system O +
. O +

The O +
v O -
- O -
myb O +
oncogene O +
, O +
carried O +
by O +
avian O +
defective O +
retroviruses O +
, O +
causes O +
leukaemias O +
in O +
the O +
chicken O +
and O +
transforms O +
haematopoietic O +
cells O +
in O +
vitro O +
. O +

Its O +
normal O +
cellular O +
equivalent O +
c O -
- O -
myb O +
, O +
has O +
been O +
shown O +
to O +
promote O +
the O +
proliferation O +
and O +
block O +
the O +
differentiation O +
of O +
haematopoietic O +
cells O +
in O +
several O +
experimental O +
models O +
and O +
is O +
required O +
for O +
fetal O +
haematopoiesis O +
. O +

Two O +
other O +
members O +
of O +
the O +
family O +
have O +
been O +
cloned O +
more O +
recently O +
, O +
A O -
- O -
myb O +
and O +
B O -
- O -
myb O +
, O +
which O +
show O +
sequence O +
homology O +
with O +
c O -
- O -
myb O +
in O +
several O +
domains O +
, O +
of O +
which O +
the O +
DNA O +
binding O +
domain O +
as O +
well O +
as O +
other O +
regulatory O +
domains O +
. O +

Both O +
have O +
been O +
shown O +
to O +
be O +
transcription O +
factors O +
. O +

B O -
- O -
myb O +
is O +
also O +
involved O +
in O +
the O +
control O +
of O +
proliferation O +
and O +
differentiation O +
, O +
but O +
, O +
unlike O +
c O -
- O -
myb O +
, O +
it O +
is O +
expressed O +
in O +
many O +
cell O +
types O +
. O +

The O +
third O +
member O +
of O +
the O +
family O +
, O +
A O -
- O -
myb O +
, O +
shows O +
the O +
most O +
restricted O +
pattern O +
of O +
expression O +
, O +
suggesting O +
a O +
very O +
specific O +
role O +
for O +
this O +
transcription O +
factor O +
. O +

A O -
- O -
myb O +
is O +
expressed O +
in O +
a O +
subpopulation O +
of O +
normal O +
B O +
lymphocytes O +
activated O +
in O +
vivo O +
and O +
localised O +
in O +
the O +
germinal O +
center O +
of O +
peripheral O +
lymphoid O +
organs O +
and O +
is O +
not O +
detected O +
at O +
significant O +
levels O +
in O +
all O +
other O +
mature O +
or O +
immature O +
haematopoietic O +
populations O +
studied O +
, O +
including O +
bone O +
marrow O +
cells O +
, O +
T O +
lymphocytes O +
, O +
granulocytes O +
, O +
monocytes O +
, O +
either O +
at O +
rest O +
or O +
after O +
in O +
vitro O +
activation O +
. O +

These O +
studies O +
indicate O +
that O +
A O -
- O -
myb O +
plays O +
a O +
role O +
during O +
a O +
narrow O +
window O +
of O +
normal O +
B O +
cell O +
differentiation O +
. O +

A O -
- O -
myb O +
expression O +
has O +
also O +
been O +
studied O +
in O +
a O +
wide O +
range O +
of O +
neoplastic O +
B O +
cells O +
, O +
representing O +
the O +
whole O +
spectrum O +
of O +
B O +
cell O +
differentiation O +
. O +

A O -
- O -
myb O +
is O +
strongly O +
expressed O +
in O +
Burkitt O +
's O +
lymphomas O +
( O +
BL O +
) O +
and O +
slg+ O +
B O -
- O -
acute O +
lymphoblastic O +
leukaemias O +
( O +
B O -
- O -
ALL O +
) O +
and O +
not O +
in O +
all O +
other O +
leukaemias O -
/ O -
lymphomas O +
tested O +
, O +
with O +
the O +
exception O +
of O +
a O +
subset O +
of O +
CLL O +
( O +
about O +
25 O +
% O +
of O +
cases O +
) O +
. O +

It O +
is O +
intriguing O +
that O +
the O +
A O -
- O -
myb O +
genome O +
has O +
been O +
localised O +
relatively O +
close O +
to O +
the O +
c O -
- O -
myc O +
gene O +
on O +
chromosome O +
8 O +
, O +
suggesting O +
that O +
the O +
c O -
- O -
myc O +
translocation O +
in O +
BL O +
and O +
B O -
- O -
ALL O +
may O +
affect O +
A O -
- O -
myb O +
transcription O +
. O +

Studies O +
are O +
in O +
progress O +
to O +
investigate O +
the O +
functional O +
relationship O +
between O +
A O -
- O -
myb O +
and O +
c O -
- O -
myc O +
, O +
particularly O +
in O +
the O +
context O +
of O +
BL O +
cells O +
and O +
to O +
determine O +
whether O +
A O -
- O -
myb O +
is O +
deregulated O +
in O +
these O +
cells O +
. O +

Interleukin-7 O +
upregulates O +
the O +
interleukin-2-gene O +
expression O +
in O +
activated O +
human O +
T O +
lymphocytes O +
at O +
the O +
transcriptional O +
level O +
by O +
enhancing O +
the O +
DNA O +
binding O +
activities O +
of O +
both O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
and O +
activator O +
protein-1 O +
. O +

In O +
the O +
present O +
report O +
, O +
we O +
studied O +
the O +
role O +
of O +
the O +
stromal O -
- O -
derived O +
cytokine O +
interleukin-7 O +
( O +
IL-7 O +
) O +
in O +
the O +
IL-2-gene O +
regulation O +
in O +
activated O +
T O +
lymphocytes O +
. O +

Production O +
of O +
IL-2 O +
requires O +
the O +
formation O +
of O +
transcription O +
factors O +
involved O +
in O +
the O +
IL-2-gene O +
regulation O +
. O +

T O -
- O -
cell O +
receptor O +
( O +
TCR O +
) O +
/CD3 O +
engagement O +
results O +
in O +
the O +
activation O +
of O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
, O +
activator O +
protein-1 O +
( O +
AP-1 O +
) O +
, O +
and O +
nuclear O +
factor O +
kappaB O +
( O +
NFkappaB O +
) O +
, O +
whereas O +
the O +
CD28 O +
responsive O +
complex O +
( O +
CD28RC O +
) O +
is O +
activated O +
in O +
response O +
to O +
the O +
CD28 O +
signal O +
. O +

Costimulation O +
of O +
phytohemagglutinin B-CellLine -
/ I-CellLine -
anti I-CellLine -
- I-CellLine -
CD28 I-CellLine +
activated I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
with O +
IL-7 O +
induces O +
a O +
fivefold O +
enhanced O +
IL-2 O +
-mRNA O +
accumulation O +
and O +
a O +
2.5-fold O +
enhanced O +
protein O +
secretion O +
. O +

The O +
IL-2-gene O +
transcription O +
rate O +
is O +
increased O +
3.4-fold O +
, O +
indicating O +
that O +
the O +
effect O +
of O +
IL-7 O +
is O +
in O +
part O +
mediated O +
at O +
the O +
transcriptional O +
level O +
. O +

The O +
molecular O +
mechanisms O +
underlying O +
the O +
IL-7 O +
effect O +
involve O +
the O +
upregulation O +
of O +
the O +
DNA O +
binding O +
activity O +
of O +
NFAT O +
( O +
60 O +
% O +
) O +
and O +
AP-1 O +
( O +
120 O +
% O +
) O +
, O +
without O +
affecting O +
the O +
activities O +
of O +
NFkappaB O +
and O +
CD28RC O +
, O +
which O +
was O +
confirmed O +
by O +
transfection O +
assays O +
. O +

We O +
also O +
show O +
that O +
the O +
IL-7 O +
-induced O +
enhancement O +
of O +
the O +
AP-1 O +
-DNA O +
binding O +
activity O +
is O +
not O +
cyclosporin O +
A O -
- O -
sensitive O +
. O +

Since O +
AP-1 O +
is O +
part O +
of O +
the O +
NFAT O +
complex O +
, O +
we O +
conclude O +
that O +
the O +
IL-7 O +
-signaling O +
pathway O +
is O +
involved O +
in O +
the O +
activation O +
of O +
the O +
fos O +
and O +
jun O +
proteins O +
of O +
which O +
AP-1 O +
consists O +
. O +

Phospholipase O +
C O +
gamma O +
1 O +
overexpression O +
and O +
activation O +
induced O +
by O +
interferon O +
beta O +
in O +
human O +
T O +
lymphocytes O +
: O +
an O +
ISGF3 O +
-independent O +
response O +
. O +

Interferons O +
exert O +
their O +
antiviral O +
, O +
antiproliferative O +
and O +
immunoregulatory O +
activities O +
by O +
stimulating O +
the O +
expression O +
of O +
several O +
genes O +
. O +

Such O +
genes O +
disclose O +
a O +
common O +
element O +
within O +
their O +
promoters O +
, O +
defined O +
Interferon O +
Stimulated O +
Response O +
Element O +
( O +
ISRE O +
) O +
, O +
which O +
binds O +
a O +
nuclear O +
factor O +
( O +
s O +
) O +
translocated O +
from O +
the O +
cytoplasm O +
to O +
the O +
nucleus O +
( O +
ISGF3 O +
) O +
after O +
the O +
binding O +
of O +
interferon O +
( O +
IFN O +
) O +
to O +
the O +
specific O +
receptor O +
. O +

Here O +
we O +
report O +
the O +
induction O +
of O +
the O +
synthesis O +
and O +
of O +
the O +
hydrolytic O +
activity O +
of O +
phospholipase O +
C O +
gamma O +
1 O +
( O +
PLC O +
gamma O +
1 O +
) O +
in O +
human O +
T O +
lymphocytes O +
by O +
IFN O -
- O -
beta O +
. O +

The O +
increased O +
level O +
of O +
PLC O +
gamma O +
1 O +
becomes O +
evident O +
after O +
90 O +
min O +
of O +
IFN O -
- O -
beta O +
treatment O +
and O +
is O +
still O +
detectable O +
after O +
24 O +
h O +
. O +

Neither O +
the O +
PLC O +
gamma O +
1 O +
overexpression O +
induced O +
by O +
IFN O +
nor O +
the O +
increased O +
hydrolytic O +
activity O +
of O +
the O +
enzyme O +
appear O +
to O +
be O +
affected O +
by O +
pretreatment O +
of O +
the O +
cells O +
with O +
the O +
protein O +
tyrosine O +
kinase O +
inhibitor O +
genistein O +
, O +
which O +
is O +
known O +
to O +
prevent O +
the O +
association O +
of O +
ISGF3 O +
components O +
. O +

These O +
results O +
suggest O +
that O +
in O +
human O +
T O +
lymphocytes O +
IFN O -
- O -
beta O +
can O +
activate O +
other O +
transcription O +
factor O +
( O +
s O +
) O +
distinct O +
from O +
ISGF3 O +
to O +
regulate O +
PLC O +
gamma O +
1 O +
expression O +
. O +

In O +
addition O +
, O +
the O +
ability O +
of O +
this O +
enzyme O +
to O +
hydrolyse O +
PIP2 O +
, O +
also O +
in O +
the O +
presence O +
of O +
genistein O +
, O +
implies O +
the O +
possibility O +
that O +
this O +
enzyme O +
can O +
exert O +
its O +
hydrolytic O +
activity O +
independently O +
of O +
protein O +
tyrosine O +
kinase O +
activation O +
. O +

Glucocorticoids O +
and O +
the O +
immune O +
function O +
in O +
the O +
human O +
immunodeficiency O +
virus O +
infection O +
: O +
a O +
study O +
in O +
hypercortisolemic O +
and O +
cortisol O -
- O -
resistant O +
patients O +
. O +

Immunological O +
studies O +
in O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
-positive O +
patients O +
suggest O +
that O +
the O +
disease O +
progression O +
is O +
accompanied O +
by O +
a O +
defective O +
production O +
of O +
type O +
1 O +
cytokines O +
( O +
interleukin-2 O +
( O +
IL-2 O +
) O +
and O +
IL-12 O +
] O +
, O +
an O +
increased O +
production O +
of O +
type O +
2 O +
cytokines O +
( O +
IL-4 O +
, O +
IL-6 O +
, O +
and O +
IL-10 O +
) O +
, O +
and O +
an O +
increased O +
production O +
of O +
IgE O +
. O +

HIV O +
infection O +
is O +
also O +
associated O +
with O +
activation O +
of O +
the O +
hypothalamo O -
- O -
pituitary O -
- O -
adrenal O +
axis O +
function O +
and O +
increased O +
plasma O +
and O +
urinary O +
cortisol O +
concentrations O +
. O +

As O +
cortisol O +
is O +
involved O +
in O +
the O +
physiological O +
regulation O +
of O +
cytokines O +
, O +
a O +
study O +
was O +
conducted O +
to O +
examine O +
cytokine O +
patterns O +
in O +
two O +
groups O +
of O +
hypercortisolemic O +
patients O +
, O +
one O +
with O +
normal O +
sensitivity O +
to O +
glucocorticoids O +
and O +
the O +
other O +
with O +
glucocorticoid O +
resistance O +
. O +

Ten O +
HIV O -
- O -
infected O +
patients O +
with O +
normal O +
receptor O +
affinity O +
to O +
glucocorticoids O +
( O +
AIDS O -
- O -
C O +
) O +
, O +
10 O +
HIV O -
- O -
infected O +
patients O +
with O +
low O +
receptor O +
affinity O +
to O +
glucocorticoids O +
( O +
AIDS O -
- O -
GR O +
) O +
, O +
and O +
20 O +
healthy O +
subjects O +
were O +
studied O +
. O +

Receptor O +
characteristics O +
of O +
peripheral O +
blood O +
mononuclear O +
cells O +
were O +
evaluated O +
by O +
[ O +
3H O +
] O +
dexamethasone O +
binding O +
. O +

Serum O +
cortisol O +
and O +
urinary O +
free O +
cortisol O +
were O +
measured O +
by O +
RIA O +
. O +

Serum O +
ACTH O +
and O +
IgE O +
were O +
measured O +
by O +
immunoradiometric O +
assay O +
, O +
and O +
IL-2 O +
, O +
IL-4 O +
, O +
and O +
IL-10 O +
cytokines O +
and O +
interferon O -
- O -
gamma O +
were O +
measured O +
by O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
. O +

AIDS O -
- O -
C O +
patients O +
showed O +
low O +
IL-2 O +
and O +
high O +
IL-4 O +
, O +
IL-10 O +
, O +
and O +
IgE O +
concentratios O +
; O +
conversely O +
, O +
AIDS O -
- O -
GR O +
patients O +
showed O +
high O +
IL-2 O +
and O +
low O +
IL-4 O +
and O +
IgE O +
concentrations O +
. O +

Thus O +
, O +
in O +
HIV O +
infection O +
, O +
elevated O +
cortisol O +
levels O +
suppress O +
cell O -
- O -
mediated O +
immunity O +
and O +
stimulate O +
humoral O +
immunity O +
, O +
whereas O +
this O +
response O +
is O +
not O +
detected O +
in O +
cortisol O -
- O -
resistant O +
patients O +
. O +

These O +
findings O +
indicate O +
that O +
cortisol O +
and O +
its O +
receptors O +
are O +
critically O +
involved O +
in O +
the O +
regulation O +
of O +
immune O +
function O +
in O +
HIV O +
infection O +
. O +

Molecular O +
characterization O +
and O +
pattern O +
of O +
tissue O +
expression O +
of O +
the O +
gene O +
for O +
neutrophil O +
gelatinase O -
- O -
associated O +
lipocalin O +
from O +
humans O +
. O +

Neutrophil O +
gelatinase O -
- O -
associated O +
lipocalin O +
( O +
NGAL O +
) O +
is O +
a O +
25-kDa O +
lipocalin O +
first O +
identified O +
as O +
a O +
protein O +
stored O +
in O +
specific O +
granules O +
of O +
the O +
human O +
neutrophil O +
. O +

The O +
protein O +
is O +
believed O +
to O +
bind O +
small O +
lipophilic O +
substances O +
such O +
as O +
bacterial O +
derived O +
formylpeptides O +
and O +
lipopolysaccharides O +
( O +
LPS O +
) O +
and O +
might O +
function O +
as O +
a O +
modulator O +
of O +
inflammation O +
. O +

To O +
characterize O +
the O +
regulation O +
of O +
NGAL O +
further O +
, O +
we O +
have O +
cloned O +
and O +
sequenced O +
a O +
5869-bp O +
region O +
of O +
the O +
NGAL O +
gene O +
including O +
1695 O +
bp O +
of O +
the O +
5 O +
' O +
nontranscribed O +
region O +
and O +
a O +
3696-bp O +
coding O +
region O +
encompassing O +
seven O +
exons O +
and O +
six O +
introns O +
. O +

The O +
transcriptional O +
start O +
sites O +
were O +
identified O +
by O +
an O +
RNase O +
protection O +
assay O +
. O +

The O +
NGAL O +
gene O +
is O +
highly O +
homologous O +
to O +
the O +
mouse O +
gene O +
24p3 O +
. O +

NGAL O +
was O +
expressed O +
in O +
bone O +
marrow O +
and O +
in O +
tissues O +
that O +
are O +
prone O +
to O +
exposure O +
to O +
microorganisms O +
. O +

Potential O +
cis O -
- O -
acting O +
elements O +
were O +
identified O +
in O +
the O +
promoter O +
region O +
of O +
the O +
NGAL O +
gene O +
by O +
computer O +
analysis O +
and O +
include O +
binding O +
sites O +
for O +
CTF O -
/ O -
CBP O +
, O +
the O +
hematopoietic O +
transcription O +
factors O +
GATA-1 O +
and O +
PU.1 O +
, O +
and O +
the O +
LPS O -
- O -
inducible O +
factor O +
NF O -
- O -
kappa O +
B O +
. O +

Monocytic O +
differentiation O +
of O +
HL-60 B-CellLine +
promyelocytic I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
correlates O +
with O +
the O +
induction O +
of O +
Bcl O -
- O -
xL O +
. O +

Treatment O +
of O +
human B-CellLine +
promyelocytic I-CellLine +
leukemia I-CellLine +
HL-60 I-CellLine +
cells I-CellLine +
with O +
phorbol O +
esters O +
ultimately O +
induces O +
the O +
differentiation O +
of O +
these O +
cells O +
along O +
the O +
monocyte O -
/ O -
macrophage O +
lineage O +
, O +
whereas O +
treatment O +
with O +
retinoic O +
acid O +
or O +
DMSO O +
induces O +
granulocytic O -
/ O -
neutrophillic O +
differentiation O +
. O +

In O +
this O +
study O +
, O +
we O +
demonstrate O +
the O +
disparate O +
fates O +
of O +
HL-60 B-CellLine +
cells I-CellLine +
treated O +
with O +
the O +
phorbol O +
ester O +
12 O +
, O +
13-phorbol O +
dibutyric O +
acid O +
( O +
PDBu O +
) O +
or O +
DMSO O +
. O +

After O +
DMSO O +
treatment O +
, O +
HL-60 B-CellLine +
cells I-CellLine +
eventually O +
died O +
via O +
apoptosis O +
, O +
whereas O +
the O +
viability O +
of O +
PDBu B-CellLine -
- I-CellLine -
treated I-CellLine +
cells I-CellLine +
was O +
not O +
affected O +
during O +
the O +
same O +
interval O +
. O +

The O +
levels O +
of O +
the O +
apoptosis O +
effector O +
proteins O +
Bak O +
and O +
Bad O +
were O +
enhanced O +
, O +
whereas O +
there O +
was O +
a O +
slight O +
down O -
- O -
regulation O +
of O +
the O +
apoptosis O +
suppressor O +
protein O +
Bcl-2 O +
after O +
treatment O +
of O +
the O +
cells O +
with O +
PDBu O +
and O +
DMSO O +
. O +

Treatment O +
with O +
DMSO O +
resulted O +
in O +
the O +
elevation O +
of O +
the O +
apoptosis O +
effector O +
Bax O +
, O +
whereas O +
treatment O +
with O +
PDBu O +
did O +
not O +
significantly O +
alter O +
the O +
levels O +
of O +
this O +
protein O +
. O +

However O +
, O +
treatment O +
of O +
HL-60 B-CellLine +
cells I-CellLine +
with O +
PDBu O +
induced O +
the O +
rapid O +
expression O +
of O +
the O +
apoptosis O +
suppressor O +
protein O +
Bcl O -
- O -
xL O +
, O +
whereas O +
the O +
expression O +
of O +
this O +
protein O +
remained O +
unaltered O +
in O +
DMSO O -
- O -
treated O +
cells O +
. O +

The O +
generality O +
of O +
this O +
finding O +
was O +
confirmed O +
by O +
the O +
induction O +
of O +
Bcl O -
- O -
xL O +
in O +
human B-CellLine +
myeloid I-CellLine +
U-937 I-CellLine +
cells I-CellLine +
, O +
human O +
peripheral O +
blood O +
monocytes O +
exposed O +
to O +
phorbol O +
ester O +
, O +
and O +
mouse B-CellLine +
thioglycollate I-CellLine -
- I-CellLine -
activated I-CellLine +
and I-CellLine +
resident I-CellLine +
peritoneal I-CellLine +
macrophages I-CellLine +
. O +

PDBu B-CellLine -
- I-CellLine -
treated I-CellLine +
HL-60 I-CellLine +
cells I-CellLine +
remained O +
viable O +
for O +
7 O +
days O +
and O +
thereafter O +
began O +
to O +
die O +
via O +
apoptosis O +
, O +
with O +
a O +
concomitant O +
down O -
- O -
regulation O +
of O +
Bcl O -
- O -
xL O +
. O +

In O +
conclusion O +
, O +
we O +
propose O +
that O +
Bcl O -
- O -
xL O +
expression O +
is O +
associated O +
with O +
differentiation O +
and O +
survival O +
of O +
hematopoietic O +
cells O +
along O +
the O +
monocyte O -
/ O -
macrophage O +
lineage O +
. O +

Induction O +
of O +
endothelial O +
cell O +
surface O +
adhesion O +
molecules O +
by O +
tumor O +
necrosis O +
factor O +
is O +
blocked O +
by O +
protein O +
tyrosine O +
phosphatase O +
inhibitors O +
: O +
role O +
of O +
the O +
nuclear O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
. O +

Recent O +
studies O +
from O +
our O +
laboratory O +
have O +
indicated O +
that O +
protein O +
tyrosine O +
phosphatase O +
( O +
PTPase O +
) O +
inhibitors O +
can O +
down O -
- O -
modulate O +
the O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
-mediated O +
activation O +
of O +
the O +
nuclear O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
in O +
ML-1a B-CellLine +
, O +
a O +
monocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
Singh O +
and O +
Aggarwal O +
, O +
J. O +
Biol O -
. O +
Chem O -
. O +
1995 O +
: O +
270 O +
: O +
10631 O +
) O +
. O +

Since O +
TNF O +
is O +
one O +
of O +
the O +
major O +
inducers O +
of O +
various O +
adhesion O +
molecules O +
in O +
human O +
endothelial O +
cells O +
and O +
their O +
expression O +
is O +
known O +
to O +
require O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
we O +
examined O +
the O +
effect O +
of O +
PTPase O +
inhibitors O +
on O +
the O +
TNF O +
-mediated O +
induction O +
of O +
intracellular O +
adhesion O +
molecule O +
( O +
ICAM O +
) O +
-1 O +
, O +
vascular O +
cell O +
adhesion O +
molecule O +
( O +
VCAM O +
) O +
-1 O +
and O +
endothelial O +
leukocyte O +
adhesion O +
molecule O +
( O +
ELAM O +
) O +
-1 O +
. O +

Like O +
ML-1a B-CellLine +
, O +
human B-CellLine +
dermal I-CellLine +
microvessel I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
( O +
MVEC B-CellLine +
) O +
treated O +
with O +
TNF O +
rapidly O +
activated O +
( O +
within O +
30 O +
min O +
) O +
NF O -
- O -
kappa O +
B O +
; O +
this O +
effect O +
was O +
completely O +
abolished O +
by O +
co O -
- O -
treatment O +
with O +
phenylarsine O +
oxide O +
( O +
PAO O +
) O +
, O +
a O +
specific O +
inhibitor O +
of O +
PTPase O +
. O +

The O +
induction O +
of O +
ICAM-1 O +
, O +
VCAM-1 O +
, O +
and O +
ELAM-1 O +
by O +
TNF O +
in O +
MVEC B-CellLine +
occurred O +
within O +
6 O +
h O +
and O +
was O +
also O +
completely O +
down O -
- O -
regulated O +
by O +
PAO O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
. O +

PAO O +
was O +
found O +
to O +
be O +
effective O +
even O +
when O +
added O +
3 O +
h O +
after O +
TNF O +
, O +
suggesting O +
a O +
rapid O +
mode O +
of O +
action O +
of O +
this O +
inhibitor O +
. O +

Besides O +
PAO O +
, O +
other O +
inhibitors O +
of O +
PTPase O +
, O +
including O +
pervanadate O +
and O +
diamide O +
, O +
also O +
blocked O +
TNF O +
-dependent O +
NF O -
- O -
kappa O +
B O +
activation O +
and O +
induction O +
of O +
all O +
the O +
three O +
adhesion O +
proteins O +
. O +

Consistent O +
with O +
these O +
results O +
, O +
the O +
attachment O +
of O +
monocytes O +
to O +
MVEC B-CellLine +
was O +
also O +
blocked O +
by O +
the O +
PTPase O +
inhibitors O +
. O +

Thus O +
, O +
overall O +
, O +
our O +
results O +
demonstrate O +
that O +
a O +
PTPase O +
is O +
involved O +
either O +
directly O +
or O +
indirectly O +
in O +
the O +
pathway O +
leading O +
to O +
the O +
induction O +
of O +
endothelial O +
cell O +
adhesion O +
molecules O +
by O +
TNF O +
. O +

Because O +
of O +
their O +
role O +
in O +
cell O +
adhesion O +
, O +
PTPase O +
may O +
provide O +
a O +
novel O +
target O +
of O +
drug O +
development O +
for O +
treatment O +
of O +
inflammation O +
, O +
atherogenesis O +
, O +
and O +
tumor O +
metastasis O +
. O +

The O +
spatial O +
distribution O +
of O +
human O +
immunoglobulin O +
genes O +
within O +
the O +
nucleus O +
: O +
evidence O +
for O +
gene O +
topography O +
independent O +
of O +
cell O +
type O +
and O +
transcriptional O +
activity O +
. O +

The O +
three O -
- O -
dimensional O +
positioning O +
of O +
immunoglobulin O +
( O +
Ig O +
) O +
genes O +
within O +
the O +
nucleus O +
of O +
human O +
cells O +
was O +
investigated O +
using O +
in O +
situ O +
hybridization O +
and O +
confocal O +
microscopy O +
. O +

The O +
visualization O +
of O +
heavy O +
and O +
light O +
chain O +
genes O +
in O +
B O -
- O -
lymphoid O +
cells O +
showed O +
that O +
the O +
three O +
Ig O +
genes O +
are O +
differentially O +
and O +
nonrandomly O +
distributed O +
in O +
different O +
nuclear O +
subvolumes O +
: O +
the O +
kappa O +
genes O +
were O +
found O +
to O +
be O +
preferentially O +
confined O +
to O +
an O +
outer O +
nuclear O +
volume O +
, O +
whereas O +
the O +
gamma O +
and O +
lambda O +
genes O +
consistently O +
occupied O +
more O +
central O +
positions O +
within O +
the O +
nucleus O +
, O +
the O +
lambda O +
genes O +
being O +
more O +
interior O +
when O +
compared O +
with O +
the O +
gamma O +
genes O +
. O +

The O +
data O +
further O +
show O +
that O +
these O +
overall O +
topographical O +
distributions O +
are O +
independent O +
of O +
gene O +
transcriptional O +
activity O +
and O +
are O +
conserved O +
in O +
different O +
cell O +
types O +
. O +

Although O +
subtle O +
gene O +
movements O +
within O +
those O +
defined O +
topographical O +
regions O +
can O +
not O +
be O +
excluded O +
by O +
this O +
study O +
, O +
the O +
results O +
indicate O +
that O +
tissue O +
specificity O +
of O +
gene O +
expression O +
is O +
not O +
accompanied O +
by O +
drastic O +
changes O +
in O +
gene O +
nuclear O +
topography O +
, O +
rather O +
suggesting O +
that O +
gene O +
organization O +
within O +
the O +
nucleus O +
may O +
be O +
primarily O +
dependent O +
on O +
structural O +
constraints O +
imposed O +
on O +
the O +
respective O +
chromosomes O +
. O +

Transcriptional O +
activation O +
of O +
the O +
vascular O +
cell O +
adhesion O +
molecule-1 O +
gene O +
in O +
T O +
lymphocytes O +
expressing O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
Tax O +
protein O +
. O +

Recruitment O +
and O +
extravasation O +
of O +
T O +
cells O +
through O +
the O +
blood O -
- O -
brain O +
barrier O +
are O +
favored O +
by O +
adhesion O +
molecule O +
-mediated O +
interactions O +
of O +
circulating O +
T O +
cells O +
with O +
endothelial O +
cells O +
. O +

Since O +
a O +
common O +
pathological O +
finding O +
in O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
( O +
HTLV-1 O +
) O +
-associated O +
diseases O +
is O +
the O +
infiltration O +
of O +
HTLV-1-infected O +
T O +
lymphocytes O +
into O +
various O +
organs O +
, O +
we O +
have O +
looked O +
for O +
the O +
profile O +
of O +
adhesion O +
molecules O +
expressed O +
by O +
HTLV-1-transformed O +
T O +
cells O +
. O +

Flow O +
cytometry O +
analysis O +
indicated O +
that O +
these O +
cells O +
were O +
expressing O +
high O +
levels O +
of O +
vascular O +
cell O +
adhesion O +
molecule O +
1 O +
( O +
VCAM-1 O +
[ O +
CD106 O +
] O +
) O +
, O +
a O +
110-kDa O +
member O +
of O +
the O +
immunoglobulin O +
gene O +
superfamily O +
, O +
first O +
identified O +
on O +
endothelial O +
cells O +
stimulated O +
with O +
inflammatory O +
cytokines O +
. O +

This O +
adhesion O +
molecule O +
was O +
also O +
expressed O +
by O +
T O +
cells O +
obtained O +
from O +
one O +
patient O +
with O +
HTLV-1-associated O +
myelopathy O -
/ O -
tropical O +
spastic O +
paraparesis O +
but O +
not O +
by O +
activated O +
T O +
cells O +
isolated O +
from O +
one O +
normal O +
blood O +
donor O +
. O +

The O +
role O +
of O +
the O +
viral O +
trans O -
- O -
activator O +
Tax O +
protein O +
in O +
the O +
induction O +
of O +
VCAM-1 O +
was O +
first O +
indicated O +
by O +
the O +
detection O +
of O +
this O +
adhesion O +
molecule O +
on O +
Jurkat B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
stably O +
expressing O +
the O +
tax O +
gene O +
. O +

The O +
effect O +
of O +
Tax O +
on O +
VCAM-1 O +
gene O +
transcription O +
was O +
next O +
confirmed O +
in O +
JPX-9 B-CellLine +
cells I-CellLine +
, O +
a O +
subclone O +
of O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
carrying O +
the O +
tax O +
sequences O +
under O +
the O +
control O +
of O +
an O +
inducible O +
promoter O +
. O +

Furthermore O +
, O +
deletion O +
and O +
mutation O +
analyses O +
of O +
the O +
VCAM-1 O +
promoter O +
performed O +
with O +
chloramphenicol O +
acetyltransferase O +
constructs O +
revealed O +
that O +
Tax O +
was O +
trans O +
activating O +
the O +
VCAM-1 O +
promoter O +
via O +
two O +
NF O -
- O -
kappaB O +
sites O +
present O +
at O +
bp O +
-72 O +
and O +
-57 O +
in O +
the O +
VCAM-1 O +
gene O +
promoter O +
, O +
with O +
both O +
of O +
them O +
being O +
required O +
for O +
the O +
Tax O +
-induced O +
expression O +
of O +
this O +
adhesion O +
molecule O +
. O +

Finally O +
, O +
gel O +
mobility O +
shift O +
assays O +
demonstrated O +
the O +
nuclear O +
translocation O +
of O +
proteins O +
specifically O +
bound O +
to O +
these O +
two O +
NF O -
- O -
kappaB O +
motifs O +
, O +
confirming O +
that O +
VCAM-1 O +
was O +
induced O +
on O +
Tax B-CellLine -
- I-CellLine -
expressing I-CellLine +
cells I-CellLine +
in O +
a O +
kappaB O +
-dependent O +
manner O +
. O +

Collectively O +
, O +
these O +
results O +
therefore O +
suggest O +
that O +
the O +
exclusive O +
Tax O +
-induced O +
expression O +
of O +
VCAM-1 O +
on O +
T O +
cells O +
may O +
represent O +
a O +
pivotal O +
event O +
in O +
the O +
progression O +
of O +
HTLV-1-associated O +
diseases O +
. O +

Blockade O +
of O +
T O -
- O -
cell O +
activation O +
by O +
dithiocarbamates O +
involves O +
novel O +
mechanisms O +
of O +
inhibition O +
of O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
. O +

Dithiocarbamates O +
( O +
DTCs O +
) O +
have O +
recently O +
been O +
reported O +
as O +
powerful O +
inhibitors O +
of O +
NF O -
- O -
kappaB O +
activation O +
in O +
a O +
number O +
of O +
cell O +
types O +
. O +

Given O +
the O +
role O +
of O +
this O +
transcription O +
factor O +
in O +
the O +
regulation O +
of O +
gene O +
expression O +
in O +
the O +
inflammatory O +
response O +
, O +
NF O -
- O -
kappaB O +
inhibitors O +
have O +
been O +
suggested O +
as O +
potential O +
therapeutic O +
drugs O +
for O +
inflammatory O +
diseases O +
. O +

We O +
show O +
here O +
that O +
DTCs O +
inhibited O +
both O +
interleukin O +
2 O +
( O +
IL-2 O +
) O +
synthesis O +
and O +
membrane O +
expression O +
of O +
antigens O +
which O +
are O +
induced O +
during O +
T O -
- O -
cell O +
activation O +
. O +

This O +
inhibition O +
, O +
which O +
occurred O +
with O +
a O +
parallel O +
activation O +
of O +
c O -
- O -
Jun O +
transactivating O +
functions O +
and O +
expression O +
, O +
was O +
reflected O +
by O +
transfection O +
experiments O +
at O +
the O +
IL-2 O +
promoter O +
level O +
, O +
and O +
involved O +
not O +
only O +
the O +
inhibition O +
of O +
NF O -
- O -
kappaB O +
-driven O +
reporter O +
activation O +
but O +
also O +
that O +
of O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
. O +

Accordingly O +
, O +
electrophoretic O +
mobility O +
shift O +
assays O +
( O +
EMSAs O +
) O +
indicated O +
that O +
pyrrolidine O +
DTC O +
( O +
PDTC O +
) O +
prevented O +
NF O -
- O -
kappaB O +
, O +
and O +
NFAT O +
DNA O -
- O -
binding O +
activity O +
in O +
T O +
cells O +
stimulated O +
with O +
either O +
phorbol O +
myristate O +
acetate O +
plus O +
ionophore O +
or O +
antibodies O +
against O +
the O +
CD3-T O -
- O -
cell O +
receptor O +
complex O +
and O +
simultaneously O +
activated O +
the O +
binding O +
of O +
AP-1 O +
. O +

Furthermore O +
, O +
PDTC O +
differentially O +
targeted O +
both O +
NFATp O +
and O +
NFATc O +
family O +
members O +
, O +
inhibiting O +
the O +
transactivation O +
functions O +
of O +
NFATp O +
and O +
mRNA O +
induction O +
of O +
NFATc O +
. O +

Strikingly O +
, O +
Western O +
blotting O +
and O +
immunocytochemical O +
experiments O +
indicated O +
that O +
PDTC O +
promoted O +
a O +
transient O +
and O +
rapid O +
shuttling O +
of O +
NFATp O +
and O +
NFATc O +
, O +
leading O +
to O +
their O +
accelerated O +
export O +
from O +
the O +
nucleus O +
of O +
activated O +
T O +
cells O +
. O +

We O +
propose O +
that O +
the O +
activation O +
of O +
an O +
NFAT O +
kinase O +
by O +
PDTC O +
could O +
be O +
responsible O +
for O +
the O +
rapid O +
shuttling O +
of O +
the O +
NFAT O +
, O +
therefore O +
transiently O +
converting O +
the O +
sustained O +
transactivation O +
of O +
this O +
transcription O +
factor O +
that O +
occurs O +
during O +
lymphocyte O +
activation O +
, O +
and O +
show O +
that O +
c O -
- O -
Jun O +
NH2-terminal O +
kinase O +
( O +
JNK O +
) O +
can O +
act O +
by O +
directly O +
phosphorylating O +
NFATp O +
. O +

In O +
addition O +
, O +
the O +
combined O +
inhibitory O +
effects O +
on O +
NFAT O +
and O +
NF O -
- O -
KB O +
support O +
a O +
potential O +
use O +
of O +
DTCs O +
as O +
immunosuppressants O +
. O +

The O +
tax O +
protein O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
mediates O +
the O +
transactivation O +
of O +
the O +
c O -
- O -
sis O -
/ O -
platelet O -
- O -
derived O +
growth O +
factor O -
- O -
B O +
promoter O +
through O +
interactions O +
with O +
the O +
zinc O +
finger O +
transcription O +
factors O +
Sp1 O +
and O +
NGFI O -
- O -
A O -
/ O -
Egr-1 O +
. O +

Transcriptional O +
up O -
- O -
regulation O +
of O +
the O +
c O -
- O -
sis O -
/ O -
platelet O -
- O -
derived O +
growth O +
factor O -
- O -
B O +
( O +
PDGF O -
- O -
B O +
) O +
proto O -
- O -
oncogene O +
by O +
the O +
Tax O +
protein O +
of O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
has O +
been O +
implicated O +
as O +
one O +
possible O +
mechanism O +
of O +
cellular O +
transformation O +
by O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
. O +

In O +
previous O +
work O +
, O +
we O +
identified O +
an O +
essential O +
site O +
in O +
the O +
c O -
- O -
sis O -
/ O -
PDGF O -
- O -
B O +
promoter O +
, O +
Tax O -
- O -
responsive O +
element O +
1 O +
( O +
TRE1 O +
) O +
, O +
necessary O +
for O +
transactivation O +
by O +
Tax O +
. O +

We O +
also O +
identified O +
Sp1 O +
, O +
Sp3 O +
, O +
and O +
NGFI O -
- O -
A O -
/ O -
Egr-1 O +
as O +
the O +
primary O +
nuclear O +
transcription O +
factors O +
binding O +
to O +
TRE1 O +
which O +
mediate O +
Tax O +
responsiveness O +
. O +

In O +
the O +
present O +
work O +
, O +
we O +
have O +
investigated O +
the O +
mechanism O +
( O +
s O +
) O +
whereby O +
Tax O +
transactivates O +
the O +
c O -
- O -
sis O -
/ O -
PDGF O -
- O -
B O +
proto O -
- O -
oncogene O +
. O +

In O +
vitro O +
transcription O +
assays O +
showed O +
that O +
Tax O +
was O +
able O +
to O +
significantly O +
increase O +
the O +
transcriptional O +
activity O +
of O +
a O +
template O +
containing O +
the O +
-257 O +
to O +
+ O -
74 O +
region O +
of O +
the O +
c O -
- O -
sis O -
/ O -
PDGF O -
- O -
B O +
promoter O +
. O +

Electrophoretic O +
mobility O +
shift O +
assay O +
analysis O +
showed O +
that O +
Tax O +
increased O +
the O +
DNA O +
binding O +
activity O +
of O +
both O +
Sp1 O +
and O +
NGFI O -
- O -
A O -
/ O -
Egr-1 O +
using O +
a O +
TRE1 O +
probe O +
. O +

Analysis O +
of O +
Tax O +
mutants O +
showed O +
that O +
two O +
mutants O +
, O +
IEXC29S O +
and O +
IEXL320 O -
G O +
, O +
were O +
unable O +
to O +
significantly O +
transactivate O +
the O +
c O -
- O -
sis O -
/ O -
PDGF O -
- O -
B O +
promoter O +
. O +

Finally O +
, O +
co O -
- O -
immunoprecipitation O +
analysis O +
revealed O +
that O +
Tax O +
is O +
able O +
to O +
stably O +
bind O +
to O +
both O +
Sp1 O +
and O +
NGFI O -
- O -
A O -
/ O -
Egr-1 O +
. O +

Interestingly O +
, O +
co O -
- O -
immunoprecipitation O +
analysis O +
also O +
revealed O +
that O +
Tax O +
mutant O +
IEXC29S O +
is O +
unable O +
to O +
interact O +
with O +
NGFI O -
- O -
A O -
/ O -
Egr-1 O +
, O +
whereas O +
Tax O +
mutant O +
IEXL320 O -
G O +
is O +
able O +
to O +
interact O +
with O +
NGFI O -
- O -
A O -
/ O -
Egr-1 O +
. O +

Suppression O +
of O +
nuclear O +
factor O +
kappa O +
B O +
and O +
CD18 O +
-mediated O +
leukocyte O +
adhesion O +
to O +
the O +
corneal O +
endothelium O +
by O +
dexamethasone O +
. O +

PURPOSE O +
: O +
To O +
demonstrate O +
that O +
leukocyte O +
adhesion O +
to O +
cultured B-CellLine +
corneal I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
is O +
mediated O +
by O +
the O +
CD18 O +
antigen O +
, O +
and O +
to O +
determine O +
whether O +
dexamethasone O +
directly O +
suppresses O +
adhesion O +
by O +
inhibiting O +
activation O +
of O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NFkappaB O +
) O +
. O +

METHODS O +
: O +
Cultured O +
bovine O +
corneal O +
endothelium O +
was O +
stimulated O +
for O +
6 O +
hours O +
by O +
40 O +
micron O -
/ O -
ml O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNFalpha O +
) O +
. O +

Dexamethasone O +
was O +
added O +
1 O +
hour O +
before O +
TNFalpha O +
stimulation O +
in O +
the O +
dexamethasone O +
group O +
. O +

After O +
stimulation O +
, O +
neutrophils O +
separated O +
from O +
a O +
healthy O +
human O +
volunteer O +
were O +
added O +
with O +
or O +
without O +
anti O -
- O -
CD18 O +
antibody O +
. O +

The O +
culture O +
plate O +
was O +
settled O +
for O +
15 O +
minutes O +
at O +
37 O +
degrees O +
C O +
, O +
and O +
then O +
neutrophils O +
were O +
activated O +
by O +
N O -
- O -
formyl O -
- O -
methionyl O -
- O -
leucyl O -
- O -
phenylalanine O +
for O +
5 O +
minutes O +
. O +

Nonadherent O +
neutrophils O +
were O +
removed O +
by O +
sealing O +
and O +
inverting O +
the O +
culture O +
well O +
. O +

The O +
intracellular O +
localization O +
of O +
NFkappaB O +
after O +
TNFalpha O +
simulation O +
was O +
determined O +
by O +
confocal O +
immunocytochemistry O +
using O +
an O +
anti O -
- O -
p65 O +
antibody O +
. O +

RESULTS O +
: O +
Neutrophil O +
adhesion O +
to O +
cultured B-CellLine +
corneal I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
increased O +
significantly O +
on O +
exposure O +
to O +
TNFalpha O +
( O +
451.4+ O -
/ O -
-45.4 O +
cells O -
/ O -
mm2 O +
, O +
n O +
= O +
16 O +
) O +
compared O +
to O +
control O +
( O +
156.7+ O -
/ O -
-27.3 O +
cells O -
/ O -
mm2 O +
, O +
n O +
= O +
16 O +
, O +
P O +
< O +
0.01 O +
) O +
. O +

This O +
increased O +
adhesion O +
was O +
suppressed O +
by O +
the O +
addition O +
of O +
anti O -
- O -
CD18 O +
antibody O +
( O +
157.6+ O -
/ O -
-25.1 O +
cells O -
/ O -
mm2 O +
, O +
n O +
= O +
8 O +
, O +
P O +
< O +
0.01 O +
) O +
and O +
by O +
pretreatment O +
with O +
10 O +
( O +
-7 O +
) O +
M O +
dexamethasone O +
( O +
207.9+ O -
/ O -
-31.5 O +
cells O -
/ O -
mm2 O +
, O +
n O +
= O +
10 O +
, O +
P O +
< O +
0.01 O +
) O +
. O +

Immunocytochemistry O +
60 O +
minutes O +
after O +
stimulation O +
revealed O +
that O +
NFkappaB O +
was O +
located O +
in O +
the O +
cytoplasm O +
in O +
unstimulated O +
cells O +
; O +
however O +
, O +
the O +
addition O +
of O +
TNFalpha O +
caused O +
NFkappaB O +
to O +
translocate O +
into O +
the O +
nucleus O +
. O +

Pretreatment O +
with O +
dexamethasone O +
tapered O +
NFkappaB O +
translocation O +
into O +
the O +
nucleus O +
. O +

CONCLUSIONS O +
: O +
Leukocyte O +
adhesion O +
to O +
the O +
corneal O +
endothelium O +
was O +
shown O +
to O +
be O +
mediated O +
by O +
CD18 O +
expressed O +
on O +
activated O +
leukocytes O +
. O +

Pretreatment O +
of O +
the O +
endothelium O +
with O +
dexamethasone O +
inhibited O +
leukocyte O +
adhesion O +
; O +
this O +
may O +
be O +
due O +
in O +
part O +
to O +
the O +
suppression O +
of O +
NFkappaB O +
entry O +
into O +
the O +
nucleus O +
. O +

Stable O +
transfection O +
of O +
U937 B-CellLine +
cells I-CellLine +
with O +
sense O +
or O +
antisense O +
RXR O -
- O -
alpha O +
cDNA O +
suggests O +
a O +
role O +
for O +
RXR O -
- O -
alpha O +
in O +
the O +
control O +
of O +
monoblastic O +
differentiation O +
induced O +
by O +
retinoic O +
acid O +
and O +
vitamin O +
D O +
. O +

Although O +
retinoic O +
acid O +
( O +
RA O +
) O +
has O +
been O +
known O +
for O +
many O +
years O +
to O +
be O +
a O +
modulating O +
agent O +
that O +
plays O +
a O +
role O +
in O +
generating O +
both O +
granulocytes O +
and O +
monocytes O +
, O +
the O +
molecular O +
mechanism O +
underlying O +
this O +
role O +
has O +
not O +
been O +
defined O +
in O +
the O +
monoblast O +
lineage O +
. O +

In O +
particular O +
, O +
the O +
part O +
played O +
by O +
the O +
retinoid O +
X O +
receptors O +
( O +
RXRs O +
) O +
, O +
which O +
are O +
members O +
of O +
the O +
steroid O -
/ O -
thyroid O +
hormone O +
nuclear O +
receptor O +
family O +
, O +
has O +
not O +
been O +
explored O +
. O +

In O +
this O +
study O +
, O +
therefore O +
, O +
the O +
human B-CellLine +
monoblastic I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
U937 I-CellLine +
has O +
been O +
used O +
as O +
a O +
model O +
system O +
to O +
investigate O +
the O +
role O +
of O +
one O +
of O +
the O +
RXRs O +
, O +
RXR O -
- O -
alpha O +
, O +
in O +
monoblast O +
differentiation O +
. O +

RXR O -
- O -
alpha O +
mRNA O +
was O +
present O +
in O +
untreated O +
U937 B-CellLine +
cells I-CellLine +
, O +
and O +
levels O +
increased O +
after O +
induction O +
of O +
differentiation O +
with O +
phorbol O +
ester O +
. O +

The O +
same O +
was O +
found O +
for O +
RXR O -
- O -
beta O +
mRNA O +
. O +

Using O +
plasmids O +
containing O +
sense O +
or O +
antisense O +
RXR O -
- O -
alpha O +
sequences O +
under O +
the O +
control O +
of O +
an O +
inducible O +
promoter O +
, O +
we O +
generated O +
stably O +
transfected O +
cell O +
lines O +
which O +
expressed O +
either O +
increased O +
or O +
decreased O +
levels O +
of O +
RXR O -
- O -
alpha O +
, O +
respectively O +
. O +

The O +
sense B-CellLine +
cell I-CellLine +
lines I-CellLine +
( O +
U B-CellLine +
alpha I-CellLine +
S I-CellLine +
and O +
its O +
clonal O +
derivative O +
alpha O +
G2S B-CellLine +
) O +
showed O +
increased O +
sensitivity O +
to O +
RA O +
, O +
while O +
the O +
antisense B-CellLine +
cell I-CellLine +
lines I-CellLine +
( O +
U B-CellLine +
alpha I-CellLine +
A I-CellLine +
and O +
its O +
clonal O +
derivative O +
alpha O +
B5A B-CellLine +
) O +
showed O +
decreased O +
sensitivity O +
to O +
RA O +
, O +
as O +
demonstrated O +
by O +
growth O +
inhibition O +
and O +
by O +
regulation O +
of O +
an O +
RA O -
- O -
responsive O +
reporter O +
gene O +
. O +

Both O +
U B-CellLine +
alpha I-CellLine +
A I-CellLine +
and O +
alpha O +
B5A B-CellLine +
also O +
failed O +
to O +
respond O +
to O +
another O +
modulating O +
agent O +
, O +
1 O +
alpha O +
, O +
25-dihydroxycholecalciferol O +
( O +
DHCC O +
) O +
, O +
but O +
only O +
U B-CellLine +
alpha I-CellLine +
S I-CellLine +
and O +
not O +
alpha O +
G2S O +
showed O +
an O +
enhanced O +
response O +
to O +
DHCC O +
. O +

The O +
combination O +
of O +
RA O +
and O +
DHCC O +
together O +
inhibited O +
growth O +
of O +
both O +
sense O +
and O +
antisense B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

In O +
addition O +
, O +
alpha O +
G2S O +
exhibited O +
increased O +
expression O +
of O +
CD11b O +
and O +
CD54 O +
, O +
while O +
alpha B-CellLine +
B5A I-CellLine +
cells I-CellLine +
showed O +
increased O +
expression O +
of O +
CD102 O +
, O +
suggesting O +
that O +
RXR O -
- O -
alpha O +
has O +
a O +
role O +
in O +
regulating O +
expression O +
of O +
cell O +
adhesion O +
molecules O +
in O +
U937 B-CellLine +
cells I-CellLine +
. O +

These O +
results O +
demonstrate O +
that O +
RXR O -
- O -
alpha O +
has O +
a O +
role O +
in O +
mediating O +
growth O +
inhibition O +
and O +
cell O +
adhesion O +
during O +
myelomonocytic O +
differentiation O +
, O +
and O +
suggest O +
that O +
different O +
species O +
of O +
heterodimers O +
involving O +
RXR O -
- O -
alpha O +
may O +
control O +
the O +
acquisition O +
of O +
different O +
features O +
of O +
mature O +
monocyte O -
/ O -
macrophage O +
function O +
. O +

B B-CellLine -
- I-CellLine -
lymphoblastoid I-CellLine +
cell I-CellLine +
lines I-CellLine +
from O +
multiple O +
sclerosis O +
patients O +
and O +
a O +
healthy O +
control O +
producing O +
a O +
putative O +
new O +
human O +
retrovirus O +
and O +
Epstein O -
- O -
Barr O +
virus O +
. O +

On O +
several O +
occasions O +
we O +
have O +
observed O +
retrovirus O -
- O -
like O +
particles O +
( O +
RVLPs O +
) O +
by O +
transmission O +
electron O +
microscopy O +
( O +
EM O +
) O +
of O +
cultured B-CellLine +
T I-CellLine +
cells I-CellLine +
from O +
a O +
patient O +
with O +
MS O +
. O +

Later O +
we O +
established O +
spontaneously O +
formed O +
B B-CellLine -
- I-CellLine -
lymphoblastoid I-CellLine +
cell I-CellLine +
lines I-CellLine +
( O +
LCLs B-CellLine +
) O +
from O +
a O +
patient O +
with O +
an O +
MS O -
- O -
like O +
disease O +
and O +
from O +
another O +
patient O +
with O +
MS O +
who O +
had O +
a O +
reactivated O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
infection O +
. O +

Both O +
LCLs B-CellLine +
were O +
found O +
by O +
EM O +
to O +
produce O +
RVLP O +
and O +
EBV O +
particles O +
. O +

Reverse O +
transcriptase O +
( O +
RT O +
) O +
assays O +
were O +
positive O +
in O +
purified O +
viral O +
material O +
from O +
both O +
LCLs B-CellLine +
. O +

To O +
substantiate O +
these O +
findings O +
we O +
initiated O +
an O +
intensified O +
culturing O +
procedure O +
and O +
were O +
able O +
to O +
establish O +
LCLs B-CellLine +
from O +
5 O +
out O +
of O +
21 O +
consecutive O +
MS O +
patients O +
and O +
1 O +
out O +
of O +
13 O +
consecutive O +
healthy O +
controls O +
. O +

All O +
LCLs B-CellLine +
were O +
found O +
to O +
produce O +
both O +
RVLP O +
and O +
EBV O +
particles O +
by O +
EM O +
. O +

Whether O +
the O +
putative O +
new O +
retrovirus O +
( O +
es O +
) O +
and O +
EBV O +
have O +
any O +
causal O +
relationship O +
to O +
MS O +
is O +
still O +
not O +
known O +
, O +
but O +
the O +
findings O +
support O +
this O +
possibility O +
. O +

Helenalin O +
, O +
an O +
anti O -
- O -
inflammatory O +
sesquiterpene O +
lactone O +
from O +
Arnica O +
, O +
selectively O +
inhibits O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
[ O +
see O +
comments O +
] O +

Alcoholic O +
extracts O +
prepared O +
form O +
Arnicae O +
flos O +
, O +
the O +
collective O +
name O +
for O +
flowerheads O +
from O +
Arnica O +
montana O +
and O +
A. O +
chamissonis O +
ssp O -
. O +
foliosa O +
, O +
are O +
used O +
therapeutically O +
as O +
anti O -
- O -
inflammatory O +
remedies O +
. O +

The O +
active O +
ingredients O +
mediating O +
the O +
pharmacological O +
effect O +
are O +
mainly O +
sesquiterpene O +
lactones O +
, O +
such O +
as O +
helenalin O +
, O +
11alpha O +
, O +
13-dihydrohelenalin O +
, O +
chamissonolid O +
and O +
their O +
ester O +
derivatives O +
. O +

While O +
these O +
compounds O +
affect O +
various O +
cellular O +
processes O +
, O +
current O +
data O +
do O +
not O +
fully O +
explain O +
how O +
sesquiterpene O +
lactones O +
exert O +
their O +
anti O -
- O -
inflammatory O +
effect O +
. O +

We O +
show O +
here O +
that O +
helenalin O +
, O +
and O +
, O +
to O +
a O +
much O +
lesser O +
degree O +
, O +
11alpha O +
, O +
13-dihydrohelenalin O +
and O +
chamissonolid O +
, O +
inhibit O +
activation O +
of O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
. O +

This O +
difference O +
in O +
efficacy O +
, O +
which O +
correlates O +
with O +
the O +
compounds O +
' O +
anti O -
- O -
inflammatory O +
potency O +
in O +
vivo O +
, O +
may O +
be O +
explained O +
by O +
differences O +
in O +
structure O +
and O +
conformation O +
. O +

NF O -
- O -
kappaB O +
, O +
which O +
resides O +
in O +
an O +
inactive O +
, O +
cytoplasmic O +
complex O +
in O +
unstimulated B-CellLine +
cells I-CellLine +
, O +
is O +
activated O +
by O +
phosphorylation O +
and O +
degradation O +
of O +
its O +
inhibitory O +
subunit O +
, O +
IkappaB O +
. O +

Helenalin O +
inhibits O +
NF O -
- O -
kappaB O +
activation O +
in O +
response O +
to O +
four O +
different O +
stimuli O +
in O +
T O -
- O -
cells O +
, O +
B O -
- O -
cells O +
and O +
epithelial O +
cells O +
and O +
abrogates O +
kappaB O +
-driven O +
gene O +
expression O +
. O +

This O +
inhibition O +
is O +
selective O +
, O +
as O +
the O +
activity O +
of O +
four O +
other O +
transcription O +
factors O +
, O +
Oct-1 O +
, O +
TBP O +
, O +
Sp1 O +
and O +
STAT O +
5 O +
was O +
not O +
affected O +
. O +

We O +
show O +
that O +
inhibition O +
is O +
not O +
due O +
to O +
a O +
direct O +
modification O +
of O +
the O +
active O +
NF O -
- O -
kappaB O +
heterodimer O +
. O +

Rather O +
, O +
helenalin O +
modifies O +
the O +
NF O -
- O -
kappaB O -
/ O -
IkappaB O +
complex O +
, O +
preventing O +
the O +
release O +
of O +
IkappaB O +
. O +

These O +
data O +
suggest O +
a O +
molecular O +
mechanism O +
for O +
the O +
anti O -
- O -
inflammatory O +
effect O +
of O +
sesquiterpene O +
lactones O +
, O +
which O +
differs O +
from O +
that O +
of O +
other O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O +
NSAIDs O +
) O +
, O +
indomethacin O +
and O +
acetyl O +
salicylic O +
acid O +
. O +

Inhibition O +
of O +
T O +
cell O +
and O +
promotion O +
of O +
natural O +
killer O +
cell O +
development O +
by O +
the O +
dominant O +
negative O +
helix O +
loop O +
helix O +
factor O +
Id3 O +
. O +

Bipotential O +
T O -
/ O -
natural O +
killer O +
( O +
NK O +
) O +
progenitor O +
cells O +
are O +
present O +
in O +
the O +
human O +
thymus O +
. O +

Despite O +
their O +
bipotential O +
capacity O +
, O +
these O +
progenitors O +
develop O +
predominantly O +
to O +
T O +
cells O +
in O +
the O +
thymus O +
. O +

The O +
mechanisms O +
controlling O +
this O +
developmental O +
choice O +
are O +
unknown O +
. O +

Here O +
we O +
present O +
evidence O +
that O +
a O +
member O +
( O +
s O +
) O +
of O +
the O +
family O +
of O +
basic O +
helix O +
loop O +
helix O +
( O +
bHLH O +
) O +
transcription O +
factors O +
determines O +
lineage O +
specification O +
of O +
NK O -
/ O -
T O +
cell O +
progenitors O +
. O +

The O +
natural O +
dominant O +
negative O +
HLH O +
factor O +
Id3 O +
, O +
which O +
blocks O +
transcriptional O +
activity O +
of O +
a O +
number O +
of O +
known O +
bHLH O +
factors O +
, O +
was O +
expressed O +
in O +
CD34 O -
+ O +
progenitor O +
cells O +
by O +
retrovirus O -
- O -
mediated O +
gene O +
transfer O +
. O +

Constitutive O +
expression O +
of O +
Id3 O +
completely O +
blocks O +
development O +
of O +
CD34 O -
+ O +
cells O +
into O +
T O +
cells O +
in O +
a O +
fetal O +
thymic O +
organ O +
culture O +
( O +
FTOC O +
) O +
. O +

In O +
contrast O +
, O +
development O +
into O +
NK O +
cells O +
in O +
an O +
FTOC O +
is O +
enhanced O +
. O +

Thus O +
, O +
the O +
activity O +
of O +
a O +
bHLH O +
transcription O +
factor O +
is O +
necessary O +
for O +
T O +
lineage O +
differentiation O +
of O +
bipotential O +
precursors O +
, O +
in O +
the O +
absence O +
of O +
which O +
a O +
default O +
pathway O +
leading O +
to O +
NK O +
cell O +
development O +
is O +
chosen O +
. O +

Our O +
results O +
identify O +
a O +
molecular O +
switch O +
for O +
lineage O +
specification O +
in O +
early O +
lymphoid O +
precursors O +
of O +
humans O +
. O +

Relationship O +
between O +
glucocorticoid O +
receptor O +
and O +
response O +
to O +
glucocorticoid O +
therapy O +
in O +
ulcerative O +
colitis O +
. O +

PURPOSE O +
: O +
To O +
clarify O +
the O +
relationship O +
between O +
the O +
glucocorticoid O +
receptor O +
and O +
the O +
effectiveness O +
of O +
glucocorticoid O +
therapy O +
in O +
patients O +
with O +
ulcerative O +
colitis O +
, O +
we O +
investigated O +
the O +
number O +
and O +
apparent O +
dissociation O +
constant O +
of O +
glucocorticoid O +
receptor O +
in O +
peripheral O +
blood O +
mononuclear O +
leukocytes O +
of O +
patients O +
with O +
ulcerative O +
colitis O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +
Eleven O +
patients O +
with O +
ulcerative O +
colitis O +
( O +
5 O +
who O +
responded O +
to O +
intravenous O +
glucocorticoids O +
and O +
6 O +
who O +
did O +
not O +
) O +
and O +
ten O +
control O +
subjects O +
were O +
studied O +
. O +

The O +
number O +
and O +
apparent O +
dissociation O +
constant O +
of O +
glucocorticoid O +
receptor O +
were O +
measured O +
using O +
a O +
whole O -
- O -
cell O +
binding O +
assay O +
. O +

Results O +
were O +
expressed O +
as O +
a O +
median O +
( O +
interquartile O +
range O +
) O +
. O +

RESULTS O +
: O +
The O +
number O +
of O +
glucocorticoid O +
receptors O +
from O +
the O +
six O +
nonresponders O +
, O +
five O +
responders O +
, O +
and O +
ten O +
healthy O +
controls O +
were O +
4922 O +
( O +
range O +
, O +
4484 O -
- O -
5643 O +
) O +
, O +
3413 O +
( O +
range O +
, O +
3183 O -
- O -
4450 O +
) O +
, O +
and O +
3610 O +
( O +
range O +
, O +
2594 O -
- O -
3979 O +
) O +
binding O +
sites O -
/ O -
cell O +
, O +
respectively O +
. O +

The O +
apparent O +
dissociation O +
constant O +
of O +
the O +
glucocorticoid O +
receptors O +
from O +
the O +
nonresponders O +
, O +
responders O +
, O +
and O +
healthy O +
controls O +
were O +
7.03 O +
( O +
range O +
, O +
5.66 O -
- O -
10 O +
) O +
, O +
4.27 O +
( O +
range O +
, O +
4 O -
- O -
5.13 O +
) O +
, O +
and O +
6.18 O +
( O +
range O +
, O +
5.86 O -
- O -
6.74 O +
) O +
nM O +
, O +
respectively O +
. O +

Nonresponders O +
had O +
a O +
significant O +
increase O +
both O +
in O +
the O +
number O +
of O +
binding O +
sites O +
and O +
in O +
the O +
apparent O +
dissociation O +
constant O +
compared O +
with O +
responders O +
( O +
P O +
= O +
0.045 O +
; O +
P O +
= O +
0.029 O +
) O +
. O +

CONCLUSIONS O +
: O +
The O +
increased O +
number O +
and O +
apparent O +
dissociation O +
constant O +
of O +
glucocorticoid O +
receptor O +
are O +
closely O +
associated O +
with O +
the O +
effectiveness O +
of O +
glucocorticoid O +
therapy O +
. O +

The O +
measurement O +
of O +
the O +
number O +
and O +
apparent O +
dissociation O +
constant O +
of O +
glucocorticoid O +
receptor O +
may O +
be O +
useful O +
in O +
predicting O +
response O +
to O +
glucocorticoids O +
. O +

CD30 O +
-dependent O +
degradation O +
of O +
TRAF2 O +
: O +
implications O +
for O +
negative O +
regulation O +
of O +
TRAF O +
signaling O +
and O +
the O +
control O +
of O +
cell O +
survival O +
. O +

CD30 O +
is O +
a O +
cell O -
- O -
surface O +
receptor O +
that O +
can O +
augment O +
lymphocyte O +
activation O +
and O +
survival O +
through O +
its O +
ability O +
to O +
induce O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
. O +

CD30 O +
, O +
however O +
, O +
has O +
also O +
been O +
implicated O +
in O +
the O +
induction O +
of O +
apoptotic O +
cell O +
death O +
of O +
lymphocytes O +
. O +

Here O +
we O +
show O +
that O +
one O +
of O +
the O +
effects O +
of O +
CD30 O +
signal O +
transduction O +
is O +
to O +
render O +
cells O +
sensitive O +
to O +
apoptosis O +
induced O +
by O +
the O +
type O +
1 O +
tumor O +
necrosis O +
factor O +
receptor O +
( O +
TNFR1 O +
) O +
. O +

This O +
sensitization O +
is O +
dependent O +
on O +
the O +
TRAF O -
- O -
binding O +
sites O +
within O +
the O +
CD30 O +
cytoplasmic O +
domain O +
. O +

One O +
of O +
the O +
proteins O +
that O +
binds O +
to O +
these O +
sites O +
is O +
TRAF2 O +
, O +
a O +
signal O +
transduction O +
molecule O +
that O +
is O +
also O +
utilized O +
by O +
TNFR1 O +
to O +
mediate O +
the O +
activation O +
of O +
several O +
downstream O +
kinases O +
and O +
transcription O +
factors O +
. O +

During O +
CD30 O +
signal O +
transduction O +
, O +
we O +
found O +
that O +
binding O +
of O +
TRAF2 O +
to O +
the O +
cytoplasmic O +
domain O +
of O +
CD30 O +
results O +
in O +
the O +
rapid O +
depletion O +
of O +
TRAF2 O +
and O +
the O +
associated O +
protein O +
TRAF1 O +
by O +
proteolysis O +
. O +

These O +
data O +
suggest O +
a O +
model O +
in O +
which O +
CD30 O +
limits O +
its O +
own O +
ability O +
to O +
transduce O +
cell O +
survival O +
signals O +
through O +
signal O -
- O -
coupled O +
depletion O +
of O +
TRAF2 O +
. O +

Depletion O +
of O +
intracellular O +
TRAF2 O +
and O +
its O +
coassociated O +
proteins O +
also O +
increased O +
the O +
sensitivity O +
of O +
the O +
cell O +
to O +
undergoing O +
apoptosis O +
during O +
activation O +
of O +
death O -
- O -
inducing O +
receptors O +
such O +
as O +
TNFR1 O +
. O +

Consistent O +
with O +
this O +
hypothesis O +
, O +
expression O +
of O +
a O +
dominant O -
- O -
negative O +
form O +
of O +
TRAF2 O +
was O +
found O +
to O +
potentiate O +
TNFR1 O +
-mediated O +
death O +
. O +

These O +
studies O +
provide O +
a O +
potential O +
mechanism O +
through O +
which O +
CD30 O +
, O +
as O +
well O +
as O +
other O +
TRAF O -
- O -
binding O +
members O +
of O +
the O +
TNFR O +
superfamily O +
, O +
can O +
negatively O +
regulate O +
cell O +
survival O +
. O +

Switching O +
gears O +
during O +
T O -
- O -
cell O +
maturation O +
: O +
RANTES O +
and O +
late O +
transcription O +
. O +

Although O +
much O +
is O +
understood O +
about O +
the O +
induction O +
of O +
genes O +
expressed O +
early O +
( O +
within O +
24 O +
h O +
) O +
after O +
T O -
- O -
cell O +
activation O +
, O +
little O +
is O +
known O +
about O +
the O +
regulation O +
of O +
expression O +
of O +
genes O +
expressed O +
' O -
late O +
' O +
( O +
three O +
or O +
more O +
days O +
) O +
post O -
- O -
stimulation O +
. O +

A O +
better O +
understanding O +
of O +
transcriptional O +
regulation O +
at O +
this O +
important O +
stage O +
of O +
T O -
- O -
cell O +
maturation O +
may O +
yield O +
new O +
insights O +
into O +
T O -
- O -
cell O +
development O +
and O +
new O +
immunotherapeutic O +
targets O +
. O +

PU.1 O -
/ O -
Pip O +
and O +
basic O +
helix O +
loop O +
helix O +
zipper O +
transcription O +
factors O +
interact O +
with O +
binding O +
sites O +
in O +
the O +
CD20 O +
promoter O +
to O +
help O +
confer O +
lineage- O +
and O +
stage O -
- O -
specific O +
expression O +
of O +
CD20 O +
in O +
B O +
lymphocytes O +
. O +

CD20 O +
is O +
a O +
B O -
- O -
lineage O -
- O -
specific O +
gene O +
expressed O +
at O +
the O +
pre O -
- O -
B O -
- O -
cell O +
stage O +
of O +
B O -
- O -
cell O +
development O +
that O +
disappears O +
on O +
differentiation O +
to O +
plasma O +
cells O +
. O +

As O +
such O +
, O +
it O +
serves O +
as O +
an O +
excellent O +
paradigm O +
for O +
the O +
study O +
of O +
lineage O +
and O +
developmental O +
stage O -
- O -
specific O +
gene O +
expression O +
. O +

Using O +
in O +
vivo O +
footprinting O +
we O +
identified O +
two O +
sites O +
in O +
the O +
promoter O +
at O +
-45 O +
and O +
-160 O +
that O +
were O +
occupied O +
only O +
in O +
CD20 O +
+ O +
B O +
cells O +
. O +

The O +
-45 O +
site O +
is O +
an O +
E O +
box O +
that O +
binds O +
basic O +
helix O -
- O -
loop O -
- O -
helix O -
- O -
zipper O +
proteins O +
whereas O +
the O +
-160 O +
site O +
is O +
a O +
composite O +
PU.1 O +
and O +
Pip O +
binding O +
site O +
. O +

Transfection O +
studies O +
with O +
reporter O +
constructs O +
and O +
various O +
expression O +
vectors O +
verified O +
the O +
importance O +
of O +
these O +
sites O +
. O +

The O +
composite O +
PU.1 O +
and O +
Pip O +
site O +
likely O +
accounts O +
for O +
both O +
lineage O +
and O +
stage O -
- O -
specific O +
expression O +
of O +
CD20 O +
whereas O +
the O +
CD20 O +
E O +
box O +
binding O +
proteins O +
enhance O +
overall O +
promoter O +
activity O +
and O +
may O +
link O +
the O +
promoter O +
to O +
a O +
distant O +
enhancer O +
. O +

The O +
Epstein O -
- O -
Barr O +
virus O +
oncogene O +
product O +
latent O +
membrane O +
protein O +
1 O +
engages O +
the O +
tumor O +
necrosis O +
factor O +
receptor O -
- O -
associated O +
death O +
domain O +
protein O +
to O +
mediate O +
B O +
lymphocyte O +
growth O +
transformation O +
and O +
activate O +
NF O -
- O -
kappaB O +
. O +

The O +
Epstein O -
- O -
Barr O +
virus O +
latent O +
membrane O +
protein O +
1 O +
( O +
LMP1 O +
) O +
is O +
essential O +
for O +
the O +
transformation O +
of O +
B O +
lymphocytes O +
into O +
lymphoblastoid B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Previous O +
data O +
are O +
consistent O +
with O +
a O +
model O +
that O +
LMP1 O +
is O +
a O +
constitutively O +
activated O +
receptor O +
that O +
transduces O +
signals O +
for O +
transformation O +
through O +
its O +
carboxyl O -
- O -
terminal O +
cytoplasmic O +
tail O +
. O +

One O +
transformation O +
effector O +
site O +
( O +
TES1 O +
) O +
, O +
located O +
within O +
the O +
membrane O +
proximal O +
45 O +
residues O +
of O +
the O +
cytoplasmic O +
tail O +
, O +
constitutively O +
engages O +
tumor O +
necrosis O +
factor O +
receptor O -
- O -
associated O +
factors O +
. O +

Signals O +
from O +
TES1 O +
are O +
sufficient O +
to O +
drive O +
initial O +
proliferation O +
of O +
infected O +
resting O +
B O +
lymphocytes O +
, O +
but O +
most O +
lymphoblastoid O +
cells O +
infected O +
with O +
a O +
virus O +
that O +
does O +
not O +
express O +
the O +
155 O +
residues O +
beyond O +
TES1 O +
fail O +
to O +
grow O +
as O +
long B-CellLine -
- I-CellLine -
term I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

We O +
now O +
find O +
that O +
mutating O +
two O +
tyrosines O +
to O +
an O +
isoleucine O +
at O +
the O +
carboxyl O +
end O +
of O +
the O +
cytoplasmic O +
tail O +
cripples O +
the O +
ability O +
of O +
EBV O +
to O +
cause O +
lymphoblastoid O +
cell O +
outgrowth O +
, O +
thereby O +
marking O +
a O +
second O +
transformation O +
effector O +
site O +
, O +
TES2 O +
. O +

A O +
yeast O +
two O -
- O -
hybrid O +
screen O +
identified O +
TES2 O +
interacting O +
proteins O +
, O +
including O +
the O +
tumor O +
necrosis O +
factor O +
receptor O -
- O -
associated O +
death O +
domain O +
protein O +
( O +
TRADD O +
) O +
. O +

TRADD O +
was O +
the O +
only O +
protein O +
that O +
interacted O +
with O +
wild O -
- O -
type O +
TES2 O +
and O +
not O +
with O +
isoleucine O -
- O -
mutated O +
TES2 O +
. O +

TRADD O +
associated O +
with O +
wild O -
- O -
type O +
LMP1 O +
but O +
not O +
with O +
isoleucine O -
- O -
mutated O +
LMP1 O +
in O +
mammalian O +
cells O +
, O +
and O +
TRADD O +
constitutively O +
associated O +
with O +
LMP1 O +
in O +
EBV B-CellLine -
- I-CellLine -
transformed I-CellLine +
cells I-CellLine +
. O +

In O +
transfection O +
assays O +
, O +
TRADD O +
and O +
TES2 O +
synergistically O +
mediated O +
high O -
- O -
level O +
NF O -
- O -
kappaB O +
activation O +
. O +

These O +
results O +
indicate O +
that O +
LMP1 O +
appropriates O +
TRADD O +
to O +
enable O +
efficient O +
long O -
- O -
term O +
lymphoblastoid O +
cell O +
outgrowth O +
. O +

High O -
- O -
level O +
NF O -
- O -
kappaB O +
activation O +
also O +
appears O +
to O +
be O +
a O +
critical O +
component O +
of O +
long O -
- O -
term O +
outgrowth O +
. O +

The O +
activation O +
of O +
the O +
JAK2 O +
/STAT5 O +
pathway O +
is O +
commonly O +
involved O +
in O +
signaling O +
through O +
the O +
human O +
IL-5 O +
receptor O +
. O +

The O +
JAK O +
( O +
Janus O +
kinase O +
) O +
family O +
of O +
protein O +
tyrosine O +
kinases O +
and O +
the O +
STATs O +
( O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
) O +
have O +
been O +
shown O +
to O +
be O +
activated O +
in O +
response O +
to O +
a O +
number O +
of O +
cytokines O +
and O +
growth O +
factors O +
. O +

In O +
this O +
study O +
, O +
we O +
evaluated O +
the O +
activation O +
of O +
JAK O +
/STAT O +
pathway O +
upon O +
human O +
interleukin-5 O +
( O +
hIL-5 O +
) O +
stimulation O +
of O +
two O +
different O +
hIL-5-responsive B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
hIL-5 B-CellLine +
receptor I-CellLine +
alpha I-CellLine -
- I-CellLine -
subunit I-CellLine +
( I-CellLine +
hIL-5R I-CellLine +
alpha I-CellLine +
) I-CellLine +
cDNA I-CellLine -
- I-CellLine -
transfected I-CellLine +
TF-1 I-CellLine +
( O +
TF B-CellLine -
- I-CellLine -
h5R I-CellLine +
alpha I-CellLine +
) O +
and O +
butyric B-CellLine -
- I-CellLine -
acid I-CellLine -
- I-CellLine -
treated I-CellLine +
YY-1 I-CellLine +
( O +
YY B-CellLine -
- I-CellLine -
Bu I-CellLine +
) O +
, O +
and O +
peripheral B-CellLine +
eosinophils I-CellLine +
. O +

Immunoprecipitation O +
and O +
electrophoretic O +
mobility O +
shift O +
analysis O +
revealed O +
that O +
tyrosine O +
phosphorylation O +
of O +
JAK2 O +
and O +
activation O +
of O +
STAT5 O +
were O +
induced O +
upon O +
stimulation O +
with O +
hIL-5 O +
in O +
all O +
three O +
cell O +
types O +
, O +
while O +
STAT1 O +
activation O +
was O +
only O +
observed O +
in O +
eosinophils O +
. O +

These O +
results O +
indicate O +
that O +
JAK2 O +
/STAT5 O +
activation O +
is O +
a O +
common O +
JAK O +
/STAT O +
pathway O +
for O +
hIL-5 O +
-mediated O +
signal O +
in O +
these O +
cells O +
. O +

Transcription O +
factor O +
NF O -
- O -
kappaB O +
regulates O +
inducible O +
Oct-2 O +
gene O +
expression O +
in O +
precursor O +
B O +
lymphocytes O +
. O +

The O +
POU O +
transcription O +
factors O +
Oct-1 O +
and O +
Oct-2 O +
regulate O +
the O +
activity O +
of O +
octamer O -
- O -
dependent O +
promoters O +
, O +
including O +
those O +
that O +
direct O +
transcription O +
from O +
rearranged O +
immunoglobulin O +
genes O +
. O +

Unlike O +
Oct-1 O +
, O +
which O +
is O +
constitutively O +
expressed O +
in O +
many O +
cell O +
types O +
, O +
Oct-2 O +
expression O +
is O +
restricted O +
primarily O +
to O +
B O +
lymphocytes O +
and O +
can O +
be O +
induced O +
in O +
precursor O +
B O +
cells O +
by O +
stimulation O +
with O +
bacterial O +
lipopolysaccharide O +
( O +
LPS O +
) O +
. O +

However O +
, O +
the O +
precise O +
factors O +
that O +
mediate O +
this O +
induction O +
mechanism O +
remain O +
unknown O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
monitored O +
Oct-2 O +
expression O +
in O +
cells O +
arrested O +
for O +
the O +
activation O +
of O +
NF O -
- O -
kappaB O +
, O +
an O +
LPS O -
- O -
responsive O +
member O +
of O +
the O +
Rel O +
transcription O +
factor O +
family O +
. O +

Despite O +
stimulation O +
with O +
LPS O +
, O +
disruption O +
of O +
the O +
NF O -
- O -
kappaB O +
signaling O +
pathway O +
in O +
precursor O +
B O +
cells O +
led O +
to O +
the O +
loss O +
of O +
inducible O +
Oct-2 O +
DNA O +
binding O +
activity O +
in O +
vitro O +
and O +
the O +
suppression O +
of O +
Oct-2 O +
-directed O +
transcription O +
in O +
vivo O +
. O +

This O +
biochemical O +
defect O +
correlated O +
with O +
a O +
specific O +
block O +
to O +
Oct-2 O +
gene O +
expression O +
at O +
the O +
level O +
of O +
transcription O +
, O +
whereas O +
the O +
expression O +
of O +
Oct-1 O +
was O +
unaffected O +
. O +

The O +
finding O +
that O +
Oct-2 O +
is O +
under O +
NF O -
- O -
kappaB O +
control O +
highlights O +
an O +
important O +
cross O -
- O -
talk O +
mechanism O +
involving O +
two O +
distinct O +
transcription O +
factor O +
families O +
that O +
regulate O +
B O +
lymphocyte O +
function O +
. O +

Is O +
celiac O +
disease O +
due O +
to O +
molecular O +
mimicry O +
between O +
gliadin O +
peptide O +
-HLA O +
class O +
II O +
molecule O +
-T O +
cell O +
interactions O +
and O +
those O +
of O +
some O +
unidentified O +
superantigen O +
? O +

This O +
paper O +
presents O +
a O +
new O +
hypothesis O +
for O +
the O +
etiology O +
and O +
pathogenesis O +
of O +
celiac O +
disease O +
( O +
CD O +
) O +
. O +

It O +
is O +
our O +
contention O +
that O +
CD O +
is O +
triggered O +
by O +
the O +
binding O +
of O +
one O +
or O +
more O +
gliadin O +
peptides O +
to O +
CD O -
- O -
associated O +
HLA O +
class O +
II O +
molecules O +
. O +

Furthermore O +
, O +
we O +
propose O +
that O +
these O +
putative O +
CD O +
peptides O +
bind O +
to O +
oligosaccharide O +
residues O +
on O +
HLA O +
class O +
II O +
molecules O +
distal O +
to O +
the O +
peptide O -
- O -
binding O +
groove O +
invoking O +
recognition O +
and O +
binding O +
by O +
specialized O +
subsets O +
of O +
gamma O +
delta O +
T O +
cell O +
receptor O -
- O -
bearing O +
lymphocytes O +
. O +

The O +
binding O +
of O +
these O +
gamma O +
delta O +
T O +
cells O +
serves O +
as O +
a O +
signal O +
for O +
abrogation O +
of O +
oral O +
tolerance O +
to O +
ingested O +
proteins O +
setting O +
in O +
motion O +
a O +
series O +
of O +
immune O +
responses O +
directed O +
against O +
the O +
small O +
intestinal O +
epithelium O +
of O +
CD O +
patients O +
. O +

CD O +
patients O +
are O +
victimized O +
by O +
this O +
self O -
- O -
distructed O +
immune O +
response O +
because O +
of O +
inheritance O +
of O +
certain O +
combinations O +
of O +
HLA O -
- O -
DQ O +
and O +
DR O +
haplotypes O +
. O +

Dimers O +
encoded O +
by O +
HLA O -
- O -
DR O +
haplotypes O +
may O +
be O +
the O +
primary O +
restriction O +
elements O +
for O +
lectin O -
- O -
like O +
, O +
gliadin O +
peptides O +
while O +
the O +
degree O +
of O +
immune O +
suppression O +
( O +
or O +
lack O +
thereof O +
) O +
to O +
ingested O +
gliadins O +
is O +
governed O +
by O +
inherited O +
HLA O -
- O -
DQ O +
haplotypes O +
. O +

Finally O +
, O +
we O +
speculate O +
that O +
molecular O +
mimicry O +
between O +
one O +
or O +
more O +
gliadin O +
peptides O +
and O +
some O +
, O +
as O +
yet O +
unidentified O +
, O +
bacterial O +
or O +
viral O +
superantigen O +
plays O +
a O +
role O +
in O +
disease O +
pathogenesis O +
. O +

Characterization O +
of O +
CD40 O +
signaling O +
determinants O +
regulating O +
nuclear O +
factor O -
- O -
kappa O +
B O +
activation O +
in O +
B O +
lymphocytes O +
. O +

CD40 O +
signaling O +
to O +
B O +
cells O +
is O +
important O +
for O +
generating O +
an O +
effective O +
humoral O +
immune O +
response O +
. O +

CD40 O +
ligation O +
leads O +
to O +
B O +
cell O +
activation O +
events O +
such O +
as O +
proliferation O +
, O +
Ig O +
secretion O +
, O +
isotype O +
switching O +
, O +
and O +
up O -
- O -
regulation O +
of O +
cell O +
surface O +
molecules O +
, O +
as O +
well O +
as O +
the O +
generation O +
of O +
memory O +
B O +
cells O +
. O +

Many O +
of O +
these O +
events O +
are O +
dependent O +
upon O +
the O +
ability O +
of O +
CD40 O +
to O +
activate O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
. O +

To O +
define O +
the O +
CD40 O +
signaling O +
components O +
upstream O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
and O +
the O +
functional O +
consequences O +
downstream O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
, O +
we O +
examined O +
mouse B-CellLine +
B I-CellLine +
cell I-CellLine +
transfectants I-CellLine +
expressing O +
wild O -
- O -
type O +
or O +
mutant O +
human O +
CD40 O +
. O +

Analysis O +
of O +
CD40 O +
cytoplasmic O +
domain O +
truncation O +
and O +
point O +
mutants O +
defined O +
a O +
10-amino O +
acid O +
CD40 O +
cytoplasmic O +
signaling O +
determinant O +
required O +
for O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

A O +
threonine O +
residue O +
at O +
position O +
234 O +
, O +
previously O +
shown O +
to O +
be O +
important O +
for O +
CD40 O +
association O +
with O +
TNF O +
receptor O -
- O -
associated O +
factor O +
2 O +
( O +
TRAF2 O +
) O +
, O +
TRAF3 O +
, O +
and O +
TRAF5 O +
, O +
was O +
not O +
required O +
for O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

This O +
suggests O +
that O +
in O +
B O +
cells O +
, O +
CD40 O +
-induced O +
NF O -
- O -
kappa O +
B O +
activation O +
can O +
occur O +
independently O +
of O +
TRAF2 O +
and O +
TRAF5 O +
association O +
. O +

NF O -
- O -
kappa O +
B O +
activation O +
was O +
independent O +
of O +
the O +
transmembrane O +
domain O +
of O +
CD40 O +
, O +
suggesting O +
that O +
it O +
is O +
independent O +
of O +
p23 O +
, O +
a O +
molecule O +
that O +
associates O +
with O +
CD40 O +
in O +
a O +
region O +
other O +
than O +
the O +
cytoplasmic O +
domain O +
. O +

Proteasome O -
- O -
dependent O +
inhibitory O +
kappa O +
B O +
alpha O +
( O +
I O +
kappa O +
B O +
alpha O +
) O +
and O +
I O +
kappa O +
B O +
beta O +
degradation O +
occurred O +
downstream O +
of O +
CD40 O +
ligation O +
and O +
preceded O +
CD40 O +
-mediated O +
NF O -
- O -
kappa O +
B O +
nuclear O +
translocation O +
. O +

CD40- O +
or O +
pervanadate O -
- O -
mediated O +
I O +
kappa O +
B O +
tyrosine O +
phosphorylation O +
was O +
not O +
detected O +
. O +

NF O -
- O -
kappa O +
B O +
activation O +
correlated O +
with O +
the O +
ability O +
of O +
CD40 O +
to O +
induce O +
Ab O +
secretion O +
and O +
the O +
up O -
- O -
regulation O +
of O +
ICAM-1 O +
and O +
LFA-1 O +
. O +

However O +
, O +
NF O -
- O -
kappa O +
B O +
activation O +
was O +
insufficient O +
for O +
CD40 O +
-mediated O +
up O -
- O -
regulation O +
of O +
B7 O -
- O -
1 O +
, O +
Fas O +
, O +
and O +
CD23 O +
. O +

Impaired O +
cortisol O +
binding O +
to O +
glucocorticoid O +
receptors O +
in O +
hypertensive O +
patients O +
. O +

We O +
compared O +
glucocorticoid O +
receptor O +
binding O +
characteristics O +
and O +
glucocorticoid O +
responsiveness O +
of O +
human O +
mononuclear O +
leukocytes O +
( O +
HML O +
) O +
from O +
hypertensive O +
patients O +
and O +
matched O +
normotensive O +
volunteers O +
. O +

We O +
also O +
considered O +
associations O +
of O +
these O +
variables O +
with O +
plasma O +
renin O +
activity O +
, O +
aldosterone O +
, O +
cortisol O +
, O +
corticotropin O +
, O +
and O +
electrolyte O +
concentrations O +
. O +

We O +
calculated O +
binding O +
affinity O +
( O +
Kd O +
; O +
nmol O -
/ O -
L O +
) O +
and O +
capacity O +
( O +
Bmax O +
; O +
sites O -
/ O -
cell O +
) O +
for O +
dexamethasone O +
and O +
cortisol O +
from O +
homologous O +
and O +
heterologous O +
competition O +
curves O +
for O +
specific O +
[ O +
3H O +
] O +
dexamethasone O +
binding O +
sites O +
on O +
HML O +
isolated O +
from O +
the O +
blood O +
of O +
normotensive O +
volunteers O +
and O +
subjects O +
with O +
essential O +
hypertension O +
. O +

Glucocorticoid O +
responsiveness O +
of O +
HML O +
was O +
evaluated O +
as O +
IC50 O +
values O +
( O +
nmol O -
/ O -
L O +
) O +
for O +
dexamethasone O +
and O +
cortisol O +
for O +
the O +
inhibition O +
of O +
lysozyme O +
release O +
. O +

We O +
measured O +
plasma O +
hormones O +
by O +
radioimmunoassay O +
. O +

Kd O +
values O +
( O +
mean+ O -
/ O -
-SE O +
) O +
for O +
cortisol O +
in O +
HML O +
of O +
hypertensive O +
patients O +
were O +
higher O +
than O +
in O +
control O +
subjects O +
( O +
24.6+ O -
/ O -
-2.4 O +
versus O +
17.5+ O -
/ O -
-1.7 O +
nmol O -
/ O -
L O +
, O +
P O +
< O +
.04 O +
) O +
. O +

Binding O +
capacity O +
( O +
4978+ O -
/ O -
-391 O +
versus O +
4131+ O -
/ O -
-321 O +
sites O -
/ O -
cell O +
) O +
, O +
Kd O +
values O +
for O +
dexamethasone O +
( O +
6.7+ O -
/ O -
-0.5 O +
versus O +
5.7+ O -
/ O -
-0.3 O +
nmol O -
/ O -
L O +
) O +
, O +
and O +
IC50 O +
values O +
for O +
dexamethasone O +
( O +
3.4+ O -
/ O -
-0.3 O +
versus O +
3.1+ O -
/ O -
-0.2 O +
nmol O -
/ O -
L O +
) O +
and O +
cortisol O +
( O +
12.2+ O -
/ O -
-1.6 O +
versus O +
9.5+ O -
/ O -
-0.3 O +
nmol O -
/ O -
L O +
) O +
were O +
not O +
significantly O +
different O +
. O +

Patients O +
with O +
renin O +
values O +
less O +
than O +
0.13 O +
ng O +
angiotensin O +
I O -
/ O -
L O +
per O +
second O +
were O +
markedly O +
less O +
sensitive O +
to O +
cortisol O +
than O +
those O +
with O +
higher O +
values O +
. O +

Both O +
Kd O +
( O +
30.3+ O -
/ O -
-2.5 O +
versus O +
19.2+ O -
/ O -
-2.4 O +
nmol O -
/ O -
L O +
) O +
and O +
IC50 O +
values O +
( O +
15.5+ O -
/ O -
-1.8 O +
versus O +
8.9+ O -
/ O -
-1.2 O +
nmol O -
/ O -
L O +
) O +
for O +
cortisol O +
were O +
significantly O +
higher O +
in O +
patients O +
with O +
lower O +
renin O +
values O +
( O +
P O +
< O +
.03 O +
) O +
. O +

Other O +
variables O +
, O +
including O +
plasma O +
hormone O +
and O +
electrolyte O +
values O +
and O +
binding O +
characteristics O +
for O +
dexamethasone O +
, O +
were O +
not O +
different O +
. O +

These O +
data O +
suggest O +
that O +
cortisol O +
binding O +
to O +
glucocorticoid O +
receptor O +
is O +
slightly O +
impaired O +
in O +
patients O +
with O +
essential O +
hypertension O +
. O +

In O +
vivo O +
, O +
this O +
could O +
lead O +
to O +
inappropriate O +
binding O +
of O +
cortisol O +
to O +
mineralocorticoid O +
receptors O +
. O +

Hence O +
, O +
decreased O +
sensitivity O +
to O +
cortisol O +
is O +
associated O +
with O +
renin O +
suppression O +
. O +

This O +
hypothesis O +
is O +
supported O +
by O +
evidence O +
of O +
hypertension O +
and O +
low O +
renin O +
activity O +
, O +
which O +
others O +
have O +
described O +
in O +
patients O +
with O +
primary O +
glucocorticoid O +
resistance O +
due O +
to O +
mutations O +
of O +
the O +
glucocorticoid O +
receptor O +
. O +

Regulation O +
of O +
Id3 O +
cell O +
cycle O +
function O +
by O +
Cdk-2-dependent O +
phosphorylation O +
. O +

The O +
functions O +
of O +
basic O +
helix O -
- O -
loop O -
- O -
helix O +
( O +
bHLH O +
) O +
transcription O +
factors O +
in O +
activating O +
differentiation O -
- O -
linked O +
gene O +
expression O +
and O +
in O +
inducing O +
G1 O +
cell O +
cycle O +
arrest O +
are O +
negatively O +
regulated O +
by O +
members O +
of O +
the O +
I O -
d O +
family O +
of O +
HLH O +
proteins O +
. O +

These O +
bHLH O +
antagonists O +
are O +
induced O +
during O +
a O +
mitogenic O +
signalling O +
response O +
, O +
and O +
they O +
function O +
by O +
sequestering O +
their O +
bHLH O +
targets O +
in O +
inactive O +
heterodimers O +
that O +
are O +
unable O +
to O +
bind O +
to O +
specific O +
gene O +
regulatory O +
( O +
E O +
box O +
) O +
sequences O +
. O +

Recently O +
, O +
cyclin O +
E O -
- O -
Cdk2- O +
and O +
cyclin O +
A O -
- O -
Cdk2-dependent O +
phosphorylation O +
of O +
a O +
single O +
conserved O +
serine O +
residue O +
( O +
Ser5 O +
) O +
in O +
Id2 O +
has O +
been O +
shown O +
to O +
occur O +
during O +
late O +
G1-to O -
- O -
S O +
phase O +
transition O +
of O +
the O +
cell O +
cycle O +
, O +
and O +
this O +
neutralizes O +
the O +
function O +
of O +
Id2 O +
in O +
abrogating O +
E O -
- O -
box O -
- O -
dependent O +
bHLH O +
homo O +
-or O +
heterodimer O +
complex O +
formation O +
in O +
vitro O +
( O +
E.Hara O +
, O +
M.Hall O +
, O +
and O +
G.Peters O +
, O +
EMBO O +
J.16 O +
: O +
332 O -
- O -
342 O +
, O +
1997 O +
) O +
. O +

We O +
now O +
show O +
that O +
an O +
analogous O +
cell O -
- O -
cycle O -
- O -
regulated O +
phosphorylation O +
of O +
Id3 O +
alters O +
the O +
specificity O +
of O +
Id3 O +
for O +
abrogating O +
both O +
E O -
- O -
box O -
- O -
dependent O +
bHLH O +
homo- O +
or O +
heterodimer O +
complex O +
formation O +
in O +
vitro O +
and O +
E O -
- O -
box O -
- O -
dependent O +
reporter O +
gene O +
function O +
in O +
vivo O +
. O +

Furthermore O +
, O +
compared O +
with O +
wild O -
- O -
type O +
Id3 O +
, O +
an O +
Id3 O +
Asp5 O +
mutant O +
( O +
mimicking O +
phosphorylation O +
) O +
is O +
unable O +
to O +
promote O +
cell O +
cycle O +
S O +
phase O +
entry O +
in O +
transfected B-CellLine +
fibroblasts I-CellLine +
, O +
whereas O +
an O +
Id3 O +
Ala5 O +
mutant O +
( O +
ablating O +
phosphorylation O +
) O +
displays O +
an O +
activity O +
significantly O +
greater O +
than O +
that O +
of O +
wild O -
- O -
type O +
Id3 O +
protein O +
. O +

Cdk2-dependent O +
phosphorylation O +
therefore O +
provides O +
a O +
switch O +
during O +
late O +
G1-to O -
- O -
S O +
phase O +
that O +
both O +
nullifies O +
an O +
early O +
G1 O +
cell O +
cycle O +
regulatory O +
function O +
of O +
Id3 O +
and O +
modulates O +
its O +
target O +
bHLH O +
specificity O +
. O +

These O +
data O +
also O +
demonstrate O +
that O +
the O +
ability O +
of O +
Id3 O +
to O +
promote O +
cell O +
cycle O +
S O +
phase O +
entry O +
is O +
not O +
simply O +
a O +
function O +
of O +
its O +
ability O +
to O +
modulate O +
bHLH O +
heterodimer O -
- O -
dependent O +
gene O +
expression O +
and O +
establish O +
a O +
biologically O +
important O +
mechanism O +
through O +
which O +
Cdk2 O +
and O +
Id O -
- O -
bHLH O +
functions O +
are O +
integrated O +
in O +
the O +
coordination O +
of O +
cell O +
proliferation O +
and O +
differentiation O +
. O +

Hypoxia O +
enhances O +
induction O +
of O +
endothelial O +
ICAM-1 O +
: O +
role O +
for O +
metabolic O +
acidosis O +
and O +
proteasomes O +
. O +

Intercellular O +
adhesion O +
molecule O +
1 O +
( O +
ICAM-1 O +
) O +
is O +
an O +
important O +
molecule O +
in O +
promotion O +
of O +
polymorphonuclear O +
neutrophil O +
transendothelial O +
migration O +
during O +
inflammation O +
. O +

Coincident O +
with O +
many O +
inflammatory O +
diseases O +
is O +
tissue O +
hypoxia O +
. O +

Thus O +
we O +
hypothesized O +
that O +
combinations O +
of O +
hypoxia O +
and O +
inflammatory O +
stimuli O +
may O +
differentially O +
regulate O +
expression O +
of O +
endothelial O +
ICAM-1 O +
. O +

Human O +
endothelial O +
cells O +
were O +
exposed O +
to O +
hypoxia O +
in O +
the O +
presence O +
or O +
absence O +
of O +
added O +
lipopolysaccharide O +
( O +
LPS O +
) O +
and O +
examined O +
for O +
expression O +
of O +
functional O +
ICAM-1 O +
. O +

Although O +
hypoxia O +
alone O +
did O +
not O +
induce O +
ICAM-1 O +
, O +
the O +
combination O +
of O +
LPS O +
and O +
hypoxia O +
enhanced O +
( O +
3 O +
+ O -
/- O +
0.4-fold O +
over O +
normoxia O +
) O +
ICAM-1 O +
expression O +
. O +

Combinations O +
of O +
hypoxia O +
and O +
LPS O +
significantly O +
increased O +
lymphocyte O +
binding O +
, O +
and O +
such O +
increases O +
were O +
inhibited O +
by O +
addition O +
of O +
anti O -
- O -
ICAM-1 O +
antibodies O +
or O +
antisense O +
oligonucleotides O +
. O +

Hypoxic O +
endothelia O +
showed O +
a O +
> O +
10-fold O +
increase O +
in O +
sensitivity O +
to O +
inhibitors O +
of O +
proteasome O +
activation O +
, O +
and O +
combinations O +
of O +
hypoxia O +
and O +
LPS O +
enhanced O +
proteasome O +
-dependent O +
cytoplasmic O -
- O -
to O -
- O -
nuclear O +
localization O +
of O +
the O +
nuclear O +
transcription O +
factor O -
- O -
kappa O +
B O +
p65 O +
( O +
Rel O +
A O +
) O +
subunit O +
. O +

Such O +
proteasome O +
activation O +
correlated O +
with O +
hypoxia O -
- O -
evoked O +
decreases O +
in O +
both O +
extracellular O +
and O +
intracellular O +
pH O +
. O +

We O +
conclude O +
from O +
these O +
studies O +
that O +
endothelial O +
hypoxia O +
provides O +
a O +
novel O +
, O +
proteasome O +
-dependent O +
stimulus O +
for O +
ICAM-1 O +
induction O +
. O +

[ O +
The O +
value O +
of O +
the O +
clinical O +
test O +
of O +
glucocorticoid O +
receptors O +
of O +
peripheral O +
blood O +
leukocytes O +
in O +
patients O +
with O +
chronic O +
pulmonary O +
heart O +
disease O +
] O +

In O +
order O +
to O +
inquire O +
into O +
the O +
functional O +
state O +
of O +
adrenal O +
cortex O +
in O +
patients O +
with O +
pulmonary O +
heart O +
disease O +
, O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
( O +
GCR O +
) O +
of O +
peripheral O +
blood O +
leukocytes O +
in O +
patients O +
with O +
chronic O +
pulmonary O +
heart O +
disease O +
was O +
determined O +
with O +
radioligand O -
- O -
binding O +
assay O +
and O +
the O +
corresponding O +
plasma O +
cortisol O +
levels O +
were O +
assessed O +
with O +
radioimmune O +
assays O +
. O +

The O +
results O +
showed O +
that O +
the O +
number O +
of O +
GCR O +
in O +
the O +
patients O +
was O +
significantly O +
reduced O +
( O +
P O +
< O +
0.01 O +
) O +
and O +
it O +
was O +
increased O +
when O +
their O +
health O +
state O +
was O +
improved O +
. O +

However O +
, O +
it O +
was O +
still O +
lower O +
than O +
that O +
in O +
healthy O +
subjects O +
( O +
P O +
< O +
0.01 O +
) O +
. O +

The O +
number O +
of O +
GCR O +
in O +
the O +
patients O +
was O +
greatly O +
increased O +
when O +
these O +
patients O +
were O +
treated O +
with O +
oxygen O +
( O +
P O +
< O +
0.01 O +
) O +
. O +

No O +
difference O +
in O +
plasma O +
cortisol O +
was O +
found O +
between O +
the O +
patients O +
and O +
the O +
healthy O +
subjects O +
( O +
P O +
> O +
0.05 O +
) O +
. O +

These O +
results O +
indicate O +
that O +
the O +
function O +
of O +
adrenal O +
cortex O +
may O +
be O +
improved O +
by O +
the O +
compensation O +
mechanism O +
of O +
the O +
patients O +
, O +
but O +
the O +
lower O +
GCR O +
number O +
was O +
the O +
result O +
of O +
lacking O +
of O +
oxygen O +
in O +
the O +
patients O +
. O +

The O +
number O +
of O +
GCR O +
may O +
be O +
improved O +
by O +
inhalation O +
of O +
oxygen O +
. O +

Therefore O +
oxygen O +
therapy O +
is O +
helpful O +
in O +
raising O +
the O +
activity O +
of O +
glucocorticoid O +
receptors O +
and O +
controlling O +
the O +
development O +
of O +
the O +
disease O +
. O +

Molecular O +
cloning O +
and O +
functional O +
characterization O +
of O +
murine O +
cDNA O +
encoding O +
transcription O +
factor O +
NFATc O +
. O +

Transcription O +
factors O +
of O +
the O +
NFAT O +
( O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
) O +
family O +
play O +
important O +
roles O +
in O +
immune O +
and O +
inflammatory O +
responses O +
by O +
regulating O +
the O +
expression O +
of O +
genes O +
encoding O +
cytokines O +
and O +
immunoregulatory O +
proteins O +
. O +

Here O +
we O +
describe O +
cloning O +
and O +
characterization O +
of O +
full O -
- O -
length O +
cDNA O +
encoding O +
murine O +
( O +
m O +
) O +
NFATc O +
which O +
predicts O +
that O +
the O +
protein O +
has O +
all O +
the O +
conserved O +
structural O +
motifs O +
of O +
NFAT O +
family O +
members O +
, O +
including O +
the O +
rel O +
homology O +
domain O +
, O +
the O +
NFAT O +
homology O +
domain O +
and O +
the O +
nuclear O +
translocation O +
signals O +
. O +

mNFATc O +
complexed O +
with O +
AP-1 O +
bound O +
specifically O +
to O +
the O +
murine O +
IL-2 O +
NFAT O +
recognition O +
sequence O +
and O +
activated O +
transcription O +
from O +
the O +
co O -
- O -
transfected O +
IL-2 O +
promoter O +
in O +
COS-7 B-CellLine +
cells I-CellLine +
. O +

Northern O +
blot O +
analysis O +
showed O +
that O +
the O +
cDNA O +
probe O +
hybridized O +
with O +
a O +
4.5 O +
kb O +
transcript O +
which O +
is O +
highly O +
inducible O +
in O +
murine O +
T O +
cells O +
. O +

By O +
Northern O +
and O +
in O +
situ O +
hybridization O +
, O +
mNFATc O +
transcript O +
was O +
detected O +
from O +
the O +
early O +
stage O +
of O +
development O +
. O +

In O +
the O +
mouse O +
embryo O +
, O +
mNFATc O +
transcript O +
was O +
strongly O +
expressed O +
in O +
thymus O +
, O +
lung O +
and O +
submandibular O +
gland O +
and O +
weakly O +
in O +
skeletal O +
muscle O +
and O +
heart O +
suggesting O +
that O +
mNFATc O +
may O +
have O +
a O +
role O +
both O +
in O +
embryogenesis O +
and O +
in O +
mature O +
T O +
cells O +
. O +

Thiol O +
modulation O +
inhibits O +
the O +
interleukin O +
( O +
IL O +
) O +
-1 O +
-mediated O +
activation O +
of O +
an O +
IL-1 O +
receptor O -
- O -
associated O +
protein O +
kinase O +
and O +
NF O -
- O -
kappa O +
B O +
. O +

The O +
interleukin-1 O +
receptor O +
type O +
I O +
( O +
IL-1RI O +
) O +
is O +
associated O +
with O +
other O +
proteins O +
thus O +
forming O +
a O +
complex O +
system O +
by O +
which O +
IL-1 O +
exerts O +
its O +
various O +
signals O +
. O +

The O +
initiating O +
event O +
is O +
still O +
uncertain O +
, O +
but O +
activation O +
of O +
a O +
recently O +
described O +
receptor O -
- O -
associated O +
protein O +
kinase O +
is O +
one O +
of O +
the O +
earliest O +
events O +
detectable O +
( O +
Martin O +
et O +
al. O +
, O +
Eur O -
. O -
J.Immunol.1994.24 O +
: O +
1566 O +
) O +
. O +

IL-1 O +
signaling O +
is O +
commonly O +
accompanied O +
by O +
oxidative O +
processes O +
and O +
is O +
thought O +
to O +
be O +
subject O +
to O +
redox O +
regulation O +
. O +

We O +
therefore O +
investigated O +
whether O +
the O +
activation O +
of O +
the O +
IL-1RI O -
- O -
associated O +
protein O +
kinase O +
could O +
be O +
a O +
target O +
for O +
redox O +
regulation O +
and O +
whether O +
an O +
altered O +
activity O +
of O +
the O +
kinase O +
could O +
influence O +
IL-1 O +
-mediated O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

A O +
murine B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
EL4 B-CellLine +
, O +
was O +
stimulated O +
with O +
IL-1 O +
with O +
and O +
without O +
pretreatment O +
with O +
different O +
compounds O +
known O +
to O +
influence O +
the O +
cellular O +
redox O +
status O +
. O +

Thiol O +
modifying O +
agents O +
like O +
diamide O +
, O +
menadione O +
, O +
pyrrolidine O +
dithiocarbamate O +
( O +
PDTC O +
) O +
, O +
diethyl O +
dithiocarbamate O +
or O +
phenylarsine O +
oxide O +
inhibited O +
the O +
IL-1 O +
-induced O +
activation O +
of O +
the O +
IL-1RI O -
- O -
associated O +
protein O +
kinase O +
. O +

N O -
- O -
Acetylcysteine O +
, O +
alpha O +
, O +
alpha'-dipyridyl O +
, O +
aminotriazole O +
or O +
nitrofurantoin O +
did O +
not O +
show O +
any O +
effect O +
. O +

The O +
inhibition O +
by O +
PDTC O +
was O +
reversible O +
unless O +
glutathione O +
synthesis O +
was O +
blocked O +
by O +
buthionine O +
sulfoximine O +
. O +

The O +
described O +
conditions O +
which O +
inhibited O +
or O +
prevented O +
the O +
activation O +
of O +
the O +
IL-1RI O -
- O -
associated O +
kinase O +
similarly O +
impaired O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
EL4 B-CellLine +
cells I-CellLine +
. O +

From O +
these O +
observations O +
we O +
conclude O +
that O +
free O +
thiols O +
in O +
the O +
IL-1RI O +
complex O +
are O +
essential O +
for O +
the O +
activation O +
of O +
the O +
IL-1RI O -
- O -
associated O +
protein O +
kinase O +
and O +
that O +
this O +
process O +
is O +
mandatory O +
for O +
IL-1 O +
signaling O +
leading O +
to O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

Differanisole O +
A O +
, O +
a O +
novel O +
antitumor O +
antibiotic O +
, O +
enhances O +
growth O +
inhibition O +
and O +
differentiation O +
of O +
human O +
myeloid O +
leukemia O +
cells O +
induced O +
by O +
9-cis O +
retinoic O +
acid O +
. O +

Differanisole O +
A O +
, O +
3 O +
, O +
5-dichloro-2-hydroxy-4-methoxy-6-n O -
- O -
propylbenzoic O +
acid O +
, O +
inhibited O +
growth O +
of O +
human O +
myeloid O +
leukemia O +
cells O +
. O +

The O +
compound O +
induced O +
G1 O +
arrest O +
and O +
granulocytic O +
differentiation O +
of O +
HL-60 B-CellLine +
cells I-CellLine +
, O +
although O +
the O +
differentiation O -
- O -
inducing O +
effect O +
was O +
modest O +
. O +

Differanisole O +
A O +
and O +
9-cis O +
retinoic O +
acid O +
( O +
9cisRA O +
) O +
synergistically O +
inhibited O +
the O +
growth O +
and O +
induced O +
functional O +
and O +
morphologic O +
differentiation O +
of O +
HL-60 B-CellLine +
and I-CellLine +
NB4 I-CellLine +
cells I-CellLine +
, O +
whereas O +
the O +
combined O +
treatment O +
with O +
differanisole O +
A O +
and O +
all O -
- O -
trans O +
retinoic O +
acid O +
or O +
1alpha O +
, O +
25-dihydroxyvitamin O +
D3 O +
was O +
less O +
effective O +
. O +

Similar O +
results O +
were O +
obtained O +
in O +
primary O +
culture O +
of O +
leukemia O +
cells O +
from O +
a O +
patient O +
with O +
acute O +
promyelocytic O +
leukemia O +
. O +

The O +
synergistic O +
effect O +
on O +
growth O +
inhibition O +
and O +
induction O +
of O +
differentiation O +
required O +
simultaneous O +
treatment O +
with O +
differanisole O +
A O +
and O +
9cisRA O +
. O +

Differanisole O +
A O +
and O +
an O +
RXR O -
- O -
specific O +
ligand O +
( O +
Ro47 O -
- O -
5944 O +
) O +
cooperatively O +
inhibited O +
the O +
cell O +
growth O +
, O +
while O +
the O +
combined O +
effect O +
of O +
differanisole O +
A O +
and O +
an O +
RAR O -
- O -
specific O +
ligand O +
Am80 O +
was O +
just O +
additive O +
. O +

Differanisole O +
A O +
in O +
combination O +
with O +
9cisRA O +
may O +
have O +
implications O +
for O +
therapy O +
of O +
acute O +
promyelocytic O +
leukemia O +
patients O +
. O +

ATF1 O +
and O +
CREB O +
trans O -
- O -
activate O +
a O +
cell O +
cycle O +
regulated O +
histone O +
H4 O +
gene O +
at O +
a O +
distal O +
nuclear O +
matrix O +
associated O +
promoter O +
element O +
. O +

Proteins O +
of O +
the O +
ATF O -
/ O +
CREB O +
class O +
of O +
transcription O +
factors O +
stimulate O +
gene O +
expression O +
of O +
several O +
cell O +
growth O -
- O -
related O +
genes O +
through O +
protein O +
kinase O +
A O -
- O -
related O +
cAMP O +
response O +
elements O +
. O +

The O +
promoter O +
activity O +
of O +
cell O +
cycle O +
regulated O +
histone O +
H4 O +
genes O +
is O +
regulated O +
by O +
at O +
least O +
four O +
principal O +
cis O -
- O -
acting O +
elements O +
which O +
mediate O +
G1 O -
/ O -
S O +
phase O +
control O +
and/or O +
enhancement O +
of O +
transcription O +
during O +
the O +
cell O +
cycle O +
. O +

Using O +
protein O -
- O -
DNA O +
interaction O +
assays O +
we O +
show O +
that O +
the O +
H4 O +
promoter O +
contains O +
two O +
ATF O -
/ O +
CREB O +
recognition O +
motifs O +
which O +
interact O +
with O +
CREB O +
, O +
ATF1 O +
, O +
and O +
ATF2 O +
but O +
not O +
with O +
ATF4 O -
/ O -
CREB2 O +
. O +

One O +
ATF O -
/ O -
CRE O +
motif O +
is O +
located O +
in O +
the O +
distal O +
promoter O +
at O +
the O +
nuclear O +
matrix O -
- O -
associated O +
Site O +
IV O +
, O +
and O +
the O +
second O +
motif O +
is O +
present O +
in O +
the O +
proximal O +
promoter O +
at O +
Site O +
I O +
. O +

Both O +
ATF O -
/ O -
CRE O +
motifs O +
overlap O +
binding O +
sequences O +
for O +
the O +
multifunctional O +
YY1 O +
transcription O +
factor O +
, O +
which O +
has O +
previously O +
been O +
shown O +
to O +
be O +
nuclear O +
matrix O +
associated O +
. O +

Subnuclear O +
fractionation O +
reveals O +
that O +
there O +
are O +
two O +
ATF1 O +
isoforms O +
which O +
appear O +
to O +
differ O +
with O +
respect O +
to O +
DNA O +
binding O +
activity O +
and O +
partition O +
selectively O +
between O +
nuclear O +
matrix O +
and O +
nonmatrix O +
compartments O +
, O +
consistent O +
with O +
the O +
role O +
of O +
the O +
nuclear O +
matrix O +
in O +
regulating O +
gene O +
expression O +
. O +

Site O -
- O -
directed O +
mutational O +
studies O +
demonstrate O +
that O +
Site O +
I O +
and O +
Site O +
IV O +
together O +
support O +
ATF1- O +
and O +
CREB O -
- O -
induced O +
trans O -
- O -
activation O +
of O +
the O +
H4 O +
promoter O +
. O +

Thus O +
, O +
our O +
data O +
establish O +
that O +
ATF O -
/ O -
CREB O +
factors O +
functionally O +
modulate O +
histone O +
H4 O +
gene O +
transcription O +
at O +
distal O +
and O +
proximal O +
promoter O +
elements O +
. O +

IL-2 O +
and O +
IL-7 O +
induce O +
heterodimerization O +
of O +
STAT5 O +
isoforms O +
in O +
human O +
peripheral O +
blood O +
T O +
lymphoblasts O +
. O +

Despite O +
differences O +
in O +
T O +
cell O +
responses O +
induced O +
by O +
interleukin O +
( O +
IL O +
) O +
-2 O +
and O +
IL-7 O +
, O +
both O +
cytokines O +
modulate O +
T O +
cell O +
functions O +
by O +
activation O +
of O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
STAT O +
) O +
proteins O +
. O +

We O +
examined O +
the O +
contribution O +
of O +
the O +
two O +
isoforms O +
of O +
STAT5 O +
, O +
STAT5A O +
and O +
STAT5B O +
, O +
to O +
IL-2- O +
and O +
IL-7-induced O +
activation O +
of O +
human O +
peripheral O +
blood O +
T O +
lymphoblasts O +
. O +

Both O +
cytokines O +
induced O +
assembly O +
of O +
STAT5A O +
and O +
STAT5B O +
containing O +
complexes O +
capable O +
of O +
binding O +
to O +
the O +
interferon O -
- O -
gamma O +
activation O +
sequence O +
( O +
GAS O +
) O +
, O +
and O +
these O +
complexes O +
rapidly O +
translocated O +
( O +
within O +
1 O +
min O +
) O +
into O +
the O +
nucleus O +
of O +
IL-2- B-CellLine +
or I-CellLine +
IL-7-treated I-CellLine +
cells I-CellLine +
. O +

The O +
kinetics O +
of O +
this O +
translocation O +
were O +
delayed O +
in O +
IL-7-treated B-CellLine +
as O +
compared O +
to O +
IL-2-treated B-CellLine +
cells I-CellLine +
. O +

IL-2 O +
and O +
IL-7 O +
were O +
equivalent O +
in O +
their O +
ability O +
to O +
induce O +
tyrosine O +
phosphorylation O +
of O +
STAT5A O +
and O +
STAT5B O +
and O +
to O +
facilitate O +
binding O +
of O +
these O +
STATs O +
to O +
an O +
immobilized O +
GAS O +
element O +
. O +

Both O +
IL-2 O +
and O +
IL-7 O +
induced O +
substantial O +
amounts O +
of O +
STAT5A O +
/STAT5B O +
heterodimerization O +
. O +

Moreover O +
, O +
we O +
observed O +
constitutive O +
association O +
of O +
STAT3 O +
with O +
each O +
STAT5 O +
isomer O +
. O +

These O +
data O +
suggest O +
that O +
IL-2 O +
and O +
IL-7 O +
induce O +
assembly O +
of O +
STAT O +
heterodimers O +
in O +
a O +
similar O +
manner O +
and O +
that O +
subsequent O +
cellular O +
responses O +
may O +
be O +
driven O +
by O +
induction O +
of O +
similar O +
sets O +
of O +
genes O +
. O +

B O +
lymphocytes O +
from O +
patients O +
with O +
chronic O +
lymphocytic O +
leukemia O +
contain O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
( O +
STAT O +
) O +
1 O +
and O +
STAT3 O +
constitutively O +
phosphorylated O +
on O +
serine O +
residues O +
. O +

To O +
explore O +
the O +
pathogenesis O +
of O +
chronic O +
lymphocytic O +
leukemia O +
( O +
CLL O +
) O +
, O +
we O +
examined O +
whether O +
phosphorylation O +
of O +
one O +
or O +
more O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
( O +
STAT O +
) O +
factors O +
was O +
abnormal O +
in O +
cells O +
from O +
CLL O +
patients O +
. O +

No O +
constitutive O +
tyrosine O +
phosphorylation O +
was O +
detected O +
on O +
any O +
STAT O +
in O +
CLL B-CellLine +
cells I-CellLine +
. O +

To O +
assess O +
the O +
phosphorylation O +
of O +
serine O +
residues O +
of O +
STAT1 O +
and O +
STAT3 O +
in O +
CLL B-CellLine +
cells I-CellLine +
, O +
we O +
raised O +
antibodies O +
that O +
specifically O +
recognize O +
the O +
form O +
of O +
STAT1 O +
phosphorylated O +
on O +
ser-727 O +
and O +
the O +
form O +
of O +
STAT3 O +
phosphorylated O +
on O +
ser-727 O +
. O +

We O +
found O +
that O +
in O +
100 O +
% O +
of O +
patients O +
with O +
CLL O +
( O +
n O +
= O +
32 O +
) O +
, O +
STAT1 O +
and O +
STAT3 O +
were O +
constitutively O +
phosphorylated O +
on O +
serine O +
. O +

This O +
was O +
in O +
contrast O +
to O +
normal O +
peripheral O +
blood O +
B O +
lymphocytes O +
or O +
CD5 O -
+ O +
) O +
B O +
cells O +
isolated O +
from O +
tonsils O +
, O +
in O +
which O +
this O +
phosphorylation O +
was O +
absent O +
. O +

Serine O +
phosphorylation O +
of O +
STAT1 O +
and O +
STAT3 O +
was O +
seen O +
occasionally O +
in O +
other O +
leukemias O +
, O +
but O +
it O +
was O +
a O +
universal O +
finding O +
only O +
in O +
CLL O +
. O +

The O +
serine O +
phosphorylation O +
of O +
these O +
STATs O +
was O +
a O +
continuous O +
process O +
, O +
as O +
incubation O +
of O +
CLL B-CellLine +
cells I-CellLine +
with O +
the O +
kinase O +
inhibitor O +
H7 O +
led O +
to O +
the O +
dephosphorylation O +
of O +
these O +
serine O +
residues O +
. O +

The O +
STAT O +
serine O +
kinase O +
in O +
CLL O +
cells O +
has O +
not O +
been O +
identified O +
, O +
and O +
appears O +
to O +
be O +
neither O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
nor O +
pp70 O +
( O +
s6k O +
) O +
. O +

In O +
summary O +
, O +
the O +
constitutive O +
serine O +
phosphorylation O +
of O +
STAT1 O +
and O +
STAT3 O +
is O +
present O +
in O +
all O +
CLL O +
samples O +
tested O +
to O +
date O +
, O +
although O +
the O +
physiologic O +
significance O +
of O +
this O +
modification O +
remains O +
to O +
be O +
determined O +
. O +

C O -
/ O -
EBP O +
activates O +
the O +
human O +
corticotropin O -
- O -
releasing O +
hormone O +
gene O +
promoter O +
. O +

The O +
purpose O +
of O +
these O +
studies O +
was O +
to O +
identify O +
whether O +
transcription O +
factors O +
, O +
associated O +
with O +
cytokine O +
signalling O +
, O +
affected O +
promoter O +
activity O +
of O +
the O +
corticotropin O +
releasing O +
hormone O +
( O +
CRH O +
) O +
gene O +
. O +

Fragments O +
of O +
a O +
3.6 O +
kb O +
sequence O +
of O +
the O +
human O +
CRH O +
gene O +
promoter O +
were O +
amplified O +
by O +
PCR O +
and O +
ligated O +
upstream O +
of O +
a O +
CAT O +
reporter O +
. O +

These O +
constructs O +
were O +
transfected O +
into O +
a O +
variety O +
of O +
cell O +
lines O +
, O +
either O +
alone O +
or O +
together O +
, O +
with O +
transcription O +
factor O +
expression O +
vectors O +
. O +

Basal O +
activity O +
of O +
a O +
3070 O +
bp O +
CRH O +
promoter O +
fragment O +
was O +
only O +
seen O +
in O +
neuronal O +
and O +
lymphoblastoid B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Promoter O +
activity O +
was O +
increased O +
by O +
the O +
transcription O +
factors O +
C O -
/ O -
EBPbeta O +
( O +
NF O -
- O -
IL6 O +
) O +
and O +
more O +
strongly O +
, O +
by O +
C O -
/ O -
EBPdelta O +
( O +
NF O -
- O -
IL6beta O +
) O +
. O +

Increased O +
CRH O +
promoter O +
activity O +
following O +
phorbol O +
ester O +
treatment O +
was O +
inhibited O +
by O +
a O +
dominant O +
negative O +
NF O -
- O -
IL6 O +
mutant O +
, O +
showing O +
that O +
the O +
effects O +
of O +
phorbol O +
ester O +
were O +
principally O +
mediated O +
by O +
C O -
/ O -
EBP O +
. O +

Moreover O +
, O +
the O +
inverse O +
changes O +
in O +
the O +
expression O +
of O +
CRH O +
in O +
the O +
hypothalamus O +
and O +
spleens O +
of O +
arthritic O +
rats O +
were O +
paralleled O +
by O +
similar O +
inverse O +
changes O +
in O +
NF O -
- O -
IL6beta O +
expression O +
in O +
these O +
organs O +
. O +

These O +
data O +
show O +
that O +
some O +
transcription O +
factors O +
associated O +
with O +
cytokine O +
signalling O +
can O +
also O +
activate O +
the O +
CRH O +
promoter O +
. O +

[ O +
Molecular O -
- O -
biologic O +
aspects O +
of O +
interaction O +
between O +
nervous O +
and O +
immune O +
systems O +
] O +

The O +
problem O +
of O +
the O +
neuro O -
- O -
immuno O +
interactions O +
on O +
the O +
level O +
of O +
the O +
protein O +
trans O -
- O -
factors O +
, O +
stimulating O +
interleukin-2 O +
( O +
IL-2 O +
) O +
gene O +
expression O +
was O +
discussed O +
. O +

The O +
physico O -
- O -
chemical O +
and O +
functional O +
parameters O +
of O +
the O +
low O +
molecular O +
nuclear O +
proteins O +
( O +
SP O +
and O +
BP- O +
14 O +
, O +
18 O +
, O +
19 O +
kDs O +
) O +
isolated O +
from O +
splenic O +
and O +
brain O +
cells O +
of O +
immunized O +
rats O +
were O +
studied O +
. O +

The O +
binding O +
of O +
these O +
proteins O +
to O +
the O +
regulatory O +
region O +
of O +
IL-2 O +
gene O +
in O +
vitro O +
and O +
stimulation O +
of O +
the O +
IL-2mRNA O +
synthesis O +
in O +
splenic B-CellLine +
T I-CellLine -
- I-CellLine -
lymphocytes I-CellLine +
culture I-CellLine +
in O +
normal O +
conditions O +
were O +
shown O +
. O +

The O +
protective O +
effect O +
of O +
SP O +
and O +
BP O +
on O +
the O +
IL-2mRNA O +
synthesis O +
in O +
stressful O +
conditions O +
and O +
by O +
the O +
T O -
- O -
cells O +
treatment O +
with O +
the O +
CsA O +
was O +
demonstrated O +
. O +

A O +
novel O +
form O +
of O +
the O +
myeloid O -
- O -
specific O +
zinc O +
finger O +
protein O +
( O +
MZF-2 O +
) O +
. O +

BACKGROUND O +
: O +
Myeloid O +
cell O +
development O +
is O +
controlled O +
by O +
tissue O -
- O -
specific O +
transcription O +
factors O +
. O +

Human O +
myeloid O +
zinc O +
finger O +
protein O +
( O +
MZF-1 O +
) O +
is O +
a O +
putative O +
transcription O +
factor O +
containing O +
13 O +
zinc O +
fingers O +
, O +
and O +
has O +
been O +
suggested O +
that O +
it O +
regulates O +
the O +
development O +
of O +
neutrophilic O +
granulocytes O +
. O +

RESULTS O +
: O +
Here O +
, O +
we O +
have O +
isolated O +
the O +
murine O +
and O +
human O +
cDNAs O +
which O +
encode O +
a O +
novel O +
form O +
of O +
MZF O +
protein O +
( O +
MZF-2 O +
) O +
. O +

Murine O +
and O +
human O +
MZF-2 O +
proteins O +
consisted O +
of O +
814 O +
and O +
775 O +
amino O +
acids O +
, O +
respectively O +
, O +
and O +
have O +
identity O +
of O +
75.3 O +
% O +
between O +
them O +
. O +

The O +
C O -
- O -
terminal O +
half O +
of O +
human O +
MZF-2 O +
, O +
carrying O +
the O +
zinc O +
finger O +
domains O +
, O +
was O +
completely O +
identical O +
with O +
that O +
of O +
human O +
MZF-1 O +
, O +
whereas O +
the O +
N O -
- O -
terminal O +
half O +
of O +
MZF-2 O +
was O +
different O +
from O +
the O +
corresponding O +
region O +
of O +
human O +
MZF-1 O +
, O +
and O +
was O +
coded O +
by O +
distinct O +
exons O +
. O +

MZF-2 O +
mRNA O +
was O +
expressed O +
in O +
myeloid O +
cells O +
, O +
particularly O +
in O +
the O +
cells O +
committed O +
to O +
the O +
neutrophilic O +
lineage O +
, O +
and O +
down O -
- O -
regulated O +
by O +
G O -
- O -
CSF O +
. O +

CONCLUSIONS O +
: O +
MZF-1 O +
and O +
MZF-2 O +
mRNAs O +
seem O +
to O +
be O +
produced O +
by O +
the O +
alternative O +
use O +
of O +
two O +
different O +
transcription O +
initiation O +
sites O +
. O +

The O +
distinct O +
N O -
- O -
terminal O +
half O +
of O +
MZF-2 O +
carries O +
two O +
characteristic O +
domains O +
, O +
a O +
leucine O -
- O -
rich O +
domain O +
called O +
LeR O +
and O +
an O +
acidic O +
domain O +
, O +
which O +
suggests O +
a O +
unique O +
function O +
of O +
MZF-2 O +
in O +
neutrophil O +
development O +
. O +

T O +
cell O +
reactivity O +
to O +
Sjogren O +
's O +
syndrome O +
related O +
antigen O +
La O +
( O +
SSB O +
) O +
. O +

OBJECTIVE O +
. O +

Many O +
patients O +
with O +
primary O +
Sjogren O +
's O +
syndrome O +
( O +
SS O +
) O +
make O +
high O +
titer O +
IgG O +
autoantibodies O +
to O +
the O +
La O +
( O +
SSB O +
) O +
antigen O +
, O +
suggesting O +
antigen O +
specific O +
T O +
cell O -
- O -
B O +
cell O +
interactions O +
. O +

T O +
cell O +
responses O +
to O +
some O +
nuclear O +
antigens O +
, O +
particularly O +
U1RNP O +
, O +
have O +
been O +
detected O +
in O +
patients O +
with O +
systemic O +
lupus O +
erythematosus O +
( O +
SLE O +
) O +
and O +
in O +
healthy O +
subjects O +
. O +

We O +
investigated O +
T O +
cell O +
reactivity O +
to O +
the O +
autoantigen O +
SSB O +
in O +
patients O +
with O +
SS O +
and O +
healthy O +
controls O +
. O +

METHODS O +
. O +

Using O +
the O +
[ O +
3H O +
] O +
thymidine O +
proliferation O +
assay O +
, O +
we O +
determined O +
reactivity O +
to O +
purified O +
recombinant O +
SSB O +
( O +
rSSB O +
) O +
in O +
20 O +
patients O +
with O +
SS O +
and O +
19 O +
controls O +
. O +

Specificity O +
was O +
determined O +
using O +
tetanus O +
toxoid O +
, O +
endotoxin O +
, O +
and O +
3 O +
other O +
autoantigens O +
( O +
PBC.M2 O +
, O +
Sc170 O +
, O +
and O +
GAD O +
) O +
. O +

Precursor O +
frequency O +
was O +
calculated O +
by O +
limiting O +
dilution O +
analysis O +
. O +

HLA O +
Class O +
II O +
dependency O +
was O +
investigated O +
using O +
anti O -
- O -
Class O +
II O +
monoclonal O +
antibodies O +
. O +

HLA O -
- O -
DR O +
typing O +
was O +
by O +
polymerase O +
chain O +
reaction O +
and O +
sequence O +
specific O +
oligonucleotide O +
typing O +
. O +

RESULTS O +
. O +

Six O +
of O +
20 O +
patients O +
with O +
SS O +
and O +
10 O -
/ O -
19 O +
controls O +
proliferated O +
to O +
La O +
( O +
rSSB O +
) O +
. O +

Precursor O +
frequency O +
of O +
anti B-CellLine -
- I-CellLine -
SSB I-CellLine +
T I-CellLine +
cells I-CellLine +
was O +
1 O +
: O +
77 O +
, O +
040 O +
and O +
1 O +
: O +
115 O +
, O +
000 O +
in O +
2 O +
healthy O +
subjects O +
and O +
1 O +
: O +
230 O +
, O +
250 O +
and O +
1 O +
: O +
103 O +
, O +
034 O +
in O +
two O +
patients O +
with O +
SS O +
. O +

Anti- O +
HLA O -
- O -
DR O +
abrogated O +
proliferation O +
to O +
SSB O +
and O +
tetanus O +
toxoid O +
. O +

Thirteen O +
of O +
15 O +
patients O +
with O +
SS O +
and O +
4 O -
/ O -
17 O +
controls O +
were O +
HLA O -
- O -
DR3 O +
positive O +
, O +
with O +
no O +
apparent O +
association O +
of O +
HLA O -
- O -
DR3 O +
with O +
SSB O +
reactivity O +
in O +
controls O +
. O +

CONCLUSION O +
. O +

Anti B-CellLine -
- I-CellLine -
La I-CellLine +
( I-CellLine +
SSB I-CellLine +
) I-CellLine +
specific I-CellLine +
T I-CellLine +
cells I-CellLine +
occur O +
in O +
a O +
significant O +
proportion O +
of O +
controls O +
and O +
in O +
some O +
patients O +
with O +
SS O +
. O +

The O +
function O +
of O +
SSB B-CellLine +
T I-CellLine +
cells I-CellLine +
in O +
controls O +
remains O +
to O +
be O +
defined O +
. O +

They O +
may O +
represent O +
immunoregulatory O +
cells O +
, O +
and O +
further O +
analysis O +
of O +
these O +
cells O +
, O +
and O +
a O +
comparison O +
to O +
those O +
found O +
in O +
patients O +
with O +
SS O +
, O +
may O +
elucidate O +
normal O +
immunoregulation O +
and O +
the O +
derangements O +
that O +
lead O +
to O +
Sjogren O +
's O +
syndrome O +
. O +

Agonistic O +
activity O +
of O +
a O +
CD40-specific O +
single O -
- O -
chain O +
Fv O +
constructed O +
from O +
the O +
variable O +
regions O +
of O +
mAb O +
G28 O -
- O -
5 O +
. O +

A O +
single O -
- O -
chain O +
Fv O +
( O +
sFv O +
) O +
was O +
expressed O +
from O +
the O +
variable O +
regions O +
of O +
the O +
CD40-specific O +
mAb O +
G28 O -
- O -
5 O +
. O +

The O +
molecule O +
bound O +
CD40 O +
with O +
a O +
high O +
affinity O +
( O +
2.2 O +
nM O +
) O +
and O +
was O +
a O +
monomer O +
in O +
solution O +
. O +

Surprisingly O +
, O +
G28 O -
- O -
5 O +
sFv O +
was O +
a O +
potent O +
CD40 O +
agonist O +
that O +
rapidly O +
crosslinked O +
CD40 O +
on O +
the O +
cell O +
surface O +
but O +
did O +
not O +
crosslink O +
CD40-Ig O +
in O +
solution O +
. O +

G28 O -
- O -
5 O +
sFv O +
was O +
a O +
more O +
potent O +
agonist O +
than O +
G28 O -
- O -
5 O +
IgG O +
and O +
was O +
able O +
to O +
stimulate O +
CD40 O +
responses O +
by O +
B O +
cells O +
and O +
monocytes O +
. O +

G28 O -
- O -
5 O +
IgG O +
partially O +
blocked O +
, O +
whereas O +
G28 O -
- O -
5 O +
sFv O +
augmented O +
CD40 O +
responses O +
during O +
stimulation O +
with O +
natural O +
ligand O +
( O +
gp39-CD8 O +
fusion O +
protein O +
) O +
. O +

These O +
results O +
indicate O +
that O +
the O +
functional O +
activity O +
of O +
ligands O +
built O +
from O +
the O +
binding O +
site O +
of O +
G28 O -
- O -
5 O +
is O +
highly O +
dependent O +
upon O +
the O +
size O +
and O +
physical O +
properties O +
of O +
the O +
molecule O +
both O +
in O +
solution O +
and O +
on O +
the O +
cell O +
surfaces O +
. O +

Cyclosporin O +
A O +
inhibits O +
early O +
mRNA O +
expression O +
of O +
G0 O -
/ O -
G1 O +
switch O +
gene O +
2 O +
( O +
G0S2 O +
) O +
in O +
cultured B-CellLine +
human I-CellLine +
blood I-CellLine +
mononuclear I-CellLine +
cells I-CellLine +
. O +

Cyclosporin O +
A O +
( O +
CsA O +
) O +
may O +
achieve O +
its O +
immunosuppressive O +
effects O +
by O +
inhibiting O +
the O +
calcium- O +
and O +
calmodulin O -
- O -
dependent O +
phosphatase O +
calcineurin O +
which O +
is O +
required O +
for O +
activation O +
of O +
target O +
genes O +
by O +
members O +
of O +
the O +
NFAT O +
( O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
) O +
transcription O +
factor O +
family O +
. O +

Among O +
these O +
target O +
genes O +
is O +
the O +
gene O +
encoding O +
interleukin-2 O +
( O +
IL2 O +
) O +
, O +
a O +
cytokine O +
facilitating O +
progression O +
through O +
the O +
G1 O +
phase O +
of O +
the O +
cell O +
cycle O +
. O +

However O +
, O +
IL2 O +
does O +
not O +
reverse O +
CsA O +
inhibition O +
, O +
suggesting O +
that O +
at O +
least O +
one O +
other O +
NFAT O -
- O -
sensitive O +
gene O +
may O +
be O +
involved O +
. O +

The O +
human O +
G0 O -
/ O -
G1 O +
switch O +
gene O +
, O +
G0S2 O +
, O +
has O +
potential O +
NFAT O -
- O -
binding O +
sites O +
in O +
the O +
5 O +
' O +
flank O +
and O +
encodes O +
a O +
small O +
basic O +
potential O +
phosphoprotein O +
of O +
unknown O +
function O +
. O +

Using O +
a O +
sensitive O +
, O +
reverse O +
transcription O -
- O -
polymerase O +
chain O +
reaction O +
( O +
RT O -
- O -
PCR O +
) O +
assay O +
, O +
G0S2 O +
mRNA O +
levels O +
were O +
assayed O +
in O +
cultured B-CellLine +
blood I-CellLine +
mononuclear I-CellLine +
cells I-CellLine +
. O +

Freshly O +
isolated O +
cells O +
contain O +
high O +
levels O +
of O +
G0S2 O +
mRNA O +
which O +
rapidly O +
decline O +
. O +

This O +
` O -
` O +
spontaneous O +
stimulation O +
'' O +
is O +
also O +
noted O +
with O +
some O +
other O +
G0S O +
genes O +
and O +
has O +
been O +
attributed O +
to O +
some O +
aspect O +
of O +
the O +
isolation O +
procedure O +
. O +

In O +
cells O +
that O +
have O +
been O +
preincubated O +
to O +
lower O +
mRNA O +
levels O +
, O +
there O +
is O +
a O +
transient O +
increase O +
in O +
G0S2 O +
mRNA O +
, O +
peaking O +
between O +
1 O -
- O -
2 O +
h O +
, O +
in O +
response O +
to O +
Concanavalin O -
- O -
A O +
( O +
ConA O +
) O +
, O +
or O +
to O +
the O +
combination O +
of O +
phorbol O +
ester O +
( O +
TPA O +
) O +
, O +
and O +
the O +
calcium O +
ionophore O +
, O +
ionomycin O +
. O +

Both O +
these O +
responses O +
are O +
inhibited O +
by O +
CsA O +
. O +

Our O +
results O +
suggest O +
that O +
G0S2 O +
expression O +
is O +
required O +
to O +
commit O +
cells O +
to O +
enter O +
the O +
G1 O +
phase O +
of O +
the O +
cell O +
cycle O +
, O +
and O +
that O +
, O +
while O +
not O +
excluding O +
other O +
possible O +
targets O +
, O +
early O +
inhibition O +
of O +
G0S2 O +
expression O +
by O +
CsA O +
may O +
be O +
important O +
in O +
achieving O +
immunosuppression O +
. O +

G0S2 O +
may O +
be O +
of O +
value O +
as O +
a O +
reporter O +
gene O +
for O +
analyzing O +
the O +
mechanism O +
of O +
action O +
of O +
CsA O +
and O +
its O +
influence O +
on O +
the O +
positive O +
and O +
negative O +
selection O +
of O +
lymphocytes O +
in O +
response O +
to O +
self O +
and O +
not O -
- O -
self O +
antigens O +
. O +

Estrogen O +
receptor O +
diminishes O +
DNA O -
- O -
binding O +
activities O +
of O +
chicken O +
GATA-1 O +
and O +
CACCC O -
- O -
binding O +
proteins O +
. O +

The O +
estrogen O +
receptor O +
( O +
ER O +
) O +
repressed O +
erythroid O +
differentiation O +
and O +
erythroid O -
- O -
specific O +
gene O +
expression O +
. O +

In O +
this O +
study O +
, O +
we O +
investigated O +
the O +
effect O +
of O +
ER O +
alpha O +
( O +
referred O +
to O +
throughout O +
as O +
ER O +
) O +
on O +
DNA O -
- O -
binding O +
activities O +
of O +
transcription O +
factors O +
involved O +
in O +
regulating O +
the O +
expression O +
of O +
erythroid O -
- O -
specific O +
genes O +
, O +
and O +
, O +
in O +
particular O +
, O +
the O +
histone O +
H5 O +
gene O +
. O +

Using O +
electrophoretic O +
mobility O +
shift O +
assays O +
, O +
we O +
found O +
that O +
in O +
the O +
presence O +
of O +
rabbit O +
reticulocyte O +
lysate O +
, O +
human O +
ER O +
reduced O +
the O +
binding O +
activities O +
of O +
chicken O +
immature O +
erythrocyte O +
nuclear O +
extracted O +
proteins O +
to O +
GATA O +
and O +
CACCC O +
sites O +
in O +
the O +
H5 O +
promoter O +
and O +
enhancer O +
. O +

In O +
contrast O +
, O +
the O +
binding O +
activities O +
of O +
NF1 O +
and O +
Sp1 O +
were O +
not O +
affected O +
by O +
ER O +
. O +

Binding O +
of O +
ER O +
to O +
an O +
estrogen O +
response O +
element O +
was O +
enhanced O +
by O +
addition O +
of O +
rabbit O +
reticulocyte O +
lysate O +
. O +

This O +
lysate O +
was O +
also O +
necessary O +
for O +
ER O +
to O +
diminish O +
the O +
DNA O -
- O -
binding O +
activity O +
of O +
GATA-1 O +
. O +

These O +
results O +
suggest O +
that O +
additional O +
factor O +
( O +
s O +
) O +
are O +
necessary O +
for O +
full O +
ER O +
function O +
. O +

Both O +
GATA-1 O +
and O +
CACCC O -
- O -
binding O +
proteins O +
are O +
critical O +
for O +
the O +
developmentally O +
regulated O +
expression O +
of O +
erythroid O -
- O -
specific O +
genes O +
. O +

We O +
hypothesize O +
that O +
interference O +
in O +
DNA O -
- O -
binding O +
activities O +
of O +
GATA-1 O +
and O +
CACCC O -
- O -
binding O +
proteins O +
is O +
the O +
mechanism O +
by O +
which O +
the O +
ER O +
inhibits O +
regulation O +
of O +
these O +
genes O +
. O +

HLA O +
binding O +
characteristics O +
and O +
generation O +
of O +
cytotoxic O +
lymphocytes O +
against O +
peptides O +
derived O +
from O +
oncogenic O +
proteins O +
. O +

AIMS O +
AND O +
BACKGROUND O +
: O +
Structurally O +
altered O +
proteins O +
( O +
derived O +
from O +
chromosomal O +
translocations O +
or O +
gene O +
mutations O +
) O +
can O +
be O +
considered O +
tumor O +
specific O +
antigens O +
and O +
represent O +
an O +
attractive O +
target O +
for O +
a O +
T O -
- O -
cell O +
mediated O +
response O +
. O +

T O +
lymphocytes O +
recognize O +
antigens O +
in O +
the O +
form O +
of O +
peptides O +
bound O +
to O +
HLA O -
- O -
molecules O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +
Peptides O +
derived O +
from O +
oncogenic O +
proteins O +
were O +
screened O +
for O +
the O +
presence O +
of O +
HLA O +
binding O +
motifs O +
; O +
actual O +
binding O +
were O +
evaluated O +
by O +
HLA O +
stabilization O +
experiments O +
using O +
transfectants O +
and O +
specific O +
anti O -
- O -
HLA O +
antibodies O +
. O +

Specific O +
lymphocytes O +
were O +
induced O +
by O +
in O +
vitro O +
peptide O +
sensitization O +
and O +
screened O +
by O +
thymidine O +
uptake O +
or O +
cellular O +
cytotoxic O +
assays O +
. O +

RESULTS O +
: O +
We O +
identified O +
peptides O +
derived O +
from O +
EWS O -
/ O -
FLI-1 O +
fusion O +
protein O +
and O +
from O +
mutated O +
K O -
- O -
RAS O +
protein O +
( O +
encompassing O +
respectively O +
the O +
fusion O +
point O +
and O +
the O +
mutation O +
at O +
position O +
12 O +
) O +
that O +
showed O +
binding O +
motif O +
for O +
HLA O -
- O -
Cw*0702 O +
and O +
HLA O -
- O -
A3 O +
respectively O +
. O +

The O +
actual O +
binding O +
of O +
these O +
peptides O +
was O +
analysed O +
in O +
a O +
stabilization O +
assay O +
. O +

We O +
detected O +
binding O +
for O +
the O +
EWS O -
/ O -
FLI-1 O +
peptide O +
and O +
for O +
5 O +
RAS O +
peptides O +
( O +
1 O +
wild O +
type O +
and O +
4 O +
mutated O +
) O +
. O +

The O +
effect O +
of O +
temperature O +
, O +
beta O +
2-microglobulin O +
( O +
beta O +
2-m O +
) O +
and O +
fetal O +
calf O +
serum O +
( O +
FCS O +
) O +
on O +
the O +
binding O +
and O +
the O +
stability O +
of O +
the O +
HLA O -
/ O -
peptide O +
complex O +
was O +
studied O +
. O +

A O +
low O +
temperature O +
( O +
26 O +
degrees O +
C O +
) O +
increased O +
the O +
binding O +
both O +
in O +
HLA O -
- O -
A3 O +
and O +
HLA O -
- O -
Cw*0702 O +
, O +
while O +
FCS O +
reduced O +
it O +
. O +

beta O +
2-m O +
increased O +
the O +
binding O +
to O +
the O +
HLA O -
- O -
A3 O +
molecule O +
but O +
did O +
not O +
influence O +
the O +
binding O +
to O +
the O +
HLA O -
- O -
Cw*0702 O +
. O +

The O +
stability O +
of O +
already O +
formed O +
complexed O +
was O +
somewhat O +
different O +
in O +
the O +
HLA O -
- O -
A3 O +
and O +
HLA O -
- O -
Cw*0702 O +
system O +
: O +
both O +
were O +
more O +
stable O +
at O +
26 O +
degrees O +
C O +
than O +
at O +
37 O +
degrees O +
C O +
but O +
while O +
the O +
beta O +
2-m O +
and O +
FCS O +
did O +
not O +
influence O +
the O +
stability O +
of O +
the O +
HLA O -
- O -
A3 O -
/ O -
peptide O +
complex O +
, O +
they O +
seemed O +
to O +
cause O +
opposite O +
effects O +
in O +
the O +
HLA O -
- O -
Cw*0702 O +
system O +
( O +
beta O +
2-m O +
stabilized O +
and O +
FCS O +
destabilized O +
the O +
complex O +
) O +
. O +

Finally O +
, O +
we O +
were O +
able O +
to O +
generate O +
a O +
specific O +
CD8 B-CellLine -
+ I-CellLine +
CTL I-CellLine +
line I-CellLine +
against O +
a O +
K O -
- O -
RAS O +
mutated O +
peptide O +
. O +

CONCLUSIONS O +
: O +
Although O +
binding O +
motifs O +
and O +
actual O +
HLA O +
binding O +
can O +
be O +
detected O +
in O +
several O +
cases O +
, O +
the O +
generation O +
of O +
a O +
cellular O +
response O +
is O +
infrequent O +
, O +
confirming O +
that O +
HLA O +
binding O +
is O +
necessary O +
but O +
not O +
sufficient O +
to O +
obtain O +
an O +
in O +
vitro O +
response O +
. O +

Further O +
optimization O +
of O +
culture O +
conditions O +
, O +
type O +
of O +
Antigen O +
Presenting O +
Cells O +
( O +
APC O +
) O +
, O +
peptides O +
, O +
use O +
of O +
stabilizers O +
like O +
beta O +
2-m O +
are O +
still O +
needed O +
. O +

Replication O +
of O +
human O +
immunodeficiency O +
virus-1 O +
in O +
primary O +
human O +
T O +
cells O +
is O +
dependent O +
on O +
the O +
autocrine O +
secretion O +
of O +
tumor O +
necrosis O +
factor O +
through O +
the O +
control O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
activation O +
. O +

Tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
-alpha O +
controls O +
T O -
- O -
cell O +
activation O +
and O +
is O +
a O +
major O +
inducer O +
of O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
-1 O +
replication O +
in O +
chronically O +
infected O +
cells O +
. O +

Therefore O +
, O +
we O +
have O +
investigated O +
its O +
role O +
in O +
primary O +
cultures O +
of O +
HIV O -
- O -
infected O +
human O +
T O +
lymphocytes O +
by O +
using O +
neutralizing O +
anti O -
- O -
TNF O -
- O -
alpha O +
antibodies O +
or O +
TNF O -
- O -
alpha O +
. O +

Primary O +
resting O +
T O +
lymphocytes O +
produced O +
TNF O -
- O -
alpha O +
and O +
supported O +
HIV O +
replication O +
after O +
T O -
- O -
cell O +
receptor O +
activation O +
. O +

Addition O +
of O +
neutralizing O +
anti O -
- O -
TNF O -
- O -
alpha O +
antibodies O +
drastically O +
reduced O +
p24 O +
antigen O +
release O +
and O +
prevented O +
CD4 O -
+ O +
cell O +
depletion O +
associated O +
with O +
infection O +
. O +

Anti O -
- O -
TNF O -
- O -
alpha O +
also O +
prevented O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
activation O +
, O +
and O +
a O +
good O +
correlation O +
between O +
this O +
inhibition O +
and O +
inhibition O +
of O +
HIV O +
replication O +
was O +
observed O +
. O +

Moreover O +
, O +
supplementing O +
the O +
cultures O +
with O +
high O +
doses O +
of O +
IL-2 O +
reverted O +
anti- O +
TNF O -
- O -
alpha O +
inhibition O +
of O +
cell O +
proliferation O +
but O +
did O +
not O +
affect O +
the O +
inhibition O +
of O +
HIV O +
p24 O +
antigen O +
release O +
or O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
the O +
same O +
cultures O +
. O +

Moreover O +
, O +
anti O -
- O -
TNF O -
- O -
alpha O +
inhibited O +
HIV-1 O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
-driven O +
transcription O +
of O +
a O +
reporter O +
gene O +
in O +
primary O +
T O +
cells O +
in O +
response O +
to O +
activation O +
, O +
either O +
in O +
the O +
presence O +
or O +
the O +
absence O +
of O +
HIV-1 O +
Tat O +
. O +

Our O +
results O +
support O +
an O +
important O +
role O +
for O +
autocrine O +
TNF O -
- O -
alpha O +
secretion O +
in O +
controlling O +
HIV O +
replication O +
in O +
primary O +
T O +
cells O +
because O +
of O +
its O +
ability O +
to O +
maintain O +
NF O -
- O -
kappa O +
B O +
elevated O +
in O +
the O +
nucleus O +
of O +
T O +
cells O +
. O +

A O +
thiol O +
antioxidant O +
regulates O +
IgE O +
isotype O +
switching O +
by O +
inhibiting O +
activation O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
. O +

The O +
binding O +
site O +
for O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
is O +
present O +
at O +
the O +
promoter O +
region O +
of O +
the O +
germline O +
Cepsilon O +
gene O +
, O +
but O +
there O +
is O +
little O +
information O +
on O +
whether O +
this O +
factor O +
is O +
involved O +
in O +
regulating O +
IgE O +
synthesis O +
by O +
human O +
B O +
cells O +
. O +

Accordingly O +
, O +
we O +
studied O +
the O +
role O +
of O +
NF O -
- O -
kappaB O +
in O +
germline O +
Cepsilon O +
transcription O +
by O +
using O +
two O +
human B-CellLine +
Burkitt I-CellLine +
's I-CellLine +
lymphoma I-CellLine +
B I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
DND39 B-CellLine +
and O +
DG75 B-CellLine +
. O +

In O +
both O +
cell B-CellLine +
lines I-CellLine +
, O +
n O -
- O -
acetyl O -
- O -
L O -
- O -
cysteine O +
( O +
NAC O +
) O +
, O +
a O +
potent O +
thiol O +
antioxidant O +
, O +
inhibited O +
the O +
triggering O +
of O +
the O +
nuclear O +
expression O +
of O +
NF O -
- O -
kappaB O +
by O +
IL-4 O +
and O +
by O +
anti O -
- O -
CD40 O +
monoclonal O +
antibody O +
. O +

Although O +
IL-4 O +
activated O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
STAT O +
) O +
6 O +
in O +
addition O +
to O +
NF O -
- O -
kappaB O +
, O +
NAC O +
treatment O +
or O +
the O +
transfection O +
of O +
decoy O +
oligodeoxynucleotides O +
for O +
NF O -
- O -
kappaB O +
or O +
STAT6 O +
only O +
partly O +
blocked O +
IL-4 O +
-induced O +
germline O +
Cepsilon O +
transcription O +
. O +

However O +
, O +
these O +
two O +
decoy O +
oligodeoxynucleotides O +
together O +
almost O +
completely O +
abrogated O +
IL-4 O +
-induced O +
germline O +
Cepsilon O +
transcription O +
. O +

Of O +
note O +
, O +
CD40 O +
-mediated O +
enhancement O +
of O +
IL-4 O +
-driven O +
germline O +
Cepsilon O +
transcription O +
was O +
markedly O +
decreased O +
by O +
NAC O +
or O +
by O +
a O +
decoy O +
oligodeoxynucleotide O +
for O +
NF O -
- O -
kappaB O +
. O +

The O +
effect O +
of O +
NAC O +
was O +
also O +
examined O +
on O +
deletional O +
switch O +
recombination O +
underlying O +
the O +
isotype O +
switch O +
to O +
IgE O +
. O +

NAC O +
inhibited O +
the O +
generation O +
of O +
Smu O -
/ O -
Sepsilon O +
switch O +
fragments O +
in O +
normal O +
human O +
B O +
cells O +
costimulated O +
with O +
IL-4 O +
and O +
anti O -
- O -
CD40 O +
monoclonal O +
antibody O +
. O +

It O +
also O +
abolished O +
IL-4 O +
-induced O +
upregulation O +
of O +
CD40 O +
but O +
promoted O +
upregulation O +
of O +
CD23 O +
. O +

These O +
results O +
suggest O +
that O +
coordination O +
of O +
NF O -
- O -
kappaB O +
and O +
STAT6 O +
may O +
be O +
required O +
for O +
induction O +
of O +
germline O +
Cepsilon O +
transcription O +
by O +
IL-4 O +
, O +
and O +
that O +
CD40 O +
-mediated O +
NF O -
- O -
kappaB O +
activation O +
may O +
be O +
important O +
in O +
regulating O +
both O +
enhancement O +
of O +
germline O +
Cepsilon O +
transcription O +
and O +
class O +
switching O +
to O +
IgE O +
. O +

LPS O +
tolerance O +
in O +
monocytes O -
/ O -
macrophages O +
: O +
three O +
3 O +
' O +
cytosins O +
are O +
required O +
in O +
the O +
DNA O +
binding O +
motif O +
for O +
detection O +
of O +
upregulated O +
NF O -
- O -
kappa O +
B O +
p50 O +
homodimers O +
. O +

When O +
monocytes O +
are O +
stimulated O +
with O +
LPS O +
( O +
lipopolysaccharide O +
) O +
repeatedly O +
then O +
the O +
initially O +
high O +
expression O +
of O +
the O +
TNF O +
( O +
tumor O +
necrosis O +
factor O +
) O +
gene O +
is O +
only O +
very O +
low O +
, O +
i.e. O +
the O +
cells O +
are O +
tolerant O +
to O +
LPS O +
. O +

Tolerant O +
cells O +
still O +
express O +
the O +
CD14 O +
receptor O +
and O +
they O +
can O +
still O +
be O +
activated O +
to O +
mobilize O +
NF O -
- O -
kappa O +
B O +
into O +
nucleus O +
. O +

Analysis O +
of O +
the O +
binding O +
proteins O +
employing O +
the O +
-605 O +
motif O +
of O +
the O +
human O +
TNF O +
promoter O +
( O +
GGGGCTGTCCC O +
) O +
revealed O +
that O +
in O +
tolerant O +
cells O +
of O +
the O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
Mono B-CellLine +
Mac I-CellLine +
6 I-CellLine +
there O +
is O +
a O +
predominance O +
of O +
p50p50 O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

We O +
now O +
show O +
that O +
a O +
mutant O +
motif O +
that O +
exchanges O +
the O +
terminal O +
3 O +
' O +
C O +
for O +
a O +
G O +
fails O +
to O +
bind O +
the O +
p50 O +
homodimer O +
that O +
is O +
upregulated O +
in O +
LPS O +
toler O +
ant O +
human B-CellLine +
Mono I-CellLine +
Mac I-CellLine +
6 I-CellLine +
cells I-CellLine +
. O +

The O +
same O +
is O +
true O +
for O +
nuclear O +
extracts O +
taken O +
from O +
the O +
murine B-CellLine +
P388D1 I-CellLine +
macrophage I-CellLine +
cell I-CellLine +
line I-CellLine +
when O +
tested O +
with O +
the O +
-516 O +
motif O +
of O +
the O +
murine O +
TNF O +
promoter O +
( O +
GGGGGCTTTCCC O +
) O +
. O +

Here O +
the O +
wild O +
type O +
motif O +
gives O +
efficient O +
binding O +
of O +
p50p50 O +
that O +
again O +
is O +
upregulated O +
in O +
tolerant O +
cells O +
whereas O +
a O +
mutant O +
with O +
a O +
3 O +
' O +
G O +
shows O +
hardly O +
any O +
binding O +
of O +
p50p50 O +
. O +

Conversely O +
, O +
the O +
murine O +
kappa O +
light O +
chain O +
enhancer O +
motif O +
( O +
GGGGACTTTCCG O +
) O +
does O +
not O +
efficiently O +
bind O +
the O +
nuclear O +
p50p50 O +
from O +
tolerant B-CellLine +
murine I-CellLine +
P388 I-CellLine +
macrophages I-CellLine +
. O +

Binding O +
is O +
, O +
however O +
, O +
readily O +
detected O +
when O +
the O +
3 O +
' O +
G O +
is O +
replaced O +
by O +
a O +
C O +
. O +

These O +
data O +
show O +
that O +
the O +
detection O +
of O +
upregulated O +
p50 O +
homodimers O +
in O +
LPS O +
tolerant O +
cells O +
is O +
dependent O +
on O +
subtle O +
differences O +
in O +
the O +
sequence O +
of O +
the O +
DNA O +
binding O +
motif O +
. O +

Inefficient O +
termination O +
of O +
antigen O +
responses O +
in O +
NF O -
- O -
ATp O +
-deficient O +
mice O +
. O +

In O +
order O +
to O +
elucidate O +
the O +
role O +
of O +
NF O -
- O -
ATp O +
, O +
one O +
of O +
the O +
most O +
prominent O +
members O +
of O +
family O +
of O +
NF O -
- O -
AT O +
transcription O +
factors O +
in O +
peripheral O +
T O +
lymphocytes O +
, O +
in O +
T O +
cell O +
activation O +
and O +
differentiation O +
we O +
created O +
NF O -
- O -
ATp O +
-deficient O +
mice O +
by O +
gene O +
targeting O +
. O +

Such O +
NF O -
- O -
ATp O +
- O -
/ O -
- O +
mice O +
are O +
born O +
and O +
appear O +
to O +
develop O +
a O +
normal O +
immune O +
system O +
. O +

Apart O +
from O +
clear O -
- O -
cut O +
defects O +
in O +
the O +
synthesis O +
of O +
mRNAs O +
for O +
Th2-type O +
lymphokines O +
, O +
such O +
as O +
IL-4 O +
, O +
IL-5 O +
, O +
IL-10 O +
and O +
IL-13 O +
, O +
in O +
primary O +
and O +
secondary O +
stimulations O +
of O +
spleen O +
cells O +
in O +
vitro O +
, O +
of O +
a O +
distinct O +
impaired O +
deletion O +
of O +
V B-CellLine +
beta I-CellLine +
11+ I-CellLine -
/ I-CellLine -
CD4 I-CellLine -
+ I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
from O +
these O +
mice O +
was O +
detected O +
after O +
superantigen O +
injection O +
. O +

Moreover O +
, O +
NF O -
- O -
ATp O +
- O -
/ O -
- O +
mice O +
older O +
than O +
6 O +
weeks O +
show O +
an O +
2 O -
- O -
5 O +
fold O +
increase O +
in O +
number O +
of O +
lymphocytes O +
. O +

This O +
is O +
correlated O +
with O +
an O +
increased O +
expression O +
of O +
activation O +
markers O +
CD44 O +
and O +
CD69 O +
and O +
decreased O +
expression O +
of O +
CD62 O +
. O +

Identification O +
of O +
target O +
genes O +
of O +
the O +
lymphoid O -
- O -
specific O +
transcription O +
factor O +
Oct2 O +
. O +

The O +
Oct2 O +
transcription O +
factor O +
is O +
expressed O +
predominantly O +
in O +
B O +
lymphocytes O +
and O +
plays O +
an O +
essential O +
role O +
during O +
the O +
terminal O +
phase O +
of O +
B O +
cell O +
differentiation O +
. O +

The O +
regulatory O +
regions O +
of O +
several O +
genes O +
specifically O +
expressed O +
in O +
B O +
cells O +
contain O +
functional O +
binding O +
sites O +
for O +
Oct2 O +
. O +

Nevertheless O +
, O +
none O +
of O +
the O +
genes O +
originally O +
thought O +
to O +
be O +
regulated O +
by O +
Oct2 O +
were O +
affected O +
in O +
their O +
expression O +
in O +
Oct2-deficient B-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

In O +
an O +
attempt O +
to O +
find O +
such O +
elusive O +
Oct2 O +
target O +
genes O +
and O +
to O +
understand O +
the O +
molecular O +
function O +
of O +
Oct2 O +
in O +
B O +
cell O +
development O +
, O +
we O +
isolated O +
cDNAs O +
for O +
Oct2 O +
target O +
genes O +
. O +

So O +
far O +
, O +
we O +
have O +
identified O +
five O +
potential O +
targets O +
for O +
Oct2 O +
: O +
the O +
membrane O +
glycoprotein O +
CD36 O +
, O +
the O +
cysteine O -
- O -
rich O +
secreted O +
protein O +
3 O +
( O +
CRISP-3 O +
) O +
, O +
a O +
mouse O +
homolog O +
of O +
the O +
human O +
monocyte O -
/ O -
neutrophil O +
elastase O +
inhibitor O +
( O +
mEI O +
) O +
and O +
two O +
unknown O +
cDNA O +
sequences O +
Nov1 O +
and O +
Nov2 O +
. O +

These O +
target O +
genes O +
show O +
quite O +
distinct O +
expression O +
patterns O +
demonstrating O +
that O +
transcription O +
factors O +
in O +
addition O +
to O +
Oct2 O +
are O +
involved O +
in O +
their O +
regulation O +
. O +

Whereas O +
CD36 O +
and O +
mEI O +
were O +
expressed O +
in O +
all O +
hematopoetic B-CellLine +
cell I-CellLine +
lines I-CellLine +
containing O +
Oct2 O +
, O +
. O +

CRISP-3 O +
is O +
pre O -
- O -
B O +
cell O -
- O -
specific O +
, O +
Nov1 O +
is O +
plasma O +
B O +
cell O -
- O -
specific O +
and O +
Nov2 O +
is O +
B O +
cell O -
- O -
specifically O +
expressed O +
. O +

Induction O +
of O +
interleukin-12 O +
p40 O +
transcript O +
by O +
CD40 O +
ligation O +
via O +
activation O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
. O +

Interleukin-12 O +
is O +
produced O +
in O +
response O +
to O +
infection O +
with O +
bacteria O +
or O +
parasites O +
or O +
to O +
bacterial O +
constituents O +
such O +
as O +
LPS O +
in O +
monocytes O -
/ O -
macrophages O +
and O +
dendritic O +
cells O +
, O +
and O +
also O +
generated O +
by O +
the O +
interaction O +
between O +
activated O +
T O +
cells O +
and O +
antigen O -
- O -
presenting O +
cells O +
via O +
CD40-CD40 O +
ligand O +
( O +
CD40L O +
) O +
. O +

So O +
far O +
, O +
transcriptional O +
analyses O +
of O +
p40 O +
have O +
been O +
carried O +
out O +
only O +
using O +
bacterial O +
constituents O +
such O +
as O +
LPS O +
as O +
stimuli O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
have O +
characterized O +
the O +
transcriptional O +
induction O +
of O +
p40 O +
by O +
CD40 O +
ligation O +
in O +
a O +
human B-CellLine +
B I-CellLine +
lymphoblastoid I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
Daudi B-CellLine +
, O +
and O +
a O +
human B-CellLine +
acute I-CellLine +
monocytic I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
THP-1 B-CellLine +
. O +

These O +
cells O +
, O +
stimulated O +
by O +
an O +
agonistic O +
monoclonal O +
antibody O +
against O +
CD40 O +
or O +
by O +
transfection O +
with O +
a O +
CD40L O +
expression O +
vector O +
, O +
secreted O +
p40 O +
and O +
showed O +
enhanced O +
p40 O +
mRNA O +
expression O +
. O +

Sequence O +
analysis O +
of O +
the O +
p40 O +
promoter O +
region O +
identified O +
two O +
potential O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappaB O +
binding O +
sites O +
conserved O +
between O +
mouse O +
and O +
human O +
. O +

Electrophoretic O +
mobility O +
shift O +
assay O +
revealed O +
that O +
the O +
potential O +
NF O -
- O -
kappaB O +
binding O +
sequence O +
which O +
is O +
located O +
around O +
120 O +
bp O +
upstream O +
of O +
the O +
transcription O +
initiation O +
site O +
in O +
murine O +
and O +
human O +
p40 O +
genes O +
formed O +
an O +
NF O -
- O -
kappaB O +
complex O +
with O +
nuclear O +
extract O +
from O +
Daudi B-CellLine +
cells I-CellLine +
stimulated O +
by O +
CD40 O +
ligation O +
. O +

Moreover O +
, O +
transfection O +
of O +
Daudi B-CellLine +
cells I-CellLine +
with O +
the O +
polymerized O +
NF O -
- O -
kappaB O +
binding O +
sequence O +
ligated O +
to O +
a O +
thymidine O +
kinase O -
/ O -
chloramphenicol O +
acetyltransferase O +
( O +
CAT O +
) O +
reporter O +
plasmid O +
greatly O +
induced O +
CAT O +
activity O +
, O +
but O +
transfection O +
with O +
the O +
polymerized O +
mutated O +
NF O -
- O -
kappaB O +
binding O +
sequence O +
did O +
not O +
. O +

These O +
results O +
suggest O +
that O +
the O +
NF O -
- O -
kappaB O +
binding O +
site O +
located O +
around O +
120 O +
bp O +
upstream O +
of O +
the O +
transcription O +
initiation O +
site O +
in O +
murine O +
and O +
human O +
p40 O +
promoter O +
regions O +
could O +
be O +
important O +
for O +
the O +
p40 O +
induction O +
by O +
CD40 O +
ligation O +
via O +
activation O +
of O +
NF O -
- O -
kappaB O +
. O +

Inhibition O +
of O +
nuclear O +
factor O +
kappa O +
B O +
subunit O +
p65 O +
mRNA O +
accumulation O +
in O +
lipopolysaccharide B-CellLine -
- I-CellLine -
stimulated I-CellLine +
human I-CellLine +
monocytic I-CellLine +
cells I-CellLine +
treated O +
with O +
sodium O +
salicylate O +
. O +

Lipopolysaccharide O +
is O +
one O +
of O +
the O +
most O +
potent O +
trigger O +
substances O +
for O +
monocytes O +
and O +
macrophages O +
causing O +
secretion O +
of O +
inflammatory O +
mediators O +
such O +
as O +
tumor O +
necrosis O +
factor O +
and O +
interleukin-1 O +
. O +

The O +
nature O +
of O +
the O +
nuclear O +
factors O +
involved O +
in O +
regulation O +
of O +
these O +
cytokine O +
genes O +
is O +
still O +
unknown O +
. O +

Nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappa O +
B O +
; O +
heterodimer O +
of O +
p50 O +
and O +
p65 O +
) O +
proteins O +
have O +
been O +
suggested O +
to O +
play O +
an O +
important O +
role O +
in O +
gene O +
transcription O +
of O +
inflammatory O +
mediators O +
when O +
monocytes O +
are O +
stimulated O +
with O +
lipopolysaccharide O +
. O +

Nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O +
such O +
as O +
salicylates O +
have O +
been O +
used O +
to O +
treat O +
symptoms O +
of O +
inflammation O +
, O +
and O +
a O +
new O +
mechanism O +
of O +
drug O +
action O +
was O +
suggested O +
recently O +
. O +

Salicylates O +
have O +
been O +
shown O +
to O +
inhibit O +
lipopolysaccharide O -
- O -
induced O +
gene O +
transcription O +
via O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
by O +
preventing O +
the O +
degradation O +
of O +
NF O -
- O -
kappa O +
B O +
inhibitor O +
` O -
` O +
I O +
kappa O +
B O +
` O -
` O +
, O +
blocking O +
the O +
translocation O +
of O +
NF O -
- O -
kappa O +
B O +
into O +
the O +
nuclear O +
compartment O +
. O +

However O +
, O +
the O +
nature O +
of O +
the O +
subunit O +
involved O +
in O +
this O +
mechanism O +
has O +
not O +
been O +
defined O +
. O +

To O +
examine O +
the O +
mechanisms O +
by O +
which O +
salicylates O +
affect O +
cytokine O +
gene O +
transcription O +
, O +
the O +
amount O +
of O +
active O +
and O +
inactive O +
NF O -
- O -
kappa O +
B O +
and O +
NF O -
- O -
kappa O +
B O +
mRNA O +
, O +
in O +
Porphyromonas O +
gingivalis O +
lipopolysaccharide B-CellLine -
- I-CellLine -
stimulated I-CellLine +
human I-CellLine +
monocytic I-CellLine +
cells I-CellLine +
was O +
assessed O +
. O +

High O +
doses O +
of O +
sodium O +
salicylate O +
suppressed O +
NF O -
- O -
kappa O +
B O +
p65 O +
mRNA O +
accumulation O +
, O +
resulting O +
in O +
suppression O +
of O +
total O +
NF O -
- O -
kappa O +
B O +
, O +
p50 O +
on O +
tissue O +
oligonucleotide O +
had O +
no O +
effects O +
on O +
lipopolysaccharide O -
- O -
induced O +
NF O -
- O -
kappa O +
B O +
activation O +
. O +

The O +
data O +
demonstrate O +
that O +
the O +
p65 O +
subunit O +
of O +
NF O -
- O -
kappa O +
B O +
is O +
inhibited O +
by O +
salicylate O +
treatment O +
and O +
highlight O +
the O +
role O +
of O +
salicylate O +
in O +
the O +
control O +
of O +
gene O +
expression O +
of O +
inflammatory O +
mediators O +
. O +

Glucocorticoid O +
receptors O +
in O +
cord O +
blood O +
lymphocytes O +
of O +
healthy O +
neonates O +
and O +
of O +
preterms O +
suffering O +
from O +
respiratory O +
distress O +
syndrome O +
. O +

We O +
measured O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
( O +
GR O +
) O +
in O +
cord O +
blood O +
lymphocytes O +
and O +
the O +
binding O +
affinity O +
( O +
Kd O +
) O +
in O +
15 O +
term O +
and O +
in O +
20 O +
preterm O +
babies O +
. O +

Thirteen O +
preterms O +
of O +
the O +
latter O +
group O +
received O +
prenatal O +
steroid O +
treatment O +
. O +

Seven O +
preterms O +
developed O +
neonatal O +
respiratory O +
distress O +
syndrome O +
( O +
NRDS O +
) O +
. O +

The O +
number O +
of O +
GR O +
and O +
the O +
Kd O +
were O +
similar O +
in O +
the O +
term O +
and O +
preterm O +
( O +
with O +
and O +
without O +
NRDS O +
) O +
babies O +
. O +

The O +
maximum O +
( O +
3H O +
) O +
-thymidine O +
incorporation O +
into O +
DNA O +
of O +
cord O +
blood O +
lymphocytes O +
from O +
all O +
preterms O +
, O +
with O +
or O +
without O +
NRDS O +
was O +
suppressed O +
when O +
compared O +
to O +
that O +
from O +
term O +
babies O +
or O +
adults O +
. O +

This O +
could O +
partly O +
be O +
explained O +
by O +
the O +
antenatal O +
steroid O +
treatment O +
. O +

Sensitivity O +
( O +
ID50 O +
) O +
of O +
the O +
lymphocytes O +
for O +
the O +
inhibitory O +
effect O +
of O +
dexamethasone O +
was O +
the O +
same O +
in O +
all O +
groups O +
. O +

In O +
this O +
study O +
on O +
the O +
number O +
and O +
function O +
of O +
GR O +
in O +
lymphocytes O +
, O +
we O +
were O +
unable O +
to O +
find O +
a O +
relation O +
between O +
the O +
functionality O +
of O +
the O +
GR O +
and O +
the O +
development O +
of O +
NRDS O +
. O +

Oxidants O +
, O +
transcription O +
factors O +
, O +
and O +
intestinal O +
inflammation O +
. O +

It O +
is O +
now O +
well O +
appreciated O +
that O +
chronic O +
gut O +
inflammation O +
is O +
characterized O +
by O +
enhanced O +
production O +
of O +
reactive O +
metabolites O +
of O +
oxygen O +
and O +
nitrogen O +
. O +

Some O +
of O +
these O +
oxidants O +
are O +
known O +
to O +
modulate O +
the O +
expression O +
of O +
a O +
variety O +
of O +
genes O +
that O +
are O +
involved O +
in O +
the O +
immune O +
and O +
inflammatory O +
responses O +
. O +

For O +
example O +
, O +
certain O +
oxidants O +
are O +
known O +
to O +
activate O +
the O +
nuclear O +
transcription O +
factor O +
kappa O +
B O +
, O +
which O +
regulates O +
the O +
expression O +
of O +
a O +
variety O +
of O +
different O +
adhesion O +
molecules O +
, O +
cytokines O +
, O +
and O +
enzymes O +
. O +

Oxidants O +
are O +
also O +
known O +
to O +
activate O +
another O +
transcription O +
factor O +
, O +
activator O +
protein-1 O +
. O +

This O +
transcription O +
factor O +
is O +
composed O +
of O +
products O +
from O +
the O +
fos O +
and O +
jun O +
proto O -
- O -
oncogene O +
family O +
and O +
is O +
believed O +
to O +
be O +
important O +
in O +
regulating O +
cell O +
growth O +
and O +
proliferation O +
. O +

Finally O +
, O +
oxidants O +
are O +
believed O +
to O +
promote O +
intestinal O +
epithelial O +
cell O +
apoptosis O +
, O +
and O +
the O +
B O -
- O -
cell O +
lymphoma O -
/ O -
leukemia-2 O +
gene O +
product O +
is O +
believed O +
to O +
inhibit O +
this O +
phenomenon O +
in O +
an O +
antioxidant O -
- O -
dependent O +
manner O +
. O +

Taken O +
together O +
, O +
these O +
observations O +
suggest O +
that O +
nontoxic O +
concentrations O +
of O +
reactive O +
metabolites O +
of O +
oxygen O +
and O +
nitrogen O +
play O +
an O +
important O +
role O +
in O +
regulating O +
the O +
expression O +
of O +
genes O +
involved O +
in O +
the O +
inflammatory O +
response O +
and O +
in O +
modulating O +
apoptosis O +
. O +

Transcription O +
factors O +
required O +
for O +
lymphoid O +
lineage O +
commitment O +
. O +

Intimate O +
interactions O +
between O +
multipotential O +
hemopoietic O +
stem O +
cells O +
and O +
their O +
microenvironment O +
work O +
towards O +
redefining O +
the O +
identity O +
and O +
the O +
differentiative O +
fate O +
of O +
these O +
primitive O +
cells O +
. O +

Molecular O +
cues O +
delivered O +
by O +
the O +
microenvironment O +
frequently O +
act O +
in O +
an O +
instructive O +
fashion O +
by O +
initiating O +
intracellular O +
signaling O +
pathways O +
that O +
ultimately O +
target O +
a O +
select O +
group O +
of O +
transcription O +
factors O +
. O +

These O +
transcriptional O +
regulators O +
in O +
turn O +
trigger O +
a O +
cascade O +
of O +
genetic O +
changes O +
that O +
ultimately O +
determine O +
the O +
course O +
of O +
the O +
cells O +
during O +
differentiation O +
. O +

Gene O +
inactivation O +
studies O +
on O +
the O +
PU.1 O +
, O +
Ikaros O +
and O +
GATA-3 O +
genes O +
have O +
revealed O +
that O +
their O +
encoded O +
factors O +
are O +
essential O +
for O +
the O +
earliest O +
commitment O +
step O +
into O +
the O +
B O +
and O +
T O +
lymphoid O +
lineages O +
. O +

Xenogeneic O +
human O +
serum O +
promotes O +
leukocyte O +
adhesion O +
to O +
porcine O +
endothelium O +
under O +
flow O +
conditions O +
, O +
possibly O +
through O +
the O +
activation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
. O +

Endothelial O +
cell O +
activation O +
and O +
leukocyte O +
infiltration O +
are O +
a O +
consistent O +
feature O +
of O +
discordant O +
xenograft O +
rejection O +
. O +

Here O +
we O +
evaluated O +
whether O +
xenogeneic O +
serum O +
, O +
as O +
a O +
source O +
of O +
xenoreactive O +
natural O +
antibodies O +
and O +
complement O +
, O +
induced O +
endothelial O +
cell O +
activation O +
with O +
consequent O +
leukocyte O +
adhesion O +
under O +
flow O +
conditions O +
. O +

Porcine B-CellLine +
aortic I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
( O +
PAEC B-CellLine +
) O +
were O +
incubated O +
for O +
1 O +
hr O +
30 O +
min O +
or O +
5 O +
hr O +
with O +
10 O +
% O +
homologous O +
porcine O +
serum O +
( O +
control O +
) O +
or O +
10 O +
% O +
xenogeneic O +
human O +
serum O +
and O +
then O +
perfused O +
with O +
total O +
human O +
leukocytes O +
in O +
a O +
parallel O +
plate O +
flow O +
chamber O +
under O +
laminar O +
flow O +
( O +
1.5 O +
dynes O -
/ O -
cm2 O +
) O +
. O +

Adherent O +
cells O +
were O +
counted O +
by O +
digital O +
image O +
analysis O +
. O +

Xenogeneic O +
human O +
serum O +
significantly O +
( O +
P O +
< O +
0.01 O +
) O +
increased O +
the O +
number O +
of O +
adherent O +
leukocytes O +
as O +
compared O +
with O +
porcine O +
serum O +
. O +

A O +
similar O +
adhesive O +
response O +
was O +
elicited O +
by O +
TNF O +
alpha O +
( O +
100 O +
U O -
/ O -
ml O +
) O +
, O +
one O +
of O +
the O +
most O +
potent O +
inducers O +
of O +
endothelial O +
cell O +
adhesive O +
properties O +
, O +
here O +
used O +
as O +
positive O +
control O +
. O +

In O +
order O +
to O +
elucidate O +
possible O +
mechanisms O +
underlying O +
endothelial O +
cell O +
activation O +
by O +
xenogeneic O +
serum O +
, O +
we O +
focussed O +
on O +
transcription O +
factor O +
NF O -
- O -
kappa O +
B O +
, O +
a O +
central O +
regulator O +
for O +
the O +
induction O +
of O +
different O +
genes O +
, O +
including O +
adhesive O +
molecules O +
and O +
chemoattractants O +
. O +

By O +
confocal O +
fluorescence O +
microscopy O +
, O +
we O +
observed O +
a O +
positive O +
staining O +
for O +
NF O -
- O -
kappa O +
B O +
( O +
p65 O +
subunit O +
) O +
in O +
the O +
nuclei O +
of O +
PAEC B-CellLine +
exposed O +
for O +
1 O +
hr O +
30 O +
min O +
to O +
human O +
serum O +
, O +
which O +
indicated O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
this O +
setting O +
. O +

At O +
variance O +
, O +
in O +
PAEC B-CellLine +
incubated O +
with O +
the O +
homologous O +
serum O +
, O +
NF O -
- O -
kappa O +
B O +
was O +
strictly O +
localized O +
in O +
the O +
cell O +
cytoplasm O +
. O +

Treatment O +
of O +
PAEC B-CellLine +
exposed O +
to O +
xenogeneic O +
serum O +
with O +
the O +
NF O -
- O -
kappa O +
B O +
inhibitors O +
pyrrolidinedithiocarbamate O +
( O +
PDTC O +
, O +
25 O +
microM O +
) O +
and O +
tosyl O -
- O -
phechloromethylketone O +
( O +
TPCK O +
, O +
25 O +
microM O +
) O +
significantly O +
( O +
P O +
< O +
0.01 O +
) O +
reduced O +
leukocyte O +
adhesion O +
in O +
respect O +
to O +
PAEC B-CellLine +
treated O +
with O +
human O +
serum O +
alone O +
. O +

Findings O +
that O +
xenogeneic O +
serum O +
promotes O +
leukocyte O -
- O -
endothelium O +
interaction O +
possibly O +
through O +
NF O -
- O -
kappa O +
B O +
activation O +
might O +
be O +
relevant O +
for O +
designing O +
future O +
therapeutic O +
strategies O +
aimed O +
at O +
prolonging O +
xenograft O +
survival O +
. O +

Delta O -
- O -
opioid O +
receptors O +
expressed O +
by O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
enhance O +
IL-2 O +
secretion O +
by O +
increasing O +
AP-1 O +
complexes O +
and O +
activity O +
of O +
the O +
NF O -
- O -
AT O -
/ O -
AP-1-binding O +
promoter O +
element O +
. O +

Recent O +
molecular O +
evidence O +
points O +
to O +
transient O +
and/or O +
stage O -
- O -
specific O +
expression O +
of O +
delta- O +
and O +
kappa O -
- O -
opioid O +
receptors O +
by O +
thymic O +
and O +
peripheral O +
T O +
lymphocytes O +
. O +

Since O +
medical O +
treatments O +
or O +
stress O +
commonly O +
increase O +
opioid O +
levels O +
, O +
it O +
is O +
important O +
to O +
understand O +
the O +
mechanisms O +
by O +
which O +
opioids O +
affect O +
T O +
lymphocyte O +
functions O +
. O +

We O +
therefore O +
created O +
and O +
studied O +
a O +
T B-CellLine +
cell I-CellLine +
line I-CellLine +
expressing O +
the O +
cloned O +
delta O -
- O -
opioid O +
receptor O +
( O +
DOR1 O +
) O +
. O +

DOR1 O +
ligation O +
by O +
a O +
specific O +
DOR1 O +
agonist O +
, O +
deltorphin O +
, O +
augmented O +
IL-2 O +
secretion O +
by O +
synergizing O +
with O +
signals O +
from O +
TCR O -
- O -
CD3 O +
and O +
CD28 O +
. O +

Reporter O +
gene O +
constructs O +
were O +
used O +
to O +
map O +
this O +
effect O +
of O +
deltorphin O +
to O +
the O +
AP-1- O +
and O +
NF O -
- O -
AT O -
/ O -
AP-1-binding O +
sites O +
of O +
the O +
IL-2 O +
promoter O +
. O +

Although O +
DOR1 O +
signaling O +
increased O +
[ O +
Ca2 O -
+ O +
] O +
i O +
, O +
deltorphin O +
enhanced O +
transcriptional O +
activity O +
of O +
the O +
NF O -
- O -
AT O -
/ O -
AP-1-binding O +
site O +
via O +
a O +
mechanism O +
independent O +
of O +
calcineurin O +
and O +
distinct O +
from O +
the O +
effects O +
of O +
elevated O +
[ O +
Ca2 O -
+ O +
] O +
i O +
. O +

Deltorphin O +
also O +
increased O +
accumulation O +
of O +
AP-1 O +
transcription O +
factor O +
complexes O +
, O +
suggesting O +
that O +
DOR1 O +
augments O +
IL-2 O +
secretion O +
by O +
increasing O +
the O +
AP-1 O +
component O +
of O +
the O +
NF O -
- O -
AT O -
/ O -
AP-1 O +
transcription O +
factor O +
. O +

These O +
results O +
advance O +
the O +
molecular O +
understanding O +
of O +
opioid O +
effects O +
on O +
lymphocytes O +
, O +
and O +
in O +
addition O +
, O +
demonstrate O +
regulation O +
of O +
IL-2 O +
synthesis O +
and O +
secretion O +
by O +
the O +
novel O +
mechanism O +
of O +
receptor O -
- O -
mediated O +
AP-1 O +
induction O +
. O +

Differential O +
induction O +
of O +
DNA O -
- O -
binding O +
activities O +
following O +
CD19 O +
cross O -
- O -
linking O +
in O +
human O +
B O +
lineage O +
cells O +
. O +

The O +
B O +
cell O -
- O -
specific O +
cell O +
surface O +
molecule O +
CD19 O +
is O +
expressed O +
at O +
all O +
stages O +
of O +
B O +
cell O +
development O +
, O +
including O +
normal O +
plasma O +
cells O +
, O +
and O +
mediates O +
signal O +
transduction O +
via O +
interaction O +
with O +
cytoplasmic O +
effector O +
proteins O +
. O +

Cross O -
- O -
linking O +
CD19 O +
on O +
early O +
human O +
B O +
lineage O +
cells O +
induces O +
the O +
formation O +
of O +
a O +
CD19 O -
/ O -
Vav O -
/ O -
phosphatidylinositol-3 O +
kinase O +
complex O +
, O +
tyrosine O +
phosphorylation O +
of O +
CD19 O +
and O +
Vav O +
, O +
and O +
activation O +
of O +
the O +
Ras O +
pathway O +
. O +

To O +
further O +
explore O +
the O +
ramifications O +
of O +
CD19 O +
signaling O +
, O +
the O +
current O +
study O +
examined O +
whether O +
phosphorylation O +
of O +
Elk-1 O +
, O +
activation O +
of O +
activator O +
protein-1 O +
( O +
AP-1 O +
) O +
, O +
or O +
activation O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
transcription O +
factors O +
occurred O +
following O +
CD19 O +
cross O -
- O -
linking O +
. O +

The O +
cells O +
used O +
were O +
the O +
BLIN-1 B-CellLine +
pre I-CellLine -
- I-CellLine -
B I-CellLine +
cell I-CellLine +
line I-CellLine +
expressing O +
low O +
levels O +
of O +
cell O +
surface O +
mu O +
heavy O +
chain O +
associated O +
with O +
surrogate O +
light O +
chain O +
and O +
the O +
1E8 O +
immature O +
B O +
cell O +
line O +
expressing O +
cell O +
surface O +
mu O -
/ O -
kappa O +
. O +

Lysates O +
from O +
CD19 O +
cross O -
- O -
linked O +
1E8 B-CellLine +
cells I-CellLine +
induced O +
robust O +
phosphorylation O +
of O +
an O +
Elk-1 O +
fusion O +
protein O +
in O +
vitro O +
, O +
whereas O +
no O +
phosphorylation O +
of O +
Elk-1 O +
fusion O +
protein O +
occurred O +
using O +
lysates O +
from O +
CD19 B-CellLine +
cross I-CellLine -
- I-CellLine -
linked I-CellLine +
BLIN-1 I-CellLine +
cells I-CellLine +
. O +

An O +
electrophoretic O +
mobility O +
shift O +
assay O +
employing O +
AP-1 O +
and O +
NF O -
- O -
kappaB O +
consensus O +
oligonucleotides O +
was O +
used O +
to O +
demonstrate O +
that O +
AP-1 O +
-binding O +
activity O +
increased O +
, O +
while O +
constitutive O +
NF O -
- O -
kappaB O +
-binding O +
activity O +
was O +
not O +
enhanced O +
, O +
following O +
2 O +
h O +
of O +
CD19 O +
cross O -
- O -
linking O +
in O +
1E8 B-CellLine +
cells I-CellLine +
. O +
Supershift O +
experiments O +
revealed O +
that O +
JunD O +
and O +
c O -
- O -
Fos O +
proteins O +
mediated O +
anti- O +
CD19 O +
induced O +
AP-1 O +
-binding O +
activity O +
in O +
1E8 B-CellLine +
cells I-CellLine +
. O +

In O +
contrast O +
, O +
CD19 O +
cross O -
- O -
linking O +
in O +
BLIN-1 B-CellLine +
cells I-CellLine +
resulted O +
in O +
the O +
induction O +
of O +
NF O -
- O -
kappaB O +
, O +
but O +
had O +
no O +
apparent O +
effect O +
on O +
AP-1 O +
-binding O +
activity O +
. O +

These O +
data O +
suggest O +
that O +
CD19 O +
-mediated O +
signal O +
transduction O +
activates O +
different O +
transcription O +
factors O +
at O +
juxtaposed O +
stages O +
of O +
B O +
cell O +
development O +
that O +
may O +
culminate O +
in O +
the O +
activation O +
or O +
suppression O +
of O +
distinct O +
sets O +
of O +
genes O +
. O +

Pharmacological O +
control O +
of O +
antigen O +
responsiveness O +
in O +
genetically B-CellLine +
modified I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
. O +

A O +
chimeric O +
TCR O +
gene O +
, O +
comprising O +
an O +
anti O -
- O -
hapten O +
single O -
- O -
chain O +
Ab O +
variable O +
fragment O +
fused O +
to O +
the O +
transmembrane O +
and O +
cytoplasmic O +
regions O +
of O +
the O +
human O +
TCR O +
zeta O -
- O -
chain O +
, O +
was O +
used O +
to O +
determine O +
whether O +
the O +
tetracycline O -
- O -
regulatable O +
system O +
could O +
be O +
used O +
to O +
regulate O +
gene O +
expression O +
in O +
T O +
cells O +
. O +

Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
were O +
stably O +
transfected O +
with O +
a O +
single O +
vector O +
encoding O +
the O +
tetracycline O +
trans O -
- O -
activator O +
protein O +
, O +
controlled O +
by O +
a O +
constitutive O +
promoter O +
, O +
and O +
the O +
chimeric O +
TCR O +
, O +
under O +
the O +
control O +
of O +
a O +
trans O -
- O -
activator O +
protein O -
- O -
responsive O +
promoter O +
. O +

In O +
the O +
absence O +
of O +
tetracyclines O +
, O +
the O +
transfected O +
T O +
cells O +
were O +
shown O +
to O +
express O +
the O +
chimeric O +
receptor O +
on O +
the O +
cell O +
surface O +
and O +
could O +
be O +
activated O +
by O +
its O +
cognate O +
Ag O +
, O +
leading O +
to O +
the O +
secretion O +
of O +
IL-2 O +
. O +

When O +
the O +
cells O +
were O +
exposed O +
to O +
increasing O +
concentrations O +
of O +
tetracyclines O +
, O +
surface O +
expression O +
of O +
the O +
chimeric O +
receptor O +
was O +
suppressed O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
, O +
and O +
this O +
suppression O +
was O +
sufficient O +
to O +
result O +
in O +
complete O +
loss O +
of O +
responsiveness O +
to O +
the O +
targeted O +
Ag O +
. O +

Prolonged O +
suppression O +
of O +
trans O -
- O -
gene O +
expression O +
for O +
up O +
to O +
7 O +
days O +
was O +
observed O +
after O +
doxycycline O +
was O +
removed O +
from O +
the O +
cultures O +
, O +
but O +
eventual O +
recovery O +
of O +
surface O +
expression O +
was O +
complete O +
, O +
and O +
the O +
absolute O +
time O +
to O +
recovery O +
was O +
directly O +
proportional O +
to O +
the O +
initial O +
concentration O +
of O +
the O +
drug O +
. O +

Pharmacologic O +
control O +
of O +
trans O -
- O -
gene O +
expression O +
in O +
gene B-CellLine -
- I-CellLine -
modified I-CellLine +
T I-CellLine +
cells I-CellLine +
will O +
not O +
only O +
facilitate O +
new O +
approaches O +
to O +
the O +
study O +
of O +
different O +
aspects O +
of O +
T O +
cell O +
biology O +
, O +
but O +
will O +
also O +
provide O +
the O +
basis O +
for O +
new O +
gene O +
therapy O +
strategies O +
. O +

IFN O -
- O -
gamma O +
and O +
IL-10 O +
inhibit O +
induction O +
of O +
IL-1 O +
receptor O +
type O +
I O +
and O +
type O +
II O +
gene O +
expression O +
by O +
IL-4 O +
and O +
IL-13 O +
in O +
human O +
monocytes O +
. O +

The O +
Th2-type O +
cytokines O +
IL-4 O +
and O +
IL-13 O +
induce O +
expression O +
of O +
a O +
distinct O +
subset O +
of O +
genes O +
in O +
human O +
monocytes O +
. O +

These O +
include O +
Fc O +
epsilonRII O +
( O +
CD23 O +
) O +
, O +
15-lipoxygenase O +
, O +
IL-1 O +
receptor O +
antagonist O +
( O +
IL-1ra O +
) O +
, O +
and O +
type O +
I O +
and O +
type O +
II O +
IL-1 O +
receptors O +
( O +
IL-1R O +
) O +
. O +

IFN O -
- O -
gamma O +
has O +
been O +
shown O +
to O +
inhibit O +
induction O +
of O +
CD23 O +
and O +
15-lipoxygenase O +
in O +
monocytes O +
; O +
however O +
, O +
the O +
effects O +
of O +
IFN O -
- O -
gamma O +
on O +
type O +
I O +
and O +
type O +
II O +
IL-1R O +
gene O +
expression O +
have O +
not O +
been O +
defined O +
. O +

We O +
examined O +
the O +
effects O +
of O +
IFN O -
- O -
gamma O +
on O +
both O +
basal O +
and O +
IL-4 O +
/ O +
IL-13 O +
-induced O +
IL-1R O +
gene O +
expression O +
in O +
primary O +
monocytes O +
. O +

IL-4 O +
and O +
IL-13 O +
induced O +
dose- O +
and O +
time O -
- O -
dependent O +
increases O +
in O +
IL-1RI O +
and O +
IL-1RII O +
mRNA O +
levels O +
. O +

IFN O -
- O -
gamma O +
decreased O +
basal O +
expression O +
as O +
well O +
as O +
the O +
induction O +
of O +
these O +
genes O +
by O +
IL-4 O +
and O +
IL-13 O +
. O +

Inhibition O +
of O +
IL-1RI O +
and O +
IL-1RII O +
mRNA O +
levels O +
by O +
IFN O -
- O -
gamma O +
was O +
transcriptionally O +
mediated O +
, O +
and O +
correlated O +
directly O +
with O +
decreased O +
production O +
of O +
soluble O +
IL-1RII O +
. O +

Furthermore O +
, O +
the O +
ability O +
to O +
suppress O +
IL-1RI O +
and O +
IL-1RII O +
mRNA O +
levels O +
was O +
not O +
unique O +
to O +
IFN O -
- O -
gamma O +
because O +
IL-10 O +
also O +
inhibited O +
expression O +
of O +
these O +
genes O +
in O +
IL-4 B-CellLine -
/ I-CellLine -
IL-13-stimulated I-CellLine +
monocytes I-CellLine +
. O +

Inhibition O +
of O +
IL-1R O +
gene O +
expression O +
by O +
IFN O -
- O -
gamma O +
and O +
IL-10 O +
was O +
not O +
due O +
to O +
down O -
- O -
regulation O +
of O +
surface O +
IL-4R O +
because O +
pretreatment O +
with O +
these O +
cytokines O +
did O +
not O +
decrease O +
the O +
number O +
of O +
IL-4 O +
binding O +
sites O +
per O +
cell O +
. O +

However O +
, O +
suppression O +
of O +
IL-1R O +
gene O +
expression O +
by O +
IFN O -
- O -
gamma O +
and O +
IL-10 O +
was O +
associated O +
with O +
decreased O +
tyrosine O +
phosphorylation O +
and O +
nuclear O +
translocation O +
of O +
the O +
IL-4 O -
/ O -
IL-13-inducible O +
transcription O +
factor O +
, O +
Stat6 O +
, O +
suggesting O +
a O +
potential O +
mechanism O +
by O +
which O +
IFN O -
- O -
gamma O +
and O +
IL-10 O +
may O +
mediate O +
their O +
suppressive O +
effects O +
. O +

These O +
findings O +
demonstrate O +
that O +
certain O +
cytokines O +
, O +
including O +
IFN O -
- O -
gamma O +
and O +
IL-10 O +
, O +
antagonize O +
the O +
ability O +
of O +
IL-4 O +
and O +
IL-13 O +
to O +
induce O +
increased O +
expression O +
of O +
the O +
IL-1RI O +
and O +
IL-1RII O +
genes O +
in O +
monocytes O +
. O +

Human O +
immunodeficiency O +
virus O +
type O +
1 O +
long O +
terminal O +
repeat O +
quasispecies O +
differ O +
in O +
basal O +
transcription O +
and O +
nuclear O +
factor O +
recruitment O +
in O +
human O +
glial O +
cells O +
and O +
lymphocytes O +
. O +

The O +
generation O +
of O +
genomic O +
diversity O +
during O +
the O +
course O +
of O +
infection O +
has O +
the O +
potential O +
to O +
affect O +
all O +
aspects O +
of O +
HIV-1 O +
replication O +
, O +
including O +
expression O +
of O +
the O +
proviral O +
genome O +
. O +

To O +
gain O +
a O +
better O +
understanding O +
of O +
the O +
impact O +
of O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
sequence O +
diversity O +
on O +
LTR O -
- O -
directed O +
gene O +
expression O +
in O +
cells O +
of O +
the O +
central O +
nervous O +
system O +
( O +
CNS O +
) O +
and O +
immune O +
system O +
, O +
we O +
amplified O +
and O +
cloned O +
LTRs O +
from O +
proviral O +
DNA O +
in O +
HIV-1-infected O +
peripheral O +
blood O +
. O +

Sequence O +
analysis O +
of O +
nineteen O +
LTRs O +
cloned O +
from O +
2 O +
adult O +
and O +
3 O +
pediatric O +
patients O +
revealed O +
an O +
average O +
of O +
33 O +
nucleotide O +
changes O +
( O +
with O +
respect O +
to O +
the O +
sequence O +
of O +
the O +
LAI O +
LTR O +
) O +
within O +
the O +
455-bp O +
U3 O +
region O +
. O +

Transient O +
expression O +
analyses O +
in O +
cells O +
of O +
neuroglial O +
and O +
lymphocytic O +
origin O +
demonstrated O +
that O +
some O +
of O +
these O +
LTRs O +
had O +
activities O +
which O +
varied O +
significantly O +
from O +
the O +
LAI O +
LTR O +
in O +
U-373 B-CellLine +
MG I-CellLine +
cells I-CellLine +
( O +
an O +
astrocytoma B-CellLine +
cell I-CellLine +
line I-CellLine +
) O +
as O +
well O +
as O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
( O +
a O +
CD4-positive B-CellLine +
lymphocyte I-CellLine +
cell I-CellLine +
line I-CellLine +
) O +
. O +

While O +
LTRs O +
which O +
demonstrated O +
the O +
highest O +
activities O +
in O +
U-373 B-CellLine +
MG I-CellLine +
cells I-CellLine +
also O +
yielded O +
high O +
activities O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
the O +
LTRs O +
were O +
generally O +
more O +
active O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
when O +
compared O +
to O +
the O +
LAI O +
LTR O +
. O +

Differences O +
in O +
LTR O +
sequence O +
also O +
resulted O +
in O +
differences O +
in O +
transcription O +
factor O +
recruitment O +
to O +
cis O -
- O -
acting O +
sites O +
within O +
the O +
U3 O +
region O +
of O +
the O +
LTR O +
, O +
as O +
demonstrated O +
by O +
electrophoretic O +
mobility O +
shift O +
assays O +
. O +

In O +
particular O +
, O +
naturally O +
occurring O +
sequence O +
variation O +
impacted O +
transcription O +
factor O +
binding O +
to O +
an O +
activating O +
transcription O +
factor O +
/ O +
cAMP O +
response O +
element O +
binding O +
( O +
ATF O +
/ O +
CREB O +
) O +
binding O +
site O +
( O +
located O +
between O +
the O +
LEF-1 O +
and O +
distal O +
NF O -
- O -
kappaB O +
transcription O +
factor O +
binding O +
sites O +
) O +
that O +
we O +
identified O +
in O +
previous O +
studies O +
of O +
the O +
HIV-1 O +
LTR O +
. O +

These O +
findings O +
suggest O +
that O +
LTR O +
sequence O +
changes O +
can O +
significantly O +
affect O +
basal O +
LTR O +
function O +
and O +
transcription O +
factor O +
recruitment O +
, O +
which O +
may O +
, O +
in O +
turn O +
, O +
alter O +
the O +
course O +
of O +
viral O +
replication O +
in O +
cells O +
of O +
CNS O +
and O +
immune O +
system O +
origin O +
. O +

Activation O +
of O +
Stat-3 O +
is O +
involved O +
in O +
the O +
induction O +
of O +
apoptosis O +
after O +
ligation O +
of O +
major O +
histocompatibility O +
complex O +
class O +
I O +
molecules O +
on O +
human B-CellLine +
Jurkat I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Activation O +
of O +
Janus O +
tyrosine O +
kinases O +
( O +
Jak O +
) O +
and O +
Signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
Stat O +
) O +
after O +
ligation O +
of O +
major O +
histocompatibility O +
complex O +
class O +
I O +
( O +
MHC O -
- O -
I O +
) O +
was O +
explored O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Cross O -
- O -
linking O +
of O +
MHC O -
- O -
I O +
mediated O +
tyrosine O +
phosphorylation O +
of O +
Tyk2 O +
, O +
but O +
not O +
Jak1 O +
, O +
Jak2 O +
, O +
and O +
Jak3 O +
. O +

In O +
addition O +
, O +
the O +
transcription O +
factor O +
Stat-3 O +
was O +
tyrosine O +
phosphorylated O +
in O +
the O +
cytoplasm O +
and O +
subsequently O +
translocated O +
to O +
the O +
cell O +
nucleus O +
. O +

Data O +
obtained O +
by O +
electrophoretic O +
mobility O +
shift O +
assay O +
suggested O +
that O +
the O +
activated O +
Stat-3 O +
protein O +
associates O +
with O +
the O +
human O +
serum O -
- O -
inducible O +
element O +
( O +
hSIE O +
) O +
DNA O -
- O -
probe O +
derived O +
from O +
the O +
interferon O -
- O -
gamma O +
activated O +
site O +
( O +
GAS O +
) O +
in O +
the O +
c O -
- O -
fos O +
promoter O +
, O +
a O +
common O +
DNA O +
sequence O +
for O +
Stat O +
protein O +
binding O +
. O +

An O +
association O +
between O +
hSIE O +
and O +
Stat-3 O +
after O +
MHC O -
- O -
I O +
ligation O +
was O +
directly O +
demonstrated O +
by O +
precipitating O +
Stat-3 O +
from O +
nuclear O +
extracts O +
with O +
biotinylated O +
hSIE O +
probe O +
and O +
avidin O +
-coupled O +
agarose O +
. O +

To O +
investigate O +
the O +
function O +
of O +
the O +
activated O +
Stat-3 O +
, O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
were O +
transiently O +
transfected O +
with O +
a O +
Stat-3 O +
isoform O +
lacking O +
the O +
transactivating O +
domain O +
. O +

This O +
dominant O -
- O -
negative O +
acting O +
Stat-3 O +
isoform O +
significantly O +
inhibited O +
apoptosis O +
induced O +
by O +
ligation O +
of O +
MHC O -
- O -
I O +
. O +

In O +
conclusion O +
, O +
our O +
data O +
suggest O +
the O +
involvement O +
of O +
the O +
Jak O -
/ O -
Stat O +
signal O +
pathway O +
in O +
MHC O -
- O -
I O +
-induced O +
signal O +
transduction O +
in O +
T O +
cells O +
. O +

IL-2 O +
-induced O +
growth O +
of O +
CD8 O -
+ O +
T O +
cell O +
prolymphocytic O +
leukemia O +
cells O +
mediated O +
by O +
NF O -
- O -
kappaB O +
induction O +
and O +
IL-2 O +
receptor O +
alpha O +
expression O +
. O +

The O +
binding O +
of O +
interleukin-2 O +
( O +
IL-2 O +
) O +
to O +
its O +
receptor O +
on O +
normal O +
T O +
cells O +
induces O +
nuclear O +
expression O +
of O +
nuclear O +
factor O +
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
, O +
activation O +
of O +
the O +
IL-2 O +
receptor O +
( O +
IL-2R O +
) O +
alpha O +
chain O +
gene O +
, O +
and O +
cell O +
proliferation O +
. O +

In O +
the O +
present O +
study O +
, O +
the O +
role O +
of O +
IL-2R O +
signaling O +
in O +
the O +
growth O +
of O +
CD8 B-CellLine -
+ I-CellLine +
T I-CellLine +
cell I-CellLine +
prolymphocytic I-CellLine +
leukemia I-CellLine +
( I-CellLine +
T I-CellLine -
- I-CellLine -
PLL I-CellLine +
) I-CellLine +
cells I-CellLine +
has O +
been O +
investigated O +
. O +

Flow O +
cytometry O +
revealed O +
that O +
primary O +
leukemia O +
cells O +
from O +
a O +
patient O +
with O +
CD8 O -
+ O +
T O -
- O -
PLL O +
expressed O +
IL-2Ralpha O +
and O +
beta O +
chains O +
, O +
and O +
the O +
cells O +
showed O +
a O +
proliferative O +
response O +
and O +
an O +
increase O +
in O +
IL-2Ralpha O +
expression O +
on O +
culture O +
with O +
exogeneous O +
IL-2 O +
. O +

Northern O +
blot O +
analysis O +
failed O +
to O +
detect O +
IL-2 O +
mRNA O +
, O +
suggesting O +
that O +
IL-2 O +
may O +
act O +
in O +
a O +
paracrine O +
manner O +
in O +
vivo O +
. O +

Electrophoretic O +
mobility O -
- O -
shift O +
assays O +
revealed O +
that O +
recombinant O +
IL-2 O +
increased O +
NF O -
- O -
kappaB O +
binding O +
activity O +
in O +
nuclear O +
extracts O +
of O +
the O +
leukemia O +
cells O +
, O +
and O +
Northern O +
blot O +
analysis O +
showed O +
that O +
IL-2 O +
increased O +
the O +
abundance O +
of O +
mRNAs O +
encoding O +
the O +
NF O -
- O -
kappaB O +
components O +
c O -
- O -
Rel O +
and O +
KBF1 O +
in O +
these O +
cells O +
. O +

IL-2 O +
binding O +
analysis O +
demonstrated O +
that O +
IL-2 O +
markedly O +
increased O +
the O +
number O +
of O +
low O +
affinity O +
IL-2Rs O +
on O +
the O +
leukemia O +
cells O +
, O +
without O +
an O +
effect O +
on O +
the O +
number O +
of O +
high O -
- O -
affinity O +
IL-2Rs O +
. O +

These O +
results O +
show O +
that O +
IL-2 O +
is O +
capable O +
of O +
inducing O +
the O +
nuclear O +
expression O +
of O +
NF O -
- O -
kappaB O +
in O +
primary B-CellLine +
CD8 I-CellLine -
+ I-CellLine +
T I-CellLine -
- I-CellLine -
PLL I-CellLine +
cells I-CellLine +
, O +
and O +
that O +
this O +
effect O +
is O +
mediated O +
, O +
at O +
least O +
in O +
part O +
, O +
at O +
a O +
pretranslational O +
level O +

HMG O +
box O +
containing O +
transcription O +
factors O +
in O +
lymphocyte O +
differentiation O +
. O +

The O +
identification O +
of O +
the O +
mammalian O +
sex O -
- O -
determining O +
gene O +
Sry O +
has O +
led O +
to O +
the O +
discovery O +
of O +
a O +
large O +
family O +
of O +
related O +
( O +
' O +
HMG O +
box O +
' O +
) O +
transcription O +
factors O +
that O +
control O +
developmental O +
events O +
in O +
yeast O +
, O +
C. O +
elegans O +
, O +
Drosophila O +
and O +
vertebrates O +
. O +

In O +
lymphocyte O +
differentiation O +
, O +
several O +
HMG O +
box O +
proteins O +
play O +
a O +
decisive O +
role O +
. O +

Sox-4 O +
is O +
important O +
for O +
very O +
early O +
B O -
- O -
cell O +
differentiation O +
, O +
while O +
TCF-1 O +
/ O +
LEF-1 O +
play O +
a O +
crucial O +
role O +
in O +
early O +
thymocyte O +
development O +
. O +

TCF O -
/ O -
LEF O +
proteins O +
have O +
recently O +
been O +
found O +
to O +
constitute O +
a O +
downstream O +
component O +
of O +
the O +
Wingless O -
/ O -
Wnt O +
signal O +
transduction O +
pathway O +
. O +

In O +
flies O +
, O +
this O +
pathway O +
controls O +
segment O +
polarity O +
; O +
in O +
Xenopus O +
it O +
controls O +
the O +
definition O +
of O +
the O +
body O +
axis O +
. O +

Deregulation O +
of O +
the O +
pathway O +
occurs O +
in O +
several O +
human O +
tumors O +
. O +

These O +
insights O +
in O +
the O +
molecular O +
events O +
that O +
are O +
involved O +
in O +
TCF O -
/ O -
LEF O +
function O +
in O +
these O +
organisms O +
may O +
eventually O +
lead O +
to O +
the O +
understanding O +
of O +
the O +
function O +
of O +
these O +
HMG O +
box O +
proteins O +
in O +
lymphoid O +
development O +

The O +
human O +
toll O +
signaling O +
pathway O +
: O +
divergence O +
of O +
nuclear O +
factor O +
kappaB O +
and O +
JNK O +
/SAPK O +
activation O +
upstream O +
of O +
tumor O +
necrosis O +
factor O +
receptor O -
- O -
associated O +
factor O +
6 O +
( O +
TRAF6 O +
) O +
. O +

The O +
human O +
homologue O +
of O +
Drosophila O +
Toll O +
( O +
hToll O +
) O +
is O +
a O +
recently O +
cloned O +
receptor O +
of O +
the O +
interleukin O +
1 O +
receptor O +
( O +
IL-1R O +
) O +
superfamily O +
, O +
and O +
has O +
been O +
implicated O +
in O +
the O +
activation O +
of O +
adaptive O +
immunity O +
. O +

Signaling O +
by O +
hToll O +
is O +
shown O +
to O +
occur O +
through O +
sequential O +
recruitment O +
of O +
the O +
adapter O +
molecule O +
MyD88 O +
and O +
the O +
IL-1R O -
- O -
associated O +
kinase O +
. O +

Tumor O +
necrosis O +
factor O +
receptor O -
- O -
activated O +
factor O +
6 O +
( O +
TRAF6 O +
) O +
and O +
the O +
nuclear O +
factor O +
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
-inducing O +
kinase O +
( O +
NIK O +
) O +
are O +
both O +
involved O +
in O +
subsequent O +
steps O +
of O +
NF O -
- O -
kappaB O +
activation O +
. O +

Conversely O +
, O +
a O +
dominant O +
negative O +
version O +
of O +
TRAF6 O +
failed O +
to O +
block O +
hToll O +
-induced O +
activation O +
of O +
stress O -
- O -
activated O +
protein O +
kinase O -
/ O -
c O -
- O -
Jun O +
NH2-terminal O +
kinases O +
, O +
thus O +
suggesting O +
an O +
early O +
divergence O +
of O +
the O +
two O +
pathways O +
. O +

IL-4 O +
-dependent O +
regulation O +
of O +
TGF O -
- O -
alpha O +
and O +
TGF O -
- O -
beta1 O +
expression O +
in O +
human O +
eosinophils O +
. O +

TGFs O +
play O +
important O +
roles O +
in O +
wound O +
healing O +
and O +
carcinogenesis O +
. O +

We O +
have O +
previously O +
demonstrated O +
that O +
eosinophils O +
infiltrating O +
into O +
different O +
pathologic O +
processes O +
elaborate O +
TGF O -
- O -
alpha O +
and O +
TGF O -
- O -
beta1 O +
. O +

Eosinophils O +
infiltrating O +
hamster O +
cutaneous O +
wounds O +
were O +
found O +
to O +
express O +
TGFs O +
sequentially O +
. O +

In O +
this O +
study O +
, O +
we O +
examined O +
the O +
biologic O +
mediators O +
that O +
may O +
regulate O +
the O +
expression O +
of O +
TGF O -
- O -
alpha O +
and O +
-beta1 O +
by O +
eosinophils O +
. O +

Eosinophils O +
were O +
isolated O +
from O +
the O +
peripheral O +
blood O +
of O +
healthy O +
donors O +
and O +
cultured O +
in O +
the O +
absence O +
or O +
presence O +
of O +
IL-3 O +
, O +
IL-4 O +
, O +
and O +
IL-5 O +
. O +

Cells O +
were O +
analyzed O +
by O +
in O +
situ O +
hybridization O +
and O +
immunohistochemistry O +
. O +

Supernatants O +
from O +
these O +
cultures O +
were O +
assayed O +
for O +
secreted O +
TGF O -
- O -
alpha O +
and O +
TGF O -
- O -
beta1 O +
using O +
TGF O +
-specific O +
ELISAs O +
. O +

IL-3 O +
, O +
IL-4 O +
, O +
and O +
IL-5 O +
independently O +
up O -
- O -
regulated O +
TGF O -
- O -
beta1 O +
mRNA O +
and O +
product O +
expression O +
by O +
eosinophils O +
in O +
all O +
donors O +
. O +

Interestingly O +
, O +
TGF O -
- O -
alpha O +
production O +
by O +
eosinophils O +
was O +
up O -
- O -
regulated O +
by O +
IL-3 O +
and O +
IL-5 O +
but O +
was O +
down O -
- O -
regulated O +
by O +
IL-4 O +
. O +

Consistent O +
with O +
the O +
ability O +
of O +
IL-4 O +
to O +
regulate O +
eosinophil O +
responses O +
, O +
IL-4 O +
signaling O +
molecules O +
are O +
present O +
in O +
human O +
eosinophils O +
. O +

The O +
observation O +
that O +
IL-4 O +
can O +
differentially O +
regulate O +
the O +
expression O +
of O +
TGF O -
- O -
alpha O +
and O +
TGF O -
- O -
beta1 O +
suggests O +
that O +
IL-4 O +
may O +
serve O +
as O +
a O +
physiologic O +
molecular O +
switch O +
of O +
TGF O +
expression O +
by O +
the O +
infiltrating O +
eosinophils O +
in O +
wound O +
healing O +
and O +
carcinogenesis O +
. O +

Erythropoietin O +
induces O +
tyrosine O +
phosphorylation O +
of O +
Jak2 O +
, O +
STAT5A O +
, O +
and O +
STAT5B O +
in O +
primary O +
cultured O +
human O +
erythroid O +
precursors O +
. O +

We O +
examined O +
signaling O +
by O +
erythropoietin O +
in O +
highly O +
purified O +
human O +
colony O +
forming O +
unit O -
- O -
erythroid O +
cells O +
, O +
generated O +
in O +
vitro O +
from O +
CD34 O +
( O +
+ O +
) O +
cells O +
. O +

We O +
found O +
that O +
erythropoietin O +
induces O +
tyrosine O +
phosphorylation O +
of O +
Jak2 O +
, O +
STAT5A O +
, O +
and O +
STAT5B O +
. O +

Tyrosine O +
phosphorylation O +
of O +
Jak2 O +
reaches O +
a O +
peak O +
around O +
10 O +
minutes O +
after O +
stimulation O +
and O +
is O +
maximum O +
at O +
5 O +
U O -
/ O -
mL O +
of O +
erythropoietin O +
. O +

Tyrosine O +
phosphorylation O +
of O +
STAT5 O +
is O +
accompanied O +
by O +
the O +
translocation O +
of O +
activated O +
STAT5 O +
to O +
the O +
nucleus O +
as O +
shown O +
by O +
electrophoretic O +
mobility O +
shift O +
assay O +
( O +
EMSA O +
) O +
using O +
32Pi O -
- O -
labeled O +
STAT5 O +
binding O +
site O +
in O +
the O +
beta O -
- O -
casein O +
promoter O +
. O +

Tyrosine O +
phosphorylation O +
STAT1 O +
or O +
STAT3 O +
was O +
not O +
detected O +
in O +
human O +
erythroid O +
precursors O +
after O +
stimulation O +
with O +
erythropoietin O +
. O +

Crkl O +
, O +
an O +
SH2 O -
/ O -
SH3 O +
adapter O +
protein O +
, O +
becomes O +
coimmunoprecipitated O +
specifically O +
with O +
STAT5 O +
from O +
erythropoietin O -
- O -
stimulated O +
erythroid O +
cells O +
; O +
although O +
it O +
was O +
shown O +
to O +
become O +
associated O +
with O +
c O -
- O -
Cbl O +
in O +
the O +
studies O +
using O +
cell B-CellLine +
lines I-CellLine +
. O +

Thus O +
, O +
human O +
erythroid O +
precursors O +
can O +
be O +
expanded O +
in O +
vitro O +
in O +
sufficient O +
numbers O +
and O +
purity O +
to O +
allow O +
its O +
usage O +
in O +
signal O +
transduction O +
studies O +
. O +

This O +
report O +
sets O +
a O +
basis O +
for O +
further O +
studies O +
on O +
signaling O +
in O +
primary O +
cultured O +
human O +
erythroid O +
precursors O +
, O +
which O +
in O +
turn O +
contribute O +
to O +
our O +
better O +
understanding O +
in O +
the O +
differentiation O +
processes O +
of O +
erythrocytes O +
and O +
their O +
precursors O +
. O +

A O +
small O +
, O +
nonpeptidyl O +
mimic O +
of O +
granulocyte O -
- O -
colony O -
- O -
stimulating O +
factor O +
[ O +
see O +
commetns O +
] O +

A O +
nonpeptidyl O +
small O +
molecule O +
SB O +
247464 O +
, O +
capable O +
of O +
activating O +
granulocyte O -
- O -
colony O -
- O -
stimulating O +
factor O +
( O +
G O -
- O -
CSF O +
) O +
signal O +
transduction O +
pathways O +
, O +
was O +
identified O +
in O +
a O +
high O -
- O -
throughput O +
assay O +
in O +
cultured O +
cells O +
. O +

Like O +
G O -
- O -
CSF O +
, O +
SB O +
247464 O +
induced O +
tyrosine O +
phosphorylation O +
of O +
multiple O +
signaling O +
proteins O +
and O +
stimulated O +
primary O +
murine O +
bone O +
marrow O +
cells O +
to O +
form O +
granulocytic O +
colonies O +
in O +
vitro O +
. O +

It O +
also O +
elevated O +
peripheral O +
blood O +
neutrophil O +
counts O +
in O +
mice O +
. O +

The O +
extracellular O +
domain O +
of O +
the O +
murine O +
G O -
- O -
CSF O +
receptor O +
was O +
required O +
for O +
the O +
activity O +
of O +
SB O +
247464 O +
, O +
suggesting O +
that O +
the O +
compound O +
acts O +
by O +
oligomerizing O +
receptor O +
chains O +
. O +

The O +
results O +
indicate O +
that O +
a O +
small O +
molecule O +
can O +
activate O +
a O +
receptor O +
that O +
normally O +
binds O +
a O +
relatively O +
large O +
protein O +
ligand O +
. O +

Thrombopoietin O +
supports O +
in O +
vitro O +
erythroid O +
differentiation O +
via O +
its O +
specific O +
receptor O +
c O -
- O -
Mpl O +
in O +
a O +
human B-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Thrombopoietin O +
( O +
TPO O +
) O +
acts O +
on O +
megakaryopoiesis O +
and O +
erythropoiesis O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

We O +
isolated O +
a O +
novel O +
subline O +
, O +
UT-7 B-CellLine -
/ I-CellLine -
GMT I-CellLine +
, O +
from O +
the O +
human B-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
UT-7 I-CellLine -
/ I-CellLine -
GM I-CellLine +
( O +
N. O +
Komatsu O +
, O +
et O +
al. O +
, O +
Blood O +
, O +
89 O +
: O +
4021 O -
- O -
4033 O +
, O +
1997 O +
) O +
. O +

A O +
small O +
population O +
of O +
UT-7 B-CellLine -
/ I-CellLine -
GM I-CellLine +
cells I-CellLine +
positively O +
stained O +
for O +
hemoglobin O +
( O +
Hb O +
) O +
after O +
a O +
7-day O +
exposure O +
to O +
TPO O +
. O +

More O +
than O +
50 O +
% O +
of O +
TPO B-CellLine -
- I-CellLine -
treated I-CellLine +
UT-7 I-CellLine -
/ I-CellLine -
GMT I-CellLine +
cells I-CellLine +
positively O +
stained O +
for O +
Hb O +
. O +

Using O +
UT-7 B-CellLine -
/ I-CellLine -
GMT I-CellLine +
cells I-CellLine +
, O +
we O +
examined O +
how O +
TPO O +
promotes O +
hemoglobinization O +
. O +

TPO O +
induced O +
tyrosine O +
phosphorylation O +
of O +
the O +
TPO O +
receptor O +
but O +
not O +
the O +
erythropoietin O +
( O +
EPO O +
) O +
receptor O +
. O +

There O +
was O +
no O +
competition O +
between O +
TPO O +
and O +
EPO O +
for O +
binding O +
to O +
EPO O +
receptor O +
. O +

These O +
findings O +
suggest O +
that O +
TPO O +
has O +
a O +
direct O +
effect O +
on O +
hemoglobinization O +
via O +
a O +
specific O +
receptor O +
on O +
UT-7 B-CellLine -
/ I-CellLine -
GMT I-CellLine +
cells I-CellLine +
. O +

Isoelectric O +
focusing O +
demonstrated O +
that O +
TPO O +
induced O +
fetal O +
and O +
adult O +
Hb O +
synthesis O +
, O +
whereas O +
EPO O +
induced O +
embryonic O +
, O +
fetal O +
, O +
and O +
adult O +
Hb O +
synthesis O +
. O +

Thus O +
, O +
our O +
data O +
suggest O +
that O +
TPO O +
has O +
a O +
distinct O +
action O +
on O +
erythropoiesis O +
. O +

Peripheral O +
blood O +
T O +
cells O +
and O +
monocytes O +
and O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
derived O +
from O +
patients O +
with O +
lupus O +
express O +
estrogen O +
receptor O +
transcripts O +
similar O +
to O +
those O +
of O +
normal O +
cells O +
. O +

OBJECTIVE O +
: O +
To O +
identify O +
and O +
characterize O +
estrogen O +
receptor O +
( O +
ER O +
) O +
transcripts O +
expressed O +
in O +
immune O +
cells O +
of O +
patients O +
with O +
systemic O +
lupus O +
erythematosus O +
( O +
SLE O +
) O +
and O +
healthy O +
donors O +
. O +

METHODS O +
: O +
Peripheral O +
blood O +
monocytes O +
and O +
T O +
cells O +
were O +
prepared O +
from O +
patients O +
with O +
SLE O +
( O +
n O +
= O +
6 O +
) O +
and O +
healthy O +
donors O +
( O +
n O +
= O +
8 O +
) O +
. O +

T O +
cells O +
were O +
separated O +
into O +
CD4 O +
and O +
CD8 O +
. O +

Some O +
monocytes O +
and O +
T O +
cells O +
were O +
stimulated O +
with O +
estradiol O +
, O +
PMA O +
, O +
and O +
ionomycin O +
. O +

Epstein O -
- O -
Barr O +
virus O -
- O -
transformed O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
( O +
n O +
= O +
7 O +
) O +
and O +
B B-CellLine +
cell I-CellLine +
hybridomas I-CellLine +
( O +
n O +
= O +
2 O +
) O +
established O +
from O +
patients O +
with O +
SLE O +
and O +
a O +
healthy O +
individual O +
were O +
used O +
as O +
a O +
B O +
cell O +
source O +
. O +

These O +
cells O +
were O +
examined O +
for O +
ER O +
mRNA O +
by O +
reverse O +
transcription O +
nested O +
polymerase O +
chain O +
reaction O +
. O +

Amplified O +
cDNA O +
were O +
sequenced O +
by O +
standard O +
methods O +
. O +

RESULTS O +
: O +
In O +
all O +
cells O +
tested O +
, O +
ER O +
mRNA O +
was O +
expressed O +
without O +
prior O +
in O +
vitro O +
stimulation O +
. O +

Partial O +
sequences O +
from O +
exons O +
1 O -
- O -
8 O +
were O +
nearly O +
identical O +
to O +
the O +
published O +
sequence O +
of O +
the O +
human O +
ER O +
mRNA O +
. O +

There O +
were O +
no O +
notable O +
differences O +
in O +
the O +
ER O +
transcripts O +
between O +
patients O +
and O +
healthy O +
controls O +
. O +

Variant O +
receptor O +
transcripts O +
lacking O +
exon O +
5 O +
or O +
exon O +
7 O +
, O +
which O +
encodes O +
the O +
hormone O +
binding O +
domain O +
, O +
were O +
identified O +
in O +
the O +
majority O +
of O +
the O +
cells O +
. O +

Precise O +
deletion O +
of O +
the O +
exons O +
suggests O +
that O +
they O +
are O +
alternatively O +
spliced O +
transcripts O +
. O +

Whether O +
the O +
detected O +
transcripts O +
are O +
translated O +
into O +
functional O +
receptor O +
proteins O +
remains O +
to O +
be O +
determined O +
. O +

In O +
vitro O +
stimulation O +
did O +
not O +
affect O +
ER O +
mRNA O +
expression O +
. O +

The O +
presence O +
of O +
variants O +
did O +
not O +
correlate O +
with O +
disease O +
activity O +
or O +
medication O +
. O +

CONCLUSION O +
: O +
Monocytes O +
, O +
T O +
cells O +
, O +
and O +
B O +
cells O +
in O +
patients O +
express O +
transcripts O +
of O +
the O +
normal O +
wild O +
type O +
ER O +
and O +
the O +
hormone O +
binding O +
domain O +
variants O +
in O +
vivo O +
. O +

A O +
novel O +
retinoic O +
acid O +
receptor O +
( O +
RAR O +
) O +
-selective O +
antagonist O +
inhibits O +
differentiation O +
and O +
apoptosis O +
of O +
HL-60 B-CellLine +
cells I-CellLine +
: O +
implications O +
of O +
RARalpha O +
-mediated O +
signals O +
in O +
myeloid O +
leukemic O +
cells O +
. O +

Retinoic O +
acid O +
( O +
RA O +
) O +
induces O +
HL-60 B-CellLine +
cells I-CellLine +
to O +
differentiate O +
terminally O +
into O +
mature O +
granulocytes O +
, O +
which O +
subsequently O +
die O +
by O +
apoptosis O +
. O +

The O +
biological O +
effects O +
of O +
RA O +
are O +
mediated O +
by O +
two O +
distinct O +
families O +
of O +
transcription O +
factors O +
: O +
retinoic O +
acid O +
receptors O +
( O +
RARs O +
) O +
and O +
retinoid O +
X O +
receptors O +
( O +
RXRs O +
) O +
. O +

RARs O +
and O +
RXRs O +
form O +
heterodimers O +
and O +
regulate O +
retinoid O -
- O -
mediated O +
gene O +
expression O +
. O +

We O +
have O +
recently O +
developed O +
a O +
novel O +
RAR O +
-selective O +
antagonist O +
( O +
ER27191 O +
) O +
which O +
prevents O +
RAR O +
activation O +
by O +
retinoids O +
. O +

Using O +
this O +
RAR O -
- O -
selective O +
antagonist O +
, O +
and O +
RXR O +
and O +
RAR O +
agonist O +
, O +
we O +
demonstrate O +
the O +
RAR O +
-mediated O +
signaling O +
pathway O +
is O +
important O +
for O +
differentiation O +
and O +
apoptosis O +
of O +
myeloid O +
leukemic O +
cells O +
. O +

Simple O +
activation O +
of O +
RXRs O +
is O +
not O +
sufficient O +
to O +
induce O +
apoptosis O +
of O +
the O +
cells O +
. O +

Interestingly O +
, O +
the O +
combination O +
of O +
the O +
RAR O -
- O -
selective O +
antagonist O +
and O +
9-cis O +
RA O +
resulted O +
in O +
partial O +
differentiation O +
and O +
apoptosis O +
of O +
HL-60 B-CellLine +
and I-CellLine +
NB4 I-CellLine +
cells I-CellLine +
, O +
whereas O +
the O +
RAR O +
antagonist O +
completely O +
blocked O +
all O -
- O -
trans O +
RA O -
- O -
induced O +
differentiation O +
and O +
apoptosis O +
of O +
the O +
cells O +
. O +

Additional O +
experiments O +
showed O +
that O +
levels O +
of O +
BCL-2 O +
protein O +
decreased O +
during O +
differentiation O +
of O +
myeloid O +
leukemic O +
cells O +
. O +

Furthermore O +
, O +
HL-60 B-CellLine +
cells I-CellLine +
transduced O +
with O +
a O +
bcl-2 O +
expression O +
vector O +
showed O +
the O +
same O +
differentiation O +
response O +
to O +
retinoids O +
as O +
did O +
parental B-CellLine +
HL-60 I-CellLine +
cells I-CellLine +
even O +
though O +
apoptosis O +
was O +
inhibited O +
in O +
these O +
bcl-2-transduced B-CellLine +
cells I-CellLine +
, O +
suggesting O +
that O +
differentiation O +
and O +
apoptosis O +
are O +
regulated O +
independently O +
in O +
myeloid O +
leukemic O +
cells O +
. O +

Expression O +
of O +
gamma O -
- O -
IFN O +
responsive O +
genes O +
in O +
scavenger O +
receptor O +
over O -
- O -
expressing O +
monocytes O +
is O +
associated O +
with O +
xanthomatosis O +
. O +

We O +
have O +
recently O +
described O +
an O +
inherited O +
over O -
- O -
expression O +
of O +
the O +
macrophage O +
scavenger O +
receptor O +
( O +
SR O +
) O +
in O +
blood O +
monocytes O +
from O +
members O +
of O +
a O +
kindred O +
, O +
only O +
two O +
of O +
whom O +
displayed O +
extensive O +
xanthomatosis O +
. O +

Using O +
mRNA O +
differential O +
display O +
we O +
demonstrated O +
abnormally O +
high O +
expression O +
of O +
the O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
( O +
STAT1alpha O +
) O +
in O +
monocytes O +
from O +
the O +
proband B-CellLine +
II-2 I-CellLine +
. O +

Expression O +
of O +
gamma O -
- O -
interferon O +
inducible O +
protein O +
10 O +
( O +
IP-10 O +
) O +
, O +
a O +
STAT1alpha O -
- O -
responsive O +
gene O +
and O +
mediator O +
of O +
inflammatory O +
response O +
, O +
was O +
also O +
abnormally O +
expressed O +
in O +
the O +
monocytes O +
from O +
II-2 B-CellLine +
. O +

Over O -
- O -
expression O +
of O +
both O +
genes O +
was O +
restricted O +
to O +
monocytes O +
from O +
II-2 B-CellLine +
and O +
was O +
not O +
observed O +
in O +
monocytes O +
from O +
the O +
clinically O +
unaffected O +
family O +
members O +
, O +
unlike O +
that O +
of O +
SR O +
. O +

Gel O +
retardation O +
assays O +
with O +
THP-1 B-CellLine +
cell I-CellLine +
extracts O +
identified O +
gamma O -
- O -
IFN O +
inducible O +
DNA O +
binding O +
activity O +
to O +
three O +
potential O +
STATI O +
DNA O +
binding O +
elements O +
in O +
the O +
human O +
IP-10 O +
promoter O +
region O +
from O +
nucleotides O +
- O +
245 O +
to O +
- O +
188 O +
. O +

Taken O +
together O +
these O +
results O +
suggest O +
that O +
gamma O -
- O -
interferon O +
mediated O +
cell O +
activation O +
is O +
responsible O +
for O +
STAT1alpha O +
-induced O +
transcription O +
of O +
the O +
IP-10 O +
gene O +
in O +
THP-1 B-CellLine +
macrophages I-CellLine +
as O +
well O +
as O +
in O +
monocytes O +
from O +
II-2 B-CellLine +
. O +

Analysis O +
of O +
monocytes O +
from O +
familial O +
hypercholesterolemic O +
( O +
FH O +
) O +
subjects O +
, O +
who O +
frequently O +
develop O +
xanthomatosis O +
, O +
revealed O +
a O +
significant O +
number O +
of O +
subjects O +
with O +
elevated O +
STAT1alpha O +
and O +
IP-10 O +
expression O +
. O +

Our O +
data O +
suggest O +
that O +
the O +
inflammatory O +
effects O +
of O +
gamma O -
- O -
IFN O +
signaling O +
could O +
play O +
a O +
role O +
in O +
foam O +
cell O +
formation O +
and O +
xanthomatosis O +
. O +

Ciprofloxacin O +
induces O +
an O +
immunomodulatory O +
stress O +
response O +
in O +
human O +
T O +
lymphocytes O +
. O +

Exposure O +
of O +
cells O +
to O +
adverse O +
environmental O +
conditions O +
invokes O +
a O +
genetically O +
programmed O +
series O +
of O +
events O +
resulting O +
in O +
the O +
induction O +
of O +
specific O +
genes O +
. O +

The O +
fluoroquinolone O +
antibiotic O +
ciprofloxacin O +
has O +
recently O +
been O +
reported O +
to O +
upregulate O +
interleukin-2 O +
( O +
IL-2 O +
) O +
gene O +
induction O +
. O +

In O +
the O +
present O +
investigation O +
, O +
the O +
effect O +
of O +
ciprofloxacin O +
at O +
supratherapeutic O +
concentrations O +
on O +
immediate O -
- O -
early O +
( O +
< O +
2 O +
h O +
) O +
gene O +
expression O +
in O +
primary O +
human O +
peripheral O +
blood O +
lymphocytes O +
was O +
studied O +
with O +
Northern O +
blots O +
. O +

In O +
addition O +
, O +
transcriptional O +
activity O +
of O +
IL-2 O +
and O +
metallothionein O +
enhancer O +
and O +
promoter O +
regions O +
and O +
transcription O +
factors O +
AP-1 O +
, O +
NF O -
- O -
kappaB O +
, O +
and O +
NF O -
- O -
AT O +
were O +
analyzed O +
by O +
chloramphenicol O +
acetyltransferase O +
( O +
CAT O +
) O +
and O +
electrophoretic O +
mobility O +
shift O +
assays O +
, O +
respectively O +
. O +

The O +
concentration O +
of O +
c O -
- O -
fos O +
, O +
c O -
- O -
jun O +
, O +
c O -
- O -
myc O +
, O +
junB O +
, O +
and O +
fra-1 O +
mRNAs O +
was O +
increased O +
in O +
activated O +
peripheral O +
blood O +
lymphocytes O +
incubated O +
with O +
ciprofloxacin O +
compared O +
to O +
that O +
in O +
untreated O +
controls O +
. O +

Ciprofloxacin O +
increased O +
CAT O +
activity O +
in O +
stimulated O +
lymphocytes O +
transfected O +
with O +
plasmids O +
containing O +
either O +
the O +
IL-2 O +
or O +
metallothionein O +
enhancer O +
. O +

Furthermore O +
, O +
among O +
the O +
transcription O +
factors O +
tested O +
, O +
AP-1 O +
activity O +
was O +
increased O +
in O +
stimulated O +
purified O +
T O +
helper O +
lymphocytes O +
incubated O +
with O +
ciprofloxacin O +
compared O +
to O +
drug O -
- O -
free O +
controls O +
. O +

Taken O +
together O +
, O +
ciprofloxacin O +
increased O +
the O +
levels O +
of O +
immediate O -
- O -
early O +
transcripts O +
, O +
enhanced O +
IL-2 O +
and O +
metallothionein O +
promoter O +
induction O +
, O +
and O +
upregulated O +
AP-1 O +
concentrations O +
in O +
primary O +
lymphocytes O +
, O +
reflecting O +
a O +
program O +
commonly O +
observed O +
in O +
mammalian O +
stress O +
responses O +
. O +

Human O +
15-lipoxygenase O +
gene O +
promoter O +
: O +
analysis O +
and O +
identification O +
of O +
DNA O +
binding O +
sites O +
for O +
IL-13-induced O +
regulatory O +
factors O +
in O +
monocytes O +
. O +

In O +
order O +
to O +
study O +
the O +
transcriptional O +
control O +
of O +
15-LO O +
expression O +
, O +
we O +
have O +
cloned O +
and O +
sequenced O +
the O +
human O +
15-LO O +
promoter O +
region O +
. O +

The O +
15-LO O +
promoter O +
is O +
associated O +
with O +
a O +
CpG O +
island O +
at O +
the O +
5'-end O +
of O +
the O +
gene O +
, O +
and O +
sequence O +
analysis O +
reveals O +
putative O +
Sp1 O +
and O +
Ap2 O +
binding O +
site O -
/ O -
s O +
and O +
absence O +
of O +
TATA O +
or O +
CAAT O +
motifs O +
. O +

Transcription O +
is O +
initiated O +
at O +
one O +
major O +
site O +
. O +

Using O +
deletion O +
constructs O +
, O +
we O +
have O +
defined O +
an O +
active O +
promoter O +
region O +
of O +
1056 O +
bp O +
. O +

Gel O -
- O -
shift O +
assays O +
revealed O +
that O +
transcriptional O +
factor O +
( O +
s O +
) O +
induced O +
only O +
in O +
response O +
to O +
IL-13 O +
treatment O +
of O +
human O +
peripheral O +
blood O +
monocytes O +
bind O +
to O +
the O +
15-LO O +
promoter O +
DNA O +
. O +

Two O +
regions O +
, O +
DP1 O +
( O +
-140 O +
to O +
-92 O +
bp O +
) O +
and O +
DP2 O +
( O +
-353 O +
to O +
-304 O +
bp O +
) O +
of O +
the O +
promoter O +
were O +
essential O +
for O +
transcription O +
in O +
HeLa B-CellLine +
cells I-CellLine +
and O +
human O +
peripheral O +
monocytes O +
. O +

Hela O +
nuclear O +
extracts O +
contained O +
a O +
specific O +
nuclear O +
factor O +
( O +
s O +
) O +
binding O +
to O +
15-LO O +
promoter O +
DNA O +
which O +
are O +
distinct O +
from O +
those O +
derived O +
from O +
IL-13-treated B-CellLine +
human I-CellLine +
peripheral I-CellLine +
monocyte I-CellLine +
nuclear O +
extracts O +
. O +

In O +
addition O +
, O +
fluorescent O +
in O +
situ O +
hybridization O +
( O +
FISH O +
) O +
results O +
refined O +
the O +
previous O +
localization O +
of O +
15-LO O +
to O +
human O +
chromosome O +
17p13.3 O +
. O +

Changes O +
in O +
PKC O +
isoforms O +
in O +
human O +
alveolar O +
macrophages O +
compared O +
with O +
blood O +
monocytes O +
. O +

Alveolar O +
macrophages O +
play O +
an O +
important O +
role O +
in O +
host O +
defense O +
and O +
in O +
other O +
types O +
of O +
inflammatory O +
processes O +
in O +
the O +
lung O +
. O +

These O +
cells O +
exhibit O +
many O +
alterations O +
in O +
function O +
compared O +
with O +
their O +
precursor O +
cells O +
, O +
blood O +
monocytes O +
. O +

To O +
evaluate O +
a O +
potential O +
mechanism O +
for O +
these O +
differences O +
in O +
function O +
, O +
we O +
evaluated O +
expression O +
of O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
isoforms O +
. O +

We O +
found O +
an O +
increase O +
in O +
Ca2 O -
+ O -
-dependent O +
PKC O +
isoforms O +
in O +
monocytes O +
compared O +
with O +
alveolar O +
macrophages O +
. O +

We O +
also O +
found O +
differential O +
expression O +
of O +
the O +
Ca2 O -
+ O -
-independent O +
isoforms O +
in O +
alveolar O +
macrophages O +
compared O +
with O +
monocytes O +
. O +

One O +
consequence O +
of O +
the O +
activation O +
of O +
PKC O +
can O +
be O +
increased O +
expression O +
of O +
mitogen O -
- O -
activated O +
protein O +
( O +
MAP O +
) O +
kinase O +
pathways O +
. O +

Therefore O +
, O +
we O +
also O +
evaluated O +
activation O +
of O +
the O +
MAP O +
kinase O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
( O +
ERK O +
) O +
2 O +
by O +
the O +
phorbol O +
ester O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
. O +

PMA O +
activated O +
ERK2 O +
kinase O +
in O +
both O +
alveolar O +
macrophages O +
and O +
monocytes O +
; O +
however O +
, O +
monocytes O +
consistently O +
showed O +
a O +
significantly O +
greater O +
activation O +
of O +
ERK2 O +
kinase O +
by O +
PMA O +
compared O +
with O +
alveolar O +
macrophages O +
. O +

Another O +
known O +
consequence O +
of O +
the O +
activation O +
of O +
PKC O +
and O +
subsequent O +
activation O +
of O +
ERK O +
kinase O +
is O +
activation O +
of O +
the O +
transcription O +
factor O +
activator O +
protein-1 O +
( O +
AP-1 O +
) O +
. O +

We O +
evaluated O +
the O +
activation O +
of O +
AP-1 O +
by O +
PMA O +
in O +
both O +
monocytes O +
and O +
macrophages O +
. O +

We O +
found O +
very O +
little O +
detectable O +
activation O +
of O +
AP-1 O +
, O +
as O +
assessed O +
in O +
a O +
gel O +
shift O +
assay O +
, O +
in O +
alveolar O +
macrophages O +
, O +
whereas O +
monocytes O +
showed O +
a O +
substantial O +
activation O +
of O +
AP-1 O +
by O +
PMA O +
. O +

These O +
studies O +
show O +
that O +
the O +
differential O +
expression O +
of O +
PKC O +
isoforms O +
in O +
alveolar O +
macrophages O +
and O +
blood O +
monocytes O +
is O +
associated O +
with O +
important O +
functional O +
alterations O +
in O +
the O +
cells O +
. O +

Dimethyldithiocarbamate O +
inhibits O +
in O +
vitro O +
activation O +
of O +
primary O +
human O +
CD4 O -
+ O +
T O +
lymphocytes O +
. O +

Dithiocarbamates O +
( O +
DTC O +
) O +
, O +
a O +
diverse O +
group O +
of O +
industrial O +
and O +
therapeutic O +
chemicals O +
, O +
have O +
been O +
reported O +
to O +
inhibit O +
, O +
enhance O +
or O +
have O +
no O +
effect O +
on O +
the O +
immune O +
system O +
. O +

These O +
apparent O +
inconsistencies O +
reflect O +
the O +
complexity O +
of O +
the O +
DTCs O +
biological O +
activities O +
and O +
are O +
probably O +
due O +
in O +
part O +
to O +
differences O +
in O +
dose O +
, O +
route O +
of O +
exposure O +
, O +
animal O +
species O +
used O +
and/or O +
specific O +
compound O +
tested O +
. O +

The O +
studies O +
described O +
herein O +
were O +
undertaken O +
to O +
investigate O +
the O +
immunotoxicity O +
of O +
one O +
member O +
of O +
this O +
family O +
, O +
dimethyldithiocarbamate O +
( O +
DMDTC O +
) O +
. O +

We O +
demonstrate O +
that O +
0.1 O -
- O -
0.5 O +
microM O +
DMDTC O +
inhibits O +
TNF O -
- O -
alpha O +
-induced O +
activation O +
of O +
NF O -
- O -
kappaB O +
in O +
primary O +
human O +
CD4 O -
+ O +
T O +
cells O +
. O +

This O +
inhibition O +
is O +
not O +
accompanied O +
by O +
a O +
loss O +
in O +
viability O +
, O +
and O +
DMDTC O -
- O -
treated O +
T O +
cells O +
retain O +
other O +
active O +
signaling O +
pathways O +
throughout O +
the O +
exposure O +
duration O +
. O +

The O +
inhibition O +
of O +
NF O -
- O -
kappaB O +
is O +
apparently O +
permanent O +
as O +
DMDTC O -
- O -
treated O +
T O +
cells O +
did O +
not O +
regain O +
normal O +
TNF O -
- O -
alpha O +
activation O +
, O +
even O +
after O +
72 O +
h O +
in O +
culture O +
. O +

DMDTC O +
does O +
not O +
appear O +
to O +
alter O +
NF O -
- O -
kappaB O +
directly O +
as O +
pre O -
- O -
incubation O +
of O +
nuclear O +
extracts O +
with O +
DMDTC O +
does O +
not O +
diminish O +
binding O +
activity O +
of O +
this O +
protein O +
. O +

We O +
further O +
demonstrate O +
that O +
0.1 O -
- O -
0.5 O +
microM O +
DMDTC O +
inhibits O +
intracellular O +
IL-2 O +
production O +
and O +
decreases O +
surface O +
expression O +
of O +
CD25 O +
( O +
the O +
alpha O +
subunit O +
of O +
the O +
IL-2 O +
receptor O +
) O +
in O +
T O +
cells O +
stimulated O +
with O +
phorbol O +
ester O +
. O +

These O +
data O +
demonstrate O +
that O +
DMDTC O +
is O +
a O +
potent O +
immunosuppressive O +
compound O +
in O +
vitro O +
. O +

A O +
regulatory O +
element O +
in O +
the O +
CD95 O +
( O +
APO-1 O -
/ O -
Fas O +
) O +
ligand O +
promoter O +
is O +
essential O +
for O +
responsiveness O +
to O +
TCR O +
-mediated O +
activation O +
. O +

Expression O +
of O +
the O +
CD95 O +
( O +
APO-1 O -
/ O -
Fas O +
) O +
ligand O +
( O +
CD95L O +
) O +
in O +
activated O +
T O +
cells O +
is O +
a O +
major O +
cause O +
of O +
T O +
cell O +
activation O -
- O -
induced O +
apoptosis O +
. O +

To O +
study O +
the O +
molecular O +
mechanisms O +
of O +
transcriptional O +
control O +
of O +
CD95L O +
expression O +
in O +
T O +
cells O +
, O +
we O +
investigated O +
the O +
human O +
CD95L O +
promoter O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Deletion O +
studies O +
revealed O +
that O +
the O +
CD95L O +
proximal O +
promoter O +
sequence O +
from O +
-220 O +
to O +
the O +
transcription O +
start O +
site O +
is O +
essential O +
for O +
T O +
cell O +
stimulation O -
- O -
induced O +
expression O +
of O +
CD95L O +
. O +

In O +
this O +
study O +
, O +
we O +
discovered O +
a O +
novel O +
regulatory O +
element O +
located O +
at O +
-120 O +
of O +
the O +
CD95L O +
promoter O +
which O +
contains O +
DNA O +
binding O +
sites O +
for O +
SP-1 O +
and O +
a O +
yet O +
unknown O +
inducible O +
factor O +
. O +

Mutation O +
analysis O +
demonstrated O +
that O +
binding O +
of O +
the O +
inducible O +
factor O +
to O +
the O +
-120 O +
region O +
is O +
crucial O +
for O +
the O +
biological O +
function O +
of O +
the O +
CD95L O +
promoter O +
upon O +
T O +
cell O +
stimulation O +
. O +

The O +
DNA O +
sequence O +
at O +
-120 O +
also O +
contains O +
two O +
DNA O +
motifs O +
homologous O +
to O +
the O +
binding O +
site O +
for O +
NF O -
- O -
AT O +
. O +

NF O -
- O -
AT O +
does O +
not O +
directly O +
bind O +
to O +
this O +
element O +
. O +

However O +
, O +
cotransfection O +
studies O +
with O +
an O +
NF O -
- O -
AT O +
expression O +
vector O +
showed O +
that O +
NF O -
- O -
AT O +
may O +
confer O +
a O +
strong O +
inducible O +
activity O +
to O +
the O +
CD95L O +
promoter O +
at O +
this O +
regulatory O +
region O +
. O +

Our O +
data O +
also O +
show O +
that O +
the O +
immunosuppressive O +
agent O +
cyclosporin O +
A O +
down O -
- O -
regulates O +
CD95L O +
transcription O +
by O +
inhibiting O +
the O +
function O +
of O +
this O +
positive O +
regulatory O +
element O +

Acetylation O +
and O +
modulation O +
of O +
erythroid O +
Kruppel O -
- O -
like O +
factor O +
( O +
EKLF O +
) O +
activity O +
by O +
interaction O +
with O +
histone O +
acetyltransferases O +
. O +

Erythroid O +
Kruppel O -
- O -
like O +
factor O +
( O +
EKLF O +
) O +
is O +
a O +
red O +
cell O -
- O -
specific O +
transcriptional O +
activator O +
that O +
is O +
crucial O +
for O +
consolidating O +
the O +
switch O +
to O +
high O +
levels O +
of O +
adult O +
beta O -
- O -
globin O +
expression O +
during O +
erythroid O +
ontogeny O +
. O +

EKLF O +
is O +
required O +
for O +
integrity O +
of O +
the O +
chromatin O +
structure O +
at O +
the O +
beta O -
- O -
like O +
globin O +
locus O +
, O +
and O +
it O +
interacts O +
with O +
a O +
positive O -
- O -
acting O +
factor O +
in O +
vivo O +
. O +

We O +
find O +
that O +
EKLF O +
is O +
an O +
acetylated O +
transcription O +
factor O +
, O +
and O +
that O +
it O +
interacts O +
in O +
vivo O +
with O +
CBP O +
, O +
p300 O +
, O +
and O +
P O -
/ O -
CAF O +
. O +

However O +
, O +
its O +
interactions O +
with O +
these O +
histone O +
acetyltransferases O +
are O +
not O +
equivalent O +
, O +
as O +
CBP O +
and O +
p300 O +
, O +
but O +
not O +
P O -
/ O -
CAF O +
, O +
utilize O +
EKLF O +
as O +
a O +
substrate O +
for O +
in O +
vitro O +
acetylation O +
within O +
its O +
trans O -
- O -
activation O +
region O +
. O +

The O +
functional O +
effects O +
of O +
these O +
interactions O +
are O +
that O +
CBP O +
and O +
p300 O +
, O +
but O +
not O +
P O -
/ O -
CAF O +
, O +
enhance O +
EKLF O +
's O +
transcriptional O +
activation O +
of O +
the O +
beta O -
- O -
globin O +
promoter O +
in O +
erythroid O +
cells O +
. O +

These O +
results O +
establish O +
EKLF O +
as O +
a O +
tissue O -
- O -
specific O +
transcription O +
factor O +
that O +
undergoes O +
post O -
- O -
translational O +
acetylation O +
and O +
suggest O +
a O +
mechanism O +
by O +
which O +
EKLF O +
is O +
able O +
to O +
alter O +
chromatin O +
structure O +
and O +
induce O +
beta O -
- O -
globin O +
expression O +
within O +
the O +
beta O -
- O -
like O +
globin O +
cluster O +
. O +

Epstein O -
- O -
Barr O +
virus O -
- O -
transforming O +
protein O +
latent O +
infection O +
membrane O +
protein O +
1 O +
activates O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
through O +
a O +
pathway O +
that O +
includes O +
the O +
NF O -
- O -
kappaB O -
- O -
inducing O +
kinase O +
and O +
the O +
IkappaB O +
kinases O +
IKKalpha O +
and O +
IKKbeta O +
. O +

The O +
Epstein O -
- O -
Barr O +
virus O +
oncoprotein O +
latent O +
infection O +
membrane O +
protein O +
1 O +
( O +
LMP1 O +
) O +
is O +
a O +
constitutively O +
aggregated O +
pseudo O -
- O -
tumor O +
necrosis O +
factor O +
receptor O +
( O +
TNFR O +
) O +
that O +
activates O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
through O +
two O +
sites O +
in O +
its O +
C O -
- O -
terminal O +
cytoplasmic O +
domain O +
. O +

One O +
site O +
is O +
similar O +
to O +
activated O +
TNFRII O +
in O +
associating O +
with O +
TNFR O -
- O -
associated O +
factors O +
TRAF1 O +
and O +
TRAF2 O +
, O +
and O +
the O +
second O +
site O +
is O +
similar O +
to O +
TNFRI O +
in O +
associating O +
with O +
the O +
TNFRI O +
death O +
domain O +
interacting O +
protein O +
TRADD O +
. O +

TNFRI O +
has O +
been O +
recently O +
shown O +
to O +
activate O +
NF O -
- O -
kappaB O +
through O +
association O +
with O +
TRADD O +
, O +
RIP O +
, O +
and O +
TRAF2 O +
; O +
activation O +
of O +
the O +
NF O -
- O -
kappaB O -
- O -
inducing O +
kinase O +
( O +
NIK O +
) O +
; O +
activation O +
of O +
the O +
IkappaB O +
alpha O +
kinases O +
( O +
IKKalpha O +
and O +
IKKbeta O +
) O +
; O +
and O +
phosphorylation O +
of O +
IkappaB O +
alpha O +
. O +

IkappaB O +
alpha O +
phosphorylation O +
on O +
Ser-32 O +
and O +
Ser-36 O +
is O +
followed O +
by O +
its O +
degradation O +
and O +
NF O -
- O -
kappaB O +
activation O +
. O +

In O +
this O +
report O +
, O +
we O +
show O +
that O +
NF O -
- O -
kappaB O +
activation O +
by O +
LMP1 O +
or O +
by O +
each O +
of O +
its O +
effector O +
sites O +
is O +
mediated O +
by O +
a O +
pathway O +
that O +
includes O +
NIK O +
, O +
IKKalpha O +
, O +
and O +
IKKbeta O +
. O +

Dominant O +
negative O +
mutants O +
of O +
NIK O +
, O +
IKKalpha O +
, O +
or O +
IKKbeta O +
substantially O +
inhibited O +
NF O -
- O -
kappaB O +
activation O +
by O +
LMP1 O +
or O +
by O +
each O +
of O +
its O +
effector O +
sites O +
. O +

Class O +
II O +
transactivator O -
- O -
independent O +
endothelial O +
cell O +
MHC O +
class O +
II O +
gene O +
activation O +
induced O +
by O +
lymphocyte O +
adhesion O +
. O +

NK O +
cells O +
induce O +
MHC O +
class O +
II O +
molecules O +
on O +
the O +
surface O +
of O +
allogeneic O +
endothelial O +
cells O +
in O +
an O +
adhesion O -
- O -
dependent O +
, O +
IFN O -
- O -
gamma O +
-independent O +
manner O +
. O +

Here O +
, O +
we O +
demonstrate O +
that O +
NK B-CellLine +
cells I-CellLine +
induce O +
HLA O -
- O -
DR O +
on O +
the O +
surface O +
of O +
a O +
mutant B-CellLine +
cell I-CellLine +
line I-CellLine +
that O +
is O +
defective O +
in O +
IFN O -
- O -
gamma O +
-induced O +
MHC O +
class O +
II O +
expression O +
. O +

RNA O +
analysis O +
in O +
these O +
cells O +
and O +
in O +
a O +
cell O +
line O +
that O +
is O +
defective O +
in O +
class O +
II O +
transactivator O +
( O +
CIITA O +
) O +
demonstrates O +
that O +
NK O +
cell O -
- O -
induced O +
HLA O -
- O -
DR O +
alpha O +
mRNA O +
expression O +
is O +
also O +
CIITA O +
-independent O +
. O +

The O +
Janus B-CellLine +
kinase-1-deficient I-CellLine +
cell I-CellLine +
line I-CellLine +
U4A I-CellLine +
expresses O +
HLA O -
- O -
DR O +
alpha O +
mRNA O +
in O +
response O +
to O +
NK O +
cell O +
activation O +
, O +
and O +
HLA O -
- O -
DR O +
alpha O +
promoter O +
constructs O +
transfected O +
into O +
these O +
cells O +
are O +
induced O +
by O +
NK B-CellLine +
cells I-CellLine +
but O +
not O +
IFN O -
- O -
gamma O +
. O +

These O +
data O +
indicate O +
that O +
the O +
IFN O -
- O -
gamma O +
-independent O +
component O +
of O +
the O +
target O +
cell O +
HLA O -
- O -
DR O +
expression O +
induced O +
by O +
lymphocyte O +
adhesion O +
uses O +
a O +
signaling O +
pathway O +
that O +
is O +
distinct O +
from O +
the O +
IFN O -
- O -
gamma O +
-dependent O +
mechanism O +
and O +
also O +
suggest O +
that O +
CIITA O +
is O +
not O +
required O +
. O +

Cyclosporin O +
A O -
- O -
resistant O +
transactivation O +
of O +
the O +
IL-2 O +
promoter O +
requires O +
activity O +
of O +
okadaic O +
acid O -
- O -
sensitive O +
serine O -
/ O -
threonine O +
phosphatases O +
. O +

Expression O +
of O +
the O +
IL-2 O +
gene O +
requires O +
activation O +
of O +
T O +
cells O +
through O +
stimulation O +
of O +
the O +
TCR O +
and O +
costimulation O +
through O +
accessory O +
receptors O +
. O +

We O +
have O +
found O +
recently O +
that O +
okadaic O +
acid O -
- O -
sensitive O +
Ser O -
/ O -
Thr O +
phosphatases O +
are O +
involved O +
in O +
a O +
cyclosporin O +
A O -
- O -
insensitive O +
pathway O +
that O +
selectively O +
transmits O +
costimulatory O +
signals O +
. O +

In O +
this O +
study O +
, O +
we O +
analyzed O +
whether O +
activities O +
of O +
these O +
phosphatases O +
are O +
necessary O +
for O +
the O +
expression O +
of O +
the O +
IL-2 O +
gene O +
. O +

In O +
both O +
activated O +
peripheral O +
blood O +
T O +
lymphocytes O +
and O +
activated B-CellLine +
tumorigenic I-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
IL-2 O +
gene O +
expression O +
was O +
blocked O +
at O +
the O +
transcriptional O +
level O +
by O +
okadaic O +
acid O +
. O +

The O +
transcription O +
factors O +
active O +
at O +
the O +
IL-2 O +
promoter O +
were O +
differentially O +
influenced O +
: O +
upon O +
down O -
- O -
modulation O +
of O +
okadaic O +
acid O -
- O -
sensitive O +
phosphatases O +
, O +
transactivation O +
by O +
octamer O +
, O +
NF O -
- O -
kappa O +
B O +
, O +
and O +
NF O +
of O +
activated O +
T O +
cells O +
proteins O +
was O +
abrogated O +
, O +
while O +
transactivation O +
by O +
AP-1 O +
proteins O +
was O +
even O +
enhanced O +
. O +

Inducible O +
nitric O +
oxide O +
: O +
an O +
autoregulatory O +
feedback O +
inhibitor O +
of O +
vascular O +
inflammation O +
. O +

Inducible O +
nitric O +
oxide O +
( O +
iNO O +
) O +
is O +
produced O +
at O +
sites O +
of O +
vascular O +
inflammation O +
by O +
resident O +
and O +
nonresident O +
vascular O +
wall O +
cells O +
, O +
but O +
its O +
role O +
in O +
the O +
inflammatory O +
process O +
is O +
not O +
known O +
. O +

In O +
this O +
study O +
, O +
we O +
show O +
that O +
a O +
novel O +
function O +
of O +
iNO O +
is O +
to O +
terminate O +
inflammatory O +
processes O +
. O +

We O +
find O +
that O +
iNO O +
produced O +
by O +
murine B-CellLine +
macrophage I-CellLine -
- I-CellLine -
like I-CellLine +
cells I-CellLine +
, O +
RAW264.7 B-CellLine +
, O +
can O +
inhibit O +
cytokine O +
-induced O +
endothelial O +
cell O +
activation O +
in O +
a O +
separated O +
and O +
mixed O +
endothelial B-CellLine -
- I-CellLine -
RAW264.7 I-CellLine +
coculture I-CellLine +
system I-CellLine +
. O +

Both O +
iNO O +
production O +
and O +
endothelial O +
VCAM-1 O +
expression O +
were O +
induced O +
simultaneously O +
with O +
bacterial O +
LPS O +
and O +
murine O -
- O -
specific O +
IFN O -
- O -
gamma O +
. O +

Inhibition O +
of O +
iNO O +
synthase O +
( O +
iNOS O +
) O +
activity O +
with O +
N O +
omega O -
- O -
monomethyl O -
- O -
L O -
- O -
arginine O +
in O +
endothelial B-CellLine -
- I-CellLine -
RAW264.7 I-CellLine +
cocultures I-CellLine +
, O +
stimulated O +
with O +
murine O -
- O -
specific O +
IFN O -
- O -
gamma O +
and O +
LPS O +
, O +
decreased O +
iNO O +
production O +
by O +
86 O +
% O +
, O +
augmented O +
VCAM-1 O +
and O +
iNOS O +
expression O +
in O +
endothelial O +
and O +
RAW264.7 B-CellLine +
cells I-CellLine +
, O +
respectively O +
, O +
and O +
increased O +
monocyte O +
adhesion O +
to O +
the O +
endothelial O +
cell O +
surface O +
. O +

Transient O +
transfection O +
studies O +
using O +
various O +
VCAM-1 O +
promoter O +
constructs O +
demonstrated O +
that O +
inhibitory O +
effects O +
of O +
iNO O +
on O +
VCAM-1 O +
gene O +
transcription O +
were O +
mediated O +
, O +
in O +
part O +
, O +
by O +
inhibitory O +
effects O +
of O +
iNO O +
on O +
kappa O +
B O +
cis O -
- O -
acting O +
elements O +
. O +

Immunofluorescence O +
studies O +
using O +
an O +
Ab O +
to O +
the O +
RelA O +
( O +
p65 O +
) O +
subunit O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
revealed O +
that O +
iNO O +
inhibited O +
the O +
activation O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
. O +

These O +
studies O +
indicate O +
that O +
iNO O +
attenuates O +
iNOS O +
expression O +
in O +
macrophages O +
and O +
inhibits O +
monocyte O +
adhesion O +
to O +
endothelial O +
cells O +
, O +
and O +
suggest O +
that O +
endogenously O +
derived O +
iNO O +
may O +
be O +
an O +
important O +
autoregulatory O +
inhibitor O +
of O +
vascular O +
inflammation O +

Highly O +
polarized O +
HLA O +
class O +
II O +
antigen O +
processing O +
and O +
presentation O +
by O +
human O +
intestinal O +
epithelial O +
cells O +
. O +

The O +
high O +
concentration O +
of O +
foreign O +
antigen O +
in O +
the O +
lumen O +
of O +
the O +
gastrointestinal O +
tract O +
is O +
separated O +
from O +
the O +
underlying O +
lymphocytes O +
by O +
a O +
single O +
cell O +
layer O +
of O +
polarized O +
epithelium O +
. O +

Intestinal O +
epithelial O +
cells O +
can O +
express O +
HLA O +
class O +
II O +
antigens O +
and O +
may O +
function O +
as O +
antigen O -
- O -
presenting O +
cells O +
to O +
CD4 O +
( O +
+ O +
) O +
T O +
cells O +
within O +
the O +
intestinal O +
mucosa O +
. O +

Using O +
tetanus O +
toxoid O +
specific O +
and O +
HLA O -
- O -
DR O -
- O -
restricted O +
T O +
lymphocytes O +
, O +
we O +
show O +
that O +
polarized O +
intestinal O +
epithelial O +
cells O +
directed O +
to O +
express O +
HLA O -
- O -
DR O +
molecules O +
are O +
able O +
to O +
initiate O +
class O +
II O +
processing O +
only O +
after O +
internalization O +
of O +
antigen O +
from O +
their O +
apical O +
surface O +
. O +

Coexpression O +
of O +
the O +
class O +
II O +
transactivator O +
CIITA O +
in O +
these O +
cells O +
, O +
which O +
stimulates O +
highly O +
efficient O +
class O +
II O +
processing O +
without O +
the O +
characteristic O +
decline O +
in O +
barrier O +
function O +
seen O +
in O +
polarized O +
monolayers O +
treated O +
with O +
the O +
proinflammatory O +
cytokine O +
gamma O -
- O -
IFN O +
, O +
facilitates O +
antigen O +
processing O +
from O +
the O +
basolateral O +
surface O +
. O +

In O +
both O +
cases O +
, O +
peptide O +
presentation O +
to O +
T O +
cells O +
via O +
class O +
II O +
molecules O +
was O +
restricted O +
to O +
the O +
basolateral O +
surface O +
. O +

These O +
data O +
indicate O +
a O +
highly O +
polarized O +
functional O +
architecture O +
for O +
antigen O +
processing O +
and O +
presentation O +
by O +
intestinal O +
epithelial O +
cells O +
, O +
and O +
suggest O +
that O +
the O +
functional O +
outcome O +
of O +
antigen O +
processing O +
by O +
the O +
intestinal O +
epithelium O +
is O +
both O +
dependent O +
on O +
the O +
cellular O +
surface O +
at O +
which O +
the O +
foreign O +
antigen O +
is O +
internalized O +
and O +
by O +
the O +
underlying O +
degree O +
of O +
mucosal O +
inflammation O +

The O +
small O +
GTP O -
- O -
binding O +
protein O +
Rho O +
potentiates O +
AP-1 O +
transcription O +
in O +
T O +
cells O +
. O +

The O +
Rho O +
family O +
of O +
small O +
GTP O -
- O -
binding O +
proteins O +
is O +
involved O +
in O +
the O +
regulation O +
of O +
cytoskeletal O +
structure O +
, O +
gene O +
transcription O +
, O +
specific O +
cell O +
fate O +
development O +
, O +
and O +
transformation O +
. O +

We O +
demonstrate O +
in O +
this O +
report O +
that O +
overexpression O +
of O +
an O +
activated O +
form O +
of O +
Rho O +
enhances O +
AP-1 O +
activity O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
in O +
the O +
presence O +
of O +
phorbol O +
myristate O +
acetate O +
( O +
PMA O +
) O +
, O +
but O +
activated O +
Rho O +
( O +
V14Rho O +
) O +
has O +
little O +
or O +
no O +
effect O +
on O +
NFAT O +
, O +
Oct-1 O +
, O +
and O +
NF O -
- O -
kappaB O +
enhancer O +
element O +
activities O +
under O +
similar O +
conditions O +
. O +

Overexpression O +
of O +
a O +
V14Rho O +
construct O +
incapable O +
of O +
membrane O +
localization O +
( O +
CAAX O +
deleted O +
) O +
abolishes O +
PMA O -
- O -
induced O +
AP-1 O +
transcriptional O +
activation O +
. O +

The O +
effect O +
of O +
Rho O +
on O +
AP-1 O +
is O +
independent O +
of O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
pathway O +
, O +
as O +
a O +
dominant O -
- O -
negative O +
MEK O +
and O +
a O +
MEK O +
inhibitor O +
( O +
PD98059 O +
) O +
did O +
not O +
affect O +
Rho O +
-induced O +
AP-1 O +
activity O +
. O +

V14Rho O +
binds O +
strongly O +
to O +
protein O +
kinase O +
Calpha O +
( O +
PKCalpha O +
) O +
in O +
vivo O +
; O +
however O +
, O +
deletion O +
of O +
the O +
CAAX O +
site O +
on O +
V14Rho O +
severely O +
diminished O +
this O +
association O +
. O +

Evidence O +
for O +
a O +
role O +
for O +
PKCalpha O +
as O +
an O +
effector O +
of O +
Rho O +
was O +
obtained O +
by O +
the O +
observation O +
that O +
coexpression O +
of O +
the O +
N O -
- O -
terminal O +
domain O +
of O +
PKCalpha O +
blocked O +
the O +
effects O +
of O +
activated O +
Rho O +
plus O +
PMA O +
on O +
AP-1 O +
transcriptional O +
activity O +
. O +

These O +
data O +
suggest O +
that O +
Rho O +
potentiates O +
AP-1 O +
transcription O +
during O +
T O -
- O -
cell O +
activation O +

Human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
Tax O +
induction O +
of O +
NF O -
- O -
kappaB O +
involves O +
activation O +
of O +
the O +
IkappaB O +
kinase O +
alpha O +
( O +
IKKalpha O +
) O +
and O +
IKKbeta O +
cellular O +
kinases O +
. O +

Tax O +
corresponds O +
to O +
a O +
40-kDa O +
transforming O +
protein O +
from O +
the O +
pathogenic O +
retrovirus O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
( O +
HTLV-1 O +
) O +
that O +
activates O +
nuclear O +
expression O +
of O +
the O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
family O +
of O +
transcription O +
factors O +
by O +
an O +
unknown O +
mechanism O +
. O +

Tax O +
expression O +
promotes O +
N O -
- O -
terminal O +
phosphorylation O +
and O +
degradation O +
of O +
IkappaB O +
alpha O +
, O +
a O +
principal O +
cytoplasmic O +
inhibitor O +
of O +
NF O -
- O -
kappaB O +
. O +

Our O +
studies O +
now O +
demonstrate O +
that O +
HTLV-1 O +
Tax O +
activates O +
the O +
recently O +
identified O +
cellular O +
kinases O +
IkappaB O +
kinase O +
alpha O +
( O +
IKKalpha O +
) O +
and O +
IKKbeta O +
, O +
which O +
normally O +
phosphorylate O +
IkappaB O +
alpha O +
on O +
both O +
of O +
its O +
N O -
- O -
terminal O +
regulatory O +
serines O +
in O +
response O +
to O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
and O +
interleukin-1 O +
( O +
IL-1 O +
) O +
stimulation O +
. O +

In O +
contrast O +
, O +
a O +
mutant O +
of O +
Tax O +
termed O +
M22 O +
, O +
which O +
does O +
not O +
induce O +
NF O -
- O -
kappaB O +
, O +
fails O +
to O +
activate O +
either O +
IKKalpha O +
or O +
IKKbeta O +
. O +

Furthermore O +
, O +
endogenous O +
IKK O +
enzymatic O +
activity O +
was O +
significantly O +
elevated O +
in O +
HTLV-1-infected B-CellLine +
and I-CellLine +
Tax I-CellLine -
- I-CellLine -
expressing I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
. O +

Transfection O +
of O +
kinase O -
- O -
deficient O +
mutants O +
of O +
IKKalpha O +
and O +
IKKbeta O +
into O +
either O +
human B-CellLine +
Jurkat I-CellLine +
T I-CellLine +
or I-CellLine +
293 I-CellLine +
cells I-CellLine +
also O +
inhibits O +
NF O -
- O -
kappaB O +
-dependent O +
reporter O +
gene O +
expression O +
induced O +
by O +
Tax O +
. O +

Similarly O +
, O +
a O +
kinase O -
- O -
deficient O +
mutant O +
of O +
NIK O +
( O +
NF O -
- O -
kappaB O -
- O -
inducing O +
kinase O +
) O +
, O +
which O +
represents O +
an O +
upstream O +
kinase O +
in O +
the O +
TNF O -
- O -
alpha O +
and O +
IL-1 O +
signaling O +
pathways O +
leading O +
to O +
IKKalpha O +
and O +
IKKbeta O +
activation O +
, O +
blocks O +
Tax O +
induction O +
of O +
NF O -
- O -
kappaB O +
. O +

However O +
, O +
plasma O +
membrane O -
- O -
proximal O +
elements O +
in O +
these O +
proinflammatory O +
cytokine O +
pathways O +
are O +
apparently O +
not O +
involved O +
since O +
dominant O +
negative O +
mutants O +
of O +
the O +
TRAF2 O +
and O +
TRAF6 O +
adaptors O +
, O +
which O +
effectively O +
block O +
signaling O +
through O +
the O +
cytoplasmic O +
tails O +
of O +
the O +
TNF O -
- O -
alpha O +
and O +
IL-1 O +
receptors O +
, O +
respectively O +
, O +
do O +
not O +
inhibit O +
Tax O +
induction O +
of O +
NF O -
- O -
kappaB O +
. O +

Together O +
, O +
these O +
studies O +
demonstrate O +
that O +
HTLV-1 O +
Tax O +
exploits O +
a O +
distal O +
part O +
of O +
the O +
proinflammatory O +
cytokine O +
signaling O +
cascade O +
leading O +
to O +
induction O +
of O +
NF O -
- O -
kappaB O +
. O +

The O +
pathological O +
alteration O +
of O +
this O +
cytokine O +
pathway O +
leading O +
to O +
NF O -
- O -
kappaB O +
activation O +
by O +
Tax O +
may O +
play O +
a O +
central O +
role O +
in O +
HTLV-1-mediated O +
transformation O +
of O +
human O +
T O +
cells O +
, O +
clinically O +
manifested O +
as O +
the O +
adult O +
T O -
- O -
cell O +
leukemia O +

Inhibition O +
of O +
HIV-1 O +
replication O +
by O +
combination O +
of O +
a O +
novel O +
inhibitor O +
of O +
TNF O -
- O -
alpha O +
with O +
AZT O +
. O +

The O +
small O +
molecule O +
S9a O +
was O +
derived O +
from O +
an O +
established O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
inhibitor O +
( O +
Canventol O +
) O +
by O +
replacement O +
of O +
the O +
isopropylidine O +
group O +
with O +
a O +
phenyl O +
ring O +
. O +

S9a O +
at O +
10 O +
to O +
100 O +
nM O +
inhibited O +
HIV O +
production O +
as O +
potently O +
as O +
3'-azido-3'-deoxythymidine O +
( O +
AZT O +
) O +
, O +
an O +
inhibitor O +
of O +
viral O +
reverse O +
transcriptase O +
. O +

Furthermore O +
, O +
S9a O +
and O +
AZT O +
in O +
combination O +
, O +
at O +
noncytoxic O +
concentrations O +
strongly O +
inhibited O +
HIV-1 O +
replication O +
that O +
was O +
more O +
than O +
additive O +
and O +
substantially O +
prolonged O +
the O +
appearance O +
of O +
virus O +
both O +
in O +
acutely O +
infected O +
CD4 O -
+ O +
lymphocytes O +
( O +
SupT B-CellLine +
) O +
in O +
culture O +
and O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMCs O +
) O +
infected O +
with O +
a O +
primary O +
HIV-1 O +
isolate O +
. O +

S9a O +
inhibited O +
TNF O -
- O -
alpha O +
promoter O -
- O -
driven O +
reporter O +
gene O +
activity O +
. O +

It O +
was O +
proposed O +
that O +
the O +
mechanism O +
of O +
antiviral O +
action O +
of O +
S9a O +
was O +
on O +
the O +
host O +
cell O +
, O +
by O +
blocking O +
TNF O -
- O -
alpha O +
transcription O +
via O +
a O +
Tat O +
-induced O +
tar O -
- O -
independent O +
loop O +
, O +
which O +
decreases O +
downstream O +
NF O -
- O -
kappaB O +
activation O +
of O +
HIV-1 O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
. O +

S9a O +
was O +
superior O +
to O +
the O +
first O +
generation O +
compound O +
Canventol O +
, O +
which O +
was O +
superior O +
to O +
the O +
natural O +
compound O +
sarcophytol O +
A O +
, O +
demonstrating O +
that O +
further O +
structure O -
- O -
based O +
enhancement O +
of O +
potency O +
of O +
these O +
compounds O +
is O +
feasible O +
. O +

This O +
study O +
suggests O +
a O +
therapeutic O +
approach O +
against O +
AIDS O +
by O +
application O +
of O +
two O +
drugs O +
, O +
one O +
against O +
a O +
cellular O +
and O +
the O +
other O +
a O +
viral O +
target O +
, O +
which O +
may O +
provide O +
an O +
approach O +
to O +
the O +
problem O +
of O +
frequent O +
emergence O +
of O +
resistant O +
variants O +
to O +
combinations O +
of O +
drugs O +
that O +
target O +
only O +
HIV O +
genes O +
. O +

Specific O +
glucocorticoid O +
binding O +
at O +
different O +
levels O +
of O +
human O +
motor O +
activity O +
. O +

We O +
studied O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
and O +
dissociation O +
constant O +
in O +
isolated O +
human O +
lymphocytes O +
as O +
well O +
as O +
blood O +
concentrations O +
of O +
hormones O +
produced O +
by O +
the O +
hypothalamic O -
- O -
hypophyseal O -
- O -
adrenocortical O +
system O +
in O +
three O +
experimental O +
series O +
: O +
at O +
normal O +
( O +
17 O +
subjects O +
) O +
, O +
decreased O +
( O +
10 O +
subjects O +
, O +
a O +
360-d O +
head O -
- O -
down O +
bed O +
rest O +
) O +
and O +
increased O +
( O +
8 O +
subjects O +
, O +
physical O +
exercise O +
on O +
bicycle O +
ergometer O +
) O +
levels O +
of O +
motor O +
activity O +
. O +

In O +
the O +
first O +
series O +
we O +
found O +
that O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
and O +
dissociation O +
constant O +
did O +
not O +
depend O +
on O +
the O +
season O +
, O +
on O +
the O +
age O +
of O +
subjects O +
nor O +
on O +
cortisol O +
concentrations O +
in O +
blood O +
. O +

In O +
the O +
second O +
series O +
we O +
observed O +
the O +
following O +
: O +
at O +
the O +
end O +
of O +
the O +
first O +
month O +
of O +
bed O +
rest O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
and O +
receptor O +
affinity O +
significantly O +
increased O +
; O +
at O +
the O +
beginning O +
of O +
the O +
third O +
month O +
of O +
bed O +
rest O +
specific O +
glucocorticoid O +
binding O +
significantly O +
decreased O +
and O +
circadian O +
rhythms O +
of O +
adrenocorticotropin O +
and O +
cortisol O +
in O +
blood O +
varied O +
markedly O +
; O +
at O +
the O +
end O +
of O +
the O +
sixth O +
month O +
of O +
bed O +
rest O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
returned O +
to O +
prebed O +
rest O +
levels O +
and O +
dissociation O +
constant O +
decreased O +
. O +

In O +
the O +
third O +
series O +
physical O +
exercises O +
that O +
induced O +
an O +
activation O +
of O +
the O +
hypothalamic O -
- O -
hypophyseal O -
- O -
adrenocortical O +
system O +
( O +
maximal O +
physical O +
exercises O +
and O +
prolonged O +
submaximal O +
exercises O +
at O +
70 O +
% O +
of O +
maximal O +
oxygen O +
uptake O +
) O +
led O +
to O +
a O +
significant O +
increase O +
in O +
the O +
number O +
of O +
glucocorticoid O +
receptors O +
without O +
changes O +
of O +
dissociation O +
constant O +
. O +

These O +
results O +
indicate O +
that O +
both O +
a O +
decrease O +
and O +
an O +
increase O +
of O +
human O +
motor O +
activity O +
resulted O +
in O +
significant O +
changes O +
of O +
specific O +
glucocorticoid O +
binding O +
which O +
were O +
not O +
influenced O +
by O +
changes O +
of O +
circulating O +
hormone O +
concentrations O +
in O +
blood O +
but O +
by O +
some O +
other O +
factors O +
affected O +
by O +
physical O +
activity O +
. O +

The O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
alpha O +
( O +
PPARalpha O +
) O +
ligand O +
WY O +
14 O +
, O +
643 O +
does O +
not O +
interfere O +
with O +
leukotriene O +
B4 O +
induced O +
adhesion O +
of O +
neutrophils O +
to O +
endothelial O +
cells O +
. O +

Peroxisome O +
proliferator O -
- O -
activated O +
receptors O +
( O +
PPAR O +
) O +
control O +
discrete O +
genes O +
involved O +
in O +
fatty O +
acid O +
and O +
lipid O +
metabolism O +
. O +

Recently O +
, O +
it O +
was O +
suggested O +
that O +
activation O +
of O +
the O +
alpha O +
isoform O +
of O +
PPAR O +
by O +
the O +
potent O +
proinflammatory O +
mediator O +
leukotriene O +
B4 O +
( O +
LTB4 O +
) O +
enhanced O +
degradation O +
of O +
this O +
eicosanoid O +
, O +
offersuggesting O +
a O +
new O +
aspect O +
of O +
down O -
- O -
regulation O +
of O +
inflammation O +
. O +

Here O +
, O +
we O +
studied O +
whether O +
PPARalpha O +
activation O +
( O +
by O +
means O +
of O +
the O +
selective O +
agonist O +
WY O +
14 O +
, O +
643 O +
) O +
of O +
endothelial O +
cells O +
, O +
pivotal O +
in O +
the O +
regulation O +
of O +
inflammatory O +
responses O +
, O +
interfered O +
with O +
LTB4 O +
induced O +
adhesion O +
of O +
PMN O +
neutrophil O +
granulocytes O +
in O +
vitro O +
. O +

When O +
endothelial O +
cells O +
were O +
treated O +
with O +
WY O +
14 O +
, O +
643 O +
prior O +
to O +
activation O +
with O +
LTB4 O +
( O +
or O +
fMLP O +
, O +
IL-1beta O +
or O +
TNFalpha O +
, O +
as O +
controls O +
) O +
we O +
could O +
not O +
document O +
any O +
effect O +
on O +
the O +
number O +
of O +
adhering O +
PMN O +
or O +
duration O +
of O +
the O +
response O +
. O +

Thus O +
, O +
this O +
study O +
provides O +
no O +
evidence O +
indicating O +
a O +
regulatory O +
function O +
of O +
PPARalpha O +
in O +
LTB4 O +
induced O +
adhesive O +
interactions O +
between O +
endothelial O +
cells O +
and O +
neutrophils O +

Stimulation O +
of O +
B O +
and O +
T O +
cells O +
activates O +
expression O +
of O +
transcription O +
and O +
differentiation O +
factors O +
. O +

During O +
B O +
and O +
T O +
cell O +
differentiation O +
and O +
proliferation O +
many O +
genes O +
are O +
induced O +
or O +
repressed O +
while O +
certain O +
genes O +
are O +
constitutively O +
expressed O +
. O +

To O +
investigate O +
processes O +
related O +
to O +
B O +
and O +
T O +
cell O +
activation O +
, O +
the O +
gene O +
expression O +
of O +
stimulated O +
and O +
nonstimulated B-CellLine +
Ramos I-CellLine +
and I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
was O +
studied O +
using O +
cDNA O +
microarray O +
technology O +
. O +

Simultaneous O +
analysis O +
of O +
close O +
to O +
600 O +
genes O +
indicated O +
highest O +
increase O +
in O +
the O +
expression O +
of O +
certain O +
transcription O +
, O +
differentiation O +
and O +
proliferation O +
factors O +
. O +

Many O +
of O +
these O +
genes O +
have O +
not O +
previously O +
been O +
shown O +
to O +
funcion O +
in O +
the O +
stimulated O +
lymphocytes O +
. O +

Also O +
genes O +
encoding O +
proteins O +
involved O +
in O +
DNA O +
replication O +
, O +
binding O +
, O +
transcription O +
and O +
translation O +
were O +
induced O +
. O +

Large O +
part O +
of O +
the O +
activated O +
genes O +
were O +
under O +
very O +
stringent O +
regulation O +
being O +
expressed O +
only O +
after O +
stimulation O +
. O +

The O +
mechanism O +
and O +
function O +
of O +
the O +
expressed O +
genes O +
during O +
lymphocyte O +
differentiation O +
and O +
in O +
disorders O +
is O +
discussed O +
. O +

The O +
transcription O +
factors O +
c O -
- O -
myb O +
and O +
C O -
/ O -
EBP O +
alpha O +
regulate O +
the O +
monocytic O -
/ O -
myeloic O +
gene O +
MRP14 O +
. O +

The O +
entry O +
of O +
microorganisms O +
into O +
the O +
body O +
induces O +
inflammatory O +
processes O +
. O +

During O +
this O +
process O +
a O +
sequence O +
of O +
cellular O +
, O +
humoral O +
, O +
non O -
- O -
specific O +
and O +
specific O +
actions O +
are O +
evoked O +
to O +
combat O +
the O +
infection O +
. O +

Macrophages O +
and O +
granulocytes O +
, O +
which O +
are O +
developed O +
from O +
a O +
common O +
progenitor O +
cell O +
, O +
are O +
the O +
cellular O +
components O +
of O +
the O +
specific O +
and O +
non O -
- O -
specific O +
immunoreaction O +
. O +

MRP14 O +
( O +
Macrophage O +
migration O +
inhibitory O +
related O +
protein O +
) O +
and O +
MRP8 O +
, O +
two O +
S-100 O +
proteins O +
contained O +
in O +
high O +
concentrations O +
in O +
these O +
cells O +
are O +
obviously O +
essential O +
for O +
adhesion O +
and O +
migration O +
of O +
monocytes O +
and O +
granulocytes O +
. O +

To O +
investigate O +
the O +
transcriptional O +
regulation O +
of O +
these O +
genes O +
we O +
cotransfected O +
constructs O +
expressing O +
CAT O +
under O +
control O +
of O +
the O +
MRP14 O +
promoter O +
and O +
expression O +
constructs O +
of O +
C O -
/ O -
EBP O +
alpha O +
and O +
v O -
- O -
myb O +
, O +
two O +
transcription O +
factors O +
involved O +
in O +
myeloid O -
/ O -
monocytic O +
differentiation O +
. O +

Transfection O +
with O +
C O -
/ O -
EBP O +
alpha O +
revealed O +
a O +
massive O +
enhancement O +
of O +
the O +
MRP14 O +
promoter O +
in O +
both O +
, O +
HL O +
60 O +
cells O +
( O +
granulocytic O +
differentiated O +
) O +
and O +
L132 O +
fibroblasts O +
. O +

In O +
contrast O +
, O +
v O -
- O -
myb O +
reduces O +
MRP14 O +
promoter O +
activity O +
. O +

Northern O +
blot O +
analysis O +
of O +
L132 O +
cells O +
transfected O +
with O +
the O +
C O -
/ O -
EBP O +
alpha O +
expression O +
vector O +
demonstrate O +
that O +
C O -
/ O -
EBP O +
alpha O +
is O +
sufficient O +
to O +
enhance O +
MRP14 O +
expression O +
in O +
the O +
context O +
of O +
the O +
whole O +
genome O +
. O +

Nuclear O +
factor O -
- O -
kappaB O +
induction O +
in O +
CD45RO+ O +
and O +
CD45RA+ O +
T O +
cell O +
subsets O +
during O +
aging O +
. O +

An O +
increase O +
in O +
the O +
ratio O +
of O +
memory O +
to O +
naive O +
T O +
cells O +
has O +
been O +
postulated O +
to O +
underlie O +
immune O +
hyporesponsiveness O +
accompanying O +
aging O +
. O +

Our O +
analyses O +
of O +
the O +
induction O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NFkappaB O +
) O +
in O +
activated O +
memory O +
( O +
CD45RO+ O +
) O +
and O +
naive O +
( O +
CD45RA+ O +
) O +
T O +
cell O +
subsets O +
from O +
young O +
and O +
elderly O +
donors O +
has O +
demonstrated O +
that O +
, O +
regardless O +
of O +
donor O +
age O +
, O +
memory O +
T O +
cells O +
are O +
not O +
significantly O +
altered O +
in O +
their O +
responsiveness O +
to O +
TNF O -
- O -
alpha O +
-mediated O +
induction O +
of O +
NFkappaB O +
. O +

Although O +
treatment O +
with O +
TNF O -
- O -
alpha O +
induced O +
nuclear O +
localization O +
of O +
NFkappaB O +
in O +
both O +
memory O +
and O +
naive O +
T O +
cell O +
subsets O +
, O +
irrespective O +
of O +
the O +
age O +
of O +
the O +
donor O +
, O +
the O +
levels O +
of O +
induced O +
NFkappaB O +
were O +
significantly O +
lower O +
in O +
both O +
subsets O +
of O +
T O +
cells O +
obtained O +
from O +
the O +
elderly O +
, O +
when O +
compared O +
to O +
those O +
in O +
young O +
. O +

Examination O +
of O +
IkappaB O +
alpha O +
regulation O +
revealed O +
that O +
TNF O -
- O -
alpha O +
-mediated O +
degradation O +
of O +
IkappaB O +
alpha O +
in O +
both O +
memory O +
and O +
naive O +
T O +
cells O +
from O +
the O +
elderly O +
was O +
severely O +
impaired O +
, O +
thus O +
contributing O +
to O +
the O +
lowered O +
induction O +
of O +
the O +
observed O +
NFkappaB O +
. O +

In O +
addition O +
, O +
this O +
age O -
- O -
related O +
decrease O +
in O +
induction O +
of O +
nuclear O +
NFkappaB O +
correlated O +
with O +
decrease O +
in O +
intracellular O +
IL-2 O +
receptor O +
expression O +
and O +
anti O -
- O -
CD3 O +
-induced O +
proliferation O +
of O +
both O +
memory O +
and O +
naive O +
T O +
cells O +
subsets O +
. O +

Taken O +
together O +
, O +
our O +
results O +
suggest O +
that O +
the O +
age O -
- O -
related O +
hyporesponsiveness O +
can O +
not O +
be O +
attributed O +
to O +
a O +
skewing O +
of O +
the O +
T O +
cell O +
population O +
towards O +
a O +
memory O +
phenotype O +
in O +
the O +
elderly O +
. O +

Glucocorticoid O -
- O -
induced O +
apoptosis O +
and O +
regulation O +
of O +
NF O -
- O -
kappaB O +
activity O +
in O +
human O +
leukemic O +
T O +
cells O +
. O +

Glucocorticoid O -
- O -
induced O +
apoptosis O +
was O +
investigated O +
in O +
glucocorticoid B-CellLine -
- I-CellLine -
sensitive I-CellLine +
6TG1.1 I-CellLine +
and O +
resistant B-CellLine +
ICR27TK.3 I-CellLine +
human O +
leukemic O +
T O +
cells O +
. O +

Following O +
glucocorticoid O +
treatment O +
of O +
6TG1.1 B-CellLine +
cells I-CellLine +
, O +
chromatin O +
fragmentation O +
was O +
observed O +
after O +
a O +
delay O +
of O +
24 O +
h O +
. O +

Fragmentation O +
was O +
not O +
observed O +
in O +
ICR27TK.3 B-CellLine +
cells I-CellLine +
containing O +
mutant O +
glucocorticoid O +
receptors O +
( O +
L753F B-CellLine +
) O +
that O +
are O +
activation O -
- O -
deficient O +
but O +
retain O +
the O +
ability O +
to O +
repress O +
AP-1 O +
activity O +
. O +

Nor O +
was O +
fragmentation O +
observed O +
after O +
treatment O +
with O +
RU38486 O +
, O +
indicating O +
that O +
repression O +
of O +
AP-1 O +
activity O +
is O +
not O +
involved O +
. O +

As O +
described O +
in O +
other O +
systems O +
, O +
fragmentation O +
required O +
ongoing O +
protein O +
synthesis O +
. O +

However O +
, O +
inhibition O +
of O +
protein O +
synthesis O +
with O +
cycloheximide O +
anytime O +
during O +
the O +
first O +
18 O +
h O +
of O +
steroid O +
treatment O +
was O +
as O +
effective O +
in O +
blocking O +
chromatin O +
fragmentation O +
as O +
inhibition O +
for O +
the O +
entire O +
period O +
, O +
suggesting O +
that O +
synthesis O +
of O +
a O +
component O +
with O +
a O +
rapid O +
turnover O +
rate O +
is O +
required O +
. O +

Dexamethasone O +
treatment O +
completely O +
blocked O +
12-O O -
- O -
tetradecanoylphorbol O +
13-acetate O +
induction O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
activity O +
and O +
elicited O +
an O +
increase O +
in O +
the O +
amount O +
of O +
immunoreactive O +
IkappaB O +
alpha O +
in O +
sensitive O +
6TG1.1 B-CellLine +
cells I-CellLine +
but O +
not O +
in O +
resistant O +
ICR27TK.3 B-CellLine +
cells I-CellLine +
. O +

In O +
addition O +
, O +
mild O +
detergent O +
treatment O +
of O +
cell O +
extracts O +
indicated O +
that O +
a O +
substantial O +
amount O +
of O +
cytoplasmic O +
NF O -
- O -
kappaB O +
is O +
complexed O +
with O +
IkappaB O +
alpha O +
or O +
some O +
other O +
inhibitory O +
factor O -
. O +
These O +
results O +
suggest O +
that O +
induction O +
of O +
a O +
labile O +
inhibitory O +
factor O +
such O +
as O +
IkappaB O +
alpha O +
may O +
contribute O +
to O +
glucocorticoid O -
- O -
induced O +
apoptosis O +
. O +

Protein O +
kinase O +
C O +
regulates O +
Fas O +
( O +
CD95 O -
/ O -
APO-1 O +
) O +
expression O +
. O +

Fas O +
( O +
CD95 O -
/ O -
APO-1 O +
) O +
is O +
a O +
transmembrane O +
protein O +
of O +
the O +
TNF O -
/ O -
neuron O +
growth O +
factor O +
receptor O +
family O +
. O +

Ligation O +
of O +
Fas O +
by O +
specific O +
Abs O +
or O +
Fas O +
ligand O +
( O +
FasL O -
/ O -
CD95 O +
ligand O +
) O +
induces O +
rapid O +
apoptotic O +
cell O +
death O +
in O +
a O +
variety O +
of O +
cell O +
types O +
. O +

Despite O +
progress O +
in O +
understanding O +
the O +
death O +
signals O +
transduced O +
from O +
Fas O +
, O +
very O +
little O +
is O +
known O +
with O +
regard O +
to O +
the O +
mechanisms O +
by O +
which O +
Fas O +
expression O +
is O +
regulated O +
. O +

Using O +
our O +
previously O +
established O +
murine B-CellLine +
T I-CellLine +
cell I-CellLine +
hybridoma I-CellLine +
model I-CellLine +
A1.1 B-CellLine +
, O +
we O +
show O +
that O +
specific O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
inhibitors O +
could O +
block O +
activation O -
- O -
induced O +
Fas O +
expression O +
and O +
apoptosis O +
. O +

The O +
activation O +
of O +
PKC O +
with O +
PMA O +
or O +
1-oleoyl-2-acetyl O -
- O -
sn O -
- O -
glycerol O +
could O +
mimic O +
the O +
TCR O +
signal O +
by O +
inducing O +
the O +
expression O +
of O +
Fas O +
but O +
not O +
FasL O +
. O +

PKC O +
-dependent O +
Fas O +
expression O +
was O +
also O +
observed O +
in O +
several O +
murine B-CellLine +
and I-CellLine +
human I-CellLine +
tumor I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Since O +
the O +
inhibition O +
of O +
Ca2 O -
+ O +
redistribution O +
by O +
an O +
inhibitor O +
of O +
intracellular O +
Ca2 O -
+ O +
mobilization O +
, O +
8- O +
( O +
diethylamino O +
) O +
-octyl-3 O +
, O +
4 O +
, O +
5-trimethoxybenzoate O +
hydrochloride O +
, O +
inhibited O +
TCR O -
- O -
induced O +
FasL O +
but O +
not O +
Fas O +
, O +
the O +
expression O +
of O +
Fas O +
appears O +
to O +
be O +
independent O +
of O +
Ca2 O -
+ O +
mobilization O +
. O +

Significantly O +
, O +
expression O +
of O +
the O +
newly O +
identified O +
Fas O -
- O -
regulatory O +
gene O +
, O +
TDAG51 O +
, O +
was O +
found O +
to O +
be O +
dependent O +
upon O +
the O +
activity O +
of O +
PKC O +
. O +

PKC O +
activation O +
only O +
induced O +
Fas O +
expression O +
in O +
cells O +
expressing O +
wild O -
- O -
type O +
TDAG51 O +
. O +

Thus O +
, O +
Fas O +
expression O +
is O +
likely O +
mediated O +
by O +
PKC O +
through O +
TDAG51 O +
. O +

Transcription O +
of O +
a O +
minimal O +
promoter O +
from O +
the O +
NF O -
- O -
IL6 O +
gene O +
is O +
regulated O +
by O +
CREB O -
/ O -
ATF O +
and O +
SP1 O +
proteins O +
in O +
U937 B-CellLine +
promonocytic I-CellLine +
cells I-CellLine +
. O +

NF O -
- O -
IL6 O +
is O +
an O +
important O +
transcriptional O +
regulator O +
of O +
genes O +
induced O +
in O +
activated O +
monocytes O -
/ O -
macrophages O +
, O +
and O +
NF O -
- O -
IL6 O +
is O +
the O +
only O +
CCAAT O -
/ O -
enhancer O -
- O -
binding O +
protein O +
( O +
C O -
/ O -
EBP O +
) O +
family O +
member O +
whose O +
steady O -
- O -
state O +
mRNA O +
levels O +
increase O +
upon O +
activation O +
of O +
monocytes O +
( O +
1 O +
) O +
. O +

We O +
show O +
that O +
increased O +
transcription O +
of O +
the O +
NF O -
- O -
IL6 O +
gene O +
is O +
responsible O +
, O +
at O +
least O +
in O +
part O +
, O +
for O +
induction O +
of O +
NF O -
- O -
IL6 O +
mRNA O +
following O +
activation O +
of O +
U937 B-CellLine +
promonocytic I-CellLine +
cells I-CellLine +
. O +

We O +
have O +
identified O +
a O +
104-bp O +
minimal O +
promoter O +
region O +
of O +
the O +
NF O -
- O -
IL6 O +
gene O +
that O +
is O +
sufficient O +
for O +
basal O +
and O +
activation O -
- O -
dependent O +
induction O +
of O +
transcription O +
in O +
U937 B-CellLine +
cells I-CellLine +
. O +

This O +
region O +
contains O +
binding O +
sites O +
for O +
the O +
cAMP O +
response O +
element O -
- O -
binding O +
protein O -
/ O -
activation O +
transcription O +
factor O +
( O +
CREB O -
/ O -
ATF O +
) O +
and O +
Sp1 O +
families O +
of O +
transcription O +
factors O +
. O +

Each O +
site O +
is O +
functionally O +
important O +
and O +
contributes O +
independently O +
to O +
transcription O +
of O +
the O +
NF O -
- O -
IL6 O +
gene O +
in O +
U937 B-CellLine +
cells I-CellLine +
. O +

The O +
MHC O +
class O +
II O +
transactivator O +
( O +
CIITA O +
) O +
requires O +
conserved O +
leucine O +
charged O +
domains O +
for O +
interactions O +
with O +
the O +
conserved O +
W O +
box O +
promoter O +
element O +
. O +

The O +
class O +
II O +
transactivator O +
CIITA O +
is O +
required O +
for O +
transcriptional O +
activation O +
of O +
the O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
class O +
II O +
genes O +
. O +

Aside O +
from O +
an O +
N O -
- O -
terminal O +
acidic O +
transcriptional O +
activation O +
domain O +
, O +
little O +
is O +
known O +
about O +
how O +
this O +
factor O +
functions O +
. O +

Extensive O +
mutagenesis O +
of O +
CIITA O +
was O +
undertaken O +
to O +
identify O +
structural O +
motifs O +
required O +
for O +
function O +
. O +

The O +
ability O +
of O +
mutants O +
to O +
activate O +
a O +
reporter O +
gene O +
under O +
the O +
control O +
of O +
MHC O +
class O +
II O +
conserved O +
W O -
- O -
X O -
- O -
Y O +
or O +
X O -
- O -
Y O +
regulatory O +
elements O +
was O +
determined O +
. O +

Two O +
mutants O +
displayed O +
differential O +
activity O +
between O +
the O +
two O +
promoters O +
, O +
activating O +
transcription O +
with O +
the O +
W O -
- O -
X O -
- O -
Y O +
but O +
not O +
the O +
X O -
- O -
Y O +
elements O +
. O +

All O +
mutants O +
were O +
tested O +
for O +
their O +
ability O +
to O +
interfere O +
with O +
wild O -
- O -
type O +
CIITA O +
activity O +
. O +

Five O +
CIITA O +
mutant O +
constructions O +
were O +
able O +
to O +
down O -
- O -
regulate O +
wild O -
- O -
type O +
CIITA O +
activity O +
. O +

Three O +
of O +
these O +
mutants O +
contained O +
targeted O +
disruptions O +
of O +
potential O +
functional O +
motifs O +
: O +
the O +
acidic O +
activation O +
domain O +
, O +
a O +
putative O +
GTP O -
- O -
binding O +
motif O +
and O +
two O +
leucine O +
charged O +
domains O +
( O +
LCD O +
motifs O +
) O +
. O +

The O +
other O +
two O +
contained O +
mutations O +
in O +
regions O +
that O +
do O +
not O +
have O +
homology O +
to O +
described O +
proteins O +
. O +

The O +
characterization O +
of O +
CIITA O +
mutants O +
that O +
are O +
able O +
to O +
discriminate O +
between O +
promoters O +
with O +
or O +
without O +
the O +
W O +
box O +
strongly O +
suggests O +
that O +
CIITA O +
requires O +
such O +
interactions O +
for O +
function O +
. O +

The O +
identification O +
of O +
LCD O +
motifs O +
required O +
for O +
CIITA O +
function O +
brings O +
to O +
light O +
a O +
previously O +
undefined O +
role O +
of O +
these O +
motifs O +
in O +
CIITA O +
function O +
. O +

Two O -
- O -
site O +
interaction O +
of O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
with O +
activated O +
calcineurin O +
. O +

Transcription O +
factors O +
belonging O +
to O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
family O +
regulate O +
the O +
expression O +
of O +
cytokine O +
genes O +
and O +
other O +
inducible O +
genes O +
during O +
the O +
immune O +
response O +
. O +

The O +
functions O +
of O +
NFAT O +
proteins O +
are O +
directly O +
controlled O +
by O +
the O +
calcium- O +
and O +
calmodulin- O +
dependent O +
phosphatase O +
calcineurin O +
. O +

Here O +
we O +
show O +
that O +
the O +
binding O +
of O +
calcineurin O +
to O +
NFAT O +
is O +
substantially O +
increased O +
when O +
calcineurin O +
is O +
activated O +
with O +
calmodulin O +
and O +
calcium O +
. O +

FK506.FKBP12 O +
drug O -
- O -
immunophilin O +
complexes O +
inhibited O +
the O +
interaction O +
of O +
NFAT O +
with O +
activated O +
calcineurin O +
much O +
more O +
effectively O +
than O +
they O +
inhibited O +
the O +
interaction O +
with O +
inactive O +
calcineurin O +
, O +
suggesting O +
that O +
part O +
of O +
the O +
interaction O +
with O +
activated O +
calcineurin O +
involved O +
the O +
enzyme O +
active O +
site O +
. O +

We O +
have O +
previously O +
shown O +
that O +
NFAT O +
is O +
targeted O +
to O +
inactive O +
calcineurin O +
at O +
a O +
region O +
distinct O +
from O +
the O +
calcineurin O +
active O +
site O +
( O +
Aramburu O +
, O +
J. O +
, O +
Garcia O -
- O -
Cozar O +
, O +
F. O +
J. O +
, O +
Raghavan O +
, O +
A. O +
, O +
Okamura O +
, O +
H. O +
, O +
Rao O +
, O +
A. O +
, O +
and O +
Hogan O +
, O +
P. O +
G. O +
( O +
1998 O +
) O +
Mol O -
. O +
Cell O +
1 O +
, O +
627 O -
- O -
637 O +
) O +
; O +
this O +
region O +
is O +
also O +
involved O +
in O +
NFAT O +
binding O +
to O +
activated O +
calcineurin O +
, O +
since O +
binding O +
is O +
inhibited O +
by O +
an O +
NFAT O +
peptide O +
spanning O +
the O +
calcineurin O +
docking O +
site O +
on O +
NFAT O +
. O +

The O +
interacting O +
surfaces O +
are O +
located O +
on O +
the O +
catalytic O +
domain O +
of O +
the O +
calcineurin O +
A O +
chain O +
and O +
on O +
an O +
86-amino O +
acid O +
fragment O +
of O +
the O +
NFAT O +
regulatory O +
domain O +
. O +

NFAT O +
binding O +
to O +
the O +
calcineurin O +
catalytic O +
domain O +
was O +
inhibited O +
by O +
the O +
calcineurin O +
autoinhibitory O +
domain O +
and O +
the O +
RII O +
substrate O +
peptide O +
, O +
which O +
bind O +
in O +
the O +
calcineurin O +
active O +
site O +
, O +
as O +
well O +
as O +
by O +
the O +
NFAT O +
docking O +
site O +
peptide O +
, O +
which O +
binds O +
to O +
a O +
region O +
of O +
calcineurin O +
distinct O +
from O +
the O +
active O +
site O +
. O +

We O +
propose O +
that O +
, O +
in O +
resting O +
cells O +
, O +
NFAT O +
is O +
targeted O +
to O +
a O +
region O +
of O +
the O +
calcineurin O +
catalytic O +
domain O +
that O +
does O +
not O +
overlap O +
the O +
calcineurin O +
active O +
site O +
. O +

Upon O +
cell O +
activation O +
, O +
displacement O +
of O +
the O +
autoinhibitory O +
domain O +
by O +
calmodulin O +
binding O +
allows O +
NFAT O +
to O +
bind O +
additionally O +
to O +
the O +
calcineurin O +
active O +
site O +
, O +
thus O +
positioning O +
NFAT O +
for O +
immediate O +
dephosphorylation O +
at O +
functional O +
phosphoserine O +
residues O +
. O +

CD30 O +
is O +
a O +
CD40-inducible O +
molecule O +
that O +
negatively O +
regulates O +
CD40-mediated O +
immunoglobulin O +
class O +
switching O +
in O +
non B-CellLine -
- I-CellLine -
antigen I-CellLine -
- I-CellLine -
selected I-CellLine +
human I-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

We O +
used O +
our O +
monoclonal O +
model O +
of O +
germinal O +
center O +
maturation O +
, O +
CL-01 O +
B O +
cells O +
, O +
to O +
investigate O +
the O +
role O +
of O +
CD30 O +
in O +
human O +
B O +
cell O +
differentiation O +
. O +

CL-01 B-CellLine +
cells I-CellLine +
are O +
IgM O +
+ O +
IgD O +
+ O +
CD30 O +
+ O +
and O +
switch O +
to O +
IgG O +
, O +
IgA O +
, O +
and O +
IgE O +
when O +
exposed O +
to O +
CD40L O +
and O +
IL-4 O +
. O +

Switching O +
is O +
hampered O +
by O +
CD30 O +
coengagement O +
, O +
possibly O +
through O +
interference O +
with O +
the O +
CD40 O +
-mediated O +
NF O -
- O -
kappaB O +
-dependent O +
transcriptional O +
activation O +
of O +
downstream O +
C O +
( O +
H O +
) O +
genes O +
. O +

The O +
physiological O +
relevance O +
of O +
this O +
phenomenon O +
is O +
emphasized O +
by O +
similar O +
CD30 O +
-mediated O +
effects O +
in O +
naive O +
B O +
cells O +
. O +

Expression O +
of O +
CD30 O +
by O +
these O +
cells O +
is O +
induced O +
by O +
CD40L O +
but O +
is O +
inhibited O +
by O +
B O +
cell O +
receptor O +
coengagement O +
and/or O +
exposure O +
to O +
IL-6 O +
and O +
IL-12 O +
. O +

Our O +
data O +
suggest O +
that O +
CD30 O +
critically O +
regulates O +
the O +
CD40 O +
-mediated O +
differentiation O +
of O +
non B-CellLine -
- I-CellLine -
antigen I-CellLine -
- I-CellLine -
selected I-CellLine +
human I-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

Retinoid O +
X O +
receptor O +
and O +
c O -
- O -
cerbA O -
/ O -
thyroid O +
hormone O +
receptor O +
regulate O +
erythroid O +
cell O +
growth O +
and O +
differentiation O +
. O +

Nuclear O +
receptors O +
are O +
important O +
regulators O +
of O +
erythroid O +
cell O +
development O +
. O +

Here O +
we O +
investigated O +
the O +
impact O +
of O +
retinoid O +
X O +
receptor O +
( O +
RXR O +
) O +
, O +
retinoic O +
acid O +
receptor O +
( O +
RAR O +
) O +
, O +
and O +
of O +
the O +
c O -
- O -
erbA O -
/ O -
thyroid O +
hormone O +
( O +
T3 O +
) O +
receptor O +
( O +
c O -
- O -
erbA O -
/ O -
TR O +
) O +
on O +
growth O +
and O +
differentiation O +
of O +
erythroid O +
cells O +
using O +
an O +
in O +
vitro O +
culture O +
system O +
of O +
stem O +
cell O +
factor O -
- O -
dependent O +
erythroid O +
progenitors O +
. O +

RXR O +
, O +
RAR O +
, O +
and O +
c O -
- O -
erbA O -
/ O -
TR O +
-specific O +
ligands O +
were O +
found O +
to O +
induce O +
erythroid O -
- O -
specific O +
gene O +
expression O +
and O +
to O +
accelerate O +
erythroid O +
differentiation O +
in O +
culture O +
, O +
with O +
T3 O +
being O +
most O +
effective O +
. O +

Furthermore O +
, O +
while O +
ligand O -
- O -
activated O +
c O -
- O -
erbA O -
/ O -
TR O +
accelerated O +
differentiation O +
, O +
unliganded O +
c O -
- O -
erbA O -
/ O -
TR O +
effectively O +
blocked O +
differentiation O +
and O +
supported O +
sustained O +
progenitor O +
growth O +
in O +
culture O +
. O +

Thus O +
, O +
c O -
- O -
erbA O -
/ O -
TR O +
appears O +
to O +
act O +
as O +
a O +
binary O +
switch O +
affecting O +
erythroid O +
cell O +
fate O +
: O +
unliganded O +
c O -
- O -
erbA O -
/ O -
TR O +
supports O +
growth O +
while O +
ligand O -
- O -
activated O +
c O -
- O -
erbA O -
/ O -
TR O +
induces O +
differentiation O +
. O +

Additionally O +
, O +
to O +
determine O +
the O +
impact O +
of O +
RXR O +
for O +
erythroid O +
cell O +
development O +
, O +
dominant O +
interfering O +
mutant O +
RXRs O +
, O +
lacking O +
the O +
transcriptional O +
activator O +
functions O +
AF-1 O +
and O +
AF-2 O +
, O +
or O +
AF-2 O +
only O +
, O +
or O +
the O +
entire O +
DNA O -
- O -
binding O +
domain O +
, O +
were O +
introduced O +
into O +
erythroid O +
progenitor O +
cells O +
via O +
recombinant O +
retrovirus O +
vectors O +
and O +
analyzed O +
for O +
RXR O +
-specific O +
effects O +
. O +

It O +
was O +
found O +
that O +
expression O +
of O +
wild O -
- O -
type O +
RXR O +
and O +
of O +
the O +
RXR O +
mutants O +
devoid O +
of O +
AF-1 O +
and/or O +
AF-2 O +
supported O +
a O +
transient O +
outgrowth O +
of O +
erythroid O +
cells O +
. O +

In O +
marked O +
contrast O +
, O +
expression O +
of O +
the O +
dominant O +
interfering O +
deltaDNA O -
- O -
binding O +
domain O +
RXR O +
, O +
containing O +
a O +
deletion O +
of O +
the O +
entire O +
DNA O -
- O -
binding O +
domain O +
, O +
was O +
incompatible O +
with O +
erythroid O +
cell O +
growth O +
in O +
vitro O +
, O +
suggesting O +
a O +
pivotal O +
role O +
of O +
RXR O +
for O +
erythroid O +
cell O +
development O +
. O +

Induction O +
of O +
Mn O +
SOD O +
in O +
human O +
monocytes O +
without O +
inflammatory O +
cytokine O +
production O +
by O +
a O +
mutant O +
endotoxin O +
. O +

Endotoxin O +
selectively O +
induces O +
monocyte O +
Mn O +
superoxide O +
dismutase O +
( O +
SOD O +
) O +
without O +
affecting O +
levels O +
of O +
Cu O +
, O +
Zn O +
SOD O +
, O +
catalase O +
, O +
or O +
glutathione O +
peroxidase O +
. O +

However O +
, O +
little O +
is O +
known O +
about O +
the O +
structure O -
- O -
activity O +
relationship O +
and O +
the O +
mechanism O +
by O +
which O +
endotoxin O +
induces O +
Mn O +
SOD O +
. O +

In O +
this O +
study O +
we O +
demonstrated O +
that O +
a O +
mutant O +
Escherichia O +
coli O +
endotoxin O +
lacking O +
myristoyl O +
fatty O +
acid O +
at O +
the O +
3 O +
' O +
R-3-hydroxymyristate O +
position O +
of O +
the O +
lipid O +
A O +
moiety O +
retained O +
its O +
full O +
capacity O +
to O +
coagulate O +
Limulus O +
amoebocyte O +
lysate O +
compared O +
with O +
the O +
wild O -
- O -
type O +
E. O +
coli O +
endotoxin O +
and O +
markedly O +
stimulated O +
the O +
activation O +
of O +
human O +
monocyte O +
nuclear O +
factor O -
- O -
kappaB O +
and O +
the O +
induction O +
of O +
Mn O +
SOD O +
mRNA O +
and O +
enzyme O +
activity O +
. O +

However O +
, O +
in O +
contrast O +
to O +
the O +
wild O -
- O -
type O +
endotoxin O +
, O +
it O +
failed O +
to O +
induce O +
significant O +
production O +
of O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
and O +
macrophage O +
inflammatory O +
protein-1alpha O +
by O +
monocytes O +
and O +
did O +
not O +
induce O +
the O +
phosphorylation O +
and O +
nuclear O +
translocation O +
of O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
. O +

These O +
results O +
suggest O +
that O +
1 O +
) O +
lipid O +
A O +
myristoyl O +
fatty O +
acid O +
, O +
although O +
it O +
is O +
important O +
for O +
the O +
induction O +
of O +
inflammatory O +
cytokine O +
production O +
by O +
human O +
monocytes O +
, O +
is O +
not O +
necessary O +
for O +
the O +
induction O +
of O +
Mn O +
SOD O +
, O +
2 O +
) O +
endotoxin O +
-mediated O +
induction O +
of O +
Mn O +
SOD O +
and O +
inflammatory O +
cytokines O +
are O +
regulated O +
, O +
at O +
least O +
in O +
part O +
, O +
through O +
different O +
signal O +
transduction O +
pathways O +
, O +
and O +
3 O +
) O +
failure O +
of O +
the O +
mutant O +
endotoxin O +
to O +
induce O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
production O +
is O +
, O +
at O +
least O +
in O +
part O +
, O +
due O +
to O +
its O +
inability O +
to O +
activate O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
. O +

An O +
allosteric O +
drug O +
, O +
o O +
, O +
o'-bismyristoyl O +
thiamine O +
disulfide O +
, O +
suppresses O +
HIV-1 O +
replication O +
through O +
prevention O +
of O +
nuclear O +
translocation O +
of O +
both O +
HIV-1 O +
Tat O +
and O +
NF O -
- O -
kappa O +
B O +
. O +

The O +
efficacy O +
of O +
o O +
, O +
o'-bismyristoyl O +
thiamine O +
disulfide O +
( O +
BMT O +
) O +
was O +
examined O +
in O +
detail O +
against O +
HIV-1 O +
laboratory O +
isolates O +
( O +
HTLV O -
- O -
IIIB O +
, O +
JRFL O +
, O +
and O +
MN O +
) O +
, O +
primary O +
isolates O +
( O +
KMT O +
and O +
KMO O +
) O +
, O +
and O +
simian O +
immunodeficiency O +
virus O +
( O +
SIVmac251 O +
) O +
in O +
vitro O +
. O +

BMT O +
inhibited O +
the O +
replication O +
of O +
HIV-1 O +
in O +
both O +
laboratory O +
and O +
primary O +
isolates O +
in O +
vitro O +
. O +

In O +
addition O +
, O +
BMT O +
exhibited O +
antiviral O +
activity O +
against O +
SIVmac251 O +
. O +

Minimizing O +
energy O +
studies O +
of O +
BMT O +
structure O +
reveal O +
that O +
a O +
trans O -
- O -
disulfide O +
of O +
thiamine O +
( O +
holo O +
drug O +
) O +
disulfide O +
( O +
TDS O +
, O +
protodrug O +
) O +
is O +
allosterically O +
transited O +
to O +
the O +
reactive O +
twisted O +
disulfide O +
of O +
BMT O +
( O +
allo O +
drug O +
) O +
by O +
o O +
, O +
o'-bismyristoyl O +
esterification O +
of O +
TDS O +
. O +

BMT O +
inhibits O +
nuclear O +
translocation O +
of O +
both O +
HIV-1 O +
transactivator O +
( O +
TAT O +
) O +
and O +
the O +
cellular O +
transcriptional O +
nuclear O +
factor O -
- O -
KB O +
( O +
NF O -
- O -
kappa O +
B O +
) O +
, O +
resulting O +
in O +
the O +
suppression O +
of O +
HIV-1 O +
replication O +
. O +

Interferon O -
- O -
gamma O -
- O -
induced O +
factor O +
binding O +
to O +
the O +
interleukin-4-responsive O +
element O +
of O +
CD23b O +
promoter O +
in O +
human O +
tonsillar O +
mononuclear O +
cells O +
: O +
role O +
in O +
transient O +
up O -
- O -
regulation O +
of O +
the O +
interleukin-4-induced O +
CD23b O +
mRNA O +
. O +

Stimulation O +
of O +
human O +
tonsillar O +
mononuclear O +
cells O +
with O +
interleukin-4 O +
( O +
IL-4 O +
) O +
and O +
interferon O -
- O -
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
rapidly O +
induced O +
the O +
activation O +
of O +
distinct O +
nuclear O +
factors O +
with O +
different O +
mobilities O +
, O +
both O +
of O +
which O +
bind O +
the O +
IL-4 O +
response O +
element O +
( O +
IL-4RE O +
) O +
of O +
CD23b O +
promoter O +
as O +
examined O +
by O +
electrophoretic O +
mobility O +
shift O +
assays O +
( O +
EMSA O +
) O +
. O +

Co O -
- O -
treatment O +
of O +
IL-4 O +
and O +
IFN O -
- O -
gamma O +
induced O +
, O +
in O +
addition O +
to O +
the O +
two O +
distinct O +
complexes O +
, O +
a O +
new O +
complex O +
with O +
an O +
intermediate O +
mobility O +
. O +

The O +
IL-4-induced O +
complex O +
reacted O +
with O +
anti O -
- O -
STAT O +
( O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
) O +
6 O +
, O +
resulting O +
in O +
a O +
supershift O +
whereas O +
the O +
formation O +
of O +
the O +
IFN O -
- O -
gamma O -
- O -
induced O +
complex O +
was O +
inhibited O +
by O +
anti O -
- O -
STAT O +
1 O +
. O +

The O +
intermediate O +
complex O +
appeared O +
to O +
react O +
with O +
both O +
anti O -
- O -
STAT O +
6 O +
and O +
anti O -
- O -
STAT O +
1 O +
. O +

Although O +
IFN O -
- O -
gamma O +
alone O +
did O +
not O +
induce O +
CD23 O +
mRNA O +
transcription O +
, O +
Northern O +
blot O +
analysis O +
revealed O +
a O +
transient O +
up O -
- O -
regulation O +
of O +
the O +
IL-4-induced O +
CD23 O +
mRNA O +
by O +
IFN O -
- O -
gamma O +
within O +
2 O +
h O +
of O +
IFN O -
- O -
gamma O +
treatment O +
in O +
these O +
tonsillar O +
cells O +
. O +

The O +
results O +
suggest O +
that O +
the O +
IL-4RE O +
of O +
the O +
IL-4-inducible O +
gene O +
can O +
accommodate O +
both O +
IL-4- O +
and O +
IFN O -
- O -
gamma O -
- O -
activated O +
factors O +
, O +
such O +
as O +
STAT O +
6 O +
and O +
STAT O +
1 O +
, O +
either O +
in O +
homodimeric O +
or O +
heterodimeric O +
forms O +
and O +
the O +
binding O +
of O +
these O +
different O +
proteins O +
to O +
the O +
respective O +
promoter O +
may O +
play O +
a O +
potential O +
regulatory O +
role O +
in O +
the O +
IL-4 O +
-inducible O +
gene O +
expression O +
. O +

The O +
Epstein O -
- O -
Barr O +
virus O +
Rta O +
protein O +
activates O +
lytic O +
cycle O +
genes O +
and O +
can O +
disrupt O +
latency O +
in O +
B O +
lymphocytes O +
. O +

The O +
transition O +
of O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
from O +
latency O +
into O +
the O +
lytic O +
cycle O +
is O +
associated O +
with O +
the O +
expression O +
of O +
two O +
immediate O -
- O -
early O +
viral O +
genes O +
, O +
BZLF1 O +
and O +
BRLF1 O +
. O +

Overexpression O +
of O +
ZEBRA O +
, O +
the O +
product O +
of O +
BZLF1 O +
, O +
is O +
sufficient O +
to O +
disrupt O +
latency O +
in O +
B O +
lymphocytes O +
and O +
epithelial O +
cells O +
by O +
stimulating O +
expression O +
of O +
lytic O +
cycle O +
genes O +
, O +
including O +
BRLF1 O +
. O +

The O +
BRLF1 O +
product O +
Rta O +
functions O +
as O +
a O +
transcriptional O +
activator O +
in O +
both O +
B O +
lymphocytes O +
and O +
epithelial O +
cells O +
. O +

However O +
, O +
Rta O +
has O +
recently O +
been O +
reported O +
to O +
disrupt O +
latency O +
in O +
an O +
epithelial O +
specific O +
manner O +
( O +
S. O +
Zalani O +
, O +
E. O +
Holley O -
- O -
Guthrie O +
, O +
and O +
S. O +
Kenney O +
, O +
Proc O -
. O +
Natl O -
. O +
Acad O -
. O +
Sci O -
. O +
USA O +
93 O +
: O +
9194 O -
- O -
9199 O +
, O +
1996 O +
) O +
. O +

Here O +
we O +
demonstrate O +
that O +
expression O +
of O +
Rta O +
is O +
also O +
sufficient O +
for O +
disruption O +
of O +
latency O +
in O +
a O +
permissive B-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
. O +

In O +
HH514 B-CellLine -
- I-CellLine -
16 I-CellLine +
cells I-CellLine +
, O +
transfection O +
of O +
Rta O +
leads O +
to O +
synthesis O +
of O +
ZEBRA O +
, O +
viral O +
DNA O +
replication O +
, O +
and O +
late O +
gene O +
expression O +
. O +

However O +
, O +
Rta O +
by O +
itself O +
is O +
less O +
potent O +
than O +
ZEBRA O +
in O +
the O +
ability O +
to O +
activate O +
most O +
early O +
and O +
late O +
lytic O +
cycle O +
genes O +
. O +

In O +
light O +
of O +
previous O +
work O +
implicating O +
ZEBRA O +
in O +
the O +
activation O +
of O +
Rta O +
, O +
we O +
suggest O +
a O +
cooperative O +
model O +
for O +
EBV O +
entry O +
into O +
the O +
lytic O +
cycle O +
. O +

Expression O +
of O +
either O +
BZLF1 O +
or O +
BRLF1 O +
triggers O +
expression O +
of O +
the O +
other O +
immediate O -
- O -
early O +
factor O +
, O +
and O +
together O +
these O +
activators O +
act O +
individually O +
or O +
in O +
synergy O +
on O +
downstream O +
targets O +
to O +
activate O +
the O +
viral O +
lytic O +
cycle O +
. O +

Molecular O +
and O +
cellular O +
analysis O +
of O +
human O +
immunodeficiency O +
virus O -
- O -
induced O +
apoptosis O +
in O +
lymphoblastoid O +
T O -
- O -
cell O -
- O -
line O -
- O -
expressing O +
wild O -
- O -
type O +
and O +
mutated O +
CD4 O +
receptors O +
. O +

We O +
have O +
previously O +
shown O +
that O +
the O +
presence O +
of O +
the O +
CD4 O +
cytoplasmic O +
tail O +
is O +
critical O +
for O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
-induced O +
apoptosis O +
( O +
J.Corbeil O +
, O +
M.Tremblay O +
, O +
and O +
D.D.Richman O +
, O +
J.Exp O -
. O -
Med.183 O +
: O +
39 O -
- O -
48 O +
, O +
1996 O +
) O +
. O +

We O +
have O +
pursued O +
our O +
investigation O +
of O +
the O +
role O +
of O +
the O +
CD4 O +
transduction O +
pathway O +
in O +
HIV O -
- O -
induced O +
apoptosis O +
. O +

To O +
do O +
this O +
, O +
wild O -
- O -
type O +
and O +
mutant O +
forms O +
of O +
the O +
CD4 O +
cytoplasmic O +
tail O +
were O +
stably O +
expressed O +
in O +
the O +
lymphoblastoid B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
A2.01 B-CellLine +
. O +

Apoptosis O +
was O +
prevented O +
when O +
CD4 O +
truncated O +
at O +
residue O +
402 O +
was O +
expressed O +
; O +
however O +
, O +
cells O +
expressing O +
mutated O +
receptors O +
that O +
do O +
not O +
associate O +
with O +
p56 O +
( O +
lck O +
) O +
( O +
mutated O +
at O +
the O +
dicysteine O +
motif O +
and O +
truncated O +
at O +
residue O +
418 O +
) O +
but O +
which O +
conserved O +
proximal O +
domains O +
of O +
the O +
cytoplasmic O +
tail O +
underwent O +
apoptosis O +
like O +
wild- O +
type O +
CD4 O +
. O +

The O +
differences O +
between O +
wild O -
- O -
type O +
and O +
mutated O +
receptors O +
in O +
the O +
induction O +
of O +
apoptosis O +
were O +
not O +
related O +
to O +
levels O +
of O +
p56 O +
( O +
lck O +
) O +
or O +
NF- O +
kappaB O +
activation O +
. O +

Initial O +
signaling O +
through O +
the O +
CD4 O +
receptor O +
played O +
a O +
major O +
role O +
in O +
the O +
sensitization O +
of O +
HIV O -
- O -
infected O +
T O +
cells O +
to O +
undergo O +
apoptosis O +
. O +

Incubation O +
of O +
HIV O -
- O -
infected O +
cells O +
with O +
monoclonal O +
antibody O +
( O +
MAb O +
) O +
13B8 O -
- O -
2 O +
, O +
which O +
binds O +
to O +
CD4 O +
in O +
a O +
region O +
critical O +
for O +
dimerization O +
of O +
the O +
receptor O +
, O +
prevented O +
apoptosis O +
without O +
inhibiting O +
HIV O +
replication O +
. O +

Moreover O +
, O +
the O +
apoptotic O +
process O +
was O +
not O +
related O +
to O +
Fas O +
-Fas O +
ligand O +
interaction O +
; O +
however O +
, O +
an O +
antagonistic O +
anti O -
- O -
Fas O +
MAb O +
( O +
ZB-4 O +
) O +
enhanced O +
apoptosis O +
in O +
HIV O -
- O -
infected O +
cells O +
without O +
inducing O +
apoptosis O +
in O +
uninfected O +
cells O +
. O +

These O +
observations O +
demonstrate O +
that O +
CD4 O +
signaling O +
mediates O +
HIV O -
- O -
induced O +
apoptosis O +
by O +
a O +
mechanism O +
independent O +
of O +
Fas O +
-Fas O +
ligand O +
interaction O +
, O +
does O +
not O +
require O +
p56 O +
( O +
lck O +
) O +
signaling O +
, O +
and O +
may O +
involve O +
a O +
critical O +
region O +
for O +
CD4 O +
dimerization O +
. O +

Models O +
of O +
lineage O +
switching O +
in O +
hematopoietic O +
development O +
: O +
a O +
new O +
myeloid B-CellLine -
- I-CellLine -
committed I-CellLine +
eosinophil I-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
YJ B-CellLine +
) O +
demonstrates O +
trilineage O +
potential O +
. O +

A O +
new O +
human B-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
with O +
an O +
eosinophilic O +
phenotype O +
, O +
designated O +
YJ B-CellLine +
, O +
was O +
established O +
from O +
the O +
peripheral O +
blood O +
cells O +
of O +
a O +
patient O +
with O +
chronic O +
myelomonocytic O +
leukemia O +
( O +
CMMoL O +
) O +
with O +
eosinophilia O +
. O +

When O +
cultured O +
in O +
RPMI O +
1640 O +
medium O +
containing O +
10 O +
% O +
fetal O +
bovine O +
serum O +
, O +
most O +
YJ B-CellLine +
cells I-CellLine +
were O +
myeloblastoid O +
with O +
a O +
small O +
number O +
of O +
the O +
cells O +
having O +
eosinophilic O +
granules O +
. O +

Cell O +
surface O +
markers O +
in O +
the O +
YJ B-CellLine +
cells I-CellLine +
were O +
positive O +
for O +
CD33 O +
and O +
were O +
negative O +
for O +
CD34 O +
, O +
CD16 O +
and O +
CD23 O +
. O +

The O +
eosinophilic O +
characteristics O +
of O +
YJ B-CellLine +
cells I-CellLine +
were O +
confirmed O +
by O +
histochemical O +
staining O +
with O +
Fast O -
- O -
Green O -
/ O -
Neutral O -
- O -
Red O +
and O +
by O +
the O +
expression O +
of O +
mRNAs O +
for O +
eosinophil O -
- O -
associated O +
granule O +
proteins O +
, O +
eosinophil O +
cationic O +
protein O +
( O +
ECP O +
) O +
, O +
eosinophil O -
- O -
derived O +
neurotoxin O +
( O +
EDN O +
) O +
, O +
eosinophil O +
peroxidase O +
( O +
EPO O +
) O +
, O +
and O +
major O +
basic O +
protein O +
( O +
MBP O +
) O +
, O +
and O +
for O +
the O +
Charcot O -
- O -
Leyden O +
crystal O +
( O +
CLC O +
) O +
protein O +
. O +

The O +
YJ B-CellLine +
cells I-CellLine +
could O +
be O +
induced O +
towards O +
monocytic O +
differentiation O +
by O +
stimulation O +
with O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
. O +

The O +
monocytic O +
characteristics O +
of O +
YJ B-CellLine +
cells I-CellLine +
treated O +
with O +
PMA O +
were O +
confirmed O +
by O +
morphological O +
analysis O +
with O +
alpha O -
- O -
naphthyl O +
butyrate O +
esterase O +
staining O +
, O +
by O +
CD14 O +
expression O +
, O +
and O +
by O +
increased O +
expression O +
of O +
Egr-1 O +
mRNA O +
. O +

Furthermore O +
, O +
YJ B-CellLine +
cells I-CellLine +
could O +
be O +
differentiated O +
towards O +
the O +
neutrophil O +
lineage O +
by O +
stimulation O +
with O +
all O -
- O -
trans O +
retinoic O +
acid O +
( O +
RA O +
) O +
. O +

YJ B-CellLine +
cells I-CellLine +
treated O +
in O +
vitro O +
with O +
2 O +
microM O +
RA O +
differentiated O +
into O +
metamyelocytes O +
and O +
band O +
neutrophils O +
, O +
and O +
increased O +
the O +
number O +
of O +
nitroblue B-CellLine +
tetrazolium I-CellLine +
( I-CellLine +
NBT I-CellLine +
) I-CellLine +
-positive I-CellLine +
cells I-CellLine +
and O +
increased O +
gp91phox O +
mRNA O +
expression O +
. O +

Thus O +
, O +
the O +
YJ B-CellLine +
cell I-CellLine +
line I-CellLine +
exhibited O +
eosinophilic O +
characteristics O +
, O +
but O +
was O +
able O +
to O +
differentiate O +
to O +
the O +
monocytic O +
or O +
neutrophilic O +
lineages O +
in O +
response O +
to O +
PMA O +
or O +
RA O +
, O +
respectively O +
. O +

The O +
expression O +
of O +
genes O +
for O +
transcription O +
factors O +
involved O +
in O +
myeloid O +
differentiation O +
was O +
evaluated O +
by O +
Northern O +
blot O +
analysis O +
. O +

Increased O +
expression O +
of O +
Egr-1 O +
was O +
observed O +
with O +
macrophage O +
differentiation O +
. O +

In O +
contrast O +
, O +
increased O +
expressions O +
of O +
C O -
/ O -
EBPbeta O +
and O +
MZF-1 O +
mRNA O +
occurred O +
with O +
neutrophilic O +
differentiation O +
. O +

The O +
YJ B-CellLine +
cell I-CellLine +
line I-CellLine +
should O +
be O +
useful O +
for O +
elucidating O +
the O +
molecular O +
mechanisms O +
governing O +
lineage O +
switching O +
from O +
the O +
eosinophil O +
to O +
monocytic O +
or O +
neutrophil O +
lineages O +
. O +

Human O +
T O +
cell O +
leukemia O +
virus O -
- O -
I O +
( O +
HTLV O -
- O -
I O +
) O +
Tax O +
-mediated O +
apoptosis O +
in O +
activated O +
T O +
cells O +
requires O +
an O +
enhanced O +
intracellular O +
prooxidant O +
state O +
. O +

We O +
have O +
shown O +
that O +
an O +
estradiol O -
- O -
dependent O +
activation O +
of O +
human O +
T O +
cell O +
leukemia O +
virus O -
- O -
I O +
Tax O +
leads O +
to O +
the O +
inhibition O +
of O +
cell O +
proliferation O +
and O +
to O +
the O +
induction O +
of O +
apoptosis O +
. O +

The O +
present O +
study O +
demonstrates O +
that O +
a O +
hormone O -
- O -
dependent O +
activation O +
of O +
Tax O +
promotes O +
an O +
enhanced O +
prooxidant O +
state O +
in O +
stably B-CellLine +
transfected I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
as O +
measured O +
by O +
changes O +
in O +
the O +
intracellular O +
levels O +
of O +
glutathione O +
and O +
H2O2 O +
; O +
these O +
changes O +
are O +
followed O +
by O +
apoptotic O +
cell O +
death O +
. O +

Additional O +
stimulation O +
of O +
the O +
CD3 O +
/TCR O +
pathway O +
enhances O +
the O +
oxidative O +
and O +
apoptotic O +
effects O +
. O +

Both O +
Tax O +
-mediated O +
apoptosis O +
and O +
oxidative O +
stress O +
can O +
be O +
potently O +
suppressed O +
by O +
antioxidants O +
, O +
as O +
is O +
seen O +
with O +
the O +
administration O +
of O +
recombinant O +
thioredoxin O +
( O +
adult O +
T O +
cell O +
leukemia O -
- O -
derived O +
factor O +
) O +
or O +
pyrrolidine O +
dithiocarbamate O +
. O +

Hormone O -
- O -
induced O +
Tax O +
activation O +
induces O +
a O +
long O -
- O -
lasting O +
activation O +
of O +
NF O -
- O -
kappaB O +
, O +
which O +
is O +
a O +
major O +
target O +
of O +
reactive O +
oxygen O +
intermediates O +
. O +

The O +
long O -
- O -
term O +
exposure O +
of O +
Jurkat B-CellLine +
cells I-CellLine +
to O +
hormone O +
eventually O +
results O +
in O +
a O +
selection O +
of O +
cell B-CellLine +
clones I-CellLine +
that O +
have O +
lost O +
Tax O +
activity O +
. O +

A O +
subsequent O +
transfection O +
of O +
these O +
apparently O +
` B-CellLine -
` I-CellLine +
nonresponsive I-CellLine +
'' I-CellLine +
clones I-CellLine +
allows O +
the O +
recovery O +
of O +
Tax O +
responses O +
in O +
these O +
cells O +
. O +

Our O +
observations O +
indicate O +
that O +
changes O +
in O +
the O +
intracellular O +
redox O +
status O +
may O +
be O +
a O +
determining O +
factor O +
in O +
Tax O +
-mediated O +
DNA O +
damage O +
, O +
apoptosis O +
, O +
and O +
selection O +
against O +
the O +
long O -
- O -
term O +
expression O +
of O +
Tax O +
function O +
. O +

Activated O +
platelets O +
induce O +
monocyte O +
chemotactic O +
protein-1 O +
secretion O +
and O +
surface O +
expression O +
of O +
intercellular O +
adhesion O +
molecule-1 O +
on O +
endothelial O +
cells O +
[ O +
see O +
comments O +
] O +

BACKGROUND O +
: O +
Platelet O -
/ O -
endothelium O +
interaction O +
plays O +
an O +
important O +
role O +
in O +
the O +
pathophysiology O +
of O +
inflammation O +
and O +
atherosclerosis O +
. O +

The O +
role O +
of O +
platelets O +
for O +
monocyte O +
chemotactic O +
protein-1 O +
( O +
MCP-1 O +
) O +
secretion O +
and O +
surface O +
expression O +
of O +
intercellular O +
adhesion O +
molecule-1 O +
( O +
ICAM-1 O +
) O +
on O +
endothelial O +
cells O +
has O +
been O +
assessed O +
. O +

METHODS O +
AND O +
RESULTS O +
: O +
Monolayers O +
of O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
were O +
incubated O +
with O +
nonstimulated O +
or O +
ADP O -
- O -
activated O +
platelets O +
for O +
6 O +
hours O +
, O +
and O +
secretion O +
of O +
MCP-1 O +
and O +
surface O +
expression O +
of O +
ICAM-1 O +
were O +
determined O +
by O +
ELISA O +
and O +
flow O +
cytometry O +
, O +
respectively O +
. O +

In O +
the O +
presence O +
of O +
ADP O -
- O -
activated O +
platelets O +
, O +
both O +
MCP-1 O +
secretion O +
and O +
ICAM-1 O +
surface O +
expression O +
were O +
significantly O +
increased O +
compared O +
with O +
nonstimulated O +
platelets O +
( O +
P O +
< O +
0.02 O +
) O +
. O +

Activation O +
of O +
the O +
transcription O +
factor O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
determined O +
by O +
electrophoretic O +
mobility O +
shift O +
assay O +
and O +
kappaB O +
-dependent O +
transcriptional O +
activity O +
was O +
enhanced O +
in O +
the O +
presence O +
of O +
activated O +
platelets O +
. O +

In O +
addition O +
, O +
ADP O -
- O -
activated O +
platelets O +
induced O +
MCP-1 O +
and O +
ICAM-1 O +
promoter O -
- O -
dependent O +
transcription O +
. O +

Liposomal O +
transfection O +
of O +
a O +
double O -
- O -
stranded O +
kappaB O +
phosphorothioate O +
oligonucleotide O +
, O +
but O +
not O +
of O +
the O +
mutated O +
form O +
, O +
inhibited O +
MCP-1 O +
secretion O +
and O +
surface O +
expression O +
of O +
ICAM-1 O +
on O +
activated O +
endothelium O +
( O +
P O +
< O +
0.05 O +
) O +
. O +

CONCLUSIONS O +
: O +
The O +
present O +
study O +
indicates O +
that O +
activated O +
platelets O +
modulate O +
chemotactic O +
( O +
MCP-1 O +
) O +
and O +
adhesive O +
( O +
ICAM-1 O +
) O +
properties O +
of O +
endothelial O +
cells O +
via O +
an O +
NF O -
- O -
kappaB O +
-dependent O +
mechanism O +
. O +

Platelet O -
- O -
induced O +
activation O +
of O +
the O +
NF O -
- O -
kappaB O +
system O +
might O +
contribute O +
to O +
early O +
inflammatory O +
events O +
in O +
atherogenesis O +
. O +

Upregulation O +
of O +
interleukin O +
6 O +
and O +
granulocyte O +
colony O -
- O -
stimulating O +
factor O +
receptors O +
by O +
transcription O +
factor O +
CCAAT O +
enhancer O +
binding O +
protein O +
alpha O +
( O +
C O -
/ O -
EBP O +
alpha O +
) O +
is O +
critical O +
for O +
granulopoiesis O +
. O +

Cytokines O +
stimulate O +
granulopoiesis O +
through O +
signaling O +
via O +
receptors O +
whose O +
expression O +
is O +
controlled O +
by O +
lineage O -
- O -
specific O +
transcription O +
factors O +
. O +

Previously O +
, O +
we O +
demonstrated O +
that O +
granulocyte O +
colony O -
- O -
stimulating O +
factor O +
( O +
G O -
- O -
CSF O +
) O +
receptor O +
mRNA O +
was O +
undetectable O +
and O +
granulocyte O +
maturation O +
blocked O +
in O +
CCAAT O +
enhancer O +
binding O +
protein O +
alpha O +
( O +
C O -
/ O -
EBPalpha O +
) O +
-deficient O +
mice O +
. O +

This O +
phenotype O +
is O +
distinct O +
from O +
that O +
of O +
G O -
- O -
CSF O +
receptor- O -
/ O -
- O +
mice O +
, O +
suggesting O +
that O +
other O +
genes O +
are O +
likely O +
to O +
be O +
adversely O +
affected O +
by O +
loss O +
of O +
C O -
/ O -
EBPalpha O +
. O +

Here O +
we O +
demonstrate O +
loss O +
of O +
interleukin O +
6 O +
( O +
IL-6 O +
) O +
receptor O +
and O +
IL-6-responsive O +
colony O -
- O -
forming O +
units O +
( O +
CFU O -
- O -
IL6 O +
) O +
in O +
C O -
/ O -
EBPalpha O +
- O -
/ O -
- O +
mice O +
. O +

The O +
observed O +
failure O +
of O +
granulopoiesis O +
could O +
be O +
rescued O +
by O +
the O +
addition O +
of O +
soluble O +
IL-6 O +
receptor O +
and O +
IL-6 O +
or O +
by O +
retroviral O +
transduction O +
of O +
G O -
- O -
CSF O +
receptors O +
, O +
demonstrating O +
that O +
loss O +
of O +
both O +
of O +
these O +
receptors O +
contributes O +
to O +
the O +
absolute O +
block O +
in O +
granulocyte O +
maturation O +
observed O +
in O +
C O -
/ O -
EBPalpha O -
- O -
deficient O +
hematopoietic O +
cells O +
. O +

The O +
results O +
of O +
these O +
and O +
other O +
studies O +
suggest O +
that O +
additional O +
C O -
/ O -
EBPalpha O +
target O +
genes O +
, O +
possibly O +
other O +
cytokine O +
receptors O +
, O +
are O +
also O +
important O +
for O +
the O +
block O +
in O +
granulocyte O +
differentiation O +
observed O +
in O +
vivo O +
in O +
C O -
/ O -
EBPalpha O +
-deficient O +
mice O +
. O +

NF O -
- O -
kappaB O +
only O +
partially O +
mediates O +
Epstein O -
- O -
Barr O +
virus O +
latent O +
membrane O +
protein O +
1 O +
activation O +
of O +
B O +
cells O +
. O +

The O +
latent O +
membrane O +
protein O +
1 O +
( O +
LMP1 O +
) O +
of O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
is O +
required O +
for O +
EBV O -
- O -
induced O +
immortalization O +
of O +
human O +
B O +
cells O +
and O +
causes O +
tumorigenic O +
transformation O +
of O +
cell B-CellLine +
lines I-CellLine +
. O +

LMP1 O +
expression O +
induces O +
phenotypic O +
changes O +
resembling O +
B O +
cell O +
activation O +
, O +
such O +
as O +
cell O +
size O +
increase O +
and O +
up O -
- O -
regulation O +
of O +
cell O +
surface O +
activation O +
markers O +
. O +

LMP1 O +
contains O +
two O +
domains O +
that O +
activate O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
, O +
one O +
through O +
interactions O +
with O +
TRAF O +
proteins O +
and O +
the O +
other O +
with O +
the O +
TRADD O +
protein O +
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
importance O +
of O +
NF O -
- O -
kappaB O +
induction O +
in O +
the O +
up O -
- O -
regulation O +
of O +
the O +
B O +
cell O +
activation O +
markers O +
ICAM-1 O +
and O +
CD71 O +
by O +
LMP1 O +
. O +

This O +
study O +
shows O +
that O +
expression O +
of O +
LMP1 O +
activates O +
transcription O +
from O +
p50 O -
/ O -
p65- O +
and O +
c O -
- O -
Rel- O +
responsive O +
promoters O +
, O +
and O +
that O +
this O +
activity O +
can O +
be O +
completely O +
inhibited O +
by O +
expression O +
of O +
a O +
dominant O +
inhibitory O +
IkappaB O +
mutant O +
. O +

ICAM-1 O +
and O +
CD71 O +
are O +
nevertheless O +
up O -
- O -
regulated O +
by O +
LMP1 O +
in O +
primary O +
B O +
cells O +
and O +
cell O +
lines O +
expressing O +
the O +
dominant O +
IkappaB O +
. O +

Furthermore O +
, O +
LMP1 O +
-induced O +
cell O +
size O +
increase O +
of O +
primary O +
B O +
cells O +
was O +
unaffected O +
by O +
IkappaB O +
expression O +
. O +

It O +
was O +
concluded O +
that O +
even O +
when O +
LMP1 O +
is O +
unable O +
to O +
activate O +
NF O -
- O -
kappaB O +
, O +
it O +
is O +
still O +
capable O +
of O +
inducing O +
certain O +
characteristics O +
of O +
activated O +
B O +
cells O +
, O +
strongly O +
suggesting O +
that O +
LMP1 O +
can O +
also O +
activate O +
cells O +
independently O +
of O +
NF O -
- O -
kappaB O +
. O +

Expression O +
status O +
of O +
BCL-6 O +
and O +
syndecan-1 O +
identifies O +
distinct O +
histogenetic O +
subtypes O +
of O +
Hodgkin O +
's O +
disease O +
. O +

The O +
tumor O +
cells O +
in O +
most O +
cases O +
of O +
Hodgkin O +
's O +
disease O +
( O +
HD O +
) O +
have O +
been O +
recently O +
recognized O +
to O +
originate O +
from O +
the O +
B O -
- O -
cell O +
lineage O +
, O +
but O +
their O +
precise O +
differentiation O +
stage O +
is O +
not O +
fully O +
clarified O +
. O +

Recently O +
, O +
we O +
have O +
reported O +
that O +
the O +
histogenesis O +
of O +
B O -
- O -
cell O +
lymphomas O +
may O +
be O +
assessed O +
by O +
monitoring O +
the O +
expression O +
pattern O +
of O +
BCL-6 O +
, O +
a O +
transcription O +
factor O +
expressed O +
in O +
germinal O +
center O +
( O +
GC O +
) O +
B O +
cells O +
, O +
and O +
CD138 O -
/ O -
syndecan-1 O +
( O +
syn-1 O +
) O +
, O +
a O +
proteoglycan O +
associated O +
with O +
post O -
- O -
GC O +
, O +
terminal O +
B O -
- O -
cell O +
differentiation O +
. O +

In O +
this O +
study O +
, O +
we O +
have O +
applied O +
these O +
two O +
markers O +
to O +
the O +
study O +
of O +
HD O +
histogenesis O +
. O +

We O +
have O +
found O +
that O +
in O +
nodular O +
lymphocyte O +
predominance O +
HD O +
( O +
NLPHD O +
) O +
tumor O +
cells O +
consistently O +
display O +
the O +
BCL-6 O +
( O +
+ O +
) O +
/ O +
syn-1 O +
( O +
- O +
) O +
phenotype O +
, O +
indicating O +
their O +
derivation O +
from O +
GC O +
B O +
cells O +
. O +

Conversely O +
, O +
classic O +
HD O +
( O +
CHD O +
) O +
is O +
heterogeneous O +
because O +
the O +
tumor O +
cells O +
of O +
a O +
fraction O +
of O +
CHD O +
display O +
the O +
BCL-6 O +
( O +
- O +
) O +
/ O +
syn-1 O +
( O +
+ O +
) O +
phenotype O +
of O +
post O -
- O -
GC O +
B O -
- O -
cells O +
, O +
whereas O +
another O +
fraction O +
of O +
CHD O +
is O +
constituted O +
by O +
a O +
mixture O +
of O +
tumor O +
cells O +
reflecting O +
the O +
GC O +
( O +
BCL-6 O +
( O +
+ O +
) O +
/ O +
syn-1 O +
( O +
- O +
) O +
) O +
or O +
post O -
- O -
GC O +
( O +
BCL-6 O +
( O +
- O +
) O +
/ O +
syn-1 O +
( O +
+ O +
) O +
) O +
phenotypes O +
. O +

BCL-6 B-CellLine +
( I-CellLine +
- I-CellLine +
) I-CellLine +
/syn-1 I-CellLine +
( I-CellLine +
+ I-CellLine +
) I-CellLine +
tumor I-CellLine +
cells I-CellLine +
of O +
CHD O +
are O +
mostly O +
found O +
surrounded O +
by O +
T O +
cells O +
expressing O +
CD40L O +
, O +
consistent O +
with O +
the O +
observation O +
that O +
CD40 O +
signaling O +
downregulates O +
BCL-6 O +
expression O +
. O +

These O +
data O +
indicate O +
that O +
tumor O +
cells O +
of O +
NLPHD O +
uniformly O +
display O +
a O +
GC O +
B O -
- O -
cell O +
phenotype O +
, O +
whereas O +
the O +
phenotype O +
of O +
tumor O +
cells O +
of O +
CHD O +
appears O +
to O +
be O +
modulated O +
by O +
the O +
surrounding O +
cellular O +
background O +
, O +
particularly O +
CD40L+ O +
reactive O +
T O +
cells O +
. O +

Interleukin-4 O +
and O +
-13 O +
induce O +
upregulation O +
of O +
the O +
murine O +
macrophage O +
12 O -
/ O -
15-lipoxygenase O +
activity O +
: O +
evidence O +
for O +
the O +
involvement O +
of O +
transcription O +
factor O +
STAT6 O +
. O +

When O +
human O +
monocytes O +
or O +
alveolar O +
macrophages O +
are O +
cultured O +
in O +
the O +
presence O +
of O +
interleukin O +
( O +
IL O +
) O +
-4 O +
or O +
IL-13 O +
, O +
the O +
expression O +
of O +
the O +
reticulocyte O -
- O -
type O +
15-lipoxygenase O +
is O +
induced O +
. O +

In O +
mice O +
a O +
15-lipoxygenase O +
is O +
not O +
expressed O +
, O +
but O +
a O +
leukocyte O -
- O -
type O +
12-lipoxygenase O +
is O +
present O +
in O +
peritoneal O +
macrophages O +
. O +

To O +
investigate O +
whether O +
both O +
lipoxygenase O +
isoforms O +
exhibit O +
a O +
similar O +
regulatory O +
response O +
toward O +
cytokine O +
stimulation O +
, O +
we O +
studied O +
the O +
regulation O +
of O +
the O +
leukocyte O -
- O -
type O +
12-lipoxygenase O +
of O +
murine O +
peritoneal O +
macrophages O +
by O +
interleukins O +
and O +
found O +
that O +
the O +
activity O +
of O +
this O +
enzyme O +
is O +
upregulated O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
when O +
the O +
cells O +
were O +
cultured O +
in O +
the O +
presence O +
of O +
the O +
IL-4 O +
or O +
IL-13 O +
but O +
not O +
by O +
IL-10 O +
. O +

When O +
peripheral O +
murine O +
monocytes O +
that O +
do O +
not O +
express O +
the O +
lipoxygenase O +
were O +
treated O +
with O +
IL-4 O +
expression O +
of O +
12 O -
/ O -
15-lipoxygenase O +
mRNA O +
was O +
induced O +
, O +
suggesting O +
pretranslational O +
control O +
mechanisms O +
. O +

In O +
contrast O +
, O +
no O +
upregulation O +
of O +
the O +
lipoxygenase O +
activity O +
was O +
observed O +
when O +
the O +
macrophages O +
were O +
prepared O +
from O +
homozygous O +
STAT6 O +
-deficient O +
mice O +
. O +

Peritoneal O +
macrophages O +
of O +
transgenic O +
mice O +
that O +
systemically O +
overexpress O +
IL-4 O +
exhibited O +
a O +
threefold O +
to O +
fourfold O +
higher O +
12-lipoxygenase O +
activity O +
than O +
cells O +
prepared O +
from O +
control O +
animals O +
. O +

A O +
similar O +
upregulation O +
of O +
12-lipoxygenase O +
activity O +
was O +
detected O +
in O +
heart O +
, O +
spleen O +
, O +
and O +
lung O +
of O +
the O +
transgenic O +
animals O +
. O +

Moreover O +
, O +
a O +
strong O +
induction O +
of O +
the O +
enzyme O +
was O +
observed O +
in O +
red O +
cells O +
during O +
experimental O +
anemia O +
in O +
mice O +
. O +

The O +
data O +
presented O +
here O +
indicate O +
that O +
( O +
1 O +
) O +
the O +
12-lipoxygenase O +
activity O +
of O +
murine O +
macrophages O +
is O +
upregulated O +
in O +
vitro O +
and O +
in O +
vivo O +
by O +
IL-4 O +
and/or O +
IL-13 O +
, O +
( O +
2 O +
) O +
this O +
upregulation O +
requires O +
expression O +
of O +
the O +
transcription O +
factor O +
STAT6 O +
, O +
and O +
( O +
3 O +
) O +
the O +
constitutive O +
expression O +
of O +
the O +
enzyme O +
appears O +
to O +
be O +
STAT6 O +
independent O +
. O +

The O +
cytokine O +
-dependent O +
upregulation O +
of O +
the O +
murine O +
macrophage O +
12-lipoxygenase O +
and O +
its O +
induction O +
during O +
experimental O +
anemia O +
suggests O +
its O +
close O +
relatedness O +
with O +
the O +
human O +
reticulocyte O -
- O -
type O +
15-lipoxygenase O +
despite O +
their O +
differences O +
in O +
the O +
positional O +
specificity O +
of O +
arachidonic O +
acid O +
oxygenation O +
. O +

The O +
PEBP2betaMYH11 O +
fusion O +
created O +
by O +
Inv O +
( O +
16 O +
) O +
( O +
p13 O +
; O +
q22 O +
) O +
in O +
myeloid O +
leukemia O +
impairs O +
neutrophil O +
maturation O +
and O +
contributes O +
to O +
granulocytic O +
dysplasia O +
. O +

Chromosomal O +
translocations O +
involving O +
the O +
genes O +
encoding O +
the O +
alpha O +
and O +
beta O +
subunits O +
of O +
the O +
Pebp2 O -
/ O -
Cbf O +
transcription O +
factor O +
have O +
been O +
associated O +
with O +
human O +
acute O +
myeloid O +
leukemia O +
and O +
the O +
preleukemic O +
condition O +
, O +
myelodysplasia O +
. O +

Inv O +
( O +
16 O +
) O +
( O +
p13 O +
; O +
q22 O +
) O +
fuses O +
the O +
gene O +
encoding O +
the O +
beta O +
subunit O +
of O +
Pebp2 O +
to O +
the O +
MYH11 O +
gene O +
encoding O +
a O +
smooth O +
muscle O +
myosin O +
heavy O +
chain O +
( O +
Smmhc O +
) O +
. O +

To O +
examine O +
the O +
effect O +
of O +
the O +
inv O +
( O +
16 O +
) O +
( O +
p13 O +
; O +
q22 O +
) O +
on O +
myelopoiesis O +
, O +
we O +
used O +
the O +
hMRP8 O +
promoter O +
element O +
to O +
generate O +
transgenic O +
mice O +
expressing O +
the O +
Pebp2beta O +
Smmhc O +
chimeric O +
fusion O +
protein O +
in O +
myeloid O +
cells O +
. O +

Neutrophil O +
maturation O +
was O +
impaired O +
in O +
PEBP2betaMYH11 O +
transgenic O +
mice O +
. O +

Although O +
the O +
transgenic O +
mice O +
had O +
normal O +
numbers O +
of O +
circulating O +
neutrophils O +
, O +
their O +
bone O +
marrow O +
contained O +
increased O +
numbers O +
of O +
immature O +
neutrophilic O +
cells O +
, O +
which O +
exhibited O +
abnormal O +
characteristics O +
. O +

In O +
addition O +
, O +
PEBP2betaMYH11 O +
inhibited O +
neutrophilic O +
differentiation O +
in O +
colonies O +
derived O +
from O +
hematopoietic O +
progenitors O +
. O +

Coexpression O +
of O +
both O +
PEBP2betaMYH11 O +
and O +
activated O +
NRAS O +
induced O +
a O +
more O +
severe O +
phenotype O +
characterized O +
by O +
abnormal O +
nuclear O +
morphology O +
indicative O +
of O +
granulocytic O +
dysplasia O +
. O +

These O +
results O +
show O +
that O +
PEBP2betaMYH11 O +
can O +
impair O +
neutrophil O +
development O +
and O +
provide O +
evidence O +
that O +
alterations O +
of O +
Pebp2 O +
can O +
contribute O +
to O +
the O +
genesis O +
of O +
myelodysplasia O +
. O +

Carboxyl O -
- O -
terminal O +
15-amino O +
acid O +
sequence O +
of O +
NFATx1 O +
is O +
possibly O +
created O +
by O +
tissue O -
- O -
specific O +
splicing O +
and O +
is O +
essential O +
for O +
transactivation O +
activity O +
in O +
T O +
cells O +
. O +

NFAT O +
regulates O +
transcription O +
of O +
a O +
number O +
of O +
cytokine O +
and O +
other O +
immunoregulatory O +
genes O +
. O +

We O +
have O +
isolated O +
NFATx O +
, O +
which O +
is O +
one O +
of O +
four O +
members O +
of O +
the O +
NFAT O +
family O +
of O +
transcription O +
factors O +
and O +
is O +
preferentially O +
expressed O +
in O +
the O +
thymus O +
and O +
peripheral O +
blood O +
leukocytes O +
, O +
and O +
an O +
isoform O +
of O +
NFATx O +
, O +
NFATx1 O +
. O +

Here O +
we O +
provide O +
evidence O +
showing O +
that O +
15 O +
amino O +
acids O +
in O +
the O +
carboxyl O -
- O -
terminal O +
end O +
of O +
NFATx1 O +
are O +
required O +
for O +
its O +
maximum O +
transactivation O +
activity O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

A O +
fusion O +
between O +
these O +
15 O +
amino O +
acids O +
and O +
the O +
GAL4 O +
DNA O +
binding O +
domain O +
was O +
capable O +
of O +
transactivating O +
reporters O +
driven O +
by O +
the O +
GAL4 O +
DNA O +
binding O +
site O +
. O +

Interestingly O +
, O +
this O +
15-amino O +
acid O +
transactivation O +
sequence O +
is O +
well O +
conserved O +
in O +
NFAT O +
family O +
proteins O +
, O +
although O +
the O +
sequences O +
contiguous O +
to O +
the O +
carboxyl O -
- O -
terminal O +
regions O +
of O +
the O +
NFAT O +
family O +
are O +
much O +
less O +
conserved O +
. O +

We O +
also O +
report O +
three O +
additional O +
isoforms O +
of O +
NFATx O +
, O +
designated O +
NFATx2 O +
, O +
NFATx3 O +
, O +
and O +
NFATx4 O +
. O +

This O +
transactivation O +
sequence O +
is O +
altered O +
by O +
tissue O -
- O -
specific O +
alternative O +
splicing O +
in O +
newly O +
isolated O +
NFATx O +
isoforms O +
, O +
resulting O +
in O +
lower O +
transactivation O +
activity O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

NFATx1 O +
is O +
expressed O +
predominantly O +
in O +
the O +
thymus O +
and O +
peripheral O +
blood O +
leukocyte O +
, O +
while O +
the O +
skeletal O +
muscle O +
expressed O +
primarily O +
NFATx2 O +
. O +

In O +
Jurkat B-CellLine +
cells I-CellLine +
, O +
transcription O +
from O +
the O +
NFAT O +
site O +
of O +
the O +
IL-2 O +
promoter O +
is O +
activated O +
strongly O +
by O +
NFATx1 O +
but O +
only O +
weakly O +
by O +
NFATx2 O +
. O +

These O +
data O +
demonstrate O +
that O +
the O +
15-amino O +
acid O +
sequence O +
of O +
NFATx1 O +
is O +
a O +
major O +
transactivation O +
sequence O +
required O +
for O +
induction O +
of O +
genes O +
by O +
NFATx1 O +
in O +
T O +
cells O +
and O +
possibly O +
regulates O +
NFAT O +
activity O +
through O +
tissue O -
- O -
specific O +
alternative O +
splicing O +
. O +

Potent O +
inhibition O +
of O +
HIV O +
type O +
1 O +
replication O +
by O +
an O +
antiinflammatory O +
alkaloid O +
, O +
cepharanthine O +
, O +
in O +
chronically O +
infected O +
monocytic O +
cells O +
. O +

Cepharanthine O +
is O +
a O +
biscoclaurine O +
alkaloid O +
isolated O +
from O +
Stephania O +
cepharantha O +
Hayata O +
and O +
has O +
been O +
shown O +
to O +
have O +
antiinflammatory O +
, O +
antiallergic O +
, O +
and O +
immunomodulatory O +
activities O +
in O +
vivo O +
. O +

As O +
several O +
inflammatory O +
cytokines O +
and O +
oxidative O +
stresses O +
are O +
involved O +
in O +
the O +
pathogenesis O +
of O +
HIV-1 O +
infection O +
, O +
we O +
investigated O +
the O +
inhibitory O +
effects O +
of O +
cepharanthine O +
on O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
- O +
and O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
-induced O +
HIV-1 O +
replication O +
in O +
chronically B-CellLine +
infected I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Two O +
chronically B-CellLine +
HIV-1-infected I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
U1 B-CellLine +
( O +
monocytic O +
) O +
and O +
ACH-2 B-CellLine +
( O +
T O +
lymphocytic O +
) O +
, O +
were O +
stimulated O +
with O +
TNF O -
- O -
alpha O +
or O +
PMA O +
and O +
cultured O +
in O +
the O +
presence O +
of O +
various O +
concentrations O +
of O +
the O +
compound O +
. O +

HIV-1 O +
replication O +
was O +
determined O +
by O +
p24 O +
antigen O +
level O +
. O +

The O +
inhibitory O +
effects O +
of O +
cepharanthine O +
on O +
HIV-1 O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
-driven O +
gene O +
expression O +
and O +
nuclear O +
factor O +
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
activation O +
were O +
also O +
examined O +
. O +

Cepharanthine O +
dose O +
dependently O +
inhibited O +
HIV-1 O +
replication O +
in O +
TNF B-CellLine -
- I-CellLine -
alpha- I-CellLine +
and I-CellLine +
PMA I-CellLine -
- I-CellLine -
stimulated I-CellLine +
U1 I-CellLine +
cells I-CellLine +
but O +
not O +
in O +
ACH-2 B-CellLine +
cells I-CellLine +
. O +

Its O +
50 O +
% O +
effective O +
and O +
cytotoxic O +
concentrations O +
were O +
0.016 O +
and O +
2.2 O +
microg O -
/ O -
ml O +
in O +
PMA B-CellLine -
- I-CellLine -
stimulated I-CellLine +
U1 I-CellLine +
cells I-CellLine +
, O +
respectively O +
. O +

Cepharanthine O +
was O +
found O +
to O +
suppress O +
HIV-1 O +
LTR O +
-driven O +
gene O +
expression O +
through O +
the O +
inhibition O +
of O +
NF O -
- O -
kappaB O +
activation O +
. O +

These O +
results O +
indicate O +
that O +
cepharanthine O +
is O +
a O +
highly O +
potent O +
inhibitor O +
of O +
HIV-1 O +
replication O +
in O +
a O +
chronically B-CellLine +
infected I-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Since O +
biscoclaurine O +
alkaloids O +
, O +
containing O +
cepharanthine O +
as O +
a O +
major O +
component O +
, O +
are O +
widely O +
used O +
for O +
the O +
treatment O +
of O +
patients O +
with O +
various O +
inflammatory O +
diseases O +
in O +
Japan O +
, O +
cepharanthine O +
should O +
be O +
further O +
pursued O +
for O +
its O +
chemotherapeutic O +
potential O +
in O +
HIV-1-infected O +
patients O +
. O +

Induction O +
of O +
T O +
cell O +
anergy O +
by O +
high O +
concentrations O +
of O +
immunodominant O +
native O +
peptide O +
is O +
accompanied O +
by O +
IL-10 O +
production O +
and O +
a O +
block O +
in O +
JNK O +
activity O +
. O +

The O +
ability O +
to O +
induce O +
anergy O +
in O +
antigen O -
- O -
specific O +
T O +
cells O +
has O +
potential O +
therapeutic O +
value O +
for O +
altering O +
pathologic O +
immune O +
responses O +
. O +

This O +
study O +
was O +
undertaken O +
to O +
further O +
analyze O +
changes O +
in O +
cytokine O +
production O +
and O +
intracellular O +
signaling O +
during O +
anergy O +
induction O +
using O +
high O +
concentrations O +
of O +
native O +
peptide O +
ligand O +
of O +
tetanus B-CellLine +
toxoid I-CellLine +
( I-CellLine +
TT I-CellLine +
) I-CellLine +
- I-CellLine +
and I-CellLine +
myelin I-CellLine +
basic I-CellLine +
protein I-CellLine +
( I-CellLine +
MBP I-CellLine +
) I-CellLine +
-specific I-CellLine +
human I-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

The O +
TT B-CellLine -
- I-CellLine -
selected I-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
could O +
be O +
rendered O +
unresponsive O +
to O +
its O +
dominant O +
epitope O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O +
IC50 O +
= O +
0.03 O +
microg O -
/ O -
ml O +
) O +
. O +

The O +
TT B-CellLine -
- I-CellLine -
selected I-CellLine +
line I-CellLine +
, O +
as O +
well O +
as O +
three O +
T O +
cell O +
clones O +
established O +
from O +
this O +
line O +
, O +
continued O +
to O +
produce O +
IFN O -
- O -
gamma O +
and O +
significantly O +
increased O +
IL-4 O +
and O +
IL-10 O +
production O +
when O +
anergy O +
was O +
induced O +
with O +
high O +
concentrations O +
of O +
the O +
immunodominant O +
epitope O +
. O +

JNK O +
enzymatic O +
activity O +
was O +
blocked O +
in O +
anergized B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

The O +
MBP O +
-selected O +
line O +
could O +
likewise O +
be O +
rendered O +
unresponsive O +
by O +
incubation O +
with O +
supraoptimal O +
concentrations O +
of O +
immunodominant O +
peptide O +
and O +
anergy O +
induction O +
was O +
accompanied O +
by O +
IL-10 O +
release O +
. O +

Both O +
T B-CellLine +
cell I-CellLine +
lines I-CellLine +
could O +
be O +
anergized O +
by O +
the O +
autopresentation O +
of O +
native O +
peptide O +
since O +
anergy O +
was O +
induced O +
in O +
cultures O +
lacking O +
fresh O +
antigen O -
- O -
presenting O +
cells O +
. O +

This O +
study O +
shows O +
that O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
cascade O +
is O +
blocked O +
when O +
anergy O +
is O +
induced O +
to O +
high O +
concentrations O +
of O +
soluble O +
peptide O +
. O +

Copyright O +
1998 O +
Academic O +
Press O +
. O +

Tumor O +
suppressor O +
proteins O +
as O +
regulators O +
of O +
cell O +
differentiation O +
. O +

The O +
products O +
of O +
the O +
tumor O +
suppressor O +
genes O +
are O +
considered O +
to O +
function O +
as O +
specific O +
inhibitors O +
of O +
tumor O +
cell O +
growth O +
. O +

In O +
this O +
communication O +
, O +
we O +
present O +
evidence O +
to O +
show O +
that O +
these O +
proteins O +
inhibit O +
tumor O +
cell O +
proliferation O +
by O +
participating O +
in O +
the O +
activation O +
of O +
tumor O +
cell O +
differentiation O +
. O +

The O +
ML-1 B-CellLine +
human I-CellLine +
myeloblastic I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
used O +
in O +
this O +
study O +
proliferate O +
when O +
treated O +
with O +
insulin O -
- O -
like O +
growth O +
factor O +
I O +
and O +
transferrin O +
but O +
differentiate O +
to O +
monocytes O +
when O +
exposed O +
to O +
tumor O +
necrosis O +
factor O +
alpha O +
or O +
transforming O +
growth O +
factor O +
beta1 O +
, O +
or O +
to O +
macrophage O -
- O -
like O +
cells O +
when O +
treated O +
with O +
both O +
these O +
cytokines O +
. O +

Initiation O +
of O +
proliferation O +
but O +
not O +
of O +
differentiation O +
was O +
followed O +
by O +
a O +
20- O +
to O +
25-fold O +
increase O +
in O +
the O +
nuclear O +
level O +
of O +
the O +
DNA O +
polymerase O -
- O -
associated O +
processivity O +
factor O +
PCNA O +
and O +
of O +
the O +
proliferation O -
- O -
specific O +
transcription O +
factor O +
E2F1 O +
. O +

In O +
contrast O +
, O +
induction O +
of O +
differentiation O +
but O +
not O +
of O +
proliferation O +
was O +
followed O +
by O +
a O +
25- O +
to O +
30-fold O +
increase O +
in O +
the O +
nuclear O +
level O +
of O +
the O +
tumor O +
suppressor O +
proteins O +
p53 O +
( O +
wild O +
type O +
) O +
, O +
pRb O +
, O +
and O +
p130 O -
/ O -
Rb2 O +
and O +
of O +
the O +
p53-dependent O +
cyclin O +
kinase O +
inhibitor O +
p21 O -
/ O -
Cip1 O +
. O +

p53 O +
and O +
p21 O -
/ O -
Cip1 O +
, O +
respectively O +
, O +
inhibit O +
the O +
expression O +
and O +
activation O +
of O +
PCNA O +
, O +
whereas O +
p130 O +
and O +
pRb O +
, O +
respectively O +
, O +
inhibit O +
the O +
expression O +
and O +
activation O +
of O +
E2F1 O +
. O +

As O +
a O +
result O +
, O +
G1-S O -
- O -
associated O +
DNA O +
and O +
mRNA O +
synthesis O +
is O +
inhibited O +
, O +
growth O +
uncoupled O +
from O +
differentiation O +
, O +
and O +
maturation O +
enabled O +
to O +
proceed O +
. O +

Where O +
this O +
function O +
of O +
the O +
tumor O +
suppressor O +
proteins O +
is O +
impaired O +
, O +
the O +
capacity O +
for O +
differentiation O +
is O +
lost O +
, O +
which O +
leads O +
to O +
the O +
sustained O +
proliferation O +
that O +
is O +
characteristic O +
of O +
the O +
cancer O +
cell O +
. O +

Fcgamma O +
receptor O +
-mediated O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
activation O +
in O +
monocytes O +
is O +
independent O +
of O +
Ras O +
. O +

Receptors O +
for O +
the O +
Fc O +
portion O +
of O +
immunoglobulin O +
molecules O +
( O +
FcR O +
) O +
present O +
on O +
leukocyte O +
cell O +
membranes O +
mediate O +
a O +
large O +
number O +
of O +
cellular O +
responses O +
that O +
are O +
very O +
important O +
in O +
host O +
defense O +
, O +
including O +
phagocytosis O +
, O +
cell O +
cytotoxicity O +
, O +
production O +
and O +
secretion O +
of O +
inflammatory O +
mediators O +
, O +
and O +
modulation O +
of O +
the O +
immune O +
response O +
. O +

Cross O -
- O -
linking O +
of O +
FcR O +
with O +
immune O +
complexes O +
leads O +
, O +
first O +
to O +
activation O +
of O +
protein O -
- O -
tyrosine O +
kinases O +
. O +

The O +
molecular O +
events O +
that O +
follow O +
and O +
that O +
transduce O +
signals O +
from O +
these O +
receptors O +
to O +
the O +
nucleus O +
are O +
still O +
poorly O +
defined O +
. O +

We O +
have O +
investigated O +
the O +
signal O +
transduction O +
pathway O +
from O +
Fc O +
receptors O +
that O +
leads O +
to O +
gene O +
activation O +
and O +
production O +
of O +
cytokines O +
in O +
monocytes O +
. O +

Cross O -
- O -
linking O +
of O +
FcR O +
, O +
on O +
the O +
THP-1 B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
by O +
immune O +
complexes O +
resulted O +
in O +
both O +
activation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
and O +
interleukin O +
1 O +
production O +
. O +

These O +
responses O +
were O +
completely O +
blocked O +
by O +
tyrosine O +
kinase O +
inhibitors O +
. O +

In O +
contrast O +
, O +
expression O +
of O +
dominant O +
negative O +
mutants O +
of O +
Ras O +
and O +
Raf-1 O +
, O +
in O +
these O +
cells O +
, O +
did O +
not O +
have O +
any O +
effect O +
on O +
FcR O +
-mediated O +
nuclear O +
factor O +
activation O +
, O +
suggesting O +
that O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
signaling O +
pathway O +
was O +
not O +
used O +
by O +
these O +
receptors O +
. O +

However O +
, O +
MAPK O +
activation O +
was O +
easily O +
detected O +
by O +
in O +
vitro O +
kinase O +
assays O +
, O +
after O +
FcR O +
cross O -
- O -
linking O +
with O +
immune O +
complexes O +
. O +

Using O +
the O +
specific O +
MAPK O +
/extracellular O +
signal O -
- O -
regulated O +
kinase O +
kinase O +
( O +
MAPK O +
kinase O +
) O +
inhibitor O +
PD98059 O +
, O +
we O +
found O +
that O +
MAPK O +
activation O +
is O +
necessary O +
for O +
FcR O +
-dependent O +
activation O +
of O +
the O +
nuclear O +
factor O +
NF O -
- O -
kappaB O +
. O +

These O +
results O +
strongly O +
suggest O +
that O +
the O +
signaling O +
pathway O +
from O +
Fc O +
receptors O +
leading O +
to O +
expression O +
of O +
different O +
genes O +
important O +
to O +
leukocyte O +
biology O +
, O +
initiates O +
with O +
tyrosine O +
kinases O +
and O +
requires O +
MAPK O +
activation O +
; O +
but O +
in O +
contrast O +
to O +
other O +
tyrosine O +
kinase O +
receptors O +
, O +
FcR O +
-mediated O +
MAPK O +
activation O +
does O +
not O +
involve O +
Ras O +
and O +
Raf O +
. O +

A O +
critical O +
role O +
of O +
the O +
p75 O +
tumor O +
necrosis O +
factor O +
receptor O +
( O +
p75TNF O -
- O -
R O +
) O +
in O +
organ O +
inflammation O +
independent O +
of O +
TNF O +
, O +
lymphotoxin O +
alpha O +
, O +
or O +
the O +
p55TNF O -
- O -
R O +
. O +

Despite O +
overwhelming O +
evidence O +
that O +
enhanced O +
production O +
of O +
the O +
p75 O +
tumor O +
necrosis O +
factor O +
receptor O +
( O +
p75TNF O -
- O -
R O +
) O +
accompanies O +
development O +
of O +
specific O +
human O +
inflammatory O +
pathologies O +
such O +
as O +
multi O -
- O -
organ O +
failure O +
during O +
sepsis O +
, O +
inflammatory O +
liver O +
disease O +
, O +
pancreatitis O +
, O +
respiratory O +
distress O +
syndrome O +
, O +
or O +
AIDS O +
, O +
the O +
function O +
of O +
this O +
receptor O +
remains O +
poorly O +
defined O +
in O +
vivo O +
. O +

We O +
show O +
here O +
that O +
at O +
levels O +
relevant O +
to O +
human O +
disease O +
, O +
production O +
of O +
the O +
human O +
p75TNF O -
- O -
R O +
in O +
transgenic O +
mice O +
results O +
in O +
a O +
severe O +
inflammatory O +
syndrome O +
involving O +
mainly O +
the O +
pancreas O +
, O +
liver O +
, O +
kidney O +
, O +
and O +
lung O +
, O +
and O +
characterized O +
by O +
constitutively O +
increased O +
NF O -
- O -
kappaB O +
activity O +
in O +
the O +
peripheral O +
blood O +
mononuclear O +
cell O +
compartment O +
. O +

This O +
process O +
is O +
shown O +
to O +
evolve O +
independently O +
of O +
the O +
presence O +
of O +
TNF O +
, O +
lymphotoxin O +
alpha O +
, O +
or O +
the O +
p55TNF O -
- O -
R O +
, O +
although O +
coexpression O +
of O +
a O +
human O +
TNF O +
transgene O +
accelerated O +
pathology O +
. O +

These O +
results O +
establish O +
an O +
independent O +
role O +
for O +
enhanced O +
p75TNF O -
- O -
R O +
production O +
in O +
the O +
pathogenesis O +
of O +
inflammatory O +
disease O +
and O +
implicate O +
the O +
direct O +
involvement O +
of O +
this O +
receptor O +
in O +
a O +
wide O +
range O +
of O +
human O +
inflammatory O +
pathologies O +
. O +

musculin O +
: O +
a O +
murine O +
basic O +
helix O -
- O -
loop O -
- O -
helix O +
transcription O +
factor O +
gene O +
expressed O +
in O +
embryonic O +
skeletal O +
muscle O +
. O +

We O +
describe O +
the O +
embryonic O +
expression O +
of O +
musculin O +
, O +
a O +
new O +
murine O +
member O +
of O +
the O +
bHLH O +
family O +
of O +
transcription O +
factors O +
. O +

Musculin O +
protein O +
is O +
closely O +
related O +
to O +
human O +
ABF-1 O +
, O +
which O +
is O +
expressed O +
in O +
activated O +
B O +
cells O +
, O +
and O +
to O +
epicardin O -
/ O -
capsulin O -
/ O -
Pod-1 O +
, O +
which O +
is O +
expressed O +
in O +
branchial O +
myoblasts O +
, O +
visceral O +
and O +
urogenital O +
mesoderm O +
and O +
epicardium O +
. O +

In O +
situ O +
hybridisation O +
revealed O +
musculin O +
expression O +
in O +
embryos O +
was O +
largely O +
restricted O +
to O +
the O +
embryonic O +
skeletal O +
muscle O +
lineage O +
. O +

While O +
all O +
skeletal O +
muscles O +
expressed O +
the O +
gene O +
, O +
only O +
a O +
subset O +
of O +
myocytes O +
within O +
each O +
muscle O +
were O +
positive O +
, O +
indicating O +
molecular O +
heterogeneity O +
within O +
fetal O +
muscle O +
. O +

Copyright O +
1998 O +
Elsevier O +
Science O +
Ireland O +
Ltd O +
. O +

All O +
Rights O +
Reserved O +
. O +

CD4 O +
promoter O +
transactivation O +
by O +
human O +
herpesvirus O +
6 O +
. O +

The O +
observation O +
that O +
human O +
herpesvirus O +
6 O +
( O +
HHV-6 O +
) O +
can O +
induce O +
CD4 O +
gene O +
transcription O +
and O +
expression O +
in O +
CD4 B-CellLine +
( I-CellLine +
- I-CellLine +
) I-CellLine +
cells I-CellLine +
was O +
reported O +
several O +
years O +
ago O +
( O +
P.Lusso O +
, O +
A.De O +
Maria O +
, O +
M.Malnati O +
, O +
F.Lori O +
, O +
S.E.DeRocco O +
, O +
M. O +
Baseler O +
, O +
and O +
R.C.Gallo O +
, O +
Nature O +
349 O +
: O +
533 O -
- O -
535 O +
, O +
1991 O +
) O +
and O +
subsequently O +
confirmed O +
( O +
P.Lusso O +
, O +
M.S.Malnati O +
, O +
A.Garzino O -
- O -
Demo O +
, O +
R.W.Crowley O +
, O +
E. O +
O.Long O +
, O +
and O +
R.C.Gallo O +
, O +
Nature O +
362 O +
: O +
458 O -
- O -
462 O +
, O +
1993 O +
; O +
G.Furlini O +
, O +
M. O +
Vignoli O +
, O +
E.Ramazzotti O +
, O +
M.C.Re O +
, O +
G.Visani O +
, O +
and O +
M.LaPlaca O +
, O +
Blood O +
87 O +
: O +
4737 O -
- O -
4745 O +
, O +
1996 O +
) O +
. O +

Our O +
objective O +
was O +
to O +
identify O +
the O +
mechanisms O +
underlying O +
such O +
phenomena O +
. O +

Using O +
reporter O +
gene O +
constructs O +
driven O +
by O +
the O +
CD4 O +
promoter O +
, O +
we O +
report O +
that O +
HHV-6 O +
can O +
efficiently O +
transactivate O +
such O +
genetic O +
elements O +
. O +

Activation O +
of O +
the O +
CD4 O +
promoter O +
occurs O +
in O +
the O +
presence O +
of O +
the O +
viral O +
DNA O +
polymerase O +
inhibitor O +
phosphonoformic O +
acid O +
, O +
which O +
limits O +
expression O +
to O +
the O +
immediate O -
- O -
early O +
and O +
early O +
classes O +
of O +
viral O +
genes O +
. O +

Using O +
deletion O +
mutants O +
and O +
specific O +
CD4 O +
promoter O +
mutants O +
, O +
we O +
identified O +
an O +
ATF O -
/ O -
CRE O +
binding O +
site O +
located O +
at O +
nucleotides O +
-67 O +
to O +
-60 O +
upstream O +
of O +
the O +
CD4 O +
gene O +
transcription O +
start O +
site O +
that O +
is O +
important O +
for O +
HHV-6 O +
transactivation O +
. O +

The O +
ATF O -
/ O -
CRE O +
site O +
is O +
also O +
essential O +
for O +
CD4 O +
promoter O +
activation O +
by O +
forskolin O +
, O +
an O +
activator O +
of O +
adenylate O +
cyclase O +
. O +

Using O +
electrophoretic O +
mobility O +
shift O +
assays O +
and O +
specific O +
antibodies O +
, O +
we O +
showed O +
that O +
CREB-1 O +
binds O +
specifically O +
to O +
the O +
-79 O +
to O +
-52 O +
region O +
of O +
the O +
CD4 O +
promoter O +
. O +

Last O +
, O +
we O +
have O +
identified O +
two O +
open O +
reading O +
frames O +
( O +
ORFs O +
) O +
of O +
HHV-6 O +
, O +
U86 O +
and O +
U89 O +
from O +
the O +
immediate O -
- O -
early O +
locus O +
A O +
, O +
that O +
can O +
transactivate O +
the O +
CD4 O +
promoter O +
in O +
HeLa B-CellLine +
cells I-CellLine +
. O +

However O +
, O +
transactivation O +
of O +
the O +
CD4 O +
promoter O +
by O +
ORFs O +
U86 O +
and O +
U89 O +
is O +
independent O +
of O +
the O +
CRE O +
element O +
, O +
suggesting O +
that O +
additional O +
HHV-6 O +
ORFs O +
are O +
likely O +
to O +
contribute O +
to O +
CD4 O +
gene O +
activation O +
. O +

Taken O +
together O +
, O +
our O +
results O +
will O +
help O +
to O +
understand O +
the O +
complex O +
interactions O +
occurring O +
between O +
HHV-6 O +
and O +
the O +
CD4 O +
promoter O +
and O +
provide O +
additional O +
information O +
regarding O +
the O +
class O +
of O +
transcription O +
factors O +
involved O +
in O +
the O +
control O +
of O +
CD4 O +
gene O +
expression O +
. O +

Cross O -
- O -
priming O +
of O +
CTL O +
responses O +
in O +
vivo O +
does O +
not O +
require O +
antigenic O +
peptides O +
in O +
the O +
endoplasmic O +
reticulum O +
of O +
immunizing O +
cells O +
. O +

It O +
has O +
been O +
proposed O +
that O +
the O +
cross O -
- O -
priming O +
of O +
CTL O +
responses O +
in O +
vivo O +
involves O +
the O +
transfer O +
to O +
host O +
APCs O +
of O +
heat O +
shock O +
protein O +
glycoprotein O +
96 O +
-chaperoned O +
antigenic O +
peptides O +
released O +
from O +
the O +
endoplasmic O +
reticulum O +
( O +
ER O +
) O +
of O +
dying O +
or O +
infected O +
cells O +
. O +

We O +
have O +
tested O +
this O +
possibility O +
directly O +
using O +
TAP B-CellLine -
- I-CellLine -
deficient I-CellLine +
cell I-CellLine +
lines I-CellLine +
lacking O +
antigenic O +
ER O +
peptides O +
derived O +
from O +
two O +
model O +
Ags O +
, O +
the O +
human O +
adenovirus O +
type O +
5 O +
early O +
regions O +
E1A O +
and O +
E1B O +
. O +

Although O +
both O +
proteins O +
were O +
well O +
expressed O +
, O +
the O +
cells O +
were O +
not O +
recognized O +
by O +
E1A- O +
or O +
E1B O -
- O -
specific O +
CTLs O +
unless O +
the O +
relevant O +
epitope O +
was O +
either O +
provided O +
exogenously O +
as O +
a O +
synthetic O +
peptide O +
or O +
targeted O +
to O +
the O +
ER O +
in O +
a O +
TAP O -
- O -
independent O +
fashion O +
. O +

Despite O +
the O +
absence O +
of O +
these O +
ER O +
peptides O +
, O +
the O +
TAP1- O -
/ O -
- O +
cells O +
were O +
able O +
to O +
efficiently O +
cross O -
- O -
prime O +
E1A- O +
and O +
E1B O -
- O -
specific O +
CTLs O +
following O +
immunization O +
of O +
syngeneic O +
mice O +
. O +

These O +
results O +
indicate O +
that O +
, O +
although O +
purified O +
peptide O -
/ O -
glycoprotein O +
96 O +
complexes O +
are O +
potent O +
immunogens O +
, O +
the O +
mechanism O +
of O +
CTL O +
cross O -
- O -
priming O +
in O +
vivo O +
does O +
not O +
depend O +
upon O +
antigenic O +
peptides O +
in O +
the O +
ER O +
of O +
immunizing O +
cells O +
. O +

Differential O +
responsiveness O +
of O +
the O +
IL-5 O +
and O +
IL-4 O +
genes O +
to O +
transcription O +
factor O +
GATA-3 O +
. O +

The O +
cytokines O +
IL-4 O +
and O +
IL-5 O +
are O +
often O +
coordinately O +
produced O +
by O +
Th2 B-CellLine +
cells I-CellLine +
as O +
in O +
asthma O +
. O +

However O +
, O +
it O +
is O +
unclear O +
whether O +
similar O +
molecular O +
mechanisms O +
underlie O +
transcription O +
of O +
the O +
two O +
genes O +
. O +

We O +
have O +
previously O +
shown O +
that O +
the O +
transcription O +
factor O +
GATA-3 O +
is O +
expressed O +
in O +
Th2 B-CellLine +
but I-CellLine +
not I-CellLine +
Th1 I-CellLine +
cells I-CellLine +
and O +
is O +
crucial O +
for O +
activation O +
of O +
the O +
IL-5 O +
promoter O +
by O +
different O +
stimuli O +
. O +

In O +
a O +
different O +
study O +
, O +
GATA-3 O +
was O +
shown O +
to O +
be O +
sufficient O +
for O +
the O +
expression O +
of O +
IL-4 O +
and O +
other O +
Th2 O +
cytokine O +
genes O +
. O +

Here O +
, O +
we O +
show O +
that O +
ectopic O +
expression O +
of O +
GATA-3 O +
is O +
sufficient O +
to O +
drive O +
IL-5 O +
but O +
not O +
IL-4 O +
gene O +
expression O +
. O +

Also O +
, O +
in O +
Th2 B-CellLine +
cells I-CellLine +
, O +
antisense O +
GATA-3 O +
RNA O +
inhibits O +
IL-5 O +
but O +
not O +
IL-4 O +
promoter O +
activation O +
. O +

The O +
induction O +
of O +
IL-5 O +
gene O +
expression O +
by O +
GATA-3 O +
involves O +
high O +
affinity O +
binding O +
of O +
GATA-3 O +
to O +
an O +
inverted O +
GATA O +
repeat O +
in O +
the O +
IL-5 O +
promoter O +
. O +

Seminoma O +
in O +
a O +
postmenopausal O +
woman O +
with O +
a O +
Y O +
; O +
15 O +
translocation O +
in O +
peripheral O +
blood O +
lymphocytes O +
and O +
a O +
t O +
( O +
Y O +
; O +
15 O +
) O +
/45 O +
, O +
X O +
Turner O +
mosaic O +
pattern O +
in O +
skin O +
fibroblasts O +
. O +

We O +
report O +
an O +
unusual O +
case O +
of O +
a O +
55 O +
year O +
old O +
Japanese O +
woman O +
with O +
a O +
seminoma O +
but O +
relatively O +
normal O +
menses O +
. O +

The O +
patient O +
was O +
a O +
phenotypic O +
female O +
with O +
late O +
onset O +
menarche O +
( O +
18 O +
years O +
of O +
age O +
) O +
, O +
who O +
was O +
amenorrhoeic O +
for O +
the O +
first O +
year O +
, O +
followed O +
by O +
menses O +
of O +
one O +
to O +
three O +
days O +
' O +
slight O +
flow O +
with O +
dysmenorrhoea O +
, O +
but O +
an O +
otherwise O +
normal O +
menstrual O +
history O +
. O +

A O +
typical O +
seminoma O +
was O +
removed O +
from O +
the O +
left O +
adnexal O +
region O +
and O +
an O +
immature O +
testis O +
was O +
identified O +
separately O +
as O +
an O +
associated O +
right O +
adnexal O +
mass O +
. O +

Repeated O +
karyotypic O +
studies O +
on O +
peripheral O +
blood O +
lymphocyte O +
cultures O +
showed O +
only O +
46 O +
, O +
X O +
, O +
-Y O +
, O +
t O +
( O +
Y O +
; O +
15 O +
) O +
( O +
q12 O +
; O +
p13 O +
) O +
. O +

Cytogenetic O +
examination O +
of O +
the O +
patient O +
's O +
younger O +
brother O +
, O +
who O +
had O +
fathered O +
three O +
healthy O +
children O +
, O +
showed O +
an O +
identical O +
karyotype O +
. O +

Mosaicism O +
of O +
46 B-CellLine +
, I-CellLine +
X I-CellLine +
, I-CellLine +
-Y I-CellLine +
, I-CellLine +
t I-CellLine +
( I-CellLine +
Y I-CellLine +
; I-CellLine +
15 I-CellLine +
) I-CellLine +
( I-CellLine +
q12 I-CellLine +
; I-CellLine +
p13 I-CellLine +
) I-CellLine +
/45 I-CellLine +
, I-CellLine +
X I-CellLine +
cell I-CellLine +
lines I-CellLine +
was O +
found O +
in O +
skin O +
samples O +
from O +
the O +
patient O +
's O +
elbow O +
and O +
genital O +
regions O +
, O +
although O +
there O +
were O +
no O +
clinical O +
stigmata O +
of O +
Turner O +
syndrome O +
. O +

An O +
androgen O +
receptor O +
binding O +
assay O +
of O +
cultured B-CellLine +
genital I-CellLine +
skin I-CellLine +
fibroblasts I-CellLine +
was O +
negative O +
. O +

Molecular O +
analysis O +
using O +
Southern O +
blot O +
hybridisation O +
, O +
PCR O +
, O +
and O +
direct O +
DNA O +
sequencing O +
showed O +
that O +
neither O +
the O +
patient O +
nor O +
her O +
brother O +
had O +
a O +
detectable O +
deletion O +
or O +
other O +
abnormalities O +
of O +
Y O +
chromosome O +
sequences O +
, O +
including O +
the O +
SRY O +
( O +
sex O +
determining O +
region O +
of O +
the O +
Y O +
chromosome O +
) O +
gene O +
sequence O +
. O +

These O +
findings O +
suggest O +
that O +
Turner O +
mosaicism O +
of O +
the O +
45 B-CellLine +
, I-CellLine +
X I-CellLine +
cell I-CellLine +
line I-CellLine +
may O +
have O +
contributed O +
to O +
this O +
atypical O +
presentation O +
in O +
an O +
XY O +
female O +
, O +
although O +
we O +
can O +
not O +
exclude O +
abnormalities O +
of O +
other O +
genes O +
related O +
to O +
sex O +
differentiation O +
. O +

Differential O +
RNA O +
display O +
identifies O +
novel O +
genes O +
associated O +
with O +
decreased O +
vitamin O +
D O +
receptor O +
expression O +
. O +

To O +
characterize O +
further O +
the O +
function O +
of O +
the O +
intracellular O +
vitamin O +
D O +
receptor O +
( O +
VDR O +
) O +
, O +
we O +
have O +
developed O +
stable B-CellLine +
transfectant I-CellLine +
variants I-CellLine +
of O +
a O +
vitamin B-CellLine +
D I-CellLine -
- I-CellLine -
responsive I-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
U937 B-CellLine +
) O +
which O +
express O +
either O +
decreased O +
or O +
increased O +
numbers O +
of O +
VDR O +
. O +

In O +
this O +
study O +
we O +
have O +
analyzed O +
changes O +
in O +
gene O +
expression O +
associated O +
with O +
this O +
variable O +
VDR O +
expression O +
. O +

Initial O +
experiments O +
indicated O +
that O +
a O +
50 O +
% O +
decrease O +
in O +
VDR O +
levels O +
was O +
associated O +
with O +
a O +
2-fold O +
increase O +
in O +
cell O +
proliferation O +
and O +
a O +
similar O +
rise O +
in O +
c O -
- O -
myc O +
mRNA O +
expression O +
. O +

Further O +
studies O +
were O +
carried O +
out O +
using O +
differential O +
RNA O +
display O +
( O +
DD O +
) O +
. O +

Sequence O +
analysis O +
of O +
DD O +
products O +
revealed O +
two O +
cDNAs O +
with O +
identity O +
to O +
known O +
gene O +
products O +
: O +
the O +
catalytic O +
sub O -
- O -
unit O +
of O +
DNA O -
- O -
protein O +
kinase O +
( O +
DNA O -
- O -
PK O +
( O +
CS O +
) O +
) O +
, O +
and O +
the O +
peroxisomal O +
enzyme O +
17beta O -
- O -
hydroxysteroid O +
dehydrogenase O +
type O +
IV O +
( O +
17beta O -
- O -
HSD O +
IV O +
) O +
. O +

Northern O +
analysis O +
confirmed O +
that O +
expression O +
of O +
both O +
mRNAs O +
was O +
reduced O +
in O +
cells O +
with O +
decreased O +
numbers O +
of O +
VDR O +
. O +

Down O -
- O -
regulation O +
of O +
17beta O -
- O -
HSD O +
IV O +
mRNA O +
expression O +
was O +
associated O +
with O +
enhanced O +
estradiol O +
inactivation O +
by O +
U937 B-CellLine +
cells I-CellLine +
, O +
suggesting O +
a O +
link O +
between O +
estrogenic O +
pathways O +
and O +
cell O +
proliferation O +
. O +

Further O +
Northern O +
analyses O +
indicated O +
that O +
there O +
was O +
no O +
significant O +
change O +
in O +
17beta O -
- O -
HSD O +
IV O +
or O +
DNA O -
- O -
PK O +
( O +
CS O +
) O +
mRNA O +
levels O +
following O +
treatment O +
with O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
, O +
although O +
expression O +
of O +
both O +
genes O +
varied O +
with O +
changes O +
in O +
cell O +
proliferation O +
. O +

These O +
data O +
suggest O +
that O +
, O +
in O +
addition O +
to O +
its O +
established O +
role O +
as O +
a O +
hormone O -
- O -
dependent O +
trans O -
- O -
activator O +
, O +
VDR O +
may O +
influence O +
gene O +
expression O +
by O +
ligand O -
- O -
independent O +
mechanisms O +
. O +

The O +
role O +
of O +
caspases O +
in O +
T O +
cell O +
development O +
and O +
the O +
control O +
of O +
immune O +
responses O +
. O +

Apoptosis O +
is O +
responsible O +
for O +
the O +
removal O +
of O +
potentially O +
autoreactive O +
or O +
useless O +
T O +
cells O +
during O +
thymic O +
selection O +
and O +
activated O +
T O +
cells O +
in O +
the O +
periphery O +
. O +

Specific O +
families O +
of O +
receptors O +
, O +
kinases O +
, O +
transcription O +
factors O +
, O +
and O +
cysteine O +
proteases O +
, O +
termed O +
caspases O +
, O +
are O +
involved O +
in O +
the O +
apoptotic O +
cascade O +
leading O +
to O +
proteolysis O +
of O +
specific O +
substrates O +
and O +
to O +
morphological O +
changes O +
associated O +
with O +
programmed O +
cell O +
death O +
. O +

Although O +
common O +
members O +
of O +
the O +
apoptotic O +
cascade O +
are O +
shared O +
between O +
different O +
cell O +
types O +
, O +
it O +
appears O +
that O +
cell O -
- O -
specific O +
factors O +
can O +
influence O +
the O +
response O +
to O +
a O +
given O +
apoptotic O +
stimuli O +
. O +

Characterization O +
and O +
understanding O +
of O +
the O +
basic O +
mechanisms O +
involved O +
in O +
the O +
different O +
pathways O +
protecting O +
or O +
leading O +
to O +
cell O +
death O +
may O +
provide O +
novel O +
ways O +
to O +
control O +
inappropriate O +
apoptosis O +
involved O +
in O +
several O +
diseases O +
. O +

Relationship O +
between O +
IkappaBalpha O +
constitutive O +
expression O +
, O +
TNFalpha O +
synthesis O +
, O +
and O +
apoptosis O +
in O +
EBV O -
- O -
infected O +
lymphoblastoid O +
cells O +
. O +

In O +
order O +
to O +
understand O +
the O +
role O +
of O +
NF O -
- O -
kappaB O +
in O +
EBV O +
transformation O +
we O +
have O +
established O +
stably O +
transfected O +
IkappaBalpha O +
into O +
lymphoblastoid O +
cells O +
. O +

Two O +
clones O +
were O +
obtained O +
in O +
which O +
the O +
loss O +
of O +
NF O -
- O -
kappaB O +
binding O +
activity O +
correlated O +
with O +
the O +
constitutive O +
expression O +
of O +
the O +
transgenic O +
IkappaBalpha O +
. O +

Protein O +
latency O +
expression O +
was O +
determined O +
by O +
immunocytochemistry O +
. O +

Expression O +
of O +
surface O +
markers O +
, O +
intracytoplasmic O +
content O +
of O +
cytokines O +
cell O +
cycle O +
analysis O +
after O +
BrdU O +
incorporation O +
and O +
DNA O +
staining O +
with O +
propidium O +
iodide O +
were O +
studied O +
by O +
flow O +
cytometry O +
. O +

Percentage O +
of O +
apoptotic O +
cells O +
was O +
determined O +
by O +
in O -
- O -
situ O +
labelling O +
of O +
DNA O +
strand O +
breaks O +
. O +

No O +
significative O +
changes O +
in O +
EBV O +
latency O +
nor O +
in O +
cell O +
surface O +
marker O +
expression O +
was O +
found O +
. O +

In O +
contrast O +
, O +
intracytoplasmic O +
TNFalpha O +
levels O +
were O +
strongly O +
reduced O +
in O +
transfected B-CellLine +
clones I-CellLine +
. O +

Furthermore O +
, O +
30 O +
% O +
of O +
IkappaBalpha B-CellLine +
transfected I-CellLine +
cells I-CellLine +
were O +
apoptotic O +
after O +
8 O +
h O +
of O +
TNFalpha O +
treatment O +
. O +

This O +
correlated O +
with O +
a O +
strong O +
reduction O +
of O +
BrdU O +
incorporation O +
after O +
24 O +
h O +
of O +
TNFalpha O +
treatment O +
. O +

No O +
effect O +
was O +
seen O +
with O +
non O +
transfected B-CellLine +
cells I-CellLine +
or O +
with O +
cells O +
transfected O +
with O +
a O +
control O +
plasmid O +
. O +

Our O +
results O +
suggest O +
that O +
the O +
TNFalpha O +
gene O +
could O +
be O +
one O +
of O +
the O +
targets O +
of O +
NF O -
- O -
kappaB O +
in O +
EBV O +
infected O +
cells O +
and O +
that O +
NF O -
- O -
kappaB O +
protects O +
EBV O -
- O -
infected O +
cells O +
from O +
apoptosis O +
induced O +
by O +
TNFalpha O +
, O +
which O +
may O +
favour O +
the O +
proliferative O +
effect O +
of O +
this O +
cytokine O +
. O +

Uncoupling O +
activation O -
- O -
dependent O +
HS1 O +
phosphorylation O +
from O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
transcriptional O +
activation O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
: O +
differential O +
signaling O +
through O +
CD3 O +
and O +
the O +
costimulatory O +
receptors O +
CD2 O +
and O +
CD28 O +
. O +

CD3 O +
, O +
CD2 O +
, O +
and O +
CD28 O +
are O +
functionally O +
distinct O +
receptors O +
on O +
T O +
lymphocytes O +
. O +

Engagement O +
of O +
any O +
of O +
these O +
receptors O +
induces O +
the O +
rapid O +
tyrosine O +
phosphorylation O +
of O +
a O +
shared O +
group O +
of O +
intracellular O +
signaling O +
proteins O +
, O +
including O +
Vav O +
, O +
Cbl O +
, O +
p85 O +
phosphoinositide O +
3-kinase O +
, O +
and O +
the O +
Src O +
family O +
kinases O +
Lck O +
and O +
Fyn O +
. O +

Ligation O +
of O +
CD3 O +
also O +
induces O +
the O +
tyrosine O +
phosphorylation O +
of O +
HS1 O +
, O +
a O +
75-kDa O +
hematopoietic O +
cell O -
- O -
specific O +
intracellular O +
signaling O +
protein O +
of O +
unknown O +
function O +
. O +

We O +
have O +
examined O +
changes O +
in O +
HS1 O +
phosphorylation O +
after O +
differential O +
stimulation O +
of O +
CD3 O +
, O +
CD2 O +
, O +
and O +
CD28 O +
to O +
elucidate O +
its O +
role O +
in O +
T O +
cells O +
and O +
to O +
further O +
delineate O +
the O +
signaling O +
pathways O +
recruited O +
by O +
these O +
receptors O +
. O +

Unlike O +
ligation O +
of O +
CD3 O +
, O +
stimulation O +
with O +
anti O -
- O -
CD28 O +
mAb O +
or O +
CHO B-CellLine +
cells I-CellLine +
expressing O +
the O +
CD28 O +
ligands O +
CD80 O +
or O +
CD86 O +
did O +
not O +
lead O +
to O +
tyrosine O +
phosphorylation O +
of O +
HS1 O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Additionally O +
, O +
no O +
tyrosine O +
phosphorylation O +
of O +
HS1 O +
was O +
induced O +
by O +
mitogenic O +
pairs O +
of O +
anti O -
- O -
CD2 O +
mAbs O +
capable O +
of O +
activating O +
the O +
transcription O +
factor O +
NFAT O +
( O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
) O +
. O +

Costimulation O +
through O +
CD28 O +
and/or O +
CD2 O +
did O +
not O +
modulate O +
the O +
CD3 O +
-dependent O +
phosphorylation O +
of O +
HS1 O +
. O +

In O +
vivo O +
studies O +
indicated O +
that O +
CD3 O +
-induced O +
HSI O +
phosphorylation O +
was O +
dependent O +
upon O +
both O +
the O +
Src O +
family O +
tyrosine O +
kinase O +
Lck O +
and O +
the O +
tyrosine O +
phosphatase O +
CD45 O +
, O +
did O +
not O +
require O +
MEK1 O +
kinase O +
activity O +
, O +
and O +
was O +
regulated O +
by O +
protein O +
kinase O +
C O +
activation O +
. O +

Thus O +
, O +
although O +
CD3 O +
, O +
CD28 O +
, O +
and O +
CD2 O +
activate O +
many O +
of O +
the O +
same O +
signaling O +
molecules O +
, O +
they O +
differed O +
in O +
their O +
capacity O +
to O +
induce O +
the O +
tyrosine O +
phosphorylation O +
of O +
HSI O +
. O +

Furthermore O +
, O +
activation O -
- O -
dependent O +
tyrosine O +
phosphorylation O +
of O +
HS1 O +
was O +
not O +
required O +
for O +
NFAT O +
transcriptional O +
activation O +
. O +

A O +
mouse O +
carrying O +
genetic O +
defect O +
in O +
the O +
choice O +
between O +
T O +
and O +
B O +
lymphocytes O +
. O +

Transgenic O +
mice O +
with O +
human O +
CD3epsilon O +
gene O +
have O +
been O +
shown O +
to O +
exhibit O +
early O +
arrest O +
of O +
T O +
cell O +
development O +
in O +
the O +
thymus O +
. O +

The O +
present O +
study O +
shows O +
that O +
, O +
instead O +
of O +
T O +
cells O +
, O +
B O +
cells O +
are O +
generated O +
in O +
the O +
thymus O +
of O +
a O +
line O +
, O +
tg O +
epsilon26 O +
, O +
of O +
the O +
human O +
CD3epsilon O +
transgenic O +
mice O +
. O +

The O +
accumulation O +
of O +
mature O +
B O +
cells O +
in O +
the O +
thymus O +
was O +
found O +
only O +
in O +
tg O +
epsilon26 O +
mice O +
, O +
not O +
in O +
other O +
human B-CellLine +
CD3epsilon I-CellLine +
transgenic I-CellLine +
mouse I-CellLine +
lines I-CellLine +
or O +
other O +
T O +
cell O -
- O -
deficient O +
mice O +
, O +
including O +
CD3-epsilon O +
knockout O +
mice O +
and O +
TCR O -
- O -
beta O -
/ O -
TCR O -
- O -
delta O +
double O +
knockout O +
mice O +
. O +

Hanging O +
drop O -
- O -
mediated O +
transfer O +
into O +
2-deoxyguanosine O -
- O -
treated O +
thymus O +
lobes O +
showed O +
that O +
lymphoid O +
progenitor O +
cells O +
rather O +
than O +
thymus O +
stromal O +
cells O +
were O +
responsible O +
for O +
abnormal O +
B O +
cell O +
development O +
in O +
tg O +
epsilon26 O +
thymus O +
, O +
and O +
that O +
tg O +
epsilon26 O +
fetal O +
liver O +
cells O +
were O +
destined O +
to O +
become O +
B O +
cells O +
in O +
normal O +
thymus O +
even O +
in O +
the O +
presence O +
of O +
normal O +
progenitor O +
cells O +
undergoing O +
T O +
cell O +
development O +
. O +

These O +
results O +
indicate O +
that O +
lymphoid O +
progenitor O +
cells O +
in O +
tg O +
epsilon26 O +
mice O +
are O +
genetically O +
defective O +
in O +
thymic O +
choice O +
between O +
T O +
cells O +
and O +
B O +
cells O +
, O +
generating O +
B O +
cells O +
even O +
in O +
normal O +
thymus O +
environment O +
. O +

Interestingly O +
, O +
tg O +
epsilon26 O +
thymocytes O +
expressed O +
GATA-3 O +
and O +
TCF-1 O +
, O +
but O +
not O +
LEF-1 O +
and O +
PEBP-2alpha O +
, O +
among O +
T O +
cell O -
- O -
specific O +
transcription O +
factors O +
that O +
are O +
involved O +
in O +
early O +
T O +
cell O +
development O +
, O +
indicating O +
that O +
GATA-3 O +
and O +
TCF-1 O +
expressed O +
during O +
thymocyte O +
development O +
do O +
not O +
necessarily O +
determine O +
the O +
cell O +
fate O +
into O +
T O +
cell O +
lineage O +
. O +

Thus O +
, O +
tg O +
epsilon26 O +
mice O +
provide O +
a O +
novel O +
mouse O +
model O +
in O +
that O +
lineage O +
choice O +
between O +
T O +
and O +
B O +
lymphocytes O +
is O +
genetically O +
defective O +
. O +

The O +
role O +
of O +
protein O +
kinase O +
C O +
signaling O +
in O +
activated O +
DRA O +
transcription O +
. O +

Expression O +
of O +
human O +
MHC O +
HLA O -
- O -
DRA O +
class O +
II O +
gene O +
can O +
be O +
up O -
- O -
regulated O +
in O +
B O +
cells O +
by O +
Ig O +
cross O -
- O -
linking O +
as O +
well O +
as O +
by O +
phorbol O +
esters O +
such O +
as O +
12-O O -
- O -
tetradecanoyl O +
phorbol O +
13-acetate O +
( O +
TPA O +
) O +
. O +

Induced O +
DRA O +
expression O +
involves O +
activation O +
of O +
restricted O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
isoforms O +
, O +
resulting O +
in O +
activated O +
activator O +
protein-1 O +
-dependent O +
transcription O +
. O +

In O +
this O +
report O +
expression O +
profiles O +
and O +
activation O +
of O +
PKC O +
were O +
analyzed O +
in O +
human B-CellLine +
Raji I-CellLine +
B I-CellLine +
lymphoblastoid I-CellLine +
cells I-CellLine +
. O +

Transient O +
transfection O +
analysis O +
with O +
target O +
plasmids O +
containing O +
either O +
DRA O +
promoter O +
( O +
wild O -
- O -
type O +
or O +
mutated O +
) O +
or O +
TPA O +
response O +
elements O +
demonstrated O +
that O +
pretreatment O +
with O +
the O +
selective O +
PKC O +
inhibitor O +
GF O +
109203X O +
repressed O +
TPA O -
- O -
mediated O +
activation O +
. O +

Western O +
analysis O +
performed O +
on O +
cellular O +
fractions O +
of O +
resting O +
cells O +
and O +
of O +
TPA O -
- O -
activated O +
cells O +
revealed O +
abundant O +
expression O +
of O +
classical O +
PKC O -
- O -
alpha O +
( O +
cPKC O -
- O -
alpha O +
) O +
, O +
cPKC O -
- O -
betaII O +
, O +
and O +
atypical O +
PKC O -
- O -
zeta O +
isoforms O +
and O +
identified O +
a O +
sustained O +
translocation O +
of O +
cPKC O -
- O -
alpha O +
and O +
cPKC O -
- O -
betaII O +
from O +
the O +
cytosolic O +
compartment O +
to O +
membranes O +
. O +

As O +
expected O +
, O +
the O +
distribution O +
of O +
atypical O +
PKC O -
- O -
zeta O +
was O +
unaffected O +
by O +
TPA O +
treatment O +
and O +
displayed O +
an O +
even O +
distribution O +
between O +
cytosol O +
and O +
membranes O +
. O +

This O +
finding O +
was O +
confirmed O +
by O +
immunofluorescence O +
microscopy O +
. O +

The O +
TPA O -
- O -
mediated O +
translocation O +
of O +
cPKC O -
- O -
alpha O +
and O +
cPKC O -
- O -
betaII O +
was O +
not O +
influenced O +
by O +
pretreatment O +
with O +
GF O +
109203X O +
. O +

Finally O +
, O +
functional O +
activation O +
and O +
translocation O +
of O +
PKC O +
were O +
investigated O +
with O +
a O +
selective O +
in O +
vitro O +
kinase O +
assay O +
. O +

Together O +
, O +
these O +
results O +
show O +
that O +
activated O +
HLA O -
- O -
DRA O +
expression O +
in O +
response O +
to O +
TPA O +
treatment O +
is O +
strictly O +
dependent O +
on O +
PKC O +
activation O +
acting O +
on O +
the O +
X2 O +
box O +
of O +
the O +
DRA O +
promoter O +
and O +
that O +
selective O +
inhibition O +
of O +
PKC O +
enzymatic O +
activity O +
does O +
not O +
influence O +
subcellular O +
localization O +
of O +
expressed O +
PKC O +
isoenzymes O +
. O +

Thus O +
, O +
the O +
translocation O +
event O +
per O +
se O +
occurs O +
independently O +
of O +
PKC O +
activation O +
in O +
these O +
cells O +
. O +

Attenuation O +
of O +
HLA O -
- O -
DR O +
expression O +
by O +
mononuclear O +
phagocytes O +
infected O +
with O +
Mycobacterium O +
tuberculosis O +
is O +
related O +
to O +
intracellular O +
sequestration O +
of O +
immature O +
class O +
II O +
heterodimers O +
. O +

MHC O +
class O +
II O +
expression O +
was O +
examined O +
in O +
macrophages O +
infected O +
with O +
Mycobacterium O +
tuberculosis O +
. O +

IFN O -
- O -
gamma O +
increased O +
the O +
surface O +
expression O +
of O +
class O +
II O +
molecules O +
in O +
THP-1 B-CellLine +
cells I-CellLine +
and O +
this O +
was O +
markedly O +
reduced O +
in O +
cells O +
infected O +
with O +
M. O +
tuberculosis O +
. O +

Despite O +
this O +
effect O +
, O +
steady O +
state O +
levels O +
of O +
HLA O -
- O -
DRalpha O +
, O +
HLA O -
- O -
DRbeta O +
, O +
and O +
invariant O +
( O +
Ii O +
) O +
chains O +
were O +
equivalent O +
in O +
control O +
and O +
infected O +
cells O +
. O +

Metabolic O +
labeling O +
combined O +
with O +
pulse O -
- O -
chase O +
experiments O +
and O +
biochemical O +
analysis O +
showed O +
that O +
the O +
majority O +
of O +
class O +
II O +
molecules O +
in O +
infected O +
cells O +
became O +
resistant O +
to O +
endoglycosidase O +
H O +
, O +
consistent O +
with O +
normal O +
Golgi O +
processing O +
. O +

However O +
, O +
results O +
of O +
intracellular O +
staining O +
and O +
dual O +
color O +
confocal O +
microscopy O +
revealed O +
a O +
significant O +
defect O +
in O +
transport O +
of O +
newly O +
synthesized O +
class O +
II O +
molecules O +
through O +
the O +
endocytic O +
compartment O +
. O +

Thus O +
, O +
compared O +
with O +
findings O +
in O +
control O +
cells O +
, O +
class O +
II O +
molecules O +
in O +
infected O +
cells O +
colocalized O +
to O +
a O +
minimal O +
extent O +
with O +
a O +
lysosomal O -
- O -
associated O +
membrane O +
protein-1 O +
+ O +
endosomal O +
compartment O +
. O +

In O +
addition O +
, O +
in O +
contrast O +
to O +
control O +
cells O +
, O +
class O +
II O +
molecules O +
in O +
infected O +
cells O +
failed O +
to O +
colocalize O +
with O +
endocytosed O +
BSA O +
under O +
conditions O +
where O +
this O +
marker O +
is O +
known O +
to O +
label O +
late O +
endosomes O +
, O +
lysosomes O +
, O +
and O +
the O +
MHC O +
class O +
II O +
compartment O +
. O +

Consistent O +
with O +
defective O +
transport O +
along O +
the O +
endocytic O +
pathway O +
, O +
the O +
maturation O +
of O +
SDS O -
- O -
stable O +
class O +
II O +
alphabeta O +
dimers O +
-- O +
dependent O +
upon O +
removal O +
of O +
Ii O +
chain O +
and O +
peptide O +
loading O +
of O +
class O +
II O +
dimers O +
in O +
the O +
MHC O +
class O +
II O +
compartment O +
-- O +
was O +
markedly O +
impaired O +
in O +
M. O +
tuberculosis O +
-infected O +
cells O +
. O +

These O +
findings O +
indicate O +
that O +
defective O +
transport O +
and O +
processing O +
of O +
class O +
II O +
molecules O +
through O +
the O +
endosomal O -
/ O -
lysosomal O +
system O +
is O +
responsible O +
for O +
diminished O +
cell O +
surface O +
expression O +
of O +
MHC O +
class O +
II O +
molecules O +
in O +
cells O +
infected O +
with O +
M. O +
tuberculosis O +
. O +

Signal O +
transduction O +
abnormalities O +
in O +
T O +
lymphocytes O +
from O +
patients O +
with O +
advanced O +
renal O +
carcinoma O +
: O +
clinical O +
relevance O +
and O +
effects O +
of O +
cytokine O +
therapy O +
. O +

Studies O +
have O +
demonstrated O +
abnormalities O +
of O +
the O +
CD3 O -
/ O -
T O -
- O -
cell O +
antigen O +
receptor O +
( O +
TCR O +
) O +
and O +
pathways O +
of O +
signal O +
transduction O +
in O +
T O +
lymphocytes O +
from O +
animals O +
and O +
patients O +
with O +
advanced O +
malignancy O +
. O +

Diminished O +
expression O +
of O +
TCRzeta O +
and O +
p56 O +
( O +
lck O +
) O +
that O +
are O +
associated O +
with O +
the O +
TCR O +
and O +
reduced O +
nuclear O +
localization O +
of O +
RelA O +
containing O +
nuclear O +
factor O +
kappaB O +
( O +
NFkappaB O +
) O +
complexes O +
have O +
been O +
noted O +
. O +

These O +
defects O +
have O +
been O +
described O +
in O +
T O +
cells O +
from O +
patients O +
with O +
malignant O +
melanoma O +
, O +
renal O +
cell O +
carcinoma O +
( O +
RCC O +
) O +
, O +
ovarian O +
cancer O +
, O +
and O +
colorectal O +
cancer O +
. O +

Preliminary O +
observations O +
also O +
indicate O +
possible O +
correlation O +
with O +
clinical O +
variables O +
such O +
as O +
stage O +
in O +
selected O +
instances O +
. O +

To O +
further O +
characterize O +
altered O +
expression O +
of O +
TCRzeta O +
, O +
p56 O +
( O +
lck O +
) O +
, O +
and O +
impaired O +
activation O +
of O +
NFkappaB O +
, O +
T O +
lymphocytes O +
were O +
obtained O +
from O +
65 O +
patients O +
with O +
RCC O +
, O +
the O +
majority O +
of O +
whom O +
were O +
receiving O +
combination O +
cytokine O +
therapy O +
[ O +
interleukin O +
( O +
IL O +
) O +
-2 O +
, O +
IFN O +
alpha O +
-containing O +
regimens O +
] O +
and O +
37 O +
control O +
individuals O +
. O +

In O +
29 O +
of O +
these O +
patients O +
, O +
levels O +
of O +
TCRzeta O +
and O +
p56 O +
( O +
lck O +
) O +
were O +
determined O +
by O +
Western O +
blots O +
of O +
T O -
- O -
cell O +
lysates O +
and O +
semiquantitated O +
using O +
densitometry O +
. O +

Relative O +
levels O +
were O +
then O +
correlated O +
with O +
a O +
series O +
of O +
clinical O +
variables O +
including O +
response O +
to O +
therapy O +
, O +
performance O +
status O +
, O +
survival O +
, O +
disease O +
sites O +
, O +
age O +
, O +
and O +
others O +
. O +

In O +
another O +
group O +
of O +
28 O +
patients O +
( O +
three O +
individuals O +
from O +
the O +
first O +
group O +
) O +
, O +
the O +
frequency O +
of O +
abnormal O +
NFkappaB O +
activation O +
was O +
studied O +
using O +
electrophoretic O +
mobility O +
shift O +
assays O +
after O +
activation O +
of O +
T O +
cells O +
with O +
phorbol O +
myristate O +
acetate O -
/ O -
ionomycin O +
or O +
anti O -
- O -
CD3 O +
monoclonal O +
antibody O +
. O +

Changes O +
in O +
these O +
signaling O +
molecules O +
during O +
cytokine O +
treatment O +
were O +
also O +
investigated O +
. O +

TCRzeta O +
and O +
p56 O +
( O +
lck O +
) O +
were O +
detected O +
in O +
the O +
peripheral O +
blood O +
T O +
cells O +
in O +
27 O +
of O +
29 O +
patients O +
, O +
and O +
overall O +
, O +
reduced O +
levels O +
were O +
noted O +
visually O +
in O +
12 O +
of O +
29 O +
( O +
41 O +
% O +
) O +
and O +
13 O +
of O +
29 O +
( O +
45 O +
% O +
) O +
individuals O +
, O +
respectively O +
. O +

When O +
levels O +
were O +
semiquantitated O +
using O +
densitometry O +
, O +
significant O +
decreases O +
of O +
TCRzeta O +
( O +
P O +
= O +
0.029 O +
) O +
and O +
p56 O +
( O +
lck O +
) O +
( O +
P O +
= O +
0.029 O +
) O +
but O +
not O +
CD3epsilon O +
( O +
P O +
= O +
0.131 O +
) O +
, O +
compared O +
with O +
control O +
levels O +
, O +
were O +
found O +
. O +

In O +
patients O +
treated O +
with O +
IL-2 O -
/ O +
IFN O +
alpha O +
-based O +
therapy O +
, O +
relative O +
levels O +
of O +
TCRzeta O +
increased O +
significantly O +
( O +
P O +
= O +
0.002 O +
) O +
on O +
day O +
15 O +
of O +
cycle O +
one O +
compared O +
with O +
the O +
baseline O +
. O +

Correlations O +
of O +
TCRzeta O +
or O +
p56 O +
( O +
lck O +
) O +
levels O +
with O +
response O +
or O +
disease O +
variables O +
, O +
except O +
for O +
lower O +
TCRzeta O +
levels O +
( O +
P O +
< O +
0.001 O +
) O +
in O +
the O +
presence O +
of O +
bone O +
metastases O +
, O +
were O +
not O +
found O +
. O +

Abnormal O +
NFkappaB O +
activation O +
after O +
stimulation O +
with O +
phorbol O +
myristate O +
acetate O -
/ O -
ionomycin O +
and/or O +
anti O -
- O -
CD3 O +
monoclonal O +
antibody O +
was O +
found O +
in O +
59 O +
% O +
of O +
patients O +
( O +
17 O +
of O +
28 O +
) O +
and O +
was O +
not O +
accounted O +
for O +
by O +
the O +
advanced O +
age O +
of O +
the O +
study O +
cohort O +
. O +

Activation O +
of O +
NFkappaB O +
in O +
peripheral O +
blood O +
T O +
cells O +
was O +
inducible O +
during O +
cytokine O +
therapy O +
in O +
four O +
of O +
six O +
individuals O +
who O +
displayed O +
impaired O +
NFkappaB O +
activity O +
prior O +
to O +
therapy O +
. O +

Moreover O +
, O +
impaired O +
activation O +
of O +
NFkappaB O +
does O +
not O +
appear O +
linked O +
to O +
a O +
reduction O +
of O +
TCRzeta O +
expression O +
, O +
because O +
in O +
five O +
patients O +
, O +
normal O +
TCRzeta O +
levels O +
were O +
present O +
although O +
kappaB O +
binding O +
was O +
not O +
inducible O +
. O +

In O +
the O +
majority O +
of O +
patients O +
with O +
advanced O +
RCC O +
, O +
peripheral O +
blood O +
T O +
cells O +
express O +
TCRzeta O +
and O +
p56 O +
( O +
lck O +
) O +
, O +
and O +
in O +
a O +
subset O +
, O +
reduced O +
levels O +
of O +
these O +
TCRzeta O +
associated O +
molecules O +
are O +
seen O +
that O +
may O +
increase O +
during O +
cytokine O +
-based O +
therapy O +
. O +

Abnormal O +
activation O +
of O +
NFkappaB O +
is O +
also O +
present O +
in O +
> O +
50 O +
% O +
of O +
patients O +
and O +
may O +
also O +
revert O +
to O +
normal O +
during O +
IL-2 O -
/ O +
IFN O +
alpha O +
-based O +
treatment O +
. O +

This O +
alteration O +
in O +
NFkappaB O +
activation O +
occurred O +
in O +
the O +
presence O +
of O +
normal O +
expression O +
of O +
TCRzeta O -
- O -
associated O +
signaling O +
elements O +
. O +

The O +
clinical O +
significance O +
of O +
these O +
findings O +
remains O +
unclear O +
. O +

The O +
nuclear O +
receptor O +
PPARgamma O +
- O +
bigger O +
than O +
fat O +
. O +

Work O +
reported O +
over O +
the O +
past O +
year O +
has O +
provided O +
insights O +
into O +
the O +
mechanisms O +
whereby O +
ligand O +
activation O +
of O +
the O +
nuclear O +
receptor O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
gamma O +
( O +
PPARgamma O +
) O +
regulates O +
systemic O +
glucose O +
and O +
lipid O +
homeostasis O +
. O +

PPARgamma O +
has O +
also O +
been O +
implicated O +
recently O +
in O +
the O +
biology O +
of O +
monocytes O +
and O +
in O +
cell O -
- O -
cycle O +
regulation O +
and O +
cancer O +
. O +

Polyunsaturated O +
fatty O +
acids O +
and O +
eicosanoids O +
bind O +
and O +
activate O +
PPARgamma O +
, O +
suggesting O +
that O +
these O +
lipids O +
may O +
serve O +
as O +
hormonal O +
regulators O +
of O +
a O +
variety O +
of O +
biological O +
processes O +
. O +

GATA-3 O +
represses O +
gp91phox O +
gene O +
expression O +
in O +
eosinophil B-CellLine -
- I-CellLine -
committed I-CellLine +
HL-60-C15 I-CellLine +
cells I-CellLine +
. O +

To O +
study O +
the O +
regulatory O +
mechanism O +
of O +
gp91phox O +
gene O +
expression O +
in O +
eosinophils O +
, O +
we O +
transiently O +
transfected O +
eosinophil B-CellLine -
- I-CellLine -
committed I-CellLine +
HL-60-C15 I-CellLine +
cells I-CellLine +
with O +
gp91phox O +
promoter O +
constructs O +
, O +
and O +
identified O +
a O +
negative O +
element O +
from O +
bp O +
-267 O +
to O +
-246 O +
of O +
the O +
gp91phox O +
gene O +
, O +
the O +
deletion O +
of O +
which O +
caused O +
an O +
83 O +
% O +
increase O +
in O +
promoter O +
activity O +
. O +

Electrophoresis O +
mobility O +
shift O +
assays O +
demonstrated O +
GATA-3 O +
binds O +
to O +
the O +
GATA O +
consensus O +
site O +
from O +
bp O +
-256 O +
to O +
-250 O +
. O +

An O +
81 O +
% O +
increment O +
in O +
promoter O +
activity O +
was O +
obtained O +
when O +
a O +
mutation O +
was O +
introduced O +
in O +
the O +
GATA-3 O +
binding O +
site O +
of O +
the O +
bp O +
-267 O +
to O +
+ O -
12 O +
construct O +
, O +
which O +
is O +
comparable O +
to O +
that O +
of O +
the O +
bp O +
-245 O +
to O +
+ O -
12 O +
construct O +
. O +

We O +
therefore O +
conclude O +
that O +
GATA-3 O +
specifically O +
binding O +
to O +
the O +
GATA O +
site O +
negatively O +
regulates O +
the O +
expression O +
of O +
the O +
gene O +
in O +
HL-60-C15 B-CellLine +
cells I-CellLine +
. O +

[ O +
Molecular O +
mechanism O +
of O +
cytokine O +
gene O +
expression O +
in O +
Th1 B-CellLine +
and O +
Th2 B-CellLine +
] O +

Upon O +
activation O +
by O +
antigens O +
, O +
helper O +
T O +
cells O +
differentiate O +
into O +
one O +
of O +
several O +
subsets O +
, O +
characterized O +
by O +
their O +
distinct O +
cytokine O +
-production O +
patterns O +
. O +

Among O +
these O +
subsets O +
, O +
Th1 B-CellLine +
cells I-CellLine +
are O +
known O +
to O +
activate O +
cellular O +
immunity O +
resulting O +
in O +
inflammatory O +
response O +
, O +
whereas O +
Th2 B-CellLine +
cells I-CellLine +
induce O +
humoral O +
and O +
allergic O +
responses O +
and O +
suppress O +
inflammation O +
. O +

Th1 O +
and O +
Th2 O +
effector O +
functions O +
and O +
their O +
development O +
are O +
attributable O +
to O +
their O +
distinct O +
cytokine O +
expression O +
patterns O +
. O +

Recent O +
reports O +
have O +
demonstrated O +
that O +
differential O +
expression O +
of O +
cell O +
surface O +
molecules O +
, O +
such O +
as O +
adhesion O +
molecule O +
and O +
chemokine O +
receptor O +
, O +
is O +
involved O +
in O +
their O +
recruitment O +
into O +
target O +
tissues O +
. O +

It O +
is O +
, O +
therefore O +
, O +
suggested O +
that O +
clarification O +
of O +
the O +
mechanisms O +
of O +
differential O +
gene O +
expression O +
in O +
Th1 B-CellLine -
/ I-CellLine -
Th2 I-CellLine +
should O +
lead O +
to O +
rational O +
strategies O +
for O +
manipulating O +
pathological O +
immune O +
responses O +
. O +

Activation O +
of O +
helper O +
T O +
cells O +
mediated O +
by O +
the O +
T O +
cell O +
receptor O +
induces O +
a O +
series O +
of O +
biochemical O +
events O +
. O +

Among O +
them O +
, O +
both O +
the O +
activation O +
of O +
PKC O -
/ O -
Ras- O +
and O +
CaM O -
/ O -
CN O -
- O -
mediated O +
pathways O +
play O +
a O +
central O +
role O +
in O +
the O +
signal O +
transduction O +
of O +
cytokine O +
gene O +
expression O +
. O +

Closer O +
examination O +
using O +
non B-CellLine -
- I-CellLine -
transformed I-CellLine +
murine I-CellLine +
Th1 I-CellLine +
and I-CellLine +
Th2 I-CellLine +
clones I-CellLine +
suggested O +
that O +
a O +
balance O +
between O +
the O +
activities O +
of O +
the O +
two O +
signaling O +
pathways O +
contributes O +
to O +
cytokine O +
gene O +
expression O +
. O +

We O +
propose O +
that O +
one O +
of O +
the O +
targets O +
of O +
PGE2 O +
, O +
whose O +
effect O +
distinguishes O +
Th1 B-CellLine +
from O +
Th2 O +
, O +
resides O +
in O +
the O +
downstream O +
PKC O -
/ O -
Ras O +
-mediated O +
pathway O +
. O +

Transcriptional O +
regulation O +
of O +
lysosomal O +
acid O +
lipase O +
in O +
differentiating O +
monocytes O +
is O +
mediated O +
by O +
transcription O +
factors O +
Sp1 O +
and O +
AP-2 O +
. O +

Human O +
lysosomal O +
acid O +
lipase O +
( O +
LAL O +
) O +
is O +
a O +
hydrolase O +
required O +
for O +
the O +
cleavage O +
of O +
cholesteryl O +
esters O +
and O +
triglycerides O +
derived O +
from O +
plasma O +
lipoproteins O +
. O +

It O +
is O +
shown O +
here O +
that O +
during O +
monocyte O +
to O +
macrophage O +
differentiation O +
, O +
the O +
expression O +
of O +
LAL O -
- O -
mRNA O +
is O +
induced O +
. O +

This O +
induction O +
is O +
dependent O +
on O +
protein O +
kinase O +
C O +
activity O +
and O +
protein O +
synthesis O +
. O +

The O +
cell O +
type O -
- O -
specific O +
increase O +
in O +
LAL O +
expression O +
is O +
further O +
investigated O +
in O +
the O +
THP-1 B-CellLine +
cell I-CellLine +
line I-CellLine +
with O +
respect O +
to O +
transcriptional O +
regulation O +
. O +

The O +
human B-CellLine +
monocytic I-CellLine +
leukemia I-CellLine +
cell I-CellLine +
line I-CellLine +
THP-1 B-CellLine +
differentiates O +
into O +
macrophage O -
- O -
like O +
cells O +
when O +
treated O +
with O +
phorbol O +
esters O +
. O +

In O +
order O +
to O +
determine O +
the O +
cis O -
- O -
acting O +
elements O +
necessary O +
for O +
both O +
basal O +
and O +
phorbol O +
12-myristate-13 O +
acetate O +
( O +
PMA O +
) O +
-enhanced O +
promoter O +
activity O +
, O +
we O +
performed O +
deletion O +
analysis O +
and O +
reporter O +
gene O +
assays O +
. O +

A O +
PMA O +
responsive O +
element O +
has O +
been O +
identified O +
between O +
-182 O +
bp O +
and O +
-107 O +
bp O +
upstream O +
of O +
the O +
major O +
transcription O +
start O +
site O +
. O +

Gel O +
mobility O +
shift O +
assays O +
demonstrated O +
that O +
binding O +
of O +
Sp1 O +
and O +
AP-2 O +
to O +
the O +
LAL O +
promoter O +
is O +
increased O +
by O +
PMA O +
in O +
THP-1 B-CellLine +
cells I-CellLine +
. O +

Co O -
- O -
transfections O +
with O +
expression O +
plasmids O +
for O +
Sp1 O +
and O +
AP-2 O +
further O +
emphasized O +
the O +
important O +
role O +
of O +
these O +
transcription O +
factors O +
in O +
both O +
basal O +
and O +
PMA O -
- O -
enhanced O +
LAL O +
expression O +
. O +

Our O +
data O +
suggest O +
that O +
differentiation O +
dependent O +
increase O +
of O +
lysosomal O +
acid O +
lipase O +
( O +
LAL O +
) O +
expression O +
in O +
THP-1 B-CellLine +
cells I-CellLine +
is O +
mediated O +
by O +
a O +
concerted O +
action O +
of O +
Sp1 O +
and O +
AP-2 O +
. O +

A O +
nongenomic O +
mechanism O +
for O +
progesterone O -
- O -
mediated O +
immunosuppression O +
: O +
inhibition O +
of O +
K+ O +
channels O +
, O +
Ca2 O -
+ O +
signaling O +
, O +
and O +
gene O +
expression O +
in O +
T O +
lymphocytes O +
. O +

The O +
mechanism O +
by O +
which O +
progesterone O +
causes O +
localized O +
suppression O +
of O +
the O +
immune O +
response O +
during O +
pregnancy O +
has O +
remained O +
elusive O +
. O +

Using O +
human O +
T O +
lymphocytes O +
and O +
T B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
we O +
show O +
that O +
progesterone O +
, O +
at O +
concentrations O +
found O +
in O +
the O +
placenta O +
, O +
rapidly O +
and O +
reversibly O +
blocks O +
voltage O -
- O -
gated O +
and O +
calcium O -
- O -
activated O +
K+ O +
channels O +
( O +
KV O +
and O +
KCa O +
, O +
respectively O +
) O +
, O +
resulting O +
in O +
depolarization O +
of O +
the O +
membrane O +
potential O +
. O +

As O +
a O +
result O +
, O +
Ca2 O -
+ O +
signaling O +
and O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NF O -
- O -
AT O +
) O +
-driven O +
gene O +
expression O +
are O +
inhibited O +
. O +

Progesterone O +
acts O +
distally O +
to O +
the O +
initial O +
steps O +
of O +
T O +
cell O +
receptor O +
( O +
TCR O +
) O +
-mediated O +
signal O +
transduction O +
, O +
since O +
it O +
blocks O +
sustained O +
Ca2 O -
+ O +
signals O +
after O +
thapsigargin O +
stimulation O +
, O +
as O +
well O +
as O +
oscillatory O +
Ca2 O -
+ O +
signals O +
, O +
but O +
not O +
the O +
Ca2 O -
+ O +
transient O +
after O +
TCR O +
stimulation O +
. O +

K+ O +
channel O +
blockade O +
by O +
progesterone O +
is O +
specific O +
; O +
other O +
steroid O +
hormones O +
had O +
little O +
or O +
no O +
effect O +
, O +
although O +
the O +
progesterone O +
antagonist O +
RU O +
486 O +
also O +
blocked O +
KV O +
and O +
KCa O +
channels O +
. O +

Progesterone O +
effectively O +
blocked O +
a O +
broad O +
spectrum O +
of O +
K+ O +
channels O +
, O +
reducing O +
both O +
Kv1.3 O +
and O +
charybdotoxin O -
- O -
resistant O +
components O +
of O +
KV O +
current O +
and O +
KCa O +
current O +
in O +
T O +
cells O +
, O +
as O +
well O +
as O +
blocking O +
several O +
cloned O +
KV O +
channels O +
expressed O +
in O +
cell B-CellLine +
lines I-CellLine +
. O +

Progesterone O +
had O +
little O +
or O +
no O +
effect O +
on O +
a O +
cloned O +
voltage O -
- O -
gated O +
Na+ O +
channel O +
, O +
an O +
inward O +
rectifier O +
K+ O +
channel O +
, O +
or O +
on O +
lymphocyte O +
Ca2 O -
+ O +
and O +
Cl- O +
channels O +
. O +

We O +
propose O +
that O +
direct O +
inhibition O +
of O +
K+ O +
channels O +
in O +
T O +
cells O +
by O +
progesterone O +
contributes O +
to O +
progesterone O -
- O -
induced O +
immunosuppression O +
. O +

Effects O +
of O +
overexpression O +
of O +
IL-1 O +
receptor O -
- O -
associated O +
kinase O +
on O +
NFkappaB O +
activation O +
, O +
IL-2 O +
production O +
and O +
stress O -
- O -
activated O +
protein O +
kinases O +
in O +
the O +
murine B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
EL4 I-CellLine +
. O +

The O +
association O +
and O +
activation O +
of O +
the O +
IL-1 O +
receptor O -
- O -
associated O +
protein O +
kinase O +
( O +
IRAK O +
) O +
to O +
the O +
IL-1 O +
receptor O +
complex O +
is O +
one O +
of O +
the O +
earliest O +
events O +
detectable O +
in O +
IL-1 O +
signal O +
transduction O +
. O +

We O +
generated O +
permanent O +
clones O +
of O +
the O +
murine B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
EL4 I-CellLine +
6.1 I-CellLine +
overexpressing O +
human O +
( O +
h O +
) O +
IRAK O +
to O +
evaluate O +
the O +
role O +
of O +
this O +
kinase O +
in O +
IL-1 O +
signaling O +
. O +

Overexpression O +
of O +
hIRAK O +
enhanced O +
IL-1 O +
-stimulated O +
activation O +
of O +
the O +
transcription O +
factor O +
NFkappaB O +
, O +
whereas O +
a O +
truncated O +
form O +
( O +
N O -
- O -
IRAK O +
) O +
specifically O +
inhibited O +
IL-1 O +
-dependent O +
NFkappaB O +
activity O +
. O +

In O +
clones O +
stably O +
overexpressing O +
hIRAK O +
a O +
weak O +
constitutive O +
activation O +
of O +
NFkappaB O +
correlated O +
with O +
a O +
low O +
basal O +
IL-2 O +
production O +
which O +
was O +
enhanced O +
in O +
an O +
IL-1 O +
-dependent O +
manner O +
. O +

Compared O +
to O +
the O +
parental B-CellLine +
cell I-CellLine +
line I-CellLine +
the O +
dose O -
- O -
response O +
curve O +
of O +
IL-1 O +
-induced O +
IL-2 O +
production O +
was O +
shifted O +
in O +
both O +
potency O +
and O +
efficacy O +
. O +

These O +
results O +
demonstrate O +
that O +
IRAK O +
directly O +
triggers O +
NFkappaB O +
-mediated O +
gene O +
expression O +
in O +
EL4 B-CellLine +
cells I-CellLine +
. O +

Qualitatively O +
different O +
effects O +
were O +
observed O +
for O +
the O +
IL-1 O +
-induced O +
activation O +
of O +
stress O -
- O -
activated O +
protein O +
( O +
SAP O +
) O +
kinases O +
: O +
permanent O +
overexpression O +
of O +
IRAK O +
did O +
not O +
affect O +
the O +
dose O +
dependence O +
but O +
prolonged O +
the O +
kinetics O +
of O +
IL-1 O +
-induced O +
activation O +
of O +
SAP O +
kinases O +
, O +
suggesting O +
that O +
this O +
signaling O +
branch O +
may O +
be O +
regulated O +
by O +
distinct O +
mechanisms O +
. O +

Decreased O +
IL-12 O +
production O +
and O +
Th1 O +
cell O +
development O +
by O +
acetyl O +
salicylic O +
acid O -
- O -
mediated O +
inhibition O +
of O +
NF O -
- O -
kappaB O +
. O +

IL-12 O +
is O +
a O +
75-kDa O +
heterodimeric O +
cytokine O +
composed O +
of O +
two O +
covalently O +
linked O +
p35 O +
and O +
p40 O +
chains O +
. O +

This O +
pro O -
- O -
inflammatory O +
cytokine O +
plays O +
a O +
prominent O +
role O +
in O +
the O +
development O +
of O +
Th1 O +
cell O -
- O -
mediated O +
immune O +
responses O +
. O +

Th1 O +
cell O -
- O -
mediated O +
immune O +
responses O +
have O +
been O +
implicated O +
in O +
the O +
pathogenesis O +
of O +
chronic O +
inflammatory O +
autoimmune O +
diseases O +
. O +

Thus O +
, O +
IL-12 O +
appears O +
to O +
be O +
a O +
critical O +
factor O +
in O +
the O +
generation O +
and O +
maintenance O +
of O +
chronic O +
inflammatory O +
conditions O +
. O +

In O +
this O +
study O +
, O +
we O +
investigated O +
the O +
effects O +
of O +
a O +
commonly O +
prescribed O +
anti O -
- O -
inflammatory O +
drug O +
, O +
acetyl O +
salicylic O +
acid O +
( O +
ASA O +
) O +
, O +
on O +
IL-12 O +
production O +
and O +
Th1 O +
cell O +
development O +
. O +

ASA O +
was O +
found O +
to O +
inhibit O +
secretion O +
of O +
the O +
IL-12 O +
heterodimer O +
as O +
well O +
as O +
p40 O +
monomer O +
by O +
human O +
monocytic O +
cells O +
. O +

This O +
was O +
associated O +
with O +
the O +
down O -
- O -
regulation O +
of O +
IL-12p40 O +
mRNA O +
expression O +
. O +

Analysis O +
of O +
the O +
regulation O +
of O +
the O +
p40 O +
gene O +
promoter O +
revealed O +
that O +
ASA O +
inhibited O +
NF O -
- O -
kappaB O +
activation O +
and O +
binding O +
to O +
the O +
p40-kappaB O +
site O +
in O +
the O +
p40 O +
promoter O +
, O +
leading O +
to O +
transcriptional O +
repression O +
of O +
the O +
p40 O +
gene O +
. O +

Addition O +
of O +
ASA O +
to O +
an O +
in O +
vitro O +
T O +
helper O +
cell O +
differentiation O +
system O +
, O +
at O +
concentrations O +
compatible O +
with O +
plasma O +
levels O +
reached O +
during O +
anti O -
- O -
inflammatory O +
therapy O +
, O +
resulted O +
in O +
reduced O +
development O +
of O +
Th1 O +
cells O +
. O +

These O +
results O +
suggest O +
that O +
the O +
inhibition O +
of O +
NF O -
- O -
kappaB O +
activation O +
by O +
ASA O +
leads O +
to O +
down O -
- O -
regulation O +
of O +
IL-12 O +
production O +
and O +
inhibition O +
of O +
Th1 O +
cell O +
development O +
. O +

YM268 O +
increases O +
the O +
glucose O +
uptake O +
, O +
cell O +
differentiation O +
, O +
and O +
mRNA O +
expression O +
of O +
glucose O +
transporter O +
in O +
3T3-L1 O +
adipocytes O +
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
examine O +
the O +
effects O +
of O +
bis O +
[ O +
4- O +
[ O +
2 O +
, O +
4-dioxo-5-thiazolidinyl O +
) O +
methyl O +
] O +
phenyl O +
] O +
methane O +
( O +
YM-268 O +
) O +
, O +
a O +
thiazolidinedione O +
derivative O +
, O +
on O +
glucose O +
uptake O +
, O +
adipocyte O +
differentiation O +
through O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
gamma O +
( O +
PPARgamma O +
) O +
, O +
and O +
phosphatidylinositol O +
3-kinase O +
( O +
PI O +
3-kinase O +
) O +
activity O +
in O +
cultured B-CellLine +
cells I-CellLine +
. O +

YM268 O +
and O +
pioglitazone O +
dose O -
- O -
dependently O +
increased O +
the O +
2-deoxyglucose O +
uptake O +
in O +
3T3-L1 B-CellLine +
cells I-CellLine +
. O +

YM268 O +
facilitated O +
the O +
insulin O -
- O -
stimulated O +
triglyceride O +
accumulation O +
in O +
3T3-L1 O +
adipocytes O +
and O +
increased O +
the O +
mRNA O +
expression O +
of O +
fatty O +
acid O -
- O -
binding O +
protein O +
. O +

YM268 O +
, O +
with O +
and O +
without O +
insulin O +
, O +
increased O +
the O +
mRNA O +
expression O +
of O +
glucose O +
transporter O +
isoforms O +
such O +
as O +
GLUT1 O +
and O +
GLUT4 O +
, O +
indicating O +
enhancement O +
of O +
adipocyte O +
differentiation O +
. O +

Additionally O +
, O +
YM268 O +
and O +
pioglitazone O +
showed O +
activity O +
of O +
the O +
PPARgamma O +
ligand O +
, O +
a O +
member O +
of O +
the O +
nuclear O +
receptor O +
superfamily O +
responsible O +
for O +
adipogenesis O +
. O +

To O +
examine O +
the O +
possible O +
involvement O +
of O +
the O +
increased O +
activity O +
of O +
PI O +
3-kinase O +
in O +
YM268-stimulated O +
glucose O +
uptake O +
, O +
the O +
enzyme O +
activity O +
was O +
estimated O +
by O +
measuring O +
the O +
phosphatidylinositol-3 O +
, O +
4 O +
, O +
5-trisphosphate O +
( O +
PI-3 O +
, O +
4 O +
, O +
5-P3 O +
) O +
concentration O +
in O +
human O +
monocytic O +
cells O +
. O +

Insulin O +
dose O -
- O -
dependently O +
increased O +
the O +
PI-3 O +
, O +
4 O +
, O +
5-P3 O +
production O +
but O +
YM268 O +
had O +
no O +
significant O +
effect O +
on O +
the O +
insulin O -
- O -
dependent O +
and O +
-independent O +
PI O +
3-kinase O +
activation O +
. O +

These O +
results O +
indicate O +
that O +
the O +
mechanism O +
by O +
which O +
YM268 O +
increased O +
glucose O +
uptake O +
, O +
may O +
be O +
accounted O +
for O +
in O +
part O +
by O +
the O +
enhancement O +
of O +
GLUT1 O +
and O +
GLUT4 O +
expression O +
through O +
PPARgamma O +
activation O +
. O +

Role O +
of O +
IKK1 O +
and O +
IKK2 O +
in O +
lipopolysaccharide O +
signaling O +
in O +
human O +
monocytic O +
cells O +
. O +

Mononuclear O +
phagocytes O +
play O +
a O +
major O +
role O +
in O +
immune O +
and O +
inflammatory O +
responses O +
. O +

Bacterial O +
lipopolysaccharide O +
( O +
LPS O +
) O +
induces O +
monocytes O +
to O +
express O +
a O +
variety O +
of O +
genes O +
by O +
activating O +
the O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
transcription O +
factor O +
family O +
. O +

Recently O +
, O +
we O +
have O +
reported O +
that O +
the O +
tumor O +
necrosis O +
factor O +
and O +
interleukin O +
1 O +
signaling O +
pathways O +
activate O +
two O +
kinases O +
, O +
IKK1 O +
and O +
IKK2 O +
. O +

Phosphorylation O +
of O +
the O +
IkappaB O +
cytoplasmic O +
inhibitors O +
, O +
IkappaBalpha O +
, O +
IkappaBbeta O +
, O +
and O +
IkappaBepsilon O +
, O +
by O +
these O +
kinases O +
triggers O +
proteolytic O +
degradation O +
and O +
the O +
release O +
of O +
NF O -
- O -
kappaB O -
/ O -
Rel O +
proteins O +
into O +
the O +
nucleus O +
. O +

At O +
present O +
, O +
the O +
role O +
of O +
the O +
IKKs O +
in O +
LPS O +
signaling O +
has O +
not O +
been O +
investigated O +
. O +

Here O +
, O +
we O +
report O +
that O +
LPS O +
induces O +
IKK O +
activity O +
in O +
human O +
monocytes O +
and O +
THP-1 B-CellLine +
monocytic I-CellLine +
cells I-CellLine +
. O +

The O +
kinetics O +
of O +
activation O +
of O +
kinase O +
activity O +
in O +
monocytic O +
cells O +
are O +
relatively O +
slow O +
with O +
maximal O +
activity O +
observed O +
at O +
60 O +
min O +
, O +
which O +
coincides O +
with O +
the O +
degradation O +
of O +
IkappaBs O +
and O +
the O +
nuclear O +
translocation O +
of O +
NF O -
- O -
kappaB O +
. O +

In O +
transfection O +
experiments O +
, O +
overexpression O +
of O +
wild O +
type O +
IKK1 O +
, O +
a O +
dominant O +
negative O +
mutant O +
IKK1 O +
( O +
K44 O -
M O +
) O +
, O +
or O +
wild O +
type O +
IKK2 O +
did O +
not O +
affect O +
LPS O -
- O -
induced O +
kappaB O +
-dependent O +
transcription O +
in O +
monocytic O +
cells O +
. O +

In O +
contrast O +
, O +
a O +
dominant O +
negative O +
mutant O +
of O +
IKK2 O +
inhibited O +
LPS O +
induction O +
of O +
kappaB O +
-dependent O +
transcription O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
. O +

These O +
results O +
indicate O +
that O +
LPS O +
induction O +
of O +
kappaB O -
- O -
dependent O +
gene O +
expression O +
in O +
human O +
monocytic O +
cells O +
requires O +
activation O +
of O +
IKK2 O +
. O +

Interaction O +
of O +
sickle O +
erythrocytes O +
with O +
endothelial O +
cells O +
in O +
the O +
presence O +
of O +
endothelial O +
cell O +
conditioned O +
medium O +
induces O +
oxidant O +
stress O +
leading O +
to O +
transendothelial O +
migration O +
of O +
monocytes O +
. O +

The O +
abnormal O +
adherence O +
of O +
sickle O +
red O +
blood O +
cells O +
( O +
SS O +
RBC O +
) O +
to O +
endothelial O +
cells O +
has O +
been O +
thought O +
to O +
contribute O +
to O +
vascular O +
occlusion O +
, O +
a O +
major O +
cause O +
of O +
morbidity O +
in O +
sickle O +
cell O +
disease O +
( O +
SCD O +
) O +
. O +

We O +
determined O +
whether O +
the O +
interaction O +
of O +
SS O +
RBC O +
with O +
cultured O +
endothelial O +
cells O +
induced O +
cellular O +
oxidant O +
stress O +
that O +
would O +
culminate O +
in O +
expression O +
of O +
cell O +
adhesion O +
molecules O +
( O +
CAMs O +
) O +
involved O +
in O +
the O +
adhesion O +
and O +
diapedesis O +
of O +
monocytes O +
and O +
the O +
adherence O +
of O +
SS O +
reticulocytes O +
. O +

We O +
showed O +
that O +
the O +
interaction O +
of O +
SS O +
RBC O +
at O +
2 O +
% O +
concentration O +
in O +
the O +
presence O +
of O +
multimers O +
of O +
von O +
Willebrand O +
factor O +
( O +
vWf O +
) O +
, O +
derived O +
from O +
endothelial O +
cell O -
- O -
derived O +
conditioned O +
medium O +
( O +
E O -
- O -
CM O +
) O +
with O +
cultured B-CellLine +
human I-CellLine +
umbilical I-CellLine +
vein I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
( O +
HUVEC B-CellLine +
) O +
, O +
resulted O +
in O +
a O +
fivefold O +
increased O +
formation O +
of O +
thiobarbituric O +
acid O -
- O -
reactive O +
substances O +
( O +
TBARS O +
) O +
and O +
activation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kB O +
, O +
both O +
indicators O +
of O +
cellular O +
oxidant O +
stress O +
. O +

Normal O +
RBC O +
show O +
none O +
of O +
these O +
phenomena O +
. O +

The O +
oxidant O +
stress O -
- O -
induced O +
signaling O +
resulted O +
in O +
an O +
increased O +
surface O +
expression O +
of O +
a O +
subset O +
of O +
CAMs O +
, O +
ICAM-1 O +
, O +
E O -
- O -
selectin O +
, O +
and O +
VCAM-1 O +
in O +
HUVEC B-CellLine +
. O +

The O +
addition O +
of O +
oxygen O +
radical O +
scavenger O +
enzymes O +
( O +
catalase O +
, O +
superoxide O +
dismutase O +
) O +
and O +
antioxidant O +
( O +
probucol O +
) O +
inhibited O +
these O +
events O +
. O +

Additionally O +
, O +
preincubation O +
of O +
HUVEC B-CellLine +
with O +
a O +
synthetic O +
peptide O +
Arg O -
- O -
Gly O -
- O -
Asp O +
( O +
RGD O +
) O +
that O +
prevents O +
vWf O +
-mediated O +
adhesion O +
of O +
SS O +
RBC O +
reduced O +
the O +
surface O +
expression O +
of O +
VCAM-1 O +
and O +
NF O -
- O -
kB O +
activation O +
. O +

Furthermore O +
, O +
SS O +
RBC O +
-induced O +
oxidant O +
stress O +
resulted O +
in O +
a O +
twofold O +
increase O +
in O +
the O +
transendothelial O +
migration O +
of O +
both O +
monocyte B-CellLine -
- I-CellLine -
like I-CellLine +
HL-60 I-CellLine +
cells I-CellLine +
and O +
human O +
peripheral O +
blood O +
monocytes O +
, O +
and O +
approximately O +
a O +
sixfold O +
increase O +
in O +
platelet O -
- O -
endothelial O +
cell O +
adhesion O +
molecule-1 O +
( O +
PECAM-1 O +
) O +
phosphorylation O +
, O +
each O +
of O +
which O +
was O +
blocked O +
by O +
protein O +
kinase O +
C O +
inhibitor O +
and O +
antioxidants O +
. O +

These O +
results O +
suggest O +
that O +
the O +
adherence O -
/ O -
contact O +
of O +
SS O +
RBC O +
to O +
endothelial O +
cells O +
in O +
large O +
vessel O +
can O +
generate O +
enhanced O +
oxidant O +
stress O +
leading O +
to O +
increased O +
adhesion O +
and O +
diapedesis O +
of O +
monocytes O +
, O +
as O +
well O +
as O +
heightened O +
adherence O +
of O +
SS O +
reticulocytes O +
, O +
indicating O +
that O +
injury O -
/ O -
activation O +
of O +
endothelium O +
can O +
contribute O +
to O +
vaso O -
- O -
occlusion O +
in O +
SCD O +
. O +

Interleukin O +
2 O +
and O +
15 O +
activate O +
Stat3alpha O +
in O +
human O +
T O +
lymphocytes O +
. O +

Signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
3 O +
( O +
Stat3 O +
) O +
has O +
recently O +
been O +
shown O +
to O +
exist O +
in O +
two O +
alternatively O +
spliced O +
isoforms O +
, O +
a O +
short O +
form O +
, O +
Stat3beta O +
, O +
and O +
a O +
longer O +
form O +
, O +
Stat3alpha O +
, O +
displaying O +
differences O +
in O +
transcriptional O +
activity O +
. O +

It O +
is O +
unknown O +
which O +
Stat3 O +
isoform O +
( O +
s O +
) O +
is O +
activated O +
in O +
response O +
to O +
interleukin O +
( O +
IL O +
) O +
-2 O +
and O +
IL-15 O +
. O +

Here O +
, O +
cytokine O +
-induced O +
activation O +
of O +
Stat3 O +
in O +
previously O +
activated O +
CD4 O +
( O +
+ O +
) O +
human O +
T O +
cells O +
was O +
examined O +
using O +
Stat3 O +
antibodies O +
directed O +
against O +
different O +
regions O +
of O +
Stat3 O +
. O +

As O +
determined O +
by O +
tyrosine O +
phosphorylation O +
, O +
nuclear O +
translocation O +
and O +
binding O +
to O +
an O +
hSIE O -
- O -
oligonucleotide O +
probe O +
, O +
IL-2 O +
and O +
IL-15 O +
activated O +
the O +
slowly O +
migrating O +
isoform O +
, O +
Stat3alpha O +
. O +

In O +
contrast O +
, O +
minimal O +
or O +
no O +
activation O +
of O +
Stat3beta O +
was O +
observed O +
, O +
suggesting O +
that O +
IL-2 O +
and O +
IL-15 O +
predominantly O +
activate O +
Stat3alpha O +
in O +
human O +
CD4 O +
( O +
+ O +
) O +
T O +
cells O +
. O +

In O +
this O +
way O +
, O +
diversity O +
in O +
the O +
expression O +
and O +
activation O +
of O +
Stat3 O +
proteins O +
may O +
provide O +
additional O +
means O +
of O +
regulating O +
cytokine O +
-induced O +
T O +
cell O +
responses O +
. O +

Copyright O +
1998 O +
Academic O +
Press O +
. O +

Promoter O +
sequence O +
, O +
exon O +
: O +
intron O +
structure O +
, O +
and O +
synteny O +
of O +
genetic O +
location O +
show O +
that O +
a O +
chicken O +
cytokine O +
with O +
T O -
- O -
cell O +
proliferative O +
activity O +
is O +
IL2 O +
and O +
not O +
IL15 O +
. O +

The O +
gene O +
encoding O +
a O +
chicken O +
cytokine O +
with O +
T O -
- O -
cell O +
proliferative O +
activity O +
was O +
cloned O +
, O +
sequenced O +
, O +
and O +
mapped O +
. O +

The O +
results O +
show O +
that O +
this O +
cytokine O +
is O +
chicken O +
IL2 O +
and O +
not O +
IL15 O +
. O +

The O +
exon O +
: O +
intron O +
structure O +
of O +
chicken O +
IL2 O +
corresponds O +
almost O +
exactly O +
to O +
those O +
of O +
mammalian O +
IL2s O +
with O +
the O +
exceptions O +
of O +
exon O +
2 O +
and O +
introns O +
2 O +
and O +
3 O +
which O +
are O +
shorter O +
. O +

Chicken O +
IL2 O +
contains O +
five O +
repeats O +
of O +
the O +
` O -
` O +
instability O +
'' O +
motif O +
ATTTA O +
in O +
the O +
3'untranslated O +
region O +
in O +
exon O +
4 O +
. O +

It O +
is O +
a O +
single O -
- O -
copy O +
gene O +
, O +
with O +
neither O +
structural O +
( O +
amino O +
acid O +
) O +
nor O +
promoter O +
sequence O +
polymorphisms O +
identified O +
. O +

Analysis O +
of O +
the O +
predicted O +
amino O +
acid O +
sequence O +
suggests O +
that O +
overall O +
protein O +
structure O +
is O +
conserved O +
, O +
but O +
the O +
receptor O +
binding O +
sites O +
are O +
not O +
. O +

A O +
number O +
of O +
potential O +
regulatory O +
sequences O +
similar O +
to O +
those O +
found O +
in O +
mammals O +
have O +
been O +
identified O +
in O +
the O +
promoter O +
. O +

These O +
include O +
( O +
5'-3 O +
' O +
) O +
a O +
composite O +
NF O -
- O -
AT O -
/ O +
` O -
` O +
AP-1 O +
'' O +
element O +
, O +
a O +
CD28 O +
response O +
element O +
, O +
an O +
AP-1 O +
element O +
, O +
an O +
NF O -
- O -
AT O +
element O +
, O +
and O +
the O +
AP-1 O +
part O +
of O +
an O +
AP-1 O -
/ O -
octamer O +
composite O +
element O +
. O +

The O +
mammalian O +
NF O -
- O -
kappaB O +
and O +
octamer O +
binding O +
sites O +
seem O +
to O +
be O +
absent O +
, O +
although O +
there O +
are O +
alternative O +
potential O +
NF O -
- O -
kappaB O +
and O +
octamer O -
- O -
binding O +
elements O +
in O +
the O +
chicken O +
IL2 O +
promoter O +
, O +
in O +
close O +
proximity O +
to O +
their O +
mammalian O +
homologues O +
. O +

Sequence O +
comparisons O +
also O +
predict O +
other O +
potential O +
transcription O +
factor O +
binding O +
sites O +
as O +
yet O +
undescribed O +
in O +
mammalian O +
IL2 O +
promoters O +
. O +

A O +
Taq O +
I O +
polymorphism O +
was O +
identified O +
which O +
enabled O +
chicken O +
IL2 O +
to O +
be O +
mapped O +
to O +
chromosome O +
4 O +
, O +
linked O +
to O +
ANX5 O +
, O +
with O +
synteny O +
with O +
mouse O +
chromosome O +
3 O +
and O +
human O +
chromosome O +
4 O +
. O +

This O +
is O +
the O +
first O +
non O -
- O -
mammalian O +
cytokine O +
gene O +
to O +
be O +
mapped O +
. O +

Transcriptional O +
regulation O +
of O +
the O +
beta O -
- O -
casein O +
gene O +
by O +
cytokines O +
: O +
cross O -
- O -
talk O +
between O +
STAT5 O +
and O +
other O +
signaling O +
molecules O +
. O +

The O +
beta O -
- O -
casein O +
promoter O +
has O +
been O +
widely O +
used O +
to O +
monitor O +
the O +
activation O +
of O +
STAT O +
( O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
) O +
5 O +
since O +
STAT5 O +
was O +
originally O +
found O +
as O +
a O +
mediator O +
of O +
PRL O -
- O -
inducible O +
beta O -
- O -
casein O +
expression O +
. O +

However O +
, O +
not O +
only O +
is O +
expression O +
of O +
the O +
beta O -
- O -
casein O +
gene O +
regulated O +
by O +
STAT5 O +
but O +
it O +
is O +
also O +
affected O +
by O +
other O +
molecules O +
such O +
as O +
glucocorticoid O +
and O +
Ras O +
. O +

In O +
this O +
report O +
, O +
we O +
describe O +
the O +
transcriptional O +
regulation O +
of O +
the O +
beta O -
- O -
casein O +
gene O +
by O +
cytokines O +
in O +
T O +
cells O +
. O +

We O +
have O +
found O +
that O +
the O +
beta O -
- O -
casein O +
gene O +
is O +
expressed O +
in O +
a O +
cytotoxic B-CellLine +
T I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
CTLL-2 B-CellLine +
, O +
in O +
response O +
to O +
interleukin-2 O +
( O +
IL-2 O +
) O +
, O +
which O +
activates O +
STAT5 O +
. O +

While O +
IL-4 O +
does O +
not O +
activate O +
STAT5 O +
, O +
it O +
induces O +
expression O +
of O +
STAT5-regulated O +
genes O +
in O +
CTLL-2 B-CellLine +
, O +
i.e O +
. O +
beta O -
- O -
casein O +
, O +
a O +
cytokine O -
- O -
inducible O +
SH2-containing O +
protein O +
( O +
CIS O +
) O +
, O +
and O +
oncostatin O +
M O +
( O +
OSM O +
) O +
, O +
suggesting O +
that O +
STAT6 O +
activated O +
by O +
IL-4 O +
substitutes O +
for O +
the O +
function O +
of O +
STAT5 O +
in O +
T O +
cells O +
. O +

IL-2 O +
-induced O +
beta O -
- O -
casein O +
expression O +
was O +
enhanced O +
by O +
dexamethasone O +
, O +
and O +
this O +
synergistic O +
effect O +
of O +
Dexamethasone O +
requires O +
the O +
sequence O +
between O +
-155 O +
and O +
-193 O +
in O +
the O +
beta O -
- O -
casein O +
promoter O +
. O +

Coincidentally O +
, O +
a O +
deletion O +
of O +
this O +
region O +
enhanced O +
the O +
IL-2 O +
-induced O +
expression O +
of O +
beta O -
- O -
casein O +
. O +

Expression O +
of O +
an O +
active O +
form O +
of O +
Ras O +
, O +
Ras O +
( O +
G12V O +
) O +
, O +
suppressed O +
the O +
IL-2 O +
-induced O +
beta O -
- O -
casein O +
and O +
OSM O +
gene O +
expression O +
, O +
and O +
the O +
negative O +
effect O +
of O +
Ras O +
is O +
mediated O +
by O +
the O +
region O +
between O +
-105 O +
and O +
-193 O +
in O +
the O +
beta O -
- O -
casein O +
promoter O +
. O +

In O +
apparent O +
contradiction O +
, O +
expression O +
of O +
a O +
dominant O +
negative O +
form O +
of O +
Ras O +
, O +
RasN17 O +
, O +
also O +
inhibited O +
IL-2 O +
-induced O +
activation O +
of O +
the O +
promoter O +
containing O +
the O +
minimal O +
beta O -
- O -
casein O +
STAT5 O +
element O +
as O +
well O +
as O +
the O +
promoters O +
of O +
CIS O +
and O +
OSM O +
. O +

In O +
addition O +
, O +
Ras O +
( O +
G12V O +
) O +
complemented O +
signaling O +
by O +
an O +
erythropoietin O +
receptor O +
mutant O +
defective O +
in O +
Ras O +
activation O +
and O +
augmented O +
the O +
activation O +
of O +
the O +
beta O -
- O -
casein O +
promoter O +
by O +
the O +
mutant O +
erythropoietin O +
receptor O +
signaling O +
, O +
suggesting O +
a O +
possible O +
role O +
of O +
Ras O +
in O +
Stat5 O +
-mediated O +
gene O +
expression O +
. O +

These O +
results O +
collectively O +
reveal O +
a O +
complex O +
interaction O +
of O +
STAT5 O +
with O +
other O +
signaling O +
pathways O +
and O +
illustrate O +
that O +
regulation O +
of O +
gene O +
expression O +
requires O +
integration O +
of O +
opposing O +
signals O +

Tobacco O +
smoke O +
induces O +
coordinate O +
activation O +
of O +
HSF O +
and O +
inhibition O +
of O +
NFkappaB O +
in O +
human O +
monocytes O +
: O +
effects O +
on O +
TNFalpha O +
release O +
. O +

Tobacco O +
smoke O +
( O +
TS O +
) O +
exposure O +
is O +
a O +
major O +
risk O +
factor O +
for O +
human O +
disease O +
, O +
and O +
macrophages O +
of O +
healthy O +
smokers O +
have O +
a O +
depressed O +
capacity O +
to O +
release O +
cytokines O +
, O +
including O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
alpha O +
. O +

TS O +
induces O +
the O +
synthesis O +
of O +
heat O +
shock O +
( O +
HS O +
) O +
/stress O +
proteins O +
( O +
HSP O +
) O +
, O +
and O +
, O +
in O +
particular O +
, O +
of O +
Hsp70 O +
. O +

We O +
determined O +
whether O +
Hsp70 O +
induction O +
by O +
TS O +
was O +
mediated O +
by O +
the O +
activation O +
of O +
the O +
HS O +
transcription O +
factor O +
, O +
HSF O +
. O +

HSF O +
activation O +
has O +
been O +
shown O +
to O +
inhibit O +
NFkappaB O +
. O +

Thus O +
, O +
we O +
also O +
determined O +
the O +
effects O +
of O +
TS O +
on O +
NFkappaB O +
. O +

U937 B-CellLine +
cells I-CellLine +
and O +
human O +
peripheral O +
blood O +
monocytes O +
were O +
exposed O +
to O +
TS O +
, O +
binding O +
activities O +
of O +
the O +
respective O +
transcription O +
factors O +
were O +
analyzed O +
, O +
and O +
Hsp70 O +
expression O +
and O +
TNFalpha O +
release O +
were O +
determined O +
in O +
parallel O +
. O +

TS O +
activated O +
HSF O +
, O +
which O +
was O +
associated O +
with O +
Hsp70 O +
overexpression O +
and O +
inhibition O +
of O +
NFkappaB O +
binding O +
activity O +
and O +
TNFalpha O +
release O +
. O +

The O +
altered O +
cytokine O +
profile O +
observed O +
in O +
smokers O +
may O +
relate O +
to O +
an O +
HSF O +
/ O +
Hsp70 O +
-mediated O +
inhibition O +
of O +
NFkappaB O +
activity O +
. O +

Copyright O +
1998 O +
Academic O +
Press O +
. O +

In O +
vivo O +
function O +
of O +
an O +
interleukin O +
2 O +
receptor O +
beta O +
chain O +
( O +
IL-2Rbeta O +
) O +
/IL-4Ralpha O +
cytokine O +
receptor O +
chimera O +
potentiates O +
allergic O +
airway O +
disease O +
. O +

Strength O +
of O +
T O +
cell O +
receptor O +
( O +
TCR O +
) O +
signaling O +
, O +
coreceptors O +
, O +
costimulation O +
, O +
antigen O -
- O -
presenting O +
cell O +
type O +
, O +
and O +
cytokines O +
all O +
play O +
crucial O +
roles O +
in O +
determining O +
the O +
efficiency O +
with O +
which O +
type O +
2 O +
T O +
lymphocytes O +
( O +
Th2 O +
, O +
Tc2 O +
) O +
develop O +
from O +
uncommitted O +
precursors O +
. O +

To O +
investigate O +
in O +
vivo O +
regulatory O +
mechanisms O +
that O +
control O +
the O +
population O +
of O +
type O +
2 O +
T O +
cells O +
and O +
disease O +
susceptibility O +
, O +
we O +
have O +
created O +
lines O +
of O +
transgenic O +
mice O +
in O +
which O +
expression O +
of O +
a O +
chimeric O +
cytokine O +
receptor O +
( O +
the O +
mouse O +
interleukin O +
2 O +
receptor O +
beta O +
chain O +
[ O +
IL-2Rbeta O +
] O +
extracellular O +
domain O +
fused O +
to O +
the O +
cytoplasmic O +
tail O +
of O +
IL-4Ralpha O +
) O +
is O +
targeted O +
to O +
the O +
T O +
lymphoid O +
lineage O +
using O +
the O +
proximal O +
lck O +
promoter O +
. O +

This O +
chimera O +
transduced O +
IL-4 O +
-specific O +
signals O +
in O +
response O +
to O +
IL-2 O +
binding O +
and O +
dramatically O +
enhanced O +
type O +
2 O +
responses O +
( O +
IL-4 O +
, O +
IL-5 O +
, O +
and O +
immunoglobulin O +
E O +
production O +
) O +
upon O +
in O +
vitro O +
TCR O +
stimulation O +
or O +
in O +
vivo O +
antigen O +
challenge O +
. O +

Thus O +
, O +
type O +
2 O +
effector O +
function O +
was O +
augmented O +
by O +
IL-4 O +
signals O +
transduced O +
through O +
a O +
chimeric O +
receptor O +
expressed O +
in O +
a O +
T O +
cell O -
- O -
specific O +
manner O +
. O +

This O +
influence O +
was O +
sufficient O +
for O +
establishment O +
of O +
antigen O -
- O -
induced O +
allergic O +
airway O +
hyperresponsiveness O +
on O +
a O +
disease O -
- O -
resistant O +
background O +

The O +
T O -
- O -
cell O +
oncogenic O +
protein O +
HOX11 O +
activates O +
Aldh1 O +
expression O +
in O +
NIH B-CellLine +
3T3 I-CellLine +
cells I-CellLine +
but O +
represses O +
its O +
expression O +
in O +
mouse O +
spleen O +
development O +
. O +

Hox11 O +
is O +
a O +
homeobox O +
gene O +
essential O +
for O +
spleen O +
formation O +
in O +
mice O +
, O +
since O +
atrophy O +
of O +
the O +
anlage O +
of O +
a O +
developing O +
spleen O +
occurs O +
in O +
early O +
embryonic O +
development O +
in O +
Hox11 O +
null O +
mice O +
. O +

HOX11 O +
is O +
also O +
expressed O +
in O +
a O +
subset O +
of O +
T O -
- O -
cell O +
acute O +
leukemias O +
after O +
specific O +
chromosomal O +
translocations O +
. O +

Since O +
the O +
protein O +
has O +
a O +
homeodomain O +
and O +
can O +
activate O +
transcription O +
, O +
it O +
probably O +
exerts O +
at O +
least O +
some O +
of O +
its O +
effects O +
in O +
vivo O +
by O +
regulation O +
of O +
target O +
genes O +
. O +

Representational O +
difference O +
analysis O +
has O +
been O +
used O +
to O +
isolate O +
cDNA O +
clones O +
corresponding O +
to O +
mRNA O +
species O +
activated O +
following O +
stable O +
expression O +
of O +
HOX11 O +
in O +
NIH B-CellLine +
3T3 I-CellLine +
cells I-CellLine +
. O +

The O +
gene O +
encoding O +
the O +
retinoic O +
acid O -
- O -
synthesizing O +
enzyme O +
aldehyde O +
dehydrogenase O +
1 O +
( O +
Aldh1 O +
) O +
, O +
initially O +
called O +
Hdg-1 O +
, O +
was O +
found O +
to O +
be O +
ectopically O +
activated O +
by O +
HOX11 O +
in O +
this O +
system O +
. O +

Study O +
of O +
Aldh1 O +
gene O +
expression O +
during O +
spleen O +
development O +
showed O +
that O +
the O +
presence O +
of O +
Aldh1 O +
mRNA O +
inversely O +
correlated O +
with O +
Hox11 O +
. O +

Hox11 O +
null O +
mouse O +
embryos O +
have O +
elevated O +
Aldh1 O +
mRNA O +
in O +
spleen O +
primordia O +
prior O +
to O +
atrophy O +
, O +
while O +
Aldh1 O +
seems O +
to O +
be O +
repressed O +
by O +
Hox11 O +
during O +
organogenesis O +
of O +
the O +
spleens O +
of O +
wild O -
- O -
type O +
mice O +
. O +

This O +
result O +
suggests O +
that O +
expression O +
of O +
Aldh1 O +
protein O +
is O +
negatively O +
regulated O +
by O +
Hox11 O +
and O +
that O +
abnormal O +
expression O +
of O +
Aldh1 O +
in O +
Hox11 O +
null O +
mice O +
may O +
cause O +
loss O +
of O +
splenic O +
precursor O +
cells O +
by O +
aberrant O +
retinoic O +
acid O +
metabolism O +

Granulocyte O +
colony O -
- O -
stimulating O +
factor O +
activates O +
a O +
72-kDa O +
isoform O +
of O +
STAT3 O +
in O +
human O +
neutrophils O +
. O +

Granulocyte O +
colony O -
- O -
stimulating O +
factor O +
( O +
G O -
- O -
CSF O +
) O +
signaling O +
involves O +
activation O +
of O +
STATs O +
, O +
proteins O +
that O +
serve O +
the O +
dual O +
function O +
of O +
signal O +
transduction O +
and O +
activation O +
of O +
transcription O +
. O +

We O +
previously O +
demonstrated O +
that O +
G O -
- O -
CSF O +
activated O +
a O +
distinct O +
Stat3-like O +
protein O +
in O +
immature O +
and O +
mature O +
normal O +
myeloid O +
cells O +
, O +
StatG O +
. O +

StatG O +
in O +
normal O +
immature O +
human O +
myeloid O +
cells O +
, O +
i.e O +
. O +
adult O +
CD34 O -
+ O +
bone O +
marrow O +
cells O +
, O +
was O +
composed O +
of O +
Stat3beta O +
. O +

This O +
investigation O +
was O +
undertaken O +
to O +
determine O +
the O +
composition O +
of O +
StatG O +
in O +
mature O +
normal O +
human O +
myeloid O +
cells O +
, O +
i.e O +
. O +
polymorphonuclear O +
neutrophilic O +
granulocytes O +
( O +
PMN O +
) O +
. O +

These O +
studies O +
revealed O +
that O +
the O +
major O +
protein O +
in O +
extracts O +
of O +
PMN O +
activated O +
by O +
G O -
- O -
CSF O +
to O +
bind O +
the O +
high O -
- O -
affinity O +
serum O -
- O -
inducible O +
element O +
( O +
hSIE O +
) O +
is O +
a O +
72-kDa O +
protein O +
that O +
cross O -
- O -
reacts O +
with O +
Stat3 O +
monoclonal O +
antibody O +
, O +
which O +
we O +
have O +
designated O +
Stat3gamma O +
. O +

Stat3gamma O +
is O +
derived O +
from O +
Stat3alpha O +
by O +
limited O +
proteolysis O +
and O +
lacks O +
the O +
carboxyl O -
- O -
terminal O +
portion O +
of O +
Stat3alpha O +
. O +

Because O +
this O +
region O +
of O +
Stat3alpha O +
is O +
involved O +
in O +
transcriptional O +
activation O +
, O +
our O +
findings O +
suggest O +
the O +
possibility O +
that O +
Stat3gamma O +
may O +
be O +
transcriptionally O +
inactive O +
and O +
may O +
compete O +
with O +
Stat3alpha O +
for O +
Stat3 O +
binding O +
sites O +
in O +
these O +
terminally O +
differentiated O +
myeloid O +
cells O +

Membrane O -
- O -
associated O +
lymphotoxin O +
on O +
natural O +
killer O +
cells O +
activates O +
endothelial O +
cells O +
via O +
an O +
NF O -
- O -
kappaB O +
-dependent O +
pathway O +
. O +

BACKGROUND O +
: O +
Inhibition O +
of O +
complement O +
in O +
small O +
animal O +
models O +
of O +
xenotransplantation O +
has O +
demonstrated O +
graft O +
infiltration O +
with O +
natural O +
killer O +
( O +
NK O +
) O +
cells O +
and O +
monocytes O +
associated O +
with O +
endothelial O +
cell O +
( O +
EC O +
) O +
activation O +
. O +

We O +
have O +
previously O +
demonstrated O +
that O +
human O +
NK O +
cells O +
activate O +
porcine O +
EC O +
in O +
vitro O +
, O +
which O +
results O +
in O +
adhesion O +
molecule O +
expression O +
and O +
cytokine O +
secretion O +
. O +

In O +
this O +
study O +
, O +
we O +
used O +
the O +
NK B-CellLine +
cell I-CellLine +
line I-CellLine +
NK92 I-CellLine +
to O +
define O +
the O +
molecular O +
and O +
cellular O +
basis O +
of O +
NK O +
cell O -
- O -
mediated O +
EC O +
activation O +
. O +

METHODS O +
: O +
EC O +
were O +
transfected O +
with O +
either O +
reporter O +
constructs O +
containing O +
the O +
luciferase O +
gene O +
driven O +
either O +
by O +
E O -
- O -
selectin O +
or O +
interleukin O +
( O +
IL O +
) O +
-8 O +
promoters O +
or O +
a O +
synthetic O +
NF O -
- O -
kappaB O -
- O -
dependent O +
promoter O +
. O +

In O +
addition O +
, O +
a O +
dominant O -
- O -
negative O +
mutant O +
tumor O +
necrosis O +
factor O +
receptor O +
I O +
( O +
TNFRI O +
) O +
expression O +
vector O +
was O +
co O -
- O -
transfected O +
in O +
inhibition O +
studies O +
. O +

Forty O -
- O -
eight O +
hours O +
after O +
transfection O +
, O +
EC O +
were O +
stimulated O +
with O +
NK O +
cells O +
or O +
NK O +
cell O +
membrane O +
extracts O +
for O +
7 O +
hr O +
and O +
activation O +
was O +
measured O +
by O +
a O +
luciferase O +
assay O +
. O +

RESULTS O +
: O +
Co O -
- O -
culture O +
of O +
NK O +
cells O +
with O +
transfected O +
EC O +
enhanced O +
E O -
- O -
selectin O +
, O +
IL-8 O +
, O +
and O +
NF O -
- O -
kappaB O +
-dependent O +
promoter O +
activity O +
. O +

NK O +
cell O +
membrane O +
extracts O +
retained O +
the O +
capacity O +
to O +
activate O +
EC O +
and O +
induced O +
nuclear O +
translocation O +
of O +
NF O -
- O -
kappaB O +
( O +
p50 O +
and O +
p65 O +
) O +
. O +

Western O +
blotting O +
of O +
NK O +
cell O +
and O +
membrane O +
extracts O +
detected O +
the O +
presence O +
of O +
Lymphotoxin O -
- O -
alpha O +
( O +
LTalpha O +
) O +
but O +
not O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
. O +

Furthermore O +
, O +
LTalpha O +
was O +
secreted O +
in O +
NK B-CellLine +
: I-CellLine +
EC I-CellLine +
co I-CellLine -
- I-CellLine -
cultures I-CellLine +
. O +

Co O -
- O -
transfection O +
with O +
dominant O -
- O -
negative O +
mutant O +
TNFRI O +
inhibited O +
EC O +
activation O +
by O +
NK O +
cell O +
membrane O +
extracts O +
and O +
by O +
NK O +
cells O +
by O +
80 O +
% O +
and O +
47 O +
% O +
, O +
respectively O +
. O +

The O +
same O +
pattern O +
of O +
inhibition O +
was O +
observed O +
using O +
anti O -
- O -
human O +
LT O +
sera O +
. O +

CONCLUSIONS O +
: O +
Human O +
NK O +
cell O +
membrane O -
- O -
bound O +
LT O +
signals O +
across O +
species O +
via O +
TNFRI O +
, O +
leading O +
to O +
NF O -
- O -
kappaB O +
nuclear O +
translocation O +
and O +
transcription O +
of O +
E O -
- O -
selectin O +
and O +
IL-8 O +
, O +
which O +
results O +
in O +
EC O +
activation O +
. O +

The O +
discrepancy O +
in O +
the O +
degree O +
of O +
inhibition O +
by O +
membrane O +
extracts O +
and O +
NK O +
cells O +
with O +
mutant O +
TNFRI O +
suggests O +
that O +
additional O +
pathways O +
are O +
utilized O +
by O +
NK O +
cells O +
to O +
activate O +
EC O +

Triptolide O +
induces O +
apoptotic O +
death O +
of O +
T O +
lymphocyte O +
. O +

Extract O +
of O +
Tripterygium O +
wilfordii O +
Hook O -
. O +
f O +
( O +
TWHf O +
) O +
has O +
immunosuppressive O +
activity O +
and O +
has O +
been O +
used O +
as O +
anti O -
- O -
inflammatory O +
agent O +
in O +
traditional O +
Chinese O +
medicine O +
for O +
centuries O +
. O +

Recent O +
studies O +
have O +
demonstrated O +
that O +
triptolide O +
is O +
the O +
major O +
active O +
component O +
in O +
the O +
extract O +
that O +
inhibits O +
antigen O +
or O +
mitogen O +
-induced O +
T O +
cell O +
proliferation O +
. O +

In O +
attempting O +
to O +
investigate O +
its O +
effect O +
on O +
activation O +
of O +
T O +
lymphocytes O +
, O +
we O +
found O +
triptolide O +
induces O +
apoptotic O +
death O +
of O +
T B-CellLine +
cell I-CellLine +
hybridomas I-CellLine +
and O +
peripheral O +
T O +
cells O +
but O +
not O +
that O +
of O +
thymocytes O +
. O +

The O +
triptolide O -
- O -
induced O +
apoptosis O +
is O +
accompanied O +
by O +
increase O +
of O +
DEVD O -
- O -
cleavable O +
caspases O +
activity O +
and O +
degradation O +
of O +
caspase O +
substrate O +
poly O +
( O +
ADP O -
- O -
ribose O +
) O +
polymerase O +
( O +
PARP O +
) O +
. O +

A O +
specific O +
inhibitor O +
of O +
caspases O +
, O +
zVAD O -
- O -
FMK O +
, O +
prevents O +
triptolide O -
- O -
induced O +
PARP O +
degradation O +
and O +
DNA O +
fragmentation O +
but O +
not O +
growth O +
arrest O +
. O +

Furthermore O +
, O +
enforced O +
expression O +
of O +
Bcl-2 O +
inhibited O +
triptolide O -
- O -
induced O +
degradation O +
of O +
PARP O +
and O +
apoptosis O +
. O +

These O +
results O +
indicate O +
that O +
triptolide O +
induces O +
T O +
cell O +
apoptosis O +
through O +
activating O +
caspases O +
, O +
and O +
suggest O +
the O +
growth O +
arrest O +
and O +
apoptotic O +
effect O +
of O +
triptolide O +
may O +
contribute O +
to O +
the O +
immunosuppressive O +
activity O +
of O +
TWHf O +
extract O +

Spi-1 O -
/ O -
PU.1 O +
proto O -
- O -
oncogene O +
induces O +
opposite O +
effects O +
on O +
monocytic O +
and O +
erythroid O +
differentiation O +
of O +
K562 B-CellLine +
cells I-CellLine +
. O +

Spi-1 O -
/ O -
PU.1 O +
is O +
a O +
hematopoietic O +
transcription O +
factor O +
of O +
the O +
Ets O +
family O +
. O +

To O +
analyze O +
the O +
effects O +
of O +
ectopic O +
expression O +
of O +
spi-1 O +
on O +
the O +
proliferation O -
/ O -
differentiation O +
of O +
human O +
myeloid O +
leukemia O +
cells O +
, O +
K562 B-CellLine +
cells I-CellLine +
were O +
stably O +
transfected O +
with O +
a O +
spi-1 O +
expression O +
vector O +
. O +

The O +
transfected B-CellLine +
cell I-CellLine +
lines I-CellLine +
expressed O +
elevated O +
levels O +
of O +
spi-1 O +
mRNA O +
and O +
protein O +
and O +
high O +
Spi-1 O +
-DNA O +
binding O +
activity O +
. O +

The O +
spi-1 B-CellLine +
transfected I-CellLine +
cells I-CellLine +
showed O +
reduced O +
growth O +
rates O +
and O +
reduced O +
clonogenic O +
cell O +
growth O +
. O +

When O +
the O +
erythroid O +
and O +
monocytic O +
differentiation O +
markers O +
were O +
analyzed O +
, O +
spi-1 O +
overexpression O +
resulted O +
in O +
opposite O +
effects O +
: O +
erythroid O +
differentiation O +
was O +
significantly O +
inhibited O +
in O +
spi-1 B-CellLine +
transfectants I-CellLine +
, O +
while O +
spi-1 O +
overexpression O +
increased O +
the O +
monocytic O +
differentiation O +
of O +
cells O +
. O +

These O +
results O +
indicate O +
a O +
differential O +
role O +
of O +
Spi-1 O +
on O +
the O +
differentiation O +
of O +
human B-CellLine +
myeloid I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
. O +

Copyright O +
1998 O +
Academic O +
Press O +
. O +

The O +
human O +
gene O +
encoding O +
the O +
lectin O -
- O -
type O +
oxidized O +
LDL O +
receptor O +
( O +
OLR1 O +
) O +
is O +
a O +
novel O +
member O +
of O +
the O +
natural O +
killer O +
gene O +
complex O +
with O +
a O +
unique O +
expression O +
profile O +
. O +

LOX-1 O +
is O +
an O +
endothelial O +
receptor O +
for O +
oxidized O +
low O -
- O -
density O +
lipoprotein O +
that O +
plays O +
essential O +
roles O +
in O +
atherogenesis O +
. O +

LOX-1 O +
has O +
the O +
highest O +
homology O +
with O +
C O -
- O -
type O +
lectin O +
receptors O +
expressed O +
on O +
natural O +
killer O +
cells O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
cloned O +
and O +
characterized O +
the O +
human O +
LOX-1 O +
gene O +
( O +
HGMW O -
- O -
approved O +
symbol O +
OLR1 O +
) O +
. O +

The O +
gene O +
structure O +
of O +
LOX-1 O +
resembles O +
that O +
of O +
the O +
natural O +
killer O +
cell O +
receptors O +
. O +

Fluorescence O +
in O +
situ O +
hybridization O +
and O +
analyses O +
of O +
a O +
yeast O +
artificial O +
chromosome O +
contig O +
revealed O +
that O +
the O +
human O +
LOX-1 O +
gene O +
is O +
located O +
in O +
the O +
natural O +
killer O +
gene O +
complex O +
on O +
chromosome O +
12p12-p13 O +
, O +
where O +
the O +
genes O +
of O +
the O +
natural O +
killer O +
cell O +
receptors O +
cluster O +
. O +

In O +
contrast O +
, O +
the O +
expression O +
pattern O +
of O +
LOX-1 O +
is O +
different O +
from O +
that O +
of O +
the O +
natural O +
killer O +
cell O +
receptors O +
; O +
LOX-1 O +
is O +
expressed O +
in O +
vascular O -
- O -
rich O +
organs O +
, O +
but O +
not O +
in O +
lymphocytes O +
. O +

A O +
1753-bp O +
fragment O +
of O +
the O +
5 O +
' O +
flanking O +
region O +
of O +
the O +
LOX-1 O +
gene O +
had O +
a O +
functional O +
promoter O +
activity O +
. O +

This O +
region O +
contains O +
binding O +
sites O +
for O +
several O +
transcription O +
factors O +
, O +
including O +
the O +
STAT O +
family O +
and O +
NF O -
- O -
IL6 O +
, O +
and O +
the O +
expression O +
of O +
LOX-1 O +
was O +
upregulated O +
by O +
several O +
cytokines O +
. O +

These O +
results O +
demonstrate O +
that O +
the O +
human O +
LOX-1 O +
gene O +
is O +
a O +
new O +
member O +
of O +
the O +
natural O +
killer O +
gene O +
complex O +
with O +
a O +
unique O +
expression O +
profile O +
. O +

Copyright O +
1998 O +
Academic O +
Press O +
. O +

Cloning O +
of O +
ARE O -
- O -
containing O +
genes O +
by O +
AU O -
- O -
motif O -
- O -
directed O +
display O +
. O +

A O +
procedure O +
suitable O +
for O +
cloning O +
labile O +
mRNAs O +
that O +
contain O +
AU O +
motifs O +
is O +
presented O +
( O +
AU O -
- O -
DD O +
) O +
. O +

These O +
motifs O +
are O +
regulatory O +
sequences O +
within O +
the O +
so O -
- O -
called O +
AU O -
- O -
rich O +
elements O +
( O +
AREs O +
) O +
often O +
found O +
in O +
3 O +
' O +
untranslated O +
regions O +
of O +
genes O +
such O +
as O +
cytokines O +
, O +
proto O -
- O -
oncogenes O +
, O +
and O +
transcription O +
factors O +
. O +

AU O -
- O -
DD O +
is O +
an O +
AU O -
- O -
motif O -
- O -
directed O +
differential O +
display O +
that O +
permits O +
the O +
identification O +
of O +
ARE O -
- O -
containing O +
genes O +
differentially O +
expressed O +
after O +
cell O +
activation O +
. O +

It O +
has O +
been O +
applied O +
to O +
peripheral O +
blood O +
monocytes O +
and O +
a O +
T B-CellLine +
cell I-CellLine +
clone I-CellLine +
to O +
isolate O +
59 O +
cDNA O +
fragments O +
associated O +
to O +
activation O +
. O +

Fourteen O +
percent O +
of O +
isolated O +
fragments O +
belong O +
to O +
already O +
known O +
genes O +
that O +
certainly O +
are O +
cytokines O +
and O +
transduction O -
/ O -
transcription O +
factors O +
. O +

The O +
remaining O +
86 O +
% O +
correspond O +
to O +
unknown O +
genes O +
of O +
which O +
92 O +
% O +
have O +
been O +
confirmed O +
to O +
be O +
differentially O +
expressed O +
. O +

These O +
data O +
demonstrate O +
the O +
efficiency O +
of O +
the O +
system O +
and O +
support O +
the O +
notion O +
that O +
numerous O +
genes O +
falling O +
into O +
those O +
categories O +
remain O +
unidentified O +
and O +
that O +
they O +
can O +
be O +
cloned O +
by O +
this O +
method O +
. O +

Copyright O +
1998 O +
Academic O +
Press O +
. O +

BASH O +
, O +
a O +
novel O +
signaling O +
molecule O +
preferentially O +
expressed O +
in O +
B O +
cells O +
of O +
the O +
bursa O +
of O +
Fabricius O +
. O +

The O +
bursa O +
of O +
Fabricius O +
is O +
a O +
gut O -
- O -
associated O +
lymphoid O +
organ O +
that O +
is O +
essential O +
for O +
the O +
generation O +
of O +
a O +
diversified O +
B O +
cell O +
repertoire O +
in O +
the O +
chicken O +
. O +

We O +
describe O +
here O +
a O +
novel O +
gene O +
preferentially O +
expressed O +
in O +
bursal O +
B O +
cells O +
. O +

The O +
gene O +
encodes O +
an O +
85-kDa O +
protein O +
, O +
designated O +
BASH O +
( O +
B O +
cell O +
adaptor O +
containing O +
SH2 O +
domain O +
) O +
, O +
that O +
contains O +
N O -
- O -
terminal O +
acidic O +
domains O +
with O +
SH2 O +
domain O -
- O -
binding O +
phosphotyrosine O -
- O -
based O +
motifs O +
, O +
a O +
proline O -
- O -
rich O +
domain O +
, O +
and O +
a O +
C O -
- O -
terminal O +
SH2 O +
domain O +
. O +

BASH O +
shows O +
a O +
substantial O +
sequence O +
similarity O +
to O +
SLP-76 O +
, O +
an O +
adaptor O +
protein O +
functioning O +
in O +
TCR O +
-signal O +
transduction O +
. O +

BASH O +
becomes O +
tyrosine O -
- O -
phosphorylated O +
with O +
the O +
B O +
cell O +
Ag O +
receptor O +
( O +
BCR O +
) O +
cross O -
- O -
link O +
or O +
by O +
coexpression O +
with O +
Syk O +
and O +
Lyn O +
and O +
associates O +
with O +
signaling O +
molecules O +
including O +
Syk O +
and O +
a O +
putative O +
chicken O +
Shc O +
homologue O +
. O +

Overexpression O +
of O +
BASH O +
results O +
in O +
suppression O +
of O +
the O +
NF O -
- O -
AT O +
activation O +
induced O +
by O +
BCR O +
-cross O -
- O -
linking O +
. O +

These O +
findings O +
suggest O +
that O +
BASH O +
is O +
involved O +
in O +
BCR O +
-mediated O +
signal O +
transduction O +
and O +
could O +
play O +
a O +
critical O +
role O +
in O +
B O +
cell O +
development O +
in O +
the O +
bursa O +
. O +

Signaling O +
pathways O +
mediated O +
by O +
the O +
TNF- O +
and O +
cytokine O -
- O -
receptor O +
families O +
target O +
a O +
common O +
cis O -
- O -
element O +
of O +
the O +
IFN O +
regulatory O +
factor O +
1 O +
promoter O +
. O +

CD40 O +
activation O +
of O +
B O +
cells O +
is O +
strongly O +
influenced O +
by O +
the O +
presence O +
of O +
cytokines O +
. O +

However O +
, O +
the O +
molecular O +
basis O +
for O +
the O +
interplay O +
between O +
these O +
distinct O +
stimuli O +
is O +
not O +
clearly O +
delineated O +
. O +

IFN O +
regulatory O +
factor O +
1 O +
( O +
IRF-1 O +
) O +
is O +
a O +
transcription O +
factor O +
activated O +
by O +
either O +
CD40 O +
or O +
cytokines O +
. O +

We O +
have O +
found O +
that O +
these O +
different O +
sets O +
of O +
signals O +
target O +
a O +
common O +
cis O -
- O -
acting O +
element O +
in O +
the O +
promoter O +
of O +
this O +
gene O +
, O +
the O +
IRF-1 O +
gamma O -
- O -
activated O +
site O +
( O +
GAS O +
) O +
. O +

Targeting O +
of O +
the O +
IRF-1 O +
GAS O +
is O +
not O +
confined O +
to O +
activation O +
via O +
CD40 O +
but O +
extends O +
to O +
other O +
stimuli O +
that O +
mimic O +
the O +
CD40 O +
signaling O +
cascade O +
, O +
like O +
TNF O -
- O -
alpha O +
and O +
EBV O +
. O +

In O +
contrast O +
to O +
induction O +
of O +
STATs O +
by O +
cytokines O +
, O +
the O +
IRF-1 O +
GAS O +
-binding O +
complex O +
activated O +
by O +
CD40 O +
, O +
TNF O -
- O -
alpha O +
, O +
or O +
EBV O +
contains O +
Rel O +
proteins O +
, O +
specifically O +
p50 O +
and O +
p65 O +
. O +

In O +
this O +
system O +
, O +
simultaneous O +
exposure O +
to O +
CD40L O +
together O +
with O +
either O +
IL-4 O +
or O +
IFN O -
- O -
gamma O +
does O +
not O +
lead O +
to O +
the O +
activation O +
of O +
novel O +
Rel O -
/ O -
STAT O +
complexes O +
. O +

Given O +
the O +
importance O +
of O +
IRF-1 O +
in O +
a O +
variety O +
of O +
biologic O +
functions O +
from O +
proliferation O +
to O +
apoptosis O +
, O +
our O +
findings O +
support O +
the O +
notion O +
that O +
modulation O +
of O +
IRF-1 O +
levels O +
may O +
be O +
a O +
critical O +
control O +
point O +
in O +
B O +
cell O +
activation O +
. O +

Regulation O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
AP-1 O +
, O +
NFAT O +
, O +
and O +
STAT1 O +
nuclear O +
import O +
in O +
T O +
lymphocytes O +
by O +
noninvasive O +
delivery O +
of O +
peptide O +
carrying O +
the O +
nuclear O +
localization O +
sequence O +
of O +
NF O -
- O -
kappa O +
B O +
p50 O +
. O +

Activation O +
of O +
T O +
lymphocytes O +
by O +
Ags O +
or O +
cytokines O +
results O +
in O +
translocation O +
of O +
the O +
transcription O +
factors O +
NF O -
- O -
kappa O +
B O +
, O +
AP-1 O +
, O +
NFAT O +
, O +
and O +
STAT O +
from O +
the O +
cytoplasm O +
into O +
the O +
nucleus O +
. O +

The O +
first O +
step O +
in O +
the O +
nuclear O +
import O +
process O +
is O +
recognition O +
of O +
a O +
nuclear O +
localization O +
sequence O +
( O +
NLS O +
) O +
within O +
the O +
karyophilic O +
protein O +
by O +
a O +
cytoplasmic O +
receptor O +
such O +
as O +
the O +
importin O +
( O +
karyopherin O +
) O +
-alpha O +
subunit O +
. O +

The O +
NLSs O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
AP-1 O +
, O +
and O +
NFAT O +
differ O +
and O +
the O +
NLS O +
of O +
STAT1 O +
has O +
not O +
yet O +
been O +
identified O +
. O +

Herein O +
we O +
demonstrate O +
that O +
the O +
inducible O +
nuclear O +
import O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
AP-1 O +
, O +
NFAT O +
, O +
and O +
STAT1 O +
in O +
Jurkat B-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
is O +
significantly O +
inhibited O +
by O +
a O +
cell O -
- O -
permeable O +
peptide O +
carrying O +
the O +
NLS O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
p50 O +
subunit O +
. O +

NLS O +
peptide O -
- O -
mediated O +
disruption O +
of O +
the O +
nuclear O +
import O +
of O +
these O +
transcription O +
factors O +
results O +
in O +
inhibition O +
of O +
I O +
kappa O +
B O +
alpha O +
and O +
IL-2 O +
gene O +
expression O +
, O +
processes O +
dependent O +
on O +
NF O -
- O -
kappa O +
B O +
or O +
the O +
combination O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
AP-1 O +
, O +
and O +
NFAT O +
. O +

Further O +
, O +
we O +
show O +
that O +
inhibitory O +
NLS O +
peptide O +
interacts O +
in O +
vitro O +
with O +
a O +
cytoplasmic O +
NLS O +
receptor O +
complex O +
comprised O +
of O +
the O +
Rch1 O -
/ O -
importin O +
( O +
karyopherin O +
) O +
-beta O +
heterodimer O +
expressed O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Taken O +
together O +
, O +
these O +
data O +
indicate O +
that O +
the O +
inducible O +
nuclear O +
import O +
of O +
NF O -
- O -
kappa O +
B O +
, O +
AP-1 O +
, O +
NFAT O +
, O +
and O +
STAT1 O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
can O +
be O +
regulated O +
by O +
NLS O +
peptide O +
delivered O +
noninvasively O +
to O +
the O +
cytoplasm O +
of O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
to O +
target O +
members O +
of O +
the O +
importin O +
( O +
karyopherin O +
) O +
-alpha O +
beta O +
NLS O +
receptor O +
complex O +
. O +

In O +
vitro O +
suppression O +
of O +
programmed O +
cell O +
death O +
of O +
B O +
cells O +
by O +
tissue O +
inhibitor O +
of O +
metalloproteinases-1 O +
. O +

Cellular O +
pathways O +
for O +
induction O +
of O +
programmed O +
cell O +
death O +
( O +
PCD O +
) O +
have O +
been O +
identified O +
, O +
but O +
little O +
is O +
known O +
about O +
specific O +
extracellular O +
matrix O +
processes O +
that O +
may O +
affect O +
apoptosis O +
along O +
those O +
pathways O +
. O +

In O +
this O +
study O +
, O +
a O +
series O +
of O +
Burkitt B-CellLine +
's I-CellLine +
lymphoma I-CellLine +
( I-CellLine +
BL I-CellLine +
) I-CellLine +
cell I-CellLine +
lines I-CellLine +
were O +
assayed O +
for O +
their O +
expression O +
of O +
tissue O +
inhibitor O +
of O +
metalloproteinases O +
( O +
TIMP O +
) O +
-1 O +
. O +

Results O +
indicate O +
that O +
TIMP-1-positive B-CellLine +
BL I-CellLine +
lines I-CellLine +
show O +
resistance O +
to O +
cold O -
- O -
shock O -
- O -
induced O +
apoptosis O +
. O +

Furthermore O +
, O +
recombinant O +
TIMP-1 O +
, O +
but O +
not O +
TIMP-2 O +
or O +
a O +
synthetic O +
metalloproteinase O +
inhibitor O +
( O +
BB-94 O +
) O +
, O +
confers O +
resistance O +
to O +
apoptosis O +
induced O +
by O +
both O +
CD95-dependent O +
and O +
-independent O +
( O +
cold O +
shock O +
, O +
serum O +
deprivation O +
, O +
and O +
gamma O -
- O -
radiation O +
) O +
pathways O +
in O +
TIMP-1-negative B-CellLine +
BL I-CellLine +
lines I-CellLine +
. O +

TIMP-1 O +
suppression O +
of O +
PCD O +
is O +
not O +
due O +
to O +
metalloproteinase O +
inhibition O +
, O +
as O +
reduction O +
and O +
alkylation O +
of O +
the O +
TIMP-1 O +
did O +
not O +
abolish O +
this O +
activity O +
. O +

Retroviral O +
induction O +
of O +
TIMP-1 O +
not O +
only O +
resulted O +
in O +
cell O +
survival O +
but O +
also O +
in O +
continued O +
DNA O +
synthesis O +
for O +
up O +
to O +
5 O +
d O +
in O +
the O +
absence O +
of O +
serum O +
, O +
while O +
controls O +
underwent O +
apoptosis O +
. O +

This O +
resistance O +
to O +
apoptosis O +
is O +
reversed O +
by O +
anti O -
- O -
TIMP-1 O +
antibodies O +
, O +
demonstrating O +
that O +
secreted O +
TIMP-1 O +
is O +
active O +
in O +
blocking O +
apoptosis O +
. O +

Furthermore O +
, O +
TIMP-1 O +
upregulation O +
induced O +
expression O +
of O +
Bcl O -
- O -
XL O +
but O +
not O +
Bcl-2 O +
as O +
well O +
as O +
decreased O +
NF O -
- O -
kappaB O +
activity O +
as O +
compared O +
with O +
controls O +
. O +

These O +
results O +
demonstrate O +
that O +
TIMP-1 O +
suppresses O +
apoptosis O +
in O +
B O +
cells O +
and O +
suggests O +
a O +
novel O +
activity O +
for O +
TIMP-1 O +
in O +
tissue O +
homeostasis O +
. O +

Epithelial O +
cell O -
- O -
initiated O +
inflammation O +
plays O +
a O +
crucial O +
role O +
in O +
early O +
tissue O +
damage O +
in O +
amebic O +
infection O +
of O +
human O +
intestine O +
. O +

BACKGROUND O +
& O +
AIMS O +
: O +
Entamoeba O +
histolytica O +
infection O +
of O +
the O +
intestine O +
can O +
induce O +
severe O +
gut O +
inflammation O +
. O +

The O +
aims O +
of O +
this O +
study O +
were O +
to O +
assess O +
the O +
role O +
of O +
the O +
host O +
inflammatory O +
response O +
in O +
the O +
tissue O +
damage O +
observed O +
with O +
amebiasis O +
and O +
the O +
role O +
of O +
the O +
intestinal O +
epithelial O +
cell O +
in O +
initiating O +
that O +
response O +
. O +

METHODS O +
: O +
E. O +
histolytica O +
infection O +
was O +
established O +
in O +
human O +
intestinal O +
xenografts O +
in O +
severe O +
combined O +
immunodeficient O +
( O +
SCID O -
- O -
HU O -
- O -
INT O +
) O +
mice O +
. O +

Human O +
intestinal O +
epithelial O +
cell O +
inflammatory O +
responses O +
to O +
amebic O +
infection O +
were O +
inhibited O +
by O +
the O +
intraluminal O +
administration O +
of O +
an O +
antisense O +
oligonucleotide O +
to O +
the O +
human O +
p65 O +
subunit O +
of O +
nuclear O +
factor O +
kappaB O +
, O +
and O +
the O +
role O +
of O +
neutrophils O +
in O +
tissue O +
damage O +
observed O +
with O +
amebiasis O +
was O +
studied O +
by O +
depleting O +
neutrophils O +
from O +
SCID O -
- O -
HU O -
- O -
INT O +
mice O +
. O +

RESULTS O +
: O +
Administration O +
of O +
the O +
antisense O +
oligonucleotide O +
blocked O +
the O +
production O +
of O +
human O +
interleukin O +
1beta O +
and O +
interleukin O +
8 O +
by O +
intestinal O +
epithelial O +
cells O +
and O +
inhibited O +
neutrophil O +
influx O +
into O +
the O +
E. O +
histolytica O -
- O -
infected O +
intestinal O +
xenografts O +
. O +

Inhibition O +
of O +
the O +
gut O +
inflammatory O +
response O +
by O +
the O +
antisense O +
oligonucleotide O +
or O +
the O +
depletion O +
of O +
neutrophils O +
from O +
SCID O -
- O -
HU- O +
INT O +
mice O +
blocked O +
the O +
increase O +
in O +
intestinal O +
permeability O +
observed O +
with O +
amebic O +
infection O +
. O +

CONCLUSIONS O +
: O +
Intestinal O +
epithelial O +
cells O +
initiate O +
an O +
inflammatory O +
response O +
with O +
resulting O +
neutrophil O -
- O -
mediated O +
tissue O +
damage O +
in O +
response O +
to O +
E. O +
histolytica O +
infection O +
; O +
this O +
inflammatory O +
cascade O +
can O +
be O +
blocked O +
by O +
inhibiting O +
the O +
transcription O +
of O +
genes O +
regulated O +
by O +
nuclear O +
factor O +
kappaB O +
. O +

Heterogeneous O +
expression O +
of O +
the O +
lipocalin O +
NGAL O +
in O +
primary O +
breast O +
cancers O +
. O +

We O +
have O +
previously O +
shown O +
that O +
neu O +
oncogene O -
- O -
initiated O +
rat O +
mammary O +
carcinomas O +
uniquely O +
over O -
- O -
express O +
neu O -
- O -
related O +
lipocalin O +
( O +
NRL O +
) O +
, O +
a O +
member O +
of O +
the O +
calycin O +
protein O +
superfamily O +
. O +

Here O +
, O +
we O +
characterize O +
the O +
putative O +
human O +
homolog O +
of O +
NRL O +
, O +
neutrophil O +
gelatinase O -
- O -
associated O +
lipocalin O +
( O +
NGAL O +
) O +
. O +

ngal O +
gene O +
expression O +
was O +
found O +
at O +
moderate O +
levels O +
in O +
only O +
2 O +
of O +
17 O +
human O +
tissues O +
examined O +
, O +
breast O +
and O +
lung O +
. O +

When O +
breast O +
cancers O +
were O +
examined O +
for O +
NGAL O +
mRNA O +
and O +
protein O +
levels O +
, O +
they O +
were O +
found O +
to O +
exhibit O +
heterogeneous O +
expression O +
. O +

NGAL O +
levels O +
varied O +
in O +
these O +
tumors O +
from O +
undetectable O +
to O +
exceeding O +
those O +
in O +
normal O +
breast O +
parenchyma O +
. O +

Immuno O -
- O -
histochemical O +
analysis O +
confirmed O +
the O +
presence O +
of O +
NGAL O +
within O +
breast O +
carcinoma O +
cells O +
but O +
detected O +
only O +
low O +
levels O +
of O +
this O +
protein O +
in O +
normal O +
ductal O +
epithelium O +
. O +

In O +
contrast O +
, O +
large O +
amounts O +
of O +
the O +
protein O +
were O +
localized O +
to O +
the O +
lumen O +
of O +
normal O +
breast O +
ducts O +
in O +
the O +
vicinity O +
of O +
NGAL O +
-expressing O +
tumors O +
. O +

Interestingly O +
, O +
unlike O +
NRL O +
in O +
rat O +
mammary O +
carcinomas O +
, O +
no O +
significant O +
association O +
between O +
NGAL O +
expression O +
and O +
HER-2 O -
/ O -
neu O +
activation O +
was O +
found O +
in O +
human O +
breast O +
tumors O +
. O +

In O +
contrast O +
, O +
a O +
significant O +
correlation O +
between O +
NGAL O +
expression O +
in O +
breast O +
cancer O +
was O +
found O +
with O +
several O +
other O +
markers O +
of O +
poor O +
prognosis O +
, O +
including O +
estrogen O +
and O +
progesterone O +
receptor O +
-negative O +
status O +
and O +
high O +
proliferation O +
( O +
S O -
- O -
phase O +
fraction O +
) O +
. O +

NGAL O +
levels O +
were O +
stratified O +
as O +
high O +
or O +
low O +
in O +
breast O +
cancers O +
from O +
a O +
cohort O +
of O +
node O -
- O -
positive O +
patients O +
with O +
known O +
outcome O +
. O +

No O +
significant O +
association O +
between O +
NGAL O +
expression O +
and O +
disease O -
- O -
free O +
or O +
overall O +
survival O +
was O +
observed O +
. O +

Interleukin-12 O +
expression O +
in O +
B O +
cells O +
by O +
transformation O +
with O +
Epstein O -
- O -
Barr O +
virus O +
. O +

Although O +
interleukin O +
( O +
IL O +
) O +
-12 O +
was O +
originally O +
purified O +
from O +
an O +
Epstein B-CellLine -
- I-CellLine -
Barr I-CellLine +
( I-CellLine +
EBV I-CellLine +
) I-CellLine +
-transformed I-CellLine +
B I-CellLine +
cell I-CellLine +
line I-CellLine +
and O +
the O +
high O +
correlation O +
of O +
EBV O +
infection O +
and O +
IL-12 O +
expression O +
has O +
been O +
suggested O +
, O +
no O +
study O +
has O +
reported O +
whether O +
EBV O +
infection O +
is O +
directly O +
linked O +
to O +
IL-12 O +
expression O +
. O +

To O +
address O +
this O +
issue O +
, O +
we O +
have O +
investigated O +
IL-12 O +
expression O +
in O +
B O +
cells O +
during O +
in O +
vitro O +
transformation O +
with O +
EBV O +
. O +

Human O +
peripheral O +
B O +
cells O +
became O +
capable O +
of O +
constitutively O +
producing O +
p40 O +
by O +
in O +
vitro O +
transformation O +
with O +
EBV O +
, O +
coincident O +
with O +
the O +
expression O +
of O +
latent O +
membrane O +
protein O +
1 O +
( O +
LMP1 O +
) O +
of O +
EBV O +
. O +

These O +
B O +
cells O +
expressed O +
p40 O +
and O +
p35 O +
mRNA O +
, O +
and O +
phorbol O +
myristate O +
acetate O +
( O +
PMA O +
) O +
stimulation O +
strongly O +
enhanced O +
p40 O +
and O +
p70 O +
production O +
. O +

Furthermore O +
, O +
transfection O +
with O +
LMP1 O +
expression O +
vector O +
into O +
a O +
human B-CellLine +
B I-CellLine +
lymphoma I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
Daudi B-CellLine +
, O +
led O +
to O +
p40 O +
production O +
with O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappaB O +
activation O +
. O +

These O +
results O +
suggest O +
that O +
transformation O +
of O +
primary O +
B O +
cells O +
with O +
EBV O +
induces O +
IL-12 O +
expression O +
potentially O +
through O +
LMP1 O +
expression O +
. O +

Copyright O +
1998 O +
Academic O +
Press O +
. O +

Anaphylatoxins O +
C5a O +
and O +
C3a O +
induce O +
nuclear O +
factor O +
kappaB O +
activation O +
in O +
human O +
peripheral O +
blood O +
monocytes O +
. O +

The O +
anaphylatoxins O +
C5a O +
and O +
C3a O +
are O +
involved O +
in O +
the O +
regulation O +
of O +
cytokine O +
production O +
. O +

In O +
this O +
study O +
the O +
capability O +
of O +
C5a O +
and O +
C3a O +
to O +
induce O +
transcription O +
factor O +
activation O +
was O +
examined O +
. O +

C5a O +
and O +
C3a O +
stimulation O +
of O +
human O +
peripheral O +
blood O +
monocytes O +
resulted O +
in O +
nuclear O +
expression O +
of O +
a O +
DNA O +
binding O +
activity O +
with O +
specificity O +
to O +
the O +
kappaB O +
sequence O +
. O +

The O +
p50 O +
and O +
p65 O +
proteins O +
, O +
constituents O +
of O +
the O +
prototypic O +
nuclear O +
factor O +
kappaB O +
, O +
were O +
identified O +
as O +
components O +
of O +
the O +
DNA O -
- O -
protein O +
complexes O +
by O +
anti O -
- O -
peptide O +
antibodies O +
in O +
gel O +
supershift O +
assays O +
. O +

C5a O +
induced O +
kappaB O +
binding O +
activity O +
was O +
detected O +
15 O +
min O +
after O +
agonist O +
stimulation O +
, O +
peaked O +
at O +
30 O -
- O -
40 O +
min O +
, O +
and O +
remained O +
detectable O +
at O +
2 O +
h O +
. O +

Binding O +
to O +
kappaB O +
sequence O +
was O +
accompanied O +
by O +
an O +
initial O +
decrease O +
and O +
subsequent O +
increase O +
in O +
the O +
cytoplasmic O +
IkappaBalpha O +
levels O +
, O +
as O +
detected O +
by O +
Western O +
blotting O +
using O +
an O +
anti O -
- O -
IkappaBalpha O +
antibody O +
. O +

Pertussis O +
toxin O +
treatment O +
markedly O +
decreased O +
kappaB O +
binding O +
activities O +
induced O +
by O +
both O +
C5a O +
and O +
C3a O +
, O +
whereas O +
cholera O +
toxin O +
displayed O +
no O +
inhibitory O +
effect O +
. O +

Neither O +
of O +
the O +
two O +
toxins O +
affected O +
kappaB O +
binding O +
activity O +
induced O +
by O +
TNFalpha O +
in O +
the O +
same O +
cells O +
. O +

These O +
results O +
imply O +
a O +
potential O +
role O +
of O +
the O +
anaphylatoxins O +
C5a O +
and O +
C3a O +
in O +
regulating O +
leukocytes O +
gene O +
expression O +
through O +
G O +
protein O -
- O -
coupled O +
transcription O +
factor O +
activation O +
. O +

Host O +
control O +
of O +
HIV-1 O +
parasitism O +
in O +
T O +
cells O +
by O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
. O +

Post O +
HIV-1 O +
entry O +
, O +
productive O +
HIV-1 O +
infection O +
of O +
primary O +
T O +
cells O +
requires O +
overcoming O +
several O +
cellular O +
blocks O +
to O +
provirus O +
establishment O +
and O +
replication O +
. O +

Activation O +
of O +
unknown O +
host O +
intracellular O +
events O +
overcomes O +
such O +
inhibitory O +
steps O +
and O +
is O +
concomitant O +
with O +
HIV-1 O +
replication O +
. O +

We O +
show O +
that O +
the O +
transcription O +
factor O +
NFATc O +
was O +
sufficient O +
as O +
a O +
cellular O +
factor O +
to O +
induce O +
a O +
highly O +
permissive O +
state O +
for O +
HIV-1 O +
replication O +
in O +
primary O +
CD4 O -
+ O +
T O +
cells O +
. O +

NFATc O +
overcame O +
a O +
blockade O +
at O +
reverse O +
transcription O +
and O +
permitted O +
active O +
HIV-1 O +
replication O +
. O +

Pharmacologic O +
blockade O +
of O +
endogenous O +
NFAT O +
activity O +
by O +
FK506 O +
or O +
CsA O +
inhibited O +
synthesis O +
of O +
reverse O +
transcription O +
and O +
also O +
potently O +
blocked O +
HIV-1 O +
replication O +
. O +

T O +
cells O +
therefore O +
can O +
become O +
competent O +
for O +
HIV-1 O +
replication O +
by O +
control O +
of O +
regulated O +
host O +
factors O +
such O +
as O +
the O +
NFATc O +
transcription O +
factor O +
. O +

The O +
host O +
mechanisms O +
regulated O +
by O +
such O +
permissivity O +
factors O +
are O +
potential O +
targets O +
for O +
anti O -
- O -
HIV-1 O +
therapy O +
. O +

Regulation O +
of O +
PAK O +
activation O +
and O +
the O +
T O +
cell O +
cytoskeleton O +
by O +
the O +
linker O +
protein O +
SLP-76 O +
. O +

Tyrosine O +
phosphorylation O +
of O +
linker O +
proteins O +
enables O +
the O +
T O +
cell O +
antigen O +
receptor O +
( O +
TCR O +
) O +
-associated O +
protein O +
tyrosine O +
kinases O +
to O +
phosphorylate O +
and O +
regulate O +
effector O +
molecules O +
that O +
generate O +
second O +
messengers O +
. O +

We O +
demonstrate O +
here O +
that O +
the O +
SLP-76 O +
linker O +
protein O +
interacts O +
with O +
both O +
nck O +
, O +
an O +
adaptor O +
protein O +
, O +
and O +
Vav O +
, O +
a O +
guanine O +
nucleotide O +
exchange O +
factor O +
for O +
Rho O -
- O -
family O +
GTPases O +
. O +

The O +
assembly O +
of O +
this O +
tri O -
- O -
molecular O +
complex O +
permits O +
the O +
activated O +
Rho O -
- O -
family O +
GTPases O +
to O +
regulate O +
target O +
effectors O +
that O +
interact O +
through O +
nck O +
. O +

In O +
turn O +
, O +
assembly O +
of O +
this O +
complex O +
mediates O +
the O +
enzymatic O +
activation O +
of O +
the O +
p21-activated O +
protein O +
kinase O +
1 O +
and O +
facilitates O +
actin O +
polymerization O +
. O +

Hence O +
, O +
phosphorylation O +
of O +
linker O +
proteins O +
not O +
only O +
bridges O +
the O +
TCR O -
- O -
associated O +
PTK O +
, O +
ZAP-70 O +
, O +
with O +
downstream O +
effector O +
proteins O +
, O +
but O +
also O +
provides O +
a O +
scaffold O +
to O +
integrate O +
distinct O +
signaling O +
complexes O +
to O +
regulate O +
T O +
cell O +
function O +
. O +

Inhibition O +
of O +
Th1 O +
development O +
mediated O +
by O +
GATA-3 O +
through O +
an O +
IL-4-independent O +
mechanism O +
. O +

Recently O +
, O +
the O +
transcription O +
factor O +
GATA-3 O +
was O +
shown O +
to O +
be O +
selectively O +
expressed O +
in O +
Th2 O +
but O +
not O +
Th1 O +
cells O +
and O +
to O +
augment O +
Th2-specific O +
cytokines O +
. O +

Here O +
, O +
we O +
show O +
that O +
loss O +
of O +
GATA-3 O +
expression O +
by O +
developing O +
Th1 O +
cells O +
requires O +
IL-12 O +
signaling O +
through O +
Stat4 O +
and O +
does O +
not O +
simply O +
result O +
from O +
an O +
absence O +
of O +
IL-4 O +
. O +

Moreover O +
, O +
we O +
demonstrate O +
a O +
novel O +
role O +
for O +
GATA-3 O +
in O +
directly O +
repressing O +
Th1 O +
development O +
distinct O +
from O +
its O +
positive O +
actions O +
on O +
Th2-specific O +
cytokines O +
. O +

GATA-3 O +
inhibits O +
Th1 O +
cytokines O +
by O +
a O +
cell O -
- O -
intrinsic O +
mechanism O +
that O +
is O +
not O +
dependent O +
on O +
IL-4 O +
and O +
that O +
may O +
involve O +
repression O +
of O +
IL-12 O +
signaling O +
. O +

Thus O +
, O +
GATA-3 O +
expression O +
and O +
IL-12 O +
signaling O +
are O +
mutually O +
antagonistic O +
, O +
which O +
facilitates O +
rapid O +
dominance O +
of O +
one O +
pathway O +
during O +
early O +
Th O +
development O +
, O +
producing O +
a O +
stable O +
divergence O +
in O +
cytokine O +
profiles O +
. O +

Stat6 O +
inhibits O +
human O +
interleukin-4 O +
promoter O +
activity O +
in O +
T O +
cells O +
. O +

The O +
differentiation O +
of O +
naive O +
T O -
- O -
helper O +
( O +
Th O +
) O +
cells O +
into O +
cytokine O -
- O -
secreting O +
effector O +
Th O +
cells O +
requires O +
exposure O +
to O +
multiple O +
signals O +
, O +
including O +
exogenous O +
cytokines O +
. O +

Interleukin-4 O +
( O +
IL-4 O +
) O +
plays O +
a O +
major O +
role O +
in O +
this O +
process O +
by O +
promoting O +
the O +
differentiation O +
of O +
IL-4 O +
-secreting O +
Th2 O +
cells O +
. O +

In O +
Th2 O +
cells O +
, O +
IL-4 O +
gene O +
expression O +
is O +
tightly O +
controlled O +
at O +
the O +
level O +
of O +
transcription O +
by O +
the O +
coordinated O +
binding O +
of O +
multiple O +
transcription O +
factors O +
to O +
regulatory O +
elements O +
in O +
the O +
proximal O +
promoter O +
region O +
. O +

Nuclear O +
factor O +
of O +
activated O +
T O +
cell O +
( O +
NFAT O +
) O +
family O +
members O +
play O +
a O +
critical O +
role O +
in O +
regulating O +
IL-4 O +
transcription O +
and O +
interact O +
with O +
up O +
to O +
five O +
sequences O +
( O +
termed O +
P0 O +
through O +
P4 O +
) O +
in O +
the O +
IL-4 O +
promoter O +
. O +

The O +
molecular O +
mechanisms O +
by O +
which O +
IL-4 O +
induces O +
expression O +
of O +
the O +
IL-4 O +
gene O +
are O +
not O +
known O +
, O +
although O +
the O +
IL-4-activated O +
transcription O +
factor O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
6 O +
( O +
Stat6 O +
) O +
is O +
required O +
for O +
this O +
effect O +
. O +

We O +
report O +
here O +
that O +
Stat6 O +
interacts O +
with O +
three O +
binding O +
sites O +
in O +
the O +
human O +
IL-4 O +
promoter O +
by O +
electrophoretic O +
mobility O +
shift O +
assays O +
. O +

These O +
sites O +
overlap O +
the O +
P1 O +
, O +
P2 O +
, O +
and O +
P4 O +
NFAT O +
elements O +
. O +

To O +
investigate O +
the O +
role O +
of O +
Stat6 O +
in O +
regulating O +
IL-4 O +
transcription O +
, O +
we O +
used O +
Stat6 O +
-deficient O +
Jurkat O +
T O +
cells O +
with O +
different O +
intact O +
IL-4 O +
promoter O +
constructs O +
in O +
cotransfection O +
assays O +
. O +

We O +
show O +
that O +
, O +
whereas O +
a O +
multimerized O +
response O +
element O +
from O +
the O +
germline O +
IgE O +
promoter O +
was O +
highly O +
induced O +
by O +
IL-4 O +
in O +
Stat6-expressing O +
Jurkat O +
cells O +
, O +
the O +
intact O +
human O +
IL-4 O +
promoter O +
was O +
repressed O +
under O +
similar O +
conditions O +
. O +

We O +
conclude O +
that O +
the O +
function O +
of O +
Stat6 O +
is O +
highly O +
dependent O +
on O +
promoter O +
context O +
and O +
that O +
this O +
factor O +
promotes O +
IL-4 O +
gene O +
expression O +
in O +
an O +
indirect O +
manner O +
. O +

Glucocorticoid O +
receptors O +
on O +
mononuclear O +
leukocytes O +
in O +
polycystic O +
ovary O +
syndrome O +
. O +

OBJECTIVE O +
: O +
Many O +
studies O +
have O +
suggested O +
that O +
there O +
is O +
a O +
possible O +
hormonal O +
dysregulation O +
of O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenal O +
( O +
HPA O +
) O +
axis O +
and O +
an O +
increased O +
cortisol O +
clearance O +
in O +
patients O +
with O +
polycystic O +
ovary O +
syndrome O +
( O +
PCOS O +
) O +
. O +

Therefore O +
in O +
this O +
study O +
, O +
we O +
have O +
examined O +
the O +
role O +
of O +
glucocorticoid O +
receptor O -
/ O -
s O +
( O +
GR O +
) O +
characteristics O +
in O +
the O +
developing O +
of O +
these O +
abnormalities O +
in O +
patients O +
with O +
PCOS O +
. O +

METHOD O +
: O +
For O +
this O +
purpose O +
, O +
the O +
number O +
and O +
affinity O +
of O +
GR O +
in O +
peripheral O +
mononuclear O +
leukocytes O +
( O +
MNL O +
) O +
of O +
10 O +
patients O +
with O +
PCOS O +
and O +
10 O +
healthy O +
women O +
( O +
controls O +
) O +
were O +
determined O +
. O +

RESULTS O +
: O +
There O +
were O +
no O +
significant O +
differences O +
in O +
the O +
number O +
( O +
6500+ O -
/ O -
-1001 O +
sites O -
/ O -
cell O +
and O +
6352+ O -
/ O -
-1697 O +
sites O -
/ O -
cell O +
, O +
respectively O +
; O +
P O +
> O +
0.05 O +
) O +
and O +
affinity O +
( O +
3.93+ O -
/ O -
-0.89 O +
nM O +
and O +
4.49+ O -
/ O -
-0.71 O +
nM O +
, O +
respectively O +
; O +
P O +
> O +
0.05 O +
) O +
of O +
GR O +
between O +
the O +
PCOS O +
patients O +
and O +
the O +
controls O +
. O +

CONCLUSIONS O +
: O +
These O +
results O +
suggest O +
that O +
the O +
alterations O +
in O +
the O +
HPA O +
axis O +
and O +
in O +
the O +
cortisol O +
metabolism O +
observed O +
in O +
PCOS O +
are O +
not O +
related O +
to O +
GR O +
deficiency O +
. O +

The O +
linkage O +
between O +
T O -
- O -
cell O +
and O +
dendritic O +
cell O +
development O +
in O +
the O +
mouse O +
thymus O +
. O +

Thymic O +
dendritic O +
cells O +
( O +
DC O +
) O +
mediate O +
negative O +
selection O +
at O +
a O +
relatively O +
late O +
stage O +
of O +
the O +
T O -
- O -
cell O +
developmental O +
pathway O +
. O +

We O +
present O +
evidence O +
that O +
the O +
development O +
of O +
thymic O +
DC O +
and O +
of O +
T O -
- O -
lineage O +
cells O +
is O +
linked O +
via O +
a O +
common O +
precursor O +
at O +
an O +
early O +
stage O +
of O +
thymocyte O +
development O +
. O +

T O -
- O -
lineage O +
precursor O +
populations O +
from O +
the O +
adult O +
mouse O +
thymus O +
, O +
prior O +
to O +
T O -
- O -
cell O +
receptor O +
gene O +
rearrangement O +
, O +
display O +
a O +
capacity O +
to O +
produce O +
DC O +
as O +
well O +
as O +
T O +
cells O +
in O +
the O +
thymus O +
, O +
and O +
are O +
very O +
efficient O +
precursors O +
of O +
DC O +
in O +
culture O +
. O +

These O +
lymphoid O -
/ O -
DC O +
precursors O +
have O +
little O +
capacity O +
to O +
form O +
myeloid O +
cells O +
, O +
indicating O +
that O +
thymic O +
DC O +
are O +
a O +
lymphoid O -
- O -
related O +
rather O +
than O +
myeloid O -
- O -
related O +
lineage O +
. O +

In O +
contrast O +
to O +
myeloid O -
- O -
related O +
DC O +
, O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
is O +
not O +
required O +
for O +
the O +
development O +
of O +
these O +
lymphoid O -
- O -
related O +
DC O +
in O +
vivo O +
or O +
in O +
vitro O +
. O +

DC O +
can O +
develop O +
in O +
mutant O +
mice O +
lacking O +
mature O +
T O +
cells O +
, O +
provided O +
the O +
common O +
precursors O +
are O +
present O +
. O +

However O +
, O +
in O +
mutant O +
mice O +
lacking O +
functional O +
Ikaros O +
transcription O +
factors O +
, O +
there O +
are O +
deficiencies O +
in O +
lymphoid O +
precursor O +
cells O +
, O +
in O +
mature O +
lymphoid O +
cells O +
and O +
in O +
DC O +
. O +

The O +
involvement O +
of O +
multiple O +
tumor O +
necrosis O +
factor O +
receptor O +
( O +
TNFR O +
) O +
-associated O +
factors O +
in O +
the O +
signaling O +
mechanisms O +
of O +
receptor O +
activator O +
of O +
NF O -
- O -
kappaB O +
, O +
a O +
member O +
of O +
the O +
TNFR O +
superfamily O +
. O +

Receptor O +
activator O +
of O +
NF O -
- O -
kappaB O +
( O +
RANK O +
) O +
is O +
a O +
recently O +
identified O +
member O +
of O +
the O +
tumor O +
necrosis O +
factor O +
receptor O +
superfamily O +
and O +
is O +
expressed O +
on O +
activated O +
T O +
cells O +
and O +
dendritic O +
cells O +
. O +

Its O +
cognate O +
ligand O +
( O +
RANKL O +
) O +
plays O +
significant O +
roles O +
in O +
the O +
activation O +
of O +
dendritic O +
cell O +
function O +
and O +
osteoclast O +
differentiation O +
. O +

We O +
demonstrate O +
here O +
the O +
interaction O +
of O +
RANK O +
with O +
tumor O +
necrosis O +
factor O +
receptor O -
- O -
associated O +
factors O +
( O +
TRAFs O +
) O +
1 O +
, O +
2 O +
, O +
3 O +
, O +
5 O +
, O +
and O +
6 O +
both O +
in O +
vitro O +
and O +
in O +
cells O +
. O +

Mapping O +
of O +
the O +
structural O +
requirements O +
for O +
TRAF O +
/RANK O +
interaction O +
revealed O +
multiple O +
TRAF O +
binding O +
sites O +
clustered O +
in O +
two O +
distinct O +
domains O +
in O +
the O +
RANK O +
cytoplasmic O +
tail O +
. O +

These O +
TRAF O +
binding O +
domains O +
were O +
shown O +
to O +
be O +
functionally O +
important O +
for O +
the O +
RANK O +
-dependent O +
induction O +
of O +
NF O -
- O -
kappaB O +
and O +
c O -
- O -
Jun O +
NH2-terminal O +
kinase O +
activities O +
. O +

Site O -
- O -
directed O +
mutagenesis O +
demonstrated O +
that O +
these O +
TRAF O +
binding O +
sites O +
exhibited O +
selective O +
binding O +
for O +
different O +
TRAF O +
proteins O +
. O +

In O +
particular O +
, O +
TRAF6 O +
interacted O +
with O +
membrane O -
- O -
proximal O +
determinants O +
distinct O +
from O +
those O +
binding O +
TRAFs O +
1 O +
, O +
2 O +
, O +
3 O +
, O +
and O +
5 O +
. O +

When O +
this O +
membrane O -
- O -
proximal O +
TRAF6 O +
interaction O +
domain O +
was O +
deleted O +
, O +
RANK O +
-mediated O +
NF O -
- O -
kappaB O +
signaling O +
was O +
completely O +
inhibited O +
while O +
c O -
- O -
Jun O +
NH2-terminal O +
kinase O +
activation O +
was O +
partially O +
inhibited O +
. O +

An O +
NH2-terminal O +
truncation O +
mutant O +
of O +
TRAF6 O +
inhibited O +
RANKL O +
-mediated O +
NF O -
- O -
kappaB O +
activation O +
, O +
but O +
failed O +
to O +
affect O +
constitutive O +
signaling O +
induced O +
by O +
receptor O +
overexpression O +
, O +
revealing O +
a O +
selective O +
role O +
for O +
TRAF6 O +
in O +
ligand O -
- O -
induced O +
activation O +
events O +
. O +

Molecular O +
cloning O +
of O +
FKHRL1P2 O +
, O +
a O +
member O +
of O +
the O +
developmentally O +
regulated O +
fork O +
head O +
domain O +
transcription O +
factor O +
family O +
. O +

Here O +
we O +
report O +
the O +
expression O +
of O +
a O +
fork O +
head O +
domain O +
protein O +
in O +
human O +
T O +
helper O +
cells O +
. O +

We O +
cloned O +
and O +
characterized O +
a O +
fork O +
head O +
cDNA O +
from O +
human O +
T O +
helper O +
cell O +
mRNA O +
using O +
differential O +
display O +
RT O -
- O -
PCR O +
. O +

The O +
cDNA O +
contains O +
a O +
546-nucleotide O +
( O +
nt O +
) O +
open O +
reading O +
frame O +
( O +
ORF O +
) O +
that O +
codes O +
for O +
the O +
carboxyl O -
- O -
terminal O +
180 O +
amino O +
acids O +
( O +
aa O +
) O +
of O +
the O +
recently O +
identified O +
fkhrl1 O +
gene O +
. O +

This O +
ORF O +
does O +
not O +
contain O +
the O +
characteristic O +
DNA O -
- O -
binding O +
domain O +
found O +
in O +
members O +
of O +
the O +
forkhead O +
protein O +
family O +
. O +

In O -
- O -
vitro O +
transcription O -
/ O -
translation O +
of O +
this O +
cDNA O +
expressed O +
a O +
protein O +
of O +
approximately O +
20 O +
kDa O +
. O +

We O +
have O +
generated O +
antibodies O +
that O +
specifically O +
immunoprecipitated O +
the O +
in O -
- O -
vitro O -
- O -
translated O +
20-kDa O +
protein O +
. O +

This O +
antibody O +
also O +
recognizes O +
in O +
human O +
T O +
lymphocytes O +
a O +
70-kDa O +
protein O +
corresponding O +
in O +
size O +
to O +
that O +
predicted O +
for O +
the O +
fkhrl1 O +
gene O +
product O +
. O +

The O +
mRNA O +
levels O +
for O +
fkhrl1 O +
is O +
elevated O +
in O +
T O +
helper O -
- O -
induced O +
lymphocytes O +
in O +
comparison O +
to O +
PHA B-CellLine -
- I-CellLine -
stimulated I-CellLine +
T I-CellLine +
lymphocytes I-CellLine +
. O +

Further O +
characterization O +
of O +
FKHRL1 O +
and O +
its O +
related O +
family O +
members O +
should O +
shed O +
light O +
on O +
the O +
transcriptional O +
mechanisms O +
of O +
this O +
fork O +
head O +
gene O +
subfamily O +
and O +
their O +
role O +
in O +
T O +
helper O +
cell O +
differentiation O +
and O +
regulation O +
of O +
cell O +
growth O +
. O +

Activation O +
of O +
the O +
human O +
delta O -
- O -
globin O +
gene O +
promoter O +
in O +
primary O +
adult O +
erythroid O +
cells O +
. O +

Restoration O +
of O +
the O +
CCAAT O +
box O +
or O +
insertion O +
of O +
an O +
erythroid O +
Kruppel O -
- O -
like O +
factor O +
( O +
EKLF O +
) O +
binding O +
site O +
in O +
the O +
delta O +
promoter O +
activates O +
its O +
expression O +
in O +
several O +
erythroid B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

We O +
extended O +
these O +
studies O +
using O +
a O +
novel O +
primary B-CellLine +
human I-CellLine +
adult I-CellLine +
erythroid I-CellLine +
cell I-CellLine +
( I-CellLine +
hAEC I-CellLine +
) I-CellLine +
system I-CellLine +
to O +
investigate O +
these O +
effects O +
at O +
the O +
late O +
erythroblast O +
stage O +
. O +

Restoration O +
of O +
the O +
CCAAT O +
box O +
at O +
-70 O +
bp O +
, O +
or O +
insertion O +
of O +
an O +
EKLF O +
binding O +
site O +
at O +
-85 O +
bp O +
or O +
-95 O +
bp O +
in O +
the O +
promoter O +
significantly O +
increased O +
delta O +
globin O +
gene O +
expression O +
in O +
hAEC O +
. O +

Our O +
results O +
demonstrate O +
that O +
the O +
altered O +
CCAAT O +
box O +
( O +
CCAAC O +
) O +
and O +
the O +
lack O +
of O +
an O +
EKLF O +
binding O +
site O +
in O +
delta O -
- O -
globin O +
contribute O +
to O +
its O +
low O +
level O +
of O +
expression O +
in O +
the O +
hAEC B-CellLine +
model I-CellLine +
as O +
well O +
. O +

The O +
control O +
of O +
lytic O +
replication O +
of O +
Epstein O -
- O -
Barr O +
virus O +
in O +
B O +
lymphocytes O +
( O +
Review O +
) O +
. O +

Uncontrolled O +
replication O +
of O +
a O +
virus O +
, O +
which O +
is O +
harmful O +
to O +
the O +
host O +
is O +
also O +
disadvantageous O +
to O +
the O +
virus O +
. O +

Most O +
viruses O +
can O +
not O +
compete O +
with O +
the O +
various O +
immune O +
mechanisms O +
and O +
become O +
eliminated O +
in O +
the O +
course O +
of O +
infection O +
. O +

Therefore O +
, O +
only O +
the O +
time O +
between O +
infection O +
and O +
eradication O +
remains O +
for O +
these O +
viruses O +
to O +
proliferate O +
. O +

A O +
few O +
viruses O +
, O +
like O +
the O +
Herpesviruses O +
or O +
the O +
papillomaviruses O +
, O +
however O +
, O +
have O +
developed O +
a O +
sophisticated O +
strategy O +
for O +
persisting O +
lifelong O +
, O +
usually O +
asymptomatically O +
in O +
the O +
host O +
, O +
hiding O +
from O +
the O +
immune O +
system O +
and O +
producing O +
infectious O +
progeny O +
at O +
the O +
same O +
time O +
. O +

This O +
strategy O +
depends O +
on O +
a O +
separation O +
of O +
latency O +
and O +
the O +
lytic O +
replication O +
, O +
either O +
by O +
time O +
due O +
to O +
differentiation O -
- O -
dependent O +
mechanisms O +
or O +
by O +
spatial O +
separation O +
as O +
the O +
result O +
of O +
different O +
host O +
cell O +
types O +
. O +

Both O +
are O +
true O +
for O +
the O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
. O +

B O +
cells O +
and O +
epithelial O +
cells O +
have O +
a O +
pivotal O +
role O +
in O +
the O +
life O +
cycle O +
of O +
the O +
virus O +
. O +

The O +
former O +
can O +
become O +
latently O +
infected O +
and O +
are O +
thought O +
to O +
be O +
the O +
virus O +
reservoir O +
in O +
vivo O +
, O +
whereas O +
the O +
latter O +
were O +
shown O +
to O +
be O +
permissive O +
for O +
lytic O +
replication O +
. O +

However O +
, O +
replication O +
of O +
EBV O +
in O +
vivo O +
is O +
controlled O +
primarily O +
by O +
host O +
immune O +
mechanisms O +
selecting O +
for O +
cells O +
that O +
are O +
not O +
permissive O +
for O +
viral O +
replication O +
as O +
the O +
result O +
of O +
a O +
particular O +
set O +
of O +
transcription O +
factors O +
. O +

These O +
factors O +
control O +
the O +
activity O +
of O +
the O +
regulatory O +
immediate O -
- O -
early O +
genes O +
and O +
, O +
in O +
addition O +
, O +
lytic O +
and O +
latent O +
cycle O +
regulatory O +
genes O +
negatively O +
interfere O +
with O +
each O +
other O +
and O +
thus O +
link O +
cellular O +
and O +
viral O +
gene O +
regulatory O +
mechanisms O +
. O +

Disturbance O +
of O +
both O +
the O +
immune O +
surveillance O +
as O +
well O +
as O +
viral O +
gene O +
regulation O +
may O +
result O +
in O +
EBV O -
- O -
associated O +
disease O +
. O +

Human O +
immunodeficiency O +
virus O +
type-1 O +
transcription O +
: O +
role O +
of O +
the O +
5'-untranslated O +
leader O +
region O +
( O +
review O +
) O +
. O +

Human O +
immunodeficiency O +
virus O +
type-1 O +
( O +
HIV-1 O +
) O +
transcription O +
is O +
dependent O +
on O +
the O +
interaction O +
of O +
host O -
- O -
cell O +
transcription O +
factors O +
with O +
cis O -
- O -
regulatory O +
DNA O +
elements O +
within O +
the O +
viral O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
. O +

Much O +
attention O +
has O +
focused O +
on O +
the O +
series O +
of O +
sequence O +
elements O +
upstream O +
of O +
the O +
transcriptional O +
initiation O +
site O +
in O +
the O +
U3 O +
region O +
of O +
the O +
LTR O +
including O +
the O +
Sp1 O +
and O +
NF O -
- O -
kappaB O +
binding O +
sites O +
. O +

Recent O +
studies O +
, O +
however O +
, O +
demonstrate O +
that O +
the O +
transcribed O +
5'-untranslated O +
leader O +
region O +
( O +
5'-UTR O +
) O +
also O +
contains O +
important O +
transcriptional O +
elements O +
. O +

These O +
regulatory O +
elements O +
situated O +
downstream O +
of O +
transcription O +
interact O +
with O +
constitutive O +
and O +
inducible O +
transcription O +
factors O +
, O +
mediate O +
transmission O +
of O +
cellular O +
activation O +
signals O +
, O +
and O +
are O +
important O +
for O +
efficient O +
HIV-1 O +
transcription O +
and O +
replication O +
. O +

The O +
5'-UTR O +
contains O +
binding O +
sites O +
for O +
the O +
transcription O +
factors O +
AP-1 O +
, O +
NF O -
- O -
kappaB O +
, O +
NF O -
- O -
AT O +
, O +
IRF O +
, O +
and O +
Sp1 O +
. O +

Mutations O +
in O +
these O +
binding O +
sites O +
can O +
interfere O +
with O +
the O +
viral O +
response O +
to O +
cell O +
activation O +
signals O +
, O +
decrease O +
LTR O +
transcription O +
, O +
and O +
inhibit O +
viral O +
replication O +
. O +

The O +
5'-UTR O +
also O +
interacts O +
with O +
a O +
specific O +
nucleosome O +
that O +
is O +
rapidly O +
displaced O +
during O +
transcriptional O +
activation O +
of O +
the O +
latent O +
provirus O +
. O +

We O +
propose O +
that O +
the O +
inducible O +
transcription O +
factor O +
binding O +
sites O +
in O +
the O +
5'-UTR O +
comprise O +
a O +
downstream O +
enhancer O +
domain O +
that O +
can O +
function O +
independent O +
of O +
, O +
or O +
in O +
concert O +
with O +
, O +
the O +
LTR O +
promoter O +
to O +
rapidly O +
increase O +
latent O +
proviral O +
transcription O +
in O +
response O +
to O +
cell O +
activation O +
signals O +
. O +

In O +
this O +
review O +
, O +
we O +
describe O +
the O +
host O -
- O -
cell O +
transcription O +
factors O +
that O +
interact O +
with O +
the O +
5'-UTR O +
and O +
discuss O +
their O +
role O +
in O +
the O +
transcriptional O +
regulation O +
of O +
HIV-1 O +
gene O +
expression O +
. O +

Enhanced O +
differentiation O +
of O +
HL-60 B-CellLine +
leukemia I-CellLine +
cells I-CellLine +
to O +
macrophages O +
induced O +
by O +
ciprofibrate O +
. O +

Ciprofibrate O +
, O +
an O +
hypolipidaemic O +
peroxisome O +
proliferator O +
, O +
induced O +
differentiation O +
of O +
HL-60 B-CellLine +
cells I-CellLine +
. O +

The O +
effect O +
was O +
greatly O +
potentiated O +
by O +
phorbol O +
12-myristate O +
13-acetate O +
at O +
a O +
concentration O +
where O +
neither O +
phorbol O +
ester O +
nor O +
ciprofibrate O +
alone O +
had O +
any O +
effect O +
on O +
these O +
cells O +
. O +

As O +
occurs O +
for O +
HL-60 O +
cell O +
differentiation O +
induced O +
by O +
high O +
phorbol O +
ester O +
concentration O +
, O +
the O +
ciprofibrate O -
- O -
induced O +
phorbol O +
ester O -
- O -
dependent O +
differentiation O +
of O +
HL-60 B-CellLine +
cells I-CellLine +
proceeded O +
through O +
the O +
monocytic O -
/ O -
macrophage O +
pathway O +
and O +
induced O +
the O +
phosphorylation O +
of O +
proteins O +
with O +
similar O +
molecular O +
weights O +
suggesting O +
that O +
increased O +
protein O +
kinase O +
C O +
activity O +
may O +
be O +
involved O +
in O +
the O +
effect O +
. O +

The O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
( O +
PPARalpha O +
) O +
transcription O +
factor O +
is O +
expressed O +
in O +
HL-60 B-CellLine +
cells I-CellLine +
, O +
but O +
no O +
changes O +
were O +
observed O +
in O +
its O +
expression O +
upon O +
HL-60 O +
cell O +
differentiation O +
. O +

Nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
and O +
AP-1 O +
are O +
insufficient O +
for O +
IL-2 O +
promoter O +
activation O +
: O +
requirement O +
for O +
CD28 O +
up O -
- O -
regulation O +
of O +
RE O -
/ O -
AP O +
. O +

IL-2 O +
gene O +
transcription O +
in O +
T O +
cells O +
requires O +
both O +
TCR O +
and O +
costimulatory O +
signals O +
. O +

IL-2 O +
promoter O +
activation O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
stimulated O +
with O +
superantigen O +
presented O +
by O +
Raji B-CellLine +
B I-CellLine +
cells I-CellLine +
requires O +
CD28 O +
activation O +
. O +

The O +
addition O +
of O +
rCTLA4Ig O +
, O +
which O +
blocks O +
CD28 O +
binding O +
to O +
its O +
ligand O +
, O +
to O +
the O +
cultures O +
decreased O +
IL-2 O +
promoter O +
activation O +
by O +
> O +
80 O +
% O +
. O +

Interestingly O +
, O +
CTLA4Ig O +
did O +
not O +
significantly O +
inhibit O +
the O +
activation O +
of O +
either O +
NF O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
or O +
AP-1 O +
reporters O +
. O +

Therefore O +
, O +
activation O +
of O +
NFAT O +
and O +
AP-1 O +
is O +
insufficient O +
for O +
IL-2 O +
promoter O +
activation O +
. O +

In O +
contrast O +
, O +
an O +
RE O -
/ O -
AP O +
reporter O +
was O +
blocked O +
by O +
CTLA4Ig O +
by O +
> O +
90 O +
% O +
. O +

Thus O +
, O +
the O +
requirement O +
for O +
CD28 O +
in O +
IL-2 O +
promoter O +
activation O +
appears O +
to O +
be O +
due O +
to O +
RE O -
/ O -
AP O +
and O +
not O +
the O +
NFAT O +
or O +
AP-1 O +
sites O +
. O +

In O +
addition O +
, O +
these O +
data O +
suggest O +
that O +
transcriptional O +
activation O +
of O +
RE O -
/ O -
AP O +
is O +
not O +
mediated O +
by O +
NFAT O +
, O +
because O +
activation O +
of O +
a O +
NFAT O +
reporter O +
is O +
not O +
affected O +
by O +
the O +
addition O +
of O +
CTLA4Ig O +
. O +

The O +
role O +
of O +
Stat4 O +
in O +
species O -
- O -
specific O +
regulation O +
of O +
Th O +
cell O +
development O +
by O +
type O +
I O +
IFNs O +
. O +

Type O +
I O +
IFNs O +
( O +
IFN O -
- O -
alpha O -
/ O -
beta O +
) O +
, O +
in O +
addition O +
to O +
IL-12 O +
, O +
have O +
been O +
shown O +
to O +
play O +
an O +
important O +
role O +
in O +
the O +
differentiation O +
of O +
human O +
, O +
but O +
not O +
mouse O +
, O +
Th O +
cells O +
. O +

We O +
show O +
here O +
that O +
IFN O -
- O -
alpha O -
/ O -
beta O +
act O +
directly O +
on O +
human O +
T O +
cells O +
to O +
drive O +
Th1 O +
development O +
, O +
bypassing O +
the O +
need O +
for O +
IL-12 O +
-induced O +
signaling O +
, O +
whereas O +
IFN O -
- O -
alpha O +
can O +
not O +
substitute O +
IL-12 O +
for O +
mouse O +
Th1 O +
development O +
. O +

The O +
molecular O +
basis O +
for O +
this O +
species O +
specificity O +
is O +
that O +
IFN O -
- O -
alpha O -
/ O -
beta O +
activate O +
Stat4 O +
in O +
differentiating O +
human O +
, O +
but O +
not O +
mouse O +
, O +
Th O +
cells O +
. O +

Unlike O +
IL-12 O +
, O +
which O +
acts O +
only O +
on O +
Th1 O +
cells O +
, O +
IFN O -
- O -
alpha O -
/ O -
beta O +
can O +
activate O +
Stat4 O +
not O +
only O +
in O +
human O +
Th1 O +
, O +
but O +
also O +
in O +
Th2 O +
cells O +
. O +

However O +
, O +
restimulation O +
of O +
human B-CellLine +
Th2 I-CellLine +
lines I-CellLine +
and O +
clones O +
in O +
the O +
presence O +
of O +
IFN O -
- O -
alpha O +
does O +
not O +
induce O +
the O +
production O +
of O +
IFN O -
- O -
gamma O +
. O +

These O +
results O +
suggest O +
that O +
activation O +
of O +
Stat4 O +
, O +
which O +
is O +
necessary O +
for O +
the O +
differentiation O +
of O +
naive O +
T O +
cells O +
into O +
polarized O +
Th1 O +
cells O +
, O +
is O +
not O +
sufficient O +
to O +
induce O +
phenotype O +
reversal O +
of O +
human O +
Th2 O +
cells O +
. O +

Interactions O +
between O +
the O +
class O +
II O +
transactivator O +
and O +
CREB O +
binding O +
protein O +
increase O +
transcription O +
of O +
major O +
histocompatibility O +
complex O +
class O +
II O +
genes O +
. O +

Class O +
II O +
major O +
histocompatibility O +
( O +
class O +
II O +
) O +
genes O +
are O +
regulated O +
in O +
a O +
B O -
- O -
cell O -
- O -
specific O +
and O +
gamma O +
interferon O -
- O -
inducible O +
fashion O +
. O +

The O +
master O +
switch O +
for O +
the O +
expression O +
of O +
these O +
genes O +
is O +
the O +
class O +
II O +
transactivator O +
( O +
CIITA O +
) O +
. O +

In O +
this O +
report O +
, O +
we O +
demonstrate O +
that O +
one O +
of O +
the O +
functions O +
of O +
CIITA O +
is O +
to O +
recruit O +
the O +
CREB O +
binding O +
protein O +
( O +
CBP O +
) O +
to O +
class O +
II O +
promoters O +
. O +

Not O +
only O +
functional O +
but O +
also O +
specific O +
binding O +
interactions O +
between O +
CIITA O +
and O +
CBP O +
were O +
demonstrated O +
. O +

Moreover O +
, O +
a O +
dominant O +
negative O +
form O +
of O +
CBP O +
decreased O +
the O +
activity O +
of O +
class O +
II O +
promoters O +
and O +
levels O +
of O +
class O +
II O +
determinants O +
on O +
the O +
surface O +
of O +
cells O +
. O +

Finally O +
, O +
the O +
inhibition O +
of O +
class O +
II O +
gene O +
expression O +
by O +
the O +
glucocorticoid O +
hormone O +
could O +
be O +
attributed O +
to O +
the O +
squelching O +
of O +
CBP O +
by O +
the O +
glucocorticoid O +
receptor O +
. O +

We O +
conclude O +
that O +
CBP O +
, O +
a O +
histone O +
acetyltransferase O +
, O +
plays O +
an O +
important O +
role O +
in O +
the O +
transcription O +
of O +
class O +
II O +
genes O +
. O +

Interdomain O +
B O +
in O +
ZAP-70 O +
regulates O +
but O +
is O +
not O +
required O +
for O +
ZAP-70 O +
signaling O +
function O +
in O +
lymphocytes O +
. O +

The O +
protein O +
tyrosine O +
kinase O +
ZAP-70 O +
plays O +
an O +
important O +
role O +
in O +
T O -
- O -
cell O +
activation O +
and O +
development O +
. O +

After O +
T O -
- O -
cell O +
receptor O +
stimulation O +
, O +
ZAP-70 O +
associates O +
with O +
the O +
receptor O +
and O +
is O +
phosphorylated O +
on O +
many O +
tyrosines O +
, O +
including O +
Y292 O +
, O +
Y315 O +
, O +
and O +
Y319 O +
within O +
interdomain O +
B O +
. O +

Previously O +
, O +
we O +
demonstrated O +
that O +
Y292 O +
negatively O +
regulates O +
ZAP-70 O +
function O +
and O +
that O +
Y315 O +
positively O +
regulates O +
ZAP-70 O +
function O +
by O +
interacting O +
with O +
Vav O +
. O +

Recent O +
studies O +
have O +
suggested O +
that O +
Y319 O +
also O +
positively O +
regulate O +
ZAP-70 O +
function O +
. O +

Paradoxically O +
, O +
removal O +
of O +
interdomain O +
B O +
( O +
to O +
create O +
the O +
construct O +
designated O +
Delta O +
) O +
, O +
containing O +
the O +
Y292 O +
, O +
Y315 O +
, O +
and O +
Y319 O +
sites O +
, O +
did O +
not O +
eliminate O +
the O +
ability O +
of O +
ZAP-70 O +
to O +
induce O +
multiple O +
gene O +
reporters O +
in O +
Syk B-CellLine -
- I-CellLine -
deficient I-CellLine +
DT-40 I-CellLine +
B I-CellLine +
cells I-CellLine +
and O +
ZAP-70 B-CellLine -
/ I-CellLine -
Syk I-CellLine -
- I-CellLine -
deficient I-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
. O +

Here O +
we O +
show O +
that O +
Delta O +
still O +
utilizes O +
the O +
same O +
pathways O +
as O +
wild O -
- O -
type O +
ZAP-70 O +
to O +
mediate O +
NF O -
- O -
AT O +
induction O +
. O +

This O +
is O +
manifested O +
by O +
the O +
ability O +
of O +
Delta O +
to O +
restore O +
induction O +
of O +
calcium O +
fluxes O +
and O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
activation O +
and O +
by O +
the O +
ability O +
of O +
dominant O +
negative O +
Ras O +
and O +
FK506 O +
to O +
block O +
the O +
induction O +
of O +
NF O -
- O -
AT O +
activity O +
mediated O +
by O +
Delta O +
. O +

Biochemically O +
we O +
show O +
that O +
the O +
stimulated O +
tyrosine O +
phosphorylation O +
of O +
Vav O +
, O +
Shc O +
, O +
and O +
ZAP-70 O +
itself O +
is O +
diminished O +
, O +
whereas O +
that O +
of O +
Slp-76 O +
is O +
increased O +
in O +
cells O +
reconstituted O +
with O +
Delta O +
. O +

Deletion O +
of O +
interdomain O +
B O +
did O +
not O +
affect O +
the O +
ability O +
of O +
ZAP-70 O +
to O +
bind O +
to O +
the O +
receptor O +
. O +

The O +
in O +
vitro O +
kinase O +
activity O +
of O +
ZAP-70 O +
lacking O +
interdomain O +
B O +
was O +
markedly O +
reduced O +
, O +
but O +
the O +
kinase O +
activity O +
was O +
still O +
required O +
for O +
the O +
protein O +
's O +
in O +
vivo O +
activity O +
. O +

Based O +
on O +
these O +
data O +
, O +
we O +
concluded O +
that O +
interdomain O +
B O +
regulates O +
but O +
is O +
not O +
required O +
for O +
ZAP-70 O +
signaling O +
function O +
leading O +
to O +
cellular O +
responses O +
. O +

Phenylarsine O +
oxide O +
inhibits O +
ex O +
vivo O +
HIV-1 O +
expression O +
. O +

Phenylarsine O +
oxide O +
( O +
PAO O +
) O +
, O +
which O +
is O +
described O +
as O +
an O +
inhibitor O +
of O +
tyrosine O +
phosphatase O +
activity O +
, O +
inhibits O +
H2O2 O +
release O +
from O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMCs O +
) O +
as O +
measured O +
by O +
electrochemistry O +
. O +

Since O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
replication O +
is O +
known O +
to O +
be O +
favored O +
under O +
oxidative O +
stress O +
conditions O +
, O +
ex O +
vivo O +
experiments O +
using O +
uninfected O +
PBMCs O +
, O +
primary O +
monocytes O +
or O +
a O +
latently O +
infected O +
promonocytic B-CellLine +
U1 I-CellLine +
cell I-CellLine +
line I-CellLine +
show O +
that O +
HIV-1 O +
replication O +
and O +
reactivation O +
, O +
monitored O +
by O +
p24 O +
antigen O +
measurement O +
, O +
are O +
inhibited O +
by O +
PAO O +
in O +
a O +
time- O +
and O +
concentration O -
- O -
dependent O +
manner O +
. O +

These O +
observations O +
can O +
be O +
linked O +
with O +
the O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
when O +
uninfected O +
monocytes O +
are O +
induced O +
by O +
either O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
or O +
lipopolysaccharide O +
( O +
LPS O +
) O +
. O +

Mechanism O +
of O +
interleukin-10 O +
inhibition O +
of O +
T O -
- O -
helper O +
cell O +
activation O +
by O +
superantigen O +
at O +
the O +
level O +
of O +
the O +
cell O +
cycle O +
. O +

We O +
have O +
analyzed O +
the O +
effects O +
of O +
interleukin-10 O +
( O +
IL-10 O +
) O +
on O +
the O +
entry O +
of O +
quiescent O +
CD4 O +
( O +
+ O +
) O +
T O +
cells O +
into O +
the O +
cell O +
cycle O +
upon O +
stimulation O +
with O +
the O +
superantigen O +
staphylococcal O +
enterotoxin O +
B O +
( O +
SEB O +
) O +
. O +

IL-10 O +
arrested O +
cells O +
at O +
G0 O -
/ O -
G1 O +
. O +

IL-10 O +
treatment O +
prevented O +
the O +
downregulation O +
of O +
p27 O +
( O +
Kip1 O +
) O +
, O +
an O +
inhibitory O +
protein O +
that O +
controls O +
progression O +
out O +
of O +
the O +
G0 O +
phase O +
of O +
the O +
cell O +
cycle O +
. O +

IL-10 O +
also O +
prevented O +
the O +
upregulation O +
of O +
the O +
G1 O +
cyclins O +
D2 O +
and O +
D3 O +
, O +
proteins O +
necessary O +
for O +
entry O +
and O +
progression O +
through O +
the O +
G1 O +
phase O +
of O +
the O +
cell O +
cycle O +
. O +

Associated O +
with O +
the O +
inhibition O +
of O +
the O +
cell O +
cycle O +
, O +
IL-10 O +
suppressed O +
SEB O +
induction O +
of O +
interleukin-2 O +
( O +
IL-2 O +
) O +
. O +

Addition O +
of O +
exogenous O +
IL-2 O +
to O +
IL-10-treated B-CellLine +
cells I-CellLine +
significantly O +
reversed O +
the O +
antiproliferative O +
effects O +
of O +
IL-10 O +
. O +

Moreover O +
, O +
IL-10 O +
effects O +
on O +
the O +
early O +
G1 O +
proteins O +
p27 O +
( O +
Kip1 O +
) O +
and O +
cyclin O +
D2 O +
were O +
similarly O +
reversed O +
by O +
exogenous O +
IL-2 O +
. O +

Although O +
this O +
reversal O +
by O +
IL-2 O +
was O +
pronounced O +
, O +
it O +
was O +
not O +
complete O +
, O +
suggesting O +
that O +
IL-10 O +
may O +
have O +
some O +
effects O +
not O +
directly O +
related O +
to O +
the O +
suppression O +
of O +
IL-2 O +
production O +
. O +

Cell O +
separation O +
experiments O +
suggest O +
that O +
IL-10 O +
can O +
effect O +
purified O +
CD4 O +
( O +
+ O +
) O +
T O +
cells O +
directly O +
, O +
providing O +
functional O +
evidence O +
for O +
the O +
presence O +
of O +
IL-10 O +
receptors O +
on O +
CD4 O +
( O +
+ O +
) O +
T O +
cells O +
. O +

IL-10 O +
also O +
inhibited O +
expression O +
of O +
IL-2 O +
transcriptional O +
regulators O +
c O -
- O -
fos O +
and O +
c O -
- O -
jun O +
, O +
which O +
also O +
inhibit O +
other O +
cell O +
functions O +
. O +

Our O +
studies O +
show O +
that O +
the O +
mechanism O +
of O +
IL-10 O +
regulation O +
of O +
quiescent O +
CD4 O +
( O +
+ O +
) O +
T O -
- O -
cell O +
activation O +
is O +
mainly O +
by O +
blocking O +
induction O +
of O +
IL-2 O +
that O +
is O +
critical O +
to O +
downregulation O +
of O +
p27 O +
( O +
Kip1 O +
) O +
and O +
upregulation O +
of O +
D O +
cyclins O +
in O +
T O -
- O -
cell O +
activation O +
and O +
entry O +
into O +
the O +
cell O +
cycle O +
. O +

The O +
position O +
of O +
the O +
ZEBRA O +
activation O +
domain O +
does O +
not O +
influence O +
its O +
biological O +
activity O +
. O +

Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
is O +
a O +
human O +
herpesvirus O +
which O +
latently O +
infects O +
B O +
lymphocytes O +
. O +

EBV O +
encodes O +
a O +
unique O +
transcriptional O +
activator O +
, O +
known O +
as O +
ZEBRA O +
, O +
which O +
can O +
disrupt O +
viral O +
latency O +
in O +
B O +
cells O +
and O +
induce O +
lytic O +
viral O +
replication O +
. O +

Furthermore O +
, O +
ZEBRA O +
has O +
been O +
shown O +
to O +
bind O +
at O +
the O +
EBV O +
origin O +
of O +
lytic O +
replication O +
, O +
and O +
is O +
necessary O +
for O +
viral O +
DNA O +
replication O +
to O +
occur O +
. O +

Previously O +
we O +
demonstrated O +
that O +
heterologous O +
activation O +
domains O +
can O +
fully O +
substitute O +
for O +
the O +
ZEBRA O +
activation O +
domain O +
. O +

Here O +
we O +
extend O +
those O +
results O +
by O +
showing O +
that O +
the O +
position O +
of O +
the O +
ZEBRA O +
activation O +
domain O +
or O +
a O +
heterologous O +
replacement O +
domain O +
does O +
not O +
influence O +
its O +
ability O +
to O +
function O +
in O +
the O +
disruption O +
of O +
EBV O +
latency O +
. O +

In O +
this O +
study O +
three O +
novel O +
clones O +
were O +
constructed O +
in O +
which O +
the O +
ZEBRA O +
activation O +
region O +
was O +
repositioned O +
to O +
the O +
carboxy O +
terminus O +
of O +
the O +
protein O +
. O +

These O +
mutants O +
were O +
used O +
to O +
demonstrate O +
that O +
the O +
ability O +
of O +
ZEBRA O +
's O +
wild O +
type O +
domain O +
to O +
function O +
in O +
the O +
complex O +
biological O +
process O +
of O +
virus O +
activation O +
is O +
not O +
compromised O +
by O +
altering O +
its O +
position O +
within O +
the O +
protein O +
. O +

Interleukin-10 O +
stabilizes O +
inhibitory O +
kappaB O -
- O -
alpha O +
in O +
human O +
monocytes O +
. O +

Interleukin-10 O +
( O +
IL-10 O +
) O +
protects O +
animals O +
from O +
lethal O +
endotoxemia O +
. O +

This O +
beneficial O +
effect O +
is O +
mediated O +
, O +
in O +
part O +
, O +
by O +
inhibition O +
of O +
inflammatory O +
cytokine O +
production O +
, O +
including O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
. O +

Evidence O +
suggests O +
that O +
IL-10 O +
may O +
inhibit O +
activation O +
of O +
the O +
transcription O +
factor O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
through O +
an O +
unknown O +
mechanism O +
. O +

NF O -
- O -
kappaB O +
activation O +
in O +
response O +
to O +
inflammatory O +
signals O +
is O +
dependent O +
upon O +
degradation O +
of O +
its O +
associated O +
inhibitory O +
peptide O +
, O +
inhibitory O +
kappaB O -
- O -
alpha O +
( O +
IkappaB O -
- O -
alpha O +
) O +
. O +

We O +
hypothesized O +
that O +
IL-10 O +
prevents O +
human O +
monocyte O +
NF O -
- O -
kappaB O +
activation O +
and O +
resultant O +
TNF O -
- O -
alpha O +
production O +
by O +
stabilization O +
of O +
IkappaB O -
- O -
alpha O +
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
effect O +
of O +
IL-10 O +
on O +
lipopolysaccharide O +
( O +
LPS O +
) O +
-induced O +
human O +
monocyte O +
TNF O -
- O -
alpha O +
production O +
, O +
NF O -
- O -
kappaB O +
activation O +
, O +
and O +
IkappaB O -
- O -
alpha O +
degradation O +
. O +

Monocytes O +
were O +
isolated O +
from O +
human O +
donors O +
. O +

Cells O +
were O +
stimulated O +
with O +
endotoxin O +
( O +
LPS O +
, O +
100 O +
ng O -
/ O -
mL O +
) O +
with O +
and O +
without O +
human O +
IL-10 O +
( O +
10 O +
ng O -
/ O -
mL O +
) O +
. O +

Following O +
stimulation O +
, O +
TNF O -
- O -
alpha O +
was O +
measured O +
in O +
cell O +
supernatants O +
by O +
ELISA O +
, O +
NF O -
- O -
kappaB O +
activity O +
by O +
electrophoretic O +
mobility O +
shift O +
assay O +
, O +
and O +
IkappaB O -
- O -
alpha O +
levels O +
by O +
Western O +
blot O +
. O +

We O +
observed O +
that O +
after O +
LPS O +
stimulation O +
of O +
human O +
monocytes O +
, O +
TNF O -
- O -
alpha O +
increased O +
to O +
798+ O -
/ O -
-67 O +
pg O -
/ O -
mL O +
( O +
p O +
< O +
.001 O +
versus O +
control O +
) O +
. O +

IL-10 O +
attenuated O +
LPS O -
- O -
stimulated O +
TNF O -
- O -
alpha O +
production O +
( O +
297+ O -
/ O -
-54 O +
; O +
p O +
< O +
.001 O +
versus O +
LPS O +
alone O +
) O +
. O +

After O +
LPS O +
stimulation O +
in O +
human O +
monocytes O +
, O +
IkappaB O -
- O -
alpha O +
protein O +
levels O +
decreased O +
, O +
and O +
NF O -
- O -
kappaB O +
DNA O +
binding O +
increased O +
. O +

IL-10 O +
pretreatment O +
prevented O +
LPS O -
- O -
induced O +
decreases O +
in O +
IkappaB O -
- O -
alpha O +
protein O +
levels O +
and O +
attenuated O +
NF O -
- O -
kappaB O +
DNA O +
binding O +
. O +

IL-10 O +
appears O +
to O +
prevent O +
activation O +
of O +
NF O -
- O -
kappaB O +
by O +
preserving O +
IkappaB O -
- O -
alpha O +
protein O +
levels O +
, O +
leading O +
to O +
a O +
reduction O +
in O +
TNF O -
- O -
alpha O +
release O +
. O +

Functional O +
testosterone O +
receptors O +
in O +
plasma O +
membranes O +
of O +
T O +
cells O +
. O +

T O +
cells O +
are O +
considered O +
to O +
be O +
unresponsive O +
to O +
testosterone O +
due O +
to O +
the O +
absence O +
of O +
androgen O +
receptors O +
( O +
AR O +
) O +
. O +

Here O +
, O +
we O +
demonstrate O +
the O +
testosterone O +
responsiveness O +
of O +
murine O +
splenic O +
T O +
cells O +
in O +
vitro O +
as O +
well O +
as O +
the O +
presence O +
of O +
unconventional O +
cell O +
surface O +
receptors O +
for O +
testosterone O +
and O +
classical O +
intracellular O +
AR O +
. O +

Binding O +
sites O +
for O +
testosterone O +
on O +
the O +
surface O +
of O +
both O +
CD4 O +
( O +
+ O +
) O +
and O +
CD8 O +
( O +
+ O +
) O +
subsets O +
of O +
T O +
cells O +
are O +
directly O +
revealed O +
with O +
the O +
impeded O +
ligand O +
testosterone O -
- O -
BSA O -
- O -
FITC O +
by O +
confocal O +
laser O +
scanning O +
microscopy O +
( O +
CLSM O +
) O +
and O +
flow O +
cytometry O +
, O +
respectively O +
. O +

Binding O +
of O +
the O +
plasma O +
membrane O +
impermeable O +
testosterone O -
- O -
BSA O +
conjugate O +
induces O +
a O +
rapid O +
rise O +
( O +
< O +
5 O +
s O +
) O +
in O +
[ O +
Ca2 O -
+ O +
] O +
i O +
of O +
Fura-2-loaded O +
T O +
cells O +
. O +

This O +
rise O +
reflects O +
influx O +
of O +
extracellular O +
Ca2 O -
+ O +
through O +
non O -
- O -
voltage O -
- O -
gated O +
and O +
Ni2 O -
+ O -
-blockable O +
Ca2 O -
+ O +
channels O +
of O +
the O +
plasma O +
membrane O +
. O +

The O +
testosterone O -
- O -
BSA O -
- O -
induced O +
Ca2 O -
+ O +
import O +
is O +
not O +
affected O +
by O +
cyproterone O +
, O +
a O +
blocker O +
of O +
the O +
AR O +
. O +

In O +
addition O +
, O +
AR O +
are O +
not O +
detectable O +
on O +
the O +
surface O +
of O +
intact O +
T O +
cells O +
when O +
using O +
anti O -
- O -
AR O +
antibodies O +
directed O +
against O +
the O +
amino O +
and O +
carboxy O +
terminus O +
of O +
the O +
AR O +
, O +
although O +
T O +
cells O +
contain O +
AR O +
, O +
as O +
revealed O +
by O +
reverse O +
transcription O -
- O -
polymerase O +
chain O +
reactions O +
and O +
Western O +
blotting O +
. O +

AR O +
can O +
be O +
visualized O +
with O +
the O +
anti O -
- O -
AR O +
antibodies O +
in O +
the O +
cytoplasm O +
of O +
permeabilized O +
T O +
cells O +
by O +
using O +
CLSM O +
, O +
though O +
AR O +
are O +
not O +
detectable O +
in O +
cytosol O +
fractions O +
when O +
using O +
the O +
charcoal O +
binding O +
assay O +
with O +
3H O -
- O -
R1881 O +
as O +
ligand O +
. O +

Cytoplasmic O +
AR O +
do O +
not O +
translocate O +
to O +
the O +
nucleus O +
of O +
T O +
cells O +
in O +
the O +
presence O +
of O +
testosterone O +
, O +
in O +
contrast O +
to O +
cytoplasmic O +
AR O +
in O +
human B-CellLine +
cancer I-CellLine +
LNCaP I-CellLine +
cells I-CellLine +
. O +

These O +
findings O +
suggest O +
that O +
the O +
classical O +
AR O +
present O +
in O +
splenic O +
T O +
cells O +
are O +
not O +
active O +
in O +
the O +
genomic O +
pathway O +
. O +

By O +
contrast O +
, O +
the O +
cell O +
surface O +
receptors O +
for O +
testosterone O +
are O +
in O +
a O +
functionally O +
active O +
state O +
, O +
enabling O +
T O +
cells O +
a O +
nongenomic O +
response O +
to O +
testosterone O +
. O +

X O +
chromosome O +
inactivation O +
patterns O +
in O +
normal O +
females O +
. O +

Since O +
one O +
of O +
the O +
two O +
X O +
chromosomes O +
is O +
randomly O +
inactivated O +
at O +
an O +
early O +
stage O +
of O +
female O +
embryonic O +
development O +
, O +
X O -
- O -
linked O +
markers O +
have O +
been O +
used O +
to O +
study O +
the O +
origin O +
and O +
development O +
of O +
various O +
neoplastic O +
disorders O +
in O +
affected O +
heterozygous O +
women O +
; O +
clonality O +
assays O +
have O +
provided O +
a O +
useful O +
tool O +
to O +
the O +
understanding O +
of O +
the O +
mechanisms O +
underlying O +
the O +
development O +
of O +
neoplasia O +
. O +

Recently O +
, O +
a O +
technique O +
of O +
clonal O +
analysis O +
has O +
been O +
devised O +
that O +
takes O +
advantage O +
of O +
a O +
highly O +
polymorphic O +
short O +
tandem O +
repeat O +
within O +
the O +
X O -
- O -
linked O +
human O +
androgen O +
receptor O +
( O +
AR O +
) O +
gene O +
, O +
resulting O +
in O +
a O +
heterozygosity O +
rate O +
approaching O +
90 O +
% O +
. O +

The O +
rapid O +
expansion O +
of O +
the O +
number O +
of O +
women O +
now O +
suitable O +
for O +
X O +
inactivation O +
analysis O +
has O +
however O +
given O +
rise O +
to O +
new O +
controversies O +
, O +
one O +
of O +
the O +
more O +
troublesome O +
being O +
the O +
possibility O +
of O +
a O +
modification O +
of O +
the O +
pattern O +
of O +
X- O +
chromosome O +
inactivation O +
pattern O +
in O +
blood O +
cells O +
of O +
elderly O +
women O +
. O +

In O +
the O +
present O +
study O +
we O +
analyze O +
with O +
the O +
AR O +
assay O +
a O +
group O +
of O +
166 O +
healthy O +
females O +
aged O +
between O +
8 O +
and O +
94 O +
years O +
, O +
with O +
no O +
history O +
of O +
genetic O +
or O +
neoplastic O +
familial O +
disorders O +
. O +

We O +
failed O +
to O +
find O +
any O +
correlation O +
between O +
age O +
and O +
X- O +
chromosome O +
inactivation O +
pattern O +
( O +
r O +
= O +
0.17 O +
) O +
, O +
even O +
subdividing O +
the O +
subjects O +
in O +
different O +
age O +
groups O +
according O +
to O +
the O +
criteria O +
used O +
by O +
other O +
researchers O +
, O +
and O +
therefore O +
reaffirm O +
that O +
, O +
when O +
tested O +
for O +
with O +
well O -
- O -
standardized O +
and O +
accurate O +
criteria O +
, O +
extremely O +
unbalanced O +
inactivation O +
of O +
the O +
X O +
chromosome O +
is O +
a O +
truly O +
uncommon O +
phenomenon O +
in O +
normal O +
women O +
. O +

Copyright O +
1998 O +
Academic O +
Press O +
. O +

Reactivation O +
of O +
Kaposi O +
's O +
sarcoma O -
- O -
associated O +
herpesvirus O +
infection O +
from O +
latency O +
by O +
expression O +
of O +
the O +
ORF O +
50 O +
transactivator O +
, O +
a O +
homolog O +
of O +
the O +
EBV O +
R O +
protein O +
. O +

Kaposi O +
's O +
sarcoma O +
( O +
KS O +
) O +
-associated O +
herpesvirus O +
( O +
KSHV O +
) O +
, O +
or O +
human O +
herpesvirus O +
8 O +
, O +
is O +
a O +
lymphotropic O +
virus O +
strongly O +
linked O +
to O +
several O +
AIDS O -
- O -
related O +
neoplasms O +
. O +

The O +
primary O +
reservoir O +
of O +
infection O +
consists O +
of O +
latently O +
infected O +
B O +
lymphocytes O +
and O +
possibly O +
other O +
mononuclear O +
cells O +
. O +

Viral O +
reactivation O +
from O +
latency O +
and O +
spread O +
from O +
this O +
lymphoid O +
reservoir O +
is O +
presumably O +
required O +
for O +
development O +
of O +
nonlymphoid O +
tumors O +
like O +
KS O +
. O +

Here O +
we O +
show O +
that O +
deregulated O +
expression O +
of O +
a O +
single O +
viral O +
gene O +
, O +
ORF O +
50 O +
, O +
which O +
encodes O +
a O +
transactivator O +
able O +
to O +
selectively O +
upregulate O +
delayed O -
- O -
early O +
viral O +
genes O +
, O +
suffices O +
to O +
disrupt O +
latency O +
and O +
induce O +
the O +
lytic O +
gene O +
cascade O +
in O +
latently O +
infected O +
B O +
cells O +
. O +

The O +
identification O +
of O +
this O +
gene O +
opens O +
the O +
way O +
to O +
studies O +
of O +
the O +
physiologic O +
mechanisms O +
controlling O +
reactvation O +
of O +
KSHV O +
from O +
latency O +
. O +

Copyright O +
1998 O +
Academic O +
Press O +
. O +

Regulation O +
of O +
interleukin-1beta O +
transcription O +
by O +
Epstein O -
- O -
Barr O +
virus O +
involves O +
a O +
number O +
of O +
latent O +
proteins O +
via O +
their O +
interaction O +
with O +
RBP O +
. O +

Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
infects O +
B O +
cells O +
, O +
resulting O +
in O +
the O +
outgrowth O +
of O +
immortalised B-CellLine +
lymphoblastoid I-CellLine +
cell I-CellLine +
lines I-CellLine +
( O +
LCLs B-CellLine +
) O +
. O +

Here O +
, O +
we O +
demonstrate O +
through O +
the O +
use O +
of O +
intracellular O +
staining O +
that O +
interleukin-1beta O +
( O +
IL-1beta O +
) O +
is O +
expressed O +
in O +
LCLs B-CellLine +
and O +
investigate O +
the O +
influence O +
of O +
the O +
individual O +
latent O +
proteins O +
on O +
the O +
expression O +
of O +
IL-1beta O +
. O +

Using O +
RT O -
- O -
PCR O +
, O +
IL-1beta O +
was O +
shown O +
to O +
be O +
up O -
- O -
regulated O +
in O +
EBV B-CellLine -
- I-CellLine -
transformed I-CellLine +
LCLs I-CellLine +
as O +
well O +
as O +
in O +
group B-CellLine +
III I-CellLine +
Burkitt I-CellLine +
's I-CellLine +
lymphoma I-CellLine +
( I-CellLine +
BL I-CellLine +
) I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
compared O +
with O +
group B-CellLine +
I I-CellLine +
BL I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

The O +
up O -
- O -
regulation O +
of O +
IL-1beta O +
message O +
could O +
be O +
mediated O +
by O +
the O +
latent O +
membrane O +
protein-1 O +
, O +
EBV O +
nuclear O +
proteins O +
2 O +
, O +
3 O +
, O +
4 O +
, O +
and O +
6 O +
genes O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
( O +
EMSAs O +
) O +
demonstrated O +
that O +
the O +
-300 O +
region O +
of O +
the O +
IL-1beta O +
promoter O +
, O +
which O +
contains O +
a O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
binding O +
site O +
, O +
contained O +
a O +
functional O +
RBP O +
binding O +
site O +
. O +

Binding O +
of O +
RBP O +
to O +
this O +
site O +
could O +
be O +
inhibited O +
by O +
addition O +
of O +
EBV O +
nuclear O +
proteins O +
3 O +
and O +
6 O +
, O +
suggesting O +
that O +
these O +
proteins O +
displace O +
RBP O +
from O +
its O +
recognition O +
sequence O +
, O +
removing O +
transcriptional O +
repression O +
and O +
allowing O +
gene O +
transcription O +
to O +
occur O +
. O +

In O +
group B-CellLine +
I I-CellLine +
BL I-CellLine +
cells I-CellLine +
, O +
containing O +
low O +
levels O +
of O +
NF O -
- O -
kappaB O +
, O +
only O +
RBP O +
binding O +
was O +
observed O +
in O +
EMSAs O +
, O +
whereas O +
NF O -
- O -
kappaB O +
binding O +
could O +
be O +
demonstrated O +
in O +
EBV B-CellLine -
- I-CellLine -
transformed I-CellLine +
B I-CellLine +
cell I-CellLine +
lines I-CellLine +
containing O +
high O +
levels O +
of O +
activated O +
NF O -
- O -
kappaB O +
. O +

In O +
addition O +
, O +
the O +
expression O +
of O +
latent O +
membrane O +
protein-1 O +
led O +
to O +
activation O +
of O +
NF O -
- O -
kappaB O +
that O +
was O +
capable O +
of O +
binding O +
the O +
IL-1beta O +
promoter O +
. O +

The O +
study O +
demonstrates O +
that O +
EBV O +
can O +
up O -
- O -
regulate O +
IL-1beta O +
expression O +
, O +
possibly O +
by O +
using O +
RBP O +
, O +
NF O -
- O -
kappaB O +
, O +
or O +
both O +
. O +

Copyright O +
1998 O +
Academic O +
Press O +
. O +

Binding O +
of O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
elicits O +
structural O +
changes O +
in O +
a O +
silencer O +
of O +
the O +
human O +
beta O -
- O -
globin O +
gene O +
. O +

Proteins O +
involved O +
in O +
repression O +
of O +
the O +
human O +
beta O -
- O -
globin O +
gene O +
may O +
be O +
useful O +
in O +
the O +
treatment O +
of O +
sickle O +
cell O +
anemia O +
, O +
in O +
conjunction O +
with O +
therapy O +
to O +
reactivate O +
fetal O +
globin O +
genes O +
. O +

If O +
there O +
is O +
a O +
reciprocal O +
elevation O +
of O +
gamma O -
- O -
globin O +
expression O +
upon O +
repression O +
, O +
this O +
approach O +
could O +
be O +
useful O +
in O +
additional O +
hemoglobinopathies O +
. O +

We O +
previously O +
showed O +
that O +
repression O +
of O +
the O +
beta O -
- O -
globin O +
gene O +
appears O +
to O +
be O +
mediated O +
through O +
two O +
DNA O +
sequences O +
, O +
silencers O +
I O +
and O +
II O +
, O +
and O +
identified O +
a O +
protein O +
termed O +
BP1 O +
which O +
binds O +
to O +
both O +
silencer O +
sequences O +
. O +

In O +
this O +
study O +
, O +
we O +
cloned O +
two O +
cDNAs O +
encoding O +
proteins O +
which O +
bind O +
to O +
an O +
oligonucleotide O +
in O +
silencer O +
I O +
containing O +
a O +
BP1 O +
binding O +
site O +
. O +

These O +
cDNAs O +
correspond O +
to O +
HMG O -
- O -
I O +
and O +
HMG O -
- O -
Y O +
, O +
isoforms O +
regarded O +
as O +
architectural O +
proteins O +
. O +

We O +
demonstrate O +
that O +
binding O +
of O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
to O +
this O +
oligonucleotide O +
causes O +
bending O -
/ O -
flexure O +
of O +
the O +
DNA O +
. O +

HMG O -
- O -
I O +
( O +
Y O +
) O +
also O +
binds O +
to O +
a O +
second O +
oligonucleotide O +
containing O +
a O +
BP1 O +
binding O +
site O +
located O +
in O +
a O +
negative O +
control O +
region O +
upstream O +
of O +
the O +
delta O -
- O -
globin O +
gene O +
, O +
suggesting O +
a O +
role O +
for O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
in O +
repression O +
of O +
adult O +
globin O +
genes O +
. O +

Expression O +
studies O +
revealed O +
that O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
is O +
ubiquitously O +
expressed O +
in O +
human O +
tissues O +
that O +
do O +
not O +
express O +
beta O -
- O -
globin O +
, O +
being O +
present O +
in O +
48 O +
of O +
50 O +
tissues O +
and O +
six O +
hematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
examined O +
. O +

Furthermore O +
, O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
expression O +
is O +
down O -
- O -
regulated O +
during O +
differentiation O +
of O +
primary O +
erythroid O +
cells O +
. O +

We O +
present O +
a O +
model O +
in O +
which O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
alters O +
DNA O +
conformation O +
to O +
allow O +
binding O +
of O +
repressor O +
proteins O +
, O +
and O +
in O +
which O +
the O +
relative O +
amount O +
of O +
HMG O -
- O -
I O +
( O +
Y O +
) O +
helps O +
to O +
determine O +
the O +
repressive O +
state O +
of O +
the O +
beta O -
- O -
globin O +
gene O +
. O +

Induction O +
of O +
the O +
pro O -
- O -
myelocytic O +
leukaemia O +
gene O +
by O +
type O +
I O +
and O +
type O +
II O +
interferons O +
. O +

The O +
physiological O +
role O +
of O +
the O +
pro O -
- O -
myelocytic O +
leukaemia O +
( O +
PML O +
) O +
gene O +
product O +
is O +
poorly O +
defined O +
. O +

Among O +
other O +
functions O +
, O +
PML O +
is O +
involved O +
in O +
haematopoietic O +
differentiation O +
and O +
in O +
control O +
of O +
cell O +
growth O +
and O +
tumorigenesis O +
. O +

We O +
investigated O +
the O +
regulation O +
of O +
human O +
PML O +
expression O +
by O +
interferons O +
( O +
IFNs O +
) O +
and O +
IL-1 O +
in O +
various O +
human B-CellLine +
haematopoietic I-CellLine +
lines I-CellLine +
( O +
U937 B-CellLine +
, O +
THP1 B-CellLine +
, O +
HL60 B-CellLine +
, O +
NB4 B-CellLine +
) O +
, O +
in O +
human O +
diploid O +
fibroblasts O +
and O +
in O +
human O +
peripheral O +
blood O +
leukocytes O +
. O +

Cytokine O -
- O -
induced O +
modulation O +
of O +
PML O +
expression O +
was O +
assessed O +
by O +
Northern O +
blot O +
analyses O +
, O +
flow O +
cytometry O +
studies O +
and O +
in O +
situ O +
immunolabelling O +
. O +

Our O +
data O +
show O +
that O +
IFNs O +
and O +
IL-1 O +
upregulate O +
PML O +
transcript O +
and O +
protein O +
expression O +
in O +
a O +
time O +
and O +
dose O -
- O -
dependent O +
manner O +
. O +

In O +
situ O +
immunolabelling O +
revealed O +
that O +
upregulation O +
of O +
protein O +
expression O +
by O +
IFN O -
- O -
alpha O +
is O +
a O +
consequence O +
of O +
a O +
marked O +
increase O +
in O +
both O +
the O +
number O +
and O +
the O +
intensity O +
of O +
the O +
staining O +
of O +
so O -
- O -
called O +
PML O +
nuclear O +
bodies O +
. O +

Our O +
data O +
suggest O +
that O +
stimulation O +
of O +
PML O +
expression O +
by O +
interferons O +
and O +
IL-1 O +
may O +
account O +
for O +
upregulation O +
of O +
PML O +
proteins O +
observed O +
in O +
inflammatory O +
tissues O +
and O +
in O +
proliferative O +
states O +
. O +

Characterization O +
of O +
the O +
human O +
elk-1 O +
promoter O +
. O +

Potential O +
role O +
of O +
a O +
downstream O +
intronic O +
sequence O +
for O +
elk-1 O +
gene O +
expression O +
in O +
monocytes O +
. O +

To O +
characterize O +
the O +
human O +
elk-1 O +
promoter O +
, O +
we O +
mapped O +
the O +
transcriptional O +
start O +
site O +
and O +
isolated O +
elk-1-specific B-CellLine +
genomic I-CellLine +
phage I-CellLine +
clones I-CellLine +
that O +
contained O +
extensive O +
upstream O +
and O +
downstream O +
sequences O +
. O +

A O +
TATA O -
- O -
like O +
motif O +
was O +
identified O +
immediately O +
upstream O +
of O +
the O +
transcriptional O +
start O +
site O +
. O +

Functional O +
analyses O +
of O +
DNA O +
fragments O +
containing O +
the O +
TATA O +
element O +
and O +
the O +
identification O +
of O +
a O +
DNase O +
I O -
- O -
hypersensitive O +
chromatin O +
site O +
( O +
HS O +
1 O +
) O +
in O +
close O +
proximity O +
to O +
the O +
TATA O +
box O +
suggest O +
that O +
the O +
identified O +
TATA O +
motif O +
is O +
important O +
for O +
elk-1 O +
transcription O +
in O +
vivo O +
. O +

Sequences O +
upstream O +
and O +
downstream O +
from O +
the O +
TATA O +
box O +
were O +
found O +
to O +
contribute O +
to O +
elk-1 O +
promoter O +
activity O +
. O +

A O +
second O +
hypersensitive O +
site O +
( O +
HS O +
2 O +
) O +
was O +
identified O +
within O +
the O +
first O +
intron O +
in O +
pre O -
- O -
monocytic O +
cells O +
, O +
which O +
express O +
Elk-1 O +
only O +
when O +
differentiating O +
to O +
monocytes O +
. O +

In O +
a O +
variety O +
of O +
other O +
cell O +
types O +
, O +
which O +
display O +
a O +
constitutive O +
Elk-1 O +
expression O +
, O +
HS O +
2 O +
did O +
not O +
exist O +
, O +
suggesting O +
that O +
inducibility O +
of O +
elk-1 O +
expression O +
is O +
associated O +
with O +
the O +
presence O +
of O +
HS O +
2 O +
. O +

Egr-1 O +
and O +
the O +
serum O +
response O +
factor O +
were O +
found O +
to O +
interact O +
specifically O +
with O +
the O +
intronic O +
sequence O +
at O +
+ O -
265 O +
and O +
+ O -
448 O +
, O +
respectively O +
. O +

Because O +
Egr-1 O +
mRNA O +
and O +
protein O +
levels O +
were O +
observed O +
to O +
increase O +
significantly O +
before O +
induction O +
of O +
elk-1 O +
expression O +
, O +
we O +
propose O +
that O +
Egr-1 O +
is O +
important O +
for O +
the O +
regulation O +
of O +
elk-1 O +
transcription O +
in O +
differentiating O +
monocytes O +
. O +

Regulation O +
of O +
IL-6 O +
synthesis O +
in O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
by O +
C3a O +
and O +
C3a O +
( O +
desArg O +
) O +
. O +

The O +
anaphylatoxin O +
C3a O +
has O +
been O +
reported O +
to O +
have O +
immunomodulatory O +
effects O +
on O +
a O +
number O +
of O +
different O +
cell O +
types O +
. O +

In O +
this O +
study O +
we O +
investigated O +
the O +
effects O +
of O +
C3a O +
and O +
C3a O +
( O +
desArg O +
) O +
on O +
gene O +
expression O +
and O +
protein O +
secretion O +
of O +
IL-6 O +
in O +
human O +
PBMCs O +
, O +
either O +
alone O +
or O +
in O +
combination O +
with O +
LPS O +
or O +
IL-1beta O +
. O +

C3a O +
or O +
C3a O +
( O +
desArg O +
) O +
alone O +
exhibited O +
no O +
effect O +
on O +
the O +
expression O +
or O +
secretion O +
of O +
IL-6 O +
. O +

However O +
, O +
when O +
PBMC O +
were O +
stimulated O +
with O +
LPS O +
or O +
IL-1beta O +
, O +
both O +
C3a O +
and O +
C3a O +
( O +
desArg O +
) O +
were O +
found O +
to O +
enhance O +
IL-6 O +
release O +
by O +
PBMC O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
. O +

Since O +
C3a O +
has O +
been O +
shown O +
to O +
induce O +
PGE2 O +
production O +
by O +
monocytes O +
, O +
and O +
PGE2 O +
has O +
been O +
shown O +
to O +
influence O +
cytokine O +
production O +
, O +
we O +
investigated O +
the O +
potential O +
role O +
of O +
PGE2 O +
in O +
C3a O +
-mediated O +
enhancement O +
of O +
LPS- O +
and O +
IL-1beta O -
- O -
induced O +
IL-6 O +
production O +
. O +

Indomethacin O +
blocked O +
PGE2 O +
release O +
, O +
but O +
had O +
no O +
influence O +
on O +
the O +
observed O +
effects O +
of O +
C3a O +
, O +
suggesting O +
that O +
the O +
effects O +
of O +
C3a O +
on O +
IL-6 O +
production O +
are O +
independent O +
of O +
PGE2 O +
formation O +
by O +
monocytes O +
. O +

Northern O +
blot O +
analysis O +
showed O +
that O +
C3a O +
as O +
well O +
as O +
C3a O +
( O +
desArg O +
) O +
enhanced O +
LPS O +
-induced O +
mRNA O +
levels O +
for O +
IL-6 O +
. O +

Pretreatment O +
of O +
PBMCs O +
with O +
pertussis O +
toxin O +
blocked O +
the O +
functions O +
of O +
C3a O +
and O +
C3a O +
( O +
desArg O +
) O +
, O +
indicating O +
that O +
the O +
actions O +
of O +
these O +
two O +
molecules O +
are O +
mediated O +
by O +
a O +
G O +
protein O +
-coupled O +
pathway O +
. O +

Furthermore O +
, O +
we O +
investigated O +
the O +
effects O +
of O +
C3a O +
and O +
C3a O +
( O +
desArg O +
) O +
on O +
induction O +
of O +
NF O -
- O -
kappaB O +
and O +
activating O +
protein-1 O +
binding O +
. O +

Both O +
molecules O +
enhanced O +
LPS O -
- O -
induced O +
NF O -
- O -
kappaB O +
and O +
activating O +
protein-1 O +
binding O +
activity O +
. O +

These O +
results O +
demonstrate O +
the O +
capacity O +
of O +
intact O +
C3a O +
and O +
its O +
circulating O +
des O -
- O -
Arg O +
form O +
to O +
exert O +
immunmodulatory O +
effects O +
in O +
vitro O +
. O +

Mildly O +
oxidized O +
low O -
- O -
density O +
lipoproteins O +
decrease O +
early O +
production O +
of O +
interleukin O +
2 O +
and O +
nuclear O +
factor O +
kappaB O +
binding O +
to O +
DNA O +
in O +
activated O +
T O -
- O -
lymphocytes O +
. O +

Activated O +
T O -
- O -
lymphocytes O +
are O +
found O +
early O +
in O +
atherosclerosis O +
lesions O +
, O +
but O +
little O +
is O +
known O +
about O +
their O +
role O +
. O +

Oxidized O +
low O -
- O -
density O +
lipoproteins O +
( O +
oxLDLs O +
) O +
are O +
considered O +
to O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
the O +
lesions O +
, O +
and O +
we O +
have O +
previously O +
demonstrated O +
that O +
oxLDLs O +
inhibit O +
not O +
only O +
interleukin O +
( O +
IL O +
) O +
-2-receptor O +
expression O +
on O +
the O +
surface O +
of O +
in O +
vitro O -
- O -
activated O +
T O -
- O -
lymphocytes O +
but O +
also O +
their O +
proliferation O +
. O +

We O +
have O +
now O +
investigated O +
the O +
effect O +
of O +
oxLDLs O +
on O +
blast O +
differentiation O +
, O +
on O +
IL-2 O +
synthesis O +
and O +
on O +
the O +
activation O +
of O +
the O +
nuclear O +
factor O +
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
system O +
in O +
activated O +
lymphocytes O +
. O +

Mildly O +
oxLDLs O +
( O +
50 O +
and O +
100 O +
microgram O -
/ O -
ml O +
) O +
decreased O +
the O +
number O +
of O +
lymphoblasts O +
and O +
the O +
level O +
of O +
IL-2 O +
concentration O +
in O +
the O +
culture O +
supernatants O +
after O +
activation O +
of O +
lymphocytes O +
by O +
phytohaemagglutinin O +
and O +
PMA+ionomycin O +
. O +

The O +
inhibition O +
of O +
IL-2 O +
production O +
was O +
observed O +
in O +
the O +
CD3 O +
( O +
+ O +
) O +
T O -
- O -
lymphocyte O +
cytoplasm O +
as O +
early O +
as O +
4 O +
h O +
after O +
activation O +
by O +
PMA+ionomycin O +
. O +

The O +
study O +
of O +
NF O -
- O -
kappaB O +
showed O +
that O +
oxLDLs O +
led O +
to O +
a O +
decrease O +
of O +
activation O -
- O -
induced O +
p65 O -
/ O -
p50 O +
NF O -
- O -
kappaB O +
heterodimer O +
binding O +
to O +
DNA O +
, O +
whereas O +
the O +
presence O +
of O +
the O +
constitutive O +
nuclear O +
form O +
of O +
p50 O +
dimer O +
was O +
unchanged O +
. O +

This O +
was O +
correlated O +
with O +
an O +
unchanged O +
level O +
of O +
the O +
active O +
form O +
of O +
the O +
cytosolic O +
inhibitor O +
protein O +
IkappaB O -
- O -
alpha O +
. O +

Taken O +
together O +
, O +
these O +
observations O +
suggest O +
that O +
the O +
immunosuppressive O +
effect O +
of O +
oxLDLs O +
might O +
operate O +
via O +
a O +
dysregulation O +
of O +
the O +
T O -
- O -
lymphocyte O +
activation O +
mechanisms O +
. O +

The O +
activity O +
of O +
the O +
CCAAT O -
- O -
box O +
binding O +
factor O +
NF O -
- O -
Y O +
is O +
modulated O +
through O +
the O +
regulated O +
expression O +
of O +
its O +
A O +
subunit O +
during O +
monocyte O +
to O +
macrophage O +
differentiation O +
: O +
regulation O +
of O +
tissue O -
- O -
specific O +
genes O +
through O +
a O +
ubiquitous O +
transcription O +
factor O +
. O +

In O +
this O +
study O +
, O +
we O +
analyzed O +
the O +
regulation O +
of O +
NF O -
- O -
Y O +
expression O +
during O +
human O +
monocyte O +
to O +
macrophage O +
maturation O +
. O +

NF O -
- O -
Y O +
is O +
a O +
ubiquitous O +
and O +
evolutionarily O +
conserved O +
transcription O +
factor O +
that O +
binds O +
specifically O +
to O +
the O +
CCAAT O +
motif O +
present O +
in O +
the O +
5 O +
' O +
promoter O +
region O +
of O +
a O +
wide O +
variety O +
of O +
genes O +
. O +

We O +
show O +
here O +
that O +
in O +
circulating O +
monocytes O +
, O +
NF O -
- O -
Y O +
binding O +
activity O +
is O +
not O +
detected O +
on O +
the O +
CCAAT O +
motif O +
present O +
in O +
the O +
promoters O +
of O +
genes O +
such O +
as O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
class O +
II O +
, O +
gp91-phox O +
, O +
mig O +
, O +
and O +
fibronectin O +
, O +
whereas O +
during O +
macrophage O +
differentiation O +
, O +
a O +
progressive O +
increase O +
in O +
NF O -
- O -
Y O +
binding O +
activity O +
is O +
observed O +
on O +
these O +
promoters O +
. O +

Analysis O +
of O +
NF O -
- O -
Y O +
subunit O +
expression O +
indicates O +
that O +
the O +
absence O +
of O +
NF O -
- O -
Y O +
activity O +
in O +
circulating O +
monocytes O +
is O +
caused O +
by O +
a O +
lack O +
of O +
the O +
A O +
subunit O +
. O +

Furthermore O +
, O +
addition O +
of O +
the O +
recombinant O +
NF O -
- O -
Y O +
A O +
subunit O +
restores O +
NF O -
- O -
Y O +
binding O +
. O +

We O +
show O +
that O +
the O +
lack O +
of O +
NF O -
- O -
YA O +
protein O +
is O +
due O +
to O +
posttranscriptional O +
regulation O +
and O +
not O +
to O +
a O +
specific O +
proteolytic O +
activity O +
. O +

In O +
fact O +
, O +
NF O -
- O -
YA O +
mRNA O +
is O +
present O +
at O +
the O +
same O +
level O +
at O +
all O +
days O +
of O +
monocyte O +
cultivation O +
, O +
whereas O +
the O +
protein O +
is O +
absent O +
in O +
freshly O +
isolated O +
monocytes O +
but O +
is O +
progressively O +
synthesized O +
during O +
the O +
maturation O +
process O +
. O +

We O +
thus O +
conclude O +
that O +
the O +
NF O -
- O -
Y O +
A O +
subunit O +
plays O +
a O +
relevant O +
role O +
in O +
activating O +
transcription O +
of O +
genes O +
highly O +
expressed O +
in O +
mature O +
monocytes O +
. O +

In O +
line O +
with O +
this O +
conclusion O +
, O +
we O +
show O +
that O +
the O +
cut O -
/ O -
CDP O +
protein O +
, O +
a O +
transcriptional O +
repressor O +
that O +
inhibits O +
gpc91-phox O +
gene O +
expression O +
by O +
preventing O +
NF O -
- O -
Y O +
binding O +
to O +
the O +
CAAT O +
box O +
, O +
is O +
absent O +
in O +
monocytes O +
. O +

Accessing O +
Epstein O -
- O -
Barr O +
virus O -
- O -
specific O +
T O -
- O -
cell O +
memory O +
with O +
peptide B-CellLine -
- I-CellLine -
loaded I-CellLine +
dendritic I-CellLine +
cells I-CellLine +
. O +

The O +
conventional O +
means O +
of O +
studying O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
-induced O +
cytotoxic O +
T O -
- O -
lymphocyte O +
( O +
CTL O +
) O +
memory O +
, O +
by O +
in O +
vitro O +
stimulation O +
with O +
the O +
latently O +
infected O +
autologous O +
lymphoblastoid B-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
LCL B-CellLine +
) O +
, O +
has O +
important O +
limitations O +
. O +

First O +
, O +
it O +
gives O +
no O +
information O +
on O +
memory O +
to O +
lytic O +
cycle O +
antigens O +
; O +
second O +
, O +
it O +
preferentially O +
amplifies O +
the O +
dominant O +
components O +
of O +
latent O +
antigen O -
- O -
specific O +
memory O +
at O +
the O +
expense O +
of O +
key O +
subdominant O +
reactivities O +
. O +

Here O +
we O +
describe O +
an O +
alternative O +
approach O +
, O +
based O +
on O +
in O +
vitro O +
stimulation O +
with O +
epitope B-CellLine +
peptide I-CellLine -
- I-CellLine -
loaded I-CellLine +
dendritic I-CellLine +
cells I-CellLine +
( O +
DCs B-CellLine +
) O +
, O +
which O +
allows O +
one O +
to O +
probe O +
the O +
CTL O +
repertoire O +
for O +
any O +
individual O +
reactivity O +
of O +
choice O +
; O +
this O +
method O +
proved O +
significantly O +
more O +
efficient O +
than O +
stimulation O +
with O +
peptide O +
alone O +
. O +

Using O +
this O +
approach O +
we O +
first O +
show O +
that O +
reactivities O +
to O +
the O +
immunodominant O +
and O +
subdominant O +
lytic O +
cycle O +
epitopes O +
identified O +
by O +
T O +
cells O +
during O +
primary O +
EBV O +
infection O +
are O +
regularly O +
detectable O +
in O +
the O +
CTL O +
memory O +
of O +
virus O +
carriers O +
; O +
this O +
implies O +
that O +
in O +
such O +
carriers O +
chronic O +
virus O +
replication O +
remains O +
under O +
direct O +
T O -
- O -
cell O +
control O +
. O +

We O +
further O +
show O +
that O +
subdominant O +
latent O +
cycle O +
reactivities O +
to O +
epitopes O +
in O +
the O +
latent O +
membrane O +
protein O +
LMP2 O +
, O +
though O +
rarely O +
undetectable O +
in O +
LCL B-CellLine +
-stimulated O +
populations O +
, O +
can O +
be O +
reactivated O +
by O +
DC O +
stimulation O +
and O +
selectively O +
expanded O +
as O +
polyclonal O +
CTL B-CellLine +
lines I-CellLine +
; O +
the O +
adoptive O +
transfer O +
of O +
such O +
preparations O +
may O +
be O +
of O +
value O +
in O +
targeting O +
certain O +
EBV O -
- O -
positive O +
malignancies O +
. O +

Regulation O +
of O +
IL-4 O +
expression O +
by O +
the O +
transcription O +
factor O +
JunB O +
during O +
T O +
helper O +
cell O +
differentiation O +
. O +

The O +
molecular O +
basis O +
for O +
restricted O +
cytokine O +
expression O +
by O +
T O +
helper O +
1 O +
( O +
Th1 O +
) O +
and O +
T O +
helper O +
2 O +
( O +
Th2 O +
) O +
cells O +
is O +
unclear O +
. O +

Previous O +
studies O +
found O +
that O +
P1 O +
, O +
an O +
element O +
of O +
the O +
interleukin O +
4 O +
( O +
IL-4 O +
) O +
promoter O +
that O +
binds O +
AP-1 O +
, O +
is O +
important O +
for O +
Th2-restricted O +
IL-4 O +
expression O +
. O +

Here O +
we O +
show O +
that O +
JunB O +
, O +
but O +
not O +
the O +
other O +
Jun O +
family O +
members O +
, O +
was O +
selectively O +
induced O +
in O +
Th2 O +
cells O +
and O +
not O +
in O +
Th1 O +
cells O +
during O +
differentiation O +
. O +

JunB O +
has O +
previously O +
been O +
considered O +
to O +
be O +
a O +
negative O +
regulator O +
of O +
transcription O +
. O +

However O +
, O +
we O +
show O +
that O +
JunB O +
binds O +
directly O +
to O +
the O +
P1 O +
site O +
and O +
synergizes O +
with O +
c O -
- O -
Maf O +
to O +
activate O +
an O +
IL-4 O +
luciferase O +
reporter O +
gene O +
. O +

JunB O +
-control O +
of O +
IL-4 O +
expression O +
is O +
mediated O +
by O +
the O +
phosphorylation O +
of O +
JunB O +
at O +
Thr102 O +
and- O +
104 O +
by O +
JNK O +
MAP O +
kinase O +
. O +

The O +
synergy O +
between O +
c O -
- O -
Maf O +
and O +
JunB O +
can O +
be O +
attributed O +
to O +
cooperative O +
DNA O +
binding O +
, O +
which O +
is O +
facilitated O +
by O +
JunB O +
phosphorylation O +
. O +

In O +
transgenic O +
mice O +
, O +
elevated O +
JunB O +
levels O +
caused O +
increased O +
expression O +
of O +
several O +
Th2 O +
cytokines O +
in O +
developing O +
Th1 O +
cells O +
. O +

JunB O +
also O +
upregulated O +
IL-4 O +
expression O +
in O +
response O +
to O +
immunization O +
. O +

Thus O +
, O +
the O +
early O +
increase O +
of O +
JunB O +
protein O +
in O +
Th2 O +
cells O +
can O +
provide O +
the O +
specificity O +
for O +
c O -
- O -
Maf O +
in O +
IL-4 O +
expression O +
during O +
T O +
cell O +
development O +
and O +
directs O +
thereby O +
Th2 O +
differentiation O +
. O +

Immunohistochemical O +
study O +
of O +
c O -
- O -
fos O -
- O -
positive O +
lymphocytes O +
infiltrated O +
into O +
human O +
squamous O +
cell O +
carcinomas O +
of O +
the O +
head O +
and O +
neck O +
during O +
radiation O +
therapy O +
and O +
its O +
clinical O +
significance O +
. O +

C O -
- O -
fos O +
has O +
been O +
reported O +
to O +
be O +
one O +
of O +
the O +
immediate O +
early O +
genes O +
in O +
signal O +
transduction O +
systems O +
after O +
many O +
kinds O +
of O +
stresses O +
, O +
including O +
ionizing O +
radiation O +
. O +

Changes O +
in O +
c O -
- O -
fos O +
expression O +
induced O +
by O +
radiation O +
therapy O +
in O +
tumor O +
tissues O +
have O +
not O +
yet O +
been O +
reported O +
. O +

In O +
this O +
study O +
, O +
we O +
have O +
attempted O +
to O +
determine O +
whether O +
c O -
- O -
fos O +
expression O +
is O +
induced O +
by O +
radiotherapy O +
in O +
human O +
squamous O +
cell O +
carcinomas O +
of O +
the O +
head O +
and O +
neck O +
and O +
to O +
establish O +
a O +
possible O +
correlation O +
between O +
c O -
- O -
fos O +
expression O +
and O +
the O +
therapeutic O +
effects O +
of O +
radiation O +
therapy O +
. O +

Twenty O -
- O -
seven O +
patients O +
with O +
tumors O +
of O +
the O +
oral O +
cavity O +
, O +
oropharynx O +
, O +
and O +
maxillary O +
sinus O +
were O +
examined O +
, O +
all O +
of O +
which O +
were O +
confirmed O +
as O +
squamous O +
cell O +
carcinomas O +
. O +

After O +
obtaining O +
the O +
patients O +
' O +
informed O +
consent O +
, O +
biopsies O +
were O +
performed O +
before O +
treatment O +
and O +
at O +
doses O +
of O +
4 O +
, O +
10 O +
, O +
and O +
20 O +
Gy O +
of O +
radiotherapy O +
, O +
and O +
the O +
specimens O +
were O +
preserved O +
in O +
liquid O +
nitrogen O +
for O +
further O +
examination O +
. O +

Serial O +
sectioning O +
of O +
6 O +
micrometer O +
was O +
performed O +
using O +
a O +
cryostat O +
, O +
and O +
samples O +
were O +
immunohistochemically O +
stained O +
using O +
the O +
streptoavidin O +
-biotin O +
peroxidase O +
method O +
and O +
a O +
monoclonal O +
antibody O +
against O +
c O -
- O -
fos O +
. O +

Three O +
of O +
the O +
27 O +
patients O +
with O +
squamous O +
cell O +
carcinoma O +
showed O +
slight O +
expression O +
of O +
c O -
- O -
fos O +
in O +
their O +
tumor O +
cells O +
before O +
and/or O +
at O +
4 O +
or O +
10 O +
Gy O +
of O +
radiotherapy O +
. O +

The O +
tumors O +
showed O +
high O +
radiosensitivity O +
. O +

Concerning O +
tumor O -
- O -
infiltrating O +
lymphocytes O +
, O +
the O +
rate O +
of O +
moderate O +
or O +
remarkable O +
grades O +
of O +
c O -
- O -
fos O -
- O -
positive O +
lymphocytes O +
before O +
radiotherapy O +
and O +
at O +
radiation O +
doses O +
of O +
4 O +
, O +
10 O +
, O +
and O +
20 O +
Gy O +
was O +
8.0 O +
, O +
29.2 O +
, O +
4.8 O +
, O +
and O +
0 O +
% O +
, O +
respectively O +
. O +

The O +
relationship O +
between O +
the O +
immunohistochemical O +
findings O +
and O +
the O +
antitumor O +
effect O +
at O +
a O +
radiation O +
dose O +
of O +
20 O +
Gy O +
was O +
examined O +
on O +
the O +
corresponding O +
H O +
& O +
E O -
- O -
stained O +
sections O +
. O +

In O +
patients O +
whose O +
infiltration O +
of O +
c O -
- O -
fos O -
- O -
positive O +
lymphocytes O +
into O +
tumor O +
tissues O +
were O +
moderate O +
or O +
remarkable O +
at O +
4 O +
Gy O +
of O +
radiotherapy O +
, O +
the O +
tumors O +
responded O +
significantly O +
well O +
to O +
radiation O +
therapy O +
( O +
P O +
< O +
0.025 O +
, O +
chi2 O +
test O +
) O +
, O +
and O +
the O +
patients O +
took O +
a O +
significantly O +
favorable O +
clinical O +
course O +
( O +
P O +
< O +
0.05 O +
, O +
chi2 O +
test O +
) O +
. O +

In O +
a O +
sample O +
from O +
one O +
of O +
the O +
patients O +
, O +
c O -
- O -
fos O -
- O -
positive O +
lymphocytes O +
were O +
identified O +
as O +
CD4 O +
positive O +
and O +
CD8 O +
negative O +
. O +

Therefore O +
, O +
the O +
high O +
radiosensitivity O +
of O +
squamous O +
cell O +
carcinomas O +
in O +
our O +
samples O +
could O +
be O +
explained O +
by O +
an O +
overexpression O +
of O +
c O -
- O -
fos O +
in O +
the O +
tumor O -
- O -
infiltrating O +
lymphocytes O +
induced O +
by O +
small O +
doses O +
of O +
radiation O +
therapy O +
, O +
and O +
these O +
activated O +
lymphocytes O +
exerted O +
a O +
cytotoxic O +
effect O +
against O +
the O +
cancer O +
cells O +
. O +

T O +
cell O +
priming O +
enhances O +
IL-4 O +
gene O +
expression O +
by O +
increasing O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
. O +

The O +
repetitive O +
activation O +
of O +
T O +
cells O +
( O +
priming O +
) O +
enhances O +
the O +
expression O +
of O +
many O +
cytokines O +
, O +
such O +
as O +
IL-4 O +
, O +
but O +
not O +
others O +
, O +
such O +
as O +
IL-2 O +
. O +

Molecular O +
mechanisms O +
underlying O +
selective O +
expression O +
of O +
cytokines O +
by O +
T O +
cells O +
remain O +
poorly O +
understood O +
. O +

Here O +
we O +
show O +
that O +
priming O +
of O +
CD4 O +
T O +
cells O +
selectively O +
enhances O +
IL-4 O +
expression O +
relative O +
to O +
IL-2 O +
expression O +
by O +
a O +
transcriptional O +
mechanism O +
involving O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
proteins O +
. O +

As O +
detected O +
by O +
in O +
vivo O +
footprinting O +
, O +
priming O +
markedly O +
increases O +
the O +
activation O -
- O -
dependent O +
engagement O +
of O +
the O +
P0 O +
and O +
P1 O +
NFAT O -
- O -
binding O +
elements O +
of O +
the O +
IL-4 O +
promoter O +
. O +

Moreover O +
, O +
each O +
proximal O +
P O +
element O +
is O +
essential O +
for O +
optimal O +
IL-4 O +
promoter O +
activity O +
. O +

Activated O +
primed O +
CD4 O +
T O +
cells O +
contain O +
more O +
NFAT1 O +
and O +
support O +
greater O +
NFAT O +
-directed O +
transcription O +
than O +
unprimed O +
CD4 O +
T O +
cells O +
, O +
while O +
activator O +
protein O +
1 O +
binding O +
and O +
activator O +
protein O +
1 O +
-mediated O +
transcription O +
by O +
both O +
cell O +
types O +
is O +
similar O +
. O +

Increased O +
expression O +
of O +
wild O -
- O -
type O +
NFAT1 O +
substantially O +
increases O +
IL-4 O +
promoter O +
activity O +
in O +
unprimed O +
CD4 O +
T O +
cells O +
, O +
suggesting O +
NFAT1 O +
may O +
be O +
limiting O +
for O +
IL-4 O +
gene O +
expression O +
in O +
this O +
cell O +
type O +
. O +

Furthermore O +
, O +
a O +
truncated O +
form O +
of O +
NFAT1 O +
acts O +
as O +
a O +
dominant O -
- O -
negative O +
, O +
reducing O +
IL-4 O +
promoter O +
activity O +
in O +
primed O +
CD4 O +
T O +
cells O +
and O +
confirming O +
the O +
importance O +
of O +
endogenous O +
NFAT O +
to O +
increased O +
IL-4 O +
gene O +
expression O +
by O +
effector O +
T O +
cells O +
. O +

NFAT1 O +
appears O +
to O +
be O +
the O +
major O +
NFAT O +
family O +
member O +
responsible O +
for O +
the O +
initial O +
increased O +
expression O +
of O +
IL-4 O +
by O +
primed O +
CD4 O +
T O +
cells O +
. O +

Anoxia O -
/ O -
reoxygenation O -
- O -
induced O +
tolerance O +
with O +
respect O +
to O +
polymorphonuclear O +
leukocyte O +
adhesion O +
to O +
cultured B-CellLine +
endothelial I-CellLine +
cells I-CellLine +
. O +

A O +
nuclear O +
factor O -
- O -
kappaB O +
-mediated O +
phenomenon O +
. O +

Exposing O +
human B-CellLine +
umbilical I-CellLine +
vein I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
( O +
HUVECs B-CellLine +
) O +
to O +
anoxia O -
/ O -
reoxygenation O +
( O +
A O -
/ O -
R O +
) O +
results O +
in O +
an O +
increase O +
in O +
polymorphonuclear O +
leukocyte O +
( O +
PMN O +
) O +
adhesion O +
to O +
HUVECs B-CellLine +
. O +

This O +
A O -
/ O -
R O -
- O -
induced O +
hyperadhesion O +
is O +
completely O +
prevented O +
by O +
a O +
previous O +
( O +
24 O +
hours O +
earlier O +
) O +
exposure O +
of O +
HUVECs B-CellLine +
to O +
A O -
/ O -
R O +
. O +

This O +
phenomenon O +
has O +
been O +
termed O +
` O -
` O +
A O -
/ O -
R O +
tolerance O -
. O +
'' O +

Exposing O +
HUVECs B-CellLine +
to O +
A O -
/ O -
R O +
induces O +
an O +
increase O +
in O +
nuclear O +
factor O +
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
in O +
HUVEC O +
nuclei O +
within O +
4 O +
hours O +
. O +

Interfering O +
with O +
either O +
NF O -
- O -
kappaB O +
activation O +
( O +
proteasome O +
inhibitor O +
) O +
or O +
translocation O +
( O +
double O -
- O -
stranded O +
oligonucleotides O +
containing O +
NF O -
- O -
kappaB O +
binding O +
sequence O +
) O +
prevents O +
the O +
development O +
of O +
A O -
/ O -
R O +
tolerance O +
( O +
ie O +
, O +
the O +
increase O +
in O +
A O -
/ O -
R O -
- O -
induced O +
PMN O +
adhesion O +
to O +
HUVECs B-CellLine +
is O +
the O +
same O +
after O +
the O +
first O +
and O +
second O +
A O -
/ O -
R O +
challenges O +
) O +
. O +

NO O +
production O +
by O +
HUVECs B-CellLine +
is O +
increased O +
after O +
the O +
second O +
A O -
/ O -
R O +
challenge O +
, O +
but O +
not O +
after O +
the O +
first O +
A O -
/ O -
R O +
challenge O +
. O +

Inhibition O +
of O +
NO O +
synthase O +
( O +
NOS O +
) O +
during O +
the O +
second O +
A O -
/ O -
R O +
challenge O +
prevents O +
the O +
development O +
of O +
A O -
/ O -
R O +
tolerance O +
with O +
respect O +
to O +
PMN O +
adhesion O +
. O +

However O +
, O +
while O +
HUVECs B-CellLine +
contained O +
endothelial O +
NOS O +
protein O +
, O +
no O +
inducible O +
NOS O +
was O +
detected O +
in O +
either O +
tolerant O +
or O +
nontolerant O +
cells O +
. O +

Further O +
studies O +
indicated O +
that O +
inhibition O +
of O +
GTP O -
- O -
cyclohydrolase O +
I O +
( O +
an O +
enzyme O +
involved O +
in O +
de O +
novo O +
synthesis O +
of O +
an O +
important O +
cofactor O +
for O +
NOS O +
activity O +
, O +
tetrahydrobiopterin O +
) O +
prevented O +
the O +
generation O +
of O +
NO O +
in O +
A B-CellLine -
/ I-CellLine -
R I-CellLine -
- I-CellLine -
tolerant I-CellLine +
cells I-CellLine +
. O +

Extracellular O +
generation O +
of O +
NO O +
( O +
NO O +
donor O +
) O +
did O +
not O +
effect O +
the O +
hyperadhesion O +
response O +
induced O +
by O +
the O +
initial O +
A O -
/ O -
R O +
challenge O +
. O +

A O -
/ O -
R O +
also O +
induced O +
an O +
oxidant O +
stress O +
in O +
naive O +
HUVECs B-CellLine +
, O +
but O +
not O +
in O +
A B-CellLine -
/ I-CellLine -
R I-CellLine -
- I-CellLine -
tolerant I-CellLine +
HUVECs I-CellLine +
. O +

Inhibition O +
of O +
NOS O +
during O +
the O +
second O +
A O -
/ O -
R O +
insult O +
results O +
in O +
the O +
generation O +
of O +
an O +
oxidant O +
stress O +
similar O +
to O +
that O +
observed O +
after O +
the O +
first O +
A O -
/ O -
R O +
challenge O +
. O +

Taken O +
together O +
, O +
the O +
findings O +
of O +
the O +
present O +
study O +
are O +
consistent O +
with O +
a O +
role O +
for O +
NF O -
- O -
kappaB O +
in O +
the O +
development O +
of O +
A O -
/ O -
R O +
tolerance O +
( O +
with O +
respect O +
to O +
PMN O +
adhesion O +
) O +
, O +
perhaps O +
by O +
transcriptional O +
regulation O +
of O +
GTP O -
- O -
cyclohydrolase O +
. O +

The O +
increased O +
NO O +
production O +
during O +
the O +
second O +
A O -
/ O -
R O +
insult O +
reduces O +
PMN O +
adhesion O +
most O +
likely O +
by O +
reducing O +
the O +
intracellular O +
oxidant O +
stress O +
induced O +
by O +
A O -
/ O -
R O +
. O +

Involvement O +
of O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
pathways O +
in O +
interleukin-8 O +
production O +
by O +
human O +
monocytes O +
and O +
polymorphonuclear O +
cells O +
stimulated O +
with O +
lipopolysaccharide O +
or O +
Mycoplasma O +
fermentans O +
membrane O +
lipoproteins O +
. O +

Interleukin-8 O +
( O +
IL-8 O +
) O +
is O +
a O +
chemokine O +
that O +
belongs O +
to O +
the O +
alpha O -
- O -
chemokine O +
or O +
CXC O +
subfamily O +
and O +
is O +
produced O +
by O +
a O +
wide O +
variety O +
of O +
human O +
cells O +
, O +
including O +
monocytes O +
and O +
polymorphonuclear O +
cells O +
( O +
PMN O +
) O +
. O +

IL-8 O +
is O +
secreted O +
in O +
response O +
to O +
inflammatory O +
stimuli O +
, O +
notably O +
bacterial O +
products O +
such O +
as O +
lipopolysaccharide O +
( O +
LPS O +
) O +
, O +
but O +
little O +
is O +
known O +
about O +
the O +
mechanisms O +
by O +
which O +
these O +
agents O +
mediate O +
IL-8 O +
induction O +
. O +

In O +
this O +
report O +
, O +
we O +
show O +
that O +
Mycoplasma O +
fermentans O +
lipid O -
- O -
associated O +
membrane O +
proteins O +
( O +
LAMPf O +
) O +
induce O +
the O +
production O +
of O +
high O +
levels O +
of O +
IL-8 O +
by O +
THP-1 B-CellLine +
( I-CellLine +
human I-CellLine +
monocyte I-CellLine +
) I-CellLine +
cells I-CellLine +
and O +
PMN O +
at O +
the O +
same O +
extent O +
as O +
LPS O +
. O +

It O +
was O +
previously O +
demonstrated O +
that O +
stimulation O +
of O +
monocytic O +
cells O +
with O +
either O +
LPS O +
or O +
LAMPf O +
led O +
to O +
a O +
series O +
of O +
common O +
downstream O +
signaling O +
events O +
, O +
including O +
the O +
activation O +
of O +
protein O +
tyrosine O +
kinase O +
and O +
of O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
cascades O +
. O +

By O +
using O +
PD-98059 O +
and O +
SB203580 O +
, O +
two O +
potent O +
and O +
selective O +
inhibitors O +
of O +
MEK1 O +
( O +
a O +
kinase O +
upstream O +
of O +
ERK1 O -
/ O -
2 O +
) O +
and O +
p38 O +
, O +
respectively O +
, O +
we O +
have O +
demonstrated O +
that O +
both O +
ERK1 O -
/ O -
2 O +
and O +
p38 O +
cascades O +
play O +
a O +
key O +
role O +
in O +
the O +
production O +
of O +
IL-8 O +
by O +
monocytes O +
and O +
PMN O +
stimulated O +
with O +
bacterial O +
fractions O +
. O +

CD80 O +
and O +
CD86 O +
are O +
not O +
equivalent O +
in O +
their O +
ability O +
to O +
induce O +
the O +
tyrosine O +
phosphorylation O +
of O +
CD28 O +
. O +

Ligation O +
of O +
either O +
CD80 O +
( O +
B7 O -
- O -
1 O +
) O +
or O +
CD86 O +
( O +
B7 O -
- O -
2 O +
) O +
, O +
two O +
principal O +
ligands O +
for O +
CD28 O +
, O +
is O +
thought O +
to O +
skew O +
the O +
immune O +
response O +
toward O +
Th1 O +
or O +
Th2 O +
differentiation O +
. O +

We O +
have O +
examined O +
early O +
signal O +
transduction O +
pathways O +
recruited O +
following O +
T O +
cell O +
stimulation O +
with O +
either O +
CD80 O +
or O +
CD86 O +
. O +

Purified B-CellLine +
human I-CellLine +
peripheral I-CellLine +
T I-CellLine +
cells I-CellLine +
or O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
were O +
stimulated O +
with O +
Chinese O +
hamster O +
ovary O +
( O +
CHO O +
) O +
cells O +
expressing O +
either O +
human O +
CD80 O +
( O +
CHO O -
- O -
CD80 O +
) O +
or O +
human O +
CD86 O +
( O +
CHO O -
- O -
CD86 O +
) O +
or O +
with O +
anti O -
- O -
CD28 O +
monoclonal O +
antibody O +
( O +
mAb O +
) O +
. O +

In O +
the O +
presence O +
of O +
phorbol O +
12-myristate O +
13-acetate O +
, O +
both O +
CHO O -
- O -
CD80 O +
and O +
CHO O -
- O -
CD86 O +
, O +
like O +
anti O -
- O -
CD28 O +
mAb O +
, O +
were O +
capable O +
of O +
stimulating O +
cytokine O +
production O +
from O +
both O +
human O +
peripheral O +
T O +
cells O +
and O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Both O +
CHO O -
- O -
CD80 O +
and O +
CHO O -
- O -
CD86 O +
, O +
in O +
the O +
presence O +
of O +
anti O -
- O -
CD3 O +
mAb O +
, O +
costimulated O +
NFAT O +
-dependent O +
transcriptional O +
activation O +
. O +

Several O +
intracellular O +
signaling O +
proteins O +
, O +
such O +
as O +
CBL O +
and O +
VAV O +
, O +
were O +
phosphorylated O +
on O +
tyrosine O +
in O +
response O +
to O +
CD80 O +
, O +
CD86 O +
, O +
and O +
anti O -
- O -
CD28 O +
mAb O +
. O +

Surprisingly O +
, O +
although O +
stimulation O +
of O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
with O +
either O +
CHO O -
- O -
CD80 O +
or O +
anti O -
- O -
CD28 O +
mAb O +
resulted O +
in O +
robust O +
tyrosine O +
phosphorylation O +
of O +
CD28 O +
itself O +
, O +
ligation O +
with O +
CHO O -
- O -
CD86 O +
was O +
unable O +
to O +
induce O +
detectable O +
CD28 O +
tyrosyl O +
phosphorylation O +
over O +
a O +
range O +
of O +
stimulation O +
conditions O +
. O +

In O +
addition O +
, O +
the O +
association O +
of O +
phosphoinositide O +
3-kinase O +
with O +
CD28 O +
and O +
enhanced O +
tyrosine O +
phosphorylation O +
of O +
phospholipase O +
Cgamma O +
were O +
seen O +
after O +
anti O -
- O -
CD28 O +
mAb O +
and O +
CHO O -
- O -
CD80 O +
stimulation O +
but O +
to O +
a O +
much O +
lesser O +
extent O +
after O +
CHO O -
- O -
CD86 O +
stimulation O +
. O +

Thus O +
, O +
ligation O +
of O +
CD28 O +
with O +
either O +
CD80 O +
or O +
CD86 O +
leads O +
to O +
shared O +
early O +
signal O +
transduction O +
events O +
such O +
as O +
the O +
tyrosine O +
phosphorylation O +
of O +
CBL O +
and O +
VAV O +
, O +
to O +
NFAT O +
-mediated O +
transcriptional O +
activation O +
, O +
and O +
to O +
the O +
costimulation O +
of O +
interleukin-2 O +
and O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
production O +
. O +

However O +
, O +
CD80 O +
and O +
CD86 O +
also O +
induce O +
distinct O +
signal O +
transduction O +
pathways O +
including O +
the O +
tyrosine O +
phosphorylation O +
of O +
CD28 O +
and O +
phospholipase O +
Cgamma1 O +
and O +
the O +
SH2 O +
-dependent O +
association O +
of O +
phosphoinositide O +
3-kinase O +
with O +
CD28 O +
. O +

These O +
quantitative O +
, O +
if O +
not O +
qualitative O +
, O +
differences O +
between O +
signaling O +
initiated O +
by O +
these O +
two O +
ligands O +
for O +
CD28 O +
may O +
contribute O +
to O +
functional O +
differences O +
( O +
e.g. O +
Th1 O +
or O +
Th2 O +
differentiation O +
) O +
in O +
T O +
cell O +
responses O +
. O +

Role O +
of O +
Egr-2 O +
in O +
up O -
- O -
regulation O +
of O +
Fas O +
ligand O +
in O +
normal O +
T O +
cells O +
and O +
aberrant O +
double O -
- O -
negative O +
lpr O +
and O +
gld O +
T O +
cells O +
. O +

We O +
previously O +
identified O +
a O +
Fas O +
ligand O +
regulatory O +
element O +
( O +
FLRE O +
) O +
in O +
the O +
Fas O +
ligand O +
( O +
fasL O +
) O +
promoter O +
that O +
binds O +
Egr O +
family O +
proteins O +
and O +
demonstrated O +
that O +
Egr-3 O +
( O +
PILOT O +
) O +
but O +
not O +
Egr-1 O +
( O +
NGFI O -
- O -
A O +
, O +
Krox-24 O +
, O +
Tis-8 O +
, O +
and O +
Zif-268 O +
) O +
induces O +
transcription O +
of O +
fasL O +
. O +

The O +
aberrant O +
CD4 O +
( O +
- O +
) O +
CD8 O +
( O +
- O +
) O +
T O +
cells O +
from O +
lpr O -
/ O -
lpr O +
and O +
gld O -
/ O -
gld O +
mice O +
, O +
which O +
have O +
mutations O +
in O +
the O +
genes O +
encoding O +
Fas O +
and O +
FasL O +
, O +
respectively O +
, O +
have O +
an O +
activated O +
phenotype O +
and O +
constitutively O +
express O +
high O +
levels O +
of O +
fasL O +
mRNA O +
, O +
prompting O +
us O +
to O +
ask O +
what O +
role O +
if O +
any O +
the O +
FLRE O +
and O +
Egr O +
family O +
proteins O +
have O +
in O +
this O +
aberrant O +
expression O +
of O +
fasL O +
. O +

Unstimulated O +
MRL B-CellLine -
- I-CellLine -
lpr I-CellLine -
/ I-CellLine -
lpr I-CellLine +
and I-CellLine +
C3H I-CellLine -
- I-CellLine -
gld I-CellLine -
/ I-CellLine -
gld I-CellLine +
CD4 I-CellLine +
( I-CellLine +
- I-CellLine +
) I-CellLine +
CD8 I-CellLine +
( I-CellLine +
- I-CellLine +
) I-CellLine +
T I-CellLine +
cells I-CellLine +
constitutively O +
contained O +
high O +
levels O +
of O +
two O +
proteins O +
that O +
bound O +
to O +
the O +
FLRE O +
. O +

Supershift O +
analysis O +
revealed O +
these O +
proteins O +
to O +
be O +
Egr-1 O +
and O +
Egr-2 O +
( O +
Krox-20 O +
) O +
; O +
Egr-3 O +
was O +
not O +
detected O +
. O +

Activation O +
of O +
normal O +
lymph O +
node O +
cells O +
resulted O +
in O +
increased O +
expression O +
of O +
Egr-1 O +
, O +
-2 O +
, O +
and O +
-3 O +
. O +

As O +
with O +
egr-3 O +
, O +
expression O +
of O +
egr-2 O +
was O +
blocked O +
by O +
cyclosporin O +
A O +
. O +

Although O +
overexpressed O +
Egr-1 O +
was O +
ineffective O +
, O +
overexpressed O +
Egr-2 O +
was O +
as O +
potent O +
as O +
Egr-3 O +
in O +
inducing O +
fasL O +
promoter O -
- O -
dependent O +
reporter O +
constructs O +
in O +
T O +
cell O +
hybridomas O +
and O +
HeLa O +
cells O +
, O +
and O +
both O +
up O -
- O -
regulated O +
endogenous O +
fasL O +
mRNA O +
in O +
HeLa B-CellLine +
cells I-CellLine +
. O +

FasL O -
- O -
dependent O +
reporter O +
constructs O +
in O +
MRL B-CellLine -
- I-CellLine -
lpr I-CellLine -
/ I-CellLine -
lpr I-CellLine +
and I-CellLine +
C3H I-CellLine -
- I-CellLine -
gld I-CellLine -
/ I-CellLine -
gld I-CellLine +
CD4 I-CellLine +
( I-CellLine +
- I-CellLine +
) I-CellLine +
CD8 I-CellLine +
( I-CellLine +
- I-CellLine +
) I-CellLine +
T I-CellLine +
cells I-CellLine +
were O +
constitutively O +
active O +
, O +
and O +
this O +
activity O +
was O +
largely O +
prevented O +
by O +
mutation O +
of O +
the O +
critical O +
Egr O +
family O +
binding O +
element O +
. O +

Thus O +
, O +
Egr-2 O +
, O +
in O +
addition O +
to O +
Egr-3 O +
, O +
regulates O +
FasL O +
expression O +
in O +
activated O +
normal O +
T O +
cells O +
, O +
and O +
Egr-2 O +
is O +
likely O +
to O +
play O +
a O +
direct O +
role O +
in O +
aberrant O +
fasL O +
up O -
- O -
regulation O +
in O +
lpr B-CellLine -
/ I-CellLine -
lpr I-CellLine +
and I-CellLine +
gld I-CellLine -
/ I-CellLine -
gld I-CellLine +
CD4 I-CellLine +
( I-CellLine +
- I-CellLine +
) I-CellLine +
CD8 I-CellLine +
( I-CellLine +
- I-CellLine +
) I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
in O +
vitro O +
and O +
in O +
vivo O +
: O +
role O +
of O +
26S O +
proteasome O +
. O +

It O +
is O +
becoming O +
increasingly O +
apparent O +
that O +
NF O -
- O -
kappa O +
B O +
plays O +
a O +
critical O +
role O +
in O +
regulating O +
the O +
inflammatory O +
response O +
. O +

Data O +
obtained O +
from O +
studies O +
in O +
our O +
laboratories O +
demonstrate O +
that O +
the O +
proteasome O +
plays O +
an O +
important O +
role O +
in O +
the O +
inflammatory O +
cascade O +
by O +
regulating O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
. O +

Indeed O +
, O +
the O +
availability O +
of O +
selective O +
and O +
orally O +
active O +
proteasome O +
inhibitors O +
should O +
prove O +
useful O +
in O +
delineating O +
the O +
roles O +
of O +
the O +
proteasome O +
and O +
NF O -
- O -
kappa O +
B O +
in O +
other O +
pathophysiological O +
conditions O +
such O +
as O +
cancer O +
and O +
heart O +
disease O +
. O +

Imbalanced O +
expression O +
of O +
the O +
glucocorticoid O +
receptor O +
isoforms O +
in O +
cultured O +
lymphocytes O +
from O +
a O +
patient O +
with O +
systemic O +
glucocorticoid O +
resistance O +
and O +
chronic O +
lymphocytic O +
leukemia O +
. O +

The O +
human O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
is O +
expressed O +
as O +
two O +
alternatively O +
spliced O +
isoforms O +
, O +
GRalpha O +
and O +
GRbeta O +
. O +

Whereas O +
GRalpha O +
is O +
a O +
hormone O -
- O -
activated O +
transcription O +
factor O +
, O +
GRbeta O +
does O +
not O +
bind O +
glucocorticoids O +
( O +
GCs O +
) O +
, O +
is O +
transcriptionally O +
inactive O +
, O +
and O +
is O +
a O +
potential O +
inhibitor O +
of O +
activated O +
GRalpha O +
. O +

Differential O +
expression O +
of O +
GR O +
isoforms O +
may O +
play O +
a O +
role O +
in O +
generalized O +
or O +
tissue O -
- O -
specific O +
GC O +
resistance O +
. O +

GCs O +
induce O +
apoptosis O +
in O +
neoplastic O +
lymphoid O +
cells O +
; O +
and O +
, O +
defective O +
apoptosis O +
is O +
implicated O +
in O +
the O +
genesis O +
of O +
chronic O +
lymphocytic O +
leukemia O +
( O +
CLL O +
) O +
. O +

We O +
studied O +
a O +
patient O +
with O +
generalized O +
GC O +
resistance O +
and O +
CLL O +
. O +

GR O +
number O +
in O +
the O +
patient O +
's O +
transformed B-CellLine +
lymphocytes I-CellLine +
was O +
approximately O +
one O +
half O +
that O +
of O +
control O +
cells O +
with O +
a O +
approximately O +
10-fold O +
reduction O +
in O +
binding O +
affinity O +
for O +
dexamethasone O +
. O +

In O +
vitro O +
apoptosis O +
induction O +
in O +
CLL B-CellLine +
cells I-CellLine +
was O +
delayed O +
in O +
response O +
to O +
GCs O +
, O +
but O +
not O +
to O +
other O +
apoptosis O +
inducers O +
. O +

Sequencing O +
of O +
the O +
GR O +
cDNA O +
and O +
gene O +
including O +
the O +
2.3-kb O +
coding O +
region O +
, O +
the O +
intron O -
/ O -
exon O +
junctions O +
, O +
the O +
known O +
5'-regulatory O +
region O +
, O +
and O +
approximately O +
300 O +
bp O +
of O +
the O +
3'-region O +
revealed O +
no O +
alterations O +
. O +

Western O +
blot O +
with O +
an O +
N O -
- O -
terminal O +
antibody O +
showed O +
normal O +
levels O +
of O +
immunoreactive O +
GR O +
, O +
but O +
quantitative O +
analysis O +
with O +
isoform O -
- O -
specific O +
C O -
- O -
terminal O +
antibodies O +
revealed O +
a O +
markedly O +
reduced O +
GRalpha O +
expression O +
, O +
and O +
high O +
GRbeta O +
expression O +
. O +

These O +
findings O +
indicate O +
that O +
imbalanced O +
expression O +
of O +
the O +
GR O +
isoforms O +
may O +
be O +
a O +
mechanism O +
of O +
GC O +
resistance O +
, O +
and O +
may O +
have O +
implications O +
for O +
tumorigenesis O +
by O +
enhancing O +
cell O +
survival O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

1 O +
, O +
25-Dihydroxyvitamin O +
D3 O +
receptors O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
from O +
patients O +
with O +
renal O +
insufficiency O +
. O +

A O +
reduced O +
expression O +
of O +
the O +
vitamin O +
D O +
receptor O +
( O +
VDR O +
) O +
in O +
parathyroid O +
glands O +
of O +
uremic O +
animals O +
and O +
humans O +
has O +
been O +
observed O +
. O +

Similar O +
results O +
have O +
been O +
obtained O +
by O +
our O +
own O +
group O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
from O +
patients O +
with O +
secondary O +
hyperparathyroidism O +
to O +
chronic O +
renal O +
failure O +
. O +

However O +
, O +
the O +
reasons O +
for O +
these O +
changes O +
are O +
not O +
clear O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
have O +
investigated O +
the O +
specific O +
uptake O +
of O +
[ O +
3H O +
] O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
by O +
PBMC O +
of O +
11 O +
women O +
with O +
advanced O +
chronic O +
renal O +
failure O +
( O +
A O -
- O -
CRF O +
) O +
, O +
6 O +
women O +
with O +
mild O -
- O -
moderate O +
renal O +
insufficiency O +
( O +
M O -
- O -
CRF O +
) O +
, O +
and O +
23 O +
healthy O +
women O +
. O +

The O +
mean O +
dissociation O +
constant O +
( O +
KD O +
) O +
was O +
similar O +
in O +
both O +
groups O +
of O +
patients O +
and O +
in O +
healthy O +
women O +
( O +
A O -
- O -
CRF O +
: O +
0.7 O +
+ O -
/- O +
0.5 O +
x O +
10 O +
( O +
-10 O +
) O +
M O +
; O +
M O -
- O -
CRF O +
: O +
1.1 O +
+ O -
/- O +
0.9 O +
x O +
10 O +
( O +
-10 O +
) O +
M O +
; O +
controls O +
: O +
1.0 O +
+ O -
/- O +
0.6 O +
x O +
10 O +
( O +
-10 O +
) O +
M O +
) O +
. O +

However O +
, O +
VDR O +
concentration O +
was O +
significantly O +
decreased O +
in O +
A O -
- O -
CRF O +
( O +
0.8 O +
+ O -
/- O +
0.5 O +
fmol O -
/ O -
10 O +
( O +
7 O +
) O +
cells O +
vs. O +
2.3 O +
+ O -
/- O +
0.9 O +
fmol O -
/ O -
10 O +
( O +
7 O +
) O +
cells O +
in O +
controls O +
, O +
p O +
< O +
0.001 O +
) O +
, O +
whereas O +
no O +
changes O +
were O +
seen O +
in O +
M O -
- O -
CRF O +
( O +
1.7 O +
+ O -
/- O +
0.7 O +
fmol O -
/ O -
10 O +
( O +
7 O +
) O +
cells O +
vs. O +
2.3 O +
+ O -
/- O +
0.9 O +
fmol O -
/ O -
10 O +
( O +
7 O +
) O +
cells O +
in O +
controls O +
) O +
. O +

No O +
correlation O +
was O +
seen O +
between O +
VDR O +
and O +
serum O +
calcitriol O +
or O +
PTH O +
levels O +
, O +
when O +
considering O +
both O +
groups O +
of O +
patients O +
together O +
or O +
separately O +
. O +

Conversely O +
, O +
a O +
significant O +
negative O +
correlation O +
was O +
found O +
between O +
VDR O +
and O +
serum O +
creatinine O +
values O +
when O +
A O -
- O -
CRF O +
and O +
M O -
- O -
CRF O +
were O +
considered O +
altogether O +
( O +
r O +
= O +
-0.63 O +
; O +
p O +
< O +
0.01 O +
) O +
. O +

Treatment O +
with O +
two O +
different O +
schedules O +
of O +
oral O +
calcitriol O +
( O +
five O +
patients O +
with O +
0.5 O +
microgram O -
/ O -
day O +
for O +
1 O +
month O +
and O +
four O +
patients O +
with O +
2 O +
micrograms O -
/ O -
day O +
for O +
7 O +
days O +
) O +
did O +
not O +
change O +
VDR O +
concentrations O +
. O +

We O +
conclude O +
that O +
the O +
low O +
levels O +
of O +
serum O +
1 O +
, O +
25 O +
( O +
OH O +
) O +
2D3 O +
of O +
uremia O +
are O +
not O +
responsible O +
for O +
the O +
decrease O +
in O +
VDR O +
concentration O +
found O +
in O +
these O +
patients O +
. O +

Transcription O +
factor O +
effects O +
on O +
chromosome O +
constitution O +
of O +
cell B-CellLine +
hybrids I-CellLine +
. O +

When O +
immunoglobulin B-CellLine +
( I-CellLine +
Ig I-CellLine +
) I-CellLine +
-secreting I-CellLine +
plasmacytomas I-CellLine +
are O +
fused O +
to O +
a O +
T O -
- O -
cell O +
lymphoma O +
, O +
Ig O +
gene O +
expression O +
ceases O +
in O +
greater O +
than O +
95 O +
% O +
of O +
the O +
resulting O +
hybrids O +
. O +

In O +
the O +
rare O +
hybrids O +
that O +
continue O +
to O +
express O +
Ig O +
, O +
all O +
other O +
tested O +
B O +
lymphocyte O -
- O -
specific O +
genes O +
also O +
remain O +
active O +
. O +

The O +
low O +
frequency O +
with O +
which O +
these O +
Ig B-CellLine -
- I-CellLine -
expressing I-CellLine +
hybrids I-CellLine +
are O +
recovered O +
, O +
along O +
with O +
the O +
fact O +
that O +
cell O +
fusions O +
can O +
lead O +
to O +
chromosome O +
loss O +
, O +
led O +
us O +
to O +
propose O +
that O +
this O +
rare O +
phenotype O +
was O +
due O +
to O +
loss O +
of O +
a O +
T O -
- O -
cell O -
- O -
derived O +
chromosome O +
encoding O +
a O +
factor O +
or O +
factors O +
with O +
gene O +
silencing O +
activity O +
. O +

To O +
identify O +
the O +
relevant O +
chromosome O +
, O +
we O +
have O +
used O +
a O +
polymerase O +
chain O +
reaction O +
( O +
PCR O +
) O +
-assisted O +
method O +
of O +
chromosome O +
mapping O +
to O +
analyze O +
both O +
Ig B-CellLine -
- I-CellLine -
silenced I-CellLine +
( I-CellLine +
common I-CellLine +
) I-CellLine +
and I-CellLine +
Ig I-CellLine -
- I-CellLine -
expressing I-CellLine +
( I-CellLine +
rare I-CellLine +
) I-CellLine +
hybrids I-CellLine +
. O +

Although O +
no O +
single O +
chromosome O +
was O +
found O +
to O +
correlate O +
with O +
Ig O +
gene O +
silencing O +
, O +
we O +
discovered O +
that O +
the O +
two O +
types O +
of O +
hybrids O +
had O +
undergone O +
distinct O +
patterns O +
of O +
chromosome O +
loss O +
. O +

Moreover O +
, O +
we O +
found O +
that O +
ectopic O +
expression O +
of O +
a O +
B O -
- O -
cell O -
- O -
specific O +
transcription O +
factor O +
( O +
Oct-2 O +
) O +
dramatically O +
altered O +
both O +
the O +
phenotype O +
and O +
chromosome O +
constitution O +
of O +
hybrids O +
arising O +
in O +
these O +
cell O +
fusions O +
. O +

Both O +
Stat3 O +
-activation O +
and O +
Stat3 O +
-independent O +
BCL2 O +
downregulation O +
are O +
important O +
for O +
interleukin-6 O +
-induced O +
apoptosis O +
of O +
1A9-M B-CellLine +
cells I-CellLine +
. O +

A O +
unique O +
subclone O +
of O +
a O +
bone B-CellLine +
marrow I-CellLine -
- I-CellLine -
derived I-CellLine +
stromal I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
BMS2.4 B-CellLine +
, O +
produces O +
soluble O +
factors O +
that O +
inhibit O +
proliferation O +
of O +
several O +
types O +
of O +
hematopoietic B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

An O +
understanding O +
of O +
these O +
molecules O +
may O +
be O +
informative O +
about O +
negative O +
regulatory O +
circuits O +
that O +
can O +
potentially O +
limit O +
blood O +
cell O +
formation O +
. O +

We O +
used O +
expression O +
cloning O +
to O +
identify O +
interleukin-6 O +
( O +
IL-6 O +
) O +
as O +
one O +
factor O +
that O +
suppressed O +
growth O +
of O +
a O +
pre B-CellLine -
- I-CellLine -
B I-CellLine -
- I-CellLine -
cell I-CellLine +
variant I-CellLine +
line I-CellLine +
, O +
1A9-M B-CellLine +
. O +

Moreover O +
, O +
IL-6 O +
induced O +
macrophage O -
- O -
differentiation O +
and O +
apoptosis O +
of O +
1A9-M B-CellLine +
cells I-CellLine +
. O +

During O +
this O +
process O +
, O +
IL-6 O +
downregulated O +
expression O +
of O +
BCL2 O +
in O +
1A9-M B-CellLine +
cells I-CellLine +
and O +
stimulated O +
BCL O -
- O -
XL O +
expression O +
, O +
but O +
had O +
no O +
effect O +
on O +
p53 O +
, O +
Bax O +
, O +
or O +
Bak O +
gene O +
expression O +
. O +

Mechanisms O +
for O +
transduction O +
of O +
IL-6 O +
-induced O +
signals O +
were O +
then O +
evaluated O +
in O +
IL-6-stimulated B-CellLine +
1A9-M I-CellLine +
cells I-CellLine +
. O +

Whereas O +
the O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
3 O +
( O +
Stat3 O +
) O +
was O +
phosphorylated O +
and O +
activated O +
, O +
there O +
was O +
no O +
effect O +
on O +
either O +
Stat1 O +
or O +
Stat5 O +
. O +

The O +
importance O +
of O +
BCL2 O +
and O +
Stat3 O +
on O +
IL-6 O +
-induced O +
macrophage O -
- O -
differentiation O +
and O +
apoptosis O +
was O +
studied O +
with O +
1A9-M B-CellLine +
cells I-CellLine +
expressing O +
human O +
BCL2 O +
or O +
a O +
dominant O -
- O -
negative O +
form O +
of O +
Stat3 O +
, O +
respectively O +
. O +

IL-6 O +
-induced O +
apoptosis O +
, O +
but O +
not O +
macrophage O -
- O -
differentiation O +
, O +
was O +
blocked O +
by O +
continuously O +
expressed O +
BCL2 O +
. O +

A O +
dominant O -
- O -
negative O +
form O +
of O +
Stat3 O +
inhibited O +
both O +
macrophage O -
- O -
differentiation O +
and O +
apoptosis O +
induced O +
by O +
IL-6 O +
. O +

However O +
, O +
diminished O +
Stat3 O +
activity O +
did O +
not O +
prevent O +
IL-6 O +
-induced O +
downregulation O +
of O +
the O +
BCL2 O +
gene O +
. O +

Therefore O +
, O +
activation O +
of O +
Stat3 O +
is O +
essential O +
for O +
IL-6 O +
-induced O +
macrophage O -
- O -
differentiation O +
and O +
programmed O +
cell O +
death O +
in O +
this O +
model O +
. O +

Whereas O +
overexpression O +
of O +
BCL2 O +
abrogates O +
the O +
apoptotic O +
response O +
, O +
Stat3 O +
-independent O +
signals O +
appear O +
to O +
downregulate O +
expression O +
of O +
the O +
BCL2 O +
gene O +
. O +

Granulosa O +
cell O +
tumor O +
of O +
the O +
ovary O +
. O +

Immunohistochemical O +
evidence O +
of O +
low O +
proliferative O +
activity O +
and O +
virtual O +
absence O +
of O +
mutation O +
of O +
the O +
p53 O +
tumor O -
- O -
suppressor O +
gene O +
. O +

BACKGROUND O +
AND O +
METHODS O +
: O +
Because O +
the O +
use O +
of O +
immunohistochemistry O +
in O +
the O +
diagnosis O +
of O +
granulosa O +
cell O +
tumor O +
( O +
GCT O +
) O +
has O +
not O +
been O +
fully O +
explored O +
, O +
routinely O +
processed O +
( O +
formalin O -
- O -
fixed O +
, O +
paraffin O -
- O -
embedded O +
) O +
tissue O +
from O +
11 O +
GCT O +
, O +
adult O +
type O +
, O +
was O +
investigated O +
immunohistochemically O +
( O +
ABC O +
method O +
) O +
with O +
a O +
broad O +
spectrum O +
of O +
antibodies O +
against O +
various O +
markers O +
, O +
including O +
p53 O +
and O +
Ki-67 O +
. O +

All O +
of O +
the O +
tumors O +
exhibited O +
typical O +
morphology O +
, O +
were O +
limited O +
to O +
the O +
ovary O +
( O +
stage O +
I O +
) O +
, O +
and O +
7 O +
cases O +
followed O +
a O +
benign O +
clinical O +
course O +
. O +

RESULTS O +
: O +
All O +
the O +
tumors O +
exhibited O +
strong O +
expression O +
of O +
vimentin O +
, O +
but O +
most O +
other O +
antigens O +
( O +
including O +
smooth O +
muscle O +
actin O +
) O +
were O +
expressed O +
infrequently O +
by O +
a O +
minority O +
of O +
tumor O +
cells O +
or O +
not O +
at O +
all O +
. O +

Tumor O +
cells O +
in O +
9 O +
GCT O +
expressed O +
inhibin O +
A O +
. O +

All O +
the O +
tumors O +
exhibited O +
very O +
low O +
proliferative O +
activity O +
, O +
fewer O +
than O +
10 O +
% O +
of O +
the O +
tumor O +
cell O +
nuclei O +
being O +
stained O +
by O +
the O +
antibody O +
MIB-1 O +
( O +
Ki-67 O +
antigen O +
) O +
. O +

The O +
antibody O +
D07 O +
revealed O +
marked O +
overexpression O +
of O +
p53 O +
protein O +
in O +
only O +
one O +
tumor O +
. O +

Clinical O +
outcome O +
was O +
not O +
found O +
to O +
be O +
related O +
to O +
immunophenotypic O +
differences O +
. O +

CONCLUSIONS O +
: O +
The O +
diagnosis O +
of O +
GCT O +
should O +
be O +
based O +
primarily O +
on O +
the O +
typical O +
morphology O +
revealed O +
by O +
conventional O +
stains O +
, O +
but O +
additional O +
immunohistochemical O +
staining O +
with O +
a O +
small O +
panel O +
of O +
selected O +
antibodies O +
( O +
for O +
example O +
, O +
against O +
keratin O +
, O +
vimentin O +
, O +
and O +
inhibin O +
A O +
) O +
may O +
be O +
helpful O +
in O +
a O +
few O +
cases O +
. O +

The O +
very O +
low O +
proliferative O +
activity O +
and O +
the O +
lack O +
of O +
overexpression O +
of O +
p53 O +
protein O +
are O +
consistent O +
with O +
the O +
benign O +
clinical O +
behavior O +
of O +
the O +
majority O +
of O +
GCT O +
. O +

Lactobacilli O +
and O +
vaginal O +
host O +
defense O +
: O +
activation O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
long O +
terminal O +
repeat O +
, O +
cytokine O +
production O +
, O +
and O +
NF O -
- O -
kappaB O +
. O +

Lactobacilli O +
, O +
a O +
component O +
of O +
the O +
normal O +
vaginal O +
flora O +
, O +
can O +
activate O +
the O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
-1 O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
in O +
the O +
Jurkat B-CellLine +
T I-CellLine +
lymphocyte I-CellLine +
and O +
THP-1 B-CellLine +
macrophage I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Activation O +
of O +
the O +
LTR O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
was O +
strongly O +
enhanced O +
by O +
vanadate O +
and O +
inhibited O +
by O +
catalase O +
, O +
implicating O +
H2O2 O +
. O +

In O +
contrast O +
, O +
activation O +
in O +
THP-1 O +
cells O +
occurred O +
in O +
the O +
absence O +
of O +
vanadate O +
and O +
was O +
unaffected O +
by O +
catalase O +
. O +

The O +
active O +
material O +
partitioned O +
into O +
the O +
phenol O +
layer O +
on O +
hot O +
aqueous O +
phenol O +
extraction O +
. O +

Lactobacilli O +
also O +
increased O +
tumor O +
necrosis O +
factor O +
-alphaand O +
interleukin O +
-1betaproduction O +
and O +
activated O +
NF O -
- O -
kappaB O +
in O +
THP-1 O +
cells O +
and O +
increased O +
tumor O +
necrosis O +
factor O +
-alphaproduction O +
by O +
human O +
monocytes O +
. O +

Human O +
vaginal O +
fluid O +
specimens O +
had O +
comparable O +
properties O +
, O +
which O +
correlated O +
with O +
their O +
bacterial O +
content O +
. O +

These O +
findings O +
suggest O +
the O +
presence O +
in O +
vaginal O +
fluid O +
of O +
agent O +
( O +
s O +
) O +
derived O +
from O +
indigenous O +
bacteria O +
that O +
can O +
activate O +
the O +
HIV-1 O +
LTR O +
, O +
cytokine O +
production O +
, O +
and O +
NF O -
- O -
kappaB O +
in O +
cells O +
of O +
macrophage O +
lineage O +
, O +
with O +
possible O +
influence O +
on O +
vaginal O +
physiology O +
and O +
host O +
defense O +
. O +

Cross O -
- O -
linking O +
of O +
CD44 O +
on O +
rheumatoid O +
synovial O +
cells O +
up O -
- O -
regulates O +
VCAM-1 O +
. O +

CD44 O +
is O +
a O +
ubiquitous O +
molecule O +
also O +
known O +
as O +
hyaluronic O +
acid O +
or O +
homing O +
receptor O +
. O +

However O +
, O +
the O +
cellular O +
functions O +
and O +
its O +
role O +
in O +
inflammation O +
, O +
for O +
example O +
, O +
rheumatoid O +
synovitis O +
, O +
are O +
currently O +
unknown O +
. O +

In O +
this O +
study O +
, O +
we O +
propose O +
a O +
novel O +
function O +
for O +
CD44 O +
. O +

Using O +
synovial O +
cells O +
from O +
rheumatoid O +
arthritis O +
( O +
RA O +
) O +
patients O +
, O +
we O +
demonstrated O +
that O +
CD44 O +
cross O -
- O -
linking O +
and O +
binding O +
to O +
hyaluronan O +
augmented O +
VCAM-1 O +
expression O +
and O +
subsequently O +
VCAM-1 O +
-mediated O +
cell O +
adhesion O +
. O +

Briefly O +
, O +
we O +
found O +
that O +
1 O +
) O +
rheumatoid O +
synovial O +
cells O +
highly O +
expressed O +
CD44 O +
; O +
2 O +
) O +
cross O -
- O -
linking O +
of O +
CD44 O +
markedly O +
but O +
transiently O +
augmented O +
VCAM-1 O +
expression O +
and O +
its O +
mRNA O +
transcription O +
much O +
more O +
than O +
did O +
IL-1beta O +
and O +
TNF O -
- O -
alpha O +
; O +
3 O +
) O +
hyaluronan O +
, O +
especially O +
when O +
fragmented O +
, O +
also O +
up O -
- O -
regulated O +
VCAM-1 O +
; O +
4 O +
) O +
CD44 O +
activated O +
the O +
transcription O +
factor O +
AP-1 O +
; O +
and O +
5 O +
) O +
the O +
integrin O +
-dependent O +
adhesive O +
function O +
of O +
RA O +
synovial O +
cells O +
to O +
T O +
cells O +
was O +
also O +
amplified O +
by O +
CD44 O +
cross O -
- O -
linking O +
. O +

These O +
results O +
indicate O +
that O +
the O +
adhesion O +
of O +
RA O +
synovial O +
cells O +
to O +
matrices O +
such O +
as O +
hyaluronic O +
acid O +
through O +
CD44 O +
could O +
up O -
- O -
regulate O +
VCAM-1 O +
expression O +
and O +
VCAM-1 O +
-mediated O +
adhesion O +
to O +
T O +
cells O +
, O +
which O +
might O +
in O +
turn O +
cause O +
activation O +
of O +
T O +
cells O +
and O +
synovial O +
cells O +
in O +
RA O +
synovitis O +
. O +

We O +
therefore O +
propose O +
that O +
such O +
cross O -
- O -
talking O +
among O +
distinct O +
adhesion O +
molecules O +
may O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
inflammation O +
, O +
including O +
RA O +
synovitis O +
. O +

High O -
- O -
level O +
replication O +
of O +
human O +
immunodeficiency O +
virus O +
in O +
thymocytes O +
requires O +
NF O -
- O -
kappaB O +
activation O +
through O +
interaction O +
with O +
thymic O +
epithelial O +
cells O +
. O +

We O +
have O +
previously O +
demonstrated O +
that O +
interaction O +
of O +
infected O +
thymocytes O +
with O +
autologous O +
thymic O +
epithelial O +
cells O +
( O +
TEC O +
) O +
is O +
a O +
prerequisite O +
for O +
a O +
high O +
level O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O +
HIV-1 O +
) O +
replication O +
in O +
thymocytes O +
( O +
M.Rothe O +
, O +
L.Chene O +
, O +
M.Nugeyre O +
, O +
F.Barre O -
- O -
Sinoussi O +
, O +
and O +
N.Israel O +
, O +
J.Virol.72 O +
: O +
5852 O -
- O -
5861 O +
, O +
1998 O +
) O +
. O +

We O +
report O +
here O +
that O +
this O +
activation O +
of O +
HIV O +
replication O +
takes O +
place O +
at O +
the O +
transcriptional O +
level O +
through O +
activation O +
of O +
the O +
Rel O -
/ O -
NF O -
- O -
kappaB O +
transcription O +
factors O +
. O +

We O +
first O +
demonstrate O +
that O +
an O +
HIV-1 O +
provirus O +
( O +
SF-2 O +
strain O +
) O +
very O +
effectively O +
replicates O +
in O +
thymocytes O +
cocultured O +
with O +
TEC O +
whereas O +
this O +
provirus O +
, O +
with O +
kappaB O +
sites O +
deleted O +
, O +
fails O +
to O +
replicate O +
. O +

We O +
provide O +
evidence O +
that O +
several O +
NF O -
- O -
kappaB O +
complexes O +
are O +
constitutively O +
found O +
in O +
the O +
nuclei O +
of O +
thymocytes O +
either O +
freshly O +
isolated O +
from O +
the O +
thymus O +
or O +
maintained O +
in O +
coculture O +
with O +
autologous O +
or O +
heterologous O +
TEC O +
. O +

The O +
prevalent O +
complex O +
is O +
the O +
heterodimer O +
p50-p65 O +
. O +

NF O -
- O -
kappaB O +
activity O +
is O +
tightly O +
correlated O +
with O +
the O +
transcriptional O +
activity O +
of O +
a O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
of O +
HIV-1 O +
transfected O +
in O +
thymocytes O +
. O +

The O +
cotransfection O +
of O +
this O +
LTR O +
with O +
a O +
mutated O +
IkappaBalpha O +
molecule O +
formally O +
demonstrates O +
that O +
LTR O +
transactivation O +
is O +
regulated O +
by O +
members O +
of O +
the O +
Rel O -
/ O -
NF O -
- O -
kappaB O +
family O +
in O +
thymocytes O +
. O +

We O +
also O +
showed O +
that O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
and O +
to O +
a O +
lesser O +
extent O +
interleukin-1 O +
( O +
IL-1 O +
) O +
, O +
secreted O +
within O +
the O +
coculture O +
, O +
induce O +
NF O -
- O -
kappaB O +
activity O +
and O +
a O +
correlative O +
LTR O +
transactivation O +
. O +

However O +
IL-7 O +
, O +
a O +
crucial O +
factor O +
for O +
thymopoiesis O +
that O +
is O +
secreted O +
mainly O +
by O +
TEC O +
, O +
is O +
a O +
necessary O +
cofactor O +
for O +
NF O -
- O -
kappaB O +
activation O +
elicited O +
by O +
TNF O +
or O +
IL-1 O +
. O +

Together O +
, O +
these O +
data O +
indicate O +
that O +
NF O -
- O -
kappaB O +
activation O +
, O +
required O +
for O +
a O +
high O +
level O +
of O +
HIV O +
replication O +
in O +
thymocytes O +
, O +
is O +
regulated O +
in O +
a O +
specific O +
manner O +
in O +
the O +
thymic O +
microenvironment O +
which O +
provides O +
the O +
necessary O +
cytokines O +
: O +
TNF O +
, O +
IL-1 O +
, O +
and O +
IL-7 O +
. O +

Clonality O +
analysis O +
of O +
refractory O +
anemia O +
with O +
ring O +
sideroblasts O +
: O +
simultaneous O +
study O +
of O +
clonality O +
and O +
cytochemistry O +
of O +
bone O +
marrow O +
progenitors O +
. O +

X O +
chromosome O +
inactivation O +
and O +
polymorphism O +
of O +
the O +
human O +
androgen O +
receptor O +
( O +
HUMARA O +
) O +
gene O +
has O +
been O +
applied O +
for O +
analyzing O +
the O +
clonality O +
of O +
blood O +
cells O +
. O +

In O +
the O +
present O +
study O +
, O +
the O +
clonal O +
relationship O +
was O +
investigated O +
between O +
peripheral O +
blood O +
polymorphonuclear O +
cells O +
( O +
PMNCs O +
) O +
and O +
marrow O +
progenitor O +
cells O +
and O +
the O +
origin O +
of O +
ringed O +
sideroblasts O +
in O +
patients O +
with O +
refractory O +
anemia O +
with O +
ring O +
sideroblasts O +
( O +
RARS O +
) O +
by O +
polymerase O +
chain O +
reaction O +
( O +
PCR O +
) O +
of O +
HUMARA O +
gene O +
. O +

The O +
X O -
- O -
inactivation O +
patterns O +
of O +
circulating O +
PMNCs O +
and O +
T O +
lymphocytes O +
as O +
well O +
as O +
individual O +
granulocyte B-CellLine +
colonies I-CellLine +
grown O +
in O +
vitro O +
from O +
bone O +
marrow O +
cells O +
were O +
analyzed O +
. O +

The O +
development O +
of O +
ringed O +
sideroblasts O +
in O +
erythroid B-CellLine +
colonies I-CellLine +
by O +
iron O +
staining O +
and O +
their O +
X O -
- O -
inactivation O +
pattern O +
were O +
also O +
examined O +
. O +

All O +
three O +
RARS O +
patients O +
showed O +
monoclonal O +
PMNCs O +
. O +

In O +
granulocyte B-CellLine +
colonies I-CellLine +
, O +
however O +
, O +
two O +
different O +
X O -
- O -
inactivation O +
patterns O +
were O +
observed O +
in O +
all O +
patients O +
, O +
indicating O +
that O +
non O -
- O -
clonal O +
progenitor O +
cells O +
remained O +
in O +
the O +
bone O +
marrow O +
. O +

All O +
erythroid B-CellLine +
colonies I-CellLine +
consisted O +
of O +
ringed O +
sideroblasts O +
exclusively O +
showed O +
one O +
pattern O +
dominant O +
in O +
those O +
of O +
PMNCs O +
. O +

Our O +
findings O +
suggest O +
that O +
non O -
- O -
clonal O +
progenitor O +
cells O +
persist O +
in O +
some O +
RARS O +
cases O +
, O +
that O +
erythroid O +
progenitors O +
show O +
mosaicism O +
, O +
and O +
that O +
ringed O +
sideroblasts O +
may O +
be O +
derived O +
from O +
an O +
abnormal O +
clone O +
involved O +
in O +
the O +
pathogenesis O +
of O +
this O +
disease O +
. O +

Oleic O +
acid O +
inhibits O +
endothelial O +
activation O +
: O +
A O +
direct O +
vascular O +
antiatherogenic O +
mechanism O +
of O +
a O +
nutritional O +
component O +
in O +
the O +
mediterranean O +
diet O +
. O +

Because O +
oleic O +
acid O +
is O +
implicated O +
in O +
the O +
antiatherogenic O +
effects O +
attributed O +
to O +
the O +
Mediterranean O +
diet O +
, O +
we O +
investigated O +
whether O +
this O +
fatty O +
acid O +
can O +
modulate O +
endothelial O +
activation O +
, O +
ie O +
, O +
the O +
concerted O +
expression O +
of O +
gene O +
products O +
involved O +
in O +
leukocyte O +
recruitment O +
and O +
early O +
atherogenesis O +
. O +

We O +
incubated O +
sodium O +
oleate O +
with O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
for O +
0 O +
to O +
72 O +
hours O +
, O +
followed O +
by O +
coincubation O +
of O +
oleate O +
with O +
human O +
recombinant O +
tumor O +
necrosis O +
factor O +
, O +
interleukin O +
( O +
IL O +
) O +
-1alpha O +
, O +
IL-1beta O +
, O +
IL-4 O +
, O +
Escherichia O +
coli O +
lipopolysaccharide O +
( O +
LPS O +
) O +
, O +
or O +
phorbol O +
12-myristate O +
13-acetate O +
for O +
a O +
further O +
6 O +
to O +
24 O +
hours O +
. O +

The O +
endothelial O +
expression O +
of O +
vascular O +
cell O +
adhesion O +
molecule-1 O +
( O +
VCAM-1 O +
) O +
, O +
E O -
- O -
selectin O +
, O +
and O +
intercellular O +
adhesion O +
molecule-1 O +
was O +
monitored O +
by O +
cell O +
surface O +
enzyme O +
immunoassays O +
or O +
flow O +
cytometry O +
, O +
and O +
steady O -
- O -
state O +
levels O +
of O +
VCAM-1 O +
mRNA O +
were O +
assessed O +
by O +
Northern O +
blot O +
analysis O +
. O +

At O +
10 O +
to O +
100 O +
micromol O -
/ O -
L O +
for O +
> O +
24 O +
hours O +
, O +
oleate O +
inhibited O +
the O +
expression O +
of O +
all O +
adhesion O +
molecules O +
tested O +
. O +

After O +
a O +
72-hour O +
incubation O +
with O +
oleate O +
and O +
a O +
further O +
16-hour O +
incubation O +
with O +
oleate O +
plus O +
1 O +
microg O -
/ O -
mL O +
LPS O +
, O +
VCAM-1 O +
expression O +
was O +
reduced O +
by O +
> O +
40 O +
% O +
compared O +
with O +
control O +
. O +

Adhesion O +
of O +
monocytoid B-CellLine +
U937 I-CellLine +
cells I-CellLine +
to O +
LPS O -
- O -
treated O +
endothelial O +
cells O +
was O +
reduced O +
concomitantly O +
. O +

Oleate O +
also O +
produced O +
a O +
quantitatively O +
similar O +
reduction O +
of O +
VCAM-1 O +
mRNA O +
levels O +
on O +
Northern O +
blot O +
analysis O +
and O +
inhibited O +
nuclear O +
factor O -
- O -
kappaB O +
activation O +
on O +
electrophoretic O +
mobility O +
shift O +
assays O +
. O +

Incubation O +
of O +
endothelial O +
cells O +
with O +
oleate O +
for O +
72 O +
hours O +
decreased O +
the O +
relative O +
proportions O +
of O +
saturated O +
( O +
palmitic O +
and O +
stearic O +
) O +
acids O +
in O +
total O +
cell O +
lipids O +
and O +
increased O +
the O +
proportions O +
of O +
oleate O +
in O +
total O +
cell O +
lipids O +
without O +
significantly O +
changing O +
the O +
relative O +
proportions O +
of O +
polyunsaturated O +
fatty O +
acids O +
. O +

Although O +
less O +
potent O +
than O +
polyunsaturated O +
fatty O +
acids O +
in O +
inhibiting O +
endothelial O +
activation O +
, O +
oleic O +
acid O +
may O +
contribute O +
to O +
the O +
prevention O +
of O +
atherogenesis O +
through O +
selective O +
displacement O +
of O +
saturated O +
fatty O +
acids O +
in O +
cell O +
membrane O +
phospholipids O +
and O +
a O +
consequent O +
modulation O +
of O +
gene O +
expression O +
for O +
molecules O +
involved O +
in O +
monocyte O +
recruitment O +
. O +

Functional O +
association O +
of O +
Nmi O +
with O +
Stat5 O +
and O +
Stat1 O +
in O +
IL-2 O +
-and O +
IFNgamma O +
-mediated O +
signaling O +
. O +

Using O +
the O +
coiled O -
- O -
coil O +
region O +
of O +
Stat5b O +
as O +
the O +
bait O +
in O +
a O +
yeast O +
two O -
- O -
hybrid O +
screen O +
, O +
we O +
identified O +
the O +
association O +
of O +
Nmi O +
, O +
a O +
protein O +
of O +
unknown O +
function O +
previously O +
reported O +
as O +
an O +
N O -
- O -
Myc O +
interactor O +
. O +

We O +
further O +
show O +
that O +
Nmi O +
interacts O +
with O +
all O +
STATs O +
except O +
Stat2 O +
. O +

We O +
evaluated O +
two O +
cytokine O +
systems O +
, O +
IL-2 O +
and O +
IFNgamma O +
, O +
and O +
demonstrate O +
that O +
Nmi O +
augments O +
STAT O +
-mediated O +
transcription O +
in O +
response O +
to O +
these O +
cytokines O +
. O +

Interestingly O +
, O +
Nmi O +
lacks O +
an O +
intrinsic O +
transcriptional O +
activation O +
domain O +
; O +
instead O +
, O +
Nmi O +
enhances O +
the O +
association O +
of O +
CBP O -
/ O -
p300 O +
coactivator O +
proteins O +
with O +
Stat1 O +
and O +
Stat5 O +
, O +
and O +
together O +
with O +
CBP O -
/ O -
p300 O +
can O +
augment O +
IL-2- O +
and O +
IFNgamma O -
- O -
dependent O +
transcription O +
. O +

Therefore O +
, O +
our O +
data O +
not O +
only O +
reveal O +
that O +
Nmi O +
can O +
potentiate O +
STAT O +
-dependent O +
transcription O +
, O +
but O +
also O +
suggest O +
that O +
it O +
can O +
augment O +
coactivator O +
protein O +
recruitment O +
to O +
at O +
least O +
some O +
members O +
of O +
a O +
group O +
of O +
sequence O -
- O -
specific O +
transcription O +
factors O +
. O +

GA O -
- O -
binding O +
protein O +
factors O +
, O +
in O +
concert O +
with O +
the O +
coactivator O +
CREB O +
binding O +
protein O -
/ O -
p300 O +
, O +
control O +
the O +
induction O +
of O +
the O +
interleukin O +
16 O +
promoter O +
in O +
T O +
lymphocytes O +
. O +

Interleukin O +
16 O +
( O +
IL-16 O +
) O +
is O +
a O +
chemotactic O +
cytokine O +
that O +
binds O +
to O +
the O +
CD4 O +
receptor O +
and O +
affects O +
the O +
activation O +
of O +
T O +
cells O +
and O +
replication O +
of O +
HIV O +
. O +

It O +
is O +
expressed O +
as O +
a O +
large O +
67-kDa O +
precursor O +
protein O +
( O +
pro O -
- O -
IL-16 O +
) O +
in O +
lymphocytes O +
, O +
macrophages O +
, O +
and O +
mast O +
cells O +
, O +
as O +
well O +
as O +
in O +
airway O +
epithelial O +
cells O +
from O +
asthmatics O +
after O +
challenge O +
with O +
allergen O +
. O +

This O +
pro O -
- O -
IL-16 O +
is O +
subsequently O +
processed O +
to O +
the O +
mature O +
cytokine O +
of O +
13 O +
kDa O +
. O +

To O +
study O +
the O +
expression O +
of O +
IL-16 O +
at O +
the O +
transcriptional O +
level O +
, O +
we O +
cloned O +
the O +
human O +
chromosomal O +
IL-16 O +
gene O +
and O +
analyzed O +
its O +
promoter O +
. O +

The O +
human O +
IL-16 O +
gene O +
consists O +
of O +
seven O +
exons O +
and O +
six O +
introns O +
. O +

The O +
5 O +
' O +
sequences O +
up O +
to O +
nucleotide O +
-120 O +
of O +
the O +
human O +
and O +
murine O +
IL-16 O +
genes O +
share O +
> O +
84 O +
% O +
sequence O +
homology O +
and O +
harbor O +
promoter O +
elements O +
for O +
constitutive O +
and O +
inducible O +
transcription O +
in O +
T O +
cells O +
. O +

Although O +
both O +
promoters O +
lack O +
any O +
TATA O +
box O +
, O +
they O +
contain O +
two O +
CAAT O +
box O -
- O -
like O +
motifs O +
and O +
three O +
binding O +
sites O +
of O +
GA O -
- O -
binding O +
protein O +
( O +
GABP O +
) O +
transcription O +
factors O +
. O +

Two O +
of O +
these O +
motifs O +
are O +
part O +
of O +
a O +
highly O +
conserved O +
and O +
inducible O +
dyad O +
symmetry O +
element O +
shown O +
previously O +
to O +
control O +
a O +
remote O +
IL-2 O +
enhancer O +
and O +
the O +
CD18 O +
promoter O +
. O +

In O +
concert O +
with O +
the O +
coactivator O +
CREB O +
binding O +
protein O -
/ O -
p300 O +
, O +
which O +
interacts O +
with O +
GABPalpha O +
, O +
the O +
binding O +
of O +
GABPalpha O +
and O +
-beta O +
to O +
the O +
dyad O +
symmetry O +
element O +
controls O +
the O +
induction O +
of O +
IL-16 O +
promoter O +
in O +
T O +
cells O +
. O +

Supplementing O +
the O +
data O +
on O +
the O +
processing O +
of O +
pro O -
- O -
IL-16 O +
, O +
our O +
results O +
indicate O +
the O +
complexity O +
of O +
IL-16 O +
expression O +
, O +
which O +
is O +
tightly O +
controlled O +
at O +
the O +
transcriptional O +
and O +
posttranslational O +
levels O +
in O +
T O +
lymphocytes O +
. O +

RFLAT-1 O +
: O +
a O +
new O +
zinc O +
finger O +
transcription O +
factor O +
that O +
activates O +
RANTES O +
gene O +
expression O +
in O +
T O +
lymphocytes O +
. O +

RANTES O +
( O +
Regulated O +
upon O +
Activation O +
, O +
Normal O +
T O +
cell O +
Expressed O +
and O +
Secreted O +
) O +
is O +
a O +
chemoattractant O +
cytokine O +
( O +
chemokine O +
) O +
important O +
in O +
the O +
generation O +
of O +
inflammatory O +
infiltrate O +
and O +
human O +
immunodeficiency O +
virus O +
entry O +
into O +
immune O +
cells O +
. O +

RANTES O +
is O +
expressed O +
late O +
( O +
3 O -
- O -
5 O +
days O +
) O +
after O +
activation O +
in O +
T O +
lymphocytes O +
. O +

Using O +
expression O +
cloning O +
, O +
we O +
identified O +
the O +
first O +
` O -
` O +
late O +
'' O +
T O +
lymphocyte O +
associated O +
transcription O +
factor O +
and O +
named O +
it O +
` O -
` O +
RANTES O +
Factor O +
of O +
Late O +
Activated O +
T O +
Lymphocytes-1 O +
` O -
` O +
( O +
RFLAT-1 O +
) O +
. O +

RFLAT-1 O +
is O +
a O +
novel O +
, O +
phosphorylated O +
, O +
zinc O +
finger O +
transcription O +
factor O +
that O +
is O +
expressed O +
in O +
T O +
cells O +
3 O +
days O +
after O +
activation O +
, O +
coincident O +
with O +
RANTES O +
expression O +
. O +

While O +
Rel O +
proteins O +
play O +
the O +
dominant O +
role O +
in O +
RANTES O +
gene O +
expression O +
in O +
fibroblasts O +
, O +
RFLAT-1 O +
is O +
a O +
strong O +
transactivator O +
for O +
RANTES O +
in O +
T O +
cells O +
. O +

Reactive O +
oxygen O +
intermediate O -
- O -
dependent O +
NF O -
- O -
kappaB O +
activation O +
by O +
interleukin-1beta O +
requires O +
5-lipoxygenase O +
or O +
NADPH O +
oxidase O +
activity O +
. O +

We O +
previously O +
reported O +
that O +
the O +
role O +
of O +
reactive O +
oxygen O +
intermediates O +
( O +
ROIs O +
) O +
in O +
NF O -
- O -
kappaB O +
activation O +
by O +
proinflammatory O +
cytokines O +
was O +
cell O +
specific O +
. O +

However O +
, O +
the O +
sources O +
for O +
ROIs O +
in O +
various O +
cell O +
types O +
are O +
yet O +
to O +
be O +
determined O +
and O +
might O +
include O +
5-lipoxygenase O +
( O +
5-LOX O +
) O +
and O +
NADPH O +
oxidase O +
. O +

5-LOX O +
and O +
5-LOX O +
activating O +
protein O +
( O +
FLAP O +
) O +
are O +
coexpressed O +
in O +
lymphoid O +
cells O +
but O +
not O +
in O +
monocytic O +
or O +
epithelial O +
cells O +
. O +

Stimulation O +
of O +
lymphoid O +
cells O +
with O +
interleukin-1beta O +
( O +
IL-1beta O +
) O +
led O +
to O +
ROI O +
production O +
and O +
NF O -
- O -
kappaB O +
activation O +
, O +
which O +
could O +
both O +
be O +
blocked O +
by O +
antioxidants O +
or O +
FLAP O +
inhibitors O +
, O +
confirming O +
that O +
5-LOX O +
was O +
the O +
source O +
of O +
ROIs O +
and O +
was O +
required O +
for O +
NF O -
- O -
kappaB O +
activation O +
in O +
these O +
cells O +
. O +

IL-1beta O +
stimulation O +
of O +
epithelial O +
cells O +
did O +
not O +
generate O +
any O +
ROIs O +
and O +
NF O -
- O -
kappaB O +
induction O +
was O +
not O +
influenced O +
by O +
5-LOX O +
inhibitors O +
. O +

However O +
, O +
reintroduction O +
of O +
a O +
functional O +
5-LOX O +
system O +
in O +
these O +
cells O +
allowed O +
ROI O +
production O +
and O +
5-LOX O +
-dependent O +
NF O -
- O -
kappaB O +
activation O +
. O +

In O +
monocytic O +
cells O +
, O +
IL-1beta O +
treatment O +
led O +
to O +
a O +
production O +
of O +
ROIs O +
which O +
is O +
independent O +
of O +
the O +
5-LOX O +
enzyme O +
but O +
requires O +
the O +
NADPH O +
oxidase O +
activity O +
. O +

This O +
pathway O +
involves O +
the O +
Rac1 O +
and O +
Cdc42 O +
GTPases O +
, O +
two O +
enzymes O +
which O +
are O +
not O +
required O +
for O +
NF O -
- O -
kappaB O +
activation O +
by O +
IL-1beta O +
in O +
epithelial O +
cells O +
. O +

In O +
conclusion O +
, O +
three O +
different O +
cell O -
- O -
specific O +
pathways O +
lead O +
to O +
NF O -
- O -
kappaB O +
activation O +
by O +
IL-1beta O +
: O +
a O +
pathway O +
dependent O +
on O +
ROI O +
production O +
by O +
5-LOX O +
in O +
lymphoid O +
cells O +
, O +
an O +
ROI- O +
and O +
5-LOX O +
-independent O +
pathway O +
in O +
epithelial O +
cells O +
, O +
and O +
a O +
pathway O +
requiring O +
ROI O +
production O +
by O +
NADPH O +
oxidase O +
in O +
monocytic O +
cells O +
. O +

Activation O -
- O -
dependent O +
transcriptional O +
regulation O +
of O +
the O +
human O +
Fas O +
promoter O +
requires O +
NF O -
- O -
kappaB O +
p50-p65 O +
recruitment O +
. O +

Fas O +
( O +
CD95 O +
) O +
and O +
Fas O +
ligand O +
( O +
CD95L O +
) O +
are O +
an O +
interacting O +
receptor O -
- O -
ligand O +
pair O +
required O +
for O +
immune O +
homeostasis O +
. O +

Lymphocyte O +
activation O +
results O +
in O +
the O +
upregulation O +
of O +
Fas O +
expression O +
and O +
the O +
acquisition O +
of O +
sensitivity O +
to O +
FasL O +
-mediated O +
apoptosis O +
. O +

Although O +
Fas O +
upregulation O +
is O +
central O +
to O +
the O +
preservation O +
of O +
immunologic O +
tolerance O +
, O +
little O +
is O +
known O +
about O +
the O +
molecular O +
machinery O +
underlying O +
this O +
process O +
. O +

To O +
investigate O +
the O +
events O +
involved O +
in O +
activation O -
- O -
induced O +
Fas O +
upregulation O +
, O +
we O +
have O +
examined O +
mRNA O +
accumulation O +
, O +
fas O +
promoter O +
activity O +
, O +
and O +
protein O +
expression O +
in O +
the O +
Jurkat B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
treated O +
with O +
phorbol O +
myristate O +
acetate O +
and O +
ionomycin O +
( O +
P O -
/ O -
I O +
) O +
, O +
pharmacological O +
mimics O +
of O +
T O -
- O -
cell O +
receptor O +
activation O +
. O +

Although O +
resting B-CellLine +
Jurkat I-CellLine +
cells I-CellLine +
express O +
Fas O +
, O +
Fas O +
mRNA O +
was O +
induced O +
approximately O +
10-fold O +
in O +
2 O +
h O +
upon O +
P O -
/ O -
I O +
stimulation O +
. O +

Using O +
sequential O +
deletion O +
mutants O +
of O +
the O +
human O +
fas O +
promoter O +
in O +
transient O +
transfection O +
assays O +
, O +
we O +
identified O +
a O +
47-bp O +
sequence O +
( O +
positions O +
-306 O +
to O +
-260 O +
relative O +
to O +
the O +
ATG O +
) O +
required O +
for O +
activation O -
- O -
driven O +
fas O +
upregulation O +
. O +

Sequence O +
analysis O +
revealed O +
the O +
presence O +
of O +
a O +
previously O +
unrecognized O +
composite O +
binding O +
site O +
for O +
both O +
the O +
Sp1 O +
and O +
NF O -
- O -
kappaB O +
transcription O +
factors O +
at O +
positions O +
-295 O +
to O +
-286 O +
. O +

Electrophoretic O +
mobility O +
shift O +
assay O +
( O +
EMSA O +
) O +
and O +
supershift O +
analyses O +
of O +
this O +
region O +
documented O +
constitutive O +
binding O +
of O +
Sp1 O +
in O +
unactivated O +
nuclear O +
extracts O +
and O +
inducible O +
binding O +
of O +
p50-p65 O +
NF O -
- O -
kappaB O +
heterodimers O +
after O +
P O -
/ O -
I O +
activation O +
. O +

Sp1 O +
and O +
NF O -
- O -
kappaB O +
transcription O +
factor O +
binding O +
was O +
shown O +
to O +
be O +
mutually O +
exclusive O +
by O +
EMSA O +
displacement O +
studies O +
with O +
purified O +
recombinant O +
Sp1 O +
and O +
recombinant O +
p50 O +
. O +

The O +
functional O +
contribution O +
of O +
the O +
kappaB O -
- O -
Sp1 O +
composite O +
site O +
in O +
P O -
/ O -
I O -
- O -
inducible O +
fas O +
promoter O +
activation O +
was O +
verified O +
by O +
using O +
kappaB- O +
Sp1 O +
concatamers O +
( O +
-295 O +
to O +
-286 O +
) O +
in O +
a O +
thymidine O +
kinase O +
promoter O -
- O -
driven O +
reporter O +
construct O +
and O +
native O +
promoter O +
constructs O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
overexpressing O +
IkappaB O -
- O -
alpha O +
. O +

Site O -
- O -
directed O +
mutagenesis O +
of O +
the O +
critical O +
guanine O +
nucleotides O +
in O +
the O +
kappaB O -
- O -
Sp1 O +
element O +
documented O +
the O +
essential O +
role O +
of O +
this O +
site O +
in O +
activation O -
- O -
dependent O +
fas O +
promoter O +
induction O +
. O +

Daidzein O +
and O +
genistein O +
glucuronides O +
in O +
vitro O +
are O +
weakly O +
estrogenic O +
and O +
activate O +
human O +
natural O +
killer O +
cells O +
at O +
nutritionally O +
relevant O +
concentrations O +
. O +

Daidzein O +
and O +
genistein O +
glucuronides O +
( O +
DG O +
and O +
GG O +
) O +
, O +
major O +
isoflavone O +
metabolites O +
, O +
may O +
be O +
partly O +
responsible O +
for O +
biological O +
effects O +
of O +
isoflavones O +
, O +
such O +
as O +
estrogen O +
receptor O +
binding O +
and O +
natural O +
killer O +
cell O +
( O +
NK O +
) O +
activation O +
or O +
inhibition O +
. O +

DG O +
and O +
GG O +
were O +
synthesized O +
using O +
3-methylcholanthrene O -
- O -
induced O +
rat O +
liver O +
microsomes O +
. O +

The O +
Km O +
and O +
Vmax O +
for O +
daidzein O +
and O +
genistein O +
were O +
9.0 O +
and O +
7.7 O +
micromol O -
/ O -
L O +
, O +
and O +
0.7 O +
and O +
1.6 O +
micromol O -
/ O +
( O +
mg O +
protein O -
. O +
min O +
) O +
, O +
respectively O +
. O +

The O +
absence O +
of O +
ultraviolet O +
absorbance O +
maxima O +
shifts O +
in O +
the O +
presence O +
of O +
sodium O +
acetate O +
confirmed O +
that O +
the O +
synthesized O +
products O +
were O +
7-O O -
- O -
glucuronides O +
. O +

DG O +
and O +
GG O +
were O +
further O +
purified O +
by O +
a O +
Sephadex O +
LH-20 O +
column O +
. O +

DG O +
and O +
GG O +
competed O +
with O +
the O +
binding O +
of O +
17beta- O +
( O +
3H O +
) O +
estradiol O +
to O +
estrogen O +
receptors O +
of O +
B6D2F1 O +
mouse O +
uterine O +
cytosol O +
. O +

The O +
concentrations O +
required O +
for O +
50 O +
% O +
displacement O +
of O +
17beta- O +
( O +
3H O +
) O +
estradiol O +
( O +
CB50 O +
) O +
were O +
: O +
17beta O -
- O -
estradiol O +
, O +
1.34 O +
nmol O -
/ O -
L O +
; O +
diethylstilbestrol O +
, O +
1.46 O +
nmol O -
/ O -
L O +
; O +
daidzein O +
, O +
1.6 O +
micromol O -
/ O -
L O +
; O +
DG O +
, O +
14.7 O +
micromol O -
/ O -
L O +
; O +
genistein O +
, O +
0.154 O +
micromol O -
/ O -
L O +
; O +
GG O +
, O +
7.27 O +
micromol O -
/ O -
L O +
. O +

In O +
human O +
peripheral O +
blood O +
NK O +
cells O +
, O +
genistein O +
at O +
< O +
0.5 O +
micromol O -
/ O -
L O +
and O +
DG O +
and O +
GG O +
at O +
0.1 O -
- O -
10 O +
micromol O -
/ O -
L O +
enhanced O +
NK O +
cell O -
- O -
mediated O +
K562 B-CellLine +
cancer I-CellLine +
cell I-CellLine +
killing O +
significantly O +
( O +
P O +
< O +
0.05 O +
) O +
. O +

At O +
> O +
0.5 O +
micromol O -
/ O -
L O +
, O +
genistein O +
inhibited O +
NK O +
cytotoxicity O +
significantly O +
( O +
P O +
< O +
0.05 O +
) O +
. O +

The O +
glucuronides O +
only O +
inhibited O +
NK O +
cytotoxicity O +
at O +
50 O +
micromol O -
/ O -
L O +
. O +

Isoflavones O +
, O +
and O +
especially O +
the O +
isoflavone O +
glucuronides O +
, O +
enhanced O +
activation O +
of O +
NK O +
cells O +
by O +
interleukin-2 O +
( O +
IL-2 O +
) O +
, O +
additively O +
. O +

At O +
physiological O +
concentrations O +
, O +
DG O +
and O +
GG O +
were O +
weakly O +
estrogenic O +
, O +
and O +
they O +
activated O +
human O +
NK O +
cells O +
in O +
nutritionally O +
relevant O +
concentrations O +
in O +
vitro O +
, O +
probably O +
at O +
a O +
site O +
different O +
from O +
IL-2 O +
action O +
. O +

Differential O +
expression O +
and O +
phosphorylation O +
of O +
CTCF O +
, O +
a O +
c O -
- O -
myc O +
transcriptional O +
regulator O +
, O +
during O +
differentiation O +
of O +
human O +
myeloid O +
cells O +
. O +

CTCF O +
is O +
a O +
transcriptional O +
repressor O +
of O +
the O +
c O -
- O -
myc O +
gene O +
. O +

Although O +
CTCF O +
has O +
been O +
characterized O +
in O +
some O +
detail O +
, O +
there O +
is O +
very O +
little O +
information O +
about O +
the O +
regulation O +
of O +
CTCF O +
activity O +
. O +

Therefore O +
we O +
investigated O +
CTCF O +
expression O +
and O +
phosphorylation O +
during O +
induced O +
differentiation O +
of O +
human O +
myeloid O +
leukemia O +
cells O +
. O +

We O +
found O +
that O +
: O +
( O +
i O +
) O +
both O +
CTCF O +
mRNA O +
and O +
protein O +
are O +
down O -
- O -
regulated O +
during O +
terminal O +
differentiation O +
in O +
most O +
cell O +
lines O +
tested O +
; O +
( O +
ii O +
) O +
CTCF O +
down O -
- O -
regulation O +
is O +
retarded O +
and O +
less O +
pronounced O +
than O +
that O +
of O +
c O -
- O -
myc O +
; O +
( O +
iii O +
) O +
CTCF O +
protein O +
is O +
differentially O +
phosphorylated O +
and O +
the O +
phosphorylation O +
profiles O +
depend O +
on O +
the O +
differentiation O +
pathway O +
. O +

We O +
concluded O +
that O +
CTCF O +
expression O +
and O +
activity O +
is O +
controlled O +
at O +
transcriptional O +
and O +
post O -
- O -
transcriptional O +
levels O +
. O +

The O +
Megakaryocyte O -
/ O -
Platelet O -
- O -
specific O +
enhancer O +
of O +
the O +
alpha2beta1 O +
integrin O +
gene O +
: O +
two O +
tandem O +
AP1 O +
sites O +
and O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
signaling O +
cascade O +
. O +

The O +
alpha2beta1 O +
integrin O +
, O +
a O +
collagen O +
receptor O +
on O +
platelets O +
and O +
megakaryocytes O +
, O +
is O +
required O +
for O +
normal O +
platelet O +
function O +
. O +

Transcriptional O +
regulation O +
of O +
the O +
alpha2 O +
integrin O +
gene O +
in O +
cells O +
undergoing O +
megakaryocytic O +
differentiation O +
requires O +
a O +
core O +
promoter O +
between O +
bp O +
-30 O +
and O +
-92 O +
, O +
a O +
silencer O +
between O +
bp O +
-92 O +
and O +
-351 O +
, O +
and O +
megakaryocytic O +
enhancers O +
in O +
the O +
distal O +
5 O +
' O +
flank O +
. O +

We O +
have O +
now O +
identified O +
a O +
229-bp O +
region O +
of O +
the O +
distal O +
5 O +
' O +
flank O +
of O +
the O +
alpha2 O +
integrin O +
gene O +
required O +
for O +
high O -
- O -
level O +
enhancer O +
activity O +
in O +
cells O +
with O +
megakaryocytic O +
features O +
. O +

Two O +
tandem O +
AP1 O +
binding O +
sites O +
with O +
dyad O +
symmetry O +
are O +
required O +
for O +
enhancer O +
activity O +
and O +
for O +
DNA O -
- O -
protein O +
complex O +
formation O +
with O +
members O +
of O +
the O +
c O -
- O -
fos O -
/ O -
c O -
- O -
jun O +
family O +
. O +

The O +
requirement O +
for O +
AP1 O +
activation O +
suggested O +
a O +
role O +
for O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
signaling O +
pathway O +
in O +
regulating O +
alpha2 O +
integrin O +
gene O +
expression O +
. O +

Inhibition O +
of O +
the O +
MAP O +
kinase O +
cascade O +
with O +
PD98059 O +
, O +
a O +
specific O +
inhibitor O +
of O +
MAPK O +
kinase O +
1 O +
, O +
prevented O +
the O +
expression O +
of O +
the O +
alpha2 O +
integrin O +
subunit O +
in O +
cells O +
induced O +
to O +
become O +
megakaryocytic O +
. O +

We O +
provide O +
a O +
model O +
of O +
megakaryocytic O +
differentiation O +
in O +
which O +
expression O +
of O +
the O +
alpha2 O +
integrin O +
gene O +
requires O +
signaling O +
via O +
the O +
MAP O +
kinase O +
pathway O +
to O +
activate O +
two O +
tandem O +
AP1 O +
binding O +
sites O +
in O +
the O +
alpha2 O +
integrin O +
enhancer O +
. O +

Clonality O +
of O +
isolated O +
eosinophils O +
in O +
the O +
hypereosinophilic O +
syndrome O +
. O +

The O +
idiopathic O +
hypereosinophilic O +
syndrome O +
( O +
IHES O +
) O +
is O +
a O +
rare O +
disorder O +
characterized O +
by O +
unexplained O +
, O +
persistent O +
eosinophilia O +
associated O +
with O +
multiple O +
organ O +
dysfunction O +
due O +
to O +
eosinophilic O +
tissue O +
infiltration O +
. O +

In O +
the O +
absence O +
of O +
karyotypic O +
abnormalities O +
, O +
there O +
is O +
no O +
specific O +
test O +
to O +
detect O +
clonal O +
eosinophilia O +
in O +
IHES O +
. O +

Analysis O +
of O +
X O -
- O -
chromosome O +
inactivation O +
patterns O +
can O +
be O +
used O +
to O +
determine O +
whether O +
proliferative O +
disorders O +
are O +
clonal O +
in O +
origin O +
. O +

Methylation O +
of O +
HpaII O +
and O +
Hha O +
I O +
sites O +
near O +
the O +
polymorphic O +
trinucleotide O +
repeat O +
of O +
the O +
human O +
androgen O +
receptor O +
gene O +
( O +
HUMARA O +
) O +
has O +
been O +
shown O +
to O +
correlate O +
with O +
X O -
- O -
inactivation O +
. O +

In O +
this O +
study O +
, O +
we O +
have O +
used O +
the O +
polymerase O +
chain O +
reaction O +
( O +
PCR O +
) O +
with O +
nested O +
primers O +
to O +
analyze O +
X O -
- O -
inactivation O +
patterns O +
of O +
the O +
HUMARA O +
loci O +
in O +
purified O +
eosinophils O +
from O +
female O +
patients O +
with O +
eosinophilia O +
. O +

Peripheral O +
blood O +
eosinophils O +
were O +
isolated O +
by O +
their O +
autofluoresence O +
using O +
flow O +
cytometric O +
sorting O +
. O +

Eosinophils O +
purified O +
from O +
a O +
female O +
patient O +
presenting O +
with O +
IHES O +
were O +
found O +
to O +
show O +
a O +
clonal O +
pattern O +
of O +
X O -
- O -
inactivation O +
. O +

Eosinophil O -
- O -
depleted O +
leukocytes O +
from O +
this O +
patient O +
were O +
polyclonal O +
by O +
HUMARA O +
analysis O +
, O +
thus O +
excluding O +
skewedness O +
of O +
random O +
X O -
- O -
inactivation O +
. O +

After O +
corticosteroid O +
suppression O +
of O +
her O +
blood O +
eosinophilia O +
, O +
a O +
clonal O +
population O +
of O +
eosinophils O +
could O +
no O +
longer O +
be O +
detected O +
in O +
purified O +
eosinophils O +
. O +

In O +
contrast O +
, O +
eosinophils O +
purified O +
from O +
a O +
patient O +
with O +
Churg O -
- O -
Strauss O +
syndrome O +
and O +
from O +
six O +
patients O +
with O +
reactive O +
eosinophilias O +
attributed O +
to O +
allergy O +
, O +
parasitic O +
infection O +
, O +
or O +
drug O +
reaction O +
showed O +
a O +
polyclonal O +
pattern O +
of O +
X O -
- O -
inactivation O +
by O +
HUMARA O +
analysis O +
. O +

The O +
finding O +
of O +
clonal O +
eosinophilia O +
in O +
a O +
patient O +
presenting O +
with O +
IHES O +
indicates O +
that O +
such O +
patients O +
may O +
have O +
, O +
in O +
reality O +
, O +
a O +
low O -
- O -
grade O +
clonal O +
disorder O +
that O +
can O +
be O +
distinguished O +
from O +
reactive O +
eosinophilias O +
by O +
HUMARA O +
analysis O +
. O +

Further O +
, O +
the O +
method O +
described O +
can O +
be O +
used O +
to O +
monitor O +
disease O +
progression O +
. O +

Peripheral O +
blood O +
mononuclear O +
cells O +
isolated O +
from O +
patients O +
with O +
diabetic O +
nephropathy O +
show O +
increased O +
activation O +
of O +
the O +
oxidative O -
- O -
stress O +
sensitive O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
. O +

Increased O +
oxidative O +
stress O +
and O +
subsequent O +
activation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
has O +
been O +
linked O +
to O +
the O +
development O +
of O +
late O +
diabetic O +
complications O +
. O +

To O +
determine O +
whether O +
oxidative O +
stress O +
dependent O +
NF O -
- O -
kappaB O +
activation O +
is O +
evident O +
in O +
patients O +
with O +
diabetic O +
nephropathy O +
we O +
used O +
an O +
Electrophoretic O +
Mobility O +
Shift O +
Assay O +
based O +
semiquantitative O +
detection O +
system O +
which O +
enabled O +
us O +
to O +
determine O +
NF O -
- O -
kappaB O +
activation O +
in O +
ex O +
vivo O +
isolated O +
peripheral O +
blood O +
mononuclear O +
cells O +
. O +

We O +
examined O +
33 O +
patients O +
with O +
diabetes O +
mellitus O +
( O +
Type O +
I O +
and O +
Type O +
II O +
) O +
. O +

Patients O +
with O +
diabetic O +
nephropathy O +
showed O +
higher O +
NF O -
- O -
kappaB O +
binding O +
activity O +
in O +
Electrophoretic O +
Mobility O +
Shift O +
Assays O +
and O +
stronger O +
immunohistological O +
staining O +
for O +
activated O +
NF O -
- O -
kappaBp65 O +
than O +
patients O +
without O +
renal O +
complications O +
. O +

NF O -
- O -
kappaB O +
binding O +
activity O +
correlated O +
with O +
the O +
degree O +
of O +
albuminuria O +
( O +
r O +
= O +
0.316 O +
) O +
and O +
with O +
thrombomodulin O +
plasma O +
concentrations O +
( O +
r O +
= O +
0.33 O +
) O +
, O +
indicative O +
for O +
albuminuria O +
associated O +
endothelial O +
dysfunction O +
. O +

In O +
a O +
3 O +
day O +
intervention O +
study O +
in O +
which O +
600 O +
mg O +
of O +
the O +
antioxidant O +
thioctic O +
acid O +
( O +
alpha O -
- O -
lipoic O +
acid O +
) O +
per O +
day O +
were O +
given O +
to O +
nine O +
patients O +
with O +
diabetic O +
nephropathy O +
oxidative O +
stress O +
in O +
plasma O +
samples O +
was O +
decreased O +
by O +
48 O +
% O +
and O +
NF O -
- O -
kappaB O +
binding O +
activity O +
in O +
ex O +
vivo O +
isolated O +
peripheral O +
blood O +
mononuclear O +
cells O +
by O +
38 O +
% O +
. O +

In O +
conclusion O +
, O +
activation O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
in O +
ex O +
vivo O +
isolated O +
peripheral O +
blood O +
mononuclear O +
cells O +
of O +
patients O +
with O +
diabetes O +
mellitus O +
correlates O +
with O +
the O +
degree O +
of O +
diabetic O +
nephropathy O +
. O +

NF O -
- O -
kappaB O +
activation O +
is O +
at O +
least O +
in O +
part O +
dependent O +
on O +
oxidative O +
stress O +
since O +
thioctic O +
acid O +
( O +
alpha O -
- O -
lipoic O +
acid O +
) O +
reduced O +
NF O -
- O -
kappaB O +
binding O +
activity O +
. O +

Crossreactive O +
recognition O +
of O +
viral O +
, O +
self O +
, O +
and O +
bacterial O +
peptide O +
ligands O +
by O +
human O +
class O +
I O -
- O -
restricted O +
cytotoxic O +
T O +
lymphocyte O +
clonotypes O +
: O +
implications O +
for O +
molecular O +
mimicry O +
in O +
autoimmune O +
disease O +
. O +

The O +
immunodominant O +
, O +
CD8 O +
( O +
+ O +
) O +
cytotoxic O +
T O +
lymphocyte O +
( O +
CTL O +
) O +
response O +
to O +
the O +
HLA O -
- O -
B8-restricted O +
peptide O +
, O +
RAKFKQLL O +
, O +
located O +
in O +
the O +
Epstein O -
- O -
Barr O +
virus O +
immediate O -
- O -
early O +
antigen O +
, O +
BZLF1 O +
, O +
is O +
characterized O +
by O +
a O +
diverse O +
T O +
cell O +
receptor O +
( O +
TCR O +
) O +
repertoire O +
. O +

Here O +
, O +
we O +
show O +
that O +
this O +
diversity O +
can O +
be O +
partitioned O +
on O +
the O +
basis O +
of O +
crossreactive O +
cytotoxicity O +
patterns O +
involving O +
the O +
recognition O +
of O +
a O +
self O +
peptide O -
- O -
RSKFRQIV O -
- O -
located O +
in O +
a O +
serine O -
/ O -
threonine O +
kinase O +
and O +
a O +
bacterial O +
peptide O -
- O -
RRKYKQII O -
- O -
located O +
in O +
Staphylococcus O +
aureus O +
replication O +
initiation O +
protein O +
. O +

Thus O +
CTL B-CellLine +
clones I-CellLine +
that O +
recognized O +
the O +
viral O +
, O +
self O +
, O +
and O +
bacterial O +
peptides O +
expressed O +
a O +
highly O +
restricted O +
alphabeta O +
TCR O +
phenotype O +
. O +

The O +
CTL B-CellLine +
clones I-CellLine +
that O +
recognized O +
viral O +
and O +
self O +
peptides O +
were O +
more O +
oligoclonal O +
, O +
whereas O +
clones O +
that O +
strictly O +
recognized O +
the O +
viral O +
peptide O +
displayed O +
a O +
diverse O +
TCR O +
profile O +
. O +

Interestingly O +
, O +
the O +
self O +
and O +
bacterial O +
peptides O +
equally O +
were O +
substantially O +
less O +
effective O +
than O +
the O +
cognate O +
viral O +
peptide O +
in O +
sensitizing O +
target O +
cell O +
lysis O +
, O +
and O +
also O +
resulted O +
only O +
in O +
a O +
weak O +
reactivation O +
of O +
memory O +
CTLs O +
in O +
limiting O +
dilution O +
assays O +
, O +
whereas O +
the O +
cognate O +
peptide O +
was O +
highly O +
immunogenic O +
. O +

The O +
described O +
crossreactions O +
show O +
that O +
human O +
antiviral O +
, O +
CD8 O +
( O +
+ O +
) O +
CTL O +
responses O +
can O +
be O +
shaped O +
by O +
peptide O +
ligands O +
derived O +
from O +
autoantigens O +
and O +
environmental O +
bacterial O +
antigens O +
, O +
thereby O +
providing O +
a O +
firm O +
structural O +
basis O +
for O +
molecular O +
mimicry O +
involving O +
class O +
I B-CellLine -
- I-CellLine -
restricted I-CellLine +
CTLs I-CellLine +
in O +
the O +
pathogenesis O +
of O +
autoimmune O +
disease O +
. O +

Anti O -
- O -
rheumatic O +
compound O +
aurothioglucose O +
inhibits O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
-induced O +
HIV-1 O +
replication O +
in O +
latently O +
infected O +
OM10.1 B-CellLine +
and I-CellLine +
Ach2 I-CellLine +
cells I-CellLine +
. O +

NF O -
- O -
kappaB O +
is O +
a O +
potent O +
cellular O +
activator O +
of O +
HIV-1 O +
gene O +
expression O +
. O +

Down O -
- O -
regulation O +
of O +
NF O -
- O -
kappaB O +
activation O +
is O +
known O +
to O +
inhibit O +
HIV O +
replication O +
from O +
the O +
latently O +
infected O +
cells O +
. O +

Gold O +
compounds O +
have O +
been O +
effectively O +
used O +
for O +
many O +
decades O +
in O +
the O +
treatment O +
of O +
rheumatoid O +
arthritis O +
. O +

We O +
previously O +
reported O +
that O +
gold O +
compounds O +
, O +
especially O +
aurothioglucose O +
( O +
AuTG O +
) O +
containing O +
monovalent O +
gold O +
ion O +
, O +
inhibited O +
the O +
DNA O -
- O -
binding O +
of O +
NF O -
- O -
kappaB O +
in O +
vitro O +
. O +

In O +
this O +
report O +
we O +
have O +
examined O +
the O +
efficacy O +
of O +
the O +
gold O +
compound O +
AuTG O +
as O +
an O +
inhibitor O +
of O +
HIV O +
replication O +
in O +
latently O +
infected O +
OM10.1 B-CellLine +
and I-CellLine +
Ach2 I-CellLine +
cells I-CellLine +
. O +

Tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
-alpha O +
-induced O +
HIV-1 O +
replication O +
in O +
OM10.1 B-CellLine +
or O +
Ach2 B-CellLine +
cells I-CellLine +
was O +
significantly O +
inhibited O +
by O +
non O -
- O -
cytotoxic O +
doses O +
of O +
AuTG O +
( O +
> O +
10 O +
microM O +
in O +
OM10.1 O +
cells O +
and O +
> O +
25 O +
F.M O +
in O +
Ach2 B-CellLine +
cells I-CellLine +
) O +
, O +
while O +
25 O +
microM O +
of O +
the O +
counter O -
- O -
anion O +
thioglucose O +
( O +
TG O +
) O +
or O +
gold O +
compound O +
containing O +
divalent O +
gold O +
ion O +
, O +
HAuCl3 O +
, O +
had O +
no O +
effect O +
. O +

The O +
effect O +
of O +
AuTG O +
on O +
NF O -
- O -
kappaB O +
-dependent O +
gene O +
expression O +
was O +
confirmed O +
by O +
a O +
transient O +
CAT O +
assay O +
. O +

Specific O +
staining O +
as O +
well O +
as O +
electron O +
microscopic O +
examinations O +
revealed O +
the O +
accumulation O +
of O +
metal O +
gold O +
in O +
the O +
cells O +
, O +
supporting O +
our O +
previous O +
hypothesis O +
that O +
gold O +
ions O +
could O +
block O +
NF O -
- O -
kappaB O +
-DNA O +
binding O +
by O +
a O +
redox O +
mechanism O +
. O +

These O +
observations O +
indicate O +
that O +
the O +
monovalent O +
gold O +
compound O +
AuTG O +
is O +
a O +
potentially O +
useful O +
drug O +
for O +
the O +
treatment O +
of O +
patients O +
infected O +
with O +
HIV O +
. O +

Evidence O +
for O +
suppressed O +
activity O +
of O +
the O +
transcription O +
factor O +
NFAT1 O +
at O +
its O +
proximal O +
binding O +
element O +
P0 O +
in O +
the O +
IL-4 O +
promoter O +
associated O +
with O +
enhanced O +
IL-4 O +
gene O +
transcription O +
in O +
T O +
cells O +
of O +
atopic O +
patients O +
. O +

Allergen O -
- O -
specific O +
T O +
cells O +
in O +
atopic O +
patients O +
are O +
polarized O +
IL-4-producing B-CellLine +
Th2 I-CellLine +
cells I-CellLine +
, O +
promoting O +
IgE O +
synthesis O +
by O +
B O +
cells O +
. O +

The O +
molecular O +
basis O +
for O +
increased O +
IL-4 O +
gene O +
expression O +
in O +
atopy O +
is O +
not O +
fully O +
understood O +
. O +

IL-4 O +
gene O +
regulation O +
in O +
general O +
involves O +
the O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
family O +
of O +
transcription O +
factors O +
, O +
of O +
which O +
NFAT1 O +
and O +
NFAT2 O +
are O +
most O +
prominent O +
in O +
peripheral O +
T O +
cells O +
. O +

Recently O +
, O +
a O +
unique O +
inhibitory O +
role O +
of O +
NFAT1 O +
in O +
IL-4 O +
gene O +
control O +
was O +
shown O +
in O +
the O +
mouse O +
. O +

In O +
a O +
series O +
of O +
electrophoretic O +
mobility O +
shift O +
assays O +
with O +
protein O +
extracts O +
of O +
highly B-CellLine +
polarized I-CellLine +
Th2 I-CellLine +
clones I-CellLine +
from O +
atopics O +
and O +
Th1 B-CellLine +
clones I-CellLine +
from O +
controls O +
we O +
compared O +
DNA O -
- O -
binding O +
activities O +
at O +
the O +
two O +
NFAT O -
- O -
binding O +
elements O +
P0 O +
and O +
P1 O +
of O +
the O +
crucial O +
proximal O +
human O +
IL-4 O +
promoter O +
. O +

At O +
the O +
most O +
proximal O +
P0 O +
site O +
, O +
NFAT O -
- O -
containing O +
complexes O +
devoid O +
of O +
NFAT2 O +
were O +
readily O +
inducible O +
in O +
the O +
Th1 B-CellLine +
clones I-CellLine +
, O +
but O +
hardly O +
or O +
not O +
in O +
the O +
Th2 B-CellLine +
clones I-CellLine +
. O +

In O +
contrast O +
, O +
both O +
in O +
Th1 B-CellLine +
and I-CellLine +
Th2 I-CellLine +
clones I-CellLine +
NFAT O -
- O -
containing O +
complexes O +
were O +
strongly O +
inducible O +
at O +
the O +
P1 O +
site O +
, O +
consisting O +
of O +
NFAT2 O +
and O +
a O +
P0 O +
-compatible O +
NFAT O +
activity O +
, O +
without O +
apparent O +
differences O +
between O +
Th1 B-CellLine +
and I-CellLine +
Th2 I-CellLine +
clones I-CellLine +
. O +

Like O +
in O +
Th2 B-CellLine +
clones I-CellLine +
, O +
suppressed O +
NFAT- O +
P0 O +
complex O +
formation O +
was O +
observed O +
also O +
at O +
the O +
polyclonal O +
level O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
of O +
three O +
of O +
five O +
severe O +
atopic O +
dermatitis O +
patients O +
with O +
strongly O +
elevated O +
serum O +
IgE O +
levels O +
, O +
but O +
not O +
in O +
control O +
PBMC O +
. O +

These O +
findings O +
suggest O +
that O +
high O -
- O -
level O +
IL-4 O +
production O +
in O +
atopic O +
Th2 O +
cells O +
is O +
associated O +
with O +
selective O +
reduction O +
of O +
suppressive O +
NFAT1 O +
activity O +
at O +
the O +
IL-4 O +
P0 O +
element O +
and O +
that O +
some O +
patients O +
with O +
this O +
multifactorial O +
disease O +
may O +
have O +
a O +
putative O +
systemic O +
disorder O +
at O +
this O +
level O +
. O +

Interferon O -
- O -
alpha O +
activates O +
multiple O +
STAT O +
proteins O +
and O +
upregulates O +
proliferation O -
- O -
associated O +
IL-2Ralpha O +
, O +
c O -
- O -
myc O +
, O +
and O +
pim-1 O +
genes O +
in O +
human O +
T O +
cells O +
. O +

Interferon O -
- O -
alpha O +
( O +
IFN O -
- O -
alpha O +
) O +
is O +
a O +
pleiotropic O +
cytokine O +
that O +
has O +
antiviral O +
, O +
antiproliferative O +
, O +
and O +
immunoregulatory O +
functions O +
. O +

There O +
is O +
increasing O +
evidence O +
that O +
IFN O -
- O -
alpha O +
has O +
an O +
important O +
role O +
in O +
T O -
- O -
cell O +
biology O +
. O +

We O +
have O +
analyzed O +
the O +
expression O +
of O +
IL-2Ralpha O +
, O +
c O -
- O -
myc O +
, O +
and O +
pim-1 O +
genes O +
in O +
anti O -
- O -
CD3-activated O +
human O +
T O +
lymphocytes O +
. O +

The O +
induction O +
of O +
these O +
genes O +
is O +
associated O +
with O +
interleukin-2 O +
( O +
IL-2 O +
) O +
-induced O +
T O -
- O -
cell O +
proliferation O +
. O +

Treatment O +
of O +
T O +
lymphocytes O +
with O +
IFN O -
- O -
alpha O +
, O +
IL-2 O +
, O +
IL-12 O +
, O +
and O +
IL-15 O +
upregulated O +
IL-2Ralpha O +
, O +
c O -
- O -
myc O +
, O +
and O +
pim-1 O +
gene O +
expression O +
. O +

IFN O -
- O -
alpha O +
also O +
sensitized B-CellLine +
T I-CellLine +
cells I-CellLine +
to O +
IL-2 O +
-induced O +
proliferation O +
, O +
further O +
suggesting O +
that O +
IFN O -
- O -
alpha O +
may O +
be O +
involved O +
in O +
the O +
regulation O +
of O +
T O -
- O -
cell O +
mitogenesis O +
. O +

When O +
we O +
analyzed O +
the O +
nature O +
of O +
STAT O +
proteins O +
capable O +
of O +
binding O +
to O +
IL-2Ralpha O +
, O +
pim-1 O +
, O +
and O +
IRF-1 O +
GAS O +
elements O +
after O +
cytokine O +
stimulation O +
, O +
we O +
observed O +
IFN O -
- O -
alpha O +
-induced O +
binding O +
of O +
STAT1 O +
, O +
STAT3 O +
, O +
and O +
STAT4 O +
, O +
but O +
not O +
STAT5 O +
to O +
all O +
of O +
these O +
elements O +
. O +

Yet O +
, O +
IFN O -
- O -
alpha O +
was O +
able O +
to O +
activate O +
binding O +
of O +
STAT5 O +
to O +
the O +
high O -
- O -
affinity O +
IFP53 O +
GAS O +
site O +
. O +

IFN O -
- O -
alpha O +
enhanced O +
tyrosine O +
phosphorylation O +
of O +
STAT1 O +
, O +
STAT3 O +
, O +
STAT4 O +
, O +
STAT5a O +
, O +
and O +
STAT5b O +
. O +

IL-12 O +
induced O +
STAT4 O +
and O +
IL-2 O +
and O +
IL-15 O +
induced O +
STAT5 O +
binding O +
to O +
the O +
GAS O +
elements O +
. O +

Taken O +
together O +
, O +
our O +
results O +
suggest O +
that O +
IFN O -
- O -
alpha O +
, O +
IL-2 O +
, O +
IL-12 O +
, O +
and O +
IL-15 O +
have O +
overlapping O +
activities O +
on O +
human O +
T O +
cells O +
. O +

These O +
findings O +
thus O +
emphasize O +
the O +
importance O +
of O +
IFN O -
- O -
alpha O +
as O +
a O +
T O -
- O -
cell O +
regulatory O +
cytokine O +
. O +

Nuclear O +
factor O -
- O -
kappa O +
B O +
activity O +
in O +
T O +
cells O +
from O +
patients O +
with O +
rheumatic O +
diseases O +
: O +
a O +
preliminary O +
report O +
. O +

OBJECTIVE O +
: O +
The O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
family O +
of O +
transcription O +
factors O +
regulates O +
the O +
expression O +
of O +
many O +
genes O +
involved O +
in O +
the O +
immune O +
or O +
inflammatory O +
response O +
at O +
the O +
transcriptional O +
level O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
determine O +
whether O +
distinctive O +
patterns O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
are O +
seen O +
in O +
different O +
forms O +
of O +
joint O +
disease O +
. O +

METHODS O +
: O +
The O +
DNA O +
binding O +
activity O +
of O +
these O +
nucleoproteins O +
was O +
examined O +
in O +
purified O +
synovial O +
and O +
peripheral O +
T O +
cells O +
from O +
patients O +
with O +
various O +
chronic O +
rheumatic O +
diseases O +
( O +
12 O +
: O +
four O +
with O +
rheumatoid O +
arthritis O +
; O +
five O +
with O +
spondyloarthropathies O +
; O +
and O +
three O +
with O +
osteoarthritis O +
) O +
. O +

RESULTS O +
: O +
Electrophoretic O +
mobility O +
shift O +
assays O +
disclosed O +
two O +
specific O +
complexes O +
bound O +
to O +
a O +
NF O -
- O -
kappa O +
B O +
specific O +
32P O -
- O -
labelled O +
oligonucleotide O +
in O +
nucleoproteins O +
extracted O +
from O +
purified O +
T O +
cells O +
isolated O +
from O +
synovial O +
fluid O +
and O +
peripheral O +
blood O +
of O +
patients O +
with O +
rheumatoid O +
arthritis O +
. O +

The O +
complexes O +
consisted O +
of O +
p50 O -
/ O -
p50 O +
homodimers O +
and O +
p50 O -
/ O -
p65 O +
heterodimers O +
. O +

Increased O +
NF O -
- O -
kappa O +
B O +
binding O +
to O +
DNA O +
in O +
synovial O +
T O +
cells O +
was O +
observed O +
relative O +
to O +
peripheral O +
T O +
cells O +
. O +

In O +
non O -
- O -
rheumatoid O +
arthritis O +
, O +
binding O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
synovial O +
T O +
cells O +
was O +
exclusively O +
mediated O +
by O +
p50 O -
/ O -
p50 O +
homodimers O +
. O +

CONCLUSION O +
: O +
Overall O +
, O +
the O +
results O +
suggest O +
that O +
NF O -
- O -
kappa O +
B O +
may O +
play O +
a O +
central O +
part O +
in O +
the O +
activation O +
of O +
infiltrating O +
T O +
cells O +
in O +
chronic O +
rheumatoid O +
arthritis O +
. O +

The O +
activation O +
of O +
this O +
nuclear O +
factor O +
is O +
qualitatively O +
different O +
in O +
rheumatoid O +
synovial O +
T O +
cells O +
to O +
that O +
in O +
other O +
forms O +
of O +
non O -
- O -
rheumatoid O +
arthritis O +
( O +
for O +
example O +
, O +
osteoarthritis O +
, O +
spondyloarthropathies O +
) O +
. O +

RFX O -
- O -
B O +
is O +
the O +
gene O +
responsible O +
for O +
the O +
most O +
common O +
cause O +
of O +
the O +
bare O +
lymphocyte O +
syndrome O +
, O +
an O +
MHC O +
class O +
II O +
immunodeficiency O +
[ O +
published O +
erratum O +
appears O +
in O +
Immunity O +
1999 O +
Mar O +
; O +
10 O +
( O +
3 O +
) O +
: O +
399 O +
] O +

The O +
bare O +
lymphocyte O +
syndrome O +
( O +
BLS O +
) O +
is O +
characterized O +
by O +
the O +
absence O +
of O +
MHC O +
class O +
II O +
transcription O +
and O +
humoral- O +
and O +
cellular O -
- O -
mediated O +
immune O +
responses O +
to O +
foreign O +
antigens O +
. O +

Three O +
of O +
the O +
four O +
BLS O +
genetic O +
complementation O +
groups O +
have O +
defects O +
in O +
the O +
activity O +
of O +
the O +
MHC O +
class O +
II O +
transcription O +
factor O +
RFX O +
. O +

We O +
have O +
purified O +
the O +
RFX O +
complex O +
and O +
sequenced O +
its O +
three O +
subunits O +
. O +

The O +
sequence O +
of O +
the O +
smallest O +
subunit O +
describes O +
a O +
novel O +
gene O +
, O +
termed O +
RFX O -
- O -
B O +
. O +

RFX O -
- O -
B O +
complements O +
the O +
predominant O +
BLS O +
complementation O +
group O +
( O +
group O +
B O +
) O +
and O +
was O +
found O +
to O +
be O +
mutant O +
in O +
cell B-CellLine +
lines I-CellLine +
from O +
this O +
BLS O +
group O +
. O +

The O +
protein O +
has O +
no O +
known O +
DNA O -
- O -
binding O +
domain O +
but O +
does O +
contain O +
three O +
ankyrin O +
repeats O +
that O +
are O +
likely O +
to O +
be O +
important O +
in O +
protein O -
- O -
protein O +
interactions O +
. O +

Glucocorticoid O +
hormone O +
suppression O +
of O +
human O +
neutrophil O +
-mediated O +
tumor O +
cell O +
cytostasis O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
have O +
investigated O +
the O +
effect O +
of O +
glucocorticoid O +
hormones O +
on O +
neutrophil O +
-mediated O +
tumor O +
cell O +
cytostasis O +
and O +
found O +
that O +
hydrocortisone O +
and O +
a O +
synthetic O +
hormone O +
, O +
dexamethasone O +
( O +
Dex O +
) O +
, O +
inhibited O +
cytostasis O +
in O +
the O +
presence O +
or O +
absence O +
of O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
. O +

The O +
effect O +
of O +
Dex O +
was O +
completely O +
reversed O +
by O +
a O +
glucocorticoid O +
receptor O +
antagonist O +
, O +
RU38486 O +
. O +

To O +
clarify O +
the O +
underlying O +
mechanisms O +
, O +
we O +
examined O +
effects O +
of O +
Dex O +
on O +
the O +
binding O +
avidity O +
of O +
beta2 O +
integrin O +
on O +
the O +
neutrophil O +
surface O +
and O +
how O +
these O +
might O +
in O +
turn O +
affect O +
neutrophil O +
-to O -
- O -
tumor O +
cell O +
binding O +
. O +

Dex O +
was O +
found O +
to O +
inhibit O +
these O +
neutrophil O +
properties O +
, O +
and O +
RU38486 O +
completely O +
suppressed O +
both O +
forms O +
of O +
Dex O +
inhibition O +
. O +

Taken O +
together O +
, O +
our O +
findings O +
suggest O +
that O +
glucocorticoid O +
hormone O +
inhibition O +
of O +
neutrophil O +
-mediated O +
tumor O +
cell O +
cytostasis O +
is O +
at O +
least O +
partially O +
due O +
to O +
a O +
lowering O +
of O +
the O +
ligand O +
binding O +
avidity O +
of O +
beta2 O +
integrin O +
on O +
the O +
neutrophil O +
surface O +
. O +

Bacterial O +
lipopolysaccharide O +
activates O +
nuclear O +
factor O -
- O -
kappaB O +
through O +
interleukin-1 O +
signaling O +
mediators O +
in O +
cultured B-CellLine +
human I-CellLine +
dermal I-CellLine +
endothelial I-CellLine +
cells I-CellLine +
and O +
mononuclear O +
phagocytes O +
. O +

Bacterial O +
lipopolysaccharide O +
( O +
LPS O +
) O +
-mediated O +
immune O +
responses O +
, O +
including O +
activation O +
of O +
monocytes O +
, O +
macrophages O +
, O +
and O +
endothelial O +
cells O +
, O +
play O +
an O +
important O +
role O +
in O +
the O +
pathogenesis O +
of O +
Gram O -
- O -
negative O +
bacteria O -
- O -
induced O +
sepsis O +
syndrome O +
. O +

Activation O +
of O +
NF O -
- O -
kappaB O +
is O +
thought O +
to O +
be O +
required O +
for O +
cytokine O +
release O +
from O +
LPS O -
- O -
responsive O +
cells O +
, O +
a O +
critical O +
step O +
for O +
endotoxic O +
effects O +
. O +

Here O +
we O +
investigated O +
the O +
role O +
and O +
involvement O +
of O +
interleukin-1 O +
( O +
IL-1 O +
) O +
and O +
tumor O +
necrosis O +
factor O +
( O +
TNF O -
- O -
alpha O +
) O +
signal O +
transducer O +
molecules O +
in O +
LPS O +
signaling O +
in O +
human O +
dermal O +
microvessel O +
endothelial O +
cells O +
( O +
HDMEC O +
) O +
and O +
THP-1 B-CellLine +
monocytic I-CellLine +
cells I-CellLine +
. O +

LPS O +
stimulation O +
of O +
HDMEC O +
and O +
THP-1 B-CellLine +
cells I-CellLine +
initiated O +
an O +
IL-1 O +
receptor O +
-like O +
NF O -
- O -
kappaB O +
signaling O +
cascade O +
. O +

In O +
transient O +
cotransfection O +
experiments O +
, O +
dominant O +
negative O +
mutants O +
of O +
the O +
IL-1 O +
signaling O +
pathway O +
, O +
including O +
MyD88 O +
, O +
IRAK O +
, O +
IRAK2 O +
, O +
and O +
TRAF6 O +
inhibited O +
both O +
IL-1 O +
-and O +
LPS O -
- O -
induced O +
NF O -
- O -
kappaB O +
-luciferase O +
activity O +
. O +

LPS O -
- O -
induced O +
NF O -
- O -
kappaB O +
activation O +
was O +
not O +
inhibited O +
by O +
a O +
dominant O +
negative O +
mutant O +
of O +
TRAF2 O +
that O +
is O +
involved O +
in O +
TNF O +
signaling O +
. O +

LPS O -
- O -
induced O +
activation O +
of O +
NF O -
- O -
kappaB O -
- O -
responsive O +
reporter O +
gene O +
was O +
not O +
inhibited O +
by O +
IL-1 O +
receptor O +
antagonist O +
. O +

TLR2 O +
and O +
TLR4 O +
were O +
expressed O +
on O +
the O +
cell O +
surface O +
of O +
HDMEC O +
and O +
THP-1 B-CellLine +
cells I-CellLine +
. O +

These O +
findings O +
suggest O +
that O +
a O +
signal O +
transduction O +
molecule O +
in O +
the O +
LPS O +
receptor O +
complex O +
may O +
belong O +
to O +
the O +
IL-1 O +
receptor O -
/ O -
toll O -
- O -
like O +
receptor O +
( O +
TLR O +
) O +
super O +
family O +
, O +
and O +
the O +
LPS O +
signaling O +
cascade O +
uses O +
an O +
analogous O +
molecular O +
framework O +
for O +
signaling O +
as O +
IL-1 O +
in O +
mononuclear O +
phagocytes O +
and O +
endothelial O +
cells O +
. O +

A O +
direct O +
interaction O +
between O +
the O +
adaptor O +
protein O +
Cbl O -
- O -
b O +
and O +
the O +
kinase O +
zap-70 O +
induces O +
a O +
positive O +
signal O +
in O +
T O +
cells O +
. O +

Engagement O +
of O +
the O +
T O -
- O -
cell O +
receptor O +
( O +
TCR O +
) O +
-CD3 O +
complex O +
induces O +
a O +
rapid O +
increase O +
in O +
the O +
activities O +
of O +
Src O -
- O -
family O +
and O +
Syk O -
/ O -
Zap-70-family O +
kinases O +
[ O +
1 O +
] O +
[ O +
2 O +
] O +
. O +

These O +
activated O +
kinases O +
then O +
induce O +
the O +
tyrosine O +
phosphorylation O +
of O +
multiple O +
intracellular O +
proteins O +
, O +
eventually O +
leading O +
to O +
T O -
- O -
cell O +
activation O +
. O +

One O +
of O +
the O +
prominent O +
substrates O +
for O +
these O +
kinases O +
is O +
the O +
adaptor O +
protein O +
Cbl O +
[ O +
3 O +
] O +
and O +
recent O +
studies O +
suggest O +
that O +
Cbl O +
negatively O +
regulates O +
upstream O +
kinases O +
such O +
as O +
Syk O +
and O +
Zap-70 O +
[ O +
4 O +
] O +
[ O +
5 O +
] O +
. O +

Cbl O -
- O -
b O +
, O +
a O +
homologue O +
of O +
Cbl O +
, O +
is O +
widely O +
expressed O +
in O +
many O +
tissues O +
and O +
cells O +
including O +
hematopoietic O +
cells O +
[ O +
6 O +
] O +
[ O +
7 O +
] O +
. O +

Cbl O -
- O -
b O +
undergoes O +
rapid O +
tyrosine O +
phosphorylation O +
upon O +
stimulation O +
of O +
the O +
TCR O +
and O +
cytokine O +
receptors O +
[ O +
8 O +
] O +
[ O +
9 O +
] O +
. O +

The O +
role O +
of O +
Cbl O -
- O -
b O +
is O +
unclear O +
, O +
however O +
. O +

Here O +
, O +
we O +
show O +
that O +
overexpression O +
of O +
Cbl O -
- O -
b O +
in O +
T O +
cells O +
induced O +
the O +
constitutive O +
activation O +
of O +
the O +
transcription O +
factor O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
. O +

A O +
loss O -
- O -
of O -
- O -
function O +
mutation O +
in O +
Cbl O -
- O -
b O +
disrupted O +
the O +
interaction O +
between O +
Cbl O -
- O -
b O +
and O +
Zap-70 O +
and O +
nearly O +
completely O +
abrogated O +
the O +
Cbl O -
- O -
b O +
-mediated O +
activation O +
of O +
NFAT O +
. O +

Unlike O +
the O +
proposed O +
role O +
of O +
Cbl O +
as O +
a O +
negative O +
regulator O +
, O +
our O +
results O +
suggest O +
that O +
the O +
Cbl O +
homologue O +
Cbl O -
- O -
b O +
has O +
a O +
positive O +
role O +
in O +
T O -
- O -
cell O +
signaling O +
, O +
most O +
likely O +
via O +
a O +
direct O +
interaction O +
with O +
the O +
upstream O +
kinase O +
Zap-70 O +
. O +

Abnormalities O +
of O +
cyclic O +
adenosine O +
monophosphate O +
signaling O +
in O +
platelets O +
from O +
untreated O +
patients O +
with O +
bipolar O +
disorder O +
. O +

BACKGROUND O +
: O +
Abnormalities O +
in O +
the O +
cyclic O +
adenosine O +
monophosphate O +
( O +
cAMP O +
) O +
-dependent O +
phosphorylation O +
system O +
have O +
been O +
recently O +
reported O +
in O +
patients O +
with O +
bipolar O +
disorder O +
. O +

We O +
evaluated O +
the O +
immunoreactivity O +
of O +
the O +
regulatory O +
and O +
catalytic O +
subunits O +
of O +
cAMP O -
- O -
dependent O +
protein O +
kinase O +
( O +
protein O +
kinase O +
A O +
) O +
and O +
1 O +
of O +
its O +
substrates O +
, O +
Rap1 O +
, O +
in O +
platelets O +
from O +
untreated O +
euthymic O +
, O +
manic O +
, O +
and O +
depressed O +
patients O +
with O +
bipolar O +
disorder O +
and O +
healthy O +
subjects O +
. O +

METHODS O +
: O +
Platelets O +
were O +
collected O +
from O +
112 O +
drug O -
- O -
free O +
patients O +
with O +
bipolar O +
disorder O +
( O +
52 O +
euthymic O +
, O +
29 O +
depressed O +
, O +
and O +
31 O +
manic O +
) O +
and O +
62 O +
healthy O +
subjects O +
. O +

The O +
levels O +
of O +
cAMP O -
- O -
dependent O +
protein O +
kinase O +
and O +
Rap1 O +
were O +
assessed O +
by O +
Western O +
blot O +
analysis O +
, O +
immunostaining O +
, O +
and O +
computer O -
- O -
assisted O +
imaging O +
. O +

RESULTS O +
: O +
The O +
immunolabeling O +
of O +
the O +
catalytic O +
subunit O +
of O +
cAMP O -
- O -
dependent O +
protein O +
kinase O +
was O +
significantly O +
different O +
among O +
groups O +
( O +
P O +
< O +
.001 O +
) O +
, O +
with O +
higher O +
values O +
in O +
untreated O +
depressed O +
and O +
manic O +
patients O +
with O +
bipolar O +
disorder O +
compared O +
with O +
untreated O +
euthymic O +
patients O +
with O +
bipolar O +
disorder O +
and O +
healthy O +
subjects O +
. O +

No O +
significant O +
differences O +
were O +
found O +
in O +
the O +
immunolabeling O +
of O +
the O +
regulatory O +
subunits O +
( O +
type O +
I O +
and O +
type O +
II O +
) O +
of O +
cAMP O -
- O -
dependent O +
protein O +
kinase O +
. O +

The O +
immunolabeling O +
of O +
Rap1 O +
was O +
significantly O +
higher O +
( O +
P O +
< O +
.001 O +
) O +
in O +
untreated O +
euthymic O +
, O +
depressed O +
, O +
and O +
manic O +
patients O +
than O +
in O +
healthy O +
persons O +
. O +

CONCLUSIONS O +
: O +
Levels O +
of O +
Rap1 O +
and O +
the O +
catalytic O +
subunit O +
of O +
cAMP O -
- O -
dependent O +
protein O +
kinase O +
are O +
altered O +
in O +
the O +
platelets O +
of O +
bipolar O +
patients O +
. O +

These O +
findings O +
may O +
provide O +
clues O +
toward O +
understanding O +
the O +
involvement O +
of O +
cAMP O +
signaling O +
in O +
the O +
pathogenesis O +
of O +
bipolar O +
disorder O +
. O +

Inhibition O +
of O +
IL-4 O +
-inducible O +
gene O +
expression O +
in O +
human O +
monocytes O +
by O +
type O +
I O +
and O +
type O +
II O +
interferons O +
. O +

The O +
Th2-type O +
cytokines O +
, O +
interleukin-4 O +
( O +
IL-4 O +
) O +
and O +
interleukin-13 O +
( O +
IL-13 O +
) O +
, O +
induce O +
expression O +
of O +
a O +
distinct O +
subset O +
of O +
genes O +
in O +
human O +
monocytes O +
, O +
including O +
FcepsilonRIIb O +
( O +
CD23 O +
) O +
, O +
15-lipoxygenase O +
, O +
IL-1 O +
receptor O +
antagonist O +
( O +
IL-1ra O +
) O +
, O +
and O +
type O +
I O +
and O +
type O +
II O +
IL-1 O +
receptors O +
( O +
IL-1R O +
) O +
. O +

Type O +
I O +
interferons O +
( O +
IFN O -
- O -
alpha O +
and O +
IFN O -
- O -
beta O +
) O +
and O +
type O +
II O +
interferon O +
( O +
IFN O -
- O -
gamma O +
) O +
inhibit O +
induction O +
of O +
these O +
genes O +
by O +
IL-4 O +
and O +
IL-13 O +
. O +

However O +
, O +
the O +
mechanism O +
by O +
which O +
IFNs O +
mediate O +
this O +
inhibition O +
has O +
not O +
been O +
defined O +
. O +

In O +
this O +
overview O +
, O +
we O +
discuss O +
the O +
role O +
of O +
the O +
transcription O +
factor O +
, O +
STAT6 O +
( O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription-6 O +
) O +
in O +
mediating O +
IL-4- O +
and O +
IL-13-induced O +
gene O +
expression O +
in O +
monocytes O +
. O +

We O +
also O +
discuss O +
our O +
recent O +
findings O +
that O +
type O +
I O +
and O +
type O +
II O +
IFNs O +
suppress O +
IL-4 O +
/ O +
IL-13 O +
-inducible O +
gene O +
expression O +
by O +
inhibiting O +
tyrosine O +
phosphorylation O +
and O +
nuclear O +
translocation O +
of O +
STAT6 O +
. O +

The O +
ability O +
of O +
type O +
I O +
and O +
type O +
II O +
IFNs O +
to O +
inhibit O +
IL-4 O +
/ O +
IL-13 O +
-induced O +
STAT6 O +
activity O +
is O +
dose- O +
and O +
time O -
- O -
dependent O +
, O +
and O +
is O +
not O +
unique O +
to O +
monocytes O +
because O +
IFNs O +
induce O +
the O +
same O +
effects O +
in O +
fibroblasts O +
. O +

Inhibition O +
of O +
STAT6 O +
activity O +
is O +
not O +
evident O +
unless O +
cells O +
are O +
preincubated O +
with O +
IFN O +
for O +
at O +
least O +
1 O +
h O +
before O +
IL-4 O +
stimulation O +
. O +

Furthermore O +
, O +
inhibition O +
can O +
be O +
blocked O +
by O +
actinomycin O +
D O +
, O +
indicating O +
a O +
requirement O +
for O +
de O +
novo O +
transcription O +
. O +

We O +
propose O +
a O +
model O +
in O +
which O +
stimulation O +
of O +
monocytes O +
by O +
IFN O +
activates O +
de O +
novo O +
synthesis O +
of O +
an O +
inhibitory O +
factor O +
, O +
possibly O +
one O +
or O +
more O +
members O +
of O +
the O +
SOCS O -
/ O +
SSI O -
/ O -
CIS O +
gene O +
family O +
, O +
capable O +
of O +
suppressing O +
activation O +
of O +
STAT6 O +
by O +
IL-4 O +
and O +
IL-13 O +
. O +

Because O +
STAT6 O +
activation O +
plays O +
an O +
essential O +
role O +
in O +
IL-4 O +
/ O +
IL-13 O +
-induced O +
gene O +
expression O +
, O +
the O +
ability O +
of O +
IFN O -
- O -
beta O +
and O +
IFN O -
- O -
gamma O +
to O +
inhibit O +
STAT6 O +
activity O +
provides O +
an O +
explanation O +
for O +
how O +
IFNs O +
can O +
suppress O +
IL-4 O +
/ O +
IL-13 O +
-inducible O +
gene O +
expression O +
. O +

Selective O +
activation O +
and O +
functional O +
significance O +
of O +
p38alpha O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
in O +
lipopolysaccharide B-CellLine -
- I-CellLine -
stimulated I-CellLine +
neutrophils I-CellLine +
. O +

Activation O +
of O +
leukocytes O +
by O +
proinflammatory O +
stimuli O +
selectively O +
initiates O +
intracellular O +
signal O +
transduction O +
via O +
sequential O +
phosphorylation O +
of O +
kinases O +
. O +

Lipopolysaccharide O +
( O +
LPS O +
) O +
stimulation O +
of O +
human O +
neutrophils O +
is O +
known O +
to O +
result O +
in O +
activation O +
of O +
p38 O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O +
MAPk O +
) O +
; O +
however O +
, O +
the O +
upstream O +
activator O +
( O +
s O +
) O +
of O +
p38 O +
MAPk O +
is O +
unknown O +
, O +
and O +
consequences O +
of O +
p38 O +
MAPk O +
activation O +
remain O +
largely O +
undefined O +
. O +

We O +
investigated O +
the O +
MAPk O +
kinase O +
( O +
MKK O +
) O +
that O +
activates O +
p38 O +
MAPk O +
in O +
response O +
to O +
LPS O +
, O +
the O +
p38 O +
MAPk O +
isoforms O +
that O +
are O +
activated O +
as O +
part O +
of O +
this O +
pathway O +
, O +
and O +
the O +
functional O +
responses O +
affected O +
by O +
p38 O +
MAPk O +
activation O +
. O +

Although O +
MKK3 O +
, O +
MKK4 O +
, O +
and O +
MKK6 O +
all O +
activated O +
p38 O +
MAPk O +
in O +
experimental O +
models O +
, O +
only O +
MKK3 O +
was O +
found O +
to O +
activate O +
recombinant O +
p38 O +
MAPk O +
in O +
LPS O -
- O -
treated O +
neutrophils O +
. O +

Of O +
p38 O +
MAPk O +
isoforms O +
studied O +
, O +
only O +
p38alpha O +
and O +
p38delta O +
were O +
detected O +
in O +
neutrophils O +
. O +

LPS O +
stimulation O +
selectively O +
activated O +
p38alpha O +
. O +

Specific O +
inhibitors O +
of O +
p38alpha O +
MAPk O +
blocked O +
LPS O -
- O -
induced O +
adhesion O +
, O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappaB O +
) O +
activation O +
, O +
and O +
synthesis O +
of O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
. O +

Inhibition O +
of O +
p38alpha O +
MAPk O +
resulted O +
in O +
a O +
transient O +
decrease O +
in O +
TNF O -
- O -
alpha O +
mRNA O +
accumulation O +
but O +
persistent O +
loss O +
of O +
TNF O -
- O -
alpha O +
synthesis O +
. O +

These O +
findings O +
support O +
a O +
pathway O +
by O +
which O +
LPS O +
stimulation O +
of O +
neutrophils O +
results O +
in O +
activation O +
of O +
MKK3 O +
, O +
which O +
in O +
turn O +
activates O +
p38alpha O +
MAPk O +
, O +
ultimately O +
regulating O +
adhesion O +
, O +
NF O -
- O -
kappaB O +
activation O +
, O +
enhanced O +
gene O +
expression O +
of O +
TNF O -
- O -
alpha O +
, O +
and O +
regulation O +
of O +
TNF O -
- O -
alpha O +
synthesis O +
. O +

Cobalt O +
chloride O -
- O -
induced O +
signaling O +
in O +
endothelium O +
leading O +
to O +
the O +
augmented O +
adherence O +
of O +
sickle O +
red O +
blood O +
cells O +
and O +
transendothelial O +
migration O +
of O +
monocyte B-CellLine -
- I-CellLine -
like I-CellLine +
HL-60 I-CellLine +
cells I-CellLine +
is O +
blocked O +
by O +
PAF O -
- O -
receptor O +
antagonist O +
. O +

In O +
response O +
to O +
hypoxia O +
, O +
sickle O +
red O +
blood O +
cells O +
( O +
SS O +
RBC O +
) O +
and O +
leukocytes O +
exhibit O +
increased O +
adherence O +
to O +
the O +
vascular O +
endothelium O +
, O +
while O +
diapedesis O +
of O +
leukocytes O +
through O +
the O +
blood O +
vessel O +
increases O +
. O +

However O +
, O +
the O +
cellular O +
signaling O +
pathway O +
( O +
s O +
) O +
caused O +
by O +
hypoxia O +
is O +
poorly O +
understood O +
. O +

We O +
utilized O +
CoCl2 O +
as O +
a O +
mimetic O +
molecule O +
for O +
hypoxia O +
to O +
study O +
cellular O +
signaling O +
pathways O +
. O +

We O +
found O +
that O +
in O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
( O +
HUVEC O +
) O +
, O +
CoCl2 O +
at O +
2 O +
mM O +
concentration O +
induced O +
the O +
surface O +
expression O +
of O +
a O +
subset O +
of O +
CAMs O +
( O +
VCAM-1 O +
) O +
and O +
activation O +
of O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
in O +
the O +
nuclear O +
extracts O +
of O +
HUVEC O +
. O +

Furthermore O +
, O +
CoCl2 O +
also O +
caused O +
time O -
- O -
dependent O +
tyrosine O +
phosphorylation O +
of O +
mitogen O -
- O -
activated O +
protein O +
( O +
MAP O +
) O +
kinase O +
isoform O +
ERK2 O +
without O +
significantly O +
affecting O +
ERK1 O +
, O +
indicating O +
ERK2 O +
is O +
the O +
preferred O +
substrate O +
for O +
upstream O +
kinase O +
of O +
the O +
MAPK O +
pathway O +
. O +

Inhibitors O +
of O +
MAP O +
kinase O +
( O +
PD98059 O +
) O +
or O +
platelet O -
- O -
activating O +
factor O +
( O +
PAF O +
) O +
- O +
receptor O +
antagonist O +
( O +
CV3988 O +
) O +
inhibited O +
the O +
CoCl2-induced O +
NF O -
- O -
kappaB O +
activation O +
and O +
VCAM-1 O +
expression O +
. O +

Augmented O +
expression O +
of O +
VCAM-1 O +
led O +
to O +
increased O +
SS O +
RBC O +
adhesion O +
, O +
inhibitable O +
by O +
a O +
VCAM-1 O +
antibody O +
. O +

Additionally O +
, O +
CoCl2 O +
caused O +
a O +
two- O +
to O +
threefold O +
increase O +
in O +
the O +
rate O +
of O +
transendothelial O +
migration O +
of O +
monocyte B-CellLine -
- I-CellLine -
like I-CellLine +
HL-60 I-CellLine +
cells I-CellLine +
and O +
a O +
twentyfold O +
increase O +
in O +
phosphorylation O +
of O +
platelet O +
endothelial O +
cell O +
adhesion O +
molecules O +
( O +
PECAM-1 O +
) O +
. O +

The O +
transendothelial O +
migration O +
of O +
monocytes O +
was O +
inhibited O +
by O +
an O +
antibody O +
to O +
PECAM-1 O +
. O +

Both O +
phosphorylation O +
of O +
PECAM-1 O +
and O +
transendothelial O +
migration O +
of O +
monocytes O +
in O +
response O +
to O +
CoCl2 O +
were O +
inhibited O +
by O +
protein O +
kinase O +
inhibitor O +
( O +
GF109203X O +
) O +
and O +
augmented O +
by O +
protein O +
phosphatase O +
inhibitor O +
( O +
Calyculin O +
A O +
) O +
. O +

Our O +
data O +
suggests O +
that O +
CoCl2-induced O +
cellular O +
signals O +
directing O +
increased O +
expression O +
of O +
VCAM-1 O +
in O +
HUVEC O +
involve O +
downstream O +
activation O +
of O +
MAP O +
kinase O +
and O +
NF O -
- O -
kappaB O +
, O +
while O +
the O +
phosphorylation O +
of O +
PECAM-1 O +
occurs O +
as O +
a O +
result O +
of O +
activation O +
of O +
PKC O +
. O +

We O +
conclude O +
that O +
PAF O -
- O -
receptor O +
antagonist O +
inhibits O +
the O +
CoCl2 O +
-or O +
hypoxia O -
- O -
induced O +
increase O +
in O +
the O +
adhesion O +
of O +
SS O +
RBC O +
, O +
PECAM-1 O +
phosphorylation O +
, O +
and O +
the O +
concomitant O +
transendothelial O +
migration O +
of O +
monocytes O +
. O +

Impaired O +
binding O +
of O +
a O +
DQ2 O +
and O +
DQ8 O +
-binding O +
HSV O +
VP16 O +
peptide O +
to O +
a O +
DQA1 O -
* O -
0501 O -
/ O -
DQB1 O -
* O -
0302 O +
trans O +
class O +
II O +
heterodimer O +
. O +

DQalpha O +
and O +
DQbeta O +
trans O +
heterodimeric O +
HLA O -
- O -
DQ O +
molecules O +
form O +
in O +
individuals O +
heterozygous O +
for O +
the O +
DQ2 O +
and O +
DQ8 O +
specificities O +
. O +

Unique O +
functions O +
and O +
disease O +
associations O +
have O +
been O +
postulated O +
for O +
such O +
trans O -
- O -
dimers O +
, O +
which O +
may O +
be O +
different O +
from O +
cis O -
- O -
encoded O +
DQ O +
molecules O +
encoded O +
by O +
the O +
corresponding O +
haplotypes O +
. O +

We O +
analyzed O +
the O +
ability O +
of O +
the O +
trans O -
- O -
dimer O +
encoded O +
by O +
HLA O -
- O -
DQA1 O -
* O -
0501 O -
/ O -
DQB1 O -
* O -
0302 O +
to O +
bind O +
a O +
peptide O +
antigen O +
which O +
interacts O +
with O +
DQ O +
molecules O +
encoded O +
by O +
both O +
parental O +
haplotypes O +
. O +

Markedly O +
impaired O +
binding O +
was O +
observed O +
, O +
consistent O +
with O +
both O +
the O +
use O +
of O +
different O +
anchor O +
residues O +
and O +
with O +
changes O +
in O +
levels O +
of O +
DQ O +
cis- O +
dimer O +
availability O +
for O +
peptide O +
binding O +
interactions O +
. O +

Phosphorylation O +
of O +
TRAF2 O +
inhibits O +
binding O +
to O +
the O +
CD40 O +
cytoplasmic O +
domain O +
. O +

TRAF2 O +
is O +
a O +
signal O +
transducing O +
adaptor O +
molecule O +
which O +
binds O +
to O +
the O +
CD40 O +
cytoplasmic O +
domain O +
. O +

We O +
have O +
found O +
that O +
it O +
is O +
phosphorylated O +
, O +
predominantly O +
on O +
serine O +
residues O +
, O +
when O +
transiently O +
overexpressed O +
in O +
293 B-CellLine +
cells I-CellLine +
. O +

The O +
phosphorylation O +
appears O +
to O +
be O +
related O +
to O +
the O +
signaling O +
events O +
that O +
are O +
activated O +
by O +
TRAF2 O +
under O +
these O +
circumstances O +
, O +
since O +
two O +
nonfunctional O +
mutants O +
were O +
found O +
to O +
be O +
phosphorylated O +
significantly O +
less O +
than O +
the O +
wild O -
- O -
type O +
protein O +
. O +

Furthermore O +
, O +
the O +
phosphorylation O +
status O +
of O +
TRAF2 O +
had O +
significant O +
effects O +
on O +
the O +
ability O +
of O +
the O +
protein O +
to O +
bind O +
to O +
CD40 O +
, O +
as O +
evidenced O +
by O +
our O +
observations O +
that O +
the O +
CD40 O +
cytoplasmic O +
domain O +
interacted O +
preferentially O +
with O +
underphosphorylated O +
TRAF2 O +
and O +
that O +
phosphatase O +
treatment O +
significantly O +
enhanced O +
the O +
binding O +
of O +
TRAF2 O +
to O +
CD40 O +
. O +

We O +
conclude O +
from O +
these O +
studies O +
that O +
the O +
phosphorylation O +
of O +
TRAF2 O +
is O +
likely O +
to O +
play O +
an O +
important O +
role O +
in O +
regulating O +
signaling O +
by O +
virtue O +
of O +
its O +
ability O +
to O +
influence O +
the O +
CD40 O +
-TRAF2 O +
interaction O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

Analysis O +
of O +
the O +
modulation O +
of O +
transcriptional O +
activity O +
in O +
myelopoiesis O +
and O +
leukemogenesis O +
. O +

Acute O +
myeloid O +
leukemia O +
( O +
AML O +
) O +
is O +
still O +
associated O +
with O +
a O +
mortality O +
of O +
60 O +
to O +
80 O +
% O +
. O +

AML O +
is O +
characterized O +
by O +
a O +
block O +
in O +
myeloid O +
differentiation O +
. O +

The O +
transcription O +
factors O +
PU.1 O +
and O +
C O -
/ O -
EBPalpha O +
are O +
responsible O +
for O +
normal O +
myeloid O +
differentiation O +
from O +
stem O +
cells O +
to O +
monocytes O +
or O +
granulocytes O +
. O +

In O +
particular O +
, O +
PU.1 O +
induces O +
expression O +
of O +
the O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O +
M O -
- O -
CSF O +
) O +
receptor O +
and O +
the O +
development O +
of O +
monocytes O +
, O +
whereas O +
C O -
/ O -
EBPalpha O +
increases O +
the O +
expression O +
of O +
the O +
granulocyte O +
colony O -
- O -
stimulating O +
factor O +
( O +
G O -
- O -
CSF O +
) O +
receptor O +
and O +
leads O +
to O +
mature O +
granulocytes O +
. O +

In O +
AML O +
, O +
chromosomal O +
aberrations O +
result O +
in O +
oncoproteins O +
such O +
as O +
AML1 O -
/ O -
ETO O +
, O +
PML O -
/ O -
RARalpha O +
, O +
or O +
activated O +
Ras O +
, O +
which O +
can O +
deregulate O +
genes O +
important O +
for O +
normal O +
myelopoiesis O +
. O +

Thus O +
, O +
AML1 O -
/ O -
ETO O +
can O +
bind O +
to O +
the O +
transcription O +
factor O +
C O -
/ O -
EBPalpha O +
, O +
inhibit O +
C O -
/ O -
EBPalpha O +
-dependent O +
transcription O +
, O +
and O +
block O +
granulocytic O +
differentiation O +
. O +

However O +
, O +
AML1 O -
/ O -
ETO O +
can O +
also O +
synergize O +
with O +
the O +
transcription O +
factor O +
AML1 O +
to O +
enhance O +
the O +
activity O +
of O +
the O +
M O -
- O -
CSF O +
receptor O +
promoter O +
. O +

On O +
the O +
other O +
hand O +
, O +
the O +
PML O -
/ O -
RARalpha O +
fusion O +
protein O +
causes O +
transcriptional O +
repression O +
by O +
recruiting O +
the O +
nuclear O +
corepressor O +
( O +
N O -
- O -
CoR O +
) O +
histone O +
deacetylase O +
complex O +
to O +
the O +
DNA O +
, O +
which O +
results O +
in O +
decreased O +
histone O +
acetylation O +
and O +
a O +
repressive O +
chromatin O +
organization O +
. O +

Here O +
we O +
describe O +
methods O +
to O +
investigate O +
whether O +
and O +
how O +
signaling O +
agonists O +
induce O +
myeloid O +
differentiation O +
and O +
how O +
oncoproteins O +
might O +
cause O +
AML O +
by O +
modulating O +
the O +
activity O +
of O +
transcription O +
factors O +
that O +
are O +
pivotal O +
for O +
normal O +
myeloid O +
development O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

Involvement O +
of O +
NF O -
- O -
kappaB O +
p50 O -
/ O -
p65 O +
heterodimer O +
in O +
activation O +
of O +
the O +
human O +
pro O -
- O -
interleukin-1beta O +
gene O +
at O +
two O +
subregions O +
of O +
the O +
upstream O +
enhancer O +
element O +
. O +

A O +
region O +
between-3134 O +
and O +
-2729 O +
bp O +
upstream O +
from O +
the O +
transcription O +
site O +
of O +
the O +
human O +
pro O -
- O -
interleukin O +
1beta O +
( O +
proIL-1beta O +
) O +
gene O +
was O +
identified O +
as O +
an O +
LPS O -
- O -
responsive O +
enhancer O +
element O +
. O +

In O +
this O +
study O +
, O +
the O +
influence O +
of O +
the O +
sequences O +
located O +
between O +
-3134 O +
and O +
-2987 O +
on O +
the O +
transcriptional O +
activity O +
of O +
the O +
proIL-1beta O +
gene O +
in O +
LPS B-CellLine -
- I-CellLine -
stimulated I-CellLine +
Raw I-CellLine +
264.7 I-CellLine +
cells I-CellLine +
was O +
examined O +
in O +
detail O +
. O +

The O +
results O +
obtained O +
by O +
transient O +
transfection O +
of O +
fos O +
-CAT O +
constructs O +
that O +
contained O +
serial O +
5'-deletion O +
mutations O +
showed O +
that O +
the O +
region O +
between O +
-3134 O +
and O +
-3059 O +
appears O +
to O +
be O +
required O +
for O +
the O +
induction O +
of O +
transcription O +
by O +
LPS O +
. O +

Gel O +
shift O +
assay O +
studies O +
with O +
synthetic O +
oligonucleotides O +
corresponding O +
to O +
partial O +
sequences O +
of O +
the O +
latter O +
region O +
and O +
nuclear O +
extracts O +
from O +
stimulated O +
cells O +
revealed O +
specific O +
protein O +
binding O +
sites O +
between O +
-3110 O +
and O +
-3090 O +
and O +
between O +
-3079 O +
and O +
-3059 O +
. O +

These O +
specific O +
bindings O +
were O +
time O +
and O +
LPS O +
dose O +
dependent O +
. O +

The O +
results O +
of O +
supershift O +
analysis O +
using O +
specific O +
antibodies O +
against O +
transcription O +
factors O +
suggested O +
that O +
both O +
binding O +
complexes O +
contained O +
the O +
NF O -
- O -
kappaB O +
components O +
p50 O +
and O +
p65 O +
, O +
and O +
did O +
not O +
contain O +
other O +
NF O -
- O -
kappaB O +
proteins O +
( O +
p52 O +
, O +
c O -
- O -
Rel O +
, O +
Rel O +
B O +
) O +
, O +
AP-1 O +
proteins O +
( O +
c O -
- O -
Fos O +
, O +
C O -
- O -
Jun O +
) O +
, O +
CREB O +
or O +
C O -
/ O -
EBPbeta O +
( O +
NF O -
- O -
IL6 O +
) O +
. O +

Mutation O +
of O +
either O +
of O +
the O +
putative O +
NF O -
- O -
kappaB O -
- O -
binding O +
sites O +
in O +
the O +
enhancer O +
element O +
decreased O +
the O +
LPS O -
- O -
stimulated O +
transcriptional O +
activity O +
. O +

These O +
data O +
indicated O +
that O +
two O +
NF O -
- O -
kappaB O -
- O -
binding O +
sites O +
, O +
which O +
are O +
located O +
between O +
-3134 O +
and O +
-3059 O +
, O +
are O +
critical O +
for O +
the O +
activation O +
of O +
proIL-1beta O +
gene O +
transcription O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

MDS1 O -
/ O -
EVI1 O +
enhances O +
TGF O -
- O -
beta1 O +
signaling O +
and O +
strengthens O +
its O +
growth O -
- O -
inhibitory O +
effect O +
but O +
the O +
leukemia O -
- O -
associated O +
fusion O +
protein O +
AML1 O -
/ O -
MDS1 O -
/ O -
EVI1 O +
, O +
product O +
of O +
the O +
t O +
( O +
3 O +
; O +
21 O +
) O +
, O +
abrogates O +
growth O -
- O -
inhibition O +
in O +
response O +
to O +
TGF O -
- O -
beta1 O +
. O +

MDS1 O -
/ O -
EVI1 O +
, O +
located O +
on O +
chromosome O +
3 O +
band O +
q26 O +
, O +
encodes O +
a O +
zinc O -
- O -
finger O +
DNA O -
- O -
binding O +
transcription O +
activator O +
not O +
detected O +
in O +
normal O +
hematopoietic O +
cells O +
but O +
expressed O +
in O +
several O +
normal O +
tissues O +
. O +

MDS1 O -
/ O -
EVI1 O +
is O +
inappropriately O +
activated O +
in O +
myeloid O +
leukemias O +
following O +
chromosomal O +
rearrangements O +
involving O +
band O +
3q26 O +
. O +

The O +
rearrangements O +
lead O +
either O +
to O +
gene O +
truncation O +
, O +
and O +
to O +
expression O +
of O +
the O +
transcription O +
repressor O +
EVI1 O +
, O +
as O +
seen O +
in O +
the O +
t O +
( O +
3 O +
; O +
3 O +
) O +
( O +
q21 O +
; O +
q26 O +
) O +
and O +
inv O +
( O +
3 O +
) O +
( O +
q21q26 O +
) O +
, O +
or O +
to O +
gene O +
fusion O +
, O +
as O +
seen O +
in O +
the O +
t O +
( O +
3 O +
; O +
21 O +
) O +
( O +
q26 O +
; O +
q22 O +
) O +
which O +
results O +
in O +
the O +
fusion O +
protein O +
AML1 O -
/ O -
MDS1 O -
/ O -
EVI1 O +
. O +

This O +
fusion O +
protein O +
contains O +
the O +
DNA O -
- O -
binding O +
domain O +
of O +
the O +
transcription O +
factor O +
AML1 O +
fused O +
in O -
- O -
frame O +
to O +
the O +
entire O +
MDS1 O -
/ O -
EVI1 O +
with O +
the O +
exclusion O +
of O +
its O +
first O +
12 O +
amino O +
acids O +
. O +

In O +
this O +
report O +
, O +
we O +
have O +
analyzed O +
the O +
response O +
of O +
the O +
hematopoietic B-CellLine +
precursor I-CellLine +
cell I-CellLine +
line I-CellLine +
32Dcl3 I-CellLine +
, O +
expressing O +
either O +
the O +
normal O +
protein O +
MDS1 O -
/ O -
EVI1 O +
or O +
the O +
fusion O +
protein O +
AML1 O -
/ O -
MDS1 O -
/ O -
EVI1 O +
, O +
to O +
factors O +
that O +
control O +
cell O +
differentiation O +
or O +
cell O +
replication O +
. O +

The O +
32Dcl3 B-CellLine +
cells I-CellLine +
are O +
IL-3 O +
-dependent O +
for O +
growth O +
and O +
they O +
differentiate O +
into O +
granulocytes O +
when O +
exposed O +
to O +
G O -
- O -
CSF O +
. O +

They O +
are O +
growth O -
- O -
inhibited O +
by O +
TGF O -
- O -
beta1 O +
. O +

We O +
show O +
that O +
whereas O +
the O +
expression O +
of O +
MDS1 O -
/ O -
EVI1 O +
has O +
no O +
effect O +
on O +
granulocytic O +
differentiation O +
induced O +
by O +
G O -
- O -
CSF O +
, O +
expression O +
of O +
AML1 O -
/ O -
MDS1 O -
/ O -
EVI1 O +
blocks O +
differentiation O +
resulting O +
in O +
cell O +
death O +
. O +

This O +
effect O +
is O +
similar O +
to O +
that O +
previously O +
described O +
by O +
others O +
for O +
32Dcl3 B-CellLine +
cells I-CellLine +
that O +
express O +
transgenic O +
Evil O +
. O +

Furthermore O +
, O +
we O +
show O +
that O +
whereas O +
the O +
expression O +
of O +
the O +
fusion O +
protein O +
AML1 O -
/ O -
MDS1 O -
/ O -
EVI1 O +
completely O +
abrogates O +
the O +
growth O -
- O -
inhibitory O +
effect O +
of O +
TGF O -
- O -
beta1 O +
and O +
allows O +
32Dcl3 B-CellLine +
cells I-CellLine +
to O +
proliferate O +
, O +
expression O +
of O +
the O +
normal O +
protein O +
MDS1 O -
/ O -
EVI1 O +
has O +
the O +
opposite O +
effect O +
, O +
and O +
it O +
strengthens O +
the O +
response O +
of O +
cells O +
to O +
the O +
growth O -
- O -
inhibitory O +
effect O +
of O +
TGF O -
- O -
beta1 O +
. O +

By O +
using O +
the O +
yeast O +
two O -
- O -
hybrid O +
system O +
, O +
we O +
also O +
show O +
that O +
EVI1 O +
( O +
contained O +
in O +
its O +
entirety O +
in O +
MDS1 O -
/ O -
EVI1 O +
and O +
AML1 O -
/ O -
MDS1 O -
/ O -
EVI1 O +
) O +
physically O +
interacts O +
with O +
SMAD3 O +
, O +
which O +
is O +
an O +
intracellular O +
mediator O +
of O +
TGF O -
- O -
beta1 O +
signaling O +
. O +

Finally O +
, O +
we O +
have O +
correlated O +
the O +
response O +
of O +
the O +
cells O +
to O +
G O -
- O -
CSF O +
or O +
TGF O -
- O -
beta1 O +
with O +
the O +
ability O +
of O +
the O +
normal O +
and O +
fusion O +
proteins O +
to O +
activate O +
or O +
repress O +
promoters O +
which O +
they O +
can O +
directly O +
regulate O +
by O +
binding O +
to O +
the O +
promoter O +
site O +
. O +

We O +
propose O +
that O +
mutations O +
of O +
MDS1 O -
/ O -
EVI1 O +
either O +
by O +
gene O +
truncation O +
resulting O +
in O +
the O +
transcription O +
repressor O +
EVI1 O +
or O +
by O +
gene O +
fusion O +
to O +
AML1 O +
lead O +
to O +
an O +
altered O +
cellular O +
response O +
to O +
growth O +
and O +
differentiation O +
factors O +
that O +
could O +
result O +
in O +
leukemic O +
transformation O +
. O +

The O +
different O +
response O +
of O +
myeloid O +
cells O +
ectopically O +
expressing O +
the O +
normal O +
or O +
the O +
fusion O +
protein O +
to O +
G O -
- O -
CSF O +
and O +
TGF O -
- O -
beta1 O +
could O +
depend O +
on O +
the O +
different O +
transactivation O +
properties O +
of O +
these O +
proteins O +
resulting O +
in O +
divergent O +
expression O +
of O +
downstream O +
genes O +
regulated O +
by O +
the O +
two O +
proteins O +
. O +

Identification O +
of O +
upstream O +
regulatory O +
elements O +
that O +
repress O +
expression O +
of O +
adult O +
beta O -
- O -
like O +
globin O +
genes O +
in O +
a O +
primitive O +
erythroid O +
environment O +
. O +

Our O +
investigations O +
have O +
focused O +
on O +
localizing O +
cis O -
- O -
elements O +
responsible O +
for O +
the O +
down O +
regulation O +
of O +
the O +
adult O +
beta O -
- O -
like O +
globin O +
genes O +
( O +
delta O +
and O +
beta O +
) O +
in O +
immature O +
, O +
or O +
primitive O +
erythroid O +
tissues O +
. O +

We O +
studied O +
their O +
activity O +
after O +
transfection O +
into O +
K562 B-CellLine +
cells I-CellLine +
, O +
an O +
erythroleukemia B-CellLine +
cell I-CellLine +
line I-CellLine +
with O +
an O +
embryonic O -
- O -
fetal O +
phenotype O +
. O +

Analyzed O +
DNA O +
sequences O +
included O +
delta O +
and O +
beta O +
5 O +
' O +
flanking O +
regions O +
extending O +
from O +
approximately O +
-500 O +
to O +
+ O -
50bp O +
( O +
promoter O +
regions O +
) O +
, O +
truncated O +
delta O +
and O +
beta O +
5 O +
' O +
flanking O +
regions O +
extending O +
from O +
approximately O +
-250 O +
to O +
+ O -
50 O +
bp O +
, O +
and O +
chimeric O +
promoter O +
constructions O +
, O +
which O +
consisted O +
of O +
a O +
distal O +
delta O +
or O +
beta O +
fragment O +
fused O +
to O +
a O +
proximal O +
beta O +
or O +
delta O +
sequence O +
. O +

In O +
CAT O +
reporter O +
constructions O +
no O +
appreciable O +
level O +
of O +
CAT O +
activity O +
was O +
supported O +
by O +
the O +
beta O +
globin O +
promoter O +
, O +
and O +
only O +
low O +
level O +
activity O +
by O +
the O +
delta O +
promoter O +
. O +

Truncation O +
of O +
the O +
beta O +
globin O +
promoter O +
led O +
to O +
a O +
2 O -
- O -
3 O +
fold O +
increase O +
in O +
promoter O +
activity O +
. O +

In O +
contrast O +
, O +
deletion O +
of O +
the O +
upstream O +
portion O +
of O +
the O +
delta O +
promoter O +
led O +
to O +
a O +
10 O +
fold O +
decrease O +
in O +
expression O +
. O +

Coupling O +
of O +
the O +
upstream O +
beta O +
globin O +
sequence O +
from O +
approximately O +
-500 O +
to O +
-250 O +
bp O +
to O +
the O +
truncated O +
delta O +
promoter O +
fragment O +
led O +
to O +
complete O +
extinction O +
of O +
transcription O +
activity O +
, O +
consistent O +
with O +
a O +
negative O +
regulatory O +
effect O +
of O +
the O +
beta O +
globin O +
gene O +
upstream O +
element O +
( O +
s O +
) O +
. O +

Fusion O +
of O +
the O +
upstream O +
portion O +
of O +
the O +
delta O +
promoter O +
to O +
the O +
truncated O +
beta O +
globin O +
promoter O +
yielded O +
a O +
modest O +
increase O +
in O +
promoter O +
strength O +
relative O +
to O +
the O +
truncated O +
beta O +
gene O +
promoter O +
, O +
indicating O +
the O +
presence O +
of O +
a O +
positive O +
transcriptional O +
element O +
( O +
s O +
) O +
in O +
the O +
upstream O +
delta O +
globin O +
regulatory O +
region O +
. O +

Site O -
- O -
directed O +
mutagenesis O +
of O +
binding O +
sites O +
for O +
the O +
repressor O +
proteins O +
BP1 O +
and O +
BP2 O +
in O +
the O +
upstream O +
portion O +
of O +
the O +
beta O +
globin O +
gene O +
flanking O +
region O +
led O +
to O +
a O +
4 O -
- O -
6 O +
fold O +
increase O +
in O +
promoter O +
activity O +
. O +

DNase O +
I O +
footprinting O +
of O +
the O +
upstream O +
delta O -
- O -
globin O +
region O +
revealed O +
protected O +
sequences O +
corresponding O +
to O +
consensus O +
binding O +
sites O +
for O +
GATA-1 O +
and O +
BP2 O +
. O +

These O +
results O +
confirm O +
that O +
sequences O +
in O +
the O +
upstream O +
promoter O +
region O +
of O +
the O +
adult O +
beta O +
globin O +
gene O +
contribute O +
to O +
its O +
factor O -
- O -
mediated O +
suppression O +
early O +
in O +
development O +
and O +
then O +
may O +
modulate O +
its O +
expression O +
at O +
a O +
later O +
stage O +
. O +

Interferon O -
- O -
alpha O +
induction O +
of O +
STATs1 O +
, O +
-3 O +
DNA O +
binding O +
and O +
growth O +
arrest O +
is O +
independent O +
of O +
Lck O +
and O +
active O +
mitogen O -
- O -
activated O +
kinase O +
in O +
T O +
cells O +
. O +

Type O +
I O +
interferons O +
( O +
IFNs O +
) O +
are O +
a O +
family O +
of O +
cytokines O +
that O +
have O +
antiviral O +
and O +
antiproliferative O +
effects O +
. O +

Data O +
regarding O +
the O +
processes O +
by O +
which O +
these O +
cytokines O +
transduce O +
signals O +
from O +
the O +
cell O +
membrane O +
to O +
the O +
nucleus O +
are O +
becoming O +
increasingly O +
complex O +
. O +

The O +
most O +
characterized O +
pathway O +
is O +
via O +
JAK O +
-STAT O +
signaling O +
. O +

Previous O +
studies O +
established O +
a O +
potential O +
role O +
for O +
the O +
Src O -
- O -
family O +
kinase O +
Lck O +
in O +
JAK O +
-STAT O +
signaling O +
. O +

Therefore O +
, O +
this O +
study O +
was O +
designed O +
to O +
analyze O +
the O +
role O +
of O +
Lck O +
in O +
IFN O -
- O -
alpha O +
signaling O +
by O +
using O +
the O +
Jurkat O +
, O +
JCam O +
( O +
an O +
Lck B-CellLine -
- I-CellLine -
defective I-CellLine +
cell I-CellLine +
line I-CellLine +
derived O +
from O +
Jurkat B-CellLine +
) O +
, O +
and O +
JCam B-CellLine -
/ I-CellLine -
Lck I-CellLine +
( O +
JCam B-CellLine +
cells I-CellLine +
with O +
Lck O +
restored O +
) O +
. O +

The O +
results O +
show O +
that O +
IFN O -
- O -
alpha O +
can O +
induce O +
MAPK O +
activity O +
, O +
but O +
only O +
in O +
cells O +
containing O +
Lck O +
. O +

Furthermore O +
, O +
STATs1 O +
and O +
-3 O +
are O +
effectively O +
phosphorylated O +
and O +
activated O +
to O +
bind O +
DNA O +
in O +
the O +
absence O +
of O +
Lck O +
expression O +
in O +
IFN B-CellLine -
- I-CellLine -
alpha I-CellLine -
- I-CellLine -
treated I-CellLine +
cells I-CellLine +
. O +

Finally O +
, O +
the O +
results O +
demonstrate O +
that O +
IFN O -
- O -
alpha O +
exerts O +
an O +
antiproliferative O +
effect O +
in O +
all O +
three O +
cell O +
lines O +
. O +

These O +
data O +
indicate O +
that O +
Lck O +
and O +
active O +
MAPK O +
do O +
not O +
affect O +
IFN O -
- O -
alpha O +
-induced O +
growth O +
arrest O +
or O +
induction O +
of O +
STAT1s1 O +
and O +
-3 O +
DNA O +
binding O +
ability O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

Decreased O +
proteasome O +
-mediated O +
degradation O +
in O +
T O +
cells O +
from O +
the O +
elderly O +
: O +
A O +
role O +
in O +
immune O +
senescence O +
. O +

Induction O +
of O +
NFkappaB O +
is O +
a O +
highly O +
regulated O +
process O +
requiring O +
phosphorylation O +
, O +
ubiquitination O +
, O +
and O +
proteasome O +
-mediated O +
degradation O +
of O +
the O +
cytosolic O +
inhibitor O +
IkappaBalpha O +
. O +

Analyses O +
of O +
the O +
regulation O +
of O +
IkappaBalpha O +
in O +
TNF O -
- O -
alpha O -
- O -
treated O +
T O +
lymphocytes O +
from O +
young O +
and O +
elderly O +
donors O +
revealed O +
severely O +
compromised O +
degradation O +
of O +
IkappaBalpha O +
in O +
T O +
cells O +
from O +
the O +
elderly O +
. O +

Examination O +
of O +
activation O -
- O -
induced O +
phosphorylation O +
and O +
ubiquitination O +
of O +
IkappaBalpha O +
did O +
not O +
demonstrate O +
any O +
significant O +
age O -
- O -
related O +
alterations O +
. O +

However O +
, O +
examination O +
of O +
proteasome O +
activity O +
in O +
these O +
T O +
cells O +
using O +
fluorogenic O +
peptide O +
assays O +
revealed O +
a O +
significant O +
age O -
- O -
related O +
decline O +
in O +
chymotryptic O +
activity O +
. O +

These O +
results O +
suggest O +
that O +
a O +
decline O +
in O +
proteasome O +
activity O +
results O +
in O +
a O +
failure O +
to O +
fully O +
degrade O +
IkappaBalpha O +
in O +
the O +
elderly O +
. O +

This O +
failure O +
to O +
degrade O +
IkappaBalpha O +
may O +
underlie O +
both O +
the O +
observed O +
decrease O +
in O +
NFkappaB O +
induction O +
and O +
the O +
IL-2 O +
receptor O +
expression O +
in O +
TNF B-CellLine -
- I-CellLine -
treated I-CellLine +
T I-CellLine +
cells I-CellLine +
during O +
aging O +
. O +

Thus O +
, O +
decreased O +
proteasome O +
-mediated O +
degradation O +
may O +
be O +
central O +
to O +
immune O +
dysfunction O +
that O +
accompanies O +
aging O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

Estrone O +
potentiates O +
myeloid O +
cell O +
differentiation O +
: O +
a O +
role O +
for O +
17 O +
beta O -
- O -
hydroxysteroid O +
dehydrogenase O +
in O +
modulating O +
hemopoiesis O +
. O +

Hormones O +
such O +
as O +
1 O +
alpha O +
, O +
25-dihydroxy O +
vitamin O +
D3 O +
( O +
D3 O +
) O +
, O +
all O -
- O -
trans O +
retinoic O +
acid O +
, O +
and O +
9-cis O +
retinoic O +
acid O +
stimulate O +
differentiation O +
of O +
myeloid O +
progenitor O +
cells O +
via O +
their O +
interaction O +
with O +
specific O +
hormone O +
receptors O +
. O +

However O +
, O +
the O +
sensitivity O +
of O +
cells O +
to O +
these O +
agents O +
is O +
not O +
merely O +
governed O +
by O +
the O +
expression O +
of O +
their O +
receptors O +
and O +
the O +
availability O +
of O +
ligand O +
to O +
bind O +
them O +
. O +

Recent O +
studies O +
from O +
our O +
group O +
suggested O +
that O +
the O +
actions O +
of O +
D3 O +
and O +
retinoids O +
on O +
myelopoiesis O +
also O +
are O +
influenced O +
by O +
endogenous O +
mechanisms O +
involving O +
other O +
steroid O +
hormones O +
. O +

In O +
this O +
study O +
we O +
examined O +
the O +
influence O +
of O +
local O +
estrogen O +
metabolism O +
on O +
the O +
differentiation O +
of O +
HL60 B-CellLine +
cells I-CellLine +
and O +
normal O +
primitive O +
myeloid O +
progenitor O +
cells O +
. O +

Quantitative O +
thin O -
- O -
layer O +
chromatography O +
( O +
TLC O +
) O +
analyses O +
showed O +
that O +
HL60 B-CellLine +
and O +
normal O +
cells O +
are O +
able O +
to O +
generate O +
estrone O +
( O +
E1 O +
) O +
from O +
estradiol O +
( O +
E2 O +
) O +
. O +

Neither O +
cell O +
population O +
generated O +
significant O +
amounts O +
of O +
E2 O +
from O +
E1 O +
. O +

Reverse O +
transcriptase O +
polymerase O +
chain O +
reaction O +
and O +
Northern O +
analyses O +
confirmed O +
that O +
normal O +
and O +
leukemic O +
myeloid O +
progenitor O +
cells O +
expressed O +
mRNA O +
for O +
the O +
type O +
I O +
and O +
IV O +
isoforms O +
of O +
17 O +
beta O -
- O -
hydroxysteroid O +
dehydrogenase O +
. O +

Conversion O +
of O +
E2 O +
to O +
E1 O +
was O +
upregulated O +
within O +
24 O +
hours O +
when O +
HL60 B-CellLine +
cells I-CellLine +
were O +
treated O +
with O +
either O +
all O -
- O -
trans O +
retinoic O +
acid O +
or O +
D3 O +
at O +
doses O +
that O +
induce O +
their O +
differentiation O +
toward O +
neutrophils O +
or O +
monocytes O +
, O +
respectively O +
. O +

Similarly O +
, O +
D3-induced O +
monocyte O +
differentiation O +
of O +
normal O +
myeloid O +
progenitor O +
cells O +
was O +
associated O +
with O +
increased O +
capacity O +
to O +
generate O +
E1 O +
from O +
E2 O +
. O +

When O +
HL60 B-CellLine +
cells I-CellLine +
or O +
normal O +
myeloid O +
progenitor O +
cells O +
were O +
exposed O +
to O +
exogenous O +
E1 O +
they O +
became O +
more O +
sensitive O +
to O +
the O +
differentiation O -
- O -
inducing O +
effects O +
of O +
D3 O +
. O +

Data O +
presented O +
provide O +
further O +
evidence O +
for O +
the O +
local O +
modulation O +
of O +
myelopoiesis O +
by O +
intracrine O +
mechanisms O +
. O +

In O +
particular O +
, O +
our O +
findings O +
suggest O +
that O +
local O +
metabolism O +
of O +
steroids O +
by O +
normal O +
as O +
well O +
as O +
leukemic O +
myeloid O +
cells O +
influences O +
their O +
responsiveness O +
to O +
D3 O +
and O +
retinoids O +
. O +

Interferon O -
- O -
beta O +
mediates O +
stromal O +
cell O +
rescue O +
of O +
T O +
cells O +
from O +
apoptosis O +
. O +

The O +
resolution O +
of O +
immune O +
responses O +
is O +
characterized O +
by O +
extensive O +
apoptosis O +
of O +
activated O +
T O +
cells O +
. O +

However O +
, O +
to O +
generate O +
and O +
maintain O +
immunological O +
memory O +
, O +
some O +
antigen O -
- O -
specific O +
T O +
cells O +
must O +
survive O +
and O +
revert O +
to O +
a O +
resting O +
G0 O -
/ O -
G1 O +
state O +
. O +

Cytokines O +
that O +
bind O +
to O +
the O +
common O +
gamma O +
chain O +
of O +
the O +
IL-2 O +
receptor O +
promote O +
the O +
survival O +
of O +
T O +
cell O +
blasts O +
, O +
but O +
also O +
induce O +
proliferation O +
. O +

In O +
contrast O +
, O +
soluble O +
factors O +
secreted O +
by O +
stromal O +
cells O +
induce O +
Tcell O +
survival O +
in O +
a O +
resting O +
G0 O -
/ O -
G1 O +
state O +
. O +

We O +
now O +
report O +
that O +
interferon O -
- O -
beta O +
is O +
the O +
principal O +
mediator O +
of O +
stromal O +
cell O -
- O -
mediated O +
Tcell O +
rescue O +
from O +
apoptosis O +
. O +

Interferon O -
- O -
alpha O +
and O +
-beta O +
promote O +
the O +
reversion O +
of O +
blast O +
Tcells O +
to O +
a O +
resting O +
G0 O -
/ O -
G1 O +
configuration O +
with O +
all O +
the O +
characteristic O +
features O +
of O +
stromal O +
cell O +
rescue O +
; O +
such O +
as O +
high O +
Bcl O -
- O -
XL O +
expression O +
and O +
low O +
Bcl-2 O +
. O +

Type O +
I O +
interferons O +
and O +
stromal O +
cells O +
stimulate O +
apparently O +
identical O +
signaling O +
pathways O +
, O +
leading O +
to O +
STAT-1 O +
activation O +
. O +

We O +
also O +
show O +
that O +
this O +
mechanism O +
may O +
play O +
a O +
fundamental O +
role O +
in O +
the O +
persistence O +
of O +
T O +
cells O +
at O +
sites O +
of O +
chronic O +
inflammation O +
; O +
suggesting O +
that O +
chronic O +
inflammation O +
is O +
an O +
aberrant O +
consequence O +
of O +
immunological O +
memory O +
. O +

Reduction O +
of O +
tumour O +
necrosis O +
factor O +
alpha O +
expression O +
and O +
signalling O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
from O +
patients O +
with O +
thalassaemia O +
or O +
sickle O +
cell O +
anaemia O +
upon O +
treatment O +
with O +
desferrioxamine O +
. O +

Recent O +
evidence O +
indicates O +
that O +
the O +
rate O +
of O +
progression O +
of O +
the O +
HIV-1 O +
disease O +
is O +
significantly O +
reduced O +
in O +
thalassaemia O +
major O +
patients O +
upon O +
treatment O +
with O +
high O +
doses O +
of O +
desferrioxamine O +
( O +
DFX O +
) O +
. O +

The O +
authors O +
have O +
previously O +
demonstrated O +
that O +
in O +
vitro O +
exposure O +
of O +
mononuclear O +
cells O +
to O +
DFX O +
decreases O +
the O +
bioavailability O +
of O +
tumour O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
which O +
has O +
a O +
stimulatory O +
effect O +
on O +
HIV-1 O +
replication O +
. O +

In O +
this O +
study O +
, O +
therefore O +
, O +
TNF O -
- O -
alpha O +
bioavailability O +
from O +
mononuclear O +
cells O +
isolated O +
from O +
10 O +
patients O +
with O +
thalassaemia O +
or O +
sickle O +
cell O +
anaemia O +
given O +
DFX O +
as O +
compared O +
to O +
10 O +
untreated O +
subjects O +
has O +
been O +
evaluated O +
. O +

Evidence O +
is O +
presented O +
showing O +
that O +
DFX O +
treatment O +
reduces O +
TNF O -
- O -
alpha O +
bioavailability O +
( O +
P O +
< O +
0.05 O +
) O +
by O +
inhibiting O +
its O +
steady O +
state O +
( O +
P O +
< O +
0.05 O +
) O +
and O +
by O +
enhancing O +
its O +
inactivation O +
through O +
binding O +
to O +
soluble O +
TNF O -
- O -
alpha O +
receptor O +
type O +
II O +
( O +
P O +
< O +
0.05 O +
) O +
. O +

We O +
also O +
show O +
that O +
DFX O +
treatment O +
limits O +
the O +
in O +
vivo O +
activation O +
of O +
NF O -
- O -
kappaB O +
, O +
a O +
transcription O +
factor O +
involved O +
in O +
both O +
TNF O -
- O -
alpha O +
gene O +
transcription O +
and O +
TNF O -
- O -
alpha O +
signalling O +
( O +
P O +
< O +
0.005 O +
) O +
. O +

We O +
conclude O +
that O +
TNF O -
- O -
alpha O +
bioavailability O +
and O +
signalling O +
are O +
impaired O +
in O +
patients O +
upon O +
DFX O +
treatment O +
. O +

This O +
mechanism O +
may O +
contribute O +
to O +
delayed O +
progression O +
of O +
the O +
HIV-1 O +
infection O +
in O +
vivo O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

Involvement O +
of O +
adenylate O +
cyclase O +
and O +
p70 O +
( O +
S6 O +
) O +
-kinase O +
activation O +
in O +
IL-10 O +
up O -
- O -
regulation O +
in O +
human O +
monocytes O +
by O +
gp41 O +
envelope O +
protein O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
. O +

Our O +
previous O +
results O +
show O +
that O +
recombinant O +
gp41 O +
( O +
aa565 O -
- O -
647 O +
) O +
, O +
the O +
extracellular O +
domain O +
of O +
HIV-1 O +
transmembrane O +
glycoprotein O +
, O +
stimulates O +
interleukin-10 O +
( O +
IL-10 O +
) O +
production O +
in O +
human O +
monocytes O +
. O +

The O +
signal O +
cascade O +
transducing O +
this O +
effect O +
is O +
not O +
yet O +
clear O +
. O +

In O +
this O +
study O +
, O +
we O +
examined O +
whether O +
gp41 O +
-induced O +
IL-10 O +
up O -
- O -
regulation O +
is O +
mediated O +
by O +
the O +
previously O +
described O +
synergistic O +
activation O +
of O +
cAMP O +
and O +
NF O -
- O -
kappaB O +
pathways O +
. O +

gp41 O +
induced O +
cAMP O +
accumulation O +
in O +
monocytes O +
in O +
a O +
time- O +
and O +
concentration O -
- O -
dependent O +
manner O +
and O +
the O +
adenylate O +
cyclase O +
inhibitor O +
SQ O +
22536 O +
suppressed O +
gp41 O +
-induced O +
IL-10 O +
production O +
in O +
monocytes O +
. O +

In O +
contrast O +
, O +
gp41 O +
failed O +
to O +
stimulate O +
NF O -
- O -
kappaB O +
binding O +
activity O +
in O +
as O +
much O +
as O +
no O +
NF O -
- O -
kappaB O +
bound O +
to O +
the O +
main O +
NF O -
- O -
kappaB O -
- O -
binding O +
site O +
2 O +
of O +
the O +
IL-10 O +
promoter O +
after O +
addition O +
of O +
gp41 O +
. O +

We O +
also O +
examined O +
the O +
involvement O +
of O +
other O +
signal O +
transduction O +
pathways O +
. O +

Specific O +
inhibitors O +
of O +
p70 O +
( O +
S6 O +
) O +
-kinase O +
( O +
rapamycin O +
) O +
, O +
and O +
Gi O +
protein O +
( O +
pertussis O +
toxin O +
) O +
, O +
prevented O +
induction O +
of O +
IL-10 O +
production O +
by O +
gp41 O +
in O +
monocytes O +
, O +
while O +
inhibitors O +
of O +
the O +
phosphatidylinositol O +
3-kinase O +
( O +
PI O +
3-kinase O +
) O +
( O +
wortmannin O +
) O +
and O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
pathway O +
( O +
PD O +
98059 O +
) O +
did O +
not O +
. O +

Thus O +
HIV-1 O +
gp41 O +
-induced O +
IL-10 O +
up O -
- O -
regulation O +
in O +
monocytes O +
may O +
not O +
involve O +
NF O -
- O -
kappaB O +
, O +
MAPK O +
, O +
or O +
PI O +
3-kinase O +
activation O +
, O +
but O +
rather O +
may O +
operate O +
through O +
activation O +
of O +
adenylate O +
cyclase O +
and O +
pertussis O -
- O -
toxin O -
- O -
sensitive O +
Gi O -
/ O -
Go O +
protein O +
to O +
effect O +
p70 O +
( O +
S6 O +
) O +
-kinase O +
activation O +
. O +

Nonimmunoglobulin O +
gene O +
hypermutation O +
in O +
germinal O +
center O +
B O +
cells O +
. O +

Somatic O +
hypermutation O +
is O +
the O +
most O +
critical O +
mechanism O +
underlying O +
the O +
diversification O +
of O +
Ig O +
genes O +
. O +

Although O +
mutation O +
occurs O +
specifically O +
in O +
B O +
cells O +
during O +
the O +
germinal O +
center O +
reaction O +
, O +
it O +
remains O +
a O +
matter O +
of O +
debate O +
whether O +
the O +
mutation O +
machinery O +
also O +
targets O +
non O -
- O -
Ig O +
genes O +
. O +

We O +
have O +
studied O +
mutations O +
in O +
the O +
5 O +
' O +
noncoding O +
region O +
of O +
the O +
Bcl6 O +
gene O +
in O +
different O +
subtypes O +
of O +
lymphomas O +
. O +

We O +
found O +
frequent O +
hypermutation O +
in O +
follicular O +
lymphoma O +
( O +
25 O +
of O +
59 O +
= O +
42 O +
% O +
) O +
( O +
germinal O +
center O +
cell O +
origin O +
) O +
and O +
mucosa O -
- O -
associated O +
lymphoid O +
tissue O +
( O +
MALT O +
) O +
lymphoma O +
( O +
19 O +
of O +
45 O +
= O +
42 O +
% O +
) O +
( O +
postgerminal O +
center O +
) O +
, O +
but O +
only O +
occasionally O +
in O +
mantle O +
cell O +
lymphoma O +
( O +
1 O +
of O +
21 O +
= O +
4.8 O +
% O +
) O +
( O +
pregerminal O +
center O +
) O +
. O +

Most O +
mutations O +
were O +
outside O +
the O +
motifs O +
potentially O +
important O +
for O +
transcription O +
, O +
suggesting O +
they O +
were O +
not O +
important O +
in O +
lymphomagenesis O +
but O +
may O +
, O +
like O +
Ig O +
mutation O +
, O +
represent O +
an O +
inherent O +
feature O +
of O +
the O +
lymphoma O +
precursor O +
cells O +
. O +

Therefore O +
, O +
we O +
investigated O +
their O +
normal O +
cell O +
counterparts O +
microdissected O +
from O +
a O +
reactive O +
tonsil O +
. O +

Bcl6 O +
mutation O +
was O +
found O +
in O +
13 O +
of O +
24 O +
( O +
54 O +
% O +
) O +
clones O +
from O +
the O +
germinal O +
centre O +
but O +
only O +
in O +
1 O +
of O +
24 O +
( O +
4 O +
% O +
) O +
clones O +
from O +
the O +
naive O +
B O +
cells O +
of O +
the O +
mantle O +
zone O +
. O +

The O +
frequency O +
, O +
distribution O +
, O +
and O +
nature O +
of O +
these O +
mutations O +
were O +
similar O +
to O +
those O +
resulting O +
from O +
the O +
Ig O +
hypermutation O +
process O +
. O +

The O +
results O +
show O +
unequivocal O +
evidence O +
of O +
non- O +
Ig O +
gene O +
hypermutation O +
in O +
germinal O +
center O +
B O +
cells O +
and O +
provide O +
fresh O +
insights O +
into O +
the O +
process O +
of O +
hypermutation O +
and O +
lymphomagenesis O +
. O +

Human O +
immunodeficiency O +
virus O -
- O -
associated O +
Hodgkin O +
's O +
disease O +
derives O +
from O +
post O -
- O -
germinal O +
center O +
B O +
cells O +
. O +

Human O +
immunodeficiency O +
virus O -
- O -
associated O +
Hodgkin O +
's O +
disease O +
( O +
HIV O -
- O -
HD O +
) O +
displays O +
several O +
peculiarities O +
when O +
compared O +
with O +
HD O +
of O +
the O +
general O +
population O +
. O +

These O +
include O +
overrepresentation O +
of O +
clinically O +
aggressive O +
histologic O +
types O +
and O +
frequent O +
infection O +
of O +
Reed B-CellLine -
- I-CellLine -
Sternberg I-CellLine +
( I-CellLine +
RS I-CellLine +
) I-CellLine +
cells I-CellLine +
by O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
. O +

Recently O +
, O +
we O +
have O +
reported O +
that O +
the O +
histogenesis O +
of O +
HD O +
of O +
the O +
general O +
population O +
may O +
be O +
assessed O +
by O +
monitoring O +
the O +
expression O +
pattern O +
of O +
BCL-6 O +
, O +
a O +
transcription O +
factor O +
expressed O +
in O +
germinal B-CellLine +
center I-CellLine +
( I-CellLine +
GC I-CellLine +
) I-CellLine +
B I-CellLine +
cells I-CellLine +
, O +
and O +
of O +
CD138 O -
/ O -
syndecan-1 O +
( O +
syn-1 O +
) O +
, O +
a O +
proteoglycan O +
associated O +
with O +
post O -
- O -
GC O +
, O +
terminal O +
B O -
- O -
cell O +
differentiation O +
. O +

In O +
this O +
study O +
, O +
we O +
have O +
applied O +
these O +
two O +
markers O +
to O +
the O +
study O +
of O +
HIV O -
- O -
HD O +
histogenesis O +
and O +
correlated O +
their O +
expression O +
status O +
to O +
the O +
virologic O +
features O +
of O +
this O +
disease O +
. O +

We O +
have O +
found O +
that O +
RS B-CellLine +
cells I-CellLine +
of O +
all O +
histologic O +
categories O +
of O +
HIV O -
- O -
HD O +
consistently O +
display O +
the O +
BCL-6 O +
( O +
- O +
) O +
/syn-1 O +
( O +
+ O +
) O +
phenotype O +
and O +
thus O +
reflect O +
post B-CellLine -
- I-CellLine -
GC I-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

Although O +
BCL-6 O +
( O +
- O +
) O +
/syn-1 O +
( O +
+ O +
) O +
RS B-CellLine +
cells I-CellLine +
of O +
HIV O -
- O -
HD O +
express O +
CD40 O +
, O +
they O +
are O +
not O +
surrounded O +
by O +
CD40 O +
ligand O -
- O -
positive O +
( O +
CD40L+ O +
) O +
reactive O +
T O +
lymphocytes O +
, O +
which O +
, O +
in O +
HD O +
of O +
the O +
general O +
population O +
, O +
are O +
thought O +
to O +
regulate O +
the O +
disease O +
phenotype O +
through O +
CD40 O +
/CD40L O +
interactions O +
. O +

Conversely O +
, O +
RS B-CellLine +
cells I-CellLine +
of O +
virtually O +
all O +
HIV O -
- O -
HD O +
express O +
the O +
EBV O -
- O -
encoded O +
latent O +
membrane O +
protein O +
1 O +
( O +
LMP1 O +
) O +
, O +
which O +
, O +
being O +
functionally O +
homologous O +
to O +
CD40 O +
, O +
may O +
contribute O +
, O +
at O +
least O +
in O +
part O +
, O +
to O +
the O +
modulation O +
of O +
the O +
HIV O -
- O -
HD O +
phenotype O +
. O +

Evidence O +
for O +
distinct O +
intracellular O +
signaling O +
pathways O +
in O +
CD34 O -
+ O +
progenitor O +
to O +
dendritic O +
cell O +
differentiation O +
from O +
a O +
human O +
cell O +
line O +
model O +
. O +

Intracellular O +
signals O +
that O +
mediate O +
differentiation O +
of O +
pluripotent O +
hemopoietic O +
progenitors O +
to O +
dendritic O +
cells O +
( O +
DC O +
) O +
are O +
largely O +
undefined O +
. O +

We O +
have O +
previously O +
shown O +
that O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
activation O +
( O +
with O +
phorbol O +
ester O +
( O +
PMA O +
) O +
alone O +
) O +
specifically O +
induces O +
differentiation O +
of O +
primary B-CellLine +
human I-CellLine +
CD34 I-CellLine -
+ I-CellLine +
hemopoietic I-CellLine +
progenitor I-CellLine +
cells I-CellLine +
( O +
HPC B-CellLine +
) O +
to O +
mature O +
DC O +
. O +

We O +
now O +
find O +
that O +
cytokine O -
- O -
driven O +
( O +
granulocyte O -
- O -
macrophage O +
CSF O +
and O +
TNF O -
- O -
alpha O +
) O +
CD34 O -
+ O +
HPC B-CellLine +
-- O +
> O +
DC O +
differentiation O +
is O +
preferentially O +
blocked O +
by O +
inhibitors O +
of O +
PKC O +
activation O +
. O +

To O +
further O +
identify O +
intracellular O +
signals O +
and O +
downstream O +
events O +
important O +
in O +
CD34 B-CellLine -
+ I-CellLine +
HPC I-CellLine +
-- O +
> O +
DC O +
differentiation O +
we O +
have O +
characterized O +
a O +
human O +
leukemic O +
cell O +
line O +
model O +
of O +
this O +
process O +
. O +

The O +
CD34 B-CellLine -
+ I-CellLine +
myelomonocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
KG1 B-CellLine +
differentiates O +
into O +
dendritic O -
- O -
like O +
cells O +
in O +
response O +
to O +
granulocyte O -
- O -
macrophage O +
CSF O +
plus O +
TNF O -
- O -
alpha O +
, O +
or O +
PMA O +
( O +
with O +
or O +
without O +
the O +
calcium O +
ionophore O +
ionomycin O +
, O +
or O +
TNF O -
- O -
alpha O +
) O +
, O +
with O +
different O +
stimuli O +
mediating O +
different O +
aspects O +
of O +
the O +
process O +
. O +

Phenotypic O +
DC O +
characteristics O +
of O +
KG1 B-CellLine +
dendritic I-CellLine -
- I-CellLine -
like I-CellLine +
cells I-CellLine +
include O +
morphology O +
( O +
loosely O +
adherent O +
cells O +
with O +
long O +
neurite O +
processes O +
) O +
, O +
MHC O +
I+ O -
/ O +
MHC O +
IIbright O -
/ O -
CD83+ O -
/ O -
CD86+ O -
/ O +
CD14 O +
- O +
surface O +
Ag O +
expression O +
, O +
and O +
RelB O +
and O +
DC O +
-CK1 O +
gene O +
expression O +
. O +

Functional O +
DC O +
characteristics O +
include O +
fluid O +
phase O +
macromolecule O +
uptake O +
( O +
FITC O -
- O -
dextran O +
) O +
and O +
activation O +
of O +
resting O +
T O +
cells O +
. O +

Comparison O +
of O +
KG1 B-CellLine +
to O +
the O +
PMA B-CellLine -
- I-CellLine -
unresponsive I-CellLine +
subline I-CellLine +
KG1a I-CellLine +
reveals O +
differences O +
in O +
expression O +
of O +
TNF O +
receptors O +
1 O +
and O +
2 O +
; O +
PKC O +
isoforms O +
alpha O +
, O +
beta O +
I O +
, O +
beta O +
II O +
, O +
and O +
mu O +
; O +
and O +
RelB O +
, O +
suggesting O +
that O +
these O +
components O -
/ O -
pathways O +
are O +
important O +
for O +
DC O +
differentiation O +
. O +

Together O +
, O +
these O +
findings O +
demonstrate O +
that O +
cytokine O +
or O +
phorbol O +
ester O +
stimulation O +
of O +
KG1 B-CellLine +
is O +
a O +
model O +
of O +
human B-CellLine +
CD34 I-CellLine -
+ I-CellLine +
HPC I-CellLine +
to O +
DC O +
differentiation O +
and O +
suggest O +
that O +
specific O +
intracellular O +
signaling O +
pathways O +
mediate O +
specific O +
events O +
in O +
DC O +
lineage O +
commitment O +
. O +

Glucocorticoids O +
promote O +
nonphlogistic O +
phagocytosis O +
of O +
apoptotic O +
leukocytes O +
. O +

Phagocyte O +
recognition O +
, O +
uptake O +
, O +
and O +
nonphlogistic O +
degradation O +
of O +
neutrophils O +
and O +
other O +
leukocytes O +
undergoing O +
apoptosis O +
promote O +
the O +
resolution O +
of O +
inflammation O +
. O +

This O +
study O +
assessed O +
the O +
effects O +
of O +
anti O -
- O -
inflammatory O +
glucocorticoids O +
on O +
this O +
leukocyte O +
clearance O +
mechanism O +
. O +

Pretreatment O +
of O +
` O -
` O +
semimature O +
'' O +
5-day O +
human O +
monocyte O -
- O -
derived O +
macrophages O +
( O +
M O +
phi O +
) O +
for O +
24 O +
h O +
with O +
methylprednisolone O +
, O +
dexamethasone O +
, O +
and O +
hydrocortisone O +
, O +
but O +
not O +
the O +
nonglucocorticoid O +
steroids O +
aldosterone O +
, O +
estradiol O +
, O +
and O +
progesterone O +
, O +
potentiated O +
phagocytosis O +
of O +
apoptotic O +
neutrophils O +
. O +

These O +
effects O +
were O +
specific O +
in O +
that O +
the O +
potentiated O +
phagocytosis O +
of O +
apoptotic O +
neutrophils O +
was O +
completely O +
blocked O +
by O +
the O +
glucocorticoid O +
receptor O +
antagonist O +
RU38486 O +
, O +
and O +
glucocorticoids O +
did O +
not O +
promote O +
5-day O +
M O +
phi O +
ingestion O +
of O +
opsonized O +
erythrocytes O +
. O +

Similar O +
glucocorticoid O -
- O -
mediated O +
potentiation O +
was O +
observed O +
with O +
5-day O +
M O +
phi O +
uptake O +
of O +
alternative O +
apoptotic O +
` O -
` O +
targets O +
'' O +
( O +
eosinophils O +
and O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
) O +
and O +
in O +
uptake O +
of O +
apoptotic O +
neutrophils O +
by O +
alternative O +
phagocytes O +
( O +
human O +
glomerular O +
mesangial O +
cells O +
and O +
murine B-CellLine +
M I-CellLine +
phi I-CellLine +
elicited O +
into O +
the O +
peritoneum O +
or O +
derived O +
from O +
bone O +
marrow O +
) O +
. O +

Importantly O +
, O +
methylprednisolone O -
- O -
mediated O +
enhancement O +
of O +
the O +
uptake O +
of O +
apoptotic O +
neutrophils O +
did O +
not O +
trigger O +
the O +
release O +
of O +
the O +
chemokines O +
IL-8 O +
and O +
monocyte O +
chemoattractant O +
protein-1 O +
. O +

Furthermore O +
, O +
longer O -
- O -
term O +
potentiation O +
by O +
methylprednisolone O +
was O +
observed O +
in O +
maturing B-CellLine +
human I-CellLine +
monocyte I-CellLine -
- I-CellLine -
derived I-CellLine +
M I-CellLine +
phi I-CellLine +
, O +
with O +
greater O +
increases O +
in O +
5-day O +
M B-CellLine +
phi I-CellLine +
uptake O +
of O +
apoptotic O +
cells O +
being O +
observed O +
the O +
earlier O +
glucocorticoids O +
were O +
added O +
during O +
monocyte O +
maturation O +
into O +
M B-CellLine +
phi I-CellLine +
. O +

We O +
conclude O +
that O +
potentiation O +
of O +
nonphlogistic O +
clearance O +
of O +
apoptotic O +
leukocytes O +
by O +
phagocytes O +
is O +
a O +
hitherto O +
unrecognized O +
property O +
of O +
glucocorticoids O +
that O +
has O +
potential O +
implications O +
for O +
therapies O +
aimed O +
at O +
promoting O +
the O +
resolution O +
of O +
inflammatory O +
diseases O +
. O +

Stimulation O +
of O +
CD40 O +
on O +
immunogenic O +
human O +
malignant O +
melanomas O +
augments O +
their O +
cytotoxic O +
T O +
lymphocyte O +
-mediated O +
lysis O +
and O +
induces O +
apoptosis O +
. O +

Here O +
, O +
we O +
report O +
the O +
functional O +
expression O +
of O +
CD40 O +
on O +
human O +
malignant O +
melanomas O +
( O +
MMs O +
) O +
. O +

Comparison O +
of O +
tumor O +
specimen O +
from O +
MM O +
precursor O +
lesions O +
, O +
primary O +
tumors O +
, O +
and O +
metastases O +
revealed O +
that O +
CD40 O +
surface O +
expression O +
is O +
down O -
- O -
regulated O +
during O +
tumor O +
progression O +
. O +

CD40 O +
expression O +
was O +
confirmed O +
in O +
7 O +
human B-CellLine +
MM I-CellLine +
cell I-CellLine +
lines I-CellLine +
established O +
from O +
immunogenic O +
primary O +
tumors O +
or O +
metastases O +
, O +
whereas O +
11 O +
cell B-CellLine +
lines I-CellLine +
established O +
from O +
advanced O +
stages O +
were O +
CD40 O +
negative O +
. O +

CD40 O +
expression O +
could O +
be O +
enhanced O +
in O +
CD40 O +
-positive O +
MM O +
by O +
stimulation O +
with O +
IFN O -
- O -
gamma O +
and O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
but O +
not O +
by O +
interleukin O +
( O +
IL O +
) O +
-1beta O +
or O +
CD40 O +
triggering O +
. O +

CD40 O +
ligation O +
on O +
MM O +
by O +
CD40L B-CellLine -
- I-CellLine -
transfected I-CellLine +
murine I-CellLine +
L I-CellLine -
- I-CellLine -
cells I-CellLine +
or O +
by O +
a O +
soluble O +
CD40L O +
fusion O +
protein O +
up O -
- O -
regulated O +
their O +
expression O +
of O +
intercellular O +
adhesion O +
molecule-1 O +
and O +
MHC O +
class O +
I O +
and O +
class O +
II O +
molecules O +
and O +
their O +
secretion O +
of O +
IL-6 O +
, O +
IL-8 O +
, O +
tumor O +
necrosis O +
factor O -
- O -
a O +
, O +
and O +
granulocyte O +
macrophage O +
colony O -
- O -
stimulating O +
factor O +
and O +
also O +
induced O +
a O +
rapid O +
activation O +
of O +
the O +
transcription O +
factor O +
nuclear O +
factor O +
kappaB O +
. O +

Furthermore O +
, O +
CD40 O +
ligation O +
of O +
a O +
HLA B-CellLine -
- I-CellLine -
A2 I-CellLine -
+ I-CellLine +
, I-CellLine +
MelanA I-CellLine -
/ I-CellLine -
MART1 I-CellLine -
+ I-CellLine +
MM I-CellLine +
cell I-CellLine +
line I-CellLine +
enhanced O +
its O +
susceptibility O +
to O +
specific O +
lysis O +
by O +
a O +
HLA B-CellLine -
- I-CellLine -
A2-restricted I-CellLine +
, I-CellLine +
MelanA I-CellLine -
/ I-CellLine -
MART-1-specific I-CellLine +
CTL I-CellLine +
clone I-CellLine +
. O +

Finally O +
, O +
CD40 O +
ligation O +
induced O +
growth O +
inhibition O +
and O +
apoptosis O +
in O +
MM O +
. O +

These O +
results O +
indicate O +
that O +
CD40 O +
-CD40L O +
interactions O +
may O +
play O +
an O +
important O +
role O +
in O +
augmenting O +
antitumor O +
immunity O +
and O +
inducing O +
apoptosis O +
in O +
some O +
CD40 O +
-positive O +
immunogenic O +
human O +
MMs O +
. O +

Glucocorticoid O -
- O -
induced O +
cell O +
death O +
requires O +
autoinduction O +
of O +
glucocorticoid O +
receptor O +
expression O +
in O +
human O +
leukemic O +
T O +
cells O +
. O +

In O +
contrast O +
to O +
the O +
negative O +
autoregulation O +
of O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
expression O +
seen O +
in O +
most O +
cells O +
and O +
tissues O +
, O +
GR O +
expression O +
is O +
positively O +
autoregulated O +
in O +
human O +
leukemic O +
T O +
cells O +
and O +
in O +
other O +
cells O +
sensitive O +
to O +
glucocorticoid O -
- O -
induced O +
cell O +
death O +
. O +

To O +
determine O +
whether O +
positive O +
autoregulation O +
is O +
a O +
necessary O +
component O +
of O +
glucocorticoid O -
- O -
induced O +
cell O +
death O +
, O +
a O +
wild O -
- O -
type O +
GR O +
gene O +
under O +
the O +
control O +
of O +
a O +
tetracycline O -
- O -
regulated O +
promoter O +
was O +
stably O +
transfected O +
into O +
glucocorticoid B-CellLine -
- I-CellLine -
resistant I-CellLine +
cells I-CellLine +
lacking O +
endogenous O +
functional O +
receptor O +
. O +

Transfectants B-CellLine +
grown O +
in O +
the O +
presence O +
of O +
tetracycline O +
contained O +
about O +
15 O +
, O +
000 O +
receptors O -
/ O -
cell O +
, O +
a O +
value O +
approximately O +
equal O +
to O +
basal O +
level O +
GR O +
expression O +
in O +
glucocorticoid B-CellLine -
- I-CellLine -
sensitive I-CellLine +
6TG1.1 I-CellLine +
cells I-CellLine +
before O +
steroid O +
treatment O +
. O +

Under O +
these O +
conditions O +
, O +
dexamethasone O +
had O +
a O +
minimal O +
effect O +
on O +
cell O +
growth O +
, O +
elicited O +
little O +
internucleosomal O +
DNA O +
fragmentation O +
, O +
and O +
induced O +
no O +
cell O +
cycle O +
perturbation O +
. O +

In O +
the O +
absence O +
of O +
tetracycline O +
, O +
GR O +
mRNA O +
and O +
protein O +
expression O +
increased O +
2 O -
- O -
3-fold O +
, O +
and O +
cells O +
expressed O +
48 O +
, O +
000 O +
receptors O +
, O +
a O +
level O +
nearly O +
equivalent O +
to O +
that O +
present O +
in O +
6TG1.1 B-CellLine +
cells I-CellLine +
after O +
18 O +
h O +
of O +
autoinduction O +
. O +

Under O +
these O +
conditions O +
, O +
dexamethasone O +
markedly O +
inhibited O +
cell O +
growth O +
, O +
caused O +
G1 O +
arrest O +
, O +
and O +
induced O +
significant O +
internucleosomal O +
DNA O +
fragmentation O +
. O +

These O +
studies O +
therefore O +
suggest O +
that O +
basal O +
level O +
GR O +
expression O +
is O +
inadequate O +
to O +
mediate O +
glucocorticoid O -
- O -
induced O +
apoptosis O +
in O +
glucocorticoid B-CellLine -
- I-CellLine -
sensitive I-CellLine +
T I-CellLine +
cells I-CellLine +
and O +
that O +
positive O +
autoregulation O +
is O +
a O +
necessary O +
component O +
of O +
this O +
process O +
. O +

Expression O +
of O +
IkappaBalpha O +
in O +
the O +
nucleus O +
of O +
human O +
peripheral O +
blood O +
T O +
lymphocytes O +
. O +

According O +
to O +
current O +
models O +
the O +
inhibitory O +
capacity O +
of O +
I O +
( O +
kappa O +
) O +
B O +
( O +
alpha O +
) O +
would O +
be O +
mediated O +
through O +
the O +
retention O +
of O +
Rel O -
/ O -
NF O -
- O -
kappaB O +
proteins O +
in O +
the O +
cytosol O +
. O +

However O +
, O +
I O +
( O +
kappa O +
) O +
B O +
( O +
alpha O +
) O +
has O +
also O +
been O +
detected O +
in O +
the O +
nucleus O +
of O +
cell O +
lines O +
and O +
when O +
overexpressed O +
by O +
transient O +
transfection O +
. O +

To O +
gain O +
better O +
insight O +
into O +
the O +
potential O +
role O +
of O +
nuclear O +
I O +
( O +
kappa O +
) O +
B O +
( O +
alpha O +
) O +
in O +
a O +
physiological O +
context O +
we O +
have O +
analysed O +
its O +
presence O +
in O +
the O +
nucleus O +
of O +
human O +
peripheral O +
blood O +
T O +
lymphocytes O +
( O +
PBL O +
) O +
. O +

We O +
demonstrate O +
the O +
nuclear O +
localization O +
of O +
I O +
( O +
kappa O +
) O +
B O +
( O +
alpha O +
) O +
in O +
PBL O +
by O +
different O +
techniques O +
: O +
Western O +
blot O +
, O +
indirect O +
immunofluorescence O +
and O +
electron O +
microscopy O +
. O +

Low O +
levels O +
of O +
nuclear O +
I O +
( O +
kappa O +
) O +
B O +
( O +
alpha O +
) O +
were O +
detected O +
in O +
resting O +
cells O +
whereas O +
a O +
superinduction O +
was O +
obtained O +
after O +
PMA O +
activation O +
. O +

The O +
nuclear O +
pool O +
of O +
I O +
( O +
kappa O +
) O +
B O +
( O +
alpha O +
) O +
showed O +
a O +
higher O +
stability O +
than O +
cytosolic O +
I O +
( O +
kappa O +
) O +
B O +
( O +
alpha O +
) O +
and O +
was O +
partially O +
independent O +
of O +
the O +
resynthesis O +
of O +
the O +
protein O +
. O +

Unexpectedly O +
, O +
the O +
presence O +
of O +
nuclear O +
I O +
( O +
kappa O +
) O +
B O +
( O +
alpha O +
) O +
did O +
not O +
inhibit O +
NF O -
- O -
kappaB O +
binding O +
to O +
DNA O +
and O +
this O +
phenomenon O +
was O +
not O +
due O +
to O +
the O +
presence O +
of O +
IkappaBbeta O +
at O +
the O +
nuclear O +
level O +
. O +

Immunoprecipitation O +
experiments O +
failed O +
to O +
demonstrate O +
an O +
association O +
between O +
nuclear O +
I O +
( O +
kappa O +
) O +
B O +
( O +
alpha O +
) O +
and O +
NF O -
- O -
kappaB O +
proteins O +
. O +

Our O +
results O +
demonstrate O +
that O +
in O +
resting O +
and O +
PMA O -
- O -
activated O +
human O +
PBL O +
, O +
I O +
( O +
kappa O +
) O +
B O +
( O +
alpha O +
) O +
is O +
present O +
in O +
the O +
nucleus O +
in O +
an O +
apparently O +
inactive O +
form O +
unable O +
to O +
disrupt O +
NF O -
- O -
kappaB O +
binding O +
from O +
DNA O +
. O +

Modulation O +
of O +
the O +
immune O +
response O +
by O +
progesterone O -
- O -
induced O +
lymphocyte O +
factors O +
. O +

Rat O +
spleen O +
and O +
peripheral O +
blood O +
lymphocytes O +
express O +
progesterone O +
receptors O +
whose O +
concentration O +
is O +
increased O +
greatly O +
during O +
the O +
early O +
phase O +
of O +
pregnancy O +
. O +

After O +
stimulation O +
of O +
progesterone O +
the O +
expression O +
of O +
receptors O +
was O +
augmented O +
2 O -
- O -
3 O +
times O +
. O +

When O +
cells O +
were O +
cultured O +
in O +
the O +
presence O +
of O +
progesterone O +
they O +
released O +
a O +
soluble O +
factor O +
that O +
inhibited O +
cellular O +
immunoreactions O +
( O +
MLR O +
, O +
CRC O +
) O +
and O +
cellular O +
proliferation O +
as O +
measured O +
by O +
thymidine O +
incorporation O +
by O +
spleen B-CellLine -
- I-CellLine -
cell I-CellLine +
culture I-CellLine +
. O +

This O +
factor O +
also O +
inhibited O +
the O +
synthesis O +
of O +
anti O -
- O -
DNP O +
antibodies O +
by O +
a O +
mouse B-CellLine +
hybridoma I-CellLine +
and O +
diminished O +
the O +
proportion O +
of O +
cells O +
in O +
phase O +
S O +
. O +

However O +
, O +
the O +
percentage O +
of O +
asymmetric O +
molecules O +
produced O +
by O +
the O +
hybridoma B-CellLine +
remained O +
unaltered O +
. O +

These O +
results O +
support O +
the O +
hypothesis O +
that O +
soluble O +
factors O +
released O +
by O +
rat O +
lymphocytes O +
modulate O +
the O +
immune O +
response O +
of O +
the O +
mother O +
and O +
participate O +
in O +
the O +
mechanism O +
that O +
protects O +
the O +
fetus O +
against O +
antipaternal O +
antibodies O +
. O +

PGG O -
- O -
glucan O +
, O +
a O +
soluble O +
beta- O +
( O +
1 O +
, O +
3 O +
) O +
-glucan O +
, O +
enhances O +
the O +
oxidative O +
burst O +
response O +
, O +
microbicidal O +
activity O +
, O +
and O +
activates O +
an O +
NF O -
- O -
kappa O +
B O -
- O -
like O +
factor O +
in O +
human O +
PMN O +
: O +
evidence O +
for O +
a O +
glycosphingolipid O +
beta- O +
( O +
1 O +
, O +
3 O +
) O +
-glucan O +
receptor O +
. O +

PGG O -
- O -
Glucan O +
, O +
a O +
soluble O +
beta- O +
( O +
1 O +
, O +
6 O +
) O +
-branched O +
beta- O +
( O +
1 O +
, O +
3 O +
) O +
-linked O +
glucose O +
homopolymer O +
derived O +
from O +
the O +
cell O +
wall O +
of O +
the O +
yeast O +
Saccharomyces O +
cerevisiae O +
, O +
is O +
an O +
immunomodulator O +
which O +
enhances O +
leukocyte O +
anti O -
- O -
infective O +
activity O +
and O +
enhances O +
myeloid O +
and O +
megakaryocyte O +
progenitor O +
proliferation O +
. O +

Incubation O +
of O +
human O +
whole O +
blood O +
with O +
PGG O -
- O -
Glucan O +
significantly O +
enhanced O +
the O +
oxidative O +
burst O +
response O +
of O +
subsequently O +
isolated O +
blood O +
leukocytes O +
to O +
both O +
soluble O +
and O +
particulate O +
activators O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
, O +
and O +
increased O +
leukocyte O +
microbicidal O +
activity O +
. O +

No O +
evidence O +
for O +
inflammatory O +
cytokine O +
production O +
was O +
obtained O +
under O +
these O +
conditions O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
demonstrated O +
that O +
PGG O -
- O -
Glucan O +
induced O +
the O +
activation O +
of O +
an O +
NF O -
- O -
kappaB O -
- O -
like O +
nuclear O +
transcription O +
factor O +
in O +
purified O +
human O +
neutrophils O +
. O +

The O +
binding O +
of O +
3H O -
- O -
PGG O -
- O -
Glucan O +
to O +
human O +
leukocyte O +
membranes O +
was O +
specific O +
, O +
concentration O -
- O -
dependent O +
, O +
saturable O +
, O +
and O +
high O +
affinity O +
( O +
Kd O +
approximately O +
6 O +
nM O +
) O +
. O +

A O +
monoclonal O +
antibody O +
specific O +
to O +
the O +
glycosphingolipid O +
lactosylceramide O +
was O +
able O +
to O +
inhibit O +
activation O +
of O +
the O +
NF O -
- O -
kappaB O -
- O -
like O +
factor O +
by O +
PGG O -
- O -
Glucan O +
, O +
and O +
ligand O +
binding O +
data O +
, O +
including O +
polysaccharide O +
specificity O +
, O +
suggested O +
that O +
the O +
PGG O -
- O -
Glucan O +
binding O +
moiety O +
was O +
lactosylceramide O +
. O +

These O +
results O +
indicate O +
that O +
PGG O -
- O -
Glucan O +
enhances O +
neutrophil O +
anti O -
- O -
microbial O +
functions O +
and O +
that O +
interaction O +
between O +
this O +
beta O -
- O -
glucan O +
and O +
human O +
neutrophils O +
is O +
mediated O +
by O +
the O +
glycosphingolipid O +
lactosylceramide O +
present O +
at O +
the O +
cell O +
surface O +
. O +

Essential O +
role O +
of O +
alveolar O +
macrophages O +
in O +
intrapulmonary O +
activation O +
of O +
NF O -
- O -
kappaB O +
. O +

Acute O +
inflammatory O +
injury O +
in O +
rat O +
lung O +
induced O +
by O +
deposition O +
of O +
immunoglobulin O +
G O +
immune O +
complexes O +
requires O +
expression O +
of O +
cytokines O +
and O +
chemokines O +
as O +
well O +
as O +
activation O +
of O +
the O +
transcription O +
factor O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappaB O +
. O +

There O +
is O +
little O +
direct O +
evidence O +
regarding O +
the O +
role O +
of O +
alveolar O +
macrophages O +
in O +
these O +
activation O +
events O +
. O +

In O +
the O +
present O +
studies O +
, O +
rat O +
lungs O +
were O +
depleted O +
of O +
alveolar O +
macrophages O +
by O +
airway O +
instillation O +
of O +
liposome O -
- O -
encapsulated O +
dichloromethylene O +
diphosphonate O +
. O +

These O +
procedures O +
, O +
which O +
greatly O +
reduced O +
the O +
number O +
of O +
retrievable O +
alveolar O +
macrophages O +
, O +
suppressed O +
activation O +
of O +
lung O +
NF O -
- O -
kappaB O +
in O +
the O +
inflammatory O +
model O +
. O +

In O +
addition O +
, O +
bronchoalveolar O +
lavage O +
levels O +
of O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
and O +
the O +
CXC O +
chemokine O +
, O +
macrophage O +
inflammatory O +
protein-2 O +
, O +
were O +
substantially O +
reduced O +
. O +

In O +
parallel O +
, O +
upregulation O +
of O +
the O +
lung O +
vascular O +
adhesion O +
molecule O +
, O +
intercellular O +
adhesion O +
molecule-1 O +
, O +
was O +
greatly O +
reduced O +
by O +
intrapulmonary O +
instillation O +
of O +
phosphonate O -
- O -
containing O +
liposomes O +
. O +

Neutrophil O +
accumulation O +
and O +
development O +
of O +
lung O +
injury O +
were O +
also O +
substantially O +
diminished O +
. O +

Lung O +
instillation O +
of O +
TNF O -
- O -
alpha O +
in O +
alveolar O +
macrophage O -
- O -
depleted O +
rats O +
restored O +
the O +
NF O -
- O -
kappaB O +
activation O +
response O +
in O +
whole O +
lung O +
. O +

These O +
data O +
suggest O +
that O +
, O +
in O +
this O +
inflammatory O +
model O +
, O +
initial O +
activation O +
of O +
NF O -
- O -
kappaB O +
occurs O +
in O +
alveolar O +
macrophages O +
and O +
the O +
ensuing O +
production O +
of O +
TNF O -
- O -
alpha O +
may O +
propagate O +
NF O -
- O -
kappaB O +
activation O +
to O +
other O +
cell O +
types O +
in O +
the O +
lung O +
. O +

Inhibition O +
of O +
cyclooxygenase-2 O +
expression O +
by O +
4-trifluoromethyl O +
derivatives O +
of O +
salicylate O +
, O +
triflusal O +
, O +
and O +
its O +
deacetylated O +
metabolite O +
, O +
2-hydroxy-4-trifluoromethylbenzoic O +
acid O +
. O +

The O +
therapeutic O +
potential O +
of O +
drugs O +
that O +
block O +
the O +
induction O +
of O +
cyclooxygenase-2 O +
has O +
been O +
emphasized O +
. O +

When O +
two O +
4-trifluoromethyl O +
salicylate O +
derivatives O +
[ O +
2-acetoxy-4-trifluoromethyl O -
- O -
benzoic O +
acid O +
( O +
triflusal O +
) O +
and O +
its O +
deacetylated O +
metabolite O +
2-hydroxy-4-trifluoromethylbenzoic O +
acid O +
( O +
HTB O +
) O +
] O +
were O +
compared O +
with O +
aspirin O +
and O +
sodium O +
salicylate O +
as O +
cyclooxygenase-2 O +
( O +
COX-2 O +
) O +
inhibitors O +
, O +
we O +
observed O +
that O +
in O +
bacterial O +
lipopolysaccharide O -
- O -
activated O +
human O +
blood O +
, O +
triflusal O +
, O +
aspirin O +
, O +
and O +
HTB O +
, O +
but O +
not O +
sodium O +
salicylate O +
, O +
inhibited O +
COX-2-mediated O +
prostaglandin O +
E2 O +
( O +
PGE2 O +
) O +
production O +
( O +
IC50 O +
= O +
0.16 O +
, O +
0.18 O +
, O +
0.39 O +
, O +
and O +
> O +
10 O +
mM O +
, O +
respectively O +
) O +
. O +

However O +
, O +
only O +
triflusal O +
and O +
aspirin O +
inhibited O +
purified O +
COX-2 O +
enzyme O +
. O +

To O +
test O +
this O +
apparent O +
discrepancy O +
, O +
we O +
realized O +
that O +
HTB O +
and O +
triflusal O +
( O +
but O +
neither O +
aspirin O +
nor O +
salicylate O +
) O +
produced O +
a O +
concentration O -
- O -
dependent O +
inhibition O +
of O +
COX-2 O +
protein O +
expression O +
in O +
peripheral O +
human O +
mononuclear O +
cells O +
. O +

This O +
observation O +
was O +
further O +
confirmed O +
in O +
a O +
rat O +
air O +
pouch O +
model O +
in O +
vivo O +
, O +
in O +
which O +
both O +
aspirin O +
and O +
triflusal O +
inhibited O +
PGE2 O +
production O +
( O +
ID50 O +
= O +
18.9 O +
and O +
11.4 O +
mg O -
/ O -
kg O +
p.o O -
. O +
, O +
respectively O +
) O +
but O +
only O +
triflusal O -
- O -
treated O +
animals O +
showed O +
a O +
decrease O +
in O +
COX-2 O +
expression O +
. O +

This O +
different O +
behavior O +
may O +
be O +
, O +
at O +
least O +
in O +
part O +
, O +
due O +
to O +
the O +
ability O +
of O +
HTB O +
and O +
triflusal O +
to O +
block O +
the O +
activation O +
of O +
the O +
transcription O +
factor O +
nuclear O +
factor O -
- O -
kappaB O +
to O +
a O +
higher O +
extent O +
than O +
aspirin O +
and O +
sodium O +
salicylate O +
. O +

Thus O +
, O +
in O +
addition O +
to O +
inhibiting O +
the O +
COX-2 O +
activity O +
at O +
therapeutic O +
concentrations O +
, O +
triflusal O +
is O +
able O +
to O +
block O +
through O +
its O +
metabolite O +
HTB O +
the O +
expression O +
of O +
new O +
enzyme O +
, O +
and O +
hence O +
the O +
resumption O +
of O +
PGE2 O +
synthesis O +
. O +

Triflusal O +
and O +
HTB O +
may O +
exert O +
beneficial O +
effects O +
in O +
processes O +
in O +
which O +
de O +
novo O +
COX-2 O +
expression O +
is O +
involved O +
and O +
, O +
in O +
a O +
broader O +
sense O +
, O +
in O +
pathological O +
situations O +
in O +
which O +
genes O +
under O +
nuclear O +
factor O -
- O -
kappaB O +
control O +
are O +
up O -
- O -
regulated O +
. O +

Vitamin O +
D O +
receptor O +
3'-untranslated O +
region O +
polymorphisms O +
: O +
lack O +
of O +
effect O +
on O +
mRNA O +
stability O +
. O +

Allelic O +
variation O +
at O +
the O +
3'-end O +
of O +
the O +
vitamin O +
D O +
receptor O +
( O +
VDR O +
) O +
gene O +
has O +
been O +
associated O +
with O +
a O +
3 O -
- O -
5-fold O +
increased O +
risk O +
of O +
developing O +
prostate O +
cancer O +
and O +
with O +
differences O +
in O +
bone O +
mineralization O +
. O +

This O +
genetic O +
diversity O +
does O +
not O +
alter O +
the O +
VDR O +
protein O +
structurally O +
, O +
but O +
instead O +
may O +
be O +
a O +
marker O +
( O +
s O +
) O +
of O +
other O +
, O +
nearby O +
polymorphisms O +
that O +
influence O +
message O +
stability O +
or O +
translation O +
. O +

The O +
work O +
reported O +
here O +
was O +
instigated O +
to O +
identify O +
additional O +
VDR O +
3'-UTR O +
polymorphisms O +
that O +
may O +
have O +
functional O +
significance O +
and O +
to O +
then O +
test O +
whether O +
these O +
genetic O +
variants O +
alter O +
message O +
stability O +
. O +

Initially O +
, O +
four O +
novel O +
, O +
frequently O +
occurring O +
sequence O +
variants O +
were O +
identified O +
that O +
associated O +
with O +
two O +
common O +
haplotypes O +
that O +
were O +
described O +
previously O +
. O +

These O +
common O +
sequence O +
variants O +
were O +
not O +
found O +
within O +
three O +
message O -
- O -
destabilizing O +
elements O +
that O +
we O +
mapped O +
within O +
the O +
3'-UTR O +
of O +
the O +
vitamin O +
D O +
receptor O +
mRNA O +
. O +

Furthermore O +
, O +
the O +
two O +
VDR O +
3'-UTR O +
haplotypes O +
conferred O +
an O +
identical O +
half O -
- O -
life O +
on O +
a O +
heterologous O +
beta O -
- O -
globin O +
reporter O +
gene O +
, O +
in O +
an O +
in O +
vitro O +
assay O +
. O +

We O +
therefore O +
conclude O +
that O +
common O +
polymorphisms O +
within O +
the O +
VDR O +
3'-UTR O +
do O +
not O +
influence O +
message O +
stability O +
. O +

Cleavage O +
of O +
transcription O +
factor O +
SP1 O +
by O +
caspases O +
during O +
anti O -
- O -
IgM O -
- O -
induced O +
B O -
- O -
cell O +
apoptosis O +
. O +

Apoptosis O +
is O +
instrumental O +
in O +
the O +
processes O +
generating O +
the O +
diversity O +
of O +
the O +
B O -
- O -
cell O +
repertoire O +
. O +

Autoreactive O +
B O -
- O -
cells O +
are O +
eliminated O +
by O +
anti O -
- O -
IgM O +
crosslinking O +
after O +
encountering O +
self O -
- O -
antigens O +
, O +
but O +
precise O +
mechanisms O +
leading O +
to O +
B O -
- O -
cell O +
apoptosis O +
are O +
still O +
not O +
well O +
understood O +
. O +

We O +
report O +
here O +
the O +
cleavage O +
of O +
the O +
transcription O +
factor O +
SP1 O +
in O +
the O +
human B-CellLine +
Burkitt I-CellLine +
lymphoma I-CellLine +
cell I-CellLine +
line I-CellLine +
BL60 I-CellLine +
during O +
anti O -
- O -
IgM O +
-induced O +
apoptosis O +
. O +

Western O +
blot O +
analysis O +
revealed O +
two O +
cleavage O +
products O +
of O +
approximately O +
68 O +
kDa O +
and O +
45 O +
kDa O +
after O +
induction O +
of O +
apoptosis O +
. O +

Cleavage O +
could O +
be O +
completely O +
inhibited O +
by O +
zDEVD O -
- O -
fmk O +
, O +
an O +
inhibitor O +
specific O +
for O +
caspase O +
3-like O +
proteases O +
. O +

In O -
- O -
vitro O +
cleavage O +
of O +
recombinant O +
SP1 O +
by O +
recombinant O +
caspase O +
3 O +
( O +
CPP32 O +
) O +
or O +
caspase O +
7 O +
( O +
Mch O +
3 O +
) O +
results O +
in O +
similar O +
cleavage O +
products O +
as O +
those O +
observed O +
in O +
vivo O +
. O +

Recombinant O +
caspase O +
6 O +
( O +
Mch O +
2 O +
) O +
primarily O +
generates O +
a O +
68-kDa O +
cleavage O +
product O +
, O +
as O +
observed O +
after O +
calcium O +
ionophore O +
( O +
CaI O +
) O +
induced O +
B O -
- O -
cell O +
apoptosis O +
. O +

In O +
contrast O +
, O +
caspase O +
1 O +
( O +
ICE O +
) O +
did O +
not O +
cleave O +
SP1 O +
in O +
vitro O +
. O +

The O +
time O +
course O +
of O +
SP1 O +
cleavage O +
during O +
anti O -
- O -
IgM O -
- O -
induced O +
apoptosis O +
is O +
paralleled O +
by O +
an O +
increase O +
of O +
caspase O +
activity O +
measured O +
by O +
DEVD O -
- O -
p O -
- O -
nitroanilide O +
( O +
DEVD O -
- O -
pNA O +
) O +
cleavage O +
. O +

DNA O +
band O -
- O -
shift O +
assays O +
revealed O +
a O +
decrease O +
in O +
the O +
intensity O +
of O +
the O +
full O +
length O +
SP1 O +
/DNA O +
complex O +
and O +
an O +
increase O +
in O +
the O +
intensity O +
of O +
a O +
smaller O +
complex O +
due O +
to O +
the O +
binding O +
of O +
one O +
SP1 O +
cleavage O +
product O +
. O +

By O +
Edman O +
sequencing O +
we O +
could O +
identify O +
a O +
caspase O +
3 O +
cleavage O +
site O +
after O +
Asp584 O +
( O +
D584AQPQAGR O +
) O +
, O +
generating O +
a O +
22-kDa O +
C O -
- O -
terminal O +
SP1 O +
protein O +
fragment O +
which O +
still O +
contains O +
the O +
DNA O +
binding O +
site O +
. O +

Our O +
results O +
show O +
the O +
cleavage O +
of O +
the O +
human O +
transcription O +
factor O +
SP1 O +
in O +
vivo O +
and O +
in O +
vitro O +
, O +
underlining O +
the O +
central O +
role O +
of O +
caspase O +
3-like O +
proteases O +
during O +
the O +
process O +
of O +
anti O -
- O -
IgM O -
- O -
induced O +
apoptosis O +
. O +

[ O +
Corticoids O +
and O +
allergy O +
] O +

Inflammation O +
is O +
constantly O +
observed O +
in O +
allergic O +
reactions O +
. O +

Corticosteroids O +
are O +
most O +
effective O +
in O +
preventing O +
the O +
late O +
phase O +
of O +
allergic O +
reaction O +
. O +

The O +
action O +
of O +
glucocorticosteroids O +
is O +
mediated O +
through O +
glucocorticoid O +
receptors O +
present O +
in O +
the O +
cellular O +
cytoplasm O +
. O +

When O +
activated O +
, O +
glucocorticoid O +
receptors O +
form O +
a O +
dimer O +
and O +
bind O +
to O +
DNA O +
after O +
migration O +
into O +
the O +
nucleus O +
. O +

Interaction O +
to O +
DNA O +
induces O +
changes O +
in O +
the O +
transcription O +
rate O +
, O +
leading O +
to O +
either O +
gene O +
induction O +
or O +
gene O +
repression O +
. O +

Glucocorticoid O +
receptors O +
are O +
also O +
able O +
to O +
interact O +
with O +
transcriptional O +
factors O +
such O +
as O +
AP-1 O +
( O +
activator O +
protein-1 O +
) O +
of O +
NF O -
- O -
kappa O +
B O +
( O +
nuclear O +
factor O -
- O -
kappa O +
B O +
) O +
. O +

Through O +
these O +
actions O +
glucocorticosteroids O +
are O +
susceptible O +
to O +
modify O +
functions O +
of O +
cells O +
involved O +
in O +
the O +
allergic O +
inflammatory O +
response O +
. O +

They O +
are O +
in O +
particular O +
able O +
to O +
inhibit O +
most O +
of O +
the O +
pro O -
- O -
inflammatory O +
functions O +
of O +
the O +
eosinophils O +
. O +

Evidence O +
for O +
a O +
polyclonal O +
etiology O +
of O +
palmar O +
fibromatosis O +
. O +

X O +
chromosome O +
inactivation O +
patterns O +
at O +
the O +
androgen O +
receptor O +
locus O +
were O +
evaluated O +
to O +
determine O +
clonality O +
in O +
microdissected O +
lesional O +
tissue O +
and O +
in O +
leukocytes O +
from O +
2 O +
women O +
with O +
Dupuytren O +
's O +
disease O +
. O +

The O +
tissue O +
from O +
both O +
patients O +
generated O +
a O +
polyclonal O +
pattern O +
of O +
X O +
chromosome O +
inactivation O +
of O +
the O +
human O +
androgen O +
receptor O +
gene O +
. O +

This O +
finding O +
supports O +
a O +
polyclonal O +
reactive O +
process O +
as O +
the O +
underlying O +
etiology O +
for O +
palmar O +
fibromatosis O +
. O +

The O +
Epstein O -
- O -
Barr O +
virus O +
nuclear O +
antigen O +
2 O +
( O +
EBNA2 O +
) O +
, O +
a O +
protein O +
required O +
for O +
B O +
lymphocyte O +
immortalization O +
, O +
induces O +
the O +
synthesis O +
of O +
type O +
I O +
interferon O +
in O +
Burkitt B-CellLine +
's I-CellLine +
lymphoma I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Epstein O -
- O -
Barr O +
virus O +
nuclear O +
antigen O +
2 O +
( O +
EBNA2 O +
) O +
, O +
a O +
protein O +
involved O +
in O +
cell O +
transformation O +
, O +
interferes O +
with O +
the O +
cellular O +
response O +
to O +
type O +
I O +
interferons O +
( O +
IFN O -
- O -
alpha O -
/ O -
beta O +
) O +
. O +

We O +
investigated O +
the O +
function O +
of O +
conditionally O +
expressed O +
EBNA2 O +
in O +
the O +
context O +
of O +
the O +
IFN O +
response O +
in O +
Burkitt B-CellLine +
's I-CellLine +
lymphoma I-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Expression O +
of O +
EBNA2 O +
led O +
to O +
the O +
transcriptional O +
activation O +
of O +
both O +
endogenous O +
or O +
transfected O +
IFN O -
- O -
stimulated O +
genes O +
( O +
ISGs O +
) O +
, O +
genes O +
which O +
contain O +
within O +
their O +
promoters O +
either O +
the O +
interferon O -
- O -
stimulated O +
response O +
element O +
( O +
ISRE O +
) O +
or O +
the O +
gamma O +
interferon O +
activation O +
site O +
( O +
GAS O +
) O +
. O +

In O +
search O +
of O +
a O +
molecular O +
mechanism O +
for O +
the O +
transcriptional O +
induction O +
of O +
ISGs O +
, O +
we O +
observed O +
an O +
EBNA2 O +
-dependent O +
synthesis O +
of O +
IFN O -
- O -
beta O +
mRNA O +
at O +
low O +
levels O +
and O +
the O +
secretion O +
of O +
low O +
amounts O +
of O +
IFN O +
. O +

A O +
transfected O +
IFN O -
- O -
beta O +
promoter O +
responded O +
to O +
EBNA2 O +
activation O +
, O +
and O +
a O +
sequence O +
closely O +
resembling O +
a O +
RBP O -
- O -
Jkappa O +
binding O +
site O +
was O +
pinpointed O +
as O +
a O +
potential O +
target O +
of O +
EBNA2 O +
activity O +
. O +

EBNA2 O +
-dependent O +
transcriptional O +
induction O +
of O +
the O +
IFN O -
- O -
beta O +
promoter O +
occurred O +
in O +
EBV B-CellLine -
- I-CellLine -
negative I-CellLine +
Burkitt I-CellLine +
's I-CellLine +
lymphoma I-CellLine +
cells I-CellLine +
, O +
indicating O +
that O +
other O +
EBV O +
genes O +
were O +
not O +
required O +
for O +
the O +
induction O +
of O +
IFN O -
- O -
beta O +
synthesis O +
. O +

Activation O +
of O +
NF O -
- O -
kappaB O +
in O +
Mycobacterium O +
tuberculosis O +
-induced O +
interleukin-2 O +
receptor O +
expression O +
in O +
mononuclear O +
phagocytes O +
. O +

Soluble O +
interleukin-2 O +
receptor O -
- O -
alpha O +
( O +
IL-2Ralpha O +
) O +
has O +
been O +
reported O +
to O +
be O +
increased O +
in O +
the O +
sera O +
of O +
patients O +
with O +
advanced O +
tuberculosis O +
, O +
and O +
levels O +
decline O +
after O +
therapy O +
in O +
accordance O +
with O +
improvement O +
of O +
radiologic O +
findings O +
. O +

We O +
investigated O +
expression O +
of O +
the O +
IL-2Ralpha O +
in O +
bronchoalveolar O +
lavage O +
( O +
BAL O +
) O +
cells O +
in O +
active O +
pulmonary O +
tuberculosis O +
, O +
and O +
evaluated O +
the O +
mechanism O +
Mycobacterium O +
tuberculosis O +
induces O +
in O +
the O +
IL-2Ralpha O +
using O +
the O +
THP-1 B-CellLine +
mononuclear I-CellLine +
phagocyte I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

We O +
found O +
IL-2Ralpha O +
expression O +
to O +
be O +
increased O +
in O +
BAL O +
cells O +
from O +
involved O +
sites O +
of O +
active O +
pulmonary O +
tuberculosis O +
. O +

Expression O +
of O +
the O +
alpha O -
- O -
chain O +
of O +
IL-2Ralpha O +
on O +
peripheral O +
blood O +
monocytes O +
( O +
PBM O +
) O +
was O +
induced O +
by O +
M. O +
tuberculosis O +
by O +
flow O +
cytometry O +
evaluation O +
. O +

Northern O +
analysis O +
demonstrated O +
increased O +
IL-2Ralpha O +
gene O +
expression O +
after O +
stimulation O +
with O +
M. O +
tuberculosis O +
which O +
was O +
further O +
induced O +
by O +
interferon O -
- O -
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
. O +

The O +
IL-2Ralpha O +
promoter O +
containing O +
the O +
nuclear O +
factor O +
kappa O +
B O +
( O +
NF O -
- O -
kappaB O +
) O +
site O +
was O +
transcriptionally O +
induced O +
by O +
M. O +
tuberculosis O +
and O +
this O +
NF O -
- O -
kappaB O +
site O +
could O +
confer O +
inducibility O +
to O +
a O +
heterologous O +
herpes O +
thymidine O +
kinase O +
( O +
TK O +
) O +
promoter O +
by O +
M. O +
tuberculosis O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
( O +
EMSAs O +
) O +
revealed O +
specific O +
binding O +
of O +
nuclear O +
protein O +
to O +
the O +
NF O -
- O -
kappaB O +
site O +
upon O +
induction O +
with O +
M. O +
tuberculosis O +
. O +

Using O +
antibodies O +
against O +
the O +
p50 O +
and O +
p65 O +
subunits O +
of O +
NF O -
- O -
kappaB O +
in O +
EMSAs O +
, O +
the O +
involvement O +
of O +
both O +
p50 O +
and O +
p65 O +
proteins O +
was O +
further O +
demonstrated O +
. O +

Functional O +
expression O +
of O +
the O +
IL-2Ralpha O +
on O +
mononuclear O +
phagocytes O +
in O +
M. O +
tuberculosis O +
infection O +
may O +
play O +
an O +
important O +
immunomodulatory O +
role O +
in O +
the O +
host O +
response O +
. O +

Regulation O +
of O +
the O +
megakaryocytic O +
glycoprotein O +
IX O +
promoter O +
by O +
the O +
oncogenic O +
Ets O +
transcription O +
factor O +
Fli-1 O +
. O +

Glycoprotein O +
( O +
GP O +
) O +
IX O +
is O +
a O +
subunit O +
of O +
the O +
von O +
Willebrand O +
receptor O +
, O +
GPIb O -
- O -
V O -
- O -
IX O +
, O +
which O +
mediates O +
adhesion O +
of O +
platelets O +
to O +
the O +
subendothelium O +
of O +
damaged O +
blood O +
vessels O +
. O +

Previous O +
characterization O +
of O +
the O +
GPIX O +
promoter O +
identified O +
a O +
functional O +
Ets O +
site O +
that O +
, O +
when O +
disrupted O +
, O +
reduced O +
promoter O +
activity O +
. O +

However O +
, O +
the O +
Ets O +
protein O +
( O +
s O +
) O +
that O +
regulated O +
GPIX O +
promoter O +
expression O +
was O +
unknown O +
. O +

In O +
this O +
study O +
, O +
transient O +
cotransfection O +
of O +
several O +
GPIX O +
promoter O -
/ O -
reporter O +
constructs O +
into O +
293 B-CellLine -
T I-CellLine +
kidney I-CellLine +
fibroblasts I-CellLine +
with O +
a O +
Fli-1 O +
expression O +
vector O +
shows O +
that O +
the O +
oncogenic O +
protein O +
Fli-1 O +
can O +
transactivate O +
the O +
GPIX O +
promoter O +
when O +
an O +
intact O +
GPIX O +
Ets O +
site O +
is O +
present O +
. O +

In O +
addition O +
, O +
Fli-1 O +
binding O +
of O +
the O +
GPIX O +
Ets O +
site O +
was O +
identified O +
in O +
antibody O +
supershift O +
experiments O +
in O +
nuclear O +
extracts O +
derived O +
from O +
hematopoietic O +
human O +
erythroleukemia O +
cells O +
. O +

Comparative O +
studies O +
showed O +
that O +
Fli-1 O +
was O +
also O +
able O +
to O +
transactivate O +
the O +
GPIbalpha O +
and O +
, O +
to O +
a O +
lesser O +
extent O +
, O +
the O +
GPIIb O +
promoter O +
. O +

Immunoblot O +
analysis O +
identified O +
Fli-1 O +
protein O +
in O +
lysates O +
derived O +
from O +
platelets O +
. O +

In O +
addition O +
, O +
expression O +
of O +
Fli-1 O +
was O +
identified O +
immunohistochemically O +
in O +
megakaryocytes O +
derived O +
from O +
CD34 O +
( O +
+ O +
) O +
cells O +
treated O +
with O +
the O +
megakaryocyte O +
differentiation O +
and O +
proliferation O +
factor O +
, O +
thrombopoietin O +
. O +

These O +
results O +
suggest O +
that O +
Fli-1 O +
is O +
likely O +
to O +
regulate O +
lineage O -
- O -
specific O +
genes O +
during O +
megakaryocytopoiesis O +
. O +

Spi O -
- O -
C O +
, O +
a O +
novel O +
Ets O +
protein O +
that O +
is O +
temporally O +
regulated O +
during O +
B O +
lymphocyte O +
development O +
. O +

A O +
novel O +
Ets O +
protein O +
was O +
isolated O +
by O +
yeast O +
one O -
- O -
hybrid O +
screening O +
of O +
a O +
cDNA O +
library O +
made O +
from O +
lipopolysaccharide B-CellLine -
- I-CellLine -
stimulated I-CellLine +
mouse I-CellLine +
splenic I-CellLine +
B I-CellLine +
cells I-CellLine +
, O +
using O +
the O +
SP6 O +
kappa O +
promoter O +
kappaY O +
element O +
as O +
a O +
bait O +
. O +

The O +
novel O +
Ets O +
protein O +
was O +
most O +
closely O +
related O +
to O +
PU.1 O +
and O +
Spi O -
- O -
B O +
within O +
the O +
DNA O +
binding O +
Ets O +
domain O +
and O +
was O +
therefore O +
named O +
Spi O -
- O -
C O +
. O +

However O +
, O +
Spi O -
- O -
C O +
may O +
represent O +
a O +
novel O +
subgroup O +
within O +
the O +
Ets O +
protein O +
family O +
, O +
as O +
it O +
differed O +
significantly O +
from O +
Spi O -
- O -
B O +
and O +
PU.1 O +
within O +
helix O +
1 O +
of O +
the O +
Ets O +
domain O +
. O +

Spi O -
- O -
C O +
was O +
encoded O +
by O +
a O +
single O -
- O -
copy O +
gene O +
that O +
was O +
mapped O +
to O +
chromosome O +
10 O +
, O +
region O +
C O +
. O +

Spi O -
- O -
C O +
interacted O +
with O +
DNA O +
similarly O +
to O +
PU.1 O +
as O +
judged O +
by O +
methylation O +
interference O +
, O +
band O -
- O -
shift O +
and O +
site O +
selection O +
analysis O +
, O +
and O +
activated O +
transcription O +
of O +
a O +
kappaY O +
element O +
reporter O +
gene O +
upon O +
co O -
- O -
transfection O +
of O +
HeLa B-CellLine +
cells I-CellLine +
. O +

Spi O -
- O -
C O +
RNA O +
was O +
expressed O +
in O +
mature O +
B O +
lymphocytes O +
and O +
at O +
lower O +
levels O +
in O +
macrophages O +
. O +

Furthermore O +
, O +
pre B-CellLine -
- I-CellLine -
B I-CellLine +
cell I-CellLine +
and I-CellLine +
plasma I-CellLine +
cell I-CellLine +
lines I-CellLine +
were O +
Spi O -
- O -
C O +
-negative O +
, O +
suggesting O +
that O +
Spi O -
- O -
C O +
might O +
be O +
a O +
regulatory O +
molecule O +
during O +
a O +
specific O +
phase O +
of O +
B O +
lymphoid O +
development O +
. O +

In O +
vivo O +
modulation O +
of O +
glucocorticoid O +
receptor O +
mRNA O +
by O +
inhaled O +
fluticasone O +
propionate O +
in O +
bronchial O +
mucosa O +
and O +
blood O +
lymphocytes O +
in O +
subjects O +
with O +
mild O +
asthma O +
. O +

BACKGROUND O +
: O +
In O +
vivo O +
regulation O +
of O +
the O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
by O +
glucocorticoids O +
provides O +
a O +
means O +
of O +
modulating O +
sensitivity O +
of O +
targeted O +
cells O +
. O +

OBJECTIVE O +
: O +
We O +
sought O +
to O +
determine O +
the O +
in O +
vivo O +
modulation O +
of O +
GR O +
mRNA O +
expression O +
by O +
fluticasone O +
propionate O +
( O +
FP O +
) O +
in O +
subjects O +
with O +
mild O +
asthma O +
. O +

METHODS O +
: O +
Ten O +
atopic O +
asthmatic O +
subjects O +
were O +
treated O +
with O +
FP O +
250 O +
microg O +
twice O +
daily O +
for O +
4 O +
weeks O +
. O +

Before O +
and O +
after O +
treatment O +
, O +
the O +
patients O +
underwent O +
fiberoptic O +
bronchoscopy O +
with O +
endobronchial O +
biopsy O +
and O +
sampling O +
of O +
venous O +
blood O +
for O +
measurements O +
of O +
GR O +
mRNA O +
levels O +
. O +

A O +
solution O +
hybridization O +
assay O +
was O +
used O +
for O +
quantitative O +
analysis O +
of O +
GR O +
mRNA O +
. O +

In O +
addition O +
, O +
a O +
24-hour O +
urinary O +
cortisol O +
excretion O +
and O +
an O +
adrenocorticotropic O +
hormone O +
test O +
before O +
and O +
after O +
treatment O +
with O +
FP O +
were O +
performed O +
. O +

RESULTS O +
: O +
A O +
high O +
interindividual O +
variation O +
in O +
GR O +
mRNA O +
expression O +
was O +
seen O +
. O +

However O +
, O +
we O +
detected O +
a O +
significant O +
reduction O +
of O +
the O +
GR O +
mRNA O +
levels O +
in O +
the O +
endobronchial O +
biopsy O +
specimens O +
after O +
FP O +
treatment O +
( O +
36.6 O +
+ O -
/- O +
23.1 O +
and O +
25.0 O +
+ O -
/- O +
10.9 O +
amol O +
GR O +
mRNA O +
/microg O +
RNA O +
, O +
respectively O +
; O +
P O +
< O +
.01 O +
) O +
. O +

In O +
the O +
peripheral O +
blood O +
lymphocytes O +
an O +
even O +
more O +
striking O +
downregulation O +
of O +
the O +
GR O +
by O +
its O +
cognate O +
ligand O +
was O +
documented O +
( O +
30.3 O +
+ O -
/- O +
26.5 O +
and O +
8.8 O +
+ O -
/- O +
5 O +
amol O +
GR O +
mRNA O +
/microg O +
RNA O +
, O +
respectively O +
; O +
P O +
< O +
.001 O +
) O +
, O +
possibly O +
reflecting O +
differences O +
in O +
glucocorticoid O +
sensitivity O +
between O +
tissues O +
. O +

A O +
small O +
but O +
significant O +
reduction O +
of O +
the O +
24-hour O +
urinary O +
cortisol O +
excretion O +
was O +
observed O +
( O +
233 O +
+ O -
/- O +
109 O +
and O +
157 O +
+ O -
/- O +
66 O +
nmol O -
/ O -
L O +
, O +
respectively O +
; O +
P O +
< O +
.01 O +
) O +
, O +
whereas O +
the O +
feedback O +
regulation O +
of O +
glucocorticoid O +
synthesis O +
by O +
means O +
of O +
the O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenal O +
axis O +
as O +
assessed O +
by O +
the O +
adrenocorticotropic O +
hormone O +
test O +
remained O +
normal O +
after O +
treatment O +
with O +
FP O +
. O +

CONCLUSION O +
: O +
The O +
results O +
in O +
this O +
study O +
confirm O +
the O +
potency O +
of O +
the O +
inhaled O +
corticosteroid O +
FP O +
and O +
provide O +
evidence O +
for O +
a O +
considerable O +
tissue O -
- O -
specific O +
interindividual O +
variation O +
in O +
the O +
expression O +
of O +
the O +
GR O +
. O +

Fludarabine O -
- O -
induced O +
immunosuppression O +
is O +
associated O +
with O +
inhibition O +
of O +
STAT1 O +
signaling O +
. O +

Fludarabine O +
is O +
a O +
nucleoside O +
analog O +
used O +
in O +
the O +
treatment O +
of O +
hematologic O +
malignancies O +
that O +
can O +
induce O +
severe O +
and O +
prolonged O +
immunosuppression O +
. O +

Although O +
it O +
can O +
be O +
incorporated O +
into O +
the O +
DNA O +
of O +
dividing O +
cells O +
, O +
fludarabine O +
is O +
also O +
a O +
potent O +
inhibitor O +
of O +
cells O +
with O +
a O +
low O +
growth O +
fraction O +
, O +
thus O +
it O +
must O +
have O +
other O +
mechanisms O +
of O +
action O +
. O +

STAT1 O +
, O +
which O +
is O +
activated O +
in O +
response O +
to O +
many O +
lymphocyte O -
- O -
activating O +
cytokines O +
including O +
the O +
interferons O +
, O +
is O +
essential O +
for O +
cell O -
- O -
mediated O +
immunity O +
, O +
as O +
the O +
absence O +
of O +
this O +
protein O +
is O +
associated O +
with O +
prominent O +
defects O +
in O +
the O +
ability O +
to O +
control O +
viral O +
infections O +
. O +

Here O +
we O +
show O +
that O +
fludarabine O +
, O +
but O +
not O +
the O +
immunosuppressant O +
cyclosporine O +
A O +
, O +
inhibits O +
the O +
cytokine O +
-induced O +
activation O +
of O +
STAT1 O +
and O +
STAT1 O +
-dependent O +
gene O +
transcription O +
in O +
normal O +
resting O +
or O +
activated O +
lymphocytes O +
. O +

Fludarabine O +
caused O +
a O +
specific O +
depletion O +
of O +
STAT1 O +
protein O +
( O +
and O +
mRNA O +
) O +
but O +
not O +
of O +
other O +
STATs O +
. O +

This O +
loss O +
of O +
STAT1 O +
was O +
also O +
seen O +
in O +
cells O +
from O +
patients O +
treated O +
with O +
fludarabine O +
in O +
vivo O +
. O +

Brief O +
exposure O +
to O +
fludarabine O +
led O +
to O +
a O +
sustained O +
loss O +
of O +
STAT1 O +
, O +
analogous O +
to O +
the O +
prolonged O +
period O +
of O +
immunosuppression O +
induced O +
by O +
exposure O +
to O +
the O +
drug O +
in O +
vivo O +
. O +

Thus O +
, O +
STAT1 O +
may O +
be O +
a O +
useful O +
target O +
in O +
the O +
development O +
of O +
new O +
immunosuppressive O +
and O +
antineoplastic O +
agents O +
. O +

A O +
novel O +
lipopolysaccharide O -
- O -
induced O +
transcription O +
factor O +
regulating O +
tumor O +
necrosis O +
factor O +
alpha O +
gene O +
expression O +
: O +
molecular O +
cloning O +
, O +
sequencing O +
, O +
characterization O +
, O +
and O +
chromosomal O +
assignment O +
. O +

Lipopolysaccharide O +
( O +
LPS O +
) O +
is O +
a O +
potent O +
stimulator O +
of O +
monocytes O +
and O +
macrophages O +
, O +
causing O +
secretion O +
of O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
and O +
other O +
inflammatory O +
mediators O +
. O +

Given O +
the O +
deleterious O +
effects O +
to O +
the O +
host O +
of O +
TNF O -
- O -
alpha O +
, O +
it O +
has O +
been O +
postulated O +
that O +
TNF O -
- O -
alpha O +
gene O +
expression O +
must O +
be O +
tightly O +
regulated O +
. O +

The O +
nature O +
of O +
the O +
nuclear O +
factor O +
( O +
s O +
) O +
that O +
control O +
TNF O -
- O -
alpha O +
gene O +
transcription O +
in O +
humans O +
remains O +
obscure O +
, O +
although O +
NF O -
- O -
kappaB O +
has O +
been O +
suggested O +
. O +

Our O +
previous O +
studies O +
pertaining O +
to O +
macrophage O +
response O +
to O +
LPS O +
identified O +
a O +
novel O +
DNA O -
- O -
binding O +
domain O +
located O +
from O +
-550 O +
to O +
-487 O +
in O +
the O +
human O +
TNF O -
- O -
alpha O +
promoter O +
that O +
contains O +
transcriptional O +
activity O +
, O +
but O +
lacks O +
any O +
known O +
NF O -
- O -
kappaB O +
-binding O +
sites O +
. O +

We O +
have O +
used O +
this O +
DNA O +
fragment O +
to O +
isolate O +
and O +
purify O +
a O +
60-kDa O +
protein O +
binding O +
to O +
this O +
fragment O +
and O +
obtained O +
its O +
amino O -
- O -
terminal O +
sequence O +
, O +
which O +
was O +
used O +
to O +
design O +
degenerate O +
probes O +
to O +
screen O +
a O +
cDNA O +
library O +
from O +
THP-1 B-CellLine +
cells I-CellLine +
. O +

A O +
novel O +
cDNA O +
clone O +
( O +
1.8 O +
kb O +
) O +
was O +
isolated O +
and O +
fully O +
sequenced O +
. O +

Characterization O +
of O +
this O +
cDNA O +
clone O +
revealed O +
that O +
its O +
induction O +
was O +
dependent O +
on O +
LPS O +
activation O +
of O +
THP-1 B-CellLine +
cells I-CellLine +
; O +
hence O +
, O +
the O +
name O +
LPS O -
- O -
induced O +
TNF O -
- O -
alpha O +
factor O +
( O +
LITAF O +
) O +
. O +

Inhibition O +
of O +
LITAF O +
mRNA O +
expression O +
in O +
THP-1 B-CellLine +
cells I-CellLine +
resulted O +
in O +
a O +
reduction O +
of O +
TNF O -
- O -
alpha O +
transcripts O +
. O +

In O +
addition O +
, O +
high O +
level O +
of O +
expression O +
of O +
LITAF O +
mRNA O +
was O +
observed O +
predominantly O +
in O +
the O +
placenta O +
, O +
peripheral O +
blood O +
leukocytes O +
, O +
lymph O +
nodes O +
, O +
and O +
the O +
spleen O +
. O +

Finally O +
, O +
chromosomal O +
localization O +
using O +
fluorescence O +
in O +
situ O +
hybridization O +
revealed O +
that O +
LITAF O +
mapped O +
to O +
chromosome O +
16p12 O -
- O -
16p13.3 O +
. O +

Together O +
, O +
these O +
findings O +
suggest O +
that O +
LITAF O +
plays O +
an O +
important O +
role O +
in O +
the O +
activation O +
of O +
the O +
human O +
TNF O -
- O -
alpha O +
gene O +
and O +
proposes O +
a O +
new O +
mechanism O +
to O +
control O +
TNF O -
- O -
alpha O +
gene O +
expression O +
. O +

p38 O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
mediates O +
signal O +
integration O +
of O +
TCR O +
/CD28 O +
costimulation O +
in O +
primary O +
murine O +
T O +
cells O +
. O +

Optimal O +
T O +
cell O +
activation O +
requires O +
two O +
signals O +
, O +
one O +
generated O +
by O +
TCR O +
and O +
another O +
by O +
the O +
CD28 O +
costimulatory O +
receptor O +
. O +

In O +
this O +
study O +
, O +
we O +
investigated O +
the O +
regulation O +
of O +
costimulation O -
- O -
induced O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
activation O +
in O +
primary O +
mouse O +
T O +
cells O +
. O +

In O +
contrast O +
to O +
that O +
reported O +
for O +
human O +
Jurkat O +
T O +
cells O +
, O +
we O +
found O +
that O +
p38 O +
MAPK O +
, O +
but O +
not O +
Jun O +
NH2-terminal O +
kinase O +
( O +
JNK O +
) O +
, O +
is O +
weakly O +
activated O +
upon O +
stimulation O +
with O +
either O +
anti O -
- O -
CD3 O +
or O +
anti O -
- O -
CD28 O +
in O +
murine O +
thymocytes O +
and O +
splenic O +
T O +
cells O +
. O +

However O +
, O +
p38 O +
MAPK O +
is O +
activated O +
strongly O +
and O +
synergistically O +
by O +
either O +
CD3 O -
/ O -
CD28 O +
coligation O +
or O +
PMA O -
/ O -
Ca2 O -
+ O +
ionophore O +
stimulation O +
, O +
which O +
mimics O +
TCR O +
- O +
CD3 O -
/ O -
CD28 O +
-mediated O +
signaling O +
. O +

Activation O +
of O +
p38 O +
MAPK O +
correlates O +
closely O +
with O +
the O +
stimulation O +
of O +
T O +
cell O +
proliferation O +
. O +

In O +
contrast O +
, O +
PMA O -
- O -
induced O +
JNK O +
activation O +
is O +
inhibited O +
by O +
Ca2 O -
+ O +
ionophore O +
. O +

T O +
cell O +
proliferation O +
and O +
production O +
of O +
IL-2 O +
, O +
IL-4 O +
, O +
and O +
IFN O -
- O -
gamma O +
induced O +
by O +
both O +
CD3 O +
and O +
CD3 O +
/CD28 O +
ligation O +
and O +
the O +
nuclear O +
expression O +
of O +
the O +
c O -
- O -
Jun O +
and O +
ATF-2 O +
proteins O +
are O +
each O +
blocked O +
by O +
the O +
p38 O +
MAPK O +
inhibitor O +
SB203580 O +
. O +

Our O +
findings O +
demonstrate O +
that O +
p38 O +
MAPK O +
1 O +
) O +
plays O +
an O +
important O +
role O +
in O +
signal O +
integration O +
during O +
costimulation O +
of O +
primary O +
mouse O +
T O +
cells O +
, O +
2 O +
) O +
may O +
be O +
involved O +
in O +
the O +
induction O +
of O +
c O -
- O -
Jun O +
activation O +
and O +
augmentation O +
of O +
AP-1 O +
transcriptional O +
activity O +
, O +
and O +
3 O +
) O +
regulates O +
whether O +
T O +
cells O +
enter O +
a O +
state O +
of O +
functional O +
unresponsiveness O +
. O +

The O +
functional O +
synergy O +
between O +
IL-12 O +
and O +
IL-2 O +
involves O +
p38 O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
and O +
is O +
associated O +
with O +
the O +
augmentation O +
of O +
STAT O +
serine O +
phosphorylation O +
. O +

IL-12 O +
and O +
IL-2 O +
can O +
stimulate O +
mitogen- O +
or O +
CD3-activated O +
T O +
cells O +
to O +
proliferate O +
, O +
produce O +
IFN O -
- O -
gamma O +
, O +
and O +
kill O +
tumor O +
cells O +
. O +

The O +
magnitude O +
of O +
these O +
functional O +
responses O +
is O +
greatly O +
augmented O +
when O +
T O +
cells O +
are O +
activated O +
by O +
the O +
combination O +
of O +
IL-12 O +
and O +
IL-2 O +
. O +

Although O +
peripheral O +
blood O +
T O +
cells O +
are O +
largely O +
unresponsive O +
to O +
these O +
cytokines O +
without O +
prior O +
activation O +
, O +
a O +
small O +
subset O +
of O +
CD8 O -
+ O +
T O +
cells O +
( O +
CD8+CD18bright O +
) O +
is O +
strongly O +
activated O +
by O +
the O +
combination O +
of O +
IL-12 O +
and O +
IL-2 O +
. O +

In O +
this O +
report O +
we O +
show O +
that O +
the O +
functional O +
synergy O +
between O +
IL-12 O +
and O +
IL-2 O +
in O +
CD8+CD18bright O +
T O +
cells O +
correlates O +
with O +
the O +
activation O +
of O +
the O +
stress O +
kinases O +
, O +
p38 O +
mitogen O -
- O -
activated O +
protein O +
( O +
MAP O +
) O +
kinase O +
and O +
stress O -
- O -
activated O +
protein O +
kinase O +
( O +
SAPK O +
) O +
/Jun O +
N O -
- O -
terminal O +
kinase O +
, O +
but O +
not O +
with O +
the O +
activation O +
of O +
the O +
extracellular O +
signal O -
- O -
regulated O +
kinases O +
. O +

The O +
functional O +
synergy O +
between O +
IL-2 O +
and O +
IL-12 O +
is O +
also O +
associated O +
with O +
a O +
prominent O +
increase O +
in O +
STAT1 O +
and O +
STAT3 O +
serine O +
phosphorylation O +
over O +
that O +
observed O +
with O +
IL-12 O +
or O +
IL-2 O +
alone O +
. O +

By O +
contrast O +
, O +
STAT O +
tyrosine O +
phosphorylation O +
is O +
not O +
augmented O +
over O +
that O +
seen O +
with O +
either O +
cytokine O +
alone O +
. O +

A O +
specific O +
inhibitor O +
of O +
p38 O +
MAP O +
kinase O +
completely O +
inhibits O +
the O +
serine O +
phosphorylation O +
of O +
STAT1 O +
and O +
STAT3 O +
induced O +
by O +
IL-12 O +
and O +
IL-2 O +
and O +
abrogates O +
the O +
functional O +
synergy O +
between O +
IL-12 O +
and O +
IL-2 O +
without O +
affecting O +
STAT O +
tyrosine O +
phosphorylation O +
. O +

This O +
suggests O +
that O +
p38 O +
MAP O +
kinase O +
may O +
play O +
an O +
important O +
role O +
in O +
regulating O +
STAT O +
serine O +
phosphorylation O +
in O +
response O +
to O +
the O +
combination O +
of O +
IL-12 O +
and O +
IL-2 O +
. O +

Furthermore O +
, O +
these O +
findings O +
indicate O +
that O +
the O +
optimal O +
activation O +
of O +
T O +
cells O +
by O +
IL-12 O +
and O +
IL-2 O +
may O +
depend O +
on O +
an O +
interaction O +
between O +
the O +
p38 O +
MAP O +
kinase O +
and O +
Janus O +
kinase O -
/ O -
STAT O +
signaling O +
pathways O +
. O +

Signal O +
transduction O +
pathways O +
activated O +
in O +
endothelial O +
cells O +
following O +
infection O +
with O +
Chlamydia O +
pneumoniae O +
. O +

Chlamydia O +
pneumoniae O +
is O +
an O +
important O +
respiratory O +
pathogen O +
. O +

Recently O +
, O +
its O +
presence O +
has O +
been O +
demonstrated O +
in O +
atherosclerotic O +
lesions O +
. O +

In O +
this O +
study O +
, O +
we O +
characterized O +
C. O +
pneumoniae O -
- O -
mediated O +
activation O +
of O +
endothelial O +
cells O +
and O +
demonstrated O +
an O +
enhanced O +
expression O +
of O +
endothelial O +
adhesion O +
molecules O +
followed O +
by O +
subsequent O +
rolling O +
, O +
adhesion O +
, O +
and O +
transmigration O +
of O +
leukocytes O +
( O +
monocytes O +
, O +
granulocytes O +
) O +
. O +

These O +
effects O +
were O +
blocked O +
by O +
mAbs O +
against O +
endothelial O +
and/or O +
leukocyte O +
adhesion O +
molecules O +
( O +
beta1 O +
and O +
beta2 O +
integrins O +
) O +
. O +

Additionally O +
, O +
activation O +
of O +
different O +
signal O +
transduction O +
pathways O +
in O +
C. O +
pneumoniae O -
- O -
infected O +
endothelial O +
cells O +
was O +
shown O +
: O +
protein O +
tyrosine O +
phosphorylation O +
, O +
up O -
- O -
regulation O +
of O +
phosphorylated O +
p42 O -
/ O -
p44 O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
, O +
and O +
NF O -
- O -
kappaB O +
activation O -
/ O -
translocation O +
occurred O +
within O +
10 O -
- O -
15 O +
min O +
. O +

Increased O +
mRNA O +
and O +
surface O +
expression O +
of O +
E O -
- O -
selectin O +
, O +
ICAM-1 O +
, O +
and O +
VCAM-1 O +
were O +
noted O +
within O +
hours O +
. O +

Thus O +
, O +
C. O +
pneumoniae O +
triggers O +
a O +
cascade O +
of O +
events O +
that O +
could O +
lead O +
to O +
endothelial O +
activation O +
, O +
inflammation O +
, O +
and O +
thrombosis O +
, O +
which O +
in O +
turn O +
may O +
result O +
in O +
or O +
may O +
promote O +
atherosclerosis O +
. O +

Differential O +
induction O +
of O +
interferon O +
( O +
IFN O +
) O +
-inducible O +
protein O +
10 O +
following O +
differentiation O +
of O +
a O +
monocyte O +
, O +
macrophage O +
cell O +
lineage O +
is O +
related O +
to O +
the O +
changes O +
of O +
nuclear O +
proteins O +
bound O +
to O +
IFN O +
stimulus O +
response O +
element O +
and O +
kappaB O +
sites O +
. O +

We O +
examined O +
chemokine O +
gene O +
expression O +
following O +
the O +
differentiation O +
of O +
a O +
monocyte O +
, O +
macrophage B-CellLine +
cell I-CellLine +
lineage I-CellLine +
. O +

The O +
human B-CellLine +
monoblastic I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
U937 B-CellLine +
was O +
differentiated O +
to O +
macrophages O +
by O +
the O +
treatment O +
with O +
either O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
, O +
retinoic O +
acid O +
( O +
RA O +
) O +
, O +
or O +
vitamin O +
D3 O +
( O +
VitD3 O +
) O +
. O +

The O +
gene O +
expression O +
of O +
interferon O +
( O +
IFN O +
) O +
-inducible O +
protein O +
10 O +
( O +
IP-10 O +
) O +
( O +
a O +
CXC O +
chemokine O +
) O +
was O +
markedly O +
augmented O +
by O +
the O +
IFNgamma O +
treatment O +
in O +
PMA O +
-or O +
RA O -
- O -
differentiated O +
U937 B-CellLine +
cells I-CellLine +
, O +
but O +
only O +
marginally O +
in O +
undifferentiated O +
or O +
VitD3-treated B-CellLine +
cells I-CellLine +
. O +

In O +
contrast O +
, O +
another O +
inducible O +
gene O +
expression O +
of O +
monocyte O +
chemotactic O +
protein-1 O +
( O +
a O +
CC O +
chemokine O +
) O +
and O +
the O +
activation O +
of O +
the O +
transcriptional O +
factor O +
( O +
FcRFgamma O +
) O +
bound O +
to O +
the O +
gamma O +
response O +
region O +
were O +
similarly O +
or O +
less O +
abundantly O +
induced O +
by O +
IFNgamma O +
treatment O +
in O +
PMA O +
-or O +
RA O -
- O -
differentiated O +
U937 B-CellLine +
cells I-CellLine +
, O +
indicating O +
that O +
increased O +
IP-10 O +
mRNA O +
induction O +
was O +
not O +
due O +
to O +
the O +
augmented O +
ability O +
of O +
the O +
cells O +
to O +
respond O +
to O +
the O +
presence O +
of O +
IFNgamma O +
. O +

Increased O +
expression O +
of O +
IFNgamma O +
-induced O +
IP-10 O +
mRNA O +
following O +
the O +
differentiation O +
of O +
U937 B-CellLine +
cells I-CellLine +
was O +
mediated O +
largely O +
by O +
augmented O +
transcriptional O +
activity O +
of O +
the O +
gene O +
and O +
was O +
related O +
to O +
differentiation O -
- O -
dependent O +
changes O +
of O +
the O +
proteins O +
bound O +
to O +
IFN O +
stimulus O +
response O +
element O +
( O +
ISRE O +
) O +
and O +
kB O +
sites O +
, O +
suggesting O +
that O +
these O +
nuclear O +
proteins O +
may O +
determine O +
the O +
IP-10 O +
mRNA O +
inducibility O +
by O +
IFNgamma O +
. O +

Amelioration O +
of O +
rat O +
cerulein O +
pancreatitis O +
by O +
guamerin O -
- O -
derived O +
peptide O +
, O +
a O +
novel O +
elastase O +
inhibitor O +
. O +

Increased O +
activity O +
of O +
various O +
proteases O +
is O +
observed O +
in O +
both O +
human O +
and O +
experimental O +
pancreatitis O +
; O +
however O +
, O +
the O +
information O +
on O +
the O +
effects O +
of O +
specific O +
protease O +
inhibitors O +
on O +
the O +
disease O +
is O +
limited O +
. O +

In O +
this O +
study O +
we O +
show O +
that O +
a O +
novel O +
elastase O +
inhibitor O +
, O +
guamerin O -
- O -
derived O +
synthetic O +
peptide O +
( O +
GDSP O +
) O +
, O +
improves O +
the O +
parameters O +
of O +
cerulein O -
- O -
induced O +
acute O +
pancreatitis O +
in O +
the O +
rat O +
. O +

The O +
effects O +
of O +
GDSP O +
on O +
pancreatic O +
weight O +
, O +
serum O +
amylase O +
and O +
lipase O +
, O +
morphologic O +
changes O +
in O +
the O +
pancreas O +
, O +
neutrophil O +
infiltration O +
, O +
and O +
nuclear O +
factor O +
KB O +
( O +
NF O -
- O -
KB O +
) O +
activation O +
were O +
measured O +
in O +
rats O +
infused O +
with O +
supramaximal O +
dose O +
of O +
cerulein O +
( O +
5 O +
( O +
g O -
/ O -
kg O -
/ O -
h O +
) O +
for O +
6 O +
h O +
. O +

The O +
effects O +
of O +
GDSP O +
were O +
also O +
measured O +
on O +
superoxide O +
formation O +
by O +
activated O +
human O +
neutrophils O +
. O +

The O +
effects O +
of O +
GDSP O +
were O +
compared O +
with O +
those O +
of O +
another O +
elastase O +
inhibitor O +
, O +
elastatinal O +
. O +

GDSP O +
significantly O +
inhibited O +
edema O +
formation O +
, O +
neutrophil O +
infiltration O +
, O +
acinar O +
cell O +
damage O +
, O +
and O +
plasma O +
lipase O +
and O +
amylase O +
increases O +
caused O +
by O +
cerulein O +
. O +

GDSP O +
also O +
completely O +
inhibited O +
superoxide O +
formation O +
in O +
the O +
human O +
neutrophils O +
stimulated O +
by O +
N O -
- O -
formyl O -
- O -
methionine O -
- O -
leucine O -
- O -
phenyl O -
- O -
alanine O +
( O +
fMLP O +
) O +
or O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
. O +

Elastatinal O +
had O +
some O +
of O +
the O +
same O +
effects O +
as O +
GDSP O +
but O +
was O +
less O +
potent O +
and O +
effective O +
. O +

These O +
results O +
demonstrate O +
a O +
beneficial O +
effect O +
of O +
GDSP O +
, O +
a O +
novel O +
specific O +
elastase O +
inhibitor O +
, O +
on O +
the O +
development O +
of O +
rat O +
cerulein O +
pancreatitis O +
. O +

Bcl-6 O +
expression O +
in O +
reactive O +
follicular O +
hyperplasia O +
, O +
follicular O +
lymphoma O +
, O +
and O +
angioimmunoblastic O +
T O -
- O -
cell O +
lymphoma O +
with O +
hyperplastic O +
germinal O +
centers O +
: O +
heterogeneity O +
of O +
intrafollicular O +
T O -
- O -
cells O +
and O +
their O +
altered O +
distribution O +
in O +
the O +
pathogenesis O +
of O +
angioimmunoblastic O +
T O -
- O -
cell O +
lymphoma O +
. O +

BACKGROUND O +
: O +
The O +
Bcl-6 O +
gene O +
product O +
, O +
a O +
nuclear O +
phosphoprotein O +
, O +
is O +
expressed O +
independently O +
of O +
Bcl-6 O +
gene O +
rearrangement O +
. O +

In O +
lymph O +
nodes O +
, O +
expression O +
of O +
Bcl-6 O +
protein O +
is O +
restricted O +
to O +
germinal O +
center O +
( O +
GC O +
) O +
B O -
- O -
cells O +
and O +
10 O +
% O +
to O +
15 O +
% O +
of O +
CD3 O -
/ O -
CD4 O -
+ O +
intrafollicular O +
T O +
cells O +
. O +

Interfollicular O +
cells O +
are O +
negative O +
for O +
Bcl-6 O +
protein O +
, O +
except O +
for O +
rare O +
CD3+ O -
/ O -
CD4 O -
+ O +
T O +
cells O +
. O +

Recently O +
, O +
we O +
reported O +
cases O +
of O +
angioimmunoblastic O +
T O -
- O -
cell O +
lymphoma O +
( O +
AITL O +
) O +
with O +
hyperplastic O +
GCs O +
( O +
AITL O -
/ O -
GC O +
) O +
, O +
and O +
observed O +
that O +
borders O +
of O +
enlarged O +
GCs O +
were O +
ill O +
defined O +
, O +
with O +
features O +
suggestive O +
of O +
an O +
outward O +
migration O +
of O +
GC O +
cells O +
to O +
surrounding O +
interfollicular O +
zones O +
. O +

This O +
prompted O +
a O +
study O +
of O +
follicular O +
borders O +
with O +
Bcl-6 O +
staining O +
in O +
reactive O +
follicular O +
hyperplasias O +
and O +
follicular O +
lymphomas O +
to O +
compare O +
with O +
AITL O -
/ O -
GC O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +
Formalin O -
- O -
fixed O +
paraffin O +
sections O +
were O +
used O +
for O +
immunostaining O +
of O +
Bcl-6 O +
. O +

Six O +
cases O +
of O +
AITL O -
/ O -
GC O +
, O +
12 O +
nonspecific O +
reactive O +
follicular O +
hyperplasia O +
( O +
FH O +
) O +
, O +
7 O +
HIV O +
adenopathy O +
, O +
10 O +
follicular O +
lymphoma O +
( O +
FL O +
) O +
, O +
and O +
8 O +
typical O +
AITL O +
( O +
ie O +
, O +
AITL O +
without O +
GC O +
) O +
were O +
studied O +
. O +

Double O +
staining O +
for O +
Bcl-6 O -
/ O -
CD20 O +
, O +
Bcl-6 O -
/ O -
CD3 O +
, O +
and O +
Bcl-6 O -
/ O -
CD57 O +
was O +
performed O +
in O +
selected O +
cases O +
. O +

RESULTS O +
: O +
In O +
FH O +
and O +
HIV O +
adenopathy O +
, O +
staining O +
for O +
Bcl-6 O +
revealed O +
densely O +
populated O +
GCs O +
with O +
well O -
- O -
defined O +
and O +
regular O +
GC O +
borders O +
, O +
whereas O +
Bcl-6 O -
+ O +
cells O +
were O +
rare O +
in O +
the O +
interfollicular O +
areas O +
. O +

An O +
occasional O +
GC O +
with O +
an O +
ill O -
- O -
defined O +
border O +
was O +
invariably O +
surrounded O +
by O +
a O +
broad O +
mantle O +
zone O +
; O +
those O +
with O +
indistinct O +
mantle O +
zones O +
had O +
well O -
- O -
defined O +
, O +
regular O +
borders O +
. O +

In O +
FL O +
, O +
follicles O +
were O +
densely O +
populated O +
, O +
and O +
their O +
borders O +
were O +
irregular O +
, O +
with O +
some O +
Bcl-6 O -
+ O +
cells O +
in O +
the O +
interfollicular O +
zones O +
. O +

In O +
AITL O -
/ O -
GC O +
, O +
GCs O +
were O +
less O +
dense O +
, O +
GC O +
borders O +
were O +
ill O +
defined O +
and O +
irregular O +
, O +
and O +
the O +
number O +
of O +
interfollicular O +
Bcl-6 O -
+ O +
cells O +
was O +
markedly O +
increased O +
. O +

Double O +
staining O +
revealed O +
that O +
these O +
interfollicular O +
Bcl-6 O -
+ O +
cells O +
in O +
AITL O -
/ O -
GC O +
were O +
Bcl6+ O -
/ O -
CD3+ O -
/ O -
CD20- O -
/ O -
CD57- O +
T O +
cells O +
. O +

Moreover O +
, O +
CD3 O -
+ O +
intrafollicular O +
T O +
cells O +
were O +
depleted O +
in O +
AITL O -
/ O -
GC O +
, O +
whereas O +
they O +
were O +
abundant O +
in O +
FH O +
. O +

Intrafollicular O +
CD57 O -
+ O +
cells O +
did O +
not O +
stain O +
for O +
Bcl-6 O +
, O +
and O +
were O +
also O +
depleted O +
in O +
AITL O -
/ O -
GC O +
. O +

In O +
typical O +
AITL O +
, O +
some O +
neoplastic O +
cells O +
were O +
positive O +
for O +
Bcl-6 O +
, O +
showing O +
variable O +
degrees O +
of O +
staining O +
. O +

CONCLUSIONS O +
: O +
( O +
1 O +
) O +
GCs O +
of O +
AITL O -
/ O -
GC O +
differed O +
from O +
those O +
of O +
other O +
reactive O +
follicular O +
hyperplasias O +
and O +
follicular O +
lymphomas O +
, O +
and O +
staining O +
for O +
Bcl-6 O +
was O +
useful O +
to O +
discern O +
them O +
. O +

( O +
2 O +
) O +
Intrafollicular O +
CD3 O -
+ O +
T O +
cells O +
, O +
many O +
of O +
which O +
were O +
also O +
positive O +
for O +
Bcl-6 O +
, O +
were O +
markedly O +
depleted O +
in O +
AITL O -
/ O -
GC O +
, O +
with O +
increased O +
interfollicular O +
Bcl-6+ O -
/ O -
CD3 O -
+ O +
cells O +
, O +
suggesting O +
an O +
outward O +
migration O +
of O +
intrafollicular O +
T O +
cells O +
in O +
this O +
condition O +
. O +

( O +
3 O +
) O +
Interfollicular O +
Bcl-6+ O -
/ O -
CD3 O -
+ O +
cells O +
in O +
AITL O -
/ O -
GC O +
were O +
too O +
numerous O +
to O +
be O +
accounted O +
for O +
by O +
migration O +
alone O +
, O +
suggesting O +
local O +
proliferation O +
. O +

( O +
4 O +
) O +
Intrafollicular O +
CD57 O -
+ O +
cells O +
were O +
negative O +
for O +
Bcl-6 O +
, O +
indicating O +
heterogeneity O +
of O +
the O +
intrafollicular O +
T O -
- O -
cell O +
population O +
. O +

( O +
5 O +
) O +
Some O +
neoplastic O +
cells O +
in O +
AITL O +
stained O +
for O +
Bcl-6 O +
, O +
suggesting O +
up O -
- O -
regulation O +
of O +
Bcl-6 O +
expression O +
in O +
this O +
tumor O +
. O +

Inhibition O +
of O +
T O +
cell O +
signaling O +
by O +
mitogen O -
- O -
activated O +
protein O +
kinase O -
- O -
targeted O +
hematopoietic O +
tyrosine O +
phosphatase O +
( O +
HePTP O +
) O +
. O +

Activation O +
of O +
T O +
lymphocytes O +
to O +
produce O +
cytokines O +
is O +
regulated O +
by O +
the O +
counterbalance O +
of O +
protein O -
- O -
tyrosine O +
kinases O +
and O +
protein O -
- O -
tyrosine O +
phosphatases O +
, O +
many O +
of O +
which O +
have O +
a O +
high O +
degree O +
of O +
substrate O +
specificity O +
because O +
of O +
physical O +
association O +
with O +
their O +
targets O +
. O +

Overexpression O +
of O +
hematopoietic O +
protein O -
- O -
tyrosine O +
phosphatase O +
( O +
HePTP O +
) O +
results O +
in O +
suppression O +
of O +
T O +
lymphocyte O +
activation O +
as O +
measured O +
by O +
T O +
cell O +
antigen O +
receptor O +
-induced O +
activation O +
of O +
transcription O +
factors O +
binding O +
to O +
the O +
5 O +
' O +
promoter O +
of O +
the O +
interleukin-2 O +
gene O +
. O +

Efforts O +
to O +
pinpoint O +
the O +
exact O +
site O +
of O +
action O +
and O +
specificity O +
of O +
HePTP O +
in O +
the O +
signaling O +
cascade O +
revealed O +
that O +
HePTP O +
acts O +
directly O +
on O +
the O +
mitogen O -
- O -
activated O +
protein O +
( O +
MAP O +
) O +
kinases O +
Erk1 O +
and O +
2 O +
and O +
consequently O +
reduces O +
the O +
magnitude O +
and O +
duration O +
of O +
their O +
catalytic O +
activation O +
in O +
intact O +
T O +
cells O +
. O +

In O +
contrast O +
, O +
HePTP O +
had O +
no O +
effects O +
on O +
N O -
- O -
terminal O +
c O -
- O -
Jun O +
kinase O +
or O +
on O +
events O +
upstream O +
of O +
the O +
MAP O +
kinases O +
. O +

The O +
specificity O +
of O +
HePTP O +
correlated O +
with O +
its O +
physical O +
association O +
through O +
its O +
noncatalytic O +
N O +
terminus O +
with O +
Erk O +
and O +
another O +
MAP O +
kinase O +
, O +
p38 O +
, O +
but O +
not O +
Jnk O +
or O +
other O +
proteins O +
. O +

We O +
propose O +
that O +
HePTP O +
plays O +
a O +
negative O +
role O +
in O +
antigen O +
receptor O +
signaling O +
by O +
specifically O +
regulating O +
MAP O +
kinases O +
in O +
the O +
cytosol O +
and O +
at O +
early O +
time O +
points O +
of O +
T O +
cell O +
activation O +
before O +
the O +
activation O -
- O -
induced O +
expression O +
of O +
nuclear O +
dual O -
- O -
specific O +
MAP O +
kinase O +
phosphatases O +
. O +

Modulation O +
of O +
E2F O +
complexes O +
during O +
G0 O +
to O +
S O +
phase O +
transition O +
in O +
human O +
primary O +
B O -
- O -
lymphocytes O +
. O +

The O +
pocket O +
protein O -
- O -
E2F O +
complexes O +
are O +
convergence O +
points O +
for O +
cell O +
cycle O +
signaling O +
. O +

In O +
the O +
present O +
report O +
, O +
we O +
identified O +
and O +
monitored O +
the O +
pocket O +
protein O -
- O -
E2F O +
complexes O +
in O +
human O +
primary O +
B O -
- O -
lymphocytes O +
after O +
activation O +
by O +
phorbol O +
12-myristate O +
13-acetate O +
. O +

Consistent O +
with O +
previous O +
data O +
from O +
human O +
and O +
mouse O +
fibroblasts O +
and O +
T O -
- O -
lymphocytes O +
, O +
E2F4 O +
and O +
DP1 O +
form O +
the O +
predominant O +
E2F O +
heterodimers O +
both O +
in O +
G0 O +
and O +
G1 O +
phases O +
of O +
the O +
human O +
B O -
- O -
lymphocyte O +
cell O +
cycle O +
, O +
whereas O +
E2F1 O +
and O +
-3 O +
are O +
first O +
detected O +
in O +
late O +
G1 O +
, O +
and O +
their O +
expression O +
levels O +
increase O +
towards O +
S O +
phase O +
. O +

Intriguingly O +
, O +
the O +
major O +
E2F O +
complex O +
that O +
we O +
detected O +
in O +
quiescent O +
human O +
B O -
- O -
lymphocytes O +
is O +
consisted O +
of O +
pRB O +
, O +
E2F4 O +
, O +
and O +
DP1 O +
. O +

Though O +
the O +
levels O +
of O +
DP1 O +
and O +
-2 O +
increase O +
when O +
cells O +
progress O +
from O +
G0 O +
to O +
S O +
, O +
the O +
proportion O +
of O +
DP1 O +
to O +
DP2 O +
remains O +
relatively O +
constant O +
during O +
the O +
cell O +
cycle O +
. O +

We O +
also O +
observed O +
an O +
increase O +
in O +
electrophoretic O +
mobility O +
of O +
the O +
predominant O +
E2F O +
components O +
, O +
DP1 O +
and O +
E2F4 O +
, O +
as O +
B O -
- O -
lymphocytes O +
progressed O +
from O +
G0 O +
into O +
early O +
G1 O +
. O +

This O +
increase O +
in O +
mobility O +
was O +
attributable O +
to O +
dephosphorylation O +
, O +
as O +
lambda O +
phosphatase O +
treatment O +
could O +
convert O +
the O +
slower O +
migrating O +
forms O +
into O +
the O +
corresponding O +
faster O +
mobility O +
forms O +
. O +

We O +
further O +
demonstrated O +
that O +
this O +
change O +
in O +
phosphorylation O +
status O +
correlates O +
with O +
a O +
decrease O +
in O +
DNA O +
binding O +
activity O +
. O +

This O +
modulation O +
of O +
DNA O +
binding O +
activity O +
mediated O +
through O +
the O +
dephosphorylation O +
of O +
DP1 O +
and O +
E2F4 O +
could O +
help O +
to O +
explain O +
the O +
lack O +
of O +
in O +
vivo O +
DNA O +
footprinting O +
in O +
late O +
G1 O +
and O +
S O +
phases O +
of O +
gene O +
promoters O +
negatively O +
regulated O +
through O +
E2F O +
sites O +
and O +
suggests O +
a O +
novel O +
mechanism O +
for O +
controlling O +
E2F O +
transcriptional O +
activity O +
during O +
the O +
transition O +
from O +
quiescence O +
to O +
proliferation O +
. O +

Unexpected O +
and O +
coordinated O +
expression O +
of O +
Spi-1 O +
, O +
Fli-1 O +
, O +
and O +
megakaryocytic O +
genes O +
in O +
four O +
Epo B-CellLine -
- I-CellLine -
dependent I-CellLine +
cell I-CellLine +
lines I-CellLine +
established O +
from O +
transgenic O +
mice O +
displaying O +
erythroid O -
- O -
specific O +
expression O +
of O +
a O +
thermosensitive O +
SV40 O +
T O +
antigen O +
. O +

Most O +
erythroleukemic B-CellLine +
cell I-CellLine +
lines I-CellLine +
established O +
in O +
vitro O +
coexpress O +
erythrocytic O +
and O +
megakaryocytic O +
markers O +
that O +
often O +
are O +
associated O +
with O +
expression O +
of O +
Spi-1 O +
and/or O +
Fli-1 O +
transcription O +
factors O +
known O +
as O +
transactivators O +
of O +
megakaryocyte O -
- O -
specific O +
promoters O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
examined O +
the O +
possibility O +
of O +
establishing O +
new B-CellLine +
cell I-CellLine +
lines I-CellLine +
keeping O +
strictly O +
erythroid O -
- O -
specific O +
properties O +
in O +
vitro O +
through O +
the O +
targeted O +
and O +
conditional O +
immortalization O +
of O +
erythrocytic O +
progenitors O +
. O +

For O +
that O +
purpose O +
, O +
we O +
established O +
several O +
lines O +
of O +
transgenic O +
mice O +
displaying O +
erythroid O -
- O -
specific O +
expression O +
of O +
a O +
thermosensitive O +
SV40 O +
T O +
antigen O +
. O +

As O +
expected O +
, O +
these O +
transgenic O +
mice O +
developed O +
splenomegaly O +
due O +
to O +
the O +
massive O +
amplification O +
of O +
Ter B-CellLine +
119 I-CellLine +
positive I-CellLine +
erythroid I-CellLine +
nucleated I-CellLine +
cells I-CellLine +
expressing O +
T O +
antigen O +
. O +

Despite O +
this O +
drastic O +
effect O +
in O +
vivo O +
, O +
the O +
in O +
vitro O +
immortalization O +
of O +
erythropoietin O -
- O -
dependent O +
erythroid O +
progenitors O +
unexpectedly O +
occurred O +
at O +
low O +
frequency O +
, O +
and O +
all O +
four O +
cell B-CellLine +
lines I-CellLine +
established O +
expressed O +
both O +
erythrocytic O +
( O +
globins O +
) O +
and O +
megakaryocytic O +
markers O +
( O +
glycoprotein O +
IIb O +
, O +
platelet O +
factor O +
4 O +
) O +
as O +
well O +
as O +
Spi-1 O +
and O +
Fli-1 O +
transcripts O +
at O +
permissive O +
temperature O +
. O +

Switching O +
the O +
cells O +
to O +
the O +
nonpermissive O +
temperature O +
led O +
to O +
a O +
marked O +
increase O +
in O +
globin O +
gene O +
expression O +
and O +
concomitant O +
decrease O +
in O +
expression O +
of O +
Spi-1 O +
, O +
Fli-1 O +
, O +
and O +
megakaryocytic O +
genes O +
in O +
an O +
erythropoietin O +
-dependent O +
manner O +
. O +

Interestingly O +
, O +
enhanced O +
expression O +
of O +
Spi-1 O +
and O +
Fli-1 O +
genes O +
already O +
was O +
detected O +
in O +
the O +
Ter B-CellLine +
119 I-CellLine +
positive I-CellLine +
cell I-CellLine +
population I-CellLine +
of O +
transgenic O +
mice O +
spleen O +
in O +
vivo O +
. O +

However O +
, O +
like O +
normal B-CellLine +
Ter I-CellLine +
119 I-CellLine +
erythroid I-CellLine +
cells I-CellLine +
, O +
these O +
Ter B-CellLine +
119 I-CellLine +
positive I-CellLine +
cells I-CellLine +
from O +
transgenic O +
mice O +
still O +
expressed O +
high O +
levels O +
of O +
beta O -
- O -
globin O +
and O +
very O +
low O +
or O +
undetectable O +
glycoprotein O +
IIb O +
and O +
platelet O +
factor O +
4 O +
megakaryocytic O +
transcripts O +
. O +

Taken O +
together O +
, O +
these O +
data O +
indicate O +
that O +
the O +
unexpected O +
expression O +
of O +
megakaryocytic O +
genes O +
is O +
a O +
specific O +
property O +
of O +
immortalized B-CellLine +
cells I-CellLine +
that O +
can O +
not O +
be O +
explained O +
only O +
by O +
enhanced O +
expression O +
of O +
Spi-1 O +
and/or O +
Fli-1 O +
genes O +
. O +

Angiotensin O +
II O +
activates O +
the O +
proinflammatory O +
transcription O +
factor O +
nuclear O +
factor O -
- O -
kappaB O +
in O +
human O +
monocytes O +
. O +

The O +
renin O +
-angiotensin O +
system O +
may O +
contribute O +
to O +
the O +
pathogenesis O +
of O +
atherosclerosis O +
. O +

A O +
common O +
feature O +
of O +
all O +
stages O +
of O +
atherosclerosis O +
is O +
inflammation O +
of O +
the O +
vessel O +
wall O +
. O +

The O +
transcription O +
factor O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
participates O +
in O +
most O +
signaling O +
pathways O +
involved O +
in O +
inflammation O +
. O +

This O +
study O +
therefore O +
examined O +
the O +
effect O +
of O +
angiotensin O +
( O +
ANG O +
) O +
II O +
on O +
NF O -
- O -
kappaB O +
activation O +
in O +
monocytic O +
cells O +
, O +
a O +
major O +
cellular O +
component O +
of O +
human O +
atheroma O +
, O +
by O +
electrophoretic O +
mobility O +
shift O +
assay O +
. O +

ANG O +
II O +
, O +
like O +
TNFalpha O +
, O +
caused O +
rapid O +
activation O +
of O +
NF O -
- O -
kappaB O +
in O +
human O +
mononuclear O +
cells O +
isolated O +
from O +
peripheral O +
blood O +
by O +
Ficoll O +
density O +
gradient O +
. O +

This O +
ANG O +
II O +
effect O +
was O +
blocked O +
by O +
the O +
angiotensin O +
AT1 O +
receptor O +
antagonist O +
losartan O +
. O +

Specificity O +
of O +
ANG O +
II O +
-induced O +
NF O -
- O -
kappaB O +
activation O +
was O +
ascertained O +
by O +
supershift O +
and O +
competition O +
experiments O +
. O +

Moreover O +
, O +
ANG O +
II O +
stimulated O +
NF O -
- O -
kappaB O +
activation O +
in O +
human O +
monocytes O +
, O +
but O +
not O +
in O +
lymphocytes O +
from O +
the O +
same O +
preparation O +
. O +

Together O +
, O +
the O +
data O +
demonstrate O +
the O +
ability O +
of O +
the O +
vasoactive O +
peptide O +
ANG O +
II O +
to O +
activate O +
inflammatory O +
pathways O +
in O +
human O +
monocytes O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

LPS O -
- O -
Induced O +
NF O -
- O -
kappaB O +
activation O +
and O +
TNF O -
- O -
alpha O +
release O +
in O +
human O +
monocytes O +
are O +
protein O +
tyrosine O +
kinase O +
dependent O +
and O +
protein O +
kinase O +
C O +
independent O +
. O +

BACKGROUND O +
: O +
Tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
is O +
an O +
important O +
mediator O +
of O +
septic O +
shock O +
. O +

Endotoxin O +
( O +
LPS O +
) O +
signal O +
transduction O +
in O +
human O +
monocytes O +
leads O +
to O +
activation O +
of O +
nuclear O +
factor O -
- O -
kappa O +
B O +
( O +
NF O -
- O -
kappaB O +
) O +
and O +
TNF O -
- O -
alpha O +
release O +
. O +

Previous O +
studies O +
have O +
implicated O +
activation O +
of O +
both O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
and O +
protein O +
tyrosine O +
kinases O +
( O +
PTK O +
) O +
in O +
LPS O -
- O -
induced O +
NF O -
- O -
kappaB O +
activation O +
and O +
TNF O -
- O -
alpha O +
production O +
. O +

We O +
hypothesized O +
that O +
inhibition O +
of O +
either O +
PKC O +
or O +
PTK O +
would O +
decrease O +
LPS O -
- O -
induced O +
NF O -
- O -
kappaB O +
DNA O +
binding O +
and O +
TNF O -
- O -
alpha O +
release O +
in O +
human O +
monocytes O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +
Human O +
monocytes O +
were O +
stimulated O +
with O +
PMA O +
( O +
50 O +
ng O -
/ O -
ml O +
) O +
alone O +
or O +
LPS O +
( O +
100 O +
ng O -
/ O -
ml O +
) O +
with O +
and O +
without O +
a O +
nonspecific O +
serine O -
/ O -
threonine O +
protein O +
kinase O +
inhibitor O +
staurosporine O +
( O +
Stauro O +
) O +
, O +
a O +
specific O +
pan- O +
PKC O +
inhibitor O +
bisindolylmaleimide O +
( O +
Bis O +
) O +
, O +
or O +
an O +
inhibitor O +
of O +
PTK O +
genistein O +
( O +
Gen O +
) O +
. O +

TNF O -
- O -
alpha O +
release O +
in O +
culture O +
supernatants O +
was O +
measured O +
by O +
an O +
ELISA O +
. O +

NF O -
- O -
kappaB O +
DNA O +
binding O +
was O +
evaluated O +
by O +
electrophoretic O +
mobility O +
shift O +
assay O +
. O +

RESULTS O +
: O +
LPS O +
increased O +
NF O -
- O -
kappaB O +
DNA O +
binding O +
and O +
TNF O -
- O -
alpha O +
release O +
in O +
human O +
monocytes O +
. O +

Nonspecific O +
protein O +
kinase O +
inhibition O +
inhibited O +
NF O -
- O -
kappaB O +
activation O +
and O +
TNF O -
- O -
alpha O +
release O +
, O +
while O +
specific O +
PKC O +
inhibition O +
with O +
Bis O +
had O +
no O +
effect O +
on O +
LPS O -
- O -
induced O +
NF O -
- O -
kappaB O +
DNA O +
binding O +
or O +
TNF O -
- O -
alpha O +
release O +
. O +

PTK O +
inhibition O +
with O +
Gen O +
attenuated O +
both O +
LPS O -
- O -
induced O +
NF O -
- O -
kappaB O +
DNA O +
binding O +
and O +
TNF O -
- O -
alpha O +
production O +
in O +
human O +
monocytes O +
. O +

Direct O +
activation O +
of O +
PKC O +
with O +
PMA O +
induced O +
both O +
NF O -
- O -
kappaB O +
activation O +
and O +
TNF O -
- O -
alpha O +
production O +
by O +
human O +
monocytes O +
. O +

CONCLUSIONS O +
: O +
These O +
results O +
suggest O +
that O +
LPS O -
- O -
induced O +
NF O -
- O -
kappaB O +
activation O +
and O +
TNF O -
- O -
alpha O +
release O +
in O +
human O +
monocytes O +
are O +
independent O +
of O +
PKC O +
activity O +
. O +

Furthermore O +
, O +
our O +
results O +
provide O +
evidence O +
that O +
PTK O +
plays O +
a O +
role O +
in O +
LPS O -
- O -
induced O +
NF O -
- O -
kappaB O +
activation O +
and O +
TNF O -
- O -
alpha O +
release O +
in O +
human O +
monocytes O +
and O +
thus O +
could O +
be O +
a O +
potential O +
therapeutic O +
target O +
in O +
inflammatory O +
states O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

Modulation O +
of O +
the O +
immune O +
response O +
and O +
tumor O +
growth O +
by O +
activated O +
Ras O +
. O +

As O +
a O +
result O +
of O +
its O +
transforming O +
abilities O +
, O +
activated O +
Ras O +
is O +
expressed O +
in O +
a O +
great O +
number O +
of O +
cancers O +
. O +

The O +
ras O +
mutation O +
frequency O +
varies O +
between O +
95 O +
% O +
in O +
pancreatic O +
cancer O +
and O +
5 O +
% O +
in O +
breast O +
cancer O +
. O +

In O +
leukemia O +
, O +
the O +
highest O +
frequency O +
( O +
30 O +
% O +
) O +
is O +
found O +
in O +
acute O +
myeloid O +
leukemia O +
. O +

The O +
presence O +
of O +
ras O +
mutations O +
has O +
been O +
correlated O +
with O +
a O +
poor O +
prognosis O +
and O +
negative O +
clinical O +
outcome O +
. O +

This O +
suggests O +
that O +
mutated O +
Ras O +
activates O +
mechanisms O +
, O +
which O +
favor O +
tumor O +
growth O +
, O +
enhance O +
the O +
metastatic O +
capacity O +
of O +
tumors O +
or O +
modulate O +
tumor O -
- O -
specific O +
immune O +
responses O +
. O +

Several O +
new O +
functions O +
of O +
Ras O +
, O +
such O +
as O +
downregulation O +
of O +
major O +
histocompatibility O +
complex O +
molecules O +
, O +
upregulation O +
of O +
certain O +
cytokines O +
, O +
growth O +
factors O +
and O +
degradative O +
enzymes O +
have O +
been O +
uncovered O +
in O +
the O +
last O +
decade O +
. O +

Additionally O +
, O +
mutated O +
Ras O +
can O +
also O +
serve O +
as O +
a O +
primary O +
target O +
for O +
the O +
development O +
of O +
immunotherapy O +
or O +
drug O +
therapy O +
. O +

This O +
review O +
will O +
discuss O +
the O +
mechanisms O +
by O +
which O +
Ras O +
expressing O +
tumors O +
are O +
able O +
to O +
evade O +
destruction O +
by O +
the O +
immune O +
system O +
and O +
enhance O +
their O +
growth O +
and O +
metastatic O +
potential O +
. O +

It O +
will O +
further O +
elaborate O +
on O +
the O +
attempts O +
to O +
develop O +
successful O +
immunotherapy O +
and O +
drug O +
therapy O +
targeting O +
Ras O +
expressing O +
tumors O +
. O +

Cellular O +
disposition O +
of O +
sulphamethoxazole O +
and O +
its O +
metabolites O +
: O +
implications O +
for O +
hypersensitivity O +
. O +

1 O -
. O +
Bioactivation O +
of O +
sulphamethoxazole O +
( O +
SMX O +
) O +
to O +
chemically O -
- O -
reactive O +
metabolites O +
and O +
subsequent O +
protein O +
conjugation O +
is O +
thought O +
to O +
be O +
involved O +
in O +
SMX O +
hypersensitivity O +
. O +

We O +
have O +
therefore O +
examined O +
the O +
cellular O +
metabolism O +
, O +
disposition O +
and O +
conjugation O +
of O +
SMX O +
and O +
its O +
metabolites O +
in O +
vitro O +
. O +

2 O -
. O +
Flow O +
cytometry O +
revealed O +
binding O +
of O +
N O -
- O -
hydroxy O +
( O +
SMX O -
- O -
NHOH O +
) O +
and O +
nitroso O +
( O +
SMX O -
- O -
NO O +
) O +
metabolites O +
of O +
SMX O +
, O +
but O +
not O +
of O +
SMX O +
itself O +
, O +
to O +
the O +
surface O +
of O +
viable O +
white O +
blood O +
cells O +
. O +

Cellular O +
haptenation O +
by O +
SMX O -
- O -
NO O +
was O +
reduced O +
by O +
exogenous O +
glutathione O +
( O +
GSH O +
) O +
. O +

3 O -
. O +
SMX O -
- O -
NHOH O +
and O +
SMX O -
- O -
NO O +
were O +
rapidly O +
reduced O +
back O +
to O +
the O +
parent O +
compound O +
by O +
cysteine O +
( O +
CYS O +
) O +
, O +
GSH O +
, O +
human O +
peripheral O +
blood O +
cells O +
and O +
plasma O +
, O +
suggesting O +
that O +
this O +
is O +
an O +
important O +
and O +
ubiquitous O +
bioinactivation O +
mechanism O +
. O +

4 O -
. O +
Fluorescence O +
HPLC O +
showed O +
that O +
SMX O -
- O -
NHOH O +
and O +
SMX O -
- O -
NO O +
depleted O +
CYS O +
and O +
GSH O +
in O +
buffer O +
, O +
and O +
to O +
a O +
lesser O +
extent O +
, O +
in O +
cells O +
and O +
plasma O +
. O +

5 O -
. O +
Neutrophil O +
apoptosis O +
and O +
inhibition O +
of O +
neutrophil O +
function O +
were O +
induced O +
at O +
lower O +
concentrations O +
of O +
SMX O -
- O -
NHOH O +
and O +
SMX O -
- O -
NO O +
than O +
those O +
inducing O +
loss O +
of O +
membrane O +
viability O +
, O +
with O +
SMX O +
having O +
no O +
effect O +
. O +

Lymphocytes O +
were O +
significantly O +
( O +
P O +
< O +
0.05 O +
) O +
more O +
sensitive O +
to O +
the O +
direct O +
cytotoxic O +
effects O +
of O +
SMX O -
- O -
NO O +
than O +
neutrophils O +
. O +

6 O -
. O +
Partitioning O +
of O +
SMX O -
- O -
NHOH O +
into O +
red O +
blood O +
cells O +
was O +
significantly O +
( O +
P O +
< O +
0.05 O +
) O +
lower O +
than O +
with O +
the O +
hydroxylamine O +
of O +
dapsone O +
. O +

7 O -
. O +
Our O +
results O +
suggest O +
that O +
the O +
balance O +
between O +
oxidation O +
of O +
SMX O +
to O +
its O +
toxic O +
metabolites O +
and O +
their O +
reduction O +
is O +
an O +
important O +
protective O +
cellular O +
mechanism O +
. O +

If O +
an O +
imbalance O +
exists O +
, O +
haptenation O +
of O +
the O +
toxic O +
metabolites O +
to O +
bodily O +
proteins O +
including O +
the O +
surface O +
of O +
viable O +
cells O +
can O +
occur O +
, O +
and O +
may O +
result O +
in O +
drug O +
hypersensitivity O +
. O +

Tcf-1 O +
-mediated O +
transcription O +
in O +
T O +
lymphocytes O +
: O +
differential O +
role O +
for O +
glycogen O +
synthase O +
kinase-3 O +
in O +
fibroblasts O +
and O +
T O +
cells O +
. O +

Beta O -
- O -
catenin O +
is O +
the O +
vertebrate O +
homolog O +
of O +
the O +
Drosophila O +
segment O +
polarity O +
gene O +
Armadillo O +
and O +
plays O +
roles O +
in O +
both O +
cell O -
- O -
cell O +
adhesion O +
and O +
transduction O +
of O +
the O +
Wnt O +
signaling O +
cascade O +
. O +

Recently O +
, O +
members O +
of O +
the O +
Lef O -
/ O -
Tcf O +
transcription O +
factor O +
family O +
have O +
been O +
identified O +
as O +
protein O +
partners O +
of O +
beta O -
- O -
catenin O +
, O +
explaining O +
how O +
beta O -
- O -
catenin O +
alters O +
gene O +
expression O +
. O +

Here O +
we O +
report O +
that O +
in O +
T O +
cells O +
, O +
Tcf-1 O +
also O +
becomes O +
transcriptionally O +
active O +
through O +
interaction O +
with O +
beta O -
- O -
catenin O +
, O +
suggesting O +
that O +
the O +
Wnt O +
signal O +
transduction O +
pathway O +
is O +
operational O +
in O +
T O +
lymphocytes O +
as O +
well O +
. O +

However O +
, O +
although O +
Wnt O +
signals O +
are O +
known O +
to O +
inhibit O +
the O +
activity O +
of O +
the O +
negative O +
regulatory O +
protein O +
kinase O +
glycogen O +
synthase O +
kinase-3beta O +
( O +
GSK-3beta O +
) O +
, O +
resulting O +
in O +
increased O +
levels O +
of O +
beta O -
- O -
catenin O +
, O +
we O +
find O +
no O +
evidence O +
for O +
involvement O +
of O +
GSK-3beta O +
in O +
Tcf O -
- O -
mediated O +
transcription O +
in O +
T O +
cells O +
. O +

That O +
is O +
, O +
a O +
dominant O +
negative O +
GSK-3beta O +
does O +
not O +
specifically O +
activate O +
Tcf O +
transcription O +
and O +
stimuli O +
( O +
lithium O +
or O +
phytohemagglutinin O +
) O +
that O +
inhibit O +
GSK-3beta O +
activity O +
also O +
do O +
not O +
activate O +
Tcf O +
reporter O +
genes O +
. O +

Thus O +
, O +
inhibition O +
of O +
GSK-3beta O +
is O +
insufficient O +
to O +
activate O +
Tcf O -
- O -
dependent O +
transcription O +
in O +
T O +
lymphocytes O +
. O +

In O +
contrast O +
, O +
in O +
C57MG B-CellLine +
fibroblast I-CellLine +
cells I-CellLine +
, O +
lithium O +
inactivates O +
GSK-3beta O +
and O +
induces O +
Tcf O -
- O -
controlled O +
transcription O +
. O +

This O +
is O +
the O +
first O +
demonstration O +
that O +
lithium O +
can O +
alter O +
gene O +
expression O +
of O +
Tcf O -
- O -
responsive O +
genes O +
, O +
and O +
points O +
to O +
a O +
difference O +
in O +
regulation O +
of O +
Wnt O +
signaling O +
between O +
fibroblasts O +
and O +
lymphocytes O +
. O +

CIITA O +
-induced O +
occupation O +
of O +
MHC O +
class O +
II O +
promoters O +
is O +
independent O +
of O +
the O +
cooperative O +
stabilization O +
of O +
the O +
promoter O -
- O -
bound O +
multi O -
- O -
protein O +
complexes O +
. O +

Precise O +
regulation O +
of O +
MHC O +
class O +
II O +
expression O +
plays O +
a O +
crucial O +
role O +
in O +
the O +
control O +
of O +
the O +
immune O +
response O +
. O +

The O +
transactivator O +
CIITA O +
behaves O +
as O +
a O +
master O +
controller O +
of O +
constitutive O +
and O +
inducible O +
MHC O +
class O +
II O +
gene O +
activation O +
, O +
but O +
its O +
exact O +
mechanism O +
of O +
action O +
is O +
not O +
known O +
. O +

Activation O +
of O +
MHC O +
class O +
II O +
promoters O +
requires O +
binding O +
of O +
at O +
least O +
three O +
distinct O +
multi O -
- O -
protein O +
complexes O +
( O +
RFX O +
, O +
X2BP O +
and O +
NF O -
- O -
Y O +
) O +
. O +

It O +
is O +
known O +
that O +
the O +
stability O +
of O +
this O +
binding O +
results O +
from O +
cooperative O +
interactions O +
between O +
these O +
proteins O +
. O +

We O +
show O +
here O +
that O +
expression O +
of O +
CIITA O +
in O +
MHC B-CellLine +
class I-CellLine +
II I-CellLine +
-cells I-CellLine +
triggers O +
occupation O +
of O +
the O +
promoters O +
by O +
these O +
complexes O +
. O +

This O +
observation O +
raised O +
the O +
possibility O +
that O +
the O +
effect O +
of O +
CIITA O +
on O +
promoter O +
occupation O +
is O +
mediated O +
by O +
an O +
effect O +
on O +
the O +
cooperative O +
stabilization O +
of O +
the O +
DNA O -
- O -
bound O +
multi O -
- O -
protein O +
complexes O +
. O +

We O +
show O +
, O +
however O +
, O +
that O +
the O +
presence O +
of O +
CIITA O +
does O +
not O +
affect O +
the O +
stability O +
of O +
the O +
higher O -
- O -
order O +
protein O +
complex O +
formed O +
on O +
DNA O +
by O +
RFX O +
, O +
X2BP O +
and O +
NF O -
- O -
Y O +
. O +

This O +
suggests O +
other O +
mechanisms O +
for O +
CIITA O +
-induced O +
promoter O +
occupancy O +
, O +
such O +
as O +
an O +
effect O +
on O +
chromatin O +
structure O +
leading O +
to O +
increased O +
accessibility O +
of O +
MHC O +
class O +
II O +
promoters O +
. O +

This O +
ability O +
of O +
CIITA O +
to O +
facilitate O +
promoter O +
occupation O +
is O +
undissociable O +
from O +
its O +
transactivation O +
potential O +
. O +

Finally O +
, O +
we O +
conclude O +
that O +
this O +
effect O +
of O +
CIITA O +
is O +
cell O -
- O -
type O +
specific O +
, O +
since O +
expression O +
of O +
CIITA O +
is O +
not O +
required O +
for O +
normal O +
occupation O +
of O +
MHC O +
class O +
II O +
promoters O +
in O +
B O +
lymphocytes O +
. O +

Activation O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
by O +
lipopolysaccharide O +
in O +
mononuclear O +
leukocytes O +
is O +
prevented O +
by O +
inhibitors O +
of O +
cytosolic O +
phospholipase O +
A2 O +
. O +

In O +
monocytes O +
, O +
lipopolysaccharide O +
induces O +
synthesis O +
and O +
activity O +
of O +
the O +
85-kDa O +
cytosolic O +
phospholipase O +
A2 O +
. O +

This O +
enzyme O +
releases O +
arachidonic O +
acid O +
and O +
lyso O -
- O -
phospholipids O +
from O +
membranes O +
which O +
are O +
metabolized O +
to O +
eicosanoids O +
and O +
platelet O -
- O -
activating O -
- O -
factor O +
. O +

These O +
lipid O +
mediators O +
increase O +
activity O +
of O +
transcription O +
factors O +
and O +
expression O +
of O +
cytokine O +
genes O +
indicating O +
a O +
function O +
for O +
cytosolic O +
phospholipase O +
A2 O +
in O +
signal O +
transduction O +
and O +
inflammation O +
. O +

We O +
have O +
shown O +
previously O +
that O +
trifluoromethylketone O +
inhibitors O +
of O +
cytosolic O +
phospholipase O +
A2 O +
suppressed O +
interleukin-1beta O +
protein O +
and O +
steady O -
- O -
state O +
mRNA O +
levels O +
in O +
human O +
lipopolysaccharide O -
- O -
stimulated O +
peripheral O +
blood O +
mononuclear O +
leukocytes O +
. O +

In O +
this O +
study O +
, O +
the O +
subcellular O +
mechanisms O +
were O +
analyzed O +
by O +
which O +
trifluoromethylketones O +
interfere O +
with O +
gene O +
expression O +
. O +

We O +
found O +
that O +
they O +
reduced O +
the O +
initial O +
interleukin-1beta O +
mRNA O +
transcription O +
rate O +
through O +
prevention O +
of O +
degradation O +
of O +
inhibitor O -
- O -
kappaB O +
alpha O +
. O +

Consequently O +
, O +
cytosolic O +
activation O +
, O +
nuclear O +
translocation O +
and O +
DNA O -
- O -
binding O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
were O +
decreased O +
. O +

Trifluoromethylketones O +
ameliorate O +
chronic O +
inflammation O +
in O +
vivo O +
. O +

Thus O +
, O +
this O +
therapeutic O +
potency O +
may O +
reside O +
in O +
retention O +
of O +
inactive O +
nuclear O +
factor O -
- O -
kappaB O +
in O +
the O +
cytosol O +
thereby O +
abrogating O +
interleukin-1beta O +
gene O +
transcription O +
. O +

Immunosuppressant O +
PG490 O +
( O +
triptolide O +
) O +
inhibits O +
T O -
- O -
cell O +
interleukin-2 O +
expression O +
at O +
the O +
level O +
of O +
purine O -
- O -
box O -
/ O -
nuclear O +
factor O +
of O +
activated O +
T O -
- O -
cells O +
and O +
NF O -
- O -
kappaB O +
transcriptional O +
activation O +
. O +

PG490 O +
( O +
triptolide O +
) O +
is O +
a O +
diterpene O +
triepoxide O +
with O +
potent O +
immunosuppressive O +
and O +
antiinflammatory O +
properties O +
. O +

PG490 O +
inhibits O +
interleukin O +
( O +
IL O +
) O +
-2 O +
expression O +
by O +
normal O +
human O +
peripheral O +
blood O +
lymphocytes O +
stimulated O +
with O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
and O +
antibody O +
to O +
CD3 O +
( O +
IC50 O +
of O +
10 O +
ng O -
/ O -
ml O +
) O +
, O +
and O +
with O +
PMA O +
and O +
ionomycin O +
( O +
Iono O +
, O +
IC50 O +
of O +
40 O +
ng O -
/ O -
ml O +
) O +
. O +

In O +
Jurkat B-CellLine +
T I-CellLine -
- I-CellLine -
cells I-CellLine +
, O +
PG490 O +
inhibits O +
PMA O -
/ O -
Iono O -
- O -
stimulated O +
IL-2 O +
transcription O +
. O +

PG490 O +
inhibits O +
the O +
induction O +
of O +
DNA O +
binding O +
activity O +
at O +
the O +
purine O -
- O -
box O -
/ O -
antigen O +
receptor O +
response O +
element O +
( O +
ARRE O +
) O +
/nuclear O +
factor O +
of O +
activated O +
T O -
- O -
cells O +
( O +
NF O -
- O -
AT O +
) O +
target O +
sequence O +
but O +
not O +
at O +
the O +
NF O -
- O -
kappaB O +
site O +
. O +

PG490 O +
can O +
completely O +
inhibit O +
transcriptional O +
activation O +
at O +
the O +
purine O -
- O -
box O -
/ O -
ARRE O -
/ O -
NF O -
- O -
AT O +
and O +
NF O -
- O -
kappaB O +
target O +
DNA O +
sequences O +
triggered O +
by O +
all O +
stimuli O +
examined O +
( O +
PMA O +
, O +
PMA O -
/ O -
Iono O +
, O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
) O +
. O +

PG490 O +
also O +
inhibits O +
PMA O -
- O -
stimulated O +
activation O +
of O +
a O +
chimeric O +
transcription O +
factor O +
in O +
which O +
the O +
C O -
- O -
terminal O +
TA1 O +
transactivation O +
domain O +
of O +
NF O -
- O -
kappaB O +
p65 O +
is O +
fused O +
to O +
the O +
DNA O +
binding O +
domain O +
of O +
GAL4 O +
. O +

In O +
16HBE O +
human O +
bronchial O +
epithelial O +
cells O +
, O +
IL-8 O +
expression O +
is O +
regulated O +
predominantly O +
by O +
NF O -
- O -
kappaB O +
, O +
and O +
PG490 O +
but O +
not O +
cyclosporin O +
A O +
can O +
completely O +
inhibit O +
expression O +
of O +
IL-8 O +
. O +

The O +
mechanism O +
of O +
PG490 O +
inhibition O +
of O +
cytokine O +
gene O +
expression O +
differs O +
from O +
cyclosporin O +
A O +
and O +
involves O +
nuclear O +
inhibition O +
of O +
transcriptional O +
activation O +
of O +
NF O -
- O -
kappaB O +
and O +
the O +
purine O -
- O -
box O +
regulator O +
operating O +
at O +
the O +
ARRE O -
/ O -
NF O -
- O -
AT O +
site O +
at O +
a O +
step O +
after O +
specific O +
DNA O +
binding O +
. O +

Signal O +
transduction O +
through O +
interferon O -
- O -
gamma O +
receptor O +
on O +
human O +
eosinophils O +
. O +

BACKGROUND O +
: O +
We O +
reported O +
on O +
the O +
constitutive O +
interferon O -
- O -
gamma O +
receptor O +
( O +
IFN O -
- O -
gammaR O +
) O +
expression O +
on O +
eosinophils O +
. O +

But O +
signal O +
transduction O +
through O +
IFN O -
- O -
gammaR O +
on O +
eosinophils O +
remains O +
to O +
be O +
elucidated O +
. O +

In O +
this O +
study O +
, O +
we O +
examined O +
the O +
involvement O +
of O +
the O +
Jak O -
/ O -
Stat O +
pathway O +
in O +
the O +
signaling O +
of O +
eosinophils O +
after O +
IFN O -
- O -
gammaR O +
conjugation O +
by O +
the O +
ligand O +
binding O +
. O +

METHODS O +
: O +
Purified O +
peripheral O +
eosinophils O +
were O +
stimulated O +
with O +
IFN O -
- O -
gamma O +
at O +
37 O +
degrees O +
C O +
for O +
1 O -
- O -
60 O +
min O +
. O +

Tyrosine O +
phosphorylation O +
of O +
IFN O -
- O -
gammaR O +
, O +
Jak1 O +
, O +
Jak2 O +
, O +
and O +
Stat1alpha O +
was O +
examined O +
by O +
immunoblotting O +
. O +

Gel O -
- O -
shift O +
assay O +
was O +
also O +
examined O +
to O +
show O +
the O +
formation O +
of O +
Stat1alpha O -
- O -
DNA O +
complexes O +
. O +

RESULTS O +
: O +
We O +
show O +
that O +
binding O +
of O +
IFN O -
- O -
gamma O +
to O +
human O +
eosinophils O +
initiated O +
a O +
series O +
of O +
events O +
that O +
resulted O +
in O +
the O +
rapid O +
tyrosine O +
phosphorylation O +
of O +
not O +
only O +
the O +
IFN O -
- O -
gammaRalpha O +
chain O +
but O +
also O +
Jak1 O +
, O +
Jak2 O +
, O +
and O +
Stat1alpha O +
. O +

In O +
addition O +
, O +
IFN O -
- O -
gamma O +
enhanced O +
the O +
DNA O -
- O -
binding O +
activity O +
of O +
Stat1alpha O +
. O +

CONCLUSION O +
: O +
These O +
data O +
indicate O +
that O +
IFN O -
- O -
gamma O +
affects O +
eosinophils O +
through O +
its O +
specific O +
receptor O +
and O +
utilizes O +
the O +
Jak O -
/ O -
Stat O +
pathway O +
as O +
its O +
mode O +
of O +
signaling O +
. O +

Estrogen O +
and O +
progesterone O +
induction O +
of O +
survival O +
of O +
monoblastoid O +
cells O +
undergoing O +
TNF O -
- O -
alpha O +
-induced O +
apoptosis O +
. O +

Induction O +
of O +
apoptosis O +
of O +
mononucleated O +
cells O +
is O +
a O +
physiological O +
process O +
for O +
regulating O +
the O +
intensity O +
of O +
the O +
immune O +
response O +
. O +

The O +
female O +
steroid O +
hormones O +
estrogen O +
( O +
E2 O +
) O +
and O +
progesterone O +
( O +
Prog O +
) O +
are O +
known O +
to O +
modulate O +
the O +
reactivity O +
of O +
the O +
immune O +
system O +
; O +
recently O +
it O +
has O +
been O +
demonstrated O +
that O +
they O +
can O +
regulate O +
induction O +
of O +
apoptosis O +
of O +
endothelial O +
cells O +
and O +
osteoblasts O +
. O +

TNF O -
- O -
alpha O +
-mediated O +
induction O +
of O +
apoptosis O +
has O +
been O +
well O +
characterized O +
in O +
myeloid O +
cells O +
. O +

We O +
investigated O +
whether O +
E2 O +
and O +
Prog O +
could O +
interfere O +
with O +
TNF O -
- O -
alpha O +
-induced O +
apoptosis O +
of O +
the O +
monoblastoid B-CellLine +
U937 I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Treatment O +
with O +
E2 O +
or O +
Prog O +
increased O +
survival O +
and O +
prevented O +
apoptosis O +
induced O +
by O +
TNF O -
- O -
alpha O +
in O +
both O +
undifferentiated O +
and O +
macrophage O -
- O -
like O +
PMA B-CellLine -
- I-CellLine -
differentiated I-CellLine +
U937 I-CellLine +
cells I-CellLine +
, O +
as O +
assessed O +
by O +
trypan O +
blue O +
exclusion O +
cell O +
counting O +
, O +
thymidine O +
incorporation O +
, O +
AnnexinV O +
labeling O +
, O +
followed O +
by O +
flow O +
cytometry O +
and O +
DNA O +
fragmentation O +
studies O +
. O +

This O +
effect O +
can O +
be O +
associated O +
with O +
the O +
activation O +
of O +
specific O +
hormone O +
receptors O +
, O +
since O +
we O +
observed O +
the O +
expression O +
of O +
the O +
estrogen O +
receptor O +
alpha O +
( O +
ER O -
- O -
alpha O +
) O +
, O +
ER O -
- O -
beta O +
, O +
and O +
progesterone O +
receptor O +
( O +
PR O +
) O +
mRNAs O +
; O +
the O +
ER O -
- O -
alpha O +
protein O +
expression O +
was O +
confirmed O +
by O +
immunocytochemical O +
analysis O +
. O +

In O +
addition O +
, O +
hormone O -
- O -
mediated O +
survival O +
against O +
apoptosis O +
was O +
concentration O +
dependent O +
, O +
reaching O +
the O +
half O -
- O -
maximal O +
effect O +
at O +
10 O +
nM O +
and O +
blocked O +
by O +
the O +
ER O +
antagonist O +
ICI O +
182 O +
, O +
780 O +
in O +
undifferentiated O +
cells O +
, O +
further O +
supporting O +
a O +
receptor O -
- O -
mediated O +
mechanism O +
of O +
cell O +
survival O +
. O +

Other O +
steroid O +
receptor O +
drugs O +
such O +
as O +
Raloxifene O +
, O +
RU486 O +
, O +
or O +
the O +
ICI O +
182 O +
, O +
780 O +
in O +
PMA B-CellLine -
- I-CellLine -
differentiated I-CellLine +
cells I-CellLine +
displayed O +
agonist O +
activity O +
by O +
preventing O +
TNF O -
- O -
alpha O +
-induced O +
apoptosis O +
as O +
efficiently O +
as O +
the O +
hormones O +
alone O +
, O +
providing O +
further O +
evidence O +
to O +
the O +
notion O +
that O +
steroid O +
receptor O +
drugs O +
may O +
manifest O +
agonist O +
or O +
antagonist O +
activities O +
depending O +
on O +
the O +
cellular O +
context O +
in O +
which O +
they O +
are O +
studied O +
. O +

Treatment O +
with O +
E2 O +
was O +
also O +
associated O +
with O +
a O +
time O -
- O -
dependent O +
decrease O +
in O +
the O +
mRNA O +
level O +
of O +
the O +
proapoptotic O +
Nip-2 O +
protein O +
, O +
supporting O +
the O +
hypothesis O +
that O +
hormone O +
responsiveness O +
of O +
U937 B-CellLine +
cells I-CellLine +
is O +
mediated O +
by O +
target O +
gene O +
transcription O +
. O +

Together O +
, O +
these O +
results O +
demonstrate O +
that O +
ER O +
and O +
PR O +
can O +
be O +
activated O +
by O +
endogenous O +
or O +
exogenous O +
ligands O +
to O +
induce O +
a O +
genetic O +
response O +
that O +
impairs O +
TNF O -
- O -
alpha O +
-induced O +
apoptosis O +
in O +
U937 B-CellLine +
cells I-CellLine +
. O +

The O +
data O +
presented O +
here O +
suggest O +
that O +
the O +
female O +
steroid O +
receptors O +
play O +
a O +
role O +
in O +
regulation O +
of O +
the O +
immune O +
response O +
by O +
preventing O +
apoptosis O +
of O +
monoblastoid O +
cells O +
; O +
this O +
effect O +
might O +
have O +
important O +
consequences O +
in O +
the O +
clinical O +
use O +
of O +
steroid O +
receptor O +
drugs O +
. O +

-- O +
Vegeto O +
, O +
E. O +
, O +
Pollio O +
, O +
G. O +
, O +
Pellicciari O +
, O +
C. O +
, O +
Maggi O +
, O +
A O +
. O +

Estrogen O +
and O +
progesterone O +
induction O +
of O +
survival O +
of O +
monoblastoid O +
cells O +
undergoing O +
TNF O -
- O -
alpha O +
-inuced O +
apoptosis O +
. O +

Constitutive O +
activation O +
of O +
an O +
epithelial O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
( O +
STAT O +
) O +
pathway O +
in O +
asthma O +
. O +

Cytokine O +
effects O +
on O +
immunity O +
and O +
inflammation O +
often O +
depend O +
on O +
the O +
transcription O +
factors O +
termed O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
STATs O +
) O +
, O +
so O +
STAT O +
signaling O +
pathways O +
are O +
candidates O +
for O +
influencing O +
inflammatory O +
disease O +
. O +

We O +
reasoned O +
that O +
selective O +
IFN O +
responsiveness O +
of O +
the O +
first O +
STAT O +
family O +
member O +
( O +
Stat1 O +
) O +
and O +
Stat1-dependent O +
immune O -
- O -
response O +
genes O +
such O +
as O +
intercellular O +
adhesion O +
molecule-1 O +
( O +
ICAM-1 O +
) O +
, O +
IFN O +
regulatory O +
factor-1 O +
( O +
IRF-1 O +
) O +
, O +
and O +
Stat1 O +
itself O +
in O +
airway O +
epithelial O +
cells O +
provides O +
a O +
basis O +
for O +
detecting O +
cytokine O +
signaling O +
abnormalities O +
in O +
inflammatory O +
airway O +
disease O +
. O +

On O +
the O +
basis O +
of O +
nuclear O +
localization O +
and O +
phosphorylation O +
, O +
we O +
found O +
that O +
epithelial O +
Stat1 O +
( O +
but O +
not O +
other O +
control O +
transcription O +
factors O +
) O +
was O +
invariably O +
activated O +
in O +
asthmatic O +
compared O +
with O +
normal O +
control O +
or O +
chronic O +
bronchitis O +
subjects O +
. O +

Furthermore O +
, O +
epithelial O +
levels O +
of O +
activated O +
Stat1 O +
correlated O +
with O +
levels O +
of O +
expression O +
for O +
epithelial O +
ICAM-1 O +
, O +
IRF-1 O +
, O +
and O +
Stat1 O +
, O +
and O +
in O +
turn O +
, O +
ICAM-1 O +
levels O +
correlated O +
with O +
T O -
- O -
cell O +
accumulation O +
in O +
tissue O +
. O +

However O +
, O +
only O +
low O +
levels O +
of O +
IFN O -
- O -
gamma O +
or O +
IFN O -
- O -
gamma O -
- O -
producing O +
cells O +
were O +
detected O +
in O +
airway O +
tissue O +
in O +
all O +
subjects O +
. O +

The O +
results O +
therefore O +
provide O +
initial O +
evidence O +
linking O +
abnormal O +
behavior O +
of O +
STAT O +
pathways O +
for O +
cytokine O +
signaling O +
to O +
the O +
development O +
of O +
an O +
inflammatory O +
disease O +
. O +

In O +
that O +
context O +
, O +
the O +
results O +
also O +
change O +
the O +
current O +
scheme O +
for O +
asthma O +
pathogenesis O +
to O +
one O +
that O +
must O +
include O +
a O +
localized O +
gain O +
in O +
transcriptional O +
signal O +
ordinarily O +
used O +
for O +
a O +
T O +
helper O +
1-type O +
cytokine O +
( O +
IFN O -
- O -
gamma O +
) O +
in O +
combination O +
with O +
allergy O -
- O -
driven O +
overproduction O +
of O +
T O +
helper O +
2-type O +
cytokines O +
. O +

Molecular O +
regulation O +
of O +
cytokine O +
gene O +
expression O +
during O +
the O +
immune O +
response O +
. O +

Cytokine O +
expression O +
by O +
immune O +
system O +
cells O +
plays O +
an O +
important O +
role O +
in O +
the O +
regulation O +
of O +
the O +
immune O +
response O +
. O +

On O +
first O +
encounter O +
with O +
antigen O +
, O +
naive O +
CD4 O -
+ O +
T O +
helper O +
( O +
Th O +
) O +
cells O +
differentiate O +
into O +
cytokine B-CellLine -
- I-CellLine -
producing I-CellLine +
effector I-CellLine +
cells I-CellLine +
. O +

Two O +
types O +
of O +
effector O +
cells O +
characterized O +
by O +
their O +
distinct O +
expression O +
of O +
cytokine O +
profiles O +
have O +
been O +
described O +
. O +

Th1 O +
cells O +
produce O +
IL-2 O +
and O +
IFN O -
- O -
gamma O +
, O +
whereas O +
Th2 B-CellLine +
cells I-CellLine +
produce O +
IL-4 O +
, O +
IL-5 O +
, O +
IL-6 O +
, O +
IL-10 O +
, O +
and O +
IL-13 O +
. O +

In O +
many O +
pathological O +
situations O +
, O +
the O +
balance O +
between O +
Th1 O +
and O +
Th2 O +
immune O +
responses O +
determines O +
the O +
outcome O +
of O +
diverse O +
immunologically O +
mediated O +
clinical O +
syndromes O +
including O +
infectious O +
, O +
autoimmune O +
, O +
and O +
allergic O +
diseases O +
. O +

However O +
, O +
the O +
molecular O +
basis O +
for O +
the O +
tissue O -
- O -
specific O +
expression O +
of O +
Th1 O -
/ O -
Th2-like O +
cytokines O +
has O +
remained O +
elusive O +
. O +

In O +
this O +
review O +
we O +
evaluate O +
the O +
possible O +
in O +
vivo O +
role O +
of O +
different O +
transcription O +
factors O +
and O +
transcriptional O +
mechanisms O +
in O +
T O +
cell O +
differentiation O +
and O +
the O +
immune O +
response O +
. O +

Differences O +
in O +
phosphorylation O +
of O +
the O +
IL-2R O +
associated O +
JAK O -
/ O -
STAT O +
proteins O +
between O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine +
( I-CellLine +
+ I-CellLine +
) I-CellLine +
, I-CellLine +
IL-2-independent I-CellLine +
and I-CellLine +
IL-2-dependent I-CellLine +
cell I-CellLine +
lines I-CellLine +
and O +
uncultured O +
leukemic O +
cells O +
from O +
patients O +
with O +
adult O +
T O -
- O -
cell O +
lymphoma O -
/ O -
leukemia O +
. O +

To O +
determine O +
activation O +
status O +
of O +
the O +
IL-2R O +
-associated O +
( O +
Jak O -
/ O -
STAT O +
) O +
pathway O +
in O +
the O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine +
infected I-CellLine +
cells I-CellLine +
, O +
we O +
examined O +
tyrosine O +
phosphorylation O +
of O +
Jak3 O +
, O +
STAT3 O +
, O +
and O +
STAT5 O +
in O +
several O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine +
( I-CellLine +
+ I-CellLine +
) I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
and O +
in O +
uncultured O +
leukemic O +
T O +
cells O +
isolated O +
from O +
patients O +
with O +
adult O +
T O -
- O -
cell O +
lymphoma O -
/ O -
leukemia O +
( O +
ATLL O +
) O +
. O +

Constitutive O +
basal O +
phosphorylation O +
of O +
Jak3 O +
and O +
, O +
usually O +
, O +
STAT3 O +
and O +
STAT5 O +
was O +
detected O +
in O +
all O +
four O +
IL-2-independent B-CellLine +
cell I-CellLine +
lines I-CellLine +
tested O +
, O +
but O +
in O +
none O +
of O +
the O +
three O +
IL-2-dependent B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Similarly O +
, O +
there O +
was O +
no O +
detectable O +
basal O +
phosphorylation O +
of O +
Jak3 O +
and O +
STAT5 O +
in O +
the O +
leukemic O +
cells O +
from O +
ATLL O +
patients O +
( O +
0 O -
/ O -
8 O +
and O +
0 O -
/ O -
3 O +
, O +
respectively O +
) O +
. O +

However O +
, O +
stimulation O +
with O +
IL-2 O +
resulted O +
in O +
Jak3 O +
and O +
STAT5 O +
phosphorylation O +
in O +
both O +
leukemic O +
ATLL O +
cells O +
and O +
IL-2-dependent B-CellLine +
lines I-CellLine +
. O +

Furthermore O +
, O +
expression O +
of O +
SHP-1 O +
phosphatase O +
which O +
is O +
a O +
negative O +
regulator O +
of O +
cytokine O +
receptor O +
signaling O +
, O +
was O +
lost O +
in O +
most O +
IL-2 B-CellLine +
independent I-CellLine +
cell I-CellLine +
lines I-CellLine +
( O +
3 O -
/ O -
4 O +
) O +
but O +
not O +
in O +
the O +
leukemic O +
ATLL O +
cells O +
( O +
0 O -
/ O -
3 O +
) O +
. O +

Finally O +
, O +
the O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine +
( I-CellLine +
+ I-CellLine +
) I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
( O +
313 O +
) O +
but O +
not O +
the O +
control O +
, O +
HTLV B-CellLine -
- I-CellLine -
I I-CellLine +
( I-CellLine +
- I-CellLine +
) I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
were O +
resistant O +
to O +
rapamycin O +
and O +
its O +
novel O +
analog O +
RAD O +
. O +

We O +
conclude O +
that O +
( O +
1 O +
) O +
HTLV O -
- O -
I O +
infection O +
per O +
se O +
does O +
not O +
result O +
in O +
a O +
constitutive O +
phosphorylation O +
of O +
the O +
Jak3 O +
, O +
STAT3 O +
, O +
and O +
STAT5 O +
proteins O +
; O +
( O +
2 O +
) O +
malignant O +
transformation O +
in O +
at O +
least O +
some O +
cases O +
of O +
ATLL O +
does O +
not O +
require O +
the O +
constitutive O +
, O +
but O +
may O +
require O +
IL-2 O +
-induced O +
, O +
activation O +
of O +
the O +
IL-2R O +
Jak O -
/ O -
STAT O +
pathway O +
; O +
and O +
( O +
3 O +
) O +
there O +
are O +
major O +
differences O +
in O +
T O -
- O -
cell O +
immortalization O +
mechanism O +
( O +
s O +
) O +
which O +
appear O +
to O +
involve O +
SHP-1 O +
and O +
target O +
molecules O +
for O +
rapamycin O +
and O +
RAD O +
. O +

The O +
evolutionarily O +
conserved O +
sequence O +
upstream O +
of O +
the O +
human O +
Ig O +
heavy O +
chain O +
S O +
gamma O +
3 O +
region O +
is O +
an O +
inducible O +
promoter O +
: O +
synergistic O +
activation O +
by O +
CD40 O +
ligand O +
and O +
IL-4 O +
via O +
cooperative O +
NF O -
- O -
kappa O +
B O +
and O +
STAT-6 O +
binding O +
sites O +
. O +

Germline O +
C O +
gamma O +
gene O +
transcription O +
is O +
a O +
crucial O +
event O +
in O +
the O +
process O +
that O +
leads O +
to O +
switch O +
DNA O +
recombination O +
to O +
IgG O +
, O +
but O +
its O +
regulation O +
in O +
the O +
human O +
is O +
poorly O +
understood O +
. O +

We O +
took O +
advantage O +
of O +
our O +
monoclonal O +
model O +
of O +
germinal O +
center O +
B O +
cell O +
differentiation O +
, O +
IgM+ B-CellLine +
IgD+ I-CellLine +
CL-01 I-CellLine +
cells I-CellLine +
, O +
to O +
define O +
the O +
role O +
of O +
the O +
I O +
gamma O +
3 O +
evolutionarily O +
conserved O +
sequence O +
( O +
ECS O +
) O +
in O +
the O +
germline O +
transcriptional O +
activation O +
of O +
the O +
human O +
C O +
gamma O +
3 O +
gene O +
. O +

The O +
I O +
gamma O +
3 O +
ECS O +
lies O +
upstream O +
of O +
the O +
major O +
I O +
gamma O +
3 O +
transcription O +
initiation O +
site O +
and O +
displays O +
more O +
than O +
90 O +
% O +
identity O +
with O +
the O +
corresponding O +
human O +
I O +
gamma O +
1 O +
, O +
I O +
gamma O +
2 O +
, O +
and O +
I O +
gamma O +
4 O +
regions O +
. O +

Reporter O +
luciferase O +
gene O +
vectors O +
containing O +
the O +
human O +
gamma O +
3 O +
ECS O +
were O +
used O +
to O +
transfect O +
CL-01 B-CellLine +
cells I-CellLine +
, O +
which O +
have O +
been O +
shown O +
to O +
undergo O +
Smu O +
-- O +
> O +
S O +
gamma O +
3 O +
DNA O +
recombination O +
, O +
upon O +
engagement O +
of O +
CD40 O +
by O +
CD40 O +
ligand O +
( O +
CD40L O +
) O +
and O +
exposure O +
to O +
IL-4 O +
. O +

In O +
these O +
transfected O +
CL-01 B-CellLine +
cells I-CellLine +
, O +
CD40 O +
: O +
CD40L O +
engagement O +
and O +
exposure O +
to O +
IL-4 O +
synergistically O +
induced O +
gamma O +
3 O +
ECS O -
- O -
dependent O +
luciferase O +
reporter O +
gene O +
activation O +
. O +

Targeted O +
mutational O +
analysis O +
demonstrated O +
that O +
a O +
tandem O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
binding O +
motif O +
is O +
critical O +
for O +
the O +
gamma O +
3 O +
ECS O +
responsiveness O +
to O +
both O +
CD40L O +
and O +
IL-4 O +
, O +
while O +
a O +
STAT-6-binding O +
site O +
is O +
additionally O +
required O +
for O +
IL-4 O +
inducibility O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
showed O +
that O +
p50 O -
/ O -
p65 O -
/ O -
c O -
- O -
Rel O +
and O +
STAT-6 O +
are O +
effectively O +
induced O +
by O +
CD40L O +
and O +
IL-4 O +
, O +
respectively O +
, O +
and O +
bind O +
to O +
specific O +
DNA O +
motifs O +
within O +
the O +
ECS O +
. O +

These O +
partially O +
overlapping O +
CD40L O +
and O +
IL-4 O +
responsive O +
elements O +
are O +
functionally O +
cooperative O +
as O +
the O +
disruption O +
of O +
one O +
of O +
them O +
prevents O +
synergistic O +
promoter O +
activation O +
. O +

Thus O +
, O +
the O +
gamma O +
3 O +
ECS O +
is O +
an O +
inducible O +
promoter O +
containing O +
cis O +
elements O +
that O +
critically O +
mediate O +
CD40L O +
and O +
IL-4 O +
-triggered O +
transcriptional O +
activation O +
of O +
the O +
human O +
C O +
gamma O +
3 O +
gene O +
. O +

Thrombin O -
- O -
induced O +
p65 O +
homodimer O +
binding O +
to O +
downstream O +
NF O -
- O -
kappa O +
B O +
site O +
of O +
the O +
promoter O +
mediates O +
endothelial O +
ICAM-1 O +
expression O +
and O +
neutrophil O +
adhesion O +
. O +

We O +
investigated O +
the O +
mechanisms O +
by O +
which O +
proinflammatory O +
mediator O +
, O +
thrombin O +
, O +
released O +
during O +
intravascular O +
coagulation O +
and O +
tissue O +
injury O +
, O +
induces O +
ICAM-1 O +
( O +
CD54 O +
) O +
expression O +
in O +
endothelial O +
cells O +
. O +

Stimulation O +
of O +
HUVEC B-CellLine +
with O +
thrombin O +
resulted O +
in O +
dose- O +
and O +
time O -
- O -
dependent O +
increases O +
in O +
ICAM-1 O +
mRNA O +
and O +
cell O +
surface O +
expression O +
and O +
in O +
ICAM-1 O +
-dependent O +
endothelial O +
adhesivity O +
toward O +
polymorphonuclear O +
leukocytes O +
. O +

Transient O +
transfection O +
of O +
endothelial O +
cells O +
with O +
ICAM-1 O +
promoter O +
luciferase O +
reporter O +
gene O +
( O +
ICAM-1LUC O +
) O +
constructs O +
indicated O +
that O +
deletion O +
of O +
upstream O +
NF O -
- O -
kappa O +
B O +
site O +
( O +
-533 O +
bases O +
from O +
translation O +
start O +
site O +
) O +
had O +
no O +
effect O +
on O +
thrombin O +
responsiveness O +
, O +
whereas O +
mutation O -
/ O -
deletion O +
of O +
downstream O +
NF O -
- O -
kappa O +
B O +
site O +
( O +
-223 O +
bases O +
from O +
the O +
translation O +
start O +
site O +
) O +
prevented O +
the O +
activation O +
of O +
ICAM-1 O +
promoter O +
, O +
indicating O +
that O +
the O +
downstream O +
NF O -
- O -
kappa O +
B O +
site O +
is O +
critical O +
for O +
thrombin O +
inducibility O +
. O +

NF O -
- O -
kappa O +
B O +
-directed O +
luciferase O +
activity O +
increased O +
approximately O +
3-fold O +
when O +
cells O +
transfected O +
with O +
the O +
plasmid O +
pNF O -
- O -
kappa O +
BLUC O +
containing O +
five O +
copies O +
of O +
consensus O +
NF O -
- O -
kappa O +
B O +
site O +
linked O +
to O +
a O +
minimal O +
adenovirus O +
E1B O +
promoter O -
- O -
luciferase O +
gene O +
were O +
exposed O +
to O +
thrombin O +
, O +
indicating O +
that O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
was O +
essential O +
for O +
thrombin O +
response O +
. O +

Gel O +
supershift O +
assays O +
demonstrated O +
that O +
thrombin O +
induced O +
binding O +
of O +
NF O -
- O -
kappa O +
Bp65 O +
( O +
Rel O +
A O +
) O +
to O +
downstream O +
NF O -
- O -
kappa O +
B O +
site O +
of O +
the O +
ICAM-1 O +
promoter O +
. O +

Thrombin O +
receptor O +
activation O +
peptide O +
, O +
a O +
14-amino O -
- O -
acid O +
peptide O +
representing O +
the O +
new O +
NH2 O +
terminus O +
of O +
proteolytically O +
activated O +
receptor-1 O +
, O +
mimicked O +
thrombin O +
's O +
action O +
in O +
inducing O +
ICAM-1 O +
expression O +
. O +

These O +
data O +
indicate O +
that O +
thrombin O +
activates O +
endothelial O +
ICAM-1 O +
expression O +
and O +
polymorphonuclear O +
leukocyte O +
adhesion O +
by O +
NF O -
- O -
kappa O +
Bp65 O +
binding O +
to O +
the O +
downstream O +
NF O -
- O -
kappa O +
B O +
site O +
of O +
ICAM-1 O +
promoter O +
after O +
proteolytically O +
activated O +
receptor-1 O +
activation O +
. O +

Increased O +
glucocorticoid O +
receptor O +
beta O +
in O +
airway O +
cells O +
of O +
glucocorticoid O -
- O -
insensitive O +
asthma O +
. O +

Glucocorticoid O +
( O +
GC O +
) O +
-insensitive O +
asthma O +
is O +
a O +
challenging O +
clinical O +
problem O +
that O +
can O +
be O +
associated O +
with O +
life O -
- O -
threatening O +
disease O +
progression O +
. O +

The O +
molecular O +
basis O +
of O +
GC O +
insensitivity O +
is O +
unknown O +
. O +

Alternative O +
splicing O +
of O +
the O +
GC O +
receptor O +
( O +
GCR O +
) O +
pre O -
- O -
mRNA O +
generates O +
a O +
second O +
GCR O +
, O +
termed O +
GCRbeta O +
, O +
which O +
does O +
not O +
bind O +
GC O +
but O +
antagonizes O +
the O +
transactivating O +
activity O +
of O +
the O +
classic O +
GCR O +
. O +

Thus O +
increased O +
expression O +
of O +
GCRbeta O +
could O +
account O +
for O +
glucocorticoid O +
insensitivity O +
. O +

Bronchoalveolar O +
lavage O +
( O +
BAL O +
) O +
cells O +
and O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
were O +
examined O +
for O +
GCRbeta O +
immunoreactivity O +
using O +
a O +
GCRbeta O -
- O -
specific O +
antibody O +
by O +
immunohistochemical O +
staining O +
. O +

Cell O +
localization O +
of O +
GCRbeta O +
expression O +
was O +
performed O +
using O +
a O +
double O +
immunostaining O +
technique O +
. O +

Patients O +
with O +
GC O -
- O -
insensitive O +
asthma O +
expressed O +
a O +
significantly O +
higher O +
number O +
of O +
GCRbeta O -
- O -
immunoreactive O +
cells O +
in O +
their O +
BAL O +
and O +
peripheral O +
blood O +
than O +
GC O -
- O -
sensitive O +
asthmatics O +
or O +
normal O +
control O +
subjects O +
. O +

Furthermore O +
, O +
GCRbeta O +
expression O +
in O +
GC O -
- O -
insensitive O +
asthma O +
was O +
particularly O +
high O +
in O +
airway O +
T O +
cells O +
, O +
which O +
are O +
thought O +
to O +
play O +
a O +
major O +
role O +
in O +
the O +
pathogenesis O +
of O +
asthma O +
. O +

We O +
also O +
examined O +
the O +
expression O +
of O +
GCRbeta O +
in O +
specimens O +
from O +
the O +
airways O +
of O +
patients O +
with O +
chronic O +
bronchitis O +
. O +

In O +
chronic O +
bronchitis O +
, O +
few O +
cells O +
were O +
GCRbeta O -
- O -
positive O +
and O +
their O +
numbers O +
did O +
not O +
differ O +
significantly O +
from O +
normal O +
control O +
subjects O +
. O +

We O +
conclude O +
that O +
GC O -
- O -
insensitive O +
asthma O +
is O +
associated O +
with O +
increased O +
expression O +
of O +
GCRbeta O +
in O +
airway O +
T O +
cells O +
. O +

Resistance O +
to O +
tumor O +
necrosis O +
factor O +
induced O +
apoptosis O +
in O +
vitro O +
correlates O +
with O +
high O +
metastatic O +
capacity O +
of O +
cells O +
in O +
vivo O +
. O +

TNF O +
is O +
one O +
of O +
the O +
cytokines O +
secreted O +
by O +
the O +
cells O +
of O +
the O +
immune O +
system O +
. O +

Our O +
data O +
demonstrate O +
that O +
those O +
cell B-CellLine +
lines I-CellLine +
lacking O +
capability O +
to O +
form O +
metastatic O +
tumors O +
in O +
vivo O +
are O +
susceptible O +
to O +
TNF O +
induced O +
apoptosis O +
in O +
vitro O +
. O +

However O +
, O +
cell B-CellLine +
lines I-CellLine +
with O +
high O +
metastatic O +
potential O +
are O +
resistant O +
to O +
TNF O +
in O +
vitro O +
. O +

Furthermore O +
, O +
the O +
same O +
cell B-CellLine +
lines I-CellLine +
were O +
resistant O +
to O +
cytolytic O +
action O +
of O +
other O +
cytotoxic O +
proteins O +
secreted O +
by O +
LAK B-CellLine +
cells I-CellLine +
. O +

Our O +
data O +
showed O +
that O +
TNF O +
resistance O +
in O +
vitro O +
correlates O +
with O +
the O +
increased O +
level O +
of O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
. O +

This O +
finding O +
may O +
provide O +
a O +
tool O +
to O +
improve O +
current O +
protocols O +
of O +
immunotherapy O +
and O +
insights O +
to O +
how O +
tumor O +
cells O +
are O +
or O +
are O +
not O +
killed O +
by O +
LAK B-CellLine +
cells I-CellLine +
. O +

CTLA-4 O +
-Mediated O +
inhibition O +
of O +
early O +
events O +
of O +
T O +
cell O +
proliferation O +
. O +

CTLA-4 O +
engagement O +
by O +
mAbs O +
inhibits O +
, O +
while O +
CD28 O +
enhances O +
, O +
IL-2 O +
production O +
and O +
proliferation O +
upon O +
T O +
cell O +
activation O +
. O +

Here O +
, O +
we O +
have O +
analyzed O +
the O +
mechanisms O +
involved O +
in O +
CTLA-4 O +
-mediated O +
inhibition O +
of O +
T O +
cell O +
activation O +
of O +
naive O +
CD4 O -
+ O +
T O +
cells O +
using O +
Ab O +
cross O -
- O -
linking O +
. O +

CTLA-4 O +
ligation O +
inhibited O +
CD3 O -
/ O +
CD28 O +
-induced O +
IL-2 O +
mRNA O +
accumulation O +
by O +
inhibiting O +
IL-2 O +
transcription O +
, O +
which O +
appears O +
to O +
be O +
mediated O +
in O +
part O +
through O +
decreasing O +
NF O -
- O -
AT O +
accumulation O +
in O +
the O +
nuclei O +
. O +

However O +
, O +
CTLA-4 O +
ligation O +
did O +
not O +
appear O +
to O +
affect O +
the O +
CD28 O +
-mediated O +
stabilization O +
of O +
IL-2 O +
mRNA O +
. O +

Further O +
, O +
CTLA-4 O +
engagement O +
inhibited O +
progression O +
through O +
the O +
cell O +
cycle O +
by O +
inhibiting O +
the O +
production O +
of O +
cyclin O +
D3 O +
, O +
cyclin O -
- O -
dependent O +
kinase O +
( O +
cdk O +
) O +
4 O +
, O +
and O +
cdk6 O +
when O +
the O +
T O +
cells O +
were O +
stimulated O +
with O +
anti O -
- O -
CD3 O -
/ O -
CD28 O +
and O +
with O +
anti O -
- O -
CD3 O +
alone O +
. O +

These O +
results O +
indicate O +
that O +
CTLA-4 O +
signaling O +
inhibits O +
events O +
early O +
in O +
T O +
cell O +
activation O +
both O +
at O +
IL-2 O +
transcription O +
and O +
at O +
the O +
level O +
of O +
IL-2 O +
-independent O +
events O +
of O +
the O +
cell O +
cycle O +
, O +
and O +
does O +
not O +
simply O +
oppose O +
CD28 O +
-mediated O +
costimulation O +
. O +

Fibroblast O +
growth O +
factor-1 O +
( O +
FGF-1 O +
) O +
enhances O +
IL-2 O +
production O +
and O +
nuclear O +
translocation O +
of O +
NF O -
- O -
kappaB O +
in O +
FGF B-CellLine +
receptor I-CellLine -
- I-CellLine -
bearing I-CellLine +
Jurkat I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Fibroblast O +
growth O +
factors O +
( O +
FGFs O +
) O +
are O +
heparin O -
- O -
binding O +
proteins O +
crucial O +
to O +
embryogenesis O +
, O +
angiogenesis O +
, O +
and O +
wound O +
healing O +
. O +

FGF-1 O +
is O +
abundantly O +
expressed O +
in O +
the O +
synovium O +
in O +
rheumatoid O +
arthritis O +
and O +
in O +
rejecting O +
allografts O +
, O +
sites O +
of O +
chronic O +
immune O -
- O -
mediated O +
inflammation O +
. O +

The O +
frequency O +
of O +
FGF-1 O +
-responsive O +
T O +
cells O +
is O +
increased O +
in O +
the O +
peripheral O +
blood O +
of O +
these O +
disorders O +
, O +
and O +
a O +
high O +
percentage O +
of O +
infiltrating O +
T O +
cells O +
in O +
rheumatoid O +
arthritis O +
synovium O +
express O +
receptors O +
for O +
FGF-1 O +
. O +

To O +
understand O +
the O +
action O +
of O +
FGF-1 O +
in O +
T O +
cells O +
, O +
studies O +
were O +
initiated O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
that O +
express O +
the O +
signaling O +
isoform O +
of O +
FGF O +
receptor-1 O +
. O +

These O +
experiments O +
show O +
that O +
FGF-1 O +
stimulation O +
of O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
provides O +
a O +
second O +
signal O +
that O +
augments O +
TCR O -
- O -
mediated O +
IL-2 O +
production O +
. O +

Analogous O +
to O +
costimulation O +
via O +
CD28 O +
, O +
this O +
activity O +
is O +
mediated O +
through O +
activation O +
of O +
Rel O -
/ O -
kappaB O +
, O +
a O +
family O +
of O +
transcription O +
factors O +
known O +
to O +
regulate O +
IL-2 O +
and O +
other O +
activation O -
- O -
inducible O +
proteins O +
. O +

FGF-1 O +
alone O +
induces O +
modest O +
nuclear O +
translocation O +
of O +
kappaB O -
- O -
binding O +
proteins O +
, O +
and O +
this O +
translocation O +
is O +
enhanced O +
by O +
the O +
combination O +
of O +
anti O -
- O -
CD3 O +
and O +
FGF-1 O +
. O +

This O +
NF O -
- O -
kappaB O +
binding O +
complex O +
is O +
composed O +
of O +
transcriptionally O +
active O +
p65 O +
( O +
RelA O +
) O +
/p50 O +
heterodimers O +
and O +
results O +
primarily O +
from O +
the O +
targeted O +
degradation O +
of O +
IkappaB O -
- O -
alpha O +
, O +
an O +
inhibitor O +
that O +
sequesters O +
Rel O -
/ O -
kappaB O +
in O +
the O +
cytoplasm O +
. O +

These O +
data O +
are O +
the O +
first O +
to O +
show O +
a O +
connection O +
between O +
FGF-1 O +
signaling O +
and O +
NF O -
- O -
kappaB O +
activation O +
outside O +
of O +
embryonic O +
development O +
. O +

The O +
signaling O +
events O +
that O +
link O +
FGF O +
receptor-1 O +
engagement O +
and O +
NF O -
- O -
kappaB O +
activation O +
in O +
Jurkat B-CellLine +
are O +
probably O +
distinct O +
from O +
the O +
CD28 O +
costimulation O +
pathway O +
, O +
since O +
FGF-1 O +
-induced O +
Rel O -
/ O -
kappaB O +
binding O +
proteins O +
do O +
not O +
contain O +
significant O +
levels O +
of O +
c O -
- O -
Rel O +
and O +
are O +
not O +
identical O +
with O +
the O +
CD28 O +
response O +
complex O +
. O +

USF O -
/ O -
c O -
- O -
Myc O +
enhances O +
, O +
while O +
Yin O -
- O -
Yang O +
1 O +
suppresses O +
, O +
the O +
promoter O +
activity O +
of O +
CXCR4 O +
, O +
a O +
coreceptor O +
for O +
HIV-1 O +
entry O +
. O +

Transcription O +
factors O +
USF1 O +
and O +
USF2 O +
up O -
- O -
regulate O +
gene O +
expression O +
( O +
i.e. O +
, O +
HIV-1 O +
long O +
terminal O +
repeats O +
) O +
via O +
interaction O +
with O +
an O +
E O +
box O +
on O +
their O +
target O +
promoters O +
, O +
which O +
is O +
also O +
a O +
binding O +
site O +
for O +
c O -
- O -
Myc O +
. O +

The O +
c O -
- O -
Myc O +
oncoprotein O +
is O +
important O +
in O +
control O +
of O +
cellular O +
proliferation O +
and O +
differentiation O +
, O +
while O +
Yin O -
- O -
Yang O +
1 O +
( O +
YY1 O +
) O +
has O +
been O +
shown O +
to O +
control O +
the O +
expression O +
of O +
a O +
number O +
of O +
cellular O +
and O +
viral O +
genes O +
. O +

These O +
two O +
proteins O +
physically O +
interact O +
with O +
each O +
other O +
and O +
mutually O +
inhibit O +
their O +
respective O +
biological O +
functions O +
. O +

In O +
this O +
study O +
, O +
we O +
show O +
that O +
USF O -
/ O -
c O -
- O -
Myc O +
up O -
- O -
regulates O +
, O +
while O +
YY1 O +
down O -
- O -
regulates O +
the O +
promoter O +
activity O +
of O +
CXCR4 O +
, O +
a O +
coreceptor O +
for O +
T O +
cell O -
- O -
tropic O +
HIV-1 O +
entry O +
. O +

We O +
have O +
identified O +
an O +
E O +
box O +
around O +
-260 O +
and O +
a O +
YY1 O +
binding O +
site O +
around O +
-300 O +
relative O +
to O +
the O +
transcription O +
start O +
site O +
. O +

Mutation O +
of O +
the O +
E O +
box O +
abolished O +
USF O -
/ O -
c O -
- O -
Myc O +
-mediated O +
up O -
- O -
regulation O +
of O +
CXCR4 O +
promoter O +
activity O +
, O +
and O +
mutation O +
of O +
the O +
YY1 O +
binding O +
site O +
was O +
associated O +
with O +
unresponsiveness O +
to O +
YY1 O +
-mediated O +
inhibition O +
. O +

These O +
data O +
suggest O +
that O +
USF O -
/ O -
c O -
- O -
Myc O +
and O +
YY1 O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
HIV-1-replicative O +
cycle O +
, O +
by O +
modulating O +
both O +
the O +
viral O +
fusion O -
/ O -
entry O +
process O +
and O +
viral O +
expression O +
. O +

Signaling O +
through O +
the O +
lymphotoxin O -
- O -
beta O +
receptor O +
stimulates O +
HIV-1 O +
replication O +
alone O +
and O +
in O +
cooperation O +
with O +
soluble O +
or O +
membrane O -
- O -
bound O +
TNF O -
- O -
alpha O +
. O +

The O +
level O +
of O +
ongoing O +
HIV-1 O +
replication O +
within O +
an O +
individual O +
is O +
critical O +
to O +
HIV-1 O +
pathogenesis O +
. O +

Among O +
host O +
immune O +
factors O +
, O +
the O +
cytokine O +
TNF O -
- O -
alpha O +
has O +
previously O +
been O +
shown O +
to O +
increase O +
HIV-1 O +
replication O +
in O +
various O +
monocyte O +
and O +
T O +
cell O +
model O +
systems O +
. O +

Here O +
, O +
we O +
demonstrate O +
that O +
signaling O +
through O +
the O +
TNF O +
receptor O +
family O +
member O +
, O +
the O +
lymphotoxin O -
- O -
beta O +
( O +
LT O -
- O -
beta O +
) O +
receptor O +
( O +
LT O -
- O -
betaR O +
) O +
, O +
also O +
regulates O +
HIV-1 O +
replication O +
. O +

Furthermore O +
, O +
HIV-1 O +
replication O +
is O +
cooperatively O +
stimulated O +
when O +
the O +
distinct O +
LT O -
- O -
betaR O +
and O +
TNF O +
receptor O +
systems O +
are O +
simultaneously O +
engaged O +
by O +
their O +
specific O +
ligands O +
. O +

Moreover O +
, O +
in O +
a O +
physiological O +
coculture O +
cellular O +
assay O +
system O +
, O +
we O +
show O +
that O +
membrane O -
- O -
bound O +
TNF O -
- O -
alpha O +
and O +
LT O -
- O -
alpha1beta2 O +
act O +
virtually O +
identically O +
to O +
their O +
soluble O +
forms O +
in O +
the O +
regulation O +
of O +
HIV-1 O +
replication O +
. O +

Thus O +
, O +
cosignaling O +
via O +
the O +
LT O -
- O -
beta O +
and O +
TNF O -
- O -
alpha O +
receptors O +
is O +
probably O +
involved O +
in O +
the O +
modulation O +
of O +
HIV-1 O +
replication O +
and O +
the O +
subsequent O +
determination O +
of O +
HIV-1 O +
viral O +
burden O +
in O +
monocytes O +
. O +

Intriguingly O +
, O +
surface O +
expression O +
of O +
LT O -
- O -
alpha1beta2 O +
is O +
up O -
- O -
regulated O +
on O +
a O +
T B-CellLine +
cell I-CellLine +
line I-CellLine +
acutely O +
infected O +
with O +
HIV-1 O +
, O +
suggesting O +
a O +
positive O +
feedback O +
loop O +
between O +
HIV-1 O +
infection O +
, O +
LT O -
- O -
alpha1beta2 O +
expression O +
, O +
and O +
HIV-1 O +
replication O +
. O +

Given O +
the O +
critical O +
role O +
that O +
LT O -
- O -
alpha1beta2 O +
plays O +
in O +
lymphoid O +
architecture O +
, O +
we O +
speculate O +
that O +
LT O -
- O -
alpha1beta2 O +
may O +
be O +
involved O +
in O +
HIV O -
- O -
associated O +
abnormalities O +
of O +
the O +
lymphoid O +
organs O +
. O +

Glucocorticoid O +
receptors O +
are O +
down O -
- O -
regulated O +
in O +
inflamed O +
colonic O +
mucosa O +
but O +
not O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
from O +
patients O +
with O +
inflammatory O +
bowel O +
disease O +
[ O +
see O +
comments O +
] O +

BACKGROUND O +
: O +
Growing O +
evidence O +
indicates O +
that O +
the O +
immune O +
system O +
and O +
the O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenal O +
system O +
are O +
linked O +
by O +
several O +
mechanisms O +
, O +
for O +
example O +
intracellular O +
glucocorticoid O +
receptors O +
( O +
hGR O +
) O +
. O +

Glucocorticoids O +
are O +
the O +
standard O +
treatment O +
of O +
acute O +
attacks O +
of O +
inflammatory O +
bowel O +
disease O +
( O +
IBD O +
) O +
. O +

Binding O +
of O +
glucocorticoids O +
to O +
hGR O +
down O -
- O -
regulates O +
the O +
transcription O +
of O +
inflammatory O +
genes O +
that O +
can O +
propagate O +
IBD O +
. O +

PATIENTS O +
AND O +
METHODS O +
: O +
IBD O +
patients O +
were O +
either O +
treated O +
with O +
5 O -
- O -
60 O +
mg O +
of O +
prednisolone O +
for O +
more O +
than O +
1 O +
week O +
or O +
were O +
without O +
glucocorticoid O +
treatment O +
for O +
more O +
than O +
4 O +
weeks O +
. O +

hGR O +
levels O +
were O +
determined O +
from O +
isolated O +
cytosol O +
of O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMCs O +
) O +
or O +
mucosal O +
biopsies O +
using O +
a O +
radioassay O +
with O +
[ O +
3H O +
] O +
-dexamethasone O +
. O +

Interleukin O +
( O +
IL O +
) O +
6 O +
levels O +
were O +
determined O +
by O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
( O +
ELISA O +
) O +
. O +

RESULTS O +
: O +
The O +
systemic O +
( O +
PBMC O +
) O +
hGR O +
levels O +
of O +
corticosteroid O -
- O -
treated O +
IBD O +
patients O +
were O +
significantly O +
lower O +
than O +
those O +
of O +
control O +
subjects O +
( O +
59.6 O +
+ O -
/- O +
57.1 O +
dpm O +
mg-1 O +
cytosol O +
protein O +
vs O +
. O +

227.0 O +
+ O -
/- O +
90.8 O +
dpm O +
mg-1 O +
cytosol O +
protein O +
, O +
P O +
= O +
0.007 O +
) O +
and O +
IBD O +
patients O +
not O +
receiving O +
glucocorticoid O +
treatment O +
( O +
179.7 O +
+ O -
/- O +
171.3 O +
dpm O +
mg-1 O +
cytosol O +
protein O +
, O +
P O +
= O +
0.002 O +
) O +
. O +

Systemic O +
hGR O +
levels O +
in O +
untreated O +
IBD O +
patients O +
did O +
not O +
differ O +
significantly O +
from O +
those O +
in O +
control O +
subjects O +
. O +

In O +
patients O +
with O +
connective O +
tissue O +
diseases O +
, O +
systemic O +
hGR O +
levels O +
were O +
also O +
found O +
to O +
be O +
decreased O +
in O +
the O +
absence O +
of O +
glucocorticoid O +
treatment O +
. O +

Systemic O +
hGR O +
levels O +
in O +
patients O +
with O +
Crohn O +
's O +
disease O +
( O +
CD O +
) O +
treated O +
with O +
steroids O +
( O +
66.6 O +
+ O -
/- O +
61.0 O +
dpm O +
mg-1 O +
cytosol O +
protein O +
) O +
were O +
not O +
different O +
from O +
those O +
in O +
patients O +
with O +
ulcerative O +
colitis O +
( O +
UC O +
) O +
( O +
56.1 O +
+ O -
/- O +
51.6 O +
dpm O +
mg-1 O +
cytosol O +
protein O +
) O +
. O +

In O +
contrast O +
to O +
these O +
findings O +
, O +
mucosal O +
hGR O +
levels O +
were O +
significantly O +
decreased O +
in O +
both O +
steroid O -
- O -
treated O +
( O +
18.0 O +
+ O -
/- O +
15.5 O +
) O +
and O +
not O +
steroid O -
- O -
treated O +
( O +
37.8 O +
+ O -
/- O +
30.5 O +
) O +
patients O +
compared O +
with O +
control O +
subjects O +
( O +
125.6 O +
+ O -
/- O +
97.1 O +
; O +
P O +
= O +
0.00009 O +
and O +
P O +
= O +
0.0008 O +
respectively O +
) O +
. O +

IL-6 O +
levels O +
in O +
all O +
IBD O +
groups O +
with O +
and O +
without O +
steroids O +
were O +
significantly O +
different O +
from O +
those O +
in O +
control O +
subjects O +
. O +

CONCLUSION O +
: O +
In O +
IBD O +
there O +
is O +
no O +
difference O +
in O +
systemic O +
hGR O +
levels O +
between O +
not O +
steroid O -
- O -
treated O +
patients O +
and O +
control O +
subjects O +
, O +
in O +
spite O +
of O +
inflammatory O +
activity O +
( O +
IL-6 O +
) O +
. O +

Mucosal O +
hGR O +
levels O +
were O +
decreased O +
independently O +
of O +
treatment O +
, O +
probably O +
leading O +
to O +
a O +
decreased O +
protection O +
against O +
NF O -
- O -
kappaB O +
action O +
in O +
the O +
intestinal O +
mucosa O +
. O +

The O +
oestrogen O +
receptor O +
codon O +
10 O +
polymorphism O +
detected O +
in O +
breast O +
cancer O +
is O +
also O +
present O +
in O +
non O -
- O -
malignant O +
cells O +
. O +

The O +
effect O +
of O +
oestrogens O +
on O +
oestrogen O -
- O -
receptive O +
organs O +
and O +
cells O +
is O +
mediated O +
via O +
intracellular O +
receptors O +
( O +
ERalpha O +
and O +
ERbeta O +
) O +
. O +

Oestrogen O +
receptor O +
gene O +
polymorphisms O +
in O +
the O +
region O +
encoding O +
the O +
N O -
- O -
terminal O +
portion O +
of O +
the O +
protein O +
are O +
reportedly O +
associated O +
with O +
pathological O +
conditions O +
including O +
breast O +
cancer O +
, O +
hypertension O +
, O +
spontaneous O +
abortion O +
and O +
coronary O +
heart O +
disease O +
. O +

A O +
silent O +
mutation O +
in O +
codon O +
10 O +
of O +
exon O +
1 O +
, O +
detected O +
in O +
ER B-CellLine -
- I-CellLine -
negative I-CellLine +
and I-CellLine +
ER I-CellLine -
- I-CellLine -
positive I-CellLine +
human I-CellLine +
breast I-CellLine +
cancer I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
in O +
breast O +
tumors O +
and O +
blood O +
DNA O +
from O +
breast O +
cancer O +
patients O +
, O +
has O +
been O +
recognized O +
as O +
a O +
polymorphic O +
site O +
. O +

In O +
this O +
study O +
we O +
examined O +
, O +
by O +
denaturing O +
gradient O -
- O -
gel O +
electrophoresis O +
and O +
DNA O +
sequence O +
analysis O +
, O +
the O +
possible O +
presence O +
of O +
a O +
codon O +
10 O +
polymorphic O +
site O +
in O +
normal O +
oestrogen O +
target O +
organs O +
and O +
cells O +
such O +
as O +
the O +
uterus O +
( O +
myometrium O +
and O +
endometrium O +
) O +
, O +
in O +
the O +
placenta O +
and O +
peripheral O +
blood O +
mononuclear O +
cells O +
and O +
in O +
a O +
benign O +
uterus O +
tumour O +
( O +
leiomyoma O +
) O +
. O +

We O +
have O +
detected O +
ER O +
codon O +
10 O +
polymorphism O +
in O +
these O +
samples O +
and O +
have O +
compared O +
them O +
to O +
those O +
observed O +
in O +
breast O +
cancer O +
samples O +
. O +

All O +
tissues O +
and O +
cells O +
studied O +
were O +
homozygous O +
for O +
the O +
wild O -
- O -
type O +
gene O +
, O +
and O +
were O +
heterozygous O +
as O +
well O +
as O +
homozygous O +
for O +
the O +
codon-10-variant O +
type O +
. O +

These O +
results O +
indicate O +
that O +
the O +
presence O +
of O +
the O +
codon-10-variant O +
type O +
is O +
not O +
a O +
characteristic O +
of O +
breast O +
cancer O +
. O +

Out O +
current O +
findings O +
suggest O +
that O +
further O +
investigations O +
are O +
warranted O +
to O +
elucidate O +
the O +
possible O +
linkage O +
of O +
ER O +
codon O +
10 O +
polymorphism O +
to O +
physiological O +
and O +
pathological O +
conditions O +
. O +

HIV-1 O +
reactivation O +
in O +
resting O +
peripheral O +
blood O +
mononuclear O +
cells O +
of O +
infected O +
adults O +
upon O +
in O +
vitro O +
CD4 O +
cross O -
- O -
linking O +
by O +
ligands O +
of O +
the O +
CDR2-loop O +
in O +
extracellular O +
domain O +
1 O +
. O +

HIV-1 O +
infects O +
resting O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMCs O +
) O +
but O +
remains O +
inactive O +
state O +
until O +
subsequent O +
cell O +
activation O +
. O +

We O +
have O +
demonstrated O +
that O +
the O +
cross O -
- O -
linking O +
of O +
cell O +
surface O +
CD4 O +
by O +
gp120-anti O -
- O -
gp120 O +
immune O +
complexes O +
or O +
heat O -
- O -
inactivated O +
HIV-1 O +
( O +
iHIV-1 O +
) O +
is O +
sufficient O +
to O +
trigger O +
activation O +
signals O +
leading O +
to O +
virus O +
reactivation O +
( O +
9 O +
) O +
. O +

In O +
this O +
study O +
, O +
we O +
demonstrate O +
that O +
NF O -
- O -
kappaB O +
nuclear O +
translocation O +
and O +
stimulation O +
of O +
virus O +
production O +
by O +
iHIV-1 O +
were O +
strictly O +
linked O +
to O +
the O +
concentrations O +
of O +
viral O +
proteins O +
used O +
as O +
exogenous O +
stimuli O +
. O +

Moreover O +
, O +
we O +
further O +
investigated O +
the O +
physiologic O +
relevance O +
of O +
these O +
observations O +
. O +

When O +
submitted O +
to O +
an O +
in O +
vitro O +
CD4 O +
cross O -
- O -
linking O +
by O +
iHIV-1 O +
, O +
PBMCs O +
from O +
HIV-1-infected O +
patients O +
were O +
found O +
to O +
produce O +
virus O +
. O +

This O +
viral O +
reactivation O +
was O +
associated O +
with O +
increased O +
NF O -
- O -
kappaB O +
nuclear O +
translocation O +
in O +
patients O +
' O +
PBMCs O +
. O +

Additionally O +
, O +
virus O +
reactivation O +
in O +
resting O +
PBMCs O +
infected O +
in O +
vitro O +
with O +
HIV-1 O +
was O +
found O +
to O +
be O +
specifically O +
induced O +
by O +
ligands O +
of O +
the O +
CDR2-loop O +
in O +
domain O +
1 O +
( O +
D1 O +
) O +
of O +
CD4 O +
( O +
virus O +
envelope O +
and O +
anti O -
- O -
CD4 O +
monoclonal O +
antibodies O +
) O +
. O +

In O +
contrast O +
, O +
virus O +
reactivation O +
was O +
not O +
observed O +
following O +
CD4 O +
oligomerization O +
by O +
antibodies O +
that O +
bind O +
other O +
epitopes O +
in O +
D1 O +
, O +
including O +
the O +
D1 O -
/ O -
CDR3-loop O +
. O +

Finally O +
, O +
soluble O +
CD4 O +
( O +
sCD4 O +
) O +
prevented O +
virus O +
reactivation O +
by O +
D1 O -
/ O -
CDR2-loop O +
ligands O +
. O +

Our O +
results O +
indicate O +
that O +
the O +
signaling O +
events O +
initiated O +
in O +
PBMCs O +
by O +
oligomerization O +
of O +
CD4 O +
at O +
the O +
D1 O -
/ O -
CDR2-loop O +
can O +
trigger O +
HIV-1 O +
upregulation O +
in O +
infected O +
individuals O +
. O +

NF O -
- O -
kappaB O +
activation O +
is O +
required O +
for O +
C5a O -
- O -
induced O +
interleukin-8 O +
gene O +
expression O +
in O +
mononuclear O +
cells O +
. O +

C5a O +
, O +
a O +
potent O +
peptide O +
chemoattractant O +
, O +
stimulates O +
interleukin-8 O +
( O +
IL-8 O +
) O +
secretion O +
from O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
. O +

Experiments O +
were O +
conducted O +
to O +
understand O +
the O +
mechanisms O +
for O +
C5a O -
- O -
induced O +
IL-8 O +
production O +
, O +
which O +
was O +
14-fold O +
greater O +
than O +
that O +
in O +
unstimulated O +
cells O +
by O +
2 O +
hours O +
. O +

IL-8 O +
secretion O +
was O +
accompanied O +
by O +
accumulation O +
of O +
IL-8 O +
mRNA O +
in O +
the O +
cytosol O +
and O +
by O +
nuclear O +
expression O +
of O +
a O +
kappaB O +
DNA O +
binding O +
activity O +
within O +
30 O +
minutes O +
. O +

AP-1 O +
but O +
not O +
NF O -
- O -
IL-6 O +
DNA O +
binding O +
activity O +
was O +
also O +
detected O +
in O +
C5a B-CellLine -
- I-CellLine -
stimulated I-CellLine +
PBMC I-CellLine +
; O +
however O +
, O +
its O +
delayed O +
expression O +
( O +
maximal O +
at O +
4 O +
hours O +
) O +
suggested O +
a O +
less O +
important O +
role O +
in O +
the O +
rapid O +
production O +
of O +
IL-8 O +
. O +

The O +
correlation O +
between O +
C5a O -
- O -
induced O +
kappaB O +
binding O +
activity O +
and O +
IL-8 O +
gene O +
expression O +
was O +
examined O +
in O +
the O +
RAW264.7 B-CellLine +
macrophage I-CellLine +
cells I-CellLine +
using O +
reporter O +
genes O +
directed O +
by O +
the O +
kappaB O +
sequence O +
from O +
IkappaBalpha O +
and O +
IL-8 O +
promoter O +
regions O +
. O +

C5a O -
- O -
induced O +
reporter O +
gene O +
expression O +
was O +
abolished O +
by O +
introducing O +
mutations O +
into O +
the O +
kappaB O +
sites O +
and O +
by O +
coexpression O +
of O +
a O +
dominant O +
negative O +
IkappaBalpha O +
construct O +
resistant O +
to O +
agonist O -
- O -
induced O +
phosphorylation O +
. O +

Pertussis O +
toxin O +
, O +
which O +
ADP O -
- O -
ribosylates O +
the O +
Gi O +
proteins O +
known O +
to O +
couple O +
to O +
the O +
C5a O +
receptor O +
, O +
produced O +
minimal O +
inhibition O +
of O +
C5a O -
- O -
induced O +
IL-8 O +
expression O +
and O +
had O +
little O +
effect O +
on O +
C5a O -
- O -
induced O +
calcium O +
mobilization O +
in O +
RAW264.7 B-CellLine +
cells I-CellLine +
. O +

These O +
results O +
suggest O +
that O +
NF O -
- O -
kappaB O +
activation O +
is O +
required O +
for O +
C5a O -
- O -
induced O +
IL-8 O +
gene O +
expression O +
and O +
that O +
this O +
response O +
is O +
mediated O +
primarily O +
through O +
a O +
pertussis O +
toxin O -
- O -
insensitive O +
pathway O +
. O +

Control O +
of O +
cell O +
cycle O +
entry O +
and O +
apoptosis O +
in O +
B O +
lymphocytes O +
infected O +
by O +
Epstein O -
- O -
Barr O +
virus O +
. O +

Infection O +
of O +
human O +
B O +
cells O +
with O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
results O +
in O +
activation O +
of O +
the O +
cell O +
cycle O +
and O +
cell O +
growth O +
. O +

To O +
interpret O +
the O +
mechanisms O +
by O +
which O +
EBV O +
activates O +
the O +
cell O +
, O +
we O +
have O +
assayed O +
many O +
proteins O +
involved O +
in O +
control O +
of O +
the O +
G0 O +
and O +
G1 O +
phases O +
of O +
the O +
cell O +
cycle O +
and O +
regulation O +
of O +
apoptosis O +
. O +

In O +
EBV O +
infection O +
most O +
of O +
the O +
changes O +
, O +
including O +
the O +
early O +
induction O +
of O +
cyclin O +
D2 O +
, O +
are O +
dependent O +
on O +
expression O +
of O +
EBV O +
genes O +
, O +
but O +
an O +
alteration O +
in O +
the O +
E2F-4 O +
profile O +
was O +
partly O +
independent O +
of O +
viral O +
gene O +
expression O +
, O +
presumably O +
occurring O +
in O +
response O +
to O +
signal O +
transduction O +
activated O +
when O +
the O +
virus O +
binds O +
to O +
its O +
receptor O +
, O +
CD21 O +
. O +

By O +
comparing O +
the O +
expression O +
of O +
genes O +
controlling O +
apoptosis O +
, O +
including O +
those O +
encoding O +
several O +
members O +
of O +
the O +
BCL-2 O +
family O +
of O +
proteins O +
, O +
the O +
known O +
relative O +
resistance O +
of O +
EBV B-CellLine -
- I-CellLine -
immortalized I-CellLine +
B I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
to O +
apoptosis O +
induced O +
by O +
low O +
serum O +
was O +
found O +
to O +
correlate O +
with O +
expression O +
of O +
both O +
BCL-2 O +
and O +
A20 O +
. O +

A20 O +
can O +
be O +
regulated O +
by O +
the O +
NF O -
- O -
kappaB O +
transcription O +
factor O +
, O +
which O +
is O +
known O +
to O +
be O +
activated O +
by O +
the O +
EBV O +
LMP-1 O +
protein O +
. O +

Quantitative O +
assays O +
demonstrated O +
a O +
direct O +
temporal O +
relationship O +
between O +
LMP-1 O +
protein O +
levels O +
and O +
active O +
NF O -
- O -
kappaB O +
during O +
the O +
time O +
course O +
of O +
infection O +
. O +

Immortalization O +
of O +
CD4 O +
( O +
+ O +
) O +
and O +
CD8 O +
( O +
+ O +
) O +
T O +
lymphocytes O +
by O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
Tax O +
mutants O +
expressed O +
in O +
a O +
functional B-CellLine +
molecular I-CellLine +
clone I-CellLine +
. O +

The O +
human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
( O +
HTLV-1 O +
) O +
transcriptional O +
trans O -
- O -
activator O +
Tax O +
has O +
been O +
demonstrated O +
to O +
have O +
transforming O +
activity O +
in O +
multiple B-CellLine +
cell I-CellLine +
culture I-CellLine +
and O +
transgenic O -
- O -
mouse O +
models O +
. O +

In O +
addition O +
to O +
activating O +
transcription O +
from O +
the O +
viral O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
through O +
the O +
cyclic O +
AMP O +
response O +
element O +
binding O +
protein O -
/ O -
activating O +
transcription O +
factor O +
( O +
CREB O -
/ O -
ATF O +
) O +
family O +
of O +
transcription O +
factors O +
, O +
Tax O +
activates O +
the O +
expression O +
of O +
multiple O +
cellular O +
promoters O +
through O +
the O +
NF O -
- O -
kappaB O +
pathway O +
of O +
transcriptional O +
activation O +
. O +

The O +
Tax O +
mutants O +
M22 O +
and O +
M47 O +
have O +
previously O +
been O +
demonstrated O +
to O +
selectively O +
abrogate O +
the O +
ability O +
of O +
Tax O +
to O +
activate O +
transcription O +
through O +
the O +
NF O -
- O -
kappaB O +
or O +
CREB O -
/ O -
ATF O +
pathway O +
, O +
respectively O +
. O +

These O +
mutations O +
were O +
introduced O +
in O +
the O +
tax O +
gene O +
of O +
the O +
ACH O +
functional O +
molecular O +
clone O +
of O +
HTLV-1 O +
, O +
and O +
virus O +
produced O +
from O +
the O +
mutant O +
ACH O +
clones O +
was O +
examined O +
for O +
the O +
ability O +
to O +
replicate O +
and O +
immortalize O +
primary O +
human O +
lymphocytes O +
. O +

While O +
virus O +
derived O +
from O +
the O +
clone O +
containing O +
the O +
M47 O +
mutation O +
retained O +
the O +
ability O +
to O +
immortalize O +
T O +
lymphocytes O +
, O +
the O +
M22 O +
mutant O +
lost O +
the O +
ability O +
to O +
immortalize O +
infected O +
cells O +
. O +

These O +
results O +
indicate O +
that O +
activation O +
of O +
the O +
CREB O -
/ O -
ATF O +
pathway O +
by O +
Tax O +
is O +
dispensable O +
for O +
the O +
immortalization O +
of O +
T O +
cells O +
by O +
HTLV-1 O +
, O +
whereas O +
activation O +
of O +
the O +
NF O -
- O -
kappaB O +
pathway O +
may O +
be O +
critical O +
. O +

Defining O +
therapeutic O +
targets O +
by O +
using O +
adenovirus O +
: O +
blocking O +
NF O -
- O -
kappaB O +
inhibits O +
both O +
inflammatory O +
and O +
destructive O +
mechanisms O +
in O +
rheumatoid O +
synovium O +
but O +
spares O +
anti O -
- O -
inflammatory O +
mediators O +
. O +

The O +
role O +
of O +
the O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
in O +
the O +
pathogenesis O +
of O +
rheumatoid O +
arthritis O +
has O +
long O +
been O +
a O +
subject O +
of O +
controversy O +
. O +

We O +
used O +
an O +
adenoviral O +
technique O +
of O +
blocking O +
NF O -
- O -
kappaB O +
through O +
overexpression O +
of O +
the O +
inhibitory O +
subunit O +
IkappaBalpha O +
, O +
which O +
has O +
the O +
advantage O +
that O +
it O +
can O +
be O +
used O +
in O +
the O +
diseased O +
tissue O +
itself O +
, O +
with O +
> O +
90 O +
% O +
of O +
the O +
synovial O +
macrophages O +
, O +
fibroblasts O +
, O +
and O +
T O +
cells O +
infected O +
. O +

We O +
found O +
that O +
the O +
spontaneous O +
production O +
of O +
tumor O +
necrosis O +
factor O +
alpha O +
and O +
other O +
pro O -
- O -
inflammatory O +
cytokines O +
is O +
NF O -
- O -
kappaB O +
-dependent O +
in O +
rheumatoid O +
synovial O +
tissue O +
, O +
in O +
contrast O +
to O +
the O +
main O +
anti O -
- O -
inflammatory O +
mediators O +
, O +
like O +
IL-10 O +
and O +
-11 O +
, O +
and O +
the O +
IL-1 O +
receptor O +
antagonist O +
. O +

Of O +
even O +
more O +
interest O +
, O +
IkappaBalpha O +
overexpression O +
inhibited O +
the O +
production O +
of O +
matrix O +
metalloproteinases O +
1 O +
and O +
3 O +
while O +
not O +
affecting O +
their O +
tissue O +
inhibitor O +
. O +

Blocking O +
NF O -
- O -
kappaB O +
in O +
the O +
rheumatoid O +
joint O +
thus O +
has O +
a O +
very O +
beneficial O +
profile O +
, O +
reducing O +
both O +
the O +
inflammatory O +
response O +
and O +
the O +
tissue O +
destruction O +
. O +

The O +
adenoviral O +
technique O +
described O +
here O +
has O +
widespread O +
applicability O +
, O +
allowing O +
rapid O +
testing O +
of O +
the O +
effects O +
of O +
blocking O +
a O +
potential O +
therapeutic O +
target O +
in O +
either O +
cultures O +
of O +
normal O +
cells O +
or O +
in O +
the O +
diseased O +
tissue O +
itself O +
. O +

Nuclear O +
factor-90 O +
of O +
activated O +
T O -
- O -
cells O +
: O +
A O +
double O -
- O -
stranded O +
RNA O +
-binding O +
protein O +
and O +
substrate O +
for O +
the O +
double O -
- O -
stranded O +
RNA O -
- O -
dependent O +
protein O +
kinase O +
, O +
PKR O +
. O +

NFAT O +
transcription O +
factors O +
play O +
a O +
central O +
role O +
in O +
initiating O +
T O -
- O -
cell O +
activation O +
through O +
the O +
induction O +
of O +
immediate O -
- O -
early O +
T O -
- O -
cell O +
specific O +
genes O +
including O +
interleukin-2 O +
( O +
IL-2 O +
) O +
. O +

NFAT O +
transcription O +
factors O +
bind O +
to O +
a O +
sequence O +
in O +
the O +
IL-2 O +
enhancer O +
known O +
as O +
the O +
antigen O +
receptor O +
response O +
element O +
2 O +
( O +
ARRE-2 O +
) O +
. O +

Multiple O +
proteins O +
exhibiting O +
ARRE-2 O +
binding O +
activity O +
have O +
been O +
isolated O +
, O +
including O +
a O +
heterodimer O +
from O +
stimulated O +
T O -
- O -
cell O +
nuclear O +
extracts O +
consisting O +
of O +
Mr O +
= O +
90 O +
000 O +
( O +
NF90 O +
) O +
and O +
Mr O +
= O +
45 O +
000 O +
( O +
NF45 O +
) O +
subunits O +
. O +

The O +
subunits O +
of O +
this O +
heterodimer O +
have O +
been O +
cloned O +
, O +
and O +
NF90 O +
was O +
found O +
to O +
encode O +
a O +
protein O +
containing O +
two O +
domains O +
that O +
are O +
predicted O +
to O +
form O +
motifs O +
capable O +
of O +
binding O +
to O +
double O -
- O -
stranded O +
RNA O +
. O +

Using O +
in O +
vitro O +
translated O +
polypeptides O +
, O +
we O +
have O +
demonstrated O +
that O +
NF90 O +
specifically O +
binds O +
to O +
double O -
- O -
stranded O +
RNA O +
. O +

Furthermore O +
, O +
NF90 O +
was O +
phosphorylated O +
in O +
a O +
double O -
- O -
stranded O +
RNA O +
-dependent O +
manner O +
likely O +
by O +
the O +
interferon O -
- O -
induced O +
, O +
double O -
- O -
stranded O +
RNA O -
- O -
dependent O +
protein O +
kinase O +
, O +
PKR O +
. O +

The O +
NF90 O +
protein O +
was O +
found O +
to O +
be O +
expressed O +
not O +
only O +
in O +
T O -
- O -
cells O +
, O +
but O +
also O +
in O +
nonimmune B-CellLine +
HeLa I-CellLine +
cells I-CellLine +
. O +

In O +
HeLa B-CellLine +
cells I-CellLine +
, O +
the O +
protein O +
was O +
almost O +
exclusively O +
localized O +
to O +
the O +
ribosome O +
salt O +
wash O +
fraction O +
of O +
cell O +
lysates O +
. O +

Cell O +
growth O -
- O -
regulated O +
expression O +
of O +
mammalian O +
MCM5 O +
and O +
MCM6 O +
genes O +
mediated O +
by O +
the O +
transcription O +
factor O +
E2F O +
. O +

Initiation O +
of O +
DNA O +
replication O +
requires O +
the O +
function O +
of O +
MCM O +
gene O +
products O +
, O +
which O +
participate O +
in O +
ensuring O +
that O +
DNA O +
replication O +
occurs O +
only O +
once O +
in O +
the O +
cell O +
cycle O +
. O +

Expression O +
of O +
all O +
mammalian O +
genes O +
of O +
the O +
MCM O +
family O +
is O +
induced O +
by O +
growth O +
stimulation O +
, O +
unlike O +
yeast O +
, O +
and O +
the O +
mRNA O +
levels O +
peak O +
at O +
G1 O -
/ O -
S O +
boundary O +
. O +

In O +
this O +
study O +
, O +
we O +
examined O +
the O +
transcriptional O +
activities O +
of O +
isolated O +
human O +
MCM O +
gene O +
promoters O +
. O +

Human O +
MCM5 O +
and O +
MCM6 O +
promoters O +
with O +
mutation O +
in O +
the O +
E2F O +
sites O +
failed O +
in O +
promoter O +
regulation O +
following O +
serum O +
stimulation O +
and O +
exogenous O +
E2F O +
expression O +
. O +

In O +
addition O +
, O +
we O +
identified O +
a O +
novel O +
E2F O -
- O -
like O +
sequence O +
in O +
human O +
MCM6 O +
promoter O +
which O +
cooperates O +
with O +
the O +
authentic O +
E2F O +
sites O +
in O +
E2F O +
-dependent O +
regulation O +
. O +

Forced O +
expression O +
of O +
E2F1 O +
could O +
induce O +
expression O +
of O +
all O +
members O +
of O +
the O +
endogenous O +
MCM O +
genes O +
in O +
rat B-CellLine +
embryonal I-CellLine +
fibroblast I-CellLine +
REF52 I-CellLine +
cells I-CellLine +
. O +

Our O +
results O +
demonstrated O +
that O +
the O +
growth O -
- O -
regulated O +
expression O +
of O +
mammalian O +
MCM5 O +
and O +
MCM6 O +
genes O +
, O +
and O +
presumably O +
other O +
MCM O +
members O +
, O +
is O +
primarily O +
regulated O +
by O +
E2F O +
through O +
binding O +
to O +
multiple O +
E2F O +
sites O +
in O +
the O +
promoters O +
. O +

Control O +
of O +
lymphocyte O +
development O +
by O +
the O +
Ikaros O +
gene O +
family O +
. O +

Lymphoid O +
cell O +
differentiation O +
relies O +
on O +
precisely O +
orchestrated O +
gene O +
activation O +
and O +
repression O +
events O +
. O +

Gene O +
targeting O +
studies O +
have O +
demonstrated O +
crucial O +
roles O +
for O +
the O +
transcription O +
factors O +
Ikaros O +
and O +
Aiolos O +
in O +
regulating O +
multiple O +
stages O +
of O +
B O +
and O +
T O +
cell O +
development O +
. O +

Recent O +
experiments O +
suggest O +
that O +
Ikaros O +
and O +
Aiolos O +
set O +
B O +
cell O +
antigen O -
- O -
receptor O +
( O +
BCR O +
) O +
- O +
and O +
TCR O -
- O -
mediated O +
signaling O +
thresholds O +
and O +
that O +
the O +
molecules O +
exist O +
within O +
T O +
cells O +
in O +
nuclear O +
complexes O +
that O +
contain O +
nucleosome O +
remodeling O +
and O +
histone O +
deacetylase O +
activities O +
. O +

Apoptosis O +
and O +
growth O +
inhibition O +
in O +
malignant O +
lymphocytes O +
after O +
treatment O +
with O +
arsenic O +
trioxide O +
at O +
clinically O +
achievable O +
concentrations O +
[ O +
see O +
comments O +
] O +

BACKGROUND O +
: O +
Arsenic O +
trioxide O +
( O +
As2O3 O +
) O +
can O +
induce O +
clinical O +
remission O +
in O +
patients O +
with O +
acute O +
promyelocytic O +
leukemia O +
via O +
induction O +
of O +
differentiation O +
and O +
programmed O +
cell O +
death O +
( O +
apoptosis O +
) O +
. O +

We O +
investigated O +
the O +
effects O +
of O +
As2O3 O +
on O +
a O +
panel O +
of O +
malignant O +
lymphocytes O +
to O +
determine O +
whether O +
growth O -
- O -
inhibitory O +
and O +
apoptotic O +
effects O +
of O +
As2O3 O +
can O +
be O +
observed O +
in O +
these O +
cells O +
at O +
clinically O +
achievable O +
concentrations O +
. O +

METHODS O +
: O +
Eight O +
malignant B-CellLine +
lymphocytic I-CellLine +
cell I-CellLine +
lines I-CellLine +
and O +
primary B-CellLine +
cultures I-CellLine +
of O +
lymphocytic O +
leukemia O +
and O +
lymphoma O +
cells O +
were O +
treated O +
with O +
As2O3 O +
, O +
with O +
or O +
without O +
dithiothreitol O +
( O +
DTT O +
) O +
or O +
buthionine O +
sulfoximine O +
( O +
BSO O +
) O +
( O +
an O +
inhibitor O +
of O +
glutathione O +
synthesis O +
) O +
. O +

Apoptosis O +
was O +
assessed O +
by O +
cell O +
morphology O +
, O +
flow O +
cytometry O +
, O +
annexin O +
V O +
protein O +
level O +
, O +
and O +
terminal O +
deoxynucleotidyl O +
transferase O +
labeling O +
of O +
DNA O +
fragments O +
. O +

Cellular O +
proliferation O +
was O +
determined O +
by O +
5-bromo-2'-deoxyuridine O +
incorporation O +
into O +
DNA O +
and O +
flow O +
cytometry O +
and O +
by O +
use O +
of O +
a O +
mitotic O +
arrest O +
assay O +
. O +

Mitochondrial O +
transmembrane O +
potential O +
( O +
delta O +
psi O +
( O +
m O +
) O +
) O +
was O +
measured O +
by O +
means O +
of O +
rhodamine O +
123 O +
staining O +
and O +
flow O +
cytometry O +
. O +

Protein O +
expression O +
was O +
assessed O +
by O +
western O +
blot O +
analysis O +
or O +
immunofluorescence O +
. O +

RESULTS O +
: O +
Therapeutic O +
concentrations O +
of O +
As2O3 O +
( O +
1 O -
- O -
2 O +
microM O +
) O +
had O +
dual O +
effects O +
on O +
malignant O +
lymphocytes O +
: O +
1 O +
) O +
inhibition O +
of O +
growth O +
through O +
adenosine O +
triphosphate O +
( O +
ATP O +
) O +
depletion O +
and O +
prolongation O +
of O +
cell O +
cycle O +
time O +
and O +
2 O +
) O +
induction O +
of O +
apoptosis O +
. O +

As2O3-induced O +
apoptosis O +
was O +
preceded O +
by O +
delta O +
psi O +
( O +
m O +
) O +
collapse O +
. O +

DTT O +
antagonized O +
and O +
BSO O +
enhanced O +
As2O3-induced O +
ATP O +
depletion O +
, O +
delta O +
psi O +
( O +
m O +
) O +
collapse O +
, O +
and O +
apoptosis O +
. O +

Caspase-3 O +
activation O +
, O +
usually O +
resulting O +
from O +
delta O +
psi O +
( O +
m O +
) O +
collapse O +
, O +
was O +
not O +
always O +
associated O +
with O +
As2O3-induced O +
apoptosis O +
. O +

As2O3 O +
induced O +
PML O +
( O +
promyelocytic O +
leukemia O +
) O +
protein O +
degradation O +
but O +
did O +
not O +
modulate O +
expression O +
of O +
cell O +
cycle O -
- O -
related O +
proteins O +
, O +
including O +
c O -
- O -
myc O +
, O +
retinoblastoma O +
protein O +
, O +
cyclin O -
- O -
dependent O +
kinase O +
4 O +
, O +
cyclin O +
D1 O +
, O +
and O +
p53 O +
, O +
or O +
expression O +
of O +
differentiation O -
- O -
related O +
antigens O +
. O +

CONCLUSIONS O +
: O +
Substantial O +
growth O +
inhibition O +
and O +
apoptosis O +
without O +
evidence O +
of O +
differentiation O +
were O +
induced O +
in O +
most O +
malignant O +
lymphocytic O +
cells O +
treated O +
with O +
1 O -
- O -
2 O +
microM O +
As2O3 O +
. O +

As2O3 O +
may O +
prove O +
useful O +
in O +
the O +
treatment O +
of O +
malignant O +
lymphoproliferative O +
disorders O +
. O +

Expression O +
of O +
Th1 O +
and O +
Th2 O +
type O +
cytokines O +
responding O +
to O +
HBsAg O +
and O +
HBxAg O +
in O +
chronic O +
hepatitis O +
B O +
patients O +
. O +

The O +
cytokine O +
pattern O +
on O +
viral O +
antigen O +
recognition O +
is O +
believed O +
to O +
exert O +
a O +
profound O +
influence O +
on O +
the O +
resolution O +
of O +
viral O +
infections O +
and O +
viral O +
clearance O +
. O +

This O +
study O +
was O +
initiated O +
to O +
investigate O +
whether O +
a O +
cytokine O +
imbalance O +
oriented O +
toward O +
Th2 O +
type O +
response O +
plays O +
a O +
role O +
in O +
chronic O +
hepatitis O +
B O +
. O +

Cytokine O +
profiles O +
of O +
peripheral O +
blood O +
mononuclear O +
cells O +
associated O +
with O +
chronic O +
hepatitis O +
B O +
were O +
analysed O +
by O +
RT O -
- O -
PCR O +
. O +

Upon O +
HBsAg O +
stimulation O +
, O +
expression O +
of O +
IFN O -
- O -
gamma O +
, O +
IL-2 O +
, O +
IL-4 O +
, O +
and O +
IL-10 O +
was O +
detected O +
in O +
41 O +
% O +
, O +
8 O +
% O +
, O +
41 O +
% O +
, O +
and O +
50 O +
% O +
of O +
the O +
patients O +
, O +
respectively O +
. O +

Among O +
these O +
cytokines O +
, O +
the O +
expression O +
of O +
IFN O -
- O -
gamma O +
was O +
associated O +
with O +
high O +
levels O +
of O +
serum O +
AST O -
/ O -
ALT O +
. O +

However O +
, O +
we O +
could O +
not O +
prove O +
that O +
Th2 O +
type O +
cytokines O +
had O +
a O +
protective O +
effect O +
on O +
hepatocytes O +
. O +

Upon O +
HBxAg O +
stimulation O +
, O +
there O +
was O +
no O +
recognizable O +
association O +
of O +
cytokine O +
patterns O +
with O +
AST O -
/ O -
ALT O +
levels O +
. O +

In O +
conclusion O +
, O +
production O +
of O +
a O +
Th1 O +
cytokine O +
, O +
IFN O -
- O -
gamma O +
, O +
by O +
HBsAg O +
-reactive O +
cells O +
was O +
associated O +
with O +
hepatocyte O +
damage O +
in O +
chronic O +
hepatitis O +
B O +
, O +
while O +
no O +
counteracting O +
effect O +
of O +
Th2 O +
cytokines O +
produced O +
by O +
those O +
cells O +
was O +
observed O +
. O +

Regulation O +
of O +
low O +
shear O +
flow O -
- O -
induced O +
HAEC B-CellLine +
VCAM-1 O +
expression O +
and O +
monocyte O +
adhesion O +
. O +

We O +
recently O +
reported O +
that O +
prolonged O +
exposure O +
of O +
human O +
aortic O +
endothelial O +
cells O +
( O +
HAEC B-CellLine +
) O +
to O +
low O +
shear O +
stress O +
flow O +
patterns O +
is O +
associated O +
with O +
a O +
sustained O +
increase O +
in O +
the O +
activated O +
form O +
of O +
the O +
transcriptional O +
regulator O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
. O +

Here O +
we O +
investigate O +
the O +
hypothesis O +
that O +
low O +
shear O -
- O -
induced O +
activation O +
of O +
NF O -
- O -
kappaB O +
is O +
responsible O +
for O +
enhanced O +
expression O +
of O +
vascular O +
cell O +
adhesion O +
molecule O +
( O +
VCAM-1 O +
) O +
resulting O +
in O +
augmented O +
endothelial O +
cell O -
- O -
monocyte O +
( O +
EC O -
- O -
Mn O +
) O +
adhesion O +
and O +
that O +
this O +
activation O +
is O +
dependent O +
on O +
intracellular O +
oxidant O +
activity O +
. O +

Before O +
exposure O +
to O +
low O +
shear O +
( O +
2 O +
dyn O -
/ O -
cm2 O +
) O +
for O +
6 O +
h O +
, O +
HAEC B-CellLine +
were O +
preincubated O +
with O +
or O +
without O +
the O +
antioxidants O +
pyrrolidine O +
dithiocarbamate O +
( O +
PDTC O +
) O +
or O +
N O -
- O -
acetyl O -
- O -
L O -
- O -
cysteine O +
( O +
NAC O +
) O +
. O +

PDTC O +
strongly O +
inhibited O +
low O +
shear O -
- O -
induced O +
activation O +
of O +
NF O -
- O -
kappaB O +
, O +
expression O +
of O +
VCAM-1 O +
, O +
and O +
EC O -
- O -
Mn O +
adhesion O +
. O +

Paradoxically O +
, O +
NAC O +
exerted O +
a O +
positive O +
effect O +
on O +
low O +
shear O -
- O -
induced O +
VCAM-1 O +
expression O +
and O +
EC O -
- O -
Mn O +
adhesion O +
and O +
only O +
slightly O +
downregulated O +
NF O -
- O -
kappaB O +
activation O +
. O +

However O +
, O +
cytokine O -
- O -
induced O +
NF O -
- O -
kappaB O +
activation O +
and O +
VCAM-1 O +
expression O +
are O +
blocked O +
by O +
both O +
PDTC O +
and O +
NAC O +
. O +

These O +
data O +
suggest O +
that O +
NF O -
- O -
kappaB O +
plays O +
a O +
key O +
role O +
in O +
low O +
shear O -
- O -
induced O +
VCAM-1 O +
expression O +
and O +
that O +
pathways O +
mediating O +
low O +
shear- O +
and O +
cytokine O -
- O -
induced O +
EC O -
- O -
Mn O +
adhesion O +
may O +
be O +
differentially O +
regulated O +
. O +

Non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drugs O +
inhibit O +
the O +
expression O +
of O +
cytokines O +
and O +
induce O +
HSP70 O +
in O +
human O +
monocytes O +
. O +

Recent O +
studies O +
have O +
shown O +
that O +
the O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O +
NSAIDs O +
) O +
activate O +
heat O +
shock O +
transcription O +
factor O +
( O +
HSF1 O +
) O +
from O +
a O +
latent O +
cytoplasmic O +
form O +
to O +
a O +
nuclear O +
, O +
DNA O +
binding O +
state O +
. O +

As O +
HSF1 O +
can O +
function O +
as O +
both O +
an O +
activator O +
of O +
heat O +
shock O +
genes O +
and O +
a O +
repressor O +
of O +
non O -
- O -
heat O +
shock O +
genes O +
such O +
as O +
IL1B O +
and O +
c- O +
fos O +
, O +
we O +
have O +
examined O +
the O +
potential O +
role O +
of O +
HSF1 O +
in O +
the O +
effects O +
of O +
NSAIDs O +
on O +
gene O +
expression O +
in O +
a O +
human O +
monocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
THP-1 I-CellLine +
. O +

We O +
found O +
that O +
two O +
members O +
of O +
the O +
NSAIDs O +
, O +
sodium O +
salicylate O +
and O +
sulindac O +
repress O +
the O +
IL1B O +
promoter O +
to O +
similar O +
degree O +
to O +
heat O +
shock O +
or O +
HSF1 O +
overexpression O +
. O +

In O +
addition O +
, O +
sodium O +
salicylate O +
and O +
additional O +
NSAIDs O +
used O +
at O +
concentrations O +
that O +
activate O +
HSF1 O +
also O +
inhibited O +
the O +
expression O +
of O +
other O +
monocytic O +
genes O +
( O +
TNF O -
- O -
alpha O +
, O +
IL-1beta O +
, O +
IL-6 O +
, O +
IL-8 O +
, O +
IL-10 O +
, O +
ICAM-1 O +
) O +
activated O +
by O +
exposure O +
to O +
a O +
pro O -
- O -
inflammatory O +
stimulus O +
( O +
lipopolysaccharide O +
, O +
LPS O +
) O +
. O +

At O +
least O +
in O +
the O +
case O +
of O +
the O +
IL1B O +
promoter O +
, O +
repression O +
did O +
not O +
seem O +
to O +
involve O +
another O +
factor O +
whose O +
activity O +
is O +
affected O +
by O +
the O +
NSAIDs O +
, O +
NFkappaB O +
as O +
the O +
IL1B O +
promoter O +
fragment O +
used O +
in O +
our O +
studies O +
is O +
not O +
NFkappaB O +
responsive O +
and O +
binds O +
specifically O +
to O +
HSF1 O +
. O +

Exposure O +
to O +
NSAIDs O +
had O +
a O +
complex O +
effect O +
on O +
HSP O +
gene O +
expression O +
and O +
while O +
sulindac O +
activated O +
the O +
stress O +
responsive O +
HSP70B O +
promoter O +
, O +
sodium O +
salicylate O +
did O +
not O +
. O +

In O +
addition O +
, O +
only O +
a O +
subset O +
of O +
the O +
NSAIDs O +
induced O +
HSP70 O +
mRNA O +
species O +
. O +

These O +
findings O +
reflect O +
the O +
properties O +
of O +
HSF1 O +
which O +
can O +
be O +
activated O +
to O +
at O +
least O +
two O +
DNA O +
binding O +
forms O +
only O +
one O +
of O +
which O +
activates O +
heat O +
shock O +
promoters O +
and O +
suggest O +
that O +
individual O +
NSAID O +
family O +
members O +
may O +
differentially O +
induce O +
one O +
or O +
other O +
of O +
these O +
forms O +
. O +

Overall O +
therefore O +
, O +
exposure O +
to O +
NSAIDs O +
leads O +
to O +
a O +
profound O +
switch O +
in O +
gene O +
expression O +
in O +
monocytic O +
cells O +
, O +
with O +
suppression O +
of O +
genes O +
involved O +
in O +
macrophage O +
activation O +
and O +
induction O +
of O +
stress O +
genes O +
and O +
HSF1 O +
appears O +
to O +
play O +
a O +
regulatory O +
role O +
in O +
these O +
effects O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

Disruption O +
of O +
alpha O +
beta O +
but O +
not O +
of O +
gamma O +
delta O +
T O +
cell O +
development O +
by O +
overexpression O +
of O +
the O +
helix O -
- O -
loop O -
- O -
helix O +
protein O +
Id3 O +
in O +
committed O +
T O +
cell O +
progenitors O +
. O +

Enforced O +
expression O +
of O +
Id3 O +
, O +
which O +
has O +
the O +
capacity O +
to O +
inhibit O +
many O +
basic O +
helix O -
- O -
loop O -
- O -
helix O +
( O +
bHLH O +
) O +
transcription O +
factors O +
, O +
in O +
human O +
CD34 O +
( O +
+ O +
) O +
hematopoietic O +
progenitor O +
cells O +
that O +
have O +
not O +
undergone O +
T O +
cell O +
receptor O +
( O +
TCR O +
) O +
gene O +
rearrangements O +
inhibits O +
development O +
of O +
the O +
transduced O +
cells O +
into O +
TCRalpha B-CellLine +
beta I-CellLine +
and I-CellLine +
gamma I-CellLine +
delta I-CellLine +
cells I-CellLine +
in O +
a O +
fetal B-CellLine +
thymic I-CellLine +
organ I-CellLine +
culture I-CellLine +
( O +
FTOC B-CellLine +
) O +
. O +

Here O +
we O +
document O +
that O +
overexpression O +
of O +
Id3 O +
, O +
in O +
progenitors O +
that O +
have O +
initiated O +
TCR O +
gene O +
rearrangements O +
( O +
pre O -
- O -
T O +
cells O +
) O +
, O +
inhibits O +
development O +
into O +
TCRalpha B-CellLine +
beta I-CellLine +
but O +
not O +
into O +
TCRgamma B-CellLine +
delta I-CellLine +
T I-CellLine +
cells I-CellLine +
. O +

Furthermore O +
, O +
Id3 O +
impedes O +
expression O +
of O +
recombination O +
activating O +
genes O +
and O +
downregulates O +
pre O -
- O -
Talpha O +
mRNA O +
. O +

These O +
observations O +
suggest O +
possible O +
mechanisms O +
by O +
which O +
Id3 O +
overexpression O +
can O +
differentially O +
affect O +
development O +
of O +
pre O -
- O -
T O +
cells O +
into O +
TCRalpha B-CellLine +
beta I-CellLine +
and I-CellLine +
gamma I-CellLine +
delta I-CellLine +
cells I-CellLine +
. O +

We O +
also O +
observed O +
that O +
cell O +
surface O +
CD4 O +
( O +
- O +
) O +
CD8 O +
( O +
- O +
) O +
CD3 O +
( O +
- O +
) O +
cells O +
with O +
rearranged O +
TCR O +
genes O +
developed O +
from O +
Id3-transduced B-CellLine +
but O +
not O +
from O +
control B-CellLine -
- I-CellLine -
transduced I-CellLine +
pre I-CellLine -
- I-CellLine -
T I-CellLine +
cells I-CellLine +
in O +
an O +
FTOC B-CellLine +
. O +

These O +
cells O +
had O +
properties O +
of O +
both O +
natural O +
killer O +
( O +
NK O +
) O +
and O +
pre O -
- O -
T O +
cells O +
. O +

These O +
findings O +
suggest O +
that O +
bHLH O +
factors O +
are O +
required O +
to O +
control O +
T O +
cell O +
development O +
after O +
the O +
T O -
/ O -
NK O +
developmental O +
checkpoint O +
. O +

Rel O -
/ O -
NF O -
- O -
kappaB O +
can O +
trigger O +
the O +
Notch O +
signaling O +
pathway O +
by O +
inducing O +
the O +
expression O +
of O +
Jagged1 O +
, O +
a O +
ligand O +
for O +
Notch O +
receptors O +
. O +

Jagged1 O +
belongs O +
to O +
the O +
DSL O +
family O +
of O +
ligands O +
for O +
Notch O +
receptors O +
that O +
control O +
the O +
proliferation O +
and O +
differentiation O +
of O +
various O +
cell O +
lineages O +
. O +

However O +
, O +
little O +
is O +
known O +
about O +
the O +
transcription O +
factors O +
that O +
regulate O +
its O +
expression O +
. O +

Here O +
, O +
we O +
show O +
that O +
Jagged1 O +
is O +
a O +
Rel O -
/ O -
NF O -
- O -
kappaB O -
- O -
responsive O +
gene O +
. O +

Both O +
c O -
- O -
Rel O +
and O +
RelA O +
induced O +
jagged1 O +
gene O +
expression O +
, O +
whereas O +
a O +
mutant O +
defective O +
for O +
transactivation O +
did O +
not O +
. O +

Importantly O +
, O +
jagged1 O +
transcripts O +
were O +
also O +
upregulated O +
by O +
endogenous O +
NF O -
- O -
kappaB O +
activation O +
and O +
this O +
effect O +
was O +
inhibited O +
by O +
a O +
dominant O +
mutant O +
of O +
IkappaBalpha O +
, O +
a O +
physiological O +
inhibitor O +
of O +
NF O -
- O -
kappaB O +
. O +

Cell O +
surface O +
expression O +
of O +
Jagged1 O +
in O +
c B-CellLine -
- I-CellLine -
Rel I-CellLine -
- I-CellLine -
expressing I-CellLine +
cell I-CellLine +
monolayers I-CellLine +
led O +
to O +
a O +
functional O +
interaction O +
with O +
lymphocytes O +
expressing O +
the O +
Notch1 O -
/ O -
TAN-1 O +
receptor O +
. O +

This O +
correlated O +
with O +
the O +
initiation O +
of O +
signaling O +
downstream O +
of O +
Notch O +
, O +
as O +
evidenced O +
by O +
increased O +
levels O +
of O +
HES-1 O +
transcripts O +
in O +
co B-CellLine -
- I-CellLine -
cultivated I-CellLine +
T I-CellLine +
cells I-CellLine +
and O +
of O +
CD23 O +
transcripts O +
in O +
co O -
- O -
cultivated O +
B O +
cells O +
. O +

Consistent O +
with O +
its O +
Rel O -
/ O -
NF O -
- O -
kappaB O +
-dependent O +
induction O +
, O +
Jagged1 O +
was O +
found O +
to O +
be O +
highly O +
expressed O +
in O +
splenic O +
B O +
cells O +
where O +
c O -
- O -
Rel O +
is O +
expressed O +
constitutively O +
. O +

These O +
results O +
demonstrate O +
that O +
c O -
- O -
Rel O +
can O +
trigger O +
the O +
Notch O +
signaling O +
pathway O +
in O +
neighboring O +
cells O +
by O +
inducing O +
jagged1 O +
gene O +
expression O +
, O +
and O +
suggest O +
a O +
role O +
for O +
Jagged1 O +
in O +
B O -
- O -
cell O +
activation O +
, O +
differentiation O +
or O +
function O +
. O +

These O +
findings O +
also O +
highlight O +
the O +
potential O +
for O +
an O +
interplay O +
between O +
the O +
Notch O +
and O +
NF O -
- O -
kappaB O +
signaling O +
pathways O +
in O +
the O +
immune O +
system O +
. O +

Transcriptional O +
control O +
of O +
the O +
IL-5 O +
gene O +
by O +
human O +
helper O +
T O +
cells O +
: O +
IL-5 O +
synthesis O +
is O +
regulated O +
independently O +
from O +
IL-2 O +
or O +
IL-4 O +
synthesis O +
. O +

BACKGROUND O +
: O +
IL-5 O +
is O +
fundamentally O +
involved O +
in O +
eosinophilic O +
inflammation O +
. O +

Control O +
of O +
IL-5 O +
production O +
may O +
be O +
effective O +
for O +
the O +
management O +
of O +
allergic O +
diseases O +
. O +

OBJECTIVE O +
: O +
We O +
aimed O +
to O +
find O +
the O +
transcriptional O +
mechanisms O +
that O +
regulate O +
the O +
IL-5 O +
gene O +
to O +
selectively O +
control O +
IL-5 O +
synthesis O +
. O +

METHODS O +
: O +
Allergen B-CellLine -
- I-CellLine -
specific I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
and O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
hybridomas I-CellLine +
were O +
established O +
from O +
the O +
peripheral O +
blood O +
lymphocytes O +
of O +
patients O +
with O +
asthma O +
, O +
and O +
the O +
transcriptional O +
regulation O +
of O +
the O +
IL-5 O +
gene O +
was O +
investigated O +
with O +
transient O +
transfection O +
and O +
electrophoretic O +
mobility O +
shift O +
analysis O +
. O +

RESULTS O +
: O +
A O +
human O +
IL-5 O +
promoter O -
/ O -
enhancer O -
- O -
luciferase O +
gene O +
construct O +
, O +
pIL-5 O +
( O +
-511 O +
) O +
Luc O +
, O +
was O +
transcribed O +
on O +
activation O +
of O +
IL-5-producing B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
, O +
but O +
not O +
IL-5-nonproducing B-CellLine +
clones I-CellLine +
. O +

pIL-5 O +
( O +
-511 O +
) O +
Luc O +
was O +
transcribed O +
by O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
hybridomas I-CellLine +
derived O +
from O +
fusion O +
between O +
IL-5-producing B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
and O +
an O +
IL-5 B-CellLine +
gene I-CellLine -
- I-CellLine -
nonexpressing I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
, O +
but O +
not O +
by O +
hybridomas B-CellLine +
derived O +
from O +
IL-5-nonproducing B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
clones I-CellLine +
. O +

IL-5 O +
synthesis O +
was O +
not O +
only O +
induced O +
by O +
T O -
- O -
cell O +
receptor O +
stimulation O +
but O +
also O +
by O +
IL-2 O +
receptor O +
stimulation O +
. O +

Binding O +
of O +
NF O -
- O -
AT O +
, O +
NF O -
- O -
kappaB O +
, O +
and O +
AP-1 O +
was O +
induced O +
by O +
T O -
- O -
cell O +
receptor O +
( O +
TcR O +
) O +
stimulation O +
, O +
although O +
there O +
was O +
no O +
significant O +
upregulation O +
of O +
binding O +
by O +
IL-2 O +
stimulation O +
. O +

CONCLUSION O +
: O +
IL-5 O +
synthesis O +
by O +
human O +
helper O +
T O +
cells O +
is O +
regulated O +
at O +
the O +
transcriptional O +
level O +
. O +

A O +
unique O +
transcriptional O +
mechanism O +
distinct O +
from O +
those O +
regulating O +
the O +
IL-2 O +
or O +
IL-4 O +
genes O +
seems O +
to O +
control O +
the O +
IL-5 O +
gene O +
. O +

Selective O +
regulation O +
of O +
IL-5 O +
gene O +
transcription O +
may O +
be O +
useful O +
for O +
treating O +
eosinophlic O +
inflammation O +
. O +

Recognition O +
of O +
NFATp O -
/ O -
AP-1 O +
composite O +
elements O +
within O +
genes O +
induced O +
upon O +
the O +
activation O +
of O +
immune O +
cells O +
. O +

Composite O +
elements O +
are O +
regulatory O +
modules O +
of O +
promoters O +
or O +
enhancers O +
that O +
consist O +
of O +
binding O +
sites O +
of O +
two O +
different O +
but O +
synergizing O +
transcription O +
factors O +
. O +

A O +
well O -
- O -
studied O +
example O +
is O +
nuclear O +
factors O +
of O +
activated O +
T O -
- O -
cell O +
( O +
NFAT O +
) O +
sites O +
which O +
are O +
composite O +
elements O +
of O +
a O +
NFATp O -
/ O -
c O +
and O +
an O +
activating O +
protein O +
1 O +
( O +
AP-1 O +
) O +
binding O +
site O +
. O +

We O +
have O +
developed O +
a O +
computational O +
approach O +
to O +
identify O +
potential O +
NFAT O +
target O +
genes O +
which O +
( O +
a O +
) O +
comprises O +
an O +
improved O +
method O +
to O +
scan O +
for O +
individual O +
NFAT O +
composite O +
elements O +
; O +
( O +
b O +
) O +
considers O +
positional O +
effects O +
relative O +
to O +
transcription O +
start O +
sites O +
; O +
and O +
( O +
c O +
) O +
involves O +
cluster O +
analysis O +
of O +
potential O +
NFAT O +
composite O +
elements O +
. O +

All O +
three O +
steps O +
progressively O +
helpX O +
? O +
ed O +
to O +
discriminate O +
T O -
- O -
cell O -
- O -
specific O +
promoter O +
sequences O +
against O +
other O +
functional O +
regions O +
( O +
coding O +
and O +
intronic O +
sequences O +
) O +
of O +
the O +
same O +
genes O +
, O +
against O +
promoters O +
of O +
muscle O -
- O -
specific O +
genes O +
or O +
against O +
random O +
sequences O +
. O +

Using O +
this O +
approach O +
, O +
we O +
identified O +
potential O +
NFAT O +
composite O +
elements O +
in O +
promoters O +
of O +
cytokine O +
genes O +
and O +
their O +
receptors O +
as O +
well O +
as O +
in O +
promoters O +
of O +
genes O +
for O +
AP-1 O +
family O +
members O +
, O +
Ca2 O -
+ O -
-binding O +
proteins O +
and O +
some O +
other O +
components O +
of O +
the O +
regulatory O +
network O +
operating O +
in O +
activated O +
T O -
- O -
cells O +
and O +
other O +
immune O +
cells O +
. O +

The O +
method O +
developed O +
can O +
be O +
adapted O +
to O +
characterize O +
and O +
identify O +
other O +
composite O +
elements O +
as O +
well O +
. O +

The O +
program O +
for O +
recognition O +
NFAT O +
composite O +
elements O +
is O +
available O +
through O +
the O +
World O +
Wide O +
Web O +
( O +
http O +
: O +
/ O -
/ O -
compel.bionet.nsc.ru O -
/ O -
FunSite O -
/ O -
CompelScan.html O +
and O +
http O +
: O +
/ O -
/ O -
transfac.gbf.de O -
/ O -
dbsearch O -
/ O -
funsitep O -
/ O -
s_comp.html O +
) O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

Nuclear O +
localization O +
and O +
formation O +
of O +
beta O -
- O -
catenin O -
- O -
lymphoid O +
enhancer O +
factor O +
1 O +
complexes O +
are O +
not O +
sufficient O +
for O +
activation O +
of O +
gene O +
expression O +
. O +

In O +
response O +
to O +
activation O +
of O +
the O +
Wnt O +
signaling O +
pathway O +
, O +
beta O -
- O -
catenin O +
accumulates O +
in O +
the O +
nucleus O +
, O +
where O +
it O +
cooperates O +
with O +
LEF O -
/ O -
TCF O +
( O +
for O +
lymphoid O +
enhancer O +
factor O +
and O +
T O -
- O -
cell O +
factor O +
) O +
transcription O +
factors O +
to O +
activate O +
gene O +
expression O +
. O +

The O +
mechanisms O +
by O +
which O +
beta O -
- O -
catenin O +
undergoes O +
this O +
shift O +
in O +
location O +
and O +
participates O +
in O +
activation O +
of O +
gene O +
transcription O +
are O +
unknown O +
. O +

We O +
demonstrate O +
here O +
that O +
beta O -
- O -
catenin O +
can O +
be O +
imported O +
into O +
the O +
nucleus O +
independently O +
of O +
LEF O -
/ O -
TCF O +
binding O +
, O +
and O +
it O +
may O +
also O +
be O +
exported O +
from O +
nuclei O +
. O +

We O +
have O +
introduced O +
a O +
small O +
deletion O +
within O +
beta O -
- O -
catenin O +
( O +
Delta19 O +
) O +
that O +
disrupts O +
binding O +
to O +
LEF-1 O +
, O +
E O -
- O -
cadherin O +
, O +
and O +
APC O +
but O +
not O +
axin O +
. O +

This O +
Delta19 O +
beta O -
- O -
catenin O +
mutant O +
localizes O +
to O +
the O +
nucleus O +
because O +
it O +
may O +
not O +
be O +
efficiently O +
sequestered O +
in O +
the O +
cytoplasm O +
. O +

The O +
nuclear O +
localization O +
of O +
Delta19 O +
definitively O +
demonstrates O +
that O +
the O +
mechanisms O +
by O +
which O +
beta O -
- O -
catenin O +
localizes O +
in O +
the O +
nucleus O +
are O +
completely O +
independent O +
of O +
LEF O -
/ O -
TCF O +
factors O +
. O +

beta O -
- O -
Catenin O +
and O +
LEF-1 O +
complexes O +
can O +
activate O +
reporter O +
gene O +
expression O +
in O +
a O +
transformed B-CellLine +
T I-CellLine -
- I-CellLine -
lymphocyte I-CellLine +
cell I-CellLine +
line I-CellLine +
( O +
Jurkat B-CellLine +
) O +
but O +
not O +
in O +
normal O +
T O +
lymphocytes O +
, O +
even O +
though O +
both O +
factors O +
are O +
nuclear O +
. O +

Thus O +
, O +
localization O +
of O +
both O +
factors O +
to O +
the O +
nucleus O +
is O +
not O +
sufficient O +
for O +
activation O +
of O +
gene O +
expression O +
. O +

Excess O +
beta O -
- O -
catenin O +
can O +
squelch O +
reporter O +
gene O +
activation O +
by O +
LEF-1-beta O -
- O -
catenin O +
complexes O +
but O +
not O +
activation O +
by O +
the O +
transcription O +
factor O +
VP16 O +
. O +

Taken O +
together O +
, O +
these O +
data O +
suggest O +
that O +
a O +
third O +
component O +
is O +
necessary O +
for O +
gene O +
activation O +
and O +
that O +
this O +
third O +
component O +
may O +
vary O +
with O +
cell O +
type O +
. O +

A O +
role O +
for O +
RanBP1 O +
in O +
the O +
release O +
of O +
CRM1 O +
from O +
the O +
nuclear O +
pore O +
complex O +
in O +
a O +
terminal O +
step O +
of O +
nuclear O +
export O +
. O +

We O +
recently O +
developed O +
an O +
assay O +
in O +
which O +
nuclear O +
export O +
of O +
the O +
shuttling O +
transcription O +
factor O +
NFAT O +
( O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
) O +
can O +
be O +
reconstituted O +
in O +
permeabilized O +
cells O +
with O +
the O +
GTPase O +
Ran O +
and O +
the O +
nuclear O +
export O +
receptor O +
CRM1 O +
. O +

We O +
have O +
now O +
used O +
this O +
assay O +
to O +
identify O +
another O +
export O +
factor O +
. O +

After O +
preincubation O +
of O +
permeabilized B-CellLine +
cells I-CellLine +
with O +
a O +
Ran O +
mutant O +
that O +
can O +
not O +
hydrolyze O +
GTP O +
( O +
RanQ69L O +
) O +
, O +
cytosol O +
supports O +
NFAT O +
export O +
, O +
but O +
CRM1 O +
and O +
Ran O +
alone O +
do O +
not O +
. O +

The O +
RanQ69L O +
preincubation O +
leads O +
to O +
accumulation O +
of O +
CRM1 O +
at O +
the O +
cytoplasmic O +
periphery O +
of O +
the O +
nuclear O +
pore O +
complex O +
( O +
NPC O +
) O +
in O +
association O +
with O +
the O +
p62 O +
complex O +
and O +
Can O -
/ O -
Nup214 O +
. O +

Ran O +
GTP O -
- O -
dependent O +
association O +
of O +
CRM1 O +
with O +
these O +
nucleoporins O +
was O +
reconstituted O +
in O +
vitro O +
. O +

By O +
biochemical O +
fractionation O +
and O +
reconstitution O +
, O +
we O +
showed O +
that O +
RanBP1 O +
restores O +
nuclear O +
export O +
after O +
the O +
RanQ69L O +
preincubation O +
. O +

It O +
also O +
stimulates O +
nuclear O +
export O +
in O +
cells O +
that O +
have O +
not O +
been O +
preincubated O +
with O +
RanQ69L O +
. O +

RanBP1 O +
as O +
well O +
as O +
Ran O -
- O -
binding O +
domains O +
of O +
the O +
cytoplasmic O +
nucleoporin O +
RanBP2 O +
promote O +
the O +
release O +
of O +
CRM1 O +
from O +
the O +
NPC O +
. O +

Taken O +
together O +
, O +
our O +
results O +
indicate O +
that O +
Ran O +
GTP O +
is O +
important O +
for O +
the O +
targeting O +
of O +
export O +
complexes O +
to O +
the O +
cytoplasmic O +
side O +
of O +
the O +
NPC O +
and O +
that O +
RanBP1 O +
and O +
probably O +
RanBP2 O +
are O +
involved O +
in O +
the O +
dissociation O +
of O +
nuclear O +
export O +
complexes O +
from O +
the O +
NPC O +
in O +
a O +
terminal O +
step O +
of O +
transport O +
. O +

Monocyte O +
arrest O +
and O +
transmigration O +
on O +
inflamed O +
endothelium O +
in O +
shear O +
flow O +
is O +
inhibited O +
by O +
adenovirus O -
- O -
mediated O +
gene O +
transfer O +
of O +
IkappaB O -
- O -
alpha O +
. O +

Mobilization O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
activates O +
transcription O +
of O +
genes O +
encoding O +
endothelial O +
adhesion O +
molecules O +
and O +
chemokines O +
that O +
contribute O +
to O +
monocyte O +
infiltration O +
critical O +
in O +
atherogenesis O +
. O +

Inhibition O +
of O +
NF O -
- O -
kappaB O +
has O +
been O +
achieved O +
by O +
pharmacological O +
and O +
genetic O +
approaches O +
; O +
however O +
, O +
monocyte O +
interactions O +
with O +
activated O +
endothelium O +
in O +
shear O +
flow O +
following O +
gene O +
transfer O +
of O +
the O +
NF O -
- O -
kappaB O +
inhibitor O +
IkappaB O -
- O -
alpha O +
have O +
not O +
been O +
studied O +
. O +

We O +
found O +
that O +
overexpression O +
of O +
IkappaB O -
- O -
alpha O +
in O +
endothelial O +
cells O +
using O +
a O +
recombinant O +
adenovirus O +
prevented O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
-induced O +
degradation O +
of O +
IkappaB O -
- O -
alpha O +
and O +
suppressed O +
the O +
upregulation O +
of O +
vascular O +
cell O +
adhesion O +
molecule-1 O +
( O +
VCAM-1 O +
) O +
, O +
intercellular O +
adhesion O +
molecule-1 O +
( O +
ICAM-1 O +
) O +
, O +
and O +
E O -
- O -
selectin O +
mRNA O +
and O +
surface O +
protein O +
expression O +
and O +
the O +
upregulation O +
of O +
transcripts O +
for O +
the O +
chemokines O +
monocyte O +
chemoattractant O +
protein O +
1 O +
( O +
MCP-1 O +
) O +
and O +
growth O -
- O -
related O +
activity O -
- O -
alpha O +
( O +
GRO O -
- O -
alpha O +
) O +
by O +
TNF O -
- O -
alpha O +
. O +

This O +
was O +
associated O +
with O +
a O +
reduction O +
in O +
endothelial O +
MCP-1 O +
secretion O +
and O +
GRO O -
- O -
alpha O +
immobilization O +
. O +

Adhesion O +
assays O +
under O +
physiological O +
shear O +
flow O +
conditions O +
showed O +
that O +
firm O +
arrest O +
, O +
spreading O +
, O +
and O +
transmigration O +
of O +
monocytes O +
on O +
TNF O -
- O -
alpha O +
-activated O +
endothelium O +
was O +
markedly O +
inhibited O +
by O +
IkappaB O -
- O -
alpha O +
overexpression O +
. O +

Inhibition O +
with O +
monoclonal O +
antibodies O +
and O +
peptide O +
antagonists O +
inferred O +
that O +
this O +
was O +
due O +
to O +
reduced O +
expression O +
of O +
Ig O +
integrin O +
ligand O +
as O +
well O +
as O +
of O +
chemokines O +
specifically O +
involved O +
in O +
these O +
events O +
. O +

In O +
contrast O +
, O +
rolling O +
of O +
monocytes O +
was O +
increased O +
by O +
IkappaB O -
- O -
alpha O +
transfer O +
and O +
was O +
partly O +
mediated O +
by O +
P O -
- O -
selectin O +
; O +
however O +
, O +
it O +
appeared O +
to O +
be O +
unaffected O +
by O +
the O +
inhibition O +
of O +
E O -
- O -
selectin O +
induction O +
. O +

Thus O +
, O +
our O +
data O +
provide O +
novel O +
evidence O +
that O +
selective O +
modulation O +
of O +
NF O -
- O -
kappaB O +
by O +
adenoviral O +
transfer O +
of O +
IkappaB O -
- O -
alpha O +
impairs O +
the O +
expression O +
of O +
multiple O +
endothelial O +
gene O +
products O +
required O +
for O +
subsequent O +
monocyte O +
arrest O +
and O +
emigration O +
in O +
shear O +
flow O +
and O +
thus O +
for O +
monocyte O +
infiltration O +
in O +
atherosclerotic O +
plaques O +
. O +

Human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
Tax O +
protein O +
induces O +
the O +
expression O +
of O +
STAT1 O +
and O +
STAT5 O +
genes O +
in O +
T O -
- O -
cells O +
. O +

Human O +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
1 O +
( O +
HTLV-1 O +
) O +
Tax O +
transforms O +
normal O +
T O -
- O -
cells O +
in O +
the O +
presence O +
of O +
interleukin O +
( O +
IL O +
) O +
-2 O +
in O +
vitro O +
. O +

STAT O +
is O +
a O +
family O +
of O +
transcription O +
factors O +
that O +
play O +
a O +
pivotal O +
role O +
in O +
cytokine O -
- O -
induced O +
functions O +
of O +
a O +
various O +
type O +
of O +
cells O +
. O +

We O +
investigated O +
the O +
involvement O +
of O +
STATs O +
in O +
the O +
transformation O +
of O +
T O -
- O -
cells O +
by O +
HTLV-1 O +
. O +

HTLV-1-transformed B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
expressed O +
higher O +
amounts O +
of O +
STAT1 O +
, O +
STAT3 O +
and O +
STAT5 O +
RNA O +
and O +
proteins O +
than O +
virus O -
- O -
negative O +
T O +
cells O +
. O +

The O +
expression O +
of O +
STAT1 O +
and O +
STAT5 O +
in O +
a O +
human B-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
was O +
induced O +
by O +
Tax O +
. O +

IL-2 O +
induced O +
the O +
DNA O +
binding O +
activity O +
of O +
STAT3 O +
and O +
STAT5 O +
of O +
a O +
HTLV-1-transformed O +
cell O +
line O +
and O +
then O +
stimulated O +
its O +
proliferation O +
. O +

In O +
contrast O +
, O +
IL-2 O +
did O +
neither O +
in O +
a O +
cell O +
line O +
lacking O +
STAT3 O +
and O +
STAT5 O +
. O +

The O +
expression O +
of O +
STAT1 O +
, O +
STAT3 O +
and O +
STAT5 O +
mRNAs O +
were O +
also O +
induced O +
by O +
a O +
T O -
- O -
cell O +
mitogen O +
in O +
normal O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
. O +

Our O +
results O +
suggest O +
that O +
the O +
induction O +
of O +
STAT1 O +
and O +
STAT5 O +
by O +
Tax O +
enhances O +
cytokine O +
-induced O +
functions O +
of O +
virus O -
- O -
infected O +
T O -
- O -
cells O +
, O +
hence O +
the O +
induction O +
may O +
play O +
a O +
role O +
in O +
IL-2 O +
-dependent O +
transformation O +
steps O +
of O +
T O -
- O -
cells O +
by O +
HTLV-1 O +
. O +

Selection O +
and O +
long O -
- O -
term O +
persistence O +
of O +
reactive O +
CTL B-CellLine +
clones I-CellLine +
during O +
an O +
EBV O +
chronic O +
response O +
are O +
determined O +
by O +
avidity O +
, O +
CD8 O +
variable O +
contribution O +
compensating O +
for O +
differences O +
in O +
TCR O +
affinities O +
. O +

Recent O +
studies O +
have O +
suggested O +
that O +
the O +
diversity O +
of O +
TCR O +
repertoire O +
after O +
primary O +
immunization O +
is O +
conserved O +
in O +
memory O +
T O +
cells O +
and O +
that O +
a O +
progressive O +
narrowing O +
of O +
this O +
repertoire O +
may O +
take O +
place O +
during O +
recall O +
infections O +
. O +

It O +
now O +
remains O +
to O +
be O +
investigated O +
which O +
parameters O +
determine O +
the O +
repertoire O +
of O +
the O +
memory O +
response O +
and O +
possibly O +
restrict O +
its O +
diversity O +
after O +
subsequent O +
antigenic O +
challenges O +
. O +

To O +
address O +
this O +
question O +
, O +
we O +
took O +
advantage O +
of O +
a O +
panel O +
of O +
CD8 B-CellLine -
+ I-CellLine +
T I-CellLine +
cell I-CellLine +
clones I-CellLine +
from O +
the O +
joint O +
of O +
a O +
rheumatoid O +
arthritis O +
patient O +
and O +
selected O +
for O +
their O +
reactivity O +
against O +
a O +
single O +
MHC O -
/ O -
peptide O +
complex O +
. O +

Characterization O +
of O +
both O +
TCR O +
chains O +
documented O +
a O +
great O +
diversity O +
among O +
those O +
clones O +
and O +
the O +
persistence O +
of O +
clonotypes O +
over O +
a O +
2-yr O +
period O +
. O +

Strikingly O +
, O +
despite O +
the O +
observed O +
repertoire O +
heterogeneity O +
, O +
all O +
clones O +
displayed O +
a O +
narrow O +
range O +
of O +
MHC O +
/peptide O +
density O +
requirements O +
in O +
cytotoxicity O +
assays O +
( O +
ED50 O +
between O +
9 O +
and O +
36 O +
nM O +
) O +
. O +

TCR O +
affinities O +
were O +
then O +
indirectly O +
estimated O +
by O +
blocking O +
CD8 O +
interaction O +
with O +
an O +
anti O -
- O -
CD8 O +
mAb O +
. O +

We O +
found O +
a O +
wide O +
range O +
of O +
TCR O +
affinities O +
among O +
the O +
different O +
clonotypes O +
that O +
segregated O +
with O +
Vbeta O +
usage O +
. O +

We O +
thus O +
propose O +
that O +
during O +
an O +
in O +
vivo O +
chronic O +
response O +
, O +
a O +
narrow O +
range O +
of O +
avidity O +
of O +
the O +
TCR O -
- O -
CD8 O +
complex O +
conditions O +
long O -
- O -
term O +
clonotype O +
persistence O +
, O +
and O +
that O +
the O +
level O +
of O +
CD8 O +
contribution O +
is O +
adjusted O +
to O +
keep O +
clonotypes O +
with O +
variable O +
TCR O +
affinities O +
within O +
this O +
avidity O +
window O +
. O +

In O +
vivo O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
in O +
T O -
- O -
lineage O +
cells O +
leads O +
to O +
a O +
dramatic O +
decrease O +
in O +
cell O +
proliferation O +
and O +
cytokine O +
production O +
and O +
to O +
increased O +
cell O +
apoptosis O +
in O +
response O +
to O +
mitogenic O +
stimuli O +
, O +
but O +
not O +
to O +
abnormal O +
thymopoiesis O +
. O +

To O +
understand O +
the O +
role O +
of O +
NF O -
- O -
kappa O +
B O +
complexes O +
in O +
T O +
cell O +
development O +
and O +
activation O +
, O +
we O +
have O +
generated O +
transgenic O +
mice O +
in O +
which O +
RelA O +
and O +
c O -
- O -
Rel O +
complexes O +
were O +
selectively O +
inhibited O +
in O +
the O +
T O -
- O -
lineage O +
cells O +
by O +
specific O +
expression O +
of O +
a O +
trans O -
- O -
dominant O +
form O +
of O +
I O +
kappa O +
B O +
alpha O +
. O +

Transgene O +
expression O +
did O +
not O +
affect O +
the O +
thymic O +
development O +
, O +
but O +
led O +
to O +
lowered O +
numbers O +
of O +
splenic O +
T O +
cells O +
and O +
to O +
a O +
dramatic O +
decrease O +
in O +
the O +
ex O +
vivo O +
proliferative O +
response O +
of O +
splenic O +
T O +
lymphocytes O +
. O +

Analysis O +
of O +
IL-2 O +
and O +
IL-2R O +
alpha O +
expression O +
demonstrated O +
that O +
the O +
perturbation O +
of O +
the O +
proliferation O +
response O +
was O +
not O +
attributable O +
to O +
an O +
abnormal O +
expression O +
of O +
these O +
genes O +
. O +

In O +
contrast O +
, O +
expression O +
of O +
IL-4 O +
, O +
IL-10 O +
, O +
and O +
IFN O -
- O -
gamma O +
was O +
strongly O +
inhibited O +
in O +
the O +
transgenic O +
T O +
cells O +
. O +

The O +
proliferative O +
deficiency O +
of O +
the O +
transgenic O +
T O +
cells O +
was O +
associated O +
with O +
an O +
increased O +
apoptosis O +
. O +

These O +
results O +
point O +
out O +
the O +
involvement O +
of O +
NF O -
- O -
kappa O +
B O -
/ O -
Rel O +
family O +
proteins O +
in O +
growth O +
signaling O +
pathways O +
by O +
either O +
regulating O +
proteins O +
involved O +
in O +
the O +
IL-2 O +
signaling O +
or O +
by O +
functionally O +
interfering O +
with O +
the O +
cell O +
cycle O +
progression O +
. O +

Glucocorticoid O +
receptors O +
in O +
anorexia O +
nervosa O +
and O +
Cushing O +
's O +
disease O +
. O +

BACKGROUND O +
: O +
Patients O +
with O +
anorexia O +
nervosa O +
do O +
not O +
display O +
cushingoid O +
features O +
in O +
spite O +
of O +
elevated O +
cortisol O +
plasma O +
levels O +
. O +

Whether O +
a O +
cortisol O +
resistance O +
or O +
a O +
reduced O +
availability O +
of O +
the O +
metabolic O +
substrates O +
necessary O +
to O +
develop O +
the O +
effect O +
of O +
glucocorticoids O +
is O +
responsible O +
for O +
this O +
has O +
not O +
been O +
established O +
. O +

METHODS O +
: O +
Twenty O -
- O -
two O +
patients O +
with O +
severe O +
restrictive O +
anorexia O +
nervosa O +
, O +
10 O +
patients O +
with O +
active O +
Cushing O +
's O +
disease O +
, O +
and O +
24 O +
healthy O +
volunteers O +
without O +
psychiatric O +
disorders O +
or O +
mood O +
alterations O +
were O +
investigated O +
. O +

Glucocorticoid O +
receptor O +
characteristics O +
were O +
examined O +
on O +
mononuclear O +
leukocytes O +
by O +
measuring O +
[ O +
3H O +
] O +
dexamethasone O +
binding O +
and O +
the O +
effect O +
of O +
dexamethasone O +
on O +
[ O +
3H O +
] O +
thymidine O +
incorporation O +
, O +
which O +
represents O +
an O +
index O +
of O +
DNA O +
synthesis O +
. O +

RESULTS O +
: O +
The O +
number O +
of O +
glucocorticoid O +
receptors O +
on O +
mononuclear O +
leukocytes O +
( O +
MNL O +
) O +
was O +
comparable O +
in O +
patients O +
with O +
anorexia O +
nervosa O +
, O +
patients O +
with O +
active O +
Cushing O +
's O +
disease O +
, O +
and O +
normal O +
subjects O +
( O +
binding O +
capacity O +
3.3 O +
+ O -
/- O +
0.23 O +
vs. O +
3.7 O +
+ O -
/- O +
0.30 O +
and O +
3.5 O +
+ O -
/- O +
0.20 O +
fmol O -
/ O -
10 O +
( O +
6 O +
) O +
cells O +
) O +
. O +

Conversely O +
, O +
glucocorticoid O +
receptor O +
affinity O +
was O +
significantly O +
decreased O +
in O +
anorexia O +
nervosa O +
as O +
well O +
as O +
in O +
Cushing O +
's O +
patients O +
compared O +
to O +
control O +
subjects O +
( O +
dissociation O +
constant O +
4.0 O +
+ O -
/- O +
0.31 O +
and O +
4.1 O +
+ O -
/- O +
0.34 O +
vs. O +
2.9 O +
+ O -
/- O +
0.29 O +
nmol O -
/ O -
L O +
, O +
p O +
< O +
.001 O +
) O +
and O +
inversely O +
correlated O +
with O +
the O +
levels O +
of O +
urinary O +
free O +
cortisol O +
in O +
both O +
groups O +
of O +
patients O +
. O +

Basal O +
[ O +
3H O +
] O +
thymidine O +
incorporation O +
in O +
MNL O +
was O +
significantly O +
reduced O +
in O +
anorexia O +
nervosa O +
as O +
well O +
as O +
in O +
Cushing O +
's O +
patients O +
compared O +
to O +
control O +
subjects O +
( O +
p O +
< O +
.001 O +
) O +
and O +
was O +
diminished O +
by O +
dexamethasone O +
to O +
an O +
extent O +
similar O +
to O +
control O +
subjects O +
in O +
patients O +
with O +
anorexia O +
nervosa O +
, O +
but O +
significantly O +
( O +
p O +
< O +
.001 O +
) O +
less O +
in O +
those O +
with O +
Cushing O +
's O +
disease O +
. O +

In O +
patients O +
with O +
anorexia O +
nervosa O +
, O +
the O +
incorporation O +
of O +
[ O +
3H O +
] O +
thymidine O +
into O +
the O +
MNL O +
was O +
inversely O +
correlated O +
with O +
urinary O +
free O +
cortisol O +
levels O +
. O +

CONCLUSIONS O +
: O +
These O +
data O +
indicate O +
that O +
the O +
lack O +
of O +
cushingoid O +
features O +
in O +
patients O +
with O +
anorexia O +
nervosa O +
is O +
not O +
ascribable O +
to O +
a O +
reduced O +
sensitivity O +
to O +
glucocorticoids O +
but O +
is O +
more O +
likely O +
due O +
to O +
the O +
paucity O +
of O +
metabolic O +
substrates O +
. O +

Phorbol O +
ester O -
- O -
induced O +
mononuclear O +
cell O +
differentiation O +
is O +
blocked O +
by O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
kinase O +
( O +
MEK O +
) O +
inhibitor O +
PD98059 O +
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
whether O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
signaling O +
pathway O +
contributes O +
to O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
-induced O +
mononuclear O +
differentiation O +
in O +
the O +
human B-CellLine +
myeloblastic I-CellLine +
leukemia I-CellLine +
ML-1 I-CellLine +
cells I-CellLine +
. O +

Upon O +
TPA O +
treatment O +
, O +
the O +
activity O +
of O +
ERK1 O +
and O +
ERK2 O +
rapidly O +
increased O +
, O +
with O +
maximal O +
induction O +
between O +
1 O +
and O +
3 O +
h O +
, O +
while O +
ERK2 O +
protein O +
levels O +
remained O +
constant O +
. O +

The O +
activity O +
of O +
JNK1 O +
was O +
also O +
significantly O +
induced O +
, O +
with O +
JNK1 O +
protein O +
levels O +
increasing O +
moderately O +
during O +
exposure O +
to O +
TPA O +
. O +

Treatment O +
of O +
cells O +
with O +
PD98059 O +
, O +
a O +
specific O +
inhibitor O +
of O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
kinase O +
( O +
MEK O +
) O +
, O +
inhibited O +
TPA O -
- O -
induced O +
ERK2 O +
activity O +
. O +

Furthermore O +
, O +
PD98059 O +
completely O +
blocked O +
the O +
TPA O -
- O -
induced O +
differentiation O +
of O +
ML-1 B-CellLine +
cells I-CellLine +
, O +
as O +
assessed O +
by O +
a O +
number O +
of O +
features O +
associated O +
with O +
mononuclear O +
differentiation O +
including O +
changes O +
in O +
morphology O +
, O +
nonspecific O +
esterase O +
activity O +
, O +
phagocytic O +
ability O +
, O +
NADPH O +
oxidase O +
activity O +
, O +
mitochondrial O +
respiration O +
, O +
and O +
c O -
- O -
jun O +
mRNA O +
inducibility O +
. O +

We O +
conclude O +
that O +
activation O +
of O +
the O +
MEK O +
/ERK O +
signaling O +
pathway O +
is O +
necessary O +
for O +
TPA O -
- O -
induced O +
mononuclear O +
cell O +
differentiation O +
. O +

Immune O +
functions O +
, O +
clinical O +
parameters O +
and O +
hormone O +
receptor O +
status O +
in O +
breast O +
cancer O +
patients O +
. O +

We O +
have O +
carried O +
out O +
a O +
detailed O +
analysis O +
of O +
the O +
cellular O +
immune O +
functions O +
of O +
breast O +
cancer O +
patients O +
in O +
comparison O +
with O +
healthy O +
controls O +
. O +

A O +
possible O +
correlation O +
between O +
immune O +
and O +
clinical O +
parameters O +
was O +
analysed O +
in O +
50 O +
breast O +
cancer O +
patients O +
. O +

Immune O +
parameters O +
, O +
natural O +
killer O +
cell O +
and O +
T O +
lymphocyte O +
functions O +
and O +
the O +
numbers O +
of O +
circulating O +
T O +
lymphocytes O +
were O +
analysed O +
against O +
the O +
clinical O +
parameters O +
comprising O +
the O +
tumour O +
burden O +
, O +
the O +
stage O +
of O +
the O +
disease O +
and O +
the O +
expression O +
of O +
hormone O +
receptors O +
on O +
the O +
tumour O +
. O +

In O +
order O +
to O +
analyse O +
the O +
immune O +
function O +
data O +
effectively O +
, O +
low O +
responders O +
were O +
identified O +
with O +
stringent O +
cut O -
- O -
off O +
values O +
. O +

Considerably O +
higher O +
proportions O +
of O +
low O +
responders O +
were O +
found O +
among O +
the O +
patient O +
population O +
. O +

Elevated O +
numbers O +
of O +
circulating O +
T O +
lymphocytes O +
and O +
CD3 O +
-directed O +
cytolysis O +
correlated O +
with O +
the O +
expression O +
of O +
oestrogen O +
receptors O +
independently O +
of O +
the O +
clinical O -
/ O -
histological O +
parameters O +
. O +

Latent O +
membrane O +
protein O +
1 O +
of O +
Epstein O -
- O -
Barr O +
virus O +
interacts O +
with O +
JAK3 O +
and O +
activates O +
STAT O +
proteins O +
. O +

Latent O +
membrane O +
protein O +
1 O +
( O +
LMP1 O +
) O +
acts O +
like O +
a O +
permanently O +
activated O +
receptor O +
of O +
the O +
tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
-receptor O +
superfamily O +
and O +
is O +
absolutely O +
required O +
for O +
B O +
cell O +
immortalization O +
by O +
Epstein O -
- O -
Barr O +
virus O +
. O +

Molecular O +
and O +
biochemical O +
approaches O +
demonstrated O +
that O +
LMP1 O +
usurps O +
cellular O +
signaling O +
pathways O +
resulting O +
in O +
the O +
induction O +
of O +
NF O -
- O -
kappaB O +
and O +
AP-1 O +
via O +
two O +
C O -
- O -
terminal O +
activating O +
regions O +
. O +

We O +
demonstrate O +
here O +
that O +
a O +
third O +
region O +
encompassing O +
a O +
proline O +
rich O +
sequence O +
within O +
the O +
33 O +
bp O +
repetitive O +
stretch O +
of O +
LMP1 O +
's O +
C O -
- O -
terminus O +
is O +
required O +
for O +
the O +
activation O +
of O +
Janus O +
kinase O +
3 O +
( O +
JAK3 O +
) O +
. O +

The O +
interaction O +
of O +
LMP1 O +
and O +
JAK3 O +
leads O +
to O +
the O +
enhanced O +
tyrosine O +
auto O -
/ O -
transphosphorylation O +
of O +
JAK3 O +
within O +
minutes O +
after O +
crosslinking O +
of O +
a O +
conditional O +
NGF O -
- O -
R O +
: O +
LMP1 O +
chimera O +
and O +
is O +
a O +
prerequisite O +
for O +
the O +
activation O +
of O +
STAT O +
transcription O +
factors O +
. O +

These O +
results O +
reveal O +
a O +
novel O +
activating O +
region O +
in O +
the O +
LMP1 O +
C O -
- O -
terminus O +
and O +
identify O +
the O +
JAK O +
/STAT O +
pathway O +
as O +
a O +
target O +
of O +
this O +
viral O +
integral O +
membrane O +
protein O +
in O +
B O +
cells O +
. O +

New O +
immunosuppressive O +
drug O +
PNU156804 O +
blocks O +
IL-2 O +
-dependent O +
proliferation O +
and O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O +
activation O +
. O +

We O +
had O +
previously O +
shown O +
that O +
the O +
drug O +
undecylprodigiosin O +
( O +
UP O +
) O +
blocks O +
human O +
lymphocyte O +
proliferation O +
in O +
vitro O +
. O +

We O +
have O +
now O +
investigated O +
the O +
mechanism O +
of O +
action O +
of O +
a O +
new O +
analogue O +
of O +
UP O +
, O +
PNU156804 O +
, O +
which O +
shows O +
a O +
more O +
favorable O +
activity O +
profile O +
than O +
UP O +
in O +
mice O +
. O +

We O +
demonstrate O +
here O +
that O +
the O +
biological O +
effect O +
of O +
PNU156804 O +
in O +
vitro O +
is O +
indistinguishable O +
from O +
UP O +
: O +
PNU156804 O +
blocks O +
human O +
T O +
cell O +
proliferation O +
in O +
mid O -
- O -
late O +
G1 O +
, O +
as O +
determined O +
by O +
cell O +
cycle O +
analysis O +
, O +
expression O +
of O +
cyclins O +
, O +
and O +
cyclin O -
- O -
dependent O +
kinases O +
and O +
retinoblastoma O +
phosphorylation O +
. O +

In O +
addition O +
, O +
we O +
show O +
that O +
PNU156804 O +
does O +
not O +
block O +
significantly O +
the O +
induction O +
of O +
either O +
IL-2 O +
or O +
IL-2R O +
alpha- O +
and O +
gamma O -
- O -
chains O +
but O +
inhibits O +
IL-2 O +
-dependent O +
T O +
cell O +
proliferation O +
. O +

We O +
have O +
investigated O +
several O +
molecular O +
pathways O +
that O +
are O +
known O +
to O +
be O +
activated O +
by O +
IL-2 O +
in O +
T O +
cells O +
. O +

We O +
show O +
that O +
PNU156804 O +
does O +
not O +
inhibit O +
c O -
- O -
myc O +
and O +
bcl-2 O +
mRNA O +
induction O +
. O +

On O +
the O +
other O +
hand O +
, O +
PNU156804 O +
efficiently O +
inhibits O +
the O +
activation O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O +
transcription O +
factors O +
. O +

PNU156804 O +
inhibition O +
of O +
NF O -
- O -
kappa O +
B O +
activation O +
is O +
due O +
to O +
the O +
inhibition O +
of O +
the O +
degradation O +
of O +
I O +
kappa O +
B O -
- O -
alpha O +
and O +
I O +
kappa O +
B O -
- O -
beta O +
. O +

PNU156804 O +
action O +
is O +
restricted O +
to O +
some O +
signaling O +
pathways O +
; O +
it O +
does O +
not O +
affect O +
NF O -
- O -
kappa O +
B O +
activation O +
by O +
PMA O +
in O +
T O +
cells O +
but O +
blocks O +
that O +
induced O +
by O +
CD40 O +
cross O -
- O -
linking O +
in O +
B O +
lymphocytes O +
. O +

We O +
conclude O +
that O +
the O +
prodigiosin O +
family O +
of O +
immunosuppressants O +
is O +
a O +
new O +
family O +
of O +
molecules O +
that O +
show O +
a O +
novel O +
target O +
specificity O +
clearly O +
distinct O +
from O +
that O +
of O +
other O +
immunosuppressive O +
drugs O +
such O +
as O +
cyclosporin O +
A O +
, O +
FK506 O +
, O +
and O +
rapamycin O +
. O +

IL-12 O +
induces O +
IFN O +
regulating O +
factor-1 O +
( O +
IRF-1 O +
) O +
gene O +
expression O +
in O +
human O +
NK O +
and O +
T O +
cells O +
. O +

IL-12 O +
is O +
a O +
critical O +
immunoregulatory O +
cytokine O +
that O +
promotes O +
cell O -
- O -
mediated O +
immune O +
responses O +
and O +
the O +
differentiation O +
of O +
naive O +
CD4 O -
+ O +
cells O +
to O +
Th1 O +
cells O +
; O +
however O +
, O +
relatively O +
few O +
IL-12 O +
target O +
genes O +
have O +
been O +
identified O +
. O +

To O +
better O +
clarify O +
the O +
molecular O +
basis O +
of O +
IL-12 O +
action O +
, O +
we O +
set O +
out O +
to O +
characterize O +
genes O +
up O -
- O -
regulated O +
by O +
IL-12 O +
, O +
first O +
by O +
contrasting O +
IL-12 O +
-and O +
IFN O -
- O -
alpha O -
- O -
inducible O +
genes O +
. O +

We O +
identified O +
several O +
genes O +
up O -
- O -
regulated O +
by O +
IL-12 O +
, O +
namely O +
, O +
MIP-1alpha O +
, O +
MIP-1beta O +
, O +
IL-1RA O +
, O +
and O +
IFN O +
regulatory O +
factor-1 O +
( O +
IRF-1 O +
) O +
. O +

IRF-1 O +
is O +
a O +
transcription O +
factor O +
regulated O +
by O +
IFNs O +
that O +
is O +
also O +
essential O +
for O +
Th1 O +
responses O +
. O +

We O +
demonstrated O +
that O +
IL-12 O +
directly O +
up O -
- O -
regulates O +
IRF-1 O +
to O +
the O +
same O +
extent O +
as O +
IFN O -
- O -
alpha O +
in O +
normal O +
human O +
T O +
cells O +
and O +
in O +
NK O +
cells O +
. O +

We O +
showed O +
that O +
IL-12 O +
had O +
a O +
direct O +
effect O +
on O +
IRF-1 O +
, O +
an O +
effect O +
not O +
mediated O +
indirectly O +
by O +
the O +
induction O +
of O +
IFN O -
- O -
gamma O +
production O +
. O +

Furthermore O +
, O +
IL-2 O +
and O +
IL-12 O +
synergistically O +
induced O +
IRF-1 O +
, O +
whereas O +
IFN O -
- O -
alpha O +
and O +
IL-12 O +
did O +
not O +
. O +

The O +
participation O +
of O +
STAT4 O +
in O +
the O +
regulation O +
of O +
IRF-1 O +
was O +
demonstrated O +
in O +
two O +
ways O +
. O +

First O +
, O +
STAT4 O +
was O +
required O +
for O +
the O +
IL-12 O +
-dependent O +
transactivation O +
of O +
an O +
IRF-1 O +
reporter O +
construct O +
, O +
and O +
second O +
, O +
STAT4 O +
binding O +
to O +
the O +
IRF-1 O +
promoter O +
was O +
shown O +
using O +
EMSA O +
. O +

In O +
contrast O +
to O +
IL-12 O +
, O +
no O +
up O -
- O -
regulation O +
of O +
IRF-1 O +
was O +
found O +
in O +
IL-4-stimulated B-CellLine +
cells I-CellLine +
, O +
and O +
IL-4 O +
did O +
not O +
block O +
IL-12 O +
-dependent O +
up O -
- O -
regulation O +
of O +
IRF-1 O +
. O +

Therefore O +
, O +
IRF-1 O +
may O +
be O +
an O +
important O +
contributor O +
to O +
IL-12 O +
signaling O +
, O +
and O +
we O +
speculate O +
that O +
the O +
defective O +
IL-12 O +
responses O +
seen O +
in O +
IRF O +
-1- O -
/ O -
- O +
mice O +
might O +
be O +
attributable O +
, O +
in O +
part O +
, O +
to O +
the O +
absence O +
of O +
this O +
transcription O +
factor O +
. O +

Direct O +
interaction O +
of O +
hematopoietic O +
transcription O +
factors O +
PU.1 O +
and O +
GATA-1 O +
: O +
functional O +
antagonism O +
in O +
erythroid O +
cells O +
. O +

Malignant O +
transformation O +
usually O +
inhibits O +
terminal O +
cell O +
differentiation O +
but O +
the O +
precise O +
mechanisms O +
involved O +
are O +
not O +
understood O +
. O +

PU.1 O +
is O +
a O +
hematopoietic O -
- O -
specific O +
Ets O +
family O +
transcription O +
factor O +
that O +
is O +
required O +
for O +
development O +
of O +
some O +
lymphoid O +
and O +
myeloid O +
lineages O +
. O +

PU.1 O +
can O +
also O +
act O +
as O +
an O +
oncoprotein O +
as O +
activation O +
of O +
its O +
expression O +
in O +
erythroid O +
precursors O +
by O +
proviral O +
insertion O +
or O +
transgenesis O +
causes O +
erythroleukemias O +
in O +
mice O +
. O +

Restoration O +
of O +
terminal O +
differentiation O +
in O +
the O +
mouse B-CellLine +
erythroleukemia I-CellLine +
( I-CellLine +
MEL I-CellLine +
) I-CellLine +
cells I-CellLine +
requires O +
a O +
decline O +
in O +
the O +
level O +
of O +
PU.1 O +
, O +
indicating O +
that O +
PU.1 O +
can O +
block O +
erythroid O +
differentiation O +
. O +

Here O +
we O +
investigate O +
the O +
mechanism O +
by O +
which O +
PU.1 O +
interferes O +
with O +
erythroid O +
differentiation O +
. O +

We O +
find O +
that O +
PU.1 O +
interacts O +
directly O +
with O +
GATA-1 O +
, O +
a O +
zinc O +
finger O +
transcription O +
factor O +
required O +
for O +
erythroid O +
differentiation O +
. O +

Interaction O +
between O +
PU.1 O +
and O +
GATA-1 O +
requires O +
intact O +
DNA O -
- O -
binding O +
domains O +
in O +
both O +
proteins O +
. O +

PU.1 O +
represses O +
GATA-1 O +
-mediated O +
transcriptional O +
activation O +
. O +

Both O +
the O +
DNA O +
binding O +
and O +
transactivation O +
domains O +
of O +
PU.1 O +
are O +
required O +
for O +
repression O +
and O +
both O +
domains O +
are O +
also O +
needed O +
to O +
block O +
terminal O +
differentiation O +
in O +
MEL B-CellLine +
cells I-CellLine +
. O +

We O +
also O +
show O +
that O +
ectopic O +
expression O +
of O +
PU.1 O +
in O +
Xenopus O +
embryos O +
is O +
sufficient O +
to O +
block O +
erythropoiesis O +
during O +
normal O +
development O +
. O +

Furthermore O +
, O +
introduction O +
of O +
exogenous O +
GATA-1 O +
in O +
both O +
MEL B-CellLine +
cells I-CellLine +
and O +
Xenopus O +
embryos O +
and O +
explants O +
relieves O +
the O +
block O +
to O +
erythroid O +
differentiation O +
imposed O +
by O +
PU.1 O +
. O +

Our O +
results O +
indicate O +
that O +
the O +
stoichiometry O +
of O +
directly O +
interacting O +
but O +
opposing O +
transcription O +
factors O +
may O +
be O +
a O +
crucial O +
determinant O +
governing O +
processes O +
of O +
normal O +
differentiation O +
and O +
malignant O +
transformation O +
. O +

Oxidative O +
stress O +
triggers O +
STAT3 O +
tyrosine O +
phosphorylation O +
and O +
nuclear O +
translocation O +
in O +
human O +
lymphocytes O +
. O +

Oxidizing O +
agents O +
are O +
powerful O +
activators O +
of O +
factors O +
responsible O +
for O +
the O +
transcriptional O +
activation O +
of O +
cytokine O -
- O -
encoding O +
genes O +
involved O +
in O +
tissue O +
injury O +
. O +

In O +
this O +
study O +
we O +
show O +
evidence O +
that O +
STAT3 O +
is O +
a O +
transcription O +
factor O +
whose O +
activity O +
is O +
modulated O +
by O +
H2O2 O +
in O +
human O +
lymphocytes O +
, O +
in O +
which O +
endogenous O +
catalase O +
had O +
previously O +
been O +
inhibited O +
. O +

H2O2-induced O +
nuclear O +
translocation O +
of O +
STAT3 O +
to O +
form O +
sequence O -
- O -
specific O +
DNA O -
- O -
bound O +
complexes O +
was O +
evidenced O +
by O +
immunoblotting O +
of O +
nuclear O +
fractions O +
and O +
electrophoretic O +
mobility O +
shift O +
assays O +
, O +
and O +
vanadate O +
was O +
found O +
to O +
strongly O +
synergize O +
with O +
H2O2 O +
. O +

Moreover O +
, O +
anti- O +
STAT3 O +
antibodies O +
specifically O +
precipitated O +
a O +
protein O +
of O +
92 O +
kDa O +
that O +
becomes O +
phosphorylated O +
on O +
tyrosine O +
upon O +
lymphocyte O +
treatment O +
with O +
H2O2 O +
. O +

Phenylarsine O +
oxide O +
, O +
a O +
tyrosine O +
phosphatase O +
inhibitor O +
, O +
and O +
genistein O +
, O +
a O +
tyrosine O +
kinase O +
inhibitor O +
, O +
cooperated O +
and O +
cancelled O +
, O +
respectively O +
, O +
the O +
H2O2-promoted O +
STAT3 O +
nuclear O +
translocation O +
. O +

Evidence O +
is O +
also O +
presented O +
, O +
using O +
Fe2+ O -
/ O -
Cu2 O -
+ O +
ions O +
, O +
that O -
. O -
OH O +
generated O +
from O +
H2O2 O +
through O +
Fenton O +
reactions O +
could O +
be O +
a O +
candidate O +
oxygen O +
reactive O +
species O +
to O +
directly O +
activate O +
STAT3 O +
. O +

Present O +
data O +
suggest O +
that O +
H2O2 O +
and O +
vanadate O +
are O +
likely O +
to O +
inhibit O +
the O +
activity O +
of O +
intracellular O +
tyrosine O +
phosphatase O +
( O +
s O +
) O +
, O +
leading O +
to O +
enhanced O +
STAT3 O +
tyrosine O +
phosphorylation O +
and O +
hence O +
its O +
translocation O +
to O +
the O +
nucleus O +
. O +

These O +
results O +
demonstrate O +
that O +
the O +
DNA O +
binding O +
activity O +
of O +
STAT3 O +
can O +
be O +
modulated O +
by O +
oxidizing O +
agents O +
and O +
provide O +
a O +
framework O +
to O +
understand O +
the O +
effects O +
of O +
oxidative O +
stress O +
on O +
the O +
JAK O +
-STAT O +
signaling O +
pathway O +
. O +

Human O +
alveolar O +
macrophages O +
are O +
markedly O +
deficient O +
in O +
REF-1 O +
and O +
AP-1 O +
DNA O +
binding O +
activity O +
. O +

Although O +
many O +
functions O +
of O +
human O +
alveolar O +
macrophages O +
are O +
altered O +
compared O +
with O +
their O +
precursor O +
cell O +
, O +
the O +
blood O +
monocyte O +
( O +
monocyte O +
) O +
, O +
the O +
reason O +
( O +
s O +
) O +
for O +
these O +
functional O +
changes O +
have O +
not O +
been O +
determined O +
. O +

We O +
recently O +
reported O +
that O +
human O +
alveolar O +
macrophages O +
do O +
not O +
express O +
AP-1 O +
DNA O +
binding O +
activity O +
( O +
Monick O +
, O +
M. O +
M. O +
, O +
Carter O +
, O +
A. O +
B. O +
, O +
Gudmundsson O +
, O +
G. O +
, O +
Geist O +
, O +
L. O +
J. O +
, O +
and O +
Hunninghake O +
, O +
G. O +
W. O +
( O +
1998 O +
) O +
Am O -
. O +
J. O +
Physiol O -
. O +
275 O +
, O +
L389-L397 O +
) O +
. O +

To O +
determine O +
why O +
alveolar O +
macrophages O +
do O +
not O +
express O +
AP-1 O +
DNA O +
binding O +
activity O +
, O +
we O +
first O +
showed O +
that O +
there O +
was O +
not O +
a O +
decrease O +
in O +
expression O +
of O +
the O +
FOS O +
and O +
JUN O +
proteins O +
that O +
make O +
up O +
the O +
AP-1 O +
complex O +
. O +

There O +
was O +
, O +
however O +
, O +
a O +
significant O +
difference O +
in O +
the O +
amounts O +
of O +
the O +
nuclear O +
protein O +
, O +
REF-1 O +
( O +
which O +
regulates O +
AP-1 O +
DNA O +
binding O +
by O +
altering O +
the O +
redox O +
status O +
of O +
FOS O +
and O +
JUN O +
proteins O +
) O +
, O +
in O +
alveolar O +
macrophages O +
compared O +
with O +
monocytes O +
. O +

In O +
addition O +
, O +
in O +
vitro O +
differentiation O +
of O +
monocytes O +
to O +
a O +
macrophage O -
- O -
like O +
cell O +
resulted O +
in O +
decreased O +
amounts O +
of O +
REF-1 O +
. O +

Finally O +
, O +
addition O +
of O +
REF-1 O +
from O +
activated O +
monocytes O +
to O +
alveolar O +
macrophage O +
nuclear O +
proteins O +
resulted O +
in O +
a O +
marked O +
increase O +
in O +
AP-1 O +
DNA O +
binding O +
. O +

These O +
studies O +
strongly O +
suggest O +
that O +
the O +
process O +
of O +
differentiation O +
of O +
monocytes O +
into O +
alveolar O +
macrophages O +
is O +
associated O +
with O +
a O +
loss O +
of O +
REF-1 O +
and O +
AP-1 O +
activity O +
. O +

This O +
observation O +
may O +
explain O +
, O +
in O +
part O +
, O +
some O +
of O +
the O +
functional O +
differences O +
observed O +
for O +
alveolar O +
macrophages O +
compared O +
with O +
monocytes O +
. O +

Binding O +
characteristics O +
of O +
the O +
glucocorticoid O +
receptor O +
in O +
peripheral O +
blood O +
lymphocytes O +
in O +
multiple O +
sclerosis O +
. O +

Although O +
the O +
exact O +
etiology O +
of O +
multiple O +
sclerosis O +
( O +
MS O +
) O +
remains O +
unresolved O +
, O +
immune O +
reactions O +
are O +
believed O +
to O +
be O +
the O +
central O +
pathogenic O +
mechanisms O +
. O +

Endogenous O +
and O +
therapeutic O +
steroid O +
hormones O +
affect O +
the O +
immune O +
system O +
, O +
and O +
inflammatory O +
diseases O +
are O +
associated O +
with O +
activation O +
of O +
the O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenal O +
axis O +
, O +
providing O +
evidence O +
of O +
an O +
immune O -
- O -
endocrine O +
interplay O +
. O +

Function O +
tests O +
in O +
MS O +
have O +
revealed O +
dysregulation O +
of O +
the O +
hypothalamic O -
- O -
pituitary O -
- O -
adrenal O +
system O +
in O +
a O +
substantial O +
proportion O +
of O +
patients O +
. O +

We O +
characterized O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
binding O +
in O +
peripheral O +
blood O +
lymphocytes O +
from O +
39 O +
MS O +
patients O +
and O +
14 O +
age- O +
and O +
sex O -
- O -
matched O +
controls O +
with O +
respect O +
to O +
dissociation O +
constant O +
and O +
binding O +
capacity O +
, O +
using O +
a O +
whole O -
- O -
cell O +
binding O +
assay O +
with O +
[ O +
3H O +
] O +
dexamethasone O +
as O +
the O +
ligand O +
. O +

GR O +
binding O +
parameters O +
did O +
not O +
differ O +
significantly O +
between O +
patients O +
( O +
Kd O +
8.98 O +
+ O -
/- O +
1.07 O +
nM O +
, O +
Bmax O +
183 O +
+ O -
/- O +
29.8 O +
fmol O -
/ O -
mg O +
) O +
and O +
controls O +
( O +
Kd O +
9.36 O +
+ O -
/- O +
1.17 O +
nM O +
, O +
Bmax O +
158 O +
+ O -
/- O +
16 O +
fmol O -
/ O -
mg O +
) O +
. O +

No O +
effect O +
of O +
age O +
, O +
sex O +
, O +
course O +
, O +
duration O +
or O +
severity O +
of O +
disease O +
, O +
or O +
prior O +
steroid O +
treatments O +
was O +
detected O +
. O +

GR O +
binding O +
parameters O +
were O +
analyzed O +
in O +
relation O +
to O +
the O +
results O +
of O +
the O +
combined O +
dexamethasone O +
-CRH O +
test O +
, O +
which O +
reflects O +
corticosteroid O +
receptor O +
function O +
at O +
the O +
hypothalamus O +
, O +
in O +
30 O +
patients O +
and O +
9 O +
controls O +
. O +

While O +
controls O +
showed O +
a O +
moderate O +
correlation O +
between O +
binding O +
affinity O +
of O +
the O +
GR O +
in O +
lymphocytes O +
and O +
regulatory O +
function O +
at O +
the O +
hypothalamic O +
level O +
, O +
the O +
patients O +
did O +
not O +
. O +

These O +
data O +
suggest O +
that O +
the O +
physiological O +
relationship O +
between O +
binding O +
and O +
function O +
of O +
the O +
glucocorticoid O +
receptor O +
is O +
disturbed O +
in O +
MS O +
. O +

Association O +
of O +
the O +
interleukin-4 O +
receptor O +
alpha O +
chain O +
with O +
p47phox O +
, O +
an O +
activator O +
of O +
the O +
phagocyte O +
NADPH O +
oxidase O +
in O +
B O +
cells O +
. O +

Interleukin O +
( O +
IL O +
) O +
-4 O +
plays O +
an O +
important O +
role O +
in O +
IgE O +
synthesis O +
in O +
B O +
cells O +
and O +
in O +
Th2 O +
differentiation O +
in O +
T B-CellLine +
cells I-CellLine +
. O +

IL-4 O +
conducts O +
its O +
biological O +
activities O +
through O +
binding O +
to O +
the O +
IL-4 O +
receptor O +
( O +
IL-4R O +
) O +
on O +
the O +
surface O +
of O +
target O +
cells O +
. O +

IL-4R O +
are O +
thought O +
to O +
be O +
composed O +
of O +
the O +
IL-4R O +
alpha O +
chain O +
( O +
IL-4R O +
alpha O +
) O +
and O +
either O +
the O +
IL-2R O +
gamma O +
chain O +
or O +
the O +
IL-13R O +
alpha O +
chain O +
. O +

We O +
have O +
previously O +
shown O +
that O +
the O +
membrane O -
- O -
proximal O +
portion O +
in O +
the O +
cytoplasmic O +
domain O +
of O +
the O +
human O +
IL-4R O +
alpha O +
( O +
hIL-4R O +
alpha O +
) O +
is O +
critical O +
for O +
proliferation O +
, O +
generation O +
of O +
germline O +
epsilon O +
transcript O +
, O +
and O +
activation O +
of O +
STAT6 O +
, O +
based O +
on O +
analyses O +
of O +
truncated O +
hIL-4R O +
alphas O +
. O +

In O +
this O +
study O +
, O +
we O +
found O +
that O +
p47phox O +
, O +
an O +
activator O +
of O +
the O +
phagocyte O +
NADPH O +
oxidase O +
, O +
binds O +
to O +
this O +
portion O +
by O +
the O +
two O -
- O -
hybrid O +
system O +
. O +

Furthermore O +
, O +
we O +
observed O +
the O +
association O +
of O +
p47phox O +
with O +
the O +
hIL-4R O +
alpha O +
in O +
B O +
cells O +
derived O +
from O +
a O +
normal O +
donor O +
. O +

These O +
results O +
suggest O +
that O +
p47phox O +
is O +
involved O +
in O +
the O +
signal O +
transduction O +
of O +
IL-4 O +
in O +
B O +
cells O +
. O +

However O +
, O +
activation O +
of O +
STAT6 O +
, O +
CD23 O +
expression O +
, O +
and O +
IgE O +
synthesis O +
induced O +
by O +
IL-4 O +
were O +
not O +
affected O +
in O +
p47phox O -
- O -
deficient O +
patients O +
, O +
which O +
raises O +
the O +
possibility O +
that O +
p47phox O +
may O +
be O +
important O +
in O +
other O +
signaling O +
activities O +
as O +
well O +
in O +
B O +
cells O +
. O +

Monocyte O +
adhesion O +
and O +
spreading O +
on O +
human O +
endothelial O +
cells O +
is O +
dependent O +
on O +
Rho O +
-regulated O +
receptor O +
clustering O +
. O +

The O +
GTPase O +
Rho O +
is O +
known O +
to O +
mediate O +
the O +
assembly O +
of O +
integrin O -
- O -
containing O +
focal O +
adhesions O +
and O +
actin O +
stress O +
fibers O +
. O +

Here O +
, O +
we O +
investigate O +
the O +
role O +
of O +
Rho O +
in O +
regulating O +
the O +
distribution O +
of O +
the O +
monocyte O -
- O -
binding O +
receptors O +
E O -
- O -
selectin O +
, O +
ICAM-1 O +
, O +
and O +
VCAM-1 O +
in O +
human O +
endothelial O +
cells O +
. O +

Inhibition O +
of O +
Rho O +
activity O +
with O +
C3 O +
transferase O +
or O +
N19RhoA O +
, O +
a O +
dominant O +
negative O +
RhoA O +
mutant O +
, O +
reduced O +
the O +
adhesion O +
of O +
monocytes O +
to O +
activated O +
endothelial O +
cells O +
and O +
inhibited O +
their O +
spreading O +
. O +

Similar O +
effects O +
were O +
observed O +
after O +
pretreatment O +
of O +
endothelial O +
cells O +
with O +
cytochalasin O +
D O +
. O +

In O +
contrast O +
, O +
dominant O +
negative O +
Rac O +
and O +
Cdc42 O +
proteins O +
did O +
not O +
affect O +
monocyte O +
adhesion O +
or O +
spreading O +
. O +

C3 O +
transferase O +
and O +
cytochalasin O +
D O +
did O +
not O +
alter O +
the O +
expression O +
levels O +
of O +
monocyte O -
- O -
binding O +
receptors O +
on O +
endothelial O +
cells O +
, O +
but O +
did O +
inhibit O +
clustering O +
of O +
E O -
- O -
selectin O +
, O +
ICAM-1 O +
, O +
and O +
VCAM-1 O +
on O +
the O +
cell O +
surface O +
induced O +
by O +
monocyte O +
adhesion O +
or O +
cross O -
- O -
linking O +
antibodies O +
. O +

Similarly O +
, O +
N19RhoA O +
inhibited O +
receptor O +
clustering O +
. O +

Monocyte O +
adhesion O +
and O +
receptor O +
cross O -
- O -
linking O +
induced O +
stress O +
fiber O +
assembly O +
, O +
and O +
inhibitors O +
of O +
myosin O +
light O +
chain O +
kinase O +
prevented O +
this O +
response O +
but O +
did O +
not O +
affect O +
receptor O +
clustering O +
. O +

Finally O +
, O +
receptor O +
clusters O +
colocalized O +
with O +
ezrin O -
/ O -
moesin O -
/ O -
radixin O +
proteins O +
. O +

These O +
results O +
suggest O +
that O +
Rho O +
is O +
required O +
in O +
endothelial O +
cells O +
for O +
the O +
assembly O +
of O +
stable O +
adhesions O +
with O +
monocytes O +
via O +
the O +
clustering O +
of O +
monocyte O -
- O -
binding O +
receptors O +
and O +
their O +
association O +
with O +
the O +
actin O +
cytoskeleton O +
, O +
independent O +
of O +
stress O +
fiber O +
formation O +
. O +

Aiolos O +
transcription O +
factor O +
controls O +
cell O +
death O +
in O +
T O +
cells O +
by O +
regulating O +
Bcl-2 O +
expression O +
and O +
its O +
cellular O +
localization O +
. O +

We O +
searched O +
for O +
proteins O +
that O +
interact O +
with O +
Ras O +
in O +
interleukin B-CellLine +
( I-CellLine +
IL I-CellLine +
) I-CellLine +
-2-stimulated I-CellLine +
or I-CellLine +
IL-2-deprived I-CellLine +
cells I-CellLine +
, O +
and O +
found O +
that O +
the O +
transcription O +
factor O +
Aiolos O +
interacts O +
with O +
Ras O +
. O +

The O +
Ras O +
-Aiolos O +
interaction O +
was O +
confirmed O +
in O +
vitro O +
and O +
in O +
vivo O +
by O +
co O -
- O -
immunoprecipitation O +
. O +

Indirect O +
immunofluorescence O +
shows O +
that O +
IL-2 O +
controls O +
the O +
cellular O +
distribution O +
of O +
Aiolos O +
and O +
induces O +
its O +
tyrosine O +
phosphorylation O +
, O +
required O +
for O +
dissociation O +
from O +
Ras O +
. O +

We O +
also O +
identified O +
functional O +
Aiolos O -
- O -
binding O +
sites O +
in O +
the O +
Bcl-2 O +
promoter O +
, O +
which O +
are O +
able O +
to O +
activate O +
the O +
luciferase O +
reporter O +
gene O +
. O +

Mutation O +
of O +
Aiolos O -
- O -
binding O +
sites O +
within O +
the O +
Bcl-2 O +
promoter O +
inhibits O +
transactivation O +
of O +
the O +
reporter O +
gene O +
luciferase O +
, O +
suggesting O +
direct O +
control O +
of O +
Bcl-2 O +
expression O +
by O +
Aiolos O +
. O +

Co O -
- O -
transfection O +
experiments O +
confirm O +
that O +
Aiolos O +
induces O +
Bcl-2 O +
expression O +
and O +
prevents O +
apoptosis O +
in O +
IL-2-deprived B-CellLine +
cells I-CellLine +
. O +

We O +
propose O +
a O +
model O +
for O +
the O +
regulation O +
of O +
Bcl-2 O +
expression O +
via O +
Aiolos O +
. O +

C O -
/ O -
EBP O +
beta O +
in O +
rheumatoid O +
arthritis O +
: O +
correlation O +
with O +
inflammation O +
, O +
not O +
disease O +
specificity O +
. O +

Rheumatoid O +
arthritis O +
synovial O +
tissue O +
was O +
examined O +
and O +
compared O +
with O +
osteoarthritis O +
tissue O +
for O +
the O +
presence O +
of O +
the O +
nuclear O +
transcription O +
factor O +
C O -
/ O -
EBP O +
beta O +
( O +
NF O -
- O -
IL-6 O +
) O +
. O +

The O +
region O +
( O +
lining O +
or O +
sublining O +
) O +
, O +
cell O +
type O +
, O +
and O +
subcellular O +
distribution O +
( O +
cytoplasmic O +
or O +
nuclear O +
) O +
of O +
the O +
expression O +
of O +
C O -
/ O -
EBP O +
beta O +
was O +
characterized O +
. O +

Rheumatoid O +
arthritis O +
synovial O +
fluid O +
and O +
blood O +
and O +
normal O +
peripheral O +
blood O +
were O +
also O +
examined O +
. O +

C O -
/ O -
EBP O +
beta O +
was O +
detected O +
in O +
the O +
synovial O +
lining O +
and O +
in O +
sublining O +
cells O +
of O +
synovial O +
tissue O +
from O +
patients O +
with O +
both O +
rheumatoid O +
and O +
osteoarthritis O +
. O +

A O +
significant O +
( O +
P O +
< O +
0.001 O +
and O +
< O +
0.05 O +
, O +
respectively O +
) O +
increase O +
in O +
the O +
percentage O +
of O +
cells O +
with O +
nuclear O +
staining O +
was O +
seen O +
in O +
the O +
lining O +
layer O +
, O +
compared O +
to O +
cells O +
in O +
the O +
sublining O +
region O +
, O +
in O +
rheumatoid O +
and O +
osteoarthritis O +
. O +

In O +
both O +
diseases O +
a O +
strong O +
correlation O +
( O +
r O +
= O +
0.79 O +
, O +
P O +
< O +
0.001 O +
) O +
was O +
observed O +
between O +
the O +
percentage O +
of O +
cells O +
in O +
the O +
synovial O +
lining O +
that O +
were O +
positive O +
for O +
nuclear O +
C O -
/ O -
EBP O +
beta O +
and O +
lining O +
cell O +
depth O +
. O +

Two O -
- O -
color O +
immunohistochemistry O +
demonstrated O +
that O +
both O +
macrophages O +
and O +
fibroblast O -
- O -
like O +
synoviocytes O +
were O +
positive O +
for O +
nuclear O +
C O -
/ O -
EBP O +
beta O +
. O +

The O +
presence O +
of O +
C O -
/ O -
EBP O +
beta O +
was O +
confirmed O +
by O +
immunohistochemistry O +
and O +
Western O +
blot O +
analysis O +
with O +
isolated O +
synovial O +
fibroblasts O +
. O +

Nuclear O +
C O -
/ O -
EBP O +
beta O +
was O +
also O +
detected O +
in O +
rheumatoid O +
synovial O +
fluid O +
monocytes O -
/ O -
macrophages O +
, O +
but O +
not O +
in O +
lymphocytes O +
or O +
neutrophils O +
. O +

Western O +
blot O +
analysis O +
confirmed O +
the O +
presence O +
of O +
C O -
/ O -
EBP O +
beta O +
in O +
these O +
cells O +
. O +

The O +
intensity O +
of O +
C O -
/ O -
EBP O +
beta O +
staining O +
was O +
greater O +
( O +
P O +
< O +
0.001 O +
) O +
in O +
synovial O +
fluid O +
monocytes O +
than O +
in O +
those O +
from O +
normal O +
or O +
rheumatoid O +
peripheral O +
blood O +
. O +

In O +
conclusion O +
, O +
the O +
enhanced O +
nuclear O +
staining O +
for O +
C O -
/ O -
EBP O +
beta O +
in O +
the O +
synovial O +
lining O +
, O +
compared O +
to O +
the O +
sublining O +
, O +
suggesting O +
activation O +
in O +
the O +
lining O +
, O +
and O +
the O +
positive O +
correlation O +
of O +
lining O +
layer O +
depth O +
with O +
the O +
percentage O +
of O +
cells O +
in O +
the O +
lining O +
positive O +
for O +
nuclear O +
C O -
/ O -
EBP O +
beta O +
, O +
suggest O +
a O +
potential O +
role O +
for O +
C O -
/ O -
EBP O +
beta O +
in O +
chronic O +
inflammation O +
. O +

The O +
regulation O +
of O +
the O +
production O +
or O +
activity O +
of O +
C O -
/ O -
EBP O +
beta O +
, O +
to O +
inhibit O +
inflammatory O +
mediator O +
expression O +
by O +
synovial O +
macrophages O +
and O +
fibroblasts O +
, O +
offers O +
a O +
novel O +
approach O +
to O +
therapeutic O +
intervention O +
. O +

The O +
role O +
of O +
gamma O -
/ O -
delta O +
T O +
cell O +
receptor O +
positive O +
cells O +
in O +
pregnancy O +
. O +

PROBLEM O +
: O +
Due O +
to O +
the O +
lack O +
of O +
classical O +
HLA O +
antigens O +
on O +
the O +
trophoblast O +
, O +
fetal O +
antigens O +
are O +
possibly O +
presented O +
in O +
a O +
non O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
restricted O +
way O +
. O +

Decidual O +
gammadelta O +
T O +
cells O +
, O +
which O +
significantly O +
increase O +
in O +
number O +
during O +
pregnancy O +
, O +
might O +
play O +
a O +
role O +
in O +
recognition O +
of O +
fetal O +
antigens O +
and O +
also O +
in O +
determining O +
the O +
quality O +
of O +
the O +
response O +
to O +
these O +
antigens O +
. O +

Our O +
study O +
was O +
aimed O +
at O +
investigating O +
the O +
role O +
of O +
this O +
cell O +
population O +
in O +
progesterone O -
- O -
dependent O +
immunomodulation O +
. O +

METHOD O +
OF O +
STUDY O +
: O +
Peripheral O +
lymphocytes O +
from O +
healthy O +
pregnant O +
women O +
and O +
from O +
habitual O +
aborters O +
were O +
tested O +
by O +
immunocytochemistry O +
for O +
the O +
presence O +
of O +
gamma O -
/ O -
delta O +
T O +
cell O +
receptor O +
( O +
TCR O +
) O +
and O +
progesterone O +
receptor O +
. O +

To O +
investigate O +
the O +
effect O +
of O +
treatment O +
with O +
a O +
pan O +
anti O +
gamma O -
/ O -
delta O +
antibody O +
, O +
lymphocytes O +
were O +
incubated O +
for O +
3 O +
hr O +
with O +
the O +
antibody O +
, O +
and O +
then O +
interleukin O +
( O +
IL O +
) O +
-10 O +
, O +
IL-12 O +
and O +
progesterone O -
- O -
induced O +
blocking O +
factor O +
( O +
PIBF O +
) O +
expression O +
( O +
by O +
immuno O -
- O -
cytochemistry O +
) O +
as O +
well O +
as O +
natural O +
killer O +
( O +
NK O +
) O +
cell O +
activity O +
were O +
determined O +
. O +

RESULTS O +
: O +
In O +
peripheral O +
blood O +
of O +
healthy O +
pregnant O +
women O +
the O +
percentage O +
of O +
gamma O -
/ O -
delta O +
TCR+ O +
cells O +
was O +
significantly O +
higher O +
( O +
P O +
< O +
0.001 O +
) O +
than O +
in O +
that O +
of O +
recurrent O +
aborters O +
or O +
of O +
non O -
- O -
pregnant O +
individuals O +
. O +

Ninety O -
- O -
seven O +
percent O +
of O +
gamma O -
/ O -
delta O +
TCR+ O +
pregnancy O +
lymphocytes O +
expressed O +
progesterone O +
receptor O +
. O +

Binding O +
of O +
a O +
specific O +
antibody O +
to O +
the O +
gamma O -
/ O -
delta O +
TCR O +
inhibited O +
PIBF O +
-as O +
well O +
as O +
IL-10 O +
production O +
, O +
whereas O +
it O +
increased O +
NK O +
activity O +
and O +
IL-12 O +
expression O +
. O +

CONCLUSIONS O +
: O +
These O +
data O +
suggest O +
the O +
role O +
of O +
gamma O -
/ O -
delta O +
TCR O -
- O -
bearing O +
lymphocytes O +
in O +
progesterone O -
- O -
dependent O +
immunomodulation O +
. O +

SOCS-3 O +
is O +
tyrosine O +
phosphorylated O +
in O +
response O +
to O +
interleukin-2 O +
and O +
suppresses O +
STAT5 O +
phosphorylation O +
and O +
lymphocyte O +
proliferation O +
. O +

Members O +
of O +
the O +
recently O +
discovered O +
SOCS O -
/ O -
CIS O -
/ O -
SSI O +
family O +
have O +
been O +
proposed O +
as O +
regulators O +
of O +
cytokine O +
signaling O +
, O +
and O +
while O +
targets O +
and O +
mechanisms O +
have O +
been O +
suggested O +
for O +
some O +
family O +
members O +
, O +
the O +
precise O +
role O +
of O +
these O +
proteins O +
remains O +
to O +
be O +
defined O +
. O +

To O +
date O +
no O +
SOCS O +
proteins O +
have O +
been O +
specifically O +
implicated O +
in O +
interleukin-2 O +
( O +
IL-2 O +
) O +
signaling O +
in O +
T O +
cells O +
. O +

Here O +
we O +
report O +
SOCS-3 O +
expression O +
in O +
response O +
to O +
IL-2 O +
in O +
both O +
T B-CellLine -
- I-CellLine -
cell I-CellLine +
lines I-CellLine +
and O +
human O +
peripheral O +
blood O +
lymphocytes O +
. O +

SOCS-3 O +
protein O +
was O +
detectable O +
as O +
early O +
as O +
30 O +
min O +
following O +
IL-2 O +
stimulation O +
, O +
while O +
CIS O +
was O +
seen O +
only O +
at O +
low O +
levels O +
after O +
2 O +
h O +
. O +

Unlike O +
CIS O +
, O +
SOCS-3 O +
was O +
rapidly O +
tyrosine O +
phosphorylated O +
in O +
response O +
to O +
IL-2 O +
. O +

Tyrosine O +
phosphorylation O +
of O +
SOCS-3 O +
was O +
observed O +
upon O +
coexpression O +
with O +
Jak1 O +
and O +
Jak2 O +
but O +
only O +
weakly O +
with O +
Jak3 O +
. O +

In O +
these O +
experiments O +
, O +
SOCS-3 O +
associated O +
with O +
Jak1 O +
and O +
inhibited O +
Jak1 O +
phosphorylation O +
, O +
and O +
this O +
inhibition O +
was O +
markedly O +
enhanced O +
by O +
the O +
presence O +
of O +
IL-2 O +
receptor O +
beta O +
chain O +
( O +
IL-2Rbeta O +
) O +
. O +

Moreover O +
, O +
following O +
IL-2 O +
stimulation O +
of O +
T O +
cells O +
, O +
SOCS-3 O +
was O +
able O +
to O +
interact O +
with O +
the O +
IL-2 O +
receptor O +
complex O +
, O +
and O +
in O +
particular O +
tyrosine O +
phosphorylated O +
Jak1 O +
and O +
IL-2Rbeta O +
. O +

Additionally O +
, O +
in O +
lymphocytes O +
expressing O +
SOCS-3 O +
but O +
not O +
CIS O +
, O +
IL-2 O +
-induced O +
tyrosine O +
phosphorylation O +
of O +
STAT5b O +
was O +
markedly O +
reduced O +
, O +
while O +
there O +
was O +
only O +
a O +
weak O +
effect O +
on O +
IL-3-mediated O +
STAT5b O +
tyrosine O +
phosphorylation O +
. O +

Finally O +
, O +
proliferation O +
induced O +
by O +
both O +
IL-2 O +
-and O +
IL-3 O +
was O +
significantly O +
inhibited O +
in O +
the O +
presence O +
of O +
SOCS-3 O +
. O +

The O +
findings O +
suggest O +
that O +
when O +
SOCS-3 O +
is O +
rapidly O +
induced O +
by O +
IL-2 O +
in O +
T O +
cells O +
, O +
it O +
acts O +
to O +
inhibit O +
IL-2 O +
responses O +
in O +
a O +
classical O +
negative O +
feedback O +
loop O +
. O +

Downregulation O +
of O +
Wilms O +
' O +
tumor O +
gene O +
( O +
WT1 O +
) O +
is O +
not O +
a O +
prerequisite O +
for O +
erythroid O +
or O +
megakaryocytic O +
differentiation O +
of O +
the O +
leukemic B-CellLine +
cell I-CellLine +
line I-CellLine +
K562 I-CellLine +
. O +

The O +
Wilms O +
' O +
tumor O +
gene O +
( O +
WT1 O +
) O +
encodes O +
a O +
transcription O +
factor O +
of O +
the O +
zinc O +
finger O +
type O +
. O +

A O +
high O +
expression O +
of O +
WT1 O +
has O +
been O +
detected O +
in O +
a O +
range O +
of O +
acute O +
leukemias O +
, O +
and O +
WT1 O +
is O +
downregulated O +
during O +
induced O +
differentiation O +
of O +
some O +
leukemic B-CellLine +
cell I-CellLine +
lines I-CellLine +
. O +

Overexpression O +
of O +
WT1 O +
in O +
some O +
myeloid B-CellLine +
cell I-CellLine +
lines I-CellLine +
confers O +
resistance O +
to O +
differentiation O +
induction O +
. O +

These O +
observations O +
suggest O +
that O +
a O +
high O +
WT1 O +
expression O +
in O +
hematopoietic O +
cells O +
is O +
incompatible O +
with O +
differentiation O +
. O +

In O +
this O +
study O +
, O +
each O +
of O +
the O +
four O +
different O +
isoforms O +
of O +
WT1 O +
was O +
constitutively O +
overexpressed O +
in O +
the O +
leukemic B-CellLine +
cell I-CellLine +
line I-CellLine +
K562 I-CellLine +
. O +

K562 B-CellLine +
cells I-CellLine +
express O +
endogenous O +
WT1 O +
, O +
which O +
is O +
downregulated O +
as O +
a O +
response O +
to O +
induced O +
differentiation O +
along O +
the O +
erythroid O +
and O +
megakaryocytic O +
pathways O +
. O +

We O +
now O +
demonstrate O +
that O +
a O +
forced O +
exogenous O +
expression O +
of O +
the O +
four O +
different O +
isoforms O +
of O +
WT1 O +
in O +
K562 B-CellLine +
does O +
not O +
affect O +
the O +
differentiation O +
response O +
, O +
as O +
judged O +
by O +
accumulation O +
of O +
hemoglobin O +
in O +
response O +
to O +
hemin O +
or O +
the O +
expression O +
of O +
megakaryocytic O +
cell O +
surface O +
markers O +
in O +
response O +
to O +
12-O O -
- O -
tetradecanoylphorbol-13-acetate O +
( O +
TPA O +
) O +
. O +

We O +
conclude O +
that O +
downregulation O +
of O +
WT1 O +
during O +
induced O +
differentiation O +
of O +
K562 B-CellLine +
cells I-CellLine +
is O +
not O +
a O +
prerequisite O +
for O +
erythroid O +
or O +
megakaryocytic O +
differentiation O +
of O +
these O +
cells O +
. O +

Tyrphostin O +
AG-490 O +
inhibits O +
cytokine O -
- O -
mediated O +
JAK3 O +
/STAT5a O -
/ O -
b O +
signal O +
transduction O +
and O +
cellular O +
proliferation O +
of O +
antigen O -
- O -
activated O +
human O +
T O +
cells O +
. O +

Janus O +
kinase O +
3 O +
( O +
JAK3 O +
) O +
is O +
a O +
cytoplasmic O +
tyrosine O +
kinase O +
required O +
for O +
T O +
cell O +
development O +
and O +
activated O +
by O +
cytokines O +
that O +
utilize O +
the O +
interleukin-2 O +
( O +
IL-2 O +
) O +
receptor O +
common O +
gamma O +
chain O +
( O +
gamma O +
( O +
c O +
) O +
) O +
. O +

Genetic O +
inactivation O +
of O +
JAK3 O +
is O +
manifested O +
as O +
severe O +
combined O +
immunodeficiency O +
disease O +
( O +
SCID O +
) O +
in O +
humans O +
and O +
mice O +
. O +

These O +
findings O +
have O +
suggested O +
that O +
JAK3 O +
represents O +
a O +
pharmacological O +
target O +
to O +
control O +
certain O +
lymphoid O -
- O -
derived O +
diseases O +
. O +

Here O +
we O +
provide O +
novel O +
evidence O +
that O +
AG-490 O +
potently O +
inhibits O +
the O +
autokinase O +
activity O +
of O +
JAK3 O +
and O +
tyrosine O +
phosphorylation O +
and O +
DNA O +
binding O +
of O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
5a O +
and O +
5b O +
( O +
STAT5a O -
/ O -
b O +
) O +
. O +

Similar O +
inhibitory O +
effects O +
were O +
observed O +
with O +
other O +
cytokines O +
that O +
use O +
gamma O +
( O +
c O +
) O +
. O +

AG-490 O +
also O +
inhibited O +
IL-2 O +
-mediated O +
proliferative O +
growth O +
in O +
human O +
T O +
cells O +
with O +
an O +
IC50 O +
) O +
= O +
25 O +
microM O +
that O +
was O +
partially O +
recoverable O +
. O +

Moreover O +
, O +
we O +
demonstrate O +
that O +
this O +
inhibitor O +
prevented O +
tetanus O +
toxoid O +
antigen O -
- O -
specific O +
T O +
cell O +
proliferation O +
and O +
expansion O +
but O +
failed O +
to O +
block O +
activation O +
of O +
Zap70 O +
or O +
p56Lck O +
after O +
anti O -
- O -
CD3 O +
stimulation O +
of O +
human O +
T O +
cells O +
. O +

Taken O +
together O +
, O +
these O +
findings O +
suggest O +
that O +
AG-490 O +
inhibits O +
the O +
JAK3 O +
-mediated O +
Type O +
II O +
signaling O +
pathway O +
but O +
not O +
the O +
T O +
cell O +
receptor O -
- O -
derived O +
Type O +
I O +
pathway O +
and O +
possesses O +
therapeutic O +
potential O +
for O +
T O +
cell O +
-derived O +
pathologies O +
such O +
as O +
graft O -
- O -
versus O -
- O -
host O +
disease O +
, O +
allergy O +
, O +
and O +
autoimmune O +
disorders O +
. O +

GATA-1 O +
and O +
erythropoietin O +
cooperate O +
to O +
promote O +
erythroid O +
cell O +
survival O +
by O +
regulating O +
bcl O -
- O -
xL O +
expression O +
. O +

The O +
transcription O +
factor O +
GATA-1 O +
is O +
essential O +
for O +
normal O +
erythropoiesis O +
. O +

By O +
examining O +
in O +
vitro B-CellLine -
- I-CellLine -
differentiated I-CellLine +
embryonic I-CellLine +
stem I-CellLine +
cells I-CellLine +
, O +
we O +
showed O +
previously O +
that O +
in O +
the O +
absence O +
of O +
GATA-1 O +
, O +
committed B-CellLine +
erythroid I-CellLine +
precursors I-CellLine +
fail O +
to O +
complete O +
maturation O +
and O +
instead O +
undergo O +
apoptosis O +
. O +

The O +
mechanisms O +
by O +
which O +
GATA-1 O +
controls O +
cell O +
survival O +
are O +
unknown O +
. O +

Here O +
we O +
report O +
that O +
in O +
erythroid O +
cells O +
, O +
GATA-1 O +
strongly O +
induces O +
the O +
expression O +
of O +
the O +
anti O -
- O -
apoptotic O +
protein O +
bcl O -
- O -
xL O +
, O +
but O +
not O +
the O +
related O +
proteins O +
bcl-2 O +
and O +
mcl-1 O +
. O +

Consistent O +
with O +
a O +
role O +
for O +
bcl O -
- O -
xL O +
in O +
mediating O +
GATA-1 O +
-induced O +
erythroid O +
cell O +
survival O +
, O +
in O +
vitro B-CellLine -
- I-CellLine -
differentiated I-CellLine +
bcl I-CellLine -
- I-CellLine -
xL- I-CellLine -
/ I-CellLine -
- I-CellLine +
embryonic I-CellLine +
stem I-CellLine +
cells I-CellLine +
fail O +
to O +
generate O +
viable O +
mature O +
definitive O +
erythroid O +
cells O +
, O +
a O +
phenotype O +
resembling O +
that O +
of O +
GATA-1 O +
gene O +
disruption O +
. O +

In O +
addition O +
, O +
we O +
show O +
that O +
erythropoietin O +
, O +
which O +
is O +
also O +
required O +
for O +
erythroid O +
cell O +
survival O +
, O +
cooperates O +
with O +
GATA-1 O +
to O +
stimulate O +
bcl O -
- O -
xL O +
gene O +
expression O +
and O +
to O +
maintain O +
erythroid O +
cell O +
viability O +
during O +
terminal O +
maturation O +
. O +

Together O +
, O +
our O +
data O +
show O +
that O +
bcl O -
- O -
xL O +
is O +
essential O +
for O +
normal O +
erythroid O +
development O +
and O +
suggest O +
a O +
regulatory O +
hierarchy O +
in O +
which O +
bcl O -
- O -
xL O +
is O +
a O +
critical O +
downstream O +
effector O +
of O +
GATA-1 O +
and O +
erythropoietin O +
-mediated O +
signals O +
. O +

STAT1 O +
activation O +
during O +
monocyte O +
to O +
macrophage O +
maturation O +
: O +
role O +
of O +
adhesion O +
molecules O +
. O +

Human O +
monocytes O +
isolated O +
from O +
peripheral O +
blood O +
of O +
healthy O +
donors O +
show O +
a O +
time O -
- O -
dependent O +
differentiation O +
into O +
macrophages O +
upon O +
in O +
vitro O +
cultivation O +
, O +
closely O +
mimicking O +
their O +
in O +
vivo O +
migration O +
and O +
maturation O +
into O +
extravascular O +
tissues O +
. O +

The O +
mediator O +
( O +
s O +
) O +
of O +
this O +
maturation O +
process O +
has O +
not O +
been O +
yet O +
defined O +
. O +

We O +
investigated O +
the O +
involvement O +
of O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
STAT O +
) O +
factors O +
in O +
this O +
phenomenon O +
and O +
reported O +
the O +
specific O +
, O +
time O -
- O -
dependent O +
, O +
activation O +
of O +
STAT1 O +
protein O +
starting O +
at O +
day O +
0 O -
/ O -
1 O +
of O +
cultivation O +
and O +
maximally O +
expressed O +
at O +
day O +
5 O +
. O +

STAT1 O +
activity O +
was O +
evident O +
on O +
the O +
STAT O +
binding O +
sequences O +
( O +
SBE O +
) O +
present O +
in O +
the O +
promoters O +
of O +
genes O +
which O +
are O +
up O -
- O -
regulated O +
during O +
monocyte O +
to O +
macrophage O +
maturation O +
such O +
as O +
FcgammaRI O +
and O +
ICAM-1 O +
, O +
and O +
in O +
the O +
promoter O +
of O +
the O +
transcription O +
factor O +
IFN O +
regulatory O +
factor-1 O +
. O +

Moreover O +
, O +
the O +
effect O +
of O +
cell O +
adhesion O +
to O +
fibronectin O +
or O +
laminin O +
was O +
studied O +
to O +
investigate O +
mechanisms O +
involved O +
in O +
STAT1 O +
activation O +
. O +

Compared O +
with O +
monocytes O +
adherent O +
on O +
plastic O +
surfaces O +
, O +
freshly O +
isolated O +
cells O +
allowed O +
to O +
adhere O +
either O +
to O +
fibronectin- O +
or O +
laminin O -
- O -
coated O +
flasks O +
exhibited O +
an O +
increased O +
STAT1 O +
binding O +
activity O +
both O +
in O +
control O +
and O +
in O +
IFN B-CellLine -
- I-CellLine -
gamma I-CellLine -
- I-CellLine -
treated I-CellLine +
cells I-CellLine +
. O +

The O +
molecular O +
events O +
leading O +
to O +
enhanced O +
STAT1 O +
activation O +
and O +
cytokine O +
responsiveness O +
concerned O +
both O +
Y701 O +
and O +
S727 O +
STAT1 O +
phosphorylation O +
. O +

Exogenous O +
addition O +
of O +
transforming O +
growth O +
factor O -
- O -
beta O +
, O +
which O +
exerts O +
an O +
inhibitory O +
effect O +
on O +
some O +
monocytic O +
differentiation O +
markers O +
, O +
inhibited O +
macrophage O +
maturation O +
, O +
integrin O +
expression O +
and O +
STAT1 O +
binding O +
activity O +
. O +

Taken O +
together O +
these O +
results O +
indicate O +
that O +
STAT1 O +
plays O +
a O +
pivotal O +
role O +
in O +
the O +
differentiation O -
/ O -
maturation O +
process O +
of O +
monocytes O +
as O +
an O +
early O +
transcription O +
factor O +
initially O +
activated O +
by O +
adherence O +
and O +
then O +
able O +
to O +
modulate O +
the O +
expression O +
of O +
functional O +
genes O +
, O +
such O +
as O +
ICAM-1 O +
and O +
FcgammaRI O +
. O +

3-deazaadenosine O +
, O +
a O +
S O -
- O -
adenosylhomocysteine O +
hydrolase O +
inhibitor O +
, O +
has O +
dual O +
effects O +
on O +
NF O -
- O -
kappaB O +
regulation O +
. O +

Inhibition O +
of O +
NF O -
- O -
kappaB O +
transcriptional O +
activity O +
and O +
promotion O +
of O +
IkappaBalpha O +
degradation O +
. O +

Previously O +
we O +
reported O +
that O +
3-deazaadenosine O +
( O +
DZA O +
) O +
, O +
a O +
potent O +
inhibitor O +
and O +
substrate O +
for O +
S O -
- O -
adenosylhomocysteine O +
hydrolase O +
inhibits O +
bacterial O +
lipopolysaccharide O -
- O -
induced O +
transcription O +
of O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
and O +
interleukin-1beta O +
in O +
mouse B-CellLine +
macrophage I-CellLine +
RAW I-CellLine +
264.7 I-CellLine +
cells I-CellLine +
. O +

In O +
this O +
study O +
, O +
we O +
demonstrate O +
the O +
effects O +
of O +
DZA O +
on O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
regulation O +
. O +

DZA O +
inhibits O +
the O +
transcriptional O +
activity O +
of O +
NF O -
- O -
kappaB O +
through O +
the O +
hindrance O +
of O +
p65 O +
( O +
Rel O -
- O -
A O +
) O +
phosphorylation O +
without O +
reduction O +
of O +
its O +
nuclear O +
translocation O +
and O +
DNA O +
binding O +
activity O +
. O +

The O +
inhibitory O +
effect O +
of O +
DZA O +
on O +
NF O -
- O -
kappaB O +
transcriptional O +
activity O +
is O +
potentiated O +
by O +
the O +
addition O +
of O +
homocysteine O +
. O +

Taken O +
together O +
, O +
DZA O +
promotes O +
the O +
proteolytic O +
degradation O +
of O +
IkappaBalpha O +
, O +
but O +
not O +
IkappaBbeta O +
, O +
resulting O +
in O +
an O +
increase O +
of O +
DNA O +
binding O +
activity O +
of O +
NF O -
- O -
kappaB O +
in O +
the O +
nucleus O +
in O +
the O +
absence O +
of O +
its O +
transcriptional O +
activity O +
in O +
RAW B-CellLine +
264.7 I-CellLine +
cells I-CellLine +
. O +

The O +
reduction O +
of O +
IkappaBalpha O +
by O +
DZA O +
is O +
neither O +
involved O +
in O +
IkappaB O +
kinase O +
complex O +
activation O +
nor O +
modulated O +
by O +
the O +
addition O +
of O +
homocysteine O +
. O +

This O +
study O +
strongly O +
suggests O +
that O +
DZA O +
may O +
be O +
a O +
potent O +
drug O +
for O +
the O +
treatment O +
of O +
diseases O +
in O +
which O +
NF O -
- O -
kappaB O +
plays O +
a O +
central O +
pathogenic O +
role O +
, O +
as O +
well O +
as O +
a O +
useful O +
tool O +
for O +
studying O +
the O +
regulation O +
and O +
physiological O +
functions O +
of O +
NF O -
- O -
kappaB O +
. O +

Altered O +
memory O +
T O +
cell O +
differentiation O +
in O +
patients O +
with O +
early O +
rheumatoid O +
arthritis O +
. O +

The O +
chronic O +
immune O +
response O +
in O +
rheumatoid O +
arthritis O +
( O +
RA O +
) O +
might O +
be O +
driven O +
by O +
activated O +
Th1 O +
cells O +
without O +
sufficient O +
Th2 O +
cell O +
differentiation O +
to O +
down O -
- O -
modulate O +
inflammation O +
. O +

To O +
test O +
whether O +
disordered O +
memory O +
T O +
cell O +
differentiation O +
contributes O +
to O +
the O +
typical O +
Th1-dominated O +
chronic O +
inflammation O +
in O +
RA O +
we O +
investigated O +
differentiation O +
of O +
resting O +
CD4 O -
+ O +
memory O +
T O +
cells O +
in O +
patients O +
with O +
early O +
( O +
6 O +
wk O +
to O +
12 O +
mo O +
) O +
untreated O +
RA O +
and O +
in O +
age- O +
and O +
sex O -
- O -
matched O +
healthy O +
controls O +
in O +
vitro O +
. O +

No O +
difference O +
in O +
cytokine O +
secretion O +
profiles O +
of O +
freshly O +
isolated O +
memory O +
T O +
cells O +
was O +
detected O +
between O +
patients O +
and O +
controls O +
. O +

A O +
cell B-CellLine +
culture I-CellLine +
system I-CellLine +
was O +
then O +
employed O +
that O +
permitted O +
the O +
differentiation O +
of O +
Th O +
effectors O +
from O +
resting O +
memory O +
T O +
cells O +
by O +
short O +
term O +
priming O +
. O +

Marked O +
differences O +
were O +
found O +
in O +
response O +
to O +
priming O +
. O +

Th2 B-CellLine +
cells I-CellLine +
could O +
be O +
induced O +
in O +
all O +
healthy O +
controls O +
by O +
priming O +
with O +
anti O -
- O -
CD28 O +
in O +
the O +
absence O +
of O +
TCR O +
ligation O +
. O +

By O +
contrast O +
, O +
priming O +
under O +
those O +
conditions O +
resulted O +
in O +
Th2 O +
differentiation O +
in O +
only O +
9 O +
of O +
24 O +
RA O +
patients O +
. O +

Exogenous O +
IL-4 O +
could O +
overcome O +
the O +
apparent O +
Th2 O +
differentiation O +
defect O +
in O +
seven O +
patients O +
but O +
was O +
without O +
effect O +
in O +
the O +
remaining O +
eight O +
patients O +
. O +

In O +
all O +
patients O +
a O +
marked O +
decrease O +
in O +
IL-2-producing O +
cells O +
and O +
a O +
significant O +
increase O +
in O +
well O -
- O -
differentiated O +
Th1 O +
cells O +
that O +
produced O +
IFN O -
- O -
gamma O +
but O +
not O +
IL-2 O +
were O +
evident O +
after O +
priming O +
with O +
anti O -
- O -
CD3 O +
and O +
anti O -
- O -
CD28 O +
. O +

The O +
data O +
suggest O +
that O +
CD4 O -
+ O +
memory O +
T O +
cells O +
from O +
patients O +
with O +
early O +
untreated O +
RA O +
manifest O +
an O +
intrinsic O +
abnormality O +
in O +
their O +
ability O +
to O +
differentiate O +
into O +
specific O +
cytokine O -
- O -
producing O +
effector O +
cells O +
that O +
might O +
contribute O +
to O +
the O +
characteristic O +
Th1-dominated O +
chronic O +
( O +
auto O +
) O +
immune O +
inflammation O +
in O +
RA O +
. O +

Ovarian O +
and O +
breast O +
cytotoxic O +
T O +
lymphocytes O +
can O +
recognize O +
peptides O +
from O +
the O +
amino O +
enhancer O +
of O +
split O +
protein O +
of O +
the O +
Notch O +
complex O +
. O +

In O +
this O +
study O +
we O +
investigated O +
recognition O +
by O +
ovarian O +
tumor O +
associated O +
lymphocyte O +
( O +
OVTAL O +
) O +
, O +
and O +
breast O +
tumor O +
associated O +
lymphocytes O +
( O +
BRTAL O +
) O +
, O +
of O +
peptides O +
corresponding O +
to O +
the O +
sequence O +
125 O -
- O -
135 O +
of O +
the O +
Aminoenhancer O +
of O +
split O +
( O +
AES O +
) O +
protein O +
. O +

Three O +
of O +
these O +
peptides O +
designated O +
as O +
G75 O +
: O +
AES1 O -
/ O -
2 O +
( O +
128 O -
- O -
135 O +
) O +
, O +
G60 O +
: O +
AES1 O -
/ O -
2 O +
( O +
127 O -
- O -
137 O +
) O +
and O +
G61 O +
: O +
AES1 O -
/ O -
2 O +
( O +
125 O -
- O -
133 O +
) O +
correspond O +
to O +
the O +
wildtype O +
AES O +
sequence O +
, O +
while O +
the O +
fourth O +
G76 O +
: O +
GPLTPLPV O +
, O +
AES1 O -
/ O -
2 O +
( O +
128 O -
- O -
135 O +
) O +
corresponds O +
to O +
a O +
variant O +
sequence O +
of O +
the O +
peptide O +
G75 O +
with O +
the O +
N O -
- O -
terminal O +
Leu O +
substituted O +
to O +
glycine O +
. O +

These O +
sequences O +
were O +
chosen O +
for O +
study O +
because O +
mass O -
- O -
spectrometric O +
analysis O +
( O +
MS O +
) O +
of O +
a O +
CTL O +
active O +
HPLC O +
peptide O +
fraction O +
eluted O +
from O +
immunoaffinity O +
precipitated O +
HLA O -
- O -
A2 O +
molecule O +
, O +
revealed O +
: O +
( O +
a O +
) O +
the O +
presence O +
of O +
an O +
ion O +
with O +
a O +
mass O -
- O -
to O -
- O -
charge O +
ratio O +
( O +
m O -
/ O -
z O +
) O +
of O +
793 O +
which O +
was O +
more O +
abundant O +
than O +
other O +
ions O +
of O +
similar O +
masses O +
; O +
( O +
b O +
) O +
the O +
tentatively O +
reconstituted O +
sequence O +
of O +
the O +
ion O +
793 O +
matched O +
the O +
sequence O +
of O +
peptide O +
G76 O +
. O +

We O +
found O +
that O +
AES O +
peptides O +
G75 O +
( O +
128 O -
- O -
135 O +
) O +
and O +
G76 O +
( O +
128 O -
- O -
135 O +
) O +
( O +
L128 O -
G O +
) O +
reconstituted O +
CTL O +
recognition O +
at O +
concentrations O +
ranging O +
between O +
200 O -
- O -
500 O +
nM O +
. O +

These O +
concentrations O +
are O +
lower O +
than O +
concentrations O +
reported O +
to O +
activate O +
effector O +
function O +
of O +
CTL O +
recognizing O +
other O +
epithelial O +
tumor O +
Ag O +
. O +

Furthermore O +
, O +
analysis O +
with O +
cloned O +
CD8 O -
+ O +
T O +
cells O +
indicated O +
that O +
G75 O +
and O +
G76 O +
were O +
not O +
cross O -
- O -
reactive O +
specificities O +
, O +
suggesting O +
a O +
key O +
role O +
for O +
the O +
N O -
- O -
terminal O +
residues O +
of O +
the O +
variant O +
peptide O +
in O +
dictating O +
specificities O +
. O +

Since O +
the O +
AES O +
proteins O +
are O +
part O +
of O +
a O +
set O +
of O +
transcriptional O +
repressors O +
encoded O +
by O +
the O +
Enhancer O +
of O +
split O +
[ O +
E O +
( O +
spl O +
) O +
] O +
genes O +
, O +
and O +
since O +
these O +
repressors O +
are O +
activated O +
to O +
suppress O +
cell O +
differentiation O +
in O +
response O +
to O +
Notch O +
receptors O +
signalling O +
, O +
the O +
AES O +
peptides O +
may O +
represent O +
a O +
novel O +
class O +
of O +
self O -
- O -
antigens O +
that O +
deserve O +
further O +
consideration O +
as O +
tumor O +
Ag O +
in O +
epithelial O +
cancers O +
. O +

Activation O +
of O +
the O +
Janus O +
kinase O +
3 O +
-STAT5a O +
pathway O +
after O +
CD40 O +
triggering O +
of O +
human O +
monocytes O +
but O +
not O +
of O +
resting O +
B O +
cells O +
. O +

CD40 O +
/CD40 O +
ligand O +
interactions O +
play O +
a O +
key O +
role O +
in O +
the O +
immune O +
responses O +
of O +
B O +
lymphocytes O +
, O +
monocytes O +
, O +
and O +
dendritic O +
cells O +
. O +

The O +
signal O +
transduction O +
events O +
triggered O +
by O +
cross O -
- O -
linking O +
of O +
the O +
CD40 O +
receptor O +
have O +
been O +
widely O +
studied O +
in O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
but O +
little O +
is O +
known O +
about O +
signaling O +
following O +
CD40 O +
stimulation O +
of O +
monocytes O +
and O +
resting B-CellLine +
tonsillar I-CellLine +
B I-CellLine +
cells I-CellLine +
. O +

Therefore O +
, O +
we O +
studied O +
the O +
CD40 O +
pathway O +
in O +
highly O +
purified O +
human O +
monocytes O +
and O +
resting O +
B O +
cells O +
. O +

After O +
CD40 O +
triggering O +
, O +
a O +
similar O +
activation O +
of O +
the O +
NF O -
- O -
kappaB O +
( O +
but O +
not O +
of O +
the O +
AP-1 O +
) O +
transcription O +
factor O +
complex O +
occurred O +
in O +
both O +
cell O +
preparations O +
. O +

However O +
, O +
the O +
components O +
of O +
the O +
NF O -
- O -
kappaB O +
complexes O +
were O +
different O +
in O +
monocytes O +
and O +
B O +
cells O +
, O +
because O +
p50 O +
is O +
part O +
of O +
the O +
NF O -
- O -
kappaB O +
complex O +
induced O +
by O +
CD40 O +
triggering O +
in O +
both O +
monocytes O +
and O +
B O +
cells O +
, O +
whereas O +
p65 O +
was O +
only O +
induced O +
in O +
B O +
cells O +
. O +
In O +
contrast O +
, O +
although O +
the O +
Janus O +
kinase O +
3 O +
tyrosine O +
kinase O +
was O +
associated O +
with O +
CD40 O +
molecules O +
in O +
both O +
monocytes O +
and O +
resting O +
B O +
cells O +
, O +
Janus O +
kinase O +
3 O +
phosphorylation O +
induction O +
was O +
observed O +
only O +
in O +
CD40-activated B-CellLine +
monocytes I-CellLine +
, O +
with O +
subsequent O +
induction O +
of O +
STAT5a O +
DNA O +
binding O +
activity O +
in O +
the O +
nucleus O +
. O +

These O +
results O +
suggest O +
that O +
the O +
activation O +
signals O +
in O +
human O +
B O +
cells O +
and O +
monocytes O +
differ O +
following O +
CD40 O +
stimulation O +
. O +

This O +
observation O +
is O +
consistent O +
with O +
the O +
detection O +
of O +
normal O +
CD40 O +
-induced O +
monocyte O +
activation O +
in O +
patients O +
with O +
CD40 O +
ligand+ O +
hyper O +
IgM O +
syndrome O +
in O +
whom O +
a O +
defect O +
in O +
CD40 O +
-induced O +
B O +
cell O +
activation O +
has O +
been O +
reported O +
. O +

Suppression O +
of O +
NF O -
- O -
kappaB O +
activation O +
in O +
normal O +
T O +
cells O +
by O +
supernatant O +
fluid O +
from O +
human O +
renal O +
cell O +
carcinomas O +
. O +

T O +
lymphocytes O +
from O +
patients O +
with O +
renal O +
cell O +
carcinoma O +
( O +
RCC O +
) O +
show O +
reduced O +
immune O +
function O +
and O +
impaired O +
activation O +
of O +
the O +
transcription O +
factor O +
, O +
NF O -
- O -
kappaB O +
. O +

We O +
determined O +
the O +
mechanism O +
of O +
NF O -
- O -
kappaB O +
suppression O +
in O +
T O +
cells O +
of O +
RCC O +
patient O +
and O +
determined O +
whether O +
supernatant O +
fluid O +
from O +
RCC O +
explants O +
( O +
RCC O -
- O -
S O +
) O +
induced O +
the O +
same O +
phenotype O +
of O +
NF O -
- O -
kappaB O +
suppression O +
in O +
normal O +
T O +
cells O +
that O +
is O +
observed O +
in O +
patient O +
T O +
cells O +
. O +

The O +
pattern O +
of O +
kappaB O +
-binding O +
activity O +
in O +
T O +
cells O +
of O +
RCC O +
patient O +
was O +
altered O +
as O +
compared O +
to O +
that O +
seen O +
in O +
T O +
cells O +
obtained O +
from O +
normal O +
volunteers O +
. O +

In O +
some O +
patients O +
, O +
no O +
activation O +
of O +
RelA O -
/ O -
NFkappaB1 O +
-binding O +
activity O +
was O +
detectable O +
, O +
while O +
in O +
others O +
kappaB O +
-binding O +
activity O +
was O +
modestly O +
induced O +
but O +
the O +
duration O +
was O +
reduced O +
. O +

IkappaBalpha O +
was O +
degraded O +
normally O +
following O +
stimulation O +
in O +
both O +
normal O +
controls O +
and O +
T O +
cells O +
from O +
RCC O +
patients O +
. O +

RCC O -
- O -
S O +
did O +
not O +
alter O +
the O +
cytoplasmic O +
levels O +
of O +
RelA O +
and O +
NF O -
- O -
kappaB1 O +
but O +
did O +
suppress O +
their O +
nuclear O +
localization O +
and O +
inhibited O +
the O +
activation O +
of O +
RelA O -
/ O -
NF O -
- O -
kappaB1 O +
binding O +
complexes O +
. O +

These O +
results O +
show O +
that O +
RCC O -
- O -
S O +
can O +
induce O +
in O +
normal O +
T O +
cells O +
the O +
same O +
phenotype O +
of O +
impaired O +
NF O -
- O -
kappaB O +
activation O +
that O +
is O +
detected O +
in O +
T O +
cells O +
of O +
RCC O +
patient O +
. O +

It O +
also O +
appears O +
that O +
NF O -
- O -
kappaB O +
suppression O +
by O +
RCC O -
- O -
S O +
may O +
contribute O +
to O +
the O +
immunosuppression O +
of O +
host O +
immunity O +
. O +

ICSAT O +
overexpression O +
is O +
not O +
sufficient O +
to O +
cause O +
adult O +
T O -
- O -
cell O +
leukemia O +
or O +
multiple O +
myeloma O +
. O +

ICSAT O +
( O +
Interferon O +
Consensus O +
Sequence O +
binding O +
protein O +
for O +
Activated O +
T O +
cells O +
) O +
is O +
a O +
lymphocyte O -
- O -
specific O +
member O +
of O +
the O +
interferon O +
regulatory O +
factor O +
( O +
IRF O +
) O +
family O +
of O +
transcription O +
factors O +
, O +
originally O +
identified O +
through O +
Southwestern O +
screening O +
of O +
the O +
ATL O +
( O +
Adult O +
T O -
- O -
cell O +
leukemia O +
) O +
-16 O -
T O +
expression O +
library O +
. O +

In O +
this O +
study O +
, O +
we O +
created O +
transgenic O +
mice O +
overexpressing O +
ICSAT O +
in O +
lymphocytes O +
. O +

Although O +
spontaneous O +
tumorigenesis O +
was O +
not O +
observed O +
, O +
IL-2 O +
production O +
with O +
Concanavalin O +
A O +
stimulation O +
was O +
significantly O +
increased O +
in O +
transgenic O +
mice O +
overexpressing O +
ICSAT O +
. O +

ICSAT O +
overexpression O +
in O +
lymphocytes O +
seems O +
insufficient O +
for O +
the O +
leukemogenesis O +
of O +
ATL O +
or O +
multiple O +
myeloma O +
( O +
MM O +
) O +
, O +
however O +
, O +
it O +
may O +
regulate O +
T O +
cell O +
activation O +
and O +
its O +
overexpression O +
may O +
lead O +
to O +
leukemogenesis O +
via O +
controlling O +
IL-2 O +
production O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

ETS O +
transcription O +
factors O +
regulate O +
an O +
enhancer O +
activity O +
in O +
the O +
third O +
intron O +
of O +
TNF O -
- O -
alpha O +
. O +

We O +
describe O +
an O +
enhancer O +
site O +
in O +
the O +
third O +
intron O +
of O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
. O +

A O +
reporter O +
construct O +
containing O +
the O +
5'-flanking O +
region O +
of O +
the O +
mouse O +
TNF O -
- O -
alpha O +
gene O +
displayed O +
weak O +
activity O +
when O +
transfected O +
into O +
RAW264.7 B-CellLine +
macrophage I-CellLine -
- I-CellLine -
like I-CellLine +
cells I-CellLine +
. O +

The O +
addition O +
of O +
the O +
third O +
intron O +
of O +
TNF O -
- O -
alpha O +
to O +
this O +
construct O +
resulted O +
in O +
an O +
enhancement O +
of O +
CAT O +
protein O +
. O +

This O +
enhancement O +
was O +
eliminated O +
if O +
a O +
conserved O +
20-bp O +
sequence O +
was O +
removed O +
from O +
the O +
intron O +
or O +
if O +
a O +
dominant O -
- O -
negative O +
ets O -
- O -
binding O +
factor O +
was O +
co O -
- O -
transfected O +
with O +
the O +
reporter O +
gene O +
. O +

Mutations O +
of O +
this O +
site O +
that O +
destroyed O +
potential O +
ets O +
transcription O +
factor O +
binding O +
sites O +
had O +
reduced O +
transcriptional O +
activity O +
. O +

The O +
major O +
transcription O +
factor O +
that O +
bound O +
to O +
the O +
oligonucleotide O +
was O +
confirmed O +
to O +
be O +
GABP O +
by O +
supershift O +
and O +
competition O +
analysis O +
. O +

In O +
RAW264.7 B-CellLine +
cells I-CellLine +
, O +
the O +
binding O +
was O +
constitutive O +
, O +
however O +
, O +
in O +
bone B-CellLine +
marrow I-CellLine -
- I-CellLine -
derived I-CellLine +
macrophages I-CellLine +
binding O +
activity O +
was O +
shown O +
to O +
be O +
interferon O -
- O -
gamma O +
inducible O +
. O +

This O +
may O +
imply O +
a O +
role O +
for O +
ets O +
transcription O +
factors O +
in O +
the O +
production O +
of O +
TNF O -
- O -
alpha O +
. O +

The O +
p53 O +
paradox O +
in O +
the O +
pathogenesis O +
of O +
tumor O +
progression O +
. O +

Recent O +
evidence O +
suggests O +
that O +
the O +
p53 O +
molecule O +
appears O +
in O +
two O +
different O +
forms O +
: O +
the O +
mutant O +
p53 O +
that O +
stimulates O +
tumor O +
progression O +
, O +
and O +
wild O +
type O +
p53 O +
that O +
inhibits O +
tumor O +
progression O +
. O +

In O +
addition O +
, O +
it O +
has O +
been O +
established O +
that O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
can O +
activate O +
the O +
expression O +
of O +
wild O +
type O +
p53 O +
in O +
concert O +
with O +
the O +
nuclear O +
transcription O +
factor O +
, O +
NF O -
- O -
kappa O +
B O +
. O +

Both O +
TNF O -
- O -
alpha O +
and O +
NF O -
- O -
kappa O +
B O +
are O +
also O +
involved O +
in O +
the O +
stimulation O +
of O +
the O +
pathway O +
that O +
leads O +
to O +
the O +
expression O +
of O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
class O +
I O +
molecules O +
and O +
, O +
hence O +
, O +
antigen O +
presentation O +
to O +
the O +
T O +
cells O +
. O +

In O +
this O +
paper O +
we O +
shall O +
advance O +
the O +
hypothesis O +
that O +
: O +
( O +
i O +
) O +
TNF O -
- O -
alpha O +
indirectly O +
controls O +
immune O +
surveillance O +
; O +
and O +
( O +
ii O +
) O +
TNF O -
- O -
alpha O +
controls O +
DNA O +
repair O +
and O +
tumor O +
suppression O +
through O +
the O +
regulation O +
of O +
wild O +
type O +
p53 O +
. O +

Thus O +
, O +
it O +
is O +
hypothesized O +
that O +
elevated O +
TNF O -
- O -
alpha O +
is O +
primarily O +
responsible O +
for O +
promoting O +
tumor O +
progression O +
. O +

Abnormal O +
NF O -
- O -
kappa O +
B O +
activity O +
in O +
T O +
lymphocytes O +
from O +
patients O +
with O +
systemic O +
lupus O +
erythematosus O +
is O +
associated O +
with O +
decreased O +
p65-RelA O +
protein O +
expression O +
. O +

Numerous O +
cellular O +
and O +
biochemical O +
abnormalities O +
in O +
immune O +
regulation O +
have O +
been O +
described O +
in O +
patients O +
with O +
systemic O +
lupus O +
erythematosus O +
( O +
SLE O +
) O +
, O +
including O +
surface O +
Ag O +
receptor O +
-initiated O +
signaling O +
events O +
and O +
lymphokine O +
production O +
. O +

Because O +
NF O -
- O -
kappa O +
B O +
contributes O +
to O +
the O +
transcription O +
of O +
numerous O +
inflammatory O +
genes O +
and O +
has O +
been O +
shown O +
to O +
be O +
a O +
molecular O +
target O +
of O +
antiinflammatory O +
drugs O +
, O +
we O +
sought O +
to O +
characterize O +
the O +
functional O +
role O +
of O +
the O +
NF O -
- O -
kappa O +
B O +
protein O +
complex O +
in O +
lupus O +
T O +
cells O +
. O +

Freshly O +
isolated O +
T O +
cells O +
from O +
lupus O +
patients O +
, O +
rheumatoid O +
arthritis O +
( O +
RA O +
) O +
patients O +
, O +
and O +
normal O +
individuals O +
were O +
activated O +
physiologically O +
via O +
the O +
TCR O +
with O +
anti O -
- O -
CD3 O +
and O +
anti O -
- O -
CD28 O +
Abs O +
to O +
assess O +
proximal O +
membrane O +
signaling O +
, O +
and O +
with O +
PMA O +
and O +
a O +
calcium O +
ionophore O +
( O +
A23187 O +
) O +
to O +
bypass O +
membrane O -
- O -
mediated O +
signaling O +
events O +
. O +

We O +
measured O +
the O +
NF O -
- O -
kappa O +
B O +
binding O +
activity O +
in O +
nuclear O +
extracts O +
by O +
gel O +
shift O +
analysis O +
. O +

When O +
compared O +
with O +
normal O +
cells O +
, O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
activity O +
in O +
SLE O +
patients O +
was O +
significantly O +
decreased O +
in O +
SLE O +
, O +
but O +
not O +
in O +
RA O +
, O +
patients O +
. O +

NF O -
- O -
kappa O +
B O +
binding O +
activity O +
was O +
absent O +
in O +
several O +
SLE O +
patients O +
who O +
were O +
not O +
receiving O +
any O +
medication O +
, O +
including O +
corticosteroids O +
. O +

Also O +
, O +
NF O -
- O -
kappa O +
B O +
activity O +
remained O +
absent O +
in O +
follow O -
- O -
up O +
studies O +
. O +

In O +
supershift O +
experiments O +
using O +
specific O +
Abs O +
, O +
we O +
showed O +
that O +
, O +
in O +
the O +
group O +
of O +
SLE O +
patients O +
who O +
displayed O +
undetectable O +
NF O -
- O -
kappa O +
B O +
activity O +
, O +
p65 O +
complexes O +
were O +
not O +
formed O +
. O +

Finally O +
, O +
immunoblot O +
analysis O +
of O +
nuclear O +
extracts O +
showed O +
decreased O +
or O +
absent O +
p65 O +
protein O +
levels O +
. O +

As O +
p65 O +
complexes O +
are O +
transcriptionally O +
active O +
in O +
comparison O +
to O +
the O +
p50 O +
homodimer O +
, O +
this O +
novel O +
finding O +
may O +
provide O +
insight O +
on O +
the O +
origin O +
of O +
abnormal O +
cytokine O +
or O +
other O +
gene O +
transcription O +
in O +
SLE O +
patients O +
. O +

Peptide O +
binding O +
affinity O +
and O +
pH O +
variation O +
establish O +
functional O +
thresholds O +
for O +
activation O +
of O +
HLA O -
- O -
DQ O +
-restricted O +
T O +
cell O +
recognition O +
. O +

Peptides O +
derived O +
from O +
the O +
HSV-2 O +
VP16 O +
protein O +
were O +
utilized O +
for O +
studies O +
of O +
peptide O +
binding O +
to O +
DQ0302 O +
molecules O +
and O +
T O +
cell O +
activation O +
at O +
both O +
neutral O +
and O +
acidic O +
pH O +
. O +

The O +
native O +
peptide O +
VP16 O +
430 O -
- O -
444 O +
contains O +
an O +
Asp O +
at O +
position O +
442 O +
, O +
binds O +
to O +
DQ0302 O +
strongly O +
, O +
with O +
a O +
Kd O +
value O +
of O +
50nM O +
at O +
acidic O +
pH O +
and O +
very O +
weakly O +
, O +
with O +
a O +
Kd O +
value O +
of O +
greater O +
than O +
10 O +
microM O +
at O +
neutral O +
pH O +
. O +

A O +
truncated O +
version O +
of O +
430 O -
- O -
444 O +
, O +
i.e. O +
, O +
VP16 O +
433 O -
- O -
442 O +
, O +
binds O +
with O +
an O +
affinity O +
10-fold O +
lower O +
compared O +
to O +
430 O -
- O -
444 O +
at O +
acidic O +
pH O +
, O +
and O +
binding O +
at O +
neutral O +
pH O +
was O +
barely O +
detectable O +
. O +

The O +
homologous O +
peptide O +
430 O -
- O -
444 O +
, O +
442A O +
has O +
an O +
Asp O +
to O +
Ala O +
substitution O +
at O +
position O +
442 O +
and O +
binds O +
to O +
DQ0302 O +
with O +
a O +
Kd O +
similar O +
to O +
433 O -
- O -
442 O +
. O +

The O +
short O +
truncated O +
analog O +
433 O -
- O -
442A O +
binds O +
very O +
poorly O +
at O +
both O +
acidic O +
and O +
neutral O +
pH O +
. O +

Both O +
the O +
wild O +
type O +
430 O -
- O -
444 O +
and O +
433 O -
- O -
442 O +
peptides O +
stimulated O +
a O +
HSV O -
- O -
specific O +
T O +
cell O +
clone O +
after O +
a O +
brief O +
incubation O +
with O +
antigen O +
presenting O +
cells O +
( O +
APC O +
) O +
expressing O +
DQ0302 O +
at O +
acidic O +
pH O +
. O +

Much O +
higher O +
concentrations O +
of O +
wild O +
type O +
peptides O +
were O +
needed O +
to O +
activate O +
T O +
cells O +
at O +
neutral O +
pH O +
. O +

In O +
contrast O +
, O +
APC O +
pulsed O +
with O +
Ala O -
- O -
substituted O +
peptides O +
430 O -
- O -
444 O +
, O +
442A O +
or O +
433 O -
- O -
442A O +
at O +
neutral O +
pH O +
failed O +
to O +
stimulate O +
the O +
T B-CellLine +
cell I-CellLine +
clone I-CellLine +
, O +
while O +
APC O +
pulsed O +
at O +
acidic O +
pH O +
and O +
subsequently O +
washed O +
led O +
to O +
successful O +
T O +
cell O +
activation O +
. O +

The O +
Ala O -
- O -
substituted O +
peptide O +
was O +
recognized O +
by O +
the O +
T B-CellLine +
cell I-CellLine +
clone I-CellLine +
at O +
neutral O +
pH O +
only O +
when O +
it O +
was O +
present O +
in O +
the O +
APC B-CellLine +
culture I-CellLine +
throughout O +
the O +
stimulation O +
process O +
. O +

While O +
the O +
MHC O -
- O -
peptide O +
complexes O +
formed O +
with O +
the O +
native O +
peptide O +
are O +
stable O +
, O +
complexes O +
formed O +
with O +
the O +
Ala O -
- O -
substituted O +
peptide O +
had O +
a O +
functional O +
t1 O -
/ O -
2 O +
of O +
less O +
than O +
4 O +
hr O +
at O +
neutral O +
pH O +
. O +

Stimulation O +
of O +
neutrophil O +
interleukin-8 O +
production O +
by O +
eosinophil O +
granule O +
major O +
basic O +
protein O +
. O +

We O +
evaluated O +
the O +
ability O +
of O +
eosinophil O +
granule O +
major O +
basic O +
protein O +
( O +
MBP O +
) O +
to O +
stimulate O +
interleukin O +
( O +
IL O +
) O +
-8 O +
production O +
by O +
neutrophils O +
. O +

MBP O +
over O +
the O +
concentration O +
range O +
of O +
0.1 O +
to O +
10 O +
microM O +
stimulated O +
the O +
release O +
of O +
up O +
to O +
approximately O +
8 O +
ng O -
/ O -
ml O +
IL-8 O +
. O +

Incubation O +
with O +
2 O +
microM O +
MBP O +
showed O +
that O +
, O +
after O +
a O +
1 O +
h O +
lag O +
, O +
the O +
level O +
of O +
IL-8 O +
release O +
increased O +
with O +
time O +
for O +
approximately O +
10 O +
h O +
. O +

At O +
the O +
2 O +
microM O +
concentration O +
, O +
eosinophil O +
cationic O +
protein O +
, O +
eosinophil O -
- O -
derived O +
neurotoxin O +
, O +
and O +
eosinophil O +
peroxidase O +
did O +
not O +
stimulate O +
significant O +
levels O +
of O +
IL-8 O +
production O +
. O +

MBP O +
stimulated O +
2-fold O +
increases O +
in O +
IL-8 O +
messenger O +
RNA O +
( O +
mRNA O +
) O +
after O +
1 O +
and O +
3 O +
h O +
of O +
incubation O +
, O +
which O +
were O +
blocked O +
by O +
pretreatment O +
with O +
actinomycin O +
D O +
. O +

However O +
, O +
stimulation O +
with O +
MBP O +
did O +
not O +
produce O +
an O +
increase O +
in O +
the O +
binding O +
activity O +
of O +
nuclear O +
factor O +
( O +
NF O +
) O +
-kappaB O +
or O +
activator O +
protein-1 O +
. O +

No O +
NF O -
- O -
IL-6 O +
binding O +
activity O +
was O +
detected O +
in O +
the O +
same O +
nuclear O +
extracts O +
. O +

In O +
addition O +
, O +
stimulation O +
with O +
MBP O +
prolonged O +
the O +
stability O +
of O +
IL-8 O +
mRNA O +
. O +

MBP O +
also O +
induced O +
transient O +
increases O +
in O +
mRNA O +
for O +
macrophage O +
inflammatory O +
protein O +
( O +
MIP O +
) O +
-1alpha O +
and O +
MIP-1beta O +
, O +
but O +
did O +
not O +
stimulate O +
the O +
release O +
of O +
either O +
chemokine O +
. O +

These O +
findings O +
indicate O +
that O +
MBP O +
is O +
selective O +
among O +
the O +
eosinophil O +
granule O +
proteins O +
as O +
a O +
stimulus O +
for O +
neutrophil O +
IL-8 O +
release O +
and O +
, O +
further O +
, O +
that O +
stimulation O +
of O +
neutrophil O +
IL-8 O +
release O +
by O +
MBP O +
involves O +
both O +
transcriptional O +
and O +
posttranscriptional O +
regulation O +
. O +

We O +
postulate O +
that O +
MBP O +
-induced O +
release O +
of O +
IL-8 O +
by O +
neutrophils O +
may O +
contribute O +
to O +
the O +
pathophysiology O +
of O +
acute O +
asthma O +
and O +
other O +
inflammatory O +
lung O +
diseases O +
. O +

Diminished O +
responses O +
to O +
IL-13 O +
by O +
human O +
monocytes O +
differentiated O +
in O +
vitro O +
: O +
role O +
of O +
the O +
IL-13Ralpha1 O +
chain O +
and O +
STAT6 O +
. O +

The O +
primary O +
IL-13 O +
receptor O +
complex O +
on O +
human O +
monocytes O +
is O +
believed O +
to O +
be O +
a O +
heterodimer O +
comprised O +
of O +
the O +
IL-4R O +
alpha O +
chain O +
and O +
the O +
IL-2R O +
gamma O +
chain O +
( O +
gamma O +
( O +
c O +
) O +
) O +
-like O +
molecule O +
, O +
IL-13R O +
alpha1 O +
. O +

mRNA O +
levels O +
for O +
IL-13R O +
alpha1 O +
, O +
but O +
not O +
IL-4R O +
alpha O +
, O +
were O +
markedly O +
decreased O +
in O +
in B-CellLine +
vitro I-CellLine +
monocyte I-CellLine -
- I-CellLine -
derived I-CellLine +
macrophages I-CellLine +
( O +
MDMac B-CellLine +
) O +
, O +
and O +
with O +
increasing O +
time O +
of O +
monocytes O +
in O +
culture O +
correlated O +
with O +
the O +
loss O +
of O +
IL-13 O +
regulation O +
of O +
lipopolysaccharide O -
- O -
induced O +
TNF O -
- O -
alpha O +
production O +
. O +

Analysis O +
of O +
cell B-CellLine +
lines I-CellLine +
Daudi B-CellLine +
and O +
THP-1 B-CellLine +
that O +
differentially O +
express O +
gamma O +
( O +
c O +
) O +
and O +
IL-13R O +
alpha1 O +
showed O +
that O +
IL-13 O +
can O +
activate O +
STAT6 O +
in O +
IL-13R B-CellLine +
alpha1-positive I-CellLine +
THP-1 I-CellLine +
cells I-CellLine +
but O +
not O +
in O +
gamma B-CellLine +
( I-CellLine +
c I-CellLine +
) I-CellLine +
-positive I-CellLine +
, I-CellLine +
IL-13R I-CellLine +
alpha1-negative I-CellLine +
Daudi I-CellLine +
cells I-CellLine +
. O +

IL-13 O +
activation O +
of O +
STAT6 O +
was O +
reduced O +
in O +
MDMac B-CellLine +
which O +
was O +
associated O +
with O +
diminished O +
IL-13 O +
-induced O +
expression O +
of O +
CD23 O +
and O +
MHC O +
class O +
II O +
. O +

However O +
, O +
with O +
reduced O +
IL-13R O +
alpha1 O +
expression O +
and O +
low O +
nuclear O +
STAT6 O +
activity O +
, O +
some O +
IL-13 O +
-induced O +
responses O +
were O +
unaltered O +
in O +
magnitude O +
in O +
MDMac B-CellLine +
. O +

In O +
the O +
absence O +
of O +
functional O +
IL-13R O +
alpha1 O +
and O +
gamma O +
( O +
c O +
) O +
, O +
IL-13 O +
must O +
signal O +
through O +
an O +
alternative O +
receptor O +
complex O +
on O +
MDMac B-CellLine +
. O +

Experiments O +
with O +
a O +
blocking O +
antibody O +
to O +
IL-4R O +
alpha O +
showed O +
that O +
this O +
chain O +
remains O +
an O +
essential O +
component O +
of O +
the O +
IL-13 O +
receptor O +
complex O +
on O +
MDMac B-CellLine +
. O +

Reactive O +
oxygen O +
intermediate O -
- O -
release O +
of O +
fibre B-CellLine -
- I-CellLine -
exposed I-CellLine +
monocytes I-CellLine +
increases O +
inflammatory O +
cytokine O -
- O -
mRNA O +
level O +
, O +
protein O +
tyrosine O +
kinase O +
and O +
NF O -
- O -
kappaB O +
activity O +
in O +
co B-CellLine -
- I-CellLine -
cultured I-CellLine +
bronchial I-CellLine +
epithelial I-CellLine +
cells I-CellLine +
( O +
BEAS-2B B-CellLine +
) O +
. O +

Some O +
pulmonary O +
diseases O +
like O +
bronchitis O +
or O +
asthma O +
bronchiale O +
are O +
mediated O +
by O +
inflammatory O +
mechanisms O +
in O +
bronchial O +
epithelial O +
cells O +
. O +

Alveolar O +
macrophages O +
are O +
located O +
directly O +
in O +
the O +
surrounding O +
of O +
these O +
cells O +
, O +
so O +
that O +
we O +
suppose O +
an O +
interaction O +
between O +
epithelial O +
cells O +
and O +
macrophages O +
regarding O +
to O +
the O +
release O +
of O +
inflammatory O +
mediators O +
. O +

For O +
measuring O +
the O +
contribution O +
of O +
macrophages O +
to O +
the O +
release O +
of O +
inflammatory O +
mediators O +
by O +
bronchial O +
epithelial O +
cells O +
, O +
we O +
established O +
an O +
in O +
vitro O +
model O +
of O +
co O -
- O -
cultured O +
blood O +
monocytes O +
( O +
BM O +
) O +
and O +
BEAS-2B B-CellLine +
cells I-CellLine +
in O +
a O +
transwell O +
system O +
( O +
Costar O +
) O +
. O +

BM O +
were O +
exposed O +
to O +
Chrysotile O +
B O +
and O +
soot O +
particle O +
FR O +
101 O +
in O +
a O +
concentration O +
of O +
100 O +
microg O -
/ O -
10 O +
( O +
6 O +
) O +
cells O +
. O +

After O +
up O +
to O +
90 O +
min O +
exposure O +
time O +
ELISA O +
, O +
EMSA O +
( O +
electromobility O +
shift O +
assay O +
) O +
and O +
RT O -
- O -
PCR O +
were O +
used O +
to O +
measure O +
protein O +
tyrosine O +
kinase O +
activity O +
, O +
protein O +
activity O +
of O +
NF O -
- O -
kappaB O +
and O +
cytokine O +
( O +
IL-1beta O +
, O +
IL-6 O +
, O +
TNF O -
- O -
alpha O +
) O +
specific O +
mRNA O +
levels O +
in O +
BEAS-2B O +
cells O +
. O +

We O +
observed O +
an O +
increase O +
in O +
protein O +
tyrosine O +
kinase O +
activity O +
( O +
up O +
to O +
1.8 O +
+ O -
/- O +
0.5-fold O +
) O +
and O +
NF O -
- O -
kappaB O +
protein O +
activity O +
in O +
BEAS-2B O +
cells O +
after O +
particle O +
or O +
fibre O +
exposure O +
of O +
co B-CellLine -
- I-CellLine -
cultured I-CellLine +
BM I-CellLine +
. O +

Consecutive O +
IL-1beta- O +
, O +
IL-6- O +
and O +
TNF O -
- O -
alpha O -
- O -
mRNA O +
were O +
elevated O +
( O +
up O +
to O +
1.9 O +
+ O -
/- O +
0.58-fold O +
) O +
. O +

Protein O +
tyrosine O +
kinase O +
activity O +
, O +
NF O -
- O -
kappaB O +
activity O +
, O +
and O +
the O +
synthesis O +
of O +
cytokine O -
- O -
specific O +
mRNA O +
were O +
inhibited O +
by O +
antioxidants O +
. O +

These O +
data O +
suggest O +
a O +
ROI O -
- O -
dependent O +
NF O -
- O -
kappaB O +
mediated O +
transcription O +
of O +
inflammatory O +
cytokines O +
in O +
bronchial O +
epithelial O +
cells O +
. O +

Monoallelic O +
expression O +
of O +
Pax5 O +
: O +
a O +
paradigm O +
for O +
the O +
haploinsufficiency O +
of O +
mammalian O +
Pax O +
genes O +
? O +

It O +
is O +
generally O +
assumed O +
that O +
most O +
mammalian O +
genes O +
are O +
transcribed O +
from O +
both O +
alleles O +
. O +

Hence O +
, O +
the O +
diploid O +
state O +
of O +
the O +
genome O +
offers O +
the O +
advantage O +
that O +
a O +
loss O -
- O -
of O -
- O -
function O +
mutation O +
in O +
one O +
allele O +
can O +
be O +
compensated O +
for O +
by O +
the O +
remaining O +
wild O -
- O -
type O +
allele O +
of O +
the O +
same O +
gene O +
. O +

Indeed O +
, O +
the O +
vast O +
majority O +
of O +
human O +
disease O +
syndromes O +
and O +
engineered O +
mutations O +
in O +
the O +
mouse O +
genome O +
are O +
recessive O +
, O +
indicating O +
that O +
recessiveness O +
is O +
the O +
' O -
default O +
' O +
state O +
. O +

However O +
, O +
a O +
minority O +
of O +
genes O +
are O +
semi O -
- O -
dominant O +
, O +
as O +
heterozygous O +
loss O -
- O -
of O -
- O -
function O +
mutation O +
in O +
these O +
genes O +
leads O +
to O +
phenotypic O +
abnormalities O +
. O +

This O +
condition O +
, O +
known O +
as O +
haploinsufficiency O +
, O +
has O +
been O +
described O +
for O +
five O +
of O +
the O +
nine O +
mammalian O +
Pax O +
genes O +
, O +
which O +
are O +
associated O +
with O +
mouse O +
developmental O +
mutants O +
and O +
human O +
disease O +
syndromes O +
. O +

Recently O +
we O +
have O +
reported O +
that O +
the O +
Pax5 O +
gene O +
is O +
subject O +
to O +
allele O +
-specific O +
regulation O +
during O +
B O +
cell O +
development O +
. O +

Pax5 O +
is O +
predominantly O +
transcribed O +
from O +
only O +
one O +
of O +
its O +
two O +
alleles O +
in O +
early O +
B O -
- O -
lymphoid O +
progenitors O +
and O +
mature O +
B O +
cells O +
, O +
while O +
it O +
transiently O +
switches O +
to O +
a O +
biallelic O +
mode O +
of O +
transcription O +
in O +
pre O -
- O -
B O +
and O +
immature O +
B O +
cells O +
. O +

As O +
a O +
consequence O +
, O +
B O -
- O -
lymphoid O +
tissues O +
are O +
mosaic O +
with O +
regard O +
to O +
the O +
transcribed O +
allele O +
, O +
and O +
heterozygous O +
mutation O +
of O +
Pax5 O +
therefore O +
results O +
in O +
deletion O +
of O +
B O +
lymphocytes O +
expressing O +
only O +
the O +
mutant O +
allele O +
. O +

The O +
allele O +
-specific O +
regulation O +
of O +
Pax5 O +
raises O +
the O +
intriguing O +
possibility O +
that O +
monoallelic O +
expression O +
may O +
also O +
be O +
the O +
mechanism O +
causing O +
the O +
haploinsufficiency O +
of O +
other O +
Pax O +
genes O +
. O +

In O +
this O +
review O +
, O +
we O +
discuss O +
different O +
models O +
accounting O +
for O +
the O +
haploinsufficiency O +
of O +
mammalian O +
Pax O +
genes O +
, O +
provide O +
further O +
evidence O +
in O +
support O +
of O +
the O +
allele O +
-specific O +
regulation O +
of O +
Pax5 O +
and O +
discuss O +
the O +
implication O +
of O +
these O +
findings O +
in O +
the O +
context O +
of O +
the O +
recent O +
literature O +
describing O +
the O +
stochastic O +
and O +
monoallelic O +
activation O +
of O +
other O +
hematopoietic O +
genes O +
. O +

Tissue O -
- O -
specific O +
regulation O +
of O +
the O +
ecto-5'-nucleotidase O +
promoter O +
. O +

Role O +
of O +
the O +
camp O +
response O +
element O +
site O +
in O +
mediating O +
repression O +
by O +
the O +
upstream O +
regulatory O +
region O +
. O +

We O +
have O +
isolated O +
the O +
5 O +
' O +
region O +
of O +
the O +
ecto-5'-nucleotidase O +
( O +
low O +
K O +
( O +
m O +
) O +
5'-NT O +
) O +
gene O +
and O +
established O +
that O +
a O +
969-base O +
pair O +
( O +
bp O +
) O +
fragment O +
confers O +
cell O -
- O -
specific O +
expression O +
of O +
a O +
CAT O +
reporter O +
gene O +
that O +
correlates O +
with O +
the O +
expression O +
of O +
endogenous O +
ecto-5'-NT O +
mRNA O +
and O +
enzymatic O +
activity O +
. O +

A O +
768-bp O +
upstream O +
negative O +
regulatory O +
region O +
has O +
been O +
identified O +
that O +
conferred O +
lymphocyte O -
- O -
specific O +
negative O +
regulation O +
in O +
a O +
heterologous O +
system O +
with O +
a O +
244-bp O +
deoxycytidine O +
kinase O +
core O +
promoter O +
. O +

DNase O +
I O +
footprinting O +
identified O +
several O +
protected O +
areas O +
including O +
Sp1 O +
, O +
Sp1 O -
/ O -
AP-2 O +
, O +
and O +
cAMP O +
response O +
element O +
( O +
CRE O +
) O +
binding O +
sites O +
within O +
the O +
201-bp O +
core O +
promoter O +
region O +
and O +
Sp1 O +
, O +
NRE-2a O +
, O +
TCF-1 O -
/ O -
LEF-1 O +
, O +
and O +
Sp1 O -
/ O -
NF O -
- O -
AT O +
binding O +
sites O +
in O +
the O +
upstream O +
regulatory O +
region O +
. O +

Whereas O +
the O +
CRE O +
site O +
was O +
essential O +
in O +
mediating O +
the O +
negative O +
activity O +
of O +
the O +
upstream O +
regulatory O +
region O +
in O +
Jurkat B-CellLine +
but O +
not O +
in O +
HeLa B-CellLine +
cells I-CellLine +
, O +
mutation O +
of O +
the O +
Sp1 O -
/ O -
AP-2 O +
site O +
decreased O +
promoter O +
activity O +
in O +
both O +
cell O +
lines O +
. O +

Electrophoretic O +
mobility O +
shift O +
assay O +
analysis O +
of O +
proteins O +
binding O +
to O +
the O +
CRE O +
site O +
identified O +
both O +
ATF-1 O +
and O +
ATF-2 O +
in O +
Jurkat B-CellLine +
cells I-CellLine +
. O +

Finally O +
, O +
phorbol O +
12-myristate O +
13-acetate O +
increased O +
the O +
activity O +
of O +
both O +
the O +
core O +
and O +
the O +
969-bp O +
promoter O +
fragments O +
, O +
and O +
this O +
increase O +
was O +
abrogated O +
by O +
mutations O +
at O +
the O +
CRE O +
site O +
. O +

In O +
summary O +
, O +
we O +
have O +
identified O +
a O +
tissue O -
- O -
specific O +
regulatory O +
region O +
5 O +
' O +
of O +
the O +
ecto-5'-NT O +
core O +
promoter O +
that O +
requires O +
the O +
presence O +
of O +
a O +
functional O +
CRE O +
site O +
within O +
the O +
basal O +
promoter O +
for O +
its O +
suppressive O +
activity O +
. O +

Cell O +
activation O +
and O +
apoptosis O +
by O +
bacterial O +
lipoproteins O +
through O +
toll O -
- O -
like O +
receptor-2 O +
. O +

Apoptosis O +
is O +
implicated O +
in O +
the O +
generation O +
and O +
resolution O +
of O +
inflammation O +
in O +
response O +
to O +
bacterial O +
pathogens O +
. O +

All O +
bacterial O +
pathogens O +
produce O +
lipoproteins O +
( O +
BLPs O +
) O +
, O +
which O +
trigger O +
the O +
innate O +
immune O +
response O +
. O +

BLPs O +
were O +
found O +
to O +
induce O +
apoptosis O +
in O +
THP-1 B-CellLine +
monocytic I-CellLine +
cells I-CellLine +
through O +
human O +
Toll O -
- O -
like O +
receptor-2 O +
( O +
hTLR2 O +
) O +
. O +

BLPs O +
also O +
initiated O +
apoptosis O +
in O +
an O +
epithelial B-CellLine +
cell I-CellLine +
line I-CellLine +
transfected O +
with O +
hTLR2 O +
. O +

In O +
addition O +
, O +
BLPs O +
stimulated O +
nuclear O +
factor O -
- O -
kappaB O +
, O +
a O +
transcriptional O +
activator O +
of O +
multiple O +
host O +
defense O +
genes O +
, O +
and O +
activated O +
the O +
respiratory O +
burst O +
through O +
hTLR2 O +
. O +

Thus O +
, O +
hTLR2 O +
is O +
a O +
molecular O +
link O +
between O +
microbial O +
products O +
, O +
apoptosis O +
, O +
and O +
host O +
defense O +
mechanisms O +
. O +

Selective O +
DNA O -
- O -
binding O +
activity O +
of O +
interleukin-10-stimulated O +
STAT O +
molecules O +
in O +
human O +
monocytes O +
. O +

It O +
has O +
been O +
demonstrated O +
that O +
interferon O -
- O -
gamma O +
( O +
IFN O -
- O -
gamma O +
) O +
and O +
interleukin-10 O +
( O +
IL-10 O +
) O +
have O +
various O +
reverse O +
effects O +
on O +
macrophages O +
; O +
however O +
, O +
the O +
molecular O +
mechanism O +
of O +
this O +
difference O +
has O +
not O +
been O +
fully O +
understood O +
. O +

In O +
this O +
study O +
, O +
we O +
analyzed O +
the O +
binding O +
activity O +
of O +
IL-10- O +
and O +
IFN O -
- O -
gamma O -
- O -
activated O +
STAT O +
molecules O +
to O +
two O +
kinds O +
of O +
GAS O +
-motif O +
sequences O +
. O +

IL-10-activated O +
STAT1 O +
could O +
bind O +
to O +
the O +
GAS O -
- O -
motif O +
sequence O +
in O +
the O +
promoter O +
region O +
of O +
the O +
Fcgamma O +
receptor O +
, O +
but O +
not O +
to O +
that O +
in O +
the O +
promoter O +
region O +
of O +
the O +
COX-2 O +
gene O +
, O +
whereas O +
IFN O -
- O -
gamma O -
- O -
activated O +
STAT1 O +
and O +
STAT5 O +
could O +
bind O +
to O +
both O +
sequences O +
. O +

IL-10 O +
inhibited O +
IFN O -
- O -
gamma O +
-induced O +
STAT O +
activation O +
without O +
newly O +
synthesized O +
protein O +
. O +

We O +
further O +
demonstrated O +
that O +
aspirin O +
, O +
but O +
not O +
dexamethasone O +
, O +
suppressed O +
IFN O -
- O -
gamma O +
-induced O +
STAT O +
activation O +
. O +

Taken O +
together O +
, O +
these O +
results O +
suggest O +
that O +
IL-10-activated O +
STAT1 O +
has O +
a O +
specificity O +
in O +
binding O +
to O +
the O +
GAS O -
- O -
motif O +
sequences O +
, O +
whereas O +
IFN O -
- O -
gamma O -
- O -
activated O +
STAT1 O +
and O +
STAT5 O +
have O +
a O +
broader O +
spectrum O +
in O +
binding O +
to O +
the O +
GAS O -
- O -
motif O +
sequences O +
. O +

This O +
may O +
explain O +
the O +
difference O +
between O +
IL-10 O +
and O +
IFN O -
- O -
gamma O +
in O +
biological O +
activity O +
, O +
and O +
the O +
inhibitory O +
effect O +
of O +
IL-10 O +
on O +
IFN O -
- O -
gamma O +
activities O +
. O +

Block O +
of O +
granulocytic O +
differentiation O +
of O +
32Dcl3 B-CellLine +
cells I-CellLine +
by O +
AML1 O -
/ O -
ETO O +
( O +
MTG8 O +
) O +
but O +
not O +
by O +
highly O +
expressed O +
Bcl-2 O +
. O +

The O +
chimeric O +
gene O +
, O +
AML1 O -
/ O -
ETO O +
( O +
MTG8 O +
) O +
, O +
generated O +
in O +
t O +
( O +
8 O +
; O +
21 O +
) O +
acute O +
myeloid O +
leukemia O +
enhances O +
the O +
expression O +
of O +
Bcl-2 O +
. O +

To O +
evaluate O +
whether O +
this O +
enhancement O +
is O +
the O +
primary O +
role O +
of O +
AML1 O -
/ O -
ETO O +
in O +
leukemogenesis O +
, O +
effects O +
of O +
over O -
- O -
expression O +
of O +
Bcl-2 O +
in O +
the O +
murine B-CellLine +
myeloid I-CellLine +
precursor I-CellLine +
cell I-CellLine +
line I-CellLine +
, O +
32Dcl3 B-CellLine +
, O +
were O +
examined O +
. O +

When O +
32Dcl3 B-CellLine +
cells I-CellLine +
expressing O +
exogenous O +
Bcl-2 O +
were O +
induced O +
to O +
differentiate O +
, O +
the O +
onset O +
of O +
morphological O +
differentiation O +
was O +
delayed O +
. O +

However O +
, O +
even O +
the O +
cells O +
expressing O +
very O +
high O +
levels O +
of O +
exogenous O +
Bcl-2 O +
eventually O +
underwent O +
differentiation O +
without O +
a O +
significant O +
decrease O +
in O +
the O +
synthesis O +
of O +
Bcl-2 O +
. O +

On O +
the O +
contrary O +
, O +
32Dcl3 B-CellLine +
cells I-CellLine +
stably O +
expressing O +
AML1 O -
/ O -
ETO O +
were O +
completely O +
resistant O +
to O +
differentiation O +
and O +
continued O +
to O +
grow O +
in O +
the O +
presence O +
of O +
G O -
- O -
CSF O +
. O +

These O +
results O +
are O +
consistent O +
with O +
the O +
interpretation O +
that O +
stimulation O +
of O +
Bcl-2 O +
expression O +
is O +
not O +
the O +
primary O +
target O +
of O +
AML1 O -
/ O -
ETO O +
. O +

NF O -
- O -
kappaB O -
- O -
mediated O +
up O -
- O -
regulation O +
of O +
Bcl O -
- O -
x O +
and O +
Bfl-1 O -
/ O -
A1 O +
is O +
required O +
for O +
CD40 O +
survival O +
signaling O +
in O +
B O +
lymphocytes O +
. O +

Activation O +
of O +
CD40 O +
is O +
essential O +
for O +
thymus O -
- O -
dependent O +
humoral O +
immune O +
responses O +
and O +
rescuing O +
B O +
cells O +
from O +
apoptosis O +
. O +

Many O +
of O +
the O +
effects O +
of O +
CD40 O +
are O +
believed O +
to O +
be O +
achieved O +
through O +
altered O +
gene O +
expression O +
. O +

In O +
addition O +
to O +
Bcl O -
- O -
x O +
, O +
a O +
known O +
CD40-regulated O +
antiapoptotic O +
molecule O +
, O +
we O +
identified O +
a O +
related O +
antiapoptotic O +
molecule O +
, O +
A1 O -
/ O -
Bfl-1 O +
, O +
as O +
a O +
CD40-inducible O +
gene O +
. O +

Inhibition O +
of O +
the O +
NF O -
- O -
kappaB O +
pathway O +
by O +
overexpression O +
of O +
a O +
dominant O -
- O -
active O +
inhibitor O +
of O +
NF O -
- O -
kappaB O +
abolished O +
CD40 O +
-induced O +
up O -
- O -
regulation O +
of O +
both O +
the O +
Bfl-1 O +
and O +
Bcl O -
- O -
x O +
genes O +
and O +
also O +
eliminated O +
the O +
ability O +
of O +
CD40 O +
to O +
rescue O +
Fas O +
-induced O +
cell O +
death O +
. O +

Within O +
the O +
upstream O +
promoter O +
region O +
of O +
Bcl O -
- O -
x O +
, O +
a O +
potential O +
NF O -
- O -
kappaB O -
- O -
binding O +
sequence O +
was O +
found O +
to O +
support O +
NF O -
- O -
kappaB O +
-dependent O +
transcriptional O +
activation O +
. O +

Furthermore O +
, O +
expression O +
of O +
physiological O +
levels O +
of O +
Bcl O -
- O -
x O +
protected O +
B O +
cells O +
from O +
Fas O -
- O -
mediated O +
apoptosis O +
in O +
the O +
absence O +
of O +
NF O -
- O -
kappaB O +
signaling O +
. O +

Thus O +
, O +
our O +
results O +
suggest O +
that O +
CD40 O +
-mediated O +
cell O +
survival O +
proceeds O +
through O +
NF O -
- O -
kappaB O +
-dependent O +
up O -
- O -
regulation O +
of O +
Bcl-2 O +
family O +
members O +
. O +

The O +
Epstein O -
- O -
Barr O +
virus O +
latency O +
BamHI O -
- O -
Q O +
promoter O +
is O +
positively O +
regulated O +
by O +
STATs O +
and O +
Zta O +
interference O +
with O +
JAK O +
/STAT O +
activation O +
leads O +
to O +
loss O +
of O +
BamHI O -
- O -
Q O +
promoter O +
activity O +
. O +

In O +
Epstein O -
- O -
Barr O +
virus O +
( O +
EBV O +
) O +
-associated O +
tumors O +
in O +
nonimmunocompromised O +
patients O +
, O +
EBV O +
gene O +
expression O +
is O +
highly O +
restricted O +
. O +

EBV O -
- O -
encoded O +
nuclear O +
antigen O +
( O +
EBNA O +
) O +
-1 O +
is O +
expressed O +
, O +
whereas O +
the O +
immunogenic O +
and O +
proliferative O +
EBNAs O +
are O +
not O +
. O +

This O +
pattern O +
of O +
EBNA O +
expression O +
is O +
generated O +
by O +
usage O +
of O +
the O +
BamHI O -
- O -
Q O +
promoter O +
( O +
Qp O +
) O +
. O +

We O +
have O +
determined O +
that O +
the O +
JAK O +
/STAT O +
pathway O +
positively O +
regulates O +
Qp O +
activity O +
. O +

In O +
transient O -
- O -
transfection O +
assays O +
, O +
a O +
Qp O -
- O -
CAT O +
reporter O +
was O +
activated O +
by O +
cotransfected O +
JAK-1 O +
and O +
by O +
treatment O +
of O +
cells O +
with O +
the O +
cytokine O +
IL-6 O +
. O +

The O +
ability O +
of O +
Qp O +
to O +
bind O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
( O +
STAT O +
) O +
proteins O +
was O +
directly O +
demonstrated O +
by O +
electrophoretic O +
mobility O -
- O -
shift O +
assay O +
, O +
and O +
mutation O +
of O +
potential O +
STAT O -
- O -
binding O +
sites O +
reduced O +
Qp O +
responsiveness O +
to O +
Janus O +
kinase O +
( O +
JAK O +
) O +
-1 O +
. O +

Consistent O +
with O +
a O +
role O +
for O +
STATs O +
in O +
Qp O +
function O +
, O +
Qp O +
using O +
Burkitt B-CellLine +
's I-CellLine +
lymphoma I-CellLine +
Rael I-CellLine +
cells I-CellLine +
and O +
cultured O +
nasopharyngeal O +
carcinoma O +
( O +
NPC O +
) O +
cells O +
contained O +
nuclear O +
STAT O +
protein O +
. O +

We O +
investigated O +
whether O +
the O +
inability O +
to O +
maintain O +
EBV B-CellLine -
- I-CellLine -
positive I-CellLine +
NPC I-CellLine +
cell I-CellLine +
lines I-CellLine +
in O +
culture O +
was O +
related O +
to O +
Qp O +
activity O +
. O +

Passaging O +
of O +
the O +
NPC B-CellLine +
cell I-CellLine +
line I-CellLine +
HK666 I-CellLine +
led O +
to O +
activation O +
of O +
expression O +
of O +
BZLF1 O +
, O +
which O +
encodes O +
Zta O +
and O +
loss O +
of O +
Qp O +
function O +
. O +

Transient O +
expression O +
assays O +
linked O +
Zta O +
expression O +
to O +
the O +
down O -
- O -
regulation O +
of O +
Qp O +
. O +

Cotransfection O +
of O +
Zta O +
reduced O +
Qp O +
activity O +
in O +
reporter O +
assays O +
. O +

This O +
negative O +
regulation O +
required O +
Zta O +
DNA O -
- O -
binding O +
activity O +
. O +

We O +
provide O +
evidence O +
that O +
Zta O +
up O -
- O -
regulation O +
of O +
p53 O +
leads O +
to O +
p53 O +
-mediated O +
interference O +
with O +
JAK O +
/STAT O +
activation O +
of O +
Qp O +
. O +

The O +
data O +
imply O +
that O +
JAK O +
/STAT O +
signaling O +
has O +
a O +
role O +
in O +
EBV O -
- O -
associated O +
malignancies O +
. O +

Retinoblastoma O +
protein O +
expression O +
leads O +
to O +
reduced O +
Oct-1 O +
DNA O +
binding O +
activity O +
and O +
enhances O +
interleukin-8 O +
expression O +
. O +

Tumor O +
cell O +
lines O +
with O +
a O +
defective O +
retinoblastoma O +
gene O +
are O +
unable O +
to O +
transcribe O +
the O +
HLA O +
class O +
II O +
genes O +
in O +
response O +
to O +
IFN O -
- O -
gamma O +
treatment O +
, O +
and O +
reconstitution O +
of O +
functional O +
Rb O +
rescues O +
IFN O -
- O -
gamma O -
- O -
induced O +
class O +
II O +
gene O +
expression O +
. O +

However O +
, O +
the O +
molecular O +
mechanism O +
of O +
Rb O +
rescue O +
of O +
the O +
class O +
II O +
genes O +
is O +
unknown O +
. O +

We O +
have O +
examined O +
the O +
effect O +
of O +
Rb O +
expression O +
on O +
the O +
activation O +
of O +
the O +
promoter O +
for O +
HLA O -
- O -
DRA O +
, O +
the O +
prototype O +
class O +
II O +
gene O +
. O +

Oct-1 O +
, O +
a O +
POU O +
domain O +
transcription O +
factor O +
, O +
was O +
identified O +
as O +
a O +
repressor O +
of O +
HLA O -
- O -
DRA O +
promoter O +
activity O +
in O +
the O +
Rb O -
- O -
defective O +
cells O +
. O +

Rb O +
expression O +
led O +
to O +
phosphorylation O +
of O +
Oct-1 O +
, O +
thus O +
relieving O +
its O +
repressive O +
effect O +
. O +

Oct-1 O +
has O +
also O +
been O +
shown O +
to O +
repress O +
interleukin O +
8 O +
promoter O +
activity O +
. O +

Consistent O +
with O +
reduced O +
levels O +
of O +
Oct-1 O +
DNA O +
binding O +
activity O +
in O +
the O +
Rb B-CellLine -
- I-CellLine -
transformed I-CellLine +
cell I-CellLine +
lines I-CellLine +
, O +
interleukin O +
8 O +
expression O +
is O +
higher O +
in O +
these O +
cell O +
lines O +
. O +

Protein O +
kinase O +
C O +
and O +
calcineurin O +
synergize O +
to O +
activate O +
IkappaB O +
kinase O +
and O +
NF O -
- O -
kappaB O +
in O +
T O +
lymphocytes O +
. O +

The O +
nuclear O +
factor O +
of O +
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
is O +
a O +
ubiquitous O +
transcription O +
factor O +
that O +
is O +
key O +
in O +
the O +
regulation O +
of O +
the O +
immune O +
response O +
and O +
inflammation O +
. O +

T O +
cell O +
receptor O +
( O +
TCR O +
) O +
cross O -
- O -
linking O +
is O +
in O +
part O +
required O +
for O +
activation O +
of O +
NF O -
- O -
kappaB O +
, O +
which O +
is O +
dependent O +
on O +
the O +
phosphorylation O +
and O +
degradation O +
of O +
IkappaBalpha O +
. O +

By O +
using O +
Jurkat B-CellLine +
and O +
primary O +
human O +
T O +
lymphocytes O +
, O +
we O +
demonstrate O +
that O +
the O +
simultaneous O +
activation O +
of O +
two O +
second O +
messengers O +
of O +
the O +
TCR O +
-initiated O +
signal O +
transduction O +
, O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
and O +
calcineurin O +
, O +
results O +
in O +
the O +
synergistic O +
activation O +
of O +
the O +
IkappaBalpha O +
kinase O +
( O +
IKK O +
) O +
complex O +
but O +
not O +
of O +
another O +
putative O +
IkappaBalpha O +
kinase O +
, O +
p90 O +
( O +
rsk O +
) O +
. O +

We O +
also O +
demonstrate O +
that O +
the O +
IKK O +
complex O +
, O +
but O +
not O +
p90 O +
( O +
rsk O +
) O +
, O +
is O +
responsible O +
for O +
the O +
in O +
vivo O +
phosphorylation O +
of O +
IkappaBalpha O +
mediated O +
by O +
the O +
co O -
- O -
activation O +
of O +
PKC O +
and O +
calcineurin O +
. O +

Each O +
second O +
messenger O +
is O +
necessary O +
, O +
as O +
inhibition O +
of O +
either O +
one O +
reverses O +
the O +
activation O +
of O +
the O +
IKK O +
complex O +
and O +
IkappaBalpha O +
phosphorylation O +
in O +
vivo O +
. O +

Overexpression O +
of O +
dominant O +
negative O +
forms O +
of O +
IKKalpha O +
and O +
-beta O +
demonstrates O +
that O +
only O +
IKKbeta O +
is O +
the O +
target O +
for O +
PKC O +
and O +
calcineurin O +
. O +

These O +
results O +
indicate O +
that O +
within O +
the O +
TCR O +
/CD3 O +
signal O +
transduction O +
pathway O +
both O +
PKC O +
and O +
calcineurin O +
are O +
required O +
for O +
the O +
effective O +
activation O +
of O +
the O +
IKK O +
complex O +
and O +
NF O -
- O -
kappaB O +
in O +
T O +
lymphocytes O +
. O +

C O -
/ O -
EBPbeta O +
and O +
GATA-1 O +
synergistically O +
regulate O +
activity O +
of O +
the O +
eosinophil O +
granule O +
major O +
basic O +
protein O +
promoter O +
: O +
implication O +
for O +
C O -
/ O -
EBPbeta O +
activity O +
in O +
eosinophil O +
gene O +
expression O +
. O +

Eosinophil O +
granule O +
major O +
basic O +
protein O +
( O +
MBP O +
) O +
is O +
expressed O +
exclusively O +
in O +
eosinophils O +
and O +
basophils O +
in O +
hematopoietic O +
cells O +
. O +

In O +
our O +
previous O +
study O +
, O +
we O +
demonstrated O +
a O +
major O +
positive O +
regulatory O +
role O +
for O +
GATA-1 O +
and O +
a O +
negative O +
regulatory O +
role O +
for O +
GATA-2 O +
in O +
MBP O +
gene O +
transcription O +
. O +

Further O +
analysis O +
of O +
the O +
MBP O +
promoter O +
region O +
identified O +
a O +
C O -
/ O -
EBP O +
( O +
CCAAT O -
/ O -
enhancer O -
- O -
binding O +
protein O +
) O +
consensus O +
binding O +
site O +
6 O +
bp O +
upstream O +
of O +
the O +
functional O +
GATA O -
- O -
binding O +
site O +
in O +
the O +
MBP O +
gene O +
. O +

In O +
the O +
cell B-CellLine +
line I-CellLine +
HT93A I-CellLine +
, O +
which O +
is O +
capable O +
of O +
differentiating O +
towards O +
both O +
the O +
eosinophil O +
and O +
neutrophil O +
lineages O +
in O +
response O +
to O +
retinoic O +
acid O +
( O +
RA O +
) O +
, O +
C O -
/ O -
EBPalpha O +
mRNA O +
expression O +
decreased O +
significantly O +
concomitant O +
with O +
eosinophilic O +
and O +
neutrophilic O +
differentiation O +
, O +
whereas O +
C O -
/ O -
EBPbeta O +
expression O +
was O +
markedly O +
increased O +
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
( O +
EMSAs O +
) O +
showed O +
that O +
recombinant O +
C O -
/ O -
EBPbeta O +
protein O +
could O +
bind O +
to O +
the O +
potential O +
C O -
/ O -
EBP O -
- O -
binding O +
site O +
( O +
bp O +
-90 O +
to O +
-82 O +
) O +
in O +
the O +
MBP O +
promoter O +
. O +

Furthermore O +
, O +
we O +
have O +
demonstrated O +
that O +
both O +
C O -
/ O -
EBPbeta O +
and O +
GATA-1 O +
can O +
bind O +
simultaneously O +
to O +
the O +
C O -
/ O -
EBP- O +
and O +
GATA O -
- O -
binding O +
sites O +
in O +
the O +
MBP O +
promoter O +
. O +

To O +
determine O +
the O +
functionality O +
of O +
both O +
the O +
C O -
/ O -
EBP- O +
and O +
GATA- O +
binding O +
sites O +
, O +
we O +
analyzed O +
whether O +
C O -
/ O -
EBPbeta O +
and O +
GATA-1 O +
can O +
stimulate O +
the O +
MBP O +
promoter O +
in O +
the O +
C B-CellLine -
/ I-CellLine -
EBPbeta I-CellLine +
and I-CellLine +
GATA-1 I-CellLine +
negative I-CellLine +
Jurkat I-CellLine +
T I-CellLine -
- I-CellLine -
cell I-CellLine +
line I-CellLine +
. O +

Cotransfection O +
with O +
C O -
/ O -
EBPbeta O +
and O +
GATA-1 O +
expression O +
vectors O +
produced O +
a O +
5-fold O +
increase O +
compared O +
with O +
cotransfection O +
with O +
the O +
C O -
/ O -
EBPbeta O +
or O +
GATA-1 O +
expression O +
vectors O +
individually O +
. O +

In O +
addition O +
, O +
GST O +
pull O -
- O -
down O +
experiments O +
demonstrated O +
a O +
physical O +
interaction O +
between O +
human O +
GATA-1 O +
and O +
C O -
/ O -
EBPbeta O +
. O +

Expression O +
of O +
FOG O +
( O +
riend O +
ATA O +
) O +
, O +
which O +
binds O +
to O +
GATA-1 O +
and O +
acts O +
as O +
a O +
cofactor O +
for O +
GATA O -
- O -
binding O +
proteins O +
, O +
decreased O +
transactivation O +
activity O +
of O +
GATA-1 O +
for O +
the O +
MBP O +
promoter O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
. O +

Our O +
results O +
provide O +
the O +
first O +
evidence O +
that O +
both O +
GATA-1 O +
and O +
C O -
/ O -
EBPbeta O +
synergistically O +
transactivate O +
the O +
promoter O +
of O +
an O +
eosinophil O -
- O -
specific O +
granule O +
protein O +
gene O +
and O +
that O +
FOG O +
may O +
act O +
as O +
a O +
negative O +
cofactor O +
for O +
the O +
eosinophil O +
lineage O +
, O +
unlike O +
its O +
positively O +
regulatory O +
function O +
for O +
the O +
erythroid O +
and O +
megakaryocyte O +
lineages O +
. O +

The O +
Legionella O +
pneumophila O +
rpoS O +
gene O +
is O +
required O +
for O +
growth O +
within O +
Acanthamoeba O +
castellanii O +
. O +

To O +
investigate O +
regulatory O +
networks O +
in O +
Legionella O +
pneumophila O +
, O +
the O +
gene O +
encoding O +
the O +
homolog O +
of O +
the O +
Escherichia O +
coli O +
stress O +
and O +
stationary O -
- O -
phase O +
sigma O +
factor O +
RpoS O +
was O +
identified O +
by O +
complementation O +
of O +
an O +
E. O +
coli O +
rpoS O +
mutation O +
. O +

An O +
open O +
reading O +
frame O +
that O +
is O +
approximately O +
60 O +
% O +
identical O +
to O +
the O +
E. O +
coli O +
rpoS O +
gene O +
was O +
identified O +
. O +

Western O +
blot O +
analysis O +
showed O +
that O +
the O +
level O +
of O +
L. O +
pneumophila O +
RpoS O +
increased O +
in O +
stationary O +
phase O +
. O +

An O +
insertion O +
mutation O +
was O +
constructed O +
in O +
the O +
rpoS O +
gene O +
on O +
the O +
chromosome O +
of O +
L. O +
pneumophila O +
, O +
and O +
the O +
ability O +
of O +
this O +
mutant O +
strain O +
to O +
survive O +
various O +
stress O +
conditions O +
was O +
assayed O +
and O +
compared O +
with O +
results O +
for O +
the O +
wild O -
- O -
type O +
strain O +
. O +

Both O +
the O +
mutant O +
and O +
wild O -
- O -
type O +
strains O +
were O +
more O +
resistant O +
to O +
stress O +
when O +
in O +
stationary O +
phase O +
than O +
when O +
in O +
the O +
logarithmic O +
phase O +
of O +
growth O +
. O +

This O +
finding O +
indicates O +
that O +
L. O +
pneumophila O +
RpoS O +
is O +
not O +
required O +
for O +
a O +
stationary O -
- O -
phase O -
- O -
dependent O +
resistance O +
to O +
stress O +
. O +

Although O +
the O +
mutant O +
strain O +
was O +
able O +
to O +
kill O +
HL-60- O +
and O +
THP-1-derived O +
macrophages O +
, O +
it O +
could O +
not O +
replicate O +
within O +
a O +
protozoan O +
host O +
, O +
Acanthamoeba O +
castellanii O +
. O +

These O +
data O +
suggest O +
that O +
L. O +
pneumophila O +
possesses O +
a O +
growth O +
phase O -
- O -
dependent O +
resistance O +
to O +
stress O +
that O +
is O +
independent O +
of O +
RpoS O +
control O +
and O +
that O +
RpoS O +
likely O +
regulates O +
genes O +
that O +
enable O +
it O +
to O +
survive O +
in O +
the O +
environment O +
within O +
protozoa O +
. O +

Our O +
data O +
indicate O +
that O +
the O +
role O +
of O +
rpoS O +
in O +
L. O +
pneumophila O +
is O +
very O +
different O +
from O +
what O +
has O +
previously O +
been O +
reported O +
for O +
E. O +
coli O +
rpoS O +
. O +

Suppression O +
of O +
TNFalpha O +
-mediated O +
NFkappaB O +
activity O +
by O +
myricetin O +
and O +
other O +
flavonoids O +
through O +
downregulating O +
the O +
activity O +
of O +
IKK O +
in O +
ECV304 B-CellLine +
cells I-CellLine +
. O +

Flavonoids O +
are O +
a O +
group O +
of O +
naturally O -
- O -
occurring O +
phenolic O +
compounds O +
in O +
the O +
plant O +
kingdom O +
, O +
and O +
many O +
flavonoids O +
are O +
found O +
with O +
vascular O +
protective O +
properties O +
. O +

Nevertheless O +
how O +
the O +
protective O +
response O +
is O +
exerted O +
by O +
flavonoids O +
is O +
not O +
well O +
characterized O +
. O +

In O +
view O +
of O +
the O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NFkappaB O +
) O +
may O +
play O +
a O +
central O +
role O +
in O +
the O +
initiation O +
of O +
atherosclerosis O +
, O +
prevention O +
of O +
the O +
activation O +
of O +
NFkappaB O +
represents O +
an O +
important O +
role O +
in O +
protecting O +
vascular O +
injury O +
. O +

In O +
this O +
study O +
, O +
the O +
effects O +
of O +
flavonoids O +
on O +
NFkappaB O +
/inhibitor O -
- O -
kappaB O +
( O +
IkappaB O +
) O +
system O +
in O +
ECV304 B-CellLine +
cells I-CellLine +
activated O +
with O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNFalpha O +
) O +
were O +
examined O +
. O +

We O +
investigated O +
the O +
inhibitory O +
action O +
of O +
six O +
flavonoids O +
on O +
IkappaB O +
kinase O +
( O +
IKK O +
) O +
activity O +
, O +
an O +
enzyme O +
recently O +
found O +
to O +
phosphorylate O +
critical O +
serine O +
residues O +
of O +
IkappaB O +
for O +
degradation O +
. O +

Of O +
six O +
flavonoids O +
tested O +
, O +
myricetin O +
was O +
found O +
to O +
strongly O +
inhibit O +
IKK O +
kinase O +
activity O +
, O +
and O +
prevent O +
the O +
degradation O +
of O +
IkappaBalpha O +
and O +
IkappaBbeta O +
in O +
activated O +
endothelial O +
cells O +
. O +

Furthermore O +
, O +
myricetin O +
was O +
also O +
found O +
to O +
inhibit O +
NFkappaB O +
activity O +
correlated O +
with O +
suppression O +
of O +
monocyte O +
adhesion O +
to O +
ECV304 B-CellLine +
cells I-CellLine +
. O +

Therefore O +
we O +
conclude O +
that O +
flavonoids O +
may O +
be O +
of O +
therapeutic O +
value O +
for O +
vascular O +
disease O +
through O +
down O +
regulation O +
of O +
NFkappaB O +
/IkappaB O +
system O +
. O +

Copyright O +
1999 O +
Wiley O -
- O -
Liss O +
, O +
Inc O +
. O +

IL-2 O +
-independent O +
activation O +
and O +
proliferation O +
in O +
human O +
T O +
cells O +
induced O +
by O +
CD28 O +
. O +

Although O +
the O +
role O +
of O +
CD28 O +
in O +
T O +
cell O +
costimulation O +
is O +
firmly O +
established O +
, O +
the O +
mechanisms O +
by O +
which O +
it O +
exerts O +
its O +
costimulatory O +
actions O +
are O +
less O +
clear O +
. O +

In O +
many O +
circumstances O +
it O +
is O +
difficult O +
to O +
distinguish O +
the O +
effects O +
of O +
CD28 O +
from O +
subsequent O +
actions O +
of O +
cytokines O +
, O +
such O +
as O +
IL-2 O +
, O +
on O +
T O +
cell O +
proliferation O +
. O +

Here O +
, O +
we O +
report O +
a O +
model O +
of O +
CD28 O +
costimulation O +
using O +
PMA O +
plus O +
the O +
natural O +
ligand O +
CD80 O +
that O +
resulted O +
in O +
very O +
limited O +
stimulation O +
of O +
IL-2 O +
, O +
as O +
evidenced O +
by O +
both O +
cytokine O +
production O +
and O +
IL-2 O +
promoter O +
stimulation O +
. O +

Promoter O +
assays O +
revealed O +
CD28 O +
-dependent O +
effects O +
on O +
both O +
NF O -
- O -
kappaB O +
and O +
AP-1 O +
, O +
but O +
not O +
on O +
NF O -
- O -
AT O +
or O +
the O +
intact O +
IL-2 O +
promoter O +
. O +

In O +
addition O +
, O +
T O +
cell O +
proliferation O +
was O +
completely O +
resistant O +
to O +
the O +
actions O +
of O +
the O +
immunosuppressant O +
cyclosporin O +
A O +
( O +
CsA O +
) O +
. O +

Moreover O +
T O +
cell O +
proliferation O +
was O +
unaffected O +
by O +
the O +
addition O +
of O +
blocking O +
Abs O +
to O +
both O +
IL-2 O +
and O +
the O +
IL-2 O +
receptor O +
, O +
demonstrating O +
that O +
this O +
form O +
of O +
costimulation O +
by O +
CD28 O +
was O +
independent O +
of O +
IL-2 O +
. O +

We O +
also O +
investigated O +
the O +
effects O +
of O +
stimulating O +
T O +
cell O +
blasts O +
with O +
CD80 O +
alone O +
and O +
found O +
that O +
there O +
was O +
a O +
limited O +
requirement O +
for O +
IL-2 O +
in O +
this O +
system O +
. O +

We O +
conclude O +
that O +
CD28 O +
costimulation O +
can O +
cause O +
substantial O +
T O +
cell O +
proliferation O +
in O +
the O +
absence O +
of O +
IL-2 O +
, O +
which O +
is O +
driven O +
by O +
a O +
soluble O +
factor O +
independent O +
of O +
NF O -
- O -
AT O +
transactivation O +
. O +

Thymocyte O -
- O -
thymic O +
epithelial O +
cell O +
interaction O +
leads O +
to O +
high O -
- O -
level O +
replication O +
of O +
human O +
immunodeficiency O +
virus O +
exclusively O +
in O +
mature O +
CD4 O +
( O +
+ O +
) O +
CD8 O +
( O +
- O +
) O +
CD3 O +
( O +
+ O +
) O +
thymocytes O +
: O +
a O +
critical O +
role O +
for O +
tumor O +
necrosis O +
factor O +
and O +
interleukin-7 O +
. O +

This O +
work O +
aims O +
at O +
identifying O +
the O +
thymocyte O +
subpopulation O +
able O +
to O +
support O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
replication O +
under O +
the O +
biological O +
stimuli O +
of O +
the O +
thymic O +
microenvironment O +
. O +

In O +
this O +
report O +
we O +
demonstrate O +
that O +
interaction O +
with O +
thymic O +
epithelial O +
cells O +
( O +
TEC O +
) O +
induces O +
a O +
high O -
- O -
level O +
replication O +
of O +
the O +
T O -
- O -
tropic O +
primary O +
isolate O +
HIV-1 O +
( O +
B O -
- O -
LAIp O +
) O +
exclusively O +
in O +
the O +
mature O +
CD4 O +
( O +
+ O +
) O +
CD8 O +
( O +
- O +
) O +
CD3 O +
( O +
+ O +
) O +
thymocytes O +
. O +

Tumor O +
necrosis O +
factor O +
( O +
TNF O +
) O +
and O +
interleukin-7 O +
( O +
IL-7 O +
) O +
, O +
secreted O +
during O +
this O +
interaction O +
, O +
are O +
critical O +
cytokines O +
for O +
HIV O +
long O +
terminal O +
repeat O +
transactivation O +
through O +
NF O -
- O -
kappaB O +
-dependent O +
activation O +
. O +

TNF O +
is O +
the O +
major O +
inducer O +
of O +
NF O -
- O -
kappaB O +
and O +
particularly O +
of O +
the O +
p50-p65 O +
complex O +
, O +
whereas O +
IL-7 O +
acts O +
as O +
a O +
cofactor O +
by O +
sustaining O +
the O +
expression O +
of O +
the O +
p75 O +
TNF O +
receptor O +
. O +

The O +
requirement O +
for O +
TNF O +
is O +
further O +
confirmed O +
by O +
the O +
observation O +
that O +
the O +
inability O +
of O +
the O +
intermediate O +
CD4 O +
( O +
+ O +
) O +
CD8 O +
( O +
- O +
) O +
CD3 O +
( O +
- O +
) O +
thymocytes O +
to O +
replicate O +
the O +
virus O +
is O +
associated O +
with O +
a O +
defect O +
in O +
TNF O +
production O +
during O +
their O +
interaction O +
with O +
TEC O +
and O +
correlates O +
with O +
the O +
absence O +
of O +
nuclear O +
NF O -
- O -
kappaB O +
activity O +
in O +
these O +
freshly O +
isolated O +
thymocytes O +
. O +

Addition O +
of O +
exogenous O +
TNF O +
to O +
the O +
intermediate B-CellLine +
thymocyte I-CellLine +
cultures I-CellLine +
induces O +
NF O -
- O -
kappaB O +
activity O +
and O +
is O +
sufficient O +
to O +
promote O +
HIV O +
replication O +
in O +
the O +
cocultures O +
with O +
TEC O +
. O +

The O +
other O +
major O +
subpopulation O +
expressing O +
the O +
CD4 O +
receptor O +
, O +
namely O +
, O +
the O +
double O -
- O -
positive O +
( O +
DP O +
) O +
CD4 O +
( O +
+ O +
) O +
CD8 O +
( O +
+ O +
) O +
CD3 O +
( O +
+ O -
/- O +
) O +
thymocytes O +
, O +
despite O +
the O +
entry O +
of O +
the O +
virus O +
, O +
do O +
not O +
produce O +
a O +
significant O +
level O +
of O +
virus O +
, O +
presumably O +
because O +
they O +
are O +
unresponsive O +
to O +
TNF O +
and O +
IL-7 O +
. O +

Together O +
, O +
these O +
data O +
suggest O +
that O +
in O +
vivo O +
, O +
despite O +
an O +
efficient O +
entry O +
of O +
the O +
virus O +
in O +
all O +
the O +
CD4 O +
( O +
+ O +
) O +
subpopulations O +
, O +
a O +
high O +
viral O +
load O +
may O +
be O +
generated O +
exclusively O +
within O +
the O +
mature O +
CD4 O +
( O +
+ O +
) O +
CD8 O +
( O +
- O +
) O +
CD3 O +
( O +
+ O +
) O +
subset O +
of O +
thymocytes O +
. O +

However O +
, O +
under O +
conditions O +
of O +
inflammatory O +
response O +
after O +
infection O +
, O +
TNF O +
might O +
also O +
be O +
present O +
in O +
the O +
intermediate O +
thymocyte O +
compartment O +
, O +
leading O +
to O +
efficient O +
HIV O +
replication O +
in O +
these O +
cells O +
. O +

Tumor O +
necrosis O +
factor O +
alpha O +
decreases O +
, O +
and O +
interleukin-10 O +
increases O +
, O +
the O +
sensitivity O +
of O +
human O +
monocytes O +
to O +
dexamethasone O +
: O +
potential O +
regulation O +
of O +
the O +
glucocorticoid O +
receptor O +
. O +

Resistance O +
to O +
glucocorticoid O +
therapy O +
has O +
been O +
observed O +
in O +
patients O +
with O +
autoimmune O -
/ O -
inflammatory O +
diseases O +
and O +
may O +
be O +
related O +
to O +
the O +
inflammatory O +
process O +
itself O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
examine O +
the O +
ability O +
of O +
tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNFalpha O +
, O +
a O +
proinflammatory O +
cytokine O +
) O +
and O +
interleukin O +
( O +
IL O +
) O +
-10 O +
( O +
an O +
anti O -
- O -
inflammatory O +
cytokine O +
) O +
to O +
differentially O +
regulate O +
the O +
sensitivity O +
of O +
human O +
monocytes O +
/macrophages O +
to O +
glucocorticoids O +
. O +

To O +
accomplish O +
this O +
, O +
we O +
first O +
analyzed O +
the O +
pattern O +
of O +
TNFalpha O +
and O +
IL-10 O +
inhibition O +
by O +
dexamethasone O +
in O +
LPS B-CellLine -
- I-CellLine -
stimulated I-CellLine +
whole I-CellLine -
- I-CellLine -
blood I-CellLine +
cell I-CellLine +
cultures I-CellLine +
. O +

Second O +
, O +
we O +
studied O +
the O +
modulation O +
of O +
the O +
sensitivity O +
of O +
these O +
cells O +
to O +
dexamethasone O +
by O +
preincubation O +
with O +
TNFalpha O +
or O +
IL-10 O +
and O +
measurement O +
of O +
LPS O -
- O -
stimulated O +
IL-6 O +
secretion O +
. O +

In O +
addition O +
, O +
we O +
evaluated O +
the O +
effect O +
of O +
dexamethasone O +
on O +
phorbolmyristate O -
- O -
acetate O -
- O -
stimulated O +
IL-1 O +
receptor O +
antagonist O +
secretion O +
by O +
the O +
human B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
U937 I-CellLine +
. O +

Finally O +
, O +
we O +
investigated O +
whether O +
the O +
modulation O +
of O +
corticosensitivity O +
in O +
TNFalpha- B-CellLine +
and I-CellLine +
IL-10-pretreated I-CellLine +
U937 I-CellLine +
cells I-CellLine +
was O +
related O +
to O +
a O +
change O +
of O +
the O +
glucocorticoid O +
receptor O +
concentration O +
and O +
affinity O +
. O +

Dexamethasone O +
had O +
different O +
effects O +
on O +
LPS O -
- O -
induced O +
TNFalpha O +
and O +
IL-10 O +
secretion O +
; O +
whereas O +
it O +
suppressed O +
TNFalpha O +
in O +
a O +
dose O -
- O -
dependent O +
fashion O +
, O +
its O +
effect O +
on O +
IL-10 O +
secretion O +
was O +
biphasic O +
, O +
producing O +
stimulation O +
at O +
lower O +
, O +
and O +
inhibition O +
at O +
higher O +
doses O +
. O +

The O +
concentration O +
of O +
LPS O +
employed O +
influenced O +
the O +
effect O +
of O +
dexamethasone O +
on O +
IL-10 O +
secretion O +
( O +
P O +
< O +
0.001 O +
) O +
. O +

Pretreatment O +
with O +
TNFalpha O +
diminished O +
, O +
and O +
with O +
IL-10 O +
improved O +
, O +
the O +
ability O +
of O +
dexamethasone O +
to O +
suppress O +
IL-6 O +
secretion O +
in O +
whole O -
- O -
blood O +
cell O +
cultures O +
( O +
P O +
< O +
0.01 O +
for O +
both O +
) O +
and O +
to O +
enhance O +
IL-1 O +
receptor O +
antagonist O +
secretion O +
by O +
U937 O +
cells O +
( O +
P O +
< O +
0.05 O +
for O +
both O +
) O +
. O +

TNFalpha O +
decreased O +
( O +
P O +
< O +
0.001 O +
) O +
, O +
while O +
IL-10 O +
increased O +
( O +
P O +
< O +
0.001 O +
) O +
, O +
the O +
concentration O +
of O +
dexamethasone O +
binding O +
sites O +
in O +
these O +
cells O +
, O +
with O +
no O +
discernible O +
effect O +
on O +
their O +
binding O +
affinity O +
. O +

We O +
conclude O +
that O +
glucocorticoids O +
differentially O +
modulate O +
TNFalpha O +
and O +
IL-10 O +
secretion O +
by O +
human O +
monocytes O +
in O +
a O +
LPS O +
dose O -
- O -
dependent O +
fashion O +
and O +
that O +
the O +
sensitivity O +
of O +
these O +
cells O +
to O +
glucocorticoids O +
is O +
altered O +
by O +
TNFalpha O +
or O +
IL-10 O +
pretreatment O +
; O +
TNFalpha O +
blocks O +
their O +
effects O +
, O +
whereas O +
IL-10 O +
acts O +
synergistically O +
with O +
glucocorticoids O +
. O +

This O +
is O +
accompanied O +
by O +
opposite O +
glucocorticoid O +
receptor O +
changes O +
, O +
respectively O +
opposing O +
and O +
favoring O +
glucocorticoid O +
actions O +
. O +

This O +
study O +
suggests O +
that O +
the O +
pattern O +
of O +
pro- O -
/ O -
antiinflammatory O +
cytokine O +
secretion O +
may O +
alter O +
the O +
response O +
of O +
patients O +
to O +
glucocorticoid O +
therapy O +
. O +

Induction O +
of O +
a O +
functional O +
vitamin O +
D O +
receptor O +
in O +
all O -
- O -
trans O -
- O -
retinoic O +
acid O -
- O -
induced O +
monocytic O +
differentiation O +
of O +
M2-type B-CellLine +
leukemic I-CellLine +
blast I-CellLine +
cells I-CellLine +
. O +

Different O +
types O +
of O +
acute O +
myeloid O +
leukemia O +
blast O +
cells O +
were O +
induced O +
to O +
differentiate O +
in O +
vitro O +
with O +
all O -
- O -
trans O -
- O -
retinoic O +
acid O +
( O +
ATRA O +
) O +
and O +
vitamin O +
D3 O +
( O +
VD O +
) O +
. O +

M0 B-CellLine -
/ I-CellLine -
M1 I-CellLine +
leukemic I-CellLine +
cells I-CellLine +
are O +
not O +
sensitive O +
to O +
differentiating O +
agents O +
, O +
whereas O +
M3 B-CellLine +
leukemic I-CellLine +
cells I-CellLine +
are O +
induced O +
to O +
undergo O +
granulocytic O +
differentiation O +
after O +
ATRA O +
treatment O +
but O +
are O +
not O +
sensitive O +
to O +
VD O +
. O +

M2 B-CellLine +
leukemic I-CellLine +
blast I-CellLine +
cells I-CellLine +
behave O +
differently O +
because O +
they O +
undergo O +
monocytic O +
differentiation O +
with O +
both O +
the O +
differentiation O +
inducers O +
. O +

To O +
gain O +
some O +
insight O +
into O +
the O +
maturation O +
of O +
M2-type O +
leukemic O +
cells O +
, O +
we O +
studied O +
the O +
molecular O +
mechanisms O +
underlying O +
monocytic O +
differentiation O +
induced O +
by O +
ATRA O +
and O +
VD O +
in O +
spontaneous O +
M2 B-CellLine +
blast I-CellLine +
cells I-CellLine +
as O +
well O +
as O +
in O +
Kasumi-1 B-CellLine +
cells I-CellLine +
( O +
an O +
acute B-CellLine +
myeloid I-CellLine +
leukemia I-CellLine +
M2-type I-CellLine +
cell I-CellLine +
line I-CellLine +
) O +
. O +

Our O +
results O +
indicate O +
that O +
ATRA O +
as O +
well O +
as O +
VD O +
efficiently O +
increases O +
the O +
nuclear O +
abundance O +
of O +
VD O +
receptor O +
( O +
VDR O +
) O +
and O +
promotes O +
monocytic O +
differentiation O +
. O +

VDR O +
is O +
functionally O +
active O +
in O +
ATRA O -
- O -
treated O +
Kasumi-1 B-CellLine +
cells I-CellLine +
because O +
it O +
efficiently O +
heterodimerizes O +
with O +
retinoid O +
X O +
receptor O +
, O +
binds O +
to O +
a O +
DR3-type O +
vitamin O +
D O -
- O -
responsive O +
element O +
, O +
and O +
activates O +
the O +
transcription O +
of O +
a O +
vitamin O +
D O -
- O -
responsive O +
element O -
- O -
regulated O +
reporter O +
gene O +
. O +

Consistent O +
with O +
these O +
findings O +
, O +
VD O -
- O -
responsive O +
genes O +
are O +
induced O +
by O +
ATRA O +
treatment O +
of O +
Kasumi-1 B-CellLine +
cells I-CellLine +
, O +
suggesting O +
that O +
the O +
genetic O +
program O +
underlying O +
monocytic O +
differentiation O +
is O +
activated O +
. O +

The O +
molecular O +
mechanism O +
by O +
which O +
ATRA O +
increases O +
the O +
nuclear O +
abundance O +
of O +
a O +
functional O +
VDR O +
is O +
still O +
unknown O +
, O +
but O +
our O +
data O +
clearly O +
indicate O +
that O +
the O +
M2 B-CellLine +
leukemic I-CellLine +
cell I-CellLine +
context O +
is O +
only O +
permissive O +
of O +
monocytic O +
differentiation O +
. O +

Dendritic O +
cells O +
and O +
the O +
pathogenesis O +
of O +
rheumatoid O +
arthritis O +
. O +

Rheumatoid O +
arthritis O +
( O +
RA O +
) O +
is O +
a O +
chronic O +
autoimmune O +
inflammatory O +
disease O +
in O +
which O +
unknown O +
arthrogenic O +
autoantigen O +
is O +
presented O +
to O +
CD4 O -
+ O +
T O +
cells O +
. O +

The O +
strong O +
association O +
of O +
the O +
disease O +
with O +
an O +
epitope O +
within O +
the O +
HLA O -
- O -
DR O +
chain O +
shared O +
between O +
various O +
alleles O +
of O +
HLA O -
- O -
DR4 O +
and O +
DR1 O +
emphasizes O +
the O +
importance O +
of O +
antigen O +
presentation O +
. O +

This O +
immune O +
response O +
predominantly O +
occurs O +
in O +
the O +
synovial O +
tissue O +
and O +
fluid O +
of O +
the O +
joints O +
and O +
autoreactive O +
T O +
cells O +
are O +
readily O +
demonstrable O +
in O +
both O +
the O +
synovial O +
compartment O +
and O +
blood O +
. O +

Circulating O +
dendritic O +
cells O +
( O +
DC O +
) O +
are O +
phenotypically O +
and O +
functionally O +
identical O +
with O +
normal O +
peripheral O +
blood O +
( O +
PB O +
) O +
DC O +
. O +

In O +
the O +
synovial O +
tissue O +
, O +
fully O +
differentiated O +
perivascular O +
DC O +
are O +
found O +
in O +
close O +
association O +
with O +
T O +
cells O +
and O +
with O +
B O +
cell O +
follicles O +
, O +
sometimes O +
containing O +
follicular O +
DC O +
. O +

These O +
perivascular O +
DC O +
migrate O +
across O +
the O +
activated O +
endothelium O +
from O +
blood O +
and O +
receive O +
differentiative O +
signals O +
within O +
the O +
joint O +
from O +
monocyte O -
- O -
derived O +
cytokines O +
and O +
CD40-ligand+ O +
T O +
cells O +
. O +

In O +
the O +
SF O +
, O +
DC O +
manifest O +
an O +
intermediate O +
phenotype O +
, O +
similar O +
to O +
that O +
of O +
monocyte O -
- O -
derived O +
DC O +
in O +
vitro O +
. O +

Like O +
a O +
delayed O -
- O -
type O +
hypersensitivity O +
response O +
, O +
the O +
rheumatoid O +
synovium O +
represents O +
an O +
effector O +
site O +
. O +

DC O +
at O +
many O +
effector O +
sites O +
have O +
a O +
characteristic O +
pattern O +
of O +
infiltration O +
and O +
differentiation O +
. O +

It O +
is O +
important O +
to O +
note O +
that O +
the O +
effector O +
response O +
is O +
not O +
self O -
- O -
limiting O +
in O +
RA O +
autoimmune O +
inflammation O +
. O +

In O +
this O +
article O +
, O +
we O +
argue O +
that O +
the O +
presentation O +
of O +
self O -
- O -
antigen O +
by O +
DC O +
and O +
by O +
autoantibody O -
- O -
producing O +
B O +
cells O +
is O +
critical O +
for O +
the O +
perpetuation O +
of O +
the O +
autoimmune O +
response O +
. O +

Permanently O +
arresting O +
this O +
ongoing O +
immune O +
response O +
with O +
either O +
pharmaceutical O +
agents O +
or O +
immunotherapy O +
is O +
a O +
major O +
challenge O +
for O +
immunology O +
. O +

Transcriptional O +
inhibition O +
by O +
interleukin-6 O +
of O +
the O +
class O +
A O +
macrophage O +
scavenger O +
receptor O +
in O +
macrophages O +
derived O +
from O +
human O +
peripheral O +
monocytes O +
and O +
the O +
THP-1 B-CellLine +
monocytic I-CellLine +
cell I-CellLine +
line I-CellLine +
. O +

Expression O +
of O +
the O +
class O +
A O +
macrophage O +
scavenger O +
receptor O +
( O +
MSR O +
) O +
contributes O +
to O +
the O +
uptake O +
of O +
modified O +
low O +
density O +
lipoproteins O +
( O +
LDL O +
) O +
by O +
macrophages O +
and O +
transformation O +
of O +
these O +
cells O +
into O +
lipid O -
- O -
laden O +
foam O +
cells O +
, O +
which O +
characterize O +
atherosclerosis O +
. O +

Many O +
environmental O +
factors O +
, O +
in O +
particular O +
, O +
proinflammatory O +
cytokines O +
and O +
growth O +
factors O +
, O +
can O +
exert O +
regulatory O +
effects O +
on O +
MSR O +
expression O +
, O +
whereas O +
intracellular O +
accumulation O +
of O +
cholesterol O +
itself O +
does O +
not O +
influence O +
MSR O +
levels O +
to O +
any O +
considerable O +
extent O +
. O +

In O +
the O +
present O +
study O +
, O +
by O +
using O +
an O +
in O +
vitro O +
model O +
, O +
we O +
examined O +
whether O +
stimulation O +
with O +
interleukin-6 O +
( O +
IL-6 O +
) O +
, O +
an O +
immunoregulatory O +
, O +
multipotential O +
cytokine O +
, O +
modulates O +
the O +
expression O +
and O +
activities O +
of O +
the O +
MSR O +
in O +
macrophages O +
. O +

When O +
treated O +
with O +
IL-6 O +
, O +
macrophages O +
derived O +
from O +
peripheral O +
monocytes O +
and O +
phorbol B-CellLine +
12-myristate I-CellLine +
13-acetate I-CellLine +
( I-CellLine +
PMA I-CellLine +
) I-CellLine +
-differentiated I-CellLine +
THP-1 I-CellLine +
monocytic I-CellLine +
cells I-CellLine +
showed O +
significantly O +
reduced O +
uptake O +
and/or O +
binding O +
of O +
the O +
MSR O +
ligand O +
, O +
acetylated O +
LDL O +
. O +

This O +
effect O +
was O +
paralleled O +
by O +
a O +
reduction O +
in O +
the O +
expression O +
of O +
MSR O +
protein O +
and O +
mRNA O +
. O +

Analysis O +
of O +
MSR O +
promoter O +
activity O +
in O +
THP-1 B-CellLine +
cells I-CellLine +
transfected O +
with O +
an O +
MSR O +
promoter O -
- O -
reporter O +
gene O +
construct O +
demonstrated O +
decreased O +
activity O +
of O +
the O +
MSR O +
promoter O +
in O +
IL-6 O +
-treated O +
THP-1 B-CellLine +
macrophages O +
. O +

Electrophoretic O +
mobility O +
gel O +
shift O +
assay O +
also O +
showed O +
a O +
reduction O +
in O +
the O +
binding O +
of O +
a O +
transcription O +
factor O +
to O +
the O +
MSR O +
promoter O +
AP-1 O -
/ O -
ets O +
elements O +
in O +
IL-6 O +
-treated O +
cells O +
. O +

Thus O +
, O +
exposure O +
to O +
IL-6 O +
may O +
inhibit O +
expression O +
of O +
the O +
class O +
A O +
MSR O +
in O +
differentiated O +
macrophages O +
at O +
transcriptional O +
levels O +
. O +

This O +
result O +
suggests O +
that O +
this O +
cytokine O +
may O +
modulate O +
foam O +
cell O +
formation O +
during O +
atherogenesis O +
. O +

Immune O +
responses O +
to O +
adenoviruses O +
: O +
viral O +
evasion O +
mechanisms O +
and O +
their O +
implications O +
for O +
the O +
clinic O +
. O +

Adenoviruses O +
encode O +
proteins O +
that O +
block O +
responses O +
to O +
interferons O +
, O +
intrinsic O +
cellular O +
apoptosis O +
, O +
killing O +
by O +
CD8 O +
( O +
+ O +
) O +
cytotoxic O +
T O +
lymphocytes O +
and O +
killing O +
by O +
the O +
death O +
ligands O +
TNF O +
, O +
Fas O +
ligand O +
and O +
TRAIL O +
. O +

The O +
viral O +
proteins O +
are O +
believed O +
to O +
prolong O +
acute O +
and O +
persistent O +
adenovirus O +
infections O +
. O +

The O +
proteins O +
may O +
prove O +
useful O +
in O +
protecting O +
adenovirus O +
gene O +
therapy O +
vectors O +
and O +
transplanted B-CellLine +
cells I-CellLine +
from O +
the O +
immune O +
system O +
. O +

Estrogen O +
decreases O +
TNF O +
gene O +
expression O +
by O +
blocking O +
JNK O +
activity O +
and O +
the O +
resulting O +
production O +
of O +
c O -
- O -
Jun O +
and O +
JunD O +
. O +

Central O +
to O +
the O +
bone O -
- O -
sparing O +
effect O +
of O +
estrogen O +
( O +
E O +
( O +
2 O +
) O +
) O +
is O +
its O +
ability O +
to O +
block O +
the O +
monocytic O +
production O +
of O +
the O +
osteoclastogenic O +
cytokine O +
TNF O -
- O -
alpha O +
( O +
TNF O +
) O +
. O +

However O +
, O +
the O +
mechanism O +
by O +
which O +
E O +
( O +
2 O +
) O +
downregulates O +
TNF O +
production O +
is O +
presently O +
unknown O +
. O +

Transient O +
transfection O +
studies O +
in O +
HeLa B-CellLine +
cells I-CellLine +
, O +
an O +
E O +
( O +
2 O +
) O +
receptor O -
- O -
negative O +
line O +
, O +
suggest O +
that O +
E O +
( O +
2 O +
) O +
inhibits O +
TNF O +
gene O +
expression O +
through O +
an O +
effect O +
mediated O +
by O +
estrogen O +
receptor O +
beta O +
( O +
ERbeta O +
) O +
. O +

We O +
also O +
report O +
that O +
in O +
RAW B-CellLine +
264.7 I-CellLine +
cells I-CellLine +
, O +
an O +
E O +
( O +
2 O +
) O +
receptor O -
- O -
positive O +
murine O +
monocytic O +
line O +
, O +
E O +
( O +
2 O +
) O +
downregulates O +
cytokine O -
- O -
induced O +
TNF O +
gene O +
expression O +
by O +
decreasing O +
the O +
activity O +
of O +
the O +
Jun O +
NH O +
( O +
2 O +
) O +
-terminal O +
kinase O +
( O +
JNK O +
) O +
. O +

The O +
resulting O +
diminished O +
phosphorylation O +
of O +
c O -
- O -
Jun O +
and O +
JunD O +
at O +
their O +
NH O +
( O +
2 O +
) O +
-termini O +
decreases O +
the O +
ability O +
of O +
these O +
nuclear O +
proteins O +
to O +
autostimulate O +
the O +
expression O +
of O +
the O +
c O -
- O -
Jun O +
and O +
JunD O +
genes O +
, O +
thus O +
leading O +
to O +
lower O +
production O +
of O +
c O -
- O -
Jun O +
and O +
JunD O +
. O +

The O +
consequent O +
decrease O +
in O +
the O +
nuclear O +
levels O +
of O +
c O -
- O -
Jun O +
and O +
JunD O +
leads O +
to O +
diminished O +
binding O +
of O +
c O -
- O -
Jun O -
/ O -
c O -
- O -
Fos O +
and O +
JunD O -
/ O -
c O -
- O -
Fos O +
heterodimers O +
to O +
the O +
AP-1 O +
consensus O +
sequence O +
in O +
the O +
TNF O +
promoter O +
and O +
, O +
thus O +
, O +
to O +
decreased O +
transactivation O +
of O +
the O +
TNF O +
gene O +
. O +

Signal O +
transduction O +
pathways O +
triggered O +
by O +
the O +
FcepsilonRIIb O +
receptor O +
( O +
CD23 O +
) O +
in O +
human O +
monocytes O +
lead O +
to O +
nuclear O +
factor O -
- O -
kappaB O +
activation O +
. O +

BACKGROUND O +
: O +
Alveolar O +
macrophages O +
play O +
a O +
key O +
role O +
in O +
the O +
initiation O +
of O +
the O +
inflammatory O +
reaction O +
of O +
allergic O +
asthma O +
. O +

Alveolar O +
macrophages O +
and O +
peripheral O +
blood O +
monocytes O +
are O +
activated O +
when O +
IgE O -
/ O -
allergen O +
immune O +
complexes O +
bind O +
to O +
the O +
CD23 O +
receptor O +
, O +
which O +
leads O +
to O +
the O +
production O +
of O +
inflammatory O +
cytokines O +
. O +

OBJECTIVE O +
: O +
We O +
sought O +
to O +
investigate O +
the O +
molecular O +
mechanisms O +
regulating O +
this O +
early O +
inflammatory O +
response O +
. O +

We O +
have O +
focused O +
on O +
the O +
study O +
of O +
the O +
signal O +
transduction O +
pathways O +
triggered O +
by O +
CD23 O +
in O +
human O +
monocytes O +
and O +
the O +
promonocytic B-CellLine +
cell I-CellLine +
line I-CellLine +
U937 I-CellLine +
. O +

METHODS O +
: O +
CD23 O +
was O +
cross O -
- O -
linked O +
in O +
human O +
monocytes O +
and O +
U937 B-CellLine +
cells I-CellLine +
with O +
IgE O +
immune O +
complexes O +
. O +

Surface O +
expression O +
of O +
CD23 O +
was O +
determined O +
by O +
FACS O +
analysis O +
. O +

Transcription O +
factor O +
activation O +
and O +
gene O +
transcription O +
were O +
studied O +
by O +
gel O -
- O -
shift O +
assays O +
and O +
Northern O +
blot O +
analysis O +
, O +
respectively O +
. O +

IkappaBalpha O +
phosphorylation O +
and O +
degradation O +
was O +
analyzed O +
by O +
Western O +
blot O +
. O +

RESULTS O +
: O +
Nuclear O +
factor O +
( O +
NF O +
) O +
-kappaB O +
is O +
the O +
main O +
transcription O +
factor O +
involved O +
in O +
the O +
gene O +
activation O +
that O +
follows O +
CD23 O +
cross O -
- O -
linking O +
in O +
monocytes O +
. O +

CD23-induced O +
NF O -
- O -
kappaB O +
is O +
a O +
heterodimer O +
composed O +
of O +
p65 O -
/ O -
p50 O +
subunits O +
. O +

NF O -
- O -
kappaB O +
nuclear O +
translocation O +
is O +
secondary O +
to O +
the O +
phosphorylation O +
and O +
subsequent O +
degradation O +
of O +
the O +
NF O -
- O -
kappaB O +
inhibitory O +
molecule O +
IkappaBalpha O +
. O +

Tyrosine O +
kinase O +
-dependent O +
, O +
and O +
not O +
protein O +
kinase O +
C O +
-dependent O +
, O +
pathways O +
mediate O +
CD23 O +
-triggered O +
NF O -
- O -
kappaB O +
activation O +
but O +
do O +
not O +
participate O +
in O +
the O +
direct O +
phosphorylation O +
of O +
IkappaBalpha O +
. O +

IkappaBalpha O +
degradation O +
and O +
NF O -
- O -
kappaB O +
nuclear O +
translocation O +
correlate O +
with O +
transcriptional O +
activation O +
of O +
the O +
inflammatory O +
cytokines O +
TNF O -
- O -
alpha O +
and O +
IL-1beta O +
. O +

CONCLUSIONS O +
: O +
NF O -
- O -
kappaB O +
is O +
the O +
main O +
transcription O +
factor O +
involved O +
in O +
the O +
signal O +
transduction O +
pathway O +
of O +
CD23 O +
in O +
monocytes O +
. O +

Dopamine O +
stimulates O +
expression O +
of O +
the O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
via O +
NF O -
- O -
kappaB O +
in O +
cells O +
of O +
the O +
immune O +
system O +
. O +

Recent O +
studies O +
have O +
reported O +
that O +
lymphocytes O +
produce O +
, O +
transport O +
and O +
bind O +
dopamine O +
present O +
in O +
plasma O +
. O +

However O +
, O +
the O +
action O +
of O +
dopamine O +
on O +
HIV-1 O +
gene O +
expression O +
in O +
cells O +
of O +
the O +
immune O +
system O +
has O +
not O +
yet O +
been O +
examined O +
. O +

Here O +
, O +
we O +
have O +
investigated O +
the O +
regulation O +
of O +
HIV-1 O +
expression O +
by O +
dopamine O +
in O +
Jurkat B-CellLine +
T I-CellLine +
cells I-CellLine +
and O +
in O +
primary O +
blood O +
mononuclear O +
cells O +
( O +
PBMC O +
) O +
. O +

HIV-1 O +
replication O +
was O +
increased O +
by O +
dopamine O +
, O +
which O +
correlated O +
with O +
the O +
increased O +
levels O +
of O +
HIV-1 O +
transactivation O +
. O +

Our O +
transient O +
expression O +
data O +
revealed O +
that O +
dopamine O +
stimulated O +
transcription O +
through O +
the O +
NF O -
- O -
kappaB O +
element O +
present O +
in O +
the O +
long O +
terminal O +
repeat O +
. O +

The O +
importance O +
of O +
NF O -
- O -
kappaB O +
sites O +
was O +
confirmed O +
by O +
using O +
vectors O +
containing O +
wild O -
- O -
type O +
or O +
mutant O +
kappaB O +
sites O +
in O +
a O +
heterologous O +
promoter O +
. O +

Consistent O +
with O +
the O +
role O +
of O +
NF O -
- O -
kappaB O +
in O +
mediating O +
dopamine O +
responsiveness O +
, O +
the O +
proteasome O +
inhibitor O +
MG132 O +
abolished O +
dopamine O -
- O -
induced O +
transcriptional O +
activation O +
. O +

We O +
further O +
explored O +
the O +
effect O +
of O +
dopamine O +
in O +
the O +
presence O +
of O +
phorbol O +
esters O +
or O +
tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O +
TNF O -
- O -
alpha O +
) O +
known O +
to O +
activate O +
NF O -
- O -
kappaB O +
. O +

The O +
combination O +
of O +
dopamine O +
and O +
TNF O -
- O -
alpha O +
led O +
to O +
a O +
stimulation O +
of O +
HIV-1 O +
transcription O +
and O +
replication O +
. O +

However O +
, O +
in O +
contrast O +
with O +
TNF O -
- O -
alpha O +
, O +
dopamine O +
treatment O +
did O +
not O +
affect O +
NF O -
- O -
kappaB O +
DNA O +
binding O +
activity O +
nor O +
the O +
concentrations O +
of O +
p50 O +
, O +
p65 O +
and O +
IkappaB O -
- O -
alpha O +
proteins O +
, O +
which O +
suggests O +
a O +
distinct O +
NF O -
- O -
kappaB O +
activation O +
mechanism O +
. O +

These O +
results O +
reveal O +
a O +
new O +
link O +
between O +
the O +
dopamine O +
system O +
, O +
cytokine O +
signaling O +
pathway O +
and O +
regulation O +
of O +
gene O +
expression O +
via O +
the O +
involvement O +
of O +
NF O -
- O -
kappaB O +
in O +
T O +
cells O +
and O +
PBMC O +
. O +

AML1 O +
( O +
CBFalpha2 O +
) O +
cooperates O +
with O +
B O +
cell O -
- O -
specific O +
activating O +
protein O +
( O +
BSAP O -
/ O -
PAX5 O +
) O +
in O +
activation O +
of O +
the O +
B O +
cell O -
- O -
specific O +
BLK O +
gene O +
promoter O +
. O +

AML1 O +
plays O +
a O +
critical O +
role O +
during O +
hematopoiesis O +
and O +
chromosomal O +
translocations O +
involving O +
AML1 O +
are O +
commonly O +
associated O +
with O +
different O +
forms O +
of O +
leukemia O +
, O +
including O +
pre O -
- O -
B O +
acute O +
lymphoblastic O +
leukemia O +
. O +

To O +
understand O +
the O +
function O +
of O +
AML1 O +
during O +
B O +
cell O +
differentiation O +
, O +
we O +
analyzed O +
regulatory O +
regions O +
of O +
B O +
cell O -
- O -
specific O +
genes O +
for O +
potential O +
AML1-binding O +
sites O +
and O +
have O +
identified O +
a O +
putative O +
AML1-binding O +
site O +
in O +
the O +
promoter O +
of O +
the O +
B O +
cell O -
- O -
specific O +
tyrosine O +
kinase O +
gene O +
, O +
blk O +
. O +

Gel O +
mobility O +
shift O +
assays O +
and O +
transient O +
transfection O +
assays O +
demonstrate O +
that O +
AML1 O +
binds O +
specifically O +
to O +
this O +
site O +
in O +
the O +
blk O +
promoter O +
and O +
this O +
binding O +
site O +
is O +
important O +
for O +
blk O +
promoter O +
activity O +
. O +

Furthermore O +
, O +
in O +
vitro O +
binding O +
analysis O +
revealed O +
that O +
the O +
AML1 O +
runt O +
DNA O -
- O -
binding O +
domain O +
physically O +
interacts O +
with O +
the O +
paired O +
DNA O -
- O -
binding O +
domain O +
of O +
BSAP O +
, O +
a O +
B O +
cell O -
- O -
specific O +
transcription O +
factor O +
. O +

BSAP O +
has O +
been O +
shown O +
previously O +
to O +
be O +
important O +
for O +
B O +
cell O -
- O -
specific O +
regulation O +
of O +
the O +
blk O +
gene O +
. O +

Physical O +
interaction O +
of O +
AML1 O +
with O +
BSAP O +
correlates O +
with O +
functional O +
cooperativity O +
in O +
transfection O +
studies O +
where O +
AML1 O +
and O +
BSAP O +
synergistically O +
activate O +
blk O +
promoter O +
transcription O +
by O +
more O +
than O +
50-fold O +
. O +

These O +
results O +
demonstrate O +
physical O +
and O +
functional O +
interactions O +
between O +
AML1 O +
and O +
BSAP O +
and O +
suggest O +
that O +
AML1 O +
is O +
an O +
important O +
factor O +
for O +
regulating O +
a O +
critical O +
B O +
cell O -
- O -
specific O +
gene O +
, O +
blk O +
. O +

Dephosphorylation O +
of O +
ZAP-70 O +
and O +
inhibition O +
of O +
T O +
cell O +
activation O +
by O +
activated O +
SHP1 O +
. O +

Studies O +
with O +
motheaten O +
mice O +
, O +
which O +
lack O +
the O +
SHP1 O +
protein O +
tyrosine O +
phosphatase O +
, O +
indicate O +
that O +
this O +
enzyme O +
plays O +
an O +
important O +
negative O +
role O +
in O +
T O +
cell O +
antigen O +
receptor O +
( O +
TCR O +
) O +
signaling O +
. O +

The O +
physiological O +
substrates O +
for O +
SHP1 O +
in O +
T O +
lymphocytes O +
, O +
however O +
, O +
have O +
remained O +
unclear O +
or O +
controversial O +
. O +

To O +
define O +
these O +
targets O +
for O +
SHP1 O +
we O +
have O +
compared O +
the O +
effects O +
of O +
constitutively O +
active O +
and O +
inactive O +
mutants O +
of O +
SHP1 O +
on O +
TCR O +
signaling O +
. O +

Expression O +
of O +
wild O -
- O -
type O +
SHP1 O +
had O +
a O +
very O +
small O +
effect O +
on O +
the O +
TCR O -
- O -
induced O +
tyrosine O +
phosphorylation O +
of O +
ZAP-70 O +
and O +
Syk O +
, O +
even O +
when O +
SHP1 O +
was O +
overexpressed O +
20 O +
- O +
100-fold O +
over O +
endogenous O +
SHP1 O +
. O +

Inactive O +
SHP1-D421A O +
and O +
wild O -
- O -
type O +
SHP2 O +
were O +
without O +
effects O +
. O +

Constitutively O +
active O +
SHP1-DeltaSH2 O +
had O +
a O +
more O +
pronounced O +
effect O +
on O +
ZAP-70 O +
and O +
Syk O +
, O +
even O +
when O +
expressed O +
at O +
near O +
physiological O +
levels O +
. O +

SHP1-DeltaSH2 O +
also O +
inhibited O +
events O +
downstream O +
of O +
ZAP-70 O +
and O +
Syk O +
, O +
such O +
as O +
activation O +
of O +
the O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
Erk2 O +
and O +
the O +
transcriptional O +
activation O +
of O +
the O +
interleukin-2 O +
gene O +
. O +

In O +
contrast O +
, O +
a O +
constitutively O +
active O +
SHP2-DeltaSH2 O +
had O +
no O +
statistically O +
significant O +
effect O +
( O +
although O +
it O +
caused O +
a O +
slight O +
augmentation O +
in O +
some O +
individual O +
experiments O +
) O +
. O +

None O +
of O +
the O +
constructs O +
influenced O +
the O +
anti O -
- O -
CD3-induced O +
tyrosine O +
phosphorylation O +
of O +
the O +
TCR O +
zeta O -
- O -
chain O +
or O +
phospholipase O +
Cgamma1 O +
, O +
indicating O +
that O +
Src O +
family O +
kinase O +
function O +
was O +
intact O +
. O +

Taken O +
together O +
, O +
our O +
findings O +
support O +
the O +
notion O +
that O +
ZAP-70 O +
and O +
Syk O +
can O +
be O +
direct O +
substrates O +
for O +
SHP1 O +
in O +
intact O +
cells O +
. O +

However O +
, O +
the O +
two O +
SH2 O +
domains O +
of O +
SHP1 O +
did O +
not O +
facilitate O +
its O +
recognition O +
of O +
ZAP-70 O +
and O +
Syk O +
as O +
substrates O +
in O +
intact O +
cells O +
. O +

Therefore O +
, O +
we O +
suggest O +
that O +
SHP1 O +
is O +
not O +
actively O +
recruited O +
to O +
inhibit O +
TCR O +
signaling O +
induced O +
by O +
ligation O +
of O +
this O +
receptor O +
alone O +
. O +

Instead O +
, O +
we O +
propose O +
that O +
ligation O +
of O +
a O +
distinct O +
inhibitory O +
receptor O +
leads O +
to O +
the O +
recruitment O +
of O +
SHP1 O +
via O +
its O +
SH2 O +
domains O +
, O +
activation O +
of O +
SHP1 O +
and O +
subsequently O +
inhibition O +
of O +
TCR O +
signals O +
if O +
the O +
inhibitory O +
receptor O +
is O +
juxtaposed O +
to O +
the O +
TCR O +
. O +

Human O +
T O -
- O -
cell O +
lymphotrophic O +
virus O +
type O -
- O -
I O +
tax O +
gene O +
induces O +
secretion O +
of O +
human O +
macrophage O +
inflammatory O +
protein-1alpha O +
. O +

Human O +
T O -
- O -
cell O +
lymphotropic O +
virus O +
I O +
( O +
HTLV O -
- O -
I O +
) O +
encodes O +
for O +
a O +
40-kDa O +
protein O +
, O +
Tax O +
, O +
which O +
is O +
important O +
for O +
the O +
immortalization O +
of O +
T O +
cells O +
. O +

Tax O +
has O +
been O +
shown O +
to O +
transactivate O +
several O +
cellular O +
genes O +
. O +

In O +
this O +
study O +
, O +
we O +
show O +
that O +
MIP-1alpha O +
is O +
selectively O +
expressed O +
and O +
secreted O +
in O +
the O +
tax B-CellLine +
transfected I-CellLine +
Jurkat I-CellLine +
cell I-CellLine +
line I-CellLine +
upon O +
mitogen O +
stimulation O +
. O +

Expression O +
of O +
MIP-1alpha O -
- O -
R O +
mRNA O +
in O +
these O +
cells O +
suggests O +
an O +
autocrine O +
role O +
for O +
this O +
chemokine O +
in O +
HTLV O -
- O -
I O +
infected O +
T O -
- O -
cells O +
. O +

Induced O +
MIP-1alpha O +
expression O +
and O +
secretion O +
in O +
PMA B-CellLine -
/ I-CellLine -
PHA I-CellLine +
stimulated I-CellLine +
tax I-CellLine +
transfected I-CellLine +
cells I-CellLine +
correlate O +
with O +
the O +
noninduction O +
of O +
MNP-1 O +
transcription O +
factor O +
, O +
which O +
is O +
intimately O +
involved O +
in O +
downmodulating O +
the O +
MIP-1alpha O +
gene O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

Gender O +
and O +
vascular O +
reactivity O +
. O +

Estrogen O +
receptors O +
are O +
found O +
on O +
vascular O +
endothelial O +
and O +
smooth O +
muscle O +
cells O +
; O +
their O +
expression O +
is O +
influenced O +
by O +
exposure O +
to O +
the O +
hormone O +
. O +

Estrogen O +
receptors O +
influence O +
non O -
- O -
genomic O +
events O +
, O +
which O +
are O +
rapid O +
in O +
onset O +
and O +
genomic O +
events O +
, O +
which O +
are O +
longer O +
acting O +
responses O +
. O +

Estrogens O +
affect O +
vascular O +
tone O +
indirectly O +
by O +
modulating O +
release O +
of O +
endothelium O -
- O -
derived O +
vasoactive O +
factors O +
and O +
directly O +
by O +
modulating O +
intracellular O +
calcium O +
in O +
vascular O +
smooth O +
muscle O +
cells O +
. O +

Estrogens O +
indirectly O +
affect O +
thrombotic O +
events O +
and O +
inflammation O +
by O +
altering O +
platelet O +
aggregation O +
and O +
leukocyte O +
adherence O +
and O +
migration O +
, O +
respectively O +
. O +

Estrogens O +
also O +
influence O +
production O +
of O +
mitogens O +
which O +
, O +
when O +
released O +
at O +
sites O +
of O +
vascular O +
injury O +
, O +
affect O +
vascular O +
remodeling O +
. O +

Although O +
estrogens O +
initiate O +
vascular O +
responses O +
, O +
genomic O +
sex O +
may O +
influence O +
and/or O +
limit O +
expression O +
of O +
estrogen O +
receptors O +
and O +
therefore O +
actions O +
of O +
sex O +
steroid O +
hormones O +
throughout O +
the O +
vasculature O +
. O +

E1A O +
oncogene O +
induction O +
of O +
cellular O +
susceptibility O +
to O +
killing O +
by O +
cytolytic O +
lymphocytes O +
through O +
target O +
cell O +
sensitization O +
to O +
apoptotic O +
injury O +
. O +

E1A O +
oncogene O +
expression O +
increases O +
mammalian O +
cell O +
susceptibility O +
to O +
lysis O +
by O +
cytolytic O +
lymphocytes O +
( O +
CLs O +
) O +
at O +
a O +
stage O +
in O +
this O +
intercellular O +
interaction O +
that O +
is O +
independent O +
of O +
cell O +
surface O +
recognition O +
events O +
. O +

Since O +
CLs O +
can O +
induce O +
either O +
apoptotic O +
or O +
necrotic O +
cell O +
death O +
, O +
we O +
asked O +
whether O +
E1A O +
sensitization O +
to O +
injury O -
- O -
induced O +
apoptosis O +
is O +
sufficient O +
to O +
explain O +
E1A O +
-induced O +
cytolytic O +
susceptibility O +
. O +

Mouse O +
, O +
rat O +
, O +
hamster O +
, O +
and O +
human O +
cells O +
that O +
were O +
rendered O +
cytolytic O +
susceptible O +
by O +
E1A O +
were O +
also O +
sensitized O +
to O +
CL O -
- O -
induced O +
and O +
chemically O +
induced O +
apoptosis O +
. O +

In O +
contrast O +
, O +
E1A O -
- O -
positive O +
cells O +
were O +
no O +
more O +
susceptible O +
to O +
injury O -
- O -
induced O +
necrosis O +
than O +
E1A O -
- O -
negative O +
cells O +
. O +

Similar O +
to O +
induction O +
of O +
cytolytic O +
susceptibility O +
and O +
in O +
contrast O +
to O +
other O +
E1A O +
activities O +
, O +
cellular O +
sensitization O +
to O +
chemically O +
induced O +
apoptosis O +
depended O +
on O +
high O -
- O -
level O +
E1A O +
oncoprotein O +
expression O +
. O +

Loss O +
of O +
both O +
cytolytic O +
susceptibility O +
and O +
sensitization O +
to O +
chemically O +
induced O +
apoptosis O +
was O +
coselected O +
during O +
in O +
vivo O +
selection O +
of O +
E1A O -
- O -
positive O +
sarcoma O +
cells O +
for O +
increased O +
tumorigenicity O +
. O +

Furthermore O +
, O +
E1A O +
mutant O +
proteins O +
that O +
can O +
not O +
bind O +
the O +
cellular O +
transcriptional O +
coactivator O +
, O +
p300 O +
, O +
and O +
that O +
fail O +
to O +
induce O +
cytolytic O +
susceptibility O +
also O +
failed O +
to O +
sensitize O +
cells O +
to O +
injury O -
- O -
induced O +
apoptosis O +
. O +

These O +
data O +
indicate O +
that O +
E1A O +
induces O +
susceptibility O +
to O +
killer O +
cell O -
- O -
induced O +
lysis O +
through O +
sensitization O +
of O +
cells O +
to O +
injury O -
- O -
induced O +
apoptosis O +
. O +

Copyright O +
1999 O +
Academic O +
Press O +
. O +

Polyamines O +
in O +
human O +
breast O +
cancer O +
and O +
its O +
relations O +
to O +
classical O +
prognostic O +
features O +
: O +
clinical O +
implications O +
. O +

Experimental O +
evidence O +
suggest O +
an O +
important O +
role O +
of O +
polyamines O +
in O +
breast O +
cancer O +
development O +
. O +

Polyamines O +
have O +
been O +
determined O +
in O +
tissue O +
and O +
erythrocyte O +
samples O +
from O +
100 O +
patients O +
with O +
primary O +
invasive O +
breast O +
cancer O +
and O +
30 O +
patients O +
with O +
fibroadenomas O +
. O +

Statistical O +
analysis O +
was O +
performed O +
in O +
order O +
to O +
determine O +
the O +
prognostic O +
value O +
of O +
the O +
polyamine O +
patterns O +
of O +
tumor O +
tissues O +
and O +
erythrocytes O +
in O +
comparison O +
with O +
clinical O +
and O +
histological O +
prognostic O +
factors O +
. O +

In O +
malignant O +
tissues O +
, O +
polyamine O +
levels O +
were O +
significantly O +
higher O +
than O +
in O +
benign O +
tissues O +
. O +

They O +
correlated O +
with O +
markers O +
of O +
tumor O +
aggressivity O +
( O +
axillary O +
node O +
involvement O +
and O +
especially O +
with O +
markers O +
of O +
high O +
mitotic O +
rate O +
as O +
Ki-67 O +
staining O +
, O +
histological O +
grade O +
) O +
. O +

No O +
correlation O +
was O +
found O +
between O +
estrogen O +
and O +
progesterone O +
status O +
, O +
tumor O +
size O +
and O +
polyamine O +
concentrations O +
. O +

Erythrocyte O +
polyamines O +
levels O +
were O +
identical O +
between O +
cancer O +
patients O +
and O +
controls O +
. O +

The O +
knowledge O +
of O +
the O +
polyamine O +
pattern O +
in O +
breast O +
cancer O +
could O +
become O +
useful O +
in O +
clinical O +
practice O +
particularly O +
if O +
polyamine O +
metabolism O +
is O +
targeted O +
as O +
a O +
therapeutic O +
approach O +
. O +

An O +
activation O -
- O -
responsive O +
element O +
in O +
single O +
C O +
motif-1 O -
/ O -
lymphotactin O +
promoter O +
is O +
a O +
site O +
of O +
constitutive O +
and O +
inducible O +
DNA O -
- O -
protein O +
interactions O +
involving O +
nuclear O +
factor O +
of O +
activated O +
T O +
cell O +
. O +

Single O +
C O +
motif-1 O +
( O +
SCM-1 O +
) O +
/lymphotactin O +
is O +
a O +
C O -
- O -
type O +
chemokine O +
whose O +
expression O +
is O +
activation O +
dependent O +
, O +
cyclosporin O +
A O +
sensitive O +
and O +
restricted O +
to O +
CD8 O -
+ O +
T O +
cells O +
, O +
double O -
- O -
negative O +
thymocytes O +
, O +
gammadelta O -
- O -
type O +
T O +
cells O +
, O +
and O +
NK O +
cells O +
. O +

In O +
humans O +
, O +
there O +
are O +
two O +
highly O +
homologous O +
genes O +
encoding O +
SCM-1alpha O +
and O +
SCM-1beta O +
. O +

Here O +
we O +
examined O +
the O +
regulatory O +
mechanism O +
of O +
the O +
SCM-1 O +
genes O +
. O +

The O +
luciferase O +
reporter O +
gene O +
under O +
the O +
control O +
of O +
the O +
5 O +
' O +
flanking O +
region O +
of O +
0.7 O +
kb O +
was O +
strongly O +
induced O +
upon O +
activation O +
with O +
anti O -
- O -
CD3 O +
or O +
PHA O +
plus O +
PMA O +
only O +
in O +
SCM-1-producer B-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
through O +
a O +
cyclosporin O +
A O -
- O -
sensitive O +
mechanism O +
. O +

An O +
element O +
termed O +
E1 O +
located O +
at O +
-108 O +
to O +
-95 O +
nt O +
relative O +
to O +
the O +
major O +
transcription O +
start O +
site O +
was O +
found O +
to O +
be O +
critical O +
for O +
the O +
promoter O +
activity O +
. O +

In O +
electrophoretic O +
mobility O +
shift O +
assays O +
using O +
the O +
E1 O +
oligonucleotide O +
as O +
probe O +
, O +
nuclear O +
extracts O +
from O +
unstimulated O +
T O +
and O +
B B-CellLine +
cell I-CellLine +
lines I-CellLine +
formed O +
a O +
constitutive O +
complex O +
termed O +
complex O +
I O +
, O +
while O +
nuclear O +
extracts O +
from O +
stimulated O +
SCM-1-producer B-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
formed O +
a O +
higher O +
mobility O +
complex O +
termed O +
complex O +
II O +
with O +
a O +
concomitant O +
decrease O +
in O +
complex O +
I O +
. O +

The O +
shift O +
from O +
complex O +
I O +
to O +
complex O +
II O +
seen O +
only O +
in O +
SCM-1-producer B-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
upon O +
activation O +
was O +
completely O +
suppressed O +
by O +
cyclosporin O +
A O +
. O +

Both O +
complexes O +
were O +
critically O +
dependent O +
on O +
the O +
NF O -
- O -
AT O +
core O +
sequence O +
TTTCC O +
in O +
the O +
E1 O +
element O +
and O +
were O +
partially O +
supershifted O +
by O +
anti O -
- O -
NF O -
- O -
ATp O +
. O +

One O -
- O -
hybrid O +
assays O +
in O +
yeast O +
isolated O +
NF O -
- O -
ATp O +
as O +
an O +
E1 O +
binding O +
protein O +
, O +
and O +
transfection O +
of O +
NF O -
- O -
ATp O +
into O +
T B-CellLine +
and I-CellLine +
B I-CellLine +
cell I-CellLine +
lines I-CellLine +
strongly O +
enhanced O +
the O +
activation O -
- O -
dependent O +
SCM-1 O +
promoter O +
activity O +
. O +

Collectively O +
, O +
a O +
unique O +
mechanism O +
involving O +
NF O -
- O -
ATp O +
appears O +
to O +
regulate O +
the O +
cell O +
type O -
- O -
specific O +
and O +
activation O -
- O -
dependent O +
expression O +
of O +
the O +
SCM-1 O +
genes O +
. O +

Glucocorticoids O +
induce O +
apoptosis O +
in O +
human O +
monocytes O +
: O +
potential O +
role O +
of O +
IL-1 O +
beta O +
. O +

Glucocorticoids O +
( O +
GC O +
) O +
are O +
potent O +
anti O -
- O -
inflammatory O +
and O +
immunosuppressive O +
agents O +
that O +
act O +
on O +
a O +
variety O +
of O +
immune O +
cells O +
, O +
including O +
monocytes O +
and O +
macrophages O +
. O +

However O +
, O +
the O +
exact O +
cellular O +
mechanisms O +
underlying O +
this O +
anti O -
- O -
inflammatory O +
capacity O +
are O +
still O +
unknown O +
. O +

In O +
our O +
study O +
, O +
we O +
determined O +
the O +
induction O +
of O +
apoptosis O +
by O +
GC O +
in O +
human O +
monocytes O +
. O +

Peripheral O +
blood O +
monocytes O +
were O +
isolated O +
by O +
density O +
centrifugation O +
methods O +
with O +
a O +
purity O +
of O +
> O +
90 O +
% O +
and O +
were O +
cultured O +
in O +
RPMI O +
1640 O +
medium O +
. O +

Monocyte O +
apoptosis O +
was O +
determined O +
by O +
four O +
independent O +
methods O +
, O +
including O +
annexin O -
- O -
V O +
staining O +
, O +
TUNEL O +
, O +
DNA O -
- O -
laddering O +
, O +
and O +
typical O +
morphology O +
by O +
means O +
of O +
transmission O +
electron O +
microscopy O +
. O +

TNF O -
- O -
alpha O +
and O +
IL-1beta O +
were O +
measured O +
by O +
ELISA O +
. O +

GC O +
receptor O +
was O +
blocked O +
with O +
mifepristone O +
. O +

Caspase O +
3 O +
was O +
inhibited O +
with O +
caspase-3 O +
inhibitor O +
( O +
DEVD O -
- O -
CHO O +
) O +
. O +

Stimulation O +
with O +
different O +
GC O +
at O +
therapeutic O +
concentrations O +
resulted O +
in O +
monocyte O +
apoptosis O +
in O +
a O +
time- O +
and O +
dose O -
- O -
dependent O +
manner O +
. O +

Necrosis O +
was O +
excluded O +
by O +
propidium O +
iodide O +
staining O +
. O +

Proinflammatory O +
cytokines O +
such O +
as O +
IL-1beta O +
and O +
TNF O -
- O -
alpha O +
were O +
down O -
- O -
regulated O +
by O +
GC O +
treatment O +
. O +

Continuous O +
treatment O +
of O +
monocytes O +
with O +
IL-1beta O +
, O +
but O +
not O +
with O +
TNF O -
- O -
alpha O +
, O +
could O +
almost O +
completely O +
prevent O +
GC O -
- O -
induced O +
cell O +
death O +
. O +

The O +
addition O +
of O +
mifepristone O +
or O +
caspase-3 O +
inhibitor O +
could O +
partially O +
abrogate O +
GC O -
- O -
induced O +
apoptosis O +
as O +
well O +
as O +
GC O -
- O -
induced O +
inhibition O +
of O +
IL-1beta O +
. O +

This O +
is O +
the O +
first O +
study O +
to O +
demonstrate O +
induction O +
of O +
apoptosis O +
by O +
GC O +
in O +
human O +
monocytes O +
. O +

GC O -
- O -
induced O +
monocyte O +
apoptosis O +
may O +
be O +
partially O +
mediated O +
through O +
effects O +
on O +
IL-1beta O +
production O +
. O +

It O +
is O +
conceivable O +
that O +
GC O +
exert O +
their O +
anti O -
- O -
inflammatory O +
capacity O +
in O +
various O +
diseases O +
, O +
at O +
least O +
in O +
part O +
, O +
by O +
the O +
induction O +
of O +
apoptosis O +
in O +
monocytes O +
. O +

Neutrophil O +
maturation O +
and O +
the O +
role O +
of O +
retinoic O +
acid O +
. O +

Neutrophil O +
maturation O +
occurs O +
in O +
well O +
defined O +
morphological O +
stages O +
that O +
correlate O +
with O +
the O +
acquisition O +
of O +
molecular O +
markers O +
associated O +
with O +
neutrophil O +
function O +
. O +

A O +
variety O +
of O +
factors O +
are O +
known O +
to O +
play O +
a O +
role O +
in O +
terminal O +
neutrophil O +
maturation O +
, O +
including O +
the O +
vitamin O +
A O +
derivative O +
, O +
retinoic O +
acid O +
. O +

Retinoic O +
acid O +
can O +
directly O +
modulate O +
gene O +
expression O +
via O +
binding O +
to O +
its O +
nuclear O +
receptors O +
, O +
which O +
can O +
, O +
in O +
turn O +
, O +
activate O +
transcription O +
of O +
target O +
genes O +
. O +

A O +
role O +
for O +
retinoic O +
acid O +
during O +
neutrophil O +
maturation O +
has O +
been O +
suggested O +
from O +
a O +
variety O +
of O +
sources O -
. O +
Here O +
we O +
present O +
a O +
review O +
of O +
the O +
mechanism O +
of O +
retinoic O +
acid O +
receptor O +
action O +
and O +
the O +
major O +
evidence O +
showing O +
that O +
normal O +
retinoid O +
signaling O +
is O +
required O +
for O +
neutrophil O +
maturation O +
. O +

Nuclear O +
factor O -
- O -
kappaB O +
-dependent O +
induction O +
of O +
interleukin-8 O +
gene O +
expression O +
by O +
tumor O +
necrosis O +
factor O +
alpha O +
: O +
evidence O +
for O +
an O +
antioxidant O +
sensitive O +
activating O +
pathway O +
distinct O +
from O +
nuclear O +
translocation O +
. O +

Tumor O +
necrosis O +
factor O +
alpha O +
( O +
TNFalpha O +
) O +
is O +
a O +
pluripotent O +
activator O +
of O +
inflammation O +
by O +
inducing O +
a O +
proinflammatory O +
cytokine O +
cascade O +
. O +

This O +
phenomenon O +
is O +
mediated O +
, O +
in O +
part O +
, O +
through O +
inducible O +
expression O +
of O +
the O +
CXC O +
chemokine O +
, O +
interleukin-8 O +
( O +
IL-8 O +
) O +
. O +

In O +
this O +
study O +
, O +
we O +
investigate O +
the O +
role O +
of O +
TNFalpha O +
-inducible O +
reactive O +
oxygen O +
species O +
( O +
ROS O +
) O +
in O +
IL-8 O +
expression O +
by O +
` O -
` O +
monocyte O -
- O -
like O +
'' O +
U937 B-CellLine +
histiocytic I-CellLine +
lymphoma I-CellLine +
cells I-CellLine +
. O +

TNFalpha O +
is O +
a O +
rapid O +
activator O +
of O +
IL-8 O +
gene O +
expression O +
by O +
U937 B-CellLine +
, O +
producing O +
a O +
50-fold O +
induction O +
of O +
mRNA O +
within O +
1 O +
hour O +
of O +
treatment O +
. O +

In O +
gene O +
transfection O +
assays O +
, O +
the O +
effect O +
of O +
TNFalpha O +
requires O +
the O +
presence O +
of O +
an O +
inducible O +
nuclear O +
factor O -
- O -
kappaB O +
( O +
NF O -
- O -
kappaB O +
) O +
( O +
Rel O +
A O +
) O +
binding O +
site O +
in O +
the O +
IL-8 O +
promoter O +
. O +

TNFalpha O +
treatment O +
induces O +
a O +
rapid O +
translocation O +
of O +
the O +
65 O +
kD O +
transcriptional O +
activator O +
NF O -
- O -
kappaB O +
subunit O +
, O +
Rel O +
A O +
, O +
whose O +
binding O +
in O +
the O +
nucleus O +
occurs O +
before O +
changes O +
in O +
intracellular O +
ROS O +
. O +

Pretreatment O +
( O +
or O +
up O +
to O +
15 O +
minutes O +
posttreatment O +
) O +
relative O +
to O +
TNFalpha O +
with O +
the O +
antioxidant O +
dimethyl O +
sulfoxide O +
( O +
DMSO O +
) O +
( O +
2 O +
% O +
[ O +
vol O -
/ O -
vol O +
] O +
) O +
blocks O +
80 O +
% O +
of O +
NF O -
- O -
kappaB O +
-dependent O +
transcription O +
. O +

Surprisingly O +
, O +
however O +
, O +
DMSO O +
has O +
no O +
effect O +
on O +
inducible O +
Rel O +
A O +
binding O +
. O +

Similar O +
selective O +
effects O +
on O +
NF O -
- O -
kappaB O +
transcription O +
are O +
seen O +
with O +
the O +
unrelated O +
antioxidants O +
, O +
N O -
- O -
acetylcysteine O +
( O +
NAC O +
) O +
and O +
vitamin O +
C O +
. O +

These O +
data O +
indicate O +
that O +
TNFalpha O +
induces O +
a O +
delayed O +
ROS O -
- O -
dependent O +
signalling O +
pathway O +
that O +
is O +
required O +
for O +
NF O -
- O -
kappaB O +
transcriptional O +
activation O +
and O +
is O +
separable O +
from O +
that O +
required O +
for O +
its O +
nuclear O +
translocation O +
. O +

Further O +
definition O +
of O +
this O +
pathway O +
will O +
yield O +
new O +
insights O +
into O +
inflammation O +
initiated O +
by O +
TNFalpha O +
signalling O +
. O +

c O -
- O -
Maf O +
induces O +
monocytic O +
differentiation O +
and O +
apoptosis O +
in O +
bipotent O +
myeloid O +
progenitors O +
. O +

The O +
transcriptional O +
mechanisms O +
that O +
drive O +
colony B-CellLine -
- I-CellLine -
forming I-CellLine +
unit I-CellLine +
granulocyte I-CellLine -
- I-CellLine -
macrophage I-CellLine +
( I-CellLine +
CFU I-CellLine -
- I-CellLine -
GM I-CellLine +
) I-CellLine +
myeloid I-CellLine +
progenitors I-CellLine +
to O +
differentiate O +
into O +
cells O +
of O +
either O +
the O +
granulocytic O +
or O +
monocytic O +
lineage O +
are O +
not O +
fully O +
understood O +
. O +

We O +
have O +
shown O +
that O +
the O +
c O -
- O -
Maf O +
and O +
c O -
- O -
Myb O +
transcription O +
factors O +
physically O +
interact O +
in O +
myeloid O +
cells O +
to O +
form O +
inhibitory O +
complexes O +
that O +
hinder O +
transactivation O +
of O +
c O -
- O -
Myb O +
target O +
genes O +
through O +
direct O +
binding O +
to O +
Myb O +
consensus O +
sites O +
. O +

These O +
complexes O +
arise O +
in O +
a O +
developmentally O +
regulated O +
pattern O +
, O +
peaking O +
at O +
the O +
promyelocyte O +
stage O +
, O +
or O +
in O +
cell B-CellLine +
model I-CellLine +
systems I-CellLine +
, O +
appearing O +
soon O +
after O +
the O +
induction O +
of O +
monocytic O +
differentiation O +
. O +

We O +
wished O +
to O +
determine O +
if O +
this O +
developmentally O +
related O +
interaction O +
is O +
a O +
consequence O +
of O +
myeloid O +
differentiation O +
or O +
an O +
intrinsic O +
differentiating O +
stimulus O +
. O +

Because O +
the O +
elevated O +
Myb O +
: O +
Maf O +
status O +
seen O +
in O +
differentiating O +
cells O +
can O +
be O +
recapitulated O +
by O +
overexpression O +
of O +
c O -
- O -
Maf O +
in O +
myeloid O +
cell O +
lines O +
, O +
we O +
inducibly O +
expressed O +
the O +
c O -
- O -
Maf O +
cDNA O +
in O +
2 O +
bipotent O +
human O +
myeloid O +
progenitor O +
cells O +
. O +

Elevated O +
levels O +
of O +
c O -
- O -
Maf O +
protein O +
led O +
to O +
marked O +
increases O +
in O +
Myb O +
: O +
Maf O +
complexes O +
and O +
the O +
accumulation O +
of O +
monocyte O -
/ O -
macrophage O +
cells O +
, O +
followed O +
by O +
eventual O +
programmed O +
cell O +
death O +
. O +

Analysis O +
of O +
targets O +
that O +
could O +
mediate O +
these O +
phenotypic O +
changes O +
indicated O +
that O +
c O -
- O -
Maf O +
likely O +
plays O +
a O +
key O +
role O +
in O +
myeloid O +
cell O +
development O +
through O +
dual O +
mechanisms O +
; O +
inhibition O +
of O +
a O +
select O +
set O +
of O +
c O -
- O -
Myb O +
regulated O +
targets O +
, O +
such O +
as O +
Bcl-2 O +
and O +
CD13 O -
/ O -
APN O +
, O +
coupled O +
with O +
the O +
activation O +
of O +
as O +
yet O +
undefined O +
differentiation O -
- O -
promoting O +
genes O +
. O +

Peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
activators O +
target O +
human O +
endothelial O +
cells O +
to O +
inhibit O +
leukocyte O +
-endothelial O +
cell O +
interaction O +
. O +

An O +
early O +
event O +
in O +
acute O +
and O +
chronic O +
inflammation O +
and O +
associated O +
diseases O +
such O +
as O +
atherosclerosis O +
and O +
rheumatoid O +
arthritis O +
is O +
the O +
induced O +
expression O +
of O +
specific O +
adhesion O +
molecules O +
on O +
the O +
surface O +
of O +
endothelial O +
cells O +
( O +
ECs O +
) O +
, O +
which O +
subsequently O +
bind O +
leukocytes O +
. O +

Peroxisome O +
proliferator O -
- O -
activated O +
receptors O +
( O +
PPARs O +
) O +
, O +
members O +
of O +
the O +
nuclear O +
receptor O +
superfamily O +
of O +
transcription O +
factors O +
, O +
are O +
activated O +
by O +
fatty O +
acid O +
metabolites O +
, O +
peroxisome O +
proliferators O +
, O +
and O +
thiazolidinediones O +
and O +
are O +
now O +
recognized O +
as O +
important O +
mediators O +
in O +
the O +
inflammatory O +
response O +
. O +

Whether O +
PPAR O +
activators O +
influence O +
the O +
inflammatory O +
responses O +
of O +
ECs O +
is O +
unknown O +
. O +

We O +
show O +
that O +
the O +
PPAR O +
activators O +
15-deoxy O -
- O -
Delta O +
( O +
12 O +
, O +
14 O +
) O +
-prostaglandin O +
J O +
( O +
2 O +
) O +
( O +
15d O -
- O -
PGJ O +
( O +
2 O +
) O +
) O +
, O +
Wyeth O +
14643 O +
, O +
ciglitazone O +
, O +
and O +
troglitazone O +
, O +
but O +
not O +
BRL O +
49653 O +
, O +
partially O +
inhibit O +
the O +
induced O +
expression O +
of O +
vascular O +
cell O +
adhesion O +
molecule-1 O +
( O +
VCAM-1 O +
) O +
, O +
as O +
measured O +
by O +
ELISA O +
, O +
and O +
monocyte O +
binding O +
to O +
human O +
aortic O +
endothelial O +
cells O +
( O +
HAECs O +
) O +
activated O +
by O +
phorbol O +
12-myristate O +
13-acetate O +
( O +
PMA O +
) O +
or O +
lipopolysaccharide O +
. O +

The O +
` O -
` O +
natural O +
'' O +
PPAR O +
activator O +
15d O -
- O -
PGJ O +
( O +
2 O +
) O +
had O +
the O +
greatest O +
potency O +
and O +
was O +
the O +
only O +
tested O +
molecule O +
capable O +
of O +
partially O +
inhibiting O +
the O +
induced O +
expression O +
of O +
E O -
- O -
selectin O +
and O +
neutrophil O -
- O -
like O +
HL60 B-CellLine +
cell I-CellLine +
binding O +
to O +
PMA O -
- O -
activated O +
HAECs O +
. O +

Intracellular O +
adhesion O +
molecule-1 O +
induction O +
by O +
PMA O +
was O +
unaffected O +
by O +
any O +
of O +
the O +
molecules O +
tested O +
. O +

Both O +
PPAR O -
- O -
alpha O +
and O +
PPAR O -
- O -
gamma O +
mRNAs O +
were O +
detected O +
in O +
HAECs O +
by O +
using O +
reverse O +
transcription O -
- O -
polymerase O +
chain O +
reaction O +
and O +
a O +
ribonuclease O +
protection O +
assay O +
; O +
however O +
, O +
we O +
have O +
yet O +
to O +
determine O +
which O +
, O +
if O +
any O +
, O +
of O +
the O +
PPARs O +
are O +
mediating O +
this O +
process O +
. O +

These O +
results O +
suggest O +
that O +
certain O +
PPAR O +
activators O +
may O +
help O +
limit O +
chronic O +
inflammation O +
mediated O +
by O +
VCAM-1 O +
and O +
monocytes O +
without O +
affecting O +
acute O +
inflammation O +
mediated O +
by O +
E O -
- O -
selectin O +
and O +
neutrophil O +
binding O +
. O +

9-cis O +
retinoic O +
acid O +
induces O +
monocyte O +
chemoattractant O +
protein-1 O +
secretion O +
in O +
human O +
monocytic O +
THP-1 O +
cells O +
. O +

Monocyte O +
migration O +
and O +
activation O +
are O +
regulated O +
by O +
monocyte O +
chemoattractant O +
protein-1 O +
( O +
MCP-1 O +
) O +
. O +

Prior O +
studies O +
have O +
shown O +
MCP-1 O +
expression O +
is O +
modulated O +
by O +
a O +
variety O +
of O +
ligands O +
that O +
act O +
through O +
extracellular O +
receptors O +
. O +

In O +
the O +
current O +
study O +
, O +
we O +
show O +
9-cis O +
retinoic O +
acid O +
( O +
RA O +
) O +
, O +
a O +
ligand O +
for O +
the O +
nuclear O +
hormone O +
receptor O +
retinoid O +
X O +
receptor O +
( O +
RXR O +
) O +
and O +
retinoic O +
acid O +
receptor O +
( O +
RAR O +
) O +
, O +
markedly O +
induces O +
the O +
expression O +
of O +
MCP-1 O +
. O +

In O +
human B-CellLine +
THP-1 I-CellLine +
monocytic I-CellLine +
leukemia I-CellLine +
cells I-CellLine +
cultured O +
with O +
RA O +
( O +
0.05 O +
to O +
500 O +
nmol O -
/ O -
L O +
) O +
, O +
MCP-1 O +
expression O +
was O +
induced O +
rapidly O +
, O +
significantly O +
, O +
and O +
dose O -
- O -
dependently O +
by O +
as O +
much O +
as O +
165-fold O +
. O +

MCP-1 O +
RNA O +
level O +
was O +
also O +
increased O +
in O +
RA O -
- O -
treated O +
cells O +
. O +

Expression O +
of O +
PPARgamma O +
, O +
a O +
heterodimer O +
partner O +
of O +
RXR O +
, O +
is O +
also O +
markedly O +
induced O +
by O +
RA O +
in O +
THP-1 O +
cells O +
. O +

However O +
, O +
BRL49653 O +
, O +
a O +
PPARgamma O +
ligand O +
, O +
failed O +
to O +
induce O +
MCP-1 O +
secretion O +
either O +
alone O +
or O +
to O +
modify O +
the O +
expression O +
level O +
induced O +
by O +
RA O +
. O +

In O +
contrast O +
, O +
BRL49653 O +
significantly O +
increased O +
MCP-1 O +
( O +
biotinylated O +
MCP-1 O +
) O +
binding O +
to O +
THP-1 O +
cells O +
, O +
whereas O +
RA O +
had O +
no O +
effect O +
. O +

Other O +
peroxisome O +
proliferator O +
activated O +
receptor O +
( O +
PPAR O +
) O +
ligands O +
, O +
15d O -
- O -
PGJ O +
( O +
2 O +
) O +
and O +
troglitazone O +
( O +
PPARgamma O +
) O +
, O +
Wy14 O +
, O +
643 O +
( O +
PPARalpha O +
) O +
, O +
and O +
PD195599 O +
( O +
PPARbeta O +
) O +
inhibited O +
the O +
induction O +
of O +
MCP-1 O +
by O +
RA O +
. O +

RA O +
's O +
effect O +
on O +
MCP-1 O +
expression O +
in O +
human O +
elutriated O +
monocytes O +
were O +
similar O +
to O +
that O +
observed O +
in O +
the O +
THP-1 B-CellLine +
cells I-CellLine +
. O +

These O +
studies O +
identify O +
RA O +
as O +
a O +
nuclear O +
signal O +
for O +
MCP-1 O +
induction O +
in O +
undifferentiated O +
human O +
monocytic O +
cells O +
. O +

These O +
studies O +
also O +
suggest O +
monocyte O +
MCP-1 O +
expression O +
induced O +
through O +
RA O +
may O +
modulate O +
cell O +
migration O +
. O +

Target O +
structures O +
of O +
the O +
CD8 O +
( O +
+ O +
) O +
-T O -
- O -
cell O +
response O +
to O +
human O +
cytomegalovirus O +
: O +
the O +
72-kilodalton O +
major O +
immediate O -
- O -
early O +
protein O +
revisited O +
. O +

Cell O -
- O -
mediated O +
immunity O +
plays O +
an O +
essential O +
role O +
in O +
the O +
control O +
of O +
infection O +
with O +
the O +
human O +
cytomegalovirus O +
( O +
HCMV O +
) O +
. O +

However O +
, O +
only O +
a O +
few O +
CD8 O +
( O +
+ O +
) O +
-T O -
- O -
cell O +
epitopes O +
are O +
known O +
, O +
with O +
the O +
majority O +
being O +
contained O +
in O +
the O +
pp65 O +
phosphoprotein O +
, O +
which O +
is O +
believed O +
to O +
dominate O +
the O +
CD8 O +
( O +
+ O +
) O +
-T O -
- O -
cell O +
response O +
to O +
HCMV O +
. O +

Here O +
, O +
we O +
have O +
readdressed O +
the O +
issue O +
of O +
CD8 O +
( O +
+ O +
) O +
T O +
cells O +
specific O +
for O +
the O +
72-kDa O +
major O +
immediate O -
- O -
early O +
protein O +
( O +
IE-1 O +
) O +
, O +
which O +
is O +
nonstructural O +
but O +
is O +
found O +
very O +
early O +
and O +
throughout O +
the O +
replicative O +
cycle O +
. O +

Using O +
a O +
novel O +
flow O -
- O -
cytometric O +
assay O +
, O +
we O +
were O +
able O +
to O +
identify O +
CD8 O +
( O +
+ O +
) O +
-T O -
- O -
cell O +
epitopes O +
( O +
by O +
IE-1 O +
peptide O -
- O -
specific O +
induction O +
of O +
cytokine O +
synthesis O +
) O +
and O +
simultaneously O +
measure O +
the O +
frequency O +
of O +
cells O +
directed O +
against O +
them O +
. O +

For O +
this O +
purpose O +
, O +
81 O +
pentadecamer O +
peptides O +
covering O +
the O +
complete O +
491-amino O -
- O -
acid O +
sequence O +
of O +
IE-1 O +
were O +
tested O +
on O +
peripheral O +
blood O +
mononuclear O +
cells O +
of O +
anti O -
- O -
HCMV O +
immunoglobulin O +
G O -
- O -
seropositive O +
donors O +
. O +

At O +
least O +
10 O +
new O +
epitopes O +
were O +
identified O +
, O +
and O +
the O +
fine O +
specificity O +
and O +
presenting O +
HLA O +
molecule O +
of O +
the O +
first O +
of O +
them O +
was O +
determined O +
. O +

The O +
frequencies O +
of O +
CD8 O +
( O +
+ O +
) O +
T O +
cells O +
directed O +
against O +
IE-1 O +
were O +
similar O +
to O +
those O +
directed O +
against O +
pp65 O +
in O +
donors O +
tested O +
with O +
known O +
pp65 O +
-derived O +
peptides O +
. O +

Importantly O +
, O +
additional O +
testing O +
of O +
a O +
corresponding O +
set O +
of O +
peptides O +
covering O +
the O +
complete O +
sequence O +
of O +
pp65 O +
on O +
10 O +
of O +
these O +
donors O +
identified O +
individuals O +
whose O +
CD8 O +
( O +
+ O +
) O +
T O +
cells O +
recognized O +
IE-1 O +
but O +
not O +
pp65 O +
and O +
vice O +
versa O +
, O +
clearly O +
illustrating O +
that O +
either O +
protein O +
may O +
be O +
a O +
major O +
target O +
. O +

In O +
summary O +
, O +
our O +
results O +
suggest O +
that O +
IE-1 O +
is O +
far O +
more O +
important O +
as O +
a O +
CD8 O +
( O +
+ O +
) O +
-T O -
- O -
cell O +
target O +
than O +
current O +
opinion O +
suggests O +
. O +

Increased O +
IkappaB O +
expression O +
and O +
diminished O +
nuclear O +
NF O -
- O -
kappaB O +
in O +
human O +
mononuclear O +
cells O +
following O +
hydrocortisone O +
injection O +
. O +

We O +
have O +
recently O +
demonstrated O +
that O +
hydrocortisone O +
and O +
other O +
glucocorticoids O +
inhibit O +
reactive O +
oxygen O +
species O +
( O +
ROS O +
) O +
generation O +
by O +
mononuclear O +
( O +
MNC O +
) O +
and O +
polymorphonuclear O +
leucocytes O +
( O +
PMNL O +
) O +
. O +

Since O +
NF O -
- O -
kappaB O -
/ O +
IkappaB O +
system O +
regulates O +
the O +
transcription O +
of O +
proinflammatory O +
genes O +
, O +
including O +
those O +
responsible O +
for O +
ROS O +
generation O +
, O +
we O +
tested O +
the O +
hypothesis O +
that O +
hydrocortisone O +
may O +
stimulate O +
IkappaB O +
production O +
thus O +
inhibiting O +
NF O -
- O -
kappaB O +
translocation O +
from O +
the O +
cytosol O +
into O +
the O +
nucleus O +
in O +
MNC O +
, O +
in O +
vivo O +
. O +

One O +
hundred O +
milligram O +
of O +
hydrocortisone O +
was O +
injected O +
intravenously O +
into O +
4 O +
normal O +
subjects O +
. O +

Blood O +
samples O +
were O +
obtained O +
prior O +
to O +
the O +
injection O +
and O +
at O +
1 O +
, O +
2 O +
, O +
4 O +
, O +
8 O +
and O +
24 O +
hr O +
after O +
the O +
injection O +
. O +

Nuclear O +
extracts O +
and O +
total O +
cell O +
lysates O +
were O +
prepared O +
from O +
MNC O +
by O +
standard O +
techniques O +
. O +

IkappaB O +
levels O +
in O +
MNC O +
homogenates O +
increased O +
at O +
1 O +
hr O +
, O +
peaked O +
at O +
2 O -
- O -
4 O +
hr O +
, O +
started O +
to O +
decrease O +
at O +
8 O +
hr O +
, O +
and O +
returned O +
to O +
baseline O +
levels O +
at O +
24 O +
hr O +
. O +

NF O -
- O -
kappaB O +
in O +
MNC O +
nuclear O +
extracts O +
decreased O +
at O +
1 O +
hr O +
, O +
reached O +
a O +
nadir O +
at O +
4 O +
hr O +
, O +
gradually O +
increased O +
at O +
8 O +
hr O +
and O +
returned O +
back O +
to O +
baseline O +
levels O +
at O +
24 O +
hr O +
. O +

The O +
total O +
protein O +
content O +
of O +
NF O -
- O -
kappaB O +
subunit O +
( O +
P65 O +
) O +
in O +
MNC O +
lysates O +
also O +
showed O +
a O +
decrease O +
following O +
hydrocortisone O +
injection O +
. O +

This O +
decrease O +
was O +
observed O +
at O +
2 O +
hr O +
, O +
reached O +
a O +
nadir O +
at O +
4 O +
hr O +
, O +
and O +
returned O +
to O +
baseline O +
levels O +
at O +
24 O +
hr O +
. O +

ROS O +
generation O +
inhibition O +
paralleled O +
NF O -
- O -
kappaB O +
levels O +
in O +
the O +
nucleus O +
. O +

It O +
was O +
inhibited O +
at O +
1 O +
hr O +
, O +
reached O +
a O +
nadir O +
at O +
2 O -
- O -
4 O +
hr O +
, O +
started O +
to O +
increase O +
at O +
8 O +
hr O +
, O +
and O +
returned O +
to O +
basal O +
levels O +
at O +
24 O +
hr O +
. O +

Our O +
data O +
demonstrate O +
that O +
hydrocortisone O +
induces O +
IkappaB O +
and O +
suppresses O +
NF O -
- O -
kappaB O +
expression O +
in O +
MNC O +
in O +
parallel O +
. O +

IkappaB O +
further O +
reduces O +
the O +
translocation O +
of O +
NF O -
- O -
kappaB O +
into O +
the O +
nucleus O +
thus O +
preventing O +
the O +
expression O +
of O +
proinflammatory O +
genes O +
. O +

Inhibition O +
of O +
protein O +
phosphatase O +
2A O +
induces O +
serine O -
/ O -
threonine O +
phosphorylation O +
, O +
subcellular O +
redistribution O +
, O +
and O +
functional O +
inhibition O +
of O +
STAT3 O +
. O +

Signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
STATs O +
) O +
are O +
rapidly O +
phosphorylated O +
on O +
tyrosine O +
residues O +
in O +
response O +
to O +
cytokine O +
and O +
growth O +
factor O +
stimulation O +
of O +
cell O +
surface O +
receptors O +
. O +

STATs O +
hereafter O +
are O +
translocated O +
to O +
the O +
nucleus O +
where O +
they O +
act O +
as O +
transcription O +
factors O +
. O +

Recent O +
reports O +
suggest O +
that O +
serine O +
phosphorylation O +
of O +
STATs O +
also O +
is O +
involved O +
in O +
the O +
regulation O +
of O +
STAT O +
-mediated O +
gene O +
transcription O +
. O +

Here O +
, O +
we O +
studied O +
the O +
role O +
of O +
serine O -
/ O -
threonine O +
phosphatases O +
in O +
STAT3 O +
signaling O +
in O +
human B-CellLine +
antigen I-CellLine -
- I-CellLine -
specific I-CellLine +
CD4 I-CellLine +
( I-CellLine +
+ I-CellLine +
) I-CellLine +
T I-CellLine +
cell I-CellLine +
lines I-CellLine +
and O +
cutaneous B-CellLine +
T I-CellLine +
cell I-CellLine +
lymphoma I-CellLine +
lines I-CellLine +
, O +
expressing O +
a O +
constitutively O +
activated O +
STAT3 O +
. O +

We O +
show O +
that O +
an O +
inhibitor O +
of O +
protein O +
phosphatases O +
( O +
PPs O +
) O +
PP1 O -
/ O -
PP2A O +
, O +
calyculin O +
A O +
, O +
induces O +
( O +
i O +
) O +
phosphorylation O +
of O +
STAT3 O +
on O +
serine O +
and O +
threonine O +
residues O +
, O +
( O +
ii O +
) O +
inhibition O +
of O +
STAT3 O +
tyrosine O +
phosphorylation O +
and O +
DNA O +
binding O +
activity O +
, O +
and O +
( O +
iii O +
) O +
relocation O +
of O +
STAT3 O +
from O +
the O +
nucleus O +
to O +
the O +
cytoplasm O +
. O +

Similar O +
results O +
were O +
obtained O +
with O +
other O +
PP2A O +
inhibitors O +
( O +
okadaic O +
acid O +
, O +
endothall O +
thioanhydride O +
) O +
but O +
not O +
with O +
inhibitors O +
of O +
PP1 O +
( O +
tautomycin O +
) O +
or O +
PP2B O +
( O +
cyclosporine O +
A O +
) O +
. O +

Pretreatment O +
with O +
the O +
broad O +
serine O -
/ O -
threonine O +
kinase O +
inhibitor O +
staurosporine O +
partly O +
blocked O +
the O +
calyculin O +
A O +
-induced O +
STAT3 O +
phosphorylation O +
, O +
whereas O +
inhibitors O +
of O +
serine O -
/ O -
threonine O +
kinases O +
, O +
such O +
as O +
mitogen O -
- O -
activated O +
protein O +
kinase-1 O +
extracellular O -
- O -
regulated O +
kinase O -
- O -
kinase O +
, O +
mitogen O -
- O -
activated O +
protein O +
p38 O +
kinase O +
, O +
and O +
phosphatidylinositol O +
3-kinase O +
, O +
did O +
not O +
. O +

In O +
conclusion O +
, O +
we O +
provide O +
evidence O +
that O +
PP2A O +
plays O +
a O +
crucial O +
role O +
in O +
the O +
regulation O +
of O +
STAT3 O +
phosphorylation O +
and O +
subcellular O +
distribution O +
in O +
T O +
cells O +
. O +

Moreover O +
, O +
our O +
findings O +
suggest O +
that O +
the O +
level O +
of O +
STAT3 O +
phosphorylation O +
is O +
balanced O +
between O +
a O +
staurosporine O -
- O -
sensitive O +
kinase O +
( O +
s O +
) O +
and O +
PP2A O +
. O +

Immunocytochemical O +
analysis O +
of O +
MNDA O +
in O +
tissue O +
sections O +
and O +
sorted O +
normal O +
bone O +
marrow O +
cells O +
documents O +
expression O +
only O +
in O +
maturing O +
normal O +
and O +
neoplastic O +
myelomonocytic O +
cells O +
and O +
a O +
subset O +
of O +
normal O +
and O +
neoplastic O +
B O +
lymphocytes O +
. O +

The O +
human O +
myeloid O +
cell O +
nuclear O +
differentiation O +
antigen O +
( O +
MNDA O +
) O +
is O +
a O +
nuclear O +
antigen O +
known O +
to O +
be O +
expressed O +
in O +
mature O +
myelomonocytic O +
cell O +
lines O +
. O +

An O +
extensive O +
immunocytochemical O +
evaluation O +
of O +
fixed O +
tissues O +
confirmed O +
MNDA O +
expression O +
in O +
normal O +
maturing O +
granulocytes O +
and O +
monocytes O +
and O +
in O +
acute O +
nonlymphocytic O +
leukemias O +
and O +
chronic O +
myelogenous O +
leukemia O +
. O +

MNDA O +
was O +
not O +
detected O +
in O +
normal O +
tissue O +
histiocytes O +
but O +
was O +
found O +
in O +
activated O +
macrophages O +
and O +
foreign O +
body O +
giant O +
cells O +
associated O +
with O +
inflammation O +
. O +

Flow O +
cytometric O +
cell O +
sorting O +
of O +
normal O +
bone O +
marrow O +
established O +
that O +
MNDA O +
is O +
initially O +
expressed O +
in O +
myeloid O +
blast O +
cells O +
. O +

Examination O +
of O +
lymphoid O +
tissues O +
showed O +
a O +
low O +
level O +
of O +
expression O +
in O +
a O +
population O +
of O +
normal O +
mande B-CellLine +
B I-CellLine +
lymphocytes I-CellLine +
but O +
not O +
in O +
germinal O +
center O +
cells O +
or O +
plasma O +
cells O +
. O +

A O +
subset O +
of O +
B O +
cell O +
neoplasms O +
expressing O +
MNDA O +
included O +
hairy O +
cell O +
leukemia O +
, O +
parafollicular O +
( O +
monocytoid O +
) O +
B O +
cell O +
lymphoma O +
, O +
mantle O +
cell O +
lymphoma O +
, O +
and O +
small O +
lymphocytic O +
lymphoma O +
. O +

Cell O +
sorting O +
of O +
normal O +
bone O +
marrow O +
showed O +
MNDA O +
expression O +
in O +
CD20 O +
+ O -
/CD10- O -
/ O -
CD5- O +
B O +
cells O +
. O +

MNDA O +
was O +
not O +
detected O +
in O +
other O +
normal O +
bone O +
marrow O +
or O +
all O +
other O +
nonhematopoietic O +
cells O +
. O +

The O +
hematopoietic O +
cell O -
- O -
specific O +
pattern O +
of O +
MNDA O +
expression O +
was O +
elucidated O +
through O +
a O +
comprehensive O +
analysis O +
of O +
normal O +
and O +
neoplastic O +
tissues O +
, O +
and O +
the O +
results O +
provide O +
further O +
evidence O +
of O +
the O +
coexpression O +
of O +
B- O +
and O +
myeloid O +
cell O +
markers O +
in O +
neoplastic O +
B O +
cells O +
and O +
identify O +
a O +
normal O +
B O +
cell O +
population O +
that O +
might O +
be O +
related O +
to O +
the O +
cell O +
of O +
origin O +
of O +
a O +
subset O +
of O +
B O +
cell O +
neoplasms O +
. O +

Activation O +
of O +
the O +
CDC42 O +
effector O +
N O -
- O -
WASP O +
by O +
the O +
Shigella O +
flexneri O +
IcsA O +
protein O +
promotes O +
actin O +
nucleation O +
by O +
Arp2 O -
/ O -
3 O +
complex O +
and O +
bacterial O +
actin O +
-based O +
motility O +
. O +

To O +
propel O +
itself O +
in O +
infected O +
cells O +
, O +
the O +
pathogen O +
Shigella O +
flexneri O +
subverts O +
the O +
Cdc42 O +
-controlled O +
machinery O +
responsible O +
for O +
actin O +
assembly O +
during O +
filopodia O +
formation O +
. O +

Using O +
a O +
combination O +
of O +
bacterial O +
motility O +
assays O +
in O +
platelet O +
extracts O +
with O +
Escherichia O +
coli O +
expressing O +
the O +
Shigella O +
IcsA O +
protein O +
and O +
in O +
vitro O +
analysis O +
of O +
reconstituted O +
systems O +
from O +
purified O +
proteins O +
, O +
we O +
show O +
here O +
that O +
the O +
bacterial O +
protein O +
IcsA O +
binds O +
N O -
- O -
WASP O +
and O +
activates O +
it O +
in O +
a O +
Cdc42 O +
-like O +
fashion O +
. O +

Dramatic O +
stimulation O +
of O +
actin O +
assembly O +
is O +
linked O +
to O +
the O +
formation O +
of O +
a O +
ternary O +
IcsA O -
- O -
N O -
- O -
WASP O -
- O -
Arp2 O -
/ O -
3 O +
complex O +
, O +
which O +
nucleates O +
actin O +
polymerization O +
. O +

The O +
Arp2 O -
/ O -
3 O +
complex O +
is O +
essential O +
in O +
initiation O +
of O +
actin O +
assembly O +
and O +
Shigella O +
movement O +
, O +
as O +
previously O +
observed O +
for O +
Listeria O +
monocytogenes O +
. O +

Activation O +
of O +
N O -
- O -
WASP O +
by O +
IcsA O +
unmasks O +
two O +
domains O +
acting O +
together O +
in O +
insertional O +
actin O +
polymerization O +
. O +

The O +
isolated O +
COOH O -
- O -
terminal O +
domain O +
of O +
N O -
- O -
WASP O +
containing O +
a O +
verprolin O -
- O -
homology O +
region O +
, O +
a O +
cofilin O -
- O -
homology O +
sequence O +
, O +
and O +
an O +
acidic O +
terminal O +
segment O +
( O +
VCA O +
) O +
interacts O +
with O +
G O -
- O -
actin O +
in O +
a O +
unique O +
profilin O -
- O -
like O +
functional O +
fashion O +
. O +

Hence O +
, O +
when O +
N O -
- O -
WASP O +
is O +
activated O +
, O +
its O +
COOH O -
- O -
terminal O +
domain O +
feeds O +
barbed O +
end O +
growth O +
of O +
filaments O +
and O +
lowers O +
the O +
critical O +
concentration O +
at O +
the O +
bacterial O +
surface O +
. O +

On O +
the O +
other O +
hand O +
, O +
the O +
NH O +
( O +
2 O +
) O +
-terminal O +
domain O +
of O +
N O -
- O -
WASP O +
interacts O +
with O +
F O -
- O -
actin O +
, O +
mediating O +
the O +
attachment O +
of O +
the O +
actin O +
tail O +
to O +
the O +
bacterium O +
surface O +
. O +

VASP O +
is O +
not O +
involved O +
in O +
Shigella O +
movement O +
, O +
and O +
the O +
function O +
of O +
profilin O +
does O +
not O +
require O +
its O +
binding O +
to O +
proline O -
- O -
rich O +
regions O +
. O +

Affinity O -
- O -
driven O +
peptide O +
selection O +
of O +
an O +
NFAT O +
inhibitor O +
more O +
selective O +
than O +
cyclosporin O +
A O +
[ O +
see O +
comments O +
] O +

The O +
flow O +
of O +
information O +
from O +
calcium O -
- O -
mobilizing O +
receptors O +
to O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O +
NFAT O +
) O +
-dependent O +
genes O +
is O +
critically O +
dependent O +
on O +
interaction O +
between O +
the O +
phosphatase O +
calcineurin O +
and O +
the O +
transcription O +
factor O +
NFAT O +
. O +

A O +
high O -
- O -
affinity O +
calcineurin O +
-binding O +
peptide O +
was O +
selected O +
from O +
combinatorial O +
peptide O +
libraries O +
based O +
on O +
the O +
calcineurin O +
docking O +
motif O +
of O +
NFAT O +
. O +

This O +
peptide O +
potently O +
inhibited O +
NFAT O +
activation O +
and O +
NFAT O +
-dependent O +
expression O +
of O +
endogenous O +
cytokine O +
genes O +
in O +
T O +
cells O +
, O +
without O +
affecting O +
the O +
expression O +
of O +
other O +
cytokines O +
that O +
require O +
calcineurin O +
but O +
not O +
NFAT O +
. O +

Substitution O +
of O +
the O +
optimized O +
peptide O +
sequence O +
into O +
the O +
natural O +
calcineurin O +
docking O +
site O +
increased O +
the O +
calcineurin O +
responsiveness O +
of O +
NFAT O +
. O +

Compounds O +
that O +
interfere O +
selectively O +
with O +
the O +
calcineurin O +
-NFAT O +
interaction O +
without O +
affecting O +
calcineurin O +
phosphatase O +
activity O +
may O +
be O +
useful O +
as O +
therapeutic O +
agents O +
that O +
are O +
less O +
toxic O +
than O +
current O +
drugs O +
. O +

